<SEC-DOCUMENT>0001628908-21-000116.txt : 20210805
<SEC-HEADER>0001628908-21-000116.hdr.sgml : 20210805
<ACCEPTANCE-DATETIME>20210804191230
ACCESSION NUMBER:		0001628908-21-000116
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		122
CONFORMED PERIOD OF REPORT:	20210630
FILED AS OF DATE:		20210805
DATE AS OF CHANGE:		20210804

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Evolent Health, Inc.
		CENTRAL INDEX KEY:			0001628908
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MANAGEMENT SERVICES [8741]
		IRS NUMBER:				320454912
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37415
		FILM NUMBER:		211145699

	BUSINESS ADDRESS:	
		STREET 1:		800 NORTH GLEBE RD, SUITE 500
		CITY:			ARLINGTON
		STATE:			VA
		ZIP:			22203
		BUSINESS PHONE:		571-389-6000

	MAIL ADDRESS:	
		STREET 1:		800 NORTH GLEBE RD, SUITE 500
		CITY:			ARLINGTON
		STATE:			VA
		ZIP:			22203
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>evh-20210630.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2021 Workiva--><!--r:e4ac7c37-8dd1-4c0a-a2d1-6d13aeec3d41,g:9a076b5a-4bc7-42a9-a1f2-350da80fade7,d:d8f403494d0a42c2868794fb470218fc--><html xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:evh="http://www.evolenthealth.com/20210630" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>evh-20210630</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183L2ZyYWc6MzdmOTM2YjczZGFhNGI5ZGIyMTNmOTM0NTAzOTZiMDAvdGFibGU6YTc5NjUyMTE4NzFhNGEyNDkyMWExZTVjYjhiYzg3YWQvdGFibGVyYW5nZTphNzk2NTIxMTg3MWE0YTI0OTIxYTFlNWNiOGJjODdhZF8xLTEtMS0xLTA_2f8274d4-504f-4b06-a9cc-e2bdeddc6f11">0001628908</ix:nonNumeric><ix:nonNumeric contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183L2ZyYWc6MzdmOTM2YjczZGFhNGI5ZGIyMTNmOTM0NTAzOTZiMDAvdGFibGU6YTc5NjUyMTE4NzFhNGEyNDkyMWExZTVjYjhiYzg3YWQvdGFibGVyYW5nZTphNzk2NTIxMTg3MWE0YTI0OTIxYTFlNWNiOGJjODdhZF8yLTEtMS0xLTA_d0b15d82-fc6c-4120-bb38-b0a830ce6b45">false</ix:nonNumeric><ix:nonNumeric contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" format="ixt:datemonthday" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183L2ZyYWc6MzdmOTM2YjczZGFhNGI5ZGIyMTNmOTM0NTAzOTZiMDAvdGFibGU6YTc5NjUyMTE4NzFhNGEyNDkyMWExZTVjYjhiYzg3YWQvdGFibGVyYW5nZTphNzk2NTIxMTg3MWE0YTI0OTIxYTFlNWNiOGJjODdhZF8zLTEtMS0xLTA_476f46b3-840e-4eea-9733-f4535c48682b">12/31</ix:nonNumeric><ix:nonNumeric contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183L2ZyYWc6MzdmOTM2YjczZGFhNGI5ZGIyMTNmOTM0NTAzOTZiMDAvdGFibGU6YTc5NjUyMTE4NzFhNGEyNDkyMWExZTVjYjhiYzg3YWQvdGFibGVyYW5nZTphNzk2NTIxMTg3MWE0YTI0OTIxYTFlNWNiOGJjODdhZF80LTEtMS0xLTA_2d719a7d-656c-4374-9175-8ceed8fcb254">2021</ix:nonNumeric><ix:nonNumeric contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183L2ZyYWc6MzdmOTM2YjczZGFhNGI5ZGIyMTNmOTM0NTAzOTZiMDAvdGFibGU6YTc5NjUyMTE4NzFhNGEyNDkyMWExZTVjYjhiYzg3YWQvdGFibGVyYW5nZTphNzk2NTIxMTg3MWE0YTI0OTIxYTFlNWNiOGJjODdhZF81LTEtMS0xLTA_d1bfc1b3-9fd6-454b-af18-fd90539999ed">Q2</ix:nonNumeric><ix:nonNumeric contextRef="ice63731bd06b4502bb0ed3b4e178ccba_D20190101-20191231" name="us-gaap:AccountingStandardsUpdateExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfMTktMC0xLTEtMzcyMg_cc0dc4d5-3936-4a6c-8644-233590d31e3c">http://fasb.org/us-gaap/2021-01-31#AccountingStandardsUpdate201613Member</ix:nonNumeric><ix:nonNumeric contextRef="i42bd67fe63d94bad9d6d9dbe6ec79900_D20200101-20200331" name="us-gaap:AccountingStandardsUpdateExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY180Ni9mcmFnOjFlZjc0Mjc4OGM3NjQ2NzQ5MGQwNWNhZWM5MzAwYjhkL3RleHRyZWdpb246MWVmNzQyNzg4Yzc2NDY3NDkwZDA1Y2FlYzkzMDBiOGRfMzI1Ng_e7fbd1cf-8213-4b7f-af71-67ed1c89dbd2">http://fasb.org/us-gaap/2021-01-31#AccountingStandardsUpdate201613Member</ix:nonNumeric><ix:nonNumeric contextRef="ia58666fd3ef747c9bd6d04b645148e3f_I20210630" format="ixt-sec:durmonth" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY182MS9mcmFnOjkyZjMwNzdlMjAzNzQzMDc5MzM1OTg2NTUwM2UyOGRlL3RhYmxlOmVjYWE0M2EyMjA2NzRlMjlhZWYxNWE5MzQyY2Y2YzAyL3RhYmxlcmFuZ2U6ZWNhYTQzYTIyMDY3NGUyOWFlZjE1YTkzNDJjZjZjMDJfMi0xLTEtMS0w_0dd0a43c-05f2-4dd5-8f29-a2887d2e2ab3">6</ix:nonNumeric><ix:nonNumeric contextRef="i486b139f28404e439444f6f0c13129da_I20210630" format="ixt-sec:durmonth" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY182MS9mcmFnOjkyZjMwNzdlMjAzNzQzMDc5MzM1OTg2NTUwM2UyOGRlL3RhYmxlOmVjYWE0M2EyMjA2NzRlMjlhZWYxNWE5MzQyY2Y2YzAyL3RhYmxlcmFuZ2U6ZWNhYTQzYTIyMDY3NGUyOWFlZjE1YTkzNDJjZjZjMDJfMy0xLTEtMS0w_3cb6be2e-357e-4e08-8598-11578d4b0201">12</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="ia9369ec0e450423b94ac833451c28d42_D20200801-20200831" decimals="7" name="us-gaap:DebtInstrumentConvertibleConversionRatio1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183Ni9mcmFnOjZjMjk1Y2I5ZTc3YzQ4ZDg5MjdiZDdmMzhlYWYwYzQ2L3RleHRyZWdpb246NmMyOTVjYjllNzdjNDhkODkyN2JkN2YzOGVhZjBjNDZfNQ_14dc3964-219b-44fc-8e5d-bf783400745c">.0548667</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="ibe41b74ddef048729f0365c76b125a47_D20181001-20181031" decimals="7" name="us-gaap:DebtInstrumentConvertibleConversionRatio1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183Ni9mcmFnOjZjMjk1Y2I5ZTc3YzQ4ZDg5MjdiZDdmMzhlYWYwYzQ2L3RleHRyZWdpb246NmMyOTVjYjllNzdjNDhkODkyN2JkN2YzOGVhZjBjNDZfMjE1_6e070c51-0a6e-4c24-a48b-6b016be5173f">.0299135</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="ifa1e9df841254737b2d83a5669c5b70d_D20161201-20161231" decimals="7" name="us-gaap:DebtInstrumentConvertibleConversionRatio1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183Ni9mcmFnOjZjMjk1Y2I5ZTc3YzQ4ZDg5MjdiZDdmMzhlYWYwYzQ2L3RleHRyZWdpb246NmMyOTVjYjllNzdjNDhkODkyN2JkN2YzOGVhZjBjNDZfMzkw_16826312-0150-4afb-a66c-0cad6531354c">.0416082</ix:nonFraction></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="evh-20210630.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i428cb8fc8d2340adb52e77c530bb0227_I20210802"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-08-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i45bff335c1434d6ba44132da1b0557db_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="icc9702daaf8a42a6b738e99ae2cf6328_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5afa72f271884055860c7e9a53ef18b2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7b3321915fe444e488ceef708a6e59c9_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:TransformationServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i78e15c27cd3e401ea6bd6fd305abeb34_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:TransformationServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8cf8298bd37b49539b40ff277f78e799_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:TransformationServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia98a39c8ecac46f5b530749d9b554995_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:TransformationServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie90c815774924e1e802eb6f3123f1004_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PlatformsAndOperationsServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd99be6d27564d4cb75996e8ce5dce17_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PlatformsAndOperationsServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaf5036ffdbc24ee8a477412be1612a0c_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PlatformsAndOperationsServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf7fe803335d432ba4201dde52789d25_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PlatformsAndOperationsServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id4ee77e0637d4c079ba08f5a8d50896f_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idf456296380c4d43be18dd320f38d79e_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e5ec0e87ee5433f83b9321c8e851948_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5780af7ffb314efcb610ffbfde88f991_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idb6c27b0e33045ad94dd37a21c51bcc5_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib32c349f6c584bddbe73d86161c5920b_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6f47fa7f09154d2791eda91f900b167d_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i455847ec36714e5290ad661b3a22ace7_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i31c050008a204703ba34fa755a536cf2_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie9109ae3615a4ff4bba0427a808423b1_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic8f27d03961c446e8a3b985b4125c35b_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9015d8c021f54578be8269eee070b2fd_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i94aea5894d5b4755a126a48cfbd95510_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i879a0ef04e854d12a3d8c0b0e4ef52a8_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if0b0ee0b6c91434b9c8abae23359e72b_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i81c425c8fa484c09a468070f04a8c93f_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia8df2ff5dddf457e82901cdf7d483ad7_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i569670e5740a45bbad372eaaf4c6523d_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i432ce00f8bd44330b83105a3a30fdfa7_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i026710848e1641728e5976c36d6751b6_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i699a6f845bb540d88c80df1abf986e42_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic75ef8266603466480bd63015a6a5944_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic59adfc6299d4f0497fd6b08ea305a09_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i57b7afbf065049aaab8f0248ad2de887_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec09d5072eea4a989bbeda84a659de90_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia89af82007e0491b902dec6c279845b4_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib53e76cbba4f4051ab162663449ef939_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i78ff7cbbd824466eab0d352e7f4b5f1c_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b480fd1921d4f1ea9972b92001a55ff_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3788ccc422524e5bab104710c747da49_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i61d42c3c86cf419a8e9f35be789f83b5_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia67d3ce8c31a428f993f4ca23b06398f_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia59baf61ed594b8fb0771be16c7deee5_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0b187f370fc84640b9c86628f855226a_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2202cb072bda4242a7bea49750347ba4_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9d6223463ab84fa6a8f5cd35e24c15d7_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i11817f96c3e24e0abaed14a17869e173_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i78d2f8ed8b384b2a93f41b0cbd0e3f03_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9482da1959ba438396e25159d07f33e3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6d3d52c0e5b94031981899cd1ecb78a1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia2be1022da19471caedc725d35d5a5bd_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7a8d015d1e3c419495ab144ddd77f1b6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9799952c3fd2440b9166bd85cc98b14e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i25b48cb725834cb78913e88a0e458e79_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieaf6b2c9ee5b475bbe4a1910426766b9_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idfc2020dff164058be58d93f3ec59267_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1baaa0777df145cfb48c213ad68538f9_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8830c28780b7440f831c87a11c1a0073_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iae1007f114dc467eb2b8a9c64881f28b_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3046b7b99a004e48a03d367e730f9ae5_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice23288885be4f779b9ab70832b538f6_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib21f2745e0714611ae3b84205a386a57_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1bcddf75950249fbaf184e1f523f0d8b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i18de6ff3304b4fda9feee31a2f415af8_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibcd7068eef4f42b895c0b83d21ea5d2b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie0ff0ad229b441d4b12bc8956f92a917_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice63731bd06b4502bb0ed3b4e178ccba_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i06c25faea1e7483786ebe928e1ff0fa4_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id8ff7726321243cbb8c00770e6603356_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e620150ffe942b388f50fab8377e007_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if955a85db5574fb9b6ccf0c7d039cee5_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i153c261aa5234592a35394b52c2c0b85_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8a113c1bdf754223baa2fb9a6344b873_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i215048e9c16a4f348373b4cb1edc7ece_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i67f38418f25c44ef862f02d73bbffaa7_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic9279f0ce4a5422aa74c787813c8d48c_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>evh:segment</xbrli:measure></xbrli:unit><xbrli:context id="ie049e920122645beab4e92d759ec4ad6_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">evh:RestrictedCashforLettersofCreditforFacilityLeasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibafea1edac4741a491dc06d42fbb6974_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">evh:RestrictedCashforLettersofCreditforFacilityLeasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i51059975ca4a4ad18ae06161620c8d07_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">evh:CollateralwithFinancialInstitutionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i84a57e99f4a84536b7f1f81b47d53542_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">evh:CollateralwithFinancialInstitutionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i724f3fb7e8664faf9d4251ef0ad9db50_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">evh:RestrictedCashforBenefitManagementServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i68d600384d87411f9808a47f7fa089b1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">evh:RestrictedCashforBenefitManagementServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if917fe9e46d74bbba565ff75862d3292_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">evh:RestrictedCashforOtherContractualCommitmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic2b7bf7f852c4e07ae4036ec1933f336_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">evh:RestrictedCashforOtherContractualCommitmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia177f909fbae4389bdaa8635f038babb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">evh:TrueHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iff2a65b6a1be4bb6b51772f3a5414255_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8abf010fb96f42a3a9c433ab04beeed6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="reportingunit"><xbrli:measure>evh:reportingUnit</xbrli:measure></xbrli:unit><xbrli:context id="i83f72281c0b7415ea503edc371882a4f_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9adc1f85abe84fe7ad21ea3765dc9836_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0de7bb52dc554f47ba2d09f4fb6ee9a6_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c645dae132a46319fcf7e651dc2048b_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i78747c549a50444ab43a62d1064b465a_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib784c8c0f9134bf48331872daaad6c4e_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractBasedIntangibleAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic82528f4a4554d6798f39cdf656b0d5f_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractBasedIntangibleAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i42bd67fe63d94bad9d6d9dbe6ec79900_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i36e8c4f14af843a5a8e48ca6d9a5c6ec_D20190528-20190528"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">evh:UniversityHealthCaredbaPassportHealthPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-05-28</xbrli:startDate><xbrli:endDate>2019-05-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i385b3b1c295f40a88f415a7f30d89c2d_I20190618"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:PassportNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i50427d2cf6854298bdb63c98b9dc7ee7_I20190618"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:PassportNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id6b6803c601248c48c645fade86aee32_D20190606-20190606"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">evh:UniversityHealthCaredbaPassportHealthPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-06-06</xbrli:startDate><xbrli:endDate>2019-06-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i267001cededb4bfdb4aa09441f453c34_I20191230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">evh:UniversityHealthCaredbaPassportHealthPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib8509d7b0e554612806781c71b9e4ddf_D20210101-20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">evh:MolinaHealthcareIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i69350541fafc4d14a84c72aba152a863_D20200901-20200901"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">evh:MolinaHealthcareIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-01</xbrli:startDate><xbrli:endDate>2020-09-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7a8609d202734bc89b28f90cabe48547_D20201116-20201116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">evh:UniversityHealthCaredbaPassportHealthPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-16</xbrli:startDate><xbrli:endDate>2020-11-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifee88f44d6c647d095b28edecae13e93_D20200901-20200901"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">evh:PassportAssetAcquisitionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-01</xbrli:startDate><xbrli:endDate>2020-09-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie9b33f26cab0425fb6895b18246f33f6_D20201231-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:PassportNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-31</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d78efa027664adba423d2ecb8ab7e70_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">evh:UniversityHealthCaredbaPassportHealthPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c70b9d982894c0dbbc1a56623c7e3e7_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">evh:UniversityHealthCaredbaPassportHealthPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0e1ba7773771404e91600efd70f89820_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">evh:UniversityHealthCaredbaPassportHealthPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id529693310384660bff0d3d357adbec3_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PlatformsAndOperationsServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">evh:TrueHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5619f887d0d546cb8c2d5bbbb39a6d8f_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PlatformsAndOperationsServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">evh:TrueHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i10851d8c3fd6447eaa0063fff7f9ed51_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PlatformsAndOperationsServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">evh:TrueHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i95135618e68647b8a930d4657c43da75_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PlatformsAndOperationsServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">evh:TrueHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7e57745d431e47bfa19e71a49e5fdf02_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PremiumsRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">evh:TrueHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia3740e6e58c749fa97b9285685be7b1e_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PremiumsRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">evh:TrueHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9034834f629c466cb0de8a2fd5acfc15_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PremiumsRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">evh:TrueHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i70101f6902e44f38a06effe5f98e83b6_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PremiumsRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">evh:TrueHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1869cd19e38f4a028448315845a440c5_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">evh:TrueHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a6bb4acf8f64d4ea88262cf96a6ca67_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">evh:TrueHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iae3e4f43e8c541128c572b22ebdd19bd_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">evh:TrueHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f626e482e054b34901a6c459f47f04b_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">evh:TrueHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7af7cd835a34469ebabe02daf06e9c2f_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">evh:TrueHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:ServicesAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ica99eb679e5f4a22856b6f0e49072449_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">evh:TrueHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:ServicesAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic748340b0cf24dd685eb9347670033fd_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">evh:TrueHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:ServicesAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i253ccf29d13d4053a5a80b95f440acbe_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">evh:TrueHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:ServicesAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4a8d60e8de004fd0945ea0051704e1de_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicaidCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c8f58d985fb4dd1817f8f943b715272_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicaidCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f70e8921395417eb51d6b5f206ee45d_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicaidCustomersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic9022249a19e41248315bc92ae2c6b84_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicaidCustomersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i80f1ac7ca97c4270a70dceff5a322554_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicaidCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i833160ecd3e14792aed807f6f5526e09_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicaidCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic9abf3a96b46413baa0783c375797a74_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicaidCustomersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a6c076167634a8aa2973b374f21a1c4_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicaidCustomersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9867dbbef41b4ff08dd51316a253355a_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicareCustomersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i35df7764bb024bb58f354c0f372efbb2_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicareCustomersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i676770c966c346949f713ef44a2dbce2_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicareCustomersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b1276ae67ae4854953f3017ca34fd0a_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicareCustomersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e93d81fa73f4e01abe8848bb63987d0_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicareCustomersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c150b72b12444a49062d1ff90c9afd3_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicareCustomersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b6c919aef4c4e57ab2545a539828a75_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicareCustomersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c9490d39e564864bc4c81a7f1b11b1b_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicareCustomersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i21361653abbc4b6aa34198f3f5c3a202_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:CommercialAndOtherCustomersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id59d1f7e03da447690dd86c33c621d88_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:CommercialAndOtherCustomersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i135f040fff0c4f58a1234a087ef110d6_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:CommercialAndOtherCustomersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3905a81b1d7b40abb4c7c12d2a5c2e77_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:CommercialAndOtherCustomersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc1d76dc32264876ae1a895cacd83b87_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:CommercialAndOtherCustomersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i43e4c78617c04287898b67968c6ce485_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:CommercialAndOtherCustomersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i52bdbef1d82e458fbfaf536f2c11d6e5_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:CommercialAndOtherCustomersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6796d59fa424ba69653cef4e3d47ff1_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:CommercialAndOtherCustomersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i679cb28be3a34242bd30bce045577c6e_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibebddd07c46e4994849d375ecea231c6_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c9bfa2d7f884c12b69f21c9b3af2888_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i16325f028066493d8ad0ddc953bde9e9_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d62628d6fb54fe0bd811fdfd0bf7b0c_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8d756ddfc980426086c7294d41dd2af3_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib887805409a54f638aeeafe3fe5d1688_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic606425dedeb4d3d9b0b453c252ea236_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia58666fd3ef747c9bd6d04b645148e3f_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2021-07-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i486b139f28404e439444f6f0c13129da_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2022-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id9deab8552a14f5eb736da5c6d86fc8c_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">evh:BonusesAndCommissionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i82a60e4d756c4c5e95ccf693e56f48a9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">evh:BonusesAndCommissionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i06ae7c987bf741caa484f758c9e8534d_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">evh:BonusesAndCommissionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idadd3c2bee534377ac63ee0a2aa2dc8c_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">evh:BonusesAndCommissionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i86cf0d7a76724f38ab859d26bde2920a_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">evh:BonusesAndCommissionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2255e38e922f4d94b90c933ab1b70b67_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">evh:BonusesAndCommissionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8514ff7930a54e788f76b2be07ba421a_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">evh:ContractFulfillmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i296b1e421ebd4c6fa47abf987a270359_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">evh:ContractFulfillmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i27ed1697f8ec480093c84d3cf0952a90_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">evh:ContractFulfillmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic6fb32c2d54b4c729398fb1ececf52fa_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">evh:ContractFulfillmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib613b60e238f47b69fde69e1a6a8f9be_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">evh:ContractFulfillmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if15e3a35bf6243958b35f8728c4cc216_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">evh:ContractFulfillmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2a6d7a68b4464c1c9d7d5339891880a1_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancingReceivablesPeriodPastDueAxis">evh:FInancialAssetLessThan60DaysMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i62715a632a4b4513bd30977aa196bcc0_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancingReceivablesPeriodPastDueAxis">evh:FInancialAssetLessThan120DaysPastDueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4306692d5e5e4a86b318371f5399f564_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifb44c2b2a28446c4b3e3caa830711368_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i57afc0d68f184fb899a29c776805bc85_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie1bcc0c9ee4f48d2804f66aff99ff763_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i786125390bf04da6ad620815caf55ac6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3bacbba21c62440980d14afff52eb1ca_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i037a95e6b16d4dcea7b2b033c338785c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0a061c9add404e629ee1ae3de0f2006f_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e1d68f35e444ab6bb440e13e80ab435_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iefe7fef4d5624963a3e8bf8250323769_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieb3c51cd38194256bde9f79f0128cf37_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i04ad35bee18d4527b458f382beff864b_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc2cefa24419498989e69466f40918b1_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6cc0ccb728fb4392be2f4d846aac50c1_D20200501-20200531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-01</xbrli:startDate><xbrli:endDate>2020-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3afcc69bcfa341e986b926e4d21107b8_D20191001-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb95849bc72e47e5b878e5e786a0ed96_D20201031-20201031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-31</xbrli:startDate><xbrli:endDate>2020-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i52907b15276944d085944daaa7867a5e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:IncomeApproachValuationTechniqueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i40bf24d71e79424985bfa9b1dc75e390_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i00a15ecaf66f4a6cbb5b4eb9fa265870_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie355e9ffef734dc6a2b8f3d027278891_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9c3ddb1ccecb442ca473281d46c1ef16_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibcf0f323376446aca3fd59b2d1a2f2ad_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9a66b42348f74ceea613fecea2deba8e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if5ff183307a4468fb0d5707822525486_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i25d27166851f4878bc9c647f69bfd2ea_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i53f945f2e79348aab95bbf3ba92010f3_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie2665c131c1e46f691f30a8a2e0eaf86_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie6df44374ded402288e7ddba99d481b4_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i613c94dbacec49fc9a7b83bf086ad005_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i73f385263f424c7b8911b8af743d7e12_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icfef255ab2b84de6a4b8638cf6a47165_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibe0ce27038e244269b2a24add102c084_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9ca6f97a31c04defa1bfbf470ae72bdc_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia4e8785ed06f43489b789e69021e517b_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i79cb86c12975465c920a2007aee927c8_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e9914c7a4fa4bb6b1f1dcc803aa9440_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4a65339b8de24dc0ad22aeaed63b43ea_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">evh:BelowMarketLeasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i06b855dce6e346bcb653c327e7599385_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">evh:BelowMarketLeasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i683282a1148d4b31b1f897062aa84ede_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">evh:BelowMarketLeasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1f772575126c46f293e485e88a16c5b2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">evh:BelowMarketLeasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4064cc6be7384542838693bded8b452e_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractBasedIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3af67d6664c9491d8b7fdecedd5f5629_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractBasedIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i27b1db7d183641a5b3e3c8ddfbffb17e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractBasedIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i965ab087aa7949539cb446e0c5221cea_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractBasedIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie8fa99474b6947149ca859e8e7009178_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">evh:TrueHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib490a7e546dd4b0987772534f6cf516c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractBasedIntangibleAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">evh:TrueHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic6cafc0c96a142d5819a5b45e9032420_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">evh:TrueHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f5ebd73deb94928a519598776e04047_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractBasedIntangibleAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">evh:TrueHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie9f0093698034c048db39ee74d23fe56_I20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0d3f73b1f2c04d3ba51586bcf12c3517_D20200801-20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-01</xbrli:startDate><xbrli:endDate>2020-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icea30d45fccd401f9bb3791275a8c40c_D20200801-20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:ConvertibleSeniorNotesdue2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-01</xbrli:startDate><xbrli:endDate>2020-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1598eae5f6ae4813b69f0cbb95358c65_D20200801-20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-01</xbrli:startDate><xbrli:endDate>2020-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iabe38bb19e7049c7a823aae107a5b0ba_D20200801-20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:NewNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-01</xbrli:startDate><xbrli:endDate>2020-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id559bfbab5954aa7bb0b5c73c4b04f85_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b496ee9129546a1943004e4d9e6e458_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibccaaf22aab2432ba1b4622538e18372_D20200801-20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-01</xbrli:startDate><xbrli:endDate>2020-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i437f571852d648ad8e14dd03e682fc47_I20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifa10c9f357cc46da8a582a78230489bf_I20191230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:InitialTermLoanFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i06948a2177d04b259e0902a18900dc29_I20191230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">evh:DelayedDrawTermLoanFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibef4bf4bc2ab41d2ad6d564857f8fb16_I20191230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:ConvertibleSeniorNotesdue2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibb12573bef604a62ac70c8f5b1d35372_D20191230-20191230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorCreditFacilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2019-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i11adbaf0c9c0475282d0187b6ac6db8f_D20191230-20191230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorCreditFacilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2019-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic8d3791c30f040c2b02c8f39bf43b812_D20191230-20191230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorCreditFacilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2019-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1868ae14255d4c95aab130080ec3175b_D20191230-20191230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">evh:DelayedDrawTermLoanFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2019-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i381ee2f518b34b78a5f3e6263b399e70_D20191230-20191230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorCreditFacilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2019-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b0d7584f95b486581d1f8fcf494bd87_D20191230-20191230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorCreditFacilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2019-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic5de6b4f322d4a41ba0b04e047d3567b_D20191230-20191230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorCreditFacilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2019-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f21b3a7685841259a7bbf081309eb0f_I20191230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorCreditFacilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ida1f309838e74abeb0e17c296af553bb_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorCreditFacilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i96b555f871384a6ab79fe625ce473698_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorCreditFacilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2e95d208160a4c749900182d52a49615_D20210108-20210108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorCreditFacilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-08</xbrli:startDate><xbrli:endDate>2021-01-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if600ab05fc8b49bca59c078f4bbb6742_D20210108-20210108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-08</xbrli:startDate><xbrli:endDate>2021-01-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1cad05e654934e308e828b864b76a508_I20191230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0bb88f4c90544362ab13fcd63aba4af7_D20191230-20191230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2019-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if7229a5e40df4a5095c25bd23977e747_D20210108-20210108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-08</xbrli:startDate><xbrli:endDate>2021-01-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia5b2225a7a85439eb9318023f5dca1ab_I20181031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifee6d13c14704a0a9bd4959cd14684b6_D20181001-20181031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-01</xbrli:startDate><xbrli:endDate>2018-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0db344c6ddf344ceab1c3071829545ff_I20181031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3533fa8477ed4bb0afb07e5b80879435_I20181022"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-10-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if3e69e58105c4d909f82068c94a4e66f_I20181024"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-10-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4deadc1ba0674142a17d227672696535_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba4a0e1b01024c46b291007f4c8b7e3f_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieeacfdfdfca8412a9c4cc31d0dfb0be6_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0489a5ac9602461ea764f0340d05dbc2_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id755146089114b63a291ebb347fe05cd_D20181001-20181031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-01</xbrli:startDate><xbrli:endDate>2018-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i263de0af39604a6985530e0395eaee6f_I20181031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0efb2207e70f43cb998170b0668f5aa4_I20161231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:ConvertibleSeniorNotesdue2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib65ee853127148cf9a525e6a17c68f39_D20161201-20161231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:ConvertibleSeniorNotesdue2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-12-01</xbrli:startDate><xbrli:endDate>2016-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic303181ec3134d098d234f848582ffd2_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:ConvertibleSeniorNotesdue2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf80add09165458a8481ba03343ec164_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:ConvertibleSeniorNotesdue2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e0425e5520c4d8ca777fd31abfdf006_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:ConvertibleSeniorNotesdue2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i424565a0d08945018985beab5025c0a3_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:ConvertibleSeniorNotesdue2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifad8a17110484cd3b275f15806410965_I20161231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:ConvertibleSeniorNotesdue2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifa1e9df841254737b2d83a5669c5b70d_D20161201-20161231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:ConvertibleSeniorNotesdue2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-12-01</xbrli:startDate><xbrli:endDate>2016-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8e9d743092e245ce8a2743fa9de0063b_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id589098e41f9432fb6f03c1f1e575a4c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8919b4a21f774b92af0611b3454001f6_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib88938e6f5a14d0f9eced78e9a885018_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6cfa2b6d88f04259ac6ccaaed1afd02a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia8e7a5b465864f39bac51a81bb700201_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7f54eab4eae24811a155de3cf38eeb86_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i82c5460e9f7e435b83787f35cd36dcb2_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i24d4b1acd996498eba5eed0fc3e84f4b_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie1e16d58e0e740b28071ebf63f24431d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i26c20cf31c1242dc950becfb29611788_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:ConvertibleSeniorNotesdue2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b41e14476334d7895158617049bccd5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:ConvertibleSeniorNotesdue2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i42998979e1154fc69a147d78134d1a26_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:ConvertibleSeniorNotesdue2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i57814fe811324e9fad5398f551936680_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:ConvertibleSeniorNotesdue2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie847f4ca71c44d2a845bf492cd0b91ed_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:ConvertibleSeniorNotesdue2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia9369ec0e450423b94ac833451c28d42_D20200801-20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-01</xbrli:startDate><xbrli:endDate>2020-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibe41b74ddef048729f0365c76b125a47_D20181001-20181031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-01</xbrli:startDate><xbrli:endDate>2018-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic57d3a037df7434482b4ac69c20ce6f0_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7d1b21babb8849389bf714849eaec38d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iced602b4d3a741e183e4dad1271a58e8_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">evh:RestrictedCashForLettersOfCreditForLetterOfCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i538e245a2b7045f18999365d98e47c51_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">evh:CollateralwithFinancialInstitutionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i154d1afeed6943c08b9da6703d2f57a3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">evh:CollateralwithFinancialInstitutionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0cd3439d51f543818ae384f535441a35_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">evh:RestrictedCashForLettersOfCreditForLetterOfCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3bfde454609344df8a691fb13c17b423_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:CookCountyHealthAndHospitalsSystemMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:FinanceReceivablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2ef1d0e83e2d422cbbb22022d1d3f276_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:CookCountyHealthAndHospitalsSystemMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:FinanceReceivablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i60ad372a207d459e88f7e372405eab34_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:FinanceReceivablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:FloridaBlueMedicareIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic8a7c423118a4e16a2ff6abc2b0d9648_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:FinanceReceivablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:NeighborhoodHealthPlanOfRhodeIslandMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idc534571524f4f7abecd4ed0645e79e6_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:CookCountyHealthAndHospitalsSystemMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i969062c619d04ffaaa1df514f89c332c_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:CookCountyHealthAndHospitalsSystemMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i944764ecb45a4413b9d526710bd5a552_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:CookCountyHealthAndHospitalsSystemMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i01f8679ac2df4d82b256eea229cf6ea6_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:CookCountyHealthAndHospitalsSystemMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia609b71d80124ac5a96f49cb69aa72ef_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:FloridaBlueMedicareIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifb4268d248fd469a943652442c7252cf_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:FloridaBlueMedicareIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i02f118a71b9b4270abff67fb98d3ae2d_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:UniversityHealthCaredbaPassportHealthPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i51acaef421854161bf36167111e9315d_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:UniversityHealthCaredbaPassportHealthPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id96b9f84ab8c4a4f8d773f444cd3a629_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idababf2dc26948949104cd43d693a4fd_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if54c2d9d6b874c56bd73c8364532a8fa_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:VA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9376f969f54d4adfb216011fc4ce908d_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:IL</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia8857bf6635f4a0a81ada9df6a84f8ce_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4c6bffe6a4634527a6262241e44da56b_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3bbdc552de74473b893173ad17ee4325_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">evh:RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if108b20cc6254ea1a1ef89bfcf74234a_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">evh:RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a86fe17944142e095851e0cc3a655ae_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">evh:RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic963db54c7f04dea9f467d5db2840678_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">evh:RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieca7dabc7fce4091b7a8bbb168559405_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iedb4828edf4e447d9b1ee9ab980c6c02_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7360937c162c4b65b0e52cff040923da_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iddd419d375b04a27b7ae24f9852b38cf_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i61e6d3ad43084e94a5c4f2bbb4e354b5_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf9351473ea6468086160063a0d7a0c4_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d293dc899f54d4c89227aabde9d3934_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie3fb28c745a64f28b8f641cb4a936a28_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia22f1c58e4244cbe9ed8fdbbaef1316f_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9fc03842c80f45108f623bfcd797411e_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia0aa4d34ea254f26a2cc4a122094cd33_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia4237d1aee594aeeaf7d421737988f0d_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1fc5b0f231654aeeb765d3a2edd42fd2_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i394c93b044f44da0bc8dae6ae1a3f9af_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia4367a6c7f1a4e8ab41b880d4b063e2e_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iefc5be4539b04aab90aaa73295d047d2_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id632fa3ae3914b9da8bf15e4c54b6686_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i89e74efc56994c9ebb87c2b0e7cd1128_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6660233c9d6b4e96811be968402ad42c_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idc0d9ae125db467ab0d22698986a0481_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if7b4268f6d62460d95263ea3eab82df8_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evh:LeveragedStockUnitsLSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i28477571d61a49d68ac8b8802530ba46_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evh:LeveragedStockUnitsLSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibce4d97bacd94dfaa609647fcaf23ca0_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evh:LeveragedStockUnitsLSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie162b42e78994c30b638363b2e6da8a0_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evh:LeveragedStockUnitsLSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i16f26157e03a422b8390af0e74420d0a_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evh:PerformanceBasedRestrictedStockUnitsPBRSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia87f608d482b4ef79558f90ef1ef2a3e_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evh:PerformanceBasedRestrictedStockUnitsPBRSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i10ed9cb15f3c48d395885e32db2ca4ff_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evh:PerformanceBasedRestrictedStockUnitsPBRSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f822367a8c44dd79b4a10071eae6fb0_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evh:PerformanceBasedRestrictedStockUnitsPBRSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idc22f08766584f8c91a9b4972f0f9f89_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib32f2800c3f24f0ca601b1fd026b593b_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b0398298a1d4101bfdde0a27cfc4235_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i78cdc5087ee24e2e99b2216043b5b6b1_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7f345cc1972943b9a0ae90973779501d_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i40db2f18e67e43439f94c81d84f13d6b_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia1c09fd265c44ccdbf4d6a40f41ce5f1_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id05098869b4b4201a380d4ccd404ff02_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if20f8ae5705c41f6910dff16d8c55578_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9b662261daa24dd0829c6be06dc0975d_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a67432b3a04429fb74ea67ee7476cc1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i644686c1853d44d8bed17fe7241635c7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i53efb4309a7d432c9067d4fceb38e1e9_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:EquityMethodInvesteeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">evh:ServicesAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0191a974415646adb1cd9c25e726b3a2_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:EquityMethodInvesteeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">evh:ServicesAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i008ff0c503394e539acc7adba9224bd0_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:EquityMethodInvesteeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">evh:ServicesAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e9654e025214c9b8e664574e724a4f5_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:EquityMethodInvesteeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">evh:ServicesAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id7302983007d47cf8a4aa6ef74f49b80_I20150531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">evh:EvolentHealthLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i46248ae6cf2f4c3bb6a08e6b7351403f_D20200901-20200901"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">evh:UniversityHealthCaredbaPassportHealthPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-01</xbrli:startDate><xbrli:endDate>2020-09-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d32a6bf57a9495e9192581ba6585e10_I20200901"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">evh:UniversityHealthCaredbaPassportHealthPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i19b1ea06ce044830b8d288022cd0a41c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">evh:UniversityHealthCaredbaPassportHealthPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8bcd87ce6e8140d4b38c9d25b675b6d0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id8df3a7cd40142e4a7fab99e3da63b6c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic31316c74dad419fa29a95505e9ad56c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie28163dd08614c3cafdece4567d5b234_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9af8cd87d8f9489980dbda44afabcdbc_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">evh:BlackScholesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia5a46affbafa4a3caf05bc97e2301da0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">evh:BlackScholesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1593077c9af8419b8c13d1d04a73de2d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">evh:BlackScholesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e3c636f0c3f4cd9a3d1b819208219a6_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icd166759aac546b39c8ff666867d34d3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i80f9c6fc9c784f1ebf7661871ea29e40_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:TransformationServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i12d000d060d24ea2a95340696a6a480c_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:TransformationServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if3045b5c28d7410fb838543b77fb8e48_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:TransformationServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b684a34ddb04cb49ab76574e8dbeca9_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:TransformationServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib2886761dda849ee81490345eb4cd5fe_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PlatformsAndOperationsServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if3ad28259229428e9fd1a3676572116f_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PlatformsAndOperationsServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if26f70dc308240eb95d27a86fe164dcb_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PlatformsAndOperationsServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c692c0dda2248aab4719ff28ac52586_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PlatformsAndOperationsServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id32a865882ba4f0f9600a62eb26f2cd9_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b14ca9b08604f019fcc80d78ee511ab_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8ba99c7ee2d04799a86890ec3064b175_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i04089c6246044d5cbf92001f57543039_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9efdfcae40144663a980937c662799c7_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">evh:EmployeeSeveranceAndTerminationBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia2840929ec444f69b484c53abba16383_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">evh:EmployeeSeveranceAndTerminationBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i17f053f839394fcd9de0dbf7fe5e0507_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">evh:EmployeeSeveranceAndTerminationBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd9a4c33807c43dda2178f4f2a358736_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:FacilityClosingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic4bacc3efa9a4c7cb0dbc8f0c6465a2e_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:FacilityClosingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibdc992c308c2409eb366952bb3e529f5_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:FacilityClosingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i78fb3e05b2884c2185234402150b6dad_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">evh:ProfessionalServicesRestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ief40b6b342f44af6974cbb1079825a19_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">evh:ProfessionalServicesRestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id4ab1843551d40e48105a1b5bf07b950_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">evh:ProfessionalServicesRestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia33818b88a6c42f5b842f5cc447c4d6f_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:TransformationServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i807d8acee29b43e1998e67d743c1650e_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:TransformationServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia356ef0e7c074058809ff566475d252e_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:TransformationServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0280276096944f8db9756b1ccc072342_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:TransformationServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iec060d1f9dc045319b07294745b086d3_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:TransformationServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iafbe04d32b3c40ae93c564f542241136_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PlatformsAndOperationsServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c922ef0f31b4ab2b388e8b7c1ab5312_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PlatformsAndOperationsServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4bd03bc4393d446e9abc787bbb40c7a8_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PlatformsAndOperationsServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaee89f0da3e144d09c4a23c928d850b8_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PlatformsAndOperationsServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b7ecb9ad2c3400db038af4f12b6a9ab_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PlatformsAndOperationsServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i953b09444cb241478eb77a7260d48527_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib66948dc799e431486e4991bc5ffa9ef_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i69cb2a622a3f4134a8e8684f7cb47aef_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic69644d995ff43218ea90302f9eae15f_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:TransformationServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id9a15a1f9bed43b2a7a6b9699a0355f6_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:TransformationServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i59d8caca505e4118a56844c68847eb29_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:TransformationServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa545ecb72a34a7c8a9f3b3fa6383b57_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:TransformationServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9ecbd6b0abc24d8a9ed6772122d27e8c_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:TransformationServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i803b5fa527c248aba9d05e7aaaf9a0ed_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PlatformsAndOperationsServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5621f56fb2874b21835554c608a4179a_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PlatformsAndOperationsServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia2e4a5d8dda94f9cbc6ae57881da0889_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PlatformsAndOperationsServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id2637cdc499c42c69c98ce75b9cedd71_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PlatformsAndOperationsServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i97c5008ce5974099bdaadf9428995770_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PlatformsAndOperationsServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ica79a35ca46143efa08136ec1e43e0d5_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id0ffe73b7f124f5b9dfa9a01b4c7dfcb_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d3bf486d496461182f54f254e8fe296_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if6c3ed9c5b31412bbfc731eadc4f9045_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:TransformationServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifbfffc16190d487496ae91da9f40ee9b_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:TransformationServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i841058299b4f4c1795217d34792246a1_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:TransformationServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i12ad1dffce3e49519ee5e99e00c3f177_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:TransformationServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iadf935fda2524029ab1baa4bbb8135d0_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:TransformationServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4fd904bfe7584429855878280cb71fbe_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PlatformsAndOperationsServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5a6d3985925f4d079a28f30c8f205377_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PlatformsAndOperationsServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b96ed23f107471690b24341345908a6_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PlatformsAndOperationsServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e627f3a42b34bd68ed1833fc5b3ff06_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PlatformsAndOperationsServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i36c5f7a5f7074897b1f640ced6ec0f6b_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PlatformsAndOperationsServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i47a5474af0444feba1cc1f919f211cc9_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia479742cadcb42f19e8a838c73672d04_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i571d8209f1eb48a5abfd5c42c7ee45e7_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i74d008e6bc3e404a8233b3b36dd1f025_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:TransformationServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i64e303d04c4e4b9e9e4bc39b1eee6997_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:TransformationServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie31b707bdbb24397b9da9c80ed837abf_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:TransformationServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib86e9afe1f8b4419938a02c0da196679_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:TransformationServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if6bf1058758a4ffa90f4649ee946bc82_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:TransformationServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5139ec3fcfe440db905c8c709c4d692a_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PlatformsAndOperationsServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib8561338bdd4433695c2fe64f2d14fac_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PlatformsAndOperationsServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if4d7479d872f485386fe9f72c2913b25_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PlatformsAndOperationsServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i44946cd02c6a44519e1f9f53797e5d47_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PlatformsAndOperationsServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idfe8d8e6c5344c9b97a29c49f343d22f_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PlatformsAndOperationsServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a5208c4b92a426f88946822bb9c7fb6_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i12a7d1eed63947fb83cf5d1b35015606_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id50759ca40e2432a8be2b863be3eeedb_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i16817704fb5d42b894f5f9c40a24d9d7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:TrueHealthSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9f5902da906645d380ce211e0eb169b8_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:TrueHealthSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i558e7ef31d4b428c9ee6d8d5a9dd5f54_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:TrueHealthSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie069c94280064225b4ffe831d6c5e5fe_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:TrueHealthSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i89185ecde2ae43c5b615a3084603455c_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:TrueHealthSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i80bca972b5164b02a2d38d8930a36773_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:TrueHealthSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i46534d0a532b4e63ade4879ed3702a19_D20210802-20210802"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:WindroseHealthInvestorsIIILPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-02</xbrli:startDate><xbrli:endDate>2021-08-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic40ea142c3e8460d8998330c2ef6c2fe_I20210802"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:WindroseHealthInvestorsIIILPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-02</xbrli:instant></xbrli:period></xbrli:context><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfNDktMS0xLTEtMA_e272ccc9-dc55-498c-89b9-404c1f9b6f6f id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfNDktMy0xLTEtMA_ceaf962b-8aea-4d5b-a2af-c8eac1cdeca1 id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfNTAtMy0xLTEtMA_54b36cb3-55b4-4c38-a985-8a95b4bae96b id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfNTAtMS0xLTEtMA_e1d467e7-008d-4f8f-808d-93de1533b6f1" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RleHRyZWdpb246ZjU1OWJmYTMxNWU4NDFiNDkwMjJlMTQ4ZjBlYWZkY2FfNjE1_f300fa04-bc09-4350-94bb-64f25b72efcf" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfMTMtMy0xLTEtMA_0bd89b3b-2068-4bdc-b1ba-4a900b749388 id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfMjItMS0xLTEtMA_1f10d8b5-1db8-4230-98e0-6ce7b5992df9 id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfMjItMy0xLTEtMA_c5e869a8-ed79-4a79-8e99-c692c6b54846 id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfMTMtMS0xLTEtMA_34df675b-2a88-454e-91a0-f1e6eeee0b7a id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfMjgtMS0xLTEtMA_b18bdc4b-8074-4572-9265-14e37f5cd14e id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfNi0xLTEtMS0w_85c2778c-749c-4408-a8dd-d5ac7fcd6a11 id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfMjgtMy0xLTEtMA_a1ac98c6-5825-4d80-94f4-d279034abf6d id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfNi0zLTEtMS0w_126095e3-ba11-4518-b942-19d719b1d746 id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfMjMtMS0xLTEtMA_5d00a01b-0f87-47ac-87ff-357987c3f073 id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfNS0zLTEtMS0w_d66e2798-abe8-4ea9-a342-c46e07beedfa id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfMjMtMy0xLTEtMA_2f78f8c5-c465-44cf-96b8-12f236568eab id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfNS0xLTEtMS0w_4ca84b48-7a2c-4c42-b349-4cc6f3d902a5" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RleHRyZWdpb246NmEwNWU3MWI1N2ZmNDBmNDkwMzUyMDE0YzNhZjNmNTZfMjA1_14702e91-5902-4688-9db4-81a13b43b8a2" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjExYWJjOWIxMWM5MjRiODM4OTZmNmRjYjRjMWY4M2NkL3RhYmxlcmFuZ2U6MTFhYmM5YjExYzkyNGI4Mzg5NmY2ZGNiNGMxZjgzY2RfMy0zLTEtMS0xMDMx_23a653a3-53f9-4fa2-825a-b0238aa1e1bc id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMjUtMS0xLTEtMA_c5ecddec-ea61-49d7-9ee4-4bc37ada6314 id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjExYWJjOWIxMWM5MjRiODM4OTZmNmRjYjRjMWY4M2NkL3RhYmxlcmFuZ2U6MTFhYmM5YjExYzkyNGI4Mzg5NmY2ZGNiNGMxZjgzY2RfMy0zLTEtMS0w_e40e5aa3-d436-463d-ae79-d4a972b39319 id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMjUtMS0xLTEtMTEw_1cdad334-f519-48e7-a442-e006607bfd0d id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjExYWJjOWIxMWM5MjRiODM4OTZmNmRjYjRjMWY4M2NkL3RhYmxlcmFuZ2U6MTFhYmM5YjExYzkyNGI4Mzg5NmY2ZGNiNGMxZjgzY2RfMy0xLTEtMS0w_c5ecddec-ea61-49d7-9ee4-4bc37ada6314 id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjExYWJjOWIxMWM5MjRiODM4OTZmNmRjYjRjMWY4M2NkL3RhYmxlcmFuZ2U6MTFhYmM5YjExYzkyNGI4Mzg5NmY2ZGNiNGMxZjgzY2RfMy0xLTEtMS0xMDMx_1cdad334-f519-48e7-a442-e006607bfd0d id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMjUtMy0xLTEtMA_e40e5aa3-d436-463d-ae79-d4a972b39319 id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMjUtMy0xLTEtMTEw_23a653a3-53f9-4fa2-825a-b0238aa1e1bc" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RleHRyZWdpb246OGQwNTJjMDNmNGQ3NGQ4Y2I5YjAzOWU0YjQ4NjVjMDVfMzU5_b7e01e4f-d0ca-407e-8cef-928f5bacc225" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMy0zLTEtMS0w_033da13e-7a60-4e5b-86d1-46b783ef6f62 id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMy0xLTEtMS0w_170ba868-793c-4ffe-bebd-eb61ff904fd1 id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfNC0xLTEtMS0w_4912914f-f7bf-4db0-8743-46164a2ce1b1 id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfOS0xLTEtMS05MA_035cf8ca-b3a4-4fa4-878b-6900e1908669 id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfOC0zLTEtMS04Nw_42941013-db98-4377-a51b-f4d23a542da8 id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfOC0xLTEtMS0w_bcd4f6f2-84b7-4b1d-9d32-1a5da0be3e1e id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMy0zLTEtMS02NA_8a291b24-c574-452f-939f-4ed838ba9580 id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfOS0zLTEtMS05MA_63fd3a46-1ce7-4e9e-afc2-84df19c21d43 id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfOC0xLTEtMS04Nw_1bc0b1dc-fe01-4de7-ba41-3ecef7ac0a30 id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfOS0xLTEtMS0w_2913840b-6e6e-4c12-a70f-0383ffa3f270 id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMy0xLTEtMS02NA_4ddfd893-22a5-4d76-b130-01774ab09be5 id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfNC0xLTEtMS02NA_1646c669-412d-40be-a8bf-033270592308 id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfNC0zLTEtMS0w_641872ca-97f5-472a-b032-425fcb904fd3 id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfNC0zLTEtMS02NA_50789944-5571-4917-817b-931e2e3b29ad id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfOC0zLTEtMS0w_a7c391ca-74f2-406d-8845-5e85413ef517 id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfOS0zLTEtMS0w_b14e9482-2674-4e3e-92ef-34edd76c896f" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RleHRyZWdpb246OGQwNTJjMDNmNGQ3NGQ4Y2I5YjAzOWU0YjQ4NjVjMDVfMzYx_567718ea-66eb-4aaf-8694-a0a35e05203a" order="1"></ix:relationship></ix:resources></ix:header></div><div id="id8f403494d0a42c2868794fb470218fc_1"></div><div style="min-height:18pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:100%">UNITED STATES</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:38.25pt;padding-right:38.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:100%">SECURITIES AND EXCHANGE COMMISSION</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:38.25pt;padding-right:38.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">WASHINGTON, D.C. 20549</span></div></td></tr></table></div><div style="padding-left:38.25pt;padding-right:38.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">_________________________</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xL2ZyYWc6YjFiNWJmMTFiZDY0NDRhYzhhODIxYmFmNWRlNjE4YzcvdGV4dHJlZ2lvbjpiMWI1YmYxMWJkNjQ0NGFjOGE4MjFiYWY1ZGU2MThjN18yMzE2_ff5b6793-3d73-4d62-988f-ad0ec750b15a">10-Q</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">_________________________</span></div><div style="text-align:center"><span><br/></span></div><div style="padding-right:38.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">(Mark One)</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" format="ixt:booleantrue" name="dei:DocumentQuarterlyReport" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xL2ZyYWc6YjFiNWJmMTFiZDY0NDRhYzhhODIxYmFmNWRlNjE4YzcvdGV4dHJlZ2lvbjpiMWI1YmYxMWJkNjQ0NGFjOGE4MjFiYWY1ZGU2MThjN18yMzE0_16fa53c0-4daf-4d98-a315-773d2c2768c3">S</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xL2ZyYWc6YjFiNWJmMTFiZDY0NDRhYzhhODIxYmFmNWRlNjE4YzcvdGV4dHJlZ2lvbjpiMWI1YmYxMWJkNjQ0NGFjOGE4MjFiYWY1ZGU2MThjN18yMDc_85678fcb-2f0f-455f-ac46-a5694ece68b9">June&#160;30, 2021</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> </span></div><div style="padding-left:19.12pt;padding-right:19.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">OR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:19.12pt;padding-right:19.12pt;text-align:center"><span><br/></span></div><div style="padding-left:18pt;padding-right:38.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" format="ixt:booleanfalse" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xL2ZyYWc6YjFiNWJmMTFiZDY0NDRhYzhhODIxYmFmNWRlNjE4YzcvdGV4dHJlZ2lvbjpiMWI1YmYxMWJkNjQ0NGFjOGE4MjFiYWY1ZGU2MThjN18yMTY_14c57ab8-164d-4957-b102-21ae7d5498d3">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">For the transition period from</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">to</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">&#160;</span></div><div style="padding-left:38.25pt;padding-right:38.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Commission File Number:&#160;&#160;<ix:nonNumeric contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xL2ZyYWc6YjFiNWJmMTFiZDY0NDRhYzhhODIxYmFmNWRlNjE4YzcvdGV4dHJlZ2lvbjpiMWI1YmYxMWJkNjQ0NGFjOGE4MjFiYWY1ZGU2MThjN18zOTg_5109c998-9489-4f4f-a9a8-4d853e0c8ec4">001-37415</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">_________________________</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xL2ZyYWc6YjFiNWJmMTFiZDY0NDRhYzhhODIxYmFmNWRlNjE4YzcvdGV4dHJlZ2lvbjpiMWI1YmYxMWJkNjQ0NGFjOGE4MjFiYWY1ZGU2MThjN180Mjg_95ab76f0-929f-473c-a749-fc95867f66f4">Evolent Health, Inc.</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">_________________________</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:479.25pt"><tr><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:102.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:7.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:7.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:46.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:7.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:37.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:34.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:75.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:49.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xL2ZyYWc6YjFiNWJmMTFiZDY0NDRhYzhhODIxYmFmNWRlNjE4YzcvdGFibGU6ZDEwYzdkODZjMzJjNGZmNzk0ZjZlYTVlYTYxZGFmMjcvdGFibGVyYW5nZTpkMTBjN2Q4NmMzMmM0ZmY3OTRmNmVhNWVhNjFkYWYyN18wLTEtMS0xLTA_746226d7-9661-439b-9488-01172193bf56">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xL2ZyYWc6YjFiNWJmMTFiZDY0NDRhYzhhODIxYmFmNWRlNjE4YzcvdGFibGU6ZDEwYzdkODZjMzJjNGZmNzk0ZjZlYTVlYTYxZGFmMjcvdGFibGVyYW5nZTpkMTBjN2Q4NmMzMmM0ZmY3OTRmNmVhNWVhNjFkYWYyN18wLTktMS0xLTA_1223d95f-dda6-4bda-b355-025a214a4175">32-0454912</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(I.R.S. Employer<br/>Identification No.)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xL2ZyYWc6YjFiNWJmMTFiZDY0NDRhYzhhODIxYmFmNWRlNjE4YzcvdGFibGU6ZDEwYzdkODZjMzJjNGZmNzk0ZjZlYTVlYTYxZGFmMjcvdGFibGVyYW5nZTpkMTBjN2Q4NmMzMmM0ZmY3OTRmNmVhNWVhNjFkYWYyN18zLTEtMS0xLTA_f60c9464-03db-44ea-95e5-939ff23935fc">800 N. Glebe Road</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">,</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xL2ZyYWc6YjFiNWJmMTFiZDY0NDRhYzhhODIxYmFmNWRlNjE4YzcvdGFibGU6ZDEwYzdkODZjMzJjNGZmNzk0ZjZlYTVlYTYxZGFmMjcvdGFibGVyYW5nZTpkMTBjN2Q4NmMzMmM0ZmY3OTRmNmVhNWVhNjFkYWYyN18zLTMtMS0xLTA_5f7fe7b6-a2d3-4dd1-b6e8-c3a87f6fe2fa">Suite 500</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">,</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xL2ZyYWc6YjFiNWJmMTFiZDY0NDRhYzhhODIxYmFmNWRlNjE4YzcvdGFibGU6ZDEwYzdkODZjMzJjNGZmNzk0ZjZlYTVlYTYxZGFmMjcvdGFibGVyYW5nZTpkMTBjN2Q4NmMzMmM0ZmY3OTRmNmVhNWVhNjFkYWYyN18zLTUtMS0xLTA_461e5da7-a7eb-40f7-8ed6-f07cd6ab8f00">Arlington</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">,</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xL2ZyYWc6YjFiNWJmMTFiZDY0NDRhYzhhODIxYmFmNWRlNjE4YzcvdGFibGU6ZDEwYzdkODZjMzJjNGZmNzk0ZjZlYTVlYTYxZGFmMjcvdGFibGVyYW5nZTpkMTBjN2Q4NmMzMmM0ZmY3OTRmNmVhNWVhNjFkYWYyN18zLTctMS0xLTA_4c58263c-0e9c-4e07-a7bd-6fa0960641df">Virginia</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xL2ZyYWc6YjFiNWJmMTFiZDY0NDRhYzhhODIxYmFmNWRlNjE4YzcvdGFibGU6ZDEwYzdkODZjMzJjNGZmNzk0ZjZlYTVlYTYxZGFmMjcvdGFibGVyYW5nZTpkMTBjN2Q4NmMzMmM0ZmY3OTRmNmVhNWVhNjFkYWYyN18zLTktMS0xLTA_0f0d34e6-4b5e-4748-adb2-d50aec5a03cf">22203</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(Zip Code)</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;           </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">(<ix:nonNumeric contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xL2ZyYWc6YjFiNWJmMTFiZDY0NDRhYzhhODIxYmFmNWRlNjE4YzcvdGV4dHJlZ2lvbjpiMWI1YmYxMWJkNjQ0NGFjOGE4MjFiYWY1ZGU2MThjN181Mzg_d88e91ad-ca97-4c20-8ed1-f1b7efa0025d">571</ix:nonNumeric>) <ix:nonNumeric contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xL2ZyYWc6YjFiNWJmMTFiZDY0NDRhYzhhODIxYmFmNWRlNjE4YzcvdGV4dHJlZ2lvbjpiMWI1YmYxMWJkNjQ0NGFjOGE4MjFiYWY1ZGU2MThjN181NDI_6f390583-a794-4894-9e7c-be4995aad4d5">389-6000</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Registrant&#8217;s telephone number, including area code</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">_________________________</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:256.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:88.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:190.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr style="height:24pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xL2ZyYWc6YjFiNWJmMTFiZDY0NDRhYzhhODIxYmFmNWRlNjE4YzcvdGFibGU6YzVmZTlhNDc0MmJhNDZlYjg0YzJhMTI5YjY4ZjYxNmIvdGFibGVyYW5nZTpjNWZlOWE0NzQyYmE0NmViODRjMmExMjliNjhmNjE2Yl8xLTAtMS0xLTA_4371e398-ce39-4d47-9cf5-bccdb1e60492">Class A Common Stock of Evolent Health, Inc., par value $0.01 per share</ix:nonNumeric></span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xL2ZyYWc6YjFiNWJmMTFiZDY0NDRhYzhhODIxYmFmNWRlNjE4YzcvdGFibGU6YzVmZTlhNDc0MmJhNDZlYjg0YzJhMTI5YjY4ZjYxNmIvdGFibGVyYW5nZTpjNWZlOWE0NzQyYmE0NmViODRjMmExMjliNjhmNjE2Yl8xLTEtMS0xLTA_b0c030b2-50f1-4f49-a64b-4a713220d976">EVH</ix:nonNumeric></span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xL2ZyYWc6YjFiNWJmMTFiZDY0NDRhYzhhODIxYmFmNWRlNjE4YzcvdGFibGU6YzVmZTlhNDc0MmJhNDZlYjg0YzJhMTI5YjY4ZjYxNmIvdGFibGVyYW5nZTpjNWZlOWE0NzQyYmE0NmViODRjMmExMjliNjhmNjE2Yl8xLTItMS0xLTA_961102ce-c512-4bcd-8860-4bbbc01435dd">New York Stock Exchange</ix:nonNumeric></span></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  <ix:nonNumeric contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xL2ZyYWc6YjFiNWJmMTFiZDY0NDRhYzhhODIxYmFmNWRlNjE4YzcvdGV4dHJlZ2lvbjpiMWI1YmYxMWJkNjQ0NGFjOGE4MjFiYWY1ZGU2MThjN18xMDQ1_265ee563-f4ac-4680-9d2a-0a6e158443c0">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">  No &#9744;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  <ix:nonNumeric contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xL2ZyYWc6YjFiNWJmMTFiZDY0NDRhYzhhODIxYmFmNWRlNjE4YzcvdGV4dHJlZ2lvbjpiMWI1YmYxMWJkNjQ0NGFjOGE4MjFiYWY1ZGU2MThjN18xMzY3_969cb24c-ef65-4a7c-8c21-b660ac8ca5a4">Yes</ix:nonNumeric>  </span><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">  No  &#9744;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company.&#160;&#160;See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221;  &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xL2ZyYWc6YjFiNWJmMTFiZDY0NDRhYzhhODIxYmFmNWRlNjE4YzcvdGV4dHJlZ2lvbjpiMWI1YmYxMWJkNjQ0NGFjOGE4MjFiYWY1ZGU2MThjN18xNzM0_6a2f10eb-fb10-4d96-a8bc-f3b1f3029a04">Large accelerated filer</ix:nonNumeric>  </span><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">  Accelerated filer  &#9744;  Non-accelerated filer &#9744;  Smaller reporting company  </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xL2ZyYWc6YjFiNWJmMTFiZDY0NDRhYzhhODIxYmFmNWRlNjE4YzcvdGV4dHJlZ2lvbjpiMWI1YmYxMWJkNjQ0NGFjOGE4MjFiYWY1ZGU2MThjN18xODE1_f987a000-fb82-47a1-887b-c310963a842b">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company  </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xL2ZyYWc6YjFiNWJmMTFiZDY0NDRhYzhhODIxYmFmNWRlNjE4YzcvdGV4dHJlZ2lvbjpiMWI1YmYxMWJkNjQ0NGFjOGE4MjFiYWY1ZGU2MThjN18yMzE1_f71644f9-877a-40bd-9f45-09189370b9f9">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13 (a) of the Exchange Act.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;Yes </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" format="ixt-sec:boolballotbox" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xL2ZyYWc6YjFiNWJmMTFiZDY0NDRhYzhhODIxYmFmNWRlNjE4YzcvdGV4dHJlZ2lvbjpiMWI1YmYxMWJkNjQ0NGFjOGE4MjFiYWY1ZGU2MThjN18yMjIw_a1cb5717-c23b-4f79-963d-f7ce5f3a9f93">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> No&#160; </span><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">S</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As of August&#160;2, 2021, there were <ix:nonFraction unitRef="shares" contextRef="i428cb8fc8d2340adb52e77c530bb0227_I20210802" decimals="INF" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xL2ZyYWc6YjFiNWJmMTFiZDY0NDRhYzhhODIxYmFmNWRlNjE4YzcvdGV4dHJlZ2lvbjpiMWI1YmYxMWJkNjQ0NGFjOGE4MjFiYWY1ZGU2MThjN18yMjUx_d20be52a-2a72-4179-82c6-cc6acce6eb5a">87,267,772</ix:nonFraction> shares of the registrant&#8217;s Class A common stock outstanding.</span></div><div><span><br/></span></div><div style="height:18pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="id8f403494d0a42c2868794fb470218fc_10"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evolent Health, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Table of Contents</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.455%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.927%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.318%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Item</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Page</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#id8f403494d0a42c2868794fb470218fc_16">PART I</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id8f403494d0a42c2868794fb470218fc_19">1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id8f403494d0a42c2868794fb470218fc_19">Financial Statements (Unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id8f403494d0a42c2868794fb470218fc_19">1</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id8f403494d0a42c2868794fb470218fc_139">2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id8f403494d0a42c2868794fb470218fc_139">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id8f403494d0a42c2868794fb470218fc_139">40</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id8f403494d0a42c2868794fb470218fc_166">3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id8f403494d0a42c2868794fb470218fc_166">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id8f403494d0a42c2868794fb470218fc_166">59</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id8f403494d0a42c2868794fb470218fc_169">4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id8f403494d0a42c2868794fb470218fc_169">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id8f403494d0a42c2868794fb470218fc_169">60</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#id8f403494d0a42c2868794fb470218fc_172">PART II</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id8f403494d0a42c2868794fb470218fc_175">1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id8f403494d0a42c2868794fb470218fc_175">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id8f403494d0a42c2868794fb470218fc_175">61</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id8f403494d0a42c2868794fb470218fc_178">1A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id8f403494d0a42c2868794fb470218fc_178">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id8f403494d0a42c2868794fb470218fc_178">61</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id8f403494d0a42c2868794fb470218fc_199">2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id8f403494d0a42c2868794fb470218fc_199">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id8f403494d0a42c2868794fb470218fc_199">62</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id8f403494d0a42c2868794fb470218fc_202">3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id8f403494d0a42c2868794fb470218fc_202">Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id8f403494d0a42c2868794fb470218fc_202">62</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id8f403494d0a42c2868794fb470218fc_205">4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id8f403494d0a42c2868794fb470218fc_205">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id8f403494d0a42c2868794fb470218fc_205">62</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id8f403494d0a42c2868794fb470218fc_208">5.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id8f403494d0a42c2868794fb470218fc_208">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id8f403494d0a42c2868794fb470218fc_208">62</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id8f403494d0a42c2868794fb470218fc_211">6.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id8f403494d0a42c2868794fb470218fc_211">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id8f403494d0a42c2868794fb470218fc_211">63</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id8f403494d0a42c2868794fb470218fc_217">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id8f403494d0a42c2868794fb470218fc_217">64</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="id8f403494d0a42c2868794fb470218fc_13"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Explanatory Note</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In this Quarterly Report on Form 10-Q, unless the context otherwise requires, &#8220;Evolent,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;our&#8221; and &#8220;us&#8221; refer to Evolent Health, Inc. and its consolidated subsidiaries. Evolent Health LLC, a subsidiary of Evolent Health, Inc. through which we conduct our operations, has owned all of our operating assets and substantially all of our business since inception. Evolent Health, Inc. is a holding company and its principal asset is all of the Class A common units of Evolent Health LLC. </span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FORWARD-LOOKING STATEMENTS - CAUTIONARY LANGUAGE</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain statements made in this report and in other written or oral statements made by us or on our behalf are &#8220;forward-looking statements&#8221; within the meaning of the Private Securities Litigation Reform Act of 1995 (&#8220;PSLRA&#8221;).&#160;A forward-looking statement is a statement that is not a historical fact and, without limitation, includes any statement that may predict, forecast, indicate or imply future results, performance or achievements, and may contain words like:&#160;&#8220;believe,&#8221; &#8220;anticipate,&#8221; &#8220;expect,&#8221; &#8220;estimate,&#8221; &#8220;aim,&#8221; &#8220;predict,&#8221; &#8220;potential,&#8221; &#8220;continue,&#8221; &#8220;plan,&#8221; &#8220;project,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;shall,&#8221; &#8220;may,&#8221; &#8220;might&#8221; and other words or phrases with similar meaning in connection with a discussion of future operating or financial performance.&#160;In particular, these include statements relating to future actions, trends in our businesses, prospective services, future performance or financial results and the closing of pending transactions and the outcome of contingencies, such as legal proceedings.&#160;We claim the protection afforded by the safe harbor for forward-looking statements provided by the PSLRA.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These statements are only predictions based on our current expectations and projections about future events. Forward-looking statements involve risks and uncertainties that may cause actual results, level of activity, performance or achievements to differ materially from the results contained in the forward-looking statements.&#160;Risks and uncertainties that may cause actual results to vary materially, some of which are described within the forward-looking statements, include, among others:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the significant portion of revenue we derive from our largest partners, and the potential loss, non-renewal, termination or renegotiation of our relationship or contract with any significant partner, or multiple partners in the aggregate;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">evolution in the market for value-based care;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">uncertainty in the health care regulatory framework, including the potential impact of policy changes;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to offer new and innovative products and services;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">risks related to completed and future acquisitions, investments, alliances and joint ventures, including the acquisitions of Valence Health Inc., excluding Cicerone Health Solutions, Inc., Aldera Holdings, Inc., New Century Health, and Passport, which may be difficult to integrate, divert management resources, or result in unanticipated costs or dilute our stockholders;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the financial benefits we expect to receive as a result of the sale of certain assets of Passport may not be realized;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the growth and success of our partners, which is difficult to predict and is subject to factors outside of our control, including governmental funding reductions and other policy changes, enrollment numbers for our partners&#8217; plans, premium pricing reductions, selection bias in at-risk membership and the ability to control and, if necessary, reduce health care costs;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">risks relating to our ability to maintain profitability for our total cost of care and New Century Health&#8217;s performance-based contracts and products, including capitation and risk-bearing contracts;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to effectively manage our growth and maintain an efficient cost structure, and to successfully implement cost cutting measures;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the potential negative impact of the COVID-19 pandemic and other public health emergencies;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to recover the significant upfront costs in our partner relationships;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to attract new partners and successfully capture new growth opportunities;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the increasing number of risk-sharing arrangements we enter into with our partners;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to estimate the size of our target markets;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to maintain and enhance our reputation and brand recognition;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">consolidation in the health care industry;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">competition which could limit our ability to maintain or expand market share within our industry;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">risks related to governmental payer audits and actions, including whistleblower claims;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to partner with providers due to exclusivity provisions in our contracts;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">risks related to our offshore operations;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to contain health care costs, implement increases in premium rates on a timely basis, maintain adequate reserves for policy benefits or maintain cost effective provider agreements;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our dependency on our key personnel, and our ability to attract, hire, integrate and retain key personnel;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of additional goodwill and intangible asset impairments on our results of operations;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our indebtedness, our ability to service our indebtedness, and our ability to obtain additional financing;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to achieve profitability in the future;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of litigation, including the ongoing class action lawsuit;</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">material weaknesses in the future may impact our ability to conclude that our internal control over financial reporting is not effective and we may be unable to produce timely and accurate financial statements;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">restrictions and penalties as a result of privacy and data protection laws;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">data loss or corruption due to failures or errors in our systems and service disruptions at our data centers;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">restrictions and penalties as a result of privacy and data protection laws;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">adequate protection of our intellectual property, including trademarks;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any alleged infringement, misappropriation or violation of third-party proprietary rights;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our use of &#8220;open source&#8221; software;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to protect the confidentiality of our trade secrets, know-how and other proprietary information;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our reliance on third parties and licensed technologies;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to use, disclose, de-identify or license data and to integrate third-party technologies;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our reliance on Internet infrastructure, bandwidth providers, data center providers, other third parties and our own systems for providing services to our partners;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our reliance on third-party vendors to host and maintain our technology platform;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our obligations to make payments to certain of our pre-IPO investors for certain tax benefits we may claim in the future;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to utilize benefits under the tax receivables agreement described herein;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our obligations to make payments under the tax receivables agreement that may be accelerated or may exceed the tax benefits we realize;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the terms of agreements between us and certain of our pre-IPO investors;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the conditional conversion features of the 2024 and 2025 convertible notes, which, if triggered, could require us to settle the 2024 or 2025 convertible notes in cash;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of the accounting method for convertible debt securities that may be settled in cash;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the potential volatility of our Class A common stock price;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the potential impact of our securities class action litigation;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the potential decline of our Class A common stock price if a substantial number of shares are sold or become available for sale;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">provisions in our second amended and restated certificate of incorporation and third amended and restated by-laws and provisions of Delaware law that discourage or prevent strategic transactions, including a takeover of us;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ability of certain of our investors to compete with us without restrictions;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">provisions in our second amended and restated certificate of incorporation which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees; and</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our intention not to pay cash dividends on our Class A common stock.</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The risks included here are not exhaustive.&#160;Although we believe the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance or achievements.&#160;&#160;Our Annual Report on Form 10-K for the year ended December 31, 2020 (the "2020 Form 10-K"), subsequent Quarterly Reports on Form 10-Q and other documents filed with the SEC include additional factors that could affect our businesses and financial performance. Moreover, we operate in a rapidly changing and competitive environment.&#160;&#160;New risk factors emerge from time to time, and it is not possible for management to predict all such risk factors.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, it is not possible to assess the effect of all risk factors on our businesses or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements.&#160;Given these risks and uncertainties, investors should not place undue reliance on forward-looking statements as a prediction of actual results.&#160;In addition, we disclaim any obligation to update any forward-looking statements to reflect events or circumstances that occur after the date of this report.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii</span></div></div></div><div id="id8f403494d0a42c2868794fb470218fc_16"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I - FINANCIAL  INFORMATION</span></div><div><span><br/></span></div><div id="id8f403494d0a42c2868794fb470218fc_19"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1.  Financial Statements</span></div><div id="id8f403494d0a42c2868794fb470218fc_22"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EVOLENT HEALTH, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(unaudited, in thousands, except share data)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:358.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:72.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:99.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfMy0xLTEtMS0w_e3fbfd72-29d8-4e8d-8377-ac0c97eaa1ce">207,273</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45bff335c1434d6ba44132da1b0557db_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfMy0zLTEtMS0w_1c37ae26-7df7-469d-aa6b-440e54893afb">319,002</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash and restricted investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashAndInvestmentsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfNC0xLTEtMS0w_5e23ea41-ed9c-4e46-be76-57fdda507613">17,742</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45bff335c1434d6ba44132da1b0557db_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashAndInvestmentsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfNC0zLTEtMS0w_d562ec08-4b81-4e2d-8690-8f520fffd63a">14,374</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfNS0xLTEtMS0w_4ca84b48-7a2c-4c42-b349-4cc6f3d902a5">242,505</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45bff335c1434d6ba44132da1b0557db_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfNS0zLTEtMS0w_d66e2798-abe8-4ea9-a342-c46e07beedfa">124,064</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfNi0xLTEtMS0w_85c2778c-749c-4408-a8dd-d5ac7fcd6a11">38,032</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45bff335c1434d6ba44132da1b0557db_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfNi0zLTEtMS0w_126095e3-ba11-4518-b942-19d719b1d746">56,295</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets of discontinued operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfNy0xLTEtMS0w_2cd770da-5fc3-4e1b-b566-48491b1cacc1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45bff335c1434d6ba44132da1b0557db_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfNy0zLTEtMS0w_c2b20308-eb37-4485-ba3b-ee4fbf6b380d">33,914</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfOC0xLTEtMS0w_7dc6261a-5897-4efb-bb4a-c305b54f378e">505,552</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45bff335c1434d6ba44132da1b0557db_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfOC0zLTEtMS0w_4b45702d-9bcf-412d-8f7f-e38d20dbf343">547,649</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash and restricted investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashAndInvestmentsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfOS0xLTEtMS0w_c02961bf-2e9f-47b6-ac78-fccbb1a3d247">13,395</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45bff335c1434d6ba44132da1b0557db_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashAndInvestmentsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfOS0zLTEtMS0w_be5c8d69-6718-42e5-b73a-4761c990a8ca">6,654</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in and advances to equity method investees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfMTAtMS0xLTEtMA_68d97603-c1f3-47c7-a552-daf3c62874a9">9,788</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45bff335c1434d6ba44132da1b0557db_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfMTAtMy0xLTEtMA_c6dba07c-376a-4693-b75b-a4a4f9b5164c">6,498</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfMTEtMS0xLTEtMA_49f3242f-b0b6-483a-906f-558b2feba1aa">82,996</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45bff335c1434d6ba44132da1b0557db_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfMTEtMy0xLTEtMA_7a34380c-ba3a-4887-a7dd-3c119293c199">86,240</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets - operating</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfMTItMS0xLTEtMA_562e32bf-237b-4f3c-86e9-94bf399518fd">51,904</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45bff335c1434d6ba44132da1b0557db_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfMTItMy0xLTEtMA_07841ac5-b30a-4023-8546-b293dfcdbfd2">57,799</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other noncurrent assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfMTMtMS0xLTEtMA_34df675b-2a88-454e-91a0-f1e6eeee0b7a">6,311</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45bff335c1434d6ba44132da1b0557db_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfMTMtMy0xLTEtMA_0bd89b3b-2068-4bdc-b1ba-4a900b749388">5,773</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract cost assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CapitalizedContractCostNetNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfMTQtMS0xLTEtMA_df1e8317-c207-4b60-8a15-54608b93bbd5">22,367</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45bff335c1434d6ba44132da1b0557db_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CapitalizedContractCostNetNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfMTQtMy0xLTEtMA_8c310f40-0697-4cea-baf4-0642275c161c">26,687</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfMTUtMS0xLTEtMA_e4e084e0-cedf-487b-995a-129ad9c7aafb">252,045</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45bff335c1434d6ba44132da1b0557db_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfMTUtMy0xLTEtMA_ed249dc4-05e5-4224-9df0-a40bb4d2e014">264,992</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfMTYtMS0xLTEtMA_0dc7fa78-2a47-4c18-8ec8-396e7928c05f">349,009</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45bff335c1434d6ba44132da1b0557db_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfMTYtMy0xLTEtMA_08b61995-8301-4f3e-809e-1b3a18022fb7">349,029</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current assets of discontinued operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfMTctMS0xLTEtMA_e2256e6a-b3d3-408c-8bbf-9963988951b3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45bff335c1434d6ba44132da1b0557db_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfMTctMy0xLTEtMA_2c7d479b-4b6c-4f33-bb64-32f921fa2c95">20,379</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfMTgtMS0xLTEtMA_1f1b2ff3-1342-400f-9025-11041b905f5d">1,293,367</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45bff335c1434d6ba44132da1b0557db_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfMTgtMy0xLTEtMA_d92ee3f7-87f4-4da2-a6c4-82c03ff3e123">1,371,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES AND SHAREHOLDERS&#8217; EQUITY</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfMjItMS0xLTEtMA_1f10d8b5-1db8-4230-98e0-6ce7b5992df9">39,879</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45bff335c1434d6ba44132da1b0557db_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfMjItMy0xLTEtMA_c5e869a8-ed79-4a79-8e99-c692c6b54846">31,975</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfMjMtMS0xLTEtMA_5d00a01b-0f87-47ac-87ff-357987c3f073">52,339</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45bff335c1434d6ba44132da1b0557db_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfMjMtMy0xLTEtMA_2f78f8c5-c465-44cf-96b8-12f236568eab">73,242</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term debt, net of discount</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfMjQtMS0xLTEtMA_9a4fc620-9ea7-4bd5-9c12-671981ea7e32">26,655</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45bff335c1434d6ba44132da1b0557db_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfMjQtMy0xLTEtMA_94b65048-6eb5-4478-8363-3ea165e061b8">26,557</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liability - current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfMjUtMS0xLTEtMA_855a0b0d-bb0c-401d-b303-c0e702fa7527">7,265</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45bff335c1434d6ba44132da1b0557db_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfMjUtMy0xLTEtMA_68422452-7a2d-4826-b5d5-effaaff6470c">7,357</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and employee benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfMjYtMS0xLTEtMA_1da19af1-949d-400c-ab1c-4f0ef26d857a">25,852</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45bff335c1434d6ba44132da1b0557db_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfMjYtMy0xLTEtMA_83ccfed6-a510-4335-a3d5-395f14297550">47,163</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfMjctMS0xLTEtMA_1cd09721-4e41-46c2-b474-d6df5f8b22bf">13,173</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45bff335c1434d6ba44132da1b0557db_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfMjctMy0xLTEtMA_bfd2e771-0125-47c7-a309-8c37ebdb8b55">10,187</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve for claims and performance - based arrangements </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630" decimals="-3" format="ixt:numdotdecimal" name="evh:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfMjgtMS0xLTEtMA_b18bdc4b-8074-4572-9265-14e37f5cd14e">238,105</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45bff335c1434d6ba44132da1b0557db_I20201231" decimals="-3" format="ixt:numdotdecimal" name="evh:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfMjgtMy0xLTEtMA_a1ac98c6-5825-4d80-94f4-d279034abf6d">178,827</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities of discontinued operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfMjktMS0xLTEtMA_5041e621-29a1-457c-98a8-355f4cc2d57c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45bff335c1434d6ba44132da1b0557db_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfMjktMy0xLTEtMA_c576e438-00e7-4d5a-912d-c52ea4f53b5e">27,986</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfMzAtMS0xLTEtMA_a995a2d0-d1ef-4704-b11b-8ea7df55592b">403,268</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45bff335c1434d6ba44132da1b0557db_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfMzAtMy0xLTEtMA_a7362345-66b8-4ae5-a232-e72ac5857aa0">403,294</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, net of discount</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfMzEtMS0xLTEtMA_b7dfd9e3-1ab5-4fdf-93f6-bbf3cc4956f3">206,550</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45bff335c1434d6ba44132da1b0557db_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfMzEtMy0xLTEtMA_d6c2fa69-59c9-493f-a75a-9726e3ed9674">263,343</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfMzItMS0xLTEtMA_9fc9ebf0-77c3-4ca5-903d-6494fc0d750f">9,784</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45bff335c1434d6ba44132da1b0557db_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfMzItMy0xLTEtMA_3fd8ce08-3295-4c17-a1fa-43197f55f587">22,081</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities - noncurrent</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfMzMtMS0xLTEtMA_78b26908-b9a5-4dda-9eca-de44f4646f6f">58,618</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45bff335c1434d6ba44132da1b0557db_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfMzMtMy0xLTEtMA_824a9c31-c338-490c-baf4-6607b0808432">62,526</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfMzQtMS0xLTEtMA_b66ff2cc-b296-433d-85e4-a709c68a28bc">957</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45bff335c1434d6ba44132da1b0557db_I20201231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfMzQtMy0xLTEtMA_de376b52-3177-4738-b88b-675c48e3c3c8">679</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current liabilities from discontinued operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfMzUtMS0xLTEtMA_76487cce-418c-4016-94ca-d277ace013cf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45bff335c1434d6ba44132da1b0557db_I20201231" decimals="-3" name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfMzUtMy0xLTEtMA_3137d4f5-3f57-4801-9dd3-5e311e17c19f">177</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfMzYtMS0xLTEtMA_1c895d05-a8f4-4f18-811d-e1d70d2c7cf2">679,177</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45bff335c1434d6ba44132da1b0557db_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfMzYtMy0xLTEtMA_63bfc7e8-1d2a-4547-9e8e-d8bea9fbb8cc">752,100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Commitments and Contingencies (See Note 11)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfMzctMS0xLTEtMA_ab4d7788-6afc-4834-bf7d-8cd7049daed3"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i45bff335c1434d6ba44132da1b0557db_I20201231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfMzctMy0xLTEtMA_74cde5c5-5fc0-483c-b669-422077a0dbad"></ix:nonFraction></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shareholders' Equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Class A common stock - $<ix:nonFraction unitRef="usdPerShare" contextRef="i45bff335c1434d6ba44132da1b0557db_I20201231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfMzktMC0xLTEtMC90ZXh0cmVnaW9uOjdmZTEyZDE2NjE5MDQ3ODViZmZjZTI1OTU2OTEzY2FkXzI3_083cb183-8f41-4036-9433-6dfb6e620ac2"><ix:nonFraction unitRef="usdPerShare" contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfMzktMC0xLTEtMC90ZXh0cmVnaW9uOjdmZTEyZDE2NjE5MDQ3ODViZmZjZTI1OTU2OTEzY2FkXzI3_8ce04cd9-0495-44ad-934a-e57c67bd1b24">0.01</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i45bff335c1434d6ba44132da1b0557db_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfMzktMC0xLTEtMC90ZXh0cmVnaW9uOjdmZTEyZDE2NjE5MDQ3ODViZmZjZTI1OTU2OTEzY2FkXzQx_0a2efa4b-0099-4a57-ba78-0ebb41f71095"><ix:nonFraction unitRef="shares" contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfMzktMC0xLTEtMC90ZXh0cmVnaW9uOjdmZTEyZDE2NjE5MDQ3ODViZmZjZTI1OTU2OTEzY2FkXzQx_34c67535-fb92-4c15-8ba5-9d71bc5e6e88">750,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfMzktMC0xLTEtMC90ZXh0cmVnaW9uOjdmZTEyZDE2NjE5MDQ3ODViZmZjZTI1OTU2OTEzY2FkXzY0_a5f19fa2-6a75-4139-9081-cc9bdd9ab851">87,195,128</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i45bff335c1434d6ba44132da1b0557db_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfMzktMC0xLTEtMC90ZXh0cmVnaW9uOjdmZTEyZDE2NjE5MDQ3ODViZmZjZTI1OTU2OTEzY2FkXzcx_80ed9cda-9311-436d-98e1-d63e871d1060">85,894,450</ix:nonFraction> shares issued, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc9702daaf8a42a6b738e99ae2cf6328_I20210630" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfMzktMS0xLTEtMA_8c5a81f6-7997-461a-86ec-3cb109ec104d">872</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5afa72f271884055860c7e9a53ef18b2_I20201231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfMzktMy0xLTEtMA_04dfcd68-adb5-4c82-8cd5-284a8feefa5a">859</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in-capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfNDAtMS0xLTEtMA_0ead8e33-ba8a-49a1-b321-cd2ad333022d">1,242,900</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45bff335c1434d6ba44132da1b0557db_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfNDAtMy0xLTEtMA_8e1b2831-e0d9-42c5-a1a5-1bc6eaf45d0e">1,229,320</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfNDEtMS0xLTEtMA_e0d9eae8-c174-4723-ac4a-593a4d170937">367</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i45bff335c1434d6ba44132da1b0557db_I20201231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfNDEtMy0xLTEtMA_fec9fcd4-90d9-429e-8dc9-ad3407d9aa3d">278</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retained earnings (accumulated deficit)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfNDItMS0xLTEtMA_6faed371-ce14-41d4-bf9b-408ae2d068c6">608,092</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i45bff335c1434d6ba44132da1b0557db_I20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfNDItMy0xLTEtMA_ab74ea78-1474-4f5b-8903-13bd3e7371c3">589,178</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury stock, at cost; <ix:nonFraction unitRef="shares" contextRef="i45bff335c1434d6ba44132da1b0557db_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfNDMtMC0xLTEtMC90ZXh0cmVnaW9uOjcxM2Q5ODQ2ODc5MDQ2NjRiY2ZiZTU3ZDY5YmNkYzc1XzI5_49f46f72-0336-4862-9ecb-e504f1d2c08c"><ix:nonFraction unitRef="shares" contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfNDMtMC0xLTEtMC90ZXh0cmVnaW9uOjcxM2Q5ODQ2ODc5MDQ2NjRiY2ZiZTU3ZDY5YmNkYzc1XzI5_d9c99244-7b7f-4447-9ac2-ca6dc82517da">1,537,582</ix:nonFraction></ix:nonFraction> shares issued, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfNDMtMS0xLTEtMA_83102857-7cd3-4d10-a106-8a6e60346c09">21,123</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i45bff335c1434d6ba44132da1b0557db_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfNDMtMy0xLTEtMA_21f1acf4-4b69-403e-a541-bd4f88668f69">21,123</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total shareholders' equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfNDQtMS0xLTEtMA_8532c16a-cef9-4e48-bb32-038e1c8b214c">614,190</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45bff335c1434d6ba44132da1b0557db_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfNDQtMy0xLTEtMA_43029e9c-7773-47f7-8cae-9ec25a183479">619,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and shareholders' equity</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfNDUtMS0xLTEtMA_66f7e935-9e0b-44b0-99de-9a048955a373">1,293,367</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45bff335c1434d6ba44132da1b0557db_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfNDUtMy0xLTEtMA_6d0a0197-340a-43fa-bbd8-cd3e17665488">1,371,700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> <ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RleHRyZWdpb246NmEwNWU3MWI1N2ZmNDBmNDkwMzUyMDE0YzNhZjNmNTZfMjA1_14702e91-5902-4688-9db4-81a13b43b8a2" footnoteRole="http://www.xbrl.org/2003/role/footnote">See Note 19 for amounts attributable to unconsolidated related parties included in these line items.</ix:footnote></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="id8f403494d0a42c2868794fb470218fc_25"></div><hr style="page-break-after:always"/><div style="min-height:18pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EVOLENT HEALTH, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <br/>(unaudited, in thousands, except per share data)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:301.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:55.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:55.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:55.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:55.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transformation services </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b3321915fe444e488ceef708a6e59c9_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMy0xLTEtMS02NA_4ddfd893-22a5-4d76-b130-01774ab09be5">2,564</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78e15c27cd3e401ea6bd6fd305abeb34_D20200401-20200630" decimals="-3" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMy0zLTEtMS02NA_8a291b24-c574-452f-939f-4ed838ba9580">755</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cf8298bd37b49539b40ff277f78e799_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMy0xLTEtMS0w_170ba868-793c-4ffe-bebd-eb61ff904fd1">2,909</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia98a39c8ecac46f5b530749d9b554995_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMy0zLTEtMS0w_033da13e-7a60-4e5b-86d1-46b783ef6f62">5,993</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Platform and operations services </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie90c815774924e1e802eb6f3123f1004_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfNC0xLTEtMS02NA_1646c669-412d-40be-a8bf-033270592308">219,493</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd99be6d27564d4cb75996e8ce5dce17_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfNC0zLTEtMS02NA_50789944-5571-4917-817b-931e2e3b29ad">216,544</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf5036ffdbc24ee8a477412be1612a0c_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfNC0xLTEtMS0w_4912914f-f7bf-4db0-8743-46164a2ce1b1">434,219</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf7fe803335d432ba4201dde52789d25_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfNC0zLTEtMS0w_641872ca-97f5-472a-b032-425fcb904fd3">432,538</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfNS0xLTEtMS02Nw_e56fbcd9-0449-4238-add8-44ca440fd47e">222,057</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfNS0zLTEtMS02Nw_09bd88e2-baf2-4546-90c9-9b6deb926054">217,299</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfNS0xLTEtMS0w_c78ab51f-dc57-4619-93b0-36b1483352c4">437,128</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfNS0zLTEtMS0w_d8150dac-4e10-46f7-937d-b2b0c07adbab">438,531</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenue (exclusive of depreciation and amortization expenses presented separately below)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="evh:CostofGoodsandServicesSoldExcludingDepreciationandAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfOC0xLTEtMS04Nw_1bc0b1dc-fe01-4de7-ba41-3ecef7ac0a30">172,113</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="evh:CostofGoodsandServicesSoldExcludingDepreciationandAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfOC0zLTEtMS04Nw_42941013-db98-4377-a51b-f4d23a542da8">164,358</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="evh:CostofGoodsandServicesSoldExcludingDepreciationandAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfOC0xLTEtMS0w_bcd4f6f2-84b7-4b1d-9d32-1a5da0be3e1e">329,945</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="evh:CostofGoodsandServicesSoldExcludingDepreciationandAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfOC0zLTEtMS0w_a7c391ca-74f2-406d-8845-5e85413ef517">339,987</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfOS0xLTEtMS05MA_035cf8ca-b3a4-4fa4-878b-6900e1908669">42,699</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfOS0zLTEtMS05MA_63fd3a46-1ce7-4e9e-afc2-84df19c21d43">47,296</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfOS0xLTEtMS0w_2913840b-6e6e-4c12-a70f-0383ffa3f270">101,290</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfOS0zLTEtMS0w_b14e9482-2674-4e3e-92ef-34edd76c896f">99,383</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMTAtMS0xLTEtOTA_51ebaf8d-58b9-4402-98a5-55882b26bfa5">14,916</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMTAtMy0xLTEtOTA_711e58dd-b3bf-4ce9-8356-febd5bd7e040">15,618</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMTAtMS0xLTEtMA_b89dfc9c-133e-4bc3-9fb0-18a0854848a9">30,103</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMTAtMy0xLTEtMA_cd4b9e49-da85-488a-ab87-c2a23a448d20">31,596</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on disposal of assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:GainLossOnDispositionOfAssets1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMTEtMS0xLTEtOTA_e0c52d50-e3a3-4512-b2e4-0b2e2ac92924">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:GainLossOnDispositionOfAssets1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMTEtMy0xLTEtOTA_131bc957-5705-4170-9460-8fbf575defa1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:GainLossOnDispositionOfAssets1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMTEtMS0xLTEtMA_41398074-199c-4312-8868-086ffc38fdf8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:GainLossOnDispositionOfAssets1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMTEtMy0xLTEtMA_26401d32-d093-49f3-806e-d549521a6e3f">6,447</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill impairment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:GoodwillImpairmentLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMTItMS0xLTEtMzU1MQ_f32dfc03-629b-45c5-8e3d-48cc179e32dc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GoodwillImpairmentLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMTItMy0xLTEtMzU1MQ_da5b8871-14a8-4074-9e69-eb2319b7e052">215,100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:GoodwillImpairmentLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMTItNS0xLTEtMzU1MQ_3970a762-5d46-42d9-8839-1e16c4304fda">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GoodwillImpairmentLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMTItNy0xLTEtMzU1MQ_385f35af-24c1-405c-96d2-39a32c53edd4">215,100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration and indemnification asset</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMTItMS0xLTEtOTM_215eb6b6-3248-48a8-a981-de622fa02e48">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMTItMy0xLTEtOTM_177db836-2be7-4ed7-8e29-c0207331895e">756</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMTItMS0xLTEtMA_967c9930-b164-4527-ac86-a7d66efb0c2d">594</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMTItMy0xLTEtMA_f81be485-c650-445e-b76e-f9b32cb95f94">3,062</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMTMtMS0xLTEtOTM_0cda2728-92ce-457e-90f3-2b8e40675396">229,728</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMTMtMy0xLTEtOTM_289326b3-6203-4a67-8852-6fe6f52cb3a8">443,128</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMTMtMS0xLTEtMA_ef0d5320-54f1-4911-b4f9-ba3433126052">460,744</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMTMtMy0xLTEtMA_3638373c-562f-4a7c-bdf0-f828e93ffc0b">689,451</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating loss</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMTQtMS0xLTEtOTM_a4a2ba00-a042-429d-bc97-ddd052de4e4c">7,671</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMTQtMy0xLTEtOTM_13c2dc1e-1a5e-4a3c-81f1-4958e709bf9b">225,829</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMTQtMS0xLTEtMA_6f64c5bc-c1c4-4f60-b90e-eb9b03eba2c5">23,616</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMTQtMy0xLTEtMA_370e5a21-eb8d-47ce-94c8-a36156df43c4">250,920</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMTUtMS0xLTEtOTc_163a4d38-74de-4cd9-a96b-712b37840fa1">68</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMTUtMy0xLTEtOTc_8b77ae30-490d-41bd-a1ad-cfd12e4ed830">705</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMTUtMS0xLTEtMA_83816d22-b67f-42bc-a14d-da7e4c5fc61c">191</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMTUtMy0xLTEtMA_287cc6db-5a69-4a02-b7e0-abc163843895">1,475</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMTYtMS0xLTEtOTc_11cc8d20-a0c9-4bc6-909e-2381fc933d5b">6,274</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMTYtMy0xLTEtOTc_6aa74fa0-94c8-413e-ba22-b441bde9cde7">6,290</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMTYtMS0xLTEtMA_0f5794e1-5476-475f-9319-40ba8fe48852">12,611</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMTYtMy0xLTEtMA_5fb34376-158e-4edf-980a-3aaca82d2ec6">12,571</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of equity method investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMTctMS0xLTEtOTc_d26c2f6d-80f1-448a-b11a-adcafc85f05e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMTctMy0xLTEtOTc_bd0af72e-4b6e-40d0-aaea-4909529ed7a2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMTctMS0xLTEtMA_06a6b585-2ed9-48b1-9439-720ebcdcf8ba">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMTctMy0xLTEtMA_03e4b414-3d33-4476-a9bd-7a2334ff1d32">47,133</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain from equity method investees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMTgtMS0xLTEtMTAw_a309bdfb-fd5b-48c0-b00f-3b00ebbb5647">4,879</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMTgtMy0xLTEtMTAw_5d71ca1e-34b5-416e-923b-dedb02c62b98">25,143</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMTgtMS0xLTEtMA_91816d87-67d5-49e9-bae2-c9d0a14c901c">12,662</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMTgtMy0xLTEtMA_ee06d9ff-1df7-4217-9324-d60d16992207">24,731</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on transfer of membership</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630" decimals="-3" format="ixt:zerodash" name="evh:GainOnTransferOfMembership" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMTktMS0xLTEtMTAz_55dc2831-29b7-4b4b-80bc-3889bb110c63">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630" decimals="-3" format="ixt:zerodash" name="evh:GainOnTransferOfMembership" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMTktMy0xLTEtMTAz_ea8e6d24-6828-40de-bc68-44c98b363708">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="evh:GainOnTransferOfMembership" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMTktMS0xLTEtMA_f2c7b3b0-04fd-4481-be68-123f4af88470">22,969</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="evh:GainOnTransferOfMembership" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMTktMy0xLTEtMA_b48bb13d-b69d-444b-94f4-99243502b599">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on repayment of debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMjAtMS0xLTEtMTA2_edc9c9cf-ae79-4619-bf15-aaecedd1a34b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMjAtMy0xLTEtMTA2_46930a50-7971-43d0-bb83-c8bf95e98c52">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMjAtMS0xLTEtMA_e87c8e89-275c-4582-8c29-0a0a99e7f386">19,158</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMjAtMy0xLTEtMA_38f20b0d-bbe4-44aa-89fb-4ea49eb451b6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMjEtMS0xLTEtMTA2_4f61e22f-ae45-44cd-9e7f-6a885da3bd78">18</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630" decimals="-3" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMjEtMy0xLTEtMTA2_06ecb6fb-7923-4555-954d-8267b9344861">354</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMjEtMS0xLTEtMA_9ae8dcdb-8ad5-42e0-b888-42c3c10a97ce">32</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="-3" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMjEtMy0xLTEtMA_592efb36-e4b6-4cc8-8b4a-76c9d8d30c78">284</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from continuing operations before income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMjItMS0xLTEtMTA2_4f956374-9e4a-4bc8-a679-22493f47aad9">9,016</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMjItMy0xLTEtMTA2_00f124ad-18b5-47bf-afee-e23a5f1b06df">205,917</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMjItMS0xLTEtMA_48454bb2-08b2-43ed-b4bd-00a22bbbff0f">19,595</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMjItMy0xLTEtMA_16cdbc84-bb0f-42f1-89ee-ee42ebdbc723">284,134</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision (benefit) for income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMjMtMS0xLTEtMTA2_cf22680b-4d17-4e8c-a258-22e220e34968">91</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMjMtMy0xLTEtMTA2_3e52d0a4-b836-4413-ba3b-5dad5cba4b2d">3,904</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMjMtMS0xLTEtMA_e194d371-a3e9-46b3-bed1-380442f9a616">702</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMjMtMy0xLTEtMA_d9472852-fc37-4316-a995-f52074b457e4">3,634</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from continuing operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMjQtMS0xLTEtMTA2_a030db38-41f2-4034-bb47-c1ea177a3f12">9,107</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMjQtMy0xLTEtMTA2_dd96325a-3f6a-4064-8bfc-1c8d6a0ccf87">202,013</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMjQtMS0xLTEtMA_228846d4-483a-4bd6-9c29-0517d59f1ace">20,297</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMjQtMy0xLTEtMA_1259824e-746f-44ea-a83e-f1b50f0b3e55">280,500</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from discontinued operations, net of tax </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMjUtMS0xLTEtMTEw_1cdad334-f519-48e7-a442-e006607bfd0d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMjUtMy0xLTEtMTEw_23a653a3-53f9-4fa2-825a-b0238aa1e1bc">1,508</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMjUtMS0xLTEtMA_c5ecddec-ea61-49d7-9ee4-4bc37ada6314">1,383</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMjUtMy0xLTEtMA_e40e5aa3-d436-463d-ae79-d4a972b39319">1,773</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMjYtMS0xLTEtMTEw_224dac42-b7ca-448a-8c6c-19553d6e70ed">9,107</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMjYtMy0xLTEtMTEw_24819732-0f1d-4a88-b203-8430f2e00104">203,521</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMjYtMS0xLTEtMA_3c6b9c11-4052-4bf7-86e1-89b8e6f56107">18,914</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMjYtMy0xLTEtMA_6133f0dd-e1f4-4ff4-96e9-42a93c1f62a1">282,273</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to non-controlling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMjctMS0xLTEtMTEw_588b0315-6ec7-4ba0-8c57-c489dff9bf4a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMjctMy0xLTEtMTEw_91d2f40b-af1d-403c-ae75-b09607128928">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMjctMS0xLTEtMA_6ebde5ba-b5bf-4879-a8ed-55bc8a2cf8f7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMjctMy0xLTEtMA_487ffa05-a8ca-4c89-8418-c5324a371639">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to common shareholders of Evolent Health, Inc.</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMjgtMS0xLTEtMTEw_09330fbb-f85e-46d5-b7ba-0c4c55c92dcd"><ix:nonFraction unitRef="usd" contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMjgtMS0xLTEtMTEw_f334614f-48c8-4335-8644-08d1c094b533">9,107</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMjgtMy0xLTEtMTEw_1f1b826f-81ea-4a16-8e51-b233cb6cb5d8"><ix:nonFraction unitRef="usd" contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMjgtMy0xLTEtMTEw_464f9ea4-79d0-46fe-b7e0-3bfbaef12c35">203,521</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMjgtMS0xLTEtMA_3f65effd-5c00-48e2-b9f0-61aa1fc1e88c"><ix:nonFraction unitRef="usd" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMjgtMS0xLTEtMA_7051b8a1-9469-4d3d-b02f-b619b054437f">18,914</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMjgtMy0xLTEtMA_0841956d-a0c8-4eca-a9f7-99ceb502bb32"><ix:nonFraction unitRef="usd" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMjgtMy0xLTEtMA_d981f43f-4d1f-4440-8d13-5cf7db63d994">282,273</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss per common share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMzItMS0xLTEtMTI2_9b468376-3abb-4b91-b544-45598236cd35"><ix:nonFraction unitRef="usdPerShare" contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMzItMS0xLTEtMTI2_a57eda48-bbd8-4cd1-9c68-3604f50ce2cf">0.11</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMzItMy0xLTEtMTI2_852b9a3c-a463-48e0-8977-f56a22c2b011"><ix:nonFraction unitRef="usdPerShare" contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMzItMy0xLTEtMTI2_9ef447ed-dde3-4a30-8002-79abb76cde61">2.37</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMzItMS0xLTEtMA_aea6d686-ea84-421d-bccd-c58e29e2aaab"><ix:nonFraction unitRef="usdPerShare" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMzItMS0xLTEtMA_ea47c458-12d3-4812-ac4e-259bd09fec29">0.24</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMzItMy0xLTEtMA_6f9f8394-7bd7-4271-8132-915268925c9a"><ix:nonFraction unitRef="usdPerShare" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMzItMy0xLTEtMA_dc90bf72-8a65-4da4-9bf9-d7c52b845d76">3.30</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630" decimals="2" format="ixt:zerodash" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMzMtMS0xLTEtMTI2_891023c2-8f2f-4aac-b882-a0c38556e0ee"><ix:nonFraction unitRef="usdPerShare" contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630" decimals="2" format="ixt:zerodash" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMzMtMS0xLTEtMTI2_aff981ea-ee53-455d-9f65-8e9eed3782e5">&#8212;</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630" decimals="2" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMzMtMy0xLTEtMTI2_1c38e201-a69b-4d9d-9544-48059e596cdd"><ix:nonFraction unitRef="usdPerShare" contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630" decimals="2" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMzMtMy0xLTEtMTI2_5aba3028-f0bb-4816-831a-d14e599f86d6">0.01</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMzMtMS0xLTEtMA_79fdbf08-c988-4fe5-8cc6-c90de5b2ae49"><ix:nonFraction unitRef="usdPerShare" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMzMtMS0xLTEtMA_a4377843-e7a2-4873-91ba-9152526441b0">0.02</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="2" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMzMtMy0xLTEtMA_0d6b51ea-d7ab-4d37-abae-c32d154ecc1c"><ix:nonFraction unitRef="usdPerShare" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="2" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMzMtMy0xLTEtMA_800c73c2-b879-48d8-a85e-64407c8de0bb">0.02</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted loss per share attributable to common shareholders of Evolent Health, Inc.</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMzUtMS0xLTEtMzY5OQ_289fe6d2-509d-4929-bc0d-716bc06e55f4"><ix:nonFraction unitRef="usdPerShare" contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMzUtMS0xLTEtMzY5OQ_a1d75a1c-6e8f-4a55-a8ba-fdf4ca86b37a"><ix:nonFraction unitRef="usdPerShare" contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMzUtMS0xLTEtMzY5OQ_a93fda02-45cf-44f3-9452-c41930c85b70"><ix:nonFraction unitRef="usdPerShare" contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMzUtMS0xLTEtMzY5OQ_d77c4081-1564-4e19-97f4-f86af17bdcc8">0.11</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMzQtMy0xLTEtMTMw_578191b1-a62d-463e-be7e-11ef55341fed"><ix:nonFraction unitRef="usdPerShare" contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMzQtMy0xLTEtMTMw_b15e7f6a-89e7-46a5-9171-d647d7fdc69c">2.38</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMzQtMS0xLTEtMA_4475b23a-7973-4d2f-8051-0da9faf1300e"><ix:nonFraction unitRef="usdPerShare" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMzQtMS0xLTEtMA_a0729353-7687-45b1-b4a0-fd57a8065aa6">0.22</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMzQtMy0xLTEtMA_9073a702-ff65-429f-b0fa-bd0027da3413"><ix:nonFraction unitRef="usdPerShare" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMzQtMy0xLTEtMA_aa85be71-08a7-444f-9d13-8b6e26540e81">3.32</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-average common shares outstanding</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMzctMS0xLTEtMTMz_615bafb3-bdfe-4b63-9036-b3537a8d3d5f"><ix:nonFraction unitRef="shares" contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMzctMS0xLTEtMTMz_e018bb7d-cfe1-4e15-983f-63502f8c7917">85,448</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMzctMy0xLTEtMTMz_1ad6606b-0da7-4d3d-b6a8-e5367eea0c7a"><ix:nonFraction unitRef="shares" contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMzctMy0xLTEtMTMz_e0eb1f1b-2f64-4b89-bf40-a7b7ee576f84">85,349</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMzctMS0xLTEtMA_4242e7a7-f111-40b8-a6cb-ff0b458cb1a5"><ix:nonFraction unitRef="shares" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMzctMS0xLTEtMA_75f40ade-b15d-4533-9a0c-5990c566b25e">85,056</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMzctMy0xLTEtMA_456e1a38-89a7-499c-bb0c-bdb8fabe2538"><ix:nonFraction unitRef="shares" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMzctMy0xLTEtMA_a4062fd1-4700-4596-ac02-4d51b453a84d">84,977</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Comprehensive loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfNDAtMS0xLTEtMTE1_e1a9ccc8-cee3-42bf-b57a-f632ad874bca">9,107</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfNDAtMy0xLTEtMTE1_1bad5c66-7281-436c-b0aa-04559d72306a">203,521</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfNDAtMS0xLTEtMA_62153268-308b-4e8c-8a87-75b9badacb6c">18,914</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfNDAtMy0xLTEtMA_762d1169-3865-4e47-a5b2-7944ff6a53e6">282,273</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss, net of taxes, related to:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfNDItMS0xLTEtMTE1_a744e1e5-d8cb-4d8a-91fc-e02049bd1f07">58</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfNDItMy0xLTEtMTE1_3c2f41b3-05a4-4ab2-bf1d-9feb2d63b200">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfNDItMS0xLTEtMA_684b5e93-e46a-483a-88a2-c32fdffe6bc7">89</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfNDItMy0xLTEtMA_f914b09f-2d2c-495b-b6dd-026262496a50">157</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfNDMtMS0xLTEtMTE1_c2635787-e0d9-4b51-8967-ce177f25fa3f">9,165</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfNDMtMy0xLTEtMTE1_cc7018d6-f0b0-4812-904b-de8334952519">203,525</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfNDMtMS0xLTEtMA_0224b927-4b1e-4d40-9445-0e8a8c580c2b">19,003</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfNDMtMy0xLTEtMA_92541769-bb62-4ac2-881a-629d17f58871">282,430</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total comprehensive loss attributable to non-controlling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfNDQtMS0xLTEtMTE1_d950645d-7854-4c8a-9d6a-20f2d369fe54">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfNDQtMy0xLTEtMTE1_ae945b71-8ae1-4572-b3b6-3e61a7b66140">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfNDQtMS0xLTEtMA_a10cdb2a-b65f-46ae-8839-220d905ac254">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfNDQtMy0xLTEtMA_05016b15-60f0-49e0-ad80-a757b724a0f3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total comprehensive loss attributable to common shareholders of Evolent Health, Inc.</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfNDUtMS0xLTEtMTE1_e70ec069-0cb2-4591-b381-ef388e9502cd">9,165</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfNDUtMy0xLTEtMTE1_1b69d3a5-e954-4844-a7b1-2d7a32f4b9a8">203,525</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfNDUtMS0xLTEtMA_10de1723-669d-4bbd-9346-12dbc42e6e44">19,003</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfNDUtMy0xLTEtMA_357c37aa-4f28-487e-84fe-caf517250e29">282,430</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RleHRyZWdpb246OGQwNTJjMDNmNGQ3NGQ4Y2I5YjAzOWU0YjQ4NjVjMDVfMzYx_567718ea-66eb-4aaf-8694-a0a35e05203a" footnoteRole="http://www.xbrl.org/2003/role/footnote">See Note 19 for amounts attributable to unconsolidated related parties included in these line items.</ix:footnote></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RleHRyZWdpb246OGQwNTJjMDNmNGQ3NGQ4Y2I5YjAzOWU0YjQ4NjVjMDVfMzU5_b7e01e4f-d0ca-407e-8cef-928f5bacc225" footnoteRole="http://www.xbrl.org/2003/role/footnote">Includes $<ix:nonFraction unitRef="usd" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RleHRyZWdpb246OGQwNTJjMDNmNGQ3NGQ4Y2I5YjAzOWU0YjQ4NjVjMDVfMjcx_21f819b6-f612-4a34-a7c9-911830c65d53">1.9</ix:nonFraction>&#160;million gain on disposal of discontinued operations for the six months ended June 30, 2021</ix:footnote>.</span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">See accompanying Notes to Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="id8f403494d0a42c2868794fb470218fc_31"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> EVOLENT HEALTH, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS&#8217; EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(unaudited, in thousands)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:756.00pt"><tr><td style="width:1.0pt"></td><td style="width:260.50pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:41.50pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:3.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:34.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:3.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:41.50pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:54.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:51.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:3.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:43.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:3.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:84.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:3.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:45.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:3.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:41.50pt"></td><td style="width:1.0pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="51" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30, 2021</span></td></tr><tr style="height:27pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Class A Common Stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional Paid-In Capital</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Other Income (Loss)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retained Earnings (Accumulated Deficit)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Treasury Stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Shareholders' Equity<br/>Attributable to<br/>Evolent Health, Inc.</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-Controlling Interests</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Equity</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance as of March 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id4ee77e0637d4c079ba08f5a8d50896f_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmNiYzhiZjFjMTUzZTRhOWI4ZDI5MjRlYTU5OTBkOWUwL3RhYmxlcmFuZ2U6Y2JjOGJmMWMxNTNlNGE5YjhkMjkyNGVhNTk5MGQ5ZTBfMy0xLTEtMS0w_9515aebc-d97a-4476-958a-8aedfdb31673">86,779</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4ee77e0637d4c079ba08f5a8d50896f_I20210331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmNiYzhiZjFjMTUzZTRhOWI4ZDI5MjRlYTU5OTBkOWUwL3RhYmxlcmFuZ2U6Y2JjOGJmMWMxNTNlNGE5YjhkMjkyNGVhNTk5MGQ5ZTBfMy0zLTEtMS0w_fd42a95a-80d4-4969-a3d9-1805e2f06412">868</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf456296380c4d43be18dd320f38d79e_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmNiYzhiZjFjMTUzZTRhOWI4ZDI5MjRlYTU5OTBkOWUwL3RhYmxlcmFuZ2U6Y2JjOGJmMWMxNTNlNGE5YjhkMjkyNGVhNTk5MGQ5ZTBfMy01LTEtMS0w_5e31f24f-be26-4671-bc28-f23be9c6e938">1,236,847</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7e5ec0e87ee5433f83b9321c8e851948_I20210331" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmNiYzhiZjFjMTUzZTRhOWI4ZDI5MjRlYTU5OTBkOWUwL3RhYmxlcmFuZ2U6Y2JjOGJmMWMxNTNlNGE5YjhkMjkyNGVhNTk5MGQ5ZTBfMy03LTEtMS0w_283a5b2a-353c-445d-8661-26b0f6ee5252">309</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5780af7ffb314efcb610ffbfde88f991_I20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmNiYzhiZjFjMTUzZTRhOWI4ZDI5MjRlYTU5OTBkOWUwL3RhYmxlcmFuZ2U6Y2JjOGJmMWMxNTNlNGE5YjhkMjkyNGVhNTk5MGQ5ZTBfMy05LTEtMS0w_919cb345-7d1f-4c3c-8802-6357e7620b89">598,985</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb6c27b0e33045ad94dd37a21c51bcc5_I20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmNiYzhiZjFjMTUzZTRhOWI4ZDI5MjRlYTU5OTBkOWUwL3RhYmxlcmFuZ2U6Y2JjOGJmMWMxNTNlNGE5YjhkMjkyNGVhNTk5MGQ5ZTBfMy0xMS0xLTEtMA_057cb48a-9a2b-4196-8fb8-d4993166a3a1">21,123</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib32c349f6c584bddbe73d86161c5920b_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmNiYzhiZjFjMTUzZTRhOWI4ZDI5MjRlYTU5OTBkOWUwL3RhYmxlcmFuZ2U6Y2JjOGJmMWMxNTNlNGE5YjhkMjkyNGVhNTk5MGQ5ZTBfMy0xMy0xLTEtMA_6cb3da3f-b022-4ab7-a311-0f3f4721bd5f">617,298</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f47fa7f09154d2791eda91f900b167d_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmNiYzhiZjFjMTUzZTRhOWI4ZDI5MjRlYTU5OTBkOWUwL3RhYmxlcmFuZ2U6Y2JjOGJmMWMxNTNlNGE5YjhkMjkyNGVhNTk5MGQ5ZTBfMy0xNy0xLTEtMA_458a464f-e34e-4185-8582-eb2e40fffbc7">617,298</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i455847ec36714e5290ad661b3a22ace7_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmNiYzhiZjFjMTUzZTRhOWI4ZDI5MjRlYTU5OTBkOWUwL3RhYmxlcmFuZ2U6Y2JjOGJmMWMxNTNlNGE5YjhkMjkyNGVhNTk5MGQ5ZTBfNS01LTEtMS0w_3d2c2877-2a95-4933-8467-8d9055457f86">3,653</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31c050008a204703ba34fa755a536cf2_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmNiYzhiZjFjMTUzZTRhOWI4ZDI5MjRlYTU5OTBkOWUwL3RhYmxlcmFuZ2U6Y2JjOGJmMWMxNTNlNGE5YjhkMjkyNGVhNTk5MGQ5ZTBfNS0xMy0xLTEtMA_44edc015-8bd3-4a99-87f4-7ff880776424">3,653</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmNiYzhiZjFjMTUzZTRhOWI4ZDI5MjRlYTU5OTBkOWUwL3RhYmxlcmFuZ2U6Y2JjOGJmMWMxNTNlNGE5YjhkMjkyNGVhNTk5MGQ5ZTBfNS0xNy0xLTEtMA_5d83d0a6-4156-4c2d-819f-506ad2f94b97">3,653</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercise of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie9109ae3615a4ff4bba0427a808423b1_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmNiYzhiZjFjMTUzZTRhOWI4ZDI5MjRlYTU5OTBkOWUwL3RhYmxlcmFuZ2U6Y2JjOGJmMWMxNTNlNGE5YjhkMjkyNGVhNTk5MGQ5ZTBfNi0xLTEtMS0w_3e7fdd3e-8fbd-4bc9-bdea-a73a1354409e">306</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9109ae3615a4ff4bba0427a808423b1_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmNiYzhiZjFjMTUzZTRhOWI4ZDI5MjRlYTU5OTBkOWUwL3RhYmxlcmFuZ2U6Y2JjOGJmMWMxNTNlNGE5YjhkMjkyNGVhNTk5MGQ5ZTBfNi0zLTEtMS0w_565fd9f9-44b3-4afd-95cf-b85fb43cd026">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i455847ec36714e5290ad661b3a22ace7_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmNiYzhiZjFjMTUzZTRhOWI4ZDI5MjRlYTU5OTBkOWUwL3RhYmxlcmFuZ2U6Y2JjOGJmMWMxNTNlNGE5YjhkMjkyNGVhNTk5MGQ5ZTBfNi01LTEtMS0w_2329c8f8-ea1a-4ee7-8286-51c81920d9fa">2,855</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31c050008a204703ba34fa755a536cf2_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmNiYzhiZjFjMTUzZTRhOWI4ZDI5MjRlYTU5OTBkOWUwL3RhYmxlcmFuZ2U6Y2JjOGJmMWMxNTNlNGE5YjhkMjkyNGVhNTk5MGQ5ZTBfNi0xMy0xLTEtMA_ff975ccb-a93a-46b2-9922-082d8a24a976">2,858</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmNiYzhiZjFjMTUzZTRhOWI4ZDI5MjRlYTU5OTBkOWUwL3RhYmxlcmFuZ2U6Y2JjOGJmMWMxNTNlNGE5YjhkMjkyNGVhNTk5MGQ5ZTBfNi0xNy0xLTEtMA_3cf2a219-89ae-43f6-a7f4-2885b7029228">2,858</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted stock units vested, net of shares withheld for taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie9109ae3615a4ff4bba0427a808423b1_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmNiYzhiZjFjMTUzZTRhOWI4ZDI5MjRlYTU5OTBkOWUwL3RhYmxlcmFuZ2U6Y2JjOGJmMWMxNTNlNGE5YjhkMjkyNGVhNTk5MGQ5ZTBfNy0xLTEtMS0w_ef780ef0-278c-4269-a2c0-ffc8c87b4cb6">110</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9109ae3615a4ff4bba0427a808423b1_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmNiYzhiZjFjMTUzZTRhOWI4ZDI5MjRlYTU5OTBkOWUwL3RhYmxlcmFuZ2U6Y2JjOGJmMWMxNTNlNGE5YjhkMjkyNGVhNTk5MGQ5ZTBfNy0zLTEtMS0w_dd4d2d89-3e48-42e3-abba-5ee864dbd45f">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i455847ec36714e5290ad661b3a22ace7_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmNiYzhiZjFjMTUzZTRhOWI4ZDI5MjRlYTU5OTBkOWUwL3RhYmxlcmFuZ2U6Y2JjOGJmMWMxNTNlNGE5YjhkMjkyNGVhNTk5MGQ5ZTBfNy01LTEtMS0w_e2de06cf-14a4-4c08-a5d3-c93b022674ab">455</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31c050008a204703ba34fa755a536cf2_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmNiYzhiZjFjMTUzZTRhOWI4ZDI5MjRlYTU5OTBkOWUwL3RhYmxlcmFuZ2U6Y2JjOGJmMWMxNTNlNGE5YjhkMjkyNGVhNTk5MGQ5ZTBfNy0xMy0xLTEtMA_f3b7ac8e-50bf-43f3-afb5-17f8b4ee3e4b">454</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmNiYzhiZjFjMTUzZTRhOWI4ZDI5MjRlYTU5OTBkOWUwL3RhYmxlcmFuZ2U6Y2JjOGJmMWMxNTNlNGE5YjhkMjkyNGVhNTk5MGQ5ZTBfNy0xNy0xLTEtMA_0a9a4ff0-c771-4e3a-96ad-a61131f0495e">454</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic8f27d03961c446e8a3b985b4125c35b_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmNiYzhiZjFjMTUzZTRhOWI4ZDI5MjRlYTU5OTBkOWUwL3RhYmxlcmFuZ2U6Y2JjOGJmMWMxNTNlNGE5YjhkMjkyNGVhNTk5MGQ5ZTBfOC03LTEtMS0w_8a97f2b8-7b38-49a6-922f-6f55e35eaa3c">58</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31c050008a204703ba34fa755a536cf2_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmNiYzhiZjFjMTUzZTRhOWI4ZDI5MjRlYTU5OTBkOWUwL3RhYmxlcmFuZ2U6Y2JjOGJmMWMxNTNlNGE5YjhkMjkyNGVhNTk5MGQ5ZTBfOC0xMy0xLTEtMA_1a2945bd-e19b-4330-bff2-615ad60f79bc">58</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmNiYzhiZjFjMTUzZTRhOWI4ZDI5MjRlYTU5OTBkOWUwL3RhYmxlcmFuZ2U6Y2JjOGJmMWMxNTNlNGE5YjhkMjkyNGVhNTk5MGQ5ZTBfOC0xNy0xLTEtMA_45cd2f0b-bc30-4e94-965c-e44132421b72">58</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9015d8c021f54578be8269eee070b2fd_D20210401-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmNiYzhiZjFjMTUzZTRhOWI4ZDI5MjRlYTU5OTBkOWUwL3RhYmxlcmFuZ2U6Y2JjOGJmMWMxNTNlNGE5YjhkMjkyNGVhNTk5MGQ5ZTBfOS05LTEtMS0w_c6fd5446-0119-4e30-a0c9-201c713dc052">9,107</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31c050008a204703ba34fa755a536cf2_D20210401-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmNiYzhiZjFjMTUzZTRhOWI4ZDI5MjRlYTU5OTBkOWUwL3RhYmxlcmFuZ2U6Y2JjOGJmMWMxNTNlNGE5YjhkMjkyNGVhNTk5MGQ5ZTBfOS0xMy0xLTEtMA_48d116b9-a291-46a5-bad9-ca2e937b31b7">9,107</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmNiYzhiZjFjMTUzZTRhOWI4ZDI5MjRlYTU5OTBkOWUwL3RhYmxlcmFuZ2U6Y2JjOGJmMWMxNTNlNGE5YjhkMjkyNGVhNTk5MGQ5ZTBfOS0xNy0xLTEtMA_019c2adf-3635-400b-83ca-593cfa02f301">9,107</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance as of June 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i94aea5894d5b4755a126a48cfbd95510_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmNiYzhiZjFjMTUzZTRhOWI4ZDI5MjRlYTU5OTBkOWUwL3RhYmxlcmFuZ2U6Y2JjOGJmMWMxNTNlNGE5YjhkMjkyNGVhNTk5MGQ5ZTBfMTEtMS0xLTEtMA_eac83ecb-2bf2-4cc7-8970-75a1c42f821e">87,195</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94aea5894d5b4755a126a48cfbd95510_I20210630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmNiYzhiZjFjMTUzZTRhOWI4ZDI5MjRlYTU5OTBkOWUwL3RhYmxlcmFuZ2U6Y2JjOGJmMWMxNTNlNGE5YjhkMjkyNGVhNTk5MGQ5ZTBfMTEtMy0xLTEtMA_8de60e04-d20e-42b5-b664-352166ca616b">872</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i879a0ef04e854d12a3d8c0b0e4ef52a8_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmNiYzhiZjFjMTUzZTRhOWI4ZDI5MjRlYTU5OTBkOWUwL3RhYmxlcmFuZ2U6Y2JjOGJmMWMxNTNlNGE5YjhkMjkyNGVhNTk5MGQ5ZTBfMTEtNS0xLTEtMA_6b89f956-dffd-4723-91e2-3b7e1e4a36f9">1,242,900</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if0b0ee0b6c91434b9c8abae23359e72b_I20210630" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmNiYzhiZjFjMTUzZTRhOWI4ZDI5MjRlYTU5OTBkOWUwL3RhYmxlcmFuZ2U6Y2JjOGJmMWMxNTNlNGE5YjhkMjkyNGVhNTk5MGQ5ZTBfMTEtNy0xLTEtMA_f032ee10-f384-4b5b-8689-cf4568f07e25">367</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i81c425c8fa484c09a468070f04a8c93f_I20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmNiYzhiZjFjMTUzZTRhOWI4ZDI5MjRlYTU5OTBkOWUwL3RhYmxlcmFuZ2U6Y2JjOGJmMWMxNTNlNGE5YjhkMjkyNGVhNTk5MGQ5ZTBfMTEtOS0xLTEtMA_23beb34b-4268-4b64-9704-da1edd7baf8b">608,092</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia8df2ff5dddf457e82901cdf7d483ad7_I20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmNiYzhiZjFjMTUzZTRhOWI4ZDI5MjRlYTU5OTBkOWUwL3RhYmxlcmFuZ2U6Y2JjOGJmMWMxNTNlNGE5YjhkMjkyNGVhNTk5MGQ5ZTBfMTEtMTEtMS0xLTA_8fb8700b-271a-46b6-9152-83593d85d3a3">21,123</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i569670e5740a45bbad372eaaf4c6523d_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmNiYzhiZjFjMTUzZTRhOWI4ZDI5MjRlYTU5OTBkOWUwL3RhYmxlcmFuZ2U6Y2JjOGJmMWMxNTNlNGE5YjhkMjkyNGVhNTk5MGQ5ZTBfMTEtMTMtMS0xLTA_580195d7-4c3c-4844-bd57-61b3990f1349">614,190</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmNiYzhiZjFjMTUzZTRhOWI4ZDI5MjRlYTU5OTBkOWUwL3RhYmxlcmFuZ2U6Y2JjOGJmMWMxNTNlNGE5YjhkMjkyNGVhNTk5MGQ5ZTBfMTEtMTctMS0xLTA_d418098d-870f-4894-b408-0b7760ea2ed4">614,190</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="51" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30, 2020</span></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Class A Common Stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional Paid-In Capital</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Other Income (Loss)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retained Earnings (Accumulated Deficit)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Treasury Stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Shareholders' Equity<br/>Attributable to<br/>Evolent Health, Inc.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-Controlling Interests</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Equity</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance as of March 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i432ce00f8bd44330b83105a3a30fdfa7_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmNiYzhiZjFjMTUzZTRhOWI4ZDI5MjRlYTU5OTBkOWUwL3RhYmxlcmFuZ2U6Y2JjOGJmMWMxNTNlNGE5YjhkMjkyNGVhNTk5MGQ5ZTBfMTctMS0xLTEtMA_b3f7d8ce-306c-4664-b8fc-f2cd1793814a">85,450</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i432ce00f8bd44330b83105a3a30fdfa7_I20200331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmNiYzhiZjFjMTUzZTRhOWI4ZDI5MjRlYTU5OTBkOWUwL3RhYmxlcmFuZ2U6Y2JjOGJmMWMxNTNlNGE5YjhkMjkyNGVhNTk5MGQ5ZTBfMTctMy0xLTEtMA_5928def0-3267-471a-bfcf-2edc726feb04">855</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i026710848e1641728e5976c36d6751b6_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmNiYzhiZjFjMTUzZTRhOWI4ZDI5MjRlYTU5OTBkOWUwL3RhYmxlcmFuZ2U6Y2JjOGJmMWMxNTNlNGE5YjhkMjkyNGVhNTk5MGQ5ZTBfMTctNS0xLTEtMA_7184ca95-2b28-41fa-adca-3c20a89dd956">1,180,288</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i699a6f845bb540d88c80df1abf986e42_I20200331" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmNiYzhiZjFjMTUzZTRhOWI4ZDI5MjRlYTU5OTBkOWUwL3RhYmxlcmFuZ2U6Y2JjOGJmMWMxNTNlNGE5YjhkMjkyNGVhNTk5MGQ5ZTBfMTctNy0xLTEtMA_501fea08-1506-4b32-833a-7ff2c1e661c5">387</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic75ef8266603466480bd63015a6a5944_I20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmNiYzhiZjFjMTUzZTRhOWI4ZDI5MjRlYTU5OTBkOWUwL3RhYmxlcmFuZ2U6Y2JjOGJmMWMxNTNlNGE5YjhkMjkyNGVhNTk5MGQ5ZTBfMTctOS0xLTEtMA_052cb699-33e5-4eef-8aaa-95cab81760b8">333,684</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic59adfc6299d4f0497fd6b08ea305a09_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmNiYzhiZjFjMTUzZTRhOWI4ZDI5MjRlYTU5OTBkOWUwL3RhYmxlcmFuZ2U6Y2JjOGJmMWMxNTNlNGE5YjhkMjkyNGVhNTk5MGQ5ZTBfMTctMTMtMS0xLTA_c469c347-96a7-4740-a200-037384a77639">847,072</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57b7afbf065049aaab8f0248ad2de887_I20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmNiYzhiZjFjMTUzZTRhOWI4ZDI5MjRlYTU5OTBkOWUwL3RhYmxlcmFuZ2U6Y2JjOGJmMWMxNTNlNGE5YjhkMjkyNGVhNTk5MGQ5ZTBfMTctMTUtMS0xLTA_d9eb7a41-f165-4732-94f5-bc53b2b1e144">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec09d5072eea4a989bbeda84a659de90_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmNiYzhiZjFjMTUzZTRhOWI4ZDI5MjRlYTU5OTBkOWUwL3RhYmxlcmFuZ2U6Y2JjOGJmMWMxNTNlNGE5YjhkMjkyNGVhNTk5MGQ5ZTBfMTctMTctMS0xLTA_7b813f84-a80e-4d03-b265-a7dfb8e9bd25">847,072</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia89af82007e0491b902dec6c279845b4_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmNiYzhiZjFjMTUzZTRhOWI4ZDI5MjRlYTU5OTBkOWUwL3RhYmxlcmFuZ2U6Y2JjOGJmMWMxNTNlNGE5YjhkMjkyNGVhNTk5MGQ5ZTBfMjAtNS0xLTEtMA_58652811-f35a-4559-8f77-20103d22afbf">3,703</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib53e76cbba4f4051ab162663449ef939_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmNiYzhiZjFjMTUzZTRhOWI4ZDI5MjRlYTU5OTBkOWUwL3RhYmxlcmFuZ2U6Y2JjOGJmMWMxNTNlNGE5YjhkMjkyNGVhNTk5MGQ5ZTBfMjAtMTMtMS0xLTA_435531a8-feea-4e9d-8ab9-106a16006bfd">3,703</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmNiYzhiZjFjMTUzZTRhOWI4ZDI5MjRlYTU5OTBkOWUwL3RhYmxlcmFuZ2U6Y2JjOGJmMWMxNTNlNGE5YjhkMjkyNGVhNTk5MGQ5ZTBfMjAtMTctMS0xLTA_16a3f1ef-b4c6-4bc4-b7d4-d6936ccb6a69">3,703</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercise of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i78ff7cbbd824466eab0d352e7f4b5f1c_D20200401-20200630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmNiYzhiZjFjMTUzZTRhOWI4ZDI5MjRlYTU5OTBkOWUwL3RhYmxlcmFuZ2U6Y2JjOGJmMWMxNTNlNGE5YjhkMjkyNGVhNTk5MGQ5ZTBfMjEtMS0xLTEtMA_cb5d0063-cde5-4485-a40d-52c36b639f71">82</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78ff7cbbd824466eab0d352e7f4b5f1c_D20200401-20200630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmNiYzhiZjFjMTUzZTRhOWI4ZDI5MjRlYTU5OTBkOWUwL3RhYmxlcmFuZ2U6Y2JjOGJmMWMxNTNlNGE5YjhkMjkyNGVhNTk5MGQ5ZTBfMjEtMy0xLTEtMA_dc4f4820-262f-4912-b112-0f10e5bdbfb2">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia89af82007e0491b902dec6c279845b4_D20200401-20200630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmNiYzhiZjFjMTUzZTRhOWI4ZDI5MjRlYTU5OTBkOWUwL3RhYmxlcmFuZ2U6Y2JjOGJmMWMxNTNlNGE5YjhkMjkyNGVhNTk5MGQ5ZTBfMjEtNS0xLTEtMA_173f6aad-44c0-4835-a8d1-65540dc6b307">442</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib53e76cbba4f4051ab162663449ef939_D20200401-20200630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmNiYzhiZjFjMTUzZTRhOWI4ZDI5MjRlYTU5OTBkOWUwL3RhYmxlcmFuZ2U6Y2JjOGJmMWMxNTNlNGE5YjhkMjkyNGVhNTk5MGQ5ZTBfMjEtMTMtMS0xLTA_2274e87a-11aa-4570-88aa-e586efc83dad">443</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmNiYzhiZjFjMTUzZTRhOWI4ZDI5MjRlYTU5OTBkOWUwL3RhYmxlcmFuZ2U6Y2JjOGJmMWMxNTNlNGE5YjhkMjkyNGVhNTk5MGQ5ZTBfMjEtMTctMS0xLTA_a7d9f020-c83e-4c31-bdf7-e84d62cab17e">443</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted stock units vested, net of shares withheld for taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i78ff7cbbd824466eab0d352e7f4b5f1c_D20200401-20200630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmNiYzhiZjFjMTUzZTRhOWI4ZDI5MjRlYTU5OTBkOWUwL3RhYmxlcmFuZ2U6Y2JjOGJmMWMxNTNlNGE5YjhkMjkyNGVhNTk5MGQ5ZTBfMjItMS0xLTEtMA_b66a28eb-b4cf-4fee-98ac-98c70410da9f">113</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78ff7cbbd824466eab0d352e7f4b5f1c_D20200401-20200630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmNiYzhiZjFjMTUzZTRhOWI4ZDI5MjRlYTU5OTBkOWUwL3RhYmxlcmFuZ2U6Y2JjOGJmMWMxNTNlNGE5YjhkMjkyNGVhNTk5MGQ5ZTBfMjItMy0xLTEtMA_86493d7c-3984-41a8-b0b3-982debec8745">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia89af82007e0491b902dec6c279845b4_D20200401-20200630" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmNiYzhiZjFjMTUzZTRhOWI4ZDI5MjRlYTU5OTBkOWUwL3RhYmxlcmFuZ2U6Y2JjOGJmMWMxNTNlNGE5YjhkMjkyNGVhNTk5MGQ5ZTBfMjItNS0xLTEtMA_101e2d59-4039-41cf-9e1c-dc02e952f2bb">145</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib53e76cbba4f4051ab162663449ef939_D20200401-20200630" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmNiYzhiZjFjMTUzZTRhOWI4ZDI5MjRlYTU5OTBkOWUwL3RhYmxlcmFuZ2U6Y2JjOGJmMWMxNTNlNGE5YjhkMjkyNGVhNTk5MGQ5ZTBfMjItMTMtMS0xLTA_9bcef18f-ac47-4288-970c-77076a0942ad">144</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmNiYzhiZjFjMTUzZTRhOWI4ZDI5MjRlYTU5OTBkOWUwL3RhYmxlcmFuZ2U6Y2JjOGJmMWMxNTNlNGE5YjhkMjkyNGVhNTk5MGQ5ZTBfMjItMTctMS0xLTA_05b83ff7-b69b-40ad-be5d-d03ce7506b99">144</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share retirement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i78ff7cbbd824466eab0d352e7f4b5f1c_D20200401-20200630" decimals="-3" name="evh:StockVestedAndRetiredDuringPeriodShares" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmNiYzhiZjFjMTUzZTRhOWI4ZDI5MjRlYTU5OTBkOWUwL3RhYmxlcmFuZ2U6Y2JjOGJmMWMxNTNlNGE5YjhkMjkyNGVhNTk5MGQ5ZTBfMjItMS0xLTEtMzcxNA_bbe74552-1942-4492-8d91-7c1493ff93c0">188</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i78ff7cbbd824466eab0d352e7f4b5f1c_D20200401-20200630" decimals="-3" name="evh:StockVestedAndRetiredDuringPeriodValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmNiYzhiZjFjMTUzZTRhOWI4ZDI5MjRlYTU5OTBkOWUwL3RhYmxlcmFuZ2U6Y2JjOGJmMWMxNTNlNGE5YjhkMjkyNGVhNTk5MGQ5ZTBfMjItMy0xLTEtMzcxNA_835a30e9-a86f-4606-adb6-0e00e64f5c14">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia89af82007e0491b902dec6c279845b4_D20200401-20200630" decimals="-3" name="evh:StockVestedAndRetiredDuringPeriodValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmNiYzhiZjFjMTUzZTRhOWI4ZDI5MjRlYTU5OTBkOWUwL3RhYmxlcmFuZ2U6Y2JjOGJmMWMxNTNlNGE5YjhkMjkyNGVhNTk5MGQ5ZTBfMjItNS0xLTEtMzcxNA_b5ecdbe3-b2d4-4cd2-aa82-58facc3e5548">683</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib53e76cbba4f4051ab162663449ef939_D20200401-20200630" decimals="-3" name="evh:StockVestedAndRetiredDuringPeriodValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmNiYzhiZjFjMTUzZTRhOWI4ZDI5MjRlYTU5OTBkOWUwL3RhYmxlcmFuZ2U6Y2JjOGJmMWMxNTNlNGE5YjhkMjkyNGVhNTk5MGQ5ZTBfMjItMTMtMS0xLTM3MTQ_242d6edd-d2e6-41d3-be7d-05e05a467a85">685</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630" decimals="-3" name="evh:StockVestedAndRetiredDuringPeriodValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmNiYzhiZjFjMTUzZTRhOWI4ZDI5MjRlYTU5OTBkOWUwL3RhYmxlcmFuZ2U6Y2JjOGJmMWMxNTNlNGE5YjhkMjkyNGVhNTk5MGQ5ZTBfMjItMTctMS0xLTM3MTQ_6e2b98da-95b3-4eb2-a1f2-b4d01cf365a3">685</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0b480fd1921d4f1ea9972b92001a55ff_D20200401-20200630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmNiYzhiZjFjMTUzZTRhOWI4ZDI5MjRlYTU5OTBkOWUwL3RhYmxlcmFuZ2U6Y2JjOGJmMWMxNTNlNGE5YjhkMjkyNGVhNTk5MGQ5ZTBfMjYtNy0xLTEtMA_bf07f014-fc9f-4f09-94d4-30e3fcc3ba16">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib53e76cbba4f4051ab162663449ef939_D20200401-20200630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmNiYzhiZjFjMTUzZTRhOWI4ZDI5MjRlYTU5OTBkOWUwL3RhYmxlcmFuZ2U6Y2JjOGJmMWMxNTNlNGE5YjhkMjkyNGVhNTk5MGQ5ZTBfMjYtMTMtMS0xLTA_79b6d7b2-37bf-42c6-a370-ca1046b1591f">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmNiYzhiZjFjMTUzZTRhOWI4ZDI5MjRlYTU5OTBkOWUwL3RhYmxlcmFuZ2U6Y2JjOGJmMWMxNTNlNGE5YjhkMjkyNGVhNTk5MGQ5ZTBfMjYtMTctMS0xLTA_92c0b8f4-1003-40b4-81fa-7bd5c6bae2ba">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3788ccc422524e5bab104710c747da49_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmNiYzhiZjFjMTUzZTRhOWI4ZDI5MjRlYTU5OTBkOWUwL3RhYmxlcmFuZ2U6Y2JjOGJmMWMxNTNlNGE5YjhkMjkyNGVhNTk5MGQ5ZTBfMjctOS0xLTEtMA_b64ec812-fb90-4b4a-b74e-57f2807f4a8a">203,521</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib53e76cbba4f4051ab162663449ef939_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmNiYzhiZjFjMTUzZTRhOWI4ZDI5MjRlYTU5OTBkOWUwL3RhYmxlcmFuZ2U6Y2JjOGJmMWMxNTNlNGE5YjhkMjkyNGVhNTk5MGQ5ZTBfMjctMTMtMS0xLTA_98b25508-aecd-4a1a-b60c-189716c53bdd">203,521</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmNiYzhiZjFjMTUzZTRhOWI4ZDI5MjRlYTU5OTBkOWUwL3RhYmxlcmFuZ2U6Y2JjOGJmMWMxNTNlNGE5YjhkMjkyNGVhNTk5MGQ5ZTBfMjctMTctMS0xLTA_62fad74a-faec-485b-b523-51ff1697dfe4">203,521</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance as of June 30, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i61d42c3c86cf419a8e9f35be789f83b5_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmNiYzhiZjFjMTUzZTRhOWI4ZDI5MjRlYTU5OTBkOWUwL3RhYmxlcmFuZ2U6Y2JjOGJmMWMxNTNlNGE5YjhkMjkyNGVhNTk5MGQ5ZTBfMjktMS0xLTEtMA_5a34f320-c35f-47a2-bec0-31a5fb36e955">85,457</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61d42c3c86cf419a8e9f35be789f83b5_I20200630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmNiYzhiZjFjMTUzZTRhOWI4ZDI5MjRlYTU5OTBkOWUwL3RhYmxlcmFuZ2U6Y2JjOGJmMWMxNTNlNGE5YjhkMjkyNGVhNTk5MGQ5ZTBfMjktMy0xLTEtMA_46b084be-c3a4-459e-a29b-c65cf4818b29">855</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia67d3ce8c31a428f993f4ca23b06398f_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmNiYzhiZjFjMTUzZTRhOWI4ZDI5MjRlYTU5OTBkOWUwL3RhYmxlcmFuZ2U6Y2JjOGJmMWMxNTNlNGE5YjhkMjkyNGVhNTk5MGQ5ZTBfMjktNS0xLTEtMA_98a42a30-a303-4eec-8434-b48775bfd57e">1,183,605</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia59baf61ed594b8fb0771be16c7deee5_I20200630" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmNiYzhiZjFjMTUzZTRhOWI4ZDI5MjRlYTU5OTBkOWUwL3RhYmxlcmFuZ2U6Y2JjOGJmMWMxNTNlNGE5YjhkMjkyNGVhNTk5MGQ5ZTBfMjktNy0xLTEtMA_4e35ba98-388e-4d4c-8b40-6f201bf69355">391</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0b187f370fc84640b9c86628f855226a_I20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmNiYzhiZjFjMTUzZTRhOWI4ZDI5MjRlYTU5OTBkOWUwL3RhYmxlcmFuZ2U6Y2JjOGJmMWMxNTNlNGE5YjhkMjkyNGVhNTk5MGQ5ZTBfMjktOS0xLTEtMA_4c6c5ddd-97a4-449d-bfcd-c664d0e2c4df">537,205</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2202cb072bda4242a7bea49750347ba4_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmNiYzhiZjFjMTUzZTRhOWI4ZDI5MjRlYTU5OTBkOWUwL3RhYmxlcmFuZ2U6Y2JjOGJmMWMxNTNlNGE5YjhkMjkyNGVhNTk5MGQ5ZTBfMjktMTMtMS0xLTA_dc3e55d2-ab88-41b8-8e7a-86def8e5ad83">646,864</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d6223463ab84fa6a8f5cd35e24c15d7_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmNiYzhiZjFjMTUzZTRhOWI4ZDI5MjRlYTU5OTBkOWUwL3RhYmxlcmFuZ2U6Y2JjOGJmMWMxNTNlNGE5YjhkMjkyNGVhNTk5MGQ5ZTBfMjktMTUtMS0xLTA_da649d74-88ce-4b6b-8ccf-24e48b96cfe1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11817f96c3e24e0abaed14a17869e173_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmNiYzhiZjFjMTUzZTRhOWI4ZDI5MjRlYTU5OTBkOWUwL3RhYmxlcmFuZ2U6Y2JjOGJmMWMxNTNlNGE5YjhkMjkyNGVhNTk5MGQ5ZTBfMjktMTctMS0xLTA_514399e8-ae63-469e-bef3-c678e831cd1b">646,864</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">See accompanying Notes to Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:756.00pt"><tr><td style="width:1.0pt"></td><td style="width:260.50pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:41.50pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:3.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:34.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:3.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:41.50pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:54.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:51.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:3.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:43.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:3.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:84.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:3.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:45.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:3.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:41.50pt"></td><td style="width:1.0pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="51" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30, 2021</span></td></tr><tr style="height:27pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Class A Common Stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional Paid-In Capital</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Other Income (Loss)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retained Earnings (Accumulated Deficit)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Treasury Stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Shareholders' Equity<br/>Attributable to<br/>Evolent Health, Inc.</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-Controlling Interests</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Equity</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance as of December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i78d2f8ed8b384b2a93f41b0cbd0e3f03_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfMy0xLTEtMS0xMzc_b3673061-07d0-4edc-9de8-fa71a47bef08">85,895</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78d2f8ed8b384b2a93f41b0cbd0e3f03_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfMy0zLTEtMS0xMzc_c3e814a3-9a95-4e8b-9229-fbab90aea36c">859</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9482da1959ba438396e25159d07f33e3_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfMy01LTEtMS0xMzc_42b253cf-6cec-4e48-b295-02afa1176c38">1,229,320</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6d3d52c0e5b94031981899cd1ecb78a1_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfMy03LTEtMS0xMzc_918ad4ca-d769-49eb-a746-bfcf07645711">278</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia2be1022da19471caedc725d35d5a5bd_I20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfMy05LTEtMS0xMzc_0530ae09-2fb3-4450-a298-2ef3a5c8cac5">589,178</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7a8d015d1e3c419495ab144ddd77f1b6_I20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfMy0xMS0xLTEtMTM3_d0eb538f-d3f9-40f1-9ef8-8e5ceb6bdb12">21,123</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9799952c3fd2440b9166bd85cc98b14e_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfMy0xMy0xLTEtMTM3_1cabe5f5-d52c-4245-b396-3ac7306c5fbf">619,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25b48cb725834cb78913e88a0e458e79_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfMy0xNS0xLTEtMTM3_280370f4-0a0e-4a99-a3f6-194f56226aa3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45bff335c1434d6ba44132da1b0557db_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfMy0xNy0xLTEtMTM3_778296b1-cc5d-4f22-b9ea-cecd3498b272">619,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieaf6b2c9ee5b475bbe4a1910426766b9_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfNS01LTEtMS0xMzc_cfb0789d-c56d-4ed4-9499-ed5ae0fe06f5">7,359</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfc2020dff164058be58d93f3ec59267_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfNS0xMy0xLTEtMTM3_22fbed2c-a8d6-4615-b638-d585e3d3dd5c">7,359</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfNS0xNy0xLTEtMTM3_cd612b3c-d2cd-41d7-b1d9-d15c39a2ff6f">7,359</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercise of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1baaa0777df145cfb48c213ad68538f9_D20210101-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfNi0xLTEtMS0xMzc_b69d6836-4415-4ca0-8aaa-d68fa170fc9a">900</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1baaa0777df145cfb48c213ad68538f9_D20210101-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfNi0zLTEtMS0xMzc_26b413a6-9dc1-46cb-a297-3a19fd82063c">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieaf6b2c9ee5b475bbe4a1910426766b9_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfNi01LTEtMS0xMzc_063d3749-0dc0-4d5f-8b64-bbd89a873715">9,367</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfc2020dff164058be58d93f3ec59267_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfNi0xMy0xLTEtMTM3_2f1307c3-f7f1-49c1-a403-845fd336dd3c">9,376</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfNi0xNy0xLTEtMTM3_f7edb432-4ade-4484-bdce-9d21d9b52997">9,376</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted stock units vested, net of shares withheld for taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1baaa0777df145cfb48c213ad68538f9_D20210101-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfNy0xLTEtMS0xMzc_4bd2f1f5-c788-4c95-9505-3f81246ecae8">400</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1baaa0777df145cfb48c213ad68538f9_D20210101-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfNy0zLTEtMS0xMzc_917ba028-1d38-4d41-9b42-9f192c45f19f">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieaf6b2c9ee5b475bbe4a1910426766b9_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfNy01LTEtMS0xMzc_9e4dbf39-16ce-4ded-9ca5-23d3c5bc735a">3,146</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idfc2020dff164058be58d93f3ec59267_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfNy0xMy0xLTEtMTM3_6c268681-56a9-40c5-a39d-c903559998b4">3,142</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfNy0xNy0xLTEtMTM3_4664b0cc-82d5-4e91-97c5-b3af56ed9264">3,142</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8830c28780b7440f831c87a11c1a0073_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfOC03LTEtMS0xMzc_fdfff1a6-234d-40f0-9219-53f1a0acc1d1">89</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idfc2020dff164058be58d93f3ec59267_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfOC0xMy0xLTEtMTM3_c68ef289-78fa-4021-bd73-043065a0ed05">89</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfOC0xNy0xLTEtMTM3_787684c3-4441-459f-b1cc-83e79bdecec9">89</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iae1007f114dc467eb2b8a9c64881f28b_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfOS05LTEtMS0xMzc_69ea4bc2-86ab-4538-8293-67661e1def05">18,914</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idfc2020dff164058be58d93f3ec59267_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfOS0xMy0xLTEtMTM3_5b550b0c-c78b-4d46-b8ff-12903daa1c35">18,914</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfOS0xNy0xLTEtMTM3_4e09c1e9-279d-4b00-b3dc-001bada26f6f">18,914</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance as of June 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i94aea5894d5b4755a126a48cfbd95510_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfMTEtMS0xLTEtMTM3_ce3139c5-d54d-4172-be01-e47a94361ef8">87,195</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94aea5894d5b4755a126a48cfbd95510_I20210630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfMTEtMy0xLTEtMTM3_09d5bd36-3c53-4ee3-b2aa-c9211ffb041e">872</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i879a0ef04e854d12a3d8c0b0e4ef52a8_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfMTEtNS0xLTEtMTM3_975182cd-f69b-4011-a316-a5244bed9976">1,242,900</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if0b0ee0b6c91434b9c8abae23359e72b_I20210630" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfMTEtNy0xLTEtMTM3_7747dffd-2e3c-44f2-938f-24cc971e18c7">367</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i81c425c8fa484c09a468070f04a8c93f_I20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfMTEtOS0xLTEtMTM3_66164b1e-509b-42ac-816e-7c29486c2825">608,092</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia8df2ff5dddf457e82901cdf7d483ad7_I20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfMTEtMTEtMS0xLTEzNw_34f3b376-05c5-44c8-8624-be92c7bdbbca">21,123</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i569670e5740a45bbad372eaaf4c6523d_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfMTEtMTMtMS0xLTEzNw_4cf248f3-4d50-4ae9-9687-9c232b978b91">614,190</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfMTEtMTctMS0xLTEzNw_4a1dcd0b-b42d-47a3-8e6c-54f816d8ae1a">614,190</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="51" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30, 2020</span></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Class A Common Stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional Paid-In Capital</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Other Income (Loss)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retained Earnings (Accumulated Deficit)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Treasury Stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Shareholders' Equity<br/>Attributable to<br/>Evolent Health, Inc.</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-Controlling Interests</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Equity</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance as of December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3046b7b99a004e48a03d367e730f9ae5_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfMTctMS0xLTEtMzcyNA_4ee13ecc-e318-456f-9962-2b36dd0addd4">84,589</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3046b7b99a004e48a03d367e730f9ae5_I20191231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfMTctMy0xLTEtMzcyNA_d4966d20-068a-4381-977b-20bda781b663">846</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice23288885be4f779b9ab70832b538f6_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfMTctNS0xLTEtMzcyNA_449b1500-e2be-4f82-ab0e-e36e73a2a0c8">1,173,708</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib21f2745e0714611ae3b84205a386a57_I20191231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfMTctNy0xLTEtMzcyNA_68fd2b16-33d9-40dd-8fe3-ff063c8ed54e">234</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1bcddf75950249fbaf184e1f523f0d8b_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfMTctOS0xLTEtMzcyNA_cad61f56-9ac9-42f4-83a2-dda72853a0eb">251,962</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18de6ff3304b4fda9feee31a2f415af8_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfMTctMTMtMS0xLTM3MjQ_7233afe0-2288-45f6-aafa-c82958822e36">922,358</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcd7068eef4f42b895c0b83d21ea5d2b_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfMTctMTUtMS0xLTM3MjQ_57557afe-790b-471d-a3bf-08270be6c430">6,689</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0ff0ad229b441d4b12bc8956f92a917_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfMTctMTctMS0xLTM3MjQ_42e0d5b0-684c-42c3-b952-9e10a7e9a5b2">929,047</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfMTktMC0xLTEtMzcyMg_cc0dc4d5-3936-4a6c-8644-233590d31e3c">Cumulative-effect adjustment from adoption of ASU 2016-13</span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i06c25faea1e7483786ebe928e1ff0fa4_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfMTktOS0xLTEtMzcyNA_56321d04-bf20-439e-834d-c4407456da86">2,970</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id8ff7726321243cbb8c00770e6603356_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfMTktMTMtMS0xLTM3MjQ_8d0aa075-d0e8-47e7-a8cf-236748d6993d">2,970</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e620150ffe942b388f50fab8377e007_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfMTktMTctMS0xLTM3MjQ_382bd9d6-6ad6-487f-93f8-8af76013398b">2,970</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if955a85db5574fb9b6ccf0c7d039cee5_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfMjAtNS0xLTEtMzcyNA_7cf23d64-d193-4a6c-8116-f6fbe7d51c4a">7,211</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i153c261aa5234592a35394b52c2c0b85_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfMjAtMTMtMS0xLTM3MjQ_ac0dde1f-3e2d-4bab-a9dc-5e6297715365">7,211</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfMjAtMTctMS0xLTM3MjQ_f3b17322-f62b-467c-a76f-0fb1172cd619">7,211</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercise of stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8a113c1bdf754223baa2fb9a6344b873_D20200101-20200630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfMjEtMS0xLTEtMzcyNA_06bdf559-f3b6-4b28-b4de-c558de5a41b6">90</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a113c1bdf754223baa2fb9a6344b873_D20200101-20200630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfMjEtMy0xLTEtMzcyNA_364ee43b-5bb8-4904-9417-f88f8953915c">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if955a85db5574fb9b6ccf0c7d039cee5_D20200101-20200630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfMjEtNS0xLTEtMzcyNA_25acbc87-d215-4907-9acb-de56678a06a1">525</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i153c261aa5234592a35394b52c2c0b85_D20200101-20200630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfMjEtMTMtMS0xLTM3MjQ_b904ded8-6884-44ad-801e-50e6b547d5c2">526</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfMjEtMTctMS0xLTM3MjQ_2c749826-8819-4f69-8ec4-cfa2c4f2b96c">526</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted stock units vested, net of shares withheld for taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8a113c1bdf754223baa2fb9a6344b873_D20200101-20200630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfMjItMS0xLTEtMzcyNA_7c24b79d-5e36-4e31-bf35-9a619d0e1e6a">350</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a113c1bdf754223baa2fb9a6344b873_D20200101-20200630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfMjItMy0xLTEtMzcyNA_d1793637-8693-4039-adae-18963c44ad51">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if955a85db5574fb9b6ccf0c7d039cee5_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfMjItNS0xLTEtMzcyNA_5bd44f1a-5e42-4ffc-8570-00310f40d6c6">1,335</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i153c261aa5234592a35394b52c2c0b85_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfMjItMTMtMS0xLTM3MjQ_7e25dbca-6d98-4241-bb37-9ae8253d1e0a">1,331</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfMjItMTctMS0xLTM3MjQ_225c797d-5682-4e22-bdc1-7d6d255a099c">1,331</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share retirement</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i8a113c1bdf754223baa2fb9a6344b873_D20200101-20200630" decimals="-3" name="evh:StockVestedAndRetiredDuringPeriodShares" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfMjMtMS0xLTEtMzcyNA_c16545f1-00c9-4a44-af6d-92cf69f64585">188</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8a113c1bdf754223baa2fb9a6344b873_D20200101-20200630" decimals="-3" name="evh:StockVestedAndRetiredDuringPeriodValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfMjMtMy0xLTEtMzcyNA_63bce90c-e7ec-4854-8a42-79fc5a733307">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if955a85db5574fb9b6ccf0c7d039cee5_D20200101-20200630" decimals="-3" name="evh:StockVestedAndRetiredDuringPeriodValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfMjMtNS0xLTEtMzcyNA_058626ab-5e95-4553-b1eb-0996fd4b7e9a">683</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i153c261aa5234592a35394b52c2c0b85_D20200101-20200630" decimals="-3" name="evh:StockVestedAndRetiredDuringPeriodValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfMjMtMTMtMS0xLTM3MjQ_d1b9d9e8-2456-4df1-b217-0fdb57ed3764">685</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="-3" name="evh:StockVestedAndRetiredDuringPeriodValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfMjMtMTctMS0xLTM3MjQ_4715f4fb-1584-44ec-a335-d5353e0e6469">685</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Class A common stock issued for payment of earn-outs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8a113c1bdf754223baa2fb9a6344b873_D20200101-20200630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfMjQtMS0xLTEtMzcyNA_30dbe967-b73c-48de-9fb6-bef6beff6f1e">616</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a113c1bdf754223baa2fb9a6344b873_D20200101-20200630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfMjQtMy0xLTEtMzcyNA_d73249cc-7fdd-4aea-9397-b9fca8567e49">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if955a85db5574fb9b6ccf0c7d039cee5_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfMjQtNS0xLTEtMzcyNA_b8a8264a-24d0-49b4-9a00-b2df41aed021">4,179</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i153c261aa5234592a35394b52c2c0b85_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfMjQtMTMtMS0xLTM3MjQ_cfc199d1-7488-4977-8411-29077e601d82">4,185</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfMjQtMTctMS0xLTM3MjQ_7e3e395d-b24b-437d-b850-637634d5313d">4,185</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Disposal of assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i215048e9c16a4f348373b4cb1edc7ece_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NoncontrollingInterestDecreaseFromDeconsolidation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfMjUtMTUtMS0xLTM3MjQ_556eb835-0580-4bed-8d5f-1ac81ae512bc">6,689</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NoncontrollingInterestDecreaseFromDeconsolidation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfMjUtMTctMS0xLTM3MjQ_5efd390e-01ad-43ad-a46d-9a625e5788dd">6,689</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i67f38418f25c44ef862f02d73bbffaa7_D20200101-20200630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfMjYtNy0xLTEtMzcyNA_7a22213d-e014-416f-a7a1-23f840fd6d91">157</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i153c261aa5234592a35394b52c2c0b85_D20200101-20200630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfMjYtMTMtMS0xLTM3MjQ_908a263c-fd79-46f6-8e48-0c065dc94669">157</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfMjYtMTctMS0xLTM3MjQ_afd741a5-a8a8-4747-8698-a92b093619a7">157</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic9279f0ce4a5422aa74c787813c8d48c_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfMjctOS0xLTEtMzcyNA_ce6d555f-d322-44f6-a641-c63476fb246f">282,273</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i153c261aa5234592a35394b52c2c0b85_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfMjctMTMtMS0xLTM3MjQ_e9ce21c4-e748-4686-bbdb-be0757fa74dd">282,273</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfMjctMTctMS0xLTM3MjQ_4ece96b7-a50c-456a-bbb4-be1004974c0f">282,273</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance as of June 30, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i61d42c3c86cf419a8e9f35be789f83b5_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfMjktMS0xLTEtMzcyNA_ee74d65b-32a0-4c54-a543-7cafa7c7f2d1">85,457</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61d42c3c86cf419a8e9f35be789f83b5_I20200630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfMjktMy0xLTEtMzcyNA_31d26e76-23a9-471e-9312-6c2b9d04b44c">855</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia67d3ce8c31a428f993f4ca23b06398f_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfMjktNS0xLTEtMzcyNA_7299088c-27f9-4aa4-bcaf-e416dc0a9280">1,183,605</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia59baf61ed594b8fb0771be16c7deee5_I20200630" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfMjktNy0xLTEtMzcyNA_e04c3c58-1906-4a30-8d17-9c392283611d">391</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0b187f370fc84640b9c86628f855226a_I20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfMjktOS0xLTEtMzcyNA_5919ad2c-0c4c-4b3f-a1f6-a66f44132c79">537,205</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2202cb072bda4242a7bea49750347ba4_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfMjktMTMtMS0xLTM3MjQ_ed96c1de-3880-4f80-8550-29c4d8c07638">646,864</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d6223463ab84fa6a8f5cd35e24c15d7_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfMjktMTUtMS0xLTM3MjQ_13c3744f-131a-4677-be66-e231453c2547">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11817f96c3e24e0abaed14a17869e173_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfMjktMTctMS0xLTM3MjQ_9d272e83-6b06-4098-9592-829b40c56de5">646,864</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">See accompanying Notes to Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="id8f403494d0a42c2868794fb470218fc_34"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EVOLENT HEALTH, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(unaudited, in thousands)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:397.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:66.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:66.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash Flows Provided by (Used In) Operating Activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfMy0xLTEtMS0w_3c6b9c11-4052-4bf7-86e1-89b8e6f56107">18,914</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfMy0zLTEtMS0w_6133f0dd-e1f4-4ff4-96e9-42a93c1f62a1">282,273</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash and restricted cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration and indemnification asset</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfNS0xLTEtMS0w_9f4c35bd-3574-4ad0-bcb4-5f52027e355c">594</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfNS0zLTEtMS0w_d779559c-b526-4b13-a883-e91aeb9dcb32">3,062</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Gain) loss on disposal of assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="evh:GainLossOnDispositionOfAssetsOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfNi0xLTEtMS0w_eac38f9d-e60b-4e3d-9066-00993401e41a">1,904</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="evh:GainLossOnDispositionOfAssetsOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfNi0zLTEtMS0w_80bf34d9-85ac-4379-85c4-a4e24348e7b2">6,447</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Gain) loss from equity method investees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfNy0xLTEtMS0w_a11bc2a6-6dd9-461f-a52c-95302159fac3">12,662</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfNy0zLTEtMS0w_981ee673-1289-431a-a56f-119e8632e870">24,731</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfOC0xLTEtMS0w_5076b826-c9ab-4b1a-9e5b-a467c93983ca">30,263</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfOC0zLTEtMS0w_7bc79ea6-03ca-4e8d-9264-353bafb3ba88">31,916</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of equity method investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfOS0xLTEtMS0w_8aca3004-cc00-42b0-88ba-4b40a4df1505">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfOS0zLTEtMS0w_d4a2f796-cc5b-4439-968a-ae4ecc12640c">47,133</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfMTAtMS0xLTEtMA_ae7bb87a-fc51-4d04-9729-f72f63364543">7,359</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfMTAtMy0xLTEtMA_418c81ac-abfd-491a-9119-f1fd0e4b049b">7,211</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax (benefit) provision</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxesAndTaxCredits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfMTEtMS0xLTEtMA_650dfeed-f3fa-4c04-93e2-e6664c031c22">268</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxesAndTaxCredits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfMTEtMy0xLTEtMA_f4d0b7c5-a23c-47dc-a7a7-76946d3bd0cb">892</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of contract cost assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CapitalizedContractCostAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfMTItMS0xLTEtMA_42253acf-f70a-4b80-a694-87cf8311bd3e">8,311</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CapitalizedContractCostAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfMTItMy0xLTEtMA_a2207834-0a0d-488d-aac5-c3e840cfede2">10,272</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of deferred financing costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfMTMtMS0xLTEtMA_920bbca5-20c0-4293-9c5f-506ff9d29dc6">8,837</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfMTMtMy0xLTEtMA_7ac94fa6-115b-485d-b478-4f2373ed7019">6,079</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest from customer advance for regulatory capital requirements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="-3" format="ixt:zerodash" name="evh:PaidinKindInterestIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfMTQtMS0xLTEtNDg4MQ_c1bd1ed2-e3a7-4be2-b33a-302bccb8df4c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="evh:PaidinKindInterestIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfMTQtMy0xLTEtNDg4MQ_7dd76bef-e5fc-4669-a22d-d2aa7e0c93df">1,316</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on transfer of membership</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="evh:GainOnTransferOfMembership" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfMTQtMS0xLTEtMA_e7c4a3e1-a87d-445c-82c1-9c940d59a2ed">22,969</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="evh:GainOnTransferOfMembership" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfMTQtMy0xLTEtMA_8c4e90a0-b044-4993-95f9-1ffeb62f858d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill impairment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:GoodwillImpairmentLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfMTUtMS0xLTEtMjU0_fedbf8b2-53c2-4be2-8e86-f792609bebc2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GoodwillImpairmentLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfMTUtMy0xLTEtMjU0_adbf0a94-4f11-4ad2-9d3e-848f8ec9bde4">215,100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on repayment of debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfMTUtMS0xLTEtMA_9266f800-2d98-42a7-a422-8b9b6097f0d4">19,158</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfMTUtMy0xLTEtMA_208d7e68-9bbc-40a0-8da4-9a67ec16b905">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current operating cash outflows, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="-3" name="us-gaap:OtherNoncashIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfMTctMS0xLTEtMA_80769c45-aa35-4751-a05b-7fa72c520a56">729</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="-3" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfMTctMy0xLTEtMA_4452b2e5-f4ad-4eaa-ae67-79e7966e7a9e">224</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in assets and liabilities, net of acquisitions:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net and contract assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="evh:IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfMTktMS0xLTEtMA_6b164277-6df3-4c23-acd0-ce0bb9cfae6f">120,066</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="evh:IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfMTktMy0xLTEtMA_8719514d-226c-4fd6-a52b-d7ea40d7b06c">23,946</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current and non-current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfMjAtMS0xLTEtMA_d94a9916-241c-48fa-adc2-ea3168f57631">3,439</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfMjAtMy0xLTEtMA_51ebc6a3-55b7-4ab6-b844-52a719117a7d">3,912</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract cost assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="evh:IncreaseDecreaseInCapitalizedContractCostNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfMjEtMS0xLTEtMA_ebc9e210-3e63-4995-a6fa-f82b5cdbdf3c">3,991</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="evh:IncreaseDecreaseInCapitalizedContractCostNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfMjEtMy0xLTEtMA_a6a39c86-c1eb-49c9-9676-0aa8ecfdf32f">5,503</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfMjItMS0xLTEtMA_def78f84-5bb5-42e9-b037-33476ece1f1c">9,904</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfMjItMy0xLTEtMA_700fb971-a572-4589-a77f-ebe0d75c5fe6">11,690</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfMjMtMS0xLTEtMA_fbd92a06-c58e-492f-8022-c905d5f3ccf5">17,725</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfMjMtMy0xLTEtMA_56f07d56-491e-4bcb-ba16-b586b4d2f947">4,071</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and employee benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfMjQtMS0xLTEtMA_e2670f48-298a-4dc5-aa7a-e90c5966e361">21,505</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfMjQtMy0xLTEtMA_78137957-4629-4b0c-9ba5-0cbd1e3bfdab">10,118</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfMjUtMS0xLTEtMA_6794543d-9111-48ea-90dc-42e332f2c53c">2,490</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfMjUtMy0xLTEtMA_3cd2df06-dc3e-4333-9b55-240a442c3d5b">6,400</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve for claims and performance-based arrangements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="evh:IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfMjYtMS0xLTEtMA_83ab9c10-9237-46f7-9e06-e4489279eff0">62,614</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="evh:IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfMjYtMy0xLTEtMA_a55b0e81-6666-4429-ba5b-4000b8a72f71">33,259</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use operating assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="evh:IncreaseDecreaseInOperatingLeaseRightofUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfMjctMS0xLTEtMA_19f04590-2ad9-4189-aeb8-2ca302879b35">4,621</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="evh:IncreaseDecreaseInOperatingLeaseRightofUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfMjctMy0xLTEtMA_e07cab5a-55cf-4208-a322-31079acda7dd">3,620</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfMjgtMS0xLTEtMA_967afdd5-2e6e-4942-b2b1-0542d248eb3f">2,719</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfMjgtMy0xLTEtMA_da66a095-94de-4cdd-9fab-b5fa1bed558a">1,783</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfMjktMS0xLTEtMA_dd4622cf-6f7e-400b-bcf4-9281e0f17d02">1,518</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfMjktMy0xLTEtMA_483f990e-7223-4ede-bfed-88c14058eb80">473</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash and restricted cash provided by (used in) operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfMzAtMS0xLTEtMA_7c86dbb0-08f7-4cf3-926c-2e8648b43089">72,410</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfMzAtMy0xLTEtMA_c1cf20cb-9066-4194-ab24-def51a8db6f3">17,125</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash Flows Provided by (Used In) Investing Activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for asset acquisitions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfMzItMS0xLTEtMA_fb39206f-3bb2-4cf3-9597-bbcf28f1bc3c">1,472</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfMzItMy0xLTEtMA_85bb5029-252b-415e-8735-480261aad46c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from transfer of membership and release of Passport escrow</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfMzMtMS0xLTEtMA_58aa19b8-660b-471e-a433-3c80acf9e788">42,996</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfMzMtMy0xLTEtMA_8f28fa01-5809-4add-9df8-eebdcaea9f75">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Disposal of non-strategic assets and divestiture of discontinued operations, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="evh:PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfMzUtMS0xLTEtMA_2900ba78-f069-4074-a35c-62ba2b24acce">3,490</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="evh:PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfMzUtMy0xLTEtMA_93281bd0-6921-472d-8b51-d2dffd558908">2,287</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Return of equity method investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfMzYtMS0xLTEtMA_ef601fa9-bbb1-491e-a79c-756981036dff">9,372</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfMzYtMy0xLTEtMA_db17f949-b4ff-45f7-976c-5fb5c4eeb3d9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireHeldToMaturitySecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfMzctMS0xLTEtMA_64a00636-054a-4f69-97cc-0ab1a05fa7db">2,994</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireHeldToMaturitySecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfMzctMy0xLTEtMA_8dc969bc-fabf-41da-811d-007cc0dcf536">1,447</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturities and sales of investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="-3" name="evh:ProceedsFromMaturityOfInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfMzgtMS0xLTEtMA_ad6b2c4b-3609-4d53-9537-1fcf98b00b29">500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="evh:ProceedsFromMaturityOfInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfMzgtMy0xLTEtMA_7105db42-7edc-4503-bee3-0fa0f3e6945c">3,099</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in internal-use software and purchases of property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireOtherProductiveAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfMzktMS0xLTEtMA_208f9776-b173-4921-8f34-4082135678eb">11,512</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireOtherProductiveAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfMzktMy0xLTEtMA_9133d0d2-c646-4b0a-90c2-8a815fe35338">17,455</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other investing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfNDItMS0xLTEtMjc1_71be37f5-6d36-4362-bd98-1cc123cdb434">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="-3" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfNDItMy0xLTEtMjc1_c8b6ce1b-7061-46f6-83aa-16d5e7dc5443">292</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash and restricted cash provided by (used in) investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfNDAtMS0xLTEtMA_300a2f68-3d6f-4a97-afb6-964fe47b7df3">40,380</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfNDAtMy0xLTEtMA_5993583c-ed48-4e10-ba39-53a191c42e75">18,382</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash Flows Provided by (Used In) Financing Activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in working capital balances related to claims processing on behalf of partners</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="evh:PaymentsForProceedsFromClaimsProcessingFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfNDItMS0xLTEtMA_4fe0af28-4f03-44f8-a31f-ff650c115358">2,399</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="evh:PaymentsForProceedsFromClaimsProcessingFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfNDItMy0xLTEtMA_0c44c268-4b63-4a39-8a4c-8a5309e09b0f">26,715</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repayment and termination of Credit Agreement including settlement of warrants.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfSeniorDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfNDMtMS0xLTEtMA_b3ad0924-3db7-43cd-9c76-088e113a68c9">98,420</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:RepaymentsOfSeniorDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfNDMtMy0xLTEtMA_de675559-d1a5-4009-95ec-e506b2e68aa2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from stock option exercises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfNDQtMS0xLTEtMA_55af5f81-51fa-401f-9193-672a01c42c0e">9,376</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfNDQtMy0xLTEtMA_52e2abc7-e04a-48c0-a410-c33e2f541754">526</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Distributions to Sponsors</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToMinorityShareholders" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfNDgtMS0xLTEtNDYwOQ_cf341037-f5c6-472e-b78c-6c985e31d58f">1,300</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="-5" format="ixt:zerodash" name="us-gaap:PaymentsToMinorityShareholders" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfNDgtMy0xLTEtNDYwOQ_59eeea76-2b83-45ec-af6f-cb16b673d662">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">See accompanying Notes to Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:397.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:66.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:66.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Taxes withheld and paid for vesting of restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfNDUtMS0xLTEtMA_5e201623-faad-4846-be76-b93c4e9d7136">3,142</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfNDUtMy0xLTEtMA_98f5ff50-ef49-4cc8-a679-b20377c6b61e">1,331</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash and restricted cash provided by (used in) financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfNDYtMS0xLTEtMA_86e0f12c-a07f-4e6f-b840-b787bd568f6c">91,087</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfNDYtMy0xLTEtMA_9b02dc21-15af-4136-8766-c8e9cb8fdcdd">25,910</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rate on cash and cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfNDctMS0xLTEtMA_ac164134-9e19-4fa4-ad7b-75e37ec30f97">54</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="-3" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfNDctMy0xLTEtMA_7f01d16b-bd23-41c5-a759-ecb239456810">26</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase (decrease) in cash and cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfNDgtMS0xLTEtMA_22114c12-dd48-4e0d-b7fa-8d8a7207f5a4">123,171</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfNDgtMy0xLTEtMA_c6915341-a74b-43b1-a4b0-fe2ccb413b75">24,679</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents and restricted cash as of beginning-of-period </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45bff335c1434d6ba44132da1b0557db_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfNDktMS0xLTEtMA_e272ccc9-dc55-498c-89b9-404c1f9b6f6f">361,581</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0ff0ad229b441d4b12bc8956f92a917_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfNDktMy0xLTEtMA_ceaf962b-8aea-4d5b-a2af-c8eac1cdeca1">128,531</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents and restricted cash as of end-of-period </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfNTAtMS0xLTEtMA_e1d467e7-008d-4f8f-808d-93de1533b6f1">238,410</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11817f96c3e24e0abaed14a17869e173_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfNTAtMy0xLTEtMA_54b36cb3-55b4-4c38-a985-8a95b4bae96b">153,210</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RleHRyZWdpb246ZjU1OWJmYTMxNWU4NDFiNDkwMjJlMTQ4ZjBlYWZkY2FfNjE1_f300fa04-bc09-4350-94bb-64f25b72efcf" footnoteRole="http://www.xbrl.org/2003/role/footnote">As a result of the closing of the sale of True Health SPA, the consolidated statements of operations, consolidated balance sheets, and related financial information reflect the Company&#8217;s operations and assets and liabilities of True Health as discontinued operations for all periods presented. Cash flows and comprehensive income have not been adjusted and are included in the consolidated statements of cash flows and consolidated statements of comprehensive income (loss) for all periods presented. See Note 5.</ix:footnote></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">See accompanying Notes to Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="id8f403494d0a42c2868794fb470218fc_37"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">EVOLENT HEALTH, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(unaudited)</span></div><div id="id8f403494d0a42c2868794fb470218fc_40"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 1.  <ix:nonNumeric contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY180MC9mcmFnOmY4OTA3N2UxMjkyMDRjNGViY2U3NjI3Nzc3NDI0NmQxL3RleHRyZWdpb246Zjg5MDc3ZTEyOTIwNGM0ZWJjZTc2Mjc3Nzc0MjQ2ZDFfMjc4OQ_4afa3c38-38c3-4b0f-bead-225d20dd95bc" continuedAt="ie481dc328cc044d5a56c1a1508119229" escape="true">Organization </ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="ie481dc328cc044d5a56c1a1508119229" continuedAt="i47cf75690986434cad459498d8916273"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Evolent Health, Inc. was incorporated in December 2014 in the state of Delaware and through its subsidiaries supports leading health systems and physician organizations as well as health plans to move their business models from traditional fee for service reimbursement to value-based care, which we consider to be an integrated clinical and financial responsibility for populations. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company made organizational changes, including re-evaluating its reportable segments, as a result of the entry into the agreement to sell True Health on January 11, 2021. Effective during the first quarter of 2021, the Company bifurcated its previous Services segment into <ix:nonFraction unitRef="segment" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY180MC9mcmFnOmY4OTA3N2UxMjkyMDRjNGViY2U3NjI3Nzc3NDI0NmQxL3RleHRyZWdpb246Zjg5MDc3ZTEyOTIwNGM0ZWJjZTc2Mjc3Nzc0MjQ2ZDFfNjkz_2cef7eab-f438-42e5-92e8-a65237f80d62">two</ix:nonFraction> segments. The Company&#8217;s Evolent Health Services segment (&#8220;EHS&#8221;) includes our administrative simplification solution and certain supporting population health infrastructure. Our Clinical Solutions segment includes our specialty management and physician-oriented total cost of care solutions, along with the New Century Health and Evolent Care Partners brands. Refer to Note 21 for a further discussion of our operating results by segment.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since its inception, the Company has incurred losses from operations. As of June&#160;30, 2021, the Company had unrestricted cash and cash equivalents of $<ix:nonFraction unitRef="usd" contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY180MC9mcmFnOmY4OTA3N2UxMjkyMDRjNGViY2U3NjI3Nzc3NDI0NmQxL3RleHRyZWdpb246Zjg5MDc3ZTEyOTIwNGM0ZWJjZTc2Mjc3Nzc0MjQ2ZDFfMTI3Mw_75be52b3-187d-4246-9671-512f1eda3b64">207.3</ix:nonFraction> million. The Company believes it has sufficient liquidity for the next twelve months as of the date the financial statements were available to be issued.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s headquarters is located in Arlington, Virginia.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Evolent Health LLC Governance</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i47cf75690986434cad459498d8916273">Our operations are conducted through Evolent Health LLC and subsequent to the offering reorganization at the time of our initial public offering (the &#8220;Offering Reorganization&#8221;), the financial results of Evolent Health LLC were consolidated in the financial statements of Evolent Health, Inc. Evolent Health, Inc. is a holding company whose only business is to act as the sole managing member of Evolent Health LLC. As such, it controls Evolent Health LLC&#8217;s business and affairs and is responsible for the management of its business.</ix:continuation> </span></div><div style="text-align:justify"><span><br/></span></div><div id="id8f403494d0a42c2868794fb470218fc_43"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 2.  <ix:nonNumeric contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY180My9mcmFnOjhjZDBhN2Q5ZmU1ODQzNGVhNWQ3MTc3MzZhMGMxODYzL3RleHRyZWdpb246OGNkMGE3ZDlmZTU4NDM0ZWE1ZDcxNzczNmEwYzE4NjNfMTU0MzE_9a2d814b-a4ac-410b-a8a8-78468952d952" continuedAt="ib430e754cdf24a88a6624b74106a83b9" escape="true">Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="ib430e754cdf24a88a6624b74106a83b9" continuedAt="i0c5218336bd24a7ba47b9dfc8b72c10d"><ix:nonNumeric contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY180My9mcmFnOjhjZDBhN2Q5ZmU1ODQzNGVhNWQ3MTc3MzZhMGMxODYzL3RleHRyZWdpb246OGNkMGE3ZDlmZTU4NDM0ZWE1ZDcxNzczNmEwYzE4NjNfMTU0Mzg_386ad26f-4db8-4e5e-86dd-40e742447c19" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our opinion, the accompanying unaudited interim consolidated financial statements include all adjustments, consisting of normal recurring adjustments, which are necessary to fairly state our financial position, results of operations, and cash flows. The consolidated balance sheet as of December 31, 2020, has been derived from audited financial statements as of that date and reflects the impact of the agreement to sell True Health. See Note 5 for a complete summary of this transaction. The interim consolidated results of operations are not necessarily indicative of the results that may occur for the full fiscal year. Certain footnote disclosures normally included in financial statements prepared in accordance with United States of America generally accepted accounting principles (&#8220;GAAP&#8221;) have been omitted pursuant to instructions, rules, and regulations prescribed by the United States Securities and Exchange Commission (&#8220;SEC&#8221;). The disclosures provided herein should be read in conjunction with the audited financial statements and notes thereto included in our 2020 Form 10-K.</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summary of Significant Accounting Policies</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain GAAP policies that significantly affect the determination of our financial position, results of operations and cash flows, are summarized below.  See &#8220;Part II - Item 8. Financial Statements and Supplementary Data - Note 2&#8221; in our 2020 Form 10-K for a complete summary of our significant accounting policies.</span></div><div><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY180My9mcmFnOjhjZDBhN2Q5ZmU1ODQzNGVhNWQ3MTc3MzZhMGMxODYzL3RleHRyZWdpb246OGNkMGE3ZDlmZTU4NDM0ZWE1ZDcxNzczNmEwYzE4NjNfMTU0NDI_5bdbe5ee-eb4e-49d0-ba15-84e0784e1309" continuedAt="id2860796aac94f119edcf4658a822093" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting Estimates and Assumptions</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions affecting the reported amounts of assets and liabilities and the disclosures of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expenses for the reporting period. Those estimates are inherently subject to change and actual results could differ from those estimates. In the accompanying consolidated financial statements, estimates are used for, but not limited to, the valuation of assets (including intangibles assets, goodwill and long-lived assets), liabilities, consideration related to business combinations and asset acquisitions, revenue recognition (including variable consideration), estimated selling </span></div></ix:nonNumeric></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i0c5218336bd24a7ba47b9dfc8b72c10d" continuedAt="i216838b696b84755923838a666baeba6"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="id2860796aac94f119edcf4658a822093">prices for performance obligations in contracts with multiple performance obligations, reserves for claims and performance-based arrangements, credit losses, depreciable lives of assets, impairment of long-lived assets, stock-based compensation, deferred income taxes and valuation allowance, contingent liabilities, purchase price allocation in taxable stock transactions and useful lives of intangible assets.</ix:continuation></span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY180My9mcmFnOjhjZDBhN2Q5ZmU1ODQzNGVhNWQ3MTc3MzZhMGMxODYzL3RleHRyZWdpb246OGNkMGE3ZDlmZTU4NDM0ZWE1ZDcxNzczNmEwYzE4NjNfMTU0NTI_76bbacc6-2a5d-4a38-ae9e-c69f388064cb" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Principles of Consolidation</span></div><div style="padding-left:18pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of Evolent Health, Inc. and its subsidiaries. All intercompany accounts and transactions are eliminated in consolidation.</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" name="us-gaap:CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY180My9mcmFnOjhjZDBhN2Q5ZmU1ODQzNGVhNWQ3MTc3MzZhMGMxODYzL3RleHRyZWdpb246OGNkMGE3ZDlmZTU4NDM0ZWE1ZDcxNzczNmEwYzE4NjNfMTU0NTM_840ccd4f-b965-432d-8c6b-399750a54048" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash and Cash Equivalents</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider all highly liquid instruments with original maturities of three months or less to be cash equivalents. The Company holds materially all of our cash in bank deposits with FDIC participating banks, at cost, which approximates fair value. Cash and cash equivalents held in money market funds are carried at fair value, which approximates cost.</span></div></ix:nonNumeric><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Cash and Restricted Investments</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" name="us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY180My9mcmFnOjhjZDBhN2Q5ZmU1ODQzNGVhNWQ3MTc3MzZhMGMxODYzL3RleHRyZWdpb246OGNkMGE3ZDlmZTU4NDM0ZWE1ZDcxNzczNmEwYzE4NjNfMTU0MDI_ce32f53a-3471-4b36-b040-878c7b625ef5" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash and restricted investments include cash and investments used to collateralize various contractual obligations as of June&#160;30, 2021 and December&#160;31, 2020 (in thousands) as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:340.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:94.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:94.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collateral for letters of credit for facility leases </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie049e920122645beab4e92d759ec4ad6_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashAndCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY180My9mcmFnOjhjZDBhN2Q5ZmU1ODQzNGVhNWQ3MTc3MzZhMGMxODYzL3RhYmxlOjNhNTFiZjM3ODlhZjRhNjViYWQzNjYwNGI3YmViODI1L3RhYmxlcmFuZ2U6M2E1MWJmMzc4OWFmNGE2NWJhZDM2NjA0YjdiZWI4MjVfMS0xLTEtMS0w_6804a77a-3a62-4e4e-a8e5-8a3fe3176795">3,510</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibafea1edac4741a491dc06d42fbb6974_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashAndCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY180My9mcmFnOjhjZDBhN2Q5ZmU1ODQzNGVhNWQ3MTc3MzZhMGMxODYzL3RhYmxlOjNhNTFiZjM3ODlhZjRhNjViYWQzNjYwNGI3YmViODI1L3RhYmxlcmFuZ2U6M2E1MWJmMzc4OWFmNGE2NWJhZDM2NjA0YjdiZWI4MjVfMS0zLTEtMS0w_8b14da3a-feee-4463-8bbc-9b4fe451ff1d">3,510</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collateral with financial institutions </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51059975ca4a4ad18ae06161620c8d07_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashAndCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY180My9mcmFnOjhjZDBhN2Q5ZmU1ODQzNGVhNWQ3MTc3MzZhMGMxODYzL3RhYmxlOjNhNTFiZjM3ODlhZjRhNjViYWQzNjYwNGI3YmViODI1L3RhYmxlcmFuZ2U6M2E1MWJmMzc4OWFmNGE2NWJhZDM2NjA0YjdiZWI4MjVfMi0xLTEtMS0w_4e31be76-7647-4a19-abd5-e08167c60904">12,352</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84a57e99f4a84536b7f1f81b47d53542_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashAndCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY180My9mcmFnOjhjZDBhN2Q5ZmU1ODQzNGVhNWQ3MTc3MzZhMGMxODYzL3RhYmxlOjNhNTFiZjM3ODlhZjRhNjViYWQzNjYwNGI3YmViODI1L3RhYmxlcmFuZ2U6M2E1MWJmMzc4OWFmNGE2NWJhZDM2NjA0YjdiZWI4MjVfMi0zLTEtMS0w_58e79ead-1bed-41e9-8b1d-e089843ffa6d">4,743</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Claims processing services </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i724f3fb7e8664faf9d4251ef0ad9db50_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashAndCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY180My9mcmFnOjhjZDBhN2Q5ZmU1ODQzNGVhNWQ3MTc3MzZhMGMxODYzL3RhYmxlOjNhNTFiZjM3ODlhZjRhNjViYWQzNjYwNGI3YmViODI1L3RhYmxlcmFuZ2U6M2E1MWJmMzc4OWFmNGE2NWJhZDM2NjA0YjdiZWI4MjVfMy0xLTEtMS0w_e3476353-9717-406e-81e4-5a3792d3729c">14,525</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68d600384d87411f9808a47f7fa089b1_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashAndCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY180My9mcmFnOjhjZDBhN2Q5ZmU1ODQzNGVhNWQ3MTc3MzZhMGMxODYzL3RhYmxlOjNhNTFiZjM3ODlhZjRhNjViYWQzNjYwNGI3YmViODI1L3RhYmxlcmFuZ2U6M2E1MWJmMzc4OWFmNGE2NWJhZDM2NjA0YjdiZWI4MjVfMy0zLTEtMS0w_50627276-5ea3-4f31-9a98-36d5353b8d23">12,064</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if917fe9e46d74bbba565ff75862d3292_I20210630" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY180My9mcmFnOjhjZDBhN2Q5ZmU1ODQzNGVhNWQ3MTc3MzZhMGMxODYzL3RhYmxlOjNhNTFiZjM3ODlhZjRhNjViYWQzNjYwNGI3YmViODI1L3RhYmxlcmFuZ2U6M2E1MWJmMzc4OWFmNGE2NWJhZDM2NjA0YjdiZWI4MjVfNC0xLTEtMS0w_f16c22ed-1728-4672-8ffc-c1f0f6a72cd0">750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2b7bf7f852c4e07ae4036ec1933f336_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashAndCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY180My9mcmFnOjhjZDBhN2Q5ZmU1ODQzNGVhNWQ3MTc3MzZhMGMxODYzL3RhYmxlOjNhNTFiZjM3ODlhZjRhNjViYWQzNjYwNGI3YmViODI1L3RhYmxlcmFuZ2U6M2E1MWJmMzc4OWFmNGE2NWJhZDM2NjA0YjdiZWI4MjVfNC0zLTEtMS0w_334ca88b-5486-4fb4-a8a2-4bfeb070f8a2">1,327</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total restricted cash and restricted investments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashAndCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY180My9mcmFnOjhjZDBhN2Q5ZmU1ODQzNGVhNWQ3MTc3MzZhMGMxODYzL3RhYmxlOjNhNTFiZjM3ODlhZjRhNjViYWQzNjYwNGI3YmViODI1L3RhYmxlcmFuZ2U6M2E1MWJmMzc4OWFmNGE2NWJhZDM2NjA0YjdiZWI4MjVfNS0xLTEtMS0w_26552208-7829-4f47-8288-ea1213f937b7">31,137</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45bff335c1434d6ba44132da1b0557db_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashAndCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY180My9mcmFnOjhjZDBhN2Q5ZmU1ODQzNGVhNWQ3MTc3MzZhMGMxODYzL3RhYmxlOjNhNTFiZjM3ODlhZjRhNjViYWQzNjYwNGI3YmViODI1L3RhYmxlcmFuZ2U6M2E1MWJmMzc4OWFmNGE2NWJhZDM2NjA0YjdiZWI4MjVfNS0zLTEtMS0w_e6cd600c-1ca0-45ad-ab1f-f26d632d2f74">21,644</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY180My9mcmFnOjhjZDBhN2Q5ZmU1ODQzNGVhNWQ3MTc3MzZhMGMxODYzL3RhYmxlOjNhNTFiZjM3ODlhZjRhNjViYWQzNjYwNGI3YmViODI1L3RhYmxlcmFuZ2U6M2E1MWJmMzc4OWFmNGE2NWJhZDM2NjA0YjdiZWI4MjVfNy0xLTEtMS0w_c75a7083-e97c-4664-a313-9f7190847c49">17,742</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45bff335c1434d6ba44132da1b0557db_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY180My9mcmFnOjhjZDBhN2Q5ZmU1ODQzNGVhNWQ3MTc3MzZhMGMxODYzL3RhYmxlOjNhNTFiZjM3ODlhZjRhNjViYWQzNjYwNGI3YmViODI1L3RhYmxlcmFuZ2U6M2E1MWJmMzc4OWFmNGE2NWJhZDM2NjA0YjdiZWI4MjVfNy0zLTEtMS0w_84e2aa31-0906-4f81-8385-8c0b753a08f6">14,374</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current restricted cash and restricted investments</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashAndInvestmentsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY180My9mcmFnOjhjZDBhN2Q5ZmU1ODQzNGVhNWQ3MTc3MzZhMGMxODYzL3RhYmxlOjNhNTFiZjM3ODlhZjRhNjViYWQzNjYwNGI3YmViODI1L3RhYmxlcmFuZ2U6M2E1MWJmMzc4OWFmNGE2NWJhZDM2NjA0YjdiZWI4MjVfOC0xLTEtMS0w_63e8fb2d-6278-443f-baba-bba4f96619ce">17,742</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45bff335c1434d6ba44132da1b0557db_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashAndInvestmentsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY180My9mcmFnOjhjZDBhN2Q5ZmU1ODQzNGVhNWQ3MTc3MzZhMGMxODYzL3RhYmxlOjNhNTFiZjM3ODlhZjRhNjViYWQzNjYwNGI3YmViODI1L3RhYmxlcmFuZ2U6M2E1MWJmMzc4OWFmNGE2NWJhZDM2NjA0YjdiZWI4MjVfOC0zLTEtMS0w_52507d96-c382-4aa3-ba1f-2b4963d39b27">14,374</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY180My9mcmFnOjhjZDBhN2Q5ZmU1ODQzNGVhNWQ3MTc3MzZhMGMxODYzL3RhYmxlOjNhNTFiZjM3ODlhZjRhNjViYWQzNjYwNGI3YmViODI1L3RhYmxlcmFuZ2U6M2E1MWJmMzc4OWFmNGE2NWJhZDM2NjA0YjdiZWI4MjVfMTAtMS0xLTEtMA_a7be6a1f-c9c7-48a4-b60f-868881552252">13,395</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45bff335c1434d6ba44132da1b0557db_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY180My9mcmFnOjhjZDBhN2Q5ZmU1ODQzNGVhNWQ3MTc3MzZhMGMxODYzL3RhYmxlOjNhNTFiZjM3ODlhZjRhNjViYWQzNjYwNGI3YmViODI1L3RhYmxlcmFuZ2U6M2E1MWJmMzc4OWFmNGE2NWJhZDM2NjA0YjdiZWI4MjVfMTAtMy0xLTEtMA_3e120e9b-e231-4fd6-adbe-7038dce599f0">6,654</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total non-current restricted cash and restricted investments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashAndInvestmentsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY180My9mcmFnOjhjZDBhN2Q5ZmU1ODQzNGVhNWQ3MTc3MzZhMGMxODYzL3RhYmxlOjNhNTFiZjM3ODlhZjRhNjViYWQzNjYwNGI3YmViODI1L3RhYmxlcmFuZ2U6M2E1MWJmMzc4OWFmNGE2NWJhZDM2NjA0YjdiZWI4MjVfMTEtMS0xLTEtMA_a38536b4-edbb-438c-8ffd-9f6274be739e">13,395</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45bff335c1434d6ba44132da1b0557db_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashAndInvestmentsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY180My9mcmFnOjhjZDBhN2Q5ZmU1ODQzNGVhNWQ3MTc3MzZhMGMxODYzL3RhYmxlOjNhNTFiZjM3ODlhZjRhNjViYWQzNjYwNGI3YmViODI1L3RhYmxlcmFuZ2U6M2E1MWJmMzc4OWFmNGE2NWJhZDM2NjA0YjdiZWI4MjVfMTEtMy0xLTEtMA_d81d41b6-8198-41a3-b5f8-9a23715db85a">6,654</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Amounts exclude $<ix:nonFraction unitRef="usd" contextRef="ia177f909fbae4389bdaa8635f038babb_I20201231" decimals="-5" format="ixt:numdotdecimal" name="evh:DisposalGroupIncludingDiscontinuedOperationRestrictedInvestmentsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY180My9mcmFnOjhjZDBhN2Q5ZmU1ODQzNGVhNWQ3MTc3MzZhMGMxODYzL3RleHRyZWdpb246OGNkMGE3ZDlmZTU4NDM0ZWE1ZDcxNzczNmEwYzE4NjNfMzM4NQ_7b534217-4ba1-42ac-8c6e-0138065d740f">0.6</ix:nonFraction> million of non-current restricted investments and $<ix:nonFraction unitRef="usd" contextRef="ia177f909fbae4389bdaa8635f038babb_I20201231" decimals="-5" format="ixt:numdotdecimal" name="evh:DisposalGroupIncludingDiscontinuedOperationRestrictedCashCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY180My9mcmFnOjhjZDBhN2Q5ZmU1ODQzNGVhNWQ3MTc3MzZhMGMxODYzL3RleHRyZWdpb246OGNkMGE3ZDlmZTU4NDM0ZWE1ZDcxNzczNmEwYzE4NjNfMzQzMA_697a00aa-e548-4bde-ae4a-0474df4c5ace">0.1</ix:nonFraction>&#160;million of current restricted cash from claims processing services reclassified to discontinued operations as of December&#160;31, 2020.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Represents restricted cash related to collateral for letters of credit required in conjunction with lease agreements. See Note 12 for further discussion of our lease commitments. </span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Represents collateral held with financial institutions for risk-sharing and other arrangements. As of June&#160;30, 2021 and December&#160;31, 2020, approximately $<ix:nonFraction unitRef="usd" contextRef="iff2a65b6a1be4bb6b51772f3a5414255_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashAndCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY180My9mcmFnOjhjZDBhN2Q5ZmU1ODQzNGVhNWQ3MTc3MzZhMGMxODYzL3RleHRyZWdpb246OGNkMGE3ZDlmZTU4NDM0ZWE1ZDcxNzczNmEwYzE4NjNfMzg0OQ_8e40a6fa-1df9-40f5-94e2-25705a7766a2">12.4</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i8abf010fb96f42a3a9c433ab04beeed6_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashAndCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY180My9mcmFnOjhjZDBhN2Q5ZmU1ODQzNGVhNWQ3MTc3MzZhMGMxODYzL3RleHRyZWdpb246OGNkMGE3ZDlmZTU4NDM0ZWE1ZDcxNzczNmEwYzE4NjNfMzg1Ng_ee69c79a-c676-4e11-8c7b-3a1cbcd65c30">4.7</ix:nonFraction> million, respectively, of the collateral amounts were held in a FDIC participating bank account. See Note 18 for discussion of fair value measurement and Note 11 for discussion of our risk-sharing arrangements. </span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Represents cash held by the Company related to claims processing services on behalf of partners. These are pass-through amounts and can fluctuate materially from period to period depending on the timing of when the claims are processed.</span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statements of cash flows as of June&#160;30, 2021 and 2020 (in thousands).</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:433.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY180My9mcmFnOjhjZDBhN2Q5ZmU1ODQzNGVhNWQ3MTc3MzZhMGMxODYzL3RhYmxlOmQxMDY0MzRkODgxNTQxOTFiYmVkYTRhOTM2Nzg2ZDJlL3RhYmxlcmFuZ2U6ZDEwNjQzNGQ4ODE1NDE5MWJiZWRhNGE5MzY3ODZkMmVfMi0xLTEtMS0w_e3fbfd72-29d8-4e8d-8377-ac0c97eaa1ce">207,273</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11817f96c3e24e0abaed14a17869e173_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY180My9mcmFnOjhjZDBhN2Q5ZmU1ODQzNGVhNWQ3MTc3MzZhMGMxODYzL3RhYmxlOmQxMDY0MzRkODgxNTQxOTFiYmVkYTRhOTM2Nzg2ZDJlL3RhYmxlcmFuZ2U6ZDEwNjQzNGQ4ODE1NDE5MWJiZWRhNGE5MzY3ODZkMmVfMi0zLTEtMS0w_71a8c124-04fa-4865-9913-c8aabe034c9f">98,272</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash and restricted investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashAndCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY180My9mcmFnOjhjZDBhN2Q5ZmU1ODQzNGVhNWQ3MTc3MzZhMGMxODYzL3RhYmxlOmQxMDY0MzRkODgxNTQxOTFiYmVkYTRhOTM2Nzg2ZDJlL3RhYmxlcmFuZ2U6ZDEwNjQzNGQ4ODE1NDE5MWJiZWRhNGE5MzY3ODZkMmVfMy0xLTEtMS0w_26552208-7829-4f47-8288-ea1213f937b7">31,137</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11817f96c3e24e0abaed14a17869e173_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashAndCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY180My9mcmFnOjhjZDBhN2Q5ZmU1ODQzNGVhNWQ3MTc3MzZhMGMxODYzL3RhYmxlOmQxMDY0MzRkODgxNTQxOTFiYmVkYTRhOTM2Nzg2ZDJlL3RhYmxlcmFuZ2U6ZDEwNjQzNGQ4ODE1NDE5MWJiZWRhNGE5MzY3ODZkMmVfMy0zLTEtMS0w_2166329f-804a-4f3d-b2b0-f859513cb319">55,653</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted investments included in restricted cash and restricted investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:RestrictedInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY180My9mcmFnOjhjZDBhN2Q5ZmU1ODQzNGVhNWQ3MTc3MzZhMGMxODYzL3RhYmxlOmQxMDY0MzRkODgxNTQxOTFiYmVkYTRhOTM2Nzg2ZDJlL3RhYmxlcmFuZ2U6ZDEwNjQzNGQ4ODE1NDE5MWJiZWRhNGE5MzY3ODZkMmVfNC0xLTEtMS0w_f0998314-b6ed-494d-8b36-c3060b249c75">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i11817f96c3e24e0abaed14a17869e173_I20200630" decimals="-3" name="us-gaap:RestrictedInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY180My9mcmFnOjhjZDBhN2Q5ZmU1ODQzNGVhNWQ3MTc3MzZhMGMxODYzL3RhYmxlOmQxMDY0MzRkODgxNTQxOTFiYmVkYTRhOTM2Nzg2ZDJlL3RhYmxlcmFuZ2U6ZDEwNjQzNGQ4ODE1NDE5MWJiZWRhNGE5MzY3ODZkMmVfNC0zLTEtMS0w_32aaa20e-deae-4156-922c-9ef8fd0a6c8b">715</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:5.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents and restricted cash shown in the consolidated statements of cash flows </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY180My9mcmFnOjhjZDBhN2Q5ZmU1ODQzNGVhNWQ3MTc3MzZhMGMxODYzL3RhYmxlOmQxMDY0MzRkODgxNTQxOTFiYmVkYTRhOTM2Nzg2ZDJlL3RhYmxlcmFuZ2U6ZDEwNjQzNGQ4ODE1NDE5MWJiZWRhNGE5MzY3ODZkMmVfNS0xLTEtMS0w_5e1f9621-dd61-4f48-a199-67ff0634c23a">238,410</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11817f96c3e24e0abaed14a17869e173_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY180My9mcmFnOjhjZDBhN2Q5ZmU1ODQzNGVhNWQ3MTc3MzZhMGMxODYzL3RhYmxlOmQxMDY0MzRkODgxNTQxOTFiYmVkYTRhOTM2Nzg2ZDJlL3RhYmxlcmFuZ2U6ZDEwNjQzNGQ4ODE1NDE5MWJiZWRhNGE5MzY3ODZkMmVfNS0zLTEtMS0w_0e2f9c74-9152-4631-9d63-5777c60134a1">153,210</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">As a result of the closing of the sale of True Health SPA, the consolidated statements of operations, consolidated balance sheets, and related financial information reflect the Company&#8217;s operations and assets and liabilities of True Health as discontinued operations for all periods presented. Cash flows and comprehensive income have not been adjusted and are included in the consolidated statements of cash flows and consolidated statements of comprehensive income (loss) for all periods presented. See Note 5.</span></div></ix:nonNumeric></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i216838b696b84755923838a666baeba6" continuedAt="iacaeca57e9514699bd9fc86110fa1597"><ix:nonNumeric contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" name="us-gaap:BusinessCombinationsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY180My9mcmFnOjhjZDBhN2Q5ZmU1ODQzNGVhNWQ3MTc3MzZhMGMxODYzL3RleHRyZWdpb246OGNkMGE3ZDlmZTU4NDM0ZWE1ZDcxNzczNmEwYzE4NjNfMTU0MjQ_0f2bb67e-6dd2-4885-85f6-7829ad5c7cc3" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Companies acquired during each reporting period are reflected in the results of the Company effective from their respective dates of acquisition through the end of the reporting period. The Company allocates the fair value of purchase consideration to the assets acquired and liabilities assumed based on their estimated fair values at the acquisition date. Our estimates of fair value are based upon assumptions believed to be reasonable, but which are inherently uncertain and unpredictable and, as a result, actual results may differ from estimates. Critical estimates used to value certain identifiable assets include, but are not limited to, expected long-term revenues, future expected operating expenses, cost of capital, and appropriate discount rates. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The excess of the fair value of purchase consideration over the fair value of the assets acquired and liabilities assumed in the acquired entity is recorded as goodwill. Goodwill is assigned to the reporting unit that benefits from the synergies arising from the business combination. If the Company obtains new information about facts and circumstances that existed as of the acquisition date during the measurement period, which may be up to one year from the acquisition date, the Company may record adjustments to the assets acquired and liabilities assumed, with the corresponding offset to goodwill. Upon the conclusion of the measurement period or final determination of the values of assets acquired or liabilities assumed, whichever comes first, any subsequent adjustments are recorded on the Company's consolidated statements of operations and comprehensive income (loss). </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For contingent consideration recorded as a liability, the Company initially measures the amount at fair value as of the acquisition date and adjusts the liability, if needed, to fair value at each reporting period. Changes in the fair value of contingent consideration, other than measurement period adjustments, are recognized as operating income or expense. Acquisition-related expenses and post-acquisition restructuring costs are recognized separately from the business combination and are expensed as incurred.</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" name="us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY180My9mcmFnOjhjZDBhN2Q5ZmU1ODQzNGVhNWQ3MTc3MzZhMGMxODYzL3RleHRyZWdpb246OGNkMGE3ZDlmZTU4NDM0ZWE1ZDcxNzczNmEwYzE4NjNfMTU0NDg_127789dc-7741-43e3-8c2e-3521728b9e27" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize the excess of the purchase price, plus the fair value of any non-controlling interests in the acquiree, over the fair value of identifiable net assets acquired as goodwill. Goodwill is not amortized, but is reviewed at least annually for indications of impairment, with consideration given to financial performance and other relevant factors. We perform impairment tests of goodwill at a reporting unit level. Following the sale of True Health, the Company has <ix:nonFraction unitRef="reportingunit" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfReportingUnits" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY180My9mcmFnOjhjZDBhN2Q5ZmU1ODQzNGVhNWQ3MTc3MzZhMGMxODYzL3RleHRyZWdpb246OGNkMGE3ZDlmZTU4NDM0ZWE1ZDcxNzczNmEwYzE4NjNfNzc1Mw_21a581a1-062c-49e4-a54c-34b0c2943d10">three</ix:nonFraction> reporting units and our annual goodwill impairment review occurs during the fourth quarter of each year. We perform impairment tests between annual tests if an event occurs, or circumstances change, that we believe would more likely than not reduce the fair value of a reporting unit below its carrying amount. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our goodwill impairment analysis first assesses qualitative factors to determine whether events or circumstances existed that would lead the Company to conclude it is more likely than not that the fair value of a reporting unit is below its carrying amount. If the Company determines that it is more likely than not that the fair value of a reporting unit is below the carrying amount, a quantitative goodwill assessment is required. In the quantitative evaluation, the fair value of the relevant reporting unit is determined and compared to the carrying value. If the fair value is greater than the carrying value, then the carrying value is deemed to be recoverable and no further action is required. If the fair value estimate is less than the carrying value, goodwill is considered impaired for the amount by which the carrying amount exceeds the reporting unit&#8217;s fair value and a charge is reported in goodwill impairment on our consolidated statements of operations and comprehensive income (loss). See Note 9 for additional discussion regarding the goodwill impairment tests conducted during 2021 and 2020.</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" name="us-gaap:IntangibleAssetsFiniteLivedPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY180My9mcmFnOjhjZDBhN2Q5ZmU1ODQzNGVhNWQ3MTc3MzZhMGMxODYzL3RleHRyZWdpb246OGNkMGE3ZDlmZTU4NDM0ZWE1ZDcxNzczNmEwYzE4NjNfMTU0MjU_d3b80b2d-8422-4a4e-8704-45c764e61705" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangible Assets, Net </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Identified intangible assets are recorded at their estimated fair values at the date of acquisition and are amortized over their respective estimated useful lives using a method of amortization that reflects the pattern in which the economic benefits of the intangible assets are used. </span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY180My9mcmFnOjhjZDBhN2Q5ZmU1ODQzNGVhNWQ3MTc3MzZhMGMxODYzL3RleHRyZWdpb246OGNkMGE3ZDlmZTU4NDM0ZWE1ZDcxNzczNmEwYzE4NjNfMTU0NTQ_f74689fc-80ed-4d58-be88-2938d12e6063" continuedAt="i5c4ee7b6b013466fa81c2778565ebd79" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes the estimated useful lives by asset classification:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:438.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:97.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate trade name</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i83f72281c0b7415ea503edc371882a4f_D20210101-20210630" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY180My9mcmFnOjhjZDBhN2Q5ZmU1ODQzNGVhNWQ3MTc3MzZhMGMxODYzL3RhYmxlOjRkZDhkMjhiZjk0MzRkNzY5N2RjNzdkMGY5MmViNjU2L3RhYmxlcmFuZ2U6NGRkOGQyOGJmOTQzNGQ3Njk3ZGM3N2QwZjkyZWI2NTZfMC0xLTEtMS0wL3RleHRyZWdpb246ZGQyMzBjZGU3ODJlNDVjYTg4YjQyM2E3MGIyZGMzMDhfNA_d6fa3db3-005c-4de0-b747-43f5332f5ce8">10</ix:nonNumeric> - <ix:nonNumeric contextRef="i9adc1f85abe84fe7ad21ea3765dc9836_D20210101-20210630" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY180My9mcmFnOjhjZDBhN2Q5ZmU1ODQzNGVhNWQ3MTc3MzZhMGMxODYzL3RhYmxlOjRkZDhkMjhiZjk0MzRkNzY5N2RjNzdkMGY5MmViNjU2L3RhYmxlcmFuZ2U6NGRkOGQyOGJmOTQzNGQ3Njk3ZGM3N2QwZjkyZWI2NTZfMC0xLTEtMS0wL3RleHRyZWdpb246ZGQyMzBjZGU3ODJlNDVjYTg4YjQyM2E3MGIyZGMzMDhfOQ_2e49eb06-2d82-4bc3-81dc-21ec16b36e3f">20</ix:nonNumeric> years</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0de7bb52dc554f47ba2d09f4fb6ee9a6_D20210101-20210630" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY180My9mcmFnOjhjZDBhN2Q5ZmU1ODQzNGVhNWQ3MTc3MzZhMGMxODYzL3RhYmxlOjRkZDhkMjhiZjk0MzRkNzY5N2RjNzdkMGY5MmViNjU2L3RhYmxlcmFuZ2U6NGRkOGQyOGJmOTQzNGQ3Njk3ZGM3N2QwZjkyZWI2NTZfMS0xLTEtMS0wL3RleHRyZWdpb246MjgwMTY1NGZiOWM3NGFjODk0YzQ2ZjBiZTVhNDRiNmJfNA_ba698616-f79f-4e4f-9001-6d8c99982f39">10</ix:nonNumeric> - <ix:nonNumeric contextRef="i2c645dae132a46319fcf7e651dc2048b_D20210101-20210630" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY180My9mcmFnOjhjZDBhN2Q5ZmU1ODQzNGVhNWQ3MTc3MzZhMGMxODYzL3RhYmxlOjRkZDhkMjhiZjk0MzRkNzY5N2RjNzdkMGY5MmViNjU2L3RhYmxlcmFuZ2U6NGRkOGQyOGJmOTQzNGQ3Njk3ZGM3N2QwZjkyZWI2NTZfMS0xLTEtMS0wL3RleHRyZWdpb246MjgwMTY1NGZiOWM3NGFjODk0YzQ2ZjBiZTVhNDRiNmJfOQ_cf4da792-debc-4253-a709-4583806ec7eb">25</ix:nonNumeric> years</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i78747c549a50444ab43a62d1064b465a_D20210101-20210630" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY180My9mcmFnOjhjZDBhN2Q5ZmU1ODQzNGVhNWQ3MTc3MzZhMGMxODYzL3RhYmxlOjRkZDhkMjhiZjk0MzRkNzY5N2RjNzdkMGY5MmViNjU2L3RhYmxlcmFuZ2U6NGRkOGQyOGJmOTQzNGQ3Njk3ZGM3N2QwZjkyZWI2NTZfMi0xLTEtMS0w_8ad8e368-526c-44a9-b370-79ae8f7f02bc">5</ix:nonNumeric> years</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provider network contracts</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib784c8c0f9134bf48331872daaad6c4e_D20210101-20210630" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY180My9mcmFnOjhjZDBhN2Q5ZmU1ODQzNGVhNWQ3MTc3MzZhMGMxODYzL3RhYmxlOjRkZDhkMjhiZjk0MzRkNzY5N2RjNzdkMGY5MmViNjU2L3RhYmxlcmFuZ2U6NGRkOGQyOGJmOTQzNGQ3Njk3ZGM3N2QwZjkyZWI2NTZfMy0xLTEtMS0wL3RleHRyZWdpb246YTQ0ZDEzY2E4MWI4NDY1OGFkOTMxYjdhZjE4MDFmZGZfNA_a551cae5-a60e-46e1-b3de-90e0633fd63a">4</ix:nonNumeric> - <ix:nonNumeric contextRef="ic82528f4a4554d6798f39cdf656b0d5f_D20210101-20210630" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY180My9mcmFnOjhjZDBhN2Q5ZmU1ODQzNGVhNWQ3MTc3MzZhMGMxODYzL3RhYmxlOjRkZDhkMjhiZjk0MzRkNzY5N2RjNzdkMGY5MmViNjU2L3RhYmxlcmFuZ2U6NGRkOGQyOGJmOTQzNGQ3Njk3ZGM3N2QwZjkyZWI2NTZfMy0xLTEtMS0wL3RleHRyZWdpb246YTQ0ZDEzY2E4MWI4NDY1OGFkOTMxYjdhZjE4MDFmZGZfOQ_24d188b2-8376-4205-96e0-3e17d5b12f85">5</ix:nonNumeric> years</span></div></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets are reviewed for impairment if circumstances indicate the Company may not be able to recover the asset&#8217;s carrying value. The Company evaluates recoverability by determining whether the undiscounted cash flows expected to result from the use and eventual disposition of that asset or group exceed the carrying value at the evaluation date. If the undiscounted cash flows are not sufficient to cover the carrying value, the Company measures an impairment loss as the excess of the carrying amount of the long-lived asset or group over its fair value. See Note 9 for additional discussion regarding our intangible assets.</span></div></ix:nonNumeric></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="iacaeca57e9514699bd9fc86110fa1597" continuedAt="i283a52050291412cbd88c6438ebf7471"><ix:nonNumeric contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" name="us-gaap:LiabilityReserveEstimatePolicy" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY180My9mcmFnOjhjZDBhN2Q5ZmU1ODQzNGVhNWQ3MTc3MzZhMGMxODYzL3RleHRyZWdpb246OGNkMGE3ZDlmZTU4NDM0ZWE1ZDcxNzczNmEwYzE4NjNfMTU0Njg_ec0e0ad2-afec-445a-bdfc-eee3ba780b56" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reserves for Claims and Performance-based Arrangements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reserves for performance-based arrangements and claims reflect estimates of payments under performance-based arrangements and the ultimate cost of claims that have been incurred but not reported, including expected development on reported claims, those that have been reported but not yet paid (reported claims in process), and other medical care expenses and services payable that are primarily composed of accruals for incentives and other amounts payable to health care professionals and facilities. The Company uses actuarial principles and assumptions that are consistently applied in each reporting period and recognizes the actuarial best estimate of the ultimate liability along with a margin for adverse deviation. This approach is consistent with actuarial standards of practice that the liabilities be adequate under moderately adverse conditions. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The process of estimating reserves involves a considerable degree of judgment by the Company and, as of any given date, is inherently uncertain. The methods for making such estimates and for establishing the resulting liability are continually reviewed, and adjustments are reflected in current results of operations in the period in which they are identified as experience develops or new information becomes known. See Note 22 for additional discussion regarding our reserves for claims and performance-based arrangements.</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" name="us-gaap:LesseeLeasesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY180My9mcmFnOjhjZDBhN2Q5ZmU1ODQzNGVhNWQ3MTc3MzZhMGMxODYzL3RleHRyZWdpb246OGNkMGE3ZDlmZTU4NDM0ZWE1ZDcxNzczNmEwYzE4NjNfMTU0Mjg_61eb8170-fc49-4eb5-9953-85d0ec3abcbb" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into various office space, data center, and equipment lease agreements in conducting its normal business operations. At the inception of any contract, the Company evaluates the agreement to determine whether the contract contains a lease. If the contract contains a lease, the Company then evaluates the term and whether the lease is an operating or finance lease. Most leases include one or more options to renew or may have a termination option. The Company determines whether these options are reasonably certain to be exercised at the inception of the lease. The rent expense is recognized on a straight-line basis in the consolidated statements of operations and comprehensive income (loss) over the terms of the respective leases. Leases with an initial term of 12 months or less are not recorded on the consolidated balance sheets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. We use the implicit rate when readily determinable. Further, the Company treats all lease and non-lease components as a single combined lease component for all classes of underlying assets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also enters into sublease agreements for some of its leased office space. Rental income attributable to subleases is immaterial and is offset against rent expense over the terms of the respective leases.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 12 for additional lease disclosures.</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY180My9mcmFnOjhjZDBhN2Q5ZmU1ODQzNGVhNWQ3MTc3MzZhMGMxODYzL3RleHRyZWdpb246OGNkMGE3ZDlmZTU4NDM0ZWE1ZDcxNzczNmEwYzE4NjNfMTU0Mzk_c612aed0-5314-4ebe-84ee-7d2b5ab40ea9" continuedAt="i2e658269c2b04a0fb65ee07cb2f0201f" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We derive revenue from two sources: (1) transformation services and (2) platform and operations services. Transformation services consist of implementation services whereby we assist the customer in launching its population health or health plan programs, or implement certain platform and operations services. In certain cases, transformation services can also include revenue associated with our support of certain one-time wind-down activities for clients who are exiting a line of business or population. Platform and operations services generally include multi-year arrangements with customers to provide various population health, health plan operations, specialty care management and claims processing services on an ongoing basis, as well as transition or run-out services to customers receiving primarily TPA services. Revenue is recognized when control of the services is transferred to our customers.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the following 5-step model, outlined in Accounting Standards Codification (&#8220;ASC&#8221;) Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 606&#8221;), to determine revenue recognition from our contracts with customers:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"> Identify the contract(s) with a customer</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"> Identify the performance obligations in the contract</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"> Determine the transaction price</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"> Allocate the transaction price to performance obligations</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"> Recognize revenue when (or as) the entity satisfies a performance obligation</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i2e658269c2b04a0fb65ee07cb2f0201f">See Note 6 for further discussion of our policies related to revenue recognition.</ix:continuation> </span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i283a52050291412cbd88c6438ebf7471"><ix:nonNumeric contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY180My9mcmFnOjhjZDBhN2Q5ZmU1ODQzNGVhNWQ3MTc3MzZhMGMxODYzL3RleHRyZWdpb246OGNkMGE3ZDlmZTU4NDM0ZWE1ZDcxNzczNmEwYzE4NjNfMTU0MTc_b6ffd520-0402-4457-9db3-874d581a123f" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign Currency</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company formed a subsidiary in India during the first quarter of 2018. The functional currency of our international subsidiary is the Indian Rupee. We translate the financial statements of this subsidiary to U.S. dollars using month-end rates of exchange for assets and liabilities, and monthly average rates of exchange for revenue and expenses. Translation gains and losses are recorded in accumulated other comprehensive income (loss) as a component of shareholders' equity. Foreign currency translation gains and losses did not have a material impact on our consolidated statements of operations and comprehensive income (loss) for the three and six months ended June 30, 2021 and 2020.</span></div></ix:nonNumeric></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="id8f403494d0a42c2868794fb470218fc_46"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 3.  <ix:nonNumeric contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" name="us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY180Ni9mcmFnOjFlZjc0Mjc4OGM3NjQ2NzQ5MGQwNWNhZWM5MzAwYjhkL3RleHRyZWdpb246MWVmNzQyNzg4Yzc2NDY3NDkwZDA1Y2FlYzkzMDBiOGRfMzI0OQ_9ce9af63-f12f-4bcf-9683-9bd6c64a84fb" continuedAt="i2b2926b9e150410aac9d36ee39298e8b" escape="true">Recently Issued Accounting Standards</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i2b2926b9e150410aac9d36ee39298e8b"><ix:nonNumeric contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY180Ni9mcmFnOjFlZjc0Mjc4OGM3NjQ2NzQ5MGQwNWNhZWM5MzAwYjhkL3RleHRyZWdpb246MWVmNzQyNzg4Yzc2NDY3NDkwZDA1Y2FlYzkzMDBiOGRfMzI2MQ_d132d076-e51e-4b52-abae-5297229cc5bd" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Adoption of New Accounting Standards</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and subsequently issued additional guidance that modified ASU 2016-13. The standard requires an entity to change its accounting approach for measuring and recognizing credit losses on certain financial assets measured at amortized cost, including trade receivables, certain non-trade receivables, contract assets, held-to-maturity securities, customer advances and certain off-balance sheet credit exposures, by replacing the existing &#8220;incurred loss&#8221; framework with an expected credit loss recognition model.&#160; The new standard results in earlier recognition of credit losses based on past events, current conditions, and reasonable and supportable forecasts.&#160; The standard is effective for entities with fiscal years beginning after December 15, 2019, including interim periods within such fiscal years. We adopted the requirements of this standard effective January 1, 2020 using the modified retrospective approach and recorded a cumulative effect adjustment of $<ix:nonFraction unitRef="usd" contextRef="i06c25faea1e7483786ebe928e1ff0fa4_I20191231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY180Ni9mcmFnOjFlZjc0Mjc4OGM3NjQ2NzQ5MGQwNWNhZWM5MzAwYjhkL3RleHRyZWdpb246MWVmNzQyNzg4Yzc2NDY3NDkwZDA1Y2FlYzkzMDBiOGRfMTIwMQ_f9d896ee-6771-4437-afaa-7a0955f58260">3.0</ix:nonFraction> million to January 1, 2020 retained earnings (accumulated deficit). Results for reporting periods beginning January 1, 2020 reflect the adoption of <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY180Ni9mcmFnOjFlZjc0Mjc4OGM3NjQ2NzQ5MGQwNWNhZWM5MzAwYjhkL3RleHRyZWdpb246MWVmNzQyNzg4Yzc2NDY3NDkwZDA1Y2FlYzkzMDBiOGRfMzI1Ng_e7fbd1cf-8213-4b7f-af71-67ed1c89dbd2">ASU 2016-13</span>, while prior period amounts were not adjusted and continue to be reported in accordance with our historical accounting practices. In our previous accounting policy for trade receivables and non-trade receivables, we maintained an allowance for doubtful accounts based solely on specific identification. Under the new accounting standard, we maintain our specific identification process but utilize several factors to develop historical losses reserves, including aging schedules, customer creditworthiness, and historical payment experience, which are then adjusted for current conditions and reasonable and supportable forecasts in measurement of the allowance.&#160; In addition, for customer advances and certain off-balance sheet credit exposures, we evaluate the allowance through a discounted cash flow approach.&#160; For held-to-maturity investment securities, we evaluate (i) historical information adjusted for current conditions and reasonable and supportable forecasts and (ii) qualitative factors to determine whether the zero-loss expectation exception applies. Refer to Note 7 for additional disclosures related to current expected credit losses.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU No. 2019-12, Simplifying the Accounting for Income Taxes. The amendments in the ASU remove certain exceptions to the intraperiod tax allocation of losses and gains from different financial statement components and to the method of recognizing income taxes on interim period losses, and the recognition of deferred tax liabilities for outside basis differences. In addition, the new guidance simplifies aspects of the accounting for franchise taxes and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. The Company adopted this standard starting in the first quarter of 2021, which did not have a material impact on our consolidated financial statements.</span></div></ix:nonNumeric></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="id8f403494d0a42c2868794fb470218fc_52"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 4.  <ix:nonNumeric contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" name="us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181Mi9mcmFnOmVjNzkwNDg1ZjE3YTQ2NDE4NWMxM2VhODY3NjkwNWNmL3RleHRyZWdpb246ZWM3OTA0ODVmMTdhNDY0MTg1YzEzZWE4Njc2OTA1Y2ZfNjI5NQ_051aaade-01eb-4ffd-949c-6d5451ada8b0" continuedAt="ifc56c4b576494a8ebb837a778d9716a9" escape="true">Transactions</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="ifc56c4b576494a8ebb837a778d9716a9" continuedAt="if4f92e16dcc94a458e4353a1674257a7"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Passport</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 28, 2019, UHC, Passport Health Solutions, LLC (&#8220;PHS I&#8221;), the Company and EVH Passport entered into an Asset Purchase Agreement (the &#8220;Passport APA&#8221;), which provided for the sale of substantially all of the assets of UHC and PHS I, including UHC&#8217;s Kentucky Medicaid contract (the &#8220;Passport Medicaid Contract&#8221;), to EVH Passport for a purchase price of $<ix:nonFraction unitRef="usd" contextRef="i36e8c4f14af843a5a8e48ca6d9a5c6ec_D20190528-20190528" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181Mi9mcmFnOmVjNzkwNDg1ZjE3YTQ2NDE4NWMxM2VhODY3NjkwNWNmL3RleHRyZWdpb246ZWM3OTA0ODVmMTdhNDY0MTg1YzEzZWE4Njc2OTA1Y2ZfMzk0_c6b0b006-680e-495b-aa34-01bda9ecb8c5">70.0</ix:nonFraction> million in cash and the issuance of a <ix:nonFraction unitRef="number" contextRef="i36e8c4f14af843a5a8e48ca6d9a5c6ec_D20190528-20190528" decimals="2" name="us-gaap:VariableInterestEntityOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181Mi9mcmFnOmVjNzkwNDg1ZjE3YTQ2NDE4NWMxM2VhODY3NjkwNWNmL3RleHRyZWdpb246ZWM3OTA0ODVmMTdhNDY0MTg1YzEzZWE4Njc2OTA1Y2ZfNDI3_0d650ff0-b951-4f21-8a3b-2a18230eadc9">30</ix:nonFraction>% interest in EVH Passport (the &#8220;Passport Purchase Price&#8221;) to The University of Louisville, the University of Louisville Physicians, University Medical Center, the Jewish Heritage Fund for Excellence, Norton Healthcare, Inc. and the Louisville/Jefferson County Primary Care Association (collectively, the &#8220;Sponsors&#8221;). </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 18, 2019, the Company contributed $<ix:nonFraction unitRef="usd" contextRef="i385b3b1c295f40a88f415a7f30d89c2d_I20190618" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NotesReceivableNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181Mi9mcmFnOmVjNzkwNDg1ZjE3YTQ2NDE4NWMxM2VhODY3NjkwNWNmL3RleHRyZWdpb246ZWM3OTA0ODVmMTdhNDY0MTg1YzEzZWE4Njc2OTA1Y2ZfNzkw_b6002f93-27c1-4375-8104-04df5a8712a7">40.0</ix:nonFraction> million to UHC in the form of an advance for regulatory capital requirements under an agreement with UHC (the &#8220;Passport Note&#8221;). The Passport Note carried a fixed interest rate of <ix:nonFraction unitRef="number" contextRef="i50427d2cf6854298bdb63c98b9dc7ee7_I20190618" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181Mi9mcmFnOmVjNzkwNDg1ZjE3YTQ2NDE4NWMxM2VhODY3NjkwNWNmL3RleHRyZWdpb246ZWM3OTA0ODVmMTdhNDY0MTg1YzEzZWE4Njc2OTA1Y2ZfOTY0_570e1a9f-48dc-416c-b265-48ae51a09b6f">6.5</ix:nonFraction>% per annum.  Additionally, on June 6, 2019, the Company and UHC entered into an Indemnity Agreement (the &#8220;Indemnity Agreement&#8221;), with an insurance company (the &#8220;Surety&#8221;). The Surety issued a performance bond in the amount of $<ix:nonFraction unitRef="usd" contextRef="id6b6803c601248c48c645fade86aee32_D20190606-20190606" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:VariableInterestEntityFinancialOrOtherSupportAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181Mi9mcmFnOmVjNzkwNDg1ZjE3YTQ2NDE4NWMxM2VhODY3NjkwNWNmL3RleHRyZWdpb246ZWM3OTA0ODVmMTdhNDY0MTg1YzEzZWE4Njc2OTA1Y2ZfMTE5MQ_2db16cd0-ae92-40de-827a-d8984c70b899">25.0</ix:nonFraction> million to secure UHC&#8217;s performance under its Medicaid Contract. Pursuant to the Indemnity Agreement, the Company and UHC were jointly and severally liable to the Surety in the maximum amount of the bond, plus certain costs of the Surety, in the event of losses arising under the bond. The bond&#8217;s original expiry date was June 30, 2020 and during the three months ended June 30, 2020, was extended to December 31, 2020. The bond was released in October 2020. </span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="if4f92e16dcc94a458e4353a1674257a7" continuedAt="i41ea84f629024114b07c0dd76a29ea97"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 30, 2019, UHC, PHS I, the Company and EVH Passport consummated the transactions contemplated by the Passport APA (the &#8220;Passport Closing&#8221;).  At the Passport Closing, $<ix:nonFraction unitRef="usd" contextRef="i267001cededb4bfdb4aa09441f453c34_I20191230" decimals="-5" format="ixt:numdotdecimal" name="evh:PaymentsToAcquireEquityMethodInvestmentsAmountHeldBack" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181Mi9mcmFnOmVjNzkwNDg1ZjE3YTQ2NDE4NWMxM2VhODY3NjkwNWNmL3RleHRyZWdpb246ZWM3OTA0ODVmMTdhNDY0MTg1YzEzZWE4Njc2OTA1Y2ZfMTgyNA_21685102-fc61-4ab0-922a-a4ed5b6876d8">16.2</ix:nonFraction> million of the cash Passport Purchase Price was held back until such time as PHS I delivers to EVH Passport certain owned real property and improvements free and clear of all encumbrances. In addition, at the Passport Closing, EVH Passport and UHC entered into an agreement that provided for the administration and assumption of the financial risks by EVH Passport of UHC&#8217;s dual eligible special needs business (the &#8220;DNP Business&#8221;) until such time as EVH Passport became certified as a Medicare Advantage Organization and the D-SNP Business could be transferred to EVH Passport.  On October 1, 2020, the D-SNP Business was transferred from UHC to EVH Passport.  At the Passport Closing, EVH Passport assumed UHC&#8217;s obligations under the Passport Note and the Indemnity Agreement. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 16, 2020, EVH Passport, Evolent Health LLC and Molina Healthcare, Inc. (&#8220;Molina&#8221;) entered into an Asset Purchase Agreement (the &#8220;Molina APA&#8221;), which contemplated the sale by EVH Passport to Molina of certain assets, including certain intellectual property rights of EVH Passport and EVH Passport&#8217;s rights under the Passport Medicaid Contract.  On September 1, 2020, EVH Passport and Molina consummated the transactions contemplated by the Molina APA (the &#8220;Molina Closing&#8221;), and the Passport Medicaid Contract was novated to Molina.  As a result, EVH Passport began to wind down its business.  In connection with the Molina Closing, Molina deposited $<ix:nonFraction unitRef="usd" contextRef="ib8509d7b0e554612806781c71b9e4ddf_D20210101-20210131" decimals="-5" format="ixt:numdotdecimal" name="evh:CashReleasedFromEscrow" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181Mi9mcmFnOmVjNzkwNDg1ZjE3YTQ2NDE4NWMxM2VhODY3NjkwNWNmL3RleHRyZWdpb246ZWM3OTA0ODVmMTdhNDY0MTg1YzEzZWE4Njc2OTA1Y2ZfMzI1Nw_4ebb7466-4d71-4b23-a22e-08c363449cbe"><ix:nonFraction unitRef="usd" contextRef="i69350541fafc4d14a84c72aba152a863_D20200901-20200901" decimals="INF" format="ixt:numdotdecimal" name="evh:AssetPurchaseAgreementEscrowPayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181Mi9mcmFnOmVjNzkwNDg1ZjE3YTQ2NDE4NWMxM2VhODY3NjkwNWNmL3RleHRyZWdpb246ZWM3OTA0ODVmMTdhNDY0MTg1YzEzZWE4Njc2OTA1Y2ZfMzI1Nw_88b7b98a-8489-4202-a3f5-90af8585725e">20.0</ix:nonFraction></ix:nonFraction>&#160;million in cash in escrow, which was subsequently released to EVH Passport in January 2021.  In addition, at the Molina Closing, Molina and EVH Passport entered into an agreement that provided for the assumption of the financial risks by Molina of the D-SNP Business until such time as Molina&#8217;s Kentucky health plan becomes certified as a Medicare Advantage Organization and the D-SNP Business is transferred Molina.  The Company and EVH Passport continued to administer the D-SNP Business until January 1, 2021, at which time Molina became responsible for its administration until the D-SNP Business is officially transferred to Molina effective September 1, 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the Molina Closing, the Company accounted for its investment in EVH Passport as an unconsolidated variable interest entity under the equity method of accounting.  As a result of the transaction, the Company concluded that a reconsideration event occurred whereby EVH Passport was determined to be a voting interest entity and that Evolent had a controlling financial interest in EVH Passport; accordingly, the Company consolidated EVH Passport as of September 1, 2020 in its consolidated financial statements. The Company accounted for the transaction as an asset acquisition, as the Company concluded that assets acquired as a result of the consolidation did not meet the criteria to be classified as a business under GAAP.  Following the Molina Closing and consolidation of EVH Passport in the Company&#8217;s consolidated financials, on November 16, 2020, EVH Passport redeemed the Sponsors&#8217; equity interests in EVH Passport for $<ix:nonFraction unitRef="usd" contextRef="i7a8609d202734bc89b28f90cabe48547_D20201116-20201116" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToMinorityShareholders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181Mi9mcmFnOmVjNzkwNDg1ZjE3YTQ2NDE4NWMxM2VhODY3NjkwNWNmL3RleHRyZWdpb246ZWM3OTA0ODVmMTdhNDY0MTg1YzEzZWE4Njc2OTA1Y2ZfNDgyNg_07cc2bc0-c706-4866-8260-2218cccf5ff9">20.0</ix:nonFraction>&#160;million in cash in accordance with the terms of EVH Passport&#8217;s Stockholders&#8217; Agreement, and, as a result, EVH Passport became a wholly owned subsidiary of the Company.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the consolidation, the Company recorded assets primarily consisting of cash and cash equivalents and restricted cash and cash equivalents of $<ix:nonFraction unitRef="usd" contextRef="ifee88f44d6c647d095b28edecae13e93_D20200901-20200901" decimals="-5" format="ixt:numdotdecimal" name="evh:AssetAcquisitionCashAndEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181Mi9mcmFnOmVjNzkwNDg1ZjE3YTQ2NDE4NWMxM2VhODY3NjkwNWNmL3RleHRyZWdpb246ZWM3OTA0ODVmMTdhNDY0MTg1YzEzZWE4Njc2OTA1Y2ZfNTE0Mg_0c989b19-5395-48b2-9c22-4a41199e0fdb">159.8</ix:nonFraction>&#160;million, available for sale securities of $<ix:nonFraction unitRef="usd" contextRef="ifee88f44d6c647d095b28edecae13e93_D20200901-20200901" decimals="-5" format="ixt:numdotdecimal" name="evh:AssetAcquisitionDebtSecuritiesAvailableForSale" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181Mi9mcmFnOmVjNzkwNDg1ZjE3YTQ2NDE4NWMxM2VhODY3NjkwNWNmL3RleHRyZWdpb246ZWM3OTA0ODVmMTdhNDY0MTg1YzEzZWE4Njc2OTA1Y2ZfNTE3OQ_78a284e2-0739-48f4-9ca6-a338b96efced">88.6</ix:nonFraction>&#160;million, receivables related to unsettled sales of securities of $<ix:nonFraction unitRef="usd" contextRef="ifee88f44d6c647d095b28edecae13e93_D20200901-20200901" decimals="-5" format="ixt:numdotdecimal" name="evh:AssetAcquisitionDebtSecuritiesAvailableForSaleUnsettledSalesReceivables" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181Mi9mcmFnOmVjNzkwNDg1ZjE3YTQ2NDE4NWMxM2VhODY3NjkwNWNmL3RleHRyZWdpb246ZWM3OTA0ODVmMTdhNDY0MTg1YzEzZWE4Njc2OTA1Y2ZfNTIzOQ_85e1f12b-086a-4fb8-9b7f-e5ad452b8797">43.0</ix:nonFraction>&#160;million and other assets of $<ix:nonFraction unitRef="usd" contextRef="ifee88f44d6c647d095b28edecae13e93_D20200901-20200901" decimals="-5" format="ixt:numdotdecimal" name="evh:AssetAcquisitionOtherAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181Mi9mcmFnOmVjNzkwNDg1ZjE3YTQ2NDE4NWMxM2VhODY3NjkwNWNmL3RleHRyZWdpb246ZWM3OTA0ODVmMTdhNDY0MTg1YzEzZWE4Njc2OTA1Y2ZfNTI2Mg_f4c2d27f-b5be-4457-bba7-1853c5f27683">50.2</ix:nonFraction>&#160;million and total liabilities primarily comprised of reserve for claims and performance-based arrangements of $<ix:nonFraction unitRef="usd" contextRef="ifee88f44d6c647d095b28edecae13e93_D20200901-20200901" decimals="-5" format="ixt:numdotdecimal" name="evh:AssetAcquisitionAccruedMedicalExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181Mi9mcmFnOmVjNzkwNDg1ZjE3YTQ2NDE4NWMxM2VhODY3NjkwNWNmL3RleHRyZWdpb246ZWM3OTA0ODVmMTdhNDY0MTg1YzEzZWE4Njc2OTA1Y2ZfNTM2Nw_49d2066d-856b-441d-b632-48ab9cf78e69">164.8</ix:nonFraction>&#160;million and accrued liabilities of $<ix:nonFraction unitRef="usd" contextRef="ifee88f44d6c647d095b28edecae13e93_D20200901-20200901" decimals="-5" format="ixt:numdotdecimal" name="evh:AssetAcquisitionAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181Mi9mcmFnOmVjNzkwNDg1ZjE3YTQ2NDE4NWMxM2VhODY3NjkwNWNmL3RleHRyZWdpb246ZWM3OTA0ODVmMTdhNDY0MTg1YzEzZWE4Njc2OTA1Y2ZfNTM5Nw_79436675-e037-4d82-b003-314989b1dc6a">50.0</ix:nonFraction>&#160;million. Subsequent to winddown activities, any remaining capital will be distributed to the Company subject to regulatory approval from the Kentucky Department of Insurance.  In addition, the Passport Note was eliminated upon consolidation, and as of December 31, 2020, the outstanding principal balance of the $<ix:nonFraction unitRef="usd" contextRef="ie9b33f26cab0425fb6895b18246f33f6_D20201231-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromCollectionOfNotesReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181Mi9mcmFnOmVjNzkwNDg1ZjE3YTQ2NDE4NWMxM2VhODY3NjkwNWNmL3RleHRyZWdpb246ZWM3OTA0ODVmMTdhNDY0MTg1YzEzZWE4Njc2OTA1Y2ZfNTcwNA_f1c35b0c-71da-44e0-8729-1d499d786fe7">40.0</ix:nonFraction>&#160;million Passport Note was repaid in full by EVH Passport including approximately $<ix:nonFraction unitRef="usd" contextRef="ie9b33f26cab0425fb6895b18246f33f6_D20201231-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromInterestReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181Mi9mcmFnOmVjNzkwNDg1ZjE3YTQ2NDE4NWMxM2VhODY3NjkwNWNmL3RleHRyZWdpb246ZWM3OTA0ODVmMTdhNDY0MTg1YzEzZWE4Njc2OTA1Y2ZfNTc4MA_18df9bed-cd7e-4f82-b748-a52b72d309d7">3.6</ix:nonFraction>&#160;million of accrued interest.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During the first quarter of 2021, pursuant to the terms of the Molina APA, EVH Passport received a cash payment from Molina in the amount of $<ix:nonFraction unitRef="usd" contextRef="i9d78efa027664adba423d2ecb8ab7e70_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="evh:ProceedsFromTransferOfMembership" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181Mi9mcmFnOmVjNzkwNDg1ZjE3YTQ2NDE4NWMxM2VhODY3NjkwNWNmL3RleHRyZWdpb246ZWM3OTA0ODVmMTdhNDY0MTg1YzEzZWE4Njc2OTA1Y2ZfNTg4Mg_e23125dd-a179-4c0b-81e0-5e7479611317">23.0</ix:nonFraction>&#160;million based on the number of enrollees above a certain threshold in the D-SNP Business and Molina's Medicaid plan following the open enrollment period for plan year 2021. The foregoing amount represents <ix:nonFraction unitRef="number" contextRef="i2c70b9d982894c0dbbc1a56623c7e3e7_I20210331" decimals="INF" name="evh:TransferOfMembershipPercentageOfPaymentBasedOnNumberOfEnrollees" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181Mi9mcmFnOmVjNzkwNDg1ZjE3YTQ2NDE4NWMxM2VhODY3NjkwNWNmL3RleHRyZWdpb246ZWM3OTA0ODVmMTdhNDY0MTg1YzEzZWE4Njc2OTA1Y2ZfNjA4Mg_d0641f70-32c3-4540-92eb-26b48661c610">50</ix:nonFraction>% of the payment that EVH Passport is eligible to receive pursuant to the terms of the Molina APA based on the number of such enrollees. The remaining <ix:nonFraction unitRef="number" contextRef="i0e1ba7773771404e91600efd70f89820_I20210630" decimals="INF" name="evh:TransferOfMembershipPercentageOfPaymentSubjectToSatisfactionOfContingencies" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181Mi9mcmFnOmVjNzkwNDg1ZjE3YTQ2NDE4NWMxM2VhODY3NjkwNWNmL3RleHRyZWdpb246ZWM3OTA0ODVmMTdhNDY0MTg1YzEzZWE4Njc2OTA1Y2ZfNjE5NA_2de904cc-f72b-476f-ac58-4e9a755016b2">50</ix:nonFraction>% will be payable in the first quarter of 2022 subject to the satisfaction of certain contingencies.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="id8f403494d0a42c2868794fb470218fc_55"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 5.  <ix:nonNumeric contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" name="us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RleHRyZWdpb246YTc2MmYwMGIxMDk2NDgzZThhYWM3ZTBlNGY2ZDgzZjBfMjU2NA_e6eab143-bcf1-45ad-b0b5-a8052ea196a9" continuedAt="ifdee40a82176497fa0e07bd15ce77c7e" escape="true">Discontinued Operations</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="ifdee40a82176497fa0e07bd15ce77c7e" continuedAt="ie8cc6b33c6cb4024a71c329401ce036a"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 11, 2021, Evolent Health LLC, EH Holdings and True Health, each wholly owned subsidiaries of the Company, entered into a Stock Purchase Agreement (the &#8220;True Health SPA&#8221;) with Bright Health Management, Inc. (&#8220;Bright HealthCare&#8221;), pursuant to which EH Holdings agreed to sell all of its equity interests in True Health to Bright HealthCare. Closing of the transactions contemplated by the True Health SPA occurred on March 31, 2021 (the &#8220;True Health Closing&#8221;) and the Company will have no continuing involvement with True Health subsequent to the closing except an existing services agreement for claims processing and other health plan administrative functions.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the first quarter of 2021, the Company determined that True Health met the discontinued operations criteria under ASC 360, and as such, True Health assets and liabilities as of December 31, 2020, and the results of operations for all periods presented are classified as held for sale and are not included in continuing operations in the consolidated financial statements.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ie8cc6b33c6cb4024a71c329401ce036a" continuedAt="i739c833161f843acbcafec55333ea524"><ix:nonNumeric contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" name="us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RleHRyZWdpb246YTc2MmYwMGIxMDk2NDgzZThhYWM3ZTBlNGY2ZDgzZjBfMjU2NQ_2705af32-4415-4762-93f5-32e6e0e2cf46" continuedAt="i81ab3b5c208f474b9e3db5bc473d4fde" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the results of operations of the Company&#8217;s True Health business, which are included in loss from discontinued operations in the consolidated statements of operations the three and six months ended June 30, 2021 and 2020:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.209%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Platform and operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id529693310384660bff0d3d357adbec3_D20210401-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOjFlMDNhMzNiMmY5MjRmODliYTc0NjdiNmY1ZGFiMjIwL3RhYmxlcmFuZ2U6MWUwM2EzM2IyZjkyNGY4OWJhNzQ2N2I2ZjVkYWIyMjBfMy0xLTEtMS0yNDk2_3502cac9-fce1-46da-a73d-24e49d073e6a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5619f887d0d546cb8c2d5bbbb39a6d8f_D20200401-20200630" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOjFlMDNhMzNiMmY5MjRmODliYTc0NjdiNmY1ZGFiMjIwL3RhYmxlcmFuZ2U6MWUwM2EzM2IyZjkyNGY4OWJhNzQ2N2I2ZjVkYWIyMjBfMy0zLTEtMS0yNDg4_bbcdec0f-f0e0-4488-818c-1617d770f64f">39</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10851d8c3fd6447eaa0063fff7f9ed51_D20210101-20210630" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOjFlMDNhMzNiMmY5MjRmODliYTc0NjdiNmY1ZGFiMjIwL3RhYmxlcmFuZ2U6MWUwM2EzM2IyZjkyNGY4OWJhNzQ2N2I2ZjVkYWIyMjBfMy0xLTEtMS0w_48bf0559-b0a7-4aca-b01e-b76997129dd0">38</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95135618e68647b8a930d4657c43da75_D20200101-20200630" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOjFlMDNhMzNiMmY5MjRmODliYTc0NjdiNmY1ZGFiMjIwL3RhYmxlcmFuZ2U6MWUwM2EzM2IyZjkyNGY4OWJhNzQ2N2I2ZjVkYWIyMjBfMy0zLTEtMS0w_e5d470b3-a691-4d12-8059-2bce677d4414">279</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Premiums</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e57745d431e47bfa19e71a49e5fdf02_D20210401-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOjFlMDNhMzNiMmY5MjRmODliYTc0NjdiNmY1ZGFiMjIwL3RhYmxlcmFuZ2U6MWUwM2EzM2IyZjkyNGY4OWJhNzQ2N2I2ZjVkYWIyMjBfNC0xLTEtMS0yNDk2_4a6cae34-8fd1-4377-a1b8-4e92da7a549e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3740e6e58c749fa97b9285685be7b1e_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOjFlMDNhMzNiMmY5MjRmODliYTc0NjdiNmY1ZGFiMjIwL3RhYmxlcmFuZ2U6MWUwM2EzM2IyZjkyNGY4OWJhNzQ2N2I2ZjVkYWIyMjBfNC0zLTEtMS0yNDg4_3df853f6-c1dc-4fe8-a4ed-5446e1cd3680">25,502</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9034834f629c466cb0de8a2fd5acfc15_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOjFlMDNhMzNiMmY5MjRmODliYTc0NjdiNmY1ZGFiMjIwL3RhYmxlcmFuZ2U6MWUwM2EzM2IyZjkyNGY4OWJhNzQ2N2I2ZjVkYWIyMjBfNC0xLTEtMS0w_6bb00dae-b6ce-4697-a734-2dad709cfcc8">44,795</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70101f6902e44f38a06effe5f98e83b6_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOjFlMDNhMzNiMmY5MjRmODliYTc0NjdiNmY1ZGFiMjIwL3RhYmxlcmFuZ2U6MWUwM2EzM2IyZjkyNGY4OWJhNzQ2N2I2ZjVkYWIyMjBfNC0zLTEtMS0w_e6406f8a-6507-41af-b323-ebed724acc7c">57,649</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1869cd19e38f4a028448315845a440c5_D20210401-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOjFlMDNhMzNiMmY5MjRmODliYTc0NjdiNmY1ZGFiMjIwL3RhYmxlcmFuZ2U6MWUwM2EzM2IyZjkyNGY4OWJhNzQ2N2I2ZjVkYWIyMjBfNS0xLTEtMS0yNDg4_55c420ba-e257-4ca7-8b36-419e6f0fbb7b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a6bb4acf8f64d4ea88262cf96a6ca67_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOjFlMDNhMzNiMmY5MjRmODliYTc0NjdiNmY1ZGFiMjIwL3RhYmxlcmFuZ2U6MWUwM2EzM2IyZjkyNGY4OWJhNzQ2N2I2ZjVkYWIyMjBfNS0zLTEtMS0yNDg4_1e922cf5-119c-452d-96c4-c445e669e580">25,541</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae3e4f43e8c541128c572b22ebdd19bd_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOjFlMDNhMzNiMmY5MjRmODliYTc0NjdiNmY1ZGFiMjIwL3RhYmxlcmFuZ2U6MWUwM2EzM2IyZjkyNGY4OWJhNzQ2N2I2ZjVkYWIyMjBfNS0xLTEtMS0w_86cb88c1-652e-4913-9ff1-c4143d55bba3">44,833</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f626e482e054b34901a6c459f47f04b_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOjFlMDNhMzNiMmY5MjRmODliYTc0NjdiNmY1ZGFiMjIwL3RhYmxlcmFuZ2U6MWUwM2EzM2IyZjkyNGY4OWJhNzQ2N2I2ZjVkYWIyMjBfNS0zLTEtMS0w_ff1c4350-449d-4717-94dc-604581ec15d9">57,928</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenue (exclusive of depreciation and amortization expenses presented separately below) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1869cd19e38f4a028448315845a440c5_D20210401-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOjFlMDNhMzNiMmY5MjRmODliYTc0NjdiNmY1ZGFiMjIwL3RhYmxlcmFuZ2U6MWUwM2EzM2IyZjkyNGY4OWJhNzQ2N2I2ZjVkYWIyMjBfOC0xLTEtMS0yNDky_333777ce-ea37-4b4e-a0d6-6e8656883a62">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a6bb4acf8f64d4ea88262cf96a6ca67_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOjFlMDNhMzNiMmY5MjRmODliYTc0NjdiNmY1ZGFiMjIwL3RhYmxlcmFuZ2U6MWUwM2EzM2IyZjkyNGY4OWJhNzQ2N2I2ZjVkYWIyMjBfOC0zLTEtMS0yNDky_c4b03d66-d88d-40f8-ba2b-1f54ad5f4550">4,640</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae3e4f43e8c541128c572b22ebdd19bd_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOjFlMDNhMzNiMmY5MjRmODliYTc0NjdiNmY1ZGFiMjIwL3RhYmxlcmFuZ2U6MWUwM2EzM2IyZjkyNGY4OWJhNzQ2N2I2ZjVkYWIyMjBfOC0xLTEtMS0w_48b6872e-59ba-4559-a38e-04c2095c1d0e">5,885</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f626e482e054b34901a6c459f47f04b_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOjFlMDNhMzNiMmY5MjRmODliYTc0NjdiNmY1ZGFiMjIwL3RhYmxlcmFuZ2U6MWUwM2EzM2IyZjkyNGY4OWJhNzQ2N2I2ZjVkYWIyMjBfOC0zLTEtMS0w_138a2d04-91ca-40b3-b945-5f216158b8dd">7,935</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Claims expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1869cd19e38f4a028448315845a440c5_D20210401-20210630" decimals="-3" format="ixt:zerodash" name="evh:DisposalGroupIncludingDiscontinuedOperationClaimsExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOjFlMDNhMzNiMmY5MjRmODliYTc0NjdiNmY1ZGFiMjIwL3RhYmxlcmFuZ2U6MWUwM2EzM2IyZjkyNGY4OWJhNzQ2N2I2ZjVkYWIyMjBfOS0xLTEtMS0yNDky_d7ddeb23-43cc-4ac3-8172-16166a3e86bc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a6bb4acf8f64d4ea88262cf96a6ca67_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="evh:DisposalGroupIncludingDiscontinuedOperationClaimsExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOjFlMDNhMzNiMmY5MjRmODliYTc0NjdiNmY1ZGFiMjIwL3RhYmxlcmFuZ2U6MWUwM2EzM2IyZjkyNGY4OWJhNzQ2N2I2ZjVkYWIyMjBfOS0zLTEtMS0yNDky_a0922cff-2979-4e78-88be-72add4e314e9">18,144</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae3e4f43e8c541128c572b22ebdd19bd_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="evh:DisposalGroupIncludingDiscontinuedOperationClaimsExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOjFlMDNhMzNiMmY5MjRmODliYTc0NjdiNmY1ZGFiMjIwL3RhYmxlcmFuZ2U6MWUwM2EzM2IyZjkyNGY4OWJhNzQ2N2I2ZjVkYWIyMjBfOS0xLTEtMS0w_44f9a7f1-3da7-4cd9-92d6-71278bbda936">33,954</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f626e482e054b34901a6c459f47f04b_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="evh:DisposalGroupIncludingDiscontinuedOperationClaimsExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOjFlMDNhMzNiMmY5MjRmODliYTc0NjdiNmY1ZGFiMjIwL3RhYmxlcmFuZ2U6MWUwM2EzM2IyZjkyNGY4OWJhNzQ2N2I2ZjVkYWIyMjBfOS0zLTEtMS0w_56decff0-0758-478f-87c6-aaa77036c818">41,811</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1869cd19e38f4a028448315845a440c5_D20210401-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOjFlMDNhMzNiMmY5MjRmODliYTc0NjdiNmY1ZGFiMjIwL3RhYmxlcmFuZ2U6MWUwM2EzM2IyZjkyNGY4OWJhNzQ2N2I2ZjVkYWIyMjBfMTAtMS0xLTEtMjQ5Mg_6cb60382-1b05-40ad-a9f5-849d042ace46">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a6bb4acf8f64d4ea88262cf96a6ca67_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOjFlMDNhMzNiMmY5MjRmODliYTc0NjdiNmY1ZGFiMjIwL3RhYmxlcmFuZ2U6MWUwM2EzM2IyZjkyNGY4OWJhNzQ2N2I2ZjVkYWIyMjBfMTAtMy0xLTEtMjQ5Mg_822d5855-23ba-4496-b5c8-4911d6471658">4,236</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae3e4f43e8c541128c572b22ebdd19bd_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOjFlMDNhMzNiMmY5MjRmODliYTc0NjdiNmY1ZGFiMjIwL3RhYmxlcmFuZ2U6MWUwM2EzM2IyZjkyNGY4OWJhNzQ2N2I2ZjVkYWIyMjBfMTAtMS0xLTEtMA_1e34b7df-1ba1-47c0-a37c-ae7324e4397f">5,764</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f626e482e054b34901a6c459f47f04b_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOjFlMDNhMzNiMmY5MjRmODliYTc0NjdiNmY1ZGFiMjIwL3RhYmxlcmFuZ2U6MWUwM2EzM2IyZjkyNGY4OWJhNzQ2N2I2ZjVkYWIyMjBfMTAtMy0xLTEtMA_30c87481-79df-4403-8f25-7bb1912b1011">9,911</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1869cd19e38f4a028448315845a440c5_D20210401-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:DepreciationAndAmortizationDiscontinuedOperations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOjFlMDNhMzNiMmY5MjRmODliYTc0NjdiNmY1ZGFiMjIwL3RhYmxlcmFuZ2U6MWUwM2EzM2IyZjkyNGY4OWJhNzQ2N2I2ZjVkYWIyMjBfMTEtMS0xLTEtMjQ5Mg_0ac4bf03-a30c-4eb2-a686-956eafb3f6ad">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a6bb4acf8f64d4ea88262cf96a6ca67_D20200401-20200630" decimals="-3" name="us-gaap:DepreciationAndAmortizationDiscontinuedOperations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOjFlMDNhMzNiMmY5MjRmODliYTc0NjdiNmY1ZGFiMjIwL3RhYmxlcmFuZ2U6MWUwM2EzM2IyZjkyNGY4OWJhNzQ2N2I2ZjVkYWIyMjBfMTEtMy0xLTEtMjQ5Mg_cb915ded-7387-4471-91e6-bfa32a0cc68a">160</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae3e4f43e8c541128c572b22ebdd19bd_D20210101-20210630" decimals="-3" name="us-gaap:DepreciationAndAmortizationDiscontinuedOperations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOjFlMDNhMzNiMmY5MjRmODliYTc0NjdiNmY1ZGFiMjIwL3RhYmxlcmFuZ2U6MWUwM2EzM2IyZjkyNGY4OWJhNzQ2N2I2ZjVkYWIyMjBfMTEtMS0xLTEtMA_315e0996-ef06-4a2d-8ead-518135ef20ad">160</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f626e482e054b34901a6c459f47f04b_D20200101-20200630" decimals="-3" name="us-gaap:DepreciationAndAmortizationDiscontinuedOperations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOjFlMDNhMzNiMmY5MjRmODliYTc0NjdiNmY1ZGFiMjIwL3RhYmxlcmFuZ2U6MWUwM2EzM2IyZjkyNGY4OWJhNzQ2N2I2ZjVkYWIyMjBfMTEtMy0xLTEtMA_2ba0d54a-cffc-4342-ab98-044ee9bf8f57">320</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1869cd19e38f4a028448315845a440c5_D20210401-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOjFlMDNhMzNiMmY5MjRmODliYTc0NjdiNmY1ZGFiMjIwL3RhYmxlcmFuZ2U6MWUwM2EzM2IyZjkyNGY4OWJhNzQ2N2I2ZjVkYWIyMjBfMTItMS0xLTEtMjQ5Mg_322e90d0-3e95-4658-b7d0-e1220c9d6c9f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a6bb4acf8f64d4ea88262cf96a6ca67_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOjFlMDNhMzNiMmY5MjRmODliYTc0NjdiNmY1ZGFiMjIwL3RhYmxlcmFuZ2U6MWUwM2EzM2IyZjkyNGY4OWJhNzQ2N2I2ZjVkYWIyMjBfMTItMy0xLTEtMjQ5Mg_513f1077-d81d-40c0-8df0-69ce7fda7b6c">27,180</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae3e4f43e8c541128c572b22ebdd19bd_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOjFlMDNhMzNiMmY5MjRmODliYTc0NjdiNmY1ZGFiMjIwL3RhYmxlcmFuZ2U6MWUwM2EzM2IyZjkyNGY4OWJhNzQ2N2I2ZjVkYWIyMjBfMTItMS0xLTEtMA_58815edd-adea-4407-ba48-394835e06d33">45,763</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f626e482e054b34901a6c459f47f04b_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOjFlMDNhMzNiMmY5MjRmODliYTc0NjdiNmY1ZGFiMjIwL3RhYmxlcmFuZ2U6MWUwM2EzM2IyZjkyNGY4OWJhNzQ2N2I2ZjVkYWIyMjBfMTItMy0xLTEtMA_3f5b3e18-008b-42de-8f16-b1c200763a13">59,977</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating loss</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1869cd19e38f4a028448315845a440c5_D20210401-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOjFlMDNhMzNiMmY5MjRmODliYTc0NjdiNmY1ZGFiMjIwL3RhYmxlcmFuZ2U6MWUwM2EzM2IyZjkyNGY4OWJhNzQ2N2I2ZjVkYWIyMjBfMTMtMS0xLTEtMjQ5Mg_a20f684e-89ae-414e-b734-201778c79a77">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1a6bb4acf8f64d4ea88262cf96a6ca67_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOjFlMDNhMzNiMmY5MjRmODliYTc0NjdiNmY1ZGFiMjIwL3RhYmxlcmFuZ2U6MWUwM2EzM2IyZjkyNGY4OWJhNzQ2N2I2ZjVkYWIyMjBfMTMtMy0xLTEtMjQ5Mg_69a51a52-5e47-43ad-a27c-9eb88f5a4655">1,639</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iae3e4f43e8c541128c572b22ebdd19bd_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOjFlMDNhMzNiMmY5MjRmODliYTc0NjdiNmY1ZGFiMjIwL3RhYmxlcmFuZ2U6MWUwM2EzM2IyZjkyNGY4OWJhNzQ2N2I2ZjVkYWIyMjBfMTMtMS0xLTEtMA_64cfc711-8c76-452b-af66-7ed8d3881751">930</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6f626e482e054b34901a6c459f47f04b_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOjFlMDNhMzNiMmY5MjRmODliYTc0NjdiNmY1ZGFiMjIwL3RhYmxlcmFuZ2U6MWUwM2EzM2IyZjkyNGY4OWJhNzQ2N2I2ZjVkYWIyMjBfMTMtMy0xLTEtMA_6af0323a-37af-44b5-bfce-043e874081a6">2,049</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1869cd19e38f4a028448315845a440c5_D20210401-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOjFlMDNhMzNiMmY5MjRmODliYTc0NjdiNmY1ZGFiMjIwL3RhYmxlcmFuZ2U6MWUwM2EzM2IyZjkyNGY4OWJhNzQ2N2I2ZjVkYWIyMjBfMTQtMS0xLTEtMjQ5Mg_d4f96746-e3a8-4872-9df0-482efdc5e8cd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a6bb4acf8f64d4ea88262cf96a6ca67_D20200401-20200630" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOjFlMDNhMzNiMmY5MjRmODliYTc0NjdiNmY1ZGFiMjIwL3RhYmxlcmFuZ2U6MWUwM2EzM2IyZjkyNGY4OWJhNzQ2N2I2ZjVkYWIyMjBfMTQtMy0xLTEtMjQ5Mg_0e82e239-bea8-4633-9777-35a486c8ec87">137</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae3e4f43e8c541128c572b22ebdd19bd_D20210101-20210630" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOjFlMDNhMzNiMmY5MjRmODliYTc0NjdiNmY1ZGFiMjIwL3RhYmxlcmFuZ2U6MWUwM2EzM2IyZjkyNGY4OWJhNzQ2N2I2ZjVkYWIyMjBfMTQtMS0xLTEtMA_0e0b3b79-4ae8-44ed-9c55-7a4758923f1b">112</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f626e482e054b34901a6c459f47f04b_D20200101-20200630" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOjFlMDNhMzNiMmY5MjRmODliYTc0NjdiNmY1ZGFiMjIwL3RhYmxlcmFuZ2U6MWUwM2EzM2IyZjkyNGY4OWJhNzQ2N2I2ZjVkYWIyMjBfMTQtMy0xLTEtMA_626b6d7d-e74e-466c-a089-c6305ecbb5c7">286</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1869cd19e38f4a028448315845a440c5_D20210401-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOjFlMDNhMzNiMmY5MjRmODliYTc0NjdiNmY1ZGFiMjIwL3RhYmxlcmFuZ2U6MWUwM2EzM2IyZjkyNGY4OWJhNzQ2N2I2ZjVkYWIyMjBfMTUtMS0xLTEtMjQ5Mg_91b639f2-54b5-4641-8e4a-b781c1784fb0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1a6bb4acf8f64d4ea88262cf96a6ca67_D20200401-20200630" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOjFlMDNhMzNiMmY5MjRmODliYTc0NjdiNmY1ZGFiMjIwL3RhYmxlcmFuZ2U6MWUwM2EzM2IyZjkyNGY4OWJhNzQ2N2I2ZjVkYWIyMjBfMTUtMy0xLTEtMjQ5Mg_1a6eff3c-9914-4022-92a7-fc126003f0f7">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iae3e4f43e8c541128c572b22ebdd19bd_D20210101-20210630" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOjFlMDNhMzNiMmY5MjRmODliYTc0NjdiNmY1ZGFiMjIwL3RhYmxlcmFuZ2U6MWUwM2EzM2IyZjkyNGY4OWJhNzQ2N2I2ZjVkYWIyMjBfMTUtMS0xLTEtMA_920a8607-6ec1-40b8-8b15-92ead7c4aa45">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6f626e482e054b34901a6c459f47f04b_D20200101-20200630" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOjFlMDNhMzNiMmY5MjRmODliYTc0NjdiNmY1ZGFiMjIwL3RhYmxlcmFuZ2U6MWUwM2EzM2IyZjkyNGY4OWJhNzQ2N2I2ZjVkYWIyMjBfMTUtMy0xLTEtMA_fcea3d26-2413-41c8-9096-4c6e968dee07">7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1869cd19e38f4a028448315845a440c5_D20210401-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOjFlMDNhMzNiMmY5MjRmODliYTc0NjdiNmY1ZGFiMjIwL3RhYmxlcmFuZ2U6MWUwM2EzM2IyZjkyNGY4OWJhNzQ2N2I2ZjVkYWIyMjBfMTYtMS0xLTEtMjQ5Mg_3c06a679-09ee-488f-be63-6801630884c8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1a6bb4acf8f64d4ea88262cf96a6ca67_D20200401-20200630" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOjFlMDNhMzNiMmY5MjRmODliYTc0NjdiNmY1ZGFiMjIwL3RhYmxlcmFuZ2U6MWUwM2EzM2IyZjkyNGY4OWJhNzQ2N2I2ZjVkYWIyMjBfMTYtMy0xLTEtMjQ5Mg_5ad6396e-b97c-434d-a342-eec2ca85d47d">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iae3e4f43e8c541128c572b22ebdd19bd_D20210101-20210630" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOjFlMDNhMzNiMmY5MjRmODliYTc0NjdiNmY1ZGFiMjIwL3RhYmxlcmFuZ2U6MWUwM2EzM2IyZjkyNGY4OWJhNzQ2N2I2ZjVkYWIyMjBfMTYtMS0xLTEtMA_b70bc8c0-d177-4bdc-8cdd-fc6f7c333483">25</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6f626e482e054b34901a6c459f47f04b_D20200101-20200630" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOjFlMDNhMzNiMmY5MjRmODliYTc0NjdiNmY1ZGFiMjIwL3RhYmxlcmFuZ2U6MWUwM2EzM2IyZjkyNGY4OWJhNzQ2N2I2ZjVkYWIyMjBfMTYtMy0xLTEtMA_7e1f1dd4-7c27-43e6-a176-1ea8822980a1">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes and non-controlling interests</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1869cd19e38f4a028448315845a440c5_D20210401-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOjFlMDNhMzNiMmY5MjRmODliYTc0NjdiNmY1ZGFiMjIwL3RhYmxlcmFuZ2U6MWUwM2EzM2IyZjkyNGY4OWJhNzQ2N2I2ZjVkYWIyMjBfMTctMS0xLTEtMjQ5Mg_407a1c60-70c0-40c2-bbd4-bf82ed5ff01b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1a6bb4acf8f64d4ea88262cf96a6ca67_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOjFlMDNhMzNiMmY5MjRmODliYTc0NjdiNmY1ZGFiMjIwL3RhYmxlcmFuZ2U6MWUwM2EzM2IyZjkyNGY4OWJhNzQ2N2I2ZjVkYWIyMjBfMTctMy0xLTEtMjQ5Mg_8f94a147-9ce1-41b8-bcc9-330697b595fd">1,508</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iae3e4f43e8c541128c572b22ebdd19bd_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOjFlMDNhMzNiMmY5MjRmODliYTc0NjdiNmY1ZGFiMjIwL3RhYmxlcmFuZ2U6MWUwM2EzM2IyZjkyNGY4OWJhNzQ2N2I2ZjVkYWIyMjBfMTctMS0xLTEtMA_782c1c78-50f5-42d7-a607-5d276c546240">847</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6f626e482e054b34901a6c459f47f04b_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOjFlMDNhMzNiMmY5MjRmODliYTc0NjdiNmY1ZGFiMjIwL3RhYmxlcmFuZ2U6MWUwM2EzM2IyZjkyNGY4OWJhNzQ2N2I2ZjVkYWIyMjBfMTctMy0xLTEtMA_c99b9dd9-5824-4922-9438-6782706b867b">1,773</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit for income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1869cd19e38f4a028448315845a440c5_D20210401-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOjFlMDNhMzNiMmY5MjRmODliYTc0NjdiNmY1ZGFiMjIwL3RhYmxlcmFuZ2U6MWUwM2EzM2IyZjkyNGY4OWJhNzQ2N2I2ZjVkYWIyMjBfMTgtMS0xLTEtMjQ5Mg_973e4ed2-c4ee-4fa7-af46-a4cb441d3ce8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i1a6bb4acf8f64d4ea88262cf96a6ca67_D20200401-20200630" xsi:nil="true" name="us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOjFlMDNhMzNiMmY5MjRmODliYTc0NjdiNmY1ZGFiMjIwL3RhYmxlcmFuZ2U6MWUwM2EzM2IyZjkyNGY4OWJhNzQ2N2I2ZjVkYWIyMjBfMTgtMy0xLTEtMjQ5Mg_58c80dce-a830-4125-99aa-de4c29504900"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iae3e4f43e8c541128c572b22ebdd19bd_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOjFlMDNhMzNiMmY5MjRmODliYTc0NjdiNmY1ZGFiMjIwL3RhYmxlcmFuZ2U6MWUwM2EzM2IyZjkyNGY4OWJhNzQ2N2I2ZjVkYWIyMjBfMTgtMS0xLTEtMA_a2928b28-96f4-4bee-bd08-040024179e09">326</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f626e482e054b34901a6c459f47f04b_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOjFlMDNhMzNiMmY5MjRmODliYTc0NjdiNmY1ZGFiMjIwL3RhYmxlcmFuZ2U6MWUwM2EzM2IyZjkyNGY4OWJhNzQ2N2I2ZjVkYWIyMjBfMTgtMy0xLTEtMA_bcd1333f-ab0d-4e77-a06a-65568c12588f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1869cd19e38f4a028448315845a440c5_D20210401-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOjFlMDNhMzNiMmY5MjRmODliYTc0NjdiNmY1ZGFiMjIwL3RhYmxlcmFuZ2U6MWUwM2EzM2IyZjkyNGY4OWJhNzQ2N2I2ZjVkYWIyMjBfMTktMS0xLTEtMjQ5Mg_673742d0-ba97-428f-9a20-53b4485fb0fc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1a6bb4acf8f64d4ea88262cf96a6ca67_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOjFlMDNhMzNiMmY5MjRmODliYTc0NjdiNmY1ZGFiMjIwL3RhYmxlcmFuZ2U6MWUwM2EzM2IyZjkyNGY4OWJhNzQ2N2I2ZjVkYWIyMjBfMTktMy0xLTEtMjQ5Mg_65488641-7bb4-47ee-859e-d1cc092fb01d">1,508</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iae3e4f43e8c541128c572b22ebdd19bd_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOjFlMDNhMzNiMmY5MjRmODliYTc0NjdiNmY1ZGFiMjIwL3RhYmxlcmFuZ2U6MWUwM2EzM2IyZjkyNGY4OWJhNzQ2N2I2ZjVkYWIyMjBfMTktMS0xLTEtMA_2f20fc1a-d03e-4b4b-901e-a9a14961c854">521</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6f626e482e054b34901a6c459f47f04b_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOjFlMDNhMzNiMmY5MjRmODliYTc0NjdiNmY1ZGFiMjIwL3RhYmxlcmFuZ2U6MWUwM2EzM2IyZjkyNGY4OWJhNzQ2N2I2ZjVkYWIyMjBfMTktMy0xLTEtMA_1191e6ff-ea0d-4e06-9665-beb73b34132b">1,773</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Cost of revenue includes intercompany expenses between the Company and True Health that are recorded in income from continuing operations on the consolidated statements of operations related an existing services agreement for claims processing and other health plan administrative functions of $<ix:nonFraction unitRef="usd" contextRef="i7af7cd835a34469ebabe02daf06e9c2f_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RleHRyZWdpb246YTc2MmYwMGIxMDk2NDgzZThhYWM3ZTBlNGY2ZDgzZjBfMTMwNg_f9361b6d-3b07-4ed7-8fdb-09be59894d64">3.2</ix:nonFraction>&#160;million for the three months ended June 30, 2020 and $<ix:nonFraction unitRef="usd" contextRef="ica99eb679e5f4a22856b6f0e49072449_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RleHRyZWdpb246YTc2MmYwMGIxMDk2NDgzZThhYWM3ZTBlNGY2ZDgzZjBfMTA5OTUxMTYzMTgwMQ_bee12838-3dc7-4e06-8261-49b13c9bbcc7">2.8</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ic748340b0cf24dd685eb9347670033fd_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RleHRyZWdpb246YTc2MmYwMGIxMDk2NDgzZThhYWM3ZTBlNGY2ZDgzZjBfMTA5OTUxMTYzMTgwMg_312989bd-e273-426c-b29e-fdbd25a09087">6.3</ix:nonFraction>&#160;million for the six months ended June 30, 2021 and 2020, respectively.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:1.12pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Selling, general and administrative expenses includes intercompany expenses between the Company and True Health that are recorded in income from continuing operations on the consolidated statements of operations related an existing services agreement for claims processing and other health plan administrative functions of  $<ix:nonFraction unitRef="usd" contextRef="i7af7cd835a34469ebabe02daf06e9c2f_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RleHRyZWdpb246YTc2MmYwMGIxMDk2NDgzZThhYWM3ZTBlNGY2ZDgzZjBfMTY2MQ_6ce76317-839c-4080-86b1-f538223915d7">1.0</ix:nonFraction>&#160;million of for the three months ended June 30, 2020 and $<ix:nonFraction unitRef="usd" contextRef="ica99eb679e5f4a22856b6f0e49072449_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RleHRyZWdpb246YTc2MmYwMGIxMDk2NDgzZThhYWM3ZTBlNGY2ZDgzZjBfMTA5OTUxMTYzMjgyNQ_906fec68-e2a4-4514-96f4-52a4d17f7d2b">1.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ic748340b0cf24dd685eb9347670033fd_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RleHRyZWdpb246YTc2MmYwMGIxMDk2NDgzZThhYWM3ZTBlNGY2ZDgzZjBfMTA5OTUxMTYzMjgxMQ_6df4c54d-1e02-4f4a-97dc-05ccbd82a92e">4.1</ix:nonFraction> million for the six months ended June 30, 2021 and 2020, respectively. </span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated statements of cash flows for all periods have not been adjusted to separately disclose cash flows related to discontinued operations. <ix:continuation id="i81ab3b5c208f474b9e3db5bc473d4fde" continuedAt="i82091e105e274e7fbb676bf8d7153d38">Cash flows related to the True Health business during the six months ended June 30, 2021 and 2020 were as follows:</ix:continuation></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i82091e105e274e7fbb676bf8d7153d38" continuedAt="i4fc75ed798e5460aad512ebbb90cd2cc"><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:79.733%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.207%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows provided by (used in) operating activities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae3e4f43e8c541128c572b22ebdd19bd_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOjYxMmUzOTVjZTQxMjRiZDg5MzVmZjIxNDhkNTFmNGFlL3RhYmxlcmFuZ2U6NjEyZTM5NWNlNDEyNGJkODkzNWZmMjE0OGQ1MWY0YWVfMi0xLTEtMS0w_99552c5c-2adb-461b-85ec-b7287e07530d">5,002</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f626e482e054b34901a6c459f47f04b_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOjYxMmUzOTVjZTQxMjRiZDg5MzVmZjIxNDhkNTFmNGFlL3RhYmxlcmFuZ2U6NjEyZTM5NWNlNDEyNGJkODkzNWZmMjE0OGQ1MWY0YWVfMi0zLTEtMS0w_65c8a5d4-9ecd-4724-9363-fbef1fb9b770">10,660</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows provided by (used in) investing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iae3e4f43e8c541128c572b22ebdd19bd_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOjYxMmUzOTVjZTQxMjRiZDg5MzVmZjIxNDhkNTFmNGFlL3RhYmxlcmFuZ2U6NjEyZTM5NWNlNDEyNGJkODkzNWZmMjE0OGQ1MWY0YWVfMy0xLTEtMS0w_2d9ff41e-e1e1-4d0c-817f-c5ff89e1748f">2,494</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f626e482e054b34901a6c459f47f04b_D20200101-20200630" decimals="-3" name="us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOjYxMmUzOTVjZTQxMjRiZDg5MzVmZjIxNDhkNTFmNGFlL3RhYmxlcmFuZ2U6NjEyZTM5NWNlNDEyNGJkODkzNWZmMjE0OGQ1MWY0YWVfMy0zLTEtMS0w_be4f7d42-cd8b-424f-853e-2bb419af910a">382</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the current and long-term assets and liabilities of the discontinued True Health business in the consolidated balance sheets as of December&#160;31, 2020:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:82.927%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.873%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia177f909fbae4389bdaa8635f038babb_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOmMyZDk5MjEzZDUwNzQ5NjE5YmJmZTA5MmQ1YzUwYzcwL3RhYmxlcmFuZ2U6YzJkOTkyMTNkNTA3NDk2MTliYmZlMDkyZDVjNTBjNzBfMy0xLTEtMS0w_01341a83-4c32-4a23-92cc-ba9a407d8d40">21,488</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash and restricted investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia177f909fbae4389bdaa8635f038babb_I20201231" decimals="-3" name="evh:DisposalGroupIncludingDiscontinuedOperationRestrictedCashAndRestrictedInvestmentsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOmMyZDk5MjEzZDUwNzQ5NjE5YmJmZTA5MmQ1YzUwYzcwL3RhYmxlcmFuZ2U6YzJkOTkyMTNkNTA3NDk2MTliYmZlMDkyZDVjNTBjNzBfNC0xLTEtMS0w_f313cba9-fa4f-4c6b-b5f8-bd8d0be7639f">63</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia177f909fbae4389bdaa8635f038babb_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOmMyZDk5MjEzZDUwNzQ5NjE5YmJmZTA5MmQ1YzUwYzcwL3RhYmxlcmFuZ2U6YzJkOTkyMTNkNTA3NDk2MTliYmZlMDkyZDVjNTBjNzBfNS0xLTEtMS0w_8cf1a370-7b37-442b-806e-da2fc720f7c7">3,437</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i739c833161f843acbcafec55333ea524"><ix:continuation id="i4fc75ed798e5460aad512ebbb90cd2cc"><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:82.927%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.873%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia177f909fbae4389bdaa8635f038babb_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOmMyZDk5MjEzZDUwNzQ5NjE5YmJmZTA5MmQ1YzUwYzcwL3RhYmxlcmFuZ2U6YzJkOTkyMTNkNTA3NDk2MTliYmZlMDkyZDVjNTBjNzBfNi0xLTEtMS0w_39a6ab88-7bec-4472-b39e-c4ecccc9de8b">5,198</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments, at amortized cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia177f909fbae4389bdaa8635f038babb_I20201231" decimals="-3" format="ixt:numdotdecimal" name="evh:DisposalGroupIncludingDiscontinuedOperationInvestmentsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOmMyZDk5MjEzZDUwNzQ5NjE5YmJmZTA5MmQ1YzUwYzcwL3RhYmxlcmFuZ2U6YzJkOTkyMTNkNTA3NDk2MTliYmZlMDkyZDVjNTBjNzBfNy0xLTEtMS0w_eb0e81ad-c96a-485c-8f14-eba7734cfa37">3,728</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia177f909fbae4389bdaa8635f038babb_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOmMyZDk5MjEzZDUwNzQ5NjE5YmJmZTA5MmQ1YzUwYzcwL3RhYmxlcmFuZ2U6YzJkOTkyMTNkNTA3NDk2MTliYmZlMDkyZDVjNTBjNzBfOC0xLTEtMS0w_7ef855ba-9772-4edb-972a-71e9b5875cae">33,914</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash and restricted investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia177f909fbae4389bdaa8635f038babb_I20201231" decimals="-3" name="evh:DisposalGroupIncludingDiscontinuedOperationRestrictedCashAndRestrictedInvestmentsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOmMyZDk5MjEzZDUwNzQ5NjE5YmJmZTA5MmQ1YzUwYzcwL3RhYmxlcmFuZ2U6YzJkOTkyMTNkNTA3NDk2MTliYmZlMDkyZDVjNTBjNzBfOS0xLTEtMS0w_5e4463a5-9e2f-4f49-a4c9-f6d1f65b4ed0">616</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments, at amortized cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia177f909fbae4389bdaa8635f038babb_I20201231" decimals="-3" format="ixt:numdotdecimal" name="evh:DisposalGroupIncludingDiscontinuedOperationInvestmentsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOmMyZDk5MjEzZDUwNzQ5NjE5YmJmZTA5MmQ1YzUwYzcwL3RhYmxlcmFuZ2U6YzJkOTkyMTNkNTA3NDk2MTliYmZlMDkyZDVjNTBjNzBfMTAtMS0xLTEtMA_f1d599c4-7d31-4dfe-b1b9-2e25b73fec35">10,919</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other noncurrent assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia177f909fbae4389bdaa8635f038babb_I20201231" decimals="-3" name="evh:DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOmMyZDk5MjEzZDUwNzQ5NjE5YmJmZTA5MmQ1YzUwYzcwL3RhYmxlcmFuZ2U6YzJkOTkyMTNkNTA3NDk2MTliYmZlMDkyZDVjNTBjNzBfMTEtMS0xLTEtMA_c46b0d1c-c1f5-479a-bfd8-87a46b0e1b79">59</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia177f909fbae4389bdaa8635f038babb_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOmMyZDk5MjEzZDUwNzQ5NjE5YmJmZTA5MmQ1YzUwYzcwL3RhYmxlcmFuZ2U6YzJkOTkyMTNkNTA3NDk2MTliYmZlMDkyZDVjNTBjNzBfMTItMS0xLTEtMA_2acfb63c-7dd1-4426-84c2-bd88583952e0">3,080</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia177f909fbae4389bdaa8635f038babb_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOmMyZDk5MjEzZDUwNzQ5NjE5YmJmZTA5MmQ1YzUwYzcwL3RhYmxlcmFuZ2U6YzJkOTkyMTNkNTA3NDk2MTliYmZlMDkyZDVjNTBjNzBfMTMtMS0xLTEtMA_093999f8-65bc-40c7-84b5-7131b77c6f1a">5,705</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia177f909fbae4389bdaa8635f038babb_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOmMyZDk5MjEzZDUwNzQ5NjE5YmJmZTA5MmQ1YzUwYzcwL3RhYmxlcmFuZ2U6YzJkOTkyMTNkNTA3NDk2MTliYmZlMDkyZDVjNTBjNzBfMTQtMS0xLTEtMA_9430165f-90d7-4bb9-876d-565dbbd5624e">54,293</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia177f909fbae4389bdaa8635f038babb_I20201231" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOmMyZDk5MjEzZDUwNzQ5NjE5YmJmZTA5MmQ1YzUwYzcwL3RhYmxlcmFuZ2U6YzJkOTkyMTNkNTA3NDk2MTliYmZlMDkyZDVjNTBjNzBfMTktMS0xLTEtMA_c6938e20-5e62-4fb4-b0dd-ba5f5f4152bc">93</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia177f909fbae4389bdaa8635f038babb_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOmMyZDk5MjEzZDUwNzQ5NjE5YmJmZTA5MmQ1YzUwYzcwL3RhYmxlcmFuZ2U6YzJkOTkyMTNkNTA3NDk2MTliYmZlMDkyZDVjNTBjNzBfMjAtMS0xLTEtMA_1caa587a-7896-49f6-83be-c474389e9a50">11,265</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and employee benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia177f909fbae4389bdaa8635f038babb_I20201231" decimals="-3" format="ixt:numdotdecimal" name="evh:DisposalGroupIncludingDiscontinuedOperationAccruedCompensationAndEmployeeBenefitsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOmMyZDk5MjEzZDUwNzQ5NjE5YmJmZTA5MmQ1YzUwYzcwL3RhYmxlcmFuZ2U6YzJkOTkyMTNkNTA3NDk2MTliYmZlMDkyZDVjNTBjNzBfMjEtMS0xLTEtMA_bb4414d1-967f-4323-ab34-93f33f2cfac1">1,115</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia177f909fbae4389bdaa8635f038babb_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOmMyZDk5MjEzZDUwNzQ5NjE5YmJmZTA5MmQ1YzUwYzcwL3RhYmxlcmFuZ2U6YzJkOTkyMTNkNTA3NDk2MTliYmZlMDkyZDVjNTBjNzBfMjItMS0xLTEtMA_566f1b5b-0951-495e-8761-38a3d8965294">4,140</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve for claims and performance-based arrangements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia177f909fbae4389bdaa8635f038babb_I20201231" decimals="-3" format="ixt:numdotdecimal" name="evh:DisposalGroupIncludingDiscontinuedOperationLiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangementsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOmMyZDk5MjEzZDUwNzQ5NjE5YmJmZTA5MmQ1YzUwYzcwL3RhYmxlcmFuZ2U6YzJkOTkyMTNkNTA3NDk2MTliYmZlMDkyZDVjNTBjNzBfMjMtMS0xLTEtMA_f1e49249-da9c-4076-8900-d3a301a3ab05">9,858</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia177f909fbae4389bdaa8635f038babb_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOmMyZDk5MjEzZDUwNzQ5NjE5YmJmZTA5MmQ1YzUwYzcwL3RhYmxlcmFuZ2U6YzJkOTkyMTNkNTA3NDk2MTliYmZlMDkyZDVjNTBjNzBfMjQtMS0xLTEtMA_aad0cef5-9d2f-4169-a82c-a2ec05e3fec0">26,471</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia177f909fbae4389bdaa8635f038babb_I20201231" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOmMyZDk5MjEzZDUwNzQ5NjE5YmJmZTA5MmQ1YzUwYzcwL3RhYmxlcmFuZ2U6YzJkOTkyMTNkNTA3NDk2MTliYmZlMDkyZDVjNTBjNzBfMjUtMS0xLTEtMA_581360bc-36dd-4d1d-b4cf-a7741c973dd9">128</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia177f909fbae4389bdaa8635f038babb_I20201231" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOmMyZDk5MjEzZDUwNzQ5NjE5YmJmZTA5MmQ1YzUwYzcwL3RhYmxlcmFuZ2U6YzJkOTkyMTNkNTA3NDk2MTliYmZlMDkyZDVjNTBjNzBfMjYtMS0xLTEtMA_aaf8bba1-7319-4ce0-8922-929c94c2c5b8">49</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia177f909fbae4389bdaa8635f038babb_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOmMyZDk5MjEzZDUwNzQ5NjE5YmJmZTA5MmQ1YzUwYzcwL3RhYmxlcmFuZ2U6YzJkOTkyMTNkNTA3NDk2MTliYmZlMDkyZDVjNTBjNzBfMjctMS0xLTEtMA_3f77a63c-560f-4add-96e9-5ffb4db52d81">26,648</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Accounts payable exclude $<ix:nonFraction unitRef="usd" contextRef="i253ccf29d13d4053a5a80b95f440acbe_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RleHRyZWdpb246YTc2MmYwMGIxMDk2NDgzZThhYWM3ZTBlNGY2ZDgzZjBfMjM5MQ_0ecff333-a53d-461d-9dc6-1aa3c3e3bdd7"><ix:nonFraction unitRef="usd" contextRef="i253ccf29d13d4053a5a80b95f440acbe_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RleHRyZWdpb246YTc2MmYwMGIxMDk2NDgzZThhYWM3ZTBlNGY2ZDgzZjBfMjM5MQ_93460396-7ee5-48f6-a96e-4b7e098c422a">1.5</ix:nonFraction></ix:nonFraction>&#160;million between the Company and True Health related an existing services agreement for claims processing and other health plan administrative functions as of December 31, 2020.</span></div></ix:continuation></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="id8f403494d0a42c2868794fb470218fc_58"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 6.  <ix:nonNumeric contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181OC9mcmFnOjQ2NmRlMDUxNjNjYjQ0MzRhMTkxNDY1YTcyZmUyMzFjL3RleHRyZWdpb246NDY2ZGUwNTE2M2NiNDQzNGExOTE0NjVhNzJmZTIzMWNfMTAxNDc_ba2e153b-c616-4783-acc4-01b917c5a1e1" continuedAt="i54aa92878b6e40f9859c74e7cef5c1c2" escape="true">Revenue Recognition</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i54aa92878b6e40f9859c74e7cef5c1c2" continuedAt="i863c58f2d5684402bf64dddd3b7db0cd"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We derive revenue from two sources: (1) transformation services and (2) platform and operations services.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Transformation Services Revenue</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Transformation services consist of implementation services whereby we assist the customer in launching its population health or health plan programs. In certain cases, transformation services can also include revenue associated with our support of certain one-time wind-down activities for clients who are exiting a line of business or population. The transformation services are usually completed within 12 months. We generally receive a fixed fee for transformation services and recognize revenue over time using an input method based on hours incurred compared to the total estimated hours required to satisfy our performance obligation.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Platform and Operations Services Revenue</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Platform and operations services are typically multi-year arrangements with customers to provide various clinical and administrative solutions. In our Clinical Solutions segment, our solutions are designed to lower the medical expenses of our partners and include our total cost of care and specialty care management services.  In our Evolent Health Services segment, our solutions are designed to provide comprehensive health plan operations and claims processing services, and also include transition or run-out services to customers receiving primarily third-party administration (&#8220;TPA&#8221;) services.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our performance obligation in these arrangements is to provide an integrated suite of services, including access to our platform that is customized to meet the specialized needs of our customers and members. Generally, we will apply the series guidance to the performance obligation as we have determined that each time increment is distinct. We primarily utilize a variable fee structure for these services that typically includes a monthly payment that is calculated based on a specified per member per month rate, multiplied by the number of members that our partners are managing under a value-based care arrangement or a percentage of plan premiums. Our arrangements may also include other variable fees related to service level agreements, shared medical savings arrangements and other performance measures. Variable consideration is estimated using the most likely amount based on our historical experience and best judgment at the time. Due to the nature of our arrangements, certain estimates may be constrained if it is probable that a significant reversal of revenue will occur when the uncertainty is resolved. We recognize revenue from platform and operations </span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i863c58f2d5684402bf64dddd3b7db0cd" continuedAt="i9a442419f33e4f709d60eb89d7232b32"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">services over time using the time elapsed output method. Fixed consideration is recognized ratably over the contract term. In accordance with the series guidance, we allocate variable consideration to the period to which the fees relate.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our Clinical Solutions segment, we enter into capitation arrangements that may include performance-based arrangements and/or gainshare features. We recognize capitation revenue on a gross basis when we have established control over the services within our scope and recognize capitation revenue on a net basis when we do not have control over the services within our scope. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contracts with Multiple Performance Obligations</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contracts with customers may contain multiple performance obligations, primarily when the customer has requested both transformation services and platform and operations services as these services are distinct from one another. When a contract has multiple performance obligations, we allocate the transaction price to each performance obligation based on the relative standalone selling price using the expected cost margin approach. This approach requires estimates regarding both the level of effort it will take to satisfy the performance obligation as well as fees that will be received under the variable pricing model. We also take into consideration customer demographics, current market conditions, the scope of services and our overall pricing strategy and objectives when determining the standalone selling price.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Principal vs. Agent</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We occasionally use third parties to assist in satisfying our performance obligations. In order to determine whether we are the principal or agent in the arrangement, we review each third-party relationship on a contract by contract basis. We are an agent when our role is to arrange for another entity to provide the services to the customer. In these instances, we do not control the service before it is provided and recognize revenue on a net basis. We are the principal when we control the good or service prior to transferring control to the customer. We recognize revenue on a gross basis when we are the principal in the arrangement.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Disaggregation of Revenue</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><ix:nonNumeric contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181OC9mcmFnOjQ2NmRlMDUxNjNjYjQ0MzRhMTkxNDY1YTcyZmUyMzFjL3RleHRyZWdpb246NDY2ZGUwNTE2M2NiNDQzNGExOTE0NjVhNzJmZTIzMWNfMTAxNDg_b997574c-5600-44c7-a5d7-eac002af0a82" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents Evolent&#8217;s revenue disaggregated by segment and end-market for the three and six months ended June 30, 2021 and 2020 (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:114.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Evolent Health Services</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Evolent Health Services</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a8d60e8de004fd0945ea0051704e1de_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181OC9mcmFnOjQ2NmRlMDUxNjNjYjQ0MzRhMTkxNDY1YTcyZmUyMzFjL3RhYmxlOjMyNWIwOGIyYjM1NDQ1ODBhNGU0YWYzZTM5NzQyOWU4L3RhYmxlcmFuZ2U6MzI1YjA4YjJiMzU0NDU4MGE0ZTRhZjNlMzk3NDI5ZThfMy0xLTEtMS0zNTk_ad683976-048a-4e16-8d1f-bdab38f45afb">52,064</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c8f58d985fb4dd1817f8f943b715272_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181OC9mcmFnOjQ2NmRlMDUxNjNjYjQ0MzRhMTkxNDY1YTcyZmUyMzFjL3RhYmxlOjMyNWIwOGIyYjM1NDQ1ODBhNGU0YWYzZTM5NzQyOWU4L3RhYmxlcmFuZ2U6MzI1YjA4YjJiMzU0NDU4MGE0ZTRhZjNlMzk3NDI5ZThfMy0zLTEtMS0zNTk_f9e6a339-0937-4450-bff1-af04992b9cd3">55,502</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f70e8921395417eb51d6b5f206ee45d_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181OC9mcmFnOjQ2NmRlMDUxNjNjYjQ0MzRhMTkxNDY1YTcyZmUyMzFjL3RhYmxlOjMyNWIwOGIyYjM1NDQ1ODBhNGU0YWYzZTM5NzQyOWU4L3RhYmxlcmFuZ2U6MzI1YjA4YjJiMzU0NDU4MGE0ZTRhZjNlMzk3NDI5ZThfMy01LTEtMS0zNjM_befd7312-3ae9-44e1-8459-a92286b0b9ca">53,648</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9022249a19e41248315bc92ae2c6b84_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181OC9mcmFnOjQ2NmRlMDUxNjNjYjQ0MzRhMTkxNDY1YTcyZmUyMzFjL3RhYmxlOjMyNWIwOGIyYjM1NDQ1ODBhNGU0YWYzZTM5NzQyOWU4L3RhYmxlcmFuZ2U6MzI1YjA4YjJiMzU0NDU4MGE0ZTRhZjNlMzk3NDI5ZThfMy03LTEtMS0zNjM_194902c6-f3d4-4be6-81f7-1ee07f0822b1">64,050</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80f1ac7ca97c4270a70dceff5a322554_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181OC9mcmFnOjQ2NmRlMDUxNjNjYjQ0MzRhMTkxNDY1YTcyZmUyMzFjL3RhYmxlOjMyNWIwOGIyYjM1NDQ1ODBhNGU0YWYzZTM5NzQyOWU4L3RhYmxlcmFuZ2U6MzI1YjA4YjJiMzU0NDU4MGE0ZTRhZjNlMzk3NDI5ZThfMy0xLTEtMS0w_d9e77113-1681-44c0-9c62-2d8dfc38f39c">112,993</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i833160ecd3e14792aed807f6f5526e09_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181OC9mcmFnOjQ2NmRlMDUxNjNjYjQ0MzRhMTkxNDY1YTcyZmUyMzFjL3RhYmxlOjMyNWIwOGIyYjM1NDQ1ODBhNGU0YWYzZTM5NzQyOWU4L3RhYmxlcmFuZ2U6MzI1YjA4YjJiMzU0NDU4MGE0ZTRhZjNlMzk3NDI5ZThfMy0zLTEtMS0w_7ffdaadd-cac7-4b42-94a6-dd07605874b6">113,947</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9abf3a96b46413baa0783c375797a74_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181OC9mcmFnOjQ2NmRlMDUxNjNjYjQ0MzRhMTkxNDY1YTcyZmUyMzFjL3RhYmxlOjMyNWIwOGIyYjM1NDQ1ODBhNGU0YWYzZTM5NzQyOWU4L3RhYmxlcmFuZ2U6MzI1YjA4YjJiMzU0NDU4MGE0ZTRhZjNlMzk3NDI5ZThfMy01LTEtMS0w_9a47446d-eaa2-44e1-b3f4-c3d6ebc5078f">96,987</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a6c076167634a8aa2973b374f21a1c4_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181OC9mcmFnOjQ2NmRlMDUxNjNjYjQ0MzRhMTkxNDY1YTcyZmUyMzFjL3RhYmxlOjMyNWIwOGIyYjM1NDQ1ODBhNGU0YWYzZTM5NzQyOWU4L3RhYmxlcmFuZ2U6MzI1YjA4YjJiMzU0NDU4MGE0ZTRhZjNlMzk3NDI5ZThfMy03LTEtMS0w_fc7745b6-036f-407a-bed3-f1c45c6c72f6">124,512</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9867dbbef41b4ff08dd51316a253355a_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181OC9mcmFnOjQ2NmRlMDUxNjNjYjQ0MzRhMTkxNDY1YTcyZmUyMzFjL3RhYmxlOjMyNWIwOGIyYjM1NDQ1ODBhNGU0YWYzZTM5NzQyOWU4L3RhYmxlcmFuZ2U6MzI1YjA4YjJiMzU0NDU4MGE0ZTRhZjNlMzk3NDI5ZThfNC0xLTEtMS0zNTk_839ff15a-1d46-4e63-95c7-50b4830c009f">6,346</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35df7764bb024bb58f354c0f372efbb2_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181OC9mcmFnOjQ2NmRlMDUxNjNjYjQ0MzRhMTkxNDY1YTcyZmUyMzFjL3RhYmxlOjMyNWIwOGIyYjM1NDQ1ODBhNGU0YWYzZTM5NzQyOWU4L3RhYmxlcmFuZ2U6MzI1YjA4YjJiMzU0NDU4MGE0ZTRhZjNlMzk3NDI5ZThfNC0zLTEtMS0zNTk_86bdc03d-3623-4784-8f83-9232af1db53b">14,061</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i676770c966c346949f713ef44a2dbce2_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181OC9mcmFnOjQ2NmRlMDUxNjNjYjQ0MzRhMTkxNDY1YTcyZmUyMzFjL3RhYmxlOjMyNWIwOGIyYjM1NDQ1ODBhNGU0YWYzZTM5NzQyOWU4L3RhYmxlcmFuZ2U6MzI1YjA4YjJiMzU0NDU4MGE0ZTRhZjNlMzk3NDI5ZThfNC01LTEtMS0zNjM_bc6cbd74-7716-4890-a4b8-c0e8483f0e5d">90,761</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b1276ae67ae4854953f3017ca34fd0a_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181OC9mcmFnOjQ2NmRlMDUxNjNjYjQ0MzRhMTkxNDY1YTcyZmUyMzFjL3RhYmxlOjMyNWIwOGIyYjM1NDQ1ODBhNGU0YWYzZTM5NzQyOWU4L3RhYmxlcmFuZ2U6MzI1YjA4YjJiMzU0NDU4MGE0ZTRhZjNlMzk3NDI5ZThfNC03LTEtMS0zNjM_5503b5a8-f6b8-4dd2-bba5-bdde7b5f7e92">64,206</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e93d81fa73f4e01abe8848bb63987d0_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181OC9mcmFnOjQ2NmRlMDUxNjNjYjQ0MzRhMTkxNDY1YTcyZmUyMzFjL3RhYmxlOjMyNWIwOGIyYjM1NDQ1ODBhNGU0YWYzZTM5NzQyOWU4L3RhYmxlcmFuZ2U6MzI1YjA4YjJiMzU0NDU4MGE0ZTRhZjNlMzk3NDI5ZThfNC0xLTEtMS0w_fa69eeb3-ba38-4191-8f04-9b2833b2e308">14,684</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c150b72b12444a49062d1ff90c9afd3_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181OC9mcmFnOjQ2NmRlMDUxNjNjYjQ0MzRhMTkxNDY1YTcyZmUyMzFjL3RhYmxlOjMyNWIwOGIyYjM1NDQ1ODBhNGU0YWYzZTM5NzQyOWU4L3RhYmxlcmFuZ2U6MzI1YjA4YjJiMzU0NDU4MGE0ZTRhZjNlMzk3NDI5ZThfNC0zLTEtMS0w_09fb8801-1699-47b9-9e7a-14d51adcc2c7">29,246</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b6c919aef4c4e57ab2545a539828a75_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181OC9mcmFnOjQ2NmRlMDUxNjNjYjQ0MzRhMTkxNDY1YTcyZmUyMzFjL3RhYmxlOjMyNWIwOGIyYjM1NDQ1ODBhNGU0YWYzZTM5NzQyOWU4L3RhYmxlcmFuZ2U6MzI1YjA4YjJiMzU0NDU4MGE0ZTRhZjNlMzk3NDI5ZThfNC01LTEtMS0w_c8c38a7e-1b6c-4728-89eb-f77b7fc35ab1">176,544</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c9490d39e564864bc4c81a7f1b11b1b_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181OC9mcmFnOjQ2NmRlMDUxNjNjYjQ0MzRhMTkxNDY1YTcyZmUyMzFjL3RhYmxlOjMyNWIwOGIyYjM1NDQ1ODBhNGU0YWYzZTM5NzQyOWU4L3RhYmxlcmFuZ2U6MzI1YjA4YjJiMzU0NDU4MGE0ZTRhZjNlMzk3NDI5ZThfNC03LTEtMS0w_d88725cc-386b-4ec7-a213-1020c8fb15e5">126,560</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21361653abbc4b6aa34198f3f5c3a202_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181OC9mcmFnOjQ2NmRlMDUxNjNjYjQ0MzRhMTkxNDY1YTcyZmUyMzFjL3RhYmxlOjMyNWIwOGIyYjM1NDQ1ODBhNGU0YWYzZTM5NzQyOWU4L3RhYmxlcmFuZ2U6MzI1YjA4YjJiMzU0NDU4MGE0ZTRhZjNlMzk3NDI5ZThfNS0xLTEtMS0zNTk_d1b8b4c9-dc58-49c0-a1a5-99c176c7626f">16,453</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id59d1f7e03da447690dd86c33c621d88_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181OC9mcmFnOjQ2NmRlMDUxNjNjYjQ0MzRhMTkxNDY1YTcyZmUyMzFjL3RhYmxlOjMyNWIwOGIyYjM1NDQ1ODBhNGU0YWYzZTM5NzQyOWU4L3RhYmxlcmFuZ2U6MzI1YjA4YjJiMzU0NDU4MGE0ZTRhZjNlMzk3NDI5ZThfNS0zLTEtMS0zNTk_49f384c5-87db-48c0-ab3b-6a31f1444268">16,958</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i135f040fff0c4f58a1234a087ef110d6_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181OC9mcmFnOjQ2NmRlMDUxNjNjYjQ0MzRhMTkxNDY1YTcyZmUyMzFjL3RhYmxlOjMyNWIwOGIyYjM1NDQ1ODBhNGU0YWYzZTM5NzQyOWU4L3RhYmxlcmFuZ2U6MzI1YjA4YjJiMzU0NDU4MGE0ZTRhZjNlMzk3NDI5ZThfNS01LTEtMS0zNjM_10ef7367-32e7-4936-b486-0a5099652379">2,785</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3905a81b1d7b40abb4c7c12d2a5c2e77_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181OC9mcmFnOjQ2NmRlMDUxNjNjYjQ0MzRhMTkxNDY1YTcyZmUyMzFjL3RhYmxlOjMyNWIwOGIyYjM1NDQ1ODBhNGU0YWYzZTM5NzQyOWU4L3RhYmxlcmFuZ2U6MzI1YjA4YjJiMzU0NDU4MGE0ZTRhZjNlMzk3NDI5ZThfNS03LTEtMS0zNjM_d297a743-f177-445c-9abd-4033d5a95055">2,522</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc1d76dc32264876ae1a895cacd83b87_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181OC9mcmFnOjQ2NmRlMDUxNjNjYjQ0MzRhMTkxNDY1YTcyZmUyMzFjL3RhYmxlOjMyNWIwOGIyYjM1NDQ1ODBhNGU0YWYzZTM5NzQyOWU4L3RhYmxlcmFuZ2U6MzI1YjA4YjJiMzU0NDU4MGE0ZTRhZjNlMzk3NDI5ZThfNS0xLTEtMS0w_42ca6d16-fd47-4ad6-92df-0c4dc08f3c4f">32,023</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43e4c78617c04287898b67968c6ce485_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181OC9mcmFnOjQ2NmRlMDUxNjNjYjQ0MzRhMTkxNDY1YTcyZmUyMzFjL3RhYmxlOjMyNWIwOGIyYjM1NDQ1ODBhNGU0YWYzZTM5NzQyOWU4L3RhYmxlcmFuZ2U6MzI1YjA4YjJiMzU0NDU4MGE0ZTRhZjNlMzk3NDI5ZThfNS0zLTEtMS0w_7657a388-247e-4e92-ba82-3489d31010c5">39,705</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52bdbef1d82e458fbfaf536f2c11d6e5_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181OC9mcmFnOjQ2NmRlMDUxNjNjYjQ0MzRhMTkxNDY1YTcyZmUyMzFjL3RhYmxlOjMyNWIwOGIyYjM1NDQ1ODBhNGU0YWYzZTM5NzQyOWU4L3RhYmxlcmFuZ2U6MzI1YjA4YjJiMzU0NDU4MGE0ZTRhZjNlMzk3NDI5ZThfNS01LTEtMS0w_337d48d8-f96a-4860-8b15-f4f73de494dc">3,897</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6796d59fa424ba69653cef4e3d47ff1_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181OC9mcmFnOjQ2NmRlMDUxNjNjYjQ0MzRhMTkxNDY1YTcyZmUyMzFjL3RhYmxlOjMyNWIwOGIyYjM1NDQ1ODBhNGU0YWYzZTM5NzQyOWU4L3RhYmxlcmFuZ2U6MzI1YjA4YjJiMzU0NDU4MGE0ZTRhZjNlMzk3NDI5ZThfNS03LTEtMS0w_79ea73ba-8d7d-4c90-9d2a-e24570f50079">4,561</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i679cb28be3a34242bd30bce045577c6e_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181OC9mcmFnOjQ2NmRlMDUxNjNjYjQ0MzRhMTkxNDY1YTcyZmUyMzFjL3RhYmxlOjMyNWIwOGIyYjM1NDQ1ODBhNGU0YWYzZTM5NzQyOWU4L3RhYmxlcmFuZ2U6MzI1YjA4YjJiMzU0NDU4MGE0ZTRhZjNlMzk3NDI5ZThfNi0xLTEtMS0zNTk_689db974-a620-44d6-b5e3-320fedf3bc82">74,863</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibebddd07c46e4994849d375ecea231c6_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181OC9mcmFnOjQ2NmRlMDUxNjNjYjQ0MzRhMTkxNDY1YTcyZmUyMzFjL3RhYmxlOjMyNWIwOGIyYjM1NDQ1ODBhNGU0YWYzZTM5NzQyOWU4L3RhYmxlcmFuZ2U6MzI1YjA4YjJiMzU0NDU4MGE0ZTRhZjNlMzk3NDI5ZThfNi0zLTEtMS0zNTk_a3356a78-a187-4601-a3b7-bbeb168a6c2a">86,521</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c9bfa2d7f884c12b69f21c9b3af2888_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181OC9mcmFnOjQ2NmRlMDUxNjNjYjQ0MzRhMTkxNDY1YTcyZmUyMzFjL3RhYmxlOjMyNWIwOGIyYjM1NDQ1ODBhNGU0YWYzZTM5NzQyOWU4L3RhYmxlcmFuZ2U6MzI1YjA4YjJiMzU0NDU4MGE0ZTRhZjNlMzk3NDI5ZThfNi01LTEtMS0zNjM_a2311711-d142-4405-ab1f-3bb6e5dd0239">147,194</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16325f028066493d8ad0ddc953bde9e9_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181OC9mcmFnOjQ2NmRlMDUxNjNjYjQ0MzRhMTkxNDY1YTcyZmUyMzFjL3RhYmxlOjMyNWIwOGIyYjM1NDQ1ODBhNGU0YWYzZTM5NzQyOWU4L3RhYmxlcmFuZ2U6MzI1YjA4YjJiMzU0NDU4MGE0ZTRhZjNlMzk3NDI5ZThfNi03LTEtMS0zNjM_5e2e5685-c6de-4c60-83e2-311b232f55c2">130,778</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d62628d6fb54fe0bd811fdfd0bf7b0c_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181OC9mcmFnOjQ2NmRlMDUxNjNjYjQ0MzRhMTkxNDY1YTcyZmUyMzFjL3RhYmxlOjMyNWIwOGIyYjM1NDQ1ODBhNGU0YWYzZTM5NzQyOWU4L3RhYmxlcmFuZ2U6MzI1YjA4YjJiMzU0NDU4MGE0ZTRhZjNlMzk3NDI5ZThfNi0xLTEtMS0w_ed1638d3-a812-4076-86d7-c3abb4ac0266">159,700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d756ddfc980426086c7294d41dd2af3_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181OC9mcmFnOjQ2NmRlMDUxNjNjYjQ0MzRhMTkxNDY1YTcyZmUyMzFjL3RhYmxlOjMyNWIwOGIyYjM1NDQ1ODBhNGU0YWYzZTM5NzQyOWU4L3RhYmxlcmFuZ2U6MzI1YjA4YjJiMzU0NDU4MGE0ZTRhZjNlMzk3NDI5ZThfNi0zLTEtMS0w_26326631-2a8a-4cc9-a763-af1d825987ab">182,898</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib887805409a54f638aeeafe3fe5d1688_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181OC9mcmFnOjQ2NmRlMDUxNjNjYjQ0MzRhMTkxNDY1YTcyZmUyMzFjL3RhYmxlOjMyNWIwOGIyYjM1NDQ1ODBhNGU0YWYzZTM5NzQyOWU4L3RhYmxlcmFuZ2U6MzI1YjA4YjJiMzU0NDU4MGE0ZTRhZjNlMzk3NDI5ZThfNi01LTEtMS0w_21c1573b-9d25-44b4-a9db-58cdd09740d6">277,428</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic606425dedeb4d3d9b0b453c252ea236_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181OC9mcmFnOjQ2NmRlMDUxNjNjYjQ0MzRhMTkxNDY1YTcyZmUyMzFjL3RhYmxlOjMyNWIwOGIyYjM1NDQ1ODBhNGU0YWYzZTM5NzQyOWU4L3RhYmxlcmFuZ2U6MzI1YjA4YjJiMzU0NDU4MGE0ZTRhZjNlMzk3NDI5ZThfNi03LTEtMS0w_64239d68-b930-47aa-8e2a-59293a805ab9">255,633</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Transaction Price Allocated to the Remaining Performance Obligations</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For contracts with a term greater than one year, we have allocated approximately $<ix:nonFraction unitRef="usd" contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueRemainingPerformanceObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181OC9mcmFnOjQ2NmRlMDUxNjNjYjQ0MzRhMTkxNDY1YTcyZmUyMzFjL3RleHRyZWdpb246NDY2ZGUwNTE2M2NiNDQzNGExOTE0NjVhNzJmZTIzMWNfNTA4Mw_ca35699a-4cf0-47d2-bdda-5f184cbc6d7c">181.2</ix:nonFraction> million of transaction price to performance obligations that are unsatisfied as of June&#160;30, 2021. We do not include variable consideration that is allocated entirely to a wholly unsatisfied performance obligation accounted for under the series guidance in the calculation. As a result, the balance represents the value of the fixed consideration in our long-term contracts that we expect will be recognized as revenue in a future period and excludes the majority of our platform and operations revenue, which is primarily derived based on variable consideration as discussed in Note 2. We expect to recognize revenue on approximately <ix:nonFraction unitRef="number" contextRef="ia58666fd3ef747c9bd6d04b645148e3f_I20210630" decimals="2" name="us-gaap:RevenueRemainingPerformanceObligationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181OC9mcmFnOjQ2NmRlMDUxNjNjYjQ0MzRhMTkxNDY1YTcyZmUyMzFjL3RleHRyZWdpb246NDY2ZGUwNTE2M2NiNDQzNGExOTE0NjVhNzJmZTIzMWNfNTcwMg_cde7177b-44d8-4588-9b2d-6fa1e0aa6979">18</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i486b139f28404e439444f6f0c13129da_I20210630" decimals="2" name="us-gaap:RevenueRemainingPerformanceObligationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181OC9mcmFnOjQ2NmRlMDUxNjNjYjQ0MzRhMTkxNDY1YTcyZmUyMzFjL3RleHRyZWdpb246NDY2ZGUwNTE2M2NiNDQzNGExOTE0NjVhNzJmZTIzMWNfNTcwOQ_a8558487-a220-4099-a63d-f5326c464588">51</ix:nonFraction>% of these remaining performance obligations by December 31, 2021 and December 31, 2022, respectively, with the remaining balance to be recognized thereafter. However, because our existing contracts may be canceled or renegotiated including for reasons outside our control, the amount of revenue that we actually receive may be less or greater than this estimate and the timing of recognition may not be as expected.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i9a442419f33e4f709d60eb89d7232b32" continuedAt="ia05db22e8ccd411998ba367499da4a84"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contract Balances</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract balances consist of accounts receivable, contract assets and deferred revenue. Contract assets are recorded when the right to consideration for services is conditional on something other than the passage of time. Contract assets relating to unbilled receivables are transferred to accounts receivable when the right to consideration becomes unconditional. We classify contract assets as current or non-current based on the timing of our rights to the unconditional payments. Our contract assets are generally classified as current and recorded within prepaid expenses and other current assets on our consolidated balance sheets. Our current accounts receivables are classified within accounts receivable, net on our consolidated balance sheets and our non-current accounts receivable are classified within prepaid expenses and other non-current assets on our consolidated balance sheets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred revenue includes advance customer payments and billings in excess of revenue recognized. We classify deferred revenue as current or non-current based on the timing of when we expect to recognize revenue. Our current deferred revenue is recorded within deferred revenue on our consolidated balance sheets, and non-current deferred revenue is recorded within other long-term liabilities on our consolidated balance sheets.</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181OC9mcmFnOjQ2NmRlMDUxNjNjYjQ0MzRhMTkxNDY1YTcyZmUyMzFjL3RleHRyZWdpb246NDY2ZGUwNTE2M2NiNDQzNGExOTE0NjVhNzJmZTIzMWNfMTAxNDU_303c575a-d8f3-434a-b39a-4922edfc2bde" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides information about receivables, contract assets and deferred revenue from contracts with customers as of June&#160;30, 2021 and December&#160;31, 2020 (in thousands):</span></div><div style="margin-top:5pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:403.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:67.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term receivables </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsNotesAndLoansReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181OC9mcmFnOjQ2NmRlMDUxNjNjYjQ0MzRhMTkxNDY1YTcyZmUyMzFjL3RhYmxlOjI5YmU0MDRkNzEzNzQ2N2U5MjVkN2Q2MTg2NDViZGVjL3RhYmxlcmFuZ2U6MjliZTQwNGQ3MTM3NDY3ZTkyNWQ3ZDYxODY0NWJkZWNfMS0xLTEtMS0w_7f63c551-5251-43e9-9935-3c90e28536a7">240,060</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45bff335c1434d6ba44132da1b0557db_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsNotesAndLoansReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181OC9mcmFnOjQ2NmRlMDUxNjNjYjQ0MzRhMTkxNDY1YTcyZmUyMzFjL3RhYmxlOjI5YmU0MDRkNzEzNzQ2N2U5MjVkN2Q2MTg2NDViZGVjL3RhYmxlcmFuZ2U6MjliZTQwNGQ3MTM3NDY3ZTkyNWQ3ZDYxODY0NWJkZWNfMS0zLTEtMS0w_1ef5b790-ee8c-45be-aa52-650cb198697f">124,064</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term receivables </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermAccountsNotesAndLoansReceivableNetNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181OC9mcmFnOjQ2NmRlMDUxNjNjYjQ0MzRhMTkxNDY1YTcyZmUyMzFjL3RhYmxlOjI5YmU0MDRkNzEzNzQ2N2U5MjVkN2Q2MTg2NDViZGVjL3RhYmxlcmFuZ2U6MjliZTQwNGQ3MTM3NDY3ZTkyNWQ3ZDYxODY0NWJkZWNfMi0xLTEtMS0w_db2e90f5-2c69-4600-88f3-8e1465746106">4,688</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45bff335c1434d6ba44132da1b0557db_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermAccountsNotesAndLoansReceivableNetNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181OC9mcmFnOjQ2NmRlMDUxNjNjYjQ0MzRhMTkxNDY1YTcyZmUyMzFjL3RhYmxlOjI5YmU0MDRkNzEzNzQ2N2U5MjVkN2Q2MTg2NDViZGVjL3RhYmxlcmFuZ2U6MjliZTQwNGQ3MTM3NDY3ZTkyNWQ3ZDYxODY0NWJkZWNfMi0zLTEtMS0w_8cbf2147-8b82-4e7f-8ef2-f31e33bd8742">4,554</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term contract assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:ContractWithCustomerAssetNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181OC9mcmFnOjQ2NmRlMDUxNjNjYjQ0MzRhMTkxNDY1YTcyZmUyMzFjL3RhYmxlOjI5YmU0MDRkNzEzNzQ2N2U5MjVkN2Q2MTg2NDViZGVjL3RhYmxlcmFuZ2U6MjliZTQwNGQ3MTM3NDY3ZTkyNWQ3ZDYxODY0NWJkZWNfMy0xLTEtMS0w_fd047251-ee27-4671-929a-451336be8b91">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45bff335c1434d6ba44132da1b0557db_I20201231" decimals="-3" name="us-gaap:ContractWithCustomerAssetNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181OC9mcmFnOjQ2NmRlMDUxNjNjYjQ0MzRhMTkxNDY1YTcyZmUyMzFjL3RhYmxlOjI5YmU0MDRkNzEzNzQ2N2U5MjVkN2Q2MTg2NDViZGVjL3RhYmxlcmFuZ2U6MjliZTQwNGQ3MTM3NDY3ZTkyNWQ3ZDYxODY0NWJkZWNfMy0zLTEtMS0w_5ca7e971-2924-4796-8844-a913a635eee9">329</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181OC9mcmFnOjQ2NmRlMDUxNjNjYjQ0MzRhMTkxNDY1YTcyZmUyMzFjL3RhYmxlOjI5YmU0MDRkNzEzNzQ2N2U5MjVkN2Q2MTg2NDViZGVjL3RhYmxlcmFuZ2U6MjliZTQwNGQ3MTM3NDY3ZTkyNWQ3ZDYxODY0NWJkZWNfNC0xLTEtMS0w_22665d5d-ad36-4b65-97c4-f78ee3eb4b65">13,173</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45bff335c1434d6ba44132da1b0557db_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181OC9mcmFnOjQ2NmRlMDUxNjNjYjQ0MzRhMTkxNDY1YTcyZmUyMzFjL3RhYmxlOjI5YmU0MDRkNzEzNzQ2N2U5MjVkN2Q2MTg2NDViZGVjL3RhYmxlcmFuZ2U6MjliZTQwNGQ3MTM3NDY3ZTkyNWQ3ZDYxODY0NWJkZWNfNC0zLTEtMS0w_5cb7ec90-cad3-4f30-b751-75c20cce1a6e">10,187</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181OC9mcmFnOjQ2NmRlMDUxNjNjYjQ0MzRhMTkxNDY1YTcyZmUyMzFjL3RhYmxlOjI5YmU0MDRkNzEzNzQ2N2U5MjVkN2Q2MTg2NDViZGVjL3RhYmxlcmFuZ2U6MjliZTQwNGQ3MTM3NDY3ZTkyNWQ3ZDYxODY0NWJkZWNfNS0xLTEtMS0w_78616fad-4b41-42cb-8f7d-f06205b84d83">4,932</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45bff335c1434d6ba44132da1b0557db_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181OC9mcmFnOjQ2NmRlMDUxNjNjYjQ0MzRhMTkxNDY1YTcyZmUyMzFjL3RhYmxlOjI5YmU0MDRkNzEzNzQ2N2U5MjVkN2Q2MTg2NDViZGVjL3RhYmxlcmFuZ2U6MjliZTQwNGQ3MTM3NDY3ZTkyNWQ3ZDYxODY0NWJkZWNfNS0zLTEtMS0w_92c2cba2-68a9-44a9-8455-e00665790c9b">3,593</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Amounts exclude $<ix:nonFraction unitRef="usd" contextRef="ia177f909fbae4389bdaa8635f038babb_I20201231" decimals="-5" format="ixt:numdotdecimal" name="evh:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNetAfterGrossUp" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181OC9mcmFnOjQ2NmRlMDUxNjNjYjQ0MzRhMTkxNDY1YTcyZmUyMzFjL3RleHRyZWdpb246NDY2ZGUwNTE2M2NiNDQzNGExOTE0NjVhNzJmZTIzMWNfNzYzOQ_7fec4e4b-b46e-4ae5-a78a-377160fa1265">3.4</ix:nonFraction>&#160;million of short-term receivables and $<ix:nonFraction unitRef="usd" contextRef="ia177f909fbae4389bdaa8635f038babb_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181OC9mcmFnOjQ2NmRlMDUxNjNjYjQ0MzRhMTkxNDY1YTcyZmUyMzFjL3RleHRyZWdpb246NDY2ZGUwNTE2M2NiNDQzNGExOTE0NjVhNzJmZTIzMWNfNzY3Mg_4be919e8-0ef0-4c00-98fe-abdb784f3b2c">4.1</ix:nonFraction>&#160;million of short-term deferred revenue reclassified to discontinued operations as of December&#160;31, 2020.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Excludes pharmacy claims receivable and premiums receivable</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in deferred revenue for the six months ended June 30, 2021 are as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:433.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:102.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of beginning-of-period</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45bff335c1434d6ba44132da1b0557db_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181OC9mcmFnOjQ2NmRlMDUxNjNjYjQ0MzRhMTkxNDY1YTcyZmUyMzFjL3RhYmxlOjVmYjI2OTk3ODc0YzQ4YzZiNWE2YTI5ZDUzMzExMDkxL3RhYmxlcmFuZ2U6NWZiMjY5OTc4NzRjNDhjNmI1YTZhMjlkNTMzMTEwOTFfNy0xLTEtMS0w_04acfe70-0db1-4b88-841f-be97cd04a292">13,780</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification to revenue, as a result of performance obligations satisfied</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181OC9mcmFnOjQ2NmRlMDUxNjNjYjQ0MzRhMTkxNDY1YTcyZmUyMzFjL3RhYmxlOjVmYjI2OTk3ODc0YzQ4YzZiNWE2YTI5ZDUzMzExMDkxL3RhYmxlcmFuZ2U6NWZiMjY5OTc4NzRjNDhjNmI1YTZhMjlkNTMzMTEwOTFfOC0xLTEtMS0w_fab0203c-a443-4985-9c3a-5d9955bf0628">8,726</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash received in advance of satisfaction of performance obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="evh:ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181OC9mcmFnOjQ2NmRlMDUxNjNjYjQ0MzRhMTkxNDY1YTcyZmUyMzFjL3RhYmxlOjVmYjI2OTk3ODc0YzQ4YzZiNWE2YTI5ZDUzMzExMDkxL3RhYmxlcmFuZ2U6NWZiMjY5OTc4NzRjNDhjNmI1YTZhMjlkNTMzMTEwOTFfOS0xLTEtMS0w_68327442-bb8d-41b9-bfd0-8063cb2b5cb5">13,051</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181OC9mcmFnOjQ2NmRlMDUxNjNjYjQ0MzRhMTkxNDY1YTcyZmUyMzFjL3RhYmxlOjVmYjI2OTk3ODc0YzQ4YzZiNWE2YTI5ZDUzMzExMDkxL3RhYmxlcmFuZ2U6NWZiMjY5OTc4NzRjNDhjNmI1YTZhMjlkNTMzMTEwOTFfMTAtMS0xLTEtMA_35bfac06-0b24-479e-86a0-623b94e977f2">18,105</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amount of revenue recognized from performance obligations satisfied (or partially satisfied) in previous period was $<ix:nonFraction unitRef="usd" contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181OC9mcmFnOjQ2NmRlMDUxNjNjYjQ0MzRhMTkxNDY1YTcyZmUyMzFjL3RleHRyZWdpb246NDY2ZGUwNTE2M2NiNDQzNGExOTE0NjVhNzJmZTIzMWNfMTA5OTUxMTYzODEwNw_6824a3e9-9e90-412e-b040-64d719483535">2.9</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181OC9mcmFnOjQ2NmRlMDUxNjNjYjQ0MzRhMTkxNDY1YTcyZmUyMzFjL3RleHRyZWdpb246NDY2ZGUwNTE2M2NiNDQzNGExOTE0NjVhNzJmZTIzMWNfODAyNw_a32fb5b5-347f-4a6a-a95b-f83b5ec0901b">16.1</ix:nonFraction> million for the three and six months ended June 30, 2021, respectively, due primarily to net gain share as well as changes in other estimates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contract Cost Assets</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain bonuses and commissions earned by our sales team are considered incremental costs of obtaining a contract with a customer that we expect to be recoverable. The capitalized contract acquisition costs are classified as non-current assets and recorded within contract cost assets on our consolidated balance sheets. Amortization expense is recorded within selling, general and administrative expenses on the accompanying consolidated statements of operations and comprehensive income (loss). As of June&#160;30, 2021 and December&#160;31, 2020, the Company had $<ix:nonFraction unitRef="usd" contextRef="id9deab8552a14f5eb736da5c6d86fc8c_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CapitalizedContractCostNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181OC9mcmFnOjQ2NmRlMDUxNjNjYjQ0MzRhMTkxNDY1YTcyZmUyMzFjL3RleHRyZWdpb246NDY2ZGUwNTE2M2NiNDQzNGExOTE0NjVhNzJmZTIzMWNfODY5Nw_f13eef59-6b4f-4a70-a43d-fd194dcaa4c4">3.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i82a60e4d756c4c5e95ccf693e56f48a9_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CapitalizedContractCostNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181OC9mcmFnOjQ2NmRlMDUxNjNjYjQ0MzRhMTkxNDY1YTcyZmUyMzFjL3RleHRyZWdpb246NDY2ZGUwNTE2M2NiNDQzNGExOTE0NjVhNzJmZTIzMWNfODcwNA_44d9982f-6d21-46f1-b621-154eb823f1b9">3.3</ix:nonFraction> million, respectively, of contract acquisition cost assets, net of accumulated amortization recorded in contract cost assets on the consolidated balance sheets. In addition, the Company recorded </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">amortiza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">tion expense of $<ix:nonFraction unitRef="usd" contextRef="i06ae7c987bf741caa484f758c9e8534d_D20210401-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CapitalizedContractCostAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181OC9mcmFnOjQ2NmRlMDUxNjNjYjQ0MzRhMTkxNDY1YTcyZmUyMzFjL3RleHRyZWdpb246NDY2ZGUwNTE2M2NiNDQzNGExOTE0NjVhNzJmZTIzMWNfMTY0OTI2NzQ1MjAwNg_39bf1708-4b03-451a-b36b-20e1a9f440c3">0.6</ix:nonFraction> million and  $<ix:nonFraction unitRef="usd" contextRef="idadd3c2bee534377ac63ee0a2aa2dc8c_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CapitalizedContractCostAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181OC9mcmFnOjQ2NmRlMDUxNjNjYjQ0MzRhMTkxNDY1YTcyZmUyMzFjL3RleHRyZWdpb246NDY2ZGUwNTE2M2NiNDQzNGExOTE0NjVhNzJmZTIzMWNfODkxOA_e2c5869e-f54d-459a-8ad1-a4aff0daa3d9">1.0</ix:nonFraction> million for the three and six months ended June 30, 2021, respectively and $<ix:nonFraction unitRef="usd" contextRef="i86cf0d7a76724f38ab859d26bde2920a_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CapitalizedContractCostAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181OC9mcmFnOjQ2NmRlMDUxNjNjYjQ0MzRhMTkxNDY1YTcyZmUyMzFjL3RleHRyZWdpb246NDY2ZGUwNTE2M2NiNDQzNGExOTE0NjVhNzJmZTIzMWNfMTY0OTI2NzQ1MjAyMA_9218f0c2-efa6-4c92-8b23-b3c0f641af21">0.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i2255e38e922f4d94b90c933ab1b70b67_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CapitalizedContractCostAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181OC9mcmFnOjQ2NmRlMDUxNjNjYjQ0MzRhMTkxNDY1YTcyZmUyMzFjL3RleHRyZWdpb246NDY2ZGUwNTE2M2NiNDQzNGExOTE0NjVhNzJmZTIzMWNfODkyNQ_adaf44d4-12b7-498b-bad6-e23060555594">0.9</ix:nonFraction> million for the three and six months ended June 30, 2020, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our platforms and operations arrangements, we incur certain costs related to the implementation of our platform before we begin to satisfy our performance obligation to the customer. The costs, which we expect to recover, are considered costs to fulfill a contract. Our contract fulfillment costs primarily include our employee labor costs and third-party vendor costs. The capitalized contract fulfillment costs are classified as non-current and recorded within contract cost assets on our consolidated balance sheets. Amortization expense is recorded within cost of revenue on the accompanying consolidated statements of operations and </span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ia05db22e8ccd411998ba367499da4a84"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">comprehensive income (loss). As of June&#160;30, 2021 and December&#160;31, 2020, the Company had $<ix:nonFraction unitRef="usd" contextRef="i8514ff7930a54e788f76b2be07ba421a_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CapitalizedContractCostNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181OC9mcmFnOjQ2NmRlMDUxNjNjYjQ0MzRhMTkxNDY1YTcyZmUyMzFjL3RleHRyZWdpb246NDY2ZGUwNTE2M2NiNDQzNGExOTE0NjVhNzJmZTIzMWNfOTY1NA_130610aa-7ce1-4531-8afc-ba5830ccdbcc">18.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i296b1e421ebd4c6fa47abf987a270359_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CapitalizedContractCostNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181OC9mcmFnOjQ2NmRlMDUxNjNjYjQ0MzRhMTkxNDY1YTcyZmUyMzFjL3RleHRyZWdpb246NDY2ZGUwNTE2M2NiNDQzNGExOTE0NjVhNzJmZTIzMWNfOTY2MQ_d7d08fae-d47f-4dbd-a037-bce0a554aed6">23.4</ix:nonFraction> million, respectively, of contract fulfillment cost assets, net of accumulated amortization recorded in contract cost assets on the consolidated balance sheets. In addition, the Company recorded amortization expense of $<ix:nonFraction unitRef="usd" contextRef="i27ed1697f8ec480093c84d3cf0952a90_D20210401-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CapitalizedContractCostAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181OC9mcmFnOjQ2NmRlMDUxNjNjYjQ0MzRhMTkxNDY1YTcyZmUyMzFjL3RleHRyZWdpb246NDY2ZGUwNTE2M2NiNDQzNGExOTE0NjVhNzJmZTIzMWNfMTY0OTI2NzQ1MjA1Ng_0fe4f215-acfd-459d-bb32-51807d1960e7">4.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ic6fb32c2d54b4c729398fb1ececf52fa_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CapitalizedContractCostAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181OC9mcmFnOjQ2NmRlMDUxNjNjYjQ0MzRhMTkxNDY1YTcyZmUyMzFjL3RleHRyZWdpb246NDY2ZGUwNTE2M2NiNDQzNGExOTE0NjVhNzJmZTIzMWNfOTg3NQ_23ea81ed-67f7-4358-9e16-36195557162b">7.3</ix:nonFraction> million for the three and six months ended June 30, 2021, respectively, $<ix:nonFraction unitRef="usd" contextRef="ib613b60e238f47b69fde69e1a6a8f9be_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CapitalizedContractCostAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181OC9mcmFnOjQ2NmRlMDUxNjNjYjQ0MzRhMTkxNDY1YTcyZmUyMzFjL3RleHRyZWdpb246NDY2ZGUwNTE2M2NiNDQzNGExOTE0NjVhNzJmZTIzMWNfMTY0OTI2NzQ1MjA5NA_781f31af-9576-40a1-95b8-50f9f4726315">4.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="if15e3a35bf6243958b35f8728c4cc216_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CapitalizedContractCostAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181OC9mcmFnOjQ2NmRlMDUxNjNjYjQ0MzRhMTkxNDY1YTcyZmUyMzFjL3RleHRyZWdpb246NDY2ZGUwNTE2M2NiNDQzNGExOTE0NjVhNzJmZTIzMWNfOTg4Mg_53a6d103-107a-4b12-81bc-9bdafdffe2e0">9.4</ix:nonFraction> million for the three and six months ended June 30, 2020, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These costs are deferred and then amortized on a straight-line basis over a period of benefit that we have determined to be <ix:nonNumeric contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630" format="ixt-sec:durwordsen" name="us-gaap:CapitalizedContractCostAmortizationPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181OC9mcmFnOjQ2NmRlMDUxNjNjYjQ0MzRhMTkxNDY1YTcyZmUyMzFjL3RleHRyZWdpb246NDY2ZGUwNTE2M2NiNDQzNGExOTE0NjVhNzJmZTIzMWNfMTAwMzI_fe803b9c-5c60-40c9-ba4c-9e6880fec8d8">five years</ix:nonNumeric>. The period of benefit was based on our technology, the nature of our customer arrangements and other factors.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="id8f403494d0a42c2868794fb470218fc_64"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 7. <ix:nonNumeric contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" name="us-gaap:CreditLossFinancialInstrumentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY182NC9mcmFnOjQ2MDYyMThjNmFjMDQyYzU4YTQwODliNmQzODJlMTM5L3RleHRyZWdpb246NDYwNjIxOGM2YWMwNDJjNThhNDA4OWI2ZDM4MmUxMzlfMjc2NQ_0b558228-b90d-4b89-bd7a-f100e5d0bfb4" continuedAt="ibade98c2d23a41e5b62be9f323ee79cb" escape="true">Credit Losses </ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="ibade98c2d23a41e5b62be9f323ee79cb"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to credit losses primarily through our accounts receivable from revenue transactions, investments held at amortized cost and customer advances for regulatory capital and other notes receivable. We estimate expected credit losses based on past events, current conditions and reasonable and supportable forecasts. Expected credit losses are measured over the remaining contractual life of these assets. As part of our consideration of current and forward-looking economic conditions, we considered the impact of the COVID-19 pandemic on our customers&#8217; and other third parties&#8217; ability to pay. We did not observe notable increases in delinquencies during the three and six months ended June 30, 2021. Given the nature of our business, our past collection experience during recessionary and pre-recessionary periods, and our forecasted impact of the COVID-19 pandemic on our business, we did not record material changes in our allowances due to the COVID-19 pandemic during the three and six months ended June 30, 2021.</span></div><div><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounts Receivable from Revenue Transactions</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable represent the amounts owed to the Company for goods or services provided to customers or third parties. Current accounts receivables are classified within accounts receivable, net on the Company&#8217;s consolidated balance sheets, while non-current accounts receivables are classified within prepaid expenses and other noncurrent assets on the Company&#8217;s consolidated balance sheets. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We monitor our ongoing credit exposure through active review of counterparty balances against contract terms, due dates and business strategy. Our activities include timely account reconciliation, dispute resolution and payment confirmation. We may employ legal counsel to pursue recovery of defaulted receivables. In addition, the Company will establish a general reserve based on delinquency rates. Historical loss rates are determined for each delinquency bucket in 30-day past-due intervals, and then applied to the composition of the reporting date balance based on delinquency. The allowance implied from application of the historical loss rates is then adjusted, as necessary, for current conditions and reasonable and supportable forecasts.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on an aging analysis of our trade accounts receivable, non-trade accounts receivable and contract assets at&#160;June&#160;30, 2021,&#160;<ix:nonFraction unitRef="number" contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630" decimals="2" name="evh:FinancingReceivablePercentNotPastDue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY182NC9mcmFnOjQ2MDYyMThjNmFjMDQyYzU4YTQwODliNmQzODJlMTM5L3RleHRyZWdpb246NDYwNjIxOGM2YWMwNDJjNThhNDA4OWI2ZDM4MmUxMzlfMjI5Mg_18e248d7-ca2b-4627-a973-f34344ed48b3">64</ix:nonFraction>% were current, <ix:nonFraction unitRef="number" contextRef="i2a6d7a68b4464c1c9d7d5339891880a1_I20210630" decimals="2" name="us-gaap:FinancingReceivablePercentPastDue1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY182NC9mcmFnOjQ2MDYyMThjNmFjMDQyYzU4YTQwODliNmQzODJlMTM5L3RleHRyZWdpb246NDYwNjIxOGM2YWMwNDJjNThhNDA4OWI2ZDM4MmUxMzlfMjMwOQ_eaaf13f0-33c5-4fd8-b64b-aa38a1e5910d">15</ix:nonFraction>%&#160;were past due less than 60 days, with <ix:nonFraction unitRef="number" contextRef="i62715a632a4b4513bd30977aa196bcc0_I20210630" decimals="2" name="us-gaap:FinancingReceivablePercentPastDue1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY182NC9mcmFnOjQ2MDYyMThjNmFjMDQyYzU4YTQwODliNmQzODJlMTM5L3RleHRyZWdpb246NDYwNjIxOGM2YWMwNDJjNThhNDA4OWI2ZDM4MmUxMzlfMjM1MA_8ca5d6e3-f6ef-45dd-b17c-76a9aba4e6e4">28</ix:nonFraction>% past due less than 120 days. At&#160;June&#160;30, 2021, we reported&#160;$<ix:nonFraction unitRef="usd" contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY182NC9mcmFnOjQ2MDYyMThjNmFjMDQyYzU4YTQwODliNmQzODJlMTM5L3RleHRyZWdpb246NDYwNjIxOGM2YWMwNDJjNThhNDA4OWI2ZDM4MmUxMzlfMjQwMQ_4c1494c4-9fe2-42fa-ab94-a15ff10e3eb0">264.1</ix:nonFraction> million&#160;of accounts receivable, certain non-trade accounts receivable included in prepaid expenses and other assets on the consolidated balance sheet and contract assets, net of allowances of&#160;$<ix:nonFraction unitRef="usd" contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY182NC9mcmFnOjQ2MDYyMThjNmFjMDQyYzU4YTQwODliNmQzODJlMTM5L3RleHRyZWdpb246NDYwNjIxOGM2YWMwNDJjNThhNDA4OWI2ZDM4MmUxMzlfMjU4MA_0753c7ec-e24b-4051-9f7f-c28d7d7255da">7.7</ix:nonFraction> million. <ix:nonNumeric contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" name="us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY182NC9mcmFnOjQ2MDYyMThjNmFjMDQyYzU4YTQwODliNmQzODJlMTM5L3RleHRyZWdpb246NDYwNjIxOGM2YWMwNDJjNThhNDA4OWI2ZDM4MmUxMzlfMjc2Ng_194ddd12-578a-4d1d-8bec-f893019fb6ce" continuedAt="ie95a5191fc4b44ceb775743b1328d5b1" escape="true">The following table summarizes the changes in allowance for credit losses on our accounts receivables, certain non-trade accounts receivable and contract assets for the six months ended June 30, 2021 and 2020 (in thousands):</ix:nonNumeric></span></div><div style="text-align:center"><ix:continuation id="ie95a5191fc4b44ceb775743b1328d5b1"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.816%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.594%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.596%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i45bff335c1434d6ba44132da1b0557db_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY182NC9mcmFnOjQ2MDYyMThjNmFjMDQyYzU4YTQwODliNmQzODJlMTM5L3RhYmxlOjlhZjc5NmM0M2FkOTRmNzdhYzYxZjE3YWVkNDlhYjUyL3RhYmxlcmFuZ2U6OWFmNzk2YzQzYWQ5NGY3N2FjNjFmMTdhZWQ0OWFiNTJfMi0xLTEtMS0w_dd53a69f-3101-4530-a17c-2f5bde5059e4">7,056</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie0ff0ad229b441d4b12bc8956f92a917_I20191231" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY182NC9mcmFnOjQ2MDYyMThjNmFjMDQyYzU4YTQwODliNmQzODJlMTM5L3RhYmxlOjlhZjc5NmM0M2FkOTRmNzdhYzYxZjE3YWVkNDlhYjUyL3RhYmxlcmFuZ2U6OWFmNzk2YzQzYWQ5NGY3N2FjNjFmMTdhZWQ0OWFiNTJfMi0zLTEtMS0w_d1dd70dc-7bfa-4061-90c5-ea50a1097a6b">41</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cumulative transition adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4306692d5e5e4a86b318371f5399f564_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY182NC9mcmFnOjQ2MDYyMThjNmFjMDQyYzU4YTQwODliNmQzODJlMTM5L3RhYmxlOjlhZjc5NmM0M2FkOTRmNzdhYzYxZjE3YWVkNDlhYjUyL3RhYmxlcmFuZ2U6OWFmNzk2YzQzYWQ5NGY3N2FjNjFmMTdhZWQ0OWFiNTJfMy0xLTEtMS0w_b64ef9d4-0ff6-49f4-bd7d-78692f13334d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e620150ffe942b388f50fab8377e007_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY182NC9mcmFnOjQ2MDYyMThjNmFjMDQyYzU4YTQwODliNmQzODJlMTM5L3RhYmxlOjlhZjc5NmM0M2FkOTRmNzdhYzYxZjE3YWVkNDlhYjUyL3RhYmxlcmFuZ2U6OWFmNzk2YzQzYWQ5NGY3N2FjNjFmMTdhZWQ0OWFiNTJfMy0zLTEtMS0w_706d5e88-b17f-4333-91af-c9cb827c379c">2,815</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for credit losses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="-3" name="us-gaap:ProvisionForDoubtfulAccounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY182NC9mcmFnOjQ2MDYyMThjNmFjMDQyYzU4YTQwODliNmQzODJlMTM5L3RhYmxlOjlhZjc5NmM0M2FkOTRmNzdhYzYxZjE3YWVkNDlhYjUyL3RhYmxlcmFuZ2U6OWFmNzk2YzQzYWQ5NGY3N2FjNjFmMTdhZWQ0OWFiNTJfNC0xLTEtMS0w_d97d92fd-847f-4041-ace3-ed66f4fc72f6">611</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="-3" name="us-gaap:ProvisionForDoubtfulAccounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY182NC9mcmFnOjQ2MDYyMThjNmFjMDQyYzU4YTQwODliNmQzODJlMTM5L3RhYmxlOjlhZjc5NmM0M2FkOTRmNzdhYzYxZjE3YWVkNDlhYjUyL3RhYmxlcmFuZ2U6OWFmNzk2YzQzYWQ5NGY3N2FjNjFmMTdhZWQ0OWFiNTJfNC0zLTEtMS0w_6e606579-bb22-465c-a442-8becd0278c04">260</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charge-offs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY182NC9mcmFnOjQ2MDYyMThjNmFjMDQyYzU4YTQwODliNmQzODJlMTM5L3RhYmxlOjlhZjc5NmM0M2FkOTRmNzdhYzYxZjE3YWVkNDlhYjUyL3RhYmxlcmFuZ2U6OWFmNzk2YzQzYWQ5NGY3N2FjNjFmMTdhZWQ0OWFiNTJfNS0xLTEtMS00MjQ_cd2a15f3-49b4-4edc-b7d6-372b8a7519ac">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY182NC9mcmFnOjQ2MDYyMThjNmFjMDQyYzU4YTQwODliNmQzODJlMTM5L3RhYmxlOjlhZjc5NmM0M2FkOTRmNzdhYzYxZjE3YWVkNDlhYjUyL3RhYmxlcmFuZ2U6OWFmNzk2YzQzYWQ5NGY3N2FjNjFmMTdhZWQ0OWFiNTJfNS0zLTEtMS00MjQ_65441b2f-f038-4a88-afd0-27b9f62d94a0">1,575</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY182NC9mcmFnOjQ2MDYyMThjNmFjMDQyYzU4YTQwODliNmQzODJlMTM5L3RhYmxlOjlhZjc5NmM0M2FkOTRmNzdhYzYxZjE3YWVkNDlhYjUyL3RhYmxlcmFuZ2U6OWFmNzk2YzQzYWQ5NGY3N2FjNjFmMTdhZWQ0OWFiNTJfNi0xLTEtMS0w_32f917c5-0de2-4634-985e-cc0c9e823d42">7,667</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i11817f96c3e24e0abaed14a17869e173_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY182NC9mcmFnOjQ2MDYyMThjNmFjMDQyYzU4YTQwODliNmQzODJlMTM5L3RhYmxlOjlhZjc5NmM0M2FkOTRmNzdhYzYxZjE3YWVkNDlhYjUyL3RhYmxlcmFuZ2U6OWFmNzk2YzQzYWQ5NGY3N2FjNjFmMTdhZWQ0OWFiNTJfNi0zLTEtMS0w_0c7594a2-8b2e-4f03-8821-1894335d9f96">1,541</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><div id="id8f403494d0a42c2868794fb470218fc_67"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 8.  <ix:nonNumeric contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY182Ny9mcmFnOmFmOTA1MDI0MWUxNTQ4NGI5NWEzOGE2MWZjYzc3ZDdlL3RleHRyZWdpb246YWY5MDUwMjQxZTE1NDg0Yjk1YTM4YTYxZmNjNzdkN2VfNTU0_952df695-6e69-4d46-8f68-dd23b318c34a" continuedAt="i80f418543a244c558f185011e3fdb1c0" escape="true">Property and Equipment, Net</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i80f418543a244c558f185011e3fdb1c0"><ix:nonNumeric contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY182Ny9mcmFnOmFmOTA1MDI0MWUxNTQ4NGI5NWEzOGE2MWZjYzc3ZDdlL3RleHRyZWdpb246YWY5MDUwMjQxZTE1NDg0Yjk1YTM4YTYxZmNjNzdkN2VfNTU3_39308b0c-b07f-4a2f-86a6-d66bd2037ebe" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes our property and equipment as of June&#160;30, 2021 and December&#160;31, 2020 (in thousands):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:408.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:54.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:67.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer hardware</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb44c2b2a28446c4b3e3caa830711368_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY182Ny9mcmFnOmFmOTA1MDI0MWUxNTQ4NGI5NWEzOGE2MWZjYzc3ZDdlL3RhYmxlOmIwNzA3OTdlYjk2ZTRlNmQ4YWJkYjgyNDI1YzljMDYzL3RhYmxlcmFuZ2U6YjA3MDc5N2ViOTZlNGU2ZDhhYmRiODI0MjVjOWMwNjNfMS0xLTEtMS0w_4c9b1c2e-7278-40ba-94c7-cfae2c516eec">19,931</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57afc0d68f184fb899a29c776805bc85_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY182Ny9mcmFnOmFmOTA1MDI0MWUxNTQ4NGI5NWEzOGE2MWZjYzc3ZDdlL3RhYmxlOmIwNzA3OTdlYjk2ZTRlNmQ4YWJkYjgyNDI1YzljMDYzL3RhYmxlcmFuZ2U6YjA3MDc5N2ViOTZlNGU2ZDhhYmRiODI0MjVjOWMwNjNfMS0zLTEtMS0w_5e08cf25-2b6f-41fe-a120-389051179ab9">18,866</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1bcc0c9ee4f48d2804f66aff99ff763_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY182Ny9mcmFnOmFmOTA1MDI0MWUxNTQ4NGI5NWEzOGE2MWZjYzc3ZDdlL3RhYmxlOmIwNzA3OTdlYjk2ZTRlNmQ4YWJkYjgyNDI1YzljMDYzL3RhYmxlcmFuZ2U6YjA3MDc5N2ViOTZlNGU2ZDhhYmRiODI0MjVjOWMwNjNfMi0xLTEtMS0w_f3094b1e-724d-4aa0-94c4-c0ba2670eaf1">3,545</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i786125390bf04da6ad620815caf55ac6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY182Ny9mcmFnOmFmOTA1MDI0MWUxNTQ4NGI5NWEzOGE2MWZjYzc3ZDdlL3RhYmxlOmIwNzA3OTdlYjk2ZTRlNmQ4YWJkYjgyNDI1YzljMDYzL3RhYmxlcmFuZ2U6YjA3MDc5N2ViOTZlNGU2ZDhhYmRiODI0MjVjOWMwNjNfMi0zLTEtMS0w_b5cb23b2-214d-460c-963a-a03628215132">3,559</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Internal-use software development costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3bacbba21c62440980d14afff52eb1ca_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY182Ny9mcmFnOmFmOTA1MDI0MWUxNTQ4NGI5NWEzOGE2MWZjYzc3ZDdlL3RhYmxlOmIwNzA3OTdlYjk2ZTRlNmQ4YWJkYjgyNDI1YzljMDYzL3RhYmxlcmFuZ2U6YjA3MDc5N2ViOTZlNGU2ZDhhYmRiODI0MjVjOWMwNjNfMy0xLTEtMS0w_53ea88ad-3d57-4bd0-9b98-94383c879922">148,171</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i037a95e6b16d4dcea7b2b033c338785c_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY182Ny9mcmFnOmFmOTA1MDI0MWUxNTQ4NGI5NWEzOGE2MWZjYzc3ZDdlL3RhYmxlOmIwNzA3OTdlYjk2ZTRlNmQ4YWJkYjgyNDI1YzljMDYzL3RhYmxlcmFuZ2U6YjA3MDc5N2ViOTZlNGU2ZDhhYmRiODI0MjVjOWMwNjNfMy0zLTEtMS0w_35bea834-d09b-42fb-ac65-04db7ad67b2a">137,085</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a061c9add404e629ee1ae3de0f2006f_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY182Ny9mcmFnOmFmOTA1MDI0MWUxNTQ4NGI5NWEzOGE2MWZjYzc3ZDdlL3RhYmxlOmIwNzA3OTdlYjk2ZTRlNmQ4YWJkYjgyNDI1YzljMDYzL3RhYmxlcmFuZ2U6YjA3MDc5N2ViOTZlNGU2ZDhhYmRiODI0MjVjOWMwNjNfNC0xLTEtMS0w_e603fdad-47ee-4169-b4f1-5c5d8a702d60">15,553</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e1d68f35e444ab6bb440e13e80ab435_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY182Ny9mcmFnOmFmOTA1MDI0MWUxNTQ4NGI5NWEzOGE2MWZjYzc3ZDdlL3RhYmxlOmIwNzA3OTdlYjk2ZTRlNmQ4YWJkYjgyNDI1YzljMDYzL3RhYmxlcmFuZ2U6YjA3MDc5N2ViOTZlNGU2ZDhhYmRiODI0MjVjOWMwNjNfNC0zLTEtMS0w_a40bb4a6-b228-406e-bc33-ec7f46b0881d">15,586</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY182Ny9mcmFnOmFmOTA1MDI0MWUxNTQ4NGI5NWEzOGE2MWZjYzc3ZDdlL3RhYmxlOmIwNzA3OTdlYjk2ZTRlNmQ4YWJkYjgyNDI1YzljMDYzL3RhYmxlcmFuZ2U6YjA3MDc5N2ViOTZlNGU2ZDhhYmRiODI0MjVjOWMwNjNfNS0xLTEtMS0w_c323a472-d14c-4b16-8871-635c5e5ddf5e">187,200</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45bff335c1434d6ba44132da1b0557db_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY182Ny9mcmFnOmFmOTA1MDI0MWUxNTQ4NGI5NWEzOGE2MWZjYzc3ZDdlL3RhYmxlOmIwNzA3OTdlYjk2ZTRlNmQ4YWJkYjgyNDI1YzljMDYzL3RhYmxlcmFuZ2U6YjA3MDc5N2ViOTZlNGU2ZDhhYmRiODI0MjVjOWMwNjNfNS0zLTEtMS0w_a365f6aa-2d93-441e-9029-cae5a170d90f">175,096</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation and amortization expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY182Ny9mcmFnOmFmOTA1MDI0MWUxNTQ4NGI5NWEzOGE2MWZjYzc3ZDdlL3RhYmxlOmIwNzA3OTdlYjk2ZTRlNmQ4YWJkYjgyNDI1YzljMDYzL3RhYmxlcmFuZ2U6YjA3MDc5N2ViOTZlNGU2ZDhhYmRiODI0MjVjOWMwNjNfNi0xLTEtMS0w_8d72cb9b-a44c-4403-b1de-600763801cff">104,204</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i45bff335c1434d6ba44132da1b0557db_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY182Ny9mcmFnOmFmOTA1MDI0MWUxNTQ4NGI5NWEzOGE2MWZjYzc3ZDdlL3RhYmxlOmIwNzA3OTdlYjk2ZTRlNmQ4YWJkYjgyNDI1YzljMDYzL3RhYmxlcmFuZ2U6YjA3MDc5N2ViOTZlNGU2ZDhhYmRiODI0MjVjOWMwNjNfNi0zLTEtMS0w_301926cf-8ae9-4356-9d11-dbdb7f588ccd">88,856</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY182Ny9mcmFnOmFmOTA1MDI0MWUxNTQ4NGI5NWEzOGE2MWZjYzc3ZDdlL3RhYmxlOmIwNzA3OTdlYjk2ZTRlNmQ4YWJkYjgyNDI1YzljMDYzL3RhYmxlcmFuZ2U6YjA3MDc5N2ViOTZlNGU2ZDhhYmRiODI0MjVjOWMwNjNfNy0xLTEtMS0w_7e6bd656-1be4-4a94-905c-41750f5bf5b9">82,996</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45bff335c1434d6ba44132da1b0557db_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY182Ny9mcmFnOmFmOTA1MDI0MWUxNTQ4NGI5NWEzOGE2MWZjYzc3ZDdlL3RhYmxlOmIwNzA3OTdlYjk2ZTRlNmQ4YWJkYjgyNDI1YzljMDYzL3RhYmxlcmFuZ2U6YjA3MDc5N2ViOTZlNGU2ZDhhYmRiODI0MjVjOWMwNjNfNy0zLTEtMS0w_857b41fc-cc63-412f-8ba9-f263f1d34fdd">86,240</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company capitalized $<ix:nonFraction unitRef="usd" contextRef="iefe7fef4d5624963a3e8bf8250323769_D20210401-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CapitalizedComputerSoftwareAdditions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY182Ny9mcmFnOmFmOTA1MDI0MWUxNTQ4NGI5NWEzOGE2MWZjYzc3ZDdlL3RleHRyZWdpb246YWY5MDUwMjQxZTE1NDg0Yjk1YTM4YTYxZmNjNzdkN2VfMTY0OTI2NzQ0MjMyMQ_9b351301-cca5-4813-9367-b442d63cf50f">5.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ieb3c51cd38194256bde9f79f0128cf37_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CapitalizedComputerSoftwareAdditions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY182Ny9mcmFnOmFmOTA1MDI0MWUxNTQ4NGI5NWEzOGE2MWZjYzc3ZDdlL3RleHRyZWdpb246YWY5MDUwMjQxZTE1NDg0Yjk1YTM4YTYxZmNjNzdkN2VfMTQx_dd6d3ea7-4715-49ac-b583-875574ddbb4e">11.1</ix:nonFraction> million of internal-use software development costs for the three and six months ended June 30, 2021, respectively, and $<ix:nonFraction unitRef="usd" contextRef="i04ad35bee18d4527b458f382beff864b_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CapitalizedComputerSoftwareAdditions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY182Ny9mcmFnOmFmOTA1MDI0MWUxNTQ4NGI5NWEzOGE2MWZjYzc3ZDdlL3RleHRyZWdpb246YWY5MDUwMjQxZTE1NDg0Yjk1YTM4YTYxZmNjNzdkN2VfMTY0OTI2NzQ0MjMzMQ_2ecbbe3e-1558-4e09-a01c-996fea5bd08c">6.4</ix:nonFraction> million and  $<ix:nonFraction unitRef="usd" contextRef="ibc2cefa24419498989e69466f40918b1_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CapitalizedComputerSoftwareAdditions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY182Ny9mcmFnOmFmOTA1MDI0MWUxNTQ4NGI5NWEzOGE2MWZjYzc3ZDdlL3RleHRyZWdpb246YWY5MDUwMjQxZTE1NDg0Yjk1YTM4YTYxZmNjNzdkN2VfMTQ4_281f0e5f-d535-4f17-a21e-be64f8f0ecb0">13.7</ix:nonFraction> million for the three and six months ended June 30, 2020, respectively. The net book value of capitalized internal-use software development costs was $<ix:nonFraction unitRef="usd" contextRef="i3bacbba21c62440980d14afff52eb1ca_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY182Ny9mcmFnOmFmOTA1MDI0MWUxNTQ4NGI5NWEzOGE2MWZjYzc3ZDdlL3RleHRyZWdpb246YWY5MDUwMjQxZTE1NDg0Yjk1YTM4YTYxZmNjNzdkN2VfMjk0_79a38516-ef61-4c14-b31b-b9210ff27565">73.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i037a95e6b16d4dcea7b2b033c338785c_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY182Ny9mcmFnOmFmOTA1MDI0MWUxNTQ4NGI5NWEzOGE2MWZjYzc3ZDdlL3RleHRyZWdpb246YWY5MDUwMjQxZTE1NDg0Yjk1YTM4YTYxZmNjNzdkN2VfMzAx_d7f57192-6063-4d0f-b435-73099821dded">75.3</ix:nonFraction> million as of June&#160;30, 2021 and December&#160;31, 2020, respectively. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense related to property and equipment was $<ix:nonFraction unitRef="usd" contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY182Ny9mcmFnOmFmOTA1MDI0MWUxNTQ4NGI5NWEzOGE2MWZjYzc3ZDdlL3RleHRyZWdpb246YWY5MDUwMjQxZTE1NDg0Yjk1YTM4YTYxZmNjNzdkN2VfMTY0OTI2NzQ0MjM3Nw_f7d7dce1-0e96-4896-88ee-63327b597110">7.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY182Ny9mcmFnOmFmOTA1MDI0MWUxNTQ4NGI5NWEzOGE2MWZjYzc3ZDdlL3RleHRyZWdpb246YWY5MDUwMjQxZTE1NDg0Yjk1YTM4YTYxZmNjNzdkN2VfMzk2_ec041cf2-cf55-445e-8db6-9cf3d56e415d">15.4</ix:nonFraction> million for the three and six months ended June 30, 2021, respectively, and $<ix:nonFraction unitRef="usd" contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY182Ny9mcmFnOmFmOTA1MDI0MWUxNTQ4NGI5NWEzOGE2MWZjYzc3ZDdlL3RleHRyZWdpb246YWY5MDUwMjQxZTE1NDg0Yjk1YTM4YTYxZmNjNzdkN2VfMTY0OTI2NzQ0MjQzOQ_a6b262db-f3f9-440d-bc1c-b30f7f2ec316">7.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY182Ny9mcmFnOmFmOTA1MDI0MWUxNTQ4NGI5NWEzOGE2MWZjYzc3ZDdlL3RleHRyZWdpb246YWY5MDUwMjQxZTE1NDg0Yjk1YTM4YTYxZmNjNzdkN2VfNDAz_be012ab0-1b79-4d02-94af-c47d60cae282">13.9</ix:nonFraction> million for the three and six months ended June 30, 2020, respectively, of which amortization expense related to capitalized internal-use software development costs was $<ix:nonFraction unitRef="usd" contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CapitalizedComputerSoftwareAmortization1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY182Ny9mcmFnOmFmOTA1MDI0MWUxNTQ4NGI5NWEzOGE2MWZjYzc3ZDdlL3RleHRyZWdpb246YWY5MDUwMjQxZTE1NDg0Yjk1YTM4YTYxZmNjNzdkN2VfMTY0OTI2NzQ0MjQ4Ng_54a75f7c-7ce8-4f21-8e4e-7a11c788f63d">6.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CapitalizedComputerSoftwareAmortization1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY182Ny9mcmFnOmFmOTA1MDI0MWUxNTQ4NGI5NWEzOGE2MWZjYzc3ZDdlL3RleHRyZWdpb246YWY5MDUwMjQxZTE1NDg0Yjk1YTM4YTYxZmNjNzdkN2VfNTI1_30f849d3-331f-456f-a9d3-907d84f1e9ca">13.3</ix:nonFraction> million for the three and six months ended June 30, 2021, respectively, and $<ix:nonFraction unitRef="usd" contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CapitalizedComputerSoftwareAmortization1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY182Ny9mcmFnOmFmOTA1MDI0MWUxNTQ4NGI5NWEzOGE2MWZjYzc3ZDdlL3RleHRyZWdpb246YWY5MDUwMjQxZTE1NDg0Yjk1YTM4YTYxZmNjNzdkN2VfMTY0OTI2NzQ0MjQ3NQ_b6412c42-a801-42d5-8208-4c77d9120790">6.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CapitalizedComputerSoftwareAmortization1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY182Ny9mcmFnOmFmOTA1MDI0MWUxNTQ4NGI5NWEzOGE2MWZjYzc3ZDdlL3RleHRyZWdpb246YWY5MDUwMjQxZTE1NDg0Yjk1YTM4YTYxZmNjNzdkN2VfNTMy_b53dc7e9-4ee8-4795-b0a5-b8ef81dbf970">11.6</ix:nonFraction> million for the three and six months ended June 30, 2020, respectively.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="id8f403494d0a42c2868794fb470218fc_70"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 9.  <ix:nonNumeric contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RleHRyZWdpb246ZDQ3OTRlNTJiZWE3NGJmZDhhZDljOTkyMmExMGFkZjZfODUyMg_1cb05975-74e9-452a-8d05-6f099399566e" continuedAt="i71b97e79c10b446f8fe5cdc96eaf2671" escape="true">Goodwill and Intangible Assets, Net</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i71b97e79c10b446f8fe5cdc96eaf2671" continuedAt="ice98326e3cad40bf9c3995da25ca975e"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill has an estimated indefinite life and is not amortized; rather, it is reviewed for impairment at least annually or whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent to the sale of True Health, the Company has <ix:nonFraction unitRef="reportingunit" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfReportingUnits" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RleHRyZWdpb246ZDQ3OTRlNTJiZWE3NGJmZDhhZDljOTkyMmExMGFkZjZfMzU2_d91287ea-fec5-413e-b46c-f8b5c4b80c39">three</ix:nonFraction> reporting units, each with </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">discrete financial information. Our assets and liabilities are employed in and relate to the operations of our reporting units. Therefore, the equity carrying value and future cash flows must be estimated each time a&#160;goodwill impairment&#160;analysis is performed on a reporting unit. As a result, our assets, liabilities and cash flows are assigned to reporting units using reasonable and consistent allocation methodologies. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our annual goodwill impairment review occurs during the fourth quarter of each fiscal </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">year. We evaluate qualitative factors that could cause us to believe the estimated fair value of each of our reporting units may be lower than the carrying value and trigger a quantitative assessment, including, but not limited to (i) macroeconomic conditions, (ii) industry and market considerations, (iii) our overall financial performance, including an analysis of our current and projected cash flows, revenues and earnings, (iv) a sustained decrease in share price and (v) other relevant entity-specific events including changes in management, strategy, partners, or litigation.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ice98326e3cad40bf9c3995da25ca975e" continuedAt="i0c5882b79f24409f8af51da38b0846c8"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2021 Goodwill Impairment Test</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not identify any qualitative factors that would trigger a quantitative goodwill impairment test during the three and six months ended June 30, 2021. We will perform our annual impairment test as of October 31, 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2020 Goodwill Impairment Test</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2020, the Company assessed whether there were additional events or changes in circumstances since its 2019 annual goodwill impairment test that would indicate that it was more likely than not that the fair values of the reporting units were less than the reporting units&#8217; carrying amounts that would require an additional interim impairment assessment after October 31, 2019. Considering the sharp decrease in the share price of the Company&#8217;s Class A common stock during the three months ended March 31, 2020, the Company determined indicators of an impairment were present and we performed an interim goodwill impairment assessment as of March 31, 2020. As a result of this test, the Company determined that there was <ix:nonFraction unitRef="usd" contextRef="i42bd67fe63d94bad9d6d9dbe6ec79900_D20200101-20200331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:GoodwillImpairmentLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RleHRyZWdpb246ZDQ3OTRlNTJiZWE3NGJmZDhhZDljOTkyMmExMGFkZjZfMjQ2NA_bcdae469-272a-4808-af11-4aab7c52e2ed">no</ix:nonFraction> goodwill impairment of the reporting unit which recognized an impairment in the year ended December 31, 2019. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During May 2020, the CHFS announced that EVH Passport was not awarded a Kentucky managed Medicaid contract for the next contract period and the Passport Medicaid Contract would expire on December 31, 2020. As a result of this announcement, the Company determined there were events or changes in circumstances since its 2019 annual goodwill impairment test that indicated it was more likely than not that the fair value of <ix:nonFraction unitRef="reportingunit" contextRef="i6cc0ccb728fb4392be2f4d846aac50c1_D20200501-20200531" decimals="INF" format="ixt-sec:numwordsen" name="evh:NumberOfReportingUnitsFairValueInExcessOfCarryingAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RleHRyZWdpb246ZDQ3OTRlNTJiZWE3NGJmZDhhZDljOTkyMmExMGFkZjZfMzAwMQ_c3e0d837-6d8b-4207-9c0f-0810087ab347">one</ix:nonFraction> of its <ix:nonFraction unitRef="reportingunit" contextRef="i6cc0ccb728fb4392be2f4d846aac50c1_D20200501-20200531" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfReportingUnits" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RleHRyZWdpb246ZDQ3OTRlNTJiZWE3NGJmZDhhZDljOTkyMmExMGFkZjZfMzAxMQ_0e0ccb26-6ff1-4cf1-8362-55cd2abfe756">two</ix:nonFraction> reporting units in the EHS segment was less than the reporting unit&#8217;s carrying amount triggering an interim quantitative assessment.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In performing this interim quantitative assessment, we estimated the fair value of the reporting unit by considering a discounted cash flow valuation approach (&#8220;income approach&#8221;). In determining the estimated fair value in a quantitative analysis, we projected future cash flows based on management&#8217;s estimates and long-term plans and applied a discount rate based on the Company&#8217;s weighted average cost of capital. This analysis required us to make judgments about revenues, expenses, fixed asset and working capital requirements, capital market assumptions, cash flows and discount rates.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of May 31, 2020, we determined that the reporting unit under review had an estimated fair value less than its carrying value.  As a result, we recorded a non-cash goodwill impairment charge of $<ix:nonFraction unitRef="usd" contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:GoodwillImpairmentLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RleHRyZWdpb246ZDQ3OTRlNTJiZWE3NGJmZDhhZDljOTkyMmExMGFkZjZfMzkzOA_1d2a38b3-f9a3-4e53-a0e6-65c45e76940b"><ix:nonFraction unitRef="usd" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:GoodwillImpairmentLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RleHRyZWdpb246ZDQ3OTRlNTJiZWE3NGJmZDhhZDljOTkyMmExMGFkZjZfMzkzOA_edcae28a-5e9c-4106-bf7b-35e7eeda0ea8">215.1</ix:nonFraction></ix:nonFraction>&#160;million on our consolidated statements of operations and comprehensive income (loss) for the three and six months ended June 30, 2020. In addition, the Company reviewed its interim goodwill impairment analysis as of June 30, 2020 and did not identify any additional information or events that would contradict or change the conclusion reached by the Company as of May 31, 2020. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September 30, 2020, we evaluated qualitative factors that could indicate the fair value of each of our reporting units may be lower than the carrying value. We did not identify any qualitative factors that would trigger a quantitative goodwill impairment test during the three months ended September 30, 2020. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the Company&#8217;s annual impairment analysis as of October 31, 2020, the Company concluded that previous impairment charges of $<ix:nonFraction unitRef="usd" contextRef="i3afcc69bcfa341e986b926e4d21107b8_D20191001-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:GoodwillImpairmentLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RleHRyZWdpb246ZDQ3OTRlNTJiZWE3NGJmZDhhZDljOTkyMmExMGFkZjZfNDc4NQ_dc0f939e-6ae1-45fb-9175-9e9437004092">199.8</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:GoodwillImpairmentLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RleHRyZWdpb246ZDQ3OTRlNTJiZWE3NGJmZDhhZDljOTkyMmExMGFkZjZfNDc5Mg_93a6a8d4-1638-48e3-a50c-b589329a1579">215.1</ix:nonFraction>&#160;million recorded during the three months ended December 31, 2019 and June 30, 2020, respectively, in <ix:nonFraction unitRef="reportingunit" contextRef="ibb95849bc72e47e5b878e5e786a0ed96_D20201031-20201031" decimals="INF" format="ixt-sec:numwordsen" name="evh:NumberOfReportingUnitsFairValueInExcessOfCarryingAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RleHRyZWdpb246ZDQ3OTRlNTJiZWE3NGJmZDhhZDljOTkyMmExMGFkZjZfNDg4OA_35b4d3dc-c16d-4146-babb-55395d23140d">one</ix:nonFraction> of our <ix:nonFraction unitRef="reportingunit" contextRef="ibb95849bc72e47e5b878e5e786a0ed96_D20201031-20201031" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfReportingUnits" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RleHRyZWdpb246ZDQ3OTRlNTJiZWE3NGJmZDhhZDljOTkyMmExMGFkZjZfNDg5OA_e1c3ae91-9497-4980-aaa7-9ccfaa187b2b">two</ix:nonFraction> reporting units in the EHS segment left that specific reporting unit with a limited fair value cushion. Therefore, the Company elected to forego the qualitative assessment and proceed directly to the quantitative assessment of the goodwill impairment test for that specific reporting unit. This election does not preclude management from performing the qualitative assessment in any subsequent period. For the remaining reporting units, after assessing the totality of events and circumstances including the results of our previous valuations, the minimal impacts of the Passport loss and COVID-19, the Company does not believe that an event occurred or circumstances changed during the period under consideration that would, more likely than not, reduce the fair value of any reporting unit below their carrying amount. Therefore, the Company concluded that the quantitative assessment was not required. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In performing our October 31, 2020 impairment test for <ix:nonFraction unitRef="reportingunit" contextRef="ibb95849bc72e47e5b878e5e786a0ed96_D20201031-20201031" decimals="INF" format="ixt-sec:numwordsen" name="evh:NumberOfReportingUnitsFairValueInExcessOfCarryingAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RleHRyZWdpb246ZDQ3OTRlNTJiZWE3NGJmZDhhZDljOTkyMmExMGFkZjZfNTg2Mw_9dfbbd07-fa6a-4363-a3eb-63aff6ef07e8">one</ix:nonFraction> of the specific reporting units referenced above, we estimated the fair value of our reporting units by considering a discounted cash flow valuation approach (&#8220;income approach&#8221;). In determining the estimated fair value using the income approach, we projected future cash flows based on management&#8217;s estimates and long-term plans and applied a discount rate based on the Company&#8217;s weighted average cost of capital. This analysis required us to make judgments about revenues, expenses, fixed asset and working capital requirements, capital market assumptions, cash flows and discount rates. As of October 31, 2020, we determined that the specific reporting unit had an estimated fair value greater than its carrying value and as a result, goodwill is not impaired.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, the Company assessed whether there were additional events or changes in circumstances since its annual goodwill impairment test that would indicate that it was more likely than not that the fair value of the reporting unit was less than the reporting unit&#8217;s carrying amounts that would require an interim impairment assessment after October 31, 2020. The Company determined there had been no such indicators, therefore, we did not perform an interim goodwill impairment assessment as of </span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i0c5882b79f24409f8af51da38b0846c8" continuedAt="ieda2ed5b1a734f09904c9f587bdb1510"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2020. As of December 31, 2020, the remaining goodwill attributable to the reporting unit from which we recognized a non-cash goodwill impairment charge earlier in the year was $<ix:nonFraction unitRef="usd" contextRef="i52907b15276944d085944daaa7867a5e_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RleHRyZWdpb246ZDQ3OTRlNTJiZWE3NGJmZDhhZDljOTkyMmExMGFkZjZfNzMzMQ_3d048cb3-e04b-49d0-9708-563f86498160">214.3</ix:nonFraction> million.</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" name="us-gaap:ScheduleOfGoodwillTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RleHRyZWdpb246ZDQ3OTRlNTJiZWE3NGJmZDhhZDljOTkyMmExMGFkZjZfODUxNg_14ece0f5-35c7-4e5f-a1c7-389561b92ff4" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in the carrying amount of goodwill, by reportable segment, for the six months ended June 30, 2021 and 2020 (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:331.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:63.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:3.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:63.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:3.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:63.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EHS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated </span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2020 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40bf24d71e79424985bfa9b1dc75e390_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RhYmxlOjJkNDYyNmMzZTY3NDQ0N2M5NWNkNWNlNDY4NDRjMWJkL3RhYmxlcmFuZ2U6MmQ0NjI2YzNlNjc0NDQ3Yzk1Y2Q1Y2U0Njg0NGMxYmRfMS0xLTEtMS0w_b0923aae-d4ca-45a2-a25b-b857eeb4d346">214,354</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00a15ecaf66f4a6cbb5b4eb9fa265870_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RhYmxlOjJkNDYyNmMzZTY3NDQ0N2M5NWNkNWNlNDY4NDRjMWJkL3RhYmxlcmFuZ2U6MmQ0NjI2YzNlNjc0NDQ3Yzk1Y2Q1Y2U0Njg0NGMxYmRfMS0zLTEtMS0w_691f8808-c0f9-437b-a21a-0aeb200af53a">134,675</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45bff335c1434d6ba44132da1b0557db_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RhYmxlOjJkNDYyNmMzZTY3NDQ0N2M5NWNkNWNlNDY4NDRjMWJkL3RhYmxlcmFuZ2U6MmQ0NjI2YzNlNjc0NDQ3Yzk1Y2Q1Y2U0Njg0NGMxYmRfMS01LTEtMS0w_25052669-ee5c-47c9-afd3-9a64d394ec77">349,029</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5d62628d6fb54fe0bd811fdfd0bf7b0c_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RhYmxlOjJkNDYyNmMzZTY3NDQ0N2M5NWNkNWNlNDY4NDRjMWJkL3RhYmxlcmFuZ2U6MmQ0NjI2YzNlNjc0NDQ3Yzk1Y2Q1Y2U0Njg0NGMxYmRfMi0xLTEtMS0w_6318bcb2-7751-4930-9835-0706284af353">20</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib887805409a54f638aeeafe3fe5d1688_D20210101-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RhYmxlOjJkNDYyNmMzZTY3NDQ0N2M5NWNkNWNlNDY4NDRjMWJkL3RhYmxlcmFuZ2U6MmQ0NjI2YzNlNjc0NDQ3Yzk1Y2Q1Y2U0Njg0NGMxYmRfMi0zLTEtMS0w_4c1a2971-c23e-49f2-8c22-642db8b139ec">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RhYmxlOjJkNDYyNmMzZTY3NDQ0N2M5NWNkNWNlNDY4NDRjMWJkL3RhYmxlcmFuZ2U6MmQ0NjI2YzNlNjc0NDQ3Yzk1Y2Q1Y2U0Njg0NGMxYmRfMi01LTEtMS0w_2cbb8a50-be72-4e66-b55a-b0714a234925">20</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of June 30, 2021</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie355e9ffef734dc6a2b8f3d027278891_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RhYmxlOjJkNDYyNmMzZTY3NDQ0N2M5NWNkNWNlNDY4NDRjMWJkL3RhYmxlcmFuZ2U6MmQ0NjI2YzNlNjc0NDQ3Yzk1Y2Q1Y2U0Njg0NGMxYmRfMy0xLTEtMS0w_5d85b069-b9ed-4926-88c7-b5e9a9bbf3cc">214,334</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c3ddb1ccecb442ca473281d46c1ef16_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RhYmxlOjJkNDYyNmMzZTY3NDQ0N2M5NWNkNWNlNDY4NDRjMWJkL3RhYmxlcmFuZ2U6MmQ0NjI2YzNlNjc0NDQ3Yzk1Y2Q1Y2U0Njg0NGMxYmRfMy0zLTEtMS0w_16102c4a-d0c2-4030-b37b-398cae6c1a82">134,675</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RhYmxlOjJkNDYyNmMzZTY3NDQ0N2M5NWNkNWNlNDY4NDRjMWJkL3RhYmxlcmFuZ2U6MmQ0NjI2YzNlNjc0NDQ3Yzk1Y2Q1Y2U0Njg0NGMxYmRfMy01LTEtMS0w_79b6c1e3-9b46-46fd-81c4-01b8185ffe16">349,009</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span><br/></span></div><div style="padding-left:9pt;text-indent:-9pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.705%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.985%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EHS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2019 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcf0f323376446aca3fd59b2d1a2f2ad_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RhYmxlOmY4MmJiOTM1MjA3ZjRlMDQ4Y2M4OGNhMzdmYzMxZTk0L3RhYmxlcmFuZ2U6ZjgyYmI5MzUyMDdmNGUwNDhjYzg4Y2EzN2ZjMzFlOTRfMS0xLTEtMS0w_dbf80612-12cf-437f-9c49-f2dc388ec6e4">431,684</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a66b42348f74ceea613fecea2deba8e_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RhYmxlOmY4MmJiOTM1MjA3ZjRlMDQ4Y2M4OGNhMzdmYzMxZTk0L3RhYmxlcmFuZ2U6ZjgyYmI5MzUyMDdmNGUwNDhjYzg4Y2EzN2ZjMzFlOTRfMS0zLTEtMS0w_7059e072-eb18-450f-b2ea-ca2aed96bd47">134,675</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0ff0ad229b441d4b12bc8956f92a917_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RhYmxlOmY4MmJiOTM1MjA3ZjRlMDQ4Y2M4OGNhMzdmYzMxZTk0L3RhYmxlcmFuZ2U6ZjgyYmI5MzUyMDdmNGUwNDhjYzg4Y2EzN2ZjMzFlOTRfMS01LTEtMS0w_311056ea-94c2-488a-b3c1-e571b1179842">566,359</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill disposal </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8d756ddfc980426086c7294d41dd2af3_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RhYmxlOmY4MmJiOTM1MjA3ZjRlMDQ4Y2M4OGNhMzdmYzMxZTk0L3RhYmxlcmFuZ2U6ZjgyYmI5MzUyMDdmNGUwNDhjYzg4Y2EzN2ZjMzFlOTRfMi0xLTEtMS0w_9ea8bf1b-d9c1-44a0-846c-986b5b95733c">2,200</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic606425dedeb4d3d9b0b453c252ea236_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RhYmxlOmY4MmJiOTM1MjA3ZjRlMDQ4Y2M4OGNhMzdmYzMxZTk0L3RhYmxlcmFuZ2U6ZjgyYmI5MzUyMDdmNGUwNDhjYzg4Y2EzN2ZjMzFlOTRfMi0zLTEtMS0w_cab6762c-b35a-4883-86a9-58a246e8639f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RhYmxlOmY4MmJiOTM1MjA3ZjRlMDQ4Y2M4OGNhMzdmYzMxZTk0L3RhYmxlcmFuZ2U6ZjgyYmI5MzUyMDdmNGUwNDhjYzg4Y2EzN2ZjMzFlOTRfMi01LTEtMS0w_7e64c57a-8d6d-4895-aaa4-511e00a6fd18">2,200</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8d756ddfc980426086c7294d41dd2af3_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GoodwillImpairmentLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RhYmxlOmY4MmJiOTM1MjA3ZjRlMDQ4Y2M4OGNhMzdmYzMxZTk0L3RhYmxlcmFuZ2U6ZjgyYmI5MzUyMDdmNGUwNDhjYzg4Y2EzN2ZjMzFlOTRfMy0xLTEtMS0yODE0_47c71c7b-754d-4218-bffc-c8a3cc8db0bc">215,100</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic606425dedeb4d3d9b0b453c252ea236_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:GoodwillImpairmentLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RhYmxlOmY4MmJiOTM1MjA3ZjRlMDQ4Y2M4OGNhMzdmYzMxZTk0L3RhYmxlcmFuZ2U6ZjgyYmI5MzUyMDdmNGUwNDhjYzg4Y2EzN2ZjMzFlOTRfMy0zLTEtMS0yODEx_610d22ec-bbd2-43af-8e75-9971489adce8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GoodwillImpairmentLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RhYmxlOmY4MmJiOTM1MjA3ZjRlMDQ4Y2M4OGNhMzdmYzMxZTk0L3RhYmxlcmFuZ2U6ZjgyYmI5MzUyMDdmNGUwNDhjYzg4Y2EzN2ZjMzFlOTRfMy01LTEtMS0yODA3_bebbf2ff-aec5-472f-87d1-d1ecd58f71e0">215,100</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8d756ddfc980426086c7294d41dd2af3_D20200101-20200630" decimals="-3" sign="-" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RhYmxlOmY4MmJiOTM1MjA3ZjRlMDQ4Y2M4OGNhMzdmYzMxZTk0L3RhYmxlcmFuZ2U6ZjgyYmI5MzUyMDdmNGUwNDhjYzg4Y2EzN2ZjMzFlOTRfMy0xLTEtMS0w_416d2565-f829-4ebe-b828-08c6b82405b7">69</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic606425dedeb4d3d9b0b453c252ea236_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RhYmxlOmY4MmJiOTM1MjA3ZjRlMDQ4Y2M4OGNhMzdmYzMxZTk0L3RhYmxlcmFuZ2U6ZjgyYmI5MzUyMDdmNGUwNDhjYzg4Y2EzN2ZjMzFlOTRfMy0zLTEtMS0w_967ecfef-e7ac-4ed5-8386-3415ce94c0f7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="-3" sign="-" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RhYmxlOmY4MmJiOTM1MjA3ZjRlMDQ4Y2M4OGNhMzdmYzMxZTk0L3RhYmxlcmFuZ2U6ZjgyYmI5MzUyMDdmNGUwNDhjYzg4Y2EzN2ZjMzFlOTRfMy01LTEtMS0w_034e9891-2b62-438d-8376-2a42d1ba7cc5">69</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of June 30, 2020</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5ff183307a4468fb0d5707822525486_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RhYmxlOmY4MmJiOTM1MjA3ZjRlMDQ4Y2M4OGNhMzdmYzMxZTk0L3RhYmxlcmFuZ2U6ZjgyYmI5MzUyMDdmNGUwNDhjYzg4Y2EzN2ZjMzFlOTRfNC0xLTEtMS0w_89ed4dee-5cda-432d-92bf-04964a7f40ba">214,315</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25d27166851f4878bc9c647f69bfd2ea_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RhYmxlOmY4MmJiOTM1MjA3ZjRlMDQ4Y2M4OGNhMzdmYzMxZTk0L3RhYmxlcmFuZ2U6ZjgyYmI5MzUyMDdmNGUwNDhjYzg4Y2EzN2ZjMzFlOTRfNC0zLTEtMS0w_a748ac34-d00a-4917-9c42-3332f7b104a5">134,675</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11817f96c3e24e0abaed14a17869e173_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RhYmxlOmY4MmJiOTM1MjA3ZjRlMDQ4Y2M4OGNhMzdmYzMxZTk0L3RhYmxlcmFuZ2U6ZjgyYmI5MzUyMDdmNGUwNDhjYzg4Y2EzN2ZjMzFlOTRfNC01LTEtMS0w_5de6740e-6acc-49a0-b1e1-886e20129870">348,990</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Net of cumulative inception to date impairment of $<ix:nonFraction unitRef="usd" contextRef="i45bff335c1434d6ba44132da1b0557db_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:GoodwillImpairedAccumulatedImpairmentLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RleHRyZWdpb246ZDQ3OTRlNTJiZWE3NGJmZDhhZDljOTkyMmExMGFkZjZfNzU1MA_461e653a-c777-42bb-b305-58954c43d39e">575.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ie0ff0ad229b441d4b12bc8956f92a917_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:GoodwillImpairedAccumulatedImpairmentLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RleHRyZWdpb246ZDQ3OTRlNTJiZWE3NGJmZDhhZDljOTkyMmExMGFkZjZfNzU1Nw_ddec7f38-4634-4485-978f-0d74c6694b24">360.4</ix:nonFraction> million as of December 31, 2020 and 2019, respectively.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Goodwill written-off upon disposal of a consolidated subsidiary.</span></div></ix:nonNumeric><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangible Assets, Net</span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i5c4ee7b6b013466fa81c2778565ebd79"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Details of our intangible assets (in thousands, except weighted-average useful lives) as of June&#160;30, 2021 and December&#160;31, 2020  are presented below:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:72.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:54.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:63.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:46.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:54.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:63.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:45.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr style="height:44pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted- Average Remaining Useful Life</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Carrying Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted- Average Remaining Useful Life</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Carrying Value</span></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate trade name</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i53f945f2e79348aab95bbf3ba92010f3_D20210101-20210630" format="ixt-sec:duryear" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RhYmxlOjhkMmNiYjkxNTliNjRkMDc4M2EwYmExMTQ1MDdjZTQ1L3RhYmxlcmFuZ2U6OGQyY2JiOTE1OWI2NGQwNzgzYTBiYTExNDUwN2NlNDVfMi0xLTEtMS0w_478b3317-ff49-4898-86fa-21400adf5b2e">12.7</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2665c131c1e46f691f30a8a2e0eaf86_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RhYmxlOjhkMmNiYjkxNTliNjRkMDc4M2EwYmExMTQ1MDdjZTQ1L3RhYmxlcmFuZ2U6OGQyY2JiOTE1OWI2NGQwNzgzYTBiYTExNDUwN2NlNDVfMi0zLTEtMS0w_4b814637-323e-44f4-9742-f2263285e581">23,300</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2665c131c1e46f691f30a8a2e0eaf86_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RhYmxlOjhkMmNiYjkxNTliNjRkMDc4M2EwYmExMTQ1MDdjZTQ1L3RhYmxlcmFuZ2U6OGQyY2JiOTE1OWI2NGQwNzgzYTBiYTExNDUwN2NlNDVfMi01LTEtMS0w_d5873328-3864-4d31-b14d-89b9ba6a594d">6,961</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2665c131c1e46f691f30a8a2e0eaf86_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RhYmxlOjhkMmNiYjkxNTliNjRkMDc4M2EwYmExMTQ1MDdjZTQ1L3RhYmxlcmFuZ2U6OGQyY2JiOTE1OWI2NGQwNzgzYTBiYTExNDUwN2NlNDVfMi03LTEtMS0w_80e5e182-f4de-48a9-a005-7d0745028a26">16,339</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie6df44374ded402288e7ddba99d481b4_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RhYmxlOjhkMmNiYjkxNTliNjRkMDc4M2EwYmExMTQ1MDdjZTQ1L3RhYmxlcmFuZ2U6OGQyY2JiOTE1OWI2NGQwNzgzYTBiYTExNDUwN2NlNDVfMi05LTEtMS0w_9d785ce7-4471-4bdd-921a-37b9055009ac">13.2</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i613c94dbacec49fc9a7b83bf086ad005_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RhYmxlOjhkMmNiYjkxNTliNjRkMDc4M2EwYmExMTQ1MDdjZTQ1L3RhYmxlcmFuZ2U6OGQyY2JiOTE1OWI2NGQwNzgzYTBiYTExNDUwN2NlNDVfMi0xMS0xLTEtMA_26856752-8b92-4b22-a517-f108771864f8">23,300</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i613c94dbacec49fc9a7b83bf086ad005_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RhYmxlOjhkMmNiYjkxNTliNjRkMDc4M2EwYmExMTQ1MDdjZTQ1L3RhYmxlcmFuZ2U6OGQyY2JiOTE1OWI2NGQwNzgzYTBiYTExNDUwN2NlNDVfMi0xMy0xLTEtMA_c1b154c8-b7d2-4167-b82a-8642e65baf81">6,271</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i613c94dbacec49fc9a7b83bf086ad005_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RhYmxlOjhkMmNiYjkxNTliNjRkMDc4M2EwYmExMTQ1MDdjZTQ1L3RhYmxlcmFuZ2U6OGQyY2JiOTE1OWI2NGQwNzgzYTBiYTExNDUwN2NlNDVfMi0xNS0xLTEtMA_a7268c86-5d5e-4ce9-8ad2-acba4efc22e6">17,029</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i73f385263f424c7b8911b8af743d7e12_D20210101-20210630" format="ixt-sec:duryear" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RhYmxlOjhkMmNiYjkxNTliNjRkMDc4M2EwYmExMTQ1MDdjZTQ1L3RhYmxlcmFuZ2U6OGQyY2JiOTE1OWI2NGQwNzgzYTBiYTExNDUwN2NlNDVfMy0xLTEtMS0w_e2873c1b-199b-4b59-8f64-3c7d5ea8c8cf">15.7</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfef255ab2b84de6a4b8638cf6a47165_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RhYmxlOjhkMmNiYjkxNTliNjRkMDc4M2EwYmExMTQ1MDdjZTQ1L3RhYmxlcmFuZ2U6OGQyY2JiOTE1OWI2NGQwNzgzYTBiYTExNDUwN2NlNDVfMy0zLTEtMS0w_91c77ce6-4d2b-4fbc-9905-4ae37b35ea7f">278,519</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfef255ab2b84de6a4b8638cf6a47165_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RhYmxlOjhkMmNiYjkxNTliNjRkMDc4M2EwYmExMTQ1MDdjZTQ1L3RhYmxlcmFuZ2U6OGQyY2JiOTE1OWI2NGQwNzgzYTBiYTExNDUwN2NlNDVfMy01LTEtMS0w_df2d95a8-13a7-4615-838d-6f42b3db8200">64,894</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfef255ab2b84de6a4b8638cf6a47165_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RhYmxlOjhkMmNiYjkxNTliNjRkMDc4M2EwYmExMTQ1MDdjZTQ1L3RhYmxlcmFuZ2U6OGQyY2JiOTE1OWI2NGQwNzgzYTBiYTExNDUwN2NlNDVfMy03LTEtMS0w_96e84295-d862-4768-bc83-cdc78ddd72f2">213,625</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibe0ce27038e244269b2a24add102c084_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RhYmxlOjhkMmNiYjkxNTliNjRkMDc4M2EwYmExMTQ1MDdjZTQ1L3RhYmxlcmFuZ2U6OGQyY2JiOTE1OWI2NGQwNzgzYTBiYTExNDUwN2NlNDVfMy05LTEtMS0w_afffbba7-b3c2-4e68-8f7a-975956c50759">16.2</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ca6f97a31c04defa1bfbf470ae72bdc_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RhYmxlOjhkMmNiYjkxNTliNjRkMDc4M2EwYmExMTQ1MDdjZTQ1L3RhYmxlcmFuZ2U6OGQyY2JiOTE1OWI2NGQwNzgzYTBiYTExNDUwN2NlNDVfMy0xMS0xLTEtMA_18273806-e728-4e90-a883-f2b12e60afb1">278,519</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ca6f97a31c04defa1bfbf470ae72bdc_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RhYmxlOjhkMmNiYjkxNTliNjRkMDc4M2EwYmExMTQ1MDdjZTQ1L3RhYmxlcmFuZ2U6OGQyY2JiOTE1OWI2NGQwNzgzYTBiYTExNDUwN2NlNDVfMy0xMy0xLTEtMA_a9f82bd7-1b72-417d-a7fe-284a932c073a">57,716</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ca6f97a31c04defa1bfbf470ae72bdc_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RhYmxlOjhkMmNiYjkxNTliNjRkMDc4M2EwYmExMTQ1MDdjZTQ1L3RhYmxlcmFuZ2U6OGQyY2JiOTE1OWI2NGQwNzgzYTBiYTExNDUwN2NlNDVfMy0xNS0xLTEtMA_51e65019-c23c-4f7a-a32c-678e759d4e8c">220,803</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i78747c549a50444ab43a62d1064b465a_D20210101-20210630" format="ixt-sec:duryear" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RhYmxlOjhkMmNiYjkxNTliNjRkMDc4M2EwYmExMTQ1MDdjZTQ1L3RhYmxlcmFuZ2U6OGQyY2JiOTE1OWI2NGQwNzgzYTBiYTExNDUwN2NlNDVfNC0xLTEtMS0w_9d268074-858a-4b53-84ac-32784bc08b99">1.3</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4e8785ed06f43489b789e69021e517b_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RhYmxlOjhkMmNiYjkxNTliNjRkMDc4M2EwYmExMTQ1MDdjZTQ1L3RhYmxlcmFuZ2U6OGQyY2JiOTE1OWI2NGQwNzgzYTBiYTExNDUwN2NlNDVfNC0zLTEtMS0w_7afca1ca-42f2-458b-8b2b-e1a4da9ffe7b">82,922</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4e8785ed06f43489b789e69021e517b_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RhYmxlOjhkMmNiYjkxNTliNjRkMDc4M2EwYmExMTQ1MDdjZTQ1L3RhYmxlcmFuZ2U6OGQyY2JiOTE1OWI2NGQwNzgzYTBiYTExNDUwN2NlNDVfNC01LTEtMS0w_aa0d5e64-adf3-466e-bf8a-4017344ec7ce">68,809</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4e8785ed06f43489b789e69021e517b_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RhYmxlOjhkMmNiYjkxNTliNjRkMDc4M2EwYmExMTQ1MDdjZTQ1L3RhYmxlcmFuZ2U6OGQyY2JiOTE1OWI2NGQwNzgzYTBiYTExNDUwN2NlNDVfNC03LTEtMS0w_cf86ba30-6420-465f-a0aa-a7d85b9a3ed9">14,113</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i79cb86c12975465c920a2007aee927c8_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RhYmxlOjhkMmNiYjkxNTliNjRkMDc4M2EwYmExMTQ1MDdjZTQ1L3RhYmxlcmFuZ2U6OGQyY2JiOTE1OWI2NGQwNzgzYTBiYTExNDUwN2NlNDVfNC05LTEtMS0w_defc247c-634d-457b-b6fe-5cd7fe435b8b">1.8</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e9914c7a4fa4bb6b1f1dcc803aa9440_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RhYmxlOjhkMmNiYjkxNTliNjRkMDc4M2EwYmExMTQ1MDdjZTQ1L3RhYmxlcmFuZ2U6OGQyY2JiOTE1OWI2NGQwNzgzYTBiYTExNDUwN2NlNDVfNC0xMS0xLTEtMA_53db53ac-9526-499c-b427-ded7c11479ac">82,922</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e9914c7a4fa4bb6b1f1dcc803aa9440_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RhYmxlOjhkMmNiYjkxNTliNjRkMDc4M2EwYmExMTQ1MDdjZTQ1L3RhYmxlcmFuZ2U6OGQyY2JiOTE1OWI2NGQwNzgzYTBiYTExNDUwN2NlNDVfNC0xMy0xLTEtMA_33c3010d-df16-491d-b3ec-aa30d9cb00ef">63,507</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e9914c7a4fa4bb6b1f1dcc803aa9440_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RhYmxlOjhkMmNiYjkxNTliNjRkMDc4M2EwYmExMTQ1MDdjZTQ1L3RhYmxlcmFuZ2U6OGQyY2JiOTE1OWI2NGQwNzgzYTBiYTExNDUwN2NlNDVfNC0xNS0xLTEtMA_6af3ca74-99c2-4887-b8bc-dc64e0d18bf7">19,415</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Below market lease, net</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4a65339b8de24dc0ad22aeaed63b43ea_D20210101-20210630" format="ixt-sec:duryear" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RhYmxlOjhkMmNiYjkxNTliNjRkMDc4M2EwYmExMTQ1MDdjZTQ1L3RhYmxlcmFuZ2U6OGQyY2JiOTE1OWI2NGQwNzgzYTBiYTExNDUwN2NlNDVfNS0xLTEtMS0w_97765be5-14fc-43f5-87cb-b31bb9481fed">1.8</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06b855dce6e346bcb653c327e7599385_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RhYmxlOjhkMmNiYjkxNTliNjRkMDc4M2EwYmExMTQ1MDdjZTQ1L3RhYmxlcmFuZ2U6OGQyY2JiOTE1OWI2NGQwNzgzYTBiYTExNDUwN2NlNDVfNS0zLTEtMS0w_7a6e3c31-b116-46ad-bbf9-0599f2c39823">1,218</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06b855dce6e346bcb653c327e7599385_I20210630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RhYmxlOjhkMmNiYjkxNTliNjRkMDc4M2EwYmExMTQ1MDdjZTQ1L3RhYmxlcmFuZ2U6OGQyY2JiOTE1OWI2NGQwNzgzYTBiYTExNDUwN2NlNDVfNS01LTEtMS0w_c857d1c9-57f9-4f43-9b47-78485421ffb6">849</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06b855dce6e346bcb653c327e7599385_I20210630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RhYmxlOjhkMmNiYjkxNTliNjRkMDc4M2EwYmExMTQ1MDdjZTQ1L3RhYmxlcmFuZ2U6OGQyY2JiOTE1OWI2NGQwNzgzYTBiYTExNDUwN2NlNDVfNS03LTEtMS0w_1d285b43-9b34-485d-80e9-807df68b37dd">369</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i683282a1148d4b31b1f897062aa84ede_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RhYmxlOjhkMmNiYjkxNTliNjRkMDc4M2EwYmExMTQ1MDdjZTQ1L3RhYmxlcmFuZ2U6OGQyY2JiOTE1OWI2NGQwNzgzYTBiYTExNDUwN2NlNDVfNS05LTEtMS0w_3017fcac-d96c-4ddb-894b-a118f48cd76c">2.3</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f772575126c46f293e485e88a16c5b2_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RhYmxlOjhkMmNiYjkxNTliNjRkMDc4M2EwYmExMTQ1MDdjZTQ1L3RhYmxlcmFuZ2U6OGQyY2JiOTE1OWI2NGQwNzgzYTBiYTExNDUwN2NlNDVfNS0xMS0xLTEtMA_a491ad36-e10d-4580-a6ba-5938e6441c02">1,118</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f772575126c46f293e485e88a16c5b2_I20201231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RhYmxlOjhkMmNiYjkxNTliNjRkMDc4M2EwYmExMTQ1MDdjZTQ1L3RhYmxlcmFuZ2U6OGQyY2JiOTE1OWI2NGQwNzgzYTBiYTExNDUwN2NlNDVfNS0xMy0xLTEtMA_bcd1b49e-263b-49b8-b2f7-36fd305d1870">648</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f772575126c46f293e485e88a16c5b2_I20201231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RhYmxlOjhkMmNiYjkxNTliNjRkMDc4M2EwYmExMTQ1MDdjZTQ1L3RhYmxlcmFuZ2U6OGQyY2JiOTE1OWI2NGQwNzgzYTBiYTExNDUwN2NlNDVfNS0xNS0xLTEtMA_5f091a3a-5dba-4a0a-8b7c-9db4991c9395">470</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:35pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provider network contracts </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4064cc6be7384542838693bded8b452e_D20210101-20210630" format="ixt-sec:duryear" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RhYmxlOjhkMmNiYjkxNTliNjRkMDc4M2EwYmExMTQ1MDdjZTQ1L3RhYmxlcmFuZ2U6OGQyY2JiOTE1OWI2NGQwNzgzYTBiYTExNDUwN2NlNDVfNi0xLTEtMS0w_bfacba8e-a923-4d77-87a7-2e0622b7d532">2.5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3af67d6664c9491d8b7fdecedd5f5629_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RhYmxlOjhkMmNiYjkxNTliNjRkMDc4M2EwYmExMTQ1MDdjZTQ1L3RhYmxlcmFuZ2U6OGQyY2JiOTE1OWI2NGQwNzgzYTBiYTExNDUwN2NlNDVfNi0zLTEtMS0w_be5db6f2-c4f1-44b4-b399-ac7afa8fa2c8">13,947</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3af67d6664c9491d8b7fdecedd5f5629_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RhYmxlOjhkMmNiYjkxNTliNjRkMDc4M2EwYmExMTQ1MDdjZTQ1L3RhYmxlcmFuZ2U6OGQyY2JiOTE1OWI2NGQwNzgzYTBiYTExNDUwN2NlNDVfNi01LTEtMS0w_494aceb6-5390-412c-9781-01e13055b5b9">6,348</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3af67d6664c9491d8b7fdecedd5f5629_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RhYmxlOjhkMmNiYjkxNTliNjRkMDc4M2EwYmExMTQ1MDdjZTQ1L3RhYmxlcmFuZ2U6OGQyY2JiOTE1OWI2NGQwNzgzYTBiYTExNDUwN2NlNDVfNi03LTEtMS0w_0cb92013-9faf-4730-a4a3-52a13cdcca26">7,599</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i27b1db7d183641a5b3e3c8ddfbffb17e_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RhYmxlOjhkMmNiYjkxNTliNjRkMDc4M2EwYmExMTQ1MDdjZTQ1L3RhYmxlcmFuZ2U6OGQyY2JiOTE1OWI2NGQwNzgzYTBiYTExNDUwN2NlNDVfNi05LTEtMS0w_8874fecd-c970-482b-9385-664070d92ba9">2.9</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i965ab087aa7949539cb446e0c5221cea_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RhYmxlOjhkMmNiYjkxNTliNjRkMDc4M2EwYmExMTQ1MDdjZTQ1L3RhYmxlcmFuZ2U6OGQyY2JiOTE1OWI2NGQwNzgzYTBiYTExNDUwN2NlNDVfNi0xMS0xLTEtMA_43442888-b456-4de6-9ec9-f6c55747ffe6">12,175</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i965ab087aa7949539cb446e0c5221cea_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RhYmxlOjhkMmNiYjkxNTliNjRkMDc4M2EwYmExMTQ1MDdjZTQ1L3RhYmxlcmFuZ2U6OGQyY2JiOTE1OWI2NGQwNzgzYTBiYTExNDUwN2NlNDVfNi0xMy0xLTEtMA_51c0dd41-421a-4863-9fce-8ea7d9866f6a">4,900</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i965ab087aa7949539cb446e0c5221cea_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RhYmxlOjhkMmNiYjkxNTliNjRkMDc4M2EwYmExMTQ1MDdjZTQ1L3RhYmxlcmFuZ2U6OGQyY2JiOTE1OWI2NGQwNzgzYTBiYTExNDUwN2NlNDVfNi0xNS0xLTEtMA_f11f7a02-96b8-409b-97cc-599c11106b1c">7,275</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:35pt"><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RhYmxlOjhkMmNiYjkxNTliNjRkMDc4M2EwYmExMTQ1MDdjZTQ1L3RhYmxlcmFuZ2U6OGQyY2JiOTE1OWI2NGQwNzgzYTBiYTExNDUwN2NlNDVfNy0zLTEtMS0w_8e29b4e3-f96a-488e-a717-681414406839">399,906</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RhYmxlOjhkMmNiYjkxNTliNjRkMDc4M2EwYmExMTQ1MDdjZTQ1L3RhYmxlcmFuZ2U6OGQyY2JiOTE1OWI2NGQwNzgzYTBiYTExNDUwN2NlNDVfNy01LTEtMS0w_651984bf-cc9f-40dc-8070-84b45776f8e0">147,861</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RhYmxlOjhkMmNiYjkxNTliNjRkMDc4M2EwYmExMTQ1MDdjZTQ1L3RhYmxlcmFuZ2U6OGQyY2JiOTE1OWI2NGQwNzgzYTBiYTExNDUwN2NlNDVfNy03LTEtMS0w_43a673ff-27f1-4206-bac9-2b7526f9d827">252,045</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45bff335c1434d6ba44132da1b0557db_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RhYmxlOjhkMmNiYjkxNTliNjRkMDc4M2EwYmExMTQ1MDdjZTQ1L3RhYmxlcmFuZ2U6OGQyY2JiOTE1OWI2NGQwNzgzYTBiYTExNDUwN2NlNDVfNy0xMS0xLTEtMA_0ece7f94-399c-43e4-ad2f-77bb4307b48f">398,034</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45bff335c1434d6ba44132da1b0557db_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RhYmxlOjhkMmNiYjkxNTliNjRkMDc4M2EwYmExMTQ1MDdjZTQ1L3RhYmxlcmFuZ2U6OGQyY2JiOTE1OWI2NGQwNzgzYTBiYTExNDUwN2NlNDVfNy0xMy0xLTEtMA_a503560b-4a2d-41cc-b4f2-d3077dc9b86c">133,042</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45bff335c1434d6ba44132da1b0557db_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RhYmxlOjhkMmNiYjkxNTliNjRkMDc4M2EwYmExMTQ1MDdjZTQ1L3RhYmxlcmFuZ2U6OGQyY2JiOTE1OWI2NGQwNzgzYTBiYTExNDUwN2NlNDVfNy0xNS0xLTEtMA_5f631774-9470-41e9-b2b2-152accf6fcbc">264,992</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Amounts exclude $<ix:nonFraction unitRef="usd" contextRef="ie8fa99474b6947149ca859e8e7009178_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RleHRyZWdpb246ZDQ3OTRlNTJiZWE3NGJmZDhhZDljOTkyMmExMGFkZjZfNzgzNQ_84a45e48-1db8-4017-b5b9-f3a5a7805f36">2.2</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ib490a7e546dd4b0987772534f6cf516c_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RleHRyZWdpb246ZDQ3OTRlNTJiZWE3NGJmZDhhZDljOTkyMmExMGFkZjZfNzg0Mg_7ec06b2c-a246-4d78-8c09-fed83c4d1390">0.9</ix:nonFraction>&#160;million of customer relationships and provider network contracts, respectively, net of accumulated amortization, with weighted average remaining useful lives of <ix:nonNumeric contextRef="ic6cafc0c96a142d5819a5b45e9032420_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RleHRyZWdpb246ZDQ3OTRlNTJiZWE3NGJmZDhhZDljOTkyMmExMGFkZjZfNzk4NA_5fb48c96-7589-4b0a-8e61-7c0e8e7fd367">15</ix:nonNumeric> years and <ix:nonNumeric contextRef="i0f5ebd73deb94928a519598776e04047_D20200101-20201231" format="ixt-sec:durmonth" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RleHRyZWdpb246ZDQ3OTRlNTJiZWE3NGJmZDhhZDljOTkyMmExMGFkZjZfNzk5MQ_be782507-9a09-4d9b-9c1a-f2ee198bde71">10</ix:nonNumeric> months reclassified to discontinued operations as of December&#160;31, 2020.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense related to intangible assets for the three and six months ended June 30, 2021, was $<ix:nonFraction unitRef="usd" contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RleHRyZWdpb246ZDQ3OTRlNTJiZWE3NGJmZDhhZDljOTkyMmExMGFkZjZfMTY0OTI2NzQ1MDI5Mg_27604310-4b27-4856-9760-9bc293a69ebd">7.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RleHRyZWdpb246ZDQ3OTRlNTJiZWE3NGJmZDhhZDljOTkyMmExMGFkZjZfODEwNw_f3f5ee89-6b35-4996-b009-39e2a402e775">14.7</ix:nonFraction> million, respectively. Amortization expense related to intangible assets for the three and six months ended June 30, 2020 was $<ix:nonFraction unitRef="usd" contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RleHRyZWdpb246ZDQ3OTRlNTJiZWE3NGJmZDhhZDljOTkyMmExMGFkZjZfMTY0OTI2NzQ1MDMzMA_39622833-0bc8-4d95-99e2-0a357e5623fd">8.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RleHRyZWdpb246ZDQ3OTRlNTJiZWE3NGJmZDhhZDljOTkyMmExMGFkZjZfODExNA_015844eb-4e3f-46bc-a5a3-91856f2decd4">17.7</ix:nonFraction> million, respectively, excluding $<ix:nonFraction unitRef="usd" contextRef="i1a6bb4acf8f64d4ea88262cf96a6ca67_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RleHRyZWdpb246ZDQ3OTRlNTJiZWE3NGJmZDhhZDljOTkyMmExMGFkZjZfMTY0OTI2NzQ1MDc5Mw_587b4b8a-9e53-4a00-a92e-631b66c31d03">0.2</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i6f626e482e054b34901a6c459f47f04b_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RleHRyZWdpb246ZDQ3OTRlNTJiZWE3NGJmZDhhZDljOTkyMmExMGFkZjZfMTY0OTI2NzQ1MDc3OQ_10f8d4fa-85d7-44d0-88b3-4ce9da6dea35">0.3</ix:nonFraction>&#160;million of amortization expense related to discontinued operations for the three and six months ended June 30, 2020.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ieda2ed5b1a734f09904c9f587bdb1510"><ix:nonNumeric contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RleHRyZWdpb246ZDQ3OTRlNTJiZWE3NGJmZDhhZDljOTkyMmExMGFkZjZfODUxMg_4e7ee247-b9df-477d-ac6b-5ec452276946" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future estimated amortization of intangible assets (in thousands) as of June&#160;30, 2021, is as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:478.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RhYmxlOjZjMzBmNmVkYmI3OTRhNzM5NDY5OGQxMDYzNmU3MDZjL3RhYmxlcmFuZ2U6NmMzMGY2ZWRiYjc5NGE3Mzk0Njk4ZDEwNjM2ZTcwNmNfMC0xLTEtMS0w_c19271c6-3d1f-40eb-ab86-28669599407c">13,762</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RhYmxlOjZjMzBmNmVkYmI3OTRhNzM5NDY5OGQxMDYzNmU3MDZjL3RhYmxlcmFuZ2U6NmMzMGY2ZWRiYjc5NGE3Mzk0Njk4ZDEwNjM2ZTcwNmNfMS0xLTEtMS0w_7618641c-2f2f-4524-98f6-77c63a77781e">24,629</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RhYmxlOjZjMzBmNmVkYmI3OTRhNzM5NDY5OGQxMDYzNmU3MDZjL3RhYmxlcmFuZ2U6NmMzMGY2ZWRiYjc5NGE3Mzk0Njk4ZDEwNjM2ZTcwNmNfMi0xLTEtMS0w_aa5752af-6ea6-4fa7-ab31-110c177cbcf2">22,325</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RhYmxlOjZjMzBmNmVkYmI3OTRhNzM5NDY5OGQxMDYzNmU3MDZjL3RhYmxlcmFuZ2U6NmMzMGY2ZWRiYjc5NGE3Mzk0Njk4ZDEwNjM2ZTcwNmNfMy0xLTEtMS0w_7791d070-49fb-4e77-9604-f876d4822f89">16,441</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RhYmxlOjZjMzBmNmVkYmI3OTRhNzM5NDY5OGQxMDYzNmU3MDZjL3RhYmxlcmFuZ2U6NmMzMGY2ZWRiYjc5NGE3Mzk0Njk4ZDEwNjM2ZTcwNmNfNC0xLTEtMS0w_adb93435-026f-44f2-8f04-e953f28d4c44">15,736</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630" decimals="-3" format="ixt:numdotdecimal" name="evh:FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RhYmxlOjZjMzBmNmVkYmI3OTRhNzM5NDY5OGQxMDYzNmU3MDZjL3RhYmxlcmFuZ2U6NmMzMGY2ZWRiYjc5NGE3Mzk0Njk4ZDEwNjM2ZTcwNmNfNS0xLTEtMS0w_967b1abe-caf7-4cdd-a7a9-e78c86f8d026">159,152</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future amortization of intangible assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RhYmxlOjZjMzBmNmVkYmI3OTRhNzM5NDY5OGQxMDYzNmU3MDZjL3RhYmxlcmFuZ2U6NmMzMGY2ZWRiYjc5NGE3Mzk0Njk4ZDEwNjM2ZTcwNmNfNi0xLTEtMS0w_25630e89-d349-4ad0-b52a-36d4df137aad">252,045</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets are reviewed for impairment if circumstances indicate the Company may not be able to recover the assets&#8217; carrying value. We did not identify any circumstances during&#160;the three and six months ended&#160;June&#160;30, 2021, that would require an impairment test for our intangible assets.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="id8f403494d0a42c2868794fb470218fc_73"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 10.  <ix:nonNumeric contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMjExNzM_61b21c14-d833-409d-b03f-ccb6a79eebb1" continuedAt="ibc956f4ad6d34732924abb0ca9cf2fef" escape="true">Long-term Debt</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="ibc956f4ad6d34732924abb0ca9cf2fef" continuedAt="i32953ec4cfeb47979b5383c2f25ac4a9"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2024 Notes</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the Company issued $<ix:nonFraction unitRef="usd" contextRef="ie9f0093698034c048db39ee74d23fe56_I20200831" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfNzg_3f3b6bf8-8b52-48d1-9efa-dca4f4cec981">117.1</ix:nonFraction>&#160;million aggregate principal amount of its <ix:nonFraction unitRef="number" contextRef="ie9f0093698034c048db39ee74d23fe56_I20200831" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMTE1_0dcbf41c-530f-49f1-b0fe-f348bb9e2120">3.50</ix:nonFraction>% Convertible Senior Notes due 2024 (the &#8220;2024 Notes&#8221;) in privately negotiated exchange and/or subscription agreements, with certain holders of its outstanding 2021 Notes and certain new investors. The Company issued $<ix:nonFraction unitRef="usd" contextRef="i0d3f73b1f2c04d3ba51586bcf12c3517_D20200801-20200831" decimals="-5" name="us-gaap:DebtConversionConvertedInstrumentAmount1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMzM0_b7793f62-ab09-4372-84bb-70d016176014">84.2</ix:nonFraction> million aggregate principal amount of 2024 Notes in exchange for $<ix:nonFraction unitRef="usd" contextRef="icea30d45fccd401f9bb3791275a8c40c_D20200801-20200831" decimals="-5" name="us-gaap:DebtConversionOriginalDebtAmount1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfNDAy_cd7790bc-9401-48cc-b9a0-cad2db8885c8">84.2</ix:nonFraction> million aggregate principal amount of the 2021 Notes and an aggregate cash payment of $<ix:nonFraction unitRef="usd" contextRef="i1598eae5f6ae4813b69f0cbb95358c65_D20200801-20200831" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfNDkx_b8b2d45f-a351-4273-80a4-c01afbba644b">2.5</ix:nonFraction>&#160;million, and issued $<ix:nonFraction unitRef="usd" contextRef="iabe38bb19e7049c7a823aae107a5b0ba_D20200801-20200831" decimals="-5" name="us-gaap:DebtConversionConvertedInstrumentAmount1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfNTA2_ce1773e1-e4c3-4992-a4bd-ff7c2c8ac54d">32.8</ix:nonFraction> million aggregate principal amount of New Notes for cash at par. We incurred $<ix:nonFraction unitRef="usd" contextRef="ie9f0093698034c048db39ee74d23fe56_I20200831" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredFinanceCostsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfNTg2_ee53e43e-cb00-4934-b9ce-5e1640b7ae44">3.0</ix:nonFraction>&#160;million of debt issuance costs in connection with the 2024 Notes, which we are amortizing to non-cash interest expense using the straight-line method over the contractual term of the 2024 Notes. The closing of the private placement of the 2024 Notes occurred on August 19, 2020.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of the 2024 Notes are entitled to cash interest payments, which are payable semiannually in arrears on June 1 and December 1 of each year, beginning on December 1, 2020, at a rate equal to <ix:nonFraction unitRef="number" contextRef="ie9f0093698034c048db39ee74d23fe56_I20200831" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMTA1OA_dc869f0f-9f09-4588-adce-63a5d9028d6e">3.50</ix:nonFraction>% per annum. The 2024 Notes will mature on December 1, 2024, unless earlier repurchased, redeemed or converted in accordance with their terms prior to such date. Upon maturity the principal amount of the notes may be settled via shares of the Company&#8217;s Class A common stock. We recorded interest expense of $<ix:nonFraction unitRef="usd" contextRef="id559bfbab5954aa7bb0b5c73c4b04f85_D20210401-20210630" decimals="-5" name="us-gaap:InterestExpenseDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMTY0OTI2NzQ2Mjg1NQ_53d4b527-fd39-4604-9e48-b32ee47763da">1.0</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i6b496ee9129546a1943004e4d9e6e458_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMTM2Ng_a5dca2c9-7a29-44e5-8cab-465b5bddeddb">2.0</ix:nonFraction> million for the three and six months ended June 30, 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2024 Notes are convertible into cash, shares of the Company's Class A common stock, or a combination of cash and shares of the Company's Class A common stock, at the Company's election, based on an initial conversion rate of 54.8667 shares of Class A common stock per $1,000 principal amount of the 2024 Notes, which is equivalent to an initial conversion price of approximately $<ix:nonFraction unitRef="usdPerShare" contextRef="ie9f0093698034c048db39ee74d23fe56_I20200831" decimals="2" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMTc2MQ_e429e4c3-c5f5-4119-acdb-db29da625ff2">18.23</ix:nonFraction> per share of the Company&#8217;s Class A common stock. In the aggregate, the 2024 Notes are initially convertible into <ix:nonFraction unitRef="shares" contextRef="i0d3f73b1f2c04d3ba51586bcf12c3517_D20200801-20200831" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMTg3Nw_75223a39-822f-4bcd-a6bb-d644605b9c53">6.4</ix:nonFraction>&#160;million shares of the Company&#8217;s Class A common stock (excluding any shares issuable by the Company upon a conversion in connection with a make-whole provision upon a fundamental change or a notice of redemption under the governing indenture). The conversion rate may be adjusted under certain circumstances. Upon conversion, the Company will pay or deliver, as the case may be, cash or shares of the Company&#8217;s Class A common stock, or a combination of cash and shares of the Company&#8217;s Class A common stock, at the Company&#8217;s election.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The option to settle the 2024 Notes in cash or shares of the Company&#8217;s Class A common stock, or a combination of cash and shares of the Company&#8217;s Class A common stock, at the Company&#8217;s election, resulted in a bifurcation of the carrying value of the 2024 Notes into a debt component and an equity component. The debt component was determined to be $<ix:nonFraction unitRef="usd" contextRef="ie9f0093698034c048db39ee74d23fe56_I20200831" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMjc1NQ_0fc982b9-f85f-4c19-ac55-62bfd06e596f">78.9</ix:nonFraction>&#160;million, before issuance costs, based on the fair value of a nonconvertible debt instrument with the same term. The equity component was determined to be $<ix:nonFraction unitRef="usd" contextRef="ibccaaf22aab2432ba1b4622538e18372_D20200801-20200831" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMjkwNA_85add333-ea51-4b19-9918-4a7b131f2b9d">38.1</ix:nonFraction>&#160;million, before issuance costs, and was recorded within additional paid-in capital. The equity component is the difference between the aggregate principal amount of the debt and the fair value of the debt component. Issuance costs of $<ix:nonFraction unitRef="usd" contextRef="ie9f0093698034c048db39ee74d23fe56_I20200831" decimals="-5" format="ixt:numdotdecimal" name="evh:DebtIssuanceCostsNetDebtComponent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMzEzMw_a1ddb381-8030-44df-b3b9-f45ca0451741">1.7</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i437f571852d648ad8e14dd03e682fc47_I20200831" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredFinanceCostsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMzE0MA_214efe44-915e-4282-b4e3-f41e139fee91">1.3</ix:nonFraction>&#160;million are allocated to the debt and equity components in proportion to the allocation of proceeds. Along with the equity component of $<ix:nonFraction unitRef="usd" contextRef="ibccaaf22aab2432ba1b4622538e18372_D20200801-20200831" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMzI3MQ_47941dd4-d426-4a73-aa02-b7d5057e2acb">38.1</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="ie9f0093698034c048db39ee74d23fe56_I20200831" decimals="-5" format="ixt:numdotdecimal" name="evh:DebtIssuanceCostsNetDebtComponent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMzI3NQ_e7eb4417-c48e-4d1d-9065-3cde95405e72">1.7</ix:nonFraction>&#160;million of issuance costs will be amortized to interest expense on the consolidated statements of operations and comprehensive income (loss) using the effective interest method over the contractual term of the 2024 Notes. The equity component recorded within additional paid-in capital will not be remeasured as long as it meets the conditions for equity classification. The Company recorded $<ix:nonFraction unitRef="usd" contextRef="id559bfbab5954aa7bb0b5c73c4b04f85_D20210401-20210630" decimals="-5" format="ixt:numdotdecimal" name="evh:AmortizationOfDebtDiscountAndDebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMTY0OTI2NzQ2Mjg3Nw_a96d4097-048c-4b34-be50-1061b4263bd9">2.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i6b496ee9129546a1943004e4d9e6e458_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="evh:AmortizationOfDebtDiscountAndDebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMzY2Mg_f09f37b6-4c4d-4117-b11b-1b5cf8b3f61a">3.9</ix:nonFraction> million of interest expense related to the amortization of the debt discount and the issuance costs allocated to the debt component for the three and six months ended June 30, 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of the 2024 Notes may require the Company to repurchase all or part of their notes upon the occurrence of a fundamental change at a price equal to <ix:nonFraction unitRef="number" contextRef="i0d3f73b1f2c04d3ba51586bcf12c3517_D20200801-20200831" decimals="INF" name="evh:DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMzk1Mw_c73209ca-d830-4758-90b5-ff58a121ea32">100.0</ix:nonFraction>% of the principal amount of the notes being repurchased, plus any accrued and unpaid interest to, but excluding, the fundamental change repurchase date. The Company may not redeem the 2024 Notes prior to March 1, 2023. The Company may redeem for cash all or any portion of the 2024 Notes, at its option, on or after March 1, 2023, if the last reported sale price of the Company&#8217;s Class A common stock has been at least <ix:nonFraction unitRef="number" contextRef="i0d3f73b1f2c04d3ba51586bcf12c3517_D20200801-20200831" decimals="INF" name="evh:DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfNDM3NA_1fd4e24c-23cf-4e28-82d4-a000fd20a292">130.0</ix:nonFraction>% of the conversion price then in effect for at least <ix:nonNumeric contextRef="i0d3f73b1f2c04d3ba51586bcf12c3517_D20200801-20200831" format="ixt-sec:durday" name="evh:DebtInstrumentRepurchaseCovenantTradingDaysMinimum" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfNDQyOQ_02157141-34a7-4889-a04f-c78fa1938ef7">20</ix:nonNumeric> trading </span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i32953ec4cfeb47979b5383c2f25ac4a9" continuedAt="i8bdf8ba76aee4c25a21f62c32387dcad"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">days (whether or not consecutive) during any <ix:nonNumeric contextRef="i0d3f73b1f2c04d3ba51586bcf12c3517_D20200801-20200831" format="ixt-sec:durday" name="evh:DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfNDQ4NQ_ba489538-8a9d-4580-80e9-c0e4950d3bbe">30</ix:nonNumeric> consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which the Company provides notice of redemption, at a redemption price equal to <ix:nonFraction unitRef="number" contextRef="i0d3f73b1f2c04d3ba51586bcf12c3517_D20200801-20200831" decimals="INF" name="evh:DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfNDcyMw_47390ff5-5d1f-4acc-8c69-969fddf589cc">100.0</ix:nonFraction>% of the principal amount of the notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Credit Agreement</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 30, 2019, the Company entered into a credit agreement, by and among the Company, Evolent Health LLC, as the borrower (the &#8220;Borrower&#8221;), certain subsidiaries of the Company, as guarantors, the lenders from time to time party thereto, and Ares Capital Corporation, as administrative agent and collateral agent, together with the Company (the &#8220;Credit Agreement&#8221;), pursuant to which the lenders agreed to extend credit to the Borrower in the form of (i) an initial secured term loan in the aggregate principal amount of $<ix:nonFraction unitRef="usd" contextRef="ifa10c9f357cc46da8a582a78230489bf_I20191230" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfNTM5OA_97bd74a5-de0d-40f9-b669-b57ecfd5c8e4">75.0</ix:nonFraction> million (the &#8220;Initial Term Loan Facility&#8221;) and (ii) a delayed draw secured term loan facility in the aggregate principal amount of up to $<ix:nonFraction unitRef="usd" contextRef="i06948a2177d04b259e0902a18900dc29_I20191230" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfNTUzMA_4fbd458e-d99c-4fd6-b38f-5ecabfbc2855">50.0</ix:nonFraction> million (the &#8220;DDTL Facility&#8221; and, together with the Initial Term Loan Facility, the &#8220;Senior Credit Facilities&#8221;), subject to the satisfaction of specified conditions. The Borrower borrowed the loan under the Initial Term Loan Facility on December 30, 2019. In connection with the Credit Agreement, on December 30, 2019, the Company entered into a Security Agreement, by and among the Company, the Borrower, the other guarantors and the collateral agent for the benefit of the secured parties, and a Guarantee Agreement, by the Company and each of the other guarantors in favor of the collateral agent for the benefit of the secured parties. The Senior Credit Facilities were guaranteed by the Company and the Company&#8217;s domestic subsidiaries, subject to certain exceptions. The Senior Credit Facilities were secured by a first priority security interest in all of the capital stock of the borrower and each guarantor (other than the Company) and substantially all of the assets of the borrower and each guarantor, subject to certain exceptions. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The proceeds of the Initial Term Loan were used to finance the transactions contemplated by the Passport APA and pay fees and expenses incurred in connection therewith. The proceeds of the DDTL Facility were permitted to be used, subject to the Company&#8217;s satisfaction of specified conditions, to finance the repayment or repurchase of the Company&#8217;s <ix:nonFraction unitRef="number" contextRef="ibef4bf4bc2ab41d2ad6d564857f8fb16_I20191230" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfNjkxOQ_f87e5322-6081-4ce5-abd9-630c7258c163">2.00</ix:nonFraction>% Convertible Senior Notes due December 1, 2021 and to fund permitted acquisitions. &#160;The Initial Term Loan and any loans under the DDTL Facility would have matured on the date that is the earliest of (a) December 30, 2024, (b) the date on which all amounts outstanding under the Credit Agreement would have been declared or have automatically become due and payable under the terms of the Credit Agreement and (c) the date that is ninety-one (<ix:nonNumeric contextRef="ibb12573bef604a62ac70c8f5b1d35372_D20191230-20191230" format="ixt-sec:durday" name="us-gaap:DebtInstrumentTerm" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfNzM2Mw_12a1fb8d-3497-4630-a4cf-8288ab68e8bf">91</ix:nonNumeric>) days prior to the maturity date of the 2021 Convertible Notes unless certain liquidity conditions were satisfied (the foregoing, the &#8220;Maturity Date&#8221;). The interest rate for each loan under the Senior Credit Facilities was calculated, at the option of the Borrower, at either the Eurodollar rate plus <ix:nonFraction unitRef="number" contextRef="i11adbaf0c9c0475282d0187b6ac6db8f_D20191230-20191230" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfNzY2Nw_6d15b94f-7ed6-4e6e-b2e3-2235caa32137">8.00</ix:nonFraction>%, or the base rate plus <ix:nonFraction unitRef="number" contextRef="ic8d3791c30f040c2b02c8f39bf43b812_D20191230-20191230" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfNzY5Mw_e152597c-89e7-4ac3-b7b7-7e1d49e42c18">7.00</ix:nonFraction>%. A commitment fee of <ix:nonFraction unitRef="number" contextRef="i1868ae14255d4c95aab130080ec3175b_D20191230-20191230" decimals="INF" name="us-gaap:LineOfCreditFacilityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfNzcxNw_6c1b6af8-a330-445a-b79a-b93de3723187">1.00</ix:nonFraction>% per annum was payable by the Borrower quarterly in arrears on the unused portion of the DDTL Facility. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts outstanding under the Senior Credit Facilities could have been prepaid at the option of the Borrower subject to applicable premiums, including a make-whole premium payable on certain prepayments made prior to the second anniversary of the closing of the Senior Credit Facilities, and a call protection premium payable on the amount prepaid in certain instances as follows: (i) <ix:nonFraction unitRef="number" contextRef="i381ee2f518b34b78a5f3e6263b399e70_D20191230-20191230" decimals="INF" name="evh:DebtInstrumentRedemptionCallProtectionPremiumPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfODMyOA_27b2f1e9-1817-441d-926c-ce3817d25a47">4.00</ix:nonFraction>% of the principal amount so prepaid after the second anniversary of the closing of the Senior Credit Facilities but prior the third anniversary of the closing of the Senior Credit Facilities; (ii) <ix:nonFraction unitRef="number" contextRef="i2b0d7584f95b486581d1f8fcf494bd87_D20191230-20191230" decimals="INF" name="evh:DebtInstrumentRedemptionCallProtectionPremiumPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfODUyNw_c99bee65-fcee-4aac-8251-0f3eb26930c8">3.00</ix:nonFraction>% of the principal amount so prepaid after the third anniversary of the closing of the Senior Credit Facilities but prior the fourth anniversary of the closing of the Senior Credit Facilities; and (iii) <ix:nonFraction unitRef="number" contextRef="ic5de6b4f322d4a41ba0b04e047d3567b_D20191230-20191230" decimals="INF" name="evh:DebtInstrumentRedemptionCallProtectionPremiumPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfODczMQ_93f23394-386d-41dc-aa19-fc38d53f29d9">2.00</ix:nonFraction>% of the principal amount so prepaid after the fourth anniversary of the closing of the Senior Credit Facilities but prior the fifth anniversary of the closing of the Senior Credit Facilities. Amounts outstanding under the Senior Credit Facility were subject to mandatory prepayment upon the occurrence of certain events and conditions, including non-ordinary course asset dispositions, receipt of certain casualty proceeds, issuances of certain debt obligations and a change of control transaction.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Senior Credit Facilities contained customary borrowing conditions, affirmative, negative and reporting covenants, representations and warranties, and events of default, including cross-defaults to other material indebtedness. In addition, the Company was required to comply at certain times with certain financial covenants comprised of a minimum net revenue test and a minimum liquidity test commencing upon closing of the Senior Credit Facilities and a total secured leverage ratio commencing on the last day of the fiscal quarter ending March 31, 2021. If an event of default had occurred, the lenders would be entitled to take enforcement action, including foreclosure on collateral and acceleration of amounts owed under the Senior Credit Facilities. We incurred $<ix:nonFraction unitRef="usd" contextRef="i6f21b3a7685841259a7bbf081309eb0f_I20191230" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredFinanceCostsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMTAwMDU_96b5812a-9f80-4bb3-ae34-8f4000d6a47a">4.7</ix:nonFraction> million of debt issuance costs in connection with this Credit Agreement, which was included in long-term debt, net of discount on our consolidated balance sheets and amortized into interest expense over the life of the agreement. The Company recorded $<ix:nonFraction unitRef="usd" contextRef="ida1f309838e74abeb0e17c296af553bb_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="evh:AmortizationOfDebtDiscountAndDebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMTY0OTI2NzQ2Mjk4NA_cbd122aa-e732-43d3-8ab0-fddf22d40a02">0.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i96b555f871384a6ab79fe625ce473698_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="evh:AmortizationOfDebtDiscountAndDebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMTAyNTE_2be3b563-5ba6-43b3-a0fd-8861419ee543">1.1</ix:nonFraction> million in interest expense related to the amortization of the debt discount and the issuance costs for the three and six months ended June 30, 2020, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 19, 2020, an amendment to the Company's Credit Agreement became effective. The amendment effected changes to, among other things, permit the Company's use of cash in the exchange transactions in connection with the issuance of the 2024 Notes, permit the issuance of the 2024 Notes and permit certain note repurchases, as well as to implement amendments to certain minimum liquidity thresholds.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i8bdf8ba76aee4c25a21f62c32387dcad" continuedAt="i94ccc760d0e9495491eae9395d654af3"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 8, 2021, the Company repaid all outstanding amounts owed under, and terminated, the Credit Agreement with Ares Capital Corporation. The total amount paid to Ares Capital Corporation under the Credit Agreement in connection with the prepayment was $<ix:nonFraction unitRef="usd" contextRef="i2e95d208160a4c749900182d52a49615_D20210108-20210108" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfLongTermLinesOfCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMzg0ODI5MDc2MDEzMw_a1cfe04d-a646-44af-bfb0-05448f32e66c">98.6</ix:nonFraction>&#160;million, which included $<ix:nonFraction unitRef="usd" contextRef="i2e95d208160a4c749900182d52a49615_D20210108-20210108" decimals="-5" format="ixt:numdotdecimal" name="evh:PaymentsOfMakeWholePremium" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMzg0ODI5MDc2MDE0OA_0db5f668-53f7-4fa8-b82f-195a93480f79">9.7</ix:nonFraction>&#160;million for the make-whole premium as well as $<ix:nonFraction unitRef="usd" contextRef="i2e95d208160a4c749900182d52a49615_D20210108-20210108" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMzg0ODI5MDc2MDE2Mg_4e01a625-4b0c-433c-a8c8-7af85b297205">0.2</ix:nonFraction>&#160;million in accrued interest. As a result of this transaction, the Company recorded loss on the repayment of debt of $<ix:nonFraction unitRef="usd" contextRef="if600ab05fc8b49bca59c078f4bbb6742_D20210108-20210108" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMTEyMTc_96432ae3-8606-437b-a87d-ec0ee6fa7567">19.2</ix:nonFraction>&#160;million, representing the remaining unamortized debt issuance costs of $<ix:nonFraction unitRef="usd" contextRef="if600ab05fc8b49bca59c078f4bbb6742_D20210108-20210108" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:WriteOffOfDeferredDebtIssuanceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMTEyODM_d7a6bc89-f77d-4748-81ce-78cf2339fa33">9.5</ix:nonFraction>&#160;million, the make-whole premium and $<ix:nonFraction unitRef="usd" contextRef="if600ab05fc8b49bca59c078f4bbb6742_D20210108-20210108" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LegalFees" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMTEzMTQ_e88c8282-52a0-45d7-9dab-03d585b8ef2b">35</ix:nonFraction>&#160;thousand of legal expenses.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Warrant Agreement</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In conjunction with the Company&#8217;s entry into the Credit Agreement, the Company entered into warrant agreements whereby it agreed to sell to the holders of the warrants an aggregate of <ix:nonFraction unitRef="shares" contextRef="i1cad05e654934e308e828b864b76a508_I20191230" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightUnissued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMTE1NDA_ac7abe6a-a6b2-498a-92c3-cc274b28f9ca">1,513,786</ix:nonFraction> shares of Class A common stock at a per share purchase price equal to $<ix:nonFraction unitRef="usdPerShare" contextRef="i1cad05e654934e308e828b864b76a508_I20191230" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMTE2MTM_6d926829-1d44-4dd6-a395-1b7b639d32b6">8.05</ix:nonFraction>.  The holders could exercise the warrants at any time until <ix:nonNumeric contextRef="i0bb88f4c90544362ab13fcd63aba4af7_D20191230-20191230" format="ixt-sec:durwordsen" name="evh:ClassOfWarrantOrRightPeriodDuringWhichWarrantsOrRightsExercisableAfterMaturityOfCreditAgreement" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMTE2NzY_5815a4bd-700f-4fe8-b61a-a715934599cb">thirty days</ix:nonNumeric> after the maturity of the Credit Agreement.  The Company, at its sole discretion, could elect to pay the holders in cash in an amount determined based on the fair market value of the Class A common stock for the shares of Class A common stock issuable upon exercise of the warrants in lieu of delivering the shares.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 8, 2021, the Company settled the outstanding warrants associated with the Credit Agreement for $<ix:nonFraction unitRef="usd" contextRef="if7229a5e40df4a5095c25bd23977e747_D20210108-20210108" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsForRepurchaseOfWarrants" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMzg0ODI5MDc2MDE5MQ_84797a79-ec85-48d8-9972-eb5574d121ff">13.7</ix:nonFraction>&#160;million.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2025 Notes</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, the Company issued $<ix:nonFraction unitRef="usd" contextRef="ia5b2225a7a85439eb9318023f5dca1ab_I20181031" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMTIxNTU_ef1194d3-5c7a-454b-9292-e2711a8c88c3">172.5</ix:nonFraction> million aggregate principal amount of its <ix:nonFraction unitRef="number" contextRef="ia5b2225a7a85439eb9318023f5dca1ab_I20181031" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMTIxOTI_59662d5f-0f7c-49b3-ba92-07fe46819cc7">1.50</ix:nonFraction>% Convertible Senior Notes due 2025 (the &#8220;2025 Notes&#8221;) in a private placement to qualified institutional buyers within the meaning of Rule 144A under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). The 2025 Notes were issued at par for net proceeds of $<ix:nonFraction unitRef="usd" contextRef="ifee6d13c14704a0a9bd4959cd14684b6_D20181001-20181031" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMTI0NjA_03f885e7-ac5a-4e90-a947-0ce2179dd82a">166.6</ix:nonFraction> million. We incurred $<ix:nonFraction unitRef="usd" contextRef="i0db344c6ddf344ceab1c3071829545ff_I20181031" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredFinanceCostsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMTI0NzY_f5e30313-a3e8-4be4-adfc-f18041204947">5.9</ix:nonFraction> million of debt issuance costs in connection with the 2025 Notes. The closing of the private placement of $<ix:nonFraction unitRef="usd" contextRef="i3533fa8477ed4bb0afb07e5b80879435_I20181022" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMTI1Nzc_1df43740-d953-47c0-824d-a59479b9de77">150.0</ix:nonFraction> million aggregate principal amount of the 2025 Notes occurred on October&#160;22, 2018, and the Company completed the offering and sale of an additional $<ix:nonFraction unitRef="usd" contextRef="if3e69e58105c4d909f82068c94a4e66f_I20181024" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMTI3MDY_8b8fae39-9c08-410a-b5c9-bd19de341585">22.5</ix:nonFraction> million aggregate principal amount of the 2025 Notes on October&#160;24, 2018, pursuant to the initial purchasers&#8217; exercise in full of their option to purchase additional notes.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of the 2025 Notes are entitled to cash interest payments, which are payable semiannually in arrears on&#160;April 15&#160;and&#160;October 15&#160;of each year, beginning on&#160;April&#160;15, 2019, at a rate equal to&#160;<ix:nonFraction unitRef="number" contextRef="ia5b2225a7a85439eb9318023f5dca1ab_I20181031" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMTMwNDY_59662d5f-0f7c-49b3-ba92-07fe46819cc7">1.50</ix:nonFraction>%&#160;per annum. The Company recorded interest expense of $<ix:nonFraction unitRef="usd" contextRef="i4deadc1ba0674142a17d227672696535_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMTY0OTI2NzUwMzc4Mg_00567e75-550c-4a45-af63-d60610d93218"><ix:nonFraction unitRef="usd" contextRef="iba4a0e1b01024c46b291007f4c8b7e3f_D20210401-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMTY0OTI2NzUwMzc4Mg_bddd0fc2-cae3-479b-810a-ad7cfb149ad6">0.7</ix:nonFraction></ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ieeacfdfdfca8412a9c4cc31d0dfb0be6_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMTMxMDE_487fb421-608a-4999-8496-dcd298f2ca14"><ix:nonFraction unitRef="usd" contextRef="i0489a5ac9602461ea764f0340d05dbc2_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMTMxMDE_fe671022-e53b-4994-9c04-a3f5b6b71b54">1.3</ix:nonFraction></ix:nonFraction> million for the three and six months ended June 30, 2021 and 2020, respectively. The 2025 Notes will mature on&#160;October&#160;15, 2025, unless earlier repurchased, redeemed or converted in accordance with their terms prior to such date.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the close of business on the business day immediately preceding April&#160;15, 2025, the 2025 Notes will be convertible at the option of the holders only upon the satisfaction of certain conditions, as described in the indenture, dated as of October&#160;22, 2018, between the Company and U.S. Bank National Association, as trustee. At any time on or after April&#160;15, 2025, until the close of business on the business day immediately preceding the maturity date, holders may convert, at their option, all or any portion of their notes at the conversion rate.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2025 Notes will be convertible at an initial conversion rate of 29.9135 shares of Class A common stock per $1,000 principal amount of notes, which is equivalent to an initial conversion price of approximately $<ix:nonFraction unitRef="usdPerShare" contextRef="ia5b2225a7a85439eb9318023f5dca1ab_I20181031" decimals="2" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMTQwMTc_f8dd4462-1ab4-4ed3-90c7-2c6bbc70b701">33.43</ix:nonFraction> per share of the Company&#8217;s Class A common stock. In the aggregate, the 2025 Notes are initially convertible into <ix:nonFraction unitRef="shares" contextRef="ifee6d13c14704a0a9bd4959cd14684b6_D20181001-20181031" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMTQxMzM_4721e4f4-7896-4e81-a8de-663552089628">5.2</ix:nonFraction> million shares of the Company&#8217;s Class A common stock (excluding any shares issuable by the Company upon a conversion in connection with a make-whole fundamental change or a notice of redemption as described in the governing indenture). The conversion rate may be adjusted under certain circumstances. Upon conversion, the Company will pay or deliver, as the case may be, cash or shares of the Company&#8217;s Class A common stock, or a combination of cash and shares of the Company&#8217;s Class A common stock, at the Company&#8217;s election.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The option to settle the 2025 Notes in cash or shares of the Company&#8217;s Class A common stock, or a combination of cash and shares of the Company&#8217;s Class A common stock, at the Company&#8217;s election, resulted in a bifurcation of the carrying value of the 2025 Notes into a debt component and an equity component. The debt component was determined to be $<ix:nonFraction unitRef="usd" contextRef="ia5b2225a7a85439eb9318023f5dca1ab_I20181031" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMTUwMDQ_48a7a078-b321-46e4-86e0-4d932f51f04a">100.7</ix:nonFraction> million, before issuance costs, based on the fair value of a nonconvertible debt instrument with the same term. The equity component was determined to be $<ix:nonFraction unitRef="usd" contextRef="id755146089114b63a291ebb347fe05cd_D20181001-20181031" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMTUxNTM_99ce81b6-ea59-4837-bc8b-072d79c6311e">71.8</ix:nonFraction> million, before issuance costs, and was recorded within additional paid-in capital. The equity component is the difference between the aggregate principal amount of the debt and the debt component. Issuance costs of $<ix:nonFraction unitRef="usd" contextRef="ia5b2225a7a85439eb9318023f5dca1ab_I20181031" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredFinanceCostsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMTUzNjQ_4c5f0382-f641-44ed-b052-87974493a088">3.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i263de0af39604a6985530e0395eaee6f_I20181031" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredFinanceCostsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMTUzNzE_4d648907-97bd-4e8d-9f47-30e34b84ea8d">2.5</ix:nonFraction> million are allocated to the debt and equity components in proportion to the allocation of proceeds. Along with the equity component of $<ix:nonFraction unitRef="usd" contextRef="id755146089114b63a291ebb347fe05cd_D20181001-20181031" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMTU1MDI_99ce81b6-ea59-4837-bc8b-072d79c6311e">71.8</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="ia5b2225a7a85439eb9318023f5dca1ab_I20181031" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredFinanceCostsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMTU1MDY_4c5f0382-f641-44ed-b052-87974493a088">3.4</ix:nonFraction> million of issuance costs will be amortized to interest expense on the consolidated statements of operations and comprehensive income (loss) using the effective interest method over the contractual term of the 2025 Notes. The equity component recorded within additional paid-in capital will not be remeasured as long as it meets the conditions for equity classification. The Company recorded $<ix:nonFraction unitRef="usd" contextRef="iba4a0e1b01024c46b291007f4c8b7e3f_D20210401-20210630" decimals="-5" format="ixt:numdotdecimal" name="evh:AmortizationOfDebtDiscountAndDebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMTY0OTI2NzQ2MzA4Ng_4532e9a7-dd11-4cb5-a9c2-30e8fe06be86">2.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i4deadc1ba0674142a17d227672696535_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="evh:AmortizationOfDebtDiscountAndDebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMTU5MDE_352e3e32-34c3-4f7a-8fc8-be1f66849e3f">4.8</ix:nonFraction> million for the three and six months ended June 30, 2021, respectively, and $<ix:nonFraction unitRef="usd" contextRef="ieeacfdfdfca8412a9c4cc31d0dfb0be6_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="evh:AmortizationOfDebtDiscountAndDebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMTY0OTI2NzQ2MzEyOA_6859495c-e701-4dd0-8e99-2e9a0c69bbbd">2.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i0489a5ac9602461ea764f0340d05dbc2_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="evh:AmortizationOfDebtDiscountAndDebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMTU5MDg_939824ce-83ef-4882-bf0c-adbcfe1b97f6">4.3</ix:nonFraction> million for the three and six months ended June 30, 2020, respectively, in interest expense related to the amortization of the debt discount and the issuance costs allocated to the debt component.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i94ccc760d0e9495491eae9395d654af3" continuedAt="i516556853af241c3b911511b9ab27dbe"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of the 2025 Notes may require the Company to repurchase all or part of their notes upon the occurrence of a fundamental change at a price equal to <ix:nonFraction unitRef="number" contextRef="ifee6d13c14704a0a9bd4959cd14684b6_D20181001-20181031" decimals="INF" name="evh:DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMTYyMDc_d004ca47-a882-4e48-aea1-8aedf646e232">100.0</ix:nonFraction>% of the principal amount of the notes being repurchased, plus any accrued and unpaid interest to, but excluding, the fundamental change repurchase date. The Company may not redeem the 2025 Notes prior to October&#160;20, 2022. The Company may redeem for cash all or any portion of the 2025 Notes, at its option, on or after October&#160;20, 2022, if the last reported sale price of the Company&#8217;s Class A common stock has been at least <ix:nonFraction unitRef="number" contextRef="ifee6d13c14704a0a9bd4959cd14684b6_D20181001-20181031" decimals="INF" name="evh:DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMTY2MDY_adbdc2ed-99c4-4253-8305-e25b4fe3e866">130.0</ix:nonFraction>% of the conversion price then in effect for at least <ix:nonNumeric contextRef="ifee6d13c14704a0a9bd4959cd14684b6_D20181001-20181031" format="ixt-sec:durday" name="evh:DebtInstrumentRepurchaseCovenantTradingDaysMinimum" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMTY2NjE_7a98b120-c078-429e-a668-448f0417627d">20</ix:nonNumeric> trading days (whether or not consecutive) during any <ix:nonNumeric contextRef="ifee6d13c14704a0a9bd4959cd14684b6_D20181001-20181031" format="ixt-sec:durday" name="evh:DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMTY3MTc_f3ef76d8-17db-47f9-bfd5-54b37f4eeb8d">30</ix:nonNumeric> consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which the Company provides notice of redemption, at a redemption price equal to <ix:nonFraction unitRef="number" contextRef="ifee6d13c14704a0a9bd4959cd14684b6_D20181001-20181031" decimals="INF" name="evh:DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMTY5NTU_025a6f46-143a-4352-a7e2-e884b332f460">100.0</ix:nonFraction>% of the principal amount of the notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2021 Notes</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2016, the Company issued $<ix:nonFraction unitRef="usd" contextRef="i0efb2207e70f43cb998170b0668f5aa4_I20161231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMTcxMjM_7ac6fd3d-4899-42e4-a7e7-900f2fe4bb1a">125.0</ix:nonFraction> million aggregate principal amount of its <ix:nonFraction unitRef="number" contextRef="i0efb2207e70f43cb998170b0668f5aa4_I20161231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMTcxNjA_1c761755-59f8-4781-957e-749e4a78e86a">2.00</ix:nonFraction>% Convertible Senior Notes due 2021 (the &#8220;2021 Notes&#8221;) in a private placement to qualified institutional buyers within the meaning of Rule 144A under the Securities Act. The 2021 Notes were issued at par for net proceeds of $<ix:nonFraction unitRef="usd" contextRef="ib65ee853127148cf9a525e6a17c68f39_D20161201-20161231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMTczODM_7ac2f0e0-0279-4ae6-9dc5-83b4955a8871">120.4</ix:nonFraction> million. We incurred $<ix:nonFraction unitRef="usd" contextRef="i0efb2207e70f43cb998170b0668f5aa4_I20161231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredFinanceCostsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMTczOTk_2a443424-7253-4a9a-9fb2-0afb1401161b">4.6</ix:nonFraction> million of debt issuance costs in connection with the 2021 Notes, which we are amortizing to non-cash interest expense using the straight-line method over the contractual term of the 2021 Notes, since this method was not materially different from the effective interest method. The closing of the private placement of the 2021 Notes occurred on December&#160;5, 2016.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of the 2021 Notes are entitled to cash interest payments, which are payable semiannually in arrears on June 1 and December 1 of each year, beginning on June&#160;1, 2017, at a rate equal to <ix:nonFraction unitRef="number" contextRef="i0efb2207e70f43cb998170b0668f5aa4_I20161231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMTc5MTU_1c761755-59f8-4781-957e-749e4a78e86a">2.00</ix:nonFraction>% per annum. The 2021 Notes will mature on December&#160;1, 2021, unless earlier repurchased or converted in accordance with their terms prior to such date. In addition, holders of the 2021 Notes may require the Company to repurchase all or part of their 2021 Notes upon the occurrence of a fundamental change at a price equal to <ix:nonFraction unitRef="number" contextRef="ib65ee853127148cf9a525e6a17c68f39_D20161201-20161231" decimals="INF" name="evh:DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMTgyMjc_00183344-c895-43b4-9f95-d9804af21f16">100.00</ix:nonFraction>% of the principal amount of the 2021 Notes being repurchased, plus any accrued and unpaid interest to, but excluding, the fundamental repurchase date. Upon maturity the principal amount of the notes may be settled via shares of the Company&#8217;s Class A common stock. We recorded interest expense of $<ix:nonFraction unitRef="usd" contextRef="ic303181ec3134d098d234f848582ffd2_D20210401-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMTY0OTI2NzQ2MzE0NA_00bea3f3-3dc5-4ae3-80ce-0cfa8fe442f9">0.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="idf80add09165458a8481ba03343ec164_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMTg1MjU_26b28b36-4e29-464c-b4e1-aa7d6e61d06e">0.3</ix:nonFraction> million for the three and six months ended June 30, 2021, respectively, and $<ix:nonFraction unitRef="usd" contextRef="i4e0425e5520c4d8ca777fd31abfdf006_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMTY0OTI2NzQ2MzE3NQ_c6a0bac3-1daa-4677-b0c0-2d53a07891c4">0.6</ix:nonFraction> million and  $<ix:nonFraction unitRef="usd" contextRef="i424565a0d08945018985beab5025c0a3_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMTg1MzI_327a2670-ec56-4c36-8d8d-66936da48536">1.2</ix:nonFraction> million for the three and six months ended June 30, 2020 , respectively. We recorded non-cash interest expense related to the amortization of deferred financing costs of $<ix:nonFraction unitRef="usd" contextRef="ic303181ec3134d098d234f848582ffd2_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMTY0OTI2NzQ2MzIyOA_0aee6e98-d88f-414b-8cee-eb8ab675c048">49</ix:nonFraction> thousand and $<ix:nonFraction unitRef="usd" contextRef="idf80add09165458a8481ba03343ec164_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfFinancingCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMTg2NTQ_88b7d615-ee7f-4858-898a-2b8949022497">0.1</ix:nonFraction> million for the three and six months ended June 30, 2021, respectively, and $<ix:nonFraction unitRef="usd" contextRef="i4e0425e5520c4d8ca777fd31abfdf006_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfFinancingCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMTY0OTI2NzQ2MzE5OQ_ea469f8f-745c-4d9a-b736-adf41091ac7c">0.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i424565a0d08945018985beab5025c0a3_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfFinancingCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMTg2NjE_2c5327ae-f550-4374-95e9-962344e6b4d2">0.5</ix:nonFraction> million for the three and six months ended June 30, 2020, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2021 Notes are convertible into shares of the Company&#8217;s Class A common stock, based on an initial conversion rate of 41.6082 shares of Class A common stock per $1,000 principal amount of the 2021 Notes, which is equivalent to an initial conversion price of approximately $<ix:nonFraction unitRef="usdPerShare" contextRef="ifad8a17110484cd3b275f15806410965_I20161231" decimals="2" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMTg5NTM_6fe9bf64-f2ac-4c7f-a9a2-5e0037765536">24.03</ix:nonFraction> per share of the Company&#8217;s Class A common stock. In the aggregate, the 2021 Notes are initially convertible into <ix:nonFraction unitRef="shares" contextRef="ifa1e9df841254737b2d83a5669c5b70d_D20161201-20161231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMTkwNjk_bdba6578-ef9f-4804-ad48-73c295694953">5.2</ix:nonFraction> million shares of the Company&#8217;s Class A common stock (excluding any shares issuable by the Company upon a conversion in connection with a make-whole provision upon a fundamental change under the governing indenture). The conversion rate may be adjusted under certain circumstances.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2021 Notes are convertible, in multiples of $1,000 principal amount, at the option of the holders at any time prior to the close of business on the business day immediately preceding the maturity date. Upon conversion, we will deliver for each $1,000 principal amount of notes converted a number of shares of our Class A common stock equal to the applicable conversion rate (together with a cash payment in lieu of delivering any fractional share) on the third business day following the relevant conversion date.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, as part of the issuance of the 2024 Notes, the Company issued $<ix:nonFraction unitRef="usd" contextRef="i0d3f73b1f2c04d3ba51586bcf12c3517_D20200801-20200831" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtConversionConvertedInstrumentAmount1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMTk5MzY_cbedf45a-971a-47ad-85c3-afcb3de38c8a">84.2</ix:nonFraction>&#160;million aggregate principal amount of the 2024 Notes in exchange for $<ix:nonFraction unitRef="usd" contextRef="icea30d45fccd401f9bb3791275a8c40c_D20200801-20200831" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtConversionOriginalDebtAmount1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMjAwMDA_e14123ef-70a2-4619-bb65-4519265979c9">84.2</ix:nonFraction>&#160;million aggregate principal of its 2021 Notes. There was no cash consideration in these exchanges outside of an aggregate cash payment of $<ix:nonFraction unitRef="usd" contextRef="i1598eae5f6ae4813b69f0cbb95358c65_D20200801-20200831" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMjAxMzM_66c1d6c0-82c7-491b-9608-1dbb24a8953b">2.5</ix:nonFraction>&#160;million paid to exchanging noteholders. These exchanges were accounted for as an extinguishment resulting in a net loss on extinguishment of debt of $<ix:nonFraction unitRef="usd" contextRef="i1598eae5f6ae4813b69f0cbb95358c65_D20200801-20200831" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMjAyNzc_40ff517d-cb78-444c-8ebe-980646158794">4.8</ix:nonFraction>&#160;million, including an aggregate cash payment of $<ix:nonFraction unitRef="usd" contextRef="i1598eae5f6ae4813b69f0cbb95358c65_D20200801-20200831" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMjAzMjA_27570fa2-794f-47c8-9d57-704858807f93">2.5</ix:nonFraction>&#160;million paid to exchanging noteholders. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, we also repurchased $<ix:nonFraction unitRef="usd" contextRef="icea30d45fccd401f9bb3791275a8c40c_D20200801-20200831" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ExtinguishmentOfDebtAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMjAzOTM_ef651547-8f7f-438d-a27d-c307b98e52f4">14.0</ix:nonFraction>&#160;million of the 2021 Notes with $<ix:nonFraction unitRef="usd" contextRef="icea30d45fccd401f9bb3791275a8c40c_D20200801-20200831" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfSeniorDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMjA0MTk_994b30bd-7f3a-4c46-865c-03017cdb1388">13.9</ix:nonFraction>&#160;million of cash and recorded an immaterial gain on extinguishment of debt.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Convertible Senior Notes Carrying Value</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2025 Notes, 2024 Notes and 2021 Notes are recorded on our accompanying consolidated balance sheets at their net carrying values as of June&#160;30, 2021. However, the 2025 Notes, 2024 Notes and 2021 Notes are privately traded by qualified institutional buyers (within the meaning of Rule 144A under the Securities Act) and their fair values are Level 2 inputs. The 2025 Notes, 2024 Notes and the 2021 Notes also have embedded conversion options and contingent interest provisions, which have not been recorded as separate financial instruments. <ix:nonNumeric contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" name="us-gaap:ConvertibleDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMjExNjc_3bf317b3-21d0-47a0-b833-e48b80d45c1e" continuedAt="if995c3245a9547c3853c4be5e90f0c3f" escape="true">The following table summarizes the carrying value of the long-term convertible debt as of June&#160;30, 2021 and December&#160;31, 2020 (in thousands):</ix:nonNumeric></span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-align:justify"><ix:continuation id="i516556853af241c3b911511b9ab27dbe"><ix:continuation id="if995c3245a9547c3853c4be5e90f0c3f"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:361.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:84.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:84.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024 Notes</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying value</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e9d743092e245ce8a2743fa9de0063b_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ConvertibleDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RhYmxlOjc3NGIzNTQ0YWM0NDQ2NjI4NTE2Nzk5ZGRmMTM4ZDk3L3RhYmxlcmFuZ2U6Nzc0YjM1NDRhYzQ0NDY2Mjg1MTY3OTlkZGYxMzhkOTdfMi0xLTEtMS0w_a89f0872-9cb4-4f34-9e5e-747d5f37e2a5">85,320</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id589098e41f9432fb6f03c1f1e575a4c_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ConvertibleDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RhYmxlOjc3NGIzNTQ0YWM0NDQ2NjI4NTE2Nzk5ZGRmMTM4ZDk3L3RhYmxlcmFuZ2U6Nzc0YjM1NDRhYzQ0NDY2Mjg1MTY3OTlkZGYxMzhkOTdfMi0zLTEtMS0w_df192b1d-0805-45c4-aa2c-d158d0f26dfd">81,462</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt discount and issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e9d743092e245ce8a2743fa9de0063b_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RhYmxlOjc3NGIzNTQ0YWM0NDQ2NjI4NTE2Nzk5ZGRmMTM4ZDk3L3RhYmxlcmFuZ2U6Nzc0YjM1NDRhYzQ0NDY2Mjg1MTY3OTlkZGYxMzhkOTdfMy0xLTEtMS0w_6c25631c-6045-467c-ae4a-f4f657b6775d">31,731</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id589098e41f9432fb6f03c1f1e575a4c_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RhYmxlOjc3NGIzNTQ0YWM0NDQ2NjI4NTE2Nzk5ZGRmMTM4ZDk3L3RhYmxlcmFuZ2U6Nzc0YjM1NDRhYzQ0NDY2Mjg1MTY3OTlkZGYxMzhkOTdfMy0zLTEtMS0w_879a7b03-3092-4dc0-b5ce-b03ed3e6a32c">35,589</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e9d743092e245ce8a2743fa9de0063b_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RhYmxlOjc3NGIzNTQ0YWM0NDQ2NjI4NTE2Nzk5ZGRmMTM4ZDk3L3RhYmxlcmFuZ2U6Nzc0YjM1NDRhYzQ0NDY2Mjg1MTY3OTlkZGYxMzhkOTdfNC0xLTEtMS0w_5906d877-9bf6-4231-aacb-be1eec67ee92">117,051</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id589098e41f9432fb6f03c1f1e575a4c_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RhYmxlOjc3NGIzNTQ0YWM0NDQ2NjI4NTE2Nzk5ZGRmMTM4ZDk3L3RhYmxlcmFuZ2U6Nzc0YjM1NDRhYzQ0NDY2Mjg1MTY3OTlkZGYxMzhkOTdfNC0zLTEtMS0w_0c0d44c5-0235-4b36-806d-04706db4e44f">117,051</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remaining amortization period (years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6b496ee9129546a1943004e4d9e6e458_D20210101-20210630" format="ixt-sec:duryear" name="us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RhYmxlOjc3NGIzNTQ0YWM0NDQ2NjI4NTE2Nzk5ZGRmMTM4ZDk3L3RhYmxlcmFuZ2U6Nzc0YjM1NDRhYzQ0NDY2Mjg1MTY3OTlkZGYxMzhkOTdfNS0xLTEtMS0w_aed11f05-273a-4952-806b-22926510f2cc">3.4</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8919b4a21f774b92af0611b3454001f6_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RhYmxlOjc3NGIzNTQ0YWM0NDQ2NjI4NTE2Nzk5ZGRmMTM4ZDk3L3RhYmxlcmFuZ2U6Nzc0YjM1NDRhYzQ0NDY2Mjg1MTY3OTlkZGYxMzhkOTdfNS0zLTEtMS0w_c39b1541-71d9-47da-b7f2-10a69dccde85">3.9</ix:nonNumeric></span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib88938e6f5a14d0f9eced78e9a885018_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtFairValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RhYmxlOjc3NGIzNTQ0YWM0NDQ2NjI4NTE2Nzk5ZGRmMTM4ZDk3L3RhYmxlcmFuZ2U6Nzc0YjM1NDRhYzQ0NDY2Mjg1MTY3OTlkZGYxMzhkOTdfNi0xLTEtMS0w_0e7c2b87-c057-421d-a0cd-4fae87a96e37">132,054</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cfa2b6d88f04259ac6ccaaed1afd02a_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtFairValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RhYmxlOjc3NGIzNTQ0YWM0NDQ2NjI4NTE2Nzk5ZGRmMTM4ZDk3L3RhYmxlcmFuZ2U6Nzc0YjM1NDRhYzQ0NDY2Mjg1MTY3OTlkZGYxMzhkOTdfNi0zLTEtMS0w_a98032a4-d4ef-481a-bf25-586d17e0aea4">153,220</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2025 Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying value</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8e7a5b465864f39bac51a81bb700201_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ConvertibleDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RhYmxlOjc3NGIzNTQ0YWM0NDQ2NjI4NTE2Nzk5ZGRmMTM4ZDk3L3RhYmxlcmFuZ2U6Nzc0YjM1NDRhYzQ0NDY2Mjg1MTY3OTlkZGYxMzhkOTdfOS0xLTEtMS0w_e349afb4-8653-48ce-9851-62c3ce6fad7e">121,230</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f54eab4eae24811a155de3cf38eeb86_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ConvertibleDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RhYmxlOjc3NGIzNTQ0YWM0NDQ2NjI4NTE2Nzk5ZGRmMTM4ZDk3L3RhYmxlcmFuZ2U6Nzc0YjM1NDRhYzQ0NDY2Mjg1MTY3OTlkZGYxMzhkOTdfOS0zLTEtMS0w_03ba8c97-92c2-4760-81fc-e90c497c4edc">116,349</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt discount and issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8e7a5b465864f39bac51a81bb700201_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RhYmxlOjc3NGIzNTQ0YWM0NDQ2NjI4NTE2Nzk5ZGRmMTM4ZDk3L3RhYmxlcmFuZ2U6Nzc0YjM1NDRhYzQ0NDY2Mjg1MTY3OTlkZGYxMzhkOTdfMTAtMS0xLTEtMA_a8b7567b-6141-4775-865e-9749e8e70751">51,270</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f54eab4eae24811a155de3cf38eeb86_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RhYmxlOjc3NGIzNTQ0YWM0NDQ2NjI4NTE2Nzk5ZGRmMTM4ZDk3L3RhYmxlcmFuZ2U6Nzc0YjM1NDRhYzQ0NDY2Mjg1MTY3OTlkZGYxMzhkOTdfMTAtMy0xLTEtMA_2cf98e27-6765-45a5-ac0a-db0524373fc3">56,151</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8e7a5b465864f39bac51a81bb700201_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RhYmxlOjc3NGIzNTQ0YWM0NDQ2NjI4NTE2Nzk5ZGRmMTM4ZDk3L3RhYmxlcmFuZ2U6Nzc0YjM1NDRhYzQ0NDY2Mjg1MTY3OTlkZGYxMzhkOTdfMTEtMS0xLTEtMA_993970b6-c200-47af-9c7e-799279d289ca">172,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f54eab4eae24811a155de3cf38eeb86_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RhYmxlOjc3NGIzNTQ0YWM0NDQ2NjI4NTE2Nzk5ZGRmMTM4ZDk3L3RhYmxlcmFuZ2U6Nzc0YjM1NDRhYzQ0NDY2Mjg1MTY3OTlkZGYxMzhkOTdfMTEtMy0xLTEtMA_9fe95dd6-0ba2-4d07-806c-886c568d07a7">172,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remaining amortization period (years)</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4deadc1ba0674142a17d227672696535_D20210101-20210630" format="ixt-sec:duryear" name="us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RhYmxlOjc3NGIzNTQ0YWM0NDQ2NjI4NTE2Nzk5ZGRmMTM4ZDk3L3RhYmxlcmFuZ2U6Nzc0YjM1NDRhYzQ0NDY2Mjg1MTY3OTlkZGYxMzhkOTdfMTItMS0xLTEtMA_62dd237e-792f-453b-b645-b103d04900be">4.3</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i82c5460e9f7e435b83787f35cd36dcb2_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RhYmxlOjc3NGIzNTQ0YWM0NDQ2NjI4NTE2Nzk5ZGRmMTM4ZDk3L3RhYmxlcmFuZ2U6Nzc0YjM1NDRhYzQ0NDY2Mjg1MTY3OTlkZGYxMzhkOTdfMTItMy0xLTEtMA_19239617-2c0c-4ff9-b643-818e12a2d9a8">4.8</ix:nonNumeric></span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24d4b1acd996498eba5eed0fc3e84f4b_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtFairValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RhYmxlOjc3NGIzNTQ0YWM0NDQ2NjI4NTE2Nzk5ZGRmMTM4ZDk3L3RhYmxlcmFuZ2U6Nzc0YjM1NDRhYzQ0NDY2Mjg1MTY3OTlkZGYxMzhkOTdfMTMtMS0xLTEtMA_2c4e869a-5c20-4026-b4c8-f2b4e2aab104">165,974</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1e16d58e0e740b28071ebf63f24431d_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtFairValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RhYmxlOjc3NGIzNTQ0YWM0NDQ2NjI4NTE2Nzk5ZGRmMTM4ZDk3L3RhYmxlcmFuZ2U6Nzc0YjM1NDRhYzQ0NDY2Mjg1MTY3OTlkZGYxMzhkOTdfMTMtMy0xLTEtMA_a4d59ce2-f041-4e00-9b0e-bad1d6b9c428">147,488</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021 Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying value</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26c20cf31c1242dc950becfb29611788_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ConvertibleDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RhYmxlOjc3NGIzNTQ0YWM0NDQ2NjI4NTE2Nzk5ZGRmMTM4ZDk3L3RhYmxlcmFuZ2U6Nzc0YjM1NDRhYzQ0NDY2Mjg1MTY3OTlkZGYxMzhkOTdfMTYtMS0xLTEtMA_9655a330-5626-4ccb-9e8e-6bc3411eab45">26,655</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b41e14476334d7895158617049bccd5_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ConvertibleDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RhYmxlOjc3NGIzNTQ0YWM0NDQ2NjI4NTE2Nzk5ZGRmMTM4ZDk3L3RhYmxlcmFuZ2U6Nzc0YjM1NDRhYzQ0NDY2Mjg1MTY3OTlkZGYxMzhkOTdfMTYtMy0xLTEtMA_ac400fe9-b951-4fae-9568-0b18441b0d26">26,557</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26c20cf31c1242dc950becfb29611788_I20210630" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RhYmxlOjc3NGIzNTQ0YWM0NDQ2NjI4NTE2Nzk5ZGRmMTM4ZDk3L3RhYmxlcmFuZ2U6Nzc0YjM1NDRhYzQ0NDY2Mjg1MTY3OTlkZGYxMzhkOTdfMTctMS0xLTEtMA_c37833a3-acab-40d4-ae72-591476e8d6ad">82</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b41e14476334d7895158617049bccd5_I20201231" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RhYmxlOjc3NGIzNTQ0YWM0NDQ2NjI4NTE2Nzk5ZGRmMTM4ZDk3L3RhYmxlcmFuZ2U6Nzc0YjM1NDRhYzQ0NDY2Mjg1MTY3OTlkZGYxMzhkOTdfMTctMy0xLTEtMA_c71ec7ce-86d4-460b-8921-c4933c7a0943">180</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26c20cf31c1242dc950becfb29611788_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RhYmxlOjc3NGIzNTQ0YWM0NDQ2NjI4NTE2Nzk5ZGRmMTM4ZDk3L3RhYmxlcmFuZ2U6Nzc0YjM1NDRhYzQ0NDY2Mjg1MTY3OTlkZGYxMzhkOTdfMTgtMS0xLTEtMA_247ea4f4-b34b-4a59-ac12-85633b839cb8">26,737</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b41e14476334d7895158617049bccd5_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RhYmxlOjc3NGIzNTQ0YWM0NDQ2NjI4NTE2Nzk5ZGRmMTM4ZDk3L3RhYmxlcmFuZ2U6Nzc0YjM1NDRhYzQ0NDY2Mjg1MTY3OTlkZGYxMzhkOTdfMTgtMy0xLTEtMA_eafa2a25-ed90-4098-9ee9-bdfcf1868440">26,737</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remaining amortization period (years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="idf80add09165458a8481ba03343ec164_D20210101-20210630" format="ixt-sec:duryear" name="us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RhYmxlOjc3NGIzNTQ0YWM0NDQ2NjI4NTE2Nzk5ZGRmMTM4ZDk3L3RhYmxlcmFuZ2U6Nzc0YjM1NDRhYzQ0NDY2Mjg1MTY3OTlkZGYxMzhkOTdfMTktMS0xLTEtMA_4aa9b368-25a4-4976-af76-ea18ced647ac">0.4</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i42998979e1154fc69a147d78134d1a26_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RhYmxlOjc3NGIzNTQ0YWM0NDQ2NjI4NTE2Nzk5ZGRmMTM4ZDk3L3RhYmxlcmFuZ2U6Nzc0YjM1NDRhYzQ0NDY2Mjg1MTY3OTlkZGYxMzhkOTdfMTktMy0xLTEtMA_261596fa-0471-4a01-99fa-564de0f9e584">0.9</ix:nonNumeric></span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57814fe811324e9fad5398f551936680_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtFairValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RhYmxlOjc3NGIzNTQ0YWM0NDQ2NjI4NTE2Nzk5ZGRmMTM4ZDk3L3RhYmxlcmFuZ2U6Nzc0YjM1NDRhYzQ0NDY2Mjg1MTY3OTlkZGYxMzhkOTdfMjAtMS0xLTEtMA_a66a034e-9bcd-4f92-96ae-1d87cfda78e6">29,279</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie847f4ca71c44d2a845bf492cd0b91ed_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtFairValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RhYmxlOjc3NGIzNTQ0YWM0NDQ2NjI4NTE2Nzk5ZGRmMTM4ZDk3L3RhYmxlcmFuZ2U6Nzc0YjM1NDRhYzQ0NDY2Mjg1MTY3OTlkZGYxMzhkOTdfMjAtMy0xLTEtMA_8b0ed085-3f0e-4daa-8222-d2733d8af98c">26,470</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></ix:continuation></div><div style="text-align:justify"><span><br/></span></div><div id="id8f403494d0a42c2868794fb470218fc_79"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 11.  <ix:nonNumeric contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183OS9mcmFnOmMyNzZiM2YyZDExNjQyNDE4YTYwMmI4MDUxZDMwM2JiL3RleHRyZWdpb246YzI3NmIzZjJkMTE2NDI0MThhNjAyYjgwNTFkMzAzYmJfMTEwODc_5f84229c-8cc1-4218-975b-9d4e25a92e8d" continuedAt="id17409d77e5443c38550336db7d9fb42" escape="true">Commitments and Contingencies </ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="id17409d77e5443c38550336db7d9fb42" continuedAt="if38aecc874de4d6db6775fc458d6b787"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commitments</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Letters of Credit</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2021 and December 31, 2020, the Company established irrevocable standby letters of credit&#160;with a bank for&#160;$<ix:nonFraction unitRef="usd" contextRef="ic57d3a037df7434482b4ac69c20ce6f0_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183OS9mcmFnOmMyNzZiM2YyZDExNjQyNDE4YTYwMmI4MDUxZDMwM2JiL3RleHRyZWdpb246YzI3NmIzZjJkMTE2NDI0MThhNjAyYjgwNTFkMzAzYmJfMjAx_3ae31a19-7d54-4ecc-9f1f-bce319b44263">15.0</ix:nonFraction> million&#160;and $<ix:nonFraction unitRef="usd" contextRef="i7d1b21babb8849389bf714849eaec38d_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183OS9mcmFnOmMyNzZiM2YyZDExNjQyNDE4YTYwMmI4MDUxZDMwM2JiL3RleHRyZWdpb246YzI3NmIzZjJkMTE2NDI0MThhNjAyYjgwNTFkMzAzYmJfMjA5_dc7e50d6-ef2d-48b9-bd88-052c3e318e1f">7.4</ix:nonFraction>&#160;million for the benefit of a regulatory authorities, real estate and risk-sharing agreements and, as such, held $<ix:nonFraction unitRef="usd" contextRef="iced602b4d3a741e183e4dad1271a58e8_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashAndCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183OS9mcmFnOmMyNzZiM2YyZDExNjQyNDE4YTYwMmI4MDUxZDMwM2JiL3RleHRyZWdpb246YzI3NmIzZjJkMTE2NDI0MThhNjAyYjgwNTFkMzAzYmJfMzE2_418274e8-4e53-48a7-9429-571a083da116"><ix:nonFraction unitRef="usd" contextRef="i538e245a2b7045f18999365d98e47c51_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashAndCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183OS9mcmFnOmMyNzZiM2YyZDExNjQyNDE4YTYwMmI4MDUxZDMwM2JiL3RleHRyZWdpb246YzI3NmIzZjJkMTE2NDI0MThhNjAyYjgwNTFkMzAzYmJfMzE2_5b435c49-4a8f-42aa-8271-9f4323a4cd38">15.0</ix:nonFraction></ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i154d1afeed6943c08b9da6703d2f57a3_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashAndCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183OS9mcmFnOmMyNzZiM2YyZDExNjQyNDE4YTYwMmI4MDUxZDMwM2JiL3RleHRyZWdpb246YzI3NmIzZjJkMTE2NDI0MThhNjAyYjgwNTFkMzAzYmJfMzI0_43de68de-2ccc-42dc-8b9b-b04a3d47fe5e"><ix:nonFraction unitRef="usd" contextRef="i0cd3439d51f543818ae384f535441a35_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashAndCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183OS9mcmFnOmMyNzZiM2YyZDExNjQyNDE4YTYwMmI4MDUxZDMwM2JiL3RleHRyZWdpb246YzI3NmIzZjJkMTE2NDI0MThhNjAyYjgwNTFkMzAzYmJfMzI0_c936fc24-3d3f-4774-ac9b-630d4f3b9028">7.4</ix:nonFraction></ix:nonFraction>&#160;million in restricted cash and restricted investments as collateral as of both June&#160;30, 2021 and December&#160;31, 2020, respectively. The letters of credit have current expiration dates between October 2021 and March 2032 and will automatically extend without amendment for an additional one-year period and will continue to automatically extend after each one-year term from the expiry date, unless the bank elects not to extend beyond the initial or any extended expiry date. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Indemnifications</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s customer agreements generally include a provision by which the Company agrees to defend its partners against third-party claims (a) for death, bodily injury, or damage to personal property caused by Company negligence or willful misconduct, (b) by former or current Company employees arising from such managed service agreements, (c) for intellectual property infringement under specified conditions and (d) for Company violation of applicable laws, and to indemnify them against any damages and costs awarded in connection with such claims. To date, the Company has not incurred any material costs as a result of such indemnities and has not accrued any liabilities related to such obligations in the accompanying consolidated financial statements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pre-IPO Investor Registration Rights Agreement</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We entered into a registration rights agreement with The Advisory Board, UPMC, TPG and another investor to register for sale under the Securities Act shares of our Class A common stock, including those delivered in exchange for Class B common stock and Class B common units. Subject to certain conditions and limitations, this agreement provides these investors with certain demand, piggyback and shelf registration rights. The registration rights granted under the registration rights agreement will terminate upon the date the holders of shares that are a party thereto no longer hold any such shares that are entitled to registration rights. Pursuant to our contractual obligations under this agreement, we filed a registration statement on Form S-3 with the SEC on July 28, 2016, which was declared effective on August 12, 2016.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="if38aecc874de4d6db6775fc458d6b787" continuedAt="i6ecc84362be04f41aa64d74355d7afc3"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will pay all expenses relating to any demand, piggyback or shelf registration, other than underwriting discounts and commissions and any transfer taxes, subject to specified conditions and limitations. The registration rights agreement includes customary indemnification provisions, including indemnification of the participating holders of shares of Class A common stock and their directors, officers and employees by us for any losses, claims, damages or liabilities in respect thereof and expenses to which such holders may become subject under the Securities Act, state law or otherwise. We did not incur any expenses related to secondary offerings or other sales of shares by our investor stockholders during the three and six months ended June 30, 2021 and 2020, respectively. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Guarantees</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In connection with the Molina Closing, the Company continued to provide administrative support services relating to the Passport Medicaid Contract to Molina through the end of 2020. Following the Molina Closing, EVH Passport began working with regulatory authorities including the Kentucky Department of Insurance (&#8220;KY DOI&#8221;) regarding the wind down of its operations throughout 2021. As part of that wind down process, the Company, as the parent of EVH Passport, entered into a guarantee for the benefit of the KY DOI to satisfy any EVH Passport liability or obligation in the event EVH Passport is not able to meet its wind down liabilities or obligations. As of June&#160;30, 2021, no amounts have been funded under this guarantee.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reinsurance Agreements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the Passport Closing, $<ix:nonFraction unitRef="usd" contextRef="i267001cededb4bfdb4aa09441f453c34_I20191230" decimals="-5" format="ixt:numdotdecimal" name="evh:PaymentsToAcquireEquityMethodInvestmentsAmountHeldBack" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183OS9mcmFnOmMyNzZiM2YyZDExNjQyNDE4YTYwMmI4MDUxZDMwM2JiL3RleHRyZWdpb246YzI3NmIzZjJkMTE2NDI0MThhNjAyYjgwNTFkMzAzYmJfMzk1OA_4995a8dc-14d8-4f66-b4c8-c41559d61af4">16.2</ix:nonFraction>&#160;million of the cash Passport Purchase Price was held back until such time as PHS I delivers to EVH Passport certain owned real property and improvements free and clear of all encumbrances. In addition, at the Passport Closing, EVH Passport and UHC entered into an agreement that provided for the administration and assumption of the financial risks by EVH Passport of the D-SNP Business until such time as EVH Passport became certified as a Medicare Advantage Organization and the D-SNP Business could be transferred to EVH Passport.  On October 1, 2020, the D-SNP Business was transferred from UHC to EVH Passport.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the Molina Closing, Molina and EVH Passport entered into an agreement that provided for the assumption of the financial risks by Molina of the D-SNP Business until such time as Molina&#8217;s Kentucky health plan becomes certified as a Medicare Advantage Organization and the D-SNP Business is transferred to Molina. The Company and EVH Passport continued to administer the D-SNP Business until January 1, 2021, at which time Molina became responsible for its administration until the D-SNP Business is officially transferred to Molina effective September 1, 2021.</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" name="us-gaap:EffectsOfReinsuranceTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183OS9mcmFnOmMyNzZiM2YyZDExNjQyNDE4YTYwMmI4MDUxZDMwM2JiL3RleHRyZWdpb246YzI3NmIzZjJkMTE2NDI0MThhNjAyYjgwNTFkMzAzYmJfMTEwODg_ff0fcaa4-8d99-43da-82ef-561f88331568" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes premiums and claims assumed under the Reinsurance Agreements for the six months ended June 30, 2021 and 2020 (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:438.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:46.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:46.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reinsurance premiums assumed</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssumedPremiumsWritten" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183OS9mcmFnOmMyNzZiM2YyZDExNjQyNDE4YTYwMmI4MDUxZDMwM2JiL3RhYmxlOjc2OWUzNmE4NzZhOTQ4ZmI4NTJmZmM2NTAyZjFmM2ZhL3RhYmxlcmFuZ2U6NzY5ZTM2YTg3NmE5NDhmYjg1MmZmYzY1MDJmMWYzZmFfMi0xLTEtMS0w_4fe59ee1-cad3-460c-b42e-34a6c0daa60d">17,576</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:AssumedPremiumsWritten" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183OS9mcmFnOmMyNzZiM2YyZDExNjQyNDE4YTYwMmI4MDUxZDMwM2JiL3RhYmxlOjc2OWUzNmE4NzZhOTQ4ZmI4NTJmZmM2NTAyZjFmM2ZhL3RhYmxlcmFuZ2U6NzY5ZTM2YTg3NmE5NDhmYjg1MmZmYzY1MDJmMWYzZmFfMi0zLTEtMS0w_48a13e76-6d75-4909-9a5b-71d341892f75">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reinsurance premiums ceded</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:CededPremiumsWritten" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183OS9mcmFnOmMyNzZiM2YyZDExNjQyNDE4YTYwMmI4MDUxZDMwM2JiL3RhYmxlOjc2OWUzNmE4NzZhOTQ4ZmI4NTJmZmM2NTAyZjFmM2ZhL3RhYmxlcmFuZ2U6NzY5ZTM2YTg3NmE5NDhmYjg1MmZmYzY1MDJmMWYzZmFfMy0xLTEtMS0w_b0654cab-dacf-4d0b-bae7-f7426c8ee31d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:CededPremiumsWritten" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183OS9mcmFnOmMyNzZiM2YyZDExNjQyNDE4YTYwMmI4MDUxZDMwM2JiL3RhYmxlOjc2OWUzNmE4NzZhOTQ4ZmI4NTJmZmM2NTAyZjFmM2ZhL3RhYmxlcmFuZ2U6NzY5ZTM2YTg3NmE5NDhmYjg1MmZmYzY1MDJmMWYzZmFfMy0zLTEtMS0w_85ae2a95-8b1b-4903-a0af-4676e7a1fc57">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Claims assumed</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183OS9mcmFnOmMyNzZiM2YyZDExNjQyNDE4YTYwMmI4MDUxZDMwM2JiL3RhYmxlOjc2OWUzNmE4NzZhOTQ4ZmI4NTJmZmM2NTAyZjFmM2ZhL3RhYmxlcmFuZ2U6NzY5ZTM2YTg3NmE5NDhmYjg1MmZmYzY1MDJmMWYzZmFfNC0xLTEtMS0w_0f99ee2f-ac24-4a85-bb1c-716fe5bae8cc">16,863</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183OS9mcmFnOmMyNzZiM2YyZDExNjQyNDE4YTYwMmI4MDUxZDMwM2JiL3RhYmxlOjc2OWUzNmE4NzZhOTQ4ZmI4NTJmZmM2NTAyZjFmM2ZhL3RhYmxlcmFuZ2U6NzY5ZTM2YTg3NmE5NDhmYjg1MmZmYzY1MDJmMWYzZmFfNC0zLTEtMS0w_2d46c835-cf49-4702-b089-04a41d75a886">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Claims ceded</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183OS9mcmFnOmMyNzZiM2YyZDExNjQyNDE4YTYwMmI4MDUxZDMwM2JiL3RhYmxlOjc2OWUzNmE4NzZhOTQ4ZmI4NTJmZmM2NTAyZjFmM2ZhL3RhYmxlcmFuZ2U6NzY5ZTM2YTg3NmE5NDhmYjg1MmZmYzY1MDJmMWYzZmFfNS0xLTEtMS0w_b403a954-9377-4426-a82e-9ba5d27b0017">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183OS9mcmFnOmMyNzZiM2YyZDExNjQyNDE4YTYwMmI4MDUxZDMwM2JiL3RhYmxlOjc2OWUzNmE4NzZhOTQ4ZmI4NTJmZmM2NTAyZjFmM2ZhL3RhYmxlcmFuZ2U6NzY5ZTM2YTg3NmE5NDhmYjg1MmZmYzY1MDJmMWYzZmFfNS0zLTEtMS0w_954c108c-0041-493d-a612-5c5f68d34bc4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Claims-related administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="-3" name="evh:PolicyholderBenefitsAndClaimsIncurredAssumedExpensesRelatedToClaims" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183OS9mcmFnOmMyNzZiM2YyZDExNjQyNDE4YTYwMmI4MDUxZDMwM2JiL3RhYmxlOjc2OWUzNmE4NzZhOTQ4ZmI4NTJmZmM2NTAyZjFmM2ZhL3RhYmxlcmFuZ2U6NzY5ZTM2YTg3NmE5NDhmYjg1MmZmYzY1MDJmMWYzZmFfNi0xLTEtMS0w_e425a871-6dd9-4047-93b4-f69ec3149a2d">545</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="evh:PolicyholderBenefitsAndClaimsIncurredAssumedExpensesRelatedToClaims" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183OS9mcmFnOmMyNzZiM2YyZDExNjQyNDE4YTYwMmI4MDUxZDMwM2JiL3RhYmxlOjc2OWUzNmE4NzZhOTQ4ZmI4NTJmZmM2NTAyZjFmM2ZhL3RhYmxlcmFuZ2U6NzY5ZTM2YTg3NmE5NDhmYjg1MmZmYzY1MDJmMWYzZmFfNi0zLTEtMS0w_234ccd55-8379-4c2f-b08b-498c861f6a16">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase in reserves for claims and performance-based arrangements attributable to the Reinsurance Agreement</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="-3" name="evh:PremiumsWrittenAndPolicyholderBenefitsAndClaimsIncurredNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183OS9mcmFnOmMyNzZiM2YyZDExNjQyNDE4YTYwMmI4MDUxZDMwM2JiL3RhYmxlOjc2OWUzNmE4NzZhOTQ4ZmI4NTJmZmM2NTAyZjFmM2ZhL3RhYmxlcmFuZ2U6NzY5ZTM2YTg3NmE5NDhmYjg1MmZmYzY1MDJmMWYzZmFfNy0xLTEtMS0w_a3a7a8fe-e376-4c49-9852-5e8fb8658df0">168</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="evh:PremiumsWrittenAndPolicyholderBenefitsAndClaimsIncurredNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183OS9mcmFnOmMyNzZiM2YyZDExNjQyNDE4YTYwMmI4MDUxZDMwM2JiL3RhYmxlOjc2OWUzNmE4NzZhOTQ4ZmI4NTJmZmM2NTAyZjFmM2ZhL3RhYmxlcmFuZ2U6NzY5ZTM2YTg3NmE5NDhmYjg1MmZmYzY1MDJmMWYzZmFfNy0zLTEtMS0w_06aa8a92-13c4-4c7d-ac72-8393d0dd0b8a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserves for claims and performance-based arrangements attributable to the Reinsurance Agreement at the beginning of the period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45bff335c1434d6ba44132da1b0557db_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183OS9mcmFnOmMyNzZiM2YyZDExNjQyNDE4YTYwMmI4MDUxZDMwM2JiL3RhYmxlOjc2OWUzNmE4NzZhOTQ4ZmI4NTJmZmM2NTAyZjFmM2ZhL3RhYmxlcmFuZ2U6NzY5ZTM2YTg3NmE5NDhmYjg1MmZmYzY1MDJmMWYzZmFfOC0xLTEtMS0w_9e3cfafb-0c30-4072-8d2f-508d48ae1596">4,002</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0ff0ad229b441d4b12bc8956f92a917_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183OS9mcmFnOmMyNzZiM2YyZDExNjQyNDE4YTYwMmI4MDUxZDMwM2JiL3RhYmxlOjc2OWUzNmE4NzZhOTQ4ZmI4NTJmZmM2NTAyZjFmM2ZhL3RhYmxlcmFuZ2U6NzY5ZTM2YTg3NmE5NDhmYjg1MmZmYzY1MDJmMWYzZmFfOC0zLTEtMS0w_c528f42c-f732-4bcf-bb9a-cf2a8a0fff72">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of consolidation on payable for claims and performance-based arrangements attributable to the Reinsurance Agreement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="-3" format="ixt:zerodash" name="evh:AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseImpactOfConsolidationOnPayables" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183OS9mcmFnOmMyNzZiM2YyZDExNjQyNDE4YTYwMmI4MDUxZDMwM2JiL3RhYmxlOjc2OWUzNmE4NzZhOTQ4ZmI4NTJmZmM2NTAyZjFmM2ZhL3RhYmxlcmFuZ2U6NzY5ZTM2YTg3NmE5NDhmYjg1MmZmYzY1MDJmMWYzZmFfOS0xLTEtMS0w_d5831821-38a6-4c7c-bc2e-2a971bac2717">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="evh:AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseImpactOfConsolidationOnPayables" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183OS9mcmFnOmMyNzZiM2YyZDExNjQyNDE4YTYwMmI4MDUxZDMwM2JiL3RhYmxlOjc2OWUzNmE4NzZhOTQ4ZmI4NTJmZmM2NTAyZjFmM2ZhL3RhYmxlcmFuZ2U6NzY5ZTM2YTg3NmE5NDhmYjg1MmZmYzY1MDJmMWYzZmFfOS0zLTEtMS0w_d862c49d-6b8a-4f80-a51f-810b25fc3cb7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reinsurance payments paid (received)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsForReinsurance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183OS9mcmFnOmMyNzZiM2YyZDExNjQyNDE4YTYwMmI4MDUxZDMwM2JiL3RhYmxlOjc2OWUzNmE4NzZhOTQ4ZmI4NTJmZmM2NTAyZjFmM2ZhL3RhYmxlcmFuZ2U6NzY5ZTM2YTg3NmE5NDhmYjg1MmZmYzY1MDJmMWYzZmFfMTAtMS0xLTEtMA_43e32c68-e3f2-4a22-b891-af3eb6a69c01">7,506</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="evh:ProceedsFromReinsurance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183OS9mcmFnOmMyNzZiM2YyZDExNjQyNDE4YTYwMmI4MDUxZDMwM2JiL3RhYmxlOjc2OWUzNmE4NzZhOTQ4ZmI4NTJmZmM2NTAyZjFmM2ZhL3RhYmxlcmFuZ2U6NzY5ZTM2YTg3NmE5NDhmYjg1MmZmYzY1MDJmMWYzZmFfMTAtMy0xLTEtMA_1796806d-ad92-471a-bbde-7415f02b15a8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivable for claims and performance-based arrangements attributable to the Reinsurance Agreement at the end of the period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ReinsuranceRecoverablesOnPaidAndUnpaidLosses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183OS9mcmFnOmMyNzZiM2YyZDExNjQyNDE4YTYwMmI4MDUxZDMwM2JiL3RhYmxlOjc2OWUzNmE4NzZhOTQ4ZmI4NTJmZmM2NTAyZjFmM2ZhL3RhYmxlcmFuZ2U6NzY5ZTM2YTg3NmE5NDhmYjg1MmZmYzY1MDJmMWYzZmFfMTEtMS0xLTEtMA_7fd6f22e-310a-441a-a7ba-22a881633aa1">3,336</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11817f96c3e24e0abaed14a17869e173_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:ReinsuranceRecoverablesOnPaidAndUnpaidLosses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183OS9mcmFnOmMyNzZiM2YyZDExNjQyNDE4YTYwMmI4MDUxZDMwM2JiL3RhYmxlOjc2OWUzNmE4NzZhOTQ4ZmI4NTJmZmM2NTAyZjFmM2ZhL3RhYmxlcmFuZ2U6NzY5ZTM2YTg3NmE5NDhmYjg1MmZmYzY1MDJmMWYzZmFfMTEtMy0xLTEtMA_2bbb566d-ee38-4caf-a503-188447c79696">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">UPMC Reseller Agreement</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and UPMC are parties to a reseller, services and non-competition agreement, dated August 31, 2011, which was amended and restated by the parties on June 27, 2013 (as amended through the date hereof, the &#8220;UPMC Reseller Agreement&#8221;). Under the terms of the UPMC Reseller Agreement, UPMC has appointed the Company as a non-exclusive reseller of certain services, subject to certain conditions and limitations specified in the UPMC Reseller Agreement. In consideration for the Company&#8217;s obligations under </span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i6ecc84362be04f41aa64d74355d7afc3" continuedAt="i0e6f5fe11072450abe95e1a40e48fe1c"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the UPMC Reseller Agreement and subject to certain conditions described therein, UPMC has agreed not to sell certain products and services directly to a defined list of 20 of the Company&#8217;s customers.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contingencies</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Tax Receivables Agreement</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Offering Reorganization, the Company entered into the Tax Receivables Agreement (the &#8220;TRA&#8221;) with certain of its investors, which provides for the payment by the Company to these investors of <ix:nonFraction unitRef="number" contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630" decimals="INF" name="evh:TaxReceivablesAgreementPercentofTaxSavingstobePaid" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183OS9mcmFnOmMyNzZiM2YyZDExNjQyNDE4YTYwMmI4MDUxZDMwM2JiL3RleHRyZWdpb246YzI3NmIzZjJkMTE2NDI0MThhNjAyYjgwNTFkMzAzYmJfNjIwNQ_b72b8389-2c53-4299-9d55-f551cad68ab1">85</ix:nonFraction>% of the amount of the tax benefits, if any, that the Company is deemed to realize as a result of increases in our tax basis related to exchanges of Class B common units as well as tax benefits attributable to the future utilization of pre-IPO NOLs. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the items noted above, and the fact that Evolent Health, Inc. is in a full valuation allowance position such that the deferred tax assets related to the Company&#8217;s historical pre-IPO losses and tax basis increase benefit from exchanges have not been realized, the Company has not recorded a liability pursuant to the TRA.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Litigation Matters</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are engaged from time to time in certain legal disputes arising in the ordinary course of business, including employment claims. When the likelihood of a loss contingency becomes probable and the amount of the loss can be reasonably estimated, we accrue a liability for the loss contingency. We continue to review accruals and adjust them to reflect ongoing negotiations, settlements, rulings, advice of legal counsel, and other relevant information. To the extent new information is obtained, and our views on the probable outcomes of claims, suits, assessments, investigations or legal proceedings change, changes in our accrued liabilities would be recorded in the period in which such determination is made.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 8, 2019, a shareholder of the Company filed a class action complaint against the Company, asserting claims under Section 10(b) and 20(a) of the Securities Exchange Act of 1934, in the United States District Court, Eastern District of Virginia, Alexandria Division.  An amended complaint was filed on January 10, 2020, and a second amended complaint was filed on June 8, 2020.  The case, Plymouth County Retirement System v. Evolent Health, Inc., Frank Williams, Nicholas McGrane, Seth Blackley, Christie Spencer, and Steven Wigginton, alleges that the Company&#8217;s executives made false or misleading statements regarding its business with Passport.  The Company filed a motion to dismiss the second amended complaint, and the Eastern District of Virginia granted in part and denied in part the motion on March 24, 2021.  The Company and Plaintiffs then filed separate motions to reconsider that are pending.  While the scope of the allegations that remain is still unclear pending the court&#8217;s further decision, the case will proceed to discovery.  Based on the Company&#8217;s investigation so far, we believe the case has little legal or factual merit.  However, the outcome of any litigation is uncertain, and at this stage, the Company is currently unable to assess the probability of loss or estimate a range of potential loss, if any, associated with this lawsuit.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 8, 2021, a shareholder of the Company filed a derivative action in the Delaware Chancery Court against some current and former Board members and against the Company as a nominal defendant, alleging that the Company&#8217;s Board was negligent in its oversight of the Company&#8217;s relationship with Passport Health Plan.  The case is </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lincolnshire Police Pension Fund, derivatively on behalf of Evolent Health, Inc., v. Blackley, Williams, Scott, Holder, Farner, D&#8217;Amato, Duffy, Felt, Samet, Hobart, and Payson, and Evolent Health, Inc. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Plaintiff, the Company, and the Director-Defendants have agreed on a schedule for a motion to dismiss and related briefing, which we expect to be completed in late November 2021.  Based on the Company&#8217;s investigation so far, we believe the case has little legal or factual merit.  However, the outcome of any litigation is uncertain, and at this stage, the Company is currently unable to assess the probability of loss or estimate a range of potential loss, if any, associated with this lawsuit.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is not aware of any other legal proceedings or claims as of June&#160;30, 2021, that the Company believes will have, individually or in the aggregate, a material adverse effect on the Company&#8217;s financial position or result of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Credit and Concentration Risk</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to significant concentrations of credit risk related to cash and cash equivalents and accounts receivable. As of June&#160;30, 2021, approximately <ix:nonFraction unitRef="number" contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630" decimals="3" name="evh:CashFDICInsuredAmountPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183OS9mcmFnOmMyNzZiM2YyZDExNjQyNDE4YTYwMmI4MDUxZDMwM2JiL3RleHRyZWdpb246YzI3NmIzZjJkMTE2NDI0MThhNjAyYjgwNTFkMzAzYmJfOTMxNg_4267dfec-7f70-4316-bdce-f1db0037d4c2">99.0</ix:nonFraction>% of our $<ix:nonFraction unitRef="usd" contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183OS9mcmFnOmMyNzZiM2YyZDExNjQyNDE4YTYwMmI4MDUxZDMwM2JiL3RleHRyZWdpb246YzI3NmIzZjJkMTE2NDI0MThhNjAyYjgwNTFkMzAzYmJfOTMyNg_3c142b7e-cf63-4ec1-83c3-8881f79ab011">238.4</ix:nonFraction> million of cash and cash equivalents (including restricted cash) were held in bank deposits with FDIC participating banks and approximately <ix:nonFraction unitRef="number" contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630" decimals="3" name="evh:CashHeldInInternationalBanksPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183OS9mcmFnOmMyNzZiM2YyZDExNjQyNDE4YTYwMmI4MDUxZDMwM2JiL3RleHRyZWdpb246YzI3NmIzZjJkMTE2NDI0MThhNjAyYjgwNTFkMzAzYmJfOTQ2MQ_2b27b7b7-60d6-4103-9a1b-e1c765721c6a">1.0</ix:nonFraction>% were held in international banks. While the Company maintains its cash and cash equivalents with financial institutions with high credit ratings, it often maintains these deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any realized losses on cash and cash equivalents to date.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i0e6f5fe11072450abe95e1a40e48fe1c" continuedAt="i89ef48f1bdcf421594b18427e6c642eb"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is also subject to significant concentration of accounts receivable risk as a substantial portion of our trade accounts receivable is derived from a small number of our partners. <ix:nonNumeric contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" name="us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183OS9mcmFnOmMyNzZiM2YyZDExNjQyNDE4YTYwMmI4MDUxZDMwM2JiL3RleHRyZWdpb246YzI3NmIzZjJkMTE2NDI0MThhNjAyYjgwNTFkMzAzYmJfMTEwOTE_14a3eedf-7293-4ffc-9163-e3f7c678cf0c" continuedAt="iaab953a0a70846be903c1c31313e1936" escape="true">The following table summarizes the partners who represented at least 10.0% of our consolidated trade accounts receivable as of June&#160;30, 2021 and December&#160;31, 2020:</ix:nonNumeric></span></div><ix:continuation id="iaab953a0a70846be903c1c31313e1936" continuedAt="i7601bce6937343bd89e1c685041c492a"><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:426.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:55.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cook County Health and Hospitals System</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3bfde454609344df8a691fb13c17b423_D20210101-20210630" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183OS9mcmFnOmMyNzZiM2YyZDExNjQyNDE4YTYwMmI4MDUxZDMwM2JiL3RhYmxlOmQ3ZGE2YTU2MjI0ODQyYWE4YWQ1YmM0NTc5ZDJmNzllL3RhYmxlcmFuZ2U6ZDdkYTZhNTYyMjQ4NDJhYThhZDViYzQ1NzlkMmY3OWVfMS0xLTEtMS0w_087f1f9a-0671-4c06-96bd-8e6951cb96d6">42.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2ef1d0e83e2d422cbbb22022d1d3f276_D20200101-20201231" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183OS9mcmFnOmMyNzZiM2YyZDExNjQyNDE4YTYwMmI4MDUxZDMwM2JiL3RhYmxlOmQ3ZGE2YTU2MjI0ODQyYWE4YWQ1YmM0NTc5ZDJmNzllL3RhYmxlcmFuZ2U6ZDdkYTZhNTYyMjQ4NDJhYThhZDViYzQ1NzlkMmY3OWVfMS0zLTEtMS0w_c543121a-ac2b-45fb-bfaf-a0cb82964f60">61.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Florida Blue Medicare, Inc</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i60ad372a207d459e88f7e372405eab34_D20210101-20210630" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183OS9mcmFnOmMyNzZiM2YyZDExNjQyNDE4YTYwMmI4MDUxZDMwM2JiL3RhYmxlOmQ3ZGE2YTU2MjI0ODQyYWE4YWQ1YmM0NTc5ZDJmNzllL3RhYmxlcmFuZ2U6ZDdkYTZhNTYyMjQ4NDJhYThhZDViYzQ1NzlkMmY3OWVfMi0xLTEtMS0w_3dcfecfa-7df3-4751-90b0-170bf25c2702">22.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neighborhood Health Plan of Rhode Island</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic8a7c423118a4e16a2ff6abc2b0d9648_D20210101-20210630" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183OS9mcmFnOmMyNzZiM2YyZDExNjQyNDE4YTYwMmI4MDUxZDMwM2JiL3RhYmxlOmQ3ZGE2YTU2MjI0ODQyYWE4YWQ1YmM0NTc5ZDJmNzllL3RhYmxlcmFuZ2U6ZDdkYTZhNTYyMjQ4NDJhYThhZDViYzQ1NzlkMmY3OWVfMy0xLTEtMS00NzI1_937fc5b0-357d-4fed-86c7-fde3ad25c040">12.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">* &#160;&#160;&#160;&#160;Represents less than 10.0% of the respective balance</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Company is subject to significant concentration of revenue risk as a substantial portion of our revenue is derived from a small number of contractual relationships with our operating partners.</span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i7601bce6937343bd89e1c685041c492a"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes those partners who represented at least 10.0% of our consolidated revenue for the three and six months ended June 30, 2021 and 2020:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:327.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cook County Health and Hospitals Systems</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idc534571524f4f7abecd4ed0645e79e6_D20210401-20210630" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183OS9mcmFnOmMyNzZiM2YyZDExNjQyNDE4YTYwMmI4MDUxZDMwM2JiL3RhYmxlOjUwZjM1MDIzZDZiNDRiOTJiNjhlNzlhM2Q2YzE5YjM0L3RhYmxlcmFuZ2U6NTBmMzUwMjNkNmI0NGI5MmI2OGU3OWEzZDZjMTliMzRfMi0xLTEtMS0yNTE5_2592a969-8030-44bb-8904-a3da87754cb3">29.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i969062c619d04ffaaa1df514f89c332c_D20200401-20200630" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183OS9mcmFnOmMyNzZiM2YyZDExNjQyNDE4YTYwMmI4MDUxZDMwM2JiL3RhYmxlOjUwZjM1MDIzZDZiNDRiOTJiNjhlNzlhM2Q2YzE5YjM0L3RhYmxlcmFuZ2U6NTBmMzUwMjNkNmI0NGI5MmI2OGU3OWEzZDZjMTliMzRfMi0zLTEtMS05NTE_4af7bc45-3f66-4f7b-8e7f-9be9783a145b">21.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i944764ecb45a4413b9d526710bd5a552_D20210101-20210630" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183OS9mcmFnOmMyNzZiM2YyZDExNjQyNDE4YTYwMmI4MDUxZDMwM2JiL3RhYmxlOjUwZjM1MDIzZDZiNDRiOTJiNjhlNzlhM2Q2YzE5YjM0L3RhYmxlcmFuZ2U6NTBmMzUwMjNkNmI0NGI5MmI2OGU3OWEzZDZjMTliMzRfMi0xLTEtMS0w_1025ed7b-9b05-41fb-a03a-4231eec7930d">29.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i01f8679ac2df4d82b256eea229cf6ea6_D20200101-20200630" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183OS9mcmFnOmMyNzZiM2YyZDExNjQyNDE4YTYwMmI4MDUxZDMwM2JiL3RhYmxlOjUwZjM1MDIzZDZiNDRiOTJiNjhlNzlhM2Q2YzE5YjM0L3RhYmxlcmFuZ2U6NTBmMzUwMjNkNmI0NGI5MmI2OGU3OWEzZDZjMTliMzRfMi0zLTEtMS0w_c834a85e-1375-4f4a-bf2e-cd8ab9e8bb7b">21.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Florida Blue Medicare, Inc.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia609b71d80124ac5a96f49cb69aa72ef_D20210401-20210630" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183OS9mcmFnOmMyNzZiM2YyZDExNjQyNDE4YTYwMmI4MDUxZDMwM2JiL3RhYmxlOjUwZjM1MDIzZDZiNDRiOTJiNjhlNzlhM2Q2YzE5YjM0L3RhYmxlcmFuZ2U6NTBmMzUwMjNkNmI0NGI5MmI2OGU3OWEzZDZjMTliMzRfMy0xLTEtMS0yNTIz_daa123c4-6624-482c-ae99-81c659bfc1d4">14.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ifb4268d248fd469a943652442c7252cf_D20210101-20210630" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183OS9mcmFnOmMyNzZiM2YyZDExNjQyNDE4YTYwMmI4MDUxZDMwM2JiL3RhYmxlOjUwZjM1MDIzZDZiNDRiOTJiNjhlNzlhM2Q2YzE5YjM0L3RhYmxlcmFuZ2U6NTBmMzUwMjNkNmI0NGI5MmI2OGU3OWEzZDZjMTliMzRfMy0xLTEtMS0w_72977a86-d94e-486e-87d2-85c8650ef6ed">14.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Passport</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i02f118a71b9b4270abff67fb98d3ae2d_D20200401-20200630" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183OS9mcmFnOmMyNzZiM2YyZDExNjQyNDE4YTYwMmI4MDUxZDMwM2JiL3RhYmxlOjUwZjM1MDIzZDZiNDRiOTJiNjhlNzlhM2Q2YzE5YjM0L3RhYmxlcmFuZ2U6NTBmMzUwMjNkNmI0NGI5MmI2OGU3OWEzZDZjMTliMzRfNC0zLTEtMS05NTU_7cd88626-2360-4341-877c-7aa9f65763de">27.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i51acaef421854161bf36167111e9315d_D20200101-20200630" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183OS9mcmFnOmMyNzZiM2YyZDExNjQyNDE4YTYwMmI4MDUxZDMwM2JiL3RhYmxlOjUwZjM1MDIzZDZiNDRiOTJiNjhlNzlhM2Q2YzE5YjM0L3RhYmxlcmFuZ2U6NTBmMzUwMjNkNmI0NGI5MmI2OGU3OWEzZDZjMTliMzRfNC0zLTEtMS0w_58cbe8a4-da3e-4f75-a73d-64f1a353207e">26.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">The denominator excludes $<ix:nonFraction unitRef="usd" contextRef="ia3740e6e58c749fa97b9285685be7b1e_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183OS9mcmFnOmMyNzZiM2YyZDExNjQyNDE4YTYwMmI4MDUxZDMwM2JiL3RleHRyZWdpb246YzI3NmIzZjJkMTE2NDI0MThhNjAyYjgwNTFkMzAzYmJfMTY0OTI2NzQ1Mjk4MA_8b0d072e-12db-4542-bf21-8abbfd4ab030">25.5</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i70101f6902e44f38a06effe5f98e83b6_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183OS9mcmFnOmMyNzZiM2YyZDExNjQyNDE4YTYwMmI4MDUxZDMwM2JiL3RleHRyZWdpb246YzI3NmIzZjJkMTE2NDI0MThhNjAyYjgwNTFkMzAzYmJfMTA2MDg_179aab8d-bc65-4563-8fe7-56199343cc01">57.6</ix:nonFraction>&#160;million of True Health premium revenue reclassified to discontinued operations for the three and six months ended June 30, 2020, respectively.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">* &#160;&#160;&#160;&#160;Represents less than 10.0% of the respective balance</span></div></ix:continuation></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i89ef48f1bdcf421594b18427e6c642eb">We derive a significant portion of our revenues from our largest partners. The loss, termination or renegotiation of our relationship or contract with any significant partner or multiple partners in the aggregate could have a material adverse effect on the Company's financial condition and results of operations.</ix:continuation>&#160;</span></div><div style="text-align:justify"><span><br/></span></div><div id="id8f403494d0a42c2868794fb470218fc_82"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 12. <ix:nonNumeric contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184Mi9mcmFnOjE1OGMzNWIzNDI3MjQyMTU4OGE5MTI4MmJlMWVjMjEzL3RleHRyZWdpb246MTU4YzM1YjM0MjcyNDIxNTg4YTkxMjgyYmUxZWMyMTNfMzIzNQ_31aa442f-0cac-4d3e-9639-d1feee31a248" continuedAt="id238e71afd0f4e898fd0a0a5ca915337" escape="true">Leases</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="id238e71afd0f4e898fd0a0a5ca915337" continuedAt="ib5cf9a7a84eb4da78110b2c28e0a053f"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into various office space, data center, and equipment lease agreements in conducting its normal business operations. At the inception of any contract, the Company evaluates the agreement to determine whether the contract contains a lease. If the contract contains a lease, the Company then evaluates the term and whether the lease is an operating or finance lease. Most leases include one or more options to renew or may have a termination option. The Company determines whether these options are reasonably certain to be exercised or not at the inception of the lease. In addition, some leases contain escalation clauses.  The rent expense is recognized on a straight-line basis in the consolidated statements of operations and comprehensive income (loss) over the term of the lease. Leases with an initial term of 12 months or less are not recorded on our consolidated balance sheets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. We use the implicit rate when readily determinable. Further, the Company treats all lease and non-lease components as a single combined lease component for all classes of underlying assets. The Company also enters into sublease agreements for some of its leased office space. Immaterial rental income attributable to subleases is offset against rent expense over the terms of the respective leases. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases office space and computer and other equipment under operating lease agreements expiring at various dates through 2031. Under the lease agreements, in addition to base rent, the Company is generally responsible for operating and maintenance costs and related fees. Several of these agreements include tenant improvement allowances, rent holidays or rent escalation clauses. When such items are included in a lease agreement, we record a deferred rent asset or liability on our consolidated balance sheets equal to the difference between rent expense and future minimum lease payments due. The rent expense related to these items is recognized on a straight-line basis over the terms of the leases. The Company&#8217;s primary office location is in Arlington, Virginia, which has served as its corporate headquarters since 2013. The Arlington, Virginia office lease expires in January 2032. Certain leases acquired as part of the Valence Health transaction included existing sublease agreements for office locations in Chicago, Illinois. </span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ib5cf9a7a84eb4da78110b2c28e0a053f"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with various lease agreements, the Company is required to maintain $<ix:nonFraction unitRef="usd" contextRef="id96b9f84ab8c4a4f8d773f444cd3a629_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LettersOfCreditOutstandingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184Mi9mcmFnOjE1OGMzNWIzNDI3MjQyMTU4OGE5MTI4MmJlMWVjMjEzL3RleHRyZWdpb246MTU4YzM1YjM0MjcyNDIxNTg4YTkxMjgyYmUxZWMyMTNfMjY2Mw_ffbf3e2f-6a17-49b9-b5db-2385689c54fb">3.5</ix:nonFraction> million in letters of credit. As of both June&#160;30, 2021 and December&#160;31, 2020, the Company held $<ix:nonFraction unitRef="usd" contextRef="idababf2dc26948949104cd43d693a4fd_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashAndCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184Mi9mcmFnOjE1OGMzNWIzNDI3MjQyMTU4OGE5MTI4MmJlMWVjMjEzL3RleHRyZWdpb246MTU4YzM1YjM0MjcyNDIxNTg4YTkxMjgyYmUxZWMyMTNfMjcyNw_42ceccf2-7710-4738-b71d-0c99d5a79c4f"><ix:nonFraction unitRef="usd" contextRef="id96b9f84ab8c4a4f8d773f444cd3a629_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashAndCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184Mi9mcmFnOjE1OGMzNWIzNDI3MjQyMTU4OGE5MTI4MmJlMWVjMjEzL3RleHRyZWdpb246MTU4YzM1YjM0MjcyNDIxNTg4YTkxMjgyYmUxZWMyMTNfMjcyNw_bb087d3f-0498-4373-9154-ab373a46806a">3.5</ix:nonFraction></ix:nonFraction> million in restricted cash and restricted investments on the consolidated balance sheet as collateral for the letters of credit, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184Mi9mcmFnOjE1OGMzNWIzNDI3MjQyMTU4OGE5MTI4MmJlMWVjMjEzL3RleHRyZWdpb246MTU4YzM1YjM0MjcyNDIxNTg4YTkxMjgyYmUxZWMyMTNfMzIzNg_2c99d3c7-1e49-4926-91a3-7a892bee7f9b" continuedAt="ieeaa6f12b16846e2bc374907936ac809" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our primary office leases as of June&#160;30, 2021 (in thousands, other than term):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:539.25pt"><tr><td style="width:1.0pt"></td><td style="width:237.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:94.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:94.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:94.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lease Termination Term (in years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Future Minimum Lease Commitments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Letter of Credit Amount Required</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Arlington, VA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if54c2d9d6b874c56bd73c8364532a8fa_I20210630" format="ixt-sec:duryear" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184Mi9mcmFnOjE1OGMzNWIzNDI3MjQyMTU4OGE5MTI4MmJlMWVjMjEzL3RhYmxlOjU0NzRmMjJiNjE2OTQwNDNhMWJhNzU4ZGY4MDVmYjA4L3RhYmxlcmFuZ2U6NTQ3NGYyMmI2MTY5NDA0M2ExYmE3NThkZjgwNWZiMDhfMS0yLTEtMS0w_3a4a37e9-bee0-4b43-87e5-6e6c274d368c">10.6</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if54c2d9d6b874c56bd73c8364532a8fa_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184Mi9mcmFnOjE1OGMzNWIzNDI3MjQyMTU4OGE5MTI4MmJlMWVjMjEzL3RhYmxlOjU0NzRmMjJiNjE2OTQwNDNhMWJhNzU4ZGY4MDVmYjA4L3RhYmxlcmFuZ2U6NTQ3NGYyMmI2MTY5NDA0M2ExYmE3NThkZjgwNWZiMDhfMS00LTEtMS0w_2c8d6492-463e-4a44-a05d-54198a01801a">37,147</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if54c2d9d6b874c56bd73c8364532a8fa_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LettersOfCreditOutstandingAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184Mi9mcmFnOjE1OGMzNWIzNDI3MjQyMTU4OGE5MTI4MmJlMWVjMjEzL3RhYmxlOjU0NzRmMjJiNjE2OTQwNDNhMWJhNzU4ZGY4MDVmYjA4L3RhYmxlcmFuZ2U6NTQ3NGYyMmI2MTY5NDA0M2ExYmE3NThkZjgwNWZiMDhfMS02LTEtMS0w_fc47bd07-070a-42dd-899e-d79501779efc">1,579</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Riverside, IL </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9376f969f54d4adfb216011fc4ce908d_I20210630" format="ixt-sec:duryear" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184Mi9mcmFnOjE1OGMzNWIzNDI3MjQyMTU4OGE5MTI4MmJlMWVjMjEzL3RhYmxlOjU0NzRmMjJiNjE2OTQwNDNhMWJhNzU4ZGY4MDVmYjA4L3RhYmxlcmFuZ2U6NTQ3NGYyMmI2MTY5NDA0M2ExYmE3NThkZjgwNWZiMDhfMi0yLTEtMS0w_1aebb238-8d2f-45e4-a2d9-e39c2c22a194">9.8</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9376f969f54d4adfb216011fc4ce908d_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184Mi9mcmFnOjE1OGMzNWIzNDI3MjQyMTU4OGE5MTI4MmJlMWVjMjEzL3RhYmxlOjU0NzRmMjJiNjE2OTQwNDNhMWJhNzU4ZGY4MDVmYjA4L3RhYmxlcmFuZ2U6NTQ3NGYyMmI2MTY5NDA0M2ExYmE3NThkZjgwNWZiMDhfMi00LTEtMS0w_f01a5aa1-7a1a-4b96-86af-0cc935e8b28b">42,956</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9376f969f54d4adfb216011fc4ce908d_I20210630" decimals="-3" name="us-gaap:LettersOfCreditOutstandingAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184Mi9mcmFnOjE1OGMzNWIzNDI3MjQyMTU4OGE5MTI4MmJlMWVjMjEzL3RhYmxlOjU0NzRmMjJiNjE2OTQwNDNhMWJhNzU4ZGY4MDVmYjA4L3RhYmxlcmFuZ2U6NTQ3NGYyMmI2MTY5NDA0M2ExYmE3NThkZjgwNWZiMDhfMi02LTEtMS0w_7544a863-7a58-48d5-80b7-3ff65d14c9d1">232</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pune, India</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia8857bf6635f4a0a81ada9df6a84f8ce_I20210630" format="ixt-sec:duryear" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184Mi9mcmFnOjE1OGMzNWIzNDI3MjQyMTU4OGE5MTI4MmJlMWVjMjEzL3RhYmxlOjU0NzRmMjJiNjE2OTQwNDNhMWJhNzU4ZGY4MDVmYjA4L3RhYmxlcmFuZ2U6NTQ3NGYyMmI2MTY5NDA0M2ExYmE3NThkZjgwNWZiMDhfMy0yLTEtMS0w_8ee08cf6-b9ce-40cf-94c4-a7ab0e9a18dd">2.3</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8857bf6635f4a0a81ada9df6a84f8ce_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184Mi9mcmFnOjE1OGMzNWIzNDI3MjQyMTU4OGE5MTI4MmJlMWVjMjEzL3RhYmxlOjU0NzRmMjJiNjE2OTQwNDNhMWJhNzU4ZGY4MDVmYjA4L3RhYmxlcmFuZ2U6NTQ3NGYyMmI2MTY5NDA0M2ExYmE3NThkZjgwNWZiMDhfMy00LTEtMS0w_821dd34d-0f3b-4480-98cb-a8a43a766fb8">1,835</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8857bf6635f4a0a81ada9df6a84f8ce_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:LettersOfCreditOutstandingAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184Mi9mcmFnOjE1OGMzNWIzNDI3MjQyMTU4OGE5MTI4MmJlMWVjMjEzL3RhYmxlOjU0NzRmMjJiNjE2OTQwNDNhMWJhNzU4ZGY4MDVmYjA4L3RhYmxlcmFuZ2U6NTQ3NGYyMmI2MTY5NDA0M2ExYmE3NThkZjgwNWZiMDhfMy02LTEtMS0w_cdbf207c-8370-442d-a72d-a1d97b5acfaa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brea, CA</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4c6bffe6a4634527a6262241e44da56b_I20210630" format="ixt-sec:duryear" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184Mi9mcmFnOjE1OGMzNWIzNDI3MjQyMTU4OGE5MTI4MmJlMWVjMjEzL3RhYmxlOjU0NzRmMjJiNjE2OTQwNDNhMWJhNzU4ZGY4MDVmYjA4L3RhYmxlcmFuZ2U6NTQ3NGYyMmI2MTY5NDA0M2ExYmE3NThkZjgwNWZiMDhfNC0yLTEtMS0w_6fb0d713-2afe-4c3a-b13c-7758f9e5319c">0.9</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c6bffe6a4634527a6262241e44da56b_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184Mi9mcmFnOjE1OGMzNWIzNDI3MjQyMTU4OGE5MTI4MmJlMWVjMjEzL3RhYmxlOjU0NzRmMjJiNjE2OTQwNDNhMWJhNzU4ZGY4MDVmYjA4L3RhYmxlcmFuZ2U6NTQ3NGYyMmI2MTY5NDA0M2ExYmE3NThkZjgwNWZiMDhfNC00LTEtMS0w_25907c39-3598-471d-be34-5834755c6fab">1,015</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c6bffe6a4634527a6262241e44da56b_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:LettersOfCreditOutstandingAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184Mi9mcmFnOjE1OGMzNWIzNDI3MjQyMTU4OGE5MTI4MmJlMWVjMjEzL3RhYmxlOjU0NzRmMjJiNjE2OTQwNDNhMWJhNzU4ZGY4MDVmYjA4L3RhYmxlcmFuZ2U6NTQ3NGYyMmI2MTY5NDA0M2ExYmE3NThkZjgwNWZiMDhfNC02LTEtMS0w_de8880d6-3ca2-40eb-a731-08a37ee37c71">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" name="us-gaap:LeaseCostTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184Mi9mcmFnOjE1OGMzNWIzNDI3MjQyMTU4OGE5MTI4MmJlMWVjMjEzL3RleHRyZWdpb246MTU4YzM1YjM0MjcyNDIxNTg4YTkxMjgyYmUxZWMyMTNfMzIzNw_7ba07475-c7e3-4c0a-aefa-cd8776134c21" continuedAt="i3b78d206cf874a4b99cf1bd2951e7ded" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the components of our lease expense for the three and six months ended June 30, 2021 and 2020 (in thousands): </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.650%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.013%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184Mi9mcmFnOjE1OGMzNWIzNDI3MjQyMTU4OGE5MTI4MmJlMWVjMjEzL3RhYmxlOjcwNzRkMmFlMDQ3OTRjZWQ5YzI4N2IzZTEzOTU4MmU1L3RhYmxlcmFuZ2U6NzA3NGQyYWUwNDc5NGNlZDljMjg3YjNlMTM5NTgyZTVfMi0xLTEtMS05ODM_da302f73-1baf-4b91-b8c7-2e6aac5089d5">2,437</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184Mi9mcmFnOjE1OGMzNWIzNDI3MjQyMTU4OGE5MTI4MmJlMWVjMjEzL3RhYmxlOjcwNzRkMmFlMDQ3OTRjZWQ5YzI4N2IzZTEzOTU4MmU1L3RhYmxlcmFuZ2U6NzA3NGQyYWUwNDc5NGNlZDljMjg3YjNlMTM5NTgyZTVfMi0zLTEtMS05Nzk_bfc3ac76-a052-4d31-a859-09fc458dd1e4">3,586</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184Mi9mcmFnOjE1OGMzNWIzNDI3MjQyMTU4OGE5MTI4MmJlMWVjMjEzL3RhYmxlOjcwNzRkMmFlMDQ3OTRjZWQ5YzI4N2IzZTEzOTU4MmU1L3RhYmxlcmFuZ2U6NzA3NGQyYWUwNDc5NGNlZDljMjg3YjNlMTM5NTgyZTVfMi0xLTEtMS0w_cf02405d-b867-40d7-a4fa-994feb5c8423">7,255</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184Mi9mcmFnOjE1OGMzNWIzNDI3MjQyMTU4OGE5MTI4MmJlMWVjMjEzL3RhYmxlOjcwNzRkMmFlMDQ3OTRjZWQ5YzI4N2IzZTEzOTU4MmU1L3RhYmxlcmFuZ2U6NzA3NGQyYWUwNDc5NGNlZDljMjg3YjNlMTM5NTgyZTVfMi0zLTEtMS0w_85d84c0c-c9f3-420c-957f-d025f9085b6a">6,642</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of right-of-use assets</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184Mi9mcmFnOjE1OGMzNWIzNDI3MjQyMTU4OGE5MTI4MmJlMWVjMjEzL3RhYmxlOjcwNzRkMmFlMDQ3OTRjZWQ5YzI4N2IzZTEzOTU4MmU1L3RhYmxlcmFuZ2U6NzA3NGQyYWUwNDc5NGNlZDljMjg3YjNlMTM5NTgyZTVfMy0xLTEtMS05ODM_98d3193a-3900-4e52-960e-bc3417865599">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184Mi9mcmFnOjE1OGMzNWIzNDI3MjQyMTU4OGE5MTI4MmJlMWVjMjEzL3RhYmxlOjcwNzRkMmFlMDQ3OTRjZWQ5YzI4N2IzZTEzOTU4MmU1L3RhYmxlcmFuZ2U6NzA3NGQyYWUwNDc5NGNlZDljMjg3YjNlMTM5NTgyZTVfMy0zLTEtMS05Nzk_2d38f19b-be2a-4c07-b47a-e6e735cddb50">150</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184Mi9mcmFnOjE1OGMzNWIzNDI3MjQyMTU4OGE5MTI4MmJlMWVjMjEzL3RhYmxlOjcwNzRkMmFlMDQ3OTRjZWQ5YzI4N2IzZTEzOTU4MmU1L3RhYmxlcmFuZ2U6NzA3NGQyYWUwNDc5NGNlZDljMjg3YjNlMTM5NTgyZTVfMy0xLTEtMS0w_bde15341-9205-4a90-8d59-05776e24a91c">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184Mi9mcmFnOjE1OGMzNWIzNDI3MjQyMTU4OGE5MTI4MmJlMWVjMjEzL3RhYmxlOjcwNzRkMmFlMDQ3OTRjZWQ5YzI4N2IzZTEzOTU4MmU1L3RhYmxlcmFuZ2U6NzA3NGQyYWUwNDc5NGNlZDljMjg3YjNlMTM5NTgyZTVfMy0zLTEtMS0w_8665e5ee-3d3c-46d8-98fc-50938ef9ca5d">299</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:FinanceLeaseInterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184Mi9mcmFnOjE1OGMzNWIzNDI3MjQyMTU4OGE5MTI4MmJlMWVjMjEzL3RhYmxlOjcwNzRkMmFlMDQ3OTRjZWQ5YzI4N2IzZTEzOTU4MmU1L3RhYmxlcmFuZ2U6NzA3NGQyYWUwNDc5NGNlZDljMjg3YjNlMTM5NTgyZTVfNC0xLTEtMS05ODM_eee51641-1cd7-4c2f-9d16-bc0f91643ee9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630" decimals="-3" name="us-gaap:FinanceLeaseInterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184Mi9mcmFnOjE1OGMzNWIzNDI3MjQyMTU4OGE5MTI4MmJlMWVjMjEzL3RhYmxlOjcwNzRkMmFlMDQ3OTRjZWQ5YzI4N2IzZTEzOTU4MmU1L3RhYmxlcmFuZ2U6NzA3NGQyYWUwNDc5NGNlZDljMjg3YjNlMTM5NTgyZTVfNC0zLTEtMS05Nzk_0c8bcfbb-6de6-460d-90e5-b8a91687daac">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:FinanceLeaseInterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184Mi9mcmFnOjE1OGMzNWIzNDI3MjQyMTU4OGE5MTI4MmJlMWVjMjEzL3RhYmxlOjcwNzRkMmFlMDQ3OTRjZWQ5YzI4N2IzZTEzOTU4MmU1L3RhYmxlcmFuZ2U6NzA3NGQyYWUwNDc5NGNlZDljMjg3YjNlMTM5NTgyZTVfNC0xLTEtMS0w_48583250-299a-4ede-b40b-916ecb2d3be4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="-3" name="us-gaap:FinanceLeaseInterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184Mi9mcmFnOjE1OGMzNWIzNDI3MjQyMTU4OGE5MTI4MmJlMWVjMjEzL3RhYmxlOjcwNzRkMmFlMDQ3OTRjZWQ5YzI4N2IzZTEzOTU4MmU1L3RhYmxlcmFuZ2U6NzA3NGQyYWUwNDc5NGNlZDljMjg3YjNlMTM5NTgyZTVfNC0zLTEtMS0w_1fba7afe-1c9f-49e0-af44-e7b427749afc">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease cost</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:VariableLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184Mi9mcmFnOjE1OGMzNWIzNDI3MjQyMTU4OGE5MTI4MmJlMWVjMjEzL3RhYmxlOjcwNzRkMmFlMDQ3OTRjZWQ5YzI4N2IzZTEzOTU4MmU1L3RhYmxlcmFuZ2U6NzA3NGQyYWUwNDc5NGNlZDljMjg3YjNlMTM5NTgyZTVfNS0xLTEtMS05ODM_2615bca3-cabd-47a1-af28-68cd2d304c55">1,192</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:VariableLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184Mi9mcmFnOjE1OGMzNWIzNDI3MjQyMTU4OGE5MTI4MmJlMWVjMjEzL3RhYmxlOjcwNzRkMmFlMDQ3OTRjZWQ5YzI4N2IzZTEzOTU4MmU1L3RhYmxlcmFuZ2U6NzA3NGQyYWUwNDc5NGNlZDljMjg3YjNlMTM5NTgyZTVfNS0zLTEtMS05Nzk_67124549-e63e-482f-8c69-557c202ec19d">1,465</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:VariableLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184Mi9mcmFnOjE1OGMzNWIzNDI3MjQyMTU4OGE5MTI4MmJlMWVjMjEzL3RhYmxlOjcwNzRkMmFlMDQ3OTRjZWQ5YzI4N2IzZTEzOTU4MmU1L3RhYmxlcmFuZ2U6NzA3NGQyYWUwNDc5NGNlZDljMjg3YjNlMTM5NTgyZTVfNS0xLTEtMS0w_854c67b5-7d27-4e35-ac1f-9c8d7be429d5">2,513</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:VariableLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184Mi9mcmFnOjE1OGMzNWIzNDI3MjQyMTU4OGE5MTI4MmJlMWVjMjEzL3RhYmxlOjcwNzRkMmFlMDQ3OTRjZWQ5YzI4N2IzZTEzOTU4MmU1L3RhYmxlcmFuZ2U6NzA3NGQyYWUwNDc5NGNlZDljMjg3YjNlMTM5NTgyZTVfNS0zLTEtMS0w_e2724aef-47ef-42cc-8400-5da5b0d41bd6">2,517</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease cost</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184Mi9mcmFnOjE1OGMzNWIzNDI3MjQyMTU4OGE5MTI4MmJlMWVjMjEzL3RhYmxlOjcwNzRkMmFlMDQ3OTRjZWQ5YzI4N2IzZTEzOTU4MmU1L3RhYmxlcmFuZ2U6NzA3NGQyYWUwNDc5NGNlZDljMjg3YjNlMTM5NTgyZTVfNi0xLTEtMS0zNzU4_e2c44edc-ec15-49ac-852a-fc65beda4072">3,629</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184Mi9mcmFnOjE1OGMzNWIzNDI3MjQyMTU4OGE5MTI4MmJlMWVjMjEzL3RhYmxlOjcwNzRkMmFlMDQ3OTRjZWQ5YzI4N2IzZTEzOTU4MmU1L3RhYmxlcmFuZ2U6NzA3NGQyYWUwNDc5NGNlZDljMjg3YjNlMTM5NTgyZTVfNi0zLTEtMS0zNzU4_7362dd28-c075-4077-b630-9229c042c852">5,202</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184Mi9mcmFnOjE1OGMzNWIzNDI3MjQyMTU4OGE5MTI4MmJlMWVjMjEzL3RhYmxlOjcwNzRkMmFlMDQ3OTRjZWQ5YzI4N2IzZTEzOTU4MmU1L3RhYmxlcmFuZ2U6NzA3NGQyYWUwNDc5NGNlZDljMjg3YjNlMTM5NTgyZTVfNi0xLTEtMS0w_c5a54f20-7498-480e-b155-7d2217622aa8">9,768</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184Mi9mcmFnOjE1OGMzNWIzNDI3MjQyMTU4OGE5MTI4MmJlMWVjMjEzL3RhYmxlOjcwNzRkMmFlMDQ3OTRjZWQ5YzI4N2IzZTEzOTU4MmU1L3RhYmxlcmFuZ2U6NzA3NGQyYWUwNDc5NGNlZDljMjg3YjNlMTM5NTgyZTVfNi0zLTEtMS0w_1e9417be-eb37-4442-b598-ede94d69e734">9,461</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><ix:continuation id="ieeaa6f12b16846e2bc374907936ac809"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturity of lease liabilities (in thousands) as of June&#160;30, 2021, is as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:87.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.012%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating lease expense</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184Mi9mcmFnOjE1OGMzNWIzNDI3MjQyMTU4OGE5MTI4MmJlMWVjMjEzL3RhYmxlOjdlMjU4Zjk1NWM4ZjQwZTRhZDgxMWU2MDcxMWUwNTM1L3RhYmxlcmFuZ2U6N2UyNThmOTU1YzhmNDBlNGFkODExZTYwNzExZTA1MzVfMS0xLTEtMS0w_55cc1c4f-f4c5-4b67-bf91-27304825b981">5,854</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184Mi9mcmFnOjE1OGMzNWIzNDI3MjQyMTU4OGE5MTI4MmJlMWVjMjEzL3RhYmxlOjdlMjU4Zjk1NWM4ZjQwZTRhZDgxMWU2MDcxMWUwNTM1L3RhYmxlcmFuZ2U6N2UyNThmOTU1YzhmNDBlNGFkODExZTYwNzExZTA1MzVfMi0xLTEtMS0w_e24f1108-5d92-4df6-9545-389a81c508f1">9,832</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184Mi9mcmFnOjE1OGMzNWIzNDI3MjQyMTU4OGE5MTI4MmJlMWVjMjEzL3RhYmxlOjdlMjU4Zjk1NWM4ZjQwZTRhZDgxMWU2MDcxMWUwNTM1L3RhYmxlcmFuZ2U6N2UyNThmOTU1YzhmNDBlNGFkODExZTYwNzExZTA1MzVfMy0xLTEtMS0w_8c04da79-5200-40b7-afee-845f9b3f44d3">8,645</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184Mi9mcmFnOjE1OGMzNWIzNDI3MjQyMTU4OGE5MTI4MmJlMWVjMjEzL3RhYmxlOjdlMjU4Zjk1NWM4ZjQwZTRhZDgxMWU2MDcxMWUwNTM1L3RhYmxlcmFuZ2U6N2UyNThmOTU1YzhmNDBlNGFkODExZTYwNzExZTA1MzVfNC0xLTEtMS0w_3d49fb22-ea88-40e5-9669-3cdf351cd866">8,378</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184Mi9mcmFnOjE1OGMzNWIzNDI3MjQyMTU4OGE5MTI4MmJlMWVjMjEzL3RhYmxlOjdlMjU4Zjk1NWM4ZjQwZTRhZDgxMWU2MDcxMWUwNTM1L3RhYmxlcmFuZ2U6N2UyNThmOTU1YzhmNDBlNGFkODExZTYwNzExZTA1MzVfNS0xLTEtMS0w_cdfd75fe-dd0f-47a1-b483-5fc8bbbacb3c">8,145</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630" decimals="-3" format="ixt:numdotdecimal" name="evh:LesseeOperatingLeaseLiabilityToBePaidAfterYearFive" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184Mi9mcmFnOjE1OGMzNWIzNDI3MjQyMTU4OGE5MTI4MmJlMWVjMjEzL3RhYmxlOjdlMjU4Zjk1NWM4ZjQwZTRhZDgxMWU2MDcxMWUwNTM1L3RhYmxlcmFuZ2U6N2UyNThmOTU1YzhmNDBlNGFkODExZTYwNzExZTA1MzVfNi0xLTEtMS0w_ed4af340-4f29-4c7f-b9b8-adf26709af5d">47,761</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184Mi9mcmFnOjE1OGMzNWIzNDI3MjQyMTU4OGE5MTI4MmJlMWVjMjEzL3RhYmxlOjdlMjU4Zjk1NWM4ZjQwZTRhZDgxMWU2MDcxMWUwNTM1L3RhYmxlcmFuZ2U6N2UyNThmOTU1YzhmNDBlNGFkODExZTYwNzExZTA1MzVfNy0xLTEtMS0w_9141da1d-24ad-463f-8a49-6589a3972f01">88,615</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less:</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184Mi9mcmFnOjE1OGMzNWIzNDI3MjQyMTU4OGE5MTI4MmJlMWVjMjEzL3RhYmxlOjdlMjU4Zjk1NWM4ZjQwZTRhZDgxMWU2MDcxMWUwNTM1L3RhYmxlcmFuZ2U6N2UyNThmOTU1YzhmNDBlNGFkODExZTYwNzExZTA1MzVfOS0xLTEtMS0w_83e4b28c-0095-4f5a-872e-54ad36674e57">22,732</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184Mi9mcmFnOjE1OGMzNWIzNDI3MjQyMTU4OGE5MTI4MmJlMWVjMjEzL3RhYmxlOjdlMjU4Zjk1NWM4ZjQwZTRhZDgxMWU2MDcxMWUwNTM1L3RhYmxlcmFuZ2U6N2UyNThmOTU1YzhmNDBlNGFkODExZTYwNzExZTA1MzVfMTAtMS0xLTEtMA_b7a1a673-b0fc-4790-b6d2-3c8c49002689">65,883</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i3b78d206cf874a4b99cf1bd2951e7ded"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our weighted-average discount rate and our weighted remaining lease terms (in years) as of June&#160;30, 2021 are as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:87.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.012%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630" decimals="4" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184Mi9mcmFnOjE1OGMzNWIzNDI3MjQyMTU4OGE5MTI4MmJlMWVjMjEzL3RhYmxlOjQzMDIyNDJiOGMwYzQ2MGQ5ZWFlNDM4YzIxNmY2MTViL3RhYmxlcmFuZ2U6NDMwMjI0MmI4YzBjNDYwZDllYWU0MzhjMjE2ZjYxNWJfMS0xLTEtMS0w_7013f308-2d08-405e-bf36-a2ae2efac6de">6.43</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining lease term</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184Mi9mcmFnOjE1OGMzNWIzNDI3MjQyMTU4OGE5MTI4MmJlMWVjMjEzL3RhYmxlOjQzMDIyNDJiOGMwYzQ2MGQ5ZWFlNDM4YzIxNmY2MTViL3RhYmxlcmFuZ2U6NDMwMjI0MmI4YzBjNDYwZDllYWU0MzhjMjE2ZjYxNWJfMi0xLTEtMS0w_d717a029-1e14-4373-87f8-7f6624d3b46c">9.2</ix:nonNumeric></span></td></tr></table></div></ix:continuation></ix:continuation><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><div id="id8f403494d0a42c2868794fb470218fc_85"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 13.  <ix:nonNumeric contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RleHRyZWdpb246ZWI3MmNiOTFiZTBmNDVlOThiNWY5ZDkzZGU3ZDUyNjlfMzYw_313e6a0f-c0b0-4646-9745-3843cc5c6a20" continuedAt="i09952cf5e2ca463a924fd7127e5bcd89" escape="true">Earnings (Loss) Per Common Share</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i09952cf5e2ca463a924fd7127e5bcd89"><ix:nonNumeric contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RleHRyZWdpb246ZWI3MmNiOTFiZTBmNDVlOThiNWY5ZDkzZGU3ZDUyNjlfMzU4_6d868168-93b2-4273-8cad-99ce9e1c7cd0" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the computation of basic and diluted earnings per share available for common stockholders for the three and six months ended June 30, 2021 and 2020 (in thousands, except per share data):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:288.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from continuing operations</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjExYWJjOWIxMWM5MjRiODM4OTZmNmRjYjRjMWY4M2NkL3RhYmxlcmFuZ2U6MTFhYmM5YjExYzkyNGI4Mzg5NmY2ZGNiNGMxZjgzY2RfMi0xLTEtMS0xMDI4_a030db38-41f2-4034-bb47-c1ea177a3f12">9,107</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjExYWJjOWIxMWM5MjRiODM4OTZmNmRjYjRjMWY4M2NkL3RhYmxlcmFuZ2U6MTFhYmM5YjExYzkyNGI4Mzg5NmY2ZGNiNGMxZjgzY2RfMi0zLTEtMS0xMDI4_dd96325a-3f6a-4064-8bfc-1c8d6a0ccf87">202,013</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjExYWJjOWIxMWM5MjRiODM4OTZmNmRjYjRjMWY4M2NkL3RhYmxlcmFuZ2U6MTFhYmM5YjExYzkyNGI4Mzg5NmY2ZGNiNGMxZjgzY2RfMi0xLTEtMS0w_228846d4-483a-4bd6-9c29-0517d59f1ace">20,297</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjExYWJjOWIxMWM5MjRiODM4OTZmNmRjYjRjMWY4M2NkL3RhYmxlcmFuZ2U6MTFhYmM5YjExYzkyNGI4Mzg5NmY2ZGNiNGMxZjgzY2RfMi0zLTEtMS0w_1259824e-746f-44ea-a83e-f1b50f0b3e55">280,500</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from discontinued operations, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjExYWJjOWIxMWM5MjRiODM4OTZmNmRjYjRjMWY4M2NkL3RhYmxlcmFuZ2U6MTFhYmM5YjExYzkyNGI4Mzg5NmY2ZGNiNGMxZjgzY2RfMy0xLTEtMS0xMDMx_1cdad334-f519-48e7-a442-e006607bfd0d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjExYWJjOWIxMWM5MjRiODM4OTZmNmRjYjRjMWY4M2NkL3RhYmxlcmFuZ2U6MTFhYmM5YjExYzkyNGI4Mzg5NmY2ZGNiNGMxZjgzY2RfMy0zLTEtMS0xMDMx_23a653a3-53f9-4fa2-825a-b0238aa1e1bc">1,508</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjExYWJjOWIxMWM5MjRiODM4OTZmNmRjYjRjMWY4M2NkL3RhYmxlcmFuZ2U6MTFhYmM5YjExYzkyNGI4Mzg5NmY2ZGNiNGMxZjgzY2RfMy0xLTEtMS0w_c5ecddec-ea61-49d7-9ee4-4bc37ada6314">1,383</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjExYWJjOWIxMWM5MjRiODM4OTZmNmRjYjRjMWY4M2NkL3RhYmxlcmFuZ2U6MTFhYmM5YjExYzkyNGI4Mzg5NmY2ZGNiNGMxZjgzY2RfMy0zLTEtMS0w_e40e5aa3-d436-463d-ae79-d4a972b39319">1,773</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjExYWJjOWIxMWM5MjRiODM4OTZmNmRjYjRjMWY4M2NkL3RhYmxlcmFuZ2U6MTFhYmM5YjExYzkyNGI4Mzg5NmY2ZGNiNGMxZjgzY2RfNC0xLTEtMS0xMDMx_224dac42-b7ca-448a-8c6c-19553d6e70ed">9,107</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjExYWJjOWIxMWM5MjRiODM4OTZmNmRjYjRjMWY4M2NkL3RhYmxlcmFuZ2U6MTFhYmM5YjExYzkyNGI4Mzg5NmY2ZGNiNGMxZjgzY2RfNC0zLTEtMS0xMDMx_24819732-0f1d-4a88-b203-8430f2e00104">203,521</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjExYWJjOWIxMWM5MjRiODM4OTZmNmRjYjRjMWY4M2NkL3RhYmxlcmFuZ2U6MTFhYmM5YjExYzkyNGI4Mzg5NmY2ZGNiNGMxZjgzY2RfNC0xLTEtMS0w_3c6b9c11-4052-4bf7-86e1-89b8e6f56107">18,914</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjExYWJjOWIxMWM5MjRiODM4OTZmNmRjYjRjMWY4M2NkL3RhYmxlcmFuZ2U6MTFhYmM5YjExYzkyNGI4Mzg5NmY2ZGNiNGMxZjgzY2RfNC0zLTEtMS0w_6133f0dd-e1f4-4ff4-96e9-42a93c1f62a1">282,273</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to non-controlling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjExYWJjOWIxMWM5MjRiODM4OTZmNmRjYjRjMWY4M2NkL3RhYmxlcmFuZ2U6MTFhYmM5YjExYzkyNGI4Mzg5NmY2ZGNiNGMxZjgzY2RfNi0xLTEtMS0xMDM0_588b0315-6ec7-4ba0-8c57-c489dff9bf4a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjExYWJjOWIxMWM5MjRiODM4OTZmNmRjYjRjMWY4M2NkL3RhYmxlcmFuZ2U6MTFhYmM5YjExYzkyNGI4Mzg5NmY2ZGNiNGMxZjgzY2RfNi0zLTEtMS0xMDM0_91d2f40b-af1d-403c-ae75-b09607128928">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjExYWJjOWIxMWM5MjRiODM4OTZmNmRjYjRjMWY4M2NkL3RhYmxlcmFuZ2U6MTFhYmM5YjExYzkyNGI4Mzg5NmY2ZGNiNGMxZjgzY2RfNi0xLTEtMS0w_6ebde5ba-b5bf-4879-a8ed-55bc8a2cf8f7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjExYWJjOWIxMWM5MjRiODM4OTZmNmRjYjRjMWY4M2NkL3RhYmxlcmFuZ2U6MTFhYmM5YjExYzkyNGI4Mzg5NmY2ZGNiNGMxZjgzY2RfNi0zLTEtMS0w_487ffa05-a8ca-4c89-8418-c5324a371639">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) available for common shareholders - basic and diluted</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjExYWJjOWIxMWM5MjRiODM4OTZmNmRjYjRjMWY4M2NkL3RhYmxlcmFuZ2U6MTFhYmM5YjExYzkyNGI4Mzg5NmY2ZGNiNGMxZjgzY2RfNy0xLTEtMS0xMDM0_09330fbb-f85e-46d5-b7ba-0c4c55c92dcd"><ix:nonFraction unitRef="usd" contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjExYWJjOWIxMWM5MjRiODM4OTZmNmRjYjRjMWY4M2NkL3RhYmxlcmFuZ2U6MTFhYmM5YjExYzkyNGI4Mzg5NmY2ZGNiNGMxZjgzY2RfNy0xLTEtMS0xMDM0_f334614f-48c8-4335-8644-08d1c094b533">9,107</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjExYWJjOWIxMWM5MjRiODM4OTZmNmRjYjRjMWY4M2NkL3RhYmxlcmFuZ2U6MTFhYmM5YjExYzkyNGI4Mzg5NmY2ZGNiNGMxZjgzY2RfNy0zLTEtMS0xMDM0_1f1b826f-81ea-4a16-8e51-b233cb6cb5d8"><ix:nonFraction unitRef="usd" contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjExYWJjOWIxMWM5MjRiODM4OTZmNmRjYjRjMWY4M2NkL3RhYmxlcmFuZ2U6MTFhYmM5YjExYzkyNGI4Mzg5NmY2ZGNiNGMxZjgzY2RfNy0zLTEtMS0xMDM0_464f9ea4-79d0-46fe-b7e0-3bfbaef12c35">203,521</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjExYWJjOWIxMWM5MjRiODM4OTZmNmRjYjRjMWY4M2NkL3RhYmxlcmFuZ2U6MTFhYmM5YjExYzkyNGI4Mzg5NmY2ZGNiNGMxZjgzY2RfNy0xLTEtMS0w_3f65effd-5c00-48e2-b9f0-61aa1fc1e88c"><ix:nonFraction unitRef="usd" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjExYWJjOWIxMWM5MjRiODM4OTZmNmRjYjRjMWY4M2NkL3RhYmxlcmFuZ2U6MTFhYmM5YjExYzkyNGI4Mzg5NmY2ZGNiNGMxZjgzY2RfNy0xLTEtMS0w_7051b8a1-9469-4d3d-b02f-b619b054437f">18,914</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjExYWJjOWIxMWM5MjRiODM4OTZmNmRjYjRjMWY4M2NkL3RhYmxlcmFuZ2U6MTFhYmM5YjExYzkyNGI4Mzg5NmY2ZGNiNGMxZjgzY2RfNy0zLTEtMS0w_0841956d-a0c8-4eca-a9f7-99ceb502bb32"><ix:nonFraction unitRef="usd" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjExYWJjOWIxMWM5MjRiODM4OTZmNmRjYjRjMWY4M2NkL3RhYmxlcmFuZ2U6MTFhYmM5YjExYzkyNGI4Mzg5NmY2ZGNiNGMxZjgzY2RfNy0zLTEtMS0w_d981f43f-4d1f-4440-8d13-5cf7db63d994">282,273</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding - basic and diluted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjExYWJjOWIxMWM5MjRiODM4OTZmNmRjYjRjMWY4M2NkL3RhYmxlcmFuZ2U6MTFhYmM5YjExYzkyNGI4Mzg5NmY2ZGNiNGMxZjgzY2RfOS0xLTEtMS0xMDM3_615bafb3-bdfe-4b63-9036-b3537a8d3d5f"><ix:nonFraction unitRef="shares" contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjExYWJjOWIxMWM5MjRiODM4OTZmNmRjYjRjMWY4M2NkL3RhYmxlcmFuZ2U6MTFhYmM5YjExYzkyNGI4Mzg5NmY2ZGNiNGMxZjgzY2RfOS0xLTEtMS0xMDM3_e018bb7d-cfe1-4e15-983f-63502f8c7917">85,448</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjExYWJjOWIxMWM5MjRiODM4OTZmNmRjYjRjMWY4M2NkL3RhYmxlcmFuZ2U6MTFhYmM5YjExYzkyNGI4Mzg5NmY2ZGNiNGMxZjgzY2RfOS0zLTEtMS0xMDM3_1ad6606b-0da7-4d3d-b6a8-e5367eea0c7a"><ix:nonFraction unitRef="shares" contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjExYWJjOWIxMWM5MjRiODM4OTZmNmRjYjRjMWY4M2NkL3RhYmxlcmFuZ2U6MTFhYmM5YjExYzkyNGI4Mzg5NmY2ZGNiNGMxZjgzY2RfOS0zLTEtMS0xMDM3_e0eb1f1b-2f64-4b89-bf40-a7b7ee576f84">85,349</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjExYWJjOWIxMWM5MjRiODM4OTZmNmRjYjRjMWY4M2NkL3RhYmxlcmFuZ2U6MTFhYmM5YjExYzkyNGI4Mzg5NmY2ZGNiNGMxZjgzY2RfOS0xLTEtMS0w_4242e7a7-f111-40b8-a6cb-ff0b458cb1a5"><ix:nonFraction unitRef="shares" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjExYWJjOWIxMWM5MjRiODM4OTZmNmRjYjRjMWY4M2NkL3RhYmxlcmFuZ2U6MTFhYmM5YjExYzkyNGI4Mzg5NmY2ZGNiNGMxZjgzY2RfOS0xLTEtMS0w_75f40ade-b15d-4533-9a0c-5990c566b25e">85,056</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjExYWJjOWIxMWM5MjRiODM4OTZmNmRjYjRjMWY4M2NkL3RhYmxlcmFuZ2U6MTFhYmM5YjExYzkyNGI4Mzg5NmY2ZGNiNGMxZjgzY2RfOS0zLTEtMS0w_456e1a38-89a7-499c-bb0c-bdb8fabe2538"><ix:nonFraction unitRef="shares" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjExYWJjOWIxMWM5MjRiODM4OTZmNmRjYjRjMWY4M2NkL3RhYmxlcmFuZ2U6MTFhYmM5YjExYzkyNGI4Mzg5NmY2ZGNiNGMxZjgzY2RfOS0zLTEtMS0w_a4062fd1-4700-4596-ac02-4d51b453a84d">84,977</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Income (loss) per common share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjExYWJjOWIxMWM5MjRiODM4OTZmNmRjYjRjMWY4M2NkL3RhYmxlcmFuZ2U6MTFhYmM5YjExYzkyNGI4Mzg5NmY2ZGNiNGMxZjgzY2RfMTMtMS0xLTEtMTA0MA_9b468376-3abb-4b91-b544-45598236cd35"><ix:nonFraction unitRef="usdPerShare" contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjExYWJjOWIxMWM5MjRiODM4OTZmNmRjYjRjMWY4M2NkL3RhYmxlcmFuZ2U6MTFhYmM5YjExYzkyNGI4Mzg5NmY2ZGNiNGMxZjgzY2RfMTMtMS0xLTEtMTA0MA_a57eda48-bbd8-4cd1-9c68-3604f50ce2cf">0.11</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjExYWJjOWIxMWM5MjRiODM4OTZmNmRjYjRjMWY4M2NkL3RhYmxlcmFuZ2U6MTFhYmM5YjExYzkyNGI4Mzg5NmY2ZGNiNGMxZjgzY2RfMTMtMy0xLTEtMTA0MA_852b9a3c-a463-48e0-8977-f56a22c2b011"><ix:nonFraction unitRef="usdPerShare" contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjExYWJjOWIxMWM5MjRiODM4OTZmNmRjYjRjMWY4M2NkL3RhYmxlcmFuZ2U6MTFhYmM5YjExYzkyNGI4Mzg5NmY2ZGNiNGMxZjgzY2RfMTMtMy0xLTEtMTA0MA_9ef447ed-dde3-4a30-8002-79abb76cde61">2.37</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjExYWJjOWIxMWM5MjRiODM4OTZmNmRjYjRjMWY4M2NkL3RhYmxlcmFuZ2U6MTFhYmM5YjExYzkyNGI4Mzg5NmY2ZGNiNGMxZjgzY2RfMTMtMS0xLTEtMA_aea6d686-ea84-421d-bccd-c58e29e2aaab"><ix:nonFraction unitRef="usdPerShare" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjExYWJjOWIxMWM5MjRiODM4OTZmNmRjYjRjMWY4M2NkL3RhYmxlcmFuZ2U6MTFhYmM5YjExYzkyNGI4Mzg5NmY2ZGNiNGMxZjgzY2RfMTMtMS0xLTEtMA_ea47c458-12d3-4812-ac4e-259bd09fec29">0.24</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjExYWJjOWIxMWM5MjRiODM4OTZmNmRjYjRjMWY4M2NkL3RhYmxlcmFuZ2U6MTFhYmM5YjExYzkyNGI4Mzg5NmY2ZGNiNGMxZjgzY2RfMTMtMy0xLTEtMA_6f9f8394-7bd7-4271-8132-915268925c9a"><ix:nonFraction unitRef="usdPerShare" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjExYWJjOWIxMWM5MjRiODM4OTZmNmRjYjRjMWY4M2NkL3RhYmxlcmFuZ2U6MTFhYmM5YjExYzkyNGI4Mzg5NmY2ZGNiNGMxZjgzY2RfMTMtMy0xLTEtMA_dc90bf72-8a65-4da4-9bf9-d7c52b845d76">3.30</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630" decimals="2" format="ixt:zerodash" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjExYWJjOWIxMWM5MjRiODM4OTZmNmRjYjRjMWY4M2NkL3RhYmxlcmFuZ2U6MTFhYmM5YjExYzkyNGI4Mzg5NmY2ZGNiNGMxZjgzY2RfMTQtMS0xLTEtMTA0MA_891023c2-8f2f-4aac-b882-a0c38556e0ee"><ix:nonFraction unitRef="usdPerShare" contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630" decimals="2" format="ixt:zerodash" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjExYWJjOWIxMWM5MjRiODM4OTZmNmRjYjRjMWY4M2NkL3RhYmxlcmFuZ2U6MTFhYmM5YjExYzkyNGI4Mzg5NmY2ZGNiNGMxZjgzY2RfMTQtMS0xLTEtMTA0MA_aff981ea-ee53-455d-9f65-8e9eed3782e5">&#8212;</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630" decimals="2" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjExYWJjOWIxMWM5MjRiODM4OTZmNmRjYjRjMWY4M2NkL3RhYmxlcmFuZ2U6MTFhYmM5YjExYzkyNGI4Mzg5NmY2ZGNiNGMxZjgzY2RfMTQtMy0xLTEtMTA0MA_1c38e201-a69b-4d9d-9544-48059e596cdd"><ix:nonFraction unitRef="usdPerShare" contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630" decimals="2" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjExYWJjOWIxMWM5MjRiODM4OTZmNmRjYjRjMWY4M2NkL3RhYmxlcmFuZ2U6MTFhYmM5YjExYzkyNGI4Mzg5NmY2ZGNiNGMxZjgzY2RfMTQtMy0xLTEtMTA0MA_5aba3028-f0bb-4816-831a-d14e599f86d6">0.01</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjExYWJjOWIxMWM5MjRiODM4OTZmNmRjYjRjMWY4M2NkL3RhYmxlcmFuZ2U6MTFhYmM5YjExYzkyNGI4Mzg5NmY2ZGNiNGMxZjgzY2RfMTQtMS0xLTEtMA_79fdbf08-c988-4fe5-8cc6-c90de5b2ae49"><ix:nonFraction unitRef="usdPerShare" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjExYWJjOWIxMWM5MjRiODM4OTZmNmRjYjRjMWY4M2NkL3RhYmxlcmFuZ2U6MTFhYmM5YjExYzkyNGI4Mzg5NmY2ZGNiNGMxZjgzY2RfMTQtMS0xLTEtMA_a4377843-e7a2-4873-91ba-9152526441b0">0.02</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="2" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjExYWJjOWIxMWM5MjRiODM4OTZmNmRjYjRjMWY4M2NkL3RhYmxlcmFuZ2U6MTFhYmM5YjExYzkyNGI4Mzg5NmY2ZGNiNGMxZjgzY2RfMTQtMy0xLTEtMA_0d6b51ea-d7ab-4d37-abae-c32d154ecc1c"><ix:nonFraction unitRef="usdPerShare" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="2" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjExYWJjOWIxMWM5MjRiODM4OTZmNmRjYjRjMWY4M2NkL3RhYmxlcmFuZ2U6MTFhYmM5YjExYzkyNGI4Mzg5NmY2ZGNiNGMxZjgzY2RfMTQtMy0xLTEtMA_800c73c2-b879-48d8-a85e-64407c8de0bb">0.02</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted income (loss) per share attributable to common shareholders of Evolent Health, Inc.</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjExYWJjOWIxMWM5MjRiODM4OTZmNmRjYjRjMWY4M2NkL3RhYmxlcmFuZ2U6MTFhYmM5YjExYzkyNGI4Mzg5NmY2ZGNiNGMxZjgzY2RfMTUtMS0xLTEtMTA0Mw_289fe6d2-509d-4929-bc0d-716bc06e55f4"><ix:nonFraction unitRef="usdPerShare" contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjExYWJjOWIxMWM5MjRiODM4OTZmNmRjYjRjMWY4M2NkL3RhYmxlcmFuZ2U6MTFhYmM5YjExYzkyNGI4Mzg5NmY2ZGNiNGMxZjgzY2RfMTUtMS0xLTEtMTA0Mw_a1d75a1c-6e8f-4a55-a8ba-fdf4ca86b37a"><ix:nonFraction unitRef="usdPerShare" contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjExYWJjOWIxMWM5MjRiODM4OTZmNmRjYjRjMWY4M2NkL3RhYmxlcmFuZ2U6MTFhYmM5YjExYzkyNGI4Mzg5NmY2ZGNiNGMxZjgzY2RfMTUtMS0xLTEtMTA0Mw_a93fda02-45cf-44f3-9452-c41930c85b70"><ix:nonFraction unitRef="usdPerShare" contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjExYWJjOWIxMWM5MjRiODM4OTZmNmRjYjRjMWY4M2NkL3RhYmxlcmFuZ2U6MTFhYmM5YjExYzkyNGI4Mzg5NmY2ZGNiNGMxZjgzY2RfMTUtMS0xLTEtMTA0Mw_d77c4081-1564-4e19-97f4-f86af17bdcc8">0.11</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjExYWJjOWIxMWM5MjRiODM4OTZmNmRjYjRjMWY4M2NkL3RhYmxlcmFuZ2U6MTFhYmM5YjExYzkyNGI4Mzg5NmY2ZGNiNGMxZjgzY2RfMTUtMy0xLTEtMTA0Mw_578191b1-a62d-463e-be7e-11ef55341fed"><ix:nonFraction unitRef="usdPerShare" contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjExYWJjOWIxMWM5MjRiODM4OTZmNmRjYjRjMWY4M2NkL3RhYmxlcmFuZ2U6MTFhYmM5YjExYzkyNGI4Mzg5NmY2ZGNiNGMxZjgzY2RfMTUtMy0xLTEtMTA0Mw_b15e7f6a-89e7-46a5-9171-d647d7fdc69c">2.38</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjExYWJjOWIxMWM5MjRiODM4OTZmNmRjYjRjMWY4M2NkL3RhYmxlcmFuZ2U6MTFhYmM5YjExYzkyNGI4Mzg5NmY2ZGNiNGMxZjgzY2RfMTUtMS0xLTEtMA_4475b23a-7973-4d2f-8051-0da9faf1300e"><ix:nonFraction unitRef="usdPerShare" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjExYWJjOWIxMWM5MjRiODM4OTZmNmRjYjRjMWY4M2NkL3RhYmxlcmFuZ2U6MTFhYmM5YjExYzkyNGI4Mzg5NmY2ZGNiNGMxZjgzY2RfMTUtMS0xLTEtMA_a0729353-7687-45b1-b4a0-fd57a8065aa6">0.22</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjExYWJjOWIxMWM5MjRiODM4OTZmNmRjYjRjMWY4M2NkL3RhYmxlcmFuZ2U6MTFhYmM5YjExYzkyNGI4Mzg5NmY2ZGNiNGMxZjgzY2RfMTUtMy0xLTEtMA_9073a702-ff65-429f-b0fa-bd0027da3413"><ix:nonFraction unitRef="usdPerShare" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjExYWJjOWIxMWM5MjRiODM4OTZmNmRjYjRjMWY4M2NkL3RhYmxlcmFuZ2U6MTFhYmM5YjExYzkyNGI4Mzg5NmY2ZGNiNGMxZjgzY2RfMTUtMy0xLTEtMA_aa85be71-08a7-444f-9d13-8b6e26540e81">3.32</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RleHRyZWdpb246ZWI3MmNiOTFiZTBmNDVlOThiNWY5ZDkzZGU3ZDUyNjlfMzU0_2d353d47-e520-4742-bada-277fe515168b" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Anti-dilutive shares (in thousands) excluded from the calculation of weighted-average common shares presented above for the three and six months ended June 30, 2021 and 2020 are presented below:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:288.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units ("RSUs"), performance-based RSUs and leveraged stock units ("LSUs")</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3bbdc552de74473b893173ad17ee4325_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjZmYTE5NTgwNjRmNDQxOTI5Njg2OTU3OGM4NjhmMThkL3RhYmxlcmFuZ2U6NmZhMTk1ODA2NGY0NDE5Mjk2ODY5NTc4Yzg2OGYxOGRfMi0xLTEtMS0xMDIw_572be195-a681-4a1b-b1a2-b1f910b3795d">2,052</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if108b20cc6254ea1a1ef89bfcf74234a_D20200401-20200630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjZmYTE5NTgwNjRmNDQxOTI5Njg2OTU3OGM4NjhmMThkL3RhYmxlcmFuZ2U6NmZhMTk1ODA2NGY0NDE5Mjk2ODY5NTc4Yzg2OGYxOGRfMi0zLTEtMS0xMDIw_b6550a3f-9a96-4177-a02c-a8a3f9499f8d">554</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6a86fe17944142e095851e0cc3a655ae_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjZmYTE5NTgwNjRmNDQxOTI5Njg2OTU3OGM4NjhmMThkL3RhYmxlcmFuZ2U6NmZhMTk1ODA2NGY0NDE5Mjk2ODY5NTc4Yzg2OGYxOGRfMi0xLTEtMS0w_cc272c16-5d9b-46f5-90d0-3326148a66b4">1,793</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic963db54c7f04dea9f467d5db2840678_D20200101-20200630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjZmYTE5NTgwNjRmNDQxOTI5Njg2OTU3OGM4NjhmMThkL3RhYmxlcmFuZ2U6NmZhMTk1ODA2NGY0NDE5Mjk2ODY5NTc4Yzg2OGYxOGRfMi0zLTEtMS0w_6827634c-5b1e-4482-95c0-3078e925c5de">376</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ieca7dabc7fce4091b7a8bbb168559405_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjZmYTE5NTgwNjRmNDQxOTI5Njg2OTU3OGM4NjhmMThkL3RhYmxlcmFuZ2U6NmZhMTk1ODA2NGY0NDE5Mjk2ODY5NTc4Yzg2OGYxOGRfMy0xLTEtMS0xMDIw_734cebcb-3b60-4baf-ab07-e9cb8d0ac7a8">1,801</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iedb4828edf4e447d9b1ee9ab980c6c02_D20200401-20200630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjZmYTE5NTgwNjRmNDQxOTI5Njg2OTU3OGM4NjhmMThkL3RhYmxlcmFuZ2U6NmZhMTk1ODA2NGY0NDE5Mjk2ODY5NTc4Yzg2OGYxOGRfMy0zLTEtMS0xMDIw_8e57b061-77a2-4df1-9805-9116bcdf6b20">711</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7360937c162c4b65b0e52cff040923da_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjZmYTE5NTgwNjRmNDQxOTI5Njg2OTU3OGM4NjhmMThkL3RhYmxlcmFuZ2U6NmZhMTk1ODA2NGY0NDE5Mjk2ODY5NTc4Yzg2OGYxOGRfMy0xLTEtMS0w_eea4216c-5b11-48d4-991c-0021d985f684">1,833</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iddd419d375b04a27b7ae24f9852b38cf_D20200101-20200630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjZmYTE5NTgwNjRmNDQxOTI5Njg2OTU3OGM4NjhmMThkL3RhYmxlcmFuZ2U6NmZhMTk1ODA2NGY0NDE5Mjk2ODY5NTc4Yzg2OGYxOGRfMy0zLTEtMS0w_ba72dfd5-95b7-48ce-8c0f-815e34a19c2a">841</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible senior notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i61e6d3ad43084e94a5c4f2bbb4e354b5_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjZmYTE5NTgwNjRmNDQxOTI5Njg2OTU3OGM4NjhmMThkL3RhYmxlcmFuZ2U6NmZhMTk1ODA2NGY0NDE5Mjk2ODY5NTc4Yzg2OGYxOGRfNC0xLTEtMS0xMDIw_21e28cde-14bc-4c4f-ba48-d31104753e74">12,696</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibf9351473ea6468086160063a0d7a0c4_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjZmYTE5NTgwNjRmNDQxOTI5Njg2OTU3OGM4NjhmMThkL3RhYmxlcmFuZ2U6NmZhMTk1ODA2NGY0NDE5Mjk2ODY5NTc4Yzg2OGYxOGRfNC0zLTEtMS0xMDIw_4cd75dbd-0db7-4a85-90e4-b6540a2652df">10,361</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3d293dc899f54d4c89227aabde9d3934_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjZmYTE5NTgwNjRmNDQxOTI5Njg2OTU3OGM4NjhmMThkL3RhYmxlcmFuZ2U6NmZhMTk1ODA2NGY0NDE5Mjk2ODY5NTc4Yzg2OGYxOGRfNC0xLTEtMS0w_146b068f-8674-4049-805d-3ec49497c14b">12,696</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie3fb28c745a64f28b8f641cb4a936a28_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjZmYTE5NTgwNjRmNDQxOTI5Njg2OTU3OGM4NjhmMThkL3RhYmxlcmFuZ2U6NmZhMTk1ODA2NGY0NDE5Mjk2ODY5NTc4Yzg2OGYxOGRfNC0zLTEtMS0w_e1749f50-5ae3-419b-9a56-ffa9746dd7a1">10,361</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjZmYTE5NTgwNjRmNDQxOTI5Njg2OTU3OGM4NjhmMThkL3RhYmxlcmFuZ2U6NmZhMTk1ODA2NGY0NDE5Mjk2ODY5NTc4Yzg2OGYxOGRfNS0xLTEtMS0xMDIw_b38eb5a7-9683-4723-934d-2007161c3e6d">16,549</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjZmYTE5NTgwNjRmNDQxOTI5Njg2OTU3OGM4NjhmMThkL3RhYmxlcmFuZ2U6NmZhMTk1ODA2NGY0NDE5Mjk2ODY5NTc4Yzg2OGYxOGRfNS0zLTEtMS0xMDIw_e3725566-8d40-408f-91e0-858ca99cd665">11,626</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjZmYTE5NTgwNjRmNDQxOTI5Njg2OTU3OGM4NjhmMThkL3RhYmxlcmFuZ2U6NmZhMTk1ODA2NGY0NDE5Mjk2ODY5NTc4Yzg2OGYxOGRfNS0xLTEtMS0w_f7597923-0c2d-4670-86f5-223b9cc2628f">16,322</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjZmYTE5NTgwNjRmNDQxOTI5Njg2OTU3OGM4NjhmMThkL3RhYmxlcmFuZ2U6NmZhMTk1ODA2NGY0NDE5Mjk2ODY5NTc4Yzg2OGYxOGRfNS0zLTEtMS0w_a7144a02-3c4e-4550-b90e-fc25ac3c449c">11,578</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="id8f403494d0a42c2868794fb470218fc_88"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 14.  <ix:nonNumeric contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184OC9mcmFnOjMwNmExZTg1ZTI5NDQ5N2JiZDQxZDY0YzFiZGNhNzE1L3RleHRyZWdpb246MzA2YTFlODVlMjk0NDk3YmJkNDFkNjRjMWJkY2E3MTVfMzYz_c53f0da4-9641-4e9c-aae8-6a1bef631a7b" continuedAt="i6a21b575b5284fda996a632e49d8e919" escape="true">Stock-based Compensation</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i6a21b575b5284fda996a632e49d8e919" continuedAt="i7a30c504f8324617a99b557dbeaf7f00"><ix:nonNumeric contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184OC9mcmFnOjMwNmExZTg1ZTI5NDQ5N2JiZDQxZDY0YzFiZGNhNzE1L3RleHRyZWdpb246MzA2YTFlODVlMjk0NDk3YmJkNDFkNjRjMWJkY2E3MTVfMzY0_083bd9ec-449d-4da5-b5dc-ef33ac751d5b" continuedAt="ic1cb95e37aae498984ba827c8860af46" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total compensation expense by award type and line item in our consolidated financial statements for the three and six months ended June 30, 2021 and 2020 was as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:288.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Award Type</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia22f1c58e4244cbe9ed8fdbbaef1316f_D20210401-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184OC9mcmFnOjMwNmExZTg1ZTI5NDQ5N2JiZDQxZDY0YzFiZGNhNzE1L3RhYmxlOmU2YjAxYjcxNWEwZjRjNmU5OTE1NjMwZTFlNzE4MWIwL3RhYmxlcmFuZ2U6ZTZiMDFiNzE1YTBmNGM2ZTk5MTU2MzBlMWU3MTgxYjBfMy0xLTEtMS0xMDYx_2a323955-3d3d-4248-8188-ec4114365f49">267</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fc03842c80f45108f623bfcd797411e_D20200401-20200630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184OC9mcmFnOjMwNmExZTg1ZTI5NDQ5N2JiZDQxZDY0YzFiZGNhNzE1L3RhYmxlOmU2YjAxYjcxNWEwZjRjNmU5OTE1NjMwZTFlNzE4MWIwL3RhYmxlcmFuZ2U6ZTZiMDFiNzE1YTBmNGM2ZTk5MTU2MzBlMWU3MTgxYjBfMy0zLTEtMS0xMDYx_ded91767-0f81-4976-9ca7-723d1e59e294">638</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0aa4d34ea254f26a2cc4a122094cd33_D20210101-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184OC9mcmFnOjMwNmExZTg1ZTI5NDQ5N2JiZDQxZDY0YzFiZGNhNzE1L3RhYmxlOmU2YjAxYjcxNWEwZjRjNmU5OTE1NjMwZTFlNzE4MWIwL3RhYmxlcmFuZ2U6ZTZiMDFiNzE1YTBmNGM2ZTk5MTU2MzBlMWU3MTgxYjBfMy0xLTEtMS0w_56960668-6b3f-4dc7-aadd-c881f8f200a8">671</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4237d1aee594aeeaf7d421737988f0d_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184OC9mcmFnOjMwNmExZTg1ZTI5NDQ5N2JiZDQxZDY0YzFiZGNhNzE1L3RhYmxlOmU2YjAxYjcxNWEwZjRjNmU5OTE1NjMwZTFlNzE4MWIwL3RhYmxlcmFuZ2U6ZTZiMDFiNzE1YTBmNGM2ZTk5MTU2MzBlMWU3MTgxYjBfMy0zLTEtMS0w_56d02e1a-22dd-4614-8c13-8d6adf7c8beb">1,388</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance-based stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fc5b0f231654aeeb765d3a2edd42fd2_D20210401-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184OC9mcmFnOjMwNmExZTg1ZTI5NDQ5N2JiZDQxZDY0YzFiZGNhNzE1L3RhYmxlOmU2YjAxYjcxNWEwZjRjNmU5OTE1NjMwZTFlNzE4MWIwL3RhYmxlcmFuZ2U6ZTZiMDFiNzE1YTBmNGM2ZTk5MTU2MzBlMWU3MTgxYjBfNC0xLTEtMS0xMDYx_0d1c579d-b050-4d1b-8d6c-524af3c1de4b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i394c93b044f44da0bc8dae6ae1a3f9af_D20200401-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184OC9mcmFnOjMwNmExZTg1ZTI5NDQ5N2JiZDQxZDY0YzFiZGNhNzE1L3RhYmxlOmU2YjAxYjcxNWEwZjRjNmU5OTE1NjMwZTFlNzE4MWIwL3RhYmxlcmFuZ2U6ZTZiMDFiNzE1YTBmNGM2ZTk5MTU2MzBlMWU3MTgxYjBfNC0zLTEtMS0xMDYx_7f428eb3-139b-4bfa-8047-52ae787fbb0b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4367a6c7f1a4e8ab41b880d4b063e2e_D20210101-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184OC9mcmFnOjMwNmExZTg1ZTI5NDQ5N2JiZDQxZDY0YzFiZGNhNzE1L3RhYmxlOmU2YjAxYjcxNWEwZjRjNmU5OTE1NjMwZTFlNzE4MWIwL3RhYmxlcmFuZ2U6ZTZiMDFiNzE1YTBmNGM2ZTk5MTU2MzBlMWU3MTgxYjBfNC0xLTEtMS0w_d5154685-aa6b-49e7-b168-8b9a88275ec4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iefc5be4539b04aab90aaa73295d047d2_D20200101-20200630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184OC9mcmFnOjMwNmExZTg1ZTI5NDQ5N2JiZDQxZDY0YzFiZGNhNzE1L3RhYmxlOmU2YjAxYjcxNWEwZjRjNmU5OTE1NjMwZTFlNzE4MWIwL3RhYmxlcmFuZ2U6ZTZiMDFiNzE1YTBmNGM2ZTk5MTU2MzBlMWU3MTgxYjBfNC0zLTEtMS0w_f215e0f5-708c-44cc-b40a-e105496c7c14">75</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id632fa3ae3914b9da8bf15e4c54b6686_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184OC9mcmFnOjMwNmExZTg1ZTI5NDQ5N2JiZDQxZDY0YzFiZGNhNzE1L3RhYmxlOmU2YjAxYjcxNWEwZjRjNmU5OTE1NjMwZTFlNzE4MWIwL3RhYmxlcmFuZ2U6ZTZiMDFiNzE1YTBmNGM2ZTk5MTU2MzBlMWU3MTgxYjBfNS0xLTEtMS0xMDYx_dd155ab3-8536-4d0b-a48e-5d8d2908851b">2,427</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89e74efc56994c9ebb87c2b0e7cd1128_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184OC9mcmFnOjMwNmExZTg1ZTI5NDQ5N2JiZDQxZDY0YzFiZGNhNzE1L3RhYmxlOmU2YjAxYjcxNWEwZjRjNmU5OTE1NjMwZTFlNzE4MWIwL3RhYmxlcmFuZ2U6ZTZiMDFiNzE1YTBmNGM2ZTk5MTU2MzBlMWU3MTgxYjBfNS0zLTEtMS0xMDYx_3121ad9a-f2c7-4bc3-a333-f5274a6f828d">2,006</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6660233c9d6b4e96811be968402ad42c_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184OC9mcmFnOjMwNmExZTg1ZTI5NDQ5N2JiZDQxZDY0YzFiZGNhNzE1L3RhYmxlOmU2YjAxYjcxNWEwZjRjNmU5OTE1NjMwZTFlNzE4MWIwL3RhYmxlcmFuZ2U6ZTZiMDFiNzE1YTBmNGM2ZTk5MTU2MzBlMWU3MTgxYjBfNS0xLTEtMS0w_97c4214d-a373-4b5c-9877-2854444d1baf">4,401</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc0d9ae125db467ab0d22698986a0481_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184OC9mcmFnOjMwNmExZTg1ZTI5NDQ5N2JiZDQxZDY0YzFiZGNhNzE1L3RhYmxlOmU2YjAxYjcxNWEwZjRjNmU5OTE1NjMwZTFlNzE4MWIwL3RhYmxlcmFuZ2U6ZTZiMDFiNzE1YTBmNGM2ZTk5MTU2MzBlMWU3MTgxYjBfNS0zLTEtMS0w_fac76d42-5873-40eb-b2f4-0986b685ded4">3,862</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7b4268f6d62460d95263ea3eab82df8_D20210401-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184OC9mcmFnOjMwNmExZTg1ZTI5NDQ5N2JiZDQxZDY0YzFiZGNhNzE1L3RhYmxlOmU2YjAxYjcxNWEwZjRjNmU5OTE1NjMwZTFlNzE4MWIwL3RhYmxlcmFuZ2U6ZTZiMDFiNzE1YTBmNGM2ZTk5MTU2MzBlMWU3MTgxYjBfNi0xLTEtMS0xMDY1_dbe647f0-50e1-4896-8125-e20cec6c0f2a">222</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28477571d61a49d68ac8b8802530ba46_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184OC9mcmFnOjMwNmExZTg1ZTI5NDQ5N2JiZDQxZDY0YzFiZGNhNzE1L3RhYmxlOmU2YjAxYjcxNWEwZjRjNmU5OTE1NjMwZTFlNzE4MWIwL3RhYmxlcmFuZ2U6ZTZiMDFiNzE1YTBmNGM2ZTk5MTU2MzBlMWU3MTgxYjBfNi0zLTEtMS0xMDY1_599fc6f4-ba3c-474d-b5e7-e63908791288">1,059</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibce4d97bacd94dfaa609647fcaf23ca0_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184OC9mcmFnOjMwNmExZTg1ZTI5NDQ5N2JiZDQxZDY0YzFiZGNhNzE1L3RhYmxlOmU2YjAxYjcxNWEwZjRjNmU5OTE1NjMwZTFlNzE4MWIwL3RhYmxlcmFuZ2U6ZTZiMDFiNzE1YTBmNGM2ZTk5MTU2MzBlMWU3MTgxYjBfNi0xLTEtMS0w_06f6a830-c88b-4b85-a4e5-9e9bba417b74">1,307</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie162b42e78994c30b638363b2e6da8a0_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184OC9mcmFnOjMwNmExZTg1ZTI5NDQ5N2JiZDQxZDY0YzFiZGNhNzE1L3RhYmxlOmU2YjAxYjcxNWEwZjRjNmU5OTE1NjMwZTFlNzE4MWIwL3RhYmxlcmFuZ2U6ZTZiMDFiNzE1YTBmNGM2ZTk5MTU2MzBlMWU3MTgxYjBfNi0zLTEtMS0w_c4aed57e-dbfa-42d5-bebb-1944f9f8ef46">1,886</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PSUs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16f26157e03a422b8390af0e74420d0a_D20210401-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184OC9mcmFnOjMwNmExZTg1ZTI5NDQ5N2JiZDQxZDY0YzFiZGNhNzE1L3RhYmxlOmU2YjAxYjcxNWEwZjRjNmU5OTE1NjMwZTFlNzE4MWIwL3RhYmxlcmFuZ2U6ZTZiMDFiNzE1YTBmNGM2ZTk5MTU2MzBlMWU3MTgxYjBfNy0xLTEtMS0xMDY1_d2339639-ca27-4b64-8e8e-766b28415177">737</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia87f608d482b4ef79558f90ef1ef2a3e_D20200401-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184OC9mcmFnOjMwNmExZTg1ZTI5NDQ5N2JiZDQxZDY0YzFiZGNhNzE1L3RhYmxlOmU2YjAxYjcxNWEwZjRjNmU5OTE1NjMwZTFlNzE4MWIwL3RhYmxlcmFuZ2U6ZTZiMDFiNzE1YTBmNGM2ZTk5MTU2MzBlMWU3MTgxYjBfNy0zLTEtMS0xMDY1_81fc1d73-ad1c-4fc5-8e05-e7af63c1966b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10ed9cb15f3c48d395885e32db2ca4ff_D20210101-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184OC9mcmFnOjMwNmExZTg1ZTI5NDQ5N2JiZDQxZDY0YzFiZGNhNzE1L3RhYmxlOmU2YjAxYjcxNWEwZjRjNmU5OTE1NjMwZTFlNzE4MWIwL3RhYmxlcmFuZ2U6ZTZiMDFiNzE1YTBmNGM2ZTk5MTU2MzBlMWU3MTgxYjBfNy0xLTEtMS0w_e332cfb3-514b-4b31-9dce-20c9b0a558d0">980</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f822367a8c44dd79b4a10071eae6fb0_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184OC9mcmFnOjMwNmExZTg1ZTI5NDQ5N2JiZDQxZDY0YzFiZGNhNzE1L3RhYmxlOmU2YjAxYjcxNWEwZjRjNmU5OTE1NjMwZTFlNzE4MWIwL3RhYmxlcmFuZ2U6ZTZiMDFiNzE1YTBmNGM2ZTk5MTU2MzBlMWU3MTgxYjBfNy0zLTEtMS0w_d57aa469-59fb-4097-8aa1-9e1fa8738b0a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total compensation expense by award type</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184OC9mcmFnOjMwNmExZTg1ZTI5NDQ5N2JiZDQxZDY0YzFiZGNhNzE1L3RhYmxlOmU2YjAxYjcxNWEwZjRjNmU5OTE1NjMwZTFlNzE4MWIwL3RhYmxlcmFuZ2U6ZTZiMDFiNzE1YTBmNGM2ZTk5MTU2MzBlMWU3MTgxYjBfOC0xLTEtMS0xMDY5_5033e433-e00b-4903-9173-0e628e7a875b">3,653</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184OC9mcmFnOjMwNmExZTg1ZTI5NDQ5N2JiZDQxZDY0YzFiZGNhNzE1L3RhYmxlOmU2YjAxYjcxNWEwZjRjNmU5OTE1NjMwZTFlNzE4MWIwL3RhYmxlcmFuZ2U6ZTZiMDFiNzE1YTBmNGM2ZTk5MTU2MzBlMWU3MTgxYjBfOC0zLTEtMS0xMDY5_bcbcd67d-3f0f-43dd-991b-ad025f91b9e1">3,703</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184OC9mcmFnOjMwNmExZTg1ZTI5NDQ5N2JiZDQxZDY0YzFiZGNhNzE1L3RhYmxlOmU2YjAxYjcxNWEwZjRjNmU5OTE1NjMwZTFlNzE4MWIwL3RhYmxlcmFuZ2U6ZTZiMDFiNzE1YTBmNGM2ZTk5MTU2MzBlMWU3MTgxYjBfOC0xLTEtMS0w_743183ef-15f7-4f7f-9e0d-ee577c9588da">7,359</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184OC9mcmFnOjMwNmExZTg1ZTI5NDQ5N2JiZDQxZDY0YzFiZGNhNzE1L3RhYmxlOmU2YjAxYjcxNWEwZjRjNmU5OTE1NjMwZTFlNzE4MWIwL3RhYmxlcmFuZ2U6ZTZiMDFiNzE1YTBmNGM2ZTk5MTU2MzBlMWU3MTgxYjBfOC0zLTEtMS0w_d9f6d412-61fb-499d-9ce3-1a0a6b26149f">7,211</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Line Item</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenue</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc22f08766584f8c91a9b4972f0f9f89_D20210401-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184OC9mcmFnOjMwNmExZTg1ZTI5NDQ5N2JiZDQxZDY0YzFiZGNhNzE1L3RhYmxlOmU2YjAxYjcxNWEwZjRjNmU5OTE1NjMwZTFlNzE4MWIwL3RhYmxlcmFuZ2U6ZTZiMDFiNzE1YTBmNGM2ZTk5MTU2MzBlMWU3MTgxYjBfMTEtMS0xLTEtMTA4MA_4c900306-af0b-42fd-ad20-825a1ac9e8de">892</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib32f2800c3f24f0ca601b1fd026b593b_D20200401-20200630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184OC9mcmFnOjMwNmExZTg1ZTI5NDQ5N2JiZDQxZDY0YzFiZGNhNzE1L3RhYmxlOmU2YjAxYjcxNWEwZjRjNmU5OTE1NjMwZTFlNzE4MWIwL3RhYmxlcmFuZ2U6ZTZiMDFiNzE1YTBmNGM2ZTk5MTU2MzBlMWU3MTgxYjBfMTEtMy0xLTEtMTA4MA_e76d6d1a-8a43-4a09-9a0f-73d7a8e9ef48">526</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b0398298a1d4101bfdde0a27cfc4235_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184OC9mcmFnOjMwNmExZTg1ZTI5NDQ5N2JiZDQxZDY0YzFiZGNhNzE1L3RhYmxlOmU2YjAxYjcxNWEwZjRjNmU5OTE1NjMwZTFlNzE4MWIwL3RhYmxlcmFuZ2U6ZTZiMDFiNzE1YTBmNGM2ZTk5MTU2MzBlMWU3MTgxYjBfMTEtMS0xLTEtMA_d5b2f9bd-32e0-4abe-a86a-2a0f67f48fc7">1,487</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78cdc5087ee24e2e99b2216043b5b6b1_D20200101-20200630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184OC9mcmFnOjMwNmExZTg1ZTI5NDQ5N2JiZDQxZDY0YzFiZGNhNzE1L3RhYmxlOmU2YjAxYjcxNWEwZjRjNmU5OTE1NjMwZTFlNzE4MWIwL3RhYmxlcmFuZ2U6ZTZiMDFiNzE1YTBmNGM2ZTk5MTU2MzBlMWU3MTgxYjBfMTEtMy0xLTEtMA_33c38f84-22d2-4a93-8a9e-8bb51abcab74">918</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i7a30c504f8324617a99b557dbeaf7f00"><div style="margin-top:5pt;text-align:justify"><ix:continuation id="ic1cb95e37aae498984ba827c8860af46"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:288.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f345cc1972943b9a0ae90973779501d_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184OC9mcmFnOjMwNmExZTg1ZTI5NDQ5N2JiZDQxZDY0YzFiZGNhNzE1L3RhYmxlOmU2YjAxYjcxNWEwZjRjNmU5OTE1NjMwZTFlNzE4MWIwL3RhYmxlcmFuZ2U6ZTZiMDFiNzE1YTBmNGM2ZTk5MTU2MzBlMWU3MTgxYjBfMTItMS0xLTEtMTA3Ng_6c609cda-92c0-4794-a0e8-cc5f45c815c7">2,761</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40db2f18e67e43439f94c81d84f13d6b_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184OC9mcmFnOjMwNmExZTg1ZTI5NDQ5N2JiZDQxZDY0YzFiZGNhNzE1L3RhYmxlOmU2YjAxYjcxNWEwZjRjNmU5OTE1NjMwZTFlNzE4MWIwL3RhYmxlcmFuZ2U6ZTZiMDFiNzE1YTBmNGM2ZTk5MTU2MzBlMWU3MTgxYjBfMTItMy0xLTEtMTA3Ng_47891a44-f96d-4b02-b935-501c83faddc1">3,177</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1c09fd265c44ccdbf4d6a40f41ce5f1_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184OC9mcmFnOjMwNmExZTg1ZTI5NDQ5N2JiZDQxZDY0YzFiZGNhNzE1L3RhYmxlOmU2YjAxYjcxNWEwZjRjNmU5OTE1NjMwZTFlNzE4MWIwL3RhYmxlcmFuZ2U6ZTZiMDFiNzE1YTBmNGM2ZTk5MTU2MzBlMWU3MTgxYjBfMTItMS0xLTEtMA_90698cef-e3bd-464b-bdfd-aa4ebb6579d9">5,872</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id05098869b4b4201a380d4ccd404ff02_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184OC9mcmFnOjMwNmExZTg1ZTI5NDQ5N2JiZDQxZDY0YzFiZGNhNzE1L3RhYmxlOmU2YjAxYjcxNWEwZjRjNmU5OTE1NjMwZTFlNzE4MWIwL3RhYmxlcmFuZ2U6ZTZiMDFiNzE1YTBmNGM2ZTk5MTU2MzBlMWU3MTgxYjBfMTItMy0xLTEtMA_3eb469fd-0170-4b7b-9731-439b840e0933">6,293</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total compensation expense by financial statement line item</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184OC9mcmFnOjMwNmExZTg1ZTI5NDQ5N2JiZDQxZDY0YzFiZGNhNzE1L3RhYmxlOmU2YjAxYjcxNWEwZjRjNmU5OTE1NjMwZTFlNzE4MWIwL3RhYmxlcmFuZ2U6ZTZiMDFiNzE1YTBmNGM2ZTk5MTU2MzBlMWU3MTgxYjBfMTMtMS0xLTEtMTA3Ng_3b64ce9e-9721-49f6-b1f9-77edafac45a2">3,653</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184OC9mcmFnOjMwNmExZTg1ZTI5NDQ5N2JiZDQxZDY0YzFiZGNhNzE1L3RhYmxlOmU2YjAxYjcxNWEwZjRjNmU5OTE1NjMwZTFlNzE4MWIwL3RhYmxlcmFuZ2U6ZTZiMDFiNzE1YTBmNGM2ZTk5MTU2MzBlMWU3MTgxYjBfMTMtMy0xLTEtMTA3Ng_775845d7-6492-444c-b8a2-786ae9512b54">3,703</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184OC9mcmFnOjMwNmExZTg1ZTI5NDQ5N2JiZDQxZDY0YzFiZGNhNzE1L3RhYmxlOmU2YjAxYjcxNWEwZjRjNmU5OTE1NjMwZTFlNzE4MWIwL3RhYmxlcmFuZ2U6ZTZiMDFiNzE1YTBmNGM2ZTk5MTU2MzBlMWU3MTgxYjBfMTMtMS0xLTEtMA_743183ef-15f7-4f7f-9e0d-ee577c9588da">7,359</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184OC9mcmFnOjMwNmExZTg1ZTI5NDQ5N2JiZDQxZDY0YzFiZGNhNzE1L3RhYmxlOmU2YjAxYjcxNWEwZjRjNmU5OTE1NjMwZTFlNzE4MWIwL3RhYmxlcmFuZ2U6ZTZiMDFiNzE1YTBmNGM2ZTk5MTU2MzBlMWU3MTgxYjBfMTMtMy0xLTEtMA_d9f6d412-61fb-499d-9ce3-1a0a6b26149f">7,211</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184OC9mcmFnOjMwNmExZTg1ZTI5NDQ5N2JiZDQxZDY0YzFiZGNhNzE1L3RleHRyZWdpb246MzA2YTFlODVlMjk0NDk3YmJkNDFkNjRjMWJkY2E3MTVfMTcy_661e97a9-2555-46e1-98c4-5c1a9ee79f0b"><ix:nonFraction unitRef="usd" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184OC9mcmFnOjMwNmExZTg1ZTI5NDQ5N2JiZDQxZDY0YzFiZGNhNzE1L3RleHRyZWdpb246MzA2YTFlODVlMjk0NDk3YmJkNDFkNjRjMWJkY2E3MTVfMTcy_a907ad86-4b19-4070-ab57-65ddd67bda84"><ix:nonFraction unitRef="usd" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184OC9mcmFnOjMwNmExZTg1ZTI5NDQ5N2JiZDQxZDY0YzFiZGNhNzE1L3RleHRyZWdpb246MzA2YTFlODVlMjk0NDk3YmJkNDFkNjRjMWJkY2E3MTVfMTcy_f4ad6c1c-db16-49f9-a390-624186b8c07d"><ix:nonFraction unitRef="usd" contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184OC9mcmFnOjMwNmExZTg1ZTI5NDQ5N2JiZDQxZDY0YzFiZGNhNzE1L3RleHRyZWdpb246MzA2YTFlODVlMjk0NDk3YmJkNDFkNjRjMWJkY2E3MTVfMTcy_fee81476-d82d-45e4-a7b9-8131d35c1f78">No</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> stock-based compensation was capitalized as software development costs for the three and six months ended June 30, 2021 and 2020.</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" name="us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184OC9mcmFnOjMwNmExZTg1ZTI5NDQ5N2JiZDQxZDY0YzFiZGNhNzE1L3RleHRyZWdpb246MzA2YTFlODVlMjk0NDk3YmJkNDFkNjRjMWJkY2E3MTVfMzY1_70440d90-1cc1-4a0d-b583-a4a37afa1702" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based awards were granted for the three and six months ended June 30, 2021 and 2020 as follows (in thousands):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:327.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id632fa3ae3914b9da8bf15e4c54b6686_D20210401-20210630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184OC9mcmFnOjMwNmExZTg1ZTI5NDQ5N2JiZDQxZDY0YzFiZGNhNzE1L3RhYmxlOjUwNmQ2ZDMyZTM2MzRhOTM4Mjk5MGMyMTRkYzA5ZmEyL3RhYmxlcmFuZ2U6NTA2ZDZkMzJlMzYzNGE5MzgyOTkwYzIxNGRjMDlmYTJfMi0xLTEtMS0xMDkx_ad4a1b94-0606-4e8f-8d74-47331586efb6">89</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i89e74efc56994c9ebb87c2b0e7cd1128_D20200401-20200630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184OC9mcmFnOjMwNmExZTg1ZTI5NDQ5N2JiZDQxZDY0YzFiZGNhNzE1L3RhYmxlOjUwNmQ2ZDMyZTM2MzRhOTM4Mjk5MGMyMTRkYzA5ZmEyL3RhYmxlcmFuZ2U6NTA2ZDZkMzJlMzYzNGE5MzgyOTkwYzIxNGRjMDlmYTJfMi0zLTEtMS0xMDkx_7f7221d5-0982-4868-b8fe-fde962b29fd3">164</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6660233c9d6b4e96811be968402ad42c_D20210101-20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184OC9mcmFnOjMwNmExZTg1ZTI5NDQ5N2JiZDQxZDY0YzFiZGNhNzE1L3RhYmxlOjUwNmQ2ZDMyZTM2MzRhOTM4Mjk5MGMyMTRkYzA5ZmEyL3RhYmxlcmFuZ2U6NTA2ZDZkMzJlMzYzNGE5MzgyOTkwYzIxNGRjMDlmYTJfMi0xLTEtMS0w_5f020b3f-0944-4015-8c8d-d763a1f4274e">1,028</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idc0d9ae125db467ab0d22698986a0481_D20200101-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184OC9mcmFnOjMwNmExZTg1ZTI5NDQ5N2JiZDQxZDY0YzFiZGNhNzE1L3RhYmxlOjUwNmQ2ZDMyZTM2MzRhOTM4Mjk5MGMyMTRkYzA5ZmEyL3RhYmxlcmFuZ2U6NTA2ZDZkMzJlMzYzNGE5MzgyOTkwYzIxNGRjMDlmYTJfMi0zLTEtMS0w_a619bc5b-419e-4222-842c-ae3d7365472a">1,140</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PSUs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i16f26157e03a422b8390af0e74420d0a_D20210401-20210630" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184OC9mcmFnOjMwNmExZTg1ZTI5NDQ5N2JiZDQxZDY0YzFiZGNhNzE1L3RhYmxlOjUwNmQ2ZDMyZTM2MzRhOTM4Mjk5MGMyMTRkYzA5ZmEyL3RhYmxlcmFuZ2U6NTA2ZDZkMzJlMzYzNGE5MzgyOTkwYzIxNGRjMDlmYTJfMy0xLTEtMS0xMDkx_63510937-f169-4213-9b01-b1c203e5b1eb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia87f608d482b4ef79558f90ef1ef2a3e_D20200401-20200630" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184OC9mcmFnOjMwNmExZTg1ZTI5NDQ5N2JiZDQxZDY0YzFiZGNhNzE1L3RhYmxlOjUwNmQ2ZDMyZTM2MzRhOTM4Mjk5MGMyMTRkYzA5ZmEyL3RhYmxlcmFuZ2U6NTA2ZDZkMzJlMzYzNGE5MzgyOTkwYzIxNGRjMDlmYTJfMy0zLTEtMS0xMDkx_ea9e177a-7120-48e6-8007-c59cd0a42f4e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i10ed9cb15f3c48d395885e32db2ca4ff_D20210101-20210630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184OC9mcmFnOjMwNmExZTg1ZTI5NDQ5N2JiZDQxZDY0YzFiZGNhNzE1L3RhYmxlOjUwNmQ2ZDMyZTM2MzRhOTM4Mjk5MGMyMTRkYzA5ZmEyL3RhYmxlcmFuZ2U6NTA2ZDZkMzJlMzYzNGE5MzgyOTkwYzIxNGRjMDlmYTJfMy0xLTEtMS0w_379c735b-2c39-423a-93dc-643eb1117c16">319</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6f822367a8c44dd79b4a10071eae6fb0_D20200101-20200630" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184OC9mcmFnOjMwNmExZTg1ZTI5NDQ5N2JiZDQxZDY0YzFiZGNhNzE1L3RhYmxlOjUwNmQ2ZDMyZTM2MzRhOTM4Mjk5MGMyMTRkYzA5ZmEyL3RhYmxlcmFuZ2U6NTA2ZDZkMzJlMzYzNGE5MzgyOTkwYzIxNGRjMDlmYTJfMy0zLTEtMS0w_13d30bde-f386-4b11-9f1f-0e8377e3b75b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if7b4268f6d62460d95263ea3eab82df8_D20210401-20210630" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184OC9mcmFnOjMwNmExZTg1ZTI5NDQ5N2JiZDQxZDY0YzFiZGNhNzE1L3RhYmxlOjUwNmQ2ZDMyZTM2MzRhOTM4Mjk5MGMyMTRkYzA5ZmEyL3RhYmxlcmFuZ2U6NTA2ZDZkMzJlMzYzNGE5MzgyOTkwYzIxNGRjMDlmYTJfNC0xLTEtMS0xMDkx_8a1657f8-a375-42ba-8f5c-bc8ca86a038f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i28477571d61a49d68ac8b8802530ba46_D20200401-20200630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184OC9mcmFnOjMwNmExZTg1ZTI5NDQ5N2JiZDQxZDY0YzFiZGNhNzE1L3RhYmxlOjUwNmQ2ZDMyZTM2MzRhOTM4Mjk5MGMyMTRkYzA5ZmEyL3RhYmxlcmFuZ2U6NTA2ZDZkMzJlMzYzNGE5MzgyOTkwYzIxNGRjMDlmYTJfNC0zLTEtMS0xMDkx_18723230-7c04-4a54-9362-a95473636a60">140</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibce4d97bacd94dfaa609647fcaf23ca0_D20210101-20210630" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184OC9mcmFnOjMwNmExZTg1ZTI5NDQ5N2JiZDQxZDY0YzFiZGNhNzE1L3RhYmxlOjUwNmQ2ZDMyZTM2MzRhOTM4Mjk5MGMyMTRkYzA5ZmEyL3RhYmxlcmFuZ2U6NTA2ZDZkMzJlMzYzNGE5MzgyOTkwYzIxNGRjMDlmYTJfNC0xLTEtMS0w_ce6f10a7-71dc-44b9-8c88-20ef5d562013">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie162b42e78994c30b638363b2e6da8a0_D20200101-20200630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184OC9mcmFnOjMwNmExZTg1ZTI5NDQ5N2JiZDQxZDY0YzFiZGNhNzE1L3RhYmxlOjUwNmQ2ZDMyZTM2MzRhOTM4Mjk5MGMyMTRkYzA5ZmEyL3RhYmxlcmFuZ2U6NTA2ZDZkMzJlMzYzNGE5MzgyOTkwYzIxNGRjMDlmYTJfNC0zLTEtMS0w_6f2516dc-312f-40a3-a41f-10e72d8b6e18">520</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="id8f403494d0a42c2868794fb470218fc_100"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 15.  </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMDAvZnJhZzozNDdhMDIyZDc3MzE0MzFjYWI3YjMxYTI3ZDAyYTMzMS90ZXh0cmVnaW9uOjM0N2EwMjJkNzczMTQzMWNhYjdiMzFhMjdkMDJhMzMxXzE3MTA_b5dff576-69ac-451a-a322-4c9c9d142f17" continuedAt="i9c0e43c6e370403e9ed4e7eb28b401b0" escape="true">Income Taxes</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i9c0e43c6e370403e9ed4e7eb28b401b0"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For interim periods, we recognize an income tax provision (benefit) based on our estimated annual effective tax rate expected for the full year.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An income tax expense (benefit) of $<ix:nonFraction unitRef="usd" contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMDAvZnJhZzozNDdhMDIyZDc3MzE0MzFjYWI3YjMxYTI3ZDAyYTMzMS90ZXh0cmVnaW9uOjM0N2EwMjJkNzczMTQzMWNhYjdiMzFhMjdkMDJhMzMxXzEwOTk1MTE2Mzc0MTk_a1f80ec6-f5d4-4d4c-9268-f298665409aa">0.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMDAvZnJhZzozNDdhMDIyZDc3MzE0MzFjYWI3YjMxYTI3ZDAyYTMzMS90ZXh0cmVnaW9uOjM0N2EwMjJkNzczMTQzMWNhYjdiMzFhMjdkMDJhMzMxXzEwOTk1MTE2MzczODg_7c17c70a-35ed-421e-b0c9-9e52df0dc50b">0.7</ix:nonFraction>&#160;million was recognized for the three and six months ended June 30, 2021, respectively, which resulted in effective tax rates of (<ix:nonFraction unitRef="number" contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMDAvZnJhZzozNDdhMDIyZDc3MzE0MzFjYWI3YjMxYTI3ZDAyYTMzMS90ZXh0cmVnaW9uOjM0N2EwMjJkNzczMTQzMWNhYjdiMzFhMjdkMDJhMzMxXzMzNw_a0bacc13-8526-451a-af22-72cd237f09cf">1.0</ix:nonFraction>)% and (<ix:nonFraction unitRef="number" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMDAvZnJhZzozNDdhMDIyZDc3MzE0MzFjYWI3YjMxYTI3ZDAyYTMzMS90ZXh0cmVnaW9uOjM0N2EwMjJkNzczMTQzMWNhYjdiMzFhMjdkMDJhMzMxXzEwOTk1MTE2MzY0NzI_a5331a26-b086-4fc0-ba23-4d3879b8bf64">3.6</ix:nonFraction>)%, respectively. An income tax expense (benefit) of $(<ix:nonFraction unitRef="usd" contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630" decimals="-5" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMDAvZnJhZzozNDdhMDIyZDc3MzE0MzFjYWI3YjMxYTI3ZDAyYTMzMS90ZXh0cmVnaW9uOjM0N2EwMjJkNzczMTQzMWNhYjdiMzFhMjdkMDJhMzMxXzEwOTk1MTE2Mzc0NDg_82c4c2cf-8089-4344-a7e5-d6bb56dd7f29">3.9</ix:nonFraction>)&#160;million and $(<ix:nonFraction unitRef="usd" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="-5" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMDAvZnJhZzozNDdhMDIyZDc3MzE0MzFjYWI3YjMxYTI3ZDAyYTMzMS90ZXh0cmVnaW9uOjM0N2EwMjJkNzczMTQzMWNhYjdiMzFhMjdkMDJhMzMxXzE2NDkyNjc0NDM2Njg_4dd9d096-5c6f-4766-a88f-ae5d12e5f72e">3.6</ix:nonFraction>)&#160;million was recognized for the three and six months ended June 30, 2020, respectively, which resulted in effective tax rates of <ix:nonFraction unitRef="number" contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMDAvZnJhZzozNDdhMDIyZDc3MzE0MzFjYWI3YjMxYTI3ZDAyYTMzMS90ZXh0cmVnaW9uOjM0N2EwMjJkNzczMTQzMWNhYjdiMzFhMjdkMDJhMzMxXzEwOTk1MTE2MzY0Njg_3a3da38e-8d5c-43cd-b819-e372243f68a4">1.9</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMDAvZnJhZzozNDdhMDIyZDc3MzE0MzFjYWI3YjMxYTI3ZDAyYTMzMS90ZXh0cmVnaW9uOjM0N2EwMjJkNzczMTQzMWNhYjdiMzFhMjdkMDJhMzMxXzE2NDkyNjc0NDM2OTA_e669ebcf-adc4-4ecf-bbb3-d996bd3727c1">1.3</ix:nonFraction>%, respectively. The Company and its U.S. subsidiaries continue to record a valuation allowance against its net deferred tax assets, with the exception of indefinite lived components. The income tax expense recorded during the three and six months ended June 30, 2021 primarily relates to foreign taxes.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December&#160;31, 2020, the Company had unrecognized tax benefits of $<ix:nonFraction unitRef="usd" contextRef="i45bff335c1434d6ba44132da1b0557db_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMDAvZnJhZzozNDdhMDIyZDc3MzE0MzFjYWI3YjMxYTI3ZDAyYTMzMS90ZXh0cmVnaW9uOjM0N2EwMjJkNzczMTQzMWNhYjdiMzFhMjdkMDJhMzMxXzc5MA_e0efc6be-a956-4d6b-840c-1df58ed36ae1">0.7</ix:nonFraction> million that, if recognized, would not affect the effective tax rate due to the valuation allowance against its net deferred tax asset. As of June&#160;30, 2021, there are no changes to the unrecognized tax benefits. The Company is not currently subject to income tax audits in any U.S., state, or foreign jurisdictions for any tax year.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Tax Receivables Agreement</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Offering Reorganization, the Company entered into the TRA with certain of its investors, which provides for the payment by the Company to these investors of <ix:nonFraction unitRef="number" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="INF" name="evh:TaxReceivableAgreementPercentofCashSavingsPaidtoShareholders" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMDAvZnJhZzozNDdhMDIyZDc3MzE0MzFjYWI3YjMxYTI3ZDAyYTMzMS90ZXh0cmVnaW9uOjM0N2EwMjJkNzczMTQzMWNhYjdiMzFhMjdkMDJhMzMxXzEzMTU_399ab6bd-a501-469d-b989-d57b3c94485e">85</ix:nonFraction>% of the amount of the tax benefits, if any, that the Company is deemed to realize as a result of increases in our tax basis related to exchanges of Class B common units as well as tax benefits attributable to the future utilization of pre-IPO NOLs. See Note 11 above and &#8220;Part II - Item 8. Financial Statements and Supplementary Data - Note 14&#8221; in our 2020 Form 10-K for discussion of our TRA.</span></div></ix:continuation><div><span><br/></span></div><div id="id8f403494d0a42c2868794fb470218fc_106"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 16.  <ix:nonNumeric contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" name="us-gaap:EquityMethodInvestmentsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMDYvZnJhZzpmZWU5YjQ5ZGNlNmM0NmUxYjRlMzYyZmY1YTM5YmVmYS90ZXh0cmVnaW9uOmZlZTliNDlkY2U2YzQ2ZTFiNGUzNjJmZjVhMzliZWZhXzIxNDM_c7b3e974-21a3-46c3-8217-bf781deadc02" continuedAt="ib1af92c294e44beabdf4786dc5db088d" escape="true">Investments in and Advances to Equity Method Investees</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="ib1af92c294e44beabdf4786dc5db088d" continuedAt="idd3c028dbde445ceafe46f257a9b9adf"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company holds ownership interests in joint ventures and other entities which are accounted for under the equity method. The Company evaluates its interests in these entities to determine whether they meet the definition of a VIE and whether the Company is required to consolidate these entities. A VIE is consolidated by its primary beneficiary, which is the party that has both (i) the power to direct the activities that most significantly impact the economic performance of the VIE and (ii) a variable interest that could potentially be significant to the VIE. To determine whether or not a variable interest the Company holds could potentially be significant to the VIE, the Company considers both qualitative and quantitative factors regarding the nature, size and form of the Company's involvement with the VIE. The Company has determined that its interests in these entities meet the definition of a variable interest, however, the Company is not the primary beneficiary since it does not have the power to direct activities, therefore, the Company did not consolidate the VIEs.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of&#160;June&#160;30, 2021 and December&#160;31, 2020, the Company&#8217;s economic interests in its equity method investments ranged between <ix:nonFraction unitRef="number" contextRef="if20f8ae5705c41f6910dff16d8c55578_I20210630" decimals="2" name="evh:EquityMethodInvestmentEconomicInterestPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMDYvZnJhZzpmZWU5YjQ5ZGNlNmM0NmUxYjRlMzYyZmY1YTM5YmVmYS90ZXh0cmVnaW9uOmZlZTliNDlkY2U2YzQ2ZTFiNGUzNjJmZjVhMzliZWZhXzEyNjA_318d0559-b035-4181-9cef-9921909afc5a">4</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i9b662261daa24dd0829c6be06dc0975d_I20210630" decimals="2" name="evh:EquityMethodInvestmentEconomicInterestPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMDYvZnJhZzpmZWU5YjQ5ZGNlNmM0NmUxYjRlMzYyZmY1YTM5YmVmYS90ZXh0cmVnaW9uOmZlZTliNDlkY2U2YzQ2ZTFiNGUzNjJmZjVhMzliZWZhXzEyNjc_55f86a28-1488-40f5-b01d-4e7b651b2c44">39</ix:nonFraction>%, and <ix:nonFraction unitRef="number" contextRef="i3a67432b3a04429fb74ea67ee7476cc1_I20201231" decimals="2" name="evh:EquityMethodInvestmentEconomicInterestPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMDYvZnJhZzpmZWU5YjQ5ZGNlNmM0NmUxYjRlMzYyZmY1YTM5YmVmYS90ZXh0cmVnaW9uOmZlZTliNDlkY2U2YzQ2ZTFiNGUzNjJmZjVhMzliZWZhXzEyNzU_6a29f785-9e4d-4827-8511-ce8119c80795">4</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i644686c1853d44d8bed17fe7241635c7_I20201231" decimals="2" name="evh:EquityMethodInvestmentEconomicInterestPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMDYvZnJhZzpmZWU5YjQ5ZGNlNmM0NmUxYjRlMzYyZmY1YTM5YmVmYS90ZXh0cmVnaW9uOmZlZTliNDlkY2U2YzQ2ZTFiNGUzNjJmZjVhMzliZWZhXzEyODI_763f3fd4-1b29-400c-98d5-a0b1fb951751">38</ix:nonFraction>%, respectively, and voting interests in its equity method investments ranged between <ix:nonFraction unitRef="number" contextRef="if20f8ae5705c41f6910dff16d8c55578_I20210630" decimals="2" name="evh:EquityMethodInvestmentVotingInterestPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMDYvZnJhZzpmZWU5YjQ5ZGNlNmM0NmUxYjRlMzYyZmY1YTM5YmVmYS90ZXh0cmVnaW9uOmZlZTliNDlkY2U2YzQ2ZTFiNGUzNjJmZjVhMzliZWZhXzEzNjk_725b8134-23cd-43a6-af7d-b3fd53273d68">25</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i9b662261daa24dd0829c6be06dc0975d_I20210630" decimals="3" name="evh:EquityMethodInvestmentVotingInterestPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMDYvZnJhZzpmZWU5YjQ5ZGNlNmM0NmUxYjRlMzYyZmY1YTM5YmVmYS90ZXh0cmVnaW9uOmZlZTliNDlkY2U2YzQ2ZTFiNGUzNjJmZjVhMzliZWZhXzEzNzY_90123630-15a3-4f0d-afac-058c34c9b1c9">40</ix:nonFraction>%, respectively. The Company determined that it has significant influence over these entities but that it does not have control over any of the entities. Accordingly, the investments are accounted for under the equity method of accounting and the Company is allocated its proportional share of the entities&#8217; earnings and losses for each reporting period. The Company&#8217;s proportional share of the (gain) losses </span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="idd3c028dbde445ceafe46f257a9b9adf"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">from these investments was approximately $<ix:nonFraction unitRef="usd" contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMDYvZnJhZzpmZWU5YjQ5ZGNlNmM0NmUxYjRlMzYyZmY1YTM5YmVmYS90ZXh0cmVnaW9uOmZlZTliNDlkY2U2YzQ2ZTFiNGUzNjJmZjVhMzliZWZhXzE2NDkyNjc0NDM5MTU_b08fd07f-2d2e-4aba-b3a2-8f2a0c9eb17c">4.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMDYvZnJhZzpmZWU5YjQ5ZGNlNmM0NmUxYjRlMzYyZmY1YTM5YmVmYS90ZXh0cmVnaW9uOmZlZTliNDlkY2U2YzQ2ZTFiNGUzNjJmZjVhMzliZWZhXzE4Mjc_53b01344-0002-4a78-ab6c-3ef6a729e6fa">12.7</ix:nonFraction> million for the three and six months ended June 30, 2021, respectively, and $<ix:nonFraction unitRef="usd" contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMDYvZnJhZzpmZWU5YjQ5ZGNlNmM0NmUxYjRlMzYyZmY1YTM5YmVmYS90ZXh0cmVnaW9uOmZlZTliNDlkY2U2YzQ2ZTFiNGUzNjJmZjVhMzliZWZhXzE2NDkyNjc0NDM4OTU_c05e69de-ab65-43cc-ae7b-86d6ce2db612">25.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMDYvZnJhZzpmZWU5YjQ5ZGNlNmM0NmUxYjRlMzYyZmY1YTM5YmVmYS90ZXh0cmVnaW9uOmZlZTliNDlkY2U2YzQ2ZTFiNGUzNjJmZjVhMzliZWZhXzE4MzQ_6c1c6321-7459-4efc-af48-ed6581b82eb1">24.7</ix:nonFraction> million for the three and six months ended June 30, 2020, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company signed services agreements with certain of the aforementioned entities to provide certain management, operational and support services to help manage elements of their service offerings. Revenue related to these services agreements were $<ix:nonFraction unitRef="usd" contextRef="i53efb4309a7d432c9067d4fceb38e1e9_D20210401-20210630" decimals="-5" format="ixt:numdotdecimal" name="evh:IncomeLossfromEquityMethodInvestmentsServicesAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMDYvZnJhZzpmZWU5YjQ5ZGNlNmM0NmUxYjRlMzYyZmY1YTM5YmVmYS90ZXh0cmVnaW9uOmZlZTliNDlkY2U2YzQ2ZTFiNGUzNjJmZjVhMzliZWZhXzE2NDkyNjc0NDM4ODQ_e1af342c-1356-4ffa-9f12-2288a7792a31">2.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i0191a974415646adb1cd9c25e726b3a2_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="evh:IncomeLossfromEquityMethodInvestmentsServicesAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMDYvZnJhZzpmZWU5YjQ5ZGNlNmM0NmUxYjRlMzYyZmY1YTM5YmVmYS90ZXh0cmVnaW9uOmZlZTliNDlkY2U2YzQ2ZTFiNGUzNjJmZjVhMzliZWZhXzIxMDk_2d75bb1c-01a9-4737-ab09-45b79fb3ea00">8.6</ix:nonFraction> million for the three and six months ended June 30, 2021, respectively, and $<ix:nonFraction unitRef="usd" contextRef="i008ff0c503394e539acc7adba9224bd0_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="evh:IncomeLossfromEquityMethodInvestmentsServicesAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMDYvZnJhZzpmZWU5YjQ5ZGNlNmM0NmUxYjRlMzYyZmY1YTM5YmVmYS90ZXh0cmVnaW9uOmZlZTliNDlkY2U2YzQ2ZTFiNGUzNjJmZjVhMzliZWZhXzE2NDkyNjc0NDM4NzI_9a89d096-e62b-4b2f-a32d-f7e3d5e81309">71.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i9e9654e025214c9b8e664574e724a4f5_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="evh:IncomeLossfromEquityMethodInvestmentsServicesAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMDYvZnJhZzpmZWU5YjQ5ZGNlNmM0NmUxYjRlMzYyZmY1YTM5YmVmYS90ZXh0cmVnaW9uOmZlZTliNDlkY2U2YzQ2ZTFiNGUzNjJmZjVhMzliZWZhXzIxMTY_3b6c14f5-68f3-404d-b91f-e44cb43e6e39">131.3</ix:nonFraction> million for the three and six months ended June 30, 2020 , respectively.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="id8f403494d0a42c2868794fb470218fc_109"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 17.  <ix:nonNumeric contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" name="us-gaap:MinorityInterestDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMDkvZnJhZzoyOWExYzMwNzA5ZDc0OGYwOGMyODM1MTBlYmE4NTNmYy90ZXh0cmVnaW9uOjI5YTFjMzA3MDlkNzQ4ZjA4YzI4MzUxMGViYTg1M2ZjXzE0Njc_b4ffb387-bbf8-4514-b9a2-edc56ed19b82" continuedAt="if3dc902929b5479b86c35d40f6045a3a" escape="true">Non-controlling Interests</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="if3dc902929b5479b86c35d40f6045a3a"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immediately following the Offering Reorganization and IPO in May 2015, the Company owned <ix:nonFraction unitRef="number" contextRef="id7302983007d47cf8a4aa6ef74f49b80_I20150531" decimals="3" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMDkvZnJhZzoyOWExYzMwNzA5ZDc0OGYwOGMyODM1MTBlYmE4NTNmYy90ZXh0cmVnaW9uOjI5YTFjMzA3MDlkNzQ4ZjA4YzI4MzUxMGViYTg1M2ZjXzEzMQ_4bca2dc3-f61d-4a4f-a0dc-61c8e34ab5e2">70.3</ix:nonFraction>% of Evolent Health LLC. The Company&#8217;s ownership percentage changes with the issuance of Class A or Class B common stock and Class B Exchanges. In order to account for any changes in the Company&#8217;s ownership of Evolent Health LLC, we record a reclassification of equity between non-controlling interests and shareholders&#8217; equity attributable to Evolent Health, Inc.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2020</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 1, 2020, in connection with the consolidation of EVH Passport, the Company recognized a $<ix:nonFraction unitRef="usd" contextRef="i46248ae6cf2f4c3bb6a08e6b7351403f_D20200901-20200901" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMDkvZnJhZzoyOWExYzMwNzA5ZDc0OGYwOGMyODM1MTBlYmE4NTNmYy90ZXh0cmVnaW9uOjI5YTFjMzA3MDlkNzQ4ZjA4YzI4MzUxMGViYTg1M2ZjXzYwNQ_6020b522-9314-4b83-ba8a-797a64794e85">25.7</ix:nonFraction>&#160;million non-controlling interest for the Sponsors&#8217; <ix:nonFraction unitRef="number" contextRef="i46248ae6cf2f4c3bb6a08e6b7351403f_D20200901-20200901" decimals="2" name="us-gaap:VariableInterestEntityOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMDkvZnJhZzoyOWExYzMwNzA5ZDc0OGYwOGMyODM1MTBlYmE4NTNmYy90ZXh0cmVnaW9uOjI5YTFjMzA3MDlkNzQ4ZjA4YzI4MzUxMGViYTg1M2ZjXzY1MQ_2c377697-39f9-4533-9fd6-cb90a2d734a5">30</ix:nonFraction>% equity interest in EVH Passport which represented the fair value of the non-controlling interest as of the date of consolidation. Pursuant to the shareholders&#8217; agreement with the Sponsors, the Company was required to acquire the Sponsors&#8217; <ix:nonFraction unitRef="number" contextRef="i46248ae6cf2f4c3bb6a08e6b7351403f_D20200901-20200901" decimals="2" name="us-gaap:VariableInterestEntityOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMDkvZnJhZzoyOWExYzMwNzA5ZDc0OGYwOGMyODM1MTBlYmE4NTNmYy90ZXh0cmVnaW9uOjI5YTFjMzA3MDlkNzQ4ZjA4YzI4MzUxMGViYTg1M2ZjXzg5Mw_51bb75c2-02cc-4ef6-9915-84ab03dd0708">30</ix:nonFraction>% ownership interest for $<ix:nonFraction unitRef="usd" contextRef="i7d32a6bf57a9495e9192581ba6585e10_I20200901" decimals="-5" format="ixt:numdotdecimal" name="evh:VariableInterestEntityNewMedicaidContractNotAwardedRequirementToAcquireOwnershipConsiderationAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMDkvZnJhZzoyOWExYzMwNzA5ZDc0OGYwOGMyODM1MTBlYmE4NTNmYy90ZXh0cmVnaW9uOjI5YTFjMzA3MDlkNzQ4ZjA4YzI4MzUxMGViYTg1M2ZjXzkxOQ_7d03d448-2251-4723-b57c-bad41a65bb8e">20.0</ix:nonFraction>&#160;million on or prior to December 31, 2021. On November 16, 2020, the Company acquired the Sponsors&#8217; <ix:nonFraction unitRef="number" contextRef="i7a8609d202734bc89b28f90cabe48547_D20201116-20201116" decimals="2" name="us-gaap:VariableInterestEntityOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMDkvZnJhZzoyOWExYzMwNzA5ZDc0OGYwOGMyODM1MTBlYmE4NTNmYy90ZXh0cmVnaW9uOjI5YTFjMzA3MDlkNzQ4ZjA4YzI4MzUxMGViYTg1M2ZjXzEwMTM_c7abce8b-9c66-4eb7-8c9d-2dc238a09da1">30</ix:nonFraction>% equity interest and reclassified the non-controlling interests into shareholders&#8217; equity attributable to Evolent Health, Inc. As a result of this transaction, the Company recorded a $<ix:nonFraction unitRef="usd" contextRef="i19b1ea06ce044830b8d288022cd0a41c_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:VariableInterestEntityInitialConsolidationGainOrLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMDkvZnJhZzoyOWExYzMwNzA5ZDc0OGYwOGMyODM1MTBlYmE4NTNmYy90ZXh0cmVnaW9uOjI5YTFjMzA3MDlkNzQ4ZjA4YzI4MzUxMGViYTg1M2ZjXzExOTg_41346c79-7ce3-4b06-a228-90f36788b659">5.7</ix:nonFraction>&#160;million gain on consolidation for the year ended December 31, 2020 in gain (loss) on disposal of assets and consolidation on the consolidated statements of operations.</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" name="evh:ScheduleofChangesinNoncontrollingInterestTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMDkvZnJhZzoyOWExYzMwNzA5ZDc0OGYwOGMyODM1MTBlYmE4NTNmYy90ZXh0cmVnaW9uOjI5YTFjMzA3MDlkNzQ4ZjA4YzI4MzUxMGViYTg1M2ZjXzE0NjQ_6faf4d0c-5f5d-42fa-be8e-28f3333a3d57" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in non-controlling interests (in thousands) for  the six months ended June 30, 2020 was as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:487.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-controlling interests balance as of beginning of period</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcd7068eef4f42b895c0b83d21ea5d2b_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:MinorityInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMDkvZnJhZzoyOWExYzMwNzA5ZDc0OGYwOGMyODM1MTBlYmE4NTNmYy90YWJsZTo4YjBmNTdhY2EyMjY0NzRjYWUxYzY4YjA5NDYyOWFjOS90YWJsZXJhbmdlOjhiMGY1N2FjYTIyNjQ3NGNhZTFjNjhiMDk0NjI5YWM5XzItMy0xLTEtMA_4eb3e443-2ee4-479c-a994-7b2907f1235d">6,889</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification of non-controlling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i215048e9c16a4f348373b4cb1edc7ece_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMDkvZnJhZzoyOWExYzMwNzA5ZDc0OGYwOGMyODM1MTBlYmE4NTNmYy90YWJsZTo4YjBmNTdhY2EyMjY0NzRjYWUxYzY4YjA5NDYyOWFjOS90YWJsZXJhbmdlOjhiMGY1N2FjYTIyNjQ3NGNhZTFjNjhiMDk0NjI5YWM5XzMtMy0xLTEtMA_0b4c990a-ba10-459c-a759-c1451a4e7ae2">6,889</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-controlling interests balance as of end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d6223463ab84fa6a8f5cd35e24c15d7_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:MinorityInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMDkvZnJhZzoyOWExYzMwNzA5ZDc0OGYwOGMyODM1MTBlYmE4NTNmYy90YWJsZTo4YjBmNTdhY2EyMjY0NzRjYWUxYzY4YjA5NDYyOWFjOS90YWJsZXJhbmdlOjhiMGY1N2FjYTIyNjQ3NGNhZTFjNjhiMDk0NjI5YWM5XzQtMy0xLTEtMA_c63633f2-2df4-489a-bf23-cf6260382126">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="id8f403494d0a42c2868794fb470218fc_112"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 18. <ix:nonNumeric contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTIvZnJhZzo2MGVjZWU4OTJmMmQ0Y2UyYjdiNmIzZjI3OGVkZjk3Mi90ZXh0cmVnaW9uOjYwZWNlZTg5MmYyZDRjZTJiN2I2YjNmMjc4ZWRmOTcyXzQ5NDc_1cd017dd-8726-4b75-866a-da3d18af18bd" continuedAt="ide0017f43bb44ba88a2b6a0dd7bbf32f" escape="true"><ix:nonNumeric contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTIvZnJhZzo2MGVjZWU4OTJmMmQ0Y2UyYjdiNmIzZjI3OGVkZjk3Mi90ZXh0cmVnaW9uOjYwZWNlZTg5MmYyZDRjZTJiN2I2YjNmMjc4ZWRmOTcyXzQ5NTY_60f073f5-daad-40dd-aa86-fcd5c101677e" continuedAt="i9b862318dd1d465d9f1222fff2ca4785" escape="true">Fair Value Measurement</ix:nonNumeric></ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="ide0017f43bb44ba88a2b6a0dd7bbf32f" continuedAt="i2534ae356f004360a8c14f9f5ba3a886"><ix:continuation id="i9b862318dd1d465d9f1222fff2ca4785" continuedAt="i8c1bf07541974a16bf8a7cc26a89c194"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GAAP defines fair value as the price that would be received from the sale of an asset or paid to transfer a liability (an exit price) assuming an orderly transaction in the most advantageous market at the measurement date. GAAP also establishes a hierarchical disclosure framework which prioritizes and ranks the level of observability of inputs used in measuring fair value. These tiers include:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 - inputs to the valuation methodology are quoted prices available in active markets for identical instruments as of the reporting date;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 - inputs to the valuation methodology are other than quoted prices in active markets, which are either directly or indirectly observable as of the reporting date and the fair value can be determined through the use of models or other valuation methodologies; and </span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 - inputs to the valuation methodology are unobservable inputs in situations where there is little or no market activity for the asset or liability.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, the level within the fair value hierarchy is based on the lowest level of input that is significant to the fair value measurement. Our assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the particular asset or liability being measured. </span></div></ix:continuation></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i8c1bf07541974a16bf8a7cc26a89c194" continuedAt="i5e8be715bacf44faa9e9cd43c4788e18"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recurring Fair Value Measurements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with GAAP, certain assets and liabilities are required to be recorded at fair value on a recurring basis. <ix:nonNumeric contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTIvZnJhZzo2MGVjZWU4OTJmMmQ0Y2UyYjdiNmIzZjI3OGVkZjk3Mi90ZXh0cmVnaW9uOjYwZWNlZTg5MmYyZDRjZTJiN2I2YjNmMjc4ZWRmOTcyXzQ5NDI_fa650fe2-5684-4130-a277-b7645cd3a3de" continuedAt="ia97d71a44b6c4790a6f542fa3b5d5c47" escape="true"><ix:nonNumeric contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTIvZnJhZzo2MGVjZWU4OTJmMmQ0Y2UyYjdiNmIzZjI3OGVkZjk3Mi90ZXh0cmVnaW9uOjYwZWNlZTg5MmYyZDRjZTJiN2I2YjNmMjc4ZWRmOTcyXzQ5NTg_e167c2d3-6556-44cd-801c-71f97f43dbfe" continuedAt="i8e6f183c56564e0f85415b19e17dcf96" escape="true">The following table summarizes the Company&#8217;s assets and liabilities measured at fair value on a recurring basis as of December&#160;31, 2020 (in thousands):</ix:nonNumeric></ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:continuation id="ia97d71a44b6c4790a6f542fa3b5d5c47" continuedAt="i635eb81e55ec402994efb9f1f70ec260"><ix:continuation id="i8e6f183c56564e0f85415b19e17dcf96" continuedAt="i830d8ef48a974fbab5112d57244c0957"> </ix:continuation></ix:continuation></span></div><ix:continuation id="i635eb81e55ec402994efb9f1f70ec260"><ix:continuation id="i830d8ef48a974fbab5112d57244c0957"><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:325.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bcd87ce6e8140d4b38c9d25b675b6d0_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTIvZnJhZzo2MGVjZWU4OTJmMmQ0Y2UyYjdiNmIzZjI3OGVkZjk3Mi90YWJsZTpkN2E1YmQ4MTg4YzY0NDQ4OGIzY2VjYzk4MTA0N2U1ZS90YWJsZXJhbmdlOmQ3YTViZDgxODhjNjQ0NDg4YjNjZWNjOTgxMDQ3ZTVlXzMtMS0xLTEtMA_bf928738-7405-48fd-af8a-dfe32957da0f">5,877</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8df3a7cd40142e4a7fab99e3da63b6c_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTIvZnJhZzo2MGVjZWU4OTJmMmQ0Y2UyYjdiNmIzZjI3OGVkZjk3Mi90YWJsZTpkN2E1YmQ4MTg4YzY0NDQ4OGIzY2VjYzk4MTA0N2U1ZS90YWJsZXJhbmdlOmQ3YTViZDgxODhjNjQ0NDg4YjNjZWNjOTgxMDQ3ZTVlXzMtMy0xLTEtMA_57cec918-2e51-46f3-8b93-730bee354ebf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic31316c74dad419fa29a95505e9ad56c_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTIvZnJhZzo2MGVjZWU4OTJmMmQ0Y2UyYjdiNmIzZjI3OGVkZjk3Mi90YWJsZTpkN2E1YmQ4MTg4YzY0NDQ4OGIzY2VjYzk4MTA0N2U1ZS90YWJsZXJhbmdlOmQ3YTViZDgxODhjNjQ0NDg4YjNjZWNjOTgxMDQ3ZTVlXzMtNS0xLTEtMA_f418ae08-8fac-48a5-846f-c1ec86b3eaad">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie28163dd08614c3cafdece4567d5b234_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTIvZnJhZzo2MGVjZWU4OTJmMmQ0Y2UyYjdiNmIzZjI3OGVkZjk3Mi90YWJsZTpkN2E1YmQ4MTg4YzY0NDQ4OGIzY2VjYzk4MTA0N2U1ZS90YWJsZXJhbmdlOmQ3YTViZDgxODhjNjQ0NDg4YjNjZWNjOTgxMDQ3ZTVlXzMtNy0xLTEtMA_86d2c6d0-5693-4c99-83b1-7377f392dd10">5,877</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fair value of assets measured on a recurring basis</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bcd87ce6e8140d4b38c9d25b675b6d0_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTIvZnJhZzo2MGVjZWU4OTJmMmQ0Y2UyYjdiNmIzZjI3OGVkZjk3Mi90YWJsZTpkN2E1YmQ4MTg4YzY0NDQ4OGIzY2VjYzk4MTA0N2U1ZS90YWJsZXJhbmdlOmQ3YTViZDgxODhjNjQ0NDg4YjNjZWNjOTgxMDQ3ZTVlXzQtMS0xLTEtMA_4c115a4c-2bce-4c62-9377-a51aca86669d">5,877</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8df3a7cd40142e4a7fab99e3da63b6c_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTIvZnJhZzo2MGVjZWU4OTJmMmQ0Y2UyYjdiNmIzZjI3OGVkZjk3Mi90YWJsZTpkN2E1YmQ4MTg4YzY0NDQ4OGIzY2VjYzk4MTA0N2U1ZS90YWJsZXJhbmdlOmQ3YTViZDgxODhjNjQ0NDg4YjNjZWNjOTgxMDQ3ZTVlXzQtMy0xLTEtMA_c22354ff-7f77-4d75-9292-92fc8562f192">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic31316c74dad419fa29a95505e9ad56c_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTIvZnJhZzo2MGVjZWU4OTJmMmQ0Y2UyYjdiNmIzZjI3OGVkZjk3Mi90YWJsZTpkN2E1YmQ4MTg4YzY0NDQ4OGIzY2VjYzk4MTA0N2U1ZS90YWJsZXJhbmdlOmQ3YTViZDgxODhjNjQ0NDg4YjNjZWNjOTgxMDQ3ZTVlXzQtNS0xLTEtMA_59f598a2-7c20-47f5-a2fe-cb05cef53a61">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie28163dd08614c3cafdece4567d5b234_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTIvZnJhZzo2MGVjZWU4OTJmMmQ0Y2UyYjdiNmIzZjI3OGVkZjk3Mi90YWJsZTpkN2E1YmQ4MTg4YzY0NDQ4OGIzY2VjYzk4MTA0N2U1ZS90YWJsZXJhbmdlOmQ3YTViZDgxODhjNjQ0NDg4YjNjZWNjOTgxMDQ3ZTVlXzQtNy0xLTEtMA_9e5db04b-4c09-4600-a369-04e4490d64b3">5,877</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bcd87ce6e8140d4b38c9d25b675b6d0_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherLiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTIvZnJhZzo2MGVjZWU4OTJmMmQ0Y2UyYjdiNmIzZjI3OGVkZjk3Mi90YWJsZTpkN2E1YmQ4MTg4YzY0NDQ4OGIzY2VjYzk4MTA0N2U1ZS90YWJsZXJhbmdlOmQ3YTViZDgxODhjNjQ0NDg4YjNjZWNjOTgxMDQ3ZTVlXzctMS0xLTEtMA_34e9904f-7f39-4961-8f0c-e016b8fbec29">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8df3a7cd40142e4a7fab99e3da63b6c_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherLiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTIvZnJhZzo2MGVjZWU4OTJmMmQ0Y2UyYjdiNmIzZjI3OGVkZjk3Mi90YWJsZTpkN2E1YmQ4MTg4YzY0NDQ4OGIzY2VjYzk4MTA0N2U1ZS90YWJsZXJhbmdlOmQ3YTViZDgxODhjNjQ0NDg4YjNjZWNjOTgxMDQ3ZTVlXzctMy0xLTEtMA_6eef1699-d53a-4480-88ec-16653515aec5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic31316c74dad419fa29a95505e9ad56c_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTIvZnJhZzo2MGVjZWU4OTJmMmQ0Y2UyYjdiNmIzZjI3OGVkZjk3Mi90YWJsZTpkN2E1YmQ4MTg4YzY0NDQ4OGIzY2VjYzk4MTA0N2U1ZS90YWJsZXJhbmdlOmQ3YTViZDgxODhjNjQ0NDg4YjNjZWNjOTgxMDQ3ZTVlXzctNS0xLTEtMA_c776b72a-6b55-4ef5-847a-d7533a78ac23">13,730</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie28163dd08614c3cafdece4567d5b234_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTIvZnJhZzo2MGVjZWU4OTJmMmQ0Y2UyYjdiNmIzZjI3OGVkZjk3Mi90YWJsZTpkN2E1YmQ4MTg4YzY0NDQ4OGIzY2VjYzk4MTA0N2U1ZS90YWJsZXJhbmdlOmQ3YTViZDgxODhjNjQ0NDg4YjNjZWNjOTgxMDQ3ZTVlXzctNy0xLTEtMA_9769bb50-f2b3-48d6-ab39-1b5405dc8ba6">13,730</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fair value of liabilities measured on a recurring basis</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bcd87ce6e8140d4b38c9d25b675b6d0_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTIvZnJhZzo2MGVjZWU4OTJmMmQ0Y2UyYjdiNmIzZjI3OGVkZjk3Mi90YWJsZTpkN2E1YmQ4MTg4YzY0NDQ4OGIzY2VjYzk4MTA0N2U1ZS90YWJsZXJhbmdlOmQ3YTViZDgxODhjNjQ0NDg4YjNjZWNjOTgxMDQ3ZTVlXzgtMS0xLTEtMA_b2f7056f-4aa1-4a72-b56f-f4328b7b4418">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8df3a7cd40142e4a7fab99e3da63b6c_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTIvZnJhZzo2MGVjZWU4OTJmMmQ0Y2UyYjdiNmIzZjI3OGVkZjk3Mi90YWJsZTpkN2E1YmQ4MTg4YzY0NDQ4OGIzY2VjYzk4MTA0N2U1ZS90YWJsZXJhbmdlOmQ3YTViZDgxODhjNjQ0NDg4YjNjZWNjOTgxMDQ3ZTVlXzgtMy0xLTEtMA_2ea19b5c-e1ac-41a4-85b9-cbd03e6be35a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic31316c74dad419fa29a95505e9ad56c_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTIvZnJhZzo2MGVjZWU4OTJmMmQ0Y2UyYjdiNmIzZjI3OGVkZjk3Mi90YWJsZTpkN2E1YmQ4MTg4YzY0NDQ4OGIzY2VjYzk4MTA0N2U1ZS90YWJsZXJhbmdlOmQ3YTViZDgxODhjNjQ0NDg4YjNjZWNjOTgxMDQ3ZTVlXzgtNS0xLTEtMA_9b635a00-04db-42ed-8b9d-19fb404fc1ee">13,730</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie28163dd08614c3cafdece4567d5b234_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTIvZnJhZzo2MGVjZWU4OTJmMmQ0Y2UyYjdiNmIzZjI3OGVkZjk3Mi90YWJsZTpkN2E1YmQ4MTg4YzY0NDQ4OGIzY2VjYzk4MTA0N2U1ZS90YWJsZXJhbmdlOmQ3YTViZDgxODhjNjQ0NDg4YjNjZWNjOTgxMDQ3ZTVlXzgtNy0xLTEtMA_7a967daa-5b88-4515-8123-e016c43f969c">13,730</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"> </span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Represents the cash and cash equivalents and restricted cash and restricted investments that were held in money market funds as of December&#160;31, 2020.</span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Represents the fair value of <ix:nonFraction unitRef="shares" contextRef="i45bff335c1434d6ba44132da1b0557db_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTIvZnJhZzo2MGVjZWU4OTJmMmQ0Y2UyYjdiNmIzZjI3OGVkZjk3Mi90ZXh0cmVnaW9uOjYwZWNlZTg5MmYyZDRjZTJiN2I2YjNmMjc4ZWRmOTcyXzE5NDA_7ab24c74-e14b-4c9f-9e1c-90ccb16688a7">1,513,786</ix:nonFraction> shares issuable under the warrant agreements discussed in Note 10.</span></div></ix:continuation></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes any transfers between levels within the hierarchy as of the beginning of the reporting period. There were no transfers between fair value levels during the three and six months ended June 30, 2021 and 2020, respectively.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the absence of observable market prices, the fair value is based on the best information available and involves a significant degree of judgment, taking into consideration a combination of internal and external factors, including the appropriate risk adjustments for non-performance and liquidity risks.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In conjunction with the Credit Agreement discussed in Note 10, the Company entered into warrant agreements whereby it agreed to sell to the holders of the warrants an aggregate of <ix:nonFraction unitRef="shares" contextRef="i1cad05e654934e308e828b864b76a508_I20191230" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightUnissued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTIvZnJhZzo2MGVjZWU4OTJmMmQ0Y2UyYjdiNmIzZjI3OGVkZjk3Mi90ZXh0cmVnaW9uOjYwZWNlZTg5MmYyZDRjZTJiN2I2YjNmMjc4ZWRmOTcyXzI3MjU_ac7abe6a-a6b2-498a-92c3-cc274b28f9ca">1,513,786</ix:nonFraction> shares of Class A common stock. The fair value of the warrants was estimated based on the Black-Scholes model which incorporates the constant price variation of the stock, the time value of money, the option's strike price, and the time to the option's expiry. The significant unobservable inputs used in the fair value measurement of the warrants are the stock price volatility and annual risk free rate. A significant increase in the stock price or discount rate in isolation would result in a significantly higher fair value of the contingent consideration.</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTIvZnJhZzo2MGVjZWU4OTJmMmQ0Y2UyYjdiNmIzZjI3OGVkZjk3Mi90ZXh0cmVnaW9uOjYwZWNlZTg5MmYyZDRjZTJiN2I2YjNmMjc4ZWRmOTcyXzQ5Njc_5b8866ff-5d8a-4be7-85d9-46b29e122f11" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in our liabilities measured at fair value for which the Company uses Level 3 inputs to determine fair value for the six months ended June 30, 2021 and 2020 are as follows (in thousands): </span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:433.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45bff335c1434d6ba44132da1b0557db_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTIvZnJhZzo2MGVjZWU4OTJmMmQ0Y2UyYjdiNmIzZjI3OGVkZjk3Mi90YWJsZTpiZDY2YmY2MWI3ZjA0ZmY2OTJkNDQ3NTY1ZTMxYTY2ZS90YWJsZXJhbmdlOmJkNjZiZjYxYjdmMDRmZjY5MmQ0NDc1NjVlMzFhNjZlXzItMS0xLTEtMA_988daaa5-e177-4132-be1a-98800fd4d4e9">13,730</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0ff0ad229b441d4b12bc8956f92a917_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTIvZnJhZzo2MGVjZWU4OTJmMmQ0Y2UyYjdiNmIzZjI3OGVkZjk3Mi90YWJsZTpiZDY2YmY2MWI3ZjA0ZmY2OTJkNDQ3NTY1ZTMxYTY2ZS90YWJsZXJhbmdlOmJkNjZiZjYxYjdmMDRmZjY5MmQ0NDc1NjVlMzFhNjZlXzItMy0xLTEtMA_5dad3dda-7cb9-448c-8c01-3916bd66b467">16,975</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTIvZnJhZzo2MGVjZWU4OTJmMmQ0Y2UyYjdiNmIzZjI3OGVkZjk3Mi90YWJsZTpiZDY2YmY2MWI3ZjA0ZmY2OTJkNDQ3NTY1ZTMxYTY2ZS90YWJsZXJhbmdlOmJkNjZiZjYxYjdmMDRmZjY5MmQ0NDc1NjVlMzFhNjZlXzMtMS0xLTEtMA_ac7fffe5-aaa7-4730-b9d6-dc8a92c9299a">13,730</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTIvZnJhZzo2MGVjZWU4OTJmMmQ0Y2UyYjdiNmIzZjI3OGVkZjk3Mi90YWJsZTpiZDY2YmY2MWI3ZjA0ZmY2OTJkNDQ3NTY1ZTMxYTY2ZS90YWJsZXJhbmdlOmJkNjZiZjYxYjdmMDRmZjY5MmQ0NDc1NjVlMzFhNjZlXzMtMy0xLTEtMA_7c70e15d-a7d0-42da-89db-5703cf5ac628">3,500</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Realized and unrealized gains (losses), net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTIvZnJhZzo2MGVjZWU4OTJmMmQ0Y2UyYjdiNmIzZjI3OGVkZjk3Mi90YWJsZTpiZDY2YmY2MWI3ZjA0ZmY2OTJkNDQ3NTY1ZTMxYTY2ZS90YWJsZXJhbmdlOmJkNjZiZjYxYjdmMDRmZjY5MmQ0NDc1NjVlMzFhNjZlXzQtMS0xLTEtMA_cea01afe-e6c7-4935-affa-a146eefa859a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTIvZnJhZzo2MGVjZWU4OTJmMmQ0Y2UyYjdiNmIzZjI3OGVkZjk3Mi90YWJsZTpiZDY2YmY2MWI3ZjA0ZmY2OTJkNDQ3NTY1ZTMxYTY2ZS90YWJsZXJhbmdlOmJkNjZiZjYxYjdmMDRmZjY5MmQ0NDc1NjVlMzFhNjZlXzQtMy0xLTEtMA_ebcbb851-12fc-46e0-8d62-38c14514ab71">4,975</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTIvZnJhZzo2MGVjZWU4OTJmMmQ0Y2UyYjdiNmIzZjI3OGVkZjk3Mi90YWJsZTpiZDY2YmY2MWI3ZjA0ZmY2OTJkNDQ3NTY1ZTMxYTY2ZS90YWJsZXJhbmdlOmJkNjZiZjYxYjdmMDRmZjY5MmQ0NDc1NjVlMzFhNjZlXzUtMS0xLTEtMA_7ebf250a-31c3-4b98-a528-343fe317ce38">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11817f96c3e24e0abaed14a17869e173_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTIvZnJhZzo2MGVjZWU4OTJmMmQ0Y2UyYjdiNmIzZjI3OGVkZjk3Mi90YWJsZTpiZDY2YmY2MWI3ZjA0ZmY2OTJkNDQ3NTY1ZTMxYTY2ZS90YWJsZXJhbmdlOmJkNjZiZjYxYjdmMDRmZjY5MmQ0NDc1NjVlMzFhNjZlXzUtMy0xLTEtMA_26538129-7663-4448-a627-4781ca8f1971">8,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTIvZnJhZzo2MGVjZWU4OTJmMmQ0Y2UyYjdiNmIzZjI3OGVkZjk3Mi90ZXh0cmVnaW9uOjYwZWNlZTg5MmYyZDRjZTJiN2I2YjNmMjc4ZWRmOTcyXzQ5NzI_92f488eb-3f3f-4530-b6fc-7136dc195ce0" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the fair value (in thousands), valuation techniques and significant unobservable inputs of our Level 3 fair value measurements as of December&#160;31, 2020:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:539.25pt"><tr><td style="width:1.0pt"></td><td style="width:118.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:100.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:168.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:67.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:13.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Valuation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assumption or</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Technique</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unobservable Inputs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Input Ranges</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9af8cd87d8f9489980dbda44afabcdbc_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTIvZnJhZzo2MGVjZWU4OTJmMmQ0Y2UyYjdiNmIzZjI3OGVkZjk3Mi90YWJsZTo5Nzg0YmEyNmE1NDM0NzBhYTJmMDI5ZGQyN2Y5YWViMC90YWJsZXJhbmdlOjk3ODRiYTI2YTU0MzQ3MGFhMmYwMjlkZDI3ZjlhZWIwXzMtMS0xLTEtMA_588dba6b-57a4-4d8d-b49e-fc0a7246addb">13,730</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Black-Scholes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock price volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia5a46affbafa4a3caf05bc97e2301da0_I20201231" decimals="3" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTIvZnJhZzo2MGVjZWU4OTJmMmQ0Y2UyYjdiNmIzZjI3OGVkZjk3Mi90YWJsZTo5Nzg0YmEyNmE1NDM0NzBhYTJmMDI5ZGQyN2Y5YWViMC90YWJsZXJhbmdlOjk3ODRiYTI2YTU0MzQ3MGFhMmYwMjlkZDI3ZjlhZWIwXzMtNy0xLTEtMA_d0b5c6ac-e091-4f2a-8f52-33a2e7efd8c8">62.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Annual risk free rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1593077c9af8419b8c13d1d04a73de2d_I20201231" decimals="3" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTIvZnJhZzo2MGVjZWU4OTJmMmQ0Y2UyYjdiNmIzZjI3OGVkZjk3Mi90YWJsZTo5Nzg0YmEyNmE1NDM0NzBhYTJmMDI5ZGQyN2Y5YWViMC90YWJsZXJhbmdlOjk3ODRiYTI2YTU0MzQ3MGFhMmYwMjlkZDI3ZjlhZWIwXzQtNy0xLTEtMA_0b150fcc-4cdb-43f2-9cb3-210188561977">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i2534ae356f004360a8c14f9f5ba3a886" continuedAt="id94f461000364aa1a970e24fdd9bd6f7"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Nonrecurring Fair Value Measurements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the assets and liabilities that are recorded at fair value on a recurring basis, the Company records certain assets and liabilities at fair value on a nonrecurring basis as required by GAAP. Generally, assets are recorded at fair value on a nonrecurring basis as a result of impairment charges. This includes assets and liabilities recorded in business combinations or asset acquisitions, goodwill, intangible assets, property, plant and equipment, held-to-maturity investments and equity method investments. While not </span></div></ix:continuation></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="id94f461000364aa1a970e24fdd9bd6f7"><ix:continuation id="i5e8be715bacf44faa9e9cd43c4788e18"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">carried at fair value on a recurring basis, these items are continually monitored for indicators of impairment that would indicate current carrying value is greater than fair value. In those situations, the assets are considered impaired and written down to current fair value. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Fair Value Disclosures</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of cash and cash equivalents (those not held in a money market fund), restricted cash, receivables, prepaid expenses, accounts payable, accrued liabilities and accrued compensation approximate their fair values because of the relatively short-term maturities of these items and financial instruments.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 10 for information regarding the fair value of the 2024 Notes, 2025 Notes and 2021 Notes.</span></div></ix:continuation></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="id8f403494d0a42c2868794fb470218fc_115"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 19. <ix:nonNumeric contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTUvZnJhZzo4YjlhZTAxYjIwYjg0ZDZjOTVmNWJhY2VkZmZjZTUwYi90ZXh0cmVnaW9uOjhiOWFlMDFiMjBiODRkNmM5NWY1YmFjZWRmZmNlNTBiXzEyNjY_26c2b4d8-b5cb-4e71-928e-9362d0115fe2" continuedAt="ibe1218888a3d49b8a906e6c39eb7d4d8" escape="true">Related Parties </ix:nonNumeric><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ibe1218888a3d49b8a906e6c39eb7d4d8" continuedAt="i3f621ce317d649e5a4ae55dfaffd1e5f"> </ix:continuation></span></div><ix:continuation id="i3f621ce317d649e5a4ae55dfaffd1e5f"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The entities described below are considered related parties and the balances and/or transactions with them are reported in our consolidated financial statements.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As discussed in Note&#160;16, the Company had economic interests in several entities that were previously accounted for under the equity method of accounting, including EVH Passport (which has been consolidated into the Company&#8217;s financial results since September 1, 2020). The Company has allocated its proportional share of the investees&#8217; earnings and losses each reporting period. In addition, Evolent has entered into services agreements with certain of the entities to provide certain management, operational and support services to help the entities manage elements of their service offerings. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also works closely with UPMC, one of its founding investors. The Company&#8217;s relationship with UPMC is a subcontractor relationship where UPMC has agreed to execute certain tasks (primarily TPA services) relating to certain customer commitments. We also conduct business with a company in which UPMC holds a significant equity interest.</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" name="us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTUvZnJhZzo4YjlhZTAxYjIwYjg0ZDZjOTVmNWJhY2VkZmZjZTUwYi90ZXh0cmVnaW9uOjhiOWFlMDFiMjBiODRkNmM5NWY1YmFjZWRmZmNlNTBiXzEyNjg_6df5e1ef-f7a9-41af-9cfc-c0176d166d46" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents assets and liabilities attributable to our related parties as of June&#160;30, 2021 and December&#160;31, 2020 (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.594%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.705%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.707%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e3c636f0c3f4cd9a3d1b819208219a6_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTUvZnJhZzo4YjlhZTAxYjIwYjg0ZDZjOTVmNWJhY2VkZmZjZTUwYi90YWJsZTowMTk5YzAwNzI1YjM0YWQ2YjY0MTE1YmU1ZjM0NTBhYS90YWJsZXJhbmdlOjAxOTljMDA3MjViMzRhZDZiNjQxMTViZTVmMzQ1MGFhXzItMS0xLTEtMA_bb266888-7caa-44aa-804c-949f81b17fb8">4,450</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd166759aac546b39c8ff666867d34d3_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTUvZnJhZzo4YjlhZTAxYjIwYjg0ZDZjOTVmNWJhY2VkZmZjZTUwYi90YWJsZTowMTk5YzAwNzI1YjM0YWQ2YjY0MTE1YmU1ZjM0NTBhYS90YWJsZXJhbmdlOjAxOTljMDA3MjViMzRhZDZiNjQxMTViZTVmMzQ1MGFhXzItMy0xLTEtMA_cb1e7fb0-f59a-4ae6-8b60-462679135963">9,474</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e3c636f0c3f4cd9a3d1b819208219a6_I20210630" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTUvZnJhZzo4YjlhZTAxYjIwYjg0ZDZjOTVmNWJhY2VkZmZjZTUwYi90YWJsZTowMTk5YzAwNzI1YjM0YWQ2YjY0MTE1YmU1ZjM0NTBhYS90YWJsZXJhbmdlOjAxOTljMDA3MjViMzRhZDZiNjQxMTViZTVmMzQ1MGFhXzMtMS0xLTEtMA_b7003c70-d57a-4230-b066-c0113d06e52f">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd166759aac546b39c8ff666867d34d3_I20201231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTUvZnJhZzo4YjlhZTAxYjIwYjg0ZDZjOTVmNWJhY2VkZmZjZTUwYi90YWJsZTowMTk5YzAwNzI1YjM0YWQ2YjY0MTE1YmU1ZjM0NTBhYS90YWJsZXJhbmdlOjAxOTljMDA3MjViMzRhZDZiNjQxMTViZTVmMzQ1MGFhXzMtMy0xLTEtMA_2f1df318-1ee2-49fb-ae82-3fee066ae59b">51</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other noncurrent assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e3c636f0c3f4cd9a3d1b819208219a6_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTUvZnJhZzo4YjlhZTAxYjIwYjg0ZDZjOTVmNWJhY2VkZmZjZTUwYi90YWJsZTowMTk5YzAwNzI1YjM0YWQ2YjY0MTE1YmU1ZjM0NTBhYS90YWJsZXJhbmdlOjAxOTljMDA3MjViMzRhZDZiNjQxMTViZTVmMzQ1MGFhXzQtMS0xLTEtMA_65e6ce70-e668-409b-a428-dcb868284642">4,688</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd166759aac546b39c8ff666867d34d3_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTUvZnJhZzo4YjlhZTAxYjIwYjg0ZDZjOTVmNWJhY2VkZmZjZTUwYi90YWJsZTowMTk5YzAwNzI1YjM0YWQ2YjY0MTE1YmU1ZjM0NTBhYS90YWJsZXJhbmdlOjAxOTljMDA3MjViMzRhZDZiNjQxMTViZTVmMzQ1MGFhXzQtMy0xLTEtMA_a29d768f-bed3-46ba-84c5-7ab1318be878">4,554</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e3c636f0c3f4cd9a3d1b819208219a6_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTUvZnJhZzo4YjlhZTAxYjIwYjg0ZDZjOTVmNWJhY2VkZmZjZTUwYi90YWJsZTowMTk5YzAwNzI1YjM0YWQ2YjY0MTE1YmU1ZjM0NTBhYS90YWJsZXJhbmdlOjAxOTljMDA3MjViMzRhZDZiNjQxMTViZTVmMzQ1MGFhXzctMS0xLTEtMA_e45bd5f8-9b66-4b5a-a005-24c23113afa9">1,923</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd166759aac546b39c8ff666867d34d3_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTUvZnJhZzo4YjlhZTAxYjIwYjg0ZDZjOTVmNWJhY2VkZmZjZTUwYi90YWJsZTowMTk5YzAwNzI1YjM0YWQ2YjY0MTE1YmU1ZjM0NTBhYS90YWJsZXJhbmdlOjAxOTljMDA3MjViMzRhZDZiNjQxMTViZTVmMzQ1MGFhXzctMy0xLTEtMA_18ec4cd3-8dad-4300-ab71-d9890a26be24">2,509</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e3c636f0c3f4cd9a3d1b819208219a6_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTUvZnJhZzo4YjlhZTAxYjIwYjg0ZDZjOTVmNWJhY2VkZmZjZTUwYi90YWJsZTowMTk5YzAwNzI1YjM0YWQ2YjY0MTE1YmU1ZjM0NTBhYS90YWJsZXJhbmdlOjAxOTljMDA3MjViMzRhZDZiNjQxMTViZTVmMzQ1MGFhXzgtMS0xLTEtMA_7c7f09ba-9b3e-44ad-8202-4b40bcad8527">1,220</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd166759aac546b39c8ff666867d34d3_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTUvZnJhZzo4YjlhZTAxYjIwYjg0ZDZjOTVmNWJhY2VkZmZjZTUwYi90YWJsZTowMTk5YzAwNzI1YjM0YWQ2YjY0MTE1YmU1ZjM0NTBhYS90YWJsZXJhbmdlOjAxOTljMDA3MjViMzRhZDZiNjQxMTViZTVmMzQ1MGFhXzgtMy0xLTEtMA_4e908528-683b-426c-90b0-bd007cca8f31">1,520</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve for claims and performance-based arrangements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e3c636f0c3f4cd9a3d1b819208219a6_I20210630" decimals="-3" name="us-gaap:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTUvZnJhZzo4YjlhZTAxYjIwYjg0ZDZjOTVmNWJhY2VkZmZjZTUwYi90YWJsZTowMTk5YzAwNzI1YjM0YWQ2YjY0MTE1YmU1ZjM0NTBhYS90YWJsZXJhbmdlOjAxOTljMDA3MjViMzRhZDZiNjQxMTViZTVmMzQ1MGFhXzktMS0xLTEtMA_7556a783-29ea-4ea8-bda2-f10f2cc22d00">149</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd166759aac546b39c8ff666867d34d3_I20201231" decimals="-3" name="us-gaap:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTUvZnJhZzo4YjlhZTAxYjIwYjg0ZDZjOTVmNWJhY2VkZmZjZTUwYi90YWJsZTowMTk5YzAwNzI1YjM0YWQ2YjY0MTE1YmU1ZjM0NTBhYS90YWJsZXJhbmdlOjAxOTljMDA3MjViMzRhZDZiNjQxMTViZTVmMzQ1MGFhXzktMy0xLTEtMA_d3a186e9-ed1c-4dde-ba0b-b715b93c6538">435</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents revenues and expenses attributable to our related parties for the three and six months ended June 30, 2021 and 2020 (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:273.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:61.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:61.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:61.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:61.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transformation services</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80f9c6fc9c784f1ebf7661871ea29e40_D20210401-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTUvZnJhZzo4YjlhZTAxYjIwYjg0ZDZjOTVmNWJhY2VkZmZjZTUwYi90YWJsZTphZmYxZTYyZjU4ZGM0YjkxYTUxNWE5MmMzZGRhOGExNC90YWJsZXJhbmdlOmFmZjFlNjJmNThkYzRiOTFhNTE1YTkyYzNkZGE4YTE0XzMtMS0xLTEtMTI2OA_56b96f0d-20d9-46a8-b0b6-b7a3297c55dd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12d000d060d24ea2a95340696a6a480c_D20200401-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTUvZnJhZzo4YjlhZTAxYjIwYjg0ZDZjOTVmNWJhY2VkZmZjZTUwYi90YWJsZTphZmYxZTYyZjU4ZGM0YjkxYTUxNWE5MmMzZGRhOGExNC90YWJsZXJhbmdlOmFmZjFlNjJmNThkYzRiOTFhNTE1YTkyYzNkZGE4YTE0XzMtMy0xLTEtMTI2OA_eb49f0c5-b4ec-44fe-a0dc-2e20852346e7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3045b5c28d7410fb838543b77fb8e48_D20210101-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTUvZnJhZzo4YjlhZTAxYjIwYjg0ZDZjOTVmNWJhY2VkZmZjZTUwYi90YWJsZTphZmYxZTYyZjU4ZGM0YjkxYTUxNWE5MmMzZGRhOGExNC90YWJsZXJhbmdlOmFmZjFlNjJmNThkYzRiOTFhNTE1YTkyYzNkZGE4YTE0XzMtMS0xLTEtMA_79df33e3-d870-4035-bd9b-e2c27a2f2b26">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b684a34ddb04cb49ab76574e8dbeca9_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTUvZnJhZzo4YjlhZTAxYjIwYjg0ZDZjOTVmNWJhY2VkZmZjZTUwYi90YWJsZTphZmYxZTYyZjU4ZGM0YjkxYTUxNWE5MmMzZGRhOGExNC90YWJsZXJhbmdlOmFmZjFlNjJmNThkYzRiOTFhNTE1YTkyYzNkZGE4YTE0XzMtMy0xLTEtMA_a3581449-d4e3-4c10-908c-d9ea144d5384">1,700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Platform and operations services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2886761dda849ee81490345eb4cd5fe_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTUvZnJhZzo4YjlhZTAxYjIwYjg0ZDZjOTVmNWJhY2VkZmZjZTUwYi90YWJsZTphZmYxZTYyZjU4ZGM0YjkxYTUxNWE5MmMzZGRhOGExNC90YWJsZXJhbmdlOmFmZjFlNjJmNThkYzRiOTFhNTE1YTkyYzNkZGE4YTE0XzQtMS0xLTEtMTI2OA_e610e03f-17f2-403c-b2e9-0c4c1919fcd6">10,368</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3ad28259229428e9fd1a3676572116f_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTUvZnJhZzo4YjlhZTAxYjIwYjg0ZDZjOTVmNWJhY2VkZmZjZTUwYi90YWJsZTphZmYxZTYyZjU4ZGM0YjkxYTUxNWE5MmMzZGRhOGExNC90YWJsZXJhbmdlOmFmZjFlNjJmNThkYzRiOTFhNTE1YTkyYzNkZGE4YTE0XzQtMy0xLTEtMTI2OA_d7d11bd2-8145-478a-9771-9bea046679c7">73,885</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if26f70dc308240eb95d27a86fe164dcb_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTUvZnJhZzo4YjlhZTAxYjIwYjg0ZDZjOTVmNWJhY2VkZmZjZTUwYi90YWJsZTphZmYxZTYyZjU4ZGM0YjkxYTUxNWE5MmMzZGRhOGExNC90YWJsZXJhbmdlOmFmZjFlNjJmNThkYzRiOTFhNTE1YTkyYzNkZGE4YTE0XzQtMS0xLTEtMA_e1ed9061-5505-4b00-b90c-ebea40e9f6a0">25,943</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c692c0dda2248aab4719ff28ac52586_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTUvZnJhZzo4YjlhZTAxYjIwYjg0ZDZjOTVmNWJhY2VkZmZjZTUwYi90YWJsZTphZmYxZTYyZjU4ZGM0YjkxYTUxNWE5MmMzZGRhOGExNC90YWJsZXJhbmdlOmFmZjFlNjJmNThkYzRiOTFhNTE1YTkyYzNkZGE4YTE0XzQtMy0xLTEtMA_32698572-27de-41d4-b91a-e68650f87962">141,833</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenue (exclusive of depreciation and amortization expenses)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id32a865882ba4f0f9600a62eb26f2cd9_D20210401-20210630" decimals="-3" name="evh:CostofGoodsandServicesSoldExcludingDepreciationandAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTUvZnJhZzo4YjlhZTAxYjIwYjg0ZDZjOTVmNWJhY2VkZmZjZTUwYi90YWJsZTphZmYxZTYyZjU4ZGM0YjkxYTUxNWE5MmMzZGRhOGExNC90YWJsZXJhbmdlOmFmZjFlNjJmNThkYzRiOTFhNTE1YTkyYzNkZGE4YTE0XzctMS0xLTEtMTI3Mg_26efd2b7-8a31-4151-9d4a-03e264e65bad">606</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0b14ca9b08604f019fcc80d78ee511ab_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="evh:CostofGoodsandServicesSoldExcludingDepreciationandAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTUvZnJhZzo4YjlhZTAxYjIwYjg0ZDZjOTVmNWJhY2VkZmZjZTUwYi90YWJsZTphZmYxZTYyZjU4ZGM0YjkxYTUxNWE5MmMzZGRhOGExNC90YWJsZXJhbmdlOmFmZjFlNjJmNThkYzRiOTFhNTE1YTkyYzNkZGE4YTE0XzctMy0xLTEtMTI3Mg_c30fdfd9-9405-49b4-bb38-42f139c9d896">2,171</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ba99c7ee2d04799a86890ec3064b175_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="evh:CostofGoodsandServicesSoldExcludingDepreciationandAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTUvZnJhZzo4YjlhZTAxYjIwYjg0ZDZjOTVmNWJhY2VkZmZjZTUwYi90YWJsZTphZmYxZTYyZjU4ZGM0YjkxYTUxNWE5MmMzZGRhOGExNC90YWJsZXJhbmdlOmFmZjFlNjJmNThkYzRiOTFhNTE1YTkyYzNkZGE4YTE0XzctMS0xLTEtMA_fb126f31-e70c-4579-a648-0a2817a82061">1,099</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04089c6246044d5cbf92001f57543039_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="evh:CostofGoodsandServicesSoldExcludingDepreciationandAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTUvZnJhZzo4YjlhZTAxYjIwYjg0ZDZjOTVmNWJhY2VkZmZjZTUwYi90YWJsZTphZmYxZTYyZjU4ZGM0YjkxYTUxNWE5MmMzZGRhOGExNC90YWJsZXJhbmdlOmFmZjFlNjJmNThkYzRiOTFhNTE1YTkyYzNkZGE4YTE0XzctMy0xLTEtMA_b8a24bfc-8b93-402b-81aa-ba12f386919f">1,076</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id32a865882ba4f0f9600a62eb26f2cd9_D20210401-20210630" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTUvZnJhZzo4YjlhZTAxYjIwYjg0ZDZjOTVmNWJhY2VkZmZjZTUwYi90YWJsZTphZmYxZTYyZjU4ZGM0YjkxYTUxNWE5MmMzZGRhOGExNC90YWJsZXJhbmdlOmFmZjFlNjJmNThkYzRiOTFhNTE1YTkyYzNkZGE4YTE0XzgtMS0xLTEtMTI3Mg_2f73f8c3-dc0c-4911-8b18-d113abd653d7">81</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b14ca9b08604f019fcc80d78ee511ab_D20200401-20200630" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTUvZnJhZzo4YjlhZTAxYjIwYjg0ZDZjOTVmNWJhY2VkZmZjZTUwYi90YWJsZTphZmYxZTYyZjU4ZGM0YjkxYTUxNWE5MmMzZGRhOGExNC90YWJsZXJhbmdlOmFmZjFlNjJmNThkYzRiOTFhNTE1YTkyYzNkZGE4YTE0XzgtMy0xLTEtMTI3Mg_337696e8-8b41-427a-abaf-05c20ef018d8">27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ba99c7ee2d04799a86890ec3064b175_D20210101-20210630" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTUvZnJhZzo4YjlhZTAxYjIwYjg0ZDZjOTVmNWJhY2VkZmZjZTUwYi90YWJsZTphZmYxZTYyZjU4ZGM0YjkxYTUxNWE5MmMzZGRhOGExNC90YWJsZXJhbmdlOmFmZjFlNjJmNThkYzRiOTFhNTE1YTkyYzNkZGE4YTE0XzgtMS0xLTEtMA_73bbb648-7916-43a0-a53a-4144bc965fbd">112</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04089c6246044d5cbf92001f57543039_D20200101-20200630" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTUvZnJhZzo4YjlhZTAxYjIwYjg0ZDZjOTVmNWJhY2VkZmZjZTUwYi90YWJsZTphZmYxZTYyZjU4ZGM0YjkxYTUxNWE5MmMzZGRhOGExNC90YWJsZXJhbmdlOmFmZjFlNjJmNThkYzRiOTFhNTE1YTkyYzNkZGE4YTE0XzgtMy0xLTEtMA_6fe04b2f-f68c-4376-816f-be29875ba12b">97</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><div id="id8f403494d0a42c2868794fb470218fc_118"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 20. <ix:continuation id="i41ea84f629024114b07c0dd76a29ea97" continuedAt="i0800eccc49274e99a0ae5ecc609dc093">Repositioning and Other Changes</ix:continuation></span></div><div><span><br/></span></div><ix:continuation id="i0800eccc49274e99a0ae5ecc609dc093"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continually assess opportunities to improve operational effectiveness and efficiency to better align our expenses with revenues, while continuing to make investments in our solutions, systems and people that we believe are important to our long-term goals. Across 2020, we divested or agreed to divest a majority of our health plan assets, including certain assets of EVH Passport, which represented a significant revenue stream for the Company. In parallel with these divestitures, we contracted with a third-party vendor to review our operating model and organizational design in order to improve our profitability, create value through our solutions and invest in strategic opportunities in future periods.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the fourth quarter of 2020, we committed to certain operational efficiency and profitability actions that we are taking in order to accomplish these objectives (&#8220;Repositioning Plan&#8221;). These actions included making organizational changes across our business as well as other profitability initiatives expected to result in reductions in force, re-aligning of resources as well as other potential operational efficiency and cost-reduction initiatives. The Repositioning Plan is expected to continue through the fourth quarter of 2021. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded approximately $<ix:nonFraction unitRef="usd" contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTgvZnJhZzo0ODM4ZWI4MmExMmQ0MTA2YjFjNTIxOWZhNzcyMzI0ZS90ZXh0cmVnaW9uOjQ4MzhlYjgyYTEyZDQxMDZiMWM1MjE5ZmE3NzIzMjRlXzEwOTk1MTE2MzI1NTM_e0f1f8ab-3d1f-4324-8a17-1a880f9fbb53">0.7</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTgvZnJhZzo0ODM4ZWI4MmExMmQ0MTA2YjFjNTIxOWZhNzcyMzI0ZS90ZXh0cmVnaW9uOjQ4MzhlYjgyYTEyZDQxMDZiMWM1MjE5ZmE3NzIzMjRlXzEwOTk1MTE2MzI1ODA_ae68633e-3c92-46ac-9729-52789b19f72f">6.0</ix:nonFraction>&#160;million of repositioning costs in selling, general and administrative expenses for the three and six months ended June 30, 2021&#160;in connection with the Repositioning Plan. <ix:nonNumeric contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" name="us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTgvZnJhZzo0ODM4ZWI4MmExMmQ0MTA2YjFjNTIxOWZhNzcyMzI0ZS90ZXh0cmVnaW9uOjQ4MzhlYjgyYTEyZDQxMDZiMWM1MjE5ZmE3NzIzMjRlXzE1OTQ_ba2de26c-e8f6-45cb-985f-f9f31c97fdf2" continuedAt="i725ed7ccded04481a276146e03f09434" escape="true">The following table provides a summary of our total costs associated with the Repositioning Plan for the three and six months ended June 30, 2021, by major type of cost (in thousands):</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><ix:continuation id="i725ed7ccded04481a276146e03f09434"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.305%"><tr><td style="width:1.0%"></td><td style="width:27.431%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.499%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.305%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.359%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.305%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.359%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.039%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.359%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.044%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Incurred For the Three Months Ended <br/>June  30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Incurred for the Six Months Ended June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Amount Expected to be Incurred in the Repositioning Plan</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cumulative Amount Incurred through June 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Severance and termination benefits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9efdfcae40144663a980937c662799c7_D20210401-20210630" decimals="-3" name="us-gaap:RestructuringCharges" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTgvZnJhZzo0ODM4ZWI4MmExMmQ0MTA2YjFjNTIxOWZhNzcyMzI0ZS90YWJsZTo0OTZhOTRlODUyMzM0MTZhODZiMmFkYzY2ZDI5OTU5NC90YWJsZXJhbmdlOjQ5NmE5NGU4NTIzMzQxNmE4NmIyYWRjNjZkMjk5NTk0XzEtMi0xLTEtMA_4c50a630-1caf-438f-ae59-b2772a68d236">76</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2840929ec444f69b484c53abba16383_D20210101-20210630" decimals="-3" name="us-gaap:RestructuringCharges" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTgvZnJhZzo0ODM4ZWI4MmExMmQ0MTA2YjFjNTIxOWZhNzcyMzI0ZS90YWJsZTo0OTZhOTRlODUyMzM0MTZhODZiMmFkYzY2ZDI5OTU5NC90YWJsZXJhbmdlOjQ5NmE5NGU4NTIzMzQxNmE4NmIyYWRjNjZkMjk5NTk0XzEtNC0xLTEtMzIzMQ_62031104-4b89-4ee6-977a-b6dde58ed34e">185</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17f053f839394fcd9de0dbf7fe5e0507_I20210630" decimals="-3" name="us-gaap:RestructuringAndRelatedCostExpectedCost1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTgvZnJhZzo0ODM4ZWI4MmExMmQ0MTA2YjFjNTIxOWZhNzcyMzI0ZS90YWJsZTo0OTZhOTRlODUyMzM0MTZhODZiMmFkYzY2ZDI5OTU5NC90YWJsZXJhbmdlOjQ5NmE5NGU4NTIzMzQxNmE4NmIyYWRjNjZkMjk5NTk0XzEtNC0xLTEtMA_6b094d2d-bc9a-4ad2-aeed-1ddf8d69801c">185</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17f053f839394fcd9de0dbf7fe5e0507_I20210630" decimals="-3" name="us-gaap:RestructuringAndRelatedCostCostIncurredToDate1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTgvZnJhZzo0ODM4ZWI4MmExMmQ0MTA2YjFjNTIxOWZhNzcyMzI0ZS90YWJsZTo0OTZhOTRlODUyMzM0MTZhODZiMmFkYzY2ZDI5OTU5NC90YWJsZXJhbmdlOjQ5NmE5NGU4NTIzMzQxNmE4NmIyYWRjNjZkMjk5NTk0XzEtNi0xLTEtMA_30351387-c957-49aa-9377-678a6f6edd30">185</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office space consolidation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd9a4c33807c43dda2178f4f2a358736_D20210401-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:RestructuringCharges" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTgvZnJhZzo0ODM4ZWI4MmExMmQ0MTA2YjFjNTIxOWZhNzcyMzI0ZS90YWJsZTo0OTZhOTRlODUyMzM0MTZhODZiMmFkYzY2ZDI5OTU5NC90YWJsZXJhbmdlOjQ5NmE5NGU4NTIzMzQxNmE4NmIyYWRjNjZkMjk5NTk0XzItMi0xLTEtMA_8f2044df-6b61-4993-9518-7f34f47dd9df">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4bacc3efa9a4c7cb0dbc8f0c6465a2e_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestructuringCharges" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTgvZnJhZzo0ODM4ZWI4MmExMmQ0MTA2YjFjNTIxOWZhNzcyMzI0ZS90YWJsZTo0OTZhOTRlODUyMzM0MTZhODZiMmFkYzY2ZDI5OTU5NC90YWJsZXJhbmdlOjQ5NmE5NGU4NTIzMzQxNmE4NmIyYWRjNjZkMjk5NTk0XzItNC0xLTEtMzIzMQ_e3ae2ec1-1f3e-47a1-8fc0-14fe4aa37ffc">2,071</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdc992c308c2409eb366952bb3e529f5_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestructuringAndRelatedCostExpectedCost1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTgvZnJhZzo0ODM4ZWI4MmExMmQ0MTA2YjFjNTIxOWZhNzcyMzI0ZS90YWJsZTo0OTZhOTRlODUyMzM0MTZhODZiMmFkYzY2ZDI5OTU5NC90YWJsZXJhbmdlOjQ5NmE5NGU4NTIzMzQxNmE4NmIyYWRjNjZkMjk5NTk0XzItNC0xLTEtMA_5fe8319a-3d5e-41bb-b0b6-2875d5b62a63">2,071</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdc992c308c2409eb366952bb3e529f5_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestructuringAndRelatedCostCostIncurredToDate1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTgvZnJhZzo0ODM4ZWI4MmExMmQ0MTA2YjFjNTIxOWZhNzcyMzI0ZS90YWJsZTo0OTZhOTRlODUyMzM0MTZhODZiMmFkYzY2ZDI5OTU5NC90YWJsZXJhbmdlOjQ5NmE5NGU4NTIzMzQxNmE4NmIyYWRjNjZkMjk5NTk0XzItNi0xLTEtMA_b10ab214-7218-46ee-a2e4-39b3601e69b3">2,071</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional services</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78fb3e05b2884c2185234402150b6dad_D20210401-20210630" decimals="-3" name="us-gaap:RestructuringCharges" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTgvZnJhZzo0ODM4ZWI4MmExMmQ0MTA2YjFjNTIxOWZhNzcyMzI0ZS90YWJsZTo0OTZhOTRlODUyMzM0MTZhODZiMmFkYzY2ZDI5OTU5NC90YWJsZXJhbmdlOjQ5NmE5NGU4NTIzMzQxNmE4NmIyYWRjNjZkMjk5NTk0XzMtMi0xLTEtMA_7b7efd4a-2934-4ea0-ae1a-2899004d98e4">587</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief40b6b342f44af6974cbb1079825a19_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestructuringCharges" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTgvZnJhZzo0ODM4ZWI4MmExMmQ0MTA2YjFjNTIxOWZhNzcyMzI0ZS90YWJsZTo0OTZhOTRlODUyMzM0MTZhODZiMmFkYzY2ZDI5OTU5NC90YWJsZXJhbmdlOjQ5NmE5NGU4NTIzMzQxNmE4NmIyYWRjNjZkMjk5NTk0XzMtNC0xLTEtMzIzMQ_59a27025-59d1-4b0f-9f30-d5b1546eb536">3,787</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4ab1843551d40e48105a1b5bf07b950_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestructuringAndRelatedCostExpectedCost1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTgvZnJhZzo0ODM4ZWI4MmExMmQ0MTA2YjFjNTIxOWZhNzcyMzI0ZS90YWJsZTo0OTZhOTRlODUyMzM0MTZhODZiMmFkYzY2ZDI5OTU5NC90YWJsZXJhbmdlOjQ5NmE5NGU4NTIzMzQxNmE4NmIyYWRjNjZkMjk5NTk0XzMtNC0xLTEtMA_ed96ef0b-b380-43ed-b091-915fbccb4639">5,162</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4ab1843551d40e48105a1b5bf07b950_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestructuringAndRelatedCostCostIncurredToDate1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTgvZnJhZzo0ODM4ZWI4MmExMmQ0MTA2YjFjNTIxOWZhNzcyMzI0ZS90YWJsZTo0OTZhOTRlODUyMzM0MTZhODZiMmFkYzY2ZDI5OTU5NC90YWJsZXJhbmdlOjQ5NmE5NGU4NTIzMzQxNmE4NmIyYWRjNjZkMjk5NTk0XzMtNi0xLTEtMA_a3b3c4b7-0611-4ac2-b914-a8938b06a406">5,062</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630" decimals="-3" name="us-gaap:RestructuringCharges" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTgvZnJhZzo0ODM4ZWI4MmExMmQ0MTA2YjFjNTIxOWZhNzcyMzI0ZS90YWJsZTo0OTZhOTRlODUyMzM0MTZhODZiMmFkYzY2ZDI5OTU5NC90YWJsZXJhbmdlOjQ5NmE5NGU4NTIzMzQxNmE4NmIyYWRjNjZkMjk5NTk0XzQtMi0xLTEtMA_5974f7d4-6efb-4114-80af-6c3e60bc2e61">663</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestructuringCharges" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTgvZnJhZzo0ODM4ZWI4MmExMmQ0MTA2YjFjNTIxOWZhNzcyMzI0ZS90YWJsZTo0OTZhOTRlODUyMzM0MTZhODZiMmFkYzY2ZDI5OTU5NC90YWJsZXJhbmdlOjQ5NmE5NGU4NTIzMzQxNmE4NmIyYWRjNjZkMjk5NTk0XzQtNC0xLTEtMzIzMQ_c663a30a-0920-4b94-97ea-508673c69149">6,043</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestructuringAndRelatedCostExpectedCost1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTgvZnJhZzo0ODM4ZWI4MmExMmQ0MTA2YjFjNTIxOWZhNzcyMzI0ZS90YWJsZTo0OTZhOTRlODUyMzM0MTZhODZiMmFkYzY2ZDI5OTU5NC90YWJsZXJhbmdlOjQ5NmE5NGU4NTIzMzQxNmE4NmIyYWRjNjZkMjk5NTk0XzQtNC0xLTEtMA_de376fe7-6d0b-4017-abe1-603dbcf7863e">7,418</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestructuringAndRelatedCostCostIncurredToDate1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTgvZnJhZzo0ODM4ZWI4MmExMmQ0MTA2YjFjNTIxOWZhNzcyMzI0ZS90YWJsZTo0OTZhOTRlODUyMzM0MTZhODZiMmFkYzY2ZDI5OTU5NC90YWJsZXJhbmdlOjQ5NmE5NGU4NTIzMzQxNmE4NmIyYWRjNjZkMjk5NTk0XzQtNi0xLTEtMA_7ac3b9c3-64b3-4fcc-a3df-4119c0087441">7,318</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="id8f403494d0a42c2868794fb470218fc_121"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 21. <ix:nonNumeric contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" name="us-gaap:SegmentReportingDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90ZXh0cmVnaW9uOjc0ZTMxNDVmNTRhODRjMWY4ZmQ5YjZmNTY5ZDUyMDk5XzM0MDg_b0fb2033-1686-4f9a-b656-7f9ee002002c" continuedAt="if3ed77d67d664363bdee15f0a716c3b5" escape="true">Segment Reporting</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="if3ed77d67d664363bdee15f0a716c3b5" continuedAt="ie30efdf6247c43279cdcb87a2c0d51b2"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commencing with the three months ended March 31, 2021, we define our reportable segments based on the way the CODM, the chief executive officer, manages the operations for purposes of allocating resources and assessing performance. We classify our operations into <ix:nonFraction unitRef="segment" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90ZXh0cmVnaW9uOjc0ZTMxNDVmNTRhODRjMWY4ZmQ5YjZmNTY5ZDUyMDk5XzI5Nw_ac8c0053-7af4-4e1e-97bf-2dc333062eb8">two</ix:nonFraction> reportable segments as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Evolent Health Services, which houses our Administrative Simplification solution and certain supporting population health infrastructure; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Clinical Solutions, which includes our specialty management and physician-oriented total cost of care solutions, along with the New Century Health and Evolent Care Partners brands. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, our reportable segments enter into transactions with one another. While intersegment transactions are treated like third-party transactions to determine segment performance, the revenues and expenses recognized by the segment that is the counterparty to the transaction are eliminated in consolidation and do not affect consolidated results.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CODM uses revenue in accordance with U.S. GAAP and Adjusted EBITDA as the relevant segment performance measures to evaluate the performance of the segments and allocate resources. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjusted EBITDA is a segment performance financial measure that offers a useful view of the overall operation of our businesses and may be different than similarly-titled segment performance financial measures used by other companies. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjusted EBITDA is defined as net loss attributable to common shareholders of Evolent Health, Inc. before interest income, interest expense, (provision) benefit for income taxes, depreciation and amortization expenses, adjusted to exclude equity method investment impairment, loss on extinguishment of debt, gain (loss) from equity method investees, gain (loss) on disposal of assets and consolidation, goodwill impairment, changes in fair value of contingent consideration and indemnification asset, other income (expense), net, net loss attributable to non-controlling interests, ASC 606 transition adjustments, purchase accounting adjustments, repositioning costs, stock-based compensation expense, severance costs, amortization of contract cost assets, shareholder advisory services, acquisition-related costs and gain (loss) from discontinued operations. </span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ie30efdf6247c43279cdcb87a2c0d51b2" continuedAt="if6cc2584236048c29b55d092dc816537"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management considers revenue and Adjusted EBITDA to be the appropriate metrics to evaluate and compare the ongoing operating performance of our segments on a consistent basis across reporting periods as they eliminate the effect of items which are not indicative of each segment's core operating performance. </span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" name="us-gaap:ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90ZXh0cmVnaW9uOjc0ZTMxNDVmNTRhODRjMWY4ZmQ5YjZmNTY5ZDUyMDk5XzM0MDk_cf1cf40c-7815-45dd-a00c-0d201faa4632" continuedAt="ic527861de3f64666a65e902e672addab" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present our segment information for the three and six months ended June 30, 2021 and 2020 (in thousands). Prior-year segment information (including segments total Adjusted EBITDA) has been restated to conform to the reporting structure change described in Note 1.</span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:145.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:52.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:52.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:67.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:60.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:61.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:67.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:33pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Evolent Health Services</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intersegment<br/>Eliminations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Subtotal</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended June 30, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transformation services</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia33818b88a6c42f5b842f5cc447c4d6f_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo5OGE5MDg0ZmRjZWQ0MWVkOGY5ODgwMTRlMmQyODNhNi90YWJsZXJhbmdlOjk4YTkwODRmZGNlZDQxZWQ4Zjk4ODAxNGUyZDI4M2E2XzMtMS0xLTEtMTMxNg_918c806d-3e27-432f-8113-e76d59f7aca6">2,564</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i807d8acee29b43e1998e67d743c1650e_D20210401-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo5OGE5MDg0ZmRjZWQ0MWVkOGY5ODgwMTRlMmQyODNhNi90YWJsZXJhbmdlOjk4YTkwODRmZGNlZDQxZWQ4Zjk4ODAxNGUyZDI4M2E2XzMtMy0xLTEtMTMxNg_a76a389e-2568-4fd6-a559-ef139a9179fa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia356ef0e7c074058809ff566475d252e_D20210401-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo5OGE5MDg0ZmRjZWQ0MWVkOGY5ODgwMTRlMmQyODNhNi90YWJsZXJhbmdlOjk4YTkwODRmZGNlZDQxZWQ4Zjk4ODAxNGUyZDI4M2E2XzMtNS0xLTEtMTMxNg_e6150c58-b7d6-4d3a-99ca-6938a31a6999">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0280276096944f8db9756b1ccc072342_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo5OGE5MDg0ZmRjZWQ0MWVkOGY5ODgwMTRlMmQyODNhNi90YWJsZXJhbmdlOjk4YTkwODRmZGNlZDQxZWQ4Zjk4ODAxNGUyZDI4M2E2XzMtNy0xLTEtMTMxNg_ba233e7e-679b-4d65-baa8-6e685d74ddee">2,564</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec060d1f9dc045319b07294745b086d3_D20210401-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo5OGE5MDg0ZmRjZWQ0MWVkOGY5ODgwMTRlMmQyODNhNi90YWJsZXJhbmdlOjk4YTkwODRmZGNlZDQxZWQ4Zjk4ODAxNGUyZDI4M2E2XzMtOS0xLTEtMTMxNg_68dfe458-630a-41e0-b18c-bca90e48f9b0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b3321915fe444e488ceef708a6e59c9_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo5OGE5MDg0ZmRjZWQ0MWVkOGY5ODgwMTRlMmQyODNhNi90YWJsZXJhbmdlOjk4YTkwODRmZGNlZDQxZWQ4Zjk4ODAxNGUyZDI4M2E2XzMtMTEtMS0xLTEzMTY_d42dd246-85dc-4a3c-892d-f8e897691952">2,564</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Platform and operations services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iafbe04d32b3c40ae93c564f542241136_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo5OGE5MDg0ZmRjZWQ0MWVkOGY5ODgwMTRlMmQyODNhNi90YWJsZXJhbmdlOjk4YTkwODRmZGNlZDQxZWQ4Zjk4ODAxNGUyZDI4M2E2XzQtMS0xLTEtMTMxNg_e14a91fd-ab54-4f98-b25e-df6b7af53fe8">72,759</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c922ef0f31b4ab2b388e8b7c1ab5312_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo5OGE5MDg0ZmRjZWQ0MWVkOGY5ODgwMTRlMmQyODNhNi90YWJsZXJhbmdlOjk4YTkwODRmZGNlZDQxZWQ4Zjk4ODAxNGUyZDI4M2E2XzQtMy0xLTEtMTMxNg_a39eadae-302f-4880-8ea3-0aff8b1d2572">147,194</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4bd03bc4393d446e9abc787bbb40c7a8_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo5OGE5MDg0ZmRjZWQ0MWVkOGY5ODgwMTRlMmQyODNhNi90YWJsZXJhbmdlOjk4YTkwODRmZGNlZDQxZWQ4Zjk4ODAxNGUyZDI4M2E2XzQtNS0xLTEtMTMxNg_0e920693-14f0-439b-a9a1-87142cc7aa8e">460</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaee89f0da3e144d09c4a23c928d850b8_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo5OGE5MDg0ZmRjZWQ0MWVkOGY5ODgwMTRlMmQyODNhNi90YWJsZXJhbmdlOjk4YTkwODRmZGNlZDQxZWQ4Zjk4ODAxNGUyZDI4M2E2XzQtNy0xLTEtMTMxNg_e4d40bce-3725-4a82-b5dc-3d1701409c60">219,493</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b7ecb9ad2c3400db038af4f12b6a9ab_D20210401-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo5OGE5MDg0ZmRjZWQ0MWVkOGY5ODgwMTRlMmQyODNhNi90YWJsZXJhbmdlOjk4YTkwODRmZGNlZDQxZWQ4Zjk4ODAxNGUyZDI4M2E2XzQtOS0xLTEtMTMxNg_9e50b47b-34eb-4e5b-930e-d7bbb8cc3c61">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie90c815774924e1e802eb6f3123f1004_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo5OGE5MDg0ZmRjZWQ0MWVkOGY5ODgwMTRlMmQyODNhNi90YWJsZXJhbmdlOjk4YTkwODRmZGNlZDQxZWQ4Zjk4ODAxNGUyZDI4M2E2XzQtMTEtMS0xLTEzMTY_302ce31d-e5db-4ad2-ad80-c01bd3b9ebbc">219,493</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i679cb28be3a34242bd30bce045577c6e_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo5OGE5MDg0ZmRjZWQ0MWVkOGY5ODgwMTRlMmQyODNhNi90YWJsZXJhbmdlOjk4YTkwODRmZGNlZDQxZWQ4Zjk4ODAxNGUyZDI4M2E2XzUtMS0xLTEtMTMxNg_9b21143a-eb7a-429d-812d-6f5ba0544cd5">75,323</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c9bfa2d7f884c12b69f21c9b3af2888_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo5OGE5MDg0ZmRjZWQ0MWVkOGY5ODgwMTRlMmQyODNhNi90YWJsZXJhbmdlOjk4YTkwODRmZGNlZDQxZWQ4Zjk4ODAxNGUyZDI4M2E2XzUtMy0xLTEtMTMxNg_55ec91f8-5be6-44f0-b611-05f4b281329f">147,194</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i953b09444cb241478eb77a7260d48527_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo5OGE5MDg0ZmRjZWQ0MWVkOGY5ODgwMTRlMmQyODNhNi90YWJsZXJhbmdlOjk4YTkwODRmZGNlZDQxZWQ4Zjk4ODAxNGUyZDI4M2E2XzUtNS0xLTEtMTMxNg_fb16eb79-f81f-483b-8fd4-70de15573e23">460</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib66948dc799e431486e4991bc5ffa9ef_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo5OGE5MDg0ZmRjZWQ0MWVkOGY5ODgwMTRlMmQyODNhNi90YWJsZXJhbmdlOjk4YTkwODRmZGNlZDQxZWQ4Zjk4ODAxNGUyZDI4M2E2XzUtNy0xLTEtMTMxNg_5da56d84-3b80-48f9-87d0-7e14cce75e15">222,057</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69cb2a622a3f4134a8e8684f7cb47aef_D20210401-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo5OGE5MDg0ZmRjZWQ0MWVkOGY5ODgwMTRlMmQyODNhNi90YWJsZXJhbmdlOjk4YTkwODRmZGNlZDQxZWQ4Zjk4ODAxNGUyZDI4M2E2XzUtOS0xLTEtMTMxNg_a4b6c5d4-4f65-46e0-a753-6904e6125586">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo5OGE5MDg0ZmRjZWQ0MWVkOGY5ODgwMTRlMmQyODNhNi90YWJsZXJhbmdlOjk4YTkwODRmZGNlZDQxZWQ4Zjk4ODAxNGUyZDI4M2E2XzUtMTEtMS0xLTEzMTY_034d15fe-96c4-43d5-aa0e-709e071cb5c1">222,057</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended June 30, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transformation services</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic69644d995ff43218ea90302f9eae15f_D20200401-20200630" decimals="-3" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo5OGE5MDg0ZmRjZWQ0MWVkOGY5ODgwMTRlMmQyODNhNi90YWJsZXJhbmdlOjk4YTkwODRmZGNlZDQxZWQ4Zjk4ODAxNGUyZDI4M2E2XzgtMS0xLTEtMTMxNg_9cc617b2-2c91-499e-a3db-379e7e8f6a9b">755</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9a15a1f9bed43b2a7a6b9699a0355f6_D20200401-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo5OGE5MDg0ZmRjZWQ0MWVkOGY5ODgwMTRlMmQyODNhNi90YWJsZXJhbmdlOjk4YTkwODRmZGNlZDQxZWQ4Zjk4ODAxNGUyZDI4M2E2XzgtMy0xLTEtMTMxNg_5bc3279e-d6ad-4f0f-a22b-6deb893dd723">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59d8caca505e4118a56844c68847eb29_D20200401-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo5OGE5MDg0ZmRjZWQ0MWVkOGY5ODgwMTRlMmQyODNhNi90YWJsZXJhbmdlOjk4YTkwODRmZGNlZDQxZWQ4Zjk4ODAxNGUyZDI4M2E2XzgtNS0xLTEtMTMxNg_a7b159e3-7c3f-406c-b427-6d53cc4629f1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa545ecb72a34a7c8a9f3b3fa6383b57_D20200401-20200630" decimals="-3" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo5OGE5MDg0ZmRjZWQ0MWVkOGY5ODgwMTRlMmQyODNhNi90YWJsZXJhbmdlOjk4YTkwODRmZGNlZDQxZWQ4Zjk4ODAxNGUyZDI4M2E2XzgtNy0xLTEtMTMxNg_2d0291b2-10bd-45a3-a021-f047878673e7">755</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ecbd6b0abc24d8a9ed6772122d27e8c_D20200401-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo5OGE5MDg0ZmRjZWQ0MWVkOGY5ODgwMTRlMmQyODNhNi90YWJsZXJhbmdlOjk4YTkwODRmZGNlZDQxZWQ4Zjk4ODAxNGUyZDI4M2E2XzgtOS0xLTEtMTMxNg_e38a14f1-bc26-4326-842c-f42ae496abb0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78e15c27cd3e401ea6bd6fd305abeb34_D20200401-20200630" decimals="-3" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo5OGE5MDg0ZmRjZWQ0MWVkOGY5ODgwMTRlMmQyODNhNi90YWJsZXJhbmdlOjk4YTkwODRmZGNlZDQxZWQ4Zjk4ODAxNGUyZDI4M2E2XzgtMTEtMS0xLTEzMTY_3916bb74-fdc4-45ad-9c32-8d0fff19a982">755</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Platform and operations services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i803b5fa527c248aba9d05e7aaaf9a0ed_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo5OGE5MDg0ZmRjZWQ0MWVkOGY5ODgwMTRlMmQyODNhNi90YWJsZXJhbmdlOjk4YTkwODRmZGNlZDQxZWQ4Zjk4ODAxNGUyZDI4M2E2XzktMS0xLTEtMTMxNg_e461926a-a4e2-4433-a6e8-c83541b87518">86,432</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5621f56fb2874b21835554c608a4179a_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo5OGE5MDg0ZmRjZWQ0MWVkOGY5ODgwMTRlMmQyODNhNi90YWJsZXJhbmdlOjk4YTkwODRmZGNlZDQxZWQ4Zjk4ODAxNGUyZDI4M2E2XzktMy0xLTEtMTMxNg_f9c7d0b3-245d-4a74-b2f6-7cf3aaaa055f">130,780</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia2e4a5d8dda94f9cbc6ae57881da0889_D20200401-20200630" decimals="-3" sign="-" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo5OGE5MDg0ZmRjZWQ0MWVkOGY5ODgwMTRlMmQyODNhNi90YWJsZXJhbmdlOjk4YTkwODRmZGNlZDQxZWQ4Zjk4ODAxNGUyZDI4M2E2XzktNS0xLTEtMTMxNg_bf24e765-334f-47f1-9f1c-904689d9da84">668</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2637cdc499c42c69c98ce75b9cedd71_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo5OGE5MDg0ZmRjZWQ0MWVkOGY5ODgwMTRlMmQyODNhNi90YWJsZXJhbmdlOjk4YTkwODRmZGNlZDQxZWQ4Zjk4ODAxNGUyZDI4M2E2XzktNy0xLTEtMTMxNg_d10fda48-bbb5-46c0-a0d9-7bb74a3ecedf">216,544</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97c5008ce5974099bdaadf9428995770_D20200401-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo5OGE5MDg0ZmRjZWQ0MWVkOGY5ODgwMTRlMmQyODNhNi90YWJsZXJhbmdlOjk4YTkwODRmZGNlZDQxZWQ4Zjk4ODAxNGUyZDI4M2E2XzktOS0xLTEtMTMxNg_848c3ba2-86c4-4ec4-a1b0-f72d84d362a3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd99be6d27564d4cb75996e8ce5dce17_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo5OGE5MDg0ZmRjZWQ0MWVkOGY5ODgwMTRlMmQyODNhNi90YWJsZXJhbmdlOjk4YTkwODRmZGNlZDQxZWQ4Zjk4ODAxNGUyZDI4M2E2XzktMTEtMS0xLTEzMTY_ae976411-e687-4e99-a9a2-66a04ad49fca">216,544</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibebddd07c46e4994849d375ecea231c6_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo5OGE5MDg0ZmRjZWQ0MWVkOGY5ODgwMTRlMmQyODNhNi90YWJsZXJhbmdlOjk4YTkwODRmZGNlZDQxZWQ4Zjk4ODAxNGUyZDI4M2E2XzEwLTEtMS0xLTEzMTY_cb6b87e9-e3e0-4ffb-8d07-5d2ac717cf2f">87,187</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16325f028066493d8ad0ddc953bde9e9_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo5OGE5MDg0ZmRjZWQ0MWVkOGY5ODgwMTRlMmQyODNhNi90YWJsZXJhbmdlOjk4YTkwODRmZGNlZDQxZWQ4Zjk4ODAxNGUyZDI4M2E2XzEwLTMtMS0xLTEzMTY_ae1f0f95-abab-4142-ab83-79ad3dab4f70">130,780</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ica79a35ca46143efa08136ec1e43e0d5_D20200401-20200630" decimals="-3" sign="-" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo5OGE5MDg0ZmRjZWQ0MWVkOGY5ODgwMTRlMmQyODNhNi90YWJsZXJhbmdlOjk4YTkwODRmZGNlZDQxZWQ4Zjk4ODAxNGUyZDI4M2E2XzEwLTUtMS0xLTEzMTY_0fe887d7-c326-496d-ad2c-cc2079b7d7a7">668</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0ffe73b7f124f5b9dfa9a01b4c7dfcb_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo5OGE5MDg0ZmRjZWQ0MWVkOGY5ODgwMTRlMmQyODNhNi90YWJsZXJhbmdlOjk4YTkwODRmZGNlZDQxZWQ4Zjk4ODAxNGUyZDI4M2E2XzEwLTctMS0xLTEzMTY_1453bb08-02f2-4355-9cf5-afa047a5051b">217,299</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d3bf486d496461182f54f254e8fe296_D20200401-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo5OGE5MDg0ZmRjZWQ0MWVkOGY5ODgwMTRlMmQyODNhNi90YWJsZXJhbmdlOjk4YTkwODRmZGNlZDQxZWQ4Zjk4ODAxNGUyZDI4M2E2XzEwLTktMS0xLTEzMTY_33e2d102-b26e-4e32-aa90-aa03a9a5e4b0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo5OGE5MDg0ZmRjZWQ0MWVkOGY5ODgwMTRlMmQyODNhNi90YWJsZXJhbmdlOjk4YTkwODRmZGNlZDQxZWQ4Zjk4ODAxNGUyZDI4M2E2XzEwLTExLTEtMS0xMzE2_49c7da2f-b66e-4c5a-aa25-03d67c369f9c">217,299</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:33pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Evolent Health Services</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Subtotal</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Segments Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="12" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended June 30, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted EBITDA</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i679cb28be3a34242bd30bce045577c6e_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo5OGE5MDg0ZmRjZWQ0MWVkOGY5ODgwMTRlMmQyODNhNi90YWJsZXJhbmdlOjk4YTkwODRmZGNlZDQxZWQ4Zjk4ODAxNGUyZDI4M2E2XzE1LTEtMS0xLTEzMTY_ad6ac508-f5ec-4189-9c0f-ff888e2eec4c">6,531</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c9bfa2d7f884c12b69f21c9b3af2888_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo5OGE5MDg0ZmRjZWQ0MWVkOGY5ODgwMTRlMmQyODNhNi90YWJsZXJhbmdlOjk4YTkwODRmZGNlZDQxZWQ4Zjk4ODAxNGUyZDI4M2E2XzE1LTMtMS0xLTEzMTY_8cdb9d60-6fb8-4e71-ae94-80413d1eb564">13,597</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib66948dc799e431486e4991bc5ffa9ef_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo5OGE5MDg0ZmRjZWQ0MWVkOGY5ODgwMTRlMmQyODNhNi90YWJsZXJhbmdlOjk4YTkwODRmZGNlZDQxZWQ4Zjk4ODAxNGUyZDI4M2E2XzE1LTUtMS0xLTEzMTY_1b5bb7b9-ef55-4c5a-a770-9ad733af8969">20,128</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i69cb2a622a3f4134a8e8684f7cb47aef_D20210401-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo5OGE5MDg0ZmRjZWQ0MWVkOGY5ODgwMTRlMmQyODNhNi90YWJsZXJhbmdlOjk4YTkwODRmZGNlZDQxZWQ4Zjk4ODAxNGUyZDI4M2E2XzE1LTctMS0xLTEzMTY_96d7c8e6-e86a-433e-ba61-7b27f149da29">6,782</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo5OGE5MDg0ZmRjZWQ0MWVkOGY5ODgwMTRlMmQyODNhNi90YWJsZXJhbmdlOjk4YTkwODRmZGNlZDQxZWQ4Zjk4ODAxNGUyZDI4M2E2XzE1LTktMS0xLTEzMTY_e7ce9961-8bfd-449d-8168-dee6a5c89c0b">13,346</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended June 30, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted EBITDA</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibebddd07c46e4994849d375ecea231c6_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo5OGE5MDg0ZmRjZWQ0MWVkOGY5ODgwMTRlMmQyODNhNi90YWJsZXJhbmdlOjk4YTkwODRmZGNlZDQxZWQ4Zjk4ODAxNGUyZDI4M2E2XzE4LTEtMS0xLTEzMTY_9f2dd305-e4dd-4f3e-b40d-f84e99bbd256">6,948</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16325f028066493d8ad0ddc953bde9e9_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo5OGE5MDg0ZmRjZWQ0MWVkOGY5ODgwMTRlMmQyODNhNi90YWJsZXJhbmdlOjk4YTkwODRmZGNlZDQxZWQ4Zjk4ODAxNGUyZDI4M2E2XzE4LTMtMS0xLTEzMTY_ac4b42a3-3c14-455e-b750-ea3119c721a8">12,200</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0ffe73b7f124f5b9dfa9a01b4c7dfcb_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo5OGE5MDg0ZmRjZWQ0MWVkOGY5ODgwMTRlMmQyODNhNi90YWJsZXJhbmdlOjk4YTkwODRmZGNlZDQxZWQ4Zjk4ODAxNGUyZDI4M2E2XzE4LTUtMS0xLTEzMTY_a6bdbf5e-2f6c-4f9f-af6e-0fb4e1513f9c">19,148</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1d3bf486d496461182f54f254e8fe296_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo5OGE5MDg0ZmRjZWQ0MWVkOGY5ODgwMTRlMmQyODNhNi90YWJsZXJhbmdlOjk4YTkwODRmZGNlZDQxZWQ4Zjk4ODAxNGUyZDI4M2E2XzE4LTctMS0xLTEzMTY_88e80016-6679-462c-be62-e41f23f0d709">8,629</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo5OGE5MDg0ZmRjZWQ0MWVkOGY5ODgwMTRlMmQyODNhNi90YWJsZXJhbmdlOjk4YTkwODRmZGNlZDQxZWQ4Zjk4ODAxNGUyZDI4M2E2XzE4LTktMS0xLTEzMTY_90bca09c-5c4f-4a79-bdfa-fb622c9939ff">10,519</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:145.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:52.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:52.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:67.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:60.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:61.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:67.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:33pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Evolent Health Services</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intersegment<br/>Eliminations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Subtotal</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Six Months Ended June 30, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transformation services</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6c3ed9c5b31412bbfc731eadc4f9045_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo4NzgzNTdmNzQ1OWM0Yjc4ODdhOGYzYmI1NWIyMzQ5ZC90YWJsZXJhbmdlOjg3ODM1N2Y3NDU5YzRiNzg4N2E4ZjNiYjU1YjIzNDlkXzMtMS0xLTEtMA_2a39cb0d-64b1-4cdb-9e78-38c912fb8e65">2,909</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbfffc16190d487496ae91da9f40ee9b_D20210101-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo4NzgzNTdmNzQ1OWM0Yjc4ODdhOGYzYmI1NWIyMzQ5ZC90YWJsZXJhbmdlOjg3ODM1N2Y3NDU5YzRiNzg4N2E4ZjNiYjU1YjIzNDlkXzMtMy0xLTEtMA_fe864099-0a49-450a-8e37-16dc6275c444">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i841058299b4f4c1795217d34792246a1_D20210101-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo4NzgzNTdmNzQ1OWM0Yjc4ODdhOGYzYmI1NWIyMzQ5ZC90YWJsZXJhbmdlOjg3ODM1N2Y3NDU5YzRiNzg4N2E4ZjNiYjU1YjIzNDlkXzMtNS0xLTEtMA_7a50a499-5f59-4bca-a97f-fd17e85c2008">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12ad1dffce3e49519ee5e99e00c3f177_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo4NzgzNTdmNzQ1OWM0Yjc4ODdhOGYzYmI1NWIyMzQ5ZC90YWJsZXJhbmdlOjg3ODM1N2Y3NDU5YzRiNzg4N2E4ZjNiYjU1YjIzNDlkXzMtNy0xLTEtMA_777ce74b-45d7-4ecb-9800-40071bd1f189">2,909</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iadf935fda2524029ab1baa4bbb8135d0_D20210101-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo4NzgzNTdmNzQ1OWM0Yjc4ODdhOGYzYmI1NWIyMzQ5ZC90YWJsZXJhbmdlOjg3ODM1N2Y3NDU5YzRiNzg4N2E4ZjNiYjU1YjIzNDlkXzMtOS0xLTEtMA_58968076-01fe-48ab-9354-1dcfae91099a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cf8298bd37b49539b40ff277f78e799_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo4NzgzNTdmNzQ1OWM0Yjc4ODdhOGYzYmI1NWIyMzQ5ZC90YWJsZXJhbmdlOjg3ODM1N2Y3NDU5YzRiNzg4N2E4ZjNiYjU1YjIzNDlkXzMtMTEtMS0xLTA_50deb4dc-4615-4617-b899-42167f686157">2,909</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Platform and operations services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fd904bfe7584429855878280cb71fbe_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo4NzgzNTdmNzQ1OWM0Yjc4ODdhOGYzYmI1NWIyMzQ5ZC90YWJsZXJhbmdlOjg3ODM1N2Y3NDU5YzRiNzg4N2E4ZjNiYjU1YjIzNDlkXzQtMS0xLTEtMA_2e10f30d-abc0-436b-a29b-3abc8b062243">157,700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a6d3985925f4d079a28f30c8f205377_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo4NzgzNTdmNzQ1OWM0Yjc4ODdhOGYzYmI1NWIyMzQ5ZC90YWJsZXJhbmdlOjg3ODM1N2Y3NDU5YzRiNzg4N2E4ZjNiYjU1YjIzNDlkXzQtMy0xLTEtMA_3f81a87b-dd3d-4a4a-b030-1282494c8daa">277,417</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8b96ed23f107471690b24341345908a6_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo4NzgzNTdmNzQ1OWM0Yjc4ODdhOGYzYmI1NWIyMzQ5ZC90YWJsZXJhbmdlOjg3ODM1N2Y3NDU5YzRiNzg4N2E4ZjNiYjU1YjIzNDlkXzQtNS0xLTEtMA_0f95daad-5f0f-4b3b-b90f-e0fbb4408c9d">898</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e627f3a42b34bd68ed1833fc5b3ff06_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo4NzgzNTdmNzQ1OWM0Yjc4ODdhOGYzYmI1NWIyMzQ5ZC90YWJsZXJhbmdlOjg3ODM1N2Y3NDU5YzRiNzg4N2E4ZjNiYjU1YjIzNDlkXzQtNy0xLTEtMA_7584bc04-090d-4e3d-9529-ea2db11beec8">434,219</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36c5f7a5f7074897b1f640ced6ec0f6b_D20210101-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo4NzgzNTdmNzQ1OWM0Yjc4ODdhOGYzYmI1NWIyMzQ5ZC90YWJsZXJhbmdlOjg3ODM1N2Y3NDU5YzRiNzg4N2E4ZjNiYjU1YjIzNDlkXzQtOS0xLTEtMA_3907af6c-cb0c-443d-a5d9-bcce7a13c08a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf5036ffdbc24ee8a477412be1612a0c_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo4NzgzNTdmNzQ1OWM0Yjc4ODdhOGYzYmI1NWIyMzQ5ZC90YWJsZXJhbmdlOjg3ODM1N2Y3NDU5YzRiNzg4N2E4ZjNiYjU1YjIzNDlkXzQtMTEtMS0xLTA_ee97e4dd-666c-4723-b9ef-27b25cca0f02">434,219</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d62628d6fb54fe0bd811fdfd0bf7b0c_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo4NzgzNTdmNzQ1OWM0Yjc4ODdhOGYzYmI1NWIyMzQ5ZC90YWJsZXJhbmdlOjg3ODM1N2Y3NDU5YzRiNzg4N2E4ZjNiYjU1YjIzNDlkXzUtMS0xLTEtMA_20881c01-b449-4c78-8c54-9dc8015dbedf">160,609</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib887805409a54f638aeeafe3fe5d1688_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo4NzgzNTdmNzQ1OWM0Yjc4ODdhOGYzYmI1NWIyMzQ5ZC90YWJsZXJhbmdlOjg3ODM1N2Y3NDU5YzRiNzg4N2E4ZjNiYjU1YjIzNDlkXzUtMy0xLTEtMA_b349d725-4930-4963-a814-53f492645efa">277,417</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i47a5474af0444feba1cc1f919f211cc9_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo4NzgzNTdmNzQ1OWM0Yjc4ODdhOGYzYmI1NWIyMzQ5ZC90YWJsZXJhbmdlOjg3ODM1N2Y3NDU5YzRiNzg4N2E4ZjNiYjU1YjIzNDlkXzUtNS0xLTEtMA_bb1ced5a-979a-4586-b5a4-ede377426e48">898</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia479742cadcb42f19e8a838c73672d04_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo4NzgzNTdmNzQ1OWM0Yjc4ODdhOGYzYmI1NWIyMzQ5ZC90YWJsZXJhbmdlOjg3ODM1N2Y3NDU5YzRiNzg4N2E4ZjNiYjU1YjIzNDlkXzUtNy0xLTEtMA_a5cf8ade-daf9-4432-a879-16d2632ab4e9">437,128</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i571d8209f1eb48a5abfd5c42c7ee45e7_D20210101-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo4NzgzNTdmNzQ1OWM0Yjc4ODdhOGYzYmI1NWIyMzQ5ZC90YWJsZXJhbmdlOjg3ODM1N2Y3NDU5YzRiNzg4N2E4ZjNiYjU1YjIzNDlkXzUtOS0xLTEtMA_e351dd54-2844-4ae3-9e77-6ed4e057fb54">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo4NzgzNTdmNzQ1OWM0Yjc4ODdhOGYzYmI1NWIyMzQ5ZC90YWJsZXJhbmdlOjg3ODM1N2Y3NDU5YzRiNzg4N2E4ZjNiYjU1YjIzNDlkXzUtMTEtMS0xLTA_8da923a8-c6eb-41c9-9b47-966774d0bf1c">437,128</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Six Months Ended June 30, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transformation services</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74d008e6bc3e404a8233b3b36dd1f025_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo4NzgzNTdmNzQ1OWM0Yjc4ODdhOGYzYmI1NWIyMzQ5ZC90YWJsZXJhbmdlOjg3ODM1N2Y3NDU5YzRiNzg4N2E4ZjNiYjU1YjIzNDlkXzgtMS0xLTEtMA_d1f43f6d-9a56-4dbc-bb5d-85c884fd3457">5,993</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64e303d04c4e4b9e9e4bc39b1eee6997_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo4NzgzNTdmNzQ1OWM0Yjc4ODdhOGYzYmI1NWIyMzQ5ZC90YWJsZXJhbmdlOjg3ODM1N2Y3NDU5YzRiNzg4N2E4ZjNiYjU1YjIzNDlkXzgtMy0xLTEtMA_b1009f94-a5a1-4031-904d-9e448d879a74">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie31b707bdbb24397b9da9c80ed837abf_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo4NzgzNTdmNzQ1OWM0Yjc4ODdhOGYzYmI1NWIyMzQ5ZC90YWJsZXJhbmdlOjg3ODM1N2Y3NDU5YzRiNzg4N2E4ZjNiYjU1YjIzNDlkXzgtNS0xLTEtMA_736fd62f-118a-46f1-898d-4406288faf0e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib86e9afe1f8b4419938a02c0da196679_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo4NzgzNTdmNzQ1OWM0Yjc4ODdhOGYzYmI1NWIyMzQ5ZC90YWJsZXJhbmdlOjg3ODM1N2Y3NDU5YzRiNzg4N2E4ZjNiYjU1YjIzNDlkXzgtNy0xLTEtMA_0c473d45-0f55-47d4-89b6-1583402d3e74">5,993</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6bf1058758a4ffa90f4649ee946bc82_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo4NzgzNTdmNzQ1OWM0Yjc4ODdhOGYzYmI1NWIyMzQ5ZC90YWJsZXJhbmdlOjg3ODM1N2Y3NDU5YzRiNzg4N2E4ZjNiYjU1YjIzNDlkXzgtOS0xLTEtMA_64446f75-d822-4a1c-9bf7-cd8928c43878">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia98a39c8ecac46f5b530749d9b554995_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo4NzgzNTdmNzQ1OWM0Yjc4ODdhOGYzYmI1NWIyMzQ5ZC90YWJsZXJhbmdlOjg3ODM1N2Y3NDU5YzRiNzg4N2E4ZjNiYjU1YjIzNDlkXzgtMTEtMS0xLTA_68e4b417-bc65-4914-9943-64d16bedb9b1">5,993</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Platform and operations services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5139ec3fcfe440db905c8c709c4d692a_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo4NzgzNTdmNzQ1OWM0Yjc4ODdhOGYzYmI1NWIyMzQ5ZC90YWJsZXJhbmdlOjg3ODM1N2Y3NDU5YzRiNzg4N2E4ZjNiYjU1YjIzNDlkXzktMS0xLTEtMA_f004d75b-7c39-4f1a-854c-98714198d865">178,222</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8561338bdd4433695c2fe64f2d14fac_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo4NzgzNTdmNzQ1OWM0Yjc4ODdhOGYzYmI1NWIyMzQ5ZC90YWJsZXJhbmdlOjg3ODM1N2Y3NDU5YzRiNzg4N2E4ZjNiYjU1YjIzNDlkXzktMy0xLTEtMA_98bde152-1e40-4e60-a3b1-f3a5122265dd">255,652</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if4d7479d872f485386fe9f72c2913b25_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo4NzgzNTdmNzQ1OWM0Yjc4ODdhOGYzYmI1NWIyMzQ5ZC90YWJsZXJhbmdlOjg3ODM1N2Y3NDU5YzRiNzg4N2E4ZjNiYjU1YjIzNDlkXzktNS0xLTEtMA_13b3c61b-83f0-444e-982a-af69d21a43f6">1,336</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44946cd02c6a44519e1f9f53797e5d47_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo4NzgzNTdmNzQ1OWM0Yjc4ODdhOGYzYmI1NWIyMzQ5ZC90YWJsZXJhbmdlOjg3ODM1N2Y3NDU5YzRiNzg4N2E4ZjNiYjU1YjIzNDlkXzktNy0xLTEtMA_1665395b-4864-4ad1-92af-a3746f771746">432,538</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfe8d8e6c5344c9b97a29c49f343d22f_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo4NzgzNTdmNzQ1OWM0Yjc4ODdhOGYzYmI1NWIyMzQ5ZC90YWJsZXJhbmdlOjg3ODM1N2Y3NDU5YzRiNzg4N2E4ZjNiYjU1YjIzNDlkXzktOS0xLTEtMA_30400830-45f3-45f8-aa26-13b6eaaf592a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf7fe803335d432ba4201dde52789d25_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo4NzgzNTdmNzQ1OWM0Yjc4ODdhOGYzYmI1NWIyMzQ5ZC90YWJsZXJhbmdlOjg3ODM1N2Y3NDU5YzRiNzg4N2E4ZjNiYjU1YjIzNDlkXzktMTEtMS0xLTA_8f20a778-b8db-4ede-a0c9-27e9f905cca5">432,538</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d756ddfc980426086c7294d41dd2af3_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo4NzgzNTdmNzQ1OWM0Yjc4ODdhOGYzYmI1NWIyMzQ5ZC90YWJsZXJhbmdlOjg3ODM1N2Y3NDU5YzRiNzg4N2E4ZjNiYjU1YjIzNDlkXzEwLTEtMS0xLTA_9faace94-33a3-4747-9a3d-e91fdaa2c789">184,215</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic606425dedeb4d3d9b0b453c252ea236_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo4NzgzNTdmNzQ1OWM0Yjc4ODdhOGYzYmI1NWIyMzQ5ZC90YWJsZXJhbmdlOjg3ODM1N2Y3NDU5YzRiNzg4N2E4ZjNiYjU1YjIzNDlkXzEwLTMtMS0xLTA_f2e45c6c-5a0d-4f9b-ae9f-78a30248f731">255,652</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6a5208c4b92a426f88946822bb9c7fb6_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo4NzgzNTdmNzQ1OWM0Yjc4ODdhOGYzYmI1NWIyMzQ5ZC90YWJsZXJhbmdlOjg3ODM1N2Y3NDU5YzRiNzg4N2E4ZjNiYjU1YjIzNDlkXzEwLTUtMS0xLTA_2c86cf5e-7419-4792-a0c6-4b256917d5cd">1,336</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12a7d1eed63947fb83cf5d1b35015606_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo4NzgzNTdmNzQ1OWM0Yjc4ODdhOGYzYmI1NWIyMzQ5ZC90YWJsZXJhbmdlOjg3ODM1N2Y3NDU5YzRiNzg4N2E4ZjNiYjU1YjIzNDlkXzEwLTctMS0xLTA_71d20862-503d-43b3-a912-a3e9a07ae983">438,531</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id50759ca40e2432a8be2b863be3eeedb_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo4NzgzNTdmNzQ1OWM0Yjc4ODdhOGYzYmI1NWIyMzQ5ZC90YWJsZXJhbmdlOjg3ODM1N2Y3NDU5YzRiNzg4N2E4ZjNiYjU1YjIzNDlkXzEwLTktMS0xLTA_2682bca6-0969-450c-8188-ab25bec99030">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo4NzgzNTdmNzQ1OWM0Yjc4ODdhOGYzYmI1NWIyMzQ5ZC90YWJsZXJhbmdlOjg3ODM1N2Y3NDU5YzRiNzg4N2E4ZjNiYjU1YjIzNDlkXzEwLTExLTEtMS0w_1c651cca-35f5-4e25-aa18-197525444202">438,531</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:33pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Evolent Health Services</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Subtotal</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Segments Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="12" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Six Months Ended June 30, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted EBITDA</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d62628d6fb54fe0bd811fdfd0bf7b0c_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo4NzgzNTdmNzQ1OWM0Yjc4ODdhOGYzYmI1NWIyMzQ5ZC90YWJsZXJhbmdlOjg3ODM1N2Y3NDU5YzRiNzg4N2E4ZjNiYjU1YjIzNDlkXzE1LTEtMS0xLTA_e5cd6635-49fa-414a-b4e4-31b204ab9acf">12,473</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib887805409a54f638aeeafe3fe5d1688_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo4NzgzNTdmNzQ1OWM0Yjc4ODdhOGYzYmI1NWIyMzQ5ZC90YWJsZXJhbmdlOjg3ODM1N2Y3NDU5YzRiNzg4N2E4ZjNiYjU1YjIzNDlkXzE1LTMtMS0xLTA_f1e3a4d9-6b8c-4186-885f-4cea7dfef7fc">29,573</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia479742cadcb42f19e8a838c73672d04_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo4NzgzNTdmNzQ1OWM0Yjc4ODdhOGYzYmI1NWIyMzQ5ZC90YWJsZXJhbmdlOjg3ODM1N2Y3NDU5YzRiNzg4N2E4ZjNiYjU1YjIzNDlkXzE1LTUtMS0xLTA_2cb01417-4784-4b2c-bbb0-8fd47341eaef">42,046</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i571d8209f1eb48a5abfd5c42c7ee45e7_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo4NzgzNTdmNzQ1OWM0Yjc4ODdhOGYzYmI1NWIyMzQ5ZC90YWJsZXJhbmdlOjg3ODM1N2Y3NDU5YzRiNzg4N2E4ZjNiYjU1YjIzNDlkXzE1LTctMS0xLTA_f642d044-5f37-41c4-8dae-0ef6ef24806d">13,793</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo4NzgzNTdmNzQ1OWM0Yjc4ODdhOGYzYmI1NWIyMzQ5ZC90YWJsZXJhbmdlOjg3ODM1N2Y3NDU5YzRiNzg4N2E4ZjNiYjU1YjIzNDlkXzE1LTktMS0xLTA_b0a120a9-20cb-477c-8bc9-032d6d998e09">28,253</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Six Months Ended June 30, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted EBITDA</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d756ddfc980426086c7294d41dd2af3_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo4NzgzNTdmNzQ1OWM0Yjc4ODdhOGYzYmI1NWIyMzQ5ZC90YWJsZXJhbmdlOjg3ODM1N2Y3NDU5YzRiNzg4N2E4ZjNiYjU1YjIzNDlkXzE4LTEtMS0xLTA_37a4efaf-ea35-4b1a-823b-781d29c18b30">11,716</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic606425dedeb4d3d9b0b453c252ea236_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo4NzgzNTdmNzQ1OWM0Yjc4ODdhOGYzYmI1NWIyMzQ5ZC90YWJsZXJhbmdlOjg3ODM1N2Y3NDU5YzRiNzg4N2E4ZjNiYjU1YjIzNDlkXzE4LTMtMS0xLTA_6c26df45-d66d-4efa-bc30-348ed31a7366">19,243</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12a7d1eed63947fb83cf5d1b35015606_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo4NzgzNTdmNzQ1OWM0Yjc4ODdhOGYzYmI1NWIyMzQ5ZC90YWJsZXJhbmdlOjg3ODM1N2Y3NDU5YzRiNzg4N2E4ZjNiYjU1YjIzNDlkXzE4LTUtMS0xLTA_310b52f8-59ab-42f6-9dca-187f508dcf9c">30,959</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id50759ca40e2432a8be2b863be3eeedb_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo4NzgzNTdmNzQ1OWM0Yjc4ODdhOGYzYmI1NWIyMzQ5ZC90YWJsZXJhbmdlOjg3ODM1N2Y3NDU5YzRiNzg4N2E4ZjNiYjU1YjIzNDlkXzE4LTctMS0xLTA_4e8060d7-62a7-4fd2-8cd9-1218f72763de">16,564</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo4NzgzNTdmNzQ1OWM0Yjc4ODdhOGYzYmI1NWIyMzQ5ZC90YWJsZXJhbmdlOjg3ODM1N2Y3NDU5YzRiNzg4N2E4ZjNiYjU1YjIzNDlkXzE4LTktMS0xLTA_3056c2a8-2ecd-4bba-8b17-0bdd32646c69">14,395</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="if6cc2584236048c29b55d092dc816537"><ix:continuation id="ic527861de3f64666a65e902e672addab"><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Corporate includes various finance, human resources, legal, executive, and other corporate infrastructure expenses.</span></div></ix:continuation><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><ix:nonNumeric contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" name="us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90ZXh0cmVnaW9uOjc0ZTMxNDVmNTRhODRjMWY4ZmQ5YjZmNTY5ZDUyMDk5XzM0MTI_5453130b-c982-439c-8556-27de853297e2" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents our reconciliation of consolidated segments total Adjusted EBITDA to net loss attributable to common shareholders of Evolent Health, Inc. for the three and six months ended June 30, 2021 and 2020 (in thousands): </span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:327.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss attributable to common shareholders of Evolent Health, Inc.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzItMS0xLTEtMTUyMQ_09330fbb-f85e-46d5-b7ba-0c4c55c92dcd"><ix:nonFraction unitRef="usd" contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzItMS0xLTEtMTUyMQ_f334614f-48c8-4335-8644-08d1c094b533">9,107</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzItMy0xLTEtMTUyMQ_1f1b826f-81ea-4a16-8e51-b233cb6cb5d8"><ix:nonFraction unitRef="usd" contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzItMy0xLTEtMTUyMQ_464f9ea4-79d0-46fe-b7e0-3bfbaef12c35">203,521</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzItMS0xLTEtMA_3f65effd-5c00-48e2-b9f0-61aa1fc1e88c"><ix:nonFraction unitRef="usd" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzItMS0xLTEtMA_7051b8a1-9469-4d3d-b02f-b619b054437f">18,914</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzItMy0xLTEtMA_0841956d-a0c8-4eca-a9f7-99ceb502bb32"><ix:nonFraction unitRef="usd" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzItMy0xLTEtMA_d981f43f-4d1f-4440-8d13-5cf7db63d994">282,273</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzQtMS0xLTEtMTUyMQ_163a4d38-74de-4cd9-a96b-712b37840fa1">68</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzQtMy0xLTEtMTUyMQ_13114419-16d4-4be7-8688-ce8ceab3b4e6">705</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzQtMS0xLTEtMA_83816d22-b67f-42bc-a14d-da7e4c5fc61c">191</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzQtMy0xLTEtMA_48ca35fa-ea12-4d7b-bd07-63289bd461ca">1,475</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzUtMS0xLTEtMTUyMQ_11cc8d20-a0c9-4bc6-909e-2381fc933d5b">6,274</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzUtMy0xLTEtMTUyMQ_5691b2a7-088a-4dfe-b75f-1ee34e3dff88">6,290</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzUtMS0xLTEtMA_0f5794e1-5476-475f-9319-40ba8fe48852">12,611</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzUtMy0xLTEtMA_548dab9c-e980-4461-861f-7e86acdbb565">12,571</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Provision) benefit for income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzYtMS0xLTEtMTUyMQ_04052006-f596-44c4-b868-a55c6d573f49">91</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzYtMy0xLTEtMTUyMQ_e10cf3f8-4eeb-4685-b5cd-e9b7e9b5e245">3,904</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzYtMS0xLTEtMA_33d280e8-12c1-4ba8-b45c-ea99f7c9933a">702</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzYtMy0xLTEtMA_8db7d2cc-91f2-4967-83ca-04bca456dfc1">3,634</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzctMS0xLTEtMTUyMQ_8a65fbca-0025-4e8a-b655-1edc1670fb2e">14,916</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzctMy0xLTEtMTUyMQ_5c78d84e-771a-4f32-9c28-f027d47d46b8">15,618</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzctMS0xLTEtMA_3c6977da-1489-48bb-a58c-c463d7627f67">30,103</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzctMy0xLTEtMA_05e9b9be-b49a-41f8-a9e0-21e21bffb266">31,596</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity method investment impairment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzgtMS0xLTEtMTUyNw_9fec52cc-fd1d-4be1-afa6-a6bc0d1b6e75">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzgtMy0xLTEtMTUyNw_49900626-35d5-4b00-8acd-68b229537d6c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzgtMS0xLTEtMA_470498e5-c9e7-4342-b704-b6e7184fc1a9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzgtMy0xLTEtMA_020eb503-215b-4104-a030-feb82d293b09">47,133</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on transfer of membership</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630" decimals="-3" format="ixt:zerodash" name="evh:GainOnTransferOfMembership" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzktMS0xLTEtMTUzNw_4d8f4c6b-cbe7-4ed2-8bf1-8f1a45c0afcd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630" decimals="-3" format="ixt:zerodash" name="evh:GainOnTransferOfMembership" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzktMy0xLTEtMTUzNw_ef6f9781-3e24-4762-9a89-148e2fbeb523">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="evh:GainOnTransferOfMembership" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzktMS0xLTEtMA_8df410f6-3f97-47d5-a059-a08b7abe9a4d">22,969</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="evh:GainOnTransferOfMembership" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzktMy0xLTEtMA_138d911e-9fba-4d96-a5c1-0f91bff812aa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on repayment of debt, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzEwLTEtMS0xLTE1NDE_f30f9245-8230-48e3-ab9a-e2c93eb5a146">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzEwLTMtMS0xLTE1NDE_8be05421-c2ec-4e11-bcc9-6101a9219616">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzEwLTEtMS0xLTA_12de13a4-a1e2-4f0b-96fd-e2653c008ef8">19,158</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzEwLTMtMS0xLTA_ef20a79b-fac1-4e98-951b-a3cdcfe51b9e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill impairment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:GoodwillImpairmentLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzExLTEtMS0xLTE1MzM_4c9b9962-435d-42b6-b7d9-29c257d393be">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GoodwillImpairmentLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzExLTMtMS0xLTE1MzM_63147517-36a8-45c1-bc1b-1d60d4b63a28">215,100</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:GoodwillImpairmentLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzExLTUtMS0xLTE1MzM_06dafbe0-615c-4fa9-9fa5-8ec0e0c5a70f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GoodwillImpairmentLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzExLTctMS0xLTE1MzM_97eb0276-5eae-4b82-a477-7a3fc47ce2e8">215,100</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain from equity method investees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzEyLTEtMS0xLTE1NDU_5389febb-fe83-4144-9888-161629606b06">4,879</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzEyLTMtMS0xLTE1NDU_bc4c368a-7e0a-4143-8b60-4a58ed94f88e">25,143</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzExLTEtMS0xLTA_ed4eccd2-42f4-4dad-a398-8345da24d3f2">12,662</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzExLTMtMS0xLTA_3338a9e1-ee9b-4544-b041-7f91dcb8128e">24,731</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on disposal of assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:GainLossOnDispositionOfAssets1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzEzLTEtMS0xLTE1NTM_d68bbafc-9fd1-4110-be89-ba5f82386975">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:GainLossOnDispositionOfAssets1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzEzLTMtMS0xLTE1NTM_60dd071d-ffb2-4dd4-8d0d-e8cc29976f2a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:GainLossOnDispositionOfAssets1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzEyLTEtMS0xLTA_040bab52-3241-4230-8c94-5abd2d6a6cd5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:GainLossOnDispositionOfAssets1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzEyLTMtMS0xLTA_eaf9136c-b3fc-48c0-b5b8-f9e358108c9c">6,447</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration and indemnification asset</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzE0LTEtMS0xLTE1NTc_ca4f3159-fa8b-4452-b17c-f57410472140">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzE0LTMtMS0xLTE1NTc_9133326a-9ed1-4027-8428-58073c039c5a">756</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzEzLTEtMS0xLTA_4e433f0c-854b-4309-aa90-c9a22f41781c">594</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzEzLTMtMS0xLTA_1f5ea248-709b-4d45-8fee-60c8240a270b">3,062</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzE1LTEtMS0xLTE1NTc_ca9e6b7b-649d-4aa1-8cb2-f3f31de509eb">18</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzE1LTMtMS0xLTE1NTc_70afdddb-1ddb-4bb3-8d4f-065a0db37047">354</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzE0LTEtMS0xLTA_7c724be6-7ece-437e-a5b1-5c916e1c77c1">32</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzE0LTMtMS0xLTA_0a35e81d-6aea-4545-9cb9-8a44885d2049">284</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repositioning costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630" decimals="-3" name="us-gaap:RestructuringCharges" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzE2LTEtMS0xLTE1NjE_9a4e4bf5-55b3-4496-b4a9-1d8427fc800a">663</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:RestructuringCharges" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzE2LTMtMS0xLTE1NjE_389b0c50-f883-435a-9b7b-65dcb33eff3e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestructuringCharges" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzE1LTEtMS0xLTA_878f2312-14aa-4411-9d7c-f8c482070931">6,043</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:RestructuringCharges" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzE1LTMtMS0xLTA_e53751d1-aa39-48ff-a196-4fbaffb032a8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="evh:SharebasedCompensationIncludingOnetimeAdjustment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzE3LTEtMS0xLTE1NjE_feaeded1-87a9-4f6b-9ddc-a9cdadebbeea">3,653</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="evh:SharebasedCompensationIncludingOnetimeAdjustment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzE3LTMtMS0xLTE1NjE_65c766d1-d706-46af-9e67-8626dcda8428">3,703</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="evh:SharebasedCompensationIncludingOnetimeAdjustment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzE2LTEtMS0xLTA_922b4358-c276-406a-8513-6354edb0e7b1">7,359</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="evh:SharebasedCompensationIncludingOnetimeAdjustment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzE2LTMtMS0xLTA_e6993cb2-c0e6-4658-894a-52d75d8c15ce">7,211</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Severance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:SeveranceCosts1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzE4LTEtMS0xLTE1NjE_34db6e77-380b-4886-a5a8-2660b6c7245b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630" decimals="-3" name="us-gaap:SeveranceCosts1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzE4LTMtMS0xLTE1NjE_20dd6179-1fd9-427b-8821-10d1ef35c723">30</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="-3" name="us-gaap:SeveranceCosts1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzE3LTEtMS0xLTA_c20b3c97-eb0c-44ac-9744-5e78148f80b4">52</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SeveranceCosts1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzE3LTMtMS0xLTA_39751549-03fc-4ce1-9ec9-b19551e78fd0">6,133</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of contract cost assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630" decimals="-3" name="evh:CapitalizedContractCostAmortizationPurchaseAccountingAdjustments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzE5LTEtMS0xLTE1NjE_fe807342-2f3f-4099-82dd-26eb3232d288">196</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630" decimals="-3" name="evh:CapitalizedContractCostAmortizationPurchaseAccountingAdjustments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzE5LTMtMS0xLTE1NjE_d4fa8055-118d-4350-9a25-a4581a0608bc">767</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="-3" name="evh:CapitalizedContractCostAmortizationPurchaseAccountingAdjustments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzE4LTEtMS0xLTA_cf560695-8617-4b84-a0e1-0dafc4e25168">323</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="evh:CapitalizedContractCostAmortizationPurchaseAccountingAdjustments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzE4LTMtMS0xLTA_95f1fc00-ea36-4064-9d52-5c9b7ac88e15">1,207</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Strategy and shareholder advisory expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="evh:ShareholderAdvisoryServices" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzIwLTEtMS0xLTE1NjU_dca355a7-52bb-4bf8-b936-1ba967ec88d7">1,513</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630" decimals="-3" format="ixt:zerodash" name="evh:ShareholderAdvisoryServices" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzIwLTMtMS0xLTE1NjU_568f4e76-d595-4db6-905c-4d6ee3e3ddcf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="evh:ShareholderAdvisoryServices" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzE5LTEtMS0xLTA_3525e267-45da-4217-9a53-2febf0004a58">6,513</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="evh:ShareholderAdvisoryServices" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzE5LTMtMS0xLTA_a6fea963-bad2-4184-8a4c-a4d464c129b1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630" decimals="-3" name="evh:TransactionCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzIxLTEtMS0xLTE1NjU_55de0874-7d45-4fc9-92f5-b0162909ee91">76</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630" decimals="-3" name="evh:TransactionCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzIxLTMtMS0xLTE1NjU_2e2c5be8-589a-4743-abec-57caa735d786">374</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="evh:TransactionCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzIwLTEtMS0xLTA_89f88066-8087-48dd-9be5-0c281d8bdd5a">2,070</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="-3" name="evh:TransactionCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzIwLTMtMS0xLTA_701abe71-f2c1-47d9-a3ef-6fb7545ceedf">683</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain (loss) from discontinued operations </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzIyLTEtMS0xLTE1NjU_f31f527b-b921-4570-bb67-dff8944def11">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzIyLTMtMS0xLTE1NjU_ecb86564-0d16-4f0b-be08-1828afc77d88">1,508</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzIxLTEtMS0xLTA_d52cdfe9-4ced-48ea-a5fe-f6f292e78e07">1,383</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzIxLTMtMS0xLTA_9bea7d8c-98bc-4e77-aa58-16662850df28">1,773</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjusted EBITDA</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzIzLTEtMS0xLTE1NjU_b8e284ea-b87a-41ef-beda-8770ae2f9c26">13,346</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzIzLTMtMS0xLTE1NjU_2c0992e5-a00f-4c59-a7a0-45c49da5acb4">10,519</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzIyLTEtMS0xLTA_34f68d73-5170-426a-8055-6d07db509995">28,253</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzIyLTMtMS0xLTA_b1687b6c-b0b8-4f89-9abb-aaf4871d77ca">14,395</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Includes $<ix:nonFraction unitRef="usd" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90ZXh0cmVnaW9uOjc0ZTMxNDVmNTRhODRjMWY4ZmQ5YjZmNTY5ZDUyMDk5XzMxNjk_21f819b6-f612-4a34-a7c9-911830c65d53">1.9</ix:nonFraction>&#160;million gain on disposal of discontinued operations for the six months ended June 30, 2021.</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Asset information by segment is not a key measure of performance used by the CODM. Accordingly, we have not disclosed asset information by segment.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="id8f403494d0a42c2868794fb470218fc_124"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 22. <ix:nonNumeric contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" name="us-gaap:InsuranceDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjQvZnJhZzo0MDI1ZmJmMmQ0MTY0MWZhODhhZTg0YmZkZDc4M2YzZS90ZXh0cmVnaW9uOjQwMjVmYmYyZDQxNjQxZmE4OGFlODRiZmRkNzgzZjNlXzUwMTI_f3c032db-f95b-485e-9ac5-52af31322674" continuedAt="icfbda332e4124c2ea04b09b1e80ee7a0" escape="true">Reserve for Claims and Performance-Based Arrangements</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="icfbda332e4124c2ea04b09b1e80ee7a0" continuedAt="ib25d83276f554fc7b9da26fd7a095c5f"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains reserves for its liabilities related to payments to providers and pharmacies under performance-based arrangements related to its total cost of care and specialty care management services. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reserves for claims and performance-based arrangements for our EHS and Clinical Solutions segments reflect actual payments under performance-based arrangements and the ultimate cost of claims that have been incurred but not reported, including expected development on reported claims, those that have been reported but not yet paid (reported claims in process), and other medical care expenses and services payable that are primarily composed of accruals for incentives and other amounts payable to health care professionals and facilities. Reserves for claims and performance-based arrangements also reflect estimated amounts owed under the reinsurance agreements, as discussed further in Note 11.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses actuarial principles and assumptions that are consistently applied each reporting period and recognizes the actuarial best estimate of the ultimate liability along with a margin for adverse deviation. This approach is consistent with actuarial standards of practice that the liabilities be adequate under moderately adverse conditions.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This liability predominately consists of incurred but not reported amounts and reported claims in process including expected development on reported claims. The liability for reserves related to its total cost of care and specialty care management services is primarily calculated using "completion factors" developed by comparing the claim incurred date to the date claims were paid. Completion factors are impacted by several key items including changes in: 1)&#160;electronic (auto-adjudication) versus manual claim processing, 2)&#160;provider claims submission rates, 3)&#160;membership and 4)&#160;the mix of products.  </span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ib25d83276f554fc7b9da26fd7a095c5f"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s policy for reserves related to its total cost of care and specialty care management services is to use historical completion factors combined with an analysis of current trends and operational factors to develop current estimates of completion factors. The Company estimates the liability for claims incurred in each month by applying the current estimates of completion factors to the current paid claims data. This approach implicitly assumes that historical completion rates will be a useful indicator for the current period. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For more recent months, and for newer lines of business where there is not sufficient paid claims history to develop completion factors, the Company expects to rely more heavily on medical cost trend and expected loss ratio analysis that reflects expected claim payment patterns and other relevant operational considerations, or authorization analysis. Medical cost trend is primarily impacted by medical service utilization and unit costs that are affected by changes in the level and mix of medical benefits offered, including inpatient, outpatient and pharmacy, the impact of copays and deductibles, changes in provider practices and changes in consumer demographics and consumption behavior. Authorization analysis projects costs on an authorization-level basis and also accounts for the impact of copays and deductibles, unit cost and historic discontinuation rates for treatment. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For each reporting period, the Company compares key assumptions used to establish the reserves for claims and performance-based arrangements to actual experience. When actual experience differs from these assumptions, reserves for claims and performance-based arrangements are adjusted through current period net income. Additionally, the Company evaluates expected future developments and emerging trends that may impact key assumptions. The process used to determine this liability requires the Company to make critical accounting estimates that involve considerable judgment, reflecting the variability inherent in forecasting future claim payments. These estimates are highly sensitive to changes in the Company's key assumptions, specifically completion factors and medical cost trends.</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" name="us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjQvZnJhZzo0MDI1ZmJmMmQ0MTY0MWZhODhhZTg0YmZkZDc4M2YzZS90ZXh0cmVnaW9uOjQwMjVmYmYyZDQxNjQxZmE4OGFlODRiZmRkNzgzZjNlXzUwMTQ_aa8c7cd3-d26d-4157-8bd6-dfe94961f20e" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Activity in reserves for claims and performance-based arrangements for the six months ended June 30, 2021 and 2020, was as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:142.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:37.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:47.50pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:47.50pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:3.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:40.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:3.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:37.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:3.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:47.50pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:3.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:47.50pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:3.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:40.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="45" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:33pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EHS </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">True Health</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EHS </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">True Health</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40bf24d71e79424985bfa9b1dc75e390_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjQvZnJhZzo0MDI1ZmJmMmQ0MTY0MWZhODhhZTg0YmZkZDc4M2YzZS90YWJsZTo2N2VlOGE3MTg5OTA0YzkwOWJkYTI1ZDY4ODA4NGU4NC90YWJsZXJhbmdlOjY3ZWU4YTcxODk5MDRjOTA5YmRhMjVkNjg4MDg0ZTg0XzMtMS0xLTEtMA_2182a43a-ec51-4d9d-8891-305e91a089ca">56,295</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00a15ecaf66f4a6cbb5b4eb9fa265870_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjQvZnJhZzo0MDI1ZmJmMmQ0MTY0MWZhODhhZTg0YmZkZDc4M2YzZS90YWJsZTo2N2VlOGE3MTg5OTA0YzkwOWJkYTI1ZDY4ODA4NGU4NC90YWJsZXJhbmdlOjY3ZWU4YTcxODk5MDRjOTA5YmRhMjVkNjg4MDg0ZTg0XzMtMy0xLTEtMA_d72f149e-2b1a-414c-8ccc-14cc7dd3c1c2">122,532</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16817704fb5d42b894f5f9c40a24d9d7_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjQvZnJhZzo0MDI1ZmJmMmQ0MTY0MWZhODhhZTg0YmZkZDc4M2YzZS90YWJsZTo2N2VlOGE3MTg5OTA0YzkwOWJkYTI1ZDY4ODA4NGU4NC90YWJsZXJhbmdlOjY3ZWU4YTcxODk5MDRjOTA5YmRhMjVkNjg4MDg0ZTg0XzMtNS0xLTEtMA_6d3cc194-e455-4384-bcab-81e676c2253e">9,859</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45bff335c1434d6ba44132da1b0557db_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjQvZnJhZzo0MDI1ZmJmMmQ0MTY0MWZhODhhZTg0YmZkZDc4M2YzZS90YWJsZTo2N2VlOGE3MTg5OTA0YzkwOWJkYTI1ZDY4ODA4NGU4NC90YWJsZXJhbmdlOjY3ZWU4YTcxODk5MDRjOTA5YmRhMjVkNjg4MDg0ZTg0XzMtNy0xLTEtMA_afad98fe-1625-434e-8102-ac313bdd6b69">188,686</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcf0f323376446aca3fd59b2d1a2f2ad_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjQvZnJhZzo0MDI1ZmJmMmQ0MTY0MWZhODhhZTg0YmZkZDc4M2YzZS90YWJsZTo2N2VlOGE3MTg5OTA0YzkwOWJkYTI1ZDY4ODA4NGU4NC90YWJsZXJhbmdlOjY3ZWU4YTcxODk5MDRjOTA5YmRhMjVkNjg4MDg0ZTg0XzMtOS0xLTEtMA_4730720f-e41d-4abe-96d9-eadb10bb140d">4,265</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a66b42348f74ceea613fecea2deba8e_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjQvZnJhZzo0MDI1ZmJmMmQ0MTY0MWZhODhhZTg0YmZkZDc4M2YzZS90YWJsZTo2N2VlOGE3MTg5OTA0YzkwOWJkYTI1ZDY4ODA4NGU4NC90YWJsZXJhbmdlOjY3ZWU4YTcxODk5MDRjOTA5YmRhMjVkNjg4MDg0ZTg0XzMtMTEtMS0xLTA_312dfd2a-bb52-434f-a973-d0cbf0605a50">50,245</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f5902da906645d380ce211e0eb169b8_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjQvZnJhZzo0MDI1ZmJmMmQ0MTY0MWZhODhhZTg0YmZkZDc4M2YzZS90YWJsZTo2N2VlOGE3MTg5OTA0YzkwOWJkYTI1ZDY4ODA4NGU4NC90YWJsZXJhbmdlOjY3ZWU4YTcxODk5MDRjOTA5YmRhMjVkNjg4MDg0ZTg0XzMtMTMtMS0xLTA_e5850c1b-1e03-476a-81eb-b507ceb3dd4b">6,640</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0ff0ad229b441d4b12bc8956f92a917_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjQvZnJhZzo0MDI1ZmJmMmQ0MTY0MWZhODhhZTg0YmZkZDc4M2YzZS90YWJsZTo2N2VlOGE3MTg5OTA0YzkwOWJkYTI1ZDY4ODA4NGU4NC90YWJsZXJhbmdlOjY3ZWU4YTcxODk5MDRjOTA5YmRhMjVkNjg4MDg0ZTg0XzMtMTUtMS0xLTA_096d218d-afc0-4726-9256-b45eccbfa5b1">61,150</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incurred costs related to current year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d62628d6fb54fe0bd811fdfd0bf7b0c_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="evh:CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjQvZnJhZzo0MDI1ZmJmMmQ0MTY0MWZhODhhZTg0YmZkZDc4M2YzZS90YWJsZTo2N2VlOGE3MTg5OTA0YzkwOWJkYTI1ZDY4ODA4NGU4NC90YWJsZXJhbmdlOjY3ZWU4YTcxODk5MDRjOTA5YmRhMjVkNjg4MDg0ZTg0XzUtMS0xLTEtMA_d82fa545-9e71-41f8-b03f-1ae84f87e028">8,669</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib887805409a54f638aeeafe3fe5d1688_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="evh:CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjQvZnJhZzo0MDI1ZmJmMmQ0MTY0MWZhODhhZTg0YmZkZDc4M2YzZS90YWJsZTo2N2VlOGE3MTg5OTA0YzkwOWJkYTI1ZDY4ODA4NGU4NC90YWJsZXJhbmdlOjY3ZWU4YTcxODk5MDRjOTA5YmRhMjVkNjg4MDg0ZTg0XzUtMy0xLTEtMA_b39e044e-a8ca-4748-9f76-be0711c55852">219,343</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i558e7ef31d4b428c9ee6d8d5a9dd5f54_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="evh:CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjQvZnJhZzo0MDI1ZmJmMmQ0MTY0MWZhODhhZTg0YmZkZDc4M2YzZS90YWJsZTo2N2VlOGE3MTg5OTA0YzkwOWJkYTI1ZDY4ODA4NGU4NC90YWJsZXJhbmdlOjY3ZWU4YTcxODk5MDRjOTA5YmRhMjVkNjg4MDg0ZTg0XzUtNS0xLTEtMA_125c1671-1cd1-435d-9d5e-04c267126bd2">34,228</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="evh:CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjQvZnJhZzo0MDI1ZmJmMmQ0MTY0MWZhODhhZTg0YmZkZDc4M2YzZS90YWJsZTo2N2VlOGE3MTg5OTA0YzkwOWJkYTI1ZDY4ODA4NGU4NC90YWJsZXJhbmdlOjY3ZWU4YTcxODk5MDRjOTA5YmRhMjVkNjg4MDg0ZTg0XzUtNy0xLTEtMA_b1a1136b-9e58-4e9c-9d69-8efcdaf9c464">262,240</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d756ddfc980426086c7294d41dd2af3_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="evh:CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjQvZnJhZzo0MDI1ZmJmMmQ0MTY0MWZhODhhZTg0YmZkZDc4M2YzZS90YWJsZTo2N2VlOGE3MTg5OTA0YzkwOWJkYTI1ZDY4ODA4NGU4NC90YWJsZXJhbmdlOjY3ZWU4YTcxODk5MDRjOTA5YmRhMjVkNjg4MDg0ZTg0XzUtOS0xLTEtMA_88a01fca-e35d-4681-879a-dd842cc4be53">2,135</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic606425dedeb4d3d9b0b453c252ea236_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="evh:CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjQvZnJhZzo0MDI1ZmJmMmQ0MTY0MWZhODhhZTg0YmZkZDc4M2YzZS90YWJsZTo2N2VlOGE3MTg5OTA0YzkwOWJkYTI1ZDY4ODA4NGU4NC90YWJsZXJhbmdlOjY3ZWU4YTcxODk5MDRjOTA5YmRhMjVkNjg4MDg0ZTg0XzUtMTEtMS0xLTA_5780321b-ad73-42b6-868c-220fe8df484b">201,977</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie069c94280064225b4ffe831d6c5e5fe_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="evh:CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjQvZnJhZzo0MDI1ZmJmMmQ0MTY0MWZhODhhZTg0YmZkZDc4M2YzZS90YWJsZTo2N2VlOGE3MTg5OTA0YzkwOWJkYTI1ZDY4ODA4NGU4NC90YWJsZXJhbmdlOjY3ZWU4YTcxODk5MDRjOTA5YmRhMjVkNjg4MDg0ZTg0XzUtMTMtMS0xLTA_b3bfa997-cbf8-4744-ab43-03863b7898ff">41,584</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="evh:CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjQvZnJhZzo0MDI1ZmJmMmQ0MTY0MWZhODhhZTg0YmZkZDc4M2YzZS90YWJsZTo2N2VlOGE3MTg5OTA0YzkwOWJkYTI1ZDY4ODA4NGU4NC90YWJsZXJhbmdlOjY3ZWU4YTcxODk5MDRjOTA5YmRhMjVkNjg4MDg0ZTg0XzUtMTUtMS0xLTA_719296c5-6e6f-4039-8d62-56f9766a601a">245,696</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incurred costs related to prior year</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d62628d6fb54fe0bd811fdfd0bf7b0c_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjQvZnJhZzo0MDI1ZmJmMmQ0MTY0MWZhODhhZTg0YmZkZDc4M2YzZS90YWJsZTo2N2VlOGE3MTg5OTA0YzkwOWJkYTI1ZDY4ODA4NGU4NC90YWJsZXJhbmdlOjY3ZWU4YTcxODk5MDRjOTA5YmRhMjVkNjg4MDg0ZTg0XzYtMS0xLTEtMA_455b5e5c-9d35-4a35-80f9-2fa06ba05271">6,293</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib887805409a54f638aeeafe3fe5d1688_D20210101-20210630" decimals="-3" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjQvZnJhZzo0MDI1ZmJmMmQ0MTY0MWZhODhhZTg0YmZkZDc4M2YzZS90YWJsZTo2N2VlOGE3MTg5OTA0YzkwOWJkYTI1ZDY4ODA4NGU4NC90YWJsZXJhbmdlOjY3ZWU4YTcxODk5MDRjOTA5YmRhMjVkNjg4MDg0ZTg0XzYtMy0xLTEtMA_573499c6-c98b-4a66-97be-c1314a0a1305">215</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i558e7ef31d4b428c9ee6d8d5a9dd5f54_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjQvZnJhZzo0MDI1ZmJmMmQ0MTY0MWZhODhhZTg0YmZkZDc4M2YzZS90YWJsZTo2N2VlOGE3MTg5OTA0YzkwOWJkYTI1ZDY4ODA4NGU4NC90YWJsZXJhbmdlOjY3ZWU4YTcxODk5MDRjOTA5YmRhMjVkNjg4MDg0ZTg0XzYtNS0xLTEtMA_d8147a29-7ce5-4513-bbb6-71f35ca3515c">241</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjQvZnJhZzo0MDI1ZmJmMmQ0MTY0MWZhODhhZTg0YmZkZDc4M2YzZS90YWJsZTo2N2VlOGE3MTg5OTA0YzkwOWJkYTI1ZDY4ODA4NGU4NC90YWJsZXJhbmdlOjY3ZWU4YTcxODk5MDRjOTA5YmRhMjVkNjg4MDg0ZTg0XzYtNy0xLTEtMA_7d4ddf23-de9b-4324-a798-4c610e7899fd">6,267</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8d756ddfc980426086c7294d41dd2af3_D20200101-20200630" decimals="-3" sign="-" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjQvZnJhZzo0MDI1ZmJmMmQ0MTY0MWZhODhhZTg0YmZkZDc4M2YzZS90YWJsZTo2N2VlOGE3MTg5OTA0YzkwOWJkYTI1ZDY4ODA4NGU4NC90YWJsZXJhbmdlOjY3ZWU4YTcxODk5MDRjOTA5YmRhMjVkNjg4MDg0ZTg0XzYtOS0xLTEtMA_938b41cb-1161-4ab0-8430-6398f5a4bc35">498</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic606425dedeb4d3d9b0b453c252ea236_D20200101-20200630" decimals="-3" sign="-" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjQvZnJhZzo0MDI1ZmJmMmQ0MTY0MWZhODhhZTg0YmZkZDc4M2YzZS90YWJsZTo2N2VlOGE3MTg5OTA0YzkwOWJkYTI1ZDY4ODA4NGU4NC90YWJsZXJhbmdlOjY3ZWU4YTcxODk5MDRjOTA5YmRhMjVkNjg4MDg0ZTg0XzYtMTEtMS0xLTA_b6f22fd2-a6ff-4f37-b2aa-98e117dea258">23</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie069c94280064225b4ffe831d6c5e5fe_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjQvZnJhZzo0MDI1ZmJmMmQ0MTY0MWZhODhhZTg0YmZkZDc4M2YzZS90YWJsZTo2N2VlOGE3MTg5OTA0YzkwOWJkYTI1ZDY4ODA4NGU4NC90YWJsZXJhbmdlOjY3ZWU4YTcxODk5MDRjOTA5YmRhMjVkNjg4MDg0ZTg0XzYtMTMtMS0xLTA_9d8c6f74-0c8c-4364-a057-873f99bcc373">1,351</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="-3" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjQvZnJhZzo0MDI1ZmJmMmQ0MTY0MWZhODhhZTg0YmZkZDc4M2YzZS90YWJsZTo2N2VlOGE3MTg5OTA0YzkwOWJkYTI1ZDY4ODA4NGU4NC90YWJsZXJhbmdlOjY3ZWU4YTcxODk5MDRjOTA5YmRhMjVkNjg4MDg0ZTg0XzYtMTUtMS0xLTA_ed92be78-e642-46c7-a49f-32d056e08da6">830</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Paid costs related to current year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d62628d6fb54fe0bd811fdfd0bf7b0c_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjQvZnJhZzo0MDI1ZmJmMmQ0MTY0MWZhODhhZTg0YmZkZDc4M2YzZS90YWJsZTo2N2VlOGE3MTg5OTA0YzkwOWJkYTI1ZDY4ODA4NGU4NC90YWJsZXJhbmdlOjY3ZWU4YTcxODk5MDRjOTA5YmRhMjVkNjg4MDg0ZTg0XzctMS0xLTEtMA_19c6842d-d3c4-401f-9148-5ac37249e042">20,801</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib887805409a54f638aeeafe3fe5d1688_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjQvZnJhZzo0MDI1ZmJmMmQ0MTY0MWZhODhhZTg0YmZkZDc4M2YzZS90YWJsZTo2N2VlOGE3MTg5OTA0YzkwOWJkYTI1ZDY4ODA4NGU4NC90YWJsZXJhbmdlOjY3ZWU4YTcxODk5MDRjOTA5YmRhMjVkNjg4MDg0ZTg0XzctMy0xLTEtMA_de0a7189-6be4-43f0-a9cc-d10253caba50">73,379</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i558e7ef31d4b428c9ee6d8d5a9dd5f54_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjQvZnJhZzo0MDI1ZmJmMmQ0MTY0MWZhODhhZTg0YmZkZDc4M2YzZS90YWJsZTo2N2VlOGE3MTg5OTA0YzkwOWJkYTI1ZDY4ODA4NGU4NC90YWJsZXJhbmdlOjY3ZWU4YTcxODk5MDRjOTA5YmRhMjVkNjg4MDg0ZTg0XzctNS0xLTEtMA_042772d6-294c-443c-84a2-79a1d7ac42a5">23,274</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjQvZnJhZzo0MDI1ZmJmMmQ0MTY0MWZhODhhZTg0YmZkZDc4M2YzZS90YWJsZTo2N2VlOGE3MTg5OTA0YzkwOWJkYTI1ZDY4ODA4NGU4NC90YWJsZXJhbmdlOjY3ZWU4YTcxODk5MDRjOTA5YmRhMjVkNjg4MDg0ZTg0XzctNy0xLTEtMA_63fa182a-b88b-447d-b647-96a1f431e92b">117,454</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d756ddfc980426086c7294d41dd2af3_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjQvZnJhZzo0MDI1ZmJmMmQ0MTY0MWZhODhhZTg0YmZkZDc4M2YzZS90YWJsZTo2N2VlOGE3MTg5OTA0YzkwOWJkYTI1ZDY4ODA4NGU4NC90YWJsZXJhbmdlOjY3ZWU4YTcxODk5MDRjOTA5YmRhMjVkNjg4MDg0ZTg0XzctOS0xLTEtMA_fe7024d9-01ee-44c5-ac3f-2d2d7385a81f">4,020</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic606425dedeb4d3d9b0b453c252ea236_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjQvZnJhZzo0MDI1ZmJmMmQ0MTY0MWZhODhhZTg0YmZkZDc4M2YzZS90YWJsZTo2N2VlOGE3MTg5OTA0YzkwOWJkYTI1ZDY4ODA4NGU4NC90YWJsZXJhbmdlOjY3ZWU4YTcxODk5MDRjOTA5YmRhMjVkNjg4MDg0ZTg0XzctMTEtMS0xLTA_e0006e90-e73f-4061-b16f-c4a83d276801">163,431</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie069c94280064225b4ffe831d6c5e5fe_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjQvZnJhZzo0MDI1ZmJmMmQ0MTY0MWZhODhhZTg0YmZkZDc4M2YzZS90YWJsZTo2N2VlOGE3MTg5OTA0YzkwOWJkYTI1ZDY4ODA4NGU4NC90YWJsZXJhbmdlOjY3ZWU4YTcxODk5MDRjOTA5YmRhMjVkNjg4MDg0ZTg0XzctMTMtMS0xLTA_f7a1e640-cdd3-491d-9b9f-4d127767dab9">33,538</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjQvZnJhZzo0MDI1ZmJmMmQ0MTY0MWZhODhhZTg0YmZkZDc4M2YzZS90YWJsZTo2N2VlOGE3MTg5OTA0YzkwOWJkYTI1ZDY4ODA4NGU4NC90YWJsZXJhbmdlOjY3ZWU4YTcxODk5MDRjOTA5YmRhMjVkNjg4MDg0ZTg0XzctMTUtMS0xLTA_0ec488ef-9fd7-4ecb-aa74-6a67148dca59">200,989</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Paid costs related to prior year</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d62628d6fb54fe0bd811fdfd0bf7b0c_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjQvZnJhZzo0MDI1ZmJmMmQ0MTY0MWZhODhhZTg0YmZkZDc4M2YzZS90YWJsZTo2N2VlOGE3MTg5OTA0YzkwOWJkYTI1ZDY4ODA4NGU4NC90YWJsZXJhbmdlOjY3ZWU4YTcxODk5MDRjOTA5YmRhMjVkNjg4MDg0ZTg0XzgtMS0xLTEtMA_3ab5496a-7581-4c42-a929-817635ef1af4">20,673</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib887805409a54f638aeeafe3fe5d1688_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjQvZnJhZzo0MDI1ZmJmMmQ0MTY0MWZhODhhZTg0YmZkZDc4M2YzZS90YWJsZTo2N2VlOGE3MTg5OTA0YzkwOWJkYTI1ZDY4ODA4NGU4NC90YWJsZXJhbmdlOjY3ZWU4YTcxODk5MDRjOTA5YmRhMjVkNjg4MDg0ZTg0XzgtMy0xLTEtMA_35fe4b6a-e9b0-40eb-bb7f-b9e282f0f4b7">71,392</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i558e7ef31d4b428c9ee6d8d5a9dd5f54_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjQvZnJhZzo0MDI1ZmJmMmQ0MTY0MWZhODhhZTg0YmZkZDc4M2YzZS90YWJsZTo2N2VlOGE3MTg5OTA0YzkwOWJkYTI1ZDY4ODA4NGU4NC90YWJsZXJhbmdlOjY3ZWU4YTcxODk5MDRjOTA5YmRhMjVkNjg4MDg0ZTg0XzgtNS0xLTEtMA_83d6ae14-fdf9-45a1-a0ae-825f34bf3462">7,378</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjQvZnJhZzo0MDI1ZmJmMmQ0MTY0MWZhODhhZTg0YmZkZDc4M2YzZS90YWJsZTo2N2VlOGE3MTg5OTA0YzkwOWJkYTI1ZDY4ODA4NGU4NC90YWJsZXJhbmdlOjY3ZWU4YTcxODk5MDRjOTA5YmRhMjVkNjg4MDg0ZTg0XzgtNy0xLTEtMA_603897f7-dc09-4377-88f2-da7d363c83be">99,443</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d756ddfc980426086c7294d41dd2af3_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjQvZnJhZzo0MDI1ZmJmMmQ0MTY0MWZhODhhZTg0YmZkZDc4M2YzZS90YWJsZTo2N2VlOGE3MTg5OTA0YzkwOWJkYTI1ZDY4ODA4NGU4NC90YWJsZXJhbmdlOjY3ZWU4YTcxODk5MDRjOTA5YmRhMjVkNjg4MDg0ZTg0XzgtOS0xLTEtMA_9ad541f4-d1c5-4412-b753-c57f070c2bd5">2,530</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic606425dedeb4d3d9b0b453c252ea236_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjQvZnJhZzo0MDI1ZmJmMmQ0MTY0MWZhODhhZTg0YmZkZDc4M2YzZS90YWJsZTo2N2VlOGE3MTg5OTA0YzkwOWJkYTI1ZDY4ODA4NGU4NC90YWJsZXJhbmdlOjY3ZWU4YTcxODk5MDRjOTA5YmRhMjVkNjg4MDg0ZTg0XzgtMTEtMS0xLTA_7bed7bae-184f-4dc2-be4d-39312c9eb9c4">7,499</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie069c94280064225b4ffe831d6c5e5fe_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjQvZnJhZzo0MDI1ZmJmMmQ0MTY0MWZhODhhZTg0YmZkZDc4M2YzZS90YWJsZTo2N2VlOGE3MTg5OTA0YzkwOWJkYTI1ZDY4ODA4NGU4NC90YWJsZXJhbmdlOjY3ZWU4YTcxODk5MDRjOTA5YmRhMjVkNjg4MDg0ZTg0XzgtMTMtMS0xLTA_18a1799d-9363-494f-83cc-1bdcd146fca9">6,975</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjQvZnJhZzo0MDI1ZmJmMmQ0MTY0MWZhODhhZTg0YmZkZDc4M2YzZS90YWJsZTo2N2VlOGE3MTg5OTA0YzkwOWJkYTI1ZDY4ODA4NGU4NC90YWJsZXJhbmdlOjY3ZWU4YTcxODk5MDRjOTA5YmRhMjVkNjg4MDg0ZTg0XzgtMTUtMS0xLTA_9281035a-e447-4843-92aa-b4969e60e97c">17,004</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change during the year</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5d62628d6fb54fe0bd811fdfd0bf7b0c_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjQvZnJhZzo0MDI1ZmJmMmQ0MTY0MWZhODhhZTg0YmZkZDc4M2YzZS90YWJsZTo2N2VlOGE3MTg5OTA0YzkwOWJkYTI1ZDY4ODA4NGU4NC90YWJsZXJhbmdlOjY3ZWU4YTcxODk5MDRjOTA5YmRhMjVkNjg4MDg0ZTg0XzktMS0xLTEtMA_b62048d2-1be6-4487-a1bd-110e1b11e9a4">26,512</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib887805409a54f638aeeafe3fe5d1688_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjQvZnJhZzo0MDI1ZmJmMmQ0MTY0MWZhODhhZTg0YmZkZDc4M2YzZS90YWJsZTo2N2VlOGE3MTg5OTA0YzkwOWJkYTI1ZDY4ODA4NGU4NC90YWJsZXJhbmdlOjY3ZWU4YTcxODk5MDRjOTA5YmRhMjVkNjg4MDg0ZTg0XzktMy0xLTEtMA_4314fa70-9d58-4d25-8751-c522efc6e901">74,787</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i558e7ef31d4b428c9ee6d8d5a9dd5f54_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjQvZnJhZzo0MDI1ZmJmMmQ0MTY0MWZhODhhZTg0YmZkZDc4M2YzZS90YWJsZTo2N2VlOGE3MTg5OTA0YzkwOWJkYTI1ZDY4ODA4NGU4NC90YWJsZXJhbmdlOjY3ZWU4YTcxODk5MDRjOTA5YmRhMjVkNjg4MDg0ZTg0XzktNS0xLTEtMA_53954d6a-ae27-454e-90be-e67d42354e97">3,335</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjQvZnJhZzo0MDI1ZmJmMmQ0MTY0MWZhODhhZTg0YmZkZDc4M2YzZS90YWJsZTo2N2VlOGE3MTg5OTA0YzkwOWJkYTI1ZDY4ODA4NGU4NC90YWJsZXJhbmdlOjY3ZWU4YTcxODk5MDRjOTA5YmRhMjVkNjg4MDg0ZTg0XzktNy0xLTEtMA_dcbec57e-b1f3-4665-b2f7-982a1c1920b4">51,610</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8d756ddfc980426086c7294d41dd2af3_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjQvZnJhZzo0MDI1ZmJmMmQ0MTY0MWZhODhhZTg0YmZkZDc4M2YzZS90YWJsZTo2N2VlOGE3MTg5OTA0YzkwOWJkYTI1ZDY4ODA4NGU4NC90YWJsZXJhbmdlOjY3ZWU4YTcxODk5MDRjOTA5YmRhMjVkNjg4MDg0ZTg0XzktOS0xLTEtMA_d8fb8b1f-9995-4227-a0a6-6d06c727ca21">4,913</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic606425dedeb4d3d9b0b453c252ea236_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjQvZnJhZzo0MDI1ZmJmMmQ0MTY0MWZhODhhZTg0YmZkZDc4M2YzZS90YWJsZTo2N2VlOGE3MTg5OTA0YzkwOWJkYTI1ZDY4ODA4NGU4NC90YWJsZXJhbmdlOjY3ZWU4YTcxODk5MDRjOTA5YmRhMjVkNjg4MDg0ZTg0XzktMTEtMS0xLTA_1824ed83-9823-4889-be8b-61140f85276e">31,024</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie069c94280064225b4ffe831d6c5e5fe_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjQvZnJhZzo0MDI1ZmJmMmQ0MTY0MWZhODhhZTg0YmZkZDc4M2YzZS90YWJsZTo2N2VlOGE3MTg5OTA0YzkwOWJkYTI1ZDY4ODA4NGU4NC90YWJsZXJhbmdlOjY3ZWU4YTcxODk5MDRjOTA5YmRhMjVkNjg4MDg0ZTg0XzktMTMtMS0xLTA_181272e6-c4ad-4eac-83a7-c3691192fd92">2,422</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjQvZnJhZzo0MDI1ZmJmMmQ0MTY0MWZhODhhZTg0YmZkZDc4M2YzZS90YWJsZTo2N2VlOGE3MTg5OTA0YzkwOWJkYTI1ZDY4ODA4NGU4NC90YWJsZXJhbmdlOjY3ZWU4YTcxODk5MDRjOTA5YmRhMjVkNjg4MDg0ZTg0XzktMTUtMS0xLTA_dcac38a8-8edf-4090-800d-1239edcc1c7e">28,533</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Disposal of discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie355e9ffef734dc6a2b8f3d027278891_I20210630" decimals="-3" format="ixt:zerodash" name="evh:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseDisposalOfDiscontinuedOperations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjQvZnJhZzo0MDI1ZmJmMmQ0MTY0MWZhODhhZTg0YmZkZDc4M2YzZS90YWJsZTo2N2VlOGE3MTg5OTA0YzkwOWJkYTI1ZDY4ODA4NGU4NC90YWJsZXJhbmdlOjY3ZWU4YTcxODk5MDRjOTA5YmRhMjVkNjg4MDg0ZTg0XzExLTEtMS0xLTA_e28db980-8372-440a-a4b6-96aadf37f311">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c3ddb1ccecb442ca473281d46c1ef16_I20210630" decimals="-3" format="ixt:zerodash" name="evh:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseDisposalOfDiscontinuedOperations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjQvZnJhZzo0MDI1ZmJmMmQ0MTY0MWZhODhhZTg0YmZkZDc4M2YzZS90YWJsZTo2N2VlOGE3MTg5OTA0YzkwOWJkYTI1ZDY4ODA4NGU4NC90YWJsZXJhbmdlOjY3ZWU4YTcxODk5MDRjOTA5YmRhMjVkNjg4MDg0ZTg0XzExLTMtMS0xLTA_912ccf40-b0e4-43c5-8d9b-a8d5612618ed">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i89185ecde2ae43c5b615a3084603455c_I20210630" decimals="-3" format="ixt:numdotdecimal" name="evh:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseDisposalOfDiscontinuedOperations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjQvZnJhZzo0MDI1ZmJmMmQ0MTY0MWZhODhhZTg0YmZkZDc4M2YzZS90YWJsZTo2N2VlOGE3MTg5OTA0YzkwOWJkYTI1ZDY4ODA4NGU4NC90YWJsZXJhbmdlOjY3ZWU4YTcxODk5MDRjOTA5YmRhMjVkNjg4MDg0ZTg0XzExLTUtMS0xLTA_83f61314-db8a-4bf2-ba0c-8f44376981cf">13,194</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630" decimals="-3" format="ixt:numdotdecimal" name="evh:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseDisposalOfDiscontinuedOperations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjQvZnJhZzo0MDI1ZmJmMmQ0MTY0MWZhODhhZTg0YmZkZDc4M2YzZS90YWJsZTo2N2VlOGE3MTg5OTA0YzkwOWJkYTI1ZDY4ODA4NGU4NC90YWJsZXJhbmdlOjY3ZWU4YTcxODk5MDRjOTA5YmRhMjVkNjg4MDg0ZTg0XzExLTctMS0xLTA_0e6bcd6b-623b-403d-929f-de64f33d0b77">13,194</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5ff183307a4468fb0d5707822525486_I20200630" decimals="-3" format="ixt:zerodash" name="evh:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseDisposalOfDiscontinuedOperations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjQvZnJhZzo0MDI1ZmJmMmQ0MTY0MWZhODhhZTg0YmZkZDc4M2YzZS90YWJsZTo2N2VlOGE3MTg5OTA0YzkwOWJkYTI1ZDY4ODA4NGU4NC90YWJsZXJhbmdlOjY3ZWU4YTcxODk5MDRjOTA5YmRhMjVkNjg4MDg0ZTg0XzExLTktMS0xLTA_6be1aa9c-7ad8-473d-8993-e053e25ea278">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25d27166851f4878bc9c647f69bfd2ea_I20200630" decimals="-3" format="ixt:zerodash" name="evh:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseDisposalOfDiscontinuedOperations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjQvZnJhZzo0MDI1ZmJmMmQ0MTY0MWZhODhhZTg0YmZkZDc4M2YzZS90YWJsZTo2N2VlOGE3MTg5OTA0YzkwOWJkYTI1ZDY4ODA4NGU4NC90YWJsZXJhbmdlOjY3ZWU4YTcxODk5MDRjOTA5YmRhMjVkNjg4MDg0ZTg0XzExLTExLTEtMS0w_2e27bb11-9a9a-4190-99ca-a2b31f1e81f5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80bca972b5164b02a2d38d8930a36773_I20200630" decimals="-3" format="ixt:zerodash" name="evh:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseDisposalOfDiscontinuedOperations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjQvZnJhZzo0MDI1ZmJmMmQ0MTY0MWZhODhhZTg0YmZkZDc4M2YzZS90YWJsZTo2N2VlOGE3MTg5OTA0YzkwOWJkYTI1ZDY4ODA4NGU4NC90YWJsZXJhbmdlOjY3ZWU4YTcxODk5MDRjOTA5YmRhMjVkNjg4MDg0ZTg0XzExLTEzLTEtMS0w_945ee1c8-a4d6-4c30-ac5a-08a4dedefe43">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11817f96c3e24e0abaed14a17869e173_I20200630" decimals="-3" format="ixt:zerodash" name="evh:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseDisposalOfDiscontinuedOperations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjQvZnJhZzo0MDI1ZmJmMmQ0MTY0MWZhODhhZTg0YmZkZDc4M2YzZS90YWJsZTo2N2VlOGE3MTg5OTA0YzkwOWJkYTI1ZDY4ODA4NGU4NC90YWJsZXJhbmdlOjY3ZWU4YTcxODk5MDRjOTA5YmRhMjVkNjg4MDg0ZTg0XzExLTE1LTEtMS0w_5475443d-bb05-4796-91bb-81385c8e8f00">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other adjustments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie355e9ffef734dc6a2b8f3d027278891_I20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjQvZnJhZzo0MDI1ZmJmMmQ0MTY0MWZhODhhZTg0YmZkZDc4M2YzZS90YWJsZTo2N2VlOGE3MTg5OTA0YzkwOWJkYTI1ZDY4ODA4NGU4NC90YWJsZXJhbmdlOjY3ZWU4YTcxODk5MDRjOTA5YmRhMjVkNjg4MDg0ZTg0XzEyLTEtMS0xLTA_d3a17603-72a7-4f68-b7fc-42731349afcf">3,721</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c3ddb1ccecb442ca473281d46c1ef16_I20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjQvZnJhZzo0MDI1ZmJmMmQ0MTY0MWZhODhhZTg0YmZkZDc4M2YzZS90YWJsZTo2N2VlOGE3MTg5OTA0YzkwOWJkYTI1ZDY4ODA4NGU4NC90YWJsZXJhbmdlOjY3ZWU4YTcxODk5MDRjOTA5YmRhMjVkNjg4MDg0ZTg0XzEyLTMtMS0xLTA_231dabb1-6d7e-44ef-aef3-ef43481d1857">7,282</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89185ecde2ae43c5b615a3084603455c_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjQvZnJhZzo0MDI1ZmJmMmQ0MTY0MWZhODhhZTg0YmZkZDc4M2YzZS90YWJsZTo2N2VlOGE3MTg5OTA0YzkwOWJkYTI1ZDY4ODA4NGU4NC90YWJsZXJhbmdlOjY3ZWU4YTcxODk5MDRjOTA5YmRhMjVkNjg4MDg0ZTg0XzEyLTUtMS0xLTA_0a5be8ad-fe85-40ea-93db-fb29161f5c7e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjQvZnJhZzo0MDI1ZmJmMmQ0MTY0MWZhODhhZTg0YmZkZDc4M2YzZS90YWJsZTo2N2VlOGE3MTg5OTA0YzkwOWJkYTI1ZDY4ODA4NGU4NC90YWJsZXJhbmdlOjY3ZWU4YTcxODk5MDRjOTA5YmRhMjVkNjg4MDg0ZTg0XzEyLTctMS0xLTA_bf764e35-57d2-47d3-b3a5-6302b8ded090">11,003</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5ff183307a4468fb0d5707822525486_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjQvZnJhZzo0MDI1ZmJmMmQ0MTY0MWZhODhhZTg0YmZkZDc4M2YzZS90YWJsZTo2N2VlOGE3MTg5OTA0YzkwOWJkYTI1ZDY4ODA4NGU4NC90YWJsZXJhbmdlOjY3ZWU4YTcxODk5MDRjOTA5YmRhMjVkNjg4MDg0ZTg0XzEyLTktMS0xLTA_50fbf5bf-9af1-49c9-acf3-88a9136f3a08">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25d27166851f4878bc9c647f69bfd2ea_I20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjQvZnJhZzo0MDI1ZmJmMmQ0MTY0MWZhODhhZTg0YmZkZDc4M2YzZS90YWJsZTo2N2VlOGE3MTg5OTA0YzkwOWJkYTI1ZDY4ODA4NGU4NC90YWJsZXJhbmdlOjY3ZWU4YTcxODk5MDRjOTA5YmRhMjVkNjg4MDg0ZTg0XzEyLTExLTEtMS0w_9caa1ac1-26d7-45dc-a7bf-570770d03be0">4,726</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80bca972b5164b02a2d38d8930a36773_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjQvZnJhZzo0MDI1ZmJmMmQ0MTY0MWZhODhhZTg0YmZkZDc4M2YzZS90YWJsZTo2N2VlOGE3MTg5OTA0YzkwOWJkYTI1ZDY4ODA4NGU4NC90YWJsZXJhbmdlOjY3ZWU4YTcxODk5MDRjOTA5YmRhMjVkNjg4MDg0ZTg0XzEyLTEzLTEtMS0w_a6814b2f-64e8-4769-9349-7862b5f7bad6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11817f96c3e24e0abaed14a17869e173_I20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjQvZnJhZzo0MDI1ZmJmMmQ0MTY0MWZhODhhZTg0YmZkZDc4M2YzZS90YWJsZTo2N2VlOGE3MTg5OTA0YzkwOWJkYTI1ZDY4ODA4NGU4NC90YWJsZXJhbmdlOjY3ZWU4YTcxODk5MDRjOTA5YmRhMjVkNjg4MDg0ZTg0XzEyLTE1LTEtMS0w_dd23fb10-a65e-4980-9f8c-ce2003941c49">4,726</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie355e9ffef734dc6a2b8f3d027278891_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjQvZnJhZzo0MDI1ZmJmMmQ0MTY0MWZhODhhZTg0YmZkZDc4M2YzZS90YWJsZTo2N2VlOGE3MTg5OTA0YzkwOWJkYTI1ZDY4ODA4NGU4NC90YWJsZXJhbmdlOjY3ZWU4YTcxODk5MDRjOTA5YmRhMjVkNjg4MDg0ZTg0XzEzLTEtMS0xLTA_7c7adfee-aad2-4d86-a105-d2100deb3b3c">33,504</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c3ddb1ccecb442ca473281d46c1ef16_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjQvZnJhZzo0MDI1ZmJmMmQ0MTY0MWZhODhhZTg0YmZkZDc4M2YzZS90YWJsZTo2N2VlOGE3MTg5OTA0YzkwOWJkYTI1ZDY4ODA4NGU4NC90YWJsZXJhbmdlOjY3ZWU4YTcxODk5MDRjOTA5YmRhMjVkNjg4MDg0ZTg0XzEzLTMtMS0xLTA_4d11b07b-df5c-4fd1-89f3-b72af0cc8c74">204,601</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89185ecde2ae43c5b615a3084603455c_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjQvZnJhZzo0MDI1ZmJmMmQ0MTY0MWZhODhhZTg0YmZkZDc4M2YzZS90YWJsZTo2N2VlOGE3MTg5OTA0YzkwOWJkYTI1ZDY4ODA4NGU4NC90YWJsZXJhbmdlOjY3ZWU4YTcxODk5MDRjOTA5YmRhMjVkNjg4MDg0ZTg0XzEzLTUtMS0xLTA_594bc202-f125-4a41-87c6-5d8767d54692">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjQvZnJhZzo0MDI1ZmJmMmQ0MTY0MWZhODhhZTg0YmZkZDc4M2YzZS90YWJsZTo2N2VlOGE3MTg5OTA0YzkwOWJkYTI1ZDY4ODA4NGU4NC90YWJsZXJhbmdlOjY3ZWU4YTcxODk5MDRjOTA5YmRhMjVkNjg4MDg0ZTg0XzEzLTctMS0xLTA_8387fe2d-bc4e-4c16-8aef-034952b4902a">238,105</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if5ff183307a4468fb0d5707822525486_I20200630" decimals="-3" sign="-" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjQvZnJhZzo0MDI1ZmJmMmQ0MTY0MWZhODhhZTg0YmZkZDc4M2YzZS90YWJsZTo2N2VlOGE3MTg5OTA0YzkwOWJkYTI1ZDY4ODA4NGU4NC90YWJsZXJhbmdlOjY3ZWU4YTcxODk5MDRjOTA5YmRhMjVkNjg4MDg0ZTg0XzEzLTktMS0xLTA_9ee07b93-4709-47fb-8383-e98d216b312b">648</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25d27166851f4878bc9c647f69bfd2ea_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjQvZnJhZzo0MDI1ZmJmMmQ0MTY0MWZhODhhZTg0YmZkZDc4M2YzZS90YWJsZTo2N2VlOGE3MTg5OTA0YzkwOWJkYTI1ZDY4ODA4NGU4NC90YWJsZXJhbmdlOjY3ZWU4YTcxODk5MDRjOTA5YmRhMjVkNjg4MDg0ZTg0XzEzLTExLTEtMS0w_85c07f9c-0306-4f05-a825-69a76e6e0feb">85,995</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80bca972b5164b02a2d38d8930a36773_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjQvZnJhZzo0MDI1ZmJmMmQ0MTY0MWZhODhhZTg0YmZkZDc4M2YzZS90YWJsZTo2N2VlOGE3MTg5OTA0YzkwOWJkYTI1ZDY4ODA4NGU4NC90YWJsZXJhbmdlOjY3ZWU4YTcxODk5MDRjOTA5YmRhMjVkNjg4MDg0ZTg0XzEzLTEzLTEtMS0w_c2393804-4ff1-47b9-b370-f54601e3c77f">9,062</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11817f96c3e24e0abaed14a17869e173_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjQvZnJhZzo0MDI1ZmJmMmQ0MTY0MWZhODhhZTg0YmZkZDc4M2YzZS90YWJsZTo2N2VlOGE3MTg5OTA0YzkwOWJkYTI1ZDY4ODA4NGU4NC90YWJsZXJhbmdlOjY3ZWU4YTcxODk5MDRjOTA5YmRhMjVkNjg4MDg0ZTg0XzEzLTE1LTEtMS0w_659d69d0-9780-4135-91f5-8fcb8e2f8be6">94,409</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:31.5pt;text-align:justify;text-indent:-31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:25.44pt">Costs incurred to provide specialty care management and EVH Passport are recorded within cost of revenue in our statement of operations. </span></div><div style="padding-left:31.5pt;text-align:justify;text-indent:-31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:25.44pt">Other adjustments to reserves for claims and performance-based arrangements reflect changes in accrual for amounts payable to facilities and amounts owed to our payer partners for claims paid on our behalf.</span></div></ix:nonNumeric></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><div id="id8f403494d0a42c2868794fb470218fc_133"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 23.  <ix:nonNumeric contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" name="us-gaap:CashFlowSupplementalDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMzMvZnJhZzplOWEyZDI1OWY1NTQ0MTAzYmYzNWQwOWVlMjBhYzg1Ni90ZXh0cmVnaW9uOmU5YTJkMjU5ZjU1NDQxMDNiZjM1ZDA5ZWUyMGFjODU2XzEzNQ_f355b29e-38e2-41b7-80cf-f2dc089f6990" continuedAt="i1a5e6c12a4a64ce19388947731bca805" escape="true">Supplemental Cash Flow Information </ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i1a5e6c12a4a64ce19388947731bca805"><ix:nonNumeric contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" name="us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMzMvZnJhZzplOWEyZDI1OWY1NTQ0MTAzYmYzNWQwOWVlMjBhYzg1Ni90ZXh0cmVnaW9uOmU5YTJkMjU5ZjU1NDQxMDNiZjM1ZDA5ZWUyMGFjODU2XzEzNA_991bc880-92be-459e-8570-da91088cb34c" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following represents supplemental cash flow information the six months ended June 30, 2021 and 2020 (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:433.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental Disclosure of Non-cash Investing and Financing Activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Increase/decrease to goodwill from measurement period adjustments/business combinations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="-3" format="ixt:zerodash" name="evh:NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationMeasurementPeriodAdjustment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMzMvZnJhZzplOWEyZDI1OWY1NTQ0MTAzYmYzNWQwOWVlMjBhYzg1Ni90YWJsZTo1Nzk2ZmNiYTk0MmE0YTY4ODUyODJjYThiMGM1MmEzZi90YWJsZXJhbmdlOjU3OTZmY2JhOTQyYTRhNjg4NTI4MmNhOGIwYzUyYTNmXzMtMS0xLTEtMA_822ceb0c-25b2-435d-865b-00499b3dc252">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="evh:NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationMeasurementPeriodAdjustment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMzMvZnJhZzplOWEyZDI1OWY1NTQ0MTAzYmYzNWQwOWVlMjBhYzg1Ni90YWJsZTo1Nzk2ZmNiYTk0MmE0YTY4ODUyODJjYThiMGM1MmEzZi90YWJsZXJhbmdlOjU3OTZmY2JhOTQyYTRhNjg4NTI4MmNhOGIwYzUyYTNmXzMtMy0xLTEtMA_2a93d153-0122-4e04-8c54-72348363c8fe">2,200</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Class A common stock issued for payment of Passport/Global earn-out</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:NoncashOrPartNoncashAcquisitionPayablesAssumed1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMzMvZnJhZzplOWEyZDI1OWY1NTQ0MTAzYmYzNWQwOWVlMjBhYzg1Ni90YWJsZTo1Nzk2ZmNiYTk0MmE0YTY4ODUyODJjYThiMGM1MmEzZi90YWJsZXJhbmdlOjU3OTZmY2JhOTQyYTRhNjg4NTI4MmNhOGIwYzUyYTNmXzQtMS0xLTEtMA_cb5807de-5197-4395-9299-9dd2dda8cf0d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NoncashOrPartNoncashAcquisitionPayablesAssumed1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMzMvZnJhZzplOWEyZDI1OWY1NTQ0MTAzYmYzNWQwOWVlMjBhYzg1Ni90YWJsZTo1Nzk2ZmNiYTk0MmE0YTY4ODUyODJjYThiMGM1MmEzZi90YWJsZXJhbmdlOjU3OTZmY2JhOTQyYTRhNjg4NTI4MmNhOGIwYzUyYTNmXzQtMy0xLTEtMA_7dd39c02-1cd3-430c-a1d1-8f2d4020eddd">4,185</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued property and equipment purchases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMzMvZnJhZzplOWEyZDI1OWY1NTQ0MTAzYmYzNWQwOWVlMjBhYzg1Ni90YWJsZTo1Nzk2ZmNiYTk0MmE0YTY4ODUyODJjYThiMGM1MmEzZi90YWJsZXJhbmdlOjU3OTZmY2JhOTQyYTRhNjg4NTI4MmNhOGIwYzUyYTNmXzUtMS0xLTEtMA_bf3248c8-295e-4b47-a9ee-cc89749596da">668</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="-3" name="evh:AccruedPropertyAndEquipmentPurchases" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMzMvZnJhZzplOWEyZDI1OWY1NTQ0MTAzYmYzNWQwOWVlMjBhYzg1Ni90YWJsZTo1Nzk2ZmNiYTk0MmE0YTY4ODUyODJjYThiMGM1MmEzZi90YWJsZXJhbmdlOjU3OTZmY2JhOTQyYTRhNjg4NTI4MmNhOGIwYzUyYTNmXzUtMy0xLTEtMA_08d8f1a4-f3d1-46e1-b2fb-29e7917a87b1">26</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Effects of Leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Operating cash flows from operating leases </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMzMvZnJhZzplOWEyZDI1OWY1NTQ0MTAzYmYzNWQwOWVlMjBhYzg1Ni90YWJsZTo1Nzk2ZmNiYTk0MmE0YTY4ODUyODJjYThiMGM1MmEzZi90YWJsZXJhbmdlOjU3OTZmY2JhOTQyYTRhNjg4NTI4MmNhOGIwYzUyYTNmXzctMS0xLTEtMA_6215fede-fdad-47a3-8df7-08d9ec156a2a">6,622</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMzMvZnJhZzplOWEyZDI1OWY1NTQ0MTAzYmYzNWQwOWVlMjBhYzg1Ni90YWJsZTo1Nzk2ZmNiYTk0MmE0YTY4ODUyODJjYThiMGM1MmEzZi90YWJsZXJhbmdlOjU3OTZmY2JhOTQyYTRhNjg4NTI4MmNhOGIwYzUyYTNmXzctMy0xLTEtMA_ad3cf0f6-bfe5-4994-acf0-5b5e3b6df9fd">6,853</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Leased assets obtained in exchange for operating lease liabilities </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="evh:RightOfUseAssetAcquiredAndDisposedOf" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMzMvZnJhZzplOWEyZDI1OWY1NTQ0MTAzYmYzNWQwOWVlMjBhYzg1Ni90YWJsZTo1Nzk2ZmNiYTk0MmE0YTY4ODUyODJjYThiMGM1MmEzZi90YWJsZXJhbmdlOjU3OTZmY2JhOTQyYTRhNjg4NTI4MmNhOGIwYzUyYTNmXzgtMS0xLTEtMA_e5652808-f1ea-4dc1-a707-8136d3a45312">2,157</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="evh:RightOfUseAssetAcquiredAndDisposedOf" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMzMvZnJhZzplOWEyZDI1OWY1NTQ0MTAzYmYzNWQwOWVlMjBhYzg1Ni90YWJsZTo1Nzk2ZmNiYTk0MmE0YTY4ODUyODJjYThiMGM1MmEzZi90YWJsZXJhbmdlOjU3OTZmY2JhOTQyYTRhNjg4NTI4MmNhOGIwYzUyYTNmXzgtMy0xLTEtMA_8bc730f7-9130-4cfb-a62a-096181b2eacc">1,354</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><div id="id8f403494d0a42c2868794fb470218fc_136"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 24.  <ix:nonNumeric contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" name="us-gaap:SubsequentEventsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMzYvZnJhZzowNmUxOWM2YmRkMmU0YjU4YjMyMmNlODUwZmQ1YzE4Ni90ZXh0cmVnaW9uOjA2ZTE5YzZiZGQyZTRiNThiMzIyY2U4NTBmZDVjMTg2XzM4NDgyOTA3MTU0NDg_c57b53f8-59ed-43e5-ad56-6e6080c56be7" continuedAt="i25cc5d94144a470592f6a2ceebd89722" escape="true"><ix:nonNumeric contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630" name="us-gaap:SubsequentEventsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMzYvZnJhZzowNmUxOWM2YmRkMmU0YjU4YjMyMmNlODUwZmQ1YzE4Ni90ZXh0cmVnaW9uOjA2ZTE5YzZiZGQyZTRiNThiMzIyY2U4NTBmZDVjMTg2XzQyMzY_09c36fd5-d144-4e88-8fa0-7d3f15f4daa7" continuedAt="i2aa08e8aec844682b6098969dcc48a56" escape="true">Subsequent Events</ix:nonNumeric></ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i25cc5d94144a470592f6a2ceebd89722"><ix:continuation id="i2aa08e8aec844682b6098969dcc48a56"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Agreement for the Acquisition of Vital Decision</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On August 2, 2021, Evolent Health LLC and EV Thunder Merger Sub, LLC, each wholly owned subsidiaries of the Company, entered into a definitive agreement for Evolent to acquire Windrose Health Investors III, L.P. portfolio company Vital Decisions for $<ix:nonFraction unitRef="usd" contextRef="i46534d0a532b4e63ade4879ed3702a19_D20210802-20210802" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationConsiderationTransferred1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMzYvZnJhZzowNmUxOWM2YmRkMmU0YjU4YjMyMmNlODUwZmQ1YzE4Ni90ZXh0cmVnaW9uOjA2ZTE5YzZiZGQyZTRiNThiMzIyY2U4NTBmZDVjMTg2XzEwOTk1MTE2NDU5ODM_cf9593fc-4ba9-4203-b85b-22c2870523c2">85</ix:nonFraction>&#160;million, with an additional earn out of up to $<ix:nonFraction unitRef="usd" contextRef="ic40ea142c3e8460d8998330c2ef6c2fe_I20210802" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMzYvZnJhZzowNmUxOWM2YmRkMmU0YjU4YjMyMmNlODUwZmQ1YzE4Ni90ZXh0cmVnaW9uOjA2ZTE5YzZiZGQyZTRiNThiMzIyY2U4NTBmZDVjMTg2XzEwOTk1MTE2NDU5OTY_4299e4bd-b40f-41bf-85ae-1338e5acaa29">45</ix:nonFraction>&#160;million. Vital Decisions will report into Evolent&#8217;s specialty management offering, New Century Health, and will be consolidated into the Company&#8217;s Clinical Solutions segment. Closing of the transaction is subject to customary closing conditions and is expected to occur in the second half of 2021.</span></div></ix:continuation></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="id8f403494d0a42c2868794fb470218fc_139"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.  Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations (&#8220;MD&amp;A&#8221;) is intended to help the reader understand the Company&#8217;s financial condition and results of operations. The MD&amp;A is provided as a supplement to, and should be read in conjunction with our consolidated financial statements and the accompanying notes to consolidated financial statements presented in &#8220;Part I &#8211; Item 1. Financial Statements&#8221; of this Form 10-Q; our 2020 Form 10-K, including the sections entitled &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221;; and our current reports on Form 8-K filed in 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div id="id8f403494d0a42c2868794fb470218fc_142"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INTRODUCTION</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="id8f403494d0a42c2868794fb470218fc_145"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Background</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Evolent Health, Inc. is a holding company whose principal asset is all of the Class A common units it holds in Evolent Health LLC, and its only business is to act as sole managing member of Evolent Health LLC. Substantially all of our operations are conducted through Evolent Health LLC and its consolidated subsidiaries. The financial results of Evolent Health LLC are consolidated in the financial statements of Evolent Health, Inc.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Overview</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a market leader in the new era of value-based care, in which the delivery of health care is increasingly funded by at-risk payment models.  We provide integrated solutions to both health care providers, including independent physicians and health systems, as well as payers, including health plans and other risk-bearing organizations, with a common end: to improve health care quality and outcomes while reducing cost. We consider value-based care to be the necessary convergence of health care payment and delivery. We believe the pace of this convergence is accelerating, driven by price pressure in traditional FFS health care, a market environment that is incentivizing value-based care models, growth in consumer-focused insurance programs, such as Medicare Advantage and managed Medicaid, and innovation in data and technology. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We were an early innovator in Value-Based Care, founded in 2011 by members of our management team, UPMC, an integrated delivery system based in Pittsburgh, Pennsylvania, and The Advisory Board Company. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Today we manage our operations and allocate resources across two reportable segments: Clinical Solutions and Evolent Health Services.  Our Clinical Solutions segment addresses a broad spectrum of clinical needs, with tailored solutions for Specialty Care Management in Oncology and Cardiology and holistic Total Cost of Care improvement. Our economic opportunity in the Clinical Solutions segment, which we believe to be significant, is largely based on (a) the total amount of medical expenses under management, and (b) the amount of savings we are able to generate relative to a benchmark or target. These partnerships, which we refer to as performance-based arrangements, include both capitation and shared savings arrangements. We also generate Clinical Solutions revenue by providing our technology and services platform on a fee basis.  We go to market for our Specialty Care Management under the brand name New Century Health, and for our Total Cost of Care solution under the brand name Evolent Care Partners.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s EHS segment provides an integrated administrative and clinical platform for health plan administration and population health management.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of our revenue is recognized in the United States and substantially all of our long-lived assets are located in the United States.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred operating losses since our inception, as we have invested heavily in resources to support our growth. We intend to invest aggressively in the success of our partners, expand our geographic footprint and further develop our capabilities. We also expect </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to continue to incur operating losses for the foreseeable future and if we are unable to achieve our revenue growth and cost management objectives, we may not be able to achieve profitability. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the date the financial statements were available to be issued, we believe we have sufficient liquidity for the next 12 months.</span></div><div><span><br/></span></div><div id="id8f403494d0a42c2868794fb470218fc_148"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Events</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evolent Health&#8217;s Response to COVID-19</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 11, 2020, the World Health Organization (the &#8220;WHO&#8221;) declared the novel strain of coronavirus (COVID-19) a global pandemic and recommended containment and mitigation measures worldwide. While response to the COVID-19 outbreak, including the emergence of variant strains of the virus, continues to rapidly evolve, it has led to aggressive actions to reduce the spread of the disease that have seriously disrupted activities in large segments of the economy. We are continuing to monitor the COVID-19 outbreak and its impact on our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the nature of the services we provide, market dynamics in our end markets and with our significant customers, to date the COVID-19 pandemic has not materially impacted our financial condition or results of operations or our outlook. As of June&#160;30, 2021, we had cash and cash equivalents of $207.3 million and as of the date the financial statements were available to be issued we believe our current cash balance is sufficient to meet our liquidity needs for the next twelve months. The COVID-19 crisis has also adversely impacted global access to capital and caused significant volatility in financial markets. Significant deterioration of the U.S. and global economies could have a significant adverse impact on our investment income, the value of our investments, or future liquidity needs. Although the impact of the COVID-19 pandemic on our business has not been severe to date, the long-term impact of the pandemic on our partners and the global economy is uncertain and will depend on various factors, including the scope, severity and duration of the pandemic, including resurgence of COVID-19 cases due to more contagious variants. A prolonged economic downturn or recession resulting from the pandemic could adversely affect many of our partners which could, in turn, adversely impact our business, financial condition and results of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Evolent&#8217;s focus throughout this pandemic has been the health and safety of its employees and their families, as well as ensuring that we continue to furnish high quality service to our partners.  Evolent has deployed a multi-faceted response to COVID-19, overseen by its Emergency Preparedness Team, led by the General Counsel and Chief Compliance Officer, that focuses on maintaining its workforce in a manner that does not disrupt service delivery or operations. Evolent is closely monitoring and overseeing any issues of noncompliance or deficiencies with client operational service level agreements and continuing to review contractual business requirements in light of state and federal mandates, emergency laws and orders, and available financial support opportunities.  Evolent is also mindful of the impact COVID-19 has on its vendors and subcontractors, and we will continue to work with them regarding our collective obligations to Evolent&#8217;s customers. We require a COVID-19 Business Continuity Attestation from subcontractors and vendors, confirming that operational and financial obligations will be met and aiming to ensure that privacy and security risks or incidents can be mitigated and disclosed in a timely manner. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Impact of COVID-19</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In evaluating the impact of COVID-19 on our business, we considered, among other factors, the nature of the services we provide, end market trends and outlook and customer-specific trends.  In evaluating our health plan businesses, we focused on possible changes in membership and medical utilization trends.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our two most significant service offerings in terms of revenue are specialty care management and administrative health services.&#160; Because both of these services offerings provide critical services to our clients and their members and have relatively long lead times to implement such services, we currently do not anticipate any material near-term disruption to the relevant contracts as a result of the pandemic.  </span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The three key end-markets we serve are Medicaid, Medicare and Commercial.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Across 2020 and into the first half of 2021, we saw changes in membership and medical utilization in our end-markets as a result of the COVID-19 pandemic. The pandemic has resulted in a significant increase in unemployment in the United States. Historically, Medicaid enrollment has increased during periods of rising unemployment as individuals lose access to employer sponsored health care and turn to government sponsored health care. In addition, with respect to Medicaid, many states (including Florida, Kentucky and Illinois) put in place new rules during the pandemic eliminating the ability of Medicaid health plans to dis-enroll non-paying members, as well as waiving certain eligibility requirements, which together we expect will result in higher membership during the period of the pandemic. It is possible that we may see an opposite trend in the commercial market, where employees who are made redundant lose access to employer sponsored health care. We do not expect to see meaningful changes in membership in the Medicare market as a result of COVID-19. In aggregate, as more than 50% of the lives on our platform are currently in Medicaid and we </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">generally earn revenue with respect to those lives based on a per member per month model, we expect to see a net benefit in our business from increased membership in that market in the near-term. We cannot predict the magnitude of this potential benefit, or how long it will last.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to medical utilization, following the declaration of the pandemic by the WHO, many state-wide mandates deferred non-essential medical procedures to allow hospitals to focus on providing care to COVID-19 patients. Across all markets, our partners  experienced declines in non-essential care throughout the year ended December 31, 2020 and through the first half of 2021, offset in part by increased costs for care of COVID-19 patients. We continue to monitor medical utilization trends closely as the pandemic progresses. Beginning late in the first quarter of 2020 after declaration of the pandemic and continuing through the first half of 2021, we have seen a modest benefit in our business from lower utilization trends. However, we cannot predict with any certainty the net impact of lower utilization on our business, as it is possible we will experience a surge in utilization if and when consumer behavior changes (for example if the novel coronavirus is controlled by a vaccine or other measures).  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our largest customers in terms of revenue, Cook County Health and Hospitals Systems and Florida Blue Medicare, Inc., together accounted for approximately 43.7% of revenue for the six months ended June 30, 2021, and Cook County Health and Hospitals Systems accounted for approximately 21.4% of revenue for the six months ended June 30, 2020. Florida Blue Medicare, Inc. utilizes our specialty management solutions provided by New Century Health.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Overall, we are unable to determine or predict the nature, duration, or scope of the overall impact the COVID-19 pandemic will have on our business, results of operations, liquidity, or capital resources. We are actively monitoring the ongoing situation and may take further actions that change our operations if required by law or that we determine are in the best interests of our employees or partners.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Customers</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Cook County Health and Hospital Systems utilizes both our administrative simplification solutions provided by Evolent Health Services which accounts for 9.5% and 9.2% of our consolidated revenue for the three and six months ended June 30, 2021 and our specialty management solutions provided by New Century Health which accounts for 20.1% and 20.0% of our consolidated revenue for the three and six months ended June 30, 2021. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Transactions</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has undertaken several transactions, some of which may impact year-to-year comparisons. The following is a discussion of certain of those transactions.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Agreement for the Acquisition of Vital Decision</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On August 2, 2021, Evolent Health LLC and EV Thunder Merger Sub, LLC, each wholly owned subsidiaries of the Company, entered into a definitive agreement for Evolent to acquire Windrose Health Investors III, L.P. portfolio company Vital Decisions for $85 million, with an additional earn out of up to $45 million. Vital Decisions will report into Evolent&#8217;s specialty management offering, New Century Health, and will be consolidated into the Company&#8217;s Clinical Solutions segment. Closing of the transaction is subject to customary closing conditions and is expected to occur in the second half of 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Agreement for the Sale of True Health New Mexico</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On January 11, 2021, Evolent LLC, EH Holdings and True Health, each wholly owned subsidiaries of the Company, entered into the SPA with Bright HealthCare, pursuant to which EH Holdings agreed to sell all of its equity interest in True Health to Bright HealthCare for a purchase price of $22.0 million plus excess risk based capital, subject to satisfaction of customary closing conditions, including regulatory approvals. The purchase price is subject to a customary purchase price adjustment following the True Health Closing based in part on actual medical claims experience. The True Health Closing occurred on March 31, 2021 and the Company will have no continuing involvement with True Health subsequent to the Closing except an existing services agreement for claims processing and other health plan administrative functions. Refer to &#8220;Part I - Item 1. Financial Statements - Note 5&#8221; for additional discussion regarding the True Health sale. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in conjunction with the sale of True Health, the Company made organizational changes, including re-evaluating its reportable segments. Effective during the first quarter of 2021, the Company bifurcated its previous Services segment into two segments. The Company&#8217;s Evolent Health Services segment (&#8220;EHS&#8221;) includes our administrative simplification solution and certain supporting population health infrastructure. Our Clinical Solutions segment includes our specialty management and physician-oriented total cost of care solutions, along with the New Century Health and Evolent Care Partners brands. Refer to &#8220;Part I - Item 1. Financial Statements - Note 21 for a further discussion of our operating results by segment.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Passport</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 30, 2019, UHC, Passport Health Solutions, LLC (&#8220;PHS I&#8221;), the Company and EVH Passport, closed a transaction whereby EVH Passport acquired substantially all of the assets and assumed substantially all of the liabilities of UHC, including the Passport Medicaid Contract.  The purchase price paid by EVH Passport consisted of $70.0 million in cash and a 30% equity interest in EVH Passport issued to the Sponsors; however, $16.2 million of the foregoing cash purchase price was held back until such time as PHS I delivers to EVH Passport certain owned real property and improvements.  </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 1, 2020, EVH Passport and Molina completed the Molina Closing and the Passport Medicaid Contract was novated to Molina. As a result, EVH Passport began to wind down its business. In connection with the Molina Closing, Molina deposited $20.0 million in cash in escrow, which was subsequently released to EVH Passport in January 2021. Prior to the Molina Closing, the Company accounted for its investment in EVH Passport as an unconsolidated variable interest entity under the equity method of accounting.  As a result of the Molina Closing, the Company concluded that a reconsideration event occurred whereby EVH Passport was determined to be a voting interest entity and that Evolent had a controlling financial interest in EVH Passport; accordingly, the Company consolidated EVH Passport as of September 1, 2020 in its consolidated financial statements. The Company accounted for the transaction as an asset acquisition, as the Company concluded that assets acquired as a result of the consolidation did not meet the criteria to be classified as a business under GAAP. Following the Molina Closing and consolidation of EVH Passport in the Company&#8217;s consolidated financials, EVH Passport redeemed the Sponsors&#8217; equity interests in EVH Passport in accordance with the terms of EVH Passport's Stockholders' Agreement , and, as a result, EVH Passport became a wholly owned subsidiary of the Company.  The Company expects a return of capital from EVH Passport, expected to be between $130 million and $170 million in total, which is subject to regulatory approval from the Kentucky Department of Insurance. Refer to &#8220;Part I - Item 1. Financial Statements - Note 4&#8221; for additional discussion regarding the Passport transactions.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Repayment and Termination of Existing Credit Agreement</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 8, 2021, the Company repaid all outstanding amounts owed under, and terminated, the Credit Agreement with Ares Capital Corporation. The total amount paid to Ares Corporation under the Credit Agreement in connection with the prepayment was $98.6&#160;million, which included $9.7&#160;million for the make-whole premium as well as $0.2&#160;million in accrued interest. In addition to the payment of the Credit Agreement, the Company settled the outstanding warrants associated with the debt for $13.7&#160;million. Refer to &#8220;Part I - Item 1. Financial Statements - Note 10&#8221; for additional discussion relating to the repayment of the Credit Agreement.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Repositioning Plan</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continually assess opportunities to improve operational effectiveness and efficiency to better align our expenses with revenues, while continuing to make investments in our solutions, systems and people that we believe are important to our long-term goals. Across 2020, we divested or agreed to divest a majority of our health plan assets, including the assets of EVH Passport, which represented a significant revenue stream for the Company. In parallel with these divestitures, we contracted with a third-party vendor to review our operating model and organizational design in order to improve our profitability, create value through our solutions and invest in strategic opportunities in future periods.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the fourth quarter of 2020, we committed to certain operational efficiency and profitability actions that we are taking in order to accomplish these objectives (&#8220;Repositioning Plan&#8221;). These actions included making organizational changes across our business as well as other profitability initiatives expected to result in reductions in force, re-aligning of resources as well as other potential operational efficiency and cost-reduction initiatives. The Repositioning Plan is expected to continue through the fourth quarter of 2021. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded approximately $0.7 million and $6.0 million of repositioning costs in selling, general and administrative expenses for the three and six months ended June 30, 2021&#160;in connection with the Repositioning Plan. The following table provides a summary of our total costs associated with the Repositioning Plan for the three and six months ended June 30, 2021, by major type of cost (in thousands):</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.305%"><tr><td style="width:1.0%"></td><td style="width:27.431%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.499%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.305%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.359%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.305%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.359%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.039%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.359%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.044%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Incurred For the Three Months Ended <br/>June  30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Incurred for the Six Months Ended June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Amount Expected to be Incurred in the Repositioning Plan</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cumulative Amount Incurred through June 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Severance and termination benefits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office space consolidation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,071&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,071&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,071&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional services</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">587&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,787&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,162&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,062&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">663&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,043&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,418&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,318&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><div id="id8f403494d0a42c2868794fb470218fc_151"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Critical Accounting Policies and Estimates</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The MD&amp;A included in our 2020 Form 10-K contains a detailed discussion of our critical accounting policies and estimates. There have been no material changes to our critical accounting policies and estimates since our 2020 Form 10-K. See &#8220;Item 1. Financial Statements - Note 2&#8221; in this Form 10-Q for a summary of our significant accounting policies and see &#8220;Item 1. Financial Statements - Note 3&#8221; in this Form 10-Q for information regarding the Company&#8217;s adoption of new accounting standards.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summary of Significant Accounting Policies</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain GAAP policies that significantly affect the determination of our financial position, results of operations and cash flows, are summarized below. See &#8220;Part II - Item 8. Financial Statements and Supplementary Data - Note 2&#8221; in our 2020 Form 10-K for a complete summary of our significant accounting policies.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize the excess of the purchase price, plus the fair value of any non-controlling interests in the acquiree, over the fair value of identifiable net assets acquired as goodwill. Goodwill is not amortized, but is reviewed at least annually for indications of impairment, with consideration given to financial performance and other relevant factors. We perform impairment tests of goodwill at a reporting unit level. The Company has three reporting units and our annual goodwill impairment review occurs during the fourth quarter of each year. We perform impairment tests between annual tests if an event occurs, or circumstances change, that we believe would more likely than not reduce the fair value of a reporting unit below its carrying amount.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our goodwill impairment analysis first assesses qualitative factors to determine whether events or circumstances existed that would lead the Company to conclude it is more likely than not that the fair value of a reporting unit is below its carrying amount. If the Company determines that it is more likely than not that the fair value of a reporting unit is below the carrying amount, a quantitative goodwill assessment is required. In the quantitative evaluation, the fair value of the relevant reporting unit is determined and compared to the carrying value. If the fair value is greater than the carrying value, then the carrying value is deemed to be recoverable and no further action is required. If the fair value estimate is less than the carrying value, goodwill is considered impaired for the amount by which the carrying amount exceeds the reporting unit&#8217;s fair value and a charge is reported in goodwill impairment on our consolidated statements of operations and comprehensive income (loss).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not identify any qualitative factors that would trigger a quantitative goodwill impairment test during the three and six months ended June 30, 2021. We will perform our annual impairment test as of October 31, 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A description of our 2020 goodwill impairment test follows below.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company performed an interim goodwill impairment assessment in one of our three reporting units in the EHS segment as of March 31, 2020 due to the decline in the Company&#8217;s stock price during the first quarter of 2020 and lack of excess of fair value over the carrying value considering the $199.8 million impairment charge taken in the fourth quarter of 2019. The Company concluded that the fair value of its reporting unit was more than its carrying value as of March 31, 2020. In addition, the Company performed an interim goodwill impairment assessment as of May 31, 2020 and concluded that the fair value of one of our three reporting units in the EHS segment was less than its carrying value by $215.1 million as of May 31, 2020. The decrease in fair value was due to our largest customer, EVH Passport, not obtaining a renewal of its Kentucky managed Medicaid contract, which was its sole business. The non-renewal of EVH Passport&#8217;s contract caused a reduction in the Company&#8217;s cash flow projections. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the impairment charges in the fourth quarter of 2019 and second quarter of 2020, the Company elected to forego the qualitative assessment and proceed directly to the quantitative assessment of the goodwill impairment test for the specific reporting unit that incurred those impairment charges. This election does not preclude Management from performing the qualitative assessment in any subsequent period. For the remaining reporting units, after assessing the totality of events and circumstances including the results of our previous valuations, the minimal impacts of the Passport loss and COVID-19, the Company does not believe that an event occurred or circumstances changed during the period under consideration that would, more likely than not, reduce the fair value of any reporting unit below their carrying amount. Therefore, the Company concluded that the quantitative assessment was not required. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In performing our October 31, 2020 impairment test for one of the specific reporting unit reference above, we estimated the fair value of our reporting units by considering a discounted cash flow valuation approach (&#8220;income approach&#8221;). In determining the estimated fair value using the income approach, we projected future cash flows based on management&#8217;s estimates and long-term plans and applied a discount rate based on the Company&#8217;s weighted average cost of capital. This analysis required us to make judgments about revenues, expenses, fixed asset and working capital requirements, capital market assumptions, cash flows and discount rates. As of </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">October 31, 2020, we determined that the specific reporting unit had an estimated fair value greater than its carrying value and as a result, goodwill is not impaired.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, the Company assessed whether there were additional events or changes in circumstances since its annual goodwill impairment test that would indicate that it was more likely than not that the fair value of the reporting units was less than the reporting unit&#8217;s carrying amounts that would require an interim impairment assessment after October 31, 2020. The Company determined there had been no such indicators, therefore, we did not perform an interim goodwill impairment assessment as of December 31, 2020. As of December 31, 2020, the remaining goodwill attributable to the reporting unit from which we recognized a non-cash goodwill impairment charge earlier in the year was $214.3 million.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Adoption of New Accounting Standards</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and subsequently issued additional guidance that modified ASU 2016-13. The standard requires an entity to change its accounting approach for measuring and recognizing credit losses on certain financial assets measured at amortized cost, including trade receivables, certain non-trade receivables, customer advances and certain off-balance sheet credit exposures, by replacing the existing &#8220;incurred loss&#8221; framework with an expected credit loss recognition model.&#160; The new standard results in earlier recognition of credit losses based on past events, current conditions, and reasonable and supportable forecasts.&#160; The standard is effective for entities with fiscal years beginning after December 15, 2019, including interim periods within such fiscal years. We adopted the requirements of this standard effective January 1, 2020 using the modified retrospective approach and recorded a cumulative effect adjustment of $3.0 million to January 1, 2020 retained earnings (accumulated deficit).&#160; In our previous accounting policy for trade receivables and non-trade receivables, we maintained an allowance for doubtful accounts based on specific identification. Under the new accounting standard, we utilize several factors to develop historical losses, including aging schedules, customer creditworthiness, and historical payment experience, which are then adjusted for current conditions and reasonable and supportable forecasts in measurement of the allowance.&#160; In addition, for customer advances and certain off-balance sheet credit exposures, we evaluate the allowance through a discounted cash flow approach.&#160; Refer to Note 7 for additional disclosures related to current expected credit losses.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><div id="id8f403494d0a42c2868794fb470218fc_154"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESULTS OF OPERATIONS</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Evolent Health, Inc. is a holding company and its principal asset is all of the Class&#160;A common units in Evolent Health LLC, which has owned all of our operating assets and substantially all of our business since inception. The financial results of Evolent Health LLC are consolidated in the financial statements of Evolent Health, Inc.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Key Components of our Results of Operations</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We derive revenue primarily from transformation services and platform and operations services.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Transformation Services Revenue</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Transformation services consist of implementation services whereby we assist the customer in launching its population health or health plan programs. In certain cases, transformation services can also include revenue associated with our support of certain one-time wind-down activities for clients who are exiting a line of business or population. The transformation services are usually completed within 12 months. We generally receive a fixed fee for transformation services and recognize revenue over time using an input method based on hours incurred compared to the total estimated hours required to satisfy our performance obligation.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Platform and Operations Services Revenue</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Platform and operations services are typically multi-year arrangements with customers to provide various clinical and administrative solutions. In our Clinical Solutions segment, our solutions are designed to lower the medical expenses of our partners and include our total cost of care and specialty care management services. In our Evolent Health Services segment, our solutions are designed to provide comprehensive health plan operations and claims processing services, and also include transition or run-out services to customers receiving primarily TPA services.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our performance obligation in these arrangements is to provide an integrated suite of services, including access to our platform that is customized to meet the specialized needs of our customers and members. Generally, we will apply the series guidance to the performance obligation as we have determined that each time increment is distinct. We primarily utilize a variable fee structure for these services that typically includes a monthly payment that is calculated based on a specified per member per month rate, multiplied by the number of members that our partners are managing under a value-based care arrangement or a percentage of plan premiums. Our arrangements may also include other variable fees related to service level agreements, shared medical savings arrangements and other performance measures. Variable consideration is estimated using the most likely amount based on our historical experience and best judgment at the time. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our Clinical Solutions segment, we enter into capitation arrangements that may include performance-based arrangements and/or gainshare features.  We recognize capitation revenue on a gross basis when we have established control over the services within our scope and recognize capitation revenue on a net basis when we do not have control over the services within our scope. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the nature of our arrangements, certain estimates may be constrained if it is probable that a significant reversal of revenue will occur when the uncertainty is resolved. We recognize revenue from platform and operations services over time using the time elapsed output method. Fixed consideration is recognized ratably over the contract term. In accordance with the series guidance, we allocate variable consideration to the period to which the fees relate.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contracts with Multiple Performance Obligations</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contracts with customers may contain multiple performance obligations, primarily when the customer has requested both transformation services and platform and operations services as these services are distinct from one another. When a contract has multiple performance obligations, we allocate the transaction price to each performance obligation based on the relative standalone selling price using the expected cost margin approach. This approach requires estimates regarding both the level of effort it will take to satisfy the performance obligation as well as fees that will be received under the variable pricing model. We also take into consideration customer demographics, current market conditions, the scope of services and our overall pricing strategy and objectives when determining the standalone selling price.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, our reportable segments enter into transactions with one another. While intersegment transactions are treated like third-party transactions to determine segment performance, the revenues and expenses recognized by the segment that is the counterparty to the transaction are eliminated in consolidation and do not affect consolidated results.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of Revenue (exclusive of depreciation and amortization)</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our cost of revenue includes direct expenses and shared resources that perform services in direct support of clients. Costs consist primarily of employee-related expenses (including compensation, benefits and stock-based compensation), expenses for TPA support and other services, as well as other professional fees. In certain cases, our cost of revenue also includes claims and capitation payments to providers and payments for pharmaceutical treatments and other health care expenditures through performance-based arrangements.  Subsequent to the consolidation of EVH Passport on September 1, 2020, our cost of revenue includes the consolidated impact of the runout of EVH Passport&#8217;s operations, consisting principally of updates to EVH Passport&#8217;s claims reserve based on actual claims payments. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, General and Administrative Expenses</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our selling, general and administrative expenses consist of employee-related expenses (including compensation, benefits and stock-based compensation) for selling and marketing, corporate development, finance, legal, human resources, corporate information technology, professional fees and other corporate expenses associated with these functional areas. Selling, general and administrative expenses also include costs associated with our centralized infrastructure and research and development activities to support our network development capabilities, claims processing services, including PBM administration, technology infrastructure, clinical program development and data analytics.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Depreciation and amortization expense</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expenses consist of the amortization of intangible assets associated with the step up in fair value of Evolent Health LLC&#8217;s assets and liabilities for the Offering Reorganization, amortization of intangible assets recorded as part of our various business combinations and asset acquisitions and depreciation of property and equipment, including the amortization of capitalized software.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evolent Health, Inc. Consolidated Results</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:108.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:51.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:51.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:51.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:51.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:51.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:43.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:21pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(in thousands, except percentages)</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change Over Prior Period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change Over Prior Period</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Transformation services</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,564&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">755&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,809&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">239.6%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,909&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,993&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,084)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(51.5)%</span></td></tr><tr style="height:21pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Platform and operations services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">219,493&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">216,544&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,949&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.4%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">434,219&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">432,538&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,681&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.4%</span></td></tr><tr style="height:21pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">222,057&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">217,299&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,758&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.2%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">437,128&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">438,531&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,403)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.3)%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:39pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of revenue (exclusive of depreciation and amortization expenses presented separately below)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">172,113&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">164,358&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,755&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.7%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">329,945&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">339,987&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10,042)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3.0)%</span></td></tr><tr style="height:21pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42,699&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47,296&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,597)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9.7)%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101,290&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">99,383&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,907&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.9%</span></td></tr><tr style="height:21pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,916&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,618&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(702)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4.5)%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,103&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31,596&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,493)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4.7)%</span></td></tr><tr style="height:21pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss on disposal of assets and consolidation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,447&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,447)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(100.0)%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill impairment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">215,100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(215,100)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(100.0)%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">215,100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(215,100)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(100.0)%</span></td></tr><tr style="height:30pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration and indemnification asset</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">756&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(756)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(100.0)%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(594)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,062)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,468&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">80.6%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">229,728&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">443,128&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(213,400)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(48.2)%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">460,744&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">689,451&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(228,707)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(33.2)%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating loss</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7,671)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(225,829)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">218,158&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">96.6%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(23,616)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(250,920)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">227,304&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">90.6%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:30pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Transformation services revenue as a % of total revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:30pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Platform and operations services revenue as a % of total revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">98.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">99.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">99.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">98.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:21pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of revenue as a % of revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:30pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative expenses as a % of total revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Comparison of the Results for the Three Months Ended June 30, 2021 to 2020 </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue increased by $4.8 million, or 2.2%, to $222.1 million for the three months ended June 30, 2021, as compared to 2020.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Transformation services revenue increased by $1.8 million, or 239.6%, to $2.6 million for the three months ended June 30, 2021, as compared to 2020, due primarily to the timing of implementation activities. Transformation services revenue accounted for 1.2% and 0.3% of our total revenue for the three months ended June 30, 2021 and 2020, respectively. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Platform and operations services revenue increased by $2.9 million, or 1.4%, to $219.5 million for the three months ended June 30, 2021, as compared to 2020. We expect our platform and operations growth rate in 2021 to increase as a result of the impact of new customer additions, offset, in part by the wind-down of EVH Passport&#8217;s operations compared to 2020.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Platform and operations services revenue accounted for 98.8% and 99.7% of our total revenue for the three months ended June 30, 2021 and 2020, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table represents Evolent&#8217;s revenue disaggregated by segment and end-market for the three months ended June 30, 2021 and 2020 (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:328.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Evolent Health Services</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,064&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,502&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,648&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,050&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,346&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,061&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,761&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,206&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,453&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,958&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,785&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,522&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,863&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,521&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147,194&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130,778&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Revenue from our Evolent Health Services segment decreased by $11.7&#160;million for the three months ended June 30, 2021 as compared to 2020 due to the runout of services for EVH Passport, partially offset by new partner additions. Revenue from our Clinical Solutions segment increased by $16.4&#160;million for the three months ended June 30, 2021 as compared to 2020 due to new partner additions as well as expansion into new markets within current New Century Technology &amp; Services Suite partners. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We had 12.2&#160;million lives on our platform as of June&#160;30, 2021, comprised of 1.5 million lives in our Evolent Health Services segment and 10.7 million lives in our Clinical Solutions segment. The Clinical Solutions lives include 1.5 million lives in our Performance Suite and 9.2 million lives in the New Century Technology &amp; Services Suite. Lives on platform are calculated by summing members on our value-based care and comprehensive health plan administrative platform, as well as members covered for oncology specialty care services and members covered for cardiology specialty care services. Lives on New Century Technology &amp; Services Suite are calculated by summing members covered for oncology specialty care services and members covered for cardiology specialty care services for contracts under ASO arrangements. Members covered for more than one category are counted in each category. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our average per member per month fees for our Performance Suite were $22.05 and $21.41 and for our New Century Technology and Services Suite were $0.37 and $0.40 for the three months ended June 30, 2021 and 2020, respectively.  Evolent Health Services PMPM fee is defined as platform and operations revenue pertaining to the Evolent Health Services segment in the quarter divided by the average of the beginning and ending Evolent Health Services segment membership during quarter divided by the number of months in the period. Clinical Solutions PMPM fee is defined as platform and operations services revenue pertaining to our Performance Suite in the quarter divided by the average of the beginning and ending Performance Suite membership during quarter divided by the number of months in the period. New Century Technology &amp; Services Suite PMPM fee is defined as platform and operations revenue pertaining to the New Century Technology &amp; Services Suite in the quarter divided by the average of the beginning and ending New Century Technology &amp; Services Suite membership during quarter divided by the number of months in the period.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Management uses Lives on our Platform and PMPM fees because we believe that they provide insight into the unit economics of our services. We believe that these measures are also useful to investors because they allow further insight into the period over period operational performance. We believe that these measures are also useful to investors because they allow further insight into the period over period operational performance. We had 41 and 34 operating partners as of June&#160;30, 2021 and 2020, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of Revenue</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The following table provides a summary of our total cost of revenue by segment for the three months ended June 30, 2021, as compared to 2020 (amounts in thousands):</span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.861%"><tr><td style="width:1.0%"></td><td style="width:30.471%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.966%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.966%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.966%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.966%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.966%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.966%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.966%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.975%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="45" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Evolent Health Services</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,256&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,361&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,355&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108,531&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">502&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,466&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172,113&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164,358&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of revenue increased by $7.8 million, or 4.7%, to $172.1 million for the three months ended June 30, 2021, as compared to 2020. Cost of revenue increased by approximately $15.1 million period over period as a result of higher growth of our revenue generating services, offset, in part by lower capitation expenses, an increase of $2.0 million in our technology services, TPA fees and other costs offset by a decrease of $2.6 million in professional fees due to the nature and timing of our projects and a decrease of $6.8 million in our personnel costs. The principal driver of these decreases was the wind-down of EVH Passport relative to 2020. Cost of revenue for three months ended June 30, 2021 includes approximately $3.6&#160;million associated with the wind-down of EVH Passport, inclusive of a reduction in Passport&#8217;s claims reserve. Approximately $0.9 million and $0.5 million of total personnel costs was attributable to stock-based compensation expense for the three months ended June 30, 2021 and 2020, respectively. Cost of revenue represented 77.5% and </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75.6% of total services revenue for the three months ended June 30, 2021 and 2020, respectively. Our cost of revenue increased as a percentage of our total services revenue due to a change in the mix of our service offerings towards higher gross margin services with divestiture of our health plans combined with our Repositioning Plan. We expect our cost of revenue to decrease as a percentage of total services revenue over the longer-term subject to the composition of our growth.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, General and Administrative Expenses</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The following table provides a summary of our selling, general and administrative expenses by segment for the three months ended June 30, 2021, as compared to 2020 (amounts in thousands):</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.816%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.261%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.261%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.705%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.122%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.261%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.261%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.261%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.267%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="45" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Evolent Health Services</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,763&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,306&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,592&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,174&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,344&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,816&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,699&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,296&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general, and administrative expenses decreased by $4.6 million, or 9.7%, to $42.7 million for the three months ended June 30, 2021, as compared to 2020. During three months ended June 30, 2021, personnel costs decreased by $1.1&#160;million period over period due to a reduction in employee headcount. Approximately $2.8 million and $3.2 million of total personnel costs were attributable to stock-based compensation expense for both three months ended June 30, 2021 and 2020, respectively. Professional fees increased by $1.2 million for the three months ended June 30, 2021, as compared to 2020, respectively, primarily due to the Repositioning Plan and shareholder advisory services. Acquisition and severance costs accounted for approximately $76&#160;thousand and $0.4&#160;million of total selling, general and administrative expenses for the three months ended June 30, 2021 and 2020, respectively. Selling, general and administrative expenses represented 19.2% and 21.8% of total revenue for the three months ended June 30, 2021, as compared to 2020, respectively. While our selling, general and administrative expenses are expected to grow as our business grows, we expect them to decrease as a percentage of our total revenue over the long term due to cost saving initiatives introduced in the fourth quarter of 2020.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Depreciation and Amortization Expenses</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expenses decreased $0.7 million, or (4.5)%, to $14.9 million for the three months ended June 30, 2021, as compared to 2020. The decrease was due primarily to lower amortization on existing technology intangibles, offset, in part by, an increase in amortization expense for internal-use software. We expect depreciation and amortization expenses to increase in future periods as we continue to capitalize internal-use software and amortize intangible assets resulting from asset acquisitions and business combinations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill Impairment</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended June 30, 2020 we recorded a non-cash impairment charge of $215.1 million on our consolidated statements of operations as we determined that the implied fair value of goodwill of one of the two reporting units in the EHS segment was less than the carrying amount. See &#8220;Part I - Item 1. Financial Statements - Note 9&#8221; for further details of the impairment charge to goodwill.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Change in Fair Value of Contingent Consideration and Indemnification Asset</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We recorded a loss on change in fair value of contingent consideration and indemnification asset of&#160;$0.8 million for the three months ended June 30, 2020. This variance is the result of changes in the fair values of contingent liabilities incurred from entering in the warrant agreements compared to the liabilities acquired as a result of business combinations and asset acquisitions during 2016, 2018, 2019 and 2020.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Comparison of the Results for the Six Months Ended June 30, 2021 to 2020 </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue decreased by $1.4 million, or 0.3%, to $437.1 million for the six months ended June 30, 2021, as compared to 2020.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Transformation services revenue decreased by $3.1 million, or 51.5%, to $2.9 million for the six months ended June 30, 2021, as compared to 2020, due primarily to the timing of implementation activities. Transformation services revenue accounted for 0.7% and 1.4% of our total revenue for the six months ended June 30, 2021 and 2020, respectively. </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Platform and operations services revenue increased by $1.7 million, or 0.4%, to $434.2 million for the six months ended June 30, 2021, as compared to 2020. We expect our platform and operations growth rate in 2021 to increase as a result of the impact of new customer additions, including Florida Blue Medicare, Inc., offset, in part by the wind-down of EVH Passport&#8217;s operations compared to 2020. Platform and operations services revenue accounted for 99.3% and 98.6% of our total revenue for the six months ended June 30, 2021 and 2020, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table represents Evolent&#8217;s revenue disaggregated by segment and end-market for the six months ended June 30, 2021 and 2020 (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:327.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Evolent Health Services</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,993&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113,947&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,987&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124,512&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,684&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,246&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176,544&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126,560&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,023&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,705&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,897&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,561&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159,700&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182,898&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277,428&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255,633&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Revenue from our Evolent Health Services segment decreased by $23.2 million for the six months ended June 30, 2021 as compared to 2020 due to the runout of services for EVH Passport, partially offset by new partner additions. Revenue from our Clinical Solutions segment increased by $21.8 million for the six months ended June 30, 2021 as compared to 2020 due to new partner additions including Florida Blue Medicare, Inc., as well as expansion into new markets within current New Century Technology &amp; Services Suite partners. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We had 12.2&#160;million lives on our platform as of June&#160;30, 2021, comprised of 1.5 million lives in our Evolent Health Services segment and 10.7 million  lives in our Clinical Solutions segment. The Clinical Solutions lives include 1.5 million lives in our Performance Suite and 9.2 million lives in the New Century Technology &amp; Services Suite. Lives on platform are calculated by summing members on our value-based care and comprehensive health plan administrative platform, as well as members covered for oncology specialty care services and members covered for cardiology specialty care services. Lives on New Century Technology &amp; Services Suite are calculated by summing members covered for oncology specialty care services and members covered for cardiology specialty care services for contracts under ASO arrangements. Members covered for more than one category are counted in each category. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our average per member per month fees for our Performance Suite were $21.25 and $20.57 and for our New Century Technology and Services Suite were $0.41 and $0.40 for the six months ended June 30, 2021 and 2020, respectively.  Evolent Health Services PMPM fee is defined as platform and operations revenue pertaining to the Evolent Health Services segment in the quarter divided by the average of the beginning and ending Evolent Health Services segment membership during quarter divided by the number of months in the period. Clinical Solutions PMPM fee is defined as platform and operations services revenue pertaining to our Performance Suite in the quarter divided by the average of the beginning and ending Performance Suite membership during quarter divided by the number of months in the period. New Century Technology &amp; Services Suite PMPM fee is defined as platform and operations revenue pertaining to the New Century Technology &amp; Services Suite in the quarter divided by the average of the beginning and ending New Century Technology &amp; Services Suite membership during quarter divided by the number of months in the period.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Management uses Lives on our Platform and PMPM fees because we believe that they provide insight into the unit economics of our services. We believe that these measures are also useful to investors because they allow further insight into the period over period operational performance. We believe that these measures are also useful to investors because they allow further insight into the period over period operational performance. We had 41 and 34 operating partners as of June&#160;30, 2021 and 2020, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of Revenue</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a summary of our total cost of revenue by segment for the six months ended June 30, 2021, as compared to 2020 (amounts in thousands):</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.861%"><tr><td style="width:1.0%"></td><td style="width:29.358%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.105%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.105%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.105%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.105%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.105%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.105%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.105%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.115%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="45" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Evolent Health Services</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,703&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,379&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225,980&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217,422&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,262&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,186&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">329,945&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">339,987&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of revenue decreased by $10.0 million, or 3.0%, to $329.9 million for the six months ended June 30, 2021, as compared to 2020. Cost of revenue decreased by approximately $15.9 million due to lower personnel costs, $3.8 million in lower professional fees and 0.2 million in our technology services, TPA fees and other costs combined with a $12.8 million increase from growth of our revenue generating services offset by lower capitation expenses. The principal driver of these decreases was the wind-down of EVH Passport relative to 2020. Cost of revenue for the six months ended June 30, 2021 includes approximately $5.8 million associated with the wind-down of EVH Passport, inclusive of a reduction in Passport&#8217;s claims reserve. Approximately $1.5 million and $0.9 million of total personnel costs was attributable to stock-based compensation expense for the six months ended June 30, 2021 and 2020, respectively. Cost of revenue represented 75.5% and 77.5% of total services revenue for the six months ended June 30, 2021 and 2020, respectively. Our cost of revenue decreased as a percentage of our total services revenue due to a change in the mix of our service offerings towards higher gross margin services with divestiture of our health plans combined with our Repositioning Plan. We expect our cost of revenue to decrease as a percentage of total services revenue over the longer-term subject to the composition of our growth.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, General and Administrative Expenses</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a summary of our total selling, general and administrative by segment for the six months ended June 30, 2021, as compared to 2020 (amounts in thousands):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.861%"><tr><td style="width:1.0%"></td><td style="width:29.358%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.105%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.105%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.105%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.105%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.105%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.105%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.105%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.115%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="45" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Evolent Health Services</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,729&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,147&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,772&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,642&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,789&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,594&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,290&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,383&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Selling, general, and administrative expenses increased by $1.9 million, or 1.9%, to $101.3 million for the six months ended June 30, 2021, as compared to 2020. Professional fees increased by $9.8 million for the six months ended June 30, 2021, as compared to 2020, respectively, primarily due to the Repositioning Plan and shareholder advisory services. During the six months ended June 30, 2021, personnel costs decreased by $3.7&#160;million period over period due to a reduction in employee headcount. Approximately $5.9 million of total personnel costs were attributable to stock-based compensation expense for both the six months ended June 30, 2021 and 2020, respectively. Acquisition and severance costs accounted for approximately $2.1&#160;million and $6.8&#160;million of total selling, general and administrative expenses for the six months ended June 30, 2021 and 2020, respectively. Selling, general and administrative expenses represented 23.2% and 22.7% of total revenue for the six months ended June 30, 2021, as compared to 2020, respectively. While our selling, general and administrative expenses are expected to grow as our business grows, we expect them to decrease as a percentage of our total revenue over the long term due to cost saving initiatives introduced in the fourth quarter of 2020.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Depreciation and Amortization Expenses</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expenses decreased $1.5 million, or (4.7)%, to $30.1 million for the six months ended June 30, 2021, as compared to 2020. The decrease was due primarily to lower amortization on existing technology intangibles, offset, in part by, an increase in amortization expense for internal-use software. We expect depreciation and amortization expenses to increase in future periods as we continue to capitalize internal-use software and amortize intangible assets resulting from asset acquisitions and business combinations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gain (Loss) on Disposal of Assets and Consolidation</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During 2019, the Company, through a non-wholly owned consolidated subsidiary, entered into an agreement with an unrelated party to provide services and support to providers, independent physician associations, and other provider groups. During the six months ended June 30, 2020, the Company sold its interest in the subsidiary and recorded a $6.4 million loss on disposal of assets and consolidation on the consolidated statements of operations. The Company did not have any continuing involvement with the entity after the consummation of this transaction.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill Impairment</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended June 30, 2020 we recorded a non-cash impairment charge of $215.1 million on our consolidated statements of operations as we determined that the implied fair value of goodwill of one of the two reporting units in the EHS segment was less than the carrying amount. See &#8220;Part I - Item 1. Financial Statements - Note 9&#8221; for further details of the impairment charge to goodwill.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Change in Fair Value of Contingent Consideration and Indemnification Asset</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We recorded a gain on change in fair value of contingent consideration and indemnification asset of&#160;$0.6 million&#160;and&#160;$3.1 million for the six months ended June 30, 2021 and 2020, respectively. This variance is the result of changes in the fair values of contingent liabilities incurred from entering in the warrant agreements compared to the liabilities acquired as a result of business combinations and asset acquisitions during 2016, 2018, 2019 and 2020.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Discussion of Non-Operating Results</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Income</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income consists of interest from investing cash in money market funds and interest from both our short-term and long-term investments, interest earned on the capital-only reinsurance agreement with NMHC and interest from the implementation loan and amounts contributed to UHC in the form of an advance for regulatory capital requirements under an agreement with UHC. We recorded interest income of $0.1 million and $0.2 million and for the three and six months ended June 30, 2021, respectively, and $0.7 million and $1.5 million for the three and six months ended June 30, 2020, respectively. Interest income decreased during 2021 as a result of the repayment of the $40.0 million Passport Note on November 24, 2020. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Expense</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our interest expense is primarily attributable to our 2021 Notes, 2024 Notes, 2025 Notes and Credit Agreement with Ares Capital Corporation. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company issued its 2021 Notes in December 2016. Holders of the 2021 Notes are entitled to cash interest payments at a rate equal to&#160;2.00%&#160;per annum. In addition, we incurred&#160;$4.6 million&#160;of debt issuance costs in connection with the 2021 Notes, which we are amortizing to non-cash interest expense using the straight-line method over the contractual term of the 2021 Notes. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company issued its 2024 Notes in August 2020. As part of the issuance of the 2024 Notes, the Company consummated an exchange offer pursuant to which it issued $84.2 million aggregate principal amount of the 2024 Notes in exchange for $84.2 million aggregate principal of its 2021 Notes.  Holders of the 2024 Notes are entitled to cash interest payments at a rate equal to&#160;3.50%&#160;per annum. In addition, the 2024 Notes contain a cash conversion option, which resulted in a debt discount of $38.1&#160;million, allocated to equity. The amount allocated to equity, along with&#160;$3.0&#160;million&#160;of debt issuance costs in connection with the 2024 Notes, will be amortized to non-cash interest expense using the effective interest method over the contractual term of the 2024 Notes. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company issued its 2025 Notes in October 2018. Holders of the 2025 Notes are entitled to cash interest payments at a rate equal to&#160;1.50%&#160;per annum. The 2025 Notes contain a cash conversion option, which resulted in a debt discount of $71.8 million, allocated to equity. The amount allocated to equity, along with $3.4 million of issuance costs, will be amortized to non-cash interest expense using the effective interest method over the contractual term of the 2025 Notes. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company entered into the Credit Agreement in December 2019 with Ares Credit Corporation in connection with the Company&#8217;s acquisition of certain assets of UHC. Ares Capital Corporation was entitled to cash interest payments. The interest rate for each loan under the Senior Credit Facilities was calculated, at the option of the Borrower, at either the Eurodollar rate plus 8.00%, or the base rate plus 7.00%. A commitment fee of 1.00% per annum was payable by the Borrower quarterly in arrears on the unused portion of the DDTL Facility. As of December 31, 2020, the Company had $75.0 million outstanding under its Credit Agreement. On January 8, 2021, the Company repaid all outstanding amounts owed under, and terminated, the Credit Agreement with Ares Capital Corporation.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recorded interest expense (including amortization of deferred financing costs) of approximately $6.3 million and $12.6 million for both the three and six months ended June 30, 2021 and 2020, respectively. See &#8220;Part I - Item 1.  Financial Statements - Note 10&#8221; in this Form 10-Q for further details.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Impairment of Equity Method Investments</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2020, the Oklahoma Insurance Division (&#8220;OID&#8221;) informed GlobalHealth, Inc. that in response to the COVID-19 pandemic, the OID required GlobalHealth, Inc. to increase its regulatory capital surplus by May 15, 2020. It would otherwise be placed into receivership if additional financing could not be secured. Certain investors agreed to provide liquidity as necessary to increase statutory capital reserves to no lower than 300%. In connection with the investment, GlobalHealth, Inc. transferred 100% of the equity interests in GlobalHealth, Inc. to the new investors for no consideration. Closing of this transaction occurred on May 13, 2020. As a result of this transaction, we have recorded a non-cash impairment charge of approximately $47.1 million, representing the </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">total value of our investment, in impairment of equity method investments on the consolidated statements of operations for the six months ended June 30, 2020.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gain (Loss) from Equity Method Investees</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has acquired economic interests in several entities that are accounted for under the equity method of accounting. The Company allocated its proportional share of the investees&#8217; earnings and losses each reporting period. The Company&#8217;s proportional share of the gains from these investments was approximately $4.9 million and $12.7 million for the three and six months ended June 30, 2021, respectively and $25.1 million and $24.7 million for the three and six months ended June 30, 2020, respectively. The change in gain from equity method investees for the three months ended June 30, 2021 compared to 2020 is driven primarily by the Company&#8217;s investment in Passport. The change in gain from equity method investees for the six months ended June 30, 2021 compared to 2020 is driven primarily by the Company&#8217;s investment in Passport during 2020 combined with gains on the sale of our Florida equity investee&#8217;s membership during 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gain from Transfer of Membership</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended June 30, 2021, EVH Passport received a cash payment from Molina in the amount of $23.0 million based on the number of enrollees above a certain threshold in the D-SNP Business and Molina's Medicaid plan following the open enrollment period for plan year 2021. The foregoing amount represents 50% of the payment that EVH Passport is eligible to receive based on the number of such enrollees. The remaining 50% will be payable in the first quarter of 2022 subject to the satisfaction of certain contingencies.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Loss On Repayment of Debt</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 8, 2021, the Company repaid all outstanding amounts owed under, and terminated, the Credit Agreement with Ares Capital Corporation. The total amount paid to Ares Corporation under the Credit Agreement in connection with the prepayment was $98.6&#160;million, which included $9.7&#160;million for the make-whole premium, $13.7&#160;million for the settlement of outstanding warrants as well as $0.2&#160;million in accrued interest. As a result of this transaction, the Company recorded loss on the repayment of debt of $19.2 million, representing the remaining unamortized debt issuance costs of $9.5&#160;million, the make-whole premium and $35&#160;thousand of legal expenses.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Provision for Income Taxes</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded $0.1 million and $0.7 million in income tax expense (benefit) for the three and six months ended June 30, 2021, respectively, which resulted in effective tax rates of (1.0)% and (3.6)%, respectively, and $(3.9) million and $(3.6) million for the three and six months ended June 30, 2020, respectively, which resulted in effective tax rates of 1.9% and 1.3%, respectively. The difference between our effective tax rate and our statutory rate is due primarily to the fact that the Company maintains a full valuation allowance recorded against its net deferred tax assets, with the exception of certain indefinite-lived components.</span></div><div><span><br/></span></div><div><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Loss from Discontinued Operations, Net of Tax</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As of June&#160;30, 2021, the Company determined that True Health met the held for sale criteria under ASC 360, and as such, True Health assets and liabilities as of December 31, 2020, and the results of operations for all periods presented are classified as held for sale and are not included in continuing operations in the consolidated financial statements. The True Health Closing occurred on March 31, 2021.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the results of operations of the Company&#8217;s True Health business, which are included in the loss from discontinued operations in the consolidated statements of operations for the three and six months ended June 30, 2021 and 2020.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.209%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Platform and operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Premiums</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,502&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,795&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,649&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,541&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,833&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,928&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.209%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenue (exclusive of depreciation and amortization expenses presented separately below) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,640&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,885&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,935&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Claims expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,144&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,954&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,811&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,236&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,764&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,911&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">320&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,180&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,763&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,977&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating loss</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,639)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(930)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,049)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes and non-controlling interests</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,508)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(847)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,773)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit for income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(326)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,508)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(521)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,773)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Cost of revenue includes intercompany expenses between the Company and True Health that are recorded in income from continuing operations on the consolidated statements of operations related an existing services agreement for claims processing and other health plan administrative functions of $3.2&#160;million for the three months ended June 30, 2020 and $2.8&#160;million and $6.3&#160;million for the six months ended June 30, 2021 and 2020, respectively.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:1.12pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Selling, general and administrative expenses includes intercompany expenses between the Company and True Health that are recorded in income from continuing operations on the consolidated statements of operations related an existing services agreement for claims processing and other health plan administrative functions of $1.0&#160;million of for the three months ended June 30, 2020 and $1.1 million and $4.1 million for the six months ended June 30, 2021 and 2020, respectively. </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div id="id8f403494d0a42c2868794fb470218fc_157"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">REVIEW OF CONSOLIDATED FINANCIAL CONDITION</span></div><div style="text-align:center"><span><br/></span></div><div id="id8f403494d0a42c2868794fb470218fc_160"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since its inception, the Company has incurred operating losses and net cash outflows from operations. The Company incurred operating losses of $23.6 million and $250.9 million for the six months ended June 30, 2021 and 2020, respectively. Net cash and restricted cash from (used in) operating activities was $(72.4) million and $17.1 million for the six months ended June 30, 2021 and 2020, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2021, the Company had $207.3 million of cash and cash equivalents and $31.1 million in restricted cash and restricted investments. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our current cash and cash equivalents will be sufficient to meet our working capital and capital expenditure requirements for the next twelve months. Our future capital requirements will depend on many factors, including our rate of revenue growth, the expansion of our sales and marketing activities and the timing and extent of our spending to support our investment efforts and expansion into other markets. We may also seek to invest in, or acquire complementary businesses, applications or technologies.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash Flows</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summary of cash flows for the six months ended June 30, 2021 and 2020</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands) has been derived from our financial statements included in &#8220;Part I - Item 1.  Financial Statements - Consolidated Statements of Cash Flows:&#8221;</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:433.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash and restricted cash provided by (used in) operating activities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(72,410)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,125&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash and restricted cash provided by (used in) investing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,380&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,382)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash and restricted cash provided by (used in) financing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(91,087)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,910&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating Activities</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash flows used in operating activities of $72.4 million for the six months ended June 30, 2021 were primarily due to our net loss of $18.9 million, a loss on the repayment and termination of our Credit Agreement of $19.2 million, a gain on the disposal of assets of $1.9 million, gain on the transfer of memberships of $23.0 million and non cash items including depreciation and amortization expenses of $30.3 million and stock-based compensation expense of $7.4 million. Our operating cash inflows were affected by the timing of our customer and vendor payments. In addition to these non-cash items, increases in accounts receivables and contract cost assets and reductions in accrued liabilities and accrued compensation and employee benefits contributed approximately $163.3 million to our cash outflows. Those cash outflows were offset, in part by increased reserves for claims and performance-based arrangements of approximately $62.6 million.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash flows from operating activities of $17.1 million in the six months ended June 30, 2020 were due primarily to our net loss of $282.3 million, partially offset by non-cash items, including an impairment of goodwill of $215.1 million, an impairment of an equity method investment of $47.1 million, depreciation and amortization expenses of $31.9 million, stock-based compensation expense of $7.2 million and a loss on the disposal of assets of $6.4 million. Our operating cash inflows were affected by the timing of our customer and vendor payments. In addition to these non-cash items, increases in accounts payable, accrued liabilities and claims reserves contributed approximately $49.0 million to our cash inflows. Those cash inflows were partially offset by an increase in accounts receivable and contract assets and contract costs assets and a decrease in accrued compensation and employee benefits contributed of approximately $39.6 million.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investing Activities</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash flows provided by investing activities of $40.4 million in the six months ended June 30, 2021 were primarily attributable to cash flows of $43.0 million from the transfer of membership and release of Passport escrow and returns of investment on equity method investments of $9.4 million offset, in part by $11.5 million from investments in internal-use software and purchases of property and equipment and $3.0 million of purchases of investments. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash flows used in investing activities of $18.4 million in the six months ended June 30, 2020 were primarily attributable to investments in internal-use software and purchases of property and equipment of $17.5 million, disposal of non-strategic assets of $2.3 million and purchases of investments of $1.4 million, offset in part by maturities of investments of $3.1 million.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financing Activities </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash flows used in financing activities of $91.1 million in the six months ended June 30, 2021 were primarily related to the repayment and termination of our Credit Agreement and settlement of our outstanding warrant agreements with Ares Capital Corporation of $98.4 million, offset, in part by a $2.4 million decrease in net working capital balances held on behalf of our partners for claims processing services. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash flows from financing activities of $25.9 million in the six months ended June 30, 2020 were primarily related to a $26.7 million increase in working capital balances held on behalf of our partners for claims processing services. These are pass-through amounts and can fluctuate materially from period to period depending on the timing of when the claims are processed. These cash inflows from claims processing services were, offset, in part by $1.3 million of taxes withheld and paid for vests of restricted stock units.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash flows from Discontinued Operations</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated statements of cash flows for all periods have not been adjusted to separately disclose cash flows related to discontinued operations. Cash flows related to the True Health business, which was sold on March 31, 2021, during the six months ended June 30, 2021 and 2020 were as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:79.733%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.207%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows provided by (used in) operating activities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,002&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,660&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows provided by (used in) investing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,494)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">382&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contractual Obligations</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our estimated contractual obligations (in thousands) as of June&#160;30, 2021, were as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:268.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:51.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022-2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024-2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2026+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases for facilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,854&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,477&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,523&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,760&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,614&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase obligations related to vendor contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,779&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,431&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,297&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt interest and termination payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,613&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,369&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,279&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,261&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt principal repayment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,737&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289,551&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316,288&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total contractual obligations</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,983&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,277&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">315,440&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,760&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">447,460&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Debt principal repayments in 2021 includes the remaining $26.7 million of 2021 Notes.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Refer to &#8220;Part I - Item 1. Financial Statements - Note 10&#8221; for additional discussion relating to the repayment of the 2021 Notes.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During the six months ended June 30, 2021, the only material change from December 31, 2020 outside the ordinary course of business in the contractual obligations set forth above was the repayment and termination of our Credit Agreement and settlement of our warrant agreements with Ares Capital Corporation. Refer to the discussion in &#8220;Part I - Item 1. Financial Statements - Note 10&#8221; for additional information on our long-term debt.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Accounts Receivable, net</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable are recorded and carried at the original invoiced amount less an allowance for any potential uncollectible amounts. During the six months ended June 30, 2021, accounts receivable, net increased due to the impact of new customers of $70.5 million and the timing of cash receipts from existing customers.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Restricted Cash and Restricted Investments</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash and restricted investments of $31.1 million is carried at cost and includes cash held on behalf of other entities for pharmacy and claims management services of $14.5 million, collateral for letters of credit required as security deposits for facility leases of $3.5 million, amounts held with financial institutions for risk-sharing arrangements of $12.4 million and other restricted balances of $0.8 million as of June&#160;30, 2021. See &#8220;Part I - Item 1. Financial Statements - Note 2&#8221; for further details of the Company&#8217;s restricted cash balances.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Uses of Capital</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our principal uses of cash are in the operation and expansion of our business. The Company does not anticipate paying a cash dividend on our Class A common stock in the foreseeable future.</span></div><div style="text-align:justify"><span><br/></span></div><div id="id8f403494d0a42c2868794fb470218fc_163"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OTHER MATTERS</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Off-balance Sheet Arrangements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through June&#160;30, 2021, the Company had not entered into any off-balance sheet arrangements, other than the operating leases and notes receivable noted above, and did not have any holdings in variable interest entities, other than the unconsolidated variable interest entities discussed in &#8220;Part I - Item 1.  Financial Statements - Note 16&#8221; within this Form 10-Q.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Related Party Transactions</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, we enter into transactions with related parties. Information regarding transactions and amounts with related parties is discussed in &#8220;Part  I - Item 1.  Financial Statements - Note 19&#8221; within this Form 10-Q.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Factors Affecting Our Business</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In general, our business is subject to a changing social, economic, legal, legislative and regulatory environment. Although the eventual impact on us of the changing environment in which we operate remains uncertain, these factors and others could have a material effect on our results of operations, liquidity and capital resources. Factors that could cause actual results to differ materially from those set forth in this section are described in &#8220;Part I - Item 1A.  Risk Factors&#8221; and &#8220;Forward-Looking Statements &#8211; Cautionary Language.&#8221; </span></div><div style="text-align:justify"><span><br/></span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><div id="id8f403494d0a42c2868794fb470218fc_166"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3.  Quantitative and Qualitative Disclosures About Market Risk</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to market risks in the ordinary course of our business. Market risk represents the risk of loss that may impact our financial position due to adverse changes in financial market prices and rates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Rate Risk</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2021, the Company had cash and cash equivalents and restricted cash and restricted investments of $238.4 million, which consisted of bank deposits with FDIC participating banks of $235.9 million, bank deposits in international banks of $2.5 million. In addition, we have unrestricted investments of $0.1 million, which are classified as held-to-maturity investments and are recorded in prepaid expenses and other current assets on the consolidated balance sheets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in interest rates affect the interest earned on our cash and cash equivalents (including restricted cash). Our investments (including restricted investments) are classified as held-to-maturity and therefore are not subject to interest rate risk. We do not enter into investments for trading or speculative purposes and have not used any derivative financial instruments to manage our interest rate risk exposure.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2021, we had $316.3 million of aggregate principal amount of convertible notes outstanding, which are fixed rate instruments and not subject to fluctuations in interest rates. Refer to the discussion in &#8220;Part I - Item 1.  Financial Statements - Note 10&#8221; for additional information on our long-term debt.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign Currency Exchange Risk</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in 2018, we have foreign currency risks related to our revenue and operating expenses denominated in currencies other than the U.S. dollar, primarily the Indian Rupee. In general, we are a net payor of currencies other than the U.S. dollar. Accordingly, changes in exchange rates, and in particular a strengthening of the U.S. dollar, may, in the future, negatively affect our operating results as expressed in U.S. dollars. At this time, we have not entered into, but in the future we may enter into, derivatives or other financial instruments in an attempt to hedge our foreign currency exchange risk. It is difficult to predict the effect hedging activities would have on our results of operations. We recognized foreign currency translation loss of $58 thousand and $89 thousand for the three and six months ended June 30, 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><div id="id8f403494d0a42c2868794fb470218fc_169"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4.  Controls and Procedures</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Evaluation of Disclosure Controls and Procedures </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, with the participation of our principal executive officer and principal financial officer, has evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, as of the end of the period covered by this Quarterly Report on Form 10-Q. The Chief Executive Officer (CEO) and the Chief Financial Officer (CFO), with assistance from other members of management, have reviewed the effectiveness of our disclosure controls and procedures as of June 30, 2021 and, based on their evaluation, have concluded that the disclosure controls and procedures were effective as of such date.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes in our internal control over financial reporting during the quarter ended June 30, 2021 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not experienced any material impact to our internal controls over financial reporting despite the fact that most of our employees are working remotely due to the COVID-19 pandemic. We are continually monitoring and assessing the COVID-19 situation on our internal controls to minimize the impact on their design and operating effectiveness.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inherent Limitations of Internal Controls</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, including our principal executive officer and principal financial officer, does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the control. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in conditions, or the degree of compliance with the policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><div id="id8f403494d0a42c2868794fb470218fc_172"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II</span></div><div style="text-align:center"><span><br/></span></div><div id="id8f403494d0a42c2868794fb470218fc_175"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1.  Legal Proceedings</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The discussion in &#8220;Part I &#8211; Item 1. Financial Statements and Supplementary Data - Note 11 - Commitments and Contingencies - Litigation Matters&#8221; is incorporated by reference into this Part II, Item 1.</span></div><div style="text-align:justify"><span><br/></span></div><div id="id8f403494d0a42c2868794fb470218fc_178"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A. Risk Factors</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our significant business risks are described in Item 1A to our Annual Report on Form 10-K for the year ended December 31, 2020. These risk factors are supplemented for the item described below. The risks and uncertainties we describe are not the only ones facing us. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also impair our business or operations. Any adverse effect on our business, financial condition or operating results could result in a decline in the value of our securities and the loss of all or part of your investment.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">We derive a significant portion of our revenues from our largest partners. The loss, termination or renegotiation of our relationship or contract with a significant partner, or multiple partners in the aggregate, could negatively impact our results.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Historically, we have relied on a limited number of partners for a substantial portion of our total revenue and accounts receivable. Our largest partner in terms of both revenue and accounts receivable, Cook County Health and Hospitals System, comprised 29.6% and 29.2% of our revenue for the three and six months ended June 30, 2021 and 42.0% and 61.5% of our accounts receivable as of June&#160;30, 2021 and December&#160;31, 2020, respectively. The loss of Cook County Health and Hospitals System or any other significant partner, pursuant to a reprocurement process or otherwise, or the non-renewal or renegotiation of any of our significant partner contracts, could adversely affect our results. In May 2020, Passport, our largest partner at the time, was not awarded a Kentucky managed Medicaid contract for the next contract period, which adversely affected our results.  We cannot assure you that similar facts will not occur with a different partner in the future as often our customers who are county or municipal run bodies have requirements to run public procurement processes for renewals.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In the ordinary course of business, we engage in active discussions and renegotiations, and at times we are required to participate in reprocurement or other RFP exercises with our partners in respect of the services we provide and the terms of our partner agreements, including our fees. As our partners&#8217; businesses respond to market dynamics and financial pressures, and as our partners make strategic business decisions in respect of the lines of business they pursue and programs in which they participate, certain of our partners have renegotiated or terminated, or not renewed, and we expect that in the future additional partners will, from time to time, seek to renegotiate or terminate or not renew their agreements with us. These discussions and future discussions have resulted and could result in reductions to the fees and changes to the scope of services contemplated by our original partner contracts and consequently have and could negatively impact our revenues, business and prospects. In addition, we may not successfully win new contracts or renewals of existing contracts through competitive market standard reprocurement or RFP processes. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Because we rely on a limited number of partners for a significant portion of our revenues, we depend on the creditworthiness of these partners. Our partners are subject to a number of risks including reductions in payment rates from governmental payers, higher than expected health care costs and lack of predictability of financial results when entering new lines of business, particularly with high-risk populations, such as plans established under the ACA and Aged, Blind and Disabled Medicaid. If the financial condition of our partners declines, our credit risk could increase. Should one or more of our significant partners (including Cook County) declare bankruptcy, be declared insolvent or otherwise be restricted by state or federal laws or regulation from continuing in some or all of their operations, this could adversely affect our ongoing revenues, the collectability of our accounts receivable and affect our bad debt reserves and net income (loss).</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Although we have long-term contracts with many partners, these contracts may be terminated before their term expires for various reasons, such as changes in the regulatory landscape and poor performance by us, subject to certain conditions. For example, after a specified period, certain of these contracts are terminable for convenience by our partners after a notice period has passed and the partner has paid a termination fee. Certain of our contracts are terminable immediately upon the occurrence of certain events. For example, some of our contracts may be terminated by the partner if we fail to achieve target performance metrics over a specified period. Certain of our contracts may be terminated by the partner immediately following repeated failures by us to provide specified levels of service over periods ranging from six months to more than a year. Certain of our contracts may be terminated immediately by the partner if we lose applicable licenses, go bankrupt, lose our liability insurance or receive an exclusion, suspension or debarment from state or federal government authorities. Additionally, if a partner were to lose applicable licenses, go bankrupt, lose liability insurance, become insolvent, file for bankruptcy or receive an exclusion, suspension or debarment from state or federal government authorities, our contract with such partner could in effect be terminated. In addition, certain of our contracts may be terminated immediately if we become insolvent or file for bankruptcy. If any of our contracts with our partners is terminated, we may not be able to recover all fees due under the terminated contract, which may adversely affect our operating results. In addition, certain of our contracts provide that if we fail to meet specified implementation targets, the contracts will terminate and we will be subject to financial penalties. Separately, the contracts of New Century Health typically run for one-year terms. While they typically contain </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">year-to-year renewal provisions, we cannot assure that any or all of these contracts will be renewed in any particular year. We expect that future contracts will contain similar provisions to those described in this paragraph.</span></div><div style="text-align:justify"><span><br/></span></div><div id="id8f403494d0a42c2868794fb470218fc_199"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="text-align:justify"><span><br/></span></div><div id="id8f403494d0a42c2868794fb470218fc_202"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Defaults Upon Senior Securities</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div><span><br/></span></div><div id="id8f403494d0a42c2868794fb470218fc_205"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4.  Mine Safety Disclosures</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="text-align:justify"><span><br/></span></div><div id="id8f403494d0a42c2868794fb470218fc_208"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5.  Other Information</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div id="id8f403494d0a42c2868794fb470218fc_211"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6.  Exhibits</span></div><div style="text-align:justify"><span><br/></span></div><div id="id8f403494d0a42c2868794fb470218fc_214"></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EVOLENT HEALTH, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit Index</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:490.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:45pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000162890816000056/a71216exhibit21.htm">2.1*</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000162890816000056/a71216exhibit21.htm">Agreement and Plan of Merger, dated July 12, 2016, by and among Evolent Health, Inc., Electra Merger Sub, LLC, Valence Health, Inc. and North Bridge Growth Management Company LLC and Philip Kamp, in their capacity as the Securityholders&#8217; Representative, filed as Exhibit 2.1 to the Company&#8217;s Report on Form 8-K filed with the SEC on July 14, 2016, and incorporated herein by reference</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:45pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000162890816000066/a10316exhibit22.htm">2.2*</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000162890816000066/a10316exhibit22.htm">First Amendment to Agreement and Plan of Merger, dated October 3, 2016, by and among Evolent Health, Inc., Electra Merger Sub, LLC, Valence Health, Inc. and North Bridge Growth Management Company LLC and Philip Kamp, in their capacity as securityholders&#8217; representative, filed as Exhibit 2.2 to the Company&#8217;s Report on Form 8-K filed with the SEC on October 3, 2016, and incorporated herein by reference</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:44pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000162890818000069/a912188-kexhibit21.htm">2.3*</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000162890818000069/a912188-kexhibit21.htm">Agreement and Plan of Merger, dated September 7, 2018, by and among Evolent Health, Inc., Evolent Health LLC, Element Merger Sub, Inc., NCIS Holdings, Inc. and New Century Investment, LLC, in the capacity set forth therein, filed as Exhibit 2.1 to the Company&#8217;s Report on Form 8-K filed with the SEC on September 12, 2018, and incorporated herein by reference</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:33pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000162890819000059/a063019exhibit24.htm">2.4*</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000162890819000059/a063019exhibit24.htm">Asset Purchase Agreement, dated May 28, 2019, by and among University Health Care, Inc., d/b/a Passport Health Plan, Passport Health Solutions, LLC, Evolent Health, Inc. and Justify Holdings, Inc., filed as Exhibit 2.4 to the Company&#8217;s Report on Form 10-Q filed with the SEC on August 9, 2019, and incorporated herein by reference</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:44pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000162890819000084/exhibit21passportfirst.htm">2.5*</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000162890819000084/exhibit21passportfirst.htm">First Amendment to Asset Purchase Agreement, dated as of December 30, 2019, by and among University Health Care, Inc., d/b/a Passport Health Plan, Passport Health Solutions, LLC, Justify Holdings, Inc., and Evolent Health, Inc., filed as Exhibit 2.1 to the Company&#8217;s Report on Form 8-K with the SEC on December 31, 2019, and incorporated herein by reference</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:33pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000162890821000066/a20210610exhibit31.htm">3.1*</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000162890821000066/a20210610exhibit31.htm">Certificate of Amendment of the Second Amended and Restated Certificate of Incorporation of Evolent Health, Inc., dated June 10, 2021, filed as Exhibit 3.1 to the Company&#8217;s report on Form 8-K filed with the SEC on June 10, 2021 and incorporated herein by reference </a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000119312521145005/d154291ddef14a.htm">10.1+</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000119312521145005/d154291ddef14a.htm">Evolent Health, Inc. Amended and Restated 2015 Omnibus Equity Incentive Plan, filed as Appendix D to the Company&#8217;s Definitive Proxy Statement on Schedule 14A filed with the SEC on April 30, 2021, and incorporated herein by reference</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:45pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000162890821000109/a202108048-kexhibit21.htm">10.2*</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000162890821000109/a202108048-kexhibit21.htm">Purchase Agreement and Agreement and Plan of Merger, dated August 2, 2021, by and among Evolent Health, Inc., Evolent Health LLC, EV Thunder Merger Sub, LLC, WindRose Health Investors III, L.P., Vital Decisions Acquisition, LLC and WindRose Health Investors, LLC, as the representative,  filed as Exhibit 2.1 to the Company&#8217;s report on Form 8-K filed with the SEC on August 4, 2021 and incorporated herein by reference</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a063021exhibit311.htm">31.1</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a063021exhibit311.htm">Certification of the Chief Executive Officer pursuant to section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a063021exhibit312.htm">31.2</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a063021exhibit312.htm">Certification of the Chief Financial Officer pursuant to section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a063021exhibit321.htm">32.1</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a063021exhibit321.htm">Certification of the Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a063021exhibit322.htm">32.2</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a063021exhibit322.htm">Certification of the Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Instance Document</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Schema Document</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Calculation Linkbase Document</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Label Linkbase Document</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Presentation Linkbase Document</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Definition Linkbase Document</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The cover page from this Quarterly Report on Form 10-Q, formatted as Inline XBRL</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">+ Constitutes a management contract or other compensatory plan or arrangement.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* The Company agrees to furnish supplementally to the SEC a copy of any omitted schedule or exhibit upon the request of the SEC in accordance with Item 601(b)(2) of Regulation S-K.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><div id="id8f403494d0a42c2868794fb470218fc_217"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div><span><br/></span></div><div style="text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:249.00pt"><tr><td style="width:1.0pt"></td><td style="width:43.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:100.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:100.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EVOLENT HEALTH, INC.</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Registrant</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="6" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ John Johnson</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name:</span></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">John Johnson</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title:</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chief Financial Officer</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="6" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Aammaad Shams</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name:</span></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aammaad Shams</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title:</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Controller</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dated:  August&#160;4, 2021 </span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>a063021exhibit311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="iceb209fa311d4f2dba803258b5d8702f_1"></div><div style="min-height:18pt;width:100%"><div><font><br></font></div></div><div style="padding-left:24.75pt;text-align:right;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification Pursuant to Section 302 of the</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Sarbanes-Oxley Act of 2002</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Seth Blackley, certify that&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this Quarterly Report on Form 10-Q of Evolent Health, Inc.&#59;</font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.944%"><tr><td style="width:1.0%"></td><td style="width:5.999%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.026%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.090%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.485%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated&#58; </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 4, 2021</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;  Seth Blackley</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;  Seth Blackley</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58;  Chief Executive Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="height:18pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>a063021exhibit312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="ifda6eafb83f14b95874c1f68084b0555_1"></div><div style="min-height:18pt;width:100%"><div><font><br></font></div></div><div style="padding-left:24.75pt;text-align:right;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification Pursuant to Section 302 of the</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Sarbanes-Oxley Act of 2002</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, John Johnson, certify that&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this Quarterly Report on Form 10-Q of Evolent Health, Inc.&#59;</font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.944%"><tr><td style="width:1.0%"></td><td style="width:5.999%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.026%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.090%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.485%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 4, 2021</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;  John Johnson</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;  John Johnson</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58;  Chief Financial Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="height:18pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>a063021exhibit321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i085d8b88168e4fa4a67cb31e697ae6ab_1"></div><div style="min-height:18pt;width:100%"><div><font><br></font></div></div><div style="padding-left:24.75pt;text-align:right;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification Pursuant to 18 U.S.C. Section 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As Adopted Pursuant to Section 906</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Of the Sarbanes-Oxley Act of 2002</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Seth Blackley, Chief Executive Officer of Evolent Health, Inc. (the &#8220;Company&#8221;), certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350, that&#58;</font></div><div><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The Quarterly Report on Form 10-Q of the Company for the quarter ended June&#160;30, 2021 (the &#8220;Report&#8221;), fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m)&#59; and</font></div><div style="padding-left:18pt"><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:496.50pt"><tr><td style="width:1.0pt"></td><td style="width:33.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:88.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:133.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:234.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 4, 2021</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;  Seth Blackley</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;  Seth Blackley</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58;  Chief Executive Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div><font><br></font></div><div style="height:18pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>a063021exhibit322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i2eb2279e9c074b4a838a4c180333a3b3_1"></div><div style="min-height:18pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.2</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification Pursuant to 18 U.S.C. Section 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As Adopted Pursuant to Section 906</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Of the Sarbanes-Oxley Act of 2002</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, John Johnson, Chief Financial Officer of Evolent Health, Inc. (the &#8220;Company&#8221;), certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350, that&#58;</font></div><div><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The Quarterly Report on Form 10-Q of the Company for the quarter ended June&#160;30, 2021 (the &#8220;Report&#8221;), fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m)&#59; and</font></div><div style="padding-left:18pt"><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:496.50pt"><tr><td style="width:1.0pt"></td><td style="width:33.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:88.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:133.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:234.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 4, 2021</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;  John Johnson</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;  John Johnson</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58;  Chief Financial Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div><font><br></font></div><div style="height:18pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>evh-20210630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:e4ac7c37-8dd1-4c0a-a2d1-6d13aeec3d41,g:9a076b5a-4bc7-42a9-a1f2-350da80fade7-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:evh="http://www.evolenthealth.com/20210630" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.evolenthealth.com/20210630">
  <xs:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021" schemaLocation="https://xbrl.sec.gov/dei/2021/dei-2021.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/stpr/2021" schemaLocation="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="evh-20210630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="evh-20210630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="evh-20210630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="evh-20210630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.evolenthealth.com/role/CoverPage">
        <link:definition>0001001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETS" roleURI="http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS">
        <link:definition>1001002 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETSParenthetical" roleURI="http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical">
        <link:definition>1002003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS" roleURI="http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS">
        <link:definition>1003004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSSParenthetical" roleURI="http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSSParenthetical">
        <link:definition>1404401 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYDEFICIT" roleURI="http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYDEFICIT">
        <link:definition>1005005 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (DEFICIT)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>1006006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Organization" roleURI="http://www.evolenthealth.com/role/Organization">
        <link:definition>2101101 - Disclosure - Organization</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationDetails" roleURI="http://www.evolenthealth.com/role/OrganizationDetails">
        <link:definition>2402402 - Disclosure - Organization (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciples" roleURI="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciples">
        <link:definition>2103102 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies" roleURI="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies">
        <link:definition>2204201 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesTables" roleURI="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesTables">
        <link:definition>2305301 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails" roleURI="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails">
        <link:definition>2406403 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Restricted Cash and Restricted Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesGoodwillDetails" roleURI="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesGoodwillDetails">
        <link:definition>2407404 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails" roleURI="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails">
        <link:definition>2408405 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Intangible Assets, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RecentlyIssuedAccountingStandards" roleURI="http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandards">
        <link:definition>2109103 - Disclosure - Recently Issued Accounting Standards</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RecentlyIssuedAccountingStandardsDetails" roleURI="http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails">
        <link:definition>2410406 - Disclosure - Recently Issued Accounting Standards (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Transactions" roleURI="http://www.evolenthealth.com/role/Transactions">
        <link:definition>2111104 - Disclosure - Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TransactionsPassportDetails" roleURI="http://www.evolenthealth.com/role/TransactionsPassportDetails">
        <link:definition>2412407 - Disclosure - Transactions - Passport (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DiscontinuedOperations" roleURI="http://www.evolenthealth.com/role/DiscontinuedOperations">
        <link:definition>2113105 - Disclosure - Discontinued Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DiscontinuedOperationsTables" roleURI="http://www.evolenthealth.com/role/DiscontinuedOperationsTables">
        <link:definition>2314302 - Disclosure - Discontinued Operations (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DiscontinuedOperationsSummaryofResultsofOperationsDetails" roleURI="http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails">
        <link:definition>2415408 - Disclosure - Discontinued Operations - Summary of Results of Operations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DiscontinuedOperationsSummaryofCashFlowsDetails" roleURI="http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCashFlowsDetails">
        <link:definition>2416409 - Disclosure - Discontinued Operations - Summary of Cash Flows (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DiscontinuedOperationsSummaryofCurrentandLongtermAssetsandLiabilitiesDetails" roleURI="http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCurrentandLongtermAssetsandLiabilitiesDetails">
        <link:definition>2417410 - Disclosure - Discontinued Operations - Summary of Current and Long-term Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognition" roleURI="http://www.evolenthealth.com/role/RevenueRecognition">
        <link:definition>2118106 - Disclosure - Revenue Recognition</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionTables" roleURI="http://www.evolenthealth.com/role/RevenueRecognitionTables">
        <link:definition>2319303 - Disclosure - Revenue Recognition (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionDisaggregationofRevenueDetails" roleURI="http://www.evolenthealth.com/role/RevenueRecognitionDisaggregationofRevenueDetails">
        <link:definition>2420411 - Disclosure - Revenue Recognition - Disaggregation of Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails" roleURI="http://www.evolenthealth.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails">
        <link:definition>2421412 - Disclosure - Revenue Recognition - Transaction Price Allocated to the Remaining Performance Obligations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails_1" roleURI="http://www.evolenthealth.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails_1">
        <link:definition>2421412 - Disclosure - Revenue Recognition - Transaction Price Allocated to the Remaining Performance Obligations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionContractBalancesDetails" roleURI="http://www.evolenthealth.com/role/RevenueRecognitionContractBalancesDetails">
        <link:definition>2422413 - Disclosure - Revenue Recognition - Contract Balances (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionContractCostsDetails" roleURI="http://www.evolenthealth.com/role/RevenueRecognitionContractCostsDetails">
        <link:definition>2423414 - Disclosure - Revenue Recognition - Contract Costs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CreditLosses" roleURI="http://www.evolenthealth.com/role/CreditLosses">
        <link:definition>2124107 - Disclosure - Credit Losses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CreditLossesTables" roleURI="http://www.evolenthealth.com/role/CreditLossesTables">
        <link:definition>2325304 - Disclosure - Credit Losses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CreditLossesAccountsReceivableNarrativeDetails" roleURI="http://www.evolenthealth.com/role/CreditLossesAccountsReceivableNarrativeDetails">
        <link:definition>2426415 - Disclosure - Credit Losses - Accounts Receivable (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CreditLossesScheduleofChangesinAllowanceforAccountsReceivableDetails" roleURI="http://www.evolenthealth.com/role/CreditLossesScheduleofChangesinAllowanceforAccountsReceivableDetails">
        <link:definition>2427416 - Disclosure - Credit Losses - Schedule of Changes in Allowance for Accounts Receivable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentNet" roleURI="http://www.evolenthealth.com/role/PropertyandEquipmentNet">
        <link:definition>2128108 - Disclosure - Property and Equipment, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentNetTables" roleURI="http://www.evolenthealth.com/role/PropertyandEquipmentNetTables">
        <link:definition>2329305 - Disclosure - Property and Equipment, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentNetDetails" roleURI="http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails">
        <link:definition>2430417 - Disclosure - Property and Equipment, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsNet" roleURI="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNet">
        <link:definition>2131109 - Disclosure - Goodwill and Intangible Assets, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsNetTables" roleURI="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetTables">
        <link:definition>2332306 - Disclosure - Goodwill and Intangible Assets, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsNetImpairmentTestingDetails" roleURI="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetImpairmentTestingDetails">
        <link:definition>2433418 - Disclosure - Goodwill and Intangible Assets, Net - Impairment Testing (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsNetScheduleofGoodwillDetails" roleURI="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetScheduleofGoodwillDetails">
        <link:definition>2434419 - Disclosure - Goodwill and Intangible Assets, Net - Schedule of Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails" roleURI="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails">
        <link:definition>2435420 - Disclosure - Goodwill and Intangible Assets, Net - Intangible Assets, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssets10KDetails" roleURI="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssets10KDetails">
        <link:definition>2436421 - Disclosure - Goodwill and Intangible Assets, Net - Amortization of Intangible Assets 10K (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongtermDebt" roleURI="http://www.evolenthealth.com/role/LongtermDebt">
        <link:definition>2137110 - Disclosure - Long-term Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongtermDebtTables" roleURI="http://www.evolenthealth.com/role/LongtermDebtTables">
        <link:definition>2338307 - Disclosure - Long-term Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongtermDebt2024NotesDetails" roleURI="http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails">
        <link:definition>2439422 - Disclosure - Long-term Debt - 2024 Notes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongtermDebtCreditAgreementDetails" roleURI="http://www.evolenthealth.com/role/LongtermDebtCreditAgreementDetails">
        <link:definition>2440423 - Disclosure - Long-term Debt - Credit Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongtermDebtWarrantAgreementDetails" roleURI="http://www.evolenthealth.com/role/LongtermDebtWarrantAgreementDetails">
        <link:definition>2441424 - Disclosure - Long-term Debt - Warrant Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongtermDebt2025NotesDetails" roleURI="http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails">
        <link:definition>2442425 - Disclosure - Long-term Debt - 2025 Notes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongtermDebt2021NotesDetails" roleURI="http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails">
        <link:definition>2443426 - Disclosure - Long-term Debt - 2021 Notes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongtermDebtConvertibleSeniorNotesCarryingValueDetails" roleURI="http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails">
        <link:definition>2444427 - Disclosure - Long-term Debt - Convertible Senior Notes Carrying Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.evolenthealth.com/role/CommitmentsandContingencies">
        <link:definition>2145111 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesTables" roleURI="http://www.evolenthealth.com/role/CommitmentsandContingenciesTables">
        <link:definition>2346308 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesAdditionalInformationDetails" roleURI="http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails">
        <link:definition>2447428 - Disclosure - Commitments and Contingencies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesReinsuranceAgreementsDetails" roleURI="http://www.evolenthealth.com/role/CommitmentsandContingenciesReinsuranceAgreementsDetails">
        <link:definition>2448429 - Disclosure - Commitments and Contingencies - Reinsurance Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesConcentrationRiskDetails" roleURI="http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails">
        <link:definition>2449430 - Disclosure - Commitments and Contingencies - Concentration Risk (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.evolenthealth.com/role/Leases">
        <link:definition>2150112 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.evolenthealth.com/role/LeasesTables">
        <link:definition>2351309 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesNarrativeDetails" roleURI="http://www.evolenthealth.com/role/LeasesNarrativeDetails">
        <link:definition>2452431 - Disclosure - Leases - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesMaterialOfficeLeasesDetails" roleURI="http://www.evolenthealth.com/role/LeasesMaterialOfficeLeasesDetails">
        <link:definition>2453432 - Disclosure - Leases - Material Office Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesComponentsofLeaseExpenseDetails" roleURI="http://www.evolenthealth.com/role/LeasesComponentsofLeaseExpenseDetails">
        <link:definition>2454433 - Disclosure - Leases - Components of Lease Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesMaturityofLeaseLiabilitiesDetails" roleURI="http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails">
        <link:definition>2455434 - Disclosure - Leases - Maturity of Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesMaturityofLeaseLiabilitiesDetails_1" roleURI="http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails_1">
        <link:definition>2455434 - Disclosure - Leases - Maturity of Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesWeightedaverageDiscountRateandWeightedremainingLeaseTermsDetails" roleURI="http://www.evolenthealth.com/role/LeasesWeightedaverageDiscountRateandWeightedremainingLeaseTermsDetails">
        <link:definition>2456435 - Disclosure - Leases - Weighted-average Discount Rate and Weighted-remaining Lease Terms (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsLossPerCommonShare" roleURI="http://www.evolenthealth.com/role/EarningsLossPerCommonShare">
        <link:definition>2157113 - Disclosure - Earnings (Loss) Per Common Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsLossPerCommonShareTables" roleURI="http://www.evolenthealth.com/role/EarningsLossPerCommonShareTables">
        <link:definition>2358310 - Disclosure - Earnings (Loss) Per Common Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsLossPerCommonShareComputationofEarningsperShareDetails" roleURI="http://www.evolenthealth.com/role/EarningsLossPerCommonShareComputationofEarningsperShareDetails">
        <link:definition>2459436 - Disclosure - Earnings (Loss) Per Common Share - Computation of Earnings per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsLossPerCommonShareAntidilutiveSecuritiesDetails" roleURI="http://www.evolenthealth.com/role/EarningsLossPerCommonShareAntidilutiveSecuritiesDetails">
        <link:definition>2460437 - Disclosure - Earnings (Loss) Per Common Share - Antidilutive Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensation" roleURI="http://www.evolenthealth.com/role/StockbasedCompensation">
        <link:definition>2161114 - Disclosure - Stock-based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensationTables" roleURI="http://www.evolenthealth.com/role/StockbasedCompensationTables">
        <link:definition>2362311 - Disclosure - Stock-based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensationStockbasedCompensationExpenseDetails" roleURI="http://www.evolenthealth.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails">
        <link:definition>2463438 - Disclosure - Stock-based Compensation - Stock-based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensationNarrativeDetails" roleURI="http://www.evolenthealth.com/role/StockbasedCompensationNarrativeDetails">
        <link:definition>2464439 - Disclosure - Stock-based Compensation - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensationScheduleofSharebasedAwardsGrantedDetails" roleURI="http://www.evolenthealth.com/role/StockbasedCompensationScheduleofSharebasedAwardsGrantedDetails">
        <link:definition>2465440 - Disclosure - Stock-based Compensation - Schedule of Share-based Awards Granted (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.evolenthealth.com/role/IncomeTaxes">
        <link:definition>2166115 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesNarrativeDetails" roleURI="http://www.evolenthealth.com/role/IncomeTaxesNarrativeDetails">
        <link:definition>2467441 - Disclosure - Income Taxes - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsInandAdvancestoEquityMethodInvestees" roleURI="http://www.evolenthealth.com/role/InvestmentsInandAdvancestoEquityMethodInvestees">
        <link:definition>2168116 - Disclosure - Investments In and Advances to Equity Method Investees</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsInandAdvancestoEquityMethodInvesteesAdditionalInformationDetails" roleURI="http://www.evolenthealth.com/role/InvestmentsInandAdvancestoEquityMethodInvesteesAdditionalInformationDetails">
        <link:definition>2469442 - Disclosure - Investments In and Advances to Equity Method Investees - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NoncontrollingInterests" roleURI="http://www.evolenthealth.com/role/NoncontrollingInterests">
        <link:definition>2170117 - Disclosure - Non-controlling Interests</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NoncontrollingInterestsTables" roleURI="http://www.evolenthealth.com/role/NoncontrollingInterestsTables">
        <link:definition>2371312 - Disclosure - Non-controlling Interests (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NoncontrollingInterestsDetails" roleURI="http://www.evolenthealth.com/role/NoncontrollingInterestsDetails">
        <link:definition>2472443 - Disclosure - Non-controlling Interests (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurement" roleURI="http://www.evolenthealth.com/role/FairValueMeasurement">
        <link:definition>2173118 - Disclosure - Fair Value Measurement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementTables" roleURI="http://www.evolenthealth.com/role/FairValueMeasurementTables">
        <link:definition>2374313 - Disclosure - Fair Value Measurement (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails" roleURI="http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails">
        <link:definition>2475444 - Disclosure - Fair Value Measurement - Assets and Liabilities on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementAdditionalInformationDetails" roleURI="http://www.evolenthealth.com/role/FairValueMeasurementAdditionalInformationDetails">
        <link:definition>2476445 - Disclosure - Fair Value Measurement - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementChangesinContingentConsiderationandOtherDetails" roleURI="http://www.evolenthealth.com/role/FairValueMeasurementChangesinContingentConsiderationandOtherDetails">
        <link:definition>2477446 - Disclosure - Fair Value Measurement - Changes in Contingent Consideration and Other (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails" roleURI="http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails">
        <link:definition>2478447 - Disclosure - Fair Value Measurement - Valuation Techniques and Significant Unobservable Inputs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedParties" roleURI="http://www.evolenthealth.com/role/RelatedParties">
        <link:definition>2179119 - Disclosure - Related Parties</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartiesTables" roleURI="http://www.evolenthealth.com/role/RelatedPartiesTables">
        <link:definition>2380314 - Disclosure - Related Parties (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartiesAssetsandLiabilitiesDetails" roleURI="http://www.evolenthealth.com/role/RelatedPartiesAssetsandLiabilitiesDetails">
        <link:definition>2481448 - Disclosure - Related Parties - Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartiesRevenuesandExpensesDetails" roleURI="http://www.evolenthealth.com/role/RelatedPartiesRevenuesandExpensesDetails">
        <link:definition>2482449 - Disclosure - Related Parties - Revenues and Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RepositioningandOtherChanges" roleURI="http://www.evolenthealth.com/role/RepositioningandOtherChanges">
        <link:definition>2183120 - Disclosure - Repositioning and Other Changes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RepositioningandOtherChangesTables" roleURI="http://www.evolenthealth.com/role/RepositioningandOtherChangesTables">
        <link:definition>2384315 - Disclosure - Repositioning and Other Changes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RepositioningandOtherChangesDetails" roleURI="http://www.evolenthealth.com/role/RepositioningandOtherChangesDetails">
        <link:definition>2485450 - Disclosure - Repositioning and Other Changes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReporting" roleURI="http://www.evolenthealth.com/role/SegmentReporting">
        <link:definition>2186121 - Disclosure - Segment Reporting</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingTables" roleURI="http://www.evolenthealth.com/role/SegmentReportingTables">
        <link:definition>2387316 - Disclosure - Segment Reporting (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingAdditionalInformationDetails" roleURI="http://www.evolenthealth.com/role/SegmentReportingAdditionalInformationDetails">
        <link:definition>2488451 - Disclosure - Segment Reporting - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingRevenuefromSegmentstoConsolidatedDetails" roleURI="http://www.evolenthealth.com/role/SegmentReportingRevenuefromSegmentstoConsolidatedDetails">
        <link:definition>2489452 - Disclosure - Segment Reporting - Revenue from Segments to Consolidated (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingReconciliationofAdjustedEBITDADetails" roleURI="http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails">
        <link:definition>2490453 - Disclosure - Segment Reporting - Reconciliation of Adjusted EBITDA (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ReservesforClaimsandPerformanceBasedArrangements" roleURI="http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangements">
        <link:definition>2191122 - Disclosure - Reserves for Claims and Performance-Based Arrangements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ReservesforClaimsandPerformanceBasedArrangementsTables" roleURI="http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsTables">
        <link:definition>2392317 - Disclosure - Reserves for Claims and Performance-Based Arrangements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ReservesforClaimsandPerformanceBasedArrangementsDetails" roleURI="http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails">
        <link:definition>2493454 - Disclosure - Reserves for Claims and Performance-Based Arrangements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementalCashFlowInformation" roleURI="http://www.evolenthealth.com/role/SupplementalCashFlowInformation">
        <link:definition>2194123 - Disclosure - Supplemental Cash Flow Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementalCashFlowInformationTables" roleURI="http://www.evolenthealth.com/role/SupplementalCashFlowInformationTables">
        <link:definition>2395318 - Disclosure - Supplemental Cash Flow Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementalCashFlowInformationDetails" roleURI="http://www.evolenthealth.com/role/SupplementalCashFlowInformationDetails">
        <link:definition>2496455 - Disclosure - Supplemental Cash Flow Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://www.evolenthealth.com/role/SubsequentEvents">
        <link:definition>2197124 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventsDetails" roleURI="http://www.evolenthealth.com/role/SubsequentEventsDetails">
        <link:definition>2498456 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="evh_ContractFulfillmentCostsMember" abstract="true" name="ContractFulfillmentCostsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_PremiumsWrittenAndPolicyholderBenefitsAndClaimsIncurredNet" abstract="false" name="PremiumsWrittenAndPolicyholderBenefitsAndClaimsIncurredNet" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationMeasurementPeriodAdjustment" abstract="false" name="NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationMeasurementPeriodAdjustment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_CashHeldInInternationalBanksPercentage" abstract="false" name="CashHeldInInternationalBanksPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="evh_RestrictedCashforBenefitManagementServicesMember" abstract="true" name="RestrictedCashforBenefitManagementServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNetAfterGrossUp" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNetAfterGrossUp" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_DisposalGroupIncludingDiscontinuedOperationRestrictedInvestmentsNoncurrent" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationRestrictedInvestmentsNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum" abstract="false" name="DebtInstrumentRepurchaseCovenantTradingDaysMinimum" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="evh_TrueHealthSegmentMember" abstract="true" name="TrueHealthSegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_AccruedPropertyAndEquipmentPurchases" abstract="false" name="AccruedPropertyAndEquipmentPurchases" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_MedicareCustomersMember" abstract="true" name="MedicareCustomersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_SeniorCreditFacilitiesMember" abstract="true" name="SeniorCreditFacilitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities" abstract="false" name="IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_StockVestedAndRetiredDuringPeriodShares" abstract="false" name="StockVestedAndRetiredDuringPeriodShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="evh_DebtIssuanceCostsNetDebtComponent" abstract="false" name="DebtIssuanceCostsNetDebtComponent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_ClassOfWarrantOrRightPeriodDuringWhichWarrantsOrRightsExercisableAfterMaturityOfCreditAgreement" abstract="false" name="ClassOfWarrantOrRightPeriodDuringWhichWarrantsOrRightsExercisableAfterMaturityOfCreditAgreement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="evh_PlatformsAndOperationsServicesMember" abstract="true" name="PlatformsAndOperationsServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_DisposalGroupIncludingDiscontinuedOperationLiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangementsCurrent" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationLiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangementsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_ChangeInContractWithCustomerLiabilityRollForward" abstract="true" name="ChangeInContractWithCustomerLiabilityRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="evh_ScheduleofChangesinNoncontrollingInterestTableTextBlock" abstract="false" name="ScheduleofChangesinNoncontrollingInterestTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="evh_EarningsLossAvailabletoCommonShareholdersAbstract" abstract="true" name="EarningsLossAvailabletoCommonShareholdersAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice" abstract="false" name="DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="evh_DisposalGroupIncludingDiscontinuedOperationClaimsExpense" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationClaimsExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" abstract="false" name="FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_MolinaHealthcareIncMember" abstract="true" name="MolinaHealthcareIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_ClinicalSolutionsSegmentMember" abstract="true" name="ClinicalSolutionsSegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_AssetPurchaseAgreementEscrowPayments" abstract="false" name="AssetPurchaseAgreementEscrowPayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_BelowMarketLeasesMember" abstract="true" name="BelowMarketLeasesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum" abstract="false" name="DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="evh_AssetAcquisitionCashAndEquivalents" abstract="false" name="AssetAcquisitionCashAndEquivalents" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_CreditAgreementMember" abstract="true" name="CreditAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseDisposalOfDiscontinuedOperations" abstract="false" name="LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseDisposalOfDiscontinuedOperations" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_WindroseHealthInvestorsIIILPMember" abstract="true" name="WindroseHealthInvestorsIIILPMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_SeniorConvertibleNotesDue2024Member" abstract="true" name="SeniorConvertibleNotesDue2024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_PaymentsOfMakeWholePremium" abstract="false" name="PaymentsOfMakeWholePremium" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet" abstract="false" name="PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_EmployeeSeveranceAndTerminationBenefitsMember" abstract="true" name="EmployeeSeveranceAndTerminationBenefitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_ConvertibleSeniorNotesdue2021Member" abstract="true" name="ConvertibleSeniorNotesdue2021Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_DisposalGroupIncludingDiscontinuedOperationRestrictedCashAndRestrictedInvestmentsNoncurrent" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationRestrictedCashAndRestrictedInvestmentsNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_CashFlowLesseeAbstract" abstract="true" name="CashFlowLesseeAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="evh_AssetAcquisitionDebtSecuritiesAvailableForSaleUnsettledSalesReceivables" abstract="false" name="AssetAcquisitionDebtSecuritiesAvailableForSaleUnsettledSalesReceivables" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount" abstract="false" name="DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="evh_BlackScholesMember" abstract="true" name="BlackScholesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFive" abstract="false" name="LesseeOperatingLeaseLiabilityToBePaidAfterYearFive" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_TransactionCosts" abstract="false" name="TransactionCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_SharebasedCompensationIncludingOnetimeAdjustment" abstract="false" name="SharebasedCompensationIncludingOnetimeAdjustment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_EquityMethodInvestmentEconomicInterestPercentage" abstract="false" name="EquityMethodInvestmentEconomicInterestPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="evh_TransformationServicesMember" abstract="true" name="TransformationServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_PremiumsRevenueMember" abstract="true" name="PremiumsRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_TaxReceivableAgreementPercentofCashSavingsPaidtoShareholders" abstract="false" name="TaxReceivableAgreementPercentofCashSavingsPaidtoShareholders" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="evh_DisposalGroupIncludingDiscontinuedOperationInvestmentsNoncurrent" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationInvestmentsNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_RightOfUseAssetAcquiredAndDisposedOf" abstract="false" name="RightOfUseAssetAcquiredAndDisposedOf" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsNoncurrent" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_FloridaBlueMedicareIncMember" abstract="true" name="FloridaBlueMedicareIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_SeniorConvertibleNotesDue2025Member" abstract="true" name="SeniorConvertibleNotesDue2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseImpactOfConsolidationOnPayables" abstract="false" name="AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseImpactOfConsolidationOnPayables" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_TransferOfMembershipPercentageOfPaymentBasedOnNumberOfEnrollees" abstract="false" name="TransferOfMembershipPercentageOfPaymentBasedOnNumberOfEnrollees" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="evh_PassportNoteMember" abstract="true" name="PassportNoteMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_DisposalGroupIncludingDiscontinuedOperationInvestmentsCurrent" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationInvestmentsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_GainOnTransferOfMembership" abstract="false" name="GainOnTransferOfMembership" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice" abstract="false" name="DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="evh_NumberOfReportingUnitsFairValueInExcessOfCarryingAmount" abstract="false" name="NumberOfReportingUnitsFairValueInExcessOfCarryingAmount" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="evh_IncreaseDecreaseInOperatingLeaseRightofUseAsset" abstract="false" name="IncreaseDecreaseInOperatingLeaseRightofUseAsset" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_DisposalGroupIncludingDiscontinuedOperationAccruedCompensationAndEmployeeBenefitsCurrent" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationAccruedCompensationAndEmployeeBenefitsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_PaidinKindInterestIncome" abstract="false" name="PaidinKindInterestIncome" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_DisposalGroupIncludingDiscontinuedOperationRestrictedCashAndRestrictedInvestmentsCurrent" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationRestrictedCashAndRestrictedInvestmentsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_TaxReceivablesAgreementPercentofTaxSavingstobePaid" abstract="false" name="TaxReceivablesAgreementPercentofTaxSavingstobePaid" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="evh_ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations" abstract="false" name="ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_VariableInterestEntityNewMedicaidContractNotAwardedRequirementToAcquireOwnershipConsiderationAmount" abstract="false" name="VariableInterestEntityNewMedicaidContractNotAwardedRequirementToAcquireOwnershipConsiderationAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_FinancingReceivablePercentNotPastDue" abstract="false" name="FinancingReceivablePercentNotPastDue" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="evh_PolicyholderBenefitsAndClaimsIncurredAssumedExpensesRelatedToClaims" abstract="false" name="PolicyholderBenefitsAndClaimsIncurredAssumedExpensesRelatedToClaims" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_ShareholderAdvisoryServices" abstract="false" name="ShareholderAdvisoryServices" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_EvolentHealthLLCMember" abstract="true" name="EvolentHealthLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_IncreaseDecreaseInCapitalizedContractCostNet" abstract="false" name="IncreaseDecreaseInCapitalizedContractCostNet" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_EvolentHealthServicesSegmentMember" abstract="true" name="EvolentHealthServicesSegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset" abstract="false" name="IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_PerformanceBasedRestrictedStockUnitsPBRSUsMember" abstract="true" name="PerformanceBasedRestrictedStockUnitsPBRSUsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_CashReleasedFromEscrow" abstract="false" name="CashReleasedFromEscrow" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_CapitalizedContractCostAmortizationPurchaseAccountingAdjustments" abstract="false" name="CapitalizedContractCostAmortizationPurchaseAccountingAdjustments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_DisposalGroupIncludingDiscontinuedOperationRestrictedCashCurrent" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationRestrictedCashCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_RestrictedCashForLettersOfCreditForLetterOfCreditFacilityMember" abstract="true" name="RestrictedCashForLettersOfCreditForLetterOfCreditFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_ProfessionalServicesRestructuringMember" abstract="true" name="ProfessionalServicesRestructuringMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_FInancialAssetLessThan120DaysPastDueMember" abstract="true" name="FInancialAssetLessThan120DaysPastDueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_FInancialAssetLessThan60DaysMember" abstract="true" name="FInancialAssetLessThan60DaysMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_TransferOfMembershipPercentageOfPaymentSubjectToSatisfactionOfContingencies" abstract="false" name="TransferOfMembershipPercentageOfPaymentSubjectToSatisfactionOfContingencies" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="evh_RestrictedCashforOtherContractualCommitmentsMember" abstract="true" name="RestrictedCashforOtherContractualCommitmentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_RestrictedCashforLettersofCreditforFacilityLeasesMember" abstract="true" name="RestrictedCashforLettersofCreditforFacilityLeasesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_AssetAcquisitionAccruedMedicalExpenses" abstract="false" name="AssetAcquisitionAccruedMedicalExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_ProceedsFromTransferOfMembership" abstract="false" name="ProceedsFromTransferOfMembership" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_StockVestedAndRetiredDuringPeriodValue" abstract="false" name="StockVestedAndRetiredDuringPeriodValue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_AssetAcquisitionAccruedLiabilities" abstract="false" name="AssetAcquisitionAccruedLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_ServicesAgreementsMember" abstract="true" name="ServicesAgreementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_CookCountyHealthAndHospitalsSystemMember" abstract="true" name="CookCountyHealthAndHospitalsSystemMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_NewNotesMember" abstract="true" name="NewNotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_CollateralwithFinancialInstitutionsMember" abstract="true" name="CollateralwithFinancialInstitutionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_IncomeLossfromEquityMethodInvestmentsServicesAgreement" abstract="false" name="IncomeLossfromEquityMethodInvestmentsServicesAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_MedicaidCustomersMember" abstract="true" name="MedicaidCustomersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_DebtInstrumentRedemptionCallProtectionPremiumPercentage" abstract="false" name="DebtInstrumentRedemptionCallProtectionPremiumPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="evh_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements" abstract="false" name="LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_CostofGoodsandServicesSoldExcludingDepreciationandAmortization" abstract="false" name="CostofGoodsandServicesSoldExcludingDepreciationandAmortization" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_CashFDICInsuredAmountPercentage" abstract="false" name="CashFDICInsuredAmountPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="evh_PassportAssetAcquisitionMember" abstract="true" name="PassportAssetAcquisitionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_AmortizationOfDebtDiscountAndDebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" abstract="false" name="AmortizationOfDebtDiscountAndDebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_NeighborhoodHealthPlanOfRhodeIslandMember" abstract="true" name="NeighborhoodHealthPlanOfRhodeIslandMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_AssetAcquisitionOtherAssets" abstract="false" name="AssetAcquisitionOtherAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember" abstract="true" name="RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_UniversityHealthCaredbaPassportHealthPlanMember" abstract="true" name="UniversityHealthCaredbaPassportHealthPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_LeveragedStockUnitsLSUsMember" abstract="true" name="LeveragedStockUnitsLSUsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_CommercialAndOtherCustomersMember" abstract="true" name="CommercialAndOtherCustomersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization" abstract="false" name="CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_ProceedsFromReinsurance" abstract="false" name="ProceedsFromReinsurance" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_PaymentsForProceedsFromClaimsProcessingFinancingActivities" abstract="false" name="PaymentsForProceedsFromClaimsProcessingFinancingActivities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_InitialTermLoanFacilityMember" abstract="true" name="InitialTermLoanFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_AssetAcquisitionDebtSecuritiesAvailableForSale" abstract="false" name="AssetAcquisitionDebtSecuritiesAvailableForSale" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_BonusesAndCommissionsMember" abstract="true" name="BonusesAndCommissionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" abstract="false" name="AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_DelayedDrawTermLoanFacilityMember" abstract="true" name="DelayedDrawTermLoanFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_PaymentsToAcquireEquityMethodInvestmentsAmountHeldBack" abstract="false" name="PaymentsToAcquireEquityMethodInvestmentsAmountHeldBack" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_ProceedsFromMaturityOfInvestments" abstract="false" name="ProceedsFromMaturityOfInvestments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_TrueHealthMember" abstract="true" name="TrueHealthMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_GainLossOnDispositionOfAssetsOperatingActivities" abstract="false" name="GainLossOnDispositionOfAssetsOperatingActivities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_EquityMethodInvestmentVotingInterestPercentage" abstract="false" name="EquityMethodInvestmentVotingInterestPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>evh-20210630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:e4ac7c37-8dd1-4c0a-a2d1-6d13aeec3d41,g:9a076b5a-4bc7-42a9-a1f2-350da80fade7-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="evh-20210630.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_b2b780fd-6490-44b5-94d5-76c4997ad4f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndInvestmentsNoncurrent_06a7db53-d21b-4652-89d5-7af93464e470" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndInvestmentsNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_b2b780fd-6490-44b5-94d5-76c4997ad4f7" xlink:to="loc_us-gaap_RestrictedCashAndInvestmentsNoncurrent_06a7db53-d21b-4652-89d5-7af93464e470" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_749f010c-a55f-4ff4-8f45-795c8ed75466" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_b2b780fd-6490-44b5-94d5-76c4997ad4f7" xlink:to="loc_us-gaap_AssetsCurrent_749f010c-a55f-4ff4-8f45-795c8ed75466" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_c6396a4a-fd46-4d5b-a487-9e85c7224921" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_b2b780fd-6490-44b5-94d5-76c4997ad4f7" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_c6396a4a-fd46-4d5b-a487-9e85c7224921" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_a233f934-90a0-419c-9e29-2a8ef843e411" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_b2b780fd-6490-44b5-94d5-76c4997ad4f7" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_a233f934-90a0-419c-9e29-2a8ef843e411" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_ea0508e0-9a04-4f8e-a6c7-892e84c62e79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_b2b780fd-6490-44b5-94d5-76c4997ad4f7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_ea0508e0-9a04-4f8e-a6c7-892e84c62e79" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostNetNoncurrent_5eba36e1-bed8-4e6d-b7bb-7e475c1afc39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedContractCostNetNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_b2b780fd-6490-44b5-94d5-76c4997ad4f7" xlink:to="loc_us-gaap_CapitalizedContractCostNetNoncurrent_5eba36e1-bed8-4e6d-b7bb-7e475c1afc39" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_b7cfb36a-f388-4421-93ed-94b17c4ad4a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_b2b780fd-6490-44b5-94d5-76c4997ad4f7" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_b7cfb36a-f388-4421-93ed-94b17c4ad4a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_302e9eb1-90e4-46b5-8a76-7b70aaaa3f99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_b2b780fd-6490-44b5-94d5-76c4997ad4f7" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_302e9eb1-90e4-46b5-8a76-7b70aaaa3f99" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_c2a6e367-3492-4893-b67c-55bc781e62cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_b2b780fd-6490-44b5-94d5-76c4997ad4f7" xlink:to="loc_us-gaap_Goodwill_c2a6e367-3492-4893-b67c-55bc781e62cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_0f7f198b-932f-4575-a7df-2220d23c0fdc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_b2b780fd-6490-44b5-94d5-76c4997ad4f7" xlink:to="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_0f7f198b-932f-4575-a7df-2220d23c0fdc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_31dba0a3-ebb2-471f-a07b-849d3d612df6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_d818f6b7-6d32-4a88-89df-db4ff1020aec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_31dba0a3-ebb2-471f-a07b-849d3d612df6" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_d818f6b7-6d32-4a88-89df-db4ff1020aec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_d65b4c8c-1433-4c47-9859-5a58cfe3d699" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_31dba0a3-ebb2-471f-a07b-849d3d612df6" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_d65b4c8c-1433-4c47-9859-5a58cfe3d699" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndInvestmentsCurrent_1bbbe0fc-5c66-4641-abc8-452ad85c6382" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndInvestmentsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_31dba0a3-ebb2-471f-a07b-849d3d612df6" xlink:to="loc_us-gaap_RestrictedCashAndInvestmentsCurrent_1bbbe0fc-5c66-4641-abc8-452ad85c6382" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3739255a-8762-447b-893f-b7687804ecce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_31dba0a3-ebb2-471f-a07b-849d3d612df6" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3739255a-8762-447b-893f-b7687804ecce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_761959c4-93e1-4668-b3bf-279f932d7df8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_31dba0a3-ebb2-471f-a07b-849d3d612df6" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_761959c4-93e1-4668-b3bf-279f932d7df8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_44e1b1c1-f819-4c45-9ddf-8eb85a4779b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_52a19e69-4609-4eb3-9aa0-3084a3305ece" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_44e1b1c1-f819-4c45-9ddf-8eb85a4779b0" xlink:to="loc_us-gaap_AccountsPayableCurrent_52a19e69-4609-4eb3-9aa0-3084a3305ece" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_e05087cd-86cc-4add-89f7-ccde87c34c25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_44e1b1c1-f819-4c45-9ddf-8eb85a4779b0" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_e05087cd-86cc-4add-89f7-ccde87c34c25" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements_058e2e28-3172-48a3-8954-ceadd0e9f9ac" xlink:href="evh-20210630.xsd#evh_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_44e1b1c1-f819-4c45-9ddf-8eb85a4779b0" xlink:to="loc_evh_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements_058e2e28-3172-48a3-8954-ceadd0e9f9ac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_11837aca-d5d8-4b2e-a477-4560c16fb0e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_44e1b1c1-f819-4c45-9ddf-8eb85a4779b0" xlink:to="loc_us-gaap_LongTermDebtCurrent_11837aca-d5d8-4b2e-a477-4560c16fb0e6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_aa9faf6b-b9da-480c-b285-13b2c79ce297" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_44e1b1c1-f819-4c45-9ddf-8eb85a4779b0" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_aa9faf6b-b9da-480c-b285-13b2c79ce297" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_4c4f6d3d-4d12-4a1a-8013-fac36ac19d93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_44e1b1c1-f819-4c45-9ddf-8eb85a4779b0" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_4c4f6d3d-4d12-4a1a-8013-fac36ac19d93" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_ba2cc0aa-bd34-4a35-b155-9cdea3823ffb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_44e1b1c1-f819-4c45-9ddf-8eb85a4779b0" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_ba2cc0aa-bd34-4a35-b155-9cdea3823ffb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_c792cd23-727e-4b36-a5e9-4fa47f64036d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_44e1b1c1-f819-4c45-9ddf-8eb85a4779b0" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_c792cd23-727e-4b36-a5e9-4fa47f64036d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_850bc005-5d42-4fb4-a437-9c4a236bc752" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_14ca9d9d-2543-4f71-8a7b-c62c16adeb16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_850bc005-5d42-4fb4-a437-9c4a236bc752" xlink:to="loc_us-gaap_LiabilitiesCurrent_14ca9d9d-2543-4f71-8a7b-c62c16adeb16" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_45eb3609-e973-4666-a87a-d0085ab5820f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_850bc005-5d42-4fb4-a437-9c4a236bc752" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_45eb3609-e973-4666-a87a-d0085ab5820f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_3245670f-3c19-4cdd-ab1f-0f66c8591b1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_850bc005-5d42-4fb4-a437-9c4a236bc752" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_3245670f-3c19-4cdd-ab1f-0f66c8591b1d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_b8dc5961-3481-4cef-be35-0cfee4957353" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_850bc005-5d42-4fb4-a437-9c4a236bc752" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_b8dc5961-3481-4cef-be35-0cfee4957353" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_4eced4c1-7cf3-49a3-bbd2-1f8bd76668be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_850bc005-5d42-4fb4-a437-9c4a236bc752" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_4eced4c1-7cf3-49a3-bbd2-1f8bd76668be" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_1014b4d9-ff7a-4be0-9f20-2dc7076334a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_850bc005-5d42-4fb4-a437-9c4a236bc752" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_1014b4d9-ff7a-4be0-9f20-2dc7076334a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_20fd4b3e-7b32-4539-859b-a27c8511fe0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_1294d442-4aa4-4cb9-8497-5cf0e504589f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_20fd4b3e-7b32-4539-859b-a27c8511fe0b" xlink:to="loc_us-gaap_AdditionalPaidInCapital_1294d442-4aa4-4cb9-8497-5cf0e504589f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_ffecab54-d5e8-4f83-82ad-931eb506261f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_20fd4b3e-7b32-4539-859b-a27c8511fe0b" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_ffecab54-d5e8-4f83-82ad-931eb506261f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_89910aeb-c585-4aba-9761-c416f78b4061" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_20fd4b3e-7b32-4539-859b-a27c8511fe0b" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_89910aeb-c585-4aba-9761-c416f78b4061" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_e325dccb-4e24-42e2-af21-7820163a81ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_20fd4b3e-7b32-4539-859b-a27c8511fe0b" xlink:to="loc_us-gaap_CommonStockValue_e325dccb-4e24-42e2-af21-7820163a81ee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_62091cdf-121c-4069-9309-ce927292e0dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_20fd4b3e-7b32-4539-859b-a27c8511fe0b" xlink:to="loc_us-gaap_TreasuryStockValue_62091cdf-121c-4069-9309-ce927292e0dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_6a5b443a-c889-48ae-9c4c-5d30118c6680" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_1d48c5e0-065a-4bb7-9d52-39f3dd3e4681" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_6a5b443a-c889-48ae-9c4c-5d30118c6680" xlink:to="loc_us-gaap_Liabilities_1d48c5e0-065a-4bb7-9d52-39f3dd3e4681" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_2943eb8d-3e6c-49c4-93ef-cc716ed9d390" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_6a5b443a-c889-48ae-9c4c-5d30118c6680" xlink:to="loc_us-gaap_CommitmentsAndContingencies_2943eb8d-3e6c-49c4-93ef-cc716ed9d390" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_adc04876-46ea-46e5-8c2a-cddddb83f1fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_6a5b443a-c889-48ae-9c4c-5d30118c6680" xlink:to="loc_us-gaap_StockholdersEquity_adc04876-46ea-46e5-8c2a-cddddb83f1fb" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS" xlink:type="simple" xlink:href="evh-20210630.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS"/>
  <link:calculationLink xlink:role="http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_3e16f94f-75dc-42b2-bef9-a69d726a449f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_b9fa3772-c7e9-4ff1-b99e-d117713ac643" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareDiluted_3e16f94f-75dc-42b2-bef9-a69d726a449f" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_b9fa3772-c7e9-4ff1-b99e-d117713ac643" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_e37a3358-6ce0-415f-b924-2c42e0042802" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareDiluted_3e16f94f-75dc-42b2-bef9-a69d726a449f" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_e37a3358-6ce0-415f-b924-2c42e0042802" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_a4ae2b7e-8a00-4d69-bfeb-44a4867c7042" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_c3b84f91-ffcb-4331-9996-2c557eb8761c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareBasic_a4ae2b7e-8a00-4d69-bfeb-44a4867c7042" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_c3b84f91-ffcb-4331-9996-2c557eb8761c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_e0231bf4-2670-4828-9f26-f4c3fe67a9e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareBasic_a4ae2b7e-8a00-4d69-bfeb-44a4867c7042" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_e0231bf4-2670-4828-9f26-f4c3fe67a9e0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_1464bd32-ce2b-4e60-b1ff-1afc08fe18dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_d2a48d0d-8f98-4362-ba81-644fabeff804" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_1464bd32-ce2b-4e60-b1ff-1afc08fe18dd" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_d2a48d0d-8f98-4362-ba81-644fabeff804" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_3a6285c2-1760-4df7-85d2-07df7c6f5186" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_1464bd32-ce2b-4e60-b1ff-1afc08fe18dd" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_3a6285c2-1760-4df7-85d2-07df7c6f5186" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_be89ae21-cdc1-4e70-8ff8-751f6d6708ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_1f0df18c-b3e6-4b65-9757-5cb46bd4c6d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_be89ae21-cdc1-4e70-8ff8-751f6d6708ad" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_1f0df18c-b3e6-4b65-9757-5cb46bd4c6d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_a3da9619-0041-4007-a0f9-d0ca02a322db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_be89ae21-cdc1-4e70-8ff8-751f6d6708ad" xlink:to="loc_us-gaap_ProfitLoss_a3da9619-0041-4007-a0f9-d0ca02a322db" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_a186de54-d628-4e0b-8157-889f1348b7dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_443cca96-0d99-4000-9874-03c72fecf1ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_a186de54-d628-4e0b-8157-889f1348b7dd" xlink:to="loc_us-gaap_OperatingExpenses_443cca96-0d99-4000-9874-03c72fecf1ac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_40eb2c81-37da-4f54-bacc-841c57bb2b08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_a186de54-d628-4e0b-8157-889f1348b7dd" xlink:to="loc_us-gaap_Revenues_40eb2c81-37da-4f54-bacc-841c57bb2b08" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_d1df36d0-ee08-4f02-a491-04128805c6ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_a033be1b-2671-4b75-ae56-2c1606bb3329" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_d1df36d0-ee08-4f02-a491-04128805c6ba" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_a033be1b-2671-4b75-ae56-2c1606bb3329" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_f68d2e3c-0f2f-4cc0-a18f-09530e86407a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_d1df36d0-ee08-4f02-a491-04128805c6ba" xlink:to="loc_us-gaap_ProfitLoss_f68d2e3c-0f2f-4cc0-a18f-09530e86407a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_57e17607-ea72-4a98-8224-5779137db5f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_905030c9-04bb-4635-a16b-8dcb0cad2c8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_57e17607-ea72-4a98-8224-5779137db5f6" xlink:to="loc_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_905030c9-04bb-4635-a16b-8dcb0cad2c8a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_c79cdbc7-b1ff-4ac2-8187-f8f501883a70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_57e17607-ea72-4a98-8224-5779137db5f6" xlink:to="loc_us-gaap_InvestmentIncomeInterest_c79cdbc7-b1ff-4ac2-8187-f8f501883a70" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_a658a699-05a2-4719-9b76-3d5c3aef31aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_57e17607-ea72-4a98-8224-5779137db5f6" xlink:to="loc_us-gaap_OperatingIncomeLoss_a658a699-05a2-4719-9b76-3d5c3aef31aa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_55bfe91a-e981-45fd-b8b5-9c828ed510ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_57e17607-ea72-4a98-8224-5779137db5f6" xlink:to="loc_us-gaap_InterestExpense_55bfe91a-e981-45fd-b8b5-9c828ed510ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_ac9663e6-238e-4ef7-bc92-94f870e2297d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_57e17607-ea72-4a98-8224-5779137db5f6" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_ac9663e6-238e-4ef7-bc92-94f870e2297d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_7150b09b-0cec-46e9-b651-49a0aadb158a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_57e17607-ea72-4a98-8224-5779137db5f6" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_7150b09b-0cec-46e9-b651-49a0aadb158a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_0eada29c-d3b9-44ac-993e-10d7e3cf9206" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_57e17607-ea72-4a98-8224-5779137db5f6" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_0eada29c-d3b9-44ac-993e-10d7e3cf9206" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_GainOnTransferOfMembership_c2b6fb54-8f05-4ad1-8e28-372dbfa1917c" xlink:href="evh-20210630.xsd#evh_GainOnTransferOfMembership"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_57e17607-ea72-4a98-8224-5779137db5f6" xlink:to="loc_evh_GainOnTransferOfMembership_c2b6fb54-8f05-4ad1-8e28-372dbfa1917c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_3af62f65-e3f7-4034-a8cd-e8aa466977f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_b9729d63-64e9-4920-9879-309fb2c17e5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_3af62f65-e3f7-4034-a8cd-e8aa466977f3" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_b9729d63-64e9-4920-9879-309fb2c17e5e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_78717493-6e28-4c6d-8155-07a760843f3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_3af62f65-e3f7-4034-a8cd-e8aa466977f3" xlink:to="loc_us-gaap_DepreciationAndAmortization_78717493-6e28-4c6d-8155-07a760843f3a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CostofGoodsandServicesSoldExcludingDepreciationandAmortization_e397f599-7de8-46b6-a704-5bb075fa69a0" xlink:href="evh-20210630.xsd#evh_CostofGoodsandServicesSoldExcludingDepreciationandAmortization"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_3af62f65-e3f7-4034-a8cd-e8aa466977f3" xlink:to="loc_evh_CostofGoodsandServicesSoldExcludingDepreciationandAmortization_e397f599-7de8-46b6-a704-5bb075fa69a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_fd880864-3e7e-4280-b046-78482ae80dec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_3af62f65-e3f7-4034-a8cd-e8aa466977f3" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_fd880864-3e7e-4280-b046-78482ae80dec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_cbc5915d-afb3-4fa2-aac9-925239bd5141" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_3af62f65-e3f7-4034-a8cd-e8aa466977f3" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_cbc5915d-afb3-4fa2-aac9-925239bd5141" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_b55d480b-ba60-44b6-8ec8-fae70c5297a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_3af62f65-e3f7-4034-a8cd-e8aa466977f3" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_b55d480b-ba60-44b6-8ec8-fae70c5297a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_58326ac5-941f-479e-b249-fb315b3d7d2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_a6bdea15-34cd-47db-bc0c-71336f7d3517" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_58326ac5-941f-479e-b249-fb315b3d7d2a" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_a6bdea15-34cd-47db-bc0c-71336f7d3517" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_ed2a5c06-40c8-4ef8-9447-9fa44eb4ac73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_58326ac5-941f-479e-b249-fb315b3d7d2a" xlink:to="loc_us-gaap_ProfitLoss_ed2a5c06-40c8-4ef8-9447-9fa44eb4ac73" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_1c769aab-1b6e-4b6f-9c87-87b2bb24572c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_bd346027-cf21-4f7d-9027-5391289028c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_1c769aab-1b6e-4b6f-9c87-87b2bb24572c" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_bd346027-cf21-4f7d-9027-5391289028c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_26c99a1b-1b82-447b-8bdb-dfe7dbfa2976" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_1c769aab-1b6e-4b6f-9c87-87b2bb24572c" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_26c99a1b-1b82-447b-8bdb-dfe7dbfa2976" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_45b946cc-a97a-4500-988f-1a62d86492c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_009fc482-c132-4253-9278-1ac8e57f0fab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_45b946cc-a97a-4500-988f-1a62d86492c6" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_009fc482-c132-4253-9278-1ac8e57f0fab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_cea26bd7-481e-4025-bf9a-ba934d46509c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_45b946cc-a97a-4500-988f-1a62d86492c6" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_cea26bd7-481e-4025-bf9a-ba934d46509c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="evh-20210630.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_5f9bc276-2ab3-4ffd-b30f-d15b1b5bfdff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates_74f0894d-5422-4375-91ae-82e216a6eff8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_5f9bc276-2ab3-4ffd-b30f-d15b1b5bfdff" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates_74f0894d-5422-4375-91ae-82e216a6eff8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet_b478d409-f71f-438f-b74c-80634afd9bd0" xlink:href="evh-20210630.xsd#evh_PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_5f9bc276-2ab3-4ffd-b30f-d15b1b5bfdff" xlink:to="loc_evh_PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet_b478d409-f71f-438f-b74c-80634afd9bd0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireHeldToMaturitySecurities_dab8550a-8c86-4b76-9d8f-a10ed4056992" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireHeldToMaturitySecurities"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_5f9bc276-2ab3-4ffd-b30f-d15b1b5bfdff" xlink:to="loc_us-gaap_PaymentsToAcquireHeldToMaturitySecurities_dab8550a-8c86-4b76-9d8f-a10ed4056992" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital_10105e77-5f5c-4f76-9745-194886a99d89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_5f9bc276-2ab3-4ffd-b30f-d15b1b5bfdff" xlink:to="loc_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital_10105e77-5f5c-4f76-9745-194886a99d89" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_aae9c8a1-d3b7-441f-b302-03b8ed4a1706" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireOtherProductiveAssets"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_5f9bc276-2ab3-4ffd-b30f-d15b1b5bfdff" xlink:to="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_aae9c8a1-d3b7-441f-b302-03b8ed4a1706" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ProceedsFromMaturityOfInvestments_390a5a7c-eca1-46d6-a650-baaee3dcb45e" xlink:href="evh-20210630.xsd#evh_ProceedsFromMaturityOfInvestments"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_5f9bc276-2ab3-4ffd-b30f-d15b1b5bfdff" xlink:to="loc_evh_ProceedsFromMaturityOfInvestments_390a5a7c-eca1-46d6-a650-baaee3dcb45e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_bb80a053-cfa6-45d5-aba9-998fa27a434d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_5f9bc276-2ab3-4ffd-b30f-d15b1b5bfdff" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_bb80a053-cfa6-45d5-aba9-998fa27a434d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_0d0ee517-8367-4e7b-b8d7-672186a7e38a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_5f9bc276-2ab3-4ffd-b30f-d15b1b5bfdff" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_0d0ee517-8367-4e7b-b8d7-672186a7e38a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_59d8f82b-670b-4a79-b3e0-2049ef7c3588" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_c16b3318-4c63-4192-a2e1-74f0b6c7781a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_59d8f82b-670b-4a79-b3e0-2049ef7c3588" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_c16b3318-4c63-4192-a2e1-74f0b6c7781a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PaymentsForProceedsFromClaimsProcessingFinancingActivities_fa57350e-9ea6-4970-a6e7-2ae1828f5e4e" xlink:href="evh-20210630.xsd#evh_PaymentsForProceedsFromClaimsProcessingFinancingActivities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_59d8f82b-670b-4a79-b3e0-2049ef7c3588" xlink:to="loc_evh_PaymentsForProceedsFromClaimsProcessingFinancingActivities_fa57350e-9ea6-4970-a6e7-2ae1828f5e4e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_ba1c56ac-e29c-48cf-b1f9-1150721ce592" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_59d8f82b-670b-4a79-b3e0-2049ef7c3588" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_ba1c56ac-e29c-48cf-b1f9-1150721ce592" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSeniorDebt_32dc36d6-ca9c-4670-8643-0da2f739fff4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfSeniorDebt"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_59d8f82b-670b-4a79-b3e0-2049ef7c3588" xlink:to="loc_us-gaap_RepaymentsOfSeniorDebt_32dc36d6-ca9c-4670-8643-0da2f739fff4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders_37f5afa0-98fc-4a7b-960a-85177e52c4a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToMinorityShareholders"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_59d8f82b-670b-4a79-b3e0-2049ef7c3588" xlink:to="loc_us-gaap_PaymentsToMinorityShareholders_37f5afa0-98fc-4a7b-960a-85177e52c4a9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d4cc5bf8-bee3-45d6-a231-a446c228f23c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_eadb2124-4c16-4481-abc4-797f4ba6b927" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d4cc5bf8-bee3-45d6-a231-a446c228f23c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_eadb2124-4c16-4481-abc4-797f4ba6b927" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4de4e25d-6aee-429c-bbb2-ac3c437f519e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d4cc5bf8-bee3-45d6-a231-a446c228f23c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4de4e25d-6aee-429c-bbb2-ac3c437f519e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_74d394a8-ceee-4d1f-b17f-c76c580b20ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d4cc5bf8-bee3-45d6-a231-a446c228f23c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_74d394a8-ceee-4d1f-b17f-c76c580b20ae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_50fd2250-2639-4fe1-b332-bd6b6139c615" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d4cc5bf8-bee3-45d6-a231-a446c228f23c" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_50fd2250-2639-4fe1-b332-bd6b6139c615" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_61d979ea-eeeb-402d-bcb9-b5d5cc6362fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_dbb72804-7ca4-4bc7-97da-d4e86398e755" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_61d979ea-eeeb-402d-bcb9-b5d5cc6362fa" xlink:to="loc_us-gaap_ProfitLoss_dbb72804-7ca4-4bc7-97da-d4e86398e755" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_35d581e7-0689-4882-a286-331f9bb664eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_61d979ea-eeeb-402d-bcb9-b5d5cc6362fa" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_35d581e7-0689-4882-a286-331f9bb664eb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_GainLossOnDispositionOfAssetsOperatingActivities_0a9a13be-c0a4-406d-ad55-d13b50ecef15" xlink:href="evh-20210630.xsd#evh_GainLossOnDispositionOfAssetsOperatingActivities"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_61d979ea-eeeb-402d-bcb9-b5d5cc6362fa" xlink:to="loc_evh_GainLossOnDispositionOfAssetsOperatingActivities_0a9a13be-c0a4-406d-ad55-d13b50ecef15" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_c0c3b4e9-e85a-4af0-8613-67fb5738b014" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_61d979ea-eeeb-402d-bcb9-b5d5cc6362fa" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_c0c3b4e9-e85a-4af0-8613-67fb5738b014" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_9f6a9a2d-3012-46ea-9895-cef669c6dc3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_61d979ea-eeeb-402d-bcb9-b5d5cc6362fa" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_9f6a9a2d-3012-46ea-9895-cef669c6dc3b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_41f2209e-dbd6-481f-b793-f3a3c30b2e1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_61d979ea-eeeb-402d-bcb9-b5d5cc6362fa" xlink:to="loc_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_41f2209e-dbd6-481f-b793-f3a3c30b2e1f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_af86ae59-2c77-406a-9574-ba90d9e08ffc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_61d979ea-eeeb-402d-bcb9-b5d5cc6362fa" xlink:to="loc_us-gaap_ShareBasedCompensation_af86ae59-2c77-406a-9574-ba90d9e08ffc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_098e507f-ed24-45c4-9dd4-9df5600f4c90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_61d979ea-eeeb-402d-bcb9-b5d5cc6362fa" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_098e507f-ed24-45c4-9dd4-9df5600f4c90" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostAmortization_1446a026-aad5-43ab-b981-e5bb163eb3a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedContractCostAmortization"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_61d979ea-eeeb-402d-bcb9-b5d5cc6362fa" xlink:to="loc_us-gaap_CapitalizedContractCostAmortization_1446a026-aad5-43ab-b981-e5bb163eb3a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_527108fe-4be4-4d94-9d87-869e9267d83a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_61d979ea-eeeb-402d-bcb9-b5d5cc6362fa" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_527108fe-4be4-4d94-9d87-869e9267d83a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_78645dd6-9a50-41b9-8ea6-03881a69f22e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_61d979ea-eeeb-402d-bcb9-b5d5cc6362fa" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_78645dd6-9a50-41b9-8ea6-03881a69f22e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset_3488c78c-1756-4e0b-9a88-5ab663fc2e36" xlink:href="evh-20210630.xsd#evh_IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_61d979ea-eeeb-402d-bcb9-b5d5cc6362fa" xlink:to="loc_evh_IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset_3488c78c-1756-4e0b-9a88-5ab663fc2e36" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_a1d4c425-dd26-45b6-86f6-5514bf9c791f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_61d979ea-eeeb-402d-bcb9-b5d5cc6362fa" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_a1d4c425-dd26-45b6-86f6-5514bf9c791f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_IncreaseDecreaseInCapitalizedContractCostNet_e5a13a10-7505-4869-96cf-b3fd1cff6478" xlink:href="evh-20210630.xsd#evh_IncreaseDecreaseInCapitalizedContractCostNet"/>
    <link:calculationArc order="14" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_61d979ea-eeeb-402d-bcb9-b5d5cc6362fa" xlink:to="loc_evh_IncreaseDecreaseInCapitalizedContractCostNet_e5a13a10-7505-4869-96cf-b3fd1cff6478" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_1e82806a-9d37-4ed1-9626-d4d56cdc863c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_61d979ea-eeeb-402d-bcb9-b5d5cc6362fa" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_1e82806a-9d37-4ed1-9626-d4d56cdc863c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_ad49003e-f0ac-4fab-be87-b10e7b5e0e7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="16" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_61d979ea-eeeb-402d-bcb9-b5d5cc6362fa" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_ad49003e-f0ac-4fab-be87-b10e7b5e0e7a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_8b89fe71-415b-4535-b699-e35b03a9292e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:calculationArc order="17" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_61d979ea-eeeb-402d-bcb9-b5d5cc6362fa" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_8b89fe71-415b-4535-b699-e35b03a9292e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_01a31432-f961-4f64-8ea8-f9cca5105052" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="18" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_61d979ea-eeeb-402d-bcb9-b5d5cc6362fa" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_01a31432-f961-4f64-8ea8-f9cca5105052" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities_1ff1010a-fcb3-446d-9bae-6b22cdbcaa73" xlink:href="evh-20210630.xsd#evh_IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities"/>
    <link:calculationArc order="19" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_61d979ea-eeeb-402d-bcb9-b5d5cc6362fa" xlink:to="loc_evh_IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities_1ff1010a-fcb3-446d-9bae-6b22cdbcaa73" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_IncreaseDecreaseInOperatingLeaseRightofUseAsset_d937fec3-4d11-4256-a656-d4763d780eaf" xlink:href="evh-20210630.xsd#evh_IncreaseDecreaseInOperatingLeaseRightofUseAsset"/>
    <link:calculationArc order="20" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_61d979ea-eeeb-402d-bcb9-b5d5cc6362fa" xlink:to="loc_evh_IncreaseDecreaseInOperatingLeaseRightofUseAsset_d937fec3-4d11-4256-a656-d4763d780eaf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_bea23089-2ec3-4e8c-872f-56711f83fc1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:calculationArc order="21" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_61d979ea-eeeb-402d-bcb9-b5d5cc6362fa" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_bea23089-2ec3-4e8c-872f-56711f83fc1e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_154594fe-33be-4237-b474-9cd20287eb72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:calculationArc order="22" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_61d979ea-eeeb-402d-bcb9-b5d5cc6362fa" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_154594fe-33be-4237-b474-9cd20287eb72" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_02374e24-6a76-4326-888b-4775b7ea9cac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="23" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_61d979ea-eeeb-402d-bcb9-b5d5cc6362fa" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_02374e24-6a76-4326-888b-4775b7ea9cac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_GainOnTransferOfMembership_fda2e928-ae04-492f-8b88-cbd7cb34d137" xlink:href="evh-20210630.xsd#evh_GainOnTransferOfMembership"/>
    <link:calculationArc order="24" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_61d979ea-eeeb-402d-bcb9-b5d5cc6362fa" xlink:to="loc_evh_GainOnTransferOfMembership_fda2e928-ae04-492f-8b88-cbd7cb34d137" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_6b5b5ceb-45d2-4fe2-a24c-5432435e927e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:calculationArc order="25" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_61d979ea-eeeb-402d-bcb9-b5d5cc6362fa" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_6b5b5ceb-45d2-4fe2-a24c-5432435e927e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PaidinKindInterestIncome_aed14999-8ed8-4145-bbc7-52bb6f5afdd4" xlink:href="evh-20210630.xsd#evh_PaidinKindInterestIncome"/>
    <link:calculationArc order="26" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_61d979ea-eeeb-402d-bcb9-b5d5cc6362fa" xlink:to="loc_evh_PaidinKindInterestIncome_aed14999-8ed8-4145-bbc7-52bb6f5afdd4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails" xlink:type="simple" xlink:href="evh-20210630.xsd#BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails"/>
  <link:calculationLink xlink:role="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8cbdd358-e0ba-47e4-b18e-e960615eb9c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_5ba7baba-b7b9-4ecd-af28-7a8f48afbe8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8cbdd358-e0ba-47e4-b18e-e960615eb9c1" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_5ba7baba-b7b9-4ecd-af28-7a8f48afbe8f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedInvestments_56349c5b-21cb-4d11-bacd-d27b64d5eb45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8cbdd358-e0ba-47e4-b18e-e960615eb9c1" xlink:to="loc_us-gaap_RestrictedInvestments_56349c5b-21cb-4d11-bacd-d27b64d5eb45" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_28a8edd0-765b-4d13-977b-9b3f601992ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8cbdd358-e0ba-47e4-b18e-e960615eb9c1" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_28a8edd0-765b-4d13-977b-9b3f601992ef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_50794fad-ff6b-467a-98e4-836e6dca9e7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndInvestmentsCurrent_44cccb60-047d-47e1-96fe-1e70d1e21c23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndInvestmentsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalents_50794fad-ff6b-467a-98e4-836e6dca9e7e" xlink:to="loc_us-gaap_RestrictedCashAndInvestmentsCurrent_44cccb60-047d-47e1-96fe-1e70d1e21c23" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndInvestmentsNoncurrent_6a0d72c5-145b-4808-9cdd-4d562ddf5325" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndInvestmentsNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalents_50794fad-ff6b-467a-98e4-836e6dca9e7e" xlink:to="loc_us-gaap_RestrictedCashAndInvestmentsNoncurrent_6a0d72c5-145b-4808-9cdd-4d562ddf5325" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndInvestmentsNoncurrent_cf10c4ba-5b17-4a68-b1f9-bbb688a4f983" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndInvestmentsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_08d746df-73dc-42ec-b8af-60163ce2413b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_RestrictedCashAndInvestmentsNoncurrent_cf10c4ba-5b17-4a68-b1f9-bbb688a4f983" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_08d746df-73dc-42ec-b8af-60163ce2413b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndInvestmentsCurrent_e903386b-b0c1-45a8-9178-a72f08bebb89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndInvestmentsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_fbbd5b67-799a-4c17-a8cf-9ca0392b2d38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_RestrictedCashAndInvestmentsCurrent_e903386b-b0c1-45a8-9178-a72f08bebb89" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_fbbd5b67-799a-4c17-a8cf-9ca0392b2d38" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails" xlink:type="simple" xlink:href="evh-20210630.xsd#DiscontinuedOperationsSummaryofResultsofOperationsDetails"/>
  <link:calculationLink xlink:role="http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_a39ad5e1-5ddc-47c7-8a42-5a91a600c03d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_74ee9199-cfdb-4e54-b83f-244c3cf0e6a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_a39ad5e1-5ddc-47c7-8a42-5a91a600c03d" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_74ee9199-cfdb-4e54-b83f-244c3cf0e6a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_1eb70ada-bb38-4460-b27a-bc8b9047067c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_a39ad5e1-5ddc-47c7-8a42-5a91a600c03d" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_1eb70ada-bb38-4460-b27a-bc8b9047067c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense_29907013-221d-4be3-83cf-8a8d5e1bfa46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_a39ad5e1-5ddc-47c7-8a42-5a91a600c03d" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense_29907013-221d-4be3-83cf-8a8d5e1bfa46" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome_3d3c34ec-ac68-484d-854d-f8efe1fef6a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_a39ad5e1-5ddc-47c7-8a42-5a91a600c03d" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome_3d3c34ec-ac68-484d-854d-f8efe1fef6a4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_2561e716-12ec-4255-8ec2-7b2e403df641" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_09abc2d9-59a6-441d-ba48-d8cf0958af7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_2561e716-12ec-4255-8ec2-7b2e403df641" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_09abc2d9-59a6-441d-ba48-d8cf0958af7e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_2bbdd4c0-7468-4d71-b2f4-5cfb03d4a122" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_2561e716-12ec-4255-8ec2-7b2e403df641" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_2bbdd4c0-7468-4d71-b2f4-5cfb03d4a122" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_3893f058-9df9-4e86-b55f-c74f99b82e95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_edc1ee36-b7b1-4d8b-a2d5-d25575ccffc5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_3893f058-9df9-4e86-b55f-c74f99b82e95" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_edc1ee36-b7b1-4d8b-a2d5-d25575ccffc5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortizationDiscontinuedOperations_8cb0ff32-62f2-4d52-a955-2bd791c9e6e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortizationDiscontinuedOperations"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_3893f058-9df9-4e86-b55f-c74f99b82e95" xlink:to="loc_us-gaap_DepreciationAndAmortizationDiscontinuedOperations_8cb0ff32-62f2-4d52-a955-2bd791c9e6e3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DisposalGroupIncludingDiscontinuedOperationClaimsExpense_4004207a-5cdd-4a93-a4ea-39cc8063cb05" xlink:href="evh-20210630.xsd#evh_DisposalGroupIncludingDiscontinuedOperationClaimsExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_3893f058-9df9-4e86-b55f-c74f99b82e95" xlink:to="loc_evh_DisposalGroupIncludingDiscontinuedOperationClaimsExpense_4004207a-5cdd-4a93-a4ea-39cc8063cb05" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_c06873eb-4280-438f-a92c-52e801a59c73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_3893f058-9df9-4e86-b55f-c74f99b82e95" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_c06873eb-4280-438f-a92c-52e801a59c73" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_dc129adb-82cf-4e38-bf55-35b085aabf9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_ae5cbaf4-f85c-4f0f-84c9-ca450d74047a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_dc129adb-82cf-4e38-bf55-35b085aabf9c" xlink:to="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_ae5cbaf4-f85c-4f0f-84c9-ca450d74047a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_f2f39742-370e-4222-808e-b22cc42fd8ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_dc129adb-82cf-4e38-bf55-35b085aabf9c" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_f2f39742-370e-4222-808e-b22cc42fd8ec" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCurrentandLongtermAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="evh-20210630.xsd#DiscontinuedOperationsSummaryofCurrentandLongtermAssetsandLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCurrentandLongtermAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_6e38213a-ccc7-4e80-820a-310b358ed8a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DisposalGroupIncludingDiscontinuedOperationLiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangementsCurrent_1f202278-1dc0-4dbc-8dd2-d5e55de9c577" xlink:href="evh-20210630.xsd#evh_DisposalGroupIncludingDiscontinuedOperationLiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangementsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_6e38213a-ccc7-4e80-820a-310b358ed8a5" xlink:to="loc_evh_DisposalGroupIncludingDiscontinuedOperationLiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangementsCurrent_1f202278-1dc0-4dbc-8dd2-d5e55de9c577" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DisposalGroupIncludingDiscontinuedOperationAccruedCompensationAndEmployeeBenefitsCurrent_b9cf2f3d-5a2f-4379-9692-bfff436babde" xlink:href="evh-20210630.xsd#evh_DisposalGroupIncludingDiscontinuedOperationAccruedCompensationAndEmployeeBenefitsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_6e38213a-ccc7-4e80-820a-310b358ed8a5" xlink:to="loc_evh_DisposalGroupIncludingDiscontinuedOperationAccruedCompensationAndEmployeeBenefitsCurrent_b9cf2f3d-5a2f-4379-9692-bfff436babde" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent_793791e4-9cfa-49c9-a5f9-9efb2f59635a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_6e38213a-ccc7-4e80-820a-310b358ed8a5" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent_793791e4-9cfa-49c9-a5f9-9efb2f59635a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent_1510d302-8277-4881-b72d-1f7619ec9cb1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_6e38213a-ccc7-4e80-820a-310b358ed8a5" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent_1510d302-8277-4881-b72d-1f7619ec9cb1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent_0732f460-9128-42a0-b1f8-ce15cc8e9de9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_6e38213a-ccc7-4e80-820a-310b358ed8a5" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent_0732f460-9128-42a0-b1f8-ce15cc8e9de9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_115c333a-ddc9-4220-b2b3-200810678910" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DisposalGroupIncludingDiscontinuedOperationInvestmentsCurrent_17f151f6-3e50-4907-b7a8-16bec51fd3c6" xlink:href="evh-20210630.xsd#evh_DisposalGroupIncludingDiscontinuedOperationInvestmentsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_115c333a-ddc9-4220-b2b3-200810678910" xlink:to="loc_evh_DisposalGroupIncludingDiscontinuedOperationInvestmentsCurrent_17f151f6-3e50-4907-b7a8-16bec51fd3c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DisposalGroupIncludingDiscontinuedOperationRestrictedCashAndRestrictedInvestmentsCurrent_c43319c4-d9f6-4cf8-9d48-a6a38d1c6101" xlink:href="evh-20210630.xsd#evh_DisposalGroupIncludingDiscontinuedOperationRestrictedCashAndRestrictedInvestmentsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_115c333a-ddc9-4220-b2b3-200810678910" xlink:to="loc_evh_DisposalGroupIncludingDiscontinuedOperationRestrictedCashAndRestrictedInvestmentsCurrent_c43319c4-d9f6-4cf8-9d48-a6a38d1c6101" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_c339d6af-f835-4977-962e-e5906fb13936" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_115c333a-ddc9-4220-b2b3-200810678910" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_c339d6af-f835-4977-962e-e5906fb13936" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_d2e2b507-d260-46ba-9893-c562d7d62e6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_115c333a-ddc9-4220-b2b3-200810678910" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_d2e2b507-d260-46ba-9893-c562d7d62e6d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_1ca94963-e775-4498-ba00-dcda97de76ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_115c333a-ddc9-4220-b2b3-200810678910" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_1ca94963-e775-4498-ba00-dcda97de76ee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_dd1977e3-9b5e-415a-805d-41624fc506e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_f8a89c58-ff21-4e3f-8533-5e3eea8d4bb8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_dd1977e3-9b5e-415a-805d-41624fc506e4" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_f8a89c58-ff21-4e3f-8533-5e3eea8d4bb8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_b4635692-20cd-43dc-8d89-a587ba40b469" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_dd1977e3-9b5e-415a-805d-41624fc506e4" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_b4635692-20cd-43dc-8d89-a587ba40b469" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities_623e4734-8536-4bdf-8f33-dfafb2d40db4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_dd1977e3-9b5e-415a-805d-41624fc506e4" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities_623e4734-8536-4bdf-8f33-dfafb2d40db4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_1d434c4c-229f-4c62-8f48-95a2d5e3a307" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DisposalGroupIncludingDiscontinuedOperationInvestmentsNoncurrent_fceade10-f2b5-4aa9-bc50-2920e7cd782b" xlink:href="evh-20210630.xsd#evh_DisposalGroupIncludingDiscontinuedOperationInvestmentsNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_1d434c4c-229f-4c62-8f48-95a2d5e3a307" xlink:to="loc_evh_DisposalGroupIncludingDiscontinuedOperationInvestmentsNoncurrent_fceade10-f2b5-4aa9-bc50-2920e7cd782b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DisposalGroupIncludingDiscontinuedOperationRestrictedCashAndRestrictedInvestmentsNoncurrent_369edfb2-f5b4-4894-a94d-64d812da694d" xlink:href="evh-20210630.xsd#evh_DisposalGroupIncludingDiscontinuedOperationRestrictedCashAndRestrictedInvestmentsNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_1d434c4c-229f-4c62-8f48-95a2d5e3a307" xlink:to="loc_evh_DisposalGroupIncludingDiscontinuedOperationRestrictedCashAndRestrictedInvestmentsNoncurrent_369edfb2-f5b4-4894-a94d-64d812da694d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsNoncurrent_cb4dd24f-bfba-4367-9912-4162b4fa268f" xlink:href="evh-20210630.xsd#evh_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_1d434c4c-229f-4c62-8f48-95a2d5e3a307" xlink:to="loc_evh_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsNoncurrent_cb4dd24f-bfba-4367-9912-4162b4fa268f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent_4c56ea4c-96f7-484b-9c22-398c58e4325c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_1d434c4c-229f-4c62-8f48-95a2d5e3a307" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent_4c56ea4c-96f7-484b-9c22-398c58e4325c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent_231db6d5-e5f2-42f3-9262-5582bfcce116" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_1d434c4c-229f-4c62-8f48-95a2d5e3a307" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent_231db6d5-e5f2-42f3-9262-5582bfcce116" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_f6c7cb37-c220-43d8-8f52-e0272dd52ae5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_1d434c4c-229f-4c62-8f48-95a2d5e3a307" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_f6c7cb37-c220-43d8-8f52-e0272dd52ae5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails" xlink:type="simple" xlink:href="evh-20210630.xsd#PropertyandEquipmentNetDetails"/>
  <link:calculationLink xlink:role="http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_ff392448-3d52-4379-b8fa-41bf7c9d04ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_02cd54a6-ff7f-44f2-a173-865544526234" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_ff392448-3d52-4379-b8fa-41bf7c9d04ba" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_02cd54a6-ff7f-44f2-a173-865544526234" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2b998440-ab33-4ce0-98de-8f96d4da1b70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_ff392448-3d52-4379-b8fa-41bf7c9d04ba" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2b998440-ab33-4ce0-98de-8f96d4da1b70" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails" xlink:type="simple" xlink:href="evh-20210630.xsd#GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails"/>
  <link:calculationLink xlink:role="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_80cced6b-fba1-4afc-8a80-d1fb2c26545e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_9a7518c1-9a11-41a1-b285-8ebb0bd21e46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_80cced6b-fba1-4afc-8a80-d1fb2c26545e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_9a7518c1-9a11-41a1-b285-8ebb0bd21e46" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_aaab99f6-1b81-45aa-96c7-94678017b21a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_80cced6b-fba1-4afc-8a80-d1fb2c26545e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_aaab99f6-1b81-45aa-96c7-94678017b21a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssets10KDetails" xlink:type="simple" xlink:href="evh-20210630.xsd#GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssets10KDetails"/>
  <link:calculationLink xlink:role="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssets10KDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_9fb32249-f54b-43b2-830f-e092ab6ed924" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_4919e394-4db8-46af-bdc4-b52a822fad91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_9fb32249-f54b-43b2-830f-e092ab6ed924" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_4919e394-4db8-46af-bdc4-b52a822fad91" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_5142c197-7b38-43e6-a79e-e68ecd6c87a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_9fb32249-f54b-43b2-830f-e092ab6ed924" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_5142c197-7b38-43e6-a79e-e68ecd6c87a3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_2b6b8103-a5d1-4b0b-9083-41a26f64b9e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_9fb32249-f54b-43b2-830f-e092ab6ed924" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_2b6b8103-a5d1-4b0b-9083-41a26f64b9e8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_d9ff608f-b62c-419c-894f-e133b6e330b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_9fb32249-f54b-43b2-830f-e092ab6ed924" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_d9ff608f-b62c-419c-894f-e133b6e330b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_5d69064a-72a5-4da8-a83c-84ae0196b9cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_9fb32249-f54b-43b2-830f-e092ab6ed924" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_5d69064a-72a5-4da8-a83c-84ae0196b9cd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_c2c433c3-194f-4654-b89a-9b0535bb35c3" xlink:href="evh-20210630.xsd#evh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_9fb32249-f54b-43b2-830f-e092ab6ed924" xlink:to="loc_evh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_c2c433c3-194f-4654-b89a-9b0535bb35c3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails" xlink:type="simple" xlink:href="evh-20210630.xsd#LongtermDebtConvertibleSeniorNotesCarryingValueDetails"/>
  <link:calculationLink xlink:role="http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebt_6dbaec85-4845-4e9e-9405-76566e9a937b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_22e0cb08-688e-428b-a290-5b8f27da69b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ConvertibleDebt_6dbaec85-4845-4e9e-9405-76566e9a937b" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_22e0cb08-688e-428b-a290-5b8f27da69b2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_6decaca6-532a-40cc-b05f-95f181ff6ce6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ConvertibleDebt_6dbaec85-4845-4e9e-9405-76566e9a937b" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_6decaca6-532a-40cc-b05f-95f181ff6ce6" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LeasesComponentsofLeaseExpenseDetails" xlink:type="simple" xlink:href="evh-20210630.xsd#LeasesComponentsofLeaseExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.evolenthealth.com/role/LeasesComponentsofLeaseExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_7592e0ff-14c1-4737-a2a7-4a091998a7cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_978f8c51-63ff-4e56-8a41-89dd37220024" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_7592e0ff-14c1-4737-a2a7-4a091998a7cf" xlink:to="loc_us-gaap_OperatingLeaseCost_978f8c51-63ff-4e56-8a41-89dd37220024" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_054c8157-42fe-4e25-9c5c-e7d539dc8eec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_7592e0ff-14c1-4737-a2a7-4a091998a7cf" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_054c8157-42fe-4e25-9c5c-e7d539dc8eec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense_c0f62129-1264-4060-aab3-b4f0de66933e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_7592e0ff-14c1-4737-a2a7-4a091998a7cf" xlink:to="loc_us-gaap_FinanceLeaseInterestExpense_c0f62129-1264-4060-aab3-b4f0de66933e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_abb31fc3-34ac-4258-8d50-31e20684435d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_7592e0ff-14c1-4737-a2a7-4a091998a7cf" xlink:to="loc_us-gaap_VariableLeaseCost_abb31fc3-34ac-4258-8d50-31e20684435d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="evh-20210630.xsd#LeasesMaturityofLeaseLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e2d1f6b2-8fb2-42a0-ae78-555bcd4f5512" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFive_26f3fe59-146f-42c7-bd3f-1f7b097f86c5" xlink:href="evh-20210630.xsd#evh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFive"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e2d1f6b2-8fb2-42a0-ae78-555bcd4f5512" xlink:to="loc_evh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFive_26f3fe59-146f-42c7-bd3f-1f7b097f86c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_6df7fc44-b848-4118-a6e2-33e94c1efa60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e2d1f6b2-8fb2-42a0-ae78-555bcd4f5512" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_6df7fc44-b848-4118-a6e2-33e94c1efa60" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_cd73dcb7-e890-482c-9c7a-1e4f8b526550" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e2d1f6b2-8fb2-42a0-ae78-555bcd4f5512" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_cd73dcb7-e890-482c-9c7a-1e4f8b526550" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear_490a9d42-fb36-4538-bdcb-7deac956cf42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e2d1f6b2-8fb2-42a0-ae78-555bcd4f5512" xlink:to="loc_us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear_490a9d42-fb36-4538-bdcb-7deac956cf42" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_34c449e5-4495-42b5-bbd1-338d7285ed59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e2d1f6b2-8fb2-42a0-ae78-555bcd4f5512" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_34c449e5-4495-42b5-bbd1-338d7285ed59" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_6b1bc172-1381-4b92-befa-e3b130679e5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e2d1f6b2-8fb2-42a0-ae78-555bcd4f5512" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_6b1bc172-1381-4b92-befa-e3b130679e5d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails_1" xlink:type="simple" xlink:href="evh-20210630.xsd#LeasesMaturityofLeaseLiabilitiesDetails_1"/>
  <link:calculationLink xlink:role="http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_619cc861-d0f5-4a9b-a46d-aa1d66917218" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_3ea9f1c2-6904-46f6-8ede-110049c6016f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_619cc861-d0f5-4a9b-a46d-aa1d66917218" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_3ea9f1c2-6904-46f6-8ede-110049c6016f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_e1ad0d74-cb2b-4c42-9034-8d2a0fe31c0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_619cc861-d0f5-4a9b-a46d-aa1d66917218" xlink:to="loc_us-gaap_OperatingLeaseLiability_e1ad0d74-cb2b-4c42-9034-8d2a0fe31c0d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails" xlink:type="simple" xlink:href="evh-20210630.xsd#FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails"/>
  <link:calculationLink xlink:role="http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_001d3752-8f13-4942-a64d-f9e07ffa02f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesFairValueDisclosure_88729754-3280-4745-9562-48658c0d17d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_001d3752-8f13-4942-a64d-f9e07ffa02f6" xlink:to="loc_us-gaap_OtherLiabilitiesFairValueDisclosure_88729754-3280-4745-9562-48658c0d17d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_05ad2165-6461-42ea-a885-ff06e131f776" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_5788f385-678e-4905-86af-c7255194cefb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_05ad2165-6461-42ea-a885-ff06e131f776" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_5788f385-678e-4905-86af-c7255194cefb" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails" xlink:type="simple" xlink:href="evh-20210630.xsd#ReservesforClaimsandPerformanceBasedArrangementsDetails"/>
  <link:calculationLink xlink:role="http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease_c570ba79-92be-48be-9f54-dbc16eb8c114" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_94f20334-438e-4df5-a599-18950975c1de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease_c570ba79-92be-48be-9f54-dbc16eb8c114" xlink:to="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_94f20334-438e-4df5-a599-18950975c1de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_61fa60f3-fa9e-457a-858b-8ef2df5bdb12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease_c570ba79-92be-48be-9f54-dbc16eb8c114" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_61fa60f3-fa9e-457a-858b-8ef2df5bdb12" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_aebcdbe6-9f04-495c-ae9b-ec8e747d8426" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease_c570ba79-92be-48be-9f54-dbc16eb8c114" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_aebcdbe6-9f04-495c-ae9b-ec8e747d8426" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization_372c0bbf-a506-4830-9336-bf86db149cfb" xlink:href="evh-20210630.xsd#evh_CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease_c570ba79-92be-48be-9f54-dbc16eb8c114" xlink:to="loc_evh_CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization_372c0bbf-a506-4830-9336-bf86db149cfb" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>evh-20210630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:e4ac7c37-8dd1-4c0a-a2d1-6d13aeec3d41,g:9a076b5a-4bc7-42a9-a1f2-350da80fade7-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="evh-20210630.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended" id="i7b9e3b57e61e4ed0b9ac211739a6e4d5_CONSOLIDATEDBALANCESHEETS">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_e886335e-b48d-4946-87b8-705903e210b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_a05c04ad-3226-4166-b7fa-130463856424" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e886335e-b48d-4946-87b8-705903e210b0" xlink:to="loc_us-gaap_AssetsAbstract_a05c04ad-3226-4166-b7fa-130463856424" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_4c209e74-2762-4838-9c36-4eb424756c1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_a05c04ad-3226-4166-b7fa-130463856424" xlink:to="loc_us-gaap_AssetsCurrentAbstract_4c209e74-2762-4838-9c36-4eb424756c1b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_0ead1194-99db-4895-9233-e3e323b7db1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_4c209e74-2762-4838-9c36-4eb424756c1b" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_0ead1194-99db-4895-9233-e3e323b7db1f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndInvestmentsCurrent_0955788a-f608-4984-9625-f51e5b8469ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndInvestmentsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_4c209e74-2762-4838-9c36-4eb424756c1b" xlink:to="loc_us-gaap_RestrictedCashAndInvestmentsCurrent_0955788a-f608-4984-9625-f51e5b8469ce" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_eb33f4f7-edd9-442e-b84b-3930a198a2cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_4c209e74-2762-4838-9c36-4eb424756c1b" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_eb33f4f7-edd9-442e-b84b-3930a198a2cd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_8c9f67f9-cf03-4d2d-aec8-873dac47dd92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_4c209e74-2762-4838-9c36-4eb424756c1b" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_8c9f67f9-cf03-4d2d-aec8-873dac47dd92" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_15564070-dee5-4fbe-a665-d70ee527babf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_4c209e74-2762-4838-9c36-4eb424756c1b" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_15564070-dee5-4fbe-a665-d70ee527babf" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_3593f7f0-861e-47d4-a0dc-05943d81b327" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_4c209e74-2762-4838-9c36-4eb424756c1b" xlink:to="loc_us-gaap_AssetsCurrent_3593f7f0-861e-47d4-a0dc-05943d81b327" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndInvestmentsNoncurrent_15d06274-043c-4402-a9b3-3427816a4d05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndInvestmentsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_a05c04ad-3226-4166-b7fa-130463856424" xlink:to="loc_us-gaap_RestrictedCashAndInvestmentsNoncurrent_15d06274-043c-4402-a9b3-3427816a4d05" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_4f071538-419c-419d-b496-19c71c461bcd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_a05c04ad-3226-4166-b7fa-130463856424" xlink:to="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_4f071538-419c-419d-b496-19c71c461bcd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_6b56812e-6a84-459c-957c-180e2c8fd075" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_a05c04ad-3226-4166-b7fa-130463856424" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_6b56812e-6a84-459c-957c-180e2c8fd075" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_84f68576-0e37-4a01-a763-86d12ed5c2fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_a05c04ad-3226-4166-b7fa-130463856424" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_84f68576-0e37-4a01-a763-86d12ed5c2fa" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_f7f78ff9-6df9-47a0-8273-6957e2c7b2f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_a05c04ad-3226-4166-b7fa-130463856424" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_f7f78ff9-6df9-47a0-8273-6957e2c7b2f3" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostNetNoncurrent_dc87451f-8e08-4e88-84fc-395bf02a5e62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedContractCostNetNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_a05c04ad-3226-4166-b7fa-130463856424" xlink:to="loc_us-gaap_CapitalizedContractCostNetNoncurrent_dc87451f-8e08-4e88-84fc-395bf02a5e62" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_3c3ee582-af89-4367-8fd1-e6893b43820d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_a05c04ad-3226-4166-b7fa-130463856424" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_3c3ee582-af89-4367-8fd1-e6893b43820d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_2af7d343-d361-4f22-910e-d51fca564afd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_a05c04ad-3226-4166-b7fa-130463856424" xlink:to="loc_us-gaap_Goodwill_2af7d343-d361-4f22-910e-d51fca564afd" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_6ca357b2-ef9e-4eba-8eb3-48c1736f0556" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_a05c04ad-3226-4166-b7fa-130463856424" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_6ca357b2-ef9e-4eba-8eb3-48c1736f0556" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_d5ac6ba8-602b-4476-bd18-3667f387275b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_a05c04ad-3226-4166-b7fa-130463856424" xlink:to="loc_us-gaap_Assets_d5ac6ba8-602b-4476-bd18-3667f387275b" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_feb34743-e716-48d0-a159-b298f70e8910" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e886335e-b48d-4946-87b8-705903e210b0" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_feb34743-e716-48d0-a159-b298f70e8910" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract_724f7eca-776e-404c-8768-304d0e476168" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_feb34743-e716-48d0-a159-b298f70e8910" xlink:to="loc_us-gaap_LiabilitiesAbstract_724f7eca-776e-404c-8768-304d0e476168" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_c594f381-c8ed-4e2c-b3b8-576f216e7945" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract_724f7eca-776e-404c-8768-304d0e476168" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_c594f381-c8ed-4e2c-b3b8-576f216e7945" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_01f3ea4d-1e91-4d1b-84ad-4e3ac6d3868a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c594f381-c8ed-4e2c-b3b8-576f216e7945" xlink:to="loc_us-gaap_AccountsPayableCurrent_01f3ea4d-1e91-4d1b-84ad-4e3ac6d3868a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_188b5e9d-2cd0-4961-a8c2-ecc58b47bd71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c594f381-c8ed-4e2c-b3b8-576f216e7945" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_188b5e9d-2cd0-4961-a8c2-ecc58b47bd71" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_5c11003f-2ab0-4cd9-bc55-7c636d12b1cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c594f381-c8ed-4e2c-b3b8-576f216e7945" xlink:to="loc_us-gaap_LongTermDebtCurrent_5c11003f-2ab0-4cd9-bc55-7c636d12b1cd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_5f8a5418-7cc8-4322-bb4a-6e9113a6ae34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c594f381-c8ed-4e2c-b3b8-576f216e7945" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_5f8a5418-7cc8-4322-bb4a-6e9113a6ae34" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_8e7fb362-465e-4a7c-ba38-9bb7bf4448f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c594f381-c8ed-4e2c-b3b8-576f216e7945" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_8e7fb362-465e-4a7c-ba38-9bb7bf4448f5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_3dcf54ed-2495-4340-9fd9-feda81477696" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c594f381-c8ed-4e2c-b3b8-576f216e7945" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_3dcf54ed-2495-4340-9fd9-feda81477696" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements_c59be174-4cf9-4e94-ac90-bd414dd47d1a" xlink:href="evh-20210630.xsd#evh_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c594f381-c8ed-4e2c-b3b8-576f216e7945" xlink:to="loc_evh_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements_c59be174-4cf9-4e94-ac90-bd414dd47d1a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_c895438d-c819-464b-aa4d-a1e7d177b288" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c594f381-c8ed-4e2c-b3b8-576f216e7945" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_c895438d-c819-464b-aa4d-a1e7d177b288" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_073efda9-de5f-42d4-841f-ddf58f6ee35a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c594f381-c8ed-4e2c-b3b8-576f216e7945" xlink:to="loc_us-gaap_LiabilitiesCurrent_073efda9-de5f-42d4-841f-ddf58f6ee35a" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_92d609bd-cfe9-4361-9c0b-f21fc1b1e0ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract_724f7eca-776e-404c-8768-304d0e476168" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_92d609bd-cfe9-4361-9c0b-f21fc1b1e0ae" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_d8f8ba80-a534-4b9b-8464-0304ee342828" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract_724f7eca-776e-404c-8768-304d0e476168" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_d8f8ba80-a534-4b9b-8464-0304ee342828" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_6d176bf4-d3c7-4303-9d4e-94d029be3905" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract_724f7eca-776e-404c-8768-304d0e476168" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_6d176bf4-d3c7-4303-9d4e-94d029be3905" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_a5f52ea8-d2e9-4171-bfcb-51723f35ce8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract_724f7eca-776e-404c-8768-304d0e476168" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_a5f52ea8-d2e9-4171-bfcb-51723f35ce8f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_bf54c174-5568-429f-8722-0dbaf6804776" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract_724f7eca-776e-404c-8768-304d0e476168" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_bf54c174-5568-429f-8722-0dbaf6804776" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_89e74357-c2da-4015-81b9-b0900d706345" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract_724f7eca-776e-404c-8768-304d0e476168" xlink:to="loc_us-gaap_Liabilities_89e74357-c2da-4015-81b9-b0900d706345" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_2bfb46f2-f2e1-4db7-a320-3bea428918fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_feb34743-e716-48d0-a159-b298f70e8910" xlink:to="loc_us-gaap_CommitmentsAndContingencies_2bfb46f2-f2e1-4db7-a320-3bea428918fe" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_61cd3e6e-e102-40d0-9216-113c2a25fe25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_feb34743-e716-48d0-a159-b298f70e8910" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_61cd3e6e-e102-40d0-9216-113c2a25fe25" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_bf66962a-25ab-4fc1-8035-b0df2d66994a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_61cd3e6e-e102-40d0-9216-113c2a25fe25" xlink:to="loc_us-gaap_CommonStockValue_bf66962a-25ab-4fc1-8035-b0df2d66994a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_71c06511-2116-4a86-a025-ead2437063df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_61cd3e6e-e102-40d0-9216-113c2a25fe25" xlink:to="loc_us-gaap_AdditionalPaidInCapital_71c06511-2116-4a86-a025-ead2437063df" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_08a3c09f-b36e-445a-8122-4f14a19bcc29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_61cd3e6e-e102-40d0-9216-113c2a25fe25" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_08a3c09f-b36e-445a-8122-4f14a19bcc29" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_3bc1851e-8789-42fd-8409-227ea03976a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_61cd3e6e-e102-40d0-9216-113c2a25fe25" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_3bc1851e-8789-42fd-8409-227ea03976a5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_f80db627-751e-4c67-b056-8d110292d587" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_61cd3e6e-e102-40d0-9216-113c2a25fe25" xlink:to="loc_us-gaap_TreasuryStockValue_f80db627-751e-4c67-b056-8d110292d587" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_253c8b90-ac9d-4f6f-b328-66084d178d5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_61cd3e6e-e102-40d0-9216-113c2a25fe25" xlink:to="loc_us-gaap_StockholdersEquity_253c8b90-ac9d-4f6f-b328-66084d178d5d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_ea261065-adcc-4eef-9a7a-d834b7e412b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_feb34743-e716-48d0-a159-b298f70e8910" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_ea261065-adcc-4eef-9a7a-d834b7e412b0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_20acaa19-b36c-46fa-b230-1f883a59cf38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_e886335e-b48d-4946-87b8-705903e210b0" xlink:to="loc_us-gaap_StatementTable_20acaa19-b36c-46fa-b230-1f883a59cf38" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1f652908-fa7e-4311-8dad-840dfc749e28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_20acaa19-b36c-46fa-b230-1f883a59cf38" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1f652908-fa7e-4311-8dad-840dfc749e28" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_1f652908-fa7e-4311-8dad-840dfc749e28_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1f652908-fa7e-4311-8dad-840dfc749e28" xlink:to="loc_us-gaap_ClassOfStockDomain_1f652908-fa7e-4311-8dad-840dfc749e28_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_8d30720a-b0c2-4f12-8852-7357b0f62d19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1f652908-fa7e-4311-8dad-840dfc749e28" xlink:to="loc_us-gaap_ClassOfStockDomain_8d30720a-b0c2-4f12-8852-7357b0f62d19" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_3657d8ad-fe12-46ec-b827-13da7a3f4e08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_8d30720a-b0c2-4f12-8852-7357b0f62d19" xlink:to="loc_us-gaap_CommonClassAMember_3657d8ad-fe12-46ec-b827-13da7a3f4e08" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS" xlink:type="simple" xlink:href="evh-20210630.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS" xlink:type="extended" id="ic73b7cc8a3c34457bc14f62cd331cb77_CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_b47e500d-8a8b-43d3-8f9a-378b9f62562c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_629fa98a-ea1b-406f-b5df-d1e59cd765b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b47e500d-8a8b-43d3-8f9a-378b9f62562c" xlink:to="loc_us-gaap_RevenuesAbstract_629fa98a-ea1b-406f-b5df-d1e59cd765b3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_6e78df9d-11d8-453a-bd2c-72ba4786cd46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_629fa98a-ea1b-406f-b5df-d1e59cd765b3" xlink:to="loc_us-gaap_Revenues_6e78df9d-11d8-453a-bd2c-72ba4786cd46" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_31a96d80-0aaf-4b28-bc30-e4960b8b008c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b47e500d-8a8b-43d3-8f9a-378b9f62562c" xlink:to="loc_us-gaap_OperatingExpensesAbstract_31a96d80-0aaf-4b28-bc30-e4960b8b008c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CostofGoodsandServicesSoldExcludingDepreciationandAmortization_227cec47-bf90-49f6-800c-495eb7284945" xlink:href="evh-20210630.xsd#evh_CostofGoodsandServicesSoldExcludingDepreciationandAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_31a96d80-0aaf-4b28-bc30-e4960b8b008c" xlink:to="loc_evh_CostofGoodsandServicesSoldExcludingDepreciationandAmortization_227cec47-bf90-49f6-800c-495eb7284945" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_87ab9b48-2094-4a9b-b552-e4a262efc1ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_31a96d80-0aaf-4b28-bc30-e4960b8b008c" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_87ab9b48-2094-4a9b-b552-e4a262efc1ff" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_2ff29f75-3286-4e08-b3d7-de5a75393271" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_31a96d80-0aaf-4b28-bc30-e4960b8b008c" xlink:to="loc_us-gaap_DepreciationAndAmortization_2ff29f75-3286-4e08-b3d7-de5a75393271" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_716b78a7-b6b7-4063-bf21-165f577d3bbc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_31a96d80-0aaf-4b28-bc30-e4960b8b008c" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_716b78a7-b6b7-4063-bf21-165f577d3bbc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_20967d2f-d36d-4aae-9a74-3b56c24bd82a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_31a96d80-0aaf-4b28-bc30-e4960b8b008c" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_20967d2f-d36d-4aae-9a74-3b56c24bd82a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_47e775f6-df6d-4ba8-8bbd-feccc7bf207b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_31a96d80-0aaf-4b28-bc30-e4960b8b008c" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_47e775f6-df6d-4ba8-8bbd-feccc7bf207b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_8416a98a-fb0b-4b82-9a62-bd95ef247fd2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_31a96d80-0aaf-4b28-bc30-e4960b8b008c" xlink:to="loc_us-gaap_OperatingExpenses_8416a98a-fb0b-4b82-9a62-bd95ef247fd2" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_be711bfb-e29d-4974-9c5f-9e5622e1ae10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b47e500d-8a8b-43d3-8f9a-378b9f62562c" xlink:to="loc_us-gaap_OperatingIncomeLoss_be711bfb-e29d-4974-9c5f-9e5622e1ae10" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_24883859-e3b0-412a-a238-d42b9d26c5f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b47e500d-8a8b-43d3-8f9a-378b9f62562c" xlink:to="loc_us-gaap_InvestmentIncomeInterest_24883859-e3b0-412a-a238-d42b9d26c5f1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_bef4aaa1-2621-49ab-a170-683d5d5db126" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b47e500d-8a8b-43d3-8f9a-378b9f62562c" xlink:to="loc_us-gaap_InterestExpense_bef4aaa1-2621-49ab-a170-683d5d5db126" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_b3f54365-2a9b-43ea-ac4b-aa0f96399e3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b47e500d-8a8b-43d3-8f9a-378b9f62562c" xlink:to="loc_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_b3f54365-2a9b-43ea-ac4b-aa0f96399e3f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_8161343d-dab7-4e78-8d31-0db3148232ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b47e500d-8a8b-43d3-8f9a-378b9f62562c" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_8161343d-dab7-4e78-8d31-0db3148232ee" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_GainOnTransferOfMembership_29640914-156d-41b4-bec6-0371de959be1" xlink:href="evh-20210630.xsd#evh_GainOnTransferOfMembership"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b47e500d-8a8b-43d3-8f9a-378b9f62562c" xlink:to="loc_evh_GainOnTransferOfMembership_29640914-156d-41b4-bec6-0371de959be1" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_b0618d76-fe98-4fab-a9d8-b65c01cc9a27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b47e500d-8a8b-43d3-8f9a-378b9f62562c" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_b0618d76-fe98-4fab-a9d8-b65c01cc9a27" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_174d129b-5387-4e29-9ae2-bbb3fe049483" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b47e500d-8a8b-43d3-8f9a-378b9f62562c" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_174d129b-5387-4e29-9ae2-bbb3fe049483" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d4cbc2dc-3ce8-40b9-be4d-4ffd754c25be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b47e500d-8a8b-43d3-8f9a-378b9f62562c" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d4cbc2dc-3ce8-40b9-be4d-4ffd754c25be" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_c48c5371-a1ad-45e3-a7c1-3f4b13800b04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b47e500d-8a8b-43d3-8f9a-378b9f62562c" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_c48c5371-a1ad-45e3-a7c1-3f4b13800b04" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_b967e44d-5d91-42a8-ad11-1a4d55d4f1c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b47e500d-8a8b-43d3-8f9a-378b9f62562c" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_b967e44d-5d91-42a8-ad11-1a4d55d4f1c3" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_fa6e96b2-a3a4-4132-945a-8c537c5f1bd1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b47e500d-8a8b-43d3-8f9a-378b9f62562c" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_fa6e96b2-a3a4-4132-945a-8c537c5f1bd1" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_640b736d-d0e2-4574-81d8-aed3b620f9cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b47e500d-8a8b-43d3-8f9a-378b9f62562c" xlink:to="loc_us-gaap_ProfitLoss_640b736d-d0e2-4574-81d8-aed3b620f9cd" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_d0dcf301-b15d-420b-b8cd-b9ac0aa82e03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b47e500d-8a8b-43d3-8f9a-378b9f62562c" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_d0dcf301-b15d-420b-b8cd-b9ac0aa82e03" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_05c00e63-4069-48ac-8394-3ceaef801572" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b47e500d-8a8b-43d3-8f9a-378b9f62562c" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_05c00e63-4069-48ac-8394-3ceaef801572" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_5d58ef72-729a-4243-8e59-d671cec0fdca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b47e500d-8a8b-43d3-8f9a-378b9f62562c" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_5d58ef72-729a-4243-8e59-d671cec0fdca" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_a4c3fb0b-2a47-4253-aece-42addf380888" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b47e500d-8a8b-43d3-8f9a-378b9f62562c" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_a4c3fb0b-2a47-4253-aece-42addf380888" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_7bab8aba-a4bd-4ca1-90bb-2055bb3586ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_a4c3fb0b-2a47-4253-aece-42addf380888" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_7bab8aba-a4bd-4ca1-90bb-2055bb3586ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_f4c30bda-0692-4da9-83b5-eca6ceed3cf9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_a4c3fb0b-2a47-4253-aece-42addf380888" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_f4c30bda-0692-4da9-83b5-eca6ceed3cf9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_fe56611c-dc4f-428c-9c30-184bf3f7a656" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_a4c3fb0b-2a47-4253-aece-42addf380888" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_fe56611c-dc4f-428c-9c30-184bf3f7a656" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_eeb860e3-764a-48c2-9cd0-ae63d7f47e38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_a4c3fb0b-2a47-4253-aece-42addf380888" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_eeb860e3-764a-48c2-9cd0-ae63d7f47e38" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_cfcdc74f-cc52-4673-81bb-61676b7f78fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_a4c3fb0b-2a47-4253-aece-42addf380888" xlink:to="loc_us-gaap_EarningsPerShareBasic_cfcdc74f-cc52-4673-81bb-61676b7f78fa" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_1feea432-6c91-4016-bf1b-50f4d52da91f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_a4c3fb0b-2a47-4253-aece-42addf380888" xlink:to="loc_us-gaap_EarningsPerShareDiluted_1feea432-6c91-4016-bf1b-50f4d52da91f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_523a3bc9-3e66-4632-946b-8096eb690072" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b47e500d-8a8b-43d3-8f9a-378b9f62562c" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_523a3bc9-3e66-4632-946b-8096eb690072" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_61aeab7b-8856-4ee2-8a2f-2001b966dcb8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_523a3bc9-3e66-4632-946b-8096eb690072" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_61aeab7b-8856-4ee2-8a2f-2001b966dcb8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_bebdfe32-2da9-4e3b-b8c9-5ba002291cec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_523a3bc9-3e66-4632-946b-8096eb690072" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_bebdfe32-2da9-4e3b-b8c9-5ba002291cec" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract_df096fc3-a92c-4b9b-b2d5-1e3757700395" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b47e500d-8a8b-43d3-8f9a-378b9f62562c" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract_df096fc3-a92c-4b9b-b2d5-1e3757700395" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_0c9ed9f2-d4ae-45cb-8f8c-3a75a7400501" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_4691ed36-c500-4162-bfaf-4e6df5d98271" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract_df096fc3-a92c-4b9b-b2d5-1e3757700395" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_4691ed36-c500-4162-bfaf-4e6df5d98271" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_3ec0e632-cd3b-403e-a47a-2266455060c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_4691ed36-c500-4162-bfaf-4e6df5d98271" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_3ec0e632-cd3b-403e-a47a-2266455060c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_281cd027-2dcb-4254-99e7-089432e2fbfb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract_df096fc3-a92c-4b9b-b2d5-1e3757700395" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_281cd027-2dcb-4254-99e7-089432e2fbfb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_ef4ce538-d256-4f06-80fa-777665dc738f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract_df096fc3-a92c-4b9b-b2d5-1e3757700395" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_ef4ce538-d256-4f06-80fa-777665dc738f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_60d1c8f6-a600-4b80-b351-70c5a55c067b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract_df096fc3-a92c-4b9b-b2d5-1e3757700395" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_60d1c8f6-a600-4b80-b351-70c5a55c067b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_8424ad67-0bd3-4460-b3d1-59dfe3631d71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_b47e500d-8a8b-43d3-8f9a-378b9f62562c" xlink:to="loc_us-gaap_StatementTable_8424ad67-0bd3-4460-b3d1-59dfe3631d71" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_86683530-308b-4926-9119-5e058dc20873" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_8424ad67-0bd3-4460-b3d1-59dfe3631d71" xlink:to="loc_srt_ProductOrServiceAxis_86683530-308b-4926-9119-5e058dc20873" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_86683530-308b-4926-9119-5e058dc20873_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_86683530-308b-4926-9119-5e058dc20873" xlink:to="loc_srt_ProductsAndServicesDomain_86683530-308b-4926-9119-5e058dc20873_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_9c1e7c28-1fca-4792-8a1a-d297b3ec1a3e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_86683530-308b-4926-9119-5e058dc20873" xlink:to="loc_srt_ProductsAndServicesDomain_9c1e7c28-1fca-4792-8a1a-d297b3ec1a3e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TransformationServicesMember_70080f30-2755-4fd3-939f-51986be16daf" xlink:href="evh-20210630.xsd#evh_TransformationServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_9c1e7c28-1fca-4792-8a1a-d297b3ec1a3e" xlink:to="loc_evh_TransformationServicesMember_70080f30-2755-4fd3-939f-51986be16daf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PlatformsAndOperationsServicesMember_ffe5b61e-1669-49a3-88c6-98bba1d5dfb4" xlink:href="evh-20210630.xsd#evh_PlatformsAndOperationsServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_9c1e7c28-1fca-4792-8a1a-d297b3ec1a3e" xlink:to="loc_evh_PlatformsAndOperationsServicesMember_ffe5b61e-1669-49a3-88c6-98bba1d5dfb4" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYDEFICIT" xlink:type="simple" xlink:href="evh-20210630.xsd#CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYDEFICIT"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYDEFICIT" xlink:type="extended" id="ibec9d58ad09b43c6897d661b0be544e3_CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYDEFICIT">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_c5c830c8-0098-41b9-b871-fb7b402f4e8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_690b78a1-3d99-489e-8b8d-f042247bbbf1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c5c830c8-0098-41b9-b871-fb7b402f4e8d" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_690b78a1-3d99-489e-8b8d-f042247bbbf1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_68f9d2ef-9798-4746-863c-7b1b098f0f0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_690b78a1-3d99-489e-8b8d-f042247bbbf1" xlink:to="loc_us-gaap_SharesIssued_68f9d2ef-9798-4746-863c-7b1b098f0f0e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2f14ca44-b031-427e-bf8a-50ee7a5967e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_690b78a1-3d99-489e-8b8d-f042247bbbf1" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2f14ca44-b031-427e-bf8a-50ee7a5967e5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList_749789d9-cdae-44b0-8282-52daf313d7b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_690b78a1-3d99-489e-8b8d-f042247bbbf1" xlink:to="loc_us-gaap_AccountingStandardsUpdateExtensibleList_749789d9-cdae-44b0-8282-52daf313d7b5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_666d365d-fe98-460d-be1c-f3ad85961862" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_690b78a1-3d99-489e-8b8d-f042247bbbf1" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_666d365d-fe98-460d-be1c-f3ad85961862" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_5cf4e911-ec59-4cbd-965f-72f632b71209" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_690b78a1-3d99-489e-8b8d-f042247bbbf1" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_5cf4e911-ec59-4cbd-965f-72f632b71209" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_171168ac-453e-40bb-b2d3-7c1c313d8f43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_690b78a1-3d99-489e-8b8d-f042247bbbf1" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_171168ac-453e-40bb-b2d3-7c1c313d8f43" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_0467eade-11d9-4406-a11c-f233ace0b32f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_690b78a1-3d99-489e-8b8d-f042247bbbf1" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_0467eade-11d9-4406-a11c-f233ace0b32f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_ef128b7a-dfc9-49db-b030-75e8a0fe896c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_690b78a1-3d99-489e-8b8d-f042247bbbf1" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_ef128b7a-dfc9-49db-b030-75e8a0fe896c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_StockVestedAndRetiredDuringPeriodShares_b202dd3d-deb0-49c1-ad55-5a19548e91a2" xlink:href="evh-20210630.xsd#evh_StockVestedAndRetiredDuringPeriodShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_690b78a1-3d99-489e-8b8d-f042247bbbf1" xlink:to="loc_evh_StockVestedAndRetiredDuringPeriodShares_b202dd3d-deb0-49c1-ad55-5a19548e91a2" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_StockVestedAndRetiredDuringPeriodValue_adc4f240-7689-451f-b205-2acb10052330" xlink:href="evh-20210630.xsd#evh_StockVestedAndRetiredDuringPeriodValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_690b78a1-3d99-489e-8b8d-f042247bbbf1" xlink:to="loc_evh_StockVestedAndRetiredDuringPeriodValue_adc4f240-7689-451f-b205-2acb10052330" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_a8e6abb6-7934-4724-940b-083f49cb4d0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_690b78a1-3d99-489e-8b8d-f042247bbbf1" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_a8e6abb6-7934-4724-940b-083f49cb4d0b" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_c1518ae9-93e1-493f-b761-d719fc73b220" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_690b78a1-3d99-489e-8b8d-f042247bbbf1" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_c1518ae9-93e1-493f-b761-d719fc73b220" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation_68d9d735-213f-4076-842d-98887d5ea368" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_690b78a1-3d99-489e-8b8d-f042247bbbf1" xlink:to="loc_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation_68d9d735-213f-4076-842d-98887d5ea368" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_088e01ea-5c1f-4703-96ec-277707d53ab7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_690b78a1-3d99-489e-8b8d-f042247bbbf1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_088e01ea-5c1f-4703-96ec-277707d53ab7" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_8c5c8ef7-1aac-40fe-b8a6-66209cc0e429" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_690b78a1-3d99-489e-8b8d-f042247bbbf1" xlink:to="loc_us-gaap_ProfitLoss_8c5c8ef7-1aac-40fe-b8a6-66209cc0e429" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_94d1ce12-a113-4c2b-9574-99f3680d2cb7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_a1a37796-7ec9-443e-8b3d-0ca9abac6ae3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_cdce430d-b937-4898-aac6-8925f2c0e2f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_c5c830c8-0098-41b9-b871-fb7b402f4e8d" xlink:to="loc_us-gaap_StatementTable_cdce430d-b937-4898-aac6-8925f2c0e2f4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_78541a8f-5b72-46e8-9852-9f9900a97221" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_cdce430d-b937-4898-aac6-8925f2c0e2f4" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_78541a8f-5b72-46e8-9852-9f9900a97221" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_78541a8f-5b72-46e8-9852-9f9900a97221_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_78541a8f-5b72-46e8-9852-9f9900a97221" xlink:to="loc_us-gaap_EquityComponentDomain_78541a8f-5b72-46e8-9852-9f9900a97221_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_08ba8e9f-f51c-4e2e-9bd8-071da32e7707" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_78541a8f-5b72-46e8-9852-9f9900a97221" xlink:to="loc_us-gaap_EquityComponentDomain_08ba8e9f-f51c-4e2e-9bd8-071da32e7707" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember_4eb5f8d3-6ed5-4197-bc8a-addab24feb26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_08ba8e9f-f51c-4e2e-9bd8-071da32e7707" xlink:to="loc_us-gaap_ParentMember_4eb5f8d3-6ed5-4197-bc8a-addab24feb26" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_ff2ed16a-ab0f-4596-bd67-869da54121b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_4eb5f8d3-6ed5-4197-bc8a-addab24feb26" xlink:to="loc_us-gaap_CommonStockMember_ff2ed16a-ab0f-4596-bd67-869da54121b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_7c7a4e7f-674a-4d58-8ffa-6b9d7f2f318d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_4eb5f8d3-6ed5-4197-bc8a-addab24feb26" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_7c7a4e7f-674a-4d58-8ffa-6b9d7f2f318d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_e977bb35-0ff9-4f12-abfe-97df7ddc1469" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_4eb5f8d3-6ed5-4197-bc8a-addab24feb26" xlink:to="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_e977bb35-0ff9-4f12-abfe-97df7ddc1469" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_ade2939a-72ae-4f46-89d3-84e84e4acb71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_4eb5f8d3-6ed5-4197-bc8a-addab24feb26" xlink:to="loc_us-gaap_RetainedEarningsMember_ade2939a-72ae-4f46-89d3-84e84e4acb71" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_90d7f79b-ab51-44df-bc35-56c845463eaf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_4eb5f8d3-6ed5-4197-bc8a-addab24feb26" xlink:to="loc_us-gaap_TreasuryStockMember_90d7f79b-ab51-44df-bc35-56c845463eaf" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_78a32b2f-55e6-4bfa-bb6c-2709a5d54087" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_08ba8e9f-f51c-4e2e-9bd8-071da32e7707" xlink:to="loc_us-gaap_NoncontrollingInterestMember_78a32b2f-55e6-4bfa-bb6c-2709a5d54087" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_91aeb924-7171-4fd2-8e5c-eef48bda0c86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_cdce430d-b937-4898-aac6-8925f2c0e2f4" xlink:to="loc_us-gaap_StatementClassOfStockAxis_91aeb924-7171-4fd2-8e5c-eef48bda0c86" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_91aeb924-7171-4fd2-8e5c-eef48bda0c86_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_91aeb924-7171-4fd2-8e5c-eef48bda0c86" xlink:to="loc_us-gaap_ClassOfStockDomain_91aeb924-7171-4fd2-8e5c-eef48bda0c86_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_ab617d9a-c62a-4b6b-af84-e08416697cae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_91aeb924-7171-4fd2-8e5c-eef48bda0c86" xlink:to="loc_us-gaap_ClassOfStockDomain_ab617d9a-c62a-4b6b-af84-e08416697cae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_835be012-aa63-47c1-9c9d-07f40f58a44a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_ab617d9a-c62a-4b6b-af84-e08416697cae" xlink:to="loc_us-gaap_CommonClassAMember_835be012-aa63-47c1-9c9d-07f40f58a44a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_c7d18e15-036a-42f8-b8e8-936ca1ab7a79" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_cdce430d-b937-4898-aac6-8925f2c0e2f4" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_c7d18e15-036a-42f8-b8e8-936ca1ab7a79" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_c7d18e15-036a-42f8-b8e8-936ca1ab7a79_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_c7d18e15-036a-42f8-b8e8-936ca1ab7a79" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_c7d18e15-036a-42f8-b8e8-936ca1ab7a79_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_2e4a1025-7fff-4f77-9d18-75e944ee0792" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_c7d18e15-036a-42f8-b8e8-936ca1ab7a79" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_2e4a1025-7fff-4f77-9d18-75e944ee0792" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_61affc29-25b9-4093-8410-f24429c38574" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_2e4a1025-7fff-4f77-9d18-75e944ee0792" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_61affc29-25b9-4093-8410-f24429c38574" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails" xlink:type="simple" xlink:href="evh-20210630.xsd#BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails" xlink:type="extended" id="iaf72ac59f81249bca8cc04469f4b1511_BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_2881e5d4-78b3-42a0-b40d-8f6413cd7913" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_f0698c7b-ebb8-4b9e-baf9-8acb26fd6d68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_2881e5d4-78b3-42a0-b40d-8f6413cd7913" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_f0698c7b-ebb8-4b9e-baf9-8acb26fd6d68" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_f8847aba-8209-4886-9b02-6f0f6b03b799" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_2881e5d4-78b3-42a0-b40d-8f6413cd7913" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_f8847aba-8209-4886-9b02-6f0f6b03b799" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndInvestmentsCurrent_81c7f1a0-52c0-419b-8c7d-a76ad3e7c562" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndInvestmentsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_2881e5d4-78b3-42a0-b40d-8f6413cd7913" xlink:to="loc_us-gaap_RestrictedCashAndInvestmentsCurrent_81c7f1a0-52c0-419b-8c7d-a76ad3e7c562" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_207a66b5-d82f-4efd-a0ef-114292dc53a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_2881e5d4-78b3-42a0-b40d-8f6413cd7913" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_207a66b5-d82f-4efd-a0ef-114292dc53a8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndInvestmentsNoncurrent_f69c0a60-9363-4d59-9e39-4fb593132ae0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndInvestmentsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_2881e5d4-78b3-42a0-b40d-8f6413cd7913" xlink:to="loc_us-gaap_RestrictedCashAndInvestmentsNoncurrent_f69c0a60-9363-4d59-9e39-4fb593132ae0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_8a1a074a-e312-415f-875e-462d66b693f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_2881e5d4-78b3-42a0-b40d-8f6413cd7913" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_8a1a074a-e312-415f-875e-462d66b693f0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_586fc64c-31bb-47c8-bf26-4de76426b0c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedInvestments_f69458eb-e715-43a2-a693-8f0d1fdcf659" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_2881e5d4-78b3-42a0-b40d-8f6413cd7913" xlink:to="loc_us-gaap_RestrictedInvestments_f69458eb-e715-43a2-a693-8f0d1fdcf659" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_68a1b6f5-7339-4c6f-8702-2d6392ff5edf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_2881e5d4-78b3-42a0-b40d-8f6413cd7913" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_68a1b6f5-7339-4c6f-8702-2d6392ff5edf" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DisposalGroupIncludingDiscontinuedOperationRestrictedInvestmentsNoncurrent_4aff4896-5eca-4218-8d04-4c7967c61109" xlink:href="evh-20210630.xsd#evh_DisposalGroupIncludingDiscontinuedOperationRestrictedInvestmentsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_2881e5d4-78b3-42a0-b40d-8f6413cd7913" xlink:to="loc_evh_DisposalGroupIncludingDiscontinuedOperationRestrictedInvestmentsNoncurrent_4aff4896-5eca-4218-8d04-4c7967c61109" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DisposalGroupIncludingDiscontinuedOperationRestrictedCashCurrent_34ab9770-67a7-4ebe-b930-acb5b4e73ba3" xlink:href="evh-20210630.xsd#evh_DisposalGroupIncludingDiscontinuedOperationRestrictedCashCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_2881e5d4-78b3-42a0-b40d-8f6413cd7913" xlink:to="loc_evh_DisposalGroupIncludingDiscontinuedOperationRestrictedCashCurrent_34ab9770-67a7-4ebe-b930-acb5b4e73ba3" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_3130c10c-5747-4fe5-a1d6-8b9cd349a301" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_2881e5d4-78b3-42a0-b40d-8f6413cd7913" xlink:to="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_3130c10c-5747-4fe5-a1d6-8b9cd349a301" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_cc978593-0b4e-4700-a016-9b63f598d087" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_3130c10c-5747-4fe5-a1d6-8b9cd349a301" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_cc978593-0b4e-4700-a016-9b63f598d087" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_cc978593-0b4e-4700-a016-9b63f598d087_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_cc978593-0b4e-4700-a016-9b63f598d087" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_cc978593-0b4e-4700-a016-9b63f598d087_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_020e50d7-9203-4427-844a-48950d67a48a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_cc978593-0b4e-4700-a016-9b63f598d087" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_020e50d7-9203-4427-844a-48950d67a48a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RestrictedCashforLettersofCreditforFacilityLeasesMember_8ffe6698-af8b-4aab-97a3-fc585e56a5d6" xlink:href="evh-20210630.xsd#evh_RestrictedCashforLettersofCreditforFacilityLeasesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_020e50d7-9203-4427-844a-48950d67a48a" xlink:to="loc_evh_RestrictedCashforLettersofCreditforFacilityLeasesMember_8ffe6698-af8b-4aab-97a3-fc585e56a5d6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CollateralwithFinancialInstitutionsMember_c127856e-11ed-4f79-978a-5ddb48b19665" xlink:href="evh-20210630.xsd#evh_CollateralwithFinancialInstitutionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_020e50d7-9203-4427-844a-48950d67a48a" xlink:to="loc_evh_CollateralwithFinancialInstitutionsMember_c127856e-11ed-4f79-978a-5ddb48b19665" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RestrictedCashforBenefitManagementServicesMember_d2dc0417-2898-4614-a88b-746bc3756cf6" xlink:href="evh-20210630.xsd#evh_RestrictedCashforBenefitManagementServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_020e50d7-9203-4427-844a-48950d67a48a" xlink:to="loc_evh_RestrictedCashforBenefitManagementServicesMember_d2dc0417-2898-4614-a88b-746bc3756cf6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RestrictedCashforOtherContractualCommitmentsMember_d7c0e1d4-7941-4946-857c-fe36e9df13bd" xlink:href="evh-20210630.xsd#evh_RestrictedCashforOtherContractualCommitmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_020e50d7-9203-4427-844a-48950d67a48a" xlink:to="loc_evh_RestrictedCashforOtherContractualCommitmentsMember_d7c0e1d4-7941-4946-857c-fe36e9df13bd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BankTimeDepositsMember_c08ab802-f5da-4814-9322-741dca66c130" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BankTimeDepositsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_020e50d7-9203-4427-844a-48950d67a48a" xlink:to="loc_us-gaap_BankTimeDepositsMember_c08ab802-f5da-4814-9322-741dca66c130" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_604f0218-0cb9-415e-b01d-7e728b0f70b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_3130c10c-5747-4fe5-a1d6-8b9cd349a301" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_604f0218-0cb9-415e-b01d-7e728b0f70b7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_604f0218-0cb9-415e-b01d-7e728b0f70b7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_604f0218-0cb9-415e-b01d-7e728b0f70b7" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_604f0218-0cb9-415e-b01d-7e728b0f70b7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_1d3f1e94-84d2-49ce-ad08-b5e5e60dec3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_604f0218-0cb9-415e-b01d-7e728b0f70b7" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_1d3f1e94-84d2-49ce-ad08-b5e5e60dec3c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_614d40e9-48a5-4b6a-9c2c-c326c9bb56ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationsDisposedOfBySaleMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_1d3f1e94-84d2-49ce-ad08-b5e5e60dec3c" xlink:to="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_614d40e9-48a5-4b6a-9c2c-c326c9bb56ae" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_cbf6eba8-96a8-401e-b1e2-15b86cb8da43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_3130c10c-5747-4fe5-a1d6-8b9cd349a301" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_cbf6eba8-96a8-401e-b1e2-15b86cb8da43" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_cbf6eba8-96a8-401e-b1e2-15b86cb8da43_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_cbf6eba8-96a8-401e-b1e2-15b86cb8da43" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_cbf6eba8-96a8-401e-b1e2-15b86cb8da43_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_76a4c54b-0ef0-4113-9338-e8c6053c7e1a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_cbf6eba8-96a8-401e-b1e2-15b86cb8da43" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_76a4c54b-0ef0-4113-9338-e8c6053c7e1a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TrueHealthMember_dbe75323-32d0-447b-a0fc-b1f7bddb5ad3" xlink:href="evh-20210630.xsd#evh_TrueHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_76a4c54b-0ef0-4113-9338-e8c6053c7e1a" xlink:to="loc_evh_TrueHealthMember_dbe75323-32d0-447b-a0fc-b1f7bddb5ad3" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails" xlink:type="simple" xlink:href="evh-20210630.xsd#BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails" xlink:type="extended" id="i91e45984f4ff4efd83deb0fa8d03eb76_BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_b4d0c693-51b0-4e62-bd59-afe5ef3d8ce8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_9477e686-bae4-41bc-8037-5148cebfd28f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_b4d0c693-51b0-4e62-bd59-afe5ef3d8ce8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_9477e686-bae4-41bc-8037-5148cebfd28f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_a4e68358-19a8-4365-91ff-3fe5f2de05bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_b4d0c693-51b0-4e62-bd59-afe5ef3d8ce8" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_a4e68358-19a8-4365-91ff-3fe5f2de05bf" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a80d5f52-63b8-41be-9556-c6bff0ea46d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_a4e68358-19a8-4365-91ff-3fe5f2de05bf" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a80d5f52-63b8-41be-9556-c6bff0ea46d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a80d5f52-63b8-41be-9556-c6bff0ea46d6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a80d5f52-63b8-41be-9556-c6bff0ea46d6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a80d5f52-63b8-41be-9556-c6bff0ea46d6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9c1b122a-6427-4d33-9fb0-f79734a4f9db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a80d5f52-63b8-41be-9556-c6bff0ea46d6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9c1b122a-6427-4d33-9fb0-f79734a4f9db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_30e6abfc-f30d-434a-9f5f-21b853ce704c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradeNamesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9c1b122a-6427-4d33-9fb0-f79734a4f9db" xlink:to="loc_us-gaap_TradeNamesMember_30e6abfc-f30d-434a-9f5f-21b853ce704c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_9a63c1b6-277f-45b8-9c7f-9039cde383d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9c1b122a-6427-4d33-9fb0-f79734a4f9db" xlink:to="loc_us-gaap_CustomerRelationshipsMember_9a63c1b6-277f-45b8-9c7f-9039cde383d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_55f06b35-982b-401c-a531-506999a2b44d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9c1b122a-6427-4d33-9fb0-f79734a4f9db" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_55f06b35-982b-401c-a531-506999a2b44d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractBasedIntangibleAssetsMember_a64c121f-4b45-43d6-a391-1764e52d9ca8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractBasedIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9c1b122a-6427-4d33-9fb0-f79734a4f9db" xlink:to="loc_us-gaap_ContractBasedIntangibleAssetsMember_a64c121f-4b45-43d6-a391-1764e52d9ca8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_a53c28a9-f242-459d-97b9-bf6f3406a576" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_a4e68358-19a8-4365-91ff-3fe5f2de05bf" xlink:to="loc_srt_RangeAxis_a53c28a9-f242-459d-97b9-bf6f3406a576" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a53c28a9-f242-459d-97b9-bf6f3406a576_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_a53c28a9-f242-459d-97b9-bf6f3406a576" xlink:to="loc_srt_RangeMember_a53c28a9-f242-459d-97b9-bf6f3406a576_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0dc4351e-5b81-4169-8e61-d0cf73807179" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_a53c28a9-f242-459d-97b9-bf6f3406a576" xlink:to="loc_srt_RangeMember_0dc4351e-5b81-4169-8e61-d0cf73807179" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_1b1f1425-1cc3-4e6c-9e39-06524f398561" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_0dc4351e-5b81-4169-8e61-d0cf73807179" xlink:to="loc_srt_MinimumMember_1b1f1425-1cc3-4e6c-9e39-06524f398561" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_d4e48355-dd69-4e1a-bc9c-9e317c12da04" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_0dc4351e-5b81-4169-8e61-d0cf73807179" xlink:to="loc_srt_MaximumMember_d4e48355-dd69-4e1a-bc9c-9e317c12da04" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails" xlink:type="simple" xlink:href="evh-20210630.xsd#RecentlyIssuedAccountingStandardsDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails" xlink:type="extended" id="i9d46578a614049f9a775b4674f68c6a5_RecentlyIssuedAccountingStandardsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_ddcebe05-6eba-4b5c-ab5c-c01a6f5a636d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_45e3f42c-b9de-41d2-ae0b-5b6ba46f18e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_ddcebe05-6eba-4b5c-ab5c-c01a6f5a636d" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_45e3f42c-b9de-41d2-ae0b-5b6ba46f18e4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList_1b047083-2b19-4f32-9bf8-bd54ec93980e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_ddcebe05-6eba-4b5c-ab5c-c01a6f5a636d" xlink:to="loc_us-gaap_AccountingStandardsUpdateExtensibleList_1b047083-2b19-4f32-9bf8-bd54ec93980e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_b43adf2a-9ffc-4af1-a48b-14e35e6371d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_ddcebe05-6eba-4b5c-ab5c-c01a6f5a636d" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_b43adf2a-9ffc-4af1-a48b-14e35e6371d0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_31e94201-1f4c-4ab1-b17f-52fac8409ed5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_b43adf2a-9ffc-4af1-a48b-14e35e6371d0" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_31e94201-1f4c-4ab1-b17f-52fac8409ed5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_31e94201-1f4c-4ab1-b17f-52fac8409ed5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_31e94201-1f4c-4ab1-b17f-52fac8409ed5" xlink:to="loc_us-gaap_EquityComponentDomain_31e94201-1f4c-4ab1-b17f-52fac8409ed5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_1dd869d2-f3b4-4ed9-b8ce-cf4e9a8f9f91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_31e94201-1f4c-4ab1-b17f-52fac8409ed5" xlink:to="loc_us-gaap_EquityComponentDomain_1dd869d2-f3b4-4ed9-b8ce-cf4e9a8f9f91" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_ca885c12-70e9-4bc7-80e1-af91cc092c4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1dd869d2-f3b4-4ed9-b8ce-cf4e9a8f9f91" xlink:to="loc_us-gaap_RetainedEarningsMember_ca885c12-70e9-4bc7-80e1-af91cc092c4a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_af04b3c8-5025-440c-95fa-61e26ede4ad7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_b43adf2a-9ffc-4af1-a48b-14e35e6371d0" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_af04b3c8-5025-440c-95fa-61e26ede4ad7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_af04b3c8-5025-440c-95fa-61e26ede4ad7_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_af04b3c8-5025-440c-95fa-61e26ede4ad7" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_af04b3c8-5025-440c-95fa-61e26ede4ad7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_b9bf7aa9-e6af-49be-b751-b2846602365f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_af04b3c8-5025-440c-95fa-61e26ede4ad7" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_b9bf7aa9-e6af-49be-b751-b2846602365f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_b2b42b88-71cb-4718-92b9-6b4964c3ccb3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_b9bf7aa9-e6af-49be-b751-b2846602365f" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_b2b42b88-71cb-4718-92b9-6b4964c3ccb3" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/TransactionsPassportDetails" xlink:type="simple" xlink:href="evh-20210630.xsd#TransactionsPassportDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/TransactionsPassportDetails" xlink:type="extended" id="i8d85b4ff20e3475ca70b77ca27c07689_TransactionsPassportDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_12f8e93a-d473-44ef-9397-2079bdc72ee6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_fd2703f2-0c58-417f-9dbc-947a6076c5d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_12f8e93a-d473-44ef-9397-2079bdc72ee6" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_fd2703f2-0c58-417f-9dbc-947a6076c5d2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityOwnershipPercentage_e97e7797-3abc-482f-a36f-8dca7cad338a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_12f8e93a-d473-44ef-9397-2079bdc72ee6" xlink:to="loc_us-gaap_VariableInterestEntityOwnershipPercentage_e97e7797-3abc-482f-a36f-8dca7cad338a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableNet_4878db3b-2f6c-43ae-9cae-135fb5838553" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesReceivableNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_12f8e93a-d473-44ef-9397-2079bdc72ee6" xlink:to="loc_us-gaap_NotesReceivableNet_4878db3b-2f6c-43ae-9cae-135fb5838553" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_7bfcb359-af5f-44a4-8cf4-4beed6501f2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_12f8e93a-d473-44ef-9397-2079bdc72ee6" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_7bfcb359-af5f-44a4-8cf4-4beed6501f2e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityFinancialOrOtherSupportAmount_2ac78e7e-efee-42a6-8587-fea975787f44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityFinancialOrOtherSupportAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_12f8e93a-d473-44ef-9397-2079bdc72ee6" xlink:to="loc_us-gaap_VariableInterestEntityFinancialOrOtherSupportAmount_2ac78e7e-efee-42a6-8587-fea975787f44" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PaymentsToAcquireEquityMethodInvestmentsAmountHeldBack_1478306d-8783-4f67-a6c4-a89d4735217b" xlink:href="evh-20210630.xsd#evh_PaymentsToAcquireEquityMethodInvestmentsAmountHeldBack"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_12f8e93a-d473-44ef-9397-2079bdc72ee6" xlink:to="loc_evh_PaymentsToAcquireEquityMethodInvestmentsAmountHeldBack_1478306d-8783-4f67-a6c4-a89d4735217b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_AssetPurchaseAgreementEscrowPayments_66ffea8d-76b9-4677-9d78-faa1a914751e" xlink:href="evh-20210630.xsd#evh_AssetPurchaseAgreementEscrowPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_12f8e93a-d473-44ef-9397-2079bdc72ee6" xlink:to="loc_evh_AssetPurchaseAgreementEscrowPayments_66ffea8d-76b9-4677-9d78-faa1a914751e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CashReleasedFromEscrow_81a399ba-54b1-41d7-b79b-30dc173a95d7" xlink:href="evh-20210630.xsd#evh_CashReleasedFromEscrow"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_12f8e93a-d473-44ef-9397-2079bdc72ee6" xlink:to="loc_evh_CashReleasedFromEscrow_81a399ba-54b1-41d7-b79b-30dc173a95d7" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders_152950e0-d23f-48bc-8b75-cc40f858ef44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToMinorityShareholders"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_12f8e93a-d473-44ef-9397-2079bdc72ee6" xlink:to="loc_us-gaap_PaymentsToMinorityShareholders_152950e0-d23f-48bc-8b75-cc40f858ef44" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_AssetAcquisitionCashAndEquivalents_a22f60c0-7056-4a69-875a-1371a4750694" xlink:href="evh-20210630.xsd#evh_AssetAcquisitionCashAndEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_12f8e93a-d473-44ef-9397-2079bdc72ee6" xlink:to="loc_evh_AssetAcquisitionCashAndEquivalents_a22f60c0-7056-4a69-875a-1371a4750694" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_AssetAcquisitionDebtSecuritiesAvailableForSale_47847ac9-1337-4c51-ab6d-ccd4599b32ca" xlink:href="evh-20210630.xsd#evh_AssetAcquisitionDebtSecuritiesAvailableForSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_12f8e93a-d473-44ef-9397-2079bdc72ee6" xlink:to="loc_evh_AssetAcquisitionDebtSecuritiesAvailableForSale_47847ac9-1337-4c51-ab6d-ccd4599b32ca" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_AssetAcquisitionDebtSecuritiesAvailableForSaleUnsettledSalesReceivables_09649940-4132-453c-9338-f6dccf30efb2" xlink:href="evh-20210630.xsd#evh_AssetAcquisitionDebtSecuritiesAvailableForSaleUnsettledSalesReceivables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_12f8e93a-d473-44ef-9397-2079bdc72ee6" xlink:to="loc_evh_AssetAcquisitionDebtSecuritiesAvailableForSaleUnsettledSalesReceivables_09649940-4132-453c-9338-f6dccf30efb2" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_AssetAcquisitionOtherAssets_1d7b4b40-3dbd-4a4f-a3f9-e2bdd259ab8d" xlink:href="evh-20210630.xsd#evh_AssetAcquisitionOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_12f8e93a-d473-44ef-9397-2079bdc72ee6" xlink:to="loc_evh_AssetAcquisitionOtherAssets_1d7b4b40-3dbd-4a4f-a3f9-e2bdd259ab8d" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_AssetAcquisitionAccruedMedicalExpenses_cc816a4f-3a52-4df6-9d98-fb0697685dfd" xlink:href="evh-20210630.xsd#evh_AssetAcquisitionAccruedMedicalExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_12f8e93a-d473-44ef-9397-2079bdc72ee6" xlink:to="loc_evh_AssetAcquisitionAccruedMedicalExpenses_cc816a4f-3a52-4df6-9d98-fb0697685dfd" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_AssetAcquisitionAccruedLiabilities_0f691050-6474-4240-aac1-726f4c7c4c1f" xlink:href="evh-20210630.xsd#evh_AssetAcquisitionAccruedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_12f8e93a-d473-44ef-9397-2079bdc72ee6" xlink:to="loc_evh_AssetAcquisitionAccruedLiabilities_0f691050-6474-4240-aac1-726f4c7c4c1f" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCollectionOfNotesReceivable_3ea8eb9e-f29c-42b9-9098-5e76b341fad4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromCollectionOfNotesReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_12f8e93a-d473-44ef-9397-2079bdc72ee6" xlink:to="loc_us-gaap_ProceedsFromCollectionOfNotesReceivable_3ea8eb9e-f29c-42b9-9098-5e76b341fad4" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromInterestReceived_481ef9fb-8dc2-4deb-b934-b465b22cb4ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromInterestReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_12f8e93a-d473-44ef-9397-2079bdc72ee6" xlink:to="loc_us-gaap_ProceedsFromInterestReceived_481ef9fb-8dc2-4deb-b934-b465b22cb4ce" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ProceedsFromTransferOfMembership_0f69ea83-f213-4b82-88cd-674f80f35b61" xlink:href="evh-20210630.xsd#evh_ProceedsFromTransferOfMembership"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_12f8e93a-d473-44ef-9397-2079bdc72ee6" xlink:to="loc_evh_ProceedsFromTransferOfMembership_0f69ea83-f213-4b82-88cd-674f80f35b61" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TransferOfMembershipPercentageOfPaymentBasedOnNumberOfEnrollees_3db586c3-a00f-47b0-a47a-b42b37c8b332" xlink:href="evh-20210630.xsd#evh_TransferOfMembershipPercentageOfPaymentBasedOnNumberOfEnrollees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_12f8e93a-d473-44ef-9397-2079bdc72ee6" xlink:to="loc_evh_TransferOfMembershipPercentageOfPaymentBasedOnNumberOfEnrollees_3db586c3-a00f-47b0-a47a-b42b37c8b332" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TransferOfMembershipPercentageOfPaymentSubjectToSatisfactionOfContingencies_7617a509-7aea-4974-a66f-a9e722782797" xlink:href="evh-20210630.xsd#evh_TransferOfMembershipPercentageOfPaymentSubjectToSatisfactionOfContingencies"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_12f8e93a-d473-44ef-9397-2079bdc72ee6" xlink:to="loc_evh_TransferOfMembershipPercentageOfPaymentSubjectToSatisfactionOfContingencies_7617a509-7aea-4974-a66f-a9e722782797" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_66991f93-11fb-4eb5-b5f6-55366abeebf3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_12f8e93a-d473-44ef-9397-2079bdc72ee6" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_66991f93-11fb-4eb5-b5f6-55366abeebf3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_832620fd-aea6-478e-9286-7e3fe2c8e9fe" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_66991f93-11fb-4eb5-b5f6-55366abeebf3" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_832620fd-aea6-478e-9286-7e3fe2c8e9fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_832620fd-aea6-478e-9286-7e3fe2c8e9fe_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_832620fd-aea6-478e-9286-7e3fe2c8e9fe" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_832620fd-aea6-478e-9286-7e3fe2c8e9fe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_e48ec67d-a5a8-4726-9070-9696822e3f4e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_832620fd-aea6-478e-9286-7e3fe2c8e9fe" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_e48ec67d-a5a8-4726-9070-9696822e3f4e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_UniversityHealthCaredbaPassportHealthPlanMember_e7c9d76c-2536-471d-9876-f4c3f51b4c2f" xlink:href="evh-20210630.xsd#evh_UniversityHealthCaredbaPassportHealthPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_e48ec67d-a5a8-4726-9070-9696822e3f4e" xlink:to="loc_evh_UniversityHealthCaredbaPassportHealthPlanMember_e7c9d76c-2536-471d-9876-f4c3f51b4c2f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_9814f7fa-f906-45e4-9a7a-eb90997af8d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_66991f93-11fb-4eb5-b5f6-55366abeebf3" xlink:to="loc_us-gaap_DebtInstrumentAxis_9814f7fa-f906-45e4-9a7a-eb90997af8d1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_9814f7fa-f906-45e4-9a7a-eb90997af8d1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_9814f7fa-f906-45e4-9a7a-eb90997af8d1" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_9814f7fa-f906-45e4-9a7a-eb90997af8d1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_0c648c6c-ad71-48f2-912f-838cfad9f942" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_9814f7fa-f906-45e4-9a7a-eb90997af8d1" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_0c648c6c-ad71-48f2-912f-838cfad9f942" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PassportNoteMember_fe536101-0060-47ab-80dd-1f77c6ca7d7e" xlink:href="evh-20210630.xsd#evh_PassportNoteMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0c648c6c-ad71-48f2-912f-838cfad9f942" xlink:to="loc_evh_PassportNoteMember_fe536101-0060-47ab-80dd-1f77c6ca7d7e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_994ef6f7-44d7-49d4-a6ca-029fb20495e1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_66991f93-11fb-4eb5-b5f6-55366abeebf3" xlink:to="loc_srt_CounterpartyNameAxis_994ef6f7-44d7-49d4-a6ca-029fb20495e1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_994ef6f7-44d7-49d4-a6ca-029fb20495e1_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_994ef6f7-44d7-49d4-a6ca-029fb20495e1" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_994ef6f7-44d7-49d4-a6ca-029fb20495e1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e164b0ad-fa02-4299-b964-57b15a643877" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_994ef6f7-44d7-49d4-a6ca-029fb20495e1" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e164b0ad-fa02-4299-b964-57b15a643877" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_MolinaHealthcareIncMember_e5753087-300e-4951-98da-d08aca36a2d8" xlink:href="evh-20210630.xsd#evh_MolinaHealthcareIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e164b0ad-fa02-4299-b964-57b15a643877" xlink:to="loc_evh_MolinaHealthcareIncMember_e5753087-300e-4951-98da-d08aca36a2d8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_db1d3bc1-c9fc-47ba-9335-c3de77b712d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_66991f93-11fb-4eb5-b5f6-55366abeebf3" xlink:to="loc_us-gaap_AssetAcquisitionAxis_db1d3bc1-c9fc-47ba-9335-c3de77b712d2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_db1d3bc1-c9fc-47ba-9335-c3de77b712d2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AssetAcquisitionAxis_db1d3bc1-c9fc-47ba-9335-c3de77b712d2" xlink:to="loc_us-gaap_AssetAcquisitionDomain_db1d3bc1-c9fc-47ba-9335-c3de77b712d2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_b90d83db-348b-496f-b4a3-90d48820f0cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AssetAcquisitionAxis_db1d3bc1-c9fc-47ba-9335-c3de77b712d2" xlink:to="loc_us-gaap_AssetAcquisitionDomain_b90d83db-348b-496f-b4a3-90d48820f0cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PassportAssetAcquisitionMember_a9df2390-9a62-40b6-82a6-e776a12deabd" xlink:href="evh-20210630.xsd#evh_PassportAssetAcquisitionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_b90d83db-348b-496f-b4a3-90d48820f0cd" xlink:to="loc_evh_PassportAssetAcquisitionMember_a9df2390-9a62-40b6-82a6-e776a12deabd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_847c2f67-00b5-4574-adfa-30f05704e181" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_66991f93-11fb-4eb5-b5f6-55366abeebf3" xlink:to="loc_srt_ConsolidatedEntitiesAxis_847c2f67-00b5-4574-adfa-30f05704e181" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_847c2f67-00b5-4574-adfa-30f05704e181_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_847c2f67-00b5-4574-adfa-30f05704e181" xlink:to="loc_srt_ConsolidatedEntitiesDomain_847c2f67-00b5-4574-adfa-30f05704e181_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_1b967bb6-7299-4cb4-b0fa-444690602651" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_847c2f67-00b5-4574-adfa-30f05704e181" xlink:to="loc_srt_ConsolidatedEntitiesDomain_1b967bb6-7299-4cb4-b0fa-444690602651" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_b0f2d681-dd66-40a7-9708-3205d1d914df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_1b967bb6-7299-4cb4-b0fa-444690602651" xlink:to="loc_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_b0f2d681-dd66-40a7-9708-3205d1d914df" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_48ff7240-3301-4fcb-bb96-cf2b960760ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_66991f93-11fb-4eb5-b5f6-55366abeebf3" xlink:to="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_48ff7240-3301-4fcb-bb96-cf2b960760ba" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_48ff7240-3301-4fcb-bb96-cf2b960760ba_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_48ff7240-3301-4fcb-bb96-cf2b960760ba" xlink:to="loc_us-gaap_ReceivableTypeDomain_48ff7240-3301-4fcb-bb96-cf2b960760ba_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_cbb51895-6f2d-4dd8-8d01-59002a5166f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_48ff7240-3301-4fcb-bb96-cf2b960760ba" xlink:to="loc_us-gaap_ReceivableTypeDomain_cbb51895-6f2d-4dd8-8d01-59002a5166f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableMember_970e9f46-0759-4bc7-958e-3ccca4a09a7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReceivableTypeDomain_cbb51895-6f2d-4dd8-8d01-59002a5166f0" xlink:to="loc_us-gaap_NotesReceivableMember_970e9f46-0759-4bc7-958e-3ccca4a09a7f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails" xlink:type="simple" xlink:href="evh-20210630.xsd#DiscontinuedOperationsSummaryofResultsofOperationsDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails" xlink:type="extended" id="i5c6b749c7974482cadbe93bb324a6bcb_DiscontinuedOperationsSummaryofResultsofOperationsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_87ee90e3-9456-4c0b-ac63-beb96c48e0e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_2f58d3e2-696b-4884-b569-c0b84a867ae2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_87ee90e3-9456-4c0b-ac63-beb96c48e0e1" xlink:to="loc_us-gaap_RevenuesAbstract_2f58d3e2-696b-4884-b569-c0b84a867ae2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_a27d003a-fabb-4fc4-b967-56dc23d9e6e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_2f58d3e2-696b-4884-b569-c0b84a867ae2" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_a27d003a-fabb-4fc4-b967-56dc23d9e6e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_63a22bb8-d585-43c8-8a94-3eb7002d9940" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_87ee90e3-9456-4c0b-ac63-beb96c48e0e1" xlink:to="loc_us-gaap_OperatingExpensesAbstract_63a22bb8-d585-43c8-8a94-3eb7002d9940" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_c2ac2377-4099-4634-9975-528e721aa19f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_63a22bb8-d585-43c8-8a94-3eb7002d9940" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_c2ac2377-4099-4634-9975-528e721aa19f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DisposalGroupIncludingDiscontinuedOperationClaimsExpense_f4d1d68f-4ac0-41bd-ba4a-3bffb1e59971" xlink:href="evh-20210630.xsd#evh_DisposalGroupIncludingDiscontinuedOperationClaimsExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_63a22bb8-d585-43c8-8a94-3eb7002d9940" xlink:to="loc_evh_DisposalGroupIncludingDiscontinuedOperationClaimsExpense_f4d1d68f-4ac0-41bd-ba4a-3bffb1e59971" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_5ff00bea-a3a9-439c-90aa-49e093c4cbed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_63a22bb8-d585-43c8-8a94-3eb7002d9940" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_5ff00bea-a3a9-439c-90aa-49e093c4cbed" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortizationDiscontinuedOperations_4fada917-a1c4-4f19-a84e-13df407096d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortizationDiscontinuedOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_63a22bb8-d585-43c8-8a94-3eb7002d9940" xlink:to="loc_us-gaap_DepreciationAndAmortizationDiscontinuedOperations_4fada917-a1c4-4f19-a84e-13df407096d6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_0396dfe6-60d6-4935-a8d5-3f561a859d5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_63a22bb8-d585-43c8-8a94-3eb7002d9940" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_0396dfe6-60d6-4935-a8d5-3f561a859d5d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_b022aa12-525c-40a3-94ed-c07b07f01c31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_87ee90e3-9456-4c0b-ac63-beb96c48e0e1" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_b022aa12-525c-40a3-94ed-c07b07f01c31" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome_a9175905-41d8-4ce1-a33d-d6fc3dfcba21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_87ee90e3-9456-4c0b-ac63-beb96c48e0e1" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome_a9175905-41d8-4ce1-a33d-d6fc3dfcba21" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense_3871c86a-3b32-4d11-835e-037915bb01c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_87ee90e3-9456-4c0b-ac63-beb96c48e0e1" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense_3871c86a-3b32-4d11-835e-037915bb01c5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_0c94bc2b-0f1e-4be9-bf16-6ea254a4fcbd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_87ee90e3-9456-4c0b-ac63-beb96c48e0e1" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_0c94bc2b-0f1e-4be9-bf16-6ea254a4fcbd" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_fc286c60-eba2-4abd-a95c-978b0d560aa8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_87ee90e3-9456-4c0b-ac63-beb96c48e0e1" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_fc286c60-eba2-4abd-a95c-978b0d560aa8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_b9dc8bb5-135c-44b1-9f3b-1c5291b7a71d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_87ee90e3-9456-4c0b-ac63-beb96c48e0e1" xlink:to="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_b9dc8bb5-135c-44b1-9f3b-1c5291b7a71d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_ef94f3eb-cec3-4db3-9031-e6af1003ea5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_87ee90e3-9456-4c0b-ac63-beb96c48e0e1" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_ef94f3eb-cec3-4db3-9031-e6af1003ea5b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_6f783584-a66c-4778-90d5-451825f7be96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_87ee90e3-9456-4c0b-ac63-beb96c48e0e1" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_6f783584-a66c-4778-90d5-451825f7be96" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_d0310830-5424-47f8-98e6-339bb0ed7315" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_6f783584-a66c-4778-90d5-451825f7be96" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_d0310830-5424-47f8-98e6-339bb0ed7315" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_d0310830-5424-47f8-98e6-339bb0ed7315_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_d0310830-5424-47f8-98e6-339bb0ed7315" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_d0310830-5424-47f8-98e6-339bb0ed7315_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_af8b6710-2ca8-43bf-9e33-9886938d90ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_d0310830-5424-47f8-98e6-339bb0ed7315" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_af8b6710-2ca8-43bf-9e33-9886938d90ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_915f4c82-cb83-4cc8-b8b4-c6eea604be0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationsDisposedOfBySaleMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_af8b6710-2ca8-43bf-9e33-9886938d90ff" xlink:to="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_915f4c82-cb83-4cc8-b8b4-c6eea604be0d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_357e30ae-8e3b-479a-b935-71c40cab2fc8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_6f783584-a66c-4778-90d5-451825f7be96" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_357e30ae-8e3b-479a-b935-71c40cab2fc8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_357e30ae-8e3b-479a-b935-71c40cab2fc8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_357e30ae-8e3b-479a-b935-71c40cab2fc8" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_357e30ae-8e3b-479a-b935-71c40cab2fc8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_939f9ad1-0ba4-45db-acdd-5aeaafa6f014" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_357e30ae-8e3b-479a-b935-71c40cab2fc8" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_939f9ad1-0ba4-45db-acdd-5aeaafa6f014" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TrueHealthMember_901c08bf-ba8d-4164-a5f8-247f724f396f" xlink:href="evh-20210630.xsd#evh_TrueHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_939f9ad1-0ba4-45db-acdd-5aeaafa6f014" xlink:to="loc_evh_TrueHealthMember_901c08bf-ba8d-4164-a5f8-247f724f396f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_ccca5283-1150-4b6b-a50b-4afff334549f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_6f783584-a66c-4778-90d5-451825f7be96" xlink:to="loc_srt_ProductOrServiceAxis_ccca5283-1150-4b6b-a50b-4afff334549f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ccca5283-1150-4b6b-a50b-4afff334549f_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_ccca5283-1150-4b6b-a50b-4afff334549f" xlink:to="loc_srt_ProductsAndServicesDomain_ccca5283-1150-4b6b-a50b-4afff334549f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_9285167a-7a41-4485-8b3d-66c6bd1da5b4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_ccca5283-1150-4b6b-a50b-4afff334549f" xlink:to="loc_srt_ProductsAndServicesDomain_9285167a-7a41-4485-8b3d-66c6bd1da5b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PlatformsAndOperationsServicesMember_1e3d27a7-8a6b-4bfb-8336-82555b2f656a" xlink:href="evh-20210630.xsd#evh_PlatformsAndOperationsServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_9285167a-7a41-4485-8b3d-66c6bd1da5b4" xlink:to="loc_evh_PlatformsAndOperationsServicesMember_1e3d27a7-8a6b-4bfb-8336-82555b2f656a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PremiumsRevenueMember_5b399804-25d8-4d24-822e-3b336974646f" xlink:href="evh-20210630.xsd#evh_PremiumsRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_9285167a-7a41-4485-8b3d-66c6bd1da5b4" xlink:to="loc_evh_PremiumsRevenueMember_5b399804-25d8-4d24-822e-3b336974646f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ServicesAgreementsMember_77b5526b-fc0c-492e-91c0-bf07b353a417" xlink:href="evh-20210630.xsd#evh_ServicesAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_9285167a-7a41-4485-8b3d-66c6bd1da5b4" xlink:to="loc_evh_ServicesAgreementsMember_77b5526b-fc0c-492e-91c0-bf07b353a417" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCashFlowsDetails" xlink:type="simple" xlink:href="evh-20210630.xsd#DiscontinuedOperationsSummaryofCashFlowsDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCashFlowsDetails" xlink:type="extended" id="iebc559052fd44b0e84e8d2b6d45c7379_DiscontinuedOperationsSummaryofCashFlowsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d7a2c515-ef4f-44f2-9ebe-945c63ce9fac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_dc327d8e-4b29-4461-b145-be346c8dc490" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d7a2c515-ef4f-44f2-9ebe-945c63ce9fac" xlink:to="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_dc327d8e-4b29-4461-b145-be346c8dc490" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_e5604bb3-d44e-4da1-b00a-de137118775c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d7a2c515-ef4f-44f2-9ebe-945c63ce9fac" xlink:to="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_e5604bb3-d44e-4da1-b00a-de137118775c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_907373dd-10f6-496f-9bc6-7231ce942242" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d7a2c515-ef4f-44f2-9ebe-945c63ce9fac" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_907373dd-10f6-496f-9bc6-7231ce942242" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_9de480c4-b91b-42d9-ae39-423fde2b631f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_907373dd-10f6-496f-9bc6-7231ce942242" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_9de480c4-b91b-42d9-ae39-423fde2b631f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_9de480c4-b91b-42d9-ae39-423fde2b631f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_9de480c4-b91b-42d9-ae39-423fde2b631f" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_9de480c4-b91b-42d9-ae39-423fde2b631f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_5e921715-8777-4241-857c-788b8f2eaf8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_9de480c4-b91b-42d9-ae39-423fde2b631f" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_5e921715-8777-4241-857c-788b8f2eaf8e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TrueHealthMember_c4673a90-f2db-436d-85f0-b61176039cad" xlink:href="evh-20210630.xsd#evh_TrueHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_5e921715-8777-4241-857c-788b8f2eaf8e" xlink:to="loc_evh_TrueHealthMember_c4673a90-f2db-436d-85f0-b61176039cad" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_952eab09-df8e-48e0-b52a-b7c2f7c83173" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_907373dd-10f6-496f-9bc6-7231ce942242" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_952eab09-df8e-48e0-b52a-b7c2f7c83173" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_952eab09-df8e-48e0-b52a-b7c2f7c83173_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_952eab09-df8e-48e0-b52a-b7c2f7c83173" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_952eab09-df8e-48e0-b52a-b7c2f7c83173_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_4dcb5015-1e01-4633-a5ce-04597dbb26d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_952eab09-df8e-48e0-b52a-b7c2f7c83173" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_4dcb5015-1e01-4633-a5ce-04597dbb26d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_2f6506b0-a3e4-4148-ad0c-af05914f5ed8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationsDisposedOfBySaleMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_4dcb5015-1e01-4633-a5ce-04597dbb26d9" xlink:to="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_2f6506b0-a3e4-4148-ad0c-af05914f5ed8" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCurrentandLongtermAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="evh-20210630.xsd#DiscontinuedOperationsSummaryofCurrentandLongtermAssetsandLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCurrentandLongtermAssetsandLiabilitiesDetails" xlink:type="extended" id="ib4fa4c10a674413e84b4d097454f5029_DiscontinuedOperationsSummaryofCurrentandLongtermAssetsandLiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_7b135880-79b5-41ee-a7d9-4d047e3750a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_70c8accc-db5d-4b6c-8e97-d51ee144307a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_7b135880-79b5-41ee-a7d9-4d047e3750a0" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_70c8accc-db5d-4b6c-8e97-d51ee144307a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_8a97c285-2d16-4faf-b4c3-fec8cb620b67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_70c8accc-db5d-4b6c-8e97-d51ee144307a" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_8a97c285-2d16-4faf-b4c3-fec8cb620b67" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_5c93ac60-4202-4128-b284-4be34829d7a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_8a97c285-2d16-4faf-b4c3-fec8cb620b67" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_5c93ac60-4202-4128-b284-4be34829d7a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DisposalGroupIncludingDiscontinuedOperationRestrictedCashAndRestrictedInvestmentsCurrent_eb54504d-f379-4ba9-87cf-c75f9d174642" xlink:href="evh-20210630.xsd#evh_DisposalGroupIncludingDiscontinuedOperationRestrictedCashAndRestrictedInvestmentsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_8a97c285-2d16-4faf-b4c3-fec8cb620b67" xlink:to="loc_evh_DisposalGroupIncludingDiscontinuedOperationRestrictedCashAndRestrictedInvestmentsCurrent_eb54504d-f379-4ba9-87cf-c75f9d174642" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_3f8f2c7a-4f11-4381-9c5c-c20cd7313383" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_8a97c285-2d16-4faf-b4c3-fec8cb620b67" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_3f8f2c7a-4f11-4381-9c5c-c20cd7313383" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_3d04e3f5-a936-4c9b-b0ac-22cd94214086" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_8a97c285-2d16-4faf-b4c3-fec8cb620b67" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_3d04e3f5-a936-4c9b-b0ac-22cd94214086" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DisposalGroupIncludingDiscontinuedOperationInvestmentsCurrent_1cf07772-947c-43c4-916f-44bcfd68ec37" xlink:href="evh-20210630.xsd#evh_DisposalGroupIncludingDiscontinuedOperationInvestmentsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_8a97c285-2d16-4faf-b4c3-fec8cb620b67" xlink:to="loc_evh_DisposalGroupIncludingDiscontinuedOperationInvestmentsCurrent_1cf07772-947c-43c4-916f-44bcfd68ec37" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_385e8ce8-cb4c-4509-811e-e014c332f851" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_8a97c285-2d16-4faf-b4c3-fec8cb620b67" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_385e8ce8-cb4c-4509-811e-e014c332f851" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DisposalGroupIncludingDiscontinuedOperationRestrictedCashAndRestrictedInvestmentsNoncurrent_4619ed95-4efc-483d-9d0a-fc0206e6e790" xlink:href="evh-20210630.xsd#evh_DisposalGroupIncludingDiscontinuedOperationRestrictedCashAndRestrictedInvestmentsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_70c8accc-db5d-4b6c-8e97-d51ee144307a" xlink:to="loc_evh_DisposalGroupIncludingDiscontinuedOperationRestrictedCashAndRestrictedInvestmentsNoncurrent_4619ed95-4efc-483d-9d0a-fc0206e6e790" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DisposalGroupIncludingDiscontinuedOperationInvestmentsNoncurrent_25ad9ce6-f16d-4f42-a087-3e04e302bfeb" xlink:href="evh-20210630.xsd#evh_DisposalGroupIncludingDiscontinuedOperationInvestmentsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_70c8accc-db5d-4b6c-8e97-d51ee144307a" xlink:to="loc_evh_DisposalGroupIncludingDiscontinuedOperationInvestmentsNoncurrent_25ad9ce6-f16d-4f42-a087-3e04e302bfeb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsNoncurrent_35df2fb2-0fce-4327-adab-7bd7d7e5ecb9" xlink:href="evh-20210630.xsd#evh_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_70c8accc-db5d-4b6c-8e97-d51ee144307a" xlink:to="loc_evh_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsNoncurrent_35df2fb2-0fce-4327-adab-7bd7d7e5ecb9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent_0cd83d98-d869-449b-baf3-14d4256093a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_70c8accc-db5d-4b6c-8e97-d51ee144307a" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent_0cd83d98-d869-449b-baf3-14d4256093a6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent_33230615-3cdc-4150-859c-be5977b68a14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_70c8accc-db5d-4b6c-8e97-d51ee144307a" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent_33230615-3cdc-4150-859c-be5977b68a14" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_83ec77d4-8dae-4469-b544-3d35122a194d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_70c8accc-db5d-4b6c-8e97-d51ee144307a" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_83ec77d4-8dae-4469-b544-3d35122a194d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_39c56e18-8636-47d2-82bf-a0334da59ce1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_7b135880-79b5-41ee-a7d9-4d047e3750a0" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_39c56e18-8636-47d2-82bf-a0334da59ce1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_44541bff-2849-4981-af03-c2a73f5898b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_39c56e18-8636-47d2-82bf-a0334da59ce1" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_44541bff-2849-4981-af03-c2a73f5898b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent_da2422de-7140-4d2b-b1e5-706c138254a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_44541bff-2849-4981-af03-c2a73f5898b1" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent_da2422de-7140-4d2b-b1e5-706c138254a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent_9154f64b-0cd6-47b9-8977-32209d820105" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_44541bff-2849-4981-af03-c2a73f5898b1" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent_9154f64b-0cd6-47b9-8977-32209d820105" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DisposalGroupIncludingDiscontinuedOperationAccruedCompensationAndEmployeeBenefitsCurrent_f39b11bc-5f49-4c84-9b9a-7674b547b5b7" xlink:href="evh-20210630.xsd#evh_DisposalGroupIncludingDiscontinuedOperationAccruedCompensationAndEmployeeBenefitsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_44541bff-2849-4981-af03-c2a73f5898b1" xlink:to="loc_evh_DisposalGroupIncludingDiscontinuedOperationAccruedCompensationAndEmployeeBenefitsCurrent_f39b11bc-5f49-4c84-9b9a-7674b547b5b7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent_9a814165-ef34-4a31-a68b-b040f1a2d7cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_44541bff-2849-4981-af03-c2a73f5898b1" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent_9a814165-ef34-4a31-a68b-b040f1a2d7cc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DisposalGroupIncludingDiscontinuedOperationLiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangementsCurrent_4c2b080f-195b-485a-9df6-0be1a02cfb0c" xlink:href="evh-20210630.xsd#evh_DisposalGroupIncludingDiscontinuedOperationLiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangementsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_44541bff-2849-4981-af03-c2a73f5898b1" xlink:to="loc_evh_DisposalGroupIncludingDiscontinuedOperationLiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangementsCurrent_4c2b080f-195b-485a-9df6-0be1a02cfb0c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_dd0cf235-61ee-41df-9193-eda0fd22c079" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_44541bff-2849-4981-af03-c2a73f5898b1" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_dd0cf235-61ee-41df-9193-eda0fd22c079" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_f43606c4-f0d4-410c-b3c4-f88a3d6bedf8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_39c56e18-8636-47d2-82bf-a0334da59ce1" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_f43606c4-f0d4-410c-b3c4-f88a3d6bedf8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities_bb8d9d90-7896-4dc5-8303-ed7073b5ca25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_39c56e18-8636-47d2-82bf-a0334da59ce1" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities_bb8d9d90-7896-4dc5-8303-ed7073b5ca25" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_f4bf282f-106c-4aae-8873-cb7eb9ca96e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_39c56e18-8636-47d2-82bf-a0334da59ce1" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_f4bf282f-106c-4aae-8873-cb7eb9ca96e0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_0b1318c6-e5fc-43b2-9ebb-196c386eab50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_7b135880-79b5-41ee-a7d9-4d047e3750a0" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_0b1318c6-e5fc-43b2-9ebb-196c386eab50" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_ce18df37-dc5f-42f8-8fda-23af3012067a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_0b1318c6-e5fc-43b2-9ebb-196c386eab50" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_ce18df37-dc5f-42f8-8fda-23af3012067a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_ce18df37-dc5f-42f8-8fda-23af3012067a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_ce18df37-dc5f-42f8-8fda-23af3012067a" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_ce18df37-dc5f-42f8-8fda-23af3012067a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_80cfeba5-1d21-41b4-ac14-29647d9aebdd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_ce18df37-dc5f-42f8-8fda-23af3012067a" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_80cfeba5-1d21-41b4-ac14-29647d9aebdd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TrueHealthMember_71db10b4-3824-4512-a9fe-54a906584d72" xlink:href="evh-20210630.xsd#evh_TrueHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_80cfeba5-1d21-41b4-ac14-29647d9aebdd" xlink:to="loc_evh_TrueHealthMember_71db10b4-3824-4512-a9fe-54a906584d72" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_1b3031b4-8142-469c-973a-4438ed3ad2c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_0b1318c6-e5fc-43b2-9ebb-196c386eab50" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_1b3031b4-8142-469c-973a-4438ed3ad2c8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_1b3031b4-8142-469c-973a-4438ed3ad2c8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_1b3031b4-8142-469c-973a-4438ed3ad2c8" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_1b3031b4-8142-469c-973a-4438ed3ad2c8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_da731e87-11b2-4280-88b6-79e57c6c8a73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_1b3031b4-8142-469c-973a-4438ed3ad2c8" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_da731e87-11b2-4280-88b6-79e57c6c8a73" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_7e1888cf-85fb-4869-aff0-b635fcd638aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationsDisposedOfBySaleMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_da731e87-11b2-4280-88b6-79e57c6c8a73" xlink:to="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_7e1888cf-85fb-4869-aff0-b635fcd638aa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_e640db72-003c-4181-906e-294e3f113299" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_0b1318c6-e5fc-43b2-9ebb-196c386eab50" xlink:to="loc_srt_ProductOrServiceAxis_e640db72-003c-4181-906e-294e3f113299" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e640db72-003c-4181-906e-294e3f113299_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_e640db72-003c-4181-906e-294e3f113299" xlink:to="loc_srt_ProductsAndServicesDomain_e640db72-003c-4181-906e-294e3f113299_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_7ec27f1f-cc96-41b5-af40-87e439b6d4db" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_e640db72-003c-4181-906e-294e3f113299" xlink:to="loc_srt_ProductsAndServicesDomain_7ec27f1f-cc96-41b5-af40-87e439b6d4db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ServicesAgreementsMember_a5a4c0ea-4780-4861-b2d2-8324392be177" xlink:href="evh-20210630.xsd#evh_ServicesAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_7ec27f1f-cc96-41b5-af40-87e439b6d4db" xlink:to="loc_evh_ServicesAgreementsMember_a5a4c0ea-4780-4861-b2d2-8324392be177" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RevenueRecognitionDisaggregationofRevenueDetails" xlink:type="simple" xlink:href="evh-20210630.xsd#RevenueRecognitionDisaggregationofRevenueDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/RevenueRecognitionDisaggregationofRevenueDetails" xlink:type="extended" id="ic113555b7f3e4bb38f05b0ca03b57d94_RevenueRecognitionDisaggregationofRevenueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_52b04d2e-7633-4e42-9999-ef816cb92d36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_21e9dd39-7129-49ff-b68f-c4aecc921bcb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_52b04d2e-7633-4e42-9999-ef816cb92d36" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_21e9dd39-7129-49ff-b68f-c4aecc921bcb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_5ef4a13a-b5d6-4c73-a9b1-17c672adbc03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_52b04d2e-7633-4e42-9999-ef816cb92d36" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_5ef4a13a-b5d6-4c73-a9b1-17c672adbc03" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_2926b921-8ff7-44dd-a53b-3109344e5c13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_5ef4a13a-b5d6-4c73-a9b1-17c672adbc03" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_2926b921-8ff7-44dd-a53b-3109344e5c13" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_2926b921-8ff7-44dd-a53b-3109344e5c13_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_2926b921-8ff7-44dd-a53b-3109344e5c13" xlink:to="loc_us-gaap_SegmentDomain_2926b921-8ff7-44dd-a53b-3109344e5c13_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_d5d10756-8622-4807-9534-82ea60e84f21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_2926b921-8ff7-44dd-a53b-3109344e5c13" xlink:to="loc_us-gaap_SegmentDomain_d5d10756-8622-4807-9534-82ea60e84f21" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EvolentHealthServicesSegmentMember_0bf65a5e-3925-4861-a205-13c5ff9f93c3" xlink:href="evh-20210630.xsd#evh_EvolentHealthServicesSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_d5d10756-8622-4807-9534-82ea60e84f21" xlink:to="loc_evh_EvolentHealthServicesSegmentMember_0bf65a5e-3925-4861-a205-13c5ff9f93c3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ClinicalSolutionsSegmentMember_235c268f-ecf3-4476-98b1-25848a6315eb" xlink:href="evh-20210630.xsd#evh_ClinicalSolutionsSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_d5d10756-8622-4807-9534-82ea60e84f21" xlink:to="loc_evh_ClinicalSolutionsSegmentMember_235c268f-ecf3-4476-98b1-25848a6315eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_c132b86e-04fd-4bd7-9096-d02b14494e7f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_5ef4a13a-b5d6-4c73-a9b1-17c672adbc03" xlink:to="loc_srt_MajorCustomersAxis_c132b86e-04fd-4bd7-9096-d02b14494e7f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_c132b86e-04fd-4bd7-9096-d02b14494e7f_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_c132b86e-04fd-4bd7-9096-d02b14494e7f" xlink:to="loc_srt_NameOfMajorCustomerDomain_c132b86e-04fd-4bd7-9096-d02b14494e7f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_0c32867a-d220-4885-880c-c6b8f9936316" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_c132b86e-04fd-4bd7-9096-d02b14494e7f" xlink:to="loc_srt_NameOfMajorCustomerDomain_0c32867a-d220-4885-880c-c6b8f9936316" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_MedicaidCustomersMember_71285939-e898-4b10-baca-3d80e332e377" xlink:href="evh-20210630.xsd#evh_MedicaidCustomersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_0c32867a-d220-4885-880c-c6b8f9936316" xlink:to="loc_evh_MedicaidCustomersMember_71285939-e898-4b10-baca-3d80e332e377" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_MedicareCustomersMember_3c2b377c-4b4d-4862-b4a0-29ae5714e738" xlink:href="evh-20210630.xsd#evh_MedicareCustomersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_0c32867a-d220-4885-880c-c6b8f9936316" xlink:to="loc_evh_MedicareCustomersMember_3c2b377c-4b4d-4862-b4a0-29ae5714e738" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CommercialAndOtherCustomersMember_f0a0c87d-a6ff-434e-8a5d-16045e56bd73" xlink:href="evh-20210630.xsd#evh_CommercialAndOtherCustomersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_0c32867a-d220-4885-880c-c6b8f9936316" xlink:to="loc_evh_CommercialAndOtherCustomersMember_f0a0c87d-a6ff-434e-8a5d-16045e56bd73" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails" xlink:type="simple" xlink:href="evh-20210630.xsd#RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails" xlink:type="extended" id="i60160529adb8459b816ceff38350ba82_RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_7aa67d75-3ec5-40b6-895c-18983099cf49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationPercentage_d561ad00-77da-433b-8331-b5fc2c8b7c1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_7aa67d75-3ec5-40b6-895c-18983099cf49" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationPercentage_d561ad00-77da-433b-8331-b5fc2c8b7c1e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_4dcaacd2-7e41-47bd-82c0-a973efb40fca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_7aa67d75-3ec5-40b6-895c-18983099cf49" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_4dcaacd2-7e41-47bd-82c0-a973efb40fca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_18bda335-08e2-4983-bc0a-63a24478588f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_7aa67d75-3ec5-40b6-895c-18983099cf49" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_18bda335-08e2-4983-bc0a-63a24478588f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_50b9f6c2-d9db-430f-b441-21ebb4e96335" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_18bda335-08e2-4983-bc0a-63a24478588f" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_50b9f6c2-d9db-430f-b441-21ebb4e96335" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails_1" xlink:type="simple" xlink:href="evh-20210630.xsd#RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails_1"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails_1" xlink:type="extended" id="ieda0b3d644374e5fac51fd9decb28ec1_RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails_1">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_7aa67d75-3ec5-40b6-895c-18983099cf49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationPercentage_d561ad00-77da-433b-8331-b5fc2c8b7c1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_7aa67d75-3ec5-40b6-895c-18983099cf49" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationPercentage_d561ad00-77da-433b-8331-b5fc2c8b7c1e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_4dcaacd2-7e41-47bd-82c0-a973efb40fca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_7aa67d75-3ec5-40b6-895c-18983099cf49" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_4dcaacd2-7e41-47bd-82c0-a973efb40fca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_18bda335-08e2-4983-bc0a-63a24478588f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_7aa67d75-3ec5-40b6-895c-18983099cf49" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_18bda335-08e2-4983-bc0a-63a24478588f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RevenueRecognitionContractBalancesDetails" xlink:type="simple" xlink:href="evh-20210630.xsd#RevenueRecognitionContractBalancesDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/RevenueRecognitionContractBalancesDetails" xlink:type="extended" id="i694100c2c8d04114949f48a06da70710_RevenueRecognitionContractBalancesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_909c1f61-f8ba-4eb3-8598-d1c0b0a54e1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNetAfterGrossUp_b2a87e8d-1a14-4b3c-943d-c02032a6c5ed" xlink:href="evh-20210630.xsd#evh_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNetAfterGrossUp"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_909c1f61-f8ba-4eb3-8598-d1c0b0a54e1c" xlink:to="loc_evh_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNetAfterGrossUp_b2a87e8d-1a14-4b3c-943d-c02032a6c5ed" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent_0982b11a-fbb4-40d5-bd5c-66d0191ed000" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_909c1f61-f8ba-4eb3-8598-d1c0b0a54e1c" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent_0982b11a-fbb4-40d5-bd5c-66d0191ed000" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_ccd774af-8e94-4acf-ab40-25547fb8f426" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_909c1f61-f8ba-4eb3-8598-d1c0b0a54e1c" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_ccd774af-8e94-4acf-ab40-25547fb8f426" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_6cbb87a6-fded-4f16-ba93-5a7800632ec0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_ccd774af-8e94-4acf-ab40-25547fb8f426" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_6cbb87a6-fded-4f16-ba93-5a7800632ec0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_6cbb87a6-fded-4f16-ba93-5a7800632ec0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_6cbb87a6-fded-4f16-ba93-5a7800632ec0" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_6cbb87a6-fded-4f16-ba93-5a7800632ec0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_7ac362c4-230e-404d-8e28-c5c74f9987d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_6cbb87a6-fded-4f16-ba93-5a7800632ec0" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_7ac362c4-230e-404d-8e28-c5c74f9987d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_1fa0b817-c932-4562-ad81-9a100e54c5f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationsDisposedOfBySaleMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_7ac362c4-230e-404d-8e28-c5c74f9987d2" xlink:to="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_1fa0b817-c932-4562-ad81-9a100e54c5f1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_88743283-2313-4187-be37-01d920e609e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_ccd774af-8e94-4acf-ab40-25547fb8f426" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_88743283-2313-4187-be37-01d920e609e5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_88743283-2313-4187-be37-01d920e609e5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_88743283-2313-4187-be37-01d920e609e5" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_88743283-2313-4187-be37-01d920e609e5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_301d00ae-dde8-429c-9a27-1436a45695ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_88743283-2313-4187-be37-01d920e609e5" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_301d00ae-dde8-429c-9a27-1436a45695ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TrueHealthMember_685e3554-72e7-4124-acec-a2901c9d7e11" xlink:href="evh-20210630.xsd#evh_TrueHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_301d00ae-dde8-429c-9a27-1436a45695ee" xlink:to="loc_evh_TrueHealthMember_685e3554-72e7-4124-acec-a2901c9d7e11" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RevenueRecognitionContractCostsDetails" xlink:type="simple" xlink:href="evh-20210630.xsd#RevenueRecognitionContractCostsDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/RevenueRecognitionContractCostsDetails" xlink:type="extended" id="ie749bcc81a8e4eb89dc148f58a77e6c1_RevenueRecognitionContractCostsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostLineItems_51351ad8-771f-4228-95a2-3977e80c9276" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedContractCostLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostNet_472a3214-ec84-48b0-81ae-5a58472059a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedContractCostNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CapitalizedContractCostLineItems_51351ad8-771f-4228-95a2-3977e80c9276" xlink:to="loc_us-gaap_CapitalizedContractCostNet_472a3214-ec84-48b0-81ae-5a58472059a7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostAmortization_a17bbec9-5994-466b-abed-caf8f2f6866e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedContractCostAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CapitalizedContractCostLineItems_51351ad8-771f-4228-95a2-3977e80c9276" xlink:to="loc_us-gaap_CapitalizedContractCostAmortization_a17bbec9-5994-466b-abed-caf8f2f6866e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostAmortizationPeriod_2a01492d-2c61-4cd0-93cb-68fe75c8b8d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedContractCostAmortizationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CapitalizedContractCostLineItems_51351ad8-771f-4228-95a2-3977e80c9276" xlink:to="loc_us-gaap_CapitalizedContractCostAmortizationPeriod_2a01492d-2c61-4cd0-93cb-68fe75c8b8d0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostTable_e6144b4e-42b2-4c37-a5c4-ccc5ad66e565" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedContractCostTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CapitalizedContractCostLineItems_51351ad8-771f-4228-95a2-3977e80c9276" xlink:to="loc_us-gaap_CapitalizedContractCostTable_e6144b4e-42b2-4c37-a5c4-ccc5ad66e565" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostAxis_509aa18e-d411-45b2-b1b3-ba5ea6d189d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedContractCostAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_CapitalizedContractCostTable_e6144b4e-42b2-4c37-a5c4-ccc5ad66e565" xlink:to="loc_us-gaap_CapitalizedContractCostAxis_509aa18e-d411-45b2-b1b3-ba5ea6d189d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostDomain_509aa18e-d411-45b2-b1b3-ba5ea6d189d1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedContractCostDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CapitalizedContractCostAxis_509aa18e-d411-45b2-b1b3-ba5ea6d189d1" xlink:to="loc_us-gaap_CapitalizedContractCostDomain_509aa18e-d411-45b2-b1b3-ba5ea6d189d1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostDomain_42ec7c0d-01c7-49e7-836e-4ca75d4992a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedContractCostDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CapitalizedContractCostAxis_509aa18e-d411-45b2-b1b3-ba5ea6d189d1" xlink:to="loc_us-gaap_CapitalizedContractCostDomain_42ec7c0d-01c7-49e7-836e-4ca75d4992a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_BonusesAndCommissionsMember_4d301bb1-d3ac-4d59-aaad-38a62ff744fe" xlink:href="evh-20210630.xsd#evh_BonusesAndCommissionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CapitalizedContractCostDomain_42ec7c0d-01c7-49e7-836e-4ca75d4992a3" xlink:to="loc_evh_BonusesAndCommissionsMember_4d301bb1-d3ac-4d59-aaad-38a62ff744fe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ContractFulfillmentCostsMember_06c408c1-526b-4e1f-981c-e07bde0f3db4" xlink:href="evh-20210630.xsd#evh_ContractFulfillmentCostsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CapitalizedContractCostDomain_42ec7c0d-01c7-49e7-836e-4ca75d4992a3" xlink:to="loc_evh_ContractFulfillmentCostsMember_06c408c1-526b-4e1f-981c-e07bde0f3db4" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CreditLossesAccountsReceivableNarrativeDetails" xlink:type="simple" xlink:href="evh-20210630.xsd#CreditLossesAccountsReceivableNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/CreditLossesAccountsReceivableNarrativeDetails" xlink:type="extended" id="i01acbb194a914e658fbec354431cdf9a_CreditLossesAccountsReceivableNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNoncurrentPastDueLineItems_8b8a769a-4af1-4141-9b75-411ede8349dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNoncurrentPastDueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_FinancingReceivablePercentNotPastDue_7f798047-ce02-4f7f-8f86-ff2cf9a54a10" xlink:href="evh-20210630.xsd#evh_FinancingReceivablePercentNotPastDue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsReceivableNoncurrentPastDueLineItems_8b8a769a-4af1-4141-9b75-411ede8349dd" xlink:to="loc_evh_FinancingReceivablePercentNotPastDue_7f798047-ce02-4f7f-8f86-ff2cf9a54a10" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivablePercentPastDue1_69ca576d-9618-45dd-a6a2-89a6fb2be1d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancingReceivablePercentPastDue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsReceivableNoncurrentPastDueLineItems_8b8a769a-4af1-4141-9b75-411ede8349dd" xlink:to="loc_us-gaap_FinancingReceivablePercentPastDue1_69ca576d-9618-45dd-a6a2-89a6fb2be1d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNet_c16292ad-c10a-4a7a-b176-dac5d62ef3dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsReceivableNoncurrentPastDueLineItems_8b8a769a-4af1-4141-9b75-411ede8349dd" xlink:to="loc_us-gaap_AccountsReceivableNet_c16292ad-c10a-4a7a-b176-dac5d62ef3dc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_d5d11216-ef6e-43ad-a245-bf8bf7560cc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsReceivableNoncurrentPastDueLineItems_8b8a769a-4af1-4141-9b75-411ede8349dd" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_d5d11216-ef6e-43ad-a245-bf8bf7560cc3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNoncurrentPastDueTable_6784e90d-0189-47b4-ba7a-623ad83cec11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNoncurrentPastDueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccountsReceivableNoncurrentPastDueLineItems_8b8a769a-4af1-4141-9b75-411ede8349dd" xlink:to="loc_us-gaap_AccountsReceivableNoncurrentPastDueTable_6784e90d-0189-47b4-ba7a-623ad83cec11" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivablesPeriodPastDueAxis_bb979454-f0a9-466a-8a13-ee26af077612" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancingReceivablesPeriodPastDueAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccountsReceivableNoncurrentPastDueTable_6784e90d-0189-47b4-ba7a-623ad83cec11" xlink:to="loc_us-gaap_FinancingReceivablesPeriodPastDueAxis_bb979454-f0a9-466a-8a13-ee26af077612" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivablesPeriodPastDueDomain_bb979454-f0a9-466a-8a13-ee26af077612_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancingReceivablesPeriodPastDueDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancingReceivablesPeriodPastDueAxis_bb979454-f0a9-466a-8a13-ee26af077612" xlink:to="loc_us-gaap_FinancingReceivablesPeriodPastDueDomain_bb979454-f0a9-466a-8a13-ee26af077612_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivablesPeriodPastDueDomain_07a1bf41-29e3-43c1-81b2-782aca1372c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancingReceivablesPeriodPastDueDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancingReceivablesPeriodPastDueAxis_bb979454-f0a9-466a-8a13-ee26af077612" xlink:to="loc_us-gaap_FinancingReceivablesPeriodPastDueDomain_07a1bf41-29e3-43c1-81b2-782aca1372c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_FInancialAssetLessThan60DaysMember_b47fbfbf-24e8-48a9-bb3c-311583ae98c3" xlink:href="evh-20210630.xsd#evh_FInancialAssetLessThan60DaysMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancingReceivablesPeriodPastDueDomain_07a1bf41-29e3-43c1-81b2-782aca1372c5" xlink:to="loc_evh_FInancialAssetLessThan60DaysMember_b47fbfbf-24e8-48a9-bb3c-311583ae98c3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_FInancialAssetLessThan120DaysPastDueMember_9dbfe7b8-eaa3-4019-8f82-bb62eef1b682" xlink:href="evh-20210630.xsd#evh_FInancialAssetLessThan120DaysPastDueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancingReceivablesPeriodPastDueDomain_07a1bf41-29e3-43c1-81b2-782aca1372c5" xlink:to="loc_evh_FInancialAssetLessThan120DaysPastDueMember_9dbfe7b8-eaa3-4019-8f82-bb62eef1b682" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CreditLossesScheduleofChangesinAllowanceforAccountsReceivableDetails" xlink:type="simple" xlink:href="evh-20210630.xsd#CreditLossesScheduleofChangesinAllowanceforAccountsReceivableDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/CreditLossesScheduleofChangesinAllowanceforAccountsReceivableDetails" xlink:type="extended" id="ib03704acf5a041aa9522bdf7e4f812f2_CreditLossesScheduleofChangesinAllowanceforAccountsReceivableDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_0dfb2aa3-d3e9-4f01-8be0-9b683baa1bac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_74def6f3-a441-4a75-af65-64e409be1c59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_0dfb2aa3-d3e9-4f01-8be0-9b683baa1bac" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_74def6f3-a441-4a75-af65-64e409be1c59" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_4531a2af-e2da-4330-9458-257ccd9d6a14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_74def6f3-a441-4a75-af65-64e409be1c59" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_4531a2af-e2da-4330-9458-257ccd9d6a14" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_ed3ecf40-9967-4291-a88a-12c4e0c7e6bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_74def6f3-a441-4a75-af65-64e409be1c59" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_ed3ecf40-9967-4291-a88a-12c4e0c7e6bb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_2ac4348b-7832-4018-a3e7-8d5d9fdaeeff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_74def6f3-a441-4a75-af65-64e409be1c59" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_2ac4348b-7832-4018-a3e7-8d5d9fdaeeff" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_cd1f1d2b-bf97-4c6b-b0d9-7599914bdd01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_aeb5e780-4625-4d52-95c8-8c00ef060684" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_0dfb2aa3-d3e9-4f01-8be0-9b683baa1bac" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_aeb5e780-4625-4d52-95c8-8c00ef060684" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_2e5ae638-49dd-445f-a7e7-9a92becc0181" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_aeb5e780-4625-4d52-95c8-8c00ef060684" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_2e5ae638-49dd-445f-a7e7-9a92becc0181" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_2e5ae638-49dd-445f-a7e7-9a92becc0181_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_2e5ae638-49dd-445f-a7e7-9a92becc0181" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_2e5ae638-49dd-445f-a7e7-9a92becc0181_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_c1d5e870-195e-45bc-bba6-ce410e39f54b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_2e5ae638-49dd-445f-a7e7-9a92becc0181" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_c1d5e870-195e-45bc-bba6-ce410e39f54b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_e5282bbe-3e1e-4903-8cd2-d9d00ced0a2f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_c1d5e870-195e-45bc-bba6-ce410e39f54b" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_e5282bbe-3e1e-4903-8cd2-d9d00ced0a2f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails" xlink:type="simple" xlink:href="evh-20210630.xsd#PropertyandEquipmentNetDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails" xlink:type="extended" id="icd0bfb3d4c364fc1ab816138e65a3ae7_PropertyandEquipmentNetDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_684223ba-b497-480b-a575-4978acd7ec3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_cf6678aa-c0bb-40e1-aa38-85f68a2428dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_684223ba-b497-480b-a575-4978acd7ec3b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_cf6678aa-c0bb-40e1-aa38-85f68a2428dc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_78cacae9-7f61-4f23-a1ca-7992b6380e2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_684223ba-b497-480b-a575-4978acd7ec3b" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_78cacae9-7f61-4f23-a1ca-7992b6380e2f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_3eaa247b-529f-4e87-bc18-d523e92e2f16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_684223ba-b497-480b-a575-4978acd7ec3b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_3eaa247b-529f-4e87-bc18-d523e92e2f16" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedComputerSoftwareAdditions_76463bcd-54c2-4fe4-91aa-f14c2c557dea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedComputerSoftwareAdditions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_684223ba-b497-480b-a575-4978acd7ec3b" xlink:to="loc_us-gaap_CapitalizedComputerSoftwareAdditions_76463bcd-54c2-4fe4-91aa-f14c2c557dea" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_c2561de0-c6ff-496d-b18a-fe5676feacb5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_684223ba-b497-480b-a575-4978acd7ec3b" xlink:to="loc_us-gaap_Depreciation_c2561de0-c6ff-496d-b18a-fe5676feacb5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedComputerSoftwareAmortization1_d5be5676-cb94-4298-a8ae-97a64813b427" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedComputerSoftwareAmortization1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_684223ba-b497-480b-a575-4978acd7ec3b" xlink:to="loc_us-gaap_CapitalizedComputerSoftwareAmortization1_d5be5676-cb94-4298-a8ae-97a64813b427" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_d228146c-490a-4894-82db-47fed7eb61f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_684223ba-b497-480b-a575-4978acd7ec3b" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_d228146c-490a-4894-82db-47fed7eb61f5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_47513067-4dd3-4ff6-8a5a-b065561bce18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_d228146c-490a-4894-82db-47fed7eb61f5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_47513067-4dd3-4ff6-8a5a-b065561bce18" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_47513067-4dd3-4ff6-8a5a-b065561bce18_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_47513067-4dd3-4ff6-8a5a-b065561bce18" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_47513067-4dd3-4ff6-8a5a-b065561bce18_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d8375468-d994-4681-a713-1eacd9ddd2ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_47513067-4dd3-4ff6-8a5a-b065561bce18" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d8375468-d994-4681-a713-1eacd9ddd2ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_5f4d7e8c-c8f2-4e81-a83f-25b9a7586480" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d8375468-d994-4681-a713-1eacd9ddd2ca" xlink:to="loc_us-gaap_ComputerEquipmentMember_5f4d7e8c-c8f2-4e81-a83f-25b9a7586480" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_dd417e55-bfb8-4c74-ab8b-6c32e79375a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d8375468-d994-4681-a713-1eacd9ddd2ca" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_dd417e55-bfb8-4c74-ab8b-6c32e79375a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareDevelopmentMember_820bfe29-a526-4d73-9a1e-732d960ffab1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SoftwareDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d8375468-d994-4681-a713-1eacd9ddd2ca" xlink:to="loc_us-gaap_SoftwareDevelopmentMember_820bfe29-a526-4d73-9a1e-732d960ffab1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_934b8d95-1791-40c7-9616-8d8d79767816" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d8375468-d994-4681-a713-1eacd9ddd2ca" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_934b8d95-1791-40c7-9616-8d8d79767816" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetImpairmentTestingDetails" xlink:type="simple" xlink:href="evh-20210630.xsd#GoodwillandIntangibleAssetsNetImpairmentTestingDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetImpairmentTestingDetails" xlink:type="extended" id="i69af4c287b8144bb820ab31f4c437f5b_GoodwillandIntangibleAssetsNetImpairmentTestingDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_bc4ed0b6-65d0-4a47-ae3c-ecc0706ca431" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportingUnits_1f31ede4-9053-4a03-8b58-19c4c24038b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfReportingUnits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_bc4ed0b6-65d0-4a47-ae3c-ecc0706ca431" xlink:to="loc_us-gaap_NumberOfReportingUnits_1f31ede4-9053-4a03-8b58-19c4c24038b4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_c1e95d4b-4063-4495-94ed-9bb800f0f583" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_bc4ed0b6-65d0-4a47-ae3c-ecc0706ca431" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_c1e95d4b-4063-4495-94ed-9bb800f0f583" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_NumberOfReportingUnitsFairValueInExcessOfCarryingAmount_01cda054-b42f-443c-bcd3-e7e67ad533fd" xlink:href="evh-20210630.xsd#evh_NumberOfReportingUnitsFairValueInExcessOfCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_bc4ed0b6-65d0-4a47-ae3c-ecc0706ca431" xlink:to="loc_evh_NumberOfReportingUnitsFairValueInExcessOfCarryingAmount_01cda054-b42f-443c-bcd3-e7e67ad533fd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_0cbb8c7c-ef65-4142-bb60-cd64a6015126" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_bc4ed0b6-65d0-4a47-ae3c-ecc0706ca431" xlink:to="loc_us-gaap_Goodwill_0cbb8c7c-ef65-4142-bb60-cd64a6015126" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_c56b217c-beb8-4fa9-aeb2-7e9bdacf3112" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_bc4ed0b6-65d0-4a47-ae3c-ecc0706ca431" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_c56b217c-beb8-4fa9-aeb2-7e9bdacf3112" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis_f3ea86fb-5470-4f5a-aece-112913ab79ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_c56b217c-beb8-4fa9-aeb2-7e9bdacf3112" xlink:to="loc_us-gaap_ValuationTechniqueAxis_f3ea86fb-5470-4f5a-aece-112913ab79ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_f3ea86fb-5470-4f5a-aece-112913ab79ab_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationTechniqueAxis_f3ea86fb-5470-4f5a-aece-112913ab79ab" xlink:to="loc_us-gaap_ValuationTechniqueDomain_f3ea86fb-5470-4f5a-aece-112913ab79ab_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_a694f300-18bb-483f-a544-e93877d32932" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationTechniqueAxis_f3ea86fb-5470-4f5a-aece-112913ab79ab" xlink:to="loc_us-gaap_ValuationTechniqueDomain_a694f300-18bb-483f-a544-e93877d32932" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeApproachValuationTechniqueMember_5e010e2f-e59a-4c04-b399-48ab0582b3a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeApproachValuationTechniqueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationTechniqueDomain_a694f300-18bb-483f-a544-e93877d32932" xlink:to="loc_us-gaap_IncomeApproachValuationTechniqueMember_5e010e2f-e59a-4c04-b399-48ab0582b3a8" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetScheduleofGoodwillDetails" xlink:type="simple" xlink:href="evh-20210630.xsd#GoodwillandIntangibleAssetsNetScheduleofGoodwillDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetScheduleofGoodwillDetails" xlink:type="extended" id="i8cbf6b2921074692aaab472d232cbf0c_GoodwillandIntangibleAssetsNetScheduleofGoodwillDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_e948acad-7c34-4bad-b799-e32b9c072995" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_282082ed-01d3-449a-89d0-e4ebc455efa8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_e948acad-7c34-4bad-b799-e32b9c072995" xlink:to="loc_us-gaap_GoodwillRollForward_282082ed-01d3-449a-89d0-e4ebc455efa8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_7260fa2f-03a0-4ab3-ba2f-61f8188bf30c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_282082ed-01d3-449a-89d0-e4ebc455efa8" xlink:to="loc_us-gaap_Goodwill_7260fa2f-03a0-4ab3-ba2f-61f8188bf30c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_0e902ff5-5107-4ffa-979a-50f05f4a04d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_282082ed-01d3-449a-89d0-e4ebc455efa8" xlink:to="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_0e902ff5-5107-4ffa-979a-50f05f4a04d2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_26f537f0-cf6f-4adb-a884-15c28900d026" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_282082ed-01d3-449a-89d0-e4ebc455efa8" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_26f537f0-cf6f-4adb-a884-15c28900d026" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_85f1c75d-198a-41b8-a9e0-0aa6cffe26b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_282082ed-01d3-449a-89d0-e4ebc455efa8" xlink:to="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_85f1c75d-198a-41b8-a9e0-0aa6cffe26b9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_9255d50d-8048-434d-b47a-f0851a21050c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_b839e4d3-ef2d-4217-a1d5-af29b4b4176c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_e948acad-7c34-4bad-b799-e32b9c072995" xlink:to="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_b839e4d3-ef2d-4217-a1d5-af29b4b4176c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_ca8fa63b-5a92-4fdd-93fd-107bea106b7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GoodwillLineItems_e948acad-7c34-4bad-b799-e32b9c072995" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_ca8fa63b-5a92-4fdd-93fd-107bea106b7c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_4f1ca97f-39b0-4131-adff-aebc076dc107" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_ca8fa63b-5a92-4fdd-93fd-107bea106b7c" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_4f1ca97f-39b0-4131-adff-aebc076dc107" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_4f1ca97f-39b0-4131-adff-aebc076dc107_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_4f1ca97f-39b0-4131-adff-aebc076dc107" xlink:to="loc_us-gaap_SegmentDomain_4f1ca97f-39b0-4131-adff-aebc076dc107_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_630a5c8e-e7e4-46f4-99ed-83459e2b59fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_4f1ca97f-39b0-4131-adff-aebc076dc107" xlink:to="loc_us-gaap_SegmentDomain_630a5c8e-e7e4-46f4-99ed-83459e2b59fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EvolentHealthServicesSegmentMember_f757e134-94b1-4e5b-b93f-4f67a688b56c" xlink:href="evh-20210630.xsd#evh_EvolentHealthServicesSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_630a5c8e-e7e4-46f4-99ed-83459e2b59fe" xlink:to="loc_evh_EvolentHealthServicesSegmentMember_f757e134-94b1-4e5b-b93f-4f67a688b56c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ClinicalSolutionsSegmentMember_d8cbab54-8982-4ecd-a94d-42bc2f557c8a" xlink:href="evh-20210630.xsd#evh_ClinicalSolutionsSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_630a5c8e-e7e4-46f4-99ed-83459e2b59fe" xlink:to="loc_evh_ClinicalSolutionsSegmentMember_d8cbab54-8982-4ecd-a94d-42bc2f557c8a" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails" xlink:type="simple" xlink:href="evh-20210630.xsd#GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails" xlink:type="extended" id="ib572590293754894961d20fdfbcda630_GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_cc26e440-1aee-41c9-b7af-91e09cbfc8ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_6c434863-f4f7-4814-adbc-0ff6688448e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_cc26e440-1aee-41c9-b7af-91e09cbfc8ad" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_6c434863-f4f7-4814-adbc-0ff6688448e9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_76b8c964-ed09-4cf8-a9b7-1799f4f37c21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_cc26e440-1aee-41c9-b7af-91e09cbfc8ad" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_76b8c964-ed09-4cf8-a9b7-1799f4f37c21" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_c705a354-0756-4ecd-a2a3-09fbe9e63925" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_cc26e440-1aee-41c9-b7af-91e09cbfc8ad" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_c705a354-0756-4ecd-a2a3-09fbe9e63925" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_1195a377-846a-43a1-b607-b8ce7b5fe4b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_cc26e440-1aee-41c9-b7af-91e09cbfc8ad" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_1195a377-846a-43a1-b607-b8ce7b5fe4b5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent_08683f2d-0db1-4b2e-ae28-54121d1b6d13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_cc26e440-1aee-41c9-b7af-91e09cbfc8ad" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent_08683f2d-0db1-4b2e-ae28-54121d1b6d13" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_aa6f15a9-c74b-4619-bc9d-16677efd1e80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_cc26e440-1aee-41c9-b7af-91e09cbfc8ad" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_aa6f15a9-c74b-4619-bc9d-16677efd1e80" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_03a4e372-6636-4b14-8ce7-b768816a537b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_cc26e440-1aee-41c9-b7af-91e09cbfc8ad" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_03a4e372-6636-4b14-8ce7-b768816a537b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6b49b9cf-bf0e-4f32-aca9-9db561e1669d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_03a4e372-6636-4b14-8ce7-b768816a537b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6b49b9cf-bf0e-4f32-aca9-9db561e1669d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6b49b9cf-bf0e-4f32-aca9-9db561e1669d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6b49b9cf-bf0e-4f32-aca9-9db561e1669d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6b49b9cf-bf0e-4f32-aca9-9db561e1669d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a48e5e05-02ba-42a8-af3f-3f58dabb2861" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6b49b9cf-bf0e-4f32-aca9-9db561e1669d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a48e5e05-02ba-42a8-af3f-3f58dabb2861" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_26a379b0-2822-45bd-ad67-f3f55b0ea8fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradeNamesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a48e5e05-02ba-42a8-af3f-3f58dabb2861" xlink:to="loc_us-gaap_TradeNamesMember_26a379b0-2822-45bd-ad67-f3f55b0ea8fd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_911d63ee-da62-432e-8915-561eb62ed149" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a48e5e05-02ba-42a8-af3f-3f58dabb2861" xlink:to="loc_us-gaap_CustomerRelationshipsMember_911d63ee-da62-432e-8915-561eb62ed149" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_26d36819-60e3-447f-b453-d80eb7fea70f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a48e5e05-02ba-42a8-af3f-3f58dabb2861" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_26d36819-60e3-447f-b453-d80eb7fea70f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_BelowMarketLeasesMember_ff1fcbf7-9ea2-47c3-9aa1-64dbeb0e9aee" xlink:href="evh-20210630.xsd#evh_BelowMarketLeasesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a48e5e05-02ba-42a8-af3f-3f58dabb2861" xlink:to="loc_evh_BelowMarketLeasesMember_ff1fcbf7-9ea2-47c3-9aa1-64dbeb0e9aee" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractBasedIntangibleAssetsMember_cdc9597b-eb00-4efd-acaf-e109eb905913" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractBasedIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a48e5e05-02ba-42a8-af3f-3f58dabb2861" xlink:to="loc_us-gaap_ContractBasedIntangibleAssetsMember_cdc9597b-eb00-4efd-acaf-e109eb905913" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_8f8187d3-2a3e-4cf8-bdbe-1f420714fc9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_03a4e372-6636-4b14-8ce7-b768816a537b" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_8f8187d3-2a3e-4cf8-bdbe-1f420714fc9e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_8f8187d3-2a3e-4cf8-bdbe-1f420714fc9e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_8f8187d3-2a3e-4cf8-bdbe-1f420714fc9e" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_8f8187d3-2a3e-4cf8-bdbe-1f420714fc9e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_3c5e3694-b59c-428b-9b3a-1f1df57b24c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_8f8187d3-2a3e-4cf8-bdbe-1f420714fc9e" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_3c5e3694-b59c-428b-9b3a-1f1df57b24c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_4ff17a39-b219-414d-bc88-4979c0f40d89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationsDisposedOfBySaleMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_3c5e3694-b59c-428b-9b3a-1f1df57b24c3" xlink:to="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_4ff17a39-b219-414d-bc88-4979c0f40d89" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_867b4ca1-eb52-4174-b7e0-4aa75b037444" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_03a4e372-6636-4b14-8ce7-b768816a537b" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_867b4ca1-eb52-4174-b7e0-4aa75b037444" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_867b4ca1-eb52-4174-b7e0-4aa75b037444_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_867b4ca1-eb52-4174-b7e0-4aa75b037444" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_867b4ca1-eb52-4174-b7e0-4aa75b037444_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_c79c5f7d-aaf1-4ee2-b43f-5ab9d1eff107" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_867b4ca1-eb52-4174-b7e0-4aa75b037444" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_c79c5f7d-aaf1-4ee2-b43f-5ab9d1eff107" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TrueHealthMember_6a7e0748-7526-4ca3-b46a-ca0479bc843c" xlink:href="evh-20210630.xsd#evh_TrueHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_c79c5f7d-aaf1-4ee2-b43f-5ab9d1eff107" xlink:to="loc_evh_TrueHealthMember_6a7e0748-7526-4ca3-b46a-ca0479bc843c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails" xlink:type="simple" xlink:href="evh-20210630.xsd#LongtermDebt2024NotesDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails" xlink:type="extended" id="i434f4900af0741ab8b6d2987e49ba03d_LongtermDebt2024NotesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_46d6f015-f7ee-448a-8a40-d22c0963aeaf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_a5975142-4adc-4cc1-a4c7-acffa9f1f695" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_46d6f015-f7ee-448a-8a40-d22c0963aeaf" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_a5975142-4adc-4cc1-a4c7-acffa9f1f695" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_f599cd60-127c-4f06-b312-c513f1f60897" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_46d6f015-f7ee-448a-8a40-d22c0963aeaf" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_f599cd60-127c-4f06-b312-c513f1f60897" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_318701bd-cdf0-4e6d-87ac-54fb43cfa10c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_46d6f015-f7ee-448a-8a40-d22c0963aeaf" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_318701bd-cdf0-4e6d-87ac-54fb43cfa10c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionOriginalDebtAmount1_541a939b-6668-4bc5-97a7-f6732e769ac8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionOriginalDebtAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_46d6f015-f7ee-448a-8a40-d22c0963aeaf" xlink:to="loc_us-gaap_DebtConversionOriginalDebtAmount1_541a939b-6668-4bc5-97a7-f6732e769ac8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_ac4c68d7-2f22-4072-aea5-47ee36e6f929" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_46d6f015-f7ee-448a-8a40-d22c0963aeaf" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_ac4c68d7-2f22-4072-aea5-47ee36e6f929" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_3c9facd1-f399-4195-837d-7c93591ba776" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_46d6f015-f7ee-448a-8a40-d22c0963aeaf" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_3c9facd1-f399-4195-837d-7c93591ba776" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_c381b4e9-ee16-4d50-80d0-a1220e04efc9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_46d6f015-f7ee-448a-8a40-d22c0963aeaf" xlink:to="loc_us-gaap_InterestExpenseDebt_c381b4e9-ee16-4d50-80d0-a1220e04efc9" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_7bc40a50-1247-4efd-a877-199e5bc95584" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_46d6f015-f7ee-448a-8a40-d22c0963aeaf" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_7bc40a50-1247-4efd-a877-199e5bc95584" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_c75d6fbc-9b11-45d2-8835-d57608129dca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_46d6f015-f7ee-448a-8a40-d22c0963aeaf" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_c75d6fbc-9b11-45d2-8835-d57608129dca" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_012a571c-3ca2-46ed-8719-c0dcecf5c9b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_46d6f015-f7ee-448a-8a40-d22c0963aeaf" xlink:to="loc_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_012a571c-3ca2-46ed-8719-c0dcecf5c9b9" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_704a5357-fd54-46e2-9b03-852a2bbbfbd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_46d6f015-f7ee-448a-8a40-d22c0963aeaf" xlink:to="loc_us-gaap_LongTermDebt_704a5357-fd54-46e2-9b03-852a2bbbfbd3" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_da12c6d2-7dab-4db9-bd23-0628f3890796" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_46d6f015-f7ee-448a-8a40-d22c0963aeaf" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_da12c6d2-7dab-4db9-bd23-0628f3890796" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtIssuanceCostsNetDebtComponent_4e6dbbcc-f77c-45a1-b23b-5b1cb73ccbd2" xlink:href="evh-20210630.xsd#evh_DebtIssuanceCostsNetDebtComponent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_46d6f015-f7ee-448a-8a40-d22c0963aeaf" xlink:to="loc_evh_DebtIssuanceCostsNetDebtComponent_4e6dbbcc-f77c-45a1-b23b-5b1cb73ccbd2" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_AmortizationOfDebtDiscountAndDebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_407b7094-b18e-45c7-9ca1-c988bd3a4c65" xlink:href="evh-20210630.xsd#evh_AmortizationOfDebtDiscountAndDebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_46d6f015-f7ee-448a-8a40-d22c0963aeaf" xlink:to="loc_evh_AmortizationOfDebtDiscountAndDebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_407b7094-b18e-45c7-9ca1-c988bd3a4c65" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount_4ed3213f-5879-43c3-88ed-ceec8fe4672b" xlink:href="evh-20210630.xsd#evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_46d6f015-f7ee-448a-8a40-d22c0963aeaf" xlink:to="loc_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount_4ed3213f-5879-43c3-88ed-ceec8fe4672b" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice_5fc82ccb-2877-452d-9c92-4cdf6693d81a" xlink:href="evh-20210630.xsd#evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_46d6f015-f7ee-448a-8a40-d22c0963aeaf" xlink:to="loc_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice_5fc82ccb-2877-452d-9c92-4cdf6693d81a" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum_51308d61-e502-4aa3-82f0-600e349d0ff1" xlink:href="evh-20210630.xsd#evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_46d6f015-f7ee-448a-8a40-d22c0963aeaf" xlink:to="loc_evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum_51308d61-e502-4aa3-82f0-600e349d0ff1" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum_223d27a4-874b-4610-b3cc-c3c61c76ed0d" xlink:href="evh-20210630.xsd#evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_46d6f015-f7ee-448a-8a40-d22c0963aeaf" xlink:to="loc_evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum_223d27a4-874b-4610-b3cc-c3c61c76ed0d" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice_f4d129d1-d83c-4548-a0e0-e3696bbe971d" xlink:href="evh-20210630.xsd#evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_46d6f015-f7ee-448a-8a40-d22c0963aeaf" xlink:to="loc_evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice_f4d129d1-d83c-4548-a0e0-e3696bbe971d" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_6bf932c2-e1dc-4e96-8024-d1ce7a6f6c50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_46d6f015-f7ee-448a-8a40-d22c0963aeaf" xlink:to="loc_us-gaap_DebtInstrumentTable_6bf932c2-e1dc-4e96-8024-d1ce7a6f6c50" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_f6aacd82-a44a-4969-a962-069ae0b3db49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_6bf932c2-e1dc-4e96-8024-d1ce7a6f6c50" xlink:to="loc_us-gaap_DebtInstrumentAxis_f6aacd82-a44a-4969-a962-069ae0b3db49" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_f6aacd82-a44a-4969-a962-069ae0b3db49_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_f6aacd82-a44a-4969-a962-069ae0b3db49" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_f6aacd82-a44a-4969-a962-069ae0b3db49_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_bac85b02-3580-496a-baf6-aaeeac0be76c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_f6aacd82-a44a-4969-a962-069ae0b3db49" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_bac85b02-3580-496a-baf6-aaeeac0be76c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SeniorConvertibleNotesDue2024Member_99523183-2205-45ee-a954-62780baa99a1" xlink:href="evh-20210630.xsd#evh_SeniorConvertibleNotesDue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_bac85b02-3580-496a-baf6-aaeeac0be76c" xlink:to="loc_evh_SeniorConvertibleNotesDue2024Member_99523183-2205-45ee-a954-62780baa99a1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ConvertibleSeniorNotesdue2021Member_9f066823-1a54-4035-8fed-e5779348e27f" xlink:href="evh-20210630.xsd#evh_ConvertibleSeniorNotesdue2021Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_bac85b02-3580-496a-baf6-aaeeac0be76c" xlink:to="loc_evh_ConvertibleSeniorNotesdue2021Member_9f066823-1a54-4035-8fed-e5779348e27f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_NewNotesMember_59609156-c567-478f-a9ee-55b718b521cf" xlink:href="evh-20210630.xsd#evh_NewNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_bac85b02-3580-496a-baf6-aaeeac0be76c" xlink:to="loc_evh_NewNotesMember_59609156-c567-478f-a9ee-55b718b521cf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_4f45ba18-77d0-4028-b9f6-60d9895c4fc2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_6bf932c2-e1dc-4e96-8024-d1ce7a6f6c50" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_4f45ba18-77d0-4028-b9f6-60d9895c4fc2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_4f45ba18-77d0-4028-b9f6-60d9895c4fc2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_4f45ba18-77d0-4028-b9f6-60d9895c4fc2" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_4f45ba18-77d0-4028-b9f6-60d9895c4fc2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_191eefba-6802-4442-b094-700d9a4b7d4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_4f45ba18-77d0-4028-b9f6-60d9895c4fc2" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_191eefba-6802-4442-b094-700d9a4b7d4f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_24f9e59c-0329-46f0-b2f9-c8ee2a92415a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_191eefba-6802-4442-b094-700d9a4b7d4f" xlink:to="loc_us-gaap_SeniorNotesMember_24f9e59c-0329-46f0-b2f9-c8ee2a92415a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_f7cd0c5c-a931-447b-a8aa-a9509c6cb920" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_6bf932c2-e1dc-4e96-8024-d1ce7a6f6c50" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_f7cd0c5c-a931-447b-a8aa-a9509c6cb920" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_f7cd0c5c-a931-447b-a8aa-a9509c6cb920_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f7cd0c5c-a931-447b-a8aa-a9509c6cb920" xlink:to="loc_us-gaap_EquityComponentDomain_f7cd0c5c-a931-447b-a8aa-a9509c6cb920_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_41d79bfb-64a7-4fd2-aae1-579b4698f071" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f7cd0c5c-a931-447b-a8aa-a9509c6cb920" xlink:to="loc_us-gaap_EquityComponentDomain_41d79bfb-64a7-4fd2-aae1-579b4698f071" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_a320f29a-5d70-4ce9-a9ac-0842450e5847" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_41d79bfb-64a7-4fd2-aae1-579b4698f071" xlink:to="loc_us-gaap_CommonStockMember_a320f29a-5d70-4ce9-a9ac-0842450e5847" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_0a830427-2de0-4aa0-b415-a1d076121714" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_6bf932c2-e1dc-4e96-8024-d1ce7a6f6c50" xlink:to="loc_us-gaap_StatementClassOfStockAxis_0a830427-2de0-4aa0-b415-a1d076121714" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_0a830427-2de0-4aa0-b415-a1d076121714_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_0a830427-2de0-4aa0-b415-a1d076121714" xlink:to="loc_us-gaap_ClassOfStockDomain_0a830427-2de0-4aa0-b415-a1d076121714_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_ec79089b-5313-4467-b6aa-ee3ca01dc80e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_0a830427-2de0-4aa0-b415-a1d076121714" xlink:to="loc_us-gaap_ClassOfStockDomain_ec79089b-5313-4467-b6aa-ee3ca01dc80e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_003a3210-e195-4e0f-ae02-1d61dbbe578d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_ec79089b-5313-4467-b6aa-ee3ca01dc80e" xlink:to="loc_us-gaap_CommonClassAMember_003a3210-e195-4e0f-ae02-1d61dbbe578d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LongtermDebtCreditAgreementDetails" xlink:type="simple" xlink:href="evh-20210630.xsd#LongtermDebtCreditAgreementDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/LongtermDebtCreditAgreementDetails" xlink:type="extended" id="iee1cbb4634b64e6b8e86debe4c27fa7d_LongtermDebtCreditAgreementDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_6b803be6-ce75-4934-9139-b7d0cf1e561f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_49e0d482-e2c9-4631-9362-e44f28fab9d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6b803be6-ce75-4934-9139-b7d0cf1e561f" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_49e0d482-e2c9-4631-9362-e44f28fab9d9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_7f8e879b-b1d1-49c0-8605-c6321c74dde5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6b803be6-ce75-4934-9139-b7d0cf1e561f" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_7f8e879b-b1d1-49c0-8605-c6321c74dde5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_92dce11a-804e-4a1b-9430-a53c8e386665" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6b803be6-ce75-4934-9139-b7d0cf1e561f" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_92dce11a-804e-4a1b-9430-a53c8e386665" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_25815249-5f66-4109-bc06-3b8840da936f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6b803be6-ce75-4934-9139-b7d0cf1e561f" xlink:to="loc_us-gaap_DebtInstrumentTerm_25815249-5f66-4109-bc06-3b8840da936f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_81190ac2-9447-4573-8261-a4bf2707e623" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6b803be6-ce75-4934-9139-b7d0cf1e561f" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_81190ac2-9447-4573-8261-a4bf2707e623" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_0314f2f1-56a5-490c-8ea3-c52043fd1fb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6b803be6-ce75-4934-9139-b7d0cf1e561f" xlink:to="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_0314f2f1-56a5-490c-8ea3-c52043fd1fb9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRedemptionCallProtectionPremiumPercentage_6853f465-a189-4b55-98bd-9e5be609ef21" xlink:href="evh-20210630.xsd#evh_DebtInstrumentRedemptionCallProtectionPremiumPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6b803be6-ce75-4934-9139-b7d0cf1e561f" xlink:to="loc_evh_DebtInstrumentRedemptionCallProtectionPremiumPercentage_6853f465-a189-4b55-98bd-9e5be609ef21" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_5f20df34-1ada-4c27-ace7-2e7de340ec52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6b803be6-ce75-4934-9139-b7d0cf1e561f" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_5f20df34-1ada-4c27-ace7-2e7de340ec52" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_AmortizationOfDebtDiscountAndDebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_9e6e1d6d-0920-4f61-9382-097bc6584b3c" xlink:href="evh-20210630.xsd#evh_AmortizationOfDebtDiscountAndDebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6b803be6-ce75-4934-9139-b7d0cf1e561f" xlink:to="loc_evh_AmortizationOfDebtDiscountAndDebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_9e6e1d6d-0920-4f61-9382-097bc6584b3c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit_44a212ec-84ae-4c54-9e98-e834f650b7c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermLinesOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6b803be6-ce75-4934-9139-b7d0cf1e561f" xlink:to="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit_44a212ec-84ae-4c54-9e98-e834f650b7c3" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PaymentsOfMakeWholePremium_3a619518-55c4-43ea-adcb-2ca02d2e1eeb" xlink:href="evh-20210630.xsd#evh_PaymentsOfMakeWholePremium"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6b803be6-ce75-4934-9139-b7d0cf1e561f" xlink:to="loc_evh_PaymentsOfMakeWholePremium_3a619518-55c4-43ea-adcb-2ca02d2e1eeb" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_8e797a35-eb99-4246-9063-fbcd4ffe5346" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6b803be6-ce75-4934-9139-b7d0cf1e561f" xlink:to="loc_us-gaap_InterestPaidNet_8e797a35-eb99-4246-9063-fbcd4ffe5346" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_3a8dacb5-a055-42c7-8bd6-1557e6ee5e0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6b803be6-ce75-4934-9139-b7d0cf1e561f" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_3a8dacb5-a055-42c7-8bd6-1557e6ee5e0f" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WriteOffOfDeferredDebtIssuanceCost_a994918c-d038-4a92-8520-b614a7649786" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WriteOffOfDeferredDebtIssuanceCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6b803be6-ce75-4934-9139-b7d0cf1e561f" xlink:to="loc_us-gaap_WriteOffOfDeferredDebtIssuanceCost_a994918c-d038-4a92-8520-b614a7649786" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalFees_2d6570f4-34e9-4d39-9128-60be53881346" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LegalFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6b803be6-ce75-4934-9139-b7d0cf1e561f" xlink:to="loc_us-gaap_LegalFees_2d6570f4-34e9-4d39-9128-60be53881346" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_8e1c5577-263d-46d2-93ae-6c088dd741be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6b803be6-ce75-4934-9139-b7d0cf1e561f" xlink:to="loc_us-gaap_DebtInstrumentTable_8e1c5577-263d-46d2-93ae-6c088dd741be" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_8de43411-c6a5-4ca7-91f9-723f99f5b3b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_8e1c5577-263d-46d2-93ae-6c088dd741be" xlink:to="loc_us-gaap_DebtInstrumentAxis_8de43411-c6a5-4ca7-91f9-723f99f5b3b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_8de43411-c6a5-4ca7-91f9-723f99f5b3b5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_8de43411-c6a5-4ca7-91f9-723f99f5b3b5" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_8de43411-c6a5-4ca7-91f9-723f99f5b3b5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_dec3371f-d94a-49ce-889e-3b384d0f07b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_8de43411-c6a5-4ca7-91f9-723f99f5b3b5" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_dec3371f-d94a-49ce-889e-3b384d0f07b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_InitialTermLoanFacilityMember_b12d46f1-17c1-4d7a-8d75-ccf6c19bfe14" xlink:href="evh-20210630.xsd#evh_InitialTermLoanFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_dec3371f-d94a-49ce-889e-3b384d0f07b4" xlink:to="loc_evh_InitialTermLoanFacilityMember_b12d46f1-17c1-4d7a-8d75-ccf6c19bfe14" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CreditAgreementMember_bf416a34-575d-4413-9c3c-495477c08be6" xlink:href="evh-20210630.xsd#evh_CreditAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_dec3371f-d94a-49ce-889e-3b384d0f07b4" xlink:to="loc_evh_CreditAgreementMember_bf416a34-575d-4413-9c3c-495477c08be6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ConvertibleSeniorNotesdue2021Member_45b9b029-cbdc-4b6d-b923-37f82f79b33e" xlink:href="evh-20210630.xsd#evh_ConvertibleSeniorNotesdue2021Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_dec3371f-d94a-49ce-889e-3b384d0f07b4" xlink:to="loc_evh_ConvertibleSeniorNotesdue2021Member_45b9b029-cbdc-4b6d-b923-37f82f79b33e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SeniorCreditFacilitiesMember_00de3c87-13c7-4164-9108-78dc99411ebe" xlink:href="evh-20210630.xsd#evh_SeniorCreditFacilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_dec3371f-d94a-49ce-889e-3b384d0f07b4" xlink:to="loc_evh_SeniorCreditFacilitiesMember_00de3c87-13c7-4164-9108-78dc99411ebe" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_1fb97582-1005-4800-8225-4127f81ed4e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_8e1c5577-263d-46d2-93ae-6c088dd741be" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_1fb97582-1005-4800-8225-4127f81ed4e3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1fb97582-1005-4800-8225-4127f81ed4e3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1fb97582-1005-4800-8225-4127f81ed4e3" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1fb97582-1005-4800-8225-4127f81ed4e3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_b2a389b0-15c5-4c04-be18-eb8a5bd64630" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1fb97582-1005-4800-8225-4127f81ed4e3" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_b2a389b0-15c5-4c04-be18-eb8a5bd64630" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_694115c8-bce5-44a8-8195-dd2af02cd119" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_b2a389b0-15c5-4c04-be18-eb8a5bd64630" xlink:to="loc_us-gaap_SecuredDebtMember_694115c8-bce5-44a8-8195-dd2af02cd119" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_3e3416f4-5916-4d9c-9f0c-a76b1eeef03f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_b2a389b0-15c5-4c04-be18-eb8a5bd64630" xlink:to="loc_us-gaap_LineOfCreditMember_3e3416f4-5916-4d9c-9f0c-a76b1eeef03f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_e6dc6105-15cc-4f39-b3b8-bdebc58f7017" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_b2a389b0-15c5-4c04-be18-eb8a5bd64630" xlink:to="loc_us-gaap_SeniorNotesMember_e6dc6105-15cc-4f39-b3b8-bdebc58f7017" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_48215f8b-cf01-4669-887f-5d33edf88ac6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_8e1c5577-263d-46d2-93ae-6c088dd741be" xlink:to="loc_us-gaap_CreditFacilityAxis_48215f8b-cf01-4669-887f-5d33edf88ac6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_48215f8b-cf01-4669-887f-5d33edf88ac6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_48215f8b-cf01-4669-887f-5d33edf88ac6" xlink:to="loc_us-gaap_CreditFacilityDomain_48215f8b-cf01-4669-887f-5d33edf88ac6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_bb633313-ea4c-47eb-b3c9-1c54421fa4ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_48215f8b-cf01-4669-887f-5d33edf88ac6" xlink:to="loc_us-gaap_CreditFacilityDomain_bb633313-ea4c-47eb-b3c9-1c54421fa4ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DelayedDrawTermLoanFacilityMember_3d0ddfde-ea71-48a1-8220-1f1f551f0b38" xlink:href="evh-20210630.xsd#evh_DelayedDrawTermLoanFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_bb633313-ea4c-47eb-b3c9-1c54421fa4ca" xlink:to="loc_evh_DelayedDrawTermLoanFacilityMember_3d0ddfde-ea71-48a1-8220-1f1f551f0b38" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_9495efaf-32d8-4e02-8ec4-1d1335b4ecb1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_8e1c5577-263d-46d2-93ae-6c088dd741be" xlink:to="loc_us-gaap_VariableRateAxis_9495efaf-32d8-4e02-8ec4-1d1335b4ecb1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_9495efaf-32d8-4e02-8ec4-1d1335b4ecb1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_9495efaf-32d8-4e02-8ec4-1d1335b4ecb1" xlink:to="loc_us-gaap_VariableRateDomain_9495efaf-32d8-4e02-8ec4-1d1335b4ecb1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_ca09076f-b483-4e59-a5b6-9c6f0890635a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_9495efaf-32d8-4e02-8ec4-1d1335b4ecb1" xlink:to="loc_us-gaap_VariableRateDomain_ca09076f-b483-4e59-a5b6-9c6f0890635a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EurodollarMember_35191889-5c4f-463b-bdb4-c2788baeac90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EurodollarMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_ca09076f-b483-4e59-a5b6-9c6f0890635a" xlink:to="loc_us-gaap_EurodollarMember_35191889-5c4f-463b-bdb4-c2788baeac90" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember_b71687f7-a55c-4519-9063-39950c201476" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BaseRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_ca09076f-b483-4e59-a5b6-9c6f0890635a" xlink:to="loc_us-gaap_BaseRateMember_b71687f7-a55c-4519-9063-39950c201476" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_f603b89f-e250-4e90-831f-12b2e6491622" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_8e1c5577-263d-46d2-93ae-6c088dd741be" xlink:to="loc_srt_RangeAxis_f603b89f-e250-4e90-831f-12b2e6491622" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f603b89f-e250-4e90-831f-12b2e6491622_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_f603b89f-e250-4e90-831f-12b2e6491622" xlink:to="loc_srt_RangeMember_f603b89f-e250-4e90-831f-12b2e6491622_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5edbb5cb-ef3f-41a8-ac8b-8a21d64e94ba" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_f603b89f-e250-4e90-831f-12b2e6491622" xlink:to="loc_srt_RangeMember_5edbb5cb-ef3f-41a8-ac8b-8a21d64e94ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_2abbe7f5-c962-451f-b190-2b1695716928" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_5edbb5cb-ef3f-41a8-ac8b-8a21d64e94ba" xlink:to="loc_srt_MaximumMember_2abbe7f5-c962-451f-b190-2b1695716928" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_3403cf34-9b7f-44ea-a75b-c73ea4974505" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_8e1c5577-263d-46d2-93ae-6c088dd741be" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_3403cf34-9b7f-44ea-a75b-c73ea4974505" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_3403cf34-9b7f-44ea-a75b-c73ea4974505_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_3403cf34-9b7f-44ea-a75b-c73ea4974505" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_3403cf34-9b7f-44ea-a75b-c73ea4974505_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_d65c9b77-8bb6-4d29-b37f-e6f85c48a5d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_3403cf34-9b7f-44ea-a75b-c73ea4974505" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_d65c9b77-8bb6-4d29-b37f-e6f85c48a5d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_d7e98041-ceec-45fc-8e7c-ea494b9e2ed5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_d65c9b77-8bb6-4d29-b37f-e6f85c48a5d8" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_d7e98041-ceec-45fc-8e7c-ea494b9e2ed5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_c80c9740-b892-42f8-9306-f08a1b21398e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_d65c9b77-8bb6-4d29-b37f-e6f85c48a5d8" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_c80c9740-b892-42f8-9306-f08a1b21398e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_915c6a34-58d4-4eba-8be2-22893ba6fc3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_d65c9b77-8bb6-4d29-b37f-e6f85c48a5d8" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_915c6a34-58d4-4eba-8be2-22893ba6fc3a" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LongtermDebtWarrantAgreementDetails" xlink:type="simple" xlink:href="evh-20210630.xsd#LongtermDebtWarrantAgreementDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/LongtermDebtWarrantAgreementDetails" xlink:type="extended" id="ia4223d6cb83545a8a2c9e7df8bdcf6ea_LongtermDebtWarrantAgreementDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_58af2bb8-618c-4d46-8e35-0b1b5f9ae89b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightUnissued_3ea30901-f7cb-4040-aa48-1b0db4b33214" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightUnissued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_58af2bb8-618c-4d46-8e35-0b1b5f9ae89b" xlink:to="loc_us-gaap_ClassOfWarrantOrRightUnissued_3ea30901-f7cb-4040-aa48-1b0db4b33214" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_ab05b3dd-75f5-4524-a8a6-459def213488" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_58af2bb8-618c-4d46-8e35-0b1b5f9ae89b" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_ab05b3dd-75f5-4524-a8a6-459def213488" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ClassOfWarrantOrRightPeriodDuringWhichWarrantsOrRightsExercisableAfterMaturityOfCreditAgreement_ee5021db-180a-4963-b343-3784f9454a2e" xlink:href="evh-20210630.xsd#evh_ClassOfWarrantOrRightPeriodDuringWhichWarrantsOrRightsExercisableAfterMaturityOfCreditAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_58af2bb8-618c-4d46-8e35-0b1b5f9ae89b" xlink:to="loc_evh_ClassOfWarrantOrRightPeriodDuringWhichWarrantsOrRightsExercisableAfterMaturityOfCreditAgreement_ee5021db-180a-4963-b343-3784f9454a2e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfWarrants_134d3b89-116a-42fc-96cd-1ff0d37119be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_58af2bb8-618c-4d46-8e35-0b1b5f9ae89b" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfWarrants_134d3b89-116a-42fc-96cd-1ff0d37119be" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_6eb6f537-79d3-4824-8130-50aaae0ef2ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_58af2bb8-618c-4d46-8e35-0b1b5f9ae89b" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_6eb6f537-79d3-4824-8130-50aaae0ef2ba" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_93ee03a3-b756-4e2f-988d-7a869fca9fce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_6eb6f537-79d3-4824-8130-50aaae0ef2ba" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_93ee03a3-b756-4e2f-988d-7a869fca9fce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_93ee03a3-b756-4e2f-988d-7a869fca9fce_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_93ee03a3-b756-4e2f-988d-7a869fca9fce" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_93ee03a3-b756-4e2f-988d-7a869fca9fce_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_05492ac9-3136-41f4-9370-d9c21123c8a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_93ee03a3-b756-4e2f-988d-7a869fca9fce" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_05492ac9-3136-41f4-9370-d9c21123c8a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_8ed7d10b-5008-4f40-ae1f-b602189adafc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_05492ac9-3136-41f4-9370-d9c21123c8a4" xlink:to="loc_us-gaap_CommonClassAMember_8ed7d10b-5008-4f40-ae1f-b602189adafc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_7f1dc011-977d-41f9-b001-f8b3ebab8be2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_6eb6f537-79d3-4824-8130-50aaae0ef2ba" xlink:to="loc_us-gaap_DebtInstrumentAxis_7f1dc011-977d-41f9-b001-f8b3ebab8be2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_7f1dc011-977d-41f9-b001-f8b3ebab8be2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_7f1dc011-977d-41f9-b001-f8b3ebab8be2" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_7f1dc011-977d-41f9-b001-f8b3ebab8be2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_7075b8a5-1826-48f0-ab6a-0c157990f339" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_7f1dc011-977d-41f9-b001-f8b3ebab8be2" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_7075b8a5-1826-48f0-ab6a-0c157990f339" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CreditAgreementMember_ead3c090-d536-4f40-92fc-1cbb1fb96ef7" xlink:href="evh-20210630.xsd#evh_CreditAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7075b8a5-1826-48f0-ab6a-0c157990f339" xlink:to="loc_evh_CreditAgreementMember_ead3c090-d536-4f40-92fc-1cbb1fb96ef7" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails" xlink:type="simple" xlink:href="evh-20210630.xsd#LongtermDebt2025NotesDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails" xlink:type="extended" id="iffb25a15f5f3409e9adc128175040030_LongtermDebt2025NotesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_26d08983-9f1a-466f-b410-c3dcff33fe2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_1b18db98-ccd3-46ad-9ee1-e1ae2316a02e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_26d08983-9f1a-466f-b410-c3dcff33fe2f" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_1b18db98-ccd3-46ad-9ee1-e1ae2316a02e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_82d1874a-210b-4693-bf40-2604e85c763b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_26d08983-9f1a-466f-b410-c3dcff33fe2f" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_82d1874a-210b-4693-bf40-2604e85c763b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_49b033f7-a0c9-4611-a848-e12f600155b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_26d08983-9f1a-466f-b410-c3dcff33fe2f" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_49b033f7-a0c9-4611-a848-e12f600155b1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_6c8c954a-6d0d-48f5-96ad-0cd8df8f09d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_26d08983-9f1a-466f-b410-c3dcff33fe2f" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_6c8c954a-6d0d-48f5-96ad-0cd8df8f09d6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_df1bb9b6-fc5c-4771-a757-a2f20b806bbd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_26d08983-9f1a-466f-b410-c3dcff33fe2f" xlink:to="loc_us-gaap_InterestExpenseDebt_df1bb9b6-fc5c-4771-a757-a2f20b806bbd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_1fd65d72-5594-46bd-a030-3cae6731abc8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_26d08983-9f1a-466f-b410-c3dcff33fe2f" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_1fd65d72-5594-46bd-a030-3cae6731abc8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_20251fe2-0898-49ac-9130-c6ca47142bb1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_26d08983-9f1a-466f-b410-c3dcff33fe2f" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_20251fe2-0898-49ac-9130-c6ca47142bb1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_d5dc93df-42b5-41c4-ae91-151d73f2e039" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_26d08983-9f1a-466f-b410-c3dcff33fe2f" xlink:to="loc_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_d5dc93df-42b5-41c4-ae91-151d73f2e039" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_a085a08c-9434-4651-abcc-cc21a0fde7ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_26d08983-9f1a-466f-b410-c3dcff33fe2f" xlink:to="loc_us-gaap_LongTermDebt_a085a08c-9434-4651-abcc-cc21a0fde7ba" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_AmortizationOfDebtDiscountAndDebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_bca52550-72ee-4420-a77d-26a65a385925" xlink:href="evh-20210630.xsd#evh_AmortizationOfDebtDiscountAndDebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_26d08983-9f1a-466f-b410-c3dcff33fe2f" xlink:to="loc_evh_AmortizationOfDebtDiscountAndDebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_bca52550-72ee-4420-a77d-26a65a385925" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount_bb0106d3-51cb-4a11-a9de-09c56dc507c7" xlink:href="evh-20210630.xsd#evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_26d08983-9f1a-466f-b410-c3dcff33fe2f" xlink:to="loc_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount_bb0106d3-51cb-4a11-a9de-09c56dc507c7" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice_18d3e7a6-c2f1-48a8-bdb9-95d7ea4a6e4e" xlink:href="evh-20210630.xsd#evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_26d08983-9f1a-466f-b410-c3dcff33fe2f" xlink:to="loc_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice_18d3e7a6-c2f1-48a8-bdb9-95d7ea4a6e4e" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum_9443491a-e2af-4c2e-bc81-e0339fee82be" xlink:href="evh-20210630.xsd#evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_26d08983-9f1a-466f-b410-c3dcff33fe2f" xlink:to="loc_evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum_9443491a-e2af-4c2e-bc81-e0339fee82be" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum_1fda0eed-b5a9-40e5-b231-a09ed9e6edf2" xlink:href="evh-20210630.xsd#evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_26d08983-9f1a-466f-b410-c3dcff33fe2f" xlink:to="loc_evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum_1fda0eed-b5a9-40e5-b231-a09ed9e6edf2" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice_9ad070eb-6689-4745-afb1-f9aa3279a6d3" xlink:href="evh-20210630.xsd#evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_26d08983-9f1a-466f-b410-c3dcff33fe2f" xlink:to="loc_evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice_9ad070eb-6689-4745-afb1-f9aa3279a6d3" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_ed9c5967-f366-4656-94f2-c8fd9cb0a095" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_26d08983-9f1a-466f-b410-c3dcff33fe2f" xlink:to="loc_us-gaap_DebtInstrumentTable_ed9c5967-f366-4656-94f2-c8fd9cb0a095" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_4479a0b3-6cd1-41f7-a61f-2e25001b9799" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_ed9c5967-f366-4656-94f2-c8fd9cb0a095" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_4479a0b3-6cd1-41f7-a61f-2e25001b9799" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_4479a0b3-6cd1-41f7-a61f-2e25001b9799_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_4479a0b3-6cd1-41f7-a61f-2e25001b9799" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_4479a0b3-6cd1-41f7-a61f-2e25001b9799_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_4cf8f14e-01f9-4101-88e0-ffb9512048f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_4479a0b3-6cd1-41f7-a61f-2e25001b9799" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_4cf8f14e-01f9-4101-88e0-ffb9512048f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_4870db0a-e2b7-459f-b116-a11043e9cca3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_4cf8f14e-01f9-4101-88e0-ffb9512048f7" xlink:to="loc_us-gaap_SeniorNotesMember_4870db0a-e2b7-459f-b116-a11043e9cca3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_58076ce8-9d4f-4672-8965-13325cc00481" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_ed9c5967-f366-4656-94f2-c8fd9cb0a095" xlink:to="loc_us-gaap_DebtInstrumentAxis_58076ce8-9d4f-4672-8965-13325cc00481" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_58076ce8-9d4f-4672-8965-13325cc00481_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_58076ce8-9d4f-4672-8965-13325cc00481" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_58076ce8-9d4f-4672-8965-13325cc00481_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_fbdd5e8c-09ec-4a94-94be-d976d68612cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_58076ce8-9d4f-4672-8965-13325cc00481" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_fbdd5e8c-09ec-4a94-94be-d976d68612cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SeniorConvertibleNotesDue2025Member_b815ffd1-3e45-4574-b1e1-b7faf55a0856" xlink:href="evh-20210630.xsd#evh_SeniorConvertibleNotesDue2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_fbdd5e8c-09ec-4a94-94be-d976d68612cf" xlink:to="loc_evh_SeniorConvertibleNotesDue2025Member_b815ffd1-3e45-4574-b1e1-b7faf55a0856" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_4f7d84ee-3ab0-4977-818a-6481281b9233" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_ed9c5967-f366-4656-94f2-c8fd9cb0a095" xlink:to="loc_us-gaap_StatementClassOfStockAxis_4f7d84ee-3ab0-4977-818a-6481281b9233" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_4f7d84ee-3ab0-4977-818a-6481281b9233_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_4f7d84ee-3ab0-4977-818a-6481281b9233" xlink:to="loc_us-gaap_ClassOfStockDomain_4f7d84ee-3ab0-4977-818a-6481281b9233_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_2f5f6c98-5d3f-4b1c-b3fa-47af80908d66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_4f7d84ee-3ab0-4977-818a-6481281b9233" xlink:to="loc_us-gaap_ClassOfStockDomain_2f5f6c98-5d3f-4b1c-b3fa-47af80908d66" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_a52be8dd-a514-4e9c-afea-b43976928b3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_2f5f6c98-5d3f-4b1c-b3fa-47af80908d66" xlink:to="loc_us-gaap_CommonClassAMember_a52be8dd-a514-4e9c-afea-b43976928b3b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_216eb2fe-d4fd-44eb-81c8-e378c3a07930" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_ed9c5967-f366-4656-94f2-c8fd9cb0a095" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_216eb2fe-d4fd-44eb-81c8-e378c3a07930" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_216eb2fe-d4fd-44eb-81c8-e378c3a07930_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_216eb2fe-d4fd-44eb-81c8-e378c3a07930" xlink:to="loc_us-gaap_EquityComponentDomain_216eb2fe-d4fd-44eb-81c8-e378c3a07930_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_f331b519-36db-4968-8668-fa8537c01da7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_216eb2fe-d4fd-44eb-81c8-e378c3a07930" xlink:to="loc_us-gaap_EquityComponentDomain_f331b519-36db-4968-8668-fa8537c01da7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_a4b34362-0b73-468e-be78-ba85e8384cba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_f331b519-36db-4968-8668-fa8537c01da7" xlink:to="loc_us-gaap_CommonStockMember_a4b34362-0b73-468e-be78-ba85e8384cba" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails" xlink:type="simple" xlink:href="evh-20210630.xsd#LongtermDebt2021NotesDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails" xlink:type="extended" id="i0b0825602c384838a72764bdce7724e3_LongtermDebt2021NotesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_421c2e5d-c872-4ef2-aee0-8cc5a5475a95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_fdc33d1e-8a9d-4ea7-a69a-65accaa2569f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_421c2e5d-c872-4ef2-aee0-8cc5a5475a95" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_fdc33d1e-8a9d-4ea7-a69a-65accaa2569f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_39659eed-99c9-4bb4-9539-85984c9f4e51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_421c2e5d-c872-4ef2-aee0-8cc5a5475a95" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_39659eed-99c9-4bb4-9539-85984c9f4e51" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_ee058ab4-8092-4646-9c54-7ad1e44922c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_421c2e5d-c872-4ef2-aee0-8cc5a5475a95" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_ee058ab4-8092-4646-9c54-7ad1e44922c8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_4016b7fc-46db-4f9f-8d01-fa9f685a3ecd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_421c2e5d-c872-4ef2-aee0-8cc5a5475a95" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_4016b7fc-46db-4f9f-8d01-fa9f685a3ecd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount_1bdbb181-0503-4be1-bcec-7bbbff90ad16" xlink:href="evh-20210630.xsd#evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_421c2e5d-c872-4ef2-aee0-8cc5a5475a95" xlink:to="loc_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount_1bdbb181-0503-4be1-bcec-7bbbff90ad16" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_6b29e485-c3f2-4828-a3ed-9dfdff0e4d04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_421c2e5d-c872-4ef2-aee0-8cc5a5475a95" xlink:to="loc_us-gaap_InterestExpenseDebt_6b29e485-c3f2-4828-a3ed-9dfdff0e4d04" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_98fa3e68-3ff6-4094-9bc7-829db5980bcf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_421c2e5d-c872-4ef2-aee0-8cc5a5475a95" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_98fa3e68-3ff6-4094-9bc7-829db5980bcf" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_71713647-48bf-49f6-b4e9-336377c66930" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_421c2e5d-c872-4ef2-aee0-8cc5a5475a95" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_71713647-48bf-49f6-b4e9-336377c66930" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_624e6bea-bb29-4b7a-a116-ba33f4c81fe7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_421c2e5d-c872-4ef2-aee0-8cc5a5475a95" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_624e6bea-bb29-4b7a-a116-ba33f4c81fe7" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_34295ce0-e55e-4fc9-b121-8cbb296926c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_421c2e5d-c872-4ef2-aee0-8cc5a5475a95" xlink:to="loc_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_34295ce0-e55e-4fc9-b121-8cbb296926c7" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_733f1c97-ae49-4971-87e7-090d6d6daf7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_421c2e5d-c872-4ef2-aee0-8cc5a5475a95" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_733f1c97-ae49-4971-87e7-090d6d6daf7f" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionOriginalDebtAmount1_08093cd4-83f5-43ff-9325-1fc1e507ce29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionOriginalDebtAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_421c2e5d-c872-4ef2-aee0-8cc5a5475a95" xlink:to="loc_us-gaap_DebtConversionOriginalDebtAmount1_08093cd4-83f5-43ff-9325-1fc1e507ce29" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_21f5ee44-65d1-43a8-a078-a47fc3bbd89a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_421c2e5d-c872-4ef2-aee0-8cc5a5475a95" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_21f5ee44-65d1-43a8-a078-a47fc3bbd89a" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost_32ce20c4-c598-4964-bf34-d3beb004705f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_421c2e5d-c872-4ef2-aee0-8cc5a5475a95" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost_32ce20c4-c598-4964-bf34-d3beb004705f" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtinguishmentOfDebtAmount_a6647e2c-0e64-4aa2-9393-966d7b118761" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ExtinguishmentOfDebtAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_421c2e5d-c872-4ef2-aee0-8cc5a5475a95" xlink:to="loc_us-gaap_ExtinguishmentOfDebtAmount_a6647e2c-0e64-4aa2-9393-966d7b118761" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSeniorDebt_0b8bc6aa-a035-4d73-894c-301ab05c13b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfSeniorDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_421c2e5d-c872-4ef2-aee0-8cc5a5475a95" xlink:to="loc_us-gaap_RepaymentsOfSeniorDebt_0b8bc6aa-a035-4d73-894c-301ab05c13b5" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_210962ae-785b-4c08-aa70-5fa40fe085ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_421c2e5d-c872-4ef2-aee0-8cc5a5475a95" xlink:to="loc_us-gaap_DebtInstrumentTable_210962ae-785b-4c08-aa70-5fa40fe085ca" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_ea6bec50-8ea2-40c4-99f0-50bb594c4628" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_210962ae-785b-4c08-aa70-5fa40fe085ca" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_ea6bec50-8ea2-40c4-99f0-50bb594c4628" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_ea6bec50-8ea2-40c4-99f0-50bb594c4628_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_ea6bec50-8ea2-40c4-99f0-50bb594c4628" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_ea6bec50-8ea2-40c4-99f0-50bb594c4628_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_6b8cc85c-81c7-40dc-bea5-fbcad4975e74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_ea6bec50-8ea2-40c4-99f0-50bb594c4628" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_6b8cc85c-81c7-40dc-bea5-fbcad4975e74" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_9c36d011-64e9-465d-ab6c-b0019de7f700" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_6b8cc85c-81c7-40dc-bea5-fbcad4975e74" xlink:to="loc_us-gaap_SeniorNotesMember_9c36d011-64e9-465d-ab6c-b0019de7f700" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_9840bb7e-59aa-4f61-87db-8ff8e776cb36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_210962ae-785b-4c08-aa70-5fa40fe085ca" xlink:to="loc_us-gaap_DebtInstrumentAxis_9840bb7e-59aa-4f61-87db-8ff8e776cb36" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_9840bb7e-59aa-4f61-87db-8ff8e776cb36_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_9840bb7e-59aa-4f61-87db-8ff8e776cb36" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_9840bb7e-59aa-4f61-87db-8ff8e776cb36_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_8869322a-506a-42bc-81ae-234acd0e7f36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_9840bb7e-59aa-4f61-87db-8ff8e776cb36" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_8869322a-506a-42bc-81ae-234acd0e7f36" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ConvertibleSeniorNotesdue2021Member_b574823d-e87d-4340-a86d-83b00351789f" xlink:href="evh-20210630.xsd#evh_ConvertibleSeniorNotesdue2021Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8869322a-506a-42bc-81ae-234acd0e7f36" xlink:to="loc_evh_ConvertibleSeniorNotesdue2021Member_b574823d-e87d-4340-a86d-83b00351789f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SeniorConvertibleNotesDue2024Member_353bdf36-7e20-4dcd-9f73-5df11ae636c7" xlink:href="evh-20210630.xsd#evh_SeniorConvertibleNotesDue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8869322a-506a-42bc-81ae-234acd0e7f36" xlink:to="loc_evh_SeniorConvertibleNotesDue2024Member_353bdf36-7e20-4dcd-9f73-5df11ae636c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_43bce4f2-d63f-4b6b-a54b-8f5907a617af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_210962ae-785b-4c08-aa70-5fa40fe085ca" xlink:to="loc_us-gaap_StatementClassOfStockAxis_43bce4f2-d63f-4b6b-a54b-8f5907a617af" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_43bce4f2-d63f-4b6b-a54b-8f5907a617af_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_43bce4f2-d63f-4b6b-a54b-8f5907a617af" xlink:to="loc_us-gaap_ClassOfStockDomain_43bce4f2-d63f-4b6b-a54b-8f5907a617af_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_403d489f-4963-4d0d-aba7-41e00e80bd83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_43bce4f2-d63f-4b6b-a54b-8f5907a617af" xlink:to="loc_us-gaap_ClassOfStockDomain_403d489f-4963-4d0d-aba7-41e00e80bd83" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_8072b12e-dc46-4d94-bf79-92954e1c434b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_403d489f-4963-4d0d-aba7-41e00e80bd83" xlink:to="loc_us-gaap_CommonClassAMember_8072b12e-dc46-4d94-bf79-92954e1c434b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_73d31921-1423-4415-aa4d-0f5005620df6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_210962ae-785b-4c08-aa70-5fa40fe085ca" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_73d31921-1423-4415-aa4d-0f5005620df6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_73d31921-1423-4415-aa4d-0f5005620df6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_73d31921-1423-4415-aa4d-0f5005620df6" xlink:to="loc_us-gaap_EquityComponentDomain_73d31921-1423-4415-aa4d-0f5005620df6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_33c2325b-36c3-4b22-b014-4f6ab48762b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_73d31921-1423-4415-aa4d-0f5005620df6" xlink:to="loc_us-gaap_EquityComponentDomain_33c2325b-36c3-4b22-b014-4f6ab48762b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_9a956d6a-4702-4c81-bdc9-c87ea4f242b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_33c2325b-36c3-4b22-b014-4f6ab48762b1" xlink:to="loc_us-gaap_CommonStockMember_9a956d6a-4702-4c81-bdc9-c87ea4f242b6" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails" xlink:type="simple" xlink:href="evh-20210630.xsd#LongtermDebtConvertibleSeniorNotesCarryingValueDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails" xlink:type="extended" id="if7e38b8e61244a85a40042d638c75802_LongtermDebtConvertibleSeniorNotesCarryingValueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_a7237aa4-5398-4ae8-a37f-57eb267d444c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebt_1fead341-8cfa-4ac9-9056-4b8fb9d70605" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a7237aa4-5398-4ae8-a37f-57eb267d444c" xlink:to="loc_us-gaap_ConvertibleDebt_1fead341-8cfa-4ac9-9056-4b8fb9d70605" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_cd8e6b27-adcf-4dc5-a4b5-adb63e1d0978" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a7237aa4-5398-4ae8-a37f-57eb267d444c" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_cd8e6b27-adcf-4dc5-a4b5-adb63e1d0978" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_1e7e3ef4-7d2d-4b58-83bb-1a133c9c3a92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a7237aa4-5398-4ae8-a37f-57eb267d444c" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_1e7e3ef4-7d2d-4b58-83bb-1a133c9c3a92" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_bc947483-3a7a-431c-9484-839c93c02a98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a7237aa4-5398-4ae8-a37f-57eb267d444c" xlink:to="loc_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_bc947483-3a7a-431c-9484-839c93c02a98" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue_d0137a53-d037-46f1-9923-2423a3cc7c8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a7237aa4-5398-4ae8-a37f-57eb267d444c" xlink:to="loc_us-gaap_LongTermDebtFairValue_d0137a53-d037-46f1-9923-2423a3cc7c8a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_b064a151-2e46-46ec-87b8-68dcec0b61c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a7237aa4-5398-4ae8-a37f-57eb267d444c" xlink:to="loc_us-gaap_DebtInstrumentTable_b064a151-2e46-46ec-87b8-68dcec0b61c2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_8612e474-7007-4dba-8231-d069463ddee3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_b064a151-2e46-46ec-87b8-68dcec0b61c2" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_8612e474-7007-4dba-8231-d069463ddee3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_8612e474-7007-4dba-8231-d069463ddee3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_8612e474-7007-4dba-8231-d069463ddee3" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_8612e474-7007-4dba-8231-d069463ddee3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_37b9a162-bbae-42f6-85a1-c841c134cb29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_8612e474-7007-4dba-8231-d069463ddee3" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_37b9a162-bbae-42f6-85a1-c841c134cb29" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_7164ca4a-eacf-40ce-848e-874c1e69515c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_37b9a162-bbae-42f6-85a1-c841c134cb29" xlink:to="loc_us-gaap_SeniorNotesMember_7164ca4a-eacf-40ce-848e-874c1e69515c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_7ed68a98-b544-4e31-8935-96779f3e5bd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_b064a151-2e46-46ec-87b8-68dcec0b61c2" xlink:to="loc_us-gaap_DebtInstrumentAxis_7ed68a98-b544-4e31-8935-96779f3e5bd4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_7ed68a98-b544-4e31-8935-96779f3e5bd4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_7ed68a98-b544-4e31-8935-96779f3e5bd4" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_7ed68a98-b544-4e31-8935-96779f3e5bd4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_f5497986-e5fc-4b95-8c69-2aee01028ceb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_7ed68a98-b544-4e31-8935-96779f3e5bd4" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_f5497986-e5fc-4b95-8c69-2aee01028ceb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SeniorConvertibleNotesDue2024Member_d94148e8-0e9d-46e4-a455-ec9236e6d464" xlink:href="evh-20210630.xsd#evh_SeniorConvertibleNotesDue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f5497986-e5fc-4b95-8c69-2aee01028ceb" xlink:to="loc_evh_SeniorConvertibleNotesDue2024Member_d94148e8-0e9d-46e4-a455-ec9236e6d464" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SeniorConvertibleNotesDue2025Member_50e33193-74db-4c37-b7a1-6e0abed68ca2" xlink:href="evh-20210630.xsd#evh_SeniorConvertibleNotesDue2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f5497986-e5fc-4b95-8c69-2aee01028ceb" xlink:to="loc_evh_SeniorConvertibleNotesDue2025Member_50e33193-74db-4c37-b7a1-6e0abed68ca2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ConvertibleSeniorNotesdue2021Member_5539a2ac-002d-490c-88dc-f744e7c33c68" xlink:href="evh-20210630.xsd#evh_ConvertibleSeniorNotesdue2021Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f5497986-e5fc-4b95-8c69-2aee01028ceb" xlink:to="loc_evh_ConvertibleSeniorNotesdue2021Member_5539a2ac-002d-490c-88dc-f744e7c33c68" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_569ce343-010b-429e-9e99-d90fae57a896" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_b064a151-2e46-46ec-87b8-68dcec0b61c2" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_569ce343-010b-429e-9e99-d90fae57a896" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_569ce343-010b-429e-9e99-d90fae57a896_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_569ce343-010b-429e-9e99-d90fae57a896" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_569ce343-010b-429e-9e99-d90fae57a896_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_62ba3941-aacb-4c9d-b302-4d3ac8739374" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_569ce343-010b-429e-9e99-d90fae57a896" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_62ba3941-aacb-4c9d-b302-4d3ac8739374" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_70869fef-53ce-467f-9097-6b6ae58c6713" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_62ba3941-aacb-4c9d-b302-4d3ac8739374" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_70869fef-53ce-467f-9097-6b6ae58c6713" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="simple" xlink:href="evh-20210630.xsd#CommitmentsandContingenciesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="extended" id="i0c11cf2e70cb43b68f51eaf855638f0e_CommitmentsandContingenciesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_02d9ace2-6fef-4364-9673-453dd5de3bd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_f51adf6b-4486-485f-b671-7ff98c60970b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_02d9ace2-6fef-4364-9673-453dd5de3bd4" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_f51adf6b-4486-485f-b671-7ff98c60970b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_6deeb03b-0a82-484d-b20b-187bcad53c85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_02d9ace2-6fef-4364-9673-453dd5de3bd4" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_6deeb03b-0a82-484d-b20b-187bcad53c85" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PaymentsToAcquireEquityMethodInvestmentsAmountHeldBack_2a2e4d0b-5d53-449a-a2cc-34cf28f86559" xlink:href="evh-20210630.xsd#evh_PaymentsToAcquireEquityMethodInvestmentsAmountHeldBack"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_02d9ace2-6fef-4364-9673-453dd5de3bd4" xlink:to="loc_evh_PaymentsToAcquireEquityMethodInvestmentsAmountHeldBack_2a2e4d0b-5d53-449a-a2cc-34cf28f86559" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TaxReceivablesAgreementPercentofTaxSavingstobePaid_447bf0f7-3bb2-4738-b153-f73045e76e38" xlink:href="evh-20210630.xsd#evh_TaxReceivablesAgreementPercentofTaxSavingstobePaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_02d9ace2-6fef-4364-9673-453dd5de3bd4" xlink:to="loc_evh_TaxReceivablesAgreementPercentofTaxSavingstobePaid_447bf0f7-3bb2-4738-b153-f73045e76e38" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_65c79b1a-5cad-4daf-966d-189b04b7c3ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_02d9ace2-6fef-4364-9673-453dd5de3bd4" xlink:to="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_65c79b1a-5cad-4daf-966d-189b04b7c3ff" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_cc824414-5bd8-46a5-85d1-6989291fa20f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_65c79b1a-5cad-4daf-966d-189b04b7c3ff" xlink:to="loc_us-gaap_CreditFacilityAxis_cc824414-5bd8-46a5-85d1-6989291fa20f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_cc824414-5bd8-46a5-85d1-6989291fa20f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_cc824414-5bd8-46a5-85d1-6989291fa20f" xlink:to="loc_us-gaap_CreditFacilityDomain_cc824414-5bd8-46a5-85d1-6989291fa20f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_06125bd7-01f4-442f-888e-2197c2c46cd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_cc824414-5bd8-46a5-85d1-6989291fa20f" xlink:to="loc_us-gaap_CreditFacilityDomain_06125bd7-01f4-442f-888e-2197c2c46cd4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_67c11ef1-0dfd-4102-bfbc-fc52f4a5c314" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LetterOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_06125bd7-01f4-442f-888e-2197c2c46cd4" xlink:to="loc_us-gaap_LetterOfCreditMember_67c11ef1-0dfd-4102-bfbc-fc52f4a5c314" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_b8753d65-1d84-4f41-9b6c-dd4da31f1114" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_65c79b1a-5cad-4daf-966d-189b04b7c3ff" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_b8753d65-1d84-4f41-9b6c-dd4da31f1114" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_b8753d65-1d84-4f41-9b6c-dd4da31f1114_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_b8753d65-1d84-4f41-9b6c-dd4da31f1114" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_b8753d65-1d84-4f41-9b6c-dd4da31f1114_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_61ce72a9-60db-4c1e-9a43-be89354c41fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_b8753d65-1d84-4f41-9b6c-dd4da31f1114" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_61ce72a9-60db-4c1e-9a43-be89354c41fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_c7b6dd14-ed44-4ccc-8297-4a8fdda29d75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_61ce72a9-60db-4c1e-9a43-be89354c41fa" xlink:to="loc_us-gaap_LineOfCreditMember_c7b6dd14-ed44-4ccc-8297-4a8fdda29d75" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_1ae19ca4-f392-4b01-9780-5f5ce69804c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_65c79b1a-5cad-4daf-966d-189b04b7c3ff" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_1ae19ca4-f392-4b01-9780-5f5ce69804c4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1ae19ca4-f392-4b01-9780-5f5ce69804c4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_1ae19ca4-f392-4b01-9780-5f5ce69804c4" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1ae19ca4-f392-4b01-9780-5f5ce69804c4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_5d161731-a0c7-4f70-bfe9-6fbc128f3a56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_1ae19ca4-f392-4b01-9780-5f5ce69804c4" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_5d161731-a0c7-4f70-bfe9-6fbc128f3a56" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RestrictedCashForLettersOfCreditForLetterOfCreditFacilityMember_da73b426-bf70-4b28-9ae2-361d8c1bf2b1" xlink:href="evh-20210630.xsd#evh_RestrictedCashForLettersOfCreditForLetterOfCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_5d161731-a0c7-4f70-bfe9-6fbc128f3a56" xlink:to="loc_evh_RestrictedCashForLettersOfCreditForLetterOfCreditFacilityMember_da73b426-bf70-4b28-9ae2-361d8c1bf2b1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CollateralwithFinancialInstitutionsMember_c6cb8ac2-a0fc-416a-8f3e-cdeb3920822d" xlink:href="evh-20210630.xsd#evh_CollateralwithFinancialInstitutionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_5d161731-a0c7-4f70-bfe9-6fbc128f3a56" xlink:to="loc_evh_CollateralwithFinancialInstitutionsMember_c6cb8ac2-a0fc-416a-8f3e-cdeb3920822d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_2ee04854-0d22-43c5-8173-5f4ef3652c24" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_65c79b1a-5cad-4daf-966d-189b04b7c3ff" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_2ee04854-0d22-43c5-8173-5f4ef3652c24" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_2ee04854-0d22-43c5-8173-5f4ef3652c24_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_2ee04854-0d22-43c5-8173-5f4ef3652c24" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_2ee04854-0d22-43c5-8173-5f4ef3652c24_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_1289d308-072c-493f-8ca0-d2415303d4e1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_2ee04854-0d22-43c5-8173-5f4ef3652c24" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_1289d308-072c-493f-8ca0-d2415303d4e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_UniversityHealthCaredbaPassportHealthPlanMember_78b33c75-5d74-4057-b9c5-6e24c00521cf" xlink:href="evh-20210630.xsd#evh_UniversityHealthCaredbaPassportHealthPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_1289d308-072c-493f-8ca0-d2415303d4e1" xlink:to="loc_evh_UniversityHealthCaredbaPassportHealthPlanMember_78b33c75-5d74-4057-b9c5-6e24c00521cf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_df0f4096-8d0e-4764-b611-13a1e44f7ba4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_65c79b1a-5cad-4daf-966d-189b04b7c3ff" xlink:to="loc_srt_ConsolidatedEntitiesAxis_df0f4096-8d0e-4764-b611-13a1e44f7ba4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_df0f4096-8d0e-4764-b611-13a1e44f7ba4_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_df0f4096-8d0e-4764-b611-13a1e44f7ba4" xlink:to="loc_srt_ConsolidatedEntitiesDomain_df0f4096-8d0e-4764-b611-13a1e44f7ba4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_c3d3c6cb-4483-4fde-9c61-432f9a5d090c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_df0f4096-8d0e-4764-b611-13a1e44f7ba4" xlink:to="loc_srt_ConsolidatedEntitiesDomain_c3d3c6cb-4483-4fde-9c61-432f9a5d090c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_5bd75052-7e21-4f5b-be89-fac20d4e4c69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_c3d3c6cb-4483-4fde-9c61-432f9a5d090c" xlink:to="loc_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_5bd75052-7e21-4f5b-be89-fac20d4e4c69" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails" xlink:type="simple" xlink:href="evh-20210630.xsd#CommitmentsandContingenciesConcentrationRiskDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails" xlink:type="extended" id="i33409f277b884613b8c5dfea7229f3f4_CommitmentsandContingenciesConcentrationRiskDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_f1de7178-73c8-4a0f-bc72-375dfaeb08e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CashFDICInsuredAmountPercentage_be757574-e22c-4970-8214-e6dfa5c6f50d" xlink:href="evh-20210630.xsd#evh_CashFDICInsuredAmountPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_f1de7178-73c8-4a0f-bc72-375dfaeb08e0" xlink:to="loc_evh_CashFDICInsuredAmountPercentage_be757574-e22c-4970-8214-e6dfa5c6f50d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_994f0bbe-fa66-485d-bae1-570bd5636e5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_f1de7178-73c8-4a0f-bc72-375dfaeb08e0" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_994f0bbe-fa66-485d-bae1-570bd5636e5a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CashHeldInInternationalBanksPercentage_1a53a052-3241-450f-82b2-6b44de852797" xlink:href="evh-20210630.xsd#evh_CashHeldInInternationalBanksPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_f1de7178-73c8-4a0f-bc72-375dfaeb08e0" xlink:to="loc_evh_CashHeldInInternationalBanksPercentage_1a53a052-3241-450f-82b2-6b44de852797" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_d525eb2a-b755-46db-8390-2e832314239a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_f1de7178-73c8-4a0f-bc72-375dfaeb08e0" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_d525eb2a-b755-46db-8390-2e832314239a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_8db36f2f-2149-4c3a-9914-cdf5cae94498" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_f1de7178-73c8-4a0f-bc72-375dfaeb08e0" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_8db36f2f-2149-4c3a-9914-cdf5cae94498" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_227fb238-1a37-4e4c-81b3-85c62edd787b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_f1de7178-73c8-4a0f-bc72-375dfaeb08e0" xlink:to="loc_us-gaap_ConcentrationRiskTable_227fb238-1a37-4e4c-81b3-85c62edd787b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_f7a53398-3ed8-4f6c-88b7-745dbc1a5f36" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_227fb238-1a37-4e4c-81b3-85c62edd787b" xlink:to="loc_srt_MajorCustomersAxis_f7a53398-3ed8-4f6c-88b7-745dbc1a5f36" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_f7a53398-3ed8-4f6c-88b7-745dbc1a5f36_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_f7a53398-3ed8-4f6c-88b7-745dbc1a5f36" xlink:to="loc_srt_NameOfMajorCustomerDomain_f7a53398-3ed8-4f6c-88b7-745dbc1a5f36_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_ab8fa31e-d68d-4586-b50b-b3e40a90a918" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_f7a53398-3ed8-4f6c-88b7-745dbc1a5f36" xlink:to="loc_srt_NameOfMajorCustomerDomain_ab8fa31e-d68d-4586-b50b-b3e40a90a918" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CookCountyHealthAndHospitalsSystemMember_ce70b98c-6ab9-4223-b63d-fc5bd74ce1ef" xlink:href="evh-20210630.xsd#evh_CookCountyHealthAndHospitalsSystemMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_ab8fa31e-d68d-4586-b50b-b3e40a90a918" xlink:to="loc_evh_CookCountyHealthAndHospitalsSystemMember_ce70b98c-6ab9-4223-b63d-fc5bd74ce1ef" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_FloridaBlueMedicareIncMember_7f34774b-e14a-44cd-87a7-82da4c067cfb" xlink:href="evh-20210630.xsd#evh_FloridaBlueMedicareIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_ab8fa31e-d68d-4586-b50b-b3e40a90a918" xlink:to="loc_evh_FloridaBlueMedicareIncMember_7f34774b-e14a-44cd-87a7-82da4c067cfb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_NeighborhoodHealthPlanOfRhodeIslandMember_a2432311-f04d-45fe-a668-5d673cb3f11c" xlink:href="evh-20210630.xsd#evh_NeighborhoodHealthPlanOfRhodeIslandMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_ab8fa31e-d68d-4586-b50b-b3e40a90a918" xlink:to="loc_evh_NeighborhoodHealthPlanOfRhodeIslandMember_a2432311-f04d-45fe-a668-5d673cb3f11c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_UniversityHealthCaredbaPassportHealthPlanMember_9476a535-8eba-4945-a2f8-2ebc30c27dac" xlink:href="evh-20210630.xsd#evh_UniversityHealthCaredbaPassportHealthPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_ab8fa31e-d68d-4586-b50b-b3e40a90a918" xlink:to="loc_evh_UniversityHealthCaredbaPassportHealthPlanMember_9476a535-8eba-4945-a2f8-2ebc30c27dac" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_326d7fac-c88f-4ae0-9853-b45184ed2dcd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_227fb238-1a37-4e4c-81b3-85c62edd787b" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_326d7fac-c88f-4ae0-9853-b45184ed2dcd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_326d7fac-c88f-4ae0-9853-b45184ed2dcd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_326d7fac-c88f-4ae0-9853-b45184ed2dcd" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_326d7fac-c88f-4ae0-9853-b45184ed2dcd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_6a87ee6d-6a58-4938-b5ca-2abd249af400" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_326d7fac-c88f-4ae0-9853-b45184ed2dcd" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_6a87ee6d-6a58-4938-b5ca-2abd249af400" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_154fcde0-a3a9-4cca-84c0-30132c6f0539" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_6a87ee6d-6a58-4938-b5ca-2abd249af400" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_154fcde0-a3a9-4cca-84c0-30132c6f0539" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_7e881131-226a-4563-909f-60b5d2ced10c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_227fb238-1a37-4e4c-81b3-85c62edd787b" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_7e881131-226a-4563-909f-60b5d2ced10c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_7e881131-226a-4563-909f-60b5d2ced10c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_7e881131-226a-4563-909f-60b5d2ced10c" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_7e881131-226a-4563-909f-60b5d2ced10c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_2b7f2a51-2e90-46a2-94e5-32182b389f80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_7e881131-226a-4563-909f-60b5d2ced10c" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_2b7f2a51-2e90-46a2-94e5-32182b389f80" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_47b71b0b-c3b0-42ee-abb5-1d7ae3683480" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_2b7f2a51-2e90-46a2-94e5-32182b389f80" xlink:to="loc_us-gaap_AccountsReceivableMember_47b71b0b-c3b0-42ee-abb5-1d7ae3683480" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_6aad0c4a-f4cb-4d83-a597-9826fa4dc81d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_2b7f2a51-2e90-46a2-94e5-32182b389f80" xlink:to="loc_us-gaap_SalesRevenueNetMember_6aad0c4a-f4cb-4d83-a597-9826fa4dc81d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_923a1f60-bbd6-48ad-a22b-8a41238b935a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_227fb238-1a37-4e4c-81b3-85c62edd787b" xlink:to="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_923a1f60-bbd6-48ad-a22b-8a41238b935a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_923a1f60-bbd6-48ad-a22b-8a41238b935a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_923a1f60-bbd6-48ad-a22b-8a41238b935a" xlink:to="loc_us-gaap_ReceivableTypeDomain_923a1f60-bbd6-48ad-a22b-8a41238b935a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_bf388578-1c3d-41a8-b1b5-195013117283" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_923a1f60-bbd6-48ad-a22b-8a41238b935a" xlink:to="loc_us-gaap_ReceivableTypeDomain_bf388578-1c3d-41a8-b1b5-195013117283" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceReceivablesMember_5ed4369f-bb6f-42bb-a657-03b7597e2255" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceReceivablesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReceivableTypeDomain_bf388578-1c3d-41a8-b1b5-195013117283" xlink:to="loc_us-gaap_FinanceReceivablesMember_5ed4369f-bb6f-42bb-a657-03b7597e2255" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_31795ce8-83f0-41d8-89a2-7c85c0d53842" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_227fb238-1a37-4e4c-81b3-85c62edd787b" xlink:to="loc_srt_ProductOrServiceAxis_31795ce8-83f0-41d8-89a2-7c85c0d53842" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_31795ce8-83f0-41d8-89a2-7c85c0d53842_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_31795ce8-83f0-41d8-89a2-7c85c0d53842" xlink:to="loc_srt_ProductsAndServicesDomain_31795ce8-83f0-41d8-89a2-7c85c0d53842_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_295155ea-f978-4e9f-8894-03b15075c7f1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_31795ce8-83f0-41d8-89a2-7c85c0d53842" xlink:to="loc_srt_ProductsAndServicesDomain_295155ea-f978-4e9f-8894-03b15075c7f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PremiumsRevenueMember_c0c3ce32-64d7-4c91-9435-0f5fd3e28e9d" xlink:href="evh-20210630.xsd#evh_PremiumsRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_295155ea-f978-4e9f-8894-03b15075c7f1" xlink:to="loc_evh_PremiumsRevenueMember_c0c3ce32-64d7-4c91-9435-0f5fd3e28e9d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_ab27e3bd-b804-4b63-8afe-21f901610e94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_227fb238-1a37-4e4c-81b3-85c62edd787b" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_ab27e3bd-b804-4b63-8afe-21f901610e94" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_ab27e3bd-b804-4b63-8afe-21f901610e94_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_ab27e3bd-b804-4b63-8afe-21f901610e94" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_ab27e3bd-b804-4b63-8afe-21f901610e94_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_332421a5-ad8b-4335-9c19-d4e769bb3abe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_ab27e3bd-b804-4b63-8afe-21f901610e94" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_332421a5-ad8b-4335-9c19-d4e769bb3abe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_ec6b073d-5ed7-4733-8d6b-1e375ad25916" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationsDisposedOfBySaleMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_332421a5-ad8b-4335-9c19-d4e769bb3abe" xlink:to="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_ec6b073d-5ed7-4733-8d6b-1e375ad25916" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_5305b613-c99a-4d23-bc0f-b73a31cf75fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_227fb238-1a37-4e4c-81b3-85c62edd787b" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_5305b613-c99a-4d23-bc0f-b73a31cf75fe" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_5305b613-c99a-4d23-bc0f-b73a31cf75fe_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_5305b613-c99a-4d23-bc0f-b73a31cf75fe" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_5305b613-c99a-4d23-bc0f-b73a31cf75fe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_1992ad70-02b3-45ef-9127-943d9e8886ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_5305b613-c99a-4d23-bc0f-b73a31cf75fe" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_1992ad70-02b3-45ef-9127-943d9e8886ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TrueHealthMember_3320909b-7a8e-468a-b335-35aa9c678369" xlink:href="evh-20210630.xsd#evh_TrueHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_1992ad70-02b3-45ef-9127-943d9e8886ca" xlink:to="loc_evh_TrueHealthMember_3320909b-7a8e-468a-b335-35aa9c678369" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="evh-20210630.xsd#LeasesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/LeasesNarrativeDetails" xlink:type="extended" id="i0a57af74df924b3ba8e52aefc90ff1d0_LeasesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_6303a5ea-30c5-40f9-bc5c-d12a22ace8a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_a423b026-95b3-4313-a2b4-993931eadd8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6303a5ea-30c5-40f9-bc5c-d12a22ace8a4" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_a423b026-95b3-4313-a2b4-993931eadd8f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_e1cd4bc0-4cdc-4fda-956e-8c2a1718824f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6303a5ea-30c5-40f9-bc5c-d12a22ace8a4" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_e1cd4bc0-4cdc-4fda-956e-8c2a1718824f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_149d2216-3ee4-480a-9cae-08ee5f15d029" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6303a5ea-30c5-40f9-bc5c-d12a22ace8a4" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_149d2216-3ee4-480a-9cae-08ee5f15d029" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsAxis_6d490664-52cd-411e-99b3-fea78fa8bc85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_149d2216-3ee4-480a-9cae-08ee5f15d029" xlink:to="loc_us-gaap_OtherCommitmentsAxis_6d490664-52cd-411e-99b3-fea78fa8bc85" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain_6d490664-52cd-411e-99b3-fea78fa8bc85_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_OtherCommitmentsAxis_6d490664-52cd-411e-99b3-fea78fa8bc85" xlink:to="loc_us-gaap_OtherCommitmentsDomain_6d490664-52cd-411e-99b3-fea78fa8bc85_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain_029d386f-e0d4-404e-a057-e0f7d9c874cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_OtherCommitmentsAxis_6d490664-52cd-411e-99b3-fea78fa8bc85" xlink:to="loc_us-gaap_OtherCommitmentsDomain_029d386f-e0d4-404e-a057-e0f7d9c874cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseAgreementsMember_6fa31625-b97c-4668-a294-a338fcabab69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsDomain_029d386f-e0d4-404e-a057-e0f7d9c874cf" xlink:to="loc_us-gaap_LeaseAgreementsMember_6fa31625-b97c-4668-a294-a338fcabab69" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LeasesMaterialOfficeLeasesDetails" xlink:type="simple" xlink:href="evh-20210630.xsd#LeasesMaterialOfficeLeasesDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/LeasesMaterialOfficeLeasesDetails" xlink:type="extended" id="i4987264ae2744816bc839c3a75c3ed06_LeasesMaterialOfficeLeasesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_a4f7dd59-99ea-4edd-b8e8-70b317a60d48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_26dff5be-3985-4941-97d5-83ae7a35f5dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a4f7dd59-99ea-4edd-b8e8-70b317a60d48" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_26dff5be-3985-4941-97d5-83ae7a35f5dd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_5afa60a4-9222-47ac-9452-e9431accf583" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a4f7dd59-99ea-4edd-b8e8-70b317a60d48" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_5afa60a4-9222-47ac-9452-e9431accf583" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_52ef1f6f-13a6-4f0d-b496-ca82c13ca3d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a4f7dd59-99ea-4edd-b8e8-70b317a60d48" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_52ef1f6f-13a6-4f0d-b496-ca82c13ca3d0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_801b4e2e-2d49-4ce9-a0d8-7f9a9cc7935d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a4f7dd59-99ea-4edd-b8e8-70b317a60d48" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_801b4e2e-2d49-4ce9-a0d8-7f9a9cc7935d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_6821ab9e-687f-451a-8a52-1fe2d0c8f482" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_801b4e2e-2d49-4ce9-a0d8-7f9a9cc7935d" xlink:to="loc_srt_StatementGeographicalAxis_6821ab9e-687f-451a-8a52-1fe2d0c8f482" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_6821ab9e-687f-451a-8a52-1fe2d0c8f482_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_6821ab9e-687f-451a-8a52-1fe2d0c8f482" xlink:to="loc_srt_SegmentGeographicalDomain_6821ab9e-687f-451a-8a52-1fe2d0c8f482_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_40e2f1ab-8273-458e-87d0-7ff9989571cf" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_6821ab9e-687f-451a-8a52-1fe2d0c8f482" xlink:to="loc_srt_SegmentGeographicalDomain_40e2f1ab-8273-458e-87d0-7ff9989571cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_VA_785ac047-64d6-473b-965f-77fd2c2aa8fa" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_VA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_40e2f1ab-8273-458e-87d0-7ff9989571cf" xlink:to="loc_stpr_VA_785ac047-64d6-473b-965f-77fd2c2aa8fa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_IL_8872cbc1-b64f-480f-a698-cba0ffbc03d5" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_IL"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_40e2f1ab-8273-458e-87d0-7ff9989571cf" xlink:to="loc_stpr_IL_8872cbc1-b64f-480f-a698-cba0ffbc03d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_IN_1ea6b33b-f3e7-4a9a-a8e4-0abb4c2f8863" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_IN"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_40e2f1ab-8273-458e-87d0-7ff9989571cf" xlink:to="loc_country_IN_1ea6b33b-f3e7-4a9a-a8e4-0abb4c2f8863" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CA_db968440-b3fb-427c-ac2f-64ef1987a74b" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_CA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_40e2f1ab-8273-458e-87d0-7ff9989571cf" xlink:to="loc_stpr_CA_db968440-b3fb-427c-ac2f-64ef1987a74b" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/EarningsLossPerCommonShareAntidilutiveSecuritiesDetails" xlink:type="simple" xlink:href="evh-20210630.xsd#EarningsLossPerCommonShareAntidilutiveSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/EarningsLossPerCommonShareAntidilutiveSecuritiesDetails" xlink:type="extended" id="idd154a03b4d94386824fe384284ff410_EarningsLossPerCommonShareAntidilutiveSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_b89d8393-af55-4cfd-abf3-96b0970e6f62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_be95cf50-ab52-4e66-a79c-48c1a91e3f4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_b89d8393-af55-4cfd-abf3-96b0970e6f62" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_be95cf50-ab52-4e66-a79c-48c1a91e3f4a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_2969f381-4365-4692-ad86-14eb3141f563" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_b89d8393-af55-4cfd-abf3-96b0970e6f62" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_2969f381-4365-4692-ad86-14eb3141f563" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_7d97b759-3bdd-4df7-8b43-1ab967f8d6ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_2969f381-4365-4692-ad86-14eb3141f563" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_7d97b759-3bdd-4df7-8b43-1ab967f8d6ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_7d97b759-3bdd-4df7-8b43-1ab967f8d6ca_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_7d97b759-3bdd-4df7-8b43-1ab967f8d6ca" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_7d97b759-3bdd-4df7-8b43-1ab967f8d6ca_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5485bed9-13b6-49ca-b4d6-f72abe58b2fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_7d97b759-3bdd-4df7-8b43-1ab967f8d6ca" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5485bed9-13b6-49ca-b4d6-f72abe58b2fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember_f756dad9-760e-4415-b21f-c59c1e1c2933" xlink:href="evh-20210630.xsd#evh_RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5485bed9-13b6-49ca-b4d6-f72abe58b2fe" xlink:to="loc_evh_RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember_f756dad9-760e-4415-b21f-c59c1e1c2933" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_9567e7e5-4672-4d7a-ba3b-2449ac57a634" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5485bed9-13b6-49ca-b4d6-f72abe58b2fe" xlink:to="loc_us-gaap_EmployeeStockOptionMember_9567e7e5-4672-4d7a-ba3b-2449ac57a634" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_5b8235e0-24e7-4e81-b954-825a9038bc78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5485bed9-13b6-49ca-b4d6-f72abe58b2fe" xlink:to="loc_us-gaap_ConvertibleDebtMember_5b8235e0-24e7-4e81-b954-825a9038bc78" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails" xlink:type="simple" xlink:href="evh-20210630.xsd#StockbasedCompensationStockbasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails" xlink:type="extended" id="i448bf7f8c2f545f8a5d88e02f21718f3_StockbasedCompensationStockbasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_00224db2-b9f5-4e7a-8793-9a29a6887147" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_f054699e-2525-4f7f-b0e9-33b219bdeefe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_00224db2-b9f5-4e7a-8793-9a29a6887147" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_f054699e-2525-4f7f-b0e9-33b219bdeefe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_5235ad6f-90b7-4350-9f2a-e8abb1a5cfdd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_00224db2-b9f5-4e7a-8793-9a29a6887147" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_5235ad6f-90b7-4350-9f2a-e8abb1a5cfdd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_50726cea-2f04-4025-9e45-575da1ae7153" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_5235ad6f-90b7-4350-9f2a-e8abb1a5cfdd" xlink:to="loc_us-gaap_AwardTypeAxis_50726cea-2f04-4025-9e45-575da1ae7153" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_50726cea-2f04-4025-9e45-575da1ae7153_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_50726cea-2f04-4025-9e45-575da1ae7153" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_50726cea-2f04-4025-9e45-575da1ae7153_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bce68255-9173-4d2e-aac3-3b9883816787" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_50726cea-2f04-4025-9e45-575da1ae7153" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bce68255-9173-4d2e-aac3-3b9883816787" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_c2122b42-ec28-4921-af14-df38c8a35ffa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bce68255-9173-4d2e-aac3-3b9883816787" xlink:to="loc_us-gaap_EmployeeStockOptionMember_c2122b42-ec28-4921-af14-df38c8a35ffa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_db4ede00-d79b-4ba9-a9d9-c3b967c8292f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bce68255-9173-4d2e-aac3-3b9883816787" xlink:to="loc_us-gaap_PerformanceSharesMember_db4ede00-d79b-4ba9-a9d9-c3b967c8292f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_bebdb924-9ffb-4d5c-b871-91a43cace584" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bce68255-9173-4d2e-aac3-3b9883816787" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_bebdb924-9ffb-4d5c-b871-91a43cace584" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_LeveragedStockUnitsLSUsMember_745ca732-1646-4460-8cb4-a9a317f3bdcb" xlink:href="evh-20210630.xsd#evh_LeveragedStockUnitsLSUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bce68255-9173-4d2e-aac3-3b9883816787" xlink:to="loc_evh_LeveragedStockUnitsLSUsMember_745ca732-1646-4460-8cb4-a9a317f3bdcb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PerformanceBasedRestrictedStockUnitsPBRSUsMember_e36d0366-8684-4e17-887a-2dbdd1dffd94" xlink:href="evh-20210630.xsd#evh_PerformanceBasedRestrictedStockUnitsPBRSUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bce68255-9173-4d2e-aac3-3b9883816787" xlink:to="loc_evh_PerformanceBasedRestrictedStockUnitsPBRSUsMember_e36d0366-8684-4e17-887a-2dbdd1dffd94" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_06039f97-3702-4dfa-8895-3202c0218b33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_5235ad6f-90b7-4350-9f2a-e8abb1a5cfdd" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_06039f97-3702-4dfa-8895-3202c0218b33" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_06039f97-3702-4dfa-8895-3202c0218b33_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_06039f97-3702-4dfa-8895-3202c0218b33" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_06039f97-3702-4dfa-8895-3202c0218b33_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_26886af8-f59d-49ba-9336-4d8004390918" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_06039f97-3702-4dfa-8895-3202c0218b33" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_26886af8-f59d-49ba-9336-4d8004390918" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_7b46c35e-712f-464e-a3ec-5775cfb5eda6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_26886af8-f59d-49ba-9336-4d8004390918" xlink:to="loc_us-gaap_CostOfSalesMember_7b46c35e-712f-464e-a3ec-5775cfb5eda6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_d2b339e9-8d89-45a3-b3df-c70d3db22cb0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_26886af8-f59d-49ba-9336-4d8004390918" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_d2b339e9-8d89-45a3-b3df-c70d3db22cb0" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/StockbasedCompensationScheduleofSharebasedAwardsGrantedDetails" xlink:type="simple" xlink:href="evh-20210630.xsd#StockbasedCompensationScheduleofSharebasedAwardsGrantedDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/StockbasedCompensationScheduleofSharebasedAwardsGrantedDetails" xlink:type="extended" id="i76ed9e47a0fe40e8ace34ddb94dab0f4_StockbasedCompensationScheduleofSharebasedAwardsGrantedDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c3fc3c8f-4048-43c6-b83b-183f11cc8fb7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1cbcb753-a196-49d3-b35d-6450f3f0a76b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c3fc3c8f-4048-43c6-b83b-183f11cc8fb7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1cbcb753-a196-49d3-b35d-6450f3f0a76b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bdd52445-0c48-45b3-84cb-aaac0061d116" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c3fc3c8f-4048-43c6-b83b-183f11cc8fb7" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bdd52445-0c48-45b3-84cb-aaac0061d116" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_61bbfe4a-a03c-4e19-93d1-5362cb5915e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bdd52445-0c48-45b3-84cb-aaac0061d116" xlink:to="loc_us-gaap_AwardTypeAxis_61bbfe4a-a03c-4e19-93d1-5362cb5915e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_61bbfe4a-a03c-4e19-93d1-5362cb5915e5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_61bbfe4a-a03c-4e19-93d1-5362cb5915e5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_61bbfe4a-a03c-4e19-93d1-5362cb5915e5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cb30b7d5-c802-4a21-9541-e3a2d910e8d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_61bbfe4a-a03c-4e19-93d1-5362cb5915e5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cb30b7d5-c802-4a21-9541-e3a2d910e8d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_9babd888-6543-4aaa-945d-c8dfed661d09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cb30b7d5-c802-4a21-9541-e3a2d910e8d6" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_9babd888-6543-4aaa-945d-c8dfed661d09" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PerformanceBasedRestrictedStockUnitsPBRSUsMember_e678ac5f-c025-4d75-a3ab-d1af284c8354" xlink:href="evh-20210630.xsd#evh_PerformanceBasedRestrictedStockUnitsPBRSUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cb30b7d5-c802-4a21-9541-e3a2d910e8d6" xlink:to="loc_evh_PerformanceBasedRestrictedStockUnitsPBRSUsMember_e678ac5f-c025-4d75-a3ab-d1af284c8354" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_LeveragedStockUnitsLSUsMember_c3cfe6a0-bf8f-4754-9319-81d2ea109978" xlink:href="evh-20210630.xsd#evh_LeveragedStockUnitsLSUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cb30b7d5-c802-4a21-9541-e3a2d910e8d6" xlink:to="loc_evh_LeveragedStockUnitsLSUsMember_c3cfe6a0-bf8f-4754-9319-81d2ea109978" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/InvestmentsInandAdvancestoEquityMethodInvesteesAdditionalInformationDetails" xlink:type="simple" xlink:href="evh-20210630.xsd#InvestmentsInandAdvancestoEquityMethodInvesteesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/InvestmentsInandAdvancestoEquityMethodInvesteesAdditionalInformationDetails" xlink:type="extended" id="if5a77dfca8434ab087d9e926290623c0_InvestmentsInandAdvancestoEquityMethodInvesteesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_ac04bd78-eab3-4a14-b621-b7c4d6a3db74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EquityMethodInvestmentEconomicInterestPercentage_d70d2bfa-e032-4cc4-841a-963e95c28f10" xlink:href="evh-20210630.xsd#evh_EquityMethodInvestmentEconomicInterestPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_ac04bd78-eab3-4a14-b621-b7c4d6a3db74" xlink:to="loc_evh_EquityMethodInvestmentEconomicInterestPercentage_d70d2bfa-e032-4cc4-841a-963e95c28f10" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EquityMethodInvestmentVotingInterestPercentage_97473bce-cb9f-46b4-a50b-f69e0324b745" xlink:href="evh-20210630.xsd#evh_EquityMethodInvestmentVotingInterestPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_ac04bd78-eab3-4a14-b621-b7c4d6a3db74" xlink:to="loc_evh_EquityMethodInvestmentVotingInterestPercentage_97473bce-cb9f-46b4-a50b-f69e0324b745" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_4cbf2c68-3ac0-4e9e-b5b1-c58300970adf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_ac04bd78-eab3-4a14-b621-b7c4d6a3db74" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_4cbf2c68-3ac0-4e9e-b5b1-c58300970adf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_IncomeLossfromEquityMethodInvestmentsServicesAgreement_14128b73-f122-4be2-814a-1e1e2fceeabb" xlink:href="evh-20210630.xsd#evh_IncomeLossfromEquityMethodInvestmentsServicesAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_ac04bd78-eab3-4a14-b621-b7c4d6a3db74" xlink:to="loc_evh_IncomeLossfromEquityMethodInvestmentsServicesAgreement_14128b73-f122-4be2-814a-1e1e2fceeabb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_ff4e8ccd-8177-4666-818d-43f8d0edb6ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_ac04bd78-eab3-4a14-b621-b7c4d6a3db74" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_ff4e8ccd-8177-4666-818d-43f8d0edb6ce" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_5eca6d37-059d-455f-b87d-9405fd1f2718" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_ff4e8ccd-8177-4666-818d-43f8d0edb6ce" xlink:to="loc_srt_RangeAxis_5eca6d37-059d-455f-b87d-9405fd1f2718" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5eca6d37-059d-455f-b87d-9405fd1f2718_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_5eca6d37-059d-455f-b87d-9405fd1f2718" xlink:to="loc_srt_RangeMember_5eca6d37-059d-455f-b87d-9405fd1f2718_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_980b7d7e-f2dc-4efe-bc94-d0108969c7c8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_5eca6d37-059d-455f-b87d-9405fd1f2718" xlink:to="loc_srt_RangeMember_980b7d7e-f2dc-4efe-bc94-d0108969c7c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_b21d8635-822f-4f33-9031-b8d9328c1273" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_980b7d7e-f2dc-4efe-bc94-d0108969c7c8" xlink:to="loc_srt_MinimumMember_b21d8635-822f-4f33-9031-b8d9328c1273" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_f420a7c6-70ad-41de-9dd7-b59f2024e48d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_980b7d7e-f2dc-4efe-bc94-d0108969c7c8" xlink:to="loc_srt_MaximumMember_f420a7c6-70ad-41de-9dd7-b59f2024e48d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2ec008c5-533e-4d96-936e-b737450a776b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_ff4e8ccd-8177-4666-818d-43f8d0edb6ce" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2ec008c5-533e-4d96-936e-b737450a776b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_2ec008c5-533e-4d96-936e-b737450a776b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2ec008c5-533e-4d96-936e-b737450a776b" xlink:to="loc_us-gaap_RelatedPartyDomain_2ec008c5-533e-4d96-936e-b737450a776b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_d2caea37-b012-428f-823f-d13591879115" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2ec008c5-533e-4d96-936e-b737450a776b" xlink:to="loc_us-gaap_RelatedPartyDomain_d2caea37-b012-428f-823f-d13591879115" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvesteeMember_f3f96910-bc79-4a26-aae5-5c383cca74eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvesteeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_d2caea37-b012-428f-823f-d13591879115" xlink:to="loc_us-gaap_EquityMethodInvesteeMember_f3f96910-bc79-4a26-aae5-5c383cca74eb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_70b4a039-1cac-4669-9143-0fbf16fcfe81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_ff4e8ccd-8177-4666-818d-43f8d0edb6ce" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_70b4a039-1cac-4669-9143-0fbf16fcfe81" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_70b4a039-1cac-4669-9143-0fbf16fcfe81_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_70b4a039-1cac-4669-9143-0fbf16fcfe81" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_70b4a039-1cac-4669-9143-0fbf16fcfe81_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_d7f2949f-f803-43f5-a425-32b895252b20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_70b4a039-1cac-4669-9143-0fbf16fcfe81" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_d7f2949f-f803-43f5-a425-32b895252b20" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ServicesAgreementsMember_9d438813-0a5f-46c7-9ad1-7b2093d44829" xlink:href="evh-20210630.xsd#evh_ServicesAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_d7f2949f-f803-43f5-a425-32b895252b20" xlink:to="loc_evh_ServicesAgreementsMember_9d438813-0a5f-46c7-9ad1-7b2093d44829" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/NoncontrollingInterestsDetails" xlink:type="simple" xlink:href="evh-20210630.xsd#NoncontrollingInterestsDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/NoncontrollingInterestsDetails" xlink:type="extended" id="i4d1ef0e1b8a4406a83f5d102609192e1_NoncontrollingInterestsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestLineItems_78dd594c-0868-4781-ac21-4b395d25d95f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_2b403bbc-eea5-4c9a-99ab-2eece8dc046e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_78dd594c-0868-4781-ac21-4b395d25d95f" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_2b403bbc-eea5-4c9a-99ab-2eece8dc046e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_be022658-f47c-417b-a80f-b7b5b300a767" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_78dd594c-0868-4781-ac21-4b395d25d95f" xlink:to="loc_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_be022658-f47c-417b-a80f-b7b5b300a767" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityOwnershipPercentage_0919027b-11e7-4af4-a59e-a837cb12dc20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_78dd594c-0868-4781-ac21-4b395d25d95f" xlink:to="loc_us-gaap_VariableInterestEntityOwnershipPercentage_0919027b-11e7-4af4-a59e-a837cb12dc20" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_VariableInterestEntityNewMedicaidContractNotAwardedRequirementToAcquireOwnershipConsiderationAmount_705b0ecc-6296-4126-9f8b-d5134e78be7c" xlink:href="evh-20210630.xsd#evh_VariableInterestEntityNewMedicaidContractNotAwardedRequirementToAcquireOwnershipConsiderationAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_78dd594c-0868-4781-ac21-4b395d25d95f" xlink:to="loc_evh_VariableInterestEntityNewMedicaidContractNotAwardedRequirementToAcquireOwnershipConsiderationAmount_705b0ecc-6296-4126-9f8b-d5134e78be7c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityInitialConsolidationGainOrLoss_4d7405be-376c-4e43-ae9e-39e2e5b067cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityInitialConsolidationGainOrLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_78dd594c-0868-4781-ac21-4b395d25d95f" xlink:to="loc_us-gaap_VariableInterestEntityInitialConsolidationGainOrLoss_4d7405be-376c-4e43-ae9e-39e2e5b067cf" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInMinorityInterestRollForward_0156cbcc-2a92-470a-b3ff-596e4eabcc68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MovementInMinorityInterestRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_78dd594c-0868-4781-ac21-4b395d25d95f" xlink:to="loc_us-gaap_MovementInMinorityInterestRollForward_0156cbcc-2a92-470a-b3ff-596e4eabcc68" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_63a44677-0a73-4b94-8a35-c7750c81fb9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_0156cbcc-2a92-470a-b3ff-596e4eabcc68" xlink:to="loc_us-gaap_MinorityInterest_63a44677-0a73-4b94-8a35-c7750c81fb9b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_b22cb438-1023-401f-9bf1-c26cd360c5e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_0156cbcc-2a92-470a-b3ff-596e4eabcc68" xlink:to="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_b22cb438-1023-401f-9bf1-c26cd360c5e4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_3f7f68f2-daf3-47a9-836a-a582d56485b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestTable_07eec214-f066-4542-b8b7-2ac89bac08f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_MinorityInterestLineItems_78dd594c-0868-4781-ac21-4b395d25d95f" xlink:to="loc_us-gaap_MinorityInterestTable_07eec214-f066-4542-b8b7-2ac89bac08f0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_4b43ea06-e375-42e8-93c4-5a0590399bd4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MinorityInterestTable_07eec214-f066-4542-b8b7-2ac89bac08f0" xlink:to="loc_srt_OwnershipAxis_4b43ea06-e375-42e8-93c4-5a0590399bd4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_4b43ea06-e375-42e8-93c4-5a0590399bd4_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_4b43ea06-e375-42e8-93c4-5a0590399bd4" xlink:to="loc_srt_OwnershipDomain_4b43ea06-e375-42e8-93c4-5a0590399bd4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_39ca1191-c0a0-4812-8a3e-f6c36b49968b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_4b43ea06-e375-42e8-93c4-5a0590399bd4" xlink:to="loc_srt_OwnershipDomain_39ca1191-c0a0-4812-8a3e-f6c36b49968b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EvolentHealthLLCMember_ce587fdd-1e72-4964-9932-73bc378be233" xlink:href="evh-20210630.xsd#evh_EvolentHealthLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_39ca1191-c0a0-4812-8a3e-f6c36b49968b" xlink:to="loc_evh_EvolentHealthLLCMember_ce587fdd-1e72-4964-9932-73bc378be233" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_27cdd24c-0820-445f-adc8-fb4b4dd0d2e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MinorityInterestTable_07eec214-f066-4542-b8b7-2ac89bac08f0" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_27cdd24c-0820-445f-adc8-fb4b4dd0d2e9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_27cdd24c-0820-445f-adc8-fb4b4dd0d2e9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_27cdd24c-0820-445f-adc8-fb4b4dd0d2e9" xlink:to="loc_us-gaap_EquityComponentDomain_27cdd24c-0820-445f-adc8-fb4b4dd0d2e9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_ec2eb552-5bfe-4481-9e16-b662bdf039a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_27cdd24c-0820-445f-adc8-fb4b4dd0d2e9" xlink:to="loc_us-gaap_EquityComponentDomain_ec2eb552-5bfe-4481-9e16-b662bdf039a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_f2f1e444-81d3-4f4d-b6d4-7da2f228ce9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_ec2eb552-5bfe-4481-9e16-b662bdf039a8" xlink:to="loc_us-gaap_NoncontrollingInterestMember_f2f1e444-81d3-4f4d-b6d4-7da2f228ce9b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_5e6da9c4-22e7-4d73-b13e-31a56307bc14" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MinorityInterestTable_07eec214-f066-4542-b8b7-2ac89bac08f0" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_5e6da9c4-22e7-4d73-b13e-31a56307bc14" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_5e6da9c4-22e7-4d73-b13e-31a56307bc14_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_5e6da9c4-22e7-4d73-b13e-31a56307bc14" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_5e6da9c4-22e7-4d73-b13e-31a56307bc14_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_e324f594-0e68-4a87-b878-a35b4d17967b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_5e6da9c4-22e7-4d73-b13e-31a56307bc14" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_e324f594-0e68-4a87-b878-a35b4d17967b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_UniversityHealthCaredbaPassportHealthPlanMember_e0923bce-a213-4d83-bad9-d2968fab8eb2" xlink:href="evh-20210630.xsd#evh_UniversityHealthCaredbaPassportHealthPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_e324f594-0e68-4a87-b878-a35b4d17967b" xlink:to="loc_evh_UniversityHealthCaredbaPassportHealthPlanMember_e0923bce-a213-4d83-bad9-d2968fab8eb2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_6d7911f7-ff91-4545-a44f-041f76e58dae" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MinorityInterestTable_07eec214-f066-4542-b8b7-2ac89bac08f0" xlink:to="loc_srt_ConsolidatedEntitiesAxis_6d7911f7-ff91-4545-a44f-041f76e58dae" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_6d7911f7-ff91-4545-a44f-041f76e58dae_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_6d7911f7-ff91-4545-a44f-041f76e58dae" xlink:to="loc_srt_ConsolidatedEntitiesDomain_6d7911f7-ff91-4545-a44f-041f76e58dae_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_813a1145-39cf-4016-8ab6-52fe86623061" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_6d7911f7-ff91-4545-a44f-041f76e58dae" xlink:to="loc_srt_ConsolidatedEntitiesDomain_813a1145-39cf-4016-8ab6-52fe86623061" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_ff157020-7c12-4bfd-92ac-813ddd169ad2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_813a1145-39cf-4016-8ab6-52fe86623061" xlink:to="loc_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_ff157020-7c12-4bfd-92ac-813ddd169ad2" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails" xlink:type="simple" xlink:href="evh-20210630.xsd#FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails" xlink:type="extended" id="i5b8a9d7c703440dcbaf9411b9918e2e1_FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_7ae04fe7-046b-4639-8952-6db86f90d79c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_49140ec7-977e-42e5-9f5a-67cf65c80572" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_7ae04fe7-046b-4639-8952-6db86f90d79c" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_49140ec7-977e-42e5-9f5a-67cf65c80572" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_1adb161d-50da-4ad6-b236-d88aecdee44a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_49140ec7-977e-42e5-9f5a-67cf65c80572" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_1adb161d-50da-4ad6-b236-d88aecdee44a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_a2c324fe-af98-4604-94db-8b35bcd775f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_49140ec7-977e-42e5-9f5a-67cf65c80572" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_a2c324fe-af98-4604-94db-8b35bcd775f0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_18ba893c-2ce1-42a7-b65c-4009700b7d99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_7ae04fe7-046b-4639-8952-6db86f90d79c" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_18ba893c-2ce1-42a7-b65c-4009700b7d99" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesFairValueDisclosure_1797d89f-e7bd-4d84-a0b2-9467c7f3fd70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_18ba893c-2ce1-42a7-b65c-4009700b7d99" xlink:to="loc_us-gaap_OtherLiabilitiesFairValueDisclosure_1797d89f-e7bd-4d84-a0b2-9467c7f3fd70" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_aea2af36-2cc1-49b5-8ce6-3a7bc5951a5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_18ba893c-2ce1-42a7-b65c-4009700b7d99" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_aea2af36-2cc1-49b5-8ce6-3a7bc5951a5b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_7bf4a855-a407-4f78-9500-76b755696c51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_7ae04fe7-046b-4639-8952-6db86f90d79c" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_7bf4a855-a407-4f78-9500-76b755696c51" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_a3f2ea45-4da1-449c-b1fe-d2e22b5da45d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_7ae04fe7-046b-4639-8952-6db86f90d79c" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_a3f2ea45-4da1-449c-b1fe-d2e22b5da45d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3bfc28a0-ff0f-4e50-8cbf-1419079a3f88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_a3f2ea45-4da1-449c-b1fe-d2e22b5da45d" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3bfc28a0-ff0f-4e50-8cbf-1419079a3f88" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3bfc28a0-ff0f-4e50-8cbf-1419079a3f88_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3bfc28a0-ff0f-4e50-8cbf-1419079a3f88" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3bfc28a0-ff0f-4e50-8cbf-1419079a3f88_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_be9ec442-6d37-41cf-8517-cad81a60df49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3bfc28a0-ff0f-4e50-8cbf-1419079a3f88" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_be9ec442-6d37-41cf-8517-cad81a60df49" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_a760cbe3-9add-49cf-b064-2ceb44b5e887" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_be9ec442-6d37-41cf-8517-cad81a60df49" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_a760cbe3-9add-49cf-b064-2ceb44b5e887" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_18dafbfa-bab0-45f0-81eb-15c83a6e9b2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_be9ec442-6d37-41cf-8517-cad81a60df49" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_18dafbfa-bab0-45f0-81eb-15c83a6e9b2d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_ec2f4022-b5f3-41e2-a57c-e84dab65aabf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_be9ec442-6d37-41cf-8517-cad81a60df49" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_ec2f4022-b5f3-41e2-a57c-e84dab65aabf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_aec4be69-62a8-43b9-a8fe-e58fa50a2c6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_a3f2ea45-4da1-449c-b1fe-d2e22b5da45d" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_aec4be69-62a8-43b9-a8fe-e58fa50a2c6b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_aec4be69-62a8-43b9-a8fe-e58fa50a2c6b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_aec4be69-62a8-43b9-a8fe-e58fa50a2c6b" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_aec4be69-62a8-43b9-a8fe-e58fa50a2c6b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_21d5378f-2310-4a7c-bcf0-a0e1740f9758" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_aec4be69-62a8-43b9-a8fe-e58fa50a2c6b" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_21d5378f-2310-4a7c-bcf0-a0e1740f9758" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_305194c3-fdfc-4a6c-ae44-5c2726ce1871" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_21d5378f-2310-4a7c-bcf0-a0e1740f9758" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_305194c3-fdfc-4a6c-ae44-5c2726ce1871" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/FairValueMeasurementAdditionalInformationDetails" xlink:type="simple" xlink:href="evh-20210630.xsd#FairValueMeasurementAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/FairValueMeasurementAdditionalInformationDetails" xlink:type="extended" id="icd7c35cf7e2f45b5a3784b7865c84478_FairValueMeasurementAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_aaa2bfdd-802f-4599-9bd3-dd38e4e3dd81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightUnissued_705516a1-fd92-4244-9f2b-4b01e80c7c20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightUnissued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_aaa2bfdd-802f-4599-9bd3-dd38e4e3dd81" xlink:to="loc_us-gaap_ClassOfWarrantOrRightUnissued_705516a1-fd92-4244-9f2b-4b01e80c7c20" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_59d40d45-b56e-4978-b2be-e3186aa5036c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_aaa2bfdd-802f-4599-9bd3-dd38e4e3dd81" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_59d40d45-b56e-4978-b2be-e3186aa5036c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_194cd083-3b33-46c8-9ac3-dd15b973202b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_59d40d45-b56e-4978-b2be-e3186aa5036c" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_194cd083-3b33-46c8-9ac3-dd15b973202b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_194cd083-3b33-46c8-9ac3-dd15b973202b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_194cd083-3b33-46c8-9ac3-dd15b973202b" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_194cd083-3b33-46c8-9ac3-dd15b973202b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_aaebdb52-bf37-42c3-9110-bd816f36a832" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_194cd083-3b33-46c8-9ac3-dd15b973202b" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_aaebdb52-bf37-42c3-9110-bd816f36a832" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_94827590-7d3f-4f16-8807-fa59e78996ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_aaebdb52-bf37-42c3-9110-bd816f36a832" xlink:to="loc_us-gaap_CommonClassAMember_94827590-7d3f-4f16-8807-fa59e78996ca" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails" xlink:type="simple" xlink:href="evh-20210630.xsd#FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails" xlink:type="extended" id="i00169f49bc204cda9bc9294b982cce24_FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_a167be6d-83d1-4d65-acab-91c5da29ba62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesFairValueDisclosure_dc3a0a6a-f629-432f-bebf-ca879d6889fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_a167be6d-83d1-4d65-acab-91c5da29ba62" xlink:to="loc_us-gaap_OtherLiabilitiesFairValueDisclosure_dc3a0a6a-f629-432f-bebf-ca879d6889fc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_d10189b5-2ee4-42f6-9b22-6fdf7b09f170" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_a167be6d-83d1-4d65-acab-91c5da29ba62" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_d10189b5-2ee4-42f6-9b22-6fdf7b09f170" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_c7d88895-7592-4e5d-ae5d-9a3e7ab50048" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_a167be6d-83d1-4d65-acab-91c5da29ba62" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_c7d88895-7592-4e5d-ae5d-9a3e7ab50048" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_0fc6d055-b8bf-456c-aad2-0fe7fae38769" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_c7d88895-7592-4e5d-ae5d-9a3e7ab50048" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_0fc6d055-b8bf-456c-aad2-0fe7fae38769" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_0fc6d055-b8bf-456c-aad2-0fe7fae38769_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_0fc6d055-b8bf-456c-aad2-0fe7fae38769" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_0fc6d055-b8bf-456c-aad2-0fe7fae38769_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_ef999066-d9f6-4e72-b6e2-6e9d0596e455" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_0fc6d055-b8bf-456c-aad2-0fe7fae38769" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_ef999066-d9f6-4e72-b6e2-6e9d0596e455" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_1a5bd719-fcc5-4469-967e-19f48c10aa92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_ef999066-d9f6-4e72-b6e2-6e9d0596e455" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_1a5bd719-fcc5-4469-967e-19f48c10aa92" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_151925bc-b989-49cf-bd33-9261768848aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_c7d88895-7592-4e5d-ae5d-9a3e7ab50048" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_151925bc-b989-49cf-bd33-9261768848aa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_151925bc-b989-49cf-bd33-9261768848aa_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_151925bc-b989-49cf-bd33-9261768848aa" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_151925bc-b989-49cf-bd33-9261768848aa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_790a9b82-bc69-4fc8-8ed8-71d094b2a553" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_151925bc-b989-49cf-bd33-9261768848aa" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_790a9b82-bc69-4fc8-8ed8-71d094b2a553" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_ae880ccc-d645-424c-91ae-b79a1bdc3a47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_790a9b82-bc69-4fc8-8ed8-71d094b2a553" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_ae880ccc-d645-424c-91ae-b79a1bdc3a47" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_2845bae8-b87e-4739-bccb-acf4b69e7a48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_c7d88895-7592-4e5d-ae5d-9a3e7ab50048" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_2845bae8-b87e-4739-bccb-acf4b69e7a48" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_2845bae8-b87e-4739-bccb-acf4b69e7a48_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_2845bae8-b87e-4739-bccb-acf4b69e7a48" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_2845bae8-b87e-4739-bccb-acf4b69e7a48_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_02c14d1d-15e9-4902-b0e0-9a214c330e58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_2845bae8-b87e-4739-bccb-acf4b69e7a48" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_02c14d1d-15e9-4902-b0e0-9a214c330e58" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_ebfb4ba4-9eee-4147-aed0-80859d937924" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_02c14d1d-15e9-4902-b0e0-9a214c330e58" xlink:to="loc_us-gaap_WarrantMember_ebfb4ba4-9eee-4147-aed0-80859d937924" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis_9303e8c9-c89d-4f26-9324-ea4c54355036" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_c7d88895-7592-4e5d-ae5d-9a3e7ab50048" xlink:to="loc_us-gaap_ValuationTechniqueAxis_9303e8c9-c89d-4f26-9324-ea4c54355036" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_9303e8c9-c89d-4f26-9324-ea4c54355036_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationTechniqueAxis_9303e8c9-c89d-4f26-9324-ea4c54355036" xlink:to="loc_us-gaap_ValuationTechniqueDomain_9303e8c9-c89d-4f26-9324-ea4c54355036_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_426f202e-d931-48f3-a9b7-94623c70b5b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationTechniqueAxis_9303e8c9-c89d-4f26-9324-ea4c54355036" xlink:to="loc_us-gaap_ValuationTechniqueDomain_426f202e-d931-48f3-a9b7-94623c70b5b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_BlackScholesMember_1883293e-c651-4608-8fc2-d9f00d0c2744" xlink:href="evh-20210630.xsd#evh_BlackScholesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationTechniqueDomain_426f202e-d931-48f3-a9b7-94623c70b5b6" xlink:to="loc_evh_BlackScholesMember_1883293e-c651-4608-8fc2-d9f00d0c2744" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_f5db5ae9-1e12-49e7-9baa-38593018b66c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_c7d88895-7592-4e5d-ae5d-9a3e7ab50048" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_f5db5ae9-1e12-49e7-9baa-38593018b66c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_f5db5ae9-1e12-49e7-9baa-38593018b66c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_f5db5ae9-1e12-49e7-9baa-38593018b66c" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_f5db5ae9-1e12-49e7-9baa-38593018b66c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_f34e5d79-c5b8-40a2-800b-d1fb9935f639" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_f5db5ae9-1e12-49e7-9baa-38593018b66c" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_f34e5d79-c5b8-40a2-800b-d1fb9935f639" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_c4293b45-6fc9-4814-8040-9c9a9258bf61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_f34e5d79-c5b8-40a2-800b-d1fb9935f639" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_c4293b45-6fc9-4814-8040-9c9a9258bf61" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_dd6f656f-e827-49c5-a5ed-b4efbe0a73ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_f34e5d79-c5b8-40a2-800b-d1fb9935f639" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_dd6f656f-e827-49c5-a5ed-b4efbe0a73ec" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RelatedPartiesAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="evh-20210630.xsd#RelatedPartiesAssetsandLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/RelatedPartiesAssetsandLiabilitiesDetails" xlink:type="extended" id="i14175074627043099147865d41525842_RelatedPartiesAssetsandLiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_a8652c8d-a4c1-48cb-90ef-def733b03675" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_5bb471d4-e391-42ca-b5aa-5bbb78970dc9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_a8652c8d-a4c1-48cb-90ef-def733b03675" xlink:to="loc_us-gaap_AssetsAbstract_5bb471d4-e391-42ca-b5aa-5bbb78970dc9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_7c03dc91-7262-45bc-b85a-2ff603fdf79c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_5bb471d4-e391-42ca-b5aa-5bbb78970dc9" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_7c03dc91-7262-45bc-b85a-2ff603fdf79c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_cc2f5fb9-f493-4424-8cbe-981908f44599" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_5bb471d4-e391-42ca-b5aa-5bbb78970dc9" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_cc2f5fb9-f493-4424-8cbe-981908f44599" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_4fb22e5e-e3aa-4937-979f-1a2c0012ee94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_5bb471d4-e391-42ca-b5aa-5bbb78970dc9" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_4fb22e5e-e3aa-4937-979f-1a2c0012ee94" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract_a7b0812e-db7a-4e4a-8035-83c8e2bc322e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_a8652c8d-a4c1-48cb-90ef-def733b03675" xlink:to="loc_us-gaap_LiabilitiesAbstract_a7b0812e-db7a-4e4a-8035-83c8e2bc322e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_8c6b1d1c-1dd8-4a82-8515-9c06823313b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract_a7b0812e-db7a-4e4a-8035-83c8e2bc322e" xlink:to="loc_us-gaap_AccountsPayableCurrent_8c6b1d1c-1dd8-4a82-8515-9c06823313b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_65630bdf-6e19-4e3f-8aaa-09ce6475a8c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract_a7b0812e-db7a-4e4a-8035-83c8e2bc322e" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_65630bdf-6e19-4e3f-8aaa-09ce6475a8c4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense_3e0bc19d-96be-435f-bed6-345627e001d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract_a7b0812e-db7a-4e4a-8035-83c8e2bc322e" xlink:to="loc_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense_3e0bc19d-96be-435f-bed6-345627e001d7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_f75a5367-e5c5-4337-92f8-a5e88aff4349" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_a8652c8d-a4c1-48cb-90ef-def733b03675" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_f75a5367-e5c5-4337-92f8-a5e88aff4349" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1093e96f-ae4b-44c5-a180-3e3f79204ac6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_f75a5367-e5c5-4337-92f8-a5e88aff4349" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1093e96f-ae4b-44c5-a180-3e3f79204ac6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_1093e96f-ae4b-44c5-a180-3e3f79204ac6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1093e96f-ae4b-44c5-a180-3e3f79204ac6" xlink:to="loc_us-gaap_RelatedPartyDomain_1093e96f-ae4b-44c5-a180-3e3f79204ac6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_996f4021-1eb1-42ac-8a77-5d20931b5055" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1093e96f-ae4b-44c5-a180-3e3f79204ac6" xlink:to="loc_us-gaap_RelatedPartyDomain_996f4021-1eb1-42ac-8a77-5d20931b5055" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_728c6d25-fe1c-46b9-836e-e9efdae55569" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_AffiliatedEntityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_996f4021-1eb1-42ac-8a77-5d20931b5055" xlink:to="loc_srt_AffiliatedEntityMember_728c6d25-fe1c-46b9-836e-e9efdae55569" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RelatedPartiesRevenuesandExpensesDetails" xlink:type="simple" xlink:href="evh-20210630.xsd#RelatedPartiesRevenuesandExpensesDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/RelatedPartiesRevenuesandExpensesDetails" xlink:type="extended" id="i3b22745471254c5d8d068cb11c86c4d3_RelatedPartiesRevenuesandExpensesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_244ec565-c575-4c0a-a1ea-95d434b87012" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_7138eb23-5bd6-4083-b4d9-3fea15654e89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_244ec565-c575-4c0a-a1ea-95d434b87012" xlink:to="loc_us-gaap_RevenuesAbstract_7138eb23-5bd6-4083-b4d9-3fea15654e89" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_9a9873e0-9c90-49e0-87a0-fdb9d32f902f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_7138eb23-5bd6-4083-b4d9-3fea15654e89" xlink:to="loc_us-gaap_Revenues_9a9873e0-9c90-49e0-87a0-fdb9d32f902f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_7efa2d91-5f33-4b42-b4a2-179fdccebf5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_244ec565-c575-4c0a-a1ea-95d434b87012" xlink:to="loc_us-gaap_OperatingExpensesAbstract_7efa2d91-5f33-4b42-b4a2-179fdccebf5e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CostofGoodsandServicesSoldExcludingDepreciationandAmortization_33f2ca7a-f91e-4a8b-bf85-b23d3498ad7a" xlink:href="evh-20210630.xsd#evh_CostofGoodsandServicesSoldExcludingDepreciationandAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7efa2d91-5f33-4b42-b4a2-179fdccebf5e" xlink:to="loc_evh_CostofGoodsandServicesSoldExcludingDepreciationandAmortization_33f2ca7a-f91e-4a8b-bf85-b23d3498ad7a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_849102f8-72da-4e58-9e07-181d84514b4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7efa2d91-5f33-4b42-b4a2-179fdccebf5e" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_849102f8-72da-4e58-9e07-181d84514b4a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_0e46ee29-2515-46c4-a489-5c04f366bd3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_244ec565-c575-4c0a-a1ea-95d434b87012" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_0e46ee29-2515-46c4-a489-5c04f366bd3a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_b3c7a909-7365-4d38-bf0f-075f7ea0ad7e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_0e46ee29-2515-46c4-a489-5c04f366bd3a" xlink:to="loc_srt_ProductOrServiceAxis_b3c7a909-7365-4d38-bf0f-075f7ea0ad7e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_b3c7a909-7365-4d38-bf0f-075f7ea0ad7e_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_b3c7a909-7365-4d38-bf0f-075f7ea0ad7e" xlink:to="loc_srt_ProductsAndServicesDomain_b3c7a909-7365-4d38-bf0f-075f7ea0ad7e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_bc8e8bce-c8cf-4ac9-850e-83636490936a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_b3c7a909-7365-4d38-bf0f-075f7ea0ad7e" xlink:to="loc_srt_ProductsAndServicesDomain_bc8e8bce-c8cf-4ac9-850e-83636490936a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TransformationServicesMember_7f162099-378d-4a14-ad3a-35d93fe69c03" xlink:href="evh-20210630.xsd#evh_TransformationServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_bc8e8bce-c8cf-4ac9-850e-83636490936a" xlink:to="loc_evh_TransformationServicesMember_7f162099-378d-4a14-ad3a-35d93fe69c03" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PlatformsAndOperationsServicesMember_7d8ab3cd-e126-4bb7-aa7c-0daef831ad9b" xlink:href="evh-20210630.xsd#evh_PlatformsAndOperationsServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_bc8e8bce-c8cf-4ac9-850e-83636490936a" xlink:to="loc_evh_PlatformsAndOperationsServicesMember_7d8ab3cd-e126-4bb7-aa7c-0daef831ad9b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_314cac0b-b258-4b02-b5d5-55c45ad6dc23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_0e46ee29-2515-46c4-a489-5c04f366bd3a" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_314cac0b-b258-4b02-b5d5-55c45ad6dc23" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_314cac0b-b258-4b02-b5d5-55c45ad6dc23_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_314cac0b-b258-4b02-b5d5-55c45ad6dc23" xlink:to="loc_us-gaap_RelatedPartyDomain_314cac0b-b258-4b02-b5d5-55c45ad6dc23_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_9dd052df-12db-425d-ae22-11f144670ead" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_314cac0b-b258-4b02-b5d5-55c45ad6dc23" xlink:to="loc_us-gaap_RelatedPartyDomain_9dd052df-12db-425d-ae22-11f144670ead" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_d341745a-5632-4698-80b0-ce59403c6e3e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_AffiliatedEntityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_9dd052df-12db-425d-ae22-11f144670ead" xlink:to="loc_srt_AffiliatedEntityMember_d341745a-5632-4698-80b0-ce59403c6e3e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RepositioningandOtherChangesDetails" xlink:type="simple" xlink:href="evh-20210630.xsd#RepositioningandOtherChangesDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/RepositioningandOtherChangesDetails" xlink:type="extended" id="icb5fe93c1fde460badf6074ef814629d_RepositioningandOtherChangesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_0409f67e-0434-494a-a78f-4d18109f8cf8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_c599f575-2556-4b56-95da-3783e580be4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_0409f67e-0434-494a-a78f-4d18109f8cf8" xlink:to="loc_us-gaap_RestructuringCharges_c599f575-2556-4b56-95da-3783e580be4b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_ef92e107-f420-4836-a617-2f0fae43bfe2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_0409f67e-0434-494a-a78f-4d18109f8cf8" xlink:to="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_ef92e107-f420-4836-a617-2f0fae43bfe2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_466ebbea-cc8a-4fea-9a7c-a31e7e65c94c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedCostCostIncurredToDate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_0409f67e-0434-494a-a78f-4d18109f8cf8" xlink:to="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_466ebbea-cc8a-4fea-9a7c-a31e7e65c94c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_b6ee4fd4-7819-4253-a97f-88a22ebb9ad4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_0409f67e-0434-494a-a78f-4d18109f8cf8" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_b6ee4fd4-7819-4253-a97f-88a22ebb9ad4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_f766b1ca-3692-4748-96bd-6c7d5dc36e88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_b6ee4fd4-7819-4253-a97f-88a22ebb9ad4" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_f766b1ca-3692-4748-96bd-6c7d5dc36e88" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_f766b1ca-3692-4748-96bd-6c7d5dc36e88_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_f766b1ca-3692-4748-96bd-6c7d5dc36e88" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_f766b1ca-3692-4748-96bd-6c7d5dc36e88_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_ca0a5cf2-e405-4b6e-931e-74daa10a3061" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_f766b1ca-3692-4748-96bd-6c7d5dc36e88" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_ca0a5cf2-e405-4b6e-931e-74daa10a3061" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EmployeeSeveranceAndTerminationBenefitsMember_408e1555-bfab-465f-9964-c9e7ce865c68" xlink:href="evh-20210630.xsd#evh_EmployeeSeveranceAndTerminationBenefitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_ca0a5cf2-e405-4b6e-931e-74daa10a3061" xlink:to="loc_evh_EmployeeSeveranceAndTerminationBenefitsMember_408e1555-bfab-465f-9964-c9e7ce865c68" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FacilityClosingMember_10717b13-433d-474f-b5e9-7cf5c57836bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FacilityClosingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_ca0a5cf2-e405-4b6e-931e-74daa10a3061" xlink:to="loc_us-gaap_FacilityClosingMember_10717b13-433d-474f-b5e9-7cf5c57836bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ProfessionalServicesRestructuringMember_13d860a5-18c0-45c7-bc13-d94b50319e14" xlink:href="evh-20210630.xsd#evh_ProfessionalServicesRestructuringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_ca0a5cf2-e405-4b6e-931e-74daa10a3061" xlink:to="loc_evh_ProfessionalServicesRestructuringMember_13d860a5-18c0-45c7-bc13-d94b50319e14" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/SegmentReportingRevenuefromSegmentstoConsolidatedDetails" xlink:type="simple" xlink:href="evh-20210630.xsd#SegmentReportingRevenuefromSegmentstoConsolidatedDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/SegmentReportingRevenuefromSegmentstoConsolidatedDetails" xlink:type="extended" id="id791808ac11249f5909cdb7e42a1653a_SegmentReportingRevenuefromSegmentstoConsolidatedDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_e5a33b8c-9932-4214-8654-90199f2ae7b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingRevenueReconcilingItemLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_fc1065e6-813f-4a4b-a69b-7f57dfb22008" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_e5a33b8c-9932-4214-8654-90199f2ae7b9" xlink:to="loc_us-gaap_Revenues_fc1065e6-813f-4a4b-a69b-7f57dfb22008" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization_ad19dac2-505a-44ba-944b-6d129fbc190a" xlink:href="evh-20210630.xsd#evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_e5a33b8c-9932-4214-8654-90199f2ae7b9" xlink:to="loc_evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization_ad19dac2-505a-44ba-944b-6d129fbc190a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_a1922bee-cbd2-435c-bd94-a001253b01bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_e5a33b8c-9932-4214-8654-90199f2ae7b9" xlink:to="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_a1922bee-cbd2-435c-bd94-a001253b01bf" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_8e55673a-1c45-4ee4-b388-c47e99c3db3e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_a1922bee-cbd2-435c-bd94-a001253b01bf" xlink:to="loc_srt_ProductOrServiceAxis_8e55673a-1c45-4ee4-b388-c47e99c3db3e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_8e55673a-1c45-4ee4-b388-c47e99c3db3e_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_8e55673a-1c45-4ee4-b388-c47e99c3db3e" xlink:to="loc_srt_ProductsAndServicesDomain_8e55673a-1c45-4ee4-b388-c47e99c3db3e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_5a8354c1-d510-4c0c-8e3b-e1d2c13208f5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_8e55673a-1c45-4ee4-b388-c47e99c3db3e" xlink:to="loc_srt_ProductsAndServicesDomain_5a8354c1-d510-4c0c-8e3b-e1d2c13208f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TransformationServicesMember_6603768f-f40d-4a3c-9cde-f4563b480267" xlink:href="evh-20210630.xsd#evh_TransformationServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5a8354c1-d510-4c0c-8e3b-e1d2c13208f5" xlink:to="loc_evh_TransformationServicesMember_6603768f-f40d-4a3c-9cde-f4563b480267" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PlatformsAndOperationsServicesMember_ce858f6d-f196-42cb-88eb-ba47164c49e0" xlink:href="evh-20210630.xsd#evh_PlatformsAndOperationsServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5a8354c1-d510-4c0c-8e3b-e1d2c13208f5" xlink:to="loc_evh_PlatformsAndOperationsServicesMember_ce858f6d-f196-42cb-88eb-ba47164c49e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_c5345c84-91b2-4567-9fa2-e17b27440172" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_a1922bee-cbd2-435c-bd94-a001253b01bf" xlink:to="loc_srt_ConsolidationItemsAxis_c5345c84-91b2-4567-9fa2-e17b27440172" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_c5345c84-91b2-4567-9fa2-e17b27440172_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_c5345c84-91b2-4567-9fa2-e17b27440172" xlink:to="loc_srt_ConsolidationItemsDomain_c5345c84-91b2-4567-9fa2-e17b27440172_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_6a5c132b-bac5-4c40-969e-15a2972fa54c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_c5345c84-91b2-4567-9fa2-e17b27440172" xlink:to="loc_srt_ConsolidationItemsDomain_6a5c132b-bac5-4c40-969e-15a2972fa54c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntersegmentEliminationMember_e56c5538-39e4-4601-b844-b570a2aa4c65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntersegmentEliminationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_6a5c132b-bac5-4c40-969e-15a2972fa54c" xlink:to="loc_us-gaap_IntersegmentEliminationMember_e56c5538-39e4-4601-b844-b570a2aa4c65" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_930ecda0-3ecd-42f5-9fd2-0506f1b537ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_6a5c132b-bac5-4c40-969e-15a2972fa54c" xlink:to="loc_us-gaap_OperatingSegmentsMember_930ecda0-3ecd-42f5-9fd2-0506f1b537ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_74d8189b-0c5d-4b71-b9a2-9d1c9340acfa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_6a5c132b-bac5-4c40-969e-15a2972fa54c" xlink:to="loc_us-gaap_CorporateNonSegmentMember_74d8189b-0c5d-4b71-b9a2-9d1c9340acfa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_80f5d02c-0da5-4cec-a47c-b547fde547a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_a1922bee-cbd2-435c-bd94-a001253b01bf" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_80f5d02c-0da5-4cec-a47c-b547fde547a6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_80f5d02c-0da5-4cec-a47c-b547fde547a6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_80f5d02c-0da5-4cec-a47c-b547fde547a6" xlink:to="loc_us-gaap_SegmentDomain_80f5d02c-0da5-4cec-a47c-b547fde547a6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_b4c31fd3-c9b2-42a4-8106-f8f7846e70e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_80f5d02c-0da5-4cec-a47c-b547fde547a6" xlink:to="loc_us-gaap_SegmentDomain_b4c31fd3-c9b2-42a4-8106-f8f7846e70e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EvolentHealthServicesSegmentMember_79eae737-05d0-4d15-a9ad-0c436e6b0085" xlink:href="evh-20210630.xsd#evh_EvolentHealthServicesSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_b4c31fd3-c9b2-42a4-8106-f8f7846e70e3" xlink:to="loc_evh_EvolentHealthServicesSegmentMember_79eae737-05d0-4d15-a9ad-0c436e6b0085" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ClinicalSolutionsSegmentMember_cb06552d-a467-40b4-a061-69b4c74e3447" xlink:href="evh-20210630.xsd#evh_ClinicalSolutionsSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_b4c31fd3-c9b2-42a4-8106-f8f7846e70e3" xlink:to="loc_evh_ClinicalSolutionsSegmentMember_cb06552d-a467-40b4-a061-69b4c74e3447" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails" xlink:type="simple" xlink:href="evh-20210630.xsd#ReservesforClaimsandPerformanceBasedArrangementsDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails" xlink:type="extended" id="i6e774cb684ba42949af347b5247d379a_ReservesforClaimsandPerformanceBasedArrangementsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems_f377dd68-4c0e-46e9-ad06-d2166ce9a717" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetRollForward_03d55761-6929-4e34-8fc1-13a265ca3da4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MovementInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems_f377dd68-4c0e-46e9-ad06-d2166ce9a717" xlink:to="loc_us-gaap_MovementInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetRollForward_03d55761-6929-4e34-8fc1-13a265ca3da4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_59e0e262-2daa-46e9-b30e-838be0c76ad3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetRollForward_03d55761-6929-4e34-8fc1-13a265ca3da4" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_59e0e262-2daa-46e9-b30e-838be0c76ad3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization_62fd15b8-fd27-4a69-a057-15eed99718e6" xlink:href="evh-20210630.xsd#evh_CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetRollForward_03d55761-6929-4e34-8fc1-13a265ca3da4" xlink:to="loc_evh_CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization_62fd15b8-fd27-4a69-a057-15eed99718e6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_393acd63-9bcc-462f-aae3-68e891f6f80f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetRollForward_03d55761-6929-4e34-8fc1-13a265ca3da4" xlink:to="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_393acd63-9bcc-462f-aae3-68e891f6f80f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_2ac99744-e591-4e27-83ff-7dc364147d6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetRollForward_03d55761-6929-4e34-8fc1-13a265ca3da4" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_2ac99744-e591-4e27-83ff-7dc364147d6a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_30b55cee-a6d6-44a6-a571-6ec4fcb33025" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetRollForward_03d55761-6929-4e34-8fc1-13a265ca3da4" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_30b55cee-a6d6-44a6-a571-6ec4fcb33025" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease_63a5f644-e8b7-41ab-8f70-f3cb410e89d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetRollForward_03d55761-6929-4e34-8fc1-13a265ca3da4" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease_63a5f644-e8b7-41ab-8f70-f3cb410e89d6" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseDisposalOfDiscontinuedOperations_d0c012f4-7719-4c67-bbf1-04b233a93766" xlink:href="evh-20210630.xsd#evh_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseDisposalOfDiscontinuedOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetRollForward_03d55761-6929-4e34-8fc1-13a265ca3da4" xlink:to="loc_evh_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseDisposalOfDiscontinuedOperations_d0c012f4-7719-4c67-bbf1-04b233a93766" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments_f09b8c8f-5c20-430f-846b-8079e8ebb32c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetRollForward_03d55761-6929-4e34-8fc1-13a265ca3da4" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments_f09b8c8f-5c20-430f-846b-8079e8ebb32c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_d269ec69-146d-4c3b-9ceb-7922bf952aa5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable_111c0d8e-9633-4ba0-bb31-e71e4f2eb636" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems_f377dd68-4c0e-46e9-ad06-d2166ce9a717" xlink:to="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable_111c0d8e-9633-4ba0-bb31-e71e4f2eb636" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_df6f2956-4ebe-4a32-b272-45db776dd1fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable_111c0d8e-9633-4ba0-bb31-e71e4f2eb636" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_df6f2956-4ebe-4a32-b272-45db776dd1fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_df6f2956-4ebe-4a32-b272-45db776dd1fc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_df6f2956-4ebe-4a32-b272-45db776dd1fc" xlink:to="loc_us-gaap_SegmentDomain_df6f2956-4ebe-4a32-b272-45db776dd1fc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_8df1d510-580a-4d0e-99d2-867921a4422c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_df6f2956-4ebe-4a32-b272-45db776dd1fc" xlink:to="loc_us-gaap_SegmentDomain_8df1d510-580a-4d0e-99d2-867921a4422c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EvolentHealthServicesSegmentMember_d495a698-39b9-43a5-accb-5c9f2e1e1915" xlink:href="evh-20210630.xsd#evh_EvolentHealthServicesSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_8df1d510-580a-4d0e-99d2-867921a4422c" xlink:to="loc_evh_EvolentHealthServicesSegmentMember_d495a698-39b9-43a5-accb-5c9f2e1e1915" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ClinicalSolutionsSegmentMember_68560491-8453-4b0a-84c6-b573409af406" xlink:href="evh-20210630.xsd#evh_ClinicalSolutionsSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_8df1d510-580a-4d0e-99d2-867921a4422c" xlink:to="loc_evh_ClinicalSolutionsSegmentMember_68560491-8453-4b0a-84c6-b573409af406" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TrueHealthSegmentMember_e564903d-ecf0-49bf-b0d1-5c0cc7ccdc3c" xlink:href="evh-20210630.xsd#evh_TrueHealthSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_8df1d510-580a-4d0e-99d2-867921a4422c" xlink:to="loc_evh_TrueHealthSegmentMember_e564903d-ecf0-49bf-b0d1-5c0cc7ccdc3c" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="evh-20210630.xsd#SubsequentEventsDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/SubsequentEventsDetails" xlink:type="extended" id="ifc5710bfbb7841c694f911c9c14b2948_SubsequentEventsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_da457573-7823-4b70-bb5e-2662e5fc18b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_2a9bc1fe-446c-4000-8816-0fa5eb8bf6aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_da457573-7823-4b70-bb5e-2662e5fc18b3" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_2a9bc1fe-446c-4000-8816-0fa5eb8bf6aa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_5dc80b7a-07a2-4315-804b-f7e940a1ecfd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_da457573-7823-4b70-bb5e-2662e5fc18b3" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_5dc80b7a-07a2-4315-804b-f7e940a1ecfd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_2a7dcd78-74cd-437a-a66f-5325a9b25000" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_da457573-7823-4b70-bb5e-2662e5fc18b3" xlink:to="loc_us-gaap_SubsequentEventTable_2a7dcd78-74cd-437a-a66f-5325a9b25000" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_31d68c0f-894b-4f7a-b672-a006cda169fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_2a7dcd78-74cd-437a-a66f-5325a9b25000" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_31d68c0f-894b-4f7a-b672-a006cda169fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_31d68c0f-894b-4f7a-b672-a006cda169fe_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_31d68c0f-894b-4f7a-b672-a006cda169fe" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_31d68c0f-894b-4f7a-b672-a006cda169fe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_d6c6ec7a-7d7d-4f17-a678-bc1c2cf25243" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_31d68c0f-894b-4f7a-b672-a006cda169fe" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_d6c6ec7a-7d7d-4f17-a678-bc1c2cf25243" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_46cd495a-622f-4936-82f8-7b84fd2f1382" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_d6c6ec7a-7d7d-4f17-a678-bc1c2cf25243" xlink:to="loc_us-gaap_SubsequentEventMember_46cd495a-622f-4936-82f8-7b84fd2f1382" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_58917341-bbdf-4287-a37e-3a0ca7688200" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_2a7dcd78-74cd-437a-a66f-5325a9b25000" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_58917341-bbdf-4287-a37e-3a0ca7688200" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_58917341-bbdf-4287-a37e-3a0ca7688200_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_58917341-bbdf-4287-a37e-3a0ca7688200" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_58917341-bbdf-4287-a37e-3a0ca7688200_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_08810bad-53ba-48c0-9de4-3111f7e535fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_58917341-bbdf-4287-a37e-3a0ca7688200" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_08810bad-53ba-48c0-9de4-3111f7e535fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_WindroseHealthInvestorsIIILPMember_e0c53bf7-95b8-4e2d-a937-27b8c399d161" xlink:href="evh-20210630.xsd#evh_WindroseHealthInvestorsIIILPMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_08810bad-53ba-48c0-9de4-3111f7e535fb" xlink:to="loc_evh_WindroseHealthInvestorsIIILPMember_e0c53bf7-95b8-4e2d-a937-27b8c399d161" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>evh-20210630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:e4ac7c37-8dd1-4c0a-a2d1-6d13aeec3d41,g:9a076b5a-4bc7-42a9-a1f2-350da80fade7-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy_0b156106-728e-4f59-8b7f-7a7c672e7920_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Unrestricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:to="lab_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_31b18f88-47ce-40c7-8ac2-60be38ad07ff_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionAxis_197d7a24-8924-4e1c-81b6-bc45d25c9a09_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionAxis" xlink:to="lab_us-gaap_AssetAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LetterOfCreditMember_a6f7342f-2ce7-421b-9404-2922c85a370a_terseLabel_en-US" xlink:label="lab_us-gaap_LetterOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of Credit</link:label>
    <link:label id="lab_us-gaap_LetterOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LetterOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LetterOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LetterOfCreditMember" xlink:to="lab_us-gaap_LetterOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_ea878389-f081-4e63-bbf4-5f4de7112b62_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible senior notes</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtMember" xlink:to="lab_us-gaap_ConvertibleDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_bb4ea639-f672-4fa4-ad55-c0cdb87e99ed_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Accounts, Notes and Loans Receivable, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_d8e669a4-b59f-4662-a622-aa848fd07ddc_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents [Axis]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5b973ad3-0e00-4f0b-b0de-3ca6ffb0fe5f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_a36b12f8-450f-4e9d-886f-1f0e62ebabfb_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_d1f4761e-629b-4c0f-a93c-d82f2669b178_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesAxis" xlink:to="lab_srt_ConsolidatedEntitiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_92bd8f41-116c-4f89-a367-8ecbddf67a64_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_4c2cf536-9fb3-47b0-ba8a-7a2e3a11111d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets - operating</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_51c522a7-0658-40ad-b498-5d4a861392fb_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation and employee benefits</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_208a5eb0-f7e7-4833-85f9-82ed8838d23b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_ad21127c-e176-440f-8426-7ed114f6172f_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_e05cc988-46f7-45e2-b2d3-f81c10b24fd5_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_label_en-US" xlink:label="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_83b6ff2e-d294-4047-b619-dc371904dc76_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_7f17182a-d392-4945-af49-0312a6c7f6ab_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_9b90d890-2f00-49a5-b897-5555c49f7365_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_VariableInterestEntityNewMedicaidContractNotAwardedRequirementToAcquireOwnershipConsiderationAmount_b767efd8-992f-445e-b6a7-975940f1d9c3_terseLabel_en-US" xlink:label="lab_evh_VariableInterestEntityNewMedicaidContractNotAwardedRequirementToAcquireOwnershipConsiderationAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Requirement to acquire ownership, consideration, amount</link:label>
    <link:label id="lab_evh_VariableInterestEntityNewMedicaidContractNotAwardedRequirementToAcquireOwnershipConsiderationAmount_label_en-US" xlink:label="lab_evh_VariableInterestEntityNewMedicaidContractNotAwardedRequirementToAcquireOwnershipConsiderationAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity, New Medicaid Contract Not Awarded, Requirement To Acquire Ownership, Consideration, Amount</link:label>
    <link:label id="lab_evh_VariableInterestEntityNewMedicaidContractNotAwardedRequirementToAcquireOwnershipConsiderationAmount_documentation_en-US" xlink:label="lab_evh_VariableInterestEntityNewMedicaidContractNotAwardedRequirementToAcquireOwnershipConsiderationAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity, New Medicaid Contract Not Awarded, Requirement To Acquire Ownership, Consideration, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_VariableInterestEntityNewMedicaidContractNotAwardedRequirementToAcquireOwnershipConsiderationAmount" xlink:href="evh-20210630.xsd#evh_VariableInterestEntityNewMedicaidContractNotAwardedRequirementToAcquireOwnershipConsiderationAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_VariableInterestEntityNewMedicaidContractNotAwardedRequirementToAcquireOwnershipConsiderationAmount" xlink:to="lab_evh_VariableInterestEntityNewMedicaidContractNotAwardedRequirementToAcquireOwnershipConsiderationAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_DisposalGroupIncludingDiscontinuedOperationRestrictedInvestmentsNoncurrent_0c81eed3-ee6f-48b7-9933-98af918aa773_terseLabel_en-US" xlink:label="lab_evh_DisposalGroupIncludingDiscontinuedOperationRestrictedInvestmentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current restricted investments</link:label>
    <link:label id="lab_evh_DisposalGroupIncludingDiscontinuedOperationRestrictedInvestmentsNoncurrent_label_en-US" xlink:label="lab_evh_DisposalGroupIncludingDiscontinuedOperationRestrictedInvestmentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Restricted Investments, Noncurrent</link:label>
    <link:label id="lab_evh_DisposalGroupIncludingDiscontinuedOperationRestrictedInvestmentsNoncurrent_documentation_en-US" xlink:label="lab_evh_DisposalGroupIncludingDiscontinuedOperationRestrictedInvestmentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Restricted Investments, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DisposalGroupIncludingDiscontinuedOperationRestrictedInvestmentsNoncurrent" xlink:href="evh-20210630.xsd#evh_DisposalGroupIncludingDiscontinuedOperationRestrictedInvestmentsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_DisposalGroupIncludingDiscontinuedOperationRestrictedInvestmentsNoncurrent" xlink:to="lab_evh_DisposalGroupIncludingDiscontinuedOperationRestrictedInvestmentsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_ec7319da-642e-4453-b893-fdb73076bbd2_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense_e82f0b31-a16a-41fa-8789-acad86d72b4e_verboseLabel_en-US" xlink:label="lab_us-gaap_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserves for claims and performance-based arrangements attributable to the Reinsurance Agreement at the beginning of the period</link:label>
    <link:label id="lab_us-gaap_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense_label_en-US" xlink:label="lab_us-gaap_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assumed Liability for Unpaid Claims and Claims Adjustment Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:to="lab_us-gaap_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_124ae4c9-f41d-43fc-993f-d46b9d199da6_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_273eb1b5-ec1b-4178-b97d-cf3d052a9018_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with customer, asset and liability</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:to="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_5b4539e2-a70d-4505-90d4-b9e2c38cf934_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_216be1ab-067d-4035-8490-bed964cea8ad_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:to="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_6d1f12a1-74e6-48bf-aa38-566e28378eed_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining lease term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_ae95eb71-8afa-41cb-bce8-6c319f237518_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable_0483e8ec-4930-4de7-976a-5109c1af2bca_terseLabel_en-US" xlink:label="lab_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-duration Insurance Contracts, Reconciliation of Claims Development to Liability [Table]</link:label>
    <link:label id="lab_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable_label_en-US" xlink:label="lab_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-duration Insurance Contracts, Reconciliation of Claims Development to Liability [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable" xlink:to="lab_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a82b6a03-d73a-452d-98f1-2ceb79d3122a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_a66243b5-1e3e-40ab-9f6a-c95bb56ef670_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_label_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_0f935c8e-23f8-4942-85d4-9396a66dd7ac_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeApproachValuationTechniqueMember_f9ab2a2f-6120-4e9f-be0d-9397d589d1a4_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeApproachValuationTechniqueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation, Income Approach</link:label>
    <link:label id="lab_us-gaap_IncomeApproachValuationTechniqueMember_label_en-US" xlink:label="lab_us-gaap_IncomeApproachValuationTechniqueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation, Income Approach [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeApproachValuationTechniqueMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeApproachValuationTechniqueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeApproachValuationTechniqueMember" xlink:to="lab_us-gaap_IncomeApproachValuationTechniqueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_b2f48dec-31c3-4413-af32-4b056faa6faf_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_859e21e8-3a4a-4e1b-90a8-9e7c0a2f8d52_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial conversion amount (in shares)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Number of Equity Instruments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments" xlink:to="lab_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_e2c283d1-acbf-47ac-b5df-92835601f92f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_768b8e4d-f0f5-4e1a-b31b-3170ec8cc649_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_fcaec8eb-033c-452a-8d55-015a145a81e5_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Realized and unrealized gains (losses), net</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets1_e6996372-ffd7-4f3b-ae78-47d7d813c4f8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on disposal of assets</link:label>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets1_17232437-3c30-46c8-aa71-68104f89aef0_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on disposal of assets</link:label>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets1_label_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDispositionOfAssets1" xlink:to="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_db3fc83c-9a55-428c-8f03-67562494fb7b_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_bce8e458-4d60-4431-bd04-4d7fbaefae70_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_16ff7f63-5074-440e-ae33-834ff6964bae_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_a69d7ff7-71c8-476f-bc4e-6cc9a5354d31_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_cddb54ae-5d4b-494b-bfed-e0e58a4847b2_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_bce6f475-8688-467c-9fa5-a305d3908753_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract_6a4e4eb8-aad8-4a2a-93eb-73f0c1df6735_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_9645549d-aef9-44bc-9b1a-6e7cfdf3eb4a_terseLabel_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Remaining Useful Life</link:label>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_label_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Finite-lived Intangible Assets, Weighted Average Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:to="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_IncreaseDecreaseInOperatingLeaseRightofUseAsset_32bc53cf-c511-48f4-9cf1-43172fb32202_negatedTerseLabel_en-US" xlink:label="lab_evh_IncreaseDecreaseInOperatingLeaseRightofUseAsset" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use operating assets</link:label>
    <link:label id="lab_evh_IncreaseDecreaseInOperatingLeaseRightofUseAsset_label_en-US" xlink:label="lab_evh_IncreaseDecreaseInOperatingLeaseRightofUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Operating Lease, Right-of-Use Asset</link:label>
    <link:label id="lab_evh_IncreaseDecreaseInOperatingLeaseRightofUseAsset_documentation_en-US" xlink:label="lab_evh_IncreaseDecreaseInOperatingLeaseRightofUseAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_IncreaseDecreaseInOperatingLeaseRightofUseAsset" xlink:href="evh-20210630.xsd#evh_IncreaseDecreaseInOperatingLeaseRightofUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_IncreaseDecreaseInOperatingLeaseRightofUseAsset" xlink:to="lab_evh_IncreaseDecreaseInOperatingLeaseRightofUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationTechniqueDomain_8abef25e-6d9c-49aa-8982-5250f7b25b1f_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationTechniqueDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Approach and Technique [Domain]</link:label>
    <link:label id="lab_us-gaap_ValuationTechniqueDomain_label_en-US" xlink:label="lab_us-gaap_ValuationTechniqueDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Approach and Technique [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationTechniqueDomain" xlink:to="lab_us-gaap_ValuationTechniqueDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableLeaseCost_557b7f82-5eb0-437c-98e7-c7efe469c688_terseLabel_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable lease cost</link:label>
    <link:label id="lab_us-gaap_VariableLeaseCost_label_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost" xlink:to="lab_us-gaap_VariableLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_3ce62f79-ca54-4724-a8c3-3b559ea9ff8a_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of antidilutive securities excluded from the calculation of earning per share (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_17241158-08b9-42ef-8cd1-6240e50ca33a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_82f089b1-2cca-46bc-87bf-72de08d45f30_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of revenue (exclusive of depreciation and amortization expenses presented separately below)</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Costs of Goods Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_6d9c9bc6-8097-495b-a19c-49a084fd4bf5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification to revenue, as a result of performance obligations satisfied</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_0ec91b82-508f-45f3-9f9b-b468f666c661_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:to="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_10690efd-39ba-46f0-892b-71ba63aca7cd_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityInitialConsolidationGainOrLoss_d0451554-d3e4-45f4-9959-73b13055156d_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityInitialConsolidationGainOrLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on consolidation</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityInitialConsolidationGainOrLoss_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityInitialConsolidationGainOrLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity, Initial Consolidation, Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityInitialConsolidationGainOrLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityInitialConsolidationGainOrLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityInitialConsolidationGainOrLoss" xlink:to="lab_us-gaap_VariableInterestEntityInitialConsolidationGainOrLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_3a367789-9e71-4857-8d8a-96b5afe0bdc9_negatedLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of equity method investments</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_f8360192-e8a7-4aba-8e7e-c47511e70372_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of equity method investments</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_ea8b4d90-98a2-4708-834e-db9914b5e599_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity method investment impairment</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Other than Temporary Impairment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment" xlink:to="lab_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_d7205af1-6306-48ea-8bd2-aff38c9aaf5a_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_811d0687-c0cc-40ec-958c-67d799344f9f_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitment fee percentage</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Commitment Fee Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:to="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_TaxReceivablesAgreementPercentofTaxSavingstobePaid_a15057de-a58f-4663-9452-04b31085cd6c_terseLabel_en-US" xlink:label="lab_evh_TaxReceivablesAgreementPercentofTaxSavingstobePaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percent of tax savings to be paid</link:label>
    <link:label id="lab_evh_TaxReceivablesAgreementPercentofTaxSavingstobePaid_label_en-US" xlink:label="lab_evh_TaxReceivablesAgreementPercentofTaxSavingstobePaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Receivables Agreement, Percent of Tax Savings to be Paid</link:label>
    <link:label id="lab_evh_TaxReceivablesAgreementPercentofTaxSavingstobePaid_documentation_en-US" xlink:label="lab_evh_TaxReceivablesAgreementPercentofTaxSavingstobePaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Receivables Agreement, Percent of Tax Savings to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TaxReceivablesAgreementPercentofTaxSavingstobePaid" xlink:href="evh-20210630.xsd#evh_TaxReceivablesAgreementPercentofTaxSavingstobePaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_TaxReceivablesAgreementPercentofTaxSavingstobePaid" xlink:to="lab_evh_TaxReceivablesAgreementPercentofTaxSavingstobePaid" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_AssetAcquisitionDebtSecuritiesAvailableForSale_c9599ab3-0203-4216-a792-7d94750e1caa_terseLabel_en-US" xlink:label="lab_evh_AssetAcquisitionDebtSecuritiesAvailableForSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities, available-for-sale</link:label>
    <link:label id="lab_evh_AssetAcquisitionDebtSecuritiesAvailableForSale_label_en-US" xlink:label="lab_evh_AssetAcquisitionDebtSecuritiesAvailableForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Debt Securities, Available-For-Sale</link:label>
    <link:label id="lab_evh_AssetAcquisitionDebtSecuritiesAvailableForSale_documentation_en-US" xlink:label="lab_evh_AssetAcquisitionDebtSecuritiesAvailableForSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Debt Securities, Available-For-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_AssetAcquisitionDebtSecuritiesAvailableForSale" xlink:href="evh-20210630.xsd#evh_AssetAcquisitionDebtSecuritiesAvailableForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_AssetAcquisitionDebtSecuritiesAvailableForSale" xlink:to="lab_evh_AssetAcquisitionDebtSecuritiesAvailableForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_e73eb9d9-6171-4b7c-a429-e7d7635285db_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of liabilities at fair value on recurring basis</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_e4962216-3e74-4795-b889-adad498671b8_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9b2ad5f6-1ad8-401d-955c-e989737fff34_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_f8c3af32-bf0a-4b90-adc7-e95d545f79d0_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents Items [Line Items]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents Items [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_EquityMethodInvestmentVotingInterestPercentage_712d630a-12a6-4030-b146-6b52045d750d_terseLabel_en-US" xlink:label="lab_evh_EquityMethodInvestmentVotingInterestPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Voting interest percentage</link:label>
    <link:label id="lab_evh_EquityMethodInvestmentVotingInterestPercentage_label_en-US" xlink:label="lab_evh_EquityMethodInvestmentVotingInterestPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Voting Interest Percentage</link:label>
    <link:label id="lab_evh_EquityMethodInvestmentVotingInterestPercentage_documentation_en-US" xlink:label="lab_evh_EquityMethodInvestmentVotingInterestPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Voting Interest Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EquityMethodInvestmentVotingInterestPercentage" xlink:href="evh-20210630.xsd#evh_EquityMethodInvestmentVotingInterestPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_EquityMethodInvestmentVotingInterestPercentage" xlink:to="lab_evh_EquityMethodInvestmentVotingInterestPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum_227afafd-1a03-467a-a2e7-4c0fd5fcfb49_terseLabel_en-US" xlink:label="lab_evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase covenant, consecutive trading days, minimum</link:label>
    <link:label id="lab_evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum_label_en-US" xlink:label="lab_evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Repurchase Covenant, Consecutive Trading Days, Minimum</link:label>
    <link:label id="lab_evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum_documentation_en-US" xlink:label="lab_evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Repurchase Covenant, Consecutive Trading Days, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum" xlink:href="evh-20210630.xsd#evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum" xlink:to="lab_evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount_8bf87b52-9d81-4752-ad51-31d5915737d5_verboseLabel_en-US" xlink:label="lab_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase covenant, repurchase price due to fundamental change as percentage of principal amount</link:label>
    <link:label id="lab_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount_label_en-US" xlink:label="lab_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Repurchase Price Due To Fundamental Change As Percentage Of Principal Amount</link:label>
    <link:label id="lab_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount_documentation_en-US" xlink:label="lab_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Repurchase Price Due To Fundamental Change As Percentage Of Principal Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount" xlink:href="evh-20210630.xsd#evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount" xlink:to="lab_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtTableTextBlock_04ea1918-ea16-4ee8-b7f4-d9af157c1252_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of convertible debt</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtTableTextBlock" xlink:to="lab_us-gaap_ConvertibleDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_b167f5da-ed21-463f-b5ac-121f84cb0216_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_6cc601cc-a58c-4fe1-b5f5-500d3086a667_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_0f9b1629-eea4-4a5d-a5b0-c4cca6b6823c_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_13e3028e-5e6f-4e86-a959-884874b3efe1_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative inception to date impairment</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impaired, Accumulated Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionPayablesAssumed1_013efaf0-d220-4d07-95ed-4f6ef6894bfd_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionPayablesAssumed1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class A common stock issued for payment of Passport/Global earn-out</link:label>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionPayablesAssumed1_label_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionPayablesAssumed1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash or Part Noncash Acquisition, Payables Assumed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionPayablesAssumed1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionPayablesAssumed1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionPayablesAssumed1" xlink:to="lab_us-gaap_NoncashOrPartNoncashAcquisitionPayablesAssumed1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_eaff7de2-9011-4423-80b0-391c12bcd2b1_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_d5ac87c4-bc67-4f69-9aca-d085647a588e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_60f066c6-af5e-41f6-bc17-f38e04531fdd_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_35c521e5-5876-456c-925c-f7dcff715480_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restrictions on Cash and Cash Equivalents [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restrictions on Cash and Cash Equivalents [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" xlink:to="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_e4434c94-b3cb-4ac6-af6e-fd12643382b8_verboseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_768e89f3-47c9-461d-9bfe-9ca3b643390a_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Net</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent_cad972a9-fa9f-41e4-b753-560f9520dc98_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Goodwill, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_d9b20aef-f63c-4529-b80c-be62b7b6cc44_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Table]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_NumberOfReportingUnitsFairValueInExcessOfCarryingAmount_a1519a3d-fe96-447e-987c-5770f11c57d5_terseLabel_en-US" xlink:label="lab_evh_NumberOfReportingUnitsFairValueInExcessOfCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of reporting units, fair value in excess of carrying amount</link:label>
    <link:label id="lab_evh_NumberOfReportingUnitsFairValueInExcessOfCarryingAmount_label_en-US" xlink:label="lab_evh_NumberOfReportingUnitsFairValueInExcessOfCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Reporting Units, Fair Value In Excess Of Carrying Amount</link:label>
    <link:label id="lab_evh_NumberOfReportingUnitsFairValueInExcessOfCarryingAmount_documentation_en-US" xlink:label="lab_evh_NumberOfReportingUnitsFairValueInExcessOfCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Reporting Units, Fair Value In Excess Of Carrying Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_NumberOfReportingUnitsFairValueInExcessOfCarryingAmount" xlink:href="evh-20210630.xsd#evh_NumberOfReportingUnitsFairValueInExcessOfCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_NumberOfReportingUnitsFairValueInExcessOfCarryingAmount" xlink:to="lab_evh_NumberOfReportingUnitsFairValueInExcessOfCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNoncurrentPastDueLineItems_8f2fddd4-c1c0-486f-b30c-24b60e583271_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNoncurrentPastDueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Noncurrent, Past Due [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNoncurrentPastDueLineItems_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNoncurrentPastDueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Noncurrent, Past Due [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNoncurrentPastDueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNoncurrentPastDueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNoncurrentPastDueLineItems" xlink:to="lab_us-gaap_AccountsReceivableNoncurrentPastDueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_0a129973-676e-4ba4-9ca5-3c73e6a90c03_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_AssetPurchaseAgreementEscrowPayments_4462bab5-00ad-4d68-b883-eabaf058018f_terseLabel_en-US" xlink:label="lab_evh_AssetPurchaseAgreementEscrowPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Purchase Agreement, escrow payments</link:label>
    <link:label id="lab_evh_AssetPurchaseAgreementEscrowPayments_label_en-US" xlink:label="lab_evh_AssetPurchaseAgreementEscrowPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Purchase Agreement, Escrow Payments</link:label>
    <link:label id="lab_evh_AssetPurchaseAgreementEscrowPayments_documentation_en-US" xlink:label="lab_evh_AssetPurchaseAgreementEscrowPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Purchase Agreement, Escrow Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_AssetPurchaseAgreementEscrowPayments" xlink:href="evh-20210630.xsd#evh_AssetPurchaseAgreementEscrowPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_AssetPurchaseAgreementEscrowPayments" xlink:to="lab_evh_AssetPurchaseAgreementEscrowPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_b8df2377-0210-4a71-b2f3-61d791bc0814_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity, Not Primary Beneficiary</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity, Not Primary Beneficiary [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:to="lab_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradeNamesMember_bc3848a3-d236-44ee-a0b1-8a02e1845ea6_terseLabel_en-US" xlink:label="lab_us-gaap_TradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate trade name</link:label>
    <link:label id="lab_us-gaap_TradeNamesMember_label_en-US" xlink:label="lab_us-gaap_TradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade Names [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradeNamesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeNamesMember" xlink:to="lab_us-gaap_TradeNamesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_d5a31db5-3e2f-4502-9c32-6c0da4acccf4_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_CommercialAndOtherCustomersMember_16035233-5677-470e-b08d-8eaaddd885c1_terseLabel_en-US" xlink:label="lab_evh_CommercialAndOtherCustomersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial and other</link:label>
    <link:label id="lab_evh_CommercialAndOtherCustomersMember_label_en-US" xlink:label="lab_evh_CommercialAndOtherCustomersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial And Other Customers [Member]</link:label>
    <link:label id="lab_evh_CommercialAndOtherCustomersMember_documentation_en-US" xlink:label="lab_evh_CommercialAndOtherCustomersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial And Other Customers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CommercialAndOtherCustomersMember" xlink:href="evh-20210630.xsd#evh_CommercialAndOtherCustomersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_CommercialAndOtherCustomersMember" xlink:to="lab_evh_CommercialAndOtherCustomersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_242db7e2-547c-4392-94e4-d8bf05053ef3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2251402c-460f-4e0b-b7c3-026dc470bfc4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current and non-current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_SharebasedCompensationIncludingOnetimeAdjustment_c8d25247-48bb-4f7d-a246-999e194c784a_negatedLabel_en-US" xlink:label="lab_evh_SharebasedCompensationIncludingOnetimeAdjustment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_evh_SharebasedCompensationIncludingOnetimeAdjustment_label_en-US" xlink:label="lab_evh_SharebasedCompensationIncludingOnetimeAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation, Including One-time Adjustment</link:label>
    <link:label id="lab_evh_SharebasedCompensationIncludingOnetimeAdjustment_documentation_en-US" xlink:label="lab_evh_SharebasedCompensationIncludingOnetimeAdjustment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation, Including One-time Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SharebasedCompensationIncludingOnetimeAdjustment" xlink:href="evh-20210630.xsd#evh_SharebasedCompensationIncludingOnetimeAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_SharebasedCompensationIncludingOnetimeAdjustment" xlink:to="lab_evh_SharebasedCompensationIncludingOnetimeAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancingReceivablesPeriodPastDueDomain_76404c6e-1124-48cb-9484-4b8afcc63e6e_terseLabel_en-US" xlink:label="lab_us-gaap_FinancingReceivablesPeriodPastDueDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Asset, Period Past Due [Domain]</link:label>
    <link:label id="lab_us-gaap_FinancingReceivablesPeriodPastDueDomain_label_en-US" xlink:label="lab_us-gaap_FinancingReceivablesPeriodPastDueDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Asset, Aging [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivablesPeriodPastDueDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancingReceivablesPeriodPastDueDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancingReceivablesPeriodPastDueDomain" xlink:to="lab_us-gaap_FinancingReceivablesPeriodPastDueDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByParent_4e79be5f-62f7-494a-83a0-253f9a3d1d51_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Parent's ownership percentage</link:label>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByParent_label_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Ownership Percentage by Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:to="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1c4e5c25-8117-4657-acc0-8e62176f7476_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_PremiumsRevenueMember_637eb2c9-8d86-4fb9-a3e5-2ae495272213_terseLabel_en-US" xlink:label="lab_evh_PremiumsRevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premiums</link:label>
    <link:label id="lab_evh_PremiumsRevenueMember_label_en-US" xlink:label="lab_evh_PremiumsRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premiums Revenue [Member]</link:label>
    <link:label id="lab_evh_PremiumsRevenueMember_documentation_en-US" xlink:label="lab_evh_PremiumsRevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premiums Revenue [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PremiumsRevenueMember" xlink:href="evh-20210630.xsd#evh_PremiumsRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_PremiumsRevenueMember" xlink:to="lab_evh_PremiumsRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_NewNotesMember_3006ff8a-0386-440d-9200-94ef10e4d260_terseLabel_en-US" xlink:label="lab_evh_NewNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Notes</link:label>
    <link:label id="lab_evh_NewNotesMember_label_en-US" xlink:label="lab_evh_NewNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Notes [Member]</link:label>
    <link:label id="lab_evh_NewNotesMember_documentation_en-US" xlink:label="lab_evh_NewNotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_NewNotesMember" xlink:href="evh-20210630.xsd#evh_NewNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_NewNotesMember" xlink:to="lab_evh_NewNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_53eafcf6-3673-46cf-99eb-eb47961409c1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityOwnershipPercentage_b04bd90b-7101-431e-8e79-2b4c263fcc76_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest in investment</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityOwnershipPercentage_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity, Qualitative or Quantitative Information, Ownership Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityOwnershipPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityOwnershipPercentage" xlink:to="lab_us-gaap_VariableInterestEntityOwnershipPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_b5fd56ee-fd6c-4556-8dd5-f3d5eee58821_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_ProceedsFromTransferOfMembership_dd72ff0b-6633-4216-a8e7-0272a10199ff_terseLabel_en-US" xlink:label="lab_evh_ProceedsFromTransferOfMembership" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from transfer of membership</link:label>
    <link:label id="lab_evh_ProceedsFromTransferOfMembership_label_en-US" xlink:label="lab_evh_ProceedsFromTransferOfMembership" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Transfer Of Membership</link:label>
    <link:label id="lab_evh_ProceedsFromTransferOfMembership_documentation_en-US" xlink:label="lab_evh_ProceedsFromTransferOfMembership" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Transfer Of Membership</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ProceedsFromTransferOfMembership" xlink:href="evh-20210630.xsd#evh_ProceedsFromTransferOfMembership"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_ProceedsFromTransferOfMembership" xlink:to="lab_evh_ProceedsFromTransferOfMembership" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecuredDebtMember_859efa18-74b9-46ef-b43d-32f7261dbad2_terseLabel_en-US" xlink:label="lab_us-gaap_SecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Debt</link:label>
    <link:label id="lab_us-gaap_SecuredDebtMember_label_en-US" xlink:label="lab_us-gaap_SecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuredDebtMember" xlink:to="lab_us-gaap_SecuredDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_1cdc6a7a-2fbc-427b-b9f3-ad41fe4399f6_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued property and equipment purchases</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_276a8c7b-1b74-4d3a-ad54-56cd86782cee_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefit for income taxes</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operation, Tax Effect of Discontinued Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:to="lab_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_FinancingReceivablePercentNotPastDue_45ca2ee2-493c-467c-b9cb-8f3619817aa3_terseLabel_en-US" xlink:label="lab_evh_FinancingReceivablePercentNotPastDue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of receivables, current</link:label>
    <link:label id="lab_evh_FinancingReceivablePercentNotPastDue_label_en-US" xlink:label="lab_evh_FinancingReceivablePercentNotPastDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, Percent Not Past Due</link:label>
    <link:label id="lab_evh_FinancingReceivablePercentNotPastDue_documentation_en-US" xlink:label="lab_evh_FinancingReceivablePercentNotPastDue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, Percent Not Past Due</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_FinancingReceivablePercentNotPastDue" xlink:href="evh-20210630.xsd#evh_FinancingReceivablePercentNotPastDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_FinancingReceivablePercentNotPastDue" xlink:to="lab_evh_FinancingReceivablePercentNotPastDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_2d88e9be-cfdc-4b93-a7a0-69cc80aceadb_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_6afc3b50-c073-45cd-8daa-ba0b30732e9d_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Paid costs related to prior year</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_label_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Prior Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" xlink:to="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_941e8924-a822-4898-b3f6-313d64ef08f0_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation capitalized as software development costs</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Amount Capitalized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6a76e9af-4bd4-40a6-9cc6-ddaeba22a7db_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_TransferOfMembershipPercentageOfPaymentBasedOnNumberOfEnrollees_f33d52c0-9b8d-4478-8d9a-1e4eb5af6625_terseLabel_en-US" xlink:label="lab_evh_TransferOfMembershipPercentageOfPaymentBasedOnNumberOfEnrollees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transfer of membership, percentage of payment based on number of enrollees</link:label>
    <link:label id="lab_evh_TransferOfMembershipPercentageOfPaymentBasedOnNumberOfEnrollees_label_en-US" xlink:label="lab_evh_TransferOfMembershipPercentageOfPaymentBasedOnNumberOfEnrollees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transfer Of Membership, Percentage Of Payment Based on Number Of Enrollees</link:label>
    <link:label id="lab_evh_TransferOfMembershipPercentageOfPaymentBasedOnNumberOfEnrollees_documentation_en-US" xlink:label="lab_evh_TransferOfMembershipPercentageOfPaymentBasedOnNumberOfEnrollees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transfer Of Membership, Percentage Of Payment Based on Number Of Enrollees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TransferOfMembershipPercentageOfPaymentBasedOnNumberOfEnrollees" xlink:href="evh-20210630.xsd#evh_TransferOfMembershipPercentageOfPaymentBasedOnNumberOfEnrollees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_TransferOfMembershipPercentageOfPaymentBasedOnNumberOfEnrollees" xlink:to="lab_evh_TransferOfMembershipPercentageOfPaymentBasedOnNumberOfEnrollees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_229e1095-49b3-474c-9963-6b3d18ad5a63_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation_25f23226-3bf5-4a3f-8bde-5322ea5d2904_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal of assets</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Decrease from Deconsolidation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation" xlink:to="lab_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_d06a7056-37d8-4dcf-9065-59a2fc165f2a_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_CashFlowLesseeAbstract_247659a9-27a8-4d91-be70-5754ba6408f4_terseLabel_en-US" xlink:label="lab_evh_CashFlowLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effects of Leases</link:label>
    <link:label id="lab_evh_CashFlowLesseeAbstract_label_en-US" xlink:label="lab_evh_CashFlowLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Lessee [Abstract]</link:label>
    <link:label id="lab_evh_CashFlowLesseeAbstract_documentation_en-US" xlink:label="lab_evh_CashFlowLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Lessee [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CashFlowLesseeAbstract" xlink:href="evh-20210630.xsd#evh_CashFlowLesseeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_CashFlowLesseeAbstract" xlink:to="lab_evh_CashFlowLesseeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_ca78af03-671e-44bf-a640-4c3269f622df_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_3800a00e-8e89-4396-9c7e-d26592867f88_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incurred costs related to prior year</link:label>
    <link:label id="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_label_en-US" xlink:label="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior Year Claims and Claims Adjustment Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" xlink:to="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_5cc39f42-014f-4e1a-a0ac-b249ac3cd3cc_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_e258b03d-6f22-4572-a509-200d5bf6f7a6_totalLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic loss per share attributable to common shareholders of Evolent Health, Inc. (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_StockVestedAndRetiredDuringPeriodValue_a66b05d8-5f01-4595-9e07-e96a59b54efe_negatedTerseLabel_en-US" xlink:label="lab_evh_StockVestedAndRetiredDuringPeriodValue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share retirement</link:label>
    <link:label id="lab_evh_StockVestedAndRetiredDuringPeriodValue_label_en-US" xlink:label="lab_evh_StockVestedAndRetiredDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Vested And Retired During Period, Value</link:label>
    <link:label id="lab_evh_StockVestedAndRetiredDuringPeriodValue_documentation_en-US" xlink:label="lab_evh_StockVestedAndRetiredDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Vested And Retired During Period, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_StockVestedAndRetiredDuringPeriodValue" xlink:href="evh-20210630.xsd#evh_StockVestedAndRetiredDuringPeriodValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_StockVestedAndRetiredDuringPeriodValue" xlink:to="lab_evh_StockVestedAndRetiredDuringPeriodValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_2deefb8e-e5a7-4905-8fdc-5fe7883a8e3d_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent_b4c3c390-0f1b-495b-aaf5-d09e393d7575_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Deferred Revenue, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense_12bbab2e-4ab4-40c4-ae47-10dc9ba148c1_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve for claims and performance-based arrangements</link:label>
    <link:label id="lab_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense_label_en-US" xlink:label="lab_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Future Policy Benefits and Unpaid Claims and Claims Adjustment Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense" xlink:to="lab_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_8e497b2a-7d9d-4fa8-a638-24cb03dd713c_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndInvestmentsCurrent_c50396ed-1fac-4a1b-955a-df79724c9f8a_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndInvestmentsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash and restricted investments</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndInvestmentsCurrent_aae7a20e-83a0-40e0-900f-51dd811b0653_totalLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndInvestmentsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current restricted cash and restricted investments</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndInvestmentsCurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndInvestmentsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Investments, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndInvestmentsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndInvestmentsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndInvestmentsCurrent" xlink:to="lab_us-gaap_RestrictedCashAndInvestmentsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseAgreementsMember_7d67e754-5872-4afe-88d1-6f848eae98d6_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Agreements</link:label>
    <link:label id="lab_us-gaap_LeaseAgreementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseAgreementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseAgreementsMember" xlink:to="lab_us-gaap_LeaseAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_164c9a5a-a9f7-44fc-95bf-dd05f99a25f4_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance as of beginning of period</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_735c4f97-bcec-49be-83be-764a281bfca0_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance as of end of period</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_5534a39f-1a00-4470-81f5-b14b58ef450c_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_f79f0ce8-ff0d-4ced-ad8b-6d70ff1c9128_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other loss</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Other Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseDebt_811b97bb-dfac-4386-9553-2b8e22988184_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebt_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebt" xlink:to="lab_us-gaap_InterestExpenseDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_18cb97d8-b5d9-4eeb-ab98-e6929e632b35_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of revenue</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_IncreaseDecreaseInCapitalizedContractCostNet_9d4b3463-10fe-4545-ae9c-9e5b4a6906fc_negatedTerseLabel_en-US" xlink:label="lab_evh_IncreaseDecreaseInCapitalizedContractCostNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract cost assets</link:label>
    <link:label id="lab_evh_IncreaseDecreaseInCapitalizedContractCostNet_label_en-US" xlink:label="lab_evh_IncreaseDecreaseInCapitalizedContractCostNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Capitalized Contract Cost, Net</link:label>
    <link:label id="lab_evh_IncreaseDecreaseInCapitalizedContractCostNet_documentation_en-US" xlink:label="lab_evh_IncreaseDecreaseInCapitalizedContractCostNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Capitalized Contract Cost, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_IncreaseDecreaseInCapitalizedContractCostNet" xlink:href="evh-20210630.xsd#evh_IncreaseDecreaseInCapitalizedContractCostNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_IncreaseDecreaseInCapitalizedContractCostNet" xlink:to="lab_evh_IncreaseDecreaseInCapitalizedContractCostNet" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_AccruedPropertyAndEquipmentPurchases_39b80fb2-208b-47d5-a363-fdcd44bf421d_negatedTerseLabel_en-US" xlink:label="lab_evh_AccruedPropertyAndEquipmentPurchases" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued property and equipment purchases</link:label>
    <link:label id="lab_evh_AccruedPropertyAndEquipmentPurchases_label_en-US" xlink:label="lab_evh_AccruedPropertyAndEquipmentPurchases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Property And Equipment Purchases</link:label>
    <link:label id="lab_evh_AccruedPropertyAndEquipmentPurchases_documentation_en-US" xlink:label="lab_evh_AccruedPropertyAndEquipmentPurchases" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Property And Equipment Purchases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_AccruedPropertyAndEquipmentPurchases" xlink:href="evh-20210630.xsd#evh_AccruedPropertyAndEquipmentPurchases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_AccruedPropertyAndEquipmentPurchases" xlink:to="lab_evh_AccruedPropertyAndEquipmentPurchases" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_feafb89d-f2e9-46d9-a22c-84f6aa8a0601_terseLabel_en-US" xlink:label="lab_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows provided by (used in) investing activities</link:label>
    <link:label id="lab_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_label_en-US" xlink:label="lab_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Provided by (Used in) Investing Activities, Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:to="lab_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_59476f6f-31ab-476a-a22a-d5c4d1263771_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedContractCostNet_bd1ba4e0-990c-4e81-8379-65d35d4f6d08_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract cost assets</link:label>
    <link:label id="lab_us-gaap_CapitalizedContractCostNet_label_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Contract Cost, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedContractCostNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedContractCostNet" xlink:to="lab_us-gaap_CapitalizedContractCostNet" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_10534c5b-1ccd-404a-aca6-031489194ac8_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption, Adjustment</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption, Adjustment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_e7c9d5ab-e816-4ac0-8786-694b2fb7d3d7_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating cash flows from operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_ScheduleofChangesinNoncontrollingInterestTableTextBlock_16072ed1-f8e6-4e92-a41e-3c4b4a56df9b_terseLabel_en-US" xlink:label="lab_evh_ScheduleofChangesinNoncontrollingInterestTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of changes in non-controlling interests</link:label>
    <link:label id="lab_evh_ScheduleofChangesinNoncontrollingInterestTableTextBlock_label_en-US" xlink:label="lab_evh_ScheduleofChangesinNoncontrollingInterestTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Changes in Noncontrolling Interest [Table Text Block]</link:label>
    <link:label id="lab_evh_ScheduleofChangesinNoncontrollingInterestTableTextBlock_documentation_en-US" xlink:label="lab_evh_ScheduleofChangesinNoncontrollingInterestTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Changes in Noncontrolling Interest [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ScheduleofChangesinNoncontrollingInterestTableTextBlock" xlink:href="evh-20210630.xsd#evh_ScheduleofChangesinNoncontrollingInterestTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_ScheduleofChangesinNoncontrollingInterestTableTextBlock" xlink:to="lab_evh_ScheduleofChangesinNoncontrollingInterestTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_c0df1cba-15c2-4c90-bd6b-b21228bac4ff_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current operating cash outflows, net</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedContractCostNetNoncurrent_34bb30ca-76b6-4b1f-aab3-64ebfb78a208_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostNetNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract cost assets</link:label>
    <link:label id="lab_us-gaap_CapitalizedContractCostNetNoncurrent_label_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostNetNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Contract Cost, Net, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostNetNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedContractCostNetNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedContractCostNetNoncurrent" xlink:to="lab_us-gaap_CapitalizedContractCostNetNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalents_9301f5f1-1aa7-4ed9-8888-739b2eb6f6cd_totalLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total restricted cash and restricted investments</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalents_011a3b4a-83cd-4e44-bb33-f28c52ee7347_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash and restricted investments</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalents_bcf3fed5-3d76-47a0-91bd-4e57e365a046_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted funds</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalents_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalents" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_BlackScholesMember_1d4c9540-7036-446d-9641-d651ff564f7e_terseLabel_en-US" xlink:label="lab_evh_BlackScholesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Black-Scholes</link:label>
    <link:label id="lab_evh_BlackScholesMember_label_en-US" xlink:label="lab_evh_BlackScholesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Black Scholes [Member]</link:label>
    <link:label id="lab_evh_BlackScholesMember_documentation_en-US" xlink:label="lab_evh_BlackScholesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Black Scholes [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_BlackScholesMember" xlink:href="evh-20210630.xsd#evh_BlackScholesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_BlackScholesMember" xlink:to="lab_evh_BlackScholesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_a2a9b9ce-a278-4511-ad37-95228c2ae4cb_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_5466fa87-4102-4b8e-8022-666ca2a8d366_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase price</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_1a32423d-1837-4a17-a6a0-b7ee612d1bdf_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for credit losses</link:label>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_label_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Credit Loss Expense (Reversal)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:to="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent_52d71b70-95f6-4564-8607-7355be670d68_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_6817a5e4-8111-402b-b416-3c5533a92254_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillRollForward_e1486520-d47d-4c46-8a03-2974dab8eb77_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_GoodwillRollForward_label_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward" xlink:to="lab_us-gaap_GoodwillRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationMeasurementPeriodAdjustment_ee25195e-4b56-4b82-96a8-46ac16f7c480_terseLabel_en-US" xlink:label="lab_evh_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationMeasurementPeriodAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase/decrease to goodwill from measurement period adjustments/business combinations</link:label>
    <link:label id="lab_evh_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationMeasurementPeriodAdjustment_label_en-US" xlink:label="lab_evh_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationMeasurementPeriodAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Or Part Noncash Acquisition, Noncash Financial Or Equity Instrument Consideration, Measurement Period Adjustment</link:label>
    <link:label id="lab_evh_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationMeasurementPeriodAdjustment_documentation_en-US" xlink:label="lab_evh_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationMeasurementPeriodAdjustment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Or Part Noncash Acquisition, Noncash Financial Or Equity Instrument Consideration, Measurement Period Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationMeasurementPeriodAdjustment" xlink:href="evh-20210630.xsd#evh_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationMeasurementPeriodAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationMeasurementPeriodAdjustment" xlink:to="lab_evh_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationMeasurementPeriodAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_69213fd0-bfc9-428f-85da-ac66675d818f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">After the Third Anniversary of the Closing of the Senior Credit Facilities but Prior to the Fourth Anniversary</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_a5ab8a1e-8df6-4a03-a17e-173fbcacfee2_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Continuing operations, diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Diluted Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_611b86c2-59b0-4972-9f11-92575b650a7e_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_f6ee284e-0a1e-471a-b38f-4067b01e69ec_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, net of discount</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_fa10e436-6211-42eb-ac6c-bcf16cab20f5_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying amount</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_1d23fde5-3901-4e14-b02d-b222a547d434_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total fair value of assets measured on a recurring basis</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital_f1edaa5b-9dd5-4a7f-92ad-933ea950b16e_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Return of equity method investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital_label_en-US" xlink:label="lab_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Equity Method Investment, Distribution, Return of Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" xlink:to="lab_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_c792fd3f-c97d-429e-8827-5e2ebc45e5c4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6e6c9032-b9e0-4fa4-b8b6-3773b7aed168_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows Provided by (Used In) Investing Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_688a4ce5-687e-41ba-96b1-c01a078e1584_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill impairment</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_4cdf34d6-9185-4312-b561-c622708633d8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_5a456b13-1ccb-48c0-8aee-8058b0c6a062_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_141b6352-2a22-4ec6-92c2-2712ffe90760_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_aa70e307-e56d-4932-ae2f-f6841d23c347_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares outstanding</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_9341fdee-9ee3-4340-8911-217890b74c34_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_NeighborhoodHealthPlanOfRhodeIslandMember_f47813c1-ba5a-401b-93a7-5f470bf4fbbe_terseLabel_en-US" xlink:label="lab_evh_NeighborhoodHealthPlanOfRhodeIslandMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Neighborhood Health Plan Of Rhode Island [Member]</link:label>
    <link:label id="lab_evh_NeighborhoodHealthPlanOfRhodeIslandMember_label_en-US" xlink:label="lab_evh_NeighborhoodHealthPlanOfRhodeIslandMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Neighborhood Health Plan Of Rhode Island [Member]</link:label>
    <link:label id="lab_evh_NeighborhoodHealthPlanOfRhodeIslandMember_documentation_en-US" xlink:label="lab_evh_NeighborhoodHealthPlanOfRhodeIslandMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Neighborhood Health Plan Of Rhode Island</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_NeighborhoodHealthPlanOfRhodeIslandMember" xlink:href="evh-20210630.xsd#evh_NeighborhoodHealthPlanOfRhodeIslandMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_NeighborhoodHealthPlanOfRhodeIslandMember" xlink:to="lab_evh_NeighborhoodHealthPlanOfRhodeIslandMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SoftwareDevelopmentMember_9e72abe3-2846-4279-87c6-713aa14a24d4_verboseLabel_en-US" xlink:label="lab_us-gaap_SoftwareDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Internal-use software development costs</link:label>
    <link:label id="lab_us-gaap_SoftwareDevelopmentMember_label_en-US" xlink:label="lab_us-gaap_SoftwareDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Software Development [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareDevelopmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SoftwareDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SoftwareDevelopmentMember" xlink:to="lab_us-gaap_SoftwareDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BaseRateMember_997aab75-4e75-4c96-9d9e-f79283f3a23f_terseLabel_en-US" xlink:label="lab_us-gaap_BaseRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base Rate</link:label>
    <link:label id="lab_us-gaap_BaseRateMember_label_en-US" xlink:label="lab_us-gaap_BaseRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BaseRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BaseRateMember" xlink:to="lab_us-gaap_BaseRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice_be5912a1-d2c4-41b0-b118-c6bf2326a1d3_terseLabel_en-US" xlink:label="lab_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase covenant, sale price as a percentage of conversion price</link:label>
    <link:label id="lab_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice_24519b44-cd61-4f21-9dc3-4b67dd9f81d3_verboseLabel_en-US" xlink:label="lab_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase covenant, sale price as a percentage of conversion price (at least)</link:label>
    <link:label id="lab_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice_label_en-US" xlink:label="lab_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Repurchase Covenant, Sale Price As A Percentage Of Conversion Price</link:label>
    <link:label id="lab_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice_documentation_en-US" xlink:label="lab_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Repurchase Covenant, Sale Price As A Percentage Of Conversion Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice" xlink:href="evh-20210630.xsd#evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice" xlink:to="lab_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_PassportNoteMember_1ef477c2-b2f0-4523-8a05-9b5b361eb955_terseLabel_en-US" xlink:label="lab_evh_PassportNoteMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Passport Note</link:label>
    <link:label id="lab_evh_PassportNoteMember_label_en-US" xlink:label="lab_evh_PassportNoteMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Passport Note [Member]</link:label>
    <link:label id="lab_evh_PassportNoteMember_documentation_en-US" xlink:label="lab_evh_PassportNoteMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Passport Note [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PassportNoteMember" xlink:href="evh-20210630.xsd#evh_PassportNoteMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_PassportNoteMember" xlink:to="lab_evh_PassportNoteMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_ed3e49f3-9fdb-4971-8b5c-cd3779be347c_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_d22ec815-4b72-43bc-8ca1-940b1cb6c739_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and shareholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_TransferOfMembershipPercentageOfPaymentSubjectToSatisfactionOfContingencies_72de187b-c372-49cb-a21b-db69cf2c780f_terseLabel_en-US" xlink:label="lab_evh_TransferOfMembershipPercentageOfPaymentSubjectToSatisfactionOfContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transfer of membership, percentage of payment subject to satisfaction of contingencies</link:label>
    <link:label id="lab_evh_TransferOfMembershipPercentageOfPaymentSubjectToSatisfactionOfContingencies_label_en-US" xlink:label="lab_evh_TransferOfMembershipPercentageOfPaymentSubjectToSatisfactionOfContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transfer Of Membership, Percentage Of Payment Subject To Satisfaction Of Contingencies</link:label>
    <link:label id="lab_evh_TransferOfMembershipPercentageOfPaymentSubjectToSatisfactionOfContingencies_documentation_en-US" xlink:label="lab_evh_TransferOfMembershipPercentageOfPaymentSubjectToSatisfactionOfContingencies" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transfer Of Membership, Percentage Of Payment Subject To Satisfaction Of Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TransferOfMembershipPercentageOfPaymentSubjectToSatisfactionOfContingencies" xlink:href="evh-20210630.xsd#evh_TransferOfMembershipPercentageOfPaymentSubjectToSatisfactionOfContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_TransferOfMembershipPercentageOfPaymentSubjectToSatisfactionOfContingencies" xlink:to="lab_evh_TransferOfMembershipPercentageOfPaymentSubjectToSatisfactionOfContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNet_b5bc5fbf-e32a-4f87-855a-7bb3eeb9459c_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNet_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNet" xlink:to="lab_us-gaap_AccountsReceivableNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_0e76bd94-e3a0-4f12-bc96-4263b55487a0_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued operations, diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_c3549f4f-a780-4cdc-828c-ca87fade3f4e_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_80792163-2358-4369-8cd4-2f7fb0a58085_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets_dfb32181-aa28-4e88-b306-8a2352387b03_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in internal-use software and purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Other Productive Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireOtherProductiveAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:to="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceReceivablesMember_76080a50-aaf9-4203-9fa3-9538f070d56d_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceReceivablesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Receivable</link:label>
    <link:label id="lab_us-gaap_FinanceReceivablesMember_label_en-US" xlink:label="lab_us-gaap_FinanceReceivablesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceReceivablesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceReceivablesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceReceivablesMember" xlink:to="lab_us-gaap_FinanceReceivablesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_e29b5436-8d12-4a94-8679-834a187ecee0_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in-capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowElementsAbstract_25d55e05-2a48-4f95-8214-8f63a24a527d_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowElementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Elements [Abstract]</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowElementsAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowElementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Elements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowElementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_648c9feb-e700-469c-88ad-3815c6e695d0_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_4594c064-f1c2-4f14-befb-422d8c06aae2_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskLineItems" xlink:to="lab_us-gaap_ConcentrationRiskLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a9894f93-1027-4240-be4f-406ac87d4355_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND SHAREHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_EarningsLossAvailabletoCommonShareholdersAbstract_e1409fd6-8c68-433e-b025-97d614bdfa6a_verboseLabel_en-US" xlink:label="lab_evh_EarningsLossAvailabletoCommonShareholdersAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less:</link:label>
    <link:label id="lab_evh_EarningsLossAvailabletoCommonShareholdersAbstract_label_en-US" xlink:label="lab_evh_EarningsLossAvailabletoCommonShareholdersAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings (Loss) Available to Common Shareholders [Abstract]</link:label>
    <link:label id="lab_evh_EarningsLossAvailabletoCommonShareholdersAbstract_documentation_en-US" xlink:label="lab_evh_EarningsLossAvailabletoCommonShareholdersAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings (Loss) Available to Common Shareholders [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EarningsLossAvailabletoCommonShareholdersAbstract" xlink:href="evh-20210630.xsd#evh_EarningsLossAvailabletoCommonShareholdersAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_EarningsLossAvailabletoCommonShareholdersAbstract" xlink:to="lab_evh_EarningsLossAvailabletoCommonShareholdersAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_1baf702a-b5dd-4e45-9984-9ac85899d6b4_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_InitialTermLoanFacilityMember_6a86aaec-e71d-4732-8b73-18d87411bbd7_terseLabel_en-US" xlink:label="lab_evh_InitialTermLoanFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial Term Loan Facility</link:label>
    <link:label id="lab_evh_InitialTermLoanFacilityMember_label_en-US" xlink:label="lab_evh_InitialTermLoanFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial Term Loan Facility [Member]</link:label>
    <link:label id="lab_evh_InitialTermLoanFacilityMember_documentation_en-US" xlink:label="lab_evh_InitialTermLoanFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial Term Loan Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_InitialTermLoanFacilityMember" xlink:href="evh-20210630.xsd#evh_InitialTermLoanFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_InitialTermLoanFacilityMember" xlink:to="lab_evh_InitialTermLoanFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_01c647d1-f307-4d95-a350-50939bf7d33f_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings (Loss) Per Common Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_b14a07ff-b8dc-4317-a685-7f4daf1a62b8_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_label_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:to="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_3061e001-3e0a-4d9a-ae34-10b4956d9e12_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_224272be-1c3e-4d9e-b17e-cf8e3abd2713_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedContractCostTable_ac257076-5700-407d-90d7-fef85fd30bcb_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Contract Cost [Table]</link:label>
    <link:label id="lab_us-gaap_CapitalizedContractCostTable_label_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Contract Cost [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedContractCostTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedContractCostTable" xlink:to="lab_us-gaap_CapitalizedContractCostTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_06097c13-10c7-47de-805c-c806153b1882_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_DebtIssuanceCostsNetDebtComponent_86f61bad-6c60-46ad-b4f6-d0f97d5a36bc_terseLabel_en-US" xlink:label="lab_evh_DebtIssuanceCostsNetDebtComponent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt issuance costs, net, debt component</link:label>
    <link:label id="lab_evh_DebtIssuanceCostsNetDebtComponent_label_en-US" xlink:label="lab_evh_DebtIssuanceCostsNetDebtComponent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Net, Debt Component</link:label>
    <link:label id="lab_evh_DebtIssuanceCostsNetDebtComponent_documentation_en-US" xlink:label="lab_evh_DebtIssuanceCostsNetDebtComponent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Net, Debt Component</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtIssuanceCostsNetDebtComponent" xlink:href="evh-20210630.xsd#evh_DebtIssuanceCostsNetDebtComponent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_DebtIssuanceCostsNetDebtComponent" xlink:to="lab_evh_DebtIssuanceCostsNetDebtComponent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_a12aae4f-ec25-48d1-b92e-b32466c04830_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of stock options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_319adb5e-770f-4086-adeb-b00995549e4b_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_244914a7-1775-4229-a9f8-a47411907b21_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_DisposalGroupIncludingDiscontinuedOperationInvestmentsNoncurrent_34504b40-2304-45d2-8ae6-ef7c374f4a52_terseLabel_en-US" xlink:label="lab_evh_DisposalGroupIncludingDiscontinuedOperationInvestmentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, at amortized cost</link:label>
    <link:label id="lab_evh_DisposalGroupIncludingDiscontinuedOperationInvestmentsNoncurrent_label_en-US" xlink:label="lab_evh_DisposalGroupIncludingDiscontinuedOperationInvestmentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Investments, Noncurrent</link:label>
    <link:label id="lab_evh_DisposalGroupIncludingDiscontinuedOperationInvestmentsNoncurrent_documentation_en-US" xlink:label="lab_evh_DisposalGroupIncludingDiscontinuedOperationInvestmentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Investments, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DisposalGroupIncludingDiscontinuedOperationInvestmentsNoncurrent" xlink:href="evh-20210630.xsd#evh_DisposalGroupIncludingDiscontinuedOperationInvestmentsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_DisposalGroupIncludingDiscontinuedOperationInvestmentsNoncurrent" xlink:to="lab_evh_DisposalGroupIncludingDiscontinuedOperationInvestmentsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_037720a3-510f-4b88-9b2f-5cb4521b6a88_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of contingent consideration and indemnification asset</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_01935563-68d0-4c8e-bcb2-71acf1555cf2_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of contingent consideration and indemnification asset</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_dd59e5cb-ebf0-4352-9c35-dc8b2761a27d_negatedLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of contingent consideration and indemnification asset</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_AffiliatedEntityMember_a3e47fb3-6067-4037-b126-164f32a1cdb3_terseLabel_en-US" xlink:label="lab_srt_AffiliatedEntityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliated Entity</link:label>
    <link:label id="lab_srt_AffiliatedEntityMember_label_en-US" xlink:label="lab_srt_AffiliatedEntityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliated Entity [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_AffiliatedEntityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_AffiliatedEntityMember" xlink:to="lab_srt_AffiliatedEntityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestAbstract_0b90d751-792a-4e6d-8fce-09c18e809fe4_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Abstract]</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract" xlink:to="lab_us-gaap_NoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_07614609-b31e-44b7-8cd4-c0b19fa34e07_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_cdbaba9b-c59d-40b8-b319-556d504ffebc_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rate on cash and cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_42a445d6-504f-44b8-8bb7-cb7a0a85bc72_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial conversion rate per $ 1000 principal amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_b6218523-49f0-43d0-bd6e-3c45f4eb26be_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial conversion rate per $ 1000 principal amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_42d73cb2-c44e-44d1-a4d1-32487898c797_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total fair value of liabilities measured on a recurring basis</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial and Nonfinancial Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_StockVestedAndRetiredDuringPeriodShares_d3465002-e820-46d0-bd73-1c4cce84d830_negatedTerseLabel_en-US" xlink:label="lab_evh_StockVestedAndRetiredDuringPeriodShares" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share retirement (in shares)</link:label>
    <link:label id="lab_evh_StockVestedAndRetiredDuringPeriodShares_label_en-US" xlink:label="lab_evh_StockVestedAndRetiredDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Vested And Retired During Period, Shares</link:label>
    <link:label id="lab_evh_StockVestedAndRetiredDuringPeriodShares_documentation_en-US" xlink:label="lab_evh_StockVestedAndRetiredDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Vested And Retired During Period, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_StockVestedAndRetiredDuringPeriodShares" xlink:href="evh-20210630.xsd#evh_StockVestedAndRetiredDuringPeriodShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_StockVestedAndRetiredDuringPeriodShares" xlink:to="lab_evh_StockVestedAndRetiredDuringPeriodShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_e66d0947-ce2e-4382-b412-a443b98c59c5_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total comprehensive loss attributable to non-controlling interests</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_792299c5-7133-4480-a0e0-6cb32b037ca8_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_365335c8-5619-4766-b3ed-099d9bc464ef_verboseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative expenses</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_eba2538d-db66-442b-bd0a-2892da7df4b9_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative expenses</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightUnissued_97723527-ddeb-4a06-a6c8-f37c6fdc80a4_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightUnissued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants agreed to be sold (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightUnissued_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightUnissued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Unissued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightUnissued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightUnissued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightUnissued" xlink:to="lab_us-gaap_ClassOfWarrantOrRightUnissued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_4c923e8d-0af9-4898-bf41-5998952191b1_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt issuance costs</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsNet" xlink:to="lab_us-gaap_DeferredFinanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_db7ea565-af35-4cfe-9879-96d58c18ab82_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_36d5acaf-5f2c-4ac8-8b9e-e61822d31df1_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_3df8498e-9eeb-4f5a-995f-075890e219d1_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_ProceedsFromReinsurance_0f2a348c-1ac4-45d1-866f-969cbcf9696b_negatedLabel_en-US" xlink:label="lab_evh_ProceedsFromReinsurance" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reinsurance payments paid (received)</link:label>
    <link:label id="lab_evh_ProceedsFromReinsurance_label_en-US" xlink:label="lab_evh_ProceedsFromReinsurance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Reinsurance</link:label>
    <link:label id="lab_evh_ProceedsFromReinsurance_documentation_en-US" xlink:label="lab_evh_ProceedsFromReinsurance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Reinsurance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ProceedsFromReinsurance" xlink:href="evh-20210630.xsd#evh_ProceedsFromReinsurance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_ProceedsFromReinsurance" xlink:to="lab_evh_ProceedsFromReinsurance" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAxis_0831deb8-e529-460e-af08-b50a051a827c_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect Period Of Adoption [Axis]</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAxis_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InsuranceDisclosureTextBlock_9db526df-09ca-4df8-9bc4-9766e74f5b9f_terseLabel_en-US" xlink:label="lab_us-gaap_InsuranceDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserves for Claims and Performance-Based Arrangements</link:label>
    <link:label id="lab_us-gaap_InsuranceDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InsuranceDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InsuranceDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InsuranceDisclosureTextBlock" xlink:to="lab_us-gaap_InsuranceDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_b2b9dec9-2135-4e77-b5f7-ed44e07f3496_totalLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_62d49433-1488-42ef-a555-8472de460635_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromInterestReceived_4243279a-3239-4c59-9f1b-743e17245530_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromInterestReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from interest received</link:label>
    <link:label id="lab_us-gaap_ProceedsFromInterestReceived_label_en-US" xlink:label="lab_us-gaap_ProceedsFromInterestReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Interest Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromInterestReceived" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromInterestReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromInterestReceived" xlink:to="lab_us-gaap_ProceedsFromInterestReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions_363f4ef8-b76e-43ec-8c1b-ac4abc7c75bd_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class A common stock issued for payment of earn-outs</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_d195c7b6-5e96-4a2f-982f-e09ef9ed485a_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_b219edaa-91ea-4ef5-95f5-3daa7358cd23_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable" xlink:to="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivableTypeDomain_e4a80fe5-b8c6-4c6c-bb1d-36443137014e_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivableTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable [Domain]</link:label>
    <link:label id="lab_us-gaap_ReceivableTypeDomain_label_en-US" xlink:label="lab_us-gaap_ReceivableTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivableTypeDomain" xlink:to="lab_us-gaap_ReceivableTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_13b96762-b293-454a-90eb-9bb4b7b4d254_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_0942d667-d88a-45c7-ad65-97c606ed9aa3_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowSupplementalDisclosuresTextBlock_33dcd4a2-c4bf-4d1a-95ce-27f4a267c843_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information</link:label>
    <link:label id="lab_us-gaap_CashFlowSupplementalDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Supplemental Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowSupplementalDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:to="lab_us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_31a24499-ca1f-4223-81da-0aae44c760fd_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditMember_8937a0c1-d64e-4602-81e6-b08618632552_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit</link:label>
    <link:label id="lab_us-gaap_LineOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditMember" xlink:to="lab_us-gaap_LineOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_3805f786-371b-472f-a227-503010467a0e_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFive_066bac0a-d073-4441-8b77-6f0859c4aa37_terseLabel_en-US" xlink:label="lab_evh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_evh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFive_label_en-US" xlink:label="lab_evh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, To Be Paid, After Year Five</link:label>
    <link:label id="lab_evh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFive_documentation_en-US" xlink:label="lab_evh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, To Be Paid, After Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFive" xlink:href="evh-20210630.xsd#evh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFive" xlink:to="lab_evh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeniorNotesMember_f15d516d-7f98-486d-86fc-c8e302fe6cb3_terseLabel_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes</link:label>
    <link:label id="lab_us-gaap_SeniorNotesMember_label_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeniorNotesMember" xlink:to="lab_us-gaap_SeniorNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_87d396ac-43de-4f41-a33b-bf63e59590a6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_a052a216-a2c9-479d-afc0-78f22a041ab7_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditLossFinancialInstrumentTextBlock_5c7e6956-9afc-4cbc-ac11-9d40932a4ba4_terseLabel_en-US" xlink:label="lab_us-gaap_CreditLossFinancialInstrumentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Losses</link:label>
    <link:label id="lab_us-gaap_CreditLossFinancialInstrumentTextBlock_label_en-US" xlink:label="lab_us-gaap_CreditLossFinancialInstrumentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Loss, Financial Instrument [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditLossFinancialInstrumentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditLossFinancialInstrumentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditLossFinancialInstrumentTextBlock" xlink:to="lab_us-gaap_CreditLossFinancialInstrumentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedContractCostLineItems_60f5e26a-9cf0-4660-88af-5601461d7825_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Contract Cost [Line Items]</link:label>
    <link:label id="lab_us-gaap_CapitalizedContractCostLineItems_label_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Contract Cost [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedContractCostLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedContractCostLineItems" xlink:to="lab_us-gaap_CapitalizedContractCostLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_9bc20199-1536-41be-9858-68fbeeb5e161_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedContractCostDomain_39cbfdbb-58a0-4c32-834d-56cec7a64dfb_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Contract Cost [Domain]</link:label>
    <link:label id="lab_us-gaap_CapitalizedContractCostDomain_label_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Contract Cost [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedContractCostDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedContractCostDomain" xlink:to="lab_us-gaap_CapitalizedContractCostDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_5a68fd83-9e7f-423d-a77b-3cef4b03d753_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MovementInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetRollForward_4aa63d3a-26a8-4a06-854c-45da4cb6875c_terseLabel_en-US" xlink:label="lab_us-gaap_MovementInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Period Increase (Decrease) [Abstract]</link:label>
    <link:label id="lab_us-gaap_MovementInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetRollForward_label_en-US" xlink:label="lab_us-gaap_MovementInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Period Increase (Decrease) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MovementInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MovementInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetRollForward" xlink:to="lab_us-gaap_MovementInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities_49584d2c-3999-4615-a486-f378cd9a2416_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities, net</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Deferred Tax Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedContractCostAmortizationPeriod_e6b83c15-0702-4cf3-bf34-3544a32a20a2_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostAmortizationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized contract cost, amortization period</link:label>
    <link:label id="lab_us-gaap_CapitalizedContractCostAmortizationPeriod_label_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostAmortizationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Contract Cost, Amortization Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostAmortizationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedContractCostAmortizationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedContractCostAmortizationPeriod" xlink:to="lab_us-gaap_CapitalizedContractCostAmortizationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_MedicareCustomersMember_da937c72-f297-40b4-a1c2-cfb25d32d8bd_terseLabel_en-US" xlink:label="lab_evh_MedicareCustomersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare</link:label>
    <link:label id="lab_evh_MedicareCustomersMember_label_en-US" xlink:label="lab_evh_MedicareCustomersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare Customers [Member]</link:label>
    <link:label id="lab_evh_MedicareCustomersMember_documentation_en-US" xlink:label="lab_evh_MedicareCustomersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare Customers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_MedicareCustomersMember" xlink:href="evh-20210630.xsd#evh_MedicareCustomersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_MedicareCustomersMember" xlink:to="lab_evh_MedicareCustomersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_94117d18-38de-44ae-ab65-523a6bb13a95_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present value of lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LettersOfCreditOutstandingAmount_7088b120-a016-4fa1-9584-cb44b509863a_verboseLabel_en-US" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letters of credit outstanding, amount</link:label>
    <link:label id="lab_us-gaap_LettersOfCreditOutstandingAmount_db07a371-3c60-4a34-adb3-6b7522e398b5_terseLabel_en-US" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of Credit Amount Required</link:label>
    <link:label id="lab_us-gaap_LettersOfCreditOutstandingAmount_label_en-US" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letters of Credit Outstanding, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LettersOfCreditOutstandingAmount" xlink:to="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_063dcff8-3a3a-4941-a122-e58ce0fb7c62_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class A common stock - $0.01 par value; 750,000,000 shares authorized; 87,195,128 and 85,894,450 shares issued, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_e4b6d432-76af-4e50-b839-67bb6d98725f_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_714fbcdd-e7b8-44b7-8fa6-16ff399274ec_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_label_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:to="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_6b900290-16d7-4d6a-93e2-f95f739de1dc_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_9c13304b-6a14-4c82-927c-2bfecb9bdfb5_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PerformanceSharesMember_9b21505d-884f-4a5e-9a1c-8e9e24b348c4_terseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance-based stock options</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember" xlink:to="lab_us-gaap_PerformanceSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_ee6ad810-7db5-48f1-9b9e-bffe30e8f2bc_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies (See Note 11)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_2b1df375-60c4-4254-8dcf-5247a7bb31b9_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_62fc1d96-ca67-49b8-a17c-97fedfcfcae3_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_4fb86182-64a1-4628-a02d-4fbce6cb8898_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_c0dc0aee-ccd3-4d57-9160-50caf409f90d_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of right-of-use assets</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_97128e38-d4a8-4912-b650-8238d478d536_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for doubtful accounts, current</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_434677e3-414a-4cab-8fae-7ea5d20059a0_negatedPeriodStartLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance as of beginning of period</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_833a32d2-5588-4c0b-ba62-b6487f8623f6_negatedPeriodEndLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance as of end of period</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_6d6c59a6-9bdc-4bc7-8000-e0f7b04fb2da_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of debt issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_a18e4170-d6d6-4575-baaf-aaa425f7d981_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification of non-controlling interests</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Increase from Subsidiary Equity Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:to="lab_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfDebt_855fe08c-4f31-4bce-9a39-0522852f9509_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of debt</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_abc6c2cc-52aa-486c-a39e-bcef6fa5e60a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of share-based awards granted</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupClassificationAxis_aa13484c-65b4-4de2-9a61-cb6f7e72ee9b_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Axis]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupClassificationAxis_label_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis" xlink:to="lab_us-gaap_DisposalGroupClassificationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipAxis_8ef3bc74-dee0-4ed8-a25e-e0908200d8ae_terseLabel_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:label id="lab_srt_OwnershipAxis_label_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipAxis" xlink:to="lab_srt_OwnershipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_2428920c-6c03-4da0-961d-14e969ad4ffd_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_6bd5f20f-4bbc-4d31-9df4-d216f28556b7_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillLineItems_035bef9f-9138-4f1a-bf49-ff4e62f04223_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:label id="lab_us-gaap_GoodwillLineItems_label_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillLineItems" xlink:to="lab_us-gaap_GoodwillLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_ef79035d-c5c6-4c96-8019-d9689df39e5b_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome_135de5be-1cf8-4f02-bbbd-6ec8148c2ff9_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Interest Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_7c545829-6503-4e8f-87e1-a7ab6a6b6b57_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockShares_ce5b919d-e8c2-41cf-932f-a162b51195a3_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock, at cost (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockShares_label_en-US" xlink:label="lab_us-gaap_TreasuryStockShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockShares" xlink:to="lab_us-gaap_TreasuryStockShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_48b6f242-0ac8-489a-aef0-a0e6bb4825ea_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and rights outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_e553d2e3-af3f-4140-8171-46b56e80e248_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_0f1d1213-92f3-4555-8612-07c8114a66f3_terseLabel_en-US" xlink:label="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows provided by (used in) operating activities</link:label>
    <link:label id="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_label_en-US" xlink:label="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Provided by (Used in) Operating Activities, Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:to="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_CA_94c51c87-06ef-46ce-a06a-03a47544f5fd_terseLabel_en-US" xlink:label="lab_stpr_CA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Brea, CA</link:label>
    <link:label id="lab_stpr_CA_label_en-US" xlink:label="lab_stpr_CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CALIFORNIA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CA" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_CA"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_CA" xlink:to="lab_stpr_CA" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseDisposalOfDiscontinuedOperations_59a8f947-39a5-4593-8696-289fe52eb27f_negatedTerseLabel_en-US" xlink:label="lab_evh_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseDisposalOfDiscontinuedOperations" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal of discontinued operations</link:label>
    <link:label id="lab_evh_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseDisposalOfDiscontinuedOperations_label_en-US" xlink:label="lab_evh_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseDisposalOfDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability For Unpaid Claims And Claims Adjustment Expense, Disposal Of Discontinued Operations</link:label>
    <link:label id="lab_evh_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseDisposalOfDiscontinuedOperations_documentation_en-US" xlink:label="lab_evh_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseDisposalOfDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability For Unpaid Claims And Claims Adjustment Expense, Disposal Of Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseDisposalOfDiscontinuedOperations" xlink:href="evh-20210630.xsd#evh_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseDisposalOfDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseDisposalOfDiscontinuedOperations" xlink:to="lab_evh_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseDisposalOfDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReinsuranceRecoverablesOnPaidAndUnpaidLosses_617164dd-a783-4f5a-9528-183b18f6e34e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ReinsuranceRecoverablesOnPaidAndUnpaidLosses" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable for claims and performance-based arrangements attributable to the Reinsurance Agreement at the end of the period</link:label>
    <link:label id="lab_us-gaap_ReinsuranceRecoverablesOnPaidAndUnpaidLosses_label_en-US" xlink:label="lab_us-gaap_ReinsuranceRecoverablesOnPaidAndUnpaidLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reinsurance Recoverable for Paid and Unpaid Claims and Claims Adjustments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReinsuranceRecoverablesOnPaidAndUnpaidLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReinsuranceRecoverablesOnPaidAndUnpaidLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReinsuranceRecoverablesOnPaidAndUnpaidLosses" xlink:to="lab_us-gaap_ReinsuranceRecoverablesOnPaidAndUnpaidLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestLineItems_4b73fa00-4194-46ff-bdfe-cad7e09aa9dd_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Line Items]</link:label>
    <link:label id="lab_us-gaap_MinorityInterestLineItems_label_en-US" xlink:label="lab_us-gaap_MinorityInterestLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestLineItems" xlink:to="lab_us-gaap_MinorityInterestLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_7d9821ea-85d7-4336-a85b-0224c06efa35_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_d4bc01f1-1f29-4451-a224-78cf2ee6cd5d_netLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements_556cfcb4-c59b-438d-8cfd-5b1ad8988302_terseLabel_en-US" xlink:label="lab_evh_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve for claims and performance-based arrangements</link:label>
    <link:label id="lab_evh_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements_label_en-US" xlink:label="lab_evh_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability For Future Policy Benefits And Unpaid Claims And Claims Adjustment Expense And Performance-Based Arrangements</link:label>
    <link:label id="lab_evh_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements_documentation_en-US" xlink:label="lab_evh_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability For Future Policy Benefits And Unpaid Claims And Claims Adjustment Expense And Performance-Based Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements" xlink:href="evh-20210630.xsd#evh_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements" xlink:to="lab_evh_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_221b13a8-e01e-4eed-8057-af4736e0b7df_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative expenses</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_98f12729-3b5f-4262-b483-4ac111e3c4cc_verboseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_b744adc8-ba58-4e45-99b6-6ddf04581be8_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ab84f633-db5d-4d6a-bbad-5a3851ec4d77_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_CollateralwithFinancialInstitutionsMember_47ccf318-62f4-4215-8763-9e8f70799150_terseLabel_en-US" xlink:label="lab_evh_CollateralwithFinancialInstitutionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collateral with financial institutions</link:label>
    <link:label id="lab_evh_CollateralwithFinancialInstitutionsMember_label_en-US" xlink:label="lab_evh_CollateralwithFinancialInstitutionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collateral with Financial Institutions [Member]</link:label>
    <link:label id="lab_evh_CollateralwithFinancialInstitutionsMember_documentation_en-US" xlink:label="lab_evh_CollateralwithFinancialInstitutionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collateral with Financial Institutions [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CollateralwithFinancialInstitutionsMember" xlink:href="evh-20210630.xsd#evh_CollateralwithFinancialInstitutionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_CollateralwithFinancialInstitutionsMember" xlink:to="lab_evh_CollateralwithFinancialInstitutionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_6ff2c7a1-f85c-41cd-97aa-fd9fc9399dd3_totalLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Operating Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedComputerSoftwareAdditions_a7971a4a-d20c-46fd-b7cf-3b09fd1a531b_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedComputerSoftwareAdditions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized computer software additions</link:label>
    <link:label id="lab_us-gaap_CapitalizedComputerSoftwareAdditions_label_en-US" xlink:label="lab_us-gaap_CapitalizedComputerSoftwareAdditions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Computer Software, Additions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedComputerSoftwareAdditions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedComputerSoftwareAdditions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedComputerSoftwareAdditions" xlink:to="lab_us-gaap_CapitalizedComputerSoftwareAdditions" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_FInancialAssetLessThan120DaysPastDueMember_24ea661d-a7bb-4ad3-872b-b51a6fc3fc26_terseLabel_en-US" xlink:label="lab_evh_FInancialAssetLessThan120DaysPastDueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Past due less than 120 days</link:label>
    <link:label id="lab_evh_FInancialAssetLessThan120DaysPastDueMember_label_en-US" xlink:label="lab_evh_FInancialAssetLessThan120DaysPastDueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FInancial Asset, Less Than 120 Days Past Due [Member]</link:label>
    <link:label id="lab_evh_FInancialAssetLessThan120DaysPastDueMember_documentation_en-US" xlink:label="lab_evh_FInancialAssetLessThan120DaysPastDueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FInancial Asset, Less Than 120 Days Past Due [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_FInancialAssetLessThan120DaysPastDueMember" xlink:href="evh-20210630.xsd#evh_FInancialAssetLessThan120DaysPastDueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_FInancialAssetLessThan120DaysPastDueMember" xlink:to="lab_evh_FInancialAssetLessThan120DaysPastDueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_RestrictedCashforOtherContractualCommitmentsMember_4b343203-9747-4a04-aae3-bb2302fb88ce_terseLabel_en-US" xlink:label="lab_evh_RestrictedCashforOtherContractualCommitmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_evh_RestrictedCashforOtherContractualCommitmentsMember_label_en-US" xlink:label="lab_evh_RestrictedCashforOtherContractualCommitmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash for Other Contractual Commitments [Member]</link:label>
    <link:label id="lab_evh_RestrictedCashforOtherContractualCommitmentsMember_documentation_en-US" xlink:label="lab_evh_RestrictedCashforOtherContractualCommitmentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash for Other Contractual Commitments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RestrictedCashforOtherContractualCommitmentsMember" xlink:href="evh-20210630.xsd#evh_RestrictedCashforOtherContractualCommitmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_RestrictedCashforOtherContractualCommitmentsMember" xlink:to="lab_evh_RestrictedCashforOtherContractualCommitmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_b085fcf2-fb2b-4eb0-90e5-6f749eaa7fd2_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_996947b8-9290-4b60-8959-7659c4612a79_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsDomain_0852c9fa-f296-4d8c-9a31-0d6da3cea58f_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:label id="lab_srt_ConsolidationItemsDomain_label_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsDomain" xlink:to="lab_srt_ConsolidationItemsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_2defa322-facb-4866-80d0-84f02c234eb5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_RestrictedCashForLettersOfCreditForLetterOfCreditFacilityMember_93fc1b9c-137a-4c5e-9ec7-829425437fd2_terseLabel_en-US" xlink:label="lab_evh_RestrictedCashForLettersOfCreditForLetterOfCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash For Letters Of Credit</link:label>
    <link:label id="lab_evh_RestrictedCashForLettersOfCreditForLetterOfCreditFacilityMember_label_en-US" xlink:label="lab_evh_RestrictedCashForLettersOfCreditForLetterOfCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash For Letters Of Credit For Letter Of Credit Facility [Member]</link:label>
    <link:label id="lab_evh_RestrictedCashForLettersOfCreditForLetterOfCreditFacilityMember_documentation_en-US" xlink:label="lab_evh_RestrictedCashForLettersOfCreditForLetterOfCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash For Letters Of Credit For Letter Of Credit Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RestrictedCashForLettersOfCreditForLetterOfCreditFacilityMember" xlink:href="evh-20210630.xsd#evh_RestrictedCashForLettersOfCreditForLetterOfCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_RestrictedCashForLettersOfCreditForLetterOfCreditFacilityMember" xlink:to="lab_evh_RestrictedCashForLettersOfCreditForLetterOfCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_MolinaHealthcareIncMember_d697d06f-d5d9-45f0-8692-dd1b9c02117e_terseLabel_en-US" xlink:label="lab_evh_MolinaHealthcareIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Molina</link:label>
    <link:label id="lab_evh_MolinaHealthcareIncMember_label_en-US" xlink:label="lab_evh_MolinaHealthcareIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Molina Healthcare, Inc. [Member]</link:label>
    <link:label id="lab_evh_MolinaHealthcareIncMember_documentation_en-US" xlink:label="lab_evh_MolinaHealthcareIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Molina Healthcare, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_MolinaHealthcareIncMember" xlink:href="evh-20210630.xsd#evh_MolinaHealthcareIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_MolinaHealthcareIncMember" xlink:to="lab_evh_MolinaHealthcareIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_62e696e7-3d5e-42cd-8ddb-ab958da67312_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_4de6d356-0fe8-4910-9362-41ffdde530cc_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_e6bb7462-c3c0-4a86-a340-374bea48a6ca_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateAxis_ad2d32d9-828c-45c9-a484-2ee92e3432de_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_1606f5e7-8b13-45e3-aaf8-8cf7527ea7ac_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForReinsurance_064844ba-6494-49f3-b48b-84749e842f5e_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForReinsurance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reinsurance payments paid (received)</link:label>
    <link:label id="lab_us-gaap_PaymentsForReinsurance_label_en-US" xlink:label="lab_us-gaap_PaymentsForReinsurance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Reinsurance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForReinsurance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForReinsurance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForReinsurance" xlink:to="lab_us-gaap_PaymentsForReinsurance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_4b4b956f-9fbf-4c56-a5ab-5d4b54f164f7_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_8094cc7a-7a04-4888-8278-32a913be19c8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancingReceivablesPeriodPastDueAxis_9127547e-d105-4f20-8b61-cb3dac87aaf9_terseLabel_en-US" xlink:label="lab_us-gaap_FinancingReceivablesPeriodPastDueAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Asset, Period Past Due [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancingReceivablesPeriodPastDueAxis_label_en-US" xlink:label="lab_us-gaap_FinancingReceivablesPeriodPastDueAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Asset, Aging [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivablesPeriodPastDueAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancingReceivablesPeriodPastDueAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancingReceivablesPeriodPastDueAxis" xlink:to="lab_us-gaap_FinancingReceivablesPeriodPastDueAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_400bc603-e5e5-42c8-bf79-fceb8ec550fe_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liability - current</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_22b9663e-8d62-403b-b761-2fd8c4e061c9_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e7b2c153-7a41-4eac-99ee-0987aa101220_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_GainOnTransferOfMembership_0fc5191d-a9bd-403c-8d80-9d4f171c9aa6_terseLabel_en-US" xlink:label="lab_evh_GainOnTransferOfMembership" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on transfer of membership</link:label>
    <link:label id="lab_evh_GainOnTransferOfMembership_e878e381-38a2-4d48-96d5-8aed1bc976b7_negatedTerseLabel_en-US" xlink:label="lab_evh_GainOnTransferOfMembership" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on transfer of membership</link:label>
    <link:label id="lab_evh_GainOnTransferOfMembership_label_en-US" xlink:label="lab_evh_GainOnTransferOfMembership" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain On Transfer Of Membership</link:label>
    <link:label id="lab_evh_GainOnTransferOfMembership_documentation_en-US" xlink:label="lab_evh_GainOnTransferOfMembership" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain On Transfer Of Membership</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_GainOnTransferOfMembership" xlink:href="evh-20210630.xsd#evh_GainOnTransferOfMembership"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_GainOnTransferOfMembership" xlink:to="lab_evh_GainOnTransferOfMembership" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization_0d9aee12-87ac-494c-be9b-741fc2f420e3_verboseLabel_en-US" xlink:label="lab_evh_CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incurred costs related to current year</link:label>
    <link:label id="lab_evh_CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization_label_en-US" xlink:label="lab_evh_CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Year Claims And Claims Adjustment Expense, Including Cost Of Goods And Services Sold, Excluding Depreciation And Amortization</link:label>
    <link:label id="lab_evh_CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization_documentation_en-US" xlink:label="lab_evh_CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Year Claims And Claims Adjustment Expense, Including Cost Of Goods And Services Sold, Excluding Depreciation And Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization" xlink:href="evh-20210630.xsd#evh_CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization" xlink:to="lab_evh_CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_cd675e77-dabc-4860-885c-a2c7cd8a6514_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_9925d286-ada8-4be9-8f5d-ccb0a440c211_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateDomain_b59b0053-f918-4970-b16f-4a9a15101469_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_6c215b7d-88db-4574-9f9e-7617405d2581_verboseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transactions</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_d0bb0f9a-8cac-4d93-b15d-f157ddaa5e48_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repositioning and Other Changes</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_91a36fbe-33be-4e27-a941-8e51278b802d_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_bde1fe70-d6ba-4e65-890c-dd413a21b783_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_5918bf02-7db5-4459-8bb1-64b9f5a835e8_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_IL_d704701f-72c3-4ee1-841f-4613be88f198_terseLabel_en-US" xlink:label="lab_stpr_IL" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Riverside, IL</link:label>
    <link:label id="lab_stpr_IL_label_en-US" xlink:label="lab_stpr_IL" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ILLINOIS</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_IL" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_IL"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_IL" xlink:to="lab_stpr_IL" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_PaymentsOfMakeWholePremium_eec83245-a134-4e3e-a6df-ea6f91c94c0f_terseLabel_en-US" xlink:label="lab_evh_PaymentsOfMakeWholePremium" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of make-whole premium</link:label>
    <link:label id="lab_evh_PaymentsOfMakeWholePremium_label_en-US" xlink:label="lab_evh_PaymentsOfMakeWholePremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments Of Make-Whole Premium</link:label>
    <link:label id="lab_evh_PaymentsOfMakeWholePremium_documentation_en-US" xlink:label="lab_evh_PaymentsOfMakeWholePremium" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments Of Make-Whole Premium</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PaymentsOfMakeWholePremium" xlink:href="evh-20210630.xsd#evh_PaymentsOfMakeWholePremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_PaymentsOfMakeWholePremium" xlink:to="lab_evh_PaymentsOfMakeWholePremium" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_ContractFulfillmentCostsMember_83d21626-062f-4296-9326-987aea8f216c_terseLabel_en-US" xlink:label="lab_evh_ContractFulfillmentCostsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Fulfillment Costs</link:label>
    <link:label id="lab_evh_ContractFulfillmentCostsMember_label_en-US" xlink:label="lab_evh_ContractFulfillmentCostsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Fulfillment Costs [Member]</link:label>
    <link:label id="lab_evh_ContractFulfillmentCostsMember_documentation_en-US" xlink:label="lab_evh_ContractFulfillmentCostsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Fulfillment Costs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ContractFulfillmentCostsMember" xlink:href="evh-20210630.xsd#evh_ContractFulfillmentCostsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_ContractFulfillmentCostsMember" xlink:to="lab_evh_ContractFulfillmentCostsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_ba8da046-d1b8-4d40-8c9d-0868e0f6c195_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments_e1b4da94-f911-4dd1-8f6d-9fe1b9deaad6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other adjustments</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments_label_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Adjustments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments" xlink:to="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockMember_e1ea1e65-3cbd-4219-a7a5-3a3f066fdc50_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockMember_label_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockMember" xlink:to="lab_us-gaap_TreasuryStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_8bd18fda-f7bb-4848-84c7-9a0318b8258f_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_a9f6d5f1-cc78-4c01-ac9e-35e4abbb849a_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_8e8ab8a1-caf2-429e-addf-1cb1c98a2b06_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other expense, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesReceivableNet_8c118642-07a5-4c3b-b77a-c821759b06cf_terseLabel_en-US" xlink:label="lab_us-gaap_NotesReceivableNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes receivable, net</link:label>
    <link:label id="lab_us-gaap_NotesReceivableNet_label_en-US" xlink:label="lab_us-gaap_NotesReceivableNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesReceivableNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesReceivableNet" xlink:to="lab_us-gaap_NotesReceivableNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtFairValue_10aa5b8a-2dc0-4bb1-9be1-f409c3dec1b0_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value</link:label>
    <link:label id="lab_us-gaap_LongTermDebtFairValue_label_en-US" xlink:label="lab_us-gaap_LongTermDebtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtFairValue" xlink:to="lab_us-gaap_LongTermDebtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_TrueHealthSegmentMember_db1947c9-a3d0-4cb6-963c-6209f304d6aa_terseLabel_en-US" xlink:label="lab_evh_TrueHealthSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">True Health</link:label>
    <link:label id="lab_evh_TrueHealthSegmentMember_label_en-US" xlink:label="lab_evh_TrueHealthSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">True Health Segment [Member]</link:label>
    <link:label id="lab_evh_TrueHealthSegmentMember_documentation_en-US" xlink:label="lab_evh_TrueHealthSegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">True Health Segment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TrueHealthSegmentMember" xlink:href="evh-20210630.xsd#evh_TrueHealthSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_TrueHealthSegmentMember" xlink:to="lab_evh_TrueHealthSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LegalFees_ab9b3fff-ea32-4409-96dd-d623471ca6ff_terseLabel_en-US" xlink:label="lab_us-gaap_LegalFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal expenses</link:label>
    <link:label id="lab_us-gaap_LegalFees_label_en-US" xlink:label="lab_us-gaap_LegalFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalFees" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LegalFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LegalFees" xlink:to="lab_us-gaap_LegalFees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_6979057d-f8f7-4121-a933-45b8d55c290c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other investing activities</link:label>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for (Proceeds from) Other Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:to="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditLossAbstract_bdf952c9-881b-4542-a945-36880157b0c2_terseLabel_en-US" xlink:label="lab_us-gaap_CreditLossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Loss [Abstract]</link:label>
    <link:label id="lab_us-gaap_CreditLossAbstract_label_en-US" xlink:label="lab_us-gaap_CreditLossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Loss [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditLossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditLossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditLossAbstract" xlink:to="lab_us-gaap_CreditLossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_UniversityHealthCaredbaPassportHealthPlanMember_f89b92a2-b894-4525-92b4-50fe5786910d_terseLabel_en-US" xlink:label="lab_evh_UniversityHealthCaredbaPassportHealthPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Passport</link:label>
    <link:label id="lab_evh_UniversityHealthCaredbaPassportHealthPlanMember_2ceb9ef7-cbba-47be-a576-f3d6fe40e96e_verboseLabel_en-US" xlink:label="lab_evh_UniversityHealthCaredbaPassportHealthPlanMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Passport</link:label>
    <link:label id="lab_evh_UniversityHealthCaredbaPassportHealthPlanMember_label_en-US" xlink:label="lab_evh_UniversityHealthCaredbaPassportHealthPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">University Health Care d/b/a Passport Health Plan [Member]</link:label>
    <link:label id="lab_evh_UniversityHealthCaredbaPassportHealthPlanMember_documentation_en-US" xlink:label="lab_evh_UniversityHealthCaredbaPassportHealthPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">University Health Care d/b/a Passport Health Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_UniversityHealthCaredbaPassportHealthPlanMember" xlink:href="evh-20210630.xsd#evh_UniversityHealthCaredbaPassportHealthPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_UniversityHealthCaredbaPassportHealthPlanMember" xlink:to="lab_evh_UniversityHealthCaredbaPassportHealthPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationTechniqueAxis_013e3b54-84c7-4d43-8624-1b9ee5b4feff_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationTechniqueAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Approach and Technique [Axis]</link:label>
    <link:label id="lab_us-gaap_ValuationTechniqueAxis_label_en-US" xlink:label="lab_us-gaap_ValuationTechniqueAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Approach and Technique [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationTechniqueAxis" xlink:to="lab_us-gaap_ValuationTechniqueAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations_e47b5e51-bfea-4a33-aa67-fa65791247a4_terseLabel_en-US" xlink:label="lab_evh_ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash received in advance of satisfaction of performance obligations</link:label>
    <link:label id="lab_evh_ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations_label_en-US" xlink:label="lab_evh_ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Liability, Cash Received In Advance Of Satisfaction Of Performance Obligations</link:label>
    <link:label id="lab_evh_ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations_documentation_en-US" xlink:label="lab_evh_ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Liability, Cash Received In Advance Of Satisfaction Of Performance Obligations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations" xlink:href="evh-20210630.xsd#evh_ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations" xlink:to="lab_evh_ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FacilityClosingMember_d4e99107-d9de-4409-a4ad-26cc3c274cfc_terseLabel_en-US" xlink:label="lab_us-gaap_FacilityClosingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office space consolidation</link:label>
    <link:label id="lab_us-gaap_FacilityClosingMember_label_en-US" xlink:label="lab_us-gaap_FacilityClosingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Closing [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FacilityClosingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FacilityClosingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FacilityClosingMember" xlink:to="lab_us-gaap_FacilityClosingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_159ecfd6-1db0-4cd0-bcb2-418d866275d6_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsAbstract" xlink:to="lab_us-gaap_BusinessCombinationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_DisposalGroupIncludingDiscontinuedOperationRestrictedCashAndRestrictedInvestmentsNoncurrent_de705b49-6395-4818-8270-fa1922532294_terseLabel_en-US" xlink:label="lab_evh_DisposalGroupIncludingDiscontinuedOperationRestrictedCashAndRestrictedInvestmentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash and restricted investments</link:label>
    <link:label id="lab_evh_DisposalGroupIncludingDiscontinuedOperationRestrictedCashAndRestrictedInvestmentsNoncurrent_label_en-US" xlink:label="lab_evh_DisposalGroupIncludingDiscontinuedOperationRestrictedCashAndRestrictedInvestmentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Restricted Cash And Restricted Investments, Noncurrent</link:label>
    <link:label id="lab_evh_DisposalGroupIncludingDiscontinuedOperationRestrictedCashAndRestrictedInvestmentsNoncurrent_documentation_en-US" xlink:label="lab_evh_DisposalGroupIncludingDiscontinuedOperationRestrictedCashAndRestrictedInvestmentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Restricted Cash And Restricted Investments, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DisposalGroupIncludingDiscontinuedOperationRestrictedCashAndRestrictedInvestmentsNoncurrent" xlink:href="evh-20210630.xsd#evh_DisposalGroupIncludingDiscontinuedOperationRestrictedCashAndRestrictedInvestmentsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_DisposalGroupIncludingDiscontinuedOperationRestrictedCashAndRestrictedInvestmentsNoncurrent" xlink:to="lab_evh_DisposalGroupIncludingDiscontinuedOperationRestrictedCashAndRestrictedInvestmentsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_93fcaf4c-76de-47e8-aeaf-9cea643f96f7_verboseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_f4b1573a-2a3b-4f26-930e-1647093ae471_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ad977a77-85e3-445f-bb8f-340e8e7ec356_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_5a2eb9f8-f0c6-4e00-b6c1-9b1bf08b1578_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermAccountsNotesAndLoansReceivableNetNoncurrent_4d477d0d-a768-4bb3-a3bc-624a82d1424d_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermAccountsNotesAndLoansReceivableNetNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term receivables</link:label>
    <link:label id="lab_us-gaap_LongTermAccountsNotesAndLoansReceivableNetNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermAccountsNotesAndLoansReceivableNetNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts and Financing Receivable, after Allowance for Credit Loss, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermAccountsNotesAndLoansReceivableNetNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermAccountsNotesAndLoansReceivableNetNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermAccountsNotesAndLoansReceivableNetNoncurrent" xlink:to="lab_us-gaap_LongTermAccountsNotesAndLoansReceivableNetNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_e0364ad1-2b65-4111-a8d4-98e40186d453_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingRevenueReconcilingItemLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Revenue Reconciling Item [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingRevenueReconcilingItemLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Revenue Reconciling Item [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingRevenueReconcilingItemLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems" xlink:to="lab_us-gaap_SegmentReportingRevenueReconcilingItemLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_d03d69b1-970f-45c6-b817-b9a84ace626c_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_a3aeba6c-b7a7-4e7c-8a9e-64e5a472e3f3_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a1583afe-5276-43ec-b8b5-47fba9e1add3_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows Provided by (Used In) Financing Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_fda7d2e7-4d72-4c7d-99c5-c00aa2cac6d8_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of maturity of lease liabilities</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsAxis_e99019bf-17b2-47ed-9b4e-dbac0e4f9b26_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:label id="lab_srt_ConsolidationItemsAxis_label_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsAxis" xlink:to="lab_srt_ConsolidationItemsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_50d49f99-12a4-456a-b4d5-1fedb2d6275b_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_a88f819b-6448-4ff1-8765-ff4afa35d0a1_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total shareholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember_9a9d25d6-d53d-49cd-bf4f-540437e40d82_terseLabel_en-US" xlink:label="lab_evh_RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units ("RSUs"), performance-based RSUs and leveraged stock units ("LSUs")</link:label>
    <link:label id="lab_evh_RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember_label_en-US" xlink:label="lab_evh_RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs), Performance-based Restricted Stock Units (PBRSUs), And Leveraged Stock Units (LSUs) [Member]</link:label>
    <link:label id="lab_evh_RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember_documentation_en-US" xlink:label="lab_evh_RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock and Restricted Stock Units [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember" xlink:href="evh-20210630.xsd#evh_RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember" xlink:to="lab_evh_RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_7c52254a-877f-4da6-9775-eb8e06eb1378_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_75ebb232-73f4-49b2-b7d5-c117abd388aa_negatedLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlements</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_cbbbfa01-dcfe-44a7-b4c9-58a3f416c48d_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_ClassOfWarrantOrRightPeriodDuringWhichWarrantsOrRightsExercisableAfterMaturityOfCreditAgreement_a6aa4b32-4c2c-425b-80b8-4d3179817be0_terseLabel_en-US" xlink:label="lab_evh_ClassOfWarrantOrRightPeriodDuringWhichWarrantsOrRightsExercisableAfterMaturityOfCreditAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period during which warrants or rights exercisable, after maturity of credit agreement</link:label>
    <link:label id="lab_evh_ClassOfWarrantOrRightPeriodDuringWhichWarrantsOrRightsExercisableAfterMaturityOfCreditAgreement_label_en-US" xlink:label="lab_evh_ClassOfWarrantOrRightPeriodDuringWhichWarrantsOrRightsExercisableAfterMaturityOfCreditAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Period During Which Warrants Or Rights Exercisable, After Maturity Of Credit Agreement</link:label>
    <link:label id="lab_evh_ClassOfWarrantOrRightPeriodDuringWhichWarrantsOrRightsExercisableAfterMaturityOfCreditAgreement_documentation_en-US" xlink:label="lab_evh_ClassOfWarrantOrRightPeriodDuringWhichWarrantsOrRightsExercisableAfterMaturityOfCreditAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Period During Which Warrants Or Rights Exercisable, After Maturity Of Credit Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ClassOfWarrantOrRightPeriodDuringWhichWarrantsOrRightsExercisableAfterMaturityOfCreditAgreement" xlink:href="evh-20210630.xsd#evh_ClassOfWarrantOrRightPeriodDuringWhichWarrantsOrRightsExercisableAfterMaturityOfCreditAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_ClassOfWarrantOrRightPeriodDuringWhichWarrantsOrRightsExercisableAfterMaturityOfCreditAgreement" xlink:to="lab_evh_ClassOfWarrantOrRightPeriodDuringWhichWarrantsOrRightsExercisableAfterMaturityOfCreditAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_21ea3fc7-1077-406b-a0d2-aea1e1c02a0e_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments In and Advances to Equity Method Investees</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments and Joint Ventures Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:to="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_f8aeb412-6a41-49ad-ae57-d3b349991250_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of cash flow, supplemental disclosures</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_ChangeInContractWithCustomerLiabilityRollForward_f903101a-8c0a-4e5f-8917-9c5cd0d11575_terseLabel_en-US" xlink:label="lab_evh_ChangeInContractWithCustomerLiabilityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_evh_ChangeInContractWithCustomerLiabilityRollForward_label_en-US" xlink:label="lab_evh_ChangeInContractWithCustomerLiabilityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Contract With Customer, Liability [Roll Forward]</link:label>
    <link:label id="lab_evh_ChangeInContractWithCustomerLiabilityRollForward_documentation_en-US" xlink:label="lab_evh_ChangeInContractWithCustomerLiabilityRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Contract With Customer, Liability [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ChangeInContractWithCustomerLiabilityRollForward" xlink:href="evh-20210630.xsd#evh_ChangeInContractWithCustomerLiabilityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_ChangeInContractWithCustomerLiabilityRollForward" xlink:to="lab_evh_ChangeInContractWithCustomerLiabilityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice_8d321beb-9511-483d-afbd-0fb9be3c80e3_terseLabel_en-US" xlink:label="lab_evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase covenant, repurchase price due to change in sale price as percentage of conversion price</link:label>
    <link:label id="lab_evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice_label_en-US" xlink:label="lab_evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Repurchase Price Due To Change In Sale Price As Percentage Of Conversion Price</link:label>
    <link:label id="lab_evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice_documentation_en-US" xlink:label="lab_evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Repurchase Price Due To Change In Sale Price As Percentage Of Conversion Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice" xlink:href="evh-20210630.xsd#evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice" xlink:to="lab_evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_667ed9d1-9521-49ef-819f-1f4d91c750f6_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_ProfessionalServicesRestructuringMember_14cbcbfe-d5da-4504-8586-42e5c20311d2_terseLabel_en-US" xlink:label="lab_evh_ProfessionalServicesRestructuringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Professional services</link:label>
    <link:label id="lab_evh_ProfessionalServicesRestructuringMember_label_en-US" xlink:label="lab_evh_ProfessionalServicesRestructuringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Professional Services, Restructuring [Member]</link:label>
    <link:label id="lab_evh_ProfessionalServicesRestructuringMember_documentation_en-US" xlink:label="lab_evh_ProfessionalServicesRestructuringMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Professional Services, Restructuring</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ProfessionalServicesRestructuringMember" xlink:href="evh-20210630.xsd#evh_ProfessionalServicesRestructuringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_ProfessionalServicesRestructuringMember" xlink:to="lab_evh_ProfessionalServicesRestructuringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfWarrants_4917bd29-0223-4393-b4f8-1c1d5e013071_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to settle outstanding warrants</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfWarrants_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfWarrants" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_a2b9d8ff-44c8-4fb4-b5d9-4613ba9d7886_terseLabel_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt conversion, converted instrument, amount</link:label>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_label_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion, Converted Instrument, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfSeniorDebt_d0838989-3c50-401e-a3a4-81d3600a147f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfSeniorDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment and termination of Credit Agreement including settlement of warrants.</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfSeniorDebt_84070e36-787b-462b-a4fd-c449b522a548_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfSeniorDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of senior debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfSeniorDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfSeniorDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Senior Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSeniorDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfSeniorDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfSeniorDebt" xlink:to="lab_us-gaap_RepaymentsOfSeniorDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_e8683f4d-da06-4946-8fec-5128aeda94a0_terseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on repayment of debt, net</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_980f466c-98c9-4ceb-9824-8867c61e14ae_negatedLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on repayment of debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EurodollarMember_9a42c048-4846-487e-a962-aea1658aff38_terseLabel_en-US" xlink:label="lab_us-gaap_EurodollarMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eurodollar</link:label>
    <link:label id="lab_us-gaap_EurodollarMember_label_en-US" xlink:label="lab_us-gaap_EurodollarMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eurodollar [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EurodollarMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EurodollarMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EurodollarMember" xlink:to="lab_us-gaap_EurodollarMember" xlink:type="arc" order="1"/>
    <link:label id="lab_country_IN_d1c6812f-9b93-4a15-86f7-c7683ac9944c_terseLabel_en-US" xlink:label="lab_country_IN" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pune, India</link:label>
    <link:label id="lab_country_IN_label_en-US" xlink:label="lab_country_IN" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INDIA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_IN" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_IN"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_IN" xlink:to="lab_country_IN" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_b48ee011-f0ff-4660-87b4-ddea55bcdb2a_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue recognized from performed obligations</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Performance Obligation Satisfied in Previous Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:to="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_cdd2b8ba-b206-4db2-a485-016985c07a38_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities - noncurrent</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_7b5fe7fe-6e94-4514-b545-253caa97dc83_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_3330db74-1cc1-409a-bf24-d8c951372bed_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Face amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_cd23fd87-a91f-43b5-88f9-efb9717db18e_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_f0f92b96-8e90-4e12-8ec2-cd9ea04df879_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_30d2f2bf-d678-442e-95ed-56dc3459666f_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation and employee benefits</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Employee Related Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations and Disposal Groups [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesReceivableMember_24aa2b87-4073-40ab-8a16-2e92f7118cdb_terseLabel_en-US" xlink:label="lab_us-gaap_NotesReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Receivable</link:label>
    <link:label id="lab_us-gaap_NotesReceivableMember_label_en-US" xlink:label="lab_us-gaap_NotesReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesReceivableMember" xlink:to="lab_us-gaap_NotesReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_DisposalGroupIncludingDiscontinuedOperationLiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangementsCurrent_b023327e-f81e-4817-9a05-476914f562c1_terseLabel_en-US" xlink:label="lab_evh_DisposalGroupIncludingDiscontinuedOperationLiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangementsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve for claims and performance-based arrangements</link:label>
    <link:label id="lab_evh_DisposalGroupIncludingDiscontinuedOperationLiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangementsCurrent_label_en-US" xlink:label="lab_evh_DisposalGroupIncludingDiscontinuedOperationLiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangementsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Liability For Future Policy Benefits And Unpaid Claims And Claims Adjustment Expense And Performance-Based Arrangements, Current</link:label>
    <link:label id="lab_evh_DisposalGroupIncludingDiscontinuedOperationLiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangementsCurrent_documentation_en-US" xlink:label="lab_evh_DisposalGroupIncludingDiscontinuedOperationLiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangementsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Liability For Future Policy Benefits And Unpaid Claims And Claims Adjustment Expense And Performance-Based Arrangements, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DisposalGroupIncludingDiscontinuedOperationLiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangementsCurrent" xlink:href="evh-20210630.xsd#evh_DisposalGroupIncludingDiscontinuedOperationLiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangementsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_DisposalGroupIncludingDiscontinuedOperationLiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangementsCurrent" xlink:to="lab_evh_DisposalGroupIncludingDiscontinuedOperationLiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangementsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedContractCostAmortization_bebd6913-eab1-4804-814b-d832a93f46d6_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of contract cost assets</link:label>
    <link:label id="lab_us-gaap_CapitalizedContractCostAmortization_6c8ee65d-56ba-4efb-ba38-4c1b91487166_verboseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract cost amortization</link:label>
    <link:label id="lab_us-gaap_CapitalizedContractCostAmortization_label_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Contract Cost, Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedContractCostAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedContractCostAmortization" xlink:to="lab_us-gaap_CapitalizedContractCostAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_c843ad55-40ed-46e0-9f6b-ee08c603f846_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_34806247-c3b5-4aa3-91ce-b6feab0c0d0e_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings (accumulated deficit)</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_1b1da0ea-6d8b-4432-8e22-2b9b2c428564_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments</link:label>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_label_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingSegmentsMember" xlink:to="lab_us-gaap_OperatingSegmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_DisposalGroupIncludingDiscontinuedOperationClaimsExpense_51dd68d5-f194-4424-adc1-6fd0dc4c1807_terseLabel_en-US" xlink:label="lab_evh_DisposalGroupIncludingDiscontinuedOperationClaimsExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Claims expenses</link:label>
    <link:label id="lab_evh_DisposalGroupIncludingDiscontinuedOperationClaimsExpense_label_en-US" xlink:label="lab_evh_DisposalGroupIncludingDiscontinuedOperationClaimsExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Claims Expense</link:label>
    <link:label id="lab_evh_DisposalGroupIncludingDiscontinuedOperationClaimsExpense_documentation_en-US" xlink:label="lab_evh_DisposalGroupIncludingDiscontinuedOperationClaimsExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Claims Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DisposalGroupIncludingDiscontinuedOperationClaimsExpense" xlink:href="evh-20210630.xsd#evh_DisposalGroupIncludingDiscontinuedOperationClaimsExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_DisposalGroupIncludingDiscontinuedOperationClaimsExpense" xlink:to="lab_evh_DisposalGroupIncludingDiscontinuedOperationClaimsExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_2a992475-810b-4d91-9f56-83badc92ec21_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Termination Term (in years)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_288cea42-39bd-42bd-9149-29176b2eb429_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_918bcd42-2447-4baf-b18b-446dca10f86f_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_fb46a3e7-99f3-43cb-8dbc-b4fc4aa359e5_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock_fec613cd-cfe9-4505-823a-d1ccb68c4a07_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of revenue from segments to consolidated</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Revenue from Segments to Consolidated [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock" xlink:to="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_a367af42-f6bf-4d37-9807-353fb3d533e4_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_89270e42-cbd0-49ae-b5af-95430c049a48_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:to="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_SeniorCreditFacilitiesMember_cb2a642e-f5f0-4423-a51f-80a9a997d4c1_terseLabel_en-US" xlink:label="lab_evh_SeniorCreditFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Credit Facilities</link:label>
    <link:label id="lab_evh_SeniorCreditFacilitiesMember_label_en-US" xlink:label="lab_evh_SeniorCreditFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Credit Facilities [Member]</link:label>
    <link:label id="lab_evh_SeniorCreditFacilitiesMember_documentation_en-US" xlink:label="lab_evh_SeniorCreditFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Credit Facilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SeniorCreditFacilitiesMember" xlink:href="evh-20210630.xsd#evh_SeniorCreditFacilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_SeniorCreditFacilitiesMember" xlink:to="lab_evh_SeniorCreditFacilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_3589ee45-5aab-49c7-976e-d57133bb6956_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of restricted cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restrictions on Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_15edb103-f766-4bc6-a159-5475252911b5_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_a8e8b3e8-6c34-4182-b003-00527c5f129b_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_241b7311-1fa8-4b56-a56c-255e8fe14a12_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTable" xlink:to="lab_us-gaap_ConcentrationRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_BelowMarketLeasesMember_942685e4-62a6-4f42-8076-837b8710e4fd_terseLabel_en-US" xlink:label="lab_evh_BelowMarketLeasesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Below market lease, net</link:label>
    <link:label id="lab_evh_BelowMarketLeasesMember_label_en-US" xlink:label="lab_evh_BelowMarketLeasesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Below Market Leases [Member]</link:label>
    <link:label id="lab_evh_BelowMarketLeasesMember_documentation_en-US" xlink:label="lab_evh_BelowMarketLeasesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Below Market Leases [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_BelowMarketLeasesMember" xlink:href="evh-20210630.xsd#evh_BelowMarketLeasesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_BelowMarketLeasesMember" xlink:to="lab_evh_BelowMarketLeasesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_047c6e81-7622-4b36-9f75-14128ee0ef0f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in contingent consideration measured at fair value</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_5f3b8d60-144b-43bc-a7ab-affbe84d8ffa_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES</link:label>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:to="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_d09e5924-c975-405d-9460-afeb9be4fa5e_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recently Issued Accounting Standards</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectsOfReinsuranceTableTextBlock_87ca4d4e-24cc-4f07-aec3-4153341b20d5_terseLabel_en-US" xlink:label="lab_us-gaap_EffectsOfReinsuranceTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of premiums and claims assumed</link:label>
    <link:label id="lab_us-gaap_EffectsOfReinsuranceTableTextBlock_label_en-US" xlink:label="lab_us-gaap_EffectsOfReinsuranceTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effects of Reinsurance [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectsOfReinsuranceTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectsOfReinsuranceTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectsOfReinsuranceTableTextBlock" xlink:to="lab_us-gaap_EffectsOfReinsuranceTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_66559b60-33d3-4de2-9c6d-4bc48c85b29b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining amortization period (years)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Remaining Discount Amortization Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebt_1f4041ba-e174-4812-9217-35a54da4ad1a_totalLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying value</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebt_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebt" xlink:to="lab_us-gaap_ConvertibleDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_6e363b02-39c4-4016-aa4d-0f41e4b396ab_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from stock option exercises</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_c3b3f9b2-a20e-4eb0-a07c-7b05e8215e38_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles</link:label>
    <link:label id="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_2bf741d5-69fc-4c87-926e-42a1cf65dd02_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_0d1db23d-e313-429f-af76-1a14e5973aee_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_95249413-aeb4-4cb3-bf01-7730ee134a0f_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_61f5b44e-41a2-4552-812a-682f2d7a1e2a_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_07d4e8ba-8ea1-4161-8645-c91b8badf779_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative effect adjustment</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_07b84ec9-6fb8-471b-8c8f-b3e5cb7932a9_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision (benefit) for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_57ec870f-f2a2-464c-aa0b-c7f5676347bc_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Provision) benefit for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsDomain_272858b7-c798-49a0-a52b-11681f71f94f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Domain]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsDomain_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsDomain" xlink:to="lab_us-gaap_OtherCommitmentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_5f5407ce-9a59-4d57-9a83-9597a4d0305a_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_06e81bee-dca4-460c-b44e-820eb59828d2_netLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InsuranceAbstract_c19c22a4-c57c-4a70-b1f0-2cbec05ddf25_terseLabel_en-US" xlink:label="lab_us-gaap_InsuranceAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance [Abstract]</link:label>
    <link:label id="lab_us-gaap_InsuranceAbstract_label_en-US" xlink:label="lab_us-gaap_InsuranceAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InsuranceAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InsuranceAbstract" xlink:to="lab_us-gaap_InsuranceAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_815b4cb3-44d3-4ea0-911a-d965456f943f_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_9aac4b3e-79df-4360-95cd-e26e2cd4ae13_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative expenses</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_CashHeldInInternationalBanksPercentage_b4280b6b-597d-4af0-bbe4-02d34f917c3a_terseLabel_en-US" xlink:label="lab_evh_CashHeldInInternationalBanksPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of cash held in international banks (less than)</link:label>
    <link:label id="lab_evh_CashHeldInInternationalBanksPercentage_label_en-US" xlink:label="lab_evh_CashHeldInInternationalBanksPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Held In International Banks, Percentage</link:label>
    <link:label id="lab_evh_CashHeldInInternationalBanksPercentage_documentation_en-US" xlink:label="lab_evh_CashHeldInInternationalBanksPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Held In International Banks, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CashHeldInInternationalBanksPercentage" xlink:href="evh-20210630.xsd#evh_CashHeldInInternationalBanksPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_CashHeldInInternationalBanksPercentage" xlink:to="lab_evh_CashHeldInInternationalBanksPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_WindroseHealthInvestorsIIILPMember_f85c2a63-96ee-4f6e-a1e7-68022a3f1382_terseLabel_en-US" xlink:label="lab_evh_WindroseHealthInvestorsIIILPMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Windrose Health Investors III, L.P.</link:label>
    <link:label id="lab_evh_WindroseHealthInvestorsIIILPMember_label_en-US" xlink:label="lab_evh_WindroseHealthInvestorsIIILPMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Windrose Health Investors III, L.P. [Member]</link:label>
    <link:label id="lab_evh_WindroseHealthInvestorsIIILPMember_documentation_en-US" xlink:label="lab_evh_WindroseHealthInvestorsIIILPMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Windrose Health Investors III, L.P.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_WindroseHealthInvestorsIIILPMember" xlink:href="evh-20210630.xsd#evh_WindroseHealthInvestorsIIILPMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_WindroseHealthInvestorsIIILPMember" xlink:to="lab_evh_WindroseHealthInvestorsIIILPMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_29531518-0c15-473d-b8e0-5ae05906439c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_f571ae90-0612-420a-b8da-62435232fe98_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_6d5e3328-216e-4bc2-90af-b3025ce6b672_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost_dd2946b2-8225-4624-aeef-b3401e7d0e10_negatedLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss on extinguishment of debt, including fees paid to lenders</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt, before Write off of Debt Issuance Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ae9d59f5-8de4-41ba-865b-30506260b4d6_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future Minimum Lease Commitments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0413e4ee-96db-4af0-b4bc-8d2bdd1c2d42_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableMember_81581cbc-1940-4494-b654-a60e30725595_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember" xlink:to="lab_us-gaap_AccountsReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_965ee742-7ef4-430d-a4a9-965e4beb153f_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_18b6ae9c-7343-46e1-b14e-352cd8856c18_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear_5a06d03d-6198-4d71-b806-b5088d3b90d8_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Obligation, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_849dd882-deb8-4fe5-bef8-decaf6d3b7f8_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_105c39b9-035a-496c-a2c2-24c1c3fed039_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments and Joint Ventures [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments and Joint Ventures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:to="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_PassportAssetAcquisitionMember_c9130f88-1e86-4b00-80f7-ee23d80fa967_terseLabel_en-US" xlink:label="lab_evh_PassportAssetAcquisitionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Passport Asset Acquisition</link:label>
    <link:label id="lab_evh_PassportAssetAcquisitionMember_label_en-US" xlink:label="lab_evh_PassportAssetAcquisitionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Passport Asset Acquisition [Member]</link:label>
    <link:label id="lab_evh_PassportAssetAcquisitionMember_documentation_en-US" xlink:label="lab_evh_PassportAssetAcquisitionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Passport Asset Acquisition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PassportAssetAcquisitionMember" xlink:href="evh-20210630.xsd#evh_PassportAssetAcquisitionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_PassportAssetAcquisitionMember" xlink:to="lab_evh_PassportAssetAcquisitionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_09cf3d93-5213-44c8-8a82-81c2ec5b9943_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_a5eb3975-49db-4a1d-b8ea-d51c37351e37_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of related parties</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_ae1bb6ba-7866-46cd-aa7f-488e438bc6c7_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interest, increase from business combination</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Increase from Business Combination</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination" xlink:to="lab_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_41566a03-814d-4a55-bfe7-6a4bec2e16ae_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_3178d214-cb11-4194-9f43-0aa9f758ba3f_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term debt, net of discount</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent" xlink:to="lab_us-gaap_LongTermDebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_eb329d51-b48e-4efb-a6da-2488e4db1148_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_44e62362-7e91-4b8d-81ab-46e4ddd92f12_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_b3858a33-4ae8-4f03-9f45-34234608b934_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_b8a33dc2-b267-497b-b2ae-247d0218b52e_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_9a300a3a-7309-4e28-8b23-c282ebbebacf_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent_4e9dd7d9-44fa-42d4-9ae2-2620634af318_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_875ab690-37b8-431d-be68-ceaa7357dd1a_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_6ac5c84c-8b36-46b8-9ddf-893ad2bf0a5f_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_label_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueNetMember" xlink:to="lab_us-gaap_SalesRevenueNetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_FloridaBlueMedicareIncMember_5ac4a7db-1983-4d0b-b0fc-425606700a6b_terseLabel_en-US" xlink:label="lab_evh_FloridaBlueMedicareIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Florida Blue Medicare, Inc.</link:label>
    <link:label id="lab_evh_FloridaBlueMedicareIncMember_label_en-US" xlink:label="lab_evh_FloridaBlueMedicareIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Florida Blue Medicare, Inc. [Member]</link:label>
    <link:label id="lab_evh_FloridaBlueMedicareIncMember_documentation_en-US" xlink:label="lab_evh_FloridaBlueMedicareIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Florida Blue Medicare, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_FloridaBlueMedicareIncMember" xlink:href="evh-20210630.xsd#evh_FloridaBlueMedicareIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_FloridaBlueMedicareIncMember" xlink:to="lab_evh_FloridaBlueMedicareIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_1e9f533d-fb79-4bb1-b248-52b61946af35_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_759b6dfc-fbb6-4ac5-bc8a-fe0de694ef54_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">After the Fourth Anniversary of the Closing of the Senior Credit Facilities but Prior to the Fifth Anniversary</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period Three [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_7a788836-37cd-4b54-b154-ed9250dfd1be_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractBasedIntangibleAssetsMember_73574315-f1cb-404d-a355-71f0c8539c40_terseLabel_en-US" xlink:label="lab_us-gaap_ContractBasedIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provider network contracts</link:label>
    <link:label id="lab_us-gaap_ContractBasedIntangibleAssetsMember_label_en-US" xlink:label="lab_us-gaap_ContractBasedIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract-Based Intangible Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractBasedIntangibleAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractBasedIntangibleAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractBasedIntangibleAssetsMember" xlink:to="lab_us-gaap_ContractBasedIntangibleAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_9b1755ec-cb66-4152-943c-54cf2a30283a_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations, Disposed of by Sale</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations, Disposed of by Sale [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationsDisposedOfBySaleMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember" xlink:to="lab_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_019f1fed-73d8-430c-aa7f-5c235f42aadf_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_17531bec-25cf-4f20-86fc-3b97c7a0828b_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_5855e634-d73e-4c6f-a0f2-ffcb3c195780_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:to="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_3cf08bd0-b60b-44b9-be2d-413e310b48a3_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_a3eeb550-53c7-4484-988a-2ce772e3cc8c_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract" xlink:to="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_84531fc1-55a3-41bd-98ff-9601f8197b50_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_1a916d40-4c4a-4dc1-9008-8cfd0218719a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_TransformationServicesMember_9ae70ffe-76bf-4e2b-9a81-ab5584fde5fd_verboseLabel_en-US" xlink:label="lab_evh_TransformationServicesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transformation services</link:label>
    <link:label id="lab_evh_TransformationServicesMember_label_en-US" xlink:label="lab_evh_TransformationServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transformation Services [Member]</link:label>
    <link:label id="lab_evh_TransformationServicesMember_documentation_en-US" xlink:label="lab_evh_TransformationServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transformation Services [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TransformationServicesMember" xlink:href="evh-20210630.xsd#evh_TransformationServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_TransformationServicesMember" xlink:to="lab_evh_TransformationServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_4db5ed6e-b53d-410b-93d4-99129cda78d7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_2ecfb9b8-fa3c-4c00-99a1-7e6e156c25d0_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_dfc1c979-7e3c-4b22-b967-6c7ad0d24981_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class A common stock issued for payment of earn-outs (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_ConvertibleSeniorNotesdue2021Member_497878cc-9ddd-4349-b40d-67e8656c92ab_terseLabel_en-US" xlink:label="lab_evh_ConvertibleSeniorNotesdue2021Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Notes</link:label>
    <link:label id="lab_evh_ConvertibleSeniorNotesdue2021Member_label_en-US" xlink:label="lab_evh_ConvertibleSeniorNotesdue2021Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Senior Notes due 2021 [Member]</link:label>
    <link:label id="lab_evh_ConvertibleSeniorNotesdue2021Member_documentation_en-US" xlink:label="lab_evh_ConvertibleSeniorNotesdue2021Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Senior Notes due 2021 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ConvertibleSeniorNotesdue2021Member" xlink:href="evh-20210630.xsd#evh_ConvertibleSeniorNotesdue2021Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_ConvertibleSeniorNotesdue2021Member" xlink:to="lab_evh_ConvertibleSeniorNotesdue2021Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_9dfa19d0-c3fe-4cc4-b2ef-0a90f719cd2f_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, remaining performance obligation</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_CashFDICInsuredAmountPercentage_91c02655-3e52-447b-8bfe-bbe7dc81d5ad_terseLabel_en-US" xlink:label="lab_evh_CashFDICInsuredAmountPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of cash and cash equivalents held with FDIC participating bank</link:label>
    <link:label id="lab_evh_CashFDICInsuredAmountPercentage_label_en-US" xlink:label="lab_evh_CashFDICInsuredAmountPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, FDIC Insured Amount, Percentage</link:label>
    <link:label id="lab_evh_CashFDICInsuredAmountPercentage_documentation_en-US" xlink:label="lab_evh_CashFDICInsuredAmountPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, FDIC Insured Amount, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CashFDICInsuredAmountPercentage" xlink:href="evh-20210630.xsd#evh_CashFDICInsuredAmountPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_CashFDICInsuredAmountPercentage" xlink:to="lab_evh_CashFDICInsuredAmountPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_TrueHealthMember_ea429b9b-1b83-4122-9f77-c60088c9db42_terseLabel_en-US" xlink:label="lab_evh_TrueHealthMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">True Health</link:label>
    <link:label id="lab_evh_TrueHealthMember_label_en-US" xlink:label="lab_evh_TrueHealthMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">True Health [Member]</link:label>
    <link:label id="lab_evh_TrueHealthMember_documentation_en-US" xlink:label="lab_evh_TrueHealthMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">True Health</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TrueHealthMember" xlink:href="evh-20210630.xsd#evh_TrueHealthMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_TrueHealthMember" xlink:to="lab_evh_TrueHealthMember" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_DisposalGroupIncludingDiscontinuedOperationRestrictedCashAndRestrictedInvestmentsCurrent_e6eb7b8b-79b3-4001-bdbb-9a9b211e0b32_terseLabel_en-US" xlink:label="lab_evh_DisposalGroupIncludingDiscontinuedOperationRestrictedCashAndRestrictedInvestmentsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash and restricted investments</link:label>
    <link:label id="lab_evh_DisposalGroupIncludingDiscontinuedOperationRestrictedCashAndRestrictedInvestmentsCurrent_label_en-US" xlink:label="lab_evh_DisposalGroupIncludingDiscontinuedOperationRestrictedCashAndRestrictedInvestmentsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Restricted Cash And Restricted Investments, Current</link:label>
    <link:label id="lab_evh_DisposalGroupIncludingDiscontinuedOperationRestrictedCashAndRestrictedInvestmentsCurrent_documentation_en-US" xlink:label="lab_evh_DisposalGroupIncludingDiscontinuedOperationRestrictedCashAndRestrictedInvestmentsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Restricted Cash And Restricted Investments, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DisposalGroupIncludingDiscontinuedOperationRestrictedCashAndRestrictedInvestmentsCurrent" xlink:href="evh-20210630.xsd#evh_DisposalGroupIncludingDiscontinuedOperationRestrictedCashAndRestrictedInvestmentsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_DisposalGroupIncludingDiscontinuedOperationRestrictedCashAndRestrictedInvestmentsCurrent" xlink:to="lab_evh_DisposalGroupIncludingDiscontinuedOperationRestrictedCashAndRestrictedInvestmentsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAbstract_e45520a3-e82b-456a-a070-67fa96c78f1b_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAbstract" xlink:to="lab_us-gaap_LiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset_c97f277a-8d12-496c-ae49-00d085a267f3_negatedTerseLabel_en-US" xlink:label="lab_evh_IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net and contract assets</link:label>
    <link:label id="lab_evh_IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset_label_en-US" xlink:label="lab_evh_IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Accounts Receivable And Contract With Customer, Asset</link:label>
    <link:label id="lab_evh_IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset_documentation_en-US" xlink:label="lab_evh_IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Accounts Receivable And Contract With Customer, Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset" xlink:href="evh-20210630.xsd#evh_IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset" xlink:to="lab_evh_IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_7749071e-e4dd-477e-b2ea-d24d29af44aa_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units vested, net of shares withheld for taxes</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_e87ee68f-a8ab-4486-91e9-07df6a7c561b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Cost by Plan [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_8ac4956a-cc9a-4211-bcdc-89ec79623a02_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_e10e6ff7-ab17-44a4-8dcc-1cc72c8566a9_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_TransactionCosts_1436e456-b4f8-4f04-b61f-433289496e92_negatedLabel_en-US" xlink:label="lab_evh_TransactionCosts" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition costs</link:label>
    <link:label id="lab_evh_TransactionCosts_label_en-US" xlink:label="lab_evh_TransactionCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction Costs</link:label>
    <link:label id="lab_evh_TransactionCosts_documentation_en-US" xlink:label="lab_evh_TransactionCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TransactionCosts" xlink:href="evh-20210630.xsd#evh_TransactionCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_TransactionCosts" xlink:to="lab_evh_TransactionCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_70a9596f-84cf-4e8b-b114-6d03d8b48dc8_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet_82a22aba-0cc3-446b-bfa9-d23f510b01c4_negatedTerseLabel_en-US" xlink:label="lab_evh_PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal of non-strategic assets and divestiture of discontinued operations, net</link:label>
    <link:label id="lab_evh_PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet_label_en-US" xlink:label="lab_evh_PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For (Proceeds From) Disposal Of Non-Strategic Assets And Divestiture Of Discontinued Operations, Net</link:label>
    <link:label id="lab_evh_PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet_documentation_en-US" xlink:label="lab_evh_PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For (Proceeds From) Disposal Of Non-Strategic Assets And Divestiture Of Discontinued Operations, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet" xlink:href="evh-20210630.xsd#evh_PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet" xlink:to="lab_evh_PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_LeveragedStockUnitsLSUsMember_a8ca0430-6664-41fc-b9a2-c0750c875286_verboseLabel_en-US" xlink:label="lab_evh_LeveragedStockUnitsLSUsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LSUs</link:label>
    <link:label id="lab_evh_LeveragedStockUnitsLSUsMember_label_en-US" xlink:label="lab_evh_LeveragedStockUnitsLSUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leveraged Stock Units (LSUs) [Member]</link:label>
    <link:label id="lab_evh_LeveragedStockUnitsLSUsMember_documentation_en-US" xlink:label="lab_evh_LeveragedStockUnitsLSUsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leveraged Stock Units (LSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_LeveragedStockUnitsLSUsMember" xlink:href="evh-20210630.xsd#evh_LeveragedStockUnitsLSUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_LeveragedStockUnitsLSUsMember" xlink:to="lab_evh_LeveragedStockUnitsLSUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_42c70c4a-81f2-4bda-beb3-4ddc4703f263_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1f1f0bd8-13f9-49ef-a536-97cad5891336_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from continuing operations before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_b4de0f0a-383f-4b8b-b8aa-f9a18a71b6e8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ca31ce4e-9869-4a43-b24e-8fcab5adc759_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_f23edc3d-f874-4f3b-b24d-5577643c5099_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_34793c36-41bf-4141-bb89-c6b08271af84_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities of discontinued operations</link:label>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_28444711-db54-4df7-8b90-71e34148214a_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities of discontinued operations</link:label>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:to="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_7f8195a4-2376-4e12-8028-f76f913bda1c_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate</link:label>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_label_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate, Non-Segment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateNonSegmentMember" xlink:to="lab_us-gaap_CorporateNonSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_5ef54321-02f6-400e-9df6-9053f069a1d5_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_8b1bb82e-549f-44a3-bc0c-99d5e8cfec45_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_label_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfRestructuringDomain" xlink:to="lab_us-gaap_TypeOfRestructuringDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_9ba48e2b-ca6e-4fb6-8cd5-5edaa2f37341_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Useful life</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsNotesAndLoansReceivableNetCurrent_7a1dfe6a-e3b1-4367-a41e-70ab77aa37f8_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsNotesAndLoansReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term receivables</link:label>
    <link:label id="lab_us-gaap_AccountsNotesAndLoansReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsNotesAndLoansReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts and Financing Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsNotesAndLoansReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsNotesAndLoansReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_2263ebc0-2d3e-48f3-a1e6-6c2924b364b7_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenue</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_9d19c193-432b-42fa-b2b7-9aeef766af12_verboseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_2ba3f3a0-dde6-4c18-a817-b2ac76d6d848_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_41406087-1b76-41be-a194-363c08e75a57_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:to="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_PerformanceBasedRestrictedStockUnitsPBRSUsMember_d9c194a2-6621-48a0-9e22-9c76799c465d_terseLabel_en-US" xlink:label="lab_evh_PerformanceBasedRestrictedStockUnitsPBRSUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PSUs</link:label>
    <link:label id="lab_evh_PerformanceBasedRestrictedStockUnitsPBRSUsMember_label_en-US" xlink:label="lab_evh_PerformanceBasedRestrictedStockUnitsPBRSUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance-Based Restricted Stock Units (PBRSUs) [Member]</link:label>
    <link:label id="lab_evh_PerformanceBasedRestrictedStockUnitsPBRSUsMember_documentation_en-US" xlink:label="lab_evh_PerformanceBasedRestrictedStockUnitsPBRSUsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance-Based Restricted Stock Units (PBRSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PerformanceBasedRestrictedStockUnitsPBRSUsMember" xlink:href="evh-20210630.xsd#evh_PerformanceBasedRestrictedStockUnitsPBRSUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_PerformanceBasedRestrictedStockUnitsPBRSUsMember" xlink:to="lab_evh_PerformanceBasedRestrictedStockUnitsPBRSUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseInterestExpense_91efeede-c930-40f7-b268-7adffe562119_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseInterestExpense_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseInterestExpense" xlink:to="lab_us-gaap_FinanceLeaseInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_4a82f43f-36d5-4488-8bc1-c0b9ddf58914_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Estimates and Assumptions</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_0fabbd5f-8671-4a39-81b5-ff28bd1f316f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computation of basic and diluted earnings per share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_6544534d-0eb0-4be2-8c47-c2f515f06319_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c49466a3-6828-455c-8d2f-50d1f8e02bbd_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_594527ed-ad64-493d-be65-6ce2ac7e5d76_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNetAfterGrossUp_41286e86-b266-49ca-80d4-dc06118370ca_terseLabel_en-US" xlink:label="lab_evh_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNetAfterGrossUp" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net, after gross-up</link:label>
    <link:label id="lab_evh_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNetAfterGrossUp_label_en-US" xlink:label="lab_evh_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNetAfterGrossUp" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Accounts, Notes And Loans Receivable, Net, After Gross-Up</link:label>
    <link:label id="lab_evh_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNetAfterGrossUp_documentation_en-US" xlink:label="lab_evh_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNetAfterGrossUp" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Accounts, Notes And Loans Receivable, Net, After Gross-Up</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNetAfterGrossUp" xlink:href="evh-20210630.xsd#evh_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNetAfterGrossUp"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNetAfterGrossUp" xlink:to="lab_evh_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNetAfterGrossUp" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_CreditAgreementMember_1603e1d5-f6ba-4d75-a05f-add6695ce542_terseLabel_en-US" xlink:label="lab_evh_CreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Agreement</link:label>
    <link:label id="lab_evh_CreditAgreementMember_label_en-US" xlink:label="lab_evh_CreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Agreement [Member]</link:label>
    <link:label id="lab_evh_CreditAgreementMember_documentation_en-US" xlink:label="lab_evh_CreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CreditAgreementMember" xlink:href="evh-20210630.xsd#evh_CreditAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_CreditAgreementMember" xlink:to="lab_evh_CreditAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_d59c0e5b-c799-4aa8-bd54-299fa56c97a3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill disposal</link:label>
    <link:label id="lab_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_label_en-US" xlink:label="lab_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Written off Related to Sale of Business Unit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" xlink:to="lab_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum_aa893b32-61a7-4c96-90ca-ed3a0513f286_terseLabel_en-US" xlink:label="lab_evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase covenant, trading days, minimum</link:label>
    <link:label id="lab_evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum_label_en-US" xlink:label="lab_evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Repurchase Covenant, Trading Days, Minimum</link:label>
    <link:label id="lab_evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum_documentation_en-US" xlink:label="lab_evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Repurchase Covenant, Trading Days, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum" xlink:href="evh-20210630.xsd#evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum" xlink:to="lab_evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_dd4b7831-b8c7-4160-9543-147bbbd22b29_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Prepaid and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_2a1cdd83-523a-4d2c-b597-8bd498efef65_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_56742d5d-4b4e-4b4d-98b3-33e981ac5bc4_terseLabel_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_label_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EquityMethodInvesteeNameDomain" xlink:to="lab_srt_EquityMethodInvesteeNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits_2637402b-7c53-47da-9149-27c906a41bf2_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax (benefit) provision</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Taxes and Tax Credits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:to="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToMinorityShareholders_97a01155-74e3-4afd-bfba-d026d714ee18_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToMinorityShareholders" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distributions to Sponsors</link:label>
    <link:label id="lab_us-gaap_PaymentsToMinorityShareholders_230ba0c6-cc12-4b68-bb76-3a81bb9655cd_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToMinorityShareholders" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to redeem Sponsors' equity</link:label>
    <link:label id="lab_us-gaap_PaymentsToMinorityShareholders_label_en-US" xlink:label="lab_us-gaap_PaymentsToMinorityShareholders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Noncontrolling Interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToMinorityShareholders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToMinorityShareholders" xlink:to="lab_us-gaap_PaymentsToMinorityShareholders" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_94d0cea5-4a31-4a9f-a487-1e547dc8f069_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndInvestmentsNoncurrent_3fd0c65d-0807-44e3-ba0a-a0087e68a581_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndInvestmentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash and restricted investments</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndInvestmentsNoncurrent_a021281e-d024-44da-9105-c391f10030f4_totalLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndInvestmentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total non-current restricted cash and restricted investments</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndInvestmentsNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndInvestmentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Investments, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndInvestmentsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndInvestmentsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndInvestmentsNoncurrent" xlink:to="lab_us-gaap_RestrictedCashAndInvestmentsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_6f728cb3-df24-4988-a06c-58d180bc81b7_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1_a444ca77-2c62-40ca-9291-43eb267dfabb_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Amount Expected to be Incurred in the Repositioning Plan</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Expected Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:to="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_7aec8000-a084-49ee-b84d-42e9b48ece36_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_ac8c1216-40c1-4f5b-828c-bf864f41cf3e_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to common shareholders of Evolent Health, Inc. - Diluted</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_0b8123ec-044e-478b-8c22-d5da7b4e9ac1_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to common shareholders of Evolent Health, Inc.</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_f719f5f8-2e12-4b29-91ef-0f637f172a2e_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to common shareholders of Evolent Health, Inc. - Diluted</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_a533a3b0-db38-4ebe-9f17-1c2250596833_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to common shareholders of Evolent Health, Inc. - Basic</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_08dc4bb8-428a-451f-be38-13c3ca08b969_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to common shareholders of Evolent Health, Inc.</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_d4eb7773-f342-47c1-b7f2-d12aa3ab0961_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to common shareholders of Evolent Health, Inc. - Basic</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_AssetAcquisitionCashAndEquivalents_0b26d6d5-ae3e-49de-bd3f-0b2e333d2ec2_terseLabel_en-US" xlink:label="lab_evh_AssetAcquisitionCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and equivalents</link:label>
    <link:label id="lab_evh_AssetAcquisitionCashAndEquivalents_label_en-US" xlink:label="lab_evh_AssetAcquisitionCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Cash And Equivalents</link:label>
    <link:label id="lab_evh_AssetAcquisitionCashAndEquivalents_documentation_en-US" xlink:label="lab_evh_AssetAcquisitionCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Cash And Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_AssetAcquisitionCashAndEquivalents" xlink:href="evh-20210630.xsd#evh_AssetAcquisitionCashAndEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_AssetAcquisitionCashAndEquivalents" xlink:to="lab_evh_AssetAcquisitionCashAndEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_b8f85633-ba6b-479e-80cb-1258e5b69186_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Controlling Interests</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_712aa2e3-8cb4-4e58-8427-c1a9e5cf63e0_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense_8e4ff357-8e57-451b-b1d7-4adc4de1c157_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Activity in claims reserves</link:label>
    <link:label id="lab_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense_label_en-US" xlink:label="lab_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Liability for Unpaid Claims and Claims Adjustment Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:to="lab_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_EvolentHealthLLCMember_4510f644-51d3-4e21-85a9-09852a0411a7_terseLabel_en-US" xlink:label="lab_evh_EvolentHealthLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Evolent Health LLC</link:label>
    <link:label id="lab_evh_EvolentHealthLLCMember_label_en-US" xlink:label="lab_evh_EvolentHealthLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Evolent Health LLC [Member]</link:label>
    <link:label id="lab_evh_EvolentHealthLLCMember_documentation_en-US" xlink:label="lab_evh_EvolentHealthLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Evolent Health LLC [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EvolentHealthLLCMember" xlink:href="evh-20210630.xsd#evh_EvolentHealthLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_EvolentHealthLLCMember" xlink:to="lab_evh_EvolentHealthLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_ffb5fcb1-ec5f-4235-9b7a-45346107f172_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization expenses</link:label>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_dbdf264c-12d0-4722-bc04-37a752e13971_negatedLabel_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization expenses</link:label>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAndAmortization" xlink:to="lab_us-gaap_DepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_093bf2ce-3710-4919-83e4-283551d97196_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax_01dfee45-ab7c-4c11-9513-f41d4d3cf32d_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on disposal of discontinued operations</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" xlink:to="lab_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_DisposalGroupIncludingDiscontinuedOperationAccruedCompensationAndEmployeeBenefitsCurrent_0c006e3b-cee2-4188-851b-4ffdc4932602_terseLabel_en-US" xlink:label="lab_evh_DisposalGroupIncludingDiscontinuedOperationAccruedCompensationAndEmployeeBenefitsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation and employee benefits</link:label>
    <link:label id="lab_evh_DisposalGroupIncludingDiscontinuedOperationAccruedCompensationAndEmployeeBenefitsCurrent_label_en-US" xlink:label="lab_evh_DisposalGroupIncludingDiscontinuedOperationAccruedCompensationAndEmployeeBenefitsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Accrued Compensation And Employee Benefits, Current</link:label>
    <link:label id="lab_evh_DisposalGroupIncludingDiscontinuedOperationAccruedCompensationAndEmployeeBenefitsCurrent_documentation_en-US" xlink:label="lab_evh_DisposalGroupIncludingDiscontinuedOperationAccruedCompensationAndEmployeeBenefitsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Accrued Compensation And Employee Benefits, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DisposalGroupIncludingDiscontinuedOperationAccruedCompensationAndEmployeeBenefitsCurrent" xlink:href="evh-20210630.xsd#evh_DisposalGroupIncludingDiscontinuedOperationAccruedCompensationAndEmployeeBenefitsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_DisposalGroupIncludingDiscontinuedOperationAccruedCompensationAndEmployeeBenefitsCurrent" xlink:to="lab_evh_DisposalGroupIncludingDiscontinuedOperationAccruedCompensationAndEmployeeBenefitsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedInvestments_569e9ac5-9f15-4584-a184-61886b437bb8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RestrictedInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted investments included in restricted cash and restricted investments</link:label>
    <link:label id="lab_us-gaap_RestrictedInvestments_label_en-US" xlink:label="lab_us-gaap_RestrictedInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedInvestments" xlink:to="lab_us-gaap_RestrictedInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_2d95e564-41f2-4c01-9e24-53a732764d99_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to non-controlling interests</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_cce2c69c-88a8-41d7-9f64-7aa06da757f6_verboseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other noncurrent assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_b71c4a87-0c1d-45be-925f-20ee57c7d66d_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration, liability</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestDisclosureTextBlock_9d697b88-f1c6-459e-b827-e0fc93c8310a_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-controlling Interests</link:label>
    <link:label id="lab_us-gaap_MinorityInterestDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_MinorityInterestDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestDisclosureTextBlock" xlink:to="lab_us-gaap_MinorityInterestDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancingReceivablePercentPastDue1_44c3e3f1-d82a-4f93-87da-c1d5ef0ed45c_terseLabel_en-US" xlink:label="lab_us-gaap_FinancingReceivablePercentPastDue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of receivables, past due</link:label>
    <link:label id="lab_us-gaap_FinancingReceivablePercentPastDue1_label_en-US" xlink:label="lab_us-gaap_FinancingReceivablePercentPastDue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, Percent Past Due</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivablePercentPastDue1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancingReceivablePercentPastDue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancingReceivablePercentPastDue1" xlink:to="lab_us-gaap_FinancingReceivablePercentPastDue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_00be84d3-c367-414c-b4dd-e825df1bb170_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_IncomeLossfromEquityMethodInvestmentsServicesAgreement_1816420c-06ad-4996-a53b-f90f0288583f_terseLabel_en-US" xlink:label="lab_evh_IncomeLossfromEquityMethodInvestmentsServicesAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from long-term services agreement</link:label>
    <link:label id="lab_evh_IncomeLossfromEquityMethodInvestmentsServicesAgreement_label_en-US" xlink:label="lab_evh_IncomeLossfromEquityMethodInvestmentsServicesAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Equity Method Investments, Services Agreement</link:label>
    <link:label id="lab_evh_IncomeLossfromEquityMethodInvestmentsServicesAgreement_documentation_en-US" xlink:label="lab_evh_IncomeLossfromEquityMethodInvestmentsServicesAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Equity Method Investments, Services Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_IncomeLossfromEquityMethodInvestmentsServicesAgreement" xlink:href="evh-20210630.xsd#evh_IncomeLossfromEquityMethodInvestmentsServicesAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_IncomeLossfromEquityMethodInvestmentsServicesAgreement" xlink:to="lab_evh_IncomeLossfromEquityMethodInvestmentsServicesAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_BonusesAndCommissionsMember_82be3c8b-d2c3-4982-abd6-883e17339744_terseLabel_en-US" xlink:label="lab_evh_BonusesAndCommissionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bonuses and Commissions</link:label>
    <link:label id="lab_evh_BonusesAndCommissionsMember_label_en-US" xlink:label="lab_evh_BonusesAndCommissionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bonuses And Commissions [Member]</link:label>
    <link:label id="lab_evh_BonusesAndCommissionsMember_documentation_en-US" xlink:label="lab_evh_BonusesAndCommissionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bonuses And Commissions [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_BonusesAndCommissionsMember" xlink:href="evh-20210630.xsd#evh_BonusesAndCommissionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_BonusesAndCommissionsMember" xlink:to="lab_evh_BonusesAndCommissionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_AssetAcquisitionOtherAssets_c0bfb4ae-b08c-446b-8967-df9ba8881725_terseLabel_en-US" xlink:label="lab_evh_AssetAcquisitionOtherAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_evh_AssetAcquisitionOtherAssets_label_en-US" xlink:label="lab_evh_AssetAcquisitionOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Other Assets</link:label>
    <link:label id="lab_evh_AssetAcquisitionOtherAssets_documentation_en-US" xlink:label="lab_evh_AssetAcquisitionOtherAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_AssetAcquisitionOtherAssets" xlink:href="evh-20210630.xsd#evh_AssetAcquisitionOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_AssetAcquisitionOtherAssets" xlink:to="lab_evh_AssetAcquisitionOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_9e4463ad-563a-40c7-8860-3190f58d18fc_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, remaining performance obligation, expected timing of satisfaction, period</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionDomain_92eed515-3db9-44d3-a7e2-33c442ca25fc_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect Period Of Adoption [Domain]</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionDomain_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_8cb5cafa-3bfb-448e-acd7-e1d00e400a5a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_7c524ce9-4fd3-4e40-a7a1-9afc617ee4a2_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash and restricted cash provided by (used in) operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems_3245250d-4d98-458f-ae99-1853e8b16e9f_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts, Notes, Loans and Financing Receivable [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems_label_en-US" xlink:label="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts, Notes, Loans and Financing Receivable [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_GainLossOnDispositionOfAssetsOperatingActivities_cbe5421a-8796-486f-b635-d190eeb1ff64_negatedLabel_en-US" xlink:label="lab_evh_GainLossOnDispositionOfAssetsOperatingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Gain) loss on disposal of assets</link:label>
    <link:label id="lab_evh_GainLossOnDispositionOfAssetsOperatingActivities_label_en-US" xlink:label="lab_evh_GainLossOnDispositionOfAssetsOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) On Disposition Of Assets, Operating Activities</link:label>
    <link:label id="lab_evh_GainLossOnDispositionOfAssetsOperatingActivities_documentation_en-US" xlink:label="lab_evh_GainLossOnDispositionOfAssetsOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) On Disposition Of Assets, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_GainLossOnDispositionOfAssetsOperatingActivities" xlink:href="evh-20210630.xsd#evh_GainLossOnDispositionOfAssetsOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_GainLossOnDispositionOfAssetsOperatingActivities" xlink:to="lab_evh_GainLossOnDispositionOfAssetsOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_a12591bb-8005-4533-9213-5227e44b5cbe_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and equipment</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_06e89e80-a426-4d1e-b69b-6d6629ee2f22_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of components of lease expense, weighted-average discount rate and weighted-remaining lease terms</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_f1ec9b5f-8e3e-4572-9f8b-f4a286c6f0af_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_738dacc8-e072-465d-982e-037d58f6718c_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_PremiumsWrittenAndPolicyholderBenefitsAndClaimsIncurredNet_8f402ffe-76a1-4cbf-a390-f044d598e949_terseLabel_en-US" xlink:label="lab_evh_PremiumsWrittenAndPolicyholderBenefitsAndClaimsIncurredNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in reserves for claims and performance-based arrangements attributable to the Reinsurance Agreement</link:label>
    <link:label id="lab_evh_PremiumsWrittenAndPolicyholderBenefitsAndClaimsIncurredNet_label_en-US" xlink:label="lab_evh_PremiumsWrittenAndPolicyholderBenefitsAndClaimsIncurredNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premiums Written And Policyholder Benefits And Claims Incurred, Net</link:label>
    <link:label id="lab_evh_PremiumsWrittenAndPolicyholderBenefitsAndClaimsIncurredNet_documentation_en-US" xlink:label="lab_evh_PremiumsWrittenAndPolicyholderBenefitsAndClaimsIncurredNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premiums Written And Policyholder Benefits And Claims Incurred, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PremiumsWrittenAndPolicyholderBenefitsAndClaimsIncurredNet" xlink:href="evh-20210630.xsd#evh_PremiumsWrittenAndPolicyholderBenefitsAndClaimsIncurredNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_PremiumsWrittenAndPolicyholderBenefitsAndClaimsIncurredNet" xlink:to="lab_evh_PremiumsWrittenAndPolicyholderBenefitsAndClaimsIncurredNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_261b1936-6c90-4807-94f7-2d9d748f9115_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed_cb948854-930b-443d-819b-81b1ab807379_terseLabel_en-US" xlink:label="lab_us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Claims assumed</link:label>
    <link:label id="lab_us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed_label_en-US" xlink:label="lab_us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Policyholder Benefits and Claims Incurred, Assumed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed" xlink:to="lab_us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedContractCostAxis_c872136e-5cc5-42ad-b002-bd7fe14970d5_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Contract Cost [Axis]</link:label>
    <link:label id="lab_us-gaap_CapitalizedContractCostAxis_label_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Contract Cost [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedContractCostAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedContractCostAxis" xlink:to="lab_us-gaap_CapitalizedContractCostAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_c9cd0daa-92dd-415f-9e5e-c71c9c1ba7b3_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_ClinicalSolutionsSegmentMember_dd567a19-f129-4d06-b5c7-dcc3c1abda70_terseLabel_en-US" xlink:label="lab_evh_ClinicalSolutionsSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical Solutions</link:label>
    <link:label id="lab_evh_ClinicalSolutionsSegmentMember_label_en-US" xlink:label="lab_evh_ClinicalSolutionsSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical Solutions Segment [Member]</link:label>
    <link:label id="lab_evh_ClinicalSolutionsSegmentMember_documentation_en-US" xlink:label="lab_evh_ClinicalSolutionsSegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical Solutions Segment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ClinicalSolutionsSegmentMember" xlink:href="evh-20210630.xsd#evh_ClinicalSolutionsSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_ClinicalSolutionsSegmentMember" xlink:to="lab_evh_ClinicalSolutionsSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_EvolentHealthServicesSegmentMember_27ffd997-2ae3-4959-8f20-b2260fa43e47_terseLabel_en-US" xlink:label="lab_evh_EvolentHealthServicesSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Evolent Health Services</link:label>
    <link:label id="lab_evh_EvolentHealthServicesSegmentMember_label_en-US" xlink:label="lab_evh_EvolentHealthServicesSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Evolent Health Services Segment [Member]</link:label>
    <link:label id="lab_evh_EvolentHealthServicesSegmentMember_documentation_en-US" xlink:label="lab_evh_EvolentHealthServicesSegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Evolent Health Services Segment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EvolentHealthServicesSegmentMember" xlink:href="evh-20210630.xsd#evh_EvolentHealthServicesSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_EvolentHealthServicesSegmentMember" xlink:to="lab_evh_EvolentHealthServicesSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_05957d98-1815-44d5-b8bb-1a9a86afe5ec_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_25d8d612-b15e-44c3-9005-94626ff1b92f_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares outstanding - basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_f6907fb6-2003-45ed-aed0-c96f17f01523_totalLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted loss per share attributable to common shareholders of Evolent Health, Inc. (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDomain_b153d34b-7371-47b1-acdc-c3553c347e0e_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_label_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermLinesOfCredit_176505f7-a3f1-4929-bde1-d167d9afb2fa_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of long-term lines of credit</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermLinesOfCredit_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Long-term Lines of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermLinesOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit" xlink:to="lab_us-gaap_RepaymentsOfLongTermLinesOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_6432d479-04c2-4ff4-8a71-89fb5e75cde6_verboseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in and advances to equity method investees</link:label>
    <link:label id="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_label_en-US" xlink:label="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:to="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy_3eed4be4-3263-4777-815e-d0d38973edf9_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Finite-Lived, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingStandardsUpdateExtensibleList_18a32345-59ce-4444-bede-c87bca835c6f_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdateExtensibleList_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:to="lab_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_MedicaidCustomersMember_342eeaa3-9fc1-4a89-b16e-909dfb332eff_terseLabel_en-US" xlink:label="lab_evh_MedicaidCustomersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicaid</link:label>
    <link:label id="lab_evh_MedicaidCustomersMember_label_en-US" xlink:label="lab_evh_MedicaidCustomersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicaid Customers [Member]</link:label>
    <link:label id="lab_evh_MedicaidCustomersMember_documentation_en-US" xlink:label="lab_evh_MedicaidCustomersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicaid Customers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_MedicaidCustomersMember" xlink:href="evh-20210630.xsd#evh_MedicaidCustomersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_MedicaidCustomersMember" xlink:to="lab_evh_MedicaidCustomersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_1efc4323-9584-425e-ae17-3d04aab67191_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_b9716b63-60f2-4d98-831e-a656b1628808_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_SeniorConvertibleNotesDue2024Member_d453d288-2b08-442b-8a45-acfa888b7994_terseLabel_en-US" xlink:label="lab_evh_SeniorConvertibleNotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024 Notes</link:label>
    <link:label id="lab_evh_SeniorConvertibleNotesDue2024Member_label_en-US" xlink:label="lab_evh_SeniorConvertibleNotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Convertible Notes Due 2024 [Member]</link:label>
    <link:label id="lab_evh_SeniorConvertibleNotesDue2024Member_documentation_en-US" xlink:label="lab_evh_SeniorConvertibleNotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Convertible Notes Due 2024</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SeniorConvertibleNotesDue2024Member" xlink:href="evh-20210630.xsd#evh_SeniorConvertibleNotesDue2024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_SeniorConvertibleNotesDue2024Member" xlink:to="lab_evh_SeniorConvertibleNotesDue2024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_1e600d88-71d3-44da-a0ab-9f32852885b3_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total comprehensive loss attributable to common shareholders of Evolent Health, Inc.</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_4f40a0f5-ff14-46bb-8905-da84525b1374_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_fc7ab920-128a-4717-802b-43e49fdfa5ad_periodStartLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance as of beginning-of-period</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_d1f1280b-7c7f-4e06-bf0e-e2936f218c00_periodEndLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance as of end of period</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_3cb83807-bb7f-4580-87d6-9e66d5354299_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash and restricted cash provided by (used in) financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_fc499cdd-c436-4209-a30b-5af5ce4e77ee_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive loss, net of taxes, related to:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValue_122b79c1-f571-40e0-9c85-49ab888b1769_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock, at cost; 1,537,582 shares issued, respectively</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValue" xlink:to="lab_us-gaap_TreasuryStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_53583fe2-7d48-41ea-bb54-9d6d633ab1ff_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities, net</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_64767c5f-fd99-417e-afb5-fc4e17312f3d_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CededPremiumsWritten_31db671a-6b43-4146-b1c7-c028920db6a6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_CededPremiumsWritten" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reinsurance premiums ceded</link:label>
    <link:label id="lab_us-gaap_CededPremiumsWritten_label_en-US" xlink:label="lab_us-gaap_CededPremiumsWritten" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ceded Premiums Written</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CededPremiumsWritten" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CededPremiumsWritten"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CededPremiumsWritten" xlink:to="lab_us-gaap_CededPremiumsWritten" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates_59226c01-809a-4433-872c-bee80669ac97_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from transfer of membership and release of Passport escrow</link:label>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates_label_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Divestiture of Interest in Subsidiaries and Affiliates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates" xlink:to="lab_us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_7af4fe64-fec2-47da-9067-6ea89d655a94_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain from equity method investees</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_784466c6-0566-4b80-95f5-b100e1523cab_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Gain) loss from equity method investees</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_5c934e3d-8c31-4fd9-ab81-a3a4364ffec0_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_AssetAcquisitionAccruedLiabilities_7e37dba9-23e2-4af2-ad69-210570774170_terseLabel_en-US" xlink:label="lab_evh_AssetAcquisitionAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_evh_AssetAcquisitionAccruedLiabilities_label_en-US" xlink:label="lab_evh_AssetAcquisitionAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Accrued Liabilities</link:label>
    <link:label id="lab_evh_AssetAcquisitionAccruedLiabilities_documentation_en-US" xlink:label="lab_evh_AssetAcquisitionAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_AssetAcquisitionAccruedLiabilities" xlink:href="evh-20210630.xsd#evh_AssetAcquisitionAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_AssetAcquisitionAccruedLiabilities" xlink:to="lab_evh_AssetAcquisitionAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_a8dbf125-eed9-442f-85cf-0444d448cca2_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Continuing operations, basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Basic Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_8ecd3bcc-475c-4650-a28f-7f30a397f433_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (loss) from discontinued operations, net of tax</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_10e7c9cf-274d-4c99-b617-41c555c8b684_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (loss) from discontinued operations, net of tax (2)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_74bc4c81-e92d-405a-b5b7-035c976a5bcf_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) from discontinued operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_ProceedsFromMaturityOfInvestments_75999d31-2ce3-4e05-a8aa-a1eb131e7285_terseLabel_en-US" xlink:label="lab_evh_ProceedsFromMaturityOfInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturities and sales of investments</link:label>
    <link:label id="lab_evh_ProceedsFromMaturityOfInvestments_label_en-US" xlink:label="lab_evh_ProceedsFromMaturityOfInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Maturity Of Investments</link:label>
    <link:label id="lab_evh_ProceedsFromMaturityOfInvestments_documentation_en-US" xlink:label="lab_evh_ProceedsFromMaturityOfInvestments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Maturity Of Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ProceedsFromMaturityOfInvestments" xlink:href="evh-20210630.xsd#evh_ProceedsFromMaturityOfInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_ProceedsFromMaturityOfInvestments" xlink:to="lab_evh_ProceedsFromMaturityOfInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_4acc7f5e-5b8d-4d1f-89b5-8b9f2883f4d9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityReserveEstimatePolicy_945ad51d-74ce-4839-9a1f-766badb576b1_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityReserveEstimatePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserves for Claims and Performance-based Arrangements</link:label>
    <link:label id="lab_us-gaap_LiabilityReserveEstimatePolicy_label_en-US" xlink:label="lab_us-gaap_LiabilityReserveEstimatePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Reserve Estimate, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityReserveEstimatePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityReserveEstimatePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityReserveEstimatePolicy" xlink:to="lab_us-gaap_LiabilityReserveEstimatePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCharges_d6f782dc-d8c2-4151-b7e6-a133b5e00217_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repositioning costs incurred</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_73e69195-1f60-4f8e-99e3-d249c816e660_negatedLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repositioning costs</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_label_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCharges" xlink:to="lab_us-gaap_RestructuringCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_e80bb7bd-0644-4d48-863d-daadadf9186b_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_57cde493-c6e8-4edc-95e1-859c59a80df7_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_EmployeeSeveranceAndTerminationBenefitsMember_0551af3b-2b16-4a41-b091-b14db995d28f_terseLabel_en-US" xlink:label="lab_evh_EmployeeSeveranceAndTerminationBenefitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Severance and termination benefits</link:label>
    <link:label id="lab_evh_EmployeeSeveranceAndTerminationBenefitsMember_label_en-US" xlink:label="lab_evh_EmployeeSeveranceAndTerminationBenefitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Severance And Termination Benefits [Member]</link:label>
    <link:label id="lab_evh_EmployeeSeveranceAndTerminationBenefitsMember_documentation_en-US" xlink:label="lab_evh_EmployeeSeveranceAndTerminationBenefitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Severance And Termination Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EmployeeSeveranceAndTerminationBenefitsMember" xlink:href="evh-20210630.xsd#evh_EmployeeSeveranceAndTerminationBenefitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_EmployeeSeveranceAndTerminationBenefitsMember" xlink:to="lab_evh_EmployeeSeveranceAndTerminationBenefitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_490421ae-7b8c-4e2f-97d2-a8e055b1f8dd_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_DelayedDrawTermLoanFacilityMember_73633c17-58db-4632-a6d4-3d10899a6be9_terseLabel_en-US" xlink:label="lab_evh_DelayedDrawTermLoanFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DDTL Facility</link:label>
    <link:label id="lab_evh_DelayedDrawTermLoanFacilityMember_label_en-US" xlink:label="lab_evh_DelayedDrawTermLoanFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Delayed Draw Term Loan Facility [Member]</link:label>
    <link:label id="lab_evh_DelayedDrawTermLoanFacilityMember_documentation_en-US" xlink:label="lab_evh_DelayedDrawTermLoanFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Delayed Draw Term Loan Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DelayedDrawTermLoanFacilityMember" xlink:href="evh-20210630.xsd#evh_DelayedDrawTermLoanFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_DelayedDrawTermLoanFacilityMember" xlink:to="lab_evh_DelayedDrawTermLoanFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_ecf0bdff-afcc-481e-b2bc-fdfc873d18dc_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization expenses</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ParentMember_349a8ef3-2ac6-4650-ac40-1dce96d82c0b_terseLabel_en-US" xlink:label="lab_us-gaap_ParentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Parent</link:label>
    <link:label id="lab_us-gaap_ParentMember_label_en-US" xlink:label="lab_us-gaap_ParentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ParentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ParentMember" xlink:to="lab_us-gaap_ParentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseImpactOfConsolidationOnPayables_f384978b-dc62-4d1f-ad25-b21198b2fb90_negatedTerseLabel_en-US" xlink:label="lab_evh_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseImpactOfConsolidationOnPayables" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impact of consolidation on payable for claims and performance-based arrangements attributable to the Reinsurance Agreement</link:label>
    <link:label id="lab_evh_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseImpactOfConsolidationOnPayables_label_en-US" xlink:label="lab_evh_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseImpactOfConsolidationOnPayables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assumed Liability For Unpaid Claims And Claims Adjustment Expense, Impact Of Consolidation On Payables</link:label>
    <link:label id="lab_evh_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseImpactOfConsolidationOnPayables_documentation_en-US" xlink:label="lab_evh_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseImpactOfConsolidationOnPayables" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assumed Liability For Unpaid Claims And Claims Adjustment Expense, Impact Of Consolidation On Payables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseImpactOfConsolidationOnPayables" xlink:href="evh-20210630.xsd#evh_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseImpactOfConsolidationOnPayables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseImpactOfConsolidationOnPayables" xlink:to="lab_evh_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseImpactOfConsolidationOnPayables" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_335d918d-4ee4-4777-b21b-e4951bc25637_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_710e5225-8b3e-4981-a1a2-f23ad05ef683_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of assets at fair value on recurring basis</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_SeniorConvertibleNotesDue2025Member_6c3a44ff-3782-4396-ad2f-1cd20dd2e5de_terseLabel_en-US" xlink:label="lab_evh_SeniorConvertibleNotesDue2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025 Notes</link:label>
    <link:label id="lab_evh_SeniorConvertibleNotesDue2025Member_label_en-US" xlink:label="lab_evh_SeniorConvertibleNotesDue2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Convertible Notes Due 2025 [Member]</link:label>
    <link:label id="lab_evh_SeniorConvertibleNotesDue2025Member_documentation_en-US" xlink:label="lab_evh_SeniorConvertibleNotesDue2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Convertible Notes Due 2025 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SeniorConvertibleNotesDue2025Member" xlink:href="evh-20210630.xsd#evh_SeniorConvertibleNotesDue2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_SeniorConvertibleNotesDue2025Member" xlink:to="lab_evh_SeniorConvertibleNotesDue2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_8aaac806-796e-4b88-8694-3357ee547ddd_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsPolicy" xlink:to="lab_us-gaap_BusinessCombinationsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_f775dd39-a1fe-476f-9c7a-3da655b8beb2_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_c611be05-1118-4968-a05e-4dbf222c1985_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs associated with the Repositioning Plan</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Costs [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseNet_7c38a8a0-c099-4e64-97bb-22727b430a2f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense), net</link:label>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseNet_label_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Operating Income (Expense), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingIncomeExpenseNet" xlink:to="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_b040a0a5-d891-476e-a07f-93c622214f17_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_329b131c-3ff7-48d8-9ba3-6c270965ffa8_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_f816825b-57e4-48a6-ac22-bfef82dbe2df_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units vested, net of shares withheld for taxes (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportingUnits_0b43e609-238e-4688-b0cb-445618eda8f6_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportingUnits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of reporting units for goodwill testing</link:label>
    <link:label id="lab_us-gaap_NumberOfReportingUnits_label_en-US" xlink:label="lab_us-gaap_NumberOfReportingUnits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Reporting Units</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportingUnits" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfReportingUnits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportingUnits" xlink:to="lab_us-gaap_NumberOfReportingUnits" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_PlatformsAndOperationsServicesMember_2c24751a-3d79-4022-94c4-9c8c9b474aff_verboseLabel_en-US" xlink:label="lab_evh_PlatformsAndOperationsServicesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Platform and operations services</link:label>
    <link:label id="lab_evh_PlatformsAndOperationsServicesMember_label_en-US" xlink:label="lab_evh_PlatformsAndOperationsServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Platforms And Operations Services [Member]</link:label>
    <link:label id="lab_evh_PlatformsAndOperationsServicesMember_documentation_en-US" xlink:label="lab_evh_PlatformsAndOperationsServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Platforms And Operations Services [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PlatformsAndOperationsServicesMember" xlink:href="evh-20210630.xsd#evh_PlatformsAndOperationsServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_PlatformsAndOperationsServicesMember" xlink:to="lab_evh_PlatformsAndOperationsServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_9c3cb503-911c-470b-9081-fbdbe5d689bd_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_99ef4fbe-6bab-486d-956e-e556028b5a99_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_RestrictedCashforLettersofCreditforFacilityLeasesMember_dbbb22e1-329b-4cd4-817e-20ac0791f986_verboseLabel_en-US" xlink:label="lab_evh_RestrictedCashforLettersofCreditforFacilityLeasesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collateral for letters of credit for facility leases</link:label>
    <link:label id="lab_evh_RestrictedCashforLettersofCreditforFacilityLeasesMember_label_en-US" xlink:label="lab_evh_RestrictedCashforLettersofCreditforFacilityLeasesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash for Letters of Credit for Facility Leases [Member]</link:label>
    <link:label id="lab_evh_RestrictedCashforLettersofCreditforFacilityLeasesMember_documentation_en-US" xlink:label="lab_evh_RestrictedCashforLettersofCreditforFacilityLeasesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash for Letters of Credit for Facility Leases [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RestrictedCashforLettersofCreditforFacilityLeasesMember" xlink:href="evh-20210630.xsd#evh_RestrictedCashforLettersofCreditforFacilityLeasesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_RestrictedCashforLettersofCreditforFacilityLeasesMember" xlink:to="lab_evh_RestrictedCashforLettersofCreditforFacilityLeasesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_11fa91de-f8ad-4976-8c25-2033ca0175ff_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesDomain" xlink:to="lab_srt_ConsolidatedEntitiesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_9239a71f-63a5-48a2-9cc4-eae9afc260e5_totalLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease cost</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_aae56490-a53b-48db-8cb9-f15d5423249a_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of property and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_c8cfb4d0-2da1-4080-a4b6-5737ae62cdef_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_ShareholderAdvisoryServices_27b38b49-a825-4482-a54a-74b93795fba7_negatedLabel_en-US" xlink:label="lab_evh_ShareholderAdvisoryServices" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Strategy and shareholder advisory expenses</link:label>
    <link:label id="lab_evh_ShareholderAdvisoryServices_label_en-US" xlink:label="lab_evh_ShareholderAdvisoryServices" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholder Advisory Services</link:label>
    <link:label id="lab_evh_ShareholderAdvisoryServices_documentation_en-US" xlink:label="lab_evh_ShareholderAdvisoryServices" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholder Advisory Services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ShareholderAdvisoryServices" xlink:href="evh-20210630.xsd#evh_ShareholderAdvisoryServices"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_ShareholderAdvisoryServices" xlink:to="lab_evh_ShareholderAdvisoryServices" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_ddbd490e-b7e0-4b4d-b04b-fa65b0af4549_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_61450271-af43-4139-b7e5-8a4b980efa89_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTerm" xlink:to="lab_us-gaap_DebtInstrumentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_TaxReceivableAgreementPercentofCashSavingsPaidtoShareholders_e865c262-88f2-40bd-8d13-3c1fb03bd7aa_terseLabel_en-US" xlink:label="lab_evh_TaxReceivableAgreementPercentofCashSavingsPaidtoShareholders" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax receivable agreement, percent of cash savings paid to shareholders</link:label>
    <link:label id="lab_evh_TaxReceivableAgreementPercentofCashSavingsPaidtoShareholders_label_en-US" xlink:label="lab_evh_TaxReceivableAgreementPercentofCashSavingsPaidtoShareholders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Receivable Agreement, Percent of Cash Savings Paid to Shareholders</link:label>
    <link:label id="lab_evh_TaxReceivableAgreementPercentofCashSavingsPaidtoShareholders_documentation_en-US" xlink:label="lab_evh_TaxReceivableAgreementPercentofCashSavingsPaidtoShareholders" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Receivable Agreement, Percent of Cash Savings Paid to Shareholders</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TaxReceivableAgreementPercentofCashSavingsPaidtoShareholders" xlink:href="evh-20210630.xsd#evh_TaxReceivableAgreementPercentofCashSavingsPaidtoShareholders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_TaxReceivableAgreementPercentofCashSavingsPaidtoShareholders" xlink:to="lab_evh_TaxReceivableAgreementPercentofCashSavingsPaidtoShareholders" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_919abb17-d71c-4ebe-a954-824e239e90eb_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_b05e2e08-ce79-49bb-99ea-9cb9b5e11287_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Disclosure of Non-cash Investing and Financing Activities</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerRelationshipsMember_dadbd59c-9e7f-4e0d-969d-28264245575e_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer relationships</link:label>
    <link:label id="lab_us-gaap_CustomerRelationshipsMember_label_en-US" xlink:label="lab_us-gaap_CustomerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Relationships [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerRelationshipsMember" xlink:to="lab_us-gaap_CustomerRelationshipsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MovementInMinorityInterestRollForward_e639cdbb-fec6-422e-b1d2-b40ffe4ac0a9_terseLabel_en-US" xlink:label="lab_us-gaap_MovementInMinorityInterestRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_MovementInMinorityInterestRollForward_label_en-US" xlink:label="lab_us-gaap_MovementInMinorityInterestRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInMinorityInterestRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MovementInMinorityInterestRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward" xlink:to="lab_us-gaap_MovementInMinorityInterestRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_21ae9d22-0563-4407-b074-1a642c034ea8_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_7f82fcd0-ad35-4c5d-be22-1a8a9f6da720_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_VA_1c48b2fc-ac57-426f-b172-f3708a296d15_terseLabel_en-US" xlink:label="lab_stpr_VA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arlington, VA</link:label>
    <link:label id="lab_stpr_VA_label_en-US" xlink:label="lab_stpr_VA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">VIRGINIA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_VA" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_VA"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_VA" xlink:to="lab_stpr_VA" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_PolicyholderBenefitsAndClaimsIncurredAssumedExpensesRelatedToClaims_2eb1464e-c370-4cae-a8ee-93cd1ef294cc_terseLabel_en-US" xlink:label="lab_evh_PolicyholderBenefitsAndClaimsIncurredAssumedExpensesRelatedToClaims" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Claims-related administrative expenses</link:label>
    <link:label id="lab_evh_PolicyholderBenefitsAndClaimsIncurredAssumedExpensesRelatedToClaims_label_en-US" xlink:label="lab_evh_PolicyholderBenefitsAndClaimsIncurredAssumedExpensesRelatedToClaims" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Policyholder Benefits And Claims Incurred, Assumed, Expenses Related To Claims</link:label>
    <link:label id="lab_evh_PolicyholderBenefitsAndClaimsIncurredAssumedExpensesRelatedToClaims_documentation_en-US" xlink:label="lab_evh_PolicyholderBenefitsAndClaimsIncurredAssumedExpensesRelatedToClaims" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Policyholder Benefits And Claims Incurred, Assumed, Expenses Related To Claims</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PolicyholderBenefitsAndClaimsIncurredAssumedExpensesRelatedToClaims" xlink:href="evh-20210630.xsd#evh_PolicyholderBenefitsAndClaimsIncurredAssumedExpensesRelatedToClaims"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_PolicyholderBenefitsAndClaimsIncurredAssumedExpensesRelatedToClaims" xlink:to="lab_evh_PolicyholderBenefitsAndClaimsIncurredAssumedExpensesRelatedToClaims" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_8f4a5ae4-8d24-4318-976d-b05bd5a5c535_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment, Net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_7c5027ed-07f0-4782-9417-e2e1f7261b22_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_8dbf1ca3-1142-4386-8284-830ff343a581_terseLabel_en-US" xlink:label="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Income (Loss)</link:label>
    <link:label id="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Including Portion Attributable to Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_609d95d8-b889-4e04-9b43-e0c193d8417d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities_0e7aa89e-4ac9-45f4-88d9-1567f52db964_terseLabel_en-US" xlink:label="lab_evh_IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve for claims and performance-based arrangements</link:label>
    <link:label id="lab_evh_IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities_label_en-US" xlink:label="lab_evh_IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Insurance And Performance-Based Arrangements Liabilities</link:label>
    <link:label id="lab_evh_IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities_documentation_en-US" xlink:label="lab_evh_IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Insurance And Performance-Based Arrangements Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities" xlink:href="evh-20210630.xsd#evh_IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities" xlink:to="lab_evh_IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_PaidinKindInterestIncome_8a7ae011-e1fa-4e19-b55b-90a3dc2e0e4e_negatedTerseLabel_en-US" xlink:label="lab_evh_PaidinKindInterestIncome" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest from customer advance for regulatory capital requirements</link:label>
    <link:label id="lab_evh_PaidinKindInterestIncome_label_en-US" xlink:label="lab_evh_PaidinKindInterestIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Paid-in-Kind Interest Income</link:label>
    <link:label id="lab_evh_PaidinKindInterestIncome_documentation_en-US" xlink:label="lab_evh_PaidinKindInterestIncome" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Paid-in-Kind Interest Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PaidinKindInterestIncome" xlink:href="evh-20210630.xsd#evh_PaidinKindInterestIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_PaidinKindInterestIncome" xlink:to="lab_evh_PaidinKindInterestIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_PaymentsToAcquireEquityMethodInvestmentsAmountHeldBack_137c79d2-740e-4e58-b4e0-ec0fefd7789b_terseLabel_en-US" xlink:label="lab_evh_PaymentsToAcquireEquityMethodInvestmentsAmountHeldBack" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to acquire equity method investments, amount held back</link:label>
    <link:label id="lab_evh_PaymentsToAcquireEquityMethodInvestmentsAmountHeldBack_label_en-US" xlink:label="lab_evh_PaymentsToAcquireEquityMethodInvestmentsAmountHeldBack" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments To Acquire Equity Method Investments, Amount Held Back</link:label>
    <link:label id="lab_evh_PaymentsToAcquireEquityMethodInvestmentsAmountHeldBack_documentation_en-US" xlink:label="lab_evh_PaymentsToAcquireEquityMethodInvestmentsAmountHeldBack" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments To Acquire Equity Method Investments, Amount Held Back</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PaymentsToAcquireEquityMethodInvestmentsAmountHeldBack" xlink:href="evh-20210630.xsd#evh_PaymentsToAcquireEquityMethodInvestmentsAmountHeldBack"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_PaymentsToAcquireEquityMethodInvestmentsAmountHeldBack" xlink:to="lab_evh_PaymentsToAcquireEquityMethodInvestmentsAmountHeldBack" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_33a3a537-ec0d-4e86-a165-104795e39a6a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of future estimated amortization of intangible assets</link:label>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1b56e7cf-b8ad-46d6-9f30-7310b5c3f5b4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesGrossDifferenceAmountAbstract_69657108-a66f-4b48-8cf0-d251fc7570c1_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesGrossDifferenceAmountAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less:</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesGrossDifferenceAmountAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesGrossDifferenceAmountAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease Liabilities, Gross Difference, Amount [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesGrossDifferenceAmountAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesGrossDifferenceAmountAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesGrossDifferenceAmountAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilitiesGrossDifferenceAmountAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_98842054-033a-4ba9-bb19-08aed0e0fb53_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_17b1aed1-d8b1-435f-b52c-469e156c660b_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_DisposalGroupIncludingDiscontinuedOperationInvestmentsCurrent_0a9e934d-6bdb-489d-821d-bcc919532939_terseLabel_en-US" xlink:label="lab_evh_DisposalGroupIncludingDiscontinuedOperationInvestmentsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, at amortized cost</link:label>
    <link:label id="lab_evh_DisposalGroupIncludingDiscontinuedOperationInvestmentsCurrent_label_en-US" xlink:label="lab_evh_DisposalGroupIncludingDiscontinuedOperationInvestmentsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Investments, Current</link:label>
    <link:label id="lab_evh_DisposalGroupIncludingDiscontinuedOperationInvestmentsCurrent_documentation_en-US" xlink:label="lab_evh_DisposalGroupIncludingDiscontinuedOperationInvestmentsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Investments, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DisposalGroupIncludingDiscontinuedOperationInvestmentsCurrent" xlink:href="evh-20210630.xsd#evh_DisposalGroupIncludingDiscontinuedOperationInvestmentsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_DisposalGroupIncludingDiscontinuedOperationInvestmentsCurrent" xlink:to="lab_evh_DisposalGroupIncludingDiscontinuedOperationInvestmentsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvesteeMember_793984fd-234c-4545-bac4-7ce928c265bd_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvesteeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investee</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvesteeMember_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvesteeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investee [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvesteeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvesteeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvesteeMember" xlink:to="lab_us-gaap_EquityMethodInvesteeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_0f1896c0-bfda-4ec6-8df1-1b21229779c4_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total property and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestTable_a3df9d78-e56e-4784-977d-c8c015ca44a6_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Table]</link:label>
    <link:label id="lab_us-gaap_MinorityInterestTable_label_en-US" xlink:label="lab_us-gaap_MinorityInterestTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestTable" xlink:to="lab_us-gaap_MinorityInterestTable" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_DebtInstrumentRedemptionCallProtectionPremiumPercentage_4ac8d929-fa39-4e5c-a70c-6d5b14dc0329_terseLabel_en-US" xlink:label="lab_evh_DebtInstrumentRedemptionCallProtectionPremiumPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redemption, call protection premium, percentage</link:label>
    <link:label id="lab_evh_DebtInstrumentRedemptionCallProtectionPremiumPercentage_label_en-US" xlink:label="lab_evh_DebtInstrumentRedemptionCallProtectionPremiumPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Call Protection Premium, Percentage</link:label>
    <link:label id="lab_evh_DebtInstrumentRedemptionCallProtectionPremiumPercentage_documentation_en-US" xlink:label="lab_evh_DebtInstrumentRedemptionCallProtectionPremiumPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Call Protection Premium, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRedemptionCallProtectionPremiumPercentage" xlink:href="evh-20210630.xsd#evh_DebtInstrumentRedemptionCallProtectionPremiumPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_DebtInstrumentRedemptionCallProtectionPremiumPercentage" xlink:to="lab_evh_DebtInstrumentRedemptionCallProtectionPremiumPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_f6635757-28ef-43ad-9e37-bb31319bdcf1_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_5249c931-c0da-4aad-9f05-c14a2cf914cd_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_a3f3fc02-0f6a-45e0-b03b-e6731930fcf0_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenue</link:label>
    <link:label id="lab_us-gaap_Revenues_c5e74f46-86a4-41e3-bcab-5957c3ae5cd4_netLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_24c09436-34f1-4d0e-abc3-8f225223e0e5_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price of warrants or rights (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationPercentage_bc35946a-6088-439b-97b0-34a0bb574502_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, remaining performance obligation, percentage</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationPercentage_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeveranceCosts1_63dd30a8-ca38-4395-90bd-b3f999442998_negatedLabel_en-US" xlink:label="lab_us-gaap_SeveranceCosts1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Severance costs</link:label>
    <link:label id="lab_us-gaap_SeveranceCosts1_label_en-US" xlink:label="lab_us-gaap_SeveranceCosts1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Severance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeveranceCosts1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeveranceCosts1" xlink:to="lab_us-gaap_SeveranceCosts1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BankTimeDepositsMember_eff8e888-a0e4-4fe7-a87b-634b8189fb73_terseLabel_en-US" xlink:label="lab_us-gaap_BankTimeDepositsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bank time deposits</link:label>
    <link:label id="lab_us-gaap_BankTimeDepositsMember_label_en-US" xlink:label="lab_us-gaap_BankTimeDepositsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bank Time Deposits [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BankTimeDepositsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BankTimeDepositsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BankTimeDepositsMember" xlink:to="lab_us-gaap_BankTimeDepositsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesFairValueDisclosure_1e53536a-ad74-45db-8608-dc7869796cc9_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesFairValueDisclosure_30eae8b8-7717-4368-8a7c-4c3430b667fe_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_OtherLiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_e2c0458b-b8a8-48af-8945-f2a1c6dcc895_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued operations, basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantMember_97a4e3c2-f9eb-4267-9da0-c9b657f0eeb8_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_us-gaap_WarrantMember_label_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_AssetAcquisitionAccruedMedicalExpenses_5608d271-5aff-4d98-99df-02c46a9f8152_terseLabel_en-US" xlink:label="lab_evh_AssetAcquisitionAccruedMedicalExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued medical expenses</link:label>
    <link:label id="lab_evh_AssetAcquisitionAccruedMedicalExpenses_label_en-US" xlink:label="lab_evh_AssetAcquisitionAccruedMedicalExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Accrued Medical Expenses</link:label>
    <link:label id="lab_evh_AssetAcquisitionAccruedMedicalExpenses_documentation_en-US" xlink:label="lab_evh_AssetAcquisitionAccruedMedicalExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Accrued Medical Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_AssetAcquisitionAccruedMedicalExpenses" xlink:href="evh-20210630.xsd#evh_AssetAcquisitionAccruedMedicalExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_AssetAcquisitionAccruedMedicalExpenses" xlink:to="lab_evh_AssetAcquisitionAccruedMedicalExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_7e641b73-629d-48cc-bddc-d63d4cb3087b_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding (in shares)</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_CapitalizedContractCostAmortizationPurchaseAccountingAdjustments_190bf8f0-379d-4349-9978-1445468a30a1_negatedLabel_en-US" xlink:label="lab_evh_CapitalizedContractCostAmortizationPurchaseAccountingAdjustments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of contract cost assets</link:label>
    <link:label id="lab_evh_CapitalizedContractCostAmortizationPurchaseAccountingAdjustments_label_en-US" xlink:label="lab_evh_CapitalizedContractCostAmortizationPurchaseAccountingAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Contract Cost, Amortization, Purchase Accounting Adjustments</link:label>
    <link:label id="lab_evh_CapitalizedContractCostAmortizationPurchaseAccountingAdjustments_documentation_en-US" xlink:label="lab_evh_CapitalizedContractCostAmortizationPurchaseAccountingAdjustments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Contract Cost, Amortization, Purchase Accounting Adjustments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CapitalizedContractCostAmortizationPurchaseAccountingAdjustments" xlink:href="evh-20210630.xsd#evh_CapitalizedContractCostAmortizationPurchaseAccountingAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_CapitalizedContractCostAmortizationPurchaseAccountingAdjustments" xlink:to="lab_evh_CapitalizedContractCostAmortizationPurchaseAccountingAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_d9889536-cf26-442f-bf61-62b5a31da041_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, net of discount</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization_b10c3ef7-56a4-4b43-9f54-f48ecd034174_terseLabel_en-US" xlink:label="lab_evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjusted EBITDA</link:label>
    <link:label id="lab_evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization_label_en-US" xlink:label="lab_evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjusted Earnings Before Interest, Taxes, Depreciation And Amortization</link:label>
    <link:label id="lab_evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization_documentation_en-US" xlink:label="lab_evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjusted Earnings Before Interest, Taxes, Depreciation And Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" xlink:href="evh-20210630.xsd#evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" xlink:to="lab_evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionDomain_4b7e162f-ea4d-45ea-a20f-7e7e92d7afd6_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Domain]</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionDomain_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionDomain" xlink:to="lab_us-gaap_AssetAcquisitionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_45f776f6-7fdd-42e1-936a-7be8e61d0266_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_46b807b5-ce3d-4b20-9722-92c80d04832b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable" xlink:to="lab_us-gaap_ScheduleOfGoodwillTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_d207e875-2fe9-4d32-a20a-761d0e230e49_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_5b58a74d-6ec3-49a5-818a-aad0ac1d3b83_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_a8aeb474-492e-4408-bf25-54ef77d95a9b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_913990b4-6ffa-4a51-9bd7-d36f3e3a5306_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual risk free rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Risk Free Interest Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_67b25c3c-d3bc-443d-89f9-27a4a15e5353_terseLabel_en-US" xlink:label="lab_evh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_evh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_label_en-US" xlink:label="lab_evh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, After Year Four</link:label>
    <link:label id="lab_evh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_documentation_en-US" xlink:label="lab_evh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, After Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:href="evh-20210630.xsd#evh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:to="lab_evh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_2d2fed38-4033-4b33-bdf8-3038d959f4bb_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss per common share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_17e5bb14-50e0-455c-a2e0-94e44ba0d33f_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss per common share, Basic and diluted</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_EquityMethodInvestmentEconomicInterestPercentage_6cdbe0a1-bcaf-47f0-9530-6ffed0e1b54a_terseLabel_en-US" xlink:label="lab_evh_EquityMethodInvestmentEconomicInterestPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Economic interest percentage</link:label>
    <link:label id="lab_evh_EquityMethodInvestmentEconomicInterestPercentage_label_en-US" xlink:label="lab_evh_EquityMethodInvestmentEconomicInterestPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Economic Interest Percentage</link:label>
    <link:label id="lab_evh_EquityMethodInvestmentEconomicInterestPercentage_documentation_en-US" xlink:label="lab_evh_EquityMethodInvestmentEconomicInterestPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Economic Interest Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EquityMethodInvestmentEconomicInterestPercentage" xlink:href="evh-20210630.xsd#evh_EquityMethodInvestmentEconomicInterestPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_EquityMethodInvestmentEconomicInterestPercentage" xlink:to="lab_evh_EquityMethodInvestmentEconomicInterestPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_bc48814a-90cb-4064-96d5-24fe07554fa4_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_47d2b34b-b9a1-4e73-8cd2-cadd5cc67c6a_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_c23475fa-9ec3-4e5f-b316-ba11537a877b_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_AssetAcquisitionDebtSecuritiesAvailableForSaleUnsettledSalesReceivables_9640bb24-d700-45f5-912d-69c0ea03ed9b_terseLabel_en-US" xlink:label="lab_evh_AssetAcquisitionDebtSecuritiesAvailableForSaleUnsettledSalesReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables related to unsettled sales of securities</link:label>
    <link:label id="lab_evh_AssetAcquisitionDebtSecuritiesAvailableForSaleUnsettledSalesReceivables_label_en-US" xlink:label="lab_evh_AssetAcquisitionDebtSecuritiesAvailableForSaleUnsettledSalesReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Debt Securities, Available-For-Sale, Unsettled Sales Receivables</link:label>
    <link:label id="lab_evh_AssetAcquisitionDebtSecuritiesAvailableForSaleUnsettledSalesReceivables_documentation_en-US" xlink:label="lab_evh_AssetAcquisitionDebtSecuritiesAvailableForSaleUnsettledSalesReceivables" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Debt Securities, Available-For-Sale, Unsettled Sales Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_AssetAcquisitionDebtSecuritiesAvailableForSaleUnsettledSalesReceivables" xlink:href="evh-20210630.xsd#evh_AssetAcquisitionDebtSecuritiesAvailableForSaleUnsettledSalesReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_AssetAcquisitionDebtSecuritiesAvailableForSaleUnsettledSalesReceivables" xlink:to="lab_evh_AssetAcquisitionDebtSecuritiesAvailableForSaleUnsettledSalesReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_4d796493-8e1c-4397-9569-57271a9d7891_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_019cef27-e208-446d-90fa-1c2318aac3ab_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_c5a9019d-ac0d-4e8f-939b-58c7dfdefc67_verboseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNoncurrentPastDueTable_2ee51835-eb80-4e9d-b540-ede6d9cbe3b4_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNoncurrentPastDueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Noncurrent, Past Due [Table]</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNoncurrentPastDueTable_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNoncurrentPastDueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Noncurrent, Past Due [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNoncurrentPastDueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNoncurrentPastDueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNoncurrentPastDueTable" xlink:to="lab_us-gaap_AccountsReceivableNoncurrentPastDueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_0eead550-5c7d-4898-b6c5-fb5d81bf8701_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of deferred financing costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_22e9ff76-c167-4725-9d40-bf8938574e51_verboseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of deferred financing costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCosts" xlink:to="lab_us-gaap_AmortizationOfFinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_2b4d9d86-a14e-4f53-b12d-29bd16f3567c_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_355237ad-8bc1-47da-be8b-26b32886c5f5_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonClassAMember_77d50d9d-5bc7-4c86-8570-98476a4439a1_terseLabel_en-US" xlink:label="lab_us-gaap_CommonClassAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class A Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonClassAMember_ac82fbdb-54d9-4ffe-92fc-d5aa8886cb4b_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonClassAMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class A Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonClassAMember_label_en-US" xlink:label="lab_us-gaap_CommonClassAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Class A [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonClassAMember" xlink:to="lab_us-gaap_CommonClassAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetCurrent_a5c9fe83-1f85-4ef3-a22f-7592e92f9ec1_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term contract assets</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:to="lab_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3f430f40-6172-4570-8080-03df57e7fede_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents and restricted cash as of beginning-of-period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_cae1b13e-0e87-45a6-b7ac-4c91e530145f_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents and restricted cash as of end-of-period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b42bc33f-1d4f-4835-8544-778b29cac77f_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash and cash equivalents and restricted cash shown in the consolidated statements of cash flows (1)</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b534b5eb-06b9-4601-a2ff-88034a74aa83_verboseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents (including restricted cash)</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesIssued_20f317ba-7cf4-47a2-94b9-397efccb7747_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_ed8b2894-569b-46d7-8741-cfd632e6aa8f_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_label_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued" xlink:to="lab_us-gaap_SharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_17416825-e2a9-47b8-afce-768074a024a8_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsNoncurrent_ac14e009-5a7e-4425-b9af-1e9d1abf5cb0_terseLabel_en-US" xlink:label="lab_evh_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other noncurrent assets</link:label>
    <link:label id="lab_evh_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsNoncurrent_label_en-US" xlink:label="lab_evh_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Prepaid And Other Assets, Noncurrent</link:label>
    <link:label id="lab_evh_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsNoncurrent_documentation_en-US" xlink:label="lab_evh_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Prepaid And Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsNoncurrent" xlink:href="evh-20210630.xsd#evh_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsNoncurrent" xlink:to="lab_evh_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_566542f3-6119-4c79-827a-5ac1fe69e63d_terseLabel_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of major customers</link:label>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_label_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedules of Concentration of Risk, by Risk Factor [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:to="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireHeldToMaturitySecurities_84ccd73b-e0bb-440f-ace7-abab087f8854_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireHeldToMaturitySecurities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireHeldToMaturitySecurities_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireHeldToMaturitySecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Held-to-maturity Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireHeldToMaturitySecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireHeldToMaturitySecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireHeldToMaturitySecurities" xlink:to="lab_us-gaap_PaymentsToAcquireHeldToMaturitySecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_3e7569d3-9346-4d21-ba92-f6f454af59ba_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember_e7ac9b01-0512-40f0-ac16-765b238be59a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">After the Second Anniversary of the Closing of the Senior Credit Facilities but Prior to the Third Anniversary</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_26922296-1afb-4cdd-97ef-5c8362262376_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Carrying Amount</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_d1a85afb-6bc2-47a8-94a1-2b1fc4dfcf7f_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_cbf6593c-b573-4e7e-867b-1b97b1d8c791_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Cash and Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_fe2e847c-dad2-4118-809a-6b8e864de3b4_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_d434a2a0-ea75-4f2b-a692-a16012cb796f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of intangible assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_cbdb223d-ae3d-45a6-8e38-9dac38d841ce_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of intangible assets details</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems_d9a10565-53d6-4fe1-ab81-650b6ece6f30_terseLabel_en-US" xlink:label="lab_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-duration Insurance Contracts, Reconciliation of Claims Development to Liability [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems_label_en-US" xlink:label="lab_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-duration Insurance Contracts, Reconciliation of Claims Development to Liability [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems" xlink:to="lab_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedComputerSoftwareAmortization1_8b189734-a902-4437-b78f-8f6a20fcf182_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedComputerSoftwareAmortization1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized computer software, amortization</link:label>
    <link:label id="lab_us-gaap_CapitalizedComputerSoftwareAmortization1_label_en-US" xlink:label="lab_us-gaap_CapitalizedComputerSoftwareAmortization1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Computer Software, Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedComputerSoftwareAmortization1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedComputerSoftwareAmortization1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedComputerSoftwareAmortization1" xlink:to="lab_us-gaap_CapitalizedComputerSoftwareAmortization1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_c470ac04-2968-4e2f-ab6e-5c4317dd49bb_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_74225766-fbfa-4a5c-b3e4-e901cb4e2257_periodStartLabel_en-US" xlink:label="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_44ce13ec-1037-4b20-9321-9e25702b04f5_periodEndLabel_en-US" xlink:label="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_label_en-US" xlink:label="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Claims and Claims Adjustment Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:to="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_4f0d5a13-a30f-4126-be8f-682e5fbdbf17_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupClassificationDomain_cb8ab9da-cff3-4149-a732-7bf9b81e4d06_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupClassificationDomain_label_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain" xlink:to="lab_us-gaap_DisposalGroupClassificationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_89b6ed4f-4c5d-4d8b-b6d7-709640c326de_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_96053c64-9b99-4a91-8918-aab2c29ea4f2_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of stock options (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_101c5ed5-10ba-4bac-9fca-5b7a04b8cee6_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_557631a9-a440-46bb-99a1-b3f88e09d6f8_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares outstanding - diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtConversionOriginalDebtAmount1_10f1ac19-eee1-4e2d-879c-01b7df8406d3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtConversionOriginalDebtAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt conversion, original debt, amount</link:label>
    <link:label id="lab_us-gaap_DebtConversionOriginalDebtAmount1_label_en-US" xlink:label="lab_us-gaap_DebtConversionOriginalDebtAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion, Original Debt, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionOriginalDebtAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionOriginalDebtAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionOriginalDebtAmount1" xlink:to="lab_us-gaap_DebtConversionOriginalDebtAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_c250ba39-0fcb-4c22-bf35-3022bee1bad7_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent_09945d69-7ad0-415c-8496-fb31f0bc9c17_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Intangible Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromCollectionOfNotesReceivable_81efa9ff-b0ad-4afe-8071-c8775acad19e_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromCollectionOfNotesReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from collection of notes receivable</link:label>
    <link:label id="lab_us-gaap_ProceedsFromCollectionOfNotesReceivable_label_en-US" xlink:label="lab_us-gaap_ProceedsFromCollectionOfNotesReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Collection of Notes Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCollectionOfNotesReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromCollectionOfNotesReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromCollectionOfNotesReceivable" xlink:to="lab_us-gaap_ProceedsFromCollectionOfNotesReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_98cb999e-a594-4895-8c01-ee351ea0f0fa_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_f85a2294-782c-4b4b-8150-4867db514ade_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current liabilities from discontinued operations</link:label>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" xlink:to="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_99f2376a-9ef1-430b-b666-faf62f22c64b_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current assets of discontinued operations</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_06d8d3f4-cc34-465d-ac83-be3b8db25832_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_df7aad24-4c6a-4eee-9e06-5c17080ce037_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_03c41fac-f9cf-46fb-b172-19883f3ece0d_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_4d821693-707e-4c35-991f-d02803ff833d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis spread on variable rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_de9ee9ee-9476-46fb-9ea8-677e78892641_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Revenue from Segments to Consolidated [Table]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Revenue from Segments to Consolidated [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:to="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_ca43e5eb-07e9-4fa8-8fae-6324678a371b_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Charge-offs</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Writeoff</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_5e063a1a-30dd-4731-8cfd-5d7bd35f34ca_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of discontinued operations</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:to="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_RightOfUseAssetAcquiredAndDisposedOf_e87301e8-df1c-4e2a-a68b-b6b43983d336_negatedTerseLabel_en-US" xlink:label="lab_evh_RightOfUseAssetAcquiredAndDisposedOf" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leased assets obtained in exchange for operating lease liabilities</link:label>
    <link:label id="lab_evh_RightOfUseAssetAcquiredAndDisposedOf_label_en-US" xlink:label="lab_evh_RightOfUseAssetAcquiredAndDisposedOf" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-Of-Use Asset Acquired And Disposed Of</link:label>
    <link:label id="lab_evh_RightOfUseAssetAcquiredAndDisposedOf_documentation_en-US" xlink:label="lab_evh_RightOfUseAssetAcquiredAndDisposedOf" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-Of-Use Asset Acquired And Disposed Of</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RightOfUseAssetAcquiredAndDisposedOf" xlink:href="evh-20210630.xsd#evh_RightOfUseAssetAcquiredAndDisposedOf"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_RightOfUseAssetAcquiredAndDisposedOf" xlink:to="lab_evh_RightOfUseAssetAcquiredAndDisposedOf" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_11f4acad-c48c-4fd8-88f2-eea1c7c852fb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of antidilutive securities excluded from computation of earnings per share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_ServicesAgreementsMember_77ee5d86-9211-4ba6-9e6f-0d21a2db68a6_terseLabel_en-US" xlink:label="lab_evh_ServicesAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Services Agreements</link:label>
    <link:label id="lab_evh_ServicesAgreementsMember_label_en-US" xlink:label="lab_evh_ServicesAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Services Agreements [Member]</link:label>
    <link:label id="lab_evh_ServicesAgreementsMember_documentation_en-US" xlink:label="lab_evh_ServicesAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Services Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ServicesAgreementsMember" xlink:href="evh-20210630.xsd#evh_ServicesAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_ServicesAgreementsMember" xlink:to="lab_evh_ServicesAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_99277d43-ce62-4d88-9317-bf9adc8e86de_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_53c2e221-7907-4a8d-91f9-a93a16177385_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to acquire interest</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_efeb728d-2475-4ffd-bbe2-f0cebb69634f_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_74515312-cb0d-4808-8de5-4bc32c61193c_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_3d70e5e9-abc0-4ffa-8f34-dd0ecedcd4b9_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash and restricted cash provided by (used in) investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_ec30883f-fba6-4c03-912e-c58ffc62a324_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Adjusted EBITDA to net loss</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:to="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_67f55dda-cafe-4156-ad98-76fac0737691_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in assets and liabilities, net of acquisitions:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_509dfa01-f822-48f1-abe0-6dc86ae1b847_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated depreciation and amortization expenses</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_b64ee534-6587-41ad-aea3-c27018fe056e_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows Provided by (Used In) Operating Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_0365fa5e-4982-4fe8-92b3-908f109e04fd_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_c25d816a-1d6f-4d95-ac38-6dec8f544b73_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_e460531b-54ee-4436-ae16-ba41f4789fb7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes withheld and paid for vesting of restricted stock units</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment, Tax Withholding, Share-based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_c0ff7e94-3be2-4e77-b203-92ebd0cec12d_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntersegmentEliminationMember_ab827709-c960-4447-b883-6a5c7b3e56b8_terseLabel_en-US" xlink:label="lab_us-gaap_IntersegmentEliminationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intersegment Eliminations</link:label>
    <link:label id="lab_us-gaap_IntersegmentEliminationMember_label_en-US" xlink:label="lab_us-gaap_IntersegmentEliminationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intersegment Eliminations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntersegmentEliminationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntersegmentEliminationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntersegmentEliminationMember" xlink:to="lab_us-gaap_IntersegmentEliminationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense_c96d34d2-1636-4b6d-af2f-119d0d99a0a7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_bc097228-8dea-48ae-9034-5fc90ef292ee_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for asset acquisitions</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityFinancialOrOtherSupportAmount_1d5ecbc6-0479-4115-8a78-47e372c67a98_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityFinancialOrOtherSupportAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance bond amount</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityFinancialOrOtherSupportAmount_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityFinancialOrOtherSupportAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity, Financial or Other Support, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityFinancialOrOtherSupportAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityFinancialOrOtherSupportAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityFinancialOrOtherSupportAmount" xlink:to="lab_us-gaap_VariableInterestEntityFinancialOrOtherSupportAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssumedPremiumsWritten_24e716ef-280e-4325-aff4-3f97d9e027f1_terseLabel_en-US" xlink:label="lab_us-gaap_AssumedPremiumsWritten" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reinsurance premiums assumed</link:label>
    <link:label id="lab_us-gaap_AssumedPremiumsWritten_label_en-US" xlink:label="lab_us-gaap_AssumedPremiumsWritten" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assumed Premiums Written</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssumedPremiumsWritten" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssumedPremiumsWritten"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssumedPremiumsWritten" xlink:to="lab_us-gaap_AssumedPremiumsWritten" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded_7d959ec5-2954-456b-8498-5593d0fdea78_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Claims ceded</link:label>
    <link:label id="lab_us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded_label_en-US" xlink:label="lab_us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Policyholder Benefits and Claims Incurred, Ceded</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded" xlink:to="lab_us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_90b200c8-139e-4f7d-a704-bc762ed5766b_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_ee11cf44-f39c-42d8-96b2-3c242ffa22af_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation</link:label>
    <link:label id="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Foreign Currency Translation Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:to="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipDomain_579d8bcd-b55c-4ab4-8f5e-3641b12dc987_terseLabel_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:label id="lab_srt_OwnershipDomain_label_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipDomain" xlink:to="lab_srt_OwnershipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_RestrictedCashforBenefitManagementServicesMember_070af06e-94ad-4c0f-abaf-e4e561ade0ca_terseLabel_en-US" xlink:label="lab_evh_RestrictedCashforBenefitManagementServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Claims processing services</link:label>
    <link:label id="lab_evh_RestrictedCashforBenefitManagementServicesMember_label_en-US" xlink:label="lab_evh_RestrictedCashforBenefitManagementServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash for Benefit Management Services [Member]</link:label>
    <link:label id="lab_evh_RestrictedCashforBenefitManagementServicesMember_documentation_en-US" xlink:label="lab_evh_RestrictedCashforBenefitManagementServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash for Benefit Management Services [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RestrictedCashforBenefitManagementServicesMember" xlink:href="evh-20210630.xsd#evh_RestrictedCashforBenefitManagementServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_RestrictedCashforBenefitManagementServicesMember" xlink:to="lab_evh_RestrictedCashforBenefitManagementServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_70a0a218-ccb9-4cf2-a161-4daaf76614a5_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_52d6efc1-fa61-4230-af89-6083d4f336d3_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized debt discount and issuance costs</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_CostofGoodsandServicesSoldExcludingDepreciationandAmortization_5766bb94-9cc2-4723-ad6f-a99454f735e8_terseLabel_en-US" xlink:label="lab_evh_CostofGoodsandServicesSoldExcludingDepreciationandAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of revenue (exclusive of depreciation and amortization expenses presented separately below)</link:label>
    <link:label id="lab_evh_CostofGoodsandServicesSoldExcludingDepreciationandAmortization_82048433-2bfc-4672-9048-c9338263568e_verboseLabel_en-US" xlink:label="lab_evh_CostofGoodsandServicesSoldExcludingDepreciationandAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of revenue (exclusive of depreciation and amortization expenses)</link:label>
    <link:label id="lab_evh_CostofGoodsandServicesSoldExcludingDepreciationandAmortization_label_en-US" xlink:label="lab_evh_CostofGoodsandServicesSoldExcludingDepreciationandAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold, Excluding Depreciation and Amortization</link:label>
    <link:label id="lab_evh_CostofGoodsandServicesSoldExcludingDepreciationandAmortization_documentation_en-US" xlink:label="lab_evh_CostofGoodsandServicesSoldExcludingDepreciationandAmortization" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold, Excluding Depreciation and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CostofGoodsandServicesSoldExcludingDepreciationandAmortization" xlink:href="evh-20210630.xsd#evh_CostofGoodsandServicesSoldExcludingDepreciationandAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_CostofGoodsandServicesSoldExcludingDepreciationandAmortization" xlink:to="lab_evh_CostofGoodsandServicesSoldExcludingDepreciationandAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_CookCountyHealthAndHospitalsSystemMember_a4f17314-f3e6-4f41-8138-c92fc6cd67f3_terseLabel_en-US" xlink:label="lab_evh_CookCountyHealthAndHospitalsSystemMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cook County Health and Hospitals System</link:label>
    <link:label id="lab_evh_CookCountyHealthAndHospitalsSystemMember_label_en-US" xlink:label="lab_evh_CookCountyHealthAndHospitalsSystemMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cook County Health And Hospitals System [Member]</link:label>
    <link:label id="lab_evh_CookCountyHealthAndHospitalsSystemMember_documentation_en-US" xlink:label="lab_evh_CookCountyHealthAndHospitalsSystemMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cook County Health And Hospitals System [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CookCountyHealthAndHospitalsSystemMember" xlink:href="evh-20210630.xsd#evh_CookCountyHealthAndHospitalsSystemMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_CookCountyHealthAndHospitalsSystemMember" xlink:to="lab_evh_CookCountyHealthAndHospitalsSystemMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_63e8bbd5-80e6-4740-bd4c-f898e59f6080_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets of discontinued operations</link:label>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_ba691acc-66f5-443d-a7d8-e9b63fd4a805_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:to="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_92b4183f-ba88-4044-86ab-d395d2c936f8_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_9d3c796d-b28a-47d1-9b51-169b154756b0_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_94eb0bed-e665-47a7-acc6-bfe796e65c3a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_8dfde911-b489-4485-9cf9-43ff0d1d3885_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adoption of New Accounting Standards</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsAxis_477f217c-781b-421e-bb29-60854766c5cf_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Axis]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsAxis_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsAxis" xlink:to="lab_us-gaap_OtherCommitmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_70bac479-cafe-468e-8fb6-2bc27036c945_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Amount Incurred through June 30, 2021</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Cost Incurred to Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedCostCostIncurredToDate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1" xlink:to="lab_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain_41085e9b-22e7-4d38-9a27-ce8b94a51a81_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_e124aa12-5ae9-4bd8-b52a-f69e2b9ef5df_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_689b2e8e-18bb-4d38-8564-0e8246cbd698_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_aca64f9f-6fa2-4bae-9684-a5b80bb8d020_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationAndAmortizationDiscontinuedOperations_054cb57e-bf6e-4fb2-bc65-f387e959aadb_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortizationDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization expenses</link:label>
    <link:label id="lab_us-gaap_DepreciationAndAmortizationDiscontinuedOperations_label_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortizationDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and Amortization, Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortizationDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortizationDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAndAmortizationDiscontinuedOperations" xlink:to="lab_us-gaap_DepreciationAndAmortizationDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_CashReleasedFromEscrow_aec81cb3-5ccd-42f7-ad43-9daeff1bcebe_terseLabel_en-US" xlink:label="lab_evh_CashReleasedFromEscrow" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Released From Escrow</link:label>
    <link:label id="lab_evh_CashReleasedFromEscrow_label_en-US" xlink:label="lab_evh_CashReleasedFromEscrow" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Released From Escrow</link:label>
    <link:label id="lab_evh_CashReleasedFromEscrow_documentation_en-US" xlink:label="lab_evh_CashReleasedFromEscrow" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Released From Escrow</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CashReleasedFromEscrow" xlink:href="evh-20210630.xsd#evh_CashReleasedFromEscrow"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_CashReleasedFromEscrow" xlink:to="lab_evh_CashReleasedFromEscrow" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_57ef166f-eb61-43fe-967b-138620ab34ca_totalLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss before income taxes and non-controlling interests</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:to="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_bbad7c14-e8ac-4577-92da-1d78a21f044c_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total future amortization of intangible assets</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_7bbef981-2499-4e0b-95d8-60eed829876d_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_1e2180a0-90c8-4f94-b54c-abc4779e4b3a_periodStartLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance as of beginning of period</link:label>
    <link:label id="lab_us-gaap_Goodwill_d569d005-b65a-4da7-97d0-507e715b34e7_periodEndLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance as of end of period</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ExtinguishmentOfDebtAmount_bfe2bef6-1452-44d9-b9a9-95e32da5385c_terseLabel_en-US" xlink:label="lab_us-gaap_ExtinguishmentOfDebtAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Face amount of debt repaid</link:label>
    <link:label id="lab_us-gaap_ExtinguishmentOfDebtAmount_label_en-US" xlink:label="lab_us-gaap_ExtinguishmentOfDebtAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Extinguishment of Debt, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtinguishmentOfDebtAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ExtinguishmentOfDebtAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ExtinguishmentOfDebtAmount" xlink:to="lab_us-gaap_ExtinguishmentOfDebtAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_d7ff1192-fb05-4df0-aa08-55e83c2e4f62_periodStartLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-controlling interests balance as of beginning of period</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_406ed566-c48a-4252-bc94-8972f5ebd4b1_periodEndLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-controlling interests balance as of end of period</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_PaymentsForProceedsFromClaimsProcessingFinancingActivities_d725f394-4bc5-4182-ac6e-b6e3b53a16aa_negatedTerseLabel_en-US" xlink:label="lab_evh_PaymentsForProceedsFromClaimsProcessingFinancingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in working capital balances related to claims processing on behalf of partners</link:label>
    <link:label id="lab_evh_PaymentsForProceedsFromClaimsProcessingFinancingActivities_label_en-US" xlink:label="lab_evh_PaymentsForProceedsFromClaimsProcessingFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For (Proceeds From) Claims Processing, Financing Activities</link:label>
    <link:label id="lab_evh_PaymentsForProceedsFromClaimsProcessingFinancingActivities_documentation_en-US" xlink:label="lab_evh_PaymentsForProceedsFromClaimsProcessingFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For (Proceeds From) Claims Processing, Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PaymentsForProceedsFromClaimsProcessingFinancingActivities" xlink:href="evh-20210630.xsd#evh_PaymentsForProceedsFromClaimsProcessingFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_PaymentsForProceedsFromClaimsProcessingFinancingActivities" xlink:to="lab_evh_PaymentsForProceedsFromClaimsProcessingFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputPriceVolatilityMember_a4a27a84-1c17-4275-89e0-62de762c9ae4_verboseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock price volatility</link:label>
    <link:label id="lab_us-gaap_MeasurementInputPriceVolatilityMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Price Volatility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_e68f058e-be70-4756-b049-84b35e2d1bf9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation techniques and significant unobservable inputs of Level 3 fair value measurements</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesMember_57a5f9c8-f2e7-41ce-8d43-20a2bb8c6737_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of revenue</link:label>
    <link:label id="lab_us-gaap_CostOfSalesMember_label_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesMember" xlink:to="lab_us-gaap_CostOfSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease_0156a288-b74d-48c4-8742-e813e497b2c4_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change during the year</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Period Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease" xlink:to="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_0396b971-748d-4520-8c3d-e3d6dfcb6e77_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assumption or Input Ranges</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and Rights Outstanding, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_71a12c88-388c-474b-a9a4-9e1fabdbf0ca_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from continuing operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_4760cc98-01c4-4a15-b80e-7659817ac69f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (loss) from continuing operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WriteOffOfDeferredDebtIssuanceCost_e6461d70-1b85-491b-acfb-67d0a3476520_terseLabel_en-US" xlink:label="lab_us-gaap_WriteOffOfDeferredDebtIssuanceCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized debt issuance cost</link:label>
    <link:label id="lab_us-gaap_WriteOffOfDeferredDebtIssuanceCost_label_en-US" xlink:label="lab_us-gaap_WriteOffOfDeferredDebtIssuanceCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Write off of Deferred Debt Issuance Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WriteOffOfDeferredDebtIssuanceCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WriteOffOfDeferredDebtIssuanceCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WriteOffOfDeferredDebtIssuanceCost" xlink:to="lab_us-gaap_WriteOffOfDeferredDebtIssuanceCost" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_FInancialAssetLessThan60DaysMember_bd57fecf-5cd6-401d-96d7-3824beb20f7f_terseLabel_en-US" xlink:label="lab_evh_FInancialAssetLessThan60DaysMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Past due less than 60 days</link:label>
    <link:label id="lab_evh_FInancialAssetLessThan60DaysMember_label_en-US" xlink:label="lab_evh_FInancialAssetLessThan60DaysMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FInancial Asset, Less Than 60 Days [Member]</link:label>
    <link:label id="lab_evh_FInancialAssetLessThan60DaysMember_documentation_en-US" xlink:label="lab_evh_FInancialAssetLessThan60DaysMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FInancial Asset, Less Than 60 Days [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_FInancialAssetLessThan60DaysMember" xlink:href="evh-20210630.xsd#evh_FInancialAssetLessThan60DaysMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_FInancialAssetLessThan60DaysMember" xlink:to="lab_evh_FInancialAssetLessThan60DaysMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_0060c887-e397-4cdb-83c3-6e0c0058dc0f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of goodwill</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6192c513-eb33-4374-adab-4ac565e3c2ff_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash and restricted cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_ef303e8b-6cae-48e5-b056-ad4109c6513e_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_21a07e2e-4909-4de8-b3e4-4860d0245473_terseLabel_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Technology</link:label>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_label_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed Technology Rights [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DevelopedTechnologyRightsMember" xlink:to="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_62488785-245c-4c4d-9de5-b050b0a29a7c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_e3f758f8-a562-4a4f-a0a7-8b4f41854804_terseLabel_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer hardware</link:label>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_label_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember" xlink:to="lab_us-gaap_ComputerEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_6d024f9a-0393-4000-9973-bafa155416b6_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Parties</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_e8e94c1e-b0e2-4ada-a18a-5df3e2b90561_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis_ebf7afe2-d61c-4dd6-b5fd-6bdf7ea862a2_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_AmortizationOfDebtDiscountAndDebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_4d87b79e-e869-4796-bba4-f5bf1998c576_terseLabel_en-US" xlink:label="lab_evh_AmortizationOfDebtDiscountAndDebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash amortization of debt discount and debt issuance costs</link:label>
    <link:label id="lab_evh_AmortizationOfDebtDiscountAndDebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_label_en-US" xlink:label="lab_evh_AmortizationOfDebtDiscountAndDebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization Of Debt Discount And Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction</link:label>
    <link:label id="lab_evh_AmortizationOfDebtDiscountAndDebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_documentation_en-US" xlink:label="lab_evh_AmortizationOfDebtDiscountAndDebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization Of Debt Discount And Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_AmortizationOfDebtDiscountAndDebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:href="evh-20210630.xsd#evh_AmortizationOfDebtDiscountAndDebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_AmortizationOfDebtDiscountAndDebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:to="lab_evh_AmortizationOfDebtDiscountAndDebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock_dc7afe03-7a6d-426c-9d04-a497881ec55b_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, allowance for credit loss</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" xlink:to="lab_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_8ae363fc-0209-4271-ad9f-5826b18c9cac_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_acab2d6a-1391-48f3-9dc5-09564d3a938b_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Paid costs related to current year</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_label_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Current Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" xlink:to="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_DisposalGroupIncludingDiscontinuedOperationRestrictedCashCurrent_f9e53ce8-eae8-44b9-aec4-a90d1678b9ad_terseLabel_en-US" xlink:label="lab_evh_DisposalGroupIncludingDiscontinuedOperationRestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current restricted cash from claims processing services</link:label>
    <link:label id="lab_evh_DisposalGroupIncludingDiscontinuedOperationRestrictedCashCurrent_label_en-US" xlink:label="lab_evh_DisposalGroupIncludingDiscontinuedOperationRestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Restricted Cash, Current</link:label>
    <link:label id="lab_evh_DisposalGroupIncludingDiscontinuedOperationRestrictedCashCurrent_documentation_en-US" xlink:label="lab_evh_DisposalGroupIncludingDiscontinuedOperationRestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Restricted Cash, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DisposalGroupIncludingDiscontinuedOperationRestrictedCashCurrent" xlink:href="evh-20210630.xsd#evh_DisposalGroupIncludingDiscontinuedOperationRestrictedCashCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_DisposalGroupIncludingDiscontinuedOperationRestrictedCashCurrent" xlink:to="lab_evh_DisposalGroupIncludingDiscontinuedOperationRestrictedCashCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201613Member_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201613Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update 2016-13 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201613Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201613Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate201613Member" xlink:to="lab_us-gaap_AccountingStandardsUpdate201613Member" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>evh-20210630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:e4ac7c37-8dd1-4c0a-a2d1-6d13aeec3d41,g:9a076b5a-4bc7-42a9-a1f2-350da80fade7-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CoverPage" xlink:type="simple" xlink:href="evh-20210630.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_127324d1-4c29-420c-b307-2d552662af1f" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_b72c881c-028c-4f81-b596-00163868111e" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_127324d1-4c29-420c-b307-2d552662af1f" xlink:to="loc_dei_DocumentType_b72c881c-028c-4f81-b596-00163868111e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_176bb433-31c2-4d0e-8e09-7051846e1980" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_127324d1-4c29-420c-b307-2d552662af1f" xlink:to="loc_dei_DocumentQuarterlyReport_176bb433-31c2-4d0e-8e09-7051846e1980" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_af6e1394-6fc4-4c9e-8438-f9e4a54894d4" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_127324d1-4c29-420c-b307-2d552662af1f" xlink:to="loc_dei_DocumentPeriodEndDate_af6e1394-6fc4-4c9e-8438-f9e4a54894d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_58092faa-cec1-4c7b-a964-e99a48de42ae" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_127324d1-4c29-420c-b307-2d552662af1f" xlink:to="loc_dei_DocumentTransitionReport_58092faa-cec1-4c7b-a964-e99a48de42ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_15c02cc6-7ad4-497f-baa5-6a19fa652036" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_127324d1-4c29-420c-b307-2d552662af1f" xlink:to="loc_dei_EntityFileNumber_15c02cc6-7ad4-497f-baa5-6a19fa652036" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_a5115f6a-674a-444e-adf5-983748d71082" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_127324d1-4c29-420c-b307-2d552662af1f" xlink:to="loc_dei_EntityRegistrantName_a5115f6a-674a-444e-adf5-983748d71082" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_99a5ca17-1c71-4676-a317-d263cd4abd9b" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_127324d1-4c29-420c-b307-2d552662af1f" xlink:to="loc_dei_EntityIncorporationStateCountryCode_99a5ca17-1c71-4676-a317-d263cd4abd9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_a116e42c-4d93-4abf-8458-d1743468d178" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_127324d1-4c29-420c-b307-2d552662af1f" xlink:to="loc_dei_EntityTaxIdentificationNumber_a116e42c-4d93-4abf-8458-d1743468d178" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_e679fcdc-4f74-457f-94b6-5f0fba96db79" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_127324d1-4c29-420c-b307-2d552662af1f" xlink:to="loc_dei_EntityAddressAddressLine1_e679fcdc-4f74-457f-94b6-5f0fba96db79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_c9557639-bb23-42c8-93ee-228480f8380e" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_127324d1-4c29-420c-b307-2d552662af1f" xlink:to="loc_dei_EntityAddressAddressLine2_c9557639-bb23-42c8-93ee-228480f8380e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_426c8308-e277-4ad8-9f42-df3354d55a98" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_127324d1-4c29-420c-b307-2d552662af1f" xlink:to="loc_dei_EntityAddressCityOrTown_426c8308-e277-4ad8-9f42-df3354d55a98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_88f5c733-a043-4d80-a8ab-bdf68a294b5f" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_127324d1-4c29-420c-b307-2d552662af1f" xlink:to="loc_dei_EntityAddressStateOrProvince_88f5c733-a043-4d80-a8ab-bdf68a294b5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_ee0656a9-ac1a-462e-8c7d-318a30317d4c" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_127324d1-4c29-420c-b307-2d552662af1f" xlink:to="loc_dei_EntityAddressPostalZipCode_ee0656a9-ac1a-462e-8c7d-318a30317d4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_2222de28-b540-4564-88c8-16a07bb5cef2" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_127324d1-4c29-420c-b307-2d552662af1f" xlink:to="loc_dei_CityAreaCode_2222de28-b540-4564-88c8-16a07bb5cef2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_7e0787da-50a1-4543-b983-3d93e471e534" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_127324d1-4c29-420c-b307-2d552662af1f" xlink:to="loc_dei_LocalPhoneNumber_7e0787da-50a1-4543-b983-3d93e471e534" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_711f6ed2-4c66-4a76-add8-1add4e41ddb2" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_127324d1-4c29-420c-b307-2d552662af1f" xlink:to="loc_dei_Security12bTitle_711f6ed2-4c66-4a76-add8-1add4e41ddb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_9fa8476e-a863-4a45-ba76-468954384c41" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_127324d1-4c29-420c-b307-2d552662af1f" xlink:to="loc_dei_TradingSymbol_9fa8476e-a863-4a45-ba76-468954384c41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_2004a0dc-e8a7-4a7c-b467-37ab36e95498" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_127324d1-4c29-420c-b307-2d552662af1f" xlink:to="loc_dei_SecurityExchangeName_2004a0dc-e8a7-4a7c-b467-37ab36e95498" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_587acb84-6a99-4b08-b19e-8159a0a33252" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_127324d1-4c29-420c-b307-2d552662af1f" xlink:to="loc_dei_EntityCurrentReportingStatus_587acb84-6a99-4b08-b19e-8159a0a33252" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_128120fa-df0a-4693-9fad-25c2a9cebc05" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_127324d1-4c29-420c-b307-2d552662af1f" xlink:to="loc_dei_EntityInteractiveDataCurrent_128120fa-df0a-4693-9fad-25c2a9cebc05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_c38e7663-0e45-4e0c-a89a-c74158cc9152" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_127324d1-4c29-420c-b307-2d552662af1f" xlink:to="loc_dei_EntityFilerCategory_c38e7663-0e45-4e0c-a89a-c74158cc9152" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_16f58108-7190-4f84-847e-d6954e130757" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_127324d1-4c29-420c-b307-2d552662af1f" xlink:to="loc_dei_EntitySmallBusiness_16f58108-7190-4f84-847e-d6954e130757" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_ae83b847-391f-4aeb-bb59-92d6379d29d2" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_127324d1-4c29-420c-b307-2d552662af1f" xlink:to="loc_dei_EntityEmergingGrowthCompany_ae83b847-391f-4aeb-bb59-92d6379d29d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_7cbf9a1e-7d66-4947-84ae-faa1d07e73e0" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_127324d1-4c29-420c-b307-2d552662af1f" xlink:to="loc_dei_EntityShellCompany_7cbf9a1e-7d66-4947-84ae-faa1d07e73e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_89921517-24e6-4c68-87cb-0adff7ad68c9" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_127324d1-4c29-420c-b307-2d552662af1f" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_89921517-24e6-4c68-87cb-0adff7ad68c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_1f82377b-e90c-4d83-9d82-f282f49b6d4c" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_127324d1-4c29-420c-b307-2d552662af1f" xlink:to="loc_dei_EntityCentralIndexKey_1f82377b-e90c-4d83-9d82-f282f49b6d4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_540bc1bc-dce3-4c39-9070-f0b960b3ae0d" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_127324d1-4c29-420c-b307-2d552662af1f" xlink:to="loc_dei_AmendmentFlag_540bc1bc-dce3-4c39-9070-f0b960b3ae0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_f506f320-9108-4f37-8058-b06b5a4c2325" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_127324d1-4c29-420c-b307-2d552662af1f" xlink:to="loc_dei_CurrentFiscalYearEndDate_f506f320-9108-4f37-8058-b06b5a4c2325" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_b8f89ef2-1e8a-43a1-b2ae-bf92b12165ff" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_127324d1-4c29-420c-b307-2d552662af1f" xlink:to="loc_dei_DocumentFiscalYearFocus_b8f89ef2-1e8a-43a1-b2ae-bf92b12165ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_3daeaeb1-0b66-4f2f-a366-0e51e462ae72" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_127324d1-4c29-420c-b307-2d552662af1f" xlink:to="loc_dei_DocumentFiscalPeriodFocus_3daeaeb1-0b66-4f2f-a366-0e51e462ae72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="evh-20210630.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_317f19f4-fca2-482f-b5d9-898724394af9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_20acaa19-b36c-46fa-b230-1f883a59cf38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_317f19f4-fca2-482f-b5d9-898724394af9" xlink:to="loc_us-gaap_StatementTable_20acaa19-b36c-46fa-b230-1f883a59cf38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1f652908-fa7e-4311-8dad-840dfc749e28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_20acaa19-b36c-46fa-b230-1f883a59cf38" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1f652908-fa7e-4311-8dad-840dfc749e28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_8d30720a-b0c2-4f12-8852-7357b0f62d19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1f652908-fa7e-4311-8dad-840dfc749e28" xlink:to="loc_us-gaap_ClassOfStockDomain_8d30720a-b0c2-4f12-8852-7357b0f62d19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_3657d8ad-fe12-46ec-b827-13da7a3f4e08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_8d30720a-b0c2-4f12-8852-7357b0f62d19" xlink:to="loc_us-gaap_CommonClassAMember_3657d8ad-fe12-46ec-b827-13da7a3f4e08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_e886335e-b48d-4946-87b8-705903e210b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_20acaa19-b36c-46fa-b230-1f883a59cf38" xlink:to="loc_us-gaap_StatementLineItems_e886335e-b48d-4946-87b8-705903e210b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_a05c04ad-3226-4166-b7fa-130463856424" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e886335e-b48d-4946-87b8-705903e210b0" xlink:to="loc_us-gaap_AssetsAbstract_a05c04ad-3226-4166-b7fa-130463856424" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_4c209e74-2762-4838-9c36-4eb424756c1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_a05c04ad-3226-4166-b7fa-130463856424" xlink:to="loc_us-gaap_AssetsCurrentAbstract_4c209e74-2762-4838-9c36-4eb424756c1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_0ead1194-99db-4895-9233-e3e323b7db1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_4c209e74-2762-4838-9c36-4eb424756c1b" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_0ead1194-99db-4895-9233-e3e323b7db1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndInvestmentsCurrent_0955788a-f608-4984-9625-f51e5b8469ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndInvestmentsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_4c209e74-2762-4838-9c36-4eb424756c1b" xlink:to="loc_us-gaap_RestrictedCashAndInvestmentsCurrent_0955788a-f608-4984-9625-f51e5b8469ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_eb33f4f7-edd9-442e-b84b-3930a198a2cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_4c209e74-2762-4838-9c36-4eb424756c1b" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_eb33f4f7-edd9-442e-b84b-3930a198a2cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_8c9f67f9-cf03-4d2d-aec8-873dac47dd92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_4c209e74-2762-4838-9c36-4eb424756c1b" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_8c9f67f9-cf03-4d2d-aec8-873dac47dd92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_15564070-dee5-4fbe-a665-d70ee527babf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_4c209e74-2762-4838-9c36-4eb424756c1b" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_15564070-dee5-4fbe-a665-d70ee527babf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_3593f7f0-861e-47d4-a0dc-05943d81b327" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_4c209e74-2762-4838-9c36-4eb424756c1b" xlink:to="loc_us-gaap_AssetsCurrent_3593f7f0-861e-47d4-a0dc-05943d81b327" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndInvestmentsNoncurrent_15d06274-043c-4402-a9b3-3427816a4d05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndInvestmentsNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_a05c04ad-3226-4166-b7fa-130463856424" xlink:to="loc_us-gaap_RestrictedCashAndInvestmentsNoncurrent_15d06274-043c-4402-a9b3-3427816a4d05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_4f071538-419c-419d-b496-19c71c461bcd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_a05c04ad-3226-4166-b7fa-130463856424" xlink:to="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_4f071538-419c-419d-b496-19c71c461bcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_6b56812e-6a84-459c-957c-180e2c8fd075" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_a05c04ad-3226-4166-b7fa-130463856424" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_6b56812e-6a84-459c-957c-180e2c8fd075" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_84f68576-0e37-4a01-a763-86d12ed5c2fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_a05c04ad-3226-4166-b7fa-130463856424" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_84f68576-0e37-4a01-a763-86d12ed5c2fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_f7f78ff9-6df9-47a0-8273-6957e2c7b2f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_a05c04ad-3226-4166-b7fa-130463856424" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_f7f78ff9-6df9-47a0-8273-6957e2c7b2f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostNetNoncurrent_dc87451f-8e08-4e88-84fc-395bf02a5e62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedContractCostNetNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_a05c04ad-3226-4166-b7fa-130463856424" xlink:to="loc_us-gaap_CapitalizedContractCostNetNoncurrent_dc87451f-8e08-4e88-84fc-395bf02a5e62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_3c3ee582-af89-4367-8fd1-e6893b43820d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_a05c04ad-3226-4166-b7fa-130463856424" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_3c3ee582-af89-4367-8fd1-e6893b43820d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_2af7d343-d361-4f22-910e-d51fca564afd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_a05c04ad-3226-4166-b7fa-130463856424" xlink:to="loc_us-gaap_Goodwill_2af7d343-d361-4f22-910e-d51fca564afd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_6ca357b2-ef9e-4eba-8eb3-48c1736f0556" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_a05c04ad-3226-4166-b7fa-130463856424" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_6ca357b2-ef9e-4eba-8eb3-48c1736f0556" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_d5ac6ba8-602b-4476-bd18-3667f387275b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_a05c04ad-3226-4166-b7fa-130463856424" xlink:to="loc_us-gaap_Assets_d5ac6ba8-602b-4476-bd18-3667f387275b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_feb34743-e716-48d0-a159-b298f70e8910" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e886335e-b48d-4946-87b8-705903e210b0" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_feb34743-e716-48d0-a159-b298f70e8910" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract_724f7eca-776e-404c-8768-304d0e476168" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_feb34743-e716-48d0-a159-b298f70e8910" xlink:to="loc_us-gaap_LiabilitiesAbstract_724f7eca-776e-404c-8768-304d0e476168" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_c594f381-c8ed-4e2c-b3b8-576f216e7945" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_724f7eca-776e-404c-8768-304d0e476168" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_c594f381-c8ed-4e2c-b3b8-576f216e7945" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_01f3ea4d-1e91-4d1b-84ad-4e3ac6d3868a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c594f381-c8ed-4e2c-b3b8-576f216e7945" xlink:to="loc_us-gaap_AccountsPayableCurrent_01f3ea4d-1e91-4d1b-84ad-4e3ac6d3868a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_188b5e9d-2cd0-4961-a8c2-ecc58b47bd71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c594f381-c8ed-4e2c-b3b8-576f216e7945" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_188b5e9d-2cd0-4961-a8c2-ecc58b47bd71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_5c11003f-2ab0-4cd9-bc55-7c636d12b1cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c594f381-c8ed-4e2c-b3b8-576f216e7945" xlink:to="loc_us-gaap_LongTermDebtCurrent_5c11003f-2ab0-4cd9-bc55-7c636d12b1cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_5f8a5418-7cc8-4322-bb4a-6e9113a6ae34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c594f381-c8ed-4e2c-b3b8-576f216e7945" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_5f8a5418-7cc8-4322-bb4a-6e9113a6ae34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_8e7fb362-465e-4a7c-ba38-9bb7bf4448f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c594f381-c8ed-4e2c-b3b8-576f216e7945" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_8e7fb362-465e-4a7c-ba38-9bb7bf4448f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_3dcf54ed-2495-4340-9fd9-feda81477696" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c594f381-c8ed-4e2c-b3b8-576f216e7945" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_3dcf54ed-2495-4340-9fd9-feda81477696" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements_c59be174-4cf9-4e94-ac90-bd414dd47d1a" xlink:href="evh-20210630.xsd#evh_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c594f381-c8ed-4e2c-b3b8-576f216e7945" xlink:to="loc_evh_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements_c59be174-4cf9-4e94-ac90-bd414dd47d1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_c895438d-c819-464b-aa4d-a1e7d177b288" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c594f381-c8ed-4e2c-b3b8-576f216e7945" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_c895438d-c819-464b-aa4d-a1e7d177b288" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_073efda9-de5f-42d4-841f-ddf58f6ee35a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c594f381-c8ed-4e2c-b3b8-576f216e7945" xlink:to="loc_us-gaap_LiabilitiesCurrent_073efda9-de5f-42d4-841f-ddf58f6ee35a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_92d609bd-cfe9-4361-9c0b-f21fc1b1e0ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_724f7eca-776e-404c-8768-304d0e476168" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_92d609bd-cfe9-4361-9c0b-f21fc1b1e0ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_d8f8ba80-a534-4b9b-8464-0304ee342828" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_724f7eca-776e-404c-8768-304d0e476168" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_d8f8ba80-a534-4b9b-8464-0304ee342828" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_6d176bf4-d3c7-4303-9d4e-94d029be3905" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_724f7eca-776e-404c-8768-304d0e476168" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_6d176bf4-d3c7-4303-9d4e-94d029be3905" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_a5f52ea8-d2e9-4171-bfcb-51723f35ce8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_724f7eca-776e-404c-8768-304d0e476168" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_a5f52ea8-d2e9-4171-bfcb-51723f35ce8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_bf54c174-5568-429f-8722-0dbaf6804776" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_724f7eca-776e-404c-8768-304d0e476168" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_bf54c174-5568-429f-8722-0dbaf6804776" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_89e74357-c2da-4015-81b9-b0900d706345" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_724f7eca-776e-404c-8768-304d0e476168" xlink:to="loc_us-gaap_Liabilities_89e74357-c2da-4015-81b9-b0900d706345" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_2bfb46f2-f2e1-4db7-a320-3bea428918fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_feb34743-e716-48d0-a159-b298f70e8910" xlink:to="loc_us-gaap_CommitmentsAndContingencies_2bfb46f2-f2e1-4db7-a320-3bea428918fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_61cd3e6e-e102-40d0-9216-113c2a25fe25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_feb34743-e716-48d0-a159-b298f70e8910" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_61cd3e6e-e102-40d0-9216-113c2a25fe25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_bf66962a-25ab-4fc1-8035-b0df2d66994a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_61cd3e6e-e102-40d0-9216-113c2a25fe25" xlink:to="loc_us-gaap_CommonStockValue_bf66962a-25ab-4fc1-8035-b0df2d66994a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_71c06511-2116-4a86-a025-ead2437063df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_61cd3e6e-e102-40d0-9216-113c2a25fe25" xlink:to="loc_us-gaap_AdditionalPaidInCapital_71c06511-2116-4a86-a025-ead2437063df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_08a3c09f-b36e-445a-8122-4f14a19bcc29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_61cd3e6e-e102-40d0-9216-113c2a25fe25" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_08a3c09f-b36e-445a-8122-4f14a19bcc29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_3bc1851e-8789-42fd-8409-227ea03976a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_61cd3e6e-e102-40d0-9216-113c2a25fe25" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_3bc1851e-8789-42fd-8409-227ea03976a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_f80db627-751e-4c67-b056-8d110292d587" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_61cd3e6e-e102-40d0-9216-113c2a25fe25" xlink:to="loc_us-gaap_TreasuryStockValue_f80db627-751e-4c67-b056-8d110292d587" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_253c8b90-ac9d-4f6f-b328-66084d178d5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_61cd3e6e-e102-40d0-9216-113c2a25fe25" xlink:to="loc_us-gaap_StockholdersEquity_253c8b90-ac9d-4f6f-b328-66084d178d5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_ea261065-adcc-4eef-9a7a-d834b7e412b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_feb34743-e716-48d0-a159-b298f70e8910" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_ea261065-adcc-4eef-9a7a-d834b7e412b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="evh-20210630.xsd#CONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_d24ebf90-7d2c-4be9-bbf8-21bc517e5ae0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_cd726de5-b471-4aea-9713-01623e9a0da7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_d24ebf90-7d2c-4be9-bbf8-21bc517e5ae0" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_cd726de5-b471-4aea-9713-01623e9a0da7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_630c2daf-f4ee-4aeb-9708-62d49bb7c8f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_d24ebf90-7d2c-4be9-bbf8-21bc517e5ae0" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_630c2daf-f4ee-4aeb-9708-62d49bb7c8f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_47972f5c-31fa-43d9-9886-5bdffb01cd82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_d24ebf90-7d2c-4be9-bbf8-21bc517e5ae0" xlink:to="loc_us-gaap_CommonStockSharesIssued_47972f5c-31fa-43d9-9886-5bdffb01cd82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares_5af267c0-6b51-48f7-b41d-023a04aca663" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockShares"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_d24ebf90-7d2c-4be9-bbf8-21bc517e5ae0" xlink:to="loc_us-gaap_TreasuryStockShares_5af267c0-6b51-48f7-b41d-023a04aca663" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS" xlink:type="simple" xlink:href="evh-20210630.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_0c997d68-4b78-4ac7-9098-de4d85cf4b42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_8424ad67-0bd3-4460-b3d1-59dfe3631d71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0c997d68-4b78-4ac7-9098-de4d85cf4b42" xlink:to="loc_us-gaap_StatementTable_8424ad67-0bd3-4460-b3d1-59dfe3631d71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_86683530-308b-4926-9119-5e058dc20873" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_8424ad67-0bd3-4460-b3d1-59dfe3631d71" xlink:to="loc_srt_ProductOrServiceAxis_86683530-308b-4926-9119-5e058dc20873" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_9c1e7c28-1fca-4792-8a1a-d297b3ec1a3e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_86683530-308b-4926-9119-5e058dc20873" xlink:to="loc_srt_ProductsAndServicesDomain_9c1e7c28-1fca-4792-8a1a-d297b3ec1a3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TransformationServicesMember_70080f30-2755-4fd3-939f-51986be16daf" xlink:href="evh-20210630.xsd#evh_TransformationServicesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_9c1e7c28-1fca-4792-8a1a-d297b3ec1a3e" xlink:to="loc_evh_TransformationServicesMember_70080f30-2755-4fd3-939f-51986be16daf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PlatformsAndOperationsServicesMember_ffe5b61e-1669-49a3-88c6-98bba1d5dfb4" xlink:href="evh-20210630.xsd#evh_PlatformsAndOperationsServicesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_9c1e7c28-1fca-4792-8a1a-d297b3ec1a3e" xlink:to="loc_evh_PlatformsAndOperationsServicesMember_ffe5b61e-1669-49a3-88c6-98bba1d5dfb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_b47e500d-8a8b-43d3-8f9a-378b9f62562c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_8424ad67-0bd3-4460-b3d1-59dfe3631d71" xlink:to="loc_us-gaap_StatementLineItems_b47e500d-8a8b-43d3-8f9a-378b9f62562c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_629fa98a-ea1b-406f-b5df-d1e59cd765b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b47e500d-8a8b-43d3-8f9a-378b9f62562c" xlink:to="loc_us-gaap_RevenuesAbstract_629fa98a-ea1b-406f-b5df-d1e59cd765b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_6e78df9d-11d8-453a-bd2c-72ba4786cd46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_629fa98a-ea1b-406f-b5df-d1e59cd765b3" xlink:to="loc_us-gaap_Revenues_6e78df9d-11d8-453a-bd2c-72ba4786cd46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_31a96d80-0aaf-4b28-bc30-e4960b8b008c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b47e500d-8a8b-43d3-8f9a-378b9f62562c" xlink:to="loc_us-gaap_OperatingExpensesAbstract_31a96d80-0aaf-4b28-bc30-e4960b8b008c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CostofGoodsandServicesSoldExcludingDepreciationandAmortization_227cec47-bf90-49f6-800c-495eb7284945" xlink:href="evh-20210630.xsd#evh_CostofGoodsandServicesSoldExcludingDepreciationandAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_31a96d80-0aaf-4b28-bc30-e4960b8b008c" xlink:to="loc_evh_CostofGoodsandServicesSoldExcludingDepreciationandAmortization_227cec47-bf90-49f6-800c-495eb7284945" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_87ab9b48-2094-4a9b-b552-e4a262efc1ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_31a96d80-0aaf-4b28-bc30-e4960b8b008c" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_87ab9b48-2094-4a9b-b552-e4a262efc1ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_2ff29f75-3286-4e08-b3d7-de5a75393271" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_31a96d80-0aaf-4b28-bc30-e4960b8b008c" xlink:to="loc_us-gaap_DepreciationAndAmortization_2ff29f75-3286-4e08-b3d7-de5a75393271" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_716b78a7-b6b7-4063-bf21-165f577d3bbc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_31a96d80-0aaf-4b28-bc30-e4960b8b008c" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_716b78a7-b6b7-4063-bf21-165f577d3bbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_20967d2f-d36d-4aae-9a74-3b56c24bd82a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_31a96d80-0aaf-4b28-bc30-e4960b8b008c" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_20967d2f-d36d-4aae-9a74-3b56c24bd82a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_47e775f6-df6d-4ba8-8bbd-feccc7bf207b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_31a96d80-0aaf-4b28-bc30-e4960b8b008c" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_47e775f6-df6d-4ba8-8bbd-feccc7bf207b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_8416a98a-fb0b-4b82-9a62-bd95ef247fd2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_31a96d80-0aaf-4b28-bc30-e4960b8b008c" xlink:to="loc_us-gaap_OperatingExpenses_8416a98a-fb0b-4b82-9a62-bd95ef247fd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_be711bfb-e29d-4974-9c5f-9e5622e1ae10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b47e500d-8a8b-43d3-8f9a-378b9f62562c" xlink:to="loc_us-gaap_OperatingIncomeLoss_be711bfb-e29d-4974-9c5f-9e5622e1ae10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_24883859-e3b0-412a-a238-d42b9d26c5f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b47e500d-8a8b-43d3-8f9a-378b9f62562c" xlink:to="loc_us-gaap_InvestmentIncomeInterest_24883859-e3b0-412a-a238-d42b9d26c5f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_bef4aaa1-2621-49ab-a170-683d5d5db126" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b47e500d-8a8b-43d3-8f9a-378b9f62562c" xlink:to="loc_us-gaap_InterestExpense_bef4aaa1-2621-49ab-a170-683d5d5db126" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_b3f54365-2a9b-43ea-ac4b-aa0f96399e3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b47e500d-8a8b-43d3-8f9a-378b9f62562c" xlink:to="loc_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_b3f54365-2a9b-43ea-ac4b-aa0f96399e3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_8161343d-dab7-4e78-8d31-0db3148232ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b47e500d-8a8b-43d3-8f9a-378b9f62562c" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_8161343d-dab7-4e78-8d31-0db3148232ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_GainOnTransferOfMembership_29640914-156d-41b4-bec6-0371de959be1" xlink:href="evh-20210630.xsd#evh_GainOnTransferOfMembership"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b47e500d-8a8b-43d3-8f9a-378b9f62562c" xlink:to="loc_evh_GainOnTransferOfMembership_29640914-156d-41b4-bec6-0371de959be1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_b0618d76-fe98-4fab-a9d8-b65c01cc9a27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b47e500d-8a8b-43d3-8f9a-378b9f62562c" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_b0618d76-fe98-4fab-a9d8-b65c01cc9a27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_174d129b-5387-4e29-9ae2-bbb3fe049483" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b47e500d-8a8b-43d3-8f9a-378b9f62562c" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_174d129b-5387-4e29-9ae2-bbb3fe049483" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d4cbc2dc-3ce8-40b9-be4d-4ffd754c25be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b47e500d-8a8b-43d3-8f9a-378b9f62562c" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d4cbc2dc-3ce8-40b9-be4d-4ffd754c25be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_c48c5371-a1ad-45e3-a7c1-3f4b13800b04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b47e500d-8a8b-43d3-8f9a-378b9f62562c" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_c48c5371-a1ad-45e3-a7c1-3f4b13800b04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_b967e44d-5d91-42a8-ad11-1a4d55d4f1c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b47e500d-8a8b-43d3-8f9a-378b9f62562c" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_b967e44d-5d91-42a8-ad11-1a4d55d4f1c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_fa6e96b2-a3a4-4132-945a-8c537c5f1bd1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b47e500d-8a8b-43d3-8f9a-378b9f62562c" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_fa6e96b2-a3a4-4132-945a-8c537c5f1bd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_640b736d-d0e2-4574-81d8-aed3b620f9cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b47e500d-8a8b-43d3-8f9a-378b9f62562c" xlink:to="loc_us-gaap_ProfitLoss_640b736d-d0e2-4574-81d8-aed3b620f9cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_d0dcf301-b15d-420b-b8cd-b9ac0aa82e03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b47e500d-8a8b-43d3-8f9a-378b9f62562c" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_d0dcf301-b15d-420b-b8cd-b9ac0aa82e03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_05c00e63-4069-48ac-8394-3ceaef801572" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b47e500d-8a8b-43d3-8f9a-378b9f62562c" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_05c00e63-4069-48ac-8394-3ceaef801572" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_5d58ef72-729a-4243-8e59-d671cec0fdca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b47e500d-8a8b-43d3-8f9a-378b9f62562c" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_5d58ef72-729a-4243-8e59-d671cec0fdca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_a4c3fb0b-2a47-4253-aece-42addf380888" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b47e500d-8a8b-43d3-8f9a-378b9f62562c" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_a4c3fb0b-2a47-4253-aece-42addf380888" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_7bab8aba-a4bd-4ca1-90bb-2055bb3586ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_a4c3fb0b-2a47-4253-aece-42addf380888" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_7bab8aba-a4bd-4ca1-90bb-2055bb3586ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_f4c30bda-0692-4da9-83b5-eca6ceed3cf9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_a4c3fb0b-2a47-4253-aece-42addf380888" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_f4c30bda-0692-4da9-83b5-eca6ceed3cf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_fe56611c-dc4f-428c-9c30-184bf3f7a656" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_a4c3fb0b-2a47-4253-aece-42addf380888" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_fe56611c-dc4f-428c-9c30-184bf3f7a656" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_eeb860e3-764a-48c2-9cd0-ae63d7f47e38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_a4c3fb0b-2a47-4253-aece-42addf380888" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_eeb860e3-764a-48c2-9cd0-ae63d7f47e38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_cfcdc74f-cc52-4673-81bb-61676b7f78fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_a4c3fb0b-2a47-4253-aece-42addf380888" xlink:to="loc_us-gaap_EarningsPerShareBasic_cfcdc74f-cc52-4673-81bb-61676b7f78fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_1feea432-6c91-4016-bf1b-50f4d52da91f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_a4c3fb0b-2a47-4253-aece-42addf380888" xlink:to="loc_us-gaap_EarningsPerShareDiluted_1feea432-6c91-4016-bf1b-50f4d52da91f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_523a3bc9-3e66-4632-946b-8096eb690072" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b47e500d-8a8b-43d3-8f9a-378b9f62562c" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_523a3bc9-3e66-4632-946b-8096eb690072" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_61aeab7b-8856-4ee2-8a2f-2001b966dcb8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_523a3bc9-3e66-4632-946b-8096eb690072" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_61aeab7b-8856-4ee2-8a2f-2001b966dcb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_bebdfe32-2da9-4e3b-b8c9-5ba002291cec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_523a3bc9-3e66-4632-946b-8096eb690072" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_bebdfe32-2da9-4e3b-b8c9-5ba002291cec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract_df096fc3-a92c-4b9b-b2d5-1e3757700395" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b47e500d-8a8b-43d3-8f9a-378b9f62562c" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract_df096fc3-a92c-4b9b-b2d5-1e3757700395" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_0c9ed9f2-d4ae-45cb-8f8c-3a75a7400501" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract_df096fc3-a92c-4b9b-b2d5-1e3757700395" xlink:to="loc_us-gaap_ProfitLoss_0c9ed9f2-d4ae-45cb-8f8c-3a75a7400501" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_4691ed36-c500-4162-bfaf-4e6df5d98271" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract_df096fc3-a92c-4b9b-b2d5-1e3757700395" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_4691ed36-c500-4162-bfaf-4e6df5d98271" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_3ec0e632-cd3b-403e-a47a-2266455060c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_4691ed36-c500-4162-bfaf-4e6df5d98271" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_3ec0e632-cd3b-403e-a47a-2266455060c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_281cd027-2dcb-4254-99e7-089432e2fbfb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract_df096fc3-a92c-4b9b-b2d5-1e3757700395" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_281cd027-2dcb-4254-99e7-089432e2fbfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_ef4ce538-d256-4f06-80fa-777665dc738f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract_df096fc3-a92c-4b9b-b2d5-1e3757700395" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_ef4ce538-d256-4f06-80fa-777665dc738f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_60d1c8f6-a600-4b80-b351-70c5a55c067b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract_df096fc3-a92c-4b9b-b2d5-1e3757700395" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_60d1c8f6-a600-4b80-b351-70c5a55c067b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSSParenthetical" xlink:type="simple" xlink:href="evh-20210630.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSSParenthetical"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_07d003d3-ec12-4bc8-950a-125016f2861b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax_28522ab2-7473-4b43-84c3-a2203e128899" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_07d003d3-ec12-4bc8-950a-125016f2861b" xlink:to="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax_28522ab2-7473-4b43-84c3-a2203e128899" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYDEFICIT" xlink:type="simple" xlink:href="evh-20210630.xsd#CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYDEFICIT"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYDEFICIT" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_7959c350-9a4c-44a6-8637-a76b7423f121" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_cdce430d-b937-4898-aac6-8925f2c0e2f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_7959c350-9a4c-44a6-8637-a76b7423f121" xlink:to="loc_us-gaap_StatementTable_cdce430d-b937-4898-aac6-8925f2c0e2f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_78541a8f-5b72-46e8-9852-9f9900a97221" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_cdce430d-b937-4898-aac6-8925f2c0e2f4" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_78541a8f-5b72-46e8-9852-9f9900a97221" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_08ba8e9f-f51c-4e2e-9bd8-071da32e7707" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_78541a8f-5b72-46e8-9852-9f9900a97221" xlink:to="loc_us-gaap_EquityComponentDomain_08ba8e9f-f51c-4e2e-9bd8-071da32e7707" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember_4eb5f8d3-6ed5-4197-bc8a-addab24feb26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ParentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_08ba8e9f-f51c-4e2e-9bd8-071da32e7707" xlink:to="loc_us-gaap_ParentMember_4eb5f8d3-6ed5-4197-bc8a-addab24feb26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_ff2ed16a-ab0f-4596-bd67-869da54121b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_4eb5f8d3-6ed5-4197-bc8a-addab24feb26" xlink:to="loc_us-gaap_CommonStockMember_ff2ed16a-ab0f-4596-bd67-869da54121b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_7c7a4e7f-674a-4d58-8ffa-6b9d7f2f318d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_4eb5f8d3-6ed5-4197-bc8a-addab24feb26" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_7c7a4e7f-674a-4d58-8ffa-6b9d7f2f318d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_e977bb35-0ff9-4f12-abfe-97df7ddc1469" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_4eb5f8d3-6ed5-4197-bc8a-addab24feb26" xlink:to="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_e977bb35-0ff9-4f12-abfe-97df7ddc1469" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_ade2939a-72ae-4f46-89d3-84e84e4acb71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_4eb5f8d3-6ed5-4197-bc8a-addab24feb26" xlink:to="loc_us-gaap_RetainedEarningsMember_ade2939a-72ae-4f46-89d3-84e84e4acb71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_90d7f79b-ab51-44df-bc35-56c845463eaf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_4eb5f8d3-6ed5-4197-bc8a-addab24feb26" xlink:to="loc_us-gaap_TreasuryStockMember_90d7f79b-ab51-44df-bc35-56c845463eaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_78a32b2f-55e6-4bfa-bb6c-2709a5d54087" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_08ba8e9f-f51c-4e2e-9bd8-071da32e7707" xlink:to="loc_us-gaap_NoncontrollingInterestMember_78a32b2f-55e6-4bfa-bb6c-2709a5d54087" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_91aeb924-7171-4fd2-8e5c-eef48bda0c86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_cdce430d-b937-4898-aac6-8925f2c0e2f4" xlink:to="loc_us-gaap_StatementClassOfStockAxis_91aeb924-7171-4fd2-8e5c-eef48bda0c86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_ab617d9a-c62a-4b6b-af84-e08416697cae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_91aeb924-7171-4fd2-8e5c-eef48bda0c86" xlink:to="loc_us-gaap_ClassOfStockDomain_ab617d9a-c62a-4b6b-af84-e08416697cae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_835be012-aa63-47c1-9c9d-07f40f58a44a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_ab617d9a-c62a-4b6b-af84-e08416697cae" xlink:to="loc_us-gaap_CommonClassAMember_835be012-aa63-47c1-9c9d-07f40f58a44a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_c7d18e15-036a-42f8-b8e8-936ca1ab7a79" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_cdce430d-b937-4898-aac6-8925f2c0e2f4" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_c7d18e15-036a-42f8-b8e8-936ca1ab7a79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_2e4a1025-7fff-4f77-9d18-75e944ee0792" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_c7d18e15-036a-42f8-b8e8-936ca1ab7a79" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_2e4a1025-7fff-4f77-9d18-75e944ee0792" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_61affc29-25b9-4093-8410-f24429c38574" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_2e4a1025-7fff-4f77-9d18-75e944ee0792" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_61affc29-25b9-4093-8410-f24429c38574" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_c5c830c8-0098-41b9-b871-fb7b402f4e8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_cdce430d-b937-4898-aac6-8925f2c0e2f4" xlink:to="loc_us-gaap_StatementLineItems_c5c830c8-0098-41b9-b871-fb7b402f4e8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_690b78a1-3d99-489e-8b8d-f042247bbbf1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c5c830c8-0098-41b9-b871-fb7b402f4e8d" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_690b78a1-3d99-489e-8b8d-f042247bbbf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_68f9d2ef-9798-4746-863c-7b1b098f0f0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_690b78a1-3d99-489e-8b8d-f042247bbbf1" xlink:to="loc_us-gaap_SharesIssued_68f9d2ef-9798-4746-863c-7b1b098f0f0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2f14ca44-b031-427e-bf8a-50ee7a5967e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_690b78a1-3d99-489e-8b8d-f042247bbbf1" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2f14ca44-b031-427e-bf8a-50ee7a5967e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList_749789d9-cdae-44b0-8282-52daf313d7b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_690b78a1-3d99-489e-8b8d-f042247bbbf1" xlink:to="loc_us-gaap_AccountingStandardsUpdateExtensibleList_749789d9-cdae-44b0-8282-52daf313d7b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_666d365d-fe98-460d-be1c-f3ad85961862" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_690b78a1-3d99-489e-8b8d-f042247bbbf1" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_666d365d-fe98-460d-be1c-f3ad85961862" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_5cf4e911-ec59-4cbd-965f-72f632b71209" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_690b78a1-3d99-489e-8b8d-f042247bbbf1" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_5cf4e911-ec59-4cbd-965f-72f632b71209" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_171168ac-453e-40bb-b2d3-7c1c313d8f43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_690b78a1-3d99-489e-8b8d-f042247bbbf1" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_171168ac-453e-40bb-b2d3-7c1c313d8f43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_0467eade-11d9-4406-a11c-f233ace0b32f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_690b78a1-3d99-489e-8b8d-f042247bbbf1" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_0467eade-11d9-4406-a11c-f233ace0b32f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_ef128b7a-dfc9-49db-b030-75e8a0fe896c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_690b78a1-3d99-489e-8b8d-f042247bbbf1" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_ef128b7a-dfc9-49db-b030-75e8a0fe896c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_StockVestedAndRetiredDuringPeriodShares_b202dd3d-deb0-49c1-ad55-5a19548e91a2" xlink:href="evh-20210630.xsd#evh_StockVestedAndRetiredDuringPeriodShares"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_690b78a1-3d99-489e-8b8d-f042247bbbf1" xlink:to="loc_evh_StockVestedAndRetiredDuringPeriodShares_b202dd3d-deb0-49c1-ad55-5a19548e91a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_StockVestedAndRetiredDuringPeriodValue_adc4f240-7689-451f-b205-2acb10052330" xlink:href="evh-20210630.xsd#evh_StockVestedAndRetiredDuringPeriodValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_690b78a1-3d99-489e-8b8d-f042247bbbf1" xlink:to="loc_evh_StockVestedAndRetiredDuringPeriodValue_adc4f240-7689-451f-b205-2acb10052330" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_a8e6abb6-7934-4724-940b-083f49cb4d0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_690b78a1-3d99-489e-8b8d-f042247bbbf1" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_a8e6abb6-7934-4724-940b-083f49cb4d0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_c1518ae9-93e1-493f-b761-d719fc73b220" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_690b78a1-3d99-489e-8b8d-f042247bbbf1" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_c1518ae9-93e1-493f-b761-d719fc73b220" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation_68d9d735-213f-4076-842d-98887d5ea368" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_690b78a1-3d99-489e-8b8d-f042247bbbf1" xlink:to="loc_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation_68d9d735-213f-4076-842d-98887d5ea368" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_088e01ea-5c1f-4703-96ec-277707d53ab7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_690b78a1-3d99-489e-8b8d-f042247bbbf1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_088e01ea-5c1f-4703-96ec-277707d53ab7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_8c5c8ef7-1aac-40fe-b8a6-66209cc0e429" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_690b78a1-3d99-489e-8b8d-f042247bbbf1" xlink:to="loc_us-gaap_ProfitLoss_8c5c8ef7-1aac-40fe-b8a6-66209cc0e429" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_94d1ce12-a113-4c2b-9574-99f3680d2cb7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_690b78a1-3d99-489e-8b8d-f042247bbbf1" xlink:to="loc_us-gaap_SharesIssued_94d1ce12-a113-4c2b-9574-99f3680d2cb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_a1a37796-7ec9-443e-8b3d-0ca9abac6ae3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_690b78a1-3d99-489e-8b8d-f042247bbbf1" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_a1a37796-7ec9-443e-8b3d-0ca9abac6ae3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="evh-20210630.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_b05d5384-a7b5-4870-8a4d-f8dc99824be4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_7bc42cea-1b01-434d-8636-449e935b4dac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_b05d5384-a7b5-4870-8a4d-f8dc99824be4" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_7bc42cea-1b01-434d-8636-449e935b4dac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_79f15d17-024c-418e-8710-d706f55f8b37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_7bc42cea-1b01-434d-8636-449e935b4dac" xlink:to="loc_us-gaap_ProfitLoss_79f15d17-024c-418e-8710-d706f55f8b37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_18621120-0591-47a2-8141-6c5b590a02e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_7bc42cea-1b01-434d-8636-449e935b4dac" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_18621120-0591-47a2-8141-6c5b590a02e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_3e619f57-1e5d-4888-a39e-dbc115dd1767" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_18621120-0591-47a2-8141-6c5b590a02e0" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_3e619f57-1e5d-4888-a39e-dbc115dd1767" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_GainLossOnDispositionOfAssetsOperatingActivities_c9ff1261-961f-4ce0-b2bb-6ef06fab6839" xlink:href="evh-20210630.xsd#evh_GainLossOnDispositionOfAssetsOperatingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_18621120-0591-47a2-8141-6c5b590a02e0" xlink:to="loc_evh_GainLossOnDispositionOfAssetsOperatingActivities_c9ff1261-961f-4ce0-b2bb-6ef06fab6839" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_5cfcf144-0edc-4d1c-b39d-464c457a5ab3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_18621120-0591-47a2-8141-6c5b590a02e0" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_5cfcf144-0edc-4d1c-b39d-464c457a5ab3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_2bbedd0d-2bc8-4cc4-8f92-15749ad65044" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_18621120-0591-47a2-8141-6c5b590a02e0" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_2bbedd0d-2bc8-4cc4-8f92-15749ad65044" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_ca457171-19e0-43f0-9c51-2ec896f9ef66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_18621120-0591-47a2-8141-6c5b590a02e0" xlink:to="loc_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_ca457171-19e0-43f0-9c51-2ec896f9ef66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_f0930f1f-4ce6-4314-b97f-53efc3d8ec82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_18621120-0591-47a2-8141-6c5b590a02e0" xlink:to="loc_us-gaap_ShareBasedCompensation_f0930f1f-4ce6-4314-b97f-53efc3d8ec82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_bca2dcdb-f58a-47f1-aef2-c4de847ed905" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_18621120-0591-47a2-8141-6c5b590a02e0" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_bca2dcdb-f58a-47f1-aef2-c4de847ed905" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostAmortization_d4b4687b-3906-4fd8-b6f1-054be8c77814" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedContractCostAmortization"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_18621120-0591-47a2-8141-6c5b590a02e0" xlink:to="loc_us-gaap_CapitalizedContractCostAmortization_d4b4687b-3906-4fd8-b6f1-054be8c77814" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_3203d272-ea3f-454e-a6b9-871733e8f131" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_18621120-0591-47a2-8141-6c5b590a02e0" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_3203d272-ea3f-454e-a6b9-871733e8f131" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PaidinKindInterestIncome_18ee7821-388d-4543-bbec-3f0cd4de5197" xlink:href="evh-20210630.xsd#evh_PaidinKindInterestIncome"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_18621120-0591-47a2-8141-6c5b590a02e0" xlink:to="loc_evh_PaidinKindInterestIncome_18ee7821-388d-4543-bbec-3f0cd4de5197" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_GainOnTransferOfMembership_426a7f0d-bbd2-4f18-9afa-86c7e45f12c0" xlink:href="evh-20210630.xsd#evh_GainOnTransferOfMembership"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_18621120-0591-47a2-8141-6c5b590a02e0" xlink:to="loc_evh_GainOnTransferOfMembership_426a7f0d-bbd2-4f18-9afa-86c7e45f12c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_ab23f30d-c7a6-46c5-b82c-0372f411c95a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_18621120-0591-47a2-8141-6c5b590a02e0" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_ab23f30d-c7a6-46c5-b82c-0372f411c95a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_58485d98-027a-4e57-8fca-00453306b9dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_18621120-0591-47a2-8141-6c5b590a02e0" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_58485d98-027a-4e57-8fca-00453306b9dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_5eb681bb-46f4-4476-b5fa-7688e10fd746" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_18621120-0591-47a2-8141-6c5b590a02e0" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_5eb681bb-46f4-4476-b5fa-7688e10fd746" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c48a526e-b02c-4935-a5f3-d80b1b7bb262" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_18621120-0591-47a2-8141-6c5b590a02e0" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c48a526e-b02c-4935-a5f3-d80b1b7bb262" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset_6cbc9460-20d0-4549-a6cc-6153f8d050ed" xlink:href="evh-20210630.xsd#evh_IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c48a526e-b02c-4935-a5f3-d80b1b7bb262" xlink:to="loc_evh_IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset_6cbc9460-20d0-4549-a6cc-6153f8d050ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_ec4e4a2f-d181-4ddf-8fd7-3a68541dd924" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c48a526e-b02c-4935-a5f3-d80b1b7bb262" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_ec4e4a2f-d181-4ddf-8fd7-3a68541dd924" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_IncreaseDecreaseInCapitalizedContractCostNet_7a4ba762-6d50-471d-86d6-dea6f024ddce" xlink:href="evh-20210630.xsd#evh_IncreaseDecreaseInCapitalizedContractCostNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c48a526e-b02c-4935-a5f3-d80b1b7bb262" xlink:to="loc_evh_IncreaseDecreaseInCapitalizedContractCostNet_7a4ba762-6d50-471d-86d6-dea6f024ddce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_240fc2e6-b87c-449a-8deb-8592a9f6dc83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c48a526e-b02c-4935-a5f3-d80b1b7bb262" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_240fc2e6-b87c-449a-8deb-8592a9f6dc83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_241216b9-660a-49e8-8116-5fe772df2b51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c48a526e-b02c-4935-a5f3-d80b1b7bb262" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_241216b9-660a-49e8-8116-5fe772df2b51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_91a5cee2-2387-4745-9c3a-9c7611ddcbb7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c48a526e-b02c-4935-a5f3-d80b1b7bb262" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_91a5cee2-2387-4745-9c3a-9c7611ddcbb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_ae855d10-652c-4495-a872-8871ba41d2b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c48a526e-b02c-4935-a5f3-d80b1b7bb262" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_ae855d10-652c-4495-a872-8871ba41d2b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities_a864f9d7-de57-43fe-b825-084e29c15787" xlink:href="evh-20210630.xsd#evh_IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c48a526e-b02c-4935-a5f3-d80b1b7bb262" xlink:to="loc_evh_IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities_a864f9d7-de57-43fe-b825-084e29c15787" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_IncreaseDecreaseInOperatingLeaseRightofUseAsset_d4d1e6e9-bad0-4370-9de3-60e3320d7775" xlink:href="evh-20210630.xsd#evh_IncreaseDecreaseInOperatingLeaseRightofUseAsset"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c48a526e-b02c-4935-a5f3-d80b1b7bb262" xlink:to="loc_evh_IncreaseDecreaseInOperatingLeaseRightofUseAsset_d4d1e6e9-bad0-4370-9de3-60e3320d7775" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_966d36d4-10d9-4d3e-a5c2-33dac5298f2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c48a526e-b02c-4935-a5f3-d80b1b7bb262" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_966d36d4-10d9-4d3e-a5c2-33dac5298f2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_08145d88-518e-40f1-88b5-6504a3523c7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c48a526e-b02c-4935-a5f3-d80b1b7bb262" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_08145d88-518e-40f1-88b5-6504a3523c7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6ff6ba58-27f7-459a-81d9-37effe3450a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_18621120-0591-47a2-8141-6c5b590a02e0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6ff6ba58-27f7-459a-81d9-37effe3450a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_e175a974-eb5f-426f-93af-c8e550408b90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_b05d5384-a7b5-4870-8a4d-f8dc99824be4" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_e175a974-eb5f-426f-93af-c8e550408b90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_bc8dd754-8223-41a6-bc17-f017759e918a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_e175a974-eb5f-426f-93af-c8e550408b90" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_bc8dd754-8223-41a6-bc17-f017759e918a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates_e067b06e-0328-4699-9898-0a48f5bff854" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_e175a974-eb5f-426f-93af-c8e550408b90" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates_e067b06e-0328-4699-9898-0a48f5bff854" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet_d0a51d7a-4170-499e-beed-0ab8b4d45836" xlink:href="evh-20210630.xsd#evh_PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_e175a974-eb5f-426f-93af-c8e550408b90" xlink:to="loc_evh_PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet_d0a51d7a-4170-499e-beed-0ab8b4d45836" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital_c06f1e98-44d1-41d5-8c6e-a486caec97b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_e175a974-eb5f-426f-93af-c8e550408b90" xlink:to="loc_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital_c06f1e98-44d1-41d5-8c6e-a486caec97b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireHeldToMaturitySecurities_cafe2397-43d5-4a23-a6b3-c0a64c4acdd8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireHeldToMaturitySecurities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_e175a974-eb5f-426f-93af-c8e550408b90" xlink:to="loc_us-gaap_PaymentsToAcquireHeldToMaturitySecurities_cafe2397-43d5-4a23-a6b3-c0a64c4acdd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ProceedsFromMaturityOfInvestments_ef712f11-432b-489d-a5d5-8814788d2174" xlink:href="evh-20210630.xsd#evh_ProceedsFromMaturityOfInvestments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_e175a974-eb5f-426f-93af-c8e550408b90" xlink:to="loc_evh_ProceedsFromMaturityOfInvestments_ef712f11-432b-489d-a5d5-8814788d2174" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_fa08ec61-b5be-40fa-9930-7dd73eb67b2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireOtherProductiveAssets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_e175a974-eb5f-426f-93af-c8e550408b90" xlink:to="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_fa08ec61-b5be-40fa-9930-7dd73eb67b2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_9190d533-4e7f-47f1-9232-0f0b5f205f79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_e175a974-eb5f-426f-93af-c8e550408b90" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_9190d533-4e7f-47f1-9232-0f0b5f205f79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_38c372da-48d7-48bf-978e-088f1a8e7c54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_e175a974-eb5f-426f-93af-c8e550408b90" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_38c372da-48d7-48bf-978e-088f1a8e7c54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ad31cd3c-2e00-48c5-ad85-521473bfef77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_b05d5384-a7b5-4870-8a4d-f8dc99824be4" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ad31cd3c-2e00-48c5-ad85-521473bfef77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PaymentsForProceedsFromClaimsProcessingFinancingActivities_64949301-c3c7-45e5-8e51-4b8f478f4f56" xlink:href="evh-20210630.xsd#evh_PaymentsForProceedsFromClaimsProcessingFinancingActivities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ad31cd3c-2e00-48c5-ad85-521473bfef77" xlink:to="loc_evh_PaymentsForProceedsFromClaimsProcessingFinancingActivities_64949301-c3c7-45e5-8e51-4b8f478f4f56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSeniorDebt_946f0de6-74e5-41f6-82a0-fac6bcda4b66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfSeniorDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ad31cd3c-2e00-48c5-ad85-521473bfef77" xlink:to="loc_us-gaap_RepaymentsOfSeniorDebt_946f0de6-74e5-41f6-82a0-fac6bcda4b66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_2600d787-6b1b-4cf7-af85-9686763a9420" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ad31cd3c-2e00-48c5-ad85-521473bfef77" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_2600d787-6b1b-4cf7-af85-9686763a9420" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders_805b5dda-3946-4660-b0e2-aac09779bc0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToMinorityShareholders"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ad31cd3c-2e00-48c5-ad85-521473bfef77" xlink:to="loc_us-gaap_PaymentsToMinorityShareholders_805b5dda-3946-4660-b0e2-aac09779bc0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_505b5e06-14d1-4eb5-9d30-d43036271f2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ad31cd3c-2e00-48c5-ad85-521473bfef77" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_505b5e06-14d1-4eb5-9d30-d43036271f2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_121a1ae4-c280-4baf-b680-2b3871e08fd8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ad31cd3c-2e00-48c5-ad85-521473bfef77" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_121a1ae4-c280-4baf-b680-2b3871e08fd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ec88d242-89f0-4ef4-aebf-4b53dd8df254" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_b05d5384-a7b5-4870-8a4d-f8dc99824be4" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ec88d242-89f0-4ef4-aebf-4b53dd8df254" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0473d186-6fd5-49ef-b5b7-bd2d1a45233a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_b05d5384-a7b5-4870-8a4d-f8dc99824be4" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0473d186-6fd5-49ef-b5b7-bd2d1a45233a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c6d21fb7-41b0-4e6b-895b-3ccd31800796" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_b05d5384-a7b5-4870-8a4d-f8dc99824be4" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c6d21fb7-41b0-4e6b-895b-3ccd31800796" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b9f96622-bf23-444d-a2c0-103dfa930645" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_b05d5384-a7b5-4870-8a4d-f8dc99824be4" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b9f96622-bf23-444d-a2c0-103dfa930645" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/Organization" xlink:type="simple" xlink:href="evh-20210630.xsd#Organization"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/Organization" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_cbc08a1f-31d8-4457-85e1-e1937f6a1fed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_d991803e-798b-4ef6-a1f0-460828662a4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_cbc08a1f-31d8-4457-85e1-e1937f6a1fed" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_d991803e-798b-4ef6-a1f0-460828662a4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/OrganizationDetails" xlink:type="simple" xlink:href="evh-20210630.xsd#OrganizationDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/OrganizationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b6f2ac3a-8d92-406f-ae20-3744950b4f1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_c4908c0f-3ad1-41a8-92cb-b46069b1054a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b6f2ac3a-8d92-406f-ae20-3744950b4f1b" xlink:to="loc_us-gaap_NumberOfOperatingSegments_c4908c0f-3ad1-41a8-92cb-b46069b1054a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_88216f40-6058-489a-8c02-80e899227c5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b6f2ac3a-8d92-406f-ae20-3744950b4f1b" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_88216f40-6058-489a-8c02-80e899227c5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciples" xlink:type="simple" xlink:href="evh-20210630.xsd#BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciples"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciples" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_3358cfe3-458c-4033-a4f0-b8423e330cde" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_2addcdd8-7500-454d-849c-3c8b35bb1b00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3358cfe3-458c-4033-a4f0-b8423e330cde" xlink:to="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_2addcdd8-7500-454d-849c-3c8b35bb1b00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies" xlink:type="simple" xlink:href="evh-20210630.xsd#BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_c9ed52d6-26a3-45c1-bd56-ec274d72bef2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_955dbbbc-75a4-4e5e-8ca7-489b18ffa320" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c9ed52d6-26a3-45c1-bd56-ec274d72bef2" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_955dbbbc-75a4-4e5e-8ca7-489b18ffa320" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_cb4b4f78-6358-47a7-b368-b911031eed69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c9ed52d6-26a3-45c1-bd56-ec274d72bef2" xlink:to="loc_us-gaap_UseOfEstimates_cb4b4f78-6358-47a7-b368-b911031eed69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_bd929a7c-f42f-495b-adc0-9c54e80de5f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c9ed52d6-26a3-45c1-bd56-ec274d72bef2" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_bd929a7c-f42f-495b-adc0-9c54e80de5f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy_fbf133f7-38ee-4ad1-bc2d-1941ef27b590" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c9ed52d6-26a3-45c1-bd56-ec274d72bef2" xlink:to="loc_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy_fbf133f7-38ee-4ad1-bc2d-1941ef27b590" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy_15d3002c-be67-4bc6-aa1d-1a72f2f0a469" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c9ed52d6-26a3-45c1-bd56-ec274d72bef2" xlink:to="loc_us-gaap_BusinessCombinationsPolicy_15d3002c-be67-4bc6-aa1d-1a72f2f0a469" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_7290b5a6-ef54-4388-9148-83800b45cb90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c9ed52d6-26a3-45c1-bd56-ec274d72bef2" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_7290b5a6-ef54-4388-9148-83800b45cb90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy_57721b87-44d7-461f-a780-c71364d444c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c9ed52d6-26a3-45c1-bd56-ec274d72bef2" xlink:to="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy_57721b87-44d7-461f-a780-c71364d444c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityReserveEstimatePolicy_16324be0-3439-4545-b10b-fb89630be2b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityReserveEstimatePolicy"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c9ed52d6-26a3-45c1-bd56-ec274d72bef2" xlink:to="loc_us-gaap_LiabilityReserveEstimatePolicy_16324be0-3439-4545-b10b-fb89630be2b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_1fe42f65-5271-4290-b9e4-a2882a820b32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c9ed52d6-26a3-45c1-bd56-ec274d72bef2" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_1fe42f65-5271-4290-b9e4-a2882a820b32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_4d81dd69-7f22-4124-8682-f0958cba18ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c9ed52d6-26a3-45c1-bd56-ec274d72bef2" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_4d81dd69-7f22-4124-8682-f0958cba18ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_dc58ef44-5092-4b33-ad29-f9c50fe1801a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c9ed52d6-26a3-45c1-bd56-ec274d72bef2" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_dc58ef44-5092-4b33-ad29-f9c50fe1801a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_fb0f186a-5f61-4966-bef8-dfc9368bffa0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c9ed52d6-26a3-45c1-bd56-ec274d72bef2" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_fb0f186a-5f61-4966-bef8-dfc9368bffa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_326ac7bc-950f-422a-a016-0d6dceeec26f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c9ed52d6-26a3-45c1-bd56-ec274d72bef2" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_326ac7bc-950f-422a-a016-0d6dceeec26f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesTables" xlink:type="simple" xlink:href="evh-20210630.xsd#BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesTables"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_d6ee372e-1f22-4f34-904c-1f6ac64ce9dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_3ae61616-9cf3-438c-9da7-0f2780fc3c31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d6ee372e-1f22-4f34-904c-1f6ac64ce9dc" xlink:to="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_3ae61616-9cf3-438c-9da7-0f2780fc3c31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_9ebed298-0c8d-49f1-85ca-5a838a61cd0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d6ee372e-1f22-4f34-904c-1f6ac64ce9dc" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_9ebed298-0c8d-49f1-85ca-5a838a61cd0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails" xlink:type="simple" xlink:href="evh-20210630.xsd#BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_4d79af4c-e02f-4da0-a442-e0ac54a27ed9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_3130c10c-5747-4fe5-a1d6-8b9cd349a301" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4d79af4c-e02f-4da0-a442-e0ac54a27ed9" xlink:to="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_3130c10c-5747-4fe5-a1d6-8b9cd349a301" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_cc978593-0b4e-4700-a016-9b63f598d087" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_3130c10c-5747-4fe5-a1d6-8b9cd349a301" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_cc978593-0b4e-4700-a016-9b63f598d087" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_020e50d7-9203-4427-844a-48950d67a48a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_cc978593-0b4e-4700-a016-9b63f598d087" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_020e50d7-9203-4427-844a-48950d67a48a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RestrictedCashforLettersofCreditforFacilityLeasesMember_8ffe6698-af8b-4aab-97a3-fc585e56a5d6" xlink:href="evh-20210630.xsd#evh_RestrictedCashforLettersofCreditforFacilityLeasesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_020e50d7-9203-4427-844a-48950d67a48a" xlink:to="loc_evh_RestrictedCashforLettersofCreditforFacilityLeasesMember_8ffe6698-af8b-4aab-97a3-fc585e56a5d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CollateralwithFinancialInstitutionsMember_c127856e-11ed-4f79-978a-5ddb48b19665" xlink:href="evh-20210630.xsd#evh_CollateralwithFinancialInstitutionsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_020e50d7-9203-4427-844a-48950d67a48a" xlink:to="loc_evh_CollateralwithFinancialInstitutionsMember_c127856e-11ed-4f79-978a-5ddb48b19665" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RestrictedCashforBenefitManagementServicesMember_d2dc0417-2898-4614-a88b-746bc3756cf6" xlink:href="evh-20210630.xsd#evh_RestrictedCashforBenefitManagementServicesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_020e50d7-9203-4427-844a-48950d67a48a" xlink:to="loc_evh_RestrictedCashforBenefitManagementServicesMember_d2dc0417-2898-4614-a88b-746bc3756cf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RestrictedCashforOtherContractualCommitmentsMember_d7c0e1d4-7941-4946-857c-fe36e9df13bd" xlink:href="evh-20210630.xsd#evh_RestrictedCashforOtherContractualCommitmentsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_020e50d7-9203-4427-844a-48950d67a48a" xlink:to="loc_evh_RestrictedCashforOtherContractualCommitmentsMember_d7c0e1d4-7941-4946-857c-fe36e9df13bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BankTimeDepositsMember_c08ab802-f5da-4814-9322-741dca66c130" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BankTimeDepositsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_020e50d7-9203-4427-844a-48950d67a48a" xlink:to="loc_us-gaap_BankTimeDepositsMember_c08ab802-f5da-4814-9322-741dca66c130" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_604f0218-0cb9-415e-b01d-7e728b0f70b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_3130c10c-5747-4fe5-a1d6-8b9cd349a301" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_604f0218-0cb9-415e-b01d-7e728b0f70b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_1d3f1e94-84d2-49ce-ad08-b5e5e60dec3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_604f0218-0cb9-415e-b01d-7e728b0f70b7" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_1d3f1e94-84d2-49ce-ad08-b5e5e60dec3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_614d40e9-48a5-4b6a-9c2c-c326c9bb56ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationsDisposedOfBySaleMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_1d3f1e94-84d2-49ce-ad08-b5e5e60dec3c" xlink:to="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_614d40e9-48a5-4b6a-9c2c-c326c9bb56ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_cbf6eba8-96a8-401e-b1e2-15b86cb8da43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_3130c10c-5747-4fe5-a1d6-8b9cd349a301" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_cbf6eba8-96a8-401e-b1e2-15b86cb8da43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_76a4c54b-0ef0-4113-9338-e8c6053c7e1a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_cbf6eba8-96a8-401e-b1e2-15b86cb8da43" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_76a4c54b-0ef0-4113-9338-e8c6053c7e1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TrueHealthMember_dbe75323-32d0-447b-a0fc-b1f7bddb5ad3" xlink:href="evh-20210630.xsd#evh_TrueHealthMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_76a4c54b-0ef0-4113-9338-e8c6053c7e1a" xlink:to="loc_evh_TrueHealthMember_dbe75323-32d0-447b-a0fc-b1f7bddb5ad3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_2881e5d4-78b3-42a0-b40d-8f6413cd7913" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_3130c10c-5747-4fe5-a1d6-8b9cd349a301" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_2881e5d4-78b3-42a0-b40d-8f6413cd7913" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_f0698c7b-ebb8-4b9e-baf9-8acb26fd6d68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_2881e5d4-78b3-42a0-b40d-8f6413cd7913" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_f0698c7b-ebb8-4b9e-baf9-8acb26fd6d68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_f8847aba-8209-4886-9b02-6f0f6b03b799" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_2881e5d4-78b3-42a0-b40d-8f6413cd7913" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_f8847aba-8209-4886-9b02-6f0f6b03b799" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndInvestmentsCurrent_81c7f1a0-52c0-419b-8c7d-a76ad3e7c562" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndInvestmentsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_2881e5d4-78b3-42a0-b40d-8f6413cd7913" xlink:to="loc_us-gaap_RestrictedCashAndInvestmentsCurrent_81c7f1a0-52c0-419b-8c7d-a76ad3e7c562" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_207a66b5-d82f-4efd-a0ef-114292dc53a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_2881e5d4-78b3-42a0-b40d-8f6413cd7913" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_207a66b5-d82f-4efd-a0ef-114292dc53a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndInvestmentsNoncurrent_f69c0a60-9363-4d59-9e39-4fb593132ae0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndInvestmentsNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_2881e5d4-78b3-42a0-b40d-8f6413cd7913" xlink:to="loc_us-gaap_RestrictedCashAndInvestmentsNoncurrent_f69c0a60-9363-4d59-9e39-4fb593132ae0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_8a1a074a-e312-415f-875e-462d66b693f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_2881e5d4-78b3-42a0-b40d-8f6413cd7913" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_8a1a074a-e312-415f-875e-462d66b693f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_586fc64c-31bb-47c8-bf26-4de76426b0c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_2881e5d4-78b3-42a0-b40d-8f6413cd7913" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_586fc64c-31bb-47c8-bf26-4de76426b0c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedInvestments_f69458eb-e715-43a2-a693-8f0d1fdcf659" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedInvestments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_2881e5d4-78b3-42a0-b40d-8f6413cd7913" xlink:to="loc_us-gaap_RestrictedInvestments_f69458eb-e715-43a2-a693-8f0d1fdcf659" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_68a1b6f5-7339-4c6f-8702-2d6392ff5edf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_2881e5d4-78b3-42a0-b40d-8f6413cd7913" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_68a1b6f5-7339-4c6f-8702-2d6392ff5edf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DisposalGroupIncludingDiscontinuedOperationRestrictedInvestmentsNoncurrent_4aff4896-5eca-4218-8d04-4c7967c61109" xlink:href="evh-20210630.xsd#evh_DisposalGroupIncludingDiscontinuedOperationRestrictedInvestmentsNoncurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_2881e5d4-78b3-42a0-b40d-8f6413cd7913" xlink:to="loc_evh_DisposalGroupIncludingDiscontinuedOperationRestrictedInvestmentsNoncurrent_4aff4896-5eca-4218-8d04-4c7967c61109" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DisposalGroupIncludingDiscontinuedOperationRestrictedCashCurrent_34ab9770-67a7-4ebe-b930-acb5b4e73ba3" xlink:href="evh-20210630.xsd#evh_DisposalGroupIncludingDiscontinuedOperationRestrictedCashCurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_2881e5d4-78b3-42a0-b40d-8f6413cd7913" xlink:to="loc_evh_DisposalGroupIncludingDiscontinuedOperationRestrictedCashCurrent_34ab9770-67a7-4ebe-b930-acb5b4e73ba3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesGoodwillDetails" xlink:type="simple" xlink:href="evh-20210630.xsd#BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesGoodwillDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_759161db-5fed-4ade-a475-737c5f84e537" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportingUnits_61725f60-0af2-4ba4-92fd-a7375f556f38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfReportingUnits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_759161db-5fed-4ade-a475-737c5f84e537" xlink:to="loc_us-gaap_NumberOfReportingUnits_61725f60-0af2-4ba4-92fd-a7375f556f38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails" xlink:type="simple" xlink:href="evh-20210630.xsd#BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_38af0e9c-02e6-4581-a43b-764ca2685ae6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_a4e68358-19a8-4365-91ff-3fe5f2de05bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_38af0e9c-02e6-4581-a43b-764ca2685ae6" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_a4e68358-19a8-4365-91ff-3fe5f2de05bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a80d5f52-63b8-41be-9556-c6bff0ea46d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_a4e68358-19a8-4365-91ff-3fe5f2de05bf" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a80d5f52-63b8-41be-9556-c6bff0ea46d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9c1b122a-6427-4d33-9fb0-f79734a4f9db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a80d5f52-63b8-41be-9556-c6bff0ea46d6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9c1b122a-6427-4d33-9fb0-f79734a4f9db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_30e6abfc-f30d-434a-9f5f-21b853ce704c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradeNamesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9c1b122a-6427-4d33-9fb0-f79734a4f9db" xlink:to="loc_us-gaap_TradeNamesMember_30e6abfc-f30d-434a-9f5f-21b853ce704c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_9a63c1b6-277f-45b8-9c7f-9039cde383d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9c1b122a-6427-4d33-9fb0-f79734a4f9db" xlink:to="loc_us-gaap_CustomerRelationshipsMember_9a63c1b6-277f-45b8-9c7f-9039cde383d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_55f06b35-982b-401c-a531-506999a2b44d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9c1b122a-6427-4d33-9fb0-f79734a4f9db" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_55f06b35-982b-401c-a531-506999a2b44d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractBasedIntangibleAssetsMember_a64c121f-4b45-43d6-a391-1764e52d9ca8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractBasedIntangibleAssetsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9c1b122a-6427-4d33-9fb0-f79734a4f9db" xlink:to="loc_us-gaap_ContractBasedIntangibleAssetsMember_a64c121f-4b45-43d6-a391-1764e52d9ca8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_a53c28a9-f242-459d-97b9-bf6f3406a576" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_a4e68358-19a8-4365-91ff-3fe5f2de05bf" xlink:to="loc_srt_RangeAxis_a53c28a9-f242-459d-97b9-bf6f3406a576" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0dc4351e-5b81-4169-8e61-d0cf73807179" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_a53c28a9-f242-459d-97b9-bf6f3406a576" xlink:to="loc_srt_RangeMember_0dc4351e-5b81-4169-8e61-d0cf73807179" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_1b1f1425-1cc3-4e6c-9e39-06524f398561" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_0dc4351e-5b81-4169-8e61-d0cf73807179" xlink:to="loc_srt_MinimumMember_1b1f1425-1cc3-4e6c-9e39-06524f398561" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_d4e48355-dd69-4e1a-bc9c-9e317c12da04" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_0dc4351e-5b81-4169-8e61-d0cf73807179" xlink:to="loc_srt_MaximumMember_d4e48355-dd69-4e1a-bc9c-9e317c12da04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_b4d0c693-51b0-4e62-bd59-afe5ef3d8ce8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_a4e68358-19a8-4365-91ff-3fe5f2de05bf" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_b4d0c693-51b0-4e62-bd59-afe5ef3d8ce8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_9477e686-bae4-41bc-8037-5148cebfd28f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_b4d0c693-51b0-4e62-bd59-afe5ef3d8ce8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_9477e686-bae4-41bc-8037-5148cebfd28f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandards" xlink:type="simple" xlink:href="evh-20210630.xsd#RecentlyIssuedAccountingStandards"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandards" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_ad13b0a5-4481-438b-a054-7dc4588b3d26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_c0c0b95b-b0fe-47a1-aab1-20528beede2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ad13b0a5-4481-438b-a054-7dc4588b3d26" xlink:to="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_c0c0b95b-b0fe-47a1-aab1-20528beede2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails" xlink:type="simple" xlink:href="evh-20210630.xsd#RecentlyIssuedAccountingStandardsDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_c4028ef5-be3d-4c52-9111-49d879a05a32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_b43adf2a-9ffc-4af1-a48b-14e35e6371d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c4028ef5-be3d-4c52-9111-49d879a05a32" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_b43adf2a-9ffc-4af1-a48b-14e35e6371d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_31e94201-1f4c-4ab1-b17f-52fac8409ed5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_b43adf2a-9ffc-4af1-a48b-14e35e6371d0" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_31e94201-1f4c-4ab1-b17f-52fac8409ed5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_1dd869d2-f3b4-4ed9-b8ce-cf4e9a8f9f91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_31e94201-1f4c-4ab1-b17f-52fac8409ed5" xlink:to="loc_us-gaap_EquityComponentDomain_1dd869d2-f3b4-4ed9-b8ce-cf4e9a8f9f91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_ca885c12-70e9-4bc7-80e1-af91cc092c4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1dd869d2-f3b4-4ed9-b8ce-cf4e9a8f9f91" xlink:to="loc_us-gaap_RetainedEarningsMember_ca885c12-70e9-4bc7-80e1-af91cc092c4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_af04b3c8-5025-440c-95fa-61e26ede4ad7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_b43adf2a-9ffc-4af1-a48b-14e35e6371d0" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_af04b3c8-5025-440c-95fa-61e26ede4ad7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_b9bf7aa9-e6af-49be-b751-b2846602365f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_af04b3c8-5025-440c-95fa-61e26ede4ad7" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_b9bf7aa9-e6af-49be-b751-b2846602365f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_b2b42b88-71cb-4718-92b9-6b4964c3ccb3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_b9bf7aa9-e6af-49be-b751-b2846602365f" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_b2b42b88-71cb-4718-92b9-6b4964c3ccb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_ddcebe05-6eba-4b5c-ab5c-c01a6f5a636d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_b43adf2a-9ffc-4af1-a48b-14e35e6371d0" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_ddcebe05-6eba-4b5c-ab5c-c01a6f5a636d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_45e3f42c-b9de-41d2-ae0b-5b6ba46f18e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_ddcebe05-6eba-4b5c-ab5c-c01a6f5a636d" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_45e3f42c-b9de-41d2-ae0b-5b6ba46f18e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList_1b047083-2b19-4f32-9bf8-bd54ec93980e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_ddcebe05-6eba-4b5c-ab5c-c01a6f5a636d" xlink:to="loc_us-gaap_AccountingStandardsUpdateExtensibleList_1b047083-2b19-4f32-9bf8-bd54ec93980e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/Transactions" xlink:type="simple" xlink:href="evh-20210630.xsd#Transactions"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/Transactions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_e5c00d8f-3667-4d75-b2f9-2efeeb093fab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_6ce2a24d-43c8-499e-bf10-1c093d0837ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_e5c00d8f-3667-4d75-b2f9-2efeeb093fab" xlink:to="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_6ce2a24d-43c8-499e-bf10-1c093d0837ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/TransactionsPassportDetails" xlink:type="simple" xlink:href="evh-20210630.xsd#TransactionsPassportDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/TransactionsPassportDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_8fb562a0-40d8-46cb-8a51-e3f7f00a5f61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_66991f93-11fb-4eb5-b5f6-55366abeebf3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_8fb562a0-40d8-46cb-8a51-e3f7f00a5f61" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_66991f93-11fb-4eb5-b5f6-55366abeebf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_832620fd-aea6-478e-9286-7e3fe2c8e9fe" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_66991f93-11fb-4eb5-b5f6-55366abeebf3" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_832620fd-aea6-478e-9286-7e3fe2c8e9fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_e48ec67d-a5a8-4726-9070-9696822e3f4e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_832620fd-aea6-478e-9286-7e3fe2c8e9fe" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_e48ec67d-a5a8-4726-9070-9696822e3f4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_UniversityHealthCaredbaPassportHealthPlanMember_e7c9d76c-2536-471d-9876-f4c3f51b4c2f" xlink:href="evh-20210630.xsd#evh_UniversityHealthCaredbaPassportHealthPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_e48ec67d-a5a8-4726-9070-9696822e3f4e" xlink:to="loc_evh_UniversityHealthCaredbaPassportHealthPlanMember_e7c9d76c-2536-471d-9876-f4c3f51b4c2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_9814f7fa-f906-45e4-9a7a-eb90997af8d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_66991f93-11fb-4eb5-b5f6-55366abeebf3" xlink:to="loc_us-gaap_DebtInstrumentAxis_9814f7fa-f906-45e4-9a7a-eb90997af8d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_0c648c6c-ad71-48f2-912f-838cfad9f942" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_9814f7fa-f906-45e4-9a7a-eb90997af8d1" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_0c648c6c-ad71-48f2-912f-838cfad9f942" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PassportNoteMember_fe536101-0060-47ab-80dd-1f77c6ca7d7e" xlink:href="evh-20210630.xsd#evh_PassportNoteMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0c648c6c-ad71-48f2-912f-838cfad9f942" xlink:to="loc_evh_PassportNoteMember_fe536101-0060-47ab-80dd-1f77c6ca7d7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_994ef6f7-44d7-49d4-a6ca-029fb20495e1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_66991f93-11fb-4eb5-b5f6-55366abeebf3" xlink:to="loc_srt_CounterpartyNameAxis_994ef6f7-44d7-49d4-a6ca-029fb20495e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e164b0ad-fa02-4299-b964-57b15a643877" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_994ef6f7-44d7-49d4-a6ca-029fb20495e1" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e164b0ad-fa02-4299-b964-57b15a643877" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_MolinaHealthcareIncMember_e5753087-300e-4951-98da-d08aca36a2d8" xlink:href="evh-20210630.xsd#evh_MolinaHealthcareIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e164b0ad-fa02-4299-b964-57b15a643877" xlink:to="loc_evh_MolinaHealthcareIncMember_e5753087-300e-4951-98da-d08aca36a2d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_db1d3bc1-c9fc-47ba-9335-c3de77b712d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_66991f93-11fb-4eb5-b5f6-55366abeebf3" xlink:to="loc_us-gaap_AssetAcquisitionAxis_db1d3bc1-c9fc-47ba-9335-c3de77b712d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_b90d83db-348b-496f-b4a3-90d48820f0cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionAxis_db1d3bc1-c9fc-47ba-9335-c3de77b712d2" xlink:to="loc_us-gaap_AssetAcquisitionDomain_b90d83db-348b-496f-b4a3-90d48820f0cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PassportAssetAcquisitionMember_a9df2390-9a62-40b6-82a6-e776a12deabd" xlink:href="evh-20210630.xsd#evh_PassportAssetAcquisitionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_b90d83db-348b-496f-b4a3-90d48820f0cd" xlink:to="loc_evh_PassportAssetAcquisitionMember_a9df2390-9a62-40b6-82a6-e776a12deabd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_847c2f67-00b5-4574-adfa-30f05704e181" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_66991f93-11fb-4eb5-b5f6-55366abeebf3" xlink:to="loc_srt_ConsolidatedEntitiesAxis_847c2f67-00b5-4574-adfa-30f05704e181" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_1b967bb6-7299-4cb4-b0fa-444690602651" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_847c2f67-00b5-4574-adfa-30f05704e181" xlink:to="loc_srt_ConsolidatedEntitiesDomain_1b967bb6-7299-4cb4-b0fa-444690602651" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_b0f2d681-dd66-40a7-9708-3205d1d914df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_1b967bb6-7299-4cb4-b0fa-444690602651" xlink:to="loc_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_b0f2d681-dd66-40a7-9708-3205d1d914df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_48ff7240-3301-4fcb-bb96-cf2b960760ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_66991f93-11fb-4eb5-b5f6-55366abeebf3" xlink:to="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_48ff7240-3301-4fcb-bb96-cf2b960760ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_cbb51895-6f2d-4dd8-8d01-59002a5166f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_48ff7240-3301-4fcb-bb96-cf2b960760ba" xlink:to="loc_us-gaap_ReceivableTypeDomain_cbb51895-6f2d-4dd8-8d01-59002a5166f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableMember_970e9f46-0759-4bc7-958e-3ccca4a09a7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesReceivableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivableTypeDomain_cbb51895-6f2d-4dd8-8d01-59002a5166f0" xlink:to="loc_us-gaap_NotesReceivableMember_970e9f46-0759-4bc7-958e-3ccca4a09a7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_12f8e93a-d473-44ef-9397-2079bdc72ee6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_66991f93-11fb-4eb5-b5f6-55366abeebf3" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_12f8e93a-d473-44ef-9397-2079bdc72ee6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_fd2703f2-0c58-417f-9dbc-947a6076c5d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_12f8e93a-d473-44ef-9397-2079bdc72ee6" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_fd2703f2-0c58-417f-9dbc-947a6076c5d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityOwnershipPercentage_e97e7797-3abc-482f-a36f-8dca7cad338a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityOwnershipPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_12f8e93a-d473-44ef-9397-2079bdc72ee6" xlink:to="loc_us-gaap_VariableInterestEntityOwnershipPercentage_e97e7797-3abc-482f-a36f-8dca7cad338a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableNet_4878db3b-2f6c-43ae-9cae-135fb5838553" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesReceivableNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_12f8e93a-d473-44ef-9397-2079bdc72ee6" xlink:to="loc_us-gaap_NotesReceivableNet_4878db3b-2f6c-43ae-9cae-135fb5838553" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_7bfcb359-af5f-44a4-8cf4-4beed6501f2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_12f8e93a-d473-44ef-9397-2079bdc72ee6" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_7bfcb359-af5f-44a4-8cf4-4beed6501f2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityFinancialOrOtherSupportAmount_2ac78e7e-efee-42a6-8587-fea975787f44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityFinancialOrOtherSupportAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_12f8e93a-d473-44ef-9397-2079bdc72ee6" xlink:to="loc_us-gaap_VariableInterestEntityFinancialOrOtherSupportAmount_2ac78e7e-efee-42a6-8587-fea975787f44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PaymentsToAcquireEquityMethodInvestmentsAmountHeldBack_1478306d-8783-4f67-a6c4-a89d4735217b" xlink:href="evh-20210630.xsd#evh_PaymentsToAcquireEquityMethodInvestmentsAmountHeldBack"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_12f8e93a-d473-44ef-9397-2079bdc72ee6" xlink:to="loc_evh_PaymentsToAcquireEquityMethodInvestmentsAmountHeldBack_1478306d-8783-4f67-a6c4-a89d4735217b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_AssetPurchaseAgreementEscrowPayments_66ffea8d-76b9-4677-9d78-faa1a914751e" xlink:href="evh-20210630.xsd#evh_AssetPurchaseAgreementEscrowPayments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_12f8e93a-d473-44ef-9397-2079bdc72ee6" xlink:to="loc_evh_AssetPurchaseAgreementEscrowPayments_66ffea8d-76b9-4677-9d78-faa1a914751e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CashReleasedFromEscrow_81a399ba-54b1-41d7-b79b-30dc173a95d7" xlink:href="evh-20210630.xsd#evh_CashReleasedFromEscrow"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_12f8e93a-d473-44ef-9397-2079bdc72ee6" xlink:to="loc_evh_CashReleasedFromEscrow_81a399ba-54b1-41d7-b79b-30dc173a95d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders_152950e0-d23f-48bc-8b75-cc40f858ef44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToMinorityShareholders"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_12f8e93a-d473-44ef-9397-2079bdc72ee6" xlink:to="loc_us-gaap_PaymentsToMinorityShareholders_152950e0-d23f-48bc-8b75-cc40f858ef44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_AssetAcquisitionCashAndEquivalents_a22f60c0-7056-4a69-875a-1371a4750694" xlink:href="evh-20210630.xsd#evh_AssetAcquisitionCashAndEquivalents"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_12f8e93a-d473-44ef-9397-2079bdc72ee6" xlink:to="loc_evh_AssetAcquisitionCashAndEquivalents_a22f60c0-7056-4a69-875a-1371a4750694" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_AssetAcquisitionDebtSecuritiesAvailableForSale_47847ac9-1337-4c51-ab6d-ccd4599b32ca" xlink:href="evh-20210630.xsd#evh_AssetAcquisitionDebtSecuritiesAvailableForSale"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_12f8e93a-d473-44ef-9397-2079bdc72ee6" xlink:to="loc_evh_AssetAcquisitionDebtSecuritiesAvailableForSale_47847ac9-1337-4c51-ab6d-ccd4599b32ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_AssetAcquisitionDebtSecuritiesAvailableForSaleUnsettledSalesReceivables_09649940-4132-453c-9338-f6dccf30efb2" xlink:href="evh-20210630.xsd#evh_AssetAcquisitionDebtSecuritiesAvailableForSaleUnsettledSalesReceivables"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_12f8e93a-d473-44ef-9397-2079bdc72ee6" xlink:to="loc_evh_AssetAcquisitionDebtSecuritiesAvailableForSaleUnsettledSalesReceivables_09649940-4132-453c-9338-f6dccf30efb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_AssetAcquisitionOtherAssets_1d7b4b40-3dbd-4a4f-a3f9-e2bdd259ab8d" xlink:href="evh-20210630.xsd#evh_AssetAcquisitionOtherAssets"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_12f8e93a-d473-44ef-9397-2079bdc72ee6" xlink:to="loc_evh_AssetAcquisitionOtherAssets_1d7b4b40-3dbd-4a4f-a3f9-e2bdd259ab8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_AssetAcquisitionAccruedMedicalExpenses_cc816a4f-3a52-4df6-9d98-fb0697685dfd" xlink:href="evh-20210630.xsd#evh_AssetAcquisitionAccruedMedicalExpenses"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_12f8e93a-d473-44ef-9397-2079bdc72ee6" xlink:to="loc_evh_AssetAcquisitionAccruedMedicalExpenses_cc816a4f-3a52-4df6-9d98-fb0697685dfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_AssetAcquisitionAccruedLiabilities_0f691050-6474-4240-aac1-726f4c7c4c1f" xlink:href="evh-20210630.xsd#evh_AssetAcquisitionAccruedLiabilities"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_12f8e93a-d473-44ef-9397-2079bdc72ee6" xlink:to="loc_evh_AssetAcquisitionAccruedLiabilities_0f691050-6474-4240-aac1-726f4c7c4c1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCollectionOfNotesReceivable_3ea8eb9e-f29c-42b9-9098-5e76b341fad4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromCollectionOfNotesReceivable"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_12f8e93a-d473-44ef-9397-2079bdc72ee6" xlink:to="loc_us-gaap_ProceedsFromCollectionOfNotesReceivable_3ea8eb9e-f29c-42b9-9098-5e76b341fad4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromInterestReceived_481ef9fb-8dc2-4deb-b934-b465b22cb4ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromInterestReceived"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_12f8e93a-d473-44ef-9397-2079bdc72ee6" xlink:to="loc_us-gaap_ProceedsFromInterestReceived_481ef9fb-8dc2-4deb-b934-b465b22cb4ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ProceedsFromTransferOfMembership_0f69ea83-f213-4b82-88cd-674f80f35b61" xlink:href="evh-20210630.xsd#evh_ProceedsFromTransferOfMembership"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_12f8e93a-d473-44ef-9397-2079bdc72ee6" xlink:to="loc_evh_ProceedsFromTransferOfMembership_0f69ea83-f213-4b82-88cd-674f80f35b61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TransferOfMembershipPercentageOfPaymentBasedOnNumberOfEnrollees_3db586c3-a00f-47b0-a47a-b42b37c8b332" xlink:href="evh-20210630.xsd#evh_TransferOfMembershipPercentageOfPaymentBasedOnNumberOfEnrollees"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_12f8e93a-d473-44ef-9397-2079bdc72ee6" xlink:to="loc_evh_TransferOfMembershipPercentageOfPaymentBasedOnNumberOfEnrollees_3db586c3-a00f-47b0-a47a-b42b37c8b332" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TransferOfMembershipPercentageOfPaymentSubjectToSatisfactionOfContingencies_7617a509-7aea-4974-a66f-a9e722782797" xlink:href="evh-20210630.xsd#evh_TransferOfMembershipPercentageOfPaymentSubjectToSatisfactionOfContingencies"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_12f8e93a-d473-44ef-9397-2079bdc72ee6" xlink:to="loc_evh_TransferOfMembershipPercentageOfPaymentSubjectToSatisfactionOfContingencies_7617a509-7aea-4974-a66f-a9e722782797" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/DiscontinuedOperations" xlink:type="simple" xlink:href="evh-20210630.xsd#DiscontinuedOperations"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/DiscontinuedOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_88c723ae-2a1c-4786-ae70-f0374c98e7e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_9e7ccd5e-dfed-4bf2-b24b-38870b6b76b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_88c723ae-2a1c-4786-ae70-f0374c98e7e3" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_9e7ccd5e-dfed-4bf2-b24b-38870b6b76b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/DiscontinuedOperationsTables" xlink:type="simple" xlink:href="evh-20210630.xsd#DiscontinuedOperationsTables"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/DiscontinuedOperationsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_241a5a21-c5cb-460f-a5c0-a3165b81b042" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_31ad10c5-acc0-47e3-9fa1-523fffdb9160" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_241a5a21-c5cb-460f-a5c0-a3165b81b042" xlink:to="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_31ad10c5-acc0-47e3-9fa1-523fffdb9160" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails" xlink:type="simple" xlink:href="evh-20210630.xsd#DiscontinuedOperationsSummaryofResultsofOperationsDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_83867f5d-80bf-4ab8-af13-4e83ff9e985d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_6f783584-a66c-4778-90d5-451825f7be96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_83867f5d-80bf-4ab8-af13-4e83ff9e985d" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_6f783584-a66c-4778-90d5-451825f7be96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_d0310830-5424-47f8-98e6-339bb0ed7315" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_6f783584-a66c-4778-90d5-451825f7be96" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_d0310830-5424-47f8-98e6-339bb0ed7315" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_af8b6710-2ca8-43bf-9e33-9886938d90ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_d0310830-5424-47f8-98e6-339bb0ed7315" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_af8b6710-2ca8-43bf-9e33-9886938d90ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_915f4c82-cb83-4cc8-b8b4-c6eea604be0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationsDisposedOfBySaleMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_af8b6710-2ca8-43bf-9e33-9886938d90ff" xlink:to="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_915f4c82-cb83-4cc8-b8b4-c6eea604be0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_357e30ae-8e3b-479a-b935-71c40cab2fc8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_6f783584-a66c-4778-90d5-451825f7be96" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_357e30ae-8e3b-479a-b935-71c40cab2fc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_939f9ad1-0ba4-45db-acdd-5aeaafa6f014" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_357e30ae-8e3b-479a-b935-71c40cab2fc8" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_939f9ad1-0ba4-45db-acdd-5aeaafa6f014" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TrueHealthMember_901c08bf-ba8d-4164-a5f8-247f724f396f" xlink:href="evh-20210630.xsd#evh_TrueHealthMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_939f9ad1-0ba4-45db-acdd-5aeaafa6f014" xlink:to="loc_evh_TrueHealthMember_901c08bf-ba8d-4164-a5f8-247f724f396f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_ccca5283-1150-4b6b-a50b-4afff334549f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_6f783584-a66c-4778-90d5-451825f7be96" xlink:to="loc_srt_ProductOrServiceAxis_ccca5283-1150-4b6b-a50b-4afff334549f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_9285167a-7a41-4485-8b3d-66c6bd1da5b4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_ccca5283-1150-4b6b-a50b-4afff334549f" xlink:to="loc_srt_ProductsAndServicesDomain_9285167a-7a41-4485-8b3d-66c6bd1da5b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PlatformsAndOperationsServicesMember_1e3d27a7-8a6b-4bfb-8336-82555b2f656a" xlink:href="evh-20210630.xsd#evh_PlatformsAndOperationsServicesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_9285167a-7a41-4485-8b3d-66c6bd1da5b4" xlink:to="loc_evh_PlatformsAndOperationsServicesMember_1e3d27a7-8a6b-4bfb-8336-82555b2f656a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PremiumsRevenueMember_5b399804-25d8-4d24-822e-3b336974646f" xlink:href="evh-20210630.xsd#evh_PremiumsRevenueMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_9285167a-7a41-4485-8b3d-66c6bd1da5b4" xlink:to="loc_evh_PremiumsRevenueMember_5b399804-25d8-4d24-822e-3b336974646f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ServicesAgreementsMember_77b5526b-fc0c-492e-91c0-bf07b353a417" xlink:href="evh-20210630.xsd#evh_ServicesAgreementsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_9285167a-7a41-4485-8b3d-66c6bd1da5b4" xlink:to="loc_evh_ServicesAgreementsMember_77b5526b-fc0c-492e-91c0-bf07b353a417" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_87ee90e3-9456-4c0b-ac63-beb96c48e0e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_6f783584-a66c-4778-90d5-451825f7be96" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_87ee90e3-9456-4c0b-ac63-beb96c48e0e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_2f58d3e2-696b-4884-b569-c0b84a867ae2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_87ee90e3-9456-4c0b-ac63-beb96c48e0e1" xlink:to="loc_us-gaap_RevenuesAbstract_2f58d3e2-696b-4884-b569-c0b84a867ae2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_a27d003a-fabb-4fc4-b967-56dc23d9e6e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_2f58d3e2-696b-4884-b569-c0b84a867ae2" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_a27d003a-fabb-4fc4-b967-56dc23d9e6e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_63a22bb8-d585-43c8-8a94-3eb7002d9940" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_87ee90e3-9456-4c0b-ac63-beb96c48e0e1" xlink:to="loc_us-gaap_OperatingExpensesAbstract_63a22bb8-d585-43c8-8a94-3eb7002d9940" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_c2ac2377-4099-4634-9975-528e721aa19f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_63a22bb8-d585-43c8-8a94-3eb7002d9940" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_c2ac2377-4099-4634-9975-528e721aa19f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DisposalGroupIncludingDiscontinuedOperationClaimsExpense_f4d1d68f-4ac0-41bd-ba4a-3bffb1e59971" xlink:href="evh-20210630.xsd#evh_DisposalGroupIncludingDiscontinuedOperationClaimsExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_63a22bb8-d585-43c8-8a94-3eb7002d9940" xlink:to="loc_evh_DisposalGroupIncludingDiscontinuedOperationClaimsExpense_f4d1d68f-4ac0-41bd-ba4a-3bffb1e59971" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_5ff00bea-a3a9-439c-90aa-49e093c4cbed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_63a22bb8-d585-43c8-8a94-3eb7002d9940" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_5ff00bea-a3a9-439c-90aa-49e093c4cbed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortizationDiscontinuedOperations_4fada917-a1c4-4f19-a84e-13df407096d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortizationDiscontinuedOperations"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_63a22bb8-d585-43c8-8a94-3eb7002d9940" xlink:to="loc_us-gaap_DepreciationAndAmortizationDiscontinuedOperations_4fada917-a1c4-4f19-a84e-13df407096d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_0396dfe6-60d6-4935-a8d5-3f561a859d5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_63a22bb8-d585-43c8-8a94-3eb7002d9940" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_0396dfe6-60d6-4935-a8d5-3f561a859d5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_b022aa12-525c-40a3-94ed-c07b07f01c31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_87ee90e3-9456-4c0b-ac63-beb96c48e0e1" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_b022aa12-525c-40a3-94ed-c07b07f01c31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome_a9175905-41d8-4ce1-a33d-d6fc3dfcba21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_87ee90e3-9456-4c0b-ac63-beb96c48e0e1" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome_a9175905-41d8-4ce1-a33d-d6fc3dfcba21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense_3871c86a-3b32-4d11-835e-037915bb01c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_87ee90e3-9456-4c0b-ac63-beb96c48e0e1" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense_3871c86a-3b32-4d11-835e-037915bb01c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_0c94bc2b-0f1e-4be9-bf16-6ea254a4fcbd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_87ee90e3-9456-4c0b-ac63-beb96c48e0e1" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_0c94bc2b-0f1e-4be9-bf16-6ea254a4fcbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_fc286c60-eba2-4abd-a95c-978b0d560aa8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_87ee90e3-9456-4c0b-ac63-beb96c48e0e1" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_fc286c60-eba2-4abd-a95c-978b0d560aa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_b9dc8bb5-135c-44b1-9f3b-1c5291b7a71d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_87ee90e3-9456-4c0b-ac63-beb96c48e0e1" xlink:to="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_b9dc8bb5-135c-44b1-9f3b-1c5291b7a71d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_ef94f3eb-cec3-4db3-9031-e6af1003ea5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_87ee90e3-9456-4c0b-ac63-beb96c48e0e1" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_ef94f3eb-cec3-4db3-9031-e6af1003ea5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCashFlowsDetails" xlink:type="simple" xlink:href="evh-20210630.xsd#DiscontinuedOperationsSummaryofCashFlowsDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCashFlowsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_410c839c-6ac6-4a20-a034-8787b12b4aa4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_907373dd-10f6-496f-9bc6-7231ce942242" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_410c839c-6ac6-4a20-a034-8787b12b4aa4" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_907373dd-10f6-496f-9bc6-7231ce942242" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_9de480c4-b91b-42d9-ae39-423fde2b631f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_907373dd-10f6-496f-9bc6-7231ce942242" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_9de480c4-b91b-42d9-ae39-423fde2b631f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_5e921715-8777-4241-857c-788b8f2eaf8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_9de480c4-b91b-42d9-ae39-423fde2b631f" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_5e921715-8777-4241-857c-788b8f2eaf8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TrueHealthMember_c4673a90-f2db-436d-85f0-b61176039cad" xlink:href="evh-20210630.xsd#evh_TrueHealthMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_5e921715-8777-4241-857c-788b8f2eaf8e" xlink:to="loc_evh_TrueHealthMember_c4673a90-f2db-436d-85f0-b61176039cad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_952eab09-df8e-48e0-b52a-b7c2f7c83173" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_907373dd-10f6-496f-9bc6-7231ce942242" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_952eab09-df8e-48e0-b52a-b7c2f7c83173" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_4dcb5015-1e01-4633-a5ce-04597dbb26d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_952eab09-df8e-48e0-b52a-b7c2f7c83173" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_4dcb5015-1e01-4633-a5ce-04597dbb26d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_2f6506b0-a3e4-4148-ad0c-af05914f5ed8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationsDisposedOfBySaleMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_4dcb5015-1e01-4633-a5ce-04597dbb26d9" xlink:to="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_2f6506b0-a3e4-4148-ad0c-af05914f5ed8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d7a2c515-ef4f-44f2-9ebe-945c63ce9fac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_907373dd-10f6-496f-9bc6-7231ce942242" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d7a2c515-ef4f-44f2-9ebe-945c63ce9fac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_dc327d8e-4b29-4461-b145-be346c8dc490" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d7a2c515-ef4f-44f2-9ebe-945c63ce9fac" xlink:to="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_dc327d8e-4b29-4461-b145-be346c8dc490" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_e5604bb3-d44e-4da1-b00a-de137118775c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d7a2c515-ef4f-44f2-9ebe-945c63ce9fac" xlink:to="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_e5604bb3-d44e-4da1-b00a-de137118775c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCurrentandLongtermAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="evh-20210630.xsd#DiscontinuedOperationsSummaryofCurrentandLongtermAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCurrentandLongtermAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_ec3a2954-ca4b-4ae3-b6c8-075ec4147246" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_0b1318c6-e5fc-43b2-9ebb-196c386eab50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_ec3a2954-ca4b-4ae3-b6c8-075ec4147246" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_0b1318c6-e5fc-43b2-9ebb-196c386eab50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_ce18df37-dc5f-42f8-8fda-23af3012067a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_0b1318c6-e5fc-43b2-9ebb-196c386eab50" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_ce18df37-dc5f-42f8-8fda-23af3012067a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_80cfeba5-1d21-41b4-ac14-29647d9aebdd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_ce18df37-dc5f-42f8-8fda-23af3012067a" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_80cfeba5-1d21-41b4-ac14-29647d9aebdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TrueHealthMember_71db10b4-3824-4512-a9fe-54a906584d72" xlink:href="evh-20210630.xsd#evh_TrueHealthMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_80cfeba5-1d21-41b4-ac14-29647d9aebdd" xlink:to="loc_evh_TrueHealthMember_71db10b4-3824-4512-a9fe-54a906584d72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_1b3031b4-8142-469c-973a-4438ed3ad2c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_0b1318c6-e5fc-43b2-9ebb-196c386eab50" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_1b3031b4-8142-469c-973a-4438ed3ad2c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_da731e87-11b2-4280-88b6-79e57c6c8a73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_1b3031b4-8142-469c-973a-4438ed3ad2c8" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_da731e87-11b2-4280-88b6-79e57c6c8a73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_7e1888cf-85fb-4869-aff0-b635fcd638aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationsDisposedOfBySaleMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_da731e87-11b2-4280-88b6-79e57c6c8a73" xlink:to="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_7e1888cf-85fb-4869-aff0-b635fcd638aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_e640db72-003c-4181-906e-294e3f113299" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_0b1318c6-e5fc-43b2-9ebb-196c386eab50" xlink:to="loc_srt_ProductOrServiceAxis_e640db72-003c-4181-906e-294e3f113299" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_7ec27f1f-cc96-41b5-af40-87e439b6d4db" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_e640db72-003c-4181-906e-294e3f113299" xlink:to="loc_srt_ProductsAndServicesDomain_7ec27f1f-cc96-41b5-af40-87e439b6d4db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ServicesAgreementsMember_a5a4c0ea-4780-4861-b2d2-8324392be177" xlink:href="evh-20210630.xsd#evh_ServicesAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_7ec27f1f-cc96-41b5-af40-87e439b6d4db" xlink:to="loc_evh_ServicesAgreementsMember_a5a4c0ea-4780-4861-b2d2-8324392be177" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_7b135880-79b5-41ee-a7d9-4d047e3750a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_0b1318c6-e5fc-43b2-9ebb-196c386eab50" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_7b135880-79b5-41ee-a7d9-4d047e3750a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_70c8accc-db5d-4b6c-8e97-d51ee144307a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_7b135880-79b5-41ee-a7d9-4d047e3750a0" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_70c8accc-db5d-4b6c-8e97-d51ee144307a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_8a97c285-2d16-4faf-b4c3-fec8cb620b67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_70c8accc-db5d-4b6c-8e97-d51ee144307a" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_8a97c285-2d16-4faf-b4c3-fec8cb620b67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_5c93ac60-4202-4128-b284-4be34829d7a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_8a97c285-2d16-4faf-b4c3-fec8cb620b67" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_5c93ac60-4202-4128-b284-4be34829d7a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DisposalGroupIncludingDiscontinuedOperationRestrictedCashAndRestrictedInvestmentsCurrent_eb54504d-f379-4ba9-87cf-c75f9d174642" xlink:href="evh-20210630.xsd#evh_DisposalGroupIncludingDiscontinuedOperationRestrictedCashAndRestrictedInvestmentsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_8a97c285-2d16-4faf-b4c3-fec8cb620b67" xlink:to="loc_evh_DisposalGroupIncludingDiscontinuedOperationRestrictedCashAndRestrictedInvestmentsCurrent_eb54504d-f379-4ba9-87cf-c75f9d174642" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_3f8f2c7a-4f11-4381-9c5c-c20cd7313383" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_8a97c285-2d16-4faf-b4c3-fec8cb620b67" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_3f8f2c7a-4f11-4381-9c5c-c20cd7313383" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_3d04e3f5-a936-4c9b-b0ac-22cd94214086" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_8a97c285-2d16-4faf-b4c3-fec8cb620b67" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_3d04e3f5-a936-4c9b-b0ac-22cd94214086" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DisposalGroupIncludingDiscontinuedOperationInvestmentsCurrent_1cf07772-947c-43c4-916f-44bcfd68ec37" xlink:href="evh-20210630.xsd#evh_DisposalGroupIncludingDiscontinuedOperationInvestmentsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_8a97c285-2d16-4faf-b4c3-fec8cb620b67" xlink:to="loc_evh_DisposalGroupIncludingDiscontinuedOperationInvestmentsCurrent_1cf07772-947c-43c4-916f-44bcfd68ec37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_385e8ce8-cb4c-4509-811e-e014c332f851" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_8a97c285-2d16-4faf-b4c3-fec8cb620b67" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_385e8ce8-cb4c-4509-811e-e014c332f851" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DisposalGroupIncludingDiscontinuedOperationRestrictedCashAndRestrictedInvestmentsNoncurrent_4619ed95-4efc-483d-9d0a-fc0206e6e790" xlink:href="evh-20210630.xsd#evh_DisposalGroupIncludingDiscontinuedOperationRestrictedCashAndRestrictedInvestmentsNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_70c8accc-db5d-4b6c-8e97-d51ee144307a" xlink:to="loc_evh_DisposalGroupIncludingDiscontinuedOperationRestrictedCashAndRestrictedInvestmentsNoncurrent_4619ed95-4efc-483d-9d0a-fc0206e6e790" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DisposalGroupIncludingDiscontinuedOperationInvestmentsNoncurrent_25ad9ce6-f16d-4f42-a087-3e04e302bfeb" xlink:href="evh-20210630.xsd#evh_DisposalGroupIncludingDiscontinuedOperationInvestmentsNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_70c8accc-db5d-4b6c-8e97-d51ee144307a" xlink:to="loc_evh_DisposalGroupIncludingDiscontinuedOperationInvestmentsNoncurrent_25ad9ce6-f16d-4f42-a087-3e04e302bfeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsNoncurrent_35df2fb2-0fce-4327-adab-7bd7d7e5ecb9" xlink:href="evh-20210630.xsd#evh_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_70c8accc-db5d-4b6c-8e97-d51ee144307a" xlink:to="loc_evh_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsNoncurrent_35df2fb2-0fce-4327-adab-7bd7d7e5ecb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent_0cd83d98-d869-449b-baf3-14d4256093a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_70c8accc-db5d-4b6c-8e97-d51ee144307a" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent_0cd83d98-d869-449b-baf3-14d4256093a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent_33230615-3cdc-4150-859c-be5977b68a14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_70c8accc-db5d-4b6c-8e97-d51ee144307a" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent_33230615-3cdc-4150-859c-be5977b68a14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_83ec77d4-8dae-4469-b544-3d35122a194d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_70c8accc-db5d-4b6c-8e97-d51ee144307a" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_83ec77d4-8dae-4469-b544-3d35122a194d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_39c56e18-8636-47d2-82bf-a0334da59ce1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_7b135880-79b5-41ee-a7d9-4d047e3750a0" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_39c56e18-8636-47d2-82bf-a0334da59ce1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_44541bff-2849-4981-af03-c2a73f5898b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_39c56e18-8636-47d2-82bf-a0334da59ce1" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_44541bff-2849-4981-af03-c2a73f5898b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent_da2422de-7140-4d2b-b1e5-706c138254a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_44541bff-2849-4981-af03-c2a73f5898b1" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent_da2422de-7140-4d2b-b1e5-706c138254a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent_9154f64b-0cd6-47b9-8977-32209d820105" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_44541bff-2849-4981-af03-c2a73f5898b1" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent_9154f64b-0cd6-47b9-8977-32209d820105" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DisposalGroupIncludingDiscontinuedOperationAccruedCompensationAndEmployeeBenefitsCurrent_f39b11bc-5f49-4c84-9b9a-7674b547b5b7" xlink:href="evh-20210630.xsd#evh_DisposalGroupIncludingDiscontinuedOperationAccruedCompensationAndEmployeeBenefitsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_44541bff-2849-4981-af03-c2a73f5898b1" xlink:to="loc_evh_DisposalGroupIncludingDiscontinuedOperationAccruedCompensationAndEmployeeBenefitsCurrent_f39b11bc-5f49-4c84-9b9a-7674b547b5b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent_9a814165-ef34-4a31-a68b-b040f1a2d7cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_44541bff-2849-4981-af03-c2a73f5898b1" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent_9a814165-ef34-4a31-a68b-b040f1a2d7cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DisposalGroupIncludingDiscontinuedOperationLiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangementsCurrent_4c2b080f-195b-485a-9df6-0be1a02cfb0c" xlink:href="evh-20210630.xsd#evh_DisposalGroupIncludingDiscontinuedOperationLiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangementsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_44541bff-2849-4981-af03-c2a73f5898b1" xlink:to="loc_evh_DisposalGroupIncludingDiscontinuedOperationLiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangementsCurrent_4c2b080f-195b-485a-9df6-0be1a02cfb0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_dd0cf235-61ee-41df-9193-eda0fd22c079" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_44541bff-2849-4981-af03-c2a73f5898b1" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_dd0cf235-61ee-41df-9193-eda0fd22c079" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_f43606c4-f0d4-410c-b3c4-f88a3d6bedf8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_39c56e18-8636-47d2-82bf-a0334da59ce1" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_f43606c4-f0d4-410c-b3c4-f88a3d6bedf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities_bb8d9d90-7896-4dc5-8303-ed7073b5ca25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_39c56e18-8636-47d2-82bf-a0334da59ce1" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities_bb8d9d90-7896-4dc5-8303-ed7073b5ca25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_f4bf282f-106c-4aae-8873-cb7eb9ca96e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_39c56e18-8636-47d2-82bf-a0334da59ce1" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_f4bf282f-106c-4aae-8873-cb7eb9ca96e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RevenueRecognition" xlink:type="simple" xlink:href="evh-20210630.xsd#RevenueRecognition"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/RevenueRecognition" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_e3ab223f-305c-4384-b6dc-72b8d6e28a30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_11dec3d0-beb5-47dc-9120-058e6ffa092c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_e3ab223f-305c-4384-b6dc-72b8d6e28a30" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_11dec3d0-beb5-47dc-9120-058e6ffa092c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RevenueRecognitionTables" xlink:type="simple" xlink:href="evh-20210630.xsd#RevenueRecognitionTables"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/RevenueRecognitionTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_26378bbc-1e61-49f3-8468-bf8f820e3f75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_26e70e78-e8f2-4e2b-8eb8-70c51fe14edb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_26378bbc-1e61-49f3-8468-bf8f820e3f75" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_26e70e78-e8f2-4e2b-8eb8-70c51fe14edb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_4bc9e19d-8343-42dd-b3d6-33893e2a6aa1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_26378bbc-1e61-49f3-8468-bf8f820e3f75" xlink:to="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_4bc9e19d-8343-42dd-b3d6-33893e2a6aa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RevenueRecognitionDisaggregationofRevenueDetails" xlink:type="simple" xlink:href="evh-20210630.xsd#RevenueRecognitionDisaggregationofRevenueDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/RevenueRecognitionDisaggregationofRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_b057e803-9dd7-46a3-9a4a-cf207029e37d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_5ef4a13a-b5d6-4c73-a9b1-17c672adbc03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_b057e803-9dd7-46a3-9a4a-cf207029e37d" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_5ef4a13a-b5d6-4c73-a9b1-17c672adbc03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_2926b921-8ff7-44dd-a53b-3109344e5c13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_5ef4a13a-b5d6-4c73-a9b1-17c672adbc03" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_2926b921-8ff7-44dd-a53b-3109344e5c13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_d5d10756-8622-4807-9534-82ea60e84f21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_2926b921-8ff7-44dd-a53b-3109344e5c13" xlink:to="loc_us-gaap_SegmentDomain_d5d10756-8622-4807-9534-82ea60e84f21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EvolentHealthServicesSegmentMember_0bf65a5e-3925-4861-a205-13c5ff9f93c3" xlink:href="evh-20210630.xsd#evh_EvolentHealthServicesSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_d5d10756-8622-4807-9534-82ea60e84f21" xlink:to="loc_evh_EvolentHealthServicesSegmentMember_0bf65a5e-3925-4861-a205-13c5ff9f93c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ClinicalSolutionsSegmentMember_235c268f-ecf3-4476-98b1-25848a6315eb" xlink:href="evh-20210630.xsd#evh_ClinicalSolutionsSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_d5d10756-8622-4807-9534-82ea60e84f21" xlink:to="loc_evh_ClinicalSolutionsSegmentMember_235c268f-ecf3-4476-98b1-25848a6315eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_c132b86e-04fd-4bd7-9096-d02b14494e7f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_5ef4a13a-b5d6-4c73-a9b1-17c672adbc03" xlink:to="loc_srt_MajorCustomersAxis_c132b86e-04fd-4bd7-9096-d02b14494e7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_0c32867a-d220-4885-880c-c6b8f9936316" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_c132b86e-04fd-4bd7-9096-d02b14494e7f" xlink:to="loc_srt_NameOfMajorCustomerDomain_0c32867a-d220-4885-880c-c6b8f9936316" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_MedicaidCustomersMember_71285939-e898-4b10-baca-3d80e332e377" xlink:href="evh-20210630.xsd#evh_MedicaidCustomersMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_0c32867a-d220-4885-880c-c6b8f9936316" xlink:to="loc_evh_MedicaidCustomersMember_71285939-e898-4b10-baca-3d80e332e377" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_MedicareCustomersMember_3c2b377c-4b4d-4862-b4a0-29ae5714e738" xlink:href="evh-20210630.xsd#evh_MedicareCustomersMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_0c32867a-d220-4885-880c-c6b8f9936316" xlink:to="loc_evh_MedicareCustomersMember_3c2b377c-4b4d-4862-b4a0-29ae5714e738" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CommercialAndOtherCustomersMember_f0a0c87d-a6ff-434e-8a5d-16045e56bd73" xlink:href="evh-20210630.xsd#evh_CommercialAndOtherCustomersMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_0c32867a-d220-4885-880c-c6b8f9936316" xlink:to="loc_evh_CommercialAndOtherCustomersMember_f0a0c87d-a6ff-434e-8a5d-16045e56bd73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_52b04d2e-7633-4e42-9999-ef816cb92d36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_5ef4a13a-b5d6-4c73-a9b1-17c672adbc03" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_52b04d2e-7633-4e42-9999-ef816cb92d36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_21e9dd39-7129-49ff-b68f-c4aecc921bcb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_52b04d2e-7633-4e42-9999-ef816cb92d36" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_21e9dd39-7129-49ff-b68f-c4aecc921bcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails" xlink:type="simple" xlink:href="evh-20210630.xsd#RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_63fdcac1-4c78-4f15-8321-4a55f69b8ed2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_b888c352-7e80-4ac3-87df-8b9a5f682146" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_63fdcac1-4c78-4f15-8321-4a55f69b8ed2" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_b888c352-7e80-4ac3-87df-8b9a5f682146" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_18bda335-08e2-4983-bc0a-63a24478588f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_63fdcac1-4c78-4f15-8321-4a55f69b8ed2" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_18bda335-08e2-4983-bc0a-63a24478588f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_50b9f6c2-d9db-430f-b441-21ebb4e96335" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_18bda335-08e2-4983-bc0a-63a24478588f" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_50b9f6c2-d9db-430f-b441-21ebb4e96335" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_7aa67d75-3ec5-40b6-895c-18983099cf49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_18bda335-08e2-4983-bc0a-63a24478588f" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_7aa67d75-3ec5-40b6-895c-18983099cf49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationPercentage_d561ad00-77da-433b-8331-b5fc2c8b7c1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_7aa67d75-3ec5-40b6-895c-18983099cf49" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationPercentage_d561ad00-77da-433b-8331-b5fc2c8b7c1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_4dcaacd2-7e41-47bd-82c0-a973efb40fca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_7aa67d75-3ec5-40b6-895c-18983099cf49" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_4dcaacd2-7e41-47bd-82c0-a973efb40fca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails_1" xlink:type="simple" xlink:href="evh-20210630.xsd#RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails_1"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RevenueRecognitionContractBalancesDetails" xlink:type="simple" xlink:href="evh-20210630.xsd#RevenueRecognitionContractBalancesDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/RevenueRecognitionContractBalancesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_d9edee90-19f9-4bff-b5d8-9fafeeefa6db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableNetCurrent_740e5301-fd19-4542-94a0-dcdfa4f9cd1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsNotesAndLoansReceivableNetCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_d9edee90-19f9-4bff-b5d8-9fafeeefa6db" xlink:to="loc_us-gaap_AccountsNotesAndLoansReceivableNetCurrent_740e5301-fd19-4542-94a0-dcdfa4f9cd1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermAccountsNotesAndLoansReceivableNetNoncurrent_cbbabf95-5be7-4149-848c-4d2f2cec5f05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermAccountsNotesAndLoansReceivableNetNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_d9edee90-19f9-4bff-b5d8-9fafeeefa6db" xlink:to="loc_us-gaap_LongTermAccountsNotesAndLoansReceivableNetNoncurrent_cbbabf95-5be7-4149-848c-4d2f2cec5f05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_4da63e42-2068-4ac6-936f-caffa0786269" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_d9edee90-19f9-4bff-b5d8-9fafeeefa6db" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_4da63e42-2068-4ac6-936f-caffa0786269" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_d468916b-b751-4305-9191-2419a10bd05b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_d9edee90-19f9-4bff-b5d8-9fafeeefa6db" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_d468916b-b751-4305-9191-2419a10bd05b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_6ee5c5a8-a80f-407b-a933-fabbdcc2a136" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_d9edee90-19f9-4bff-b5d8-9fafeeefa6db" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_6ee5c5a8-a80f-407b-a933-fabbdcc2a136" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_ccd774af-8e94-4acf-ab40-25547fb8f426" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_d9edee90-19f9-4bff-b5d8-9fafeeefa6db" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_ccd774af-8e94-4acf-ab40-25547fb8f426" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_6cbb87a6-fded-4f16-ba93-5a7800632ec0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_ccd774af-8e94-4acf-ab40-25547fb8f426" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_6cbb87a6-fded-4f16-ba93-5a7800632ec0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_7ac362c4-230e-404d-8e28-c5c74f9987d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_6cbb87a6-fded-4f16-ba93-5a7800632ec0" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_7ac362c4-230e-404d-8e28-c5c74f9987d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_1fa0b817-c932-4562-ad81-9a100e54c5f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationsDisposedOfBySaleMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_7ac362c4-230e-404d-8e28-c5c74f9987d2" xlink:to="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_1fa0b817-c932-4562-ad81-9a100e54c5f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_88743283-2313-4187-be37-01d920e609e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_ccd774af-8e94-4acf-ab40-25547fb8f426" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_88743283-2313-4187-be37-01d920e609e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_301d00ae-dde8-429c-9a27-1436a45695ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_88743283-2313-4187-be37-01d920e609e5" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_301d00ae-dde8-429c-9a27-1436a45695ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TrueHealthMember_685e3554-72e7-4124-acec-a2901c9d7e11" xlink:href="evh-20210630.xsd#evh_TrueHealthMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_301d00ae-dde8-429c-9a27-1436a45695ee" xlink:to="loc_evh_TrueHealthMember_685e3554-72e7-4124-acec-a2901c9d7e11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_909c1f61-f8ba-4eb3-8598-d1c0b0a54e1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_ccd774af-8e94-4acf-ab40-25547fb8f426" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_909c1f61-f8ba-4eb3-8598-d1c0b0a54e1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNetAfterGrossUp_b2a87e8d-1a14-4b3c-943d-c02032a6c5ed" xlink:href="evh-20210630.xsd#evh_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNetAfterGrossUp"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_909c1f61-f8ba-4eb3-8598-d1c0b0a54e1c" xlink:to="loc_evh_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNetAfterGrossUp_b2a87e8d-1a14-4b3c-943d-c02032a6c5ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent_0982b11a-fbb4-40d5-bd5c-66d0191ed000" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_909c1f61-f8ba-4eb3-8598-d1c0b0a54e1c" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent_0982b11a-fbb4-40d5-bd5c-66d0191ed000" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ChangeInContractWithCustomerLiabilityRollForward_7625d6e1-cec5-4675-9f6d-2d21e25a8c81" xlink:href="evh-20210630.xsd#evh_ChangeInContractWithCustomerLiabilityRollForward"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_d9edee90-19f9-4bff-b5d8-9fafeeefa6db" xlink:to="loc_evh_ChangeInContractWithCustomerLiabilityRollForward_7625d6e1-cec5-4675-9f6d-2d21e25a8c81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_60dd2c5d-987d-404a-97af-561d69cb4342" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evh_ChangeInContractWithCustomerLiabilityRollForward_7625d6e1-cec5-4675-9f6d-2d21e25a8c81" xlink:to="loc_us-gaap_ContractWithCustomerLiability_60dd2c5d-987d-404a-97af-561d69cb4342" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_b4fb013f-1406-4ae1-a8bf-e7d83aa414c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evh_ChangeInContractWithCustomerLiabilityRollForward_7625d6e1-cec5-4675-9f6d-2d21e25a8c81" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_b4fb013f-1406-4ae1-a8bf-e7d83aa414c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations_6c2d603b-4426-4298-9f99-1ddbd865caec" xlink:href="evh-20210630.xsd#evh_ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evh_ChangeInContractWithCustomerLiabilityRollForward_7625d6e1-cec5-4675-9f6d-2d21e25a8c81" xlink:to="loc_evh_ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations_6c2d603b-4426-4298-9f99-1ddbd865caec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_2b63e6c1-688c-4823-8583-70053df52dbb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evh_ChangeInContractWithCustomerLiabilityRollForward_7625d6e1-cec5-4675-9f6d-2d21e25a8c81" xlink:to="loc_us-gaap_ContractWithCustomerLiability_2b63e6c1-688c-4823-8583-70053df52dbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_d57327a4-345f-4e85-b62f-3c644051d27b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_d9edee90-19f9-4bff-b5d8-9fafeeefa6db" xlink:to="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_d57327a4-345f-4e85-b62f-3c644051d27b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RevenueRecognitionContractCostsDetails" xlink:type="simple" xlink:href="evh-20210630.xsd#RevenueRecognitionContractCostsDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/RevenueRecognitionContractCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_64afeb72-1026-421f-892c-732c329a15fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostTable_e6144b4e-42b2-4c37-a5c4-ccc5ad66e565" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedContractCostTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_64afeb72-1026-421f-892c-732c329a15fb" xlink:to="loc_us-gaap_CapitalizedContractCostTable_e6144b4e-42b2-4c37-a5c4-ccc5ad66e565" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostAxis_509aa18e-d411-45b2-b1b3-ba5ea6d189d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedContractCostAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedContractCostTable_e6144b4e-42b2-4c37-a5c4-ccc5ad66e565" xlink:to="loc_us-gaap_CapitalizedContractCostAxis_509aa18e-d411-45b2-b1b3-ba5ea6d189d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostDomain_42ec7c0d-01c7-49e7-836e-4ca75d4992a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedContractCostDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedContractCostAxis_509aa18e-d411-45b2-b1b3-ba5ea6d189d1" xlink:to="loc_us-gaap_CapitalizedContractCostDomain_42ec7c0d-01c7-49e7-836e-4ca75d4992a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_BonusesAndCommissionsMember_4d301bb1-d3ac-4d59-aaad-38a62ff744fe" xlink:href="evh-20210630.xsd#evh_BonusesAndCommissionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedContractCostDomain_42ec7c0d-01c7-49e7-836e-4ca75d4992a3" xlink:to="loc_evh_BonusesAndCommissionsMember_4d301bb1-d3ac-4d59-aaad-38a62ff744fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ContractFulfillmentCostsMember_06c408c1-526b-4e1f-981c-e07bde0f3db4" xlink:href="evh-20210630.xsd#evh_ContractFulfillmentCostsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedContractCostDomain_42ec7c0d-01c7-49e7-836e-4ca75d4992a3" xlink:to="loc_evh_ContractFulfillmentCostsMember_06c408c1-526b-4e1f-981c-e07bde0f3db4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostLineItems_51351ad8-771f-4228-95a2-3977e80c9276" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedContractCostLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedContractCostTable_e6144b4e-42b2-4c37-a5c4-ccc5ad66e565" xlink:to="loc_us-gaap_CapitalizedContractCostLineItems_51351ad8-771f-4228-95a2-3977e80c9276" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostNet_472a3214-ec84-48b0-81ae-5a58472059a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedContractCostNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedContractCostLineItems_51351ad8-771f-4228-95a2-3977e80c9276" xlink:to="loc_us-gaap_CapitalizedContractCostNet_472a3214-ec84-48b0-81ae-5a58472059a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostAmortization_a17bbec9-5994-466b-abed-caf8f2f6866e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedContractCostAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedContractCostLineItems_51351ad8-771f-4228-95a2-3977e80c9276" xlink:to="loc_us-gaap_CapitalizedContractCostAmortization_a17bbec9-5994-466b-abed-caf8f2f6866e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostAmortizationPeriod_2a01492d-2c61-4cd0-93cb-68fe75c8b8d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedContractCostAmortizationPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedContractCostLineItems_51351ad8-771f-4228-95a2-3977e80c9276" xlink:to="loc_us-gaap_CapitalizedContractCostAmortizationPeriod_2a01492d-2c61-4cd0-93cb-68fe75c8b8d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CreditLosses" xlink:type="simple" xlink:href="evh-20210630.xsd#CreditLosses"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/CreditLosses" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditLossAbstract_f21bbb44-e593-488e-9377-a3d70bc87478" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditLossAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditLossFinancialInstrumentTextBlock_7e188309-1344-45bc-a394-f66004252ff7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditLossFinancialInstrumentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditLossAbstract_f21bbb44-e593-488e-9377-a3d70bc87478" xlink:to="loc_us-gaap_CreditLossFinancialInstrumentTextBlock_7e188309-1344-45bc-a394-f66004252ff7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CreditLossesTables" xlink:type="simple" xlink:href="evh-20210630.xsd#CreditLossesTables"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/CreditLossesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditLossAbstract_e6f1c05e-6d31-4644-9eee-86bceb1baac6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditLossAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock_0d8b797c-6cd0-49ab-bf4f-a7402a20a99c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditLossAbstract_e6f1c05e-6d31-4644-9eee-86bceb1baac6" xlink:to="loc_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock_0d8b797c-6cd0-49ab-bf4f-a7402a20a99c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CreditLossesAccountsReceivableNarrativeDetails" xlink:type="simple" xlink:href="evh-20210630.xsd#CreditLossesAccountsReceivableNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/CreditLossesAccountsReceivableNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditLossAbstract_b713f6ba-c198-4c38-bab1-518a1b9652e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditLossAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNoncurrentPastDueTable_6784e90d-0189-47b4-ba7a-623ad83cec11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNoncurrentPastDueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditLossAbstract_b713f6ba-c198-4c38-bab1-518a1b9652e5" xlink:to="loc_us-gaap_AccountsReceivableNoncurrentPastDueTable_6784e90d-0189-47b4-ba7a-623ad83cec11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivablesPeriodPastDueAxis_bb979454-f0a9-466a-8a13-ee26af077612" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancingReceivablesPeriodPastDueAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsReceivableNoncurrentPastDueTable_6784e90d-0189-47b4-ba7a-623ad83cec11" xlink:to="loc_us-gaap_FinancingReceivablesPeriodPastDueAxis_bb979454-f0a9-466a-8a13-ee26af077612" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivablesPeriodPastDueDomain_07a1bf41-29e3-43c1-81b2-782aca1372c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancingReceivablesPeriodPastDueDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancingReceivablesPeriodPastDueAxis_bb979454-f0a9-466a-8a13-ee26af077612" xlink:to="loc_us-gaap_FinancingReceivablesPeriodPastDueDomain_07a1bf41-29e3-43c1-81b2-782aca1372c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_FInancialAssetLessThan60DaysMember_b47fbfbf-24e8-48a9-bb3c-311583ae98c3" xlink:href="evh-20210630.xsd#evh_FInancialAssetLessThan60DaysMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancingReceivablesPeriodPastDueDomain_07a1bf41-29e3-43c1-81b2-782aca1372c5" xlink:to="loc_evh_FInancialAssetLessThan60DaysMember_b47fbfbf-24e8-48a9-bb3c-311583ae98c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_FInancialAssetLessThan120DaysPastDueMember_9dbfe7b8-eaa3-4019-8f82-bb62eef1b682" xlink:href="evh-20210630.xsd#evh_FInancialAssetLessThan120DaysPastDueMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancingReceivablesPeriodPastDueDomain_07a1bf41-29e3-43c1-81b2-782aca1372c5" xlink:to="loc_evh_FInancialAssetLessThan120DaysPastDueMember_9dbfe7b8-eaa3-4019-8f82-bb62eef1b682" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNoncurrentPastDueLineItems_8b8a769a-4af1-4141-9b75-411ede8349dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNoncurrentPastDueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsReceivableNoncurrentPastDueTable_6784e90d-0189-47b4-ba7a-623ad83cec11" xlink:to="loc_us-gaap_AccountsReceivableNoncurrentPastDueLineItems_8b8a769a-4af1-4141-9b75-411ede8349dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_FinancingReceivablePercentNotPastDue_7f798047-ce02-4f7f-8f86-ff2cf9a54a10" xlink:href="evh-20210630.xsd#evh_FinancingReceivablePercentNotPastDue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsReceivableNoncurrentPastDueLineItems_8b8a769a-4af1-4141-9b75-411ede8349dd" xlink:to="loc_evh_FinancingReceivablePercentNotPastDue_7f798047-ce02-4f7f-8f86-ff2cf9a54a10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivablePercentPastDue1_69ca576d-9618-45dd-a6a2-89a6fb2be1d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancingReceivablePercentPastDue1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsReceivableNoncurrentPastDueLineItems_8b8a769a-4af1-4141-9b75-411ede8349dd" xlink:to="loc_us-gaap_FinancingReceivablePercentPastDue1_69ca576d-9618-45dd-a6a2-89a6fb2be1d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNet_c16292ad-c10a-4a7a-b176-dac5d62ef3dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsReceivableNoncurrentPastDueLineItems_8b8a769a-4af1-4141-9b75-411ede8349dd" xlink:to="loc_us-gaap_AccountsReceivableNet_c16292ad-c10a-4a7a-b176-dac5d62ef3dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_d5d11216-ef6e-43ad-a245-bf8bf7560cc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsReceivableNoncurrentPastDueLineItems_8b8a769a-4af1-4141-9b75-411ede8349dd" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_d5d11216-ef6e-43ad-a245-bf8bf7560cc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CreditLossesScheduleofChangesinAllowanceforAccountsReceivableDetails" xlink:type="simple" xlink:href="evh-20210630.xsd#CreditLossesScheduleofChangesinAllowanceforAccountsReceivableDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/CreditLossesScheduleofChangesinAllowanceforAccountsReceivableDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditLossAbstract_eed505a3-c6cd-42d8-a4d5-eb3bbe6d3c28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditLossAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_aeb5e780-4625-4d52-95c8-8c00ef060684" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditLossAbstract_eed505a3-c6cd-42d8-a4d5-eb3bbe6d3c28" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_aeb5e780-4625-4d52-95c8-8c00ef060684" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_2e5ae638-49dd-445f-a7e7-9a92becc0181" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_aeb5e780-4625-4d52-95c8-8c00ef060684" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_2e5ae638-49dd-445f-a7e7-9a92becc0181" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_c1d5e870-195e-45bc-bba6-ce410e39f54b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_2e5ae638-49dd-445f-a7e7-9a92becc0181" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_c1d5e870-195e-45bc-bba6-ce410e39f54b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_e5282bbe-3e1e-4903-8cd2-d9d00ced0a2f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_c1d5e870-195e-45bc-bba6-ce410e39f54b" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_e5282bbe-3e1e-4903-8cd2-d9d00ced0a2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_0dfb2aa3-d3e9-4f01-8be0-9b683baa1bac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_aeb5e780-4625-4d52-95c8-8c00ef060684" xlink:to="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_0dfb2aa3-d3e9-4f01-8be0-9b683baa1bac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_74def6f3-a441-4a75-af65-64e409be1c59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_0dfb2aa3-d3e9-4f01-8be0-9b683baa1bac" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_74def6f3-a441-4a75-af65-64e409be1c59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_4531a2af-e2da-4330-9458-257ccd9d6a14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_74def6f3-a441-4a75-af65-64e409be1c59" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_4531a2af-e2da-4330-9458-257ccd9d6a14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_ed3ecf40-9967-4291-a88a-12c4e0c7e6bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_74def6f3-a441-4a75-af65-64e409be1c59" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_ed3ecf40-9967-4291-a88a-12c4e0c7e6bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_2ac4348b-7832-4018-a3e7-8d5d9fdaeeff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_74def6f3-a441-4a75-af65-64e409be1c59" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_2ac4348b-7832-4018-a3e7-8d5d9fdaeeff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_cd1f1d2b-bf97-4c6b-b0d9-7599914bdd01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_74def6f3-a441-4a75-af65-64e409be1c59" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_cd1f1d2b-bf97-4c6b-b0d9-7599914bdd01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/PropertyandEquipmentNet" xlink:type="simple" xlink:href="evh-20210630.xsd#PropertyandEquipmentNet"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/PropertyandEquipmentNet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_e3534c37-e62e-49b2-aaa1-7044e8b7dc4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_b6a00b2b-8f39-4155-bc66-07305f774760" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_e3534c37-e62e-49b2-aaa1-7044e8b7dc4c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_b6a00b2b-8f39-4155-bc66-07305f774760" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/PropertyandEquipmentNetTables" xlink:type="simple" xlink:href="evh-20210630.xsd#PropertyandEquipmentNetTables"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/PropertyandEquipmentNetTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_9291b081-9823-4756-bd2d-60f409a760a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_f42859b2-1724-430a-97c2-1fc8d2d429a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_9291b081-9823-4756-bd2d-60f409a760a7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_f42859b2-1724-430a-97c2-1fc8d2d429a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails" xlink:type="simple" xlink:href="evh-20210630.xsd#PropertyandEquipmentNetDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_c5555c5d-a99f-484e-a2b8-72292f9215f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_d228146c-490a-4894-82db-47fed7eb61f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_c5555c5d-a99f-484e-a2b8-72292f9215f2" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_d228146c-490a-4894-82db-47fed7eb61f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_47513067-4dd3-4ff6-8a5a-b065561bce18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_d228146c-490a-4894-82db-47fed7eb61f5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_47513067-4dd3-4ff6-8a5a-b065561bce18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d8375468-d994-4681-a713-1eacd9ddd2ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_47513067-4dd3-4ff6-8a5a-b065561bce18" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d8375468-d994-4681-a713-1eacd9ddd2ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_5f4d7e8c-c8f2-4e81-a83f-25b9a7586480" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d8375468-d994-4681-a713-1eacd9ddd2ca" xlink:to="loc_us-gaap_ComputerEquipmentMember_5f4d7e8c-c8f2-4e81-a83f-25b9a7586480" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_dd417e55-bfb8-4c74-ab8b-6c32e79375a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d8375468-d994-4681-a713-1eacd9ddd2ca" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_dd417e55-bfb8-4c74-ab8b-6c32e79375a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareDevelopmentMember_820bfe29-a526-4d73-9a1e-732d960ffab1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SoftwareDevelopmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d8375468-d994-4681-a713-1eacd9ddd2ca" xlink:to="loc_us-gaap_SoftwareDevelopmentMember_820bfe29-a526-4d73-9a1e-732d960ffab1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_934b8d95-1791-40c7-9616-8d8d79767816" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d8375468-d994-4681-a713-1eacd9ddd2ca" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_934b8d95-1791-40c7-9616-8d8d79767816" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_684223ba-b497-480b-a575-4978acd7ec3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_d228146c-490a-4894-82db-47fed7eb61f5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_684223ba-b497-480b-a575-4978acd7ec3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_cf6678aa-c0bb-40e1-aa38-85f68a2428dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_684223ba-b497-480b-a575-4978acd7ec3b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_cf6678aa-c0bb-40e1-aa38-85f68a2428dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_78cacae9-7f61-4f23-a1ca-7992b6380e2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_684223ba-b497-480b-a575-4978acd7ec3b" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_78cacae9-7f61-4f23-a1ca-7992b6380e2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_3eaa247b-529f-4e87-bc18-d523e92e2f16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_684223ba-b497-480b-a575-4978acd7ec3b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_3eaa247b-529f-4e87-bc18-d523e92e2f16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedComputerSoftwareAdditions_76463bcd-54c2-4fe4-91aa-f14c2c557dea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedComputerSoftwareAdditions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_684223ba-b497-480b-a575-4978acd7ec3b" xlink:to="loc_us-gaap_CapitalizedComputerSoftwareAdditions_76463bcd-54c2-4fe4-91aa-f14c2c557dea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_c2561de0-c6ff-496d-b18a-fe5676feacb5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_684223ba-b497-480b-a575-4978acd7ec3b" xlink:to="loc_us-gaap_Depreciation_c2561de0-c6ff-496d-b18a-fe5676feacb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedComputerSoftwareAmortization1_d5be5676-cb94-4298-a8ae-97a64813b427" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedComputerSoftwareAmortization1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_684223ba-b497-480b-a575-4978acd7ec3b" xlink:to="loc_us-gaap_CapitalizedComputerSoftwareAmortization1_d5be5676-cb94-4298-a8ae-97a64813b427" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNet" xlink:type="simple" xlink:href="evh-20210630.xsd#GoodwillandIntangibleAssetsNet"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_9bb037b7-30cd-46e4-b835-332fde24f3f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_164d7122-84f1-4ac2-895f-48f97df1cb26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_9bb037b7-30cd-46e4-b835-332fde24f3f7" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_164d7122-84f1-4ac2-895f-48f97df1cb26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetTables" xlink:type="simple" xlink:href="evh-20210630.xsd#GoodwillandIntangibleAssetsNetTables"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0d075530-51e9-4c40-889a-064d3f9f83fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_904eeff6-e203-4fbc-acda-dcce6015ffdb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0d075530-51e9-4c40-889a-064d3f9f83fe" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_904eeff6-e203-4fbc-acda-dcce6015ffdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_26caa372-0201-4390-a403-02c295c1aa0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0d075530-51e9-4c40-889a-064d3f9f83fe" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_26caa372-0201-4390-a403-02c295c1aa0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_74f80e57-8dbf-428d-bfd2-59fe1d5595c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0d075530-51e9-4c40-889a-064d3f9f83fe" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_74f80e57-8dbf-428d-bfd2-59fe1d5595c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetImpairmentTestingDetails" xlink:type="simple" xlink:href="evh-20210630.xsd#GoodwillandIntangibleAssetsNetImpairmentTestingDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetImpairmentTestingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_59238147-0cff-4b54-abe7-e2282159a31e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_c56b217c-beb8-4fa9-aeb2-7e9bdacf3112" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_59238147-0cff-4b54-abe7-e2282159a31e" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_c56b217c-beb8-4fa9-aeb2-7e9bdacf3112" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis_f3ea86fb-5470-4f5a-aece-112913ab79ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_c56b217c-beb8-4fa9-aeb2-7e9bdacf3112" xlink:to="loc_us-gaap_ValuationTechniqueAxis_f3ea86fb-5470-4f5a-aece-112913ab79ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_a694f300-18bb-483f-a544-e93877d32932" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueAxis_f3ea86fb-5470-4f5a-aece-112913ab79ab" xlink:to="loc_us-gaap_ValuationTechniqueDomain_a694f300-18bb-483f-a544-e93877d32932" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeApproachValuationTechniqueMember_5e010e2f-e59a-4c04-b399-48ab0582b3a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeApproachValuationTechniqueMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueDomain_a694f300-18bb-483f-a544-e93877d32932" xlink:to="loc_us-gaap_IncomeApproachValuationTechniqueMember_5e010e2f-e59a-4c04-b399-48ab0582b3a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_bc4ed0b6-65d0-4a47-ae3c-ecc0706ca431" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_c56b217c-beb8-4fa9-aeb2-7e9bdacf3112" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_bc4ed0b6-65d0-4a47-ae3c-ecc0706ca431" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportingUnits_1f31ede4-9053-4a03-8b58-19c4c24038b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfReportingUnits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_bc4ed0b6-65d0-4a47-ae3c-ecc0706ca431" xlink:to="loc_us-gaap_NumberOfReportingUnits_1f31ede4-9053-4a03-8b58-19c4c24038b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_c1e95d4b-4063-4495-94ed-9bb800f0f583" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_bc4ed0b6-65d0-4a47-ae3c-ecc0706ca431" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_c1e95d4b-4063-4495-94ed-9bb800f0f583" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_NumberOfReportingUnitsFairValueInExcessOfCarryingAmount_01cda054-b42f-443c-bcd3-e7e67ad533fd" xlink:href="evh-20210630.xsd#evh_NumberOfReportingUnitsFairValueInExcessOfCarryingAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_bc4ed0b6-65d0-4a47-ae3c-ecc0706ca431" xlink:to="loc_evh_NumberOfReportingUnitsFairValueInExcessOfCarryingAmount_01cda054-b42f-443c-bcd3-e7e67ad533fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_0cbb8c7c-ef65-4142-bb60-cd64a6015126" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_bc4ed0b6-65d0-4a47-ae3c-ecc0706ca431" xlink:to="loc_us-gaap_Goodwill_0cbb8c7c-ef65-4142-bb60-cd64a6015126" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetScheduleofGoodwillDetails" xlink:type="simple" xlink:href="evh-20210630.xsd#GoodwillandIntangibleAssetsNetScheduleofGoodwillDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetScheduleofGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_747167a3-52ed-4284-b2f4-1078cd804d69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_ca8fa63b-5a92-4fdd-93fd-107bea106b7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_747167a3-52ed-4284-b2f4-1078cd804d69" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_ca8fa63b-5a92-4fdd-93fd-107bea106b7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_4f1ca97f-39b0-4131-adff-aebc076dc107" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_ca8fa63b-5a92-4fdd-93fd-107bea106b7c" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_4f1ca97f-39b0-4131-adff-aebc076dc107" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_630a5c8e-e7e4-46f4-99ed-83459e2b59fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_4f1ca97f-39b0-4131-adff-aebc076dc107" xlink:to="loc_us-gaap_SegmentDomain_630a5c8e-e7e4-46f4-99ed-83459e2b59fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EvolentHealthServicesSegmentMember_f757e134-94b1-4e5b-b93f-4f67a688b56c" xlink:href="evh-20210630.xsd#evh_EvolentHealthServicesSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_630a5c8e-e7e4-46f4-99ed-83459e2b59fe" xlink:to="loc_evh_EvolentHealthServicesSegmentMember_f757e134-94b1-4e5b-b93f-4f67a688b56c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ClinicalSolutionsSegmentMember_d8cbab54-8982-4ecd-a94d-42bc2f557c8a" xlink:href="evh-20210630.xsd#evh_ClinicalSolutionsSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_630a5c8e-e7e4-46f4-99ed-83459e2b59fe" xlink:to="loc_evh_ClinicalSolutionsSegmentMember_d8cbab54-8982-4ecd-a94d-42bc2f557c8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_e948acad-7c34-4bad-b799-e32b9c072995" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_ca8fa63b-5a92-4fdd-93fd-107bea106b7c" xlink:to="loc_us-gaap_GoodwillLineItems_e948acad-7c34-4bad-b799-e32b9c072995" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_282082ed-01d3-449a-89d0-e4ebc455efa8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_e948acad-7c34-4bad-b799-e32b9c072995" xlink:to="loc_us-gaap_GoodwillRollForward_282082ed-01d3-449a-89d0-e4ebc455efa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_7260fa2f-03a0-4ab3-ba2f-61f8188bf30c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_282082ed-01d3-449a-89d0-e4ebc455efa8" xlink:to="loc_us-gaap_Goodwill_7260fa2f-03a0-4ab3-ba2f-61f8188bf30c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_0e902ff5-5107-4ffa-979a-50f05f4a04d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_282082ed-01d3-449a-89d0-e4ebc455efa8" xlink:to="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_0e902ff5-5107-4ffa-979a-50f05f4a04d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_26f537f0-cf6f-4adb-a884-15c28900d026" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_282082ed-01d3-449a-89d0-e4ebc455efa8" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_26f537f0-cf6f-4adb-a884-15c28900d026" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_85f1c75d-198a-41b8-a9e0-0aa6cffe26b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_282082ed-01d3-449a-89d0-e4ebc455efa8" xlink:to="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_85f1c75d-198a-41b8-a9e0-0aa6cffe26b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_9255d50d-8048-434d-b47a-f0851a21050c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_282082ed-01d3-449a-89d0-e4ebc455efa8" xlink:to="loc_us-gaap_Goodwill_9255d50d-8048-434d-b47a-f0851a21050c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_b839e4d3-ef2d-4217-a1d5-af29b4b4176c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_e948acad-7c34-4bad-b799-e32b9c072995" xlink:to="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_b839e4d3-ef2d-4217-a1d5-af29b4b4176c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails" xlink:type="simple" xlink:href="evh-20210630.xsd#GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0c26057c-e0cc-46bc-9e1f-56a4ee0637b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_03a4e372-6636-4b14-8ce7-b768816a537b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0c26057c-e0cc-46bc-9e1f-56a4ee0637b3" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_03a4e372-6636-4b14-8ce7-b768816a537b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6b49b9cf-bf0e-4f32-aca9-9db561e1669d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_03a4e372-6636-4b14-8ce7-b768816a537b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6b49b9cf-bf0e-4f32-aca9-9db561e1669d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a48e5e05-02ba-42a8-af3f-3f58dabb2861" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6b49b9cf-bf0e-4f32-aca9-9db561e1669d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a48e5e05-02ba-42a8-af3f-3f58dabb2861" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_26a379b0-2822-45bd-ad67-f3f55b0ea8fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradeNamesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a48e5e05-02ba-42a8-af3f-3f58dabb2861" xlink:to="loc_us-gaap_TradeNamesMember_26a379b0-2822-45bd-ad67-f3f55b0ea8fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_911d63ee-da62-432e-8915-561eb62ed149" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a48e5e05-02ba-42a8-af3f-3f58dabb2861" xlink:to="loc_us-gaap_CustomerRelationshipsMember_911d63ee-da62-432e-8915-561eb62ed149" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_26d36819-60e3-447f-b453-d80eb7fea70f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a48e5e05-02ba-42a8-af3f-3f58dabb2861" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_26d36819-60e3-447f-b453-d80eb7fea70f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_BelowMarketLeasesMember_ff1fcbf7-9ea2-47c3-9aa1-64dbeb0e9aee" xlink:href="evh-20210630.xsd#evh_BelowMarketLeasesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a48e5e05-02ba-42a8-af3f-3f58dabb2861" xlink:to="loc_evh_BelowMarketLeasesMember_ff1fcbf7-9ea2-47c3-9aa1-64dbeb0e9aee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractBasedIntangibleAssetsMember_cdc9597b-eb00-4efd-acaf-e109eb905913" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractBasedIntangibleAssetsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a48e5e05-02ba-42a8-af3f-3f58dabb2861" xlink:to="loc_us-gaap_ContractBasedIntangibleAssetsMember_cdc9597b-eb00-4efd-acaf-e109eb905913" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_8f8187d3-2a3e-4cf8-bdbe-1f420714fc9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_03a4e372-6636-4b14-8ce7-b768816a537b" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_8f8187d3-2a3e-4cf8-bdbe-1f420714fc9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_3c5e3694-b59c-428b-9b3a-1f1df57b24c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_8f8187d3-2a3e-4cf8-bdbe-1f420714fc9e" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_3c5e3694-b59c-428b-9b3a-1f1df57b24c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_4ff17a39-b219-414d-bc88-4979c0f40d89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationsDisposedOfBySaleMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_3c5e3694-b59c-428b-9b3a-1f1df57b24c3" xlink:to="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_4ff17a39-b219-414d-bc88-4979c0f40d89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_867b4ca1-eb52-4174-b7e0-4aa75b037444" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_03a4e372-6636-4b14-8ce7-b768816a537b" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_867b4ca1-eb52-4174-b7e0-4aa75b037444" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_c79c5f7d-aaf1-4ee2-b43f-5ab9d1eff107" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_867b4ca1-eb52-4174-b7e0-4aa75b037444" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_c79c5f7d-aaf1-4ee2-b43f-5ab9d1eff107" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TrueHealthMember_6a7e0748-7526-4ca3-b46a-ca0479bc843c" xlink:href="evh-20210630.xsd#evh_TrueHealthMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_c79c5f7d-aaf1-4ee2-b43f-5ab9d1eff107" xlink:to="loc_evh_TrueHealthMember_6a7e0748-7526-4ca3-b46a-ca0479bc843c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_cc26e440-1aee-41c9-b7af-91e09cbfc8ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_03a4e372-6636-4b14-8ce7-b768816a537b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_cc26e440-1aee-41c9-b7af-91e09cbfc8ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_6c434863-f4f7-4814-adbc-0ff6688448e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_cc26e440-1aee-41c9-b7af-91e09cbfc8ad" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_6c434863-f4f7-4814-adbc-0ff6688448e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_76b8c964-ed09-4cf8-a9b7-1799f4f37c21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_cc26e440-1aee-41c9-b7af-91e09cbfc8ad" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_76b8c964-ed09-4cf8-a9b7-1799f4f37c21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_c705a354-0756-4ecd-a2a3-09fbe9e63925" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_cc26e440-1aee-41c9-b7af-91e09cbfc8ad" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_c705a354-0756-4ecd-a2a3-09fbe9e63925" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_1195a377-846a-43a1-b607-b8ce7b5fe4b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_cc26e440-1aee-41c9-b7af-91e09cbfc8ad" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_1195a377-846a-43a1-b607-b8ce7b5fe4b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent_08683f2d-0db1-4b2e-ae28-54121d1b6d13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_cc26e440-1aee-41c9-b7af-91e09cbfc8ad" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent_08683f2d-0db1-4b2e-ae28-54121d1b6d13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_aa6f15a9-c74b-4619-bc9d-16677efd1e80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_cc26e440-1aee-41c9-b7af-91e09cbfc8ad" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_aa6f15a9-c74b-4619-bc9d-16677efd1e80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssets10KDetails" xlink:type="simple" xlink:href="evh-20210630.xsd#GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssets10KDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssets10KDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_edefcbb6-3aba-46f0-b62e-a89fea8d84e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_3645d003-24b6-43c0-8175-45ef4fbc4dab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_edefcbb6-3aba-46f0-b62e-a89fea8d84e4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_3645d003-24b6-43c0-8175-45ef4fbc4dab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_e25a3589-ebd3-42a0-8bce-d5171822f2ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_edefcbb6-3aba-46f0-b62e-a89fea8d84e4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_e25a3589-ebd3-42a0-8bce-d5171822f2ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_0796b2d2-9448-4494-bdf9-ab464abc5309" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_edefcbb6-3aba-46f0-b62e-a89fea8d84e4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_0796b2d2-9448-4494-bdf9-ab464abc5309" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_133c1f57-cd3c-4af3-850e-aac423d5fb06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_edefcbb6-3aba-46f0-b62e-a89fea8d84e4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_133c1f57-cd3c-4af3-850e-aac423d5fb06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_3a180445-900f-4311-abd6-6286a8014938" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_edefcbb6-3aba-46f0-b62e-a89fea8d84e4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_3a180445-900f-4311-abd6-6286a8014938" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_3779e79d-1bcd-4efb-9db0-536ab2648fce" xlink:href="evh-20210630.xsd#evh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_edefcbb6-3aba-46f0-b62e-a89fea8d84e4" xlink:to="loc_evh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_3779e79d-1bcd-4efb-9db0-536ab2648fce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_ca1a6ac6-d9de-4fb4-9df7-5e4f2117337c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_edefcbb6-3aba-46f0-b62e-a89fea8d84e4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_ca1a6ac6-d9de-4fb4-9df7-5e4f2117337c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LongtermDebt" xlink:type="simple" xlink:href="evh-20210630.xsd#LongtermDebt"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/LongtermDebt" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_cffeba49-6702-420d-bc7d-064d1a7aaa3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_5703c2e1-246e-48f7-8f0f-98f09b5a8cf2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_cffeba49-6702-420d-bc7d-064d1a7aaa3a" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_5703c2e1-246e-48f7-8f0f-98f09b5a8cf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LongtermDebtTables" xlink:type="simple" xlink:href="evh-20210630.xsd#LongtermDebtTables"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/LongtermDebtTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_e3c31510-a264-40f9-8dbb-60a971f247f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtTableTextBlock_11382f35-76e6-4673-91a2-c9a715934f09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_e3c31510-a264-40f9-8dbb-60a971f247f8" xlink:to="loc_us-gaap_ConvertibleDebtTableTextBlock_11382f35-76e6-4673-91a2-c9a715934f09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails" xlink:type="simple" xlink:href="evh-20210630.xsd#LongtermDebt2024NotesDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_eaa79e47-5a89-47a6-853f-6fa7ca21c810" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_6bf932c2-e1dc-4e96-8024-d1ce7a6f6c50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_eaa79e47-5a89-47a6-853f-6fa7ca21c810" xlink:to="loc_us-gaap_DebtInstrumentTable_6bf932c2-e1dc-4e96-8024-d1ce7a6f6c50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_f6aacd82-a44a-4969-a962-069ae0b3db49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_6bf932c2-e1dc-4e96-8024-d1ce7a6f6c50" xlink:to="loc_us-gaap_DebtInstrumentAxis_f6aacd82-a44a-4969-a962-069ae0b3db49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_bac85b02-3580-496a-baf6-aaeeac0be76c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_f6aacd82-a44a-4969-a962-069ae0b3db49" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_bac85b02-3580-496a-baf6-aaeeac0be76c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SeniorConvertibleNotesDue2024Member_99523183-2205-45ee-a954-62780baa99a1" xlink:href="evh-20210630.xsd#evh_SeniorConvertibleNotesDue2024Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_bac85b02-3580-496a-baf6-aaeeac0be76c" xlink:to="loc_evh_SeniorConvertibleNotesDue2024Member_99523183-2205-45ee-a954-62780baa99a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ConvertibleSeniorNotesdue2021Member_9f066823-1a54-4035-8fed-e5779348e27f" xlink:href="evh-20210630.xsd#evh_ConvertibleSeniorNotesdue2021Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_bac85b02-3580-496a-baf6-aaeeac0be76c" xlink:to="loc_evh_ConvertibleSeniorNotesdue2021Member_9f066823-1a54-4035-8fed-e5779348e27f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_NewNotesMember_59609156-c567-478f-a9ee-55b718b521cf" xlink:href="evh-20210630.xsd#evh_NewNotesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_bac85b02-3580-496a-baf6-aaeeac0be76c" xlink:to="loc_evh_NewNotesMember_59609156-c567-478f-a9ee-55b718b521cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_4f45ba18-77d0-4028-b9f6-60d9895c4fc2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_6bf932c2-e1dc-4e96-8024-d1ce7a6f6c50" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_4f45ba18-77d0-4028-b9f6-60d9895c4fc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_191eefba-6802-4442-b094-700d9a4b7d4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_4f45ba18-77d0-4028-b9f6-60d9895c4fc2" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_191eefba-6802-4442-b094-700d9a4b7d4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_24f9e59c-0329-46f0-b2f9-c8ee2a92415a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_191eefba-6802-4442-b094-700d9a4b7d4f" xlink:to="loc_us-gaap_SeniorNotesMember_24f9e59c-0329-46f0-b2f9-c8ee2a92415a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_f7cd0c5c-a931-447b-a8aa-a9509c6cb920" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_6bf932c2-e1dc-4e96-8024-d1ce7a6f6c50" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_f7cd0c5c-a931-447b-a8aa-a9509c6cb920" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_41d79bfb-64a7-4fd2-aae1-579b4698f071" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f7cd0c5c-a931-447b-a8aa-a9509c6cb920" xlink:to="loc_us-gaap_EquityComponentDomain_41d79bfb-64a7-4fd2-aae1-579b4698f071" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_a320f29a-5d70-4ce9-a9ac-0842450e5847" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_41d79bfb-64a7-4fd2-aae1-579b4698f071" xlink:to="loc_us-gaap_CommonStockMember_a320f29a-5d70-4ce9-a9ac-0842450e5847" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_0a830427-2de0-4aa0-b415-a1d076121714" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_6bf932c2-e1dc-4e96-8024-d1ce7a6f6c50" xlink:to="loc_us-gaap_StatementClassOfStockAxis_0a830427-2de0-4aa0-b415-a1d076121714" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_ec79089b-5313-4467-b6aa-ee3ca01dc80e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_0a830427-2de0-4aa0-b415-a1d076121714" xlink:to="loc_us-gaap_ClassOfStockDomain_ec79089b-5313-4467-b6aa-ee3ca01dc80e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_003a3210-e195-4e0f-ae02-1d61dbbe578d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_ec79089b-5313-4467-b6aa-ee3ca01dc80e" xlink:to="loc_us-gaap_CommonClassAMember_003a3210-e195-4e0f-ae02-1d61dbbe578d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_46d6f015-f7ee-448a-8a40-d22c0963aeaf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_6bf932c2-e1dc-4e96-8024-d1ce7a6f6c50" xlink:to="loc_us-gaap_DebtInstrumentLineItems_46d6f015-f7ee-448a-8a40-d22c0963aeaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_a5975142-4adc-4cc1-a4c7-acffa9f1f695" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_46d6f015-f7ee-448a-8a40-d22c0963aeaf" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_a5975142-4adc-4cc1-a4c7-acffa9f1f695" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_f599cd60-127c-4f06-b312-c513f1f60897" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_46d6f015-f7ee-448a-8a40-d22c0963aeaf" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_f599cd60-127c-4f06-b312-c513f1f60897" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_318701bd-cdf0-4e6d-87ac-54fb43cfa10c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_46d6f015-f7ee-448a-8a40-d22c0963aeaf" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_318701bd-cdf0-4e6d-87ac-54fb43cfa10c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionOriginalDebtAmount1_541a939b-6668-4bc5-97a7-f6732e769ac8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionOriginalDebtAmount1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_46d6f015-f7ee-448a-8a40-d22c0963aeaf" xlink:to="loc_us-gaap_DebtConversionOriginalDebtAmount1_541a939b-6668-4bc5-97a7-f6732e769ac8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_ac4c68d7-2f22-4072-aea5-47ee36e6f929" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_46d6f015-f7ee-448a-8a40-d22c0963aeaf" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_ac4c68d7-2f22-4072-aea5-47ee36e6f929" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_3c9facd1-f399-4195-837d-7c93591ba776" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_46d6f015-f7ee-448a-8a40-d22c0963aeaf" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_3c9facd1-f399-4195-837d-7c93591ba776" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_c381b4e9-ee16-4d50-80d0-a1220e04efc9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_46d6f015-f7ee-448a-8a40-d22c0963aeaf" xlink:to="loc_us-gaap_InterestExpenseDebt_c381b4e9-ee16-4d50-80d0-a1220e04efc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_7bc40a50-1247-4efd-a877-199e5bc95584" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_46d6f015-f7ee-448a-8a40-d22c0963aeaf" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_7bc40a50-1247-4efd-a877-199e5bc95584" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_c75d6fbc-9b11-45d2-8835-d57608129dca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_46d6f015-f7ee-448a-8a40-d22c0963aeaf" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_c75d6fbc-9b11-45d2-8835-d57608129dca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_012a571c-3ca2-46ed-8719-c0dcecf5c9b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_46d6f015-f7ee-448a-8a40-d22c0963aeaf" xlink:to="loc_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_012a571c-3ca2-46ed-8719-c0dcecf5c9b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_704a5357-fd54-46e2-9b03-852a2bbbfbd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_46d6f015-f7ee-448a-8a40-d22c0963aeaf" xlink:to="loc_us-gaap_LongTermDebt_704a5357-fd54-46e2-9b03-852a2bbbfbd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_da12c6d2-7dab-4db9-bd23-0628f3890796" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_46d6f015-f7ee-448a-8a40-d22c0963aeaf" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_da12c6d2-7dab-4db9-bd23-0628f3890796" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtIssuanceCostsNetDebtComponent_4e6dbbcc-f77c-45a1-b23b-5b1cb73ccbd2" xlink:href="evh-20210630.xsd#evh_DebtIssuanceCostsNetDebtComponent"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_46d6f015-f7ee-448a-8a40-d22c0963aeaf" xlink:to="loc_evh_DebtIssuanceCostsNetDebtComponent_4e6dbbcc-f77c-45a1-b23b-5b1cb73ccbd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_AmortizationOfDebtDiscountAndDebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_407b7094-b18e-45c7-9ca1-c988bd3a4c65" xlink:href="evh-20210630.xsd#evh_AmortizationOfDebtDiscountAndDebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_46d6f015-f7ee-448a-8a40-d22c0963aeaf" xlink:to="loc_evh_AmortizationOfDebtDiscountAndDebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_407b7094-b18e-45c7-9ca1-c988bd3a4c65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount_4ed3213f-5879-43c3-88ed-ceec8fe4672b" xlink:href="evh-20210630.xsd#evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_46d6f015-f7ee-448a-8a40-d22c0963aeaf" xlink:to="loc_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount_4ed3213f-5879-43c3-88ed-ceec8fe4672b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice_5fc82ccb-2877-452d-9c92-4cdf6693d81a" xlink:href="evh-20210630.xsd#evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_46d6f015-f7ee-448a-8a40-d22c0963aeaf" xlink:to="loc_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice_5fc82ccb-2877-452d-9c92-4cdf6693d81a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum_51308d61-e502-4aa3-82f0-600e349d0ff1" xlink:href="evh-20210630.xsd#evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_46d6f015-f7ee-448a-8a40-d22c0963aeaf" xlink:to="loc_evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum_51308d61-e502-4aa3-82f0-600e349d0ff1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum_223d27a4-874b-4610-b3cc-c3c61c76ed0d" xlink:href="evh-20210630.xsd#evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_46d6f015-f7ee-448a-8a40-d22c0963aeaf" xlink:to="loc_evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum_223d27a4-874b-4610-b3cc-c3c61c76ed0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice_f4d129d1-d83c-4548-a0e0-e3696bbe971d" xlink:href="evh-20210630.xsd#evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_46d6f015-f7ee-448a-8a40-d22c0963aeaf" xlink:to="loc_evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice_f4d129d1-d83c-4548-a0e0-e3696bbe971d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LongtermDebtCreditAgreementDetails" xlink:type="simple" xlink:href="evh-20210630.xsd#LongtermDebtCreditAgreementDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/LongtermDebtCreditAgreementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_e59715a6-e5b7-4300-b31b-cbde6ac39105" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_8e1c5577-263d-46d2-93ae-6c088dd741be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_e59715a6-e5b7-4300-b31b-cbde6ac39105" xlink:to="loc_us-gaap_DebtInstrumentTable_8e1c5577-263d-46d2-93ae-6c088dd741be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_8de43411-c6a5-4ca7-91f9-723f99f5b3b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_8e1c5577-263d-46d2-93ae-6c088dd741be" xlink:to="loc_us-gaap_DebtInstrumentAxis_8de43411-c6a5-4ca7-91f9-723f99f5b3b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_dec3371f-d94a-49ce-889e-3b384d0f07b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_8de43411-c6a5-4ca7-91f9-723f99f5b3b5" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_dec3371f-d94a-49ce-889e-3b384d0f07b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_InitialTermLoanFacilityMember_b12d46f1-17c1-4d7a-8d75-ccf6c19bfe14" xlink:href="evh-20210630.xsd#evh_InitialTermLoanFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_dec3371f-d94a-49ce-889e-3b384d0f07b4" xlink:to="loc_evh_InitialTermLoanFacilityMember_b12d46f1-17c1-4d7a-8d75-ccf6c19bfe14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CreditAgreementMember_bf416a34-575d-4413-9c3c-495477c08be6" xlink:href="evh-20210630.xsd#evh_CreditAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_dec3371f-d94a-49ce-889e-3b384d0f07b4" xlink:to="loc_evh_CreditAgreementMember_bf416a34-575d-4413-9c3c-495477c08be6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ConvertibleSeniorNotesdue2021Member_45b9b029-cbdc-4b6d-b923-37f82f79b33e" xlink:href="evh-20210630.xsd#evh_ConvertibleSeniorNotesdue2021Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_dec3371f-d94a-49ce-889e-3b384d0f07b4" xlink:to="loc_evh_ConvertibleSeniorNotesdue2021Member_45b9b029-cbdc-4b6d-b923-37f82f79b33e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SeniorCreditFacilitiesMember_00de3c87-13c7-4164-9108-78dc99411ebe" xlink:href="evh-20210630.xsd#evh_SeniorCreditFacilitiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_dec3371f-d94a-49ce-889e-3b384d0f07b4" xlink:to="loc_evh_SeniorCreditFacilitiesMember_00de3c87-13c7-4164-9108-78dc99411ebe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_1fb97582-1005-4800-8225-4127f81ed4e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_8e1c5577-263d-46d2-93ae-6c088dd741be" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_1fb97582-1005-4800-8225-4127f81ed4e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_b2a389b0-15c5-4c04-be18-eb8a5bd64630" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1fb97582-1005-4800-8225-4127f81ed4e3" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_b2a389b0-15c5-4c04-be18-eb8a5bd64630" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_694115c8-bce5-44a8-8195-dd2af02cd119" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_b2a389b0-15c5-4c04-be18-eb8a5bd64630" xlink:to="loc_us-gaap_SecuredDebtMember_694115c8-bce5-44a8-8195-dd2af02cd119" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_3e3416f4-5916-4d9c-9f0c-a76b1eeef03f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_b2a389b0-15c5-4c04-be18-eb8a5bd64630" xlink:to="loc_us-gaap_LineOfCreditMember_3e3416f4-5916-4d9c-9f0c-a76b1eeef03f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_e6dc6105-15cc-4f39-b3b8-bdebc58f7017" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_b2a389b0-15c5-4c04-be18-eb8a5bd64630" xlink:to="loc_us-gaap_SeniorNotesMember_e6dc6105-15cc-4f39-b3b8-bdebc58f7017" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_48215f8b-cf01-4669-887f-5d33edf88ac6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_8e1c5577-263d-46d2-93ae-6c088dd741be" xlink:to="loc_us-gaap_CreditFacilityAxis_48215f8b-cf01-4669-887f-5d33edf88ac6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_bb633313-ea4c-47eb-b3c9-1c54421fa4ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_48215f8b-cf01-4669-887f-5d33edf88ac6" xlink:to="loc_us-gaap_CreditFacilityDomain_bb633313-ea4c-47eb-b3c9-1c54421fa4ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DelayedDrawTermLoanFacilityMember_3d0ddfde-ea71-48a1-8220-1f1f551f0b38" xlink:href="evh-20210630.xsd#evh_DelayedDrawTermLoanFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_bb633313-ea4c-47eb-b3c9-1c54421fa4ca" xlink:to="loc_evh_DelayedDrawTermLoanFacilityMember_3d0ddfde-ea71-48a1-8220-1f1f551f0b38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_9495efaf-32d8-4e02-8ec4-1d1335b4ecb1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_8e1c5577-263d-46d2-93ae-6c088dd741be" xlink:to="loc_us-gaap_VariableRateAxis_9495efaf-32d8-4e02-8ec4-1d1335b4ecb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_ca09076f-b483-4e59-a5b6-9c6f0890635a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_9495efaf-32d8-4e02-8ec4-1d1335b4ecb1" xlink:to="loc_us-gaap_VariableRateDomain_ca09076f-b483-4e59-a5b6-9c6f0890635a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EurodollarMember_35191889-5c4f-463b-bdb4-c2788baeac90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EurodollarMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_ca09076f-b483-4e59-a5b6-9c6f0890635a" xlink:to="loc_us-gaap_EurodollarMember_35191889-5c4f-463b-bdb4-c2788baeac90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember_b71687f7-a55c-4519-9063-39950c201476" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BaseRateMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_ca09076f-b483-4e59-a5b6-9c6f0890635a" xlink:to="loc_us-gaap_BaseRateMember_b71687f7-a55c-4519-9063-39950c201476" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_f603b89f-e250-4e90-831f-12b2e6491622" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_8e1c5577-263d-46d2-93ae-6c088dd741be" xlink:to="loc_srt_RangeAxis_f603b89f-e250-4e90-831f-12b2e6491622" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5edbb5cb-ef3f-41a8-ac8b-8a21d64e94ba" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_f603b89f-e250-4e90-831f-12b2e6491622" xlink:to="loc_srt_RangeMember_5edbb5cb-ef3f-41a8-ac8b-8a21d64e94ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_2abbe7f5-c962-451f-b190-2b1695716928" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_5edbb5cb-ef3f-41a8-ac8b-8a21d64e94ba" xlink:to="loc_srt_MaximumMember_2abbe7f5-c962-451f-b190-2b1695716928" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_3403cf34-9b7f-44ea-a75b-c73ea4974505" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_8e1c5577-263d-46d2-93ae-6c088dd741be" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_3403cf34-9b7f-44ea-a75b-c73ea4974505" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_d65c9b77-8bb6-4d29-b37f-e6f85c48a5d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_3403cf34-9b7f-44ea-a75b-c73ea4974505" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_d65c9b77-8bb6-4d29-b37f-e6f85c48a5d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_d7e98041-ceec-45fc-8e7c-ea494b9e2ed5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_d65c9b77-8bb6-4d29-b37f-e6f85c48a5d8" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_d7e98041-ceec-45fc-8e7c-ea494b9e2ed5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_c80c9740-b892-42f8-9306-f08a1b21398e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_d65c9b77-8bb6-4d29-b37f-e6f85c48a5d8" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_c80c9740-b892-42f8-9306-f08a1b21398e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_915c6a34-58d4-4eba-8be2-22893ba6fc3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_d65c9b77-8bb6-4d29-b37f-e6f85c48a5d8" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_915c6a34-58d4-4eba-8be2-22893ba6fc3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_6b803be6-ce75-4934-9139-b7d0cf1e561f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_8e1c5577-263d-46d2-93ae-6c088dd741be" xlink:to="loc_us-gaap_DebtInstrumentLineItems_6b803be6-ce75-4934-9139-b7d0cf1e561f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_49e0d482-e2c9-4631-9362-e44f28fab9d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6b803be6-ce75-4934-9139-b7d0cf1e561f" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_49e0d482-e2c9-4631-9362-e44f28fab9d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_7f8e879b-b1d1-49c0-8605-c6321c74dde5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6b803be6-ce75-4934-9139-b7d0cf1e561f" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_7f8e879b-b1d1-49c0-8605-c6321c74dde5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_92dce11a-804e-4a1b-9430-a53c8e386665" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6b803be6-ce75-4934-9139-b7d0cf1e561f" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_92dce11a-804e-4a1b-9430-a53c8e386665" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_25815249-5f66-4109-bc06-3b8840da936f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6b803be6-ce75-4934-9139-b7d0cf1e561f" xlink:to="loc_us-gaap_DebtInstrumentTerm_25815249-5f66-4109-bc06-3b8840da936f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_81190ac2-9447-4573-8261-a4bf2707e623" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6b803be6-ce75-4934-9139-b7d0cf1e561f" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_81190ac2-9447-4573-8261-a4bf2707e623" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_0314f2f1-56a5-490c-8ea3-c52043fd1fb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6b803be6-ce75-4934-9139-b7d0cf1e561f" xlink:to="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_0314f2f1-56a5-490c-8ea3-c52043fd1fb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRedemptionCallProtectionPremiumPercentage_6853f465-a189-4b55-98bd-9e5be609ef21" xlink:href="evh-20210630.xsd#evh_DebtInstrumentRedemptionCallProtectionPremiumPercentage"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6b803be6-ce75-4934-9139-b7d0cf1e561f" xlink:to="loc_evh_DebtInstrumentRedemptionCallProtectionPremiumPercentage_6853f465-a189-4b55-98bd-9e5be609ef21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_5f20df34-1ada-4c27-ace7-2e7de340ec52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6b803be6-ce75-4934-9139-b7d0cf1e561f" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_5f20df34-1ada-4c27-ace7-2e7de340ec52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_AmortizationOfDebtDiscountAndDebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_9e6e1d6d-0920-4f61-9382-097bc6584b3c" xlink:href="evh-20210630.xsd#evh_AmortizationOfDebtDiscountAndDebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6b803be6-ce75-4934-9139-b7d0cf1e561f" xlink:to="loc_evh_AmortizationOfDebtDiscountAndDebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_9e6e1d6d-0920-4f61-9382-097bc6584b3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit_44a212ec-84ae-4c54-9e98-e834f650b7c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermLinesOfCredit"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6b803be6-ce75-4934-9139-b7d0cf1e561f" xlink:to="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit_44a212ec-84ae-4c54-9e98-e834f650b7c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PaymentsOfMakeWholePremium_3a619518-55c4-43ea-adcb-2ca02d2e1eeb" xlink:href="evh-20210630.xsd#evh_PaymentsOfMakeWholePremium"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6b803be6-ce75-4934-9139-b7d0cf1e561f" xlink:to="loc_evh_PaymentsOfMakeWholePremium_3a619518-55c4-43ea-adcb-2ca02d2e1eeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_8e797a35-eb99-4246-9063-fbcd4ffe5346" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6b803be6-ce75-4934-9139-b7d0cf1e561f" xlink:to="loc_us-gaap_InterestPaidNet_8e797a35-eb99-4246-9063-fbcd4ffe5346" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_3a8dacb5-a055-42c7-8bd6-1557e6ee5e0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6b803be6-ce75-4934-9139-b7d0cf1e561f" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_3a8dacb5-a055-42c7-8bd6-1557e6ee5e0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WriteOffOfDeferredDebtIssuanceCost_a994918c-d038-4a92-8520-b614a7649786" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WriteOffOfDeferredDebtIssuanceCost"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6b803be6-ce75-4934-9139-b7d0cf1e561f" xlink:to="loc_us-gaap_WriteOffOfDeferredDebtIssuanceCost_a994918c-d038-4a92-8520-b614a7649786" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalFees_2d6570f4-34e9-4d39-9128-60be53881346" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LegalFees"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6b803be6-ce75-4934-9139-b7d0cf1e561f" xlink:to="loc_us-gaap_LegalFees_2d6570f4-34e9-4d39-9128-60be53881346" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LongtermDebtWarrantAgreementDetails" xlink:type="simple" xlink:href="evh-20210630.xsd#LongtermDebtWarrantAgreementDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/LongtermDebtWarrantAgreementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_f7155769-5e8b-4142-b11f-999f2685dda3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_6eb6f537-79d3-4824-8130-50aaae0ef2ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_f7155769-5e8b-4142-b11f-999f2685dda3" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_6eb6f537-79d3-4824-8130-50aaae0ef2ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_93ee03a3-b756-4e2f-988d-7a869fca9fce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_6eb6f537-79d3-4824-8130-50aaae0ef2ba" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_93ee03a3-b756-4e2f-988d-7a869fca9fce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_05492ac9-3136-41f4-9370-d9c21123c8a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_93ee03a3-b756-4e2f-988d-7a869fca9fce" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_05492ac9-3136-41f4-9370-d9c21123c8a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_8ed7d10b-5008-4f40-ae1f-b602189adafc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_05492ac9-3136-41f4-9370-d9c21123c8a4" xlink:to="loc_us-gaap_CommonClassAMember_8ed7d10b-5008-4f40-ae1f-b602189adafc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_7f1dc011-977d-41f9-b001-f8b3ebab8be2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_6eb6f537-79d3-4824-8130-50aaae0ef2ba" xlink:to="loc_us-gaap_DebtInstrumentAxis_7f1dc011-977d-41f9-b001-f8b3ebab8be2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_7075b8a5-1826-48f0-ab6a-0c157990f339" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_7f1dc011-977d-41f9-b001-f8b3ebab8be2" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_7075b8a5-1826-48f0-ab6a-0c157990f339" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CreditAgreementMember_ead3c090-d536-4f40-92fc-1cbb1fb96ef7" xlink:href="evh-20210630.xsd#evh_CreditAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7075b8a5-1826-48f0-ab6a-0c157990f339" xlink:to="loc_evh_CreditAgreementMember_ead3c090-d536-4f40-92fc-1cbb1fb96ef7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_58af2bb8-618c-4d46-8e35-0b1b5f9ae89b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_6eb6f537-79d3-4824-8130-50aaae0ef2ba" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_58af2bb8-618c-4d46-8e35-0b1b5f9ae89b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightUnissued_3ea30901-f7cb-4040-aa48-1b0db4b33214" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightUnissued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_58af2bb8-618c-4d46-8e35-0b1b5f9ae89b" xlink:to="loc_us-gaap_ClassOfWarrantOrRightUnissued_3ea30901-f7cb-4040-aa48-1b0db4b33214" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_ab05b3dd-75f5-4524-a8a6-459def213488" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_58af2bb8-618c-4d46-8e35-0b1b5f9ae89b" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_ab05b3dd-75f5-4524-a8a6-459def213488" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ClassOfWarrantOrRightPeriodDuringWhichWarrantsOrRightsExercisableAfterMaturityOfCreditAgreement_ee5021db-180a-4963-b343-3784f9454a2e" xlink:href="evh-20210630.xsd#evh_ClassOfWarrantOrRightPeriodDuringWhichWarrantsOrRightsExercisableAfterMaturityOfCreditAgreement"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_58af2bb8-618c-4d46-8e35-0b1b5f9ae89b" xlink:to="loc_evh_ClassOfWarrantOrRightPeriodDuringWhichWarrantsOrRightsExercisableAfterMaturityOfCreditAgreement_ee5021db-180a-4963-b343-3784f9454a2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfWarrants_134d3b89-116a-42fc-96cd-1ff0d37119be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfWarrants"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_58af2bb8-618c-4d46-8e35-0b1b5f9ae89b" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfWarrants_134d3b89-116a-42fc-96cd-1ff0d37119be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails" xlink:type="simple" xlink:href="evh-20210630.xsd#LongtermDebt2025NotesDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_7d4af5ac-762e-43a2-a331-60e047c19bfb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_ed9c5967-f366-4656-94f2-c8fd9cb0a095" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_7d4af5ac-762e-43a2-a331-60e047c19bfb" xlink:to="loc_us-gaap_DebtInstrumentTable_ed9c5967-f366-4656-94f2-c8fd9cb0a095" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_4479a0b3-6cd1-41f7-a61f-2e25001b9799" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_ed9c5967-f366-4656-94f2-c8fd9cb0a095" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_4479a0b3-6cd1-41f7-a61f-2e25001b9799" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_4cf8f14e-01f9-4101-88e0-ffb9512048f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_4479a0b3-6cd1-41f7-a61f-2e25001b9799" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_4cf8f14e-01f9-4101-88e0-ffb9512048f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_4870db0a-e2b7-459f-b116-a11043e9cca3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_4cf8f14e-01f9-4101-88e0-ffb9512048f7" xlink:to="loc_us-gaap_SeniorNotesMember_4870db0a-e2b7-459f-b116-a11043e9cca3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_58076ce8-9d4f-4672-8965-13325cc00481" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_ed9c5967-f366-4656-94f2-c8fd9cb0a095" xlink:to="loc_us-gaap_DebtInstrumentAxis_58076ce8-9d4f-4672-8965-13325cc00481" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_fbdd5e8c-09ec-4a94-94be-d976d68612cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_58076ce8-9d4f-4672-8965-13325cc00481" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_fbdd5e8c-09ec-4a94-94be-d976d68612cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SeniorConvertibleNotesDue2025Member_b815ffd1-3e45-4574-b1e1-b7faf55a0856" xlink:href="evh-20210630.xsd#evh_SeniorConvertibleNotesDue2025Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_fbdd5e8c-09ec-4a94-94be-d976d68612cf" xlink:to="loc_evh_SeniorConvertibleNotesDue2025Member_b815ffd1-3e45-4574-b1e1-b7faf55a0856" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_4f7d84ee-3ab0-4977-818a-6481281b9233" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_ed9c5967-f366-4656-94f2-c8fd9cb0a095" xlink:to="loc_us-gaap_StatementClassOfStockAxis_4f7d84ee-3ab0-4977-818a-6481281b9233" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_2f5f6c98-5d3f-4b1c-b3fa-47af80908d66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_4f7d84ee-3ab0-4977-818a-6481281b9233" xlink:to="loc_us-gaap_ClassOfStockDomain_2f5f6c98-5d3f-4b1c-b3fa-47af80908d66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_a52be8dd-a514-4e9c-afea-b43976928b3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_2f5f6c98-5d3f-4b1c-b3fa-47af80908d66" xlink:to="loc_us-gaap_CommonClassAMember_a52be8dd-a514-4e9c-afea-b43976928b3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_216eb2fe-d4fd-44eb-81c8-e378c3a07930" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_ed9c5967-f366-4656-94f2-c8fd9cb0a095" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_216eb2fe-d4fd-44eb-81c8-e378c3a07930" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_f331b519-36db-4968-8668-fa8537c01da7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_216eb2fe-d4fd-44eb-81c8-e378c3a07930" xlink:to="loc_us-gaap_EquityComponentDomain_f331b519-36db-4968-8668-fa8537c01da7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_a4b34362-0b73-468e-be78-ba85e8384cba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_f331b519-36db-4968-8668-fa8537c01da7" xlink:to="loc_us-gaap_CommonStockMember_a4b34362-0b73-468e-be78-ba85e8384cba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_26d08983-9f1a-466f-b410-c3dcff33fe2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_ed9c5967-f366-4656-94f2-c8fd9cb0a095" xlink:to="loc_us-gaap_DebtInstrumentLineItems_26d08983-9f1a-466f-b410-c3dcff33fe2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_1b18db98-ccd3-46ad-9ee1-e1ae2316a02e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_26d08983-9f1a-466f-b410-c3dcff33fe2f" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_1b18db98-ccd3-46ad-9ee1-e1ae2316a02e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_82d1874a-210b-4693-bf40-2604e85c763b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_26d08983-9f1a-466f-b410-c3dcff33fe2f" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_82d1874a-210b-4693-bf40-2604e85c763b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_49b033f7-a0c9-4611-a848-e12f600155b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_26d08983-9f1a-466f-b410-c3dcff33fe2f" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_49b033f7-a0c9-4611-a848-e12f600155b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_6c8c954a-6d0d-48f5-96ad-0cd8df8f09d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_26d08983-9f1a-466f-b410-c3dcff33fe2f" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_6c8c954a-6d0d-48f5-96ad-0cd8df8f09d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_df1bb9b6-fc5c-4771-a757-a2f20b806bbd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_26d08983-9f1a-466f-b410-c3dcff33fe2f" xlink:to="loc_us-gaap_InterestExpenseDebt_df1bb9b6-fc5c-4771-a757-a2f20b806bbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_1fd65d72-5594-46bd-a030-3cae6731abc8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_26d08983-9f1a-466f-b410-c3dcff33fe2f" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_1fd65d72-5594-46bd-a030-3cae6731abc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_20251fe2-0898-49ac-9130-c6ca47142bb1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_26d08983-9f1a-466f-b410-c3dcff33fe2f" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_20251fe2-0898-49ac-9130-c6ca47142bb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_d5dc93df-42b5-41c4-ae91-151d73f2e039" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_26d08983-9f1a-466f-b410-c3dcff33fe2f" xlink:to="loc_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_d5dc93df-42b5-41c4-ae91-151d73f2e039" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_a085a08c-9434-4651-abcc-cc21a0fde7ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_26d08983-9f1a-466f-b410-c3dcff33fe2f" xlink:to="loc_us-gaap_LongTermDebt_a085a08c-9434-4651-abcc-cc21a0fde7ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_AmortizationOfDebtDiscountAndDebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_bca52550-72ee-4420-a77d-26a65a385925" xlink:href="evh-20210630.xsd#evh_AmortizationOfDebtDiscountAndDebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_26d08983-9f1a-466f-b410-c3dcff33fe2f" xlink:to="loc_evh_AmortizationOfDebtDiscountAndDebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_bca52550-72ee-4420-a77d-26a65a385925" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount_bb0106d3-51cb-4a11-a9de-09c56dc507c7" xlink:href="evh-20210630.xsd#evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_26d08983-9f1a-466f-b410-c3dcff33fe2f" xlink:to="loc_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount_bb0106d3-51cb-4a11-a9de-09c56dc507c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice_18d3e7a6-c2f1-48a8-bdb9-95d7ea4a6e4e" xlink:href="evh-20210630.xsd#evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_26d08983-9f1a-466f-b410-c3dcff33fe2f" xlink:to="loc_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice_18d3e7a6-c2f1-48a8-bdb9-95d7ea4a6e4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum_9443491a-e2af-4c2e-bc81-e0339fee82be" xlink:href="evh-20210630.xsd#evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_26d08983-9f1a-466f-b410-c3dcff33fe2f" xlink:to="loc_evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum_9443491a-e2af-4c2e-bc81-e0339fee82be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum_1fda0eed-b5a9-40e5-b231-a09ed9e6edf2" xlink:href="evh-20210630.xsd#evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_26d08983-9f1a-466f-b410-c3dcff33fe2f" xlink:to="loc_evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum_1fda0eed-b5a9-40e5-b231-a09ed9e6edf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice_9ad070eb-6689-4745-afb1-f9aa3279a6d3" xlink:href="evh-20210630.xsd#evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_26d08983-9f1a-466f-b410-c3dcff33fe2f" xlink:to="loc_evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice_9ad070eb-6689-4745-afb1-f9aa3279a6d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails" xlink:type="simple" xlink:href="evh-20210630.xsd#LongtermDebt2021NotesDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_8ab6c5d0-17b6-4684-828c-336023862997" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_210962ae-785b-4c08-aa70-5fa40fe085ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_8ab6c5d0-17b6-4684-828c-336023862997" xlink:to="loc_us-gaap_DebtInstrumentTable_210962ae-785b-4c08-aa70-5fa40fe085ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_ea6bec50-8ea2-40c4-99f0-50bb594c4628" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_210962ae-785b-4c08-aa70-5fa40fe085ca" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_ea6bec50-8ea2-40c4-99f0-50bb594c4628" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_6b8cc85c-81c7-40dc-bea5-fbcad4975e74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_ea6bec50-8ea2-40c4-99f0-50bb594c4628" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_6b8cc85c-81c7-40dc-bea5-fbcad4975e74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_9c36d011-64e9-465d-ab6c-b0019de7f700" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_6b8cc85c-81c7-40dc-bea5-fbcad4975e74" xlink:to="loc_us-gaap_SeniorNotesMember_9c36d011-64e9-465d-ab6c-b0019de7f700" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_9840bb7e-59aa-4f61-87db-8ff8e776cb36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_210962ae-785b-4c08-aa70-5fa40fe085ca" xlink:to="loc_us-gaap_DebtInstrumentAxis_9840bb7e-59aa-4f61-87db-8ff8e776cb36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_8869322a-506a-42bc-81ae-234acd0e7f36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_9840bb7e-59aa-4f61-87db-8ff8e776cb36" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_8869322a-506a-42bc-81ae-234acd0e7f36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ConvertibleSeniorNotesdue2021Member_b574823d-e87d-4340-a86d-83b00351789f" xlink:href="evh-20210630.xsd#evh_ConvertibleSeniorNotesdue2021Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8869322a-506a-42bc-81ae-234acd0e7f36" xlink:to="loc_evh_ConvertibleSeniorNotesdue2021Member_b574823d-e87d-4340-a86d-83b00351789f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SeniorConvertibleNotesDue2024Member_353bdf36-7e20-4dcd-9f73-5df11ae636c7" xlink:href="evh-20210630.xsd#evh_SeniorConvertibleNotesDue2024Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8869322a-506a-42bc-81ae-234acd0e7f36" xlink:to="loc_evh_SeniorConvertibleNotesDue2024Member_353bdf36-7e20-4dcd-9f73-5df11ae636c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_43bce4f2-d63f-4b6b-a54b-8f5907a617af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_210962ae-785b-4c08-aa70-5fa40fe085ca" xlink:to="loc_us-gaap_StatementClassOfStockAxis_43bce4f2-d63f-4b6b-a54b-8f5907a617af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_403d489f-4963-4d0d-aba7-41e00e80bd83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_43bce4f2-d63f-4b6b-a54b-8f5907a617af" xlink:to="loc_us-gaap_ClassOfStockDomain_403d489f-4963-4d0d-aba7-41e00e80bd83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_8072b12e-dc46-4d94-bf79-92954e1c434b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_403d489f-4963-4d0d-aba7-41e00e80bd83" xlink:to="loc_us-gaap_CommonClassAMember_8072b12e-dc46-4d94-bf79-92954e1c434b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_73d31921-1423-4415-aa4d-0f5005620df6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_210962ae-785b-4c08-aa70-5fa40fe085ca" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_73d31921-1423-4415-aa4d-0f5005620df6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_33c2325b-36c3-4b22-b014-4f6ab48762b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_73d31921-1423-4415-aa4d-0f5005620df6" xlink:to="loc_us-gaap_EquityComponentDomain_33c2325b-36c3-4b22-b014-4f6ab48762b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_9a956d6a-4702-4c81-bdc9-c87ea4f242b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_33c2325b-36c3-4b22-b014-4f6ab48762b1" xlink:to="loc_us-gaap_CommonStockMember_9a956d6a-4702-4c81-bdc9-c87ea4f242b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_421c2e5d-c872-4ef2-aee0-8cc5a5475a95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_210962ae-785b-4c08-aa70-5fa40fe085ca" xlink:to="loc_us-gaap_DebtInstrumentLineItems_421c2e5d-c872-4ef2-aee0-8cc5a5475a95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_fdc33d1e-8a9d-4ea7-a69a-65accaa2569f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_421c2e5d-c872-4ef2-aee0-8cc5a5475a95" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_fdc33d1e-8a9d-4ea7-a69a-65accaa2569f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_39659eed-99c9-4bb4-9539-85984c9f4e51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_421c2e5d-c872-4ef2-aee0-8cc5a5475a95" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_39659eed-99c9-4bb4-9539-85984c9f4e51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_ee058ab4-8092-4646-9c54-7ad1e44922c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_421c2e5d-c872-4ef2-aee0-8cc5a5475a95" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_ee058ab4-8092-4646-9c54-7ad1e44922c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_4016b7fc-46db-4f9f-8d01-fa9f685a3ecd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_421c2e5d-c872-4ef2-aee0-8cc5a5475a95" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_4016b7fc-46db-4f9f-8d01-fa9f685a3ecd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount_1bdbb181-0503-4be1-bcec-7bbbff90ad16" xlink:href="evh-20210630.xsd#evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_421c2e5d-c872-4ef2-aee0-8cc5a5475a95" xlink:to="loc_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount_1bdbb181-0503-4be1-bcec-7bbbff90ad16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_6b29e485-c3f2-4828-a3ed-9dfdff0e4d04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_421c2e5d-c872-4ef2-aee0-8cc5a5475a95" xlink:to="loc_us-gaap_InterestExpenseDebt_6b29e485-c3f2-4828-a3ed-9dfdff0e4d04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_98fa3e68-3ff6-4094-9bc7-829db5980bcf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_421c2e5d-c872-4ef2-aee0-8cc5a5475a95" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_98fa3e68-3ff6-4094-9bc7-829db5980bcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_71713647-48bf-49f6-b4e9-336377c66930" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_421c2e5d-c872-4ef2-aee0-8cc5a5475a95" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_71713647-48bf-49f6-b4e9-336377c66930" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_624e6bea-bb29-4b7a-a116-ba33f4c81fe7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_421c2e5d-c872-4ef2-aee0-8cc5a5475a95" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_624e6bea-bb29-4b7a-a116-ba33f4c81fe7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_34295ce0-e55e-4fc9-b121-8cbb296926c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_421c2e5d-c872-4ef2-aee0-8cc5a5475a95" xlink:to="loc_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_34295ce0-e55e-4fc9-b121-8cbb296926c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_733f1c97-ae49-4971-87e7-090d6d6daf7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_421c2e5d-c872-4ef2-aee0-8cc5a5475a95" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_733f1c97-ae49-4971-87e7-090d6d6daf7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionOriginalDebtAmount1_08093cd4-83f5-43ff-9325-1fc1e507ce29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionOriginalDebtAmount1"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_421c2e5d-c872-4ef2-aee0-8cc5a5475a95" xlink:to="loc_us-gaap_DebtConversionOriginalDebtAmount1_08093cd4-83f5-43ff-9325-1fc1e507ce29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_21f5ee44-65d1-43a8-a078-a47fc3bbd89a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_421c2e5d-c872-4ef2-aee0-8cc5a5475a95" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_21f5ee44-65d1-43a8-a078-a47fc3bbd89a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost_32ce20c4-c598-4964-bf34-d3beb004705f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_421c2e5d-c872-4ef2-aee0-8cc5a5475a95" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost_32ce20c4-c598-4964-bf34-d3beb004705f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtinguishmentOfDebtAmount_a6647e2c-0e64-4aa2-9393-966d7b118761" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ExtinguishmentOfDebtAmount"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_421c2e5d-c872-4ef2-aee0-8cc5a5475a95" xlink:to="loc_us-gaap_ExtinguishmentOfDebtAmount_a6647e2c-0e64-4aa2-9393-966d7b118761" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSeniorDebt_0b8bc6aa-a035-4d73-894c-301ab05c13b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfSeniorDebt"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_421c2e5d-c872-4ef2-aee0-8cc5a5475a95" xlink:to="loc_us-gaap_RepaymentsOfSeniorDebt_0b8bc6aa-a035-4d73-894c-301ab05c13b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails" xlink:type="simple" xlink:href="evh-20210630.xsd#LongtermDebtConvertibleSeniorNotesCarryingValueDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_832632c1-7d9e-4797-91c0-d437f5e353d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_b064a151-2e46-46ec-87b8-68dcec0b61c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_832632c1-7d9e-4797-91c0-d437f5e353d5" xlink:to="loc_us-gaap_DebtInstrumentTable_b064a151-2e46-46ec-87b8-68dcec0b61c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_8612e474-7007-4dba-8231-d069463ddee3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_b064a151-2e46-46ec-87b8-68dcec0b61c2" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_8612e474-7007-4dba-8231-d069463ddee3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_37b9a162-bbae-42f6-85a1-c841c134cb29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_8612e474-7007-4dba-8231-d069463ddee3" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_37b9a162-bbae-42f6-85a1-c841c134cb29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_7164ca4a-eacf-40ce-848e-874c1e69515c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_37b9a162-bbae-42f6-85a1-c841c134cb29" xlink:to="loc_us-gaap_SeniorNotesMember_7164ca4a-eacf-40ce-848e-874c1e69515c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_7ed68a98-b544-4e31-8935-96779f3e5bd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_b064a151-2e46-46ec-87b8-68dcec0b61c2" xlink:to="loc_us-gaap_DebtInstrumentAxis_7ed68a98-b544-4e31-8935-96779f3e5bd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_f5497986-e5fc-4b95-8c69-2aee01028ceb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_7ed68a98-b544-4e31-8935-96779f3e5bd4" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_f5497986-e5fc-4b95-8c69-2aee01028ceb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SeniorConvertibleNotesDue2024Member_d94148e8-0e9d-46e4-a455-ec9236e6d464" xlink:href="evh-20210630.xsd#evh_SeniorConvertibleNotesDue2024Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f5497986-e5fc-4b95-8c69-2aee01028ceb" xlink:to="loc_evh_SeniorConvertibleNotesDue2024Member_d94148e8-0e9d-46e4-a455-ec9236e6d464" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SeniorConvertibleNotesDue2025Member_50e33193-74db-4c37-b7a1-6e0abed68ca2" xlink:href="evh-20210630.xsd#evh_SeniorConvertibleNotesDue2025Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f5497986-e5fc-4b95-8c69-2aee01028ceb" xlink:to="loc_evh_SeniorConvertibleNotesDue2025Member_50e33193-74db-4c37-b7a1-6e0abed68ca2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ConvertibleSeniorNotesdue2021Member_5539a2ac-002d-490c-88dc-f744e7c33c68" xlink:href="evh-20210630.xsd#evh_ConvertibleSeniorNotesdue2021Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f5497986-e5fc-4b95-8c69-2aee01028ceb" xlink:to="loc_evh_ConvertibleSeniorNotesdue2021Member_5539a2ac-002d-490c-88dc-f744e7c33c68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_569ce343-010b-429e-9e99-d90fae57a896" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_b064a151-2e46-46ec-87b8-68dcec0b61c2" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_569ce343-010b-429e-9e99-d90fae57a896" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_62ba3941-aacb-4c9d-b302-4d3ac8739374" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_569ce343-010b-429e-9e99-d90fae57a896" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_62ba3941-aacb-4c9d-b302-4d3ac8739374" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_70869fef-53ce-467f-9097-6b6ae58c6713" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_62ba3941-aacb-4c9d-b302-4d3ac8739374" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_70869fef-53ce-467f-9097-6b6ae58c6713" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_a7237aa4-5398-4ae8-a37f-57eb267d444c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_b064a151-2e46-46ec-87b8-68dcec0b61c2" xlink:to="loc_us-gaap_DebtInstrumentLineItems_a7237aa4-5398-4ae8-a37f-57eb267d444c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebt_1fead341-8cfa-4ac9-9056-4b8fb9d70605" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a7237aa4-5398-4ae8-a37f-57eb267d444c" xlink:to="loc_us-gaap_ConvertibleDebt_1fead341-8cfa-4ac9-9056-4b8fb9d70605" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_cd8e6b27-adcf-4dc5-a4b5-adb63e1d0978" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a7237aa4-5398-4ae8-a37f-57eb267d444c" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_cd8e6b27-adcf-4dc5-a4b5-adb63e1d0978" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_1e7e3ef4-7d2d-4b58-83bb-1a133c9c3a92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a7237aa4-5398-4ae8-a37f-57eb267d444c" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_1e7e3ef4-7d2d-4b58-83bb-1a133c9c3a92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_bc947483-3a7a-431c-9484-839c93c02a98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a7237aa4-5398-4ae8-a37f-57eb267d444c" xlink:to="loc_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_bc947483-3a7a-431c-9484-839c93c02a98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue_d0137a53-d037-46f1-9923-2423a3cc7c8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a7237aa4-5398-4ae8-a37f-57eb267d444c" xlink:to="loc_us-gaap_LongTermDebtFairValue_d0137a53-d037-46f1-9923-2423a3cc7c8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="evh-20210630.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_a21caf78-fe43-4aa1-8330-db533e26b531" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_553b3a2c-7186-4fca-bdc8-266f261951b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_a21caf78-fe43-4aa1-8330-db533e26b531" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_553b3a2c-7186-4fca-bdc8-266f261951b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CommitmentsandContingenciesTables" xlink:type="simple" xlink:href="evh-20210630.xsd#CommitmentsandContingenciesTables"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/CommitmentsandContingenciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0533658b-1af4-4072-9c3d-093b08f1d860" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectsOfReinsuranceTableTextBlock_423e7736-b1b3-4c98-96f3-c25a19baa733" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectsOfReinsuranceTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0533658b-1af4-4072-9c3d-093b08f1d860" xlink:to="loc_us-gaap_EffectsOfReinsuranceTableTextBlock_423e7736-b1b3-4c98-96f3-c25a19baa733" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_8cb07c1b-6014-414a-90b5-3e45bdc204c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0533658b-1af4-4072-9c3d-093b08f1d860" xlink:to="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_8cb07c1b-6014-414a-90b5-3e45bdc204c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="simple" xlink:href="evh-20210630.xsd#CommitmentsandContingenciesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e541577e-3440-47aa-9d0a-5571327bc6b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_65c79b1a-5cad-4daf-966d-189b04b7c3ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e541577e-3440-47aa-9d0a-5571327bc6b7" xlink:to="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_65c79b1a-5cad-4daf-966d-189b04b7c3ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_cc824414-5bd8-46a5-85d1-6989291fa20f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_65c79b1a-5cad-4daf-966d-189b04b7c3ff" xlink:to="loc_us-gaap_CreditFacilityAxis_cc824414-5bd8-46a5-85d1-6989291fa20f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_06125bd7-01f4-442f-888e-2197c2c46cd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_cc824414-5bd8-46a5-85d1-6989291fa20f" xlink:to="loc_us-gaap_CreditFacilityDomain_06125bd7-01f4-442f-888e-2197c2c46cd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_67c11ef1-0dfd-4102-bfbc-fc52f4a5c314" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LetterOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_06125bd7-01f4-442f-888e-2197c2c46cd4" xlink:to="loc_us-gaap_LetterOfCreditMember_67c11ef1-0dfd-4102-bfbc-fc52f4a5c314" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_b8753d65-1d84-4f41-9b6c-dd4da31f1114" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_65c79b1a-5cad-4daf-966d-189b04b7c3ff" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_b8753d65-1d84-4f41-9b6c-dd4da31f1114" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_61ce72a9-60db-4c1e-9a43-be89354c41fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_b8753d65-1d84-4f41-9b6c-dd4da31f1114" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_61ce72a9-60db-4c1e-9a43-be89354c41fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_c7b6dd14-ed44-4ccc-8297-4a8fdda29d75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_61ce72a9-60db-4c1e-9a43-be89354c41fa" xlink:to="loc_us-gaap_LineOfCreditMember_c7b6dd14-ed44-4ccc-8297-4a8fdda29d75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_1ae19ca4-f392-4b01-9780-5f5ce69804c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_65c79b1a-5cad-4daf-966d-189b04b7c3ff" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_1ae19ca4-f392-4b01-9780-5f5ce69804c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_5d161731-a0c7-4f70-bfe9-6fbc128f3a56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_1ae19ca4-f392-4b01-9780-5f5ce69804c4" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_5d161731-a0c7-4f70-bfe9-6fbc128f3a56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RestrictedCashForLettersOfCreditForLetterOfCreditFacilityMember_da73b426-bf70-4b28-9ae2-361d8c1bf2b1" xlink:href="evh-20210630.xsd#evh_RestrictedCashForLettersOfCreditForLetterOfCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_5d161731-a0c7-4f70-bfe9-6fbc128f3a56" xlink:to="loc_evh_RestrictedCashForLettersOfCreditForLetterOfCreditFacilityMember_da73b426-bf70-4b28-9ae2-361d8c1bf2b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CollateralwithFinancialInstitutionsMember_c6cb8ac2-a0fc-416a-8f3e-cdeb3920822d" xlink:href="evh-20210630.xsd#evh_CollateralwithFinancialInstitutionsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_5d161731-a0c7-4f70-bfe9-6fbc128f3a56" xlink:to="loc_evh_CollateralwithFinancialInstitutionsMember_c6cb8ac2-a0fc-416a-8f3e-cdeb3920822d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_2ee04854-0d22-43c5-8173-5f4ef3652c24" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_65c79b1a-5cad-4daf-966d-189b04b7c3ff" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_2ee04854-0d22-43c5-8173-5f4ef3652c24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_1289d308-072c-493f-8ca0-d2415303d4e1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_2ee04854-0d22-43c5-8173-5f4ef3652c24" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_1289d308-072c-493f-8ca0-d2415303d4e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_UniversityHealthCaredbaPassportHealthPlanMember_78b33c75-5d74-4057-b9c5-6e24c00521cf" xlink:href="evh-20210630.xsd#evh_UniversityHealthCaredbaPassportHealthPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_1289d308-072c-493f-8ca0-d2415303d4e1" xlink:to="loc_evh_UniversityHealthCaredbaPassportHealthPlanMember_78b33c75-5d74-4057-b9c5-6e24c00521cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_df0f4096-8d0e-4764-b611-13a1e44f7ba4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_65c79b1a-5cad-4daf-966d-189b04b7c3ff" xlink:to="loc_srt_ConsolidatedEntitiesAxis_df0f4096-8d0e-4764-b611-13a1e44f7ba4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_c3d3c6cb-4483-4fde-9c61-432f9a5d090c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_df0f4096-8d0e-4764-b611-13a1e44f7ba4" xlink:to="loc_srt_ConsolidatedEntitiesDomain_c3d3c6cb-4483-4fde-9c61-432f9a5d090c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_5bd75052-7e21-4f5b-be89-fac20d4e4c69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_c3d3c6cb-4483-4fde-9c61-432f9a5d090c" xlink:to="loc_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_5bd75052-7e21-4f5b-be89-fac20d4e4c69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_02d9ace2-6fef-4364-9673-453dd5de3bd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_65c79b1a-5cad-4daf-966d-189b04b7c3ff" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_02d9ace2-6fef-4364-9673-453dd5de3bd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_f51adf6b-4486-485f-b671-7ff98c60970b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_02d9ace2-6fef-4364-9673-453dd5de3bd4" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_f51adf6b-4486-485f-b671-7ff98c60970b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_6deeb03b-0a82-484d-b20b-187bcad53c85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_02d9ace2-6fef-4364-9673-453dd5de3bd4" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_6deeb03b-0a82-484d-b20b-187bcad53c85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PaymentsToAcquireEquityMethodInvestmentsAmountHeldBack_2a2e4d0b-5d53-449a-a2cc-34cf28f86559" xlink:href="evh-20210630.xsd#evh_PaymentsToAcquireEquityMethodInvestmentsAmountHeldBack"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_02d9ace2-6fef-4364-9673-453dd5de3bd4" xlink:to="loc_evh_PaymentsToAcquireEquityMethodInvestmentsAmountHeldBack_2a2e4d0b-5d53-449a-a2cc-34cf28f86559" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TaxReceivablesAgreementPercentofTaxSavingstobePaid_447bf0f7-3bb2-4738-b153-f73045e76e38" xlink:href="evh-20210630.xsd#evh_TaxReceivablesAgreementPercentofTaxSavingstobePaid"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_02d9ace2-6fef-4364-9673-453dd5de3bd4" xlink:to="loc_evh_TaxReceivablesAgreementPercentofTaxSavingstobePaid_447bf0f7-3bb2-4738-b153-f73045e76e38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CommitmentsandContingenciesReinsuranceAgreementsDetails" xlink:type="simple" xlink:href="evh-20210630.xsd#CommitmentsandContingenciesReinsuranceAgreementsDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/CommitmentsandContingenciesReinsuranceAgreementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_daf9bf7f-1d46-4af2-8da3-0dc5d3ab2d53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssumedPremiumsWritten_4b9042a0-bf0f-4ba6-8dae-78e0569d7146" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssumedPremiumsWritten"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_daf9bf7f-1d46-4af2-8da3-0dc5d3ab2d53" xlink:to="loc_us-gaap_AssumedPremiumsWritten_4b9042a0-bf0f-4ba6-8dae-78e0569d7146" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CededPremiumsWritten_3efa757e-64fd-4d9f-8588-384bac6e2d2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CededPremiumsWritten"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_daf9bf7f-1d46-4af2-8da3-0dc5d3ab2d53" xlink:to="loc_us-gaap_CededPremiumsWritten_3efa757e-64fd-4d9f-8588-384bac6e2d2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed_40865ecf-8b5a-491f-b9b1-69268934afbd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_daf9bf7f-1d46-4af2-8da3-0dc5d3ab2d53" xlink:to="loc_us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed_40865ecf-8b5a-491f-b9b1-69268934afbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded_278276f9-ec08-4471-b1b2-6be0dff28e49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_daf9bf7f-1d46-4af2-8da3-0dc5d3ab2d53" xlink:to="loc_us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded_278276f9-ec08-4471-b1b2-6be0dff28e49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PolicyholderBenefitsAndClaimsIncurredAssumedExpensesRelatedToClaims_78fe60c8-1aa6-4791-8018-bc8f4b0f86bf" xlink:href="evh-20210630.xsd#evh_PolicyholderBenefitsAndClaimsIncurredAssumedExpensesRelatedToClaims"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_daf9bf7f-1d46-4af2-8da3-0dc5d3ab2d53" xlink:to="loc_evh_PolicyholderBenefitsAndClaimsIncurredAssumedExpensesRelatedToClaims_78fe60c8-1aa6-4791-8018-bc8f4b0f86bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PremiumsWrittenAndPolicyholderBenefitsAndClaimsIncurredNet_35c0b966-dff1-44ef-b84d-245bb9a10dc1" xlink:href="evh-20210630.xsd#evh_PremiumsWrittenAndPolicyholderBenefitsAndClaimsIncurredNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_daf9bf7f-1d46-4af2-8da3-0dc5d3ab2d53" xlink:to="loc_evh_PremiumsWrittenAndPolicyholderBenefitsAndClaimsIncurredNet_35c0b966-dff1-44ef-b84d-245bb9a10dc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense_6de81075-7381-49b7-9bcc-c78263d0ef0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_daf9bf7f-1d46-4af2-8da3-0dc5d3ab2d53" xlink:to="loc_us-gaap_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense_6de81075-7381-49b7-9bcc-c78263d0ef0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseImpactOfConsolidationOnPayables_793c941f-c73f-46db-942e-fb2582b55d7f" xlink:href="evh-20210630.xsd#evh_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseImpactOfConsolidationOnPayables"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_daf9bf7f-1d46-4af2-8da3-0dc5d3ab2d53" xlink:to="loc_evh_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseImpactOfConsolidationOnPayables_793c941f-c73f-46db-942e-fb2582b55d7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForReinsurance_3c77d5db-f9d3-489b-aee7-4df98a1adaf6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForReinsurance"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_daf9bf7f-1d46-4af2-8da3-0dc5d3ab2d53" xlink:to="loc_us-gaap_PaymentsForReinsurance_3c77d5db-f9d3-489b-aee7-4df98a1adaf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ProceedsFromReinsurance_ce5b04d5-1d4c-4a1a-9c50-454abea43420" xlink:href="evh-20210630.xsd#evh_ProceedsFromReinsurance"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_daf9bf7f-1d46-4af2-8da3-0dc5d3ab2d53" xlink:to="loc_evh_ProceedsFromReinsurance_ce5b04d5-1d4c-4a1a-9c50-454abea43420" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReinsuranceRecoverablesOnPaidAndUnpaidLosses_788545da-6ef5-419d-8c3f-6b23138646a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReinsuranceRecoverablesOnPaidAndUnpaidLosses"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_daf9bf7f-1d46-4af2-8da3-0dc5d3ab2d53" xlink:to="loc_us-gaap_ReinsuranceRecoverablesOnPaidAndUnpaidLosses_788545da-6ef5-419d-8c3f-6b23138646a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails" xlink:type="simple" xlink:href="evh-20210630.xsd#CommitmentsandContingenciesConcentrationRiskDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_9fa7ee5c-0251-47de-af84-666514413568" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_227fb238-1a37-4e4c-81b3-85c62edd787b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_9fa7ee5c-0251-47de-af84-666514413568" xlink:to="loc_us-gaap_ConcentrationRiskTable_227fb238-1a37-4e4c-81b3-85c62edd787b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_f7a53398-3ed8-4f6c-88b7-745dbc1a5f36" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_227fb238-1a37-4e4c-81b3-85c62edd787b" xlink:to="loc_srt_MajorCustomersAxis_f7a53398-3ed8-4f6c-88b7-745dbc1a5f36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_ab8fa31e-d68d-4586-b50b-b3e40a90a918" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_f7a53398-3ed8-4f6c-88b7-745dbc1a5f36" xlink:to="loc_srt_NameOfMajorCustomerDomain_ab8fa31e-d68d-4586-b50b-b3e40a90a918" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CookCountyHealthAndHospitalsSystemMember_ce70b98c-6ab9-4223-b63d-fc5bd74ce1ef" xlink:href="evh-20210630.xsd#evh_CookCountyHealthAndHospitalsSystemMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_ab8fa31e-d68d-4586-b50b-b3e40a90a918" xlink:to="loc_evh_CookCountyHealthAndHospitalsSystemMember_ce70b98c-6ab9-4223-b63d-fc5bd74ce1ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_FloridaBlueMedicareIncMember_7f34774b-e14a-44cd-87a7-82da4c067cfb" xlink:href="evh-20210630.xsd#evh_FloridaBlueMedicareIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_ab8fa31e-d68d-4586-b50b-b3e40a90a918" xlink:to="loc_evh_FloridaBlueMedicareIncMember_7f34774b-e14a-44cd-87a7-82da4c067cfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_NeighborhoodHealthPlanOfRhodeIslandMember_a2432311-f04d-45fe-a668-5d673cb3f11c" xlink:href="evh-20210630.xsd#evh_NeighborhoodHealthPlanOfRhodeIslandMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_ab8fa31e-d68d-4586-b50b-b3e40a90a918" xlink:to="loc_evh_NeighborhoodHealthPlanOfRhodeIslandMember_a2432311-f04d-45fe-a668-5d673cb3f11c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_UniversityHealthCaredbaPassportHealthPlanMember_9476a535-8eba-4945-a2f8-2ebc30c27dac" xlink:href="evh-20210630.xsd#evh_UniversityHealthCaredbaPassportHealthPlanMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_ab8fa31e-d68d-4586-b50b-b3e40a90a918" xlink:to="loc_evh_UniversityHealthCaredbaPassportHealthPlanMember_9476a535-8eba-4945-a2f8-2ebc30c27dac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_326d7fac-c88f-4ae0-9853-b45184ed2dcd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_227fb238-1a37-4e4c-81b3-85c62edd787b" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_326d7fac-c88f-4ae0-9853-b45184ed2dcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_6a87ee6d-6a58-4938-b5ca-2abd249af400" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_326d7fac-c88f-4ae0-9853-b45184ed2dcd" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_6a87ee6d-6a58-4938-b5ca-2abd249af400" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_154fcde0-a3a9-4cca-84c0-30132c6f0539" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_6a87ee6d-6a58-4938-b5ca-2abd249af400" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_154fcde0-a3a9-4cca-84c0-30132c6f0539" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_7e881131-226a-4563-909f-60b5d2ced10c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_227fb238-1a37-4e4c-81b3-85c62edd787b" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_7e881131-226a-4563-909f-60b5d2ced10c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_2b7f2a51-2e90-46a2-94e5-32182b389f80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_7e881131-226a-4563-909f-60b5d2ced10c" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_2b7f2a51-2e90-46a2-94e5-32182b389f80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_47b71b0b-c3b0-42ee-abb5-1d7ae3683480" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_2b7f2a51-2e90-46a2-94e5-32182b389f80" xlink:to="loc_us-gaap_AccountsReceivableMember_47b71b0b-c3b0-42ee-abb5-1d7ae3683480" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_6aad0c4a-f4cb-4d83-a597-9826fa4dc81d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_2b7f2a51-2e90-46a2-94e5-32182b389f80" xlink:to="loc_us-gaap_SalesRevenueNetMember_6aad0c4a-f4cb-4d83-a597-9826fa4dc81d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_923a1f60-bbd6-48ad-a22b-8a41238b935a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_227fb238-1a37-4e4c-81b3-85c62edd787b" xlink:to="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_923a1f60-bbd6-48ad-a22b-8a41238b935a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_bf388578-1c3d-41a8-b1b5-195013117283" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_923a1f60-bbd6-48ad-a22b-8a41238b935a" xlink:to="loc_us-gaap_ReceivableTypeDomain_bf388578-1c3d-41a8-b1b5-195013117283" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceReceivablesMember_5ed4369f-bb6f-42bb-a657-03b7597e2255" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceReceivablesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivableTypeDomain_bf388578-1c3d-41a8-b1b5-195013117283" xlink:to="loc_us-gaap_FinanceReceivablesMember_5ed4369f-bb6f-42bb-a657-03b7597e2255" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_31795ce8-83f0-41d8-89a2-7c85c0d53842" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_227fb238-1a37-4e4c-81b3-85c62edd787b" xlink:to="loc_srt_ProductOrServiceAxis_31795ce8-83f0-41d8-89a2-7c85c0d53842" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_295155ea-f978-4e9f-8894-03b15075c7f1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_31795ce8-83f0-41d8-89a2-7c85c0d53842" xlink:to="loc_srt_ProductsAndServicesDomain_295155ea-f978-4e9f-8894-03b15075c7f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PremiumsRevenueMember_c0c3ce32-64d7-4c91-9435-0f5fd3e28e9d" xlink:href="evh-20210630.xsd#evh_PremiumsRevenueMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_295155ea-f978-4e9f-8894-03b15075c7f1" xlink:to="loc_evh_PremiumsRevenueMember_c0c3ce32-64d7-4c91-9435-0f5fd3e28e9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_ab27e3bd-b804-4b63-8afe-21f901610e94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_227fb238-1a37-4e4c-81b3-85c62edd787b" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_ab27e3bd-b804-4b63-8afe-21f901610e94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_332421a5-ad8b-4335-9c19-d4e769bb3abe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_ab27e3bd-b804-4b63-8afe-21f901610e94" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_332421a5-ad8b-4335-9c19-d4e769bb3abe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_ec6b073d-5ed7-4733-8d6b-1e375ad25916" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationsDisposedOfBySaleMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_332421a5-ad8b-4335-9c19-d4e769bb3abe" xlink:to="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_ec6b073d-5ed7-4733-8d6b-1e375ad25916" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_5305b613-c99a-4d23-bc0f-b73a31cf75fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_227fb238-1a37-4e4c-81b3-85c62edd787b" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_5305b613-c99a-4d23-bc0f-b73a31cf75fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_1992ad70-02b3-45ef-9127-943d9e8886ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_5305b613-c99a-4d23-bc0f-b73a31cf75fe" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_1992ad70-02b3-45ef-9127-943d9e8886ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TrueHealthMember_3320909b-7a8e-468a-b335-35aa9c678369" xlink:href="evh-20210630.xsd#evh_TrueHealthMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_1992ad70-02b3-45ef-9127-943d9e8886ca" xlink:to="loc_evh_TrueHealthMember_3320909b-7a8e-468a-b335-35aa9c678369" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_f1de7178-73c8-4a0f-bc72-375dfaeb08e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_227fb238-1a37-4e4c-81b3-85c62edd787b" xlink:to="loc_us-gaap_ConcentrationRiskLineItems_f1de7178-73c8-4a0f-bc72-375dfaeb08e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CashFDICInsuredAmountPercentage_be757574-e22c-4970-8214-e6dfa5c6f50d" xlink:href="evh-20210630.xsd#evh_CashFDICInsuredAmountPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_f1de7178-73c8-4a0f-bc72-375dfaeb08e0" xlink:to="loc_evh_CashFDICInsuredAmountPercentage_be757574-e22c-4970-8214-e6dfa5c6f50d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_994f0bbe-fa66-485d-bae1-570bd5636e5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_f1de7178-73c8-4a0f-bc72-375dfaeb08e0" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_994f0bbe-fa66-485d-bae1-570bd5636e5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CashHeldInInternationalBanksPercentage_1a53a052-3241-450f-82b2-6b44de852797" xlink:href="evh-20210630.xsd#evh_CashHeldInInternationalBanksPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_f1de7178-73c8-4a0f-bc72-375dfaeb08e0" xlink:to="loc_evh_CashHeldInInternationalBanksPercentage_1a53a052-3241-450f-82b2-6b44de852797" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_d525eb2a-b755-46db-8390-2e832314239a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_f1de7178-73c8-4a0f-bc72-375dfaeb08e0" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_d525eb2a-b755-46db-8390-2e832314239a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_8db36f2f-2149-4c3a-9914-cdf5cae94498" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_f1de7178-73c8-4a0f-bc72-375dfaeb08e0" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_8db36f2f-2149-4c3a-9914-cdf5cae94498" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/Leases" xlink:type="simple" xlink:href="evh-20210630.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_daba0331-068a-4ea9-94a7-6ac12a5cc702" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_de7508b8-538f-47aa-80be-f9cb2f89f8c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_daba0331-068a-4ea9-94a7-6ac12a5cc702" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_de7508b8-538f-47aa-80be-f9cb2f89f8c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LeasesTables" xlink:type="simple" xlink:href="evh-20210630.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_025c3dd4-3132-43fd-bdcb-6de0ce221767" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_ff9b2cde-eb6d-4930-a3cc-edffe6e34f4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_025c3dd4-3132-43fd-bdcb-6de0ce221767" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_ff9b2cde-eb6d-4930-a3cc-edffe6e34f4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_aea276af-a54f-4d5c-b279-b45d299aa731" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_025c3dd4-3132-43fd-bdcb-6de0ce221767" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_aea276af-a54f-4d5c-b279-b45d299aa731" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="evh-20210630.xsd#LeasesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_f349f2ba-6d44-406a-9c5c-c413dbd244d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_149d2216-3ee4-480a-9cae-08ee5f15d029" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f349f2ba-6d44-406a-9c5c-c413dbd244d7" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_149d2216-3ee4-480a-9cae-08ee5f15d029" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsAxis_6d490664-52cd-411e-99b3-fea78fa8bc85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_149d2216-3ee4-480a-9cae-08ee5f15d029" xlink:to="loc_us-gaap_OtherCommitmentsAxis_6d490664-52cd-411e-99b3-fea78fa8bc85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain_029d386f-e0d4-404e-a057-e0f7d9c874cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsAxis_6d490664-52cd-411e-99b3-fea78fa8bc85" xlink:to="loc_us-gaap_OtherCommitmentsDomain_029d386f-e0d4-404e-a057-e0f7d9c874cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseAgreementsMember_6fa31625-b97c-4668-a294-a338fcabab69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsDomain_029d386f-e0d4-404e-a057-e0f7d9c874cf" xlink:to="loc_us-gaap_LeaseAgreementsMember_6fa31625-b97c-4668-a294-a338fcabab69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_6303a5ea-30c5-40f9-bc5c-d12a22ace8a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_149d2216-3ee4-480a-9cae-08ee5f15d029" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_6303a5ea-30c5-40f9-bc5c-d12a22ace8a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_a423b026-95b3-4313-a2b4-993931eadd8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6303a5ea-30c5-40f9-bc5c-d12a22ace8a4" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_a423b026-95b3-4313-a2b4-993931eadd8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_e1cd4bc0-4cdc-4fda-956e-8c2a1718824f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6303a5ea-30c5-40f9-bc5c-d12a22ace8a4" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_e1cd4bc0-4cdc-4fda-956e-8c2a1718824f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LeasesMaterialOfficeLeasesDetails" xlink:type="simple" xlink:href="evh-20210630.xsd#LeasesMaterialOfficeLeasesDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/LeasesMaterialOfficeLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_90791bc2-33f4-42d1-8233-a5f91de7f02c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_801b4e2e-2d49-4ce9-a0d8-7f9a9cc7935d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_90791bc2-33f4-42d1-8233-a5f91de7f02c" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_801b4e2e-2d49-4ce9-a0d8-7f9a9cc7935d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_6821ab9e-687f-451a-8a52-1fe2d0c8f482" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_801b4e2e-2d49-4ce9-a0d8-7f9a9cc7935d" xlink:to="loc_srt_StatementGeographicalAxis_6821ab9e-687f-451a-8a52-1fe2d0c8f482" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_40e2f1ab-8273-458e-87d0-7ff9989571cf" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_6821ab9e-687f-451a-8a52-1fe2d0c8f482" xlink:to="loc_srt_SegmentGeographicalDomain_40e2f1ab-8273-458e-87d0-7ff9989571cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_VA_785ac047-64d6-473b-965f-77fd2c2aa8fa" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_VA"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_40e2f1ab-8273-458e-87d0-7ff9989571cf" xlink:to="loc_stpr_VA_785ac047-64d6-473b-965f-77fd2c2aa8fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_IL_8872cbc1-b64f-480f-a698-cba0ffbc03d5" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_IL"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_40e2f1ab-8273-458e-87d0-7ff9989571cf" xlink:to="loc_stpr_IL_8872cbc1-b64f-480f-a698-cba0ffbc03d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_IN_1ea6b33b-f3e7-4a9a-a8e4-0abb4c2f8863" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_IN"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_40e2f1ab-8273-458e-87d0-7ff9989571cf" xlink:to="loc_country_IN_1ea6b33b-f3e7-4a9a-a8e4-0abb4c2f8863" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CA_db968440-b3fb-427c-ac2f-64ef1987a74b" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_CA"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_40e2f1ab-8273-458e-87d0-7ff9989571cf" xlink:to="loc_stpr_CA_db968440-b3fb-427c-ac2f-64ef1987a74b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_a4f7dd59-99ea-4edd-b8e8-70b317a60d48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_801b4e2e-2d49-4ce9-a0d8-7f9a9cc7935d" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_a4f7dd59-99ea-4edd-b8e8-70b317a60d48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_26dff5be-3985-4941-97d5-83ae7a35f5dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a4f7dd59-99ea-4edd-b8e8-70b317a60d48" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_26dff5be-3985-4941-97d5-83ae7a35f5dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_5afa60a4-9222-47ac-9452-e9431accf583" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a4f7dd59-99ea-4edd-b8e8-70b317a60d48" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_5afa60a4-9222-47ac-9452-e9431accf583" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_52ef1f6f-13a6-4f0d-b496-ca82c13ca3d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a4f7dd59-99ea-4edd-b8e8-70b317a60d48" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_52ef1f6f-13a6-4f0d-b496-ca82c13ca3d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LeasesComponentsofLeaseExpenseDetails" xlink:type="simple" xlink:href="evh-20210630.xsd#LeasesComponentsofLeaseExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/LeasesComponentsofLeaseExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_0af5b3b4-9bbe-4941-9369-96638f06d4bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_b771bfa6-f37e-4d8a-a678-751fd03fa834" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0af5b3b4-9bbe-4941-9369-96638f06d4bd" xlink:to="loc_us-gaap_OperatingLeaseCost_b771bfa6-f37e-4d8a-a678-751fd03fa834" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_5cf7cb8f-9792-4193-b428-725c23e2b75d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0af5b3b4-9bbe-4941-9369-96638f06d4bd" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_5cf7cb8f-9792-4193-b428-725c23e2b75d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense_f66df9e5-5dbe-48dc-91f5-6826b5578f0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0af5b3b4-9bbe-4941-9369-96638f06d4bd" xlink:to="loc_us-gaap_FinanceLeaseInterestExpense_f66df9e5-5dbe-48dc-91f5-6826b5578f0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_cda1464b-c115-4755-a4f5-85e809d15456" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0af5b3b4-9bbe-4941-9369-96638f06d4bd" xlink:to="loc_us-gaap_VariableLeaseCost_cda1464b-c115-4755-a4f5-85e809d15456" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_427474a3-49b3-4556-9810-a8a72609ebe6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0af5b3b4-9bbe-4941-9369-96638f06d4bd" xlink:to="loc_us-gaap_LeaseCost_427474a3-49b3-4556-9810-a8a72609ebe6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="evh-20210630.xsd#LeasesMaturityofLeaseLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_891fad7b-1eba-4c85-8123-b719ab33dd58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear_9a94634d-a0e1-4923-9e1b-421fc3118114" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_891fad7b-1eba-4c85-8123-b719ab33dd58" xlink:to="loc_us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear_9a94634d-a0e1-4923-9e1b-421fc3118114" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_718b0ba5-12fb-460c-a615-1e9330f40819" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_891fad7b-1eba-4c85-8123-b719ab33dd58" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_718b0ba5-12fb-460c-a615-1e9330f40819" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_ef06ba10-d611-4927-8f05-81feef88b058" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_891fad7b-1eba-4c85-8123-b719ab33dd58" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_ef06ba10-d611-4927-8f05-81feef88b058" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_c24937a2-2aa3-4ed0-bc5b-319b0f47d03f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_891fad7b-1eba-4c85-8123-b719ab33dd58" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_c24937a2-2aa3-4ed0-bc5b-319b0f47d03f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_7ddb7e7d-fe0f-4e2c-ae79-fbbefc3ca14c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_891fad7b-1eba-4c85-8123-b719ab33dd58" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_7ddb7e7d-fe0f-4e2c-ae79-fbbefc3ca14c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFive_c0ac5583-5ace-471e-ac9f-d82c9053d8b6" xlink:href="evh-20210630.xsd#evh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_891fad7b-1eba-4c85-8123-b719ab33dd58" xlink:to="loc_evh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFive_c0ac5583-5ace-471e-ac9f-d82c9053d8b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_00509af2-b692-4b96-923b-253742086d1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_891fad7b-1eba-4c85-8123-b719ab33dd58" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_00509af2-b692-4b96-923b-253742086d1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesGrossDifferenceAmountAbstract_9cb9845d-38bf-45b7-80f6-e6bd8a4fbaa3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesGrossDifferenceAmountAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_891fad7b-1eba-4c85-8123-b719ab33dd58" xlink:to="loc_us-gaap_OperatingLeaseLiabilitiesGrossDifferenceAmountAbstract_9cb9845d-38bf-45b7-80f6-e6bd8a4fbaa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_6c51d0e3-8350-4f9c-9287-461e43d9f600" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesGrossDifferenceAmountAbstract_9cb9845d-38bf-45b7-80f6-e6bd8a4fbaa3" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_6c51d0e3-8350-4f9c-9287-461e43d9f600" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_700e200d-b792-4799-8d54-f7971081a8e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_891fad7b-1eba-4c85-8123-b719ab33dd58" xlink:to="loc_us-gaap_OperatingLeaseLiability_700e200d-b792-4799-8d54-f7971081a8e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails_1" xlink:type="simple" xlink:href="evh-20210630.xsd#LeasesMaturityofLeaseLiabilitiesDetails_1"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LeasesWeightedaverageDiscountRateandWeightedremainingLeaseTermsDetails" xlink:type="simple" xlink:href="evh-20210630.xsd#LeasesWeightedaverageDiscountRateandWeightedremainingLeaseTermsDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/LeasesWeightedaverageDiscountRateandWeightedremainingLeaseTermsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_cf0244e1-611e-45c7-98fe-d33ae0c66f3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_d428aa21-6b60-4015-9ec6-edb8121cc5b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_cf0244e1-611e-45c7-98fe-d33ae0c66f3c" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_d428aa21-6b60-4015-9ec6-edb8121cc5b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_306144a5-e140-4ec8-81ef-9c8938682d9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_cf0244e1-611e-45c7-98fe-d33ae0c66f3c" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_306144a5-e140-4ec8-81ef-9c8938682d9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/EarningsLossPerCommonShare" xlink:type="simple" xlink:href="evh-20210630.xsd#EarningsLossPerCommonShare"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/EarningsLossPerCommonShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_938117b1-0968-46aa-8185-f63d5a364bbd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_8aea5990-3468-4d7a-ad52-254baeda2476" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_938117b1-0968-46aa-8185-f63d5a364bbd" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_8aea5990-3468-4d7a-ad52-254baeda2476" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/EarningsLossPerCommonShareTables" xlink:type="simple" xlink:href="evh-20210630.xsd#EarningsLossPerCommonShareTables"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/EarningsLossPerCommonShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_11f67d95-4c32-4340-81d4-afec3d653db1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_07c2c064-f3d8-42af-a207-ccc6f9d4dcda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_11f67d95-4c32-4340-81d4-afec3d653db1" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_07c2c064-f3d8-42af-a207-ccc6f9d4dcda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_a71d992f-75d0-4434-9abd-aaab793222aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_11f67d95-4c32-4340-81d4-afec3d653db1" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_a71d992f-75d0-4434-9abd-aaab793222aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/EarningsLossPerCommonShareComputationofEarningsperShareDetails" xlink:type="simple" xlink:href="evh-20210630.xsd#EarningsLossPerCommonShareComputationofEarningsperShareDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/EarningsLossPerCommonShareComputationofEarningsperShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_0b672bf4-46d8-455e-a482-246fc9116ce2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_f928a94f-be38-4d7d-a77c-c0fa056c20ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0b672bf4-46d8-455e-a482-246fc9116ce2" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_f928a94f-be38-4d7d-a77c-c0fa056c20ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_3b2295c2-7fa4-43b5-bbee-af90f8fd0b06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0b672bf4-46d8-455e-a482-246fc9116ce2" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_3b2295c2-7fa4-43b5-bbee-af90f8fd0b06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_f9e4857e-fbe8-453c-89e4-198ec32a8516" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0b672bf4-46d8-455e-a482-246fc9116ce2" xlink:to="loc_us-gaap_ProfitLoss_f9e4857e-fbe8-453c-89e4-198ec32a8516" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EarningsLossAvailabletoCommonShareholdersAbstract_72f9a7ba-ec2e-4683-94c7-2a2d79131f94" xlink:href="evh-20210630.xsd#evh_EarningsLossAvailabletoCommonShareholdersAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0b672bf4-46d8-455e-a482-246fc9116ce2" xlink:to="loc_evh_EarningsLossAvailabletoCommonShareholdersAbstract_72f9a7ba-ec2e-4683-94c7-2a2d79131f94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_0d0ad1b2-0a1f-452e-b039-6221c666c492" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evh_EarningsLossAvailabletoCommonShareholdersAbstract_72f9a7ba-ec2e-4683-94c7-2a2d79131f94" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_0d0ad1b2-0a1f-452e-b039-6221c666c492" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_800abd7e-3b69-4ad0-af33-3127fe5fc683" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0b672bf4-46d8-455e-a482-246fc9116ce2" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_800abd7e-3b69-4ad0-af33-3127fe5fc683" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_32854bb5-5af2-4845-b91e-d8879bb723d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0b672bf4-46d8-455e-a482-246fc9116ce2" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_32854bb5-5af2-4845-b91e-d8879bb723d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3ff819f1-97fc-4234-afbd-f09fdbe8c053" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0b672bf4-46d8-455e-a482-246fc9116ce2" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3ff819f1-97fc-4234-afbd-f09fdbe8c053" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1043619d-2b66-4001-816b-332ec6e9037b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0b672bf4-46d8-455e-a482-246fc9116ce2" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1043619d-2b66-4001-816b-332ec6e9037b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_40eaf2a4-d766-4635-86b4-39e684bb3ea8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0b672bf4-46d8-455e-a482-246fc9116ce2" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_40eaf2a4-d766-4635-86b4-39e684bb3ea8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_124977dd-69ba-402d-82c6-09cf0bff4359" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_40eaf2a4-d766-4635-86b4-39e684bb3ea8" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_124977dd-69ba-402d-82c6-09cf0bff4359" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_0e61a418-4449-4090-ad05-f3aee9ed79e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_40eaf2a4-d766-4635-86b4-39e684bb3ea8" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_0e61a418-4449-4090-ad05-f3aee9ed79e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_f037e1cd-bf3f-403c-8ff8-f9e8e0ba8853" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_40eaf2a4-d766-4635-86b4-39e684bb3ea8" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_f037e1cd-bf3f-403c-8ff8-f9e8e0ba8853" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_4403b790-590e-46b4-b787-993023cc7fd0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_40eaf2a4-d766-4635-86b4-39e684bb3ea8" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_4403b790-590e-46b4-b787-993023cc7fd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_12bf7d8c-94a8-4e86-b044-40a8f593d99d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_40eaf2a4-d766-4635-86b4-39e684bb3ea8" xlink:to="loc_us-gaap_EarningsPerShareDiluted_12bf7d8c-94a8-4e86-b044-40a8f593d99d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_8b3021fe-57d9-4ced-b51d-8014aa6aec50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_40eaf2a4-d766-4635-86b4-39e684bb3ea8" xlink:to="loc_us-gaap_EarningsPerShareBasic_8b3021fe-57d9-4ced-b51d-8014aa6aec50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/EarningsLossPerCommonShareAntidilutiveSecuritiesDetails" xlink:type="simple" xlink:href="evh-20210630.xsd#EarningsLossPerCommonShareAntidilutiveSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/EarningsLossPerCommonShareAntidilutiveSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_c7f16a8a-fd26-4c08-a0c2-e0b1aadf3d29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_2969f381-4365-4692-ad86-14eb3141f563" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_c7f16a8a-fd26-4c08-a0c2-e0b1aadf3d29" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_2969f381-4365-4692-ad86-14eb3141f563" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_7d97b759-3bdd-4df7-8b43-1ab967f8d6ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_2969f381-4365-4692-ad86-14eb3141f563" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_7d97b759-3bdd-4df7-8b43-1ab967f8d6ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5485bed9-13b6-49ca-b4d6-f72abe58b2fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_7d97b759-3bdd-4df7-8b43-1ab967f8d6ca" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5485bed9-13b6-49ca-b4d6-f72abe58b2fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember_f756dad9-760e-4415-b21f-c59c1e1c2933" xlink:href="evh-20210630.xsd#evh_RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5485bed9-13b6-49ca-b4d6-f72abe58b2fe" xlink:to="loc_evh_RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember_f756dad9-760e-4415-b21f-c59c1e1c2933" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_9567e7e5-4672-4d7a-ba3b-2449ac57a634" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5485bed9-13b6-49ca-b4d6-f72abe58b2fe" xlink:to="loc_us-gaap_EmployeeStockOptionMember_9567e7e5-4672-4d7a-ba3b-2449ac57a634" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_5b8235e0-24e7-4e81-b954-825a9038bc78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5485bed9-13b6-49ca-b4d6-f72abe58b2fe" xlink:to="loc_us-gaap_ConvertibleDebtMember_5b8235e0-24e7-4e81-b954-825a9038bc78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_b89d8393-af55-4cfd-abf3-96b0970e6f62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_2969f381-4365-4692-ad86-14eb3141f563" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_b89d8393-af55-4cfd-abf3-96b0970e6f62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_be95cf50-ab52-4e66-a79c-48c1a91e3f4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_b89d8393-af55-4cfd-abf3-96b0970e6f62" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_be95cf50-ab52-4e66-a79c-48c1a91e3f4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/StockbasedCompensation" xlink:type="simple" xlink:href="evh-20210630.xsd#StockbasedCompensation"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/StockbasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_21ce9c19-a1aa-49b3-8071-af1a8b916f4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_a640575a-c56e-4693-a825-9493a7a6bc29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_21ce9c19-a1aa-49b3-8071-af1a8b916f4e" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_a640575a-c56e-4693-a825-9493a7a6bc29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/StockbasedCompensationTables" xlink:type="simple" xlink:href="evh-20210630.xsd#StockbasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/StockbasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ce8f389f-e294-48e6-bfc2-edb27f3c05d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_836f4f48-3cae-4d32-9e1d-f4bbe37f34f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ce8f389f-e294-48e6-bfc2-edb27f3c05d7" xlink:to="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_836f4f48-3cae-4d32-9e1d-f4bbe37f34f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_f497c416-b033-4d4b-92f4-1b4121c5a846" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ce8f389f-e294-48e6-bfc2-edb27f3c05d7" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_f497c416-b033-4d4b-92f4-1b4121c5a846" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails" xlink:type="simple" xlink:href="evh-20210630.xsd#StockbasedCompensationStockbasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_38f3bf6a-44a1-41b1-b9c8-ea61f27b29f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_5235ad6f-90b7-4350-9f2a-e8abb1a5cfdd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_38f3bf6a-44a1-41b1-b9c8-ea61f27b29f3" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_5235ad6f-90b7-4350-9f2a-e8abb1a5cfdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_50726cea-2f04-4025-9e45-575da1ae7153" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_5235ad6f-90b7-4350-9f2a-e8abb1a5cfdd" xlink:to="loc_us-gaap_AwardTypeAxis_50726cea-2f04-4025-9e45-575da1ae7153" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bce68255-9173-4d2e-aac3-3b9883816787" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_50726cea-2f04-4025-9e45-575da1ae7153" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bce68255-9173-4d2e-aac3-3b9883816787" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_c2122b42-ec28-4921-af14-df38c8a35ffa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bce68255-9173-4d2e-aac3-3b9883816787" xlink:to="loc_us-gaap_EmployeeStockOptionMember_c2122b42-ec28-4921-af14-df38c8a35ffa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_db4ede00-d79b-4ba9-a9d9-c3b967c8292f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bce68255-9173-4d2e-aac3-3b9883816787" xlink:to="loc_us-gaap_PerformanceSharesMember_db4ede00-d79b-4ba9-a9d9-c3b967c8292f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_bebdb924-9ffb-4d5c-b871-91a43cace584" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bce68255-9173-4d2e-aac3-3b9883816787" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_bebdb924-9ffb-4d5c-b871-91a43cace584" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_LeveragedStockUnitsLSUsMember_745ca732-1646-4460-8cb4-a9a317f3bdcb" xlink:href="evh-20210630.xsd#evh_LeveragedStockUnitsLSUsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bce68255-9173-4d2e-aac3-3b9883816787" xlink:to="loc_evh_LeveragedStockUnitsLSUsMember_745ca732-1646-4460-8cb4-a9a317f3bdcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PerformanceBasedRestrictedStockUnitsPBRSUsMember_e36d0366-8684-4e17-887a-2dbdd1dffd94" xlink:href="evh-20210630.xsd#evh_PerformanceBasedRestrictedStockUnitsPBRSUsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bce68255-9173-4d2e-aac3-3b9883816787" xlink:to="loc_evh_PerformanceBasedRestrictedStockUnitsPBRSUsMember_e36d0366-8684-4e17-887a-2dbdd1dffd94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_06039f97-3702-4dfa-8895-3202c0218b33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_5235ad6f-90b7-4350-9f2a-e8abb1a5cfdd" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_06039f97-3702-4dfa-8895-3202c0218b33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_26886af8-f59d-49ba-9336-4d8004390918" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_06039f97-3702-4dfa-8895-3202c0218b33" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_26886af8-f59d-49ba-9336-4d8004390918" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_7b46c35e-712f-464e-a3ec-5775cfb5eda6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_26886af8-f59d-49ba-9336-4d8004390918" xlink:to="loc_us-gaap_CostOfSalesMember_7b46c35e-712f-464e-a3ec-5775cfb5eda6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_d2b339e9-8d89-45a3-b3df-c70d3db22cb0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_26886af8-f59d-49ba-9336-4d8004390918" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_d2b339e9-8d89-45a3-b3df-c70d3db22cb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_00224db2-b9f5-4e7a-8793-9a29a6887147" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_5235ad6f-90b7-4350-9f2a-e8abb1a5cfdd" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_00224db2-b9f5-4e7a-8793-9a29a6887147" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_f054699e-2525-4f7f-b0e9-33b219bdeefe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_00224db2-b9f5-4e7a-8793-9a29a6887147" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_f054699e-2525-4f7f-b0e9-33b219bdeefe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/StockbasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="evh-20210630.xsd#StockbasedCompensationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/StockbasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3f9caa0d-a306-4fec-82cd-d28093680755" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_6d2d4d10-b477-4fd4-a06a-35c0ab38484d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3f9caa0d-a306-4fec-82cd-d28093680755" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_6d2d4d10-b477-4fd4-a06a-35c0ab38484d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/StockbasedCompensationScheduleofSharebasedAwardsGrantedDetails" xlink:type="simple" xlink:href="evh-20210630.xsd#StockbasedCompensationScheduleofSharebasedAwardsGrantedDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/StockbasedCompensationScheduleofSharebasedAwardsGrantedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_83028ac5-f1f7-4448-b318-1ab5d5ce65d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bdd52445-0c48-45b3-84cb-aaac0061d116" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_83028ac5-f1f7-4448-b318-1ab5d5ce65d3" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bdd52445-0c48-45b3-84cb-aaac0061d116" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_61bbfe4a-a03c-4e19-93d1-5362cb5915e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bdd52445-0c48-45b3-84cb-aaac0061d116" xlink:to="loc_us-gaap_AwardTypeAxis_61bbfe4a-a03c-4e19-93d1-5362cb5915e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cb30b7d5-c802-4a21-9541-e3a2d910e8d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_61bbfe4a-a03c-4e19-93d1-5362cb5915e5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cb30b7d5-c802-4a21-9541-e3a2d910e8d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_9babd888-6543-4aaa-945d-c8dfed661d09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cb30b7d5-c802-4a21-9541-e3a2d910e8d6" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_9babd888-6543-4aaa-945d-c8dfed661d09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PerformanceBasedRestrictedStockUnitsPBRSUsMember_e678ac5f-c025-4d75-a3ab-d1af284c8354" xlink:href="evh-20210630.xsd#evh_PerformanceBasedRestrictedStockUnitsPBRSUsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cb30b7d5-c802-4a21-9541-e3a2d910e8d6" xlink:to="loc_evh_PerformanceBasedRestrictedStockUnitsPBRSUsMember_e678ac5f-c025-4d75-a3ab-d1af284c8354" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_LeveragedStockUnitsLSUsMember_c3cfe6a0-bf8f-4754-9319-81d2ea109978" xlink:href="evh-20210630.xsd#evh_LeveragedStockUnitsLSUsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cb30b7d5-c802-4a21-9541-e3a2d910e8d6" xlink:to="loc_evh_LeveragedStockUnitsLSUsMember_c3cfe6a0-bf8f-4754-9319-81d2ea109978" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c3fc3c8f-4048-43c6-b83b-183f11cc8fb7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bdd52445-0c48-45b3-84cb-aaac0061d116" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c3fc3c8f-4048-43c6-b83b-183f11cc8fb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1cbcb753-a196-49d3-b35d-6450f3f0a76b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c3fc3c8f-4048-43c6-b83b-183f11cc8fb7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1cbcb753-a196-49d3-b35d-6450f3f0a76b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/IncomeTaxes" xlink:type="simple" xlink:href="evh-20210630.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_915ed7dc-9036-413d-8ccc-7b32d3202758" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_59487003-bc39-44dd-a45e-9c05aaafec5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_915ed7dc-9036-413d-8ccc-7b32d3202758" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_59487003-bc39-44dd-a45e-9c05aaafec5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="evh-20210630.xsd#IncomeTaxesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_5781c94f-3555-4b85-bb76-56e695af0933" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_410cb46e-803d-48ae-8310-030c4da59b1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_5781c94f-3555-4b85-bb76-56e695af0933" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_410cb46e-803d-48ae-8310-030c4da59b1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_c5e8686d-c4ec-4d2f-874a-aabf69fe2ac4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_5781c94f-3555-4b85-bb76-56e695af0933" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_c5e8686d-c4ec-4d2f-874a-aabf69fe2ac4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_e3b126da-aeb0-4fd6-9a4f-ade04c7eeb54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_5781c94f-3555-4b85-bb76-56e695af0933" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_e3b126da-aeb0-4fd6-9a4f-ade04c7eeb54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TaxReceivableAgreementPercentofCashSavingsPaidtoShareholders_8eceae0b-f7fb-44f7-b812-6239940a2e0b" xlink:href="evh-20210630.xsd#evh_TaxReceivableAgreementPercentofCashSavingsPaidtoShareholders"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_5781c94f-3555-4b85-bb76-56e695af0933" xlink:to="loc_evh_TaxReceivableAgreementPercentofCashSavingsPaidtoShareholders_8eceae0b-f7fb-44f7-b812-6239940a2e0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/InvestmentsInandAdvancestoEquityMethodInvestees" xlink:type="simple" xlink:href="evh-20210630.xsd#InvestmentsInandAdvancestoEquityMethodInvestees"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/InvestmentsInandAdvancestoEquityMethodInvestees" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_cc410d0d-00b6-4f6f-be91-cda7612c0475" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_c4065147-62f5-42dc-903a-45b1d5d49f75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_cc410d0d-00b6-4f6f-be91-cda7612c0475" xlink:to="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_c4065147-62f5-42dc-903a-45b1d5d49f75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/InvestmentsInandAdvancestoEquityMethodInvesteesAdditionalInformationDetails" xlink:type="simple" xlink:href="evh-20210630.xsd#InvestmentsInandAdvancestoEquityMethodInvesteesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/InvestmentsInandAdvancestoEquityMethodInvesteesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_9d460068-30c9-4c65-b043-f0c55cdcd778" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_ff4e8ccd-8177-4666-818d-43f8d0edb6ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_9d460068-30c9-4c65-b043-f0c55cdcd778" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_ff4e8ccd-8177-4666-818d-43f8d0edb6ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_5eca6d37-059d-455f-b87d-9405fd1f2718" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_ff4e8ccd-8177-4666-818d-43f8d0edb6ce" xlink:to="loc_srt_RangeAxis_5eca6d37-059d-455f-b87d-9405fd1f2718" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_980b7d7e-f2dc-4efe-bc94-d0108969c7c8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_5eca6d37-059d-455f-b87d-9405fd1f2718" xlink:to="loc_srt_RangeMember_980b7d7e-f2dc-4efe-bc94-d0108969c7c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_b21d8635-822f-4f33-9031-b8d9328c1273" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_980b7d7e-f2dc-4efe-bc94-d0108969c7c8" xlink:to="loc_srt_MinimumMember_b21d8635-822f-4f33-9031-b8d9328c1273" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_f420a7c6-70ad-41de-9dd7-b59f2024e48d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_980b7d7e-f2dc-4efe-bc94-d0108969c7c8" xlink:to="loc_srt_MaximumMember_f420a7c6-70ad-41de-9dd7-b59f2024e48d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2ec008c5-533e-4d96-936e-b737450a776b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_ff4e8ccd-8177-4666-818d-43f8d0edb6ce" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2ec008c5-533e-4d96-936e-b737450a776b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_d2caea37-b012-428f-823f-d13591879115" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2ec008c5-533e-4d96-936e-b737450a776b" xlink:to="loc_us-gaap_RelatedPartyDomain_d2caea37-b012-428f-823f-d13591879115" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvesteeMember_f3f96910-bc79-4a26-aae5-5c383cca74eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvesteeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_d2caea37-b012-428f-823f-d13591879115" xlink:to="loc_us-gaap_EquityMethodInvesteeMember_f3f96910-bc79-4a26-aae5-5c383cca74eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_70b4a039-1cac-4669-9143-0fbf16fcfe81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_ff4e8ccd-8177-4666-818d-43f8d0edb6ce" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_70b4a039-1cac-4669-9143-0fbf16fcfe81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_d7f2949f-f803-43f5-a425-32b895252b20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_70b4a039-1cac-4669-9143-0fbf16fcfe81" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_d7f2949f-f803-43f5-a425-32b895252b20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ServicesAgreementsMember_9d438813-0a5f-46c7-9ad1-7b2093d44829" xlink:href="evh-20210630.xsd#evh_ServicesAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_d7f2949f-f803-43f5-a425-32b895252b20" xlink:to="loc_evh_ServicesAgreementsMember_9d438813-0a5f-46c7-9ad1-7b2093d44829" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_ac04bd78-eab3-4a14-b621-b7c4d6a3db74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_ff4e8ccd-8177-4666-818d-43f8d0edb6ce" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_ac04bd78-eab3-4a14-b621-b7c4d6a3db74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EquityMethodInvestmentEconomicInterestPercentage_d70d2bfa-e032-4cc4-841a-963e95c28f10" xlink:href="evh-20210630.xsd#evh_EquityMethodInvestmentEconomicInterestPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_ac04bd78-eab3-4a14-b621-b7c4d6a3db74" xlink:to="loc_evh_EquityMethodInvestmentEconomicInterestPercentage_d70d2bfa-e032-4cc4-841a-963e95c28f10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EquityMethodInvestmentVotingInterestPercentage_97473bce-cb9f-46b4-a50b-f69e0324b745" xlink:href="evh-20210630.xsd#evh_EquityMethodInvestmentVotingInterestPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_ac04bd78-eab3-4a14-b621-b7c4d6a3db74" xlink:to="loc_evh_EquityMethodInvestmentVotingInterestPercentage_97473bce-cb9f-46b4-a50b-f69e0324b745" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_4cbf2c68-3ac0-4e9e-b5b1-c58300970adf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_ac04bd78-eab3-4a14-b621-b7c4d6a3db74" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_4cbf2c68-3ac0-4e9e-b5b1-c58300970adf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_IncomeLossfromEquityMethodInvestmentsServicesAgreement_14128b73-f122-4be2-814a-1e1e2fceeabb" xlink:href="evh-20210630.xsd#evh_IncomeLossfromEquityMethodInvestmentsServicesAgreement"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_ac04bd78-eab3-4a14-b621-b7c4d6a3db74" xlink:to="loc_evh_IncomeLossfromEquityMethodInvestmentsServicesAgreement_14128b73-f122-4be2-814a-1e1e2fceeabb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/NoncontrollingInterests" xlink:type="simple" xlink:href="evh-20210630.xsd#NoncontrollingInterests"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/NoncontrollingInterests" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract_8421ed26-6032-49e7-b9c6-44fdeb086989" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDisclosureTextBlock_ff86e69e-6986-44a4-9747-c61345414fd2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_8421ed26-6032-49e7-b9c6-44fdeb086989" xlink:to="loc_us-gaap_MinorityInterestDisclosureTextBlock_ff86e69e-6986-44a4-9747-c61345414fd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/NoncontrollingInterestsTables" xlink:type="simple" xlink:href="evh-20210630.xsd#NoncontrollingInterestsTables"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/NoncontrollingInterestsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract_0f404259-5738-44c3-89b2-3ea257a79bf6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ScheduleofChangesinNoncontrollingInterestTableTextBlock_04661513-522e-4425-b3e0-4e2ec9d3b331" xlink:href="evh-20210630.xsd#evh_ScheduleofChangesinNoncontrollingInterestTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_0f404259-5738-44c3-89b2-3ea257a79bf6" xlink:to="loc_evh_ScheduleofChangesinNoncontrollingInterestTableTextBlock_04661513-522e-4425-b3e0-4e2ec9d3b331" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/NoncontrollingInterestsDetails" xlink:type="simple" xlink:href="evh-20210630.xsd#NoncontrollingInterestsDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/NoncontrollingInterestsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract_4f3cc7e2-f265-44e0-8f7b-7b44ce10f1fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestTable_07eec214-f066-4542-b8b7-2ac89bac08f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_4f3cc7e2-f265-44e0-8f7b-7b44ce10f1fb" xlink:to="loc_us-gaap_MinorityInterestTable_07eec214-f066-4542-b8b7-2ac89bac08f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_4b43ea06-e375-42e8-93c4-5a0590399bd4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_07eec214-f066-4542-b8b7-2ac89bac08f0" xlink:to="loc_srt_OwnershipAxis_4b43ea06-e375-42e8-93c4-5a0590399bd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_39ca1191-c0a0-4812-8a3e-f6c36b49968b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_4b43ea06-e375-42e8-93c4-5a0590399bd4" xlink:to="loc_srt_OwnershipDomain_39ca1191-c0a0-4812-8a3e-f6c36b49968b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EvolentHealthLLCMember_ce587fdd-1e72-4964-9932-73bc378be233" xlink:href="evh-20210630.xsd#evh_EvolentHealthLLCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_39ca1191-c0a0-4812-8a3e-f6c36b49968b" xlink:to="loc_evh_EvolentHealthLLCMember_ce587fdd-1e72-4964-9932-73bc378be233" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_27cdd24c-0820-445f-adc8-fb4b4dd0d2e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_07eec214-f066-4542-b8b7-2ac89bac08f0" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_27cdd24c-0820-445f-adc8-fb4b4dd0d2e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_ec2eb552-5bfe-4481-9e16-b662bdf039a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_27cdd24c-0820-445f-adc8-fb4b4dd0d2e9" xlink:to="loc_us-gaap_EquityComponentDomain_ec2eb552-5bfe-4481-9e16-b662bdf039a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_f2f1e444-81d3-4f4d-b6d4-7da2f228ce9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_ec2eb552-5bfe-4481-9e16-b662bdf039a8" xlink:to="loc_us-gaap_NoncontrollingInterestMember_f2f1e444-81d3-4f4d-b6d4-7da2f228ce9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_5e6da9c4-22e7-4d73-b13e-31a56307bc14" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_07eec214-f066-4542-b8b7-2ac89bac08f0" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_5e6da9c4-22e7-4d73-b13e-31a56307bc14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_e324f594-0e68-4a87-b878-a35b4d17967b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_5e6da9c4-22e7-4d73-b13e-31a56307bc14" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_e324f594-0e68-4a87-b878-a35b4d17967b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_UniversityHealthCaredbaPassportHealthPlanMember_e0923bce-a213-4d83-bad9-d2968fab8eb2" xlink:href="evh-20210630.xsd#evh_UniversityHealthCaredbaPassportHealthPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_e324f594-0e68-4a87-b878-a35b4d17967b" xlink:to="loc_evh_UniversityHealthCaredbaPassportHealthPlanMember_e0923bce-a213-4d83-bad9-d2968fab8eb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_6d7911f7-ff91-4545-a44f-041f76e58dae" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_07eec214-f066-4542-b8b7-2ac89bac08f0" xlink:to="loc_srt_ConsolidatedEntitiesAxis_6d7911f7-ff91-4545-a44f-041f76e58dae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_813a1145-39cf-4016-8ab6-52fe86623061" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_6d7911f7-ff91-4545-a44f-041f76e58dae" xlink:to="loc_srt_ConsolidatedEntitiesDomain_813a1145-39cf-4016-8ab6-52fe86623061" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_ff157020-7c12-4bfd-92ac-813ddd169ad2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_813a1145-39cf-4016-8ab6-52fe86623061" xlink:to="loc_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_ff157020-7c12-4bfd-92ac-813ddd169ad2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestLineItems_78dd594c-0868-4781-ac21-4b395d25d95f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_07eec214-f066-4542-b8b7-2ac89bac08f0" xlink:to="loc_us-gaap_MinorityInterestLineItems_78dd594c-0868-4781-ac21-4b395d25d95f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_2b403bbc-eea5-4c9a-99ab-2eece8dc046e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_78dd594c-0868-4781-ac21-4b395d25d95f" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_2b403bbc-eea5-4c9a-99ab-2eece8dc046e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_be022658-f47c-417b-a80f-b7b5b300a767" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_78dd594c-0868-4781-ac21-4b395d25d95f" xlink:to="loc_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_be022658-f47c-417b-a80f-b7b5b300a767" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityOwnershipPercentage_0919027b-11e7-4af4-a59e-a837cb12dc20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityOwnershipPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_78dd594c-0868-4781-ac21-4b395d25d95f" xlink:to="loc_us-gaap_VariableInterestEntityOwnershipPercentage_0919027b-11e7-4af4-a59e-a837cb12dc20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_VariableInterestEntityNewMedicaidContractNotAwardedRequirementToAcquireOwnershipConsiderationAmount_705b0ecc-6296-4126-9f8b-d5134e78be7c" xlink:href="evh-20210630.xsd#evh_VariableInterestEntityNewMedicaidContractNotAwardedRequirementToAcquireOwnershipConsiderationAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_78dd594c-0868-4781-ac21-4b395d25d95f" xlink:to="loc_evh_VariableInterestEntityNewMedicaidContractNotAwardedRequirementToAcquireOwnershipConsiderationAmount_705b0ecc-6296-4126-9f8b-d5134e78be7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityInitialConsolidationGainOrLoss_4d7405be-376c-4e43-ae9e-39e2e5b067cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityInitialConsolidationGainOrLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_78dd594c-0868-4781-ac21-4b395d25d95f" xlink:to="loc_us-gaap_VariableInterestEntityInitialConsolidationGainOrLoss_4d7405be-376c-4e43-ae9e-39e2e5b067cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInMinorityInterestRollForward_0156cbcc-2a92-470a-b3ff-596e4eabcc68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MovementInMinorityInterestRollForward"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_78dd594c-0868-4781-ac21-4b395d25d95f" xlink:to="loc_us-gaap_MovementInMinorityInterestRollForward_0156cbcc-2a92-470a-b3ff-596e4eabcc68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_63a44677-0a73-4b94-8a35-c7750c81fb9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_0156cbcc-2a92-470a-b3ff-596e4eabcc68" xlink:to="loc_us-gaap_MinorityInterest_63a44677-0a73-4b94-8a35-c7750c81fb9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_b22cb438-1023-401f-9bf1-c26cd360c5e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_0156cbcc-2a92-470a-b3ff-596e4eabcc68" xlink:to="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_b22cb438-1023-401f-9bf1-c26cd360c5e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_3f7f68f2-daf3-47a9-836a-a582d56485b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_0156cbcc-2a92-470a-b3ff-596e4eabcc68" xlink:to="loc_us-gaap_MinorityInterest_3f7f68f2-daf3-47a9-836a-a582d56485b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/FairValueMeasurement" xlink:type="simple" xlink:href="evh-20210630.xsd#FairValueMeasurement"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/FairValueMeasurement" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_1ee0e64e-0d98-4ade-801c-0b78e2bce451" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_b498cea7-49ba-47ce-9608-1767dcc48bd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_1ee0e64e-0d98-4ade-801c-0b78e2bce451" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_b498cea7-49ba-47ce-9608-1767dcc48bd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/FairValueMeasurementTables" xlink:type="simple" xlink:href="evh-20210630.xsd#FairValueMeasurementTables"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/FairValueMeasurementTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_26d6bb8b-e067-44ec-8eb5-96fbf9f50128" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_2b60e91f-b470-4444-8e38-c52d0a91a55a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_26d6bb8b-e067-44ec-8eb5-96fbf9f50128" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_2b60e91f-b470-4444-8e38-c52d0a91a55a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_93b329f5-4a65-4151-b327-046e6a4e9d55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_26d6bb8b-e067-44ec-8eb5-96fbf9f50128" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_93b329f5-4a65-4151-b327-046e6a4e9d55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_06e1cb7c-5ff1-498b-9f14-e5f03063f5e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_26d6bb8b-e067-44ec-8eb5-96fbf9f50128" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_06e1cb7c-5ff1-498b-9f14-e5f03063f5e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_44b8c8c9-8f9d-442c-81f8-3e2eb0448f04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_26d6bb8b-e067-44ec-8eb5-96fbf9f50128" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_44b8c8c9-8f9d-442c-81f8-3e2eb0448f04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails" xlink:type="simple" xlink:href="evh-20210630.xsd#FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_703f3cfa-c69d-487f-8076-e243a0f121a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_a3f2ea45-4da1-449c-b1fe-d2e22b5da45d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_703f3cfa-c69d-487f-8076-e243a0f121a3" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_a3f2ea45-4da1-449c-b1fe-d2e22b5da45d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3bfc28a0-ff0f-4e50-8cbf-1419079a3f88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_a3f2ea45-4da1-449c-b1fe-d2e22b5da45d" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3bfc28a0-ff0f-4e50-8cbf-1419079a3f88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_be9ec442-6d37-41cf-8517-cad81a60df49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3bfc28a0-ff0f-4e50-8cbf-1419079a3f88" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_be9ec442-6d37-41cf-8517-cad81a60df49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_a760cbe3-9add-49cf-b064-2ceb44b5e887" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_be9ec442-6d37-41cf-8517-cad81a60df49" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_a760cbe3-9add-49cf-b064-2ceb44b5e887" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_18dafbfa-bab0-45f0-81eb-15c83a6e9b2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_be9ec442-6d37-41cf-8517-cad81a60df49" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_18dafbfa-bab0-45f0-81eb-15c83a6e9b2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_ec2f4022-b5f3-41e2-a57c-e84dab65aabf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_be9ec442-6d37-41cf-8517-cad81a60df49" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_ec2f4022-b5f3-41e2-a57c-e84dab65aabf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_aec4be69-62a8-43b9-a8fe-e58fa50a2c6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_a3f2ea45-4da1-449c-b1fe-d2e22b5da45d" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_aec4be69-62a8-43b9-a8fe-e58fa50a2c6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_21d5378f-2310-4a7c-bcf0-a0e1740f9758" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_aec4be69-62a8-43b9-a8fe-e58fa50a2c6b" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_21d5378f-2310-4a7c-bcf0-a0e1740f9758" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_305194c3-fdfc-4a6c-ae44-5c2726ce1871" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_21d5378f-2310-4a7c-bcf0-a0e1740f9758" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_305194c3-fdfc-4a6c-ae44-5c2726ce1871" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_7ae04fe7-046b-4639-8952-6db86f90d79c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_a3f2ea45-4da1-449c-b1fe-d2e22b5da45d" xlink:to="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_7ae04fe7-046b-4639-8952-6db86f90d79c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_49140ec7-977e-42e5-9f5a-67cf65c80572" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_7ae04fe7-046b-4639-8952-6db86f90d79c" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_49140ec7-977e-42e5-9f5a-67cf65c80572" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_1adb161d-50da-4ad6-b236-d88aecdee44a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_49140ec7-977e-42e5-9f5a-67cf65c80572" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_1adb161d-50da-4ad6-b236-d88aecdee44a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_a2c324fe-af98-4604-94db-8b35bcd775f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_49140ec7-977e-42e5-9f5a-67cf65c80572" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_a2c324fe-af98-4604-94db-8b35bcd775f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_18ba893c-2ce1-42a7-b65c-4009700b7d99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_7ae04fe7-046b-4639-8952-6db86f90d79c" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_18ba893c-2ce1-42a7-b65c-4009700b7d99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesFairValueDisclosure_1797d89f-e7bd-4d84-a0b2-9467c7f3fd70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_18ba893c-2ce1-42a7-b65c-4009700b7d99" xlink:to="loc_us-gaap_OtherLiabilitiesFairValueDisclosure_1797d89f-e7bd-4d84-a0b2-9467c7f3fd70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_aea2af36-2cc1-49b5-8ce6-3a7bc5951a5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_18ba893c-2ce1-42a7-b65c-4009700b7d99" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_aea2af36-2cc1-49b5-8ce6-3a7bc5951a5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_7bf4a855-a407-4f78-9500-76b755696c51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_7ae04fe7-046b-4639-8952-6db86f90d79c" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_7bf4a855-a407-4f78-9500-76b755696c51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/FairValueMeasurementAdditionalInformationDetails" xlink:type="simple" xlink:href="evh-20210630.xsd#FairValueMeasurementAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/FairValueMeasurementAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_3c0e6f21-e39d-4129-b7da-3f60b27e2180" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_59d40d45-b56e-4978-b2be-e3186aa5036c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_3c0e6f21-e39d-4129-b7da-3f60b27e2180" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_59d40d45-b56e-4978-b2be-e3186aa5036c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_194cd083-3b33-46c8-9ac3-dd15b973202b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_59d40d45-b56e-4978-b2be-e3186aa5036c" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_194cd083-3b33-46c8-9ac3-dd15b973202b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_aaebdb52-bf37-42c3-9110-bd816f36a832" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_194cd083-3b33-46c8-9ac3-dd15b973202b" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_aaebdb52-bf37-42c3-9110-bd816f36a832" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_94827590-7d3f-4f16-8807-fa59e78996ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_aaebdb52-bf37-42c3-9110-bd816f36a832" xlink:to="loc_us-gaap_CommonClassAMember_94827590-7d3f-4f16-8807-fa59e78996ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_aaa2bfdd-802f-4599-9bd3-dd38e4e3dd81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_59d40d45-b56e-4978-b2be-e3186aa5036c" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_aaa2bfdd-802f-4599-9bd3-dd38e4e3dd81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightUnissued_705516a1-fd92-4244-9f2b-4b01e80c7c20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightUnissued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_aaa2bfdd-802f-4599-9bd3-dd38e4e3dd81" xlink:to="loc_us-gaap_ClassOfWarrantOrRightUnissued_705516a1-fd92-4244-9f2b-4b01e80c7c20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/FairValueMeasurementChangesinContingentConsiderationandOtherDetails" xlink:type="simple" xlink:href="evh-20210630.xsd#FairValueMeasurementChangesinContingentConsiderationandOtherDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/FairValueMeasurementChangesinContingentConsiderationandOtherDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_5ac85721-8528-4c01-a025-e1be310a00cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_b0a2fcb8-9274-4e86-ba53-5b0d816fa97e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_5ac85721-8528-4c01-a025-e1be310a00cd" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_b0a2fcb8-9274-4e86-ba53-5b0d816fa97e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_452a2edf-b215-4b4c-b3fd-e0ff5de61f24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_b0a2fcb8-9274-4e86-ba53-5b0d816fa97e" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_452a2edf-b215-4b4c-b3fd-e0ff5de61f24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_79a0fc05-09e4-4c29-b0b1-787e415469c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_b0a2fcb8-9274-4e86-ba53-5b0d816fa97e" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_79a0fc05-09e4-4c29-b0b1-787e415469c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_3554c9a8-7162-485b-9caa-273776f517c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_b0a2fcb8-9274-4e86-ba53-5b0d816fa97e" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_3554c9a8-7162-485b-9caa-273776f517c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_18f29526-92e0-4715-9837-de64c570804e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_b0a2fcb8-9274-4e86-ba53-5b0d816fa97e" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_18f29526-92e0-4715-9837-de64c570804e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails" xlink:type="simple" xlink:href="evh-20210630.xsd#FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_d18dff44-6bf4-4fcb-b8e8-4f1d18094d8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_c7d88895-7592-4e5d-ae5d-9a3e7ab50048" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_d18dff44-6bf4-4fcb-b8e8-4f1d18094d8b" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_c7d88895-7592-4e5d-ae5d-9a3e7ab50048" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_0fc6d055-b8bf-456c-aad2-0fe7fae38769" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_c7d88895-7592-4e5d-ae5d-9a3e7ab50048" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_0fc6d055-b8bf-456c-aad2-0fe7fae38769" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_ef999066-d9f6-4e72-b6e2-6e9d0596e455" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_0fc6d055-b8bf-456c-aad2-0fe7fae38769" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_ef999066-d9f6-4e72-b6e2-6e9d0596e455" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_1a5bd719-fcc5-4469-967e-19f48c10aa92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_ef999066-d9f6-4e72-b6e2-6e9d0596e455" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_1a5bd719-fcc5-4469-967e-19f48c10aa92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_151925bc-b989-49cf-bd33-9261768848aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_c7d88895-7592-4e5d-ae5d-9a3e7ab50048" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_151925bc-b989-49cf-bd33-9261768848aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_790a9b82-bc69-4fc8-8ed8-71d094b2a553" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_151925bc-b989-49cf-bd33-9261768848aa" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_790a9b82-bc69-4fc8-8ed8-71d094b2a553" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_ae880ccc-d645-424c-91ae-b79a1bdc3a47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_790a9b82-bc69-4fc8-8ed8-71d094b2a553" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_ae880ccc-d645-424c-91ae-b79a1bdc3a47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_2845bae8-b87e-4739-bccb-acf4b69e7a48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_c7d88895-7592-4e5d-ae5d-9a3e7ab50048" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_2845bae8-b87e-4739-bccb-acf4b69e7a48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_02c14d1d-15e9-4902-b0e0-9a214c330e58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_2845bae8-b87e-4739-bccb-acf4b69e7a48" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_02c14d1d-15e9-4902-b0e0-9a214c330e58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_ebfb4ba4-9eee-4147-aed0-80859d937924" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_02c14d1d-15e9-4902-b0e0-9a214c330e58" xlink:to="loc_us-gaap_WarrantMember_ebfb4ba4-9eee-4147-aed0-80859d937924" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis_9303e8c9-c89d-4f26-9324-ea4c54355036" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_c7d88895-7592-4e5d-ae5d-9a3e7ab50048" xlink:to="loc_us-gaap_ValuationTechniqueAxis_9303e8c9-c89d-4f26-9324-ea4c54355036" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_426f202e-d931-48f3-a9b7-94623c70b5b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueAxis_9303e8c9-c89d-4f26-9324-ea4c54355036" xlink:to="loc_us-gaap_ValuationTechniqueDomain_426f202e-d931-48f3-a9b7-94623c70b5b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_BlackScholesMember_1883293e-c651-4608-8fc2-d9f00d0c2744" xlink:href="evh-20210630.xsd#evh_BlackScholesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueDomain_426f202e-d931-48f3-a9b7-94623c70b5b6" xlink:to="loc_evh_BlackScholesMember_1883293e-c651-4608-8fc2-d9f00d0c2744" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_f5db5ae9-1e12-49e7-9baa-38593018b66c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_c7d88895-7592-4e5d-ae5d-9a3e7ab50048" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_f5db5ae9-1e12-49e7-9baa-38593018b66c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_f34e5d79-c5b8-40a2-800b-d1fb9935f639" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_f5db5ae9-1e12-49e7-9baa-38593018b66c" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_f34e5d79-c5b8-40a2-800b-d1fb9935f639" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_c4293b45-6fc9-4814-8040-9c9a9258bf61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_f34e5d79-c5b8-40a2-800b-d1fb9935f639" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_c4293b45-6fc9-4814-8040-9c9a9258bf61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_dd6f656f-e827-49c5-a5ed-b4efbe0a73ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_f34e5d79-c5b8-40a2-800b-d1fb9935f639" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_dd6f656f-e827-49c5-a5ed-b4efbe0a73ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_a167be6d-83d1-4d65-acab-91c5da29ba62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_c7d88895-7592-4e5d-ae5d-9a3e7ab50048" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_a167be6d-83d1-4d65-acab-91c5da29ba62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesFairValueDisclosure_dc3a0a6a-f629-432f-bebf-ca879d6889fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_a167be6d-83d1-4d65-acab-91c5da29ba62" xlink:to="loc_us-gaap_OtherLiabilitiesFairValueDisclosure_dc3a0a6a-f629-432f-bebf-ca879d6889fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_d10189b5-2ee4-42f6-9b22-6fdf7b09f170" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_a167be6d-83d1-4d65-acab-91c5da29ba62" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_d10189b5-2ee4-42f6-9b22-6fdf7b09f170" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RelatedParties" xlink:type="simple" xlink:href="evh-20210630.xsd#RelatedParties"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/RelatedParties" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_3838d022-2b2c-4337-8208-32ccfbb07d05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_271aae3c-e3d3-4206-b809-70dbb57c10d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_3838d022-2b2c-4337-8208-32ccfbb07d05" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_271aae3c-e3d3-4206-b809-70dbb57c10d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RelatedPartiesTables" xlink:type="simple" xlink:href="evh-20210630.xsd#RelatedPartiesTables"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/RelatedPartiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_ec49109a-0609-4c12-b7ca-0e92dc31a202" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_a89c4b38-3885-4706-92f5-97c7d05967d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_ec49109a-0609-4c12-b7ca-0e92dc31a202" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_a89c4b38-3885-4706-92f5-97c7d05967d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RelatedPartiesAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="evh-20210630.xsd#RelatedPartiesAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/RelatedPartiesAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_52db0c75-28e4-4e6c-9f24-fa50d24194e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_f75a5367-e5c5-4337-92f8-a5e88aff4349" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_52db0c75-28e4-4e6c-9f24-fa50d24194e0" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_f75a5367-e5c5-4337-92f8-a5e88aff4349" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1093e96f-ae4b-44c5-a180-3e3f79204ac6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_f75a5367-e5c5-4337-92f8-a5e88aff4349" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1093e96f-ae4b-44c5-a180-3e3f79204ac6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_996f4021-1eb1-42ac-8a77-5d20931b5055" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1093e96f-ae4b-44c5-a180-3e3f79204ac6" xlink:to="loc_us-gaap_RelatedPartyDomain_996f4021-1eb1-42ac-8a77-5d20931b5055" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_728c6d25-fe1c-46b9-836e-e9efdae55569" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_AffiliatedEntityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_996f4021-1eb1-42ac-8a77-5d20931b5055" xlink:to="loc_srt_AffiliatedEntityMember_728c6d25-fe1c-46b9-836e-e9efdae55569" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_a8652c8d-a4c1-48cb-90ef-def733b03675" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_f75a5367-e5c5-4337-92f8-a5e88aff4349" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_a8652c8d-a4c1-48cb-90ef-def733b03675" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_5bb471d4-e391-42ca-b5aa-5bbb78970dc9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_a8652c8d-a4c1-48cb-90ef-def733b03675" xlink:to="loc_us-gaap_AssetsAbstract_5bb471d4-e391-42ca-b5aa-5bbb78970dc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_7c03dc91-7262-45bc-b85a-2ff603fdf79c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5bb471d4-e391-42ca-b5aa-5bbb78970dc9" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_7c03dc91-7262-45bc-b85a-2ff603fdf79c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_cc2f5fb9-f493-4424-8cbe-981908f44599" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5bb471d4-e391-42ca-b5aa-5bbb78970dc9" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_cc2f5fb9-f493-4424-8cbe-981908f44599" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_4fb22e5e-e3aa-4937-979f-1a2c0012ee94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5bb471d4-e391-42ca-b5aa-5bbb78970dc9" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_4fb22e5e-e3aa-4937-979f-1a2c0012ee94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract_a7b0812e-db7a-4e4a-8035-83c8e2bc322e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_a8652c8d-a4c1-48cb-90ef-def733b03675" xlink:to="loc_us-gaap_LiabilitiesAbstract_a7b0812e-db7a-4e4a-8035-83c8e2bc322e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_8c6b1d1c-1dd8-4a82-8515-9c06823313b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_a7b0812e-db7a-4e4a-8035-83c8e2bc322e" xlink:to="loc_us-gaap_AccountsPayableCurrent_8c6b1d1c-1dd8-4a82-8515-9c06823313b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_65630bdf-6e19-4e3f-8aaa-09ce6475a8c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_a7b0812e-db7a-4e4a-8035-83c8e2bc322e" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_65630bdf-6e19-4e3f-8aaa-09ce6475a8c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense_3e0bc19d-96be-435f-bed6-345627e001d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_a7b0812e-db7a-4e4a-8035-83c8e2bc322e" xlink:to="loc_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense_3e0bc19d-96be-435f-bed6-345627e001d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RelatedPartiesRevenuesandExpensesDetails" xlink:type="simple" xlink:href="evh-20210630.xsd#RelatedPartiesRevenuesandExpensesDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/RelatedPartiesRevenuesandExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_f9d088e2-aba0-4dcc-afc3-99d08d0e07a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_0e46ee29-2515-46c4-a489-5c04f366bd3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_f9d088e2-aba0-4dcc-afc3-99d08d0e07a6" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_0e46ee29-2515-46c4-a489-5c04f366bd3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_b3c7a909-7365-4d38-bf0f-075f7ea0ad7e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_0e46ee29-2515-46c4-a489-5c04f366bd3a" xlink:to="loc_srt_ProductOrServiceAxis_b3c7a909-7365-4d38-bf0f-075f7ea0ad7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_bc8e8bce-c8cf-4ac9-850e-83636490936a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_b3c7a909-7365-4d38-bf0f-075f7ea0ad7e" xlink:to="loc_srt_ProductsAndServicesDomain_bc8e8bce-c8cf-4ac9-850e-83636490936a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TransformationServicesMember_7f162099-378d-4a14-ad3a-35d93fe69c03" xlink:href="evh-20210630.xsd#evh_TransformationServicesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_bc8e8bce-c8cf-4ac9-850e-83636490936a" xlink:to="loc_evh_TransformationServicesMember_7f162099-378d-4a14-ad3a-35d93fe69c03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PlatformsAndOperationsServicesMember_7d8ab3cd-e126-4bb7-aa7c-0daef831ad9b" xlink:href="evh-20210630.xsd#evh_PlatformsAndOperationsServicesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_bc8e8bce-c8cf-4ac9-850e-83636490936a" xlink:to="loc_evh_PlatformsAndOperationsServicesMember_7d8ab3cd-e126-4bb7-aa7c-0daef831ad9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_314cac0b-b258-4b02-b5d5-55c45ad6dc23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_0e46ee29-2515-46c4-a489-5c04f366bd3a" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_314cac0b-b258-4b02-b5d5-55c45ad6dc23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_9dd052df-12db-425d-ae22-11f144670ead" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_314cac0b-b258-4b02-b5d5-55c45ad6dc23" xlink:to="loc_us-gaap_RelatedPartyDomain_9dd052df-12db-425d-ae22-11f144670ead" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_d341745a-5632-4698-80b0-ce59403c6e3e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_AffiliatedEntityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_9dd052df-12db-425d-ae22-11f144670ead" xlink:to="loc_srt_AffiliatedEntityMember_d341745a-5632-4698-80b0-ce59403c6e3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_244ec565-c575-4c0a-a1ea-95d434b87012" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_0e46ee29-2515-46c4-a489-5c04f366bd3a" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_244ec565-c575-4c0a-a1ea-95d434b87012" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_7138eb23-5bd6-4083-b4d9-3fea15654e89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_244ec565-c575-4c0a-a1ea-95d434b87012" xlink:to="loc_us-gaap_RevenuesAbstract_7138eb23-5bd6-4083-b4d9-3fea15654e89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_9a9873e0-9c90-49e0-87a0-fdb9d32f902f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_7138eb23-5bd6-4083-b4d9-3fea15654e89" xlink:to="loc_us-gaap_Revenues_9a9873e0-9c90-49e0-87a0-fdb9d32f902f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_7efa2d91-5f33-4b42-b4a2-179fdccebf5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_244ec565-c575-4c0a-a1ea-95d434b87012" xlink:to="loc_us-gaap_OperatingExpensesAbstract_7efa2d91-5f33-4b42-b4a2-179fdccebf5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CostofGoodsandServicesSoldExcludingDepreciationandAmortization_33f2ca7a-f91e-4a8b-bf85-b23d3498ad7a" xlink:href="evh-20210630.xsd#evh_CostofGoodsandServicesSoldExcludingDepreciationandAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7efa2d91-5f33-4b42-b4a2-179fdccebf5e" xlink:to="loc_evh_CostofGoodsandServicesSoldExcludingDepreciationandAmortization_33f2ca7a-f91e-4a8b-bf85-b23d3498ad7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_849102f8-72da-4e58-9e07-181d84514b4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7efa2d91-5f33-4b42-b4a2-179fdccebf5e" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_849102f8-72da-4e58-9e07-181d84514b4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RepositioningandOtherChanges" xlink:type="simple" xlink:href="evh-20210630.xsd#RepositioningandOtherChanges"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/RepositioningandOtherChanges" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_2527c6fd-d20a-4b1b-9824-c6def450b6a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_b7e21362-0ef8-4b0a-849c-d4200cdb5adc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_2527c6fd-d20a-4b1b-9824-c6def450b6a8" xlink:to="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_b7e21362-0ef8-4b0a-849c-d4200cdb5adc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RepositioningandOtherChangesTables" xlink:type="simple" xlink:href="evh-20210630.xsd#RepositioningandOtherChangesTables"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/RepositioningandOtherChangesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_9e6b52b7-2bd2-43b1-bd71-d60ef1ae6c43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_1cd0316a-4275-406c-ba27-05aa345100d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_9e6b52b7-2bd2-43b1-bd71-d60ef1ae6c43" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_1cd0316a-4275-406c-ba27-05aa345100d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RepositioningandOtherChangesDetails" xlink:type="simple" xlink:href="evh-20210630.xsd#RepositioningandOtherChangesDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/RepositioningandOtherChangesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_2ccf3973-a236-4e0c-8a66-92c674cb1519" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_b6ee4fd4-7819-4253-a97f-88a22ebb9ad4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_2ccf3973-a236-4e0c-8a66-92c674cb1519" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_b6ee4fd4-7819-4253-a97f-88a22ebb9ad4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_f766b1ca-3692-4748-96bd-6c7d5dc36e88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_b6ee4fd4-7819-4253-a97f-88a22ebb9ad4" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_f766b1ca-3692-4748-96bd-6c7d5dc36e88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_ca0a5cf2-e405-4b6e-931e-74daa10a3061" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_f766b1ca-3692-4748-96bd-6c7d5dc36e88" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_ca0a5cf2-e405-4b6e-931e-74daa10a3061" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EmployeeSeveranceAndTerminationBenefitsMember_408e1555-bfab-465f-9964-c9e7ce865c68" xlink:href="evh-20210630.xsd#evh_EmployeeSeveranceAndTerminationBenefitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_ca0a5cf2-e405-4b6e-931e-74daa10a3061" xlink:to="loc_evh_EmployeeSeveranceAndTerminationBenefitsMember_408e1555-bfab-465f-9964-c9e7ce865c68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FacilityClosingMember_10717b13-433d-474f-b5e9-7cf5c57836bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FacilityClosingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_ca0a5cf2-e405-4b6e-931e-74daa10a3061" xlink:to="loc_us-gaap_FacilityClosingMember_10717b13-433d-474f-b5e9-7cf5c57836bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ProfessionalServicesRestructuringMember_13d860a5-18c0-45c7-bc13-d94b50319e14" xlink:href="evh-20210630.xsd#evh_ProfessionalServicesRestructuringMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_ca0a5cf2-e405-4b6e-931e-74daa10a3061" xlink:to="loc_evh_ProfessionalServicesRestructuringMember_13d860a5-18c0-45c7-bc13-d94b50319e14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_0409f67e-0434-494a-a78f-4d18109f8cf8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_b6ee4fd4-7819-4253-a97f-88a22ebb9ad4" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_0409f67e-0434-494a-a78f-4d18109f8cf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_c599f575-2556-4b56-95da-3783e580be4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_0409f67e-0434-494a-a78f-4d18109f8cf8" xlink:to="loc_us-gaap_RestructuringCharges_c599f575-2556-4b56-95da-3783e580be4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_ef92e107-f420-4836-a617-2f0fae43bfe2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_0409f67e-0434-494a-a78f-4d18109f8cf8" xlink:to="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_ef92e107-f420-4836-a617-2f0fae43bfe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_466ebbea-cc8a-4fea-9a7c-a31e7e65c94c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedCostCostIncurredToDate1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_0409f67e-0434-494a-a78f-4d18109f8cf8" xlink:to="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_466ebbea-cc8a-4fea-9a7c-a31e7e65c94c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/SegmentReporting" xlink:type="simple" xlink:href="evh-20210630.xsd#SegmentReporting"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/SegmentReporting" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_e9f94f01-f146-42f9-bc8b-b74d54927455" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_3ed9a51e-e578-4c19-b531-2e3e290d69ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_e9f94f01-f146-42f9-bc8b-b74d54927455" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_3ed9a51e-e578-4c19-b531-2e3e290d69ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/SegmentReportingTables" xlink:type="simple" xlink:href="evh-20210630.xsd#SegmentReportingTables"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/SegmentReportingTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_68d9540d-82b4-4f3b-9653-ee6ce670c81b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock_1b04a207-0fec-49d3-bcc1-dfb9258196db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_68d9540d-82b4-4f3b-9653-ee6ce670c81b" xlink:to="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock_1b04a207-0fec-49d3-bcc1-dfb9258196db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_0d23241e-68b0-4bdd-b1d0-840585bab915" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_68d9540d-82b4-4f3b-9653-ee6ce670c81b" xlink:to="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_0d23241e-68b0-4bdd-b1d0-840585bab915" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/SegmentReportingAdditionalInformationDetails" xlink:type="simple" xlink:href="evh-20210630.xsd#SegmentReportingAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/SegmentReportingAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_30e6997b-cf45-4a2c-9ae8-9eba62374d8c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_df545c34-b0e4-4d8f-b0aa-9b9cd9cddccd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_30e6997b-cf45-4a2c-9ae8-9eba62374d8c" xlink:to="loc_us-gaap_NumberOfOperatingSegments_df545c34-b0e4-4d8f-b0aa-9b9cd9cddccd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/SegmentReportingRevenuefromSegmentstoConsolidatedDetails" xlink:type="simple" xlink:href="evh-20210630.xsd#SegmentReportingRevenuefromSegmentstoConsolidatedDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/SegmentReportingRevenuefromSegmentstoConsolidatedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_4c1341c0-046d-4d8c-9a7f-70f2fd3cc58b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_a1922bee-cbd2-435c-bd94-a001253b01bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_4c1341c0-046d-4d8c-9a7f-70f2fd3cc58b" xlink:to="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_a1922bee-cbd2-435c-bd94-a001253b01bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_8e55673a-1c45-4ee4-b388-c47e99c3db3e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_a1922bee-cbd2-435c-bd94-a001253b01bf" xlink:to="loc_srt_ProductOrServiceAxis_8e55673a-1c45-4ee4-b388-c47e99c3db3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_5a8354c1-d510-4c0c-8e3b-e1d2c13208f5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_8e55673a-1c45-4ee4-b388-c47e99c3db3e" xlink:to="loc_srt_ProductsAndServicesDomain_5a8354c1-d510-4c0c-8e3b-e1d2c13208f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TransformationServicesMember_6603768f-f40d-4a3c-9cde-f4563b480267" xlink:href="evh-20210630.xsd#evh_TransformationServicesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5a8354c1-d510-4c0c-8e3b-e1d2c13208f5" xlink:to="loc_evh_TransformationServicesMember_6603768f-f40d-4a3c-9cde-f4563b480267" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PlatformsAndOperationsServicesMember_ce858f6d-f196-42cb-88eb-ba47164c49e0" xlink:href="evh-20210630.xsd#evh_PlatformsAndOperationsServicesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5a8354c1-d510-4c0c-8e3b-e1d2c13208f5" xlink:to="loc_evh_PlatformsAndOperationsServicesMember_ce858f6d-f196-42cb-88eb-ba47164c49e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_c5345c84-91b2-4567-9fa2-e17b27440172" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_a1922bee-cbd2-435c-bd94-a001253b01bf" xlink:to="loc_srt_ConsolidationItemsAxis_c5345c84-91b2-4567-9fa2-e17b27440172" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_6a5c132b-bac5-4c40-969e-15a2972fa54c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_c5345c84-91b2-4567-9fa2-e17b27440172" xlink:to="loc_srt_ConsolidationItemsDomain_6a5c132b-bac5-4c40-969e-15a2972fa54c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntersegmentEliminationMember_e56c5538-39e4-4601-b844-b570a2aa4c65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntersegmentEliminationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_6a5c132b-bac5-4c40-969e-15a2972fa54c" xlink:to="loc_us-gaap_IntersegmentEliminationMember_e56c5538-39e4-4601-b844-b570a2aa4c65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_930ecda0-3ecd-42f5-9fd2-0506f1b537ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_6a5c132b-bac5-4c40-969e-15a2972fa54c" xlink:to="loc_us-gaap_OperatingSegmentsMember_930ecda0-3ecd-42f5-9fd2-0506f1b537ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_74d8189b-0c5d-4b71-b9a2-9d1c9340acfa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_6a5c132b-bac5-4c40-969e-15a2972fa54c" xlink:to="loc_us-gaap_CorporateNonSegmentMember_74d8189b-0c5d-4b71-b9a2-9d1c9340acfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_80f5d02c-0da5-4cec-a47c-b547fde547a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_a1922bee-cbd2-435c-bd94-a001253b01bf" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_80f5d02c-0da5-4cec-a47c-b547fde547a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_b4c31fd3-c9b2-42a4-8106-f8f7846e70e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_80f5d02c-0da5-4cec-a47c-b547fde547a6" xlink:to="loc_us-gaap_SegmentDomain_b4c31fd3-c9b2-42a4-8106-f8f7846e70e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EvolentHealthServicesSegmentMember_79eae737-05d0-4d15-a9ad-0c436e6b0085" xlink:href="evh-20210630.xsd#evh_EvolentHealthServicesSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_b4c31fd3-c9b2-42a4-8106-f8f7846e70e3" xlink:to="loc_evh_EvolentHealthServicesSegmentMember_79eae737-05d0-4d15-a9ad-0c436e6b0085" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ClinicalSolutionsSegmentMember_cb06552d-a467-40b4-a061-69b4c74e3447" xlink:href="evh-20210630.xsd#evh_ClinicalSolutionsSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_b4c31fd3-c9b2-42a4-8106-f8f7846e70e3" xlink:to="loc_evh_ClinicalSolutionsSegmentMember_cb06552d-a467-40b4-a061-69b4c74e3447" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_e5a33b8c-9932-4214-8654-90199f2ae7b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingRevenueReconcilingItemLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_a1922bee-cbd2-435c-bd94-a001253b01bf" xlink:to="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_e5a33b8c-9932-4214-8654-90199f2ae7b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_fc1065e6-813f-4a4b-a69b-7f57dfb22008" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_e5a33b8c-9932-4214-8654-90199f2ae7b9" xlink:to="loc_us-gaap_Revenues_fc1065e6-813f-4a4b-a69b-7f57dfb22008" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization_ad19dac2-505a-44ba-944b-6d129fbc190a" xlink:href="evh-20210630.xsd#evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_e5a33b8c-9932-4214-8654-90199f2ae7b9" xlink:to="loc_evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization_ad19dac2-505a-44ba-944b-6d129fbc190a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails" xlink:type="simple" xlink:href="evh-20210630.xsd#SegmentReportingReconciliationofAdjustedEBITDADetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_a93da3dc-b0ed-4e8b-80e8-43187c9bcc52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_c0b9b1e7-1da4-4a88-8284-227a53b4af17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_a93da3dc-b0ed-4e8b-80e8-43187c9bcc52" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_c0b9b1e7-1da4-4a88-8284-227a53b4af17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_b3849ce0-2a73-4e7e-a793-4a81e77321e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_a93da3dc-b0ed-4e8b-80e8-43187c9bcc52" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_b3849ce0-2a73-4e7e-a793-4a81e77321e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_858eeccd-7c74-4475-82d4-06b0dca74177" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_a93da3dc-b0ed-4e8b-80e8-43187c9bcc52" xlink:to="loc_us-gaap_InvestmentIncomeInterest_858eeccd-7c74-4475-82d4-06b0dca74177" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_ee825d9c-ad9f-4e3e-8d6d-301b45409ff6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_a93da3dc-b0ed-4e8b-80e8-43187c9bcc52" xlink:to="loc_us-gaap_InterestExpense_ee825d9c-ad9f-4e3e-8d6d-301b45409ff6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_c03f0e3c-bfa2-43e0-8790-5800b2a5573e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_a93da3dc-b0ed-4e8b-80e8-43187c9bcc52" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_c03f0e3c-bfa2-43e0-8790-5800b2a5573e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_5595702d-0efe-4c81-8b1d-8c7862f49f59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_a93da3dc-b0ed-4e8b-80e8-43187c9bcc52" xlink:to="loc_us-gaap_DepreciationAndAmortization_5595702d-0efe-4c81-8b1d-8c7862f49f59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_0f7d1514-b389-42fa-beaf-c8776deb35eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_a93da3dc-b0ed-4e8b-80e8-43187c9bcc52" xlink:to="loc_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_0f7d1514-b389-42fa-beaf-c8776deb35eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_GainOnTransferOfMembership_b6f1600b-8331-489e-b28e-c565da662a2d" xlink:href="evh-20210630.xsd#evh_GainOnTransferOfMembership"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_a93da3dc-b0ed-4e8b-80e8-43187c9bcc52" xlink:to="loc_evh_GainOnTransferOfMembership_b6f1600b-8331-489e-b28e-c565da662a2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_bd2c9362-1080-487e-a9c9-6d10b3a5ae58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_a93da3dc-b0ed-4e8b-80e8-43187c9bcc52" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_bd2c9362-1080-487e-a9c9-6d10b3a5ae58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_6a43d380-2387-411b-925f-b4c2d9fdf4c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_a93da3dc-b0ed-4e8b-80e8-43187c9bcc52" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_6a43d380-2387-411b-925f-b4c2d9fdf4c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_9dd05166-81ff-47e5-a9f2-d1c4cea883db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_a93da3dc-b0ed-4e8b-80e8-43187c9bcc52" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_9dd05166-81ff-47e5-a9f2-d1c4cea883db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_0cc1ad62-0b7d-4ca0-a4f6-96404ef2c05c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_a93da3dc-b0ed-4e8b-80e8-43187c9bcc52" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_0cc1ad62-0b7d-4ca0-a4f6-96404ef2c05c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_1c638bce-1da1-4552-ad6d-f13d8d60484b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_a93da3dc-b0ed-4e8b-80e8-43187c9bcc52" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_1c638bce-1da1-4552-ad6d-f13d8d60484b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_455ff06a-2801-4c4f-baa7-76f5b1060d10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_a93da3dc-b0ed-4e8b-80e8-43187c9bcc52" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_455ff06a-2801-4c4f-baa7-76f5b1060d10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_2ceb2e04-ec22-44ac-ad99-4cc9713b3047" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_a93da3dc-b0ed-4e8b-80e8-43187c9bcc52" xlink:to="loc_us-gaap_RestructuringCharges_2ceb2e04-ec22-44ac-ad99-4cc9713b3047" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SharebasedCompensationIncludingOnetimeAdjustment_cbb404da-9e7a-44e1-b3d5-4bbf8a1634a8" xlink:href="evh-20210630.xsd#evh_SharebasedCompensationIncludingOnetimeAdjustment"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_a93da3dc-b0ed-4e8b-80e8-43187c9bcc52" xlink:to="loc_evh_SharebasedCompensationIncludingOnetimeAdjustment_cbb404da-9e7a-44e1-b3d5-4bbf8a1634a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_99e8af1e-e52c-41f3-b15e-6a46ddf10db9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeveranceCosts1"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_a93da3dc-b0ed-4e8b-80e8-43187c9bcc52" xlink:to="loc_us-gaap_SeveranceCosts1_99e8af1e-e52c-41f3-b15e-6a46ddf10db9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CapitalizedContractCostAmortizationPurchaseAccountingAdjustments_67dd566c-4095-4246-b406-63eb64f22d1e" xlink:href="evh-20210630.xsd#evh_CapitalizedContractCostAmortizationPurchaseAccountingAdjustments"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_a93da3dc-b0ed-4e8b-80e8-43187c9bcc52" xlink:to="loc_evh_CapitalizedContractCostAmortizationPurchaseAccountingAdjustments_67dd566c-4095-4246-b406-63eb64f22d1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ShareholderAdvisoryServices_2b749063-f50e-477d-a1b1-ab78ac9a975b" xlink:href="evh-20210630.xsd#evh_ShareholderAdvisoryServices"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_a93da3dc-b0ed-4e8b-80e8-43187c9bcc52" xlink:to="loc_evh_ShareholderAdvisoryServices_2b749063-f50e-477d-a1b1-ab78ac9a975b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TransactionCosts_95dd3629-d2b9-4c5c-a55a-0756ebc362f5" xlink:href="evh-20210630.xsd#evh_TransactionCosts"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_a93da3dc-b0ed-4e8b-80e8-43187c9bcc52" xlink:to="loc_evh_TransactionCosts_95dd3629-d2b9-4c5c-a55a-0756ebc362f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_b8e5cfd2-8cc3-4bfe-b06c-343db42b9315" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_a93da3dc-b0ed-4e8b-80e8-43187c9bcc52" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_b8e5cfd2-8cc3-4bfe-b06c-343db42b9315" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization_9e702e8f-7144-4e40-b2d1-408805c6a4e5" xlink:href="evh-20210630.xsd#evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_a93da3dc-b0ed-4e8b-80e8-43187c9bcc52" xlink:to="loc_evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization_9e702e8f-7144-4e40-b2d1-408805c6a4e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangements" xlink:type="simple" xlink:href="evh-20210630.xsd#ReservesforClaimsandPerformanceBasedArrangements"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceAbstract_b1ca79fd-a668-4e95-9208-1726510ac9ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InsuranceAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceDisclosureTextBlock_7e5363cc-708f-421d-b03d-c93ba96618fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InsuranceDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InsuranceAbstract_b1ca79fd-a668-4e95-9208-1726510ac9ea" xlink:to="loc_us-gaap_InsuranceDisclosureTextBlock_7e5363cc-708f-421d-b03d-c93ba96618fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsTables" xlink:type="simple" xlink:href="evh-20210630.xsd#ReservesforClaimsandPerformanceBasedArrangementsTables"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceAbstract_7a20879e-f481-4d82-a503-f153382a6626" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InsuranceAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense_83f8b0ca-9317-43b2-8dd5-d113b91fc0a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InsuranceAbstract_7a20879e-f481-4d82-a503-f153382a6626" xlink:to="loc_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense_83f8b0ca-9317-43b2-8dd5-d113b91fc0a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails" xlink:type="simple" xlink:href="evh-20210630.xsd#ReservesforClaimsandPerformanceBasedArrangementsDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceAbstract_29f341d6-5cf1-4f3c-84c1-e3abe7c67e8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InsuranceAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable_111c0d8e-9633-4ba0-bb31-e71e4f2eb636" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InsuranceAbstract_29f341d6-5cf1-4f3c-84c1-e3abe7c67e8d" xlink:to="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable_111c0d8e-9633-4ba0-bb31-e71e4f2eb636" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_df6f2956-4ebe-4a32-b272-45db776dd1fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable_111c0d8e-9633-4ba0-bb31-e71e4f2eb636" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_df6f2956-4ebe-4a32-b272-45db776dd1fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_8df1d510-580a-4d0e-99d2-867921a4422c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_df6f2956-4ebe-4a32-b272-45db776dd1fc" xlink:to="loc_us-gaap_SegmentDomain_8df1d510-580a-4d0e-99d2-867921a4422c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EvolentHealthServicesSegmentMember_d495a698-39b9-43a5-accb-5c9f2e1e1915" xlink:href="evh-20210630.xsd#evh_EvolentHealthServicesSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_8df1d510-580a-4d0e-99d2-867921a4422c" xlink:to="loc_evh_EvolentHealthServicesSegmentMember_d495a698-39b9-43a5-accb-5c9f2e1e1915" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ClinicalSolutionsSegmentMember_68560491-8453-4b0a-84c6-b573409af406" xlink:href="evh-20210630.xsd#evh_ClinicalSolutionsSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_8df1d510-580a-4d0e-99d2-867921a4422c" xlink:to="loc_evh_ClinicalSolutionsSegmentMember_68560491-8453-4b0a-84c6-b573409af406" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TrueHealthSegmentMember_e564903d-ecf0-49bf-b0d1-5c0cc7ccdc3c" xlink:href="evh-20210630.xsd#evh_TrueHealthSegmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_8df1d510-580a-4d0e-99d2-867921a4422c" xlink:to="loc_evh_TrueHealthSegmentMember_e564903d-ecf0-49bf-b0d1-5c0cc7ccdc3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems_f377dd68-4c0e-46e9-ad06-d2166ce9a717" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable_111c0d8e-9633-4ba0-bb31-e71e4f2eb636" xlink:to="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems_f377dd68-4c0e-46e9-ad06-d2166ce9a717" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetRollForward_03d55761-6929-4e34-8fc1-13a265ca3da4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MovementInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems_f377dd68-4c0e-46e9-ad06-d2166ce9a717" xlink:to="loc_us-gaap_MovementInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetRollForward_03d55761-6929-4e34-8fc1-13a265ca3da4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_59e0e262-2daa-46e9-b30e-838be0c76ad3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetRollForward_03d55761-6929-4e34-8fc1-13a265ca3da4" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_59e0e262-2daa-46e9-b30e-838be0c76ad3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization_62fd15b8-fd27-4a69-a057-15eed99718e6" xlink:href="evh-20210630.xsd#evh_CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetRollForward_03d55761-6929-4e34-8fc1-13a265ca3da4" xlink:to="loc_evh_CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization_62fd15b8-fd27-4a69-a057-15eed99718e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_393acd63-9bcc-462f-aae3-68e891f6f80f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetRollForward_03d55761-6929-4e34-8fc1-13a265ca3da4" xlink:to="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_393acd63-9bcc-462f-aae3-68e891f6f80f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_2ac99744-e591-4e27-83ff-7dc364147d6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetRollForward_03d55761-6929-4e34-8fc1-13a265ca3da4" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_2ac99744-e591-4e27-83ff-7dc364147d6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_30b55cee-a6d6-44a6-a571-6ec4fcb33025" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetRollForward_03d55761-6929-4e34-8fc1-13a265ca3da4" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_30b55cee-a6d6-44a6-a571-6ec4fcb33025" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease_63a5f644-e8b7-41ab-8f70-f3cb410e89d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetRollForward_03d55761-6929-4e34-8fc1-13a265ca3da4" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease_63a5f644-e8b7-41ab-8f70-f3cb410e89d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseDisposalOfDiscontinuedOperations_d0c012f4-7719-4c67-bbf1-04b233a93766" xlink:href="evh-20210630.xsd#evh_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseDisposalOfDiscontinuedOperations"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetRollForward_03d55761-6929-4e34-8fc1-13a265ca3da4" xlink:to="loc_evh_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseDisposalOfDiscontinuedOperations_d0c012f4-7719-4c67-bbf1-04b233a93766" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments_f09b8c8f-5c20-430f-846b-8079e8ebb32c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetRollForward_03d55761-6929-4e34-8fc1-13a265ca3da4" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments_f09b8c8f-5c20-430f-846b-8079e8ebb32c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_d269ec69-146d-4c3b-9ceb-7922bf952aa5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetRollForward_03d55761-6929-4e34-8fc1-13a265ca3da4" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_d269ec69-146d-4c3b-9ceb-7922bf952aa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/SupplementalCashFlowInformation" xlink:type="simple" xlink:href="evh-20210630.xsd#SupplementalCashFlowInformation"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/SupplementalCashFlowInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract_b891f3d6-4cd2-4b4b-8ba9-b738c9c1cefe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowSupplementalDisclosuresTextBlock_7d54f3e7-45a8-4d54-a431-d3e956b9073b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowSupplementalDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_b891f3d6-4cd2-4b4b-8ba9-b738c9c1cefe" xlink:to="loc_us-gaap_CashFlowSupplementalDisclosuresTextBlock_7d54f3e7-45a8-4d54-a431-d3e956b9073b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/SupplementalCashFlowInformationTables" xlink:type="simple" xlink:href="evh-20210630.xsd#SupplementalCashFlowInformationTables"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/SupplementalCashFlowInformationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract_cdd35576-1aff-45af-b5d9-bbc3a0c066f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_6b55a1ef-a2a8-4f22-8446-f5648ca15dca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_cdd35576-1aff-45af-b5d9-bbc3a0c066f4" xlink:to="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_6b55a1ef-a2a8-4f22-8446-f5648ca15dca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/SupplementalCashFlowInformationDetails" xlink:type="simple" xlink:href="evh-20210630.xsd#SupplementalCashFlowInformationDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/SupplementalCashFlowInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract_4221c3fd-7a2c-48b7-9d17-6fa1d9efd049" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_6070e3e9-24f8-4537-988b-6a5586083125" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_4221c3fd-7a2c-48b7-9d17-6fa1d9efd049" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_6070e3e9-24f8-4537-988b-6a5586083125" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationMeasurementPeriodAdjustment_f9f77233-e58a-4f4c-8c2d-4335bb7c2e5b" xlink:href="evh-20210630.xsd#evh_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationMeasurementPeriodAdjustment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_6070e3e9-24f8-4537-988b-6a5586083125" xlink:to="loc_evh_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationMeasurementPeriodAdjustment_f9f77233-e58a-4f4c-8c2d-4335bb7c2e5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionPayablesAssumed1_a8ea276b-7976-4664-a38a-4ee54fe651bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionPayablesAssumed1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_6070e3e9-24f8-4537-988b-6a5586083125" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionPayablesAssumed1_a8ea276b-7976-4664-a38a-4ee54fe651bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_cd4914c4-1388-4650-9be2-57097f96140f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_6070e3e9-24f8-4537-988b-6a5586083125" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_cd4914c4-1388-4650-9be2-57097f96140f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_AccruedPropertyAndEquipmentPurchases_a0633268-07e3-4d47-a9df-4fe3a90e3087" xlink:href="evh-20210630.xsd#evh_AccruedPropertyAndEquipmentPurchases"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_6070e3e9-24f8-4537-988b-6a5586083125" xlink:to="loc_evh_AccruedPropertyAndEquipmentPurchases_a0633268-07e3-4d47-a9df-4fe3a90e3087" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CashFlowLesseeAbstract_7373a9ba-c265-49c6-b77d-c557ec8da923" xlink:href="evh-20210630.xsd#evh_CashFlowLesseeAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_4221c3fd-7a2c-48b7-9d17-6fa1d9efd049" xlink:to="loc_evh_CashFlowLesseeAbstract_7373a9ba-c265-49c6-b77d-c557ec8da923" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_bf11745f-aa0a-43a6-9472-dd7358ce99a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evh_CashFlowLesseeAbstract_7373a9ba-c265-49c6-b77d-c557ec8da923" xlink:to="loc_us-gaap_OperatingLeasePayments_bf11745f-aa0a-43a6-9472-dd7358ce99a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RightOfUseAssetAcquiredAndDisposedOf_a66803a9-83fb-4a1b-922f-4565d273bfca" xlink:href="evh-20210630.xsd#evh_RightOfUseAssetAcquiredAndDisposedOf"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evh_CashFlowLesseeAbstract_7373a9ba-c265-49c6-b77d-c557ec8da923" xlink:to="loc_evh_RightOfUseAssetAcquiredAndDisposedOf_a66803a9-83fb-4a1b-922f-4565d273bfca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/SubsequentEvents" xlink:type="simple" xlink:href="evh-20210630.xsd#SubsequentEvents"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_415033b9-2cf9-4d77-a6fb-b89e2a90bce5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_a4830bb1-03fd-42b9-9573-b4b8b221d461" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_415033b9-2cf9-4d77-a6fb-b89e2a90bce5" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_a4830bb1-03fd-42b9-9573-b4b8b221d461" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="evh-20210630.xsd#SubsequentEventsDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/SubsequentEventsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_67c12e7a-d777-4c04-8b61-317d980e31f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_2a7dcd78-74cd-437a-a66f-5325a9b25000" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_67c12e7a-d777-4c04-8b61-317d980e31f9" xlink:to="loc_us-gaap_SubsequentEventTable_2a7dcd78-74cd-437a-a66f-5325a9b25000" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_31d68c0f-894b-4f7a-b672-a006cda169fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_2a7dcd78-74cd-437a-a66f-5325a9b25000" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_31d68c0f-894b-4f7a-b672-a006cda169fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_d6c6ec7a-7d7d-4f17-a678-bc1c2cf25243" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_31d68c0f-894b-4f7a-b672-a006cda169fe" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_d6c6ec7a-7d7d-4f17-a678-bc1c2cf25243" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_46cd495a-622f-4936-82f8-7b84fd2f1382" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_d6c6ec7a-7d7d-4f17-a678-bc1c2cf25243" xlink:to="loc_us-gaap_SubsequentEventMember_46cd495a-622f-4936-82f8-7b84fd2f1382" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_58917341-bbdf-4287-a37e-3a0ca7688200" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_2a7dcd78-74cd-437a-a66f-5325a9b25000" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_58917341-bbdf-4287-a37e-3a0ca7688200" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_08810bad-53ba-48c0-9de4-3111f7e535fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_58917341-bbdf-4287-a37e-3a0ca7688200" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_08810bad-53ba-48c0-9de4-3111f7e535fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_WindroseHealthInvestorsIIILPMember_e0c53bf7-95b8-4e2d-a937-27b8c399d161" xlink:href="evh-20210630.xsd#evh_WindroseHealthInvestorsIIILPMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_08810bad-53ba-48c0-9de4-3111f7e535fb" xlink:to="loc_evh_WindroseHealthInvestorsIIILPMember_e0c53bf7-95b8-4e2d-a937-27b8c399d161" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_da457573-7823-4b70-bb5e-2662e5fc18b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_2a7dcd78-74cd-437a-a66f-5325a9b25000" xlink:to="loc_us-gaap_SubsequentEventLineItems_da457573-7823-4b70-bb5e-2662e5fc18b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_2a9bc1fe-446c-4000-8816-0fa5eb8bf6aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_da457573-7823-4b70-bb5e-2662e5fc18b3" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_2a9bc1fe-446c-4000-8816-0fa5eb8bf6aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_5dc80b7a-07a2-4315-804b-f7e940a1ecfd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_da457573-7823-4b70-bb5e-2662e5fc18b3" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_5dc80b7a-07a2-4315-804b-f7e940a1ecfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>evh-20210630_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2021"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:evh="http://www.evolenthealth.com/20210630"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2021"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="evh-20210630.xsd" xlink:type="simple"/>
    <context id="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i428cb8fc8d2340adb52e77c530bb0227_I20210802">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
        </entity>
        <period>
            <instant>2021-08-02</instant>
        </period>
    </context>
    <context id="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i45bff335c1434d6ba44132da1b0557db_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="icc9702daaf8a42a6b738e99ae2cf6328_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i5afa72f271884055860c7e9a53ef18b2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7b3321915fe444e488ceef708a6e59c9_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:TransformationServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i78e15c27cd3e401ea6bd6fd305abeb34_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:TransformationServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i8cf8298bd37b49539b40ff277f78e799_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:TransformationServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ia98a39c8ecac46f5b530749d9b554995_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:TransformationServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ie90c815774924e1e802eb6f3123f1004_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PlatformsAndOperationsServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="icd99be6d27564d4cb75996e8ce5dce17_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PlatformsAndOperationsServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="iaf5036ffdbc24ee8a477412be1612a0c_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PlatformsAndOperationsServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ibf7fe803335d432ba4201dde52789d25_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PlatformsAndOperationsServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="id4ee77e0637d4c079ba08f5a8d50896f_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="idf456296380c4d43be18dd320f38d79e_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i7e5ec0e87ee5433f83b9321c8e851948_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i5780af7ffb314efcb610ffbfde88f991_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="idb6c27b0e33045ad94dd37a21c51bcc5_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ib32c349f6c584bddbe73d86161c5920b_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i6f47fa7f09154d2791eda91f900b167d_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i455847ec36714e5290ad661b3a22ace7_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i31c050008a204703ba34fa755a536cf2_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ie9109ae3615a4ff4bba0427a808423b1_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ic8f27d03961c446e8a3b985b4125c35b_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i9015d8c021f54578be8269eee070b2fd_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i94aea5894d5b4755a126a48cfbd95510_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i879a0ef04e854d12a3d8c0b0e4ef52a8_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="if0b0ee0b6c91434b9c8abae23359e72b_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i81c425c8fa484c09a468070f04a8c93f_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ia8df2ff5dddf457e82901cdf7d483ad7_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i569670e5740a45bbad372eaaf4c6523d_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i432ce00f8bd44330b83105a3a30fdfa7_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i026710848e1641728e5976c36d6751b6_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i699a6f845bb540d88c80df1abf986e42_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ic75ef8266603466480bd63015a6a5944_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ic59adfc6299d4f0497fd6b08ea305a09_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i57b7afbf065049aaab8f0248ad2de887_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="iec09d5072eea4a989bbeda84a659de90_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ia89af82007e0491b902dec6c279845b4_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ib53e76cbba4f4051ab162663449ef939_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i78ff7cbbd824466eab0d352e7f4b5f1c_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i0b480fd1921d4f1ea9972b92001a55ff_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i3788ccc422524e5bab104710c747da49_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i61d42c3c86cf419a8e9f35be789f83b5_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ia67d3ce8c31a428f993f4ca23b06398f_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ia59baf61ed594b8fb0771be16c7deee5_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i0b187f370fc84640b9c86628f855226a_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i2202cb072bda4242a7bea49750347ba4_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i9d6223463ab84fa6a8f5cd35e24c15d7_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i11817f96c3e24e0abaed14a17869e173_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i78d2f8ed8b384b2a93f41b0cbd0e3f03_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9482da1959ba438396e25159d07f33e3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6d3d52c0e5b94031981899cd1ecb78a1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia2be1022da19471caedc725d35d5a5bd_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7a8d015d1e3c419495ab144ddd77f1b6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9799952c3fd2440b9166bd85cc98b14e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i25b48cb725834cb78913e88a0e458e79_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ieaf6b2c9ee5b475bbe4a1910426766b9_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="idfc2020dff164058be58d93f3ec59267_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i1baaa0777df145cfb48c213ad68538f9_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i8830c28780b7440f831c87a11c1a0073_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="iae1007f114dc467eb2b8a9c64881f28b_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i3046b7b99a004e48a03d367e730f9ae5_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ice23288885be4f779b9ab70832b538f6_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib21f2745e0714611ae3b84205a386a57_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1bcddf75950249fbaf184e1f523f0d8b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i18de6ff3304b4fda9feee31a2f415af8_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ibcd7068eef4f42b895c0b83d21ea5d2b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie0ff0ad229b441d4b12bc8956f92a917_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ice63731bd06b4502bb0ed3b4e178ccba_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i06c25faea1e7483786ebe928e1ff0fa4_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id8ff7726321243cbb8c00770e6603356_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i6e620150ffe942b388f50fab8377e007_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if955a85db5574fb9b6ccf0c7d039cee5_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i153c261aa5234592a35394b52c2c0b85_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i8a113c1bdf754223baa2fb9a6344b873_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i215048e9c16a4f348373b4cb1edc7ece_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i67f38418f25c44ef862f02d73bbffaa7_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ic9279f0ce4a5422aa74c787813c8d48c_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ie049e920122645beab4e92d759ec4ad6_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">evh:RestrictedCashforLettersofCreditforFacilityLeasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ibafea1edac4741a491dc06d42fbb6974_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">evh:RestrictedCashforLettersofCreditforFacilityLeasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i51059975ca4a4ad18ae06161620c8d07_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">evh:CollateralwithFinancialInstitutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i84a57e99f4a84536b7f1f81b47d53542_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">evh:CollateralwithFinancialInstitutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i724f3fb7e8664faf9d4251ef0ad9db50_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">evh:RestrictedCashforBenefitManagementServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i68d600384d87411f9808a47f7fa089b1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">evh:RestrictedCashforBenefitManagementServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if917fe9e46d74bbba565ff75862d3292_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">evh:RestrictedCashforOtherContractualCommitmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ic2b7bf7f852c4e07ae4036ec1933f336_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">evh:RestrictedCashforOtherContractualCommitmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia177f909fbae4389bdaa8635f038babb_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">evh:TrueHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iff2a65b6a1be4bb6b51772f3a5414255_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i8abf010fb96f42a3a9c433ab04beeed6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i83f72281c0b7415ea503edc371882a4f_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i9adc1f85abe84fe7ad21ea3765dc9836_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i0de7bb52dc554f47ba2d09f4fb6ee9a6_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i2c645dae132a46319fcf7e651dc2048b_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i78747c549a50444ab43a62d1064b465a_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ib784c8c0f9134bf48331872daaad6c4e_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractBasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ic82528f4a4554d6798f39cdf656b0d5f_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractBasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i42bd67fe63d94bad9d6d9dbe6ec79900_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i36e8c4f14af843a5a8e48ca6d9a5c6ec_D20190528-20190528">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">evh:UniversityHealthCaredbaPassportHealthPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-05-28</startDate>
            <endDate>2019-05-28</endDate>
        </period>
    </context>
    <context id="i385b3b1c295f40a88f415a7f30d89c2d_I20190618">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:PassportNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-18</instant>
        </period>
    </context>
    <context id="i50427d2cf6854298bdb63c98b9dc7ee7_I20190618">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:PassportNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-18</instant>
        </period>
    </context>
    <context id="id6b6803c601248c48c645fade86aee32_D20190606-20190606">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">evh:UniversityHealthCaredbaPassportHealthPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-06</startDate>
            <endDate>2019-06-06</endDate>
        </period>
    </context>
    <context id="i267001cededb4bfdb4aa09441f453c34_I20191230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">evh:UniversityHealthCaredbaPassportHealthPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-30</instant>
        </period>
    </context>
    <context id="ib8509d7b0e554612806781c71b9e4ddf_D20210101-20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">evh:MolinaHealthcareIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="i69350541fafc4d14a84c72aba152a863_D20200901-20200901">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">evh:MolinaHealthcareIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-01</endDate>
        </period>
    </context>
    <context id="i7a8609d202734bc89b28f90cabe48547_D20201116-20201116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">evh:UniversityHealthCaredbaPassportHealthPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-16</startDate>
            <endDate>2020-11-16</endDate>
        </period>
    </context>
    <context id="ifee88f44d6c647d095b28edecae13e93_D20200901-20200901">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">evh:PassportAssetAcquisitionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-01</endDate>
        </period>
    </context>
    <context id="ie9b33f26cab0425fb6895b18246f33f6_D20201231-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:PassportNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-31</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9d78efa027664adba423d2ecb8ab7e70_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">evh:UniversityHealthCaredbaPassportHealthPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i2c70b9d982894c0dbbc1a56623c7e3e7_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">evh:UniversityHealthCaredbaPassportHealthPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i0e1ba7773771404e91600efd70f89820_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">evh:UniversityHealthCaredbaPassportHealthPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="id529693310384660bff0d3d357adbec3_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PlatformsAndOperationsServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">evh:TrueHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i5619f887d0d546cb8c2d5bbbb39a6d8f_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PlatformsAndOperationsServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">evh:TrueHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i10851d8c3fd6447eaa0063fff7f9ed51_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PlatformsAndOperationsServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">evh:TrueHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i95135618e68647b8a930d4657c43da75_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PlatformsAndOperationsServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">evh:TrueHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i7e57745d431e47bfa19e71a49e5fdf02_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PremiumsRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">evh:TrueHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ia3740e6e58c749fa97b9285685be7b1e_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PremiumsRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">evh:TrueHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i9034834f629c466cb0de8a2fd5acfc15_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PremiumsRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">evh:TrueHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i70101f6902e44f38a06effe5f98e83b6_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PremiumsRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">evh:TrueHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i1869cd19e38f4a028448315845a440c5_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">evh:TrueHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i1a6bb4acf8f64d4ea88262cf96a6ca67_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">evh:TrueHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="iae3e4f43e8c541128c572b22ebdd19bd_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">evh:TrueHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i6f626e482e054b34901a6c459f47f04b_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">evh:TrueHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i7af7cd835a34469ebabe02daf06e9c2f_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:ServicesAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">evh:TrueHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ica99eb679e5f4a22856b6f0e49072449_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:ServicesAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">evh:TrueHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ic748340b0cf24dd685eb9347670033fd_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:ServicesAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">evh:TrueHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i253ccf29d13d4053a5a80b95f440acbe_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:ServicesAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">evh:TrueHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4a8d60e8de004fd0945ea0051704e1de_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicaidCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i7c8f58d985fb4dd1817f8f943b715272_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicaidCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i0f70e8921395417eb51d6b5f206ee45d_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicaidCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ic9022249a19e41248315bc92ae2c6b84_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicaidCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i80f1ac7ca97c4270a70dceff5a322554_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicaidCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i833160ecd3e14792aed807f6f5526e09_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicaidCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ic9abf3a96b46413baa0783c375797a74_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicaidCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i6a6c076167634a8aa2973b374f21a1c4_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicaidCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i9867dbbef41b4ff08dd51316a253355a_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicareCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i35df7764bb024bb58f354c0f372efbb2_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicareCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i676770c966c346949f713ef44a2dbce2_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicareCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i6b1276ae67ae4854953f3017ca34fd0a_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicareCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i5e93d81fa73f4e01abe8848bb63987d0_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicareCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i6c150b72b12444a49062d1ff90c9afd3_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicareCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i2b6c919aef4c4e57ab2545a539828a75_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicareCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i0c9490d39e564864bc4c81a7f1b11b1b_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicareCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i21361653abbc4b6aa34198f3f5c3a202_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:CommercialAndOtherCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="id59d1f7e03da447690dd86c33c621d88_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:CommercialAndOtherCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i135f040fff0c4f58a1234a087ef110d6_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:CommercialAndOtherCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i3905a81b1d7b40abb4c7c12d2a5c2e77_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:CommercialAndOtherCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="icc1d76dc32264876ae1a895cacd83b87_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:CommercialAndOtherCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i43e4c78617c04287898b67968c6ce485_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:CommercialAndOtherCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i52bdbef1d82e458fbfaf536f2c11d6e5_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:CommercialAndOtherCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ib6796d59fa424ba69653cef4e3d47ff1_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:CommercialAndOtherCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i679cb28be3a34242bd30bce045577c6e_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ibebddd07c46e4994849d375ecea231c6_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i1c9bfa2d7f884c12b69f21c9b3af2888_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i16325f028066493d8ad0ddc953bde9e9_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i5d62628d6fb54fe0bd811fdfd0bf7b0c_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i8d756ddfc980426086c7294d41dd2af3_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ib887805409a54f638aeeafe3fe5d1688_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ic606425dedeb4d3d9b0b453c252ea236_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ia58666fd3ef747c9bd6d04b645148e3f_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2021-07-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i486b139f28404e439444f6f0c13129da_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2022-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="id9deab8552a14f5eb736da5c6d86fc8c_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">evh:BonusesAndCommissionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i82a60e4d756c4c5e95ccf693e56f48a9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">evh:BonusesAndCommissionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i06ae7c987bf741caa484f758c9e8534d_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">evh:BonusesAndCommissionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="idadd3c2bee534377ac63ee0a2aa2dc8c_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">evh:BonusesAndCommissionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i86cf0d7a76724f38ab859d26bde2920a_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">evh:BonusesAndCommissionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i2255e38e922f4d94b90c933ab1b70b67_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">evh:BonusesAndCommissionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i8514ff7930a54e788f76b2be07ba421a_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">evh:ContractFulfillmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i296b1e421ebd4c6fa47abf987a270359_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">evh:ContractFulfillmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i27ed1697f8ec480093c84d3cf0952a90_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">evh:ContractFulfillmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ic6fb32c2d54b4c729398fb1ececf52fa_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">evh:ContractFulfillmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ib613b60e238f47b69fde69e1a6a8f9be_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">evh:ContractFulfillmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="if15e3a35bf6243958b35f8728c4cc216_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">evh:ContractFulfillmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i2a6d7a68b4464c1c9d7d5339891880a1_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivablesPeriodPastDueAxis">evh:FInancialAssetLessThan60DaysMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i62715a632a4b4513bd30977aa196bcc0_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivablesPeriodPastDueAxis">evh:FInancialAssetLessThan120DaysPastDueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i4306692d5e5e4a86b318371f5399f564_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifb44c2b2a28446c4b3e3caa830711368_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i57afc0d68f184fb899a29c776805bc85_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie1bcc0c9ee4f48d2804f66aff99ff763_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i786125390bf04da6ad620815caf55ac6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3bacbba21c62440980d14afff52eb1ca_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i037a95e6b16d4dcea7b2b033c338785c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0a061c9add404e629ee1ae3de0f2006f_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i6e1d68f35e444ab6bb440e13e80ab435_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iefe7fef4d5624963a3e8bf8250323769_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ieb3c51cd38194256bde9f79f0128cf37_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i04ad35bee18d4527b458f382beff864b_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ibc2cefa24419498989e69466f40918b1_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i6cc0ccb728fb4392be2f4d846aac50c1_D20200501-20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-05-31</endDate>
        </period>
    </context>
    <context id="i3afcc69bcfa341e986b926e4d21107b8_D20191001-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ibb95849bc72e47e5b878e5e786a0ed96_D20201031-20201031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
        </entity>
        <period>
            <startDate>2020-10-31</startDate>
            <endDate>2020-10-31</endDate>
        </period>
    </context>
    <context id="i52907b15276944d085944daaa7867a5e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:IncomeApproachValuationTechniqueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i40bf24d71e79424985bfa9b1dc75e390_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i00a15ecaf66f4a6cbb5b4eb9fa265870_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie355e9ffef734dc6a2b8f3d027278891_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i9c3ddb1ccecb442ca473281d46c1ef16_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ibcf0f323376446aca3fd59b2d1a2f2ad_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i9a66b42348f74ceea613fecea2deba8e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if5ff183307a4468fb0d5707822525486_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i25d27166851f4878bc9c647f69bfd2ea_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i53f945f2e79348aab95bbf3ba92010f3_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ie2665c131c1e46f691f30a8a2e0eaf86_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ie6df44374ded402288e7ddba99d481b4_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i613c94dbacec49fc9a7b83bf086ad005_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i73f385263f424c7b8911b8af743d7e12_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="icfef255ab2b84de6a4b8638cf6a47165_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ibe0ce27038e244269b2a24add102c084_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9ca6f97a31c04defa1bfbf470ae72bdc_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia4e8785ed06f43489b789e69021e517b_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i79cb86c12975465c920a2007aee927c8_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0e9914c7a4fa4bb6b1f1dcc803aa9440_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4a65339b8de24dc0ad22aeaed63b43ea_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">evh:BelowMarketLeasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i06b855dce6e346bcb653c327e7599385_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">evh:BelowMarketLeasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i683282a1148d4b31b1f897062aa84ede_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">evh:BelowMarketLeasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1f772575126c46f293e485e88a16c5b2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">evh:BelowMarketLeasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4064cc6be7384542838693bded8b452e_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractBasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i3af67d6664c9491d8b7fdecedd5f5629_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractBasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i27b1db7d183641a5b3e3c8ddfbffb17e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractBasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i965ab087aa7949539cb446e0c5221cea_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractBasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie8fa99474b6947149ca859e8e7009178_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">evh:TrueHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib490a7e546dd4b0987772534f6cf516c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractBasedIntangibleAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">evh:TrueHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic6cafc0c96a142d5819a5b45e9032420_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">evh:TrueHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0f5ebd73deb94928a519598776e04047_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractBasedIntangibleAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">evh:TrueHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie9f0093698034c048db39ee74d23fe56_I20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-31</instant>
        </period>
    </context>
    <context id="i0d3f73b1f2c04d3ba51586bcf12c3517_D20200801-20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="icea30d45fccd401f9bb3791275a8c40c_D20200801-20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:ConvertibleSeniorNotesdue2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="i1598eae5f6ae4813b69f0cbb95358c65_D20200801-20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="iabe38bb19e7049c7a823aae107a5b0ba_D20200801-20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:NewNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="id559bfbab5954aa7bb0b5c73c4b04f85_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i6b496ee9129546a1943004e4d9e6e458_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ibccaaf22aab2432ba1b4622538e18372_D20200801-20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="i437f571852d648ad8e14dd03e682fc47_I20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-31</instant>
        </period>
    </context>
    <context id="ifa10c9f357cc46da8a582a78230489bf_I20191230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:InitialTermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-30</instant>
        </period>
    </context>
    <context id="i06948a2177d04b259e0902a18900dc29_I20191230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">evh:DelayedDrawTermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-30</instant>
        </period>
    </context>
    <context id="ibef4bf4bc2ab41d2ad6d564857f8fb16_I20191230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:ConvertibleSeniorNotesdue2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-30</instant>
        </period>
    </context>
    <context id="ibb12573bef604a62ac70c8f5b1d35372_D20191230-20191230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorCreditFacilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2019-12-30</endDate>
        </period>
    </context>
    <context id="i11adbaf0c9c0475282d0187b6ac6db8f_D20191230-20191230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorCreditFacilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2019-12-30</endDate>
        </period>
    </context>
    <context id="ic8d3791c30f040c2b02c8f39bf43b812_D20191230-20191230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorCreditFacilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2019-12-30</endDate>
        </period>
    </context>
    <context id="i1868ae14255d4c95aab130080ec3175b_D20191230-20191230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">evh:DelayedDrawTermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2019-12-30</endDate>
        </period>
    </context>
    <context id="i381ee2f518b34b78a5f3e6263b399e70_D20191230-20191230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorCreditFacilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2019-12-30</endDate>
        </period>
    </context>
    <context id="i2b0d7584f95b486581d1f8fcf494bd87_D20191230-20191230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorCreditFacilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2019-12-30</endDate>
        </period>
    </context>
    <context id="ic5de6b4f322d4a41ba0b04e047d3567b_D20191230-20191230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorCreditFacilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2019-12-30</endDate>
        </period>
    </context>
    <context id="i6f21b3a7685841259a7bbf081309eb0f_I20191230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorCreditFacilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-30</instant>
        </period>
    </context>
    <context id="ida1f309838e74abeb0e17c296af553bb_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorCreditFacilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i96b555f871384a6ab79fe625ce473698_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorCreditFacilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i2e95d208160a4c749900182d52a49615_D20210108-20210108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorCreditFacilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-08</startDate>
            <endDate>2021-01-08</endDate>
        </period>
    </context>
    <context id="if600ab05fc8b49bca59c078f4bbb6742_D20210108-20210108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-08</startDate>
            <endDate>2021-01-08</endDate>
        </period>
    </context>
    <context id="i1cad05e654934e308e828b864b76a508_I20191230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-30</instant>
        </period>
    </context>
    <context id="i0bb88f4c90544362ab13fcd63aba4af7_D20191230-20191230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2019-12-30</endDate>
        </period>
    </context>
    <context id="if7229a5e40df4a5095c25bd23977e747_D20210108-20210108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-08</startDate>
            <endDate>2021-01-08</endDate>
        </period>
    </context>
    <context id="ia5b2225a7a85439eb9318023f5dca1ab_I20181031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-31</instant>
        </period>
    </context>
    <context id="ifee6d13c14704a0a9bd4959cd14684b6_D20181001-20181031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-10-31</endDate>
        </period>
    </context>
    <context id="i0db344c6ddf344ceab1c3071829545ff_I20181031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-31</instant>
        </period>
    </context>
    <context id="i3533fa8477ed4bb0afb07e5b80879435_I20181022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-22</instant>
        </period>
    </context>
    <context id="if3e69e58105c4d909f82068c94a4e66f_I20181024">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-24</instant>
        </period>
    </context>
    <context id="i4deadc1ba0674142a17d227672696535_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="iba4a0e1b01024c46b291007f4c8b7e3f_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ieeacfdfdfca8412a9c4cc31d0dfb0be6_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i0489a5ac9602461ea764f0340d05dbc2_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="id755146089114b63a291ebb347fe05cd_D20181001-20181031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-10-31</endDate>
        </period>
    </context>
    <context id="i263de0af39604a6985530e0395eaee6f_I20181031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-31</instant>
        </period>
    </context>
    <context id="i0efb2207e70f43cb998170b0668f5aa4_I20161231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:ConvertibleSeniorNotesdue2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="ib65ee853127148cf9a525e6a17c68f39_D20161201-20161231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:ConvertibleSeniorNotesdue2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-12-01</startDate>
            <endDate>2016-12-31</endDate>
        </period>
    </context>
    <context id="ic303181ec3134d098d234f848582ffd2_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:ConvertibleSeniorNotesdue2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="idf80add09165458a8481ba03343ec164_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:ConvertibleSeniorNotesdue2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i4e0425e5520c4d8ca777fd31abfdf006_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:ConvertibleSeniorNotesdue2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i424565a0d08945018985beab5025c0a3_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:ConvertibleSeniorNotesdue2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ifad8a17110484cd3b275f15806410965_I20161231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:ConvertibleSeniorNotesdue2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="ifa1e9df841254737b2d83a5669c5b70d_D20161201-20161231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:ConvertibleSeniorNotesdue2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-12-01</startDate>
            <endDate>2016-12-31</endDate>
        </period>
    </context>
    <context id="i8e9d743092e245ce8a2743fa9de0063b_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="id589098e41f9432fb6f03c1f1e575a4c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8919b4a21f774b92af0611b3454001f6_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib88938e6f5a14d0f9eced78e9a885018_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i6cfa2b6d88f04259ac6ccaaed1afd02a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia8e7a5b465864f39bac51a81bb700201_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i7f54eab4eae24811a155de3cf38eeb86_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i82c5460e9f7e435b83787f35cd36dcb2_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i24d4b1acd996498eba5eed0fc3e84f4b_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ie1e16d58e0e740b28071ebf63f24431d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i26c20cf31c1242dc950becfb29611788_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:ConvertibleSeniorNotesdue2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i1b41e14476334d7895158617049bccd5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:ConvertibleSeniorNotesdue2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i42998979e1154fc69a147d78134d1a26_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:ConvertibleSeniorNotesdue2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i57814fe811324e9fad5398f551936680_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:ConvertibleSeniorNotesdue2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ie847f4ca71c44d2a845bf492cd0b91ed_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:ConvertibleSeniorNotesdue2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia9369ec0e450423b94ac833451c28d42_D20200801-20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="ibe41b74ddef048729f0365c76b125a47_D20181001-20181031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-10-31</endDate>
        </period>
    </context>
    <context id="ic57d3a037df7434482b4ac69c20ce6f0_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i7d1b21babb8849389bf714849eaec38d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iced602b4d3a741e183e4dad1271a58e8_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">evh:RestrictedCashForLettersOfCreditForLetterOfCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i538e245a2b7045f18999365d98e47c51_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">evh:CollateralwithFinancialInstitutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i154d1afeed6943c08b9da6703d2f57a3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">evh:CollateralwithFinancialInstitutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0cd3439d51f543818ae384f535441a35_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">evh:RestrictedCashForLettersOfCreditForLetterOfCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3bfde454609344df8a691fb13c17b423_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:CookCountyHealthAndHospitalsSystemMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:FinanceReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i2ef1d0e83e2d422cbbb22022d1d3f276_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:CookCountyHealthAndHospitalsSystemMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:FinanceReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i60ad372a207d459e88f7e372405eab34_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:FloridaBlueMedicareIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:FinanceReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ic8a7c423118a4e16a2ff6abc2b0d9648_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:NeighborhoodHealthPlanOfRhodeIslandMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:FinanceReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="idc534571524f4f7abecd4ed0645e79e6_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:CookCountyHealthAndHospitalsSystemMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i969062c619d04ffaaa1df514f89c332c_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:CookCountyHealthAndHospitalsSystemMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i944764ecb45a4413b9d526710bd5a552_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:CookCountyHealthAndHospitalsSystemMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i01f8679ac2df4d82b256eea229cf6ea6_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:CookCountyHealthAndHospitalsSystemMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ia609b71d80124ac5a96f49cb69aa72ef_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:FloridaBlueMedicareIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ifb4268d248fd469a943652442c7252cf_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:FloridaBlueMedicareIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i02f118a71b9b4270abff67fb98d3ae2d_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:UniversityHealthCaredbaPassportHealthPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i51acaef421854161bf36167111e9315d_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:UniversityHealthCaredbaPassportHealthPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="id96b9f84ab8c4a4f8d773f444cd3a629_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="idababf2dc26948949104cd43d693a4fd_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if54c2d9d6b874c56bd73c8364532a8fa_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:VA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i9376f969f54d4adfb216011fc4ce908d_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:IL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ia8857bf6635f4a0a81ada9df6a84f8ce_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i4c6bffe6a4634527a6262241e44da56b_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i3bbdc552de74473b893173ad17ee4325_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">evh:RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="if108b20cc6254ea1a1ef89bfcf74234a_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">evh:RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i6a86fe17944142e095851e0cc3a655ae_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">evh:RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ic963db54c7f04dea9f467d5db2840678_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">evh:RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ieca7dabc7fce4091b7a8bbb168559405_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="iedb4828edf4e447d9b1ee9ab980c6c02_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i7360937c162c4b65b0e52cff040923da_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="iddd419d375b04a27b7ae24f9852b38cf_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i61e6d3ad43084e94a5c4f2bbb4e354b5_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ibf9351473ea6468086160063a0d7a0c4_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i3d293dc899f54d4c89227aabde9d3934_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ie3fb28c745a64f28b8f641cb4a936a28_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ia22f1c58e4244cbe9ed8fdbbaef1316f_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i9fc03842c80f45108f623bfcd797411e_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ia0aa4d34ea254f26a2cc4a122094cd33_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ia4237d1aee594aeeaf7d421737988f0d_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i1fc5b0f231654aeeb765d3a2edd42fd2_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i394c93b044f44da0bc8dae6ae1a3f9af_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ia4367a6c7f1a4e8ab41b880d4b063e2e_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="iefc5be4539b04aab90aaa73295d047d2_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="id632fa3ae3914b9da8bf15e4c54b6686_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i89e74efc56994c9ebb87c2b0e7cd1128_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i6660233c9d6b4e96811be968402ad42c_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="idc0d9ae125db467ab0d22698986a0481_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="if7b4268f6d62460d95263ea3eab82df8_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evh:LeveragedStockUnitsLSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i28477571d61a49d68ac8b8802530ba46_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evh:LeveragedStockUnitsLSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ibce4d97bacd94dfaa609647fcaf23ca0_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evh:LeveragedStockUnitsLSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ie162b42e78994c30b638363b2e6da8a0_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evh:LeveragedStockUnitsLSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i16f26157e03a422b8390af0e74420d0a_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evh:PerformanceBasedRestrictedStockUnitsPBRSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ia87f608d482b4ef79558f90ef1ef2a3e_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evh:PerformanceBasedRestrictedStockUnitsPBRSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i10ed9cb15f3c48d395885e32db2ca4ff_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evh:PerformanceBasedRestrictedStockUnitsPBRSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i6f822367a8c44dd79b4a10071eae6fb0_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evh:PerformanceBasedRestrictedStockUnitsPBRSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="idc22f08766584f8c91a9b4972f0f9f89_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ib32f2800c3f24f0ca601b1fd026b593b_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i8b0398298a1d4101bfdde0a27cfc4235_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i78cdc5087ee24e2e99b2216043b5b6b1_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i7f345cc1972943b9a0ae90973779501d_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i40db2f18e67e43439f94c81d84f13d6b_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ia1c09fd265c44ccdbf4d6a40f41ce5f1_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="id05098869b4b4201a380d4ccd404ff02_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="if20f8ae5705c41f6910dff16d8c55578_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i9b662261daa24dd0829c6be06dc0975d_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i3a67432b3a04429fb74ea67ee7476cc1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i644686c1853d44d8bed17fe7241635c7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i53efb4309a7d432c9067d4fceb38e1e9_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">evh:ServicesAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:EquityMethodInvesteeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i0191a974415646adb1cd9c25e726b3a2_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">evh:ServicesAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:EquityMethodInvesteeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i008ff0c503394e539acc7adba9224bd0_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">evh:ServicesAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:EquityMethodInvesteeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i9e9654e025214c9b8e664574e724a4f5_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">evh:ServicesAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:EquityMethodInvesteeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="id7302983007d47cf8a4aa6ef74f49b80_I20150531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">evh:EvolentHealthLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-05-31</instant>
        </period>
    </context>
    <context id="i46248ae6cf2f4c3bb6a08e6b7351403f_D20200901-20200901">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">evh:UniversityHealthCaredbaPassportHealthPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-01</endDate>
        </period>
    </context>
    <context id="i7d32a6bf57a9495e9192581ba6585e10_I20200901">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">evh:UniversityHealthCaredbaPassportHealthPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-01</instant>
        </period>
    </context>
    <context id="i19b1ea06ce044830b8d288022cd0a41c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">evh:UniversityHealthCaredbaPassportHealthPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8bcd87ce6e8140d4b38c9d25b675b6d0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id8df3a7cd40142e4a7fab99e3da63b6c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic31316c74dad419fa29a95505e9ad56c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie28163dd08614c3cafdece4567d5b234_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9af8cd87d8f9489980dbda44afabcdbc_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">evh:BlackScholesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia5a46affbafa4a3caf05bc97e2301da0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">evh:BlackScholesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1593077c9af8419b8c13d1d04a73de2d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">evh:BlackScholesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5e3c636f0c3f4cd9a3d1b819208219a6_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="icd166759aac546b39c8ff666867d34d3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i80f9c6fc9c784f1ebf7661871ea29e40_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:TransformationServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i12d000d060d24ea2a95340696a6a480c_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:TransformationServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="if3045b5c28d7410fb838543b77fb8e48_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:TransformationServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i4b684a34ddb04cb49ab76574e8dbeca9_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:TransformationServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ib2886761dda849ee81490345eb4cd5fe_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PlatformsAndOperationsServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="if3ad28259229428e9fd1a3676572116f_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PlatformsAndOperationsServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="if26f70dc308240eb95d27a86fe164dcb_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PlatformsAndOperationsServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i2c692c0dda2248aab4719ff28ac52586_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PlatformsAndOperationsServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="id32a865882ba4f0f9600a62eb26f2cd9_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i0b14ca9b08604f019fcc80d78ee511ab_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i8ba99c7ee2d04799a86890ec3064b175_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i04089c6246044d5cbf92001f57543039_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i9efdfcae40144663a980937c662799c7_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">evh:EmployeeSeveranceAndTerminationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ia2840929ec444f69b484c53abba16383_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">evh:EmployeeSeveranceAndTerminationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i17f053f839394fcd9de0dbf7fe5e0507_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">evh:EmployeeSeveranceAndTerminationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="idd9a4c33807c43dda2178f4f2a358736_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:FacilityClosingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ic4bacc3efa9a4c7cb0dbc8f0c6465a2e_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:FacilityClosingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ibdc992c308c2409eb366952bb3e529f5_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:FacilityClosingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i78fb3e05b2884c2185234402150b6dad_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">evh:ProfessionalServicesRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ief40b6b342f44af6974cbb1079825a19_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">evh:ProfessionalServicesRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="id4ab1843551d40e48105a1b5bf07b950_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">evh:ProfessionalServicesRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ia33818b88a6c42f5b842f5cc447c4d6f_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:TransformationServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i807d8acee29b43e1998e67d743c1650e_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:TransformationServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ia356ef0e7c074058809ff566475d252e_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:TransformationServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i0280276096944f8db9756b1ccc072342_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:TransformationServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="iec060d1f9dc045319b07294745b086d3_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:TransformationServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="iafbe04d32b3c40ae93c564f542241136_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PlatformsAndOperationsServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i8c922ef0f31b4ab2b388e8b7c1ab5312_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PlatformsAndOperationsServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i4bd03bc4393d446e9abc787bbb40c7a8_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PlatformsAndOperationsServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="iaee89f0da3e144d09c4a23c928d850b8_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PlatformsAndOperationsServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i7b7ecb9ad2c3400db038af4f12b6a9ab_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PlatformsAndOperationsServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i953b09444cb241478eb77a7260d48527_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ib66948dc799e431486e4991bc5ffa9ef_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i69cb2a622a3f4134a8e8684f7cb47aef_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ic69644d995ff43218ea90302f9eae15f_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:TransformationServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="id9a15a1f9bed43b2a7a6b9699a0355f6_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:TransformationServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i59d8caca505e4118a56844c68847eb29_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:TransformationServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ifa545ecb72a34a7c8a9f3b3fa6383b57_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:TransformationServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i9ecbd6b0abc24d8a9ed6772122d27e8c_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:TransformationServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i803b5fa527c248aba9d05e7aaaf9a0ed_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PlatformsAndOperationsServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i5621f56fb2874b21835554c608a4179a_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PlatformsAndOperationsServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ia2e4a5d8dda94f9cbc6ae57881da0889_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PlatformsAndOperationsServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="id2637cdc499c42c69c98ce75b9cedd71_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PlatformsAndOperationsServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i97c5008ce5974099bdaadf9428995770_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PlatformsAndOperationsServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ica79a35ca46143efa08136ec1e43e0d5_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="id0ffe73b7f124f5b9dfa9a01b4c7dfcb_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i1d3bf486d496461182f54f254e8fe296_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="if6c3ed9c5b31412bbfc731eadc4f9045_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:TransformationServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ifbfffc16190d487496ae91da9f40ee9b_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:TransformationServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i841058299b4f4c1795217d34792246a1_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:TransformationServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i12ad1dffce3e49519ee5e99e00c3f177_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:TransformationServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="iadf935fda2524029ab1baa4bbb8135d0_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:TransformationServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i4fd904bfe7584429855878280cb71fbe_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PlatformsAndOperationsServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i5a6d3985925f4d079a28f30c8f205377_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PlatformsAndOperationsServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i8b96ed23f107471690b24341345908a6_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PlatformsAndOperationsServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i9e627f3a42b34bd68ed1833fc5b3ff06_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PlatformsAndOperationsServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i36c5f7a5f7074897b1f640ced6ec0f6b_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PlatformsAndOperationsServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i47a5474af0444feba1cc1f919f211cc9_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ia479742cadcb42f19e8a838c73672d04_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i571d8209f1eb48a5abfd5c42c7ee45e7_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i74d008e6bc3e404a8233b3b36dd1f025_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:TransformationServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i64e303d04c4e4b9e9e4bc39b1eee6997_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:TransformationServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ie31b707bdbb24397b9da9c80ed837abf_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:TransformationServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ib86e9afe1f8b4419938a02c0da196679_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:TransformationServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="if6bf1058758a4ffa90f4649ee946bc82_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:TransformationServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i5139ec3fcfe440db905c8c709c4d692a_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PlatformsAndOperationsServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ib8561338bdd4433695c2fe64f2d14fac_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PlatformsAndOperationsServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="if4d7479d872f485386fe9f72c2913b25_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PlatformsAndOperationsServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i44946cd02c6a44519e1f9f53797e5d47_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PlatformsAndOperationsServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="idfe8d8e6c5344c9b97a29c49f343d22f_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PlatformsAndOperationsServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i6a5208c4b92a426f88946822bb9c7fb6_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i12a7d1eed63947fb83cf5d1b35015606_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="id50759ca40e2432a8be2b863be3eeedb_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i16817704fb5d42b894f5f9c40a24d9d7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:TrueHealthSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9f5902da906645d380ce211e0eb169b8_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:TrueHealthSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i558e7ef31d4b428c9ee6d8d5a9dd5f54_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:TrueHealthSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ie069c94280064225b4ffe831d6c5e5fe_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:TrueHealthSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i89185ecde2ae43c5b615a3084603455c_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:TrueHealthSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i80bca972b5164b02a2d38d8930a36773_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:TrueHealthSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i46534d0a532b4e63ade4879ed3702a19_D20210802-20210802">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:WindroseHealthInvestorsIIILPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-02</startDate>
            <endDate>2021-08-02</endDate>
        </period>
    </context>
    <context id="ic40ea142c3e8460d8998330c2ef6c2fe_I20210802">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:WindroseHealthInvestorsIIILPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-02</instant>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="segment">
        <measure>evh:segment</measure>
    </unit>
    <unit id="reportingunit">
        <measure>evh:reportingUnit</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183L2ZyYWc6MzdmOTM2YjczZGFhNGI5ZGIyMTNmOTM0NTAzOTZiMDAvdGFibGU6YTc5NjUyMTE4NzFhNGEyNDkyMWExZTVjYjhiYzg3YWQvdGFibGVyYW5nZTphNzk2NTIxMTg3MWE0YTI0OTIxYTFlNWNiOGJjODdhZF8xLTEtMS0xLTA_2f8274d4-504f-4b06-a9cc-e2bdeddc6f11">0001628908</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183L2ZyYWc6MzdmOTM2YjczZGFhNGI5ZGIyMTNmOTM0NTAzOTZiMDAvdGFibGU6YTc5NjUyMTE4NzFhNGEyNDkyMWExZTVjYjhiYzg3YWQvdGFibGVyYW5nZTphNzk2NTIxMTg3MWE0YTI0OTIxYTFlNWNiOGJjODdhZF8yLTEtMS0xLTA_d0b15d82-fc6c-4120-bb38-b0a830ce6b45">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183L2ZyYWc6MzdmOTM2YjczZGFhNGI5ZGIyMTNmOTM0NTAzOTZiMDAvdGFibGU6YTc5NjUyMTE4NzFhNGEyNDkyMWExZTVjYjhiYzg3YWQvdGFibGVyYW5nZTphNzk2NTIxMTg3MWE0YTI0OTIxYTFlNWNiOGJjODdhZF8zLTEtMS0xLTA_476f46b3-840e-4eea-9733-f4535c48682b">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183L2ZyYWc6MzdmOTM2YjczZGFhNGI5ZGIyMTNmOTM0NTAzOTZiMDAvdGFibGU6YTc5NjUyMTE4NzFhNGEyNDkyMWExZTVjYjhiYzg3YWQvdGFibGVyYW5nZTphNzk2NTIxMTg3MWE0YTI0OTIxYTFlNWNiOGJjODdhZF80LTEtMS0xLTA_2d719a7d-656c-4374-9175-8ceed8fcb254">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183L2ZyYWc6MzdmOTM2YjczZGFhNGI5ZGIyMTNmOTM0NTAzOTZiMDAvdGFibGU6YTc5NjUyMTE4NzFhNGEyNDkyMWExZTVjYjhiYzg3YWQvdGFibGVyYW5nZTphNzk2NTIxMTg3MWE0YTI0OTIxYTFlNWNiOGJjODdhZF81LTEtMS0xLTA_d1bfc1b3-9fd6-454b-af18-fd90539999ed">Q2</dei:DocumentFiscalPeriodFocus>
    <us-gaap:AccountingStandardsUpdateExtensibleList
      contextRef="ice63731bd06b4502bb0ed3b4e178ccba_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfMTktMC0xLTEtMzcyMg_cc0dc4d5-3936-4a6c-8644-233590d31e3c">http://fasb.org/us-gaap/2021-01-31#AccountingStandardsUpdate201613Member</us-gaap:AccountingStandardsUpdateExtensibleList>
    <us-gaap:AccountingStandardsUpdateExtensibleList
      contextRef="i42bd67fe63d94bad9d6d9dbe6ec79900_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY180Ni9mcmFnOjFlZjc0Mjc4OGM3NjQ2NzQ5MGQwNWNhZWM5MzAwYjhkL3RleHRyZWdpb246MWVmNzQyNzg4Yzc2NDY3NDkwZDA1Y2FlYzkzMDBiOGRfMzI1Ng_e7fbd1cf-8213-4b7f-af71-67ed1c89dbd2">http://fasb.org/us-gaap/2021-01-31#AccountingStandardsUpdate201613Member</us-gaap:AccountingStandardsUpdateExtensibleList>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
      contextRef="ia58666fd3ef747c9bd6d04b645148e3f_I20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY182MS9mcmFnOjkyZjMwNzdlMjAzNzQzMDc5MzM1OTg2NTUwM2UyOGRlL3RhYmxlOmVjYWE0M2EyMjA2NzRlMjlhZWYxNWE5MzQyY2Y2YzAyL3RhYmxlcmFuZ2U6ZWNhYTQzYTIyMDY3NGUyOWFlZjE1YTkzNDJjZjZjMDJfMi0xLTEtMS0w_0dd0a43c-05f2-4dd5-8f29-a2887d2e2ab3">P6M</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
      contextRef="i486b139f28404e439444f6f0c13129da_I20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY182MS9mcmFnOjkyZjMwNzdlMjAzNzQzMDc5MzM1OTg2NTUwM2UyOGRlL3RhYmxlOmVjYWE0M2EyMjA2NzRlMjlhZWYxNWE5MzQyY2Y2YzAyL3RhYmxlcmFuZ2U6ZWNhYTQzYTIyMDY3NGUyOWFlZjE1YTkzNDJjZjZjMDJfMy0xLTEtMS0w_3cb6be2e-357e-4e08-8598-11578d4b0201">P12M</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <us-gaap:DebtInstrumentConvertibleConversionRatio1
      contextRef="ia9369ec0e450423b94ac833451c28d42_D20200801-20200831"
      decimals="7"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183Ni9mcmFnOjZjMjk1Y2I5ZTc3YzQ4ZDg5MjdiZDdmMzhlYWYwYzQ2L3RleHRyZWdpb246NmMyOTVjYjllNzdjNDhkODkyN2JkN2YzOGVhZjBjNDZfNQ_14dc3964-219b-44fc-8e5d-bf783400745c"
      unitRef="number">0.0548667</us-gaap:DebtInstrumentConvertibleConversionRatio1>
    <us-gaap:DebtInstrumentConvertibleConversionRatio1
      contextRef="ibe41b74ddef048729f0365c76b125a47_D20181001-20181031"
      decimals="7"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183Ni9mcmFnOjZjMjk1Y2I5ZTc3YzQ4ZDg5MjdiZDdmMzhlYWYwYzQ2L3RleHRyZWdpb246NmMyOTVjYjllNzdjNDhkODkyN2JkN2YzOGVhZjBjNDZfMjE1_6e070c51-0a6e-4c24-a48b-6b016be5173f"
      unitRef="number">0.0299135</us-gaap:DebtInstrumentConvertibleConversionRatio1>
    <us-gaap:DebtInstrumentConvertibleConversionRatio1
      contextRef="ifa1e9df841254737b2d83a5669c5b70d_D20161201-20161231"
      decimals="7"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183Ni9mcmFnOjZjMjk1Y2I5ZTc3YzQ4ZDg5MjdiZDdmMzhlYWYwYzQ2L3RleHRyZWdpb246NmMyOTVjYjllNzdjNDhkODkyN2JkN2YzOGVhZjBjNDZfMzkw_16826312-0150-4afb-a66c-0cad6531354c"
      unitRef="number">0.0416082</us-gaap:DebtInstrumentConvertibleConversionRatio1>
    <dei:DocumentType
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xL2ZyYWc6YjFiNWJmMTFiZDY0NDRhYzhhODIxYmFmNWRlNjE4YzcvdGV4dHJlZ2lvbjpiMWI1YmYxMWJkNjQ0NGFjOGE4MjFiYWY1ZGU2MThjN18yMzE2_ff5b6793-3d73-4d62-988f-ad0ec750b15a">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xL2ZyYWc6YjFiNWJmMTFiZDY0NDRhYzhhODIxYmFmNWRlNjE4YzcvdGV4dHJlZ2lvbjpiMWI1YmYxMWJkNjQ0NGFjOGE4MjFiYWY1ZGU2MThjN18yMzE0_16fa53c0-4daf-4d98-a315-773d2c2768c3">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xL2ZyYWc6YjFiNWJmMTFiZDY0NDRhYzhhODIxYmFmNWRlNjE4YzcvdGV4dHJlZ2lvbjpiMWI1YmYxMWJkNjQ0NGFjOGE4MjFiYWY1ZGU2MThjN18yMDc_85678fcb-2f0f-455f-ac46-a5694ece68b9">2021-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xL2ZyYWc6YjFiNWJmMTFiZDY0NDRhYzhhODIxYmFmNWRlNjE4YzcvdGV4dHJlZ2lvbjpiMWI1YmYxMWJkNjQ0NGFjOGE4MjFiYWY1ZGU2MThjN18yMTY_14c57ab8-164d-4957-b102-21ae7d5498d3">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xL2ZyYWc6YjFiNWJmMTFiZDY0NDRhYzhhODIxYmFmNWRlNjE4YzcvdGV4dHJlZ2lvbjpiMWI1YmYxMWJkNjQ0NGFjOGE4MjFiYWY1ZGU2MThjN18zOTg_5109c998-9489-4f4f-a9a8-4d853e0c8ec4">001-37415</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xL2ZyYWc6YjFiNWJmMTFiZDY0NDRhYzhhODIxYmFmNWRlNjE4YzcvdGV4dHJlZ2lvbjpiMWI1YmYxMWJkNjQ0NGFjOGE4MjFiYWY1ZGU2MThjN180Mjg_95ab76f0-929f-473c-a749-fc95867f66f4">Evolent Health, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xL2ZyYWc6YjFiNWJmMTFiZDY0NDRhYzhhODIxYmFmNWRlNjE4YzcvdGFibGU6ZDEwYzdkODZjMzJjNGZmNzk0ZjZlYTVlYTYxZGFmMjcvdGFibGVyYW5nZTpkMTBjN2Q4NmMzMmM0ZmY3OTRmNmVhNWVhNjFkYWYyN18wLTEtMS0xLTA_746226d7-9661-439b-9488-01172193bf56">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xL2ZyYWc6YjFiNWJmMTFiZDY0NDRhYzhhODIxYmFmNWRlNjE4YzcvdGFibGU6ZDEwYzdkODZjMzJjNGZmNzk0ZjZlYTVlYTYxZGFmMjcvdGFibGVyYW5nZTpkMTBjN2Q4NmMzMmM0ZmY3OTRmNmVhNWVhNjFkYWYyN18wLTktMS0xLTA_1223d95f-dda6-4bda-b355-025a214a4175">32-0454912</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xL2ZyYWc6YjFiNWJmMTFiZDY0NDRhYzhhODIxYmFmNWRlNjE4YzcvdGFibGU6ZDEwYzdkODZjMzJjNGZmNzk0ZjZlYTVlYTYxZGFmMjcvdGFibGVyYW5nZTpkMTBjN2Q4NmMzMmM0ZmY3OTRmNmVhNWVhNjFkYWYyN18zLTEtMS0xLTA_f60c9464-03db-44ea-95e5-939ff23935fc">800 N. Glebe Road</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xL2ZyYWc6YjFiNWJmMTFiZDY0NDRhYzhhODIxYmFmNWRlNjE4YzcvdGFibGU6ZDEwYzdkODZjMzJjNGZmNzk0ZjZlYTVlYTYxZGFmMjcvdGFibGVyYW5nZTpkMTBjN2Q4NmMzMmM0ZmY3OTRmNmVhNWVhNjFkYWYyN18zLTMtMS0xLTA_5f7fe7b6-a2d3-4dd1-b6e8-c3a87f6fe2fa">Suite 500</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xL2ZyYWc6YjFiNWJmMTFiZDY0NDRhYzhhODIxYmFmNWRlNjE4YzcvdGFibGU6ZDEwYzdkODZjMzJjNGZmNzk0ZjZlYTVlYTYxZGFmMjcvdGFibGVyYW5nZTpkMTBjN2Q4NmMzMmM0ZmY3OTRmNmVhNWVhNjFkYWYyN18zLTUtMS0xLTA_461e5da7-a7eb-40f7-8ed6-f07cd6ab8f00">Arlington</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xL2ZyYWc6YjFiNWJmMTFiZDY0NDRhYzhhODIxYmFmNWRlNjE4YzcvdGFibGU6ZDEwYzdkODZjMzJjNGZmNzk0ZjZlYTVlYTYxZGFmMjcvdGFibGVyYW5nZTpkMTBjN2Q4NmMzMmM0ZmY3OTRmNmVhNWVhNjFkYWYyN18zLTctMS0xLTA_4c58263c-0e9c-4e07-a7bd-6fa0960641df">VA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xL2ZyYWc6YjFiNWJmMTFiZDY0NDRhYzhhODIxYmFmNWRlNjE4YzcvdGFibGU6ZDEwYzdkODZjMzJjNGZmNzk0ZjZlYTVlYTYxZGFmMjcvdGFibGVyYW5nZTpkMTBjN2Q4NmMzMmM0ZmY3OTRmNmVhNWVhNjFkYWYyN18zLTktMS0xLTA_0f0d34e6-4b5e-4748-adb2-d50aec5a03cf">22203</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xL2ZyYWc6YjFiNWJmMTFiZDY0NDRhYzhhODIxYmFmNWRlNjE4YzcvdGV4dHJlZ2lvbjpiMWI1YmYxMWJkNjQ0NGFjOGE4MjFiYWY1ZGU2MThjN181Mzg_d88e91ad-ca97-4c20-8ed1-f1b7efa0025d">571</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xL2ZyYWc6YjFiNWJmMTFiZDY0NDRhYzhhODIxYmFmNWRlNjE4YzcvdGV4dHJlZ2lvbjpiMWI1YmYxMWJkNjQ0NGFjOGE4MjFiYWY1ZGU2MThjN181NDI_6f390583-a794-4894-9e7c-be4995aad4d5">389-6000</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xL2ZyYWc6YjFiNWJmMTFiZDY0NDRhYzhhODIxYmFmNWRlNjE4YzcvdGFibGU6YzVmZTlhNDc0MmJhNDZlYjg0YzJhMTI5YjY4ZjYxNmIvdGFibGVyYW5nZTpjNWZlOWE0NzQyYmE0NmViODRjMmExMjliNjhmNjE2Yl8xLTAtMS0xLTA_4371e398-ce39-4d47-9cf5-bccdb1e60492">Class A Common Stock of Evolent Health, Inc., par value $0.01 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xL2ZyYWc6YjFiNWJmMTFiZDY0NDRhYzhhODIxYmFmNWRlNjE4YzcvdGFibGU6YzVmZTlhNDc0MmJhNDZlYjg0YzJhMTI5YjY4ZjYxNmIvdGFibGVyYW5nZTpjNWZlOWE0NzQyYmE0NmViODRjMmExMjliNjhmNjE2Yl8xLTEtMS0xLTA_b0c030b2-50f1-4f49-a64b-4a713220d976">EVH</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xL2ZyYWc6YjFiNWJmMTFiZDY0NDRhYzhhODIxYmFmNWRlNjE4YzcvdGFibGU6YzVmZTlhNDc0MmJhNDZlYjg0YzJhMTI5YjY4ZjYxNmIvdGFibGVyYW5nZTpjNWZlOWE0NzQyYmE0NmViODRjMmExMjliNjhmNjE2Yl8xLTItMS0xLTA_961102ce-c512-4bcd-8860-4bbbc01435dd">NYSE</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xL2ZyYWc6YjFiNWJmMTFiZDY0NDRhYzhhODIxYmFmNWRlNjE4YzcvdGV4dHJlZ2lvbjpiMWI1YmYxMWJkNjQ0NGFjOGE4MjFiYWY1ZGU2MThjN18xMDQ1_265ee563-f4ac-4680-9d2a-0a6e158443c0">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xL2ZyYWc6YjFiNWJmMTFiZDY0NDRhYzhhODIxYmFmNWRlNjE4YzcvdGV4dHJlZ2lvbjpiMWI1YmYxMWJkNjQ0NGFjOGE4MjFiYWY1ZGU2MThjN18xMzY3_969cb24c-ef65-4a7c-8c21-b660ac8ca5a4">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xL2ZyYWc6YjFiNWJmMTFiZDY0NDRhYzhhODIxYmFmNWRlNjE4YzcvdGV4dHJlZ2lvbjpiMWI1YmYxMWJkNjQ0NGFjOGE4MjFiYWY1ZGU2MThjN18xNzM0_6a2f10eb-fb10-4d96-a8bc-f3b1f3029a04">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xL2ZyYWc6YjFiNWJmMTFiZDY0NDRhYzhhODIxYmFmNWRlNjE4YzcvdGV4dHJlZ2lvbjpiMWI1YmYxMWJkNjQ0NGFjOGE4MjFiYWY1ZGU2MThjN18xODE1_f987a000-fb82-47a1-887b-c310963a842b">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xL2ZyYWc6YjFiNWJmMTFiZDY0NDRhYzhhODIxYmFmNWRlNjE4YzcvdGV4dHJlZ2lvbjpiMWI1YmYxMWJkNjQ0NGFjOGE4MjFiYWY1ZGU2MThjN18yMzE1_f71644f9-877a-40bd-9f45-09189370b9f9">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xL2ZyYWc6YjFiNWJmMTFiZDY0NDRhYzhhODIxYmFmNWRlNjE4YzcvdGV4dHJlZ2lvbjpiMWI1YmYxMWJkNjQ0NGFjOGE4MjFiYWY1ZGU2MThjN18yMjIw_a1cb5717-c23b-4f79-963d-f7ce5f3a9f93">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i428cb8fc8d2340adb52e77c530bb0227_I20210802"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xL2ZyYWc6YjFiNWJmMTFiZDY0NDRhYzhhODIxYmFmNWRlNjE4YzcvdGV4dHJlZ2lvbjpiMWI1YmYxMWJkNjQ0NGFjOGE4MjFiYWY1ZGU2MThjN18yMjUx_d20be52a-2a72-4179-82c6-cc6acce6eb5a"
      unitRef="shares">87267772</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfMy0xLTEtMS0w_e3fbfd72-29d8-4e8d-8377-ac0c97eaa1ce"
      unitRef="usd">207273000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i45bff335c1434d6ba44132da1b0557db_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfMy0zLTEtMS0w_1c37ae26-7df7-469d-aa6b-440e54893afb"
      unitRef="usd">319002000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndInvestmentsCurrent
      contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfNC0xLTEtMS0w_5e23ea41-ed9c-4e46-be76-57fdda507613"
      unitRef="usd">17742000</us-gaap:RestrictedCashAndInvestmentsCurrent>
    <us-gaap:RestrictedCashAndInvestmentsCurrent
      contextRef="i45bff335c1434d6ba44132da1b0557db_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfNC0zLTEtMS0w_d562ec08-4b81-4e2d-8690-8f520fffd63a"
      unitRef="usd">14374000</us-gaap:RestrictedCashAndInvestmentsCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfNS0xLTEtMS0w_4ca84b48-7a2c-4c42-b349-4cc6f3d902a5"
      unitRef="usd">242505000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i45bff335c1434d6ba44132da1b0557db_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfNS0zLTEtMS0w_d66e2798-abe8-4ea9-a342-c46e07beedfa"
      unitRef="usd">124064000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfNi0xLTEtMS0w_85c2778c-749c-4408-a8dd-d5ac7fcd6a11"
      unitRef="usd">38032000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i45bff335c1434d6ba44132da1b0557db_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfNi0zLTEtMS0w_126095e3-ba11-4518-b942-19d719b1d746"
      unitRef="usd">56295000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfNy0xLTEtMS0w_2cd770da-5fc3-4e1b-b566-48491b1cacc1"
      unitRef="usd">0</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="i45bff335c1434d6ba44132da1b0557db_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfNy0zLTEtMS0w_c2b20308-eb37-4485-ba3b-ee4fbf6b380d"
      unitRef="usd">33914000</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:AssetsCurrent
      contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfOC0xLTEtMS0w_7dc6261a-5897-4efb-bb4a-c305b54f378e"
      unitRef="usd">505552000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i45bff335c1434d6ba44132da1b0557db_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfOC0zLTEtMS0w_4b45702d-9bcf-412d-8f7f-e38d20dbf343"
      unitRef="usd">547649000</us-gaap:AssetsCurrent>
    <us-gaap:RestrictedCashAndInvestmentsNoncurrent
      contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfOS0xLTEtMS0w_c02961bf-2e9f-47b6-ac78-fccbb1a3d247"
      unitRef="usd">13395000</us-gaap:RestrictedCashAndInvestmentsNoncurrent>
    <us-gaap:RestrictedCashAndInvestmentsNoncurrent
      contextRef="i45bff335c1434d6ba44132da1b0557db_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfOS0zLTEtMS0w_be5c8d69-6718-42e5-b73a-4761c990a8ca"
      unitRef="usd">6654000</us-gaap:RestrictedCashAndInvestmentsNoncurrent>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
      contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfMTAtMS0xLTEtMA_68d97603-c1f3-47c7-a552-daf3c62874a9"
      unitRef="usd">9788000</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
      contextRef="i45bff335c1434d6ba44132da1b0557db_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfMTAtMy0xLTEtMA_c6dba07c-376a-4693-b75b-a4a4f9b5164c"
      unitRef="usd">6498000</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfMTEtMS0xLTEtMA_49f3242f-b0b6-483a-906f-558b2feba1aa"
      unitRef="usd">82996000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i45bff335c1434d6ba44132da1b0557db_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfMTEtMy0xLTEtMA_7a34380c-ba3a-4887-a7dd-3c119293c199"
      unitRef="usd">86240000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfMTItMS0xLTEtMA_562e32bf-237b-4f3c-86e9-94bf399518fd"
      unitRef="usd">51904000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i45bff335c1434d6ba44132da1b0557db_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfMTItMy0xLTEtMA_07841ac5-b30a-4023-8546-b293dfcdbfd2"
      unitRef="usd">57799000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent
      contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfMTMtMS0xLTEtMA_34df675b-2a88-454e-91a0-f1e6eeee0b7a"
      unitRef="usd">6311000</us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent
      contextRef="i45bff335c1434d6ba44132da1b0557db_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfMTMtMy0xLTEtMA_0bd89b3b-2068-4bdc-b1ba-4a900b749388"
      unitRef="usd">5773000</us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent>
    <us-gaap:CapitalizedContractCostNetNoncurrent
      contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfMTQtMS0xLTEtMA_df1e8317-c207-4b60-8a15-54608b93bbd5"
      unitRef="usd">22367000</us-gaap:CapitalizedContractCostNetNoncurrent>
    <us-gaap:CapitalizedContractCostNetNoncurrent
      contextRef="i45bff335c1434d6ba44132da1b0557db_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfMTQtMy0xLTEtMA_8c310f40-0697-4cea-baf4-0642275c161c"
      unitRef="usd">26687000</us-gaap:CapitalizedContractCostNetNoncurrent>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfMTUtMS0xLTEtMA_e4e084e0-cedf-487b-995a-129ad9c7aafb"
      unitRef="usd">252045000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i45bff335c1434d6ba44132da1b0557db_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfMTUtMy0xLTEtMA_ed249dc4-05e5-4224-9df0-a40bb4d2e014"
      unitRef="usd">264992000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfMTYtMS0xLTEtMA_0dc7fa78-2a47-4c18-8ec8-396e7928c05f"
      unitRef="usd">349009000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i45bff335c1434d6ba44132da1b0557db_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfMTYtMy0xLTEtMA_08b61995-8301-4f3e-809e-1b3a18022fb7"
      unitRef="usd">349029000</us-gaap:Goodwill>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent
      contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfMTctMS0xLTEtMA_e2256e6a-b3d3-408c-8bbf-9963988951b3"
      unitRef="usd">0</us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent
      contextRef="i45bff335c1434d6ba44132da1b0557db_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfMTctMy0xLTEtMA_2c7d479b-4b6c-4f33-bb64-32f921fa2c95"
      unitRef="usd">20379000</us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfMTgtMS0xLTEtMA_1f1b2ff3-1342-400f-9025-11041b905f5d"
      unitRef="usd">1293367000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i45bff335c1434d6ba44132da1b0557db_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfMTgtMy0xLTEtMA_d92ee3f7-87f4-4da2-a6c4-82c03ff3e123"
      unitRef="usd">1371700000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfMjItMS0xLTEtMA_1f10d8b5-1db8-4230-98e0-6ce7b5992df9"
      unitRef="usd">39879000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i45bff335c1434d6ba44132da1b0557db_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfMjItMy0xLTEtMA_c5e869a8-ed79-4a79-8e99-c692c6b54846"
      unitRef="usd">31975000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfMjMtMS0xLTEtMA_5d00a01b-0f87-47ac-87ff-357987c3f073"
      unitRef="usd">52339000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i45bff335c1434d6ba44132da1b0557db_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfMjMtMy0xLTEtMA_2f78f8c5-c465-44cf-96b8-12f236568eab"
      unitRef="usd">73242000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfMjQtMS0xLTEtMA_9a4fc620-9ea7-4bd5-9c12-671981ea7e32"
      unitRef="usd">26655000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="i45bff335c1434d6ba44132da1b0557db_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfMjQtMy0xLTEtMA_94b65048-6eb5-4478-8363-3ea165e061b8"
      unitRef="usd">26557000</us-gaap:LongTermDebtCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfMjUtMS0xLTEtMA_855a0b0d-bb0c-401d-b303-c0e702fa7527"
      unitRef="usd">7265000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i45bff335c1434d6ba44132da1b0557db_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfMjUtMy0xLTEtMA_68422452-7a2d-4826-b5d5-effaaff6470c"
      unitRef="usd">7357000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfMjYtMS0xLTEtMA_1da19af1-949d-400c-ab1c-4f0ef26d857a"
      unitRef="usd">25852000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i45bff335c1434d6ba44132da1b0557db_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfMjYtMy0xLTEtMA_83ccfed6-a510-4335-a3d5-395f14297550"
      unitRef="usd">47163000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfMjctMS0xLTEtMA_1cd09721-4e41-46c2-b474-d6df5f8b22bf"
      unitRef="usd">13173000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i45bff335c1434d6ba44132da1b0557db_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfMjctMy0xLTEtMA_bfd2e771-0125-47c7-a309-8c37ebdb8b55"
      unitRef="usd">10187000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <evh:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements
      contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfMjgtMS0xLTEtMA_b18bdc4b-8074-4572-9265-14e37f5cd14e"
      unitRef="usd">238105000</evh:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements>
    <evh:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements
      contextRef="i45bff335c1434d6ba44132da1b0557db_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfMjgtMy0xLTEtMA_a1ac98c6-5825-4d80-94f4-d279034abf6d"
      unitRef="usd">178827000</evh:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfMjktMS0xLTEtMA_5041e621-29a1-457c-98a8-355f4cc2d57c"
      unitRef="usd">0</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="i45bff335c1434d6ba44132da1b0557db_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfMjktMy0xLTEtMA_c576e438-00e7-4d5a-912d-c52ea4f53b5e"
      unitRef="usd">27986000</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfMzAtMS0xLTEtMA_a995a2d0-d1ef-4704-b11b-8ea7df55592b"
      unitRef="usd">403268000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i45bff335c1434d6ba44132da1b0557db_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfMzAtMy0xLTEtMA_a7362345-66b8-4ae5-a232-e72ac5857aa0"
      unitRef="usd">403294000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfMzEtMS0xLTEtMA_b7dfd9e3-1ab5-4fdf-93f6-bbf3cc4956f3"
      unitRef="usd">206550000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i45bff335c1434d6ba44132da1b0557db_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfMzEtMy0xLTEtMA_d6c2fa69-59c9-493f-a75a-9726e3ed9674"
      unitRef="usd">263343000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfMzItMS0xLTEtMA_9fc9ebf0-77c3-4ca5-903d-6494fc0d750f"
      unitRef="usd">9784000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i45bff335c1434d6ba44132da1b0557db_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfMzItMy0xLTEtMA_3fd8ce08-3295-4c17-a1fa-43197f55f587"
      unitRef="usd">22081000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfMzMtMS0xLTEtMA_78b26908-b9a5-4dda-9eca-de44f4646f6f"
      unitRef="usd">58618000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i45bff335c1434d6ba44132da1b0557db_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfMzMtMy0xLTEtMA_824a9c31-c338-490c-baf4-6607b0808432"
      unitRef="usd">62526000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfMzQtMS0xLTEtMA_b66ff2cc-b296-433d-85e4-a709c68a28bc"
      unitRef="usd">957000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i45bff335c1434d6ba44132da1b0557db_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfMzQtMy0xLTEtMA_de376b52-3177-4738-b88b-675c48e3c3c8"
      unitRef="usd">679000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent
      contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfMzUtMS0xLTEtMA_76487cce-418c-4016-94ca-d277ace013cf"
      unitRef="usd">0</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent
      contextRef="i45bff335c1434d6ba44132da1b0557db_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfMzUtMy0xLTEtMA_3137d4f5-3f57-4801-9dd3-5e311e17c19f"
      unitRef="usd">177000</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent>
    <us-gaap:Liabilities
      contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfMzYtMS0xLTEtMA_1c895d05-a8f4-4f18-811d-e1d70d2c7cf2"
      unitRef="usd">679177000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i45bff335c1434d6ba44132da1b0557db_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfMzYtMy0xLTEtMA_63bfc7e8-1d2a-4547-9e8e-d8bea9fbb8cc"
      unitRef="usd">752100000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfMzctMS0xLTEtMA_ab4d7788-6afc-4834-bf7d-8cd7049daed3"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i45bff335c1434d6ba44132da1b0557db_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfMzctMy0xLTEtMA_74cde5c5-5fc0-483c-b669-422077a0dbad"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i45bff335c1434d6ba44132da1b0557db_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfMzktMC0xLTEtMC90ZXh0cmVnaW9uOjdmZTEyZDE2NjE5MDQ3ODViZmZjZTI1OTU2OTEzY2FkXzI3_083cb183-8f41-4036-9433-6dfb6e620ac2"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfMzktMC0xLTEtMC90ZXh0cmVnaW9uOjdmZTEyZDE2NjE5MDQ3ODViZmZjZTI1OTU2OTEzY2FkXzI3_8ce04cd9-0495-44ad-934a-e57c67bd1b24"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i45bff335c1434d6ba44132da1b0557db_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfMzktMC0xLTEtMC90ZXh0cmVnaW9uOjdmZTEyZDE2NjE5MDQ3ODViZmZjZTI1OTU2OTEzY2FkXzQx_0a2efa4b-0099-4a57-ba78-0ebb41f71095"
      unitRef="shares">750000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfMzktMC0xLTEtMC90ZXh0cmVnaW9uOjdmZTEyZDE2NjE5MDQ3ODViZmZjZTI1OTU2OTEzY2FkXzQx_34c67535-fb92-4c15-8ba5-9d71bc5e6e88"
      unitRef="shares">750000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfMzktMC0xLTEtMC90ZXh0cmVnaW9uOjdmZTEyZDE2NjE5MDQ3ODViZmZjZTI1OTU2OTEzY2FkXzY0_a5f19fa2-6a75-4139-9081-cc9bdd9ab851"
      unitRef="shares">87195128</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="i45bff335c1434d6ba44132da1b0557db_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfMzktMC0xLTEtMC90ZXh0cmVnaW9uOjdmZTEyZDE2NjE5MDQ3ODViZmZjZTI1OTU2OTEzY2FkXzcx_80ed9cda-9311-436d-98e1-d63e871d1060"
      unitRef="shares">85894450</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="icc9702daaf8a42a6b738e99ae2cf6328_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfMzktMS0xLTEtMA_8c5a81f6-7997-461a-86ec-3cb109ec104d"
      unitRef="usd">872000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i5afa72f271884055860c7e9a53ef18b2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfMzktMy0xLTEtMA_04dfcd68-adb5-4c82-8cd5-284a8feefa5a"
      unitRef="usd">859000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfNDAtMS0xLTEtMA_0ead8e33-ba8a-49a1-b321-cd2ad333022d"
      unitRef="usd">1242900000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i45bff335c1434d6ba44132da1b0557db_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfNDAtMy0xLTEtMA_8e1b2831-e0d9-42c5-a1a5-1bc6eaf45d0e"
      unitRef="usd">1229320000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfNDEtMS0xLTEtMA_e0d9eae8-c174-4723-ac4a-593a4d170937"
      unitRef="usd">-367000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i45bff335c1434d6ba44132da1b0557db_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfNDEtMy0xLTEtMA_fec9fcd4-90d9-429e-8dc9-ad3407d9aa3d"
      unitRef="usd">-278000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfNDItMS0xLTEtMA_6faed371-ce14-41d4-bf9b-408ae2d068c6"
      unitRef="usd">-608092000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i45bff335c1434d6ba44132da1b0557db_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfNDItMy0xLTEtMA_ab74ea78-1474-4f5b-8903-13bd3e7371c3"
      unitRef="usd">-589178000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:TreasuryStockShares
      contextRef="i45bff335c1434d6ba44132da1b0557db_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfNDMtMC0xLTEtMC90ZXh0cmVnaW9uOjcxM2Q5ODQ2ODc5MDQ2NjRiY2ZiZTU3ZDY5YmNkYzc1XzI5_49f46f72-0336-4862-9ecb-e504f1d2c08c"
      unitRef="shares">1537582</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockShares
      contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfNDMtMC0xLTEtMC90ZXh0cmVnaW9uOjcxM2Q5ODQ2ODc5MDQ2NjRiY2ZiZTU3ZDY5YmNkYzc1XzI5_d9c99244-7b7f-4447-9ac2-ca6dc82517da"
      unitRef="shares">1537582</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockValue
      contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfNDMtMS0xLTEtMA_83102857-7cd3-4d10-a106-8a6e60346c09"
      unitRef="usd">21123000</us-gaap:TreasuryStockValue>
    <us-gaap:TreasuryStockValue
      contextRef="i45bff335c1434d6ba44132da1b0557db_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfNDMtMy0xLTEtMA_21f1acf4-4b69-403e-a541-bd4f88668f69"
      unitRef="usd">21123000</us-gaap:TreasuryStockValue>
    <us-gaap:StockholdersEquity
      contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfNDQtMS0xLTEtMA_8532c16a-cef9-4e48-bb32-038e1c8b214c"
      unitRef="usd">614190000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i45bff335c1434d6ba44132da1b0557db_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfNDQtMy0xLTEtMA_43029e9c-7773-47f7-8cae-9ec25a183479"
      unitRef="usd">619600000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfNDUtMS0xLTEtMA_66f7e935-9e0b-44b0-99de-9a048955a373"
      unitRef="usd">1293367000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i45bff335c1434d6ba44132da1b0557db_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfNDUtMy0xLTEtMA_6d0a0197-340a-43fa-bbd8-cd3e17665488"
      unitRef="usd">1371700000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues
      contextRef="i7b3321915fe444e488ceef708a6e59c9_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMy0xLTEtMS02NA_4ddfd893-22a5-4d76-b130-01774ab09be5"
      unitRef="usd">2564000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i78e15c27cd3e401ea6bd6fd305abeb34_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMy0zLTEtMS02NA_8a291b24-c574-452f-939f-4ed838ba9580"
      unitRef="usd">755000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8cf8298bd37b49539b40ff277f78e799_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMy0xLTEtMS0w_170ba868-793c-4ffe-bebd-eb61ff904fd1"
      unitRef="usd">2909000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia98a39c8ecac46f5b530749d9b554995_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMy0zLTEtMS0w_033da13e-7a60-4e5b-86d1-46b783ef6f62"
      unitRef="usd">5993000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie90c815774924e1e802eb6f3123f1004_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfNC0xLTEtMS02NA_1646c669-412d-40be-a8bf-033270592308"
      unitRef="usd">219493000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="icd99be6d27564d4cb75996e8ce5dce17_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfNC0zLTEtMS02NA_50789944-5571-4917-817b-931e2e3b29ad"
      unitRef="usd">216544000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iaf5036ffdbc24ee8a477412be1612a0c_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfNC0xLTEtMS0w_4912914f-f7bf-4db0-8743-46164a2ce1b1"
      unitRef="usd">434219000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ibf7fe803335d432ba4201dde52789d25_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfNC0zLTEtMS0w_641872ca-97f5-472a-b032-425fcb904fd3"
      unitRef="usd">432538000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfNS0xLTEtMS02Nw_e56fbcd9-0449-4238-add8-44ca440fd47e"
      unitRef="usd">222057000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfNS0zLTEtMS02Nw_09bd88e2-baf2-4546-90c9-9b6deb926054"
      unitRef="usd">217299000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfNS0xLTEtMS0w_c78ab51f-dc57-4619-93b0-36b1483352c4"
      unitRef="usd">437128000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfNS0zLTEtMS0w_d8150dac-4e10-46f7-937d-b2b0c07adbab"
      unitRef="usd">438531000</us-gaap:Revenues>
    <evh:CostofGoodsandServicesSoldExcludingDepreciationandAmortization
      contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfOC0xLTEtMS04Nw_1bc0b1dc-fe01-4de7-ba41-3ecef7ac0a30"
      unitRef="usd">172113000</evh:CostofGoodsandServicesSoldExcludingDepreciationandAmortization>
    <evh:CostofGoodsandServicesSoldExcludingDepreciationandAmortization
      contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfOC0zLTEtMS04Nw_42941013-db98-4377-a51b-f4d23a542da8"
      unitRef="usd">164358000</evh:CostofGoodsandServicesSoldExcludingDepreciationandAmortization>
    <evh:CostofGoodsandServicesSoldExcludingDepreciationandAmortization
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfOC0xLTEtMS0w_bcd4f6f2-84b7-4b1d-9d32-1a5da0be3e1e"
      unitRef="usd">329945000</evh:CostofGoodsandServicesSoldExcludingDepreciationandAmortization>
    <evh:CostofGoodsandServicesSoldExcludingDepreciationandAmortization
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfOC0zLTEtMS0w_a7c391ca-74f2-406d-8845-5e85413ef517"
      unitRef="usd">339987000</evh:CostofGoodsandServicesSoldExcludingDepreciationandAmortization>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfOS0xLTEtMS05MA_035cf8ca-b3a4-4fa4-878b-6900e1908669"
      unitRef="usd">42699000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfOS0zLTEtMS05MA_63fd3a46-1ce7-4e9e-afc2-84df19c21d43"
      unitRef="usd">47296000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfOS0xLTEtMS0w_2913840b-6e6e-4c12-a70f-0383ffa3f270"
      unitRef="usd">101290000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfOS0zLTEtMS0w_b14e9482-2674-4e3e-92ef-34edd76c896f"
      unitRef="usd">99383000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:DepreciationAndAmortization
      contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMTAtMS0xLTEtOTA_51ebaf8d-58b9-4402-98a5-55882b26bfa5"
      unitRef="usd">14916000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMTAtMy0xLTEtOTA_711e58dd-b3bf-4ce9-8356-febd5bd7e040"
      unitRef="usd">15618000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMTAtMS0xLTEtMA_b89dfc9c-133e-4bc3-9fb0-18a0854848a9"
      unitRef="usd">30103000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMTAtMy0xLTEtMA_cd4b9e49-da85-488a-ab87-c2a23a448d20"
      unitRef="usd">31596000</us-gaap:DepreciationAndAmortization>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMTEtMS0xLTEtOTA_e0c52d50-e3a3-4512-b2e4-0b2e2ac92924"
      unitRef="usd">0</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMTEtMy0xLTEtOTA_131bc957-5705-4170-9460-8fbf575defa1"
      unitRef="usd">0</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMTEtMS0xLTEtMA_41398074-199c-4312-8868-086ffc38fdf8"
      unitRef="usd">0</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMTEtMy0xLTEtMA_26401d32-d093-49f3-806e-d549521a6e3f"
      unitRef="usd">-6447000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMTItMS0xLTEtMzU1MQ_f32dfc03-629b-45c5-8e3d-48cc179e32dc"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMTItMy0xLTEtMzU1MQ_da5b8871-14a8-4074-9e69-eb2319b7e052"
      unitRef="usd">215100000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMTItNS0xLTEtMzU1MQ_3970a762-5d46-42d9-8839-1e16c4304fda"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMTItNy0xLTEtMzU1MQ_385f35af-24c1-405c-96d2-39a32c53edd4"
      unitRef="usd">215100000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMTItMS0xLTEtOTM_215eb6b6-3248-48a8-a981-de622fa02e48"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMTItMy0xLTEtOTM_177db836-2be7-4ed7-8e29-c0207331895e"
      unitRef="usd">756000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMTItMS0xLTEtMA_967c9930-b164-4527-ac86-a7d66efb0c2d"
      unitRef="usd">-594000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMTItMy0xLTEtMA_f81be485-c650-445e-b76e-f9b32cb95f94"
      unitRef="usd">-3062000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:OperatingExpenses
      contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMTMtMS0xLTEtOTM_0cda2728-92ce-457e-90f3-2b8e40675396"
      unitRef="usd">229728000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMTMtMy0xLTEtOTM_289326b3-6203-4a67-8852-6fe6f52cb3a8"
      unitRef="usd">443128000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMTMtMS0xLTEtMA_ef0d5320-54f1-4911-b4f9-ba3433126052"
      unitRef="usd">460744000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMTMtMy0xLTEtMA_3638373c-562f-4a7c-bdf0-f828e93ffc0b"
      unitRef="usd">689451000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMTQtMS0xLTEtOTM_a4a2ba00-a042-429d-bc97-ddd052de4e4c"
      unitRef="usd">-7671000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMTQtMy0xLTEtOTM_13c2dc1e-1a5e-4a3c-81f1-4958e709bf9b"
      unitRef="usd">-225829000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMTQtMS0xLTEtMA_6f64c5bc-c1c4-4f60-b90e-eb9b03eba2c5"
      unitRef="usd">-23616000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMTQtMy0xLTEtMA_370e5a21-eb8d-47ce-94c8-a36156df43c4"
      unitRef="usd">-250920000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMTUtMS0xLTEtOTc_163a4d38-74de-4cd9-a96b-712b37840fa1"
      unitRef="usd">68000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMTUtMy0xLTEtOTc_8b77ae30-490d-41bd-a1ad-cfd12e4ed830"
      unitRef="usd">705000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMTUtMS0xLTEtMA_83816d22-b67f-42bc-a14d-da7e4c5fc61c"
      unitRef="usd">191000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMTUtMy0xLTEtMA_287cc6db-5a69-4a02-b7e0-abc163843895"
      unitRef="usd">1475000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense
      contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMTYtMS0xLTEtOTc_11cc8d20-a0c9-4bc6-909e-2381fc933d5b"
      unitRef="usd">6274000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMTYtMy0xLTEtOTc_6aa74fa0-94c8-413e-ba22-b441bde9cde7"
      unitRef="usd">6290000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMTYtMS0xLTEtMA_0f5794e1-5476-475f-9319-40ba8fe48852"
      unitRef="usd">12611000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMTYtMy0xLTEtMA_5fb34376-158e-4edf-980a-3aaca82d2ec6"
      unitRef="usd">12571000</us-gaap:InterestExpense>
    <us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment
      contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMTctMS0xLTEtOTc_d26c2f6d-80f1-448a-b11a-adcafc85f05e"
      unitRef="usd">0</us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment>
    <us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment
      contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMTctMy0xLTEtOTc_bd0af72e-4b6e-40d0-aaea-4909529ed7a2"
      unitRef="usd">0</us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment>
    <us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMTctMS0xLTEtMA_06a6b585-2ed9-48b1-9439-720ebcdcf8ba"
      unitRef="usd">0</us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment>
    <us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMTctMy0xLTEtMA_03e4b414-3d33-4476-a9bd-7a2334ff1d32"
      unitRef="usd">47133000</us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMTgtMS0xLTEtMTAw_a309bdfb-fd5b-48c0-b00f-3b00ebbb5647"
      unitRef="usd">4879000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMTgtMy0xLTEtMTAw_5d71ca1e-34b5-416e-923b-dedb02c62b98"
      unitRef="usd">25143000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMTgtMS0xLTEtMA_91816d87-67d5-49e9-bae2-c9d0a14c901c"
      unitRef="usd">12662000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMTgtMy0xLTEtMA_ee06d9ff-1df7-4217-9324-d60d16992207"
      unitRef="usd">24731000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <evh:GainOnTransferOfMembership
      contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMTktMS0xLTEtMTAz_55dc2831-29b7-4b4b-80bc-3889bb110c63"
      unitRef="usd">0</evh:GainOnTransferOfMembership>
    <evh:GainOnTransferOfMembership
      contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMTktMy0xLTEtMTAz_ea8e6d24-6828-40de-bc68-44c98b363708"
      unitRef="usd">0</evh:GainOnTransferOfMembership>
    <evh:GainOnTransferOfMembership
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMTktMS0xLTEtMA_f2c7b3b0-04fd-4481-be68-123f4af88470"
      unitRef="usd">22969000</evh:GainOnTransferOfMembership>
    <evh:GainOnTransferOfMembership
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMTktMy0xLTEtMA_b48bb13d-b69d-444b-94f4-99243502b599"
      unitRef="usd">0</evh:GainOnTransferOfMembership>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMjAtMS0xLTEtMTA2_edc9c9cf-ae79-4619-bf15-aaecedd1a34b"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMjAtMy0xLTEtMTA2_46930a50-7971-43d0-bb83-c8bf95e98c52"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMjAtMS0xLTEtMA_e87c8e89-275c-4582-8c29-0a0a99e7f386"
      unitRef="usd">-19158000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMjAtMy0xLTEtMA_38f20b0d-bbe4-44aa-89fb-4ea49eb451b6"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMjEtMS0xLTEtMTA2_4f61e22f-ae45-44cd-9e7f-6a885da3bd78"
      unitRef="usd">-18000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMjEtMy0xLTEtMTA2_06ecb6fb-7923-4555-954d-8267b9344861"
      unitRef="usd">354000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMjEtMS0xLTEtMA_9ae8dcdb-8ad5-42e0-b888-42c3c10a97ce"
      unitRef="usd">-32000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMjEtMy0xLTEtMA_592efb36-e4b6-4cc8-8b4a-76c9d8d30c78"
      unitRef="usd">284000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMjItMS0xLTEtMTA2_4f956374-9e4a-4bc8-a679-22493f47aad9"
      unitRef="usd">-9016000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMjItMy0xLTEtMTA2_00f124ad-18b5-47bf-afee-e23a5f1b06df"
      unitRef="usd">-205917000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMjItMS0xLTEtMA_48454bb2-08b2-43ed-b4bd-00a22bbbff0f"
      unitRef="usd">-19595000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMjItMy0xLTEtMA_16cdbc84-bb0f-42f1-89ee-ee42ebdbc723"
      unitRef="usd">-284134000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMjMtMS0xLTEtMTA2_cf22680b-4d17-4e8c-a258-22e220e34968"
      unitRef="usd">91000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMjMtMy0xLTEtMTA2_3e52d0a4-b836-4413-ba3b-5dad5cba4b2d"
      unitRef="usd">-3904000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMjMtMS0xLTEtMA_e194d371-a3e9-46b3-bed1-380442f9a616"
      unitRef="usd">702000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMjMtMy0xLTEtMA_d9472852-fc37-4316-a995-f52074b457e4"
      unitRef="usd">-3634000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMjQtMS0xLTEtMTA2_a030db38-41f2-4034-bb47-c1ea177a3f12"
      unitRef="usd">-9107000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMjQtMy0xLTEtMTA2_dd96325a-3f6a-4064-8bfc-1c8d6a0ccf87"
      unitRef="usd">-202013000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMjQtMS0xLTEtMA_228846d4-483a-4bd6-9c29-0517d59f1ace"
      unitRef="usd">-20297000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMjQtMy0xLTEtMA_1259824e-746f-44ea-a83e-f1b50f0b3e55"
      unitRef="usd">-280500000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMjUtMS0xLTEtMTEw_1cdad334-f519-48e7-a442-e006607bfd0d"
      unitRef="usd">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMjUtMy0xLTEtMTEw_23a653a3-53f9-4fa2-825a-b0238aa1e1bc"
      unitRef="usd">-1508000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMjUtMS0xLTEtMA_c5ecddec-ea61-49d7-9ee4-4bc37ada6314"
      unitRef="usd">1383000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMjUtMy0xLTEtMA_e40e5aa3-d436-463d-ae79-d4a972b39319"
      unitRef="usd">-1773000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:ProfitLoss
      contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMjYtMS0xLTEtMTEw_224dac42-b7ca-448a-8c6c-19553d6e70ed"
      unitRef="usd">-9107000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMjYtMy0xLTEtMTEw_24819732-0f1d-4a88-b203-8430f2e00104"
      unitRef="usd">-203521000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMjYtMS0xLTEtMA_3c6b9c11-4052-4bf7-86e1-89b8e6f56107"
      unitRef="usd">-18914000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMjYtMy0xLTEtMA_6133f0dd-e1f4-4ff4-96e9-42a93c1f62a1"
      unitRef="usd">-282273000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMjctMS0xLTEtMTEw_588b0315-6ec7-4ba0-8c57-c489dff9bf4a"
      unitRef="usd">0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMjctMy0xLTEtMTEw_91d2f40b-af1d-403c-ae75-b09607128928"
      unitRef="usd">0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMjctMS0xLTEtMA_6ebde5ba-b5bf-4879-a8ed-55bc8a2cf8f7"
      unitRef="usd">0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMjctMy0xLTEtMA_487ffa05-a8ca-4c89-8418-c5324a371639"
      unitRef="usd">0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMjgtMS0xLTEtMTEw_09330fbb-f85e-46d5-b7ba-0c4c55c92dcd"
      unitRef="usd">-9107000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMjgtMS0xLTEtMTEw_f334614f-48c8-4335-8644-08d1c094b533"
      unitRef="usd">-9107000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMjgtMy0xLTEtMTEw_1f1b826f-81ea-4a16-8e51-b233cb6cb5d8"
      unitRef="usd">-203521000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMjgtMy0xLTEtMTEw_464f9ea4-79d0-46fe-b7e0-3bfbaef12c35"
      unitRef="usd">-203521000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMjgtMS0xLTEtMA_3f65effd-5c00-48e2-b9f0-61aa1fc1e88c"
      unitRef="usd">-18914000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMjgtMS0xLTEtMA_7051b8a1-9469-4d3d-b02f-b619b054437f"
      unitRef="usd">-18914000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMjgtMy0xLTEtMA_0841956d-a0c8-4eca-a9f7-99ceb502bb32"
      unitRef="usd">-282273000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMjgtMy0xLTEtMA_d981f43f-4d1f-4440-8d13-5cf7db63d994"
      unitRef="usd">-282273000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMzItMS0xLTEtMTI2_9b468376-3abb-4b91-b544-45598236cd35"
      unitRef="usdPerShare">-0.11</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMzItMS0xLTEtMTI2_a57eda48-bbd8-4cd1-9c68-3604f50ce2cf"
      unitRef="usdPerShare">-0.11</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMzItMy0xLTEtMTI2_852b9a3c-a463-48e0-8977-f56a22c2b011"
      unitRef="usdPerShare">-2.37</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMzItMy0xLTEtMTI2_9ef447ed-dde3-4a30-8002-79abb76cde61"
      unitRef="usdPerShare">-2.37</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMzItMS0xLTEtMA_aea6d686-ea84-421d-bccd-c58e29e2aaab"
      unitRef="usdPerShare">-0.24</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMzItMS0xLTEtMA_ea47c458-12d3-4812-ac4e-259bd09fec29"
      unitRef="usdPerShare">-0.24</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMzItMy0xLTEtMA_6f9f8394-7bd7-4271-8132-915268925c9a"
      unitRef="usdPerShare">-3.30</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMzItMy0xLTEtMA_dc90bf72-8a65-4da4-9bf9-d7c52b845d76"
      unitRef="usdPerShare">-3.30</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMzMtMS0xLTEtMTI2_891023c2-8f2f-4aac-b882-a0c38556e0ee"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMzMtMS0xLTEtMTI2_aff981ea-ee53-455d-9f65-8e9eed3782e5"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMzMtMy0xLTEtMTI2_1c38e201-a69b-4d9d-9544-48059e596cdd"
      unitRef="usdPerShare">-0.01</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMzMtMy0xLTEtMTI2_5aba3028-f0bb-4816-831a-d14e599f86d6"
      unitRef="usdPerShare">-0.01</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMzMtMS0xLTEtMA_79fdbf08-c988-4fe5-8cc6-c90de5b2ae49"
      unitRef="usdPerShare">0.02</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMzMtMS0xLTEtMA_a4377843-e7a2-4873-91ba-9152526441b0"
      unitRef="usdPerShare">0.02</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMzMtMy0xLTEtMA_0d6b51ea-d7ab-4d37-abae-c32d154ecc1c"
      unitRef="usdPerShare">-0.02</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMzMtMy0xLTEtMA_800c73c2-b879-48d8-a85e-64407c8de0bb"
      unitRef="usdPerShare">-0.02</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMzUtMS0xLTEtMzY5OQ_289fe6d2-509d-4929-bc0d-716bc06e55f4"
      unitRef="usdPerShare">-0.11</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMzUtMS0xLTEtMzY5OQ_a1d75a1c-6e8f-4a55-a8ba-fdf4ca86b37a"
      unitRef="usdPerShare">-0.11</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMzUtMS0xLTEtMzY5OQ_a93fda02-45cf-44f3-9452-c41930c85b70"
      unitRef="usdPerShare">-0.11</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMzUtMS0xLTEtMzY5OQ_d77c4081-1564-4e19-97f4-f86af17bdcc8"
      unitRef="usdPerShare">-0.11</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMzQtMy0xLTEtMTMw_578191b1-a62d-463e-be7e-11ef55341fed"
      unitRef="usdPerShare">-2.38</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMzQtMy0xLTEtMTMw_b15e7f6a-89e7-46a5-9171-d647d7fdc69c"
      unitRef="usdPerShare">-2.38</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMzQtMS0xLTEtMA_4475b23a-7973-4d2f-8051-0da9faf1300e"
      unitRef="usdPerShare">-0.22</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMzQtMS0xLTEtMA_a0729353-7687-45b1-b4a0-fd57a8065aa6"
      unitRef="usdPerShare">-0.22</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMzQtMy0xLTEtMA_9073a702-ff65-429f-b0fa-bd0027da3413"
      unitRef="usdPerShare">-3.32</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMzQtMy0xLTEtMA_aa85be71-08a7-444f-9d13-8b6e26540e81"
      unitRef="usdPerShare">-3.32</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMzctMS0xLTEtMTMz_615bafb3-bdfe-4b63-9036-b3537a8d3d5f"
      unitRef="shares">85448000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMzctMS0xLTEtMTMz_e018bb7d-cfe1-4e15-983f-63502f8c7917"
      unitRef="shares">85448000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMzctMy0xLTEtMTMz_1ad6606b-0da7-4d3d-b6a8-e5367eea0c7a"
      unitRef="shares">85349000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMzctMy0xLTEtMTMz_e0eb1f1b-2f64-4b89-bf40-a7b7ee576f84"
      unitRef="shares">85349000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMzctMS0xLTEtMA_4242e7a7-f111-40b8-a6cb-ff0b458cb1a5"
      unitRef="shares">85056000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMzctMS0xLTEtMA_75f40ade-b15d-4533-9a0c-5990c566b25e"
      unitRef="shares">85056000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMzctMy0xLTEtMA_456e1a38-89a7-499c-bb0c-bdb8fabe2538"
      unitRef="shares">84977000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMzctMy0xLTEtMA_a4062fd1-4700-4596-ac02-4d51b453a84d"
      unitRef="shares">84977000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:ProfitLoss
      contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfNDAtMS0xLTEtMTE1_e1a9ccc8-cee3-42bf-b57a-f632ad874bca"
      unitRef="usd">-9107000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfNDAtMy0xLTEtMTE1_1bad5c66-7281-436c-b0aa-04559d72306a"
      unitRef="usd">-203521000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfNDAtMS0xLTEtMA_62153268-308b-4e8c-8a87-75b9badacb6c"
      unitRef="usd">-18914000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfNDAtMy0xLTEtMA_762d1169-3865-4e47-a5b2-7944ff6a53e6"
      unitRef="usd">-282273000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfNDItMS0xLTEtMTE1_a744e1e5-d8cb-4d8a-91fc-e02049bd1f07"
      unitRef="usd">-58000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfNDItMy0xLTEtMTE1_3c2f41b3-05a4-4ab2-bf1d-9feb2d63b200"
      unitRef="usd">-4000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfNDItMS0xLTEtMA_684b5e93-e46a-483a-88a2-c32fdffe6bc7"
      unitRef="usd">-89000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfNDItMy0xLTEtMA_f914b09f-2d2c-495b-b6dd-026262496a50"
      unitRef="usd">-157000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfNDMtMS0xLTEtMTE1_c2635787-e0d9-4b51-8967-ce177f25fa3f"
      unitRef="usd">-9165000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfNDMtMy0xLTEtMTE1_cc7018d6-f0b0-4812-904b-de8334952519"
      unitRef="usd">-203525000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfNDMtMS0xLTEtMA_0224b927-4b1e-4d40-9445-0e8a8c580c2b"
      unitRef="usd">-19003000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfNDMtMy0xLTEtMA_92541769-bb62-4ac2-881a-629d17f58871"
      unitRef="usd">-282430000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfNDQtMS0xLTEtMTE1_d950645d-7854-4c8a-9d6a-20f2d369fe54"
      unitRef="usd">0</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfNDQtMy0xLTEtMTE1_ae945b71-8ae1-4572-b3b6-3e61a7b66140"
      unitRef="usd">0</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfNDQtMS0xLTEtMA_a10cdb2a-b65f-46ae-8839-220d905ac254"
      unitRef="usd">0</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfNDQtMy0xLTEtMA_05016b15-60f0-49e0-ad80-a757b724a0f3"
      unitRef="usd">0</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfNDUtMS0xLTEtMTE1_e70ec069-0cb2-4591-b381-ef388e9502cd"
      unitRef="usd">-9165000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfNDUtMy0xLTEtMTE1_1b69d3a5-e954-4844-a7b1-2d7a32f4b9a8"
      unitRef="usd">-203525000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfNDUtMS0xLTEtMA_10de1723-669d-4bbd-9346-12dbc42e6e44"
      unitRef="usd">-19003000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfNDUtMy0xLTEtMA_357c37aa-4f28-487e-84fe-caf517250e29"
      unitRef="usd">-282430000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RleHRyZWdpb246OGQwNTJjMDNmNGQ3NGQ4Y2I5YjAzOWU0YjQ4NjVjMDVfMjcx_21f819b6-f612-4a34-a7c9-911830c65d53"
      unitRef="usd">1900000</us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax>
    <us-gaap:SharesIssued
      contextRef="id4ee77e0637d4c079ba08f5a8d50896f_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmNiYzhiZjFjMTUzZTRhOWI4ZDI5MjRlYTU5OTBkOWUwL3RhYmxlcmFuZ2U6Y2JjOGJmMWMxNTNlNGE5YjhkMjkyNGVhNTk5MGQ5ZTBfMy0xLTEtMS0w_9515aebc-d97a-4476-958a-8aedfdb31673"
      unitRef="shares">86779000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id4ee77e0637d4c079ba08f5a8d50896f_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmNiYzhiZjFjMTUzZTRhOWI4ZDI5MjRlYTU5OTBkOWUwL3RhYmxlcmFuZ2U6Y2JjOGJmMWMxNTNlNGE5YjhkMjkyNGVhNTk5MGQ5ZTBfMy0zLTEtMS0w_fd42a95a-80d4-4969-a3d9-1805e2f06412"
      unitRef="usd">868000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="idf456296380c4d43be18dd320f38d79e_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmNiYzhiZjFjMTUzZTRhOWI4ZDI5MjRlYTU5OTBkOWUwL3RhYmxlcmFuZ2U6Y2JjOGJmMWMxNTNlNGE5YjhkMjkyNGVhNTk5MGQ5ZTBfMy01LTEtMS0w_5e31f24f-be26-4671-bc28-f23be9c6e938"
      unitRef="usd">1236847000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7e5ec0e87ee5433f83b9321c8e851948_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmNiYzhiZjFjMTUzZTRhOWI4ZDI5MjRlYTU5OTBkOWUwL3RhYmxlcmFuZ2U6Y2JjOGJmMWMxNTNlNGE5YjhkMjkyNGVhNTk5MGQ5ZTBfMy03LTEtMS0w_283a5b2a-353c-445d-8661-26b0f6ee5252"
      unitRef="usd">-309000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5780af7ffb314efcb610ffbfde88f991_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmNiYzhiZjFjMTUzZTRhOWI4ZDI5MjRlYTU5OTBkOWUwL3RhYmxlcmFuZ2U6Y2JjOGJmMWMxNTNlNGE5YjhkMjkyNGVhNTk5MGQ5ZTBfMy05LTEtMS0w_919cb345-7d1f-4c3c-8802-6357e7620b89"
      unitRef="usd">-598985000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="idb6c27b0e33045ad94dd37a21c51bcc5_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmNiYzhiZjFjMTUzZTRhOWI4ZDI5MjRlYTU5OTBkOWUwL3RhYmxlcmFuZ2U6Y2JjOGJmMWMxNTNlNGE5YjhkMjkyNGVhNTk5MGQ5ZTBfMy0xMS0xLTEtMA_057cb48a-9a2b-4196-8fb8-d4993166a3a1"
      unitRef="usd">-21123000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib32c349f6c584bddbe73d86161c5920b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmNiYzhiZjFjMTUzZTRhOWI4ZDI5MjRlYTU5OTBkOWUwL3RhYmxlcmFuZ2U6Y2JjOGJmMWMxNTNlNGE5YjhkMjkyNGVhNTk5MGQ5ZTBfMy0xMy0xLTEtMA_6cb3da3f-b022-4ab7-a311-0f3f4721bd5f"
      unitRef="usd">617298000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6f47fa7f09154d2791eda91f900b167d_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmNiYzhiZjFjMTUzZTRhOWI4ZDI5MjRlYTU5OTBkOWUwL3RhYmxlcmFuZ2U6Y2JjOGJmMWMxNTNlNGE5YjhkMjkyNGVhNTk5MGQ5ZTBfMy0xNy0xLTEtMA_458a464f-e34e-4185-8582-eb2e40fffbc7"
      unitRef="usd">617298000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i455847ec36714e5290ad661b3a22ace7_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmNiYzhiZjFjMTUzZTRhOWI4ZDI5MjRlYTU5OTBkOWUwL3RhYmxlcmFuZ2U6Y2JjOGJmMWMxNTNlNGE5YjhkMjkyNGVhNTk5MGQ5ZTBfNS01LTEtMS0w_3d2c2877-2a95-4933-8467-8d9055457f86"
      unitRef="usd">3653000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i31c050008a204703ba34fa755a536cf2_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmNiYzhiZjFjMTUzZTRhOWI4ZDI5MjRlYTU5OTBkOWUwL3RhYmxlcmFuZ2U6Y2JjOGJmMWMxNTNlNGE5YjhkMjkyNGVhNTk5MGQ5ZTBfNS0xMy0xLTEtMA_44edc015-8bd3-4a99-87f4-7ff880776424"
      unitRef="usd">3653000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmNiYzhiZjFjMTUzZTRhOWI4ZDI5MjRlYTU5OTBkOWUwL3RhYmxlcmFuZ2U6Y2JjOGJmMWMxNTNlNGE5YjhkMjkyNGVhNTk5MGQ5ZTBfNS0xNy0xLTEtMA_5d83d0a6-4156-4c2d-819f-506ad2f94b97"
      unitRef="usd">3653000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ie9109ae3615a4ff4bba0427a808423b1_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmNiYzhiZjFjMTUzZTRhOWI4ZDI5MjRlYTU5OTBkOWUwL3RhYmxlcmFuZ2U6Y2JjOGJmMWMxNTNlNGE5YjhkMjkyNGVhNTk5MGQ5ZTBfNi0xLTEtMS0w_3e7fdd3e-8fbd-4bc9-bdea-a73a1354409e"
      unitRef="shares">306000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ie9109ae3615a4ff4bba0427a808423b1_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmNiYzhiZjFjMTUzZTRhOWI4ZDI5MjRlYTU5OTBkOWUwL3RhYmxlcmFuZ2U6Y2JjOGJmMWMxNTNlNGE5YjhkMjkyNGVhNTk5MGQ5ZTBfNi0zLTEtMS0w_565fd9f9-44b3-4afd-95cf-b85fb43cd026"
      unitRef="usd">3000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i455847ec36714e5290ad661b3a22ace7_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmNiYzhiZjFjMTUzZTRhOWI4ZDI5MjRlYTU5OTBkOWUwL3RhYmxlcmFuZ2U6Y2JjOGJmMWMxNTNlNGE5YjhkMjkyNGVhNTk5MGQ5ZTBfNi01LTEtMS0w_2329c8f8-ea1a-4ee7-8286-51c81920d9fa"
      unitRef="usd">2855000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i31c050008a204703ba34fa755a536cf2_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmNiYzhiZjFjMTUzZTRhOWI4ZDI5MjRlYTU5OTBkOWUwL3RhYmxlcmFuZ2U6Y2JjOGJmMWMxNTNlNGE5YjhkMjkyNGVhNTk5MGQ5ZTBfNi0xMy0xLTEtMA_ff975ccb-a93a-46b2-9922-082d8a24a976"
      unitRef="usd">2858000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmNiYzhiZjFjMTUzZTRhOWI4ZDI5MjRlYTU5OTBkOWUwL3RhYmxlcmFuZ2U6Y2JjOGJmMWMxNTNlNGE5YjhkMjkyNGVhNTk5MGQ5ZTBfNi0xNy0xLTEtMA_3cf2a219-89ae-43f6-a7f4-2885b7029228"
      unitRef="usd">2858000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="ie9109ae3615a4ff4bba0427a808423b1_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmNiYzhiZjFjMTUzZTRhOWI4ZDI5MjRlYTU5OTBkOWUwL3RhYmxlcmFuZ2U6Y2JjOGJmMWMxNTNlNGE5YjhkMjkyNGVhNTk5MGQ5ZTBfNy0xLTEtMS0w_ef780ef0-278c-4269-a2c0-ffc8c87b4cb6"
      unitRef="shares">110000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="ie9109ae3615a4ff4bba0427a808423b1_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmNiYzhiZjFjMTUzZTRhOWI4ZDI5MjRlYTU5OTBkOWUwL3RhYmxlcmFuZ2U6Y2JjOGJmMWMxNTNlNGE5YjhkMjkyNGVhNTk5MGQ5ZTBfNy0zLTEtMS0w_dd4d2d89-3e48-42e3-abba-5ee864dbd45f"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i455847ec36714e5290ad661b3a22ace7_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmNiYzhiZjFjMTUzZTRhOWI4ZDI5MjRlYTU5OTBkOWUwL3RhYmxlcmFuZ2U6Y2JjOGJmMWMxNTNlNGE5YjhkMjkyNGVhNTk5MGQ5ZTBfNy01LTEtMS0w_e2de06cf-14a4-4c08-a5d3-c93b022674ab"
      unitRef="usd">-455000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i31c050008a204703ba34fa755a536cf2_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmNiYzhiZjFjMTUzZTRhOWI4ZDI5MjRlYTU5OTBkOWUwL3RhYmxlcmFuZ2U6Y2JjOGJmMWMxNTNlNGE5YjhkMjkyNGVhNTk5MGQ5ZTBfNy0xMy0xLTEtMA_f3b7ac8e-50bf-43f3-afb5-17f8b4ee3e4b"
      unitRef="usd">-454000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmNiYzhiZjFjMTUzZTRhOWI4ZDI5MjRlYTU5OTBkOWUwL3RhYmxlcmFuZ2U6Y2JjOGJmMWMxNTNlNGE5YjhkMjkyNGVhNTk5MGQ5ZTBfNy0xNy0xLTEtMA_0a9a4ff0-c771-4e3a-96ad-a61131f0495e"
      unitRef="usd">-454000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="ic8f27d03961c446e8a3b985b4125c35b_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmNiYzhiZjFjMTUzZTRhOWI4ZDI5MjRlYTU5OTBkOWUwL3RhYmxlcmFuZ2U6Y2JjOGJmMWMxNTNlNGE5YjhkMjkyNGVhNTk5MGQ5ZTBfOC03LTEtMS0w_8a97f2b8-7b38-49a6-922f-6f55e35eaa3c"
      unitRef="usd">-58000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i31c050008a204703ba34fa755a536cf2_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmNiYzhiZjFjMTUzZTRhOWI4ZDI5MjRlYTU5OTBkOWUwL3RhYmxlcmFuZ2U6Y2JjOGJmMWMxNTNlNGE5YjhkMjkyNGVhNTk5MGQ5ZTBfOC0xMy0xLTEtMA_1a2945bd-e19b-4330-bff2-615ad60f79bc"
      unitRef="usd">-58000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmNiYzhiZjFjMTUzZTRhOWI4ZDI5MjRlYTU5OTBkOWUwL3RhYmxlcmFuZ2U6Y2JjOGJmMWMxNTNlNGE5YjhkMjkyNGVhNTk5MGQ5ZTBfOC0xNy0xLTEtMA_45cd2f0b-bc30-4e94-965c-e44132421b72"
      unitRef="usd">-58000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:ProfitLoss
      contextRef="i9015d8c021f54578be8269eee070b2fd_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmNiYzhiZjFjMTUzZTRhOWI4ZDI5MjRlYTU5OTBkOWUwL3RhYmxlcmFuZ2U6Y2JjOGJmMWMxNTNlNGE5YjhkMjkyNGVhNTk5MGQ5ZTBfOS05LTEtMS0w_c6fd5446-0119-4e30-a0c9-201c713dc052"
      unitRef="usd">-9107000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i31c050008a204703ba34fa755a536cf2_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmNiYzhiZjFjMTUzZTRhOWI4ZDI5MjRlYTU5OTBkOWUwL3RhYmxlcmFuZ2U6Y2JjOGJmMWMxNTNlNGE5YjhkMjkyNGVhNTk5MGQ5ZTBfOS0xMy0xLTEtMA_48d116b9-a291-46a5-bad9-ca2e937b31b7"
      unitRef="usd">-9107000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmNiYzhiZjFjMTUzZTRhOWI4ZDI5MjRlYTU5OTBkOWUwL3RhYmxlcmFuZ2U6Y2JjOGJmMWMxNTNlNGE5YjhkMjkyNGVhNTk5MGQ5ZTBfOS0xNy0xLTEtMA_019c2adf-3635-400b-83ca-593cfa02f301"
      unitRef="usd">-9107000</us-gaap:ProfitLoss>
    <us-gaap:SharesIssued
      contextRef="i94aea5894d5b4755a126a48cfbd95510_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmNiYzhiZjFjMTUzZTRhOWI4ZDI5MjRlYTU5OTBkOWUwL3RhYmxlcmFuZ2U6Y2JjOGJmMWMxNTNlNGE5YjhkMjkyNGVhNTk5MGQ5ZTBfMTEtMS0xLTEtMA_eac83ecb-2bf2-4cc7-8970-75a1c42f821e"
      unitRef="shares">87195000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i94aea5894d5b4755a126a48cfbd95510_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmNiYzhiZjFjMTUzZTRhOWI4ZDI5MjRlYTU5OTBkOWUwL3RhYmxlcmFuZ2U6Y2JjOGJmMWMxNTNlNGE5YjhkMjkyNGVhNTk5MGQ5ZTBfMTEtMy0xLTEtMA_8de60e04-d20e-42b5-b664-352166ca616b"
      unitRef="usd">872000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i879a0ef04e854d12a3d8c0b0e4ef52a8_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmNiYzhiZjFjMTUzZTRhOWI4ZDI5MjRlYTU5OTBkOWUwL3RhYmxlcmFuZ2U6Y2JjOGJmMWMxNTNlNGE5YjhkMjkyNGVhNTk5MGQ5ZTBfMTEtNS0xLTEtMA_6b89f956-dffd-4723-91e2-3b7e1e4a36f9"
      unitRef="usd">1242900000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if0b0ee0b6c91434b9c8abae23359e72b_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmNiYzhiZjFjMTUzZTRhOWI4ZDI5MjRlYTU5OTBkOWUwL3RhYmxlcmFuZ2U6Y2JjOGJmMWMxNTNlNGE5YjhkMjkyNGVhNTk5MGQ5ZTBfMTEtNy0xLTEtMA_f032ee10-f384-4b5b-8689-cf4568f07e25"
      unitRef="usd">-367000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i81c425c8fa484c09a468070f04a8c93f_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmNiYzhiZjFjMTUzZTRhOWI4ZDI5MjRlYTU5OTBkOWUwL3RhYmxlcmFuZ2U6Y2JjOGJmMWMxNTNlNGE5YjhkMjkyNGVhNTk5MGQ5ZTBfMTEtOS0xLTEtMA_23beb34b-4268-4b64-9704-da1edd7baf8b"
      unitRef="usd">-608092000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia8df2ff5dddf457e82901cdf7d483ad7_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmNiYzhiZjFjMTUzZTRhOWI4ZDI5MjRlYTU5OTBkOWUwL3RhYmxlcmFuZ2U6Y2JjOGJmMWMxNTNlNGE5YjhkMjkyNGVhNTk5MGQ5ZTBfMTEtMTEtMS0xLTA_8fb8700b-271a-46b6-9152-83593d85d3a3"
      unitRef="usd">-21123000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i569670e5740a45bbad372eaaf4c6523d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmNiYzhiZjFjMTUzZTRhOWI4ZDI5MjRlYTU5OTBkOWUwL3RhYmxlcmFuZ2U6Y2JjOGJmMWMxNTNlNGE5YjhkMjkyNGVhNTk5MGQ5ZTBfMTEtMTMtMS0xLTA_580195d7-4c3c-4844-bd57-61b3990f1349"
      unitRef="usd">614190000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmNiYzhiZjFjMTUzZTRhOWI4ZDI5MjRlYTU5OTBkOWUwL3RhYmxlcmFuZ2U6Y2JjOGJmMWMxNTNlNGE5YjhkMjkyNGVhNTk5MGQ5ZTBfMTEtMTctMS0xLTA_d418098d-870f-4894-b408-0b7760ea2ed4"
      unitRef="usd">614190000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="i432ce00f8bd44330b83105a3a30fdfa7_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmNiYzhiZjFjMTUzZTRhOWI4ZDI5MjRlYTU5OTBkOWUwL3RhYmxlcmFuZ2U6Y2JjOGJmMWMxNTNlNGE5YjhkMjkyNGVhNTk5MGQ5ZTBfMTctMS0xLTEtMA_b3f7d8ce-306c-4664-b8fc-f2cd1793814a"
      unitRef="shares">85450000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i432ce00f8bd44330b83105a3a30fdfa7_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmNiYzhiZjFjMTUzZTRhOWI4ZDI5MjRlYTU5OTBkOWUwL3RhYmxlcmFuZ2U6Y2JjOGJmMWMxNTNlNGE5YjhkMjkyNGVhNTk5MGQ5ZTBfMTctMy0xLTEtMA_5928def0-3267-471a-bfcf-2edc726feb04"
      unitRef="usd">855000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i026710848e1641728e5976c36d6751b6_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmNiYzhiZjFjMTUzZTRhOWI4ZDI5MjRlYTU5OTBkOWUwL3RhYmxlcmFuZ2U6Y2JjOGJmMWMxNTNlNGE5YjhkMjkyNGVhNTk5MGQ5ZTBfMTctNS0xLTEtMA_7184ca95-2b28-41fa-adca-3c20a89dd956"
      unitRef="usd">1180288000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i699a6f845bb540d88c80df1abf986e42_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmNiYzhiZjFjMTUzZTRhOWI4ZDI5MjRlYTU5OTBkOWUwL3RhYmxlcmFuZ2U6Y2JjOGJmMWMxNTNlNGE5YjhkMjkyNGVhNTk5MGQ5ZTBfMTctNy0xLTEtMA_501fea08-1506-4b32-833a-7ff2c1e661c5"
      unitRef="usd">-387000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic75ef8266603466480bd63015a6a5944_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmNiYzhiZjFjMTUzZTRhOWI4ZDI5MjRlYTU5OTBkOWUwL3RhYmxlcmFuZ2U6Y2JjOGJmMWMxNTNlNGE5YjhkMjkyNGVhNTk5MGQ5ZTBfMTctOS0xLTEtMA_052cb699-33e5-4eef-8aaa-95cab81760b8"
      unitRef="usd">-333684000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic59adfc6299d4f0497fd6b08ea305a09_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmNiYzhiZjFjMTUzZTRhOWI4ZDI5MjRlYTU5OTBkOWUwL3RhYmxlcmFuZ2U6Y2JjOGJmMWMxNTNlNGE5YjhkMjkyNGVhNTk5MGQ5ZTBfMTctMTMtMS0xLTA_c469c347-96a7-4740-a200-037384a77639"
      unitRef="usd">847072000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i57b7afbf065049aaab8f0248ad2de887_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmNiYzhiZjFjMTUzZTRhOWI4ZDI5MjRlYTU5OTBkOWUwL3RhYmxlcmFuZ2U6Y2JjOGJmMWMxNTNlNGE5YjhkMjkyNGVhNTk5MGQ5ZTBfMTctMTUtMS0xLTA_d9eb7a41-f165-4732-94f5-bc53b2b1e144"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iec09d5072eea4a989bbeda84a659de90_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmNiYzhiZjFjMTUzZTRhOWI4ZDI5MjRlYTU5OTBkOWUwL3RhYmxlcmFuZ2U6Y2JjOGJmMWMxNTNlNGE5YjhkMjkyNGVhNTk5MGQ5ZTBfMTctMTctMS0xLTA_7b813f84-a80e-4d03-b265-a7dfb8e9bd25"
      unitRef="usd">847072000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ia89af82007e0491b902dec6c279845b4_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmNiYzhiZjFjMTUzZTRhOWI4ZDI5MjRlYTU5OTBkOWUwL3RhYmxlcmFuZ2U6Y2JjOGJmMWMxNTNlNGE5YjhkMjkyNGVhNTk5MGQ5ZTBfMjAtNS0xLTEtMA_58652811-f35a-4559-8f77-20103d22afbf"
      unitRef="usd">3703000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ib53e76cbba4f4051ab162663449ef939_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmNiYzhiZjFjMTUzZTRhOWI4ZDI5MjRlYTU5OTBkOWUwL3RhYmxlcmFuZ2U6Y2JjOGJmMWMxNTNlNGE5YjhkMjkyNGVhNTk5MGQ5ZTBfMjAtMTMtMS0xLTA_435531a8-feea-4e9d-8ab9-106a16006bfd"
      unitRef="usd">3703000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmNiYzhiZjFjMTUzZTRhOWI4ZDI5MjRlYTU5OTBkOWUwL3RhYmxlcmFuZ2U6Y2JjOGJmMWMxNTNlNGE5YjhkMjkyNGVhNTk5MGQ5ZTBfMjAtMTctMS0xLTA_16a3f1ef-b4c6-4bc4-b7d4-d6936ccb6a69"
      unitRef="usd">3703000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i78ff7cbbd824466eab0d352e7f4b5f1c_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmNiYzhiZjFjMTUzZTRhOWI4ZDI5MjRlYTU5OTBkOWUwL3RhYmxlcmFuZ2U6Y2JjOGJmMWMxNTNlNGE5YjhkMjkyNGVhNTk5MGQ5ZTBfMjEtMS0xLTEtMA_cb5d0063-cde5-4485-a40d-52c36b639f71"
      unitRef="shares">82000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i78ff7cbbd824466eab0d352e7f4b5f1c_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmNiYzhiZjFjMTUzZTRhOWI4ZDI5MjRlYTU5OTBkOWUwL3RhYmxlcmFuZ2U6Y2JjOGJmMWMxNTNlNGE5YjhkMjkyNGVhNTk5MGQ5ZTBfMjEtMy0xLTEtMA_dc4f4820-262f-4912-b112-0f10e5bdbfb2"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ia89af82007e0491b902dec6c279845b4_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmNiYzhiZjFjMTUzZTRhOWI4ZDI5MjRlYTU5OTBkOWUwL3RhYmxlcmFuZ2U6Y2JjOGJmMWMxNTNlNGE5YjhkMjkyNGVhNTk5MGQ5ZTBfMjEtNS0xLTEtMA_173f6aad-44c0-4835-a8d1-65540dc6b307"
      unitRef="usd">442000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ib53e76cbba4f4051ab162663449ef939_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmNiYzhiZjFjMTUzZTRhOWI4ZDI5MjRlYTU5OTBkOWUwL3RhYmxlcmFuZ2U6Y2JjOGJmMWMxNTNlNGE5YjhkMjkyNGVhNTk5MGQ5ZTBfMjEtMTMtMS0xLTA_2274e87a-11aa-4570-88aa-e586efc83dad"
      unitRef="usd">443000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmNiYzhiZjFjMTUzZTRhOWI4ZDI5MjRlYTU5OTBkOWUwL3RhYmxlcmFuZ2U6Y2JjOGJmMWMxNTNlNGE5YjhkMjkyNGVhNTk5MGQ5ZTBfMjEtMTctMS0xLTA_a7d9f020-c83e-4c31-bdf7-e84d62cab17e"
      unitRef="usd">443000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="i78ff7cbbd824466eab0d352e7f4b5f1c_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmNiYzhiZjFjMTUzZTRhOWI4ZDI5MjRlYTU5OTBkOWUwL3RhYmxlcmFuZ2U6Y2JjOGJmMWMxNTNlNGE5YjhkMjkyNGVhNTk5MGQ5ZTBfMjItMS0xLTEtMA_b66a28eb-b4cf-4fee-98ac-98c70410da9f"
      unitRef="shares">113000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i78ff7cbbd824466eab0d352e7f4b5f1c_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmNiYzhiZjFjMTUzZTRhOWI4ZDI5MjRlYTU5OTBkOWUwL3RhYmxlcmFuZ2U6Y2JjOGJmMWMxNTNlNGE5YjhkMjkyNGVhNTk5MGQ5ZTBfMjItMy0xLTEtMA_86493d7c-3984-41a8-b0b3-982debec8745"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="ia89af82007e0491b902dec6c279845b4_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmNiYzhiZjFjMTUzZTRhOWI4ZDI5MjRlYTU5OTBkOWUwL3RhYmxlcmFuZ2U6Y2JjOGJmMWMxNTNlNGE5YjhkMjkyNGVhNTk5MGQ5ZTBfMjItNS0xLTEtMA_101e2d59-4039-41cf-9e1c-dc02e952f2bb"
      unitRef="usd">-145000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="ib53e76cbba4f4051ab162663449ef939_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmNiYzhiZjFjMTUzZTRhOWI4ZDI5MjRlYTU5OTBkOWUwL3RhYmxlcmFuZ2U6Y2JjOGJmMWMxNTNlNGE5YjhkMjkyNGVhNTk5MGQ5ZTBfMjItMTMtMS0xLTA_9bcef18f-ac47-4288-970c-77076a0942ad"
      unitRef="usd">-144000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmNiYzhiZjFjMTUzZTRhOWI4ZDI5MjRlYTU5OTBkOWUwL3RhYmxlcmFuZ2U6Y2JjOGJmMWMxNTNlNGE5YjhkMjkyNGVhNTk5MGQ5ZTBfMjItMTctMS0xLTA_05b83ff7-b69b-40ad-be5d-d03ce7506b99"
      unitRef="usd">-144000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <evh:StockVestedAndRetiredDuringPeriodShares
      contextRef="i78ff7cbbd824466eab0d352e7f4b5f1c_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmNiYzhiZjFjMTUzZTRhOWI4ZDI5MjRlYTU5OTBkOWUwL3RhYmxlcmFuZ2U6Y2JjOGJmMWMxNTNlNGE5YjhkMjkyNGVhNTk5MGQ5ZTBfMjItMS0xLTEtMzcxNA_bbe74552-1942-4492-8d91-7c1493ff93c0"
      unitRef="shares">188000</evh:StockVestedAndRetiredDuringPeriodShares>
    <evh:StockVestedAndRetiredDuringPeriodValue
      contextRef="i78ff7cbbd824466eab0d352e7f4b5f1c_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmNiYzhiZjFjMTUzZTRhOWI4ZDI5MjRlYTU5OTBkOWUwL3RhYmxlcmFuZ2U6Y2JjOGJmMWMxNTNlNGE5YjhkMjkyNGVhNTk5MGQ5ZTBfMjItMy0xLTEtMzcxNA_835a30e9-a86f-4606-adb6-0e00e64f5c14"
      unitRef="usd">2000</evh:StockVestedAndRetiredDuringPeriodValue>
    <evh:StockVestedAndRetiredDuringPeriodValue
      contextRef="ia89af82007e0491b902dec6c279845b4_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmNiYzhiZjFjMTUzZTRhOWI4ZDI5MjRlYTU5OTBkOWUwL3RhYmxlcmFuZ2U6Y2JjOGJmMWMxNTNlNGE5YjhkMjkyNGVhNTk5MGQ5ZTBfMjItNS0xLTEtMzcxNA_b5ecdbe3-b2d4-4cd2-aa82-58facc3e5548"
      unitRef="usd">683000</evh:StockVestedAndRetiredDuringPeriodValue>
    <evh:StockVestedAndRetiredDuringPeriodValue
      contextRef="ib53e76cbba4f4051ab162663449ef939_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmNiYzhiZjFjMTUzZTRhOWI4ZDI5MjRlYTU5OTBkOWUwL3RhYmxlcmFuZ2U6Y2JjOGJmMWMxNTNlNGE5YjhkMjkyNGVhNTk5MGQ5ZTBfMjItMTMtMS0xLTM3MTQ_242d6edd-d2e6-41d3-be7d-05e05a467a85"
      unitRef="usd">685000</evh:StockVestedAndRetiredDuringPeriodValue>
    <evh:StockVestedAndRetiredDuringPeriodValue
      contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmNiYzhiZjFjMTUzZTRhOWI4ZDI5MjRlYTU5OTBkOWUwL3RhYmxlcmFuZ2U6Y2JjOGJmMWMxNTNlNGE5YjhkMjkyNGVhNTk5MGQ5ZTBfMjItMTctMS0xLTM3MTQ_6e2b98da-95b3-4eb2-a1f2-b4d01cf365a3"
      unitRef="usd">685000</evh:StockVestedAndRetiredDuringPeriodValue>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i0b480fd1921d4f1ea9972b92001a55ff_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmNiYzhiZjFjMTUzZTRhOWI4ZDI5MjRlYTU5OTBkOWUwL3RhYmxlcmFuZ2U6Y2JjOGJmMWMxNTNlNGE5YjhkMjkyNGVhNTk5MGQ5ZTBfMjYtNy0xLTEtMA_bf07f014-fc9f-4f09-94d4-30e3fcc3ba16"
      unitRef="usd">-4000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="ib53e76cbba4f4051ab162663449ef939_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmNiYzhiZjFjMTUzZTRhOWI4ZDI5MjRlYTU5OTBkOWUwL3RhYmxlcmFuZ2U6Y2JjOGJmMWMxNTNlNGE5YjhkMjkyNGVhNTk5MGQ5ZTBfMjYtMTMtMS0xLTA_79b6d7b2-37bf-42c6-a370-ca1046b1591f"
      unitRef="usd">-4000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmNiYzhiZjFjMTUzZTRhOWI4ZDI5MjRlYTU5OTBkOWUwL3RhYmxlcmFuZ2U6Y2JjOGJmMWMxNTNlNGE5YjhkMjkyNGVhNTk5MGQ5ZTBfMjYtMTctMS0xLTA_92c0b8f4-1003-40b4-81fa-7bd5c6bae2ba"
      unitRef="usd">-4000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:ProfitLoss
      contextRef="i3788ccc422524e5bab104710c747da49_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmNiYzhiZjFjMTUzZTRhOWI4ZDI5MjRlYTU5OTBkOWUwL3RhYmxlcmFuZ2U6Y2JjOGJmMWMxNTNlNGE5YjhkMjkyNGVhNTk5MGQ5ZTBfMjctOS0xLTEtMA_b64ec812-fb90-4b4a-b74e-57f2807f4a8a"
      unitRef="usd">-203521000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ib53e76cbba4f4051ab162663449ef939_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmNiYzhiZjFjMTUzZTRhOWI4ZDI5MjRlYTU5OTBkOWUwL3RhYmxlcmFuZ2U6Y2JjOGJmMWMxNTNlNGE5YjhkMjkyNGVhNTk5MGQ5ZTBfMjctMTMtMS0xLTA_98b25508-aecd-4a1a-b60c-189716c53bdd"
      unitRef="usd">-203521000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmNiYzhiZjFjMTUzZTRhOWI4ZDI5MjRlYTU5OTBkOWUwL3RhYmxlcmFuZ2U6Y2JjOGJmMWMxNTNlNGE5YjhkMjkyNGVhNTk5MGQ5ZTBfMjctMTctMS0xLTA_62fad74a-faec-485b-b523-51ff1697dfe4"
      unitRef="usd">-203521000</us-gaap:ProfitLoss>
    <us-gaap:SharesIssued
      contextRef="i61d42c3c86cf419a8e9f35be789f83b5_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmNiYzhiZjFjMTUzZTRhOWI4ZDI5MjRlYTU5OTBkOWUwL3RhYmxlcmFuZ2U6Y2JjOGJmMWMxNTNlNGE5YjhkMjkyNGVhNTk5MGQ5ZTBfMjktMS0xLTEtMA_5a34f320-c35f-47a2-bec0-31a5fb36e955"
      unitRef="shares">85457000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i61d42c3c86cf419a8e9f35be789f83b5_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmNiYzhiZjFjMTUzZTRhOWI4ZDI5MjRlYTU5OTBkOWUwL3RhYmxlcmFuZ2U6Y2JjOGJmMWMxNTNlNGE5YjhkMjkyNGVhNTk5MGQ5ZTBfMjktMy0xLTEtMA_46b084be-c3a4-459e-a29b-c65cf4818b29"
      unitRef="usd">855000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia67d3ce8c31a428f993f4ca23b06398f_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmNiYzhiZjFjMTUzZTRhOWI4ZDI5MjRlYTU5OTBkOWUwL3RhYmxlcmFuZ2U6Y2JjOGJmMWMxNTNlNGE5YjhkMjkyNGVhNTk5MGQ5ZTBfMjktNS0xLTEtMA_98a42a30-a303-4eec-8434-b48775bfd57e"
      unitRef="usd">1183605000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia59baf61ed594b8fb0771be16c7deee5_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmNiYzhiZjFjMTUzZTRhOWI4ZDI5MjRlYTU5OTBkOWUwL3RhYmxlcmFuZ2U6Y2JjOGJmMWMxNTNlNGE5YjhkMjkyNGVhNTk5MGQ5ZTBfMjktNy0xLTEtMA_4e35ba98-388e-4d4c-8b40-6f201bf69355"
      unitRef="usd">-391000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0b187f370fc84640b9c86628f855226a_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmNiYzhiZjFjMTUzZTRhOWI4ZDI5MjRlYTU5OTBkOWUwL3RhYmxlcmFuZ2U6Y2JjOGJmMWMxNTNlNGE5YjhkMjkyNGVhNTk5MGQ5ZTBfMjktOS0xLTEtMA_4c6c5ddd-97a4-449d-bfcd-c664d0e2c4df"
      unitRef="usd">-537205000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2202cb072bda4242a7bea49750347ba4_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmNiYzhiZjFjMTUzZTRhOWI4ZDI5MjRlYTU5OTBkOWUwL3RhYmxlcmFuZ2U6Y2JjOGJmMWMxNTNlNGE5YjhkMjkyNGVhNTk5MGQ5ZTBfMjktMTMtMS0xLTA_dc3e55d2-ab88-41b8-8e7a-86def8e5ad83"
      unitRef="usd">646864000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9d6223463ab84fa6a8f5cd35e24c15d7_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmNiYzhiZjFjMTUzZTRhOWI4ZDI5MjRlYTU5OTBkOWUwL3RhYmxlcmFuZ2U6Y2JjOGJmMWMxNTNlNGE5YjhkMjkyNGVhNTk5MGQ5ZTBfMjktMTUtMS0xLTA_da649d74-88ce-4b6b-8ccf-24e48b96cfe1"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i11817f96c3e24e0abaed14a17869e173_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmNiYzhiZjFjMTUzZTRhOWI4ZDI5MjRlYTU5OTBkOWUwL3RhYmxlcmFuZ2U6Y2JjOGJmMWMxNTNlNGE5YjhkMjkyNGVhNTk5MGQ5ZTBfMjktMTctMS0xLTA_514399e8-ae63-469e-bef3-c678e831cd1b"
      unitRef="usd">646864000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="i78d2f8ed8b384b2a93f41b0cbd0e3f03_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfMy0xLTEtMS0xMzc_b3673061-07d0-4edc-9de8-fa71a47bef08"
      unitRef="shares">85895000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i78d2f8ed8b384b2a93f41b0cbd0e3f03_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfMy0zLTEtMS0xMzc_c3e814a3-9a95-4e8b-9229-fbab90aea36c"
      unitRef="usd">859000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9482da1959ba438396e25159d07f33e3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfMy01LTEtMS0xMzc_42b253cf-6cec-4e48-b295-02afa1176c38"
      unitRef="usd">1229320000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6d3d52c0e5b94031981899cd1ecb78a1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfMy03LTEtMS0xMzc_918ad4ca-d769-49eb-a746-bfcf07645711"
      unitRef="usd">-278000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia2be1022da19471caedc725d35d5a5bd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfMy05LTEtMS0xMzc_0530ae09-2fb3-4450-a298-2ef3a5c8cac5"
      unitRef="usd">-589178000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7a8d015d1e3c419495ab144ddd77f1b6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfMy0xMS0xLTEtMTM3_d0eb538f-d3f9-40f1-9ef8-8e5ceb6bdb12"
      unitRef="usd">-21123000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9799952c3fd2440b9166bd85cc98b14e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfMy0xMy0xLTEtMTM3_1cabe5f5-d52c-4245-b396-3ac7306c5fbf"
      unitRef="usd">619600000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i25b48cb725834cb78913e88a0e458e79_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfMy0xNS0xLTEtMTM3_280370f4-0a0e-4a99-a3f6-194f56226aa3"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i45bff335c1434d6ba44132da1b0557db_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfMy0xNy0xLTEtMTM3_778296b1-cc5d-4f22-b9ea-cecd3498b272"
      unitRef="usd">619600000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ieaf6b2c9ee5b475bbe4a1910426766b9_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfNS01LTEtMS0xMzc_cfb0789d-c56d-4ed4-9499-ed5ae0fe06f5"
      unitRef="usd">7359000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="idfc2020dff164058be58d93f3ec59267_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfNS0xMy0xLTEtMTM3_22fbed2c-a8d6-4615-b638-d585e3d3dd5c"
      unitRef="usd">7359000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfNS0xNy0xLTEtMTM3_cd612b3c-d2cd-41d7-b1d9-d15c39a2ff6f"
      unitRef="usd">7359000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i1baaa0777df145cfb48c213ad68538f9_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfNi0xLTEtMS0xMzc_b69d6836-4415-4ca0-8aaa-d68fa170fc9a"
      unitRef="shares">900000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i1baaa0777df145cfb48c213ad68538f9_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfNi0zLTEtMS0xMzc_26b413a6-9dc1-46cb-a297-3a19fd82063c"
      unitRef="usd">9000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ieaf6b2c9ee5b475bbe4a1910426766b9_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfNi01LTEtMS0xMzc_063d3749-0dc0-4d5f-8b64-bbd89a873715"
      unitRef="usd">9367000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="idfc2020dff164058be58d93f3ec59267_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfNi0xMy0xLTEtMTM3_2f1307c3-f7f1-49c1-a403-845fd336dd3c"
      unitRef="usd">9376000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfNi0xNy0xLTEtMTM3_f7edb432-4ade-4484-bdce-9d21d9b52997"
      unitRef="usd">9376000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="i1baaa0777df145cfb48c213ad68538f9_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfNy0xLTEtMS0xMzc_4bd2f1f5-c788-4c95-9505-3f81246ecae8"
      unitRef="shares">400000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i1baaa0777df145cfb48c213ad68538f9_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfNy0zLTEtMS0xMzc_917ba028-1d38-4d41-9b42-9f192c45f19f"
      unitRef="usd">4000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="ieaf6b2c9ee5b475bbe4a1910426766b9_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfNy01LTEtMS0xMzc_9e4dbf39-16ce-4ded-9ca5-23d3c5bc735a"
      unitRef="usd">-3146000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="idfc2020dff164058be58d93f3ec59267_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfNy0xMy0xLTEtMTM3_6c268681-56a9-40c5-a39d-c903559998b4"
      unitRef="usd">-3142000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfNy0xNy0xLTEtMTM3_4664b0cc-82d5-4e91-97c5-b3af56ed9264"
      unitRef="usd">-3142000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i8830c28780b7440f831c87a11c1a0073_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfOC03LTEtMS0xMzc_fdfff1a6-234d-40f0-9219-53f1a0acc1d1"
      unitRef="usd">-89000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="idfc2020dff164058be58d93f3ec59267_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfOC0xMy0xLTEtMTM3_c68ef289-78fa-4021-bd73-043065a0ed05"
      unitRef="usd">-89000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfOC0xNy0xLTEtMTM3_787684c3-4441-459f-b1cc-83e79bdecec9"
      unitRef="usd">-89000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:ProfitLoss
      contextRef="iae1007f114dc467eb2b8a9c64881f28b_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfOS05LTEtMS0xMzc_69ea4bc2-86ab-4538-8293-67661e1def05"
      unitRef="usd">-18914000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="idfc2020dff164058be58d93f3ec59267_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfOS0xMy0xLTEtMTM3_5b550b0c-c78b-4d46-b8ff-12903daa1c35"
      unitRef="usd">-18914000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfOS0xNy0xLTEtMTM3_4e09c1e9-279d-4b00-b3dc-001bada26f6f"
      unitRef="usd">-18914000</us-gaap:ProfitLoss>
    <us-gaap:SharesIssued
      contextRef="i94aea5894d5b4755a126a48cfbd95510_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfMTEtMS0xLTEtMTM3_ce3139c5-d54d-4172-be01-e47a94361ef8"
      unitRef="shares">87195000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i94aea5894d5b4755a126a48cfbd95510_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfMTEtMy0xLTEtMTM3_09d5bd36-3c53-4ee3-b2aa-c9211ffb041e"
      unitRef="usd">872000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i879a0ef04e854d12a3d8c0b0e4ef52a8_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfMTEtNS0xLTEtMTM3_975182cd-f69b-4011-a316-a5244bed9976"
      unitRef="usd">1242900000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if0b0ee0b6c91434b9c8abae23359e72b_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfMTEtNy0xLTEtMTM3_7747dffd-2e3c-44f2-938f-24cc971e18c7"
      unitRef="usd">-367000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i81c425c8fa484c09a468070f04a8c93f_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfMTEtOS0xLTEtMTM3_66164b1e-509b-42ac-816e-7c29486c2825"
      unitRef="usd">-608092000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia8df2ff5dddf457e82901cdf7d483ad7_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfMTEtMTEtMS0xLTEzNw_34f3b376-05c5-44c8-8624-be92c7bdbbca"
      unitRef="usd">-21123000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i569670e5740a45bbad372eaaf4c6523d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfMTEtMTMtMS0xLTEzNw_4cf248f3-4d50-4ae9-9687-9c232b978b91"
      unitRef="usd">614190000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfMTEtMTctMS0xLTEzNw_4a1dcd0b-b42d-47a3-8e6c-54f816d8ae1a"
      unitRef="usd">614190000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="i3046b7b99a004e48a03d367e730f9ae5_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfMTctMS0xLTEtMzcyNA_4ee13ecc-e318-456f-9962-2b36dd0addd4"
      unitRef="shares">84589000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3046b7b99a004e48a03d367e730f9ae5_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfMTctMy0xLTEtMzcyNA_d4966d20-068a-4381-977b-20bda781b663"
      unitRef="usd">846000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ice23288885be4f779b9ab70832b538f6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfMTctNS0xLTEtMzcyNA_449b1500-e2be-4f82-ab0e-e36e73a2a0c8"
      unitRef="usd">1173708000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib21f2745e0714611ae3b84205a386a57_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfMTctNy0xLTEtMzcyNA_68fd2b16-33d9-40dd-8fe3-ff063c8ed54e"
      unitRef="usd">-234000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1bcddf75950249fbaf184e1f523f0d8b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfMTctOS0xLTEtMzcyNA_cad61f56-9ac9-42f4-83a2-dda72853a0eb"
      unitRef="usd">-251962000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i18de6ff3304b4fda9feee31a2f415af8_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfMTctMTMtMS0xLTM3MjQ_7233afe0-2288-45f6-aafa-c82958822e36"
      unitRef="usd">922358000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ibcd7068eef4f42b895c0b83d21ea5d2b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfMTctMTUtMS0xLTM3MjQ_57557afe-790b-471d-a3bf-08270be6c430"
      unitRef="usd">6689000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie0ff0ad229b441d4b12bc8956f92a917_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfMTctMTctMS0xLTM3MjQ_42e0d5b0-684c-42c3-b952-9e10a7e9a5b2"
      unitRef="usd">929047000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i06c25faea1e7483786ebe928e1ff0fa4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfMTktOS0xLTEtMzcyNA_56321d04-bf20-439e-834d-c4407456da86"
      unitRef="usd">-2970000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id8ff7726321243cbb8c00770e6603356_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfMTktMTMtMS0xLTM3MjQ_8d0aa075-d0e8-47e7-a8cf-236748d6993d"
      unitRef="usd">-2970000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6e620150ffe942b388f50fab8377e007_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfMTktMTctMS0xLTM3MjQ_382bd9d6-6ad6-487f-93f8-8af76013398b"
      unitRef="usd">-2970000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="if955a85db5574fb9b6ccf0c7d039cee5_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfMjAtNS0xLTEtMzcyNA_7cf23d64-d193-4a6c-8116-f6fbe7d51c4a"
      unitRef="usd">7211000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i153c261aa5234592a35394b52c2c0b85_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfMjAtMTMtMS0xLTM3MjQ_ac0dde1f-3e2d-4bab-a9dc-5e6297715365"
      unitRef="usd">7211000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfMjAtMTctMS0xLTM3MjQ_f3b17322-f62b-467c-a76f-0fb1172cd619"
      unitRef="usd">7211000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i8a113c1bdf754223baa2fb9a6344b873_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfMjEtMS0xLTEtMzcyNA_06bdf559-f3b6-4b28-b4de-c558de5a41b6"
      unitRef="shares">90000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i8a113c1bdf754223baa2fb9a6344b873_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfMjEtMy0xLTEtMzcyNA_364ee43b-5bb8-4904-9417-f88f8953915c"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="if955a85db5574fb9b6ccf0c7d039cee5_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfMjEtNS0xLTEtMzcyNA_25acbc87-d215-4907-9acb-de56678a06a1"
      unitRef="usd">525000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i153c261aa5234592a35394b52c2c0b85_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfMjEtMTMtMS0xLTM3MjQ_b904ded8-6884-44ad-801e-50e6b547d5c2"
      unitRef="usd">526000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfMjEtMTctMS0xLTM3MjQ_2c749826-8819-4f69-8ec4-cfa2c4f2b96c"
      unitRef="usd">526000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="i8a113c1bdf754223baa2fb9a6344b873_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfMjItMS0xLTEtMzcyNA_7c24b79d-5e36-4e31-bf35-9a619d0e1e6a"
      unitRef="shares">350000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i8a113c1bdf754223baa2fb9a6344b873_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfMjItMy0xLTEtMzcyNA_d1793637-8693-4039-adae-18963c44ad51"
      unitRef="usd">4000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="if955a85db5574fb9b6ccf0c7d039cee5_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfMjItNS0xLTEtMzcyNA_5bd44f1a-5e42-4ffc-8570-00310f40d6c6"
      unitRef="usd">-1335000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i153c261aa5234592a35394b52c2c0b85_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfMjItMTMtMS0xLTM3MjQ_7e25dbca-6d98-4241-bb37-9ae8253d1e0a"
      unitRef="usd">-1331000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfMjItMTctMS0xLTM3MjQ_225c797d-5682-4e22-bdc1-7d6d255a099c"
      unitRef="usd">-1331000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <evh:StockVestedAndRetiredDuringPeriodShares
      contextRef="i8a113c1bdf754223baa2fb9a6344b873_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfMjMtMS0xLTEtMzcyNA_c16545f1-00c9-4a44-af6d-92cf69f64585"
      unitRef="shares">188000</evh:StockVestedAndRetiredDuringPeriodShares>
    <evh:StockVestedAndRetiredDuringPeriodValue
      contextRef="i8a113c1bdf754223baa2fb9a6344b873_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfMjMtMy0xLTEtMzcyNA_63bce90c-e7ec-4854-8a42-79fc5a733307"
      unitRef="usd">2000</evh:StockVestedAndRetiredDuringPeriodValue>
    <evh:StockVestedAndRetiredDuringPeriodValue
      contextRef="if955a85db5574fb9b6ccf0c7d039cee5_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfMjMtNS0xLTEtMzcyNA_058626ab-5e95-4553-b1eb-0996fd4b7e9a"
      unitRef="usd">683000</evh:StockVestedAndRetiredDuringPeriodValue>
    <evh:StockVestedAndRetiredDuringPeriodValue
      contextRef="i153c261aa5234592a35394b52c2c0b85_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfMjMtMTMtMS0xLTM3MjQ_d1b9d9e8-2456-4df1-b217-0fdb57ed3764"
      unitRef="usd">685000</evh:StockVestedAndRetiredDuringPeriodValue>
    <evh:StockVestedAndRetiredDuringPeriodValue
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfMjMtMTctMS0xLTM3MjQ_4715f4fb-1584-44ec-a335-d5353e0e6469"
      unitRef="usd">685000</evh:StockVestedAndRetiredDuringPeriodValue>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="i8a113c1bdf754223baa2fb9a6344b873_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfMjQtMS0xLTEtMzcyNA_30dbe967-b73c-48de-9fb6-bef6beff6f1e"
      unitRef="shares">616000</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="i8a113c1bdf754223baa2fb9a6344b873_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfMjQtMy0xLTEtMzcyNA_d73249cc-7fdd-4aea-9397-b9fca8567e49"
      unitRef="usd">6000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="if955a85db5574fb9b6ccf0c7d039cee5_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfMjQtNS0xLTEtMzcyNA_b8a8264a-24d0-49b4-9a00-b2df41aed021"
      unitRef="usd">4179000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="i153c261aa5234592a35394b52c2c0b85_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfMjQtMTMtMS0xLTM3MjQ_cfc199d1-7488-4977-8411-29077e601d82"
      unitRef="usd">4185000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfMjQtMTctMS0xLTM3MjQ_7e3e395d-b24b-437d-b850-637634d5313d"
      unitRef="usd">4185000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:NoncontrollingInterestDecreaseFromDeconsolidation
      contextRef="i215048e9c16a4f348373b4cb1edc7ece_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfMjUtMTUtMS0xLTM3MjQ_556eb835-0580-4bed-8d5f-1ac81ae512bc"
      unitRef="usd">6689000</us-gaap:NoncontrollingInterestDecreaseFromDeconsolidation>
    <us-gaap:NoncontrollingInterestDecreaseFromDeconsolidation
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfMjUtMTctMS0xLTM3MjQ_5efd390e-01ad-43ad-a46d-9a625e5788dd"
      unitRef="usd">6689000</us-gaap:NoncontrollingInterestDecreaseFromDeconsolidation>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i67f38418f25c44ef862f02d73bbffaa7_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfMjYtNy0xLTEtMzcyNA_7a22213d-e014-416f-a7a1-23f840fd6d91"
      unitRef="usd">-157000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i153c261aa5234592a35394b52c2c0b85_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfMjYtMTMtMS0xLTM3MjQ_908a263c-fd79-46f6-8e48-0c065dc94669"
      unitRef="usd">-157000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfMjYtMTctMS0xLTM3MjQ_afd741a5-a8a8-4747-8698-a92b093619a7"
      unitRef="usd">-157000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:ProfitLoss
      contextRef="ic9279f0ce4a5422aa74c787813c8d48c_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfMjctOS0xLTEtMzcyNA_ce6d555f-d322-44f6-a641-c63476fb246f"
      unitRef="usd">-282273000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i153c261aa5234592a35394b52c2c0b85_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfMjctMTMtMS0xLTM3MjQ_e9ce21c4-e748-4686-bbdb-be0757fa74dd"
      unitRef="usd">-282273000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfMjctMTctMS0xLTM3MjQ_4ece96b7-a50c-456a-bbb4-be1004974c0f"
      unitRef="usd">-282273000</us-gaap:ProfitLoss>
    <us-gaap:SharesIssued
      contextRef="i61d42c3c86cf419a8e9f35be789f83b5_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfMjktMS0xLTEtMzcyNA_ee74d65b-32a0-4c54-a543-7cafa7c7f2d1"
      unitRef="shares">85457000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i61d42c3c86cf419a8e9f35be789f83b5_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfMjktMy0xLTEtMzcyNA_31d26e76-23a9-471e-9312-6c2b9d04b44c"
      unitRef="usd">855000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia67d3ce8c31a428f993f4ca23b06398f_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfMjktNS0xLTEtMzcyNA_7299088c-27f9-4aa4-bcaf-e416dc0a9280"
      unitRef="usd">1183605000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia59baf61ed594b8fb0771be16c7deee5_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfMjktNy0xLTEtMzcyNA_e04c3c58-1906-4a30-8d17-9c392283611d"
      unitRef="usd">-391000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0b187f370fc84640b9c86628f855226a_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfMjktOS0xLTEtMzcyNA_5919ad2c-0c4c-4b3f-a1f6-a66f44132c79"
      unitRef="usd">-537205000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2202cb072bda4242a7bea49750347ba4_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfMjktMTMtMS0xLTM3MjQ_ed96c1de-3880-4f80-8550-29c4d8c07638"
      unitRef="usd">646864000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9d6223463ab84fa6a8f5cd35e24c15d7_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfMjktMTUtMS0xLTM3MjQ_13c3744f-131a-4677-be66-e231453c2547"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i11817f96c3e24e0abaed14a17869e173_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zMS9mcmFnOjFmZDE5NDIwNjg4ZDQ2NTdhZTM1NmJmY2Y2MWUwNGVkL3RhYmxlOmEyNTE1YzAxODYwYTQ3ODU4NjQ0NmM1YWFiOTBlOWNmL3RhYmxlcmFuZ2U6YTI1MTVjMDE4NjBhNDc4NTg2NDQ2YzVhYWI5MGU5Y2ZfMjktMTctMS0xLTM3MjQ_9d272e83-6b06-4098-9592-829b40c56de5"
      unitRef="usd">646864000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfMy0xLTEtMS0w_3c6b9c11-4052-4bf7-86e1-89b8e6f56107"
      unitRef="usd">-18914000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfMy0zLTEtMS0w_6133f0dd-e1f4-4ff4-96e9-42a93c1f62a1"
      unitRef="usd">-282273000</us-gaap:ProfitLoss>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfNS0xLTEtMS0w_9f4c35bd-3574-4ad0-bcb4-5f52027e355c"
      unitRef="usd">-594000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfNS0zLTEtMS0w_d779559c-b526-4b13-a883-e91aeb9dcb32"
      unitRef="usd">-3062000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <evh:GainLossOnDispositionOfAssetsOperatingActivities
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfNi0xLTEtMS0w_eac38f9d-e60b-4e3d-9066-00993401e41a"
      unitRef="usd">1904000</evh:GainLossOnDispositionOfAssetsOperatingActivities>
    <evh:GainLossOnDispositionOfAssetsOperatingActivities
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfNi0zLTEtMS0w_80bf34d9-85ac-4379-85c4-a4e24348e7b2"
      unitRef="usd">-6447000</evh:GainLossOnDispositionOfAssetsOperatingActivities>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfNy0xLTEtMS0w_a11bc2a6-6dd9-461f-a52c-95302159fac3"
      unitRef="usd">12662000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfNy0zLTEtMS0w_981ee673-1289-431a-a56f-119e8632e870"
      unitRef="usd">24731000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfOC0xLTEtMS0w_5076b826-c9ab-4b1a-9e5b-a467c93983ca"
      unitRef="usd">30263000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfOC0zLTEtMS0w_7bc79ea6-03ca-4e8d-9264-353bafb3ba88"
      unitRef="usd">31916000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfOS0xLTEtMS0w_8aca3004-cc00-42b0-88ba-4b40a4df1505"
      unitRef="usd">0</us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment>
    <us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfOS0zLTEtMS0w_d4a2f796-cc5b-4439-968a-ae4ecc12640c"
      unitRef="usd">47133000</us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment>
    <us-gaap:ShareBasedCompensation
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfMTAtMS0xLTEtMA_ae7bb87a-fc51-4d04-9729-f72f63364543"
      unitRef="usd">7359000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfMTAtMy0xLTEtMA_418c81ac-abfd-491a-9119-f1fd0e4b049b"
      unitRef="usd">7211000</us-gaap:ShareBasedCompensation>
    <us-gaap:DeferredIncomeTaxesAndTaxCredits
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfMTEtMS0xLTEtMA_650dfeed-f3fa-4c04-93e2-e6664c031c22"
      unitRef="usd">-268000</us-gaap:DeferredIncomeTaxesAndTaxCredits>
    <us-gaap:DeferredIncomeTaxesAndTaxCredits
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfMTEtMy0xLTEtMA_f4d0b7c5-a23c-47dc-a7a7-76946d3bd0cb"
      unitRef="usd">-892000</us-gaap:DeferredIncomeTaxesAndTaxCredits>
    <us-gaap:CapitalizedContractCostAmortization
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfMTItMS0xLTEtMA_42253acf-f70a-4b80-a694-87cf8311bd3e"
      unitRef="usd">8311000</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:CapitalizedContractCostAmortization
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfMTItMy0xLTEtMA_a2207834-0a0d-488d-aac5-c3e840cfede2"
      unitRef="usd">10272000</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfMTMtMS0xLTEtMA_920bbca5-20c0-4293-9c5f-506ff9d29dc6"
      unitRef="usd">8837000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfMTMtMy0xLTEtMA_7ac94fa6-115b-485d-b478-4f2373ed7019"
      unitRef="usd">6079000</us-gaap:AmortizationOfFinancingCosts>
    <evh:PaidinKindInterestIncome
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfMTQtMS0xLTEtNDg4MQ_c1bd1ed2-e3a7-4be2-b33a-302bccb8df4c"
      unitRef="usd">0</evh:PaidinKindInterestIncome>
    <evh:PaidinKindInterestIncome
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfMTQtMy0xLTEtNDg4MQ_7dd76bef-e5fc-4669-a22d-d2aa7e0c93df"
      unitRef="usd">1316000</evh:PaidinKindInterestIncome>
    <evh:GainOnTransferOfMembership
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfMTQtMS0xLTEtMA_e7c4a3e1-a87d-445c-82c1-9c940d59a2ed"
      unitRef="usd">22969000</evh:GainOnTransferOfMembership>
    <evh:GainOnTransferOfMembership
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfMTQtMy0xLTEtMA_8c4e90a0-b044-4993-95f9-1ffeb62f858d"
      unitRef="usd">0</evh:GainOnTransferOfMembership>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfMTUtMS0xLTEtMjU0_fedbf8b2-53c2-4be2-8e86-f792609bebc2"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfMTUtMy0xLTEtMjU0_adbf0a94-4f11-4ad2-9d3e-848f8ec9bde4"
      unitRef="usd">215100000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfMTUtMS0xLTEtMA_9266f800-2d98-42a7-a422-8b9b6097f0d4"
      unitRef="usd">-19158000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfMTUtMy0xLTEtMA_208d7e68-9bbc-40a0-8da4-9a67ec16b905"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfMTctMS0xLTEtMA_80769c45-aa35-4751-a05b-7fa72c520a56"
      unitRef="usd">729000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfMTctMy0xLTEtMA_4452b2e5-f4ad-4eaa-ae67-79e7966e7a9e"
      unitRef="usd">-224000</us-gaap:OtherNoncashIncomeExpense>
    <evh:IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfMTktMS0xLTEtMA_6b164277-6df3-4c23-acd0-ce0bb9cfae6f"
      unitRef="usd">120066000</evh:IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset>
    <evh:IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfMTktMy0xLTEtMA_8719514d-226c-4fd6-a52b-d7ea40d7b06c"
      unitRef="usd">23946000</evh:IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfMjAtMS0xLTEtMA_d94a9916-241c-48fa-adc2-ea3168f57631"
      unitRef="usd">3439000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfMjAtMy0xLTEtMA_51ebc6a3-55b7-4ab6-b844-52a719117a7d"
      unitRef="usd">3912000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <evh:IncreaseDecreaseInCapitalizedContractCostNet
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfMjEtMS0xLTEtMA_ebc9e210-3e63-4995-a6fa-f82b5cdbdf3c"
      unitRef="usd">3991000</evh:IncreaseDecreaseInCapitalizedContractCostNet>
    <evh:IncreaseDecreaseInCapitalizedContractCostNet
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfMjEtMy0xLTEtMA_a6a39c86-c1eb-49c9-9676-0aa8ecfdf32f"
      unitRef="usd">5503000</evh:IncreaseDecreaseInCapitalizedContractCostNet>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfMjItMS0xLTEtMA_def78f84-5bb5-42e9-b037-33476ece1f1c"
      unitRef="usd">9904000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfMjItMy0xLTEtMA_700fb971-a572-4589-a77f-ebe0d75c5fe6"
      unitRef="usd">11690000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfMjMtMS0xLTEtMA_fbd92a06-c58e-492f-8022-c905d5f3ccf5"
      unitRef="usd">-17725000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfMjMtMy0xLTEtMA_56f07d56-491e-4bcb-ba16-b586b4d2f947"
      unitRef="usd">4071000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfMjQtMS0xLTEtMA_e2670f48-298a-4dc5-aa7a-e90c5966e361"
      unitRef="usd">-21505000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfMjQtMy0xLTEtMA_78137957-4629-4b0c-9ba5-0cbd1e3bfdab"
      unitRef="usd">-10118000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfMjUtMS0xLTEtMA_6794543d-9111-48ea-90dc-42e332f2c53c"
      unitRef="usd">2490000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfMjUtMy0xLTEtMA_3cd2df06-dc3e-4333-9b55-240a442c3d5b"
      unitRef="usd">-6400000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <evh:IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfMjYtMS0xLTEtMA_83ab9c10-9237-46f7-9e06-e4489279eff0"
      unitRef="usd">62614000</evh:IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities>
    <evh:IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfMjYtMy0xLTEtMA_a55b0e81-6666-4429-ba5b-4000b8a72f71"
      unitRef="usd">33259000</evh:IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities>
    <evh:IncreaseDecreaseInOperatingLeaseRightofUseAsset
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfMjctMS0xLTEtMA_19f04590-2ad9-4189-aeb8-2ca302879b35"
      unitRef="usd">-4621000</evh:IncreaseDecreaseInOperatingLeaseRightofUseAsset>
    <evh:IncreaseDecreaseInOperatingLeaseRightofUseAsset
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfMjctMy0xLTEtMA_e07cab5a-55cf-4208-a322-31079acda7dd"
      unitRef="usd">-3620000</evh:IncreaseDecreaseInOperatingLeaseRightofUseAsset>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfMjgtMS0xLTEtMA_967afdd5-2e6e-4942-b2b1-0542d248eb3f"
      unitRef="usd">-2719000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfMjgtMy0xLTEtMA_da66a095-94de-4cdd-9fab-b5fa1bed558a"
      unitRef="usd">1783000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfMjktMS0xLTEtMA_dd4622cf-6f7e-400b-bcf4-9281e0f17d02"
      unitRef="usd">1518000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfMjktMy0xLTEtMA_483f990e-7223-4ede-bfed-88c14058eb80"
      unitRef="usd">473000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfMzAtMS0xLTEtMA_7c86dbb0-08f7-4cf3-926c-2e8648b43089"
      unitRef="usd">-72410000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfMzAtMy0xLTEtMA_c1cf20cb-9066-4194-ab24-def51a8db6f3"
      unitRef="usd">17125000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfMzItMS0xLTEtMA_fb39206f-3bb2-4cf3-9597-bbcf28f1bc3c"
      unitRef="usd">1472000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfMzItMy0xLTEtMA_85bb5029-252b-415e-8735-480261aad46c"
      unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfMzMtMS0xLTEtMA_58aa19b8-660b-471e-a433-3c80acf9e788"
      unitRef="usd">42996000</us-gaap:ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates>
    <us-gaap:ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfMzMtMy0xLTEtMA_8f28fa01-5809-4add-9df8-eebdcaea9f75"
      unitRef="usd">0</us-gaap:ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates>
    <evh:PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfMzUtMS0xLTEtMA_2900ba78-f069-4074-a35c-62ba2b24acce"
      unitRef="usd">-3490000</evh:PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet>
    <evh:PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfMzUtMy0xLTEtMA_93281bd0-6921-472d-8b51-d2dffd558908"
      unitRef="usd">2287000</evh:PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet>
    <us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfMzYtMS0xLTEtMA_ef601fa9-bbb1-491e-a79c-756981036dff"
      unitRef="usd">9372000</us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital>
    <us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfMzYtMy0xLTEtMA_db17f949-b4ff-45f7-976c-5fb5c4eeb3d9"
      unitRef="usd">0</us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital>
    <us-gaap:PaymentsToAcquireHeldToMaturitySecurities
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfMzctMS0xLTEtMA_64a00636-054a-4f69-97cc-0ab1a05fa7db"
      unitRef="usd">2994000</us-gaap:PaymentsToAcquireHeldToMaturitySecurities>
    <us-gaap:PaymentsToAcquireHeldToMaturitySecurities
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfMzctMy0xLTEtMA_8dc969bc-fabf-41da-811d-007cc0dcf536"
      unitRef="usd">1447000</us-gaap:PaymentsToAcquireHeldToMaturitySecurities>
    <evh:ProceedsFromMaturityOfInvestments
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfMzgtMS0xLTEtMA_ad6b2c4b-3609-4d53-9537-1fcf98b00b29"
      unitRef="usd">500000</evh:ProceedsFromMaturityOfInvestments>
    <evh:ProceedsFromMaturityOfInvestments
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfMzgtMy0xLTEtMA_7105db42-7edc-4503-bee3-0fa0f3e6945c"
      unitRef="usd">3099000</evh:ProceedsFromMaturityOfInvestments>
    <us-gaap:PaymentsToAcquireOtherProductiveAssets
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfMzktMS0xLTEtMA_208f9776-b173-4921-8f34-4082135678eb"
      unitRef="usd">11512000</us-gaap:PaymentsToAcquireOtherProductiveAssets>
    <us-gaap:PaymentsToAcquireOtherProductiveAssets
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfMzktMy0xLTEtMA_9133d0d2-c646-4b0a-90c2-8a815fe35338"
      unitRef="usd">17455000</us-gaap:PaymentsToAcquireOtherProductiveAssets>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfNDItMS0xLTEtMjc1_71be37f5-6d36-4362-bd98-1cc123cdb434"
      unitRef="usd">0</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfNDItMy0xLTEtMjc1_c8b6ce1b-7061-46f6-83aa-16d5e7dc5443"
      unitRef="usd">292000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfNDAtMS0xLTEtMA_300a2f68-3d6f-4a97-afb6-964fe47b7df3"
      unitRef="usd">40380000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfNDAtMy0xLTEtMA_5993583c-ed48-4e10-ba39-53a191c42e75"
      unitRef="usd">-18382000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <evh:PaymentsForProceedsFromClaimsProcessingFinancingActivities
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfNDItMS0xLTEtMA_4fe0af28-4f03-44f8-a31f-ff650c115358"
      unitRef="usd">-2399000</evh:PaymentsForProceedsFromClaimsProcessingFinancingActivities>
    <evh:PaymentsForProceedsFromClaimsProcessingFinancingActivities
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfNDItMy0xLTEtMA_0c44c268-4b63-4a39-8a4c-8a5309e09b0f"
      unitRef="usd">-26715000</evh:PaymentsForProceedsFromClaimsProcessingFinancingActivities>
    <us-gaap:RepaymentsOfSeniorDebt
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfNDMtMS0xLTEtMA_b3ad0924-3db7-43cd-9c76-088e113a68c9"
      unitRef="usd">98420000</us-gaap:RepaymentsOfSeniorDebt>
    <us-gaap:RepaymentsOfSeniorDebt
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfNDMtMy0xLTEtMA_de675559-d1a5-4009-95ec-e506b2e68aa2"
      unitRef="usd">0</us-gaap:RepaymentsOfSeniorDebt>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfNDQtMS0xLTEtMA_55af5f81-51fa-401f-9193-672a01c42c0e"
      unitRef="usd">9376000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfNDQtMy0xLTEtMA_52e2abc7-e04a-48c0-a410-c33e2f541754"
      unitRef="usd">526000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:PaymentsToMinorityShareholders
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfNDgtMS0xLTEtNDYwOQ_cf341037-f5c6-472e-b78c-6c985e31d58f"
      unitRef="usd">1300000</us-gaap:PaymentsToMinorityShareholders>
    <us-gaap:PaymentsToMinorityShareholders
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfNDgtMy0xLTEtNDYwOQ_59eeea76-2b83-45ec-af6f-cb16b673d662"
      unitRef="usd">0</us-gaap:PaymentsToMinorityShareholders>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfNDUtMS0xLTEtMA_5e201623-faad-4846-be76-b93c4e9d7136"
      unitRef="usd">3142000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfNDUtMy0xLTEtMA_98f5ff50-ef49-4cc8-a679-b20377c6b61e"
      unitRef="usd">1331000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfNDYtMS0xLTEtMA_86e0f12c-a07f-4e6f-b840-b787bd568f6c"
      unitRef="usd">-91087000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfNDYtMy0xLTEtMA_9b02dc21-15af-4136-8766-c8e9cb8fdcdd"
      unitRef="usd">25910000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfNDctMS0xLTEtMA_ac164134-9e19-4fa4-ad7b-75e37ec30f97"
      unitRef="usd">-54000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfNDctMy0xLTEtMA_7f01d16b-bd23-41c5-a759-ecb239456810"
      unitRef="usd">26000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfNDgtMS0xLTEtMA_22114c12-dd48-4e0d-b7fa-8d8a7207f5a4"
      unitRef="usd">-123171000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfNDgtMy0xLTEtMA_c6915341-a74b-43b1-a4b0-fe2ccb413b75"
      unitRef="usd">24679000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i45bff335c1434d6ba44132da1b0557db_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfNDktMS0xLTEtMA_e272ccc9-dc55-498c-89b9-404c1f9b6f6f"
      unitRef="usd">361581000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ie0ff0ad229b441d4b12bc8956f92a917_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfNDktMy0xLTEtMA_ceaf962b-8aea-4d5b-a2af-c8eac1cdeca1"
      unitRef="usd">128531000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfNTAtMS0xLTEtMA_e1d467e7-008d-4f8f-808d-93de1533b6f1"
      unitRef="usd">238410000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i11817f96c3e24e0abaed14a17869e173_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfNTAtMy0xLTEtMA_54b36cb3-55b4-4c38-a985-8a95b4bae96b"
      unitRef="usd">153210000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY180MC9mcmFnOmY4OTA3N2UxMjkyMDRjNGViY2U3NjI3Nzc3NDI0NmQxL3RleHRyZWdpb246Zjg5MDc3ZTEyOTIwNGM0ZWJjZTc2Mjc3Nzc0MjQ2ZDFfMjc4OQ_4afa3c38-38c3-4b0f-bead-225d20dd95bc">Organization &lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Evolent Health, Inc. was incorporated in December 2014 in the state of Delaware and through its subsidiaries supports leading health systems and physician organizations as well as health plans to move their business models from traditional fee for service reimbursement to value-based care, which we consider to be an integrated clinical and financial responsibility for populations. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company made organizational changes, including re-evaluating its reportable segments, as a result of the entry into the agreement to sell True Health on January 11, 2021. Effective during the first quarter of 2021, the Company bifurcated its previous Services segment into two segments. The Company&#x2019;s Evolent Health Services segment (&#x201c;EHS&#x201d;) includes our administrative simplification solution and certain supporting population health infrastructure. Our Clinical Solutions segment includes our specialty management and physician-oriented total cost of care solutions, along with the New Century Health and Evolent Care Partners brands. Refer to Note 21 for a further discussion of our operating results by segment.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Since its inception, the Company has incurred losses from operations. As of June&#160;30, 2021, the Company had unrestricted cash and cash equivalents of $207.3 million. The Company believes it has sufficient liquidity for the next twelve months as of the date the financial statements were available to be issued.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s headquarters is located in Arlington, Virginia.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Evolent Health LLC Governance&lt;/span&gt;&lt;/div&gt;Our operations are conducted through Evolent Health LLC and subsequent to the offering reorganization at the time of our initial public offering (the &#x201c;Offering Reorganization&#x201d;), the financial results of Evolent Health LLC were consolidated in the financial statements of Evolent Health, Inc. Evolent Health, Inc. is a holding company whose only business is to act as the sole managing member of Evolent Health LLC. As such, it controls Evolent Health LLC&#x2019;s business and affairs and is responsible for the management of its business.</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY180MC9mcmFnOmY4OTA3N2UxMjkyMDRjNGViY2U3NjI3Nzc3NDI0NmQxL3RleHRyZWdpb246Zjg5MDc3ZTEyOTIwNGM0ZWJjZTc2Mjc3Nzc0MjQ2ZDFfNjkz_2cef7eab-f438-42e5-92e8-a65237f80d62"
      unitRef="segment">2</us-gaap:NumberOfOperatingSegments>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY180MC9mcmFnOmY4OTA3N2UxMjkyMDRjNGViY2U3NjI3Nzc3NDI0NmQxL3RleHRyZWdpb246Zjg5MDc3ZTEyOTIwNGM0ZWJjZTc2Mjc3Nzc0MjQ2ZDFfMTI3Mw_75be52b3-187d-4246-9671-512f1eda3b64"
      unitRef="usd">207300000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY180My9mcmFnOjhjZDBhN2Q5ZmU1ODQzNGVhNWQ3MTc3MzZhMGMxODYzL3RleHRyZWdpb246OGNkMGE3ZDlmZTU4NDM0ZWE1ZDcxNzczNmEwYzE4NjNfMTU0MzE_9a2d814b-a4ac-410b-a8a8-78468952d952">Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In our opinion, the accompanying unaudited interim consolidated financial statements include all adjustments, consisting of normal recurring adjustments, which are necessary to fairly state our financial position, results of operations, and cash flows. The consolidated balance sheet as of December 31, 2020, has been derived from audited financial statements as of that date and reflects the impact of the agreement to sell True Health. See Note 5 for a complete summary of this transaction. The interim consolidated results of operations are not necessarily indicative of the results that may occur for the full fiscal year. Certain footnote disclosures normally included in financial statements prepared in accordance with United States of America generally accepted accounting principles (&#x201c;GAAP&#x201d;) have been omitted pursuant to instructions, rules, and regulations prescribed by the United States Securities and Exchange Commission (&#x201c;SEC&#x201d;). The disclosures provided herein should be read in conjunction with the audited financial statements and notes thereto included in our 2020 Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Summary of Significant Accounting Policies&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain GAAP policies that significantly affect the determination of our financial position, results of operations and cash flows, are summarized below.  See &#x201c;Part II - Item 8. Financial Statements and Supplementary Data - Note 2&#x201d; in our 2020 Form 10-K for a complete summary of our significant accounting policies.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounting Estimates and Assumptions&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions affecting the reported amounts of assets and liabilities and the disclosures of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expenses for the reporting period. Those estimates are inherently subject to change and actual results could differ from those estimates. In the accompanying consolidated financial statements, estimates are used for, but not limited to, the valuation of assets (including intangibles assets, goodwill and long-lived assets), liabilities, consideration related to business combinations and asset acquisitions, revenue recognition (including variable consideration), estimated selling &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;prices for performance obligations in contracts with multiple performance obligations, reserves for claims and performance-based arrangements, credit losses, depreciable lives of assets, impairment of long-lived assets, stock-based compensation, deferred income taxes and valuation allowance, contingent liabilities, purchase price allocation in taxable stock transactions and useful lives of intangible assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements include the accounts of Evolent Health, Inc. and its subsidiaries. All intercompany accounts and transactions are eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We consider all highly liquid instruments with original maturities of three months or less to be cash equivalents. The Company holds materially all of our cash in bank deposits with FDIC participating banks, at cost, which approximates fair value. Cash and cash equivalents held in money market funds are carried at fair value, which approximates cost.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Restricted Cash and Restricted Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted cash and restricted investments include cash and investments used to collateralize various contractual obligations as of June&#160;30, 2021 and December&#160;31, 2020 (in thousands) as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:340.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:94.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:94.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collateral for letters of credit for facility leases &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collateral with financial institutions &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Claims processing services &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,327&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total restricted cash and restricted investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,644&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current restricted cash and restricted investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total non-current restricted cash and restricted investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Amounts exclude $0.6 million of non-current restricted investments and $0.1&#160;million of current restricted cash from claims processing services reclassified to discontinued operations as of December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Represents restricted cash related to collateral for letters of credit required in conjunction with lease agreements. See Note 12 for further discussion of our lease commitments. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Represents collateral held with financial institutions for risk-sharing and other arrangements. As of June&#160;30, 2021 and December&#160;31, 2020, approximately $12.4&#160;million and $4.7 million, respectively, of the collateral amounts were held in a FDIC participating bank account. See Note 18 for discussion of fair value measurement and Note 11 for discussion of our risk-sharing arrangements. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Represents cash held by the Company related to claims processing services on behalf of partners. These are pass-through amounts and can fluctuate materially from period to period depending on the timing of when the claims are processed.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statements of cash flows as of June&#160;30, 2021 and 2020 (in thousands).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:433.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;207,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98,272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash and restricted investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted investments included in restricted cash and restricted investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(715)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:5.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash and cash equivalents and restricted cash shown in the consolidated statements of cash flows &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;238,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;153,210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;As a result of the closing of the sale of True Health SPA, the consolidated statements of operations, consolidated balance sheets, and related financial information reflect the Company&#x2019;s operations and assets and liabilities of True Health as discontinued operations for all periods presented. Cash flows and comprehensive income have not been adjusted and are included in the consolidated statements of cash flows and consolidated statements of comprehensive income (loss) for all periods presented. See Note 5.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Business Combinations&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Companies acquired during each reporting period are reflected in the results of the Company effective from their respective dates of acquisition through the end of the reporting period. The Company allocates the fair value of purchase consideration to the assets acquired and liabilities assumed based on their estimated fair values at the acquisition date. Our estimates of fair value are based upon assumptions believed to be reasonable, but which are inherently uncertain and unpredictable and, as a result, actual results may differ from estimates. Critical estimates used to value certain identifiable assets include, but are not limited to, expected long-term revenues, future expected operating expenses, cost of capital, and appropriate discount rates. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The excess of the fair value of purchase consideration over the fair value of the assets acquired and liabilities assumed in the acquired entity is recorded as goodwill. Goodwill is assigned to the reporting unit that benefits from the synergies arising from the business combination. If the Company obtains new information about facts and circumstances that existed as of the acquisition date during the measurement period, which may be up to one year from the acquisition date, the Company may record adjustments to the assets acquired and liabilities assumed, with the corresponding offset to goodwill. Upon the conclusion of the measurement period or final determination of the values of assets acquired or liabilities assumed, whichever comes first, any subsequent adjustments are recorded on the Company's consolidated statements of operations and comprehensive income (loss). &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For contingent consideration recorded as a liability, the Company initially measures the amount at fair value as of the acquisition date and adjusts the liability, if needed, to fair value at each reporting period. Changes in the fair value of contingent consideration, other than measurement period adjustments, are recognized as operating income or expense. Acquisition-related expenses and post-acquisition restructuring costs are recognized separately from the business combination and are expensed as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize the excess of the purchase price, plus the fair value of any non-controlling interests in the acquiree, over the fair value of identifiable net assets acquired as goodwill. Goodwill is not amortized, but is reviewed at least annually for indications of impairment, with consideration given to financial performance and other relevant factors. We perform impairment tests of goodwill at a reporting unit level. Following the sale of True Health, the Company has three reporting units and our annual goodwill impairment review occurs during the fourth quarter of each year. We perform impairment tests between annual tests if an event occurs, or circumstances change, that we believe would more likely than not reduce the fair value of a reporting unit below its carrying amount. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our goodwill impairment analysis first assesses qualitative factors to determine whether events or circumstances existed that would lead the Company to conclude it is more likely than not that the fair value of a reporting unit is below its carrying amount. If the Company determines that it is more likely than not that the fair value of a reporting unit is below the carrying amount, a quantitative goodwill assessment is required. In the quantitative evaluation, the fair value of the relevant reporting unit is determined and compared to the carrying value. If the fair value is greater than the carrying value, then the carrying value is deemed to be recoverable and no further action is required. If the fair value estimate is less than the carrying value, goodwill is considered impaired for the amount by which the carrying amount exceeds the reporting unit&#x2019;s fair value and a charge is reported in goodwill impairment on our consolidated statements of operations and comprehensive income (loss). See Note 9 for additional discussion regarding the goodwill impairment tests conducted during 2021 and 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Intangible Assets, Net &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Identified intangible assets are recorded at their estimated fair values at the date of acquisition and are amortized over their respective estimated useful lives using a method of amortization that reflects the pattern in which the economic benefits of the intangible assets are used. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following summarizes the estimated useful lives by asset classification:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:438.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:97.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate trade name&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10 - 20 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10 - 25 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provider network contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4 - 5 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets are reviewed for impairment if circumstances indicate the Company may not be able to recover the asset&#x2019;s carrying value. The Company evaluates recoverability by determining whether the undiscounted cash flows expected to result from the use and eventual disposition of that asset or group exceed the carrying value at the evaluation date. If the undiscounted cash flows are not sufficient to cover the carrying value, the Company measures an impairment loss as the excess of the carrying amount of the long-lived asset or group over its fair value. See Note 9 for additional discussion regarding our intangible assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Reserves for Claims and Performance-based Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Reserves for performance-based arrangements and claims reflect estimates of payments under performance-based arrangements and the ultimate cost of claims that have been incurred but not reported, including expected development on reported claims, those that have been reported but not yet paid (reported claims in process), and other medical care expenses and services payable that are primarily composed of accruals for incentives and other amounts payable to health care professionals and facilities. The Company uses actuarial principles and assumptions that are consistently applied in each reporting period and recognizes the actuarial best estimate of the ultimate liability along with a margin for adverse deviation. This approach is consistent with actuarial standards of practice that the liabilities be adequate under moderately adverse conditions. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The process of estimating reserves involves a considerable degree of judgment by the Company and, as of any given date, is inherently uncertain. The methods for making such estimates and for establishing the resulting liability are continually reviewed, and adjustments are reflected in current results of operations in the period in which they are identified as experience develops or new information becomes known. See Note 22 for additional discussion regarding our reserves for claims and performance-based arrangements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company enters into various office space, data center, and equipment lease agreements in conducting its normal business operations. At the inception of any contract, the Company evaluates the agreement to determine whether the contract contains a lease. If the contract contains a lease, the Company then evaluates the term and whether the lease is an operating or finance lease. Most leases include one or more options to renew or may have a termination option. The Company determines whether these options are reasonably certain to be exercised at the inception of the lease. The rent expense is recognized on a straight-line basis in the consolidated statements of operations and comprehensive income (loss) over the terms of the respective leases. Leases with an initial term of 12 months or less are not recorded on the consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. We use the implicit rate when readily determinable. Further, the Company treats all lease and non-lease components as a single combined lease component for all classes of underlying assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also enters into sublease agreements for some of its leased office space. Rental income attributable to subleases is immaterial and is offset against rent expense over the terms of the respective leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Refer to Note 12 for additional lease disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We derive revenue from two sources: (1) transformation services and (2) platform and operations services. Transformation services consist of implementation services whereby we assist the customer in launching its population health or health plan programs, or implement certain platform and operations services. In certain cases, transformation services can also include revenue associated with our support of certain one-time wind-down activities for clients who are exiting a line of business or population. Platform and operations services generally include multi-year arrangements with customers to provide various population health, health plan operations, specialty care management and claims processing services on an ongoing basis, as well as transition or run-out services to customers receiving primarily TPA services. Revenue is recognized when control of the services is transferred to our customers.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We use the following 5-step model, outlined in Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASC 606&#x201d;), to determine revenue recognition from our contracts with customers:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt; Identify the contract(s) with a customer&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt; Identify the performance obligations in the contract&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt; Determine the transaction price&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt; Allocate the transaction price to performance obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt; Recognize revenue when (or as) the entity satisfies a performance obligation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See Note 6 for further discussion of our policies related to revenue recognition. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Foreign Currency&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company formed a subsidiary in India during the first quarter of 2018. The functional currency of our international subsidiary is the Indian Rupee. We translate the financial statements of this subsidiary to U.S. dollars using month-end rates of exchange for assets and liabilities, and monthly average rates of exchange for revenue and expenses. Translation gains and losses are recorded in accumulated other comprehensive income (loss) as a component of shareholders' equity. Foreign currency translation gains and losses did not have a material impact on our consolidated statements of operations and comprehensive income (loss) for the three and six months ended June 30, 2021 and 2020.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY180My9mcmFnOjhjZDBhN2Q5ZmU1ODQzNGVhNWQ3MTc3MzZhMGMxODYzL3RleHRyZWdpb246OGNkMGE3ZDlmZTU4NDM0ZWE1ZDcxNzczNmEwYzE4NjNfMTU0Mzg_386ad26f-4db8-4e5e-86dd-40e742447c19">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In our opinion, the accompanying unaudited interim consolidated financial statements include all adjustments, consisting of normal recurring adjustments, which are necessary to fairly state our financial position, results of operations, and cash flows. The consolidated balance sheet as of December 31, 2020, has been derived from audited financial statements as of that date and reflects the impact of the agreement to sell True Health. See Note 5 for a complete summary of this transaction. The interim consolidated results of operations are not necessarily indicative of the results that may occur for the full fiscal year. Certain footnote disclosures normally included in financial statements prepared in accordance with United States of America generally accepted accounting principles (&#x201c;GAAP&#x201d;) have been omitted pursuant to instructions, rules, and regulations prescribed by the United States Securities and Exchange Commission (&#x201c;SEC&#x201d;). The disclosures provided herein should be read in conjunction with the audited financial statements and notes thereto included in our 2020 Form 10-K.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY180My9mcmFnOjhjZDBhN2Q5ZmU1ODQzNGVhNWQ3MTc3MzZhMGMxODYzL3RleHRyZWdpb246OGNkMGE3ZDlmZTU4NDM0ZWE1ZDcxNzczNmEwYzE4NjNfMTU0NDI_5bdbe5ee-eb4e-49d0-ba15-84e0784e1309">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounting Estimates and Assumptions&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions affecting the reported amounts of assets and liabilities and the disclosures of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expenses for the reporting period. Those estimates are inherently subject to change and actual results could differ from those estimates. In the accompanying consolidated financial statements, estimates are used for, but not limited to, the valuation of assets (including intangibles assets, goodwill and long-lived assets), liabilities, consideration related to business combinations and asset acquisitions, revenue recognition (including variable consideration), estimated selling &lt;/span&gt;&lt;/div&gt;prices for performance obligations in contracts with multiple performance obligations, reserves for claims and performance-based arrangements, credit losses, depreciable lives of assets, impairment of long-lived assets, stock-based compensation, deferred income taxes and valuation allowance, contingent liabilities, purchase price allocation in taxable stock transactions and useful lives of intangible assets.</us-gaap:UseOfEstimates>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY180My9mcmFnOjhjZDBhN2Q5ZmU1ODQzNGVhNWQ3MTc3MzZhMGMxODYzL3RleHRyZWdpb246OGNkMGE3ZDlmZTU4NDM0ZWE1ZDcxNzczNmEwYzE4NjNfMTU0NTI_76bbacc6-2a5d-4a38-ae9e-c69f388064cb">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements include the accounts of Evolent Health, Inc. and its subsidiaries. All intercompany accounts and transactions are eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY180My9mcmFnOjhjZDBhN2Q5ZmU1ODQzNGVhNWQ3MTc3MzZhMGMxODYzL3RleHRyZWdpb246OGNkMGE3ZDlmZTU4NDM0ZWE1ZDcxNzczNmEwYzE4NjNfMTU0NTM_840ccd4f-b965-432d-8c6b-399750a54048">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We consider all highly liquid instruments with original maturities of three months or less to be cash equivalents. The Company holds materially all of our cash in bank deposits with FDIC participating banks, at cost, which approximates fair value. Cash and cash equivalents held in money market funds are carried at fair value, which approximates cost.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY180My9mcmFnOjhjZDBhN2Q5ZmU1ODQzNGVhNWQ3MTc3MzZhMGMxODYzL3RleHRyZWdpb246OGNkMGE3ZDlmZTU4NDM0ZWE1ZDcxNzczNmEwYzE4NjNfMTU0MDI_ce32f53a-3471-4b36-b040-878c7b625ef5">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted cash and restricted investments include cash and investments used to collateralize various contractual obligations as of June&#160;30, 2021 and December&#160;31, 2020 (in thousands) as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:340.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:94.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:94.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collateral for letters of credit for facility leases &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collateral with financial institutions &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Claims processing services &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,327&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total restricted cash and restricted investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,644&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current restricted cash and restricted investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total non-current restricted cash and restricted investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Amounts exclude $0.6 million of non-current restricted investments and $0.1&#160;million of current restricted cash from claims processing services reclassified to discontinued operations as of December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Represents restricted cash related to collateral for letters of credit required in conjunction with lease agreements. See Note 12 for further discussion of our lease commitments. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Represents collateral held with financial institutions for risk-sharing and other arrangements. As of June&#160;30, 2021 and December&#160;31, 2020, approximately $12.4&#160;million and $4.7 million, respectively, of the collateral amounts were held in a FDIC participating bank account. See Note 18 for discussion of fair value measurement and Note 11 for discussion of our risk-sharing arrangements. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Represents cash held by the Company related to claims processing services on behalf of partners. These are pass-through amounts and can fluctuate materially from period to period depending on the timing of when the claims are processed.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statements of cash flows as of June&#160;30, 2021 and 2020 (in thousands).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:433.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;207,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98,272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash and restricted investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted investments included in restricted cash and restricted investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(715)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:5.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash and cash equivalents and restricted cash shown in the consolidated statements of cash flows &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;238,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;153,210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;As a result of the closing of the sale of True Health SPA, the consolidated statements of operations, consolidated balance sheets, and related financial information reflect the Company&#x2019;s operations and assets and liabilities of True Health as discontinued operations for all periods presented. Cash flows and comprehensive income have not been adjusted and are included in the consolidated statements of cash flows and consolidated statements of comprehensive income (loss) for all periods presented. See Note 5.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="ie049e920122645beab4e92d759ec4ad6_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY180My9mcmFnOjhjZDBhN2Q5ZmU1ODQzNGVhNWQ3MTc3MzZhMGMxODYzL3RhYmxlOjNhNTFiZjM3ODlhZjRhNjViYWQzNjYwNGI3YmViODI1L3RhYmxlcmFuZ2U6M2E1MWJmMzc4OWFmNGE2NWJhZDM2NjA0YjdiZWI4MjVfMS0xLTEtMS0w_6804a77a-3a62-4e4e-a8e5-8a3fe3176795"
      unitRef="usd">3510000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="ibafea1edac4741a491dc06d42fbb6974_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY180My9mcmFnOjhjZDBhN2Q5ZmU1ODQzNGVhNWQ3MTc3MzZhMGMxODYzL3RhYmxlOjNhNTFiZjM3ODlhZjRhNjViYWQzNjYwNGI3YmViODI1L3RhYmxlcmFuZ2U6M2E1MWJmMzc4OWFmNGE2NWJhZDM2NjA0YjdiZWI4MjVfMS0zLTEtMS0w_8b14da3a-feee-4463-8bbc-9b4fe451ff1d"
      unitRef="usd">3510000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="i51059975ca4a4ad18ae06161620c8d07_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY180My9mcmFnOjhjZDBhN2Q5ZmU1ODQzNGVhNWQ3MTc3MzZhMGMxODYzL3RhYmxlOjNhNTFiZjM3ODlhZjRhNjViYWQzNjYwNGI3YmViODI1L3RhYmxlcmFuZ2U6M2E1MWJmMzc4OWFmNGE2NWJhZDM2NjA0YjdiZWI4MjVfMi0xLTEtMS0w_4e31be76-7647-4a19-abd5-e08167c60904"
      unitRef="usd">12352000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="i84a57e99f4a84536b7f1f81b47d53542_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY180My9mcmFnOjhjZDBhN2Q5ZmU1ODQzNGVhNWQ3MTc3MzZhMGMxODYzL3RhYmxlOjNhNTFiZjM3ODlhZjRhNjViYWQzNjYwNGI3YmViODI1L3RhYmxlcmFuZ2U6M2E1MWJmMzc4OWFmNGE2NWJhZDM2NjA0YjdiZWI4MjVfMi0zLTEtMS0w_58e79ead-1bed-41e9-8b1d-e089843ffa6d"
      unitRef="usd">4743000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="i724f3fb7e8664faf9d4251ef0ad9db50_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY180My9mcmFnOjhjZDBhN2Q5ZmU1ODQzNGVhNWQ3MTc3MzZhMGMxODYzL3RhYmxlOjNhNTFiZjM3ODlhZjRhNjViYWQzNjYwNGI3YmViODI1L3RhYmxlcmFuZ2U6M2E1MWJmMzc4OWFmNGE2NWJhZDM2NjA0YjdiZWI4MjVfMy0xLTEtMS0w_e3476353-9717-406e-81e4-5a3792d3729c"
      unitRef="usd">14525000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="i68d600384d87411f9808a47f7fa089b1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY180My9mcmFnOjhjZDBhN2Q5ZmU1ODQzNGVhNWQ3MTc3MzZhMGMxODYzL3RhYmxlOjNhNTFiZjM3ODlhZjRhNjViYWQzNjYwNGI3YmViODI1L3RhYmxlcmFuZ2U6M2E1MWJmMzc4OWFmNGE2NWJhZDM2NjA0YjdiZWI4MjVfMy0zLTEtMS0w_50627276-5ea3-4f31-9a98-36d5353b8d23"
      unitRef="usd">12064000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="if917fe9e46d74bbba565ff75862d3292_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY180My9mcmFnOjhjZDBhN2Q5ZmU1ODQzNGVhNWQ3MTc3MzZhMGMxODYzL3RhYmxlOjNhNTFiZjM3ODlhZjRhNjViYWQzNjYwNGI3YmViODI1L3RhYmxlcmFuZ2U6M2E1MWJmMzc4OWFmNGE2NWJhZDM2NjA0YjdiZWI4MjVfNC0xLTEtMS0w_f16c22ed-1728-4672-8ffc-c1f0f6a72cd0"
      unitRef="usd">750000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="ic2b7bf7f852c4e07ae4036ec1933f336_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY180My9mcmFnOjhjZDBhN2Q5ZmU1ODQzNGVhNWQ3MTc3MzZhMGMxODYzL3RhYmxlOjNhNTFiZjM3ODlhZjRhNjViYWQzNjYwNGI3YmViODI1L3RhYmxlcmFuZ2U6M2E1MWJmMzc4OWFmNGE2NWJhZDM2NjA0YjdiZWI4MjVfNC0zLTEtMS0w_334ca88b-5486-4fb4-a8a2-4bfeb070f8a2"
      unitRef="usd">1327000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY180My9mcmFnOjhjZDBhN2Q5ZmU1ODQzNGVhNWQ3MTc3MzZhMGMxODYzL3RhYmxlOjNhNTFiZjM3ODlhZjRhNjViYWQzNjYwNGI3YmViODI1L3RhYmxlcmFuZ2U6M2E1MWJmMzc4OWFmNGE2NWJhZDM2NjA0YjdiZWI4MjVfNS0xLTEtMS0w_26552208-7829-4f47-8288-ea1213f937b7"
      unitRef="usd">31137000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="i45bff335c1434d6ba44132da1b0557db_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY180My9mcmFnOjhjZDBhN2Q5ZmU1ODQzNGVhNWQ3MTc3MzZhMGMxODYzL3RhYmxlOjNhNTFiZjM3ODlhZjRhNjViYWQzNjYwNGI3YmViODI1L3RhYmxlcmFuZ2U6M2E1MWJmMzc4OWFmNGE2NWJhZDM2NjA0YjdiZWI4MjVfNS0zLTEtMS0w_e6cd600c-1ca0-45ad-ab1f-f26d632d2f74"
      unitRef="usd">21644000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY180My9mcmFnOjhjZDBhN2Q5ZmU1ODQzNGVhNWQ3MTc3MzZhMGMxODYzL3RhYmxlOjNhNTFiZjM3ODlhZjRhNjViYWQzNjYwNGI3YmViODI1L3RhYmxlcmFuZ2U6M2E1MWJmMzc4OWFmNGE2NWJhZDM2NjA0YjdiZWI4MjVfNy0xLTEtMS0w_c75a7083-e97c-4664-a313-9f7190847c49"
      unitRef="usd">17742000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="i45bff335c1434d6ba44132da1b0557db_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY180My9mcmFnOjhjZDBhN2Q5ZmU1ODQzNGVhNWQ3MTc3MzZhMGMxODYzL3RhYmxlOjNhNTFiZjM3ODlhZjRhNjViYWQzNjYwNGI3YmViODI1L3RhYmxlcmFuZ2U6M2E1MWJmMzc4OWFmNGE2NWJhZDM2NjA0YjdiZWI4MjVfNy0zLTEtMS0w_84e2aa31-0906-4f81-8385-8c0b753a08f6"
      unitRef="usd">14374000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndInvestmentsCurrent
      contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY180My9mcmFnOjhjZDBhN2Q5ZmU1ODQzNGVhNWQ3MTc3MzZhMGMxODYzL3RhYmxlOjNhNTFiZjM3ODlhZjRhNjViYWQzNjYwNGI3YmViODI1L3RhYmxlcmFuZ2U6M2E1MWJmMzc4OWFmNGE2NWJhZDM2NjA0YjdiZWI4MjVfOC0xLTEtMS0w_63e8fb2d-6278-443f-baba-bba4f96619ce"
      unitRef="usd">17742000</us-gaap:RestrictedCashAndInvestmentsCurrent>
    <us-gaap:RestrictedCashAndInvestmentsCurrent
      contextRef="i45bff335c1434d6ba44132da1b0557db_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY180My9mcmFnOjhjZDBhN2Q5ZmU1ODQzNGVhNWQ3MTc3MzZhMGMxODYzL3RhYmxlOjNhNTFiZjM3ODlhZjRhNjViYWQzNjYwNGI3YmViODI1L3RhYmxlcmFuZ2U6M2E1MWJmMzc4OWFmNGE2NWJhZDM2NjA0YjdiZWI4MjVfOC0zLTEtMS0w_52507d96-c382-4aa3-ba1f-2b4963d39b27"
      unitRef="usd">14374000</us-gaap:RestrictedCashAndInvestmentsCurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY180My9mcmFnOjhjZDBhN2Q5ZmU1ODQzNGVhNWQ3MTc3MzZhMGMxODYzL3RhYmxlOjNhNTFiZjM3ODlhZjRhNjViYWQzNjYwNGI3YmViODI1L3RhYmxlcmFuZ2U6M2E1MWJmMzc4OWFmNGE2NWJhZDM2NjA0YjdiZWI4MjVfMTAtMS0xLTEtMA_a7be6a1f-c9c7-48a4-b60f-868881552252"
      unitRef="usd">13395000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="i45bff335c1434d6ba44132da1b0557db_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY180My9mcmFnOjhjZDBhN2Q5ZmU1ODQzNGVhNWQ3MTc3MzZhMGMxODYzL3RhYmxlOjNhNTFiZjM3ODlhZjRhNjViYWQzNjYwNGI3YmViODI1L3RhYmxlcmFuZ2U6M2E1MWJmMzc4OWFmNGE2NWJhZDM2NjA0YjdiZWI4MjVfMTAtMy0xLTEtMA_3e120e9b-e231-4fd6-adbe-7038dce599f0"
      unitRef="usd">6654000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndInvestmentsNoncurrent
      contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY180My9mcmFnOjhjZDBhN2Q5ZmU1ODQzNGVhNWQ3MTc3MzZhMGMxODYzL3RhYmxlOjNhNTFiZjM3ODlhZjRhNjViYWQzNjYwNGI3YmViODI1L3RhYmxlcmFuZ2U6M2E1MWJmMzc4OWFmNGE2NWJhZDM2NjA0YjdiZWI4MjVfMTEtMS0xLTEtMA_a38536b4-edbb-438c-8ffd-9f6274be739e"
      unitRef="usd">13395000</us-gaap:RestrictedCashAndInvestmentsNoncurrent>
    <us-gaap:RestrictedCashAndInvestmentsNoncurrent
      contextRef="i45bff335c1434d6ba44132da1b0557db_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY180My9mcmFnOjhjZDBhN2Q5ZmU1ODQzNGVhNWQ3MTc3MzZhMGMxODYzL3RhYmxlOjNhNTFiZjM3ODlhZjRhNjViYWQzNjYwNGI3YmViODI1L3RhYmxlcmFuZ2U6M2E1MWJmMzc4OWFmNGE2NWJhZDM2NjA0YjdiZWI4MjVfMTEtMy0xLTEtMA_d81d41b6-8198-41a3-b5f8-9a23715db85a"
      unitRef="usd">6654000</us-gaap:RestrictedCashAndInvestmentsNoncurrent>
    <evh:DisposalGroupIncludingDiscontinuedOperationRestrictedInvestmentsNoncurrent
      contextRef="ia177f909fbae4389bdaa8635f038babb_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY180My9mcmFnOjhjZDBhN2Q5ZmU1ODQzNGVhNWQ3MTc3MzZhMGMxODYzL3RleHRyZWdpb246OGNkMGE3ZDlmZTU4NDM0ZWE1ZDcxNzczNmEwYzE4NjNfMzM4NQ_7b534217-4ba1-42ac-8c6e-0138065d740f"
      unitRef="usd">600000</evh:DisposalGroupIncludingDiscontinuedOperationRestrictedInvestmentsNoncurrent>
    <evh:DisposalGroupIncludingDiscontinuedOperationRestrictedCashCurrent
      contextRef="ia177f909fbae4389bdaa8635f038babb_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY180My9mcmFnOjhjZDBhN2Q5ZmU1ODQzNGVhNWQ3MTc3MzZhMGMxODYzL3RleHRyZWdpb246OGNkMGE3ZDlmZTU4NDM0ZWE1ZDcxNzczNmEwYzE4NjNfMzQzMA_697a00aa-e548-4bde-ae4a-0474df4c5ace"
      unitRef="usd">100000</evh:DisposalGroupIncludingDiscontinuedOperationRestrictedCashCurrent>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="iff2a65b6a1be4bb6b51772f3a5414255_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY180My9mcmFnOjhjZDBhN2Q5ZmU1ODQzNGVhNWQ3MTc3MzZhMGMxODYzL3RleHRyZWdpb246OGNkMGE3ZDlmZTU4NDM0ZWE1ZDcxNzczNmEwYzE4NjNfMzg0OQ_8e40a6fa-1df9-40f5-94e2-25705a7766a2"
      unitRef="usd">12400000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="i8abf010fb96f42a3a9c433ab04beeed6_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY180My9mcmFnOjhjZDBhN2Q5ZmU1ODQzNGVhNWQ3MTc3MzZhMGMxODYzL3RleHRyZWdpb246OGNkMGE3ZDlmZTU4NDM0ZWE1ZDcxNzczNmEwYzE4NjNfMzg1Ng_ee69c79a-c676-4e11-8c7b-3a1cbcd65c30"
      unitRef="usd">4700000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY180My9mcmFnOjhjZDBhN2Q5ZmU1ODQzNGVhNWQ3MTc3MzZhMGMxODYzL3RhYmxlOmQxMDY0MzRkODgxNTQxOTFiYmVkYTRhOTM2Nzg2ZDJlL3RhYmxlcmFuZ2U6ZDEwNjQzNGQ4ODE1NDE5MWJiZWRhNGE5MzY3ODZkMmVfMi0xLTEtMS0w_e3fbfd72-29d8-4e8d-8377-ac0c97eaa1ce"
      unitRef="usd">207273000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i11817f96c3e24e0abaed14a17869e173_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY180My9mcmFnOjhjZDBhN2Q5ZmU1ODQzNGVhNWQ3MTc3MzZhMGMxODYzL3RhYmxlOmQxMDY0MzRkODgxNTQxOTFiYmVkYTRhOTM2Nzg2ZDJlL3RhYmxlcmFuZ2U6ZDEwNjQzNGQ4ODE1NDE5MWJiZWRhNGE5MzY3ODZkMmVfMi0zLTEtMS0w_71a8c124-04fa-4865-9913-c8aabe034c9f"
      unitRef="usd">98272000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY180My9mcmFnOjhjZDBhN2Q5ZmU1ODQzNGVhNWQ3MTc3MzZhMGMxODYzL3RhYmxlOmQxMDY0MzRkODgxNTQxOTFiYmVkYTRhOTM2Nzg2ZDJlL3RhYmxlcmFuZ2U6ZDEwNjQzNGQ4ODE1NDE5MWJiZWRhNGE5MzY3ODZkMmVfMy0xLTEtMS0w_26552208-7829-4f47-8288-ea1213f937b7"
      unitRef="usd">31137000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="i11817f96c3e24e0abaed14a17869e173_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY180My9mcmFnOjhjZDBhN2Q5ZmU1ODQzNGVhNWQ3MTc3MzZhMGMxODYzL3RhYmxlOmQxMDY0MzRkODgxNTQxOTFiYmVkYTRhOTM2Nzg2ZDJlL3RhYmxlcmFuZ2U6ZDEwNjQzNGQ4ODE1NDE5MWJiZWRhNGE5MzY3ODZkMmVfMy0zLTEtMS0w_2166329f-804a-4f3d-b2b0-f859513cb319"
      unitRef="usd">55653000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedInvestments
      contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY180My9mcmFnOjhjZDBhN2Q5ZmU1ODQzNGVhNWQ3MTc3MzZhMGMxODYzL3RhYmxlOmQxMDY0MzRkODgxNTQxOTFiYmVkYTRhOTM2Nzg2ZDJlL3RhYmxlcmFuZ2U6ZDEwNjQzNGQ4ODE1NDE5MWJiZWRhNGE5MzY3ODZkMmVfNC0xLTEtMS0w_f0998314-b6ed-494d-8b36-c3060b249c75"
      unitRef="usd">0</us-gaap:RestrictedInvestments>
    <us-gaap:RestrictedInvestments
      contextRef="i11817f96c3e24e0abaed14a17869e173_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY180My9mcmFnOjhjZDBhN2Q5ZmU1ODQzNGVhNWQ3MTc3MzZhMGMxODYzL3RhYmxlOmQxMDY0MzRkODgxNTQxOTFiYmVkYTRhOTM2Nzg2ZDJlL3RhYmxlcmFuZ2U6ZDEwNjQzNGQ4ODE1NDE5MWJiZWRhNGE5MzY3ODZkMmVfNC0zLTEtMS0w_32aaa20e-deae-4156-922c-9ef8fd0a6c8b"
      unitRef="usd">715000</us-gaap:RestrictedInvestments>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY180My9mcmFnOjhjZDBhN2Q5ZmU1ODQzNGVhNWQ3MTc3MzZhMGMxODYzL3RhYmxlOmQxMDY0MzRkODgxNTQxOTFiYmVkYTRhOTM2Nzg2ZDJlL3RhYmxlcmFuZ2U6ZDEwNjQzNGQ4ODE1NDE5MWJiZWRhNGE5MzY3ODZkMmVfNS0xLTEtMS0w_5e1f9621-dd61-4f48-a199-67ff0634c23a"
      unitRef="usd">238410000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i11817f96c3e24e0abaed14a17869e173_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY180My9mcmFnOjhjZDBhN2Q5ZmU1ODQzNGVhNWQ3MTc3MzZhMGMxODYzL3RhYmxlOmQxMDY0MzRkODgxNTQxOTFiYmVkYTRhOTM2Nzg2ZDJlL3RhYmxlcmFuZ2U6ZDEwNjQzNGQ4ODE1NDE5MWJiZWRhNGE5MzY3ODZkMmVfNS0zLTEtMS0w_0e2f9c74-9152-4631-9d63-5777c60134a1"
      unitRef="usd">153210000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:BusinessCombinationsPolicy
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY180My9mcmFnOjhjZDBhN2Q5ZmU1ODQzNGVhNWQ3MTc3MzZhMGMxODYzL3RleHRyZWdpb246OGNkMGE3ZDlmZTU4NDM0ZWE1ZDcxNzczNmEwYzE4NjNfMTU0MjQ_0f2bb67e-6dd2-4885-85f6-7829ad5c7cc3">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Business Combinations&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Companies acquired during each reporting period are reflected in the results of the Company effective from their respective dates of acquisition through the end of the reporting period. The Company allocates the fair value of purchase consideration to the assets acquired and liabilities assumed based on their estimated fair values at the acquisition date. Our estimates of fair value are based upon assumptions believed to be reasonable, but which are inherently uncertain and unpredictable and, as a result, actual results may differ from estimates. Critical estimates used to value certain identifiable assets include, but are not limited to, expected long-term revenues, future expected operating expenses, cost of capital, and appropriate discount rates. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The excess of the fair value of purchase consideration over the fair value of the assets acquired and liabilities assumed in the acquired entity is recorded as goodwill. Goodwill is assigned to the reporting unit that benefits from the synergies arising from the business combination. If the Company obtains new information about facts and circumstances that existed as of the acquisition date during the measurement period, which may be up to one year from the acquisition date, the Company may record adjustments to the assets acquired and liabilities assumed, with the corresponding offset to goodwill. Upon the conclusion of the measurement period or final determination of the values of assets acquired or liabilities assumed, whichever comes first, any subsequent adjustments are recorded on the Company's consolidated statements of operations and comprehensive income (loss). &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For contingent consideration recorded as a liability, the Company initially measures the amount at fair value as of the acquisition date and adjusts the liability, if needed, to fair value at each reporting period. Changes in the fair value of contingent consideration, other than measurement period adjustments, are recognized as operating income or expense. Acquisition-related expenses and post-acquisition restructuring costs are recognized separately from the business combination and are expensed as incurred.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessCombinationsPolicy>
    <us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY180My9mcmFnOjhjZDBhN2Q5ZmU1ODQzNGVhNWQ3MTc3MzZhMGMxODYzL3RleHRyZWdpb246OGNkMGE3ZDlmZTU4NDM0ZWE1ZDcxNzczNmEwYzE4NjNfMTU0NDg_127789dc-7741-43e3-8c2e-3521728b9e27">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize the excess of the purchase price, plus the fair value of any non-controlling interests in the acquiree, over the fair value of identifiable net assets acquired as goodwill. Goodwill is not amortized, but is reviewed at least annually for indications of impairment, with consideration given to financial performance and other relevant factors. We perform impairment tests of goodwill at a reporting unit level. Following the sale of True Health, the Company has three reporting units and our annual goodwill impairment review occurs during the fourth quarter of each year. We perform impairment tests between annual tests if an event occurs, or circumstances change, that we believe would more likely than not reduce the fair value of a reporting unit below its carrying amount. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our goodwill impairment analysis first assesses qualitative factors to determine whether events or circumstances existed that would lead the Company to conclude it is more likely than not that the fair value of a reporting unit is below its carrying amount. If the Company determines that it is more likely than not that the fair value of a reporting unit is below the carrying amount, a quantitative goodwill assessment is required. In the quantitative evaluation, the fair value of the relevant reporting unit is determined and compared to the carrying value. If the fair value is greater than the carrying value, then the carrying value is deemed to be recoverable and no further action is required. If the fair value estimate is less than the carrying value, goodwill is considered impaired for the amount by which the carrying amount exceeds the reporting unit&#x2019;s fair value and a charge is reported in goodwill impairment on our consolidated statements of operations and comprehensive income (loss). See Note 9 for additional discussion regarding the goodwill impairment tests conducted during 2021 and 2020.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy>
    <us-gaap:NumberOfReportingUnits
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY180My9mcmFnOjhjZDBhN2Q5ZmU1ODQzNGVhNWQ3MTc3MzZhMGMxODYzL3RleHRyZWdpb246OGNkMGE3ZDlmZTU4NDM0ZWE1ZDcxNzczNmEwYzE4NjNfNzc1Mw_21a581a1-062c-49e4-a54c-34b0c2943d10"
      unitRef="reportingunit">3</us-gaap:NumberOfReportingUnits>
    <us-gaap:IntangibleAssetsFiniteLivedPolicy
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY180My9mcmFnOjhjZDBhN2Q5ZmU1ODQzNGVhNWQ3MTc3MzZhMGMxODYzL3RleHRyZWdpb246OGNkMGE3ZDlmZTU4NDM0ZWE1ZDcxNzczNmEwYzE4NjNfMTU0MjU_d3b80b2d-8422-4a4e-8704-45c764e61705">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Intangible Assets, Net &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Identified intangible assets are recorded at their estimated fair values at the date of acquisition and are amortized over their respective estimated useful lives using a method of amortization that reflects the pattern in which the economic benefits of the intangible assets are used. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following summarizes the estimated useful lives by asset classification:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:438.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:97.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate trade name&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10 - 20 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10 - 25 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provider network contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4 - 5 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets are reviewed for impairment if circumstances indicate the Company may not be able to recover the asset&#x2019;s carrying value. The Company evaluates recoverability by determining whether the undiscounted cash flows expected to result from the use and eventual disposition of that asset or group exceed the carrying value at the evaluation date. If the undiscounted cash flows are not sufficient to cover the carrying value, the Company measures an impairment loss as the excess of the carrying amount of the long-lived asset or group over its fair value. See Note 9 for additional discussion regarding our intangible assets.&lt;/span&gt;&lt;/div&gt;</us-gaap:IntangibleAssetsFiniteLivedPolicy>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY180My9mcmFnOjhjZDBhN2Q5ZmU1ODQzNGVhNWQ3MTc3MzZhMGMxODYzL3RleHRyZWdpb246OGNkMGE3ZDlmZTU4NDM0ZWE1ZDcxNzczNmEwYzE4NjNfMTU0NTQ_f74689fc-80ed-4d58-be88-2938d12e6063">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following summarizes the estimated useful lives by asset classification:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:438.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:97.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate trade name&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10 - 20 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10 - 25 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provider network contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4 - 5 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Details of our intangible assets (in thousands, except weighted-average useful lives) as of June&#160;30, 2021 and December&#160;31, 2020  are presented below:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:72.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:54.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:63.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:46.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:54.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:63.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:45.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:44pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted- Average Remaining Useful Life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted- Average Remaining Useful Life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate trade name&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,961&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,029&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;278,519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,894&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;213,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;278,519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,716&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;220,803&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Below market lease, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:35pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provider network contracts &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:35pt"&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;399,906&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;147,861&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;252,045&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;398,034&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;133,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;264,992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Amounts exclude $2.2&#160;million and $0.9&#160;million of customer relationships and provider network contracts, respectively, net of accumulated amortization, with weighted average remaining useful lives of 15 years and 10 months reclassified to discontinued operations as of December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i83f72281c0b7415ea503edc371882a4f_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY180My9mcmFnOjhjZDBhN2Q5ZmU1ODQzNGVhNWQ3MTc3MzZhMGMxODYzL3RhYmxlOjRkZDhkMjhiZjk0MzRkNzY5N2RjNzdkMGY5MmViNjU2L3RhYmxlcmFuZ2U6NGRkOGQyOGJmOTQzNGQ3Njk3ZGM3N2QwZjkyZWI2NTZfMC0xLTEtMS0wL3RleHRyZWdpb246ZGQyMzBjZGU3ODJlNDVjYTg4YjQyM2E3MGIyZGMzMDhfNA_d6fa3db3-005c-4de0-b747-43f5332f5ce8">P10Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i9adc1f85abe84fe7ad21ea3765dc9836_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY180My9mcmFnOjhjZDBhN2Q5ZmU1ODQzNGVhNWQ3MTc3MzZhMGMxODYzL3RhYmxlOjRkZDhkMjhiZjk0MzRkNzY5N2RjNzdkMGY5MmViNjU2L3RhYmxlcmFuZ2U6NGRkOGQyOGJmOTQzNGQ3Njk3ZGM3N2QwZjkyZWI2NTZfMC0xLTEtMS0wL3RleHRyZWdpb246ZGQyMzBjZGU3ODJlNDVjYTg4YjQyM2E3MGIyZGMzMDhfOQ_2e49eb06-2d82-4bc3-81dc-21ec16b36e3f">P20Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i0de7bb52dc554f47ba2d09f4fb6ee9a6_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY180My9mcmFnOjhjZDBhN2Q5ZmU1ODQzNGVhNWQ3MTc3MzZhMGMxODYzL3RhYmxlOjRkZDhkMjhiZjk0MzRkNzY5N2RjNzdkMGY5MmViNjU2L3RhYmxlcmFuZ2U6NGRkOGQyOGJmOTQzNGQ3Njk3ZGM3N2QwZjkyZWI2NTZfMS0xLTEtMS0wL3RleHRyZWdpb246MjgwMTY1NGZiOWM3NGFjODk0YzQ2ZjBiZTVhNDRiNmJfNA_ba698616-f79f-4e4f-9001-6d8c99982f39">P10Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i2c645dae132a46319fcf7e651dc2048b_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY180My9mcmFnOjhjZDBhN2Q5ZmU1ODQzNGVhNWQ3MTc3MzZhMGMxODYzL3RhYmxlOjRkZDhkMjhiZjk0MzRkNzY5N2RjNzdkMGY5MmViNjU2L3RhYmxlcmFuZ2U6NGRkOGQyOGJmOTQzNGQ3Njk3ZGM3N2QwZjkyZWI2NTZfMS0xLTEtMS0wL3RleHRyZWdpb246MjgwMTY1NGZiOWM3NGFjODk0YzQ2ZjBiZTVhNDRiNmJfOQ_cf4da792-debc-4253-a709-4583806ec7eb">P25Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i78747c549a50444ab43a62d1064b465a_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY180My9mcmFnOjhjZDBhN2Q5ZmU1ODQzNGVhNWQ3MTc3MzZhMGMxODYzL3RhYmxlOjRkZDhkMjhiZjk0MzRkNzY5N2RjNzdkMGY5MmViNjU2L3RhYmxlcmFuZ2U6NGRkOGQyOGJmOTQzNGQ3Njk3ZGM3N2QwZjkyZWI2NTZfMi0xLTEtMS0w_8ad8e368-526c-44a9-b370-79ae8f7f02bc">P5Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="ib784c8c0f9134bf48331872daaad6c4e_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY180My9mcmFnOjhjZDBhN2Q5ZmU1ODQzNGVhNWQ3MTc3MzZhMGMxODYzL3RhYmxlOjRkZDhkMjhiZjk0MzRkNzY5N2RjNzdkMGY5MmViNjU2L3RhYmxlcmFuZ2U6NGRkOGQyOGJmOTQzNGQ3Njk3ZGM3N2QwZjkyZWI2NTZfMy0xLTEtMS0wL3RleHRyZWdpb246YTQ0ZDEzY2E4MWI4NDY1OGFkOTMxYjdhZjE4MDFmZGZfNA_a551cae5-a60e-46e1-b3de-90e0633fd63a">P4Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="ic82528f4a4554d6798f39cdf656b0d5f_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY180My9mcmFnOjhjZDBhN2Q5ZmU1ODQzNGVhNWQ3MTc3MzZhMGMxODYzL3RhYmxlOjRkZDhkMjhiZjk0MzRkNzY5N2RjNzdkMGY5MmViNjU2L3RhYmxlcmFuZ2U6NGRkOGQyOGJmOTQzNGQ3Njk3ZGM3N2QwZjkyZWI2NTZfMy0xLTEtMS0wL3RleHRyZWdpb246YTQ0ZDEzY2E4MWI4NDY1OGFkOTMxYjdhZjE4MDFmZGZfOQ_24d188b2-8376-4205-96e0-3e17d5b12f85">P5Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:LiabilityReserveEstimatePolicy
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY180My9mcmFnOjhjZDBhN2Q5ZmU1ODQzNGVhNWQ3MTc3MzZhMGMxODYzL3RleHRyZWdpb246OGNkMGE3ZDlmZTU4NDM0ZWE1ZDcxNzczNmEwYzE4NjNfMTU0Njg_ec0e0ad2-afec-445a-bdfc-eee3ba780b56">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Reserves for Claims and Performance-based Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Reserves for performance-based arrangements and claims reflect estimates of payments under performance-based arrangements and the ultimate cost of claims that have been incurred but not reported, including expected development on reported claims, those that have been reported but not yet paid (reported claims in process), and other medical care expenses and services payable that are primarily composed of accruals for incentives and other amounts payable to health care professionals and facilities. The Company uses actuarial principles and assumptions that are consistently applied in each reporting period and recognizes the actuarial best estimate of the ultimate liability along with a margin for adverse deviation. This approach is consistent with actuarial standards of practice that the liabilities be adequate under moderately adverse conditions. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The process of estimating reserves involves a considerable degree of judgment by the Company and, as of any given date, is inherently uncertain. The methods for making such estimates and for establishing the resulting liability are continually reviewed, and adjustments are reflected in current results of operations in the period in which they are identified as experience develops or new information becomes known. See Note 22 for additional discussion regarding our reserves for claims and performance-based arrangements.&lt;/span&gt;&lt;/div&gt;</us-gaap:LiabilityReserveEstimatePolicy>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY180My9mcmFnOjhjZDBhN2Q5ZmU1ODQzNGVhNWQ3MTc3MzZhMGMxODYzL3RleHRyZWdpb246OGNkMGE3ZDlmZTU4NDM0ZWE1ZDcxNzczNmEwYzE4NjNfMTU0Mjg_61eb8170-fc49-4eb5-9953-85d0ec3abcbb">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company enters into various office space, data center, and equipment lease agreements in conducting its normal business operations. At the inception of any contract, the Company evaluates the agreement to determine whether the contract contains a lease. If the contract contains a lease, the Company then evaluates the term and whether the lease is an operating or finance lease. Most leases include one or more options to renew or may have a termination option. The Company determines whether these options are reasonably certain to be exercised at the inception of the lease. The rent expense is recognized on a straight-line basis in the consolidated statements of operations and comprehensive income (loss) over the terms of the respective leases. Leases with an initial term of 12 months or less are not recorded on the consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. We use the implicit rate when readily determinable. Further, the Company treats all lease and non-lease components as a single combined lease component for all classes of underlying assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also enters into sublease agreements for some of its leased office space. Rental income attributable to subleases is immaterial and is offset against rent expense over the terms of the respective leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Refer to Note 12 for additional lease disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY180My9mcmFnOjhjZDBhN2Q5ZmU1ODQzNGVhNWQ3MTc3MzZhMGMxODYzL3RleHRyZWdpb246OGNkMGE3ZDlmZTU4NDM0ZWE1ZDcxNzczNmEwYzE4NjNfMTU0Mzk_c612aed0-5314-4ebe-84ee-7d2b5ab40ea9">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We derive revenue from two sources: (1) transformation services and (2) platform and operations services. Transformation services consist of implementation services whereby we assist the customer in launching its population health or health plan programs, or implement certain platform and operations services. In certain cases, transformation services can also include revenue associated with our support of certain one-time wind-down activities for clients who are exiting a line of business or population. Platform and operations services generally include multi-year arrangements with customers to provide various population health, health plan operations, specialty care management and claims processing services on an ongoing basis, as well as transition or run-out services to customers receiving primarily TPA services. Revenue is recognized when control of the services is transferred to our customers.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We use the following 5-step model, outlined in Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASC 606&#x201d;), to determine revenue recognition from our contracts with customers:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt; Identify the contract(s) with a customer&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt; Identify the performance obligations in the contract&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt; Determine the transaction price&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt; Allocate the transaction price to performance obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt; Recognize revenue when (or as) the entity satisfies a performance obligation&lt;/span&gt;&lt;/div&gt;See Note 6 for further discussion of our policies related to revenue recognition.</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY180My9mcmFnOjhjZDBhN2Q5ZmU1ODQzNGVhNWQ3MTc3MzZhMGMxODYzL3RleHRyZWdpb246OGNkMGE3ZDlmZTU4NDM0ZWE1ZDcxNzczNmEwYzE4NjNfMTU0MTc_b6ffd520-0402-4457-9db3-874d581a123f">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Foreign Currency&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company formed a subsidiary in India during the first quarter of 2018. The functional currency of our international subsidiary is the Indian Rupee. We translate the financial statements of this subsidiary to U.S. dollars using month-end rates of exchange for assets and liabilities, and monthly average rates of exchange for revenue and expenses. Translation gains and losses are recorded in accumulated other comprehensive income (loss) as a component of shareholders' equity. Foreign currency translation gains and losses did not have a material impact on our consolidated statements of operations and comprehensive income (loss) for the three and six months ended June 30, 2021 and 2020.&lt;/span&gt;&lt;/div&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY180Ni9mcmFnOjFlZjc0Mjc4OGM3NjQ2NzQ5MGQwNWNhZWM5MzAwYjhkL3RleHRyZWdpb246MWVmNzQyNzg4Yzc2NDY3NDkwZDA1Y2FlYzkzMDBiOGRfMzI0OQ_9ce9af63-f12f-4bcf-9683-9bd6c64a84fb">Recently Issued Accounting Standards&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Adoption of New Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the FASB issued ASU 2016-13, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and subsequently issued additional guidance that modified ASU 2016-13. The standard requires an entity to change its accounting approach for measuring and recognizing credit losses on certain financial assets measured at amortized cost, including trade receivables, certain non-trade receivables, contract assets, held-to-maturity securities, customer advances and certain off-balance sheet credit exposures, by replacing the existing &#x201c;incurred loss&#x201d; framework with an expected credit loss recognition model.&#160; The new standard results in earlier recognition of credit losses based on past events, current conditions, and reasonable and supportable forecasts.&#160; The standard is effective for entities with fiscal years beginning after December 15, 2019, including interim periods within such fiscal years. We adopted the requirements of this standard effective January 1, 2020 using the modified retrospective approach and recorded a cumulative effect adjustment of $3.0 million to January 1, 2020 retained earnings (accumulated deficit). Results for reporting periods beginning January 1, 2020 reflect the adoption of &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY180Ni9mcmFnOjFlZjc0Mjc4OGM3NjQ2NzQ5MGQwNWNhZWM5MzAwYjhkL3RleHRyZWdpb246MWVmNzQyNzg4Yzc2NDY3NDkwZDA1Y2FlYzkzMDBiOGRfMzI1Ng_e7fbd1cf-8213-4b7f-af71-67ed1c89dbd2"&gt;ASU 2016-13&lt;/span&gt;, while prior period amounts were not adjusted and continue to be reported in accordance with our historical accounting practices. In our previous accounting policy for trade receivables and non-trade receivables, we maintained an allowance for doubtful accounts based solely on specific identification. Under the new accounting standard, we maintain our specific identification process but utilize several factors to develop historical losses reserves, including aging schedules, customer creditworthiness, and historical payment experience, which are then adjusted for current conditions and reasonable and supportable forecasts in measurement of the allowance.&#160; In addition, for customer advances and certain off-balance sheet credit exposures, we evaluate the allowance through a discounted cash flow approach.&#160; For held-to-maturity investment securities, we evaluate (i) historical information adjusted for current conditions and reasonable and supportable forecasts and (ii) qualitative factors to determine whether the zero-loss expectation exception applies. Refer to Note 7 for additional disclosures related to current expected credit losses.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, the FASB issued ASU No. 2019-12, Simplifying the Accounting for Income Taxes. The amendments in the ASU remove certain exceptions to the intraperiod tax allocation of losses and gains from different financial statement components and to the method of recognizing income taxes on interim period losses, and the recognition of deferred tax liabilities for outside basis differences. In addition, the new guidance simplifies aspects of the accounting for franchise taxes and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. The Company adopted this standard starting in the first quarter of 2021, which did not have a material impact on our consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY180Ni9mcmFnOjFlZjc0Mjc4OGM3NjQ2NzQ5MGQwNWNhZWM5MzAwYjhkL3RleHRyZWdpb246MWVmNzQyNzg4Yzc2NDY3NDkwZDA1Y2FlYzkzMDBiOGRfMzI2MQ_d132d076-e51e-4b52-abae-5297229cc5bd">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Adoption of New Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the FASB issued ASU 2016-13, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and subsequently issued additional guidance that modified ASU 2016-13. The standard requires an entity to change its accounting approach for measuring and recognizing credit losses on certain financial assets measured at amortized cost, including trade receivables, certain non-trade receivables, contract assets, held-to-maturity securities, customer advances and certain off-balance sheet credit exposures, by replacing the existing &#x201c;incurred loss&#x201d; framework with an expected credit loss recognition model.&#160; The new standard results in earlier recognition of credit losses based on past events, current conditions, and reasonable and supportable forecasts.&#160; The standard is effective for entities with fiscal years beginning after December 15, 2019, including interim periods within such fiscal years. We adopted the requirements of this standard effective January 1, 2020 using the modified retrospective approach and recorded a cumulative effect adjustment of $3.0 million to January 1, 2020 retained earnings (accumulated deficit). Results for reporting periods beginning January 1, 2020 reflect the adoption of &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY180Ni9mcmFnOjFlZjc0Mjc4OGM3NjQ2NzQ5MGQwNWNhZWM5MzAwYjhkL3RleHRyZWdpb246MWVmNzQyNzg4Yzc2NDY3NDkwZDA1Y2FlYzkzMDBiOGRfMzI1Ng_e7fbd1cf-8213-4b7f-af71-67ed1c89dbd2"&gt;ASU 2016-13&lt;/span&gt;, while prior period amounts were not adjusted and continue to be reported in accordance with our historical accounting practices. In our previous accounting policy for trade receivables and non-trade receivables, we maintained an allowance for doubtful accounts based solely on specific identification. Under the new accounting standard, we maintain our specific identification process but utilize several factors to develop historical losses reserves, including aging schedules, customer creditworthiness, and historical payment experience, which are then adjusted for current conditions and reasonable and supportable forecasts in measurement of the allowance.&#160; In addition, for customer advances and certain off-balance sheet credit exposures, we evaluate the allowance through a discounted cash flow approach.&#160; For held-to-maturity investment securities, we evaluate (i) historical information adjusted for current conditions and reasonable and supportable forecasts and (ii) qualitative factors to determine whether the zero-loss expectation exception applies. Refer to Note 7 for additional disclosures related to current expected credit losses.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, the FASB issued ASU No. 2019-12, Simplifying the Accounting for Income Taxes. The amendments in the ASU remove certain exceptions to the intraperiod tax allocation of losses and gains from different financial statement components and to the method of recognizing income taxes on interim period losses, and the recognition of deferred tax liabilities for outside basis differences. In addition, the new guidance simplifies aspects of the accounting for franchise taxes and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. The Company adopted this standard starting in the first quarter of 2021, which did not have a material impact on our consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i06c25faea1e7483786ebe928e1ff0fa4_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY180Ni9mcmFnOjFlZjc0Mjc4OGM3NjQ2NzQ5MGQwNWNhZWM5MzAwYjhkL3RleHRyZWdpb246MWVmNzQyNzg4Yzc2NDY3NDkwZDA1Y2FlYzkzMDBiOGRfMTIwMQ_f9d896ee-6771-4437-afaa-7a0955f58260"
      unitRef="usd">-3000000.0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181Mi9mcmFnOmVjNzkwNDg1ZjE3YTQ2NDE4NWMxM2VhODY3NjkwNWNmL3RleHRyZWdpb246ZWM3OTA0ODVmMTdhNDY0MTg1YzEzZWE4Njc2OTA1Y2ZfNjI5NQ_051aaade-01eb-4ffd-949c-6d5451ada8b0">Transactions&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Passport&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 28, 2019, UHC, Passport Health Solutions, LLC (&#x201c;PHS I&#x201d;), the Company and EVH Passport entered into an Asset Purchase Agreement (the &#x201c;Passport APA&#x201d;), which provided for the sale of substantially all of the assets of UHC and PHS I, including UHC&#x2019;s Kentucky Medicaid contract (the &#x201c;Passport Medicaid Contract&#x201d;), to EVH Passport for a purchase price of $70.0 million in cash and the issuance of a 30% interest in EVH Passport (the &#x201c;Passport Purchase Price&#x201d;) to The University of Louisville, the University of Louisville Physicians, University Medical Center, the Jewish Heritage Fund for Excellence, Norton Healthcare, Inc. and the Louisville/Jefferson County Primary Care Association (collectively, the &#x201c;Sponsors&#x201d;). &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 18, 2019, the Company contributed $40.0 million to UHC in the form of an advance for regulatory capital requirements under an agreement with UHC (the &#x201c;Passport Note&#x201d;). The Passport Note carried a fixed interest rate of 6.5% per annum.  Additionally, on June 6, 2019, the Company and UHC entered into an Indemnity Agreement (the &#x201c;Indemnity Agreement&#x201d;), with an insurance company (the &#x201c;Surety&#x201d;). The Surety issued a performance bond in the amount of $25.0 million to secure UHC&#x2019;s performance under its Medicaid Contract. Pursuant to the Indemnity Agreement, the Company and UHC were jointly and severally liable to the Surety in the maximum amount of the bond, plus certain costs of the Surety, in the event of losses arising under the bond. The bond&#x2019;s original expiry date was June 30, 2020 and during the three months ended June 30, 2020, was extended to December 31, 2020. The bond was released in October 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 30, 2019, UHC, PHS I, the Company and EVH Passport consummated the transactions contemplated by the Passport APA (the &#x201c;Passport Closing&#x201d;).  At the Passport Closing, $16.2 million of the cash Passport Purchase Price was held back until such time as PHS I delivers to EVH Passport certain owned real property and improvements free and clear of all encumbrances. In addition, at the Passport Closing, EVH Passport and UHC entered into an agreement that provided for the administration and assumption of the financial risks by EVH Passport of UHC&#x2019;s dual eligible special needs business (the &#x201c;DNP Business&#x201d;) until such time as EVH Passport became certified as a Medicare Advantage Organization and the D-SNP Business could be transferred to EVH Passport.  On October 1, 2020, the D-SNP Business was transferred from UHC to EVH Passport.  At the Passport Closing, EVH Passport assumed UHC&#x2019;s obligations under the Passport Note and the Indemnity Agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 16, 2020, EVH Passport, Evolent Health LLC and Molina Healthcare, Inc. (&#x201c;Molina&#x201d;) entered into an Asset Purchase Agreement (the &#x201c;Molina APA&#x201d;), which contemplated the sale by EVH Passport to Molina of certain assets, including certain intellectual property rights of EVH Passport and EVH Passport&#x2019;s rights under the Passport Medicaid Contract.  On September 1, 2020, EVH Passport and Molina consummated the transactions contemplated by the Molina APA (the &#x201c;Molina Closing&#x201d;), and the Passport Medicaid Contract was novated to Molina.  As a result, EVH Passport began to wind down its business.  In connection with the Molina Closing, Molina deposited $20.0&#160;million in cash in escrow, which was subsequently released to EVH Passport in January 2021.  In addition, at the Molina Closing, Molina and EVH Passport entered into an agreement that provided for the assumption of the financial risks by Molina of the D-SNP Business until such time as Molina&#x2019;s Kentucky health plan becomes certified as a Medicare Advantage Organization and the D-SNP Business is transferred Molina.  The Company and EVH Passport continued to administer the D-SNP Business until January 1, 2021, at which time Molina became responsible for its administration until the D-SNP Business is officially transferred to Molina effective September 1, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to the Molina Closing, the Company accounted for its investment in EVH Passport as an unconsolidated variable interest entity under the equity method of accounting.  As a result of the transaction, the Company concluded that a reconsideration event occurred whereby EVH Passport was determined to be a voting interest entity and that Evolent had a controlling financial interest in EVH Passport; accordingly, the Company consolidated EVH Passport as of September 1, 2020 in its consolidated financial statements. The Company accounted for the transaction as an asset acquisition, as the Company concluded that assets acquired as a result of the consolidation did not meet the criteria to be classified as a business under GAAP.  Following the Molina Closing and consolidation of EVH Passport in the Company&#x2019;s consolidated financials, on November 16, 2020, EVH Passport redeemed the Sponsors&#x2019; equity interests in EVH Passport for $20.0&#160;million in cash in accordance with the terms of EVH Passport&#x2019;s Stockholders&#x2019; Agreement, and, as a result, EVH Passport became a wholly owned subsidiary of the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of the consolidation, the Company recorded assets primarily consisting of cash and cash equivalents and restricted cash and cash equivalents of $159.8&#160;million, available for sale securities of $88.6&#160;million, receivables related to unsettled sales of securities of $43.0&#160;million and other assets of $50.2&#160;million and total liabilities primarily comprised of reserve for claims and performance-based arrangements of $164.8&#160;million and accrued liabilities of $50.0&#160;million. Subsequent to winddown activities, any remaining capital will be distributed to the Company subject to regulatory approval from the Kentucky Department of Insurance.  In addition, the Passport Note was eliminated upon consolidation, and as of December 31, 2020, the outstanding principal balance of the $40.0&#160;million Passport Note was repaid in full by EVH Passport including approximately $3.6&#160;million of accrued interest.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;During the first quarter of 2021, pursuant to the terms of the Molina APA, EVH Passport received a cash payment from Molina in the amount of $23.0&#160;million based on the number of enrollees above a certain threshold in the D-SNP Business and Molina's Medicaid plan following the open enrollment period for plan year 2021. The foregoing amount represents 50% of the payment that EVH Passport is eligible to receive pursuant to the terms of the Molina APA based on the number of such enrollees. The remaining 50% will be payable in the first quarter of 2022 subject to the satisfaction of certain contingencies.&lt;/span&gt;&lt;/div&gt;Repositioning and Other Changes&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We continually assess opportunities to improve operational effectiveness and efficiency to better align our expenses with revenues, while continuing to make investments in our solutions, systems and people that we believe are important to our long-term goals. Across 2020, we divested or agreed to divest a majority of our health plan assets, including certain assets of EVH Passport, which represented a significant revenue stream for the Company. In parallel with these divestitures, we contracted with a third-party vendor to review our operating model and organizational design in order to improve our profitability, create value through our solutions and invest in strategic opportunities in future periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the fourth quarter of 2020, we committed to certain operational efficiency and profitability actions that we are taking in order to accomplish these objectives (&#x201c;Repositioning Plan&#x201d;). These actions included making organizational changes across our business as well as other profitability initiatives expected to result in reductions in force, re-aligning of resources as well as other potential operational efficiency and cost-reduction initiatives. The Repositioning Plan is expected to continue through the fourth quarter of 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded approximately $0.7&#160;million and $6.0&#160;million of repositioning costs in selling, general and administrative expenses for the three and six months ended June 30, 2021&#160;in connection with the Repositioning Plan. The following table provides a summary of our total costs associated with the Repositioning Plan for the three and six months ended June 30, 2021, by major type of cost (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.305%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:27.431%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.499%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.305%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.359%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.305%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.359%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.039%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.359%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.044%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Incurred For the Three Months Ended &lt;br/&gt;June  30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Incurred for the Six Months Ended June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total Amount Expected to be Incurred in the Repositioning Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cumulative Amount Incurred through June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Severance and termination benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Office space consolidation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Professional services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,062&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,043&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="i36e8c4f14af843a5a8e48ca6d9a5c6ec_D20190528-20190528"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181Mi9mcmFnOmVjNzkwNDg1ZjE3YTQ2NDE4NWMxM2VhODY3NjkwNWNmL3RleHRyZWdpb246ZWM3OTA0ODVmMTdhNDY0MTg1YzEzZWE4Njc2OTA1Y2ZfMzk0_c6b0b006-680e-495b-aa34-01bda9ecb8c5"
      unitRef="usd">70000000.0</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:VariableInterestEntityOwnershipPercentage
      contextRef="i36e8c4f14af843a5a8e48ca6d9a5c6ec_D20190528-20190528"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181Mi9mcmFnOmVjNzkwNDg1ZjE3YTQ2NDE4NWMxM2VhODY3NjkwNWNmL3RleHRyZWdpb246ZWM3OTA0ODVmMTdhNDY0MTg1YzEzZWE4Njc2OTA1Y2ZfNDI3_0d650ff0-b951-4f21-8a3b-2a18230eadc9"
      unitRef="number">0.30</us-gaap:VariableInterestEntityOwnershipPercentage>
    <us-gaap:NotesReceivableNet
      contextRef="i385b3b1c295f40a88f415a7f30d89c2d_I20190618"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181Mi9mcmFnOmVjNzkwNDg1ZjE3YTQ2NDE4NWMxM2VhODY3NjkwNWNmL3RleHRyZWdpb246ZWM3OTA0ODVmMTdhNDY0MTg1YzEzZWE4Njc2OTA1Y2ZfNzkw_b6002f93-27c1-4375-8104-04df5a8712a7"
      unitRef="usd">40000000.0</us-gaap:NotesReceivableNet>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i50427d2cf6854298bdb63c98b9dc7ee7_I20190618"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181Mi9mcmFnOmVjNzkwNDg1ZjE3YTQ2NDE4NWMxM2VhODY3NjkwNWNmL3RleHRyZWdpb246ZWM3OTA0ODVmMTdhNDY0MTg1YzEzZWE4Njc2OTA1Y2ZfOTY0_570e1a9f-48dc-416c-b265-48ae51a09b6f"
      unitRef="number">0.065</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:VariableInterestEntityFinancialOrOtherSupportAmount
      contextRef="id6b6803c601248c48c645fade86aee32_D20190606-20190606"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181Mi9mcmFnOmVjNzkwNDg1ZjE3YTQ2NDE4NWMxM2VhODY3NjkwNWNmL3RleHRyZWdpb246ZWM3OTA0ODVmMTdhNDY0MTg1YzEzZWE4Njc2OTA1Y2ZfMTE5MQ_2db16cd0-ae92-40de-827a-d8984c70b899"
      unitRef="usd">25000000.0</us-gaap:VariableInterestEntityFinancialOrOtherSupportAmount>
    <evh:PaymentsToAcquireEquityMethodInvestmentsAmountHeldBack
      contextRef="i267001cededb4bfdb4aa09441f453c34_I20191230"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181Mi9mcmFnOmVjNzkwNDg1ZjE3YTQ2NDE4NWMxM2VhODY3NjkwNWNmL3RleHRyZWdpb246ZWM3OTA0ODVmMTdhNDY0MTg1YzEzZWE4Njc2OTA1Y2ZfMTgyNA_21685102-fc61-4ab0-922a-a4ed5b6876d8"
      unitRef="usd">16200000</evh:PaymentsToAcquireEquityMethodInvestmentsAmountHeldBack>
    <evh:CashReleasedFromEscrow
      contextRef="ib8509d7b0e554612806781c71b9e4ddf_D20210101-20210131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181Mi9mcmFnOmVjNzkwNDg1ZjE3YTQ2NDE4NWMxM2VhODY3NjkwNWNmL3RleHRyZWdpb246ZWM3OTA0ODVmMTdhNDY0MTg1YzEzZWE4Njc2OTA1Y2ZfMzI1Nw_4ebb7466-4d71-4b23-a22e-08c363449cbe"
      unitRef="usd">20000000.0</evh:CashReleasedFromEscrow>
    <evh:AssetPurchaseAgreementEscrowPayments
      contextRef="i69350541fafc4d14a84c72aba152a863_D20200901-20200901"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181Mi9mcmFnOmVjNzkwNDg1ZjE3YTQ2NDE4NWMxM2VhODY3NjkwNWNmL3RleHRyZWdpb246ZWM3OTA0ODVmMTdhNDY0MTg1YzEzZWE4Njc2OTA1Y2ZfMzI1Nw_88b7b98a-8489-4202-a3f5-90af8585725e"
      unitRef="usd">20000000.0</evh:AssetPurchaseAgreementEscrowPayments>
    <us-gaap:PaymentsToMinorityShareholders
      contextRef="i7a8609d202734bc89b28f90cabe48547_D20201116-20201116"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181Mi9mcmFnOmVjNzkwNDg1ZjE3YTQ2NDE4NWMxM2VhODY3NjkwNWNmL3RleHRyZWdpb246ZWM3OTA0ODVmMTdhNDY0MTg1YzEzZWE4Njc2OTA1Y2ZfNDgyNg_07cc2bc0-c706-4866-8260-2218cccf5ff9"
      unitRef="usd">20000000.0</us-gaap:PaymentsToMinorityShareholders>
    <evh:AssetAcquisitionCashAndEquivalents
      contextRef="ifee88f44d6c647d095b28edecae13e93_D20200901-20200901"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181Mi9mcmFnOmVjNzkwNDg1ZjE3YTQ2NDE4NWMxM2VhODY3NjkwNWNmL3RleHRyZWdpb246ZWM3OTA0ODVmMTdhNDY0MTg1YzEzZWE4Njc2OTA1Y2ZfNTE0Mg_0c989b19-5395-48b2-9c22-4a41199e0fdb"
      unitRef="usd">159800000</evh:AssetAcquisitionCashAndEquivalents>
    <evh:AssetAcquisitionDebtSecuritiesAvailableForSale
      contextRef="ifee88f44d6c647d095b28edecae13e93_D20200901-20200901"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181Mi9mcmFnOmVjNzkwNDg1ZjE3YTQ2NDE4NWMxM2VhODY3NjkwNWNmL3RleHRyZWdpb246ZWM3OTA0ODVmMTdhNDY0MTg1YzEzZWE4Njc2OTA1Y2ZfNTE3OQ_78a284e2-0739-48f4-9ca6-a338b96efced"
      unitRef="usd">88600000</evh:AssetAcquisitionDebtSecuritiesAvailableForSale>
    <evh:AssetAcquisitionDebtSecuritiesAvailableForSaleUnsettledSalesReceivables
      contextRef="ifee88f44d6c647d095b28edecae13e93_D20200901-20200901"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181Mi9mcmFnOmVjNzkwNDg1ZjE3YTQ2NDE4NWMxM2VhODY3NjkwNWNmL3RleHRyZWdpb246ZWM3OTA0ODVmMTdhNDY0MTg1YzEzZWE4Njc2OTA1Y2ZfNTIzOQ_85e1f12b-086a-4fb8-9b7f-e5ad452b8797"
      unitRef="usd">43000000.0</evh:AssetAcquisitionDebtSecuritiesAvailableForSaleUnsettledSalesReceivables>
    <evh:AssetAcquisitionOtherAssets
      contextRef="ifee88f44d6c647d095b28edecae13e93_D20200901-20200901"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181Mi9mcmFnOmVjNzkwNDg1ZjE3YTQ2NDE4NWMxM2VhODY3NjkwNWNmL3RleHRyZWdpb246ZWM3OTA0ODVmMTdhNDY0MTg1YzEzZWE4Njc2OTA1Y2ZfNTI2Mg_f4c2d27f-b5be-4457-bba7-1853c5f27683"
      unitRef="usd">50200000</evh:AssetAcquisitionOtherAssets>
    <evh:AssetAcquisitionAccruedMedicalExpenses
      contextRef="ifee88f44d6c647d095b28edecae13e93_D20200901-20200901"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181Mi9mcmFnOmVjNzkwNDg1ZjE3YTQ2NDE4NWMxM2VhODY3NjkwNWNmL3RleHRyZWdpb246ZWM3OTA0ODVmMTdhNDY0MTg1YzEzZWE4Njc2OTA1Y2ZfNTM2Nw_49d2066d-856b-441d-b632-48ab9cf78e69"
      unitRef="usd">164800000</evh:AssetAcquisitionAccruedMedicalExpenses>
    <evh:AssetAcquisitionAccruedLiabilities
      contextRef="ifee88f44d6c647d095b28edecae13e93_D20200901-20200901"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181Mi9mcmFnOmVjNzkwNDg1ZjE3YTQ2NDE4NWMxM2VhODY3NjkwNWNmL3RleHRyZWdpb246ZWM3OTA0ODVmMTdhNDY0MTg1YzEzZWE4Njc2OTA1Y2ZfNTM5Nw_79436675-e037-4d82-b003-314989b1dc6a"
      unitRef="usd">50000000.0</evh:AssetAcquisitionAccruedLiabilities>
    <us-gaap:ProceedsFromCollectionOfNotesReceivable
      contextRef="ie9b33f26cab0425fb6895b18246f33f6_D20201231-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181Mi9mcmFnOmVjNzkwNDg1ZjE3YTQ2NDE4NWMxM2VhODY3NjkwNWNmL3RleHRyZWdpb246ZWM3OTA0ODVmMTdhNDY0MTg1YzEzZWE4Njc2OTA1Y2ZfNTcwNA_f1c35b0c-71da-44e0-8729-1d499d786fe7"
      unitRef="usd">40000000.0</us-gaap:ProceedsFromCollectionOfNotesReceivable>
    <us-gaap:ProceedsFromInterestReceived
      contextRef="ie9b33f26cab0425fb6895b18246f33f6_D20201231-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181Mi9mcmFnOmVjNzkwNDg1ZjE3YTQ2NDE4NWMxM2VhODY3NjkwNWNmL3RleHRyZWdpb246ZWM3OTA0ODVmMTdhNDY0MTg1YzEzZWE4Njc2OTA1Y2ZfNTc4MA_18df9bed-cd7e-4f82-b748-a52b72d309d7"
      unitRef="usd">3600000</us-gaap:ProceedsFromInterestReceived>
    <evh:ProceedsFromTransferOfMembership
      contextRef="i9d78efa027664adba423d2ecb8ab7e70_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181Mi9mcmFnOmVjNzkwNDg1ZjE3YTQ2NDE4NWMxM2VhODY3NjkwNWNmL3RleHRyZWdpb246ZWM3OTA0ODVmMTdhNDY0MTg1YzEzZWE4Njc2OTA1Y2ZfNTg4Mg_e23125dd-a179-4c0b-81e0-5e7479611317"
      unitRef="usd">23000000.0</evh:ProceedsFromTransferOfMembership>
    <evh:TransferOfMembershipPercentageOfPaymentBasedOnNumberOfEnrollees
      contextRef="i2c70b9d982894c0dbbc1a56623c7e3e7_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181Mi9mcmFnOmVjNzkwNDg1ZjE3YTQ2NDE4NWMxM2VhODY3NjkwNWNmL3RleHRyZWdpb246ZWM3OTA0ODVmMTdhNDY0MTg1YzEzZWE4Njc2OTA1Y2ZfNjA4Mg_d0641f70-32c3-4540-92eb-26b48661c610"
      unitRef="number">0.50</evh:TransferOfMembershipPercentageOfPaymentBasedOnNumberOfEnrollees>
    <evh:TransferOfMembershipPercentageOfPaymentSubjectToSatisfactionOfContingencies
      contextRef="i0e1ba7773771404e91600efd70f89820_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181Mi9mcmFnOmVjNzkwNDg1ZjE3YTQ2NDE4NWMxM2VhODY3NjkwNWNmL3RleHRyZWdpb246ZWM3OTA0ODVmMTdhNDY0MTg1YzEzZWE4Njc2OTA1Y2ZfNjE5NA_2de904cc-f72b-476f-ac58-4e9a755016b2"
      unitRef="number">0.50</evh:TransferOfMembershipPercentageOfPaymentSubjectToSatisfactionOfContingencies>
    <us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RleHRyZWdpb246YTc2MmYwMGIxMDk2NDgzZThhYWM3ZTBlNGY2ZDgzZjBfMjU2NA_e6eab143-bcf1-45ad-b0b5-a8052ea196a9">Discontinued Operations&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 11, 2021, Evolent Health LLC, EH Holdings and True Health, each wholly owned subsidiaries of the Company, entered into a Stock Purchase Agreement (the &#x201c;True Health SPA&#x201d;) with Bright Health Management, Inc. (&#x201c;Bright HealthCare&#x201d;), pursuant to which EH Holdings agreed to sell all of its equity interests in True Health to Bright HealthCare. Closing of the transactions contemplated by the True Health SPA occurred on March 31, 2021 (the &#x201c;True Health Closing&#x201d;) and the Company will have no continuing involvement with True Health subsequent to the closing except an existing services agreement for claims processing and other health plan administrative functions.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of the first quarter of 2021, the Company determined that True Health met the discontinued operations criteria under ASC 360, and as such, True Health assets and liabilities as of December 31, 2020, and the results of operations for all periods presented are classified as held for sale and are not included in continuing operations in the consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the results of operations of the Company&#x2019;s True Health business, which are included in loss from discontinued operations in the consolidated statements of operations the three and six months ended June 30, 2021 and 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.209%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Platform and operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Premiums&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,649&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of revenue (exclusive of depreciation and amortization expenses presented separately below) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,885&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Claims expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative expenses &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,639)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(930)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,049)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss before income taxes and non-controlling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,508)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(847)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,773)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Benefit for income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(326)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,508)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(521)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,773)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Cost of revenue includes intercompany expenses between the Company and True Health that are recorded in income from continuing operations on the consolidated statements of operations related an existing services agreement for claims processing and other health plan administrative functions of $3.2&#160;million for the three months ended June 30, 2020 and $2.8&#160;million and $6.3&#160;million for the six months ended June 30, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:1.12pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Selling, general and administrative expenses includes intercompany expenses between the Company and True Health that are recorded in income from continuing operations on the consolidated statements of operations related an existing services agreement for claims processing and other health plan administrative functions of  $1.0&#160;million of for the three months ended June 30, 2020 and $1.1 million and $4.1 million for the six months ended June 30, 2021 and 2020, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated statements of cash flows for all periods have not been adjusted to separately disclose cash flows related to discontinued operations. Cash flows related to the True Health business during the six months ended June 30, 2021 and 2020 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:79.733%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.207%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash flows provided by (used in) operating activities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash flows provided by (used in) investing activities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,494)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the current and long-term assets and liabilities of the discontinued True Health business in the consolidated balance sheets as of December&#160;31, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:82.927%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.873%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;ASSETS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash and restricted investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:82.927%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.873%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investments, at amortized cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,914&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash and restricted investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;616&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investments, at amortized cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,080&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,705&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54,293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;LIABILITIES&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation and employee benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reserve for claims and performance-based arrangements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,858&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Accounts payable exclude $1.5&#160;million between the Company and True Health related an existing services agreement for claims processing and other health plan administrative functions as of December 31, 2020.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock>
    <us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RleHRyZWdpb246YTc2MmYwMGIxMDk2NDgzZThhYWM3ZTBlNGY2ZDgzZjBfMjU2NQ_2705af32-4415-4762-93f5-32e6e0e2cf46">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the results of operations of the Company&#x2019;s True Health business, which are included in loss from discontinued operations in the consolidated statements of operations the three and six months ended June 30, 2021 and 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.209%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Platform and operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Premiums&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,649&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of revenue (exclusive of depreciation and amortization expenses presented separately below) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,885&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Claims expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative expenses &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,639)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(930)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,049)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss before income taxes and non-controlling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,508)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(847)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,773)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Benefit for income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(326)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,508)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(521)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,773)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Cost of revenue includes intercompany expenses between the Company and True Health that are recorded in income from continuing operations on the consolidated statements of operations related an existing services agreement for claims processing and other health plan administrative functions of $3.2&#160;million for the three months ended June 30, 2020 and $2.8&#160;million and $6.3&#160;million for the six months ended June 30, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:1.12pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Selling, general and administrative expenses includes intercompany expenses between the Company and True Health that are recorded in income from continuing operations on the consolidated statements of operations related an existing services agreement for claims processing and other health plan administrative functions of  $1.0&#160;million of for the three months ended June 30, 2020 and $1.1 million and $4.1 million for the six months ended June 30, 2021 and 2020, respectively. &lt;/span&gt;&lt;/div&gt;Cash flows related to the True Health business during the six months ended June 30, 2021 and 2020 were as follows:&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:79.733%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.207%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash flows provided by (used in) operating activities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash flows provided by (used in) investing activities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,494)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the current and long-term assets and liabilities of the discontinued True Health business in the consolidated balance sheets as of December&#160;31, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:82.927%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.873%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;ASSETS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash and restricted investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:82.927%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.873%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investments, at amortized cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,914&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash and restricted investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;616&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investments, at amortized cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,080&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,705&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54,293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;LIABILITIES&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation and employee benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reserve for claims and performance-based arrangements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,858&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Accounts payable exclude $1.5&#160;million between the Company and True Health related an existing services agreement for claims processing and other health plan administrative functions as of December 31, 2020.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="id529693310384660bff0d3d357adbec3_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOjFlMDNhMzNiMmY5MjRmODliYTc0NjdiNmY1ZGFiMjIwL3RhYmxlcmFuZ2U6MWUwM2EzM2IyZjkyNGY4OWJhNzQ2N2I2ZjVkYWIyMjBfMy0xLTEtMS0yNDk2_3502cac9-fce1-46da-a73d-24e49d073e6a"
      unitRef="usd">0</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="i5619f887d0d546cb8c2d5bbbb39a6d8f_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOjFlMDNhMzNiMmY5MjRmODliYTc0NjdiNmY1ZGFiMjIwL3RhYmxlcmFuZ2U6MWUwM2EzM2IyZjkyNGY4OWJhNzQ2N2I2ZjVkYWIyMjBfMy0zLTEtMS0yNDg4_bbcdec0f-f0e0-4488-818c-1617d770f64f"
      unitRef="usd">39000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="i10851d8c3fd6447eaa0063fff7f9ed51_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOjFlMDNhMzNiMmY5MjRmODliYTc0NjdiNmY1ZGFiMjIwL3RhYmxlcmFuZ2U6MWUwM2EzM2IyZjkyNGY4OWJhNzQ2N2I2ZjVkYWIyMjBfMy0xLTEtMS0w_48bf0559-b0a7-4aca-b01e-b76997129dd0"
      unitRef="usd">38000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="i95135618e68647b8a930d4657c43da75_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOjFlMDNhMzNiMmY5MjRmODliYTc0NjdiNmY1ZGFiMjIwL3RhYmxlcmFuZ2U6MWUwM2EzM2IyZjkyNGY4OWJhNzQ2N2I2ZjVkYWIyMjBfMy0zLTEtMS0w_e5d470b3-a691-4d12-8059-2bce677d4414"
      unitRef="usd">279000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="i7e57745d431e47bfa19e71a49e5fdf02_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOjFlMDNhMzNiMmY5MjRmODliYTc0NjdiNmY1ZGFiMjIwL3RhYmxlcmFuZ2U6MWUwM2EzM2IyZjkyNGY4OWJhNzQ2N2I2ZjVkYWIyMjBfNC0xLTEtMS0yNDk2_4a6cae34-8fd1-4377-a1b8-4e92da7a549e"
      unitRef="usd">0</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="ia3740e6e58c749fa97b9285685be7b1e_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOjFlMDNhMzNiMmY5MjRmODliYTc0NjdiNmY1ZGFiMjIwL3RhYmxlcmFuZ2U6MWUwM2EzM2IyZjkyNGY4OWJhNzQ2N2I2ZjVkYWIyMjBfNC0zLTEtMS0yNDg4_3df853f6-c1dc-4fe8-a4ed-5446e1cd3680"
      unitRef="usd">25502000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="i9034834f629c466cb0de8a2fd5acfc15_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOjFlMDNhMzNiMmY5MjRmODliYTc0NjdiNmY1ZGFiMjIwL3RhYmxlcmFuZ2U6MWUwM2EzM2IyZjkyNGY4OWJhNzQ2N2I2ZjVkYWIyMjBfNC0xLTEtMS0w_6bb00dae-b6ce-4697-a734-2dad709cfcc8"
      unitRef="usd">44795000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="i70101f6902e44f38a06effe5f98e83b6_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOjFlMDNhMzNiMmY5MjRmODliYTc0NjdiNmY1ZGFiMjIwL3RhYmxlcmFuZ2U6MWUwM2EzM2IyZjkyNGY4OWJhNzQ2N2I2ZjVkYWIyMjBfNC0zLTEtMS0w_e6406f8a-6507-41af-b323-ebed724acc7c"
      unitRef="usd">57649000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="i1869cd19e38f4a028448315845a440c5_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOjFlMDNhMzNiMmY5MjRmODliYTc0NjdiNmY1ZGFiMjIwL3RhYmxlcmFuZ2U6MWUwM2EzM2IyZjkyNGY4OWJhNzQ2N2I2ZjVkYWIyMjBfNS0xLTEtMS0yNDg4_55c420ba-e257-4ca7-8b36-419e6f0fbb7b"
      unitRef="usd">0</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="i1a6bb4acf8f64d4ea88262cf96a6ca67_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOjFlMDNhMzNiMmY5MjRmODliYTc0NjdiNmY1ZGFiMjIwL3RhYmxlcmFuZ2U6MWUwM2EzM2IyZjkyNGY4OWJhNzQ2N2I2ZjVkYWIyMjBfNS0zLTEtMS0yNDg4_1e922cf5-119c-452d-96c4-c445e669e580"
      unitRef="usd">25541000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="iae3e4f43e8c541128c572b22ebdd19bd_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOjFlMDNhMzNiMmY5MjRmODliYTc0NjdiNmY1ZGFiMjIwL3RhYmxlcmFuZ2U6MWUwM2EzM2IyZjkyNGY4OWJhNzQ2N2I2ZjVkYWIyMjBfNS0xLTEtMS0w_86cb88c1-652e-4913-9ff1-c4143d55bba3"
      unitRef="usd">44833000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="i6f626e482e054b34901a6c459f47f04b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOjFlMDNhMzNiMmY5MjRmODliYTc0NjdiNmY1ZGFiMjIwL3RhYmxlcmFuZ2U6MWUwM2EzM2IyZjkyNGY4OWJhNzQ2N2I2ZjVkYWIyMjBfNS0zLTEtMS0w_ff1c4350-449d-4717-94dc-604581ec15d9"
      unitRef="usd">57928000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold
      contextRef="i1869cd19e38f4a028448315845a440c5_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOjFlMDNhMzNiMmY5MjRmODliYTc0NjdiNmY1ZGFiMjIwL3RhYmxlcmFuZ2U6MWUwM2EzM2IyZjkyNGY4OWJhNzQ2N2I2ZjVkYWIyMjBfOC0xLTEtMS0yNDky_333777ce-ea37-4b4e-a0d6-6e8656883a62"
      unitRef="usd">0</us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold
      contextRef="i1a6bb4acf8f64d4ea88262cf96a6ca67_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOjFlMDNhMzNiMmY5MjRmODliYTc0NjdiNmY1ZGFiMjIwL3RhYmxlcmFuZ2U6MWUwM2EzM2IyZjkyNGY4OWJhNzQ2N2I2ZjVkYWIyMjBfOC0zLTEtMS0yNDky_c4b03d66-d88d-40f8-ba2b-1f54ad5f4550"
      unitRef="usd">4640000</us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold
      contextRef="iae3e4f43e8c541128c572b22ebdd19bd_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOjFlMDNhMzNiMmY5MjRmODliYTc0NjdiNmY1ZGFiMjIwL3RhYmxlcmFuZ2U6MWUwM2EzM2IyZjkyNGY4OWJhNzQ2N2I2ZjVkYWIyMjBfOC0xLTEtMS0w_48b6872e-59ba-4559-a38e-04c2095c1d0e"
      unitRef="usd">5885000</us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold
      contextRef="i6f626e482e054b34901a6c459f47f04b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOjFlMDNhMzNiMmY5MjRmODliYTc0NjdiNmY1ZGFiMjIwL3RhYmxlcmFuZ2U6MWUwM2EzM2IyZjkyNGY4OWJhNzQ2N2I2ZjVkYWIyMjBfOC0zLTEtMS0w_138a2d04-91ca-40b3-b945-5f216158b8dd"
      unitRef="usd">7935000</us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold>
    <evh:DisposalGroupIncludingDiscontinuedOperationClaimsExpense
      contextRef="i1869cd19e38f4a028448315845a440c5_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOjFlMDNhMzNiMmY5MjRmODliYTc0NjdiNmY1ZGFiMjIwL3RhYmxlcmFuZ2U6MWUwM2EzM2IyZjkyNGY4OWJhNzQ2N2I2ZjVkYWIyMjBfOS0xLTEtMS0yNDky_d7ddeb23-43cc-4ac3-8172-16166a3e86bc"
      unitRef="usd">0</evh:DisposalGroupIncludingDiscontinuedOperationClaimsExpense>
    <evh:DisposalGroupIncludingDiscontinuedOperationClaimsExpense
      contextRef="i1a6bb4acf8f64d4ea88262cf96a6ca67_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOjFlMDNhMzNiMmY5MjRmODliYTc0NjdiNmY1ZGFiMjIwL3RhYmxlcmFuZ2U6MWUwM2EzM2IyZjkyNGY4OWJhNzQ2N2I2ZjVkYWIyMjBfOS0zLTEtMS0yNDky_a0922cff-2979-4e78-88be-72add4e314e9"
      unitRef="usd">18144000</evh:DisposalGroupIncludingDiscontinuedOperationClaimsExpense>
    <evh:DisposalGroupIncludingDiscontinuedOperationClaimsExpense
      contextRef="iae3e4f43e8c541128c572b22ebdd19bd_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOjFlMDNhMzNiMmY5MjRmODliYTc0NjdiNmY1ZGFiMjIwL3RhYmxlcmFuZ2U6MWUwM2EzM2IyZjkyNGY4OWJhNzQ2N2I2ZjVkYWIyMjBfOS0xLTEtMS0w_44f9a7f1-3da7-4cd9-92d6-71278bbda936"
      unitRef="usd">33954000</evh:DisposalGroupIncludingDiscontinuedOperationClaimsExpense>
    <evh:DisposalGroupIncludingDiscontinuedOperationClaimsExpense
      contextRef="i6f626e482e054b34901a6c459f47f04b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOjFlMDNhMzNiMmY5MjRmODliYTc0NjdiNmY1ZGFiMjIwL3RhYmxlcmFuZ2U6MWUwM2EzM2IyZjkyNGY4OWJhNzQ2N2I2ZjVkYWIyMjBfOS0zLTEtMS0w_56decff0-0758-478f-87c6-aaa77036c818"
      unitRef="usd">41811000</evh:DisposalGroupIncludingDiscontinuedOperationClaimsExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense
      contextRef="i1869cd19e38f4a028448315845a440c5_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOjFlMDNhMzNiMmY5MjRmODliYTc0NjdiNmY1ZGFiMjIwL3RhYmxlcmFuZ2U6MWUwM2EzM2IyZjkyNGY4OWJhNzQ2N2I2ZjVkYWIyMjBfMTAtMS0xLTEtMjQ5Mg_6cb60382-1b05-40ad-a9f5-849d042ace46"
      unitRef="usd">0</us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense
      contextRef="i1a6bb4acf8f64d4ea88262cf96a6ca67_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOjFlMDNhMzNiMmY5MjRmODliYTc0NjdiNmY1ZGFiMjIwL3RhYmxlcmFuZ2U6MWUwM2EzM2IyZjkyNGY4OWJhNzQ2N2I2ZjVkYWIyMjBfMTAtMy0xLTEtMjQ5Mg_822d5855-23ba-4496-b5c8-4911d6471658"
      unitRef="usd">4236000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense
      contextRef="iae3e4f43e8c541128c572b22ebdd19bd_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOjFlMDNhMzNiMmY5MjRmODliYTc0NjdiNmY1ZGFiMjIwL3RhYmxlcmFuZ2U6MWUwM2EzM2IyZjkyNGY4OWJhNzQ2N2I2ZjVkYWIyMjBfMTAtMS0xLTEtMA_1e34b7df-1ba1-47c0-a37c-ae7324e4397f"
      unitRef="usd">5764000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense
      contextRef="i6f626e482e054b34901a6c459f47f04b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOjFlMDNhMzNiMmY5MjRmODliYTc0NjdiNmY1ZGFiMjIwL3RhYmxlcmFuZ2U6MWUwM2EzM2IyZjkyNGY4OWJhNzQ2N2I2ZjVkYWIyMjBfMTAtMy0xLTEtMA_30c87481-79df-4403-8f25-7bb1912b1011"
      unitRef="usd">9911000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense>
    <us-gaap:DepreciationAndAmortizationDiscontinuedOperations
      contextRef="i1869cd19e38f4a028448315845a440c5_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOjFlMDNhMzNiMmY5MjRmODliYTc0NjdiNmY1ZGFiMjIwL3RhYmxlcmFuZ2U6MWUwM2EzM2IyZjkyNGY4OWJhNzQ2N2I2ZjVkYWIyMjBfMTEtMS0xLTEtMjQ5Mg_0ac4bf03-a30c-4eb2-a686-956eafb3f6ad"
      unitRef="usd">0</us-gaap:DepreciationAndAmortizationDiscontinuedOperations>
    <us-gaap:DepreciationAndAmortizationDiscontinuedOperations
      contextRef="i1a6bb4acf8f64d4ea88262cf96a6ca67_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOjFlMDNhMzNiMmY5MjRmODliYTc0NjdiNmY1ZGFiMjIwL3RhYmxlcmFuZ2U6MWUwM2EzM2IyZjkyNGY4OWJhNzQ2N2I2ZjVkYWIyMjBfMTEtMy0xLTEtMjQ5Mg_cb915ded-7387-4471-91e6-bfa32a0cc68a"
      unitRef="usd">160000</us-gaap:DepreciationAndAmortizationDiscontinuedOperations>
    <us-gaap:DepreciationAndAmortizationDiscontinuedOperations
      contextRef="iae3e4f43e8c541128c572b22ebdd19bd_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOjFlMDNhMzNiMmY5MjRmODliYTc0NjdiNmY1ZGFiMjIwL3RhYmxlcmFuZ2U6MWUwM2EzM2IyZjkyNGY4OWJhNzQ2N2I2ZjVkYWIyMjBfMTEtMS0xLTEtMA_315e0996-ef06-4a2d-8ead-518135ef20ad"
      unitRef="usd">160000</us-gaap:DepreciationAndAmortizationDiscontinuedOperations>
    <us-gaap:DepreciationAndAmortizationDiscontinuedOperations
      contextRef="i6f626e482e054b34901a6c459f47f04b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOjFlMDNhMzNiMmY5MjRmODliYTc0NjdiNmY1ZGFiMjIwL3RhYmxlcmFuZ2U6MWUwM2EzM2IyZjkyNGY4OWJhNzQ2N2I2ZjVkYWIyMjBfMTEtMy0xLTEtMA_2ba0d54a-cffc-4342-ab98-044ee9bf8f57"
      unitRef="usd">320000</us-gaap:DepreciationAndAmortizationDiscontinuedOperations>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense
      contextRef="i1869cd19e38f4a028448315845a440c5_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOjFlMDNhMzNiMmY5MjRmODliYTc0NjdiNmY1ZGFiMjIwL3RhYmxlcmFuZ2U6MWUwM2EzM2IyZjkyNGY4OWJhNzQ2N2I2ZjVkYWIyMjBfMTItMS0xLTEtMjQ5Mg_322e90d0-3e95-4658-b7d0-e1220c9d6c9f"
      unitRef="usd">0</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense
      contextRef="i1a6bb4acf8f64d4ea88262cf96a6ca67_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOjFlMDNhMzNiMmY5MjRmODliYTc0NjdiNmY1ZGFiMjIwL3RhYmxlcmFuZ2U6MWUwM2EzM2IyZjkyNGY4OWJhNzQ2N2I2ZjVkYWIyMjBfMTItMy0xLTEtMjQ5Mg_513f1077-d81d-40c0-8df0-69ce7fda7b6c"
      unitRef="usd">27180000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense
      contextRef="iae3e4f43e8c541128c572b22ebdd19bd_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOjFlMDNhMzNiMmY5MjRmODliYTc0NjdiNmY1ZGFiMjIwL3RhYmxlcmFuZ2U6MWUwM2EzM2IyZjkyNGY4OWJhNzQ2N2I2ZjVkYWIyMjBfMTItMS0xLTEtMA_58815edd-adea-4407-ba48-394835e06d33"
      unitRef="usd">45763000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense
      contextRef="i6f626e482e054b34901a6c459f47f04b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOjFlMDNhMzNiMmY5MjRmODliYTc0NjdiNmY1ZGFiMjIwL3RhYmxlcmFuZ2U6MWUwM2EzM2IyZjkyNGY4OWJhNzQ2N2I2ZjVkYWIyMjBfMTItMy0xLTEtMA_3f5b3e18-008b-42de-8f16-b1c200763a13"
      unitRef="usd">59977000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss
      contextRef="i1869cd19e38f4a028448315845a440c5_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOjFlMDNhMzNiMmY5MjRmODliYTc0NjdiNmY1ZGFiMjIwL3RhYmxlcmFuZ2U6MWUwM2EzM2IyZjkyNGY4OWJhNzQ2N2I2ZjVkYWIyMjBfMTMtMS0xLTEtMjQ5Mg_a20f684e-89ae-414e-b734-201778c79a77"
      unitRef="usd">0</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss
      contextRef="i1a6bb4acf8f64d4ea88262cf96a6ca67_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOjFlMDNhMzNiMmY5MjRmODliYTc0NjdiNmY1ZGFiMjIwL3RhYmxlcmFuZ2U6MWUwM2EzM2IyZjkyNGY4OWJhNzQ2N2I2ZjVkYWIyMjBfMTMtMy0xLTEtMjQ5Mg_69a51a52-5e47-43ad-a27c-9eb88f5a4655"
      unitRef="usd">-1639000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss
      contextRef="iae3e4f43e8c541128c572b22ebdd19bd_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOjFlMDNhMzNiMmY5MjRmODliYTc0NjdiNmY1ZGFiMjIwL3RhYmxlcmFuZ2U6MWUwM2EzM2IyZjkyNGY4OWJhNzQ2N2I2ZjVkYWIyMjBfMTMtMS0xLTEtMA_64cfc711-8c76-452b-af66-7ed8d3881751"
      unitRef="usd">-930000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss
      contextRef="i6f626e482e054b34901a6c459f47f04b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOjFlMDNhMzNiMmY5MjRmODliYTc0NjdiNmY1ZGFiMjIwL3RhYmxlcmFuZ2U6MWUwM2EzM2IyZjkyNGY4OWJhNzQ2N2I2ZjVkYWIyMjBfMTMtMy0xLTEtMA_6af0323a-37af-44b5-bfce-043e874081a6"
      unitRef="usd">-2049000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestIncome
      contextRef="i1869cd19e38f4a028448315845a440c5_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOjFlMDNhMzNiMmY5MjRmODliYTc0NjdiNmY1ZGFiMjIwL3RhYmxlcmFuZ2U6MWUwM2EzM2IyZjkyNGY4OWJhNzQ2N2I2ZjVkYWIyMjBfMTQtMS0xLTEtMjQ5Mg_d4f96746-e3a8-4872-9df0-482efdc5e8cd"
      unitRef="usd">0</us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestIncome>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestIncome
      contextRef="i1a6bb4acf8f64d4ea88262cf96a6ca67_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOjFlMDNhMzNiMmY5MjRmODliYTc0NjdiNmY1ZGFiMjIwL3RhYmxlcmFuZ2U6MWUwM2EzM2IyZjkyNGY4OWJhNzQ2N2I2ZjVkYWIyMjBfMTQtMy0xLTEtMjQ5Mg_0e82e239-bea8-4633-9777-35a486c8ec87"
      unitRef="usd">137000</us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestIncome>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestIncome
      contextRef="iae3e4f43e8c541128c572b22ebdd19bd_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOjFlMDNhMzNiMmY5MjRmODliYTc0NjdiNmY1ZGFiMjIwL3RhYmxlcmFuZ2U6MWUwM2EzM2IyZjkyNGY4OWJhNzQ2N2I2ZjVkYWIyMjBfMTQtMS0xLTEtMA_0e0b3b79-4ae8-44ed-9c55-7a4758923f1b"
      unitRef="usd">112000</us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestIncome>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestIncome
      contextRef="i6f626e482e054b34901a6c459f47f04b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOjFlMDNhMzNiMmY5MjRmODliYTc0NjdiNmY1ZGFiMjIwL3RhYmxlcmFuZ2U6MWUwM2EzM2IyZjkyNGY4OWJhNzQ2N2I2ZjVkYWIyMjBfMTQtMy0xLTEtMA_626b6d7d-e74e-466c-a089-c6305ecbb5c7"
      unitRef="usd">286000</us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestIncome>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestExpense
      contextRef="i1869cd19e38f4a028448315845a440c5_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOjFlMDNhMzNiMmY5MjRmODliYTc0NjdiNmY1ZGFiMjIwL3RhYmxlcmFuZ2U6MWUwM2EzM2IyZjkyNGY4OWJhNzQ2N2I2ZjVkYWIyMjBfMTUtMS0xLTEtMjQ5Mg_91b639f2-54b5-4641-8e4a-b781c1784fb0"
      unitRef="usd">0</us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestExpense
      contextRef="i1a6bb4acf8f64d4ea88262cf96a6ca67_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOjFlMDNhMzNiMmY5MjRmODliYTc0NjdiNmY1ZGFiMjIwL3RhYmxlcmFuZ2U6MWUwM2EzM2IyZjkyNGY4OWJhNzQ2N2I2ZjVkYWIyMjBfMTUtMy0xLTEtMjQ5Mg_1a6eff3c-9914-4022-92a7-fc126003f0f7"
      unitRef="usd">3000</us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestExpense
      contextRef="iae3e4f43e8c541128c572b22ebdd19bd_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOjFlMDNhMzNiMmY5MjRmODliYTc0NjdiNmY1ZGFiMjIwL3RhYmxlcmFuZ2U6MWUwM2EzM2IyZjkyNGY4OWJhNzQ2N2I2ZjVkYWIyMjBfMTUtMS0xLTEtMA_920a8607-6ec1-40b8-8b15-92ead7c4aa45"
      unitRef="usd">4000</us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestExpense
      contextRef="i6f626e482e054b34901a6c459f47f04b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOjFlMDNhMzNiMmY5MjRmODliYTc0NjdiNmY1ZGFiMjIwL3RhYmxlcmFuZ2U6MWUwM2EzM2IyZjkyNGY4OWJhNzQ2N2I2ZjVkYWIyMjBfMTUtMy0xLTEtMA_fcea3d26-2413-41c8-9096-4c6e968dee07"
      unitRef="usd">7000</us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense
      contextRef="i1869cd19e38f4a028448315845a440c5_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOjFlMDNhMzNiMmY5MjRmODliYTc0NjdiNmY1ZGFiMjIwL3RhYmxlcmFuZ2U6MWUwM2EzM2IyZjkyNGY4OWJhNzQ2N2I2ZjVkYWIyMjBfMTYtMS0xLTEtMjQ5Mg_3c06a679-09ee-488f-be63-6801630884c8"
      unitRef="usd">0</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense
      contextRef="i1a6bb4acf8f64d4ea88262cf96a6ca67_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOjFlMDNhMzNiMmY5MjRmODliYTc0NjdiNmY1ZGFiMjIwL3RhYmxlcmFuZ2U6MWUwM2EzM2IyZjkyNGY4OWJhNzQ2N2I2ZjVkYWIyMjBfMTYtMy0xLTEtMjQ5Mg_5ad6396e-b97c-434d-a342-eec2ca85d47d"
      unitRef="usd">3000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense
      contextRef="iae3e4f43e8c541128c572b22ebdd19bd_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOjFlMDNhMzNiMmY5MjRmODliYTc0NjdiNmY1ZGFiMjIwL3RhYmxlcmFuZ2U6MWUwM2EzM2IyZjkyNGY4OWJhNzQ2N2I2ZjVkYWIyMjBfMTYtMS0xLTEtMA_b70bc8c0-d177-4bdc-8cdd-fc6f7c333483"
      unitRef="usd">25000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense
      contextRef="i6f626e482e054b34901a6c459f47f04b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOjFlMDNhMzNiMmY5MjRmODliYTc0NjdiNmY1ZGFiMjIwL3RhYmxlcmFuZ2U6MWUwM2EzM2IyZjkyNGY4OWJhNzQ2N2I2ZjVkYWIyMjBfMTYtMy0xLTEtMA_7e1f1dd4-7c27-43e6-a176-1ea8822980a1"
      unitRef="usd">3000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
      contextRef="i1869cd19e38f4a028448315845a440c5_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOjFlMDNhMzNiMmY5MjRmODliYTc0NjdiNmY1ZGFiMjIwL3RhYmxlcmFuZ2U6MWUwM2EzM2IyZjkyNGY4OWJhNzQ2N2I2ZjVkYWIyMjBfMTctMS0xLTEtMjQ5Mg_407a1c60-70c0-40c2-bbd4-bf82ed5ff01b"
      unitRef="usd">0</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
      contextRef="i1a6bb4acf8f64d4ea88262cf96a6ca67_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOjFlMDNhMzNiMmY5MjRmODliYTc0NjdiNmY1ZGFiMjIwL3RhYmxlcmFuZ2U6MWUwM2EzM2IyZjkyNGY4OWJhNzQ2N2I2ZjVkYWIyMjBfMTctMy0xLTEtMjQ5Mg_8f94a147-9ce1-41b8-bcc9-330697b595fd"
      unitRef="usd">-1508000</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
      contextRef="iae3e4f43e8c541128c572b22ebdd19bd_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOjFlMDNhMzNiMmY5MjRmODliYTc0NjdiNmY1ZGFiMjIwL3RhYmxlcmFuZ2U6MWUwM2EzM2IyZjkyNGY4OWJhNzQ2N2I2ZjVkYWIyMjBfMTctMS0xLTEtMA_782c1c78-50f5-42d7-a607-5d276c546240"
      unitRef="usd">-847000</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
      contextRef="i6f626e482e054b34901a6c459f47f04b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOjFlMDNhMzNiMmY5MjRmODliYTc0NjdiNmY1ZGFiMjIwL3RhYmxlcmFuZ2U6MWUwM2EzM2IyZjkyNGY4OWJhNzQ2N2I2ZjVkYWIyMjBfMTctMy0xLTEtMA_c99b9dd9-5824-4922-9438-6782706b867b"
      unitRef="usd">-1773000</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax>
    <us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation
      contextRef="i1869cd19e38f4a028448315845a440c5_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOjFlMDNhMzNiMmY5MjRmODliYTc0NjdiNmY1ZGFiMjIwL3RhYmxlcmFuZ2U6MWUwM2EzM2IyZjkyNGY4OWJhNzQ2N2I2ZjVkYWIyMjBfMTgtMS0xLTEtMjQ5Mg_973e4ed2-c4ee-4fa7-af46-a4cb441d3ce8"
      unitRef="usd">0</us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation>
    <us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation
      contextRef="i1a6bb4acf8f64d4ea88262cf96a6ca67_D20200401-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOjFlMDNhMzNiMmY5MjRmODliYTc0NjdiNmY1ZGFiMjIwL3RhYmxlcmFuZ2U6MWUwM2EzM2IyZjkyNGY4OWJhNzQ2N2I2ZjVkYWIyMjBfMTgtMy0xLTEtMjQ5Mg_58c80dce-a830-4125-99aa-de4c29504900"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation
      contextRef="iae3e4f43e8c541128c572b22ebdd19bd_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOjFlMDNhMzNiMmY5MjRmODliYTc0NjdiNmY1ZGFiMjIwL3RhYmxlcmFuZ2U6MWUwM2EzM2IyZjkyNGY4OWJhNzQ2N2I2ZjVkYWIyMjBfMTgtMS0xLTEtMA_a2928b28-96f4-4bee-bd08-040024179e09"
      unitRef="usd">-326000</us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation>
    <us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation
      contextRef="i6f626e482e054b34901a6c459f47f04b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOjFlMDNhMzNiMmY5MjRmODliYTc0NjdiNmY1ZGFiMjIwL3RhYmxlcmFuZ2U6MWUwM2EzM2IyZjkyNGY4OWJhNzQ2N2I2ZjVkYWIyMjBfMTgtMy0xLTEtMA_bcd1333f-ab0d-4e77-a06a-65568c12588f"
      unitRef="usd">0</us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i1869cd19e38f4a028448315845a440c5_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOjFlMDNhMzNiMmY5MjRmODliYTc0NjdiNmY1ZGFiMjIwL3RhYmxlcmFuZ2U6MWUwM2EzM2IyZjkyNGY4OWJhNzQ2N2I2ZjVkYWIyMjBfMTktMS0xLTEtMjQ5Mg_673742d0-ba97-428f-9a20-53b4485fb0fc"
      unitRef="usd">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i1a6bb4acf8f64d4ea88262cf96a6ca67_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOjFlMDNhMzNiMmY5MjRmODliYTc0NjdiNmY1ZGFiMjIwL3RhYmxlcmFuZ2U6MWUwM2EzM2IyZjkyNGY4OWJhNzQ2N2I2ZjVkYWIyMjBfMTktMy0xLTEtMjQ5Mg_65488641-7bb4-47ee-859e-d1cc092fb01d"
      unitRef="usd">-1508000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="iae3e4f43e8c541128c572b22ebdd19bd_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOjFlMDNhMzNiMmY5MjRmODliYTc0NjdiNmY1ZGFiMjIwL3RhYmxlcmFuZ2U6MWUwM2EzM2IyZjkyNGY4OWJhNzQ2N2I2ZjVkYWIyMjBfMTktMS0xLTEtMA_2f20fc1a-d03e-4b4b-901e-a9a14961c854"
      unitRef="usd">-521000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i6f626e482e054b34901a6c459f47f04b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOjFlMDNhMzNiMmY5MjRmODliYTc0NjdiNmY1ZGFiMjIwL3RhYmxlcmFuZ2U6MWUwM2EzM2IyZjkyNGY4OWJhNzQ2N2I2ZjVkYWIyMjBfMTktMy0xLTEtMA_1191e6ff-ea0d-4e06-9665-beb73b34132b"
      unitRef="usd">-1773000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold
      contextRef="i7af7cd835a34469ebabe02daf06e9c2f_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RleHRyZWdpb246YTc2MmYwMGIxMDk2NDgzZThhYWM3ZTBlNGY2ZDgzZjBfMTMwNg_f9361b6d-3b07-4ed7-8fdb-09be59894d64"
      unitRef="usd">3200000</us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold
      contextRef="ica99eb679e5f4a22856b6f0e49072449_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RleHRyZWdpb246YTc2MmYwMGIxMDk2NDgzZThhYWM3ZTBlNGY2ZDgzZjBfMTA5OTUxMTYzMTgwMQ_bee12838-3dc7-4e06-8261-49b13c9bbcc7"
      unitRef="usd">2800000</us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold
      contextRef="ic748340b0cf24dd685eb9347670033fd_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RleHRyZWdpb246YTc2MmYwMGIxMDk2NDgzZThhYWM3ZTBlNGY2ZDgzZjBfMTA5OTUxMTYzMTgwMg_312989bd-e273-426c-b29e-fdbd25a09087"
      unitRef="usd">6300000</us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense
      contextRef="i7af7cd835a34469ebabe02daf06e9c2f_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RleHRyZWdpb246YTc2MmYwMGIxMDk2NDgzZThhYWM3ZTBlNGY2ZDgzZjBfMTY2MQ_6ce76317-839c-4080-86b1-f538223915d7"
      unitRef="usd">1000000.0</us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense
      contextRef="ica99eb679e5f4a22856b6f0e49072449_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RleHRyZWdpb246YTc2MmYwMGIxMDk2NDgzZThhYWM3ZTBlNGY2ZDgzZjBfMTA5OTUxMTYzMjgyNQ_906fec68-e2a4-4514-96f4-52a4d17f7d2b"
      unitRef="usd">1100000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense
      contextRef="ic748340b0cf24dd685eb9347670033fd_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RleHRyZWdpb246YTc2MmYwMGIxMDk2NDgzZThhYWM3ZTBlNGY2ZDgzZjBfMTA5OTUxMTYzMjgxMQ_6df4c54d-1e02-4f4a-97dc-05ccbd82a92e"
      unitRef="usd">4100000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense>
    <us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
      contextRef="iae3e4f43e8c541128c572b22ebdd19bd_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOjYxMmUzOTVjZTQxMjRiZDg5MzVmZjIxNDhkNTFmNGFlL3RhYmxlcmFuZ2U6NjEyZTM5NWNlNDEyNGJkODkzNWZmMjE0OGQ1MWY0YWVfMi0xLTEtMS0w_99552c5c-2adb-461b-85ec-b7287e07530d"
      unitRef="usd">5002000</us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
      contextRef="i6f626e482e054b34901a6c459f47f04b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOjYxMmUzOTVjZTQxMjRiZDg5MzVmZjIxNDhkNTFmNGFlL3RhYmxlcmFuZ2U6NjEyZTM5NWNlNDEyNGJkODkzNWZmMjE0OGQ1MWY0YWVfMi0zLTEtMS0w_65c8a5d4-9ecd-4724-9363-fbef1fb9b770"
      unitRef="usd">10660000</us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations
      contextRef="iae3e4f43e8c541128c572b22ebdd19bd_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOjYxMmUzOTVjZTQxMjRiZDg5MzVmZjIxNDhkNTFmNGFlL3RhYmxlcmFuZ2U6NjEyZTM5NWNlNDEyNGJkODkzNWZmMjE0OGQ1MWY0YWVfMy0xLTEtMS0w_2d9ff41e-e1e1-4d0c-817f-c5ff89e1748f"
      unitRef="usd">-2494000</us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations
      contextRef="i6f626e482e054b34901a6c459f47f04b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOjYxMmUzOTVjZTQxMjRiZDg5MzVmZjIxNDhkNTFmNGFlL3RhYmxlcmFuZ2U6NjEyZTM5NWNlNDEyNGJkODkzNWZmMjE0OGQ1MWY0YWVfMy0zLTEtMS0w_be4f7d42-cd8b-424f-853e-2bb419af910a"
      unitRef="usd">382000</us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents
      contextRef="ia177f909fbae4389bdaa8635f038babb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOmMyZDk5MjEzZDUwNzQ5NjE5YmJmZTA5MmQ1YzUwYzcwL3RhYmxlcmFuZ2U6YzJkOTkyMTNkNTA3NDk2MTliYmZlMDkyZDVjNTBjNzBfMy0xLTEtMS0w_01341a83-4c32-4a23-92cc-ba9a407d8d40"
      unitRef="usd">21488000</us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents>
    <evh:DisposalGroupIncludingDiscontinuedOperationRestrictedCashAndRestrictedInvestmentsCurrent
      contextRef="ia177f909fbae4389bdaa8635f038babb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOmMyZDk5MjEzZDUwNzQ5NjE5YmJmZTA5MmQ1YzUwYzcwL3RhYmxlcmFuZ2U6YzJkOTkyMTNkNTA3NDk2MTliYmZlMDkyZDVjNTBjNzBfNC0xLTEtMS0w_f313cba9-fa4f-4c6b-b5f8-bd8d0be7639f"
      unitRef="usd">63000</evh:DisposalGroupIncludingDiscontinuedOperationRestrictedCashAndRestrictedInvestmentsCurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet
      contextRef="ia177f909fbae4389bdaa8635f038babb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOmMyZDk5MjEzZDUwNzQ5NjE5YmJmZTA5MmQ1YzUwYzcwL3RhYmxlcmFuZ2U6YzJkOTkyMTNkNTA3NDk2MTliYmZlMDkyZDVjNTBjNzBfNS0xLTEtMS0w_8cf1a370-7b37-442b-806e-da2fc720f7c7"
      unitRef="usd">3437000</us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent
      contextRef="ia177f909fbae4389bdaa8635f038babb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOmMyZDk5MjEzZDUwNzQ5NjE5YmJmZTA5MmQ1YzUwYzcwL3RhYmxlcmFuZ2U6YzJkOTkyMTNkNTA3NDk2MTliYmZlMDkyZDVjNTBjNzBfNi0xLTEtMS0w_39a6ab88-7bec-4472-b39e-c4ecccc9de8b"
      unitRef="usd">5198000</us-gaap:DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent>
    <evh:DisposalGroupIncludingDiscontinuedOperationInvestmentsCurrent
      contextRef="ia177f909fbae4389bdaa8635f038babb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOmMyZDk5MjEzZDUwNzQ5NjE5YmJmZTA5MmQ1YzUwYzcwL3RhYmxlcmFuZ2U6YzJkOTkyMTNkNTA3NDk2MTliYmZlMDkyZDVjNTBjNzBfNy0xLTEtMS0w_eb0e81ad-c96a-485c-8f14-eba7734cfa37"
      unitRef="usd">3728000</evh:DisposalGroupIncludingDiscontinuedOperationInvestmentsCurrent>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="ia177f909fbae4389bdaa8635f038babb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOmMyZDk5MjEzZDUwNzQ5NjE5YmJmZTA5MmQ1YzUwYzcwL3RhYmxlcmFuZ2U6YzJkOTkyMTNkNTA3NDk2MTliYmZlMDkyZDVjNTBjNzBfOC0xLTEtMS0w_7ef855ba-9772-4edb-972a-71e9b5875cae"
      unitRef="usd">33914000</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <evh:DisposalGroupIncludingDiscontinuedOperationRestrictedCashAndRestrictedInvestmentsNoncurrent
      contextRef="ia177f909fbae4389bdaa8635f038babb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOmMyZDk5MjEzZDUwNzQ5NjE5YmJmZTA5MmQ1YzUwYzcwL3RhYmxlcmFuZ2U6YzJkOTkyMTNkNTA3NDk2MTliYmZlMDkyZDVjNTBjNzBfOS0xLTEtMS0w_5e4463a5-9e2f-4f49-a4c9-f6d1f65b4ed0"
      unitRef="usd">616000</evh:DisposalGroupIncludingDiscontinuedOperationRestrictedCashAndRestrictedInvestmentsNoncurrent>
    <evh:DisposalGroupIncludingDiscontinuedOperationInvestmentsNoncurrent
      contextRef="ia177f909fbae4389bdaa8635f038babb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOmMyZDk5MjEzZDUwNzQ5NjE5YmJmZTA5MmQ1YzUwYzcwL3RhYmxlcmFuZ2U6YzJkOTkyMTNkNTA3NDk2MTliYmZlMDkyZDVjNTBjNzBfMTAtMS0xLTEtMA_f1d599c4-7d31-4dfe-b1b9-2e25b73fec35"
      unitRef="usd">10919000</evh:DisposalGroupIncludingDiscontinuedOperationInvestmentsNoncurrent>
    <evh:DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsNoncurrent
      contextRef="ia177f909fbae4389bdaa8635f038babb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOmMyZDk5MjEzZDUwNzQ5NjE5YmJmZTA5MmQ1YzUwYzcwL3RhYmxlcmFuZ2U6YzJkOTkyMTNkNTA3NDk2MTliYmZlMDkyZDVjNTBjNzBfMTEtMS0xLTEtMA_c46b0d1c-c1f5-479a-bfd8-87a46b0e1b79"
      unitRef="usd">59000</evh:DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsNoncurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent
      contextRef="ia177f909fbae4389bdaa8635f038babb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOmMyZDk5MjEzZDUwNzQ5NjE5YmJmZTA5MmQ1YzUwYzcwL3RhYmxlcmFuZ2U6YzJkOTkyMTNkNTA3NDk2MTliYmZlMDkyZDVjNTBjNzBfMTItMS0xLTEtMA_2acfb63c-7dd1-4426-84c2-bd88583952e0"
      unitRef="usd">3080000</us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent
      contextRef="ia177f909fbae4389bdaa8635f038babb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOmMyZDk5MjEzZDUwNzQ5NjE5YmJmZTA5MmQ1YzUwYzcwL3RhYmxlcmFuZ2U6YzJkOTkyMTNkNTA3NDk2MTliYmZlMDkyZDVjNTBjNzBfMTMtMS0xLTEtMA_093999f8-65bc-40c7-84b5-7131b77c6f1a"
      unitRef="usd">5705000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation
      contextRef="ia177f909fbae4389bdaa8635f038babb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOmMyZDk5MjEzZDUwNzQ5NjE5YmJmZTA5MmQ1YzUwYzcwL3RhYmxlcmFuZ2U6YzJkOTkyMTNkNTA3NDk2MTliYmZlMDkyZDVjNTBjNzBfMTQtMS0xLTEtMA_9430165f-90d7-4bb9-876d-565dbbd5624e"
      unitRef="usd">54293000</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent
      contextRef="ia177f909fbae4389bdaa8635f038babb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOmMyZDk5MjEzZDUwNzQ5NjE5YmJmZTA5MmQ1YzUwYzcwL3RhYmxlcmFuZ2U6YzJkOTkyMTNkNTA3NDk2MTliYmZlMDkyZDVjNTBjNzBfMTktMS0xLTEtMA_c6938e20-5e62-4fb4-b0dd-ba5f5f4152bc"
      unitRef="usd">93000</us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent
      contextRef="ia177f909fbae4389bdaa8635f038babb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOmMyZDk5MjEzZDUwNzQ5NjE5YmJmZTA5MmQ1YzUwYzcwL3RhYmxlcmFuZ2U6YzJkOTkyMTNkNTA3NDk2MTliYmZlMDkyZDVjNTBjNzBfMjAtMS0xLTEtMA_1caa587a-7896-49f6-83be-c474389e9a50"
      unitRef="usd">11265000</us-gaap:DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent>
    <evh:DisposalGroupIncludingDiscontinuedOperationAccruedCompensationAndEmployeeBenefitsCurrent
      contextRef="ia177f909fbae4389bdaa8635f038babb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOmMyZDk5MjEzZDUwNzQ5NjE5YmJmZTA5MmQ1YzUwYzcwL3RhYmxlcmFuZ2U6YzJkOTkyMTNkNTA3NDk2MTliYmZlMDkyZDVjNTBjNzBfMjEtMS0xLTEtMA_bb4414d1-967f-4323-ab34-93f33f2cfac1"
      unitRef="usd">1115000</evh:DisposalGroupIncludingDiscontinuedOperationAccruedCompensationAndEmployeeBenefitsCurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent
      contextRef="ia177f909fbae4389bdaa8635f038babb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOmMyZDk5MjEzZDUwNzQ5NjE5YmJmZTA5MmQ1YzUwYzcwL3RhYmxlcmFuZ2U6YzJkOTkyMTNkNTA3NDk2MTliYmZlMDkyZDVjNTBjNzBfMjItMS0xLTEtMA_566f1b5b-0951-495e-8761-38a3d8965294"
      unitRef="usd">4140000</us-gaap:DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent>
    <evh:DisposalGroupIncludingDiscontinuedOperationLiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangementsCurrent
      contextRef="ia177f909fbae4389bdaa8635f038babb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOmMyZDk5MjEzZDUwNzQ5NjE5YmJmZTA5MmQ1YzUwYzcwL3RhYmxlcmFuZ2U6YzJkOTkyMTNkNTA3NDk2MTliYmZlMDkyZDVjNTBjNzBfMjMtMS0xLTEtMA_f1e49249-da9c-4076-8900-d3a301a3ab05"
      unitRef="usd">9858000</evh:DisposalGroupIncludingDiscontinuedOperationLiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangementsCurrent>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="ia177f909fbae4389bdaa8635f038babb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOmMyZDk5MjEzZDUwNzQ5NjE5YmJmZTA5MmQ1YzUwYzcwL3RhYmxlcmFuZ2U6YzJkOTkyMTNkNTA3NDk2MTliYmZlMDkyZDVjNTBjNzBfMjQtMS0xLTEtMA_aad0cef5-9d2f-4169-a82c-a2ec05e3fec0"
      unitRef="usd">26471000</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities
      contextRef="ia177f909fbae4389bdaa8635f038babb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOmMyZDk5MjEzZDUwNzQ5NjE5YmJmZTA5MmQ1YzUwYzcwL3RhYmxlcmFuZ2U6YzJkOTkyMTNkNTA3NDk2MTliYmZlMDkyZDVjNTBjNzBfMjUtMS0xLTEtMA_581360bc-36dd-4d1d-b4cf-a7741c973dd9"
      unitRef="usd">128000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities
      contextRef="ia177f909fbae4389bdaa8635f038babb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOmMyZDk5MjEzZDUwNzQ5NjE5YmJmZTA5MmQ1YzUwYzcwL3RhYmxlcmFuZ2U6YzJkOTkyMTNkNTA3NDk2MTliYmZlMDkyZDVjNTBjNzBfMjYtMS0xLTEtMA_aaf8bba1-7319-4ce0-8922-929c94c2c5b8"
      unitRef="usd">49000</us-gaap:DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation
      contextRef="ia177f909fbae4389bdaa8635f038babb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RhYmxlOmMyZDk5MjEzZDUwNzQ5NjE5YmJmZTA5MmQ1YzUwYzcwL3RhYmxlcmFuZ2U6YzJkOTkyMTNkNTA3NDk2MTliYmZlMDkyZDVjNTBjNzBfMjctMS0xLTEtMA_3f77a63c-560f-4add-96e9-5ffb4db52d81"
      unitRef="usd">26648000</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet
      contextRef="i253ccf29d13d4053a5a80b95f440acbe_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RleHRyZWdpb246YTc2MmYwMGIxMDk2NDgzZThhYWM3ZTBlNGY2ZDgzZjBfMjM5MQ_0ecff333-a53d-461d-9dc6-1aa3c3e3bdd7"
      unitRef="usd">1500000</us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent
      contextRef="i253ccf29d13d4053a5a80b95f440acbe_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181NS9mcmFnOmE3NjJmMDBiMTA5NjQ4M2U4YWFjN2UwZTRmNmQ4M2YwL3RleHRyZWdpb246YTc2MmYwMGIxMDk2NDgzZThhYWM3ZTBlNGY2ZDgzZjBfMjM5MQ_93460396-7ee5-48f6-a96e-4b7e098c422a"
      unitRef="usd">1500000</us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181OC9mcmFnOjQ2NmRlMDUxNjNjYjQ0MzRhMTkxNDY1YTcyZmUyMzFjL3RleHRyZWdpb246NDY2ZGUwNTE2M2NiNDQzNGExOTE0NjVhNzJmZTIzMWNfMTAxNDc_ba2e153b-c616-4783-acc4-01b917c5a1e1">Revenue Recognition&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We derive revenue from two sources: (1) transformation services and (2) platform and operations services.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Transformation Services Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Transformation services consist of implementation services whereby we assist the customer in launching its population health or health plan programs. In certain cases, transformation services can also include revenue associated with our support of certain one-time wind-down activities for clients who are exiting a line of business or population. The transformation services are usually completed within 12 months. We generally receive a fixed fee for transformation services and recognize revenue over time using an input method based on hours incurred compared to the total estimated hours required to satisfy our performance obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Platform and Operations Services Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Platform and operations services are typically multi-year arrangements with customers to provide various clinical and administrative solutions. In our Clinical Solutions segment, our solutions are designed to lower the medical expenses of our partners and include our total cost of care and specialty care management services.  In our Evolent Health Services segment, our solutions are designed to provide comprehensive health plan operations and claims processing services, and also include transition or run-out services to customers receiving primarily third-party administration (&#x201c;TPA&#x201d;) services.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our performance obligation in these arrangements is to provide an integrated suite of services, including access to our platform that is customized to meet the specialized needs of our customers and members. Generally, we will apply the series guidance to the performance obligation as we have determined that each time increment is distinct. We primarily utilize a variable fee structure for these services that typically includes a monthly payment that is calculated based on a specified per member per month rate, multiplied by the number of members that our partners are managing under a value-based care arrangement or a percentage of plan premiums. Our arrangements may also include other variable fees related to service level agreements, shared medical savings arrangements and other performance measures. Variable consideration is estimated using the most likely amount based on our historical experience and best judgment at the time. Due to the nature of our arrangements, certain estimates may be constrained if it is probable that a significant reversal of revenue will occur when the uncertainty is resolved. We recognize revenue from platform and operations &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;services over time using the time elapsed output method. Fixed consideration is recognized ratably over the contract term. In accordance with the series guidance, we allocate variable consideration to the period to which the fees relate.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In our Clinical Solutions segment, we enter into capitation arrangements that may include performance-based arrangements and/or gainshare features. We recognize capitation revenue on a gross basis when we have established control over the services within our scope and recognize capitation revenue on a net basis when we do not have control over the services within our scope. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contracts with Multiple Performance Obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our contracts with customers may contain multiple performance obligations, primarily when the customer has requested both transformation services and platform and operations services as these services are distinct from one another. When a contract has multiple performance obligations, we allocate the transaction price to each performance obligation based on the relative standalone selling price using the expected cost margin approach. This approach requires estimates regarding both the level of effort it will take to satisfy the performance obligation as well as fees that will be received under the variable pricing model. We also take into consideration customer demographics, current market conditions, the scope of services and our overall pricing strategy and objectives when determining the standalone selling price.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Principal vs. Agent&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We occasionally use third parties to assist in satisfying our performance obligations. In order to determine whether we are the principal or agent in the arrangement, we review each third-party relationship on a contract by contract basis. We are an agent when our role is to arrange for another entity to provide the services to the customer. In these instances, we do not control the service before it is provided and recognize revenue on a net basis. We are the principal when we control the good or service prior to transferring control to the customer. We recognize revenue on a gross basis when we are the principal in the arrangement.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Disaggregation of Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table represents Evolent&#x2019;s revenue disaggregated by segment and end-market for the three and six months ended June 30, 2021 and 2020 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:114.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Evolent Health Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Clinical Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Evolent Health Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Clinical Solutions&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicaid&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124,512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;176,544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126,560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,705&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,897&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,561&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;147,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;182,898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;277,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;255,633&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Transaction Price Allocated to the Remaining Performance Obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For contracts with a term greater than one year, we have allocated approximately $181.2 million of transaction price to performance obligations that are unsatisfied as of June&#160;30, 2021. We do not include variable consideration that is allocated entirely to a wholly unsatisfied performance obligation accounted for under the series guidance in the calculation. As a result, the balance represents the value of the fixed consideration in our long-term contracts that we expect will be recognized as revenue in a future period and excludes the majority of our platform and operations revenue, which is primarily derived based on variable consideration as discussed in Note 2. We expect to recognize revenue on approximately 18% and 51% of these remaining performance obligations by December 31, 2021 and December 31, 2022, respectively, with the remaining balance to be recognized thereafter. However, because our existing contracts may be canceled or renegotiated including for reasons outside our control, the amount of revenue that we actually receive may be less or greater than this estimate and the timing of recognition may not be as expected.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contract Balances&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contract balances consist of accounts receivable, contract assets and deferred revenue. Contract assets are recorded when the right to consideration for services is conditional on something other than the passage of time. Contract assets relating to unbilled receivables are transferred to accounts receivable when the right to consideration becomes unconditional. We classify contract assets as current or non-current based on the timing of our rights to the unconditional payments. Our contract assets are generally classified as current and recorded within prepaid expenses and other current assets on our consolidated balance sheets. Our current accounts receivables are classified within accounts receivable, net on our consolidated balance sheets and our non-current accounts receivable are classified within prepaid expenses and other non-current assets on our consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred revenue includes advance customer payments and billings in excess of revenue recognized. We classify deferred revenue as current or non-current based on the timing of when we expect to recognize revenue. Our current deferred revenue is recorded within deferred revenue on our consolidated balance sheets, and non-current deferred revenue is recorded within other long-term liabilities on our consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides information about receivables, contract assets and deferred revenue from contracts with customers as of June&#160;30, 2021 and December&#160;31, 2020 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:403.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:67.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term receivables &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;240,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term receivables &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term contract assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Amounts exclude $3.4&#160;million of short-term receivables and $4.1&#160;million of short-term deferred revenue reclassified to discontinued operations as of December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Excludes pharmacy claims receivable and premiums receivable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in deferred revenue for the six months ended June 30, 2021 are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:433.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:102.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of beginning-of-period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reclassification to revenue, as a result of performance obligations satisfied&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,726)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash received in advance of satisfaction of performance obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,051&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amount of revenue recognized from performance obligations satisfied (or partially satisfied) in previous period was $2.9&#160;million and $16.1 million for the three and six months ended June 30, 2021, respectively, due primarily to net gain share as well as changes in other estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contract Cost Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain bonuses and commissions earned by our sales team are considered incremental costs of obtaining a contract with a customer that we expect to be recoverable. The capitalized contract acquisition costs are classified as non-current assets and recorded within contract cost assets on our consolidated balance sheets. Amortization expense is recorded within selling, general and administrative expenses on the accompanying consolidated statements of operations and comprehensive income (loss). As of June&#160;30, 2021 and December&#160;31, 2020, the Company had $3.6 million and $3.3 million, respectively, of contract acquisition cost assets, net of accumulated amortization recorded in contract cost assets on the consolidated balance sheets. In addition, the Company recorded &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;amortiza&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;tion expense of $0.6 million and  $1.0 million for the three and six months ended June 30, 2021, respectively and $0.4 million and $0.9 million for the three and six months ended June 30, 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In our platforms and operations arrangements, we incur certain costs related to the implementation of our platform before we begin to satisfy our performance obligation to the customer. The costs, which we expect to recover, are considered costs to fulfill a contract. Our contract fulfillment costs primarily include our employee labor costs and third-party vendor costs. The capitalized contract fulfillment costs are classified as non-current and recorded within contract cost assets on our consolidated balance sheets. Amortization expense is recorded within cost of revenue on the accompanying consolidated statements of operations and &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;comprehensive income (loss). As of June&#160;30, 2021 and December&#160;31, 2020, the Company had $18.8 million and $23.4 million, respectively, of contract fulfillment cost assets, net of accumulated amortization recorded in contract cost assets on the consolidated balance sheets. In addition, the Company recorded amortization expense of $4.6 million and $7.3 million for the three and six months ended June 30, 2021, respectively, $4.3 million and $9.4 million for the three and six months ended June 30, 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These costs are deferred and then amortized on a straight-line basis over a period of benefit that we have determined to be five years. The period of benefit was based on our technology, the nature of our customer arrangements and other factors.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181OC9mcmFnOjQ2NmRlMDUxNjNjYjQ0MzRhMTkxNDY1YTcyZmUyMzFjL3RleHRyZWdpb246NDY2ZGUwNTE2M2NiNDQzNGExOTE0NjVhNzJmZTIzMWNfMTAxNDg_b997574c-5600-44c7-a5d7-eac002af0a82">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table represents Evolent&#x2019;s revenue disaggregated by segment and end-market for the three and six months ended June 30, 2021 and 2020 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:114.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Evolent Health Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Clinical Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Evolent Health Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Clinical Solutions&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicaid&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124,512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;176,544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126,560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,705&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,897&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,561&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;147,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;182,898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;277,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;255,633&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4a8d60e8de004fd0945ea0051704e1de_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181OC9mcmFnOjQ2NmRlMDUxNjNjYjQ0MzRhMTkxNDY1YTcyZmUyMzFjL3RhYmxlOjMyNWIwOGIyYjM1NDQ1ODBhNGU0YWYzZTM5NzQyOWU4L3RhYmxlcmFuZ2U6MzI1YjA4YjJiMzU0NDU4MGE0ZTRhZjNlMzk3NDI5ZThfMy0xLTEtMS0zNTk_ad683976-048a-4e16-8d1f-bdab38f45afb"
      unitRef="usd">52064000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7c8f58d985fb4dd1817f8f943b715272_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181OC9mcmFnOjQ2NmRlMDUxNjNjYjQ0MzRhMTkxNDY1YTcyZmUyMzFjL3RhYmxlOjMyNWIwOGIyYjM1NDQ1ODBhNGU0YWYzZTM5NzQyOWU4L3RhYmxlcmFuZ2U6MzI1YjA4YjJiMzU0NDU4MGE0ZTRhZjNlMzk3NDI5ZThfMy0zLTEtMS0zNTk_f9e6a339-0937-4450-bff1-af04992b9cd3"
      unitRef="usd">55502000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0f70e8921395417eb51d6b5f206ee45d_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181OC9mcmFnOjQ2NmRlMDUxNjNjYjQ0MzRhMTkxNDY1YTcyZmUyMzFjL3RhYmxlOjMyNWIwOGIyYjM1NDQ1ODBhNGU0YWYzZTM5NzQyOWU4L3RhYmxlcmFuZ2U6MzI1YjA4YjJiMzU0NDU4MGE0ZTRhZjNlMzk3NDI5ZThfMy01LTEtMS0zNjM_befd7312-3ae9-44e1-8459-a92286b0b9ca"
      unitRef="usd">53648000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic9022249a19e41248315bc92ae2c6b84_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181OC9mcmFnOjQ2NmRlMDUxNjNjYjQ0MzRhMTkxNDY1YTcyZmUyMzFjL3RhYmxlOjMyNWIwOGIyYjM1NDQ1ODBhNGU0YWYzZTM5NzQyOWU4L3RhYmxlcmFuZ2U6MzI1YjA4YjJiMzU0NDU4MGE0ZTRhZjNlMzk3NDI5ZThfMy03LTEtMS0zNjM_194902c6-f3d4-4be6-81f7-1ee07f0822b1"
      unitRef="usd">64050000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i80f1ac7ca97c4270a70dceff5a322554_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181OC9mcmFnOjQ2NmRlMDUxNjNjYjQ0MzRhMTkxNDY1YTcyZmUyMzFjL3RhYmxlOjMyNWIwOGIyYjM1NDQ1ODBhNGU0YWYzZTM5NzQyOWU4L3RhYmxlcmFuZ2U6MzI1YjA4YjJiMzU0NDU4MGE0ZTRhZjNlMzk3NDI5ZThfMy0xLTEtMS0w_d9e77113-1681-44c0-9c62-2d8dfc38f39c"
      unitRef="usd">112993000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i833160ecd3e14792aed807f6f5526e09_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181OC9mcmFnOjQ2NmRlMDUxNjNjYjQ0MzRhMTkxNDY1YTcyZmUyMzFjL3RhYmxlOjMyNWIwOGIyYjM1NDQ1ODBhNGU0YWYzZTM5NzQyOWU4L3RhYmxlcmFuZ2U6MzI1YjA4YjJiMzU0NDU4MGE0ZTRhZjNlMzk3NDI5ZThfMy0zLTEtMS0w_7ffdaadd-cac7-4b42-94a6-dd07605874b6"
      unitRef="usd">113947000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic9abf3a96b46413baa0783c375797a74_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181OC9mcmFnOjQ2NmRlMDUxNjNjYjQ0MzRhMTkxNDY1YTcyZmUyMzFjL3RhYmxlOjMyNWIwOGIyYjM1NDQ1ODBhNGU0YWYzZTM5NzQyOWU4L3RhYmxlcmFuZ2U6MzI1YjA4YjJiMzU0NDU4MGE0ZTRhZjNlMzk3NDI5ZThfMy01LTEtMS0w_9a47446d-eaa2-44e1-b3f4-c3d6ebc5078f"
      unitRef="usd">96987000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6a6c076167634a8aa2973b374f21a1c4_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181OC9mcmFnOjQ2NmRlMDUxNjNjYjQ0MzRhMTkxNDY1YTcyZmUyMzFjL3RhYmxlOjMyNWIwOGIyYjM1NDQ1ODBhNGU0YWYzZTM5NzQyOWU4L3RhYmxlcmFuZ2U6MzI1YjA4YjJiMzU0NDU4MGE0ZTRhZjNlMzk3NDI5ZThfMy03LTEtMS0w_fc7745b6-036f-407a-bed3-f1c45c6c72f6"
      unitRef="usd">124512000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9867dbbef41b4ff08dd51316a253355a_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181OC9mcmFnOjQ2NmRlMDUxNjNjYjQ0MzRhMTkxNDY1YTcyZmUyMzFjL3RhYmxlOjMyNWIwOGIyYjM1NDQ1ODBhNGU0YWYzZTM5NzQyOWU4L3RhYmxlcmFuZ2U6MzI1YjA4YjJiMzU0NDU4MGE0ZTRhZjNlMzk3NDI5ZThfNC0xLTEtMS0zNTk_839ff15a-1d46-4e63-95c7-50b4830c009f"
      unitRef="usd">6346000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i35df7764bb024bb58f354c0f372efbb2_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181OC9mcmFnOjQ2NmRlMDUxNjNjYjQ0MzRhMTkxNDY1YTcyZmUyMzFjL3RhYmxlOjMyNWIwOGIyYjM1NDQ1ODBhNGU0YWYzZTM5NzQyOWU4L3RhYmxlcmFuZ2U6MzI1YjA4YjJiMzU0NDU4MGE0ZTRhZjNlMzk3NDI5ZThfNC0zLTEtMS0zNTk_86bdc03d-3623-4784-8f83-9232af1db53b"
      unitRef="usd">14061000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i676770c966c346949f713ef44a2dbce2_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181OC9mcmFnOjQ2NmRlMDUxNjNjYjQ0MzRhMTkxNDY1YTcyZmUyMzFjL3RhYmxlOjMyNWIwOGIyYjM1NDQ1ODBhNGU0YWYzZTM5NzQyOWU4L3RhYmxlcmFuZ2U6MzI1YjA4YjJiMzU0NDU4MGE0ZTRhZjNlMzk3NDI5ZThfNC01LTEtMS0zNjM_bc6cbd74-7716-4890-a4b8-c0e8483f0e5d"
      unitRef="usd">90761000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6b1276ae67ae4854953f3017ca34fd0a_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181OC9mcmFnOjQ2NmRlMDUxNjNjYjQ0MzRhMTkxNDY1YTcyZmUyMzFjL3RhYmxlOjMyNWIwOGIyYjM1NDQ1ODBhNGU0YWYzZTM5NzQyOWU4L3RhYmxlcmFuZ2U6MzI1YjA4YjJiMzU0NDU4MGE0ZTRhZjNlMzk3NDI5ZThfNC03LTEtMS0zNjM_5503b5a8-f6b8-4dd2-bba5-bdde7b5f7e92"
      unitRef="usd">64206000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5e93d81fa73f4e01abe8848bb63987d0_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181OC9mcmFnOjQ2NmRlMDUxNjNjYjQ0MzRhMTkxNDY1YTcyZmUyMzFjL3RhYmxlOjMyNWIwOGIyYjM1NDQ1ODBhNGU0YWYzZTM5NzQyOWU4L3RhYmxlcmFuZ2U6MzI1YjA4YjJiMzU0NDU4MGE0ZTRhZjNlMzk3NDI5ZThfNC0xLTEtMS0w_fa69eeb3-ba38-4191-8f04-9b2833b2e308"
      unitRef="usd">14684000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6c150b72b12444a49062d1ff90c9afd3_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181OC9mcmFnOjQ2NmRlMDUxNjNjYjQ0MzRhMTkxNDY1YTcyZmUyMzFjL3RhYmxlOjMyNWIwOGIyYjM1NDQ1ODBhNGU0YWYzZTM5NzQyOWU4L3RhYmxlcmFuZ2U6MzI1YjA4YjJiMzU0NDU4MGE0ZTRhZjNlMzk3NDI5ZThfNC0zLTEtMS0w_09fb8801-1699-47b9-9e7a-14d51adcc2c7"
      unitRef="usd">29246000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2b6c919aef4c4e57ab2545a539828a75_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181OC9mcmFnOjQ2NmRlMDUxNjNjYjQ0MzRhMTkxNDY1YTcyZmUyMzFjL3RhYmxlOjMyNWIwOGIyYjM1NDQ1ODBhNGU0YWYzZTM5NzQyOWU4L3RhYmxlcmFuZ2U6MzI1YjA4YjJiMzU0NDU4MGE0ZTRhZjNlMzk3NDI5ZThfNC01LTEtMS0w_c8c38a7e-1b6c-4728-89eb-f77b7fc35ab1"
      unitRef="usd">176544000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0c9490d39e564864bc4c81a7f1b11b1b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181OC9mcmFnOjQ2NmRlMDUxNjNjYjQ0MzRhMTkxNDY1YTcyZmUyMzFjL3RhYmxlOjMyNWIwOGIyYjM1NDQ1ODBhNGU0YWYzZTM5NzQyOWU4L3RhYmxlcmFuZ2U6MzI1YjA4YjJiMzU0NDU4MGE0ZTRhZjNlMzk3NDI5ZThfNC03LTEtMS0w_d88725cc-386b-4ec7-a213-1020c8fb15e5"
      unitRef="usd">126560000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i21361653abbc4b6aa34198f3f5c3a202_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181OC9mcmFnOjQ2NmRlMDUxNjNjYjQ0MzRhMTkxNDY1YTcyZmUyMzFjL3RhYmxlOjMyNWIwOGIyYjM1NDQ1ODBhNGU0YWYzZTM5NzQyOWU4L3RhYmxlcmFuZ2U6MzI1YjA4YjJiMzU0NDU4MGE0ZTRhZjNlMzk3NDI5ZThfNS0xLTEtMS0zNTk_d1b8b4c9-dc58-49c0-a1a5-99c176c7626f"
      unitRef="usd">16453000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id59d1f7e03da447690dd86c33c621d88_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181OC9mcmFnOjQ2NmRlMDUxNjNjYjQ0MzRhMTkxNDY1YTcyZmUyMzFjL3RhYmxlOjMyNWIwOGIyYjM1NDQ1ODBhNGU0YWYzZTM5NzQyOWU4L3RhYmxlcmFuZ2U6MzI1YjA4YjJiMzU0NDU4MGE0ZTRhZjNlMzk3NDI5ZThfNS0zLTEtMS0zNTk_49f384c5-87db-48c0-ab3b-6a31f1444268"
      unitRef="usd">16958000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i135f040fff0c4f58a1234a087ef110d6_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181OC9mcmFnOjQ2NmRlMDUxNjNjYjQ0MzRhMTkxNDY1YTcyZmUyMzFjL3RhYmxlOjMyNWIwOGIyYjM1NDQ1ODBhNGU0YWYzZTM5NzQyOWU4L3RhYmxlcmFuZ2U6MzI1YjA4YjJiMzU0NDU4MGE0ZTRhZjNlMzk3NDI5ZThfNS01LTEtMS0zNjM_10ef7367-32e7-4936-b486-0a5099652379"
      unitRef="usd">2785000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3905a81b1d7b40abb4c7c12d2a5c2e77_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181OC9mcmFnOjQ2NmRlMDUxNjNjYjQ0MzRhMTkxNDY1YTcyZmUyMzFjL3RhYmxlOjMyNWIwOGIyYjM1NDQ1ODBhNGU0YWYzZTM5NzQyOWU4L3RhYmxlcmFuZ2U6MzI1YjA4YjJiMzU0NDU4MGE0ZTRhZjNlMzk3NDI5ZThfNS03LTEtMS0zNjM_d297a743-f177-445c-9abd-4033d5a95055"
      unitRef="usd">2522000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icc1d76dc32264876ae1a895cacd83b87_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181OC9mcmFnOjQ2NmRlMDUxNjNjYjQ0MzRhMTkxNDY1YTcyZmUyMzFjL3RhYmxlOjMyNWIwOGIyYjM1NDQ1ODBhNGU0YWYzZTM5NzQyOWU4L3RhYmxlcmFuZ2U6MzI1YjA4YjJiMzU0NDU4MGE0ZTRhZjNlMzk3NDI5ZThfNS0xLTEtMS0w_42ca6d16-fd47-4ad6-92df-0c4dc08f3c4f"
      unitRef="usd">32023000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i43e4c78617c04287898b67968c6ce485_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181OC9mcmFnOjQ2NmRlMDUxNjNjYjQ0MzRhMTkxNDY1YTcyZmUyMzFjL3RhYmxlOjMyNWIwOGIyYjM1NDQ1ODBhNGU0YWYzZTM5NzQyOWU4L3RhYmxlcmFuZ2U6MzI1YjA4YjJiMzU0NDU4MGE0ZTRhZjNlMzk3NDI5ZThfNS0zLTEtMS0w_7657a388-247e-4e92-ba82-3489d31010c5"
      unitRef="usd">39705000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i52bdbef1d82e458fbfaf536f2c11d6e5_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181OC9mcmFnOjQ2NmRlMDUxNjNjYjQ0MzRhMTkxNDY1YTcyZmUyMzFjL3RhYmxlOjMyNWIwOGIyYjM1NDQ1ODBhNGU0YWYzZTM5NzQyOWU4L3RhYmxlcmFuZ2U6MzI1YjA4YjJiMzU0NDU4MGE0ZTRhZjNlMzk3NDI5ZThfNS01LTEtMS0w_337d48d8-f96a-4860-8b15-f4f73de494dc"
      unitRef="usd">3897000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib6796d59fa424ba69653cef4e3d47ff1_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181OC9mcmFnOjQ2NmRlMDUxNjNjYjQ0MzRhMTkxNDY1YTcyZmUyMzFjL3RhYmxlOjMyNWIwOGIyYjM1NDQ1ODBhNGU0YWYzZTM5NzQyOWU4L3RhYmxlcmFuZ2U6MzI1YjA4YjJiMzU0NDU4MGE0ZTRhZjNlMzk3NDI5ZThfNS03LTEtMS0w_79ea73ba-8d7d-4c90-9d2a-e24570f50079"
      unitRef="usd">4561000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i679cb28be3a34242bd30bce045577c6e_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181OC9mcmFnOjQ2NmRlMDUxNjNjYjQ0MzRhMTkxNDY1YTcyZmUyMzFjL3RhYmxlOjMyNWIwOGIyYjM1NDQ1ODBhNGU0YWYzZTM5NzQyOWU4L3RhYmxlcmFuZ2U6MzI1YjA4YjJiMzU0NDU4MGE0ZTRhZjNlMzk3NDI5ZThfNi0xLTEtMS0zNTk_689db974-a620-44d6-b5e3-320fedf3bc82"
      unitRef="usd">74863000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibebddd07c46e4994849d375ecea231c6_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181OC9mcmFnOjQ2NmRlMDUxNjNjYjQ0MzRhMTkxNDY1YTcyZmUyMzFjL3RhYmxlOjMyNWIwOGIyYjM1NDQ1ODBhNGU0YWYzZTM5NzQyOWU4L3RhYmxlcmFuZ2U6MzI1YjA4YjJiMzU0NDU4MGE0ZTRhZjNlMzk3NDI5ZThfNi0zLTEtMS0zNTk_a3356a78-a187-4601-a3b7-bbeb168a6c2a"
      unitRef="usd">86521000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1c9bfa2d7f884c12b69f21c9b3af2888_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181OC9mcmFnOjQ2NmRlMDUxNjNjYjQ0MzRhMTkxNDY1YTcyZmUyMzFjL3RhYmxlOjMyNWIwOGIyYjM1NDQ1ODBhNGU0YWYzZTM5NzQyOWU4L3RhYmxlcmFuZ2U6MzI1YjA4YjJiMzU0NDU4MGE0ZTRhZjNlMzk3NDI5ZThfNi01LTEtMS0zNjM_a2311711-d142-4405-ab1f-3bb6e5dd0239"
      unitRef="usd">147194000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i16325f028066493d8ad0ddc953bde9e9_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181OC9mcmFnOjQ2NmRlMDUxNjNjYjQ0MzRhMTkxNDY1YTcyZmUyMzFjL3RhYmxlOjMyNWIwOGIyYjM1NDQ1ODBhNGU0YWYzZTM5NzQyOWU4L3RhYmxlcmFuZ2U6MzI1YjA4YjJiMzU0NDU4MGE0ZTRhZjNlMzk3NDI5ZThfNi03LTEtMS0zNjM_5e2e5685-c6de-4c60-83e2-311b232f55c2"
      unitRef="usd">130778000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5d62628d6fb54fe0bd811fdfd0bf7b0c_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181OC9mcmFnOjQ2NmRlMDUxNjNjYjQ0MzRhMTkxNDY1YTcyZmUyMzFjL3RhYmxlOjMyNWIwOGIyYjM1NDQ1ODBhNGU0YWYzZTM5NzQyOWU4L3RhYmxlcmFuZ2U6MzI1YjA4YjJiMzU0NDU4MGE0ZTRhZjNlMzk3NDI5ZThfNi0xLTEtMS0w_ed1638d3-a812-4076-86d7-c3abb4ac0266"
      unitRef="usd">159700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8d756ddfc980426086c7294d41dd2af3_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181OC9mcmFnOjQ2NmRlMDUxNjNjYjQ0MzRhMTkxNDY1YTcyZmUyMzFjL3RhYmxlOjMyNWIwOGIyYjM1NDQ1ODBhNGU0YWYzZTM5NzQyOWU4L3RhYmxlcmFuZ2U6MzI1YjA4YjJiMzU0NDU4MGE0ZTRhZjNlMzk3NDI5ZThfNi0zLTEtMS0w_26326631-2a8a-4cc9-a763-af1d825987ab"
      unitRef="usd">182898000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib887805409a54f638aeeafe3fe5d1688_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181OC9mcmFnOjQ2NmRlMDUxNjNjYjQ0MzRhMTkxNDY1YTcyZmUyMzFjL3RhYmxlOjMyNWIwOGIyYjM1NDQ1ODBhNGU0YWYzZTM5NzQyOWU4L3RhYmxlcmFuZ2U6MzI1YjA4YjJiMzU0NDU4MGE0ZTRhZjNlMzk3NDI5ZThfNi01LTEtMS0w_21c1573b-9d25-44b4-a9db-58cdd09740d6"
      unitRef="usd">277428000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic606425dedeb4d3d9b0b453c252ea236_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181OC9mcmFnOjQ2NmRlMDUxNjNjYjQ0MzRhMTkxNDY1YTcyZmUyMzFjL3RhYmxlOjMyNWIwOGIyYjM1NDQ1ODBhNGU0YWYzZTM5NzQyOWU4L3RhYmxlcmFuZ2U6MzI1YjA4YjJiMzU0NDU4MGE0ZTRhZjNlMzk3NDI5ZThfNi03LTEtMS0w_64239d68-b930-47aa-8e2a-59293a805ab9"
      unitRef="usd">255633000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181OC9mcmFnOjQ2NmRlMDUxNjNjYjQ0MzRhMTkxNDY1YTcyZmUyMzFjL3RleHRyZWdpb246NDY2ZGUwNTE2M2NiNDQzNGExOTE0NjVhNzJmZTIzMWNfNTA4Mw_ca35699a-4cf0-47d2-bdda-5f184cbc6d7c"
      unitRef="usd">181200000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligationPercentage
      contextRef="ia58666fd3ef747c9bd6d04b645148e3f_I20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181OC9mcmFnOjQ2NmRlMDUxNjNjYjQ0MzRhMTkxNDY1YTcyZmUyMzFjL3RleHRyZWdpb246NDY2ZGUwNTE2M2NiNDQzNGExOTE0NjVhNzJmZTIzMWNfNTcwMg_cde7177b-44d8-4588-9b2d-6fa1e0aa6979"
      unitRef="number">0.18</us-gaap:RevenueRemainingPerformanceObligationPercentage>
    <us-gaap:RevenueRemainingPerformanceObligationPercentage
      contextRef="i486b139f28404e439444f6f0c13129da_I20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181OC9mcmFnOjQ2NmRlMDUxNjNjYjQ0MzRhMTkxNDY1YTcyZmUyMzFjL3RleHRyZWdpb246NDY2ZGUwNTE2M2NiNDQzNGExOTE0NjVhNzJmZTIzMWNfNTcwOQ_a8558487-a220-4099-a63d-f5326c464588"
      unitRef="number">0.51</us-gaap:RevenueRemainingPerformanceObligationPercentage>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181OC9mcmFnOjQ2NmRlMDUxNjNjYjQ0MzRhMTkxNDY1YTcyZmUyMzFjL3RleHRyZWdpb246NDY2ZGUwNTE2M2NiNDQzNGExOTE0NjVhNzJmZTIzMWNfMTAxNDU_303c575a-d8f3-434a-b39a-4922edfc2bde">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides information about receivables, contract assets and deferred revenue from contracts with customers as of June&#160;30, 2021 and December&#160;31, 2020 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:403.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:67.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term receivables &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;240,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term receivables &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term contract assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Amounts exclude $3.4&#160;million of short-term receivables and $4.1&#160;million of short-term deferred revenue reclassified to discontinued operations as of December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Excludes pharmacy claims receivable and premiums receivable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in deferred revenue for the six months ended June 30, 2021 are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:433.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:102.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of beginning-of-period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reclassification to revenue, as a result of performance obligations satisfied&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,726)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash received in advance of satisfaction of performance obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,051&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <us-gaap:AccountsNotesAndLoansReceivableNetCurrent
      contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181OC9mcmFnOjQ2NmRlMDUxNjNjYjQ0MzRhMTkxNDY1YTcyZmUyMzFjL3RhYmxlOjI5YmU0MDRkNzEzNzQ2N2U5MjVkN2Q2MTg2NDViZGVjL3RhYmxlcmFuZ2U6MjliZTQwNGQ3MTM3NDY3ZTkyNWQ3ZDYxODY0NWJkZWNfMS0xLTEtMS0w_7f63c551-5251-43e9-9935-3c90e28536a7"
      unitRef="usd">240060000</us-gaap:AccountsNotesAndLoansReceivableNetCurrent>
    <us-gaap:AccountsNotesAndLoansReceivableNetCurrent
      contextRef="i45bff335c1434d6ba44132da1b0557db_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181OC9mcmFnOjQ2NmRlMDUxNjNjYjQ0MzRhMTkxNDY1YTcyZmUyMzFjL3RhYmxlOjI5YmU0MDRkNzEzNzQ2N2U5MjVkN2Q2MTg2NDViZGVjL3RhYmxlcmFuZ2U6MjliZTQwNGQ3MTM3NDY3ZTkyNWQ3ZDYxODY0NWJkZWNfMS0zLTEtMS0w_1ef5b790-ee8c-45be-aa52-650cb198697f"
      unitRef="usd">124064000</us-gaap:AccountsNotesAndLoansReceivableNetCurrent>
    <us-gaap:LongTermAccountsNotesAndLoansReceivableNetNoncurrent
      contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181OC9mcmFnOjQ2NmRlMDUxNjNjYjQ0MzRhMTkxNDY1YTcyZmUyMzFjL3RhYmxlOjI5YmU0MDRkNzEzNzQ2N2U5MjVkN2Q2MTg2NDViZGVjL3RhYmxlcmFuZ2U6MjliZTQwNGQ3MTM3NDY3ZTkyNWQ3ZDYxODY0NWJkZWNfMi0xLTEtMS0w_db2e90f5-2c69-4600-88f3-8e1465746106"
      unitRef="usd">4688000</us-gaap:LongTermAccountsNotesAndLoansReceivableNetNoncurrent>
    <us-gaap:LongTermAccountsNotesAndLoansReceivableNetNoncurrent
      contextRef="i45bff335c1434d6ba44132da1b0557db_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181OC9mcmFnOjQ2NmRlMDUxNjNjYjQ0MzRhMTkxNDY1YTcyZmUyMzFjL3RhYmxlOjI5YmU0MDRkNzEzNzQ2N2U5MjVkN2Q2MTg2NDViZGVjL3RhYmxlcmFuZ2U6MjliZTQwNGQ3MTM3NDY3ZTkyNWQ3ZDYxODY0NWJkZWNfMi0zLTEtMS0w_8cbf2147-8b82-4e7f-8ef2-f31e33bd8742"
      unitRef="usd">4554000</us-gaap:LongTermAccountsNotesAndLoansReceivableNetNoncurrent>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181OC9mcmFnOjQ2NmRlMDUxNjNjYjQ0MzRhMTkxNDY1YTcyZmUyMzFjL3RhYmxlOjI5YmU0MDRkNzEzNzQ2N2U5MjVkN2Q2MTg2NDViZGVjL3RhYmxlcmFuZ2U6MjliZTQwNGQ3MTM3NDY3ZTkyNWQ3ZDYxODY0NWJkZWNfMy0xLTEtMS0w_fd047251-ee27-4671-929a-451336be8b91"
      unitRef="usd">0</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="i45bff335c1434d6ba44132da1b0557db_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181OC9mcmFnOjQ2NmRlMDUxNjNjYjQ0MzRhMTkxNDY1YTcyZmUyMzFjL3RhYmxlOjI5YmU0MDRkNzEzNzQ2N2U5MjVkN2Q2MTg2NDViZGVjL3RhYmxlcmFuZ2U6MjliZTQwNGQ3MTM3NDY3ZTkyNWQ3ZDYxODY0NWJkZWNfMy0zLTEtMS0w_5ca7e971-2924-4796-8844-a913a635eee9"
      unitRef="usd">329000</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181OC9mcmFnOjQ2NmRlMDUxNjNjYjQ0MzRhMTkxNDY1YTcyZmUyMzFjL3RhYmxlOjI5YmU0MDRkNzEzNzQ2N2U5MjVkN2Q2MTg2NDViZGVjL3RhYmxlcmFuZ2U6MjliZTQwNGQ3MTM3NDY3ZTkyNWQ3ZDYxODY0NWJkZWNfNC0xLTEtMS0w_22665d5d-ad36-4b65-97c4-f78ee3eb4b65"
      unitRef="usd">13173000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i45bff335c1434d6ba44132da1b0557db_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181OC9mcmFnOjQ2NmRlMDUxNjNjYjQ0MzRhMTkxNDY1YTcyZmUyMzFjL3RhYmxlOjI5YmU0MDRkNzEzNzQ2N2U5MjVkN2Q2MTg2NDViZGVjL3RhYmxlcmFuZ2U6MjliZTQwNGQ3MTM3NDY3ZTkyNWQ3ZDYxODY0NWJkZWNfNC0zLTEtMS0w_5cb7ec90-cad3-4f30-b751-75c20cce1a6e"
      unitRef="usd">10187000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181OC9mcmFnOjQ2NmRlMDUxNjNjYjQ0MzRhMTkxNDY1YTcyZmUyMzFjL3RhYmxlOjI5YmU0MDRkNzEzNzQ2N2U5MjVkN2Q2MTg2NDViZGVjL3RhYmxlcmFuZ2U6MjliZTQwNGQ3MTM3NDY3ZTkyNWQ3ZDYxODY0NWJkZWNfNS0xLTEtMS0w_78616fad-4b41-42cb-8f7d-f06205b84d83"
      unitRef="usd">4932000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i45bff335c1434d6ba44132da1b0557db_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181OC9mcmFnOjQ2NmRlMDUxNjNjYjQ0MzRhMTkxNDY1YTcyZmUyMzFjL3RhYmxlOjI5YmU0MDRkNzEzNzQ2N2U5MjVkN2Q2MTg2NDViZGVjL3RhYmxlcmFuZ2U6MjliZTQwNGQ3MTM3NDY3ZTkyNWQ3ZDYxODY0NWJkZWNfNS0zLTEtMS0w_92c2cba2-68a9-44a9-8455-e00665790c9b"
      unitRef="usd">3593000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <evh:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNetAfterGrossUp
      contextRef="ia177f909fbae4389bdaa8635f038babb_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181OC9mcmFnOjQ2NmRlMDUxNjNjYjQ0MzRhMTkxNDY1YTcyZmUyMzFjL3RleHRyZWdpb246NDY2ZGUwNTE2M2NiNDQzNGExOTE0NjVhNzJmZTIzMWNfNzYzOQ_7fec4e4b-b46e-4ae5-a78a-377160fa1265"
      unitRef="usd">3400000</evh:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNetAfterGrossUp>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent
      contextRef="ia177f909fbae4389bdaa8635f038babb_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181OC9mcmFnOjQ2NmRlMDUxNjNjYjQ0MzRhMTkxNDY1YTcyZmUyMzFjL3RleHRyZWdpb246NDY2ZGUwNTE2M2NiNDQzNGExOTE0NjVhNzJmZTIzMWNfNzY3Mg_4be919e8-0ef0-4c00-98fe-abdb784f3b2c"
      unitRef="usd">4100000</us-gaap:DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i45bff335c1434d6ba44132da1b0557db_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181OC9mcmFnOjQ2NmRlMDUxNjNjYjQ0MzRhMTkxNDY1YTcyZmUyMzFjL3RhYmxlOjVmYjI2OTk3ODc0YzQ4YzZiNWE2YTI5ZDUzMzExMDkxL3RhYmxlcmFuZ2U6NWZiMjY5OTc4NzRjNDhjNmI1YTZhMjlkNTMzMTEwOTFfNy0xLTEtMS0w_04acfe70-0db1-4b88-841f-be97cd04a292"
      unitRef="usd">13780000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181OC9mcmFnOjQ2NmRlMDUxNjNjYjQ0MzRhMTkxNDY1YTcyZmUyMzFjL3RhYmxlOjVmYjI2OTk3ODc0YzQ4YzZiNWE2YTI5ZDUzMzExMDkxL3RhYmxlcmFuZ2U6NWZiMjY5OTc4NzRjNDhjNmI1YTZhMjlkNTMzMTEwOTFfOC0xLTEtMS0w_fab0203c-a443-4985-9c3a-5d9955bf0628"
      unitRef="usd">8726000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <evh:ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181OC9mcmFnOjQ2NmRlMDUxNjNjYjQ0MzRhMTkxNDY1YTcyZmUyMzFjL3RhYmxlOjVmYjI2OTk3ODc0YzQ4YzZiNWE2YTI5ZDUzMzExMDkxL3RhYmxlcmFuZ2U6NWZiMjY5OTc4NzRjNDhjNmI1YTZhMjlkNTMzMTEwOTFfOS0xLTEtMS0w_68327442-bb8d-41b9-bfd0-8063cb2b5cb5"
      unitRef="usd">13051000</evh:ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations>
    <us-gaap:ContractWithCustomerLiability
      contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181OC9mcmFnOjQ2NmRlMDUxNjNjYjQ0MzRhMTkxNDY1YTcyZmUyMzFjL3RhYmxlOjVmYjI2OTk3ODc0YzQ4YzZiNWE2YTI5ZDUzMzExMDkxL3RhYmxlcmFuZ2U6NWZiMjY5OTc4NzRjNDhjNmI1YTZhMjlkNTMzMTEwOTFfMTAtMS0xLTEtMA_35bfac06-0b24-479e-86a0-623b94e977f2"
      unitRef="usd">18105000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
      contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181OC9mcmFnOjQ2NmRlMDUxNjNjYjQ0MzRhMTkxNDY1YTcyZmUyMzFjL3RleHRyZWdpb246NDY2ZGUwNTE2M2NiNDQzNGExOTE0NjVhNzJmZTIzMWNfMTA5OTUxMTYzODEwNw_6824a3e9-9e90-412e-b040-64d719483535"
      unitRef="usd">2900000</us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod>
    <us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181OC9mcmFnOjQ2NmRlMDUxNjNjYjQ0MzRhMTkxNDY1YTcyZmUyMzFjL3RleHRyZWdpb246NDY2ZGUwNTE2M2NiNDQzNGExOTE0NjVhNzJmZTIzMWNfODAyNw_a32fb5b5-347f-4a6a-a95b-f83b5ec0901b"
      unitRef="usd">16100000</us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod>
    <us-gaap:CapitalizedContractCostNet
      contextRef="id9deab8552a14f5eb736da5c6d86fc8c_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181OC9mcmFnOjQ2NmRlMDUxNjNjYjQ0MzRhMTkxNDY1YTcyZmUyMzFjL3RleHRyZWdpb246NDY2ZGUwNTE2M2NiNDQzNGExOTE0NjVhNzJmZTIzMWNfODY5Nw_f13eef59-6b4f-4a70-a43d-fd194dcaa4c4"
      unitRef="usd">3600000</us-gaap:CapitalizedContractCostNet>
    <us-gaap:CapitalizedContractCostNet
      contextRef="i82a60e4d756c4c5e95ccf693e56f48a9_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181OC9mcmFnOjQ2NmRlMDUxNjNjYjQ0MzRhMTkxNDY1YTcyZmUyMzFjL3RleHRyZWdpb246NDY2ZGUwNTE2M2NiNDQzNGExOTE0NjVhNzJmZTIzMWNfODcwNA_44d9982f-6d21-46f1-b621-154eb823f1b9"
      unitRef="usd">3300000</us-gaap:CapitalizedContractCostNet>
    <us-gaap:CapitalizedContractCostAmortization
      contextRef="i06ae7c987bf741caa484f758c9e8534d_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181OC9mcmFnOjQ2NmRlMDUxNjNjYjQ0MzRhMTkxNDY1YTcyZmUyMzFjL3RleHRyZWdpb246NDY2ZGUwNTE2M2NiNDQzNGExOTE0NjVhNzJmZTIzMWNfMTY0OTI2NzQ1MjAwNg_39bf1708-4b03-451a-b36b-20e1a9f440c3"
      unitRef="usd">600000</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:CapitalizedContractCostAmortization
      contextRef="idadd3c2bee534377ac63ee0a2aa2dc8c_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181OC9mcmFnOjQ2NmRlMDUxNjNjYjQ0MzRhMTkxNDY1YTcyZmUyMzFjL3RleHRyZWdpb246NDY2ZGUwNTE2M2NiNDQzNGExOTE0NjVhNzJmZTIzMWNfODkxOA_e2c5869e-f54d-459a-8ad1-a4aff0daa3d9"
      unitRef="usd">1000000.0</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:CapitalizedContractCostAmortization
      contextRef="i86cf0d7a76724f38ab859d26bde2920a_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181OC9mcmFnOjQ2NmRlMDUxNjNjYjQ0MzRhMTkxNDY1YTcyZmUyMzFjL3RleHRyZWdpb246NDY2ZGUwNTE2M2NiNDQzNGExOTE0NjVhNzJmZTIzMWNfMTY0OTI2NzQ1MjAyMA_9218f0c2-efa6-4c92-8b23-b3c0f641af21"
      unitRef="usd">400000</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:CapitalizedContractCostAmortization
      contextRef="i2255e38e922f4d94b90c933ab1b70b67_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181OC9mcmFnOjQ2NmRlMDUxNjNjYjQ0MzRhMTkxNDY1YTcyZmUyMzFjL3RleHRyZWdpb246NDY2ZGUwNTE2M2NiNDQzNGExOTE0NjVhNzJmZTIzMWNfODkyNQ_adaf44d4-12b7-498b-bad6-e23060555594"
      unitRef="usd">900000</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:CapitalizedContractCostNet
      contextRef="i8514ff7930a54e788f76b2be07ba421a_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181OC9mcmFnOjQ2NmRlMDUxNjNjYjQ0MzRhMTkxNDY1YTcyZmUyMzFjL3RleHRyZWdpb246NDY2ZGUwNTE2M2NiNDQzNGExOTE0NjVhNzJmZTIzMWNfOTY1NA_130610aa-7ce1-4531-8afc-ba5830ccdbcc"
      unitRef="usd">18800000</us-gaap:CapitalizedContractCostNet>
    <us-gaap:CapitalizedContractCostNet
      contextRef="i296b1e421ebd4c6fa47abf987a270359_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181OC9mcmFnOjQ2NmRlMDUxNjNjYjQ0MzRhMTkxNDY1YTcyZmUyMzFjL3RleHRyZWdpb246NDY2ZGUwNTE2M2NiNDQzNGExOTE0NjVhNzJmZTIzMWNfOTY2MQ_d7d08fae-d47f-4dbd-a037-bce0a554aed6"
      unitRef="usd">23400000</us-gaap:CapitalizedContractCostNet>
    <us-gaap:CapitalizedContractCostAmortization
      contextRef="i27ed1697f8ec480093c84d3cf0952a90_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181OC9mcmFnOjQ2NmRlMDUxNjNjYjQ0MzRhMTkxNDY1YTcyZmUyMzFjL3RleHRyZWdpb246NDY2ZGUwNTE2M2NiNDQzNGExOTE0NjVhNzJmZTIzMWNfMTY0OTI2NzQ1MjA1Ng_0fe4f215-acfd-459d-bb32-51807d1960e7"
      unitRef="usd">4600000</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:CapitalizedContractCostAmortization
      contextRef="ic6fb32c2d54b4c729398fb1ececf52fa_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181OC9mcmFnOjQ2NmRlMDUxNjNjYjQ0MzRhMTkxNDY1YTcyZmUyMzFjL3RleHRyZWdpb246NDY2ZGUwNTE2M2NiNDQzNGExOTE0NjVhNzJmZTIzMWNfOTg3NQ_23ea81ed-67f7-4358-9e16-36195557162b"
      unitRef="usd">7300000</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:CapitalizedContractCostAmortization
      contextRef="ib613b60e238f47b69fde69e1a6a8f9be_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181OC9mcmFnOjQ2NmRlMDUxNjNjYjQ0MzRhMTkxNDY1YTcyZmUyMzFjL3RleHRyZWdpb246NDY2ZGUwNTE2M2NiNDQzNGExOTE0NjVhNzJmZTIzMWNfMTY0OTI2NzQ1MjA5NA_781f31af-9576-40a1-95b8-50f9f4726315"
      unitRef="usd">4300000</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:CapitalizedContractCostAmortization
      contextRef="if15e3a35bf6243958b35f8728c4cc216_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181OC9mcmFnOjQ2NmRlMDUxNjNjYjQ0MzRhMTkxNDY1YTcyZmUyMzFjL3RleHRyZWdpb246NDY2ZGUwNTE2M2NiNDQzNGExOTE0NjVhNzJmZTIzMWNfOTg4Mg_53a6d103-107a-4b12-81bc-9bdafdffe2e0"
      unitRef="usd">9400000</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:CapitalizedContractCostAmortizationPeriod
      contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY181OC9mcmFnOjQ2NmRlMDUxNjNjYjQ0MzRhMTkxNDY1YTcyZmUyMzFjL3RleHRyZWdpb246NDY2ZGUwNTE2M2NiNDQzNGExOTE0NjVhNzJmZTIzMWNfMTAwMzI_fe803b9c-5c60-40c9-ba4c-9e6880fec8d8">P5Y</us-gaap:CapitalizedContractCostAmortizationPeriod>
    <us-gaap:CreditLossFinancialInstrumentTextBlock
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY182NC9mcmFnOjQ2MDYyMThjNmFjMDQyYzU4YTQwODliNmQzODJlMTM5L3RleHRyZWdpb246NDYwNjIxOGM2YWMwNDJjNThhNDA4OWI2ZDM4MmUxMzlfMjc2NQ_0b558228-b90d-4b89-bd7a-f100e5d0bfb4">Credit Losses &lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are exposed to credit losses primarily through our accounts receivable from revenue transactions, investments held at amortized cost and customer advances for regulatory capital and other notes receivable. We estimate expected credit losses based on past events, current conditions and reasonable and supportable forecasts. Expected credit losses are measured over the remaining contractual life of these assets. As part of our consideration of current and forward-looking economic conditions, we considered the impact of the COVID-19 pandemic on our customers&#x2019; and other third parties&#x2019; ability to pay. We did not observe notable increases in delinquencies during the three and six months ended June 30, 2021. Given the nature of our business, our past collection experience during recessionary and pre-recessionary periods, and our forecasted impact of the COVID-19 pandemic on our business, we did not record material changes in our allowances due to the COVID-19 pandemic during the three and six months ended June 30, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounts Receivable from Revenue Transactions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts receivable represent the amounts owed to the Company for goods or services provided to customers or third parties. Current accounts receivables are classified within accounts receivable, net on the Company&#x2019;s consolidated balance sheets, while non-current accounts receivables are classified within prepaid expenses and other noncurrent assets on the Company&#x2019;s consolidated balance sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We monitor our ongoing credit exposure through active review of counterparty balances against contract terms, due dates and business strategy. Our activities include timely account reconciliation, dispute resolution and payment confirmation. We may employ legal counsel to pursue recovery of defaulted receivables. In addition, the Company will establish a general reserve based on delinquency rates. Historical loss rates are determined for each delinquency bucket in 30-day past-due intervals, and then applied to the composition of the reporting date balance based on delinquency. The allowance implied from application of the historical loss rates is then adjusted, as necessary, for current conditions and reasonable and supportable forecasts.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Based on an aging analysis of our trade accounts receivable, non-trade accounts receivable and contract assets at&#160;June&#160;30, 2021,&#160;64% were current, 15%&#160;were past due less than 60 days, with 28% past due less than 120 days. At&#160;June&#160;30, 2021, we reported&#160;$264.1 million&#160;of accounts receivable, certain non-trade accounts receivable included in prepaid expenses and other assets on the consolidated balance sheet and contract assets, net of allowances of&#160;$7.7 million. The following table summarizes the changes in allowance for credit losses on our accounts receivables, certain non-trade accounts receivable and contract assets for the six months ended June 30, 2021 and 2020 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.816%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.594%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,056)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(41)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cumulative transition adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,815)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision for credit losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(611)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(260)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Charge-offs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,667)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,541)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:CreditLossFinancialInstrumentTextBlock>
    <evh:FinancingReceivablePercentNotPastDue
      contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY182NC9mcmFnOjQ2MDYyMThjNmFjMDQyYzU4YTQwODliNmQzODJlMTM5L3RleHRyZWdpb246NDYwNjIxOGM2YWMwNDJjNThhNDA4OWI2ZDM4MmUxMzlfMjI5Mg_18e248d7-ca2b-4627-a973-f34344ed48b3"
      unitRef="number">0.64</evh:FinancingReceivablePercentNotPastDue>
    <us-gaap:FinancingReceivablePercentPastDue1
      contextRef="i2a6d7a68b4464c1c9d7d5339891880a1_I20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY182NC9mcmFnOjQ2MDYyMThjNmFjMDQyYzU4YTQwODliNmQzODJlMTM5L3RleHRyZWdpb246NDYwNjIxOGM2YWMwNDJjNThhNDA4OWI2ZDM4MmUxMzlfMjMwOQ_eaaf13f0-33c5-4fd8-b64b-aa38a1e5910d"
      unitRef="number">0.15</us-gaap:FinancingReceivablePercentPastDue1>
    <us-gaap:FinancingReceivablePercentPastDue1
      contextRef="i62715a632a4b4513bd30977aa196bcc0_I20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY182NC9mcmFnOjQ2MDYyMThjNmFjMDQyYzU4YTQwODliNmQzODJlMTM5L3RleHRyZWdpb246NDYwNjIxOGM2YWMwNDJjNThhNDA4OWI2ZDM4MmUxMzlfMjM1MA_8ca5d6e3-f6ef-45dd-b17c-76a9aba4e6e4"
      unitRef="number">0.28</us-gaap:FinancingReceivablePercentPastDue1>
    <us-gaap:AccountsReceivableNet
      contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY182NC9mcmFnOjQ2MDYyMThjNmFjMDQyYzU4YTQwODliNmQzODJlMTM5L3RleHRyZWdpb246NDYwNjIxOGM2YWMwNDJjNThhNDA4OWI2ZDM4MmUxMzlfMjQwMQ_4c1494c4-9fe2-42fa-ab94-a15ff10e3eb0"
      unitRef="usd">264100000</us-gaap:AccountsReceivableNet>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY182NC9mcmFnOjQ2MDYyMThjNmFjMDQyYzU4YTQwODliNmQzODJlMTM5L3RleHRyZWdpb246NDYwNjIxOGM2YWMwNDJjNThhNDA4OWI2ZDM4MmUxMzlfMjU4MA_0753c7ec-e24b-4051-9f7f-c28d7d7255da"
      unitRef="usd">7700000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY182NC9mcmFnOjQ2MDYyMThjNmFjMDQyYzU4YTQwODliNmQzODJlMTM5L3RleHRyZWdpb246NDYwNjIxOGM2YWMwNDJjNThhNDA4OWI2ZDM4MmUxMzlfMjc2Ng_194ddd12-578a-4d1d-8bec-f893019fb6ce">The following table summarizes the changes in allowance for credit losses on our accounts receivables, certain non-trade accounts receivable and contract assets for the six months ended June 30, 2021 and 2020 (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.816%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.594%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,056)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(41)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cumulative transition adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,815)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision for credit losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(611)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(260)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Charge-offs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,667)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,541)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="i45bff335c1434d6ba44132da1b0557db_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY182NC9mcmFnOjQ2MDYyMThjNmFjMDQyYzU4YTQwODliNmQzODJlMTM5L3RhYmxlOjlhZjc5NmM0M2FkOTRmNzdhYzYxZjE3YWVkNDlhYjUyL3RhYmxlcmFuZ2U6OWFmNzk2YzQzYWQ5NGY3N2FjNjFmMTdhZWQ0OWFiNTJfMi0xLTEtMS0w_dd53a69f-3101-4530-a17c-2f5bde5059e4"
      unitRef="usd">7056000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="ie0ff0ad229b441d4b12bc8956f92a917_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY182NC9mcmFnOjQ2MDYyMThjNmFjMDQyYzU4YTQwODliNmQzODJlMTM5L3RhYmxlOjlhZjc5NmM0M2FkOTRmNzdhYzYxZjE3YWVkNDlhYjUyL3RhYmxlcmFuZ2U6OWFmNzk2YzQzYWQ5NGY3N2FjNjFmMTdhZWQ0OWFiNTJfMi0zLTEtMS0w_d1dd70dc-7bfa-4061-90c5-ea50a1097a6b"
      unitRef="usd">41000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="i4306692d5e5e4a86b318371f5399f564_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY182NC9mcmFnOjQ2MDYyMThjNmFjMDQyYzU4YTQwODliNmQzODJlMTM5L3RhYmxlOjlhZjc5NmM0M2FkOTRmNzdhYzYxZjE3YWVkNDlhYjUyL3RhYmxlcmFuZ2U6OWFmNzk2YzQzYWQ5NGY3N2FjNjFmMTdhZWQ0OWFiNTJfMy0xLTEtMS0w_b64ef9d4-0ff6-49f4-bd7d-78692f13334d"
      unitRef="usd">0</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="i6e620150ffe942b388f50fab8377e007_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY182NC9mcmFnOjQ2MDYyMThjNmFjMDQyYzU4YTQwODliNmQzODJlMTM5L3RhYmxlOjlhZjc5NmM0M2FkOTRmNzdhYzYxZjE3YWVkNDlhYjUyL3RhYmxlcmFuZ2U6OWFmNzk2YzQzYWQ5NGY3N2FjNjFmMTdhZWQ0OWFiNTJfMy0zLTEtMS0w_706d5e88-b17f-4333-91af-c9cb827c379c"
      unitRef="usd">2815000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY182NC9mcmFnOjQ2MDYyMThjNmFjMDQyYzU4YTQwODliNmQzODJlMTM5L3RhYmxlOjlhZjc5NmM0M2FkOTRmNzdhYzYxZjE3YWVkNDlhYjUyL3RhYmxlcmFuZ2U6OWFmNzk2YzQzYWQ5NGY3N2FjNjFmMTdhZWQ0OWFiNTJfNC0xLTEtMS0w_d97d92fd-847f-4041-ace3-ed66f4fc72f6"
      unitRef="usd">611000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY182NC9mcmFnOjQ2MDYyMThjNmFjMDQyYzU4YTQwODliNmQzODJlMTM5L3RhYmxlOjlhZjc5NmM0M2FkOTRmNzdhYzYxZjE3YWVkNDlhYjUyL3RhYmxlcmFuZ2U6OWFmNzk2YzQzYWQ5NGY3N2FjNjFmMTdhZWQ0OWFiNTJfNC0zLTEtMS0w_6e606579-bb22-465c-a442-8becd0278c04"
      unitRef="usd">260000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY182NC9mcmFnOjQ2MDYyMThjNmFjMDQyYzU4YTQwODliNmQzODJlMTM5L3RhYmxlOjlhZjc5NmM0M2FkOTRmNzdhYzYxZjE3YWVkNDlhYjUyL3RhYmxlcmFuZ2U6OWFmNzk2YzQzYWQ5NGY3N2FjNjFmMTdhZWQ0OWFiNTJfNS0xLTEtMS00MjQ_cd2a15f3-49b4-4edc-b7d6-372b8a7519ac"
      unitRef="usd">0</us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY182NC9mcmFnOjQ2MDYyMThjNmFjMDQyYzU4YTQwODliNmQzODJlMTM5L3RhYmxlOjlhZjc5NmM0M2FkOTRmNzdhYzYxZjE3YWVkNDlhYjUyL3RhYmxlcmFuZ2U6OWFmNzk2YzQzYWQ5NGY3N2FjNjFmMTdhZWQ0OWFiNTJfNS0zLTEtMS00MjQ_65441b2f-f038-4a88-afd0-27b9f62d94a0"
      unitRef="usd">1575000</us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY182NC9mcmFnOjQ2MDYyMThjNmFjMDQyYzU4YTQwODliNmQzODJlMTM5L3RhYmxlOjlhZjc5NmM0M2FkOTRmNzdhYzYxZjE3YWVkNDlhYjUyL3RhYmxlcmFuZ2U6OWFmNzk2YzQzYWQ5NGY3N2FjNjFmMTdhZWQ0OWFiNTJfNi0xLTEtMS0w_32f917c5-0de2-4634-985e-cc0c9e823d42"
      unitRef="usd">7667000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="i11817f96c3e24e0abaed14a17869e173_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY182NC9mcmFnOjQ2MDYyMThjNmFjMDQyYzU4YTQwODliNmQzODJlMTM5L3RhYmxlOjlhZjc5NmM0M2FkOTRmNzdhYzYxZjE3YWVkNDlhYjUyL3RhYmxlcmFuZ2U6OWFmNzk2YzQzYWQ5NGY3N2FjNjFmMTdhZWQ0OWFiNTJfNi0zLTEtMS0w_0c7594a2-8b2e-4f03-8821-1894335d9f96"
      unitRef="usd">1541000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY182Ny9mcmFnOmFmOTA1MDI0MWUxNTQ4NGI5NWEzOGE2MWZjYzc3ZDdlL3RleHRyZWdpb246YWY5MDUwMjQxZTE1NDg0Yjk1YTM4YTYxZmNjNzdkN2VfNTU0_952df695-6e69-4d46-8f68-dd23b318c34a">Property and Equipment, Net&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following summarizes our property and equipment as of June&#160;30, 2021 and December&#160;31, 2020 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:408.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:54.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:67.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer hardware&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,866&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,545&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Internal-use software development costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148,171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137,085&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;187,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;175,096&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated depreciation and amortization expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(104,204)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(88,856)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company capitalized $5.6 million and $11.1 million of internal-use software development costs for the three and six months ended June 30, 2021, respectively, and $6.4 million and  $13.7 million for the three and six months ended June 30, 2020, respectively. The net book value of capitalized internal-use software development costs was $73.0 million and $75.3 million as of June&#160;30, 2021 and December&#160;31, 2020, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation expense related to property and equipment was $7.6 million and $15.4 million for the three and six months ended June 30, 2021, respectively, and $7.1 million and $13.9 million for the three and six months ended June 30, 2020, respectively, of which amortization expense related to capitalized internal-use software development costs was $6.6 million and $13.3 million for the three and six months ended June 30, 2021, respectively, and $6.0 million and $11.6 million for the three and six months ended June 30, 2020, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY182Ny9mcmFnOmFmOTA1MDI0MWUxNTQ4NGI5NWEzOGE2MWZjYzc3ZDdlL3RleHRyZWdpb246YWY5MDUwMjQxZTE1NDg0Yjk1YTM4YTYxZmNjNzdkN2VfNTU3_39308b0c-b07f-4a2f-86a6-d66bd2037ebe">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following summarizes our property and equipment as of June&#160;30, 2021 and December&#160;31, 2020 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:408.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:54.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:67.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer hardware&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,866&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,545&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Internal-use software development costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148,171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137,085&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;187,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;175,096&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated depreciation and amortization expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(104,204)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(88,856)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ifb44c2b2a28446c4b3e3caa830711368_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY182Ny9mcmFnOmFmOTA1MDI0MWUxNTQ4NGI5NWEzOGE2MWZjYzc3ZDdlL3RhYmxlOmIwNzA3OTdlYjk2ZTRlNmQ4YWJkYjgyNDI1YzljMDYzL3RhYmxlcmFuZ2U6YjA3MDc5N2ViOTZlNGU2ZDhhYmRiODI0MjVjOWMwNjNfMS0xLTEtMS0w_4c9b1c2e-7278-40ba-94c7-cfae2c516eec"
      unitRef="usd">19931000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i57afc0d68f184fb899a29c776805bc85_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY182Ny9mcmFnOmFmOTA1MDI0MWUxNTQ4NGI5NWEzOGE2MWZjYzc3ZDdlL3RhYmxlOmIwNzA3OTdlYjk2ZTRlNmQ4YWJkYjgyNDI1YzljMDYzL3RhYmxlcmFuZ2U6YjA3MDc5N2ViOTZlNGU2ZDhhYmRiODI0MjVjOWMwNjNfMS0zLTEtMS0w_5e08cf25-2b6f-41fe-a120-389051179ab9"
      unitRef="usd">18866000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ie1bcc0c9ee4f48d2804f66aff99ff763_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY182Ny9mcmFnOmFmOTA1MDI0MWUxNTQ4NGI5NWEzOGE2MWZjYzc3ZDdlL3RhYmxlOmIwNzA3OTdlYjk2ZTRlNmQ4YWJkYjgyNDI1YzljMDYzL3RhYmxlcmFuZ2U6YjA3MDc5N2ViOTZlNGU2ZDhhYmRiODI0MjVjOWMwNjNfMi0xLTEtMS0w_f3094b1e-724d-4aa0-94c4-c0ba2670eaf1"
      unitRef="usd">3545000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i786125390bf04da6ad620815caf55ac6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY182Ny9mcmFnOmFmOTA1MDI0MWUxNTQ4NGI5NWEzOGE2MWZjYzc3ZDdlL3RhYmxlOmIwNzA3OTdlYjk2ZTRlNmQ4YWJkYjgyNDI1YzljMDYzL3RhYmxlcmFuZ2U6YjA3MDc5N2ViOTZlNGU2ZDhhYmRiODI0MjVjOWMwNjNfMi0zLTEtMS0w_b5cb23b2-214d-460c-963a-a03628215132"
      unitRef="usd">3559000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i3bacbba21c62440980d14afff52eb1ca_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY182Ny9mcmFnOmFmOTA1MDI0MWUxNTQ4NGI5NWEzOGE2MWZjYzc3ZDdlL3RhYmxlOmIwNzA3OTdlYjk2ZTRlNmQ4YWJkYjgyNDI1YzljMDYzL3RhYmxlcmFuZ2U6YjA3MDc5N2ViOTZlNGU2ZDhhYmRiODI0MjVjOWMwNjNfMy0xLTEtMS0w_53ea88ad-3d57-4bd0-9b98-94383c879922"
      unitRef="usd">148171000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i037a95e6b16d4dcea7b2b033c338785c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY182Ny9mcmFnOmFmOTA1MDI0MWUxNTQ4NGI5NWEzOGE2MWZjYzc3ZDdlL3RhYmxlOmIwNzA3OTdlYjk2ZTRlNmQ4YWJkYjgyNDI1YzljMDYzL3RhYmxlcmFuZ2U6YjA3MDc5N2ViOTZlNGU2ZDhhYmRiODI0MjVjOWMwNjNfMy0zLTEtMS0w_35bea834-d09b-42fb-ac65-04db7ad67b2a"
      unitRef="usd">137085000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i0a061c9add404e629ee1ae3de0f2006f_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY182Ny9mcmFnOmFmOTA1MDI0MWUxNTQ4NGI5NWEzOGE2MWZjYzc3ZDdlL3RhYmxlOmIwNzA3OTdlYjk2ZTRlNmQ4YWJkYjgyNDI1YzljMDYzL3RhYmxlcmFuZ2U6YjA3MDc5N2ViOTZlNGU2ZDhhYmRiODI0MjVjOWMwNjNfNC0xLTEtMS0w_e603fdad-47ee-4169-b4f1-5c5d8a702d60"
      unitRef="usd">15553000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i6e1d68f35e444ab6bb440e13e80ab435_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY182Ny9mcmFnOmFmOTA1MDI0MWUxNTQ4NGI5NWEzOGE2MWZjYzc3ZDdlL3RhYmxlOmIwNzA3OTdlYjk2ZTRlNmQ4YWJkYjgyNDI1YzljMDYzL3RhYmxlcmFuZ2U6YjA3MDc5N2ViOTZlNGU2ZDhhYmRiODI0MjVjOWMwNjNfNC0zLTEtMS0w_a40bb4a6-b228-406e-bc33-ec7f46b0881d"
      unitRef="usd">15586000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY182Ny9mcmFnOmFmOTA1MDI0MWUxNTQ4NGI5NWEzOGE2MWZjYzc3ZDdlL3RhYmxlOmIwNzA3OTdlYjk2ZTRlNmQ4YWJkYjgyNDI1YzljMDYzL3RhYmxlcmFuZ2U6YjA3MDc5N2ViOTZlNGU2ZDhhYmRiODI0MjVjOWMwNjNfNS0xLTEtMS0w_c323a472-d14c-4b16-8871-635c5e5ddf5e"
      unitRef="usd">187200000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i45bff335c1434d6ba44132da1b0557db_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY182Ny9mcmFnOmFmOTA1MDI0MWUxNTQ4NGI5NWEzOGE2MWZjYzc3ZDdlL3RhYmxlOmIwNzA3OTdlYjk2ZTRlNmQ4YWJkYjgyNDI1YzljMDYzL3RhYmxlcmFuZ2U6YjA3MDc5N2ViOTZlNGU2ZDhhYmRiODI0MjVjOWMwNjNfNS0zLTEtMS0w_a365f6aa-2d93-441e-9029-cae5a170d90f"
      unitRef="usd">175096000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY182Ny9mcmFnOmFmOTA1MDI0MWUxNTQ4NGI5NWEzOGE2MWZjYzc3ZDdlL3RhYmxlOmIwNzA3OTdlYjk2ZTRlNmQ4YWJkYjgyNDI1YzljMDYzL3RhYmxlcmFuZ2U6YjA3MDc5N2ViOTZlNGU2ZDhhYmRiODI0MjVjOWMwNjNfNi0xLTEtMS0w_8d72cb9b-a44c-4403-b1de-600763801cff"
      unitRef="usd">104204000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i45bff335c1434d6ba44132da1b0557db_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY182Ny9mcmFnOmFmOTA1MDI0MWUxNTQ4NGI5NWEzOGE2MWZjYzc3ZDdlL3RhYmxlOmIwNzA3OTdlYjk2ZTRlNmQ4YWJkYjgyNDI1YzljMDYzL3RhYmxlcmFuZ2U6YjA3MDc5N2ViOTZlNGU2ZDhhYmRiODI0MjVjOWMwNjNfNi0zLTEtMS0w_301926cf-8ae9-4356-9d11-dbdb7f588ccd"
      unitRef="usd">88856000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY182Ny9mcmFnOmFmOTA1MDI0MWUxNTQ4NGI5NWEzOGE2MWZjYzc3ZDdlL3RhYmxlOmIwNzA3OTdlYjk2ZTRlNmQ4YWJkYjgyNDI1YzljMDYzL3RhYmxlcmFuZ2U6YjA3MDc5N2ViOTZlNGU2ZDhhYmRiODI0MjVjOWMwNjNfNy0xLTEtMS0w_7e6bd656-1be4-4a94-905c-41750f5bf5b9"
      unitRef="usd">82996000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i45bff335c1434d6ba44132da1b0557db_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY182Ny9mcmFnOmFmOTA1MDI0MWUxNTQ4NGI5NWEzOGE2MWZjYzc3ZDdlL3RhYmxlOmIwNzA3OTdlYjk2ZTRlNmQ4YWJkYjgyNDI1YzljMDYzL3RhYmxlcmFuZ2U6YjA3MDc5N2ViOTZlNGU2ZDhhYmRiODI0MjVjOWMwNjNfNy0zLTEtMS0w_857b41fc-cc63-412f-8ba9-f263f1d34fdd"
      unitRef="usd">86240000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:CapitalizedComputerSoftwareAdditions
      contextRef="iefe7fef4d5624963a3e8bf8250323769_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY182Ny9mcmFnOmFmOTA1MDI0MWUxNTQ4NGI5NWEzOGE2MWZjYzc3ZDdlL3RleHRyZWdpb246YWY5MDUwMjQxZTE1NDg0Yjk1YTM4YTYxZmNjNzdkN2VfMTY0OTI2NzQ0MjMyMQ_9b351301-cca5-4813-9367-b442d63cf50f"
      unitRef="usd">5600000</us-gaap:CapitalizedComputerSoftwareAdditions>
    <us-gaap:CapitalizedComputerSoftwareAdditions
      contextRef="ieb3c51cd38194256bde9f79f0128cf37_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY182Ny9mcmFnOmFmOTA1MDI0MWUxNTQ4NGI5NWEzOGE2MWZjYzc3ZDdlL3RleHRyZWdpb246YWY5MDUwMjQxZTE1NDg0Yjk1YTM4YTYxZmNjNzdkN2VfMTQx_dd6d3ea7-4715-49ac-b583-875574ddbb4e"
      unitRef="usd">11100000</us-gaap:CapitalizedComputerSoftwareAdditions>
    <us-gaap:CapitalizedComputerSoftwareAdditions
      contextRef="i04ad35bee18d4527b458f382beff864b_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY182Ny9mcmFnOmFmOTA1MDI0MWUxNTQ4NGI5NWEzOGE2MWZjYzc3ZDdlL3RleHRyZWdpb246YWY5MDUwMjQxZTE1NDg0Yjk1YTM4YTYxZmNjNzdkN2VfMTY0OTI2NzQ0MjMzMQ_2ecbbe3e-1558-4e09-a01c-996fea5bd08c"
      unitRef="usd">6400000</us-gaap:CapitalizedComputerSoftwareAdditions>
    <us-gaap:CapitalizedComputerSoftwareAdditions
      contextRef="ibc2cefa24419498989e69466f40918b1_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY182Ny9mcmFnOmFmOTA1MDI0MWUxNTQ4NGI5NWEzOGE2MWZjYzc3ZDdlL3RleHRyZWdpb246YWY5MDUwMjQxZTE1NDg0Yjk1YTM4YTYxZmNjNzdkN2VfMTQ4_281f0e5f-d535-4f17-a21e-be64f8f0ecb0"
      unitRef="usd">13700000</us-gaap:CapitalizedComputerSoftwareAdditions>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i3bacbba21c62440980d14afff52eb1ca_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY182Ny9mcmFnOmFmOTA1MDI0MWUxNTQ4NGI5NWEzOGE2MWZjYzc3ZDdlL3RleHRyZWdpb246YWY5MDUwMjQxZTE1NDg0Yjk1YTM4YTYxZmNjNzdkN2VfMjk0_79a38516-ef61-4c14-b31b-b9210ff27565"
      unitRef="usd">73000000.0</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i037a95e6b16d4dcea7b2b033c338785c_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY182Ny9mcmFnOmFmOTA1MDI0MWUxNTQ4NGI5NWEzOGE2MWZjYzc3ZDdlL3RleHRyZWdpb246YWY5MDUwMjQxZTE1NDg0Yjk1YTM4YTYxZmNjNzdkN2VfMzAx_d7f57192-6063-4d0f-b435-73099821dded"
      unitRef="usd">75300000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY182Ny9mcmFnOmFmOTA1MDI0MWUxNTQ4NGI5NWEzOGE2MWZjYzc3ZDdlL3RleHRyZWdpb246YWY5MDUwMjQxZTE1NDg0Yjk1YTM4YTYxZmNjNzdkN2VfMTY0OTI2NzQ0MjM3Nw_f7d7dce1-0e96-4896-88ee-63327b597110"
      unitRef="usd">7600000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY182Ny9mcmFnOmFmOTA1MDI0MWUxNTQ4NGI5NWEzOGE2MWZjYzc3ZDdlL3RleHRyZWdpb246YWY5MDUwMjQxZTE1NDg0Yjk1YTM4YTYxZmNjNzdkN2VfMzk2_ec041cf2-cf55-445e-8db6-9cf3d56e415d"
      unitRef="usd">15400000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY182Ny9mcmFnOmFmOTA1MDI0MWUxNTQ4NGI5NWEzOGE2MWZjYzc3ZDdlL3RleHRyZWdpb246YWY5MDUwMjQxZTE1NDg0Yjk1YTM4YTYxZmNjNzdkN2VfMTY0OTI2NzQ0MjQzOQ_a6b262db-f3f9-440d-bc1c-b30f7f2ec316"
      unitRef="usd">7100000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY182Ny9mcmFnOmFmOTA1MDI0MWUxNTQ4NGI5NWEzOGE2MWZjYzc3ZDdlL3RleHRyZWdpb246YWY5MDUwMjQxZTE1NDg0Yjk1YTM4YTYxZmNjNzdkN2VfNDAz_be012ab0-1b79-4d02-94af-c47d60cae282"
      unitRef="usd">13900000</us-gaap:Depreciation>
    <us-gaap:CapitalizedComputerSoftwareAmortization1
      contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY182Ny9mcmFnOmFmOTA1MDI0MWUxNTQ4NGI5NWEzOGE2MWZjYzc3ZDdlL3RleHRyZWdpb246YWY5MDUwMjQxZTE1NDg0Yjk1YTM4YTYxZmNjNzdkN2VfMTY0OTI2NzQ0MjQ4Ng_54a75f7c-7ce8-4f21-8e4e-7a11c788f63d"
      unitRef="usd">6600000</us-gaap:CapitalizedComputerSoftwareAmortization1>
    <us-gaap:CapitalizedComputerSoftwareAmortization1
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY182Ny9mcmFnOmFmOTA1MDI0MWUxNTQ4NGI5NWEzOGE2MWZjYzc3ZDdlL3RleHRyZWdpb246YWY5MDUwMjQxZTE1NDg0Yjk1YTM4YTYxZmNjNzdkN2VfNTI1_30f849d3-331f-456f-a9d3-907d84f1e9ca"
      unitRef="usd">13300000</us-gaap:CapitalizedComputerSoftwareAmortization1>
    <us-gaap:CapitalizedComputerSoftwareAmortization1
      contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY182Ny9mcmFnOmFmOTA1MDI0MWUxNTQ4NGI5NWEzOGE2MWZjYzc3ZDdlL3RleHRyZWdpb246YWY5MDUwMjQxZTE1NDg0Yjk1YTM4YTYxZmNjNzdkN2VfMTY0OTI2NzQ0MjQ3NQ_b6412c42-a801-42d5-8208-4c77d9120790"
      unitRef="usd">6000000.0</us-gaap:CapitalizedComputerSoftwareAmortization1>
    <us-gaap:CapitalizedComputerSoftwareAmortization1
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY182Ny9mcmFnOmFmOTA1MDI0MWUxNTQ4NGI5NWEzOGE2MWZjYzc3ZDdlL3RleHRyZWdpb246YWY5MDUwMjQxZTE1NDg0Yjk1YTM4YTYxZmNjNzdkN2VfNTMy_b53dc7e9-4ee8-4795-b0a5-b8ef81dbf970"
      unitRef="usd">11600000</us-gaap:CapitalizedComputerSoftwareAmortization1>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RleHRyZWdpb246ZDQ3OTRlNTJiZWE3NGJmZDhhZDljOTkyMmExMGFkZjZfODUyMg_1cb05975-74e9-452a-8d05-6f099399566e">Goodwill and Intangible Assets, Net&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill has an estimated indefinite life and is not amortized; rather, it is reviewed for impairment at least annually or whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Subsequent to the sale of True Health, the Company has three reporting units, each with &lt;/span&gt;&lt;span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;discrete financial information. Our assets and liabilities are employed in and relate to the operations of our reporting units. Therefore, the equity carrying value and future cash flows must be estimated each time a&#160;goodwill impairment&#160;analysis is performed on a reporting unit. As a result, our assets, liabilities and cash flows are assigned to reporting units using reasonable and consistent allocation methodologies. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our annual goodwill impairment review occurs during the fourth quarter of each fiscal &lt;/span&gt;&lt;span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;year. We evaluate qualitative factors that could cause us to believe the estimated fair value of each of our reporting units may be lower than the carrying value and trigger a quantitative assessment, including, but not limited to (i) macroeconomic conditions, (ii) industry and market considerations, (iii) our overall financial performance, including an analysis of our current and projected cash flows, revenues and earnings, (iv) a sustained decrease in share price and (v) other relevant entity-specific events including changes in management, strategy, partners, or litigation.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2021 Goodwill Impairment Test&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We did not identify any qualitative factors that would trigger a quantitative goodwill impairment test during the three and six months ended June 30, 2021. We will perform our annual impairment test as of October 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2020 Goodwill Impairment Test&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March 31, 2020, the Company assessed whether there were additional events or changes in circumstances since its 2019 annual goodwill impairment test that would indicate that it was more likely than not that the fair values of the reporting units were less than the reporting units&#x2019; carrying amounts that would require an additional interim impairment assessment after October 31, 2019. Considering the sharp decrease in the share price of the Company&#x2019;s Class A common stock during the three months ended March 31, 2020, the Company determined indicators of an impairment were present and we performed an interim goodwill impairment assessment as of March 31, 2020. As a result of this test, the Company determined that there was no goodwill impairment of the reporting unit which recognized an impairment in the year ended December 31, 2019. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During May 2020, the CHFS announced that EVH Passport was not awarded a Kentucky managed Medicaid contract for the next contract period and the Passport Medicaid Contract would expire on December 31, 2020. As a result of this announcement, the Company determined there were events or changes in circumstances since its 2019 annual goodwill impairment test that indicated it was more likely than not that the fair value of one of its two reporting units in the EHS segment was less than the reporting unit&#x2019;s carrying amount triggering an interim quantitative assessment.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In performing this interim quantitative assessment, we estimated the fair value of the reporting unit by considering a discounted cash flow valuation approach (&#x201c;income approach&#x201d;). In determining the estimated fair value in a quantitative analysis, we projected future cash flows based on management&#x2019;s estimates and long-term plans and applied a discount rate based on the Company&#x2019;s weighted average cost of capital. This analysis required us to make judgments about revenues, expenses, fixed asset and working capital requirements, capital market assumptions, cash flows and discount rates.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of May 31, 2020, we determined that the reporting unit under review had an estimated fair value less than its carrying value.  As a result, we recorded a non-cash goodwill impairment charge of $215.1&#160;million on our consolidated statements of operations and comprehensive income (loss) for the three and six months ended June 30, 2020. In addition, the Company reviewed its interim goodwill impairment analysis as of June 30, 2020 and did not identify any additional information or events that would contradict or change the conclusion reached by the Company as of May 31, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended September 30, 2020, we evaluated qualitative factors that could indicate the fair value of each of our reporting units may be lower than the carrying value. We did not identify any qualitative factors that would trigger a quantitative goodwill impairment test during the three months ended September 30, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the Company&#x2019;s annual impairment analysis as of October 31, 2020, the Company concluded that previous impairment charges of $199.8&#160;million and $215.1&#160;million recorded during the three months ended December 31, 2019 and June 30, 2020, respectively, in one of our two reporting units in the EHS segment left that specific reporting unit with a limited fair value cushion. Therefore, the Company elected to forego the qualitative assessment and proceed directly to the quantitative assessment of the goodwill impairment test for that specific reporting unit. This election does not preclude management from performing the qualitative assessment in any subsequent period. For the remaining reporting units, after assessing the totality of events and circumstances including the results of our previous valuations, the minimal impacts of the Passport loss and COVID-19, the Company does not believe that an event occurred or circumstances changed during the period under consideration that would, more likely than not, reduce the fair value of any reporting unit below their carrying amount. Therefore, the Company concluded that the quantitative assessment was not required. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In performing our October 31, 2020 impairment test for one of the specific reporting units referenced above, we estimated the fair value of our reporting units by considering a discounted cash flow valuation approach (&#x201c;income approach&#x201d;). In determining the estimated fair value using the income approach, we projected future cash flows based on management&#x2019;s estimates and long-term plans and applied a discount rate based on the Company&#x2019;s weighted average cost of capital. This analysis required us to make judgments about revenues, expenses, fixed asset and working capital requirements, capital market assumptions, cash flows and discount rates. As of October 31, 2020, we determined that the specific reporting unit had an estimated fair value greater than its carrying value and as a result, goodwill is not impaired.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2020, the Company assessed whether there were additional events or changes in circumstances since its annual goodwill impairment test that would indicate that it was more likely than not that the fair value of the reporting unit was less than the reporting unit&#x2019;s carrying amounts that would require an interim impairment assessment after October 31, 2020. The Company determined there had been no such indicators, therefore, we did not perform an interim goodwill impairment assessment as of &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December 31, 2020. As of December 31, 2020, the remaining goodwill attributable to the reporting unit from which we recognized a non-cash goodwill impairment charge earlier in the year was $214.3 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the changes in the carrying amount of goodwill, by reportable segment, for the six months ended June 30, 2021 and 2020 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:331.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:63.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:3.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:63.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:3.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:63.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;EHS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Clinical Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Consolidated &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2020 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;214,354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;134,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;349,029&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency translation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;214,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;134,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;349,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.705%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;EHS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Clinical Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Consolidated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2019 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;431,684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;134,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;566,359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill disposal &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,200)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,200)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Impairment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(215,100)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(215,100)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency translation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(69)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(69)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;214,315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;134,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;348,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Net of cumulative inception to date impairment of $575.5 million and $360.4 million as of December 31, 2020 and 2019, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Goodwill written-off upon disposal of a consolidated subsidiary.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Intangible Assets, Net&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Details of our intangible assets (in thousands, except weighted-average useful lives) as of June&#160;30, 2021 and December&#160;31, 2020  are presented below:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:72.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:54.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:63.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:46.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:54.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:63.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:45.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:44pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted- Average Remaining Useful Life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted- Average Remaining Useful Life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate trade name&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,961&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,029&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;278,519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,894&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;213,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;278,519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,716&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;220,803&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Below market lease, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:35pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provider network contracts &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:35pt"&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;399,906&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;147,861&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;252,045&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;398,034&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;133,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;264,992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Amounts exclude $2.2&#160;million and $0.9&#160;million of customer relationships and provider network contracts, respectively, net of accumulated amortization, with weighted average remaining useful lives of 15 years and 10 months reclassified to discontinued operations as of December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization expense related to intangible assets for the three and six months ended June 30, 2021, was $7.2 million and $14.7 million, respectively. Amortization expense related to intangible assets for the three and six months ended June 30, 2020 was $8.4 million and $17.7 million, respectively, excluding $0.2&#160;million and $0.3&#160;million of amortization expense related to discontinued operations for the three and six months ended June 30, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future estimated amortization of intangible assets (in thousands) as of June&#160;30, 2021, is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:478.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159,152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total future amortization of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;252,045&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets are reviewed for impairment if circumstances indicate the Company may not be able to recover the assets&#x2019; carrying value. We did not identify any circumstances during&#160;the three and six months ended&#160;June&#160;30, 2021, that would require an impairment test for our intangible assets.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:NumberOfReportingUnits
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RleHRyZWdpb246ZDQ3OTRlNTJiZWE3NGJmZDhhZDljOTkyMmExMGFkZjZfMzU2_d91287ea-fec5-413e-b46c-f8b5c4b80c39"
      unitRef="reportingunit">3</us-gaap:NumberOfReportingUnits>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i42bd67fe63d94bad9d6d9dbe6ec79900_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RleHRyZWdpb246ZDQ3OTRlNTJiZWE3NGJmZDhhZDljOTkyMmExMGFkZjZfMjQ2NA_bcdae469-272a-4808-af11-4aab7c52e2ed"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <evh:NumberOfReportingUnitsFairValueInExcessOfCarryingAmount
      contextRef="i6cc0ccb728fb4392be2f4d846aac50c1_D20200501-20200531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RleHRyZWdpb246ZDQ3OTRlNTJiZWE3NGJmZDhhZDljOTkyMmExMGFkZjZfMzAwMQ_c3e0d837-6d8b-4207-9c0f-0810087ab347"
      unitRef="reportingunit">1</evh:NumberOfReportingUnitsFairValueInExcessOfCarryingAmount>
    <us-gaap:NumberOfReportingUnits
      contextRef="i6cc0ccb728fb4392be2f4d846aac50c1_D20200501-20200531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RleHRyZWdpb246ZDQ3OTRlNTJiZWE3NGJmZDhhZDljOTkyMmExMGFkZjZfMzAxMQ_0e0ccb26-6ff1-4cf1-8362-55cd2abfe756"
      unitRef="reportingunit">2</us-gaap:NumberOfReportingUnits>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RleHRyZWdpb246ZDQ3OTRlNTJiZWE3NGJmZDhhZDljOTkyMmExMGFkZjZfMzkzOA_1d2a38b3-f9a3-4e53-a0e6-65c45e76940b"
      unitRef="usd">215100000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RleHRyZWdpb246ZDQ3OTRlNTJiZWE3NGJmZDhhZDljOTkyMmExMGFkZjZfMzkzOA_edcae28a-5e9c-4106-bf7b-35e7eeda0ea8"
      unitRef="usd">215100000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i3afcc69bcfa341e986b926e4d21107b8_D20191001-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RleHRyZWdpb246ZDQ3OTRlNTJiZWE3NGJmZDhhZDljOTkyMmExMGFkZjZfNDc4NQ_dc0f939e-6ae1-45fb-9175-9e9437004092"
      unitRef="usd">199800000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RleHRyZWdpb246ZDQ3OTRlNTJiZWE3NGJmZDhhZDljOTkyMmExMGFkZjZfNDc5Mg_93a6a8d4-1638-48e3-a50c-b589329a1579"
      unitRef="usd">215100000</us-gaap:GoodwillImpairmentLoss>
    <evh:NumberOfReportingUnitsFairValueInExcessOfCarryingAmount
      contextRef="ibb95849bc72e47e5b878e5e786a0ed96_D20201031-20201031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RleHRyZWdpb246ZDQ3OTRlNTJiZWE3NGJmZDhhZDljOTkyMmExMGFkZjZfNDg4OA_35b4d3dc-c16d-4146-babb-55395d23140d"
      unitRef="reportingunit">1</evh:NumberOfReportingUnitsFairValueInExcessOfCarryingAmount>
    <us-gaap:NumberOfReportingUnits
      contextRef="ibb95849bc72e47e5b878e5e786a0ed96_D20201031-20201031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RleHRyZWdpb246ZDQ3OTRlNTJiZWE3NGJmZDhhZDljOTkyMmExMGFkZjZfNDg5OA_e1c3ae91-9497-4980-aaa7-9ccfaa187b2b"
      unitRef="reportingunit">2</us-gaap:NumberOfReportingUnits>
    <evh:NumberOfReportingUnitsFairValueInExcessOfCarryingAmount
      contextRef="ibb95849bc72e47e5b878e5e786a0ed96_D20201031-20201031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RleHRyZWdpb246ZDQ3OTRlNTJiZWE3NGJmZDhhZDljOTkyMmExMGFkZjZfNTg2Mw_9dfbbd07-fa6a-4363-a3eb-63aff6ef07e8"
      unitRef="reportingunit">1</evh:NumberOfReportingUnitsFairValueInExcessOfCarryingAmount>
    <us-gaap:Goodwill
      contextRef="i52907b15276944d085944daaa7867a5e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RleHRyZWdpb246ZDQ3OTRlNTJiZWE3NGJmZDhhZDljOTkyMmExMGFkZjZfNzMzMQ_3d048cb3-e04b-49d0-9708-563f86498160"
      unitRef="usd">214300000</us-gaap:Goodwill>
    <us-gaap:ScheduleOfGoodwillTextBlock
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RleHRyZWdpb246ZDQ3OTRlNTJiZWE3NGJmZDhhZDljOTkyMmExMGFkZjZfODUxNg_14ece0f5-35c7-4e5f-a1c7-389561b92ff4">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the changes in the carrying amount of goodwill, by reportable segment, for the six months ended June 30, 2021 and 2020 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:331.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:63.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:3.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:63.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:3.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:63.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;EHS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Clinical Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Consolidated &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2020 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;214,354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;134,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;349,029&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency translation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;214,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;134,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;349,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.705%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;EHS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Clinical Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Consolidated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2019 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;431,684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;134,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;566,359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill disposal &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,200)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,200)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Impairment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(215,100)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(215,100)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency translation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(69)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(69)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;214,315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;134,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;348,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Net of cumulative inception to date impairment of $575.5 million and $360.4 million as of December 31, 2020 and 2019, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Goodwill written-off upon disposal of a consolidated subsidiary.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:Goodwill
      contextRef="i40bf24d71e79424985bfa9b1dc75e390_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RhYmxlOjJkNDYyNmMzZTY3NDQ0N2M5NWNkNWNlNDY4NDRjMWJkL3RhYmxlcmFuZ2U6MmQ0NjI2YzNlNjc0NDQ3Yzk1Y2Q1Y2U0Njg0NGMxYmRfMS0xLTEtMS0w_b0923aae-d4ca-45a2-a25b-b857eeb4d346"
      unitRef="usd">214354000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i00a15ecaf66f4a6cbb5b4eb9fa265870_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RhYmxlOjJkNDYyNmMzZTY3NDQ0N2M5NWNkNWNlNDY4NDRjMWJkL3RhYmxlcmFuZ2U6MmQ0NjI2YzNlNjc0NDQ3Yzk1Y2Q1Y2U0Njg0NGMxYmRfMS0zLTEtMS0w_691f8808-c0f9-437b-a21a-0aeb200af53a"
      unitRef="usd">134675000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i45bff335c1434d6ba44132da1b0557db_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RhYmxlOjJkNDYyNmMzZTY3NDQ0N2M5NWNkNWNlNDY4NDRjMWJkL3RhYmxlcmFuZ2U6MmQ0NjI2YzNlNjc0NDQ3Yzk1Y2Q1Y2U0Njg0NGMxYmRfMS01LTEtMS0w_25052669-ee5c-47c9-afd3-9a64d394ec77"
      unitRef="usd">349029000</us-gaap:Goodwill>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="i5d62628d6fb54fe0bd811fdfd0bf7b0c_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RhYmxlOjJkNDYyNmMzZTY3NDQ0N2M5NWNkNWNlNDY4NDRjMWJkL3RhYmxlcmFuZ2U6MmQ0NjI2YzNlNjc0NDQ3Yzk1Y2Q1Y2U0Njg0NGMxYmRfMi0xLTEtMS0w_6318bcb2-7751-4930-9835-0706284af353"
      unitRef="usd">-20000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="ib887805409a54f638aeeafe3fe5d1688_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RhYmxlOjJkNDYyNmMzZTY3NDQ0N2M5NWNkNWNlNDY4NDRjMWJkL3RhYmxlcmFuZ2U6MmQ0NjI2YzNlNjc0NDQ3Yzk1Y2Q1Y2U0Njg0NGMxYmRfMi0zLTEtMS0w_4c1a2971-c23e-49f2-8c22-642db8b139ec"
      unitRef="usd">0</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RhYmxlOjJkNDYyNmMzZTY3NDQ0N2M5NWNkNWNlNDY4NDRjMWJkL3RhYmxlcmFuZ2U6MmQ0NjI2YzNlNjc0NDQ3Yzk1Y2Q1Y2U0Njg0NGMxYmRfMi01LTEtMS0w_2cbb8a50-be72-4e66-b55a-b0714a234925"
      unitRef="usd">-20000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:Goodwill
      contextRef="ie355e9ffef734dc6a2b8f3d027278891_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RhYmxlOjJkNDYyNmMzZTY3NDQ0N2M5NWNkNWNlNDY4NDRjMWJkL3RhYmxlcmFuZ2U6MmQ0NjI2YzNlNjc0NDQ3Yzk1Y2Q1Y2U0Njg0NGMxYmRfMy0xLTEtMS0w_5d85b069-b9ed-4926-88c7-b5e9a9bbf3cc"
      unitRef="usd">214334000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i9c3ddb1ccecb442ca473281d46c1ef16_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RhYmxlOjJkNDYyNmMzZTY3NDQ0N2M5NWNkNWNlNDY4NDRjMWJkL3RhYmxlcmFuZ2U6MmQ0NjI2YzNlNjc0NDQ3Yzk1Y2Q1Y2U0Njg0NGMxYmRfMy0zLTEtMS0w_16102c4a-d0c2-4030-b37b-398cae6c1a82"
      unitRef="usd">134675000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RhYmxlOjJkNDYyNmMzZTY3NDQ0N2M5NWNkNWNlNDY4NDRjMWJkL3RhYmxlcmFuZ2U6MmQ0NjI2YzNlNjc0NDQ3Yzk1Y2Q1Y2U0Njg0NGMxYmRfMy01LTEtMS0w_79b6c1e3-9b46-46fd-81c4-01b8185ffe16"
      unitRef="usd">349009000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="ibcf0f323376446aca3fd59b2d1a2f2ad_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RhYmxlOmY4MmJiOTM1MjA3ZjRlMDQ4Y2M4OGNhMzdmYzMxZTk0L3RhYmxlcmFuZ2U6ZjgyYmI5MzUyMDdmNGUwNDhjYzg4Y2EzN2ZjMzFlOTRfMS0xLTEtMS0w_dbf80612-12cf-437f-9c49-f2dc388ec6e4"
      unitRef="usd">431684000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i9a66b42348f74ceea613fecea2deba8e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RhYmxlOmY4MmJiOTM1MjA3ZjRlMDQ4Y2M4OGNhMzdmYzMxZTk0L3RhYmxlcmFuZ2U6ZjgyYmI5MzUyMDdmNGUwNDhjYzg4Y2EzN2ZjMzFlOTRfMS0zLTEtMS0w_7059e072-eb18-450f-b2ea-ca2aed96bd47"
      unitRef="usd">134675000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="ie0ff0ad229b441d4b12bc8956f92a917_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RhYmxlOmY4MmJiOTM1MjA3ZjRlMDQ4Y2M4OGNhMzdmYzMxZTk0L3RhYmxlcmFuZ2U6ZjgyYmI5MzUyMDdmNGUwNDhjYzg4Y2EzN2ZjMzFlOTRfMS01LTEtMS0w_311056ea-94c2-488a-b3c1-e571b1179842"
      unitRef="usd">566359000</us-gaap:Goodwill>
    <us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit
      contextRef="i8d756ddfc980426086c7294d41dd2af3_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RhYmxlOmY4MmJiOTM1MjA3ZjRlMDQ4Y2M4OGNhMzdmYzMxZTk0L3RhYmxlcmFuZ2U6ZjgyYmI5MzUyMDdmNGUwNDhjYzg4Y2EzN2ZjMzFlOTRfMi0xLTEtMS0w_9ea8bf1b-d9c1-44a0-846c-986b5b95733c"
      unitRef="usd">2200000</us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit>
    <us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit
      contextRef="ic606425dedeb4d3d9b0b453c252ea236_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RhYmxlOmY4MmJiOTM1MjA3ZjRlMDQ4Y2M4OGNhMzdmYzMxZTk0L3RhYmxlcmFuZ2U6ZjgyYmI5MzUyMDdmNGUwNDhjYzg4Y2EzN2ZjMzFlOTRfMi0zLTEtMS0w_cab6762c-b35a-4883-86a9-58a246e8639f"
      unitRef="usd">0</us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit>
    <us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RhYmxlOmY4MmJiOTM1MjA3ZjRlMDQ4Y2M4OGNhMzdmYzMxZTk0L3RhYmxlcmFuZ2U6ZjgyYmI5MzUyMDdmNGUwNDhjYzg4Y2EzN2ZjMzFlOTRfMi01LTEtMS0w_7e64c57a-8d6d-4895-aaa4-511e00a6fd18"
      unitRef="usd">2200000</us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i8d756ddfc980426086c7294d41dd2af3_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RhYmxlOmY4MmJiOTM1MjA3ZjRlMDQ4Y2M4OGNhMzdmYzMxZTk0L3RhYmxlcmFuZ2U6ZjgyYmI5MzUyMDdmNGUwNDhjYzg4Y2EzN2ZjMzFlOTRfMy0xLTEtMS0yODE0_47c71c7b-754d-4218-bffc-c8a3cc8db0bc"
      unitRef="usd">215100000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="ic606425dedeb4d3d9b0b453c252ea236_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RhYmxlOmY4MmJiOTM1MjA3ZjRlMDQ4Y2M4OGNhMzdmYzMxZTk0L3RhYmxlcmFuZ2U6ZjgyYmI5MzUyMDdmNGUwNDhjYzg4Y2EzN2ZjMzFlOTRfMy0zLTEtMS0yODEx_610d22ec-bbd2-43af-8e75-9971489adce8"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RhYmxlOmY4MmJiOTM1MjA3ZjRlMDQ4Y2M4OGNhMzdmYzMxZTk0L3RhYmxlcmFuZ2U6ZjgyYmI5MzUyMDdmNGUwNDhjYzg4Y2EzN2ZjMzFlOTRfMy01LTEtMS0yODA3_bebbf2ff-aec5-472f-87d1-d1ecd58f71e0"
      unitRef="usd">215100000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="i8d756ddfc980426086c7294d41dd2af3_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RhYmxlOmY4MmJiOTM1MjA3ZjRlMDQ4Y2M4OGNhMzdmYzMxZTk0L3RhYmxlcmFuZ2U6ZjgyYmI5MzUyMDdmNGUwNDhjYzg4Y2EzN2ZjMzFlOTRfMy0xLTEtMS0w_416d2565-f829-4ebe-b828-08c6b82405b7"
      unitRef="usd">-69000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="ic606425dedeb4d3d9b0b453c252ea236_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RhYmxlOmY4MmJiOTM1MjA3ZjRlMDQ4Y2M4OGNhMzdmYzMxZTk0L3RhYmxlcmFuZ2U6ZjgyYmI5MzUyMDdmNGUwNDhjYzg4Y2EzN2ZjMzFlOTRfMy0zLTEtMS0w_967ecfef-e7ac-4ed5-8386-3415ce94c0f7"
      unitRef="usd">0</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RhYmxlOmY4MmJiOTM1MjA3ZjRlMDQ4Y2M4OGNhMzdmYzMxZTk0L3RhYmxlcmFuZ2U6ZjgyYmI5MzUyMDdmNGUwNDhjYzg4Y2EzN2ZjMzFlOTRfMy01LTEtMS0w_034e9891-2b62-438d-8376-2a42d1ba7cc5"
      unitRef="usd">-69000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:Goodwill
      contextRef="if5ff183307a4468fb0d5707822525486_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RhYmxlOmY4MmJiOTM1MjA3ZjRlMDQ4Y2M4OGNhMzdmYzMxZTk0L3RhYmxlcmFuZ2U6ZjgyYmI5MzUyMDdmNGUwNDhjYzg4Y2EzN2ZjMzFlOTRfNC0xLTEtMS0w_89ed4dee-5cda-432d-92bf-04964a7f40ba"
      unitRef="usd">214315000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i25d27166851f4878bc9c647f69bfd2ea_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RhYmxlOmY4MmJiOTM1MjA3ZjRlMDQ4Y2M4OGNhMzdmYzMxZTk0L3RhYmxlcmFuZ2U6ZjgyYmI5MzUyMDdmNGUwNDhjYzg4Y2EzN2ZjMzFlOTRfNC0zLTEtMS0w_a748ac34-d00a-4917-9c42-3332f7b104a5"
      unitRef="usd">134675000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i11817f96c3e24e0abaed14a17869e173_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RhYmxlOmY4MmJiOTM1MjA3ZjRlMDQ4Y2M4OGNhMzdmYzMxZTk0L3RhYmxlcmFuZ2U6ZjgyYmI5MzUyMDdmNGUwNDhjYzg4Y2EzN2ZjMzFlOTRfNC01LTEtMS0w_5de6740e-6acc-49a0-b1e1-886e20129870"
      unitRef="usd">348990000</us-gaap:Goodwill>
    <us-gaap:GoodwillImpairedAccumulatedImpairmentLoss
      contextRef="i45bff335c1434d6ba44132da1b0557db_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RleHRyZWdpb246ZDQ3OTRlNTJiZWE3NGJmZDhhZDljOTkyMmExMGFkZjZfNzU1MA_461e653a-c777-42bb-b305-58954c43d39e"
      unitRef="usd">575500000</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
    <us-gaap:GoodwillImpairedAccumulatedImpairmentLoss
      contextRef="ie0ff0ad229b441d4b12bc8956f92a917_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RleHRyZWdpb246ZDQ3OTRlNTJiZWE3NGJmZDhhZDljOTkyMmExMGFkZjZfNzU1Nw_ddec7f38-4634-4485-978f-0d74c6694b24"
      unitRef="usd">360400000</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i53f945f2e79348aab95bbf3ba92010f3_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RhYmxlOjhkMmNiYjkxNTliNjRkMDc4M2EwYmExMTQ1MDdjZTQ1L3RhYmxlcmFuZ2U6OGQyY2JiOTE1OWI2NGQwNzgzYTBiYTExNDUwN2NlNDVfMi0xLTEtMS0w_478b3317-ff49-4898-86fa-21400adf5b2e">P12Y8M12D</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ie2665c131c1e46f691f30a8a2e0eaf86_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RhYmxlOjhkMmNiYjkxNTliNjRkMDc4M2EwYmExMTQ1MDdjZTQ1L3RhYmxlcmFuZ2U6OGQyY2JiOTE1OWI2NGQwNzgzYTBiYTExNDUwN2NlNDVfMi0zLTEtMS0w_4b814637-323e-44f4-9742-f2263285e581"
      unitRef="usd">23300000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ie2665c131c1e46f691f30a8a2e0eaf86_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RhYmxlOjhkMmNiYjkxNTliNjRkMDc4M2EwYmExMTQ1MDdjZTQ1L3RhYmxlcmFuZ2U6OGQyY2JiOTE1OWI2NGQwNzgzYTBiYTExNDUwN2NlNDVfMi01LTEtMS0w_d5873328-3864-4d31-b14d-89b9ba6a594d"
      unitRef="usd">6961000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ie2665c131c1e46f691f30a8a2e0eaf86_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RhYmxlOjhkMmNiYjkxNTliNjRkMDc4M2EwYmExMTQ1MDdjZTQ1L3RhYmxlcmFuZ2U6OGQyY2JiOTE1OWI2NGQwNzgzYTBiYTExNDUwN2NlNDVfMi03LTEtMS0w_80e5e182-f4de-48a9-a005-7d0745028a26"
      unitRef="usd">16339000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="ie6df44374ded402288e7ddba99d481b4_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RhYmxlOjhkMmNiYjkxNTliNjRkMDc4M2EwYmExMTQ1MDdjZTQ1L3RhYmxlcmFuZ2U6OGQyY2JiOTE1OWI2NGQwNzgzYTBiYTExNDUwN2NlNDVfMi05LTEtMS0w_9d785ce7-4471-4bdd-921a-37b9055009ac">P13Y2M12D</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i613c94dbacec49fc9a7b83bf086ad005_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RhYmxlOjhkMmNiYjkxNTliNjRkMDc4M2EwYmExMTQ1MDdjZTQ1L3RhYmxlcmFuZ2U6OGQyY2JiOTE1OWI2NGQwNzgzYTBiYTExNDUwN2NlNDVfMi0xMS0xLTEtMA_26856752-8b92-4b22-a517-f108771864f8"
      unitRef="usd">23300000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i613c94dbacec49fc9a7b83bf086ad005_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RhYmxlOjhkMmNiYjkxNTliNjRkMDc4M2EwYmExMTQ1MDdjZTQ1L3RhYmxlcmFuZ2U6OGQyY2JiOTE1OWI2NGQwNzgzYTBiYTExNDUwN2NlNDVfMi0xMy0xLTEtMA_c1b154c8-b7d2-4167-b82a-8642e65baf81"
      unitRef="usd">6271000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i613c94dbacec49fc9a7b83bf086ad005_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RhYmxlOjhkMmNiYjkxNTliNjRkMDc4M2EwYmExMTQ1MDdjZTQ1L3RhYmxlcmFuZ2U6OGQyY2JiOTE1OWI2NGQwNzgzYTBiYTExNDUwN2NlNDVfMi0xNS0xLTEtMA_a7268c86-5d5e-4ce9-8ad2-acba4efc22e6"
      unitRef="usd">17029000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i73f385263f424c7b8911b8af743d7e12_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RhYmxlOjhkMmNiYjkxNTliNjRkMDc4M2EwYmExMTQ1MDdjZTQ1L3RhYmxlcmFuZ2U6OGQyY2JiOTE1OWI2NGQwNzgzYTBiYTExNDUwN2NlNDVfMy0xLTEtMS0w_e2873c1b-199b-4b59-8f64-3c7d5ea8c8cf">P15Y8M12D</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="icfef255ab2b84de6a4b8638cf6a47165_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RhYmxlOjhkMmNiYjkxNTliNjRkMDc4M2EwYmExMTQ1MDdjZTQ1L3RhYmxlcmFuZ2U6OGQyY2JiOTE1OWI2NGQwNzgzYTBiYTExNDUwN2NlNDVfMy0zLTEtMS0w_91c77ce6-4d2b-4fbc-9905-4ae37b35ea7f"
      unitRef="usd">278519000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="icfef255ab2b84de6a4b8638cf6a47165_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RhYmxlOjhkMmNiYjkxNTliNjRkMDc4M2EwYmExMTQ1MDdjZTQ1L3RhYmxlcmFuZ2U6OGQyY2JiOTE1OWI2NGQwNzgzYTBiYTExNDUwN2NlNDVfMy01LTEtMS0w_df2d95a8-13a7-4615-838d-6f42b3db8200"
      unitRef="usd">64894000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="icfef255ab2b84de6a4b8638cf6a47165_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RhYmxlOjhkMmNiYjkxNTliNjRkMDc4M2EwYmExMTQ1MDdjZTQ1L3RhYmxlcmFuZ2U6OGQyY2JiOTE1OWI2NGQwNzgzYTBiYTExNDUwN2NlNDVfMy03LTEtMS0w_96e84295-d862-4768-bc83-cdc78ddd72f2"
      unitRef="usd">213625000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="ibe0ce27038e244269b2a24add102c084_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RhYmxlOjhkMmNiYjkxNTliNjRkMDc4M2EwYmExMTQ1MDdjZTQ1L3RhYmxlcmFuZ2U6OGQyY2JiOTE1OWI2NGQwNzgzYTBiYTExNDUwN2NlNDVfMy05LTEtMS0w_afffbba7-b3c2-4e68-8f7a-975956c50759">P16Y2M12D</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i9ca6f97a31c04defa1bfbf470ae72bdc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RhYmxlOjhkMmNiYjkxNTliNjRkMDc4M2EwYmExMTQ1MDdjZTQ1L3RhYmxlcmFuZ2U6OGQyY2JiOTE1OWI2NGQwNzgzYTBiYTExNDUwN2NlNDVfMy0xMS0xLTEtMA_18273806-e728-4e90-a883-f2b12e60afb1"
      unitRef="usd">278519000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i9ca6f97a31c04defa1bfbf470ae72bdc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RhYmxlOjhkMmNiYjkxNTliNjRkMDc4M2EwYmExMTQ1MDdjZTQ1L3RhYmxlcmFuZ2U6OGQyY2JiOTE1OWI2NGQwNzgzYTBiYTExNDUwN2NlNDVfMy0xMy0xLTEtMA_a9f82bd7-1b72-417d-a7fe-284a932c073a"
      unitRef="usd">57716000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i9ca6f97a31c04defa1bfbf470ae72bdc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RhYmxlOjhkMmNiYjkxNTliNjRkMDc4M2EwYmExMTQ1MDdjZTQ1L3RhYmxlcmFuZ2U6OGQyY2JiOTE1OWI2NGQwNzgzYTBiYTExNDUwN2NlNDVfMy0xNS0xLTEtMA_51e65019-c23c-4f7a-a32c-678e759d4e8c"
      unitRef="usd">220803000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i78747c549a50444ab43a62d1064b465a_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RhYmxlOjhkMmNiYjkxNTliNjRkMDc4M2EwYmExMTQ1MDdjZTQ1L3RhYmxlcmFuZ2U6OGQyY2JiOTE1OWI2NGQwNzgzYTBiYTExNDUwN2NlNDVfNC0xLTEtMS0w_9d268074-858a-4b53-84ac-32784bc08b99">P1Y3M18D</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ia4e8785ed06f43489b789e69021e517b_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RhYmxlOjhkMmNiYjkxNTliNjRkMDc4M2EwYmExMTQ1MDdjZTQ1L3RhYmxlcmFuZ2U6OGQyY2JiOTE1OWI2NGQwNzgzYTBiYTExNDUwN2NlNDVfNC0zLTEtMS0w_7afca1ca-42f2-458b-8b2b-e1a4da9ffe7b"
      unitRef="usd">82922000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ia4e8785ed06f43489b789e69021e517b_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RhYmxlOjhkMmNiYjkxNTliNjRkMDc4M2EwYmExMTQ1MDdjZTQ1L3RhYmxlcmFuZ2U6OGQyY2JiOTE1OWI2NGQwNzgzYTBiYTExNDUwN2NlNDVfNC01LTEtMS0w_aa0d5e64-adf3-466e-bf8a-4017344ec7ce"
      unitRef="usd">68809000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ia4e8785ed06f43489b789e69021e517b_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RhYmxlOjhkMmNiYjkxNTliNjRkMDc4M2EwYmExMTQ1MDdjZTQ1L3RhYmxlcmFuZ2U6OGQyY2JiOTE1OWI2NGQwNzgzYTBiYTExNDUwN2NlNDVfNC03LTEtMS0w_cf86ba30-6420-465f-a0aa-a7d85b9a3ed9"
      unitRef="usd">14113000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i79cb86c12975465c920a2007aee927c8_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RhYmxlOjhkMmNiYjkxNTliNjRkMDc4M2EwYmExMTQ1MDdjZTQ1L3RhYmxlcmFuZ2U6OGQyY2JiOTE1OWI2NGQwNzgzYTBiYTExNDUwN2NlNDVfNC05LTEtMS0w_defc247c-634d-457b-b6fe-5cd7fe435b8b">P1Y9M18D</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i0e9914c7a4fa4bb6b1f1dcc803aa9440_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RhYmxlOjhkMmNiYjkxNTliNjRkMDc4M2EwYmExMTQ1MDdjZTQ1L3RhYmxlcmFuZ2U6OGQyY2JiOTE1OWI2NGQwNzgzYTBiYTExNDUwN2NlNDVfNC0xMS0xLTEtMA_53db53ac-9526-499c-b427-ded7c11479ac"
      unitRef="usd">82922000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i0e9914c7a4fa4bb6b1f1dcc803aa9440_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RhYmxlOjhkMmNiYjkxNTliNjRkMDc4M2EwYmExMTQ1MDdjZTQ1L3RhYmxlcmFuZ2U6OGQyY2JiOTE1OWI2NGQwNzgzYTBiYTExNDUwN2NlNDVfNC0xMy0xLTEtMA_33c3010d-df16-491d-b3ec-aa30d9cb00ef"
      unitRef="usd">63507000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i0e9914c7a4fa4bb6b1f1dcc803aa9440_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RhYmxlOjhkMmNiYjkxNTliNjRkMDc4M2EwYmExMTQ1MDdjZTQ1L3RhYmxlcmFuZ2U6OGQyY2JiOTE1OWI2NGQwNzgzYTBiYTExNDUwN2NlNDVfNC0xNS0xLTEtMA_6af3ca74-99c2-4887-b8bc-dc64e0d18bf7"
      unitRef="usd">19415000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i4a65339b8de24dc0ad22aeaed63b43ea_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RhYmxlOjhkMmNiYjkxNTliNjRkMDc4M2EwYmExMTQ1MDdjZTQ1L3RhYmxlcmFuZ2U6OGQyY2JiOTE1OWI2NGQwNzgzYTBiYTExNDUwN2NlNDVfNS0xLTEtMS0w_97765be5-14fc-43f5-87cb-b31bb9481fed">P1Y9M18D</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i06b855dce6e346bcb653c327e7599385_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RhYmxlOjhkMmNiYjkxNTliNjRkMDc4M2EwYmExMTQ1MDdjZTQ1L3RhYmxlcmFuZ2U6OGQyY2JiOTE1OWI2NGQwNzgzYTBiYTExNDUwN2NlNDVfNS0zLTEtMS0w_7a6e3c31-b116-46ad-bbf9-0599f2c39823"
      unitRef="usd">1218000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i06b855dce6e346bcb653c327e7599385_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RhYmxlOjhkMmNiYjkxNTliNjRkMDc4M2EwYmExMTQ1MDdjZTQ1L3RhYmxlcmFuZ2U6OGQyY2JiOTE1OWI2NGQwNzgzYTBiYTExNDUwN2NlNDVfNS01LTEtMS0w_c857d1c9-57f9-4f43-9b47-78485421ffb6"
      unitRef="usd">849000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i06b855dce6e346bcb653c327e7599385_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RhYmxlOjhkMmNiYjkxNTliNjRkMDc4M2EwYmExMTQ1MDdjZTQ1L3RhYmxlcmFuZ2U6OGQyY2JiOTE1OWI2NGQwNzgzYTBiYTExNDUwN2NlNDVfNS03LTEtMS0w_1d285b43-9b34-485d-80e9-807df68b37dd"
      unitRef="usd">369000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i683282a1148d4b31b1f897062aa84ede_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RhYmxlOjhkMmNiYjkxNTliNjRkMDc4M2EwYmExMTQ1MDdjZTQ1L3RhYmxlcmFuZ2U6OGQyY2JiOTE1OWI2NGQwNzgzYTBiYTExNDUwN2NlNDVfNS05LTEtMS0w_3017fcac-d96c-4ddb-894b-a118f48cd76c">P2Y3M18D</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i1f772575126c46f293e485e88a16c5b2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RhYmxlOjhkMmNiYjkxNTliNjRkMDc4M2EwYmExMTQ1MDdjZTQ1L3RhYmxlcmFuZ2U6OGQyY2JiOTE1OWI2NGQwNzgzYTBiYTExNDUwN2NlNDVfNS0xMS0xLTEtMA_a491ad36-e10d-4580-a6ba-5938e6441c02"
      unitRef="usd">1118000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i1f772575126c46f293e485e88a16c5b2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RhYmxlOjhkMmNiYjkxNTliNjRkMDc4M2EwYmExMTQ1MDdjZTQ1L3RhYmxlcmFuZ2U6OGQyY2JiOTE1OWI2NGQwNzgzYTBiYTExNDUwN2NlNDVfNS0xMy0xLTEtMA_bcd1b49e-263b-49b8-b2f7-36fd305d1870"
      unitRef="usd">648000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i1f772575126c46f293e485e88a16c5b2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RhYmxlOjhkMmNiYjkxNTliNjRkMDc4M2EwYmExMTQ1MDdjZTQ1L3RhYmxlcmFuZ2U6OGQyY2JiOTE1OWI2NGQwNzgzYTBiYTExNDUwN2NlNDVfNS0xNS0xLTEtMA_5f091a3a-5dba-4a0a-8b7c-9db4991c9395"
      unitRef="usd">470000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i4064cc6be7384542838693bded8b452e_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RhYmxlOjhkMmNiYjkxNTliNjRkMDc4M2EwYmExMTQ1MDdjZTQ1L3RhYmxlcmFuZ2U6OGQyY2JiOTE1OWI2NGQwNzgzYTBiYTExNDUwN2NlNDVfNi0xLTEtMS0w_bfacba8e-a923-4d77-87a7-2e0622b7d532">P2Y6M</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i3af67d6664c9491d8b7fdecedd5f5629_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RhYmxlOjhkMmNiYjkxNTliNjRkMDc4M2EwYmExMTQ1MDdjZTQ1L3RhYmxlcmFuZ2U6OGQyY2JiOTE1OWI2NGQwNzgzYTBiYTExNDUwN2NlNDVfNi0zLTEtMS0w_be5db6f2-c4f1-44b4-b399-ac7afa8fa2c8"
      unitRef="usd">13947000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i3af67d6664c9491d8b7fdecedd5f5629_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RhYmxlOjhkMmNiYjkxNTliNjRkMDc4M2EwYmExMTQ1MDdjZTQ1L3RhYmxlcmFuZ2U6OGQyY2JiOTE1OWI2NGQwNzgzYTBiYTExNDUwN2NlNDVfNi01LTEtMS0w_494aceb6-5390-412c-9781-01e13055b5b9"
      unitRef="usd">6348000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i3af67d6664c9491d8b7fdecedd5f5629_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RhYmxlOjhkMmNiYjkxNTliNjRkMDc4M2EwYmExMTQ1MDdjZTQ1L3RhYmxlcmFuZ2U6OGQyY2JiOTE1OWI2NGQwNzgzYTBiYTExNDUwN2NlNDVfNi03LTEtMS0w_0cb92013-9faf-4730-a4a3-52a13cdcca26"
      unitRef="usd">7599000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i27b1db7d183641a5b3e3c8ddfbffb17e_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RhYmxlOjhkMmNiYjkxNTliNjRkMDc4M2EwYmExMTQ1MDdjZTQ1L3RhYmxlcmFuZ2U6OGQyY2JiOTE1OWI2NGQwNzgzYTBiYTExNDUwN2NlNDVfNi05LTEtMS0w_8874fecd-c970-482b-9385-664070d92ba9">P2Y10M24D</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i965ab087aa7949539cb446e0c5221cea_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RhYmxlOjhkMmNiYjkxNTliNjRkMDc4M2EwYmExMTQ1MDdjZTQ1L3RhYmxlcmFuZ2U6OGQyY2JiOTE1OWI2NGQwNzgzYTBiYTExNDUwN2NlNDVfNi0xMS0xLTEtMA_43442888-b456-4de6-9ec9-f6c55747ffe6"
      unitRef="usd">12175000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i965ab087aa7949539cb446e0c5221cea_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RhYmxlOjhkMmNiYjkxNTliNjRkMDc4M2EwYmExMTQ1MDdjZTQ1L3RhYmxlcmFuZ2U6OGQyY2JiOTE1OWI2NGQwNzgzYTBiYTExNDUwN2NlNDVfNi0xMy0xLTEtMA_51c0dd41-421a-4863-9fce-8ea7d9866f6a"
      unitRef="usd">4900000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i965ab087aa7949539cb446e0c5221cea_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RhYmxlOjhkMmNiYjkxNTliNjRkMDc4M2EwYmExMTQ1MDdjZTQ1L3RhYmxlcmFuZ2U6OGQyY2JiOTE1OWI2NGQwNzgzYTBiYTExNDUwN2NlNDVfNi0xNS0xLTEtMA_f11f7a02-96b8-409b-97cc-599c11106b1c"
      unitRef="usd">7275000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RhYmxlOjhkMmNiYjkxNTliNjRkMDc4M2EwYmExMTQ1MDdjZTQ1L3RhYmxlcmFuZ2U6OGQyY2JiOTE1OWI2NGQwNzgzYTBiYTExNDUwN2NlNDVfNy0zLTEtMS0w_8e29b4e3-f96a-488e-a717-681414406839"
      unitRef="usd">399906000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RhYmxlOjhkMmNiYjkxNTliNjRkMDc4M2EwYmExMTQ1MDdjZTQ1L3RhYmxlcmFuZ2U6OGQyY2JiOTE1OWI2NGQwNzgzYTBiYTExNDUwN2NlNDVfNy01LTEtMS0w_651984bf-cc9f-40dc-8070-84b45776f8e0"
      unitRef="usd">147861000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RhYmxlOjhkMmNiYjkxNTliNjRkMDc4M2EwYmExMTQ1MDdjZTQ1L3RhYmxlcmFuZ2U6OGQyY2JiOTE1OWI2NGQwNzgzYTBiYTExNDUwN2NlNDVfNy03LTEtMS0w_43a673ff-27f1-4206-bac9-2b7526f9d827"
      unitRef="usd">252045000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i45bff335c1434d6ba44132da1b0557db_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RhYmxlOjhkMmNiYjkxNTliNjRkMDc4M2EwYmExMTQ1MDdjZTQ1L3RhYmxlcmFuZ2U6OGQyY2JiOTE1OWI2NGQwNzgzYTBiYTExNDUwN2NlNDVfNy0xMS0xLTEtMA_0ece7f94-399c-43e4-ad2f-77bb4307b48f"
      unitRef="usd">398034000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i45bff335c1434d6ba44132da1b0557db_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RhYmxlOjhkMmNiYjkxNTliNjRkMDc4M2EwYmExMTQ1MDdjZTQ1L3RhYmxlcmFuZ2U6OGQyY2JiOTE1OWI2NGQwNzgzYTBiYTExNDUwN2NlNDVfNy0xMy0xLTEtMA_a503560b-4a2d-41cc-b4f2-d3077dc9b86c"
      unitRef="usd">133042000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i45bff335c1434d6ba44132da1b0557db_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RhYmxlOjhkMmNiYjkxNTliNjRkMDc4M2EwYmExMTQ1MDdjZTQ1L3RhYmxlcmFuZ2U6OGQyY2JiOTE1OWI2NGQwNzgzYTBiYTExNDUwN2NlNDVfNy0xNS0xLTEtMA_5f631774-9470-41e9-b2b2-152accf6fcbc"
      unitRef="usd">264992000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent
      contextRef="ie8fa99474b6947149ca859e8e7009178_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RleHRyZWdpb246ZDQ3OTRlNTJiZWE3NGJmZDhhZDljOTkyMmExMGFkZjZfNzgzNQ_84a45e48-1db8-4017-b5b9-f3a5a7805f36"
      unitRef="usd">2200000</us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent
      contextRef="ib490a7e546dd4b0987772534f6cf516c_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RleHRyZWdpb246ZDQ3OTRlNTJiZWE3NGJmZDhhZDljOTkyMmExMGFkZjZfNzg0Mg_7ec06b2c-a246-4d78-8c09-fed83c4d1390"
      unitRef="usd">900000</us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="ic6cafc0c96a142d5819a5b45e9032420_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RleHRyZWdpb246ZDQ3OTRlNTJiZWE3NGJmZDhhZDljOTkyMmExMGFkZjZfNzk4NA_5fb48c96-7589-4b0a-8e61-7c0e8e7fd367">P15Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i0f5ebd73deb94928a519598776e04047_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RleHRyZWdpb246ZDQ3OTRlNTJiZWE3NGJmZDhhZDljOTkyMmExMGFkZjZfNzk5MQ_be782507-9a09-4d9b-9c1a-f2ee198bde71">P10M</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RleHRyZWdpb246ZDQ3OTRlNTJiZWE3NGJmZDhhZDljOTkyMmExMGFkZjZfMTY0OTI2NzQ1MDI5Mg_27604310-4b27-4856-9760-9bc293a69ebd"
      unitRef="usd">7200000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RleHRyZWdpb246ZDQ3OTRlNTJiZWE3NGJmZDhhZDljOTkyMmExMGFkZjZfODEwNw_f3f5ee89-6b35-4996-b009-39e2a402e775"
      unitRef="usd">14700000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RleHRyZWdpb246ZDQ3OTRlNTJiZWE3NGJmZDhhZDljOTkyMmExMGFkZjZfMTY0OTI2NzQ1MDMzMA_39622833-0bc8-4d95-99e2-0a357e5623fd"
      unitRef="usd">8400000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RleHRyZWdpb246ZDQ3OTRlNTJiZWE3NGJmZDhhZDljOTkyMmExMGFkZjZfODExNA_015844eb-4e3f-46bc-a5a3-91856f2decd4"
      unitRef="usd">17700000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i1a6bb4acf8f64d4ea88262cf96a6ca67_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RleHRyZWdpb246ZDQ3OTRlNTJiZWE3NGJmZDhhZDljOTkyMmExMGFkZjZfMTY0OTI2NzQ1MDc5Mw_587b4b8a-9e53-4a00-a92e-631b66c31d03"
      unitRef="usd">200000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i6f626e482e054b34901a6c459f47f04b_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RleHRyZWdpb246ZDQ3OTRlNTJiZWE3NGJmZDhhZDljOTkyMmExMGFkZjZfMTY0OTI2NzQ1MDc3OQ_10f8d4fa-85d7-44d0-88b3-4ce9da6dea35"
      unitRef="usd">300000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RleHRyZWdpb246ZDQ3OTRlNTJiZWE3NGJmZDhhZDljOTkyMmExMGFkZjZfODUxMg_4e7ee247-b9df-477d-ac6b-5ec452276946">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future estimated amortization of intangible assets (in thousands) as of June&#160;30, 2021, is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:478.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159,152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total future amortization of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;252,045&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
      contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RhYmxlOjZjMzBmNmVkYmI3OTRhNzM5NDY5OGQxMDYzNmU3MDZjL3RhYmxlcmFuZ2U6NmMzMGY2ZWRiYjc5NGE3Mzk0Njk4ZDEwNjM2ZTcwNmNfMC0xLTEtMS0w_c19271c6-3d1f-40eb-ab86-28669599407c"
      unitRef="usd">13762000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RhYmxlOjZjMzBmNmVkYmI3OTRhNzM5NDY5OGQxMDYzNmU3MDZjL3RhYmxlcmFuZ2U6NmMzMGY2ZWRiYjc5NGE3Mzk0Njk4ZDEwNjM2ZTcwNmNfMS0xLTEtMS0w_7618641c-2f2f-4524-98f6-77c63a77781e"
      unitRef="usd">24629000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RhYmxlOjZjMzBmNmVkYmI3OTRhNzM5NDY5OGQxMDYzNmU3MDZjL3RhYmxlcmFuZ2U6NmMzMGY2ZWRiYjc5NGE3Mzk0Njk4ZDEwNjM2ZTcwNmNfMi0xLTEtMS0w_aa5752af-6ea6-4fa7-ab31-110c177cbcf2"
      unitRef="usd">22325000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RhYmxlOjZjMzBmNmVkYmI3OTRhNzM5NDY5OGQxMDYzNmU3MDZjL3RhYmxlcmFuZ2U6NmMzMGY2ZWRiYjc5NGE3Mzk0Njk4ZDEwNjM2ZTcwNmNfMy0xLTEtMS0w_7791d070-49fb-4e77-9604-f876d4822f89"
      unitRef="usd">16441000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RhYmxlOjZjMzBmNmVkYmI3OTRhNzM5NDY5OGQxMDYzNmU3MDZjL3RhYmxlcmFuZ2U6NmMzMGY2ZWRiYjc5NGE3Mzk0Njk4ZDEwNjM2ZTcwNmNfNC0xLTEtMS0w_adb93435-026f-44f2-8f04-e953f28d4c44"
      unitRef="usd">15736000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <evh:FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour
      contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RhYmxlOjZjMzBmNmVkYmI3OTRhNzM5NDY5OGQxMDYzNmU3MDZjL3RhYmxlcmFuZ2U6NmMzMGY2ZWRiYjc5NGE3Mzk0Njk4ZDEwNjM2ZTcwNmNfNS0xLTEtMS0w_967b1abe-caf7-4cdd-a7a9-e78c86f8d026"
      unitRef="usd">159152000</evh:FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183MC9mcmFnOmQ0Nzk0ZTUyYmVhNzRiZmQ4YWQ5Yzk5MjJhMTBhZGY2L3RhYmxlOjZjMzBmNmVkYmI3OTRhNzM5NDY5OGQxMDYzNmU3MDZjL3RhYmxlcmFuZ2U6NmMzMGY2ZWRiYjc5NGE3Mzk0Njk4ZDEwNjM2ZTcwNmNfNi0xLTEtMS0w_25630e89-d349-4ad0-b52a-36d4df137aad"
      unitRef="usd">252045000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMjExNzM_61b21c14-d833-409d-b03f-ccb6a79eebb1">Long-term Debt&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2024 Notes&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, the Company issued $117.1&#160;million aggregate principal amount of its 3.50% Convertible Senior Notes due 2024 (the &#x201c;2024 Notes&#x201d;) in privately negotiated exchange and/or subscription agreements, with certain holders of its outstanding 2021 Notes and certain new investors. The Company issued $84.2 million aggregate principal amount of 2024 Notes in exchange for $84.2 million aggregate principal amount of the 2021 Notes and an aggregate cash payment of $2.5&#160;million, and issued $32.8 million aggregate principal amount of New Notes for cash at par. We incurred $3.0&#160;million of debt issuance costs in connection with the 2024 Notes, which we are amortizing to non-cash interest expense using the straight-line method over the contractual term of the 2024 Notes. The closing of the private placement of the 2024 Notes occurred on August 19, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Holders of the 2024 Notes are entitled to cash interest payments, which are payable semiannually in arrears on June 1 and December 1 of each year, beginning on December 1, 2020, at a rate equal to 3.50% per annum. The 2024 Notes will mature on December 1, 2024, unless earlier repurchased, redeemed or converted in accordance with their terms prior to such date. Upon maturity the principal amount of the notes may be settled via shares of the Company&#x2019;s Class A common stock. We recorded interest expense of $1.0 and $2.0 million for the three and six months ended June 30, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2024 Notes are convertible into cash, shares of the Company's Class A common stock, or a combination of cash and shares of the Company's Class A common stock, at the Company's election, based on an initial conversion rate of 54.8667 shares of Class A common stock per $1,000 principal amount of the 2024 Notes, which is equivalent to an initial conversion price of approximately $18.23 per share of the Company&#x2019;s Class A common stock. In the aggregate, the 2024 Notes are initially convertible into 6.4&#160;million shares of the Company&#x2019;s Class A common stock (excluding any shares issuable by the Company upon a conversion in connection with a make-whole provision upon a fundamental change or a notice of redemption under the governing indenture). The conversion rate may be adjusted under certain circumstances. Upon conversion, the Company will pay or deliver, as the case may be, cash or shares of the Company&#x2019;s Class A common stock, or a combination of cash and shares of the Company&#x2019;s Class A common stock, at the Company&#x2019;s election.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The option to settle the 2024 Notes in cash or shares of the Company&#x2019;s Class A common stock, or a combination of cash and shares of the Company&#x2019;s Class A common stock, at the Company&#x2019;s election, resulted in a bifurcation of the carrying value of the 2024 Notes into a debt component and an equity component. The debt component was determined to be $78.9&#160;million, before issuance costs, based on the fair value of a nonconvertible debt instrument with the same term. The equity component was determined to be $38.1&#160;million, before issuance costs, and was recorded within additional paid-in capital. The equity component is the difference between the aggregate principal amount of the debt and the fair value of the debt component. Issuance costs of $1.7&#160;million and $1.3&#160;million are allocated to the debt and equity components in proportion to the allocation of proceeds. Along with the equity component of $38.1&#160;million, $1.7&#160;million of issuance costs will be amortized to interest expense on the consolidated statements of operations and comprehensive income (loss) using the effective interest method over the contractual term of the 2024 Notes. The equity component recorded within additional paid-in capital will not be remeasured as long as it meets the conditions for equity classification. The Company recorded $2.0 million and $3.9 million of interest expense related to the amortization of the debt discount and the issuance costs allocated to the debt component for the three and six months ended June 30, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Holders of the 2024 Notes may require the Company to repurchase all or part of their notes upon the occurrence of a fundamental change at a price equal to 100.0% of the principal amount of the notes being repurchased, plus any accrued and unpaid interest to, but excluding, the fundamental change repurchase date. The Company may not redeem the 2024 Notes prior to March 1, 2023. The Company may redeem for cash all or any portion of the 2024 Notes, at its option, on or after March 1, 2023, if the last reported sale price of the Company&#x2019;s Class A common stock has been at least 130.0% of the conversion price then in effect for at least 20 trading &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which the Company provides notice of redemption, at a redemption price equal to 100.0% of the principal amount of the notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Credit Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 30, 2019, the Company entered into a credit agreement, by and among the Company, Evolent Health LLC, as the borrower (the &#x201c;Borrower&#x201d;), certain subsidiaries of the Company, as guarantors, the lenders from time to time party thereto, and Ares Capital Corporation, as administrative agent and collateral agent, together with the Company (the &#x201c;Credit Agreement&#x201d;), pursuant to which the lenders agreed to extend credit to the Borrower in the form of (i) an initial secured term loan in the aggregate principal amount of $75.0 million (the &#x201c;Initial Term Loan Facility&#x201d;) and (ii) a delayed draw secured term loan facility in the aggregate principal amount of up to $50.0 million (the &#x201c;DDTL Facility&#x201d; and, together with the Initial Term Loan Facility, the &#x201c;Senior Credit Facilities&#x201d;), subject to the satisfaction of specified conditions. The Borrower borrowed the loan under the Initial Term Loan Facility on December 30, 2019. In connection with the Credit Agreement, on December 30, 2019, the Company entered into a Security Agreement, by and among the Company, the Borrower, the other guarantors and the collateral agent for the benefit of the secured parties, and a Guarantee Agreement, by the Company and each of the other guarantors in favor of the collateral agent for the benefit of the secured parties. The Senior Credit Facilities were guaranteed by the Company and the Company&#x2019;s domestic subsidiaries, subject to certain exceptions. The Senior Credit Facilities were secured by a first priority security interest in all of the capital stock of the borrower and each guarantor (other than the Company) and substantially all of the assets of the borrower and each guarantor, subject to certain exceptions. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The proceeds of the Initial Term Loan were used to finance the transactions contemplated by the Passport APA and pay fees and expenses incurred in connection therewith. The proceeds of the DDTL Facility were permitted to be used, subject to the Company&#x2019;s satisfaction of specified conditions, to finance the repayment or repurchase of the Company&#x2019;s 2.00% Convertible Senior Notes due December 1, 2021 and to fund permitted acquisitions. &#160;The Initial Term Loan and any loans under the DDTL Facility would have matured on the date that is the earliest of (a) December 30, 2024, (b) the date on which all amounts outstanding under the Credit Agreement would have been declared or have automatically become due and payable under the terms of the Credit Agreement and (c) the date that is ninety-one (91) days prior to the maturity date of the 2021 Convertible Notes unless certain liquidity conditions were satisfied (the foregoing, the &#x201c;Maturity Date&#x201d;). The interest rate for each loan under the Senior Credit Facilities was calculated, at the option of the Borrower, at either the Eurodollar rate plus 8.00%, or the base rate plus 7.00%. A commitment fee of 1.00% per annum was payable by the Borrower quarterly in arrears on the unused portion of the DDTL Facility. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts outstanding under the Senior Credit Facilities could have been prepaid at the option of the Borrower subject to applicable premiums, including a make-whole premium payable on certain prepayments made prior to the second anniversary of the closing of the Senior Credit Facilities, and a call protection premium payable on the amount prepaid in certain instances as follows: (i) 4.00% of the principal amount so prepaid after the second anniversary of the closing of the Senior Credit Facilities but prior the third anniversary of the closing of the Senior Credit Facilities; (ii) 3.00% of the principal amount so prepaid after the third anniversary of the closing of the Senior Credit Facilities but prior the fourth anniversary of the closing of the Senior Credit Facilities; and (iii) 2.00% of the principal amount so prepaid after the fourth anniversary of the closing of the Senior Credit Facilities but prior the fifth anniversary of the closing of the Senior Credit Facilities. Amounts outstanding under the Senior Credit Facility were subject to mandatory prepayment upon the occurrence of certain events and conditions, including non-ordinary course asset dispositions, receipt of certain casualty proceeds, issuances of certain debt obligations and a change of control transaction.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Senior Credit Facilities contained customary borrowing conditions, affirmative, negative and reporting covenants, representations and warranties, and events of default, including cross-defaults to other material indebtedness. In addition, the Company was required to comply at certain times with certain financial covenants comprised of a minimum net revenue test and a minimum liquidity test commencing upon closing of the Senior Credit Facilities and a total secured leverage ratio commencing on the last day of the fiscal quarter ending March 31, 2021. If an event of default had occurred, the lenders would be entitled to take enforcement action, including foreclosure on collateral and acceleration of amounts owed under the Senior Credit Facilities. We incurred $4.7 million of debt issuance costs in connection with this Credit Agreement, which was included in long-term debt, net of discount on our consolidated balance sheets and amortized into interest expense over the life of the agreement. The Company recorded $0.5 million and $1.1 million in interest expense related to the amortization of the debt discount and the issuance costs for the three and six months ended June 30, 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 19, 2020, an amendment to the Company's Credit Agreement became effective. The amendment effected changes to, among other things, permit the Company's use of cash in the exchange transactions in connection with the issuance of the 2024 Notes, permit the issuance of the 2024 Notes and permit certain note repurchases, as well as to implement amendments to certain minimum liquidity thresholds.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 8, 2021, the Company repaid all outstanding amounts owed under, and terminated, the Credit Agreement with Ares Capital Corporation. The total amount paid to Ares Capital Corporation under the Credit Agreement in connection with the prepayment was $98.6&#160;million, which included $9.7&#160;million for the make-whole premium as well as $0.2&#160;million in accrued interest. As a result of this transaction, the Company recorded loss on the repayment of debt of $19.2&#160;million, representing the remaining unamortized debt issuance costs of $9.5&#160;million, the make-whole premium and $35&#160;thousand of legal expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Warrant Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In conjunction with the Company&#x2019;s entry into the Credit Agreement, the Company entered into warrant agreements whereby it agreed to sell to the holders of the warrants an aggregate of 1,513,786 shares of Class A common stock at a per share purchase price equal to $8.05.  The holders could exercise the warrants at any time until thirty days after the maturity of the Credit Agreement.  The Company, at its sole discretion, could elect to pay the holders in cash in an amount determined based on the fair market value of the Class A common stock for the shares of Class A common stock issuable upon exercise of the warrants in lieu of delivering the shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 8, 2021, the Company settled the outstanding warrants associated with the Credit Agreement for $13.7&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2025 Notes&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2018, the Company issued $172.5 million aggregate principal amount of its 1.50% Convertible Senior Notes due 2025 (the &#x201c;2025 Notes&#x201d;) in a private placement to qualified institutional buyers within the meaning of Rule 144A under the Securities Act of 1933, as amended (the &#x201c;Securities Act&#x201d;). The 2025 Notes were issued at par for net proceeds of $166.6 million. We incurred $5.9 million of debt issuance costs in connection with the 2025 Notes. The closing of the private placement of $150.0 million aggregate principal amount of the 2025 Notes occurred on October&#160;22, 2018, and the Company completed the offering and sale of an additional $22.5 million aggregate principal amount of the 2025 Notes on October&#160;24, 2018, pursuant to the initial purchasers&#x2019; exercise in full of their option to purchase additional notes.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Holders of the 2025 Notes are entitled to cash interest payments, which are payable semiannually in arrears on&#160;April 15&#160;and&#160;October 15&#160;of each year, beginning on&#160;April&#160;15, 2019, at a rate equal to&#160;1.50%&#160;per annum. The Company recorded interest expense of $0.7 million and $1.3 million for the three and six months ended June 30, 2021 and 2020, respectively. The 2025 Notes will mature on&#160;October&#160;15, 2025, unless earlier repurchased, redeemed or converted in accordance with their terms prior to such date.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to the close of business on the business day immediately preceding April&#160;15, 2025, the 2025 Notes will be convertible at the option of the holders only upon the satisfaction of certain conditions, as described in the indenture, dated as of October&#160;22, 2018, between the Company and U.S. Bank National Association, as trustee. At any time on or after April&#160;15, 2025, until the close of business on the business day immediately preceding the maturity date, holders may convert, at their option, all or any portion of their notes at the conversion rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2025 Notes will be convertible at an initial conversion rate of 29.9135 shares of Class A common stock per $1,000 principal amount of notes, which is equivalent to an initial conversion price of approximately $33.43 per share of the Company&#x2019;s Class A common stock. In the aggregate, the 2025 Notes are initially convertible into 5.2 million shares of the Company&#x2019;s Class A common stock (excluding any shares issuable by the Company upon a conversion in connection with a make-whole fundamental change or a notice of redemption as described in the governing indenture). The conversion rate may be adjusted under certain circumstances. Upon conversion, the Company will pay or deliver, as the case may be, cash or shares of the Company&#x2019;s Class A common stock, or a combination of cash and shares of the Company&#x2019;s Class A common stock, at the Company&#x2019;s election.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The option to settle the 2025 Notes in cash or shares of the Company&#x2019;s Class A common stock, or a combination of cash and shares of the Company&#x2019;s Class A common stock, at the Company&#x2019;s election, resulted in a bifurcation of the carrying value of the 2025 Notes into a debt component and an equity component. The debt component was determined to be $100.7 million, before issuance costs, based on the fair value of a nonconvertible debt instrument with the same term. The equity component was determined to be $71.8 million, before issuance costs, and was recorded within additional paid-in capital. The equity component is the difference between the aggregate principal amount of the debt and the debt component. Issuance costs of $3.4 million and $2.5 million are allocated to the debt and equity components in proportion to the allocation of proceeds. Along with the equity component of $71.8 million, $3.4 million of issuance costs will be amortized to interest expense on the consolidated statements of operations and comprehensive income (loss) using the effective interest method over the contractual term of the 2025 Notes. The equity component recorded within additional paid-in capital will not be remeasured as long as it meets the conditions for equity classification. The Company recorded $2.4 million and $4.8 million for the three and six months ended June 30, 2021, respectively, and $2.1 million and $4.3 million for the three and six months ended June 30, 2020, respectively, in interest expense related to the amortization of the debt discount and the issuance costs allocated to the debt component.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Holders of the 2025 Notes may require the Company to repurchase all or part of their notes upon the occurrence of a fundamental change at a price equal to 100.0% of the principal amount of the notes being repurchased, plus any accrued and unpaid interest to, but excluding, the fundamental change repurchase date. The Company may not redeem the 2025 Notes prior to October&#160;20, 2022. The Company may redeem for cash all or any portion of the 2025 Notes, at its option, on or after October&#160;20, 2022, if the last reported sale price of the Company&#x2019;s Class A common stock has been at least 130.0% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which the Company provides notice of redemption, at a redemption price equal to 100.0% of the principal amount of the notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2021 Notes&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2016, the Company issued $125.0 million aggregate principal amount of its 2.00% Convertible Senior Notes due 2021 (the &#x201c;2021 Notes&#x201d;) in a private placement to qualified institutional buyers within the meaning of Rule 144A under the Securities Act. The 2021 Notes were issued at par for net proceeds of $120.4 million. We incurred $4.6 million of debt issuance costs in connection with the 2021 Notes, which we are amortizing to non-cash interest expense using the straight-line method over the contractual term of the 2021 Notes, since this method was not materially different from the effective interest method. The closing of the private placement of the 2021 Notes occurred on December&#160;5, 2016.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Holders of the 2021 Notes are entitled to cash interest payments, which are payable semiannually in arrears on June 1 and December 1 of each year, beginning on June&#160;1, 2017, at a rate equal to 2.00% per annum. The 2021 Notes will mature on December&#160;1, 2021, unless earlier repurchased or converted in accordance with their terms prior to such date. In addition, holders of the 2021 Notes may require the Company to repurchase all or part of their 2021 Notes upon the occurrence of a fundamental change at a price equal to 100.00% of the principal amount of the 2021 Notes being repurchased, plus any accrued and unpaid interest to, but excluding, the fundamental repurchase date. Upon maturity the principal amount of the notes may be settled via shares of the Company&#x2019;s Class A common stock. We recorded interest expense of $0.2 million and $0.3 million for the three and six months ended June 30, 2021, respectively, and $0.6 million and  $1.2 million for the three and six months ended June 30, 2020 , respectively. We recorded non-cash interest expense related to the amortization of deferred financing costs of $49 thousand and $0.1 million for the three and six months ended June 30, 2021, respectively, and $0.3 million and $0.5 million for the three and six months ended June 30, 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2021 Notes are convertible into shares of the Company&#x2019;s Class A common stock, based on an initial conversion rate of 41.6082 shares of Class A common stock per $1,000 principal amount of the 2021 Notes, which is equivalent to an initial conversion price of approximately $24.03 per share of the Company&#x2019;s Class A common stock. In the aggregate, the 2021 Notes are initially convertible into 5.2 million shares of the Company&#x2019;s Class A common stock (excluding any shares issuable by the Company upon a conversion in connection with a make-whole provision upon a fundamental change under the governing indenture). The conversion rate may be adjusted under certain circumstances.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2021 Notes are convertible, in multiples of $1,000 principal amount, at the option of the holders at any time prior to the close of business on the business day immediately preceding the maturity date. Upon conversion, we will deliver for each $1,000 principal amount of notes converted a number of shares of our Class A common stock equal to the applicable conversion rate (together with a cash payment in lieu of delivering any fractional share) on the third business day following the relevant conversion date.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, as part of the issuance of the 2024 Notes, the Company issued $84.2&#160;million aggregate principal amount of the 2024 Notes in exchange for $84.2&#160;million aggregate principal of its 2021 Notes. There was no cash consideration in these exchanges outside of an aggregate cash payment of $2.5&#160;million paid to exchanging noteholders. These exchanges were accounted for as an extinguishment resulting in a net loss on extinguishment of debt of $4.8&#160;million, including an aggregate cash payment of $2.5&#160;million paid to exchanging noteholders. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, we also repurchased $14.0&#160;million of the 2021 Notes with $13.9&#160;million of cash and recorded an immaterial gain on extinguishment of debt.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Convertible Senior Notes Carrying Value&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2025 Notes, 2024 Notes and 2021 Notes are recorded on our accompanying consolidated balance sheets at their net carrying values as of June&#160;30, 2021. However, the 2025 Notes, 2024 Notes and 2021 Notes are privately traded by qualified institutional buyers (within the meaning of Rule 144A under the Securities Act) and their fair values are Level 2 inputs. The 2025 Notes, 2024 Notes and the 2021 Notes also have embedded conversion options and contingent interest provisions, which have not been recorded as separate financial instruments. The following table summarizes the carrying value of the long-term convertible debt as of June&#160;30, 2021 and December&#160;31, 2020 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:361.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:84.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:84.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:20pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024 Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85,320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized debt discount and issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Principal amount&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,051&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,051&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remaining amortization period (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132,054&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;153,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2025 Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121,230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116,349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized debt discount and issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Principal amount&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;172,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;172,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remaining amortization period (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;165,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;147,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021 Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Principal amount&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remaining amortization period (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ie9f0093698034c048db39ee74d23fe56_I20200831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfNzg_3f3b6bf8-8b52-48d1-9efa-dca4f4cec981"
      unitRef="usd">117100000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ie9f0093698034c048db39ee74d23fe56_I20200831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMTE1_0dcbf41c-530f-49f1-b0fe-f348bb9e2120"
      unitRef="number">0.0350</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="i0d3f73b1f2c04d3ba51586bcf12c3517_D20200801-20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMzM0_b7793f62-ab09-4372-84bb-70d016176014"
      unitRef="usd">84200000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionOriginalDebtAmount1
      contextRef="icea30d45fccd401f9bb3791275a8c40c_D20200801-20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfNDAy_cd7790bc-9401-48cc-b9a0-cad2db8885c8"
      unitRef="usd">84200000</us-gaap:DebtConversionOriginalDebtAmount1>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="i1598eae5f6ae4813b69f0cbb95358c65_D20200801-20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfNDkx_b8b2d45f-a351-4273-80a4-c01afbba644b"
      unitRef="usd">2500000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="iabe38bb19e7049c7a823aae107a5b0ba_D20200801-20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfNTA2_ce1773e1-e4c3-4992-a4bd-ff7c2c8ac54d"
      unitRef="usd">32800000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="ie9f0093698034c048db39ee74d23fe56_I20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfNTg2_ee53e43e-cb00-4934-b9ce-5e1640b7ae44"
      unitRef="usd">3000000.0</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ie9f0093698034c048db39ee74d23fe56_I20200831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMTA1OA_dc869f0f-9f09-4588-adce-63a5d9028d6e"
      unitRef="number">0.0350</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:InterestExpenseDebt
      contextRef="id559bfbab5954aa7bb0b5c73c4b04f85_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMTY0OTI2NzQ2Mjg1NQ_53d4b527-fd39-4604-9e48-b32ee47763da"
      unitRef="usd">1000000.0</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="i6b496ee9129546a1943004e4d9e6e458_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMTM2Ng_a5dca2c9-7a29-44e5-8cab-465b5bddeddb"
      unitRef="usd">2000000.0</us-gaap:InterestExpenseDebt>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="ie9f0093698034c048db39ee74d23fe56_I20200831"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMTc2MQ_e429e4c3-c5f5-4119-acdb-db29da625ff2"
      unitRef="usdPerShare">18.23</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments
      contextRef="i0d3f73b1f2c04d3ba51586bcf12c3517_D20200801-20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMTg3Nw_75223a39-822f-4bcd-a6bb-d644605b9c53"
      unitRef="shares">6400000</us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments>
    <us-gaap:LongTermDebt
      contextRef="ie9f0093698034c048db39ee74d23fe56_I20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMjc1NQ_0fc982b9-f85f-4c19-ac55-62bfd06e596f"
      unitRef="usd">78900000</us-gaap:LongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="ibccaaf22aab2432ba1b4622538e18372_D20200801-20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMjkwNA_85add333-ea51-4b19-9918-4a7b131f2b9d"
      unitRef="usd">38100000</us-gaap:ProceedsFromIssuanceOfDebt>
    <evh:DebtIssuanceCostsNetDebtComponent
      contextRef="ie9f0093698034c048db39ee74d23fe56_I20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMzEzMw_a1ddb381-8030-44df-b3b9-f45ca0451741"
      unitRef="usd">1700000</evh:DebtIssuanceCostsNetDebtComponent>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="i437f571852d648ad8e14dd03e682fc47_I20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMzE0MA_214efe44-915e-4282-b4e3-f41e139fee91"
      unitRef="usd">1300000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="ibccaaf22aab2432ba1b4622538e18372_D20200801-20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMzI3MQ_47941dd4-d426-4a73-aa02-b7d5057e2acb"
      unitRef="usd">38100000</us-gaap:ProceedsFromIssuanceOfDebt>
    <evh:DebtIssuanceCostsNetDebtComponent
      contextRef="ie9f0093698034c048db39ee74d23fe56_I20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMzI3NQ_e7eb4417-c48e-4d1d-9065-3cde95405e72"
      unitRef="usd">1700000</evh:DebtIssuanceCostsNetDebtComponent>
    <evh:AmortizationOfDebtDiscountAndDebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
      contextRef="id559bfbab5954aa7bb0b5c73c4b04f85_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMTY0OTI2NzQ2Mjg3Nw_a96d4097-048c-4b34-be50-1061b4263bd9"
      unitRef="usd">2000000.0</evh:AmortizationOfDebtDiscountAndDebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction>
    <evh:AmortizationOfDebtDiscountAndDebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
      contextRef="i6b496ee9129546a1943004e4d9e6e458_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMzY2Mg_f09f37b6-4c4d-4117-b11b-1b5cf8b3f61a"
      unitRef="usd">3900000</evh:AmortizationOfDebtDiscountAndDebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction>
    <evh:DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount
      contextRef="i0d3f73b1f2c04d3ba51586bcf12c3517_D20200801-20200831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMzk1Mw_c73209ca-d830-4758-90b5-ff58a121ea32"
      unitRef="number">1.000</evh:DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount>
    <evh:DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice
      contextRef="i0d3f73b1f2c04d3ba51586bcf12c3517_D20200801-20200831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfNDM3NA_1fd4e24c-23cf-4e28-82d4-a000fd20a292"
      unitRef="number">1.300</evh:DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice>
    <evh:DebtInstrumentRepurchaseCovenantTradingDaysMinimum
      contextRef="i0d3f73b1f2c04d3ba51586bcf12c3517_D20200801-20200831"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfNDQyOQ_02157141-34a7-4889-a04f-c78fa1938ef7">P20D</evh:DebtInstrumentRepurchaseCovenantTradingDaysMinimum>
    <evh:DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum
      contextRef="i0d3f73b1f2c04d3ba51586bcf12c3517_D20200801-20200831"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfNDQ4NQ_ba489538-8a9d-4580-80e9-c0e4950d3bbe">P30D</evh:DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum>
    <evh:DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice
      contextRef="i0d3f73b1f2c04d3ba51586bcf12c3517_D20200801-20200831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfNDcyMw_47390ff5-5d1f-4acc-8c69-969fddf589cc"
      unitRef="number">1.000</evh:DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ifa10c9f357cc46da8a582a78230489bf_I20191230"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfNTM5OA_97bd74a5-de0d-40f9-b669-b57ecfd5c8e4"
      unitRef="usd">75000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i06948a2177d04b259e0902a18900dc29_I20191230"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfNTUzMA_4fbd458e-d99c-4fd6-b38f-5ecabfbc2855"
      unitRef="usd">50000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ibef4bf4bc2ab41d2ad6d564857f8fb16_I20191230"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfNjkxOQ_f87e5322-6081-4ce5-abd9-630c7258c163"
      unitRef="number">0.0200</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentTerm
      contextRef="ibb12573bef604a62ac70c8f5b1d35372_D20191230-20191230"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfNzM2Mw_12a1fb8d-3497-4630-a4cf-8288ab68e8bf">P91D</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i11adbaf0c9c0475282d0187b6ac6db8f_D20191230-20191230"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfNzY2Nw_6d15b94f-7ed6-4e6e-b2e3-2235caa32137"
      unitRef="number">0.0800</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="ic8d3791c30f040c2b02c8f39bf43b812_D20191230-20191230"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfNzY5Mw_e152597c-89e7-4ac3-b7b7-7e1d49e42c18"
      unitRef="number">0.0700</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:LineOfCreditFacilityCommitmentFeePercentage
      contextRef="i1868ae14255d4c95aab130080ec3175b_D20191230-20191230"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfNzcxNw_6c1b6af8-a330-445a-b79a-b93de3723187"
      unitRef="number">0.0100</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
    <evh:DebtInstrumentRedemptionCallProtectionPremiumPercentage
      contextRef="i381ee2f518b34b78a5f3e6263b399e70_D20191230-20191230"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfODMyOA_27b2f1e9-1817-441d-926c-ce3817d25a47"
      unitRef="number">0.0400</evh:DebtInstrumentRedemptionCallProtectionPremiumPercentage>
    <evh:DebtInstrumentRedemptionCallProtectionPremiumPercentage
      contextRef="i2b0d7584f95b486581d1f8fcf494bd87_D20191230-20191230"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfODUyNw_c99bee65-fcee-4aac-8251-0f3eb26930c8"
      unitRef="number">0.0300</evh:DebtInstrumentRedemptionCallProtectionPremiumPercentage>
    <evh:DebtInstrumentRedemptionCallProtectionPremiumPercentage
      contextRef="ic5de6b4f322d4a41ba0b04e047d3567b_D20191230-20191230"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfODczMQ_93f23394-386d-41dc-aa19-fc38d53f29d9"
      unitRef="number">0.0200</evh:DebtInstrumentRedemptionCallProtectionPremiumPercentage>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="i6f21b3a7685841259a7bbf081309eb0f_I20191230"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMTAwMDU_96b5812a-9f80-4bb3-ae34-8f4000d6a47a"
      unitRef="usd">4700000</us-gaap:DeferredFinanceCostsNet>
    <evh:AmortizationOfDebtDiscountAndDebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
      contextRef="ida1f309838e74abeb0e17c296af553bb_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMTY0OTI2NzQ2Mjk4NA_cbd122aa-e732-43d3-8ab0-fddf22d40a02"
      unitRef="usd">500000</evh:AmortizationOfDebtDiscountAndDebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction>
    <evh:AmortizationOfDebtDiscountAndDebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
      contextRef="i96b555f871384a6ab79fe625ce473698_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMTAyNTE_2be3b563-5ba6-43b3-a0fd-8861419ee543"
      unitRef="usd">1100000</evh:AmortizationOfDebtDiscountAndDebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction>
    <us-gaap:RepaymentsOfLongTermLinesOfCredit
      contextRef="i2e95d208160a4c749900182d52a49615_D20210108-20210108"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMzg0ODI5MDc2MDEzMw_a1cfe04d-a646-44af-bfb0-05448f32e66c"
      unitRef="usd">98600000</us-gaap:RepaymentsOfLongTermLinesOfCredit>
    <evh:PaymentsOfMakeWholePremium
      contextRef="i2e95d208160a4c749900182d52a49615_D20210108-20210108"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMzg0ODI5MDc2MDE0OA_0db5f668-53f7-4fa8-b82f-195a93480f79"
      unitRef="usd">9700000</evh:PaymentsOfMakeWholePremium>
    <us-gaap:InterestPaidNet
      contextRef="i2e95d208160a4c749900182d52a49615_D20210108-20210108"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMzg0ODI5MDc2MDE2Mg_4e01a625-4b0c-433c-a8c8-7af85b297205"
      unitRef="usd">200000</us-gaap:InterestPaidNet>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="if600ab05fc8b49bca59c078f4bbb6742_D20210108-20210108"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMTEyMTc_96432ae3-8606-437b-a87d-ec0ee6fa7567"
      unitRef="usd">19200000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:WriteOffOfDeferredDebtIssuanceCost
      contextRef="if600ab05fc8b49bca59c078f4bbb6742_D20210108-20210108"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMTEyODM_d7a6bc89-f77d-4748-81ce-78cf2339fa33"
      unitRef="usd">9500000</us-gaap:WriteOffOfDeferredDebtIssuanceCost>
    <us-gaap:LegalFees
      contextRef="if600ab05fc8b49bca59c078f4bbb6742_D20210108-20210108"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMTEzMTQ_e88c8282-52a0-45d7-9dab-03d585b8ef2b"
      unitRef="usd">35000</us-gaap:LegalFees>
    <us-gaap:ClassOfWarrantOrRightUnissued
      contextRef="i1cad05e654934e308e828b864b76a508_I20191230"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMTE1NDA_ac7abe6a-a6b2-498a-92c3-cc274b28f9ca"
      unitRef="shares">1513786</us-gaap:ClassOfWarrantOrRightUnissued>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i1cad05e654934e308e828b864b76a508_I20191230"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMTE2MTM_6d926829-1d44-4dd6-a395-1b7b639d32b6"
      unitRef="usdPerShare">8.05</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <evh:ClassOfWarrantOrRightPeriodDuringWhichWarrantsOrRightsExercisableAfterMaturityOfCreditAgreement
      contextRef="i0bb88f4c90544362ab13fcd63aba4af7_D20191230-20191230"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMTE2NzY_5815a4bd-700f-4fe8-b61a-a715934599cb">P30D</evh:ClassOfWarrantOrRightPeriodDuringWhichWarrantsOrRightsExercisableAfterMaturityOfCreditAgreement>
    <us-gaap:PaymentsForRepurchaseOfWarrants
      contextRef="if7229a5e40df4a5095c25bd23977e747_D20210108-20210108"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMzg0ODI5MDc2MDE5MQ_84797a79-ec85-48d8-9972-eb5574d121ff"
      unitRef="usd">13700000</us-gaap:PaymentsForRepurchaseOfWarrants>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ia5b2225a7a85439eb9318023f5dca1ab_I20181031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMTIxNTU_ef1194d3-5c7a-454b-9292-e2711a8c88c3"
      unitRef="usd">172500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ia5b2225a7a85439eb9318023f5dca1ab_I20181031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMTIxOTI_59662d5f-0f7c-49b3-ba92-07fe46819cc7"
      unitRef="number">0.0150</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="ifee6d13c14704a0a9bd4959cd14684b6_D20181001-20181031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMTI0NjA_03f885e7-ac5a-4e90-a947-0ce2179dd82a"
      unitRef="usd">166600000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="i0db344c6ddf344ceab1c3071829545ff_I20181031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMTI0NzY_f5e30313-a3e8-4be4-adfc-f18041204947"
      unitRef="usd">5900000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i3533fa8477ed4bb0afb07e5b80879435_I20181022"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMTI1Nzc_1df43740-d953-47c0-824d-a59479b9de77"
      unitRef="usd">150000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="if3e69e58105c4d909f82068c94a4e66f_I20181024"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMTI3MDY_8b8fae39-9c08-410a-b5c9-bd19de341585"
      unitRef="usd">22500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ia5b2225a7a85439eb9318023f5dca1ab_I20181031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMTMwNDY_59662d5f-0f7c-49b3-ba92-07fe46819cc7"
      unitRef="number">0.0150</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:InterestExpenseDebt
      contextRef="i4deadc1ba0674142a17d227672696535_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMTY0OTI2NzUwMzc4Mg_00567e75-550c-4a45-af63-d60610d93218"
      unitRef="usd">700000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="iba4a0e1b01024c46b291007f4c8b7e3f_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMTY0OTI2NzUwMzc4Mg_bddd0fc2-cae3-479b-810a-ad7cfb149ad6"
      unitRef="usd">700000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="ieeacfdfdfca8412a9c4cc31d0dfb0be6_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMTMxMDE_487fb421-608a-4999-8496-dcd298f2ca14"
      unitRef="usd">1300000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="i0489a5ac9602461ea764f0340d05dbc2_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMTMxMDE_fe671022-e53b-4994-9c04-a3f5b6b71b54"
      unitRef="usd">1300000</us-gaap:InterestExpenseDebt>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="ia5b2225a7a85439eb9318023f5dca1ab_I20181031"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMTQwMTc_f8dd4462-1ab4-4ed3-90c7-2c6bbc70b701"
      unitRef="usdPerShare">33.43</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments
      contextRef="ifee6d13c14704a0a9bd4959cd14684b6_D20181001-20181031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMTQxMzM_4721e4f4-7896-4e81-a8de-663552089628"
      unitRef="shares">5200000</us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments>
    <us-gaap:LongTermDebt
      contextRef="ia5b2225a7a85439eb9318023f5dca1ab_I20181031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMTUwMDQ_48a7a078-b321-46e4-86e0-4d932f51f04a"
      unitRef="usd">100700000</us-gaap:LongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="id755146089114b63a291ebb347fe05cd_D20181001-20181031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMTUxNTM_99ce81b6-ea59-4837-bc8b-072d79c6311e"
      unitRef="usd">71800000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="ia5b2225a7a85439eb9318023f5dca1ab_I20181031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMTUzNjQ_4c5f0382-f641-44ed-b052-87974493a088"
      unitRef="usd">3400000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="i263de0af39604a6985530e0395eaee6f_I20181031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMTUzNzE_4d648907-97bd-4e8d-9f47-30e34b84ea8d"
      unitRef="usd">2500000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="id755146089114b63a291ebb347fe05cd_D20181001-20181031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMTU1MDI_99ce81b6-ea59-4837-bc8b-072d79c6311e"
      unitRef="usd">71800000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="ia5b2225a7a85439eb9318023f5dca1ab_I20181031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMTU1MDY_4c5f0382-f641-44ed-b052-87974493a088"
      unitRef="usd">3400000</us-gaap:DeferredFinanceCostsNet>
    <evh:AmortizationOfDebtDiscountAndDebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
      contextRef="iba4a0e1b01024c46b291007f4c8b7e3f_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMTY0OTI2NzQ2MzA4Ng_4532e9a7-dd11-4cb5-a9c2-30e8fe06be86"
      unitRef="usd">2400000</evh:AmortizationOfDebtDiscountAndDebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction>
    <evh:AmortizationOfDebtDiscountAndDebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
      contextRef="i4deadc1ba0674142a17d227672696535_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMTU5MDE_352e3e32-34c3-4f7a-8fc8-be1f66849e3f"
      unitRef="usd">4800000</evh:AmortizationOfDebtDiscountAndDebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction>
    <evh:AmortizationOfDebtDiscountAndDebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
      contextRef="ieeacfdfdfca8412a9c4cc31d0dfb0be6_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMTY0OTI2NzQ2MzEyOA_6859495c-e701-4dd0-8e99-2e9a0c69bbbd"
      unitRef="usd">2100000</evh:AmortizationOfDebtDiscountAndDebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction>
    <evh:AmortizationOfDebtDiscountAndDebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
      contextRef="i0489a5ac9602461ea764f0340d05dbc2_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMTU5MDg_939824ce-83ef-4882-bf0c-adbcfe1b97f6"
      unitRef="usd">4300000</evh:AmortizationOfDebtDiscountAndDebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction>
    <evh:DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount
      contextRef="ifee6d13c14704a0a9bd4959cd14684b6_D20181001-20181031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMTYyMDc_d004ca47-a882-4e48-aea1-8aedf646e232"
      unitRef="number">1.000</evh:DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount>
    <evh:DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice
      contextRef="ifee6d13c14704a0a9bd4959cd14684b6_D20181001-20181031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMTY2MDY_adbdc2ed-99c4-4253-8305-e25b4fe3e866"
      unitRef="number">1.300</evh:DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice>
    <evh:DebtInstrumentRepurchaseCovenantTradingDaysMinimum
      contextRef="ifee6d13c14704a0a9bd4959cd14684b6_D20181001-20181031"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMTY2NjE_7a98b120-c078-429e-a668-448f0417627d">P20D</evh:DebtInstrumentRepurchaseCovenantTradingDaysMinimum>
    <evh:DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum
      contextRef="ifee6d13c14704a0a9bd4959cd14684b6_D20181001-20181031"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMTY3MTc_f3ef76d8-17db-47f9-bfd5-54b37f4eeb8d">P30D</evh:DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum>
    <evh:DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice
      contextRef="ifee6d13c14704a0a9bd4959cd14684b6_D20181001-20181031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMTY5NTU_025a6f46-143a-4352-a7e2-e884b332f460"
      unitRef="number">1.000</evh:DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i0efb2207e70f43cb998170b0668f5aa4_I20161231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMTcxMjM_7ac6fd3d-4899-42e4-a7e7-900f2fe4bb1a"
      unitRef="usd">125000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i0efb2207e70f43cb998170b0668f5aa4_I20161231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMTcxNjA_1c761755-59f8-4781-957e-749e4a78e86a"
      unitRef="number">0.0200</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="ib65ee853127148cf9a525e6a17c68f39_D20161201-20161231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMTczODM_7ac2f0e0-0279-4ae6-9dc5-83b4955a8871"
      unitRef="usd">120400000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="i0efb2207e70f43cb998170b0668f5aa4_I20161231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMTczOTk_2a443424-7253-4a9a-9fb2-0afb1401161b"
      unitRef="usd">4600000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i0efb2207e70f43cb998170b0668f5aa4_I20161231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMTc5MTU_1c761755-59f8-4781-957e-749e4a78e86a"
      unitRef="number">0.0200</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <evh:DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount
      contextRef="ib65ee853127148cf9a525e6a17c68f39_D20161201-20161231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMTgyMjc_00183344-c895-43b4-9f95-d9804af21f16"
      unitRef="number">1.0000</evh:DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount>
    <us-gaap:InterestExpenseDebt
      contextRef="ic303181ec3134d098d234f848582ffd2_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMTY0OTI2NzQ2MzE0NA_00bea3f3-3dc5-4ae3-80ce-0cfa8fe442f9"
      unitRef="usd">200000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="idf80add09165458a8481ba03343ec164_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMTg1MjU_26b28b36-4e29-464c-b4e1-aa7d6e61d06e"
      unitRef="usd">300000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="i4e0425e5520c4d8ca777fd31abfdf006_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMTY0OTI2NzQ2MzE3NQ_c6a0bac3-1daa-4677-b0c0-2d53a07891c4"
      unitRef="usd">600000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="i424565a0d08945018985beab5025c0a3_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMTg1MzI_327a2670-ec56-4c36-8d8d-66936da48536"
      unitRef="usd">1200000</us-gaap:InterestExpenseDebt>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="ic303181ec3134d098d234f848582ffd2_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMTY0OTI2NzQ2MzIyOA_0aee6e98-d88f-414b-8cee-eb8ab675c048"
      unitRef="usd">49000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="idf80add09165458a8481ba03343ec164_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMTg2NTQ_88b7d615-ee7f-4858-898a-2b8949022497"
      unitRef="usd">100000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="i4e0425e5520c4d8ca777fd31abfdf006_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMTY0OTI2NzQ2MzE5OQ_ea469f8f-745c-4d9a-b736-adf41091ac7c"
      unitRef="usd">300000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="i424565a0d08945018985beab5025c0a3_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMTg2NjE_2c5327ae-f550-4374-95e9-962344e6b4d2"
      unitRef="usd">500000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="ifad8a17110484cd3b275f15806410965_I20161231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMTg5NTM_6fe9bf64-f2ac-4c7f-a9a2-5e0037765536"
      unitRef="usdPerShare">24.03</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments
      contextRef="ifa1e9df841254737b2d83a5669c5b70d_D20161201-20161231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMTkwNjk_bdba6578-ef9f-4804-ad48-73c295694953"
      unitRef="shares">5200000</us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="i0d3f73b1f2c04d3ba51586bcf12c3517_D20200801-20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMTk5MzY_cbedf45a-971a-47ad-85c3-afcb3de38c8a"
      unitRef="usd">84200000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionOriginalDebtAmount1
      contextRef="icea30d45fccd401f9bb3791275a8c40c_D20200801-20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMjAwMDA_e14123ef-70a2-4619-bb65-4519265979c9"
      unitRef="usd">84200000</us-gaap:DebtConversionOriginalDebtAmount1>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="i1598eae5f6ae4813b69f0cbb95358c65_D20200801-20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMjAxMzM_66c1d6c0-82c7-491b-9608-1dbb24a8953b"
      unitRef="usd">2500000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost
      contextRef="i1598eae5f6ae4813b69f0cbb95358c65_D20200801-20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMjAyNzc_40ff517d-cb78-444c-8ebe-980646158794"
      unitRef="usd">-4800000</us-gaap:GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="i1598eae5f6ae4813b69f0cbb95358c65_D20200801-20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMjAzMjA_27570fa2-794f-47c8-9d57-704858807f93"
      unitRef="usd">2500000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:ExtinguishmentOfDebtAmount
      contextRef="icea30d45fccd401f9bb3791275a8c40c_D20200801-20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMjAzOTM_ef651547-8f7f-438d-a27d-c307b98e52f4"
      unitRef="usd">14000000.0</us-gaap:ExtinguishmentOfDebtAmount>
    <us-gaap:RepaymentsOfSeniorDebt
      contextRef="icea30d45fccd401f9bb3791275a8c40c_D20200801-20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMjA0MTk_994b30bd-7f3a-4c46-865c-03017cdb1388"
      unitRef="usd">13900000</us-gaap:RepaymentsOfSeniorDebt>
    <us-gaap:ConvertibleDebtTableTextBlock
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RleHRyZWdpb246OGRlZGE4MmFmZWEwNDdhNDg5ZmIzZTU5ZDliNTQ0YzhfMjExNjc_3bf317b3-21d0-47a0-b833-e48b80d45c1e">The following table summarizes the carrying value of the long-term convertible debt as of June&#160;30, 2021 and December&#160;31, 2020 (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:361.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:84.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:84.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:20pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024 Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85,320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized debt discount and issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Principal amount&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,051&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,051&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remaining amortization period (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132,054&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;153,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2025 Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121,230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116,349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized debt discount and issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Principal amount&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;172,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;172,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remaining amortization period (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;165,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;147,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021 Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Principal amount&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remaining amortization period (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ConvertibleDebtTableTextBlock>
    <us-gaap:ConvertibleDebt
      contextRef="i8e9d743092e245ce8a2743fa9de0063b_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RhYmxlOjc3NGIzNTQ0YWM0NDQ2NjI4NTE2Nzk5ZGRmMTM4ZDk3L3RhYmxlcmFuZ2U6Nzc0YjM1NDRhYzQ0NDY2Mjg1MTY3OTlkZGYxMzhkOTdfMi0xLTEtMS0w_a89f0872-9cb4-4f34-9e5e-747d5f37e2a5"
      unitRef="usd">85320000</us-gaap:ConvertibleDebt>
    <us-gaap:ConvertibleDebt
      contextRef="id589098e41f9432fb6f03c1f1e575a4c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RhYmxlOjc3NGIzNTQ0YWM0NDQ2NjI4NTE2Nzk5ZGRmMTM4ZDk3L3RhYmxlcmFuZ2U6Nzc0YjM1NDRhYzQ0NDY2Mjg1MTY3OTlkZGYxMzhkOTdfMi0zLTEtMS0w_df192b1d-0805-45c4-aa2c-d158d0f26dfd"
      unitRef="usd">81462000</us-gaap:ConvertibleDebt>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="i8e9d743092e245ce8a2743fa9de0063b_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RhYmxlOjc3NGIzNTQ0YWM0NDQ2NjI4NTE2Nzk5ZGRmMTM4ZDk3L3RhYmxlcmFuZ2U6Nzc0YjM1NDRhYzQ0NDY2Mjg1MTY3OTlkZGYxMzhkOTdfMy0xLTEtMS0w_6c25631c-6045-467c-ae4a-f4f657b6775d"
      unitRef="usd">31731000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="id589098e41f9432fb6f03c1f1e575a4c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RhYmxlOjc3NGIzNTQ0YWM0NDQ2NjI4NTE2Nzk5ZGRmMTM4ZDk3L3RhYmxlcmFuZ2U6Nzc0YjM1NDRhYzQ0NDY2Mjg1MTY3OTlkZGYxMzhkOTdfMy0zLTEtMS0w_879a7b03-3092-4dc0-b5ce-b03ed3e6a32c"
      unitRef="usd">35589000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i8e9d743092e245ce8a2743fa9de0063b_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RhYmxlOjc3NGIzNTQ0YWM0NDQ2NjI4NTE2Nzk5ZGRmMTM4ZDk3L3RhYmxlcmFuZ2U6Nzc0YjM1NDRhYzQ0NDY2Mjg1MTY3OTlkZGYxMzhkOTdfNC0xLTEtMS0w_5906d877-9bf6-4231-aacb-be1eec67ee92"
      unitRef="usd">117051000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="id589098e41f9432fb6f03c1f1e575a4c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RhYmxlOjc3NGIzNTQ0YWM0NDQ2NjI4NTE2Nzk5ZGRmMTM4ZDk3L3RhYmxlcmFuZ2U6Nzc0YjM1NDRhYzQ0NDY2Mjg1MTY3OTlkZGYxMzhkOTdfNC0zLTEtMS0w_0c0d44c5-0235-4b36-806d-04706db4e44f"
      unitRef="usd">117051000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1
      contextRef="i6b496ee9129546a1943004e4d9e6e458_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RhYmxlOjc3NGIzNTQ0YWM0NDQ2NjI4NTE2Nzk5ZGRmMTM4ZDk3L3RhYmxlcmFuZ2U6Nzc0YjM1NDRhYzQ0NDY2Mjg1MTY3OTlkZGYxMzhkOTdfNS0xLTEtMS0w_aed11f05-273a-4952-806b-22926510f2cc">P3Y4M24D</us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1>
    <us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1
      contextRef="i8919b4a21f774b92af0611b3454001f6_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RhYmxlOjc3NGIzNTQ0YWM0NDQ2NjI4NTE2Nzk5ZGRmMTM4ZDk3L3RhYmxlcmFuZ2U6Nzc0YjM1NDRhYzQ0NDY2Mjg1MTY3OTlkZGYxMzhkOTdfNS0zLTEtMS0w_c39b1541-71d9-47da-b7f2-10a69dccde85">P3Y10M24D</us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1>
    <us-gaap:LongTermDebtFairValue
      contextRef="ib88938e6f5a14d0f9eced78e9a885018_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RhYmxlOjc3NGIzNTQ0YWM0NDQ2NjI4NTE2Nzk5ZGRmMTM4ZDk3L3RhYmxlcmFuZ2U6Nzc0YjM1NDRhYzQ0NDY2Mjg1MTY3OTlkZGYxMzhkOTdfNi0xLTEtMS0w_0e7c2b87-c057-421d-a0cd-4fae87a96e37"
      unitRef="usd">132054000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="i6cfa2b6d88f04259ac6ccaaed1afd02a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RhYmxlOjc3NGIzNTQ0YWM0NDQ2NjI4NTE2Nzk5ZGRmMTM4ZDk3L3RhYmxlcmFuZ2U6Nzc0YjM1NDRhYzQ0NDY2Mjg1MTY3OTlkZGYxMzhkOTdfNi0zLTEtMS0w_a98032a4-d4ef-481a-bf25-586d17e0aea4"
      unitRef="usd">153220000</us-gaap:LongTermDebtFairValue>
    <us-gaap:ConvertibleDebt
      contextRef="ia8e7a5b465864f39bac51a81bb700201_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RhYmxlOjc3NGIzNTQ0YWM0NDQ2NjI4NTE2Nzk5ZGRmMTM4ZDk3L3RhYmxlcmFuZ2U6Nzc0YjM1NDRhYzQ0NDY2Mjg1MTY3OTlkZGYxMzhkOTdfOS0xLTEtMS0w_e349afb4-8653-48ce-9851-62c3ce6fad7e"
      unitRef="usd">121230000</us-gaap:ConvertibleDebt>
    <us-gaap:ConvertibleDebt
      contextRef="i7f54eab4eae24811a155de3cf38eeb86_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RhYmxlOjc3NGIzNTQ0YWM0NDQ2NjI4NTE2Nzk5ZGRmMTM4ZDk3L3RhYmxlcmFuZ2U6Nzc0YjM1NDRhYzQ0NDY2Mjg1MTY3OTlkZGYxMzhkOTdfOS0zLTEtMS0w_03ba8c97-92c2-4760-81fc-e90c497c4edc"
      unitRef="usd">116349000</us-gaap:ConvertibleDebt>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="ia8e7a5b465864f39bac51a81bb700201_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RhYmxlOjc3NGIzNTQ0YWM0NDQ2NjI4NTE2Nzk5ZGRmMTM4ZDk3L3RhYmxlcmFuZ2U6Nzc0YjM1NDRhYzQ0NDY2Mjg1MTY3OTlkZGYxMzhkOTdfMTAtMS0xLTEtMA_a8b7567b-6141-4775-865e-9749e8e70751"
      unitRef="usd">51270000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="i7f54eab4eae24811a155de3cf38eeb86_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RhYmxlOjc3NGIzNTQ0YWM0NDQ2NjI4NTE2Nzk5ZGRmMTM4ZDk3L3RhYmxlcmFuZ2U6Nzc0YjM1NDRhYzQ0NDY2Mjg1MTY3OTlkZGYxMzhkOTdfMTAtMy0xLTEtMA_2cf98e27-6765-45a5-ac0a-db0524373fc3"
      unitRef="usd">56151000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ia8e7a5b465864f39bac51a81bb700201_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RhYmxlOjc3NGIzNTQ0YWM0NDQ2NjI4NTE2Nzk5ZGRmMTM4ZDk3L3RhYmxlcmFuZ2U6Nzc0YjM1NDRhYzQ0NDY2Mjg1MTY3OTlkZGYxMzhkOTdfMTEtMS0xLTEtMA_993970b6-c200-47af-9c7e-799279d289ca"
      unitRef="usd">172500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i7f54eab4eae24811a155de3cf38eeb86_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RhYmxlOjc3NGIzNTQ0YWM0NDQ2NjI4NTE2Nzk5ZGRmMTM4ZDk3L3RhYmxlcmFuZ2U6Nzc0YjM1NDRhYzQ0NDY2Mjg1MTY3OTlkZGYxMzhkOTdfMTEtMy0xLTEtMA_9fe95dd6-0ba2-4d07-806c-886c568d07a7"
      unitRef="usd">172500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1
      contextRef="i4deadc1ba0674142a17d227672696535_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RhYmxlOjc3NGIzNTQ0YWM0NDQ2NjI4NTE2Nzk5ZGRmMTM4ZDk3L3RhYmxlcmFuZ2U6Nzc0YjM1NDRhYzQ0NDY2Mjg1MTY3OTlkZGYxMzhkOTdfMTItMS0xLTEtMA_62dd237e-792f-453b-b645-b103d04900be">P4Y3M18D</us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1>
    <us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1
      contextRef="i82c5460e9f7e435b83787f35cd36dcb2_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RhYmxlOjc3NGIzNTQ0YWM0NDQ2NjI4NTE2Nzk5ZGRmMTM4ZDk3L3RhYmxlcmFuZ2U6Nzc0YjM1NDRhYzQ0NDY2Mjg1MTY3OTlkZGYxMzhkOTdfMTItMy0xLTEtMA_19239617-2c0c-4ff9-b643-818e12a2d9a8">P4Y9M18D</us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1>
    <us-gaap:LongTermDebtFairValue
      contextRef="i24d4b1acd996498eba5eed0fc3e84f4b_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RhYmxlOjc3NGIzNTQ0YWM0NDQ2NjI4NTE2Nzk5ZGRmMTM4ZDk3L3RhYmxlcmFuZ2U6Nzc0YjM1NDRhYzQ0NDY2Mjg1MTY3OTlkZGYxMzhkOTdfMTMtMS0xLTEtMA_2c4e869a-5c20-4026-b4c8-f2b4e2aab104"
      unitRef="usd">165974000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="ie1e16d58e0e740b28071ebf63f24431d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RhYmxlOjc3NGIzNTQ0YWM0NDQ2NjI4NTE2Nzk5ZGRmMTM4ZDk3L3RhYmxlcmFuZ2U6Nzc0YjM1NDRhYzQ0NDY2Mjg1MTY3OTlkZGYxMzhkOTdfMTMtMy0xLTEtMA_a4d59ce2-f041-4e00-9b0e-bad1d6b9c428"
      unitRef="usd">147488000</us-gaap:LongTermDebtFairValue>
    <us-gaap:ConvertibleDebt
      contextRef="i26c20cf31c1242dc950becfb29611788_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RhYmxlOjc3NGIzNTQ0YWM0NDQ2NjI4NTE2Nzk5ZGRmMTM4ZDk3L3RhYmxlcmFuZ2U6Nzc0YjM1NDRhYzQ0NDY2Mjg1MTY3OTlkZGYxMzhkOTdfMTYtMS0xLTEtMA_9655a330-5626-4ccb-9e8e-6bc3411eab45"
      unitRef="usd">26655000</us-gaap:ConvertibleDebt>
    <us-gaap:ConvertibleDebt
      contextRef="i1b41e14476334d7895158617049bccd5_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RhYmxlOjc3NGIzNTQ0YWM0NDQ2NjI4NTE2Nzk5ZGRmMTM4ZDk3L3RhYmxlcmFuZ2U6Nzc0YjM1NDRhYzQ0NDY2Mjg1MTY3OTlkZGYxMzhkOTdfMTYtMy0xLTEtMA_ac400fe9-b951-4fae-9568-0b18441b0d26"
      unitRef="usd">26557000</us-gaap:ConvertibleDebt>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="i26c20cf31c1242dc950becfb29611788_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RhYmxlOjc3NGIzNTQ0YWM0NDQ2NjI4NTE2Nzk5ZGRmMTM4ZDk3L3RhYmxlcmFuZ2U6Nzc0YjM1NDRhYzQ0NDY2Mjg1MTY3OTlkZGYxMzhkOTdfMTctMS0xLTEtMA_c37833a3-acab-40d4-ae72-591476e8d6ad"
      unitRef="usd">82000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="i1b41e14476334d7895158617049bccd5_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RhYmxlOjc3NGIzNTQ0YWM0NDQ2NjI4NTE2Nzk5ZGRmMTM4ZDk3L3RhYmxlcmFuZ2U6Nzc0YjM1NDRhYzQ0NDY2Mjg1MTY3OTlkZGYxMzhkOTdfMTctMy0xLTEtMA_c71ec7ce-86d4-460b-8921-c4933c7a0943"
      unitRef="usd">180000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i26c20cf31c1242dc950becfb29611788_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RhYmxlOjc3NGIzNTQ0YWM0NDQ2NjI4NTE2Nzk5ZGRmMTM4ZDk3L3RhYmxlcmFuZ2U6Nzc0YjM1NDRhYzQ0NDY2Mjg1MTY3OTlkZGYxMzhkOTdfMTgtMS0xLTEtMA_247ea4f4-b34b-4a59-ac12-85633b839cb8"
      unitRef="usd">26737000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i1b41e14476334d7895158617049bccd5_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RhYmxlOjc3NGIzNTQ0YWM0NDQ2NjI4NTE2Nzk5ZGRmMTM4ZDk3L3RhYmxlcmFuZ2U6Nzc0YjM1NDRhYzQ0NDY2Mjg1MTY3OTlkZGYxMzhkOTdfMTgtMy0xLTEtMA_eafa2a25-ed90-4098-9ee9-bdfcf1868440"
      unitRef="usd">26737000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1
      contextRef="idf80add09165458a8481ba03343ec164_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RhYmxlOjc3NGIzNTQ0YWM0NDQ2NjI4NTE2Nzk5ZGRmMTM4ZDk3L3RhYmxlcmFuZ2U6Nzc0YjM1NDRhYzQ0NDY2Mjg1MTY3OTlkZGYxMzhkOTdfMTktMS0xLTEtMA_4aa9b368-25a4-4976-af76-ea18ced647ac">P0Y4M24D</us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1>
    <us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1
      contextRef="i42998979e1154fc69a147d78134d1a26_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RhYmxlOjc3NGIzNTQ0YWM0NDQ2NjI4NTE2Nzk5ZGRmMTM4ZDk3L3RhYmxlcmFuZ2U6Nzc0YjM1NDRhYzQ0NDY2Mjg1MTY3OTlkZGYxMzhkOTdfMTktMy0xLTEtMA_261596fa-0471-4a01-99fa-564de0f9e584">P0Y10M24D</us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1>
    <us-gaap:LongTermDebtFairValue
      contextRef="i57814fe811324e9fad5398f551936680_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RhYmxlOjc3NGIzNTQ0YWM0NDQ2NjI4NTE2Nzk5ZGRmMTM4ZDk3L3RhYmxlcmFuZ2U6Nzc0YjM1NDRhYzQ0NDY2Mjg1MTY3OTlkZGYxMzhkOTdfMjAtMS0xLTEtMA_a66a034e-9bcd-4f92-96ae-1d87cfda78e6"
      unitRef="usd">29279000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="ie847f4ca71c44d2a845bf492cd0b91ed_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183My9mcmFnOjhkZWRhODJhZmVhMDQ3YTQ4OWZiM2U1OWQ5YjU0NGM4L3RhYmxlOjc3NGIzNTQ0YWM0NDQ2NjI4NTE2Nzk5ZGRmMTM4ZDk3L3RhYmxlcmFuZ2U6Nzc0YjM1NDRhYzQ0NDY2Mjg1MTY3OTlkZGYxMzhkOTdfMjAtMy0xLTEtMA_8b0ed085-3f0e-4daa-8222-d2733d8af98c"
      unitRef="usd">26470000</us-gaap:LongTermDebtFairValue>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183OS9mcmFnOmMyNzZiM2YyZDExNjQyNDE4YTYwMmI4MDUxZDMwM2JiL3RleHRyZWdpb246YzI3NmIzZjJkMTE2NDI0MThhNjAyYjgwNTFkMzAzYmJfMTEwODc_5f84229c-8cc1-4218-975b-9d4e25a92e8d">Commitments and Contingencies &lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Commitments&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Letters of Credit&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2021 and December 31, 2020, the Company established irrevocable standby letters of credit&#160;with a bank for&#160;$15.0 million&#160;and $7.4&#160;million for the benefit of a regulatory authorities, real estate and risk-sharing agreements and, as such, held $15.0 million and $7.4&#160;million in restricted cash and restricted investments as collateral as of both June&#160;30, 2021 and December&#160;31, 2020, respectively. The letters of credit have current expiration dates between October 2021 and March 2032 and will automatically extend without amendment for an additional one-year period and will continue to automatically extend after each one-year term from the expiry date, unless the bank elects not to extend beyond the initial or any extended expiry date. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Indemnifications&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s customer agreements generally include a provision by which the Company agrees to defend its partners against third-party claims (a) for death, bodily injury, or damage to personal property caused by Company negligence or willful misconduct, (b) by former or current Company employees arising from such managed service agreements, (c) for intellectual property infringement under specified conditions and (d) for Company violation of applicable laws, and to indemnify them against any damages and costs awarded in connection with such claims. To date, the Company has not incurred any material costs as a result of such indemnities and has not accrued any liabilities related to such obligations in the accompanying consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Pre-IPO Investor Registration Rights Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We entered into a registration rights agreement with The Advisory Board, UPMC, TPG and another investor to register for sale under the Securities Act shares of our Class A common stock, including those delivered in exchange for Class B common stock and Class B common units. Subject to certain conditions and limitations, this agreement provides these investors with certain demand, piggyback and shelf registration rights. The registration rights granted under the registration rights agreement will terminate upon the date the holders of shares that are a party thereto no longer hold any such shares that are entitled to registration rights. Pursuant to our contractual obligations under this agreement, we filed a registration statement on Form S-3 with the SEC on July 28, 2016, which was declared effective on August 12, 2016.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We will pay all expenses relating to any demand, piggyback or shelf registration, other than underwriting discounts and commissions and any transfer taxes, subject to specified conditions and limitations. The registration rights agreement includes customary indemnification provisions, including indemnification of the participating holders of shares of Class A common stock and their directors, officers and employees by us for any losses, claims, damages or liabilities in respect thereof and expenses to which such holders may become subject under the Securities Act, state law or otherwise. We did not incur any expenses related to secondary offerings or other sales of shares by our investor stockholders during the three and six months ended June 30, 2021 and 2020, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Guarantees&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In connection with the Molina Closing, the Company continued to provide administrative support services relating to the Passport Medicaid Contract to Molina through the end of 2020. Following the Molina Closing, EVH Passport began working with regulatory authorities including the Kentucky Department of Insurance (&#x201c;KY DOI&#x201d;) regarding the wind down of its operations throughout 2021. As part of that wind down process, the Company, as the parent of EVH Passport, entered into a guarantee for the benefit of the KY DOI to satisfy any EVH Passport liability or obligation in the event EVH Passport is not able to meet its wind down liabilities or obligations. As of June&#160;30, 2021, no amounts have been funded under this guarantee.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Reinsurance Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the Passport Closing, $16.2&#160;million of the cash Passport Purchase Price was held back until such time as PHS I delivers to EVH Passport certain owned real property and improvements free and clear of all encumbrances. In addition, at the Passport Closing, EVH Passport and UHC entered into an agreement that provided for the administration and assumption of the financial risks by EVH Passport of the D-SNP Business until such time as EVH Passport became certified as a Medicare Advantage Organization and the D-SNP Business could be transferred to EVH Passport.  On October 1, 2020, the D-SNP Business was transferred from UHC to EVH Passport.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the Molina Closing, Molina and EVH Passport entered into an agreement that provided for the assumption of the financial risks by Molina of the D-SNP Business until such time as Molina&#x2019;s Kentucky health plan becomes certified as a Medicare Advantage Organization and the D-SNP Business is transferred to Molina. The Company and EVH Passport continued to administer the D-SNP Business until January 1, 2021, at which time Molina became responsible for its administration until the D-SNP Business is officially transferred to Molina effective September 1, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following summarizes premiums and claims assumed under the Reinsurance Agreements for the six months ended June 30, 2021 and 2020 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:438.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:46.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:46.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reinsurance premiums assumed&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reinsurance premiums ceded&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Claims assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Claims ceded&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Claims-related administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;545&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increase in reserves for claims and performance-based arrangements attributable to the Reinsurance Agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reserves for claims and performance-based arrangements attributable to the Reinsurance Agreement at the beginning of the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Impact of consolidation on payable for claims and performance-based arrangements attributable to the Reinsurance Agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reinsurance payments paid (received)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Receivable for claims and performance-based arrangements attributable to the Reinsurance Agreement at the end of the period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,336)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;UPMC Reseller Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company and UPMC are parties to a reseller, services and non-competition agreement, dated August 31, 2011, which was amended and restated by the parties on June 27, 2013 (as amended through the date hereof, the &#x201c;UPMC Reseller Agreement&#x201d;). Under the terms of the UPMC Reseller Agreement, UPMC has appointed the Company as a non-exclusive reseller of certain services, subject to certain conditions and limitations specified in the UPMC Reseller Agreement. In consideration for the Company&#x2019;s obligations under &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the UPMC Reseller Agreement and subject to certain conditions described therein, UPMC has agreed not to sell certain products and services directly to a defined list of 20 of the Company&#x2019;s customers.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contingencies&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Tax Receivables Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the Offering Reorganization, the Company entered into the Tax Receivables Agreement (the &#x201c;TRA&#x201d;) with certain of its investors, which provides for the payment by the Company to these investors of 85% of the amount of the tax benefits, if any, that the Company is deemed to realize as a result of increases in our tax basis related to exchanges of Class B common units as well as tax benefits attributable to the future utilization of pre-IPO NOLs. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Due to the items noted above, and the fact that Evolent Health, Inc. is in a full valuation allowance position such that the deferred tax assets related to the Company&#x2019;s historical pre-IPO losses and tax basis increase benefit from exchanges have not been realized, the Company has not recorded a liability pursuant to the TRA.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Litigation Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are engaged from time to time in certain legal disputes arising in the ordinary course of business, including employment claims. When the likelihood of a loss contingency becomes probable and the amount of the loss can be reasonably estimated, we accrue a liability for the loss contingency. We continue to review accruals and adjust them to reflect ongoing negotiations, settlements, rulings, advice of legal counsel, and other relevant information. To the extent new information is obtained, and our views on the probable outcomes of claims, suits, assessments, investigations or legal proceedings change, changes in our accrued liabilities would be recorded in the period in which such determination is made.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 8, 2019, a shareholder of the Company filed a class action complaint against the Company, asserting claims under Section 10(b) and 20(a) of the Securities Exchange Act of 1934, in the United States District Court, Eastern District of Virginia, Alexandria Division.  An amended complaint was filed on January 10, 2020, and a second amended complaint was filed on June 8, 2020.  The case, Plymouth County Retirement System v. Evolent Health, Inc., Frank Williams, Nicholas McGrane, Seth Blackley, Christie Spencer, and Steven Wigginton, alleges that the Company&#x2019;s executives made false or misleading statements regarding its business with Passport.  The Company filed a motion to dismiss the second amended complaint, and the Eastern District of Virginia granted in part and denied in part the motion on March 24, 2021.  The Company and Plaintiffs then filed separate motions to reconsider that are pending.  While the scope of the allegations that remain is still unclear pending the court&#x2019;s further decision, the case will proceed to discovery.  Based on the Company&#x2019;s investigation so far, we believe the case has little legal or factual merit.  However, the outcome of any litigation is uncertain, and at this stage, the Company is currently unable to assess the probability of loss or estimate a range of potential loss, if any, associated with this lawsuit.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 8, 2021, a shareholder of the Company filed a derivative action in the Delaware Chancery Court against some current and former Board members and against the Company as a nominal defendant, alleging that the Company&#x2019;s Board was negligent in its oversight of the Company&#x2019;s relationship with Passport Health Plan.  The case is &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Lincolnshire Police Pension Fund, derivatively on behalf of Evolent Health, Inc., v. Blackley, Williams, Scott, Holder, Farner, D&#x2019;Amato, Duffy, Felt, Samet, Hobart, and Payson, and Evolent Health, Inc. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Plaintiff, the Company, and the Director-Defendants have agreed on a schedule for a motion to dismiss and related briefing, which we expect to be completed in late November 2021.  Based on the Company&#x2019;s investigation so far, we believe the case has little legal or factual merit.  However, the outcome of any litigation is uncertain, and at this stage, the Company is currently unable to assess the probability of loss or estimate a range of potential loss, if any, associated with this lawsuit.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is not aware of any other legal proceedings or claims as of June&#160;30, 2021, that the Company believes will have, individually or in the aggregate, a material adverse effect on the Company&#x2019;s financial position or result of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Credit and Concentration Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to significant concentrations of credit risk related to cash and cash equivalents and accounts receivable. As of June&#160;30, 2021, approximately 99.0% of our $238.4 million of cash and cash equivalents (including restricted cash) were held in bank deposits with FDIC participating banks and approximately 1.0% were held in international banks. While the Company maintains its cash and cash equivalents with financial institutions with high credit ratings, it often maintains these deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any realized losses on cash and cash equivalents to date.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is also subject to significant concentration of accounts receivable risk as a substantial portion of our trade accounts receivable is derived from a small number of our partners. The following table summarizes the partners who represented at least 10.0% of our consolidated trade accounts receivable as of June&#160;30, 2021 and December&#160;31, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:426.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:55.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cook County Health and Hospitals System&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Florida Blue Medicare, Inc&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Neighborhood Health Plan of Rhode Island&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;* &#160;&#160;&#160;&#160;Represents less than 10.0% of the respective balance&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, the Company is subject to significant concentration of revenue risk as a substantial portion of our revenue is derived from a small number of contractual relationships with our operating partners.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes those partners who represented at least 10.0% of our consolidated revenue for the three and six months ended June 30, 2021 and 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:327.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cook County Health and Hospitals Systems&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Florida Blue Medicare, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Passport&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;The denominator excludes $25.5&#160;million and $57.6&#160;million of True Health premium revenue reclassified to discontinued operations for the three and six months ended June 30, 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;* &#160;&#160;&#160;&#160;Represents less than 10.0% of the respective balance&lt;/span&gt;&lt;/div&gt;We derive a significant portion of our revenues from our largest partners. The loss, termination or renegotiation of our relationship or contract with any significant partner or multiple partners in the aggregate could have a material adverse effect on the Company's financial condition and results of operations.</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="ic57d3a037df7434482b4ac69c20ce6f0_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183OS9mcmFnOmMyNzZiM2YyZDExNjQyNDE4YTYwMmI4MDUxZDMwM2JiL3RleHRyZWdpb246YzI3NmIzZjJkMTE2NDI0MThhNjAyYjgwNTFkMzAzYmJfMjAx_3ae31a19-7d54-4ecc-9f1f-bce319b44263"
      unitRef="usd">15000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i7d1b21babb8849389bf714849eaec38d_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183OS9mcmFnOmMyNzZiM2YyZDExNjQyNDE4YTYwMmI4MDUxZDMwM2JiL3RleHRyZWdpb246YzI3NmIzZjJkMTE2NDI0MThhNjAyYjgwNTFkMzAzYmJfMjA5_dc7e50d6-ef2d-48b9-bd88-052c3e318e1f"
      unitRef="usd">7400000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="iced602b4d3a741e183e4dad1271a58e8_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183OS9mcmFnOmMyNzZiM2YyZDExNjQyNDE4YTYwMmI4MDUxZDMwM2JiL3RleHRyZWdpb246YzI3NmIzZjJkMTE2NDI0MThhNjAyYjgwNTFkMzAzYmJfMzE2_418274e8-4e53-48a7-9429-571a083da116"
      unitRef="usd">15000000.0</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="i538e245a2b7045f18999365d98e47c51_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183OS9mcmFnOmMyNzZiM2YyZDExNjQyNDE4YTYwMmI4MDUxZDMwM2JiL3RleHRyZWdpb246YzI3NmIzZjJkMTE2NDI0MThhNjAyYjgwNTFkMzAzYmJfMzE2_5b435c49-4a8f-42aa-8271-9f4323a4cd38"
      unitRef="usd">15000000.0</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="i154d1afeed6943c08b9da6703d2f57a3_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183OS9mcmFnOmMyNzZiM2YyZDExNjQyNDE4YTYwMmI4MDUxZDMwM2JiL3RleHRyZWdpb246YzI3NmIzZjJkMTE2NDI0MThhNjAyYjgwNTFkMzAzYmJfMzI0_43de68de-2ccc-42dc-8b9b-b04a3d47fe5e"
      unitRef="usd">7400000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="i0cd3439d51f543818ae384f535441a35_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183OS9mcmFnOmMyNzZiM2YyZDExNjQyNDE4YTYwMmI4MDUxZDMwM2JiL3RleHRyZWdpb246YzI3NmIzZjJkMTE2NDI0MThhNjAyYjgwNTFkMzAzYmJfMzI0_c936fc24-3d3f-4774-ac9b-630d4f3b9028"
      unitRef="usd">7400000</us-gaap:RestrictedCashAndCashEquivalents>
    <evh:PaymentsToAcquireEquityMethodInvestmentsAmountHeldBack
      contextRef="i267001cededb4bfdb4aa09441f453c34_I20191230"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183OS9mcmFnOmMyNzZiM2YyZDExNjQyNDE4YTYwMmI4MDUxZDMwM2JiL3RleHRyZWdpb246YzI3NmIzZjJkMTE2NDI0MThhNjAyYjgwNTFkMzAzYmJfMzk1OA_4995a8dc-14d8-4f66-b4c8-c41559d61af4"
      unitRef="usd">16200000</evh:PaymentsToAcquireEquityMethodInvestmentsAmountHeldBack>
    <us-gaap:EffectsOfReinsuranceTableTextBlock
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183OS9mcmFnOmMyNzZiM2YyZDExNjQyNDE4YTYwMmI4MDUxZDMwM2JiL3RleHRyZWdpb246YzI3NmIzZjJkMTE2NDI0MThhNjAyYjgwNTFkMzAzYmJfMTEwODg_ff0fcaa4-8d99-43da-82ef-561f88331568">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following summarizes premiums and claims assumed under the Reinsurance Agreements for the six months ended June 30, 2021 and 2020 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:438.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:46.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:46.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reinsurance premiums assumed&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reinsurance premiums ceded&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Claims assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Claims ceded&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Claims-related administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;545&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increase in reserves for claims and performance-based arrangements attributable to the Reinsurance Agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reserves for claims and performance-based arrangements attributable to the Reinsurance Agreement at the beginning of the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Impact of consolidation on payable for claims and performance-based arrangements attributable to the Reinsurance Agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reinsurance payments paid (received)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Receivable for claims and performance-based arrangements attributable to the Reinsurance Agreement at the end of the period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,336)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EffectsOfReinsuranceTableTextBlock>
    <us-gaap:AssumedPremiumsWritten
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183OS9mcmFnOmMyNzZiM2YyZDExNjQyNDE4YTYwMmI4MDUxZDMwM2JiL3RhYmxlOjc2OWUzNmE4NzZhOTQ4ZmI4NTJmZmM2NTAyZjFmM2ZhL3RhYmxlcmFuZ2U6NzY5ZTM2YTg3NmE5NDhmYjg1MmZmYzY1MDJmMWYzZmFfMi0xLTEtMS0w_4fe59ee1-cad3-460c-b42e-34a6c0daa60d"
      unitRef="usd">17576000</us-gaap:AssumedPremiumsWritten>
    <us-gaap:AssumedPremiumsWritten
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183OS9mcmFnOmMyNzZiM2YyZDExNjQyNDE4YTYwMmI4MDUxZDMwM2JiL3RhYmxlOjc2OWUzNmE4NzZhOTQ4ZmI4NTJmZmM2NTAyZjFmM2ZhL3RhYmxlcmFuZ2U6NzY5ZTM2YTg3NmE5NDhmYjg1MmZmYzY1MDJmMWYzZmFfMi0zLTEtMS0w_48a13e76-6d75-4909-9a5b-71d341892f75"
      unitRef="usd">0</us-gaap:AssumedPremiumsWritten>
    <us-gaap:CededPremiumsWritten
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183OS9mcmFnOmMyNzZiM2YyZDExNjQyNDE4YTYwMmI4MDUxZDMwM2JiL3RhYmxlOjc2OWUzNmE4NzZhOTQ4ZmI4NTJmZmM2NTAyZjFmM2ZhL3RhYmxlcmFuZ2U6NzY5ZTM2YTg3NmE5NDhmYjg1MmZmYzY1MDJmMWYzZmFfMy0xLTEtMS0w_b0654cab-dacf-4d0b-bae7-f7426c8ee31d"
      unitRef="usd">0</us-gaap:CededPremiumsWritten>
    <us-gaap:CededPremiumsWritten
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183OS9mcmFnOmMyNzZiM2YyZDExNjQyNDE4YTYwMmI4MDUxZDMwM2JiL3RhYmxlOjc2OWUzNmE4NzZhOTQ4ZmI4NTJmZmM2NTAyZjFmM2ZhL3RhYmxlcmFuZ2U6NzY5ZTM2YTg3NmE5NDhmYjg1MmZmYzY1MDJmMWYzZmFfMy0zLTEtMS0w_85ae2a95-8b1b-4903-a0af-4676e7a1fc57"
      unitRef="usd">0</us-gaap:CededPremiumsWritten>
    <us-gaap:ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183OS9mcmFnOmMyNzZiM2YyZDExNjQyNDE4YTYwMmI4MDUxZDMwM2JiL3RhYmxlOjc2OWUzNmE4NzZhOTQ4ZmI4NTJmZmM2NTAyZjFmM2ZhL3RhYmxlcmFuZ2U6NzY5ZTM2YTg3NmE5NDhmYjg1MmZmYzY1MDJmMWYzZmFfNC0xLTEtMS0w_0f99ee2f-ac24-4a85-bb1c-716fe5bae8cc"
      unitRef="usd">16863000</us-gaap:ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed>
    <us-gaap:ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183OS9mcmFnOmMyNzZiM2YyZDExNjQyNDE4YTYwMmI4MDUxZDMwM2JiL3RhYmxlOjc2OWUzNmE4NzZhOTQ4ZmI4NTJmZmM2NTAyZjFmM2ZhL3RhYmxlcmFuZ2U6NzY5ZTM2YTg3NmE5NDhmYjg1MmZmYzY1MDJmMWYzZmFfNC0zLTEtMS0w_2d46c835-cf49-4702-b089-04a41d75a886"
      unitRef="usd">0</us-gaap:ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed>
    <us-gaap:ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183OS9mcmFnOmMyNzZiM2YyZDExNjQyNDE4YTYwMmI4MDUxZDMwM2JiL3RhYmxlOjc2OWUzNmE4NzZhOTQ4ZmI4NTJmZmM2NTAyZjFmM2ZhL3RhYmxlcmFuZ2U6NzY5ZTM2YTg3NmE5NDhmYjg1MmZmYzY1MDJmMWYzZmFfNS0xLTEtMS0w_b403a954-9377-4426-a82e-9ba5d27b0017"
      unitRef="usd">0</us-gaap:ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded>
    <us-gaap:ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183OS9mcmFnOmMyNzZiM2YyZDExNjQyNDE4YTYwMmI4MDUxZDMwM2JiL3RhYmxlOjc2OWUzNmE4NzZhOTQ4ZmI4NTJmZmM2NTAyZjFmM2ZhL3RhYmxlcmFuZ2U6NzY5ZTM2YTg3NmE5NDhmYjg1MmZmYzY1MDJmMWYzZmFfNS0zLTEtMS0w_954c108c-0041-493d-a612-5c5f68d34bc4"
      unitRef="usd">0</us-gaap:ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded>
    <evh:PolicyholderBenefitsAndClaimsIncurredAssumedExpensesRelatedToClaims
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183OS9mcmFnOmMyNzZiM2YyZDExNjQyNDE4YTYwMmI4MDUxZDMwM2JiL3RhYmxlOjc2OWUzNmE4NzZhOTQ4ZmI4NTJmZmM2NTAyZjFmM2ZhL3RhYmxlcmFuZ2U6NzY5ZTM2YTg3NmE5NDhmYjg1MmZmYzY1MDJmMWYzZmFfNi0xLTEtMS0w_e425a871-6dd9-4047-93b4-f69ec3149a2d"
      unitRef="usd">545000</evh:PolicyholderBenefitsAndClaimsIncurredAssumedExpensesRelatedToClaims>
    <evh:PolicyholderBenefitsAndClaimsIncurredAssumedExpensesRelatedToClaims
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183OS9mcmFnOmMyNzZiM2YyZDExNjQyNDE4YTYwMmI4MDUxZDMwM2JiL3RhYmxlOjc2OWUzNmE4NzZhOTQ4ZmI4NTJmZmM2NTAyZjFmM2ZhL3RhYmxlcmFuZ2U6NzY5ZTM2YTg3NmE5NDhmYjg1MmZmYzY1MDJmMWYzZmFfNi0zLTEtMS0w_234ccd55-8379-4c2f-b08b-498c861f6a16"
      unitRef="usd">0</evh:PolicyholderBenefitsAndClaimsIncurredAssumedExpensesRelatedToClaims>
    <evh:PremiumsWrittenAndPolicyholderBenefitsAndClaimsIncurredNet
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183OS9mcmFnOmMyNzZiM2YyZDExNjQyNDE4YTYwMmI4MDUxZDMwM2JiL3RhYmxlOjc2OWUzNmE4NzZhOTQ4ZmI4NTJmZmM2NTAyZjFmM2ZhL3RhYmxlcmFuZ2U6NzY5ZTM2YTg3NmE5NDhmYjg1MmZmYzY1MDJmMWYzZmFfNy0xLTEtMS0w_a3a7a8fe-e376-4c49-9852-5e8fb8658df0"
      unitRef="usd">168000</evh:PremiumsWrittenAndPolicyholderBenefitsAndClaimsIncurredNet>
    <evh:PremiumsWrittenAndPolicyholderBenefitsAndClaimsIncurredNet
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183OS9mcmFnOmMyNzZiM2YyZDExNjQyNDE4YTYwMmI4MDUxZDMwM2JiL3RhYmxlOjc2OWUzNmE4NzZhOTQ4ZmI4NTJmZmM2NTAyZjFmM2ZhL3RhYmxlcmFuZ2U6NzY5ZTM2YTg3NmE5NDhmYjg1MmZmYzY1MDJmMWYzZmFfNy0zLTEtMS0w_06aa8a92-13c4-4c7d-ac72-8393d0dd0b8a"
      unitRef="usd">0</evh:PremiumsWrittenAndPolicyholderBenefitsAndClaimsIncurredNet>
    <us-gaap:AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense
      contextRef="i45bff335c1434d6ba44132da1b0557db_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183OS9mcmFnOmMyNzZiM2YyZDExNjQyNDE4YTYwMmI4MDUxZDMwM2JiL3RhYmxlOjc2OWUzNmE4NzZhOTQ4ZmI4NTJmZmM2NTAyZjFmM2ZhL3RhYmxlcmFuZ2U6NzY5ZTM2YTg3NmE5NDhmYjg1MmZmYzY1MDJmMWYzZmFfOC0xLTEtMS0w_9e3cfafb-0c30-4072-8d2f-508d48ae1596"
      unitRef="usd">4002000</us-gaap:AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense>
    <us-gaap:AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense
      contextRef="ie0ff0ad229b441d4b12bc8956f92a917_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183OS9mcmFnOmMyNzZiM2YyZDExNjQyNDE4YTYwMmI4MDUxZDMwM2JiL3RhYmxlOjc2OWUzNmE4NzZhOTQ4ZmI4NTJmZmM2NTAyZjFmM2ZhL3RhYmxlcmFuZ2U6NzY5ZTM2YTg3NmE5NDhmYjg1MmZmYzY1MDJmMWYzZmFfOC0zLTEtMS0w_c528f42c-f732-4bcf-bb9a-cf2a8a0fff72"
      unitRef="usd">0</us-gaap:AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense>
    <evh:AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseImpactOfConsolidationOnPayables
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183OS9mcmFnOmMyNzZiM2YyZDExNjQyNDE4YTYwMmI4MDUxZDMwM2JiL3RhYmxlOjc2OWUzNmE4NzZhOTQ4ZmI4NTJmZmM2NTAyZjFmM2ZhL3RhYmxlcmFuZ2U6NzY5ZTM2YTg3NmE5NDhmYjg1MmZmYzY1MDJmMWYzZmFfOS0xLTEtMS0w_d5831821-38a6-4c7c-bc2e-2a971bac2717"
      unitRef="usd">0</evh:AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseImpactOfConsolidationOnPayables>
    <evh:AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseImpactOfConsolidationOnPayables
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183OS9mcmFnOmMyNzZiM2YyZDExNjQyNDE4YTYwMmI4MDUxZDMwM2JiL3RhYmxlOjc2OWUzNmE4NzZhOTQ4ZmI4NTJmZmM2NTAyZjFmM2ZhL3RhYmxlcmFuZ2U6NzY5ZTM2YTg3NmE5NDhmYjg1MmZmYzY1MDJmMWYzZmFfOS0zLTEtMS0w_d862c49d-6b8a-4f80-a51f-810b25fc3cb7"
      unitRef="usd">0</evh:AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseImpactOfConsolidationOnPayables>
    <us-gaap:PaymentsForReinsurance
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183OS9mcmFnOmMyNzZiM2YyZDExNjQyNDE4YTYwMmI4MDUxZDMwM2JiL3RhYmxlOjc2OWUzNmE4NzZhOTQ4ZmI4NTJmZmM2NTAyZjFmM2ZhL3RhYmxlcmFuZ2U6NzY5ZTM2YTg3NmE5NDhmYjg1MmZmYzY1MDJmMWYzZmFfMTAtMS0xLTEtMA_43e32c68-e3f2-4a22-b891-af3eb6a69c01"
      unitRef="usd">7506000</us-gaap:PaymentsForReinsurance>
    <evh:ProceedsFromReinsurance
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183OS9mcmFnOmMyNzZiM2YyZDExNjQyNDE4YTYwMmI4MDUxZDMwM2JiL3RhYmxlOjc2OWUzNmE4NzZhOTQ4ZmI4NTJmZmM2NTAyZjFmM2ZhL3RhYmxlcmFuZ2U6NzY5ZTM2YTg3NmE5NDhmYjg1MmZmYzY1MDJmMWYzZmFfMTAtMy0xLTEtMA_1796806d-ad92-471a-bbde-7415f02b15a8"
      unitRef="usd">0</evh:ProceedsFromReinsurance>
    <us-gaap:ReinsuranceRecoverablesOnPaidAndUnpaidLosses
      contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183OS9mcmFnOmMyNzZiM2YyZDExNjQyNDE4YTYwMmI4MDUxZDMwM2JiL3RhYmxlOjc2OWUzNmE4NzZhOTQ4ZmI4NTJmZmM2NTAyZjFmM2ZhL3RhYmxlcmFuZ2U6NzY5ZTM2YTg3NmE5NDhmYjg1MmZmYzY1MDJmMWYzZmFfMTEtMS0xLTEtMA_7fd6f22e-310a-441a-a7ba-22a881633aa1"
      unitRef="usd">3336000</us-gaap:ReinsuranceRecoverablesOnPaidAndUnpaidLosses>
    <us-gaap:ReinsuranceRecoverablesOnPaidAndUnpaidLosses
      contextRef="i11817f96c3e24e0abaed14a17869e173_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183OS9mcmFnOmMyNzZiM2YyZDExNjQyNDE4YTYwMmI4MDUxZDMwM2JiL3RhYmxlOjc2OWUzNmE4NzZhOTQ4ZmI4NTJmZmM2NTAyZjFmM2ZhL3RhYmxlcmFuZ2U6NzY5ZTM2YTg3NmE5NDhmYjg1MmZmYzY1MDJmMWYzZmFfMTEtMy0xLTEtMA_2bbb566d-ee38-4caf-a503-188447c79696"
      unitRef="usd">0</us-gaap:ReinsuranceRecoverablesOnPaidAndUnpaidLosses>
    <evh:TaxReceivablesAgreementPercentofTaxSavingstobePaid
      contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183OS9mcmFnOmMyNzZiM2YyZDExNjQyNDE4YTYwMmI4MDUxZDMwM2JiL3RleHRyZWdpb246YzI3NmIzZjJkMTE2NDI0MThhNjAyYjgwNTFkMzAzYmJfNjIwNQ_b72b8389-2c53-4299-9d55-f551cad68ab1"
      unitRef="number">0.85</evh:TaxReceivablesAgreementPercentofTaxSavingstobePaid>
    <evh:CashFDICInsuredAmountPercentage
      contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183OS9mcmFnOmMyNzZiM2YyZDExNjQyNDE4YTYwMmI4MDUxZDMwM2JiL3RleHRyZWdpb246YzI3NmIzZjJkMTE2NDI0MThhNjAyYjgwNTFkMzAzYmJfOTMxNg_4267dfec-7f70-4316-bdce-f1db0037d4c2"
      unitRef="number">0.990</evh:CashFDICInsuredAmountPercentage>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183OS9mcmFnOmMyNzZiM2YyZDExNjQyNDE4YTYwMmI4MDUxZDMwM2JiL3RleHRyZWdpb246YzI3NmIzZjJkMTE2NDI0MThhNjAyYjgwNTFkMzAzYmJfOTMyNg_3c142b7e-cf63-4ec1-83c3-8881f79ab011"
      unitRef="usd">238400000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <evh:CashHeldInInternationalBanksPercentage
      contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183OS9mcmFnOmMyNzZiM2YyZDExNjQyNDE4YTYwMmI4MDUxZDMwM2JiL3RleHRyZWdpb246YzI3NmIzZjJkMTE2NDI0MThhNjAyYjgwNTFkMzAzYmJfOTQ2MQ_2b27b7b7-60d6-4103-9a1b-e1c765721c6a"
      unitRef="number">0.010</evh:CashHeldInInternationalBanksPercentage>
    <us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183OS9mcmFnOmMyNzZiM2YyZDExNjQyNDE4YTYwMmI4MDUxZDMwM2JiL3RleHRyZWdpb246YzI3NmIzZjJkMTE2NDI0MThhNjAyYjgwNTFkMzAzYmJfMTEwOTE_14a3eedf-7293-4ffc-9163-e3f7c678cf0c">The following table summarizes the partners who represented at least 10.0% of our consolidated trade accounts receivable as of June&#160;30, 2021 and December&#160;31, 2020:&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:426.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:55.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cook County Health and Hospitals System&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Florida Blue Medicare, Inc&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Neighborhood Health Plan of Rhode Island&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;* &#160;&#160;&#160;&#160;Represents less than 10.0% of the respective balance&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes those partners who represented at least 10.0% of our consolidated revenue for the three and six months ended June 30, 2021 and 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:327.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cook County Health and Hospitals Systems&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Florida Blue Medicare, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Passport&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;The denominator excludes $25.5&#160;million and $57.6&#160;million of True Health premium revenue reclassified to discontinued operations for the three and six months ended June 30, 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;* &#160;&#160;&#160;&#160;Represents less than 10.0% of the respective balance&lt;/span&gt;&lt;/div&gt;</us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i3bfde454609344df8a691fb13c17b423_D20210101-20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183OS9mcmFnOmMyNzZiM2YyZDExNjQyNDE4YTYwMmI4MDUxZDMwM2JiL3RhYmxlOmQ3ZGE2YTU2MjI0ODQyYWE4YWQ1YmM0NTc5ZDJmNzllL3RhYmxlcmFuZ2U6ZDdkYTZhNTYyMjQ4NDJhYThhZDViYzQ1NzlkMmY3OWVfMS0xLTEtMS0w_087f1f9a-0671-4c06-96bd-8e6951cb96d6"
      unitRef="number">0.420</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i2ef1d0e83e2d422cbbb22022d1d3f276_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183OS9mcmFnOmMyNzZiM2YyZDExNjQyNDE4YTYwMmI4MDUxZDMwM2JiL3RhYmxlOmQ3ZGE2YTU2MjI0ODQyYWE4YWQ1YmM0NTc5ZDJmNzllL3RhYmxlcmFuZ2U6ZDdkYTZhNTYyMjQ4NDJhYThhZDViYzQ1NzlkMmY3OWVfMS0zLTEtMS0w_c543121a-ac2b-45fb-bfaf-a0cb82964f60"
      unitRef="number">0.615</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i60ad372a207d459e88f7e372405eab34_D20210101-20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183OS9mcmFnOmMyNzZiM2YyZDExNjQyNDE4YTYwMmI4MDUxZDMwM2JiL3RhYmxlOmQ3ZGE2YTU2MjI0ODQyYWE4YWQ1YmM0NTc5ZDJmNzllL3RhYmxlcmFuZ2U6ZDdkYTZhNTYyMjQ4NDJhYThhZDViYzQ1NzlkMmY3OWVfMi0xLTEtMS0w_3dcfecfa-7df3-4751-90b0-170bf25c2702"
      unitRef="number">0.221</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ic8a7c423118a4e16a2ff6abc2b0d9648_D20210101-20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183OS9mcmFnOmMyNzZiM2YyZDExNjQyNDE4YTYwMmI4MDUxZDMwM2JiL3RhYmxlOmQ3ZGE2YTU2MjI0ODQyYWE4YWQ1YmM0NTc5ZDJmNzllL3RhYmxlcmFuZ2U6ZDdkYTZhNTYyMjQ4NDJhYThhZDViYzQ1NzlkMmY3OWVfMy0xLTEtMS00NzI1_937fc5b0-357d-4fed-86c7-fde3ad25c040"
      unitRef="number">0.121</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="idc534571524f4f7abecd4ed0645e79e6_D20210401-20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183OS9mcmFnOmMyNzZiM2YyZDExNjQyNDE4YTYwMmI4MDUxZDMwM2JiL3RhYmxlOjUwZjM1MDIzZDZiNDRiOTJiNjhlNzlhM2Q2YzE5YjM0L3RhYmxlcmFuZ2U6NTBmMzUwMjNkNmI0NGI5MmI2OGU3OWEzZDZjMTliMzRfMi0xLTEtMS0yNTE5_2592a969-8030-44bb-8904-a3da87754cb3"
      unitRef="number">0.296</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i969062c619d04ffaaa1df514f89c332c_D20200401-20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183OS9mcmFnOmMyNzZiM2YyZDExNjQyNDE4YTYwMmI4MDUxZDMwM2JiL3RhYmxlOjUwZjM1MDIzZDZiNDRiOTJiNjhlNzlhM2Q2YzE5YjM0L3RhYmxlcmFuZ2U6NTBmMzUwMjNkNmI0NGI5MmI2OGU3OWEzZDZjMTliMzRfMi0zLTEtMS05NTE_4af7bc45-3f66-4f7b-8e7f-9be9783a145b"
      unitRef="number">0.218</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i944764ecb45a4413b9d526710bd5a552_D20210101-20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183OS9mcmFnOmMyNzZiM2YyZDExNjQyNDE4YTYwMmI4MDUxZDMwM2JiL3RhYmxlOjUwZjM1MDIzZDZiNDRiOTJiNjhlNzlhM2Q2YzE5YjM0L3RhYmxlcmFuZ2U6NTBmMzUwMjNkNmI0NGI5MmI2OGU3OWEzZDZjMTliMzRfMi0xLTEtMS0w_1025ed7b-9b05-41fb-a03a-4231eec7930d"
      unitRef="number">0.292</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i01f8679ac2df4d82b256eea229cf6ea6_D20200101-20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183OS9mcmFnOmMyNzZiM2YyZDExNjQyNDE4YTYwMmI4MDUxZDMwM2JiL3RhYmxlOjUwZjM1MDIzZDZiNDRiOTJiNjhlNzlhM2Q2YzE5YjM0L3RhYmxlcmFuZ2U6NTBmMzUwMjNkNmI0NGI5MmI2OGU3OWEzZDZjMTliMzRfMi0zLTEtMS0w_c834a85e-1375-4f4a-bf2e-cd8ab9e8bb7b"
      unitRef="number">0.214</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ia609b71d80124ac5a96f49cb69aa72ef_D20210401-20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183OS9mcmFnOmMyNzZiM2YyZDExNjQyNDE4YTYwMmI4MDUxZDMwM2JiL3RhYmxlOjUwZjM1MDIzZDZiNDRiOTJiNjhlNzlhM2Q2YzE5YjM0L3RhYmxlcmFuZ2U6NTBmMzUwMjNkNmI0NGI5MmI2OGU3OWEzZDZjMTliMzRfMy0xLTEtMS0yNTIz_daa123c4-6624-482c-ae99-81c659bfc1d4"
      unitRef="number">0.142</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ifb4268d248fd469a943652442c7252cf_D20210101-20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183OS9mcmFnOmMyNzZiM2YyZDExNjQyNDE4YTYwMmI4MDUxZDMwM2JiL3RhYmxlOjUwZjM1MDIzZDZiNDRiOTJiNjhlNzlhM2Q2YzE5YjM0L3RhYmxlcmFuZ2U6NTBmMzUwMjNkNmI0NGI5MmI2OGU3OWEzZDZjMTliMzRfMy0xLTEtMS0w_72977a86-d94e-486e-87d2-85c8650ef6ed"
      unitRef="number">0.145</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i02f118a71b9b4270abff67fb98d3ae2d_D20200401-20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183OS9mcmFnOmMyNzZiM2YyZDExNjQyNDE4YTYwMmI4MDUxZDMwM2JiL3RhYmxlOjUwZjM1MDIzZDZiNDRiOTJiNjhlNzlhM2Q2YzE5YjM0L3RhYmxlcmFuZ2U6NTBmMzUwMjNkNmI0NGI5MmI2OGU3OWEzZDZjMTliMzRfNC0zLTEtMS05NTU_7cd88626-2360-4341-877c-7aa9f65763de"
      unitRef="number">0.277</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i51acaef421854161bf36167111e9315d_D20200101-20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183OS9mcmFnOmMyNzZiM2YyZDExNjQyNDE4YTYwMmI4MDUxZDMwM2JiL3RhYmxlOjUwZjM1MDIzZDZiNDRiOTJiNjhlNzlhM2Q2YzE5YjM0L3RhYmxlcmFuZ2U6NTBmMzUwMjNkNmI0NGI5MmI2OGU3OWEzZDZjMTliMzRfNC0zLTEtMS0w_58cbe8a4-da3e-4f75-a73d-64f1a353207e"
      unitRef="number">0.261</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="ia3740e6e58c749fa97b9285685be7b1e_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183OS9mcmFnOmMyNzZiM2YyZDExNjQyNDE4YTYwMmI4MDUxZDMwM2JiL3RleHRyZWdpb246YzI3NmIzZjJkMTE2NDI0MThhNjAyYjgwNTFkMzAzYmJfMTY0OTI2NzQ1Mjk4MA_8b0d072e-12db-4542-bf21-8abbfd4ab030"
      unitRef="usd">25500000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="i70101f6902e44f38a06effe5f98e83b6_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY183OS9mcmFnOmMyNzZiM2YyZDExNjQyNDE4YTYwMmI4MDUxZDMwM2JiL3RleHRyZWdpb246YzI3NmIzZjJkMTE2NDI0MThhNjAyYjgwNTFkMzAzYmJfMTA2MDg_179aab8d-bc65-4563-8fe7-56199343cc01"
      unitRef="usd">57600000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184Mi9mcmFnOjE1OGMzNWIzNDI3MjQyMTU4OGE5MTI4MmJlMWVjMjEzL3RleHRyZWdpb246MTU4YzM1YjM0MjcyNDIxNTg4YTkxMjgyYmUxZWMyMTNfMzIzNQ_31aa442f-0cac-4d3e-9639-d1feee31a248">Leases&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company enters into various office space, data center, and equipment lease agreements in conducting its normal business operations. At the inception of any contract, the Company evaluates the agreement to determine whether the contract contains a lease. If the contract contains a lease, the Company then evaluates the term and whether the lease is an operating or finance lease. Most leases include one or more options to renew or may have a termination option. The Company determines whether these options are reasonably certain to be exercised or not at the inception of the lease. In addition, some leases contain escalation clauses.  The rent expense is recognized on a straight-line basis in the consolidated statements of operations and comprehensive income (loss) over the term of the lease. Leases with an initial term of 12 months or less are not recorded on our consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. We use the implicit rate when readily determinable. Further, the Company treats all lease and non-lease components as a single combined lease component for all classes of underlying assets. The Company also enters into sublease agreements for some of its leased office space. Immaterial rental income attributable to subleases is offset against rent expense over the terms of the respective leases. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company leases office space and computer and other equipment under operating lease agreements expiring at various dates through 2031. Under the lease agreements, in addition to base rent, the Company is generally responsible for operating and maintenance costs and related fees. Several of these agreements include tenant improvement allowances, rent holidays or rent escalation clauses. When such items are included in a lease agreement, we record a deferred rent asset or liability on our consolidated balance sheets equal to the difference between rent expense and future minimum lease payments due. The rent expense related to these items is recognized on a straight-line basis over the terms of the leases. The Company&#x2019;s primary office location is in Arlington, Virginia, which has served as its corporate headquarters since 2013. The Arlington, Virginia office lease expires in January 2032. Certain leases acquired as part of the Valence Health transaction included existing sublease agreements for office locations in Chicago, Illinois. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with various lease agreements, the Company is required to maintain $3.5 million in letters of credit. As of both June&#160;30, 2021 and December&#160;31, 2020, the Company held $3.5 million in restricted cash and restricted investments on the consolidated balance sheet as collateral for the letters of credit, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our primary office leases as of June&#160;30, 2021 (in thousands, other than term):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:539.25pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:237.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:94.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:94.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:94.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Lease Termination Term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Future Minimum Lease Commitments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Letter of Credit Amount Required&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Arlington, VA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Riverside, IL &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,956&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pune, India&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,835&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Brea, CA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,015&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the components of our lease expense for the three and six months ended June 30, 2021 and 2020 (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.650%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.013%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Variable lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,768&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,461&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Maturity of lease liabilities (in thousands) as of June&#160;30, 2021, is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.012%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Operating lease expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,645&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,732&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65,883&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our weighted-average discount rate and our weighted remaining lease terms (in years) as of June&#160;30, 2021 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.012%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average remaining lease term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LettersOfCreditOutstandingAmount
      contextRef="id96b9f84ab8c4a4f8d773f444cd3a629_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184Mi9mcmFnOjE1OGMzNWIzNDI3MjQyMTU4OGE5MTI4MmJlMWVjMjEzL3RleHRyZWdpb246MTU4YzM1YjM0MjcyNDIxNTg4YTkxMjgyYmUxZWMyMTNfMjY2Mw_ffbf3e2f-6a17-49b9-b5db-2385689c54fb"
      unitRef="usd">3500000</us-gaap:LettersOfCreditOutstandingAmount>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="idababf2dc26948949104cd43d693a4fd_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184Mi9mcmFnOjE1OGMzNWIzNDI3MjQyMTU4OGE5MTI4MmJlMWVjMjEzL3RleHRyZWdpb246MTU4YzM1YjM0MjcyNDIxNTg4YTkxMjgyYmUxZWMyMTNfMjcyNw_42ceccf2-7710-4738-b71d-0c99d5a79c4f"
      unitRef="usd">3500000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="id96b9f84ab8c4a4f8d773f444cd3a629_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184Mi9mcmFnOjE1OGMzNWIzNDI3MjQyMTU4OGE5MTI4MmJlMWVjMjEzL3RleHRyZWdpb246MTU4YzM1YjM0MjcyNDIxNTg4YTkxMjgyYmUxZWMyMTNfMjcyNw_bb087d3f-0498-4373-9154-ab373a46806a"
      unitRef="usd">3500000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184Mi9mcmFnOjE1OGMzNWIzNDI3MjQyMTU4OGE5MTI4MmJlMWVjMjEzL3RleHRyZWdpb246MTU4YzM1YjM0MjcyNDIxNTg4YTkxMjgyYmUxZWMyMTNfMzIzNg_2c99d3c7-1e49-4926-91a3-7a892bee7f9b">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our primary office leases as of June&#160;30, 2021 (in thousands, other than term):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:539.25pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:237.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:94.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:94.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:94.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Lease Termination Term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Future Minimum Lease Commitments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Letter of Credit Amount Required&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Arlington, VA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Riverside, IL &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,956&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pune, India&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,835&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Brea, CA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,015&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Maturity of lease liabilities (in thousands) as of June&#160;30, 2021, is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.012%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Operating lease expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,645&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,732&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65,883&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="if54c2d9d6b874c56bd73c8364532a8fa_I20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184Mi9mcmFnOjE1OGMzNWIzNDI3MjQyMTU4OGE5MTI4MmJlMWVjMjEzL3RhYmxlOjU0NzRmMjJiNjE2OTQwNDNhMWJhNzU4ZGY4MDVmYjA4L3RhYmxlcmFuZ2U6NTQ3NGYyMmI2MTY5NDA0M2ExYmE3NThkZjgwNWZiMDhfMS0yLTEtMS0w_3a4a37e9-bee0-4b43-87e5-6e6c274d368c">P10Y7M6D</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="if54c2d9d6b874c56bd73c8364532a8fa_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184Mi9mcmFnOjE1OGMzNWIzNDI3MjQyMTU4OGE5MTI4MmJlMWVjMjEzL3RhYmxlOjU0NzRmMjJiNjE2OTQwNDNhMWJhNzU4ZGY4MDVmYjA4L3RhYmxlcmFuZ2U6NTQ3NGYyMmI2MTY5NDA0M2ExYmE3NThkZjgwNWZiMDhfMS00LTEtMS0w_2c8d6492-463e-4a44-a05d-54198a01801a"
      unitRef="usd">37147000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LettersOfCreditOutstandingAmount
      contextRef="if54c2d9d6b874c56bd73c8364532a8fa_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184Mi9mcmFnOjE1OGMzNWIzNDI3MjQyMTU4OGE5MTI4MmJlMWVjMjEzL3RhYmxlOjU0NzRmMjJiNjE2OTQwNDNhMWJhNzU4ZGY4MDVmYjA4L3RhYmxlcmFuZ2U6NTQ3NGYyMmI2MTY5NDA0M2ExYmE3NThkZjgwNWZiMDhfMS02LTEtMS0w_fc47bd07-070a-42dd-899e-d79501779efc"
      unitRef="usd">1579000</us-gaap:LettersOfCreditOutstandingAmount>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i9376f969f54d4adfb216011fc4ce908d_I20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184Mi9mcmFnOjE1OGMzNWIzNDI3MjQyMTU4OGE5MTI4MmJlMWVjMjEzL3RhYmxlOjU0NzRmMjJiNjE2OTQwNDNhMWJhNzU4ZGY4MDVmYjA4L3RhYmxlcmFuZ2U6NTQ3NGYyMmI2MTY5NDA0M2ExYmE3NThkZjgwNWZiMDhfMi0yLTEtMS0w_1aebb238-8d2f-45e4-a2d9-e39c2c22a194">P9Y9M18D</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i9376f969f54d4adfb216011fc4ce908d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184Mi9mcmFnOjE1OGMzNWIzNDI3MjQyMTU4OGE5MTI4MmJlMWVjMjEzL3RhYmxlOjU0NzRmMjJiNjE2OTQwNDNhMWJhNzU4ZGY4MDVmYjA4L3RhYmxlcmFuZ2U6NTQ3NGYyMmI2MTY5NDA0M2ExYmE3NThkZjgwNWZiMDhfMi00LTEtMS0w_f01a5aa1-7a1a-4b96-86af-0cc935e8b28b"
      unitRef="usd">42956000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LettersOfCreditOutstandingAmount
      contextRef="i9376f969f54d4adfb216011fc4ce908d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184Mi9mcmFnOjE1OGMzNWIzNDI3MjQyMTU4OGE5MTI4MmJlMWVjMjEzL3RhYmxlOjU0NzRmMjJiNjE2OTQwNDNhMWJhNzU4ZGY4MDVmYjA4L3RhYmxlcmFuZ2U6NTQ3NGYyMmI2MTY5NDA0M2ExYmE3NThkZjgwNWZiMDhfMi02LTEtMS0w_7544a863-7a58-48d5-80b7-3ff65d14c9d1"
      unitRef="usd">232000</us-gaap:LettersOfCreditOutstandingAmount>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="ia8857bf6635f4a0a81ada9df6a84f8ce_I20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184Mi9mcmFnOjE1OGMzNWIzNDI3MjQyMTU4OGE5MTI4MmJlMWVjMjEzL3RhYmxlOjU0NzRmMjJiNjE2OTQwNDNhMWJhNzU4ZGY4MDVmYjA4L3RhYmxlcmFuZ2U6NTQ3NGYyMmI2MTY5NDA0M2ExYmE3NThkZjgwNWZiMDhfMy0yLTEtMS0w_8ee08cf6-b9ce-40cf-94c4-a7ab0e9a18dd">P2Y3M18D</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="ia8857bf6635f4a0a81ada9df6a84f8ce_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184Mi9mcmFnOjE1OGMzNWIzNDI3MjQyMTU4OGE5MTI4MmJlMWVjMjEzL3RhYmxlOjU0NzRmMjJiNjE2OTQwNDNhMWJhNzU4ZGY4MDVmYjA4L3RhYmxlcmFuZ2U6NTQ3NGYyMmI2MTY5NDA0M2ExYmE3NThkZjgwNWZiMDhfMy00LTEtMS0w_821dd34d-0f3b-4480-98cb-a8a43a766fb8"
      unitRef="usd">1835000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LettersOfCreditOutstandingAmount
      contextRef="ia8857bf6635f4a0a81ada9df6a84f8ce_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184Mi9mcmFnOjE1OGMzNWIzNDI3MjQyMTU4OGE5MTI4MmJlMWVjMjEzL3RhYmxlOjU0NzRmMjJiNjE2OTQwNDNhMWJhNzU4ZGY4MDVmYjA4L3RhYmxlcmFuZ2U6NTQ3NGYyMmI2MTY5NDA0M2ExYmE3NThkZjgwNWZiMDhfMy02LTEtMS0w_cdbf207c-8370-442d-a72d-a1d97b5acfaa"
      unitRef="usd">0</us-gaap:LettersOfCreditOutstandingAmount>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i4c6bffe6a4634527a6262241e44da56b_I20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184Mi9mcmFnOjE1OGMzNWIzNDI3MjQyMTU4OGE5MTI4MmJlMWVjMjEzL3RhYmxlOjU0NzRmMjJiNjE2OTQwNDNhMWJhNzU4ZGY4MDVmYjA4L3RhYmxlcmFuZ2U6NTQ3NGYyMmI2MTY5NDA0M2ExYmE3NThkZjgwNWZiMDhfNC0yLTEtMS0w_6fb0d713-2afe-4c3a-b13c-7758f9e5319c">P0Y10M24D</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i4c6bffe6a4634527a6262241e44da56b_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184Mi9mcmFnOjE1OGMzNWIzNDI3MjQyMTU4OGE5MTI4MmJlMWVjMjEzL3RhYmxlOjU0NzRmMjJiNjE2OTQwNDNhMWJhNzU4ZGY4MDVmYjA4L3RhYmxlcmFuZ2U6NTQ3NGYyMmI2MTY5NDA0M2ExYmE3NThkZjgwNWZiMDhfNC00LTEtMS0w_25907c39-3598-471d-be34-5834755c6fab"
      unitRef="usd">1015000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LettersOfCreditOutstandingAmount
      contextRef="i4c6bffe6a4634527a6262241e44da56b_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184Mi9mcmFnOjE1OGMzNWIzNDI3MjQyMTU4OGE5MTI4MmJlMWVjMjEzL3RhYmxlOjU0NzRmMjJiNjE2OTQwNDNhMWJhNzU4ZGY4MDVmYjA4L3RhYmxlcmFuZ2U6NTQ3NGYyMmI2MTY5NDA0M2ExYmE3NThkZjgwNWZiMDhfNC02LTEtMS0w_de8880d6-3ca2-40eb-a731-08a37ee37c71"
      unitRef="usd">0</us-gaap:LettersOfCreditOutstandingAmount>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184Mi9mcmFnOjE1OGMzNWIzNDI3MjQyMTU4OGE5MTI4MmJlMWVjMjEzL3RleHRyZWdpb246MTU4YzM1YjM0MjcyNDIxNTg4YTkxMjgyYmUxZWMyMTNfMzIzNw_7ba07475-c7e3-4c0a-aefa-cd8776134c21">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the components of our lease expense for the three and six months ended June 30, 2021 and 2020 (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.650%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.013%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Variable lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,768&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,461&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our weighted-average discount rate and our weighted remaining lease terms (in years) as of June&#160;30, 2021 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.012%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average remaining lease term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184Mi9mcmFnOjE1OGMzNWIzNDI3MjQyMTU4OGE5MTI4MmJlMWVjMjEzL3RhYmxlOjcwNzRkMmFlMDQ3OTRjZWQ5YzI4N2IzZTEzOTU4MmU1L3RhYmxlcmFuZ2U6NzA3NGQyYWUwNDc5NGNlZDljMjg3YjNlMTM5NTgyZTVfMi0xLTEtMS05ODM_da302f73-1baf-4b91-b8c7-2e6aac5089d5"
      unitRef="usd">2437000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184Mi9mcmFnOjE1OGMzNWIzNDI3MjQyMTU4OGE5MTI4MmJlMWVjMjEzL3RhYmxlOjcwNzRkMmFlMDQ3OTRjZWQ5YzI4N2IzZTEzOTU4MmU1L3RhYmxlcmFuZ2U6NzA3NGQyYWUwNDc5NGNlZDljMjg3YjNlMTM5NTgyZTVfMi0zLTEtMS05Nzk_bfc3ac76-a052-4d31-a859-09fc458dd1e4"
      unitRef="usd">3586000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184Mi9mcmFnOjE1OGMzNWIzNDI3MjQyMTU4OGE5MTI4MmJlMWVjMjEzL3RhYmxlOjcwNzRkMmFlMDQ3OTRjZWQ5YzI4N2IzZTEzOTU4MmU1L3RhYmxlcmFuZ2U6NzA3NGQyYWUwNDc5NGNlZDljMjg3YjNlMTM5NTgyZTVfMi0xLTEtMS0w_cf02405d-b867-40d7-a4fa-994feb5c8423"
      unitRef="usd">7255000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184Mi9mcmFnOjE1OGMzNWIzNDI3MjQyMTU4OGE5MTI4MmJlMWVjMjEzL3RhYmxlOjcwNzRkMmFlMDQ3OTRjZWQ5YzI4N2IzZTEzOTU4MmU1L3RhYmxlcmFuZ2U6NzA3NGQyYWUwNDc5NGNlZDljMjg3YjNlMTM5NTgyZTVfMi0zLTEtMS0w_85d84c0c-c9f3-420c-957f-d025f9085b6a"
      unitRef="usd">6642000</us-gaap:OperatingLeaseCost>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184Mi9mcmFnOjE1OGMzNWIzNDI3MjQyMTU4OGE5MTI4MmJlMWVjMjEzL3RhYmxlOjcwNzRkMmFlMDQ3OTRjZWQ5YzI4N2IzZTEzOTU4MmU1L3RhYmxlcmFuZ2U6NzA3NGQyYWUwNDc5NGNlZDljMjg3YjNlMTM5NTgyZTVfMy0xLTEtMS05ODM_98d3193a-3900-4e52-960e-bc3417865599"
      unitRef="usd">0</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184Mi9mcmFnOjE1OGMzNWIzNDI3MjQyMTU4OGE5MTI4MmJlMWVjMjEzL3RhYmxlOjcwNzRkMmFlMDQ3OTRjZWQ5YzI4N2IzZTEzOTU4MmU1L3RhYmxlcmFuZ2U6NzA3NGQyYWUwNDc5NGNlZDljMjg3YjNlMTM5NTgyZTVfMy0zLTEtMS05Nzk_2d38f19b-be2a-4c07-b47a-e6e735cddb50"
      unitRef="usd">150000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184Mi9mcmFnOjE1OGMzNWIzNDI3MjQyMTU4OGE5MTI4MmJlMWVjMjEzL3RhYmxlOjcwNzRkMmFlMDQ3OTRjZWQ5YzI4N2IzZTEzOTU4MmU1L3RhYmxlcmFuZ2U6NzA3NGQyYWUwNDc5NGNlZDljMjg3YjNlMTM5NTgyZTVfMy0xLTEtMS0w_bde15341-9205-4a90-8d59-05776e24a91c"
      unitRef="usd">0</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184Mi9mcmFnOjE1OGMzNWIzNDI3MjQyMTU4OGE5MTI4MmJlMWVjMjEzL3RhYmxlOjcwNzRkMmFlMDQ3OTRjZWQ5YzI4N2IzZTEzOTU4MmU1L3RhYmxlcmFuZ2U6NzA3NGQyYWUwNDc5NGNlZDljMjg3YjNlMTM5NTgyZTVfMy0zLTEtMS0w_8665e5ee-3d3c-46d8-98fc-50938ef9ca5d"
      unitRef="usd">299000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184Mi9mcmFnOjE1OGMzNWIzNDI3MjQyMTU4OGE5MTI4MmJlMWVjMjEzL3RhYmxlOjcwNzRkMmFlMDQ3OTRjZWQ5YzI4N2IzZTEzOTU4MmU1L3RhYmxlcmFuZ2U6NzA3NGQyYWUwNDc5NGNlZDljMjg3YjNlMTM5NTgyZTVfNC0xLTEtMS05ODM_eee51641-1cd7-4c2f-9d16-bc0f91643ee9"
      unitRef="usd">0</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184Mi9mcmFnOjE1OGMzNWIzNDI3MjQyMTU4OGE5MTI4MmJlMWVjMjEzL3RhYmxlOjcwNzRkMmFlMDQ3OTRjZWQ5YzI4N2IzZTEzOTU4MmU1L3RhYmxlcmFuZ2U6NzA3NGQyYWUwNDc5NGNlZDljMjg3YjNlMTM5NTgyZTVfNC0zLTEtMS05Nzk_0c8bcfbb-6de6-460d-90e5-b8a91687daac"
      unitRef="usd">1000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184Mi9mcmFnOjE1OGMzNWIzNDI3MjQyMTU4OGE5MTI4MmJlMWVjMjEzL3RhYmxlOjcwNzRkMmFlMDQ3OTRjZWQ5YzI4N2IzZTEzOTU4MmU1L3RhYmxlcmFuZ2U6NzA3NGQyYWUwNDc5NGNlZDljMjg3YjNlMTM5NTgyZTVfNC0xLTEtMS0w_48583250-299a-4ede-b40b-916ecb2d3be4"
      unitRef="usd">0</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184Mi9mcmFnOjE1OGMzNWIzNDI3MjQyMTU4OGE5MTI4MmJlMWVjMjEzL3RhYmxlOjcwNzRkMmFlMDQ3OTRjZWQ5YzI4N2IzZTEzOTU4MmU1L3RhYmxlcmFuZ2U6NzA3NGQyYWUwNDc5NGNlZDljMjg3YjNlMTM5NTgyZTVfNC0zLTEtMS0w_1fba7afe-1c9f-49e0-af44-e7b427749afc"
      unitRef="usd">3000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:VariableLeaseCost
      contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184Mi9mcmFnOjE1OGMzNWIzNDI3MjQyMTU4OGE5MTI4MmJlMWVjMjEzL3RhYmxlOjcwNzRkMmFlMDQ3OTRjZWQ5YzI4N2IzZTEzOTU4MmU1L3RhYmxlcmFuZ2U6NzA3NGQyYWUwNDc5NGNlZDljMjg3YjNlMTM5NTgyZTVfNS0xLTEtMS05ODM_2615bca3-cabd-47a1-af28-68cd2d304c55"
      unitRef="usd">1192000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184Mi9mcmFnOjE1OGMzNWIzNDI3MjQyMTU4OGE5MTI4MmJlMWVjMjEzL3RhYmxlOjcwNzRkMmFlMDQ3OTRjZWQ5YzI4N2IzZTEzOTU4MmU1L3RhYmxlcmFuZ2U6NzA3NGQyYWUwNDc5NGNlZDljMjg3YjNlMTM5NTgyZTVfNS0zLTEtMS05Nzk_67124549-e63e-482f-8c69-557c202ec19d"
      unitRef="usd">1465000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184Mi9mcmFnOjE1OGMzNWIzNDI3MjQyMTU4OGE5MTI4MmJlMWVjMjEzL3RhYmxlOjcwNzRkMmFlMDQ3OTRjZWQ5YzI4N2IzZTEzOTU4MmU1L3RhYmxlcmFuZ2U6NzA3NGQyYWUwNDc5NGNlZDljMjg3YjNlMTM5NTgyZTVfNS0xLTEtMS0w_854c67b5-7d27-4e35-ac1f-9c8d7be429d5"
      unitRef="usd">2513000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184Mi9mcmFnOjE1OGMzNWIzNDI3MjQyMTU4OGE5MTI4MmJlMWVjMjEzL3RhYmxlOjcwNzRkMmFlMDQ3OTRjZWQ5YzI4N2IzZTEzOTU4MmU1L3RhYmxlcmFuZ2U6NzA3NGQyYWUwNDc5NGNlZDljMjg3YjNlMTM5NTgyZTVfNS0zLTEtMS0w_e2724aef-47ef-42cc-8400-5da5b0d41bd6"
      unitRef="usd">2517000</us-gaap:VariableLeaseCost>
    <us-gaap:LeaseCost
      contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184Mi9mcmFnOjE1OGMzNWIzNDI3MjQyMTU4OGE5MTI4MmJlMWVjMjEzL3RhYmxlOjcwNzRkMmFlMDQ3OTRjZWQ5YzI4N2IzZTEzOTU4MmU1L3RhYmxlcmFuZ2U6NzA3NGQyYWUwNDc5NGNlZDljMjg3YjNlMTM5NTgyZTVfNi0xLTEtMS0zNzU4_e2c44edc-ec15-49ac-852a-fc65beda4072"
      unitRef="usd">3629000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184Mi9mcmFnOjE1OGMzNWIzNDI3MjQyMTU4OGE5MTI4MmJlMWVjMjEzL3RhYmxlOjcwNzRkMmFlMDQ3OTRjZWQ5YzI4N2IzZTEzOTU4MmU1L3RhYmxlcmFuZ2U6NzA3NGQyYWUwNDc5NGNlZDljMjg3YjNlMTM5NTgyZTVfNi0zLTEtMS0zNzU4_7362dd28-c075-4077-b630-9229c042c852"
      unitRef="usd">5202000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184Mi9mcmFnOjE1OGMzNWIzNDI3MjQyMTU4OGE5MTI4MmJlMWVjMjEzL3RhYmxlOjcwNzRkMmFlMDQ3OTRjZWQ5YzI4N2IzZTEzOTU4MmU1L3RhYmxlcmFuZ2U6NzA3NGQyYWUwNDc5NGNlZDljMjg3YjNlMTM5NTgyZTVfNi0xLTEtMS0w_c5a54f20-7498-480e-b155-7d2217622aa8"
      unitRef="usd">9768000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184Mi9mcmFnOjE1OGMzNWIzNDI3MjQyMTU4OGE5MTI4MmJlMWVjMjEzL3RhYmxlOjcwNzRkMmFlMDQ3OTRjZWQ5YzI4N2IzZTEzOTU4MmU1L3RhYmxlcmFuZ2U6NzA3NGQyYWUwNDc5NGNlZDljMjg3YjNlMTM5NTgyZTVfNi0zLTEtMS0w_1e9417be-eb37-4442-b598-ede94d69e734"
      unitRef="usd">9461000</us-gaap:LeaseCost>
    <us-gaap:PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear
      contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184Mi9mcmFnOjE1OGMzNWIzNDI3MjQyMTU4OGE5MTI4MmJlMWVjMjEzL3RhYmxlOjdlMjU4Zjk1NWM4ZjQwZTRhZDgxMWU2MDcxMWUwNTM1L3RhYmxlcmFuZ2U6N2UyNThmOTU1YzhmNDBlNGFkODExZTYwNzExZTA1MzVfMS0xLTEtMS0w_55cc1c4f-f4c5-4b67-bf91-27304825b981"
      unitRef="usd">5854000</us-gaap:PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184Mi9mcmFnOjE1OGMzNWIzNDI3MjQyMTU4OGE5MTI4MmJlMWVjMjEzL3RhYmxlOjdlMjU4Zjk1NWM4ZjQwZTRhZDgxMWU2MDcxMWUwNTM1L3RhYmxlcmFuZ2U6N2UyNThmOTU1YzhmNDBlNGFkODExZTYwNzExZTA1MzVfMi0xLTEtMS0w_e24f1108-5d92-4df6-9545-389a81c508f1"
      unitRef="usd">9832000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184Mi9mcmFnOjE1OGMzNWIzNDI3MjQyMTU4OGE5MTI4MmJlMWVjMjEzL3RhYmxlOjdlMjU4Zjk1NWM4ZjQwZTRhZDgxMWU2MDcxMWUwNTM1L3RhYmxlcmFuZ2U6N2UyNThmOTU1YzhmNDBlNGFkODExZTYwNzExZTA1MzVfMy0xLTEtMS0w_8c04da79-5200-40b7-afee-845f9b3f44d3"
      unitRef="usd">8645000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184Mi9mcmFnOjE1OGMzNWIzNDI3MjQyMTU4OGE5MTI4MmJlMWVjMjEzL3RhYmxlOjdlMjU4Zjk1NWM4ZjQwZTRhZDgxMWU2MDcxMWUwNTM1L3RhYmxlcmFuZ2U6N2UyNThmOTU1YzhmNDBlNGFkODExZTYwNzExZTA1MzVfNC0xLTEtMS0w_3d49fb22-ea88-40e5-9669-3cdf351cd866"
      unitRef="usd">8378000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184Mi9mcmFnOjE1OGMzNWIzNDI3MjQyMTU4OGE5MTI4MmJlMWVjMjEzL3RhYmxlOjdlMjU4Zjk1NWM4ZjQwZTRhZDgxMWU2MDcxMWUwNTM1L3RhYmxlcmFuZ2U6N2UyNThmOTU1YzhmNDBlNGFkODExZTYwNzExZTA1MzVfNS0xLTEtMS0w_cdfd75fe-dd0f-47a1-b483-5fc8bbbacb3c"
      unitRef="usd">8145000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <evh:LesseeOperatingLeaseLiabilityToBePaidAfterYearFive
      contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184Mi9mcmFnOjE1OGMzNWIzNDI3MjQyMTU4OGE5MTI4MmJlMWVjMjEzL3RhYmxlOjdlMjU4Zjk1NWM4ZjQwZTRhZDgxMWU2MDcxMWUwNTM1L3RhYmxlcmFuZ2U6N2UyNThmOTU1YzhmNDBlNGFkODExZTYwNzExZTA1MzVfNi0xLTEtMS0w_ed4af340-4f29-4c7f-b9b8-adf26709af5d"
      unitRef="usd">47761000</evh:LesseeOperatingLeaseLiabilityToBePaidAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184Mi9mcmFnOjE1OGMzNWIzNDI3MjQyMTU4OGE5MTI4MmJlMWVjMjEzL3RhYmxlOjdlMjU4Zjk1NWM4ZjQwZTRhZDgxMWU2MDcxMWUwNTM1L3RhYmxlcmFuZ2U6N2UyNThmOTU1YzhmNDBlNGFkODExZTYwNzExZTA1MzVfNy0xLTEtMS0w_9141da1d-24ad-463f-8a49-6589a3972f01"
      unitRef="usd">88615000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184Mi9mcmFnOjE1OGMzNWIzNDI3MjQyMTU4OGE5MTI4MmJlMWVjMjEzL3RhYmxlOjdlMjU4Zjk1NWM4ZjQwZTRhZDgxMWU2MDcxMWUwNTM1L3RhYmxlcmFuZ2U6N2UyNThmOTU1YzhmNDBlNGFkODExZTYwNzExZTA1MzVfOS0xLTEtMS0w_83e4b28c-0095-4f5a-872e-54ad36674e57"
      unitRef="usd">22732000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184Mi9mcmFnOjE1OGMzNWIzNDI3MjQyMTU4OGE5MTI4MmJlMWVjMjEzL3RhYmxlOjdlMjU4Zjk1NWM4ZjQwZTRhZDgxMWU2MDcxMWUwNTM1L3RhYmxlcmFuZ2U6N2UyNThmOTU1YzhmNDBlNGFkODExZTYwNzExZTA1MzVfMTAtMS0xLTEtMA_b7a1a673-b0fc-4790-b6d2-3c8c49002689"
      unitRef="usd">65883000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184Mi9mcmFnOjE1OGMzNWIzNDI3MjQyMTU4OGE5MTI4MmJlMWVjMjEzL3RhYmxlOjQzMDIyNDJiOGMwYzQ2MGQ5ZWFlNDM4YzIxNmY2MTViL3RhYmxlcmFuZ2U6NDMwMjI0MmI4YzBjNDYwZDllYWU0MzhjMjE2ZjYxNWJfMS0xLTEtMS0w_7013f308-2d08-405e-bf36-a2ae2efac6de"
      unitRef="number">0.0643</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184Mi9mcmFnOjE1OGMzNWIzNDI3MjQyMTU4OGE5MTI4MmJlMWVjMjEzL3RhYmxlOjQzMDIyNDJiOGMwYzQ2MGQ5ZWFlNDM4YzIxNmY2MTViL3RhYmxlcmFuZ2U6NDMwMjI0MmI4YzBjNDYwZDllYWU0MzhjMjE2ZjYxNWJfMi0xLTEtMS0w_d717a029-1e14-4373-87f8-7f6624d3b46c">P9Y2M12D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RleHRyZWdpb246ZWI3MmNiOTFiZTBmNDVlOThiNWY5ZDkzZGU3ZDUyNjlfMzYw_313e6a0f-c0b0-4646-9745-3843cc5c6a20">Earnings (Loss) Per Common Share&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the computation of basic and diluted earnings per share available for common stockholders for the three and six months ended June 30, 2021 and 2020 (in thousands, except per share data):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:288.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income (loss) from continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,107)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(202,013)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20,297)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(280,500)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income (loss) from discontinued operations, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,508)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,773)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,107)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(203,521)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18,914)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(282,273)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss attributable to non-controlling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) available for common shareholders - basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,107)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(203,521)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18,914)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(282,273)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average common shares outstanding - basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85,448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85,349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Income (loss) per common share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.37)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.24)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.30)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.01)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.02)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic and diluted income (loss) per share attributable to common shareholders of Evolent Health, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.32)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Anti-dilutive shares (in thousands) excluded from the calculation of weighted-average common shares presented above for the three and six months ended June 30, 2021 and 2020 are presented below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:288.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units ("RSUs"), performance-based RSUs and leveraged stock units ("LSUs")&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,801&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible senior notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,626&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,578&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RleHRyZWdpb246ZWI3MmNiOTFiZTBmNDVlOThiNWY5ZDkzZGU3ZDUyNjlfMzU4_6d868168-93b2-4273-8cad-99ce9e1c7cd0">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the computation of basic and diluted earnings per share available for common stockholders for the three and six months ended June 30, 2021 and 2020 (in thousands, except per share data):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:288.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income (loss) from continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,107)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(202,013)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20,297)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(280,500)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income (loss) from discontinued operations, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,508)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,773)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,107)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(203,521)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18,914)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(282,273)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss attributable to non-controlling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) available for common shareholders - basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,107)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(203,521)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18,914)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(282,273)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average common shares outstanding - basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85,448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85,349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Income (loss) per common share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.37)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.24)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.30)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.01)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.02)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic and diluted income (loss) per share attributable to common shareholders of Evolent Health, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.32)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjExYWJjOWIxMWM5MjRiODM4OTZmNmRjYjRjMWY4M2NkL3RhYmxlcmFuZ2U6MTFhYmM5YjExYzkyNGI4Mzg5NmY2ZGNiNGMxZjgzY2RfMi0xLTEtMS0xMDI4_a030db38-41f2-4034-bb47-c1ea177a3f12"
      unitRef="usd">-9107000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjExYWJjOWIxMWM5MjRiODM4OTZmNmRjYjRjMWY4M2NkL3RhYmxlcmFuZ2U6MTFhYmM5YjExYzkyNGI4Mzg5NmY2ZGNiNGMxZjgzY2RfMi0zLTEtMS0xMDI4_dd96325a-3f6a-4064-8bfc-1c8d6a0ccf87"
      unitRef="usd">-202013000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjExYWJjOWIxMWM5MjRiODM4OTZmNmRjYjRjMWY4M2NkL3RhYmxlcmFuZ2U6MTFhYmM5YjExYzkyNGI4Mzg5NmY2ZGNiNGMxZjgzY2RfMi0xLTEtMS0w_228846d4-483a-4bd6-9c29-0517d59f1ace"
      unitRef="usd">-20297000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjExYWJjOWIxMWM5MjRiODM4OTZmNmRjYjRjMWY4M2NkL3RhYmxlcmFuZ2U6MTFhYmM5YjExYzkyNGI4Mzg5NmY2ZGNiNGMxZjgzY2RfMi0zLTEtMS0w_1259824e-746f-44ea-a83e-f1b50f0b3e55"
      unitRef="usd">-280500000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjExYWJjOWIxMWM5MjRiODM4OTZmNmRjYjRjMWY4M2NkL3RhYmxlcmFuZ2U6MTFhYmM5YjExYzkyNGI4Mzg5NmY2ZGNiNGMxZjgzY2RfMy0xLTEtMS0xMDMx_1cdad334-f519-48e7-a442-e006607bfd0d"
      unitRef="usd">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjExYWJjOWIxMWM5MjRiODM4OTZmNmRjYjRjMWY4M2NkL3RhYmxlcmFuZ2U6MTFhYmM5YjExYzkyNGI4Mzg5NmY2ZGNiNGMxZjgzY2RfMy0zLTEtMS0xMDMx_23a653a3-53f9-4fa2-825a-b0238aa1e1bc"
      unitRef="usd">-1508000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjExYWJjOWIxMWM5MjRiODM4OTZmNmRjYjRjMWY4M2NkL3RhYmxlcmFuZ2U6MTFhYmM5YjExYzkyNGI4Mzg5NmY2ZGNiNGMxZjgzY2RfMy0xLTEtMS0w_c5ecddec-ea61-49d7-9ee4-4bc37ada6314"
      unitRef="usd">1383000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjExYWJjOWIxMWM5MjRiODM4OTZmNmRjYjRjMWY4M2NkL3RhYmxlcmFuZ2U6MTFhYmM5YjExYzkyNGI4Mzg5NmY2ZGNiNGMxZjgzY2RfMy0zLTEtMS0w_e40e5aa3-d436-463d-ae79-d4a972b39319"
      unitRef="usd">-1773000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:ProfitLoss
      contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjExYWJjOWIxMWM5MjRiODM4OTZmNmRjYjRjMWY4M2NkL3RhYmxlcmFuZ2U6MTFhYmM5YjExYzkyNGI4Mzg5NmY2ZGNiNGMxZjgzY2RfNC0xLTEtMS0xMDMx_224dac42-b7ca-448a-8c6c-19553d6e70ed"
      unitRef="usd">-9107000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjExYWJjOWIxMWM5MjRiODM4OTZmNmRjYjRjMWY4M2NkL3RhYmxlcmFuZ2U6MTFhYmM5YjExYzkyNGI4Mzg5NmY2ZGNiNGMxZjgzY2RfNC0zLTEtMS0xMDMx_24819732-0f1d-4a88-b203-8430f2e00104"
      unitRef="usd">-203521000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjExYWJjOWIxMWM5MjRiODM4OTZmNmRjYjRjMWY4M2NkL3RhYmxlcmFuZ2U6MTFhYmM5YjExYzkyNGI4Mzg5NmY2ZGNiNGMxZjgzY2RfNC0xLTEtMS0w_3c6b9c11-4052-4bf7-86e1-89b8e6f56107"
      unitRef="usd">-18914000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjExYWJjOWIxMWM5MjRiODM4OTZmNmRjYjRjMWY4M2NkL3RhYmxlcmFuZ2U6MTFhYmM5YjExYzkyNGI4Mzg5NmY2ZGNiNGMxZjgzY2RfNC0zLTEtMS0w_6133f0dd-e1f4-4ff4-96e9-42a93c1f62a1"
      unitRef="usd">-282273000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjExYWJjOWIxMWM5MjRiODM4OTZmNmRjYjRjMWY4M2NkL3RhYmxlcmFuZ2U6MTFhYmM5YjExYzkyNGI4Mzg5NmY2ZGNiNGMxZjgzY2RfNi0xLTEtMS0xMDM0_588b0315-6ec7-4ba0-8c57-c489dff9bf4a"
      unitRef="usd">0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjExYWJjOWIxMWM5MjRiODM4OTZmNmRjYjRjMWY4M2NkL3RhYmxlcmFuZ2U6MTFhYmM5YjExYzkyNGI4Mzg5NmY2ZGNiNGMxZjgzY2RfNi0zLTEtMS0xMDM0_91d2f40b-af1d-403c-ae75-b09607128928"
      unitRef="usd">0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjExYWJjOWIxMWM5MjRiODM4OTZmNmRjYjRjMWY4M2NkL3RhYmxlcmFuZ2U6MTFhYmM5YjExYzkyNGI4Mzg5NmY2ZGNiNGMxZjgzY2RfNi0xLTEtMS0w_6ebde5ba-b5bf-4879-a8ed-55bc8a2cf8f7"
      unitRef="usd">0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjExYWJjOWIxMWM5MjRiODM4OTZmNmRjYjRjMWY4M2NkL3RhYmxlcmFuZ2U6MTFhYmM5YjExYzkyNGI4Mzg5NmY2ZGNiNGMxZjgzY2RfNi0zLTEtMS0w_487ffa05-a8ca-4c89-8418-c5324a371639"
      unitRef="usd">0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjExYWJjOWIxMWM5MjRiODM4OTZmNmRjYjRjMWY4M2NkL3RhYmxlcmFuZ2U6MTFhYmM5YjExYzkyNGI4Mzg5NmY2ZGNiNGMxZjgzY2RfNy0xLTEtMS0xMDM0_09330fbb-f85e-46d5-b7ba-0c4c55c92dcd"
      unitRef="usd">-9107000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjExYWJjOWIxMWM5MjRiODM4OTZmNmRjYjRjMWY4M2NkL3RhYmxlcmFuZ2U6MTFhYmM5YjExYzkyNGI4Mzg5NmY2ZGNiNGMxZjgzY2RfNy0xLTEtMS0xMDM0_f334614f-48c8-4335-8644-08d1c094b533"
      unitRef="usd">-9107000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjExYWJjOWIxMWM5MjRiODM4OTZmNmRjYjRjMWY4M2NkL3RhYmxlcmFuZ2U6MTFhYmM5YjExYzkyNGI4Mzg5NmY2ZGNiNGMxZjgzY2RfNy0zLTEtMS0xMDM0_1f1b826f-81ea-4a16-8e51-b233cb6cb5d8"
      unitRef="usd">-203521000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjExYWJjOWIxMWM5MjRiODM4OTZmNmRjYjRjMWY4M2NkL3RhYmxlcmFuZ2U6MTFhYmM5YjExYzkyNGI4Mzg5NmY2ZGNiNGMxZjgzY2RfNy0zLTEtMS0xMDM0_464f9ea4-79d0-46fe-b7e0-3bfbaef12c35"
      unitRef="usd">-203521000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjExYWJjOWIxMWM5MjRiODM4OTZmNmRjYjRjMWY4M2NkL3RhYmxlcmFuZ2U6MTFhYmM5YjExYzkyNGI4Mzg5NmY2ZGNiNGMxZjgzY2RfNy0xLTEtMS0w_3f65effd-5c00-48e2-b9f0-61aa1fc1e88c"
      unitRef="usd">-18914000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjExYWJjOWIxMWM5MjRiODM4OTZmNmRjYjRjMWY4M2NkL3RhYmxlcmFuZ2U6MTFhYmM5YjExYzkyNGI4Mzg5NmY2ZGNiNGMxZjgzY2RfNy0xLTEtMS0w_7051b8a1-9469-4d3d-b02f-b619b054437f"
      unitRef="usd">-18914000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjExYWJjOWIxMWM5MjRiODM4OTZmNmRjYjRjMWY4M2NkL3RhYmxlcmFuZ2U6MTFhYmM5YjExYzkyNGI4Mzg5NmY2ZGNiNGMxZjgzY2RfNy0zLTEtMS0w_0841956d-a0c8-4eca-a9f7-99ceb502bb32"
      unitRef="usd">-282273000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjExYWJjOWIxMWM5MjRiODM4OTZmNmRjYjRjMWY4M2NkL3RhYmxlcmFuZ2U6MTFhYmM5YjExYzkyNGI4Mzg5NmY2ZGNiNGMxZjgzY2RfNy0zLTEtMS0w_d981f43f-4d1f-4440-8d13-5cf7db63d994"
      unitRef="usd">-282273000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjExYWJjOWIxMWM5MjRiODM4OTZmNmRjYjRjMWY4M2NkL3RhYmxlcmFuZ2U6MTFhYmM5YjExYzkyNGI4Mzg5NmY2ZGNiNGMxZjgzY2RfOS0xLTEtMS0xMDM3_615bafb3-bdfe-4b63-9036-b3537a8d3d5f"
      unitRef="shares">85448000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjExYWJjOWIxMWM5MjRiODM4OTZmNmRjYjRjMWY4M2NkL3RhYmxlcmFuZ2U6MTFhYmM5YjExYzkyNGI4Mzg5NmY2ZGNiNGMxZjgzY2RfOS0xLTEtMS0xMDM3_e018bb7d-cfe1-4e15-983f-63502f8c7917"
      unitRef="shares">85448000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjExYWJjOWIxMWM5MjRiODM4OTZmNmRjYjRjMWY4M2NkL3RhYmxlcmFuZ2U6MTFhYmM5YjExYzkyNGI4Mzg5NmY2ZGNiNGMxZjgzY2RfOS0zLTEtMS0xMDM3_1ad6606b-0da7-4d3d-b6a8-e5367eea0c7a"
      unitRef="shares">85349000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjExYWJjOWIxMWM5MjRiODM4OTZmNmRjYjRjMWY4M2NkL3RhYmxlcmFuZ2U6MTFhYmM5YjExYzkyNGI4Mzg5NmY2ZGNiNGMxZjgzY2RfOS0zLTEtMS0xMDM3_e0eb1f1b-2f64-4b89-bf40-a7b7ee576f84"
      unitRef="shares">85349000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjExYWJjOWIxMWM5MjRiODM4OTZmNmRjYjRjMWY4M2NkL3RhYmxlcmFuZ2U6MTFhYmM5YjExYzkyNGI4Mzg5NmY2ZGNiNGMxZjgzY2RfOS0xLTEtMS0w_4242e7a7-f111-40b8-a6cb-ff0b458cb1a5"
      unitRef="shares">85056000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjExYWJjOWIxMWM5MjRiODM4OTZmNmRjYjRjMWY4M2NkL3RhYmxlcmFuZ2U6MTFhYmM5YjExYzkyNGI4Mzg5NmY2ZGNiNGMxZjgzY2RfOS0xLTEtMS0w_75f40ade-b15d-4533-9a0c-5990c566b25e"
      unitRef="shares">85056000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjExYWJjOWIxMWM5MjRiODM4OTZmNmRjYjRjMWY4M2NkL3RhYmxlcmFuZ2U6MTFhYmM5YjExYzkyNGI4Mzg5NmY2ZGNiNGMxZjgzY2RfOS0zLTEtMS0w_456e1a38-89a7-499c-bb0c-bdb8fabe2538"
      unitRef="shares">84977000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjExYWJjOWIxMWM5MjRiODM4OTZmNmRjYjRjMWY4M2NkL3RhYmxlcmFuZ2U6MTFhYmM5YjExYzkyNGI4Mzg5NmY2ZGNiNGMxZjgzY2RfOS0zLTEtMS0w_a4062fd1-4700-4596-ac02-4d51b453a84d"
      unitRef="shares">84977000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjExYWJjOWIxMWM5MjRiODM4OTZmNmRjYjRjMWY4M2NkL3RhYmxlcmFuZ2U6MTFhYmM5YjExYzkyNGI4Mzg5NmY2ZGNiNGMxZjgzY2RfMTMtMS0xLTEtMTA0MA_9b468376-3abb-4b91-b544-45598236cd35"
      unitRef="usdPerShare">-0.11</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjExYWJjOWIxMWM5MjRiODM4OTZmNmRjYjRjMWY4M2NkL3RhYmxlcmFuZ2U6MTFhYmM5YjExYzkyNGI4Mzg5NmY2ZGNiNGMxZjgzY2RfMTMtMS0xLTEtMTA0MA_a57eda48-bbd8-4cd1-9c68-3604f50ce2cf"
      unitRef="usdPerShare">-0.11</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjExYWJjOWIxMWM5MjRiODM4OTZmNmRjYjRjMWY4M2NkL3RhYmxlcmFuZ2U6MTFhYmM5YjExYzkyNGI4Mzg5NmY2ZGNiNGMxZjgzY2RfMTMtMy0xLTEtMTA0MA_852b9a3c-a463-48e0-8977-f56a22c2b011"
      unitRef="usdPerShare">-2.37</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjExYWJjOWIxMWM5MjRiODM4OTZmNmRjYjRjMWY4M2NkL3RhYmxlcmFuZ2U6MTFhYmM5YjExYzkyNGI4Mzg5NmY2ZGNiNGMxZjgzY2RfMTMtMy0xLTEtMTA0MA_9ef447ed-dde3-4a30-8002-79abb76cde61"
      unitRef="usdPerShare">-2.37</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjExYWJjOWIxMWM5MjRiODM4OTZmNmRjYjRjMWY4M2NkL3RhYmxlcmFuZ2U6MTFhYmM5YjExYzkyNGI4Mzg5NmY2ZGNiNGMxZjgzY2RfMTMtMS0xLTEtMA_aea6d686-ea84-421d-bccd-c58e29e2aaab"
      unitRef="usdPerShare">-0.24</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjExYWJjOWIxMWM5MjRiODM4OTZmNmRjYjRjMWY4M2NkL3RhYmxlcmFuZ2U6MTFhYmM5YjExYzkyNGI4Mzg5NmY2ZGNiNGMxZjgzY2RfMTMtMS0xLTEtMA_ea47c458-12d3-4812-ac4e-259bd09fec29"
      unitRef="usdPerShare">-0.24</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjExYWJjOWIxMWM5MjRiODM4OTZmNmRjYjRjMWY4M2NkL3RhYmxlcmFuZ2U6MTFhYmM5YjExYzkyNGI4Mzg5NmY2ZGNiNGMxZjgzY2RfMTMtMy0xLTEtMA_6f9f8394-7bd7-4271-8132-915268925c9a"
      unitRef="usdPerShare">-3.30</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjExYWJjOWIxMWM5MjRiODM4OTZmNmRjYjRjMWY4M2NkL3RhYmxlcmFuZ2U6MTFhYmM5YjExYzkyNGI4Mzg5NmY2ZGNiNGMxZjgzY2RfMTMtMy0xLTEtMA_dc90bf72-8a65-4da4-9bf9-d7c52b845d76"
      unitRef="usdPerShare">-3.30</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjExYWJjOWIxMWM5MjRiODM4OTZmNmRjYjRjMWY4M2NkL3RhYmxlcmFuZ2U6MTFhYmM5YjExYzkyNGI4Mzg5NmY2ZGNiNGMxZjgzY2RfMTQtMS0xLTEtMTA0MA_891023c2-8f2f-4aac-b882-a0c38556e0ee"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjExYWJjOWIxMWM5MjRiODM4OTZmNmRjYjRjMWY4M2NkL3RhYmxlcmFuZ2U6MTFhYmM5YjExYzkyNGI4Mzg5NmY2ZGNiNGMxZjgzY2RfMTQtMS0xLTEtMTA0MA_aff981ea-ee53-455d-9f65-8e9eed3782e5"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjExYWJjOWIxMWM5MjRiODM4OTZmNmRjYjRjMWY4M2NkL3RhYmxlcmFuZ2U6MTFhYmM5YjExYzkyNGI4Mzg5NmY2ZGNiNGMxZjgzY2RfMTQtMy0xLTEtMTA0MA_1c38e201-a69b-4d9d-9544-48059e596cdd"
      unitRef="usdPerShare">-0.01</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjExYWJjOWIxMWM5MjRiODM4OTZmNmRjYjRjMWY4M2NkL3RhYmxlcmFuZ2U6MTFhYmM5YjExYzkyNGI4Mzg5NmY2ZGNiNGMxZjgzY2RfMTQtMy0xLTEtMTA0MA_5aba3028-f0bb-4816-831a-d14e599f86d6"
      unitRef="usdPerShare">-0.01</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjExYWJjOWIxMWM5MjRiODM4OTZmNmRjYjRjMWY4M2NkL3RhYmxlcmFuZ2U6MTFhYmM5YjExYzkyNGI4Mzg5NmY2ZGNiNGMxZjgzY2RfMTQtMS0xLTEtMA_79fdbf08-c988-4fe5-8cc6-c90de5b2ae49"
      unitRef="usdPerShare">0.02</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjExYWJjOWIxMWM5MjRiODM4OTZmNmRjYjRjMWY4M2NkL3RhYmxlcmFuZ2U6MTFhYmM5YjExYzkyNGI4Mzg5NmY2ZGNiNGMxZjgzY2RfMTQtMS0xLTEtMA_a4377843-e7a2-4873-91ba-9152526441b0"
      unitRef="usdPerShare">0.02</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjExYWJjOWIxMWM5MjRiODM4OTZmNmRjYjRjMWY4M2NkL3RhYmxlcmFuZ2U6MTFhYmM5YjExYzkyNGI4Mzg5NmY2ZGNiNGMxZjgzY2RfMTQtMy0xLTEtMA_0d6b51ea-d7ab-4d37-abae-c32d154ecc1c"
      unitRef="usdPerShare">-0.02</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjExYWJjOWIxMWM5MjRiODM4OTZmNmRjYjRjMWY4M2NkL3RhYmxlcmFuZ2U6MTFhYmM5YjExYzkyNGI4Mzg5NmY2ZGNiNGMxZjgzY2RfMTQtMy0xLTEtMA_800c73c2-b879-48d8-a85e-64407c8de0bb"
      unitRef="usdPerShare">-0.02</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjExYWJjOWIxMWM5MjRiODM4OTZmNmRjYjRjMWY4M2NkL3RhYmxlcmFuZ2U6MTFhYmM5YjExYzkyNGI4Mzg5NmY2ZGNiNGMxZjgzY2RfMTUtMS0xLTEtMTA0Mw_289fe6d2-509d-4929-bc0d-716bc06e55f4"
      unitRef="usdPerShare">-0.11</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjExYWJjOWIxMWM5MjRiODM4OTZmNmRjYjRjMWY4M2NkL3RhYmxlcmFuZ2U6MTFhYmM5YjExYzkyNGI4Mzg5NmY2ZGNiNGMxZjgzY2RfMTUtMS0xLTEtMTA0Mw_a1d75a1c-6e8f-4a55-a8ba-fdf4ca86b37a"
      unitRef="usdPerShare">-0.11</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjExYWJjOWIxMWM5MjRiODM4OTZmNmRjYjRjMWY4M2NkL3RhYmxlcmFuZ2U6MTFhYmM5YjExYzkyNGI4Mzg5NmY2ZGNiNGMxZjgzY2RfMTUtMS0xLTEtMTA0Mw_a93fda02-45cf-44f3-9452-c41930c85b70"
      unitRef="usdPerShare">-0.11</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjExYWJjOWIxMWM5MjRiODM4OTZmNmRjYjRjMWY4M2NkL3RhYmxlcmFuZ2U6MTFhYmM5YjExYzkyNGI4Mzg5NmY2ZGNiNGMxZjgzY2RfMTUtMS0xLTEtMTA0Mw_d77c4081-1564-4e19-97f4-f86af17bdcc8"
      unitRef="usdPerShare">-0.11</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjExYWJjOWIxMWM5MjRiODM4OTZmNmRjYjRjMWY4M2NkL3RhYmxlcmFuZ2U6MTFhYmM5YjExYzkyNGI4Mzg5NmY2ZGNiNGMxZjgzY2RfMTUtMy0xLTEtMTA0Mw_578191b1-a62d-463e-be7e-11ef55341fed"
      unitRef="usdPerShare">-2.38</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjExYWJjOWIxMWM5MjRiODM4OTZmNmRjYjRjMWY4M2NkL3RhYmxlcmFuZ2U6MTFhYmM5YjExYzkyNGI4Mzg5NmY2ZGNiNGMxZjgzY2RfMTUtMy0xLTEtMTA0Mw_b15e7f6a-89e7-46a5-9171-d647d7fdc69c"
      unitRef="usdPerShare">-2.38</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjExYWJjOWIxMWM5MjRiODM4OTZmNmRjYjRjMWY4M2NkL3RhYmxlcmFuZ2U6MTFhYmM5YjExYzkyNGI4Mzg5NmY2ZGNiNGMxZjgzY2RfMTUtMS0xLTEtMA_4475b23a-7973-4d2f-8051-0da9faf1300e"
      unitRef="usdPerShare">-0.22</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjExYWJjOWIxMWM5MjRiODM4OTZmNmRjYjRjMWY4M2NkL3RhYmxlcmFuZ2U6MTFhYmM5YjExYzkyNGI4Mzg5NmY2ZGNiNGMxZjgzY2RfMTUtMS0xLTEtMA_a0729353-7687-45b1-b4a0-fd57a8065aa6"
      unitRef="usdPerShare">-0.22</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjExYWJjOWIxMWM5MjRiODM4OTZmNmRjYjRjMWY4M2NkL3RhYmxlcmFuZ2U6MTFhYmM5YjExYzkyNGI4Mzg5NmY2ZGNiNGMxZjgzY2RfMTUtMy0xLTEtMA_9073a702-ff65-429f-b0fa-bd0027da3413"
      unitRef="usdPerShare">-3.32</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjExYWJjOWIxMWM5MjRiODM4OTZmNmRjYjRjMWY4M2NkL3RhYmxlcmFuZ2U6MTFhYmM5YjExYzkyNGI4Mzg5NmY2ZGNiNGMxZjgzY2RfMTUtMy0xLTEtMA_aa85be71-08a7-444f-9d13-8b6e26540e81"
      unitRef="usdPerShare">-3.32</us-gaap:EarningsPerShareBasic>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RleHRyZWdpb246ZWI3MmNiOTFiZTBmNDVlOThiNWY5ZDkzZGU3ZDUyNjlfMzU0_2d353d47-e520-4742-bada-277fe515168b">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Anti-dilutive shares (in thousands) excluded from the calculation of weighted-average common shares presented above for the three and six months ended June 30, 2021 and 2020 are presented below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:288.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units ("RSUs"), performance-based RSUs and leveraged stock units ("LSUs")&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,801&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible senior notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,626&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,578&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i3bbdc552de74473b893173ad17ee4325_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjZmYTE5NTgwNjRmNDQxOTI5Njg2OTU3OGM4NjhmMThkL3RhYmxlcmFuZ2U6NmZhMTk1ODA2NGY0NDE5Mjk2ODY5NTc4Yzg2OGYxOGRfMi0xLTEtMS0xMDIw_572be195-a681-4a1b-b1a2-b1f910b3795d"
      unitRef="shares">2052000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="if108b20cc6254ea1a1ef89bfcf74234a_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjZmYTE5NTgwNjRmNDQxOTI5Njg2OTU3OGM4NjhmMThkL3RhYmxlcmFuZ2U6NmZhMTk1ODA2NGY0NDE5Mjk2ODY5NTc4Yzg2OGYxOGRfMi0zLTEtMS0xMDIw_b6550a3f-9a96-4177-a02c-a8a3f9499f8d"
      unitRef="shares">554000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i6a86fe17944142e095851e0cc3a655ae_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjZmYTE5NTgwNjRmNDQxOTI5Njg2OTU3OGM4NjhmMThkL3RhYmxlcmFuZ2U6NmZhMTk1ODA2NGY0NDE5Mjk2ODY5NTc4Yzg2OGYxOGRfMi0xLTEtMS0w_cc272c16-5d9b-46f5-90d0-3326148a66b4"
      unitRef="shares">1793000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ic963db54c7f04dea9f467d5db2840678_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjZmYTE5NTgwNjRmNDQxOTI5Njg2OTU3OGM4NjhmMThkL3RhYmxlcmFuZ2U6NmZhMTk1ODA2NGY0NDE5Mjk2ODY5NTc4Yzg2OGYxOGRfMi0zLTEtMS0w_6827634c-5b1e-4482-95c0-3078e925c5de"
      unitRef="shares">376000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ieca7dabc7fce4091b7a8bbb168559405_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjZmYTE5NTgwNjRmNDQxOTI5Njg2OTU3OGM4NjhmMThkL3RhYmxlcmFuZ2U6NmZhMTk1ODA2NGY0NDE5Mjk2ODY5NTc4Yzg2OGYxOGRfMy0xLTEtMS0xMDIw_734cebcb-3b60-4baf-ab07-e9cb8d0ac7a8"
      unitRef="shares">1801000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="iedb4828edf4e447d9b1ee9ab980c6c02_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjZmYTE5NTgwNjRmNDQxOTI5Njg2OTU3OGM4NjhmMThkL3RhYmxlcmFuZ2U6NmZhMTk1ODA2NGY0NDE5Mjk2ODY5NTc4Yzg2OGYxOGRfMy0zLTEtMS0xMDIw_8e57b061-77a2-4df1-9805-9116bcdf6b20"
      unitRef="shares">711000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i7360937c162c4b65b0e52cff040923da_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjZmYTE5NTgwNjRmNDQxOTI5Njg2OTU3OGM4NjhmMThkL3RhYmxlcmFuZ2U6NmZhMTk1ODA2NGY0NDE5Mjk2ODY5NTc4Yzg2OGYxOGRfMy0xLTEtMS0w_eea4216c-5b11-48d4-991c-0021d985f684"
      unitRef="shares">1833000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="iddd419d375b04a27b7ae24f9852b38cf_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjZmYTE5NTgwNjRmNDQxOTI5Njg2OTU3OGM4NjhmMThkL3RhYmxlcmFuZ2U6NmZhMTk1ODA2NGY0NDE5Mjk2ODY5NTc4Yzg2OGYxOGRfMy0zLTEtMS0w_ba72dfd5-95b7-48ce-8c0f-815e34a19c2a"
      unitRef="shares">841000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i61e6d3ad43084e94a5c4f2bbb4e354b5_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjZmYTE5NTgwNjRmNDQxOTI5Njg2OTU3OGM4NjhmMThkL3RhYmxlcmFuZ2U6NmZhMTk1ODA2NGY0NDE5Mjk2ODY5NTc4Yzg2OGYxOGRfNC0xLTEtMS0xMDIw_21e28cde-14bc-4c4f-ba48-d31104753e74"
      unitRef="shares">12696000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ibf9351473ea6468086160063a0d7a0c4_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjZmYTE5NTgwNjRmNDQxOTI5Njg2OTU3OGM4NjhmMThkL3RhYmxlcmFuZ2U6NmZhMTk1ODA2NGY0NDE5Mjk2ODY5NTc4Yzg2OGYxOGRfNC0zLTEtMS0xMDIw_4cd75dbd-0db7-4a85-90e4-b6540a2652df"
      unitRef="shares">10361000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i3d293dc899f54d4c89227aabde9d3934_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjZmYTE5NTgwNjRmNDQxOTI5Njg2OTU3OGM4NjhmMThkL3RhYmxlcmFuZ2U6NmZhMTk1ODA2NGY0NDE5Mjk2ODY5NTc4Yzg2OGYxOGRfNC0xLTEtMS0w_146b068f-8674-4049-805d-3ec49497c14b"
      unitRef="shares">12696000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ie3fb28c745a64f28b8f641cb4a936a28_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjZmYTE5NTgwNjRmNDQxOTI5Njg2OTU3OGM4NjhmMThkL3RhYmxlcmFuZ2U6NmZhMTk1ODA2NGY0NDE5Mjk2ODY5NTc4Yzg2OGYxOGRfNC0zLTEtMS0w_e1749f50-5ae3-419b-9a56-ffa9746dd7a1"
      unitRef="shares">10361000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjZmYTE5NTgwNjRmNDQxOTI5Njg2OTU3OGM4NjhmMThkL3RhYmxlcmFuZ2U6NmZhMTk1ODA2NGY0NDE5Mjk2ODY5NTc4Yzg2OGYxOGRfNS0xLTEtMS0xMDIw_b38eb5a7-9683-4723-934d-2007161c3e6d"
      unitRef="shares">16549000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjZmYTE5NTgwNjRmNDQxOTI5Njg2OTU3OGM4NjhmMThkL3RhYmxlcmFuZ2U6NmZhMTk1ODA2NGY0NDE5Mjk2ODY5NTc4Yzg2OGYxOGRfNS0zLTEtMS0xMDIw_e3725566-8d40-408f-91e0-858ca99cd665"
      unitRef="shares">11626000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjZmYTE5NTgwNjRmNDQxOTI5Njg2OTU3OGM4NjhmMThkL3RhYmxlcmFuZ2U6NmZhMTk1ODA2NGY0NDE5Mjk2ODY5NTc4Yzg2OGYxOGRfNS0xLTEtMS0w_f7597923-0c2d-4670-86f5-223b9cc2628f"
      unitRef="shares">16322000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjZmYTE5NTgwNjRmNDQxOTI5Njg2OTU3OGM4NjhmMThkL3RhYmxlcmFuZ2U6NmZhMTk1ODA2NGY0NDE5Mjk2ODY5NTc4Yzg2OGYxOGRfNS0zLTEtMS0w_a7144a02-3c4e-4550-b90e-fc25ac3c449c"
      unitRef="shares">11578000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184OC9mcmFnOjMwNmExZTg1ZTI5NDQ5N2JiZDQxZDY0YzFiZGNhNzE1L3RleHRyZWdpb246MzA2YTFlODVlMjk0NDk3YmJkNDFkNjRjMWJkY2E3MTVfMzYz_c53f0da4-9641-4e9c-aae8-6a1bef631a7b">Stock-based Compensation&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total compensation expense by award type and line item in our consolidated financial statements for the three and six months ended June 30, 2021 and 2020 was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:288.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Award Type&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;638&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Performance-based stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,006&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,862&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;LSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,059&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;PSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total compensation expense by award type&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Line Item&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;892&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;526&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;918&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:288.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total compensation expense by financial statement line item&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;No stock-based compensation was capitalized as software development costs for the three and six months ended June 30, 2021 and 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based awards were granted for the three and six months ended June 30, 2021 and 2020 as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:327.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,028&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;PSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;LSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184OC9mcmFnOjMwNmExZTg1ZTI5NDQ5N2JiZDQxZDY0YzFiZGNhNzE1L3RleHRyZWdpb246MzA2YTFlODVlMjk0NDk3YmJkNDFkNjRjMWJkY2E3MTVfMzY0_083bd9ec-449d-4da5-b5dc-ef33ac751d5b">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total compensation expense by award type and line item in our consolidated financial statements for the three and six months ended June 30, 2021 and 2020 was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:288.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Award Type&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;638&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Performance-based stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,006&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,862&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;LSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,059&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;PSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total compensation expense by award type&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Line Item&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;892&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;526&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;918&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:288.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total compensation expense by financial statement line item&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ia22f1c58e4244cbe9ed8fdbbaef1316f_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184OC9mcmFnOjMwNmExZTg1ZTI5NDQ5N2JiZDQxZDY0YzFiZGNhNzE1L3RhYmxlOmU2YjAxYjcxNWEwZjRjNmU5OTE1NjMwZTFlNzE4MWIwL3RhYmxlcmFuZ2U6ZTZiMDFiNzE1YTBmNGM2ZTk5MTU2MzBlMWU3MTgxYjBfMy0xLTEtMS0xMDYx_2a323955-3d3d-4248-8188-ec4114365f49"
      unitRef="usd">267000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i9fc03842c80f45108f623bfcd797411e_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184OC9mcmFnOjMwNmExZTg1ZTI5NDQ5N2JiZDQxZDY0YzFiZGNhNzE1L3RhYmxlOmU2YjAxYjcxNWEwZjRjNmU5OTE1NjMwZTFlNzE4MWIwL3RhYmxlcmFuZ2U6ZTZiMDFiNzE1YTBmNGM2ZTk5MTU2MzBlMWU3MTgxYjBfMy0zLTEtMS0xMDYx_ded91767-0f81-4976-9ca7-723d1e59e294"
      unitRef="usd">638000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ia0aa4d34ea254f26a2cc4a122094cd33_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184OC9mcmFnOjMwNmExZTg1ZTI5NDQ5N2JiZDQxZDY0YzFiZGNhNzE1L3RhYmxlOmU2YjAxYjcxNWEwZjRjNmU5OTE1NjMwZTFlNzE4MWIwL3RhYmxlcmFuZ2U6ZTZiMDFiNzE1YTBmNGM2ZTk5MTU2MzBlMWU3MTgxYjBfMy0xLTEtMS0w_56960668-6b3f-4dc7-aadd-c881f8f200a8"
      unitRef="usd">671000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ia4237d1aee594aeeaf7d421737988f0d_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184OC9mcmFnOjMwNmExZTg1ZTI5NDQ5N2JiZDQxZDY0YzFiZGNhNzE1L3RhYmxlOmU2YjAxYjcxNWEwZjRjNmU5OTE1NjMwZTFlNzE4MWIwL3RhYmxlcmFuZ2U6ZTZiMDFiNzE1YTBmNGM2ZTk5MTU2MzBlMWU3MTgxYjBfMy0zLTEtMS0w_56d02e1a-22dd-4614-8c13-8d6adf7c8beb"
      unitRef="usd">1388000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i1fc5b0f231654aeeb765d3a2edd42fd2_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184OC9mcmFnOjMwNmExZTg1ZTI5NDQ5N2JiZDQxZDY0YzFiZGNhNzE1L3RhYmxlOmU2YjAxYjcxNWEwZjRjNmU5OTE1NjMwZTFlNzE4MWIwL3RhYmxlcmFuZ2U6ZTZiMDFiNzE1YTBmNGM2ZTk5MTU2MzBlMWU3MTgxYjBfNC0xLTEtMS0xMDYx_0d1c579d-b050-4d1b-8d6c-524af3c1de4b"
      unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i394c93b044f44da0bc8dae6ae1a3f9af_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184OC9mcmFnOjMwNmExZTg1ZTI5NDQ5N2JiZDQxZDY0YzFiZGNhNzE1L3RhYmxlOmU2YjAxYjcxNWEwZjRjNmU5OTE1NjMwZTFlNzE4MWIwL3RhYmxlcmFuZ2U6ZTZiMDFiNzE1YTBmNGM2ZTk5MTU2MzBlMWU3MTgxYjBfNC0zLTEtMS0xMDYx_7f428eb3-139b-4bfa-8047-52ae787fbb0b"
      unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ia4367a6c7f1a4e8ab41b880d4b063e2e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184OC9mcmFnOjMwNmExZTg1ZTI5NDQ5N2JiZDQxZDY0YzFiZGNhNzE1L3RhYmxlOmU2YjAxYjcxNWEwZjRjNmU5OTE1NjMwZTFlNzE4MWIwL3RhYmxlcmFuZ2U6ZTZiMDFiNzE1YTBmNGM2ZTk5MTU2MzBlMWU3MTgxYjBfNC0xLTEtMS0w_d5154685-aa6b-49e7-b168-8b9a88275ec4"
      unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iefc5be4539b04aab90aaa73295d047d2_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184OC9mcmFnOjMwNmExZTg1ZTI5NDQ5N2JiZDQxZDY0YzFiZGNhNzE1L3RhYmxlOmU2YjAxYjcxNWEwZjRjNmU5OTE1NjMwZTFlNzE4MWIwL3RhYmxlcmFuZ2U6ZTZiMDFiNzE1YTBmNGM2ZTk5MTU2MzBlMWU3MTgxYjBfNC0zLTEtMS0w_f215e0f5-708c-44cc-b40a-e105496c7c14"
      unitRef="usd">75000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="id632fa3ae3914b9da8bf15e4c54b6686_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184OC9mcmFnOjMwNmExZTg1ZTI5NDQ5N2JiZDQxZDY0YzFiZGNhNzE1L3RhYmxlOmU2YjAxYjcxNWEwZjRjNmU5OTE1NjMwZTFlNzE4MWIwL3RhYmxlcmFuZ2U6ZTZiMDFiNzE1YTBmNGM2ZTk5MTU2MzBlMWU3MTgxYjBfNS0xLTEtMS0xMDYx_dd155ab3-8536-4d0b-a48e-5d8d2908851b"
      unitRef="usd">2427000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i89e74efc56994c9ebb87c2b0e7cd1128_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184OC9mcmFnOjMwNmExZTg1ZTI5NDQ5N2JiZDQxZDY0YzFiZGNhNzE1L3RhYmxlOmU2YjAxYjcxNWEwZjRjNmU5OTE1NjMwZTFlNzE4MWIwL3RhYmxlcmFuZ2U6ZTZiMDFiNzE1YTBmNGM2ZTk5MTU2MzBlMWU3MTgxYjBfNS0zLTEtMS0xMDYx_3121ad9a-f2c7-4bc3-a333-f5274a6f828d"
      unitRef="usd">2006000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i6660233c9d6b4e96811be968402ad42c_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184OC9mcmFnOjMwNmExZTg1ZTI5NDQ5N2JiZDQxZDY0YzFiZGNhNzE1L3RhYmxlOmU2YjAxYjcxNWEwZjRjNmU5OTE1NjMwZTFlNzE4MWIwL3RhYmxlcmFuZ2U6ZTZiMDFiNzE1YTBmNGM2ZTk5MTU2MzBlMWU3MTgxYjBfNS0xLTEtMS0w_97c4214d-a373-4b5c-9877-2854444d1baf"
      unitRef="usd">4401000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="idc0d9ae125db467ab0d22698986a0481_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184OC9mcmFnOjMwNmExZTg1ZTI5NDQ5N2JiZDQxZDY0YzFiZGNhNzE1L3RhYmxlOmU2YjAxYjcxNWEwZjRjNmU5OTE1NjMwZTFlNzE4MWIwL3RhYmxlcmFuZ2U6ZTZiMDFiNzE1YTBmNGM2ZTk5MTU2MzBlMWU3MTgxYjBfNS0zLTEtMS0w_fac76d42-5873-40eb-b2f4-0986b685ded4"
      unitRef="usd">3862000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if7b4268f6d62460d95263ea3eab82df8_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184OC9mcmFnOjMwNmExZTg1ZTI5NDQ5N2JiZDQxZDY0YzFiZGNhNzE1L3RhYmxlOmU2YjAxYjcxNWEwZjRjNmU5OTE1NjMwZTFlNzE4MWIwL3RhYmxlcmFuZ2U6ZTZiMDFiNzE1YTBmNGM2ZTk5MTU2MzBlMWU3MTgxYjBfNi0xLTEtMS0xMDY1_dbe647f0-50e1-4896-8125-e20cec6c0f2a"
      unitRef="usd">222000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i28477571d61a49d68ac8b8802530ba46_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184OC9mcmFnOjMwNmExZTg1ZTI5NDQ5N2JiZDQxZDY0YzFiZGNhNzE1L3RhYmxlOmU2YjAxYjcxNWEwZjRjNmU5OTE1NjMwZTFlNzE4MWIwL3RhYmxlcmFuZ2U6ZTZiMDFiNzE1YTBmNGM2ZTk5MTU2MzBlMWU3MTgxYjBfNi0zLTEtMS0xMDY1_599fc6f4-ba3c-474d-b5e7-e63908791288"
      unitRef="usd">1059000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ibce4d97bacd94dfaa609647fcaf23ca0_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184OC9mcmFnOjMwNmExZTg1ZTI5NDQ5N2JiZDQxZDY0YzFiZGNhNzE1L3RhYmxlOmU2YjAxYjcxNWEwZjRjNmU5OTE1NjMwZTFlNzE4MWIwL3RhYmxlcmFuZ2U6ZTZiMDFiNzE1YTBmNGM2ZTk5MTU2MzBlMWU3MTgxYjBfNi0xLTEtMS0w_06f6a830-c88b-4b85-a4e5-9e9bba417b74"
      unitRef="usd">1307000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie162b42e78994c30b638363b2e6da8a0_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184OC9mcmFnOjMwNmExZTg1ZTI5NDQ5N2JiZDQxZDY0YzFiZGNhNzE1L3RhYmxlOmU2YjAxYjcxNWEwZjRjNmU5OTE1NjMwZTFlNzE4MWIwL3RhYmxlcmFuZ2U6ZTZiMDFiNzE1YTBmNGM2ZTk5MTU2MzBlMWU3MTgxYjBfNi0zLTEtMS0w_c4aed57e-dbfa-42d5-bebb-1944f9f8ef46"
      unitRef="usd">1886000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i16f26157e03a422b8390af0e74420d0a_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184OC9mcmFnOjMwNmExZTg1ZTI5NDQ5N2JiZDQxZDY0YzFiZGNhNzE1L3RhYmxlOmU2YjAxYjcxNWEwZjRjNmU5OTE1NjMwZTFlNzE4MWIwL3RhYmxlcmFuZ2U6ZTZiMDFiNzE1YTBmNGM2ZTk5MTU2MzBlMWU3MTgxYjBfNy0xLTEtMS0xMDY1_d2339639-ca27-4b64-8e8e-766b28415177"
      unitRef="usd">737000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ia87f608d482b4ef79558f90ef1ef2a3e_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184OC9mcmFnOjMwNmExZTg1ZTI5NDQ5N2JiZDQxZDY0YzFiZGNhNzE1L3RhYmxlOmU2YjAxYjcxNWEwZjRjNmU5OTE1NjMwZTFlNzE4MWIwL3RhYmxlcmFuZ2U6ZTZiMDFiNzE1YTBmNGM2ZTk5MTU2MzBlMWU3MTgxYjBfNy0zLTEtMS0xMDY1_81fc1d73-ad1c-4fc5-8e05-e7af63c1966b"
      unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i10ed9cb15f3c48d395885e32db2ca4ff_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184OC9mcmFnOjMwNmExZTg1ZTI5NDQ5N2JiZDQxZDY0YzFiZGNhNzE1L3RhYmxlOmU2YjAxYjcxNWEwZjRjNmU5OTE1NjMwZTFlNzE4MWIwL3RhYmxlcmFuZ2U6ZTZiMDFiNzE1YTBmNGM2ZTk5MTU2MzBlMWU3MTgxYjBfNy0xLTEtMS0w_e332cfb3-514b-4b31-9dce-20c9b0a558d0"
      unitRef="usd">980000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i6f822367a8c44dd79b4a10071eae6fb0_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184OC9mcmFnOjMwNmExZTg1ZTI5NDQ5N2JiZDQxZDY0YzFiZGNhNzE1L3RhYmxlOmU2YjAxYjcxNWEwZjRjNmU5OTE1NjMwZTFlNzE4MWIwL3RhYmxlcmFuZ2U6ZTZiMDFiNzE1YTBmNGM2ZTk5MTU2MzBlMWU3MTgxYjBfNy0zLTEtMS0w_d57aa469-59fb-4097-8aa1-9e1fa8738b0a"
      unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184OC9mcmFnOjMwNmExZTg1ZTI5NDQ5N2JiZDQxZDY0YzFiZGNhNzE1L3RhYmxlOmU2YjAxYjcxNWEwZjRjNmU5OTE1NjMwZTFlNzE4MWIwL3RhYmxlcmFuZ2U6ZTZiMDFiNzE1YTBmNGM2ZTk5MTU2MzBlMWU3MTgxYjBfOC0xLTEtMS0xMDY5_5033e433-e00b-4903-9173-0e628e7a875b"
      unitRef="usd">3653000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184OC9mcmFnOjMwNmExZTg1ZTI5NDQ5N2JiZDQxZDY0YzFiZGNhNzE1L3RhYmxlOmU2YjAxYjcxNWEwZjRjNmU5OTE1NjMwZTFlNzE4MWIwL3RhYmxlcmFuZ2U6ZTZiMDFiNzE1YTBmNGM2ZTk5MTU2MzBlMWU3MTgxYjBfOC0zLTEtMS0xMDY5_bcbcd67d-3f0f-43dd-991b-ad025f91b9e1"
      unitRef="usd">3703000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184OC9mcmFnOjMwNmExZTg1ZTI5NDQ5N2JiZDQxZDY0YzFiZGNhNzE1L3RhYmxlOmU2YjAxYjcxNWEwZjRjNmU5OTE1NjMwZTFlNzE4MWIwL3RhYmxlcmFuZ2U6ZTZiMDFiNzE1YTBmNGM2ZTk5MTU2MzBlMWU3MTgxYjBfOC0xLTEtMS0w_743183ef-15f7-4f7f-9e0d-ee577c9588da"
      unitRef="usd">7359000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184OC9mcmFnOjMwNmExZTg1ZTI5NDQ5N2JiZDQxZDY0YzFiZGNhNzE1L3RhYmxlOmU2YjAxYjcxNWEwZjRjNmU5OTE1NjMwZTFlNzE4MWIwL3RhYmxlcmFuZ2U6ZTZiMDFiNzE1YTBmNGM2ZTk5MTU2MzBlMWU3MTgxYjBfOC0zLTEtMS0w_d9f6d412-61fb-499d-9ce3-1a0a6b26149f"
      unitRef="usd">7211000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="idc22f08766584f8c91a9b4972f0f9f89_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184OC9mcmFnOjMwNmExZTg1ZTI5NDQ5N2JiZDQxZDY0YzFiZGNhNzE1L3RhYmxlOmU2YjAxYjcxNWEwZjRjNmU5OTE1NjMwZTFlNzE4MWIwL3RhYmxlcmFuZ2U6ZTZiMDFiNzE1YTBmNGM2ZTk5MTU2MzBlMWU3MTgxYjBfMTEtMS0xLTEtMTA4MA_4c900306-af0b-42fd-ad20-825a1ac9e8de"
      unitRef="usd">892000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib32f2800c3f24f0ca601b1fd026b593b_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184OC9mcmFnOjMwNmExZTg1ZTI5NDQ5N2JiZDQxZDY0YzFiZGNhNzE1L3RhYmxlOmU2YjAxYjcxNWEwZjRjNmU5OTE1NjMwZTFlNzE4MWIwL3RhYmxlcmFuZ2U6ZTZiMDFiNzE1YTBmNGM2ZTk5MTU2MzBlMWU3MTgxYjBfMTEtMy0xLTEtMTA4MA_e76d6d1a-8a43-4a09-9a0f-73d7a8e9ef48"
      unitRef="usd">526000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i8b0398298a1d4101bfdde0a27cfc4235_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184OC9mcmFnOjMwNmExZTg1ZTI5NDQ5N2JiZDQxZDY0YzFiZGNhNzE1L3RhYmxlOmU2YjAxYjcxNWEwZjRjNmU5OTE1NjMwZTFlNzE4MWIwL3RhYmxlcmFuZ2U6ZTZiMDFiNzE1YTBmNGM2ZTk5MTU2MzBlMWU3MTgxYjBfMTEtMS0xLTEtMA_d5b2f9bd-32e0-4abe-a86a-2a0f67f48fc7"
      unitRef="usd">1487000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i78cdc5087ee24e2e99b2216043b5b6b1_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184OC9mcmFnOjMwNmExZTg1ZTI5NDQ5N2JiZDQxZDY0YzFiZGNhNzE1L3RhYmxlOmU2YjAxYjcxNWEwZjRjNmU5OTE1NjMwZTFlNzE4MWIwL3RhYmxlcmFuZ2U6ZTZiMDFiNzE1YTBmNGM2ZTk5MTU2MzBlMWU3MTgxYjBfMTEtMy0xLTEtMA_33c38f84-22d2-4a93-8a9e-8bb51abcab74"
      unitRef="usd">918000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i7f345cc1972943b9a0ae90973779501d_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184OC9mcmFnOjMwNmExZTg1ZTI5NDQ5N2JiZDQxZDY0YzFiZGNhNzE1L3RhYmxlOmU2YjAxYjcxNWEwZjRjNmU5OTE1NjMwZTFlNzE4MWIwL3RhYmxlcmFuZ2U6ZTZiMDFiNzE1YTBmNGM2ZTk5MTU2MzBlMWU3MTgxYjBfMTItMS0xLTEtMTA3Ng_6c609cda-92c0-4794-a0e8-cc5f45c815c7"
      unitRef="usd">2761000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i40db2f18e67e43439f94c81d84f13d6b_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184OC9mcmFnOjMwNmExZTg1ZTI5NDQ5N2JiZDQxZDY0YzFiZGNhNzE1L3RhYmxlOmU2YjAxYjcxNWEwZjRjNmU5OTE1NjMwZTFlNzE4MWIwL3RhYmxlcmFuZ2U6ZTZiMDFiNzE1YTBmNGM2ZTk5MTU2MzBlMWU3MTgxYjBfMTItMy0xLTEtMTA3Ng_47891a44-f96d-4b02-b935-501c83faddc1"
      unitRef="usd">3177000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ia1c09fd265c44ccdbf4d6a40f41ce5f1_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184OC9mcmFnOjMwNmExZTg1ZTI5NDQ5N2JiZDQxZDY0YzFiZGNhNzE1L3RhYmxlOmU2YjAxYjcxNWEwZjRjNmU5OTE1NjMwZTFlNzE4MWIwL3RhYmxlcmFuZ2U6ZTZiMDFiNzE1YTBmNGM2ZTk5MTU2MzBlMWU3MTgxYjBfMTItMS0xLTEtMA_90698cef-e3bd-464b-bdfd-aa4ebb6579d9"
      unitRef="usd">5872000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="id05098869b4b4201a380d4ccd404ff02_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184OC9mcmFnOjMwNmExZTg1ZTI5NDQ5N2JiZDQxZDY0YzFiZGNhNzE1L3RhYmxlOmU2YjAxYjcxNWEwZjRjNmU5OTE1NjMwZTFlNzE4MWIwL3RhYmxlcmFuZ2U6ZTZiMDFiNzE1YTBmNGM2ZTk5MTU2MzBlMWU3MTgxYjBfMTItMy0xLTEtMA_3eb469fd-0170-4b7b-9731-439b840e0933"
      unitRef="usd">6293000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184OC9mcmFnOjMwNmExZTg1ZTI5NDQ5N2JiZDQxZDY0YzFiZGNhNzE1L3RhYmxlOmU2YjAxYjcxNWEwZjRjNmU5OTE1NjMwZTFlNzE4MWIwL3RhYmxlcmFuZ2U6ZTZiMDFiNzE1YTBmNGM2ZTk5MTU2MzBlMWU3MTgxYjBfMTMtMS0xLTEtMTA3Ng_3b64ce9e-9721-49f6-b1f9-77edafac45a2"
      unitRef="usd">3653000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184OC9mcmFnOjMwNmExZTg1ZTI5NDQ5N2JiZDQxZDY0YzFiZGNhNzE1L3RhYmxlOmU2YjAxYjcxNWEwZjRjNmU5OTE1NjMwZTFlNzE4MWIwL3RhYmxlcmFuZ2U6ZTZiMDFiNzE1YTBmNGM2ZTk5MTU2MzBlMWU3MTgxYjBfMTMtMy0xLTEtMTA3Ng_775845d7-6492-444c-b8a2-786ae9512b54"
      unitRef="usd">3703000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184OC9mcmFnOjMwNmExZTg1ZTI5NDQ5N2JiZDQxZDY0YzFiZGNhNzE1L3RhYmxlOmU2YjAxYjcxNWEwZjRjNmU5OTE1NjMwZTFlNzE4MWIwL3RhYmxlcmFuZ2U6ZTZiMDFiNzE1YTBmNGM2ZTk5MTU2MzBlMWU3MTgxYjBfMTMtMS0xLTEtMA_743183ef-15f7-4f7f-9e0d-ee577c9588da"
      unitRef="usd">7359000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184OC9mcmFnOjMwNmExZTg1ZTI5NDQ5N2JiZDQxZDY0YzFiZGNhNzE1L3RhYmxlOmU2YjAxYjcxNWEwZjRjNmU5OTE1NjMwZTFlNzE4MWIwL3RhYmxlcmFuZ2U6ZTZiMDFiNzE1YTBmNGM2ZTk5MTU2MzBlMWU3MTgxYjBfMTMtMy0xLTEtMA_d9f6d412-61fb-499d-9ce3-1a0a6b26149f"
      unitRef="usd">7211000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184OC9mcmFnOjMwNmExZTg1ZTI5NDQ5N2JiZDQxZDY0YzFiZGNhNzE1L3RleHRyZWdpb246MzA2YTFlODVlMjk0NDk3YmJkNDFkNjRjMWJkY2E3MTVfMTcy_661e97a9-2555-46e1-98c4-5c1a9ee79f0b"
      unitRef="usd">0</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184OC9mcmFnOjMwNmExZTg1ZTI5NDQ5N2JiZDQxZDY0YzFiZGNhNzE1L3RleHRyZWdpb246MzA2YTFlODVlMjk0NDk3YmJkNDFkNjRjMWJkY2E3MTVfMTcy_a907ad86-4b19-4070-ab57-65ddd67bda84"
      unitRef="usd">0</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184OC9mcmFnOjMwNmExZTg1ZTI5NDQ5N2JiZDQxZDY0YzFiZGNhNzE1L3RleHRyZWdpb246MzA2YTFlODVlMjk0NDk3YmJkNDFkNjRjMWJkY2E3MTVfMTcy_f4ad6c1c-db16-49f9-a390-624186b8c07d"
      unitRef="usd">0</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184OC9mcmFnOjMwNmExZTg1ZTI5NDQ5N2JiZDQxZDY0YzFiZGNhNzE1L3RleHRyZWdpb246MzA2YTFlODVlMjk0NDk3YmJkNDFkNjRjMWJkY2E3MTVfMTcy_fee81476-d82d-45e4-a7b9-8131d35c1f78"
      unitRef="usd">0</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184OC9mcmFnOjMwNmExZTg1ZTI5NDQ5N2JiZDQxZDY0YzFiZGNhNzE1L3RleHRyZWdpb246MzA2YTFlODVlMjk0NDk3YmJkNDFkNjRjMWJkY2E3MTVfMzY1_70440d90-1cc1-4a0d-b583-a4a37afa1702">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based awards were granted for the three and six months ended June 30, 2021 and 2020 as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:327.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,028&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;PSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;LSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="id632fa3ae3914b9da8bf15e4c54b6686_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184OC9mcmFnOjMwNmExZTg1ZTI5NDQ5N2JiZDQxZDY0YzFiZGNhNzE1L3RhYmxlOjUwNmQ2ZDMyZTM2MzRhOTM4Mjk5MGMyMTRkYzA5ZmEyL3RhYmxlcmFuZ2U6NTA2ZDZkMzJlMzYzNGE5MzgyOTkwYzIxNGRjMDlmYTJfMi0xLTEtMS0xMDkx_ad4a1b94-0606-4e8f-8d74-47331586efb6"
      unitRef="shares">89000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i89e74efc56994c9ebb87c2b0e7cd1128_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184OC9mcmFnOjMwNmExZTg1ZTI5NDQ5N2JiZDQxZDY0YzFiZGNhNzE1L3RhYmxlOjUwNmQ2ZDMyZTM2MzRhOTM4Mjk5MGMyMTRkYzA5ZmEyL3RhYmxlcmFuZ2U6NTA2ZDZkMzJlMzYzNGE5MzgyOTkwYzIxNGRjMDlmYTJfMi0zLTEtMS0xMDkx_7f7221d5-0982-4868-b8fe-fde962b29fd3"
      unitRef="shares">164000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i6660233c9d6b4e96811be968402ad42c_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184OC9mcmFnOjMwNmExZTg1ZTI5NDQ5N2JiZDQxZDY0YzFiZGNhNzE1L3RhYmxlOjUwNmQ2ZDMyZTM2MzRhOTM4Mjk5MGMyMTRkYzA5ZmEyL3RhYmxlcmFuZ2U6NTA2ZDZkMzJlMzYzNGE5MzgyOTkwYzIxNGRjMDlmYTJfMi0xLTEtMS0w_5f020b3f-0944-4015-8c8d-d763a1f4274e"
      unitRef="shares">1028000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="idc0d9ae125db467ab0d22698986a0481_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184OC9mcmFnOjMwNmExZTg1ZTI5NDQ5N2JiZDQxZDY0YzFiZGNhNzE1L3RhYmxlOjUwNmQ2ZDMyZTM2MzRhOTM4Mjk5MGMyMTRkYzA5ZmEyL3RhYmxlcmFuZ2U6NTA2ZDZkMzJlMzYzNGE5MzgyOTkwYzIxNGRjMDlmYTJfMi0zLTEtMS0w_a619bc5b-419e-4222-842c-ae3d7365472a"
      unitRef="shares">1140000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i16f26157e03a422b8390af0e74420d0a_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184OC9mcmFnOjMwNmExZTg1ZTI5NDQ5N2JiZDQxZDY0YzFiZGNhNzE1L3RhYmxlOjUwNmQ2ZDMyZTM2MzRhOTM4Mjk5MGMyMTRkYzA5ZmEyL3RhYmxlcmFuZ2U6NTA2ZDZkMzJlMzYzNGE5MzgyOTkwYzIxNGRjMDlmYTJfMy0xLTEtMS0xMDkx_63510937-f169-4213-9b01-b1c203e5b1eb"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ia87f608d482b4ef79558f90ef1ef2a3e_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184OC9mcmFnOjMwNmExZTg1ZTI5NDQ5N2JiZDQxZDY0YzFiZGNhNzE1L3RhYmxlOjUwNmQ2ZDMyZTM2MzRhOTM4Mjk5MGMyMTRkYzA5ZmEyL3RhYmxlcmFuZ2U6NTA2ZDZkMzJlMzYzNGE5MzgyOTkwYzIxNGRjMDlmYTJfMy0zLTEtMS0xMDkx_ea9e177a-7120-48e6-8007-c59cd0a42f4e"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i10ed9cb15f3c48d395885e32db2ca4ff_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184OC9mcmFnOjMwNmExZTg1ZTI5NDQ5N2JiZDQxZDY0YzFiZGNhNzE1L3RhYmxlOjUwNmQ2ZDMyZTM2MzRhOTM4Mjk5MGMyMTRkYzA5ZmEyL3RhYmxlcmFuZ2U6NTA2ZDZkMzJlMzYzNGE5MzgyOTkwYzIxNGRjMDlmYTJfMy0xLTEtMS0w_379c735b-2c39-423a-93dc-643eb1117c16"
      unitRef="shares">319000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i6f822367a8c44dd79b4a10071eae6fb0_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184OC9mcmFnOjMwNmExZTg1ZTI5NDQ5N2JiZDQxZDY0YzFiZGNhNzE1L3RhYmxlOjUwNmQ2ZDMyZTM2MzRhOTM4Mjk5MGMyMTRkYzA5ZmEyL3RhYmxlcmFuZ2U6NTA2ZDZkMzJlMzYzNGE5MzgyOTkwYzIxNGRjMDlmYTJfMy0zLTEtMS0w_13d30bde-f386-4b11-9f1f-0e8377e3b75b"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="if7b4268f6d62460d95263ea3eab82df8_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184OC9mcmFnOjMwNmExZTg1ZTI5NDQ5N2JiZDQxZDY0YzFiZGNhNzE1L3RhYmxlOjUwNmQ2ZDMyZTM2MzRhOTM4Mjk5MGMyMTRkYzA5ZmEyL3RhYmxlcmFuZ2U6NTA2ZDZkMzJlMzYzNGE5MzgyOTkwYzIxNGRjMDlmYTJfNC0xLTEtMS0xMDkx_8a1657f8-a375-42ba-8f5c-bc8ca86a038f"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i28477571d61a49d68ac8b8802530ba46_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184OC9mcmFnOjMwNmExZTg1ZTI5NDQ5N2JiZDQxZDY0YzFiZGNhNzE1L3RhYmxlOjUwNmQ2ZDMyZTM2MzRhOTM4Mjk5MGMyMTRkYzA5ZmEyL3RhYmxlcmFuZ2U6NTA2ZDZkMzJlMzYzNGE5MzgyOTkwYzIxNGRjMDlmYTJfNC0zLTEtMS0xMDkx_18723230-7c04-4a54-9362-a95473636a60"
      unitRef="shares">140000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ibce4d97bacd94dfaa609647fcaf23ca0_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184OC9mcmFnOjMwNmExZTg1ZTI5NDQ5N2JiZDQxZDY0YzFiZGNhNzE1L3RhYmxlOjUwNmQ2ZDMyZTM2MzRhOTM4Mjk5MGMyMTRkYzA5ZmEyL3RhYmxlcmFuZ2U6NTA2ZDZkMzJlMzYzNGE5MzgyOTkwYzIxNGRjMDlmYTJfNC0xLTEtMS0w_ce6f10a7-71dc-44b9-8c88-20ef5d562013"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ie162b42e78994c30b638363b2e6da8a0_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184OC9mcmFnOjMwNmExZTg1ZTI5NDQ5N2JiZDQxZDY0YzFiZGNhNzE1L3RhYmxlOjUwNmQ2ZDMyZTM2MzRhOTM4Mjk5MGMyMTRkYzA5ZmEyL3RhYmxlcmFuZ2U6NTA2ZDZkMzJlMzYzNGE5MzgyOTkwYzIxNGRjMDlmYTJfNC0zLTEtMS0w_6f2516dc-312f-40a3-a41f-10e72d8b6e18"
      unitRef="shares">520000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMDAvZnJhZzozNDdhMDIyZDc3MzE0MzFjYWI3YjMxYTI3ZDAyYTMzMS90ZXh0cmVnaW9uOjM0N2EwMjJkNzczMTQzMWNhYjdiMzFhMjdkMDJhMzMxXzE3MTA_b5dff576-69ac-451a-a322-4c9c9d142f17">Income Taxes&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For interim periods, we recognize an income tax provision (benefit) based on our estimated annual effective tax rate expected for the full year.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;An income tax expense (benefit) of $0.1&#160;million and $0.7&#160;million was recognized for the three and six months ended June 30, 2021, respectively, which resulted in effective tax rates of (1.0)% and (3.6)%, respectively. An income tax expense (benefit) of $(3.9)&#160;million and $(3.6)&#160;million was recognized for the three and six months ended June 30, 2020, respectively, which resulted in effective tax rates of 1.9% and 1.3%, respectively. The Company and its U.S. subsidiaries continue to record a valuation allowance against its net deferred tax assets, with the exception of indefinite lived components. The income tax expense recorded during the three and six months ended June 30, 2021 primarily relates to foreign taxes.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As of December&#160;31, 2020, the Company had unrecognized tax benefits of $0.7 million that, if recognized, would not affect the effective tax rate due to the valuation allowance against its net deferred tax asset. As of June&#160;30, 2021, there are no changes to the unrecognized tax benefits. The Company is not currently subject to income tax audits in any U.S., state, or foreign jurisdictions for any tax year.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Tax Receivables Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the Offering Reorganization, the Company entered into the TRA with certain of its investors, which provides for the payment by the Company to these investors of 85% of the amount of the tax benefits, if any, that the Company is deemed to realize as a result of increases in our tax basis related to exchanges of Class B common units as well as tax benefits attributable to the future utilization of pre-IPO NOLs. See Note 11 above and &#x201c;Part II - Item 8. Financial Statements and Supplementary Data - Note 14&#x201d; in our 2020 Form 10-K for discussion of our TRA.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMDAvZnJhZzozNDdhMDIyZDc3MzE0MzFjYWI3YjMxYTI3ZDAyYTMzMS90ZXh0cmVnaW9uOjM0N2EwMjJkNzczMTQzMWNhYjdiMzFhMjdkMDJhMzMxXzEwOTk1MTE2Mzc0MTk_a1f80ec6-f5d4-4d4c-9268-f298665409aa"
      unitRef="usd">100000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMDAvZnJhZzozNDdhMDIyZDc3MzE0MzFjYWI3YjMxYTI3ZDAyYTMzMS90ZXh0cmVnaW9uOjM0N2EwMjJkNzczMTQzMWNhYjdiMzFhMjdkMDJhMzMxXzEwOTk1MTE2MzczODg_7c17c70a-35ed-421e-b0c9-9e52df0dc50b"
      unitRef="usd">700000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMDAvZnJhZzozNDdhMDIyZDc3MzE0MzFjYWI3YjMxYTI3ZDAyYTMzMS90ZXh0cmVnaW9uOjM0N2EwMjJkNzczMTQzMWNhYjdiMzFhMjdkMDJhMzMxXzMzNw_a0bacc13-8526-451a-af22-72cd237f09cf"
      unitRef="number">-0.010</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMDAvZnJhZzozNDdhMDIyZDc3MzE0MzFjYWI3YjMxYTI3ZDAyYTMzMS90ZXh0cmVnaW9uOjM0N2EwMjJkNzczMTQzMWNhYjdiMzFhMjdkMDJhMzMxXzEwOTk1MTE2MzY0NzI_a5331a26-b086-4fc0-ba23-4d3879b8bf64"
      unitRef="number">-0.036</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMDAvZnJhZzozNDdhMDIyZDc3MzE0MzFjYWI3YjMxYTI3ZDAyYTMzMS90ZXh0cmVnaW9uOjM0N2EwMjJkNzczMTQzMWNhYjdiMzFhMjdkMDJhMzMxXzEwOTk1MTE2Mzc0NDg_82c4c2cf-8089-4344-a7e5-d6bb56dd7f29"
      unitRef="usd">-3900000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMDAvZnJhZzozNDdhMDIyZDc3MzE0MzFjYWI3YjMxYTI3ZDAyYTMzMS90ZXh0cmVnaW9uOjM0N2EwMjJkNzczMTQzMWNhYjdiMzFhMjdkMDJhMzMxXzE2NDkyNjc0NDM2Njg_4dd9d096-5c6f-4766-a88f-ae5d12e5f72e"
      unitRef="usd">-3600000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMDAvZnJhZzozNDdhMDIyZDc3MzE0MzFjYWI3YjMxYTI3ZDAyYTMzMS90ZXh0cmVnaW9uOjM0N2EwMjJkNzczMTQzMWNhYjdiMzFhMjdkMDJhMzMxXzEwOTk1MTE2MzY0Njg_3a3da38e-8d5c-43cd-b819-e372243f68a4"
      unitRef="number">0.019</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMDAvZnJhZzozNDdhMDIyZDc3MzE0MzFjYWI3YjMxYTI3ZDAyYTMzMS90ZXh0cmVnaW9uOjM0N2EwMjJkNzczMTQzMWNhYjdiMzFhMjdkMDJhMzMxXzE2NDkyNjc0NDM2OTA_e669ebcf-adc4-4ecf-bbb3-d996bd3727c1"
      unitRef="number">0.013</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i45bff335c1434d6ba44132da1b0557db_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMDAvZnJhZzozNDdhMDIyZDc3MzE0MzFjYWI3YjMxYTI3ZDAyYTMzMS90ZXh0cmVnaW9uOjM0N2EwMjJkNzczMTQzMWNhYjdiMzFhMjdkMDJhMzMxXzc5MA_e0efc6be-a956-4d6b-840c-1df58ed36ae1"
      unitRef="usd">700000</us-gaap:UnrecognizedTaxBenefits>
    <evh:TaxReceivableAgreementPercentofCashSavingsPaidtoShareholders
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMDAvZnJhZzozNDdhMDIyZDc3MzE0MzFjYWI3YjMxYTI3ZDAyYTMzMS90ZXh0cmVnaW9uOjM0N2EwMjJkNzczMTQzMWNhYjdiMzFhMjdkMDJhMzMxXzEzMTU_399ab6bd-a501-469d-b989-d57b3c94485e"
      unitRef="number">0.85</evh:TaxReceivableAgreementPercentofCashSavingsPaidtoShareholders>
    <us-gaap:EquityMethodInvestmentsDisclosureTextBlock
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMDYvZnJhZzpmZWU5YjQ5ZGNlNmM0NmUxYjRlMzYyZmY1YTM5YmVmYS90ZXh0cmVnaW9uOmZlZTliNDlkY2U2YzQ2ZTFiNGUzNjJmZjVhMzliZWZhXzIxNDM_c7b3e974-21a3-46c3-8217-bf781deadc02">Investments in and Advances to Equity Method Investees&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company holds ownership interests in joint ventures and other entities which are accounted for under the equity method. The Company evaluates its interests in these entities to determine whether they meet the definition of a VIE and whether the Company is required to consolidate these entities. A VIE is consolidated by its primary beneficiary, which is the party that has both (i) the power to direct the activities that most significantly impact the economic performance of the VIE and (ii) a variable interest that could potentially be significant to the VIE. To determine whether or not a variable interest the Company holds could potentially be significant to the VIE, the Company considers both qualitative and quantitative factors regarding the nature, size and form of the Company's involvement with the VIE. The Company has determined that its interests in these entities meet the definition of a variable interest, however, the Company is not the primary beneficiary since it does not have the power to direct activities, therefore, the Company did not consolidate the VIEs.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of&#160;June&#160;30, 2021 and December&#160;31, 2020, the Company&#x2019;s economic interests in its equity method investments ranged between 4% and 39%, and 4% and 38%, respectively, and voting interests in its equity method investments ranged between 25% and 40%, respectively. The Company determined that it has significant influence over these entities but that it does not have control over any of the entities. Accordingly, the investments are accounted for under the equity method of accounting and the Company is allocated its proportional share of the entities&#x2019; earnings and losses for each reporting period. The Company&#x2019;s proportional share of the (gain) losses &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;from these investments was approximately $4.9 million and $12.7 million for the three and six months ended June 30, 2021, respectively, and $25.1 million and $24.7 million for the three and six months ended June 30, 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company signed services agreements with certain of the aforementioned entities to provide certain management, operational and support services to help manage elements of their service offerings. Revenue related to these services agreements were $2.3 million and $8.6 million for the three and six months ended June 30, 2021, respectively, and $71.4 million and $131.3 million for the three and six months ended June 30, 2020 , respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:EquityMethodInvestmentsDisclosureTextBlock>
    <evh:EquityMethodInvestmentEconomicInterestPercentage
      contextRef="if20f8ae5705c41f6910dff16d8c55578_I20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMDYvZnJhZzpmZWU5YjQ5ZGNlNmM0NmUxYjRlMzYyZmY1YTM5YmVmYS90ZXh0cmVnaW9uOmZlZTliNDlkY2U2YzQ2ZTFiNGUzNjJmZjVhMzliZWZhXzEyNjA_318d0559-b035-4181-9cef-9921909afc5a"
      unitRef="number">0.04</evh:EquityMethodInvestmentEconomicInterestPercentage>
    <evh:EquityMethodInvestmentEconomicInterestPercentage
      contextRef="i9b662261daa24dd0829c6be06dc0975d_I20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMDYvZnJhZzpmZWU5YjQ5ZGNlNmM0NmUxYjRlMzYyZmY1YTM5YmVmYS90ZXh0cmVnaW9uOmZlZTliNDlkY2U2YzQ2ZTFiNGUzNjJmZjVhMzliZWZhXzEyNjc_55f86a28-1488-40f5-b01d-4e7b651b2c44"
      unitRef="number">0.39</evh:EquityMethodInvestmentEconomicInterestPercentage>
    <evh:EquityMethodInvestmentEconomicInterestPercentage
      contextRef="i3a67432b3a04429fb74ea67ee7476cc1_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMDYvZnJhZzpmZWU5YjQ5ZGNlNmM0NmUxYjRlMzYyZmY1YTM5YmVmYS90ZXh0cmVnaW9uOmZlZTliNDlkY2U2YzQ2ZTFiNGUzNjJmZjVhMzliZWZhXzEyNzU_6a29f785-9e4d-4827-8511-ce8119c80795"
      unitRef="number">0.04</evh:EquityMethodInvestmentEconomicInterestPercentage>
    <evh:EquityMethodInvestmentEconomicInterestPercentage
      contextRef="i644686c1853d44d8bed17fe7241635c7_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMDYvZnJhZzpmZWU5YjQ5ZGNlNmM0NmUxYjRlMzYyZmY1YTM5YmVmYS90ZXh0cmVnaW9uOmZlZTliNDlkY2U2YzQ2ZTFiNGUzNjJmZjVhMzliZWZhXzEyODI_763f3fd4-1b29-400c-98d5-a0b1fb951751"
      unitRef="number">0.38</evh:EquityMethodInvestmentEconomicInterestPercentage>
    <evh:EquityMethodInvestmentVotingInterestPercentage
      contextRef="if20f8ae5705c41f6910dff16d8c55578_I20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMDYvZnJhZzpmZWU5YjQ5ZGNlNmM0NmUxYjRlMzYyZmY1YTM5YmVmYS90ZXh0cmVnaW9uOmZlZTliNDlkY2U2YzQ2ZTFiNGUzNjJmZjVhMzliZWZhXzEzNjk_725b8134-23cd-43a6-af7d-b3fd53273d68"
      unitRef="number">0.25</evh:EquityMethodInvestmentVotingInterestPercentage>
    <evh:EquityMethodInvestmentVotingInterestPercentage
      contextRef="i9b662261daa24dd0829c6be06dc0975d_I20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMDYvZnJhZzpmZWU5YjQ5ZGNlNmM0NmUxYjRlMzYyZmY1YTM5YmVmYS90ZXh0cmVnaW9uOmZlZTliNDlkY2U2YzQ2ZTFiNGUzNjJmZjVhMzliZWZhXzEzNzY_90123630-15a3-4f0d-afac-058c34c9b1c9"
      unitRef="number">0.40</evh:EquityMethodInvestmentVotingInterestPercentage>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMDYvZnJhZzpmZWU5YjQ5ZGNlNmM0NmUxYjRlMzYyZmY1YTM5YmVmYS90ZXh0cmVnaW9uOmZlZTliNDlkY2U2YzQ2ZTFiNGUzNjJmZjVhMzliZWZhXzE2NDkyNjc0NDM5MTU_b08fd07f-2d2e-4aba-b3a2-8f2a0c9eb17c"
      unitRef="usd">4900000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMDYvZnJhZzpmZWU5YjQ5ZGNlNmM0NmUxYjRlMzYyZmY1YTM5YmVmYS90ZXh0cmVnaW9uOmZlZTliNDlkY2U2YzQ2ZTFiNGUzNjJmZjVhMzliZWZhXzE4Mjc_53b01344-0002-4a78-ab6c-3ef6a729e6fa"
      unitRef="usd">12700000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMDYvZnJhZzpmZWU5YjQ5ZGNlNmM0NmUxYjRlMzYyZmY1YTM5YmVmYS90ZXh0cmVnaW9uOmZlZTliNDlkY2U2YzQ2ZTFiNGUzNjJmZjVhMzliZWZhXzE2NDkyNjc0NDM4OTU_c05e69de-ab65-43cc-ae7b-86d6ce2db612"
      unitRef="usd">25100000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMDYvZnJhZzpmZWU5YjQ5ZGNlNmM0NmUxYjRlMzYyZmY1YTM5YmVmYS90ZXh0cmVnaW9uOmZlZTliNDlkY2U2YzQ2ZTFiNGUzNjJmZjVhMzliZWZhXzE4MzQ_6c1c6321-7459-4efc-af48-ed6581b82eb1"
      unitRef="usd">24700000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <evh:IncomeLossfromEquityMethodInvestmentsServicesAgreement
      contextRef="i53efb4309a7d432c9067d4fceb38e1e9_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMDYvZnJhZzpmZWU5YjQ5ZGNlNmM0NmUxYjRlMzYyZmY1YTM5YmVmYS90ZXh0cmVnaW9uOmZlZTliNDlkY2U2YzQ2ZTFiNGUzNjJmZjVhMzliZWZhXzE2NDkyNjc0NDM4ODQ_e1af342c-1356-4ffa-9f12-2288a7792a31"
      unitRef="usd">2300000</evh:IncomeLossfromEquityMethodInvestmentsServicesAgreement>
    <evh:IncomeLossfromEquityMethodInvestmentsServicesAgreement
      contextRef="i0191a974415646adb1cd9c25e726b3a2_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMDYvZnJhZzpmZWU5YjQ5ZGNlNmM0NmUxYjRlMzYyZmY1YTM5YmVmYS90ZXh0cmVnaW9uOmZlZTliNDlkY2U2YzQ2ZTFiNGUzNjJmZjVhMzliZWZhXzIxMDk_2d75bb1c-01a9-4737-ab09-45b79fb3ea00"
      unitRef="usd">8600000</evh:IncomeLossfromEquityMethodInvestmentsServicesAgreement>
    <evh:IncomeLossfromEquityMethodInvestmentsServicesAgreement
      contextRef="i008ff0c503394e539acc7adba9224bd0_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMDYvZnJhZzpmZWU5YjQ5ZGNlNmM0NmUxYjRlMzYyZmY1YTM5YmVmYS90ZXh0cmVnaW9uOmZlZTliNDlkY2U2YzQ2ZTFiNGUzNjJmZjVhMzliZWZhXzE2NDkyNjc0NDM4NzI_9a89d096-e62b-4b2f-a32d-f7e3d5e81309"
      unitRef="usd">71400000</evh:IncomeLossfromEquityMethodInvestmentsServicesAgreement>
    <evh:IncomeLossfromEquityMethodInvestmentsServicesAgreement
      contextRef="i9e9654e025214c9b8e664574e724a4f5_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMDYvZnJhZzpmZWU5YjQ5ZGNlNmM0NmUxYjRlMzYyZmY1YTM5YmVmYS90ZXh0cmVnaW9uOmZlZTliNDlkY2U2YzQ2ZTFiNGUzNjJmZjVhMzliZWZhXzIxMTY_3b6c14f5-68f3-404d-b91f-e44cb43e6e39"
      unitRef="usd">131300000</evh:IncomeLossfromEquityMethodInvestmentsServicesAgreement>
    <us-gaap:MinorityInterestDisclosureTextBlock
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMDkvZnJhZzoyOWExYzMwNzA5ZDc0OGYwOGMyODM1MTBlYmE4NTNmYy90ZXh0cmVnaW9uOjI5YTFjMzA3MDlkNzQ4ZjA4YzI4MzUxMGViYTg1M2ZjXzE0Njc_b4ffb387-bbf8-4514-b9a2-edc56ed19b82">Non-controlling Interests&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Immediately following the Offering Reorganization and IPO in May 2015, the Company owned 70.3% of Evolent Health LLC. The Company&#x2019;s ownership percentage changes with the issuance of Class A or Class B common stock and Class B Exchanges. In order to account for any changes in the Company&#x2019;s ownership of Evolent Health LLC, we record a reclassification of equity between non-controlling interests and shareholders&#x2019; equity attributable to Evolent Health, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 1, 2020, in connection with the consolidation of EVH Passport, the Company recognized a $25.7&#160;million non-controlling interest for the Sponsors&#x2019; 30% equity interest in EVH Passport which represented the fair value of the non-controlling interest as of the date of consolidation. Pursuant to the shareholders&#x2019; agreement with the Sponsors, the Company was required to acquire the Sponsors&#x2019; 30% ownership interest for $20.0&#160;million on or prior to December 31, 2021. On November 16, 2020, the Company acquired the Sponsors&#x2019; 30% equity interest and reclassified the non-controlling interests into shareholders&#x2019; equity attributable to Evolent Health, Inc. As a result of this transaction, the Company recorded a $5.7&#160;million gain on consolidation for the year ended December 31, 2020 in gain (loss) on disposal of assets and consolidation on the consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in non-controlling interests (in thousands) for  the six months ended June 30, 2020 was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:487.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-controlling interests balance as of beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,889&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reclassification of non-controlling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,889)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-controlling interests balance as of end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:MinorityInterestDisclosureTextBlock>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="id7302983007d47cf8a4aa6ef74f49b80_I20150531"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMDkvZnJhZzoyOWExYzMwNzA5ZDc0OGYwOGMyODM1MTBlYmE4NTNmYy90ZXh0cmVnaW9uOjI5YTFjMzA3MDlkNzQ4ZjA4YzI4MzUxMGViYTg1M2ZjXzEzMQ_4bca2dc3-f61d-4a4f-a0dc-61c8e34ab5e2"
      unitRef="number">0.703</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination
      contextRef="i46248ae6cf2f4c3bb6a08e6b7351403f_D20200901-20200901"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMDkvZnJhZzoyOWExYzMwNzA5ZDc0OGYwOGMyODM1MTBlYmE4NTNmYy90ZXh0cmVnaW9uOjI5YTFjMzA3MDlkNzQ4ZjA4YzI4MzUxMGViYTg1M2ZjXzYwNQ_6020b522-9314-4b83-ba8a-797a64794e85"
      unitRef="usd">25700000</us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination>
    <us-gaap:VariableInterestEntityOwnershipPercentage
      contextRef="i46248ae6cf2f4c3bb6a08e6b7351403f_D20200901-20200901"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMDkvZnJhZzoyOWExYzMwNzA5ZDc0OGYwOGMyODM1MTBlYmE4NTNmYy90ZXh0cmVnaW9uOjI5YTFjMzA3MDlkNzQ4ZjA4YzI4MzUxMGViYTg1M2ZjXzY1MQ_2c377697-39f9-4533-9fd6-cb90a2d734a5"
      unitRef="number">0.30</us-gaap:VariableInterestEntityOwnershipPercentage>
    <us-gaap:VariableInterestEntityOwnershipPercentage
      contextRef="i46248ae6cf2f4c3bb6a08e6b7351403f_D20200901-20200901"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMDkvZnJhZzoyOWExYzMwNzA5ZDc0OGYwOGMyODM1MTBlYmE4NTNmYy90ZXh0cmVnaW9uOjI5YTFjMzA3MDlkNzQ4ZjA4YzI4MzUxMGViYTg1M2ZjXzg5Mw_51bb75c2-02cc-4ef6-9915-84ab03dd0708"
      unitRef="number">0.30</us-gaap:VariableInterestEntityOwnershipPercentage>
    <evh:VariableInterestEntityNewMedicaidContractNotAwardedRequirementToAcquireOwnershipConsiderationAmount
      contextRef="i7d32a6bf57a9495e9192581ba6585e10_I20200901"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMDkvZnJhZzoyOWExYzMwNzA5ZDc0OGYwOGMyODM1MTBlYmE4NTNmYy90ZXh0cmVnaW9uOjI5YTFjMzA3MDlkNzQ4ZjA4YzI4MzUxMGViYTg1M2ZjXzkxOQ_7d03d448-2251-4723-b57c-bad41a65bb8e"
      unitRef="usd">20000000.0</evh:VariableInterestEntityNewMedicaidContractNotAwardedRequirementToAcquireOwnershipConsiderationAmount>
    <us-gaap:VariableInterestEntityOwnershipPercentage
      contextRef="i7a8609d202734bc89b28f90cabe48547_D20201116-20201116"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMDkvZnJhZzoyOWExYzMwNzA5ZDc0OGYwOGMyODM1MTBlYmE4NTNmYy90ZXh0cmVnaW9uOjI5YTFjMzA3MDlkNzQ4ZjA4YzI4MzUxMGViYTg1M2ZjXzEwMTM_c7abce8b-9c66-4eb7-8c9d-2dc238a09da1"
      unitRef="number">0.30</us-gaap:VariableInterestEntityOwnershipPercentage>
    <us-gaap:VariableInterestEntityInitialConsolidationGainOrLoss
      contextRef="i19b1ea06ce044830b8d288022cd0a41c_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMDkvZnJhZzoyOWExYzMwNzA5ZDc0OGYwOGMyODM1MTBlYmE4NTNmYy90ZXh0cmVnaW9uOjI5YTFjMzA3MDlkNzQ4ZjA4YzI4MzUxMGViYTg1M2ZjXzExOTg_41346c79-7ce3-4b06-a228-90f36788b659"
      unitRef="usd">5700000</us-gaap:VariableInterestEntityInitialConsolidationGainOrLoss>
    <evh:ScheduleofChangesinNoncontrollingInterestTableTextBlock
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMDkvZnJhZzoyOWExYzMwNzA5ZDc0OGYwOGMyODM1MTBlYmE4NTNmYy90ZXh0cmVnaW9uOjI5YTFjMzA3MDlkNzQ4ZjA4YzI4MzUxMGViYTg1M2ZjXzE0NjQ_6faf4d0c-5f5d-42fa-be8e-28f3333a3d57">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in non-controlling interests (in thousands) for  the six months ended June 30, 2020 was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:487.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-controlling interests balance as of beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,889&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reclassification of non-controlling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,889)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-controlling interests balance as of end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</evh:ScheduleofChangesinNoncontrollingInterestTableTextBlock>
    <us-gaap:MinorityInterest
      contextRef="ibcd7068eef4f42b895c0b83d21ea5d2b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMDkvZnJhZzoyOWExYzMwNzA5ZDc0OGYwOGMyODM1MTBlYmE4NTNmYy90YWJsZTo4YjBmNTdhY2EyMjY0NzRjYWUxYzY4YjA5NDYyOWFjOS90YWJsZXJhbmdlOjhiMGY1N2FjYTIyNjQ3NGNhZTFjNjhiMDk0NjI5YWM5XzItMy0xLTEtMA_4eb3e443-2ee4-479c-a994-7b2907f1235d"
      unitRef="usd">6889000</us-gaap:MinorityInterest>
    <us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance
      contextRef="i215048e9c16a4f348373b4cb1edc7ece_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMDkvZnJhZzoyOWExYzMwNzA5ZDc0OGYwOGMyODM1MTBlYmE4NTNmYy90YWJsZTo4YjBmNTdhY2EyMjY0NzRjYWUxYzY4YjA5NDYyOWFjOS90YWJsZXJhbmdlOjhiMGY1N2FjYTIyNjQ3NGNhZTFjNjhiMDk0NjI5YWM5XzMtMy0xLTEtMA_0b4c990a-ba10-459c-a759-c1451a4e7ae2"
      unitRef="usd">-6889000</us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance>
    <us-gaap:MinorityInterest
      contextRef="i9d6223463ab84fa6a8f5cd35e24c15d7_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMDkvZnJhZzoyOWExYzMwNzA5ZDc0OGYwOGMyODM1MTBlYmE4NTNmYy90YWJsZTo4YjBmNTdhY2EyMjY0NzRjYWUxYzY4YjA5NDYyOWFjOS90YWJsZXJhbmdlOjhiMGY1N2FjYTIyNjQ3NGNhZTFjNjhiMDk0NjI5YWM5XzQtMy0xLTEtMA_c63633f2-2df4-489a-bf23-cf6260382126"
      unitRef="usd">0</us-gaap:MinorityInterest>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTIvZnJhZzo2MGVjZWU4OTJmMmQ0Y2UyYjdiNmIzZjI3OGVkZjk3Mi90ZXh0cmVnaW9uOjYwZWNlZTg5MmYyZDRjZTJiN2I2YjNmMjc4ZWRmOTcyXzQ5NDc_1cd017dd-8726-4b75-866a-da3d18af18bd">Fair Value Measurement&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;GAAP defines fair value as the price that would be received from the sale of an asset or paid to transfer a liability (an exit price) assuming an orderly transaction in the most advantageous market at the measurement date. GAAP also establishes a hierarchical disclosure framework which prioritizes and ranks the level of observability of inputs used in measuring fair value. These tiers include:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 1 - inputs to the valuation methodology are quoted prices available in active markets for identical instruments as of the reporting date;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 2 - inputs to the valuation methodology are other than quoted prices in active markets, which are either directly or indirectly observable as of the reporting date and the fair value can be determined through the use of models or other valuation methodologies; and &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 3 - inputs to the valuation methodology are unobservable inputs in situations where there is little or no market activity for the asset or liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, the level within the fair value hierarchy is based on the lowest level of input that is significant to the fair value measurement. Our assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the particular asset or liability being measured. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Nonrecurring Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to the assets and liabilities that are recorded at fair value on a recurring basis, the Company records certain assets and liabilities at fair value on a nonrecurring basis as required by GAAP. Generally, assets are recorded at fair value on a nonrecurring basis as a result of impairment charges. This includes assets and liabilities recorded in business combinations or asset acquisitions, goodwill, intangible assets, property, plant and equipment, held-to-maturity investments and equity method investments. While not &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;carried at fair value on a recurring basis, these items are continually monitored for indicators of impairment that would indicate current carrying value is greater than fair value. In those situations, the assets are considered impaired and written down to current fair value. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Other Fair Value Disclosures&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts of cash and cash equivalents (those not held in a money market fund), restricted cash, receivables, prepaid expenses, accounts payable, accrued liabilities and accrued compensation approximate their fair values because of the relatively short-term maturities of these items and financial instruments.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See Note 10 for information regarding the fair value of the 2024 Notes, 2025 Notes and 2021 Notes.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTIvZnJhZzo2MGVjZWU4OTJmMmQ0Y2UyYjdiNmIzZjI3OGVkZjk3Mi90ZXh0cmVnaW9uOjYwZWNlZTg5MmYyZDRjZTJiN2I2YjNmMjc4ZWRmOTcyXzQ5NTY_60f073f5-daad-40dd-aa86-fcd5c101677e">Fair Value Measurement&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;GAAP defines fair value as the price that would be received from the sale of an asset or paid to transfer a liability (an exit price) assuming an orderly transaction in the most advantageous market at the measurement date. GAAP also establishes a hierarchical disclosure framework which prioritizes and ranks the level of observability of inputs used in measuring fair value. These tiers include:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 1 - inputs to the valuation methodology are quoted prices available in active markets for identical instruments as of the reporting date;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 2 - inputs to the valuation methodology are other than quoted prices in active markets, which are either directly or indirectly observable as of the reporting date and the fair value can be determined through the use of models or other valuation methodologies; and &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 3 - inputs to the valuation methodology are unobservable inputs in situations where there is little or no market activity for the asset or liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, the level within the fair value hierarchy is based on the lowest level of input that is significant to the fair value measurement. Our assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the particular asset or liability being measured. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recurring Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with GAAP, certain assets and liabilities are required to be recorded at fair value on a recurring basis. The following table summarizes the Company&#x2019;s assets and liabilities measured at fair value on a recurring basis as of December&#160;31, 2020 (in thousands):&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:325.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total fair value of assets measured on a recurring basis&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total fair value of liabilities measured on a recurring basis&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; Represents the cash and cash equivalents and restricted cash and restricted investments that were held in money market funds as of December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Represents the fair value of 1,513,786 shares issuable under the warrant agreements discussed in Note 10.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes any transfers between levels within the hierarchy as of the beginning of the reporting period. There were no transfers between fair value levels during the three and six months ended June 30, 2021 and 2020, respectively.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the absence of observable market prices, the fair value is based on the best information available and involves a significant degree of judgment, taking into consideration a combination of internal and external factors, including the appropriate risk adjustments for non-performance and liquidity risks.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In conjunction with the Credit Agreement discussed in Note 10, the Company entered into warrant agreements whereby it agreed to sell to the holders of the warrants an aggregate of 1,513,786 shares of Class A common stock. The fair value of the warrants was estimated based on the Black-Scholes model which incorporates the constant price variation of the stock, the time value of money, the option's strike price, and the time to the option's expiry. The significant unobservable inputs used in the fair value measurement of the warrants are the stock price volatility and annual risk free rate. A significant increase in the stock price or discount rate in isolation would result in a significantly higher fair value of the contingent consideration.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The changes in our liabilities measured at fair value for which the Company uses Level 3 inputs to determine fair value for the six months ended June 30, 2021 and 2020 are as follows (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:433.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,730)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,500)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Realized and unrealized gains (losses), net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,975)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the fair value (in thousands), valuation techniques and significant unobservable inputs of our Level 3 fair value measurements as of December&#160;31, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:539.25pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:118.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:100.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:168.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:67.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:13.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Valuation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Significant&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assumption or&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Technique&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unobservable Inputs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Input Ranges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Black-Scholes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock price volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Annual risk free rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Nonrecurring Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to the assets and liabilities that are recorded at fair value on a recurring basis, the Company records certain assets and liabilities at fair value on a nonrecurring basis as required by GAAP. Generally, assets are recorded at fair value on a nonrecurring basis as a result of impairment charges. This includes assets and liabilities recorded in business combinations or asset acquisitions, goodwill, intangible assets, property, plant and equipment, held-to-maturity investments and equity method investments. While not &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;carried at fair value on a recurring basis, these items are continually monitored for indicators of impairment that would indicate current carrying value is greater than fair value. In those situations, the assets are considered impaired and written down to current fair value. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Other Fair Value Disclosures&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts of cash and cash equivalents (those not held in a money market fund), restricted cash, receivables, prepaid expenses, accounts payable, accrued liabilities and accrued compensation approximate their fair values because of the relatively short-term maturities of these items and financial instruments.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See Note 10 for information regarding the fair value of the 2024 Notes, 2025 Notes and 2021 Notes.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTIvZnJhZzo2MGVjZWU4OTJmMmQ0Y2UyYjdiNmIzZjI3OGVkZjk3Mi90ZXh0cmVnaW9uOjYwZWNlZTg5MmYyZDRjZTJiN2I2YjNmMjc4ZWRmOTcyXzQ5NDI_fa650fe2-5684-4130-a277-b7645cd3a3de">The following table summarizes the Company&#x2019;s assets and liabilities measured at fair value on a recurring basis as of December&#160;31, 2020 (in thousands): &lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:325.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total fair value of assets measured on a recurring basis&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total fair value of liabilities measured on a recurring basis&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; Represents the cash and cash equivalents and restricted cash and restricted investments that were held in money market funds as of December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Represents the fair value of 1,513,786 shares issuable under the warrant agreements discussed in Note 10.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTIvZnJhZzo2MGVjZWU4OTJmMmQ0Y2UyYjdiNmIzZjI3OGVkZjk3Mi90ZXh0cmVnaW9uOjYwZWNlZTg5MmYyZDRjZTJiN2I2YjNmMjc4ZWRmOTcyXzQ5NTg_e167c2d3-6556-44cd-801c-71f97f43dbfe">The following table summarizes the Company&#x2019;s assets and liabilities measured at fair value on a recurring basis as of December&#160;31, 2020 (in thousands): &lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:325.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total fair value of assets measured on a recurring basis&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total fair value of liabilities measured on a recurring basis&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; Represents the cash and cash equivalents and restricted cash and restricted investments that were held in money market funds as of December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Represents the fair value of 1,513,786 shares issuable under the warrant agreements discussed in Note 10.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i8bcd87ce6e8140d4b38c9d25b675b6d0_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTIvZnJhZzo2MGVjZWU4OTJmMmQ0Y2UyYjdiNmIzZjI3OGVkZjk3Mi90YWJsZTpkN2E1YmQ4MTg4YzY0NDQ4OGIzY2VjYzk4MTA0N2U1ZS90YWJsZXJhbmdlOmQ3YTViZDgxODhjNjQ0NDg4YjNjZWNjOTgxMDQ3ZTVlXzMtMS0xLTEtMA_bf928738-7405-48fd-af8a-dfe32957da0f"
      unitRef="usd">5877000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="id8df3a7cd40142e4a7fab99e3da63b6c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTIvZnJhZzo2MGVjZWU4OTJmMmQ0Y2UyYjdiNmIzZjI3OGVkZjk3Mi90YWJsZTpkN2E1YmQ4MTg4YzY0NDQ4OGIzY2VjYzk4MTA0N2U1ZS90YWJsZXJhbmdlOmQ3YTViZDgxODhjNjQ0NDg4YjNjZWNjOTgxMDQ3ZTVlXzMtMy0xLTEtMA_57cec918-2e51-46f3-8b93-730bee354ebf"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ic31316c74dad419fa29a95505e9ad56c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTIvZnJhZzo2MGVjZWU4OTJmMmQ0Y2UyYjdiNmIzZjI3OGVkZjk3Mi90YWJsZTpkN2E1YmQ4MTg4YzY0NDQ4OGIzY2VjYzk4MTA0N2U1ZS90YWJsZXJhbmdlOmQ3YTViZDgxODhjNjQ0NDg4YjNjZWNjOTgxMDQ3ZTVlXzMtNS0xLTEtMA_f418ae08-8fac-48a5-846f-c1ec86b3eaad"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ie28163dd08614c3cafdece4567d5b234_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTIvZnJhZzo2MGVjZWU4OTJmMmQ0Y2UyYjdiNmIzZjI3OGVkZjk3Mi90YWJsZTpkN2E1YmQ4MTg4YzY0NDQ4OGIzY2VjYzk4MTA0N2U1ZS90YWJsZXJhbmdlOmQ3YTViZDgxODhjNjQ0NDg4YjNjZWNjOTgxMDQ3ZTVlXzMtNy0xLTEtMA_86d2c6d0-5693-4c99-83b1-7377f392dd10"
      unitRef="usd">5877000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i8bcd87ce6e8140d4b38c9d25b675b6d0_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTIvZnJhZzo2MGVjZWU4OTJmMmQ0Y2UyYjdiNmIzZjI3OGVkZjk3Mi90YWJsZTpkN2E1YmQ4MTg4YzY0NDQ4OGIzY2VjYzk4MTA0N2U1ZS90YWJsZXJhbmdlOmQ3YTViZDgxODhjNjQ0NDg4YjNjZWNjOTgxMDQ3ZTVlXzQtMS0xLTEtMA_4c115a4c-2bce-4c62-9377-a51aca86669d"
      unitRef="usd">5877000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="id8df3a7cd40142e4a7fab99e3da63b6c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTIvZnJhZzo2MGVjZWU4OTJmMmQ0Y2UyYjdiNmIzZjI3OGVkZjk3Mi90YWJsZTpkN2E1YmQ4MTg4YzY0NDQ4OGIzY2VjYzk4MTA0N2U1ZS90YWJsZXJhbmdlOmQ3YTViZDgxODhjNjQ0NDg4YjNjZWNjOTgxMDQ3ZTVlXzQtMy0xLTEtMA_c22354ff-7f77-4d75-9292-92fc8562f192"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ic31316c74dad419fa29a95505e9ad56c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTIvZnJhZzo2MGVjZWU4OTJmMmQ0Y2UyYjdiNmIzZjI3OGVkZjk3Mi90YWJsZTpkN2E1YmQ4MTg4YzY0NDQ4OGIzY2VjYzk4MTA0N2U1ZS90YWJsZXJhbmdlOmQ3YTViZDgxODhjNjQ0NDg4YjNjZWNjOTgxMDQ3ZTVlXzQtNS0xLTEtMA_59f598a2-7c20-47f5-a2fe-cb05cef53a61"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ie28163dd08614c3cafdece4567d5b234_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTIvZnJhZzo2MGVjZWU4OTJmMmQ0Y2UyYjdiNmIzZjI3OGVkZjk3Mi90YWJsZTpkN2E1YmQ4MTg4YzY0NDQ4OGIzY2VjYzk4MTA0N2U1ZS90YWJsZXJhbmdlOmQ3YTViZDgxODhjNjQ0NDg4YjNjZWNjOTgxMDQ3ZTVlXzQtNy0xLTEtMA_9e5db04b-4c09-4600-a369-04e4490d64b3"
      unitRef="usd">5877000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:OtherLiabilitiesFairValueDisclosure
      contextRef="i8bcd87ce6e8140d4b38c9d25b675b6d0_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTIvZnJhZzo2MGVjZWU4OTJmMmQ0Y2UyYjdiNmIzZjI3OGVkZjk3Mi90YWJsZTpkN2E1YmQ4MTg4YzY0NDQ4OGIzY2VjYzk4MTA0N2U1ZS90YWJsZXJhbmdlOmQ3YTViZDgxODhjNjQ0NDg4YjNjZWNjOTgxMDQ3ZTVlXzctMS0xLTEtMA_34e9904f-7f39-4961-8f0c-e016b8fbec29"
      unitRef="usd">0</us-gaap:OtherLiabilitiesFairValueDisclosure>
    <us-gaap:OtherLiabilitiesFairValueDisclosure
      contextRef="id8df3a7cd40142e4a7fab99e3da63b6c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTIvZnJhZzo2MGVjZWU4OTJmMmQ0Y2UyYjdiNmIzZjI3OGVkZjk3Mi90YWJsZTpkN2E1YmQ4MTg4YzY0NDQ4OGIzY2VjYzk4MTA0N2U1ZS90YWJsZXJhbmdlOmQ3YTViZDgxODhjNjQ0NDg4YjNjZWNjOTgxMDQ3ZTVlXzctMy0xLTEtMA_6eef1699-d53a-4480-88ec-16653515aec5"
      unitRef="usd">0</us-gaap:OtherLiabilitiesFairValueDisclosure>
    <us-gaap:OtherLiabilitiesFairValueDisclosure
      contextRef="ic31316c74dad419fa29a95505e9ad56c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTIvZnJhZzo2MGVjZWU4OTJmMmQ0Y2UyYjdiNmIzZjI3OGVkZjk3Mi90YWJsZTpkN2E1YmQ4MTg4YzY0NDQ4OGIzY2VjYzk4MTA0N2U1ZS90YWJsZXJhbmdlOmQ3YTViZDgxODhjNjQ0NDg4YjNjZWNjOTgxMDQ3ZTVlXzctNS0xLTEtMA_c776b72a-6b55-4ef5-847a-d7533a78ac23"
      unitRef="usd">13730000</us-gaap:OtherLiabilitiesFairValueDisclosure>
    <us-gaap:OtherLiabilitiesFairValueDisclosure
      contextRef="ie28163dd08614c3cafdece4567d5b234_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTIvZnJhZzo2MGVjZWU4OTJmMmQ0Y2UyYjdiNmIzZjI3OGVkZjk3Mi90YWJsZTpkN2E1YmQ4MTg4YzY0NDQ4OGIzY2VjYzk4MTA0N2U1ZS90YWJsZXJhbmdlOmQ3YTViZDgxODhjNjQ0NDg4YjNjZWNjOTgxMDQ3ZTVlXzctNy0xLTEtMA_9769bb50-f2b3-48d6-ab39-1b5405dc8ba6"
      unitRef="usd">13730000</us-gaap:OtherLiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i8bcd87ce6e8140d4b38c9d25b675b6d0_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTIvZnJhZzo2MGVjZWU4OTJmMmQ0Y2UyYjdiNmIzZjI3OGVkZjk3Mi90YWJsZTpkN2E1YmQ4MTg4YzY0NDQ4OGIzY2VjYzk4MTA0N2U1ZS90YWJsZXJhbmdlOmQ3YTViZDgxODhjNjQ0NDg4YjNjZWNjOTgxMDQ3ZTVlXzgtMS0xLTEtMA_b2f7056f-4aa1-4a72-b56f-f4328b7b4418"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="id8df3a7cd40142e4a7fab99e3da63b6c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTIvZnJhZzo2MGVjZWU4OTJmMmQ0Y2UyYjdiNmIzZjI3OGVkZjk3Mi90YWJsZTpkN2E1YmQ4MTg4YzY0NDQ4OGIzY2VjYzk4MTA0N2U1ZS90YWJsZXJhbmdlOmQ3YTViZDgxODhjNjQ0NDg4YjNjZWNjOTgxMDQ3ZTVlXzgtMy0xLTEtMA_2ea19b5c-e1ac-41a4-85b9-cbd03e6be35a"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ic31316c74dad419fa29a95505e9ad56c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTIvZnJhZzo2MGVjZWU4OTJmMmQ0Y2UyYjdiNmIzZjI3OGVkZjk3Mi90YWJsZTpkN2E1YmQ4MTg4YzY0NDQ4OGIzY2VjYzk4MTA0N2U1ZS90YWJsZXJhbmdlOmQ3YTViZDgxODhjNjQ0NDg4YjNjZWNjOTgxMDQ3ZTVlXzgtNS0xLTEtMA_9b635a00-04db-42ed-8b9d-19fb404fc1ee"
      unitRef="usd">13730000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ie28163dd08614c3cafdece4567d5b234_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTIvZnJhZzo2MGVjZWU4OTJmMmQ0Y2UyYjdiNmIzZjI3OGVkZjk3Mi90YWJsZTpkN2E1YmQ4MTg4YzY0NDQ4OGIzY2VjYzk4MTA0N2U1ZS90YWJsZXJhbmdlOmQ3YTViZDgxODhjNjQ0NDg4YjNjZWNjOTgxMDQ3ZTVlXzgtNy0xLTEtMA_7a967daa-5b88-4515-8123-e016c43f969c"
      unitRef="usd">13730000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i45bff335c1434d6ba44132da1b0557db_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTIvZnJhZzo2MGVjZWU4OTJmMmQ0Y2UyYjdiNmIzZjI3OGVkZjk3Mi90ZXh0cmVnaW9uOjYwZWNlZTg5MmYyZDRjZTJiN2I2YjNmMjc4ZWRmOTcyXzE5NDA_7ab24c74-e14b-4c9f-9e1c-90ccb16688a7"
      unitRef="shares">1513786</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightUnissued
      contextRef="i1cad05e654934e308e828b864b76a508_I20191230"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTIvZnJhZzo2MGVjZWU4OTJmMmQ0Y2UyYjdiNmIzZjI3OGVkZjk3Mi90ZXh0cmVnaW9uOjYwZWNlZTg5MmYyZDRjZTJiN2I2YjNmMjc4ZWRmOTcyXzI3MjU_ac7abe6a-a6b2-498a-92c3-cc274b28f9ca"
      unitRef="shares">1513786</us-gaap:ClassOfWarrantOrRightUnissued>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTIvZnJhZzo2MGVjZWU4OTJmMmQ0Y2UyYjdiNmIzZjI3OGVkZjk3Mi90ZXh0cmVnaW9uOjYwZWNlZTg5MmYyZDRjZTJiN2I2YjNmMjc4ZWRmOTcyXzQ5Njc_5b8866ff-5d8a-4be7-85d9-46b29e122f11">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The changes in our liabilities measured at fair value for which the Company uses Level 3 inputs to determine fair value for the six months ended June 30, 2021 and 2020 are as follows (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:433.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,730)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,500)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Realized and unrealized gains (losses), net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,975)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i45bff335c1434d6ba44132da1b0557db_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTIvZnJhZzo2MGVjZWU4OTJmMmQ0Y2UyYjdiNmIzZjI3OGVkZjk3Mi90YWJsZTpiZDY2YmY2MWI3ZjA0ZmY2OTJkNDQ3NTY1ZTMxYTY2ZS90YWJsZXJhbmdlOmJkNjZiZjYxYjdmMDRmZjY5MmQ0NDc1NjVlMzFhNjZlXzItMS0xLTEtMA_988daaa5-e177-4132-be1a-98800fd4d4e9"
      unitRef="usd">13730000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="ie0ff0ad229b441d4b12bc8956f92a917_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTIvZnJhZzo2MGVjZWU4OTJmMmQ0Y2UyYjdiNmIzZjI3OGVkZjk3Mi90YWJsZTpiZDY2YmY2MWI3ZjA0ZmY2OTJkNDQ3NTY1ZTMxYTY2ZS90YWJsZXJhbmdlOmJkNjZiZjYxYjdmMDRmZjY5MmQ0NDc1NjVlMzFhNjZlXzItMy0xLTEtMA_5dad3dda-7cb9-448c-8c01-3916bd66b467"
      unitRef="usd">16975000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTIvZnJhZzo2MGVjZWU4OTJmMmQ0Y2UyYjdiNmIzZjI3OGVkZjk3Mi90YWJsZTpiZDY2YmY2MWI3ZjA0ZmY2OTJkNDQ3NTY1ZTMxYTY2ZS90YWJsZXJhbmdlOmJkNjZiZjYxYjdmMDRmZjY5MmQ0NDc1NjVlMzFhNjZlXzMtMS0xLTEtMA_ac7fffe5-aaa7-4730-b9d6-dc8a92c9299a"
      unitRef="usd">13730000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTIvZnJhZzo2MGVjZWU4OTJmMmQ0Y2UyYjdiNmIzZjI3OGVkZjk3Mi90YWJsZTpiZDY2YmY2MWI3ZjA0ZmY2OTJkNDQ3NTY1ZTMxYTY2ZS90YWJsZXJhbmdlOmJkNjZiZjYxYjdmMDRmZjY5MmQ0NDc1NjVlMzFhNjZlXzMtMy0xLTEtMA_7c70e15d-a7d0-42da-89db-5703cf5ac628"
      unitRef="usd">3500000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTIvZnJhZzo2MGVjZWU4OTJmMmQ0Y2UyYjdiNmIzZjI3OGVkZjk3Mi90YWJsZTpiZDY2YmY2MWI3ZjA0ZmY2OTJkNDQ3NTY1ZTMxYTY2ZS90YWJsZXJhbmdlOmJkNjZiZjYxYjdmMDRmZjY5MmQ0NDc1NjVlMzFhNjZlXzQtMS0xLTEtMA_cea01afe-e6c7-4935-affa-a146eefa859a"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTIvZnJhZzo2MGVjZWU4OTJmMmQ0Y2UyYjdiNmIzZjI3OGVkZjk3Mi90YWJsZTpiZDY2YmY2MWI3ZjA0ZmY2OTJkNDQ3NTY1ZTMxYTY2ZS90YWJsZXJhbmdlOmJkNjZiZjYxYjdmMDRmZjY5MmQ0NDc1NjVlMzFhNjZlXzQtMy0xLTEtMA_ebcbb851-12fc-46e0-8d62-38c14514ab71"
      unitRef="usd">-4975000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTIvZnJhZzo2MGVjZWU4OTJmMmQ0Y2UyYjdiNmIzZjI3OGVkZjk3Mi90YWJsZTpiZDY2YmY2MWI3ZjA0ZmY2OTJkNDQ3NTY1ZTMxYTY2ZS90YWJsZXJhbmdlOmJkNjZiZjYxYjdmMDRmZjY5MmQ0NDc1NjVlMzFhNjZlXzUtMS0xLTEtMA_7ebf250a-31c3-4b98-a528-343fe317ce38"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i11817f96c3e24e0abaed14a17869e173_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTIvZnJhZzo2MGVjZWU4OTJmMmQ0Y2UyYjdiNmIzZjI3OGVkZjk3Mi90YWJsZTpiZDY2YmY2MWI3ZjA0ZmY2OTJkNDQ3NTY1ZTMxYTY2ZS90YWJsZXJhbmdlOmJkNjZiZjYxYjdmMDRmZjY5MmQ0NDc1NjVlMzFhNjZlXzUtMy0xLTEtMA_26538129-7663-4448-a627-4781ca8f1971"
      unitRef="usd">8500000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTIvZnJhZzo2MGVjZWU4OTJmMmQ0Y2UyYjdiNmIzZjI3OGVkZjk3Mi90ZXh0cmVnaW9uOjYwZWNlZTg5MmYyZDRjZTJiN2I2YjNmMjc4ZWRmOTcyXzQ5NzI_92f488eb-3f3f-4530-b6fc-7136dc195ce0">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the fair value (in thousands), valuation techniques and significant unobservable inputs of our Level 3 fair value measurements as of December&#160;31, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:539.25pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:118.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:100.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:168.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:67.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:13.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Valuation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Significant&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assumption or&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Technique&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unobservable Inputs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Input Ranges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Black-Scholes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock price volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Annual risk free rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:OtherLiabilitiesFairValueDisclosure
      contextRef="i9af8cd87d8f9489980dbda44afabcdbc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTIvZnJhZzo2MGVjZWU4OTJmMmQ0Y2UyYjdiNmIzZjI3OGVkZjk3Mi90YWJsZTo5Nzg0YmEyNmE1NDM0NzBhYTJmMDI5ZGQyN2Y5YWViMC90YWJsZXJhbmdlOjk3ODRiYTI2YTU0MzQ3MGFhMmYwMjlkZDI3ZjlhZWIwXzMtMS0xLTEtMA_588dba6b-57a4-4d8d-b49e-fc0a7246addb"
      unitRef="usd">13730000</us-gaap:OtherLiabilitiesFairValueDisclosure>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="ia5a46affbafa4a3caf05bc97e2301da0_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTIvZnJhZzo2MGVjZWU4OTJmMmQ0Y2UyYjdiNmIzZjI3OGVkZjk3Mi90YWJsZTo5Nzg0YmEyNmE1NDM0NzBhYTJmMDI5ZGQyN2Y5YWViMC90YWJsZXJhbmdlOjk3ODRiYTI2YTU0MzQ3MGFhMmYwMjlkZDI3ZjlhZWIwXzMtNy0xLTEtMA_d0b5c6ac-e091-4f2a-8f52-33a2e7efd8c8"
      unitRef="number">0.622</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i1593077c9af8419b8c13d1d04a73de2d_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTIvZnJhZzo2MGVjZWU4OTJmMmQ0Y2UyYjdiNmIzZjI3OGVkZjk3Mi90YWJsZTo5Nzg0YmEyNmE1NDM0NzBhYTJmMDI5ZGQyN2Y5YWViMC90YWJsZXJhbmdlOjk3ODRiYTI2YTU0MzQ3MGFhMmYwMjlkZDI3ZjlhZWIwXzQtNy0xLTEtMA_0b150fcc-4cdb-43f2-9cb3-210188561977"
      unitRef="number">0.002</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTUvZnJhZzo4YjlhZTAxYjIwYjg0ZDZjOTVmNWJhY2VkZmZjZTUwYi90ZXh0cmVnaW9uOjhiOWFlMDFiMjBiODRkNmM5NWY1YmFjZWRmZmNlNTBiXzEyNjY_26c2b4d8-b5cb-4e71-928e-9362d0115fe2">Related Parties  &lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The entities described below are considered related parties and the balances and/or transactions with them are reported in our consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;As discussed in Note&#160;16, the Company had economic interests in several entities that were previously accounted for under the equity method of accounting, including EVH Passport (which has been consolidated into the Company&#x2019;s financial results since September 1, 2020). The Company has allocated its proportional share of the investees&#x2019; earnings and losses each reporting period. In addition, Evolent has entered into services agreements with certain of the entities to provide certain management, operational and support services to help the entities manage elements of their service offerings. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also works closely with UPMC, one of its founding investors. The Company&#x2019;s relationship with UPMC is a subcontractor relationship where UPMC has agreed to execute certain tasks (primarily TPA services) relating to certain customer commitments. We also conduct business with a company in which UPMC holds a significant equity interest.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents assets and liabilities attributable to our related parties as of June&#160;30, 2021 and December&#160;31, 2020 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.594%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.705%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.707%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reserve for claims and performance-based arrangements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents revenues and expenses attributable to our related parties for the three and six months ended June 30, 2021 and 2020 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:273.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:61.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:61.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:61.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:61.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Transformation services&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Platform and operations services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73,885&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,943&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;141,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of revenue (exclusive of depreciation and amortization expenses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,171)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,099&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTUvZnJhZzo4YjlhZTAxYjIwYjg0ZDZjOTVmNWJhY2VkZmZjZTUwYi90ZXh0cmVnaW9uOjhiOWFlMDFiMjBiODRkNmM5NWY1YmFjZWRmZmNlNTBiXzEyNjg_6df5e1ef-f7a9-41af-9cfc-c0176d166d46">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents assets and liabilities attributable to our related parties as of June&#160;30, 2021 and December&#160;31, 2020 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.594%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.705%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.707%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reserve for claims and performance-based arrangements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents revenues and expenses attributable to our related parties for the three and six months ended June 30, 2021 and 2020 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:273.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:61.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:61.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:61.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:61.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Transformation services&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Platform and operations services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73,885&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,943&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;141,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of revenue (exclusive of depreciation and amortization expenses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,171)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,099&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i5e3c636f0c3f4cd9a3d1b819208219a6_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTUvZnJhZzo4YjlhZTAxYjIwYjg0ZDZjOTVmNWJhY2VkZmZjZTUwYi90YWJsZTowMTk5YzAwNzI1YjM0YWQ2YjY0MTE1YmU1ZjM0NTBhYS90YWJsZXJhbmdlOjAxOTljMDA3MjViMzRhZDZiNjQxMTViZTVmMzQ1MGFhXzItMS0xLTEtMA_bb266888-7caa-44aa-804c-949f81b17fb8"
      unitRef="usd">4450000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="icd166759aac546b39c8ff666867d34d3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTUvZnJhZzo4YjlhZTAxYjIwYjg0ZDZjOTVmNWJhY2VkZmZjZTUwYi90YWJsZTowMTk5YzAwNzI1YjM0YWQ2YjY0MTE1YmU1ZjM0NTBhYS90YWJsZXJhbmdlOjAxOTljMDA3MjViMzRhZDZiNjQxMTViZTVmMzQ1MGFhXzItMy0xLTEtMA_cb1e7fb0-f59a-4ae6-8b60-462679135963"
      unitRef="usd">9474000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i5e3c636f0c3f4cd9a3d1b819208219a6_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTUvZnJhZzo4YjlhZTAxYjIwYjg0ZDZjOTVmNWJhY2VkZmZjZTUwYi90YWJsZTowMTk5YzAwNzI1YjM0YWQ2YjY0MTE1YmU1ZjM0NTBhYS90YWJsZXJhbmdlOjAxOTljMDA3MjViMzRhZDZiNjQxMTViZTVmMzQ1MGFhXzMtMS0xLTEtMA_b7003c70-d57a-4230-b066-c0113d06e52f"
      unitRef="usd">17000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="icd166759aac546b39c8ff666867d34d3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTUvZnJhZzo4YjlhZTAxYjIwYjg0ZDZjOTVmNWJhY2VkZmZjZTUwYi90YWJsZTowMTk5YzAwNzI1YjM0YWQ2YjY0MTE1YmU1ZjM0NTBhYS90YWJsZXJhbmdlOjAxOTljMDA3MjViMzRhZDZiNjQxMTViZTVmMzQ1MGFhXzMtMy0xLTEtMA_2f1df318-1ee2-49fb-ae82-3fee066ae59b"
      unitRef="usd">51000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent
      contextRef="i5e3c636f0c3f4cd9a3d1b819208219a6_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTUvZnJhZzo4YjlhZTAxYjIwYjg0ZDZjOTVmNWJhY2VkZmZjZTUwYi90YWJsZTowMTk5YzAwNzI1YjM0YWQ2YjY0MTE1YmU1ZjM0NTBhYS90YWJsZXJhbmdlOjAxOTljMDA3MjViMzRhZDZiNjQxMTViZTVmMzQ1MGFhXzQtMS0xLTEtMA_65e6ce70-e668-409b-a428-dcb868284642"
      unitRef="usd">4688000</us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent
      contextRef="icd166759aac546b39c8ff666867d34d3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTUvZnJhZzo4YjlhZTAxYjIwYjg0ZDZjOTVmNWJhY2VkZmZjZTUwYi90YWJsZTowMTk5YzAwNzI1YjM0YWQ2YjY0MTE1YmU1ZjM0NTBhYS90YWJsZXJhbmdlOjAxOTljMDA3MjViMzRhZDZiNjQxMTViZTVmMzQ1MGFhXzQtMy0xLTEtMA_a29d768f-bed3-46ba-84c5-7ab1318be878"
      unitRef="usd">4554000</us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i5e3c636f0c3f4cd9a3d1b819208219a6_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTUvZnJhZzo4YjlhZTAxYjIwYjg0ZDZjOTVmNWJhY2VkZmZjZTUwYi90YWJsZTowMTk5YzAwNzI1YjM0YWQ2YjY0MTE1YmU1ZjM0NTBhYS90YWJsZXJhbmdlOjAxOTljMDA3MjViMzRhZDZiNjQxMTViZTVmMzQ1MGFhXzctMS0xLTEtMA_e45bd5f8-9b66-4b5a-a005-24c23113afa9"
      unitRef="usd">1923000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="icd166759aac546b39c8ff666867d34d3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTUvZnJhZzo4YjlhZTAxYjIwYjg0ZDZjOTVmNWJhY2VkZmZjZTUwYi90YWJsZTowMTk5YzAwNzI1YjM0YWQ2YjY0MTE1YmU1ZjM0NTBhYS90YWJsZXJhbmdlOjAxOTljMDA3MjViMzRhZDZiNjQxMTViZTVmMzQ1MGFhXzctMy0xLTEtMA_18ec4cd3-8dad-4300-ab71-d9890a26be24"
      unitRef="usd">2509000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i5e3c636f0c3f4cd9a3d1b819208219a6_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTUvZnJhZzo4YjlhZTAxYjIwYjg0ZDZjOTVmNWJhY2VkZmZjZTUwYi90YWJsZTowMTk5YzAwNzI1YjM0YWQ2YjY0MTE1YmU1ZjM0NTBhYS90YWJsZXJhbmdlOjAxOTljMDA3MjViMzRhZDZiNjQxMTViZTVmMzQ1MGFhXzgtMS0xLTEtMA_7c7f09ba-9b3e-44ad-8202-4b40bcad8527"
      unitRef="usd">1220000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="icd166759aac546b39c8ff666867d34d3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTUvZnJhZzo4YjlhZTAxYjIwYjg0ZDZjOTVmNWJhY2VkZmZjZTUwYi90YWJsZTowMTk5YzAwNzI1YjM0YWQ2YjY0MTE1YmU1ZjM0NTBhYS90YWJsZXJhbmdlOjAxOTljMDA3MjViMzRhZDZiNjQxMTViZTVmMzQ1MGFhXzgtMy0xLTEtMA_4e908528-683b-426c-90b0-bd007cca8f31"
      unitRef="usd">1520000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense
      contextRef="i5e3c636f0c3f4cd9a3d1b819208219a6_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTUvZnJhZzo4YjlhZTAxYjIwYjg0ZDZjOTVmNWJhY2VkZmZjZTUwYi90YWJsZTowMTk5YzAwNzI1YjM0YWQ2YjY0MTE1YmU1ZjM0NTBhYS90YWJsZXJhbmdlOjAxOTljMDA3MjViMzRhZDZiNjQxMTViZTVmMzQ1MGFhXzktMS0xLTEtMA_7556a783-29ea-4ea8-bda2-f10f2cc22d00"
      unitRef="usd">149000</us-gaap:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense
      contextRef="icd166759aac546b39c8ff666867d34d3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTUvZnJhZzo4YjlhZTAxYjIwYjg0ZDZjOTVmNWJhY2VkZmZjZTUwYi90YWJsZTowMTk5YzAwNzI1YjM0YWQ2YjY0MTE1YmU1ZjM0NTBhYS90YWJsZXJhbmdlOjAxOTljMDA3MjViMzRhZDZiNjQxMTViZTVmMzQ1MGFhXzktMy0xLTEtMA_d3a186e9-ed1c-4dde-ba0b-b715b93c6538"
      unitRef="usd">435000</us-gaap:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense>
    <us-gaap:Revenues
      contextRef="i80f9c6fc9c784f1ebf7661871ea29e40_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTUvZnJhZzo4YjlhZTAxYjIwYjg0ZDZjOTVmNWJhY2VkZmZjZTUwYi90YWJsZTphZmYxZTYyZjU4ZGM0YjkxYTUxNWE5MmMzZGRhOGExNC90YWJsZXJhbmdlOmFmZjFlNjJmNThkYzRiOTFhNTE1YTkyYzNkZGE4YTE0XzMtMS0xLTEtMTI2OA_56b96f0d-20d9-46a8-b0b6-b7a3297c55dd"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i12d000d060d24ea2a95340696a6a480c_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTUvZnJhZzo4YjlhZTAxYjIwYjg0ZDZjOTVmNWJhY2VkZmZjZTUwYi90YWJsZTphZmYxZTYyZjU4ZGM0YjkxYTUxNWE5MmMzZGRhOGExNC90YWJsZXJhbmdlOmFmZjFlNjJmNThkYzRiOTFhNTE1YTkyYzNkZGE4YTE0XzMtMy0xLTEtMTI2OA_eb49f0c5-b4ec-44fe-a0dc-2e20852346e7"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if3045b5c28d7410fb838543b77fb8e48_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTUvZnJhZzo4YjlhZTAxYjIwYjg0ZDZjOTVmNWJhY2VkZmZjZTUwYi90YWJsZTphZmYxZTYyZjU4ZGM0YjkxYTUxNWE5MmMzZGRhOGExNC90YWJsZXJhbmdlOmFmZjFlNjJmNThkYzRiOTFhNTE1YTkyYzNkZGE4YTE0XzMtMS0xLTEtMA_79df33e3-d870-4035-bd9b-e2c27a2f2b26"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4b684a34ddb04cb49ab76574e8dbeca9_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTUvZnJhZzo4YjlhZTAxYjIwYjg0ZDZjOTVmNWJhY2VkZmZjZTUwYi90YWJsZTphZmYxZTYyZjU4ZGM0YjkxYTUxNWE5MmMzZGRhOGExNC90YWJsZXJhbmdlOmFmZjFlNjJmNThkYzRiOTFhNTE1YTkyYzNkZGE4YTE0XzMtMy0xLTEtMA_a3581449-d4e3-4c10-908c-d9ea144d5384"
      unitRef="usd">1700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib2886761dda849ee81490345eb4cd5fe_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTUvZnJhZzo4YjlhZTAxYjIwYjg0ZDZjOTVmNWJhY2VkZmZjZTUwYi90YWJsZTphZmYxZTYyZjU4ZGM0YjkxYTUxNWE5MmMzZGRhOGExNC90YWJsZXJhbmdlOmFmZjFlNjJmNThkYzRiOTFhNTE1YTkyYzNkZGE4YTE0XzQtMS0xLTEtMTI2OA_e610e03f-17f2-403c-b2e9-0c4c1919fcd6"
      unitRef="usd">10368000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if3ad28259229428e9fd1a3676572116f_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTUvZnJhZzo4YjlhZTAxYjIwYjg0ZDZjOTVmNWJhY2VkZmZjZTUwYi90YWJsZTphZmYxZTYyZjU4ZGM0YjkxYTUxNWE5MmMzZGRhOGExNC90YWJsZXJhbmdlOmFmZjFlNjJmNThkYzRiOTFhNTE1YTkyYzNkZGE4YTE0XzQtMy0xLTEtMTI2OA_d7d11bd2-8145-478a-9771-9bea046679c7"
      unitRef="usd">73885000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if26f70dc308240eb95d27a86fe164dcb_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTUvZnJhZzo4YjlhZTAxYjIwYjg0ZDZjOTVmNWJhY2VkZmZjZTUwYi90YWJsZTphZmYxZTYyZjU4ZGM0YjkxYTUxNWE5MmMzZGRhOGExNC90YWJsZXJhbmdlOmFmZjFlNjJmNThkYzRiOTFhNTE1YTkyYzNkZGE4YTE0XzQtMS0xLTEtMA_e1ed9061-5505-4b00-b90c-ebea40e9f6a0"
      unitRef="usd">25943000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2c692c0dda2248aab4719ff28ac52586_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTUvZnJhZzo4YjlhZTAxYjIwYjg0ZDZjOTVmNWJhY2VkZmZjZTUwYi90YWJsZTphZmYxZTYyZjU4ZGM0YjkxYTUxNWE5MmMzZGRhOGExNC90YWJsZXJhbmdlOmFmZjFlNjJmNThkYzRiOTFhNTE1YTkyYzNkZGE4YTE0XzQtMy0xLTEtMA_32698572-27de-41d4-b91a-e68650f87962"
      unitRef="usd">141833000</us-gaap:Revenues>
    <evh:CostofGoodsandServicesSoldExcludingDepreciationandAmortization
      contextRef="id32a865882ba4f0f9600a62eb26f2cd9_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTUvZnJhZzo4YjlhZTAxYjIwYjg0ZDZjOTVmNWJhY2VkZmZjZTUwYi90YWJsZTphZmYxZTYyZjU4ZGM0YjkxYTUxNWE5MmMzZGRhOGExNC90YWJsZXJhbmdlOmFmZjFlNjJmNThkYzRiOTFhNTE1YTkyYzNkZGE4YTE0XzctMS0xLTEtMTI3Mg_26efd2b7-8a31-4151-9d4a-03e264e65bad"
      unitRef="usd">606000</evh:CostofGoodsandServicesSoldExcludingDepreciationandAmortization>
    <evh:CostofGoodsandServicesSoldExcludingDepreciationandAmortization
      contextRef="i0b14ca9b08604f019fcc80d78ee511ab_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTUvZnJhZzo4YjlhZTAxYjIwYjg0ZDZjOTVmNWJhY2VkZmZjZTUwYi90YWJsZTphZmYxZTYyZjU4ZGM0YjkxYTUxNWE5MmMzZGRhOGExNC90YWJsZXJhbmdlOmFmZjFlNjJmNThkYzRiOTFhNTE1YTkyYzNkZGE4YTE0XzctMy0xLTEtMTI3Mg_c30fdfd9-9405-49b4-bb38-42f139c9d896"
      unitRef="usd">-2171000</evh:CostofGoodsandServicesSoldExcludingDepreciationandAmortization>
    <evh:CostofGoodsandServicesSoldExcludingDepreciationandAmortization
      contextRef="i8ba99c7ee2d04799a86890ec3064b175_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTUvZnJhZzo4YjlhZTAxYjIwYjg0ZDZjOTVmNWJhY2VkZmZjZTUwYi90YWJsZTphZmYxZTYyZjU4ZGM0YjkxYTUxNWE5MmMzZGRhOGExNC90YWJsZXJhbmdlOmFmZjFlNjJmNThkYzRiOTFhNTE1YTkyYzNkZGE4YTE0XzctMS0xLTEtMA_fb126f31-e70c-4579-a648-0a2817a82061"
      unitRef="usd">1099000</evh:CostofGoodsandServicesSoldExcludingDepreciationandAmortization>
    <evh:CostofGoodsandServicesSoldExcludingDepreciationandAmortization
      contextRef="i04089c6246044d5cbf92001f57543039_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTUvZnJhZzo4YjlhZTAxYjIwYjg0ZDZjOTVmNWJhY2VkZmZjZTUwYi90YWJsZTphZmYxZTYyZjU4ZGM0YjkxYTUxNWE5MmMzZGRhOGExNC90YWJsZXJhbmdlOmFmZjFlNjJmNThkYzRiOTFhNTE1YTkyYzNkZGE4YTE0XzctMy0xLTEtMA_b8a24bfc-8b93-402b-81aa-ba12f386919f"
      unitRef="usd">1076000</evh:CostofGoodsandServicesSoldExcludingDepreciationandAmortization>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="id32a865882ba4f0f9600a62eb26f2cd9_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTUvZnJhZzo4YjlhZTAxYjIwYjg0ZDZjOTVmNWJhY2VkZmZjZTUwYi90YWJsZTphZmYxZTYyZjU4ZGM0YjkxYTUxNWE5MmMzZGRhOGExNC90YWJsZXJhbmdlOmFmZjFlNjJmNThkYzRiOTFhNTE1YTkyYzNkZGE4YTE0XzgtMS0xLTEtMTI3Mg_2f73f8c3-dc0c-4911-8b18-d113abd653d7"
      unitRef="usd">81000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i0b14ca9b08604f019fcc80d78ee511ab_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTUvZnJhZzo4YjlhZTAxYjIwYjg0ZDZjOTVmNWJhY2VkZmZjZTUwYi90YWJsZTphZmYxZTYyZjU4ZGM0YjkxYTUxNWE5MmMzZGRhOGExNC90YWJsZXJhbmdlOmFmZjFlNjJmNThkYzRiOTFhNTE1YTkyYzNkZGE4YTE0XzgtMy0xLTEtMTI3Mg_337696e8-8b41-427a-abaf-05c20ef018d8"
      unitRef="usd">27000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i8ba99c7ee2d04799a86890ec3064b175_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTUvZnJhZzo4YjlhZTAxYjIwYjg0ZDZjOTVmNWJhY2VkZmZjZTUwYi90YWJsZTphZmYxZTYyZjU4ZGM0YjkxYTUxNWE5MmMzZGRhOGExNC90YWJsZXJhbmdlOmFmZjFlNjJmNThkYzRiOTFhNTE1YTkyYzNkZGE4YTE0XzgtMS0xLTEtMA_73bbb648-7916-43a0-a53a-4144bc965fbd"
      unitRef="usd">112000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i04089c6246044d5cbf92001f57543039_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTUvZnJhZzo4YjlhZTAxYjIwYjg0ZDZjOTVmNWJhY2VkZmZjZTUwYi90YWJsZTphZmYxZTYyZjU4ZGM0YjkxYTUxNWE5MmMzZGRhOGExNC90YWJsZXJhbmdlOmFmZjFlNjJmNThkYzRiOTFhNTE1YTkyYzNkZGE4YTE0XzgtMy0xLTEtMA_6fe04b2f-f68c-4376-816f-be29875ba12b"
      unitRef="usd">97000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:RestructuringCharges
      contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTgvZnJhZzo0ODM4ZWI4MmExMmQ0MTA2YjFjNTIxOWZhNzcyMzI0ZS90ZXh0cmVnaW9uOjQ4MzhlYjgyYTEyZDQxMDZiMWM1MjE5ZmE3NzIzMjRlXzEwOTk1MTE2MzI1NTM_e0f1f8ab-3d1f-4324-8a17-1a880f9fbb53"
      unitRef="usd">700000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTgvZnJhZzo0ODM4ZWI4MmExMmQ0MTA2YjFjNTIxOWZhNzcyMzI0ZS90ZXh0cmVnaW9uOjQ4MzhlYjgyYTEyZDQxMDZiMWM1MjE5ZmE3NzIzMjRlXzEwOTk1MTE2MzI1ODA_ae68633e-3c92-46ac-9729-52789b19f72f"
      unitRef="usd">6000000.0</us-gaap:RestructuringCharges>
    <us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTgvZnJhZzo0ODM4ZWI4MmExMmQ0MTA2YjFjNTIxOWZhNzcyMzI0ZS90ZXh0cmVnaW9uOjQ4MzhlYjgyYTEyZDQxMDZiMWM1MjE5ZmE3NzIzMjRlXzE1OTQ_ba2de26c-e8f6-45cb-985f-f9f31c97fdf2">The following table provides a summary of our total costs associated with the Repositioning Plan for the three and six months ended June 30, 2021, by major type of cost (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.305%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:27.431%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.499%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.305%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.359%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.305%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.359%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.039%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.359%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.044%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Incurred For the Three Months Ended &lt;br/&gt;June  30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Incurred for the Six Months Ended June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total Amount Expected to be Incurred in the Repositioning Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cumulative Amount Incurred through June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Severance and termination benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Office space consolidation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Professional services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,062&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,043&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock>
    <us-gaap:RestructuringCharges
      contextRef="i9efdfcae40144663a980937c662799c7_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTgvZnJhZzo0ODM4ZWI4MmExMmQ0MTA2YjFjNTIxOWZhNzcyMzI0ZS90YWJsZTo0OTZhOTRlODUyMzM0MTZhODZiMmFkYzY2ZDI5OTU5NC90YWJsZXJhbmdlOjQ5NmE5NGU4NTIzMzQxNmE4NmIyYWRjNjZkMjk5NTk0XzEtMi0xLTEtMA_4c50a630-1caf-438f-ae59-b2772a68d236"
      unitRef="usd">76000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="ia2840929ec444f69b484c53abba16383_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTgvZnJhZzo0ODM4ZWI4MmExMmQ0MTA2YjFjNTIxOWZhNzcyMzI0ZS90YWJsZTo0OTZhOTRlODUyMzM0MTZhODZiMmFkYzY2ZDI5OTU5NC90YWJsZXJhbmdlOjQ5NmE5NGU4NTIzMzQxNmE4NmIyYWRjNjZkMjk5NTk0XzEtNC0xLTEtMzIzMQ_62031104-4b89-4ee6-977a-b6dde58ed34e"
      unitRef="usd">185000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringAndRelatedCostExpectedCost1
      contextRef="i17f053f839394fcd9de0dbf7fe5e0507_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTgvZnJhZzo0ODM4ZWI4MmExMmQ0MTA2YjFjNTIxOWZhNzcyMzI0ZS90YWJsZTo0OTZhOTRlODUyMzM0MTZhODZiMmFkYzY2ZDI5OTU5NC90YWJsZXJhbmdlOjQ5NmE5NGU4NTIzMzQxNmE4NmIyYWRjNjZkMjk5NTk0XzEtNC0xLTEtMA_6b094d2d-bc9a-4ad2-aeed-1ddf8d69801c"
      unitRef="usd">185000</us-gaap:RestructuringAndRelatedCostExpectedCost1>
    <us-gaap:RestructuringAndRelatedCostCostIncurredToDate1
      contextRef="i17f053f839394fcd9de0dbf7fe5e0507_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTgvZnJhZzo0ODM4ZWI4MmExMmQ0MTA2YjFjNTIxOWZhNzcyMzI0ZS90YWJsZTo0OTZhOTRlODUyMzM0MTZhODZiMmFkYzY2ZDI5OTU5NC90YWJsZXJhbmdlOjQ5NmE5NGU4NTIzMzQxNmE4NmIyYWRjNjZkMjk5NTk0XzEtNi0xLTEtMA_30351387-c957-49aa-9377-678a6f6edd30"
      unitRef="usd">185000</us-gaap:RestructuringAndRelatedCostCostIncurredToDate1>
    <us-gaap:RestructuringCharges
      contextRef="idd9a4c33807c43dda2178f4f2a358736_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTgvZnJhZzo0ODM4ZWI4MmExMmQ0MTA2YjFjNTIxOWZhNzcyMzI0ZS90YWJsZTo0OTZhOTRlODUyMzM0MTZhODZiMmFkYzY2ZDI5OTU5NC90YWJsZXJhbmdlOjQ5NmE5NGU4NTIzMzQxNmE4NmIyYWRjNjZkMjk5NTk0XzItMi0xLTEtMA_8f2044df-6b61-4993-9518-7f34f47dd9df"
      unitRef="usd">0</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="ic4bacc3efa9a4c7cb0dbc8f0c6465a2e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTgvZnJhZzo0ODM4ZWI4MmExMmQ0MTA2YjFjNTIxOWZhNzcyMzI0ZS90YWJsZTo0OTZhOTRlODUyMzM0MTZhODZiMmFkYzY2ZDI5OTU5NC90YWJsZXJhbmdlOjQ5NmE5NGU4NTIzMzQxNmE4NmIyYWRjNjZkMjk5NTk0XzItNC0xLTEtMzIzMQ_e3ae2ec1-1f3e-47a1-8fc0-14fe4aa37ffc"
      unitRef="usd">2071000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringAndRelatedCostExpectedCost1
      contextRef="ibdc992c308c2409eb366952bb3e529f5_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTgvZnJhZzo0ODM4ZWI4MmExMmQ0MTA2YjFjNTIxOWZhNzcyMzI0ZS90YWJsZTo0OTZhOTRlODUyMzM0MTZhODZiMmFkYzY2ZDI5OTU5NC90YWJsZXJhbmdlOjQ5NmE5NGU4NTIzMzQxNmE4NmIyYWRjNjZkMjk5NTk0XzItNC0xLTEtMA_5fe8319a-3d5e-41bb-b0b6-2875d5b62a63"
      unitRef="usd">2071000</us-gaap:RestructuringAndRelatedCostExpectedCost1>
    <us-gaap:RestructuringAndRelatedCostCostIncurredToDate1
      contextRef="ibdc992c308c2409eb366952bb3e529f5_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTgvZnJhZzo0ODM4ZWI4MmExMmQ0MTA2YjFjNTIxOWZhNzcyMzI0ZS90YWJsZTo0OTZhOTRlODUyMzM0MTZhODZiMmFkYzY2ZDI5OTU5NC90YWJsZXJhbmdlOjQ5NmE5NGU4NTIzMzQxNmE4NmIyYWRjNjZkMjk5NTk0XzItNi0xLTEtMA_b10ab214-7218-46ee-a2e4-39b3601e69b3"
      unitRef="usd">2071000</us-gaap:RestructuringAndRelatedCostCostIncurredToDate1>
    <us-gaap:RestructuringCharges
      contextRef="i78fb3e05b2884c2185234402150b6dad_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTgvZnJhZzo0ODM4ZWI4MmExMmQ0MTA2YjFjNTIxOWZhNzcyMzI0ZS90YWJsZTo0OTZhOTRlODUyMzM0MTZhODZiMmFkYzY2ZDI5OTU5NC90YWJsZXJhbmdlOjQ5NmE5NGU4NTIzMzQxNmE4NmIyYWRjNjZkMjk5NTk0XzMtMi0xLTEtMA_7b7efd4a-2934-4ea0-ae1a-2899004d98e4"
      unitRef="usd">587000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="ief40b6b342f44af6974cbb1079825a19_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTgvZnJhZzo0ODM4ZWI4MmExMmQ0MTA2YjFjNTIxOWZhNzcyMzI0ZS90YWJsZTo0OTZhOTRlODUyMzM0MTZhODZiMmFkYzY2ZDI5OTU5NC90YWJsZXJhbmdlOjQ5NmE5NGU4NTIzMzQxNmE4NmIyYWRjNjZkMjk5NTk0XzMtNC0xLTEtMzIzMQ_59a27025-59d1-4b0f-9f30-d5b1546eb536"
      unitRef="usd">3787000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringAndRelatedCostExpectedCost1
      contextRef="id4ab1843551d40e48105a1b5bf07b950_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTgvZnJhZzo0ODM4ZWI4MmExMmQ0MTA2YjFjNTIxOWZhNzcyMzI0ZS90YWJsZTo0OTZhOTRlODUyMzM0MTZhODZiMmFkYzY2ZDI5OTU5NC90YWJsZXJhbmdlOjQ5NmE5NGU4NTIzMzQxNmE4NmIyYWRjNjZkMjk5NTk0XzMtNC0xLTEtMA_ed96ef0b-b380-43ed-b091-915fbccb4639"
      unitRef="usd">5162000</us-gaap:RestructuringAndRelatedCostExpectedCost1>
    <us-gaap:RestructuringAndRelatedCostCostIncurredToDate1
      contextRef="id4ab1843551d40e48105a1b5bf07b950_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTgvZnJhZzo0ODM4ZWI4MmExMmQ0MTA2YjFjNTIxOWZhNzcyMzI0ZS90YWJsZTo0OTZhOTRlODUyMzM0MTZhODZiMmFkYzY2ZDI5OTU5NC90YWJsZXJhbmdlOjQ5NmE5NGU4NTIzMzQxNmE4NmIyYWRjNjZkMjk5NTk0XzMtNi0xLTEtMA_a3b3c4b7-0611-4ac2-b914-a8938b06a406"
      unitRef="usd">5062000</us-gaap:RestructuringAndRelatedCostCostIncurredToDate1>
    <us-gaap:RestructuringCharges
      contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTgvZnJhZzo0ODM4ZWI4MmExMmQ0MTA2YjFjNTIxOWZhNzcyMzI0ZS90YWJsZTo0OTZhOTRlODUyMzM0MTZhODZiMmFkYzY2ZDI5OTU5NC90YWJsZXJhbmdlOjQ5NmE5NGU4NTIzMzQxNmE4NmIyYWRjNjZkMjk5NTk0XzQtMi0xLTEtMA_5974f7d4-6efb-4114-80af-6c3e60bc2e61"
      unitRef="usd">663000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTgvZnJhZzo0ODM4ZWI4MmExMmQ0MTA2YjFjNTIxOWZhNzcyMzI0ZS90YWJsZTo0OTZhOTRlODUyMzM0MTZhODZiMmFkYzY2ZDI5OTU5NC90YWJsZXJhbmdlOjQ5NmE5NGU4NTIzMzQxNmE4NmIyYWRjNjZkMjk5NTk0XzQtNC0xLTEtMzIzMQ_c663a30a-0920-4b94-97ea-508673c69149"
      unitRef="usd">6043000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringAndRelatedCostExpectedCost1
      contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTgvZnJhZzo0ODM4ZWI4MmExMmQ0MTA2YjFjNTIxOWZhNzcyMzI0ZS90YWJsZTo0OTZhOTRlODUyMzM0MTZhODZiMmFkYzY2ZDI5OTU5NC90YWJsZXJhbmdlOjQ5NmE5NGU4NTIzMzQxNmE4NmIyYWRjNjZkMjk5NTk0XzQtNC0xLTEtMA_de376fe7-6d0b-4017-abe1-603dbcf7863e"
      unitRef="usd">7418000</us-gaap:RestructuringAndRelatedCostExpectedCost1>
    <us-gaap:RestructuringAndRelatedCostCostIncurredToDate1
      contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMTgvZnJhZzo0ODM4ZWI4MmExMmQ0MTA2YjFjNTIxOWZhNzcyMzI0ZS90YWJsZTo0OTZhOTRlODUyMzM0MTZhODZiMmFkYzY2ZDI5OTU5NC90YWJsZXJhbmdlOjQ5NmE5NGU4NTIzMzQxNmE4NmIyYWRjNjZkMjk5NTk0XzQtNi0xLTEtMA_7ac3b9c3-64b3-4fcc-a3df-4119c0087441"
      unitRef="usd">7318000</us-gaap:RestructuringAndRelatedCostCostIncurredToDate1>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90ZXh0cmVnaW9uOjc0ZTMxNDVmNTRhODRjMWY4ZmQ5YjZmNTY5ZDUyMDk5XzM0MDg_b0fb2033-1686-4f9a-b656-7f9ee002002c">Segment Reporting&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Commencing with the three months ended March 31, 2021, we define our reportable segments based on the way the CODM, the chief executive officer, manages the operations for purposes of allocating resources and assessing performance. We classify our operations into two reportable segments as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt"&gt;Evolent Health Services, which houses our Administrative Simplification solution and certain supporting population health infrastructure; and&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt"&gt;Clinical Solutions, which includes our specialty management and physician-oriented total cost of care solutions, along with the New Century Health and Evolent Care Partners brands. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the ordinary course of business, our reportable segments enter into transactions with one another. While intersegment transactions are treated like third-party transactions to determine segment performance, the revenues and expenses recognized by the segment that is the counterparty to the transaction are eliminated in consolidation and do not affect consolidated results.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The CODM uses revenue in accordance with U.S. GAAP and Adjusted EBITDA as the relevant segment performance measures to evaluate the performance of the segments and allocate resources. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Adjusted EBITDA is a segment performance financial measure that offers a useful view of the overall operation of our businesses and may be different than similarly-titled segment performance financial measures used by other companies. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Adjusted EBITDA is defined as net loss attributable to common shareholders of Evolent Health, Inc. before interest income, interest expense, (provision) benefit for income taxes, depreciation and amortization expenses, adjusted to exclude equity method investment impairment, loss on extinguishment of debt, gain (loss) from equity method investees, gain (loss) on disposal of assets and consolidation, goodwill impairment, changes in fair value of contingent consideration and indemnification asset, other income (expense), net, net loss attributable to non-controlling interests, ASC 606 transition adjustments, purchase accounting adjustments, repositioning costs, stock-based compensation expense, severance costs, amortization of contract cost assets, shareholder advisory services, acquisition-related costs and gain (loss) from discontinued operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Management considers revenue and Adjusted EBITDA to be the appropriate metrics to evaluate and compare the ongoing operating performance of our segments on a consistent basis across reporting periods as they eliminate the effect of items which are not indicative of each segment's core operating performance. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables present our segment information for the three and six months ended June 30, 2021 and 2020 (in thousands). Prior-year segment information (including segments total Adjusted EBITDA) has been restated to conform to the reporting structure change described in Note 1.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:145.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:52.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:52.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:67.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:60.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:61.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:67.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:33pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Evolent Health Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Clinical Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Intersegment&lt;br/&gt;Eliminations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Corporate &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Consolidated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Transformation services&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Platform and operations services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72,759&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;147,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(460)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;219,493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;219,493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;147,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(460)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;222,057&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;222,057&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Transformation services&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Platform and operations services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86,432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130,780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(668)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;216,544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;216,544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130,780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(668)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;217,299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;217,299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:33pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Evolent Health Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Clinical Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Corporate &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Segments Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="12" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjusted EBITDA&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,782)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjusted EBITDA&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,629)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:145.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:52.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:52.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:67.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:60.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:61.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:67.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:33pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Evolent Health Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Clinical Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Intersegment&lt;br/&gt;Eliminations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Corporate &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Consolidated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Transformation services&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,909&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,909&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,909&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Platform and operations services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;157,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;277,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(898)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;434,219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;434,219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160,609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;277,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(898)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;437,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;437,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Transformation services&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Platform and operations services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178,222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;255,652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,336)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;432,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;432,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;184,215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;255,652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,336)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;438,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;438,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:33pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Evolent Health Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Clinical Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Corporate &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Segments Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="12" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjusted EBITDA&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,793)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjusted EBITDA&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,716&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,564)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Corporate includes various finance, human resources, legal, executive, and other corporate infrastructure expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents our reconciliation of consolidated segments total Adjusted EBITDA to net loss attributable to common shareholders of Evolent Health, Inc. for the three and six months ended June 30, 2021 and 2020 (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:327.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net loss attributable to common shareholders of Evolent Health, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,107)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(203,521)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18,914)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(282,273)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;705&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,274)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,290)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,611)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,571)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(Provision) benefit for income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(91)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(702)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,634&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,916)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,618)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30,103)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31,596)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity method investment impairment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(47,133)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain on transfer of membership&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,969&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss on repayment of debt, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19,158)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill impairment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(215,100)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(215,100)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain from equity method investees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,879&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss on disposal of assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,447)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value of contingent consideration and indemnification asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(756)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,062&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Repositioning costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(663)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,043)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,653)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,703)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,359)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,211)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Severance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(52)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,133)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of contract cost assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(196)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(767)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(323)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,207)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Strategy and shareholder advisory expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,513)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,513)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisition costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(76)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(374)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,070)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(683)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain (loss) from discontinued operations &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,508)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,773)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Adjusted EBITDA&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Includes $1.9&#160;million gain on disposal of discontinued operations for the six months ended June 30, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Asset information by segment is not a key measure of performance used by the CODM. Accordingly, we have not disclosed asset information by segment.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90ZXh0cmVnaW9uOjc0ZTMxNDVmNTRhODRjMWY4ZmQ5YjZmNTY5ZDUyMDk5XzI5Nw_ac8c0053-7af4-4e1e-97bf-2dc333062eb8"
      unitRef="segment">2</us-gaap:NumberOfOperatingSegments>
    <us-gaap:ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90ZXh0cmVnaW9uOjc0ZTMxNDVmNTRhODRjMWY4ZmQ5YjZmNTY5ZDUyMDk5XzM0MDk_cf1cf40c-7815-45dd-a00c-0d201faa4632">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables present our segment information for the three and six months ended June 30, 2021 and 2020 (in thousands). Prior-year segment information (including segments total Adjusted EBITDA) has been restated to conform to the reporting structure change described in Note 1.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:145.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:52.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:52.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:67.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:60.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:61.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:67.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:33pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Evolent Health Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Clinical Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Intersegment&lt;br/&gt;Eliminations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Corporate &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Consolidated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Transformation services&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Platform and operations services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72,759&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;147,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(460)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;219,493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;219,493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;147,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(460)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;222,057&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;222,057&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Transformation services&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Platform and operations services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86,432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130,780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(668)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;216,544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;216,544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130,780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(668)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;217,299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;217,299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:33pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Evolent Health Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Clinical Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Corporate &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Segments Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="12" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjusted EBITDA&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,782)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjusted EBITDA&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,629)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:145.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:52.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:52.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:67.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:60.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:61.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:67.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:33pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Evolent Health Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Clinical Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Intersegment&lt;br/&gt;Eliminations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Corporate &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Consolidated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Transformation services&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,909&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,909&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,909&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Platform and operations services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;157,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;277,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(898)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;434,219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;434,219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160,609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;277,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(898)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;437,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;437,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Transformation services&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Platform and operations services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178,222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;255,652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,336)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;432,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;432,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;184,215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;255,652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,336)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;438,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;438,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:33pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Evolent Health Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Clinical Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Corporate &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Segments Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="12" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjusted EBITDA&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,793)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjusted EBITDA&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,716&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,564)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Corporate includes various finance, human resources, legal, executive, and other corporate infrastructure expenses.&lt;/span&gt;&lt;/div&gt;</us-gaap:ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock>
    <us-gaap:Revenues
      contextRef="ia33818b88a6c42f5b842f5cc447c4d6f_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo5OGE5MDg0ZmRjZWQ0MWVkOGY5ODgwMTRlMmQyODNhNi90YWJsZXJhbmdlOjk4YTkwODRmZGNlZDQxZWQ4Zjk4ODAxNGUyZDI4M2E2XzMtMS0xLTEtMTMxNg_918c806d-3e27-432f-8113-e76d59f7aca6"
      unitRef="usd">2564000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i807d8acee29b43e1998e67d743c1650e_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo5OGE5MDg0ZmRjZWQ0MWVkOGY5ODgwMTRlMmQyODNhNi90YWJsZXJhbmdlOjk4YTkwODRmZGNlZDQxZWQ4Zjk4ODAxNGUyZDI4M2E2XzMtMy0xLTEtMTMxNg_a76a389e-2568-4fd6-a559-ef139a9179fa"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia356ef0e7c074058809ff566475d252e_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo5OGE5MDg0ZmRjZWQ0MWVkOGY5ODgwMTRlMmQyODNhNi90YWJsZXJhbmdlOjk4YTkwODRmZGNlZDQxZWQ4Zjk4ODAxNGUyZDI4M2E2XzMtNS0xLTEtMTMxNg_e6150c58-b7d6-4d3a-99ca-6938a31a6999"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0280276096944f8db9756b1ccc072342_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo5OGE5MDg0ZmRjZWQ0MWVkOGY5ODgwMTRlMmQyODNhNi90YWJsZXJhbmdlOjk4YTkwODRmZGNlZDQxZWQ4Zjk4ODAxNGUyZDI4M2E2XzMtNy0xLTEtMTMxNg_ba233e7e-679b-4d65-baa8-6e685d74ddee"
      unitRef="usd">2564000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iec060d1f9dc045319b07294745b086d3_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo5OGE5MDg0ZmRjZWQ0MWVkOGY5ODgwMTRlMmQyODNhNi90YWJsZXJhbmdlOjk4YTkwODRmZGNlZDQxZWQ4Zjk4ODAxNGUyZDI4M2E2XzMtOS0xLTEtMTMxNg_68dfe458-630a-41e0-b18c-bca90e48f9b0"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7b3321915fe444e488ceef708a6e59c9_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo5OGE5MDg0ZmRjZWQ0MWVkOGY5ODgwMTRlMmQyODNhNi90YWJsZXJhbmdlOjk4YTkwODRmZGNlZDQxZWQ4Zjk4ODAxNGUyZDI4M2E2XzMtMTEtMS0xLTEzMTY_d42dd246-85dc-4a3c-892d-f8e897691952"
      unitRef="usd">2564000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iafbe04d32b3c40ae93c564f542241136_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo5OGE5MDg0ZmRjZWQ0MWVkOGY5ODgwMTRlMmQyODNhNi90YWJsZXJhbmdlOjk4YTkwODRmZGNlZDQxZWQ4Zjk4ODAxNGUyZDI4M2E2XzQtMS0xLTEtMTMxNg_e14a91fd-ab54-4f98-b25e-df6b7af53fe8"
      unitRef="usd">72759000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8c922ef0f31b4ab2b388e8b7c1ab5312_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo5OGE5MDg0ZmRjZWQ0MWVkOGY5ODgwMTRlMmQyODNhNi90YWJsZXJhbmdlOjk4YTkwODRmZGNlZDQxZWQ4Zjk4ODAxNGUyZDI4M2E2XzQtMy0xLTEtMTMxNg_a39eadae-302f-4880-8ea3-0aff8b1d2572"
      unitRef="usd">147194000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4bd03bc4393d446e9abc787bbb40c7a8_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo5OGE5MDg0ZmRjZWQ0MWVkOGY5ODgwMTRlMmQyODNhNi90YWJsZXJhbmdlOjk4YTkwODRmZGNlZDQxZWQ4Zjk4ODAxNGUyZDI4M2E2XzQtNS0xLTEtMTMxNg_0e920693-14f0-439b-a9a1-87142cc7aa8e"
      unitRef="usd">-460000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iaee89f0da3e144d09c4a23c928d850b8_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo5OGE5MDg0ZmRjZWQ0MWVkOGY5ODgwMTRlMmQyODNhNi90YWJsZXJhbmdlOjk4YTkwODRmZGNlZDQxZWQ4Zjk4ODAxNGUyZDI4M2E2XzQtNy0xLTEtMTMxNg_e4d40bce-3725-4a82-b5dc-3d1701409c60"
      unitRef="usd">219493000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7b7ecb9ad2c3400db038af4f12b6a9ab_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo5OGE5MDg0ZmRjZWQ0MWVkOGY5ODgwMTRlMmQyODNhNi90YWJsZXJhbmdlOjk4YTkwODRmZGNlZDQxZWQ4Zjk4ODAxNGUyZDI4M2E2XzQtOS0xLTEtMTMxNg_9e50b47b-34eb-4e5b-930e-d7bbb8cc3c61"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie90c815774924e1e802eb6f3123f1004_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo5OGE5MDg0ZmRjZWQ0MWVkOGY5ODgwMTRlMmQyODNhNi90YWJsZXJhbmdlOjk4YTkwODRmZGNlZDQxZWQ4Zjk4ODAxNGUyZDI4M2E2XzQtMTEtMS0xLTEzMTY_302ce31d-e5db-4ad2-ad80-c01bd3b9ebbc"
      unitRef="usd">219493000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i679cb28be3a34242bd30bce045577c6e_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo5OGE5MDg0ZmRjZWQ0MWVkOGY5ODgwMTRlMmQyODNhNi90YWJsZXJhbmdlOjk4YTkwODRmZGNlZDQxZWQ4Zjk4ODAxNGUyZDI4M2E2XzUtMS0xLTEtMTMxNg_9b21143a-eb7a-429d-812d-6f5ba0544cd5"
      unitRef="usd">75323000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1c9bfa2d7f884c12b69f21c9b3af2888_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo5OGE5MDg0ZmRjZWQ0MWVkOGY5ODgwMTRlMmQyODNhNi90YWJsZXJhbmdlOjk4YTkwODRmZGNlZDQxZWQ4Zjk4ODAxNGUyZDI4M2E2XzUtMy0xLTEtMTMxNg_55ec91f8-5be6-44f0-b611-05f4b281329f"
      unitRef="usd">147194000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i953b09444cb241478eb77a7260d48527_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo5OGE5MDg0ZmRjZWQ0MWVkOGY5ODgwMTRlMmQyODNhNi90YWJsZXJhbmdlOjk4YTkwODRmZGNlZDQxZWQ4Zjk4ODAxNGUyZDI4M2E2XzUtNS0xLTEtMTMxNg_fb16eb79-f81f-483b-8fd4-70de15573e23"
      unitRef="usd">-460000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib66948dc799e431486e4991bc5ffa9ef_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo5OGE5MDg0ZmRjZWQ0MWVkOGY5ODgwMTRlMmQyODNhNi90YWJsZXJhbmdlOjk4YTkwODRmZGNlZDQxZWQ4Zjk4ODAxNGUyZDI4M2E2XzUtNy0xLTEtMTMxNg_5da56d84-3b80-48f9-87d0-7e14cce75e15"
      unitRef="usd">222057000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i69cb2a622a3f4134a8e8684f7cb47aef_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo5OGE5MDg0ZmRjZWQ0MWVkOGY5ODgwMTRlMmQyODNhNi90YWJsZXJhbmdlOjk4YTkwODRmZGNlZDQxZWQ4Zjk4ODAxNGUyZDI4M2E2XzUtOS0xLTEtMTMxNg_a4b6c5d4-4f65-46e0-a753-6904e6125586"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo5OGE5MDg0ZmRjZWQ0MWVkOGY5ODgwMTRlMmQyODNhNi90YWJsZXJhbmdlOjk4YTkwODRmZGNlZDQxZWQ4Zjk4ODAxNGUyZDI4M2E2XzUtMTEtMS0xLTEzMTY_034d15fe-96c4-43d5-aa0e-709e071cb5c1"
      unitRef="usd">222057000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic69644d995ff43218ea90302f9eae15f_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo5OGE5MDg0ZmRjZWQ0MWVkOGY5ODgwMTRlMmQyODNhNi90YWJsZXJhbmdlOjk4YTkwODRmZGNlZDQxZWQ4Zjk4ODAxNGUyZDI4M2E2XzgtMS0xLTEtMTMxNg_9cc617b2-2c91-499e-a3db-379e7e8f6a9b"
      unitRef="usd">755000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id9a15a1f9bed43b2a7a6b9699a0355f6_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo5OGE5MDg0ZmRjZWQ0MWVkOGY5ODgwMTRlMmQyODNhNi90YWJsZXJhbmdlOjk4YTkwODRmZGNlZDQxZWQ4Zjk4ODAxNGUyZDI4M2E2XzgtMy0xLTEtMTMxNg_5bc3279e-d6ad-4f0f-a22b-6deb893dd723"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i59d8caca505e4118a56844c68847eb29_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo5OGE5MDg0ZmRjZWQ0MWVkOGY5ODgwMTRlMmQyODNhNi90YWJsZXJhbmdlOjk4YTkwODRmZGNlZDQxZWQ4Zjk4ODAxNGUyZDI4M2E2XzgtNS0xLTEtMTMxNg_a7b159e3-7c3f-406c-b427-6d53cc4629f1"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ifa545ecb72a34a7c8a9f3b3fa6383b57_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo5OGE5MDg0ZmRjZWQ0MWVkOGY5ODgwMTRlMmQyODNhNi90YWJsZXJhbmdlOjk4YTkwODRmZGNlZDQxZWQ4Zjk4ODAxNGUyZDI4M2E2XzgtNy0xLTEtMTMxNg_2d0291b2-10bd-45a3-a021-f047878673e7"
      unitRef="usd">755000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9ecbd6b0abc24d8a9ed6772122d27e8c_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo5OGE5MDg0ZmRjZWQ0MWVkOGY5ODgwMTRlMmQyODNhNi90YWJsZXJhbmdlOjk4YTkwODRmZGNlZDQxZWQ4Zjk4ODAxNGUyZDI4M2E2XzgtOS0xLTEtMTMxNg_e38a14f1-bc26-4326-842c-f42ae496abb0"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i78e15c27cd3e401ea6bd6fd305abeb34_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo5OGE5MDg0ZmRjZWQ0MWVkOGY5ODgwMTRlMmQyODNhNi90YWJsZXJhbmdlOjk4YTkwODRmZGNlZDQxZWQ4Zjk4ODAxNGUyZDI4M2E2XzgtMTEtMS0xLTEzMTY_3916bb74-fdc4-45ad-9c32-8d0fff19a982"
      unitRef="usd">755000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i803b5fa527c248aba9d05e7aaaf9a0ed_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo5OGE5MDg0ZmRjZWQ0MWVkOGY5ODgwMTRlMmQyODNhNi90YWJsZXJhbmdlOjk4YTkwODRmZGNlZDQxZWQ4Zjk4ODAxNGUyZDI4M2E2XzktMS0xLTEtMTMxNg_e461926a-a4e2-4433-a6e8-c83541b87518"
      unitRef="usd">86432000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5621f56fb2874b21835554c608a4179a_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo5OGE5MDg0ZmRjZWQ0MWVkOGY5ODgwMTRlMmQyODNhNi90YWJsZXJhbmdlOjk4YTkwODRmZGNlZDQxZWQ4Zjk4ODAxNGUyZDI4M2E2XzktMy0xLTEtMTMxNg_f9c7d0b3-245d-4a74-b2f6-7cf3aaaa055f"
      unitRef="usd">130780000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia2e4a5d8dda94f9cbc6ae57881da0889_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo5OGE5MDg0ZmRjZWQ0MWVkOGY5ODgwMTRlMmQyODNhNi90YWJsZXJhbmdlOjk4YTkwODRmZGNlZDQxZWQ4Zjk4ODAxNGUyZDI4M2E2XzktNS0xLTEtMTMxNg_bf24e765-334f-47f1-9f1c-904689d9da84"
      unitRef="usd">-668000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id2637cdc499c42c69c98ce75b9cedd71_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo5OGE5MDg0ZmRjZWQ0MWVkOGY5ODgwMTRlMmQyODNhNi90YWJsZXJhbmdlOjk4YTkwODRmZGNlZDQxZWQ4Zjk4ODAxNGUyZDI4M2E2XzktNy0xLTEtMTMxNg_d10fda48-bbb5-46c0-a0d9-7bb74a3ecedf"
      unitRef="usd">216544000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i97c5008ce5974099bdaadf9428995770_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo5OGE5MDg0ZmRjZWQ0MWVkOGY5ODgwMTRlMmQyODNhNi90YWJsZXJhbmdlOjk4YTkwODRmZGNlZDQxZWQ4Zjk4ODAxNGUyZDI4M2E2XzktOS0xLTEtMTMxNg_848c3ba2-86c4-4ec4-a1b0-f72d84d362a3"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="icd99be6d27564d4cb75996e8ce5dce17_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo5OGE5MDg0ZmRjZWQ0MWVkOGY5ODgwMTRlMmQyODNhNi90YWJsZXJhbmdlOjk4YTkwODRmZGNlZDQxZWQ4Zjk4ODAxNGUyZDI4M2E2XzktMTEtMS0xLTEzMTY_ae976411-e687-4e99-a9a2-66a04ad49fca"
      unitRef="usd">216544000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ibebddd07c46e4994849d375ecea231c6_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo5OGE5MDg0ZmRjZWQ0MWVkOGY5ODgwMTRlMmQyODNhNi90YWJsZXJhbmdlOjk4YTkwODRmZGNlZDQxZWQ4Zjk4ODAxNGUyZDI4M2E2XzEwLTEtMS0xLTEzMTY_cb6b87e9-e3e0-4ffb-8d07-5d2ac717cf2f"
      unitRef="usd">87187000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i16325f028066493d8ad0ddc953bde9e9_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo5OGE5MDg0ZmRjZWQ0MWVkOGY5ODgwMTRlMmQyODNhNi90YWJsZXJhbmdlOjk4YTkwODRmZGNlZDQxZWQ4Zjk4ODAxNGUyZDI4M2E2XzEwLTMtMS0xLTEzMTY_ae1f0f95-abab-4142-ab83-79ad3dab4f70"
      unitRef="usd">130780000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ica79a35ca46143efa08136ec1e43e0d5_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo5OGE5MDg0ZmRjZWQ0MWVkOGY5ODgwMTRlMmQyODNhNi90YWJsZXJhbmdlOjk4YTkwODRmZGNlZDQxZWQ4Zjk4ODAxNGUyZDI4M2E2XzEwLTUtMS0xLTEzMTY_0fe887d7-c326-496d-ad2c-cc2079b7d7a7"
      unitRef="usd">-668000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id0ffe73b7f124f5b9dfa9a01b4c7dfcb_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo5OGE5MDg0ZmRjZWQ0MWVkOGY5ODgwMTRlMmQyODNhNi90YWJsZXJhbmdlOjk4YTkwODRmZGNlZDQxZWQ4Zjk4ODAxNGUyZDI4M2E2XzEwLTctMS0xLTEzMTY_1453bb08-02f2-4355-9cf5-afa047a5051b"
      unitRef="usd">217299000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1d3bf486d496461182f54f254e8fe296_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo5OGE5MDg0ZmRjZWQ0MWVkOGY5ODgwMTRlMmQyODNhNi90YWJsZXJhbmdlOjk4YTkwODRmZGNlZDQxZWQ4Zjk4ODAxNGUyZDI4M2E2XzEwLTktMS0xLTEzMTY_33e2d102-b26e-4e32-aa90-aa03a9a5e4b0"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo5OGE5MDg0ZmRjZWQ0MWVkOGY5ODgwMTRlMmQyODNhNi90YWJsZXJhbmdlOjk4YTkwODRmZGNlZDQxZWQ4Zjk4ODAxNGUyZDI4M2E2XzEwLTExLTEtMS0xMzE2_49c7da2f-b66e-4c5a-aa25-03d67c369f9c"
      unitRef="usd">217299000</us-gaap:Revenues>
    <evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="i679cb28be3a34242bd30bce045577c6e_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo5OGE5MDg0ZmRjZWQ0MWVkOGY5ODgwMTRlMmQyODNhNi90YWJsZXJhbmdlOjk4YTkwODRmZGNlZDQxZWQ4Zjk4ODAxNGUyZDI4M2E2XzE1LTEtMS0xLTEzMTY_ad6ac508-f5ec-4189-9c0f-ff888e2eec4c"
      unitRef="usd">6531000</evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization>
    <evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="i1c9bfa2d7f884c12b69f21c9b3af2888_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo5OGE5MDg0ZmRjZWQ0MWVkOGY5ODgwMTRlMmQyODNhNi90YWJsZXJhbmdlOjk4YTkwODRmZGNlZDQxZWQ4Zjk4ODAxNGUyZDI4M2E2XzE1LTMtMS0xLTEzMTY_8cdb9d60-6fb8-4e71-ae94-80413d1eb564"
      unitRef="usd">13597000</evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization>
    <evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="ib66948dc799e431486e4991bc5ffa9ef_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo5OGE5MDg0ZmRjZWQ0MWVkOGY5ODgwMTRlMmQyODNhNi90YWJsZXJhbmdlOjk4YTkwODRmZGNlZDQxZWQ4Zjk4ODAxNGUyZDI4M2E2XzE1LTUtMS0xLTEzMTY_1b5bb7b9-ef55-4c5a-a770-9ad733af8969"
      unitRef="usd">20128000</evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization>
    <evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="i69cb2a622a3f4134a8e8684f7cb47aef_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo5OGE5MDg0ZmRjZWQ0MWVkOGY5ODgwMTRlMmQyODNhNi90YWJsZXJhbmdlOjk4YTkwODRmZGNlZDQxZWQ4Zjk4ODAxNGUyZDI4M2E2XzE1LTctMS0xLTEzMTY_96d7c8e6-e86a-433e-ba61-7b27f149da29"
      unitRef="usd">-6782000</evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization>
    <evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo5OGE5MDg0ZmRjZWQ0MWVkOGY5ODgwMTRlMmQyODNhNi90YWJsZXJhbmdlOjk4YTkwODRmZGNlZDQxZWQ4Zjk4ODAxNGUyZDI4M2E2XzE1LTktMS0xLTEzMTY_e7ce9961-8bfd-449d-8168-dee6a5c89c0b"
      unitRef="usd">13346000</evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization>
    <evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="ibebddd07c46e4994849d375ecea231c6_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo5OGE5MDg0ZmRjZWQ0MWVkOGY5ODgwMTRlMmQyODNhNi90YWJsZXJhbmdlOjk4YTkwODRmZGNlZDQxZWQ4Zjk4ODAxNGUyZDI4M2E2XzE4LTEtMS0xLTEzMTY_9f2dd305-e4dd-4f3e-b40d-f84e99bbd256"
      unitRef="usd">6948000</evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization>
    <evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="i16325f028066493d8ad0ddc953bde9e9_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo5OGE5MDg0ZmRjZWQ0MWVkOGY5ODgwMTRlMmQyODNhNi90YWJsZXJhbmdlOjk4YTkwODRmZGNlZDQxZWQ4Zjk4ODAxNGUyZDI4M2E2XzE4LTMtMS0xLTEzMTY_ac4b42a3-3c14-455e-b750-ea3119c721a8"
      unitRef="usd">12200000</evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization>
    <evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="id0ffe73b7f124f5b9dfa9a01b4c7dfcb_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo5OGE5MDg0ZmRjZWQ0MWVkOGY5ODgwMTRlMmQyODNhNi90YWJsZXJhbmdlOjk4YTkwODRmZGNlZDQxZWQ4Zjk4ODAxNGUyZDI4M2E2XzE4LTUtMS0xLTEzMTY_a6bdbf5e-2f6c-4f9f-af6e-0fb4e1513f9c"
      unitRef="usd">19148000</evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization>
    <evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="i1d3bf486d496461182f54f254e8fe296_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo5OGE5MDg0ZmRjZWQ0MWVkOGY5ODgwMTRlMmQyODNhNi90YWJsZXJhbmdlOjk4YTkwODRmZGNlZDQxZWQ4Zjk4ODAxNGUyZDI4M2E2XzE4LTctMS0xLTEzMTY_88e80016-6679-462c-be62-e41f23f0d709"
      unitRef="usd">-8629000</evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization>
    <evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo5OGE5MDg0ZmRjZWQ0MWVkOGY5ODgwMTRlMmQyODNhNi90YWJsZXJhbmdlOjk4YTkwODRmZGNlZDQxZWQ4Zjk4ODAxNGUyZDI4M2E2XzE4LTktMS0xLTEzMTY_90bca09c-5c4f-4a79-bdfa-fb622c9939ff"
      unitRef="usd">10519000</evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization>
    <us-gaap:Revenues
      contextRef="if6c3ed9c5b31412bbfc731eadc4f9045_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo4NzgzNTdmNzQ1OWM0Yjc4ODdhOGYzYmI1NWIyMzQ5ZC90YWJsZXJhbmdlOjg3ODM1N2Y3NDU5YzRiNzg4N2E4ZjNiYjU1YjIzNDlkXzMtMS0xLTEtMA_2a39cb0d-64b1-4cdb-9e78-38c912fb8e65"
      unitRef="usd">2909000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ifbfffc16190d487496ae91da9f40ee9b_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo4NzgzNTdmNzQ1OWM0Yjc4ODdhOGYzYmI1NWIyMzQ5ZC90YWJsZXJhbmdlOjg3ODM1N2Y3NDU5YzRiNzg4N2E4ZjNiYjU1YjIzNDlkXzMtMy0xLTEtMA_fe864099-0a49-450a-8e37-16dc6275c444"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i841058299b4f4c1795217d34792246a1_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo4NzgzNTdmNzQ1OWM0Yjc4ODdhOGYzYmI1NWIyMzQ5ZC90YWJsZXJhbmdlOjg3ODM1N2Y3NDU5YzRiNzg4N2E4ZjNiYjU1YjIzNDlkXzMtNS0xLTEtMA_7a50a499-5f59-4bca-a97f-fd17e85c2008"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i12ad1dffce3e49519ee5e99e00c3f177_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo4NzgzNTdmNzQ1OWM0Yjc4ODdhOGYzYmI1NWIyMzQ5ZC90YWJsZXJhbmdlOjg3ODM1N2Y3NDU5YzRiNzg4N2E4ZjNiYjU1YjIzNDlkXzMtNy0xLTEtMA_777ce74b-45d7-4ecb-9800-40071bd1f189"
      unitRef="usd">2909000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iadf935fda2524029ab1baa4bbb8135d0_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo4NzgzNTdmNzQ1OWM0Yjc4ODdhOGYzYmI1NWIyMzQ5ZC90YWJsZXJhbmdlOjg3ODM1N2Y3NDU5YzRiNzg4N2E4ZjNiYjU1YjIzNDlkXzMtOS0xLTEtMA_58968076-01fe-48ab-9354-1dcfae91099a"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8cf8298bd37b49539b40ff277f78e799_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo4NzgzNTdmNzQ1OWM0Yjc4ODdhOGYzYmI1NWIyMzQ5ZC90YWJsZXJhbmdlOjg3ODM1N2Y3NDU5YzRiNzg4N2E4ZjNiYjU1YjIzNDlkXzMtMTEtMS0xLTA_50deb4dc-4615-4617-b899-42167f686157"
      unitRef="usd">2909000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4fd904bfe7584429855878280cb71fbe_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo4NzgzNTdmNzQ1OWM0Yjc4ODdhOGYzYmI1NWIyMzQ5ZC90YWJsZXJhbmdlOjg3ODM1N2Y3NDU5YzRiNzg4N2E4ZjNiYjU1YjIzNDlkXzQtMS0xLTEtMA_2e10f30d-abc0-436b-a29b-3abc8b062243"
      unitRef="usd">157700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5a6d3985925f4d079a28f30c8f205377_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo4NzgzNTdmNzQ1OWM0Yjc4ODdhOGYzYmI1NWIyMzQ5ZC90YWJsZXJhbmdlOjg3ODM1N2Y3NDU5YzRiNzg4N2E4ZjNiYjU1YjIzNDlkXzQtMy0xLTEtMA_3f81a87b-dd3d-4a4a-b030-1282494c8daa"
      unitRef="usd">277417000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8b96ed23f107471690b24341345908a6_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo4NzgzNTdmNzQ1OWM0Yjc4ODdhOGYzYmI1NWIyMzQ5ZC90YWJsZXJhbmdlOjg3ODM1N2Y3NDU5YzRiNzg4N2E4ZjNiYjU1YjIzNDlkXzQtNS0xLTEtMA_0f95daad-5f0f-4b3b-b90f-e0fbb4408c9d"
      unitRef="usd">-898000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9e627f3a42b34bd68ed1833fc5b3ff06_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo4NzgzNTdmNzQ1OWM0Yjc4ODdhOGYzYmI1NWIyMzQ5ZC90YWJsZXJhbmdlOjg3ODM1N2Y3NDU5YzRiNzg4N2E4ZjNiYjU1YjIzNDlkXzQtNy0xLTEtMA_7584bc04-090d-4e3d-9529-ea2db11beec8"
      unitRef="usd">434219000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i36c5f7a5f7074897b1f640ced6ec0f6b_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo4NzgzNTdmNzQ1OWM0Yjc4ODdhOGYzYmI1NWIyMzQ5ZC90YWJsZXJhbmdlOjg3ODM1N2Y3NDU5YzRiNzg4N2E4ZjNiYjU1YjIzNDlkXzQtOS0xLTEtMA_3907af6c-cb0c-443d-a5d9-bcce7a13c08a"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iaf5036ffdbc24ee8a477412be1612a0c_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo4NzgzNTdmNzQ1OWM0Yjc4ODdhOGYzYmI1NWIyMzQ5ZC90YWJsZXJhbmdlOjg3ODM1N2Y3NDU5YzRiNzg4N2E4ZjNiYjU1YjIzNDlkXzQtMTEtMS0xLTA_ee97e4dd-666c-4723-b9ef-27b25cca0f02"
      unitRef="usd">434219000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5d62628d6fb54fe0bd811fdfd0bf7b0c_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo4NzgzNTdmNzQ1OWM0Yjc4ODdhOGYzYmI1NWIyMzQ5ZC90YWJsZXJhbmdlOjg3ODM1N2Y3NDU5YzRiNzg4N2E4ZjNiYjU1YjIzNDlkXzUtMS0xLTEtMA_20881c01-b449-4c78-8c54-9dc8015dbedf"
      unitRef="usd">160609000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib887805409a54f638aeeafe3fe5d1688_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo4NzgzNTdmNzQ1OWM0Yjc4ODdhOGYzYmI1NWIyMzQ5ZC90YWJsZXJhbmdlOjg3ODM1N2Y3NDU5YzRiNzg4N2E4ZjNiYjU1YjIzNDlkXzUtMy0xLTEtMA_b349d725-4930-4963-a814-53f492645efa"
      unitRef="usd">277417000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i47a5474af0444feba1cc1f919f211cc9_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo4NzgzNTdmNzQ1OWM0Yjc4ODdhOGYzYmI1NWIyMzQ5ZC90YWJsZXJhbmdlOjg3ODM1N2Y3NDU5YzRiNzg4N2E4ZjNiYjU1YjIzNDlkXzUtNS0xLTEtMA_bb1ced5a-979a-4586-b5a4-ede377426e48"
      unitRef="usd">-898000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia479742cadcb42f19e8a838c73672d04_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo4NzgzNTdmNzQ1OWM0Yjc4ODdhOGYzYmI1NWIyMzQ5ZC90YWJsZXJhbmdlOjg3ODM1N2Y3NDU5YzRiNzg4N2E4ZjNiYjU1YjIzNDlkXzUtNy0xLTEtMA_a5cf8ade-daf9-4432-a879-16d2632ab4e9"
      unitRef="usd">437128000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i571d8209f1eb48a5abfd5c42c7ee45e7_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo4NzgzNTdmNzQ1OWM0Yjc4ODdhOGYzYmI1NWIyMzQ5ZC90YWJsZXJhbmdlOjg3ODM1N2Y3NDU5YzRiNzg4N2E4ZjNiYjU1YjIzNDlkXzUtOS0xLTEtMA_e351dd54-2844-4ae3-9e77-6ed4e057fb54"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo4NzgzNTdmNzQ1OWM0Yjc4ODdhOGYzYmI1NWIyMzQ5ZC90YWJsZXJhbmdlOjg3ODM1N2Y3NDU5YzRiNzg4N2E4ZjNiYjU1YjIzNDlkXzUtMTEtMS0xLTA_8da923a8-c6eb-41c9-9b47-966774d0bf1c"
      unitRef="usd">437128000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i74d008e6bc3e404a8233b3b36dd1f025_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo4NzgzNTdmNzQ1OWM0Yjc4ODdhOGYzYmI1NWIyMzQ5ZC90YWJsZXJhbmdlOjg3ODM1N2Y3NDU5YzRiNzg4N2E4ZjNiYjU1YjIzNDlkXzgtMS0xLTEtMA_d1f43f6d-9a56-4dbc-bb5d-85c884fd3457"
      unitRef="usd">5993000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i64e303d04c4e4b9e9e4bc39b1eee6997_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo4NzgzNTdmNzQ1OWM0Yjc4ODdhOGYzYmI1NWIyMzQ5ZC90YWJsZXJhbmdlOjg3ODM1N2Y3NDU5YzRiNzg4N2E4ZjNiYjU1YjIzNDlkXzgtMy0xLTEtMA_b1009f94-a5a1-4031-904d-9e448d879a74"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie31b707bdbb24397b9da9c80ed837abf_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo4NzgzNTdmNzQ1OWM0Yjc4ODdhOGYzYmI1NWIyMzQ5ZC90YWJsZXJhbmdlOjg3ODM1N2Y3NDU5YzRiNzg4N2E4ZjNiYjU1YjIzNDlkXzgtNS0xLTEtMA_736fd62f-118a-46f1-898d-4406288faf0e"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib86e9afe1f8b4419938a02c0da196679_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo4NzgzNTdmNzQ1OWM0Yjc4ODdhOGYzYmI1NWIyMzQ5ZC90YWJsZXJhbmdlOjg3ODM1N2Y3NDU5YzRiNzg4N2E4ZjNiYjU1YjIzNDlkXzgtNy0xLTEtMA_0c473d45-0f55-47d4-89b6-1583402d3e74"
      unitRef="usd">5993000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if6bf1058758a4ffa90f4649ee946bc82_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo4NzgzNTdmNzQ1OWM0Yjc4ODdhOGYzYmI1NWIyMzQ5ZC90YWJsZXJhbmdlOjg3ODM1N2Y3NDU5YzRiNzg4N2E4ZjNiYjU1YjIzNDlkXzgtOS0xLTEtMA_64446f75-d822-4a1c-9bf7-cd8928c43878"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia98a39c8ecac46f5b530749d9b554995_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo4NzgzNTdmNzQ1OWM0Yjc4ODdhOGYzYmI1NWIyMzQ5ZC90YWJsZXJhbmdlOjg3ODM1N2Y3NDU5YzRiNzg4N2E4ZjNiYjU1YjIzNDlkXzgtMTEtMS0xLTA_68e4b417-bc65-4914-9943-64d16bedb9b1"
      unitRef="usd">5993000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5139ec3fcfe440db905c8c709c4d692a_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo4NzgzNTdmNzQ1OWM0Yjc4ODdhOGYzYmI1NWIyMzQ5ZC90YWJsZXJhbmdlOjg3ODM1N2Y3NDU5YzRiNzg4N2E4ZjNiYjU1YjIzNDlkXzktMS0xLTEtMA_f004d75b-7c39-4f1a-854c-98714198d865"
      unitRef="usd">178222000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib8561338bdd4433695c2fe64f2d14fac_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo4NzgzNTdmNzQ1OWM0Yjc4ODdhOGYzYmI1NWIyMzQ5ZC90YWJsZXJhbmdlOjg3ODM1N2Y3NDU5YzRiNzg4N2E4ZjNiYjU1YjIzNDlkXzktMy0xLTEtMA_98bde152-1e40-4e60-a3b1-f3a5122265dd"
      unitRef="usd">255652000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if4d7479d872f485386fe9f72c2913b25_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo4NzgzNTdmNzQ1OWM0Yjc4ODdhOGYzYmI1NWIyMzQ5ZC90YWJsZXJhbmdlOjg3ODM1N2Y3NDU5YzRiNzg4N2E4ZjNiYjU1YjIzNDlkXzktNS0xLTEtMA_13b3c61b-83f0-444e-982a-af69d21a43f6"
      unitRef="usd">-1336000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i44946cd02c6a44519e1f9f53797e5d47_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo4NzgzNTdmNzQ1OWM0Yjc4ODdhOGYzYmI1NWIyMzQ5ZC90YWJsZXJhbmdlOjg3ODM1N2Y3NDU5YzRiNzg4N2E4ZjNiYjU1YjIzNDlkXzktNy0xLTEtMA_1665395b-4864-4ad1-92af-a3746f771746"
      unitRef="usd">432538000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="idfe8d8e6c5344c9b97a29c49f343d22f_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo4NzgzNTdmNzQ1OWM0Yjc4ODdhOGYzYmI1NWIyMzQ5ZC90YWJsZXJhbmdlOjg3ODM1N2Y3NDU5YzRiNzg4N2E4ZjNiYjU1YjIzNDlkXzktOS0xLTEtMA_30400830-45f3-45f8-aa26-13b6eaaf592a"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ibf7fe803335d432ba4201dde52789d25_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo4NzgzNTdmNzQ1OWM0Yjc4ODdhOGYzYmI1NWIyMzQ5ZC90YWJsZXJhbmdlOjg3ODM1N2Y3NDU5YzRiNzg4N2E4ZjNiYjU1YjIzNDlkXzktMTEtMS0xLTA_8f20a778-b8db-4ede-a0c9-27e9f905cca5"
      unitRef="usd">432538000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8d756ddfc980426086c7294d41dd2af3_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo4NzgzNTdmNzQ1OWM0Yjc4ODdhOGYzYmI1NWIyMzQ5ZC90YWJsZXJhbmdlOjg3ODM1N2Y3NDU5YzRiNzg4N2E4ZjNiYjU1YjIzNDlkXzEwLTEtMS0xLTA_9faace94-33a3-4747-9a3d-e91fdaa2c789"
      unitRef="usd">184215000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic606425dedeb4d3d9b0b453c252ea236_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo4NzgzNTdmNzQ1OWM0Yjc4ODdhOGYzYmI1NWIyMzQ5ZC90YWJsZXJhbmdlOjg3ODM1N2Y3NDU5YzRiNzg4N2E4ZjNiYjU1YjIzNDlkXzEwLTMtMS0xLTA_f2e45c6c-5a0d-4f9b-ae9f-78a30248f731"
      unitRef="usd">255652000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6a5208c4b92a426f88946822bb9c7fb6_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo4NzgzNTdmNzQ1OWM0Yjc4ODdhOGYzYmI1NWIyMzQ5ZC90YWJsZXJhbmdlOjg3ODM1N2Y3NDU5YzRiNzg4N2E4ZjNiYjU1YjIzNDlkXzEwLTUtMS0xLTA_2c86cf5e-7419-4792-a0c6-4b256917d5cd"
      unitRef="usd">-1336000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i12a7d1eed63947fb83cf5d1b35015606_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo4NzgzNTdmNzQ1OWM0Yjc4ODdhOGYzYmI1NWIyMzQ5ZC90YWJsZXJhbmdlOjg3ODM1N2Y3NDU5YzRiNzg4N2E4ZjNiYjU1YjIzNDlkXzEwLTctMS0xLTA_71d20862-503d-43b3-a912-a3e9a07ae983"
      unitRef="usd">438531000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id50759ca40e2432a8be2b863be3eeedb_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo4NzgzNTdmNzQ1OWM0Yjc4ODdhOGYzYmI1NWIyMzQ5ZC90YWJsZXJhbmdlOjg3ODM1N2Y3NDU5YzRiNzg4N2E4ZjNiYjU1YjIzNDlkXzEwLTktMS0xLTA_2682bca6-0969-450c-8188-ab25bec99030"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo4NzgzNTdmNzQ1OWM0Yjc4ODdhOGYzYmI1NWIyMzQ5ZC90YWJsZXJhbmdlOjg3ODM1N2Y3NDU5YzRiNzg4N2E4ZjNiYjU1YjIzNDlkXzEwLTExLTEtMS0w_1c651cca-35f5-4e25-aa18-197525444202"
      unitRef="usd">438531000</us-gaap:Revenues>
    <evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="i5d62628d6fb54fe0bd811fdfd0bf7b0c_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo4NzgzNTdmNzQ1OWM0Yjc4ODdhOGYzYmI1NWIyMzQ5ZC90YWJsZXJhbmdlOjg3ODM1N2Y3NDU5YzRiNzg4N2E4ZjNiYjU1YjIzNDlkXzE1LTEtMS0xLTA_e5cd6635-49fa-414a-b4e4-31b204ab9acf"
      unitRef="usd">12473000</evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization>
    <evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="ib887805409a54f638aeeafe3fe5d1688_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo4NzgzNTdmNzQ1OWM0Yjc4ODdhOGYzYmI1NWIyMzQ5ZC90YWJsZXJhbmdlOjg3ODM1N2Y3NDU5YzRiNzg4N2E4ZjNiYjU1YjIzNDlkXzE1LTMtMS0xLTA_f1e3a4d9-6b8c-4186-885f-4cea7dfef7fc"
      unitRef="usd">29573000</evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization>
    <evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="ia479742cadcb42f19e8a838c73672d04_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo4NzgzNTdmNzQ1OWM0Yjc4ODdhOGYzYmI1NWIyMzQ5ZC90YWJsZXJhbmdlOjg3ODM1N2Y3NDU5YzRiNzg4N2E4ZjNiYjU1YjIzNDlkXzE1LTUtMS0xLTA_2cb01417-4784-4b2c-bbb0-8fd47341eaef"
      unitRef="usd">42046000</evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization>
    <evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="i571d8209f1eb48a5abfd5c42c7ee45e7_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo4NzgzNTdmNzQ1OWM0Yjc4ODdhOGYzYmI1NWIyMzQ5ZC90YWJsZXJhbmdlOjg3ODM1N2Y3NDU5YzRiNzg4N2E4ZjNiYjU1YjIzNDlkXzE1LTctMS0xLTA_f642d044-5f37-41c4-8dae-0ef6ef24806d"
      unitRef="usd">-13793000</evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization>
    <evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo4NzgzNTdmNzQ1OWM0Yjc4ODdhOGYzYmI1NWIyMzQ5ZC90YWJsZXJhbmdlOjg3ODM1N2Y3NDU5YzRiNzg4N2E4ZjNiYjU1YjIzNDlkXzE1LTktMS0xLTA_b0a120a9-20cb-477c-8bc9-032d6d998e09"
      unitRef="usd">28253000</evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization>
    <evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="i8d756ddfc980426086c7294d41dd2af3_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo4NzgzNTdmNzQ1OWM0Yjc4ODdhOGYzYmI1NWIyMzQ5ZC90YWJsZXJhbmdlOjg3ODM1N2Y3NDU5YzRiNzg4N2E4ZjNiYjU1YjIzNDlkXzE4LTEtMS0xLTA_37a4efaf-ea35-4b1a-823b-781d29c18b30"
      unitRef="usd">11716000</evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization>
    <evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="ic606425dedeb4d3d9b0b453c252ea236_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo4NzgzNTdmNzQ1OWM0Yjc4ODdhOGYzYmI1NWIyMzQ5ZC90YWJsZXJhbmdlOjg3ODM1N2Y3NDU5YzRiNzg4N2E4ZjNiYjU1YjIzNDlkXzE4LTMtMS0xLTA_6c26df45-d66d-4efa-bc30-348ed31a7366"
      unitRef="usd">19243000</evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization>
    <evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="i12a7d1eed63947fb83cf5d1b35015606_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo4NzgzNTdmNzQ1OWM0Yjc4ODdhOGYzYmI1NWIyMzQ5ZC90YWJsZXJhbmdlOjg3ODM1N2Y3NDU5YzRiNzg4N2E4ZjNiYjU1YjIzNDlkXzE4LTUtMS0xLTA_310b52f8-59ab-42f6-9dca-187f508dcf9c"
      unitRef="usd">30959000</evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization>
    <evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="id50759ca40e2432a8be2b863be3eeedb_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo4NzgzNTdmNzQ1OWM0Yjc4ODdhOGYzYmI1NWIyMzQ5ZC90YWJsZXJhbmdlOjg3ODM1N2Y3NDU5YzRiNzg4N2E4ZjNiYjU1YjIzNDlkXzE4LTctMS0xLTA_4e8060d7-62a7-4fd2-8cd9-1218f72763de"
      unitRef="usd">-16564000</evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization>
    <evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTo4NzgzNTdmNzQ1OWM0Yjc4ODdhOGYzYmI1NWIyMzQ5ZC90YWJsZXJhbmdlOjg3ODM1N2Y3NDU5YzRiNzg4N2E4ZjNiYjU1YjIzNDlkXzE4LTktMS0xLTA_3056c2a8-2ecd-4bba-8b17-0bdd32646c69"
      unitRef="usd">14395000</evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization>
    <us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90ZXh0cmVnaW9uOjc0ZTMxNDVmNTRhODRjMWY4ZmQ5YjZmNTY5ZDUyMDk5XzM0MTI_5453130b-c982-439c-8556-27de853297e2">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents our reconciliation of consolidated segments total Adjusted EBITDA to net loss attributable to common shareholders of Evolent Health, Inc. for the three and six months ended June 30, 2021 and 2020 (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:327.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net loss attributable to common shareholders of Evolent Health, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,107)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(203,521)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18,914)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(282,273)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;705&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,274)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,290)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,611)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,571)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(Provision) benefit for income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(91)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(702)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,634&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,916)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,618)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30,103)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31,596)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity method investment impairment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(47,133)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain on transfer of membership&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,969&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss on repayment of debt, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19,158)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill impairment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(215,100)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(215,100)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain from equity method investees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,879&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss on disposal of assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,447)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value of contingent consideration and indemnification asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(756)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,062&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Repositioning costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(663)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,043)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,653)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,703)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,359)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,211)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Severance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(52)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,133)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of contract cost assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(196)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(767)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(323)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,207)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Strategy and shareholder advisory expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,513)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,513)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisition costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(76)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(374)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,070)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(683)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain (loss) from discontinued operations &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,508)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,773)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Adjusted EBITDA&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Includes $1.9&#160;million gain on disposal of discontinued operations for the six months ended June 30, 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzItMS0xLTEtMTUyMQ_09330fbb-f85e-46d5-b7ba-0c4c55c92dcd"
      unitRef="usd">-9107000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzItMS0xLTEtMTUyMQ_f334614f-48c8-4335-8644-08d1c094b533"
      unitRef="usd">-9107000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzItMy0xLTEtMTUyMQ_1f1b826f-81ea-4a16-8e51-b233cb6cb5d8"
      unitRef="usd">-203521000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzItMy0xLTEtMTUyMQ_464f9ea4-79d0-46fe-b7e0-3bfbaef12c35"
      unitRef="usd">-203521000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzItMS0xLTEtMA_3f65effd-5c00-48e2-b9f0-61aa1fc1e88c"
      unitRef="usd">-18914000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzItMS0xLTEtMA_7051b8a1-9469-4d3d-b02f-b619b054437f"
      unitRef="usd">-18914000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzItMy0xLTEtMA_0841956d-a0c8-4eca-a9f7-99ceb502bb32"
      unitRef="usd">-282273000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzItMy0xLTEtMA_d981f43f-4d1f-4440-8d13-5cf7db63d994"
      unitRef="usd">-282273000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzQtMS0xLTEtMTUyMQ_163a4d38-74de-4cd9-a96b-712b37840fa1"
      unitRef="usd">68000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzQtMy0xLTEtMTUyMQ_13114419-16d4-4be7-8688-ce8ceab3b4e6"
      unitRef="usd">705000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzQtMS0xLTEtMA_83816d22-b67f-42bc-a14d-da7e4c5fc61c"
      unitRef="usd">191000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzQtMy0xLTEtMA_48ca35fa-ea12-4d7b-bd07-63289bd461ca"
      unitRef="usd">1475000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense
      contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzUtMS0xLTEtMTUyMQ_11cc8d20-a0c9-4bc6-909e-2381fc933d5b"
      unitRef="usd">6274000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzUtMy0xLTEtMTUyMQ_5691b2a7-088a-4dfe-b75f-1ee34e3dff88"
      unitRef="usd">6290000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzUtMS0xLTEtMA_0f5794e1-5476-475f-9319-40ba8fe48852"
      unitRef="usd">12611000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzUtMy0xLTEtMA_548dab9c-e980-4461-861f-7e86acdbb565"
      unitRef="usd">12571000</us-gaap:InterestExpense>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzYtMS0xLTEtMTUyMQ_04052006-f596-44c4-b868-a55c6d573f49"
      unitRef="usd">91000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzYtMy0xLTEtMTUyMQ_e10cf3f8-4eeb-4685-b5cd-e9b7e9b5e245"
      unitRef="usd">-3904000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzYtMS0xLTEtMA_33d280e8-12c1-4ba8-b45c-ea99f7c9933a"
      unitRef="usd">702000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzYtMy0xLTEtMA_8db7d2cc-91f2-4967-83ca-04bca456dfc1"
      unitRef="usd">-3634000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:DepreciationAndAmortization
      contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzctMS0xLTEtMTUyMQ_8a65fbca-0025-4e8a-b655-1edc1670fb2e"
      unitRef="usd">14916000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzctMy0xLTEtMTUyMQ_5c78d84e-771a-4f32-9c28-f027d47d46b8"
      unitRef="usd">15618000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzctMS0xLTEtMA_3c6977da-1489-48bb-a58c-c463d7627f67"
      unitRef="usd">30103000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzctMy0xLTEtMA_05e9b9be-b49a-41f8-a9e0-21e21bffb266"
      unitRef="usd">31596000</us-gaap:DepreciationAndAmortization>
    <us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment
      contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzgtMS0xLTEtMTUyNw_9fec52cc-fd1d-4be1-afa6-a6bc0d1b6e75"
      unitRef="usd">0</us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment>
    <us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment
      contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzgtMy0xLTEtMTUyNw_49900626-35d5-4b00-8acd-68b229537d6c"
      unitRef="usd">0</us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment>
    <us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzgtMS0xLTEtMA_470498e5-c9e7-4342-b704-b6e7184fc1a9"
      unitRef="usd">0</us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment>
    <us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzgtMy0xLTEtMA_020eb503-215b-4104-a030-feb82d293b09"
      unitRef="usd">47133000</us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment>
    <evh:GainOnTransferOfMembership
      contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzktMS0xLTEtMTUzNw_4d8f4c6b-cbe7-4ed2-8bf1-8f1a45c0afcd"
      unitRef="usd">0</evh:GainOnTransferOfMembership>
    <evh:GainOnTransferOfMembership
      contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzktMy0xLTEtMTUzNw_ef6f9781-3e24-4762-9a89-148e2fbeb523"
      unitRef="usd">0</evh:GainOnTransferOfMembership>
    <evh:GainOnTransferOfMembership
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzktMS0xLTEtMA_8df410f6-3f97-47d5-a059-a08b7abe9a4d"
      unitRef="usd">22969000</evh:GainOnTransferOfMembership>
    <evh:GainOnTransferOfMembership
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzktMy0xLTEtMA_138d911e-9fba-4d96-a5c1-0f91bff812aa"
      unitRef="usd">0</evh:GainOnTransferOfMembership>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzEwLTEtMS0xLTE1NDE_f30f9245-8230-48e3-ab9a-e2c93eb5a146"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzEwLTMtMS0xLTE1NDE_8be05421-c2ec-4e11-bcc9-6101a9219616"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzEwLTEtMS0xLTA_12de13a4-a1e2-4f0b-96fd-e2653c008ef8"
      unitRef="usd">-19158000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzEwLTMtMS0xLTA_ef20a79b-fac1-4e98-951b-a3cdcfe51b9e"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzExLTEtMS0xLTE1MzM_4c9b9962-435d-42b6-b7d9-29c257d393be"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzExLTMtMS0xLTE1MzM_63147517-36a8-45c1-bc1b-1d60d4b63a28"
      unitRef="usd">215100000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzExLTUtMS0xLTE1MzM_06dafbe0-615c-4fa9-9fa5-8ec0e0c5a70f"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzExLTctMS0xLTE1MzM_97eb0276-5eae-4b82-a477-7a3fc47ce2e8"
      unitRef="usd">215100000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzEyLTEtMS0xLTE1NDU_5389febb-fe83-4144-9888-161629606b06"
      unitRef="usd">4879000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzEyLTMtMS0xLTE1NDU_bc4c368a-7e0a-4143-8b60-4a58ed94f88e"
      unitRef="usd">25143000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzExLTEtMS0xLTA_ed4eccd2-42f4-4dad-a398-8345da24d3f2"
      unitRef="usd">12662000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzExLTMtMS0xLTA_3338a9e1-ee9b-4544-b041-7f91dcb8128e"
      unitRef="usd">24731000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzEzLTEtMS0xLTE1NTM_d68bbafc-9fd1-4110-be89-ba5f82386975"
      unitRef="usd">0</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzEzLTMtMS0xLTE1NTM_60dd071d-ffb2-4dd4-8d0d-e8cc29976f2a"
      unitRef="usd">0</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzEyLTEtMS0xLTA_040bab52-3241-4230-8c94-5abd2d6a6cd5"
      unitRef="usd">0</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzEyLTMtMS0xLTA_eaf9136c-b3fc-48c0-b5b8-f9e358108c9c"
      unitRef="usd">-6447000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzE0LTEtMS0xLTE1NTc_ca4f3159-fa8b-4452-b17c-f57410472140"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzE0LTMtMS0xLTE1NTc_9133326a-9ed1-4027-8428-58073c039c5a"
      unitRef="usd">756000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzEzLTEtMS0xLTA_4e433f0c-854b-4309-aa90-c9a22f41781c"
      unitRef="usd">-594000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzEzLTMtMS0xLTA_1f5ea248-709b-4d45-8fee-60c8240a270b"
      unitRef="usd">-3062000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzE1LTEtMS0xLTE1NTc_ca9e6b7b-649d-4aa1-8cb2-f3f31de509eb"
      unitRef="usd">-18000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzE1LTMtMS0xLTE1NTc_70afdddb-1ddb-4bb3-8d4f-065a0db37047"
      unitRef="usd">354000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzE0LTEtMS0xLTA_7c724be6-7ece-437e-a5b1-5c916e1c77c1"
      unitRef="usd">-32000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzE0LTMtMS0xLTA_0a35e81d-6aea-4545-9cb9-8a44885d2049"
      unitRef="usd">284000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:RestructuringCharges
      contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzE2LTEtMS0xLTE1NjE_9a4e4bf5-55b3-4496-b4a9-1d8427fc800a"
      unitRef="usd">663000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzE2LTMtMS0xLTE1NjE_389b0c50-f883-435a-9b7b-65dcb33eff3e"
      unitRef="usd">0</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzE1LTEtMS0xLTA_878f2312-14aa-4411-9d7c-f8c482070931"
      unitRef="usd">6043000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzE1LTMtMS0xLTA_e53751d1-aa39-48ff-a196-4fbaffb032a8"
      unitRef="usd">0</us-gaap:RestructuringCharges>
    <evh:SharebasedCompensationIncludingOnetimeAdjustment
      contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzE3LTEtMS0xLTE1NjE_feaeded1-87a9-4f6b-9ddc-a9cdadebbeea"
      unitRef="usd">3653000</evh:SharebasedCompensationIncludingOnetimeAdjustment>
    <evh:SharebasedCompensationIncludingOnetimeAdjustment
      contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzE3LTMtMS0xLTE1NjE_65c766d1-d706-46af-9e67-8626dcda8428"
      unitRef="usd">3703000</evh:SharebasedCompensationIncludingOnetimeAdjustment>
    <evh:SharebasedCompensationIncludingOnetimeAdjustment
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzE2LTEtMS0xLTA_922b4358-c276-406a-8513-6354edb0e7b1"
      unitRef="usd">7359000</evh:SharebasedCompensationIncludingOnetimeAdjustment>
    <evh:SharebasedCompensationIncludingOnetimeAdjustment
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzE2LTMtMS0xLTA_e6993cb2-c0e6-4658-894a-52d75d8c15ce"
      unitRef="usd">7211000</evh:SharebasedCompensationIncludingOnetimeAdjustment>
    <us-gaap:SeveranceCosts1
      contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzE4LTEtMS0xLTE1NjE_34db6e77-380b-4886-a5a8-2660b6c7245b"
      unitRef="usd">0</us-gaap:SeveranceCosts1>
    <us-gaap:SeveranceCosts1
      contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzE4LTMtMS0xLTE1NjE_20dd6179-1fd9-427b-8821-10d1ef35c723"
      unitRef="usd">30000</us-gaap:SeveranceCosts1>
    <us-gaap:SeveranceCosts1
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzE3LTEtMS0xLTA_c20b3c97-eb0c-44ac-9744-5e78148f80b4"
      unitRef="usd">52000</us-gaap:SeveranceCosts1>
    <us-gaap:SeveranceCosts1
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzE3LTMtMS0xLTA_39751549-03fc-4ce1-9ec9-b19551e78fd0"
      unitRef="usd">6133000</us-gaap:SeveranceCosts1>
    <evh:CapitalizedContractCostAmortizationPurchaseAccountingAdjustments
      contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzE5LTEtMS0xLTE1NjE_fe807342-2f3f-4099-82dd-26eb3232d288"
      unitRef="usd">196000</evh:CapitalizedContractCostAmortizationPurchaseAccountingAdjustments>
    <evh:CapitalizedContractCostAmortizationPurchaseAccountingAdjustments
      contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzE5LTMtMS0xLTE1NjE_d4fa8055-118d-4350-9a25-a4581a0608bc"
      unitRef="usd">767000</evh:CapitalizedContractCostAmortizationPurchaseAccountingAdjustments>
    <evh:CapitalizedContractCostAmortizationPurchaseAccountingAdjustments
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzE4LTEtMS0xLTA_cf560695-8617-4b84-a0e1-0dafc4e25168"
      unitRef="usd">323000</evh:CapitalizedContractCostAmortizationPurchaseAccountingAdjustments>
    <evh:CapitalizedContractCostAmortizationPurchaseAccountingAdjustments
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzE4LTMtMS0xLTA_95f1fc00-ea36-4064-9d52-5c9b7ac88e15"
      unitRef="usd">1207000</evh:CapitalizedContractCostAmortizationPurchaseAccountingAdjustments>
    <evh:ShareholderAdvisoryServices
      contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzIwLTEtMS0xLTE1NjU_dca355a7-52bb-4bf8-b936-1ba967ec88d7"
      unitRef="usd">1513000</evh:ShareholderAdvisoryServices>
    <evh:ShareholderAdvisoryServices
      contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzIwLTMtMS0xLTE1NjU_568f4e76-d595-4db6-905c-4d6ee3e3ddcf"
      unitRef="usd">0</evh:ShareholderAdvisoryServices>
    <evh:ShareholderAdvisoryServices
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzE5LTEtMS0xLTA_3525e267-45da-4217-9a53-2febf0004a58"
      unitRef="usd">6513000</evh:ShareholderAdvisoryServices>
    <evh:ShareholderAdvisoryServices
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzE5LTMtMS0xLTA_a6fea963-bad2-4184-8a4c-a4d464c129b1"
      unitRef="usd">0</evh:ShareholderAdvisoryServices>
    <evh:TransactionCosts
      contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzIxLTEtMS0xLTE1NjU_55de0874-7d45-4fc9-92f5-b0162909ee91"
      unitRef="usd">76000</evh:TransactionCosts>
    <evh:TransactionCosts
      contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzIxLTMtMS0xLTE1NjU_2e2c5be8-589a-4743-abec-57caa735d786"
      unitRef="usd">374000</evh:TransactionCosts>
    <evh:TransactionCosts
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzIwLTEtMS0xLTA_89f88066-8087-48dd-9be5-0c281d8bdd5a"
      unitRef="usd">2070000</evh:TransactionCosts>
    <evh:TransactionCosts
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzIwLTMtMS0xLTA_701abe71-f2c1-47d9-a3ef-6fb7545ceedf"
      unitRef="usd">683000</evh:TransactionCosts>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzIyLTEtMS0xLTE1NjU_f31f527b-b921-4570-bb67-dff8944def11"
      unitRef="usd">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzIyLTMtMS0xLTE1NjU_ecb86564-0d16-4f0b-be08-1828afc77d88"
      unitRef="usd">-1508000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzIxLTEtMS0xLTA_d52cdfe9-4ced-48ea-a5fe-f6f292e78e07"
      unitRef="usd">1383000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzIxLTMtMS0xLTA_9bea7d8c-98bc-4e77-aa58-16662850df28"
      unitRef="usd">-1773000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzIzLTEtMS0xLTE1NjU_b8e284ea-b87a-41ef-beda-8770ae2f9c26"
      unitRef="usd">13346000</evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization>
    <evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="i9fea1c30a46e4568b082d40f04d16a73_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzIzLTMtMS0xLTE1NjU_2c0992e5-a00f-4c59-a7a0-45c49da5acb4"
      unitRef="usd">10519000</evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization>
    <evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzIyLTEtMS0xLTA_34f68d73-5170-426a-8055-6d07db509995"
      unitRef="usd">28253000</evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization>
    <evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90YWJsZTowOTZkNWYzMmNkYTQ0Y2IyOGFjYTMzNTZhMmE3YWE0Yy90YWJsZXJhbmdlOjA5NmQ1ZjMyY2RhNDRjYjI4YWNhMzM1NmEyYTdhYTRjXzIyLTMtMS0xLTA_b1687b6c-b0b8-4f89-9abb-aaf4871d77ca"
      unitRef="usd">14395000</evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization>
    <us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjEvZnJhZzo3NGUzMTQ1ZjU0YTg0YzFmOGZkOWI2ZjU2OWQ1MjA5OS90ZXh0cmVnaW9uOjc0ZTMxNDVmNTRhODRjMWY4ZmQ5YjZmNTY5ZDUyMDk5XzMxNjk_21f819b6-f612-4a34-a7c9-911830c65d53"
      unitRef="usd">1900000</us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax>
    <us-gaap:InsuranceDisclosureTextBlock
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjQvZnJhZzo0MDI1ZmJmMmQ0MTY0MWZhODhhZTg0YmZkZDc4M2YzZS90ZXh0cmVnaW9uOjQwMjVmYmYyZDQxNjQxZmE4OGFlODRiZmRkNzgzZjNlXzUwMTI_f3c032db-f95b-485e-9ac5-52af31322674">Reserve for Claims and Performance-Based Arrangements&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company maintains reserves for its liabilities related to payments to providers and pharmacies under performance-based arrangements related to its total cost of care and specialty care management services. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Reserves for claims and performance-based arrangements for our EHS and Clinical Solutions segments reflect actual payments under performance-based arrangements and the ultimate cost of claims that have been incurred but not reported, including expected development on reported claims, those that have been reported but not yet paid (reported claims in process), and other medical care expenses and services payable that are primarily composed of accruals for incentives and other amounts payable to health care professionals and facilities. Reserves for claims and performance-based arrangements also reflect estimated amounts owed under the reinsurance agreements, as discussed further in Note 11.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses actuarial principles and assumptions that are consistently applied each reporting period and recognizes the actuarial best estimate of the ultimate liability along with a margin for adverse deviation. This approach is consistent with actuarial standards of practice that the liabilities be adequate under moderately adverse conditions.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;This liability predominately consists of incurred but not reported amounts and reported claims in process including expected development on reported claims. The liability for reserves related to its total cost of care and specialty care management services is primarily calculated using "completion factors" developed by comparing the claim incurred date to the date claims were paid. Completion factors are impacted by several key items including changes in: 1)&#160;electronic (auto-adjudication) versus manual claim processing, 2)&#160;provider claims submission rates, 3)&#160;membership and 4)&#160;the mix of products.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s policy for reserves related to its total cost of care and specialty care management services is to use historical completion factors combined with an analysis of current trends and operational factors to develop current estimates of completion factors. The Company estimates the liability for claims incurred in each month by applying the current estimates of completion factors to the current paid claims data. This approach implicitly assumes that historical completion rates will be a useful indicator for the current period. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For more recent months, and for newer lines of business where there is not sufficient paid claims history to develop completion factors, the Company expects to rely more heavily on medical cost trend and expected loss ratio analysis that reflects expected claim payment patterns and other relevant operational considerations, or authorization analysis. Medical cost trend is primarily impacted by medical service utilization and unit costs that are affected by changes in the level and mix of medical benefits offered, including inpatient, outpatient and pharmacy, the impact of copays and deductibles, changes in provider practices and changes in consumer demographics and consumption behavior. Authorization analysis projects costs on an authorization-level basis and also accounts for the impact of copays and deductibles, unit cost and historic discontinuation rates for treatment. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For each reporting period, the Company compares key assumptions used to establish the reserves for claims and performance-based arrangements to actual experience. When actual experience differs from these assumptions, reserves for claims and performance-based arrangements are adjusted through current period net income. Additionally, the Company evaluates expected future developments and emerging trends that may impact key assumptions. The process used to determine this liability requires the Company to make critical accounting estimates that involve considerable judgment, reflecting the variability inherent in forecasting future claim payments. These estimates are highly sensitive to changes in the Company's key assumptions, specifically completion factors and medical cost trends.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Activity in reserves for claims and performance-based arrangements for the six months ended June 30, 2021 and 2020, was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:142.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:37.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:47.50pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:47.50pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:3.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:40.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:3.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:37.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:3.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:47.50pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:3.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:47.50pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:3.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:40.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="45" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:33pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;EHS &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Clinical Solutions &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;True Health&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;EHS &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Clinical Solutions &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;True Health&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;188,686&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Incurred costs related to current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,669&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;219,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;262,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;245,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Incurred costs related to prior year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(241)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(498)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Paid costs related to current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,801&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73,379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,020&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;163,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Paid costs related to prior year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99,443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change during the year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26,512)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,913)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,024&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Disposal of discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,194)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,194)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other adjustments &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,003&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,504&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;204,601&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;238,105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(648)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85,995&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,062&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:31.5pt;text-align:justify;text-indent:-31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:25.44pt"&gt;Costs incurred to provide specialty care management and EVH Passport are recorded within cost of revenue in our statement of operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:31.5pt;text-align:justify;text-indent:-31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:25.44pt"&gt;Other adjustments to reserves for claims and performance-based arrangements reflect changes in accrual for amounts payable to facilities and amounts owed to our payer partners for claims paid on our behalf.&lt;/span&gt;&lt;/div&gt;</us-gaap:InsuranceDisclosureTextBlock>
    <us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjQvZnJhZzo0MDI1ZmJmMmQ0MTY0MWZhODhhZTg0YmZkZDc4M2YzZS90ZXh0cmVnaW9uOjQwMjVmYmYyZDQxNjQxZmE4OGFlODRiZmRkNzgzZjNlXzUwMTQ_aa8c7cd3-d26d-4157-8bd6-dfe94961f20e">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Activity in reserves for claims and performance-based arrangements for the six months ended June 30, 2021 and 2020, was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:142.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:37.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:47.50pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:47.50pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:3.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:40.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:3.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:37.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:3.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:47.50pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:3.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:47.50pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:3.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:40.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="45" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:33pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;EHS &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Clinical Solutions &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;True Health&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;EHS &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Clinical Solutions &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;True Health&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;188,686&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Incurred costs related to current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,669&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;219,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;262,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;245,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Incurred costs related to prior year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(241)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(498)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Paid costs related to current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,801&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73,379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,020&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;163,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Paid costs related to prior year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99,443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change during the year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26,512)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,913)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,024&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Disposal of discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,194)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,194)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other adjustments &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,003&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,504&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;204,601&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;238,105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(648)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85,995&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,062&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:31.5pt;text-align:justify;text-indent:-31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:25.44pt"&gt;Costs incurred to provide specialty care management and EVH Passport are recorded within cost of revenue in our statement of operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:31.5pt;text-align:justify;text-indent:-31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:25.44pt"&gt;Other adjustments to reserves for claims and performance-based arrangements reflect changes in accrual for amounts payable to facilities and amounts owed to our payer partners for claims paid on our behalf.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i40bf24d71e79424985bfa9b1dc75e390_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjQvZnJhZzo0MDI1ZmJmMmQ0MTY0MWZhODhhZTg0YmZkZDc4M2YzZS90YWJsZTo2N2VlOGE3MTg5OTA0YzkwOWJkYTI1ZDY4ODA4NGU4NC90YWJsZXJhbmdlOjY3ZWU4YTcxODk5MDRjOTA5YmRhMjVkNjg4MDg0ZTg0XzMtMS0xLTEtMA_2182a43a-ec51-4d9d-8891-305e91a089ca"
      unitRef="usd">56295000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i00a15ecaf66f4a6cbb5b4eb9fa265870_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjQvZnJhZzo0MDI1ZmJmMmQ0MTY0MWZhODhhZTg0YmZkZDc4M2YzZS90YWJsZTo2N2VlOGE3MTg5OTA0YzkwOWJkYTI1ZDY4ODA4NGU4NC90YWJsZXJhbmdlOjY3ZWU4YTcxODk5MDRjOTA5YmRhMjVkNjg4MDg0ZTg0XzMtMy0xLTEtMA_d72f149e-2b1a-414c-8ccc-14cc7dd3c1c2"
      unitRef="usd">122532000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i16817704fb5d42b894f5f9c40a24d9d7_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjQvZnJhZzo0MDI1ZmJmMmQ0MTY0MWZhODhhZTg0YmZkZDc4M2YzZS90YWJsZTo2N2VlOGE3MTg5OTA0YzkwOWJkYTI1ZDY4ODA4NGU4NC90YWJsZXJhbmdlOjY3ZWU4YTcxODk5MDRjOTA5YmRhMjVkNjg4MDg0ZTg0XzMtNS0xLTEtMA_6d3cc194-e455-4384-bcab-81e676c2253e"
      unitRef="usd">9859000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i45bff335c1434d6ba44132da1b0557db_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjQvZnJhZzo0MDI1ZmJmMmQ0MTY0MWZhODhhZTg0YmZkZDc4M2YzZS90YWJsZTo2N2VlOGE3MTg5OTA0YzkwOWJkYTI1ZDY4ODA4NGU4NC90YWJsZXJhbmdlOjY3ZWU4YTcxODk5MDRjOTA5YmRhMjVkNjg4MDg0ZTg0XzMtNy0xLTEtMA_afad98fe-1625-434e-8102-ac313bdd6b69"
      unitRef="usd">188686000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="ibcf0f323376446aca3fd59b2d1a2f2ad_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjQvZnJhZzo0MDI1ZmJmMmQ0MTY0MWZhODhhZTg0YmZkZDc4M2YzZS90YWJsZTo2N2VlOGE3MTg5OTA0YzkwOWJkYTI1ZDY4ODA4NGU4NC90YWJsZXJhbmdlOjY3ZWU4YTcxODk5MDRjOTA5YmRhMjVkNjg4MDg0ZTg0XzMtOS0xLTEtMA_4730720f-e41d-4abe-96d9-eadb10bb140d"
      unitRef="usd">4265000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i9a66b42348f74ceea613fecea2deba8e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjQvZnJhZzo0MDI1ZmJmMmQ0MTY0MWZhODhhZTg0YmZkZDc4M2YzZS90YWJsZTo2N2VlOGE3MTg5OTA0YzkwOWJkYTI1ZDY4ODA4NGU4NC90YWJsZXJhbmdlOjY3ZWU4YTcxODk5MDRjOTA5YmRhMjVkNjg4MDg0ZTg0XzMtMTEtMS0xLTA_312dfd2a-bb52-434f-a973-d0cbf0605a50"
      unitRef="usd">50245000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i9f5902da906645d380ce211e0eb169b8_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjQvZnJhZzo0MDI1ZmJmMmQ0MTY0MWZhODhhZTg0YmZkZDc4M2YzZS90YWJsZTo2N2VlOGE3MTg5OTA0YzkwOWJkYTI1ZDY4ODA4NGU4NC90YWJsZXJhbmdlOjY3ZWU4YTcxODk5MDRjOTA5YmRhMjVkNjg4MDg0ZTg0XzMtMTMtMS0xLTA_e5850c1b-1e03-476a-81eb-b507ceb3dd4b"
      unitRef="usd">6640000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="ie0ff0ad229b441d4b12bc8956f92a917_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjQvZnJhZzo0MDI1ZmJmMmQ0MTY0MWZhODhhZTg0YmZkZDc4M2YzZS90YWJsZTo2N2VlOGE3MTg5OTA0YzkwOWJkYTI1ZDY4ODA4NGU4NC90YWJsZXJhbmdlOjY3ZWU4YTcxODk5MDRjOTA5YmRhMjVkNjg4MDg0ZTg0XzMtMTUtMS0xLTA_096d218d-afc0-4726-9256-b45eccbfa5b1"
      unitRef="usd">61150000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <evh:CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization
      contextRef="i5d62628d6fb54fe0bd811fdfd0bf7b0c_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjQvZnJhZzo0MDI1ZmJmMmQ0MTY0MWZhODhhZTg0YmZkZDc4M2YzZS90YWJsZTo2N2VlOGE3MTg5OTA0YzkwOWJkYTI1ZDY4ODA4NGU4NC90YWJsZXJhbmdlOjY3ZWU4YTcxODk5MDRjOTA5YmRhMjVkNjg4MDg0ZTg0XzUtMS0xLTEtMA_d82fa545-9e71-41f8-b03f-1ae84f87e028"
      unitRef="usd">8669000</evh:CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization>
    <evh:CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization
      contextRef="ib887805409a54f638aeeafe3fe5d1688_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjQvZnJhZzo0MDI1ZmJmMmQ0MTY0MWZhODhhZTg0YmZkZDc4M2YzZS90YWJsZTo2N2VlOGE3MTg5OTA0YzkwOWJkYTI1ZDY4ODA4NGU4NC90YWJsZXJhbmdlOjY3ZWU4YTcxODk5MDRjOTA5YmRhMjVkNjg4MDg0ZTg0XzUtMy0xLTEtMA_b39e044e-a8ca-4748-9f76-be0711c55852"
      unitRef="usd">219343000</evh:CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization>
    <evh:CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization
      contextRef="i558e7ef31d4b428c9ee6d8d5a9dd5f54_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjQvZnJhZzo0MDI1ZmJmMmQ0MTY0MWZhODhhZTg0YmZkZDc4M2YzZS90YWJsZTo2N2VlOGE3MTg5OTA0YzkwOWJkYTI1ZDY4ODA4NGU4NC90YWJsZXJhbmdlOjY3ZWU4YTcxODk5MDRjOTA5YmRhMjVkNjg4MDg0ZTg0XzUtNS0xLTEtMA_125c1671-1cd1-435d-9d5e-04c267126bd2"
      unitRef="usd">34228000</evh:CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization>
    <evh:CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjQvZnJhZzo0MDI1ZmJmMmQ0MTY0MWZhODhhZTg0YmZkZDc4M2YzZS90YWJsZTo2N2VlOGE3MTg5OTA0YzkwOWJkYTI1ZDY4ODA4NGU4NC90YWJsZXJhbmdlOjY3ZWU4YTcxODk5MDRjOTA5YmRhMjVkNjg4MDg0ZTg0XzUtNy0xLTEtMA_b1a1136b-9e58-4e9c-9d69-8efcdaf9c464"
      unitRef="usd">262240000</evh:CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization>
    <evh:CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization
      contextRef="i8d756ddfc980426086c7294d41dd2af3_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjQvZnJhZzo0MDI1ZmJmMmQ0MTY0MWZhODhhZTg0YmZkZDc4M2YzZS90YWJsZTo2N2VlOGE3MTg5OTA0YzkwOWJkYTI1ZDY4ODA4NGU4NC90YWJsZXJhbmdlOjY3ZWU4YTcxODk5MDRjOTA5YmRhMjVkNjg4MDg0ZTg0XzUtOS0xLTEtMA_88a01fca-e35d-4681-879a-dd842cc4be53"
      unitRef="usd">2135000</evh:CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization>
    <evh:CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization
      contextRef="ic606425dedeb4d3d9b0b453c252ea236_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjQvZnJhZzo0MDI1ZmJmMmQ0MTY0MWZhODhhZTg0YmZkZDc4M2YzZS90YWJsZTo2N2VlOGE3MTg5OTA0YzkwOWJkYTI1ZDY4ODA4NGU4NC90YWJsZXJhbmdlOjY3ZWU4YTcxODk5MDRjOTA5YmRhMjVkNjg4MDg0ZTg0XzUtMTEtMS0xLTA_5780321b-ad73-42b6-868c-220fe8df484b"
      unitRef="usd">201977000</evh:CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization>
    <evh:CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization
      contextRef="ie069c94280064225b4ffe831d6c5e5fe_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjQvZnJhZzo0MDI1ZmJmMmQ0MTY0MWZhODhhZTg0YmZkZDc4M2YzZS90YWJsZTo2N2VlOGE3MTg5OTA0YzkwOWJkYTI1ZDY4ODA4NGU4NC90YWJsZXJhbmdlOjY3ZWU4YTcxODk5MDRjOTA5YmRhMjVkNjg4MDg0ZTg0XzUtMTMtMS0xLTA_b3bfa997-cbf8-4744-ab43-03863b7898ff"
      unitRef="usd">41584000</evh:CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization>
    <evh:CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjQvZnJhZzo0MDI1ZmJmMmQ0MTY0MWZhODhhZTg0YmZkZDc4M2YzZS90YWJsZTo2N2VlOGE3MTg5OTA0YzkwOWJkYTI1ZDY4ODA4NGU4NC90YWJsZXJhbmdlOjY3ZWU4YTcxODk5MDRjOTA5YmRhMjVkNjg4MDg0ZTg0XzUtMTUtMS0xLTA_719296c5-6e6f-4039-8d62-56f9766a601a"
      unitRef="usd">245696000</evh:CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
      contextRef="i5d62628d6fb54fe0bd811fdfd0bf7b0c_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjQvZnJhZzo0MDI1ZmJmMmQ0MTY0MWZhODhhZTg0YmZkZDc4M2YzZS90YWJsZTo2N2VlOGE3MTg5OTA0YzkwOWJkYTI1ZDY4ODA4NGU4NC90YWJsZXJhbmdlOjY3ZWU4YTcxODk5MDRjOTA5YmRhMjVkNjg4MDg0ZTg0XzYtMS0xLTEtMA_455b5e5c-9d35-4a35-80f9-2fa06ba05271"
      unitRef="usd">6293000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
      contextRef="ib887805409a54f638aeeafe3fe5d1688_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjQvZnJhZzo0MDI1ZmJmMmQ0MTY0MWZhODhhZTg0YmZkZDc4M2YzZS90YWJsZTo2N2VlOGE3MTg5OTA0YzkwOWJkYTI1ZDY4ODA4NGU4NC90YWJsZXJhbmdlOjY3ZWU4YTcxODk5MDRjOTA5YmRhMjVkNjg4MDg0ZTg0XzYtMy0xLTEtMA_573499c6-c98b-4a66-97be-c1314a0a1305"
      unitRef="usd">215000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
      contextRef="i558e7ef31d4b428c9ee6d8d5a9dd5f54_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjQvZnJhZzo0MDI1ZmJmMmQ0MTY0MWZhODhhZTg0YmZkZDc4M2YzZS90YWJsZTo2N2VlOGE3MTg5OTA0YzkwOWJkYTI1ZDY4ODA4NGU4NC90YWJsZXJhbmdlOjY3ZWU4YTcxODk5MDRjOTA5YmRhMjVkNjg4MDg0ZTg0XzYtNS0xLTEtMA_d8147a29-7ce5-4513-bbb6-71f35ca3515c"
      unitRef="usd">-241000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjQvZnJhZzo0MDI1ZmJmMmQ0MTY0MWZhODhhZTg0YmZkZDc4M2YzZS90YWJsZTo2N2VlOGE3MTg5OTA0YzkwOWJkYTI1ZDY4ODA4NGU4NC90YWJsZXJhbmdlOjY3ZWU4YTcxODk5MDRjOTA5YmRhMjVkNjg4MDg0ZTg0XzYtNy0xLTEtMA_7d4ddf23-de9b-4324-a798-4c610e7899fd"
      unitRef="usd">6267000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
      contextRef="i8d756ddfc980426086c7294d41dd2af3_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjQvZnJhZzo0MDI1ZmJmMmQ0MTY0MWZhODhhZTg0YmZkZDc4M2YzZS90YWJsZTo2N2VlOGE3MTg5OTA0YzkwOWJkYTI1ZDY4ODA4NGU4NC90YWJsZXJhbmdlOjY3ZWU4YTcxODk5MDRjOTA5YmRhMjVkNjg4MDg0ZTg0XzYtOS0xLTEtMA_938b41cb-1161-4ab0-8430-6398f5a4bc35"
      unitRef="usd">-498000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
      contextRef="ic606425dedeb4d3d9b0b453c252ea236_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjQvZnJhZzo0MDI1ZmJmMmQ0MTY0MWZhODhhZTg0YmZkZDc4M2YzZS90YWJsZTo2N2VlOGE3MTg5OTA0YzkwOWJkYTI1ZDY4ODA4NGU4NC90YWJsZXJhbmdlOjY3ZWU4YTcxODk5MDRjOTA5YmRhMjVkNjg4MDg0ZTg0XzYtMTEtMS0xLTA_b6f22fd2-a6ff-4f37-b2aa-98e117dea258"
      unitRef="usd">-23000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
      contextRef="ie069c94280064225b4ffe831d6c5e5fe_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjQvZnJhZzo0MDI1ZmJmMmQ0MTY0MWZhODhhZTg0YmZkZDc4M2YzZS90YWJsZTo2N2VlOGE3MTg5OTA0YzkwOWJkYTI1ZDY4ODA4NGU4NC90YWJsZXJhbmdlOjY3ZWU4YTcxODk5MDRjOTA5YmRhMjVkNjg4MDg0ZTg0XzYtMTMtMS0xLTA_9d8c6f74-0c8c-4364-a057-873f99bcc373"
      unitRef="usd">1351000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjQvZnJhZzo0MDI1ZmJmMmQ0MTY0MWZhODhhZTg0YmZkZDc4M2YzZS90YWJsZTo2N2VlOGE3MTg5OTA0YzkwOWJkYTI1ZDY4ODA4NGU4NC90YWJsZXJhbmdlOjY3ZWU4YTcxODk5MDRjOTA5YmRhMjVkNjg4MDg0ZTg0XzYtMTUtMS0xLTA_ed92be78-e642-46c7-a49f-32d056e08da6"
      unitRef="usd">830000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1
      contextRef="i5d62628d6fb54fe0bd811fdfd0bf7b0c_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjQvZnJhZzo0MDI1ZmJmMmQ0MTY0MWZhODhhZTg0YmZkZDc4M2YzZS90YWJsZTo2N2VlOGE3MTg5OTA0YzkwOWJkYTI1ZDY4ODA4NGU4NC90YWJsZXJhbmdlOjY3ZWU4YTcxODk5MDRjOTA5YmRhMjVkNjg4MDg0ZTg0XzctMS0xLTEtMA_19c6842d-d3c4-401f-9148-5ac37249e042"
      unitRef="usd">20801000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1
      contextRef="ib887805409a54f638aeeafe3fe5d1688_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjQvZnJhZzo0MDI1ZmJmMmQ0MTY0MWZhODhhZTg0YmZkZDc4M2YzZS90YWJsZTo2N2VlOGE3MTg5OTA0YzkwOWJkYTI1ZDY4ODA4NGU4NC90YWJsZXJhbmdlOjY3ZWU4YTcxODk5MDRjOTA5YmRhMjVkNjg4MDg0ZTg0XzctMy0xLTEtMA_de0a7189-6be4-43f0-a9cc-d10253caba50"
      unitRef="usd">73379000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1
      contextRef="i558e7ef31d4b428c9ee6d8d5a9dd5f54_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjQvZnJhZzo0MDI1ZmJmMmQ0MTY0MWZhODhhZTg0YmZkZDc4M2YzZS90YWJsZTo2N2VlOGE3MTg5OTA0YzkwOWJkYTI1ZDY4ODA4NGU4NC90YWJsZXJhbmdlOjY3ZWU4YTcxODk5MDRjOTA5YmRhMjVkNjg4MDg0ZTg0XzctNS0xLTEtMA_042772d6-294c-443c-84a2-79a1d7ac42a5"
      unitRef="usd">23274000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjQvZnJhZzo0MDI1ZmJmMmQ0MTY0MWZhODhhZTg0YmZkZDc4M2YzZS90YWJsZTo2N2VlOGE3MTg5OTA0YzkwOWJkYTI1ZDY4ODA4NGU4NC90YWJsZXJhbmdlOjY3ZWU4YTcxODk5MDRjOTA5YmRhMjVkNjg4MDg0ZTg0XzctNy0xLTEtMA_63fa182a-b88b-447d-b647-96a1f431e92b"
      unitRef="usd">117454000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1
      contextRef="i8d756ddfc980426086c7294d41dd2af3_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjQvZnJhZzo0MDI1ZmJmMmQ0MTY0MWZhODhhZTg0YmZkZDc4M2YzZS90YWJsZTo2N2VlOGE3MTg5OTA0YzkwOWJkYTI1ZDY4ODA4NGU4NC90YWJsZXJhbmdlOjY3ZWU4YTcxODk5MDRjOTA5YmRhMjVkNjg4MDg0ZTg0XzctOS0xLTEtMA_fe7024d9-01ee-44c5-ac3f-2d2d7385a81f"
      unitRef="usd">4020000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1
      contextRef="ic606425dedeb4d3d9b0b453c252ea236_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjQvZnJhZzo0MDI1ZmJmMmQ0MTY0MWZhODhhZTg0YmZkZDc4M2YzZS90YWJsZTo2N2VlOGE3MTg5OTA0YzkwOWJkYTI1ZDY4ODA4NGU4NC90YWJsZXJhbmdlOjY3ZWU4YTcxODk5MDRjOTA5YmRhMjVkNjg4MDg0ZTg0XzctMTEtMS0xLTA_e0006e90-e73f-4061-b16f-c4a83d276801"
      unitRef="usd">163431000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1
      contextRef="ie069c94280064225b4ffe831d6c5e5fe_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjQvZnJhZzo0MDI1ZmJmMmQ0MTY0MWZhODhhZTg0YmZkZDc4M2YzZS90YWJsZTo2N2VlOGE3MTg5OTA0YzkwOWJkYTI1ZDY4ODA4NGU4NC90YWJsZXJhbmdlOjY3ZWU4YTcxODk5MDRjOTA5YmRhMjVkNjg4MDg0ZTg0XzctMTMtMS0xLTA_f7a1e640-cdd3-491d-9b9f-4d127767dab9"
      unitRef="usd">33538000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjQvZnJhZzo0MDI1ZmJmMmQ0MTY0MWZhODhhZTg0YmZkZDc4M2YzZS90YWJsZTo2N2VlOGE3MTg5OTA0YzkwOWJkYTI1ZDY4ODA4NGU4NC90YWJsZXJhbmdlOjY3ZWU4YTcxODk5MDRjOTA5YmRhMjVkNjg4MDg0ZTg0XzctMTUtMS0xLTA_0ec488ef-9fd7-4ecb-aa74-6a67148dca59"
      unitRef="usd">200989000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1
      contextRef="i5d62628d6fb54fe0bd811fdfd0bf7b0c_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjQvZnJhZzo0MDI1ZmJmMmQ0MTY0MWZhODhhZTg0YmZkZDc4M2YzZS90YWJsZTo2N2VlOGE3MTg5OTA0YzkwOWJkYTI1ZDY4ODA4NGU4NC90YWJsZXJhbmdlOjY3ZWU4YTcxODk5MDRjOTA5YmRhMjVkNjg4MDg0ZTg0XzgtMS0xLTEtMA_3ab5496a-7581-4c42-a929-817635ef1af4"
      unitRef="usd">20673000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1
      contextRef="ib887805409a54f638aeeafe3fe5d1688_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjQvZnJhZzo0MDI1ZmJmMmQ0MTY0MWZhODhhZTg0YmZkZDc4M2YzZS90YWJsZTo2N2VlOGE3MTg5OTA0YzkwOWJkYTI1ZDY4ODA4NGU4NC90YWJsZXJhbmdlOjY3ZWU4YTcxODk5MDRjOTA5YmRhMjVkNjg4MDg0ZTg0XzgtMy0xLTEtMA_35fe4b6a-e9b0-40eb-bb7f-b9e282f0f4b7"
      unitRef="usd">71392000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1
      contextRef="i558e7ef31d4b428c9ee6d8d5a9dd5f54_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjQvZnJhZzo0MDI1ZmJmMmQ0MTY0MWZhODhhZTg0YmZkZDc4M2YzZS90YWJsZTo2N2VlOGE3MTg5OTA0YzkwOWJkYTI1ZDY4ODA4NGU4NC90YWJsZXJhbmdlOjY3ZWU4YTcxODk5MDRjOTA5YmRhMjVkNjg4MDg0ZTg0XzgtNS0xLTEtMA_83d6ae14-fdf9-45a1-a0ae-825f34bf3462"
      unitRef="usd">7378000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjQvZnJhZzo0MDI1ZmJmMmQ0MTY0MWZhODhhZTg0YmZkZDc4M2YzZS90YWJsZTo2N2VlOGE3MTg5OTA0YzkwOWJkYTI1ZDY4ODA4NGU4NC90YWJsZXJhbmdlOjY3ZWU4YTcxODk5MDRjOTA5YmRhMjVkNjg4MDg0ZTg0XzgtNy0xLTEtMA_603897f7-dc09-4377-88f2-da7d363c83be"
      unitRef="usd">99443000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1
      contextRef="i8d756ddfc980426086c7294d41dd2af3_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjQvZnJhZzo0MDI1ZmJmMmQ0MTY0MWZhODhhZTg0YmZkZDc4M2YzZS90YWJsZTo2N2VlOGE3MTg5OTA0YzkwOWJkYTI1ZDY4ODA4NGU4NC90YWJsZXJhbmdlOjY3ZWU4YTcxODk5MDRjOTA5YmRhMjVkNjg4MDg0ZTg0XzgtOS0xLTEtMA_9ad541f4-d1c5-4412-b753-c57f070c2bd5"
      unitRef="usd">2530000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1
      contextRef="ic606425dedeb4d3d9b0b453c252ea236_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjQvZnJhZzo0MDI1ZmJmMmQ0MTY0MWZhODhhZTg0YmZkZDc4M2YzZS90YWJsZTo2N2VlOGE3MTg5OTA0YzkwOWJkYTI1ZDY4ODA4NGU4NC90YWJsZXJhbmdlOjY3ZWU4YTcxODk5MDRjOTA5YmRhMjVkNjg4MDg0ZTg0XzgtMTEtMS0xLTA_7bed7bae-184f-4dc2-be4d-39312c9eb9c4"
      unitRef="usd">7499000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1
      contextRef="ie069c94280064225b4ffe831d6c5e5fe_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjQvZnJhZzo0MDI1ZmJmMmQ0MTY0MWZhODhhZTg0YmZkZDc4M2YzZS90YWJsZTo2N2VlOGE3MTg5OTA0YzkwOWJkYTI1ZDY4ODA4NGU4NC90YWJsZXJhbmdlOjY3ZWU4YTcxODk5MDRjOTA5YmRhMjVkNjg4MDg0ZTg0XzgtMTMtMS0xLTA_18a1799d-9363-494f-83cc-1bdcd146fca9"
      unitRef="usd">6975000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjQvZnJhZzo0MDI1ZmJmMmQ0MTY0MWZhODhhZTg0YmZkZDc4M2YzZS90YWJsZTo2N2VlOGE3MTg5OTA0YzkwOWJkYTI1ZDY4ODA4NGU4NC90YWJsZXJhbmdlOjY3ZWU4YTcxODk5MDRjOTA5YmRhMjVkNjg4MDg0ZTg0XzgtMTUtMS0xLTA_9281035a-e447-4843-92aa-b4969e60e97c"
      unitRef="usd">17004000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease
      contextRef="i5d62628d6fb54fe0bd811fdfd0bf7b0c_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjQvZnJhZzo0MDI1ZmJmMmQ0MTY0MWZhODhhZTg0YmZkZDc4M2YzZS90YWJsZTo2N2VlOGE3MTg5OTA0YzkwOWJkYTI1ZDY4ODA4NGU4NC90YWJsZXJhbmdlOjY3ZWU4YTcxODk5MDRjOTA5YmRhMjVkNjg4MDg0ZTg0XzktMS0xLTEtMA_b62048d2-1be6-4487-a1bd-110e1b11e9a4"
      unitRef="usd">-26512000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease
      contextRef="ib887805409a54f638aeeafe3fe5d1688_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjQvZnJhZzo0MDI1ZmJmMmQ0MTY0MWZhODhhZTg0YmZkZDc4M2YzZS90YWJsZTo2N2VlOGE3MTg5OTA0YzkwOWJkYTI1ZDY4ODA4NGU4NC90YWJsZXJhbmdlOjY3ZWU4YTcxODk5MDRjOTA5YmRhMjVkNjg4MDg0ZTg0XzktMy0xLTEtMA_4314fa70-9d58-4d25-8751-c522efc6e901"
      unitRef="usd">74787000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease
      contextRef="i558e7ef31d4b428c9ee6d8d5a9dd5f54_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjQvZnJhZzo0MDI1ZmJmMmQ0MTY0MWZhODhhZTg0YmZkZDc4M2YzZS90YWJsZTo2N2VlOGE3MTg5OTA0YzkwOWJkYTI1ZDY4ODA4NGU4NC90YWJsZXJhbmdlOjY3ZWU4YTcxODk5MDRjOTA5YmRhMjVkNjg4MDg0ZTg0XzktNS0xLTEtMA_53954d6a-ae27-454e-90be-e67d42354e97"
      unitRef="usd">3335000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjQvZnJhZzo0MDI1ZmJmMmQ0MTY0MWZhODhhZTg0YmZkZDc4M2YzZS90YWJsZTo2N2VlOGE3MTg5OTA0YzkwOWJkYTI1ZDY4ODA4NGU4NC90YWJsZXJhbmdlOjY3ZWU4YTcxODk5MDRjOTA5YmRhMjVkNjg4MDg0ZTg0XzktNy0xLTEtMA_dcbec57e-b1f3-4665-b2f7-982a1c1920b4"
      unitRef="usd">51610000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease
      contextRef="i8d756ddfc980426086c7294d41dd2af3_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjQvZnJhZzo0MDI1ZmJmMmQ0MTY0MWZhODhhZTg0YmZkZDc4M2YzZS90YWJsZTo2N2VlOGE3MTg5OTA0YzkwOWJkYTI1ZDY4ODA4NGU4NC90YWJsZXJhbmdlOjY3ZWU4YTcxODk5MDRjOTA5YmRhMjVkNjg4MDg0ZTg0XzktOS0xLTEtMA_d8fb8b1f-9995-4227-a0a6-6d06c727ca21"
      unitRef="usd">-4913000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease
      contextRef="ic606425dedeb4d3d9b0b453c252ea236_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjQvZnJhZzo0MDI1ZmJmMmQ0MTY0MWZhODhhZTg0YmZkZDc4M2YzZS90YWJsZTo2N2VlOGE3MTg5OTA0YzkwOWJkYTI1ZDY4ODA4NGU4NC90YWJsZXJhbmdlOjY3ZWU4YTcxODk5MDRjOTA5YmRhMjVkNjg4MDg0ZTg0XzktMTEtMS0xLTA_1824ed83-9823-4889-be8b-61140f85276e"
      unitRef="usd">31024000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease
      contextRef="ie069c94280064225b4ffe831d6c5e5fe_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjQvZnJhZzo0MDI1ZmJmMmQ0MTY0MWZhODhhZTg0YmZkZDc4M2YzZS90YWJsZTo2N2VlOGE3MTg5OTA0YzkwOWJkYTI1ZDY4ODA4NGU4NC90YWJsZXJhbmdlOjY3ZWU4YTcxODk5MDRjOTA5YmRhMjVkNjg4MDg0ZTg0XzktMTMtMS0xLTA_181272e6-c4ad-4eac-83a7-c3691192fd92"
      unitRef="usd">2422000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjQvZnJhZzo0MDI1ZmJmMmQ0MTY0MWZhODhhZTg0YmZkZDc4M2YzZS90YWJsZTo2N2VlOGE3MTg5OTA0YzkwOWJkYTI1ZDY4ODA4NGU4NC90YWJsZXJhbmdlOjY3ZWU4YTcxODk5MDRjOTA5YmRhMjVkNjg4MDg0ZTg0XzktMTUtMS0xLTA_dcac38a8-8edf-4090-800d-1239edcc1c7e"
      unitRef="usd">28533000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease>
    <evh:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseDisposalOfDiscontinuedOperations
      contextRef="ie355e9ffef734dc6a2b8f3d027278891_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjQvZnJhZzo0MDI1ZmJmMmQ0MTY0MWZhODhhZTg0YmZkZDc4M2YzZS90YWJsZTo2N2VlOGE3MTg5OTA0YzkwOWJkYTI1ZDY4ODA4NGU4NC90YWJsZXJhbmdlOjY3ZWU4YTcxODk5MDRjOTA5YmRhMjVkNjg4MDg0ZTg0XzExLTEtMS0xLTA_e28db980-8372-440a-a4b6-96aadf37f311"
      unitRef="usd">0</evh:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseDisposalOfDiscontinuedOperations>
    <evh:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseDisposalOfDiscontinuedOperations
      contextRef="i9c3ddb1ccecb442ca473281d46c1ef16_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjQvZnJhZzo0MDI1ZmJmMmQ0MTY0MWZhODhhZTg0YmZkZDc4M2YzZS90YWJsZTo2N2VlOGE3MTg5OTA0YzkwOWJkYTI1ZDY4ODA4NGU4NC90YWJsZXJhbmdlOjY3ZWU4YTcxODk5MDRjOTA5YmRhMjVkNjg4MDg0ZTg0XzExLTMtMS0xLTA_912ccf40-b0e4-43c5-8d9b-a8d5612618ed"
      unitRef="usd">0</evh:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseDisposalOfDiscontinuedOperations>
    <evh:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseDisposalOfDiscontinuedOperations
      contextRef="i89185ecde2ae43c5b615a3084603455c_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjQvZnJhZzo0MDI1ZmJmMmQ0MTY0MWZhODhhZTg0YmZkZDc4M2YzZS90YWJsZTo2N2VlOGE3MTg5OTA0YzkwOWJkYTI1ZDY4ODA4NGU4NC90YWJsZXJhbmdlOjY3ZWU4YTcxODk5MDRjOTA5YmRhMjVkNjg4MDg0ZTg0XzExLTUtMS0xLTA_83f61314-db8a-4bf2-ba0c-8f44376981cf"
      unitRef="usd">13194000</evh:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseDisposalOfDiscontinuedOperations>
    <evh:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseDisposalOfDiscontinuedOperations
      contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjQvZnJhZzo0MDI1ZmJmMmQ0MTY0MWZhODhhZTg0YmZkZDc4M2YzZS90YWJsZTo2N2VlOGE3MTg5OTA0YzkwOWJkYTI1ZDY4ODA4NGU4NC90YWJsZXJhbmdlOjY3ZWU4YTcxODk5MDRjOTA5YmRhMjVkNjg4MDg0ZTg0XzExLTctMS0xLTA_0e6bcd6b-623b-403d-929f-de64f33d0b77"
      unitRef="usd">13194000</evh:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseDisposalOfDiscontinuedOperations>
    <evh:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseDisposalOfDiscontinuedOperations
      contextRef="if5ff183307a4468fb0d5707822525486_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjQvZnJhZzo0MDI1ZmJmMmQ0MTY0MWZhODhhZTg0YmZkZDc4M2YzZS90YWJsZTo2N2VlOGE3MTg5OTA0YzkwOWJkYTI1ZDY4ODA4NGU4NC90YWJsZXJhbmdlOjY3ZWU4YTcxODk5MDRjOTA5YmRhMjVkNjg4MDg0ZTg0XzExLTktMS0xLTA_6be1aa9c-7ad8-473d-8993-e053e25ea278"
      unitRef="usd">0</evh:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseDisposalOfDiscontinuedOperations>
    <evh:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseDisposalOfDiscontinuedOperations
      contextRef="i25d27166851f4878bc9c647f69bfd2ea_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjQvZnJhZzo0MDI1ZmJmMmQ0MTY0MWZhODhhZTg0YmZkZDc4M2YzZS90YWJsZTo2N2VlOGE3MTg5OTA0YzkwOWJkYTI1ZDY4ODA4NGU4NC90YWJsZXJhbmdlOjY3ZWU4YTcxODk5MDRjOTA5YmRhMjVkNjg4MDg0ZTg0XzExLTExLTEtMS0w_2e27bb11-9a9a-4190-99ca-a2b31f1e81f5"
      unitRef="usd">0</evh:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseDisposalOfDiscontinuedOperations>
    <evh:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseDisposalOfDiscontinuedOperations
      contextRef="i80bca972b5164b02a2d38d8930a36773_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjQvZnJhZzo0MDI1ZmJmMmQ0MTY0MWZhODhhZTg0YmZkZDc4M2YzZS90YWJsZTo2N2VlOGE3MTg5OTA0YzkwOWJkYTI1ZDY4ODA4NGU4NC90YWJsZXJhbmdlOjY3ZWU4YTcxODk5MDRjOTA5YmRhMjVkNjg4MDg0ZTg0XzExLTEzLTEtMS0w_945ee1c8-a4d6-4c30-ac5a-08a4dedefe43"
      unitRef="usd">0</evh:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseDisposalOfDiscontinuedOperations>
    <evh:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseDisposalOfDiscontinuedOperations
      contextRef="i11817f96c3e24e0abaed14a17869e173_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjQvZnJhZzo0MDI1ZmJmMmQ0MTY0MWZhODhhZTg0YmZkZDc4M2YzZS90YWJsZTo2N2VlOGE3MTg5OTA0YzkwOWJkYTI1ZDY4ODA4NGU4NC90YWJsZXJhbmdlOjY3ZWU4YTcxODk5MDRjOTA5YmRhMjVkNjg4MDg0ZTg0XzExLTE1LTEtMS0w_5475443d-bb05-4796-91bb-81385c8e8f00"
      unitRef="usd">0</evh:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseDisposalOfDiscontinuedOperations>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments
      contextRef="ie355e9ffef734dc6a2b8f3d027278891_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjQvZnJhZzo0MDI1ZmJmMmQ0MTY0MWZhODhhZTg0YmZkZDc4M2YzZS90YWJsZTo2N2VlOGE3MTg5OTA0YzkwOWJkYTI1ZDY4ODA4NGU4NC90YWJsZXJhbmdlOjY3ZWU4YTcxODk5MDRjOTA5YmRhMjVkNjg4MDg0ZTg0XzEyLTEtMS0xLTA_d3a17603-72a7-4f68-b7fc-42731349afcf"
      unitRef="usd">-3721000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments
      contextRef="i9c3ddb1ccecb442ca473281d46c1ef16_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjQvZnJhZzo0MDI1ZmJmMmQ0MTY0MWZhODhhZTg0YmZkZDc4M2YzZS90YWJsZTo2N2VlOGE3MTg5OTA0YzkwOWJkYTI1ZDY4ODA4NGU4NC90YWJsZXJhbmdlOjY3ZWU4YTcxODk5MDRjOTA5YmRhMjVkNjg4MDg0ZTg0XzEyLTMtMS0xLTA_231dabb1-6d7e-44ef-aef3-ef43481d1857"
      unitRef="usd">-7282000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments
      contextRef="i89185ecde2ae43c5b615a3084603455c_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjQvZnJhZzo0MDI1ZmJmMmQ0MTY0MWZhODhhZTg0YmZkZDc4M2YzZS90YWJsZTo2N2VlOGE3MTg5OTA0YzkwOWJkYTI1ZDY4ODA4NGU4NC90YWJsZXJhbmdlOjY3ZWU4YTcxODk5MDRjOTA5YmRhMjVkNjg4MDg0ZTg0XzEyLTUtMS0xLTA_0a5be8ad-fe85-40ea-93db-fb29161f5c7e"
      unitRef="usd">0</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments
      contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjQvZnJhZzo0MDI1ZmJmMmQ0MTY0MWZhODhhZTg0YmZkZDc4M2YzZS90YWJsZTo2N2VlOGE3MTg5OTA0YzkwOWJkYTI1ZDY4ODA4NGU4NC90YWJsZXJhbmdlOjY3ZWU4YTcxODk5MDRjOTA5YmRhMjVkNjg4MDg0ZTg0XzEyLTctMS0xLTA_bf764e35-57d2-47d3-b3a5-6302b8ded090"
      unitRef="usd">-11003000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments
      contextRef="if5ff183307a4468fb0d5707822525486_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjQvZnJhZzo0MDI1ZmJmMmQ0MTY0MWZhODhhZTg0YmZkZDc4M2YzZS90YWJsZTo2N2VlOGE3MTg5OTA0YzkwOWJkYTI1ZDY4ODA4NGU4NC90YWJsZXJhbmdlOjY3ZWU4YTcxODk5MDRjOTA5YmRhMjVkNjg4MDg0ZTg0XzEyLTktMS0xLTA_50fbf5bf-9af1-49c9-acf3-88a9136f3a08"
      unitRef="usd">0</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments
      contextRef="i25d27166851f4878bc9c647f69bfd2ea_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjQvZnJhZzo0MDI1ZmJmMmQ0MTY0MWZhODhhZTg0YmZkZDc4M2YzZS90YWJsZTo2N2VlOGE3MTg5OTA0YzkwOWJkYTI1ZDY4ODA4NGU4NC90YWJsZXJhbmdlOjY3ZWU4YTcxODk5MDRjOTA5YmRhMjVkNjg4MDg0ZTg0XzEyLTExLTEtMS0w_9caa1ac1-26d7-45dc-a7bf-570770d03be0"
      unitRef="usd">-4726000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments
      contextRef="i80bca972b5164b02a2d38d8930a36773_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjQvZnJhZzo0MDI1ZmJmMmQ0MTY0MWZhODhhZTg0YmZkZDc4M2YzZS90YWJsZTo2N2VlOGE3MTg5OTA0YzkwOWJkYTI1ZDY4ODA4NGU4NC90YWJsZXJhbmdlOjY3ZWU4YTcxODk5MDRjOTA5YmRhMjVkNjg4MDg0ZTg0XzEyLTEzLTEtMS0w_a6814b2f-64e8-4769-9349-7862b5f7bad6"
      unitRef="usd">0</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments
      contextRef="i11817f96c3e24e0abaed14a17869e173_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjQvZnJhZzo0MDI1ZmJmMmQ0MTY0MWZhODhhZTg0YmZkZDc4M2YzZS90YWJsZTo2N2VlOGE3MTg5OTA0YzkwOWJkYTI1ZDY4ODA4NGU4NC90YWJsZXJhbmdlOjY3ZWU4YTcxODk5MDRjOTA5YmRhMjVkNjg4MDg0ZTg0XzEyLTE1LTEtMS0w_dd23fb10-a65e-4980-9f8c-ce2003941c49"
      unitRef="usd">-4726000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="ie355e9ffef734dc6a2b8f3d027278891_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjQvZnJhZzo0MDI1ZmJmMmQ0MTY0MWZhODhhZTg0YmZkZDc4M2YzZS90YWJsZTo2N2VlOGE3MTg5OTA0YzkwOWJkYTI1ZDY4ODA4NGU4NC90YWJsZXJhbmdlOjY3ZWU4YTcxODk5MDRjOTA5YmRhMjVkNjg4MDg0ZTg0XzEzLTEtMS0xLTA_7c7adfee-aad2-4d86-a105-d2100deb3b3c"
      unitRef="usd">33504000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i9c3ddb1ccecb442ca473281d46c1ef16_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjQvZnJhZzo0MDI1ZmJmMmQ0MTY0MWZhODhhZTg0YmZkZDc4M2YzZS90YWJsZTo2N2VlOGE3MTg5OTA0YzkwOWJkYTI1ZDY4ODA4NGU4NC90YWJsZXJhbmdlOjY3ZWU4YTcxODk5MDRjOTA5YmRhMjVkNjg4MDg0ZTg0XzEzLTMtMS0xLTA_4d11b07b-df5c-4fd1-89f3-b72af0cc8c74"
      unitRef="usd">204601000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i89185ecde2ae43c5b615a3084603455c_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjQvZnJhZzo0MDI1ZmJmMmQ0MTY0MWZhODhhZTg0YmZkZDc4M2YzZS90YWJsZTo2N2VlOGE3MTg5OTA0YzkwOWJkYTI1ZDY4ODA4NGU4NC90YWJsZXJhbmdlOjY3ZWU4YTcxODk5MDRjOTA5YmRhMjVkNjg4MDg0ZTg0XzEzLTUtMS0xLTA_594bc202-f125-4a41-87c6-5d8767d54692"
      unitRef="usd">0</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="if6c0e91c6c854cf38504ed9bee64b0fa_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjQvZnJhZzo0MDI1ZmJmMmQ0MTY0MWZhODhhZTg0YmZkZDc4M2YzZS90YWJsZTo2N2VlOGE3MTg5OTA0YzkwOWJkYTI1ZDY4ODA4NGU4NC90YWJsZXJhbmdlOjY3ZWU4YTcxODk5MDRjOTA5YmRhMjVkNjg4MDg0ZTg0XzEzLTctMS0xLTA_8387fe2d-bc4e-4c16-8aef-034952b4902a"
      unitRef="usd">238105000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="if5ff183307a4468fb0d5707822525486_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjQvZnJhZzo0MDI1ZmJmMmQ0MTY0MWZhODhhZTg0YmZkZDc4M2YzZS90YWJsZTo2N2VlOGE3MTg5OTA0YzkwOWJkYTI1ZDY4ODA4NGU4NC90YWJsZXJhbmdlOjY3ZWU4YTcxODk5MDRjOTA5YmRhMjVkNjg4MDg0ZTg0XzEzLTktMS0xLTA_9ee07b93-4709-47fb-8383-e98d216b312b"
      unitRef="usd">-648000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i25d27166851f4878bc9c647f69bfd2ea_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjQvZnJhZzo0MDI1ZmJmMmQ0MTY0MWZhODhhZTg0YmZkZDc4M2YzZS90YWJsZTo2N2VlOGE3MTg5OTA0YzkwOWJkYTI1ZDY4ODA4NGU4NC90YWJsZXJhbmdlOjY3ZWU4YTcxODk5MDRjOTA5YmRhMjVkNjg4MDg0ZTg0XzEzLTExLTEtMS0w_85c07f9c-0306-4f05-a825-69a76e6e0feb"
      unitRef="usd">85995000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i80bca972b5164b02a2d38d8930a36773_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjQvZnJhZzo0MDI1ZmJmMmQ0MTY0MWZhODhhZTg0YmZkZDc4M2YzZS90YWJsZTo2N2VlOGE3MTg5OTA0YzkwOWJkYTI1ZDY4ODA4NGU4NC90YWJsZXJhbmdlOjY3ZWU4YTcxODk5MDRjOTA5YmRhMjVkNjg4MDg0ZTg0XzEzLTEzLTEtMS0w_c2393804-4ff1-47b9-b370-f54601e3c77f"
      unitRef="usd">9062000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i11817f96c3e24e0abaed14a17869e173_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMjQvZnJhZzo0MDI1ZmJmMmQ0MTY0MWZhODhhZTg0YmZkZDc4M2YzZS90YWJsZTo2N2VlOGE3MTg5OTA0YzkwOWJkYTI1ZDY4ODA4NGU4NC90YWJsZXJhbmdlOjY3ZWU4YTcxODk5MDRjOTA5YmRhMjVkNjg4MDg0ZTg0XzEzLTE1LTEtMS0w_659d69d0-9780-4135-91f5-8fcb8e2f8be6"
      unitRef="usd">94409000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:CashFlowSupplementalDisclosuresTextBlock
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMzMvZnJhZzplOWEyZDI1OWY1NTQ0MTAzYmYzNWQwOWVlMjBhYzg1Ni90ZXh0cmVnaW9uOmU5YTJkMjU5ZjU1NDQxMDNiZjM1ZDA5ZWUyMGFjODU2XzEzNQ_f355b29e-38e2-41b7-80cf-f2dc089f6990">Supplemental Cash Flow Information &lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following represents supplemental cash flow information the six months ended June 30, 2021 and 2020 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:433.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Supplemental Disclosure of Non-cash Investing and Financing Activities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;Increase/decrease to goodwill from measurement period adjustments/business combinations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Class A common stock issued for payment of Passport/Global earn-out&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued property and equipment purchases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Effects of Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;Operating cash flows from operating leases &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;Leased assets obtained in exchange for operating lease liabilities &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,157)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,354)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:CashFlowSupplementalDisclosuresTextBlock>
    <us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMzMvZnJhZzplOWEyZDI1OWY1NTQ0MTAzYmYzNWQwOWVlMjBhYzg1Ni90ZXh0cmVnaW9uOmU5YTJkMjU5ZjU1NDQxMDNiZjM1ZDA5ZWUyMGFjODU2XzEzNA_991bc880-92be-459e-8570-da91088cb34c">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following represents supplemental cash flow information the six months ended June 30, 2021 and 2020 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:433.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Supplemental Disclosure of Non-cash Investing and Financing Activities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;Increase/decrease to goodwill from measurement period adjustments/business combinations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Class A common stock issued for payment of Passport/Global earn-out&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued property and equipment purchases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Effects of Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;Operating cash flows from operating leases &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;Leased assets obtained in exchange for operating lease liabilities &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,157)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,354)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock>
    <evh:NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationMeasurementPeriodAdjustment
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMzMvZnJhZzplOWEyZDI1OWY1NTQ0MTAzYmYzNWQwOWVlMjBhYzg1Ni90YWJsZTo1Nzk2ZmNiYTk0MmE0YTY4ODUyODJjYThiMGM1MmEzZi90YWJsZXJhbmdlOjU3OTZmY2JhOTQyYTRhNjg4NTI4MmNhOGIwYzUyYTNmXzMtMS0xLTEtMA_822ceb0c-25b2-435d-865b-00499b3dc252"
      unitRef="usd">0</evh:NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationMeasurementPeriodAdjustment>
    <evh:NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationMeasurementPeriodAdjustment
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMzMvZnJhZzplOWEyZDI1OWY1NTQ0MTAzYmYzNWQwOWVlMjBhYzg1Ni90YWJsZTo1Nzk2ZmNiYTk0MmE0YTY4ODUyODJjYThiMGM1MmEzZi90YWJsZXJhbmdlOjU3OTZmY2JhOTQyYTRhNjg4NTI4MmNhOGIwYzUyYTNmXzMtMy0xLTEtMA_2a93d153-0122-4e04-8c54-72348363c8fe"
      unitRef="usd">2200000</evh:NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationMeasurementPeriodAdjustment>
    <us-gaap:NoncashOrPartNoncashAcquisitionPayablesAssumed1
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMzMvZnJhZzplOWEyZDI1OWY1NTQ0MTAzYmYzNWQwOWVlMjBhYzg1Ni90YWJsZTo1Nzk2ZmNiYTk0MmE0YTY4ODUyODJjYThiMGM1MmEzZi90YWJsZXJhbmdlOjU3OTZmY2JhOTQyYTRhNjg4NTI4MmNhOGIwYzUyYTNmXzQtMS0xLTEtMA_cb5807de-5197-4395-9299-9dd2dda8cf0d"
      unitRef="usd">0</us-gaap:NoncashOrPartNoncashAcquisitionPayablesAssumed1>
    <us-gaap:NoncashOrPartNoncashAcquisitionPayablesAssumed1
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMzMvZnJhZzplOWEyZDI1OWY1NTQ0MTAzYmYzNWQwOWVlMjBhYzg1Ni90YWJsZTo1Nzk2ZmNiYTk0MmE0YTY4ODUyODJjYThiMGM1MmEzZi90YWJsZXJhbmdlOjU3OTZmY2JhOTQyYTRhNjg4NTI4MmNhOGIwYzUyYTNmXzQtMy0xLTEtMA_7dd39c02-1cd3-430c-a1d1-8f2d4020eddd"
      unitRef="usd">4185000</us-gaap:NoncashOrPartNoncashAcquisitionPayablesAssumed1>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMzMvZnJhZzplOWEyZDI1OWY1NTQ0MTAzYmYzNWQwOWVlMjBhYzg1Ni90YWJsZTo1Nzk2ZmNiYTk0MmE0YTY4ODUyODJjYThiMGM1MmEzZi90YWJsZXJhbmdlOjU3OTZmY2JhOTQyYTRhNjg4NTI4MmNhOGIwYzUyYTNmXzUtMS0xLTEtMA_bf3248c8-295e-4b47-a9ee-cc89749596da"
      unitRef="usd">668000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <evh:AccruedPropertyAndEquipmentPurchases
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMzMvZnJhZzplOWEyZDI1OWY1NTQ0MTAzYmYzNWQwOWVlMjBhYzg1Ni90YWJsZTo1Nzk2ZmNiYTk0MmE0YTY4ODUyODJjYThiMGM1MmEzZi90YWJsZXJhbmdlOjU3OTZmY2JhOTQyYTRhNjg4NTI4MmNhOGIwYzUyYTNmXzUtMy0xLTEtMA_08d8f1a4-f3d1-46e1-b2fb-29e7917a87b1"
      unitRef="usd">26000</evh:AccruedPropertyAndEquipmentPurchases>
    <us-gaap:OperatingLeasePayments
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMzMvZnJhZzplOWEyZDI1OWY1NTQ0MTAzYmYzNWQwOWVlMjBhYzg1Ni90YWJsZTo1Nzk2ZmNiYTk0MmE0YTY4ODUyODJjYThiMGM1MmEzZi90YWJsZXJhbmdlOjU3OTZmY2JhOTQyYTRhNjg4NTI4MmNhOGIwYzUyYTNmXzctMS0xLTEtMA_6215fede-fdad-47a3-8df7-08d9ec156a2a"
      unitRef="usd">6622000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMzMvZnJhZzplOWEyZDI1OWY1NTQ0MTAzYmYzNWQwOWVlMjBhYzg1Ni90YWJsZTo1Nzk2ZmNiYTk0MmE0YTY4ODUyODJjYThiMGM1MmEzZi90YWJsZXJhbmdlOjU3OTZmY2JhOTQyYTRhNjg4NTI4MmNhOGIwYzUyYTNmXzctMy0xLTEtMA_ad3cf0f6-bfe5-4994-acf0-5b5e3b6df9fd"
      unitRef="usd">6853000</us-gaap:OperatingLeasePayments>
    <evh:RightOfUseAssetAcquiredAndDisposedOf
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMzMvZnJhZzplOWEyZDI1OWY1NTQ0MTAzYmYzNWQwOWVlMjBhYzg1Ni90YWJsZTo1Nzk2ZmNiYTk0MmE0YTY4ODUyODJjYThiMGM1MmEzZi90YWJsZXJhbmdlOjU3OTZmY2JhOTQyYTRhNjg4NTI4MmNhOGIwYzUyYTNmXzgtMS0xLTEtMA_e5652808-f1ea-4dc1-a707-8136d3a45312"
      unitRef="usd">2157000</evh:RightOfUseAssetAcquiredAndDisposedOf>
    <evh:RightOfUseAssetAcquiredAndDisposedOf
      contextRef="i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMzMvZnJhZzplOWEyZDI1OWY1NTQ0MTAzYmYzNWQwOWVlMjBhYzg1Ni90YWJsZTo1Nzk2ZmNiYTk0MmE0YTY4ODUyODJjYThiMGM1MmEzZi90YWJsZXJhbmdlOjU3OTZmY2JhOTQyYTRhNjg4NTI4MmNhOGIwYzUyYTNmXzgtMy0xLTEtMA_8bc730f7-9130-4cfb-a62a-096181b2eacc"
      unitRef="usd">1354000</evh:RightOfUseAssetAcquiredAndDisposedOf>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMzYvZnJhZzowNmUxOWM2YmRkMmU0YjU4YjMyMmNlODUwZmQ1YzE4Ni90ZXh0cmVnaW9uOjA2ZTE5YzZiZGQyZTRiNThiMzIyY2U4NTBmZDVjMTg2XzM4NDgyOTA3MTU0NDg_c57b53f8-59ed-43e5-ad56-6e6080c56be7">Subsequent Events&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Agreement for the Acquisition of Vital Decision&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;On August 2, 2021, Evolent Health LLC and EV Thunder Merger Sub, LLC, each wholly owned subsidiaries of the Company, entered into a definitive agreement for Evolent to acquire Windrose Health Investors III, L.P. portfolio company Vital Decisions for $85&#160;million, with an additional earn out of up to $45&#160;million. Vital Decisions will report into Evolent&#x2019;s specialty management offering, New Century Health, and will be consolidated into the Company&#x2019;s Clinical Solutions segment. Closing of the transaction is subject to customary closing conditions and is expected to occur in the second half of 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMzYvZnJhZzowNmUxOWM2YmRkMmU0YjU4YjMyMmNlODUwZmQ1YzE4Ni90ZXh0cmVnaW9uOjA2ZTE5YzZiZGQyZTRiNThiMzIyY2U4NTBmZDVjMTg2XzQyMzY_09c36fd5-d144-4e88-8fa0-7d3f15f4daa7">Subsequent Events&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Agreement for the Acquisition of Vital Decision&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;On August 2, 2021, Evolent Health LLC and EV Thunder Merger Sub, LLC, each wholly owned subsidiaries of the Company, entered into a definitive agreement for Evolent to acquire Windrose Health Investors III, L.P. portfolio company Vital Decisions for $85&#160;million, with an additional earn out of up to $45&#160;million. Vital Decisions will report into Evolent&#x2019;s specialty management offering, New Century Health, and will be consolidated into the Company&#x2019;s Clinical Solutions segment. Closing of the transaction is subject to customary closing conditions and is expected to occur in the second half of 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="i46534d0a532b4e63ade4879ed3702a19_D20210802-20210802"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMzYvZnJhZzowNmUxOWM2YmRkMmU0YjU4YjMyMmNlODUwZmQ1YzE4Ni90ZXh0cmVnaW9uOjA2ZTE5YzZiZGQyZTRiNThiMzIyY2U4NTBmZDVjMTg2XzEwOTk1MTE2NDU5ODM_cf9593fc-4ba9-4203-b85b-22c2870523c2"
      unitRef="usd">85000000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ic40ea142c3e8460d8998330c2ef6c2fe_I20210802"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18xMzYvZnJhZzowNmUxOWM2YmRkMmU0YjU4YjMyMmNlODUwZmQ1YzE4Ni90ZXh0cmVnaW9uOjA2ZTE5YzZiZGQyZTRiNThiMzIyY2U4NTBmZDVjMTg2XzEwOTk1MTE2NDU5OTY_4299e4bd-b40f-41bf-85ae-1338e5acaa29"
      unitRef="usd">45000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfNDktMy0xLTEtMA_ceaf962b-8aea-4d5b-a2af-c8eac1cdeca1"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfNDktMy0xLTEtMA_ceaf962b-8aea-4d5b-a2af-c8eac1cdeca1"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfNTAtMy0xLTEtMA_54b36cb3-55b4-4c38-a985-8a95b4bae96b"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfNTAtMy0xLTEtMA_54b36cb3-55b4-4c38-a985-8a95b4bae96b"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfNTAtMS0xLTEtMA_e1d467e7-008d-4f8f-808d-93de1533b6f1"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfNTAtMS0xLTEtMA_e1d467e7-008d-4f8f-808d-93de1533b6f1"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfNDktMS0xLTEtMA_e272ccc9-dc55-498c-89b9-404c1f9b6f6f"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfNDktMS0xLTEtMA_e272ccc9-dc55-498c-89b9-404c1f9b6f6f"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RleHRyZWdpb246ZjU1OWJmYTMxNWU4NDFiNDkwMjJlMTQ4ZjBlYWZkY2FfNjE1_f300fa04-bc09-4350-94bb-64f25b72efcf" xlink:label="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RleHRyZWdpb246ZjU1OWJmYTMxNWU4NDFiNDkwMjJlMTQ4ZjBlYWZkY2FfNjE1_f300fa04-bc09-4350-94bb-64f25b72efcf" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">As a result of the closing of the sale of True Health SPA, the consolidated statements of operations, consolidated balance sheets, and related financial information reflect the Company&#x2019;s operations and assets and liabilities of True Health as discontinued operations for all periods presented. Cash flows and comprehensive income have not been adjusted and are included in the consolidated statements of cash flows and consolidated statements of comprehensive income (loss) for all periods presented. See Note 5.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfNDktMy0xLTEtMA_ceaf962b-8aea-4d5b-a2af-c8eac1cdeca1"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RleHRyZWdpb246ZjU1OWJmYTMxNWU4NDFiNDkwMjJlMTQ4ZjBlYWZkY2FfNjE1_f300fa04-bc09-4350-94bb-64f25b72efcf"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfNTAtMy0xLTEtMA_54b36cb3-55b4-4c38-a985-8a95b4bae96b"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RleHRyZWdpb246ZjU1OWJmYTMxNWU4NDFiNDkwMjJlMTQ4ZjBlYWZkY2FfNjE1_f300fa04-bc09-4350-94bb-64f25b72efcf"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfNTAtMS0xLTEtMA_e1d467e7-008d-4f8f-808d-93de1533b6f1"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RleHRyZWdpb246ZjU1OWJmYTMxNWU4NDFiNDkwMjJlMTQ4ZjBlYWZkY2FfNjE1_f300fa04-bc09-4350-94bb-64f25b72efcf"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RhYmxlOmJlMDc3M2UxYWZjNzQzYWU4MWYwMDMzMjJiMzE5MTQ4L3RhYmxlcmFuZ2U6YmUwNzczZTFhZmM3NDNhZTgxZjAwMzMyMmIzMTkxNDhfNDktMS0xLTEtMA_e272ccc9-dc55-498c-89b9-404c1f9b6f6f"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18zNC9mcmFnOmY1NTliZmEzMTVlODQxYjQ5MDIyZTE0OGYwZWFmZGNhL3RleHRyZWdpb246ZjU1OWJmYTMxNWU4NDFiNDkwMjJlMTQ4ZjBlYWZkY2FfNjE1_f300fa04-bc09-4350-94bb-64f25b72efcf"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfNi0zLTEtMS0w_126095e3-ba11-4518-b942-19d719b1d746"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfNi0zLTEtMS0w_126095e3-ba11-4518-b942-19d719b1d746"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfMTMtMS0xLTEtMA_34df675b-2a88-454e-91a0-f1e6eeee0b7a"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfMTMtMS0xLTEtMA_34df675b-2a88-454e-91a0-f1e6eeee0b7a"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfNS0xLTEtMS0w_4ca84b48-7a2c-4c42-b349-4cc6f3d902a5"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfNS0xLTEtMS0w_4ca84b48-7a2c-4c42-b349-4cc6f3d902a5"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfMTMtMy0xLTEtMA_0bd89b3b-2068-4bdc-b1ba-4a900b749388"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfMTMtMy0xLTEtMA_0bd89b3b-2068-4bdc-b1ba-4a900b749388"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfMjgtMS0xLTEtMA_b18bdc4b-8074-4572-9265-14e37f5cd14e"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfMjgtMS0xLTEtMA_b18bdc4b-8074-4572-9265-14e37f5cd14e"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfMjMtMy0xLTEtMA_2f78f8c5-c465-44cf-96b8-12f236568eab"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfMjMtMy0xLTEtMA_2f78f8c5-c465-44cf-96b8-12f236568eab"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfMjgtMy0xLTEtMA_a1ac98c6-5825-4d80-94f4-d279034abf6d"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfMjgtMy0xLTEtMA_a1ac98c6-5825-4d80-94f4-d279034abf6d"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfMjItMy0xLTEtMA_c5e869a8-ed79-4a79-8e99-c692c6b54846"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfMjItMy0xLTEtMA_c5e869a8-ed79-4a79-8e99-c692c6b54846"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfMjItMS0xLTEtMA_1f10d8b5-1db8-4230-98e0-6ce7b5992df9"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfMjItMS0xLTEtMA_1f10d8b5-1db8-4230-98e0-6ce7b5992df9"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfMjMtMS0xLTEtMA_5d00a01b-0f87-47ac-87ff-357987c3f073"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfMjMtMS0xLTEtMA_5d00a01b-0f87-47ac-87ff-357987c3f073"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfNi0xLTEtMS0w_85c2778c-749c-4408-a8dd-d5ac7fcd6a11"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfNi0xLTEtMS0w_85c2778c-749c-4408-a8dd-d5ac7fcd6a11"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfNS0zLTEtMS0w_d66e2798-abe8-4ea9-a342-c46e07beedfa"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfNS0zLTEtMS0w_d66e2798-abe8-4ea9-a342-c46e07beedfa"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RleHRyZWdpb246NmEwNWU3MWI1N2ZmNDBmNDkwMzUyMDE0YzNhZjNmNTZfMjA1_14702e91-5902-4688-9db4-81a13b43b8a2" xlink:label="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RleHRyZWdpb246NmEwNWU3MWI1N2ZmNDBmNDkwMzUyMDE0YzNhZjNmNTZfMjA1_14702e91-5902-4688-9db4-81a13b43b8a2" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">See Note 19 for amounts attributable to unconsolidated related parties included in these line items.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfNi0zLTEtMS0w_126095e3-ba11-4518-b942-19d719b1d746"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RleHRyZWdpb246NmEwNWU3MWI1N2ZmNDBmNDkwMzUyMDE0YzNhZjNmNTZfMjA1_14702e91-5902-4688-9db4-81a13b43b8a2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfMTMtMS0xLTEtMA_34df675b-2a88-454e-91a0-f1e6eeee0b7a"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RleHRyZWdpb246NmEwNWU3MWI1N2ZmNDBmNDkwMzUyMDE0YzNhZjNmNTZfMjA1_14702e91-5902-4688-9db4-81a13b43b8a2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfNS0xLTEtMS0w_4ca84b48-7a2c-4c42-b349-4cc6f3d902a5"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RleHRyZWdpb246NmEwNWU3MWI1N2ZmNDBmNDkwMzUyMDE0YzNhZjNmNTZfMjA1_14702e91-5902-4688-9db4-81a13b43b8a2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfMTMtMy0xLTEtMA_0bd89b3b-2068-4bdc-b1ba-4a900b749388"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RleHRyZWdpb246NmEwNWU3MWI1N2ZmNDBmNDkwMzUyMDE0YzNhZjNmNTZfMjA1_14702e91-5902-4688-9db4-81a13b43b8a2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfMjgtMS0xLTEtMA_b18bdc4b-8074-4572-9265-14e37f5cd14e"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RleHRyZWdpb246NmEwNWU3MWI1N2ZmNDBmNDkwMzUyMDE0YzNhZjNmNTZfMjA1_14702e91-5902-4688-9db4-81a13b43b8a2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfMjMtMy0xLTEtMA_2f78f8c5-c465-44cf-96b8-12f236568eab"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RleHRyZWdpb246NmEwNWU3MWI1N2ZmNDBmNDkwMzUyMDE0YzNhZjNmNTZfMjA1_14702e91-5902-4688-9db4-81a13b43b8a2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfMjgtMy0xLTEtMA_a1ac98c6-5825-4d80-94f4-d279034abf6d"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RleHRyZWdpb246NmEwNWU3MWI1N2ZmNDBmNDkwMzUyMDE0YzNhZjNmNTZfMjA1_14702e91-5902-4688-9db4-81a13b43b8a2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfMjItMy0xLTEtMA_c5e869a8-ed79-4a79-8e99-c692c6b54846"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RleHRyZWdpb246NmEwNWU3MWI1N2ZmNDBmNDkwMzUyMDE0YzNhZjNmNTZfMjA1_14702e91-5902-4688-9db4-81a13b43b8a2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfMjItMS0xLTEtMA_1f10d8b5-1db8-4230-98e0-6ce7b5992df9"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RleHRyZWdpb246NmEwNWU3MWI1N2ZmNDBmNDkwMzUyMDE0YzNhZjNmNTZfMjA1_14702e91-5902-4688-9db4-81a13b43b8a2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfMjMtMS0xLTEtMA_5d00a01b-0f87-47ac-87ff-357987c3f073"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RleHRyZWdpb246NmEwNWU3MWI1N2ZmNDBmNDkwMzUyMDE0YzNhZjNmNTZfMjA1_14702e91-5902-4688-9db4-81a13b43b8a2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfNi0xLTEtMS0w_85c2778c-749c-4408-a8dd-d5ac7fcd6a11"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RleHRyZWdpb246NmEwNWU3MWI1N2ZmNDBmNDkwMzUyMDE0YzNhZjNmNTZfMjA1_14702e91-5902-4688-9db4-81a13b43b8a2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RhYmxlOjQyY2E5Njk2OGRhYjQ1YmFiNGYxNDQwZjE1NDlhOWU1L3RhYmxlcmFuZ2U6NDJjYTk2OTY4ZGFiNDViYWI0ZjE0NDBmMTU0OWE5ZTVfNS0zLTEtMS0w_d66e2798-abe8-4ea9-a342-c46e07beedfa"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yMi9mcmFnOjZhMDVlNzFiNTdmZjQwZjQ5MDM1MjAxNGMzYWYzZjU2L3RleHRyZWdpb246NmEwNWU3MWI1N2ZmNDBmNDkwMzUyMDE0YzNhZjNmNTZfMjA1_14702e91-5902-4688-9db4-81a13b43b8a2"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjExYWJjOWIxMWM5MjRiODM4OTZmNmRjYjRjMWY4M2NkL3RhYmxlcmFuZ2U6MTFhYmM5YjExYzkyNGI4Mzg5NmY2ZGNiNGMxZjgzY2RfMy0zLTEtMS0xMDMx_23a653a3-53f9-4fa2-825a-b0238aa1e1bc"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjExYWJjOWIxMWM5MjRiODM4OTZmNmRjYjRjMWY4M2NkL3RhYmxlcmFuZ2U6MTFhYmM5YjExYzkyNGI4Mzg5NmY2ZGNiNGMxZjgzY2RfMy0zLTEtMS0xMDMx_23a653a3-53f9-4fa2-825a-b0238aa1e1bc"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjExYWJjOWIxMWM5MjRiODM4OTZmNmRjYjRjMWY4M2NkL3RhYmxlcmFuZ2U6MTFhYmM5YjExYzkyNGI4Mzg5NmY2ZGNiNGMxZjgzY2RfMy0zLTEtMS0w_e40e5aa3-d436-463d-ae79-d4a972b39319"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjExYWJjOWIxMWM5MjRiODM4OTZmNmRjYjRjMWY4M2NkL3RhYmxlcmFuZ2U6MTFhYmM5YjExYzkyNGI4Mzg5NmY2ZGNiNGMxZjgzY2RfMy0zLTEtMS0w_e40e5aa3-d436-463d-ae79-d4a972b39319"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMjUtMS0xLTEtMA_c5ecddec-ea61-49d7-9ee4-4bc37ada6314"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMjUtMS0xLTEtMA_c5ecddec-ea61-49d7-9ee4-4bc37ada6314"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMjUtMy0xLTEtMTEw_23a653a3-53f9-4fa2-825a-b0238aa1e1bc"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMjUtMy0xLTEtMTEw_23a653a3-53f9-4fa2-825a-b0238aa1e1bc"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjExYWJjOWIxMWM5MjRiODM4OTZmNmRjYjRjMWY4M2NkL3RhYmxlcmFuZ2U6MTFhYmM5YjExYzkyNGI4Mzg5NmY2ZGNiNGMxZjgzY2RfMy0xLTEtMS0xMDMx_1cdad334-f519-48e7-a442-e006607bfd0d"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjExYWJjOWIxMWM5MjRiODM4OTZmNmRjYjRjMWY4M2NkL3RhYmxlcmFuZ2U6MTFhYmM5YjExYzkyNGI4Mzg5NmY2ZGNiNGMxZjgzY2RfMy0xLTEtMS0xMDMx_1cdad334-f519-48e7-a442-e006607bfd0d"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMjUtMS0xLTEtMTEw_1cdad334-f519-48e7-a442-e006607bfd0d"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMjUtMS0xLTEtMTEw_1cdad334-f519-48e7-a442-e006607bfd0d"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMjUtMy0xLTEtMA_e40e5aa3-d436-463d-ae79-d4a972b39319"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMjUtMy0xLTEtMA_e40e5aa3-d436-463d-ae79-d4a972b39319"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjExYWJjOWIxMWM5MjRiODM4OTZmNmRjYjRjMWY4M2NkL3RhYmxlcmFuZ2U6MTFhYmM5YjExYzkyNGI4Mzg5NmY2ZGNiNGMxZjgzY2RfMy0xLTEtMS0w_c5ecddec-ea61-49d7-9ee4-4bc37ada6314"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjExYWJjOWIxMWM5MjRiODM4OTZmNmRjYjRjMWY4M2NkL3RhYmxlcmFuZ2U6MTFhYmM5YjExYzkyNGI4Mzg5NmY2ZGNiNGMxZjgzY2RfMy0xLTEtMS0w_c5ecddec-ea61-49d7-9ee4-4bc37ada6314"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RleHRyZWdpb246OGQwNTJjMDNmNGQ3NGQ4Y2I5YjAzOWU0YjQ4NjVjMDVfMzU5_b7e01e4f-d0ca-407e-8cef-928f5bacc225" xlink:label="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RleHRyZWdpb246OGQwNTJjMDNmNGQ3NGQ4Y2I5YjAzOWU0YjQ4NjVjMDVfMzU5_b7e01e4f-d0ca-407e-8cef-928f5bacc225" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Includes $1.9&#160;million gain on disposal of discontinued operations for the six months ended June 30, 2021</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjExYWJjOWIxMWM5MjRiODM4OTZmNmRjYjRjMWY4M2NkL3RhYmxlcmFuZ2U6MTFhYmM5YjExYzkyNGI4Mzg5NmY2ZGNiNGMxZjgzY2RfMy0zLTEtMS0xMDMx_23a653a3-53f9-4fa2-825a-b0238aa1e1bc"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RleHRyZWdpb246OGQwNTJjMDNmNGQ3NGQ4Y2I5YjAzOWU0YjQ4NjVjMDVfMzU5_b7e01e4f-d0ca-407e-8cef-928f5bacc225"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjExYWJjOWIxMWM5MjRiODM4OTZmNmRjYjRjMWY4M2NkL3RhYmxlcmFuZ2U6MTFhYmM5YjExYzkyNGI4Mzg5NmY2ZGNiNGMxZjgzY2RfMy0zLTEtMS0w_e40e5aa3-d436-463d-ae79-d4a972b39319"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RleHRyZWdpb246OGQwNTJjMDNmNGQ3NGQ4Y2I5YjAzOWU0YjQ4NjVjMDVfMzU5_b7e01e4f-d0ca-407e-8cef-928f5bacc225"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMjUtMS0xLTEtMA_c5ecddec-ea61-49d7-9ee4-4bc37ada6314"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RleHRyZWdpb246OGQwNTJjMDNmNGQ3NGQ4Y2I5YjAzOWU0YjQ4NjVjMDVfMzU5_b7e01e4f-d0ca-407e-8cef-928f5bacc225"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMjUtMy0xLTEtMTEw_23a653a3-53f9-4fa2-825a-b0238aa1e1bc"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RleHRyZWdpb246OGQwNTJjMDNmNGQ3NGQ4Y2I5YjAzOWU0YjQ4NjVjMDVfMzU5_b7e01e4f-d0ca-407e-8cef-928f5bacc225"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjExYWJjOWIxMWM5MjRiODM4OTZmNmRjYjRjMWY4M2NkL3RhYmxlcmFuZ2U6MTFhYmM5YjExYzkyNGI4Mzg5NmY2ZGNiNGMxZjgzY2RfMy0xLTEtMS0xMDMx_1cdad334-f519-48e7-a442-e006607bfd0d"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RleHRyZWdpb246OGQwNTJjMDNmNGQ3NGQ4Y2I5YjAzOWU0YjQ4NjVjMDVfMzU5_b7e01e4f-d0ca-407e-8cef-928f5bacc225"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMjUtMS0xLTEtMTEw_1cdad334-f519-48e7-a442-e006607bfd0d"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RleHRyZWdpb246OGQwNTJjMDNmNGQ3NGQ4Y2I5YjAzOWU0YjQ4NjVjMDVfMzU5_b7e01e4f-d0ca-407e-8cef-928f5bacc225"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMjUtMy0xLTEtMA_e40e5aa3-d436-463d-ae79-d4a972b39319"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RleHRyZWdpb246OGQwNTJjMDNmNGQ3NGQ4Y2I5YjAzOWU0YjQ4NjVjMDVfMzU5_b7e01e4f-d0ca-407e-8cef-928f5bacc225"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY184NS9mcmFnOmViNzJjYjkxYmUwZjQ1ZTk4YjVmOWQ5M2RlN2Q1MjY5L3RhYmxlOjExYWJjOWIxMWM5MjRiODM4OTZmNmRjYjRjMWY4M2NkL3RhYmxlcmFuZ2U6MTFhYmM5YjExYzkyNGI4Mzg5NmY2ZGNiNGMxZjgzY2RfMy0xLTEtMS0w_c5ecddec-ea61-49d7-9ee4-4bc37ada6314"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RleHRyZWdpb246OGQwNTJjMDNmNGQ3NGQ4Y2I5YjAzOWU0YjQ4NjVjMDVfMzU5_b7e01e4f-d0ca-407e-8cef-928f5bacc225"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfOC0zLTEtMS04Nw_42941013-db98-4377-a51b-f4d23a542da8"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfOC0zLTEtMS04Nw_42941013-db98-4377-a51b-f4d23a542da8"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfNC0xLTEtMS0w_4912914f-f7bf-4db0-8743-46164a2ce1b1"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfNC0xLTEtMS0w_4912914f-f7bf-4db0-8743-46164a2ce1b1"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfOS0zLTEtMS05MA_63fd3a46-1ce7-4e9e-afc2-84df19c21d43"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfOS0zLTEtMS05MA_63fd3a46-1ce7-4e9e-afc2-84df19c21d43"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfOC0xLTEtMS04Nw_1bc0b1dc-fe01-4de7-ba41-3ecef7ac0a30"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfOC0xLTEtMS04Nw_1bc0b1dc-fe01-4de7-ba41-3ecef7ac0a30"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMy0xLTEtMS0w_170ba868-793c-4ffe-bebd-eb61ff904fd1"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMy0xLTEtMS0w_170ba868-793c-4ffe-bebd-eb61ff904fd1"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMy0zLTEtMS0w_033da13e-7a60-4e5b-86d1-46b783ef6f62"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMy0zLTEtMS0w_033da13e-7a60-4e5b-86d1-46b783ef6f62"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfOC0zLTEtMS0w_a7c391ca-74f2-406d-8845-5e85413ef517"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfOC0zLTEtMS0w_a7c391ca-74f2-406d-8845-5e85413ef517"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfOS0xLTEtMS05MA_035cf8ca-b3a4-4fa4-878b-6900e1908669"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfOS0xLTEtMS05MA_035cf8ca-b3a4-4fa4-878b-6900e1908669"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMy0xLTEtMS02NA_4ddfd893-22a5-4d76-b130-01774ab09be5"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMy0xLTEtMS02NA_4ddfd893-22a5-4d76-b130-01774ab09be5"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMy0zLTEtMS02NA_8a291b24-c574-452f-939f-4ed838ba9580"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMy0zLTEtMS02NA_8a291b24-c574-452f-939f-4ed838ba9580"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfOC0xLTEtMS0w_bcd4f6f2-84b7-4b1d-9d32-1a5da0be3e1e"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfOC0xLTEtMS0w_bcd4f6f2-84b7-4b1d-9d32-1a5da0be3e1e"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfNC0xLTEtMS02NA_1646c669-412d-40be-a8bf-033270592308"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfNC0xLTEtMS02NA_1646c669-412d-40be-a8bf-033270592308"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfNC0zLTEtMS02NA_50789944-5571-4917-817b-931e2e3b29ad"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfNC0zLTEtMS02NA_50789944-5571-4917-817b-931e2e3b29ad"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfNC0zLTEtMS0w_641872ca-97f5-472a-b032-425fcb904fd3"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfNC0zLTEtMS0w_641872ca-97f5-472a-b032-425fcb904fd3"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfOS0xLTEtMS0w_2913840b-6e6e-4c12-a70f-0383ffa3f270"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfOS0xLTEtMS0w_2913840b-6e6e-4c12-a70f-0383ffa3f270"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfOS0zLTEtMS0w_b14e9482-2674-4e3e-92ef-34edd76c896f"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfOS0zLTEtMS0w_b14e9482-2674-4e3e-92ef-34edd76c896f"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RleHRyZWdpb246OGQwNTJjMDNmNGQ3NGQ4Y2I5YjAzOWU0YjQ4NjVjMDVfMzYx_567718ea-66eb-4aaf-8694-a0a35e05203a" xlink:label="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RleHRyZWdpb246OGQwNTJjMDNmNGQ3NGQ4Y2I5YjAzOWU0YjQ4NjVjMDVfMzYx_567718ea-66eb-4aaf-8694-a0a35e05203a" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">See Note 19 for amounts attributable to unconsolidated related parties included in these line items.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfOC0zLTEtMS04Nw_42941013-db98-4377-a51b-f4d23a542da8"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RleHRyZWdpb246OGQwNTJjMDNmNGQ3NGQ4Y2I5YjAzOWU0YjQ4NjVjMDVfMzYx_567718ea-66eb-4aaf-8694-a0a35e05203a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfNC0xLTEtMS0w_4912914f-f7bf-4db0-8743-46164a2ce1b1"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RleHRyZWdpb246OGQwNTJjMDNmNGQ3NGQ4Y2I5YjAzOWU0YjQ4NjVjMDVfMzYx_567718ea-66eb-4aaf-8694-a0a35e05203a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfOS0zLTEtMS05MA_63fd3a46-1ce7-4e9e-afc2-84df19c21d43"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RleHRyZWdpb246OGQwNTJjMDNmNGQ3NGQ4Y2I5YjAzOWU0YjQ4NjVjMDVfMzYx_567718ea-66eb-4aaf-8694-a0a35e05203a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfOC0xLTEtMS04Nw_1bc0b1dc-fe01-4de7-ba41-3ecef7ac0a30"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RleHRyZWdpb246OGQwNTJjMDNmNGQ3NGQ4Y2I5YjAzOWU0YjQ4NjVjMDVfMzYx_567718ea-66eb-4aaf-8694-a0a35e05203a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMy0xLTEtMS0w_170ba868-793c-4ffe-bebd-eb61ff904fd1"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RleHRyZWdpb246OGQwNTJjMDNmNGQ3NGQ4Y2I5YjAzOWU0YjQ4NjVjMDVfMzYx_567718ea-66eb-4aaf-8694-a0a35e05203a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMy0zLTEtMS0w_033da13e-7a60-4e5b-86d1-46b783ef6f62"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RleHRyZWdpb246OGQwNTJjMDNmNGQ3NGQ4Y2I5YjAzOWU0YjQ4NjVjMDVfMzYx_567718ea-66eb-4aaf-8694-a0a35e05203a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfOC0zLTEtMS0w_a7c391ca-74f2-406d-8845-5e85413ef517"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RleHRyZWdpb246OGQwNTJjMDNmNGQ3NGQ4Y2I5YjAzOWU0YjQ4NjVjMDVfMzYx_567718ea-66eb-4aaf-8694-a0a35e05203a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfOS0xLTEtMS05MA_035cf8ca-b3a4-4fa4-878b-6900e1908669"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RleHRyZWdpb246OGQwNTJjMDNmNGQ3NGQ4Y2I5YjAzOWU0YjQ4NjVjMDVfMzYx_567718ea-66eb-4aaf-8694-a0a35e05203a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMy0xLTEtMS02NA_4ddfd893-22a5-4d76-b130-01774ab09be5"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RleHRyZWdpb246OGQwNTJjMDNmNGQ3NGQ4Y2I5YjAzOWU0YjQ4NjVjMDVfMzYx_567718ea-66eb-4aaf-8694-a0a35e05203a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfMy0zLTEtMS02NA_8a291b24-c574-452f-939f-4ed838ba9580"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RleHRyZWdpb246OGQwNTJjMDNmNGQ3NGQ4Y2I5YjAzOWU0YjQ4NjVjMDVfMzYx_567718ea-66eb-4aaf-8694-a0a35e05203a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfOC0xLTEtMS0w_bcd4f6f2-84b7-4b1d-9d32-1a5da0be3e1e"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RleHRyZWdpb246OGQwNTJjMDNmNGQ3NGQ4Y2I5YjAzOWU0YjQ4NjVjMDVfMzYx_567718ea-66eb-4aaf-8694-a0a35e05203a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfNC0xLTEtMS02NA_1646c669-412d-40be-a8bf-033270592308"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RleHRyZWdpb246OGQwNTJjMDNmNGQ3NGQ4Y2I5YjAzOWU0YjQ4NjVjMDVfMzYx_567718ea-66eb-4aaf-8694-a0a35e05203a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfNC0zLTEtMS02NA_50789944-5571-4917-817b-931e2e3b29ad"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RleHRyZWdpb246OGQwNTJjMDNmNGQ3NGQ4Y2I5YjAzOWU0YjQ4NjVjMDVfMzYx_567718ea-66eb-4aaf-8694-a0a35e05203a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfNC0zLTEtMS0w_641872ca-97f5-472a-b032-425fcb904fd3"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RleHRyZWdpb246OGQwNTJjMDNmNGQ3NGQ4Y2I5YjAzOWU0YjQ4NjVjMDVfMzYx_567718ea-66eb-4aaf-8694-a0a35e05203a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfOS0xLTEtMS0w_2913840b-6e6e-4c12-a70f-0383ffa3f270"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RleHRyZWdpb246OGQwNTJjMDNmNGQ3NGQ4Y2I5YjAzOWU0YjQ4NjVjMDVfMzYx_567718ea-66eb-4aaf-8694-a0a35e05203a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RhYmxlOjVmZTE1ODY1NmY1MDQxYjNhZDE1OGFjYzI1MzgyYWZmL3RhYmxlcmFuZ2U6NWZlMTU4NjU2ZjUwNDFiM2FkMTU4YWNjMjUzODJhZmZfOS0zLTEtMS0w_b14e9482-2674-4e3e-92ef-34edd76c896f"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY18yNS9mcmFnOjhkMDUyYzAzZjRkNzRkOGNiOWIwMzllNGI0ODY1YzA1L3RleHRyZWdpb246OGQwNTJjMDNmNGQ3NGQ4Y2I5YjAzOWU0YjQ4NjVjMDVfMzYx_567718ea-66eb-4aaf-8694-a0a35e05203a"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140179459119512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Aug. 02, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Evolent Health, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">32-0454912<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">800 N. Glebe Road<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Arlington<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">VA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">22203<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">571<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">389-6000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Class A Common Stock of Evolent Health, Inc., par value $0.01 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">EVH<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87,267,772<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001628908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140179458956168">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 207,273<span></span>
</td>
<td class="nump">$ 319,002<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndInvestmentsCurrent', window );">Restricted cash and restricted investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">17,742<span></span>
</td>
<td class="nump">14,374<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">242,505<span></span>
</td>
<td class="nump">124,064<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">38,032<span></span>
</td>
<td class="nump">56,295<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Current assets of discontinued operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">33,914<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">505,552<span></span>
</td>
<td class="nump">547,649<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndInvestmentsNoncurrent', window );">Restricted cash and restricted investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">13,395<span></span>
</td>
<td class="nump">6,654<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures', window );">Investments in and advances to equity method investees</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">9,788<span></span>
</td>
<td class="nump">6,498<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">82,996<span></span>
</td>
<td class="nump">86,240<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets - operating</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">51,904<span></span>
</td>
<td class="nump">57,799<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent', window );">Prepaid expenses and other noncurrent assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">6,311<span></span>
</td>
<td class="nump">5,773<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostNetNoncurrent', window );">Contract cost assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">22,367<span></span>
</td>
<td class="nump">26,687<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">252,045<span></span>
</td>
<td class="nump">264,992<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">349,009<span></span>
</td>
<td class="nump">349,029<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent', window );">Non-current assets of discontinued operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">20,379<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,293,367<span></span>
</td>
<td class="nump">1,371,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">39,879<span></span>
</td>
<td class="nump">31,975<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">52,339<span></span>
</td>
<td class="nump">73,242<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Short-term debt, net of discount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">26,655<span></span>
</td>
<td class="nump">26,557<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability - current</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7,265<span></span>
</td>
<td class="nump">7,357<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation and employee benefits</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">25,852<span></span>
</td>
<td class="nump">47,163<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">13,173<span></span>
</td>
<td class="nump">10,187<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements', window );">Reserve for claims and performance-based arrangements</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">238,105<span></span>
</td>
<td class="nump">178,827<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Current liabilities of discontinued operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">27,986<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">403,268<span></span>
</td>
<td class="nump">403,294<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt, net of discount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">206,550<span></span>
</td>
<td class="nump">263,343<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">9,784<span></span>
</td>
<td class="nump">22,081<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities - noncurrent</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">58,618<span></span>
</td>
<td class="nump">62,526<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liabilities, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">957<span></span>
</td>
<td class="nump">679<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent', window );">Non-current liabilities from discontinued operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">177<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">679,177<span></span>
</td>
<td class="nump">752,100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies (See Note 11)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Shareholders' Equity</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in-capital</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,242,900<span></span>
</td>
<td class="nump">1,229,320<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(367)<span></span>
</td>
<td class="num">(278)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings (accumulated deficit)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(608,092)<span></span>
</td>
<td class="num">(589,178)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury stock, at cost; 1,537,582 shares issued, respectively</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(21,123)<span></span>
</td>
<td class="num">(21,123)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total shareholders' equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">614,190<span></span>
</td>
<td class="nump">619,600<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and shareholders' equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,293,367<span></span>
</td>
<td class="nump">1,371,700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Common Stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Shareholders' Equity</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Class A common stock - $0.01 par value; 750,000,000 shares authorized; 87,195,128 and 85,894,450 shares issued, respectively</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 872<span></span>
</td>
<td class="nump">$ 859<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">See Note 19 for amounts attributable to unconsolidated related parties included in these line items.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liability For Future Policy Benefits And Unpaid Claims And Claims Adjustment Expense And Performance-Based Arrangements</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2473-110228<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostNetNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer; classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123353750&amp;loc=SL49131252-203054<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostNetNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2510-110228<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity method investee and investment in and advance to affiliate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2473-110228<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2510-110228<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndInvestmentsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current cash, cash equivalents and investments that are restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. Includes current cash equivalents and investments that are similarly restricted as to withdrawal, usage or disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL6242262-115580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120413209&amp;loc=SL6242269-115581<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndInvestmentsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndInvestmentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The noncurrent cash, cash equivalents and investments that is restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits classified as long-term; that is not expected to be released from such existing restrictions within one year of the balance sheet date or operating cycle, whichever is longer. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. Includes noncurrent cash equivalents and investments that are similarly restricted as to withdrawal, usage or disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL6242262-115580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120413209&amp;loc=SL6242269-115581<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndInvestmentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140179457983400">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">750,000,000<span></span>
</td>
<td class="nump">750,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">87,195,128<span></span>
</td>
<td class="nump">85,894,450<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury stock, at cost (in shares)</a></td>
<td class="nump">1,537,582<span></span>
</td>
<td class="nump">1,537,582<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140179460399160">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) - USD ($)<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 222,057,000<span></span>
</td>
<td class="nump">$ 217,299,000<span></span>
</td>
<td class="nump">$ 437,128,000<span></span>
</td>
<td class="nump">$ 438,531,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Expenses</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_CostofGoodsandServicesSoldExcludingDepreciationandAmortization', window );">Cost of revenue (exclusive of depreciation and amortization expenses presented separately below)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">172,113,000<span></span>
</td>
<td class="nump">164,358,000<span></span>
</td>
<td class="nump">329,945,000<span></span>
</td>
<td class="nump">339,987,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">42,699,000<span></span>
</td>
<td class="nump">47,296,000<span></span>
</td>
<td class="nump">101,290,000<span></span>
</td>
<td class="nump">99,383,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">14,916,000<span></span>
</td>
<td class="nump">15,618,000<span></span>
</td>
<td class="nump">30,103,000<span></span>
</td>
<td class="nump">31,596,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Loss on disposal of assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,447,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">215,100,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">215,100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in fair value of contingent consideration and indemnification asset</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">756,000<span></span>
</td>
<td class="num">(594,000)<span></span>
</td>
<td class="num">(3,062,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">229,728,000<span></span>
</td>
<td class="nump">443,128,000<span></span>
</td>
<td class="nump">460,744,000<span></span>
</td>
<td class="nump">689,451,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(7,671,000)<span></span>
</td>
<td class="num">(225,829,000)<span></span>
</td>
<td class="num">(23,616,000)<span></span>
</td>
<td class="num">(250,920,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">68,000<span></span>
</td>
<td class="nump">705,000<span></span>
</td>
<td class="nump">191,000<span></span>
</td>
<td class="nump">1,475,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(6,274,000)<span></span>
</td>
<td class="num">(6,290,000)<span></span>
</td>
<td class="num">(12,611,000)<span></span>
</td>
<td class="num">(12,571,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment', window );">Impairment of equity method investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(47,133,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Gain from equity method investees</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,879,000<span></span>
</td>
<td class="nump">25,143,000<span></span>
</td>
<td class="nump">12,662,000<span></span>
</td>
<td class="nump">24,731,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_GainOnTransferOfMembership', window );">Gain on transfer of membership</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">22,969,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on repayment of debt, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(19,158,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other income (expense), net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(18,000)<span></span>
</td>
<td class="nump">354,000<span></span>
</td>
<td class="num">(32,000)<span></span>
</td>
<td class="nump">284,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss from continuing operations before income taxes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(9,016,000)<span></span>
</td>
<td class="num">(205,917,000)<span></span>
</td>
<td class="num">(19,595,000)<span></span>
</td>
<td class="num">(284,134,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision (benefit) for income taxes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">91,000<span></span>
</td>
<td class="num">(3,904,000)<span></span>
</td>
<td class="nump">702,000<span></span>
</td>
<td class="num">(3,634,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">Loss from continuing operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(9,107,000)<span></span>
</td>
<td class="num">(202,013,000)<span></span>
</td>
<td class="num">(20,297,000)<span></span>
</td>
<td class="num">(280,500,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Income (loss) from discontinued operations, net of tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,508,000)<span></span>
</td>
<td class="nump">1,383,000<span></span>
</td>
<td class="num">(1,773,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(9,107,000)<span></span>
</td>
<td class="num">(203,521,000)<span></span>
</td>
<td class="num">(18,914,000)<span></span>
</td>
<td class="num">(282,273,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss attributable to non-controlling interests</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common shareholders of Evolent Health, Inc. - Basic</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(9,107,000)<span></span>
</td>
<td class="num">(203,521,000)<span></span>
</td>
<td class="num">(18,914,000)<span></span>
</td>
<td class="num">(282,273,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net loss attributable to common shareholders of Evolent Health, Inc. - Diluted</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (9,107,000)<span></span>
</td>
<td class="num">$ (203,521,000)<span></span>
</td>
<td class="num">$ (18,914,000)<span></span>
</td>
<td class="num">$ (282,273,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract', window );"><strong>Loss per common share</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare', window );">Continuing operations, basic (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (0.11)<span></span>
</td>
<td class="num">$ (2.37)<span></span>
</td>
<td class="num">$ (0.24)<span></span>
</td>
<td class="num">$ (3.30)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare', window );">Continuing operations, diluted (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(0.11)<span></span>
</td>
<td class="num">(2.37)<span></span>
</td>
<td class="num">(0.24)<span></span>
</td>
<td class="num">(3.30)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare', window );">Discontinued operations, basic (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="num">(0.01)<span></span>
</td>
<td class="nump">0.02<span></span>
</td>
<td class="num">(0.02)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare', window );">Discontinued operations, diluted (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="num">(0.01)<span></span>
</td>
<td class="nump">0.02<span></span>
</td>
<td class="num">(0.02)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic loss per share attributable to common shareholders of Evolent Health, Inc. (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(0.11)<span></span>
</td>
<td class="num">(2.38)<span></span>
</td>
<td class="num">(0.22)<span></span>
</td>
<td class="num">(3.32)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted loss per share attributable to common shareholders of Evolent Health, Inc. (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (0.11)<span></span>
</td>
<td class="num">$ (2.38)<span></span>
</td>
<td class="num">$ (0.22)<span></span>
</td>
<td class="num">$ (3.32)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract', window );"><strong>Weighted-average common shares outstanding</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">85,448<span></span>
</td>
<td class="nump">85,349<span></span>
</td>
<td class="nump">85,056<span></span>
</td>
<td class="nump">84,977<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">85,448<span></span>
</td>
<td class="nump">85,349<span></span>
</td>
<td class="nump">85,056<span></span>
</td>
<td class="nump">84,977<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Comprehensive loss</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (9,107,000)<span></span>
</td>
<td class="num">$ (203,521,000)<span></span>
</td>
<td class="num">$ (18,914,000)<span></span>
</td>
<td class="num">$ (282,273,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive loss, net of taxes, related to:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(58,000)<span></span>
</td>
<td class="num">(4,000)<span></span>
</td>
<td class="num">(89,000)<span></span>
</td>
<td class="num">(157,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Total comprehensive loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(9,165,000)<span></span>
</td>
<td class="num">(203,525,000)<span></span>
</td>
<td class="num">(19,003,000)<span></span>
</td>
<td class="num">(282,430,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest', window );">Total comprehensive loss attributable to non-controlling interests</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Total comprehensive loss attributable to common shareholders of Evolent Health, Inc.</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(9,165,000)<span></span>
</td>
<td class="num">(203,525,000)<span></span>
</td>
<td class="num">(19,003,000)<span></span>
</td>
<td class="num">(282,430,000)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=evh_TransformationServicesMember', window );">Transformation services</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">2,564,000<span></span>
</td>
<td class="nump">755,000<span></span>
</td>
<td class="nump">2,909,000<span></span>
</td>
<td class="nump">5,993,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=evh_PlatformsAndOperationsServicesMember', window );">Platform and operations services</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 219,493,000<span></span>
</td>
<td class="nump">$ 216,544,000<span></span>
</td>
<td class="nump">$ 434,219,000<span></span>
</td>
<td class="nump">$ 432,538,000<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">See Note 19 for amounts attributable to unconsolidated related parties included in these line items.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Includes $1.9&#160;million gain on disposal of discontinued operations for the six months ended June 30, 2021</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_CostofGoodsandServicesSoldExcludingDepreciationandAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cost of Goods and Services Sold, Excluding Depreciation and Amortization</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_CostofGoodsandServicesSoldExcludingDepreciationandAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_GainOnTransferOfMembership">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain On Transfer Of Membership</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_GainOnTransferOfMembership</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4613674-111683<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents an other than temporary decline in value that has been recognized against an investment accounted for under the equity method of accounting. The excess of the carrying amount over the fair value of the investment represents the amount of the write down which is or was reflected in earnings. The written down value is a new cost basis with the adjusted value of the investment becoming its new carrying value subject to the equity accounting method. Evidence of a loss in value might include, but would not necessarily be limited to, absence of an ability to recover the carrying amount of the investment or inability of the investee to sustain an earnings capacity which would justify the carrying amount of the investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 35<br> -Paragraph 32<br> -URI http://asc.fasb.org/extlink&amp;oid=124268079&amp;loc=d3e32787-111569<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868656-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868656-224227<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109227538&amp;loc=d3e44648-109337<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1278-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 5.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398118&amp;loc=d3e355146-122828<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1278-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1930-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1930-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1930-109256<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1930-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=evh_TransformationServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=evh_TransformationServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=evh_PlatformsAndOperationsServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=evh_PlatformsAndOperationsServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140179455424936">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (DEFICIT) - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Cumulative Effect, Period of Adoption, Adjustment</div></th>
<th class="th"><div>Parent</div></th>
<th class="th">
<div>Parent </div>
<div>Cumulative Effect, Period of Adoption, Adjustment</div>
</th>
<th class="th">
<div>Common Stock </div>
<div>Class A Common Stock</div>
</th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Other Income (Loss)</div></th>
<th class="th"><div>Retained Earnings (Accumulated Deficit)</div></th>
<th class="th">
<div>Retained Earnings (Accumulated Deficit) </div>
<div>Cumulative Effect, Period of Adoption, Adjustment</div>
</th>
<th class="th"><div>Treasury Stock</div></th>
<th class="th"><div>Non-Controlling Interests</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84,589<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2019</a></td>
<td class="nump">$ 929,047<span></span>
</td>
<td class="num">$ (2,970)<span></span>
</td>
<td class="nump">$ 922,358<span></span>
</td>
<td class="num">$ (2,970)<span></span>
</td>
<td class="nump">$ 846<span></span>
</td>
<td class="nump">$ 1,173,708<span></span>
</td>
<td class="num">$ (234)<span></span>
</td>
<td class="num">$ (251,962)<span></span>
</td>
<td class="num">$ (2,970)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,689<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingStandardsUpdateExtensibleList', window );">Accounting Standards Update [Extensible Enumeration]</a></td>
<td class="text">us-gaap:AccountingStandardsUpdate201613Member<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Mar. 31, 2020</a></td>
<td class="nump">$ 847,072<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">847,072<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 855<span></span>
</td>
<td class="nump">1,180,288<span></span>
</td>
<td class="num">(387)<span></span>
</td>
<td class="num">(333,684)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84,589<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2019</a></td>
<td class="nump">929,047<span></span>
</td>
<td class="num">$ (2,970)<span></span>
</td>
<td class="nump">922,358<span></span>
</td>
<td class="num">$ (2,970)<span></span>
</td>
<td class="nump">$ 846<span></span>
</td>
<td class="nump">1,173,708<span></span>
</td>
<td class="num">(234)<span></span>
</td>
<td class="num">(251,962)<span></span>
</td>
<td class="num">$ (2,970)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,689<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">7,211<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,211<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,211<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">526<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">526<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">525<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Restricted stock units vested, net of shares withheld for taxes (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Restricted stock units vested, net of shares withheld for taxes</a></td>
<td class="num">(1,331)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,331)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="num">(1,335)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_StockVestedAndRetiredDuringPeriodShares', window );">Share retirement (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(188)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_StockVestedAndRetiredDuringPeriodValue', window );">Share retirement</a></td>
<td class="num">(685)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(685)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2)<span></span>
</td>
<td class="num">(683)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Class A common stock issued for payment of earn-outs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">616<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Class A common stock issued for payment of earn-outs</a></td>
<td class="nump">4,185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">4,179<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation', window );">Disposal of assets</a></td>
<td class="num">(6,689)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,689)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="num">(157)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(157)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(157)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(282,273)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(282,273)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(282,273)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Jun. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85,457<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Jun. 30, 2020</a></td>
<td class="nump">646,864<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">646,864<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 855<span></span>
</td>
<td class="nump">1,183,605<span></span>
</td>
<td class="num">(391)<span></span>
</td>
<td class="num">(537,205)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Mar. 31, 2020</a></td>
<td class="nump">847,072<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">847,072<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 855<span></span>
</td>
<td class="nump">1,180,288<span></span>
</td>
<td class="num">(387)<span></span>
</td>
<td class="num">(333,684)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">3,703<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,703<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,703<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">443<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">443<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">442<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Restricted stock units vested, net of shares withheld for taxes (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">113<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Restricted stock units vested, net of shares withheld for taxes</a></td>
<td class="num">(144)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(144)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="num">(145)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_StockVestedAndRetiredDuringPeriodShares', window );">Share retirement (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(188)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_StockVestedAndRetiredDuringPeriodValue', window );">Share retirement</a></td>
<td class="num">(685)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(685)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2)<span></span>
</td>
<td class="num">(683)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="num">(4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(203,521)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(203,521)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(203,521)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Jun. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85,457<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Jun. 30, 2020</a></td>
<td class="nump">646,864<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">646,864<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 855<span></span>
</td>
<td class="nump">1,183,605<span></span>
</td>
<td class="num">(391)<span></span>
</td>
<td class="num">(537,205)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85,895<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">619,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">619,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 859<span></span>
</td>
<td class="nump">1,229,320<span></span>
</td>
<td class="num">(278)<span></span>
</td>
<td class="num">(589,178)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (21,123)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">7,359<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,359<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,359<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">9,376<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,376<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">9,367<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Restricted stock units vested, net of shares withheld for taxes (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Restricted stock units vested, net of shares withheld for taxes</a></td>
<td class="num">(3,142)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,142)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="num">(3,146)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="num">(89)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(89)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(89)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(18,914)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(18,914)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(18,914)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87,195<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Jun. 30, 2021</a></td>
<td class="nump">614,190<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">614,190<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 872<span></span>
</td>
<td class="nump">1,242,900<span></span>
</td>
<td class="num">(367)<span></span>
</td>
<td class="num">(608,092)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(21,123)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86,779<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Mar. 31, 2021</a></td>
<td class="nump">617,298<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">617,298<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 868<span></span>
</td>
<td class="nump">1,236,847<span></span>
</td>
<td class="num">(309)<span></span>
</td>
<td class="num">(598,985)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(21,123)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">3,653<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,653<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,653<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">306<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">2,858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">2,855<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Restricted stock units vested, net of shares withheld for taxes (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Restricted stock units vested, net of shares withheld for taxes</a></td>
<td class="num">(454)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(454)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="num">(455)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="num">(58)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(58)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(58)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(9,107)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,107)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,107)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87,195<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Jun. 30, 2021</a></td>
<td class="nump">$ 614,190<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 614,190<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 872<span></span>
</td>
<td class="nump">$ 1,242,900<span></span>
</td>
<td class="num">$ (367)<span></span>
</td>
<td class="num">$ (608,092)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (21,123)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_StockVestedAndRetiredDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Vested And Retired During Period, Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_StockVestedAndRetiredDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_StockVestedAndRetiredDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Vested And Retired During Period, Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_StockVestedAndRetiredDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingStandardsUpdateExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates amendment to accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL122642865-165497<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL120254526-165497<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=122150657&amp;loc=SL122150809-237846<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL122642865-165497<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S65<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124359872&amp;loc=SL124427846-239511<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124402435&amp;loc=SL124402458-218513<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124402435&amp;loc=SL124402458-218513<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL120254526-165497<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 51: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 52: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 53: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 54: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 55: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 56: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 57: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 58: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 59: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 60: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 61: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)<br><br>Reference 62: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(1)<br><br>Reference 63: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(2)<br><br>Reference 64: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(01)<br><br>Reference 65: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(03)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingStandardsUpdateExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the reduction or elimination during the period of a noncontrolling interest resulting from the parent's loss of control and deconsolidation of the entity in which one or more outside parties had a noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to acquisitions during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568447-111683<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(03)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140179459020856">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash Flows Provided by (Used In) Operating Activities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (18,914,000)<span></span>
</td>
<td class="num">$ (282,273,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash and restricted cash used in operating activities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in fair value of contingent consideration and indemnification asset</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(594,000)<span></span>
</td>
<td class="num">(3,062,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_GainLossOnDispositionOfAssetsOperatingActivities', window );">(Gain) loss on disposal of assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,904,000)<span></span>
</td>
<td class="nump">6,447,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">(Gain) loss from equity method investees</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(12,662,000)<span></span>
</td>
<td class="num">(24,731,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">30,263,000<span></span>
</td>
<td class="nump">31,916,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment', window );">Impairment of equity method investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">47,133,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7,359,000<span></span>
</td>
<td class="nump">7,211,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxesAndTaxCredits', window );">Deferred tax (benefit) provision</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(268,000)<span></span>
</td>
<td class="num">(892,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostAmortization', window );">Amortization of contract cost assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">8,311,000<span></span>
</td>
<td class="nump">10,272,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of deferred financing costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">8,837,000<span></span>
</td>
<td class="nump">6,079,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_PaidinKindInterestIncome', window );">Interest from customer advance for regulatory capital requirements</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,316,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_GainOnTransferOfMembership', window );">Gain on transfer of membership</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(22,969,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">215,100,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on repayment of debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">19,158,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other current operating cash outflows, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(729,000)<span></span>
</td>
<td class="nump">224,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities, net of acquisitions:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset', window );">Accounts receivable, net and contract assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(120,066,000)<span></span>
</td>
<td class="num">(23,946,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current and non-current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(3,439,000)<span></span>
</td>
<td class="num">(3,912,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_IncreaseDecreaseInCapitalizedContractCostNet', window );">Contract cost assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(3,991,000)<span></span>
</td>
<td class="num">(5,503,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">9,904,000<span></span>
</td>
<td class="nump">11,690,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(17,725,000)<span></span>
</td>
<td class="nump">4,071,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Accrued compensation and employee benefits</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(21,505,000)<span></span>
</td>
<td class="num">(10,118,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,490,000<span></span>
</td>
<td class="num">(6,400,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities', window );">Reserve for claims and performance-based arrangements</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">62,614,000<span></span>
</td>
<td class="nump">33,259,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_IncreaseDecreaseInOperatingLeaseRightofUseAsset', window );">Right-of-use operating assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,621,000<span></span>
</td>
<td class="nump">3,620,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(2,719,000)<span></span>
</td>
<td class="nump">1,783,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities', window );">Other long-term liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,518,000<span></span>
</td>
<td class="nump">473,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash and restricted cash provided by (used in) operating activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(72,410,000)<span></span>
</td>
<td class="nump">17,125,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash Flows Provided by (Used In) Investing Activities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash paid for asset acquisitions</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,472,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates', window );">Proceeds from transfer of membership and release of Passport escrow</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">42,996,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet', window );">Disposal of non-strategic assets and divestiture of discontinued operations, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,490,000<span></span>
</td>
<td class="num">(2,287,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital', window );">Return of equity method investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">9,372,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireHeldToMaturitySecurities', window );">Purchases of investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(2,994,000)<span></span>
</td>
<td class="num">(1,447,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_ProceedsFromMaturityOfInvestments', window );">Maturities and sales of investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">500,000<span></span>
</td>
<td class="nump">3,099,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireOtherProductiveAssets', window );">Investments in internal-use software and purchases of property and equipment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(11,512,000)<span></span>
</td>
<td class="num">(17,455,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Other investing activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="num">(292,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash and restricted cash provided by (used in) investing activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">40,380,000<span></span>
</td>
<td class="num">(18,382,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash Flows Provided by (Used In) Financing Activities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_PaymentsForProceedsFromClaimsProcessingFinancingActivities', window );">Changes in working capital balances related to claims processing on behalf of partners</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,399,000<span></span>
</td>
<td class="nump">26,715,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfSeniorDebt', window );">Repayment and termination of Credit Agreement including settlement of warrants.</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(98,420,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from stock option exercises</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">9,376,000<span></span>
</td>
<td class="nump">526,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToMinorityShareholders', window );">Distributions to Sponsors</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,300,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Taxes withheld and paid for vesting of restricted stock units</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(3,142,000)<span></span>
</td>
<td class="num">(1,331,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash and restricted cash provided by (used in) financing activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(91,087,000)<span></span>
</td>
<td class="nump">25,910,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate on cash and cash equivalents and restricted cash</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(54,000)<span></span>
</td>
<td class="nump">26,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash and cash equivalents and restricted cash</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(123,171,000)<span></span>
</td>
<td class="nump">24,679,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents and restricted cash as of beginning-of-period</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">361,581,000<span></span>
</td>
<td class="nump">128,531,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents and restricted cash as of end-of-period</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 238,410,000<span></span>
</td>
<td class="nump">$ 153,210,000<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">As a result of the closing of the sale of True Health SPA, the consolidated statements of operations, consolidated balance sheets, and related financial information reflect the Company&#8217;s operations and assets and liabilities of True Health as discontinued operations for all periods presented. Cash flows and comprehensive income have not been adjusted and are included in the consolidated statements of cash flows and consolidated statements of comprehensive income (loss) for all periods presented. See Note 5.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_GainLossOnDispositionOfAssetsOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) On Disposition Of Assets, Operating Activities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_GainLossOnDispositionOfAssetsOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_GainOnTransferOfMembership">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain On Transfer Of Membership</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_GainOnTransferOfMembership</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Accounts Receivable And Contract With Customer, Asset</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_IncreaseDecreaseInCapitalizedContractCostNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Capitalized Contract Cost, Net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_IncreaseDecreaseInCapitalizedContractCostNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Insurance And Performance-Based Arrangements Liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_IncreaseDecreaseInOperatingLeaseRightofUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Operating Lease, Right-of-Use Asset</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_IncreaseDecreaseInOperatingLeaseRightofUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_PaidinKindInterestIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Paid-in-Kind Interest Income</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_PaidinKindInterestIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_PaymentsForProceedsFromClaimsProcessingFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments For (Proceeds From) Claims Processing, Financing Activities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_PaymentsForProceedsFromClaimsProcessingFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments For (Proceeds From) Disposal Of Non-Strategic Assets And Divestiture Of Discontinued Operations, Net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_ProceedsFromMaturityOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Maturity Of Investments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_ProceedsFromMaturityOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for asset recognized from cost incurred to obtain or fulfill contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123353750&amp;loc=SL49131252-203054<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxesAndTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) and income tax credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxesAndTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents an other than temporary decline in value that has been recognized against an investment accounted for under the equity method of accounting. The excess of the carrying amount over the fair value of the investment represents the amount of the write down which is or was reflected in earnings. The written down value is a new cost basis with the adjusted value of the investment becoming its new carrying value subject to the equity accounting method. Evidence of a loss in value might include, but would not necessarily be limited to, absence of an ability to recover the carrying amount of the investment or inability of the investee to sustain an earnings capacity which would justify the carrying amount of the investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 35<br> -Paragraph 32<br> -URI http://asc.fasb.org/extlink&amp;oid=124268079&amp;loc=d3e32787-111569<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123371682&amp;loc=d3e55415-109406<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash (inflow) outflow from investing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromOtherInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireHeldToMaturitySecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow through purchase of long-term held-to-maturity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireHeldToMaturitySecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireOtherProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for the purchase of or improvements to tangible or intangible assets, used to produce goods or deliver services, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireOtherProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToMinorityShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to a noncontrolling interest. Includes, but not limited to, reduction of noncontrolling interest ownership. Excludes dividends paid to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToMinorityShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the deconsolidation of a previously consolidated subsidiary or sale of an entity that is related to it but not strictly controlled.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of distribution received from equity method investee for return of investment, classified as investing activities. Excludes distribution for return on investment, classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21D<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=SL94080555-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfSeniorDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a long-term debt where the holder has highest claim on the entity's asset in case of bankruptcy or liquidation during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfSeniorDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140179565742296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (Parenthetical)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax', window );">Gain on disposal of discontinued operations</a></td>
<td class="nump">$ 1.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of gain (loss) not previously recognized resulting from the disposal of a discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140179453776120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization</a></td>
<td class="text">Organization <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Evolent Health, Inc. was incorporated in December 2014 in the state of Delaware and through its subsidiaries supports leading health systems and physician organizations as well as health plans to move their business models from traditional fee for service reimbursement to value-based care, which we consider to be an integrated clinical and financial responsibility for populations. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company made organizational changes, including re-evaluating its reportable segments, as a result of the entry into the agreement to sell True Health on January 11, 2021. Effective during the first quarter of 2021, the Company bifurcated its previous Services segment into two segments. The Company&#8217;s Evolent Health Services segment (&#8220;EHS&#8221;) includes our administrative simplification solution and certain supporting population health infrastructure. Our Clinical Solutions segment includes our specialty management and physician-oriented total cost of care solutions, along with the New Century Health and Evolent Care Partners brands. Refer to Note 21 for a further discussion of our operating results by segment.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since its inception, the Company has incurred losses from operations. As of June&#160;30, 2021, the Company had unrestricted cash and cash equivalents of $207.3 million. The Company believes it has sufficient liquidity for the next twelve months as of the date the financial statements were available to be issued.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s headquarters is located in Arlington, Virginia.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Evolent Health LLC Governance</span></div>Our operations are conducted through Evolent Health LLC and subsequent to the offering reorganization at the time of our initial public offering (the &#8220;Offering Reorganization&#8221;), the financial results of Evolent Health LLC were consolidated in the financial statements of Evolent Health, Inc. Evolent Health, Inc. is a holding company whose only business is to act as the sole managing member of Evolent Health LLC. As such, it controls Evolent Health LLC&#8217;s business and affairs and is responsible for the management of its business.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140179452430664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles</a></td>
<td class="text">Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our opinion, the accompanying unaudited interim consolidated financial statements include all adjustments, consisting of normal recurring adjustments, which are necessary to fairly state our financial position, results of operations, and cash flows. The consolidated balance sheet as of December 31, 2020, has been derived from audited financial statements as of that date and reflects the impact of the agreement to sell True Health. See Note 5 for a complete summary of this transaction. The interim consolidated results of operations are not necessarily indicative of the results that may occur for the full fiscal year. Certain footnote disclosures normally included in financial statements prepared in accordance with United States of America generally accepted accounting principles (&#8220;GAAP&#8221;) have been omitted pursuant to instructions, rules, and regulations prescribed by the United States Securities and Exchange Commission (&#8220;SEC&#8221;). The disclosures provided herein should be read in conjunction with the audited financial statements and notes thereto included in our 2020 Form 10-K.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summary of Significant Accounting Policies</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain GAAP policies that significantly affect the determination of our financial position, results of operations and cash flows, are summarized below.  See &#8220;Part II - Item 8. Financial Statements and Supplementary Data - Note 2&#8221; in our 2020 Form 10-K for a complete summary of our significant accounting policies.</span></div><div><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting Estimates and Assumptions</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions affecting the reported amounts of assets and liabilities and the disclosures of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expenses for the reporting period. Those estimates are inherently subject to change and actual results could differ from those estimates. In the accompanying consolidated financial statements, estimates are used for, but not limited to, the valuation of assets (including intangibles assets, goodwill and long-lived assets), liabilities, consideration related to business combinations and asset acquisitions, revenue recognition (including variable consideration), estimated selling </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">prices for performance obligations in contracts with multiple performance obligations, reserves for claims and performance-based arrangements, credit losses, depreciable lives of assets, impairment of long-lived assets, stock-based compensation, deferred income taxes and valuation allowance, contingent liabilities, purchase price allocation in taxable stock transactions and useful lives of intangible assets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Principles of Consolidation</span></div><div style="padding-left:18pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of Evolent Health, Inc. and its subsidiaries. All intercompany accounts and transactions are eliminated in consolidation.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash and Cash Equivalents</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider all highly liquid instruments with original maturities of three months or less to be cash equivalents. The Company holds materially all of our cash in bank deposits with FDIC participating banks, at cost, which approximates fair value. Cash and cash equivalents held in money market funds are carried at fair value, which approximates cost.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Cash and Restricted Investments</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash and restricted investments include cash and investments used to collateralize various contractual obligations as of June&#160;30, 2021 and December&#160;31, 2020 (in thousands) as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:340.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:94.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:94.75pt"/><td style="width:1.0pt"/></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collateral for letters of credit for facility leases </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,510&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,510&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collateral with financial institutions </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,352&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,743&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Claims processing services </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,525&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,064&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,327&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total restricted cash and restricted investments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,137&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,644&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,742&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,374&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current restricted cash and restricted investments</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,742&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,374&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,395&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,654&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total non-current restricted cash and restricted investments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,395&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,654&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Amounts exclude $0.6 million of non-current restricted investments and $0.1&#160;million of current restricted cash from claims processing services reclassified to discontinued operations as of December&#160;31, 2020.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Represents restricted cash related to collateral for letters of credit required in conjunction with lease agreements. See Note 12 for further discussion of our lease commitments. </span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Represents collateral held with financial institutions for risk-sharing and other arrangements. As of June&#160;30, 2021 and December&#160;31, 2020, approximately $12.4&#160;million and $4.7 million, respectively, of the collateral amounts were held in a FDIC participating bank account. See Note 18 for discussion of fair value measurement and Note 11 for discussion of our risk-sharing arrangements. </span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Represents cash held by the Company related to claims processing services on behalf of partners. These are pass-through amounts and can fluctuate materially from period to period depending on the timing of when the claims are processed.</span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statements of cash flows as of June&#160;30, 2021 and 2020 (in thousands).</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:433.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207,273&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,272&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash and restricted investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,137&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,653&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted investments included in restricted cash and restricted investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(715)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:5.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents and restricted cash shown in the consolidated statements of cash flows </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238,410&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153,210&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">As a result of the closing of the sale of True Health SPA, the consolidated statements of operations, consolidated balance sheets, and related financial information reflect the Company&#8217;s operations and assets and liabilities of True Health as discontinued operations for all periods presented. Cash flows and comprehensive income have not been adjusted and are included in the consolidated statements of cash flows and consolidated statements of comprehensive income (loss) for all periods presented. See Note 5.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Companies acquired during each reporting period are reflected in the results of the Company effective from their respective dates of acquisition through the end of the reporting period. The Company allocates the fair value of purchase consideration to the assets acquired and liabilities assumed based on their estimated fair values at the acquisition date. Our estimates of fair value are based upon assumptions believed to be reasonable, but which are inherently uncertain and unpredictable and, as a result, actual results may differ from estimates. Critical estimates used to value certain identifiable assets include, but are not limited to, expected long-term revenues, future expected operating expenses, cost of capital, and appropriate discount rates. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The excess of the fair value of purchase consideration over the fair value of the assets acquired and liabilities assumed in the acquired entity is recorded as goodwill. Goodwill is assigned to the reporting unit that benefits from the synergies arising from the business combination. If the Company obtains new information about facts and circumstances that existed as of the acquisition date during the measurement period, which may be up to one year from the acquisition date, the Company may record adjustments to the assets acquired and liabilities assumed, with the corresponding offset to goodwill. Upon the conclusion of the measurement period or final determination of the values of assets acquired or liabilities assumed, whichever comes first, any subsequent adjustments are recorded on the Company's consolidated statements of operations and comprehensive income (loss). </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For contingent consideration recorded as a liability, the Company initially measures the amount at fair value as of the acquisition date and adjusts the liability, if needed, to fair value at each reporting period. Changes in the fair value of contingent consideration, other than measurement period adjustments, are recognized as operating income or expense. Acquisition-related expenses and post-acquisition restructuring costs are recognized separately from the business combination and are expensed as incurred.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize the excess of the purchase price, plus the fair value of any non-controlling interests in the acquiree, over the fair value of identifiable net assets acquired as goodwill. Goodwill is not amortized, but is reviewed at least annually for indications of impairment, with consideration given to financial performance and other relevant factors. We perform impairment tests of goodwill at a reporting unit level. Following the sale of True Health, the Company has three reporting units and our annual goodwill impairment review occurs during the fourth quarter of each year. We perform impairment tests between annual tests if an event occurs, or circumstances change, that we believe would more likely than not reduce the fair value of a reporting unit below its carrying amount. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our goodwill impairment analysis first assesses qualitative factors to determine whether events or circumstances existed that would lead the Company to conclude it is more likely than not that the fair value of a reporting unit is below its carrying amount. If the Company determines that it is more likely than not that the fair value of a reporting unit is below the carrying amount, a quantitative goodwill assessment is required. In the quantitative evaluation, the fair value of the relevant reporting unit is determined and compared to the carrying value. If the fair value is greater than the carrying value, then the carrying value is deemed to be recoverable and no further action is required. If the fair value estimate is less than the carrying value, goodwill is considered impaired for the amount by which the carrying amount exceeds the reporting unit&#8217;s fair value and a charge is reported in goodwill impairment on our consolidated statements of operations and comprehensive income (loss). See Note 9 for additional discussion regarding the goodwill impairment tests conducted during 2021 and 2020.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangible Assets, Net </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Identified intangible assets are recorded at their estimated fair values at the date of acquisition and are amortized over their respective estimated useful lives using a method of amortization that reflects the pattern in which the economic benefits of the intangible assets are used. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes the estimated useful lives by asset classification:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:438.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:97.75pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate trade name</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 - 20 years</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 - 25 years</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 years</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provider network contracts</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 - 5 years</span></div></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets are reviewed for impairment if circumstances indicate the Company may not be able to recover the asset&#8217;s carrying value. The Company evaluates recoverability by determining whether the undiscounted cash flows expected to result from the use and eventual disposition of that asset or group exceed the carrying value at the evaluation date. If the undiscounted cash flows are not sufficient to cover the carrying value, the Company measures an impairment loss as the excess of the carrying amount of the long-lived asset or group over its fair value. See Note 9 for additional discussion regarding our intangible assets.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reserves for Claims and Performance-based Arrangements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reserves for performance-based arrangements and claims reflect estimates of payments under performance-based arrangements and the ultimate cost of claims that have been incurred but not reported, including expected development on reported claims, those that have been reported but not yet paid (reported claims in process), and other medical care expenses and services payable that are primarily composed of accruals for incentives and other amounts payable to health care professionals and facilities. The Company uses actuarial principles and assumptions that are consistently applied in each reporting period and recognizes the actuarial best estimate of the ultimate liability along with a margin for adverse deviation. This approach is consistent with actuarial standards of practice that the liabilities be adequate under moderately adverse conditions. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The process of estimating reserves involves a considerable degree of judgment by the Company and, as of any given date, is inherently uncertain. The methods for making such estimates and for establishing the resulting liability are continually reviewed, and adjustments are reflected in current results of operations in the period in which they are identified as experience develops or new information becomes known. See Note 22 for additional discussion regarding our reserves for claims and performance-based arrangements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into various office space, data center, and equipment lease agreements in conducting its normal business operations. At the inception of any contract, the Company evaluates the agreement to determine whether the contract contains a lease. If the contract contains a lease, the Company then evaluates the term and whether the lease is an operating or finance lease. Most leases include one or more options to renew or may have a termination option. The Company determines whether these options are reasonably certain to be exercised at the inception of the lease. The rent expense is recognized on a straight-line basis in the consolidated statements of operations and comprehensive income (loss) over the terms of the respective leases. Leases with an initial term of 12 months or less are not recorded on the consolidated balance sheets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. We use the implicit rate when readily determinable. Further, the Company treats all lease and non-lease components as a single combined lease component for all classes of underlying assets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also enters into sublease agreements for some of its leased office space. Rental income attributable to subleases is immaterial and is offset against rent expense over the terms of the respective leases.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 12 for additional lease disclosures.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We derive revenue from two sources: (1) transformation services and (2) platform and operations services. Transformation services consist of implementation services whereby we assist the customer in launching its population health or health plan programs, or implement certain platform and operations services. In certain cases, transformation services can also include revenue associated with our support of certain one-time wind-down activities for clients who are exiting a line of business or population. Platform and operations services generally include multi-year arrangements with customers to provide various population health, health plan operations, specialty care management and claims processing services on an ongoing basis, as well as transition or run-out services to customers receiving primarily TPA services. Revenue is recognized when control of the services is transferred to our customers.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the following 5-step model, outlined in Accounting Standards Codification (&#8220;ASC&#8221;) Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 606&#8221;), to determine revenue recognition from our contracts with customers:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"> Identify the contract(s) with a customer</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"> Identify the performance obligations in the contract</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"> Determine the transaction price</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"> Allocate the transaction price to performance obligations</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"> Recognize revenue when (or as) the entity satisfies a performance obligation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 6 for further discussion of our policies related to revenue recognition. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign Currency</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company formed a subsidiary in India during the first quarter of 2018. The functional currency of our international subsidiary is the Indian Rupee. We translate the financial statements of this subsidiary to U.S. dollars using month-end rates of exchange for assets and liabilities, and monthly average rates of exchange for revenue and expenses. Translation gains and losses are recorded in accumulated other comprehensive income (loss) as a component of shareholders' equity. Foreign currency translation gains and losses did not have a material impact on our consolidated statements of operations and comprehensive income (loss) for the three and six months ended June 30, 2021 and 2020.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140179453680568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Recently Issued Accounting Standards<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock', window );">Recently Issued Accounting Standards</a></td>
<td class="text">Recently Issued Accounting Standards<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Adoption of New Accounting Standards</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and subsequently issued additional guidance that modified ASU 2016-13. The standard requires an entity to change its accounting approach for measuring and recognizing credit losses on certain financial assets measured at amortized cost, including trade receivables, certain non-trade receivables, contract assets, held-to-maturity securities, customer advances and certain off-balance sheet credit exposures, by replacing the existing &#8220;incurred loss&#8221; framework with an expected credit loss recognition model.&#160; The new standard results in earlier recognition of credit losses based on past events, current conditions, and reasonable and supportable forecasts.&#160; The standard is effective for entities with fiscal years beginning after December 15, 2019, including interim periods within such fiscal years. We adopted the requirements of this standard effective January 1, 2020 using the modified retrospective approach and recorded a cumulative effect adjustment of $3.0 million to January 1, 2020 retained earnings (accumulated deficit). Results for reporting periods beginning January 1, 2020 reflect the adoption of <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY180Ni9mcmFnOjFlZjc0Mjc4OGM3NjQ2NzQ5MGQwNWNhZWM5MzAwYjhkL3RleHRyZWdpb246MWVmNzQyNzg4Yzc2NDY3NDkwZDA1Y2FlYzkzMDBiOGRfMzI1Ng_e7fbd1cf-8213-4b7f-af71-67ed1c89dbd2">ASU 2016-13</span>, while prior period amounts were not adjusted and continue to be reported in accordance with our historical accounting practices. In our previous accounting policy for trade receivables and non-trade receivables, we maintained an allowance for doubtful accounts based solely on specific identification. Under the new accounting standard, we maintain our specific identification process but utilize several factors to develop historical losses reserves, including aging schedules, customer creditworthiness, and historical payment experience, which are then adjusted for current conditions and reasonable and supportable forecasts in measurement of the allowance.&#160; In addition, for customer advances and certain off-balance sheet credit exposures, we evaluate the allowance through a discounted cash flow approach.&#160; For held-to-maturity investment securities, we evaluate (i) historical information adjusted for current conditions and reasonable and supportable forecasts and (ii) qualitative factors to determine whether the zero-loss expectation exception applies. Refer to Note 7 for additional disclosures related to current expected credit losses.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU No. 2019-12, Simplifying the Accounting for Income Taxes. The amendments in the ASU remove certain exceptions to the intraperiod tax allocation of losses and gains from different financial statement components and to the method of recognizing income taxes on interim period losses, and the recognition of deferred tax liabilities for outside basis differences. In addition, the new guidance simplifies aspects of the accounting for franchise taxes and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. The Company adopted this standard starting in the first quarter of 2021, which did not have a material impact on our consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123338486&amp;loc=SL49131195-203048<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -URI http://asc.fasb.org/topic&amp;trid=2122394<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123338486&amp;loc=SL49131195-203048<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section S99<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=122038215&amp;loc=SL108384541-122693<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124402435&amp;loc=SL124402458-218513<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (i)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123338486&amp;loc=SL49131195-203048<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124402435&amp;loc=SL124402458-218513<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (j)<br> -URI http://asc.fasb.org/extlink&amp;oid=123338486&amp;loc=SL49131195-203048<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 11.M.Q2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038215&amp;loc=d3e31137-122693<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122150657&amp;loc=SL122150809-237846<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (c)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140179452450280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Transactions<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock', window );">Transactions</a></td>
<td class="text">Transactions<div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Passport</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 28, 2019, UHC, Passport Health Solutions, LLC (&#8220;PHS I&#8221;), the Company and EVH Passport entered into an Asset Purchase Agreement (the &#8220;Passport APA&#8221;), which provided for the sale of substantially all of the assets of UHC and PHS I, including UHC&#8217;s Kentucky Medicaid contract (the &#8220;Passport Medicaid Contract&#8221;), to EVH Passport for a purchase price of $70.0 million in cash and the issuance of a 30% interest in EVH Passport (the &#8220;Passport Purchase Price&#8221;) to The University of Louisville, the University of Louisville Physicians, University Medical Center, the Jewish Heritage Fund for Excellence, Norton Healthcare, Inc. and the Louisville/Jefferson County Primary Care Association (collectively, the &#8220;Sponsors&#8221;). </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 18, 2019, the Company contributed $40.0 million to UHC in the form of an advance for regulatory capital requirements under an agreement with UHC (the &#8220;Passport Note&#8221;). The Passport Note carried a fixed interest rate of 6.5% per annum.  Additionally, on June 6, 2019, the Company and UHC entered into an Indemnity Agreement (the &#8220;Indemnity Agreement&#8221;), with an insurance company (the &#8220;Surety&#8221;). The Surety issued a performance bond in the amount of $25.0 million to secure UHC&#8217;s performance under its Medicaid Contract. Pursuant to the Indemnity Agreement, the Company and UHC were jointly and severally liable to the Surety in the maximum amount of the bond, plus certain costs of the Surety, in the event of losses arising under the bond. The bond&#8217;s original expiry date was June 30, 2020 and during the three months ended June 30, 2020, was extended to December 31, 2020. The bond was released in October 2020. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 30, 2019, UHC, PHS I, the Company and EVH Passport consummated the transactions contemplated by the Passport APA (the &#8220;Passport Closing&#8221;).  At the Passport Closing, $16.2 million of the cash Passport Purchase Price was held back until such time as PHS I delivers to EVH Passport certain owned real property and improvements free and clear of all encumbrances. In addition, at the Passport Closing, EVH Passport and UHC entered into an agreement that provided for the administration and assumption of the financial risks by EVH Passport of UHC&#8217;s dual eligible special needs business (the &#8220;DNP Business&#8221;) until such time as EVH Passport became certified as a Medicare Advantage Organization and the D-SNP Business could be transferred to EVH Passport.  On October 1, 2020, the D-SNP Business was transferred from UHC to EVH Passport.  At the Passport Closing, EVH Passport assumed UHC&#8217;s obligations under the Passport Note and the Indemnity Agreement. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 16, 2020, EVH Passport, Evolent Health LLC and Molina Healthcare, Inc. (&#8220;Molina&#8221;) entered into an Asset Purchase Agreement (the &#8220;Molina APA&#8221;), which contemplated the sale by EVH Passport to Molina of certain assets, including certain intellectual property rights of EVH Passport and EVH Passport&#8217;s rights under the Passport Medicaid Contract.  On September 1, 2020, EVH Passport and Molina consummated the transactions contemplated by the Molina APA (the &#8220;Molina Closing&#8221;), and the Passport Medicaid Contract was novated to Molina.  As a result, EVH Passport began to wind down its business.  In connection with the Molina Closing, Molina deposited $20.0&#160;million in cash in escrow, which was subsequently released to EVH Passport in January 2021.  In addition, at the Molina Closing, Molina and EVH Passport entered into an agreement that provided for the assumption of the financial risks by Molina of the D-SNP Business until such time as Molina&#8217;s Kentucky health plan becomes certified as a Medicare Advantage Organization and the D-SNP Business is transferred Molina.  The Company and EVH Passport continued to administer the D-SNP Business until January 1, 2021, at which time Molina became responsible for its administration until the D-SNP Business is officially transferred to Molina effective September 1, 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the Molina Closing, the Company accounted for its investment in EVH Passport as an unconsolidated variable interest entity under the equity method of accounting.  As a result of the transaction, the Company concluded that a reconsideration event occurred whereby EVH Passport was determined to be a voting interest entity and that Evolent had a controlling financial interest in EVH Passport; accordingly, the Company consolidated EVH Passport as of September 1, 2020 in its consolidated financial statements. The Company accounted for the transaction as an asset acquisition, as the Company concluded that assets acquired as a result of the consolidation did not meet the criteria to be classified as a business under GAAP.  Following the Molina Closing and consolidation of EVH Passport in the Company&#8217;s consolidated financials, on November 16, 2020, EVH Passport redeemed the Sponsors&#8217; equity interests in EVH Passport for $20.0&#160;million in cash in accordance with the terms of EVH Passport&#8217;s Stockholders&#8217; Agreement, and, as a result, EVH Passport became a wholly owned subsidiary of the Company.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the consolidation, the Company recorded assets primarily consisting of cash and cash equivalents and restricted cash and cash equivalents of $159.8&#160;million, available for sale securities of $88.6&#160;million, receivables related to unsettled sales of securities of $43.0&#160;million and other assets of $50.2&#160;million and total liabilities primarily comprised of reserve for claims and performance-based arrangements of $164.8&#160;million and accrued liabilities of $50.0&#160;million. Subsequent to winddown activities, any remaining capital will be distributed to the Company subject to regulatory approval from the Kentucky Department of Insurance.  In addition, the Passport Note was eliminated upon consolidation, and as of December 31, 2020, the outstanding principal balance of the $40.0&#160;million Passport Note was repaid in full by EVH Passport including approximately $3.6&#160;million of accrued interest.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During the first quarter of 2021, pursuant to the terms of the Molina APA, EVH Passport received a cash payment from Molina in the amount of $23.0&#160;million based on the number of enrollees above a certain threshold in the D-SNP Business and Molina's Medicaid plan following the open enrollment period for plan year 2021. The foregoing amount represents 50% of the payment that EVH Passport is eligible to receive pursuant to the terms of the Molina APA based on the number of such enrollees. The remaining 50% will be payable in the first quarter of 2022 subject to the satisfaction of certain contingencies.</span></div>Repositioning and Other Changes<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continually assess opportunities to improve operational effectiveness and efficiency to better align our expenses with revenues, while continuing to make investments in our solutions, systems and people that we believe are important to our long-term goals. Across 2020, we divested or agreed to divest a majority of our health plan assets, including certain assets of EVH Passport, which represented a significant revenue stream for the Company. In parallel with these divestitures, we contracted with a third-party vendor to review our operating model and organizational design in order to improve our profitability, create value through our solutions and invest in strategic opportunities in future periods.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the fourth quarter of 2020, we committed to certain operational efficiency and profitability actions that we are taking in order to accomplish these objectives (&#8220;Repositioning Plan&#8221;). These actions included making organizational changes across our business as well as other profitability initiatives expected to result in reductions in force, re-aligning of resources as well as other potential operational efficiency and cost-reduction initiatives. The Repositioning Plan is expected to continue through the fourth quarter of 2021. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded approximately $0.7&#160;million and $6.0&#160;million of repositioning costs in selling, general and administrative expenses for the three and six months ended June 30, 2021&#160;in connection with the Repositioning Plan. The following table provides a summary of our total costs associated with the Repositioning Plan for the three and six months ended June 30, 2021, by major type of cost (in thousands):</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.305%"><tr><td style="width:1.0%"/><td style="width:27.431%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.499%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.305%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.359%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.305%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.359%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.039%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.359%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.044%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Incurred For the Three Months Ended <br/>June  30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Incurred for the Six Months Ended June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Amount Expected to be Incurred in the Repositioning Plan</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cumulative Amount Incurred through June 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Severance and termination benefits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office space consolidation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,071&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,071&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,071&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional services</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">587&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,787&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,162&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,062&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">663&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,043&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,418&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,318&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -URI http://asc.fasb.org/topic&amp;trid=2175745<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140179452148312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Discontinued Operations<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock', window );">Discontinued Operations</a></td>
<td class="text">Discontinued Operations<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 11, 2021, Evolent Health LLC, EH Holdings and True Health, each wholly owned subsidiaries of the Company, entered into a Stock Purchase Agreement (the &#8220;True Health SPA&#8221;) with Bright Health Management, Inc. (&#8220;Bright HealthCare&#8221;), pursuant to which EH Holdings agreed to sell all of its equity interests in True Health to Bright HealthCare. Closing of the transactions contemplated by the True Health SPA occurred on March 31, 2021 (the &#8220;True Health Closing&#8221;) and the Company will have no continuing involvement with True Health subsequent to the closing except an existing services agreement for claims processing and other health plan administrative functions.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the first quarter of 2021, the Company determined that True Health met the discontinued operations criteria under ASC 360, and as such, True Health assets and liabilities as of December 31, 2020, and the results of operations for all periods presented are classified as held for sale and are not included in continuing operations in the consolidated financial statements.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the results of operations of the Company&#8217;s True Health business, which are included in loss from discontinued operations in the consolidated statements of operations the three and six months ended June 30, 2021 and 2020:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.011%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.209%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Platform and operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Premiums</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,502&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,795&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,649&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,541&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,833&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,928&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenue (exclusive of depreciation and amortization expenses presented separately below) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,640&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,885&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,935&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Claims expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,144&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,954&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,811&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,236&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,764&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,911&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">320&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,180&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,763&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,977&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating loss</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,639)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(930)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,049)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes and non-controlling interests</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,508)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(847)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,773)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit for income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(326)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,508)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(521)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,773)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Cost of revenue includes intercompany expenses between the Company and True Health that are recorded in income from continuing operations on the consolidated statements of operations related an existing services agreement for claims processing and other health plan administrative functions of $3.2&#160;million for the three months ended June 30, 2020 and $2.8&#160;million and $6.3&#160;million for the six months ended June 30, 2021 and 2020, respectively.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:1.12pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Selling, general and administrative expenses includes intercompany expenses between the Company and True Health that are recorded in income from continuing operations on the consolidated statements of operations related an existing services agreement for claims processing and other health plan administrative functions of  $1.0&#160;million of for the three months ended June 30, 2020 and $1.1 million and $4.1 million for the six months ended June 30, 2021 and 2020, respectively. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated statements of cash flows for all periods have not been adjusted to separately disclose cash flows related to discontinued operations. Cash flows related to the True Health business during the six months ended June 30, 2021 and 2020 were as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:79.733%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.207%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows provided by (used in) operating activities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,002&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,660&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows provided by (used in) investing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,494)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">382&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the current and long-term assets and liabilities of the discontinued True Health business in the consolidated balance sheets as of December&#160;31, 2020:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.927%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.873%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,488&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash and restricted investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,437&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.927%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.873%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,198&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments, at amortized cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,728&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,914&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash and restricted investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">616&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments, at amortized cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,919&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other noncurrent assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,080&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,705&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,293&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,265&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and employee benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,115&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,140&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve for claims and performance-based arrangements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,858&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,471&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,648&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Accounts payable exclude $1.5&#160;million between the Company and True Health related an existing services agreement for claims processing and other health plan administrative functions as of December 31, 2020.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=2122178<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140179452409000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenue Recognition</a></td>
<td class="text">Revenue Recognition<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We derive revenue from two sources: (1) transformation services and (2) platform and operations services.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Transformation Services Revenue</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Transformation services consist of implementation services whereby we assist the customer in launching its population health or health plan programs. In certain cases, transformation services can also include revenue associated with our support of certain one-time wind-down activities for clients who are exiting a line of business or population. The transformation services are usually completed within 12 months. We generally receive a fixed fee for transformation services and recognize revenue over time using an input method based on hours incurred compared to the total estimated hours required to satisfy our performance obligation.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Platform and Operations Services Revenue</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Platform and operations services are typically multi-year arrangements with customers to provide various clinical and administrative solutions. In our Clinical Solutions segment, our solutions are designed to lower the medical expenses of our partners and include our total cost of care and specialty care management services.  In our Evolent Health Services segment, our solutions are designed to provide comprehensive health plan operations and claims processing services, and also include transition or run-out services to customers receiving primarily third-party administration (&#8220;TPA&#8221;) services.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our performance obligation in these arrangements is to provide an integrated suite of services, including access to our platform that is customized to meet the specialized needs of our customers and members. Generally, we will apply the series guidance to the performance obligation as we have determined that each time increment is distinct. We primarily utilize a variable fee structure for these services that typically includes a monthly payment that is calculated based on a specified per member per month rate, multiplied by the number of members that our partners are managing under a value-based care arrangement or a percentage of plan premiums. Our arrangements may also include other variable fees related to service level agreements, shared medical savings arrangements and other performance measures. Variable consideration is estimated using the most likely amount based on our historical experience and best judgment at the time. Due to the nature of our arrangements, certain estimates may be constrained if it is probable that a significant reversal of revenue will occur when the uncertainty is resolved. We recognize revenue from platform and operations </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">services over time using the time elapsed output method. Fixed consideration is recognized ratably over the contract term. In accordance with the series guidance, we allocate variable consideration to the period to which the fees relate.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our Clinical Solutions segment, we enter into capitation arrangements that may include performance-based arrangements and/or gainshare features. We recognize capitation revenue on a gross basis when we have established control over the services within our scope and recognize capitation revenue on a net basis when we do not have control over the services within our scope. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contracts with Multiple Performance Obligations</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contracts with customers may contain multiple performance obligations, primarily when the customer has requested both transformation services and platform and operations services as these services are distinct from one another. When a contract has multiple performance obligations, we allocate the transaction price to each performance obligation based on the relative standalone selling price using the expected cost margin approach. This approach requires estimates regarding both the level of effort it will take to satisfy the performance obligation as well as fees that will be received under the variable pricing model. We also take into consideration customer demographics, current market conditions, the scope of services and our overall pricing strategy and objectives when determining the standalone selling price.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Principal vs. Agent</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We occasionally use third parties to assist in satisfying our performance obligations. In order to determine whether we are the principal or agent in the arrangement, we review each third-party relationship on a contract by contract basis. We are an agent when our role is to arrange for another entity to provide the services to the customer. In these instances, we do not control the service before it is provided and recognize revenue on a net basis. We are the principal when we control the good or service prior to transferring control to the customer. We recognize revenue on a gross basis when we are the principal in the arrangement.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Disaggregation of Revenue</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents Evolent&#8217;s revenue disaggregated by segment and end-market for the three and six months ended June 30, 2021 and 2020 (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:114.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Evolent Health Services</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Evolent Health Services</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,064&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,502&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,648&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,050&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,993&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113,947&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,987&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124,512&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,346&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,061&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,761&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,206&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,684&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,246&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176,544&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126,560&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,453&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,958&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,785&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,522&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,023&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,705&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,897&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,561&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,863&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,521&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147,194&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130,778&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159,700&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182,898&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277,428&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255,633&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Transaction Price Allocated to the Remaining Performance Obligations</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For contracts with a term greater than one year, we have allocated approximately $181.2 million of transaction price to performance obligations that are unsatisfied as of June&#160;30, 2021. We do not include variable consideration that is allocated entirely to a wholly unsatisfied performance obligation accounted for under the series guidance in the calculation. As a result, the balance represents the value of the fixed consideration in our long-term contracts that we expect will be recognized as revenue in a future period and excludes the majority of our platform and operations revenue, which is primarily derived based on variable consideration as discussed in Note 2. We expect to recognize revenue on approximately 18% and 51% of these remaining performance obligations by December 31, 2021 and December 31, 2022, respectively, with the remaining balance to be recognized thereafter. However, because our existing contracts may be canceled or renegotiated including for reasons outside our control, the amount of revenue that we actually receive may be less or greater than this estimate and the timing of recognition may not be as expected.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contract Balances</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract balances consist of accounts receivable, contract assets and deferred revenue. Contract assets are recorded when the right to consideration for services is conditional on something other than the passage of time. Contract assets relating to unbilled receivables are transferred to accounts receivable when the right to consideration becomes unconditional. We classify contract assets as current or non-current based on the timing of our rights to the unconditional payments. Our contract assets are generally classified as current and recorded within prepaid expenses and other current assets on our consolidated balance sheets. Our current accounts receivables are classified within accounts receivable, net on our consolidated balance sheets and our non-current accounts receivable are classified within prepaid expenses and other non-current assets on our consolidated balance sheets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred revenue includes advance customer payments and billings in excess of revenue recognized. We classify deferred revenue as current or non-current based on the timing of when we expect to recognize revenue. Our current deferred revenue is recorded within deferred revenue on our consolidated balance sheets, and non-current deferred revenue is recorded within other long-term liabilities on our consolidated balance sheets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides information about receivables, contract assets and deferred revenue from contracts with customers as of June&#160;30, 2021 and December&#160;31, 2020 (in thousands):</span></div><div style="margin-top:5pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:403.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:67.75pt"/><td style="width:1.0pt"/></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term receivables </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240,060&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124,064&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term receivables </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,688&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,554&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term contract assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">329&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,173&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,187&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,932&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,593&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Amounts exclude $3.4&#160;million of short-term receivables and $4.1&#160;million of short-term deferred revenue reclassified to discontinued operations as of December&#160;31, 2020.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Excludes pharmacy claims receivable and premiums receivable</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in deferred revenue for the six months ended June 30, 2021 are as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:433.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:102.25pt"/><td style="width:1.0pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of beginning-of-period</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,780&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification to revenue, as a result of performance obligations satisfied</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,726)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash received in advance of satisfaction of performance obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,051&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,105&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amount of revenue recognized from performance obligations satisfied (or partially satisfied) in previous period was $2.9&#160;million and $16.1 million for the three and six months ended June 30, 2021, respectively, due primarily to net gain share as well as changes in other estimates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contract Cost Assets</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain bonuses and commissions earned by our sales team are considered incremental costs of obtaining a contract with a customer that we expect to be recoverable. The capitalized contract acquisition costs are classified as non-current assets and recorded within contract cost assets on our consolidated balance sheets. Amortization expense is recorded within selling, general and administrative expenses on the accompanying consolidated statements of operations and comprehensive income (loss). As of June&#160;30, 2021 and December&#160;31, 2020, the Company had $3.6 million and $3.3 million, respectively, of contract acquisition cost assets, net of accumulated amortization recorded in contract cost assets on the consolidated balance sheets. In addition, the Company recorded </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">amortiza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">tion expense of $0.6 million and  $1.0 million for the three and six months ended June 30, 2021, respectively and $0.4 million and $0.9 million for the three and six months ended June 30, 2020, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our platforms and operations arrangements, we incur certain costs related to the implementation of our platform before we begin to satisfy our performance obligation to the customer. The costs, which we expect to recover, are considered costs to fulfill a contract. Our contract fulfillment costs primarily include our employee labor costs and third-party vendor costs. The capitalized contract fulfillment costs are classified as non-current and recorded within contract cost assets on our consolidated balance sheets. Amortization expense is recorded within cost of revenue on the accompanying consolidated statements of operations and </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">comprehensive income (loss). As of June&#160;30, 2021 and December&#160;31, 2020, the Company had $18.8 million and $23.4 million, respectively, of contract fulfillment cost assets, net of accumulated amortization recorded in contract cost assets on the consolidated balance sheets. In addition, the Company recorded amortization expense of $4.6 million and $7.3 million for the three and six months ended June 30, 2021, respectively, $4.3 million and $9.4 million for the three and six months ended June 30, 2020, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These costs are deferred and then amortized on a straight-line basis over a period of benefit that we have determined to be five years. The period of benefit was based on our technology, the nature of our customer arrangements and other factors.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140179452140184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Credit Losses<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditLossAbstract', window );"><strong>Credit Loss [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditLossFinancialInstrumentTextBlock', window );">Credit Losses</a></td>
<td class="text">Credit Losses <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to credit losses primarily through our accounts receivable from revenue transactions, investments held at amortized cost and customer advances for regulatory capital and other notes receivable. We estimate expected credit losses based on past events, current conditions and reasonable and supportable forecasts. Expected credit losses are measured over the remaining contractual life of these assets. As part of our consideration of current and forward-looking economic conditions, we considered the impact of the COVID-19 pandemic on our customers&#8217; and other third parties&#8217; ability to pay. We did not observe notable increases in delinquencies during the three and six months ended June 30, 2021. Given the nature of our business, our past collection experience during recessionary and pre-recessionary periods, and our forecasted impact of the COVID-19 pandemic on our business, we did not record material changes in our allowances due to the COVID-19 pandemic during the three and six months ended June 30, 2021.</span></div><div><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounts Receivable from Revenue Transactions</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable represent the amounts owed to the Company for goods or services provided to customers or third parties. Current accounts receivables are classified within accounts receivable, net on the Company&#8217;s consolidated balance sheets, while non-current accounts receivables are classified within prepaid expenses and other noncurrent assets on the Company&#8217;s consolidated balance sheets. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We monitor our ongoing credit exposure through active review of counterparty balances against contract terms, due dates and business strategy. Our activities include timely account reconciliation, dispute resolution and payment confirmation. We may employ legal counsel to pursue recovery of defaulted receivables. In addition, the Company will establish a general reserve based on delinquency rates. Historical loss rates are determined for each delinquency bucket in 30-day past-due intervals, and then applied to the composition of the reporting date balance based on delinquency. The allowance implied from application of the historical loss rates is then adjusted, as necessary, for current conditions and reasonable and supportable forecasts.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on an aging analysis of our trade accounts receivable, non-trade accounts receivable and contract assets at&#160;June&#160;30, 2021,&#160;64% were current, 15%&#160;were past due less than 60 days, with 28% past due less than 120 days. At&#160;June&#160;30, 2021, we reported&#160;$264.1 million&#160;of accounts receivable, certain non-trade accounts receivable included in prepaid expenses and other assets on the consolidated balance sheet and contract assets, net of allowances of&#160;$7.7 million. The following table summarizes the changes in allowance for credit losses on our accounts receivables, certain non-trade accounts receivable and contract assets for the six months ended June 30, 2021 and 2020 (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.816%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.594%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.596%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,056)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cumulative transition adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,815)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for credit losses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(611)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(260)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charge-offs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,575&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,667)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,541)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditLossFinancialInstrumentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for credit loss on financial instrument measured at amortized cost basis, net investment in lease, off-balance sheet credit exposure, and available-for-sale debt security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922895-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919272-210447<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919236-210447<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919269-210447<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919244-210447<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919230-210447<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditLossFinancialInstrumentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140179452517672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text">Property and Equipment, Net<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes our property and equipment as of June&#160;30, 2021 and December&#160;31, 2020 (in thousands):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:408.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:54.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:67.75pt"/><td style="width:1.0pt"/></tr><tr style="height:23pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer hardware</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,931&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,866&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,545&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,559&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Internal-use software development costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148,171&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137,085&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,553&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,586&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187,200&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175,096&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation and amortization expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(104,204)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(88,856)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,996&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,240&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company capitalized $5.6 million and $11.1 million of internal-use software development costs for the three and six months ended June 30, 2021, respectively, and $6.4 million and  $13.7 million for the three and six months ended June 30, 2020, respectively. The net book value of capitalized internal-use software development costs was $73.0 million and $75.3 million as of June&#160;30, 2021 and December&#160;31, 2020, respectively. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense related to property and equipment was $7.6 million and $15.4 million for the three and six months ended June 30, 2021, respectively, and $7.1 million and $13.9 million for the three and six months ended June 30, 2020, respectively, of which amortization expense related to capitalized internal-use software development costs was $6.6 million and $13.3 million for the three and six months ended June 30, 2021, respectively, and $6.0 million and $11.6 million for the three and six months ended June 30, 2020, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140179453531752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets, Net<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Goodwill and Intangible Assets, Net</a></td>
<td class="text">Goodwill and Intangible Assets, Net<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill has an estimated indefinite life and is not amortized; rather, it is reviewed for impairment at least annually or whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent to the sale of True Health, the Company has three reporting units, each with </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">discrete financial information. Our assets and liabilities are employed in and relate to the operations of our reporting units. Therefore, the equity carrying value and future cash flows must be estimated each time a&#160;goodwill impairment&#160;analysis is performed on a reporting unit. As a result, our assets, liabilities and cash flows are assigned to reporting units using reasonable and consistent allocation methodologies. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our annual goodwill impairment review occurs during the fourth quarter of each fiscal </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">year. We evaluate qualitative factors that could cause us to believe the estimated fair value of each of our reporting units may be lower than the carrying value and trigger a quantitative assessment, including, but not limited to (i) macroeconomic conditions, (ii) industry and market considerations, (iii) our overall financial performance, including an analysis of our current and projected cash flows, revenues and earnings, (iv) a sustained decrease in share price and (v) other relevant entity-specific events including changes in management, strategy, partners, or litigation.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2021 Goodwill Impairment Test</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not identify any qualitative factors that would trigger a quantitative goodwill impairment test during the three and six months ended June 30, 2021. We will perform our annual impairment test as of October 31, 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2020 Goodwill Impairment Test</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2020, the Company assessed whether there were additional events or changes in circumstances since its 2019 annual goodwill impairment test that would indicate that it was more likely than not that the fair values of the reporting units were less than the reporting units&#8217; carrying amounts that would require an additional interim impairment assessment after October 31, 2019. Considering the sharp decrease in the share price of the Company&#8217;s Class A common stock during the three months ended March 31, 2020, the Company determined indicators of an impairment were present and we performed an interim goodwill impairment assessment as of March 31, 2020. As a result of this test, the Company determined that there was no goodwill impairment of the reporting unit which recognized an impairment in the year ended December 31, 2019. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During May 2020, the CHFS announced that EVH Passport was not awarded a Kentucky managed Medicaid contract for the next contract period and the Passport Medicaid Contract would expire on December 31, 2020. As a result of this announcement, the Company determined there were events or changes in circumstances since its 2019 annual goodwill impairment test that indicated it was more likely than not that the fair value of one of its two reporting units in the EHS segment was less than the reporting unit&#8217;s carrying amount triggering an interim quantitative assessment.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In performing this interim quantitative assessment, we estimated the fair value of the reporting unit by considering a discounted cash flow valuation approach (&#8220;income approach&#8221;). In determining the estimated fair value in a quantitative analysis, we projected future cash flows based on management&#8217;s estimates and long-term plans and applied a discount rate based on the Company&#8217;s weighted average cost of capital. This analysis required us to make judgments about revenues, expenses, fixed asset and working capital requirements, capital market assumptions, cash flows and discount rates.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of May 31, 2020, we determined that the reporting unit under review had an estimated fair value less than its carrying value.  As a result, we recorded a non-cash goodwill impairment charge of $215.1&#160;million on our consolidated statements of operations and comprehensive income (loss) for the three and six months ended June 30, 2020. In addition, the Company reviewed its interim goodwill impairment analysis as of June 30, 2020 and did not identify any additional information or events that would contradict or change the conclusion reached by the Company as of May 31, 2020. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September 30, 2020, we evaluated qualitative factors that could indicate the fair value of each of our reporting units may be lower than the carrying value. We did not identify any qualitative factors that would trigger a quantitative goodwill impairment test during the three months ended September 30, 2020. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the Company&#8217;s annual impairment analysis as of October 31, 2020, the Company concluded that previous impairment charges of $199.8&#160;million and $215.1&#160;million recorded during the three months ended December 31, 2019 and June 30, 2020, respectively, in one of our two reporting units in the EHS segment left that specific reporting unit with a limited fair value cushion. Therefore, the Company elected to forego the qualitative assessment and proceed directly to the quantitative assessment of the goodwill impairment test for that specific reporting unit. This election does not preclude management from performing the qualitative assessment in any subsequent period. For the remaining reporting units, after assessing the totality of events and circumstances including the results of our previous valuations, the minimal impacts of the Passport loss and COVID-19, the Company does not believe that an event occurred or circumstances changed during the period under consideration that would, more likely than not, reduce the fair value of any reporting unit below their carrying amount. Therefore, the Company concluded that the quantitative assessment was not required. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In performing our October 31, 2020 impairment test for one of the specific reporting units referenced above, we estimated the fair value of our reporting units by considering a discounted cash flow valuation approach (&#8220;income approach&#8221;). In determining the estimated fair value using the income approach, we projected future cash flows based on management&#8217;s estimates and long-term plans and applied a discount rate based on the Company&#8217;s weighted average cost of capital. This analysis required us to make judgments about revenues, expenses, fixed asset and working capital requirements, capital market assumptions, cash flows and discount rates. As of October 31, 2020, we determined that the specific reporting unit had an estimated fair value greater than its carrying value and as a result, goodwill is not impaired.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, the Company assessed whether there were additional events or changes in circumstances since its annual goodwill impairment test that would indicate that it was more likely than not that the fair value of the reporting unit was less than the reporting unit&#8217;s carrying amounts that would require an interim impairment assessment after October 31, 2020. The Company determined there had been no such indicators, therefore, we did not perform an interim goodwill impairment assessment as of </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2020. As of December 31, 2020, the remaining goodwill attributable to the reporting unit from which we recognized a non-cash goodwill impairment charge earlier in the year was $214.3 million.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in the carrying amount of goodwill, by reportable segment, for the six months ended June 30, 2021 and 2020 (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:331.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:63.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:3.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:63.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:3.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:63.25pt"/><td style="width:1.0pt"/></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EHS</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated </span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2020 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214,354&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134,675&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">349,029&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of June 30, 2021</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214,334&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134,675&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">349,009&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span><br/></span></div><div style="padding-left:9pt;text-indent:-9pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.705%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.985%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EHS</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2019 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">431,684&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134,675&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">566,359&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill disposal </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,200)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,200)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(215,100)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(215,100)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(69)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(69)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of June 30, 2020</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214,315&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134,675&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">348,990&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Net of cumulative inception to date impairment of $575.5 million and $360.4 million as of December 31, 2020 and 2019, respectively.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Goodwill written-off upon disposal of a consolidated subsidiary.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangible Assets, Net</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Details of our intangible assets (in thousands, except weighted-average useful lives) as of June&#160;30, 2021 and December&#160;31, 2020  are presented below:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:72.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:54.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:63.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:46.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:54.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:63.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:45.25pt"/><td style="width:1.0pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr style="height:44pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted- Average Remaining Useful Life</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Carrying Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted- Average Remaining Useful Life</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Carrying Value</span></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate trade name</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,300&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,961&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,339&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,300&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,271&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,029&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.7</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278,519&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,894&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213,625&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278,519&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,716&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220,803&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,922&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,809&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,113&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,922&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,507&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,415&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Below market lease, net</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,218&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">849&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">369&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,118&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">648&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">470&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:35pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provider network contracts </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,947&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,348&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,599&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,175&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,900&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,275&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:35pt"><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">399,906&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147,861&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252,045&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">398,034&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133,042&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264,992&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Amounts exclude $2.2&#160;million and $0.9&#160;million of customer relationships and provider network contracts, respectively, net of accumulated amortization, with weighted average remaining useful lives of 15 years and 10 months reclassified to discontinued operations as of December&#160;31, 2020.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense related to intangible assets for the three and six months ended June 30, 2021, was $7.2 million and $14.7 million, respectively. Amortization expense related to intangible assets for the three and six months ended June 30, 2020 was $8.4 million and $17.7 million, respectively, excluding $0.2&#160;million and $0.3&#160;million of amortization expense related to discontinued operations for the three and six months ended June 30, 2020.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future estimated amortization of intangible assets (in thousands) as of June&#160;30, 2021, is as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:478.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,762&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,629&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,325&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,441&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,736&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159,152&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future amortization of intangible assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252,045&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets are reviewed for impairment if circumstances indicate the Company may not be able to recover the assets&#8217; carrying value. We did not identify any circumstances during&#160;the three and six months ended&#160;June&#160;30, 2021, that would require an impairment test for our intangible assets.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140179452482632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-term Debt<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Long-term Debt</a></td>
<td class="text">Long-term Debt<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2024 Notes</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the Company issued $117.1&#160;million aggregate principal amount of its 3.50% Convertible Senior Notes due 2024 (the &#8220;2024 Notes&#8221;) in privately negotiated exchange and/or subscription agreements, with certain holders of its outstanding 2021 Notes and certain new investors. The Company issued $84.2 million aggregate principal amount of 2024 Notes in exchange for $84.2 million aggregate principal amount of the 2021 Notes and an aggregate cash payment of $2.5&#160;million, and issued $32.8 million aggregate principal amount of New Notes for cash at par. We incurred $3.0&#160;million of debt issuance costs in connection with the 2024 Notes, which we are amortizing to non-cash interest expense using the straight-line method over the contractual term of the 2024 Notes. The closing of the private placement of the 2024 Notes occurred on August 19, 2020.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of the 2024 Notes are entitled to cash interest payments, which are payable semiannually in arrears on June 1 and December 1 of each year, beginning on December 1, 2020, at a rate equal to 3.50% per annum. The 2024 Notes will mature on December 1, 2024, unless earlier repurchased, redeemed or converted in accordance with their terms prior to such date. Upon maturity the principal amount of the notes may be settled via shares of the Company&#8217;s Class A common stock. We recorded interest expense of $1.0 and $2.0 million for the three and six months ended June 30, 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2024 Notes are convertible into cash, shares of the Company's Class A common stock, or a combination of cash and shares of the Company's Class A common stock, at the Company's election, based on an initial conversion rate of 54.8667 shares of Class A common stock per $1,000 principal amount of the 2024 Notes, which is equivalent to an initial conversion price of approximately $18.23 per share of the Company&#8217;s Class A common stock. In the aggregate, the 2024 Notes are initially convertible into 6.4&#160;million shares of the Company&#8217;s Class A common stock (excluding any shares issuable by the Company upon a conversion in connection with a make-whole provision upon a fundamental change or a notice of redemption under the governing indenture). The conversion rate may be adjusted under certain circumstances. Upon conversion, the Company will pay or deliver, as the case may be, cash or shares of the Company&#8217;s Class A common stock, or a combination of cash and shares of the Company&#8217;s Class A common stock, at the Company&#8217;s election.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The option to settle the 2024 Notes in cash or shares of the Company&#8217;s Class A common stock, or a combination of cash and shares of the Company&#8217;s Class A common stock, at the Company&#8217;s election, resulted in a bifurcation of the carrying value of the 2024 Notes into a debt component and an equity component. The debt component was determined to be $78.9&#160;million, before issuance costs, based on the fair value of a nonconvertible debt instrument with the same term. The equity component was determined to be $38.1&#160;million, before issuance costs, and was recorded within additional paid-in capital. The equity component is the difference between the aggregate principal amount of the debt and the fair value of the debt component. Issuance costs of $1.7&#160;million and $1.3&#160;million are allocated to the debt and equity components in proportion to the allocation of proceeds. Along with the equity component of $38.1&#160;million, $1.7&#160;million of issuance costs will be amortized to interest expense on the consolidated statements of operations and comprehensive income (loss) using the effective interest method over the contractual term of the 2024 Notes. The equity component recorded within additional paid-in capital will not be remeasured as long as it meets the conditions for equity classification. The Company recorded $2.0 million and $3.9 million of interest expense related to the amortization of the debt discount and the issuance costs allocated to the debt component for the three and six months ended June 30, 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of the 2024 Notes may require the Company to repurchase all or part of their notes upon the occurrence of a fundamental change at a price equal to 100.0% of the principal amount of the notes being repurchased, plus any accrued and unpaid interest to, but excluding, the fundamental change repurchase date. The Company may not redeem the 2024 Notes prior to March 1, 2023. The Company may redeem for cash all or any portion of the 2024 Notes, at its option, on or after March 1, 2023, if the last reported sale price of the Company&#8217;s Class A common stock has been at least 130.0% of the conversion price then in effect for at least 20 trading </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which the Company provides notice of redemption, at a redemption price equal to 100.0% of the principal amount of the notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Credit Agreement</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 30, 2019, the Company entered into a credit agreement, by and among the Company, Evolent Health LLC, as the borrower (the &#8220;Borrower&#8221;), certain subsidiaries of the Company, as guarantors, the lenders from time to time party thereto, and Ares Capital Corporation, as administrative agent and collateral agent, together with the Company (the &#8220;Credit Agreement&#8221;), pursuant to which the lenders agreed to extend credit to the Borrower in the form of (i) an initial secured term loan in the aggregate principal amount of $75.0 million (the &#8220;Initial Term Loan Facility&#8221;) and (ii) a delayed draw secured term loan facility in the aggregate principal amount of up to $50.0 million (the &#8220;DDTL Facility&#8221; and, together with the Initial Term Loan Facility, the &#8220;Senior Credit Facilities&#8221;), subject to the satisfaction of specified conditions. The Borrower borrowed the loan under the Initial Term Loan Facility on December 30, 2019. In connection with the Credit Agreement, on December 30, 2019, the Company entered into a Security Agreement, by and among the Company, the Borrower, the other guarantors and the collateral agent for the benefit of the secured parties, and a Guarantee Agreement, by the Company and each of the other guarantors in favor of the collateral agent for the benefit of the secured parties. The Senior Credit Facilities were guaranteed by the Company and the Company&#8217;s domestic subsidiaries, subject to certain exceptions. The Senior Credit Facilities were secured by a first priority security interest in all of the capital stock of the borrower and each guarantor (other than the Company) and substantially all of the assets of the borrower and each guarantor, subject to certain exceptions. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The proceeds of the Initial Term Loan were used to finance the transactions contemplated by the Passport APA and pay fees and expenses incurred in connection therewith. The proceeds of the DDTL Facility were permitted to be used, subject to the Company&#8217;s satisfaction of specified conditions, to finance the repayment or repurchase of the Company&#8217;s 2.00% Convertible Senior Notes due December 1, 2021 and to fund permitted acquisitions. &#160;The Initial Term Loan and any loans under the DDTL Facility would have matured on the date that is the earliest of (a) December 30, 2024, (b) the date on which all amounts outstanding under the Credit Agreement would have been declared or have automatically become due and payable under the terms of the Credit Agreement and (c) the date that is ninety-one (91) days prior to the maturity date of the 2021 Convertible Notes unless certain liquidity conditions were satisfied (the foregoing, the &#8220;Maturity Date&#8221;). The interest rate for each loan under the Senior Credit Facilities was calculated, at the option of the Borrower, at either the Eurodollar rate plus 8.00%, or the base rate plus 7.00%. A commitment fee of 1.00% per annum was payable by the Borrower quarterly in arrears on the unused portion of the DDTL Facility. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts outstanding under the Senior Credit Facilities could have been prepaid at the option of the Borrower subject to applicable premiums, including a make-whole premium payable on certain prepayments made prior to the second anniversary of the closing of the Senior Credit Facilities, and a call protection premium payable on the amount prepaid in certain instances as follows: (i) 4.00% of the principal amount so prepaid after the second anniversary of the closing of the Senior Credit Facilities but prior the third anniversary of the closing of the Senior Credit Facilities; (ii) 3.00% of the principal amount so prepaid after the third anniversary of the closing of the Senior Credit Facilities but prior the fourth anniversary of the closing of the Senior Credit Facilities; and (iii) 2.00% of the principal amount so prepaid after the fourth anniversary of the closing of the Senior Credit Facilities but prior the fifth anniversary of the closing of the Senior Credit Facilities. Amounts outstanding under the Senior Credit Facility were subject to mandatory prepayment upon the occurrence of certain events and conditions, including non-ordinary course asset dispositions, receipt of certain casualty proceeds, issuances of certain debt obligations and a change of control transaction.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Senior Credit Facilities contained customary borrowing conditions, affirmative, negative and reporting covenants, representations and warranties, and events of default, including cross-defaults to other material indebtedness. In addition, the Company was required to comply at certain times with certain financial covenants comprised of a minimum net revenue test and a minimum liquidity test commencing upon closing of the Senior Credit Facilities and a total secured leverage ratio commencing on the last day of the fiscal quarter ending March 31, 2021. If an event of default had occurred, the lenders would be entitled to take enforcement action, including foreclosure on collateral and acceleration of amounts owed under the Senior Credit Facilities. We incurred $4.7 million of debt issuance costs in connection with this Credit Agreement, which was included in long-term debt, net of discount on our consolidated balance sheets and amortized into interest expense over the life of the agreement. The Company recorded $0.5 million and $1.1 million in interest expense related to the amortization of the debt discount and the issuance costs for the three and six months ended June 30, 2020, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 19, 2020, an amendment to the Company's Credit Agreement became effective. The amendment effected changes to, among other things, permit the Company's use of cash in the exchange transactions in connection with the issuance of the 2024 Notes, permit the issuance of the 2024 Notes and permit certain note repurchases, as well as to implement amendments to certain minimum liquidity thresholds.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 8, 2021, the Company repaid all outstanding amounts owed under, and terminated, the Credit Agreement with Ares Capital Corporation. The total amount paid to Ares Capital Corporation under the Credit Agreement in connection with the prepayment was $98.6&#160;million, which included $9.7&#160;million for the make-whole premium as well as $0.2&#160;million in accrued interest. As a result of this transaction, the Company recorded loss on the repayment of debt of $19.2&#160;million, representing the remaining unamortized debt issuance costs of $9.5&#160;million, the make-whole premium and $35&#160;thousand of legal expenses.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Warrant Agreement</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In conjunction with the Company&#8217;s entry into the Credit Agreement, the Company entered into warrant agreements whereby it agreed to sell to the holders of the warrants an aggregate of 1,513,786 shares of Class A common stock at a per share purchase price equal to $8.05.  The holders could exercise the warrants at any time until thirty days after the maturity of the Credit Agreement.  The Company, at its sole discretion, could elect to pay the holders in cash in an amount determined based on the fair market value of the Class A common stock for the shares of Class A common stock issuable upon exercise of the warrants in lieu of delivering the shares.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 8, 2021, the Company settled the outstanding warrants associated with the Credit Agreement for $13.7&#160;million.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2025 Notes</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, the Company issued $172.5 million aggregate principal amount of its 1.50% Convertible Senior Notes due 2025 (the &#8220;2025 Notes&#8221;) in a private placement to qualified institutional buyers within the meaning of Rule 144A under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). The 2025 Notes were issued at par for net proceeds of $166.6 million. We incurred $5.9 million of debt issuance costs in connection with the 2025 Notes. The closing of the private placement of $150.0 million aggregate principal amount of the 2025 Notes occurred on October&#160;22, 2018, and the Company completed the offering and sale of an additional $22.5 million aggregate principal amount of the 2025 Notes on October&#160;24, 2018, pursuant to the initial purchasers&#8217; exercise in full of their option to purchase additional notes.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of the 2025 Notes are entitled to cash interest payments, which are payable semiannually in arrears on&#160;April 15&#160;and&#160;October 15&#160;of each year, beginning on&#160;April&#160;15, 2019, at a rate equal to&#160;1.50%&#160;per annum. The Company recorded interest expense of $0.7 million and $1.3 million for the three and six months ended June 30, 2021 and 2020, respectively. The 2025 Notes will mature on&#160;October&#160;15, 2025, unless earlier repurchased, redeemed or converted in accordance with their terms prior to such date.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the close of business on the business day immediately preceding April&#160;15, 2025, the 2025 Notes will be convertible at the option of the holders only upon the satisfaction of certain conditions, as described in the indenture, dated as of October&#160;22, 2018, between the Company and U.S. Bank National Association, as trustee. At any time on or after April&#160;15, 2025, until the close of business on the business day immediately preceding the maturity date, holders may convert, at their option, all or any portion of their notes at the conversion rate.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2025 Notes will be convertible at an initial conversion rate of 29.9135 shares of Class A common stock per $1,000 principal amount of notes, which is equivalent to an initial conversion price of approximately $33.43 per share of the Company&#8217;s Class A common stock. In the aggregate, the 2025 Notes are initially convertible into 5.2 million shares of the Company&#8217;s Class A common stock (excluding any shares issuable by the Company upon a conversion in connection with a make-whole fundamental change or a notice of redemption as described in the governing indenture). The conversion rate may be adjusted under certain circumstances. Upon conversion, the Company will pay or deliver, as the case may be, cash or shares of the Company&#8217;s Class A common stock, or a combination of cash and shares of the Company&#8217;s Class A common stock, at the Company&#8217;s election.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The option to settle the 2025 Notes in cash or shares of the Company&#8217;s Class A common stock, or a combination of cash and shares of the Company&#8217;s Class A common stock, at the Company&#8217;s election, resulted in a bifurcation of the carrying value of the 2025 Notes into a debt component and an equity component. The debt component was determined to be $100.7 million, before issuance costs, based on the fair value of a nonconvertible debt instrument with the same term. The equity component was determined to be $71.8 million, before issuance costs, and was recorded within additional paid-in capital. The equity component is the difference between the aggregate principal amount of the debt and the debt component. Issuance costs of $3.4 million and $2.5 million are allocated to the debt and equity components in proportion to the allocation of proceeds. Along with the equity component of $71.8 million, $3.4 million of issuance costs will be amortized to interest expense on the consolidated statements of operations and comprehensive income (loss) using the effective interest method over the contractual term of the 2025 Notes. The equity component recorded within additional paid-in capital will not be remeasured as long as it meets the conditions for equity classification. The Company recorded $2.4 million and $4.8 million for the three and six months ended June 30, 2021, respectively, and $2.1 million and $4.3 million for the three and six months ended June 30, 2020, respectively, in interest expense related to the amortization of the debt discount and the issuance costs allocated to the debt component.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of the 2025 Notes may require the Company to repurchase all or part of their notes upon the occurrence of a fundamental change at a price equal to 100.0% of the principal amount of the notes being repurchased, plus any accrued and unpaid interest to, but excluding, the fundamental change repurchase date. The Company may not redeem the 2025 Notes prior to October&#160;20, 2022. The Company may redeem for cash all or any portion of the 2025 Notes, at its option, on or after October&#160;20, 2022, if the last reported sale price of the Company&#8217;s Class A common stock has been at least 130.0% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which the Company provides notice of redemption, at a redemption price equal to 100.0% of the principal amount of the notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2021 Notes</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2016, the Company issued $125.0 million aggregate principal amount of its 2.00% Convertible Senior Notes due 2021 (the &#8220;2021 Notes&#8221;) in a private placement to qualified institutional buyers within the meaning of Rule 144A under the Securities Act. The 2021 Notes were issued at par for net proceeds of $120.4 million. We incurred $4.6 million of debt issuance costs in connection with the 2021 Notes, which we are amortizing to non-cash interest expense using the straight-line method over the contractual term of the 2021 Notes, since this method was not materially different from the effective interest method. The closing of the private placement of the 2021 Notes occurred on December&#160;5, 2016.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of the 2021 Notes are entitled to cash interest payments, which are payable semiannually in arrears on June 1 and December 1 of each year, beginning on June&#160;1, 2017, at a rate equal to 2.00% per annum. The 2021 Notes will mature on December&#160;1, 2021, unless earlier repurchased or converted in accordance with their terms prior to such date. In addition, holders of the 2021 Notes may require the Company to repurchase all or part of their 2021 Notes upon the occurrence of a fundamental change at a price equal to 100.00% of the principal amount of the 2021 Notes being repurchased, plus any accrued and unpaid interest to, but excluding, the fundamental repurchase date. Upon maturity the principal amount of the notes may be settled via shares of the Company&#8217;s Class A common stock. We recorded interest expense of $0.2 million and $0.3 million for the three and six months ended June 30, 2021, respectively, and $0.6 million and  $1.2 million for the three and six months ended June 30, 2020 , respectively. We recorded non-cash interest expense related to the amortization of deferred financing costs of $49 thousand and $0.1 million for the three and six months ended June 30, 2021, respectively, and $0.3 million and $0.5 million for the three and six months ended June 30, 2020, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2021 Notes are convertible into shares of the Company&#8217;s Class A common stock, based on an initial conversion rate of 41.6082 shares of Class A common stock per $1,000 principal amount of the 2021 Notes, which is equivalent to an initial conversion price of approximately $24.03 per share of the Company&#8217;s Class A common stock. In the aggregate, the 2021 Notes are initially convertible into 5.2 million shares of the Company&#8217;s Class A common stock (excluding any shares issuable by the Company upon a conversion in connection with a make-whole provision upon a fundamental change under the governing indenture). The conversion rate may be adjusted under certain circumstances.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2021 Notes are convertible, in multiples of $1,000 principal amount, at the option of the holders at any time prior to the close of business on the business day immediately preceding the maturity date. Upon conversion, we will deliver for each $1,000 principal amount of notes converted a number of shares of our Class A common stock equal to the applicable conversion rate (together with a cash payment in lieu of delivering any fractional share) on the third business day following the relevant conversion date.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, as part of the issuance of the 2024 Notes, the Company issued $84.2&#160;million aggregate principal amount of the 2024 Notes in exchange for $84.2&#160;million aggregate principal of its 2021 Notes. There was no cash consideration in these exchanges outside of an aggregate cash payment of $2.5&#160;million paid to exchanging noteholders. These exchanges were accounted for as an extinguishment resulting in a net loss on extinguishment of debt of $4.8&#160;million, including an aggregate cash payment of $2.5&#160;million paid to exchanging noteholders. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, we also repurchased $14.0&#160;million of the 2021 Notes with $13.9&#160;million of cash and recorded an immaterial gain on extinguishment of debt.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Convertible Senior Notes Carrying Value</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2025 Notes, 2024 Notes and 2021 Notes are recorded on our accompanying consolidated balance sheets at their net carrying values as of June&#160;30, 2021. However, the 2025 Notes, 2024 Notes and 2021 Notes are privately traded by qualified institutional buyers (within the meaning of Rule 144A under the Securities Act) and their fair values are Level 2 inputs. The 2025 Notes, 2024 Notes and the 2021 Notes also have embedded conversion options and contingent interest provisions, which have not been recorded as separate financial instruments. The following table summarizes the carrying value of the long-term convertible debt as of June&#160;30, 2021 and December&#160;31, 2020 (in thousands):</span></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:361.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:84.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:84.25pt"/><td style="width:1.0pt"/></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024 Notes</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying value</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,320&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,462&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt discount and issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,731&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,589&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,051&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,051&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remaining amortization period (years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132,054&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153,220&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2025 Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying value</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121,230&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,349&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt discount and issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,270&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,151&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172,500&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172,500&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remaining amortization period (years)</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165,974&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147,488&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021 Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying value</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,655&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,557&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,737&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,737&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remaining amortization period (years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,279&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,470&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140179454325576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commitments</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Letters of Credit</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2021 and December 31, 2020, the Company established irrevocable standby letters of credit&#160;with a bank for&#160;$15.0 million&#160;and $7.4&#160;million for the benefit of a regulatory authorities, real estate and risk-sharing agreements and, as such, held $15.0 million and $7.4&#160;million in restricted cash and restricted investments as collateral as of both June&#160;30, 2021 and December&#160;31, 2020, respectively. The letters of credit have current expiration dates between October 2021 and March 2032 and will automatically extend without amendment for an additional one-year period and will continue to automatically extend after each one-year term from the expiry date, unless the bank elects not to extend beyond the initial or any extended expiry date. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Indemnifications</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s customer agreements generally include a provision by which the Company agrees to defend its partners against third-party claims (a) for death, bodily injury, or damage to personal property caused by Company negligence or willful misconduct, (b) by former or current Company employees arising from such managed service agreements, (c) for intellectual property infringement under specified conditions and (d) for Company violation of applicable laws, and to indemnify them against any damages and costs awarded in connection with such claims. To date, the Company has not incurred any material costs as a result of such indemnities and has not accrued any liabilities related to such obligations in the accompanying consolidated financial statements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pre-IPO Investor Registration Rights Agreement</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We entered into a registration rights agreement with The Advisory Board, UPMC, TPG and another investor to register for sale under the Securities Act shares of our Class A common stock, including those delivered in exchange for Class B common stock and Class B common units. Subject to certain conditions and limitations, this agreement provides these investors with certain demand, piggyback and shelf registration rights. The registration rights granted under the registration rights agreement will terminate upon the date the holders of shares that are a party thereto no longer hold any such shares that are entitled to registration rights. Pursuant to our contractual obligations under this agreement, we filed a registration statement on Form S-3 with the SEC on July 28, 2016, which was declared effective on August 12, 2016.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will pay all expenses relating to any demand, piggyback or shelf registration, other than underwriting discounts and commissions and any transfer taxes, subject to specified conditions and limitations. The registration rights agreement includes customary indemnification provisions, including indemnification of the participating holders of shares of Class A common stock and their directors, officers and employees by us for any losses, claims, damages or liabilities in respect thereof and expenses to which such holders may become subject under the Securities Act, state law or otherwise. We did not incur any expenses related to secondary offerings or other sales of shares by our investor stockholders during the three and six months ended June 30, 2021 and 2020, respectively. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Guarantees</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In connection with the Molina Closing, the Company continued to provide administrative support services relating to the Passport Medicaid Contract to Molina through the end of 2020. Following the Molina Closing, EVH Passport began working with regulatory authorities including the Kentucky Department of Insurance (&#8220;KY DOI&#8221;) regarding the wind down of its operations throughout 2021. As part of that wind down process, the Company, as the parent of EVH Passport, entered into a guarantee for the benefit of the KY DOI to satisfy any EVH Passport liability or obligation in the event EVH Passport is not able to meet its wind down liabilities or obligations. As of June&#160;30, 2021, no amounts have been funded under this guarantee.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reinsurance Agreements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the Passport Closing, $16.2&#160;million of the cash Passport Purchase Price was held back until such time as PHS I delivers to EVH Passport certain owned real property and improvements free and clear of all encumbrances. In addition, at the Passport Closing, EVH Passport and UHC entered into an agreement that provided for the administration and assumption of the financial risks by EVH Passport of the D-SNP Business until such time as EVH Passport became certified as a Medicare Advantage Organization and the D-SNP Business could be transferred to EVH Passport.  On October 1, 2020, the D-SNP Business was transferred from UHC to EVH Passport.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the Molina Closing, Molina and EVH Passport entered into an agreement that provided for the assumption of the financial risks by Molina of the D-SNP Business until such time as Molina&#8217;s Kentucky health plan becomes certified as a Medicare Advantage Organization and the D-SNP Business is transferred to Molina. The Company and EVH Passport continued to administer the D-SNP Business until January 1, 2021, at which time Molina became responsible for its administration until the D-SNP Business is officially transferred to Molina effective September 1, 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes premiums and claims assumed under the Reinsurance Agreements for the six months ended June 30, 2021 and 2020 (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:438.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:46.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:46.00pt"/><td style="width:1.0pt"/></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reinsurance premiums assumed</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,576&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reinsurance premiums ceded</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Claims assumed</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,863&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Claims ceded</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Claims-related administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">545&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:24pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase in reserves for claims and performance-based arrangements attributable to the Reinsurance Agreement</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:24pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserves for claims and performance-based arrangements attributable to the Reinsurance Agreement at the beginning of the period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,002&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:23pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of consolidation on payable for claims and performance-based arrangements attributable to the Reinsurance Agreement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reinsurance payments paid (received)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,506&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:24pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivable for claims and performance-based arrangements attributable to the Reinsurance Agreement at the end of the period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,336)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">UPMC Reseller Agreement</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and UPMC are parties to a reseller, services and non-competition agreement, dated August 31, 2011, which was amended and restated by the parties on June 27, 2013 (as amended through the date hereof, the &#8220;UPMC Reseller Agreement&#8221;). Under the terms of the UPMC Reseller Agreement, UPMC has appointed the Company as a non-exclusive reseller of certain services, subject to certain conditions and limitations specified in the UPMC Reseller Agreement. In consideration for the Company&#8217;s obligations under </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the UPMC Reseller Agreement and subject to certain conditions described therein, UPMC has agreed not to sell certain products and services directly to a defined list of 20 of the Company&#8217;s customers.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contingencies</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Tax Receivables Agreement</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Offering Reorganization, the Company entered into the Tax Receivables Agreement (the &#8220;TRA&#8221;) with certain of its investors, which provides for the payment by the Company to these investors of 85% of the amount of the tax benefits, if any, that the Company is deemed to realize as a result of increases in our tax basis related to exchanges of Class B common units as well as tax benefits attributable to the future utilization of pre-IPO NOLs. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the items noted above, and the fact that Evolent Health, Inc. is in a full valuation allowance position such that the deferred tax assets related to the Company&#8217;s historical pre-IPO losses and tax basis increase benefit from exchanges have not been realized, the Company has not recorded a liability pursuant to the TRA.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Litigation Matters</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are engaged from time to time in certain legal disputes arising in the ordinary course of business, including employment claims. When the likelihood of a loss contingency becomes probable and the amount of the loss can be reasonably estimated, we accrue a liability for the loss contingency. We continue to review accruals and adjust them to reflect ongoing negotiations, settlements, rulings, advice of legal counsel, and other relevant information. To the extent new information is obtained, and our views on the probable outcomes of claims, suits, assessments, investigations or legal proceedings change, changes in our accrued liabilities would be recorded in the period in which such determination is made.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 8, 2019, a shareholder of the Company filed a class action complaint against the Company, asserting claims under Section 10(b) and 20(a) of the Securities Exchange Act of 1934, in the United States District Court, Eastern District of Virginia, Alexandria Division.  An amended complaint was filed on January 10, 2020, and a second amended complaint was filed on June 8, 2020.  The case, Plymouth County Retirement System v. Evolent Health, Inc., Frank Williams, Nicholas McGrane, Seth Blackley, Christie Spencer, and Steven Wigginton, alleges that the Company&#8217;s executives made false or misleading statements regarding its business with Passport.  The Company filed a motion to dismiss the second amended complaint, and the Eastern District of Virginia granted in part and denied in part the motion on March 24, 2021.  The Company and Plaintiffs then filed separate motions to reconsider that are pending.  While the scope of the allegations that remain is still unclear pending the court&#8217;s further decision, the case will proceed to discovery.  Based on the Company&#8217;s investigation so far, we believe the case has little legal or factual merit.  However, the outcome of any litigation is uncertain, and at this stage, the Company is currently unable to assess the probability of loss or estimate a range of potential loss, if any, associated with this lawsuit.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 8, 2021, a shareholder of the Company filed a derivative action in the Delaware Chancery Court against some current and former Board members and against the Company as a nominal defendant, alleging that the Company&#8217;s Board was negligent in its oversight of the Company&#8217;s relationship with Passport Health Plan.  The case is </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lincolnshire Police Pension Fund, derivatively on behalf of Evolent Health, Inc., v. Blackley, Williams, Scott, Holder, Farner, D&#8217;Amato, Duffy, Felt, Samet, Hobart, and Payson, and Evolent Health, Inc. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Plaintiff, the Company, and the Director-Defendants have agreed on a schedule for a motion to dismiss and related briefing, which we expect to be completed in late November 2021.  Based on the Company&#8217;s investigation so far, we believe the case has little legal or factual merit.  However, the outcome of any litigation is uncertain, and at this stage, the Company is currently unable to assess the probability of loss or estimate a range of potential loss, if any, associated with this lawsuit.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is not aware of any other legal proceedings or claims as of June&#160;30, 2021, that the Company believes will have, individually or in the aggregate, a material adverse effect on the Company&#8217;s financial position or result of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Credit and Concentration Risk</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to significant concentrations of credit risk related to cash and cash equivalents and accounts receivable. As of June&#160;30, 2021, approximately 99.0% of our $238.4 million of cash and cash equivalents (including restricted cash) were held in bank deposits with FDIC participating banks and approximately 1.0% were held in international banks. While the Company maintains its cash and cash equivalents with financial institutions with high credit ratings, it often maintains these deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any realized losses on cash and cash equivalents to date.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is also subject to significant concentration of accounts receivable risk as a substantial portion of our trade accounts receivable is derived from a small number of our partners. The following table summarizes the partners who represented at least 10.0% of our consolidated trade accounts receivable as of June&#160;30, 2021 and December&#160;31, 2020:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:426.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:55.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/></tr><tr style="height:23pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cook County Health and Hospitals System</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Florida Blue Medicare, Inc</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neighborhood Health Plan of Rhode Island</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">* &#160;&#160;&#160;&#160;Represents less than 10.0% of the respective balance</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Company is subject to significant concentration of revenue risk as a substantial portion of our revenue is derived from a small number of contractual relationships with our operating partners.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes those partners who represented at least 10.0% of our consolidated revenue for the three and six months ended June 30, 2021 and 2020:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:327.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cook County Health and Hospitals Systems</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Florida Blue Medicare, Inc.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Passport</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">The denominator excludes $25.5&#160;million and $57.6&#160;million of True Health premium revenue reclassified to discontinued operations for the three and six months ended June 30, 2020, respectively.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">* &#160;&#160;&#160;&#160;Represents less than 10.0% of the respective balance</span></div>We derive a significant portion of our revenues from our largest partners. The loss, termination or renegotiation of our relationship or contract with any significant partner or multiple partners in the aggregate could have a material adverse effect on the Company's financial condition and results of operations.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140179453626712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into various office space, data center, and equipment lease agreements in conducting its normal business operations. At the inception of any contract, the Company evaluates the agreement to determine whether the contract contains a lease. If the contract contains a lease, the Company then evaluates the term and whether the lease is an operating or finance lease. Most leases include one or more options to renew or may have a termination option. The Company determines whether these options are reasonably certain to be exercised or not at the inception of the lease. In addition, some leases contain escalation clauses.  The rent expense is recognized on a straight-line basis in the consolidated statements of operations and comprehensive income (loss) over the term of the lease. Leases with an initial term of 12 months or less are not recorded on our consolidated balance sheets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. We use the implicit rate when readily determinable. Further, the Company treats all lease and non-lease components as a single combined lease component for all classes of underlying assets. The Company also enters into sublease agreements for some of its leased office space. Immaterial rental income attributable to subleases is offset against rent expense over the terms of the respective leases. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases office space and computer and other equipment under operating lease agreements expiring at various dates through 2031. Under the lease agreements, in addition to base rent, the Company is generally responsible for operating and maintenance costs and related fees. Several of these agreements include tenant improvement allowances, rent holidays or rent escalation clauses. When such items are included in a lease agreement, we record a deferred rent asset or liability on our consolidated balance sheets equal to the difference between rent expense and future minimum lease payments due. The rent expense related to these items is recognized on a straight-line basis over the terms of the leases. The Company&#8217;s primary office location is in Arlington, Virginia, which has served as its corporate headquarters since 2013. The Arlington, Virginia office lease expires in January 2032. Certain leases acquired as part of the Valence Health transaction included existing sublease agreements for office locations in Chicago, Illinois. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with various lease agreements, the Company is required to maintain $3.5 million in letters of credit. As of both June&#160;30, 2021 and December&#160;31, 2020, the Company held $3.5 million in restricted cash and restricted investments on the consolidated balance sheet as collateral for the letters of credit, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our primary office leases as of June&#160;30, 2021 (in thousands, other than term):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:539.25pt"><tr><td style="width:1.0pt"/><td style="width:237.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:94.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:94.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:94.00pt"/><td style="width:1.0pt"/></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lease Termination Term (in years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Future Minimum Lease Commitments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Letter of Credit Amount Required</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Arlington, VA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,147&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,579&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Riverside, IL </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.8</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,956&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pune, India</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,835&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brea, CA</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,015&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the components of our lease expense for the three and six months ended June 30, 2021 and 2020 (in thousands): </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:52.650%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.013%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,437&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,586&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,255&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,642&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of right-of-use assets</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">299&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease cost</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,192&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,465&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,513&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,517&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease cost</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,629&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,202&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,768&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,461&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturity of lease liabilities (in thousands) as of June&#160;30, 2021, is as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.788%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.012%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating lease expense</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,854&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,832&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,645&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,378&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,145&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,761&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,615&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less:</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,732&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,883&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our weighted-average discount rate and our weighted remaining lease terms (in years) as of June&#160;30, 2021 are as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.788%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.012%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining lease term</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.2</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140179453755416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings (Loss) Per Common Share<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings (Loss) Per Common Share</a></td>
<td class="text">Earnings (Loss) Per Common Share<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the computation of basic and diluted earnings per share available for common stockholders for the three and six months ended June 30, 2021 and 2020 (in thousands, except per share data):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:288.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from continuing operations</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,107)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(202,013)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,297)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(280,500)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from discontinued operations, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,508)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,383&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,773)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,107)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(203,521)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,914)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(282,273)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to non-controlling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:23pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) available for common shareholders - basic and diluted</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,107)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(203,521)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,914)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(282,273)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding - basic and diluted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,448&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,349&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,056&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,977&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Income (loss) per common share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.37)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.24)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.30)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.01)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.02&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.02)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:23pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted income (loss) per share attributable to common shareholders of Evolent Health, Inc.</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.11)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.38)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.22)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.32)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Anti-dilutive shares (in thousands) excluded from the calculation of weighted-average common shares presented above for the three and six months ended June 30, 2021 and 2020 are presented below:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:288.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units ("RSUs"), performance-based RSUs and leveraged stock units ("LSUs")</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,052&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">554&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,793&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">376&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,801&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">711&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,833&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">841&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible senior notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,696&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,361&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,696&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,361&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,549&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,626&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,322&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,578&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140179453741256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-based Compensation</a></td>
<td class="text">Stock-based Compensation<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total compensation expense by award type and line item in our consolidated financial statements for the three and six months ended June 30, 2021 and 2020 was as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:288.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Award Type</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">638&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">671&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,388&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance-based stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,427&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,006&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,401&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,862&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,059&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,307&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,886&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PSUs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">737&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">980&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total compensation expense by award type</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,653&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,703&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,359&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,211&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Line Item</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenue</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">892&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">526&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,487&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">918&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:288.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,761&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,177&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,872&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,293&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total compensation expense by financial statement line item</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,653&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,703&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,359&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,211&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No stock-based compensation was capitalized as software development costs for the three and six months ended June 30, 2021 and 2020.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based awards were granted for the three and six months ended June 30, 2021 and 2020 as follows (in thousands):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:327.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,028&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,140&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PSUs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">319&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">520&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140179450371896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For interim periods, we recognize an income tax provision (benefit) based on our estimated annual effective tax rate expected for the full year.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An income tax expense (benefit) of $0.1&#160;million and $0.7&#160;million was recognized for the three and six months ended June 30, 2021, respectively, which resulted in effective tax rates of (1.0)% and (3.6)%, respectively. An income tax expense (benefit) of $(3.9)&#160;million and $(3.6)&#160;million was recognized for the three and six months ended June 30, 2020, respectively, which resulted in effective tax rates of 1.9% and 1.3%, respectively. The Company and its U.S. subsidiaries continue to record a valuation allowance against its net deferred tax assets, with the exception of indefinite lived components. The income tax expense recorded during the three and six months ended June 30, 2021 primarily relates to foreign taxes.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December&#160;31, 2020, the Company had unrecognized tax benefits of $0.7 million that, if recognized, would not affect the effective tax rate due to the valuation allowance against its net deferred tax asset. As of June&#160;30, 2021, there are no changes to the unrecognized tax benefits. The Company is not currently subject to income tax audits in any U.S., state, or foreign jurisdictions for any tax year.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Tax Receivables Agreement</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Offering Reorganization, the Company entered into the TRA with certain of its investors, which provides for the payment by the Company to these investors of 85% of the amount of the tax benefits, if any, that the Company is deemed to realize as a result of increases in our tax basis related to exchanges of Class B common units as well as tax benefits attributable to the future utilization of pre-IPO NOLs. See Note 11 above and &#8220;Part II - Item 8. Financial Statements and Supplementary Data - Note 14&#8221; in our 2020 Form 10-K for discussion of our TRA.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140179453679736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments In and Advances to Equity Method Investees<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract', window );"><strong>Equity Method Investments and Joint Ventures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsDisclosureTextBlock', window );">Investments In and Advances to Equity Method Investees</a></td>
<td class="text">Investments in and Advances to Equity Method Investees<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company holds ownership interests in joint ventures and other entities which are accounted for under the equity method. The Company evaluates its interests in these entities to determine whether they meet the definition of a VIE and whether the Company is required to consolidate these entities. A VIE is consolidated by its primary beneficiary, which is the party that has both (i) the power to direct the activities that most significantly impact the economic performance of the VIE and (ii) a variable interest that could potentially be significant to the VIE. To determine whether or not a variable interest the Company holds could potentially be significant to the VIE, the Company considers both qualitative and quantitative factors regarding the nature, size and form of the Company's involvement with the VIE. The Company has determined that its interests in these entities meet the definition of a variable interest, however, the Company is not the primary beneficiary since it does not have the power to direct activities, therefore, the Company did not consolidate the VIEs.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of&#160;June&#160;30, 2021 and December&#160;31, 2020, the Company&#8217;s economic interests in its equity method investments ranged between 4% and 39%, and 4% and 38%, respectively, and voting interests in its equity method investments ranged between 25% and 40%, respectively. The Company determined that it has significant influence over these entities but that it does not have control over any of the entities. Accordingly, the investments are accounted for under the equity method of accounting and the Company is allocated its proportional share of the entities&#8217; earnings and losses for each reporting period. The Company&#8217;s proportional share of the (gain) losses </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">from these investments was approximately $4.9 million and $12.7 million for the three and six months ended June 30, 2021, respectively, and $25.1 million and $24.7 million for the three and six months ended June 30, 2020, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company signed services agreements with certain of the aforementioned entities to provide certain management, operational and support services to help manage elements of their service offerings. Revenue related to these services agreements were $2.3 million and $8.6 million for the three and six months ended June 30, 2021, respectively, and $71.4 million and $131.3 million for the three and six months ended June 30, 2020 , respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -URI http://asc.fasb.org/topic&amp;trid=2196965<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140179453796936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Non-controlling Interests<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestAbstract', window );"><strong>Noncontrolling Interest [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDisclosureTextBlock', window );">Non-controlling Interests</a></td>
<td class="text">Non-controlling Interests<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immediately following the Offering Reorganization and IPO in May 2015, the Company owned 70.3% of Evolent Health LLC. The Company&#8217;s ownership percentage changes with the issuance of Class A or Class B common stock and Class B Exchanges. In order to account for any changes in the Company&#8217;s ownership of Evolent Health LLC, we record a reclassification of equity between non-controlling interests and shareholders&#8217; equity attributable to Evolent Health, Inc.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2020</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 1, 2020, in connection with the consolidation of EVH Passport, the Company recognized a $25.7&#160;million non-controlling interest for the Sponsors&#8217; 30% equity interest in EVH Passport which represented the fair value of the non-controlling interest as of the date of consolidation. Pursuant to the shareholders&#8217; agreement with the Sponsors, the Company was required to acquire the Sponsors&#8217; 30% ownership interest for $20.0&#160;million on or prior to December 31, 2021. On November 16, 2020, the Company acquired the Sponsors&#8217; 30% equity interest and reclassified the non-controlling interests into shareholders&#8217; equity attributable to Evolent Health, Inc. As a result of this transaction, the Company recorded a $5.7&#160;million gain on consolidation for the year ended December 31, 2020 in gain (loss) on disposal of assets and consolidation on the consolidated statements of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in non-controlling interests (in thousands) for  the six months ended June 30, 2020 was as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:487.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-controlling interests balance as of beginning of period</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,889&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification of non-controlling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,889)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-controlling interests balance as of end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for noncontrolling interest in consolidated subsidiaries, which could include the name of the subsidiary, the ownership percentage held by the parent, the ownership percentage held by the noncontrolling owners, the amount of the noncontrolling interest, the location of this amount on the balance sheet (when not reported separately), an explanation of the increase or decrease in the amount of the noncontrolling interest, the noncontrolling interest share of the net Income or Loss of the subsidiary, the location of this amount on the income statement (when not reported separately), the nature of the noncontrolling interest such as background information and terms, the amount of the noncontrolling interest represented by preferred stock, a description of the preferred stock, and the dividend requirements of the preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140179452435448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurement<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurement</a></td>
<td class="text">Fair Value Measurement<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GAAP defines fair value as the price that would be received from the sale of an asset or paid to transfer a liability (an exit price) assuming an orderly transaction in the most advantageous market at the measurement date. GAAP also establishes a hierarchical disclosure framework which prioritizes and ranks the level of observability of inputs used in measuring fair value. These tiers include:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 - inputs to the valuation methodology are quoted prices available in active markets for identical instruments as of the reporting date;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 - inputs to the valuation methodology are other than quoted prices in active markets, which are either directly or indirectly observable as of the reporting date and the fair value can be determined through the use of models or other valuation methodologies; and </span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 - inputs to the valuation methodology are unobservable inputs in situations where there is little or no market activity for the asset or liability.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, the level within the fair value hierarchy is based on the lowest level of input that is significant to the fair value measurement. Our assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the particular asset or liability being measured. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recurring Fair Value Measurements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with GAAP, certain assets and liabilities are required to be recorded at fair value on a recurring basis. The following table summarizes the Company&#8217;s assets and liabilities measured at fair value on a recurring basis as of December&#160;31, 2020 (in thousands):</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:325.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,877&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,877&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fair value of assets measured on a recurring basis</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,877&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,877&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,730&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,730&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fair value of liabilities measured on a recurring basis</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,730&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,730&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"> </span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Represents the cash and cash equivalents and restricted cash and restricted investments that were held in money market funds as of December&#160;31, 2020.</span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Represents the fair value of 1,513,786 shares issuable under the warrant agreements discussed in Note 10.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes any transfers between levels within the hierarchy as of the beginning of the reporting period. There were no transfers between fair value levels during the three and six months ended June 30, 2021 and 2020, respectively.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the absence of observable market prices, the fair value is based on the best information available and involves a significant degree of judgment, taking into consideration a combination of internal and external factors, including the appropriate risk adjustments for non-performance and liquidity risks.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In conjunction with the Credit Agreement discussed in Note 10, the Company entered into warrant agreements whereby it agreed to sell to the holders of the warrants an aggregate of 1,513,786 shares of Class A common stock. The fair value of the warrants was estimated based on the Black-Scholes model which incorporates the constant price variation of the stock, the time value of money, the option's strike price, and the time to the option's expiry. The significant unobservable inputs used in the fair value measurement of the warrants are the stock price volatility and annual risk free rate. A significant increase in the stock price or discount rate in isolation would result in a significantly higher fair value of the contingent consideration.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in our liabilities measured at fair value for which the Company uses Level 3 inputs to determine fair value for the six months ended June 30, 2021 and 2020 are as follows (in thousands): </span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:433.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,730&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,975&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,730)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,500)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Realized and unrealized gains (losses), net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,975)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,500&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the fair value (in thousands), valuation techniques and significant unobservable inputs of our Level 3 fair value measurements as of December&#160;31, 2020:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:539.25pt"><tr><td style="width:1.0pt"/><td style="width:118.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:100.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:168.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:67.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:13.75pt"/><td style="width:1.0pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Valuation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assumption or</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Technique</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unobservable Inputs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Input Ranges</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,730&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Black-Scholes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock price volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Annual risk free rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Nonrecurring Fair Value Measurements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the assets and liabilities that are recorded at fair value on a recurring basis, the Company records certain assets and liabilities at fair value on a nonrecurring basis as required by GAAP. Generally, assets are recorded at fair value on a nonrecurring basis as a result of impairment charges. This includes assets and liabilities recorded in business combinations or asset acquisitions, goodwill, intangible assets, property, plant and equipment, held-to-maturity investments and equity method investments. While not </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">carried at fair value on a recurring basis, these items are continually monitored for indicators of impairment that would indicate current carrying value is greater than fair value. In those situations, the assets are considered impaired and written down to current fair value. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Fair Value Disclosures</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of cash and cash equivalents (those not held in a money market fund), restricted cash, receivables, prepaid expenses, accounts payable, accrued liabilities and accrued compensation approximate their fair values because of the relatively short-term maturities of these items and financial instruments.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 10 for information regarding the fair value of the 2024 Notes, 2025 Notes and 2021 Notes.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140179453796936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Parties<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Parties</a></td>
<td class="text">Related Parties  <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The entities described below are considered related parties and the balances and/or transactions with them are reported in our consolidated financial statements.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As discussed in Note&#160;16, the Company had economic interests in several entities that were previously accounted for under the equity method of accounting, including EVH Passport (which has been consolidated into the Company&#8217;s financial results since September 1, 2020). The Company has allocated its proportional share of the investees&#8217; earnings and losses each reporting period. In addition, Evolent has entered into services agreements with certain of the entities to provide certain management, operational and support services to help the entities manage elements of their service offerings. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also works closely with UPMC, one of its founding investors. The Company&#8217;s relationship with UPMC is a subcontractor relationship where UPMC has agreed to execute certain tasks (primarily TPA services) relating to certain customer commitments. We also conduct business with a company in which UPMC holds a significant equity interest.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents assets and liabilities attributable to our related parties as of June&#160;30, 2021 and December&#160;31, 2020 (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.594%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.705%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.707%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,450&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,474&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other noncurrent assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,688&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,554&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,923&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,509&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,220&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,520&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve for claims and performance-based arrangements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">435&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents revenues and expenses attributable to our related parties for the three and six months ended June 30, 2021 and 2020 (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:273.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:61.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:61.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:61.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:61.75pt"/><td style="width:1.0pt"/></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transformation services</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Platform and operations services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,368&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,885&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,943&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141,833&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:23pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenue (exclusive of depreciation and amortization expenses)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">606&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,171)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,099&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,076&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140179553143256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Repositioning and Other Changes<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock', window );">Repositioning and Other Changes</a></td>
<td class="text">Transactions<div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Passport</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 28, 2019, UHC, Passport Health Solutions, LLC (&#8220;PHS I&#8221;), the Company and EVH Passport entered into an Asset Purchase Agreement (the &#8220;Passport APA&#8221;), which provided for the sale of substantially all of the assets of UHC and PHS I, including UHC&#8217;s Kentucky Medicaid contract (the &#8220;Passport Medicaid Contract&#8221;), to EVH Passport for a purchase price of $70.0 million in cash and the issuance of a 30% interest in EVH Passport (the &#8220;Passport Purchase Price&#8221;) to The University of Louisville, the University of Louisville Physicians, University Medical Center, the Jewish Heritage Fund for Excellence, Norton Healthcare, Inc. and the Louisville/Jefferson County Primary Care Association (collectively, the &#8220;Sponsors&#8221;). </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 18, 2019, the Company contributed $40.0 million to UHC in the form of an advance for regulatory capital requirements under an agreement with UHC (the &#8220;Passport Note&#8221;). The Passport Note carried a fixed interest rate of 6.5% per annum.  Additionally, on June 6, 2019, the Company and UHC entered into an Indemnity Agreement (the &#8220;Indemnity Agreement&#8221;), with an insurance company (the &#8220;Surety&#8221;). The Surety issued a performance bond in the amount of $25.0 million to secure UHC&#8217;s performance under its Medicaid Contract. Pursuant to the Indemnity Agreement, the Company and UHC were jointly and severally liable to the Surety in the maximum amount of the bond, plus certain costs of the Surety, in the event of losses arising under the bond. The bond&#8217;s original expiry date was June 30, 2020 and during the three months ended June 30, 2020, was extended to December 31, 2020. The bond was released in October 2020. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 30, 2019, UHC, PHS I, the Company and EVH Passport consummated the transactions contemplated by the Passport APA (the &#8220;Passport Closing&#8221;).  At the Passport Closing, $16.2 million of the cash Passport Purchase Price was held back until such time as PHS I delivers to EVH Passport certain owned real property and improvements free and clear of all encumbrances. In addition, at the Passport Closing, EVH Passport and UHC entered into an agreement that provided for the administration and assumption of the financial risks by EVH Passport of UHC&#8217;s dual eligible special needs business (the &#8220;DNP Business&#8221;) until such time as EVH Passport became certified as a Medicare Advantage Organization and the D-SNP Business could be transferred to EVH Passport.  On October 1, 2020, the D-SNP Business was transferred from UHC to EVH Passport.  At the Passport Closing, EVH Passport assumed UHC&#8217;s obligations under the Passport Note and the Indemnity Agreement. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 16, 2020, EVH Passport, Evolent Health LLC and Molina Healthcare, Inc. (&#8220;Molina&#8221;) entered into an Asset Purchase Agreement (the &#8220;Molina APA&#8221;), which contemplated the sale by EVH Passport to Molina of certain assets, including certain intellectual property rights of EVH Passport and EVH Passport&#8217;s rights under the Passport Medicaid Contract.  On September 1, 2020, EVH Passport and Molina consummated the transactions contemplated by the Molina APA (the &#8220;Molina Closing&#8221;), and the Passport Medicaid Contract was novated to Molina.  As a result, EVH Passport began to wind down its business.  In connection with the Molina Closing, Molina deposited $20.0&#160;million in cash in escrow, which was subsequently released to EVH Passport in January 2021.  In addition, at the Molina Closing, Molina and EVH Passport entered into an agreement that provided for the assumption of the financial risks by Molina of the D-SNP Business until such time as Molina&#8217;s Kentucky health plan becomes certified as a Medicare Advantage Organization and the D-SNP Business is transferred Molina.  The Company and EVH Passport continued to administer the D-SNP Business until January 1, 2021, at which time Molina became responsible for its administration until the D-SNP Business is officially transferred to Molina effective September 1, 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the Molina Closing, the Company accounted for its investment in EVH Passport as an unconsolidated variable interest entity under the equity method of accounting.  As a result of the transaction, the Company concluded that a reconsideration event occurred whereby EVH Passport was determined to be a voting interest entity and that Evolent had a controlling financial interest in EVH Passport; accordingly, the Company consolidated EVH Passport as of September 1, 2020 in its consolidated financial statements. The Company accounted for the transaction as an asset acquisition, as the Company concluded that assets acquired as a result of the consolidation did not meet the criteria to be classified as a business under GAAP.  Following the Molina Closing and consolidation of EVH Passport in the Company&#8217;s consolidated financials, on November 16, 2020, EVH Passport redeemed the Sponsors&#8217; equity interests in EVH Passport for $20.0&#160;million in cash in accordance with the terms of EVH Passport&#8217;s Stockholders&#8217; Agreement, and, as a result, EVH Passport became a wholly owned subsidiary of the Company.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the consolidation, the Company recorded assets primarily consisting of cash and cash equivalents and restricted cash and cash equivalents of $159.8&#160;million, available for sale securities of $88.6&#160;million, receivables related to unsettled sales of securities of $43.0&#160;million and other assets of $50.2&#160;million and total liabilities primarily comprised of reserve for claims and performance-based arrangements of $164.8&#160;million and accrued liabilities of $50.0&#160;million. Subsequent to winddown activities, any remaining capital will be distributed to the Company subject to regulatory approval from the Kentucky Department of Insurance.  In addition, the Passport Note was eliminated upon consolidation, and as of December 31, 2020, the outstanding principal balance of the $40.0&#160;million Passport Note was repaid in full by EVH Passport including approximately $3.6&#160;million of accrued interest.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During the first quarter of 2021, pursuant to the terms of the Molina APA, EVH Passport received a cash payment from Molina in the amount of $23.0&#160;million based on the number of enrollees above a certain threshold in the D-SNP Business and Molina's Medicaid plan following the open enrollment period for plan year 2021. The foregoing amount represents 50% of the payment that EVH Passport is eligible to receive pursuant to the terms of the Molina APA based on the number of such enrollees. The remaining 50% will be payable in the first quarter of 2022 subject to the satisfaction of certain contingencies.</span></div>Repositioning and Other Changes<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continually assess opportunities to improve operational effectiveness and efficiency to better align our expenses with revenues, while continuing to make investments in our solutions, systems and people that we believe are important to our long-term goals. Across 2020, we divested or agreed to divest a majority of our health plan assets, including certain assets of EVH Passport, which represented a significant revenue stream for the Company. In parallel with these divestitures, we contracted with a third-party vendor to review our operating model and organizational design in order to improve our profitability, create value through our solutions and invest in strategic opportunities in future periods.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the fourth quarter of 2020, we committed to certain operational efficiency and profitability actions that we are taking in order to accomplish these objectives (&#8220;Repositioning Plan&#8221;). These actions included making organizational changes across our business as well as other profitability initiatives expected to result in reductions in force, re-aligning of resources as well as other potential operational efficiency and cost-reduction initiatives. The Repositioning Plan is expected to continue through the fourth quarter of 2021. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded approximately $0.7&#160;million and $6.0&#160;million of repositioning costs in selling, general and administrative expenses for the three and six months ended June 30, 2021&#160;in connection with the Repositioning Plan. The following table provides a summary of our total costs associated with the Repositioning Plan for the three and six months ended June 30, 2021, by major type of cost (in thousands):</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.305%"><tr><td style="width:1.0%"/><td style="width:27.431%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.499%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.305%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.359%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.305%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.359%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.039%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.359%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.044%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Incurred For the Three Months Ended <br/>June  30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Incurred for the Six Months Ended June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Amount Expected to be Incurred in the Repositioning Plan</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cumulative Amount Incurred through June 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Severance and termination benefits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office space consolidation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,071&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,071&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,071&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional services</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">587&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,787&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,162&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,062&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">663&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,043&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,418&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,318&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -URI http://asc.fasb.org/topic&amp;trid=2175745<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140179453807672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Reporting</a></td>
<td class="text">Segment Reporting<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commencing with the three months ended March 31, 2021, we define our reportable segments based on the way the CODM, the chief executive officer, manages the operations for purposes of allocating resources and assessing performance. We classify our operations into two reportable segments as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Evolent Health Services, which houses our Administrative Simplification solution and certain supporting population health infrastructure; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Clinical Solutions, which includes our specialty management and physician-oriented total cost of care solutions, along with the New Century Health and Evolent Care Partners brands. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, our reportable segments enter into transactions with one another. While intersegment transactions are treated like third-party transactions to determine segment performance, the revenues and expenses recognized by the segment that is the counterparty to the transaction are eliminated in consolidation and do not affect consolidated results.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CODM uses revenue in accordance with U.S. GAAP and Adjusted EBITDA as the relevant segment performance measures to evaluate the performance of the segments and allocate resources. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjusted EBITDA is a segment performance financial measure that offers a useful view of the overall operation of our businesses and may be different than similarly-titled segment performance financial measures used by other companies. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjusted EBITDA is defined as net loss attributable to common shareholders of Evolent Health, Inc. before interest income, interest expense, (provision) benefit for income taxes, depreciation and amortization expenses, adjusted to exclude equity method investment impairment, loss on extinguishment of debt, gain (loss) from equity method investees, gain (loss) on disposal of assets and consolidation, goodwill impairment, changes in fair value of contingent consideration and indemnification asset, other income (expense), net, net loss attributable to non-controlling interests, ASC 606 transition adjustments, purchase accounting adjustments, repositioning costs, stock-based compensation expense, severance costs, amortization of contract cost assets, shareholder advisory services, acquisition-related costs and gain (loss) from discontinued operations. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management considers revenue and Adjusted EBITDA to be the appropriate metrics to evaluate and compare the ongoing operating performance of our segments on a consistent basis across reporting periods as they eliminate the effect of items which are not indicative of each segment's core operating performance. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present our segment information for the three and six months ended June 30, 2021 and 2020 (in thousands). Prior-year segment information (including segments total Adjusted EBITDA) has been restated to conform to the reporting structure change described in Note 1.</span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:145.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:52.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:52.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:67.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:60.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:61.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:67.00pt"/><td style="width:1.0pt"/></tr><tr style="height:33pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Evolent Health Services</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intersegment<br/>Eliminations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Subtotal</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended June 30, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transformation services</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,564&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,564&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,564&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Platform and operations services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,759&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147,194&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(460)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219,493&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219,493&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,323&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147,194&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(460)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222,057&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222,057&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended June 30, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transformation services</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">755&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">755&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">755&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Platform and operations services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,432&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130,780&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(668)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216,544&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216,544&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,187&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130,780&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(668)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217,299&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217,299&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:33pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Evolent Health Services</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Subtotal</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Segments Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="12" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended June 30, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted EBITDA</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,531&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,597&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,128&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,782)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,346&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended June 30, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted EBITDA</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,948&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,200&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,148&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,629)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,519&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:145.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:52.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:52.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:67.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:60.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:61.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:67.00pt"/><td style="width:1.0pt"/></tr><tr style="height:33pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Evolent Health Services</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intersegment<br/>Eliminations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Subtotal</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Six Months Ended June 30, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transformation services</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,909&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,909&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,909&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Platform and operations services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277,417&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(898)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">434,219&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">434,219&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160,609&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277,417&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(898)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">437,128&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">437,128&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Six Months Ended June 30, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transformation services</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,993&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,993&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,993&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Platform and operations services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178,222&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255,652&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,336)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">432,538&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">432,538&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184,215&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255,652&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,336)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">438,531&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">438,531&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:33pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Evolent Health Services</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Subtotal</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Segments Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="12" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Six Months Ended June 30, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted EBITDA</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,473&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,573&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,046&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,793)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,253&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Six Months Ended June 30, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted EBITDA</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,716&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,243&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,959&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,564)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,395&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Corporate includes various finance, human resources, legal, executive, and other corporate infrastructure expenses.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents our reconciliation of consolidated segments total Adjusted EBITDA to net loss attributable to common shareholders of Evolent Health, Inc. for the three and six months ended June 30, 2021 and 2020 (in thousands): </span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:327.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss attributable to common shareholders of Evolent Health, Inc.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,107)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(203,521)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,914)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(282,273)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">705&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,475&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,274)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,290)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,611)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,571)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Provision) benefit for income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(91)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,904&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(702)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,634&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,916)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,618)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30,103)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31,596)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity method investment impairment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47,133)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on transfer of membership</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,969&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on repayment of debt, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,158)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill impairment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(215,100)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(215,100)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain from equity method investees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,879&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,143&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,662&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,731&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on disposal of assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,447)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration and indemnification asset</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(756)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">594&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,062&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">354&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repositioning costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(663)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,043)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,653)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,703)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,359)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,211)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Severance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,133)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of contract cost assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(196)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(767)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(323)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,207)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Strategy and shareholder advisory expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,513)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,513)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(76)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(374)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,070)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(683)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain (loss) from discontinued operations </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,508)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,383&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,773)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjusted EBITDA</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,346&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,519&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,253&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,395&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Includes $1.9&#160;million gain on disposal of discontinued operations for the six months ended June 30, 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Asset information by segment is not a key measure of performance used by the CODM. Accordingly, we have not disclosed asset information by segment.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 34<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8981-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8721-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8844-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8657-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8721-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI http://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140179453830904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Reserves for Claims and Performance-Based Arrangements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InsuranceAbstract', window );"><strong>Insurance [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InsuranceDisclosureTextBlock', window );">Reserves for Claims and Performance-Based Arrangements</a></td>
<td class="text">Reserve for Claims and Performance-Based Arrangements<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains reserves for its liabilities related to payments to providers and pharmacies under performance-based arrangements related to its total cost of care and specialty care management services. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reserves for claims and performance-based arrangements for our EHS and Clinical Solutions segments reflect actual payments under performance-based arrangements and the ultimate cost of claims that have been incurred but not reported, including expected development on reported claims, those that have been reported but not yet paid (reported claims in process), and other medical care expenses and services payable that are primarily composed of accruals for incentives and other amounts payable to health care professionals and facilities. Reserves for claims and performance-based arrangements also reflect estimated amounts owed under the reinsurance agreements, as discussed further in Note 11.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses actuarial principles and assumptions that are consistently applied each reporting period and recognizes the actuarial best estimate of the ultimate liability along with a margin for adverse deviation. This approach is consistent with actuarial standards of practice that the liabilities be adequate under moderately adverse conditions.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This liability predominately consists of incurred but not reported amounts and reported claims in process including expected development on reported claims. The liability for reserves related to its total cost of care and specialty care management services is primarily calculated using "completion factors" developed by comparing the claim incurred date to the date claims were paid. Completion factors are impacted by several key items including changes in: 1)&#160;electronic (auto-adjudication) versus manual claim processing, 2)&#160;provider claims submission rates, 3)&#160;membership and 4)&#160;the mix of products.  </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s policy for reserves related to its total cost of care and specialty care management services is to use historical completion factors combined with an analysis of current trends and operational factors to develop current estimates of completion factors. The Company estimates the liability for claims incurred in each month by applying the current estimates of completion factors to the current paid claims data. This approach implicitly assumes that historical completion rates will be a useful indicator for the current period. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For more recent months, and for newer lines of business where there is not sufficient paid claims history to develop completion factors, the Company expects to rely more heavily on medical cost trend and expected loss ratio analysis that reflects expected claim payment patterns and other relevant operational considerations, or authorization analysis. Medical cost trend is primarily impacted by medical service utilization and unit costs that are affected by changes in the level and mix of medical benefits offered, including inpatient, outpatient and pharmacy, the impact of copays and deductibles, changes in provider practices and changes in consumer demographics and consumption behavior. Authorization analysis projects costs on an authorization-level basis and also accounts for the impact of copays and deductibles, unit cost and historic discontinuation rates for treatment. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For each reporting period, the Company compares key assumptions used to establish the reserves for claims and performance-based arrangements to actual experience. When actual experience differs from these assumptions, reserves for claims and performance-based arrangements are adjusted through current period net income. Additionally, the Company evaluates expected future developments and emerging trends that may impact key assumptions. The process used to determine this liability requires the Company to make critical accounting estimates that involve considerable judgment, reflecting the variability inherent in forecasting future claim payments. These estimates are highly sensitive to changes in the Company's key assumptions, specifically completion factors and medical cost trends.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Activity in reserves for claims and performance-based arrangements for the six months ended June 30, 2021 and 2020, was as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:142.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:37.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:47.50pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:47.50pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:3.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:40.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:3.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:37.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:3.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:47.50pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:3.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:47.50pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:3.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:40.00pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="45" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:33pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EHS </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">True Health</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EHS </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">True Health</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,295&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,532&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,859&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188,686&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,265&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,245&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,640&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,150&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:23pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incurred costs related to current year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,669&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219,343&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,228&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">262,240&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,135&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201,977&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,584&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245,696&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incurred costs related to prior year</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,293&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(241)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,267&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(498)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,351&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">830&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Paid costs related to current year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,801&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,379&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,274&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,454&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,020&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163,431&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,538&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200,989&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Paid costs related to prior year</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,673&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,392&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,378&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,443&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,530&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,499&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,975&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,004&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change during the year</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26,512)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,787&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,335&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,610&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,913)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,024&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,422&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,533&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:23pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Disposal of discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,194)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,194)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other adjustments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,721&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,282&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,003&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,726&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,726&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,504&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204,601&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238,105&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(648)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,995&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,062&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,409&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:31.5pt;text-align:justify;text-indent:-31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:25.44pt">Costs incurred to provide specialty care management and EVH Passport are recorded within cost of revenue in our statement of operations. </span></div><div style="padding-left:31.5pt;text-align:justify;text-indent:-31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:25.44pt">Other adjustments to reserves for claims and performance-based arrangements reflect changes in accrual for amounts payable to facilities and amounts owed to our payer partners for claims paid on our behalf.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InsuranceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InsuranceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InsuranceDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the types of coverages and products sold, and the assets, obligations, recorded liabilities, revenues and expenses arising therefrom, and the amounts of and methodologies and assumptions used in determining the amounts of such items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -URI http://asc.fasb.org/topic&amp;trid=2303980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InsuranceDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140179453673304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplemental Cash Flow Information<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowElementsAbstract', window );"><strong>Supplemental Cash Flow Elements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowSupplementalDisclosuresTextBlock', window );">Supplemental Cash Flow Information</a></td>
<td class="text">Supplemental Cash Flow Information <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following represents supplemental cash flow information the six months ended June 30, 2021 and 2020 (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:433.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental Disclosure of Non-cash Investing and Financing Activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Increase/decrease to goodwill from measurement period adjustments/business combinations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Class A common stock issued for payment of Passport/Global earn-out</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,185&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued property and equipment purchases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">668&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Effects of Leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Operating cash flows from operating leases </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,622&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,853&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Leased assets obtained in exchange for operating lease liabilities </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,157)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,354)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowSupplementalDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental cash flow activities, including cash, noncash, and part noncash transactions, for the period. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -URI http://asc.fasb.org/topic&amp;trid=2134446<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowSupplementalDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowElementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowElementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140179452422952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">Subsequent Events<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Agreement for the Acquisition of Vital Decision</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On August 2, 2021, Evolent Health LLC and EV Thunder Merger Sub, LLC, each wholly owned subsidiaries of the Company, entered into a definitive agreement for Evolent to acquire Windrose Health Investors III, L.P. portfolio company Vital Decisions for $85&#160;million, with an additional earn out of up to $45&#160;million. Vital Decisions will report into Evolent&#8217;s specialty management offering, New Century Health, and will be consolidated into the Company&#8217;s Clinical Solutions segment. Closing of the transaction is subject to customary closing conditions and is expected to occur in the second half of 2021.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140179460814712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our opinion, the accompanying unaudited interim consolidated financial statements include all adjustments, consisting of normal recurring adjustments, which are necessary to fairly state our financial position, results of operations, and cash flows. The consolidated balance sheet as of December 31, 2020, has been derived from audited financial statements as of that date and reflects the impact of the agreement to sell True Health. See Note 5 for a complete summary of this transaction. The interim consolidated results of operations are not necessarily indicative of the results that may occur for the full fiscal year. Certain footnote disclosures normally included in financial statements prepared in accordance with United States of America generally accepted accounting principles (&#8220;GAAP&#8221;) have been omitted pursuant to instructions, rules, and regulations prescribed by the United States Securities and Exchange Commission (&#8220;SEC&#8221;). The disclosures provided herein should be read in conjunction with the audited financial statements and notes thereto included in our 2020 Form 10-K.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Accounting Estimates and Assumptions</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting Estimates and Assumptions</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions affecting the reported amounts of assets and liabilities and the disclosures of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expenses for the reporting period. Those estimates are inherently subject to change and actual results could differ from those estimates. In the accompanying consolidated financial statements, estimates are used for, but not limited to, the valuation of assets (including intangibles assets, goodwill and long-lived assets), liabilities, consideration related to business combinations and asset acquisitions, revenue recognition (including variable consideration), estimated selling </span></div>prices for performance obligations in contracts with multiple performance obligations, reserves for claims and performance-based arrangements, credit losses, depreciable lives of assets, impairment of long-lived assets, stock-based compensation, deferred income taxes and valuation allowance, contingent liabilities, purchase price allocation in taxable stock transactions and useful lives of intangible assets.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Principles of Consolidation</span></div><div style="padding-left:18pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of Evolent Health, Inc. and its subsidiaries. All intercompany accounts and transactions are eliminated in consolidation.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash and Cash Equivalents</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider all highly liquid instruments with original maturities of three months or less to be cash equivalents. The Company holds materially all of our cash in bank deposits with FDIC participating banks, at cost, which approximates fair value. Cash and cash equivalents held in money market funds are carried at fair value, which approximates cost.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Business Combinations</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Companies acquired during each reporting period are reflected in the results of the Company effective from their respective dates of acquisition through the end of the reporting period. The Company allocates the fair value of purchase consideration to the assets acquired and liabilities assumed based on their estimated fair values at the acquisition date. Our estimates of fair value are based upon assumptions believed to be reasonable, but which are inherently uncertain and unpredictable and, as a result, actual results may differ from estimates. Critical estimates used to value certain identifiable assets include, but are not limited to, expected long-term revenues, future expected operating expenses, cost of capital, and appropriate discount rates. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The excess of the fair value of purchase consideration over the fair value of the assets acquired and liabilities assumed in the acquired entity is recorded as goodwill. Goodwill is assigned to the reporting unit that benefits from the synergies arising from the business combination. If the Company obtains new information about facts and circumstances that existed as of the acquisition date during the measurement period, which may be up to one year from the acquisition date, the Company may record adjustments to the assets acquired and liabilities assumed, with the corresponding offset to goodwill. Upon the conclusion of the measurement period or final determination of the values of assets acquired or liabilities assumed, whichever comes first, any subsequent adjustments are recorded on the Company's consolidated statements of operations and comprehensive income (loss). </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For contingent consideration recorded as a liability, the Company initially measures the amount at fair value as of the acquisition date and adjusts the liability, if needed, to fair value at each reporting period. Changes in the fair value of contingent consideration, other than measurement period adjustments, are recognized as operating income or expense. Acquisition-related expenses and post-acquisition restructuring costs are recognized separately from the business combination and are expensed as incurred.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy', window );">Goodwill</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize the excess of the purchase price, plus the fair value of any non-controlling interests in the acquiree, over the fair value of identifiable net assets acquired as goodwill. Goodwill is not amortized, but is reviewed at least annually for indications of impairment, with consideration given to financial performance and other relevant factors. We perform impairment tests of goodwill at a reporting unit level. Following the sale of True Health, the Company has three reporting units and our annual goodwill impairment review occurs during the fourth quarter of each year. We perform impairment tests between annual tests if an event occurs, or circumstances change, that we believe would more likely than not reduce the fair value of a reporting unit below its carrying amount. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our goodwill impairment analysis first assesses qualitative factors to determine whether events or circumstances existed that would lead the Company to conclude it is more likely than not that the fair value of a reporting unit is below its carrying amount. If the Company determines that it is more likely than not that the fair value of a reporting unit is below the carrying amount, a quantitative goodwill assessment is required. In the quantitative evaluation, the fair value of the relevant reporting unit is determined and compared to the carrying value. If the fair value is greater than the carrying value, then the carrying value is deemed to be recoverable and no further action is required. If the fair value estimate is less than the carrying value, goodwill is considered impaired for the amount by which the carrying amount exceeds the reporting unit&#8217;s fair value and a charge is reported in goodwill impairment on our consolidated statements of operations and comprehensive income (loss). See Note 9 for additional discussion regarding the goodwill impairment tests conducted during 2021 and 2020.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicy', window );">Intangible Assets, Net</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangible Assets, Net </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Identified intangible assets are recorded at their estimated fair values at the date of acquisition and are amortized over their respective estimated useful lives using a method of amortization that reflects the pattern in which the economic benefits of the intangible assets are used. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes the estimated useful lives by asset classification:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:438.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:97.75pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate trade name</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 - 20 years</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 - 25 years</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 years</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provider network contracts</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 - 5 years</span></div></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets are reviewed for impairment if circumstances indicate the Company may not be able to recover the asset&#8217;s carrying value. The Company evaluates recoverability by determining whether the undiscounted cash flows expected to result from the use and eventual disposition of that asset or group exceed the carrying value at the evaluation date. If the undiscounted cash flows are not sufficient to cover the carrying value, the Company measures an impairment loss as the excess of the carrying amount of the long-lived asset or group over its fair value. See Note 9 for additional discussion regarding our intangible assets.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityReserveEstimatePolicy', window );">Reserves for Claims and Performance-based Arrangements</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reserves for Claims and Performance-based Arrangements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reserves for performance-based arrangements and claims reflect estimates of payments under performance-based arrangements and the ultimate cost of claims that have been incurred but not reported, including expected development on reported claims, those that have been reported but not yet paid (reported claims in process), and other medical care expenses and services payable that are primarily composed of accruals for incentives and other amounts payable to health care professionals and facilities. The Company uses actuarial principles and assumptions that are consistently applied in each reporting period and recognizes the actuarial best estimate of the ultimate liability along with a margin for adverse deviation. This approach is consistent with actuarial standards of practice that the liabilities be adequate under moderately adverse conditions. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The process of estimating reserves involves a considerable degree of judgment by the Company and, as of any given date, is inherently uncertain. The methods for making such estimates and for establishing the resulting liability are continually reviewed, and adjustments are reflected in current results of operations in the period in which they are identified as experience develops or new information becomes known. See Note 22 for additional discussion regarding our reserves for claims and performance-based arrangements.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into various office space, data center, and equipment lease agreements in conducting its normal business operations. At the inception of any contract, the Company evaluates the agreement to determine whether the contract contains a lease. If the contract contains a lease, the Company then evaluates the term and whether the lease is an operating or finance lease. Most leases include one or more options to renew or may have a termination option. The Company determines whether these options are reasonably certain to be exercised at the inception of the lease. The rent expense is recognized on a straight-line basis in the consolidated statements of operations and comprehensive income (loss) over the terms of the respective leases. Leases with an initial term of 12 months or less are not recorded on the consolidated balance sheets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. We use the implicit rate when readily determinable. Further, the Company treats all lease and non-lease components as a single combined lease component for all classes of underlying assets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also enters into sublease agreements for some of its leased office space. Rental income attributable to subleases is immaterial and is offset against rent expense over the terms of the respective leases.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 12 for additional lease disclosures.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We derive revenue from two sources: (1) transformation services and (2) platform and operations services. Transformation services consist of implementation services whereby we assist the customer in launching its population health or health plan programs, or implement certain platform and operations services. In certain cases, transformation services can also include revenue associated with our support of certain one-time wind-down activities for clients who are exiting a line of business or population. Platform and operations services generally include multi-year arrangements with customers to provide various population health, health plan operations, specialty care management and claims processing services on an ongoing basis, as well as transition or run-out services to customers receiving primarily TPA services. Revenue is recognized when control of the services is transferred to our customers.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the following 5-step model, outlined in Accounting Standards Codification (&#8220;ASC&#8221;) Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 606&#8221;), to determine revenue recognition from our contracts with customers:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"> Identify the contract(s) with a customer</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"> Identify the performance obligations in the contract</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"> Determine the transaction price</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"> Allocate the transaction price to performance obligations</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"> Recognize revenue when (or as) the entity satisfies a performance obligation</span></div>See Note 6 for further discussion of our policies related to revenue recognition.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign Currency</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company formed a subsidiary in India during the first quarter of 2018. The functional currency of our international subsidiary is the Indian Rupee. We translate the financial statements of this subsidiary to U.S. dollars using month-end rates of exchange for assets and liabilities, and monthly average rates of exchange for revenue and expenses. Translation gains and losses are recorded in accumulated other comprehensive income (loss) as a component of shareholders' equity. Foreign currency translation gains and losses did not have a material impact on our consolidated statements of operations and comprehensive income (loss) for the three and six months ended June 30, 2021 and 2020.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Adoption of New Accounting Standards</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Adoption of New Accounting Standards</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and subsequently issued additional guidance that modified ASU 2016-13. The standard requires an entity to change its accounting approach for measuring and recognizing credit losses on certain financial assets measured at amortized cost, including trade receivables, certain non-trade receivables, contract assets, held-to-maturity securities, customer advances and certain off-balance sheet credit exposures, by replacing the existing &#8220;incurred loss&#8221; framework with an expected credit loss recognition model.&#160; The new standard results in earlier recognition of credit losses based on past events, current conditions, and reasonable and supportable forecasts.&#160; The standard is effective for entities with fiscal years beginning after December 15, 2019, including interim periods within such fiscal years. We adopted the requirements of this standard effective January 1, 2020 using the modified retrospective approach and recorded a cumulative effect adjustment of $3.0 million to January 1, 2020 retained earnings (accumulated deficit). Results for reporting periods beginning January 1, 2020 reflect the adoption of <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmQ4ZjQwMzQ5NGQwYTQyYzI4Njg3OTRmYjQ3MDIxOGZjL3NlYzpkOGY0MDM0OTRkMGE0MmMyODY4Nzk0ZmI0NzAyMThmY180Ni9mcmFnOjFlZjc0Mjc4OGM3NjQ2NzQ5MGQwNWNhZWM5MzAwYjhkL3RleHRyZWdpb246MWVmNzQyNzg4Yzc2NDY3NDkwZDA1Y2FlYzkzMDBiOGRfMzI1Ng_e7fbd1cf-8213-4b7f-af71-67ed1c89dbd2">ASU 2016-13</span>, while prior period amounts were not adjusted and continue to be reported in accordance with our historical accounting practices. In our previous accounting policy for trade receivables and non-trade receivables, we maintained an allowance for doubtful accounts based solely on specific identification. Under the new accounting standard, we maintain our specific identification process but utilize several factors to develop historical losses reserves, including aging schedules, customer creditworthiness, and historical payment experience, which are then adjusted for current conditions and reasonable and supportable forecasts in measurement of the allowance.&#160; In addition, for customer advances and certain off-balance sheet credit exposures, we evaluate the allowance through a discounted cash flow approach.&#160; For held-to-maturity investment securities, we evaluate (i) historical information adjusted for current conditions and reasonable and supportable forecasts and (ii) qualitative factors to determine whether the zero-loss expectation exception applies. Refer to Note 7 for additional disclosures related to current expected credit losses.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU No. 2019-12, Simplifying the Accounting for Income Taxes. The amendments in the ASU remove certain exceptions to the intraperiod tax allocation of losses and gains from different financial statement components and to the method of recognizing income taxes on interim period losses, and the recognition of deferred tax liabilities for outside basis differences. In addition, the new guidance simplifies aspects of the accounting for franchise taxes and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. The Company adopted this standard starting in the first quarter of 2021, which did not have a material impact on our consolidated financial statements.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurement</a></td>
<td class="text">Fair Value Measurement<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GAAP defines fair value as the price that would be received from the sale of an asset or paid to transfer a liability (an exit price) assuming an orderly transaction in the most advantageous market at the measurement date. GAAP also establishes a hierarchical disclosure framework which prioritizes and ranks the level of observability of inputs used in measuring fair value. These tiers include:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 - inputs to the valuation methodology are quoted prices available in active markets for identical instruments as of the reporting date;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 - inputs to the valuation methodology are other than quoted prices in active markets, which are either directly or indirectly observable as of the reporting date and the fair value can be determined through the use of models or other valuation methodologies; and </span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 - inputs to the valuation methodology are unobservable inputs in situations where there is little or no market activity for the asset or liability.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, the level within the fair value hierarchy is based on the lowest level of input that is significant to the fair value measurement. Our assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the particular asset or liability being measured. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Nonrecurring Fair Value Measurements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the assets and liabilities that are recorded at fair value on a recurring basis, the Company records certain assets and liabilities at fair value on a nonrecurring basis as required by GAAP. Generally, assets are recorded at fair value on a nonrecurring basis as a result of impairment charges. This includes assets and liabilities recorded in business combinations or asset acquisitions, goodwill, intangible assets, property, plant and equipment, held-to-maturity investments and equity method investments. While not </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">carried at fair value on a recurring basis, these items are continually monitored for indicators of impairment that would indicate current carrying value is greater than fair value. In those situations, the assets are considered impaired and written down to current fair value. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Fair Value Disclosures</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of cash and cash equivalents (those not held in a money market fund), restricted cash, receivables, prepaid expenses, accounts payable, accrued liabilities and accrued compensation approximate their fair values because of the relatively short-term maturities of these items and financial instruments.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 10 for information regarding the fair value of the 2024 Notes, 2025 Notes and 2021 Notes.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (a)-(d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6909625&amp;loc=d3e227-128457<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents with respect to unrestricted balances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI http://asc.fasb.org/topic&amp;trid=2175825<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155638-234783<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155628-234783<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155628-234783<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsFiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityReserveEstimatePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for estimating its liability as of the balance sheet date for the ultimate cost of settling reported and unreported claims incurred and claims adjustment expenses (including effects of inflation and other societal and economic factors).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -URI http://asc.fasb.org/subtopic&amp;trid=2560295<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityReserveEstimatePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140179452468136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock', window );">Schedule of restricted cash and cash equivalents</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash and restricted investments include cash and investments used to collateralize various contractual obligations as of June&#160;30, 2021 and December&#160;31, 2020 (in thousands) as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:340.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:94.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:94.75pt"/><td style="width:1.0pt"/></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collateral for letters of credit for facility leases </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,510&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,510&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collateral with financial institutions </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,352&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,743&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Claims processing services </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,525&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,064&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,327&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total restricted cash and restricted investments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,137&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,644&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,742&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,374&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current restricted cash and restricted investments</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,742&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,374&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,395&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,654&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total non-current restricted cash and restricted investments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,395&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,654&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Amounts exclude $0.6 million of non-current restricted investments and $0.1&#160;million of current restricted cash from claims processing services reclassified to discontinued operations as of December&#160;31, 2020.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Represents restricted cash related to collateral for letters of credit required in conjunction with lease agreements. See Note 12 for further discussion of our lease commitments. </span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Represents collateral held with financial institutions for risk-sharing and other arrangements. As of June&#160;30, 2021 and December&#160;31, 2020, approximately $12.4&#160;million and $4.7 million, respectively, of the collateral amounts were held in a FDIC participating bank account. See Note 18 for discussion of fair value measurement and Note 11 for discussion of our risk-sharing arrangements. </span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Represents cash held by the Company related to claims processing services on behalf of partners. These are pass-through amounts and can fluctuate materially from period to period depending on the timing of when the claims are processed.</span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statements of cash flows as of June&#160;30, 2021 and 2020 (in thousands).</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:433.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207,273&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,272&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash and restricted investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,137&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,653&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted investments included in restricted cash and restricted investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(715)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:5.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents and restricted cash shown in the consolidated statements of cash flows </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238,410&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153,210&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">As a result of the closing of the sale of True Health SPA, the consolidated statements of operations, consolidated balance sheets, and related financial information reflect the Company&#8217;s operations and assets and liabilities of True Health as discontinued operations for all periods presented. Cash flows and comprehensive income have not been adjusted and are included in the consolidated statements of cash flows and consolidated statements of comprehensive income (loss) for all periods presented. See Note 5.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of intangible assets</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes the estimated useful lives by asset classification:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:438.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:97.75pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate trade name</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 - 20 years</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 - 25 years</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 years</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provider network contracts</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 - 5 years</span></div></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Details of our intangible assets (in thousands, except weighted-average useful lives) as of June&#160;30, 2021 and December&#160;31, 2020  are presented below:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:72.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:54.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:63.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:46.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:54.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:63.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:45.25pt"/><td style="width:1.0pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr style="height:44pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted- Average Remaining Useful Life</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Carrying Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted- Average Remaining Useful Life</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Carrying Value</span></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate trade name</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,300&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,961&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,339&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,300&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,271&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,029&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.7</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278,519&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,894&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213,625&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278,519&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,716&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220,803&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,922&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,809&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,113&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,922&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,507&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,415&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Below market lease, net</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,218&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">849&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">369&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,118&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">648&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">470&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:35pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provider network contracts </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,947&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,348&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,599&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,175&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,900&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,275&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:35pt"><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">399,906&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147,861&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252,045&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">398,034&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133,042&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264,992&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Amounts exclude $2.2&#160;million and $0.9&#160;million of customer relationships and provider network contracts, respectively, net of accumulated amortization, with weighted average remaining useful lives of 15 years and 10 months reclassified to discontinued operations as of December&#160;31, 2020.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140179551746344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Discontinued Operations (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock', window );">Schedule of discontinued operations</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the results of operations of the Company&#8217;s True Health business, which are included in loss from discontinued operations in the consolidated statements of operations the three and six months ended June 30, 2021 and 2020:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.011%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.209%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Platform and operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Premiums</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,502&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,795&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,649&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,541&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,833&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,928&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenue (exclusive of depreciation and amortization expenses presented separately below) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,640&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,885&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,935&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Claims expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,144&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,954&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,811&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,236&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,764&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,911&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">320&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,180&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,763&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,977&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating loss</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,639)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(930)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,049)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes and non-controlling interests</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,508)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(847)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,773)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit for income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(326)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,508)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(521)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,773)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Cost of revenue includes intercompany expenses between the Company and True Health that are recorded in income from continuing operations on the consolidated statements of operations related an existing services agreement for claims processing and other health plan administrative functions of $3.2&#160;million for the three months ended June 30, 2020 and $2.8&#160;million and $6.3&#160;million for the six months ended June 30, 2021 and 2020, respectively.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:1.12pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Selling, general and administrative expenses includes intercompany expenses between the Company and True Health that are recorded in income from continuing operations on the consolidated statements of operations related an existing services agreement for claims processing and other health plan administrative functions of  $1.0&#160;million of for the three months ended June 30, 2020 and $1.1 million and $4.1 million for the six months ended June 30, 2021 and 2020, respectively. </span></div>Cash flows related to the True Health business during the six months ended June 30, 2021 and 2020 were as follows:<div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:79.733%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.207%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows provided by (used in) operating activities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,002&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,660&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows provided by (used in) investing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,494)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">382&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the current and long-term assets and liabilities of the discontinued True Health business in the consolidated balance sheets as of December&#160;31, 2020:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.927%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.873%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,488&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash and restricted investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,437&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.927%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.873%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,198&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments, at amortized cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,728&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,914&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash and restricted investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">616&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments, at amortized cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,919&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other noncurrent assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,080&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,705&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,293&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,265&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and employee benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,115&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,140&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve for claims and performance-based arrangements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,858&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,471&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,648&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Accounts payable exclude $1.5&#160;million between the Company and True Health related an existing services agreement for claims processing and other health plan administrative functions as of December 31, 2020.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=SL51724579-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1474-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5D<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721677-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721659-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721665-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721671-107760<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721663-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140179452162472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Disaggregation of revenue</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents Evolent&#8217;s revenue disaggregated by segment and end-market for the three and six months ended June 30, 2021 and 2020 (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:114.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Evolent Health Services</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Evolent Health Services</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,064&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,502&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,648&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,050&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,993&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113,947&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,987&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124,512&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,346&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,061&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,761&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,206&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,684&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,246&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176,544&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126,560&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,453&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,958&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,785&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,522&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,023&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,705&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,897&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,561&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,863&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,521&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147,194&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130,778&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159,700&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182,898&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277,428&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255,633&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Contract with customer, asset and liability</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides information about receivables, contract assets and deferred revenue from contracts with customers as of June&#160;30, 2021 and December&#160;31, 2020 (in thousands):</span></div><div style="margin-top:5pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:403.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:67.75pt"/><td style="width:1.0pt"/></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term receivables </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240,060&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124,064&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term receivables </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,688&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,554&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term contract assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">329&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,173&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,187&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,932&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,593&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Amounts exclude $3.4&#160;million of short-term receivables and $4.1&#160;million of short-term deferred revenue reclassified to discontinued operations as of December&#160;31, 2020.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Excludes pharmacy claims receivable and premiums receivable</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in deferred revenue for the six months ended June 30, 2021 are as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:433.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:102.25pt"/><td style="width:1.0pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of beginning-of-period</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,780&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification to revenue, as a result of performance obligations satisfied</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,726)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash received in advance of satisfaction of performance obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,051&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,105&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140179452419368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Credit Losses (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditLossAbstract', window );"><strong>Credit Loss [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock', window );">Accounts receivable, allowance for credit loss</a></td>
<td class="text">The following table summarizes the changes in allowance for credit losses on our accounts receivables, certain non-trade accounts receivable and contract assets for the six months ended June 30, 2021 and 2020 (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.816%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.594%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.596%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,056)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cumulative transition adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,815)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for credit losses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(611)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(260)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charge-offs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,575&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,667)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,541)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140179548892920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Summary of property and equipment</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes our property and equipment as of June&#160;30, 2021 and December&#160;31, 2020 (in thousands):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:408.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:54.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:67.75pt"/><td style="width:1.0pt"/></tr><tr style="height:23pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer hardware</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,931&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,866&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,545&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,559&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Internal-use software development costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148,171&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137,085&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,553&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,586&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187,200&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175,096&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation and amortization expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(104,204)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(88,856)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,996&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,240&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140179548258616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Schedule of goodwill</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in the carrying amount of goodwill, by reportable segment, for the six months ended June 30, 2021 and 2020 (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:331.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:63.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:3.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:63.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:3.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:63.25pt"/><td style="width:1.0pt"/></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EHS</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated </span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2020 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214,354&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134,675&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">349,029&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of June 30, 2021</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214,334&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134,675&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">349,009&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span><br/></span></div><div style="padding-left:9pt;text-indent:-9pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.705%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.985%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EHS</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2019 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">431,684&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134,675&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">566,359&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill disposal </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,200)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,200)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(215,100)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(215,100)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(69)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(69)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of June 30, 2020</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214,315&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134,675&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">348,990&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Net of cumulative inception to date impairment of $575.5 million and $360.4 million as of December 31, 2020 and 2019, respectively.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Goodwill written-off upon disposal of a consolidated subsidiary.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of intangible assets details</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes the estimated useful lives by asset classification:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:438.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:97.75pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate trade name</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 - 20 years</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 - 25 years</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 years</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provider network contracts</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 - 5 years</span></div></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Details of our intangible assets (in thousands, except weighted-average useful lives) as of June&#160;30, 2021 and December&#160;31, 2020  are presented below:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:72.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:54.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:63.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:46.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:54.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:63.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:45.25pt"/><td style="width:1.0pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr style="height:44pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted- Average Remaining Useful Life</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Carrying Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted- Average Remaining Useful Life</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Carrying Value</span></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate trade name</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,300&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,961&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,339&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,300&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,271&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,029&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.7</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278,519&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,894&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213,625&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278,519&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,716&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220,803&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,922&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,809&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,113&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,922&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,507&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,415&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Below market lease, net</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,218&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">849&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">369&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,118&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">648&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">470&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:35pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provider network contracts </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,947&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,348&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,599&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,175&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,900&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,275&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:35pt"><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">399,906&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147,861&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252,045&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">398,034&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133,042&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264,992&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Amounts exclude $2.2&#160;million and $0.9&#160;million of customer relationships and provider network contracts, respectively, net of accumulated amortization, with weighted average remaining useful lives of 15 years and 10 months reclassified to discontinued operations as of December&#160;31, 2020.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of future estimated amortization of intangible assets</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future estimated amortization of intangible assets (in thousands) as of June&#160;30, 2021, is as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:478.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,762&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,629&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,325&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,441&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,736&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159,152&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future amortization of intangible assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252,045&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140179454334616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-term Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtTableTextBlock', window );">Schedule of convertible debt</a></td>
<td class="text">The following table summarizes the carrying value of the long-term convertible debt as of June&#160;30, 2021 and December&#160;31, 2020 (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:361.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:84.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:84.25pt"/><td style="width:1.0pt"/></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024 Notes</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying value</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,320&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,462&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt discount and issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,731&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,589&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,051&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,051&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remaining amortization period (years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132,054&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153,220&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2025 Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying value</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121,230&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,349&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt discount and issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,270&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,151&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172,500&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172,500&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remaining amortization period (years)</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165,974&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147,488&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021 Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying value</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,655&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,557&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,737&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,737&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remaining amortization period (years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,279&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,470&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of convertible debt instrument. Includes, but is not limited to, principal amount and amortized premium or discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140179565727496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectsOfReinsuranceTableTextBlock', window );">Summary of premiums and claims assumed</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes premiums and claims assumed under the Reinsurance Agreements for the six months ended June 30, 2021 and 2020 (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:438.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:46.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:46.00pt"/><td style="width:1.0pt"/></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reinsurance premiums assumed</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,576&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reinsurance premiums ceded</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Claims assumed</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,863&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Claims ceded</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Claims-related administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">545&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:24pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase in reserves for claims and performance-based arrangements attributable to the Reinsurance Agreement</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:24pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserves for claims and performance-based arrangements attributable to the Reinsurance Agreement at the beginning of the period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,002&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:23pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of consolidation on payable for claims and performance-based arrangements attributable to the Reinsurance Agreement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reinsurance payments paid (received)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,506&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:24pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivable for claims and performance-based arrangements attributable to the Reinsurance Agreement at the end of the period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,336)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock', window );">Summary of major customers</a></td>
<td class="text">The following table summarizes the partners who represented at least 10.0% of our consolidated trade accounts receivable as of June&#160;30, 2021 and December&#160;31, 2020:<div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:426.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:55.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/></tr><tr style="height:23pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cook County Health and Hospitals System</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Florida Blue Medicare, Inc</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neighborhood Health Plan of Rhode Island</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">* &#160;&#160;&#160;&#160;Represents less than 10.0% of the respective balance</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes those partners who represented at least 10.0% of our consolidated revenue for the three and six months ended June 30, 2021 and 2020:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:327.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cook County Health and Hospitals Systems</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Florida Blue Medicare, Inc.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Passport</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">The denominator excludes $25.5&#160;million and $57.6&#160;million of True Health premium revenue reclassified to discontinued operations for the three and six months ended June 30, 2020, respectively.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">* &#160;&#160;&#160;&#160;Represents less than 10.0% of the respective balance</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectsOfReinsuranceTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the effects of reinsurance, for example, but not limited to, disclosure of direct, assumed, and ceded insurance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 605<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6486672&amp;loc=d3e27261-158547<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectsOfReinsuranceTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6327-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6442-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140179452706040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of maturity of lease liabilities</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our primary office leases as of June&#160;30, 2021 (in thousands, other than term):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:539.25pt"><tr><td style="width:1.0pt"/><td style="width:237.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:94.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:94.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:94.00pt"/><td style="width:1.0pt"/></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lease Termination Term (in years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Future Minimum Lease Commitments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Letter of Credit Amount Required</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Arlington, VA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,147&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,579&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Riverside, IL </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.8</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,956&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pune, India</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,835&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brea, CA</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,015&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturity of lease liabilities (in thousands) as of June&#160;30, 2021, is as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.788%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.012%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating lease expense</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,854&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,832&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,645&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,378&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,145&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,761&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,615&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less:</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,732&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,883&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of components of lease expense, weighted-average discount rate and weighted-remaining lease terms</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the components of our lease expense for the three and six months ended June 30, 2021 and 2020 (in thousands): </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:52.650%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.013%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,437&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,586&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,255&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,642&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of right-of-use assets</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">299&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease cost</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,192&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,465&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,513&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,517&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease cost</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,629&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,202&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,768&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,461&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our weighted-average discount rate and our weighted remaining lease terms (in years) as of June&#160;30, 2021 are as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.788%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.012%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining lease term</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.2</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140179452417128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings (Loss) Per Common Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Computation of basic and diluted earnings per share</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the computation of basic and diluted earnings per share available for common stockholders for the three and six months ended June 30, 2021 and 2020 (in thousands, except per share data):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:288.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from continuing operations</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,107)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(202,013)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,297)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(280,500)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from discontinued operations, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,508)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,383&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,773)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,107)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(203,521)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,914)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(282,273)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to non-controlling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:23pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) available for common shareholders - basic and diluted</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,107)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(203,521)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,914)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(282,273)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding - basic and diluted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,448&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,349&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,056&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,977&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Income (loss) per common share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.37)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.24)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.30)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.01)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.02&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.02)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:23pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted income (loss) per share attributable to common shareholders of Evolent Health, Inc.</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.11)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.38)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.22)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.32)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of antidilutive securities excluded from computation of earnings per share</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Anti-dilutive shares (in thousands) excluded from the calculation of weighted-average common shares presented above for the three and six months ended June 30, 2021 and 2020 are presented below:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:288.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units ("RSUs"), performance-based RSUs and leveraged stock units ("LSUs")</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,052&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">554&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,793&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">376&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,801&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">711&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,833&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">841&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible senior notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,696&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,361&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,696&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,361&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,549&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,626&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,322&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,578&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140179565742296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Stock-based compensation expense</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total compensation expense by award type and line item in our consolidated financial statements for the three and six months ended June 30, 2021 and 2020 was as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:288.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Award Type</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">638&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">671&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,388&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance-based stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,427&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,006&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,401&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,862&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,059&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,307&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,886&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PSUs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">737&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">980&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total compensation expense by award type</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,653&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,703&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,359&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,211&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Line Item</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenue</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">892&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">526&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,487&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">918&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:288.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,761&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,177&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,872&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,293&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total compensation expense by financial statement line item</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,653&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,703&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,359&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,211&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock', window );">Schedule of share-based awards granted</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based awards were granted for the three and six months ended June 30, 2021 and 2020 as follows (in thousands):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:327.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,028&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,140&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PSUs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">319&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">520&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140179453659704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Non-controlling Interests (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestAbstract', window );"><strong>Noncontrolling Interest [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_ScheduleofChangesinNoncontrollingInterestTableTextBlock', window );">Schedule of changes in non-controlling interests</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in non-controlling interests (in thousands) for  the six months ended June 30, 2020 was as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:487.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-controlling interests balance as of beginning of period</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,889&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification of non-controlling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,889)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-controlling interests balance as of end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_ScheduleofChangesinNoncontrollingInterestTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Changes in Noncontrolling Interest [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_ScheduleofChangesinNoncontrollingInterestTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140179453838152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurement (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Summary of assets at fair value on recurring basis</a></td>
<td class="text">The following table summarizes the Company&#8217;s assets and liabilities measured at fair value on a recurring basis as of December&#160;31, 2020 (in thousands): <div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:325.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,877&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,877&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fair value of assets measured on a recurring basis</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,877&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,877&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,730&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,730&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fair value of liabilities measured on a recurring basis</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,730&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,730&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"> </span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Represents the cash and cash equivalents and restricted cash and restricted investments that were held in money market funds as of December&#160;31, 2020.</span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Represents the fair value of 1,513,786 shares issuable under the warrant agreements discussed in Note 10.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock', window );">Summary of liabilities at fair value on recurring basis</a></td>
<td class="text">The following table summarizes the Company&#8217;s assets and liabilities measured at fair value on a recurring basis as of December&#160;31, 2020 (in thousands): <div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:325.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,877&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,877&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fair value of assets measured on a recurring basis</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,877&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,877&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,730&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,730&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fair value of liabilities measured on a recurring basis</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,730&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,730&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"> </span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Represents the cash and cash equivalents and restricted cash and restricted investments that were held in money market funds as of December&#160;31, 2020.</span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Represents the fair value of 1,513,786 shares issuable under the warrant agreements discussed in Note 10.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Changes in contingent consideration measured at fair value</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in our liabilities measured at fair value for which the Company uses Level 3 inputs to determine fair value for the six months ended June 30, 2021 and 2020 are as follows (in thousands): </span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:433.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,730&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,975&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,730)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,500)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Realized and unrealized gains (losses), net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,975)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,500&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Valuation techniques and significant unobservable inputs of Level 3 fair value measurements</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the fair value (in thousands), valuation techniques and significant unobservable inputs of our Level 3 fair value measurements as of December&#160;31, 2020:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:539.25pt"><tr><td style="width:1.0pt"/><td style="width:118.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:100.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:168.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:67.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:13.75pt"/><td style="width:1.0pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Valuation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assumption or</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Technique</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unobservable Inputs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Input Ranges</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,730&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Black-Scholes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock price volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Annual risk free rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).  Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140179453691256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Parties (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock', window );">Schedule of related parties</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents assets and liabilities attributable to our related parties as of June&#160;30, 2021 and December&#160;31, 2020 (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.594%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.705%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.707%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,450&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,474&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other noncurrent assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,688&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,554&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,923&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,509&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,220&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,520&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve for claims and performance-based arrangements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">435&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents revenues and expenses attributable to our related parties for the three and six months ended June 30, 2021 and 2020 (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:273.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:61.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:61.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:61.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:61.75pt"/><td style="width:1.0pt"/></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transformation services</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Platform and operations services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,368&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,885&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,943&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141,833&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:23pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenue (exclusive of depreciation and amortization expenses)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">606&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,171)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,099&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,076&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140179454334616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Repositioning and Other Changes (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock', window );">Costs associated with the Repositioning Plan</a></td>
<td class="text">The following table provides a summary of our total costs associated with the Repositioning Plan for the three and six months ended June 30, 2021, by major type of cost (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.305%"><tr><td style="width:1.0%"/><td style="width:27.431%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.499%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.305%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.359%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.305%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.359%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.039%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.359%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.044%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Incurred For the Three Months Ended <br/>June  30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Incurred for the Six Months Ended June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Amount Expected to be Incurred in the Repositioning Plan</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cumulative Amount Incurred through June 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Severance and termination benefits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office space consolidation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,071&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,071&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,071&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional services</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">587&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,787&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,162&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,062&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">663&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,043&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,418&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,318&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140179452496296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock', window );">Reconciliation of revenue from segments to consolidated</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present our segment information for the three and six months ended June 30, 2021 and 2020 (in thousands). Prior-year segment information (including segments total Adjusted EBITDA) has been restated to conform to the reporting structure change described in Note 1.</span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:145.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:52.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:52.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:67.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:60.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:61.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:67.00pt"/><td style="width:1.0pt"/></tr><tr style="height:33pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Evolent Health Services</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intersegment<br/>Eliminations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Subtotal</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended June 30, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transformation services</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,564&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,564&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,564&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Platform and operations services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,759&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147,194&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(460)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219,493&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219,493&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,323&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147,194&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(460)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222,057&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222,057&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended June 30, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transformation services</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">755&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">755&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">755&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Platform and operations services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,432&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130,780&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(668)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216,544&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216,544&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,187&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130,780&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(668)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217,299&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217,299&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:33pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Evolent Health Services</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Subtotal</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Segments Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="12" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended June 30, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted EBITDA</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,531&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,597&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,128&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,782)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,346&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended June 30, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted EBITDA</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,948&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,200&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,148&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,629)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,519&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:145.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:52.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:52.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:67.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:60.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:61.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:67.00pt"/><td style="width:1.0pt"/></tr><tr style="height:33pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Evolent Health Services</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intersegment<br/>Eliminations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Subtotal</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Six Months Ended June 30, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transformation services</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,909&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,909&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,909&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Platform and operations services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277,417&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(898)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">434,219&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">434,219&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160,609&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277,417&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(898)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">437,128&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">437,128&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Six Months Ended June 30, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transformation services</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,993&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,993&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,993&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Platform and operations services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178,222&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255,652&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,336)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">432,538&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">432,538&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184,215&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255,652&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,336)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">438,531&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">438,531&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:33pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Evolent Health Services</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Subtotal</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Segments Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="12" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Six Months Ended June 30, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted EBITDA</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,473&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,573&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,046&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,793)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,253&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Six Months Ended June 30, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted EBITDA</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,716&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,243&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,959&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,564)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,395&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Corporate includes various finance, human resources, legal, executive, and other corporate infrastructure expenses.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock', window );">Reconciliation of Adjusted EBITDA to net loss</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents our reconciliation of consolidated segments total Adjusted EBITDA to net loss attributable to common shareholders of Evolent Health, Inc. for the three and six months ended June 30, 2021 and 2020 (in thousands): </span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:327.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss attributable to common shareholders of Evolent Health, Inc.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,107)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(203,521)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,914)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(282,273)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">705&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,475&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,274)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,290)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,611)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,571)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Provision) benefit for income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(91)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,904&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(702)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,634&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,916)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,618)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30,103)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31,596)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity method investment impairment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47,133)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on transfer of membership</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,969&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on repayment of debt, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,158)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill impairment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(215,100)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(215,100)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain from equity method investees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,879&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,143&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,662&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,731&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on disposal of assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,447)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration and indemnification asset</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(756)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">594&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,062&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">354&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repositioning costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(663)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,043)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,653)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,703)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,359)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,211)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Severance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,133)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of contract cost assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(196)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(767)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(323)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,207)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Strategy and shareholder advisory expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,513)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,513)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(76)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(374)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,070)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(683)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain (loss) from discontinued operations </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,508)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,383&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,773)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjusted EBITDA</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,346&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,519&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,253&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,395&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Includes $1.9&#160;million gain on disposal of discontinued operations for the six months ended June 30, 2021.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of all significant reconciling items in the reconciliation of total revenues from reportable segments to the entity's consolidated revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140179454329800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Reserves for Claims and Performance-Based Arrangements (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InsuranceAbstract', window );"><strong>Insurance [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense', window );">Activity in claims reserves</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Activity in reserves for claims and performance-based arrangements for the six months ended June 30, 2021 and 2020, was as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:142.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:37.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:47.50pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:47.50pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:3.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:40.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:3.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:37.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:3.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:47.50pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:3.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:47.50pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:3.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:40.00pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="45" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:33pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EHS </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">True Health</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EHS </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">True Health</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,295&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,532&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,859&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188,686&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,265&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,245&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,640&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,150&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:23pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incurred costs related to current year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,669&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219,343&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,228&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">262,240&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,135&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201,977&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,584&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245,696&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incurred costs related to prior year</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,293&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(241)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,267&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(498)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,351&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">830&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Paid costs related to current year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,801&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,379&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,274&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,454&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,020&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163,431&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,538&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200,989&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Paid costs related to prior year</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,673&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,392&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,378&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,443&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,530&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,499&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,975&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,004&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change during the year</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26,512)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,787&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,335&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,610&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,913)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,024&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,422&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,533&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:23pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Disposal of discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,194)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,194)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other adjustments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,721&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,282&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,003&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,726&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,726&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,504&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204,601&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238,105&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(648)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,995&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,062&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,409&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:31.5pt;text-align:justify;text-indent:-31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:25.44pt">Costs incurred to provide specialty care management and EVH Passport are recorded within cost of revenue in our statement of operations. </span></div><div style="padding-left:31.5pt;text-align:justify;text-indent:-31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:25.44pt">Other adjustments to reserves for claims and performance-based arrangements reflect changes in accrual for amounts payable to facilities and amounts owed to our payer partners for claims paid on our behalf.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InsuranceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InsuranceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the activity in the reserve for settling insured claims and expenses incurred in the claims settlement process for the period. The estimated liability includes the amount of money that will be required for future payments of (a) claims that have been reported to the insurer, (b) claims related to insured events that have occurred but that have not been reported to the insurer as of the date the liability is estimated, and (c) claim adjustment expenses. Claim adjustment expenses include costs incurred in the claim settlement process such as legal fees; outside adjuster fees; and costs to record, process, and adjust claims.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140179454326968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplemental Cash Flow Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowElementsAbstract', window );"><strong>Supplemental Cash Flow Elements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock', window );">Schedule of cash flow, supplemental disclosures</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following represents supplemental cash flow information the six months ended June 30, 2021 and 2020 (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:433.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental Disclosure of Non-cash Investing and Financing Activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Increase/decrease to goodwill from measurement period adjustments/business combinations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Class A common stock issued for payment of Passport/Global earn-out</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,185&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued property and equipment purchases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">668&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Effects of Leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Operating cash flows from operating leases </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,622&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,853&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Leased assets obtained in exchange for operating lease liabilities </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,157)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,354)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of supplemental cash flow information for the periods presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowElementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowElementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140179453518424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents | $</a></td>
<td class="nump">$ 207,273<span></span>
</td>
<td class="nump">$ 319,002<span></span>
</td>
<td class="nump">$ 98,272<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140179460918344">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Restricted Cash and Restricted Investments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems', window );"><strong>Restricted Cash and Cash Equivalents Items [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Total restricted cash and restricted investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 31,137<span></span>
</td>
<td class="nump">$ 21,644<span></span>
</td>
<td class="nump">$ 55,653<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Current restricted cash</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">17,742<span></span>
</td>
<td class="nump">14,374<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndInvestmentsCurrent', window );">Total current restricted cash and restricted investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">17,742<span></span>
</td>
<td class="nump">14,374<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Non-current restricted cash</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">13,395<span></span>
</td>
<td class="nump">6,654<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndInvestmentsNoncurrent', window );">Total non-current restricted cash and restricted investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">13,395<span></span>
</td>
<td class="nump">6,654<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">207,273<span></span>
</td>
<td class="nump">319,002<span></span>
</td>
<td class="nump">98,272<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted cash and restricted investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">31,137<span></span>
</td>
<td class="nump">21,644<span></span>
</td>
<td class="nump">55,653<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedInvestments', window );">Restricted investments included in restricted cash and restricted investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(715)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash and cash equivalents and restricted cash shown in the consolidated statements of cash flows (1)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">238,410<span></span>
</td>
<td class="nump">361,581<span></span>
</td>
<td class="nump">$ 153,210<span></span>
</td>
<td class="nump">$ 128,531<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember', window );">Discontinued Operations, Disposed of by Sale | True Health</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems', window );"><strong>Restricted Cash and Cash Equivalents Items [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_DisposalGroupIncludingDiscontinuedOperationRestrictedInvestmentsNoncurrent', window );">Non-current restricted investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_DisposalGroupIncludingDiscontinuedOperationRestrictedCashCurrent', window );">Current restricted cash from claims processing services</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=evh_RestrictedCashforLettersofCreditforFacilityLeasesMember', window );">Collateral for letters of credit for facility leases</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems', window );"><strong>Restricted Cash and Cash Equivalents Items [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Total restricted cash and restricted investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,510<span></span>
</td>
<td class="nump">3,510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted cash and restricted investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,510<span></span>
</td>
<td class="nump">3,510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=evh_CollateralwithFinancialInstitutionsMember', window );">Collateral with financial institutions</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems', window );"><strong>Restricted Cash and Cash Equivalents Items [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Total restricted cash and restricted investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">12,352<span></span>
</td>
<td class="nump">4,743<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted cash and restricted investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">12,352<span></span>
</td>
<td class="nump">4,743<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=evh_RestrictedCashforBenefitManagementServicesMember', window );">Claims processing services</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems', window );"><strong>Restricted Cash and Cash Equivalents Items [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Total restricted cash and restricted investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">14,525<span></span>
</td>
<td class="nump">12,064<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted cash and restricted investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">14,525<span></span>
</td>
<td class="nump">12,064<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=evh_RestrictedCashforOtherContractualCommitmentsMember', window );">Other</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems', window );"><strong>Restricted Cash and Cash Equivalents Items [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Total restricted cash and restricted investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">750<span></span>
</td>
<td class="nump">1,327<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted cash and restricted investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">750<span></span>
</td>
<td class="nump">1,327<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=us-gaap_BankTimeDepositsMember', window );">Bank time deposits</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems', window );"><strong>Restricted Cash and Cash Equivalents Items [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Total restricted cash and restricted investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">12,400<span></span>
</td>
<td class="nump">4,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted cash and restricted investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 12,400<span></span>
</td>
<td class="nump">$ 4,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">As a result of the closing of the sale of True Health SPA, the consolidated statements of operations, consolidated balance sheets, and related financial information reflect the Company&#8217;s operations and assets and liabilities of True Health as discontinued operations for all periods presented. Cash flows and comprehensive income have not been adjusted and are included in the consolidated statements of cash flows and consolidated statements of comprehensive income (loss) for all periods presented. See Note 5.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_DisposalGroupIncludingDiscontinuedOperationRestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Restricted Cash, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_DisposalGroupIncludingDiscontinuedOperationRestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_DisposalGroupIncludingDiscontinuedOperationRestrictedInvestmentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Restricted Investments, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_DisposalGroupIncludingDiscontinuedOperationRestrictedInvestmentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6812-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndInvestmentsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current cash, cash equivalents and investments that are restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. Includes current cash equivalents and investments that are similarly restricted as to withdrawal, usage or disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL6242262-115580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120413209&amp;loc=SL6242269-115581<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndInvestmentsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndInvestmentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The noncurrent cash, cash equivalents and investments that is restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits classified as long-term; that is not expected to be released from such existing restrictions within one year of the balance sheet date or operating cycle, whichever is longer. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. Includes noncurrent cash equivalents and investments that are similarly restricted as to withdrawal, usage or disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL6242262-115580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120413209&amp;loc=SL6242269-115581<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndInvestmentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investments which are not defined as or included in marketable (debt, equity, or other) securities whose use is restricted in whole or in part, generally by contractual agreements or regulatory requirements. For use in an unclassified balance sheet.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL6242262-115580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120413209&amp;loc=SL6242269-115581<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=evh_TrueHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=evh_TrueHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=evh_RestrictedCashforLettersofCreditforFacilityLeasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=evh_RestrictedCashforLettersofCreditforFacilityLeasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=evh_CollateralwithFinancialInstitutionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=evh_CollateralwithFinancialInstitutionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=evh_RestrictedCashforBenefitManagementServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=evh_RestrictedCashforBenefitManagementServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=evh_RestrictedCashforOtherContractualCommitmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=evh_RestrictedCashforOtherContractualCommitmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=us-gaap_BankTimeDepositsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=us-gaap_BankTimeDepositsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140179453863336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Goodwill (Details) - reportingUnit<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2020</div></th>
<th class="th"><div>May 31, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportingUnits', window );">Number of reporting units for goodwill testing</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportingUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportingUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140179459815512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Intangible Assets, Net (Details)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember', window );">Corporate trade name | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful life</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember', window );">Corporate trade name | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful life</a></td>
<td class="text">20 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember', window );">Customer relationships | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful life</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember', window );">Customer relationships | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful life</a></td>
<td class="text">25 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Technology</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ContractBasedIntangibleAssetsMember', window );">Provider network contracts | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful life</a></td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ContractBasedIntangibleAssetsMember', window );">Provider network contracts | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ContractBasedIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ContractBasedIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140179457973208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Recently Issued Accounting Standards (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Cumulative effect adjustment</a></td>
<td class="num">$ (847,072)<span></span>
</td>
<td class="num">$ (929,047)<span></span>
</td>
<td class="num">$ (614,190)<span></span>
</td>
<td class="num">$ (617,298)<span></span>
</td>
<td class="num">$ (619,600)<span></span>
</td>
<td class="num">$ (646,864)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingStandardsUpdateExtensibleList', window );">Accounting Standards Update [Extensible Enumeration]</a></td>
<td class="text">us-gaap:AccountingStandardsUpdate201613Member<span></span>
</td>
<td class="text">us-gaap:AccountingStandardsUpdate201613Member<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember', window );">Cumulative Effect, Period of Adoption, Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Cumulative effect adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,970<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember', window );">Retained Earnings (Accumulated Deficit)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Cumulative effect adjustment</a></td>
<td class="nump">$ 333,684<span></span>
</td>
<td class="nump">251,962<span></span>
</td>
<td class="nump">$ 608,092<span></span>
</td>
<td class="nump">$ 598,985<span></span>
</td>
<td class="nump">$ 589,178<span></span>
</td>
<td class="nump">$ 537,205<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember', window );">Retained Earnings (Accumulated Deficit) | Cumulative Effect, Period of Adoption, Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Cumulative effect adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,970<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingStandardsUpdateExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates amendment to accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL122642865-165497<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL120254526-165497<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=122150657&amp;loc=SL122150809-237846<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL122642865-165497<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S65<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124359872&amp;loc=SL124427846-239511<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124402435&amp;loc=SL124402458-218513<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124402435&amp;loc=SL124402458-218513<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL120254526-165497<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 51: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 52: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 53: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 54: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 55: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 56: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 57: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 58: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 59: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 60: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 61: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)<br><br>Reference 62: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(1)<br><br>Reference 63: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(2)<br><br>Reference 64: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(01)<br><br>Reference 65: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(03)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingStandardsUpdateExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568447-111683<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(03)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140179457116696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Transactions - Passport (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Nov. 16, 2020</div></th>
<th class="th"><div>Sep. 01, 2020</div></th>
<th class="th"><div>Jun. 06, 2019</div></th>
<th class="th"><div>May 28, 2019</div></th>
<th class="th"><div>Jan. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 30, 2019</div></th>
<th class="th"><div>Jun. 18, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToMinorityShareholders', window );">Payments to redeem Sponsors' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=evh_PassportAssetAcquisitionMember', window );">Passport Asset Acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_AssetAcquisitionCashAndEquivalents', window );">Cash and equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 159,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_AssetAcquisitionDebtSecuritiesAvailableForSale', window );">Debt securities, available-for-sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">88,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_AssetAcquisitionDebtSecuritiesAvailableForSaleUnsettledSalesReceivables', window );">Receivables related to unsettled sales of securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_AssetAcquisitionOtherAssets', window );">Other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_AssetAcquisitionAccruedMedicalExpenses', window );">Accrued medical expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">164,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_AssetAcquisitionAccruedLiabilities', window );">Accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=evh_MolinaHealthcareIncMember', window );">Molina</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_AssetPurchaseAgreementEscrowPayments', window );">Asset Purchase Agreement, escrow payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_CashReleasedFromEscrow', window );">Cash Released From Escrow</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=evh_PassportNoteMember', window );">Passport Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromCollectionOfNotesReceivable', window );">Proceeds from collection of notes receivable</a></td>
<td class="nump">$ 40,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromInterestReceived', window );">Proceeds from interest received</a></td>
<td class="nump">$ 3,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=evh_PassportNoteMember', window );">Passport Note | Notes Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesReceivableNet', window );">Notes receivable, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000,000.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=evh_UniversityHealthCaredbaPassportHealthPlanMember', window );">Passport | Variable Interest Entity, Not Primary Beneficiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquityMethodInvestments', window );">Payments to acquire interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityOwnershipPercentage', window );">Interest in investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityFinancialOrOtherSupportAmount', window );">Performance bond amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_PaymentsToAcquireEquityMethodInvestmentsAmountHeldBack', window );">Payments to acquire equity method investments, amount held back</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToMinorityShareholders', window );">Payments to redeem Sponsors' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_ProceedsFromTransferOfMembership', window );">Proceeds from transfer of membership</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_TransferOfMembershipPercentageOfPaymentBasedOnNumberOfEnrollees', window );">Transfer of membership, percentage of payment based on number of enrollees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_TransferOfMembershipPercentageOfPaymentSubjectToSatisfactionOfContingencies', window );">Transfer of membership, percentage of payment subject to satisfaction of contingencies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_AssetAcquisitionAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition, Accrued Liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_AssetAcquisitionAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_AssetAcquisitionAccruedMedicalExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition, Accrued Medical Expenses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_AssetAcquisitionAccruedMedicalExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_AssetAcquisitionCashAndEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition, Cash And Equivalents</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_AssetAcquisitionCashAndEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_AssetAcquisitionDebtSecuritiesAvailableForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition, Debt Securities, Available-For-Sale</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_AssetAcquisitionDebtSecuritiesAvailableForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_AssetAcquisitionDebtSecuritiesAvailableForSaleUnsettledSalesReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition, Debt Securities, Available-For-Sale, Unsettled Sales Receivables</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_AssetAcquisitionDebtSecuritiesAvailableForSaleUnsettledSalesReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_AssetAcquisitionOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition, Other Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_AssetAcquisitionOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_AssetPurchaseAgreementEscrowPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset Purchase Agreement, Escrow Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_AssetPurchaseAgreementEscrowPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_CashReleasedFromEscrow">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash Released From Escrow</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_CashReleasedFromEscrow</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_PaymentsToAcquireEquityMethodInvestmentsAmountHeldBack">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments To Acquire Equity Method Investments, Amount Held Back</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_PaymentsToAcquireEquityMethodInvestmentsAmountHeldBack</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_ProceedsFromTransferOfMembership">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Transfer Of Membership</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_ProceedsFromTransferOfMembership</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_TransferOfMembershipPercentageOfPaymentBasedOnNumberOfEnrollees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Transfer Of Membership, Percentage Of Payment Based on Number Of Enrollees</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_TransferOfMembershipPercentageOfPaymentBasedOnNumberOfEnrollees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_TransferOfMembershipPercentageOfPaymentSubjectToSatisfactionOfContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Transfer Of Membership, Percentage Of Payment Subject To Satisfaction Of Contingencies</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_TransferOfMembershipPercentageOfPaymentSubjectToSatisfactionOfContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of financing receivable. Excludes financing receivable covered under loss sharing agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919230-210447<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToMinorityShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to a noncontrolling interest. Includes, but not limited to, reduction of noncontrolling interest ownership. Excludes dividends paid to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToMinorityShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromCollectionOfNotesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with principal collections from a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromCollectionOfNotesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromInterestReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest received on loans and other debt instruments during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3337-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromInterestReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityFinancialOrOtherSupportAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of financial or other support the reporting entity has provided (explicitly or implicitly) to the Variable Interest Entity (VIE) that it was not previously contractually required to provide or that the reporting entity intends to provide, including, for example, situations in which the reporting entity assisted the VIE in obtaining another type of support.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=SL6759159-111685<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityFinancialOrOtherSupportAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the Variable Interest Entity's (VIE) voting interest owned by (or beneficial interest in) the reporting entity (directly or indirectly).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=SL6759159-111685<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=evh_PassportAssetAcquisitionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=evh_PassportAssetAcquisitionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=evh_MolinaHealthcareIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=evh_MolinaHealthcareIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=evh_PassportNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=evh_PassportNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_NotesReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_NotesReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=evh_UniversityHealthCaredbaPassportHealthPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=evh_UniversityHealthCaredbaPassportHealthPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140179460306392">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Discontinued Operations - Summary of Results of Operations (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Expenses</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Income (loss) from discontinued operations, net of tax (2)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (1,508)<span></span>
</td>
<td class="nump">$ 1,383<span></span>
</td>
<td class="num">$ (1,773)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember', window );">Discontinued Operations, Disposed of by Sale | True Health</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue', window );">Total revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">25,541<span></span>
</td>
<td class="nump">44,833<span></span>
</td>
<td class="nump">57,928<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Expenses</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold', window );">Cost of revenue (exclusive of depreciation and amortization expenses presented separately below)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,640<span></span>
</td>
<td class="nump">5,885<span></span>
</td>
<td class="nump">7,935<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_DisposalGroupIncludingDiscontinuedOperationClaimsExpense', window );">Claims expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">18,144<span></span>
</td>
<td class="nump">33,954<span></span>
</td>
<td class="nump">41,811<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense', window );">Selling, general and administrative expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,236<span></span>
</td>
<td class="nump">5,764<span></span>
</td>
<td class="nump">9,911<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortizationDiscontinuedOperations', window );">Depreciation and amortization expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">160<span></span>
</td>
<td class="nump">160<span></span>
</td>
<td class="nump">320<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense', window );">Total operating expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">27,180<span></span>
</td>
<td class="nump">45,763<span></span>
</td>
<td class="nump">59,977<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss', window );">Operating loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,639)<span></span>
</td>
<td class="num">(930)<span></span>
</td>
<td class="num">(2,049)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome', window );">Interest income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">137<span></span>
</td>
<td class="nump">112<span></span>
</td>
<td class="nump">286<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense', window );">Interest expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense', window );">Other loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="num">(25)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax', window );">Loss before income taxes and non-controlling interests</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,508)<span></span>
</td>
<td class="num">(847)<span></span>
</td>
<td class="num">(1,773)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation', window );">Benefit for income taxes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(326)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Income (loss) from discontinued operations, net of tax (2)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,508)<span></span>
</td>
<td class="num">(521)<span></span>
</td>
<td class="num">(1,773)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember', window );">Discontinued Operations, Disposed of by Sale | True Health | Platform and operations services</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue', window );">Total revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">39<span></span>
</td>
<td class="nump">38<span></span>
</td>
<td class="nump">279<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember', window );">Discontinued Operations, Disposed of by Sale | True Health | Premiums</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue', window );">Total revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">25,502<span></span>
</td>
<td class="nump">44,795<span></span>
</td>
<td class="nump">57,649<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember', window );">Discontinued Operations, Disposed of by Sale | True Health | Services Agreements</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Expenses</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold', window );">Cost of revenue (exclusive of depreciation and amortization expenses presented separately below)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,200<span></span>
</td>
<td class="nump">2,800<span></span>
</td>
<td class="nump">6,300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense', window );">Selling, general and administrative expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="nump">$ 4,100<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Includes $1.9&#160;million gain on disposal of discontinued operations for the six months ended June 30, 2021</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_DisposalGroupIncludingDiscontinuedOperationClaimsExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Claims Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_DisposalGroupIncludingDiscontinuedOperationClaimsExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortizationDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deprecation and amortization expense attributable to property, plant and equipment and intangible assets of discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortizationDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of income (loss) from a discontinued operation. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) related to a discontinued operation. Includes, but is not limited to, tax expense (benefit) related to income (loss) from operations during the phase-out period, tax expense (benefit) related to gain (loss) on disposal, tax expense (benefit) related to gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and tax expense (benefit) related to adjustments of a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of costs of goods sold attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of general and administrative expense attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section S99<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=26872618&amp;loc=d3e7436-122677<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1063-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1060-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating expense attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating income (loss) attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other expense attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109227538&amp;loc=d3e44648-109337<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=evh_TrueHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=evh_TrueHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=evh_PlatformsAndOperationsServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=evh_PlatformsAndOperationsServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=evh_PremiumsRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=evh_PremiumsRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=evh_ServicesAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=evh_ServicesAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140179454394296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Discontinued Operations - Summary of Cash Flows (Details) - True Health - Discontinued Operations, Disposed of by Sale - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations', window );">Cash flows provided by (used in) operating activities</a></td>
<td class="nump">$ 5,002<span></span>
</td>
<td class="nump">$ 10,660<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations', window );">Cash flows provided by (used in) investing activities</a></td>
<td class="num">$ (2,494)<span></span>
</td>
<td class="nump">$ 382<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of investing activities of discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of operating activities of discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=evh_TrueHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=evh_TrueHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140179461297416">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Discontinued Operations - Summary of Current and Long-term Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Total current assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 33,914<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Current liabilities of discontinued operations</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">27,986<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=evh_TrueHealthMember', window );">True Health | Discontinued Operations, Disposed of by Sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,488<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_DisposalGroupIncludingDiscontinuedOperationRestrictedCashAndRestrictedInvestmentsCurrent', window );">Restricted cash and restricted investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet', window );">Accounts receivable, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,437<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,198<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_DisposalGroupIncludingDiscontinuedOperationInvestmentsCurrent', window );">Investments, at amortized cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,728<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Total current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,914<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_DisposalGroupIncludingDiscontinuedOperationRestrictedCashAndRestrictedInvestmentsNoncurrent', window );">Restricted cash and restricted investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">616<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_DisposalGroupIncludingDiscontinuedOperationInvestmentsNoncurrent', window );">Investments, at amortized cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,919<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsNoncurrent', window );">Prepaid expenses and other noncurrent assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent', window );">Intangible assets, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,080<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,705<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation', window );">Total assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,293<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,265<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_DisposalGroupIncludingDiscontinuedOperationAccruedCompensationAndEmployeeBenefitsCurrent', window );">Accrued compensation and employee benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,115<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,140<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_DisposalGroupIncludingDiscontinuedOperationLiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangementsCurrent', window );">Reserve for claims and performance-based arrangements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,858<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Current liabilities of discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,471<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities', window );">Other long-term liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">128<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities', window );">Deferred tax liabilities, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation', window );">Total liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,648<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=evh_TrueHealthMember', window );">True Health | Discontinued Operations, Disposed of by Sale | Services Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet', window );">Accounts receivable, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_DisposalGroupIncludingDiscontinuedOperationAccruedCompensationAndEmployeeBenefitsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Accrued Compensation And Employee Benefits, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_DisposalGroupIncludingDiscontinuedOperationAccruedCompensationAndEmployeeBenefitsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_DisposalGroupIncludingDiscontinuedOperationInvestmentsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Investments, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_DisposalGroupIncludingDiscontinuedOperationInvestmentsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_DisposalGroupIncludingDiscontinuedOperationInvestmentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Investments, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_DisposalGroupIncludingDiscontinuedOperationInvestmentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_DisposalGroupIncludingDiscontinuedOperationLiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangementsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Liability For Future Policy Benefits And Unpaid Claims And Claims Adjustment Expense And Performance-Based Arrangements, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_DisposalGroupIncludingDiscontinuedOperationLiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangementsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Prepaid And Other Assets, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_DisposalGroupIncludingDiscontinuedOperationRestrictedCashAndRestrictedInvestmentsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Restricted Cash And Restricted Investments, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_DisposalGroupIncludingDiscontinuedOperationRestrictedCashAndRestrictedInvestmentsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_DisposalGroupIncludingDiscontinuedOperationRestrictedCashAndRestrictedInvestmentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Restricted Cash And Restricted Investments, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_DisposalGroupIncludingDiscontinuedOperationRestrictedCashAndRestrictedInvestmentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2473-110228<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as accounts, notes and loans receivable attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as accounts payable attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2473-110228<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as accrued liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2473-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as cash and cash equivalents attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as deferred revenue attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2473-110228<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as deferred tax liabilities attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as goodwill attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2510-110228<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as intangible assets, excluding goodwill, attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2510-110228<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as other liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2510-110228<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as prepaid and other assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2473-110228<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as liabilities attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2473-110228<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=evh_TrueHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=evh_TrueHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=evh_ServicesAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=evh_ServicesAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140179450634952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition - Disaggregation of Revenue (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=evh_EvolentHealthServicesSegmentMember', window );">Evolent Health Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 74,863<span></span>
</td>
<td class="nump">$ 86,521<span></span>
</td>
<td class="nump">$ 159,700<span></span>
</td>
<td class="nump">$ 182,898<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=evh_EvolentHealthServicesSegmentMember', window );">Evolent Health Services | Medicaid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">52,064<span></span>
</td>
<td class="nump">55,502<span></span>
</td>
<td class="nump">112,993<span></span>
</td>
<td class="nump">113,947<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=evh_EvolentHealthServicesSegmentMember', window );">Evolent Health Services | Medicare</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">6,346<span></span>
</td>
<td class="nump">14,061<span></span>
</td>
<td class="nump">14,684<span></span>
</td>
<td class="nump">29,246<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=evh_EvolentHealthServicesSegmentMember', window );">Evolent Health Services | Commercial and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">16,453<span></span>
</td>
<td class="nump">16,958<span></span>
</td>
<td class="nump">32,023<span></span>
</td>
<td class="nump">39,705<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=evh_ClinicalSolutionsSegmentMember', window );">Clinical Solutions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">147,194<span></span>
</td>
<td class="nump">130,778<span></span>
</td>
<td class="nump">277,428<span></span>
</td>
<td class="nump">255,633<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=evh_ClinicalSolutionsSegmentMember', window );">Clinical Solutions | Medicaid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">53,648<span></span>
</td>
<td class="nump">64,050<span></span>
</td>
<td class="nump">96,987<span></span>
</td>
<td class="nump">124,512<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=evh_ClinicalSolutionsSegmentMember', window );">Clinical Solutions | Medicare</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">90,761<span></span>
</td>
<td class="nump">64,206<span></span>
</td>
<td class="nump">176,544<span></span>
</td>
<td class="nump">126,560<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=evh_ClinicalSolutionsSegmentMember', window );">Clinical Solutions | Commercial and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 2,785<span></span>
</td>
<td class="nump">$ 2,522<span></span>
</td>
<td class="nump">$ 3,897<span></span>
</td>
<td class="nump">$ 4,561<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=evh_EvolentHealthServicesSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=evh_EvolentHealthServicesSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=evh_MedicaidCustomersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=evh_MedicaidCustomersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=evh_MedicareCustomersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=evh_MedicareCustomersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=evh_CommercialAndOtherCustomersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=evh_CommercialAndOtherCustomersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=evh_ClinicalSolutionsSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=evh_ClinicalSolutionsSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140179453981608">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Revenue Recognition - Transaction Price Allocated to the Remaining Performance Obligations (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Revenue, remaining performance obligation</a></td>
<td class="nump">$ 181.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2021-07-01', window );">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-07-01</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationPercentage', window );">Revenue, remaining performance obligation, percentage</a></td>
<td class="nump">18.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Revenue, remaining performance obligation, expected timing of satisfaction, period</a></td>
<td class="text">6 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2022-01-01', window );">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-01-01</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationPercentage', window );">Revenue, remaining performance obligation, percentage</a></td>
<td class="nump">51.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Revenue, remaining performance obligation, expected timing of satisfaction, period</a></td>
<td class="text">12 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of remaining performance obligation to total remaining performance obligation not recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2021-07-01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2021-07-01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2022-01-01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2022-01-01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140179459608376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition - Contract Balances (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableNetCurrent', window );">Short-term receivables</a></td>
<td class="nump">$ 240,060<span></span>
</td>
<td class="nump">$ 240,060<span></span>
</td>
<td class="nump">$ 124,064<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermAccountsNotesAndLoansReceivableNetNoncurrent', window );">Long-term receivables</a></td>
<td class="nump">4,688<span></span>
</td>
<td class="nump">4,688<span></span>
</td>
<td class="nump">4,554<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Short-term contract assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">329<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Short-term deferred revenue</a></td>
<td class="nump">13,173<span></span>
</td>
<td class="nump">13,173<span></span>
</td>
<td class="nump">10,187<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Long-term deferred revenue</a></td>
<td class="nump">4,932<span></span>
</td>
<td class="nump">4,932<span></span>
</td>
<td class="nump">3,593<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_ChangeInContractWithCustomerLiabilityRollForward', window );"><strong>Deferred revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Balance as of beginning-of-period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,780<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Reclassification to revenue, as a result of performance obligations satisfied</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,726)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations', window );">Cash received in advance of satisfaction of performance obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,051<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Balance as of end of period</a></td>
<td class="nump">18,105<span></span>
</td>
<td class="nump">18,105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod', window );">Revenue recognized from performed obligations</a></td>
<td class="nump">$ 2,900<span></span>
</td>
<td class="nump">$ 16,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember', window );">Discontinued Operations, Disposed of by Sale | True Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNetAfterGrossUp', window );">Accounts receivable, net, after gross-up</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,140<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_ChangeInContractWithCustomerLiabilityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change In Contract With Customer, Liability [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_ChangeInContractWithCustomerLiabilityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Liability, Cash Received In Advance Of Satisfaction Of Performance Obligations</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNetAfterGrossUp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Accounts, Notes And Loans Receivable, Net, After Gross-Up</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNetAfterGrossUp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesAndLoansReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of accounts and financing receivables, classified as current. Includes, but is not limited to, notes and loan receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3,4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesAndLoansReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130533-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from performance obligation satisfied or partially satisfied in previous reporting periods. Includes, but is not limited to, change in transaction price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12A<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL108322424-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as deferred revenue attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2473-110228<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermAccountsNotesAndLoansReceivableNetNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of accounts and financing receivables, classified as noncurrent. Includes, but is not limited to, notes and loan receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermAccountsNotesAndLoansReceivableNetNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=evh_TrueHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=evh_TrueHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140179461028888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition - Contract Costs (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostLineItems', window );"><strong>Capitalized Contract Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostAmortization', window );">Contract cost amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,311<span></span>
</td>
<td class="nump">$ 10,272<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostAmortizationPeriod', window );">Capitalized contract cost, amortization period</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostAxis=evh_BonusesAndCommissionsMember', window );">Bonuses and Commissions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostLineItems', window );"><strong>Capitalized Contract Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostNet', window );">Contract cost assets</a></td>
<td class="nump">$ 3,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostAmortization', window );">Contract cost amortization</a></td>
<td class="nump">600<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostAxis=evh_ContractFulfillmentCostsMember', window );">Contract Fulfillment Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostLineItems', window );"><strong>Capitalized Contract Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostNet', window );">Contract cost assets</a></td>
<td class="nump">18,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostAmortization', window );">Contract cost amortization</a></td>
<td class="nump">$ 4,600<span></span>
</td>
<td class="nump">$ 4,300<span></span>
</td>
<td class="nump">$ 7,300<span></span>
</td>
<td class="nump">$ 9,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for asset recognized from cost incurred to obtain or fulfill contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123353750&amp;loc=SL49131252-203054<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostAmortizationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortization period of cost capitalized in obtaining or fulfilling contract with customer, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 40<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123353750&amp;loc=SL49131251-203054<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostAmortizationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123353750&amp;loc=SL49131252-203054<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostAxis=evh_BonusesAndCommissionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostAxis=evh_BonusesAndCommissionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostAxis=evh_ContractFulfillmentCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostAxis=evh_ContractFulfillmentCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140179460995064">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Credit Losses - Accounts Receivable (Narrative) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNoncurrentPastDueLineItems', window );"><strong>Accounts Receivable, Noncurrent, Past Due [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_FinancingReceivablePercentNotPastDue', window );">Percentage of receivables, current</a></td>
<td class="nump">64.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNet', window );">Accounts receivable, net</a></td>
<td class="nump">$ 264,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Allowance for doubtful accounts, current</a></td>
<td class="nump">$ 7,667<span></span>
</td>
<td class="nump">$ 7,056<span></span>
</td>
<td class="nump">$ 1,541<span></span>
</td>
<td class="nump">$ 41<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancingReceivablesPeriodPastDueAxis=evh_FInancialAssetLessThan60DaysMember', window );">Past due less than 60 days</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNoncurrentPastDueLineItems', window );"><strong>Accounts Receivable, Noncurrent, Past Due [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancingReceivablePercentPastDue1', window );">Percentage of receivables, past due</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancingReceivablesPeriodPastDueAxis=evh_FInancialAssetLessThan120DaysPastDueMember', window );">Past due less than 120 days</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNoncurrentPastDueLineItems', window );"><strong>Accounts Receivable, Noncurrent, Past Due [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancingReceivablePercentPastDue1', window );">Percentage of receivables, past due</a></td>
<td class="nump">28.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_FinancingReceivablePercentNotPastDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Financing Receivable, Percent Not Past Due</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_FinancingReceivablePercentNotPastDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 310<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123366838&amp;loc=d3e3073-115593<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNoncurrentPastDueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNoncurrentPastDueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancingReceivablePercentPastDue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of financing receivable balance that is past due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancingReceivablePercentPastDue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancingReceivablesPeriodPastDueAxis=evh_FInancialAssetLessThan60DaysMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancingReceivablesPeriodPastDueAxis=evh_FInancialAssetLessThan60DaysMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancingReceivablesPeriodPastDueAxis=evh_FInancialAssetLessThan120DaysPastDueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancingReceivablesPeriodPastDueAxis=evh_FInancialAssetLessThan120DaysPastDueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140179553432120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Credit Losses - Schedule of Changes in Allowance for Accounts Receivable (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward', window );"><strong>Accounts Receivable, Allowance for Credit Loss [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Balance as of beginning of period</a></td>
<td class="num">$ (7,056)<span></span>
</td>
<td class="num">$ (41)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Provision for credit losses</a></td>
<td class="num">(611)<span></span>
</td>
<td class="num">(260)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs', window );">Charge-offs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,575<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Balance as of end of period</a></td>
<td class="num">(7,667)<span></span>
</td>
<td class="num">(1,541)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember', window );">Cumulative Effect, Period of Adoption, Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward', window );"><strong>Accounts Receivable, Allowance for Credit Loss [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Balance as of beginning of period</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (2,815)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of direct write-downs of accounts receivable charged against the allowance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140179461361368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 187,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 187,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 175,096<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation and amortization expenses</a></td>
<td class="num">(104,204)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(104,204)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(88,856)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total property and equipment, net</a></td>
<td class="nump">82,996<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82,996<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86,240<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">7,600<span></span>
</td>
<td class="nump">$ 7,100<span></span>
</td>
<td class="nump">15,400<span></span>
</td>
<td class="nump">$ 13,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedComputerSoftwareAmortization1', window );">Capitalized computer software, amortization</a></td>
<td class="nump">6,600<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
<td class="nump">13,300<span></span>
</td>
<td class="nump">11,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer hardware</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">19,931<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,931<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,866<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">3,545<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,545<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,559<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember', window );">Internal-use software development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">148,171<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">148,171<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">137,085<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total property and equipment, net</a></td>
<td class="nump">73,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">73,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedComputerSoftwareAdditions', window );">Capitalized computer software additions</a></td>
<td class="nump">5,600<span></span>
</td>
<td class="nump">$ 6,400<span></span>
</td>
<td class="nump">11,100<span></span>
</td>
<td class="nump">$ 13,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 15,553<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,553<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,586<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedComputerSoftwareAdditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additions made to capitalized computer software costs during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedComputerSoftwareAdditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedComputerSoftwareAmortization1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for amortization of capitalized computer software costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128487-111756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedComputerSoftwareAmortization1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140179460056504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets, Net - Impairment Testing (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 31, 2020 </div>
<div>reportingUnit</div>
</th>
<th class="th">
<div>May 31, 2020 </div>
<div>reportingUnit</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($) </div>
<div>reportingUnit</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportingUnits', window );">Number of reporting units for goodwill testing | reportingUnit</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 215,100,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 199,800,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 215,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_NumberOfReportingUnitsFairValueInExcessOfCarryingAmount', window );">Number of reporting units, fair value in excess of carrying amount | reportingUnit</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 349,009,000<span></span>
</td>
<td class="nump">$ 348,990,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 566,359,000<span></span>
</td>
<td class="nump">$ 349,009,000<span></span>
</td>
<td class="nump">$ 348,990,000<span></span>
</td>
<td class="nump">$ 349,029,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAxis=us-gaap_IncomeApproachValuationTechniqueMember', window );">Valuation, Income Approach</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 214,300,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_NumberOfReportingUnitsFairValueInExcessOfCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Reporting Units, Fair Value In Excess Of Carrying Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_NumberOfReportingUnitsFairValueInExcessOfCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportingUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportingUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationTechniqueAxis=us-gaap_IncomeApproachValuationTechniqueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationTechniqueAxis=us-gaap_IncomeApproachValuationTechniqueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140179454596008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets, Net - Schedule of Goodwill (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance as of beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 566,359,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 349,029,000<span></span>
</td>
<td class="nump">$ 566,359,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit', window );">Goodwill disposal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,200,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (215,100,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">$ (199,800,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(215,100,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Foreign currency translation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(20,000)<span></span>
</td>
<td class="num">(69,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance as of end of period</a></td>
<td class="nump">349,009,000<span></span>
</td>
<td class="nump">348,990,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">566,359,000<span></span>
</td>
<td class="nump">349,009,000<span></span>
</td>
<td class="nump">348,990,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss', window );">Cumulative inception to date impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">360,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 575,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=evh_EvolentHealthServicesSegmentMember', window );">Evolent Health Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance as of beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">431,684,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">214,354,000<span></span>
</td>
<td class="nump">431,684,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit', window );">Goodwill disposal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,200,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(215,100,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Foreign currency translation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(20,000)<span></span>
</td>
<td class="num">(69,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance as of end of period</a></td>
<td class="nump">214,334,000<span></span>
</td>
<td class="nump">214,315,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">431,684,000<span></span>
</td>
<td class="nump">214,334,000<span></span>
</td>
<td class="nump">214,315,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=evh_ClinicalSolutionsSegmentMember', window );">Clinical Solutions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance as of beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 134,675,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">134,675,000<span></span>
</td>
<td class="nump">134,675,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit', window );">Goodwill disposal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Foreign currency translation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance as of end of period</a></td>
<td class="nump">$ 134,675,000<span></span>
</td>
<td class="nump">$ 134,675,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 134,675,000<span></span>
</td>
<td class="nump">$ 134,675,000<span></span>
</td>
<td class="nump">$ 134,675,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillForeignCurrencyTranslationGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairedAccumulatedImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of divestiture of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=evh_EvolentHealthServicesSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=evh_EvolentHealthServicesSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=evh_ClinicalSolutionsSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=evh_ClinicalSolutionsSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140179460064248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets, Net - Intangible Assets, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 399,906<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 399,906<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 398,034<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">147,861<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">147,861<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">133,042<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total future amortization of intangible assets</a></td>
<td class="nump">252,045<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">252,045<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">264,992<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">7,200<span></span>
</td>
<td class="nump">$ 8,400<span></span>
</td>
<td class="nump">$ 14,700<span></span>
</td>
<td class="nump">$ 17,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember', window );">Discontinued Operations, Disposed of by Sale | True Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent', window );">Intangible assets, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,080<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember', window );">Corporate trade name</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted- Average Remaining Useful Life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">13 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">23,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">6,961<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,961<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,271<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total future amortization of intangible assets</a></td>
<td class="nump">16,339<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,339<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,029<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember', window );">Customer relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted- Average Remaining Useful Life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">16 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">278,519<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 278,519<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 278,519<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">64,894<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64,894<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57,716<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total future amortization of intangible assets</a></td>
<td class="nump">213,625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 213,625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 220,803<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember', window );">Customer relationships | Discontinued Operations, Disposed of by Sale | True Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted- Average Remaining Useful Life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent', window );">Intangible assets, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted- Average Remaining Useful Life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 9 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">82,922<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 82,922<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 82,922<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">68,809<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68,809<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,507<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total future amortization of intangible assets</a></td>
<td class="nump">14,113<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,113<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,415<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=evh_BelowMarketLeasesMember', window );">Below market lease, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted- Average Remaining Useful Life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 3 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">1,218<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,218<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,118<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">849<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">849<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">648<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total future amortization of intangible assets</a></td>
<td class="nump">369<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 369<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 470<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ContractBasedIntangibleAssetsMember', window );">Provider network contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted- Average Remaining Useful Life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 10 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">13,947<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,947<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,175<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">6,348<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,348<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,900<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total future amortization of intangible assets</a></td>
<td class="nump">$ 7,599<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,599<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,275<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ContractBasedIntangibleAssetsMember', window );">Provider network contracts | Discontinued Operations, Disposed of by Sale | True Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted- Average Remaining Useful Life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent', window );">Intangible assets, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as intangible assets, excluding goodwill, attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2510-110228<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=evh_TrueHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=evh_TrueHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=evh_BelowMarketLeasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=evh_BelowMarketLeasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ContractBasedIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ContractBasedIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140179453890824">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Goodwill and Intangible Assets, Net - Amortization of Intangible Assets 10K (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear', window );">2021</a></td>
<td class="nump">$ 13,762<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2022</a></td>
<td class="nump">24,629<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2023</a></td>
<td class="nump">22,325<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2024</a></td>
<td class="nump">16,441<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2025</a></td>
<td class="nump">15,736<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour', window );">Thereafter</a></td>
<td class="nump">159,152<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total future amortization of intangible assets</a></td>
<td class="nump">$ 252,045<span></span>
</td>
<td class="nump">$ 264,992<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finite-Lived Intangible Asset, Expected Amortization, After Year Four</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140179460539240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-term Debt - 2024 Notes (Details) - Senior Notes<br> $ / shares in Units, shares in Millions</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Aug. 31, 2020 </div>
<div>USD ($) </div>
<div>shares </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($) </div>
<div>shares </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Dec. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payments of debt issuance costs</a></td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=evh_SeniorConvertibleNotesDue2024Member', window );">2024 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="nump">$ 117,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 117,051,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 117,051,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 117,051,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="nump">3.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Debt conversion, converted instrument, amount</a></td>
<td class="nump">$ 84,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt issuance costs</a></td>
<td class="nump">$ 3,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 18.23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments', window );">Initial conversion amount (in shares) | shares</a></td>
<td class="nump">6.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt, net of discount</a></td>
<td class="nump">$ 78,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_DebtIssuanceCostsNetDebtComponent', window );">Debt issuance costs, net, debt component</a></td>
<td class="nump">$ 1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_AmortizationOfDebtDiscountAndDebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction', window );">Non-cash amortization of debt discount and debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount', window );">Repurchase covenant, repurchase price due to fundamental change as percentage of principal amount</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice', window );">Repurchase covenant, sale price as a percentage of conversion price</a></td>
<td class="nump">130.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum', window );">Repurchase covenant, trading days, minimum</a></td>
<td class="text">20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum', window );">Repurchase covenant, consecutive trading days, minimum</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice', window );">Repurchase covenant, repurchase price due to change in sale price as percentage of conversion price</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=evh_SeniorConvertibleNotesDue2024Member', window );">2024 Notes | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt issuance costs</a></td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from issuance of debt</a></td>
<td class="nump">$ 38,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=evh_SeniorConvertibleNotesDue2024Member', window );">2024 Notes | Common Stock | Class A Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Initial conversion rate per $ 1000 principal amount</a></td>
<td class="nump">0.0548667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=evh_ConvertibleSeniorNotesdue2021Member', window );">2021 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,000,000.0<span></span>
</td>
<td class="nump">26,737,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,737,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,737,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtAmount1', window );">Debt conversion, original debt, amount</a></td>
<td class="nump">$ 84,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from issuance of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount', window );">Repurchase covenant, repurchase price due to fundamental change as percentage of principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=evh_ConvertibleSeniorNotesdue2021Member', window );">2021 Notes | Common Stock | Class A Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Initial conversion rate per $ 1000 principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0416082<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments', window );">Initial conversion amount (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=evh_NewNotesMember', window );">New Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Debt conversion, converted instrument, amount</a></td>
<td class="nump">$ 32,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_AmortizationOfDebtDiscountAndDebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortization Of Debt Discount And Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_AmortizationOfDebtDiscountAndDebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Repurchase Covenant, Consecutive Trading Days, Minimum</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Repurchase Covenant, Sale Price As A Percentage Of Conversion Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Repurchase Covenant, Trading Days, Minimum</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Repurchase Price Due To Change In Sale Price As Percentage Of Conversion Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Repurchase Price Due To Fundamental Change As Percentage Of Principal Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_DebtIssuanceCostsNetDebtComponent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Issuance Costs, Net, Debt Component</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_DebtIssuanceCostsNetDebtComponent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionOriginalDebtAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionOriginalDebtAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031898-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21521-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21506-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity instruments that the holder of the debt instrument would receive if the debt was converted to equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21521-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21506-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=evh_SeniorConvertibleNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=evh_SeniorConvertibleNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=evh_ConvertibleSeniorNotesdue2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=evh_ConvertibleSeniorNotesdue2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=evh_NewNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=evh_NewNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140179460537384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-term Debt - Credit Agreement (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 08, 2021</div></th>
<th class="th"><div>Dec. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on repayment of debt, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (19,158,000)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=evh_InitialTermLoanFacilityMember', window );">Initial Term Loan Facility | Secured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=evh_CreditAgreementMember', window );">Credit Agreement | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on repayment of debt, net</a></td>
<td class="nump">$ 19,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WriteOffOfDeferredDebtIssuanceCost', window );">Unamortized debt issuance cost</a></td>
<td class="nump">9,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LegalFees', window );">Legal expenses</a></td>
<td class="nump">35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=evh_CreditAgreementMember', window );">Credit Agreement | Line of Credit | DDTL Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage', window );">Commitment fee percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=evh_ConvertibleSeniorNotesdue2021Member', window );">2021 Notes | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,737,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,737,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,737,000<span></span>
</td>
<td class="nump">$ 125,000,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,600,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=evh_SeniorCreditFacilitiesMember', window );">Senior Credit Facilities | Secured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_AmortizationOfDebtDiscountAndDebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction', window );">Non-cash amortization of debt discount and debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermLinesOfCredit', window );">Repayments of long-term lines of credit</a></td>
<td class="nump">98,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_PaymentsOfMakeWholePremium', window );">Payments of make-whole premium</a></td>
<td class="nump">9,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Accrued interest</a></td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=evh_SeniorCreditFacilitiesMember', window );">Senior Credit Facilities | Secured Debt | After the Second Anniversary of the Closing of the Senior Credit Facilities but Prior to the Third Anniversary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_DebtInstrumentRedemptionCallProtectionPremiumPercentage', window );">Redemption, call protection premium, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=evh_SeniorCreditFacilitiesMember', window );">Senior Credit Facilities | Secured Debt | After the Third Anniversary of the Closing of the Senior Credit Facilities but Prior to the Fourth Anniversary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_DebtInstrumentRedemptionCallProtectionPremiumPercentage', window );">Redemption, call protection premium, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=evh_SeniorCreditFacilitiesMember', window );">Senior Credit Facilities | Secured Debt | After the Fourth Anniversary of the Closing of the Senior Credit Facilities but Prior to the Fifth Anniversary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_DebtInstrumentRedemptionCallProtectionPremiumPercentage', window );">Redemption, call protection premium, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=evh_SeniorCreditFacilitiesMember', window );">Senior Credit Facilities | Secured Debt | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">91 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=evh_SeniorCreditFacilitiesMember', window );">Senior Credit Facilities | Secured Debt | Eurodollar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=evh_SeniorCreditFacilitiesMember', window );">Senior Credit Facilities | Secured Debt | Base Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_AmortizationOfDebtDiscountAndDebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortization Of Debt Discount And Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_AmortizationOfDebtDiscountAndDebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_DebtInstrumentRedemptionCallProtectionPremiumPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Redemption, Call Protection Premium, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_DebtInstrumentRedemptionCallProtectionPremiumPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_PaymentsOfMakeWholePremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments Of Make-Whole Premium</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_PaymentsOfMakeWholePremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityCommitmentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the settlement of obligation drawn from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WriteOffOfDeferredDebtIssuanceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Write-off of amounts previously capitalized as debt issuance cost in an extinguishment of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WriteOffOfDeferredDebtIssuanceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=evh_InitialTermLoanFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=evh_InitialTermLoanFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=evh_CreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=evh_CreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=evh_DelayedDrawTermLoanFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=evh_DelayedDrawTermLoanFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=evh_ConvertibleSeniorNotesdue2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=evh_ConvertibleSeniorNotesdue2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=evh_SeniorCreditFacilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=evh_SeniorCreditFacilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_EurodollarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_EurodollarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_BaseRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_BaseRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140179464037448">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Long-term Debt - Warrant Agreement (Details) - Class A Common Stock - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th"><div>Jan. 08, 2021</div></th>
<th class="th"><div>Dec. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightUnissued', window );">Warrants agreed to be sold (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,513,786<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants or rights (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.05<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_ClassOfWarrantOrRightPeriodDuringWhichWarrantsOrRightsExercisableAfterMaturityOfCreditAgreement', window );">Period during which warrants or rights exercisable, after maturity of credit agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfWarrants', window );">Payments to settle outstanding warrants</a></td>
<td class="nump">$ 13.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_ClassOfWarrantOrRightPeriodDuringWhichWarrantsOrRightsExercisableAfterMaturityOfCreditAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Period During Which Warrants Or Rights Exercisable, After Maturity Of Credit Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_ClassOfWarrantOrRightPeriodDuringWhichWarrantsOrRightsExercisableAfterMaturityOfCreditAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightUnissued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of warrants or rights which entitle the entity to receive future services in exchange for the unvested, forfeitable warrants or rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightUnissued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount paid by the entity to reacquire the right to purchase equity shares at a predetermined price, usually issued together with corporate debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140179550995336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-term Debt - 2025 Notes (Details) - 2025 Notes<br> $ / shares in Units, shares in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 31, 2018 </div>
<div>USD ($) </div>
<div>shares </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 24, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 22, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt issuance costs</a></td>
<td class="nump">$ 5,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="nump">$ 172,500,000<span></span>
</td>
<td class="nump">$ 172,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 172,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 172,500,000<span></span>
</td>
<td class="nump">$ 22,500,000<span></span>
</td>
<td class="nump">$ 150,000,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from issuance of debt</a></td>
<td class="nump">$ 166,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt issuance costs</a></td>
<td class="nump">$ 3,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 33.43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments', window );">Initial conversion amount (in shares) | shares</a></td>
<td class="nump">5.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Carrying amount</a></td>
<td class="nump">$ 100,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_AmortizationOfDebtDiscountAndDebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction', window );">Non-cash amortization of debt discount and debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,400,000<span></span>
</td>
<td class="nump">$ 2,100,000<span></span>
</td>
<td class="nump">$ 4,800,000<span></span>
</td>
<td class="nump">$ 4,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount', window );">Repurchase covenant, repurchase price due to fundamental change as percentage of principal amount</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice', window );">Repurchase covenant, sale price as a percentage of conversion price (at least)</a></td>
<td class="nump">130.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum', window );">Repurchase covenant, trading days, minimum</a></td>
<td class="text">20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum', window );">Repurchase covenant, consecutive trading days, minimum</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice', window );">Repurchase covenant, repurchase price due to change in sale price as percentage of conversion price</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from issuance of debt</a></td>
<td class="nump">$ 71,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt issuance costs</a></td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | Class A Common Stock | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Initial conversion rate per $ 1000 principal amount</a></td>
<td class="nump">0.0299135<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_AmortizationOfDebtDiscountAndDebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortization Of Debt Discount And Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_AmortizationOfDebtDiscountAndDebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Repurchase Covenant, Consecutive Trading Days, Minimum</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Repurchase Covenant, Sale Price As A Percentage Of Conversion Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Repurchase Covenant, Trading Days, Minimum</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Repurchase Price Due To Change In Sale Price As Percentage Of Conversion Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Repurchase Price Due To Fundamental Change As Percentage Of Principal Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031898-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21521-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21506-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity instruments that the holder of the debt instrument would receive if the debt was converted to equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21521-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21506-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=evh_SeniorConvertibleNotesDue2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=evh_SeniorConvertibleNotesDue2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140179461200552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-term Debt - 2021 Notes (Details)<br> $ / shares in Units, shares in Millions</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Aug. 31, 2020 </div>
<div>USD ($) </div>
<div>shares </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($) </div>
<div>shares </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Dec. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of deferred financing costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,837,000<span></span>
</td>
<td class="nump">$ 6,079,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfSeniorDebt', window );">Repayments of senior debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98,420,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payments of debt issuance costs</a></td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost', window );">Net loss on extinguishment of debt, including fees paid to lenders</a></td>
<td class="nump">4,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 2021 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,000,000.0<span></span>
</td>
<td class="nump">$ 26,737,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,737,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,737,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from issuance of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount', window );">Repurchase covenant, repurchase price due to fundamental change as percentage of principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of deferred financing costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,000<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtAmount1', window );">Debt conversion, original debt, amount</a></td>
<td class="nump">84,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtAmount', window );">Face amount of debt repaid</a></td>
<td class="nump">14,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfSeniorDebt', window );">Repayments of senior debt</a></td>
<td class="nump">13,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 2021 Notes | Class A Common Stock | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Initial conversion rate per $ 1000 principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0416082<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments', window );">Initial conversion amount (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 2024 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="nump">$ 117,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">117,051,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">117,051,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 117,051,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="nump">3.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt issuance costs</a></td>
<td class="nump">$ 3,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount', window );">Repurchase covenant, repurchase price due to fundamental change as percentage of principal amount</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 18.23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments', window );">Initial conversion amount (in shares) | shares</a></td>
<td class="nump">6.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Debt conversion, converted instrument, amount</a></td>
<td class="nump">$ 84,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 2024 Notes | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from issuance of debt</a></td>
<td class="nump">38,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt issuance costs</a></td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 2024 Notes | Class A Common Stock | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Initial conversion rate per $ 1000 principal amount</a></td>
<td class="nump">0.0548667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Repurchase Price Due To Fundamental Change As Percentage Of Principal Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionOriginalDebtAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionOriginalDebtAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031898-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21521-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21506-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity instruments that the holder of the debt instrument would receive if the debt was converted to equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21521-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21506-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExtinguishmentOfDebtAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross amount of debt extinguished.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExtinguishmentOfDebtAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reflects the difference between the fair value of payments made to legally extinguish a debt and its carrying value at that time. This item excludes the write-off of amounts previously capitalized as debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12317-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12355-112629<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfSeniorDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a long-term debt where the holder has highest claim on the entity's asset in case of bankruptcy or liquidation during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfSeniorDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=evh_ConvertibleSeniorNotesdue2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=evh_ConvertibleSeniorNotesdue2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=evh_SeniorConvertibleNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=evh_SeniorConvertibleNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140179460100904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-term Debt - Convertible Senior Notes Carrying Value (Details) - Senior Notes - USD ($)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Aug. 31, 2020</div></th>
<th class="th"><div>Oct. 31, 2018</div></th>
<th class="th"><div>Oct. 24, 2018</div></th>
<th class="th"><div>Oct. 22, 2018</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">2024 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Carrying value</a></td>
<td class="nump">$ 85,320,000<span></span>
</td>
<td class="nump">$ 81,462,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Unamortized debt discount and issuance costs</a></td>
<td class="nump">31,731,000<span></span>
</td>
<td class="nump">35,589,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="nump">$ 117,051,000<span></span>
</td>
<td class="nump">$ 117,051,000<span></span>
</td>
<td class="nump">$ 117,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1', window );">Remaining amortization period (years)</a></td>
<td class="text">3 years 4 months 24 days<span></span>
</td>
<td class="text">3 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">2024 Notes | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Fair value</a></td>
<td class="nump">$ 132,054,000<span></span>
</td>
<td class="nump">$ 153,220,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">2025 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Carrying value</a></td>
<td class="nump">121,230,000<span></span>
</td>
<td class="nump">116,349,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Unamortized debt discount and issuance costs</a></td>
<td class="nump">51,270,000<span></span>
</td>
<td class="nump">56,151,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="nump">$ 172,500,000<span></span>
</td>
<td class="nump">$ 172,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 172,500,000<span></span>
</td>
<td class="nump">$ 22,500,000<span></span>
</td>
<td class="nump">$ 150,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1', window );">Remaining amortization period (years)</a></td>
<td class="text">4 years 3 months 18 days<span></span>
</td>
<td class="text">4 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">2025 Notes | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Fair value</a></td>
<td class="nump">$ 165,974,000<span></span>
</td>
<td class="nump">$ 147,488,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">2021 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Carrying value</a></td>
<td class="nump">26,655,000<span></span>
</td>
<td class="nump">26,557,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Unamortized debt discount and issuance costs</a></td>
<td class="nump">82,000<span></span>
</td>
<td class="nump">180,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="nump">$ 26,737,000<span></span>
</td>
<td class="nump">$ 26,737,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,000,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1', window );">Remaining amortization period (years)</a></td>
<td class="text">4 months 24 days<span></span>
</td>
<td class="text">10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">2021 Notes | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Fair value</a></td>
<td class="nump">$ 29,279,000<span></span>
</td>
<td class="nump">$ 26,470,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remaining amortization period for discount on the liability component of convertible debt which may be settled in cash upon conversion, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031898-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=evh_SeniorConvertibleNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=evh_SeniorConvertibleNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=evh_SeniorConvertibleNotesDue2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=evh_SeniorConvertibleNotesDue2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=evh_ConvertibleSeniorNotesdue2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=evh_ConvertibleSeniorNotesdue2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140179460495160">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems', window );"><strong>Restricted Cash and Cash Equivalents Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted funds</a></td>
<td class="nump">$ 31,137,000<span></span>
</td>
<td class="nump">$ 21,644,000<span></span>
</td>
<td class="nump">$ 55,653,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_TaxReceivablesAgreementPercentofTaxSavingstobePaid', window );">Percent of tax savings to be paid</a></td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=evh_UniversityHealthCaredbaPassportHealthPlanMember', window );">Passport | Variable Interest Entity, Not Primary Beneficiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems', window );"><strong>Restricted Cash and Cash Equivalents Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_PaymentsToAcquireEquityMethodInvestmentsAmountHeldBack', window );">Payments to acquire equity method investments, amount held back</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=evh_CollateralwithFinancialInstitutionsMember', window );">Collateral with financial institutions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems', window );"><strong>Restricted Cash and Cash Equivalents Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted funds</a></td>
<td class="nump">$ 12,352,000<span></span>
</td>
<td class="nump">4,743,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember', window );">Letter of Credit | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems', window );"><strong>Restricted Cash and Cash Equivalents Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="nump">15,000,000.0<span></span>
</td>
<td class="nump">7,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember', window );">Letter of Credit | Line of Credit | Restricted Cash For Letters Of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems', window );"><strong>Restricted Cash and Cash Equivalents Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted funds</a></td>
<td class="nump">15,000,000.0<span></span>
</td>
<td class="nump">7,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember', window );">Letter of Credit | Line of Credit | Collateral with financial institutions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems', window );"><strong>Restricted Cash and Cash Equivalents Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted funds</a></td>
<td class="nump">$ 15,000,000.0<span></span>
</td>
<td class="nump">$ 7,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_PaymentsToAcquireEquityMethodInvestmentsAmountHeldBack">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments To Acquire Equity Method Investments, Amount Held Back</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_PaymentsToAcquireEquityMethodInvestmentsAmountHeldBack</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_TaxReceivablesAgreementPercentofTaxSavingstobePaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax Receivables Agreement, Percent of Tax Savings to be Paid</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_TaxReceivablesAgreementPercentofTaxSavingstobePaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=evh_UniversityHealthCaredbaPassportHealthPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=evh_UniversityHealthCaredbaPassportHealthPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=evh_CollateralwithFinancialInstitutionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=evh_CollateralwithFinancialInstitutionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=evh_RestrictedCashForLettersOfCreditForLetterOfCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=evh_RestrictedCashForLettersOfCreditForLetterOfCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140179460295944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Reinsurance Agreements (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssumedPremiumsWritten', window );">Reinsurance premiums assumed</a></td>
<td class="nump">$ 17,576<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CededPremiumsWritten', window );">Reinsurance premiums ceded</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed', window );">Claims assumed</a></td>
<td class="nump">16,863<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded', window );">Claims ceded</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_PolicyholderBenefitsAndClaimsIncurredAssumedExpensesRelatedToClaims', window );">Claims-related administrative expenses</a></td>
<td class="nump">545<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_PremiumsWrittenAndPolicyholderBenefitsAndClaimsIncurredNet', window );">Increase in reserves for claims and performance-based arrangements attributable to the Reinsurance Agreement</a></td>
<td class="nump">168<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense', window );">Reserves for claims and performance-based arrangements attributable to the Reinsurance Agreement at the beginning of the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,002<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseImpactOfConsolidationOnPayables', window );">Impact of consolidation on payable for claims and performance-based arrangements attributable to the Reinsurance Agreement</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForReinsurance', window );">Reinsurance payments paid (received)</a></td>
<td class="nump">7,506<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_ProceedsFromReinsurance', window );">Reinsurance payments paid (received)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReinsuranceRecoverablesOnPaidAndUnpaidLosses', window );">Receivable for claims and performance-based arrangements attributable to the Reinsurance Agreement at the end of the period</a></td>
<td class="num">$ (3,336)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseImpactOfConsolidationOnPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Assumed Liability For Unpaid Claims And Claims Adjustment Expense, Impact Of Consolidation On Payables</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseImpactOfConsolidationOnPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_PolicyholderBenefitsAndClaimsIncurredAssumedExpensesRelatedToClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Policyholder Benefits And Claims Incurred, Assumed, Expenses Related To Claims</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_PolicyholderBenefitsAndClaimsIncurredAssumedExpensesRelatedToClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_PremiumsWrittenAndPolicyholderBenefitsAndClaimsIncurredNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Premiums Written And Policyholder Benefits And Claims Incurred, Net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_PremiumsWrittenAndPolicyholderBenefitsAndClaimsIncurredNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_ProceedsFromReinsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Reinsurance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_ProceedsFromReinsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liability as of the balance sheet date for the estimated ultimate cost of settling claims and claim adjustment expense relating to insured events that have occurred on or before the balance sheet date for those liabilities owed to another party as a result of assuming another insurer's primary obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (cc)<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssumedPremiumsWritten">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of written premiums assumed from other entities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 605<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6486672&amp;loc=d3e27261-158547<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssumedPremiumsWritten</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CededPremiumsWritten">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of written premiums ceded to other entities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 605<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6486672&amp;loc=d3e27261-158547<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 605<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6486672&amp;loc=d3e27261-158547<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CededPremiumsWritten</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForReinsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash payments made for reinsurance during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForReinsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of policy benefits and costs incurred for policies assumed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=99397103&amp;loc=d3e6811-158387<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of reduction of provision for policy benefits and costs incurred for policies ceded.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=99397103&amp;loc=d3e6811-158387<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReinsuranceRecoverablesOnPaidAndUnpaidLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after valuation allowance, recoverable under reinsurance contracts. Examples include, but are not limited to, settled and unsettled claims, incurred but not reported losses, loss adjustment expense, policy benefits and policy reserves. Excludes premiums paid under reinsurance contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 310<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=99404803&amp;loc=d3e21412-158489<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 310<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=99404803&amp;loc=d3e21409-158489<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=99397103&amp;loc=d3e6824-158387<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123600520&amp;loc=SL75241803-196195<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReinsuranceRecoverablesOnPaidAndUnpaidLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140179460106312">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Concentration Risk (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_CashFDICInsuredAmountPercentage', window );">Percentage of cash and cash equivalents held with FDIC participating bank</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">99.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents (including restricted cash)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 238,410<span></span>
</td>
<td class="nump">$ 153,210<span></span>
</td>
<td class="nump">$ 238,410<span></span>
</td>
<td class="nump">$ 153,210<span></span>
</td>
<td class="nump">$ 361,581<span></span>
</td>
<td class="nump">$ 128,531<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_CashHeldInInternationalBanksPercentage', window );">Percentage of cash held in international banks (less than)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember', window );">Discontinued Operations, Disposed of by Sale | True Health</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue', window );">Revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">25,541<span></span>
</td>
<td class="nump">$ 44,833<span></span>
</td>
<td class="nump">57,928<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=evh_PremiumsRevenueMember', window );">Premiums | Discontinued Operations, Disposed of by Sale | True Health</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue', window );">Revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 25,502<span></span>
</td>
<td class="nump">$ 44,795<span></span>
</td>
<td class="nump">$ 57,649<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=evh_CookCountyHealthAndHospitalsSystemMember', window );">Cook County Health and Hospitals System | Customer Concentration Risk | Accounts Receivable | Customer Receivable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=evh_CookCountyHealthAndHospitalsSystemMember', window );">Cook County Health and Hospitals System | Customer Concentration Risk | Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">29.60%<span></span>
</td>
<td class="nump">21.80%<span></span>
</td>
<td class="nump">29.20%<span></span>
</td>
<td class="nump">21.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=evh_FloridaBlueMedicareIncMember', window );">Florida Blue Medicare, Inc. | Customer Concentration Risk | Accounts Receivable | Customer Receivable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=evh_FloridaBlueMedicareIncMember', window );">Florida Blue Medicare, Inc. | Customer Concentration Risk | Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">14.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=evh_NeighborhoodHealthPlanOfRhodeIslandMember', window );">Neighborhood Health Plan Of Rhode Island [Member] | Customer Concentration Risk | Accounts Receivable | Customer Receivable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=evh_UniversityHealthCaredbaPassportHealthPlanMember', window );">Passport | Customer Concentration Risk | Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="7"></td></tr>
<tr><td colspan="7"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">As a result of the closing of the sale of True Health SPA, the consolidated statements of operations, consolidated balance sheets, and related financial information reflect the Company&#8217;s operations and assets and liabilities of True Health as discontinued operations for all periods presented. Cash flows and comprehensive income have not been adjusted and are included in the consolidated statements of cash flows and consolidated statements of comprehensive income (loss) for all periods presented. See Note 5.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_CashFDICInsuredAmountPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, FDIC Insured Amount, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_CashFDICInsuredAmountPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_CashHeldInInternationalBanksPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, Held In International Banks, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_CashHeldInInternationalBanksPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=evh_TrueHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=evh_TrueHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=evh_PremiumsRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=evh_PremiumsRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=evh_CookCountyHealthAndHospitalsSystemMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=evh_CookCountyHealthAndHospitalsSystemMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_FinanceReceivablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_FinanceReceivablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=evh_FloridaBlueMedicareIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=evh_FloridaBlueMedicareIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=evh_NeighborhoodHealthPlanOfRhodeIslandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=evh_NeighborhoodHealthPlanOfRhodeIslandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=evh_UniversityHealthCaredbaPassportHealthPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=evh_UniversityHealthCaredbaPassportHealthPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140179452341272">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted funds</a></td>
<td class="nump">$ 31,137<span></span>
</td>
<td class="nump">$ 21,644<span></span>
</td>
<td class="nump">$ 55,653<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAxis=us-gaap_LeaseAgreementsMember', window );">Lease Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Letters of credit outstanding, amount</a></td>
<td class="nump">3,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted funds</a></td>
<td class="nump">$ 3,500<span></span>
</td>
<td class="nump">$ 3,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LettersOfCreditOutstandingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LettersOfCreditOutstandingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=us-gaap_LeaseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=us-gaap_LeaseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140179563841688">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Material Office Leases (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Future Minimum Lease Commitments</a></td>
<td class="nump">$ 88,615<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_VA', window );">Arlington, VA</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease Termination Term (in years)</a></td>
<td class="text">10 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Future Minimum Lease Commitments</a></td>
<td class="nump">$ 37,147<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Letter of Credit Amount Required</a></td>
<td class="nump">$ 1,579<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_IL', window );">Riverside, IL</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease Termination Term (in years)</a></td>
<td class="text">9 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Future Minimum Lease Commitments</a></td>
<td class="nump">$ 42,956<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Letter of Credit Amount Required</a></td>
<td class="nump">$ 232<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_IN', window );">Pune, India</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease Termination Term (in years)</a></td>
<td class="text">2 years 3 months 18 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Future Minimum Lease Commitments</a></td>
<td class="nump">$ 1,835<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Letter of Credit Amount Required</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_CA', window );">Brea, CA</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease Termination Term (in years)</a></td>
<td class="text">10 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Future Minimum Lease Commitments</a></td>
<td class="nump">$ 1,015<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Letter of Credit Amount Required</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LettersOfCreditOutstandingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LettersOfCreditOutstandingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_VA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_VA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_IL">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_IL</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_IN">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_IN</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140179454135736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Components of Lease Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 2,437<span></span>
</td>
<td class="nump">$ 3,586<span></span>
</td>
<td class="nump">$ 7,255<span></span>
</td>
<td class="nump">$ 6,642<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Amortization of right-of-use assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">150<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">299<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestExpense', window );">Interest expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease cost</a></td>
<td class="nump">1,192<span></span>
</td>
<td class="nump">1,465<span></span>
</td>
<td class="nump">2,513<span></span>
</td>
<td class="nump">2,517<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease cost</a></td>
<td class="nump">$ 3,629<span></span>
</td>
<td class="nump">$ 5,202<span></span>
</td>
<td class="nump">$ 9,768<span></span>
</td>
<td class="nump">$ 9,461<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140179540905288">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Maturity of Lease Liabilities (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear', window );">2021</a></td>
<td class="nump">$ 5,854<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2022</a></td>
<td class="nump">9,832<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2023</a></td>
<td class="nump">8,645<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2024</a></td>
<td class="nump">8,378<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2025</a></td>
<td class="nump">8,145<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFive', window );">Thereafter</a></td>
<td class="nump">47,761<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">88,615<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesGrossDifferenceAmountAbstract', window );"><strong>Less:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Interest</a></td>
<td class="nump">22,732<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">$ 65,883<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, To Be Paid, After Year Five</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesGrossDifferenceAmountAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesGrossDifferenceAmountAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of purchase arrangement to be paid in remainder of current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140179452439336">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Weighted-average Discount Rate and Weighted-remaining Lease Terms (Details)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate</a></td>
<td class="nump">6.43%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term</a></td>
<td class="text">9 years 2 months 12 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140179457134584">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Earnings (Loss) Per Common Share - Computation of Earnings per Share (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">Income (loss) from continuing operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (9,107)<span></span>
</td>
<td class="num">$ (202,013)<span></span>
</td>
<td class="num">$ (20,297)<span></span>
</td>
<td class="num">$ (280,500)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Income (loss) from discontinued operations, net of tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,508)<span></span>
</td>
<td class="nump">1,383<span></span>
</td>
<td class="num">(1,773)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(9,107)<span></span>
</td>
<td class="num">(203,521)<span></span>
</td>
<td class="num">(18,914)<span></span>
</td>
<td class="num">(282,273)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_EarningsLossAvailabletoCommonShareholdersAbstract', window );"><strong>Less:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss attributable to non-controlling interests</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common shareholders of Evolent Health, Inc.</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(9,107)<span></span>
</td>
<td class="num">(203,521)<span></span>
</td>
<td class="num">(18,914)<span></span>
</td>
<td class="num">(282,273)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net loss attributable to common shareholders of Evolent Health, Inc.</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (9,107)<span></span>
</td>
<td class="num">$ (203,521)<span></span>
</td>
<td class="num">$ (18,914)<span></span>
</td>
<td class="num">$ (282,273)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares outstanding - basic (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">85,448<span></span>
</td>
<td class="nump">85,349<span></span>
</td>
<td class="nump">85,056<span></span>
</td>
<td class="nump">84,977<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common shares outstanding - diluted (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">85,448<span></span>
</td>
<td class="nump">85,349<span></span>
</td>
<td class="nump">85,056<span></span>
</td>
<td class="nump">84,977<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract', window );"><strong>Loss per common share, Basic and diluted</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare', window );">Continuing operations, basic (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (0.11)<span></span>
</td>
<td class="num">$ (2.37)<span></span>
</td>
<td class="num">$ (0.24)<span></span>
</td>
<td class="num">$ (3.30)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare', window );">Continuing operations, diluted (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(0.11)<span></span>
</td>
<td class="num">(2.37)<span></span>
</td>
<td class="num">(0.24)<span></span>
</td>
<td class="num">(3.30)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare', window );">Discontinued operations, diluted (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="num">(0.01)<span></span>
</td>
<td class="nump">0.02<span></span>
</td>
<td class="num">(0.02)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare', window );">Discontinued operations, basic (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="num">(0.01)<span></span>
</td>
<td class="nump">0.02<span></span>
</td>
<td class="num">(0.02)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted loss per share attributable to common shareholders of Evolent Health, Inc. (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(0.11)<span></span>
</td>
<td class="num">(2.38)<span></span>
</td>
<td class="num">(0.22)<span></span>
</td>
<td class="num">(3.32)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic loss per share attributable to common shareholders of Evolent Health, Inc. (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (0.11)<span></span>
</td>
<td class="num">$ (2.38)<span></span>
</td>
<td class="num">$ (0.22)<span></span>
</td>
<td class="num">$ (3.32)<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Includes $1.9&#160;million gain on disposal of discontinued operations for the six months ended June 30, 2021</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_EarningsLossAvailabletoCommonShareholdersAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Earnings (Loss) Available to Common Shareholders [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_EarningsLossAvailabletoCommonShareholdersAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868656-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868656-224227<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109227538&amp;loc=d3e44648-109337<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1278-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 5.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398118&amp;loc=d3e355146-122828<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1278-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1930-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1930-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1930-109256<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1930-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140179461295176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings (Loss) Per Common Share - Antidilutive Securities (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Number of antidilutive securities excluded from the calculation of earning per share (in shares)</a></td>
<td class="nump">16,549<span></span>
</td>
<td class="nump">11,626<span></span>
</td>
<td class="nump">16,322<span></span>
</td>
<td class="nump">11,578<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=evh_RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember', window );">Restricted stock units ("RSUs"), performance-based RSUs and leveraged stock units ("LSUs")</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Number of antidilutive securities excluded from the calculation of earning per share (in shares)</a></td>
<td class="nump">2,052<span></span>
</td>
<td class="nump">554<span></span>
</td>
<td class="nump">1,793<span></span>
</td>
<td class="nump">376<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Number of antidilutive securities excluded from the calculation of earning per share (in shares)</a></td>
<td class="nump">1,801<span></span>
</td>
<td class="nump">711<span></span>
</td>
<td class="nump">1,833<span></span>
</td>
<td class="nump">841<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtMember', window );">Convertible senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Number of antidilutive securities excluded from the calculation of earning per share (in shares)</a></td>
<td class="nump">12,696<span></span>
</td>
<td class="nump">10,361<span></span>
</td>
<td class="nump">12,696<span></span>
</td>
<td class="nump">10,361<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=evh_RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=evh_RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140179460450872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Stock-based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 3,653<span></span>
</td>
<td class="nump">$ 3,703<span></span>
</td>
<td class="nump">$ 7,359<span></span>
</td>
<td class="nump">$ 7,211<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">892<span></span>
</td>
<td class="nump">526<span></span>
</td>
<td class="nump">1,487<span></span>
</td>
<td class="nump">918<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">2,761<span></span>
</td>
<td class="nump">3,177<span></span>
</td>
<td class="nump">5,872<span></span>
</td>
<td class="nump">6,293<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">267<span></span>
</td>
<td class="nump">638<span></span>
</td>
<td class="nump">671<span></span>
</td>
<td class="nump">1,388<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance-based stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">75<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">2,427<span></span>
</td>
<td class="nump">2,006<span></span>
</td>
<td class="nump">4,401<span></span>
</td>
<td class="nump">3,862<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=evh_LeveragedStockUnitsLSUsMember', window );">LSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">222<span></span>
</td>
<td class="nump">1,059<span></span>
</td>
<td class="nump">1,307<span></span>
</td>
<td class="nump">1,886<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=evh_PerformanceBasedRestrictedStockUnitsPBRSUsMember', window );">PSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 737<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 980<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=evh_LeveragedStockUnitsLSUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=evh_LeveragedStockUnitsLSUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=evh_PerformanceBasedRestrictedStockUnitsPBRSUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=evh_PerformanceBasedRestrictedStockUnitsPBRSUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140179453613768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount', window );">Stock-based compensation capitalized as software development costs</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost capitalized for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140179460798584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Schedule of Share-based Awards Granted (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">89,000<span></span>
</td>
<td class="nump">164,000<span></span>
</td>
<td class="nump">1,028,000<span></span>
</td>
<td class="nump">1,140,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=evh_PerformanceBasedRestrictedStockUnitsPBRSUsMember', window );">PSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">319,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=evh_LeveragedStockUnitsLSUsMember', window );">LSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">140,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">520,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=evh_PerformanceBasedRestrictedStockUnitsPBRSUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=evh_PerformanceBasedRestrictedStockUnitsPBRSUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=evh_LeveragedStockUnitsLSUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=evh_LeveragedStockUnitsLSUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R90.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140179453546472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision (benefit) for income taxes</a></td>
<td class="nump">$ 91<span></span>
</td>
<td class="num">$ (3,904)<span></span>
</td>
<td class="nump">$ 702<span></span>
</td>
<td class="num">$ (3,634)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective rate</a></td>
<td class="num">(1.00%)<span></span>
</td>
<td class="nump">1.90%<span></span>
</td>
<td class="num">(3.60%)<span></span>
</td>
<td class="nump">1.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_TaxReceivableAgreementPercentofCashSavingsPaidtoShareholders', window );">Tax receivable agreement, percent of cash savings paid to shareholders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_TaxReceivableAgreementPercentofCashSavingsPaidtoShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax Receivable Agreement, Percent of Cash Savings Paid to Shareholders</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_TaxReceivableAgreementPercentofCashSavingsPaidtoShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R91.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140179460707176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments In and Advances to Equity Method Investees - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">(Gain) loss from equity method investees</a></td>
<td class="num">$ (4,879)<span></span>
</td>
<td class="num">$ (25,143)<span></span>
</td>
<td class="num">$ (12,662)<span></span>
</td>
<td class="num">$ (24,731)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_EquityMethodInvesteeMember', window );">Equity Method Investee | Services Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_IncomeLossfromEquityMethodInvestmentsServicesAgreement', window );">Income from long-term services agreement</a></td>
<td class="nump">$ 2,300<span></span>
</td>
<td class="nump">$ 71,400<span></span>
</td>
<td class="nump">$ 8,600<span></span>
</td>
<td class="nump">$ 131,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_EquityMethodInvestmentEconomicInterestPercentage', window );">Economic interest percentage</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_EquityMethodInvestmentVotingInterestPercentage', window );">Voting interest percentage</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_EquityMethodInvestmentEconomicInterestPercentage', window );">Economic interest percentage</a></td>
<td class="nump">39.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_EquityMethodInvestmentVotingInterestPercentage', window );">Voting interest percentage</a></td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_EquityMethodInvestmentEconomicInterestPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Economic Interest Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_EquityMethodInvestmentEconomicInterestPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_EquityMethodInvestmentVotingInterestPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Voting Interest Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_EquityMethodInvestmentVotingInterestPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_IncomeLossfromEquityMethodInvestmentsServicesAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income (Loss) from Equity Method Investments, Services Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_IncomeLossfromEquityMethodInvestmentsServicesAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEquityMethodInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_EquityMethodInvesteeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_EquityMethodInvesteeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=evh_ServicesAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=evh_ServicesAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R92.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140179461259704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Non-controlling Interests (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 16, 2020</div></th>
<th class="th"><div>Sep. 01, 2020</div></th>
<th class="th"><div>May 28, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>May 31, 2015</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=evh_UniversityHealthCaredbaPassportHealthPlanMember', window );">Passport | Variable Interest Entity, Not Primary Beneficiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination', window );">Noncontrolling interest, increase from business combination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityOwnershipPercentage', window );">Interest in investment</a></td>
<td class="nump">30.00%<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_VariableInterestEntityNewMedicaidContractNotAwardedRequirementToAcquireOwnershipConsiderationAmount', window );">Requirement to acquire ownership, consideration, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityInitialConsolidationGainOrLoss', window );">Gain on consolidation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_NoncontrollingInterestMember', window );">Non-Controlling Interests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInMinorityInterestRollForward', window );"><strong>Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Non-controlling interests balance as of beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,889<span></span>
</td>
<td class="nump">$ 6,889<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance', window );">Reclassification of non-controlling interests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,889)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Non-controlling interests balance as of end of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=evh_EvolentHealthLLCMember', window );">Evolent Health LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Parent's ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70.30%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_VariableInterestEntityNewMedicaidContractNotAwardedRequirementToAcquireOwnershipConsiderationAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Variable Interest Entity, New Medicaid Contract Not Awarded, Requirement To Acquire Ownership, Consideration, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_VariableInterestEntityNewMedicaidContractNotAwardedRequirementToAcquireOwnershipConsiderationAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The parent entity's interest in net assets of the subsidiary, expressed as a percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MovementInMinorityInterestRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MovementInMinorityInterestRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in noncontrolling interest from a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in noncontrolling interest from subsidiary issuance of equity interests to noncontrolling interest holders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569655-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityInitialConsolidationGainOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gain (loss) recognized on initial consolidation of a variable interest entity (VIE) when the VIE is not a business (as defined).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityInitialConsolidationGainOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the Variable Interest Entity's (VIE) voting interest owned by (or beneficial interest in) the reporting entity (directly or indirectly).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=SL6759159-111685<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=evh_UniversityHealthCaredbaPassportHealthPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=evh_UniversityHealthCaredbaPassportHealthPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_NoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_NoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=evh_EvolentHealthLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=evh_EvolentHealthLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R93.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140179456622520">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurement - Assets and Liabilities on Recurring Basis (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants and rights outstanding (in shares) | shares</a></td>
<td class="nump">1,513,786<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 5,877<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total fair value of assets measured on a recurring basis</a></td>
<td class="nump">5,877<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesFairValueDisclosure', window );">Warrants</a></td>
<td class="nump">13,730<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total fair value of liabilities measured on a recurring basis</a></td>
<td class="nump">13,730<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">5,877<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total fair value of assets measured on a recurring basis</a></td>
<td class="nump">5,877<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesFairValueDisclosure', window );">Warrants</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total fair value of liabilities measured on a recurring basis</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total fair value of assets measured on a recurring basis</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesFairValueDisclosure', window );">Warrants</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total fair value of liabilities measured on a recurring basis</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total fair value of assets measured on a recurring basis</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesFairValueDisclosure', window );">Warrants</a></td>
<td class="nump">13,730<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total fair value of liabilities measured on a recurring basis</a></td>
<td class="nump">$ 13,730<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of other liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R94.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140179452310632">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurement - Additional Information (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 30, 2019 </div>
<div>shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_CommonClassAMember', window );">Class A Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightUnissued', window );">Warrants agreed to be sold (in shares)</a></td>
<td class="nump">1,513,786<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightUnissued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of warrants or rights which entitle the entity to receive future services in exchange for the unvested, forfeitable warrants or rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightUnissued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R95.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140179452414616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurement - Changes in Contingent Consideration and Other (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance as of beginning of period</a></td>
<td class="nump">$ 13,730<span></span>
</td>
<td class="nump">$ 16,975<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Settlements</a></td>
<td class="num">(13,730)<span></span>
</td>
<td class="num">(3,500)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Realized and unrealized gains (losses), net</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(4,975)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance as of end of period</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 8,500<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R96.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140179459593272">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurement - Valuation Techniques and Significant Unobservable Inputs (Details) - Fair Value, Recurring<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesFairValueDisclosure', window );">Fair Value</a></td>
<td class="nump">$ 13,730<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesFairValueDisclosure', window );">Fair Value</a></td>
<td class="nump">13,730<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | Warrants | Black-Scholes</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesFairValueDisclosure', window );">Fair Value</a></td>
<td class="nump">$ 13,730<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | Warrants | Black-Scholes | Stock price volatility</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Assumption or Input Ranges</a></td>
<td class="nump">0.622<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | Warrants | Black-Scholes | Annual risk free rate</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Assumption or Input Ranges</a></td>
<td class="nump">0.002<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of other liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationTechniqueAxis=evh_BlackScholesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationTechniqueAxis=evh_BlackScholesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R97.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140179461462488">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Related Parties - Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>ASSETS</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 242,505<span></span>
</td>
<td class="nump">$ 124,064<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">38,032<span></span>
</td>
<td class="nump">56,295<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent', window );">Prepaid expenses and other noncurrent assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">6,311<span></span>
</td>
<td class="nump">5,773<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">39,879<span></span>
</td>
<td class="nump">31,975<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">52,339<span></span>
</td>
<td class="nump">73,242<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember', window );">Affiliated Entity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>ASSETS</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,450<span></span>
</td>
<td class="nump">9,474<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">17<span></span>
</td>
<td class="nump">51<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent', window );">Prepaid expenses and other noncurrent assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,688<span></span>
</td>
<td class="nump">4,554<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,923<span></span>
</td>
<td class="nump">2,509<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,220<span></span>
</td>
<td class="nump">1,520<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense', window );">Reserve for claims and performance-based arrangements</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 149<span></span>
</td>
<td class="nump">$ 435<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">See Note 19 for amounts attributable to unconsolidated related parties included in these line items.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of policy reserves (provided for future obligations including unpaid claims and claims adjustment expenses) and policy benefits (liability for future policy benefits) as of the balance sheet date; grouped amount of all the liabilities associated with the company's insurance policies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(13)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (cc)<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R98.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140179540035864">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Related Parties - Revenues and Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 222,057<span></span>
</td>
<td class="nump">$ 217,299<span></span>
</td>
<td class="nump">$ 437,128<span></span>
</td>
<td class="nump">$ 438,531<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Expenses</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_CostofGoodsandServicesSoldExcludingDepreciationandAmortization', window );">Cost of revenue (exclusive of depreciation and amortization expenses)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">172,113<span></span>
</td>
<td class="nump">164,358<span></span>
</td>
<td class="nump">329,945<span></span>
</td>
<td class="nump">339,987<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">42,699<span></span>
</td>
<td class="nump">47,296<span></span>
</td>
<td class="nump">101,290<span></span>
</td>
<td class="nump">99,383<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember', window );">Affiliated Entity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Expenses</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_CostofGoodsandServicesSoldExcludingDepreciationandAmortization', window );">Cost of revenue (exclusive of depreciation and amortization expenses)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">606<span></span>
</td>
<td class="num">(2,171)<span></span>
</td>
<td class="nump">1,099<span></span>
</td>
<td class="nump">1,076<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">81<span></span>
</td>
<td class="nump">27<span></span>
</td>
<td class="nump">112<span></span>
</td>
<td class="nump">97<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=evh_TransformationServicesMember', window );">Transformation services</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">2,564<span></span>
</td>
<td class="nump">755<span></span>
</td>
<td class="nump">2,909<span></span>
</td>
<td class="nump">5,993<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=evh_TransformationServicesMember', window );">Transformation services | Affiliated Entity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=evh_PlatformsAndOperationsServicesMember', window );">Platform and operations services</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">219,493<span></span>
</td>
<td class="nump">216,544<span></span>
</td>
<td class="nump">434,219<span></span>
</td>
<td class="nump">432,538<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=evh_PlatformsAndOperationsServicesMember', window );">Platform and operations services | Affiliated Entity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 10,368<span></span>
</td>
<td class="nump">$ 73,885<span></span>
</td>
<td class="nump">$ 25,943<span></span>
</td>
<td class="nump">$ 141,833<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">See Note 19 for amounts attributable to unconsolidated related parties included in these line items.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_CostofGoodsandServicesSoldExcludingDepreciationandAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cost of Goods and Services Sold, Excluding Depreciation and Amortization</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_CostofGoodsandServicesSoldExcludingDepreciationandAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=evh_TransformationServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=evh_TransformationServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=evh_PlatformsAndOperationsServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=evh_PlatformsAndOperationsServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R99.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140179464997400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Repositioning and Other Changes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Repositioning costs incurred</a></td>
<td class="nump">$ 663<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 6,043<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostExpectedCost1', window );">Total Amount Expected to be Incurred in the Repositioning Plan</a></td>
<td class="nump">7,418<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,418<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1', window );">Cumulative Amount Incurred through June 30, 2021</a></td>
<td class="nump">7,318<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,318<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=evh_EmployeeSeveranceAndTerminationBenefitsMember', window );">Severance and termination benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Repositioning costs incurred</a></td>
<td class="nump">76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostExpectedCost1', window );">Total Amount Expected to be Incurred in the Repositioning Plan</a></td>
<td class="nump">185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1', window );">Cumulative Amount Incurred through June 30, 2021</a></td>
<td class="nump">185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_FacilityClosingMember', window );">Office space consolidation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Repositioning costs incurred</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,071<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostExpectedCost1', window );">Total Amount Expected to be Incurred in the Repositioning Plan</a></td>
<td class="nump">2,071<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,071<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1', window );">Cumulative Amount Incurred through June 30, 2021</a></td>
<td class="nump">2,071<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,071<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=evh_ProfessionalServicesRestructuringMember', window );">Professional services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Repositioning costs incurred</a></td>
<td class="nump">587<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,787<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostExpectedCost1', window );">Total Amount Expected to be Incurred in the Repositioning Plan</a></td>
<td class="nump">5,162<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,162<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1', window );">Cumulative Amount Incurred through June 30, 2021</a></td>
<td class="nump">$ 5,062<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,062<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of costs incurred to date for the specified restructuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostCostIncurredToDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostExpectedCost1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount expected to be recognized in earnings for the specified restructuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostExpectedCost1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109237686&amp;loc=d3e17752-110868<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=evh_EmployeeSeveranceAndTerminationBenefitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=evh_EmployeeSeveranceAndTerminationBenefitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_FacilityClosingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_FacilityClosingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=evh_ProfessionalServicesRestructuringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=evh_ProfessionalServicesRestructuringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R100.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140179453677368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2021 </div>
<div>segment</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments</a></td>
<td class="nump">2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R101.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140179458596808">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting - Revenue from Segments to Consolidated (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems', window );"><strong>Segment Reporting, Revenue Reconciling Item [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 222,057<span></span>
</td>
<td class="nump">$ 217,299<span></span>
</td>
<td class="nump">$ 437,128<span></span>
</td>
<td class="nump">$ 438,531<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization', window );">Adjusted EBITDA</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">13,346<span></span>
</td>
<td class="nump">10,519<span></span>
</td>
<td class="nump">28,253<span></span>
</td>
<td class="nump">14,395<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=evh_EvolentHealthServicesSegmentMember', window );">Evolent Health Services</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems', window );"><strong>Segment Reporting, Revenue Reconciling Item [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">75,323<span></span>
</td>
<td class="nump">87,187<span></span>
</td>
<td class="nump">160,609<span></span>
</td>
<td class="nump">184,215<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization', window );">Adjusted EBITDA</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,531<span></span>
</td>
<td class="nump">6,948<span></span>
</td>
<td class="nump">12,473<span></span>
</td>
<td class="nump">11,716<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=evh_ClinicalSolutionsSegmentMember', window );">Clinical Solutions</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems', window );"><strong>Segment Reporting, Revenue Reconciling Item [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">147,194<span></span>
</td>
<td class="nump">130,780<span></span>
</td>
<td class="nump">277,417<span></span>
</td>
<td class="nump">255,652<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization', window );">Adjusted EBITDA</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">13,597<span></span>
</td>
<td class="nump">12,200<span></span>
</td>
<td class="nump">29,573<span></span>
</td>
<td class="nump">19,243<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_IntersegmentEliminationMember', window );">Intersegment Eliminations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems', window );"><strong>Segment Reporting, Revenue Reconciling Item [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(460)<span></span>
</td>
<td class="num">(668)<span></span>
</td>
<td class="num">(898)<span></span>
</td>
<td class="num">(1,336)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems', window );"><strong>Segment Reporting, Revenue Reconciling Item [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">222,057<span></span>
</td>
<td class="nump">217,299<span></span>
</td>
<td class="nump">437,128<span></span>
</td>
<td class="nump">438,531<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization', window );">Adjusted EBITDA</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">20,128<span></span>
</td>
<td class="nump">19,148<span></span>
</td>
<td class="nump">42,046<span></span>
</td>
<td class="nump">30,959<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember', window );">Corporate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems', window );"><strong>Segment Reporting, Revenue Reconciling Item [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization', window );">Adjusted EBITDA</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(6,782)<span></span>
</td>
<td class="num">(8,629)<span></span>
</td>
<td class="num">(13,793)<span></span>
</td>
<td class="num">(16,564)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=evh_TransformationServicesMember', window );">Transformation services</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems', window );"><strong>Segment Reporting, Revenue Reconciling Item [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">2,564<span></span>
</td>
<td class="nump">755<span></span>
</td>
<td class="nump">2,909<span></span>
</td>
<td class="nump">5,993<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=evh_TransformationServicesMember', window );">Transformation services | Evolent Health Services</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems', window );"><strong>Segment Reporting, Revenue Reconciling Item [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,564<span></span>
</td>
<td class="nump">755<span></span>
</td>
<td class="nump">2,909<span></span>
</td>
<td class="nump">5,993<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=evh_TransformationServicesMember', window );">Transformation services | Clinical Solutions</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems', window );"><strong>Segment Reporting, Revenue Reconciling Item [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=evh_TransformationServicesMember', window );">Transformation services | Intersegment Eliminations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems', window );"><strong>Segment Reporting, Revenue Reconciling Item [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=evh_TransformationServicesMember', window );">Transformation services | Operating Segments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems', window );"><strong>Segment Reporting, Revenue Reconciling Item [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,564<span></span>
</td>
<td class="nump">755<span></span>
</td>
<td class="nump">2,909<span></span>
</td>
<td class="nump">5,993<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=evh_TransformationServicesMember', window );">Transformation services | Corporate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems', window );"><strong>Segment Reporting, Revenue Reconciling Item [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=evh_PlatformsAndOperationsServicesMember', window );">Platform and operations services</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems', window );"><strong>Segment Reporting, Revenue Reconciling Item [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">219,493<span></span>
</td>
<td class="nump">216,544<span></span>
</td>
<td class="nump">434,219<span></span>
</td>
<td class="nump">432,538<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=evh_PlatformsAndOperationsServicesMember', window );">Platform and operations services | Evolent Health Services</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems', window );"><strong>Segment Reporting, Revenue Reconciling Item [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">72,759<span></span>
</td>
<td class="nump">86,432<span></span>
</td>
<td class="nump">157,700<span></span>
</td>
<td class="nump">178,222<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=evh_PlatformsAndOperationsServicesMember', window );">Platform and operations services | Clinical Solutions</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems', window );"><strong>Segment Reporting, Revenue Reconciling Item [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">147,194<span></span>
</td>
<td class="nump">130,780<span></span>
</td>
<td class="nump">277,417<span></span>
</td>
<td class="nump">255,652<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=evh_PlatformsAndOperationsServicesMember', window );">Platform and operations services | Intersegment Eliminations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems', window );"><strong>Segment Reporting, Revenue Reconciling Item [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(460)<span></span>
</td>
<td class="num">(668)<span></span>
</td>
<td class="num">(898)<span></span>
</td>
<td class="num">(1,336)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=evh_PlatformsAndOperationsServicesMember', window );">Platform and operations services | Operating Segments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems', window );"><strong>Segment Reporting, Revenue Reconciling Item [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">219,493<span></span>
</td>
<td class="nump">216,544<span></span>
</td>
<td class="nump">434,219<span></span>
</td>
<td class="nump">432,538<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=evh_PlatformsAndOperationsServicesMember', window );">Platform and operations services | Corporate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems', window );"><strong>Segment Reporting, Revenue Reconciling Item [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">See Note 19 for amounts attributable to unconsolidated related parties included in these line items.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjusted Earnings Before Interest, Taxes, Depreciation And Amortization</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingRevenueReconcilingItemLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=evh_EvolentHealthServicesSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=evh_EvolentHealthServicesSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=evh_ClinicalSolutionsSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=evh_ClinicalSolutionsSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_IntersegmentEliminationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_IntersegmentEliminationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=evh_TransformationServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=evh_TransformationServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=evh_PlatformsAndOperationsServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=evh_PlatformsAndOperationsServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R102.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140179460215832">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting - Reconciliation of Adjusted EBITDA (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common shareholders of Evolent Health, Inc. - Basic</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (9,107,000)<span></span>
</td>
<td class="num">$ (203,521,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (18,914,000)<span></span>
</td>
<td class="num">$ (282,273,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net loss attributable to common shareholders of Evolent Health, Inc. - Diluted</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(9,107,000)<span></span>
</td>
<td class="num">(203,521,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(18,914,000)<span></span>
</td>
<td class="num">(282,273,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">68,000<span></span>
</td>
<td class="nump">705,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">191,000<span></span>
</td>
<td class="nump">1,475,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(6,274,000)<span></span>
</td>
<td class="num">(6,290,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12,611,000)<span></span>
</td>
<td class="num">(12,571,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">(Provision) benefit for income taxes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(91,000)<span></span>
</td>
<td class="nump">3,904,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(702,000)<span></span>
</td>
<td class="nump">3,634,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(14,916,000)<span></span>
</td>
<td class="num">(15,618,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(30,103,000)<span></span>
</td>
<td class="num">(31,596,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment', window );">Equity method investment impairment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(47,133,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_GainOnTransferOfMembership', window );">Gain on transfer of membership</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,969,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on repayment of debt, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(19,158,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="num">(215,100,000)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (199,800,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(215,100,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Gain from equity method investees</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,879,000<span></span>
</td>
<td class="nump">25,143,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,662,000<span></span>
</td>
<td class="nump">24,731,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Loss on disposal of assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(6,447,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in fair value of contingent consideration and indemnification asset</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="num">(756,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">594,000<span></span>
</td>
<td class="nump">3,062,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expense, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(18,000)<span></span>
</td>
<td class="nump">354,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(32,000)<span></span>
</td>
<td class="nump">284,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Repositioning costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(663,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,043,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_SharebasedCompensationIncludingOnetimeAdjustment', window );">Stock-based compensation expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(3,653,000)<span></span>
</td>
<td class="num">(3,703,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,359,000)<span></span>
</td>
<td class="num">(7,211,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="num">(30,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(52,000)<span></span>
</td>
<td class="num">(6,133,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_CapitalizedContractCostAmortizationPurchaseAccountingAdjustments', window );">Amortization of contract cost assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(196,000)<span></span>
</td>
<td class="num">(767,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(323,000)<span></span>
</td>
<td class="num">(1,207,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_ShareholderAdvisoryServices', window );">Strategy and shareholder advisory expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,513,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,513,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_TransactionCosts', window );">Acquisition costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(76,000)<span></span>
</td>
<td class="num">(374,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,070,000)<span></span>
</td>
<td class="num">(683,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Gain (loss) from discontinued operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,508,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,383,000<span></span>
</td>
<td class="num">(1,773,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization', window );">Adjusted EBITDA</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 13,346,000<span></span>
</td>
<td class="nump">$ 10,519,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,253,000<span></span>
</td>
<td class="nump">$ 14,395,000<span></span>
</td>
</tr>
<tr><td colspan="7"></td></tr>
<tr><td colspan="7"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Includes $1.9&#160;million gain on disposal of discontinued operations for the six months ended June 30, 2021</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjusted Earnings Before Interest, Taxes, Depreciation And Amortization</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_CapitalizedContractCostAmortizationPurchaseAccountingAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Capitalized Contract Cost, Amortization, Purchase Accounting Adjustments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_CapitalizedContractCostAmortizationPurchaseAccountingAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_GainOnTransferOfMembership">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain On Transfer Of Membership</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_GainOnTransferOfMembership</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_SharebasedCompensationIncludingOnetimeAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation, Including One-time Adjustment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_SharebasedCompensationIncludingOnetimeAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_ShareholderAdvisoryServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shareholder Advisory Services</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_ShareholderAdvisoryServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_TransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Transaction Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_TransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents an other than temporary decline in value that has been recognized against an investment accounted for under the equity method of accounting. The excess of the carrying amount over the fair value of the investment represents the amount of the write down which is or was reflected in earnings. The written down value is a new cost basis with the adjusted value of the investment becoming its new carrying value subject to the equity accounting method. Evidence of a loss in value might include, but would not necessarily be limited to, absence of an ability to recover the carrying amount of the investment or inability of the investee to sustain an earnings capacity which would justify the carrying amount of the investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 35<br> -Paragraph 32<br> -URI http://asc.fasb.org/extlink&amp;oid=124268079&amp;loc=d3e32787-111569<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109227538&amp;loc=d3e44648-109337<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1930-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1930-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1930-109256<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1930-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109237686&amp;loc=d3e17752-110868<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R103.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140179460956904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Reserves for Claims and Performance-Based Arrangements (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetRollForward', window );"><strong>Liability for Unpaid Claims and Claims Adjustment Expense, Period Increase (Decrease) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Beginning balance</a></td>
<td class="nump">$ 188,686<span></span>
</td>
<td class="nump">$ 61,150<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization', window );">Incurred costs related to current year</a></td>
<td class="nump">262,240<span></span>
</td>
<td class="nump">245,696<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense', window );">Incurred costs related to prior year</a></td>
<td class="nump">6,267<span></span>
</td>
<td class="nump">830<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1', window );">Paid costs related to current year</a></td>
<td class="nump">117,454<span></span>
</td>
<td class="nump">200,989<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1', window );">Paid costs related to prior year</a></td>
<td class="nump">99,443<span></span>
</td>
<td class="nump">17,004<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease', window );">Change during the year</a></td>
<td class="nump">51,610<span></span>
</td>
<td class="nump">28,533<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseDisposalOfDiscontinuedOperations', window );">Disposal of discontinued operations</a></td>
<td class="num">(13,194)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments', window );">Other adjustments</a></td>
<td class="nump">11,003<span></span>
</td>
<td class="nump">4,726<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Ending balance</a></td>
<td class="nump">238,105<span></span>
</td>
<td class="nump">94,409<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=evh_EvolentHealthServicesSegmentMember', window );">Evolent Health Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetRollForward', window );"><strong>Liability for Unpaid Claims and Claims Adjustment Expense, Period Increase (Decrease) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Beginning balance</a></td>
<td class="nump">56,295<span></span>
</td>
<td class="nump">4,265<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization', window );">Incurred costs related to current year</a></td>
<td class="nump">8,669<span></span>
</td>
<td class="nump">2,135<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense', window );">Incurred costs related to prior year</a></td>
<td class="nump">6,293<span></span>
</td>
<td class="num">(498)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1', window );">Paid costs related to current year</a></td>
<td class="nump">20,801<span></span>
</td>
<td class="nump">4,020<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1', window );">Paid costs related to prior year</a></td>
<td class="nump">20,673<span></span>
</td>
<td class="nump">2,530<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease', window );">Change during the year</a></td>
<td class="num">(26,512)<span></span>
</td>
<td class="num">(4,913)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseDisposalOfDiscontinuedOperations', window );">Disposal of discontinued operations</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments', window );">Other adjustments</a></td>
<td class="nump">3,721<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Ending balance</a></td>
<td class="nump">33,504<span></span>
</td>
<td class="num">(648)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=evh_ClinicalSolutionsSegmentMember', window );">Clinical Solutions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetRollForward', window );"><strong>Liability for Unpaid Claims and Claims Adjustment Expense, Period Increase (Decrease) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Beginning balance</a></td>
<td class="nump">122,532<span></span>
</td>
<td class="nump">50,245<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization', window );">Incurred costs related to current year</a></td>
<td class="nump">219,343<span></span>
</td>
<td class="nump">201,977<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense', window );">Incurred costs related to prior year</a></td>
<td class="nump">215<span></span>
</td>
<td class="num">(23)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1', window );">Paid costs related to current year</a></td>
<td class="nump">73,379<span></span>
</td>
<td class="nump">163,431<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1', window );">Paid costs related to prior year</a></td>
<td class="nump">71,392<span></span>
</td>
<td class="nump">7,499<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease', window );">Change during the year</a></td>
<td class="nump">74,787<span></span>
</td>
<td class="nump">31,024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseDisposalOfDiscontinuedOperations', window );">Disposal of discontinued operations</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments', window );">Other adjustments</a></td>
<td class="nump">7,282<span></span>
</td>
<td class="nump">4,726<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Ending balance</a></td>
<td class="nump">204,601<span></span>
</td>
<td class="nump">85,995<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=evh_TrueHealthSegmentMember', window );">True Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetRollForward', window );"><strong>Liability for Unpaid Claims and Claims Adjustment Expense, Period Increase (Decrease) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Beginning balance</a></td>
<td class="nump">9,859<span></span>
</td>
<td class="nump">6,640<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization', window );">Incurred costs related to current year</a></td>
<td class="nump">34,228<span></span>
</td>
<td class="nump">41,584<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense', window );">Incurred costs related to prior year</a></td>
<td class="num">(241)<span></span>
</td>
<td class="nump">1,351<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1', window );">Paid costs related to current year</a></td>
<td class="nump">23,274<span></span>
</td>
<td class="nump">33,538<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1', window );">Paid costs related to prior year</a></td>
<td class="nump">7,378<span></span>
</td>
<td class="nump">6,975<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease', window );">Change during the year</a></td>
<td class="nump">3,335<span></span>
</td>
<td class="nump">2,422<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseDisposalOfDiscontinuedOperations', window );">Disposal of discontinued operations</a></td>
<td class="num">(13,194)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments', window );">Other adjustments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Ending balance</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 9,062<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Current Year Claims And Claims Adjustment Expense, Including Cost Of Goods And Services Sold, Excluding Depreciation And Amortization</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseDisposalOfDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liability For Unpaid Claims And Claims Adjustment Expense, Disposal Of Discontinued Operations</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseDisposalOfDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount needed to reflect the estimated ultimate cost of settling claims relating to insured events that have occurred on or before the balance sheet date, whether or not reported to the insurer at that date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (cc)<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of payments to settle claims incurred in the current period and related claims settlement costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of payments to settle claims incurred in prior periods and related claims settlement costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of adjustments to the estimated reserve for unpaid claims and claims adjustment expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of increase (decrease) in the liability for unpaid claims and claims adjustment expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MovementInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MovementInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of expense (reversal of expense) for claims incurred in prior reporting periods and related claims settlement costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=evh_EvolentHealthServicesSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=evh_EvolentHealthServicesSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=evh_ClinicalSolutionsSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=evh_ClinicalSolutionsSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=evh_TrueHealthSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=evh_TrueHealthSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R104.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140179452243656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplemental Cash Flow Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental Disclosure of Non-cash Investing and Financing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationMeasurementPeriodAdjustment', window );">Increase/decrease to goodwill from measurement period adjustments/business combinations</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionPayablesAssumed1', window );">Class A common stock issued for payment of Passport/Global earn-out</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,185<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Accrued property and equipment purchases</a></td>
<td class="nump">668<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_AccruedPropertyAndEquipmentPurchases', window );">Accrued property and equipment purchases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(26)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_CashFlowLesseeAbstract', window );"><strong>Effects of Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows from operating leases</a></td>
<td class="nump">6,622<span></span>
</td>
<td class="nump">6,853<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_RightOfUseAssetAcquiredAndDisposedOf', window );">Leased assets obtained in exchange for operating lease liabilities</a></td>
<td class="num">$ (2,157)<span></span>
</td>
<td class="num">$ (1,354)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_AccruedPropertyAndEquipmentPurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Property And Equipment Purchases</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_AccruedPropertyAndEquipmentPurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_CashFlowLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash Flow, Lessee [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_CashFlowLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationMeasurementPeriodAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Noncash Or Part Noncash Acquisition, Noncash Financial Or Equity Instrument Consideration, Measurement Period Adjustment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationMeasurementPeriodAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_RightOfUseAssetAcquiredAndDisposedOf">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Right-Of-Use Asset Acquired And Disposed Of</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_RightOfUseAssetAcquiredAndDisposedOf</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionPayablesAssumed1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of payables that an Entity assumes in acquiring a business or in consideration for an asset received in a noncash (or part noncash) acquisition. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionPayablesAssumed1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R105.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140179453576376">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Subsequent Events (Details) - Subsequent event - Windrose Health Investors III, L.P.<br> $ in Millions</strong></div></th>
<th class="th">
<div>Aug. 02, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Purchase price</a></td>
<td class="nump">$ 85<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration, liability</a></td>
<td class="nump">$ 45<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=evh_WindroseHealthInvestorsIIILPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=evh_WindroseHealthInvestorsIIILPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>117
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M^*$/VK;PYHR;I.#C@$2A/BK:Z6)N'J2$?JB/"M.8#(T?Z@]?#0!AAWJ1/BH
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MT@:8\[T0^N38"[IW*?X+4$L#!!0    ( (F9!%,G)OG.W@0  &T*   8
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M,5.QFH_%<KY<?,??JB][%?VMON%O4.:-U2I3Y,6?YVL?'&CRUW<"'/4!CF*
MH_\9U__N59SGMHZ,MX5XC[%X<M.U$<"4@.?B>"Q"2>+J_.Y"J-;OW<?X9;)8
MC<65,M)D2FH8 : &(QG\Y-)1KH+XW7H/['[^8&N5B=7R^-DK\8ZD;QSQ/L[A
M<"?R>M*A0&:0AK6G^R;5V.8B<UBC'&S?-"J')2%?&41E<U6HPVRGX@-*\6V9
M4(W[1CEBYP).57@4P8JLE&9#0G'0/3:RKIV562F@=***)<37AMUD=F/4%UYG
MJ1K=5Y.1"Q _4?1527R"[^2#*PA"5M8%]06+S/HP%LIDNLG9'QB7$T<@]2#7
MFORX]VBLF3SU&:/%-&WCC$5).I\$.X%&(6?4Z"GC!Q5W1PTA!QP?&+L$=!?"
M%L5D+74$-1T";7VTJRUG#P_K1\2OM<QBNH"7=LI'R'[ZX>5R.7^-8AK'A3(H
M\=WBM2B<K(@5&8(6RMB 70TI9@CV$';01KZBH:13!PUX.^BBA\9Z@"9(.JU0
MS- ,%#ML"JMTSJVII4<E#TPO!@(Y@I& +Q$*[U)SI0>[@&U+P;I&K^(:3* ,
M/OQ7M%)>4%%0/% B72*W6$-BK87R&6CPB&21#&V4,9%)14#F;]#*:HV'Q7-6
ML\4O0S(H@RVJ$C7^VCRY0]6^R0Z]3L4G9,MSCD*Y)2W1TR0!$)CY?;[[9-]*
MT^#L%8NHI'/1^*ZI_30Y"L[ZNC7HIZ*; Y<SHX%FU6@9MR3O2.=O4*T;^A]7
MTSG.*ZVY0YBYKP,C"O@'5RB'T8&$8!:34[S%N0I1#L^FXK9M/L,,&O(8(>,.
MH#VZ_PY0\,D?:Y,#11R(!8M@WX[4BJ>$\+V=QJ^3Q7(L[E15:U4\=K -Q)4S
MO#89ADU\D#MJ28,I,'GJ"SH93> 3K;* KAM#VF44,_2,%6]2/..I2A'D3DBM
M;2:[(EJB<T\VL <ZSE8"#2PH<GRO1>! 2$J,Q&IK>JEMXU042H2 SZ'(J51&
MX#)XD YYV89/XY/8=S"-:!Y%/>#$M9)KI=-T,$*X&'H%2<.0@J)=RAG#A79T
M8I\ZP2K0:[Y/R+,?&>G9$IV&(LX1H#PF _^[_*/>:>F2[1,&0-IXF;7X\]&2
M%(<;)H$@U9.F[KK'-:7<$7UC;;X%R5.K+X&P-(^#P1P.(1X2=UM'A7)0IWN0
MEF4!SOAJ,Q;;4F':<I5#_H,H)<\@+GR,/]H)#%CY&>?&L91YW%[R.#)/]-Q/
MG[K)S :W11P,FW@G]B)"DBZ._=O^VGV>;IO[[>G._DZZ#=-/4P'3^?3%\Y%P
MZ1Z<%L'6\>ZYM@&G4'PL\=.!'&_ ]\+:T"TX0/]CY.P?4$L#!!0    ( (F9
M!%.B+=I>\@T  -LF   9    >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;*U:
M69/;-A+^*ZC9R:Y3)6LDS9GXJ!J/[;6]L3V5<9*'K7V 2$A"3!(* (Y&^^OW
MZP; 0Z(F1^V+#A)H]-U?-_E\8^Q7MU+*BX>RJ-R+HY7WZ^]/3ERV4J5T8[-6
M%>XLC"VEQU^[/'%KJV3.F\KB9#:97)R44E='+Y_SM5O[\KFI?:$K=6N%J\M2
MVNTK59C-BZ/I4;KPHUZN/%TX>?E\+9?J3OF?UK<6_TX:*KDN5>6TJ815BQ='
MU]/O7YW1>E[PLU8;U_DM2)*Y,5_IS_O\Q=&$&%*%RCQ1D/BZ5S>J*(@0V/@M
MTCQJCJ2-W=^)^EN6';+,I5,WIOA%YW[UXNCJ2.1J(>O"_V@V[U24YYSH9:9P
M_"DV8>WIZ9'(:N=-&3>#@U)7X5L^1#UT-EQ-#FR8Q0TSYCL<Q%R^EEZ^?&[-
M1EA:#6KT@T7EW6!.5V24.V]Q5V.??_G%RLI)UI![?N)!D:Z?9''WJ[![=F#W
MA?AH*K]RXDV5J[R__P2<-.S,$CNO9H\2_%!78W$Z&8G99#9]A-YI(]XITSL]
M0.]5[7#%.7%CRKFN),LI_GT]=]Y"ZO\\<L19<\09'W'V%S7XZ&Z*N>_=6F;J
MQ1&"RBE[KXYZ),6M=&YMK!>?*_%1;L7LBK0S_6XD?GIW,VIOOU.R\"MQ9XJ:
M-X[$#S_<B"=__]O5;#9Y=OON3KSGW]-GWXZ$7RE2R5I66R&K7+SY^5U+255>
M694+77F#N^+:.62'V]IF*_B_N%Y:I1"77CPA,NF M/OZ]KH]9[/2V4JLK;G7
M<!"!),)'.UDH819(!3"$K+R610%&BH(NT@))1SKZ!R&90Q9@!)ZRHLYUM:0;
M=,[T\ID3_P(W=?9U*SZJ7&=2YR*#7Y*%AWELEMW$91W-F+XRB&4IUDGXM=49
MLWY\.1E/$)%%0<E%5R*3;L6<TH':N5I68:6$0W]#RH12G:>EO0,&&6R4?4OG
M)>Z(N2]8_5.%3&:=]ENB_X.IM;L'(RK8]=!=<;O:.IUI2;[1612448@;MGN@
M\4%M-,1YIZSVR,WB;5T%Z[UYR)!!%40;B4_@%+('Q\NDQ:7W539NE- >??)!
M+18X#JMO3%WA4,A%14#<8!LYF %?G*:?(*-QRKY7Q38P$Y5SMX97&^N2-L84
M$4@82DR;D.CZ-;N GM<>CG=\UK46U$AN!4O0>JIL;"?4B/R>K4:26K6L"^D-
MF,SD&FHH<.FW6EOV?2>@$65Y4Q,/&XT ),J#-OUDO&IY)SOV;N$4:S5XE6*A
M'T+X!8^QTK,C78S/OQ%K/K2JR[&XSG--.J/@&0D3E7$QI LR"3&V&]KO(419
MD1<,1_7 _4YPD[B2G-_5EO66Q>.Z).YJJ_RV+WBXQE'" D,HQA=$8VZJ/)E&
MEN0M'&ZS\[X!G<I I)<%NE2"=33LM!?K8XHN"D]/=.B8 2F'U;>!\L2O!MHK
MPD6G$$6<O HMYXBQ2#$)&,1 O=9E77;$H:LDZ$BLB]J)3%DO*8<8%[)>2V.4
MB."DL+<P2(Y.2*L=Y<$@:2(8]$N_&K48JY<H?850#VL-;\[)G3;2!7>)Q7;"
MXN2U)9)$S*^@"5&&\JZHO/?7CYB$>O#A'N1^K3)5SL'+Z30L:7GAM190#"F-
MC?LY\X:6AF6(XW;SI%_>0MI_M%XAT!E34J SZ]WR25E E>N"[\ZWO*!;JX9C
M]09*AB9:K[WV_9UQP4@<3R_&L\8QH^FX%AQ(YJR+E2K C<R^PGQ>%RB$*),>
M:!>5+\@,:%EPBMZK2,E9S*:"2$#B!158.+\/NM$EU=N8I19D1;J:0?F6TQRJ
M+/)W7<XY9MT8[H_$%U+)2,A#@O9X.)1/VESH5Z"T5_AE#@RK"7P%3 XR(%F7
M:]_1W@+>6J$>(.%J]]61U7J'!U30^'=>DV\7<'(*0+=6O+52*L?6A/^Z5G[]
MZ58D8-B4U@$[] Z=JTSB,BE?+SA-(P1C<J$21I6#2^5GNY25_F\K()W\^NE=
MYU X94WVCZZ*RFA#"'5/Y+!(<3)-03= C/RI2V=A3<G&V2-XT(G[MB6#J+RG
M8S.'?B-Z;A-.OWXE60>R:2S52)/3BR1)]TS\NS<%N4U$L01=B=Y' \ L]R%&
M@K7A?F/$OX1<XQD#N+67.QK<NNN.."J2@&.FX P MHM7TQTJZXQPZF[@6NH>
M.?7OQ5GW0F.0N'[ %@/U#LJ_4VL?$NQTR !=9?_I=-HJ<$BO.ZETU/C)88[9
MI2MS'UA(ZH7_4L@!$J'C'NU&)X*.EFXTE3&D1J[]*?PYQX'U*LX"&+ET6&\"
M(?[/U1H7&#C.AF ^OI7+T"@F3R&&J9D!0%0,#IIBMYN]L?6#K&K"OM3C#F??
M VS];J?VN^GWC^3:UID'DLU FFQCL-^+K4(HPU<JRIZF5.[_E#YU/^$E]_CR
M.R#!ZZH.%DEE*,;.H(S)2B%>IFR;8&P6/&HIE@4X)74G7(%(V>1\.[4N4!V6
MQBP6U)@1CMRI"/$8:I^X)]H+9'@08 79UPRZ3@\Y91D!T.@0Q*.N[M%AL,?L
M]J5D(.*:T@%HYAR,]T"=C'.;Y@1;*=6WB8AZ)%PHE5^9G %'.!7<]"(X.5@G
MO>SU;Y0[.0M!][2/>(%#1XU&1)RA$2!M;5;@:#<Y4V#F"KS"%D&CJ+I2W!OB
M9T^*X&\X+)6CE:3VA#M)M*6TI0V80QW],Y;84M)/'6Q'I%:7N]J&/O:R--$F
M._4VMBPXCPL,]':\OV?H'2U'RW*%PDJ8RZ7LXQXU0)C)\ Z;(KAORY9-.B='
M2J^,ARNHD-8RBYP*!XIFR J0[&2#>1N Y$S_O+Z^'8NWT+O9I*ZD[]T!V/;.
MW"V@L7F*(C5):EB?CKOH3P2>V0:#6 4BYY1D0V;J#B5 .7E_\@VW%U9DD(-%
M)3@.-[!-B2+?W0,&C2!WWF1?5Z: PAH>.DVLI!93/E(V.7M)Q(ZAY!-:"BID
M.M>4_*)=H_HX?M?2#MN[[^H4K#9GT[+;K'G@HXL0!$B+9#\"3&ELQC](??>R
MX-:%+I(.T321E0XOI/' ]/R[\552*42^E[J0*1LS;..! 1Q=A0U75^.+=CVX
M5:"'#=RG)N!15^#=%Z03682-.V3.3CN6).X,E& [\\OC\TFG/^0$8VB61/,"
M701"7=V@>=.$&[ USH-9!,2*+H-..F..IW/&&-(BNI>QXV-M7)RUV@A=5I99
M*G[=8R-W#?]C<== F(2E&$KQHQ/>0QY%MJ7'/0QJXV1L PH4TCG5NSASBP4I
M.02\ZE?4,+K<&:W)-8$44."NA=8W^.&U(E<KX]3C?1HR[2"F_3Z$YQ*%+FG<
M#S9J1.BNHX:^D\CN#2T"15-[&DPS<(=!D!W6X'$NBS34I47]H>(^$Q8":!YW
M+&I2SW8W-:76@)7PH ERPP>.3UO/C/6339=RREB\;L<T"VU1@7X#4B$P@]4!
MJZQW)EQ-$NGC];W,1E' $SD.LK7<LOK9-G'7P&2N&P+!(4U85-6L6BQ2%=5/
M16.K.=(K'1#;(9HS.4I@B?(..FH;DW]T9GD,*A>]TD#/*>,YS#3"1)M0 'GU
MEN8? 3!]"5-?M32L_2 *K$4!1R%T/ODFZ2JI(*""GOE<.W1@GV;=_5'-'U(4
M(^M&6X'5-MR(L11JX"PBL8..,.L&7>A?O7:+" ,ZW6H QTL%/Z=#?U$)+H?G
M,C1OA QKDKNN0O( Q3AH(LT'1$9SF 14&^,IQK8@O0UEWQ-_$IH#![6EH:2J
M:)[)!<\2IJLISP!J%PT;;&,C2OE5=2 K%U>BX=IG7FX+5-\D2K,FXY#I-NC;
M82Y%OH=^ ZQ#EF@F(E&8:OF4;"66!D  E0[M'22(HT[*;'0LF<R&-HL37+@*
M=R[EK\;&1RY$K]O\')X%M&6B/PT)?4;CD1R1#AH#6,HD^RJK"?C/*EDV(*\I
MT\B0R)TPGBH:(.&2#-K7EC6LFJ=DA)YYF(^%VN9/*?%N!<[(0V.!\^@!.PD6
MC0TA2I.#/->\3L\&'\@5\<K&L=P5=%P%%/!K@:+!90CX.(,(2)BH 35/G4V]
M7/6M&J::;'8BRAV56NILQR,YSY)L,?1#UQ^>\-06TO6#8Q(U4);:QW+53%;[
M#IW<EWVJR[Q(4Y'D8N1:7GX-K44K/<&Z<EW0$[5@",-12=9H)ED_AI$#R-'N
M6_A-[Y$)-J7#=$+E93AI1_O9BK  X71V8-)D ZQ1E#8*Z8-J'^.4OCB:-"D#
M7Q276=1+!/F:7L/(ZX8-\CMZ#FC54X[GB.BP&H=F:N@XE$9^VON8BNDAR-/F
MH"Y3(1WN:XIS<8??U.LW[G30":;]OJD%K?V*/!E?]M#4\46GY+'(79;"4QSR
M5,4]XT@@L])CHH [.F,!1$23_YI.;95&]DX_''X ,Q5Z>*2UKYY4\)IJR74C
M#H>H-XAOY*3<%0!JD$+&1[,I0PR?\*>9'Q$:XIPI_';-B(K.$T^XFIG:@83[
M]GL:]H;F_FT\X L?T'WKI%V3F+C#T;T5?;U]8?&N0]5_TW&;N6IIQ:HZ(.I-
M71)X)=M%&LVFY&[]\^[X&2'A1D;_/(H(S>H<;K&@]OY87%[@8WIUWOO\3(%!
MCS1DMMM;<Z\W>R9FH\GEM/=YBY!&K(?0H@9"4RB>7UV*T]$E/L]'TXL9/B?X
M#*HX%A<7I_0YFIS1]^7H;'K%WZ?X'GI%YJ3SPE&I[))?J^+'&I4/[QXU5YLW
MMZ[#"TOM\O#:UT=IEQKII% +;$6@G1^%X7;ZX\V:7U^:&^]-R3]17)%9:0'N
M+PR22OQ#!S3OL[W\'U!+ P04    " ")F013++@(+%0(  #4%P  &0   'AL
M+W=O<FMS:&5E=',O<VAE970Q,BYX;6SM6%UOV[H9_BN$%PP)H-KZLBVG:8 D
M[4YST*Y!DVT7PRYHB8ZY(XDN2<7)^?5[7E*2Y33IDA4X5[MP(E$OG_?[@SS9
M*OV;60MAV7U5UN;=:&WMYG@R,?E:5-R,U4;4^+)2NN(6K_IV8C9:\,)MJLI)
M'(:S2<5E/3H]<6M7^O1$-;:4M;C2S#15Q?7#N2C5]MTH&G4+7^7MVM+"Y/1D
MPV_%M;!_VUQIO$UZE$)6HC92U4R+U;O1671\GA*](_B[%%LS>&:DR5*IW^CE
MLG@W"DD@48K<$@+'OSMQ(<J2@"#&MQ9SU+.DC</G#OTO3G?HLN1&7*CR'[*P
MZW>C;,0*L>)-:;^J[4?1ZC,EO%R5QOUE6T\[G8Y8WABKJG8S)*AD[?_S^]8.
M@PU9^,R&N-T0.[D](R?E>V[YZ8E66Z:)&FCTX%1UNR&<K,DIUU;CJ\0^>_I>
MFES55M:-*-B7C="<C&5.)A;@1#+)6Z!S#Q0_ S1CGX&S-NQ#78AB?_\$0O62
MQ9UDY_$/ 7]MZC%+PH#%81S] "_I-4T<7O(Z31FO"X9O&V5XR7[1JMD8]L^S
MI;$:$?.O'S!.>\:I8YS^O(G_)R#VI6:_\KI!3K$H\O8*V(<[58K:LH^"EW;-
M/GVZP-I']E&5A:QOO=HWNA$M0< $S]=LNU9E^<#4M@8+TRR-+"374ABF5LRN
M!;M0U8;7#R"OK= @DK55C+-KJ_+?V%6C\S5RA)W=:B$JXG](N_[\IRR.P[<#
M?NSZZLRM1F^/$/)8.->40-WGS[Q&32"$@%W6^9@=MAA[9!=<BPXE8)M&FX:#
M)R3:KB74V5.81"KH&VI"R3A^T$E:P\2W1MH'T@0:&2S(>F@:VO(=US&[*)4!
M<&<8A$MM>.X]0FX2U:;D%AR7#X[@D?),Y7FCR8*H39\Y[,:2UGG/VJQEV=N-
M?#AP"NP(I=;\3K!:L3942$19(QCNO#^<K8>@Y&580'B[$5S>:B;N<[&QX((G
M:2PM&:'O9"Y::SI - ;LX+(R;*,5OKF]))H"F&9KSP;&0 TN4,(DI1;58K9J
M:F^P,3OK(VPEM;'L&\(9[J!%'\]#/0N!3T B=ZZYW5.G0B,CVF*8+&J7++F6
MV"PY:U"G-#N[OF#)#%6&!.8&ULB1"T- ;HRP/E]*R9>RE);R@3N!WXM<5$O@
MM+YK@4@ A!(Z@Z,:L"=K4>AA1:J"3"8,I1*8:[(\N,F5%$Z6M2@+MP&527@!
M-;G6PJ%YV10N^X9^'O#!!^=*/*M2%BX05[+F=2Y1YHS% GD/EK\AFR/KU98@
M+%^"EV_1\G?H^;PJ^Q6!@C*:OS5[MELV" 9$1-#F(\D_E!V!!I-H53WKKJ?T
MV$G_2"*7AVL$IC.6D?>L\CU)4$]BZ"BB[RB.A#QVS-#>?8:ZK<,VMMO2T5P#
M]&D*!TJ @Z>OXDY (W:%2D #E$^+G<#.:/%;EBQ8DK%XOF!76E2RJ7:?XFDP
M#6.6IL%\,673>3!+%^Q&67A1M^A#TC0BTBQ)B'019^S#/>8W T=>**05[-7M
M.D1ZE_ /\A"KA4 D(C;\J$2A5BEMY>]^070@NW U8L.AAD"W6-)H=\0.HZ->
ME!1BAFP:9-F408YDBMKE2D2/U%%&61"E*4N28#%-61H%612Q:U1H1&/ ;D4-
M8Y5>HOWBT2,=QD.^<3(#W_DL98M@ :CW+U.L%V<6NE\"[WDKM^YR]? 1<3P/
MHBQD*?&#P<%P/N\:,^A=='>TAU$P2Q:PTB()\3<.PA1OEVW/H:Q0U<Z543)'
M+X]9G,UV-"W_'60"H!2_^1'[XFKM/D?Z'$^/W,,G^K(4"$+1\;+\7OBZ5JOZ
M#66?5L[L@TXXD'X:9H#*TCEY.IC/ 7H.[ZRD;P%[H#L1XMG..7]%:782'O1+
M!STRGJ9Q=.17''I+\^I_+A ?1WM;=8S7+6\;2>_1I;!;(>J]+O-H0O*MABH8
MXDGIMH*U:KL:]G0E5J^I8%KXF>$/Z+G$^2 9QSA5P.N0<M66.%]!GZV<H>-S
M$(^S?J=;F(V3[Z!>6((#ZC ;X0YHY</89?2K2L#_O?ND=Z-QV+L$[Z]S<#2.
M]AV<#A9^TL$W/S99SLV:K=!4OI^7VNG6PJ>"M/\WCLC=5-\W)!HF4&C$$*BS
M/2B?F34PTC])_GAX[X8:5C3:C4POMP/;HJ[2:.<'+G/\JKEB(![BXDX6_G!Q
MV!@7K4>#5N4N._R@>H!V&&*".&!1&,QF+X#!<4&8QS#H6.D"S2;)XI>,C.YL
M4UL_-JOZ]@U-[,_-TNTDN>>7)RW^U#2XY,B#' +0'<BS<_GQ]TN8_:\_W%RS
MBTY4)]RQMP^)Z**'#H=WO'2A><!P$DFS#',=,D[FQ#[OJ/5NS1O0AS,&@[,\
M5PT]H[0(@,%< :O1#),@19_'R+?ALMB5JUVFYWNBP9'1(L,\T*/CM&&[@89D
MH::7!'.,?7YV>;2?AJPH?97TT>R_\4-4+:+%C[3 >/%8D05--;R^E10Z?K$S
M28B)ZA>E"G>8Q6053EMEVKV(9TQYBX1]NCP[O_QT>7/Y8>?#050=[^R^X0\N
M1FDP6#A_: JQ80A&41#/IOTG:B%08S<UTFE>/:!L+OW,@QU!%$T152OA3O'=
MH)%BG*7!G^JZ&)9R0D%^NGM4Q.L;NDND$YV&&=K2MPBRZ6/7#86,9T$ZC_I9
MK\NJ/3W@^UXF#&/#C]["_?%AN.V L&=I]G-#UW<&=T>,0E SF?:]XR7=^(_L
ME,]4C/%35W^3P4UK)?2MNT^F^QZH[2]=^]7^ROK,W]3NR/U]]V>N;R78EV*%
MK>%X/ATQ[>^0_8M5&W=ONU36JLH]0I]":"+ ]Y52MGLA!OU%_NE_ %!+ P04
M    " ")F013Y OZ GL0  !],@  &0   'AL+W=O<FMS:&5E=',O<VAE970Q
M,RYX;6S-6VUSVSB2_BLH7_8JJ:)EO4N>25+E>&9N=FMG)Y7D=C]<W0>(A"1.
M2$(#D):UO_Z>;@ DJ!?;N;FJVP^)*0KL;O3KTPWJ[5Z;KW:K5"T>RZ*R[ZZV
M=;W[[N;&IEM52CO0.U7AF[4VI:SQT6QN[,XHF?%#97$S'@[G-Z7,JZOW;_G>
M1_/^K6[J(J_41R-L4Y;2'#ZH0N_?78VNPHU/^69;TXV;]V]W<J,^J_H_=Q\-
M/MVT5+*\5)7-=26,6K^[NAM]]V%*ZWG!WW.UM]&UH)VLM/Y*'_Z<O;L:DD"J
M4&E-%"3^/*A[511$"&+\[FE>M2SIP?@Z4/^)]XZ]K*15][KX1Y[5VW=7RRN1
MJ;5LBOJ3WO^L_'YF1"_5A>7_Q=ZMG2ZN1-K86I?^84A0YI7[*Q^]'J('EL,+
M#XS] V.6VS%B*7^0M7S_UNB],+0:U.B"M\I/0[B\(J-\K@V^S?%<_?Z3>E!5
MH\0GE>I-E9.FWM[4($Q?WZ2>R ='9'R!R%S\HJMZ:\6/5::R_O,W$*B5:ARD
M^C!^DN!?FFH@)L-$C(?CT1/T)NTN)TQO\LPNUT:7XAZR&G@#-%UOQ3WK6!GQ
M7W<KR_?_^PF&TY;AE!E._YA:OYF(^(>"SQDX,B(BVE.]U\+JQJ3*?B=>C]X(
M[*2R+F;I,:O,0XXOA:PR\7K\1NP*6=/7? ,A;GB=;1<.Q)<^A<^!0I#JRP4.
M*<CDMA9Z+?)R5RA$<'VT9+]51JT.8J^$M+RXWBKO[;!$7HE"-E6ZS:N-R&LK
M=GK7%([&5LD"5M,F7&$CE=@9O3&RA-1_KD2J3(UL)%($JTTN:B+%<[*P&NS2
MHLDZA4(DG>:R5IGS$*@5.6NWTX8W%<CK2EW7R$]85&77F=[[% ,[@3H8BK3(
ML7?:KA;2**$>\1VV) 59FFBM&HLK:VD_W2:A>ZCCH@5!J;&-+(H#=$T:#I)"
MJ-%8E!R* _*4C:I@6%IH5*K(::18YX]8OE:*17S*38QSNW]VFM$/L [OF>3&
M1BHH;]?4HE3U5F><'N%-L!)T9DFQC3&X0V)*NJ@U6[K6M2R$LB#%:G;+C?J]
MR?TJ"WGL^L"ZAW.RA%4*"59%OO%*^AB[\*^="Y]XZL=G?)U56A]V><JZ*I'0
M\^N#D@9?0#\;=F'KG"$XJ24IX78/.3SG09I<-Y8,7A$19B0SI.N<4@K5'41G
MT3!;]E':UWU8_3E\!8DVQ"MQ/M?>)ODR9?--Y;2#2DJ&@"9+E3$)]8@J#7<G
MIV*=25-7)"5)$AR<OG"J3[4+T)0HTQ*[4W#YHCZX6U"V=-N.$H(7^\<'7= 7
M/[OX:[7]0MF#SL@GC-I2>8=VXF".+$2BI87,2TO/@0N[71 I<7J.8YC]V65*
M>+=IJFL D<[0X-\9T,4$$=P9.*+)87L$D<FN27N'G@%![_6__]MR/!Y^_^7C
M'5^-OG\3*>?7BXY*Z0RFLJKO37G/@SB2:H4D1O%@F[SF_-#MU&V0@RXE/=##
M;.C@V_56UD34[0]1R]HN"=>1HW@#\_U*J:SUE$X?I,Q2E2M<#\1_A-214);>
MYP6<>K=C#2D2BW+<ILDSWJP/ZPO[EY9(;.4#.4*M#+1*PI&\2J9;EU"P/^,<
M#GO(H'7<J#F)=<:!1]$&D,0HX.2J4)S'8*$FK1OC,QJKNK,XL>EBV_L)-NOR
M)&[MY('YM@J414J)6$7Y3#K]K7-\Q"Z]FMPED1%DM\1ECEU!JU9.4U7#"Z%K
MKUG'IA^B(>#(N@T0E.$=%HVZ=@*X*.V<AUQ;$O.42NN&/<67057F3>G=L>=N
MI3ST(T5#/--3)$6$VS<E8*= 42"'PO0;HQRA1-@MI_*0>:RD$+)];IQHF4'L
M$Z62%F:">'\/;!DL9#[>2?M=47 EAI,<9:LB_ZI@+5GJ!AIH+4.:W,)=M&GS
M('R3N)$,*Y 3OS499R8A72B0OPW$#TWKMY5D[_$!$6\D::M]D,MI<N4D1VI@
M7\X!==AW$,XKWA=;&5Z#M >O =2HN8@:"QG!)Q14CBN=HDP2)N(\ 0_P/)&"
M<K()<NF#RC@63DLRH[_GP-Q)X0YJ$##XCC79U%T='XB?&"2<&*=EGY'#8Z,'
M3WG+^G"HFB*<BP42E38N07#I/),Y.+D@,'4*U7;.V&?<99=<LV_NMWGJR$5>
M^Z*R"F[XRQ"32H'<Y1Z:]KR7C4=F#K$2.;$/R6-OOT%(;F S#@Z(Q1YECVP6
M\6L1%>66C=%(Z""<6^<&(5W"Z:"/'-U=YO2+]K!5>(>F'?3CLIO"^D?@[1+7
M2M5'/#,M*ET[UB]G-V@;*@^1?G%9$+@KBOU?VWI@.3FE_6>Z*D1ZIR\IZ,I
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M2C@>M9]18S":)]/9A/[<SI9BG"R6,_P_&X_%!)*/)V)RFRR&,S%)EK<+ 5'
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M#@>+V96;484/M=[Q#PQ6NH:\?+E5$HF2%N#[M=9U^$ ,VE^<O/\?4$L#!!0
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M?3&_3O?1C7BZU;\$3$PJ]-,<JJ/!V6E/^'133HOH:KZ=SES$"8,?2X4*\"2
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M<VAE970Q-BYX;6SM6FN3V[85_2N8K:>S.T-K1>KMU\QZ'<=NZ\:3=9P/G7Z
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MVW$8XF#G8E]P\_"/1S[^.Y0V/G(R3#)=2H.EF:L8#D.$:9H".8[13?LFGS*
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M4]A8Y?;'BV':)]Z?3G8^SDT@4=A/Z(SGSN7AY)FJB[4[@6#=-A,(J(FX4O*
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MA[BS$+[RU(\^:[N"(Q*XKC7"L$;5<,IN80Y6E+J >F.X5*U1I0"6Y=1WU.[
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MZHX& >BFWVHF5JU\CS-7ECHF/RRH147M#.C[0A')=N("[)K>JW\ 4$L#!!0
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MVS5TUFY?]^+M#OM:^27:E0P74,6,>-(CW^Z%[4MTM>QB"Q>QV<ECB56:?1+
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M%:("]>)>9'<OC-VFPF"J,\)J&PBM >&<D?/2B7F&S&,;RR%QC'M< 2'<*7C
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M2%E;X8(>F.RCH1S?#3*L$RE%A?;M="/"9:%%:XKC:)K:^[@[!_HY%_53T(!
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M,3A] =NM5^,=2NM<X=3=P+74<C+T[\19]T)CD+!^P!8#^0[*OU5EY0%V.F2
MKK+_-)RV"AS2ZQ:4CAH_V<\QNW1A[CT+4;WP7PHYE$1HTT?;T8F@HZ5K36D,
MT,BY/X8_8QQ8+\( @2N7#NM-((3_J6_SJ'"<#97Y^%8N0>\8/848IF8&!:+B
MXJ!)=MOHC:T?9%%3[4M=\##Z[F'KNYW:=^'WCV!MZ\P#8#, DVT,]GNQE0]E
M^$I!Z&ERY?XB^-1]P(ON\>T[14*EB]I;)*:A$#N#,D8K^7B9LFV\L5GPH*60
M%N"4U)UP!B)ED_-MY3I/=5@:LUA08T9UY%9&",=0^\0]T4X@PX-05I!]S:#K
M]"JG)*$"-#@$\:B+>W08[#';?2D9B+@F. #-E(/Q'E4GU[E-<X*M!/4M$%&/
MA NYJE8FY8+#GPIN>A$<':P#+SO]&V$GHQ!T3_N(%SATT&BHB!,T J2M]0H<
M;8,S!6:JP"MLX36*K"O%O2%^=J3P_H;#8CI:26I/N)-$6TI;VH#9U]$_9XDM
M@7[L8#LBM;K<UC;TL8/21)OLU-O8LN J7.!";\O[>X;>TG*P+&<HK(2Y7$0?
M]Z@!_$R&=]@8P7U;MFS2.2D@O3 57$%Y6$LL,!4.%,R09"#908-Y&X#D3/^\
MNKH9B[?0NUG'KJ3OW;ZP[9VYG4!#\Q1$:D!J6)^.N^C/5#RS#09K%8B<$LAZ
M9.H.)4 Y>G_T#;<35F20O4G%.PXWL$V*(M_=*0P:06XKD]RM3 :%-3QTFEA)
M+:9\)&TR>DG$CB'P\2T%)3*=:@*_8->@/H[?4MIA>_==G8+5IFQ:=IN2!SXZ
M\T$ 6"3[4<$4QV;\@]1W+S-N7>@BZ1!-$UEI_T(:#TQ/?QI?1)5"Y'NI,QG1
MF,LV'ACXD3!MN+@8G[7KP:T"/6S@/C46'G4!WJN,="(SOW&+S,EQQY+$G>%Y
M<#N_/#R==/I#!AA#LR2:%^C,$^KJ!LV;IKH!6\,\F$5 K.C<ZZ0SYG@ZYQI#
M6DOCY[S5QME)JPW?926)I>37/39PU_ _%K=-"1-K*2ZE9#--)X\BV](S(BYJ
MPV1L#0H4TBGENS!S"PDI.@2\ZC?D,+K<&:W)DHH44."NA=8W]<-K1:Z6AZG'
M^SADVJJ8=OL0GDMD&H#/9JP1H=N.ZOM.(KLSM/ 435W18)H+=Q@$Z%""Q[G,
MXE"7%O6'BKM,6 B@>=RQJ$D]FVUHBJT!*^%!4\D-'S@\;CTSY$\V7<24L7C=
MCFD6VB(#_8Y*A8H9K/:U2KDUX6I I%^O[R ;10%/Y#C(2KEA];-MPJZ!R5PW
M!+Q#&K^HJ%FU6*0*RI^*QE9SP"L=$-HAFC,Y K!(>:LZ:AN3?W1F>5Q4+GJI
M@1YNAG.8:82)-CX!\NH-S3]\P?3-3WW5TK#VO2BP%@4<A=#IY(>HJZ@"7Q7T
MS.?:H0/[-.ONCVI^GZ*XLFZTY5EMPXT8BZ$&SD(EMM<19MV@\_UKI=TBE &=
M;M47QTL%/Z=#?U6Q7/;/96C>"!E*DKLN/'B 8A@TD>9]149SF%BH-L937-N"
M],:G_8KXD] <.*@M#2550?-,3GB6:KJ:< :E=M:PP38V(I=WJE.R<G(E&JY]
MYN4VJ.H;H#0E&8=,MT;?#G,I\CWT&V =L@0S$8G,%,NG9"NQ-"@$D.G0WD&"
M,.HD9*-CR636MUD,</XJW#F7OQD;'KD0O6[SLW\6T*:)_C3$]QF-1W)$.F@,
MQ5(BV5=93:C_K))Y4^0U:1H(">R$\536%!(NRJ"KVK*&5?.4C*IG'N9CH;;I
M4P+>C< 9J6\L<!X]E2?!@K$A1&Y2D.><U^G9X .I(E[9.):[@HZK@ )^+9 T
M. VA/DX@ @ 3.:#FJ;.IEZN^5?U4D\U.1+FC4DN=;'DDXRS)%D+?=_W^"4]M
M(5T_."9! WFNJY"NFLEJWZ&C^[)/=9D7<2H278Q<JY)WOK5HI:>R+B\S>J+F
M#6$X*LD:S22K_V3Y!G[3>V2"3?$P':ORW)^TI?W$/XK&<G9@TF136",IK17@
M@W(?URE]<31I4GJ^*"Z3H)=0Y&MZ=R.M&S;([^@YH%5/.9Y#18?5.#110\<A
M-?+3WL=43 ]!GC8'=9GR<+BK*<;B#K^QUV_<::\33/M]4UNT]C/R9'S>JZ8.
MSSHICT7NLN2?XI"G*NX91P+(2H^)?-W1&0L@(AK\:SJU51S9._VP_P',5.CA
MD=:N>F+":[(EYXTP'*+>(+S&$['+%ZA>"AD>S4:$&#[A3S,_HFJ(,5-4FY(K
M*CI//.%L9FH'$N['9S3L]<W]VW# -SZ@^UY*NR8R<8NC>ROZ>OO&XEWYK/^F
MXS9SU=(*675 U.LZI^*5;!=H-)NBN_7/N^5GA%0W<O7/HPC?K,[A%@MJ[P_%
M^1D^IA>GO<\O%!CT2$,FV[TU]WJSYV(VFIQ/>Y\W"&G$N@\M:B TA>+IQ;DX
M'IWC\W0T/9OA<X)/KXI#<79V3)^CR0E]GX].IA?\?8SOH;=FCCIO*>7*+OE=
M+'ZL453^A:7F:O.ZUY5_RZE=[M\5^R3M4@-.,K7 5@3:Z8$?;L<_E2GYG:>Y
MJ2J3\T\D5R K+<#]A0&HA#]T0/,2W.7_ %!+ P04    " ")F013E@?F4? *
M   @'P  &0   'AL+W=O<FMS:&5E=',O<VAE970R."YX;6RU65MSVS86_BL8
MKV=7GJ%EWBFF268<)TW3:5)/E&X?=O8!(B$+&Y)00=*V^NOW.P!OLN5+MMD'
M6R NY_J="\B7-TI_K3="-.RV+*KZU=&F:;8OSL[J;"-*7L_55E1862M=\@:/
M^NJLWFK!<W.H+,Y\UXW/2BZKH]<OS=RE?OU2M4TA*W&I6=V6)=>[-Z)0-Z^.
MO*-^XK.\VC0T<?;ZY99?B:5H?MM>:CR=#51R68JJEJIB6JQ?'9U[+]Z$M-]L
M^*<4-_5DS$B3E5)?Z>%#_NK()8%$(;*&*'#\7(L+411$"&+\T=$\&EC2P>FX
MI_ZCT1VZK'@M+E3QN\R;S:NCQ1'+Q9JW1?-9W?PD.GTBHI>IHC;_V8W=ZZ='
M+&OK1I7=84A0RLK^\MO.#I,#"_>! WYWP#=R6T9&RK>\X:]?:G7#-.T&-1H8
M5<UI""<K<LJRT5B5.->\7HHKF+AAG\56Z4965R_/&I"EQ;.L(_'&DO ?(!&S
MCZIJ-C5[5^4BWS]_!G$&F?Q>IC?^HP1_;JLY"UR'^:[O/4(O&'0,#+W@N3JR
M?YVOZD8#$?]^A'PXD \-^?"OF/ ;2; +56(FH^&-;#:LV0C\:2%8:8TMR-CL
M(]?9A@6>M97#;@1!$M29:C6"ALCQ52%8;3G4!L(Y0SP0Q1N^,[\7O[[]Z)A1
MMI%BS<2MR%H*%Z;6:YD)[0!S%8*T-IN0$C2GH*H9T@+;MGJK:JRI->-%H3)N
M5-"BAA 9YGF5,UYC1TWS.&R2296).?L=+ NLR?7.B#PA+:M&L>9&'52#$VOP
MNJE?L+__;>'[\0_LW;4JR(H_"5[ 9$NAKR%[#:ML)*RT4:T1$ES.<X22) @8
M)9>RW!82BAK.K%9%:U,&Y(;R#7(;LM:V]\U6;=O";MU85K)::PYR;=:T6OQ@
M#O927<#9H%RP94=V$$A66='FG4CU5F02Q':=I0T>B,YVLZLEEJI3I24FX;U&
M-:"7J;HADV=<BT%F$.>%FJ+F$S+C!<ZU>M=;ALCVQKJ@TY=<-Y700(?&6CUG
M'RP^E,YEA5P-7JVN"0ULU<*)\*3S(,)(1MUY#^1JGEE_&HD4H,DK!>(:SM](
M')2TOSN]?X)$:U!J2.="?J4(D#H_W4+:W?Y.\,H%R)0$_9[6!&@6W%I<BZKM
M "EN4=@($%IDZJJ2?X+)RH;#(,R&-TQ:S,,")&?'6]F '$4PLHI"0@ C+A"3
M03!5R)P/6,H5@^J,K]>H29-U[$>PH([ \E^Z<&2ME<U(3.1XEL$=I(RUY&_S
MY9R]/S^_-*3/\_^@6(#0NS<?OKP]I_BP&A?BFD.5 S9AI> UX&JLAUU%"TG,
MJ>DFN'QBDBZ6;9"+,<3G]P2 V?A!KLA.^ 74>_[6S$@T!$!.>J_;@EU31>^8
MJVLDA:(8DP,M$/QZ,'8N+9'.5LB DFAU#D3DPBD%U\7NM)%- 0F?)55-@AA$
M&+#"6^665_(!56W2I2S'*G12A:HA4=-HN6IM=,#$H%!2=MD *AM5Y*0N]-C/
M6@Y"+YM#"TC6A89 F"-5J!(H'B8Z]#ILMM7J6E*/=()3%>1H3%*V)UC#;RD#
MY@(M&]0;H,A+2F9_VHD^%) [>M4($K<F/3'Q1RLI+8EFHPC8U^!O[(>LR:6F
MH6,U-J0H1;:RWI@MT"\7*ZQ?40Z=T:X3MM:J/$A5D C3G2"8RQK%!7ZAX@)/
M=Q#<"RX<4BJ_D8#(5*8,WJ>2!7IK3#*"N $T#I.4)"#1D7D/*Z(L45C+:JP&
MAJG3H:"SZJRSV(E#[G8>]GFEJE/BIE&KJ'3T_H.>Y\L+%KNQ32+2LC+6-W'F
M4%6% DBZ%/BM$7A_ ^5>>Y"6J!I@$@UC]O74%GF"+*3<\S%V"(HFPGQW9 \*
MG76H-[(%QMK<F<(68@!Q"F6A'DHLS^!/*\TIDH[):8:^L>D][\.KU@DM-2-#
MS9^CH1F*7^^:,0L>2G0P\LIF+;Y%*&RUI,0$6&F9[6<V"QO@0]O]J)**+->Q
MW^],^@PSY#URCQ4)W"$=3$PI+M/D=CWT;2 A55YW^7<WE@3#4MC,#]JR$67=
M]0$D$-4%(,^ SK1=3' L=>S_48.U%H=%M37#=D.T9,!7,P1\;4)PU(+Z%'.5
M(4]3DAB[2C).+6_WNTLTXF)HQ,T6#%PVD]0=H)NB7N%DSBZALC[="7Z8T<SV
M.23:8$W;P=SQY0D#WN%-0=>]NN%='H+1B5A?=$=;#PU7%^E(-76&\+/E]Y."
MT;WY0UWA@;X,J7?2B2S;E97R0J&]U>3"F7>"ITG5_MP!\\?.EE^,+:?7H3LV
M_$+!/IJFCQ]VS'PGBD/\4MOH^3_LC>ZOV9E+Q)DQ#;EFTCD/9!/?2:*4>6'B
M>&G(9F'LGC#?2YTP#09J_?,7HVT?:\<LB9S #S#HCQ]W!,#>]QTW2O9%ZN:>
M:0OW$5LD4?2 )>ZNT/.35EC$3ACXS /G9 'XQO&"K! [41A.K&"?[UIA =T7
MI&E__+@C (V]Q/'3=-\*W=PWH.X!H"W[6+$2/1MB=Q/D,8-B@6<T<**45/%=
MQ_,71A.HY)_8M2",G^^\0US2D&AZON.[9"; RC,SLX43^ZGAXCJ1]TW&^<LA
MN412^Q\#,G73!V!X?\W./ E%+TJ<!-;QD\0)O02F20&E, @=1.% KG^^BT4O
M=IW8,.[/'W<4CG$FZ9PZ"M7//<L6CP5DY*1I\( M[J_9F:=MD2P<) WF1Y$3
M1SY<Z01!3-9 =@L6$VO8YWO66)"5*!_T%(X'&J3[HH/]U!YV[O\6G$^ [7[0
M(%C"A*SGITYD!B&R* *15 F<) U,HH&AHN"Y;CS Q7,2+[8AZ8?$!9O3*#5<
M8BHE)CA#)TBCWES?_-.%8F^EX>7&-4=[T-;=#0L-Z*9%VS)>'7%W$%>\<,:7
M3HZ%3'?M&@E.W[$,=Y:#W4_?_-3=2PJT$)DLY+3%'3/&XTV)Z>*_QY7N>_5;
M+YZ5I)^)2$-_''WZ'HH"5,C\;D*8FODNBH[OF;&W<%(OM-,+5(D$X/X%M_<7
M-LN/]UP6+UCB1H"KQSP$2#1NZ-Q.E<M/0(M^4_0D,T12['EV$"4TN'SZ8@Q)
ML3- [D9SE+@^C>,@9&^?=5T&KQ :Q<04"<A#'I[!LIX;T,!#L<72NZ=OST.&
MNOL[H\8K +7W='^B=[8F0R,L8/M2E"NX82.W]\ZA$TOCL9S\TMW-T3GSW?ZU
MG)!]CRL5[@C*]!/O[U^NQ\W(P-#8/3DP8Z1^[++/0F>1I$C?:!0"RH5QC'(0
M.@ER="_T@?O_@^9"GQ<"=A?V-O =KOTCZ22"+R,TP8'C0LA?37(:[M1DQAGY
M/X@ I  X\A>A>9M_YX).O6-P,I78#2?/RR=N[Z"-0F?@A3:"?A,GB%+SZWNF
M+NU=[D=& <5(Y)N ,9 Z?\:MGZ! Z$[BA%CZQ-!#=X>G);T[%U<[F\@.O1N8
M1 F:OGVE]Y[/QU<'O9$2XAJ8^$8Y3$CV>-''P3/>(YA:-.+9B5SX!JW!(J"G
MA!+/@2II6^"A2QWJ[O<IC1_Z@GCLS5-6(IY(X:LNLJ<P?TBIOH(\7C?F[-Q
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M:,&IOHC&4T[T+,K&BV[/-_^$XN,X]]/^X=7A$\\\1!^O?GF-1'&..CB3)KW
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MA<^2?D1HV8#.<V/\;L$!AE_;XAM02P,$%     @ B9D$4R?HF=@A&@  ^U
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M\,?Y\X=T[K1M/OAN8WL,W@[.#UJ.R;:D\T,59,T--,TLG/-J: )/B6I?.;N
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MA:>=)!0L,Y!4.E4X/NO@$L$* ![R=AQ/%*P0LQZD+Y >N/<7/P9?!>3:2T)
M FB,,VLD@^]@EK"^>D#QC*?(E\+-,I[9Q\19]G7:UFY\D!:8EW%"X*(8? EC
MQB[YE,2Q;>#=R_AB-;LD*3<UN!A26'&Z?MHC7H2<JH]Z/38,Q_8[4QU"<RA)
M.R42HP1;/!V"_'\$74HF,/"86!N,(<'8O-_S&&JDD Y[)RC5GY=<(49R0D0T
M$;;4[R_J)9(VQ/N3QD.8&\QUZX5<(G(@E:E/P:%O$QSZ]B2.B>9P"@%]VDB
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M;"]W;W)K<VAE971S+W-H965T,S,N>&ULO5A;;^,V%OXKA#=83 #%UM6VIDF
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M0'<O/KH'JQKWLF&IK%65&Y(_!6H6H/654G;WP J&MT]G_P502P,$%     @
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M/AH$H.MA52^LVOH!L5:6QHTW"YKOJ)T#G>=*V?W"!6C_,69_ %!+ P04
M" ")F013,X,Y2OH"  !=!@  &0   'AL+W=O<FMS:&5E=',O<VAE970S-RYX
M;6R%5=]OVS@,_E<(8P\MX-6_$Z=( K3=AFVX#<':[1X.]Z#83"Q,ECQ);KK]
M]4?)B9=N2^[%)BGR^TA:I.<[I;^:!M'"4RND602-M=UU%)FJP9:9*]6AI).-
MTBVSI.IM9#J-K/9!K8C2.)Y$+>,R6,Z];:67<]5;P26N-)B^;9G^?HM"[19!
M$AP,G_BVL<X0+><=V^(]VL_=2I,6C2@U;U$:KB1HW"R"F^3Z-G?^WN$+QYTY
MDL%5LE;JJU/>U8L@=@FAP,HZ!$:O1[Q#(1P0I?%MCQF,E"[P6#Z@O_&U4RUK
M9O!.B;]Y;9M%4 90XX;UPGY2N[>XKZ=P>)42QC]A-_CFQ%CUQJIV'TQZR^7P
M9D_[/AP%E/&)@'0?D/J\!R*?Y2MFV7*NU0ZT\R8T)_A2?30EQZ7[*/=6TRFG
M.+M<:?J^VGX')FMX_:WG'77<AO"1[L/% UL+-)?SR!*3\X^J/>KM@)J>0)W
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M?!7-'<0+T[$:%P&=-(/Z 8/EQRW"6@DZ15QNP+HZ[8\2_XX&+"W73.M'M_K
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M9:EE>W-+=R1JYT#K:T5YW0_<!N.MN_P/4$L#!!0    ( (F9!%,=!<?RQP0
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M@TZ?]*+J2TO]8N3&713FTM"UPYEKNN>AL@'T?2FEV;W8!=J;X^1?4$L#!!0
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M4).-VFV@[W-%0;83YV#3MD_^!E!+ P04    " ")F013"="V@*P#  !*"0
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M8H.PQJ5C!$G;(]Y@73,0F?'W 3/H5+)@GSZBO_>^DR\+:?%&UW]4I=M,@B*
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M[>CN]>2&?G;0, -]7VGMC@=6T/T^3?\!4$L#!!0    ( (F9!%-I/"RU>@(
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MFAR_.XG =N.A,YRI0TLNC>,&#\N2)RI:[\#GA3%N8WB"?D;/_P%02P,$%
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MNJ&_ :BL )VOI#2'A34P_+&8_P=02P,$%     @ B9D$4RU"8XX? P  U08
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MS.F_@]H9T'FFE-TOG$#S)YO\!5!+ P04    " ")F0134N /78 '   =%0
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M;"]W;W)K<VAE971S+W-H965T-#DN>&ULG59;;]LV%/XK!UXPV  7BQ?=NB1
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M$,#Z3 *V<F $;*^(3_\#4$L#!!0    ( (F9!%/V:UX,1P(  %X%   9
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M0OM:_+*R Q"T ]CS0BD\&.[)C",U_0U02P,$%     @ B9D$4\0H00\R P
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M!QL/EP9K_2.0[:C+=A3<SA>-Q8H#9P7^ZV.%P6D"]TB5#M0QZ>J8_)>L]&Y
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MR%A"'M]RH[W"IP%6KQ^M7V>#Q\$LN8(+$?T=!GISVIOT2  KGD;Z5MR_A7Q
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M> #2?(#O5P(K8GYC3B2+_T"8_P]02P,$%     @ B9D$4X6P.+9!!@  G1P
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MV"Y^/LL-*_KK=5CZ&" Z.P.&=/NNW=$^O5;VX,!*[U<@!KIBQ0M6UZK2\2!
MU(*<\_Q,"=B"E_T* %6^S:$(AD.A0TR"W00+W$DW'"9GO9(=M^H-V^7;-?3D
M52(1A&0O(D;.P[K+/IHZF+H0VVC)KD:EY"L>V6B*C!MK?:PS2OQN5&PSVM]A
MM]*,V*79?[H7G)%A%6> F.K$!/-(9U.Q,#KKK1/2BCAB%W$_OKF#J]LTDNK8
ML7S-VO@A50#)TKH-(:W (N3('2!I]0HY1*]8]H!D6*08(%K;-F&";D9-8J>G
M99-6G!"[.#DNGP7+DEUFS5LK'HAW;-[:%DWL+7HX;_[@,0O1^RKLWAW239T.
M<]U)V&UC!IC:<_3EKVW4Q-ZHC\K???W>H7?K@K$,=M[65+;ME1Q]K$#:SD3^
M=P<+<Z+W$]C]=/<5!A0)NJB% >53IZ<]T;8]47M[.G(W/:_=[QT0.AI%$PIK
M% TH%_=25+UF_TZ[ME/[YME\9GH]8 6=/-W%4 5O\'GX\T^PV?TE2R!Z4"#K
M*,D1_(_+MT7M35=]7;Z41B"+D4B>45:=YS-UGH\^[G+6<QY>\1R_^A*2L6)=
M?K,2:,EWN:S.59N[S7>QZ_)K4.?^#%_,L>'^#;Y8F.Z_H_CBAIJ>0,S@23G&
MN)U2]>'N4U2L$R"<LA5,SSF?0.T6U;>PZD+R;?GMYH%+R;/RYX9%,2L4 )ZO
M.)<O%VJ YHOD]%]02P,$%     @ B9D$4W_,*67$ @  I08  !D   !X;"]W
M;W)K<VAE971S+W-H965T-3@N>&ULI57?3]LP$/Y73M$>0 *2IC_&4!N)MF,P
M#0U1V!ZF/;C)M;%P[,QV6OCO=W;2K!2*D/;2VN>[[[[OSKX,UTH_F!S1PF,A
MI!D%N;7E61B:-,>"F1-5HJ23A=(%L[35R]"4&EGF@PH1QE$T" O&99 ,O>U&
M)T-56<$EWF@P55$P_31&H=:CH!-L#+=\F5MG")-AR98X0WM?WFC:A2U*Q@N4
MABL)&A>CX+QS-ND[?^_P@^/:;*W!*9DK]> V5]DHB!PA%)A:A\#H;X43%,(!
M$8T_#6;0IG2!V^L-^H773EKFS.!$B9\\L_DH. T@PP6KA+U5ZTML]'B"J1+&
M_\*Z\8T"2"MC5=$$$X."R_J?/39UV H@G-<#XB8@W@WH[0GH-@%=+[1FYF5-
MF67)4*LU:.=-:&[A:^.C20V7KHLSJ^F44YQ-IMRD2EHN*\S@>XF:N>H:.(99
MW5=0"Y@PD\,%-=S P10MX\(<DL>=KA ND0F;TVX/TI$[*)4A(R'-GV#&!)+[
M_6P*!Q\.X0-P"7>YJ@R3F1F&ED0Y:F':"!C7 N(] @9P35ES Y]EAMGS^)"*
MT58DWE1D'+\)^+62)]"-CB".XLXK?";O#X_>H--M&]3U>-T]>%<R507"S#*+
M]'KL$8R98#(EDW_E5#4XSS+NBLV$[X)0IM)H7+'KVI/]BU952<T@.%%E7"[W
M]0M^?2,&<$79S.\W^/=:_CW/O[>'O[\["W]W2JU6G)KDB!U4[D9P>0BJ3DV,
M_),F(?CJ-:C3#'P:-YM623^*XF&XVN[-2Z=.-!A$K=<S"?U60O__)'"Y0O,.
M"?T7[([CWJ?>CH:77MW3>$=!N/7B"]1+/P@-I*J2MK[JK;6=M>=^Q.S8QS2#
MZY'Y#Z8>X-=,+SG=!X$+@HQ./A(O70_%>F-5Z>?*7%F:4GZ9TW<$M7.@\X52
M=K-Q"=HO4_(74$L#!!0    ( (F9!%./]"+)UP0  "84   9    >&PO=V]R
M:W-H965T<R]S:&5E=#4Y+GAM;+68;6_;-A#'OPIA]$4+)+%(/=@.' .IC:T=
M-C2(V^TU+9]MHI+HDK2=#/OP(R5%5""1-KKLC:T'WO%_Q^./I*8G+K[+'8!"
M3WE6R+O!3JG][7 HTQWD5-[P/13ZS8:+G"I]*[9#N1= UZ51G@U)$"3#G+)B
M,)N6SQ[$;,H/*F,%/ @D#WE.Q?-'R/CI;H '+P\>V7:GS(/A;+JG6UB"^K9_
M$/INV'A9LQP*R7B!!&SN!O?X=AY&QJ!L\2>#DVQ=(Q/*BO/OYN;S^FX0&$60
M0:J,"ZK_CC"'+#.>M(X?M=-!TZ<Q;%^_>/^E#%X'LZ(2YCS[BZW5[FXP'J U
M;.@A4X_\] GJ@&+C+^69+'_1J6X;#%!ZD(KGM;%6D+.B^J=/=2):!CAR&)#:
M@%QJ$-8&81EHI:P,:T$5G4T%/R%A6FMOYJ+,36FMHV&%&<:E$OHMTW9JMF R
MY85BQ0'6Z,L>!#79E>@:+:N!17R#Y@<AH%"(%FOT.R^VUPI$CNZE!"6KAXRN
M6,84 XG>+T!1ELD/VL>WY0*]?_<!O4.L0%]W_"!U:SD=*JW<]#],:Y4?*Y7$
MH?*W0W&#PN *D8#@'O.YWWP!J3;'I7GPVGRH\]4DC31)(Z6_T.&OR4>9@5N/
MQ[#Q&)8>(X?'KUS13(]WVV]?FBHO2>G%S-#C3,=S;&>BVR(,)SAJ6KV2%S7R
MHHL"SNPX^Z*.&[>Q-^H>MZ;<UNV:Y$U-]N4C/IN/JD7<:D%&DW'2GX^D$9[X
MATL< 'T"FJD=^@<YYM"5>;'GT@2Q0:MGM*09>+(V:CH?O5'UC1N/8_\X4+DK
MYW%J+N#'@1VUU**W!.?C;D)Q-![W)W32*)AX%3R"5(*E"FH-1HRPSUAQU#>Y
M2]*D(RD)^_7@P'(Q\"JZ3U-^T/UI&2GH?*PRN$(%J%[Z!!T!812.'!)::,9>
M"0\"]I2M$3SI15M"A5JN=B#.DV)>^VYKBO'$,4S8D@\3KZ;/=B2N$-4"<BX4
M^]N,&Y?]R2'=Y(R(2X@%)GX38LYK-_%E0,26B#CZ'RNV=OZJ9+$#2MCB%/MY
M^A.#T\4C#B9XXE!B^8C]@/24;L&+"T8MZ5:O2Y3E)AZ=28^BQ9;IF5SW[)[0
MHV[1!./ (<!B%OLY^ROGZQ/+LMXNNUR-1T'LZ-)R%?O!6DT33Z*[[(PC,G'@
MDUA\DN M=PS$0I'XH=AP>4^?#93[@B)=]CDC:NWY_.33'0NSP+<BZNV[BSN,
M2>(82&)Y1_R\>^D^Y;F94K0Z!.E9!?D^X\\ : 4%;%C_,),N!3'&+E$6@L0/
MP05L0(^S(=\1]/:GM^LNZB(<.>82L:PC?M9I_H(X M(G691FE.458_3NJSS;
M%BE<F^/=&E$A]*P')XI)%X&3<>Q8GX@E(/$3\#_O;>>DRT"21"/L4&8Q2/P8
M_%)B.&O.<><*NLM"[%J^B44A\:.PJ1Q%G]H*G$@F73Y&CA6!6#J22^AX+@%=
M1)(DB1PI""TB0_\.\^</$;KY4A<_2W5-W6\%]!7W:U$6KR%^JZ.M)6=XEIP7
M;Z7#'GS&@8,68>MX';[E<A1: H9^ EZR'-4N$G],P]9''/,%[0\JMJR0*(.-
M-@MN1CHGHOHH5=THOB^_ZZRX4CPO+W= UR!, _U^P[EZN3&?BII/@[-_ 5!+
M P04    " ")F013WIB@^D,$   Z$P  &0   'AL+W=O<FMS:&5E=',O<VAE
M970V,"YX;6RU6%V/HS84_2L6VH==J1VPL0V,DD@[2:K=JB.-)KOM0]4'#S@)
M6L I.,E6ZH^O^0@0X[#3B?(R 7/.O;[WV/=Z/#F*_%NQY5R"[VF2%5-K*^7N
MWK:+<,M35MR)'<_4E[7(4R;5:[ZQBUW.6521TL1&CD/ME,69-9M48T_Y;"+V
M,HDS_I2#8I^F+/_G@2?B.+6@=1IXCC=;60[8L\F.;?B*RZ^[IUR]V:V5*$YY
M5L0B SE?3ZV/\'Z):$FH$+_'_%CTGD$9RHL0W\J7S]'4<LH9\82'LC3!U,^!
MSWF2E);4//YNC%JMSY+8?SY9_Z4*7@7SP@H^%\D?<22W4\NW0,37;)_(9W'\
MQ)N 2&DO%$E1_07'!NM8(-P74J0-6<T@C;/ZEWUO$M$C*#MF FH(2"?@"P2W
M(;BO]8 ; GZM!](0JM#M.O8J<0LFV6R2BR/(2[2R5CY4V:_8*E]Q5BZ4E<S5
MUUCQY.R9'WBVY^"9AV*3Q95X/X-%7+#-)N<;5@V(-3CAWB^X9'%2?%"HKZL%
M>/_N W@'X@Q\V8I]P;*HF-A2S:NT;H?-'![J.: +<W#!H\CDM@#++.*1@;\8
MY],1OJWRT28%G9+R@$8-_KK/[H#K_ 20@Z!A/O/7TQU3.-=Y7[[9^UDRW':%
MN)4]?,'>\B 2GDGPB;-$;L&*YX<XY,6(9=Q:QI5E]X+ERZOLS]\4%'R6/"W^
M&G%$6D=D-(0O0K)$E;7*N&E]UG1:T<O2>IAYV*?NQ#[T51^B?$I*B?JHQ1 %
M2> YSCEL:8#YR _\%G86*6TCI6\1"_P+'GD4ARP>VQY>Z\2[K6Y^Z\B_3K>:
M3GI)),BA6-/-@"+$09IN0Q2$* BT1; TP=P >V;=@C;2X"K=<CZ23NATQ=ZY
MK7*PUU?@==HU_'XFJ8NIIIT!!;%#]4UGA%%?6PE+ PP%J.?T/%C4!8O>*-]<
MI"G/PUCE0C5'(.26YV/Y[:HR=&\L95>F(;Y22CS,/L5$KY]&6$!\7<LAS%6]
M3-^()IBJL^2"EEVO@./-8JX&U(Y+P$HD^S*W8ZT.=H49TAOKU95GZ%VIEV?8
M+1X,],)IPKF.YPT4&^*0YV'DZY(9<(10U[V@6=<GX'BC&&KVNHX'N_H,@]O*
MA[HBC9SKY&OX9PW-I5C+]MP H]@AVD%D88 %-/ ]33L##"),(#)KA[I&@<8;
MQ8AVHUT/==49H1MKUU5E-'Y8_K%V[C#;CJ?WL[D!1K$ZVNC:#6'0HP3K?<^$
M0Y10YX)X76M XZW!*-[_['FH*\V(W%C(KERC\8/TCX6D@P,\\GRBZVA $:0?
M/0THUP\&.W"(PJ2W<NI([=Y=@%)A4UW"%" 4^TS6__2UH^U%S\?J>D,;?X#W
M<V@87\#[97V-TYFO;Y4>6;Z)U0I(^%JY<NX\I69>7]34+U+LJIN(%R&E2*O'
M+6<1STN ^KX60IY>2@?M==GL/U!+ P04    " ")F013^.AW?-@"  #+"0
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M_?1T<7,H)E;-?;<>*TLMR \SNFVA=@=H?ZJ4W4[<!:"\O_7^ %!+ P04
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M<4&*3-ZQS2>L @HT7\0R87YA4]DZ%D2%D"ROP$I!GM+R29ZJ1.P 7/\ P*L
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MVD!]7S FMQM]"M?WNO%O4$L#!!0    ( (F9!%-YTT[S#@,  /8(   9
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M*?B\99E0!#$SI-I#;LD(*W^WI3_4X\\"'UDJMP*LTXA$&OYJF.\.\ VEO0X
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M)7.8;8[-FXF@<7I FE(A#USI<"F_-( I@'P^IU1L)^K,E7^[]'X#4$L#!!0
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M\,(.: >I(I,*^;"G'$T@:$?0\T$+NT""'L9ANTH#1[JRR"3S'13VU*EY ^W
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MM">%XQ_C=%"/J0WWGW?>K\K@53#W1- YR_Y,$[D^'4P'(*%+LLWD%_9X34U
M)<"89:+\&SR:OL$ Q%LA66Z,%8(\+:I_R7>3B#T#/&DQ0,8 ]37 Q@ ?&"#8
M8A :@["OP=@8C/L:1,8@ZFLP,0:3O@938S ],(!AB\',&,S*<JCFKYS\!9'D
M[(2S1\!U;^5-/Y055%JK.4\+7>QWDJM?4V4GSSZR8O5>4IZ#!;V7X#U  0K!
M9R:I &\75)(T$^]4\QTM4L;-#V_ "(@UX>HQ+<#7(I7B:*_A4YIEJI#%R4@J
MA'J<46S07%1H4 L:"#ZQ0JX%N"P2FCCL%WY[W&5_Y;>///8CE=DZO6B7W@OD
M=7B^70T!AD<ZK<'7NP5X^^9=E2B;0P?,N=_K@L8[KS#J[W7A]_K[ME!>@Q(K
M-%X=7B[[>PG:O5R]")8/+X+ENG>V?5YN^G@IL<"9I[)PO7!QZ0^W^E/+]:80
MDF^5]DCPUT?5 =Q(FHN_/>[#VGU8N@];W-^2']JM &RIM$,-E0JQ)45,0<R$
M="[MRF%4.M0:^W"&QH'^<S)Z<" 9UTC&7B26D#QA1;6SZ#6R-JG=3[Q8KXA*
M$,G9MI"N#$T:&8)P I_FJ%JISI[!&#9Z7O7N>=VGYY.HIW744V_4-X42$"HD
MX$125]Q^<SP<![]YDC^K8<R\?LJYC5GQ0+G>BAV99TD3)4J[&3_R3,^LD:!I
MB#P5# ,KLD$WM.X59+SL(\"!#\">RL-^4T2_JVVR<,W2PK@8[Q=(X"C.*T='
MY(6)+$SDA3FO9P]L>*I2]59M)Q*6980+L*&\TK9WX"?P"MV%&6:R'\ITB' +
M/LNY$'>D,94IR?:JS)13";3"H]%YD%4#Z)FNH47#L 6896OHIVN[C=-D?00*
M=4S2S)V*N*W:89.O)].9;QHM8T,_93O*O81T5$E)S/(-*V@+K'&3IB8^5);Z
M8>1%]9D5[V,BUGK*N$S_)>5I:Z=ONU0!4B0]%6]A!O0M!+-BFAVQ-]56<*!?
M<;[0S9;':W7<4S ?:$$TQ7';6"VC9$N!9&"Y+1*B65"7\)H4*R56Y;J*=9MZ
M4\E0!D6<;E2/=J+LP*188QAX*1U::8%^<7#&)TBVBTSA)P<1Q <DXHS /RK$
MG1%858)^67)&(#E)TF(%$O)#+0UUKDOS;>X$ZG>.@M*%[Z1B10KY1<H)5"53
MT'BK;R3Z@^X8"'>#ML*&_,+VK/HW-:^I^DD%/;]^.E!UKP!D-1'Y-7'O0/X3
MS%F>*UQWDL7??-ZMHJ%7.48@JTS(KTP]MSZHJ480>Q@263%"?C&ZY2RF-!%@
MR5END1C>=V)I2A">0A\8JT'(KT&MDZE?,R($..\]QU8CT.15YMB2-.HZ #2V
M1?HH4.[8W@"=N5ZR8D:!<"_Q:AV-PVD435HR;VD8=3$E@IW'2&S)$@>OD5-L
MB0W[*<1_E)P;ZR?KQ1RW#\^2V+%=CR9XTMRF].YY[1B^T?-IX);OL)_ONDZ3
M\PY[U&3>ZG[F^79/(]B[F?&?$AH'4<;355JHVJ\VY^TKP#CN?P3%EH?Q2_#P
M'#=Y.(Q\ "P/8S\/]SF"XB;S(D=)7SKZ1:Y]MZ,?=O3[X.@'O6FWA(_]A/]L
M]9D;AP=80A\:JP3X_W=:F'=@ZMXK82M$V"]$EN1_65ZQ518\>Y6;6*LUH7^_
M_#+R.C>C',IK"*-@BMR5%5JY"OUR]4(W-W,SS/[-#0J'0<O-36A5)>Q2E5^\
MN9F; 9[<W(R';8FS8A'ZQ>(S?>S<EH1[M_;AJ]2B9?&PQ]7.KURRA@Y*1E,7
MNXWVOFKFE*_*3^("E+<TU8>,NK7^['Y>?FP^:+^ QW/H:%_ XTM7^Q4\_E!]
M;+?#5M_^/Q&NA%R C"X5A& X4<'PZG-Z]2+9IOS6>L^D9'GYN*8DH5QW4+\O
MF9IJ\Z('J/]3P]E_4$L#!!0    ( (F9!%.#P&NGU04  )D=   9    >&PO
M=V]R:W-H965T<R]S:&5E=#<R+GAM;+59;6_;-A#^*X2Q 2V0Q"(EOQ6)@<1N
M5@]I$23M]F'8!UJF;:*2Z)%4G S]\2-E1K0C^:PN<3[$HL3G[GAW?.Y$G:^%
M_*Z6C&GTF":9NF@MM5Y]:+=5O&0I56=BQ3+S9"YD2K49RD5;K22CLP*4)FT2
M!-UV2GG6&IX7]V[E\%SD.N$9NY5(Y6E*Y=,52\3ZHH5;SS?N^&*I[8WV\'Q%
M%^R>Z6^K6VE&[5+*C*<L4UQD2++Y1>L2?YA$'0LH9OS!V5IM72.[E*D0W^U@
M,KMH!=8BEK!86Q'4_#RP$4L2*\G8\8\3VBIU6N#V];/TZV+Q9C%3JMA()'_R
MF5Y>M/HM-&-SFB?Z3JP_,;>@PL!8)*KXC]9N;M!"<:ZT2!W86)#R;/-+'YTC
MM@ XV@,@#D!> CI[ *$#A$TU1 X0-05T'*#3%-!U@&Y30,\!>DT!?0?HOP1T
M]P &#C HTF$3OR+X8ZKI\%R*-9)VMI%F+XH,*M FYCRSR7ZOI7G*#4X/;T2V
M.-5,IFC,IAJ=HI%D,Z[1Y4(R9I):HW=CIBE/U'OS\-O]&+W[Y?UY6QO55D [
M=FJN-FK('C6_T^P,!?T31 *":^ C&#YF\1D* PO'@QKX^(#V/'N&UVK_V!P>
MU,"O7Z?]M]=I_]3$=7@O?-(8CKN[\+9)M3+?2)EOI) 7[I5GLFR2*2WS(KO^
MNC$3T$2S5/T-B ]+\6$A/MJ;SDJA@H97]*E0(.:&^Z;Z!&5,UV7.1EZWD&<K
MP\/0>.EA.SD.SKBNSCC% ]SI!\&+F;]!LG86')4+CL %3S*N.4W05[N%;P3-
MT#6-><+U$_J![EF<F^U<;&W N9U25^<8L>N6XKO@4HSA#-%4Y%E=H$;=BNMZ
MG:#XJ_=@KU3; ]56".\'*M9E$F?S"%A:O]31/X;G!J7XP=MF_=6@XDP\(( S
M<>#K20#:\BTS(92:_VORSIJ N%(YS4QH8Z%J;7$".UO&##J0+5NU#<-^80NS
M-=BCZ0P54[6Z<45WV-FOV;,<)J]+*G-C//YZ4^Y6( NP)S\<'B/-L"<;#+/-
M9_K(TSQ%4R$-EF<+%-.56<%+^UU-CRI9YG;L/O]Z)L(=V+\B3;DN%CEG#*V8
MC,VUZ<YK[8!EX;,@^!5RCR<P##.8+?#HB]!,%>2;<2$W0TBZYRG<.TIT/4GA
M_BL(>.S0V^$DW5[8JU2YZ\8S/S6>.:F9B0E8 +"G3PSSYR0S'3!3&DFJZS,(
MQI-J!CFC?QJWVU1YUB4PZXXK3%M'=Q,G9=N)41=P(?%42V"J==GNR,VQ&G<;
MH5$70K9:R*/TD,3S*(&[R&;>')%J-Q?U(&]ZGB4PSWX1V6E,U1*Y6DJ+@P%7
MU-&,J]AN4D2SNAI;9^M'LH^+7S2H-?,PAM;D*9O -'OWW)PHNY"D?.^T\XI;
M<4VWM:G23O).A] '\]93-H$I^W;+II1^9Z?KI4A,09$LY7E::TRW:@P8=4_P
M!.Y$+^-8YF:C<$='M=I[5<*$E'OR)S#Y-]S 9G@Y-^8AO63V@3 I>)EE_(%)
M1>63=:-],DJ$LNV!&^X5/LTUNI7VF1;%S*]++G<D0AO:$SP9'.6MT_-O"//O
M'9NQ=&5WZ8EIB9+$))"I^YOS/)=+)P>ZE ,:H@.U(O14';X)5>]$NA*65P?Z
M6N12+QM&.O2U(3S.^<+6 0-<&]XBTK"&\%"D?1D)X3+R?R)=C<OK0\WGS2/M
MZTEXE-.(T)>&$"X-;Q'I ^\+AR+M2T<(EX[FD7:O<)!67S/"HQQKA)ZW0[A!
MMJ=:M7Z%80.,9O0)>NN*/+-',.\V]^S'7(J92!(J(<6>IB-\#.=&GBHC^(SB
MBBJNT.8;F3T]>J"2TZEI?O:]!1V0US^0S9'GV AFP.8^-VM@Z*YB[Z[>K;/4
MZ"@N]YP5P3WPS[L<EM?;Y_+VUA<A^]'R,Y4+GBF4L+D1%)SUC%RY^0ZX&6BQ
M*CX23876(BTNE\9()NT$\WPN#/>Y@?WN5'Z-'?X'4$L#!!0    ( (F9!%-D
M7),@SP(  *@&   9    >&PO=V]R:W-H965T<R]S:&5E=#<S+GAM;(U5RV[;
M,!#\E8600P(DULNO!+:!Q&[1% E@Q$AS*'J@I;5%A!)5<AW%?U^2D@6WD(WJ
M(/$UNS.S)#6II'K7&2+!9RX*/?4RHO+.]W628<YT3Y98F)F-5#DCTU5;7Y<*
M6>I N?"C(!CZ.>.%-YNXL:6:3>2.!"]PJ4#O\IRI_0,*64V]T#L,O/!M1G;
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M06]DA*KZ7JP[)$MWM:PEF8O*-3/S*T%E%YCYC91TZ-C;JOTYS?X 4$L#!!0
M   ( (F9!%/ MFLW3@4  "$7   9    >&PO=V]R:W-H965T<R]S:&5E=#<T
M+GAM;+58;V_;*!S^*BC:29NTQ08G<5*ED=:D73-MNVK5[EZ<[@6U28)F0PYP
MNYWNPQ]@:B<-(:[4]45C8YZ'WS]X@.D#%]_EAA %?I0%D^>]C5+;LRB2V8:4
M6/;YEC#]9<5%B95^%>M(;@7!N065183B>!25F++>;&K;;L1LRBM54$9N!)!5
M66+Q\X(4_.&\!WN/#5_I>J-,0S2;;O&:W!+U;7LC]%O4L.2T)$Q2SH @J_/>
M>WBV1*D!V!Y_4/(@=YZ!<>6.\^_F99F?]V)C$2E(I@P%UC_W9$Z*PC!I._YQ
MI+UF3 /<?7YDO[+.:V?NL"1S7OQ)<[4Y[XU[("<K7!7J*W^X)LZAH>'+>"'M
M?_#@^L8]D%52\=*!M04E9?4O_N$"L0-(TB, Y #H"0#!(X#$ 9*N@($##+H"
MA@XP[ H8.<"H*R!U@+0K8.P XZZ B0-,;#G4^;/)7V"%9U/!'X PO36;>; 5
M9-$ZYY298K]50G^E&J=FGSA;OU-$E&!![A1X!U",AN +5T2"UPNB,"WDF_WF
M5R "<H.%?J0,?&-4R;<[#9]I4>@REM-(:?O,*%'F;+FH;4%';('@,V=J(\$E
MRTGNP<_#^.04_C*,'P7PD8YK$UST&-P+%"3\/5-]D,"W.GIP_.UV 5Z_>E,'
MJHVAS\TPZ\>*:=;8L"+H6#TLB^XL\7&6RQ>QY>I%;/D09EF0[#':(9;K#CE#
M@[V<>5B675A0@&6OH))FMB:6-CGJHIZC2R:5J+3@*/#7)]T!+!4IY=\!^D%#
M/[#T@Q ]E;+"+",@XU)Y9W%-,K(D1DSO9\-);/ZFT;UG]&$S^C X^BUAE(MZ
MD0DX,VKH1K\B5FE#GP:MO<(Z1+CD%5.^&*4',8(I&NY'J9[LG7M>=N[YH7//
MZ\.>R-MQZ:&L^QU+^[@)Y#@8R"73\D.D @(KX@ME& [[P_BW0#XGC1F3(,^-
MX!DAN00KP<MV$O"5WCK=>5,\.8S(:#0*1 3&K2C'+S$1'<NN"<D@9,#.K@!V
M2PKYH;?5TI>7N:,8[HR>>BIGX?KM!2KQU7='PJL.A/MNH]9M%'1[SMD]$78C
MOQ54A_ZUWM#DO"BPD&!+1*W9;\!_("C@%VZ8=#<Q27^0'+&O7?YA<B(M5%%<
MZ(IH[*R7(&MH;8^Q+F!9/8"IG';U[J,CAK7" </*,<="_*1L'5@1X:%LP#A.
M0WEKE0.&I>,+9^\R+#=F>*'HO]@>I-S<!3F5F0T29GG=<G)JS=V >POCP%O=
MGH[06]V''0=C;WE[.@;+NU5$. J&Z2O95B+;Z+.A=OR>,,S46WUB;1KKFL\K
M A0'JXKEV"BGJ;<-9FLM=W829*9M;9=&#6 9W>H>@;R';=*QZL?!%1RVD@S#
MFNSU3^+BT3-M/W[B078PX[$"!<%2^79]%R<,T,O0*6=:681A8?,ZHP3.S33+
M\4]]Z-+G05I6I=?0,#F*+47(T%8X85@YO8;JN$J25>8FXQE&AP=*3AJ-6H5%
M885]UE1PY6^6V+UB"I>2S\,35IV>#*B5<!26\-WMM):$.2]+;=FMXMGW$'^K
ME0C]BOTU:L4.A<7N^3LR1[B[<J9P'%@Z42MPZ$6.1NA0Y)YNI_<-:"4.=3\=
MF7066$KP?B^MS\AR*QGHEYRB4+MFH_"2Z=G2F(. W6V] D9).ZF,&P7"G<CK
MN80F$Y@,G\0^VKDN*XE8V[M6">P>H3Z+-ZW-?>Y[>XOYI'T.SQ;0TWX)SZ[J
MV]J6OKX\_HS%FC*I%6:EAXK[J4ZZJ.]CZQ?%M_:R[HXKQ4O[N"$X)\)TT-]7
M7!> >S$#-+?BL_\!4$L#!!0    ( (F9!%/*T5YJD 8  , ?   9    >&PO
M=V]R:W-H965T<R]S:&5E=#<U+GAM;,59T6[;-A3]%<+H@!9(;9&493E( L1V
MW&1HBZ!!MX=A#XI-VT(ET2/I)!WV\;N4&%&V)%I=$^PEL6C>PZ/+RW.NK+-'
M+K[)#6,*/:5))L][&Z6VIX.!7&Q8&LD^W[(,OEEQD48*+L5Z(+>"1<L\*$T&
MQ/."01K%6>_B+!^[%1=G?*>2.&.W LE=FD;B^X0E_/&\AWO/ U_B]4;I@<'%
MV39:LSNFOFYO!5P-2I1EG+),QCQ#@JW.>Y?X],:G.B"?\5O,'F7E,]*W<L_Y
M-WUQLSSO>9H12]A":8@(_CVP*4L2C00\_C*@O7)-'5C]_(P^SV\>;N8^DFS*
MD]_CI=J<]\(>6K)5M$O4%_YXS<P-#37>@B<R_XL>S5ROAQ8[J7AJ@H%!&F?%
M_^C))*(20$<M <0$D*X!U 30@P""6P)\$^!W#1B:@&'7@, $!%T#1B9@U#4@
M- 'A00#V6P+&)F"<ET.Q?_GFSR(579P)_HB$G@UH^D->07DT['F<Z6*_4P*^
MC2%.77SDV?J]8B)%,W:OT'M$/(+19ZZ81&]G3$5Q(M^A-VB Y"82,!AGZ&L6
M*WE2&?@4)PE4KCP;**"D@0<+L_RD6)ZT+(_1)YZIC417V9(M&^)G[GAZ+'[N
MC@\<\0-(99E/\IS/"7$"7N[6?43QB<ZC]_5NAMZ^>5<DRN:P@>;4C3ICBV=4
M''1'G;E1?]UE@.KE7+%!;4"YZH[BM:/,7X3+AQ?A<MTYVRZ4FRXH.1<\=E06
M+4\JS?%H*QZ<SYM,*K$#LU'HCX\P =THELH_'?!^">_G\'Y;X:9<J/CO*+<@
MOM*&P81@2[2*LRA;Q-D:+;A4364V+Y"#'%F[Z\-%&-*1YWEG@X?JYM7G!=YH
M7)VW1WU84A\ZJ7]AV^B[SHG4Q"7+8BZ _[UJXEI #2L<QJ$/K4&-;'UB"\V@
MI!DX:=X5Q')M=6S8J(0;O48]A"5\Z&1[6TFISB6*I=Q!(;#6,IB$M>TE0\]K
MW=YQR63L9/(96KZ$2V"2(?:DH!)WL=SD]VRXG8 )+9+=4A?IBH$G;:-XB11'
M"0-9%XUDQ[7M]4,'6>Q90_4Z;S/ZI^*GCDW!%;O&K['KF-@%B)/^/((MCE*^
MRYJ.S]1$5S<9FUT^.$"SAJDD&#7HPMS,'!Z=>=T%<__&K;QBZKSQFPS:("85
M$I%BC;?NCB=]S_NER29^/&[_#JR"8[>$WPJ^8&PIT4KPU)Y7<T@:;ZFNR)AX
MONL<6%'&;E6>=1*-J4&I4O #%P$KM]BMMV +.['8P),0K/[ P,5 *(0=W(H8
MB"UW3"O%:I<M(WVBH@3!U]D:#@'H"!,+/;;.LP@!8(1;F.$X'VY.V/..;;?5
M?SSJ5K#L"1Y]95/-S@S$WLEJ.*M79MZ^-=?GS1OP:,.\#PWS,''MJK4E[/:E
MG^A39@9Z3_3'#<FH&UG33<X;X'!C,NIX+E_$UABQVQGS([;@V0-X'*3C!'$1
MKR$-B7'%UC*=X+K]F2ZHA12Q_D?<_E<QD+)W@%,'CMQ$Q(#MY=#W7$2L51+\
M8FWAQ&#M\:!C%P_KJ,3MJ*T- 5Q,DP@:FTLTY6D*]7RG^.*;'JY<NAY*K;F1
M5WEX(-9[B-M[;K)8Q5H[RVK,?50K*'J#]+'H))]F%8RK;7??\W'@A:1E(ZPC
M$;<C32VW0OO?QAE:\B2)1"[UQ8/T.\C_D6?U8IE1553]OD=;^%G#(FYS:,BA
M.4>::,%'LW,P*Q;0':J5FGY;XJS3$+?3U"O8/]K2$JOH)'R5VK0R2=PRZ6YI
M)R9ZKPG"HR8EGY&Z;,)4;XCKYM!]ZG4S@8.I^[\96#6F;C4^UM5.CL33_M#9
MKE KQ]0MQ]WZP8E!J9MO6RJL#E.W#O\?_>#D"*?C_2"M_#[4\0'&T0\:B*#6
MLAR6;\-$XMP&ZQ34[10OI,(3LTQ5A7'8)RTJ3*U+4+=+_+0*3\P">RH<]/T6
M8M8>J-L>:MU>\5E![QN7ZNEJ^@S^WN]TSJ:/6H>@_]$ANC<SU!H&?17#H-8P
MJ-LP?OA!>D+K:D]#[$BM;Q7<=RMP1]TT*'LGF[H(6.'VW<+MW-N?ZE]]J]T^
M>94?OZUX^L?$\R7ZUXE9Y;!_'?IA$(P.-F)0>6N7,K'.7_E*8 #8Q>_VY6CY
M6ODR?YEZ,#[!IU/<,#[#IU=-XW-\^J%XF6R7+=YM?XH$/#]*E+ 54/#Z(RAH
M4;PN+BX4W^;O$N^Y4CS-/VY8M&1"3X#O5QP*PUSH!<J7]A?_ E!+ P04
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MPI61U?6A&FA1V//Q2F@\;=O7%*]<((T ?E\+H7<#8Z"YQ,W^ 5!+ P04
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MRFC"E"6 \:F$M2@;5L#B=>[P/U!+ P04    " ")F013QT8_/WL"  #H!@
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M,I\Z?DI";T8"+_!WP"\/PS/(-=RW<&\'/'N[^E]P5_LUFA:,I@66+]QKFE(
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M5V Y+H;J=4(AJ<5J'^WUQS)0.74BN#.G <F^]J+>ZY#\\.+Q3@/QS@-R+,.
MX,Z:@.R+2-I>1<Z*5(AW&Y@)^6<*AA^!Z)^WV! 9++;Z-PSNS3DBB<A@L361
MW%>DM+TDS??Z7\-Q=-Y.CL@PCJBW8XZ(K)FCHXO6PY9]<>:T%V?XM^_M"2M@
M&&<A5"<7M#?Z_3<ZM/]((O@B OSK -#"/WRI;[D,8CT%#5_M9,4%41M&9/1"
MDOS BND#*_(A2UG#@4\>IU4Y'DR86)N#7 DID*4J/V H6\O#XEMS1%IKG]+K
M&47:Y_1Z@;6_=>SK.0 _?@+,X$E^?+P?4GZ:_2D0ZP@"CMD*AF?W/-C;1'Y
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MPQ,:2%. []<"\UH_F Z:,]_T'U!+ P04    " ")F013.VJY "<$   .%
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MD?:HSM&7D1^%_M!].635 HH] S3I@F(_'+P%32T@!&$#>I-VV*0=]J8]IEP
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M8 H@OR\I%;N)VJ!J4,._4$L#!!0    ( (F9!%.6. XY&@,  (,)   9
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M]A.V\8P,7\8K:9^P;6S'6C%;2\7K%JSG-67-F]RU>=@!:!XW(&H!T6/ \!E
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M0% #@E,]A#4@/-5#IP9T3@5$-2 JM:_$*I4>Q2H>]@5?(V&L-9MY*--5HK7
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M$,9 OY]SKC8#XZ"Y>@[_!U!+ P04    " ")F013<25Q,=L#   7#0  &0
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M4A;#!+]<J+('<'\MI7F>V'=E]2TT_0=02P,$%     @ B9D$4P+U,<*= P
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M'8T/</M;K>ED^./7_SRR3U!+ P04    " ")F013!=PYGO0"  "5!P  &0
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MW$3M'.A\H93=&.Z">A*/?P-02P,$%     @ B9D$4VB=.$_> @  _@D  !D
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MW@@UX$S&6[PFCT1\WMZ7\LYIO*0T)P6GK  E6=V,;N'U @7*0".^4++G!]=
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M%AU1G,%9F&5?F 97O^+J]W+]RB1)T7W&<BK1\FFGSDJ(D&1HK0I:<M9;2VU
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M\A*M6RL?*G=5TGJ DZR,K#N5ZU\3+:<N[L2CCA.%;L5*YBK)'M$'_?PDLK5
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M2Q;:7$ TO-D)F71#ID[(OF&&A:B;2MJ]^:KU"S7)G?:^?J$FQ]/CUR\46)<
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MWK/+15K]7\7:I3IHDFR6KN?Z0Y(AM1"%0*4BE)2>/($\.=RY';@4^6-UC[-
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MP0A QCZP&D*X$$AV"!>YE"/IE2-Q*\>K_7U#5PG-&5 3OV,U(+:>TXL^L(N
M@'%D'S>D$- GP"0 FR;>\/I >D5)W(I2/U/%5L]-W=\[:D$TUWM.43\[MU8$
MTH4A!F8%@+3H )Q%D+.YT]DA$;W&)&Z->95I>=260<=, )1:#*4 @/.!<X@4
M K8#:\4,(*.I8T+T"I&<H!#?F".XMZU0U.JHE0=;72#%IE,&$"'71US_@?\$
M:;05GL6@#=&9Y0%;<0")_2F4-9#+V'$.1WI=2=RZ\M5=!AAS:.T9=#T+H.0!
MD%Z([64A!9!D2H!%:0[Y#/QD^%2.&(5Y^*774<2MH^!1OSYB=5=EQ39G$GV+
MWR???8,C[_N2%X69CZMNL[\OVP>2M#D9TSH.2?Z$RO8NAYF['/3#MF(#MQ%M
MG).]&Z^2U:OF]E/J8K"M5'N<O?NZNV&];NX57WV_P6<?,/ ]Q6=SZ/L5B<Y2
M$@&_:,[T+\TUWJ3O4GL%_)'6*ZX#+MA2=\]['^LAKMM;U?9%B4US1[<02HFR
M>5PSJFN[ >C?ET*HEQ?3P.YN^_(?4$L#!!0    ( (F9!%/.Z:^X/08  /$?
M   :    >&PO=V]R:W-H965T<R]S:&5E=#$P,RYX;6S-F5MOVS88AO\*8?2B
M!9I:/(B2"L= XG1HAQ4+FG:[&':A6(RM518]DD[2?S]*5D1;/-C356\227[Y
MZ>7'PT.*LR<NOLLU8PH\;ZI:7D[62FW?3Z=RN6:;7+[C6U;K7QZXV.1*WXK5
M5&X%RXNVT*::HBBBTTU>UI/YK'UV*^8SOE-56;-; >1NL\G%CVM6\:?+"9R\
M//A2KM:J>3"=S[;YBMTQ]6U[*_3=M(]2E!M6RY+70+"'R\D5?+\@<5.@5?Q1
MLB=Y< V:JMQS_KVY^51<3J+&$:O84C4A<OWOD2U85361M(]_NZ"3_IU-P</K
ME^B_M)77E;G/)5OPZL^R4.O+23H!!7O(=Y7ZPI\^LJY"K<$EKV3[%SQUVF@"
MECNI^*8KK!ULRGK_/W_N$G%00,=Q%T!= 30L0#P%<%< MQ7=.VNK=9.K?#X3
M_ F(1JVC-1=M;MK2NC9EW33CG1+ZUU*74_,O3#+QR"30/0(LJKS<2)#7!;AE
MHNTC]9)=7.LT%>!*B+Q>,=V$2H+7-TSE927?@ OP[>X&O'[U!KP"90V^KOE.
MZ@!R-E7:7O.2Z;*S<KVW@CQ6*/C,:[66X$-=L.*X_%17JZ\;>JG;-0H&_'57
MOP,X>@M0A*##S^+\XE' #NY3C=MXV!/OMS*_+ZM2_6AS_:W>YF5QF/+N\JKX
M1S=[DV;PX5F/5LG>-JU1\@)\JI=ZJ$K6I']_]0;\=74OE="CX>^ 1=);)*U%
MXK%XS59E79?U2@^-JFE[5RON0] V1#-+/,YAFM*4SJ:/A\FU913"..I51P;C
MWF <-*@SL!-"]\8EE[H;"E;E2M\I#MKG.F<_6"Y<KO=QXP,[B")$HH%KAXS$
M-*-NV[2W34?:WNJ&%5[3U')#$4T&EFU1BCUI3GJ_2=#O;=,U_W>*$\L(A F)
MR<"O+=/,R=+,;3GM+:<C+(?3FUI.LHP0//!KJV 21<1M-^OM9D&[BW4SF8)B
M)YK1IM;,:S*S7A]#"H?]UE:A-,;8;1)&A@Y1T.9-*;=<YA7@#Z HY5)/T&6]
MT[G5ZPB1-R!V3_219><"8I@-NX)#Y^FY\ !H,&CY=YU, ?)^%G4;A(Z^&D7#
MIG?(2((\DP%$QB(*6M2 .S''=@&.VA.G,(J'!FV=[L&19RQ!@RJ(PPX?>=4,
M]8\LK]0:W.DU0KED,H 8:!@#R<_*06@X \.@.8N$T*9%3%%F-9(M(XC&GC8R
M3(%CH7)JHH8.9%":#6W;*@2QS[9!"PRS92P+H<T-G6MKQ-JJ"Y*E'M,&+G ,
M74[FV48'BM((#CW;,M(N.9V>#6%@&#%CB @='(EH8F79(8M]BPYD:(/"M#D?
MBL@!&#VD(!H8=>E(!CU<1 8R* R9D5Q$-D^&( ]*CMT:WJ P;\Y"(K)1@A,T
M[*L.E<^>@0TZ 9N3..P"''G#<31<3CAD%Y1X!C\RP$+A7=%"/RB7NK'O>+5S
MM.UQ6(,8%/^L'$0&,B@,F;,XB&Q20*0G!&LTVKHXTOLK3P,9I*"Q2#DU0R/'
M9@1FV-H#N'01S)+$8]V !87!,I:&R($6.%QX.$07R#?W&:Z@,5PYF6D;&0G&
MR7#1X9!!JML#NEUCPQ8<9LL8&F*;'@G$V;!;NV0D\ZS!L6$,#C/F?!IBFQD)
M2=+AAP*'#$,]_CQ&#5YP&"\C88A#*.D<GTT;?/ 5+DR;LV"(;9(D*+4:WE;Y
MMX?8\ :'>7.:AUV X^F(4&MEZ="E<99Y)EQLT(7#NZ.O8L>ZO6'HPZBA#*8_
M*PJQH0P.4^8L%&(;%)E.^;!=''L92GQ=V\ $CX7)J=D9VZ3 !*%TZ-NQ4X%Q
MZIM!#%)P&"EC*8AM6EP@8HT"!U-P["$*,40A8XAR*M/$A@7"*!DN91TRO>+%
MGK4L,5 A8:B,P2!QX 4GP[[A4-$L\4PUQ,"%A.%R/@6)8P.#\7!-Y% AW=,]
M-@U52)@J(QE('#L6UX=2A\XS6Y"#LYXP9LX"(;$),H1T4'+LS0"&A %S&H%=
M !HR9DNRB Z;>GIP>+IA8M6>*4L]1G:UVI\U]D_[<^NK]K1V\/P:OE_L3Y]-
MF/UA^.=<:'1(4+$''3)ZEVAC8G^^O+]1?-L>T=YSI?BFO5RSO&"B$>C?'SA7
M+S?-"_I3_OE_4$L#!!0    ( (F9!%,Z!/PP<@,  $P)   :    >&PO=V]R
M:W-H965T<R]S:&5E=#$P-"YX;6RU5EMOVS84_BL'0A]:8(YDV9:=PC;@.,V6
M8MV"9MV>:>G(XD*1*DG%R;_?(:6HCJT(?=F+35+G\GWG1BX/2C^8 M'"4RFD
M606%M=7',#1I@24S%ZI"25]RI4MF::OWH:DTLLPKE2*,HR@)2\9EL%[ZLSN]
M7JK:"B[Q3H.IRY+IYRL4ZK *QL'+P5>^+ZP["-?+BNWQ'NVWZD[3+NRL9+Q$
M:;B2H#%?!9OQQ^TX<@I>XF^.!W.T!D=EI]2#V]QFJR!RB%!@:IT)1G^/N$4A
MG"7"\;TU&G0^G>+Q^L7ZC2=/9';,X%:)?WAFBU6P""##G-7"?E6'W[ E-'/V
M4B6,_X5#*QL%D-;&JK)5)@0EE\T_>VH#<:1 =OH5XE8A/E68OJ$P:14FGFB#
MS-.Z9I:MEUH=0#MILN86/C9>F]APZ=)X;S5]Y:1GU_=U50FDO%@F8,M, 3>4
M6;B5386X2+^_1LNX,!]@!-_NK^']NP_P#KB$OPI5&R8SLPPM07$&P[1U>]6X
MC=]PF\ 7)6UAX)/,,'NM'Q*%CD?\PN,J'C3XN987,(E^@3B*QSUXMC^O'@W
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MHAVE?QW']I#3Z:]C(K1Z6^CY<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%
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M]JJW!^CM56\/T-NKWAZ@MU>]/4!OKWI[@-Y!]0X O8/J'0!Z!]4[ /0.JG<
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M;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ B9D$4^G8DH_O    *P(  !$
M             ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @
MB9D$4YE<G",0!@  G"<  !,              ( !S0$  'AL+W1H96UE+W1H
M96UE,2YX;6Q02P$"% ,4    " ")F013LM/E:UX%   L%@  &
M    @($."   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @
MB9D$4P4P8=*""   XR,  !@              ("!H@T  'AL+W=O<FMS:&5E
M=',O<VAE970R+GAM;%!+ 0(4 Q0    ( (F9!%-FA4;?F (  ,$&   8
M          " @5H6  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4
M    " ")F013@;<KIL *  "U-0  &               @($H&0  >&PO=V]R
M:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @ B9D$4W:]E7& "@  KST
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M965T.2YX;6Q02P$"% ,4    " ")F013^W>UQ(<%  "8#   &0
M    @('U6   >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    (
M (F9!%.B+=I>\@T  -LF   9              " @;->  !X;"]W;W)K<VAE
M971S+W-H965T,3$N>&UL4$L! A0#%     @ B9D$4RRX""Q4"   U!<  !D
M             ("!W&P  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"
M% ,4    " ")F013Y OZ GL0  !],@  &0              @(%G=0  >&PO
M=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( (F9!%.'NY/NN 8
M +H0   9              " @1F&  !X;"]W;W)K<VAE971S+W-H965T,30N
M>&UL4$L! A0#%     @ B9D$4Y_AKZ2: P  ( H  !D              ("!
M"(T  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4    " ")F013
M[K^9O@H.  #D+0  &0              @('9D   >&PO=V]R:W-H965T<R]S
M:&5E=#$V+GAM;%!+ 0(4 Q0    ( (F9!%..4UQ1]Q8  /Y?   9
M      " @1J?  !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%
M  @ B9D$4[+X\L</%   73D  !D              ("!2+8  'AL+W=O<FMS
M:&5E=',O<VAE970Q."YX;6Q02P$"% ,4    " ")F013$XMAKV8(  !U%
M&0              @(&.R@  >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+
M 0(4 Q0    ( (F9!%/0=SYP= 0    +   9              " @2O3  !X
M;"]W;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%     @ B9D$4Y!CVW^M
M P  )PD  !D              ("!UM<  'AL+W=O<FMS:&5E=',O<VAE970R
M,2YX;6Q02P$"% ,4    " ")F0137NJA'^\$  "H"P  &0
M@(&ZVP  >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( (F9
M!%.'I?F!3P4  &4.   9              " @>#@  !X;"]W;W)K<VAE971S
M+W-H965T,C,N>&UL4$L! A0#%     @ B9D$4S\U=[QN!   ) L  !D
M         ("!9N8  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4
M    " ")F0134&9"A/D)    &P  &0              @($+ZP  >&PO=V]R
M:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( (F9!%,IK;RHK04  ,$,
M   9              " @3OU  !X;"]W;W)K<VAE971S+W-H965T,C8N>&UL
M4$L! A0#%     @ B9D$4UU$]HP$#@  $"<  !D              ("!'_L
M 'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"% ,4    " ")F013E@?F
M4? *   @'P  &0              @(%:"0$ >&PO=V]R:W-H965T<R]S:&5E
M=#(X+GAM;%!+ 0(4 Q0    ( (F9!%/KOKNZ& H  (4:   9
M  " @8$4 0!X;"]W;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#%     @
MB9D$4S&+3_DO P   @<  !D              ("!T!X! 'AL+W=O<FMS:&5E
M=',O<VAE970S,"YX;6Q02P$"% ,4    " ")F013+W&LSS4#  #F!@  &0
M            @($V(@$ >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4
M Q0    ( (F9!%,GZ)G8(1H  /M0   9              " @:(E 0!X;"]W
M;W)K<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @ B9D$4XP'10DF"
M@Q8  !D              ("!^C\! 'AL+W=O<FMS:&5E=',O<VAE970S,RYX
M;6Q02P$"% ,4    " ")F013@<X4OY\&  ")$@  &0              @(%7
M2 $ >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    ( (F9!%-.
MA$?'_@0   $,   9              " @2U/ 0!X;"]W;W)K<VAE971S+W-H
M965T,S4N>&UL4$L! A0#%     @ B9D$4T=F\+#9 @  /08  !D
M     ("!8E0! 'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( (F9!%-!T9UD6 0  $4*   9              "
M@65I 0!X;"]W;W)K<VAE971S+W-H965T-#$N>&UL4$L! A0#%     @ B9D$
M4[0>BU^A!   P@L  !D              ("!]&T! 'AL+W=O<FMS:&5E=',O
M<VAE970T,BYX;6Q02P$"% ,4    " ")F013"="V@*P#  !*"0  &0
M        @(',<@$ >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0
M   ( (F9!%-I/"RU>@(  *\%   9              " @:]V 0!X;"]W;W)K
M<VAE971S+W-H965T-#0N>&UL4$L! A0#%     @ B9D$4PZ!BNN_!   XP\
M !D              ("!8'D! 'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6Q0
M2P$"% ,4    " ")F013?5K?/[@#  !D"   &0              @(%6?@$
M>&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0    ( (F9!%,M0F..
M'P,  -4&   9              " @46" 0!X;"]W;W)K<VAE971S+W-H965T
M-#<N>&UL4$L! A0#%     @ B9D$4U+@#UV !P  '14  !D
M ("!FX4! 'AL+W=O<FMS:&5E=',O<VAE970T."YX;6Q02P$"% ,4    " ")
MF013I>O);;($   _"@  &0              @(%2C0$ >&PO=V]R:W-H965T
M<R]S:&5E=#0Y+GAM;%!+ 0(4 Q0    ( (F9!%-E]K1W20,  /4&   9
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M970U-"YX;6Q02P$"% ,4    " ")F013ZPY:MM8#  "@#@  &0
M    @($HI0$ >&PO=V]R:W-H965T<R]S:&5E=#4U+GAM;%!+ 0(4 Q0    (
M (F9!%,B^&]?K 4  $P8   9              " @36I 0!X;"]W;W)K<VAE
M971S+W-H965T-38N>&UL4$L! A0#%     @ B9D$4X6P.+9!!@  G1P  !D
M             ("!&*\! 'AL+W=O<FMS:&5E=',O<VAE970U-RYX;6Q02P$"
M% ,4    " ")F013?\PI9<0"  "E!@  &0              @(&0M0$ >&PO
M=V]R:W-H965T<R]S:&5E=#4X+GAM;%!+ 0(4 Q0    ( (F9!%./]"+)UP0
M "84   9              " @8NX 0!X;"]W;W)K<VAE971S+W-H965T-3DN
M>&UL4$L! A0#%     @ B9D$4]Z8H/I#!   .A,  !D              ("!
MF;T! 'AL+W=O<FMS:&5E=',O<VAE970V,"YX;6Q02P$"% ,4    " ")F013
M^.AW?-@"  #+"0  &0              @($3P@$ >&PO=V]R:W-H965T<R]S
M:&5E=#8Q+GAM;%!+ 0(4 Q0    ( (F9!%/"@AS ;@0  !\/   9
M      " @2+% 0!X;"]W;W)K<VAE971S+W-H965T-C(N>&UL4$L! A0#%
M  @ B9D$4S!JH4%7 P  NPP  !D              ("!Q\D! 'AL+W=O<FMS
M:&5E=',O<VAE970V,RYX;6Q02P$"% ,4    " ")F0138%,$_NT"  #C"0
M&0              @(%5S0$ >&PO=V]R:W-H965T<R]S:&5E=#8T+GAM;%!+
M 0(4 Q0    ( (F9!%-YTT[S#@,  /8(   9              " @7G0 0!X
M;"]W;W)K<VAE971S+W-H965T-C4N>&UL4$L! A0#%     @ B9D$4RRV)J!H
M!   ]1(  !D              ("!OM,! 'AL+W=O<FMS:&5E=',O<VAE970V
M-BYX;6Q02P$"% ,4    " ")F013%RBYX&H#  #'#   &0
M@(%=V $ >&PO=V]R:W-H965T<R]S:&5E=#8W+GAM;%!+ 0(4 Q0    ( (F9
M!%.',BHCDP0  !45   9              " @?[; 0!X;"]W;W)K<VAE971S
M+W-H965T-C@N>&UL4$L! A0#%     @ B9D$4Q3H \6]!@  $B8  !D
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M=#<S+GAM;%!+ 0(4 Q0    ( (F9!%/ MFLW3@4  "$7   9
M  " @6?Z 0!X;"]W;W)K<VAE971S+W-H965T-S0N>&UL4$L! A0#%     @
MB9D$4\K17FJ0!@  P!\  !D              ("![/\! 'AL+W=O<FMS:&5E
M=',O<VAE970W-2YX;6Q02P$"% ,4    " ")F0135,W4R,H$  "B%@  &0
M            @(&S!@( >&PO=V]R:W-H965T<R]S:&5E=#<V+GAM;%!+ 0(4
M Q0    ( (F9!%-'\RC-R ,  &0.   9              " @;0+ @!X;"]W
M;W)K<VAE971S+W-H965T-S<N>&UL4$L! A0#%     @ B9D$4[[^K@_+ P
MT T  !D              ("!LP\" 'AL+W=O<FMS:&5E=',O<VAE970W."YX
M;6Q02P$"% ,4    " ")F013L4QVA3@&  "I&P  &0              @(&U
M$P( >&PO=V]R:W-H965T<R]S:&5E=#<Y+GAM;%!+ 0(4 Q0    ( (F9!%/'
M1C\_>P(  .@&   9              " @20: @!X;"]W;W)K<VAE971S+W-H
M965T.# N>&UL4$L! A0#%     @ B9D$4XL.=UM> P  X@T  !D
M     ("!UAP" 'AL+W=O<FMS:&5E=',O<VAE970X,2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( (F9!%/0HW -F@,  /\-   9              "
M@6@N @!X;"]W;W)K<VAE971S+W-H965T.#8N>&UL4$L! A0#%     @ B9D$
M4SMJN0 G!   #A0  !D              ("!.3(" 'AL+W=O<FMS:&5E=',O
M<VAE970X-RYX;6Q02P$"% ,4    " ")F013%ZM5 78"  "[!@  &0
M        @(&7-@( >&PO=V]R:W-H965T<R]S:&5E=#@X+GAM;%!+ 0(4 Q0
M   ( (F9!%-#%.F<[ (  *P*   9              " @40Y @!X;"]W;W)K
M<VAE971S+W-H965T.#DN>&UL4$L! A0#%     @ B9D$4Y8X#CD: P  @PD
M !D              ("!9SP" 'AL+W=O<FMS:&5E=',O<VAE970Y,"YX;6Q0
M2P$"% ,4    " ")F013ZD'WF*X#  "&#@  &0              @(&X/P(
M>&PO=V]R:W-H965T<R]S:&5E=#DQ+GAM;%!+ 0(4 Q0    ( (F9!%-Q)7$Q
MVP,  !<-   9              " @9U# @!X;"]W;W)K<VAE971S+W-H965T
M.3(N>&UL4$L! A0#%     @ B9D$4P+U,<*= P  ZA   !D
M ("!KT<" 'AL+W=O<FMS:&5E=',O<VAE970Y,RYX;6Q02P$"% ,4    " ")
MF013#0'I/!4"  !(!   &0              @(&#2P( >&PO=V]R:W-H965T
M<R]S:&5E=#DT+GAM;%!+ 0(4 Q0    ( (F9!%,%W#F>] (  )4'   9
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M970Y.2YX;6Q02P$"% ,4    " ")F0136=C-&PH"  !D!   &@
M    @(&@80( >&PO=V]R:W-H965T<R]S:&5E=#$P,"YX;6Q02P$"% ,4
M" ")F013RA *33<'  "Q*P  &@              @('B8P( >&PO=V]R:W-H
M965T<R]S:&5E=#$P,2YX;6Q02P$"% ,4    " ")F013!Y&=VP@'  #G'@
M&@              @(%1:P( >&PO=V]R:W-H965T<R]S:&5E=#$P,BYX;6Q0
M2P$"% ,4    " ")F013SNFON#T&  #Q'P  &@              @(&1<@(
M>&PO=V]R:W-H965T<R]S:&5E=#$P,RYX;6Q02P$"% ,4    " ")F013.@3\
M,'(#  !,"0  &@              @($&>0( >&PO=V]R:W-H965T<R]S:&5E
M=#$P-"YX;6Q02P$"% ,4    " ")F0131KH:J"4"  "#!   &@
M    @(&P? ( >&PO=V]R:W-H965T<R]S:&5E=#$P-2YX;6Q02P$"% ,4
M" ")F013,Q#KA#0#  #6$P  #0              @ $-?P( >&PO<W1Y;&5S
M+GAM;%!+ 0(4 Q0    ( (F9!%.7BKL<P    !,"   +              "
M 6R" @!?<F5L<R\N<F5L<U!+ 0(4 Q0    ( (F9!%.:;3E8E@<  .9$   /
M              "  56# @!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " ")
MF013XE4/'/@"  "P/0  &@              @ $8BP( >&PO7W)E;',O=V]R
M:V)O;VLN>&UL+G)E;'-02P$"% ,4    " ")F013#D@O.6H"  !U.P  $P
M            @ %(C@( 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     <0!Q
+ !0?  #CD (    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>456</ContextCount>
  <ElementCount>517</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>111</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="evh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="evh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="evh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="evh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="evh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1005005 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (DEFICIT)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYDEFICIT</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (DEFICIT)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="evh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1006006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="evh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1404401 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSSParenthetical</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="evh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Organization</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/Organization</Role>
      <ShortName>Organization</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="evh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2103102 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciples</Role>
      <ShortName>Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="evh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2109103 - Disclosure - Recently Issued Accounting Standards</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandards</Role>
      <ShortName>Recently Issued Accounting Standards</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="evh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2111104 - Disclosure - Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/Transactions</Role>
      <ShortName>Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="evh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2113105 - Disclosure - Discontinued Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/DiscontinuedOperations</Role>
      <ShortName>Discontinued Operations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="evh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2118106 - Disclosure - Revenue Recognition</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/RevenueRecognition</Role>
      <ShortName>Revenue Recognition</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="evh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2124107 - Disclosure - Credit Losses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/CreditLosses</Role>
      <ShortName>Credit Losses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="evh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2128108 - Disclosure - Property and Equipment, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/PropertyandEquipmentNet</Role>
      <ShortName>Property and Equipment, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="evh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2131109 - Disclosure - Goodwill and Intangible Assets, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNet</Role>
      <ShortName>Goodwill and Intangible Assets, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="evh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2137110 - Disclosure - Long-term Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/LongtermDebt</Role>
      <ShortName>Long-term Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="evh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2145111 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="evh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2150112 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="evh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2157113 - Disclosure - Earnings (Loss) Per Common Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/EarningsLossPerCommonShare</Role>
      <ShortName>Earnings (Loss) Per Common Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="evh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2161114 - Disclosure - Stock-based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/StockbasedCompensation</Role>
      <ShortName>Stock-based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="evh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2166115 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="evh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2168116 - Disclosure - Investments In and Advances to Equity Method Investees</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/InvestmentsInandAdvancestoEquityMethodInvestees</Role>
      <ShortName>Investments In and Advances to Equity Method Investees</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="evh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2170117 - Disclosure - Non-controlling Interests</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/NoncontrollingInterests</Role>
      <ShortName>Non-controlling Interests</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="evh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2173118 - Disclosure - Fair Value Measurement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/FairValueMeasurement</Role>
      <ShortName>Fair Value Measurement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="evh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2179119 - Disclosure - Related Parties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/RelatedParties</Role>
      <ShortName>Related Parties</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="evh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2183120 - Disclosure - Repositioning and Other Changes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/RepositioningandOtherChanges</Role>
      <ShortName>Repositioning and Other Changes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="evh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2186121 - Disclosure - Segment Reporting</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/SegmentReporting</Role>
      <ShortName>Segment Reporting</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="evh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2191122 - Disclosure - Reserves for Claims and Performance-Based Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangements</Role>
      <ShortName>Reserves for Claims and Performance-Based Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="evh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2194123 - Disclosure - Supplemental Cash Flow Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/SupplementalCashFlowInformation</Role>
      <ShortName>Supplemental Cash Flow Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="evh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2197124 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="evh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2204201 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies</Role>
      <ShortName>Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciples</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="evh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesTables</Role>
      <ShortName>Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciples</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="evh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2314302 - Disclosure - Discontinued Operations (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/DiscontinuedOperationsTables</Role>
      <ShortName>Discontinued Operations (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/DiscontinuedOperations</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="evh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2319303 - Disclosure - Revenue Recognition (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/RevenueRecognitionTables</Role>
      <ShortName>Revenue Recognition (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/RevenueRecognition</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="evh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2325304 - Disclosure - Credit Losses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/CreditLossesTables</Role>
      <ShortName>Credit Losses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/CreditLosses</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="evh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2329305 - Disclosure - Property and Equipment, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/PropertyandEquipmentNetTables</Role>
      <ShortName>Property and Equipment, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/PropertyandEquipmentNet</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="evh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2332306 - Disclosure - Goodwill and Intangible Assets, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetTables</Role>
      <ShortName>Goodwill and Intangible Assets, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNet</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="evh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2338307 - Disclosure - Long-term Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/LongtermDebtTables</Role>
      <ShortName>Long-term Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/LongtermDebt</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="evh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2346308 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/CommitmentsandContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/CommitmentsandContingencies</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="evh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2351309 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/Leases</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="evh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2358310 - Disclosure - Earnings (Loss) Per Common Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/EarningsLossPerCommonShareTables</Role>
      <ShortName>Earnings (Loss) Per Common Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/EarningsLossPerCommonShare</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="evh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2362311 - Disclosure - Stock-based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/StockbasedCompensationTables</Role>
      <ShortName>Stock-based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/StockbasedCompensation</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="evh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2371312 - Disclosure - Non-controlling Interests (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/NoncontrollingInterestsTables</Role>
      <ShortName>Non-controlling Interests (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/NoncontrollingInterests</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="evh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2374313 - Disclosure - Fair Value Measurement (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/FairValueMeasurementTables</Role>
      <ShortName>Fair Value Measurement (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/FairValueMeasurement</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="evh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2380314 - Disclosure - Related Parties (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/RelatedPartiesTables</Role>
      <ShortName>Related Parties (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/RelatedParties</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="evh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2384315 - Disclosure - Repositioning and Other Changes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/RepositioningandOtherChangesTables</Role>
      <ShortName>Repositioning and Other Changes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/RepositioningandOtherChanges</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="evh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2387316 - Disclosure - Segment Reporting (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/SegmentReportingTables</Role>
      <ShortName>Segment Reporting (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/SegmentReporting</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="evh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2392317 - Disclosure - Reserves for Claims and Performance-Based Arrangements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsTables</Role>
      <ShortName>Reserves for Claims and Performance-Based Arrangements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangements</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="evh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2395318 - Disclosure - Supplemental Cash Flow Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/SupplementalCashFlowInformationTables</Role>
      <ShortName>Supplemental Cash Flow Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/SupplementalCashFlowInformation</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="evh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2402402 - Disclosure - Organization (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/OrganizationDetails</Role>
      <ShortName>Organization (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/Organization</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="evh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2406403 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Restricted Cash and Restricted Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails</Role>
      <ShortName>Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Restricted Cash and Restricted Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="evh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2407404 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesGoodwillDetails</Role>
      <ShortName>Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="evh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2408405 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Intangible Assets, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails</Role>
      <ShortName>Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Intangible Assets, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="evh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2410406 - Disclosure - Recently Issued Accounting Standards (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails</Role>
      <ShortName>Recently Issued Accounting Standards (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandards</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="evh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2412407 - Disclosure - Transactions - Passport (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/TransactionsPassportDetails</Role>
      <ShortName>Transactions - Passport (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="evh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2415408 - Disclosure - Discontinued Operations - Summary of Results of Operations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails</Role>
      <ShortName>Discontinued Operations - Summary of Results of Operations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="evh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2416409 - Disclosure - Discontinued Operations - Summary of Cash Flows (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCashFlowsDetails</Role>
      <ShortName>Discontinued Operations - Summary of Cash Flows (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="evh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2417410 - Disclosure - Discontinued Operations - Summary of Current and Long-term Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCurrentandLongtermAssetsandLiabilitiesDetails</Role>
      <ShortName>Discontinued Operations - Summary of Current and Long-term Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="evh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>2420411 - Disclosure - Revenue Recognition - Disaggregation of Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/RevenueRecognitionDisaggregationofRevenueDetails</Role>
      <ShortName>Revenue Recognition - Disaggregation of Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="evh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>2421412 - Disclosure - Revenue Recognition - Transaction Price Allocated to the Remaining Performance Obligations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails</Role>
      <ShortName>Revenue Recognition - Transaction Price Allocated to the Remaining Performance Obligations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="evh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>2422413 - Disclosure - Revenue Recognition - Contract Balances (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/RevenueRecognitionContractBalancesDetails</Role>
      <ShortName>Revenue Recognition - Contract Balances (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="evh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>2423414 - Disclosure - Revenue Recognition - Contract Costs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/RevenueRecognitionContractCostsDetails</Role>
      <ShortName>Revenue Recognition - Contract Costs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="evh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>2426415 - Disclosure - Credit Losses - Accounts Receivable (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/CreditLossesAccountsReceivableNarrativeDetails</Role>
      <ShortName>Credit Losses - Accounts Receivable (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="evh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>2427416 - Disclosure - Credit Losses - Schedule of Changes in Allowance for Accounts Receivable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/CreditLossesScheduleofChangesinAllowanceforAccountsReceivableDetails</Role>
      <ShortName>Credit Losses - Schedule of Changes in Allowance for Accounts Receivable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="evh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>2430417 - Disclosure - Property and Equipment, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails</Role>
      <ShortName>Property and Equipment, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/PropertyandEquipmentNetTables</ParentRole>
      <Position>66</Position>
    </Report>
    <Report instance="evh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>2433418 - Disclosure - Goodwill and Intangible Assets, Net - Impairment Testing (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetImpairmentTestingDetails</Role>
      <ShortName>Goodwill and Intangible Assets, Net - Impairment Testing (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="evh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>2434419 - Disclosure - Goodwill and Intangible Assets, Net - Schedule of Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetScheduleofGoodwillDetails</Role>
      <ShortName>Goodwill and Intangible Assets, Net - Schedule of Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="evh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>2435420 - Disclosure - Goodwill and Intangible Assets, Net - Intangible Assets, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails</Role>
      <ShortName>Goodwill and Intangible Assets, Net - Intangible Assets, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="evh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>2436421 - Disclosure - Goodwill and Intangible Assets, Net - Amortization of Intangible Assets 10K (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssets10KDetails</Role>
      <ShortName>Goodwill and Intangible Assets, Net - Amortization of Intangible Assets 10K (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="evh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>2439422 - Disclosure - Long-term Debt - 2024 Notes (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails</Role>
      <ShortName>Long-term Debt - 2024 Notes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="evh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>2440423 - Disclosure - Long-term Debt - Credit Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/LongtermDebtCreditAgreementDetails</Role>
      <ShortName>Long-term Debt - Credit Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="evh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>2441424 - Disclosure - Long-term Debt - Warrant Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/LongtermDebtWarrantAgreementDetails</Role>
      <ShortName>Long-term Debt - Warrant Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="evh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>2442425 - Disclosure - Long-term Debt - 2025 Notes (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails</Role>
      <ShortName>Long-term Debt - 2025 Notes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="evh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>2443426 - Disclosure - Long-term Debt - 2021 Notes (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails</Role>
      <ShortName>Long-term Debt - 2021 Notes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="evh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>2444427 - Disclosure - Long-term Debt - Convertible Senior Notes Carrying Value (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails</Role>
      <ShortName>Long-term Debt - Convertible Senior Notes Carrying Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="evh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>2447428 - Disclosure - Commitments and Contingencies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="evh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>2448429 - Disclosure - Commitments and Contingencies - Reinsurance Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/CommitmentsandContingenciesReinsuranceAgreementsDetails</Role>
      <ShortName>Commitments and Contingencies - Reinsurance Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="evh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>2449430 - Disclosure - Commitments and Contingencies - Concentration Risk (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails</Role>
      <ShortName>Commitments and Contingencies - Concentration Risk (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="evh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>2452431 - Disclosure - Leases - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/LeasesNarrativeDetails</Role>
      <ShortName>Leases - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="evh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>2453432 - Disclosure - Leases - Material Office Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/LeasesMaterialOfficeLeasesDetails</Role>
      <ShortName>Leases - Material Office Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report instance="evh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>2454433 - Disclosure - Leases - Components of Lease Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/LeasesComponentsofLeaseExpenseDetails</Role>
      <ShortName>Leases - Components of Lease Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report instance="evh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>2455434 - Disclosure - Leases - Maturity of Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails</Role>
      <ShortName>Leases - Maturity of Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>83</Position>
    </Report>
    <Report instance="evh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>2456435 - Disclosure - Leases - Weighted-average Discount Rate and Weighted-remaining Lease Terms (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/LeasesWeightedaverageDiscountRateandWeightedremainingLeaseTermsDetails</Role>
      <ShortName>Leases - Weighted-average Discount Rate and Weighted-remaining Lease Terms (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>84</Position>
    </Report>
    <Report instance="evh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>2459436 - Disclosure - Earnings (Loss) Per Common Share - Computation of Earnings per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/EarningsLossPerCommonShareComputationofEarningsperShareDetails</Role>
      <ShortName>Earnings (Loss) Per Common Share - Computation of Earnings per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/EarningsLossPerCommonShareTables</ParentRole>
      <Position>85</Position>
    </Report>
    <Report instance="evh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>2460437 - Disclosure - Earnings (Loss) Per Common Share - Antidilutive Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/EarningsLossPerCommonShareAntidilutiveSecuritiesDetails</Role>
      <ShortName>Earnings (Loss) Per Common Share - Antidilutive Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/EarningsLossPerCommonShareTables</ParentRole>
      <Position>86</Position>
    </Report>
    <Report instance="evh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>2463438 - Disclosure - Stock-based Compensation - Stock-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails</Role>
      <ShortName>Stock-based Compensation - Stock-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>87</Position>
    </Report>
    <Report instance="evh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>2464439 - Disclosure - Stock-based Compensation - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/StockbasedCompensationNarrativeDetails</Role>
      <ShortName>Stock-based Compensation - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>88</Position>
    </Report>
    <Report instance="evh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>2465440 - Disclosure - Stock-based Compensation - Schedule of Share-based Awards Granted (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/StockbasedCompensationScheduleofSharebasedAwardsGrantedDetails</Role>
      <ShortName>Stock-based Compensation - Schedule of Share-based Awards Granted (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>89</Position>
    </Report>
    <Report instance="evh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R90.htm</HtmlFileName>
      <LongName>2467441 - Disclosure - Income Taxes - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/IncomeTaxesNarrativeDetails</Role>
      <ShortName>Income Taxes - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>90</Position>
    </Report>
    <Report instance="evh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R91.htm</HtmlFileName>
      <LongName>2469442 - Disclosure - Investments In and Advances to Equity Method Investees - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/InvestmentsInandAdvancestoEquityMethodInvesteesAdditionalInformationDetails</Role>
      <ShortName>Investments In and Advances to Equity Method Investees - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>91</Position>
    </Report>
    <Report instance="evh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R92.htm</HtmlFileName>
      <LongName>2472443 - Disclosure - Non-controlling Interests (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/NoncontrollingInterestsDetails</Role>
      <ShortName>Non-controlling Interests (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/NoncontrollingInterestsTables</ParentRole>
      <Position>92</Position>
    </Report>
    <Report instance="evh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R93.htm</HtmlFileName>
      <LongName>2475444 - Disclosure - Fair Value Measurement - Assets and Liabilities on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurement - Assets and Liabilities on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>93</Position>
    </Report>
    <Report instance="evh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R94.htm</HtmlFileName>
      <LongName>2476445 - Disclosure - Fair Value Measurement - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/FairValueMeasurementAdditionalInformationDetails</Role>
      <ShortName>Fair Value Measurement - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>94</Position>
    </Report>
    <Report instance="evh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R95.htm</HtmlFileName>
      <LongName>2477446 - Disclosure - Fair Value Measurement - Changes in Contingent Consideration and Other (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/FairValueMeasurementChangesinContingentConsiderationandOtherDetails</Role>
      <ShortName>Fair Value Measurement - Changes in Contingent Consideration and Other (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>95</Position>
    </Report>
    <Report instance="evh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R96.htm</HtmlFileName>
      <LongName>2478447 - Disclosure - Fair Value Measurement - Valuation Techniques and Significant Unobservable Inputs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails</Role>
      <ShortName>Fair Value Measurement - Valuation Techniques and Significant Unobservable Inputs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>96</Position>
    </Report>
    <Report instance="evh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R97.htm</HtmlFileName>
      <LongName>2481448 - Disclosure - Related Parties - Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/RelatedPartiesAssetsandLiabilitiesDetails</Role>
      <ShortName>Related Parties - Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>97</Position>
    </Report>
    <Report instance="evh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R98.htm</HtmlFileName>
      <LongName>2482449 - Disclosure - Related Parties - Revenues and Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/RelatedPartiesRevenuesandExpensesDetails</Role>
      <ShortName>Related Parties - Revenues and Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>98</Position>
    </Report>
    <Report instance="evh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R99.htm</HtmlFileName>
      <LongName>2485450 - Disclosure - Repositioning and Other Changes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/RepositioningandOtherChangesDetails</Role>
      <ShortName>Repositioning and Other Changes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/RepositioningandOtherChangesTables</ParentRole>
      <Position>99</Position>
    </Report>
    <Report instance="evh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R100.htm</HtmlFileName>
      <LongName>2488451 - Disclosure - Segment Reporting - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/SegmentReportingAdditionalInformationDetails</Role>
      <ShortName>Segment Reporting - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>100</Position>
    </Report>
    <Report instance="evh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R101.htm</HtmlFileName>
      <LongName>2489452 - Disclosure - Segment Reporting - Revenue from Segments to Consolidated (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/SegmentReportingRevenuefromSegmentstoConsolidatedDetails</Role>
      <ShortName>Segment Reporting - Revenue from Segments to Consolidated (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>101</Position>
    </Report>
    <Report instance="evh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R102.htm</HtmlFileName>
      <LongName>2490453 - Disclosure - Segment Reporting - Reconciliation of Adjusted EBITDA (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails</Role>
      <ShortName>Segment Reporting - Reconciliation of Adjusted EBITDA (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>102</Position>
    </Report>
    <Report instance="evh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R103.htm</HtmlFileName>
      <LongName>2493454 - Disclosure - Reserves for Claims and Performance-Based Arrangements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails</Role>
      <ShortName>Reserves for Claims and Performance-Based Arrangements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsTables</ParentRole>
      <Position>103</Position>
    </Report>
    <Report instance="evh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R104.htm</HtmlFileName>
      <LongName>2496455 - Disclosure - Supplemental Cash Flow Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/SupplementalCashFlowInformationDetails</Role>
      <ShortName>Supplemental Cash Flow Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/SupplementalCashFlowInformationTables</ParentRole>
      <Position>104</Position>
    </Report>
    <Report instance="evh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R105.htm</HtmlFileName>
      <LongName>2498456 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/SubsequentEvents</ParentRole>
      <Position>105</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="evh-20210630.htm">evh-20210630.htm</File>
    <File>a063021exhibit311.htm</File>
    <File>a063021exhibit312.htm</File>
    <File>a063021exhibit321.htm</File>
    <File>a063021exhibit322.htm</File>
    <File>evh-20210630.xsd</File>
    <File>evh-20210630_cal.xml</File>
    <File>evh-20210630_def.xml</File>
    <File>evh-20210630_lab.xml</File>
    <File>evh-20210630_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/stpr/2021</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/country/2021</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>123
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "evh-20210630.htm": {
   "axisCustom": 0,
   "axisStandard": 45,
   "contextCount": 456,
   "dts": {
    "calculationLink": {
     "local": [
      "evh-20210630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "evh-20210630_def.xml"
     ]
    },
    "inline": {
     "local": [
      "evh-20210630.htm"
     ]
    },
    "labelLink": {
     "local": [
      "evh-20210630_lab.xml"
     ],
     "remote": [
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-doc-2021-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "evh-20210630_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-ref-2021-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "evh-20210630.xsd"
     ],
     "remote": [
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021.xsd",
      "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-parts-codification-2021-01-31.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021_doc.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021_ref.xsd"
     ]
    }
   },
   "elementCount": 766,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 7,
    "http://xbrl.sec.gov/dei/2021": 5,
    "total": 12
   },
   "keyCustom": 75,
   "keyStandard": 442,
   "memberCustom": 44,
   "memberStandard": 63,
   "nsprefix": "evh",
   "nsuri": "http://www.evolenthealth.com/20210630",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Page",
     "role": "http://www.evolenthealth.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2109103 - Disclosure - Recently Issued Accounting Standards",
     "role": "http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandards",
     "shortName": "Recently Issued Accounting Standards",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R100": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2488451 - Disclosure - Segment Reporting - Additional Information (Details)",
     "role": "http://www.evolenthealth.com/role/SegmentReportingAdditionalInformationDetails",
     "shortName": "Segment Reporting - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R101": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2489452 - Disclosure - Segment Reporting - Revenue from Segments to Consolidated (Details)",
     "role": "http://www.evolenthealth.com/role/SegmentReportingRevenuefromSegmentstoConsolidatedDetails",
     "shortName": "Segment Reporting - Revenue from Segments to Consolidated (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "i679cb28be3a34242bd30bce045577c6e_D20210401-20210630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R102": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2490453 - Disclosure - Segment Reporting - Reconciliation of Adjusted EBITDA (Details)",
     "role": "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails",
     "shortName": "Segment Reporting - Reconciliation of Adjusted EBITDA (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OtherNonoperatingIncomeExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R103": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "i45bff335c1434d6ba44132da1b0557db_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2493454 - Disclosure - Reserves for Claims and Performance-Based Arrangements (Details)",
     "role": "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails",
     "shortName": "Reserves for Claims and Performance-Based Arrangements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "i45bff335c1434d6ba44132da1b0557db_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R104": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "evh:NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationMeasurementPeriodAdjustment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2496455 - Disclosure - Supplemental Cash Flow Information (Details)",
     "role": "http://www.evolenthealth.com/role/SupplementalCashFlowInformationDetails",
     "shortName": "Supplemental Cash Flow Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "evh:NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationMeasurementPeriodAdjustment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R105": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "i46534d0a532b4e63ade4879ed3702a19_D20210802-20210802",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationConsiderationTransferred1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2498456 - Disclosure - Subsequent Events (Details)",
     "role": "http://www.evolenthealth.com/role/SubsequentEventsDetails",
     "shortName": "Subsequent Events (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "i46534d0a532b4e63ade4879ed3702a19_D20210802-20210802",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationConsiderationTransferred1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2111104 - Disclosure - Transactions",
     "role": "http://www.evolenthealth.com/role/Transactions",
     "shortName": "Transactions",
     "subGroupType": "",
     "uniqueAnchor": null
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2113105 - Disclosure - Discontinued Operations",
     "role": "http://www.evolenthealth.com/role/DiscontinuedOperations",
     "shortName": "Discontinued Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2118106 - Disclosure - Revenue Recognition",
     "role": "http://www.evolenthealth.com/role/RevenueRecognition",
     "shortName": "Revenue Recognition",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CreditLossFinancialInstrumentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2124107 - Disclosure - Credit Losses",
     "role": "http://www.evolenthealth.com/role/CreditLosses",
     "shortName": "Credit Losses",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CreditLossFinancialInstrumentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2128108 - Disclosure - Property and Equipment, Net",
     "role": "http://www.evolenthealth.com/role/PropertyandEquipmentNet",
     "shortName": "Property and Equipment, Net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2131109 - Disclosure - Goodwill and Intangible Assets, Net",
     "role": "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNet",
     "shortName": "Goodwill and Intangible Assets, Net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2137110 - Disclosure - Long-term Debt",
     "role": "http://www.evolenthealth.com/role/LongtermDebt",
     "shortName": "Long-term Debt",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2145111 - Disclosure - Commitments and Contingencies",
     "role": "http://www.evolenthealth.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2150112 - Disclosure - Leases",
     "role": "http://www.evolenthealth.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "if6c0e91c6c854cf38504ed9bee64b0fa_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - CONSOLIDATED BALANCE SHEETS",
     "role": "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "if6c0e91c6c854cf38504ed9bee64b0fa_I20210630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AssetsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2157113 - Disclosure - Earnings (Loss) Per Common Share",
     "role": "http://www.evolenthealth.com/role/EarningsLossPerCommonShare",
     "shortName": "Earnings (Loss) Per Common Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2161114 - Disclosure - Stock-based Compensation",
     "role": "http://www.evolenthealth.com/role/StockbasedCompensation",
     "shortName": "Stock-based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2166115 - Disclosure - Income Taxes",
     "role": "http://www.evolenthealth.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2168116 - Disclosure - Investments In and Advances to Equity Method Investees",
     "role": "http://www.evolenthealth.com/role/InvestmentsInandAdvancestoEquityMethodInvestees",
     "shortName": "Investments In and Advances to Equity Method Investees",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MinorityInterestDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2170117 - Disclosure - Non-controlling Interests",
     "role": "http://www.evolenthealth.com/role/NoncontrollingInterests",
     "shortName": "Non-controlling Interests",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MinorityInterestDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:FairValueMeasurementPolicyPolicyTextBlock",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2173118 - Disclosure - Fair Value Measurement",
     "role": "http://www.evolenthealth.com/role/FairValueMeasurement",
     "shortName": "Fair Value Measurement",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:FairValueMeasurementPolicyPolicyTextBlock",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2179119 - Disclosure - Related Parties",
     "role": "http://www.evolenthealth.com/role/RelatedParties",
     "shortName": "Related Parties",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2183120 - Disclosure - Repositioning and Other Changes",
     "role": "http://www.evolenthealth.com/role/RepositioningandOtherChanges",
     "shortName": "Repositioning and Other Changes",
     "subGroupType": "",
     "uniqueAnchor": null
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2186121 - Disclosure - Segment Reporting",
     "role": "http://www.evolenthealth.com/role/SegmentReporting",
     "shortName": "Segment Reporting",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InsuranceDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2191122 - Disclosure - Reserves for Claims and Performance-Based Arrangements",
     "role": "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangements",
     "shortName": "Reserves for Claims and Performance-Based Arrangements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InsuranceDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "if6c0e91c6c854cf38504ed9bee64b0fa_I20210630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "role": "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "if6c0e91c6c854cf38504ed9bee64b0fa_I20210630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2194123 - Disclosure - Supplemental Cash Flow Information",
     "role": "http://www.evolenthealth.com/role/SupplementalCashFlowInformation",
     "shortName": "Supplemental Cash Flow Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SubsequentEventsTextBlock",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2197124 - Disclosure - Subsequent Events",
     "role": "http://www.evolenthealth.com/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SubsequentEventsTextBlock",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2204201 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles (Policies)",
     "role": "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies",
     "shortName": "Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2305301 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles (Tables)",
     "role": "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesTables",
     "shortName": "Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2314302 - Disclosure - Discontinued Operations (Tables)",
     "role": "http://www.evolenthealth.com/role/DiscontinuedOperationsTables",
     "shortName": "Discontinued Operations (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2319303 - Disclosure - Revenue Recognition (Tables)",
     "role": "http://www.evolenthealth.com/role/RevenueRecognitionTables",
     "shortName": "Revenue Recognition (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2325304 - Disclosure - Credit Losses (Tables)",
     "role": "http://www.evolenthealth.com/role/CreditLossesTables",
     "shortName": "Credit Losses (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2329305 - Disclosure - Property and Equipment, Net (Tables)",
     "role": "http://www.evolenthealth.com/role/PropertyandEquipmentNetTables",
     "shortName": "Property and Equipment, Net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2332306 - Disclosure - Goodwill and Intangible Assets, Net (Tables)",
     "role": "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetTables",
     "shortName": "Goodwill and Intangible Assets, Net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConvertibleDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2338307 - Disclosure - Long-term Debt (Tables)",
     "role": "http://www.evolenthealth.com/role/LongtermDebtTables",
     "shortName": "Long-term Debt (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConvertibleDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)",
     "role": "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OperatingExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectsOfReinsuranceTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2346308 - Disclosure - Commitments and Contingencies (Tables)",
     "role": "http://www.evolenthealth.com/role/CommitmentsandContingenciesTables",
     "shortName": "Commitments and Contingencies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectsOfReinsuranceTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2351309 - Disclosure - Leases (Tables)",
     "role": "http://www.evolenthealth.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2358310 - Disclosure - Earnings (Loss) Per Common Share (Tables)",
     "role": "http://www.evolenthealth.com/role/EarningsLossPerCommonShareTables",
     "shortName": "Earnings (Loss) Per Common Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2362311 - Disclosure - Stock-based Compensation (Tables)",
     "role": "http://www.evolenthealth.com/role/StockbasedCompensationTables",
     "shortName": "Stock-based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "evh:ScheduleofChangesinNoncontrollingInterestTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2371312 - Disclosure - Non-controlling Interests (Tables)",
     "role": "http://www.evolenthealth.com/role/NoncontrollingInterestsTables",
     "shortName": "Non-controlling Interests (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "evh:ScheduleofChangesinNoncontrollingInterestTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2374313 - Disclosure - Fair Value Measurement (Tables)",
     "role": "http://www.evolenthealth.com/role/FairValueMeasurementTables",
     "shortName": "Fair Value Measurement (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2380314 - Disclosure - Related Parties (Tables)",
     "role": "http://www.evolenthealth.com/role/RelatedPartiesTables",
     "shortName": "Related Parties (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2384315 - Disclosure - Repositioning and Other Changes (Tables)",
     "role": "http://www.evolenthealth.com/role/RepositioningandOtherChangesTables",
     "shortName": "Repositioning and Other Changes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2387316 - Disclosure - Segment Reporting (Tables)",
     "role": "http://www.evolenthealth.com/role/SegmentReportingTables",
     "shortName": "Segment Reporting (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2392317 - Disclosure - Reserves for Claims and Performance-Based Arrangements (Tables)",
     "role": "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsTables",
     "shortName": "Reserves for Claims and Performance-Based Arrangements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "i3046b7b99a004e48a03d367e730f9ae5_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesIssued",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005005 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (DEFICIT)",
     "role": "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYDEFICIT",
     "shortName": "CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (DEFICIT)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2395318 - Disclosure - Supplemental Cash Flow Information (Tables)",
     "role": "http://www.evolenthealth.com/role/SupplementalCashFlowInformationTables",
     "shortName": "Supplemental Cash Flow Information (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402402 - Disclosure - Organization (Details)",
     "role": "http://www.evolenthealth.com/role/OrganizationDetails",
     "shortName": "Organization (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "if6c0e91c6c854cf38504ed9bee64b0fa_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestrictedCashAndCashEquivalents",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406403 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Restricted Cash and Restricted Investments (Details)",
     "role": "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails",
     "shortName": "Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Restricted Cash and Restricted Investments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "if6c0e91c6c854cf38504ed9bee64b0fa_I20210630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "ibb95849bc72e47e5b878e5e786a0ed96_D20201031-20201031",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfReportingUnits",
      "reportCount": 1,
      "unitRef": "reportingunit",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407404 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Goodwill (Details)",
     "role": "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesGoodwillDetails",
     "shortName": "Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Goodwill (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:IntangibleAssetsFiniteLivedPolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "i83f72281c0b7415ea503edc371882a4f_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408405 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Intangible Assets, Net (Details)",
     "role": "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails",
     "shortName": "Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Intangible Assets, Net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:IntangibleAssetsFiniteLivedPolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "i83f72281c0b7415ea503edc371882a4f_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "iec09d5072eea4a989bbeda84a659de90_I20200331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410406 - Disclosure - Recently Issued Accounting Standards (Details)",
     "role": "http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails",
     "shortName": "Recently Issued Accounting Standards (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsToMinorityShareholders",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412407 - Disclosure - Transactions - Passport (Details)",
     "role": "http://www.evolenthealth.com/role/TransactionsPassportDetails",
     "shortName": "Transactions - Passport (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "ifee88f44d6c647d095b28edecae13e93_D20200901-20200901",
      "decimals": "-5",
      "lang": "en-US",
      "name": "evh:AssetAcquisitionCashAndEquivalents",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415408 - Disclosure - Discontinued Operations - Summary of Results of Operations (Details)",
     "role": "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails",
     "shortName": "Discontinued Operations - Summary of Results of Operations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "i1869cd19e38f4a028448315845a440c5_D20210401-20210630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "iae3e4f43e8c541128c572b22ebdd19bd_D20210101-20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416409 - Disclosure - Discontinued Operations - Summary of Cash Flows (Details)",
     "role": "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCashFlowsDetails",
     "shortName": "Discontinued Operations - Summary of Cash Flows (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "iae3e4f43e8c541128c572b22ebdd19bd_D20210101-20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "if6c0e91c6c854cf38504ed9bee64b0fa_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417410 - Disclosure - Discontinued Operations - Summary of Current and Long-term Assets and Liabilities (Details)",
     "role": "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCurrentandLongtermAssetsandLiabilitiesDetails",
     "shortName": "Discontinued Operations - Summary of Current and Long-term Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "ia177f909fbae4389bdaa8635f038babb_I20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "role": "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "evh:GainLossOnDispositionOfAssetsOperatingActivities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "i679cb28be3a34242bd30bce045577c6e_D20210401-20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420411 - Disclosure - Revenue Recognition - Disaggregation of Revenue (Details)",
     "role": "http://www.evolenthealth.com/role/RevenueRecognitionDisaggregationofRevenueDetails",
     "shortName": "Revenue Recognition - Disaggregation of Revenue (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "i679cb28be3a34242bd30bce045577c6e_D20210401-20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "if6c0e91c6c854cf38504ed9bee64b0fa_I20210630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueRemainingPerformanceObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421412 - Disclosure - Revenue Recognition - Transaction Price Allocated to the Remaining Performance Obligations (Details)",
     "role": "http://www.evolenthealth.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails",
     "shortName": "Revenue Recognition - Transaction Price Allocated to the Remaining Performance Obligations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "if6c0e91c6c854cf38504ed9bee64b0fa_I20210630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueRemainingPerformanceObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "if6c0e91c6c854cf38504ed9bee64b0fa_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsNotesAndLoansReceivableNetCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422413 - Disclosure - Revenue Recognition - Contract Balances (Details)",
     "role": "http://www.evolenthealth.com/role/RevenueRecognitionContractBalancesDetails",
     "shortName": "Revenue Recognition - Contract Balances (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "i45bff335c1434d6ba44132da1b0557db_I20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AccountsNotesAndLoansReceivableNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CapitalizedContractCostAmortization",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423414 - Disclosure - Revenue Recognition - Contract Costs (Details)",
     "role": "http://www.evolenthealth.com/role/RevenueRecognitionContractCostsDetails",
     "shortName": "Revenue Recognition - Contract Costs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "i82a60e4d756c4c5e95ccf693e56f48a9_I20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:CapitalizedContractCostNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "if6c0e91c6c854cf38504ed9bee64b0fa_I20210630",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "evh:FinancingReceivablePercentNotPastDue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2426415 - Disclosure - Credit Losses - Accounts Receivable (Narrative) (Details)",
     "role": "http://www.evolenthealth.com/role/CreditLossesAccountsReceivableNarrativeDetails",
     "shortName": "Credit Losses - Accounts Receivable (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "if6c0e91c6c854cf38504ed9bee64b0fa_I20210630",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "evh:FinancingReceivablePercentNotPastDue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "i45bff335c1434d6ba44132da1b0557db_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2427416 - Disclosure - Credit Losses - Schedule of Changes in Allowance for Accounts Receivable (Details)",
     "role": "http://www.evolenthealth.com/role/CreditLossesScheduleofChangesinAllowanceforAccountsReceivableDetails",
     "shortName": "Credit Losses - Schedule of Changes in Allowance for Accounts Receivable (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ProvisionForDoubtfulAccounts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "if6c0e91c6c854cf38504ed9bee64b0fa_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2430417 - Disclosure - Property and Equipment, Net (Details)",
     "role": "http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails",
     "shortName": "Property and Equipment, Net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "i45bff335c1434d6ba44132da1b0557db_I20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "ibb95849bc72e47e5b878e5e786a0ed96_D20201031-20201031",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfReportingUnits",
      "reportCount": 1,
      "unitRef": "reportingunit",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2433418 - Disclosure - Goodwill and Intangible Assets, Net - Impairment Testing (Details)",
     "role": "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetImpairmentTestingDetails",
     "shortName": "Goodwill and Intangible Assets, Net - Impairment Testing (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "ibb95849bc72e47e5b878e5e786a0ed96_D20201031-20201031",
      "decimals": "INF",
      "lang": "en-US",
      "name": "evh:NumberOfReportingUnitsFairValueInExcessOfCarryingAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "reportingunit",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "ie0ff0ad229b441d4b12bc8956f92a917_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434419 - Disclosure - Goodwill and Intangible Assets, Net - Schedule of Goodwill (Details)",
     "role": "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetScheduleofGoodwillDetails",
     "shortName": "Goodwill and Intangible Assets, Net - Schedule of Goodwill (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "i1329c4578fb4440eb76f4615f13ab8b6_D20200101-20200630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "if6c0e91c6c854cf38504ed9bee64b0fa_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2435420 - Disclosure - Goodwill and Intangible Assets, Net - Intangible Assets, Net (Details)",
     "role": "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails",
     "shortName": "Goodwill and Intangible Assets, Net - Intangible Assets, Net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "i45bff335c1434d6ba44132da1b0557db_I20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1404401 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (Parenthetical)",
     "role": "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSSParenthetical",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "if6c0e91c6c854cf38504ed9bee64b0fa_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2436421 - Disclosure - Goodwill and Intangible Assets, Net - Amortization of Intangible Assets 10K (Details)",
     "role": "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssets10KDetails",
     "shortName": "Goodwill and Intangible Assets, Net - Amortization of Intangible Assets 10K (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "if6c0e91c6c854cf38504ed9bee64b0fa_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "i1598eae5f6ae4813b69f0cbb95358c65_D20200801-20200831",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsOfDebtIssuanceCosts",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2439422 - Disclosure - Long-term Debt - 2024 Notes (Details)",
     "role": "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
     "shortName": "Long-term Debt - 2024 Notes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "ie9f0093698034c048db39ee74d23fe56_I20200831",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:LongTermDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GainsLossesOnExtinguishmentOfDebt",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2440423 - Disclosure - Long-term Debt - Credit Agreement (Details)",
     "role": "http://www.evolenthealth.com/role/LongtermDebtCreditAgreementDetails",
     "shortName": "Long-term Debt - Credit Agreement (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "ifa10c9f357cc46da8a582a78230489bf_I20191230",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "i1cad05e654934e308e828b864b76a508_I20191230",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightUnissued",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2441424 - Disclosure - Long-term Debt - Warrant Agreement (Details)",
     "role": "http://www.evolenthealth.com/role/LongtermDebtWarrantAgreementDetails",
     "shortName": "Long-term Debt - Warrant Agreement (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "i1cad05e654934e308e828b864b76a508_I20191230",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "i0db344c6ddf344ceab1c3071829545ff_I20181031",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredFinanceCostsNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2442425 - Disclosure - Long-term Debt - 2025 Notes (Details)",
     "role": "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails",
     "shortName": "Long-term Debt - 2025 Notes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "i0db344c6ddf344ceab1c3071829545ff_I20181031",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredFinanceCostsNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AmortizationOfFinancingCosts",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2443426 - Disclosure - Long-term Debt - 2021 Notes (Details)",
     "role": "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails",
     "shortName": "Long-term Debt - 2021 Notes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "i1598eae5f6ae4813b69f0cbb95358c65_D20200801-20200831",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R76": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "i8e9d743092e245ce8a2743fa9de0063b_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConvertibleDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2444427 - Disclosure - Long-term Debt - Convertible Senior Notes Carrying Value (Details)",
     "role": "http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails",
     "shortName": "Long-term Debt - Convertible Senior Notes Carrying Value (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "i8e9d743092e245ce8a2743fa9de0063b_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConvertibleDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R77": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "if6c0e91c6c854cf38504ed9bee64b0fa_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestrictedCashAndCashEquivalents",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2447428 - Disclosure - Commitments and Contingencies - Additional Information (Details)",
     "role": "http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
     "shortName": "Commitments and Contingencies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "if6c0e91c6c854cf38504ed9bee64b0fa_I20210630",
      "decimals": "INF",
      "lang": "en-US",
      "name": "evh:TaxReceivablesAgreementPercentofTaxSavingstobePaid",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R78": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:EffectsOfReinsuranceTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssumedPremiumsWritten",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2448429 - Disclosure - Commitments and Contingencies - Reinsurance Agreements (Details)",
     "role": "http://www.evolenthealth.com/role/CommitmentsandContingenciesReinsuranceAgreementsDetails",
     "shortName": "Commitments and Contingencies - Reinsurance Agreements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:EffectsOfReinsuranceTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssumedPremiumsWritten",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R79": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "if6c0e91c6c854cf38504ed9bee64b0fa_I20210630",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "evh:CashFDICInsuredAmountPercentage",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2449430 - Disclosure - Commitments and Contingencies - Concentration Risk (Details)",
     "role": "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails",
     "shortName": "Commitments and Contingencies - Concentration Risk (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "i3bfde454609344df8a691fb13c17b423_D20210101-20210630",
      "decimals": "3",
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Organization",
     "role": "http://www.evolenthealth.com/role/Organization",
     "shortName": "Organization",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R80": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "if6c0e91c6c854cf38504ed9bee64b0fa_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestrictedCashAndCashEquivalents",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2452431 - Disclosure - Leases - Narrative (Details)",
     "role": "http://www.evolenthealth.com/role/LeasesNarrativeDetails",
     "shortName": "Leases - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "id96b9f84ab8c4a4f8d773f444cd3a629_I20210630",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:LettersOfCreditOutstandingAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R81": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "if6c0e91c6c854cf38504ed9bee64b0fa_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2453432 - Disclosure - Leases - Material Office Leases (Details)",
     "role": "http://www.evolenthealth.com/role/LeasesMaterialOfficeLeasesDetails",
     "shortName": "Leases - Material Office Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "if54c2d9d6b874c56bd73c8364532a8fa_I20210630",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseTermOfContract",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R82": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2454433 - Disclosure - Leases - Components of Lease Expense (Details)",
     "role": "http://www.evolenthealth.com/role/LeasesComponentsofLeaseExpenseDetails",
     "shortName": "Leases - Components of Lease Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R83": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "if6c0e91c6c854cf38504ed9bee64b0fa_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2455434 - Disclosure - Leases - Maturity of Lease Liabilities (Details)",
     "role": "http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails",
     "shortName": "Leases - Maturity of Lease Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "if6c0e91c6c854cf38504ed9bee64b0fa_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R84": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "if6c0e91c6c854cf38504ed9bee64b0fa_I20210630",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2456435 - Disclosure - Leases - Weighted-average Discount Rate and Weighted-remaining Lease Terms (Details)",
     "role": "http://www.evolenthealth.com/role/LeasesWeightedaverageDiscountRateandWeightedremainingLeaseTermsDetails",
     "shortName": "Leases - Weighted-average Discount Rate and Weighted-remaining Lease Terms (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "if6c0e91c6c854cf38504ed9bee64b0fa_I20210630",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R85": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2459436 - Disclosure - Earnings (Loss) Per Common Share - Computation of Earnings per Share (Details)",
     "role": "http://www.evolenthealth.com/role/EarningsLossPerCommonShareComputationofEarningsperShareDetails",
     "shortName": "Earnings (Loss) Per Common Share - Computation of Earnings per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R86": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2460437 - Disclosure - Earnings (Loss) Per Common Share - Antidilutive Securities (Details)",
     "role": "http://www.evolenthealth.com/role/EarningsLossPerCommonShareAntidilutiveSecuritiesDetails",
     "shortName": "Earnings (Loss) Per Common Share - Antidilutive Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R87": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2463438 - Disclosure - Stock-based Compensation - Stock-based Compensation Expense (Details)",
     "role": "http://www.evolenthealth.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails",
     "shortName": "Stock-based Compensation - Stock-based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R88": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2464439 - Disclosure - Stock-based Compensation - Narrative (Details)",
     "role": "http://www.evolenthealth.com/role/StockbasedCompensationNarrativeDetails",
     "shortName": "Stock-based Compensation - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R89": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "id632fa3ae3914b9da8bf15e4c54b6686_D20210401-20210630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2465440 - Disclosure - Stock-based Compensation - Schedule of Share-based Awards Granted (Details)",
     "role": "http://www.evolenthealth.com/role/StockbasedCompensationScheduleofSharebasedAwardsGrantedDetails",
     "shortName": "Stock-based Compensation - Schedule of Share-based Awards Granted (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "id632fa3ae3914b9da8bf15e4c54b6686_D20210401-20210630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103102 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles",
     "role": "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciples",
     "shortName": "Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "i927c9bfad38c4d70a0178ba712489ef4_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R90": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2467441 - Disclosure - Income Taxes - Narrative (Details)",
     "role": "http://www.evolenthealth.com/role/IncomeTaxesNarrativeDetails",
     "shortName": "Income Taxes - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630",
      "decimals": "3",
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R91": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromEquityMethodInvestments",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2469442 - Disclosure - Investments In and Advances to Equity Method Investees - Additional Information (Details)",
     "role": "http://www.evolenthealth.com/role/InvestmentsInandAdvancestoEquityMethodInvesteesAdditionalInformationDetails",
     "shortName": "Investments In and Advances to Equity Method Investees - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "i53efb4309a7d432c9067d4fceb38e1e9_D20210401-20210630",
      "decimals": "-5",
      "lang": "en-US",
      "name": "evh:IncomeLossfromEquityMethodInvestmentsServicesAgreement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R92": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "i46248ae6cf2f4c3bb6a08e6b7351403f_D20200901-20200901",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2472443 - Disclosure - Non-controlling Interests (Details)",
     "role": "http://www.evolenthealth.com/role/NoncontrollingInterestsDetails",
     "shortName": "Non-controlling Interests (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "i46248ae6cf2f4c3bb6a08e6b7351403f_D20200901-20200901",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R93": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "i45bff335c1434d6ba44132da1b0557db_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2475444 - Disclosure - Fair Value Measurement - Assets and Liabilities on Recurring Basis (Details)",
     "role": "http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails",
     "shortName": "Fair Value Measurement - Assets and Liabilities on Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "i45bff335c1434d6ba44132da1b0557db_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R94": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "i1cad05e654934e308e828b864b76a508_I20191230",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightUnissued",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2476445 - Disclosure - Fair Value Measurement - Additional Information (Details)",
     "role": "http://www.evolenthealth.com/role/FairValueMeasurementAdditionalInformationDetails",
     "shortName": "Fair Value Measurement - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R95": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "i45bff335c1434d6ba44132da1b0557db_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2477446 - Disclosure - Fair Value Measurement - Changes in Contingent Consideration and Other (Details)",
     "role": "http://www.evolenthealth.com/role/FairValueMeasurementChangesinContingentConsiderationandOtherDetails",
     "shortName": "Fair Value Measurement - Changes in Contingent Consideration and Other (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "i45bff335c1434d6ba44132da1b0557db_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R96": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "ie28163dd08614c3cafdece4567d5b234_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherLiabilitiesFairValueDisclosure",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2478447 - Disclosure - Fair Value Measurement - Valuation Techniques and Significant Unobservable Inputs (Details)",
     "role": "http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails",
     "shortName": "Fair Value Measurement - Valuation Techniques and Significant Unobservable Inputs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "i9af8cd87d8f9489980dbda44afabcdbc_I20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OtherLiabilitiesFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R97": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "if6c0e91c6c854cf38504ed9bee64b0fa_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2481448 - Disclosure - Related Parties - Assets and Liabilities (Details)",
     "role": "http://www.evolenthealth.com/role/RelatedPartiesAssetsandLiabilitiesDetails",
     "shortName": "Related Parties - Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "i5e3c636f0c3f4cd9a3d1b819208219a6_I20210630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R98": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2482449 - Disclosure - Related Parties - Revenues and Expenses (Details)",
     "role": "http://www.evolenthealth.com/role/RelatedPartiesRevenuesandExpensesDetails",
     "shortName": "Related Parties - Revenues and Expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "id32a865882ba4f0f9600a62eb26f2cd9_D20210401-20210630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "evh:CostofGoodsandServicesSoldExcludingDepreciationandAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R99": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "i4bf204d286474499ba2c2c344f32cf7b_D20210401-20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringCharges",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2485450 - Disclosure - Repositioning and Other Changes (Details)",
     "role": "http://www.evolenthealth.com/role/RepositioningandOtherChangesDetails",
     "shortName": "Repositioning and Other Changes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20210630.htm",
      "contextRef": "i9efdfcae40144663a980937c662799c7_D20210401-20210630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RestructuringCharges",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 111,
   "tag": {
    "country_IN": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "INDIA",
        "terseLabel": "Pune, India"
       }
      }
     },
     "localname": "IN",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesMaterialOfficeLeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r813"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r814"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r815"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding (in shares)"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r815"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r815"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r817"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r815"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r815"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r815"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r815"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r811"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r812"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "evh_AccruedPropertyAndEquipmentPurchases": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Property And Equipment Purchases",
        "label": "Accrued Property And Equipment Purchases",
        "negatedTerseLabel": "Accrued property and equipment purchases"
       }
      }
     },
     "localname": "AccruedPropertyAndEquipmentPurchases",
     "nsuri": "http://www.evolenthealth.com/20210630",
     "presentation": [
      "http://www.evolenthealth.com/role/SupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjusted Earnings Before Interest, Taxes, Depreciation And Amortization",
        "label": "Adjusted Earnings Before Interest, Taxes, Depreciation And Amortization",
        "terseLabel": "Adjusted EBITDA"
       }
      }
     },
     "localname": "AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization",
     "nsuri": "http://www.evolenthealth.com/20210630",
     "presentation": [
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails",
      "http://www.evolenthealth.com/role/SegmentReportingRevenuefromSegmentstoConsolidatedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_AmortizationOfDebtDiscountAndDebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortization Of Debt Discount And Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction",
        "label": "Amortization Of Debt Discount And Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction",
        "terseLabel": "Non-cash amortization of debt discount and debt issuance costs"
       }
      }
     },
     "localname": "AmortizationOfDebtDiscountAndDebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction",
     "nsuri": "http://www.evolenthealth.com/20210630",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebtCreditAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_AssetAcquisitionAccruedLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Acquisition, Accrued Liabilities",
        "label": "Asset Acquisition, Accrued Liabilities",
        "terseLabel": "Accrued liabilities"
       }
      }
     },
     "localname": "AssetAcquisitionAccruedLiabilities",
     "nsuri": "http://www.evolenthealth.com/20210630",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsPassportDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_AssetAcquisitionAccruedMedicalExpenses": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Acquisition, Accrued Medical Expenses",
        "label": "Asset Acquisition, Accrued Medical Expenses",
        "terseLabel": "Accrued medical expenses"
       }
      }
     },
     "localname": "AssetAcquisitionAccruedMedicalExpenses",
     "nsuri": "http://www.evolenthealth.com/20210630",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsPassportDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_AssetAcquisitionCashAndEquivalents": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Acquisition, Cash And Equivalents",
        "label": "Asset Acquisition, Cash And Equivalents",
        "terseLabel": "Cash and equivalents"
       }
      }
     },
     "localname": "AssetAcquisitionCashAndEquivalents",
     "nsuri": "http://www.evolenthealth.com/20210630",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsPassportDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_AssetAcquisitionDebtSecuritiesAvailableForSale": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Acquisition, Debt Securities, Available-For-Sale",
        "label": "Asset Acquisition, Debt Securities, Available-For-Sale",
        "terseLabel": "Debt securities, available-for-sale"
       }
      }
     },
     "localname": "AssetAcquisitionDebtSecuritiesAvailableForSale",
     "nsuri": "http://www.evolenthealth.com/20210630",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsPassportDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_AssetAcquisitionDebtSecuritiesAvailableForSaleUnsettledSalesReceivables": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Acquisition, Debt Securities, Available-For-Sale, Unsettled Sales Receivables",
        "label": "Asset Acquisition, Debt Securities, Available-For-Sale, Unsettled Sales Receivables",
        "terseLabel": "Receivables related to unsettled sales of securities"
       }
      }
     },
     "localname": "AssetAcquisitionDebtSecuritiesAvailableForSaleUnsettledSalesReceivables",
     "nsuri": "http://www.evolenthealth.com/20210630",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsPassportDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_AssetAcquisitionOtherAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Acquisition, Other Assets",
        "label": "Asset Acquisition, Other Assets",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "AssetAcquisitionOtherAssets",
     "nsuri": "http://www.evolenthealth.com/20210630",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsPassportDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_AssetPurchaseAgreementEscrowPayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Purchase Agreement, Escrow Payments",
        "label": "Asset Purchase Agreement, Escrow Payments",
        "terseLabel": "Asset Purchase Agreement, escrow payments"
       }
      }
     },
     "localname": "AssetPurchaseAgreementEscrowPayments",
     "nsuri": "http://www.evolenthealth.com/20210630",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsPassportDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseImpactOfConsolidationOnPayables": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assumed Liability For Unpaid Claims And Claims Adjustment Expense, Impact Of Consolidation On Payables",
        "label": "Assumed Liability For Unpaid Claims And Claims Adjustment Expense, Impact Of Consolidation On Payables",
        "negatedTerseLabel": "Impact of consolidation on payable for claims and performance-based arrangements attributable to the Reinsurance Agreement"
       }
      }
     },
     "localname": "AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseImpactOfConsolidationOnPayables",
     "nsuri": "http://www.evolenthealth.com/20210630",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesReinsuranceAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_BelowMarketLeasesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Below Market Leases [Member]",
        "label": "Below Market Leases [Member]",
        "terseLabel": "Below market lease, net"
       }
      }
     },
     "localname": "BelowMarketLeasesMember",
     "nsuri": "http://www.evolenthealth.com/20210630",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_BlackScholesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Black Scholes [Member]",
        "label": "Black Scholes [Member]",
        "terseLabel": "Black-Scholes"
       }
      }
     },
     "localname": "BlackScholesMember",
     "nsuri": "http://www.evolenthealth.com/20210630",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_BonusesAndCommissionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bonuses And Commissions [Member]",
        "label": "Bonuses And Commissions [Member]",
        "terseLabel": "Bonuses and Commissions"
       }
      }
     },
     "localname": "BonusesAndCommissionsMember",
     "nsuri": "http://www.evolenthealth.com/20210630",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionContractCostsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_CapitalizedContractCostAmortizationPurchaseAccountingAdjustments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Capitalized Contract Cost, Amortization, Purchase Accounting Adjustments",
        "label": "Capitalized Contract Cost, Amortization, Purchase Accounting Adjustments",
        "negatedLabel": "Amortization of contract cost assets"
       }
      }
     },
     "localname": "CapitalizedContractCostAmortizationPurchaseAccountingAdjustments",
     "nsuri": "http://www.evolenthealth.com/20210630",
     "presentation": [
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_CashFDICInsuredAmountPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, FDIC Insured Amount, Percentage",
        "label": "Cash, FDIC Insured Amount, Percentage",
        "terseLabel": "Percentage of cash and cash equivalents held with FDIC participating bank"
       }
      }
     },
     "localname": "CashFDICInsuredAmountPercentage",
     "nsuri": "http://www.evolenthealth.com/20210630",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "evh_CashFlowLesseeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash Flow, Lessee [Abstract]",
        "label": "Cash Flow, Lessee [Abstract]",
        "terseLabel": "Effects of Leases"
       }
      }
     },
     "localname": "CashFlowLesseeAbstract",
     "nsuri": "http://www.evolenthealth.com/20210630",
     "presentation": [
      "http://www.evolenthealth.com/role/SupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "evh_CashHeldInInternationalBanksPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, Held In International Banks, Percentage",
        "label": "Cash, Held In International Banks, Percentage",
        "terseLabel": "Percentage of cash held in international banks (less than)"
       }
      }
     },
     "localname": "CashHeldInInternationalBanksPercentage",
     "nsuri": "http://www.evolenthealth.com/20210630",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "evh_CashReleasedFromEscrow": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash Released From Escrow",
        "label": "Cash Released From Escrow",
        "terseLabel": "Cash Released From Escrow"
       }
      }
     },
     "localname": "CashReleasedFromEscrow",
     "nsuri": "http://www.evolenthealth.com/20210630",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsPassportDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_ChangeInContractWithCustomerLiabilityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change In Contract With Customer, Liability [Roll Forward]",
        "label": "Change In Contract With Customer, Liability [Roll Forward]",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ChangeInContractWithCustomerLiabilityRollForward",
     "nsuri": "http://www.evolenthealth.com/20210630",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionContractBalancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "evh_ClassOfWarrantOrRightPeriodDuringWhichWarrantsOrRightsExercisableAfterMaturityOfCreditAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Of Warrant Or Right, Period During Which Warrants Or Rights Exercisable, After Maturity Of Credit Agreement",
        "label": "Class Of Warrant Or Right, Period During Which Warrants Or Rights Exercisable, After Maturity Of Credit Agreement",
        "terseLabel": "Period during which warrants or rights exercisable, after maturity of credit agreement"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightPeriodDuringWhichWarrantsOrRightsExercisableAfterMaturityOfCreditAgreement",
     "nsuri": "http://www.evolenthealth.com/20210630",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebtWarrantAgreementDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "evh_ClinicalSolutionsSegmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Clinical Solutions Segment",
        "label": "Clinical Solutions Segment [Member]",
        "terseLabel": "Clinical Solutions"
       }
      }
     },
     "localname": "ClinicalSolutionsSegmentMember",
     "nsuri": "http://www.evolenthealth.com/20210630",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetScheduleofGoodwillDetails",
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails",
      "http://www.evolenthealth.com/role/RevenueRecognitionDisaggregationofRevenueDetails",
      "http://www.evolenthealth.com/role/SegmentReportingRevenuefromSegmentstoConsolidatedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_CollateralwithFinancialInstitutionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collateral with Financial Institutions [Member]",
        "label": "Collateral with Financial Institutions [Member]",
        "terseLabel": "Collateral with financial institutions"
       }
      }
     },
     "localname": "CollateralwithFinancialInstitutionsMember",
     "nsuri": "http://www.evolenthealth.com/20210630",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails",
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_CommercialAndOtherCustomersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commercial And Other Customers",
        "label": "Commercial And Other Customers [Member]",
        "terseLabel": "Commercial and other"
       }
      }
     },
     "localname": "CommercialAndOtherCustomersMember",
     "nsuri": "http://www.evolenthealth.com/20210630",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_ContractFulfillmentCostsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract Fulfillment Costs [Member]",
        "label": "Contract Fulfillment Costs [Member]",
        "terseLabel": "Contract Fulfillment Costs"
       }
      }
     },
     "localname": "ContractFulfillmentCostsMember",
     "nsuri": "http://www.evolenthealth.com/20210630",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionContractCostsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract With Customer, Liability, Cash Received In Advance Of Satisfaction Of Performance Obligations",
        "label": "Contract With Customer, Liability, Cash Received In Advance Of Satisfaction Of Performance Obligations",
        "terseLabel": "Cash received in advance of satisfaction of performance obligations"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations",
     "nsuri": "http://www.evolenthealth.com/20210630",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionContractBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_ConvertibleSeniorNotesdue2021Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible Senior Notes due 2021 [Member]",
        "label": "Convertible Senior Notes due 2021 [Member]",
        "terseLabel": "2021 Notes"
       }
      }
     },
     "localname": "ConvertibleSeniorNotesdue2021Member",
     "nsuri": "http://www.evolenthealth.com/20210630",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails",
      "http://www.evolenthealth.com/role/LongtermDebtCreditAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_CookCountyHealthAndHospitalsSystemMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cook County Health And Hospitals System [Member]",
        "label": "Cook County Health And Hospitals System [Member]",
        "terseLabel": "Cook County Health and Hospitals System"
       }
      }
     },
     "localname": "CookCountyHealthAndHospitalsSystemMember",
     "nsuri": "http://www.evolenthealth.com/20210630",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_CostofGoodsandServicesSoldExcludingDepreciationandAmortization": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost of Goods and Services Sold, Excluding Depreciation and Amortization",
        "label": "Cost of Goods and Services Sold, Excluding Depreciation and Amortization",
        "terseLabel": "Cost of revenue (exclusive of depreciation and amortization expenses presented separately below)",
        "verboseLabel": "Cost of revenue (exclusive of depreciation and amortization expenses)"
       }
      }
     },
     "localname": "CostofGoodsandServicesSoldExcludingDepreciationandAmortization",
     "nsuri": "http://www.evolenthealth.com/20210630",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/RelatedPartiesRevenuesandExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_CreditAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Credit Agreement [Member]",
        "label": "Credit Agreement [Member]",
        "terseLabel": "Credit Agreement"
       }
      }
     },
     "localname": "CreditAgreementMember",
     "nsuri": "http://www.evolenthealth.com/20210630",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebtCreditAgreementDetails",
      "http://www.evolenthealth.com/role/LongtermDebtWarrantAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Current Year Claims And Claims Adjustment Expense, Including Cost Of Goods And Services Sold, Excluding Depreciation And Amortization",
        "label": "Current Year Claims And Claims Adjustment Expense, Including Cost Of Goods And Services Sold, Excluding Depreciation And Amortization",
        "verboseLabel": "Incurred costs related to current year"
       }
      }
     },
     "localname": "CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization",
     "nsuri": "http://www.evolenthealth.com/20210630",
     "presentation": [
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_DebtInstrumentRedemptionCallProtectionPremiumPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Redemption, Call Protection Premium, Percentage",
        "label": "Debt Instrument, Redemption, Call Protection Premium, Percentage",
        "terseLabel": "Redemption, call protection premium, percentage"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionCallProtectionPremiumPercentage",
     "nsuri": "http://www.evolenthealth.com/20210630",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebtCreditAgreementDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Repurchase Covenant, Consecutive Trading Days, Minimum",
        "label": "Debt Instrument, Repurchase Covenant, Consecutive Trading Days, Minimum",
        "terseLabel": "Repurchase covenant, consecutive trading days, minimum"
       }
      }
     },
     "localname": "DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum",
     "nsuri": "http://www.evolenthealth.com/20210630",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Repurchase Covenant, Sale Price As A Percentage Of Conversion Price",
        "label": "Debt Instrument, Repurchase Covenant, Sale Price As A Percentage Of Conversion Price",
        "terseLabel": "Repurchase covenant, sale price as a percentage of conversion price",
        "verboseLabel": "Repurchase covenant, sale price as a percentage of conversion price (at least)"
       }
      }
     },
     "localname": "DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice",
     "nsuri": "http://www.evolenthealth.com/20210630",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Repurchase Covenant, Trading Days, Minimum",
        "label": "Debt Instrument, Repurchase Covenant, Trading Days, Minimum",
        "terseLabel": "Repurchase covenant, trading days, minimum"
       }
      }
     },
     "localname": "DebtInstrumentRepurchaseCovenantTradingDaysMinimum",
     "nsuri": "http://www.evolenthealth.com/20210630",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Repurchase Price Due To Change In Sale Price As Percentage Of Conversion Price",
        "label": "Debt Instrument, Repurchase Price Due To Change In Sale Price As Percentage Of Conversion Price",
        "terseLabel": "Repurchase covenant, repurchase price due to change in sale price as percentage of conversion price"
       }
      }
     },
     "localname": "DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice",
     "nsuri": "http://www.evolenthealth.com/20210630",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Repurchase Price Due To Fundamental Change As Percentage Of Principal Amount",
        "label": "Debt Instrument, Repurchase Price Due To Fundamental Change As Percentage Of Principal Amount",
        "verboseLabel": "Repurchase covenant, repurchase price due to fundamental change as percentage of principal amount"
       }
      }
     },
     "localname": "DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount",
     "nsuri": "http://www.evolenthealth.com/20210630",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "evh_DebtIssuanceCostsNetDebtComponent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Issuance Costs, Net, Debt Component",
        "label": "Debt Issuance Costs, Net, Debt Component",
        "terseLabel": "Debt issuance costs, net, debt component"
       }
      }
     },
     "localname": "DebtIssuanceCostsNetDebtComponent",
     "nsuri": "http://www.evolenthealth.com/20210630",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_DelayedDrawTermLoanFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Delayed Draw Term Loan Facility [Member]",
        "label": "Delayed Draw Term Loan Facility [Member]",
        "terseLabel": "DDTL Facility"
       }
      }
     },
     "localname": "DelayedDrawTermLoanFacilityMember",
     "nsuri": "http://www.evolenthealth.com/20210630",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebtCreditAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNetAfterGrossUp": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal Group, Including Discontinued Operation, Accounts, Notes And Loans Receivable, Net, After Gross-Up",
        "label": "Disposal Group, Including Discontinued Operation, Accounts, Notes And Loans Receivable, Net, After Gross-Up",
        "terseLabel": "Accounts receivable, net, after gross-up"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNetAfterGrossUp",
     "nsuri": "http://www.evolenthealth.com/20210630",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionContractBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_DisposalGroupIncludingDiscontinuedOperationAccruedCompensationAndEmployeeBenefitsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCurrentandLongtermAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal Group, Including Discontinued Operation, Accrued Compensation And Employee Benefits, Current",
        "label": "Disposal Group, Including Discontinued Operation, Accrued Compensation And Employee Benefits, Current",
        "terseLabel": "Accrued compensation and employee benefits"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationAccruedCompensationAndEmployeeBenefitsCurrent",
     "nsuri": "http://www.evolenthealth.com/20210630",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCurrentandLongtermAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_DisposalGroupIncludingDiscontinuedOperationClaimsExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal Group, Including Discontinued Operation, Claims Expense",
        "label": "Disposal Group, Including Discontinued Operation, Claims Expense",
        "terseLabel": "Claims expenses"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationClaimsExpense",
     "nsuri": "http://www.evolenthealth.com/20210630",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_DisposalGroupIncludingDiscontinuedOperationInvestmentsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCurrentandLongtermAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal Group, Including Discontinued Operation, Investments, Current",
        "label": "Disposal Group, Including Discontinued Operation, Investments, Current",
        "terseLabel": "Investments, at amortized cost"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationInvestmentsCurrent",
     "nsuri": "http://www.evolenthealth.com/20210630",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCurrentandLongtermAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_DisposalGroupIncludingDiscontinuedOperationInvestmentsNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCurrentandLongtermAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal Group, Including Discontinued Operation, Investments, Noncurrent",
        "label": "Disposal Group, Including Discontinued Operation, Investments, Noncurrent",
        "terseLabel": "Investments, at amortized cost"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationInvestmentsNoncurrent",
     "nsuri": "http://www.evolenthealth.com/20210630",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCurrentandLongtermAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_DisposalGroupIncludingDiscontinuedOperationLiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangementsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCurrentandLongtermAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal Group, Including Discontinued Operation, Liability For Future Policy Benefits And Unpaid Claims And Claims Adjustment Expense And Performance-Based Arrangements, Current",
        "label": "Disposal Group, Including Discontinued Operation, Liability For Future Policy Benefits And Unpaid Claims And Claims Adjustment Expense And Performance-Based Arrangements, Current",
        "terseLabel": "Reserve for claims and performance-based arrangements"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationLiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangementsCurrent",
     "nsuri": "http://www.evolenthealth.com/20210630",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCurrentandLongtermAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCurrentandLongtermAssetsandLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal Group, Including Discontinued Operation, Prepaid And Other Assets, Noncurrent",
        "label": "Disposal Group, Including Discontinued Operation, Prepaid And Other Assets, Noncurrent",
        "terseLabel": "Prepaid expenses and other noncurrent assets"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsNoncurrent",
     "nsuri": "http://www.evolenthealth.com/20210630",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCurrentandLongtermAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_DisposalGroupIncludingDiscontinuedOperationRestrictedCashAndRestrictedInvestmentsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCurrentandLongtermAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal Group, Including Discontinued Operation, Restricted Cash And Restricted Investments, Current",
        "label": "Disposal Group, Including Discontinued Operation, Restricted Cash And Restricted Investments, Current",
        "terseLabel": "Restricted cash and restricted investments"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationRestrictedCashAndRestrictedInvestmentsCurrent",
     "nsuri": "http://www.evolenthealth.com/20210630",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCurrentandLongtermAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_DisposalGroupIncludingDiscontinuedOperationRestrictedCashAndRestrictedInvestmentsNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCurrentandLongtermAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal Group, Including Discontinued Operation, Restricted Cash And Restricted Investments, Noncurrent",
        "label": "Disposal Group, Including Discontinued Operation, Restricted Cash And Restricted Investments, Noncurrent",
        "terseLabel": "Restricted cash and restricted investments"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationRestrictedCashAndRestrictedInvestmentsNoncurrent",
     "nsuri": "http://www.evolenthealth.com/20210630",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCurrentandLongtermAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_DisposalGroupIncludingDiscontinuedOperationRestrictedCashCurrent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal Group, Including Discontinued Operation, Restricted Cash, Current",
        "label": "Disposal Group, Including Discontinued Operation, Restricted Cash, Current",
        "terseLabel": "Current restricted cash from claims processing services"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationRestrictedCashCurrent",
     "nsuri": "http://www.evolenthealth.com/20210630",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_DisposalGroupIncludingDiscontinuedOperationRestrictedInvestmentsNoncurrent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal Group, Including Discontinued Operation, Restricted Investments, Noncurrent",
        "label": "Disposal Group, Including Discontinued Operation, Restricted Investments, Noncurrent",
        "terseLabel": "Non-current restricted investments"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationRestrictedInvestmentsNoncurrent",
     "nsuri": "http://www.evolenthealth.com/20210630",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_EarningsLossAvailabletoCommonShareholdersAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Earnings (Loss) Available to Common Shareholders [Abstract]",
        "label": "Earnings (Loss) Available to Common Shareholders [Abstract]",
        "verboseLabel": "Less:"
       }
      }
     },
     "localname": "EarningsLossAvailabletoCommonShareholdersAbstract",
     "nsuri": "http://www.evolenthealth.com/20210630",
     "presentation": [
      "http://www.evolenthealth.com/role/EarningsLossPerCommonShareComputationofEarningsperShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "evh_EmployeeSeveranceAndTerminationBenefitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee Severance And Termination Benefits",
        "label": "Employee Severance And Termination Benefits [Member]",
        "terseLabel": "Severance and termination benefits"
       }
      }
     },
     "localname": "EmployeeSeveranceAndTerminationBenefitsMember",
     "nsuri": "http://www.evolenthealth.com/20210630",
     "presentation": [
      "http://www.evolenthealth.com/role/RepositioningandOtherChangesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_EquityMethodInvestmentEconomicInterestPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Method Investment, Economic Interest Percentage",
        "label": "Equity Method Investment, Economic Interest Percentage",
        "terseLabel": "Economic interest percentage"
       }
      }
     },
     "localname": "EquityMethodInvestmentEconomicInterestPercentage",
     "nsuri": "http://www.evolenthealth.com/20210630",
     "presentation": [
      "http://www.evolenthealth.com/role/InvestmentsInandAdvancestoEquityMethodInvesteesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "evh_EquityMethodInvestmentVotingInterestPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Method Investment, Voting Interest Percentage",
        "label": "Equity Method Investment, Voting Interest Percentage",
        "terseLabel": "Voting interest percentage"
       }
      }
     },
     "localname": "EquityMethodInvestmentVotingInterestPercentage",
     "nsuri": "http://www.evolenthealth.com/20210630",
     "presentation": [
      "http://www.evolenthealth.com/role/InvestmentsInandAdvancestoEquityMethodInvesteesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "evh_EvolentHealthLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Evolent Health LLC [Member]",
        "label": "Evolent Health LLC [Member]",
        "terseLabel": "Evolent Health LLC"
       }
      }
     },
     "localname": "EvolentHealthLLCMember",
     "nsuri": "http://www.evolenthealth.com/20210630",
     "presentation": [
      "http://www.evolenthealth.com/role/NoncontrollingInterestsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_EvolentHealthServicesSegmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Evolent Health Services Segment",
        "label": "Evolent Health Services Segment [Member]",
        "terseLabel": "Evolent Health Services"
       }
      }
     },
     "localname": "EvolentHealthServicesSegmentMember",
     "nsuri": "http://www.evolenthealth.com/20210630",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetScheduleofGoodwillDetails",
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails",
      "http://www.evolenthealth.com/role/RevenueRecognitionDisaggregationofRevenueDetails",
      "http://www.evolenthealth.com/role/SegmentReportingRevenuefromSegmentstoConsolidatedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_FInancialAssetLessThan120DaysPastDueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "FInancial Asset, Less Than 120 Days Past Due [Member]",
        "label": "FInancial Asset, Less Than 120 Days Past Due [Member]",
        "terseLabel": "Past due less than 120 days"
       }
      }
     },
     "localname": "FInancialAssetLessThan120DaysPastDueMember",
     "nsuri": "http://www.evolenthealth.com/20210630",
     "presentation": [
      "http://www.evolenthealth.com/role/CreditLossesAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_FInancialAssetLessThan60DaysMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "FInancial Asset, Less Than 60 Days [Member]",
        "label": "FInancial Asset, Less Than 60 Days [Member]",
        "terseLabel": "Past due less than 60 days"
       }
      }
     },
     "localname": "FInancialAssetLessThan60DaysMember",
     "nsuri": "http://www.evolenthealth.com/20210630",
     "presentation": [
      "http://www.evolenthealth.com/role/CreditLossesAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_FinancingReceivablePercentNotPastDue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financing Receivable, Percent Not Past Due",
        "label": "Financing Receivable, Percent Not Past Due",
        "terseLabel": "Percentage of receivables, current"
       }
      }
     },
     "localname": "FinancingReceivablePercentNotPastDue",
     "nsuri": "http://www.evolenthealth.com/20210630",
     "presentation": [
      "http://www.evolenthealth.com/role/CreditLossesAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "evh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssets10KDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finite-Lived Intangible Asset, Expected Amortization, After Year Four",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, After Year Four",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour",
     "nsuri": "http://www.evolenthealth.com/20210630",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssets10KDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_FloridaBlueMedicareIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Florida Blue Medicare, Inc.",
        "label": "Florida Blue Medicare, Inc. [Member]",
        "terseLabel": "Florida Blue Medicare, Inc."
       }
      }
     },
     "localname": "FloridaBlueMedicareIncMember",
     "nsuri": "http://www.evolenthealth.com/20210630",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_GainLossOnDispositionOfAssetsOperatingActivities": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain (Loss) On Disposition Of Assets, Operating Activities",
        "label": "Gain (Loss) On Disposition Of Assets, Operating Activities",
        "negatedLabel": "(Gain) loss on disposal of assets"
       }
      }
     },
     "localname": "GainLossOnDispositionOfAssetsOperatingActivities",
     "nsuri": "http://www.evolenthealth.com/20210630",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_GainOnTransferOfMembership": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 24.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 8.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain On Transfer Of Membership",
        "label": "Gain On Transfer Of Membership",
        "negatedTerseLabel": "Gain on transfer of membership",
        "terseLabel": "Gain on transfer of membership"
       }
      }
     },
     "localname": "GainOnTransferOfMembership",
     "nsuri": "http://www.evolenthealth.com/20210630",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_IncomeLossfromEquityMethodInvestmentsServicesAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income (Loss) from Equity Method Investments, Services Agreement",
        "label": "Income (Loss) from Equity Method Investments, Services Agreement",
        "terseLabel": "Income from long-term services agreement"
       }
      }
     },
     "localname": "IncomeLossfromEquityMethodInvestmentsServicesAgreement",
     "nsuri": "http://www.evolenthealth.com/20210630",
     "presentation": [
      "http://www.evolenthealth.com/role/InvestmentsInandAdvancestoEquityMethodInvesteesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Accounts Receivable And Contract With Customer, Asset",
        "label": "Increase (Decrease) In Accounts Receivable And Contract With Customer, Asset",
        "negatedTerseLabel": "Accounts receivable, net and contract assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset",
     "nsuri": "http://www.evolenthealth.com/20210630",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_IncreaseDecreaseInCapitalizedContractCostNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Capitalized Contract Cost, Net",
        "label": "Increase (Decrease) In Capitalized Contract Cost, Net",
        "negatedTerseLabel": "Contract cost assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInCapitalizedContractCostNet",
     "nsuri": "http://www.evolenthealth.com/20210630",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 19.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Insurance And Performance-Based Arrangements Liabilities",
        "label": "Increase (Decrease) In Insurance And Performance-Based Arrangements Liabilities",
        "terseLabel": "Reserve for claims and performance-based arrangements"
       }
      }
     },
     "localname": "IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities",
     "nsuri": "http://www.evolenthealth.com/20210630",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_IncreaseDecreaseInOperatingLeaseRightofUseAsset": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 20.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Operating Lease, Right-of-Use Asset",
        "label": "Increase (Decrease) In Operating Lease, Right-of-Use Asset",
        "negatedTerseLabel": "Right-of-use operating assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseRightofUseAsset",
     "nsuri": "http://www.evolenthealth.com/20210630",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_InitialTermLoanFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Initial Term Loan Facility [Member]",
        "label": "Initial Term Loan Facility [Member]",
        "terseLabel": "Initial Term Loan Facility"
       }
      }
     },
     "localname": "InitialTermLoanFacilityMember",
     "nsuri": "http://www.evolenthealth.com/20210630",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebtCreditAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFive": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Liability, To Be Paid, After Year Five",
        "label": "Lessee, Operating Lease, Liability, To Be Paid, After Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityToBePaidAfterYearFive",
     "nsuri": "http://www.evolenthealth.com/20210630",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_LeveragedStockUnitsLSUsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Leveraged Stock Units (LSUs) [Member]",
        "label": "Leveraged Stock Units (LSUs) [Member]",
        "verboseLabel": "LSUs"
       }
      }
     },
     "localname": "LeveragedStockUnitsLSUsMember",
     "nsuri": "http://www.evolenthealth.com/20210630",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationScheduleofSharebasedAwardsGrantedDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liability For Future Policy Benefits And Unpaid Claims And Claims Adjustment Expense And Performance-Based Arrangements",
        "label": "Liability For Future Policy Benefits And Unpaid Claims And Claims Adjustment Expense And Performance-Based Arrangements",
        "terseLabel": "Reserve for claims and performance-based arrangements"
       }
      }
     },
     "localname": "LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements",
     "nsuri": "http://www.evolenthealth.com/20210630",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseDisposalOfDiscontinuedOperations": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liability For Unpaid Claims And Claims Adjustment Expense, Disposal Of Discontinued Operations",
        "label": "Liability For Unpaid Claims And Claims Adjustment Expense, Disposal Of Discontinued Operations",
        "negatedTerseLabel": "Disposal of discontinued operations"
       }
      }
     },
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseDisposalOfDiscontinuedOperations",
     "nsuri": "http://www.evolenthealth.com/20210630",
     "presentation": [
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_MedicaidCustomersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medicaid Customers",
        "label": "Medicaid Customers [Member]",
        "terseLabel": "Medicaid"
       }
      }
     },
     "localname": "MedicaidCustomersMember",
     "nsuri": "http://www.evolenthealth.com/20210630",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_MedicareCustomersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medicare Customers",
        "label": "Medicare Customers [Member]",
        "terseLabel": "Medicare"
       }
      }
     },
     "localname": "MedicareCustomersMember",
     "nsuri": "http://www.evolenthealth.com/20210630",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_MolinaHealthcareIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Molina Healthcare, Inc.",
        "label": "Molina Healthcare, Inc. [Member]",
        "terseLabel": "Molina"
       }
      }
     },
     "localname": "MolinaHealthcareIncMember",
     "nsuri": "http://www.evolenthealth.com/20210630",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsPassportDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_NeighborhoodHealthPlanOfRhodeIslandMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Neighborhood Health Plan Of Rhode Island",
        "label": "Neighborhood Health Plan Of Rhode Island [Member]",
        "terseLabel": "Neighborhood Health Plan Of Rhode Island [Member]"
       }
      }
     },
     "localname": "NeighborhoodHealthPlanOfRhodeIslandMember",
     "nsuri": "http://www.evolenthealth.com/20210630",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_NewNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "New Notes",
        "label": "New Notes [Member]",
        "terseLabel": "New Notes"
       }
      }
     },
     "localname": "NewNotesMember",
     "nsuri": "http://www.evolenthealth.com/20210630",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationMeasurementPeriodAdjustment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncash Or Part Noncash Acquisition, Noncash Financial Or Equity Instrument Consideration, Measurement Period Adjustment",
        "label": "Noncash Or Part Noncash Acquisition, Noncash Financial Or Equity Instrument Consideration, Measurement Period Adjustment",
        "terseLabel": "Increase/decrease to goodwill from measurement period adjustments/business combinations"
       }
      }
     },
     "localname": "NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationMeasurementPeriodAdjustment",
     "nsuri": "http://www.evolenthealth.com/20210630",
     "presentation": [
      "http://www.evolenthealth.com/role/SupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_NumberOfReportingUnitsFairValueInExcessOfCarryingAmount": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Reporting Units, Fair Value In Excess Of Carrying Amount",
        "label": "Number Of Reporting Units, Fair Value In Excess Of Carrying Amount",
        "terseLabel": "Number of reporting units, fair value in excess of carrying amount"
       }
      }
     },
     "localname": "NumberOfReportingUnitsFairValueInExcessOfCarryingAmount",
     "nsuri": "http://www.evolenthealth.com/20210630",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetImpairmentTestingDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "evh_PaidinKindInterestIncome": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 26.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Paid-in-Kind Interest Income",
        "label": "Paid-in-Kind Interest Income",
        "negatedTerseLabel": "Interest from customer advance for regulatory capital requirements"
       }
      }
     },
     "localname": "PaidinKindInterestIncome",
     "nsuri": "http://www.evolenthealth.com/20210630",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_PassportAssetAcquisitionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Passport Asset Acquisition",
        "label": "Passport Asset Acquisition [Member]",
        "terseLabel": "Passport Asset Acquisition"
       }
      }
     },
     "localname": "PassportAssetAcquisitionMember",
     "nsuri": "http://www.evolenthealth.com/20210630",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsPassportDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_PassportNoteMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Passport Note [Member]",
        "label": "Passport Note [Member]",
        "terseLabel": "Passport Note"
       }
      }
     },
     "localname": "PassportNoteMember",
     "nsuri": "http://www.evolenthealth.com/20210630",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsPassportDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_PaymentsForProceedsFromClaimsProcessingFinancingActivities": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments For (Proceeds From) Claims Processing, Financing Activities",
        "label": "Payments For (Proceeds From) Claims Processing, Financing Activities",
        "negatedTerseLabel": "Changes in working capital balances related to claims processing on behalf of partners"
       }
      }
     },
     "localname": "PaymentsForProceedsFromClaimsProcessingFinancingActivities",
     "nsuri": "http://www.evolenthealth.com/20210630",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments For (Proceeds From) Disposal Of Non-Strategic Assets And Divestiture Of Discontinued Operations, Net",
        "label": "Payments For (Proceeds From) Disposal Of Non-Strategic Assets And Divestiture Of Discontinued Operations, Net",
        "negatedTerseLabel": "Disposal of non-strategic assets and divestiture of discontinued operations, net"
       }
      }
     },
     "localname": "PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet",
     "nsuri": "http://www.evolenthealth.com/20210630",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_PaymentsOfMakeWholePremium": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments Of Make-Whole Premium",
        "label": "Payments Of Make-Whole Premium",
        "terseLabel": "Payments of make-whole premium"
       }
      }
     },
     "localname": "PaymentsOfMakeWholePremium",
     "nsuri": "http://www.evolenthealth.com/20210630",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebtCreditAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_PaymentsToAcquireEquityMethodInvestmentsAmountHeldBack": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments To Acquire Equity Method Investments, Amount Held Back",
        "label": "Payments To Acquire Equity Method Investments, Amount Held Back",
        "terseLabel": "Payments to acquire equity method investments, amount held back"
       }
      }
     },
     "localname": "PaymentsToAcquireEquityMethodInvestmentsAmountHeldBack",
     "nsuri": "http://www.evolenthealth.com/20210630",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.evolenthealth.com/role/TransactionsPassportDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_PerformanceBasedRestrictedStockUnitsPBRSUsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Performance-Based Restricted Stock Units (PBRSUs) [Member]",
        "label": "Performance-Based Restricted Stock Units (PBRSUs) [Member]",
        "terseLabel": "PSUs"
       }
      }
     },
     "localname": "PerformanceBasedRestrictedStockUnitsPBRSUsMember",
     "nsuri": "http://www.evolenthealth.com/20210630",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationScheduleofSharebasedAwardsGrantedDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_PlatformsAndOperationsServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Platforms And Operations Services [Member]",
        "label": "Platforms And Operations Services [Member]",
        "verboseLabel": "Platform and operations services"
       }
      }
     },
     "localname": "PlatformsAndOperationsServicesMember",
     "nsuri": "http://www.evolenthealth.com/20210630",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails",
      "http://www.evolenthealth.com/role/RelatedPartiesRevenuesandExpensesDetails",
      "http://www.evolenthealth.com/role/SegmentReportingRevenuefromSegmentstoConsolidatedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_PolicyholderBenefitsAndClaimsIncurredAssumedExpensesRelatedToClaims": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Policyholder Benefits And Claims Incurred, Assumed, Expenses Related To Claims",
        "label": "Policyholder Benefits And Claims Incurred, Assumed, Expenses Related To Claims",
        "terseLabel": "Claims-related administrative expenses"
       }
      }
     },
     "localname": "PolicyholderBenefitsAndClaimsIncurredAssumedExpensesRelatedToClaims",
     "nsuri": "http://www.evolenthealth.com/20210630",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesReinsuranceAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_PremiumsRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Premiums Revenue [Member]",
        "label": "Premiums Revenue [Member]",
        "terseLabel": "Premiums"
       }
      }
     },
     "localname": "PremiumsRevenueMember",
     "nsuri": "http://www.evolenthealth.com/20210630",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails",
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_PremiumsWrittenAndPolicyholderBenefitsAndClaimsIncurredNet": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Premiums Written And Policyholder Benefits And Claims Incurred, Net",
        "label": "Premiums Written And Policyholder Benefits And Claims Incurred, Net",
        "terseLabel": "Increase in reserves for claims and performance-based arrangements attributable to the Reinsurance Agreement"
       }
      }
     },
     "localname": "PremiumsWrittenAndPolicyholderBenefitsAndClaimsIncurredNet",
     "nsuri": "http://www.evolenthealth.com/20210630",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesReinsuranceAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_ProceedsFromMaturityOfInvestments": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From Maturity Of Investments",
        "label": "Proceeds From Maturity Of Investments",
        "terseLabel": "Maturities and sales of investments"
       }
      }
     },
     "localname": "ProceedsFromMaturityOfInvestments",
     "nsuri": "http://www.evolenthealth.com/20210630",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_ProceedsFromReinsurance": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From Reinsurance",
        "label": "Proceeds From Reinsurance",
        "negatedLabel": "Reinsurance payments paid (received)"
       }
      }
     },
     "localname": "ProceedsFromReinsurance",
     "nsuri": "http://www.evolenthealth.com/20210630",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesReinsuranceAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_ProceedsFromTransferOfMembership": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From Transfer Of Membership",
        "label": "Proceeds From Transfer Of Membership",
        "terseLabel": "Proceeds from transfer of membership"
       }
      }
     },
     "localname": "ProceedsFromTransferOfMembership",
     "nsuri": "http://www.evolenthealth.com/20210630",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsPassportDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_ProfessionalServicesRestructuringMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Professional Services, Restructuring",
        "label": "Professional Services, Restructuring [Member]",
        "terseLabel": "Professional services"
       }
      }
     },
     "localname": "ProfessionalServicesRestructuringMember",
     "nsuri": "http://www.evolenthealth.com/20210630",
     "presentation": [
      "http://www.evolenthealth.com/role/RepositioningandOtherChangesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_RestrictedCashForLettersOfCreditForLetterOfCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted Cash For Letters Of Credit For Letter Of Credit Facility [Member]",
        "label": "Restricted Cash For Letters Of Credit For Letter Of Credit Facility [Member]",
        "terseLabel": "Restricted Cash For Letters Of Credit"
       }
      }
     },
     "localname": "RestrictedCashForLettersOfCreditForLetterOfCreditFacilityMember",
     "nsuri": "http://www.evolenthealth.com/20210630",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_RestrictedCashforBenefitManagementServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted Cash for Benefit Management Services [Member]",
        "label": "Restricted Cash for Benefit Management Services [Member]",
        "terseLabel": "Claims processing services"
       }
      }
     },
     "localname": "RestrictedCashforBenefitManagementServicesMember",
     "nsuri": "http://www.evolenthealth.com/20210630",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_RestrictedCashforLettersofCreditforFacilityLeasesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted Cash for Letters of Credit for Facility Leases [Member]",
        "label": "Restricted Cash for Letters of Credit for Facility Leases [Member]",
        "verboseLabel": "Collateral for letters of credit for facility leases"
       }
      }
     },
     "localname": "RestrictedCashforLettersofCreditforFacilityLeasesMember",
     "nsuri": "http://www.evolenthealth.com/20210630",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_RestrictedCashforOtherContractualCommitmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted Cash for Other Contractual Commitments [Member]",
        "label": "Restricted Cash for Other Contractual Commitments [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "RestrictedCashforOtherContractualCommitmentsMember",
     "nsuri": "http://www.evolenthealth.com/20210630",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted Stock and Restricted Stock Units [Member]",
        "label": "Restricted Stock Units (RSUs), Performance-based Restricted Stock Units (PBRSUs), And Leveraged Stock Units (LSUs) [Member]",
        "terseLabel": "Restricted stock units (\"RSUs\"), performance-based RSUs and leveraged stock units (\"LSUs\")"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember",
     "nsuri": "http://www.evolenthealth.com/20210630",
     "presentation": [
      "http://www.evolenthealth.com/role/EarningsLossPerCommonShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_RightOfUseAssetAcquiredAndDisposedOf": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right-Of-Use Asset Acquired And Disposed Of",
        "label": "Right-Of-Use Asset Acquired And Disposed Of",
        "negatedTerseLabel": "Leased assets obtained in exchange for operating lease liabilities"
       }
      }
     },
     "localname": "RightOfUseAssetAcquiredAndDisposedOf",
     "nsuri": "http://www.evolenthealth.com/20210630",
     "presentation": [
      "http://www.evolenthealth.com/role/SupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_ScheduleofChangesinNoncontrollingInterestTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Changes in Noncontrolling Interest [Table Text Block]",
        "label": "Schedule of Changes in Noncontrolling Interest [Table Text Block]",
        "terseLabel": "Schedule of changes in non-controlling interests"
       }
      }
     },
     "localname": "ScheduleofChangesinNoncontrollingInterestTableTextBlock",
     "nsuri": "http://www.evolenthealth.com/20210630",
     "presentation": [
      "http://www.evolenthealth.com/role/NoncontrollingInterestsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "evh_SeniorConvertibleNotesDue2024Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Convertible Notes Due 2024",
        "label": "Senior Convertible Notes Due 2024 [Member]",
        "terseLabel": "2024 Notes"
       }
      }
     },
     "localname": "SeniorConvertibleNotesDue2024Member",
     "nsuri": "http://www.evolenthealth.com/20210630",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_SeniorConvertibleNotesDue2025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Convertible Notes Due 2025 [Member]",
        "label": "Senior Convertible Notes Due 2025 [Member]",
        "terseLabel": "2025 Notes"
       }
      }
     },
     "localname": "SeniorConvertibleNotesDue2025Member",
     "nsuri": "http://www.evolenthealth.com/20210630",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_SeniorCreditFacilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Credit Facilities [Member]",
        "label": "Senior Credit Facilities [Member]",
        "terseLabel": "Senior Credit Facilities"
       }
      }
     },
     "localname": "SeniorCreditFacilitiesMember",
     "nsuri": "http://www.evolenthealth.com/20210630",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebtCreditAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_ServicesAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Services Agreements [Member]",
        "label": "Services Agreements [Member]",
        "terseLabel": "Services Agreements"
       }
      }
     },
     "localname": "ServicesAgreementsMember",
     "nsuri": "http://www.evolenthealth.com/20210630",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCurrentandLongtermAssetsandLiabilitiesDetails",
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails",
      "http://www.evolenthealth.com/role/InvestmentsInandAdvancestoEquityMethodInvesteesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_SharebasedCompensationIncludingOnetimeAdjustment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation, Including One-time Adjustment",
        "label": "Share-based Compensation, Including One-time Adjustment",
        "negatedLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "SharebasedCompensationIncludingOnetimeAdjustment",
     "nsuri": "http://www.evolenthealth.com/20210630",
     "presentation": [
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_ShareholderAdvisoryServices": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shareholder Advisory Services",
        "label": "Shareholder Advisory Services",
        "negatedLabel": "Strategy and shareholder advisory expenses"
       }
      }
     },
     "localname": "ShareholderAdvisoryServices",
     "nsuri": "http://www.evolenthealth.com/20210630",
     "presentation": [
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_StockVestedAndRetiredDuringPeriodShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Vested And Retired During Period, Shares",
        "label": "Stock Vested And Retired During Period, Shares",
        "negatedTerseLabel": "Share retirement (in shares)"
       }
      }
     },
     "localname": "StockVestedAndRetiredDuringPeriodShares",
     "nsuri": "http://www.evolenthealth.com/20210630",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "sharesItemType"
    },
    "evh_StockVestedAndRetiredDuringPeriodValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Vested And Retired During Period, Value",
        "label": "Stock Vested And Retired During Period, Value",
        "negatedTerseLabel": "Share retirement"
       }
      }
     },
     "localname": "StockVestedAndRetiredDuringPeriodValue",
     "nsuri": "http://www.evolenthealth.com/20210630",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_TaxReceivableAgreementPercentofCashSavingsPaidtoShareholders": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Receivable Agreement, Percent of Cash Savings Paid to Shareholders",
        "label": "Tax Receivable Agreement, Percent of Cash Savings Paid to Shareholders",
        "terseLabel": "Tax receivable agreement, percent of cash savings paid to shareholders"
       }
      }
     },
     "localname": "TaxReceivableAgreementPercentofCashSavingsPaidtoShareholders",
     "nsuri": "http://www.evolenthealth.com/20210630",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "evh_TaxReceivablesAgreementPercentofTaxSavingstobePaid": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Receivables Agreement, Percent of Tax Savings to be Paid",
        "label": "Tax Receivables Agreement, Percent of Tax Savings to be Paid",
        "terseLabel": "Percent of tax savings to be paid"
       }
      }
     },
     "localname": "TaxReceivablesAgreementPercentofTaxSavingstobePaid",
     "nsuri": "http://www.evolenthealth.com/20210630",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "evh_TransactionCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction Costs",
        "label": "Transaction Costs",
        "negatedLabel": "Acquisition costs"
       }
      }
     },
     "localname": "TransactionCosts",
     "nsuri": "http://www.evolenthealth.com/20210630",
     "presentation": [
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_TransferOfMembershipPercentageOfPaymentBasedOnNumberOfEnrollees": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transfer Of Membership, Percentage Of Payment Based on Number Of Enrollees",
        "label": "Transfer Of Membership, Percentage Of Payment Based on Number Of Enrollees",
        "terseLabel": "Transfer of membership, percentage of payment based on number of enrollees"
       }
      }
     },
     "localname": "TransferOfMembershipPercentageOfPaymentBasedOnNumberOfEnrollees",
     "nsuri": "http://www.evolenthealth.com/20210630",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsPassportDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "evh_TransferOfMembershipPercentageOfPaymentSubjectToSatisfactionOfContingencies": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transfer Of Membership, Percentage Of Payment Subject To Satisfaction Of Contingencies",
        "label": "Transfer Of Membership, Percentage Of Payment Subject To Satisfaction Of Contingencies",
        "terseLabel": "Transfer of membership, percentage of payment subject to satisfaction of contingencies"
       }
      }
     },
     "localname": "TransferOfMembershipPercentageOfPaymentSubjectToSatisfactionOfContingencies",
     "nsuri": "http://www.evolenthealth.com/20210630",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsPassportDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "evh_TransformationServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transformation Services [Member]",
        "label": "Transformation Services [Member]",
        "verboseLabel": "Transformation services"
       }
      }
     },
     "localname": "TransformationServicesMember",
     "nsuri": "http://www.evolenthealth.com/20210630",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/RelatedPartiesRevenuesandExpensesDetails",
      "http://www.evolenthealth.com/role/SegmentReportingRevenuefromSegmentstoConsolidatedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_TrueHealthMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "True Health",
        "label": "True Health [Member]",
        "terseLabel": "True Health"
       }
      }
     },
     "localname": "TrueHealthMember",
     "nsuri": "http://www.evolenthealth.com/20210630",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails",
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails",
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCashFlowsDetails",
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCurrentandLongtermAssetsandLiabilitiesDetails",
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails",
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails",
      "http://www.evolenthealth.com/role/RevenueRecognitionContractBalancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_TrueHealthSegmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "True Health Segment [Member]",
        "label": "True Health Segment [Member]",
        "terseLabel": "True Health"
       }
      }
     },
     "localname": "TrueHealthSegmentMember",
     "nsuri": "http://www.evolenthealth.com/20210630",
     "presentation": [
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_UniversityHealthCaredbaPassportHealthPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "University Health Care d/b/a Passport Health Plan [Member]",
        "label": "University Health Care d/b/a Passport Health Plan [Member]",
        "terseLabel": "Passport",
        "verboseLabel": "Passport"
       }
      }
     },
     "localname": "UniversityHealthCaredbaPassportHealthPlanMember",
     "nsuri": "http://www.evolenthealth.com/20210630",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails",
      "http://www.evolenthealth.com/role/NoncontrollingInterestsDetails",
      "http://www.evolenthealth.com/role/TransactionsPassportDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_VariableInterestEntityNewMedicaidContractNotAwardedRequirementToAcquireOwnershipConsiderationAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Variable Interest Entity, New Medicaid Contract Not Awarded, Requirement To Acquire Ownership, Consideration, Amount",
        "label": "Variable Interest Entity, New Medicaid Contract Not Awarded, Requirement To Acquire Ownership, Consideration, Amount",
        "terseLabel": "Requirement to acquire ownership, consideration, amount"
       }
      }
     },
     "localname": "VariableInterestEntityNewMedicaidContractNotAwardedRequirementToAcquireOwnershipConsiderationAmount",
     "nsuri": "http://www.evolenthealth.com/20210630",
     "presentation": [
      "http://www.evolenthealth.com/role/NoncontrollingInterestsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_WindroseHealthInvestorsIIILPMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Windrose Health Investors III, L.P.",
        "label": "Windrose Health Investors III, L.P. [Member]",
        "terseLabel": "Windrose Health Investors III, L.P."
       }
      }
     },
     "localname": "WindroseHealthInvestorsIIILPMember",
     "nsuri": "http://www.evolenthealth.com/20210630",
     "presentation": [
      "http://www.evolenthealth.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_AffiliatedEntityMember": {
     "auth_ref": [
      "r477",
      "r656",
      "r657",
      "r659",
      "r806"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Affiliated Entity [Member]",
        "terseLabel": "Affiliated Entity"
       }
      }
     },
     "localname": "AffiliatedEntityMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/RelatedPartiesAssetsandLiabilitiesDetails",
      "http://www.evolenthealth.com/role/RelatedPartiesRevenuesandExpensesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ConsolidatedEntitiesAxis": {
     "auth_ref": [
      "r160",
      "r357",
      "r362",
      "r370",
      "r561",
      "r562",
      "r570",
      "r571",
      "r662",
      "r806"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Axis]",
        "terseLabel": "Consolidated Entities [Axis]"
       }
      }
     },
     "localname": "ConsolidatedEntitiesAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.evolenthealth.com/role/NoncontrollingInterestsDetails",
      "http://www.evolenthealth.com/role/TransactionsPassportDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidatedEntitiesDomain": {
     "auth_ref": [
      "r160",
      "r357",
      "r362",
      "r370",
      "r561",
      "r562",
      "r570",
      "r571",
      "r662",
      "r806"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Domain]",
        "terseLabel": "Consolidated Entities [Domain]"
       }
      }
     },
     "localname": "ConsolidatedEntitiesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.evolenthealth.com/role/NoncontrollingInterestsDetails",
      "http://www.evolenthealth.com/role/TransactionsPassportDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ConsolidationItemsAxis": {
     "auth_ref": [
      "r160",
      "r226",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r244",
      "r248",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r364",
      "r365",
      "r367",
      "r369",
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Axis]",
        "terseLabel": "Consolidation Items [Axis]"
       }
      }
     },
     "localname": "ConsolidationItemsAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/SegmentReportingRevenuefromSegmentstoConsolidatedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidationItemsDomain": {
     "auth_ref": [
      "r160",
      "r226",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r244",
      "r248",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r364",
      "r365",
      "r367",
      "r369",
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Domain]",
        "terseLabel": "Consolidation Items [Domain]"
       }
      }
     },
     "localname": "ConsolidationItemsDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/SegmentReportingRevenuefromSegmentstoConsolidatedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r83",
      "r85",
      "r158",
      "r159",
      "r377",
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsPassportDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": {
     "auth_ref": [
      "r2",
      "r165",
      "r176",
      "r182",
      "r277",
      "r503",
      "r504",
      "r505",
      "r523",
      "r524",
      "r583",
      "r586",
      "r589",
      "r590",
      "r820"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption, Adjustment [Member]",
        "terseLabel": "Cumulative Effect, Period of Adoption, Adjustment"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYDEFICIT",
      "http://www.evolenthealth.com/role/CreditLossesScheduleofChangesinAllowanceforAccountsReceivableDetails",
      "http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAxis": {
     "auth_ref": [
      "r2",
      "r165",
      "r176",
      "r182",
      "r277",
      "r503",
      "r504",
      "r505",
      "r523",
      "r524",
      "r583",
      "r586",
      "r589",
      "r590",
      "r820"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption [Axis]",
        "terseLabel": "Cumulative Effect Period Of Adoption [Axis]"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYDEFICIT",
      "http://www.evolenthealth.com/role/CreditLossesScheduleofChangesinAllowanceforAccountsReceivableDetails",
      "http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionDomain": {
     "auth_ref": [
      "r2",
      "r165",
      "r176",
      "r182",
      "r277",
      "r503",
      "r504",
      "r505",
      "r523",
      "r524",
      "r583",
      "r586",
      "r589",
      "r590",
      "r820"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption [Domain]",
        "terseLabel": "Cumulative Effect Period Of Adoption [Domain]"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYDEFICIT",
      "http://www.evolenthealth.com/role/CreditLossesScheduleofChangesinAllowanceforAccountsReceivableDetails",
      "http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Domain]",
        "terseLabel": "Investment, Name [Domain]"
       }
      }
     },
     "localname": "EquityMethodInvesteeNameDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.evolenthealth.com/role/NoncontrollingInterestsDetails",
      "http://www.evolenthealth.com/role/TransactionsPassportDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r255",
      "r453",
      "r459",
      "r765"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails",
      "http://www.evolenthealth.com/role/RevenueRecognitionDisaggregationofRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r376",
      "r415",
      "r480",
      "r482",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r762",
      "r766",
      "r807",
      "r808"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum",
        "verboseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails",
      "http://www.evolenthealth.com/role/InvestmentsInandAdvancestoEquityMethodInvesteesAdditionalInformationDetails",
      "http://www.evolenthealth.com/role/LongtermDebtCreditAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r376",
      "r415",
      "r480",
      "r482",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r762",
      "r766",
      "r807",
      "r808"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails",
      "http://www.evolenthealth.com/role/InvestmentsInandAdvancestoEquityMethodInvesteesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r255",
      "r453",
      "r459",
      "r765"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails",
      "http://www.evolenthealth.com/role/RevenueRecognitionDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_OwnershipAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Axis]",
        "terseLabel": "Ownership [Axis]"
       }
      }
     },
     "localname": "OwnershipAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/NoncontrollingInterestsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_OwnershipDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Domain]",
        "terseLabel": "Ownership [Domain]"
       }
      }
     },
     "localname": "OwnershipDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/NoncontrollingInterestsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r251",
      "r453",
      "r457",
      "r683",
      "r761",
      "r763"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails",
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCurrentandLongtermAssetsandLiabilitiesDetails",
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails",
      "http://www.evolenthealth.com/role/RelatedPartiesRevenuesandExpensesDetails",
      "http://www.evolenthealth.com/role/SegmentReportingRevenuefromSegmentstoConsolidatedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r251",
      "r453",
      "r457",
      "r683",
      "r761",
      "r763"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails",
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCurrentandLongtermAssetsandLiabilitiesDetails",
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails",
      "http://www.evolenthealth.com/role/RelatedPartiesRevenuesandExpensesDetails",
      "http://www.evolenthealth.com/role/SegmentReportingRevenuefromSegmentstoConsolidatedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r376",
      "r415",
      "r469",
      "r480",
      "r482",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r762",
      "r766",
      "r807",
      "r808"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails",
      "http://www.evolenthealth.com/role/InvestmentsInandAdvancestoEquityMethodInvesteesAdditionalInformationDetails",
      "http://www.evolenthealth.com/role/LongtermDebtCreditAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r376",
      "r415",
      "r469",
      "r480",
      "r482",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r762",
      "r766",
      "r807",
      "r808"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails",
      "http://www.evolenthealth.com/role/InvestmentsInandAdvancestoEquityMethodInvesteesAdditionalInformationDetails",
      "http://www.evolenthealth.com/role/LongtermDebtCreditAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r84",
      "r85",
      "r158",
      "r159",
      "r377",
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsPassportDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "auth_ref": [
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Axis]",
        "terseLabel": "Investment, Name [Axis]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.evolenthealth.com/role/NoncontrollingInterestsDetails",
      "http://www.evolenthealth.com/role/TransactionsPassportDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r252",
      "r253",
      "r453",
      "r458",
      "r764",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r804",
      "r805"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesMaterialOfficeLeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r252",
      "r253",
      "r453",
      "r458",
      "r764",
      "r787",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r804",
      "r805"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesMaterialOfficeLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "stpr_CA": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CALIFORNIA",
        "terseLabel": "Brea, CA"
       }
      }
     },
     "localname": "CA",
     "nsuri": "http://xbrl.sec.gov/stpr/2021",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesMaterialOfficeLeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_IL": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ILLINOIS",
        "terseLabel": "Riverside, IL"
       }
      }
     },
     "localname": "IL",
     "nsuri": "http://xbrl.sec.gov/stpr/2021",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesMaterialOfficeLeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_VA": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "VIRGINIA",
        "terseLabel": "Arlington, VA"
       }
      }
     },
     "localname": "VA",
     "nsuri": "http://xbrl.sec.gov/stpr/2021",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesMaterialOfficeLeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdateExtensibleList": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r168",
      "r169",
      "r170",
      "r172",
      "r262",
      "r263",
      "r274",
      "r275",
      "r276",
      "r277",
      "r280",
      "r281",
      "r356",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r507",
      "r523",
      "r524",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r588",
      "r589",
      "r590",
      "r591",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r618",
      "r619",
      "r652",
      "r767",
      "r768",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773",
      "r774",
      "r775",
      "r776",
      "r777",
      "r778",
      "r818",
      "r819",
      "r820",
      "r821",
      "r822"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates amendment to accounting standards.",
        "label": "Accounting Standards Update [Extensible Enumeration]",
        "terseLabel": "Accounting Standards Update [Extensible Enumeration]"
       }
      }
     },
     "localname": "AccountingStandardsUpdateExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYDEFICIT",
      "http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_AccountsNotesAndLoansReceivableLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accounts, Notes, Loans and Financing Receivable [Line Items]",
        "terseLabel": "Accounts, Notes, Loans and Financing Receivable [Line Items]"
       }
      }
     },
     "localname": "AccountsNotesAndLoansReceivableLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CreditLossesScheduleofChangesinAllowanceforAccountsReceivableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsNotesAndLoansReceivableNetCurrent": {
     "auth_ref": [
      "r38",
      "r52",
      "r80",
      "r257",
      "r258",
      "r731"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of accounts and financing receivables, classified as current. Includes, but is not limited to, notes and loan receivable.",
        "label": "Accounts and Financing Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Short-term receivables"
       }
      }
     },
     "localname": "AccountsNotesAndLoansReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionContractBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis": {
     "auth_ref": [
      "r80"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of receivable.",
        "label": "Receivable Type [Axis]",
        "terseLabel": "Receivable Type [Axis]"
       }
      }
     },
     "localname": "AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails",
      "http://www.evolenthealth.com/role/TransactionsPassportDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r67",
      "r665"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable",
        "verboseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.evolenthealth.com/role/RelatedPartiesAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock": {
     "auth_ref": [
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allowance for credit loss on accounts receivable.",
        "label": "Accounts Receivable, Allowance for Credit Loss [Table Text Block]",
        "terseLabel": "Accounts receivable, allowance for credit loss"
       }
      }
     },
     "localname": "AccountsReceivableAllowanceForCreditLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CreditLossesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [
      "r792"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]",
        "terseLabel": "Accounts Receivable"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableNet": {
     "auth_ref": [
      "r52",
      "r731",
      "r791"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.",
        "label": "Accounts Receivable, after Allowance for Credit Loss",
        "terseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "AccountsReceivableNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CreditLossesAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r38",
      "r52",
      "r257",
      "r258"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "netLabel": "Accounts receivable, net",
        "terseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.evolenthealth.com/role/RelatedPartiesAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNoncurrentPastDueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accounts Receivable, Noncurrent, Past Due [Line Items]",
        "terseLabel": "Accounts Receivable, Noncurrent, Past Due [Line Items]"
       }
      }
     },
     "localname": "AccountsReceivableNoncurrentPastDueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CreditLossesAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsReceivableNoncurrentPastDueTable": {
     "auth_ref": [
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about aging analysis for accounts receivable, classified as noncurrent.",
        "label": "Accounts Receivable, Noncurrent, Past Due [Table]",
        "terseLabel": "Accounts Receivable, Noncurrent, Past Due [Table]"
       }
      }
     },
     "localname": "AccountsReceivableNoncurrentPastDueTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CreditLossesAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued liabilities",
        "verboseLabel": "Accrued liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.evolenthealth.com/role/RelatedPartiesAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r65",
      "r326"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedTerseLabel": "Accumulated depreciation and amortization expenses"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r55",
      "r88",
      "r89",
      "r90",
      "r737",
      "r774",
      "r778"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive income (loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": {
     "auth_ref": [
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Acquired Finite-lived Intangible Assets, Weighted Average Useful Life",
        "terseLabel": "Weighted- Average Remaining Useful Life"
       }
      }
     },
     "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r53",
      "r507",
      "r665"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in-capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r162",
      "r163",
      "r164",
      "r503",
      "r504",
      "r505",
      "r589"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r483",
      "r485",
      "r509",
      "r510"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash and restricted cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r485",
      "r495",
      "r508"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Share-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": {
     "auth_ref": [
      "r59",
      "r259",
      "r282"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.",
        "label": "Accounts Receivable, Allowance for Credit Loss, Current",
        "negatedPeriodEndLabel": "Balance as of end of period",
        "negatedPeriodStartLabel": "Balance as of beginning of period",
        "terseLabel": "Allowance for doubtful accounts, current"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CreditLossesAccountsReceivableNarrativeDetails",
      "http://www.evolenthealth.com/role/CreditLossesScheduleofChangesinAllowanceforAccountsReceivableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Accounts Receivable, Allowance for Credit Loss [Roll Forward]",
        "terseLabel": "Accounts Receivable, Allowance for Credit Loss [Roll Forward]"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableRollforward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CreditLossesScheduleofChangesinAllowanceforAccountsReceivableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs": {
     "auth_ref": [
      "r285"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of direct write-downs of accounts receivable charged against the allowance.",
        "label": "Accounts Receivable, Allowance for Credit Loss, Writeoff",
        "terseLabel": "Charge-offs"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableWriteOffs",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CreditLossesScheduleofChangesinAllowanceforAccountsReceivableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "auth_ref": [
      "r110",
      "r139",
      "r396",
      "r632"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs",
        "terseLabel": "Amortization of deferred financing costs",
        "verboseLabel": "Amortization of deferred financing costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r139",
      "r311",
      "r318"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization of intangible assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r199"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Number of antidilutive securities excluded from the calculation of earning per share (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/EarningsLossPerCommonShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r199"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/EarningsLossPerCommonShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/EarningsLossPerCommonShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r199"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/EarningsLossPerCommonShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember": {
     "auth_ref": [
      "r87",
      "r90",
      "r96",
      "r97",
      "r98",
      "r568"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, including the portion attributable to the noncontrolling interest. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Including Portion Attributable to Noncontrolling Interest [Member]",
        "terseLabel": "Accumulated Other Income (Loss)"
       }
      }
     },
     "localname": "AociIncludingPortionAttributableToNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetAcquisitionAxis": {
     "auth_ref": [
      "r554"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by asset acquisition.",
        "label": "Asset Acquisition [Axis]",
        "terseLabel": "Asset Acquisition [Axis]"
       }
      }
     },
     "localname": "AssetAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsPassportDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetAcquisitionDomain": {
     "auth_ref": [
      "r554"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset acquisition.",
        "label": "Asset Acquisition [Domain]",
        "terseLabel": "Asset Acquisition [Domain]"
       }
      }
     },
     "localname": "AssetAcquisitionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsPassportDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r155",
      "r234",
      "r240",
      "r246",
      "r272",
      "r357",
      "r358",
      "r359",
      "r361",
      "r362",
      "r363",
      "r364",
      "r366",
      "r368",
      "r370",
      "r371",
      "r561",
      "r570",
      "r608",
      "r663",
      "r665",
      "r708",
      "r733"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.evolenthealth.com/role/RelatedPartiesAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r39",
      "r40",
      "r82",
      "r155",
      "r272",
      "r357",
      "r358",
      "r359",
      "r361",
      "r362",
      "r363",
      "r364",
      "r366",
      "r368",
      "r370",
      "r371",
      "r561",
      "r570",
      "r608",
      "r663",
      "r665"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r592"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total fair value of assets measured on a recurring basis"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation": {
     "auth_ref": [
      "r6",
      "r7",
      "r27",
      "r29",
      "r33",
      "r329"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCurrentandLongtermAssetsandLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCurrentandLongtermAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group, Including Discontinued Operation, Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCurrentandLongtermAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r27",
      "r29",
      "r33",
      "r323",
      "r329"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCurrentandLongtermAssetsandLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Assets, Current",
        "terseLabel": "Current assets of discontinued operations",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCurrentandLongtermAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group, Including Discontinued Operation, Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCurrentandLongtermAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense": {
     "auth_ref": [
      "r755",
      "r758"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liability as of the balance sheet date for the estimated ultimate cost of settling claims and claim adjustment expense relating to insured events that have occurred on or before the balance sheet date for those liabilities owed to another party as a result of assuming another insurer's primary obligation.",
        "label": "Assumed Liability for Unpaid Claims and Claims Adjustment Expense",
        "verboseLabel": "Reserves for claims and performance-based arrangements attributable to the Reinsurance Agreement at the beginning of the period"
       }
      }
     },
     "localname": "AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesReinsuranceAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssumedPremiumsWritten": {
     "auth_ref": [
      "r780"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of written premiums assumed from other entities.",
        "label": "Assumed Premiums Written",
        "terseLabel": "Reinsurance premiums assumed"
       }
      }
     },
     "localname": "AssumedPremiumsWritten",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesReinsuranceAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r486",
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationScheduleofSharebasedAwardsGrantedDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BankTimeDepositsMember": {
     "auth_ref": [
      "r723"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Certificates of deposit (CD) or savings accounts with a fixed term or understanding the customer can only withdraw by giving advanced notice with a bank or other financial institution. A CD is a short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest.",
        "label": "Bank Time Deposits [Member]",
        "terseLabel": "Bank time deposits"
       }
      }
     },
     "localname": "BankTimeDepositsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BaseRateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum rate investor will accept.",
        "label": "Base Rate [Member]",
        "terseLabel": "Base Rate"
       }
      }
     },
     "localname": "BaseRateMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebtCreditAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r161"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.",
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
        "terseLabel": "Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles"
       }
      }
     },
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciples"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r479",
      "r481"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r479",
      "r481",
      "r538",
      "r539"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementAdditionalInformationDetails",
      "http://www.evolenthealth.com/role/TransactionsPassportDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "auth_ref": [
      "r547",
      "r548",
      "r550"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.",
        "label": "Business Combination, Consideration Transferred",
        "terseLabel": "Purchase price"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferred1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": {
     "auth_ref": [
      "r138",
      "r553"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.",
        "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability",
        "negatedLabel": "Change in fair value of contingent consideration and indemnification asset",
        "terseLabel": "Change in fair value of contingent consideration and indemnification asset",
        "verboseLabel": "Change in fair value of contingent consideration and indemnification asset"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r546",
      "r549",
      "r552"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability",
        "terseLabel": "Contingent consideration, liability"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combinations [Abstract]",
        "terseLabel": "Business Combinations [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationsPolicy": {
     "auth_ref": [
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.",
        "label": "Business Combinations Policy [Policy Text Block]",
        "terseLabel": "Business Combinations"
       }
      }
     },
     "localname": "BusinessCombinationsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r144",
      "r145",
      "r146"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Accrued property and equipment purchases"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/SupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalizedComputerSoftwareAdditions": {
     "auth_ref": [
      "r312"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions made to capitalized computer software costs during the period.",
        "label": "Capitalized Computer Software, Additions",
        "terseLabel": "Capitalized computer software additions"
       }
      }
     },
     "localname": "CapitalizedComputerSoftwareAdditions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalizedComputerSoftwareAmortization1": {
     "auth_ref": [
      "r809",
      "r810"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for amortization of capitalized computer software costs.",
        "label": "Capitalized Computer Software, Amortization",
        "terseLabel": "Capitalized computer software, amortization"
       }
      }
     },
     "localname": "CapitalizedComputerSoftwareAmortization1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalizedContractCostAmortization": {
     "auth_ref": [
      "r298"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for asset recognized from cost incurred to obtain or fulfill contract with customer.",
        "label": "Capitalized Contract Cost, Amortization",
        "terseLabel": "Amortization of contract cost assets",
        "verboseLabel": "Contract cost amortization"
       }
      }
     },
     "localname": "CapitalizedContractCostAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.evolenthealth.com/role/RevenueRecognitionContractCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalizedContractCostAmortizationPeriod": {
     "auth_ref": [
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortization period of cost capitalized in obtaining or fulfilling contract with customer, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Capitalized Contract Cost, Amortization Period",
        "terseLabel": "Capitalized contract cost, amortization period"
       }
      }
     },
     "localname": "CapitalizedContractCostAmortizationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionContractCostsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_CapitalizedContractCostAxis": {
     "auth_ref": [
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by cost capitalized in obtaining or fulfilling contract with customer.",
        "label": "Capitalized Contract Cost [Axis]",
        "terseLabel": "Capitalized Contract Cost [Axis]"
       }
      }
     },
     "localname": "CapitalizedContractCostAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionContractCostsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CapitalizedContractCostDomain": {
     "auth_ref": [
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost capitalized in obtaining and fulfilling contract with customer.",
        "label": "Capitalized Contract Cost [Domain]",
        "terseLabel": "Capitalized Contract Cost [Domain]"
       }
      }
     },
     "localname": "CapitalizedContractCostDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionContractCostsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CapitalizedContractCostLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Capitalized Contract Cost [Line Items]",
        "terseLabel": "Capitalized Contract Cost [Line Items]"
       }
      }
     },
     "localname": "CapitalizedContractCostLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionContractCostsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CapitalizedContractCostNet": {
     "auth_ref": [
      "r297"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer.",
        "label": "Capitalized Contract Cost, Net",
        "terseLabel": "Contract cost assets"
       }
      }
     },
     "localname": "CapitalizedContractCostNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionContractCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalizedContractCostNetNoncurrent": {
     "auth_ref": [
      "r297"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer; classified as noncurrent.",
        "label": "Capitalized Contract Cost, Net, Noncurrent",
        "terseLabel": "Contract cost assets"
       }
      }
     },
     "localname": "CapitalizedContractCostNetNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalizedContractCostTable": {
     "auth_ref": [
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about cost capitalized in obtaining or fulfilling contract with customer.",
        "label": "Capitalized Contract Cost [Table]",
        "terseLabel": "Capitalized Contract Cost [Table]"
       }
      }
     },
     "localname": "CapitalizedContractCostTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionContractCostsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r37",
      "r62",
      "r141"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      },
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails",
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.evolenthealth.com/role/OrganizationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r142"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents with respect to unrestricted balances.",
        "label": "Cash and Cash Equivalents, Unrestricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r134",
      "r141",
      "r147"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents and restricted cash as of end-of-period",
        "periodStartLabel": "Cash and cash equivalents and restricted cash as of beginning-of-period",
        "totalLabel": "Total cash and cash equivalents and restricted cash shown in the consolidated statements of cash flows (1)",
        "verboseLabel": "Cash and cash equivalents (including restricted cash)"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails",
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r134",
      "r620"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash and cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Supplemental Disclosure of Non-cash Investing and Financing Activities"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/SupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashFlowSupplementalDisclosuresTextBlock": {
     "auth_ref": [
      "r148"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for supplemental cash flow activities, including cash, noncash, and part noncash transactions, for the period. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Cash Flow, Supplemental Disclosures [Text Block]",
        "terseLabel": "Supplemental Cash Flow Information"
       }
      }
     },
     "localname": "CashFlowSupplementalDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/SupplementalCashFlowInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations": {
     "auth_ref": [
      "r25",
      "r134"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) of investing activities of discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Cash Provided by (Used in) Investing Activities, Discontinued Operations",
        "terseLabel": "Cash flows provided by (used in) investing activities"
       }
      }
     },
     "localname": "CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCashFlowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations": {
     "auth_ref": [
      "r25",
      "r134"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) of operating activities of discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Cash Provided by (Used in) Operating Activities, Discontinued Operations",
        "terseLabel": "Cash flows provided by (used in) operating activities"
       }
      }
     },
     "localname": "CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCashFlowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CededPremiumsWritten": {
     "auth_ref": [
      "r781",
      "r782"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of written premiums ceded to other entities.",
        "label": "Ceded Premiums Written",
        "negatedTerseLabel": "Reinsurance premiums ceded"
       }
      }
     },
     "localname": "CededPremiumsWritten",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesReinsuranceAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r153",
      "r155",
      "r188",
      "r189",
      "r194",
      "r196",
      "r198",
      "r206",
      "r207",
      "r208",
      "r272",
      "r357",
      "r362",
      "r363",
      "r364",
      "r370",
      "r371",
      "r413",
      "r414",
      "r417",
      "r418",
      "r608",
      "r816"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYDEFICIT",
      "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r429",
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class of Warrant or Right [Axis]",
        "terseLabel": "Class of Warrant or Right [Axis]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementAdditionalInformationDetails",
      "http://www.evolenthealth.com/role/LongtermDebtWarrantAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.",
        "label": "Class of Warrant or Right [Domain]",
        "terseLabel": "Class of Warrant or Right [Domain]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementAdditionalInformationDetails",
      "http://www.evolenthealth.com/role/LongtermDebtWarrantAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Exercise price of warrants or rights (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebtWarrantAgreementDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Warrant or Right [Line Items]",
        "terseLabel": "Class of Warrant or Right [Line Items]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebtWarrantAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Outstanding",
        "terseLabel": "Warrants and rights outstanding (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "auth_ref": [
      "r429",
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Class of Warrant or Right [Table]",
        "terseLabel": "Class of Warrant or Right [Table]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebtWarrantAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightUnissued": {
     "auth_ref": [
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of warrants or rights which entitle the entity to receive future services in exchange for the unvested, forfeitable warrants or rights.",
        "label": "Class of Warrant or Right, Unissued",
        "terseLabel": "Warrants agreed to be sold (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightUnissued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementAdditionalInformationDetails",
      "http://www.evolenthealth.com/role/LongtermDebtWarrantAgreementDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r77",
      "r353",
      "r713",
      "r742"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and Contingencies (See Note 11)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r350",
      "r351",
      "r352",
      "r354",
      "r793"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonClassAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Classification of common stock representing ownership interest in a corporation.",
        "label": "Common Class A [Member]",
        "terseLabel": "Class A Common Stock",
        "verboseLabel": "Class A Common Stock"
       }
      }
     },
     "localname": "CommonClassAMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYDEFICIT",
      "http://www.evolenthealth.com/role/FairValueMeasurementAdditionalInformationDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebtWarrantAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r162",
      "r163",
      "r589"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYDEFICIT",
      "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r51"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r51"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r51"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r51",
      "r665"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Class A common stock - $0.01 par value; 750,000,000 shares authorized; 87,195,128 and 85,894,450 shares issued, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r92",
      "r94",
      "r95",
      "r107",
      "r720",
      "r749"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Total comprehensive loss attributable to common shareholders of Evolent Health, Inc."
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r92",
      "r94",
      "r106",
      "r558",
      "r559",
      "r577",
      "r719",
      "r748"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest",
        "terseLabel": "Total comprehensive loss attributable to non-controlling interests"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r92",
      "r94",
      "r105",
      "r557",
      "r577",
      "r718",
      "r747"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Total comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest [Abstract]",
        "terseLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]",
        "terseLabel": "Computer hardware"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r215",
      "r216",
      "r255",
      "r605",
      "r606",
      "r792"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r215",
      "r216",
      "r255",
      "r605",
      "r606",
      "r785",
      "r792"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r215",
      "r216",
      "r255",
      "r605",
      "r606",
      "r785",
      "r792"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Concentration Risk [Line Items]",
        "terseLabel": "Concentration Risk [Line Items]"
       }
      }
     },
     "localname": "ConcentrationRiskLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r215",
      "r216",
      "r255",
      "r605",
      "r606"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "verboseLabel": "Concentration risk"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTable": {
     "auth_ref": [
      "r213",
      "r215",
      "r216",
      "r217",
      "r605",
      "r607",
      "r792"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Concentration Risk [Table]",
        "terseLabel": "Concentration Risk [Table]"
       }
      }
     },
     "localname": "ConcentrationRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r215",
      "r216",
      "r255",
      "r605",
      "r606",
      "r792"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r149",
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractBasedIntangibleAssetsMember": {
     "auth_ref": [
      "r541"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right received from contract, including, but not limited to, advertising contract, broadcast rights, franchise agreement, lease agreement, licensing agreement, and use rights.",
        "label": "Contract-Based Intangible Assets [Member]",
        "terseLabel": "Provider network contracts"
       }
      }
     },
     "localname": "ContractBasedIntangibleAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails",
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": {
     "auth_ref": [
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.",
        "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]",
        "terseLabel": "Contract with customer, asset and liability"
       }
      }
     },
     "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerAssetNetCurrent": {
     "auth_ref": [
      "r430",
      "r432",
      "r454"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.",
        "label": "Contract with Customer, Asset, after Allowance for Credit Loss, Current",
        "verboseLabel": "Short-term contract assets"
       }
      }
     },
     "localname": "ContractWithCustomerAssetNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionContractBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r430",
      "r431",
      "r454"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "periodEndLabel": "Balance as of end of period",
        "periodStartLabel": "Balance as of beginning-of-period"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionContractBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r430",
      "r431",
      "r454"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Deferred revenue",
        "verboseLabel": "Short-term deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.evolenthealth.com/role/RevenueRecognitionContractBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r430",
      "r431",
      "r454"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "terseLabel": "Long-term deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionContractBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "auth_ref": [
      "r455"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "negatedTerseLabel": "Reclassification to revenue, as a result of performance obligations satisfied"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionContractBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod": {
     "auth_ref": [
      "r439"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from performance obligation satisfied or partially satisfied in previous reporting periods. Includes, but is not limited to, change in transaction price.",
        "label": "Contract with Customer, Performance Obligation Satisfied in Previous Period",
        "terseLabel": "Revenue recognized from performed obligations"
       }
      }
     },
     "localname": "ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionContractBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebt": {
     "auth_ref": [
      "r48",
      "r710",
      "r735"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.",
        "label": "Convertible Debt",
        "totalLabel": "Carrying value"
       }
      }
     },
     "localname": "ConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebtMember": {
     "auth_ref": [
      "r372",
      "r373",
      "r374",
      "r376",
      "r386",
      "r387",
      "r388",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r406",
      "r407",
      "r408",
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.",
        "label": "Convertible Debt [Member]",
        "terseLabel": "Convertible senior notes"
       }
      }
     },
     "localname": "ConvertibleDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/EarningsLossPerCommonShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertibleDebtTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of convertible debt instrument. Includes, but is not limited to, principal amount and amortized premium or discount.",
        "label": "Convertible Debt [Table Text Block]",
        "terseLabel": "Schedule of convertible debt"
       }
      }
     },
     "localname": "ConvertibleDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CorporateNonSegmentMember": {
     "auth_ref": [
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r248",
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment.",
        "label": "Corporate, Non-Segment [Member]",
        "terseLabel": "Corporate"
       }
      }
     },
     "localname": "CorporateNonSegmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/SegmentReportingRevenuefromSegmentstoConsolidatedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing cost of sales.",
        "label": "Cost of Sales [Member]",
        "terseLabel": "Cost of revenue"
       }
      }
     },
     "localname": "CostOfSalesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.evolenthealth.com/role/LongtermDebtCreditAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.evolenthealth.com/role/LongtermDebtCreditAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CreditLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Credit Loss [Abstract]",
        "terseLabel": "Credit Loss [Abstract]"
       }
      }
     },
     "localname": "CreditLossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditLossFinancialInstrumentTextBlock": {
     "auth_ref": [
      "r283",
      "r288",
      "r289",
      "r291",
      "r292",
      "r294",
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for credit loss on financial instrument measured at amortized cost basis, net investment in lease, off-balance sheet credit exposure, and available-for-sale debt security.",
        "label": "Credit Loss, Financial Instrument [Text Block]",
        "terseLabel": "Credit Losses"
       }
      }
     },
     "localname": "CreditLossFinancialInstrumentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CreditLosses"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r214",
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer Concentration Risk"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CustomerRelationshipsMember": {
     "auth_ref": [
      "r543"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships.",
        "label": "Customer Relationships [Member]",
        "terseLabel": "Customer relationships"
       }
      }
     },
     "localname": "CustomerRelationshipsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails",
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtConversionConvertedInstrumentAmount1": {
     "auth_ref": [
      "r144",
      "r146"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Debt Conversion, Converted Instrument, Amount",
        "terseLabel": "Debt conversion, converted instrument, amount"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentAmount1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtConversionOriginalDebtAmount1": {
     "auth_ref": [
      "r144",
      "r146"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Debt Conversion, Original Debt, Amount",
        "terseLabel": "Debt conversion, original debt, amount"
       }
      }
     },
     "localname": "DebtConversionOriginalDebtAmount1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r152",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r390",
      "r397",
      "r398",
      "r400",
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Long-term Debt"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r46",
      "r47",
      "r48",
      "r154",
      "r160",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r380",
      "r386",
      "r387",
      "r388",
      "r389",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r406",
      "r407",
      "r408",
      "r409",
      "r633",
      "r709",
      "r710",
      "r730"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails",
      "http://www.evolenthealth.com/role/LongtermDebtCreditAgreementDetails",
      "http://www.evolenthealth.com/role/LongtermDebtWarrantAgreementDetails",
      "http://www.evolenthealth.com/role/TransactionsPassportDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Basis spread on variable rate"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebtCreditAgreementDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "auth_ref": [
      "r375",
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The price per share of the conversion feature embedded in the debt instrument.",
        "label": "Debt Instrument, Convertible, Conversion Price",
        "terseLabel": "Conversion price (in dollars per share)"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionRatio1": {
     "auth_ref": [
      "r74",
      "r375",
      "r420",
      "r421",
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.",
        "label": "Debt Instrument, Convertible, Conversion Ratio",
        "terseLabel": "Initial conversion rate per $ 1000 principal amount",
        "verboseLabel": "Initial conversion rate per $ 1000 principal amount"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments": {
     "auth_ref": [
      "r74",
      "r375",
      "r420",
      "r421",
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity instruments that the holder of the debt instrument would receive if the debt was converted to equity.",
        "label": "Debt Instrument, Convertible, Number of Equity Instruments",
        "terseLabel": "Initial conversion amount (in shares)"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleNumberOfEquityInstruments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1": {
     "auth_ref": [
      "r403"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining amortization period for discount on the liability component of convertible debt which may be settled in cash upon conversion, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, Convertible, Remaining Discount Amortization Period",
        "terseLabel": "Remaining amortization period (years)"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r373",
      "r406",
      "r407",
      "r631",
      "r633",
      "r634"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_ConvertibleDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Face amount",
        "verboseLabel": "Principal amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails",
      "http://www.evolenthealth.com/role/LongtermDebtCreditAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r73",
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebtCreditAgreementDetails",
      "http://www.evolenthealth.com/role/TransactionsPassportDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails",
      "http://www.evolenthealth.com/role/LongtermDebtCreditAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r75",
      "r154",
      "r160",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r380",
      "r386",
      "r387",
      "r388",
      "r389",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r406",
      "r407",
      "r408",
      "r409",
      "r633"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails",
      "http://www.evolenthealth.com/role/LongtermDebtCreditAgreementDetails",
      "http://www.evolenthealth.com/role/LongtermDebtWarrantAgreementDetails",
      "http://www.evolenthealth.com/role/TransactionsPassportDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodAxis": {
     "auth_ref": [
      "r726"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about timing of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period [Axis]",
        "terseLabel": "Debt Instrument, Redemption, Period [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebtCreditAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodDomain": {
     "auth_ref": [
      "r726"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period as defined under terms of the debt agreement for debt redemption features.",
        "label": "Debt Instrument, Redemption, Period [Domain]",
        "terseLabel": "Debt Instrument, Redemption, Period [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebtCreditAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodOneMember": {
     "auth_ref": [
      "r726"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period one representing most current period of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period One [Member]",
        "terseLabel": "After the Second Anniversary of the Closing of the Senior Credit Facilities but Prior to the Third Anniversary"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodOneMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebtCreditAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodThreeMember": {
     "auth_ref": [
      "r726"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period three representing third most current period of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period Three [Member]",
        "terseLabel": "After the Fourth Anniversary of the Closing of the Senior Credit Facilities but Prior to the Fifth Anniversary"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodThreeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebtCreditAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodTwoMember": {
     "auth_ref": [
      "r726"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period two representing second most current period of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period Two [Member]",
        "terseLabel": "After the Third Anniversary of the Closing of the Senior Credit Facilities but Prior to the Fourth Anniversary"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodTwoMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebtCreditAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r75",
      "r154",
      "r160",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r380",
      "r386",
      "r387",
      "r388",
      "r389",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r399",
      "r406",
      "r407",
      "r408",
      "r409",
      "r420",
      "r422",
      "r423",
      "r424",
      "r630",
      "r631",
      "r633",
      "r634",
      "r727"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails",
      "http://www.evolenthealth.com/role/LongtermDebtCreditAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, Term",
        "terseLabel": "Term"
       }
      }
     },
     "localname": "DebtInstrumentTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebtCreditAgreementDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": {
     "auth_ref": [
      "r386",
      "r401",
      "r406",
      "r407",
      "r632"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_ConvertibleDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs.",
        "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net",
        "verboseLabel": "Unamortized debt discount and issuance costs"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFinanceCostsNet": {
     "auth_ref": [
      "r66",
      "r386",
      "r632"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Net",
        "terseLabel": "Debt issuance costs"
       }
      }
     },
     "localname": "DeferredFinanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebtCreditAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r513",
      "r514"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "terseLabel": "Deferred tax liabilities, net"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxesAndTaxCredits": {
     "auth_ref": [
      "r140"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) and income tax credits.",
        "label": "Deferred Income Taxes and Tax Credits",
        "terseLabel": "Deferred tax (benefit) provision"
       }
      }
     },
     "localname": "DeferredIncomeTaxesAndTaxCredits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r139",
      "r324"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r139",
      "r324"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "negatedLabel": "Depreciation and amortization expenses",
        "terseLabel": "Depreciation and amortization expenses"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationAndAmortizationDiscontinuedOperations": {
     "auth_ref": [
      "r26",
      "r139"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deprecation and amortization expense attributable to property, plant and equipment and intangible assets of discontinued operations.",
        "label": "Depreciation and Amortization, Discontinued Operations",
        "terseLabel": "Depreciation and amortization expenses"
       }
      }
     },
     "localname": "DepreciationAndAmortizationDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r139",
      "r229"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization expenses"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DevelopedTechnologyRightsMember": {
     "auth_ref": [
      "r545"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property.",
        "label": "Developed Technology Rights [Member]",
        "terseLabel": "Technology"
       }
      }
     },
     "localname": "DevelopedTechnologyRightsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails",
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionDisaggregationofRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r453",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionDisaggregationofRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Disaggregation of revenue"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r511"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax": {
     "auth_ref": [
      "r9",
      "r11",
      "r15",
      "r30"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of gain (loss) not previously recognized resulting from the disposal of a discontinued operation.",
        "label": "Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax",
        "terseLabel": "Gain on disposal of discontinued operations"
       }
      }
     },
     "localname": "DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSSParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax": {
     "auth_ref": [
      "r9",
      "r10",
      "r11",
      "r12",
      "r15",
      "r23",
      "r104",
      "r745"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of income (loss) from a discontinued operation. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.",
        "label": "Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax",
        "totalLabel": "Loss before income taxes and non-controlling interests"
       }
      }
     },
     "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation": {
     "auth_ref": [
      "r10",
      "r11",
      "r12",
      "r15",
      "r23",
      "r30",
      "r515",
      "r529",
      "r532"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax expense (benefit) related to a discontinued operation. Includes, but is not limited to, tax expense (benefit) related to income (loss) from operations during the phase-out period, tax expense (benefit) related to gain (loss) on disposal, tax expense (benefit) related to gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and tax expense (benefit) related to adjustments of a prior period gain (loss) on disposal.",
        "label": "Discontinued Operation, Tax Effect of Discontinued Operation",
        "terseLabel": "Benefit for income taxes"
       }
      }
     },
     "localname": "DiscontinuedOperationTaxEffectOfDiscontinuedOperation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Discontinued Operations and Disposal Groups [Abstract]"
       }
      }
     },
     "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DiscontinuedOperationsDisposedOfBySaleMember": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Component or group of components disposed of by sale and representing a strategic shift that has or will have a major effect on operations and financial results.",
        "label": "Discontinued Operations, Disposed of by Sale [Member]",
        "terseLabel": "Discontinued Operations, Disposed of by Sale"
       }
      }
     },
     "localname": "DiscontinuedOperationsDisposedOfBySaleMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails",
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails",
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCashFlowsDetails",
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCurrentandLongtermAssetsandLiabilitiesDetails",
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails",
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails",
      "http://www.evolenthealth.com/role/RevenueRecognitionContractBalancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisposalGroupClassificationAxis": {
     "auth_ref": [
      "r29"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by disposal group classification.",
        "label": "Disposal Group Classification [Axis]",
        "terseLabel": "Disposal Group Classification [Axis]"
       }
      }
     },
     "localname": "DisposalGroupClassificationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails",
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails",
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCashFlowsDetails",
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCurrentandLongtermAssetsandLiabilitiesDetails",
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails",
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails",
      "http://www.evolenthealth.com/role/RevenueRecognitionContractBalancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisposalGroupClassificationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations.",
        "label": "Disposal Group Classification [Domain]",
        "terseLabel": "Disposal Group Classification [Domain]"
       }
      }
     },
     "localname": "DisposalGroupClassificationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails",
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails",
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCashFlowsDetails",
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCurrentandLongtermAssetsandLiabilitiesDetails",
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails",
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails",
      "http://www.evolenthealth.com/role/RevenueRecognitionContractBalancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet": {
     "auth_ref": [
      "r6",
      "r7",
      "r27",
      "r329"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCurrentandLongtermAssetsandLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as accounts, notes and loans receivable attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Accounts, Notes and Loans Receivable, Net",
        "terseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCurrentandLongtermAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r27",
      "r323",
      "r329"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCurrentandLongtermAssetsandLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as accounts payable attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCurrentandLongtermAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r27",
      "r323",
      "r329"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCurrentandLongtermAssetsandLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as accrued liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Accrued Liabilities, Current",
        "terseLabel": "Accrued liabilities"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCurrentandLongtermAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r27",
      "r29",
      "r33",
      "r322",
      "r329"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Assets, Noncurrent",
        "terseLabel": "Non-current assets of discontinued operations"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents": {
     "auth_ref": [
      "r6",
      "r7",
      "r27",
      "r329"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCurrentandLongtermAssetsandLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as cash and cash equivalents attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Cash and Cash Equivalents",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCurrentandLongtermAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold": {
     "auth_ref": [
      "r24",
      "r33"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of costs of goods sold attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Costs of Goods Sold",
        "terseLabel": "Cost of revenue (exclusive of depreciation and amortization expenses presented separately below)"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r27",
      "r323",
      "r329"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCurrentandLongtermAssetsandLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as deferred revenue attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Deferred Revenue, Current",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCurrentandLongtermAssetsandLiabilitiesDetails",
      "http://www.evolenthealth.com/role/RevenueRecognitionContractBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities": {
     "auth_ref": [
      "r6",
      "r7",
      "r27",
      "r329"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCurrentandLongtermAssetsandLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as deferred tax liabilities attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Deferred Tax Liabilities",
        "terseLabel": "Deferred tax liabilities, net"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCurrentandLongtermAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of general and administrative expense attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative expenses"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r27",
      "r322",
      "r329"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCurrentandLongtermAssetsandLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as goodwill attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Goodwill, Noncurrent",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCurrentandLongtermAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r27",
      "r322",
      "r329"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCurrentandLongtermAssetsandLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as intangible assets, excluding goodwill, attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Intangible Assets, Noncurrent",
        "terseLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCurrentandLongtermAssetsandLiabilitiesDetails",
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense": {
     "auth_ref": [
      "r13",
      "r14",
      "r24",
      "r34"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest expense attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Interest Expense",
        "negatedTerseLabel": "Interest expense"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest income attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Interest Income",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationInterestIncome",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating expense attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Operating Expense",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating income (loss) attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Operating Income (Loss)",
        "totalLabel": "Operating loss"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other expense attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Other Expense",
        "negatedTerseLabel": "Other loss"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationOtherExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities": {
     "auth_ref": [
      "r6",
      "r7",
      "r27",
      "r322",
      "r329"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCurrentandLongtermAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as other liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCurrentandLongtermAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r27",
      "r323",
      "r329"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCurrentandLongtermAssetsandLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as prepaid and other assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Prepaid and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCurrentandLongtermAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue": {
     "auth_ref": [
      "r24",
      "r33"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Revenue",
        "terseLabel": "Total revenue",
        "verboseLabel": "Revenue"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationRevenue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails",
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": {
     "auth_ref": [
      "r35",
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]",
        "terseLabel": "Discontinued Operations"
       }
      }
     },
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": {
     "auth_ref": [
      "r479",
      "r481"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of disposal group.",
        "label": "Disposal Group Name [Domain]",
        "terseLabel": "Disposal Group Name [Domain]"
       }
      }
     },
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails",
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails",
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCashFlowsDetails",
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCurrentandLongtermAssetsandLiabilitiesDetails",
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails",
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails",
      "http://www.evolenthealth.com/role/RevenueRecognitionContractBalancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r108",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r185",
      "r188",
      "r196",
      "r197",
      "r198",
      "r202",
      "r203",
      "r590",
      "r591",
      "r721",
      "r750"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "totalLabel": "Basic loss per share attributable to common shareholders of Evolent Health, Inc. (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/EarningsLossPerCommonShareComputationofEarningsperShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic and Diluted [Abstract]",
        "terseLabel": "Loss per common share",
        "verboseLabel": "Loss per common share, Basic and diluted"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDilutedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/EarningsLossPerCommonShareComputationofEarningsperShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract]",
        "terseLabel": "Weighted-average common shares outstanding"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r108",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r188",
      "r196",
      "r197",
      "r198",
      "r202",
      "r203",
      "r590",
      "r591",
      "r721",
      "r750"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "totalLabel": "Diluted loss per share attributable to common shareholders of Evolent Health, Inc. (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/EarningsLossPerCommonShareComputationofEarningsperShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r199",
      "r200",
      "r201",
      "r204"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Earnings (Loss) Per Common Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/EarningsLossPerCommonShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r620"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "terseLabel": "Effect of exchange rate on cash and cash equivalents and restricted cash"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r516"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "terseLabel": "Effective rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectsOfReinsuranceTableTextBlock": {
     "auth_ref": [
      "r783"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the effects of reinsurance, for example, but not limited to, disclosure of direct, assumed, and ceded insurance.",
        "label": "Effects of Reinsurance [Table Text Block]",
        "terseLabel": "Summary of premiums and claims assumed"
       }
      }
     },
     "localname": "EffectsOfReinsuranceTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued compensation and employee benefits"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount": {
     "auth_ref": [
      "r496"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost capitalized for award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Amount Capitalized",
        "terseLabel": "Stock-based compensation capitalized as software development costs"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r493"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/EarningsLossPerCommonShareAntidilutiveSecuritiesDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r2",
      "r96",
      "r97",
      "r98",
      "r162",
      "r163",
      "r164",
      "r169",
      "r179",
      "r181",
      "r205",
      "r277",
      "r419",
      "r425",
      "r503",
      "r504",
      "r505",
      "r523",
      "r524",
      "r589",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r769",
      "r770",
      "r771",
      "r822"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYDEFICIT",
      "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails",
      "http://www.evolenthealth.com/role/NoncontrollingInterestsDetails",
      "http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvesteeMember": {
     "auth_ref": [
      "r267",
      "r693",
      "r695",
      "r697",
      "r699",
      "r701",
      "r703"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An entity that issued voting stock held by an investor and that is accounted for under the equity method of accounting by the investor.",
        "label": "Equity Method Investee [Member]",
        "terseLabel": "Equity Method Investee"
       }
      }
     },
     "localname": "EquityMethodInvesteeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/InvestmentsInandAdvancestoEquityMethodInvesteesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment": {
     "auth_ref": [
      "r268"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents an other than temporary decline in value that has been recognized against an investment accounted for under the equity method of accounting. The excess of the carrying amount over the fair value of the investment represents the amount of the write down which is or was reflected in earnings. The written down value is a new cost basis with the adjusted value of the investment becoming its new carrying value subject to the equity accounting method. Evidence of a loss in value might include, but would not necessarily be limited to, absence of an ability to recover the carrying amount of the investment or inability of the investee to sustain an earnings capacity which would justify the carrying amount of the investment.",
        "label": "Equity Method Investment, Other than Temporary Impairment",
        "negatedLabel": "Impairment of equity method investments",
        "negatedTerseLabel": "Equity method investment impairment",
        "terseLabel": "Impairment of equity method investments"
       }
      }
     },
     "localname": "EquityMethodInvestmentOtherThanTemporaryImpairment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Method Investments and Joint Ventures [Abstract]",
        "terseLabel": "Equity Method Investments and Joint Ventures [Abstract]"
       }
      }
     },
     "localname": "EquityMethodInvestmentsAndJointVenturesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityMethodInvestmentsDisclosureTextBlock": {
     "auth_ref": [
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group.",
        "label": "Equity Method Investments and Joint Ventures Disclosure [Text Block]",
        "terseLabel": "Investments In and Advances to Equity Method Investees"
       }
      }
     },
     "localname": "EquityMethodInvestmentsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/InvestmentsInandAdvancestoEquityMethodInvestees"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EurodollarMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate based on U.S. dollar denominated deposits at foreign banks or foreign branches of U.S. banks.",
        "label": "Eurodollar [Member]",
        "terseLabel": "Eurodollar"
       }
      }
     },
     "localname": "EurodollarMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebtCreditAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ExtinguishmentOfDebtAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross amount of debt extinguished.",
        "label": "Extinguishment of Debt, Amount",
        "terseLabel": "Face amount of debt repaid"
       }
      }
     },
     "localname": "ExtinguishmentOfDebtAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FacilityClosingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Closing of a facility associated with exit from or disposal of business activities or restructurings pursuant to a plan.",
        "label": "Facility Closing [Member]",
        "terseLabel": "Office space consolidation"
       }
      }
     },
     "localname": "FacilityClosingMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/RepositioningandOtherChangesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]",
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "auth_ref": [
      "r594"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]",
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "auth_ref": [
      "r594"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "terseLabel": "Valuation techniques and significant unobservable inputs of Level 3 fair value measurements"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r592",
      "r593"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Summary of assets at fair value on recurring basis"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]",
        "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]"
       }
      }
     },
     "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByBalanceSheetGroupingTable": {
     "auth_ref": [
      "r592",
      "r603",
      "r604"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.",
        "label": "Fair Value, by Balance Sheet Grouping [Table]",
        "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]"
       }
      }
     },
     "localname": "FairValueByBalanceSheetGroupingTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r388",
      "r406",
      "r407",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r478",
      "r593",
      "r669",
      "r670",
      "r671"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails",
      "http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails",
      "http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByLiabilityClassAxis": {
     "auth_ref": [
      "r600",
      "r601"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of liability.",
        "label": "Liability Class [Axis]",
        "terseLabel": "Liability Class [Axis]"
       }
      }
     },
     "localname": "FairValueByLiabilityClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r592",
      "r593",
      "r595",
      "r596",
      "r602"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails",
      "http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r600"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurement"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurement"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r388",
      "r470",
      "r471",
      "r476",
      "r478",
      "r593",
      "r669"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r388",
      "r406",
      "r407",
      "r470",
      "r471",
      "r476",
      "r478",
      "r593",
      "r670"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails",
      "http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r388",
      "r406",
      "r407",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r478",
      "r593",
      "r671"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails",
      "http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r592",
      "r593"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).  Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Summary of liabilities at fair value on recurring basis"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": {
     "auth_ref": [
      "r597"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents classes of liabilities measured and disclosed at fair value.",
        "label": "Fair Value by Liability Class [Domain]",
        "terseLabel": "Fair Value by Liability Class [Domain]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementChangesinContingentConsiderationandOtherDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r597",
      "r601"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Changes in contingent consideration measured at fair value"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails",
      "http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurement"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "auth_ref": [
      "r598"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "verboseLabel": "Realized and unrealized gains (losses), net"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementChangesinContingentConsiderationandOtherDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": {
     "auth_ref": [
      "r599"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements",
        "negatedLabel": "Settlements"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementChangesinContingentConsiderationandOtherDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "auth_ref": [
      "r597"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodEndLabel": "Balance as of end of period",
        "periodStartLabel": "Balance as of beginning of period"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementChangesinContingentConsiderationandOtherDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r388",
      "r406",
      "r407",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r478",
      "r669",
      "r670",
      "r671"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails",
      "http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails",
      "http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r600",
      "r602"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "verboseLabel": "Fair Value, Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails",
      "http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinanceLeaseInterestExpense": {
     "auth_ref": [
      "r637",
      "r642",
      "r650"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/LeasesComponentsofLeaseExpenseDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest expense on finance lease liability.",
        "label": "Finance Lease, Interest Expense",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "FinanceLeaseInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesComponentsofLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAmortization": {
     "auth_ref": [
      "r637",
      "r642",
      "r650"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/LeasesComponentsofLeaseExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset, Amortization",
        "terseLabel": "Amortization of right-of-use assets"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAssetAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesComponentsofLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceReceivablesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amounts due the Company from customers, clients, lessees, borrowers, or others under the terms of its agreements therewith. Such amount may include accrued interest receivable in accordance with the terms of the agreements. The agreements also may contain provisions and related items including a discount or premium, payable on demand, secured, or unsecured, interest bearing or noninterest bearing, among myriad other features and characteristics.",
        "label": "Financing Receivable [Member]",
        "terseLabel": "Customer Receivable"
       }
      }
     },
     "localname": "FinanceReceivablesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancingReceivablePercentPastDue1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of financing receivable balance that is past due.",
        "label": "Financing Receivable, Percent Past Due",
        "terseLabel": "Percentage of receivables, past due"
       }
      }
     },
     "localname": "FinancingReceivablePercentPastDue1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CreditLossesAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_FinancingReceivablesPeriodPastDueAxis": {
     "auth_ref": [
      "r260",
      "r287",
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by period in which financial asset is past due or not past due.",
        "label": "Financial Asset, Aging [Axis]",
        "terseLabel": "Financial Asset, Period Past Due [Axis]"
       }
      }
     },
     "localname": "FinancingReceivablesPeriodPastDueAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CreditLossesAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancingReceivablesPeriodPastDueDomain": {
     "auth_ref": [
      "r260",
      "r287",
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period in which financial asset is past due or not past due. For past due, element name and standard label in Financial Asset, [numeric lower end] to [numeric higher end] [date measure] Past Due [Member] or Financial Asset, Greater than [low end numeric value] [date measure] Past Due [Member] or Financial Asset, Less than [high end numeric value] [date measure] Past Due [Member] formats.",
        "label": "Financial Asset, Aging [Domain]",
        "terseLabel": "Financial Asset, Period Past Due [Domain]"
       }
      }
     },
     "localname": "FinancingReceivablesPeriodPastDueDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CreditLossesAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "terseLabel": "Useful life"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r317"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "terseLabel": "Accumulated Amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r319"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssets10KDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssets10KDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssets10KDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssets10KDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r319"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssets10KDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssets10KDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r319"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssets10KDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssets10KDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r319"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssets10KDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssets10KDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r312",
      "r314",
      "r317",
      "r320",
      "r684",
      "r691"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails",
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r317",
      "r691"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Gross Carrying Amount"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails",
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetImpairmentTestingDetails",
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r312",
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails",
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r317",
      "r684"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssets10KDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "totalLabel": "Total future amortization of intangible assets"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssets10KDetails",
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r628"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Foreign Currency"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and equipment"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnDispositionOfAssets1": {
     "auth_ref": [
      "r139"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 5.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.",
        "label": "Gain (Loss) on Disposition of Assets",
        "negatedTerseLabel": "Loss on disposal of assets",
        "terseLabel": "Loss on disposal of assets"
       }
      }
     },
     "localname": "GainLossOnDispositionOfAssets1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r139",
      "r410",
      "r411"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 23.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "negatedLabel": "Loss on repayment of debt",
        "terseLabel": "Loss on repayment of debt, net"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/LongtermDebtCreditAgreementDetails",
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost": {
     "auth_ref": [
      "r410",
      "r411"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the difference between the fair value of payments made to legally extinguish a debt and its carrying value at that time. This item excludes the write-off of amounts previously capitalized as debt issuance costs.",
        "label": "Gain (Loss) on Extinguishment of Debt, before Write off of Debt Issuance Cost",
        "negatedLabel": "Net loss on extinguishment of debt, including fees paid to lenders"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r299",
      "r301",
      "r665",
      "r706"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 9.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "periodEndLabel": "Balance as of end of period",
        "periodStartLabel": "Balance as of beginning of period",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetImpairmentTestingDetails",
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetScheduleofGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "terseLabel": "Goodwill and Intangible Assets, Net"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": {
     "auth_ref": [
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.",
        "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": {
     "auth_ref": [
      "r305"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Foreign Currency Translation Gain (Loss)",
        "terseLabel": "Foreign currency translation"
       }
      }
     },
     "localname": "GoodwillForeignCurrencyTranslationGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetScheduleofGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillImpairedAccumulatedImpairmentLoss": {
     "auth_ref": [
      "r302",
      "r306"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impaired, Accumulated Impairment Loss",
        "terseLabel": "Cumulative inception to date impairment"
       }
      }
     },
     "localname": "GoodwillImpairedAccumulatedImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetScheduleofGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "auth_ref": [
      "r139",
      "r300",
      "r304",
      "r308"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 25.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 4.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impairment Loss",
        "negatedTerseLabel": "Impairment",
        "terseLabel": "Goodwill impairment"
       }
      }
     },
     "localname": "GoodwillImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetImpairmentTestingDetails",
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetScheduleofGoodwillDetails",
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Goodwill [Line Items]",
        "terseLabel": "Goodwill [Line Items]"
       }
      }
     },
     "localname": "GoodwillLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetScheduleofGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Goodwill [Roll Forward]",
        "terseLabel": "Goodwill [Roll Forward]"
       }
      }
     },
     "localname": "GoodwillRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetScheduleofGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit": {
     "auth_ref": [
      "r303"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of divestiture of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Written off Related to Sale of Business Unit",
        "negatedTerseLabel": "Goodwill disposal"
       }
      }
     },
     "localname": "GoodwillWrittenOffRelatedToSaleOfBusinessUnit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetScheduleofGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeApproachValuationTechniqueMember": {
     "auth_ref": [
      "r594"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation approach converting future amounts to single current discounted amount.",
        "label": "Valuation, Income Approach [Member]",
        "terseLabel": "Valuation, Income Approach"
       }
      }
     },
     "localname": "IncomeApproachValuationTechniqueMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetImpairmentTestingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r102",
      "r234",
      "r239",
      "r242",
      "r245",
      "r248",
      "r704",
      "r716",
      "r724",
      "r751"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss from continuing operations before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r155",
      "r168",
      "r234",
      "r239",
      "r242",
      "r245",
      "r248",
      "r272",
      "r357",
      "r358",
      "r359",
      "r362",
      "r363",
      "r364",
      "r366",
      "r368",
      "r370",
      "r371",
      "r557",
      "r591",
      "r608"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Income (loss) from continuing operations",
        "totalLabel": "Loss from continuing operations"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/EarningsLossPerCommonShareComputationofEarningsperShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerBasicShare": {
     "auth_ref": [
      "r99",
      "r108",
      "r168",
      "r174",
      "r175",
      "r176",
      "r177",
      "r188",
      "r196",
      "r197",
      "r591",
      "r714",
      "r717",
      "r721",
      "r744"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_EarningsPerShareBasic",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.",
        "label": "Income (Loss) from Continuing Operations, Per Basic Share",
        "terseLabel": "Continuing operations, basic (in dollars per share)"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsPerBasicShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/EarningsLossPerCommonShareComputationofEarningsperShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare": {
     "auth_ref": [
      "r99",
      "r108",
      "r168",
      "r174",
      "r175",
      "r176",
      "r177",
      "r188",
      "r196",
      "r197",
      "r198",
      "r591",
      "r721",
      "r744",
      "r746",
      "r750"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_EarningsPerShareDiluted",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Income (Loss) from Continuing Operations, Per Diluted Share",
        "terseLabel": "Continuing operations, diluted (in dollars per share)"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsPerDilutedShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/EarningsLossPerCommonShareComputationofEarningsperShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax": {
     "auth_ref": [
      "r9",
      "r10",
      "r11",
      "r12",
      "r15",
      "r30",
      "r33",
      "r533",
      "r745"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      },
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.",
        "label": "Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Income (loss) from discontinued operations, net of tax",
        "totalLabel": "Income (loss) from discontinued operations, net of tax (2)",
        "verboseLabel": "Gain (loss) from discontinued operations"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails",
      "http://www.evolenthealth.com/role/EarningsLossPerCommonShareComputationofEarningsperShareDetails",
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare": {
     "auth_ref": [
      "r104",
      "r108",
      "r189",
      "r196",
      "r197",
      "r721",
      "r745",
      "r746",
      "r750"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_EarningsPerShareBasic",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.",
        "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share",
        "terseLabel": "Discontinued operations, basic (in dollars per share)"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/EarningsLossPerCommonShareComputationofEarningsperShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare": {
     "auth_ref": [
      "r189",
      "r196",
      "r197",
      "r578"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_EarningsPerShareDiluted",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.",
        "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share",
        "terseLabel": "Discontinued operations, diluted (in dollars per share)"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/EarningsLossPerCommonShareComputationofEarningsperShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r103",
      "r139",
      "r231",
      "r269",
      "r715",
      "r743"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 7.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).",
        "label": "Income (Loss) from Equity Method Investments",
        "negatedLabel": "(Gain) loss from equity method investees",
        "terseLabel": "Gain from equity method investees"
       }
      }
     },
     "localname": "IncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/InvestmentsInandAdvancestoEquityMethodInvesteesAdditionalInformationDetails",
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": {
     "auth_ref": [
      "r479",
      "r481"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of disposal group.",
        "label": "Disposal Group Name [Axis]",
        "terseLabel": "Disposal Group Name [Axis]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails",
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails",
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCashFlowsDetails",
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCurrentandLongtermAssetsandLiabilitiesDetails",
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails",
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails",
      "http://www.evolenthealth.com/role/RevenueRecognitionContractBalancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]",
        "terseLabel": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCashFlowsDetails",
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCurrentandLongtermAssetsandLiabilitiesDetails",
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails",
      "http://www.evolenthealth.com/role/RevenueRecognitionContractBalancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": {
     "auth_ref": [
      "r7",
      "r17",
      "r18",
      "r19",
      "r20",
      "r21",
      "r22",
      "r28",
      "r31",
      "r32",
      "r33",
      "r331",
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations [Table]",
        "terseLabel": "Disposal Groups, Including Discontinued Operations [Table]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCashFlowsDetails",
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCurrentandLongtermAssetsandLiabilitiesDetails",
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails",
      "http://www.evolenthealth.com/role/RevenueRecognitionContractBalancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r328",
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r156",
      "r517",
      "r519",
      "r520",
      "r528",
      "r530",
      "r534",
      "r535",
      "r536"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r157",
      "r180",
      "r181",
      "r232",
      "r515",
      "r529",
      "r531",
      "r752"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedLabel": "(Provision) benefit for income taxes",
        "terseLabel": "Provision (benefit) for income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/IncomeTaxesNarrativeDetails",
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r138"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r138"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r138",
      "r679"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 18.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": {
     "auth_ref": [
      "r138"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Increase (Decrease) in Employee Related Liabilities",
        "terseLabel": "Accrued compensation and employee benefits"
       }
      }
     },
     "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in assets and liabilities, net of acquisitions:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "auth_ref": [
      "r138",
      "r645"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 21.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation for operating lease.",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 22.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Liabilities",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r138"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedTerseLabel": "Prepaid expenses and other current and non-current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InsuranceAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insurance [Abstract]",
        "terseLabel": "Insurance [Abstract]"
       }
      }
     },
     "localname": "InsuranceAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InsuranceDisclosureTextBlock": {
     "auth_ref": [
      "r786"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the types of coverages and products sold, and the assets, obligations, recorded liabilities, revenues and expenses arising therefrom, and the amounts of and methodologies and assumptions used in determining the amounts of such items.",
        "label": "Insurance Disclosure [Text Block]",
        "terseLabel": "Reserves for Claims and Performance-Based Arrangements"
       }
      }
     },
     "localname": "InsuranceDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IntangibleAssetsFiniteLivedPolicy": {
     "auth_ref": [
      "r150",
      "r316",
      "r680",
      "r681",
      "r682",
      "r684"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.",
        "label": "Intangible Assets, Finite-Lived, Policy [Policy Text Block]",
        "terseLabel": "Intangible Assets, Net"
       }
      }
     },
     "localname": "IntangibleAssetsFiniteLivedPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r310",
      "r315"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r100",
      "r228",
      "r629",
      "r632",
      "r722"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedTerseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseDebt": {
     "auth_ref": [
      "r115",
      "r394",
      "r405",
      "r408",
      "r409"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.",
        "label": "Interest Expense, Debt",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpenseDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r131",
      "r135",
      "r143"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Accrued interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebtCreditAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntersegmentEliminationMember": {
     "auth_ref": [
      "r226",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r244",
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Eliminating entries used in operating segment consolidation.",
        "label": "Intersegment Eliminations [Member]",
        "terseLabel": "Intersegment Eliminations"
       }
      }
     },
     "localname": "IntersegmentEliminationMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/SegmentReportingRevenuefromSegmentstoConsolidatedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r114",
      "r227"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 10.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity method investee and investment in and advance to affiliate.",
        "label": "Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures",
        "verboseLabel": "Investments in and advances to equity method investees"
       }
      }
     },
     "localname": "InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseAgreementsMember": {
     "auth_ref": [
      "r544"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual agreement that stipulates the lessee pay the lessor for use of an asset.",
        "label": "Lease Agreements [Member]",
        "terseLabel": "Lease Agreements"
       }
      }
     },
     "localname": "LeaseAgreementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r648",
      "r650"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/LeasesComponentsofLeaseExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "totalLabel": "Total lease cost"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesComponentsofLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r648"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Schedule of components of lease expense, weighted-average discount rate and weighted-remaining lease terms"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]",
        "terseLabel": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LegalFees": {
     "auth_ref": [
      "r112"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.",
        "label": "Legal Fees",
        "terseLabel": "Legal expenses"
       }
      }
     },
     "localname": "LegalFees",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebtCreditAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesMaterialOfficeLeasesDetails",
      "http://www.evolenthealth.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r641"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesMaterialOfficeLeasesDetails",
      "http://www.evolenthealth.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r639"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r649"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of maturity of lease liabilities"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r649"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "terseLabel": "Future Minimum Lease Commitments",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesMaterialOfficeLeasesDetails",
      "http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r649"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r649"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r649"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r649"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r649"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "terseLabel": "Interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r640"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Lease Termination Term (in years)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesMaterialOfficeLeasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r651"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LetterOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit).",
        "label": "Letter of Credit [Member]",
        "terseLabel": "Letter of Credit"
       }
      }
     },
     "localname": "LetterOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LettersOfCreditOutstandingAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.",
        "label": "Letters of Credit Outstanding, Amount",
        "terseLabel": "Letter of Credit Amount Required",
        "verboseLabel": "Letters of credit outstanding, amount"
       }
      }
     },
     "localname": "LettersOfCreditOutstandingAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesMaterialOfficeLeasesDetails",
      "http://www.evolenthealth.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r70",
      "r155",
      "r241",
      "r272",
      "r357",
      "r358",
      "r359",
      "r362",
      "r363",
      "r364",
      "r366",
      "r368",
      "r370",
      "r371",
      "r562",
      "r570",
      "r571",
      "r608",
      "r663",
      "r664"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities [Abstract]",
        "terseLabel": "Liabilities"
       }
      }
     },
     "localname": "LiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.evolenthealth.com/role/RelatedPartiesAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r58",
      "r155",
      "r272",
      "r608",
      "r665",
      "r712",
      "r740"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and shareholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND SHAREHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r72",
      "r155",
      "r272",
      "r357",
      "r358",
      "r359",
      "r362",
      "r363",
      "r364",
      "r366",
      "r368",
      "r370",
      "r371",
      "r562",
      "r570",
      "r571",
      "r608",
      "r663",
      "r664",
      "r665"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "auth_ref": [
      "r592"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial and nonfinancial obligations.",
        "label": "Financial and Nonfinancial Liabilities, Fair Value Disclosure",
        "totalLabel": "Total fair value of liabilities measured on a recurring basis"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Fair Value Disclosure [Abstract]",
        "terseLabel": "Liabilities"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation": {
     "auth_ref": [
      "r6",
      "r7",
      "r27",
      "r29",
      "r33",
      "r329"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCurrentandLongtermAssetsandLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCurrentandLongtermAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group, Including Discontinued Operation, Liabilities [Abstract]",
        "terseLabel": "LIABILITIES"
       }
      }
     },
     "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCurrentandLongtermAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r27",
      "r29",
      "r33",
      "r323",
      "r329"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 8.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCurrentandLongtermAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Liabilities, Current",
        "terseLabel": "Current liabilities of discontinued operations",
        "totalLabel": "Current liabilities of discontinued operations"
       }
      }
     },
     "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCurrentandLongtermAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group, Including Discontinued Operation, Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCurrentandLongtermAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r27",
      "r29",
      "r33",
      "r322",
      "r329"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Liabilities, Noncurrent",
        "terseLabel": "Non-current liabilities from discontinued operations"
       }
      }
     },
     "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense": {
     "auth_ref": [
      "r755",
      "r758"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount needed to reflect the estimated ultimate cost of settling claims relating to insured events that have occurred on or before the balance sheet date, whether or not reported to the insurer at that date.",
        "label": "Liability for Claims and Claims Adjustment Expense",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "LiabilityForClaimsAndClaimsAdjustmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense": {
     "auth_ref": [
      "r734",
      "r755",
      "r758"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of policy reserves (provided for future obligations including unpaid claims and claims adjustment expenses) and policy benefits (liability for future policy benefits) as of the balance sheet date; grouped amount of all the liabilities associated with the company's insurance policies.",
        "label": "Liability for Future Policy Benefits and Unpaid Claims and Claims Adjustment Expense",
        "terseLabel": "Reserve for claims and performance-based arrangements"
       }
      }
     },
     "localname": "LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/RelatedPartiesAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1": {
     "auth_ref": [
      "r757"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after effects of reinsurance, of payments to settle claims incurred in the current period and related claims settlement costs.",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Current Year",
        "terseLabel": "Paid costs related to current year"
       }
      }
     },
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1": {
     "auth_ref": [
      "r757"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after effects of reinsurance, of payments to settle claims incurred in prior periods and related claims settlement costs.",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Prior Years",
        "terseLabel": "Paid costs related to prior year"
       }
      }
     },
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments": {
     "auth_ref": [
      "r759"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of adjustments to the estimated reserve for unpaid claims and claims adjustment expense.",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Adjustments",
        "negatedTerseLabel": "Other adjustments"
       }
      }
     },
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease": {
     "auth_ref": [
      "r759"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after effects of reinsurance, of increase (decrease) in the liability for unpaid claims and claims adjustment expense.",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Period Increase (Decrease)",
        "totalLabel": "Change during the year"
       }
      }
     },
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilityReserveEstimatePolicy": {
     "auth_ref": [
      "r779"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for estimating its liability as of the balance sheet date for the ultimate cost of settling reported and unreported claims incurred and claims adjustment expenses (including effects of inflation and other societal and economic factors).",
        "label": "Liability Reserve Estimate, Policy [Policy Text Block]",
        "terseLabel": "Reserves for Claims and Performance-based Arrangements"
       }
      }
     },
     "localname": "LiabilityReserveEstimatePolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LineOfCreditFacilityCommitmentFeePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.",
        "label": "Line of Credit Facility, Commitment Fee Percentage",
        "terseLabel": "Commitment fee percentage"
       }
      }
     },
     "localname": "LineOfCreditFacilityCommitmentFeePercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebtCreditAgreementDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r68"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Maximum borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.evolenthealth.com/role/LongtermDebtCreditAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.",
        "label": "Line of Credit [Member]",
        "terseLabel": "Line of Credit"
       }
      }
     },
     "localname": "LineOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.evolenthealth.com/role/LongtermDebtCreditAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermAccountsNotesAndLoansReceivableNetNoncurrent": {
     "auth_ref": [
      "r52",
      "r257"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of accounts and financing receivables, classified as noncurrent. Includes, but is not limited to, notes and loan receivable.",
        "label": "Accounts and Financing Receivable, after Allowance for Credit Loss, Noncurrent",
        "terseLabel": "Long-term receivables"
       }
      }
     },
     "localname": "LongTermAccountsNotesAndLoansReceivableNetNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionContractBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r48",
      "r387",
      "r402",
      "r406",
      "r407",
      "r710",
      "r735"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt",
        "terseLabel": "Long-term debt, net of discount",
        "verboseLabel": "Carrying amount"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtCurrent": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Current Maturities",
        "terseLabel": "Short-term debt, net of discount"
       }
      }
     },
     "localname": "LongTermDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtFairValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.",
        "label": "Long-term Debt, Fair Value",
        "terseLabel": "Fair value"
       }
      }
     },
     "localname": "LongTermDebtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Excluding Current Maturities",
        "terseLabel": "Long-term debt, net of discount"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r75"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails",
      "http://www.evolenthealth.com/role/LongtermDebtCreditAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r75",
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails",
      "http://www.evolenthealth.com/role/LongtermDebtCreditAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "auth_ref": [
      "r594"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns.",
        "label": "Measurement Input, Price Volatility [Member]",
        "verboseLabel": "Stock price volatility"
       }
      }
     },
     "localname": "MeasurementInputPriceVolatilityMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "auth_ref": [
      "r594"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss.",
        "label": "Measurement Input, Risk Free Interest Rate [Member]",
        "terseLabel": "Annual risk free rate"
       }
      }
     },
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r594"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r81",
      "r155",
      "r272",
      "r357",
      "r362",
      "r363",
      "r364",
      "r370",
      "r371",
      "r608",
      "r711",
      "r739"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
        "periodEndLabel": "Non-controlling interests balance as of end of period",
        "periodStartLabel": "Non-controlling interests balance as of beginning of period"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/NoncontrollingInterestsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestDisclosureTextBlock": {
     "auth_ref": [
      "r579"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for noncontrolling interest in consolidated subsidiaries, which could include the name of the subsidiary, the ownership percentage held by the parent, the ownership percentage held by the noncontrolling owners, the amount of the noncontrolling interest, the location of this amount on the balance sheet (when not reported separately), an explanation of the increase or decrease in the amount of the noncontrolling interest, the noncontrolling interest share of the net Income or Loss of the subsidiary, the location of this amount on the income statement (when not reported separately), the nature of the noncontrolling interest such as background information and terms, the amount of the noncontrolling interest represented by preferred stock, a description of the preferred stock, and the dividend requirements of the preferred stock.",
        "label": "Noncontrolling Interest Disclosure [Text Block]",
        "terseLabel": "Non-controlling Interests"
       }
      }
     },
     "localname": "MinorityInterestDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/NoncontrollingInterests"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MinorityInterestLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Noncontrolling Interest [Line Items]",
        "terseLabel": "Noncontrolling Interest [Line Items]"
       }
      }
     },
     "localname": "MinorityInterestLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/NoncontrollingInterestsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MinorityInterestOwnershipPercentageByParent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage.",
        "label": "Noncontrolling Interest, Ownership Percentage by Parent",
        "terseLabel": "Parent's ownership percentage"
       }
      }
     },
     "localname": "MinorityInterestOwnershipPercentageByParent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/NoncontrollingInterestsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_MinorityInterestTable": {
     "auth_ref": [
      "r81",
      "r111",
      "r556",
      "r569"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of noncontrolling interest disclosure which includes the name of the subsidiary, the ownership percentage held by the parent, the ownership percentage held by the noncontrolling owners, the amount of the noncontrolling interest, the location of this amount on the balance sheet (when not reported separately), an explanation of the increase or decrease in the amount of the noncontrolling interest, the noncontrolling interest share of the net Income or Loss of the subsidiary, the location of this amount on the income statement (when not reported separately), the nature of the noncontrolling interest such as background information and terms, the amount of the noncontrolling interest represented by preferred stock, a description of the preferred stock, and the dividend requirements of the preferred stock.",
        "label": "Noncontrolling Interest [Table]",
        "terseLabel": "Noncontrolling Interest [Table]"
       }
      }
     },
     "localname": "MinorityInterestTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/NoncontrollingInterestsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MovementInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Period Increase (Decrease) [Abstract]",
        "terseLabel": "Liability for Unpaid Claims and Claims Adjustment Expense, Period Increase (Decrease) [Abstract]"
       }
      }
     },
     "localname": "MovementInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MovementInMinorityInterestRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]",
        "terseLabel": "Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]"
       }
      }
     },
     "localname": "MovementInMinorityInterestRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/NoncontrollingInterestsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r134"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash and restricted cash provided by (used in) financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash Flows Provided by (Used In) Financing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r134"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash and restricted cash provided by (used in) investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash Flows Provided by (Used In) Investing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r134",
      "r137",
      "r140"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash and restricted cash provided by (used in) operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash Flows Provided by (Used In) Operating Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r91",
      "r93",
      "r98",
      "r180",
      "r181",
      "r565",
      "r576"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss attributable to non-controlling interests"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/EarningsLossPerCommonShareComputationofEarningsperShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r174",
      "r175",
      "r176",
      "r177",
      "r185",
      "r186",
      "r195",
      "r198",
      "r234",
      "r239",
      "r242",
      "r245",
      "r248"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "terseLabel": "Net loss attributable to common shareholders of Evolent Health, Inc.",
        "totalLabel": "Net loss attributable to common shareholders of Evolent Health, Inc. - Basic",
        "verboseLabel": "Net loss attributable to common shareholders of Evolent Health, Inc. - Basic"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/EarningsLossPerCommonShareComputationofEarningsperShareDetails",
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": {
     "auth_ref": [
      "r187",
      "r190",
      "r191",
      "r192",
      "r193",
      "r195",
      "r198"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted",
        "terseLabel": "Net loss attributable to common shareholders of Evolent Health, Inc.",
        "totalLabel": "Net loss attributable to common shareholders of Evolent Health, Inc. - Diluted",
        "verboseLabel": "Net loss attributable to common shareholders of Evolent Health, Inc. - Diluted"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/EarningsLossPerCommonShareComputationofEarningsperShareDetails",
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": {
     "auth_ref": [
      "r5",
      "r166",
      "r167",
      "r170",
      "r171",
      "r182",
      "r183",
      "r184",
      "r264",
      "r265",
      "r278",
      "r279",
      "r464",
      "r465",
      "r466",
      "r467",
      "r506",
      "r525",
      "r526",
      "r527",
      "r587",
      "r615",
      "r616",
      "r617",
      "r653",
      "r688",
      "r689",
      "r690",
      "r773",
      "r774",
      "r775",
      "r776",
      "r778",
      "r823"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.",
        "label": "Accounting Standards Update and Change in Accounting Principle [Text Block]",
        "terseLabel": "Recently Issued Accounting Standards"
       }
      }
     },
     "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandards"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]",
        "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r165",
      "r168",
      "r169",
      "r170",
      "r172",
      "r173",
      "r176",
      "r182",
      "r202",
      "r262",
      "r263",
      "r274",
      "r275",
      "r276",
      "r277",
      "r280",
      "r281",
      "r356",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r507",
      "r521",
      "r522",
      "r523",
      "r524",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r588",
      "r589",
      "r590",
      "r591",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r618",
      "r619",
      "r652",
      "r685",
      "r686",
      "r687",
      "r767",
      "r768",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773",
      "r774",
      "r775",
      "r776",
      "r777",
      "r778",
      "r818",
      "r819",
      "r820",
      "r821",
      "r822"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items.",
        "label": "Accounting Standards Update and Change in Accounting Principle [Table]",
        "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Table]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Adoption of New Accounting Standards"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashOrPartNoncashAcquisitionPayablesAssumed1": {
     "auth_ref": [
      "r144",
      "r145",
      "r146"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of payables that an Entity assumes in acquiring a business or in consideration for an asset received in a noncash (or part noncash) acquisition. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Noncash or Part Noncash Acquisition, Payables Assumed",
        "terseLabel": "Class A common stock issued for payment of Passport/Global earn-out"
       }
      }
     },
     "localname": "NoncashOrPartNoncashAcquisitionPayablesAssumed1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/SupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncontrolling Interest [Abstract]",
        "terseLabel": "Noncontrolling Interest [Abstract]"
       }
      }
     },
     "localname": "NoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation": {
     "auth_ref": [
      "r426",
      "r567"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the reduction or elimination during the period of a noncontrolling interest resulting from the parent's loss of control and deconsolidation of the entity in which one or more outside parties had a noncontrolling interest.",
        "label": "Noncontrolling Interest, Decrease from Deconsolidation",
        "negatedTerseLabel": "Disposal of assets"
       }
      }
     },
     "localname": "NoncontrollingInterestDecreaseFromDeconsolidation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination": {
     "auth_ref": [
      "r426",
      "r540",
      "r567"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in noncontrolling interest from a business combination.",
        "label": "Noncontrolling Interest, Increase from Business Combination",
        "terseLabel": "Noncontrolling interest, increase from business combination"
       }
      }
     },
     "localname": "NoncontrollingInterestIncreaseFromBusinessCombination",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/NoncontrollingInterestsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance": {
     "auth_ref": [
      "r426",
      "r560",
      "r567"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in noncontrolling interest from subsidiary issuance of equity interests to noncontrolling interest holders.",
        "label": "Noncontrolling Interest, Increase from Subsidiary Equity Issuance",
        "terseLabel": "Reclassification of non-controlling interests"
       }
      }
     },
     "localname": "NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/NoncontrollingInterestsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r162",
      "r163",
      "r164",
      "r425",
      "r555"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "terseLabel": "Non-Controlling Interests"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYDEFICIT",
      "http://www.evolenthealth.com/role/NoncontrollingInterestsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NotesReceivableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An amount representing an agreement for an unconditional promise by the maker to pay the Entity (holder) a definite sum of money at a future date(s) within one year of the balance sheet date. Such amount may include accrued interest receivable in accordance with the terms of the note. The note also may contain provisions including a discount or premium, payable on demand, secured, or unsecured, interest bearing or noninterest bearing, among myriad other features and characteristics.",
        "label": "Notes Receivable [Member]",
        "terseLabel": "Notes Receivable"
       }
      }
     },
     "localname": "NotesReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsPassportDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NotesReceivableNet": {
     "auth_ref": [
      "r52",
      "r257",
      "r290"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of financing receivable. Excludes financing receivable covered under loss sharing agreement.",
        "label": "Financing Receivable, after Allowance for Credit Loss",
        "terseLabel": "Notes receivable, net"
       }
      }
     },
     "localname": "NotesReceivableNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsPassportDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r222"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/OrganizationDetails",
      "http://www.evolenthealth.com/role/SegmentReportingAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NumberOfReportingUnits": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment.",
        "label": "Number of Reporting Units",
        "terseLabel": "Number of reporting units for goodwill testing"
       }
      }
     },
     "localname": "NumberOfReportingUnits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesGoodwillDetails",
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetImpairmentTestingDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Expenses"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails",
      "http://www.evolenthealth.com/role/RelatedPartiesRevenuesandExpensesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r234",
      "r239",
      "r242",
      "r245",
      "r248"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Operating loss"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r643",
      "r650"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/LeasesComponentsofLeaseExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesComponentsofLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesGrossDifferenceAmountAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease Liabilities, Gross Difference, Amount [Abstract]",
        "terseLabel": "Less:"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesGrossDifferenceAmountAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r636"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Present value of lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r636"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 7.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liability - current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r636"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities - noncurrent"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r638",
      "r645"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Operating cash flows from operating leases"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/SupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r635"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right-of-use assets - operating"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r647",
      "r650"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesWeightedaverageDiscountRateandWeightedremainingLeaseTermsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r646",
      "r650"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average remaining lease term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesWeightedaverageDiscountRateandWeightedremainingLeaseTermsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingSegmentsMember": {
     "auth_ref": [
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Operating Segments [Member]",
        "terseLabel": "Operating Segments"
       }
      }
     },
     "localname": "OperatingSegmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/SegmentReportingRevenuefromSegmentstoConsolidatedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r36",
      "r579"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Organization"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/Organization"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherCommitmentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of other commitment.",
        "label": "Other Commitments [Axis]",
        "terseLabel": "Other Commitments [Axis]"
       }
      }
     },
     "localname": "OtherCommitmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherCommitmentsDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other future obligation.",
        "label": "Other Commitments [Domain]",
        "terseLabel": "Other Commitments [Domain]"
       }
      }
     },
     "localname": "OtherCommitmentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "terseLabel": "Foreign currency translation adjustment",
        "verboseLabel": "Foreign currency translation adjustment"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYDEFICIT",
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "Other comprehensive loss, net of taxes, related to:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherLiabilitiesFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of other liabilities.",
        "label": "Other Liabilities, Fair Value Disclosure",
        "terseLabel": "Warrants",
        "verboseLabel": "Fair Value"
       }
      }
     },
     "localname": "OtherLiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails",
      "http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r140"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedTerseLabel": "Other current operating cash outflows, net"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r116"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other expense, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherOperatingIncomeExpenseNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 6.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.",
        "label": "Other Operating Income (Expense), Net",
        "terseLabel": "Other income (expense), net"
       }
      }
     },
     "localname": "OtherOperatingIncomeExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ParentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Portion of equity, or net assets, in the consolidated entity attributable, directly or indirectly, to the parent. Excludes noncontrolling interests.",
        "label": "Parent [Member]",
        "terseLabel": "Parent"
       }
      }
     },
     "localname": "ParentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": {
     "auth_ref": [
      "r119",
      "r123"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.",
        "label": "Payments for (Proceeds from) Other Investing Activities",
        "negatedTerseLabel": "Other investing activities"
       }
      }
     },
     "localname": "PaymentsForProceedsFromOtherInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForReinsurance": {
     "auth_ref": [
      "r136"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash payments made for reinsurance during the current period.",
        "label": "Payments for Reinsurance",
        "terseLabel": "Reinsurance payments paid (received)"
       }
      }
     },
     "localname": "PaymentsForReinsurance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesReinsuranceAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfWarrants": {
     "auth_ref": [
      "r126"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount paid by the entity to reacquire the right to purchase equity shares at a predetermined price, usually issued together with corporate debt.",
        "label": "Payments for Repurchase of Warrants",
        "terseLabel": "Payments to settle outstanding warrants"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfWarrants",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebtWarrantAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "auth_ref": [
      "r128"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.",
        "label": "Payments of Debt Issuance Costs",
        "terseLabel": "Payments of debt issuance costs"
       }
      }
     },
     "localname": "PaymentsOfDebtIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r126"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payment, Tax Withholding, Share-based Payment Arrangement",
        "negatedTerseLabel": "Taxes withheld and paid for vesting of restricted stock units"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "auth_ref": [
      "r121",
      "r551"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.",
        "label": "Payments to Acquire Businesses, Gross",
        "negatedTerseLabel": "Cash paid for asset acquisitions"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireEquityMethodInvestments": {
     "auth_ref": [
      "r121"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.",
        "label": "Payments to Acquire Equity Method Investments",
        "terseLabel": "Payments to acquire interest"
       }
      }
     },
     "localname": "PaymentsToAcquireEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsPassportDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireHeldToMaturitySecurities": {
     "auth_ref": [
      "r120",
      "r266"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow through purchase of long-term held-to-maturity securities.",
        "label": "Payments to Acquire Held-to-maturity Securities",
        "negatedLabel": "Purchases of investments"
       }
      }
     },
     "localname": "PaymentsToAcquireHeldToMaturitySecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireOtherProductiveAssets": {
     "auth_ref": [
      "r122"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for the purchase of or improvements to tangible or intangible assets, used to produce goods or deliver services, classified as other.",
        "label": "Payments to Acquire Other Productive Assets",
        "negatedTerseLabel": "Investments in internal-use software and purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquireOtherProductiveAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToMinorityShareholders": {
     "auth_ref": [
      "r129"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to a noncontrolling interest. Includes, but not limited to, reduction of noncontrolling interest ownership. Excludes dividends paid to the noncontrolling interest.",
        "label": "Payments to Noncontrolling Interests",
        "negatedTerseLabel": "Distributions to Sponsors",
        "terseLabel": "Payments to redeem Sponsors' equity"
       }
      }
     },
     "localname": "PaymentsToMinorityShareholders",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.evolenthealth.com/role/TransactionsPassportDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PerformanceSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement awarded for meeting performance target.",
        "label": "Performance Shares [Member]",
        "terseLabel": "Performance-based stock options"
       }
      }
     },
     "localname": "PerformanceSharesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r39",
      "r60",
      "r61"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "netLabel": "Prepaid expenses and other current assets",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.evolenthealth.com/role/RelatedPartiesAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent": {
     "auth_ref": [
      "r45",
      "r707",
      "r732"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 8.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed after one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Noncurrent",
        "verboseLabel": "Prepaid expenses and other noncurrent assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.evolenthealth.com/role/RelatedPartiesAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromCollectionOfNotesReceivable": {
     "auth_ref": [
      "r117"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with principal collections from a borrowing supported by a written promise to pay an obligation.",
        "label": "Proceeds from Collection of Notes Receivable",
        "terseLabel": "Proceeds from collection of notes receivable"
       }
      }
     },
     "localname": "ProceedsFromCollectionOfNotesReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsPassportDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates": {
     "auth_ref": [
      "r118"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the deconsolidation of a previously consolidated subsidiary or sale of an entity that is related to it but not strictly controlled.",
        "label": "Proceeds from Divestiture of Interest in Subsidiaries and Affiliates",
        "terseLabel": "Proceeds from transfer of membership and release of Passport escrow"
       }
      }
     },
     "localname": "ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital": {
     "auth_ref": [
      "r118",
      "r133"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of distribution received from equity method investee for return of investment, classified as investing activities. Excludes distribution for return on investment, classified as operating activities.",
        "label": "Proceeds from Equity Method Investment, Distribution, Return of Capital",
        "terseLabel": "Return of equity method investments"
       }
      }
     },
     "localname": "ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromInterestReceived": {
     "auth_ref": [
      "r130"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest received on loans and other debt instruments during the current period.",
        "label": "Proceeds from Interest Received",
        "terseLabel": "Proceeds from interest received"
       }
      }
     },
     "localname": "ProceedsFromInterestReceived",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsPassportDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfDebt": {
     "auth_ref": [
      "r125"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.",
        "label": "Proceeds from Issuance of Debt",
        "terseLabel": "Proceeds from issuance of debt"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r124",
      "r498"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from stock option exercises"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r33",
      "r91",
      "r93",
      "r98",
      "r132",
      "r155",
      "r168",
      "r180",
      "r181",
      "r234",
      "r239",
      "r242",
      "r245",
      "r248",
      "r272",
      "r357",
      "r358",
      "r359",
      "r362",
      "r363",
      "r364",
      "r366",
      "r368",
      "r370",
      "r371",
      "r557",
      "r564",
      "r566",
      "r576",
      "r577",
      "r591",
      "r608",
      "r724"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss",
        "verboseLabel": "Net income (loss)"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYDEFICIT",
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/EarningsLossPerCommonShareComputationofEarningsperShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]",
        "terseLabel": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r65",
      "r327"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r333",
      "r794",
      "r795",
      "r796"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/PropertyandEquipmentNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r64",
      "r325"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Total property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r43",
      "r44",
      "r327",
      "r665",
      "r725",
      "r741"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Total property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r43",
      "r327"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "verboseLabel": "Summary of property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/PropertyandEquipmentNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r43",
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProvisionForDoubtfulAccounts": {
     "auth_ref": [
      "r109",
      "r284"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.",
        "label": "Accounts Receivable, Credit Loss Expense (Reversal)",
        "negatedTerseLabel": "Provision for credit losses"
       }
      }
     },
     "localname": "ProvisionForDoubtfulAccounts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CreditLossesScheduleofChangesinAllowanceforAccountsReceivableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of purchase arrangement to be paid in remainder of current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment.",
        "label": "Purchase Obligation, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReceivableTypeDomain": {
     "auth_ref": [
      "r80"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financing arrangement representing a contractual right to receive money either on demand or on fixed and determinable dates.",
        "label": "Receivable [Domain]",
        "terseLabel": "Receivable [Domain]"
       }
      }
     },
     "localname": "ReceivableTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails",
      "http://www.evolenthealth.com/role/TransactionsPassportDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock": {
     "auth_ref": [
      "r239",
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.",
        "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]",
        "terseLabel": "Reconciliation of Adjusted EBITDA to net loss"
       }
      }
     },
     "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/SegmentReportingTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable": {
     "auth_ref": [
      "r238",
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification, description, and amounts of all significant reconciling items in the reconciliation of total revenues from reportable segments to the entity's consolidated revenues.",
        "label": "Reconciliation of Revenue from Segments to Consolidated [Table]",
        "terseLabel": "Reconciliation of Revenue from Segments to Consolidated [Table]"
       }
      }
     },
     "localname": "ReconciliationOfRevenueFromSegmentsToConsolidatedTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/SegmentReportingRevenuefromSegmentstoConsolidatedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock": {
     "auth_ref": [
      "r238",
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of all significant reconciling items in the reconciliation of total revenues from reportable segments to the entity's consolidated revenues.",
        "label": "Reconciliation of Revenue from Segments to Consolidated [Table Text Block]",
        "terseLabel": "Reconciliation of revenue from segments to consolidated"
       }
      }
     },
     "localname": "ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/SegmentReportingTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed": {
     "auth_ref": [
      "r728"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of policy benefits and costs incurred for policies assumed.",
        "label": "Policyholder Benefits and Claims Incurred, Assumed",
        "terseLabel": "Claims assumed"
       }
      }
     },
     "localname": "ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesReinsuranceAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded": {
     "auth_ref": [
      "r728"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of reduction of provision for policy benefits and costs incurred for policies ceded.",
        "label": "Policyholder Benefits and Claims Incurred, Ceded",
        "negatedTerseLabel": "Claims ceded"
       }
      }
     },
     "localname": "ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesReinsuranceAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReinsuranceRecoverablesOnPaidAndUnpaidLosses": {
     "auth_ref": [
      "r729",
      "r753",
      "r754",
      "r784"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after valuation allowance, recoverable under reinsurance contracts. Examples include, but are not limited to, settled and unsettled claims, incurred but not reported losses, loss adjustment expense, policy benefits and policy reserves. Excludes premiums paid under reinsurance contracts.",
        "label": "Reinsurance Recoverable for Paid and Unpaid Claims and Claims Adjustments",
        "negatedTerseLabel": "Receivable for claims and performance-based arrangements attributable to the Reinsurance Agreement at the end of the period"
       }
      }
     },
     "localname": "ReinsuranceRecoverablesOnPaidAndUnpaidLosses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesReinsuranceAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r477",
      "r656",
      "r657"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/InvestmentsInandAdvancestoEquityMethodInvesteesAdditionalInformationDetails",
      "http://www.evolenthealth.com/role/RelatedPartiesAssetsandLiabilitiesDetails",
      "http://www.evolenthealth.com/role/RelatedPartiesRevenuesandExpensesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r477",
      "r656",
      "r657",
      "r659"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]",
        "terseLabel": "Related Party Transaction [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/InvestmentsInandAdvancestoEquityMethodInvesteesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [
      "r477"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party.",
        "label": "Related Party Transaction [Domain]",
        "terseLabel": "Related Party Transaction [Domain]"
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/InvestmentsInandAdvancestoEquityMethodInvesteesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/RelatedPartiesAssetsandLiabilitiesDetails",
      "http://www.evolenthealth.com/role/RelatedPartiesRevenuesandExpensesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]",
        "terseLabel": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r477",
      "r656",
      "r659",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/InvestmentsInandAdvancestoEquityMethodInvesteesAdditionalInformationDetails",
      "http://www.evolenthealth.com/role/RelatedPartiesAssetsandLiabilitiesDetails",
      "http://www.evolenthealth.com/role/RelatedPartiesRevenuesandExpensesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r654",
      "r655",
      "r657",
      "r660",
      "r661"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related Parties"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/RelatedParties"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfLongTermLinesOfCredit": {
     "auth_ref": [
      "r127"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for the settlement of obligation drawn from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.",
        "label": "Repayments of Long-term Lines of Credit",
        "terseLabel": "Repayments of long-term lines of credit"
       }
      }
     },
     "localname": "RepaymentsOfLongTermLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebtCreditAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfSeniorDebt": {
     "auth_ref": [
      "r127"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for a long-term debt where the holder has highest claim on the entity's asset in case of bankruptcy or liquidation during the period.",
        "label": "Repayments of Senior Debt",
        "negatedTerseLabel": "Repayment and termination of Credit Agreement including settlement of warrants.",
        "terseLabel": "Repayments of senior debt"
       }
      }
     },
     "localname": "RepaymentsOfSeniorDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalents": {
     "auth_ref": [
      "r42",
      "r141",
      "r147",
      "r705",
      "r736"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents",
        "terseLabel": "Restricted funds",
        "totalLabel": "Total restricted cash and restricted investments",
        "verboseLabel": "Restricted cash and restricted investments"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails",
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.evolenthealth.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r37",
      "r42",
      "r141",
      "r147"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_RestrictedCashAndInvestmentsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents, Current",
        "verboseLabel": "Current restricted cash"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis": {
     "auth_ref": [
      "r62"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by category of cash or cash equivalent items which are restricted as to withdrawal or usage.",
        "label": "Restricted Cash and Cash Equivalents [Axis]",
        "terseLabel": "Restricted Cash and Cash Equivalents [Axis]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails",
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Domain]",
        "terseLabel": "Cash and Cash Equivalents [Domain]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails",
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Restricted Cash and Cash Equivalents Items [Line Items]",
        "terseLabel": "Restricted Cash and Cash Equivalents Items [Line Items]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsItemsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails",
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsNoncurrent": {
     "auth_ref": [
      "r41",
      "r45",
      "r141",
      "r147",
      "r789"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_RestrictedCashAndInvestmentsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents, Noncurrent",
        "verboseLabel": "Non-current restricted cash"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndInvestmentsCurrent": {
     "auth_ref": [
      "r62",
      "r788",
      "r790"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_RestrictedCashAndCashEquivalents",
       "weight": 1.0
      },
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current cash, cash equivalents and investments that are restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. Includes current cash equivalents and investments that are similarly restricted as to withdrawal, usage or disposal.",
        "label": "Restricted Cash and Investments, Current",
        "terseLabel": "Restricted cash and restricted investments",
        "totalLabel": "Total current restricted cash and restricted investments"
       }
      }
     },
     "localname": "RestrictedCashAndInvestmentsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails",
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndInvestmentsNoncurrent": {
     "auth_ref": [
      "r788",
      "r790"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_RestrictedCashAndCashEquivalents",
       "weight": 1.0
      },
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The noncurrent cash, cash equivalents and investments that is restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits classified as long-term; that is not expected to be released from such existing restrictions within one year of the balance sheet date or operating cycle, whichever is longer. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. Includes noncurrent cash equivalents and investments that are similarly restricted as to withdrawal, usage or disposal.",
        "label": "Restricted Cash and Investments, Noncurrent",
        "totalLabel": "Total non-current restricted cash and restricted investments",
        "verboseLabel": "Restricted cash and restricted investments"
       }
      }
     },
     "localname": "RestrictedCashAndInvestmentsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails",
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedInvestments": {
     "auth_ref": [
      "r788",
      "r790"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments which are not defined as or included in marketable (debt, equity, or other) securities whose use is restricted in whole or in part, generally by contractual agreements or regulatory requirements. For use in an unclassified balance sheet.",
        "label": "Restricted Investments",
        "negatedTerseLabel": "Restricted investments included in restricted cash and restricted investments"
       }
      }
     },
     "localname": "RestrictedInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "RSUs"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationScheduleofSharebasedAwardsGrantedDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Activities [Abstract]"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": {
     "auth_ref": [
      "r335",
      "r337",
      "r340",
      "r348",
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.",
        "label": "Restructuring and Related Activities Disclosure [Text Block]",
        "terseLabel": "Repositioning and Other Changes",
        "verboseLabel": "Transactions"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/RepositioningandOtherChanges",
      "http://www.evolenthealth.com/role/Transactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestructuringAndRelatedCostCostIncurredToDate1": {
     "auth_ref": [
      "r336",
      "r339",
      "r345",
      "r347"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of costs incurred to date for the specified restructuring cost.",
        "label": "Restructuring and Related Cost, Cost Incurred to Date",
        "terseLabel": "Cumulative Amount Incurred through June 30, 2021"
       }
      }
     },
     "localname": "RestructuringAndRelatedCostCostIncurredToDate1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/RepositioningandOtherChangesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringAndRelatedCostExpectedCost1": {
     "auth_ref": [
      "r336",
      "r339",
      "r345",
      "r347"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount expected to be recognized in earnings for the specified restructuring cost.",
        "label": "Restructuring and Related Cost, Expected Cost",
        "terseLabel": "Total Amount Expected to be Incurred in the Repositioning Plan"
       }
      }
     },
     "localname": "RestructuringAndRelatedCostExpectedCost1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/RepositioningandOtherChangesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringCharges": {
     "auth_ref": [
      "r139",
      "r334",
      "r343",
      "r345"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.",
        "label": "Restructuring Charges",
        "negatedLabel": "Repositioning costs",
        "terseLabel": "Repositioning costs incurred"
       }
      }
     },
     "localname": "RestructuringCharges",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/RepositioningandOtherChangesDetails",
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringCostAndReserveAxis": {
     "auth_ref": [
      "r336",
      "r337",
      "r345",
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of restructuring cost.",
        "label": "Restructuring Type [Axis]",
        "terseLabel": "Restructuring Type [Axis]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/RepositioningandOtherChangesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringCostAndReserveLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Restructuring Cost and Reserve [Line Items]",
        "terseLabel": "Restructuring Cost and Reserve [Line Items]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/RepositioningandOtherChangesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r54",
      "r425",
      "r507",
      "r665",
      "r738",
      "r773",
      "r778"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Retained earnings (accumulated deficit)"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r2",
      "r162",
      "r163",
      "r164",
      "r169",
      "r179",
      "r181",
      "r277",
      "r503",
      "r504",
      "r505",
      "r523",
      "r524",
      "r589",
      "r769",
      "r771"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Retained Earnings (Accumulated Deficit)"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYDEFICIT",
      "http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]",
        "terseLabel": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r225",
      "r226",
      "r238",
      "r243",
      "r244",
      "r251",
      "r252",
      "r255",
      "r452",
      "r453",
      "r683"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Total revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionDisaggregationofRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r151",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r468"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r442",
      "r443",
      "r456",
      "r468"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognition"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "auth_ref": [
      "r440"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.",
        "label": "Revenue, Remaining Performance Obligation, Amount",
        "terseLabel": "Revenue, remaining performance obligation"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]",
        "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1": {
     "auth_ref": [
      "r441"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period",
        "terseLabel": "Revenue, remaining performance obligation, expected timing of satisfaction, period"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis": {
     "auth_ref": [
      "r441"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Start date of time band for expected timing of satisfaction of remaining performance obligation, in YYYY-MM-DD format.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]",
        "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about expected timing for satisfying remaining performance obligation.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]",
        "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationPercentage": {
     "auth_ref": [
      "r441"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of remaining performance obligation to total remaining performance obligation not recognized as revenue.",
        "label": "Revenue, Remaining Performance Obligation, Percentage",
        "terseLabel": "Revenue, remaining performance obligation, percentage"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r101",
      "r155",
      "r225",
      "r226",
      "r238",
      "r243",
      "r244",
      "r251",
      "r252",
      "r255",
      "r272",
      "r357",
      "r358",
      "r359",
      "r362",
      "r363",
      "r364",
      "r366",
      "r368",
      "r370",
      "r371",
      "r608",
      "r724"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "netLabel": "Revenues",
        "terseLabel": "Total revenue"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/RelatedPartiesRevenuesandExpensesDetails",
      "http://www.evolenthealth.com/role/SegmentReportingRevenuefromSegmentstoConsolidatedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails",
      "http://www.evolenthealth.com/role/RelatedPartiesRevenuesandExpensesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SalesRevenueNetMember": {
     "auth_ref": [
      "r215",
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue Benchmark [Member]",
        "terseLabel": "Revenues"
       }
      }
     },
     "localname": "SalesRevenueNetMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable": {
     "auth_ref": [
      "r80"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule itemizing specific types of trade accounts and notes receivable, and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.",
        "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]",
        "terseLabel": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]"
       }
      }
     },
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CreditLossesScheduleofChangesinAllowanceforAccountsReceivableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r199"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/EarningsLossPerCommonShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r199"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of antidilutive securities excluded from computation of earnings per share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/EarningsLossPerCommonShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r538",
      "r539"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementAdditionalInformationDetails",
      "http://www.evolenthealth.com/role/TransactionsPassportDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of supplemental cash flow information for the periods presented.",
        "label": "Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]",
        "terseLabel": "Schedule of cash flow, supplemental disclosures"
       }
      }
     },
     "localname": "ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/SupplementalCashFlowInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "auth_ref": [
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.",
        "label": "Share-based Payment Arrangement, Cost by Plan [Table Text Block]",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock": {
     "auth_ref": [
      "r7",
      "r17",
      "r18",
      "r19",
      "r20",
      "r21",
      "r22",
      "r28",
      "r31",
      "r32",
      "r33",
      "r331",
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations [Table Text Block]",
        "terseLabel": "Schedule of discontinued operations"
       }
      }
     },
     "localname": "ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r198"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Computation of basic and diluted earnings per share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/EarningsLossPerCommonShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r485",
      "r494",
      "r508"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Schedule of Equity Method Investments [Line Items]",
        "terseLabel": "Schedule of Equity Method Investments [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/InvestmentsInandAdvancestoEquityMethodInvesteesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsTable": {
     "auth_ref": [
      "r33",
      "r155",
      "r271",
      "r272",
      "r608"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of information required and determined to be disclosed concerning equity method investments in common stock. The summarized information includes: (a) the name of each investee or group of investees for which combined disclosure is appropriate, (2) the percentage ownership of common stock, (3) the difference, if any, between the carrying amount of an investment and the value of the underlying equity in the net assets and the accounting treatment of difference, if any, and (4) the aggregate value of each identified investment based on its quoted market price, if available.",
        "label": "Schedule of Equity Method Investments [Table]",
        "terseLabel": "Schedule of Equity Method Investments [Table]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/InvestmentsInandAdvancestoEquityMethodInvesteesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r312",
      "r316",
      "r684"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails",
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetImpairmentTestingDetails",
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r312",
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of intangible assets",
        "verboseLabel": "Schedule of intangible assets details"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesTables",
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfGoodwillTable": {
     "auth_ref": [
      "r307",
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons.",
        "label": "Schedule of Goodwill [Table]",
        "terseLabel": "Schedule of Goodwill [Table]"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetScheduleofGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "auth_ref": [
      "r307",
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.",
        "label": "Schedule of Goodwill [Table Text Block]",
        "terseLabel": "Schedule of goodwill"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense": {
     "auth_ref": [
      "r759"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the activity in the reserve for settling insured claims and expenses incurred in the claims settlement process for the period. The estimated liability includes the amount of money that will be required for future payments of (a) claims that have been reported to the insurer, (b) claims related to insured events that have occurred but that have not been reported to the insurer as of the date the liability is estimated, and (c) claim adjustment expenses. Claim adjustment expenses include costs incurred in the claim settlement process such as legal fees; outside adjuster fees; and costs to record, process, and adjust claims.",
        "label": "Schedule of Liability for Unpaid Claims and Claims Adjustment Expense [Table Text Block]",
        "terseLabel": "Activity in claims reserves"
       }
      }
     },
     "localname": "ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r65",
      "r327"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r658",
      "r659"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/RelatedPartiesAssetsandLiabilitiesDetails",
      "http://www.evolenthealth.com/role/RelatedPartiesRevenuesandExpensesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.",
        "label": "Schedule of Related Party Transactions [Table Text Block]",
        "terseLabel": "Schedule of related parties"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/RelatedPartiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable": {
     "auth_ref": [
      "r42",
      "r147",
      "r705",
      "r736"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about cash and cash equivalents restricted as to withdrawal or usage.",
        "label": "Restrictions on Cash and Cash Equivalents [Table]",
        "terseLabel": "Restrictions on Cash and Cash Equivalents [Table]"
       }
      }
     },
     "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails",
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": {
     "auth_ref": [
      "r42",
      "r147",
      "r705",
      "r736"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.",
        "label": "Restrictions on Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Schedule of restricted cash and cash equivalents"
       }
      }
     },
     "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
     "auth_ref": [
      "r336",
      "r337",
      "r338",
      "r339",
      "r345",
      "r346",
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.",
        "label": "Schedule of Restructuring and Related Costs [Table]",
        "terseLabel": "Schedule of Restructuring and Related Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/RepositioningandOtherChangesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": {
     "auth_ref": [
      "r341",
      "r342",
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.",
        "label": "Restructuring and Related Costs [Table Text Block]",
        "terseLabel": "Costs associated with the Repositioning Plan"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/RepositioningandOtherChangesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock": {
     "auth_ref": [
      "r489",
      "r491",
      "r492"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Activity [Table Text Block]",
        "terseLabel": "Schedule of share-based awards granted"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r486",
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationScheduleofSharebasedAwardsGrantedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "auth_ref": [
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "terseLabel": "Schedule of future estimated amortization of intangible assets"
       }
      }
     },
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": {
     "auth_ref": [
      "r213",
      "r215",
      "r216",
      "r217",
      "r605",
      "r607"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]",
        "terseLabel": "Summary of major customers"
       }
      }
     },
     "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SecuredDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets.",
        "label": "Secured Debt [Member]",
        "terseLabel": "Secured Debt"
       }
      }
     },
     "localname": "SecuredDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebtCreditAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentDomain": {
     "auth_ref": [
      "r221",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r248",
      "r255",
      "r339",
      "r347",
      "r761"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Segments [Domain]",
        "terseLabel": "Segments [Domain]"
       }
      }
     },
     "localname": "SegmentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetScheduleofGoodwillDetails",
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails",
      "http://www.evolenthealth.com/role/RevenueRecognitionDisaggregationofRevenueDetails",
      "http://www.evolenthealth.com/role/SegmentReportingRevenuefromSegmentstoConsolidatedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]",
        "terseLabel": "Segment Reporting [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "auth_ref": [
      "r221",
      "r223",
      "r224",
      "r234",
      "r237",
      "r242",
      "r246",
      "r247",
      "r248",
      "r249",
      "r251",
      "r254",
      "r255",
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "Segment Reporting"
       }
      }
     },
     "localname": "SegmentReportingDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/SegmentReporting"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingRevenueReconcilingItemLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Segment Reporting, Revenue Reconciling Item [Line Items]",
        "terseLabel": "Segment Reporting, Revenue Reconciling Item [Line Items]"
       }
      }
     },
     "localname": "SegmentReportingRevenueReconcilingItemLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/SegmentReportingRevenuefromSegmentstoConsolidatedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r113"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 6.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative expenses",
        "verboseLabel": "Selling, general and administrative expenses"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/RelatedPartiesRevenuesandExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative Expenses [Member]",
        "terseLabel": "Selling, general and administrative expenses"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeniorNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors.",
        "label": "Senior Notes [Member]",
        "terseLabel": "Senior Notes"
       }
      }
     },
     "localname": "SeniorNotesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails",
      "http://www.evolenthealth.com/role/LongtermDebtCreditAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeveranceCosts1": {
     "auth_ref": [
      "r139"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.",
        "label": "Severance Costs",
        "negatedLabel": "Severance costs"
       }
      }
     },
     "localname": "SeveranceCosts1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r138"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationScheduleofSharebasedAwardsGrantedDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationScheduleofSharebasedAwardsGrantedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r484",
      "r487"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationScheduleofSharebasedAwardsGrantedDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "Shares, Issued",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Short-duration Insurance Contracts, Reconciliation of Claims Development to Liability [Line Items]",
        "terseLabel": "Short-duration Insurance Contracts, Reconciliation of Claims Development to Liability [Line Items]"
       }
      }
     },
     "localname": "ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable": {
     "auth_ref": [
      "r760"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the reconciliation of claims development to the liability for unpaid claims and claim adjustment expense for short-duration insurance contracts.",
        "label": "Short-duration Insurance Contracts, Reconciliation of Claims Development to Liability [Table]",
        "terseLabel": "Short-duration Insurance Contracts, Reconciliation of Claims Development to Liability [Table]"
       }
      }
     },
     "localname": "ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SoftwareDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Internally developed software for sale, licensing or long-term internal use.",
        "label": "Software Development [Member]",
        "verboseLabel": "Internal-use software development costs"
       }
      }
     },
     "localname": "SoftwareDevelopmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "auth_ref": [
      "r16",
      "r221",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r248",
      "r255",
      "r307",
      "r330",
      "r339",
      "r347",
      "r761"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business segments.",
        "label": "Segments [Axis]",
        "terseLabel": "Segments [Axis]"
       }
      }
     },
     "localname": "StatementBusinessSegmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetScheduleofGoodwillDetails",
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails",
      "http://www.evolenthealth.com/role/RevenueRecognitionDisaggregationofRevenueDetails",
      "http://www.evolenthealth.com/role/SegmentReportingRevenuefromSegmentstoConsolidatedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r49",
      "r50",
      "r51",
      "r153",
      "r155",
      "r188",
      "r189",
      "r194",
      "r196",
      "r198",
      "r206",
      "r207",
      "r208",
      "r272",
      "r357",
      "r362",
      "r363",
      "r364",
      "r370",
      "r371",
      "r413",
      "r414",
      "r417",
      "r418",
      "r419",
      "r608",
      "r816"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYDEFICIT",
      "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r2",
      "r79",
      "r96",
      "r97",
      "r98",
      "r162",
      "r163",
      "r164",
      "r169",
      "r179",
      "r181",
      "r205",
      "r277",
      "r419",
      "r425",
      "r503",
      "r504",
      "r505",
      "r523",
      "r524",
      "r589",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r769",
      "r770",
      "r771",
      "r822"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYDEFICIT",
      "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails",
      "http://www.evolenthealth.com/role/NoncontrollingInterestsDetails",
      "http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYDEFICIT",
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r162",
      "r163",
      "r164",
      "r205",
      "r683"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYDEFICIT",
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": {
     "auth_ref": [
      "r50",
      "r51",
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued during the period pursuant to acquisitions.",
        "label": "Stock Issued During Period, Shares, Acquisitions",
        "terseLabel": "Class A common stock issued for payment of earn-outs (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesAcquisitions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r50",
      "r51",
      "r419",
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures",
        "terseLabel": "Restricted stock units vested, net of shares withheld for taxes (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r50",
      "r51",
      "r419",
      "r425",
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "terseLabel": "Exercise of stock options (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueAcquisitions": {
     "auth_ref": [
      "r79",
      "r419",
      "r425"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued pursuant to acquisitions during the period.",
        "label": "Stock Issued During Period, Value, Acquisitions",
        "terseLabel": "Class A common stock issued for payment of earn-outs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueAcquisitions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r419",
      "r425"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures",
        "terseLabel": "Restricted stock units vested, net of shares withheld for taxes"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r79",
      "r419",
      "r425"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r51",
      "r56",
      "r57",
      "r155",
      "r261",
      "r272",
      "r608",
      "r665"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total shareholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r2",
      "r3",
      "r97",
      "r155",
      "r162",
      "r163",
      "r164",
      "r169",
      "r179",
      "r272",
      "r277",
      "r425",
      "r503",
      "r504",
      "r505",
      "r523",
      "r524",
      "r555",
      "r556",
      "r575",
      "r589",
      "r608",
      "r621",
      "r622",
      "r626",
      "r770",
      "r771",
      "r822"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "negatedTerseLabel": "Cumulative effect adjustment",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYDEFICIT",
      "http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]",
        "terseLabel": "Shareholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r627",
      "r667"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r627",
      "r667"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r627",
      "r667"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r627",
      "r667"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]",
        "terseLabel": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r666",
      "r668"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowElementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Elements [Abstract]",
        "terseLabel": "Supplemental Cash Flow Elements [Abstract]"
       }
      }
     },
     "localname": "SupplementalCashFlowElementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense": {
     "auth_ref": [
      "r756"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after effects of reinsurance, of expense (reversal of expense) for claims incurred in prior reporting periods and related claims settlement costs.",
        "label": "Prior Year Claims and Claims Adjustment Expense",
        "terseLabel": "Incurred costs related to prior year"
       }
      }
     },
     "localname": "SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TradeNamesMember": {
     "auth_ref": [
      "r542"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof.",
        "label": "Trade Names [Member]",
        "terseLabel": "Corporate trade name"
       }
      }
     },
     "localname": "TradeNamesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails",
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockMember": {
     "auth_ref": [
      "r78",
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Treasury Stock [Member]",
        "terseLabel": "Treasury Stock"
       }
      }
     },
     "localname": "TreasuryStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockShares": {
     "auth_ref": [
      "r78",
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.",
        "label": "Treasury Stock, Shares",
        "terseLabel": "Treasury stock, at cost (in shares)"
       }
      }
     },
     "localname": "TreasuryStockShares",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockValue": {
     "auth_ref": [
      "r78",
      "r427",
      "r428"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.",
        "label": "Treasury Stock, Value",
        "negatedTerseLabel": "Treasury stock, at cost; 1,537,582 shares issued, respectively"
       }
      }
     },
     "localname": "TreasuryStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TypeOfRestructuringDomain": {
     "auth_ref": [
      "r336",
      "r337",
      "r345",
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the types of restructuring costs.",
        "label": "Type of Restructuring [Domain]",
        "terseLabel": "Type of Restructuring [Domain]"
       }
      }
     },
     "localname": "TypeOfRestructuringDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/RepositioningandOtherChangesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r512",
      "r518"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "terseLabel": "Unrecognized tax benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r209",
      "r210",
      "r211",
      "r212",
      "r218",
      "r219",
      "r220"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Accounting Estimates and Assumptions"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationTechniqueAxis": {
     "auth_ref": [
      "r594"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by valuation approach and technique.",
        "label": "Valuation Approach and Technique [Axis]",
        "terseLabel": "Valuation Approach and Technique [Axis]"
       }
      }
     },
     "localname": "ValuationTechniqueAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails",
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetImpairmentTestingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ValuationTechniqueDomain": {
     "auth_ref": [
      "r594"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation approach and technique.",
        "label": "Valuation Approach and Technique [Domain]",
        "terseLabel": "Valuation Approach and Technique [Domain]"
       }
      }
     },
     "localname": "ValuationTechniqueDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails",
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetImpairmentTestingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_VariableInterestEntityFinancialOrOtherSupportAmount": {
     "auth_ref": [
      "r573"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of financial or other support the reporting entity has provided (explicitly or implicitly) to the Variable Interest Entity (VIE) that it was not previously contractually required to provide or that the reporting entity intends to provide, including, for example, situations in which the reporting entity assisted the VIE in obtaining another type of support.",
        "label": "Variable Interest Entity, Financial or Other Support, Amount",
        "terseLabel": "Performance bond amount"
       }
      }
     },
     "localname": "VariableInterestEntityFinancialOrOtherSupportAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsPassportDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VariableInterestEntityInitialConsolidationGainOrLoss": {
     "auth_ref": [
      "r572"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The gain (loss) recognized on initial consolidation of a variable interest entity (VIE) when the VIE is not a business (as defined).",
        "label": "Variable Interest Entity, Initial Consolidation, Gain (Loss)",
        "terseLabel": "Gain on consolidation"
       }
      }
     },
     "localname": "VariableInterestEntityInitialConsolidationGainOrLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/NoncontrollingInterestsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Variable Interest Entities (VIE) in which the entity does not have a controlling financial interest (as defined) and of which it is therefore not the primary beneficiary. VIEs of which the entity is not the primary beneficiary because it does not have the power to direct the activities of the VIE that most significantly impact the VIE's economic performance and for which it does not have the obligation to absorb losses of the VIE that could potentially be significant to the VIE or the right to receive benefits from the VIE that could potentially be significant to the VIE are not included in the consolidated financial statements of the entity.",
        "label": "Variable Interest Entity, Not Primary Beneficiary [Member]",
        "terseLabel": "Variable Interest Entity, Not Primary Beneficiary"
       }
      }
     },
     "localname": "VariableInterestEntityNotPrimaryBeneficiaryMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.evolenthealth.com/role/NoncontrollingInterestsDetails",
      "http://www.evolenthealth.com/role/TransactionsPassportDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_VariableInterestEntityOwnershipPercentage": {
     "auth_ref": [
      "r574"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the Variable Interest Entity's (VIE) voting interest owned by (or beneficial interest in) the reporting entity (directly or indirectly).",
        "label": "Variable Interest Entity, Qualitative or Quantitative Information, Ownership Percentage",
        "terseLabel": "Interest in investment"
       }
      }
     },
     "localname": "VariableInterestEntityOwnershipPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/NoncontrollingInterestsDetails",
      "http://www.evolenthealth.com/role/TransactionsPassportDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r644",
      "r650"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/LeasesComponentsofLeaseExpenseDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable lease cost"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesComponentsofLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]",
        "terseLabel": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebtCreditAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]",
        "terseLabel": "Variable Rate [Domain]"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebtCreditAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "terseLabel": "Warrants"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": {
     "auth_ref": [
      "r596"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.",
        "label": "Warrants and Rights Outstanding, Measurement Input",
        "terseLabel": "Assumption or Input Ranges"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r187",
      "r198"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted-average common shares outstanding - diluted (in shares)",
        "verboseLabel": "Diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/EarningsLossPerCommonShareComputationofEarningsperShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r185",
      "r198"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average common shares outstanding - basic (in shares)",
        "verboseLabel": "Basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/EarningsLossPerCommonShareComputationofEarningsperShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WriteOffOfDeferredDebtIssuanceCost": {
     "auth_ref": [
      "r115"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Write-off of amounts previously capitalized as debt issuance cost in an extinguishment of debt.",
        "label": "Write off of Deferred Debt Issuance Cost",
        "terseLabel": "Unamortized debt issuance cost"
       }
      }
     },
     "localname": "WriteOffOfDeferredDebtIssuanceCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebtCreditAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    }
   },
   "unitCount": 6
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721523-107759"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(12))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(14))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(22))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(23))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(5))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721525-107759"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(8))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.19)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.3)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e1012-107759"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e1060-107759"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3337-108585"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21D",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=SL94080555-108585"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e1063-107759"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "230",
   "URI": "http://asc.fasb.org/topic&trid=2134446"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21728-107793"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=SL108384541-122693"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "250",
   "URI": "http://asc.fasb.org/topic&trid=2122394"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1377-109256"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8657-108599"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8844-108599"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "34",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8981-108599"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8475-108599"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "280",
   "URI": "http://asc.fasb.org/topic&trid=2134510"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=SL6953401-111524"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)(1)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)(2)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=125513658&loc=d3e32014-111567"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=124268079&loc=d3e32787-111569"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(b)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "323",
   "URI": "http://asc.fasb.org/topic&trid=2196965"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919269-210447"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919272-210447"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919236-210447"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "80",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124267575&loc=SL82922355-210448"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=123353750&loc=SL49131251-203054"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=123353750&loc=SL49131252-203054"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=123353750&loc=SL49131252-203054"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "http://asc.fasb.org/topic&trid=2144416"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2510-110228"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2473-110228"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=109237686&loc=d3e17752-110868"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=26872618&loc=d3e7436-122677"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.3)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.4)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(1))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(e))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "420",
   "URI": "http://asc.fasb.org/topic&trid=2175745"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/subtopic&trid=2122178"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S65",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359872&loc=SL124427846-239511"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466302&loc=d3e4852-112606"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031898-161870"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031898-161870"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6812-107765"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12317-112629"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12355-112629"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130533-203044"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL108322424-203045"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130558-203045"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130561-203045"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130564-203045"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130550-203045"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(i)(2)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=109227538&loc=d3e44648-109337"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6909625&loc=d3e227-128457"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5227-128473"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5263-128473"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5333-128473"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5419-128473"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e7008-128479"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911878&loc=d3e8732-128492"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568447-111683"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568740-111683"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569643-111683"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4613674-111683"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569655-111683"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=SL6759159-111685"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=SL6759159-111685"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.E)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120398118&loc=d3e355146-122828"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13467-108611"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13476-108611"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "http://asc.fasb.org/topic&trid=2175825"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918666-209980"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "http://asc.fasb.org/extlink&oid=122150657&loc=SL122150809-237846"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "848",
   "URI": "http://asc.fasb.org/extlink&oid=122150657&loc=SL122150809-237846"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124437977&loc=d3e55792-112764"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r665": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r666": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r667": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r668": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r669": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r670": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r671": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r672": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r673": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r674": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r675": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r676": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r677": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r678": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r679": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=123371682&loc=d3e55415-109406"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r680": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(a)",
   "Topic": "920",
   "URI": "http://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783"
  },
  "r681": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(b)",
   "Topic": "920",
   "URI": "http://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783"
  },
  "r682": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(a)",
   "Topic": "920",
   "URI": "http://asc.fasb.org/extlink&oid=120155617&loc=SL120155638-234783"
  },
  "r683": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r684": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r685": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r686": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r687": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r688": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(1)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r689": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(2)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r690": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(3)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r691": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r692": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r693": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r694": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r695": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r696": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r697": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r698": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r699": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r700": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r701": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r702": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r703": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r704": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953"
  },
  "r705": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r706": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r707": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r708": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r709": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r710": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r711": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r712": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r713": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r714": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r715": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(13)(f))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r716": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r717": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(20))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r718": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(24))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r719": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(25))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r720": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r721": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r722": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r723": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Subparagraph": "b.",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123398031&loc=d3e60009-112784"
  },
  "r724": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r725": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r726": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "e",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r727": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r728": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=99397103&loc=d3e6811-158387"
  },
  "r729": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=99397103&loc=d3e6824-158387"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r730": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r731": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(5))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r732": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(10))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r733": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r734": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(13)(a)(1))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r735": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r736": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r737": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r738": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r739": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(5))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r740": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r741": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r742": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r743": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(10))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r744": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(11))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r745": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r746": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r747": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(20))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r748": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(21))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r749": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r750": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r751": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r752": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r753": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=99404803&loc=d3e21409-158489"
  },
  "r754": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=99404803&loc=d3e21412-158489"
  },
  "r755": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437"
  },
  "r756": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437"
  },
  "r757": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437"
  },
  "r758": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(cc)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437"
  },
  "r759": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r760": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671315-158438"
  },
  "r761": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r762": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r763": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r764": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r765": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r766": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r767": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r768": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r769": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r770": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r771": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r772": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r773": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r774": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r775": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r776": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r777": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r778": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r779": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/subtopic&trid=2560295"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29,30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r780": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "605",
   "Subparagraph": "(b)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6486672&loc=d3e27261-158547"
  },
  "r781": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "605",
   "Subparagraph": "(b)(3)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6486672&loc=d3e27261-158547"
  },
  "r782": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "605",
   "Subparagraph": "(c)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6486672&loc=d3e27261-158547"
  },
  "r783": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "605",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6486672&loc=d3e27261-158547"
  },
  "r784": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195"
  },
  "r785": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195"
  },
  "r786": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "944",
   "URI": "http://asc.fasb.org/topic&trid=2303980"
  },
  "r787": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r788": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL6242262-115580"
  },
  "r789": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r790": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=120413209&loc=SL6242269-115581"
  },
  "r791": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=123366838&loc=d3e3073-115593"
  },
  "r792": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=123364037&loc=d3e3115-115594"
  },
  "r793": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r794": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r795": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r796": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916"
  },
  "r797": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r798": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r799": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721494-107759"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3,4)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r800": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r801": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r802": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r803": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r804": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r805": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r806": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r807": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r808": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r809": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r810": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128487-111756"
  },
  "r811": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r812": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r813": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r814": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r815": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r816": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r817": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r818": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848"
  },
  "r819": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "848"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r820": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "848"
  },
  "r821": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848"
  },
  "r822": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r823": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "848"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e957-107759"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(13))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868656-224227"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>124
<FILENAME>0001628908-21-000116-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628908-21-000116-xbrl.zip
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MT&A"H9%"X A<%HP74U85SE2 'B"I\/P"4<!9CD]&<L4R3BG,,)U+GY.]W)I
M 2E8R\V41')^"Y2L%SHMOA-H# ZI/#D)V9RETB 90;$"NZ,E @R;C&0Z8K:B
MGT7_"1BHE9 #N;0*60L1H(G$M&3 EE@L:'326Z)I6J";8^PF6#)=GH8MX-P[
M_(? N?=TX PLDP4"AK"W $@3L8SBV&R6VF6187(+Q$(6J:H$ZD00+J&AB0"6
ME!!+Q!#!G\)"J06^:VC9>T-C" E/[)LD42D40%!K1)X?SGI[4FY'+%-Z8F>(
M-S"4UADB.)Q>!KO1RN82<.W,F#5KOV%W';O]G</NS<I"/]L[[L9'I[9&9\V;
M*'7I#&DOF'W[PJ/@FG$#'F^('YDH(%PP0) G2MH1]2"Q'#,W96]Z%M*F2ML*
M^U%.-UH%X)5&IR#PM67[B#,!"-P IJN[=,2+(7AJ^KY2*!'W>"L^V(=@17P@
MPE-XE$2FBP!XTL\HIR[%0< EV?+H@;*5@3(<B/R\'QTH001F6VJY DN*@>T!
M_T#D[ S@^>X /FY'1S0/EV!QIG#A?=W^-"J;1"E27MG'=Z':G@ BK!XIL 5=
M&52 :7,LK4_&* 6%UT,;DT4:7RX%!A3WD*WIP@)VS;I,4*/$E(ZV6*VD\ <N
MMDJL%)(;20[(0&I\<2I(4V6):/@@MYZ5^-2M+:!!#DL%=2J1?LNT4IPJ#KKE
MC5@0%NP1Z,\R:\._$B!!+ K8'\37* *['A/)[L1$70160^+1:70M,AZ?@!\=
M(!A48RD(]]SJ@E.EX19CAF@X!0,W8@9,#!7)$ZFDFQ*%V30LA:G'L(=GB+ 5
MT24:[PO:7>U069D2P\-ZRI6FV@AO@"?T0RB022F,$FR!DL*/1'"S$B(!PU26
M6%,^'@O_!.2GNX/\636X&G-5^91)N( LHW.\,:ZHW<"#Y_3H$24@/&ZFQA[I
MV!'3MPT$/-&5>]B"QQ0I/I<&VEUDG]Y<LF2V;_'!"V$FT!X/5!K@6^)>@:_8
M'?C.$G< QCK Z+2DYK2^92.*MTC7Q$]TFE:&8+1$!C9HS;5U^)Z.ME&735'1
M;^$HC^VO=GE.2;8RF$+OR=4FXY84_!$/G?X4U=RB%\&>$;=SSD3)UT<."%^5
M_$S4%6/*E+P%59_WW)-O?O;D?*UHV?6][L'.1<L?WNOZTVDQB[7F(G%2'E_&
M^R*'$FZW(%)K['YN'4>&[[2Q<^[B7Z#*/)?. 7RD2B4:V1&U"XGV>27[&!M8
M%"P5'?R?]AFS4(;?*HGF^["M"O\UR[[XMJ5]"EO:5PJ9*\Z5_S2)-M'11BH!
M4583D?G6<@+\EIA%8+*>6W@.[H_-9P>"6V&WW@6&XZ -&9<+[&AAGG ?Q'G-
MW+$+@A4)=C/0&XO<QE9YCEO9W\$[4Y>XC4>G6R;C+_8-:-=!NWM[SE?(4#*#
MR:R)" *?@A&#_H-)#=9F*/.R&&LU!JKU!1_6WWU,G;4A+Y6> K9.1CKD:;X2
M"@C=+T*!VA]/@JL9S_E]:MV>();!M'"N%2\M#&9_G&)!*16?#F3A9\QW.D6<
M#V712K1S.A_019(Q%29D1S6R_'"AN;ZR<A*W3_I]NK7B$*Y.S :N+[2T_866
MCA/K;0?MDY.3!UNC=OQ@V\>TQD?MJ'OXQ=5V#]O1R</-?U1M_[#=/SYXE-J.
MG]\PQ[B*MN3%RT:O<2\A#+KE'8M7TP$A__Y"AC7\Z_.!O^!T25M>7]S9'-BU
M^T_<LU?5$',OZS?]K;*_F7//]OJ8M?PO6[WDLH6C$;FY):97^GRV:)T2G2X'
M*,O\L36;S=Y36H\W/ ]??9[R:CRE";^A>Z#UC%^,)&3LZ@[2B@[,V-NP;?NL
MN>_X*KSES;?E6Z2E#G=H!^'#S1C6[I4N@L"7^&C1A2<8"95;[_*)JZCU;[@5
MZ^_GGO\?4$L#!!0    ( (F9!%-J%=B\.P@  /8K   5    83 V,S R,65X
M:&EB:70S,3(N:'1M[5I;<]NV$G[OKT#E.8DSHPLI2[[(CF=2VYVZTR9IZDZF
M3V= <BFB!@D6 "6KO[Z[ '6S9$=JTD9NDP?%)!:+7>#;W0\@SKZ^?'-Q\^O;
M*Y;97+*WOWSSP_4%:[0ZG?<'%YW.Y<TE^^[FQQ]8KQV$[$;SP@@K5,%EIW/U
MNL$:F;7EH-,9C\?M\4%;Z6'GYEV'5/4Z4BD#[<0FC?,S>H._P)/SK\Z^;K78
MI8JK' K+8@W<0L(J(XHA>Y^ N66M5BUUH<J)%L/,LF[0#=E[I6_%B/MV*ZR$
M\ZF>LXY_/NNX0<XBE4S.SQ(Q8B)YV1!IP@^!I]'Q01KVHI/^\5$O#M/#X^"X
M%P7]?O__(1K907'?Q]B)A)>-7!2M#&C\07A<VM.Q2&PV"(/@?PTG=WZ6JL+B
M8!H[^S^]CA5-)4\2]*\E(;6#;J]]U$=U%NYLBTLQ+ ;.2?]"% GZ,VAUNVT4
M:O@QIGIB)94>[ 7NWRFUM%*>"SD9/+\1.1CV&L;LG<IY\;QI<+%:!K1(O: 1
M?P :CP.[Q[%W[ CU2%' S-$N>7=UEXE(6'80MKO+KLW<_OM,ZJTUZ=E>>!B<
MKA@S-6-A,F.</]"?:>8N0%N1BIA3F+"WE3851RNL8C]#[-X=!%VF4F8SV'EG
M?N8ZX@68UIL["1/V*K9D>3<('@+%FEA8[]9OE<%IFOSM?JW'TG63?:^RPOT8
M5319[%9M@HO"[;.]_O%&.%OVX7'7EQ* 2R:KBI;CGX0^T_2$[:D?__SHI\LS
M%?@D>,TR/@*F821@C-7"9L*PGRJN,3;DA+V#4FG$9L&^53IG8=#ZB8!Z-5*2
M:LQWP*7-FNRZB-NXNB</K^XFR_3O6^_NSJWW-]S@*N-ZYA-V6ZBQA&0(3;_L
MVB]VHM"$0B&#P!&X*!@O)JPJK*X /4!.X>@%HH"S')^TX)*EG#*89BH7+B4[
MN16! F(PANL)B>3\%BA7SW4:?)>@,3BD=-S$)W,6"XU<!,4*[(Z6)*#9.!-Q
MQDQ%/_/^8]!0*R$'<F$DDA;B/V-A,W30E%@K:'326Z)I*D$W1]@M8=%D<1JV
M@//!X7\$S@=/!\[ 4E$@8 A[<X T$<LHCLUZH5T4*28WSRM$$<LJ09T(P@4T
M-!' @A)BB1@B^%-82#G'=PTM<V]H#*'$\?HF2502!1#4"I'GAC/.GIB;C*52
MC<T4\1J&PEA-_(;32V\W6ME< *Z9&K-B[1?LKF*WMW/8O5E:Z&=[Q]WPZ-34
MZ*QY$Z4NE2+K!;UO7C@47#.NP>$-\2,B"80+!@CR2 J340\2RS%S4_:FYT28
M6"I383_*Z5I)#[Q2JQ@2?&W8/N(L 02N!]/579SQ8@B.F;ZK)$J$![P5]O?!
M6Q'V$__D'P5QZ<(#GO0SRJD+<>!Q2;9L/%"Z-%"* Y&?]Z,#)8C ;$LMEV!)
M,; ]X!^(G)T!/-\=P(?MX(CFX1(,SA0NO*O;'T9EDRA%S"NS>1>J[1$@PNJ1
M/%M0E48%F#9'PKADC%)0.#VT,9FG\<52H$%R!]F:+LQAUZS+!#4*3.EHBU%2
M).Z\Q521$8G@6I #PI,:5YP*TE09(AHNR(UC)2YU*P-HD,5209U*I-\BKB2G
MBH-N.2/FA 5[>/JSR-KPKPA($(L"]H?D<Q2!78^):'=BHBX"RR&Q<1I=B8S-
M$_#& 8)!-1()X9[C5IY3I>$&8X9H. 4#U\D4F!@J@D=""CLA"K-N6 I3AV$'
M3Q]A2Z(+--X5M+O:H;+2)8:'<90KCI5.G &.T ^A0"8E,4JP!4H*/Q+!S8J/
M! Q346)->3P6_@O(CW<'^=-J<#7BLG(IDW !:4K'>"-<4;.&!\_HT08EP#^N
MI\8.Z=@1T[?Q!#Q2E7W8@DV*%)]) ^TNT@]O+EDTW;>XX 4_$VB/ RH-\"5Q
M+\$WV1WX3A.W!\8JP.BTI.:TKF4MBK=(U\1/5!Q7FF"T0 ;6:,V5L?B>3K91
MEXE1T>_^*(_M+W=Y3DFVTIA"[\G5)N.6%-P1#YW^%-7,HA?>GHR;&6>BY.LB
M!Q)7E=Q,U!5CPJ2X!5F?]]R3;W[TY'RN:-GUO6Y_YZ+E+^]UW>ET,HVUYCQQ
M4AY?Q/L\AQ)NMR!2*^Q^9AU'AF^5-C/NXEZ@RCP7U@(\4J4BA>R(VA.!]CDE
M^Q@;6!0,%1W\G_89TU"&WRN!YKNPK0KW,<N\^+*E?0I;VE<2F2O.E?LRB3;1
MT48L %%6$Y'9UG(,_):8A6>RCELX#NZ.S:<'@EMAM]X%^N.@-1F7)]C1P"SA
M/HCSFKEC%P0K$NRFIS<&N8VI\ARWLG^ <Z8N<6N/3K=,QI_L&]"N@W;W]IRO
MD*&D&I-9$Q$$+@4C!MT'DQJL35_F13%2<@14ZPL^K+_[Z#IK0UY*-0%L'6?*
MYVF^% H(W4]"@=J/)\'EC&?=/K5NCQ#+H%LXUY*7!@;3/TZQH)223P:B<#/F
M.ITBSH>B:$7*6I4/Z![)B H3LJ,:66XXWUS?6#D)VR>]'EU:L0A7FTP'KN^S
MM-U]EHY-5MOZ[9.3DP=;@W;X8-MC6L.C=M ]_.1JNX?MX.3AYK^JMG?8[AWW
M-U+;<?/KYQA7T92\>-DX:-Q+"(-N><?"Y71 R+^_D'X-__E\X.XW7=*6=[FX
MU]X_<<=>54-,O:S7='?*_F7./=OK8=)ROVSIBLL6?@;DY9:(7NKST:)U0K2J
M'* L<X?6;#IY3VDY7O/<?_-YPHOQE.;[ANZ UA-^D0E(V;>S0OW&[]D^:NX[
MK@1O>>MM\09IJ?S]V8'_:C."E3NE\QAP]3V8=^$1!D)E5[M\X!IJ_>MOQ+J[
MN>=_ E!+ P04    " ")F013U[@ 1M\$  !&%0  %0   &$P-C,P,C%E>&AI
M8FET,S(Q+FAT;=U86U/;.!1^WU]Q&F8IS,377 A.R@P-[)2=;NDEG<X^[<BV
M'&LJ6ZXD$[*_?H_D& @!EFZ7%IH'3VR=^_DD?=+DV='I=/;GVV/(=<'A[<>7
MKT^FT'$\[U-OZGE'LR-X-?OC-?1=/X"9)*5BFHF2<,\[?M.!3JYU%7G>8K%P
M%SU7R+DW>^\94WV/"Z&HF^JT<S Q7_!)27KPR^29X\"12.J"EAH228FF*=2*
ME7/XE%+U&1QG)345U5*R>:XA],, /@GYF9V19EPSS>E!:V?B->\3SSJ9Q")=
M'DQ2=@8L?=%A_FB0CN+1*!B.:#\C?3+<2^)>0(?[>X0.2?Q7@$%Z*-[H*+WD
M]$6G8*634^,_"D:5'B]8JO,H\/U?.U;N8)*)4J,SB<K-W\;&AJ6*I"GFYW":
MZ2CLNWL#-*?IN78(9_,RLDDV'UB98CZ1$X8N"G4:'ZV=1' AHRW?_L9FQ,E(
MP?@R>CYC!57PAB[@O2A(^;RKL%F.HI)EC:!B?U,,'AW;UT63V![:X:RD%XF&
M)KOC\YS%3$,O=(/UU"[2?KB0^C>&M+T5#/WQ1C!M&%>*F6#]J/Q!E9M2J5G&
M$F*F";RMI:H)1J$%!"/XZ'YPIRY\H(D=#7H#O_OH,SI4<)B*RDS2J^FT2>S[
MPT>?PFD&.J?P@<B8E%0YI^><+N$PT2 R7%K\\!:,WS"U?QC^3[I8<IW#2TZ2
MSQA^%Z8YHQD<G].DUNR,PFF&N*/2Y'1\)KA975]1PG7>A9,R<6''U&![:Q2&
M_G@JBHJ42_L6C'>[D%C<HM7JYAX;JW?7L'L;PE&/Z.VMP6AS]MY5YAO73KL.
MKZV3YLN#P^KFE@1N&_3W]SY>+XO?;!8S[-"[FDB<:GP)[VDE)/:GA-^$+"#P
MG7=M&U?]ATQ(^_ZE40**54WA][JDS7K;P_;9O?<J>!J[E]C):H[>$C3)&>:W
M8 A3(R[IEYI):O9G91Q?HF*'[ )Z#@8[Z>X%LA#'$MD%6C@^3W)2SFD+KV"_
MUX>=8-#":V]4["*@]L= RO3^P.D\;;B%CQ)NK$0,%<UVEZ 5@IHI?K4]72$P
M(\S@L9)4&2QTS3#A'% -@R$<D:(J!(?J6JV,E:1,S'<TF%K":1IMI&K>0$E4
M5%J?ZAJBW:_:C#2).6T%8B%3*ATL*">5HE'[9YPR57&RC%AIRV*5Q@61<^2'
ML=!:%)'A<V=F"4T(7SFQ_IKA%7/L[P_=@6_QHQ&!.FT]KXBEVXQY.MT<[/7<
M<'#[\)VZ=PZ.1J[_7W7O'L20'\9RV.O?OQB>+;5L)5I,-^JHB5U6")P7G5[G
MVA(0A=4Y!.M$W<#_>J.;'G__1<&>0X[,Z6E]<UV5Y(DG=EC/:Z6AW^P_/UER
MVUO]O;&R3UBG=5^1J&_2_!]@OF;GFT57JZ@6582RH 1G*;05?4H]>D,*:B?6
MS]:AI]2$F;G5677AEO/.-_7#LYOYHS[X'8+"-B"G$I(AXT!69!D/0Z*-=%G3
M$@/"3<#>IJT8=PKQ<NWPEA,%,4712HHS9B@^GNZNG@,,O5HPI&2QH>TK$H=&
MKLMDM2R9RB\-7&'M9OR"N:-2P90R 2#19\C:,,HL@[K"+R9,JO0F5[L/0;]Z
M(U>)YCXRDI03 XJ-.[K+9<GR-/]2A<2X-M5Z4^5?KO56S^:&T=YU'OP#4$L#
M!!0    ( (F9!%-.X@0SS@0  !H5   5    83 V,S R,65X:&EB:70S,C(N
M:'1MW5A;;]LV%'[?KSASL#0!K+O=.+(;('-2M$77].*BV-- 291%E!)5DHKC
M_?H=4E)N3K)V7=ND?A L'9[#<_EX^)&S7X].YHL_7Q]#H4L.K]___O+Y' :.
MYWV(YIYWM#B"9XL_7L+(]0-82%(IIIFH"/>\XU<#&!1:U['GK58K=Q6Y0BZ]
MQ5O/F!IY7 A%W4QG@X.9^8)/2K*#7V:_.@X<B;0I::4AE91HFD&C6+6$#QE5
M'\%QNE%S4:\E6Q8:0C\,X(.0']DI:>6::4X/>CLSKWV?>7:262*R]<$L8Z?
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MS9!X!P]O8E9)]P\'V'CO6GL7$8+@Q?!TM0HC&E:,-0Y &?8.U!M1A^RI M@
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M^J)-"@XD36Q-JL2%!F1.)I2X[B[U%O'KWJTJ3DF+J$6HHG:RS[IJ*B4JBY@
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M!78YJA@26'>.CC%]1>>N6O9U.ABS"H]OV2=V K@K0$FE&HWRL21 8.\OC-7
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M%P=_<NC\1>N\-AM-]E<EN3^YI8N7_Y ?B;-R<-+63XS_PUT]G1P=+^;+(_1
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M-)6N+:L/@%F*5<BM8X%C;A1ES,+_N?<D8CJ.YUCD[CH+OB,TW[CJYV_HD_/
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M;LG>4^<ZCM@S'I)?703$)5?(>$N1%]@$)PQF#MB;4HK9T_K54U[0_1TPE+Q
M[^>(O5-<U$D/5'?SQ+2R<!;<<-#\GL*E8M.%_B.[SU_.](%"R))&>)A[^,8"
M+7?,Q)M/-M03ALS?+>9[T7YFT_^>)UOMKND2OSWAZIGLOO5>,$N[7MX[P#:5
M#OSJE0J:&(^<T1)Q1W&RW@B*Q,H L Y3X5?6A+R2D/W[4U;H^= %M?G/4;?S
M*J/^26-CZVL>F<9",4#8FB.8-8YTD [9P+46QGCNTTZ_TBC'5UUC2Q#M/(UM
M___^2U$B_^QG@] *)XGJ6:<@>RV#E;XU3*M19D!&LY1._=2KR7+K\D4N.+84
M9+J!O7Y14^"ILWQO"7%V 0_WFH,FW+','@B]X+.38:\_3&D$@VX&9Q2A H3^
M9G]/:#KE!*^[P9O;*XP_KWG9YPW/%QR/XZGO')Y/Q5/%>"OU1#<F&M_^SC=8
ME.(6%N6\BYG>KJ;D7G/0*O)C@G%'F6N9?O\.1LV2O&//%(O>[GG;=EN_W<FN
M78XW;(R2G HBAC-W9#J'\$4G.SUJPC=3[75=N=J[Q*L\K@W?;GK?"L^OW9_:
MASA:.,X)M85\+27@+CV'^Q>I:'KKJ+'AX!E_P^^#UO[Q(=Z_^/NHOI?*=>_#
MV/?/&NVM'SV'QZEH^O:731@+O$\;?K<_-[<W=H[K[<VS^G&KV3@^:L/SZ'Y+
M)8_AU#'.) E,*^3@)^*>2Z1=%,@ZYRT).>::KJR]3;HJ6\]21C5P^NZ@Z[XE
M&;@N?;&6G9A>]MVTAB'[;U#_)%7KR/I']PO;KX3@-D(PTKJETJTDX!82,(W,
MLMAAABU% D>2DM0U,CE/5>\E891BKV6^LK;Y^:^*>Y]T(S0MI5?W0,?J?7.T
MT"YM-OES,_C6A,%U3@BF+B G"$WMVU.7D=31UEKK,.%,> ^P!MADO]O[-E+N
MX_G^*=-?[UJ_A0/]>;SKMRT'L]7Q*0X]9/8\<T<!WKZ=JA*?'H4B%2+9F3,9
M[;^1W[,CT\]BLP46JFFUX& J+Y<,U_\,F\EL!6O5AM$)<,^)Y<I2TD19FVMD
MO\Z8O>,93S9M.IQJ<V4>C@*:3J>>]((+!;8F-"O*=_:SW^!^($=9?PC(LW_4
M36GUX^)8@R,S^''LI^;R*-,0RXM'[_![+3,=G_U&RW>T((UPW![#&Z3SBU/A
MHC2*T7U2I;U^,8ABD*8_R#3.O#GOKV9/Z6@M]X[?#GL]&$!9X"^M@ ,S&/:7
M4D'<V^EZ5M_X2+[27(0@<H8B-P[Q7&&D/34(FSP0H3AG#J^L[8?^C0[76\K>
MXQ6QWGT2]]JMBT!EC6XV*7WXXM14$E^0W'9S, !9#RV0X%ZWD]!$ZSP+@"S.
M :V#NC"NV(;>, -35DGZ08M-[S'KC-L9PID<BZ2H=L+AL.S\D^VBO>RWY(V4
M?U)&5T<G#(Z:1=&/DU3TXZE56CG>B:8*_=^?0P_-3&6:R9%:>FUZZ&*? =K0
MSE+N4(BY2"#:(>5H"H_.L7'*&6'X]7KH52NB%ZR)0/A-UC(]@#;&.=!$/9/4
M21+.7H(;UWZ; 6>@:P_TVZ#"X"F]\9H/XMR&63BO)70%MP-(DOSRA]EAKWLZ
M.!H?7IW=*]D-H1BF#['9*6J*%@$Z:3^/PAO?,-CB,/ES?-K-)XS/N'FLXS,3
MVAJ=?,.XQV<V.Z76)=0B.L:/LZ!Q-;NZ=[J(W//TEF2AD@N*)"X][/;.KPNL
M3:M=[^WHA%>FJAL7=?PU-S02'"R*EJ16%CI/W68=BLR2R##5!H.J_G"],%3J
M>Z*^UW^<FXDV3ZK]&C4V/;Q[DX*X\W3>LG#[P@AIJMYNX>6[ ]L]NRJ<Q<3\
M>]B'@?5?FSVWO;%)OD:MI $J@W JBK@T!"DE+7*,8)TSHSBUSUNZ?;[5=6\9
M1[!Y_2+Z5.)TRU'-6YK&L_*^F)2WY9R\+JE*C9M JB3).8\:*2E-:K#ND8Y<
M(*R)TDQBJZ->[(8(<X%VMQSD5OP)_DXA<=>:#<UXG>^B\%C @MGI%@Z'8;\$
M[" V98>D:[H! /Q/SVJ=IX>?-N'12?([\&[=M,)^;_:+!;AC.BX)-RS+J5Q;
M.KD_ !QN>KZ?I4RLIK\I](AEOYG??X&]YZ)S;[(>KXORHG1U6CQ\L4R#>QB6
M_:/0:DW4_&_ .85-5U:;_;G!]/O()-R'-WCE:"M-XBM=%HZW3K\:XJR01")'
MF44\2HT 8WD4I0LB,@.KPC/WR;DUV&IT1ZD0\S>_EE7KK!>^G_7AX; _*">3
MEJW<:DEE]$)VFGZ,9/1=X>:%Q6#8:9826H2V@(UR26HY5<ZJZ)2GC&/CK:!!
M2B<8MA93*K]N%<*J,%T!A>6:8.[T_V=EJ_'N<H^KSK#MNX/1"==L?Q7Q.,6.
M[6XQBNWAH%C+@+ K6=^9-(_XU4GTI[.OGF(;!#6(&@GF$P&)5M3ER+D\F>-Y
ML*E3L)(UFLN:E)-R@V/RKI412_WQNM&[&O,_#HIR95!4OPR*FA)@]7X!V6/6
M+-J[=4N(\Z87T@[+]_#GN*!VL6K,7#4*0L;32XSM=UO#P<V7W"7U;?9GND7)
M4"IRS+CF'AM.'56YDII'RR6P-O#^5X)7QA<=34(?3\QA0+87S#=D(CSUC6F=
MFO/^RA^7!M=N=L9"RE+O[1]?XE=#?=:>"[?)$KNIUO^\DEUN.>B](CP>A.!M
MTFZ=0?_&$8^BX5.LDYA#9#VPQBHNV>.&R/K_<V/][54NQ(U'\2JY\=C/[JKD
M*D"W1[\M7V5$W>JNHY#C1XNZ?J;PL^NBKG^68KDU"),F<"^J0,.#9^8?<Q@N
MS<PM.>)A4Y3Z5EV?0'X_]1;C7";O7V9AQI(=]1*F_*];++@Y4'U]9R_;^M<?
MYL=U\7X%'AZ; YZ:SM=%K\Z+SG<<RQWHK%?6R.J]:'Q?B;W<@8[^H@%=1<R[
M$?/=Q"M9U'DJ@RI_^]0Q0]\<!/_[LY)ZYOR"VA69'TUF;Z!CI6L7F&X,"$>?
M5-E.\&-%LT>D6=UT   G53IQV6PT^VY8=@1-@5?K'=,Z[S<+)\]4 X.EZ\N-
MI73.3N@/6X/BE.V34(ZI_US,4&GD)^<2CBN=O"!CN8N= X8.JP#P"Z+FQ[39
MWAP47NY"\<(7K?'?26^WNOUA<LBOV^YPD-5-[UL89#O-_K<*&[\,#A"ZTL0+
M,I:[4"ZMH94F?D'43#L]/:!:H87_Z75=\$GQ5FKV99 W_P7@_7$?^I%;*CVP
MX=/S[UW\PAZ[IK(8TL^@CU['?H:DXPV-:D=C$2C]=*HI=?^\R3U:.=D6EF0?
MPJ%IE2BAR.2N7&,OA[9YM5VQ*&.Y"^44*-+U:K]B_F.Y(]&2+RM[9]R@VZNT
MZ,LA:Z5%%V8L=]FLKS9]%V,L=Z39I\Y,^?!=TRHC^#?_,VP.SF>KK27?UJ=^
M$=D\ J^5SGTY7)#32N<NR%AN3SF*Z5-OZE8Z]REHMA&B*6)D/IVD&G"AT^SV
M9G1MI5=?#*4KO;HP8[D+Y<13;]%6>O4I:%:':P##Q@#0=28"IM*G+X;"E3Y=
MF+'<A7)J94U4(2\OB)K;17F9K4Y9>@%N506[O S"5@IV8<9R!\H1 I2K .O\
MQW)'FFV>'35M<U"%"KX0>N:L"A6L8-N"\J=<6=N%23>#*CCYY5 TYS_3.'=K
M-?6#=BK*2"U[02U6%=0JF*XLJ'5VTC*@ +J]\ZS1'5SMKW[-@(^'_4$SGO^$
M,K>Y[NG>]*:ZJ&43G8]#D_KAM,ZSLN-5:CO[#FS6C&#TL98-.ZW0[Q?UZD;%
M"+-NLFQ/F_U)7Y]^;=QO8E2/;-**(ETV.O3VARX5HZ]/PX_?=(>]:SI9#/OC
M+T'X4]W6[K6=0HM+ "ZFP1:M$8L*^?VA[3=]T_2:H;_ZPW79AP]OBQX@XW/.
M;^I""F_3ZPX/CT9=>4^+&?'#U%IMV,NZDTSN6E%LN'O:&?5R@]O-G- YS$R_
M'P9EO$!ZZB!E*18]E&;.MJ,Z]1G\<B%+/T[2W7\<_FAH1=W:HV[+S];['\_%
M20\N;YZD^L3IR<7)Y9,2?7ZH.9AJ4/:O3D&:IM4[5HQ>-.%^M[WS97UG WW8
MWOY_6XWWV>[>^MYF?;.QMYNA[.WZI[VM[<;ZSG[V8;WQ_M/Z^\U%$N+KWZ@L
M+;I(X[Q>V;P%^&.:Z;&32C1MXQ-;ETJH[%51,FRG5##9:2_U".ND0MN  5I7
MKK7GV;!?'.V4$A..3"MFIC=1.;';.S4]CUK=[K=12>[1'<:Z)%7T+L80LG8P
MG7322"K^Z36_IZK1,_$]'^#78=F4;"<DM]ZTK:(6J4=9\=!_=C_LK(_N/ZX&
MO9[=.)11Q>G)GT4_,O@NU2@'B6[V82E*P#&+QA435"L&G?*56\UVD<S<[:0Z
MZ*XU]$40TOF/=VN;\]06S3?=H)8&$ISI#V9*I\,4-E.)\RP.$_ %8A3E*6JI
M"'KAO4P**/5!<D?-\+V<P+*G8[IS6A42:4^[J=9YJ_DMO!EW12KFPX96NNI*
MHR/0>4DG#:X<"6<GP0VN? OLV[[F;--L__C5^%U__+J;BDV"HOWQ0'J#9F=X
MY=8)"5R]=_?XFM&=-EM7;ML'(K7\U6_-U5-A'J]\E:1G=AT<"44QRT",DZ.>
MZ0.]BYKT?>"$ENE->!C( 2_5&968+\O69WY:J 1X=D3KZ:*4>N1-ZI7,4'[$
MP@ 73DRR88;PH**(<3^,N6Y6-$L0G)KQ=<?/**O? LL,>J$#HV]V+JUP"3[
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M*@E[!LT(D 1,K6(;M$31A4L_P9'4?+2(/NKU$N(N]Z62L9<B<I(UWRU][;.
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M&L:!FL-.JFI1QG1UBZBED;%2.G+<L("ITQM/LW@J=?RDSH#0'_2:,Z%P8'2
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MRD,N"A@5];:J+:.YK:*#9DK<GM*E*,1<4".1JTP03][F_C1>9:9T%.C>T*S
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MD>;)G4&E-"Y@PERL,EQ>@9 _%@*IQ/GYQ7EF.X4PZ7D4B$4!($5A@K3W#(G
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MP!BR1AG$4VL)RR@8:IX:SQC#E*:..37*:4T_6FS,D@:ZO6P!?H9PMDJ 'TF
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M5.HR NU*I3ZV2ITIA>RQP41+Q#A.K:VC 2/;*^0\"T3FN>"I1@RI,4EJ\N'
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M@*!-!A3%__<<$R1O"*/*4?.XL\O=JO*:#:D=1.HF*Q,:B%>L;^L 2FMBU"F
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M 8HK;0#)1O!"61""A& DT6F[L]O666\=4K<DOM+@O#2<YV,CDI1(18X0K-2
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MF&Z]@NDC2>V=<]3^V6F@\4&>+\&>'%PR55O M) I&N>ZLU]^."H>0O YR.*
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M%W5154XYDPZQ-KM>;V1J6'\06%]E-*YAO8M8OPS?9<<Q,)=!)!$!G0H0=$K
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M_F9T0L-I[Q_D3Z;'_5Z!W9,[!JG.W\--\^"6"QAW[IW?OHUX]2^HVSIEF^N
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MH0H)B+L *"6#D+. 6N^4-,O&A:8VMPOJC9"W04K="#HW0NX$(5]9XQ.3R"Q
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MIKX#":Q+0<Z^;>^M'Z=]FA[D'T;C3(/IV>P&&Z_=GM<^6]^!(14#,RN(QEK
MZ!0XQ13(;(O2TA0]V9U=7%F3;:N_N6]4WW,^JR%Z]8C^<'4,L0F>"0N\6*&
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MM*FZVJ1:3 Z,# $@K"!Q6B-+,LJNG_YFE%T'*;4^83FC[)U1=C[UV$-ED5<
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MW\!B9K\S'L."\@LX*9WSO5=Y]__F[O_O\&#G,N9S\/&#M=!9ZA@@BG! -;=
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M-YD#/6<.=-6QK2UTSJ, B$_C!8TV0"MG ?,<*R'B6N$LDZ"UA(0,W.L@I66
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M^6UZ#/H!C 9^IH/?BRSJ:6NP:#'&'4V$]7OZNY9C/_PY\+FYPO)H-M?J#ZD
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M^I]+%_\R%\4/HY2T4O9^G WX1/%]OK<;Q?0KYRLP[)^]2K=MT.^6KDA7OHY
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M;9E.5G_E4L3Y P&F7-CDVC^/1S,0/')$CYSZ1E0.<WVA>F?J?+SQK_E\H>Z
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M:Z6GI[*\*L-N_FYN-O!T[/)I#^3L=W_EX_&UU0=]8N@OYXJ!BDLU%+[%]6#
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M(64<$1E;ZDRDM-'ZD6I\X9B?-AA7?A8T31%B?#TF )@IHD^.,@VFAFG@ *2
MR/ZY@&28KQ7T)$RT!AF'^%RVD"ISB'Q6^ 2SM0$(>K/J$3-8VVIM3XK@?>-.
M2W\+SJF\&YEW=,P\0EX=*%^Z/&&Q*#3CA_$_^&H]*LRX\L>L?&+^S3[=;?[U
MOM(4;D;]A6$[NMX5,RO:492R03PNWMY&M=7_7%6X\@5\4 QA:N*P5)[0786X
M[>73>= [56NN(,YIJ< L37JLS6X\&S>(GZ(FV'E5@"OD[+D?;F2ZXRI99/YX
MJF6&5WJA56BM9;FFHH8(YHP 88\4$AY!(L1J9=U*FMU)_MNLN@ N>3S+CZSR
M4<(V;[4"3Q?*W* L+A/.$;[%.&S]8'+L1:7/-"Q]<HLU@'Y2*';KZ4+&-F;-
M!F,+)7]!O';HM^@T7&X6'DC V&ZHEK:)6=WH8 W>/Q.JWB :#$>CD,?@P\7K
M-?+FJVE]5]U>R!Y%'NWW4:OQ3.]3E("2ZJY@KR.%XK&S=-G DZ6=Z5/9I^/@
MLYZ;*[(*ZC?*HEU559V"=V^UWH:<U050P"39L:]<6\"@3W =D/";M\P&0=M#
M6,'\IYXKBN<XVUIXJJJ"ZS,U@G'L389><-4N\Y<^)?J:+\HX'L[)I3&6-U^0
M-+A?8U\,*?=RQC]@YT375NMC(+<",M1D,NJ"H5[:ON6P8V\E]%'C]Q8>'F1W
M7!8Q4T<H&";S4'==V'FZ!P::-6[!,!@-[)+1$ X,30< :KR?>)1J_\=02_+M
M:-A_7>@*7T""E '%C270OOAV:!+&E;.4Q-@_$2P!1Z1PCJ26ZUAI09W*+GGQ
M71)+GF2&:RH4S742.T=3HWE..67Y([4<"GH!X/%Z$/+"TX6 +^A@&"':%257
MBUO5,X!6D/C&C5^T_F!_8C;88#P3ZI5?$W'V#_YGZ[2G)KZVC/=4SG2_\D%0
M-5>,4'CIBHI.O:!>S#]RALX?K/;@+QWQ8:_$E1D!H$+TU'1@CDM[Y71X.@U)
M J5O%'"M^ DFZIVX1R/5#P5MJK=62O35B]D=5 \;Y6O0KMH@ Z_SPK T$LI]
MAI4,3==KH%ZA1?UJ/#U%)ZIWAQ?##S$/$TX<'AI88K&''KHKOP?O9'#:=+TT
M/3L>%G7\NI.0J.T5=AAK9KB-:GNSU7I_Q3I;1V"YC+P?K)Q]'SUFQ%<IG7/K
MAP)<Q8EXJZ=4*$N#]-*A;,X=2;V/ TI@$.*3\^#3!B)7X3WUNXC"$^D=?N5\
M?8X[_/-HB'_VIHIW*IXY7[XE'%(1%C!JC:8#@I5>JZ_C?7VU!+ 9'&PS^K,K
M5_W^^^T:$91 ,6\S>1VTJ*M6-;<HW] MY@!RMRCHXLN(E"]]PKI&36>?94#'
M@,WNU'O4>\"+TTG/Z]5 ]MO&AUC@0Y\J9_WKH:WRGUM_8 @*IW]M?WKM?V)_
M_=G:'YZ" I'09/-^>D?^LDSQX%IJ(077E(K(^)ZG_-,)UK<3-[#<TLUYUTP)
M7J.9; QK*JKAU-=54?4-4]6O0=5S369\&,-#-/&Y00LCGOSU<*>[T)-';/DD
M^%91<>1\SHOVQ_C/\K:M/+_F%'[;*=0+5 XU[./\Y5%Y2,V)W.>)[%1HYYT#
M**Z+0F>^IFJS^?>Y^=M%,X_E>^_URN4\TAS+?1[+QZKD<*D!>#7W#_07@<3P
M :JAW\,8CF.<^[K]*X[J?GQ(ZZCSKNB =97;Y&5UCY]X Z\LMUB[PR]<^*?H
MN^KZ^.I0-=[?-EU2T;8NA^&V+I]"$Z;[J^>-"==K':?[X'&W;X<C6-/@M0^5
M,>?[,X ?;P^L_[57;['VK-VR^^90)WENX<0(%91C2&Y*,JP\(U.LFL84X]%C
M=;,6I- J:>'INC[J]V(H#_%:WG>LZ=JN&J%OK;4[@!_G2GG[(L^U2MX@&62X
MK\^G U-<T)AB[TIYX$OXAZ@"C'*LO2)$//C7#%H?IZ?.^6O42<%QA6.FJI0_
M?Y<_P<C*VF@@93YO?=IJ6:P;-RH+0_J[=X)MVT9E:+#[$>J#AXNEI3U30SB*
M_RX&5&*2$#R_?(3*=3J8]4<I',N%9_$H!(#@*X;^"G:N<B;V13-FVI\&81D"
M:G\6F:!"(&-YOPOS&1_#B,?#GG6C\?_Q4323<ZSV'VBY.H_)S^9DN]9?N1>A
M(-6=)6;^F+NM+5R53/;5YT-(<O='&28!9P5C_V<*IDY$-V]4*/AN%8: [3(7
M-!*9L%0);KA,9)J)7(L4YB5S<RB2C=J7[IN7TZ6\[-6R:*OU\TI>ORXH8;HS
M%^C[T7 PG!9A$R@HBPY&NX/Z,V7\]KK(S$ZWE)EO>P<GAK9/C-C#9-*3#[P#
M[VS#.SM?.L<'7]IQ^V+[[.O)\;=+)4V^_-.'9\\[%T?BZX7AG9VO46?GV]G!
MSC;[RM_"G+Y=M'=>=??>?<S;%[MT[\-A9ERF\B0B.>,Y%M;*29;(B&3:)J#K
M* DD=>DF4_.,)SIS+*:"4:5,9J/$N2CCF73R4@PDF$,A&'EW/,;&SLN\U9=9
M9H'J?WH?OD1WNVJ.]ZV[_80D@[*V7BK; Y ?;W\XM"SBEJ8)<3%S0'XQ)THK
M1V*>I9QGQL3:KHO&]E.DV[;#*F(0AUQ.XT]59]L=!+D(:E<28L;>;G]Z!7I4
MX/=/G_TGA$7K=M/TMM+A=@?8(\[S)WF-C6 GK;^# O)'N">+>/+GBU:[ULL.
MCGK^23C^I0/>]Z)_ND2OQ50-'_%R.IQ*+7+I: J*TZ#,Z>G[>\/Y<PNZ=)D(
M5#:P\&&_A2<+;X.#[NG[\LS(O\HQ\CDG?OO\GVOY3KXK7]C)7K63Y97^3,TN
M5.(B_=M'Z\YJLV-B7#W++13D#=?2&/Z&C6^+$3%D<=G'96BT*DKH'[N>)9,A
M 943YHS>.F?P!Z^'5_$4RGX/U0&\<EG&(>0YF8N4+=<'BG@(#MO$E)Z1.^TI
M4UHQOK4,_E)<+E;9?+@IQ15C*Q^!F/'U=,K WBJ?K[:%<U>._L)XZW__+Y;0
MO_PY8H!U[2Q# H[/3!OUNKYHY.S+&%PQ=S15Z.HIMAP+;7(VJW2>66[79G'$
M92/FH$Z'D W_.]"#,S#&N#ZU:EI@0]6:8F-"$M)9MPQHSKO812O4M6AI=]0=
M^(!8[R)J[<"Q8NNM%HM13V=9G3"\U=?M%[E%83A8NT^#JH_J+3Z%L%X4/BB(
M?L'.*^<[F^Q_%&@B8/<Q;R/0PM[#$2K.&KG):%A%3E8<4O)$:%S0*FPOWV/
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ML*T:)XV/6RL<)1[?,::BA4U:6WAWV@M1E+X %WSH:1W.O>?='Y?<MU4@R-G
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M:,$IZ$:@!L,\TDAH(S/-99Y1H[03,A9I4)L88PDI?[B#P+=V=S#$W)M/M<)
MSU9G@O'/.T>'-#6&:T.)22FHQ1)T8\SM)&")26-,'N=YMD)G6JDB+>;VS35N
M66JLUI-V2Z*KW8R5#2=76G9>$BLLJX^"-/CT:D6P"DXN^.4)B\UM;#8[6@Y=
M\Z@]R_0."%CO<>N;//A6:ODLDM'_@$#P7?6JG!U$@U'75.EO2Q^\X6UZ[AS&
M*PE? BBU-(L!' "=C'(L<ME5)M6U+61O46W/1 5:S-L#^V8V\^>+#?LP'\ &
MDP$RLXS$48;1(IJ3S'!.A!*,99FCN=4;+UF<;<F?@\-FK;.8;R2%7K)9UN-C
MH1 ,./I4S7J[7-+;X>@3+.@Y4TNT]^$PE8I+X3BA:036-QP04(M*P 2/I,X2
MEQMG-UY*N95<12SUU.U:5NAT ,<QZ2&TJUZ@FJ=&0Y_+)>(OM>C*YPQ%NQ=
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MHHA0P3N9KB_N7!UP[8*FJ)M=!M6%>[]Z='(]4/?[K%W?4RXQO%VQS@K_0/T
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MI)$5H*RN6?.[U2U[:_X_;RG[[-01##+^B828UR"K6.2Z2"JC]^OM+>HBP;=
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M>!8^R?5S ?A3:Z#I-M#T]5+Q"4/!ODLS0C/GB) R)]HE$4DD97"24@HCFZ"
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MR-(5ZU=C'.)8?4<:Q_BRKJ=RG*]3YCA(<5C?*# 3K,%Z9XJ9>,UA1G? ++@
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MTOW#8]K8^[OY]?>_3Z]E/IVVFE\//U[ ,[']PWT&]V!?#[]=-CY_9%_WOOR
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M9,PZXA1V4@UW ZEVPZ/#R67CXY$-%M1&X(A0IW+ZCT/.!HDB95AB ?\Q/.^
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MB*XV%PL1>O/ ZJ=5(IQ!4DEUD,D)GB)V01.20@HX'V;%_K;&87DWP0/#;\M
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M7(],B&A2BDDQ'KRTU.G$ J:**JT-*?Q"MW*TRB^T=OB^G#*H1-#"86F0,S$
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MIF"O!(XIU3JJ$)PU)G!-')\K_5(FH5>.HPV1>C$IYA24%CXJL.H40=R%7%F
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M:'' WN$K>"X(P3]@N/Y2 2;@1E,I&$37@1NDJ];$P8^("Y$[X;4#._KDF=F
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M&H:CT? <;KI,#_3/]H<S<J"=><TMLO_TP>Z.^I>J(^LE7T_]"%SL<#1N'GZ
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M(/)37#-,YL!#PLU@5\*LFF)E"WTI?3RV!9G<P6EQ;5'6:6J[I)K/-_76=?]
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M]BR@;'8XV@1TY[DIU&VRA37H&V+;"EEE=YLE&1?5;N"T/*(N@@ALFT*W^0/
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M_B\ XLA_.VFMQPQCE165P%L:C/JE0M@O.41"\>__=[NUOOFA_$)^_S4/#M[
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M,V7J59NZFX?5,JT=AC=5*N/@0WWDL$JPJCVG!K;F@*V-MU-&!T[&Q$@3LKE
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MMD_;XR<,+S!8\X+E_R%,I@85'@@5SBPE+*W5UE!$F.> "BH@ZQ4%P\FP@$/
M3MM%!W(>*<EV3C/J"49Y/MZSZ30N>^+B7N?P,)_B'A<0++7QF_#15>"9.]DF
MQH0GG/$@G>4<\#18XK 0*K@%M+:M7<G_C"M_O>_U/Q\>V4Z8!,+K'T(^OYY7
ML_8Z&^R< SLWI[-N3&0^V>00]@PCCC-L!G U!=:!:QN),.!E\A6,KRJ(U 23
MGH%P1YP2MH'2W)*/!.X(=5X;(9.AUA UJ55VK7#_Y%11(]?W+==G-I$75"=.
M/4J*4<2=3\@Y8Y%/%&PE6.VDZ!.*'EU7K>)Y1(\.CG(]TMPW:-(YHM2P.LP%
MH>VXXM*2Q9*>-RC><V9/=A=OC8P5OVRFM]/<LGGX=\4K3=A]+N"<3OL)0C,"
MJ(B8MCG$I#QRGD8$:E 1$ 2JFK2?%R']#Q L:J1_.:3_S&P*6E+/34#2:8MX
MTAA901+2!#LJDF?>+:7T7Y$3))Y_M&CJ2'9=$+F5):CU2S_ZV/D>PZ]-2&<9
M3E2-RU4#QDTM6H-4\YSRW%K+*%79*FN[G$5&O=0HL@0NGJ44.6T(LHE%)ZTT
M'I-7K]6*P(NJG].$;I90B!]D4ZL'E R#]_W>02.\=Q#>DXGP$F6DQC(@&PP(
MKR(6.1<B4AQ6#E-'A-5/*#[S[+-[/A9KXC[C,..-J;KYS-5;4C?<FJS+\C)8
MZ- ;Y;>/J?1BRX<MGD#+K45^F4.-).EQ-,1+KP7WB6F!>0S&Q2BYP\F6[;V%
M':H'<>H!I8JWFOW63@!GM_)]_U/:JC6Z92[=\F[:,%0IR$1S*46"P8GEH%NL
M<A91:K4FDC%KP3!D*XQ=- PO>$L/)TR/'/EJ8+6!U<4;YT03E8ST+%(>L74V
M!L(MN-G21*)8E32Q@".##: N'%#/C'7JG!,2C/48F4;<VX2LP P1K3E7'DQY
ML[A4_*7!U6+J_W<Q7*<[+I_U3WER?8G*B#?O>I>;K+=R/EJW&_LOH3W]^=9"
MA0"Y=U%IKEOUJK7E<$.FR,I9Q\U\,_ %L/#!41QVJL9&9SW#0SFP63?S9J6C
M#R'3W;\!U4H;ACP.##\L][N3L\:^N5_C8=6E@:KR/&O],O7@=/?.TER]ZK1;
M]>"JFV=>L9SC;IJKK<^3/BVY9?M@[(5=\=Q*=6$_S^+HJ-<IC>&G>Y>6]D^9
M*O&'[XX&^9#JF'1EG[]N[C8FXDR7Y?'%JWLL3S5BKCMB7C'/TO4M)Q5T0MT.
M=-)OII[II*_5Q>[O<S1<?WF-T^62-T[_:2/T<XW3<91)I$@(5I0+,%:B$9%8
MCB/7\,]^27LR7</[5??I:\4JQ('O=UPENWTPJ*;E.H]3]<\N3;*[W<D(1V"1
MC7S=0GV"@U4+\=S?+ -EB*F3&S=V.X-AU4]X#"GG!:_J@1[[@V?1]^]"SY.R
M3&\+K^W%0]]YXDVNYS0CMNR/UEGX</ 2#(DK.GUOULWE@1R]J1Z(LRV_9QH^
MY@M7TJ_URY1VW_JX-NF+75XX:9Y:-<,>MZL?C.V.NG/D6?>U>O]X;'>,YU/-
MHISKK$?(0U[I QZ.<MO"A037/FR\G]Z% 3I,D6%"A;]C/ZO!7H+KG^QW(.\@
M]R'-+N#$YT/T:3I]MVX\N/'UP_'&/[M.4:>9-HAZP1"GQB"3CU0G(8BW06KK
MR*O7^F*=A/\:(W75^'O\VQ!8L>YD#GS42:W2&[TT(IUFF4Y6*_&@ZFV9V_:"
MZ%3F(!B HVX9KE,?%\Z<V>J-^M78=M"I^]=7#X/IN)_W$@K/O>W:P:#U!ECK
MX*!FN5PVMG6<%5-N+#LUNTOW'=)H. )K?C3L=,?M1V'8HWY$'_[>;&UL_F>P
MVGJ^H+0^FA"B,XP'I5E\]CE<[WM<F?1A33D-MZSHN^^];L:#/TN3UQ4PH_UJ
M7EI8+PND!)I_M]W:WK*Y)625A5+;L74#V3%K@"U0=SN%18)EC,.9=;[,*-CO
M9+3)[OEDB;HEE%/-=<(N8TX:KWW55/B,<TK/^FS#E+[U-3N&6=#-UDZ^!<R7
M'%8 JH#54F>EM8Y&_<'('@['$P6H?=IVRIP*_#^PH)5;U&J#6(&9]J2__MIO
M_1*+PQ\/]\!OJ?M3ET[ >>WSW]EZKC5K-^X!;^;6H."N 5?V.[F5\]@=!3[J
M'.;6PA[0#;@3D,;5S8!7,L]V1SE"U8H'1]U>I7BK3=75UI?]6 W1[7R+W<Y^
MKU=V1&UA_]IGR7;DR:3G,NAR5X!N+,6SL%T]5WHT9_X?] [A9K T@- '60+!
M)(!'O.\#0DPS_M@R./]>F&*<^$X5QG_O /W+$*"ZJV[G)6DS/W]0W9*ZV0OI
M'>[U\G<?QKW>L%,YVSF2,AQVJQWCE59_U,U:'# I9+<B?T5%:J#D(7@A%5CU
MLK^2,23FOM) T2IB#..MMK8J006FRG0]A*E-72ZMF%U>P?SE92A0/_D#2I"E
MF$)C>O9&PXK".6!1EB>'*8KVRR V&-13KFRC2?  Z%;-^*C*',F?TZKP:*4U
MQJ5:[U5T#Q.RYUC/\;CI^@2/:J:J=L3S;Y415T VQ!RO 68;?]V!#?%I(]2U
M,KIY.(ZEZ1(*,[ 8K<$^R&UUROR<E]E*G6Y!=%_LA]I@S:$Z6-#L(^_!7X,9
M"Z9:W7[F]W&J0Q4/^E2;] 3_XGZM&Q+_8G\=OQ$NC_K5$KZK]4]KK3K60@SC
M*Y-0%9@N,*5/.= W:*WG*FX=N.TM\,-PI?7.YI[EAV?_#H__V\F]ACMVI;76
MC3_@Q?V.A1N^ ^1DAF^M'4YB@6=?ED.+U<?GX.&XTWG53AE7K ^$BSD:\-.G
M<^A15T_"ZW*DU(/.76G]W3T!K %_XVU&G!/P5(:=?N6>?#J![SAH?5^]U)18
M:8&U>?BM]:73!=;/@K4!'-WKYG;S_@^X!(-_BC#PFZ[UW[H1%N7M/D L4+?U
MZ0A@*$=@\R=\&L;O )A?.GM[V6<"=PJLD9@E[+QA.C$MX@]8J!R7JV0%C)YN
M1NA^ZZ SZ$9;@+E$8:L<EC[(<K_\8[8LQRA>N5GCUO,U4<[SW$&O\ L (.@)
M&'U0-;J^@N9G9MAU/-#: ^H,*U#(T>'R4(B'G:E_RF/4[RYJNP\X07G=2WYV
MJOGIO\OK.RF5^1W6TQ]$&"M'DZN1!A6.CV.I%7E+>!P^ Z@#XW[9[V1S.W^B
M[QW%B1>1%Z3&QO(4<$C6H(!5L)Y@28Y 'T;;'X]4'LIZ<SA9L@2_9,#/[N%@
MXC1G'H1UZ$Z0MJ9TV0P$/=5Z4S*2:E@_SP8SJ-T:]( /^D47.E"[P%1GK\CV
M(6 SZ*@:V(%7LJ4,VJZ5]X+R\O_9.X9G^M7$:L51]#;0N'MF0G4REM0F1"V#
M>;D**6S6#^<\J5(@XS 'U4:'8V>FTCU3JJK2UUE19E4-DQOK]NQS%1C*CDXO
MJ\,.3#G?=>:_P6@]WRFF>!VJ@-=V[7%6=,];C4RA&KFA$H%+G>]5R<U:D]28
MO@[>S'&6AK?[V1$"I"UP/E$O@\P.]6*69<\&";SG30^P!9@HATUJR^FB0AIO
MIF0MWRW.U&&P!2^R9%42<P765>-G, >3"\@>B[%4D"P+R2!3Y*JX;+5] 5*[
MWSF:A;L:RC-P'$[I@\RPXY5?%N?E$%Z>OP"6IM2B@;_B88:0UGM0ZBM3*PHR
MULM&\K[MIDR2R]46Z+,SE72FO3[YWA 6Y,_"/:#<;/\P_[U>$W,-I+$'OXY2
M@L?>QR[<^PD40'G$V7Z-_7_;DT&OQH5+'?![INZUM)QHB95SQE*MM-9+^+_7
M1^MC!JV][WHC(0<*0#'LQS"J\T@O4Y#5)F@5&G#]3MY$V)MLEE:%;JO=#!<K
MS1EK79@?:6T 4V=1&FNZ1@$T"N &V_V=*OY3(7B]9I6'>=&1F\I_+HYAUB)5
MD@O#8UUR(29:<]2@LE:R5&1O ,C2"<!#&7GZ8TUB]_:RQ3G,4;E67L-^7C)P
MAF..(\12'/TJC@9A >V3[Y\$XGK]J; K&&75)OBSWFKKPTI52O9M[S#O#M0;
M_Q\[@V_/X;-OQ,]3^[Z@Y \[J>-SH,1/4Z0*;%3D M_JVW1,%G!OO]"P_!#_
MWPBT9+?*Z<^8Y7,TICA'XSV9U=;:E?)@CT""?A1$ EY_B-VCF6*5;^$3WJ]_
M>/LAYPN.^P?4.T> N2]WHVASJ_UC8V^74ZD"X I226'$&9'(!1]1(L%AS%3@
MGKYZ;<PJOGRK* >R_N?]9]N+.;+M\Y+G_[\[8]R/L7*F8\@7U@[#[#],W3EA
M"/GR^.$$^(%YPJE3$?DD&>+1$Z299TAK39(RUF%"7KVF3*_R"PS1.L@V<;6W
M=C6&_'(6 N]/5J'<]BL88/V<P=8M5IW+0:(0BSJK8RY9DJN\.-\YLB5*E^^J
M@>GQD>9/F/J'PP]Y([\*RMKNFSR_!G R@_U#V__L4D>5@_^0Q$$B3C!#QA*'
M(O%*"D5A#>RKU^12O)EAC\XTE2LV6)T*0XWU80XW98-[4!S?J]FR\->9$97]
M\,YP5*G*<FT?%.Y$8Q;>RX9TMJW MIYZ394S,>%;F&F*.0$QFWJ=2@M=]1ZX
M-_[PV;X'";KX5$F"A(^<5O?C_<OL'('+!!H^%!-VO-LYWCG-@>\KOSW[8" U
MJW,D/=[69GIYR9)JR9,E?YK\>"Y9LA1(T(F F9 X)<)P1S2G*DHO.8UN29,E
MS]G(@-^]&QG*Q2>\:/)61G,)SL$HX+]7[G6.D-4/E=26?MYDN.SQDBG3SV4Z
MJJUF& 9T2K=5::?Q\UG5'>;LR+$ZJP\@+*":Q:S-]*F.S0Q*:9VSK]],V7-Z
M<Y+_?&]SB&<+7ONFV_/?7ICZ@NO'FUOO=@FW+,:0D*(&#*24/#($3*7(DO)2
M:9_P!9&QUAG!++8*:RY!P#"869X1^"\2P\#4C& 5'&5QZ8]BQ:NIES-K2H"W
M,,Q@='!@^\#P@\GA@,P9K>/]O#5SE!/LR]:0';:ZT0Z&+8)7\<1$/ZNMEUV\
M*[GRJK!&41OK<%]FSOH2J?8$?[MP-F8&>"Z%G)_38Y9^2F+B?)2&*<:9"\#5
M8"9D&XUX;JB] >341!RKDW*""*"G:X\&\;?Q#[_GE(ZN/?FM<U@ I#ST.Y!]
M#X"WUD'BZ,+IH?+"ZG(-R8(#\7%5&J _?>JI1NQ5?-D)S.HB>&2K5%Q]_=J'
MK[THQ*JZEX')/8W+]<TI<8OZF4^I#,/E9^GF^ZC*#GJDS[H0L"N?5?;AQB@S
MQ]==617GJ1)B#*ZM,:[.$..**F?/OB;^VU[OVSB_I-YWS)KHS][@*.\##NI,
MD[L4.GLQ74$NC7LPET+D@DML&.<A:2L-28Z /E:.4_:30FCL0NQMVGC,1N-9
MY(,\^=!'=1+[X!^V\\<[NKWUF;:_?L";ZS"W+_#,EW_(]D$;;VQYL;/^U\'&
M:;=[_B3VSGKXMKVUL[^QM7W2_OH/WUC_:W\;[,V=]7\[VZ?_$'CF6_M@FVU^
M^3>UIVNS8JT22<8B+!5!W&.)C'0!:;")!/'.R)"+U=-+HB:WJYATGV>L'T,J
M_NL&NN5>2[&];)BA,9& HV:1!DZI=\Y1P!,:2&")JO.EVLZ7VV]@YCYA9KIV
M/F>$YJHYGCK$17+(I5SS 7NGJ9$\2?SJM22KB^JO^KQA9B%6VQ,L&?<>7M,)
MMO6F.XJM=@PPKWXL64Q-R?UK0%)B&YBBEF(5N#!1ZZ0B_ /'(EK'?E:4M@')
M^P/)Z1[4+/@4?;)(A<005X(@@QU&1&&7J/!48?KJ-:6K9#G*9#\^#BZZ0O_=
MX/)1G?_+R?6_&V<?J+"1?P&+H!Q[F\HRSB'IC_N]$%L?!O!KTZGN.B7BM54>
M''="M.612$M3DM:!/8<#&'"Z42*/ID3.^OG"W#^07<-4\@(T!Q,J()XB^//2
M*Y1"9#: )L$\]_1=@")93!GDIZ-(;NJWWPU GX8BF:UCMV0[\T3\UZ1\X-Q_
M/6)>KK[1A_WO5B6G%__\.-ZP';2Z53J_/3S;L,W[NW YGW;(IXV<[>9S10^0
MG+,,+#$NHY/E[F*-G!MF-V<J]O/AT-$-$S7&-_\\+2,3O5^?_Y@^)55GB>7!
MZE3[P[VS_(W%Y)Y?NIF^@,WQQ\K'N3;'H3>X6Y;#>$G'M0R&^_U8U4D8='ZT
M#F""^X-6=0QW9A>R/MQ=,ANN6+0Z(R"'K<2L3GB*"0>,JGM*.)AG_W[>BW=X
MM)GPLT_IN-+D,T\T/^!]C6);!<7:%7J]FT&O1:1//'7R? )H_SEQKHBPT+LP
MUI0O<=6FQM(Z$Y?3](8I.3__W/NBV;41K$=-!;^2H/A^CG'+57&#&5R2<)\)
MCMCJ)39&[NB3!WCU^A?RZSG?8R'Y68V8-&+R_,7D%JKF603S;YBY-[B7U+WG
M'^8/7C N%!&4)YZ4==$''@.67$1EHJS#_+P)\Y]U4/E\O/.U3>#]ISOK.YV-
M]8^=S:V_.AM?][L;I]W]-OV';I^^$]M?V_A"!Y6M-P?MT\_'[:\;WS;RG/[X
M(. ]=/./SVSSR[L\WM?V5K?3/OTXO5=\LK'U3NQ28:@UTB"-&4:<.X>TP1Q9
M%JQ62G#O&(">65U4L](;*XEF Z !F>M !I@62^HE,0'SE*RU)"1!>-+&,T9]
MG;7'KVBPVH#,?8+,.&M/ ,CL<IN4\UP@EJ1$H!  8Z)*R+AHE&:6<.$ 8\BJ
M;C"FP9BEPAC.E>31.RXLYX0Y$P25BF 7A!6"-OD*2V#('.\23$4, "O&88$X
M20Y9S"S*F28Q>F48#L6(H0W - "S3 "#2=)2&>MI2#QHZJB0,5I*C4\RVI]U
MB6\ YB&,F.-=KQFW6D1$F * 2=PBEVA$/FCK3-3.J<J"N5AVJ &8FYT[F"_F
M]*S.':PV!P^N@4@KL7&*!(T)Y=8+:V3BQCMIK%4TIB:8]&@0>3(=3/IPNAO
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M\["(RJHY28-IY#PQ;;',W<-$,CIJYGZVZ=VPR'VQR!IMK^_M$F6L=3H@YZ4
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M,5B.%<V'EB5=<&O9!0C. ^TB_'3"=SP1V&!L@['+&01J,/:6&'LZ@[&*21I
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MZ0DTO6QQ]V9S:"2CR3(;F2'<F6"U2T1$[@5W4FIYFQN2&1-_OF'?!4OPL$@
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M>)Q%.@F/G-<^-R[$3*>%P5M5&GJID8%JKI10)$ABN0E26Z^=UI@*D("6RRI
MY;5@P+33@VA%&648*8\YXE9P,'HD1=8(KIADTDJ\LKZX.Z"*_Y>3_YV//!@%
M&Q ,#\G"L1O)5?(V4>8MOFND2:49O"Q4N'2#>#!R";8*@3#PB/.< >ZUAF./
M200A*2:LT@K>!BI$(BE8#%'I'+8*FH!D&H2"HU$&J^VM7"$5_[\$_K]T>LA$
M!9' ^HS0A#BV.8N>)$1P5#1H)R/1*^N"+I-&<-_FP3>7\BKI1B>.&0>AF*^
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M[USN8B?5_NL)FZ:(.T34CI%L6/;TKW+.8T5'OCTX.P-EAM1WWX%BY'%]]^3
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M7FJ8NZV>&=OA_AKFT,X96B[L--<T&&0[:+2^X1?ZG=,_\MX5_HKQ']^ ?KK
M#5INR7&7,.\@*65<YKQ#GJRT.@D?F(B4>R+"L#S2/'DQ*28N8K<3;.^H4FP7
MBON?)G'?2R892Q31D$"QU08D0*(,^22IQ$Q30N7*>N&!IW\N2+5=',<\=?OY
MQXX[SSG!2Q'8=5/<N5Y[[+#S][;1_99#+^J@\@W*>^"/0 3^O/SWTKB(=[=&
M_$[K'[X=[W__RG=V_VG56Y_P'OUZGBO^;[>V+O:/M]C.AV\G^\<GK-Z8=1'O
MG>U_WV[N[QZ*.J#!_N;GX_W=?QK;=(ON'6^WZL>>[W__W-K9]>?_R>O8!#KQ
M 38U!*15;EWJE$!:2HN"98%HFXAV5XM91U#45>+,.<Z=U=K2'-\1@G(N,9JN
MN)2?Z(@O4PIZ;_I8=_<.)$Y8L23@'&U ',X&6:LE2CX(#YLIE8JSQYHC\FFN
M7AI(X%*$G#%**2C9U%NNM)@]UKSOM6+C:Q/,-1?]GB;!X-=T.;U@*ABWD0F9
M,.9,8JMSQI))PED&3\N5:][SZXV:?@\,Z^ X!"=&<4ND2]HJ[RGH,F /&[ZD
MERX?-C8^EB6H<V6NRQ@VVQM5EO:QK$Y6]GQR101X+'JUC:H?U7J@3177D^WR
MAK*(";&-,C<]7Z*G7+^LUFQ8UVCF*_G?X)OQ9Z-?CO][?FK0*DN/E<'KS?/)
MV_=1O'I1_MSF'@$YYJ(SZ-5:MGL"[QNV*6E=4F@16K=6*Y8'RF('R#J+[T;O
M*"?(UXX:L6N[_BA+_*(G1PDIL"1 G;-.]V3<7Z>154?8T/+6%>9T4NY,,_Z(
MQ9ULQ^7$^]'*B@8HIP.PJ0:]LO5F.:F\N,OM+5($>K"QC5S#O-'VS4&(B[^5
M&JH^*!M-?P@^;4D-1RH_RGWXVOT_$-&%/?P<E%CT3I%CY?#II_#GU'81OE;<
M6_V[.&=20Z-SO=+/K*RA!U,\/"]*[OW?H).OWPO2!JKY81O-83WWLM)Z'%)M
M60FOD3>^(,/<"JT[&);N&X>(7A;)RQ3]9W76CW[6] YGW1DVDX#Y3Q_[E<->
MG6B.$1O%8V7Y?8"Z3 ;MR]^&@-*,UY+!N$3C!&)[F(.+T^4HP9HZ+&.# 8WR
M4*U.B,U>?F$Y\WDK:\3>GV5!TXK6'IO6V!UH;=">H(SA0T!FO4:_?""W7XEE
M8'<W9Y*!O.WWLV#.+3G&DK+L]7 ^CD8:"^RQ='[9F56_;-(WK-/C<XNR4<W4
M2X$-IS#4(B9YJV5APVRS6<8:AD;."<U*1J$$C'ETXH&1?G%>Y./U!L#X$R\L
M=8<<MS]4;.8]F4_0V3RG87!7LW.6HR/'BD<Q[6'EV-Z\MBF3"[C4C-9J.X-N
M<>R]7J$I#6=_.4"9?FB+;C4-/VC:[NA=-XT[KH<-XJP;^^>CI(->[7@0#HMO
MC.+6RM8MH\8L.94_OW@T_,1KKQ(G0%P&P>%[P]HOR[XNUB_S9@O(TB4O(/M+
M\VO&7!-1NZ@(6($^<9ZL-='XP)D'VTY'HI_=7)OO4?L<<Z_:S 'S#?/>J\9N
M6U2[+@"J2'K*UMWJ&-$G@F-'<)%KM&71.9G_Y"8ZB -T3N9MM<NTYN$.%STK
MG\YWN5%,?WB68:<]/NJ_\CS>M*]K<^L@62EPBA0)J3GBA&%DJ5+(*<GS59%E
MX8JORQH5%+&<.PEL;;"52>3X6.9$$/#)<[DP_WU)G=5QSW-M'AY$(I6G@2$I
M<FT[[@/2F'BD2#+9^1=<NG+<.LI$-/-""LDC3AJ$@7#$1**"3T;.'G>NTC!1
MZZ,,UAVT0%$NW#WS"B1< S$C;>06>#(TZ>9W%)N);O[CMF[6A<*QO!4:SY?"
MO^:XZ2.33$2G210B>HZI,3PF9Q))"D>0W?BZ]_SZJ&=(@^&@@4MU+EZ8G'6"
M$!J$HD!9V BULEZ[E>KX:_?TO5?TRQE.J5!E>'B^\!1SK>\7%7W.<J+^LT>?
MW_&/U81?_X3O$3,VBC; .=9@XB4W?'5.E%-IZUWANL[ITYL=A5DV=()?&_KZ
M-M9/W_CZV9M=_VZG;YM3JW_&7*7GVX;21+T%%?PJE.OF2*U;T,XO]_(A8U23
M?+Y)7L-7_ E24$J^NNZ:2X[TD><(I?W;]HY*[WG^(3NSP,(L+HH?QP3,5U2_
MG-8<SW<^:,36YE@,^28C#["R_AOY?<:K>X\L@-<6&SYOB:\FNEL['[3R449-
M. [<L5P9A HG%?P3\/SFMW?*7<P,LM$.^3_O+KEC3M#@\L1^W].S5L9^GYYL
MTW=D#^98WSWD>Q=[>'OS$]_YL'6Q1[\=[UV<P.<;>)M^)?NSL=^M3VQO]UMC
M?_/PY\[FT?'V\2=X%L: G_:_;Q_O[![^K&]^8ON[WYI%SL^7<>RW2X9JQ312
M' O$=<K],[5%(45&C5#!XK2R+E:UNJY QG,D_MQ3:,R*O0J=7BDZ!1T2L\H'
MC@FGD5N5K#,FLF!EKF]_.W2Z+O>D J9' Z;+I!0!PL4;HA&-N9R93 QI9QA2
M#+L8F>#1I84EI5305$'3$T&39X01Z14/N2Z?298::X3 (AH;1 5-RPI-VY<Z
M4^)$VX@UTKG3.-<V%^F4"7D2O9:Y)9,-%315T+04:[L#-$6JB<R59K4DW#-O
M$P!0[BNK@G"4\<JF6V9\NE2=M S4@PV.A 2%*==T0)HY JJ34HD9&@+!RV?3
M+<1+>$,Q!T*+2\*E!J+B3F*F[/@P/F4<CS(O N6>V==7?;BO&KSOMOA7 ^M/
MX*HK+Y$J&'\HC'^:=,UQ3XBPW"/J? 08E[DUAE+("F*]U5)*$Q8$XW?BC,=6
M/W]Q5U5A6X5M3^3HJV!M8; V46V&4B9X2D@E #,>E$"&&L VFKP6DB9BZ"-5
MFZF ;5E8O *V9W435L"V*&";< L*DX31EB+E*49<)8$L31%YAX6/23 K205L
M%;"];6![ B=CA6X+0[=+M<U$$1SF#N7<%<0EQL@R:1#FD7.#@^2.O21K]#&"
M$N\55CD<8V*U,]40%S)\-<67.L5'](LOB22])C_A,AGS(='IRQ(V78UQBS&>
M,5)\3.M+&2S^W7:[]H7&AM,J-OQMQ1$LYL+I.M_%3JZ%-2$<*CW_H7J^G[QU
M8CP:@WEVSS+0\XTD2"?L4<1$.IU<]-14P4T5*"W%VI;FIJ@"I4< I4OG@P25
MD4AC4!#,(LXU1EI'CXB4@@DB;/2B J4*E)9B;4]^RW.C,[1"IL4CT\2ECU=*
M.D4MDDX(Q&/*L>#*HJ $ W&CK:=L99VP536G37H%3!4P+2<P/<$M305,CP!,
M$_<U2AKG!$:).H:X#A)9!Q8=<8)C$;QV5BXA,%51X/.CP.>6)EQ@*'C5VZ_J
M[;<L'KY**"Q0*!Q.57N@26$A$^+6$OB7HLCE7Q-G5#OE.,]5LE];I[^G#6.J
MD+1"TF5Q2U9(NE@DO52O:;3$..%1)#D'G%B.M' &>1<PB])%)FR%I!625DCZ
MBGRI%9PN%$XGW*C&20!,C!'FP2$0A"%7^PD(SM%QS),G,2[*6U&A:86F%9H^
MOP.X0M/%HNFE<JJL@7.R%@FG->*""*3AJ(H8'L]9,M+X5X>FA>?X7T6SB_7G
M:'EUNQXKMVS :6[1?],L/AI5K-%;-;^<'PA*U_0MBP0O=-+Z=AO_.9YV8Z\H
ML)S; /EKRR\7/:%CK]]M^-S\=?S%B<\:[1_P2VLX6&ZDG=MS'L5FV1VZTX[G
MH^:<"7CEY@Y!U_?F?/TD07^O/4Y(\^V(8H8FIJ]<KI66O2,+3\T(3"Y<2HP)
M3SCC03K+.6$T6.*P$"JX^0)S:_O]7:IG-6VOMY.&P> [W<]Y*3N#?J\/] F$
M,I:9^(7*S/NW&'LGMC>SX'.4@PF((BDRU4Q")A*/#/;>$2FUM@H$WZK(LD_+
M*[*O5AYMK='K#8I62\"\L>RI>U9N>LT>=F/9EK'H,3_H#5O";W?ZL49FF?F)
M>I<N34/'W<L&:T5'QL-VT7<M_]J'[>NEW"36Q?Y9C.U1I]V)GKF7C7(ONV2[
M>-AHM_/]YI6VV:<PR4Y8J^T6W9$+#&YWYKQH@J^'[PR#XL8T#]<_@@,M +[7
M^)FQNW^4&][F5I+_#-JQQG !TZ3X2N;AU2P)3F/1";QYOE:[7J2_^./<*H_%
M.L#(LH/P1+OJH8 KFZ.OS@+H;*=CE_L<-]HEUF4XM3]LHUEV1&\7$K73_)%)
M9:KK<8B9W?*+1PV'X47V))]=T;9YU'EX."3\WG*-=OE;T4ZY'[MMVRQ> 9M:
M_C)L4KP*?_;-01@1@CT][79@-;D7>[?1.ZG9D'>_Y/54=-QN(R"Y8@EY.\J6
M@: YA-S$.#_2NT>?[86=J7F@ KI,5 ?G>CQHEW*W: M;=&[L1MCIVL8(@><"
M\.IDD\=:T7.H^#L0RQP(+[JKN_-:8_AIT4T6M)/FJ''U4:=9-+8>8L_9* \+
M=L4>PA.'F5KNK"P0;P,640IN&(\,ZZBI=EIRIZ056&=E@1A0%O""E86O[2S:
M8GC#FL(6JQ]_/; >=(4H+;+24<2-MLA0SY#W5'%'=3+>WD93@*,O-KJVD;$'
MI <P2\>?%#)I1I^<HI\S$'" B'!PV9Z80LJ_FF!DHR\>2"\'^W1"[BM_U/!'
M&:\Z71!^\,S0B 'XZV>2+D 87I71:XA]1?_W/)>2(^!5\7(NA8E2_J%SFI_X
M?[U:MFY.8CG4:@%NX^>&S##^:OQYVNB>EXN<A.M!>T(^%/WE>[7!D#]OZ#)_
MA;FZ\7+ZH[5ULEU1M(O/4[-MT)^:)4ZG+"+RIJS!*4Q.!_:K"Z^)H]=/C@=X
MGN&C,X#OY6>+5O>]XB49<SJ#9F'Q#9IYF&FIU#P'1>40D&/. 9>JW6%>U91L
MNH=@F*<D+$\WXZ\31[V53QK^W&E[>*I8[YMN=GSL#[+G3<J4D @ +=Q%A;0(
MN7"&HV"24)H(N=*K>AF%<69Q?V2!I'N9$3J#[FW:)&=UJ<2L26D,4-"K#?L.
MCN !H"5$$-(M>//L" 7/WDXI+S##]H;-GWNS79>OUWI>5]M=SM@2]%A])4UA
M*7M(4UAS_Z:8SUIWX_V0\;X X]5+QGLWQ7BWZ9EY4[SV7:I'W.'28,FW-:/5
M;>J8+*H%Y*O:.7P+FKN16U]819SYU[=_V6;I=RC,CBF_6.D)J\K 5X7WKKW1
MO]\%Q9UN],?V0_W2N/O>Z!]=L15ZT\9";]JT&%D?Y\58KR40H+&_N4?W6GNT
M_GV+[1]OP/A[%)X_V=[\Q+9W]\C^;OWGWNX>O1H( -\YWF_L'^_]A'>TZIN?
M6_"SR._=WO1D^_A;LW[Q_@B^T_S/Q=9DO+_1.EAK!8HDUUJ&\T8N$HO@<XQ3
MX(%'\SB! *^T(NE;Q\;7"X\1IX1MH-3D+)C ':'.:R-D,M0:HL8NV0H>7S@\
M3O28##:P$"Q2WIE<5L0C[3%!S!#I@I2.RWQ=+%>-$H\-CPL-@WKF$GK/P>I?
M8K_?+&]UKC6SZ-V6/!?<EP_D?KL#RMW+2?S$<'<-VDT<<(5Y=\*\J8;?UBN@
M\R@0Z(6@$H+BAYP)$@6OK:'>4&/LM2KA[\]1$F#1-7HK%  [P'@NE$Z@ZW <
MG9*)2R(28=9I)PL4P",4P!4*O!(4F(@0]PI'(@*R*F#$*>A V@2'A,+,)V&]
MI'IEG:T*O"0@\/JK8,]GZ\\1)G&1[]?: 5BZ._KUT#;:O=IOS4ZO%WN_K];:
ML7\OM6?.EKP0P'L^K>>Z;.L%0]T'..)_P_EN%5%J,6RUW]EN=OA6R'<WY)OJ
MJN@CG+Y-$47I0?\Q##2AE"RRA.<JDU8+L_#$[27R?+UR4'AB+2@'!<%/SZ<.
M51BQ.(RXU(ZB\\YI01"AR2/ !8QTD!2!^"!<$&Z=(BOK?*Y;Z/;:T0+!X1&=
M/L5\5!&CL=2*TO3E: 1MZ>[7HM,=6JJ$Z2?8H.46)W>0)DEZ' WQTFO!?6):
M8!Z#<3%*[G"RQ?7JDZN6U=7!XD3$UTDU4D67J, 6,>(9XLYH9 75B'&6(B/*
M1[:X2FH+9[LE+QM< 7 %P'<&8$(T4<E(SR+E$5MG8P!5#2Q]:2)1K(QO>19?
M9H7""T7AB2IL4C!-J$%*2D!AS@&%)<W7&IIXJQ,Q65'7<]V8+Q6#Y]2Y^-=4
M6LC29Y>4_5DWVN'F-!/XPG:GW9UBG?S\,+_$'[4;_S>(O=V\$V\ZW>1BZ\#0
MQ+6.#K'$$N(BW^I)L%T583)X8H2/^,6DFY0Y'$5:;IEX,6BU;+=())])(IO.
M\E@M/BT3N/IC^ABF=M^<I)8SFP?=<6[*_#RUF\MX_/$T:>!/G(O"S"B+XLZY
M*""01WDL;ST7!9291]J*1YNQ?&E[+-5C;<4=4JJN<<31Q:3#O*R\C2SO:[=(
M>7FU&S!65M[R)GRYE+QO>1M YQVT3LO<_.Y]-Z)"EVGFBF^9HL86T%O>A$G/
M2ZUTO;SE[2AVH/:YR-9?,,B(UQYI-6JQ_GBY,J_,%_UV<X6,33HW0 HZ&:Z-
MT3BX8#FWR3H?7-6V\RZ.XX[8OCC$>ZUWY]NM=V0;WKE]\=?17GY^<TOL?_AT
MODWWQ-[W;XWZWS..8QAG9_-S8V]WB^[M?L6P/E;_\/ZHWMH[JQ\W3_8WLR.Z
M>;3_?>ML)@I>:!V<E3G@U7+$@P[(<1-1\M@JRB60K7NJQ,BGOIR[;838+<9X
MD54&KHD?F:RZ=9M"#<NXKTLG3;[,K>#UJ-M[B\#&AXGL%R2Z0,2XV)V17E98
M +B4'(@K;G-I?RR<-RI2ADFPUS3O8[,2:J0O;;1#45JP-U&(>.)^M%!)QZ(*
MT4I6W4I6353S#]@)+ZU'$1N">*(6Z20H8LS2J&(*VNN5=4G7Z N05,_!'O^]
M<+Q9B(UTVWRU:HQ7G;B\,:^2Y;TH]FTG0-Y-"!)A&%;*9U..$^.T)RR0@+E5
M+$0:*B'X[$+PTZ00Q(X(G+Q'W.<&82Q19+QC*,><:"TD,4JMK..'R\#%Y"R^
M'#%W$V@\;JC19!>$DA^H8-Q&)F3"F#.);<ZW2"8)9YG56JX,R^L.8MC(3I1@
M>,[8@6UE,G<TMD;A2'D*P;@@DWKV&)<K7MHBQF4RJJE6W)(6GIW:!&#TGB:8
MY#DB?+;:M4QK991.65?:%@%APWKZE[5EB\XZN:YK[B31#5>*S!85_R]WTN4
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MV\*2I,3G1-H@N8G"<AN%",FF%$@4J>AC=A4#?NEA^/6X2PFO6?*"!"G%#1B
MO@L["E9H;';.9M6T[I!"3H<4,FKDY,H""<4'_\H]'B9X>-QCK34T7W.'Q=*.
MS&DQ>?1\"52,>RG:>GWX8,&2[<GWE] B.O=J+[G2;TCDM$?AR((: OO1:0'$
M%NT%07,I.N/TXH_L";@\I\O&P*"__&AT!CW0((:*RU##OVPO.FTD@V0<?A'$
MYF2?PG??_A=8O]?+YU/[K>RP<V2SRA+;T\=4=+R;F'F1BJ[^[$V<7^EQZ('Z
MGPMG?(FG_2*MJ39,:/J][.]UN7(@G2; >SE\UKVZG:(39R<W52SZH8U$>FGD
MQ]@;OK46AU5I2I=%4;0,/H/)7VWF.>$?6JV]^]')FF3Q\JE>?CGHLU%0\T0S
MOTS$(U?/<":7I]')\_T!3#+^"I -6,BE%R.[..QP*47"V."TV./Q>^!Y4&%/
MIP<M1ZC%847"X4M!P1D^!A^DF(V_WNNPAG[=]-4V>QTP3;LGO5K6"K+27!S+
MUX_UOV&7VP6)-(J&FH/BEF1(*V#D3I';F%Q+[1LH^ZAQ>CE4MFLM')++$-\M
M^GG.?+-H"5M\M2#<<7/'^!,,\OXE$?1M#^;ZVVFWD7,,8;J['S?&I_[[<-"L
MNW;&CP!.]#L@;HN.?XVQ+RN6BX<9A8'O7SK@BDD7K4F+'8(!2KXM)]=IAMFF
MIT,L&*'+BV@=]\4?Q3!HQIUTG9ZX9'FZSZ$B'A[(D$0D,:&DK$&<V(2,3QYY
MV'$9B)2!RQ>;ISONI7ZMFQUL?#<HOPS\E%6+*]I* :*YU=0PNW:RT=O\Q-O9
M7F_W:/4V=N8^;79MF19::,W79-?^]W59AXJO"<.O_3->(]?^[:9A"5Y36-QK
MV)O_QA]KLNI6PPX#=MY<0LA4L\2WG!DS@H[:"#7F=11[)?DMUV8@QEME1STL
M+O A8<]/%CH]+YCOK11*W!BYSB]=['/+1S\X1&SI5G[G,ENO,WM)1.8EDPE[
MEK@/QK) G":&8C"YC)6WJU1X8_;2B,8^CTEL._;_+J\(ERAMZ7XVP# *[JR^
M>R+V+C;.MB^VR-YQ'3[_1/>.X?V[[T#__TKVX3/0_8_V9NM='6_\W-EM'M<W
M-UC]^%NC?O'Y"-[7V#[^!'/ZUMB']\*:28Z,F^GGYAR54FN-E+<6<0[_TIA[
M9+A)FCBBDM.Y,"T7BZIW]8*J!E: M$QKNP,@^6SX*F&L]8)+QXS7*4D@=*D"
MXX$M()VR J1% M)E6*YW) +H8)3@^!"W42+M)$9<4JD,8<)(MK)N5KGB2P1(
M"U+W7XK&]W$F?*+PI72*$)91V,[08U.U$%F\TC0-1,.S>%<>Q48[%*%$I6U6
MX=%]\&@JK]N![<N\PB@(!7A$<QU$+&7VKQ(6L(R"II5UHJK&'J^75>^O3E2L
M^NBL.E&[-Y&0&-&(Q$@1&# .V:@I8BE&8%D;A7$KZX(L$:N^,4_1#7H#G,>T
MZO#&>JXNE[OE)J3:'I]4!59W JNIKF%21.DCZ!41Y CBV !8<:I1\$Y+3367
MG&;'B]1ZB>R<*G%X:52+BI>?F9<O%0]+35!2)^1B8 B.T2+-O4#*.@+ZB(M:
M%4Y4(9;09['0LGS/?5?W:&,L2%%;$NUL_GWN1'&X1ZT6\9QCO#%'W<9,5M-#
M;)S7=@,R;XFO1J]XPBO9CR5I50Z,^^@1?M(FB%RX())&QDF)N!,668P%HMR#
M DB83=:LK)-50]D2^3 6)*(K*'JE4/2$E[$5%#T,BBY-&J*C![G!D XV(,XP
M1KE',0I&&VRI=)'RE76Z*K!9(BAZ8^[4C:L9ZI77]'DUHGP>$W94A43W0:+#
MJ;ZX7B5LG 6EB,4<H1:0AI,"]8ACYVW0@JJL%%'Z"B/4*O9]6BVB8M_%L.^E
M(L&CP3KWL9::.<2I],A@AY$+&"N?6ZK"B0'[BJ5BWS?F)OH<<WYJ+#+(?=,V
MAC5G3F.W8)ZVC\C9G,E>%"<]G"DH6,6+/%)HU[BM\_M.]_V@/^C&CYUFPY__
M%=LQ-8H:L5_;^6[G[^+,X-?A#R&G<N9#&E[Z5 !V)P [F=(_A)!6:8:HB1;Q
M:#5@EZ4H$9RH]Y0"D & \66R@ZH(L*71/BJ.7A*.GFA_P"S1,AH4 _&(AY"E
M&W;(Y3*1!J!;L'Q=R\02<?2<PLFOK>#'M<G_W?@CMD=]MR]#QVZ1^Y_UF5Q>
MI7^4R^"7;;M_YG*!_:-<_247MIW*9QZ5B%M$!8!G:[#-QYVA[]Q@FRKV2#V:
MY:.UE7ZD-MC5A!^]O?8=!IX?JT+90_K4FA=:>.#]$-1V"U"KEV#V;@K,%E&7
MX:5OSQ= ^E]OSC5!4'PQ#9"O+1VPM*WLYN_I+6M]_'JY;VO/\&+KH[S(WHB/
M0U"+HJD7N7-S*\W<!<%>1?69SZ554)6?J2;YV(5\'L9;+SO&H"BX>%EZ?53'
MLJKM\T9*:6B<C)?)&Z\T3R2ZI*0D6I%HJ8D<#RMY\JE*GM=?P%[$;B?8WM'5
M6O"EC^>5^#5/C_9;>S_W=_?.]X^_\OT/=;QW?/)S;_?KS^WO[P2\]V+_P^>C
MG0_O?F[/=K1KO8?1WC>WC_]I;>\>G>Q=?&[L[+X_VL[^T-T36./VR?Z'=WQO
M]QV>2E7?W:([&P=".B,3#G 8P2 N\VT%=A(Y91DUR@L1PLIZ40N7_KE$%ZY5
M19\*AFZ"(9*OV7# $@?* 7JL$8QC::25EFOL"QC"(QC"%0P]-0R=3\%0=-PD
M[ 5R/'K$>8K(XN 1C31'@S NHZI@J(*AI5C;'6 H,<R%$Y[JH#C!R6FF!6=.
MY3IYD>NY=<TK&'IZ;6CC0)F0&(L,!:TPXI@!& 7C4*2>*DL3=516$%1!T%*L
M[0X0Q)W4W#(>@L/<@YRU3DFA>-0AMYDS0TV(W%(3NC$BML*AAZI#&P>6"4TX
M-RAP "/N"48&:X^"B18^#X)IG@-@%5[" -C'\"J_%,_7QZ;M9TXIBQ2-NOGT
MKG6!5=%R(XAR5&NI) G!:FYB!/HWF'$!5H$/(L4[^HPJB%H\1'V:=1Q%27#$
M+"&B$LWJDD>.1H.P!\@RQ"0?0%TB>)7)!Q<DJB)=EY=W$[.!:BH,I893'4T*
MQ#*950Q*B$QW=+14O/LHO#OM;0DJ$.("10"T G&E+3(J]PIUT6(NI3)>K:PK
MMJKU,L6T5KR[:-ZE,BD</,.:<AR=$0%,72U3))('[^[HG:AX]U'E+LA<$H/!
MDB A,/"MPQ@Y@SV*P+=P?B9)BU?6J5@U_!46_*CX=L2WU$M#/09UF5*NK75<
M@<*5J+9>4*%E9=(O ]]>FO2,2J-!'T)4A8@X"1SXEE@4I98")ZV,I#DEC*QJ
MMDR,>XU13Q\2SK*45=ZJ,1ZM<MZ;BS,<)MP]J,_=LD3 56/<8HQ[Y)J\MJ"_
MOSN]?NZ:.\R\J_T6?_KFH-?X433;#O&T"\I%&1"8G:.VE3NN7Y0?C!+T?J]*
M$5VG[P5&P2H36E-G><+)2(RMI-&!_49],+?PCY9*7?QQ]$<^JT[ZT.F$G*OX
M9>B<_M)IAG?YT/(V;DX<&'QG8^*X*C7P3FJ@GW2;LOKA 94Q!>H4TI814 4%
M029PBS"+5/(HA;-A95UBN41W.U5MHMOP\V]W8&CL"/?6.*PE!H;.WG*O<5 Z
M1D&(=;=PFO9@P?#3+2RYBNF?GNG/IYC>,YQ""@89GOTVQH']YYA&G";"C#=!
M&YF+(Q)UM=?,%;%8<?RR</Q=HN*=-<:K&&G 7!D#XEP;'($P)'=$B45X6BL^
M?S[AOG&0' %M#&1Z5-@C+I1!5G*-L*6:**LIED7=,FP>7/BG8O3E9720V=IX
M23D(=AZ$=\ED3VP22G"&V4*BK2I&?SZ!OG'@M*7<)8^T,PQQ3!W2Q%KD+*&)
M:9EC'PI&5\NDPU?Q6>M?8A,^/%RM'<9V[-IFZ8H(K4:[T>OG8*T?<>R,J&*U
M'MT7,;I@&A[+A_)0-@"HIH[D==4O>RK$.KSB=TB*)>T9"CZK)X80P"^B4<AM
M(ER0@@6ULJZ7J==E=6V\:-WDX5Z'BG6?@G6GO0>,*6EDU,"PG"!.E476V82P
M\!1'.$<=],HZK3I*OV+678#_H&+=IY2Z&P>*.>>R!T 9(A%G%B,KF$6<<.Z\
MD2*Y '8"H17?OEZ^78 [H.+;IQ2Y&P<R1<P=32A)#9HR"%^P[V7NU4J-5B*;
M^6YEW2R3N)U3['<XN>U!"VC<E[]GRFRT!X4':"'E@(=<P22PS6FGU\@#_U'4
MU 52'):7';+,Q%/#XK3X\A'K>IWFH'_](U=*K#T]YQ=EAQF?WHO)?^?IEKRF
M$\>,&QZPY=13$-7*\.2X LFLDS\@1*^,GCH:NV1.[6%$KAOM";()EOB';9[9
M\][*OZ;K!S?::'+;9W?L^G,;S_+)PZ**K=ON]&.-XK7:_\Q08KEIG$2K>9+4
M8,H)X0ZK'."J9*X:9(TJ<16>B6$C^T:QQJ#^>,\-53R"0H1M%/"!Q 8L7,-R
MO;<1?>42T=G74_2QKOU]E#M2].9PQ"R97[^7<Y?PZRDM92GM[W&TM;;9/*_9
M7B_V>K7.Z6FGV\^2+=?%[G=JC=9IMY/C>4:)C;99 _R*/O-Z.S]25-M.J>$;
ML>W/\S,N]H&0:\4JBWK;XV+<9XW^T;A.]VKM[*C1'$^CJ.C=J;7L2:PUVC]B
M6<>^!S\78Q10D1,K5VN]\UX_CGN/=$YS8>\CVZ^=17AULP'#UVPWYJG#6FR[
M/RK[W>RT#Q',K%4[[("<7:MM^&X'5I!%\&I^&LX)7AM#K0.S/^Q&^ D>+3^M
M69C:<:?;Z)_GX*8\WE&T35C/:1-.SQ9]TE=AMD,W?,T#=-O&Z"_YF7??_K?V
M$7[-TRH6[_-F#.N7YZXIQ>U^ [8R3WH45 4R/MK6N$;YWYT64,OY6FVKG>N7
MP^'%9KFO\-?>: V-W#.@5RPJ;V^65?""XFL6OMCH!I2+GY_7X!TAC]S)[VL
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M=&F:+X P9SQ$_@BD3C/NI"G*VVB'SV6WFQPZTMN%5_[5[/B3MT> 9&?WTP'
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MQ&9!"9H03*(&XF5)DQ-]76'\D&&,-.Z9 2$EBT 3&$81O5[Z3+6WDE:GP#U
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M2%O;N@_,5!*M)%I)] &1:'78KH%*%_(B7!#>!D%P[02!' )Q(N9BU=M J=$
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M"^#5,NP"%RTK2]YQ(9).1&GKD8N4)-XY0U121J**&V-*Z[4,*Q-5)MIXDYY
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MBG>2<DT,<$.DH5H$*FR0I2^\O$G+J(K\[FH$ZRR;4!G@'C# UT4/""00(M-
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M0$H"P@#QP7EB6%):!<ZE2%O;MF_DC0O@/A9%K_+>0^4]0(LV"R$# P%1>0?
M!(^.>2JECK[R7L=Y[US=<]E%:W(B3/'">Y"0\B@G+@@F?,3%51;5/6/ZRMRX
MP4)EOLI\]YOY?,@T"RZ$5@#*!2=RE-;SR!S/W,7"?,Q6YNLJ\[T^U_A "ZHY
MS:CQL4C ^42LBI8D%SVCWC.@<6L;^EQ5UUYU[3U:UYYU2GG@ DS6@%/@%!,Y
MA>1X3-Z95!FOVXRWN]B$@/&8(W?$>\F+LI>)LUJ02(//5%'I)-W:EK3/8>.<
M]R ([[%SW@.FO2PM19/64J7@_[/WI<UM&]FB?P7EE]SG5 $,]L6^SU6.[22>
M.[8\D9W<Y,M4 VA(B$F" Y!2E%__SCG=C86+)&HEJ9ZJB6V2:'3WV?<@]V([
MXZ[C<)NG3IBDL69[N\[VNLD /(@#.W-2"\#G67Z$LU<<GEII8$<93[T\]]-G
MKT(S]&VMZ6G&][09'[>+PF:YZR:I#X:1GSINFL5)$!:)RQ(GTHQOUQG?EY;Q
MV6#0NDZ<6ZS(;&!\;F@E;A!:J1_P#%0^%J0.,#['=(*]X7SW,5?[.HF>>@V]
MAE[CP-=8SUS<RTI&KYOQO-.*T7O5EU%T0NNUKU3-IRXXJS?FU;O;W<9:97&O
ME:8@#]W0C?.P2 ._X'::QXY3Y$5NIT64VME=#?!\(Z#Q.P#C*L7IO6K2]P9
M>E3\5%4Y_OI8=A8]KL;YN[_D3_9C)-T^Z%]?^MG#>>R"BN4'5L(CQ_*=(K92
MVRLLA_'8+^*(VV[\[%5LAN%=Y93LD&FIF4,;,XSC*+8#WTX &8K0BQGGK.!>
MP8/<">-8,X>GPQRZQ(O42[CM^]QB<<; -O-C*RDBL,VX'3E.%@1QX#Y[Y3J)
MZ?FWG@BLV</NL@> -(]XX:&OQ7?C+.$\S.,\8$F>!T5P9\._-7O8>?;0RT=U
MW"!S0E ;G"P'W<$+<BO) V[9?N;"QVZ8YL >/-]TW5ASA\/E#K<=KZJYP^%P
MAY[RX##'\<(4+(L@MGR>9, =PL2*>9'E#$L00A^4A] UW3N+:6GVL(/L(<ZC
M(,SS(DMBVW=#.PZSR$W\W'?R' =CWM5<>\T>=IX]]%(;XQC$1 %F!4>]P0]C
MQXJCA%EY'OMNEODIQP'/KNEX=Y7FHYG##C*'++1#WPURGO/4S[T\2>W4#[S,
M#5S.7"_4S.'),(=^%F 0Q;;G.JG%\LBS?#<-K3B,,\MU[8+'>>''F [CVHZ9
M1)'F#X?+'[@=)EGBN[&-?,(-4K\ !/"</,P"'A1<\X<GQ!^Z=+G4PWXU261E
M:1&C9]*W6.I[ENW%H9=&<1(7Q;-7OF,&L:_9P^&R!\=SP9 $:5&DON_;/(W"
MP@^=H' \EL:I5A^>$GOHDLHB)W$3D!!6R,/"\FTOL>(\="W,$(S"D(6VPT!]
M\ ,S3.ZJ8O0>$\>VZV:WE#RRW[D=L[JLZNMF=APVKWN(!(YV=-9B-AO3'"0V
M?C\5C\'V?JSJ3S7.C9Q?O&'- N?"OE>#[;_@5/+SNISSNOF$4+L.L]1<;BLN
M]WL_=<,/@A1T8'2K>H'E,_A/;!>)Y1;,#E-F!VZ$F;.FFVP9F[T_36<+A>:P
M:?D.\BTTP>X'P781D2#R_"3)0BM+XA0(-@RM)$JYE3F>XS.;.9X=8#K%E@Y/
M3:XW(]?G#YL T<"!X6^:</>$<#_VDR0=/V)N8D49!TD;.)Z5IFEH14[A!1D(
M7B?(T)QP5@CW.TVSAYR5H(EXUXFXD[Y1[N=YX7I6SA.0OI[K6RQ*8LO/0L?F
M49PD14[J<KAE0$'3\OW+WSO((=#R=[](MY<KD'AQZCM9:CE.Z& ;)-N*?<^V
M0B^)BX#Y:>:!XNPGJUF&6OX^'LW>06A?T^Q^T6P_A)^&A>L6N6NQL"@LO_ B
M*W49LY*8.TZ4 PH$,2C-J[XI3;,''6W71+SS1-S%V9,\SL(B\BT[BS-0FD-0
MFNT@LN+(*Y(DS3(O\IZ]<DPP@;72O&/$? >Q<4VQ>T*Q7>B;YXF;@CEK<>#@
ME@]VDL7\I+ \-[>#D-MQSL)GKV)ORY3[G8EN[V'G@D^LU%T+]B#HW>_Y]&4Z
M ZA=Q:G$QPC?7H*0H_G75OPKZP>UG20+8]_-K=S+?,NWG<)*'#^V @:JANMC
M/3*6'-MF;&^I<>C$OGVB^X=H2*#I_K'IOC?2B]LL<N+$"E,.=.\5ML62++-R
MQW8#+V,IM?V-/-.+=".2 Z;[A^@TH.G^D>F^%UH'<1Y%;AY:;N)GEN][F17[
MS+6BA#EYQ#+?99@3XYENI!/Y#YCN'S):K^G^L>B^D_>A5S <7&R!HI<"W4>Y
ME89^9"4A<PK?<WCBIL]>.4YD^H$F_ ,F_(?H#J )_Y$)OQ?++WADX^11RW8X
M!\+/ ISC5EAN[N:1%P<L=K!RSP18:[(_7+)_B+I_3?:/;=_WT@$XH%[($]OB
MD8<E>:%CI4Y86)G/8B]WHS"V'1#XH6>"]->4?[B4_Y Y!IKR'XWRNQR"(F(.
M#WW;RO+<L_S$R:TD38 'Y [8_F&4LS1Y]LKSS,#3;0(/F/ ?HE9?$_ZC$WYO
MM O/_#CFA944>63Y/$LMQB+?"ED8.7Z<9RQ(,)9GFTF\2T[]IUJ%OSY/05?@
M[UTR0IMIU6@&MAT#.^GG(H!8"OPD9%84Q([E9[YKL<1-K-B)0B_@A<,*GW(1
MPDA7V.\:K>Y+ H&FU5O0:A=/\,!R]%.@59ZDMH7:I96F46&E"7=CM[ +/XV>
MO8H<TTM<3:L[1JO[$O37M'IS6NW%_&,O#QEW? M4I\3R ^98S&;<BMV@\/P4
M_A^Z0*NF%VWI#]"DJN/TFE1O3ZJ],+WMQ4E41%:>V4"J7A19<5RX5LZBW N]
M+/92_NQ5DIC^M@. -*WJT+JFU5O3:K]*GN6![Q2^E3M98/F^XUII%'A6%D2%
M'=F9F^:82F<&CU'[HTGU(,+AFE1O8:WVHN%1RO,H!9W7B7V,A&5 J]S/+2_Q
M'!?LGS3)?%2!_61+Q[BF51W UK1Z![3:Q:^=F#E1DN16 AJOY2= L+&799:3
MYEGN^&&1L00;1R61;MRX:[2Z+S%G3:NWH=4NY)RXL6-[ ;.X[T>6'_N>E6#3
MF=1/PH2'-D^B[-DK)S)M>\NL\IT)+%\2Z(Y&4;#C,>8WIVQZPHU\4</FC?DI
MOW7]>UK5.:^M>35[@??05.,R-]1!]I"[;=66]O8!Z;;%UCWRN4]P$U7^?IK5
MG#7\+1=_:D:W%:/[V@]-IZ%K^W'N@A+"0[#UX\ABH(]8CF-S)W4<GC :KFD&
MSFJX:U.#K=N3V![EVAT:VSB8T+AF%G?#+#HGON\Y?L$B&Z=SQY:?NX$51X%C
M98'K\B+#K'SGV:O(-Z/XKF;I:8YQ4!QCMP/TFF/<"<?H1>@#+PG\/&06XRZ8
M48'/K<1.N<7#*/==#_Z=1,]>>:9W9\-Y-<,X*(:QVVD"FF'<#</HM>_)4IX%
M$;=2I_ L/PP#*W6+R$IBESF9D[AV"O9(X)BA<U=EO9IC[#['>*P6_YIW[#KO
M..I/URG2.,5&?TD26+X+&@>S66B%N8TH$&7,=; C0.)<OU>XYAI[S#4.)F]"
M\XJ[<67T$B><V/5Y'GNH68"B$<>)E?(XM4+'\>TB#MPHY&"9.*;MWE7;(,TR
M#HIE[';ZAF89=\0R^OD;CANY/,16([GE<Y99L<<B*_/"Q '3I,@3;"EL C)H
MCJ$YQKXED6B.<4<<H\LBR3.6>3&+K9CGV*LHL2V0%KGEN%["\RQSL@B4##<V
M V_+JH?'8QD;<D^"VS0UV,A/KK'&M0Y\FQ?H3>I-ZDWJ3=[E)M<S4==[0@E\
M;\MF5C5L;%2%D9<-*DKE=,%S R= T3RH1D^SV6A[>D' $[ WB\CS\RQD;AH7
M7FZ#?1+%<>+\^_UUHF%_\[K*67.J=$=^=GH#O5$!\JAXVP/C40M%K4%NI4&^
M$^YLU>W2C?,TB4%O]"+7 J.!6<Q/0VQOS?+"BPK/<9Z!JAB[COMRAUI?Z:9W
M=QT(S[P\3QTX:P;&HYLQ/_+<V,G],'-XX82:XO>:XGN3,ATWRPK?ME*;!MAD
M@17G26JQ. ]"QPT=L"4UQ>\KQ6\5R$Z<..!9SEW&$0_2T F89\=^:'M^$&37
M(_FU7B)-]SM"]YVO*/:*T/$<W\K3F%E^6KA6RNS,B@O?]Z(PB9VL>/;*\4PG
M60U(;1V^UA2_BQ1?A)G-$R<+LSCPL\*+ ]OGP/PY#_W4+IBF^/VG^*S7UC9,
MLSQ,K=#U4LNWO=Q*W*2P<H!VX8$UET:1IOC]H_AM"#XH"B?V/#MBOA_&16KG
M061'L>L&;N#'0JN_,A"DM?H=I?6O+:V'*7<82S(K8GEL@>V66W&2>!:W X^[
M 6=N%&NM_@E0O!OD;N2$81PXA1]'<9HE6>A'19BD1>YRIBE^KRF^]=Z=_]OE
M;I2FCF,E+ &%WDEL*TDR9C$W]9S"X;%3!)KDGP#)QW::L21RT\!!-=YE;N[%
M>9QX-O/"*/(TR>\WR?_=DGSB!YP[66PQ/P\M/_-LBV4!L^P8/N Y+[CO:9)_
M B3O.+$3%4F8@7+G<YNEC.>.SYPH#A/N:)+?=Y)W6I(/_"CP?5#GT]0.0+%/
M0BMQTM2*'2\.LIC'A6WO(LGOPFR:O#Q;ZHIDX>]?A)2]\$A4?C0_Y;7!6BIJ
M# 6>.]U-. JNL9V70+DE8LH+&J13GO&7F&5B>?3T\KVRAN,"SUX]=SOW$%SR
MEAQZ#50/CT/?/(/B(8H#@3M/X>Y_8&,VS7CWM6;66S+KBWXR1>Z!! YMSXI<
M%EE^$<96&A69Y;N1YWA^P@H,L7AFY-YZ<.AZSGBORMEU$]J>/.G?/)5"D_Y^
MD7Z75>%Z3L[2U+'"/,)IX;RP&"\\BQ>^YP/LG3C L3ZF&]^Z=D>3_NZ2_MVD
M5"S;99K8=X'8>_-"69#RF.56P>, 9W@Q*_'RU"I2-W%"IPBH[.:.;#)-[KM+
M[C?/I]"2?K^(O\NJ2(LH],&ZLX(H=RT_RCTK]5A@ 9#!Q,MY;B?VLU>.8]KV
MK6ON-.WO,.W?2VJ%IO9=H/8NKR*PB[0(TL("X]VQ_"1++ :,WHICECA>6'C,
MOKN\"DWNNTON-\^KT*)^OXB_EV*19(PY+',L%\QZRP_RS&(1, -D])&=VU[*
M;>SX%;FAIOW#I?W[2;#0U+X3U-YE5[ P=OS4+2S0[S&',DS K/<3*XI# 'T1
MI2P/M:Q_ O1^\^P*+>OWC/J[1(L\=[TB=6R+A0$'33^VK:2(,ROC &HO\9W,
M3W9/UM_WI";'';F[WNGAW12W;:2"(&[8T$B<X(4'Y\ZK13KF;8.-VS44V[G;
M^N81+^A@),3=],>XMF"X2B1HSK\=Y_^[G[4191'+"\XMQM"AF\>AQ1P[L'(
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M4M_W;9Y&8>&'3E X'DOC-"2&8"N&<+.PO^8*.\T5+EJNX++$RYW LVS'!:[
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M"M2NKMT3[$2PE>:T6HQS9"RX'X/ZDT[_7$P%/R#!B*TB!URGVU/;M%3P SP
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MHJ @<"4XODE&T> 7K4":L*_<0HY%RT[*Q:1?DO.-/7*'SPEN6B]$A(%8[J!
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MM0:*) )YWJC&:[T;;JV)WAY%JVS@933H6(V=$$;D.F*4PT@'O4F[#J_K]$>
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M,<M:,TA-)^M,*.$"P&.VHY=J-N&H]LOI+--N&$3O4M1E$9.AH2PCD94N'(>
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M:FS439ST;F(IG-<REE[6Q;WQ,6($2D.GL >9";3'K*H!Q=&,DUG8PF,J<NI
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M0T-)0TE#23L++P&0#BAIU#Y(*(6F[Q]0K.(@8?2<@*2S#790/#R'/ZZ9>'=
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MT*^".(/_(!CY_.YB.#SGDG*;/IAZ49P94_<.&<)"<A"N!MS%X9UR%?@.^$<
M5T!M:XJ78G6X;".030/@5:!UIBYIUN?%"^+8OX<;-*X!O$&"H#M>6N>B?E/T
M1_&C(#/2O^>F4R,H(($].!*NF;YR[*XB],4,^XWP5T@ZGZ'V2LTUY+AW?%48
MH'$#+S3NW#"G=TWDG> R$1.M:HSL/D9+ <4?G \GWJ>21-__=E-T+4 M(D3Y
M!F\15.8FR0)_PWL2H''"#&P%X[1^^8K*P;5Q85S#WL'4-SZ 2(R SX3&37F>
M"^-SG#%C2#^R?R$M0<Z;AW.Y09C*72Y##RT$<:+5I'5^?;><X^J[=4#DOR6+
MNRH:Z7Q ,OM#DMD5"8X)8BKJ.BA#2XWV&OC%+ K&@<<_(\7HJ 7#6@7ISPHK
MG*"""(<N6Q!5&9170LY;@EQ0@QQ7P^,Q=\J\:ED]R47Y)_ ;\55[:ZMJI?OE
M%F7Z'1A1Y$L*>%\O;A_0 >A@!?LL3Y?6CA<&[B@(@;5P!V6>H-Y'U@7Q#JYT
M\,Y<P&1=^$6A#%;-/7)A*(N169+([E#ESAJM$V[X+)LS?J'6]A >]H#^?UA
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M[RYN/G\U?I6I=\BD^*O_;PJ7YP<>.J9P0*(Z<8X\@D"!_#VT:5&LBU1-3R]
M#' B,/BX.K#8XM*I56K>J=$MS1 ) A)C%6 !V3.XZT D"PC8K0) FH.\*:#
MMY"P&4  MX OE/YVZ5*4^4-!DF:U<DFG/HL1BX'3L;1E2G]ND3SI@2@^*^)'
ME0V]G-_4=*!W;'2::<,\P>6@?+J$X=PD$01&;P>$Y3]1H@FE+M@4_&CR*<S+
M+"]4LUX-!U:O%A46P7@^VM?''@:UPGXI[F?N=T:U9K3L+,AG)BAF2WT "NV
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MQ]8W>WHW"_)]T-YV3J&^V2.X6= )ALZ.3I!GF#&9%17D<M==NK=#\L<??L1
M[_"I=GA:(9?FT.72Z+NGX+MZC<-9HWFZ;XT1GU&'D\ZA=SC1&;9'F@FJ]WK
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M&=>8J>A36A[>)OP<=D#-I(IS4YPZ82[/YP1,\H ;99@TZ;'@#GD'CQ%3^RG
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MO208K1-OE\  O@7I=[DC2>ZX;_$+H/9[8$$7'^.8!BPK7(),<GCZRB7O S+
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ME9))<UT4#@LI)Y)'"W%4#DO+..-_(N.H!(@P*P?G)GK:F^Q.BY[CY1M#\KH
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M7TO.MLER>KM'&#ZI.)$J;<GB]>SLO12GCHY^X)P[3LK228)1>PV9N(UR$*#
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MJ/@9W-\M]P9"S2&FTYU#)N*_5?0,K)]_8,1NZ))E=M)>-,VT5^_$!!P@%?X
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MW>8NN'X/S@8(DJB33-^/W<H>$MK@$<7Z=3T2]+U5FHP!3:\D%N8C"L%KN$0
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M:3Y^^V[Y2##!;_]U_B=4(=DD+;B<.:C$ @1!KTSF,B FF17_WV__Y .S)NH
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MM@RRF49@NAV*/PSZD,+5X3.X@?A/P=K+VXB_O'[X>NI2\,H;"6@M+3GE'<3
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MW3(-4$W6&L6K.GMGY;?%A2O_Q98JTRHYKFVM%"=3AD*#3SH!VJRES\EAITN
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MSJ;?KFS7Q;$<C;!@*RR5C*6=6AMPF9,$O,C:M2GF=1/+DR9/1]4T"%;>%,Y
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M7P=Y^,!3OS39>"'KIJX&#O<=4"^!7K'M-X';-&"T)>##!(J:$6!SHO6FO0=
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M13A!A@RK7?9";=7I+.U+T6+T*7B#;>[;[HKXB3%S+XIMD&*VKSIZ+'+)73*
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M=M.7?ZZLLUI]@?Y?,ZL&@J//67JP7-1TV5+(\G8TNU5 FN&"Q[31/K6U,'8
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M![F__FN+QH=O)G.LUW=?3\@3([+@\&M=/][0P,H<I_2DV>SW+X,H@K/H,O#
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MYF)1%<=%$8->$/3CB]]2@.O2JV2Y1%$YG"72YEG(0' 1&;F6QLD8:"*%MN'
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M/IQ)2!M]X$9 C %!B6+ Z< A.<43ERK%1J08E]X&TL 2#I'U(&T@EAN5@@J
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M#,E9Z64C4IH+L+ ]T<G%&=@ANFII6*\GG^]NYPL)B'7:C3GC"Q;0,B%MX+:
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MIM*_1@M6Z1P3G:5%=JH0[)0)?/S\<UT1]*'0:6^"[3GQ6^_ WI;O,*V)A#N
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M@HTIF"PML$6AG-:E]H1E\(KIDGD1MEL5<J<I:O>//?\U9G_JG)XJUIXGYBU
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MNC"NZ9L6C<\P*.U[T,ZQ"\7SH"5-9-PP*V@7ILTTDP&HFM.-W7C&IQIM]/6
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M:#O6)7GF,7OF1.9!1PG&J.=J86T*=,<SL'UT-7))':#W/*7$LJWU/G6B6!"
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M1KG4N>O>]X">@1VT$'6'7>'-;/YY1L#PM^JG+)%M2N5U]L*'R'@R!"PZ,LU
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M'=2Z3V&8YSJRXC!H#H)VV3XC=@\ ^ZQ-JIV:>KB7W\MA%4V1X'+*SC.G:W,
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ML6IFW>2ZDUKLN*Y9?[M^B+# __ZO_P=02P,$%     @ B9D$4]8FL&0U< $
MKC</ !0   !E=F@M,C R,3 V,S!?;&%B+GAM;.2]:V_D.)8M^OW\"MX>X)XJ
MP.S2@WJP[\P<.)V9/0EDI7TR7=UG4+@(\&EK*BRYI0AG>G[])?6(D!TO4D')
M:MS&3*4=5HAK+TJ+F^3FWO_ZOWX\+,&3**NLR/_M3_Z?O3\!D;."9_G=O_WI
MM]N/,/W3__KW__$__O7_@O#_O/OZ&;POV/I!Y"MP50JR$AQ\SU;WX.]<5'\
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M_-/#8UD\-6UUFP)A3/U IA!%GG(!!>8P36,)?>F).!"44$GM-@4.MC4WR=I
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M1A+#-! \3<.4!Z&5ZAQI:VYZTT %&ZR@ SMH/_L8R6;ZXHBZD95E,&O6HF+
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M?0)CD3#)I1I+D%5:]7/ S&V4Z(#"/;7*&M1 P[9T>L_I+4.7>*(^&-MA;LT
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MV2@SO810*Y+.*+&(HH0F4@N$H)YR(_4.5"H2R!(A!8HQBU.KXL4[+<Q/*!J
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MB$CA4<YPMRAEIHKV( :L28VLBEML=4A+4WWWH38)9!N;+ ]!#^@=F8:QY^,
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MM?K>L#GGWTB9:1^OJYG4C -?BM5-F3V0\OF=R(7,6*9^_%7H2?&"IEP&89)
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M 8PP]2#"20"Q]'V(@RB):!QYQ.P GG&+<Q._RP$9,T[3:J9>3LD:6:T:K!=
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MP-44NK(-]3[,M9F3Z(2_D<6ZPPAZ($<(0#Q)A5/O\'!KD_J&)XU^[1F>_L+
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M!.:/K &X;&VRQ8,1*.JO.HQQ^X&YD5F=]KSZ*IC(ZO.E7\1J02/*(DDE%&%
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MN#<C84]<O>$7[7W13[ER=<GR5I0/GPN2?R2LCM!LHV-BDNH5-09%XBMM2<(
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M&[ \\\V+<H4=:#X:W%Q&PU>=PL/A7JM&X1FU!^H3GKO#88Q@DQ) XTBQ 2$
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M"0549HE(<8I#DMFLZX&QYK;":]F"Q&YQ#V%IMLP=(>1YP6LIN[RP1E!E*32
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MG9%JKEVHAD&\HA'5A0<[=27>/I7K3?&O>MS&SEB(C**$*<8-\S &D,D$4)E
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M!LNDJJ;YPT8:8J3Z]GE=?B^XX&]^_%8)?K?:2= &OQ>B.NG$J1:AC'@41PG
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M1DD=*+$#KN0VWV9:H'YY ^\'2\]\M!.Z"4^^";3<P4,'IQ8]J*%6PH_8QUL
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MP^/H@I'5I]MTEP_E^O.Z9$+PZH.2IG9HW*V^BTI[,_9%?189SG&8YAQ()',
M(P4:P4D"H-J,\#1E,0[9B/A(2S&,7NG7BH$L.GD#LA/8LC*UY:28$8(/C"=.
M$-1NC)\ZX0.];'YN2[OM%.C5'G-8Q'H<=&Y+6EO*,&V!ZW$ '96['OF8D56
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M/U=[AP3&882I!%&N,_5RH3B00@$X)2P44&(:&T67G1]B;A3W0LK&%VWE91L
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M;ZR;GS:Z9'.W4;]]TEW0H@6)*>9(2@ ATP7#* 0TY1C +$HHP3Q'R*X=M>'
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M<[,Z^[*UU=";*&VF! ](74G2,CK> /B,(2&R5!]]4-TU15)EVR8(0!91M<5
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M_M'&_L.(YDD4@4@2I#[#J?H,IQD#<9H*)/\_]MZMN7%<RQ+^*WS[LB*,T[R
M)##?D_-V.B>RTH[,K#XQ40\*7&V>(TMN47*E^]</P(M$6Q()4 #-GIF(BBRG
M4R3V7A 7-X"]UQ81)%%LV6S\Q#!S>QQ?6!EH,\=EY)\!U>P=?#E4GA_:$2B-
M:=+= X+KQMNGAIJZF7:/NR<:9/=]VGZK][U8KO_ZG6S^);95C5*[NX9AG*%4
M0)#%1 7C^N =A;DN7<PIRJ-00&G4^[%GC+E10&5F\%#96?>VO@I6PD*V^!R6
MPUN[#A#R_.37X-0FUN6'8S9TSR%DOI?K *F)MG%'(6:U@SN 1<_F[;DK)]NW
M'3"]NV4[]-$+RR?[ZVFJ IH_5FNJU?HUU58%7R\SI X[A2',6290!/(LCE7H
ME&0 RSP%$8QB)$0H9&A5].+#R+FQ[H=[+05<ZF9E]5GFG5X3Z 30@C<GFL%#
MXW- MH'4A7A/&I21I9(N)]PLK'OK:?3\:CB41EYUV\NU=9)<[R?OG0PJ+Z^"
MKI]U%67P*BG5YT:SSQGQ4SWITM"WJ9KT /79:DD?8XU4"3E8,BX-*I4)13P+
MU4L$4MTZG &2$PJ(E%0@R)&4Q$I#Y$*#YO;^^/KE^OV7KU]^?OEDF9MV\<R8
MD?^4>'LF^O%-.JKL!0^[]:[ =2MB<JE1TTJ<.(+P2 #%U7U'ME@4?UTSIMNW
MJX%N-^N5^I'5'2?TR68=='Y9=3]3*/9_7(K.R3\/L4AQ# '#N9853SG 4%$Q
MD8)B*J DJ964L0NCYL:_NDG>:KM\#KZ4I7[Z#\;KD[H5)QMNF:/A9.K,R'GJ
M"?%]IG("^^"/1UVD4R=S5 [II5;GDWN75,3M(]9VB;';GI0N#)NVA:5#*(\Z
M7KJ\]SC._B2E8#K;^;LH5BIHU_V"JD7@X;%&.2.00P%BR!B ,LP!$2P!,$J3
M!$8T#KE5CLCPD'/CVQ^[AP>R>=;I<8\;\5#LFLZ1;1-)Q<(/MD6S!L";\:E;
M.#VS96-L7?VZ-]?KOH,Y/DZ9SF#827G,'(;7+&5QY3@.^BCH]LM*A:#5$<&'
M]>I);+:%&N"[>"#%JHU:%05V6]C<BDVQYM$BR](44Q4A)@E7I,1%###+N$YF
M@XBAE!IFKSBQ9F[,M;?Y1>\KW?)661N\&Z,'>MELF7':9'/@>_6N_ @.CEP%
M'5>N@L/DM-Z\:*H5U/ZX8T(GJ#HER<LLFI0_G8#WFEK=W'1T*E([FC9C$4D8
MJFB. !'E4/<D5SP:1[K8GZ20$TAX1!;;]98LS7CTU?VMF'$_BL<S,++9/.MG
M;\2YUFOHS$CM D \TU3'LD";YC2QZ)3/KC.*7HPQ=2K1*0=/Y!"=_-BX1U<M
M%9D0O*SD0;0>T\UC547RZ9?8L*(4?)&))$MHJ,6$F7J8PR@#1"WB0"AA)"!-
M<$:L@J+!$><6^+0&-SI'E>;ANK(Y$(W-EEMDPZ";T8!3*#T3PTL4:^7(QMQ@
M;Z\[MC"&QBE_#(\Z*:,8@_":8\PO'"D5I(]P;^2M^H*UF5S7*_ZCN%L5LF!$
MQ2B'?2K=MKKH[@VSA"82TQB0.!0 "AH"$N8,Y#1,!8JC5"16(A^7&#,WKJI\
MT5LB76^N@LZN4\>O%]O(C6<&&\V69'?17)OQX%0SZ)DB3TY>-2%#D^9GZ]\%
MK&XUDRXQ:%I-)0?0'6DNN;CG6$'-J@/D+=ELGW]NR*HD5:WQ]:^B7,14YC#B
M*<BP9  RE*O%7J:(.281DUG*>6A5<-(SUMS8MC$UJ&P-.L8&?VIS+6M/^D V
MXT%'T'FFN=&HC="D',3#L>CD^?$F5I4<=/Q8-G+XDI&YVL6JV(JOQ9/@7Q1O
MK>[TTK561GK__#OYYWKS84G*LOJ>ASSB-$XX$$F4* K!$A"99R B$10ISA,B
MK%(V+,:>&[G4IH/*]N!@?"L=1I^#ROZ@<F 4X=A,C!D!>8+;,R$Y1=H^F=D>
M,[<YRA;C3YMZ; _,44;QB%N,[8OP6LM\GR=WJ[?;%9-NMYN"[K;5<>?ZF\)
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M.3G2M%4??<X>E7;T?MA>D^#S<KTI.'E?90OR@I&-4&%"\X5-"8,DYQ1$&"4
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M+"04?X8R@Q"D$4]4Q*4F#*4$@Q"C-"8AC")BQ*;GAY@;1[[<WP^4G>9;.6=
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M;DMQK);^=U*L=!+,S:J56+^1)S_X36QOY$_R:Q%&7 H!4T!HS@!D401P&B5
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M$HQ1$F4(1FE*-?51 AF+"8PPE2*2D6)9VK_?S.>Y]J]]U6QE0'O9<\"Z<5H
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M%40I%9#(M(",I7$:$R:X\HJ.ZQQM?OM,72?02@L.Q 5_U )[6JS=4+M9KL$
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M5>20QWD!49%DD B]4VB@28JS NF-Q,\Z# 7X-/;B&T#NN!D$@G'L#> 5?O9
MY5-5/6IQI6U[$K!]@ LF86F^:\!IJ=U!]2,Z=_F,'X57F^WBQNP1<O-@2OS\
MIK\:US]+S2,,"2)P#FF,)$0J2R$S)_P)82+.59KE!7>A[7,#S(VJ#V4$1DCP
MAQ'3T8 \"V,W-X0 9V0^\,;%F00N*=^U\/5G#Q:]_M?K!7_VY9,L\DNJM0O[
MXG/][+&;):VJ+ZKIR/QE\ZW\<;>U7\<TRY*TH )BQF-M'0@*F<0,)CE+$XRU
M7:8R'V/L[$BS6]Y&4+.?M2W UQM@A?5:YI<!=K,%@L V]L+OBYBW%7 1C: F
MP/G1)MW_+RK]>O.__(&>9&'3 >W;KYM2)$4ALDCO_C!C7/L07%L!VG.((,&H
MR"E"*:%>+MOQ$/.DA^L7S64]*>$81LIQHIA@,-.FE#:AE(0D41R*C%)LR)8A
MYN>*#0-R&@=L%"@=:740/*,;4A:/%I[PA6[.:Q^6/X^'F98XSZIYQ)CGG^Q+
ME74_R'^6V[N;QVJ[OI<;>^G\F]PV7?86-.-$29S"6.$,(JE22)-$P2(CB=3+
MGTCN>?[B,.K\6.#[G795ZX2:76]AG[;"/I"[DD-0&$=GBP:TO[2XH)7WJJU4
M8LOW %,3\R][+J.T<7:SD:+< G,M==4V?0S)+L[P!::;R^-.S#_.0!P3DOM'
M>S(4K>[,_YMTQ2>ZE/;LO]IN2E/^Q/SA>B5>_N+@R46J4!HI%,$\+A*(C,F'
M(QS!*!4J*V2AI)"+!QL\_WVK_55'_AHBD\^2?"W9B*M3"VD+/'#S@]R+:W^Y
MV2E3_YU:-XK)'^7*5!B :P5K43VI<-#<<BIC%J<21A)KFSZC.60%Y=JZ)[',
MTBA&F6KF]L-*S')F6[GF-:]R)=YF1AE*&$]3!6.!%$0F.@!G",&BP"PAG/*B
M4#[199/-YA0!:;=FC&::7.>SNEO_M0+E"FSOI+%:JO6R%#9NN]KJ_ZDK[.H9
MMP\KO?56X)?8,QYIX)1G*6*99##*F?8H<[U=TD0IB'&4(EH@[5>FGL;E5),^
MD?-Y=L)_*7<!4Z_F?=(9=+15IYJ5L:U8+9FV1<U<' AX!?:R@]V,O?[=P0<"
M6K$A@ UKWPZ2:%K+-P1X1S9QD)?V+/=OZCQ5YG);BD42J30N&(4%5PBB@B:0
M(,VR*2FDXIP5!2K\C=_#(>9IR[YK[5+ Z-(ZDYHJZ^IPOL&V+_"40ILAF""8
MY83IO4H4$!<HAER)/$UDKO<J;X-S&)KCVX]ZA/! NFT9?:$9>0>HQ;H"M6 !
M6Q*<4#=LTX'# :9M*W!"M:/& :>>&7+_8X_IO]+-E\UW8^L*VUZS+86WB/7"
MS7&209E0;7<6#$.JN(1%CB-M=48)HMC_0JASS-G=$#55,XW,5^"!;L"3;2%K
MUKA8+Y=T4U?7M.O=UZ1TF *?&Y!@P$YS)?*]QE0+;.Z8:Y&;!KV[JIJAKTF<
M(!KAWJ1[W#>X2'$"XO3-BMM'_9/4/2KY?-W(!UH*;2/:FC[V,+7:QS@O*(^1
MC"(",UJ8+DV:PABA"L:2B)@RE7$6N>:IAQ-K;MS6B-MVE:M/1]:VP-9J)[37
M]4W@:>PFO[>;G)'YT;\J6CN36KFF0EJMGE-QM#%GT#U=_6UF<J*,]8EGU"MI
M/3SP'7GK 0>;+'4]/$"'V>LCO'U8$\3JB[HQH)@[RSKBW'3X>?=L^_Q0KK](
MM_+G]IU&Y\]%EN<92E0*\SC6#@(O",1)0?6VRV,E<R+S5/3IAN@AP]PVU>^/
M]_=T\VPN#.[IO[1ARYL;7\\(B#[3X7AD,"[(8Y\LM-(;A%_(;UM::]GKYM6V
MT9C5HDE9!$8;8-49H4=B#S!':9;H(\>;=$WL =2Y]HE]7M6SN$?=.+BZ7=LZ
M(QOY[W(I;M>_TJVI,O*\KS:RP(AS4:0,RH@QTQ]60?T]+B!EE$6X4!AG:+&2
M/XSCY,:)SF,[+5)2+])#"49T,/2+[FA5K]5RW][2LY:#,_AN_!<6T&E8KY79
M%'AHI 9&;+A=P_M&\(/Z1P&+/?B"%;86A//HTY:*\ 7EJ)*$]PMZ9FA;$[&)
M,=LUY4EED>5$I)"D*(=(:.@9)0E4N4(9HBHCS*DP<><H<[/+;EX<9_R;9Q[P
M21S=Z&8P.B-32^M7M@"-T;2H$X.PF;XG1YHVQ;=+V:/<WLZ'>W:1D&S[::5?
M98\VODDA[Q^L_VBO0[^LVM;#LJ"<,(UAE,4)U*9*I&V5.(=%GK$DQ4QFQ(L'
M',>=&S/4?1Y-\-=W4T77G+FLRB<]<./&F;_<+->5.:YI_OE=KLI]Z+6V-9LZ
M\H ];L'7C?F;WJC-D[=WY>;%&SV;2SA.I1L5C3!!8Q^%VC($.Y%-"%$K]%5;
M-5W+/4):C2=687L\.(X];1<'/T".^C1X?KP?]9UO!EK]?6.JP24Y29*$Y#"F
M2OMG7 AH GU@QG&:)TF>I(57F_M+ \Z-[*Q0X(9N-L^&SZ[O31JZ'R==Q-B-
MC$(B-S(+=?8/UJ:3E3<<];@B$Y1S+@XZ*=FX0O":99P_UX]>/DMSFK%S $1,
M<69X)&<\,;&#&!)$8YBP6'$D%%<F%-^=3%Z^?F[444OGXA^X8.=&$OT1&9D2
MW,'P7OZG=0ZZV%\-,>G2/JW>ZX5\YJG1V^HUH<=':51,Y1E).6198;JX%!+B
MO& P9J1@L<"\(%ZE$09+-#=R.)N!,5HSO3,SY>@)38G_V#Z2=W#!;K+&R[@(
M!O!;-<\[(]5<&^=U@SB@:=Z%%_LWS/N@1]@^W]A;N^6GE9 __[=\7BB92(P*
M#@45VI2*8PQQ1*BVK+#$.1*NE8[/CC WPJR%!(V4P(H)M)SN3?). ]G-?T'@
M&9G/O)'Q:HS7J7VOIGBGWSA90[Q.A0Z;X74_."QHR):E/.=YV?"+?92*0"FB
M"8V@I$4&D4H8I#E)((WS*$XX*TCNY37UD&%N9-"J4-^3[\X7^E1.Z3,CG F6
M)*F 5.K_V"(!6*;:F164IUA@%'/IEU\\\IQ,5,RF:U: D%M:+B>8'3>+=F3$
M1^;\0ZB[3]LFB>;J >(HT5P^<KQ)-%</H,Y%<_5Y5=_\W_5F*QYK^_;3JM(_
M::7;*CW5RUZ:7]3-DI;WU7OY))?K!W-Y<;MN6T<_?RY7\M-6WE<+06@<97D&
MLU3D>E>3,:0,QS#/(I9++G.5.J6<C"GD[+8]6RVL51+LM 0[-:]>=3:U09]6
M57"@J[ELW6D+_C#Z JNPYQ'E*%\,1_I^X^D>F]_?;J9[Y!B/-Q6!<Y5'$'3B
MG.?QH#[.G1YQK+YEVQ[*+5V6_R7%S?K^X5%S[O>UVOY%-_*PYG^\P"S&I$@1
MI"1*($)I 5F!%<0JITFDN(IQXI6([3CPW#:, [D!;P0'52/Y%: 'LOM6]W&<
M"3<V'P/?D1GZ$-I69O!]!^VU"[0]ZO+XX12X!(_CX!-7V_&#Y+BPCN?G_4]P
MF_#DYP\_^9W^"DG3OF#!41%1'B&8D!Q#)!.E[=]<PHRC-"Z$0(0Y=?(\-\#<
MJ*B5$;1"VBX9[J>W)T&\?'@[%)JQ[3P_5+Q.;KM4[W5P>_*%DYW;=JES>&S;
M^5S/,);6D/FXWM1VCKGAJ7\0_WJLLW0^U%4!%@5*DJS(<ZB8HA#1C$.62@0E
MB6+.]$+7?_4OD.4C@L_W^PT+:'F&P_C, 4)<QJGD,(ZTZ8=8$D&2ZDV-2 U^
ME+ (J<RWJ-:X,S!UT:T1P7<S^<:"<V3"WCO3MI9X[7#;T(#ZQ[WLH!$^8*!3
M#\C"AD'Y"#!MD%0/:(Y"J/J\HW_]\>,@@8^TW-CB0":P8+G6'K=F,A6)C,8I
MI&FD((J3W'2B4C#'B<Q,UQ05%WZ>K./(<[,? P5,N2/OZKF.@.?HKNN9<*8K
M8 1O:HKM10];5]8+K> U9-U&G[Q>K!<HIVK#^KT@0%BH[1=3JI);]_C]^IZ6
MJP5GF#(B*.1*I9JM$(&T2!-8,$48CB42D5>VR,41Y\92+V,+P4N1P1^UT)ZW
M+)=A=Z.JH&".3%$#<1P6?MF%S7CAE2='?;OPR2X0.L,C.S_8CWB^R2>Y>I0?
MM<2G>L-\72]+_KP/ ,&$Y=(V>^"9@$A@!IFIJUQ$)$<13Y-<2!\6\AM^;I34
M2&^O"W^L2O^S?D_TW<AH/$Q'9J863K-\=K>Q+]M/@3]J\<>)N>F'7%#>\A1A
M4A+K!\]K1NOYEI[Q-:9 ;%VD^OWCIES]J'-\Z^+5]H]?;.IO]>&GW/"RDF)!
M\BA+>8X@881 1$D,,8DQI)0E/"&2(N5UP>DOPMQHKA7,Q$'8ZM-@74L\H+R\
M_[RXD=^X:(]]96&DA(Q6S<6G7%6U579M.N[^L/U_3$6YP^>:^CW@^B^Z$5>@
MT>X*M/I5IIW0U^[64/YQ*;U1#AMUXB_&M#$EO6$ZBACI_Z9^Q/E/:9H[2W']
M)#?TA_SMT51$^*+>E\M'_=MZW"^/VVI+[=GW(HYBGDF1P3AB%")&.22*4YBQ
M@D:(82YE[A>W[2F!SS*>)F:[D;0_2?K.0985>1I3 BE"$40Y8Y 0&D.6*HQE
M1$2NO'HDC#@#4VQ;K?B0UO*;,!W;0,$*#M9[R0$$8NK)<MO.1IR"D?>R5G+0
MB YJV8T-48L-#N2^ HU&X;:HGL@%W9]\99AT<^H)T.N=J>]K^M<3TUZ#*6!E
M0B,WY8]R19?FMW7YF%AO1"JF/"902AF;X!\!<4&XGAU6"(51E(O4MY)8YXAS
MHSU;IXKO)+[2^-8R Z'_8B,3O>OL7(;=\9PT))ACGY,:'&\.<&S%!>\MCA?J
M%?6J\N6$3?#Z7MVC3E[9RPF$4S6]W#[8LYI7>^7SJZ3FON>^;A-HZMUK5FM*
MW_$DT]9O2F"DN*GHE220J32#:90D3-,1HZ+P,X)=AIV?Y;N_ZK2I%+6PGI6]
M7/!V(YW0&([,.R?!&Z&JH \L8<M[N0P\;8DO#RB.RGSY?';TFD&ODQ4/^M]$
MA*!,Y 065&CO,,XXQ(B86,HT5A'CA/N%NP21:F[&TZ?7N=578"5]C:4@T]7C
MXGF*29CT<MJE@-")&H@AVQ*- O1;%1+JD&RNQ80N@SF@H)##RWLVZ=BLN92B
MJB^YEDO)ZTR^W]9;:38'63Z9+/(%CJ6B1"G((BH@HDI"'!4QY+@H,LJIB(G7
M=;KCN'-CW5;L^N:7[P0WAT4K(SK8[&3W;-CA.!%N;#L"O"/SZ4MD;UX@:Z4&
MWRXCZ]^IPP^GL'TZ',>>MDN''R!'/3H\/]Z/M#17KN_E+?VYCVK<AYX0S!DA
M1$*:$001)AG$7*,O99K%DD8J4EX%^KL&FQL]U;("+6Q'.QM_2-TX)Q10(Q/-
M'J.#Z&;PQRAA.BZ0!.64S@$G)1(7U5^SA]-GAF7OE:8!FH?A=>#G*)S1)-&<
M4N"$0\00@SC.M(.*\T*P+$;4+Z)PN$ASHQ\M&6P[("_WVM5;NCATB]:M,IXT
M%6 :W<ALVLF9G:]ZH/XX7FHX?$=);AL@UINDO V'\5PB7( WCWZ6>'0D18@R
M/4DH)%+%$*61"?XVV=A4Y8E*$IXCI[H* 629,T<W11FUAQ6$G(?,6/!#Q/]?
M'1W.Y+QP;J>$_]><#8YP(ACX'/";7)K>ME_I9OO<))1%N< B50ARGFI'.L\$
MI!RGD,F48<&2#*=>X>7'0\R-&QL)@16Q9Z+>"2#=N&T8/"-3EB<R/?)9SBD?
M.&?E:)B)\U+.J7F<>W+VR9X.\'KU0Z^A>Q-H<JM?<?VSK!9"%92*1*]NKHTE
M)*74%E.4PXS'180C+J/4ZZ;UU"!S6^1&1FB$;**CC)S@#R.I;V^F4X@Z>I<#
M<1IYM?>!R-\#[, @K$]W:J!IO;0.58_\KJYG_<O.-4UR/VH3@B[_0]+-AY5X
MKYEE$:4<Q8IRJ A7>G=7VD6*BP3&!.-4I5*O?>%:>N[<('-;^FVWYEI08"0%
M6E1@9'4O0G<6TNZU'PJHD==^+XR\2M)= J%76;JS+YVL--TEM0[+TUU\-D0/
MZW>T*JOO#QM)Q9?5/^BF-#=OW_0H\0()G,0Y26$1%5)O_FD&"8D5%%&"HU0I
MG*9.B]]WX+D1@I445%94L%Z!IT98L'%F!&_L'4\Z1D!T[&.-UVVG:W2_[]!M
M!0??@G!)7ZA&[#K=,?@;MIV^#$EWWVF'S_<]='A9/OP@X?Z[_&'C4V_7-^M5
MM5Z6PKA#MJ.%9E BS?]!@HJ\-EV(I!CF12$+C$F2(Z^^DOW$F!N7'7<">%&E
MHM7$- ,XU*5I#>-]RM%KYEQ/0L:>C]%/2\:9BA['*D.0#'STTDN4B8]GAL!U
M?(0SZ&W]*/5ZN5S_96J[?EQOWJ\?V58]+J\Y-XE%!_%7_]R46_E%J6K!*4IE
M)AG4AB"!2&D:Q8I*F*<)R@M,TR+VNBGS'']N)'IS1S<_)%QKT?P(T1=W-R8<
M$<V1*;"5\B!J\PKLU*GKYFZD*+?@\[JJKH#50<,>COMZ8A>4]'QEF)3M>@+T
MFN;ZOF9H[\P7=V55]V5954>6?=]JFJTM6EO_^ON=E-OKE;@6PI9$H\M]X%FU
M#W_,9)2G-*8PC82 J$ACB+D2,!,%$VFF4L2](DK?0(>Y\>QAZ\(@L0=O\;UP
MX_"9S_:DL0[5Y6"'J7I53CX9(_6ZG$Z/-^J5.?E$G>^U.;TH?IND?+I;?#-%
M3KZHWZLZ4^R:_^=CJ0TM/60MO191+20NTBB6& H5<U-ZA$*:VPJI#*4$IR)-
M\\5*_K!>R>6-S75<)UXB-2\=C3[B=:>T]>G::#BVI>5*_[M< =DVY#'V:K,U
M:>9:F@\<1CB[[57.T].]L01%>Z(#$2,N_**@%K@.9@.MR.#:7"XU0H,OYQV
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MVT66B%PJ'D-%#3LD:02IP@3F$4X%4FF:BW3Q)#=L[1QB/TPBGR5R*-=X*^5
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M*<X3FOB=KEX:<FYT4T<V[T2^ GNA=XGR?5C' 7S7,]B0D(Y^##L8S1Z'L:X
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M4XFL#6Z5"K=*)X,F*M,<T&5*P;@! ++AT5N!P[4.CGUEVB@P^"0ZI8P6CH3
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M)+_NEA?SI9_^NIA?7KR;Q>EEJ0W#5^-\MNIFEY!.+F#=CNOFAH)"W[04B20
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M9P/I]_>=#]VT6W5]XJPOK#Z;3U'JRY+Z6'V[$4U&*$N#)A@,0]'81(EGRI'
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MY;J;:,A:.\T]X<H'(G-DQ%*A<%-(F2?\FY-UTK'W*1F[F_1XJ-C8UWY'%34
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MPF1/,8_<=N'3PL^6_1WZ(O]K/GZ#\P"+B:'4THR2X4:5,8:XBIQPF2CFK [
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MPGXS0>.6T8\!IUTTT2"@[HFJ+X<KQGDZ7UXN;EW.5%QX$:(C K3&==,?)NI
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M$8G! ZZ?C';:I&Q2BDSJ.MFJ_>@>]\AW."0>3GD-0/4CK- K@'1=GGW%A4_
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M?K+?1\3\R:PP6_Y?#N&_^.EZD9;C]H@KHOSA:);NOG#KG1.(Y31*<F)=1A%
MEL1#R"@,)5*R*?-*.<D*S(SK/%3+"XVM]@:<V;V8_0"+KM2EW+\4$Z>79>NZ
M+=:UJ"<4C4QB5A.=R_F_@UR.SPP)B2?FI>)"U"EZ/BR?XSHPU=9+PV!I8!/9
MSVY$G3C+R)UDH=@-'=""J$!$Q.V:64J-JY,8J[\Q5/-_V@3ZLU2Y,VXO^N6$
M$EBL&D!O<-EIS3D)N=R2D"AGSR,EC(J4O1-4RSHEIO716ZVLI5'T/D>5>Z+W
MS>QVD=Z__O) #>_QA?Y/_5_*O_P(^:?R_8^/[^X\ [[,"_EGX*>KL[_$^?GZ
M.2>+SWYV/4[J#M'+[OQB^J-^BG?^^2_?*;E/X]6G/(#'LZF"KRN886SU\YZ]
MT&\]H$PDGT^[Y*^&EGZX1?O-R!X_O4'C=PS&$*GU+..:2Z6&N+2 5\ (,"=,
MUOB7^PU]A^J;/@3Y>_>3WX>(<AEA.E]>+N 3JO05?NX_)LDY-/X"B'$VE,A
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MSZ18E(E@@D9&(U%&&C1<H(AG&.+8X&(2TGE!1_=*"J'->B3/P= >'LFSE=6
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M=UIE;1")O[3:@R>&51]=EX0LWVT>\'HS(##22(-3@02:RS@4SXCW@2$WBML
MD(#7:4TY!/7-UBL\!VW/F$%>1ZTOVQ#N7BVV]4<?T"R.5)D5)>46LB(!1"(R
M*H[>("L=[),U#J'K19TF(:-8QY/%>A5M7$1K]SA(X5/FY3@R1R)]+@5'N(J9
M!*% "\-2G?O9>Y'=K#U\#KZ>80\'5F0#8<A-:\QR.63U[7A^?C&?P?7L,E'Z
M'W,$#2N#)&4QZ(&93!3//EI)':0Z%[>?)&M<U!T0'O<+"P?350/ N\?#3<_M
M9+5+G&01,)Z"Y$C 0(K$+,%YFUUV=::^;B1GY/K X=0]'UKV#0#H8_%<9I#>
M^,4,U]G-N!)OK8J,$]-W5 _18$0.N,J0^ABIXU'6&FZYB9YQ(32 HA_<]-];
MZB,G_H\OSR]+S<X7>),SQ-4'6'3S=)*/TOSB9O2$SU0&$2U1E)>@BD;B5/9$
M,^ :@QGITU9WM;8Z#]B&HG&/C@^_YU715./(NUJ>P85LO'<$M,_HL98[L4:A
M>>=6:DVYT&JKI.\@V!MS(ZR#@6< ; >%- ZQH_0?E^O^ %>&._ @>;"6&!9+
MWQ]FB>/!$1VDTS**&,-67;6',73WJ&L7=KL@XSF6;1\U->";[;I??#^Y22E"
M *I(F:N #H6*Q)<OD3*OL_):Z#I%IWN3/NZ)['C1Z6%UW@#(3U?S^(^S^105
MNEP[VC<=,#Z4*]FH\-5JT87+59'MIWEIR%+J*>=3_,3/[V9("2Q7$ZE 9,DC
M"2X!D0S]<@\T$!5T\%)G9F&KTI,=<BQ#T/\RDS$[@NY!0N;@"&BG3]J&PX0_
M+A(^XTTY/5B6T_+W'7+' I6&6D%X8*6)JN $=TU;#N(E1"<<!HJ54_U/$O@R
M(ZMA %Q#ATV?[GU:^-G2Q_[&S@XG>'?^^7"G=(]3-=!)W*O+)>)EN3R>GX=N
M=C6XZOJL!%2D--E,A-;E@H!1Z+]F1S@J#P)U(OLZMV*?HFJ0]J"7<76)"^9S
MW]1O6LS?$0KY2[?J8/E]XM?W0VP=@7LNR\5 #":E*_-",J.$191"0OR;2F,S
M=Z%VW(UW,$1M;"5:4W$#%I[6ME ?_')9NOOL7G+PU*?5L5]/TGP(<V9S4+IT
ML),(02(UQLO68TR./I;)E'J5MZOD;\J<?2^TO7[*442'<]F/+UR^^G;KMW4D
MI[5S+#M!&,NA--;#)8B<$Z5P3>+G0\AUIJ4]E]*&S=ASD/1X$Y@*"ALYR?B=
MMW70\QNLSN:W6H\^?!7Z2_A]KM8*KCDM'<G :R*-!>*XU<2@5(%'"RYOM<=N
ME7#<A])6FL/4P,]\!&6.#-K'^+C*Y(*T$'69?J3*]03#-7'44.*TTY;S$J /
M!\NG:1DOZWTX+,RK*&;DWL5_S#KT$7%1?EN/93U&@:?@KSVB]8L?IGYVE=0'
M$UTR.A*.:[0D]1-QUFB29119L2 CSS_P[W9X['CP&E+3\\.(O8$T\VL(JW>S
M$A25)=@O-6>91!?$D^QHZ4X'DCAO/('@J'/&9YOJN+@/:6GE2GO%77(@130'
MI5M+CT8M;<0EX9-A1-I<RF5Y)E;8F'URV<DZY=B/433R).\]-?TD<'84^\A[
MV[4U_7V^NKXSG $7#4.=4JIIN?*!X1%-B;!L##+E33(_2D]L_N26E+^KMN:#
MB6[LBI)R0  +E-WJVXVOYYR$K+,A4B93BNHE\4@VH=SEP*ET"H;KEK")@E:N
M/5<.SO86_MBM5>#B<A'/_!*./B^@/]:ZS]*U\\>T#-0GDCWE1'+G2'!:$F4"
M4UY+8<UP!9=;DS5B =+>FI_75L/(.])O<WS5K[W[B/)\-XO7#KXR2E!KB* 4
M4$R*H8.?/$G4^NB%]CS9+3:F1Q\P8L>6.HJ<#RW5!GS=_J;^+4/<+Z 46!(A
M,A)=J6\RP1,GA")1)# F&,93I6N'&Z@9MXW<04.GO971(*!N2D!ILB(%(DJA
MG'0ZDR"](/BRM);33&.=0L7-](Q\(W-O/?\ .#L(O9' Z3XGU]T37<I<.(K1
MI$8[38,FEGM-4#+:HV3 A[3%7O7T4]H"Q2XZW!!.#2#0T4.KV1*WVU)OE=[,
M5GUUPSJ5+DWD61L,#]'*2F70STO9X\Z;J3)4 K-#AE>;J1AW+/P!0ZP!E- @
MD*[O^J'79P(N E-<0!F#+!TZ/$804CNJ*=>J+I3&#Z2&T.\/ +.#L!OP:/[F
M%UU9.]>%R#TWWWZ?KSXLNC(&ZA7,('>QPQ^OKZ'0S).VK#3XTVA<O2'.4$L$
MIRJQY)BL--WXV:2V!;A=\#$_I+(:0.-5+?*RI$F7[^=^5KH/O<5@=!:[V>?2
MR*;[4@3PZMOWGS_A9_>+6=J<#9>4"('@D3D&$E#8)&:.WZC1--2Y];T/U5MA
M5+_H'?;@RFT R'<YN%KZ,03%K%-$XZ(D,J5^!#,CRE'*O6):YSK]?391TT3;
MG@-@X4%I\9Z*:0!<O="^,W(]<:2T7<A2$VK45?L%IRP0$6/TTE/G39U]>2,Y
MX\)K?RW?O]BXM\@;P,T&&__^Y@H1X]F"$YXD:01Z(Y")$\Z@THT+*1H.E>9D
M/D755B@R_Q2[XV#*:0!H'_RW_O;:IWG/S0(VEQ(N)SEQ0T7FA$951L>5 4DI
M1.*D\<601U4I%[\MA6U4IN^/B?D!%-0 \#8'2"=_SO )9]W%!UB45IC^,TS
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M-[[+S<@@1(P.LB9G3<GD*.;R"B1&RYC(==)/$\0]2M+/GE(;QSB.H]$.H'G
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MTRZA/!=P-]/[:"9\@OEQ=5WCZXOEG^VFQCWXAI/-BGN:MXDFQ"G.DJO)1T/
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M65U\YG6-\CZ9SU;T39O;F@CAW2C\O,S[BY26U\3I[\LKK(\3;Y9AL7J/">G
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MYJ?LA91'R9ANK=6Q>EV.+>2)KY>_8R:K.,_?1?)]J[-PVDL/Z+PCH7 &,:0
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MR^10.F/NSP9M8M6.7C=X\L&UX]FYT?33'?)JQ=1,:,>U4!YT,>2B<D8R2A3
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M%FUJ$VT\2UJG^^:.L9CCJF-BVWF['/OOX5_XST_+.OUX[4S,9##<:^Y ZZ1
MR5HHD^O>@128R (YXCZ;2Q[_ADZ7R TU6B.)L@.#<_/&]R[,<_4%'%IO@]2
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MT_(OO,BO0_IS(H) E8DE3=S0RO(!@D@)I$I%N.*,UO?<QITG(<>]?=RT@S,
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M+[[.Y_FF&<'[\O'K/./;)7V=MTP%H22%D1P*4U52A5PW8QSH;*Q,41;.TQX
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M+=4;))?BHT@9 :/)M>*WUN>F!)A+08-2%=7F*O$(8KNR+H=@9A_K,J2B.@C
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MYE>%7K;F;OJ#%A@+26LG08>$H"Q'",D7R$XDS[3,+MX[-=G9=OKP-X\[]7
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MW$9:1]XXBHSJ2!E.3G0Q,NL@C8J-"BH>H^A4.W7_N3<C"5S H+UG(%5E-=L
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M7U[GIFAFA4D80!16T_AKH(U* T7@F8)_M+Q1J=H=,GK)9!L-%O>/HX_640<
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M>UZ0._$J?YO.IO7VJ"9W;R]NKT-M08O)HP>7G0>E@X0H<X%D698Y"I%BFU9
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M;?9@M?2*K^TM90@8<R3'(Y::\R.("\\Y@Y@=-^3'!B?;7%0\0=2X&!M([?N
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MY_.\GLZ^/=?X-+_(O_R5+BYKUZ1_(!&6-K,NZ'=>?9LO5M/_N_YV(F41*=@
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MS-\A"'LJ36]HW;U8RW=*>O+S3SV/[6N;E+SWSIQ2D=Y*"$(:B@]8;2]B:G/
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MAK0=RTX.<AW_L9E'RRRWD<O:>RS7558@UA'M-A6=M'72Q#97Z#O)&??:8%A
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MQHX/0E+GBZ2Z S+.A^SU4%3T*,?!.\@M\P;<VU/(2DN'$< <"R72!>Q(G!B
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MRL&&HGV=>HQ]1CDJT_M 7+QRT/6^2*,%(-[^/D\)?2@HGJ@4+0T&>Y)[CKV
M%;$4'&+0_4Y2SW(L=7IR'3#841GR->'8WY+5OSU9_P#_";[)__./_P=02P$"
M% ,4    " ")F013X2\%7D,(  #Z*P  %0              @ $     83 V
M,S R,65X:&EB:70S,3$N:'1M4$L! A0#%     @ B9D$4VH5V+P["   ]BL
M !4              ( !=@@  &$P-C,P,C%E>&AI8FET,S$R+FAT;5!+ 0(4
M Q0    ( (F9!%/7N !&WP0  $85   5              "  >00  !A,#8S
M,#(Q97AH:6)I=#,R,2YH=&U02P$"% ,4    " ")F0133N($,\X$   :%0
M%0              @ 'V%0  83 V,S R,65X:&EB:70S,C(N:'1M4$L! A0#
M%     @ B9D$4R3"&T(6P0, 7(TK !               ( !]QH  &5V:"TR
M,#(Q,#8S,"YH=&U02P$"% ,4    " ")F013V7G I=X<   Q3 $ $
M        @ $[W , 979H+3(P,C$P-C,P+GAS9%!+ 0(4 Q0    ( (F9!%,4
M^0G:"C   $;V 0 4              "  4?Y P!E=F@M,C R,3 V,S!?8V%L
M+GAM;%!+ 0(4 Q0    ( (F9!%-&ABPQA[L  ,M:"  4              "
M 8,I! !E=F@M,C R,3 V,S!?9&5F+GAM;%!+ 0(4 Q0    ( (F9!%/6)K!D
M-7 ! *XW#P 4              "  3SE! !E=F@M,C R,3 V,S!?;&%B+GAM
M;%!+ 0(4 Q0    ( (F9!%-@1GL6ZOT   J8"P 4              "  :-5
L!@!E=F@M,C R,3 V,S!?<')E+GAM;%!+!08     "@ * ) "  "_4P<    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
